<SEC-DOCUMENT>0001213900-24-060183.txt : 20240709
<SEC-HEADER>0001213900-24-060183.hdr.sgml : 20240709
<ACCEPTANCE-DATETIME>20240709172901
ACCESSION NUMBER:		0001213900-24-060183
CONFORMED SUBMISSION TYPE:	S-4/A
PUBLIC DOCUMENT COUNT:		81
FILED AS OF DATE:		20240709
DATE AS OF CHANGE:		20240709

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ARCA biopharma, Inc.
		CENTRAL INDEX KEY:			0000907654
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				363855489
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-4/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-279387
		FILM NUMBER:		241108193

	BUSINESS ADDRESS:	
		STREET 1:		10170 CHURCH RANCH WAY
		STREET 2:		SUITE 100
		CITY:			WESTMINSTER
		STATE:			CO
		ZIP:			80021
		BUSINESS PHONE:		7209402200

	MAIL ADDRESS:	
		STREET 1:		10170 CHURCH RANCH WAY
		STREET 2:		SUITE 100
		CITY:			WESTMINSTER
		STATE:			CO
		ZIP:			80021

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NUVELO INC
		DATE OF NAME CHANGE:	20030203

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HYSEQ INC
		DATE OF NAME CHANGE:	19970610
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-4/A
<SEQUENCE>1
<FILENAME>ea0205122-04.htm
<DESCRIPTION>REGISTRATION STATEMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Tue Jul 09 21:08:05 UTC 2024 -->
<html xmlns:abio="http://www.arcabiopharma.com/20240331" xmlns:compsci="http://compsciresources.com" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:dtr="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:srt="http://fasb.org/srt/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.w3.org/1999/xhtml">
<head><title> </title>
<meta content="text/html" http-equiv="Content-Type"/>
</head>
<body><div style="margin:0;padding:0;border-width:0;text-justify-trim: punctuation; margin: 0; padding: 10pt;"><div style="margin:0;padding:0;border-width:0;width:600px;margin: 0 auto;">
	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">As filed with the Securities and Exchange Commission on July 9, 2024</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:0pt;text-align:right;margin-top:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">No. 333-279387</span></p>
		<div style="border: none; border-bottom: double windowtext 6.0pt; padding: 0in 0in 4.0pt 0in; margin-left: 0in; margin-right: 0.0pt;"></div>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:0pt;text-align:center;margin-top:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"> UNITED STATES<br/>SECURITIES AND EXCHANGE COMMISSION<br/>Washington, D.C. 20549</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:0pt;text-align:center;margin-top:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:6pt;">__________________________</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:2pt;text-align:center;margin-top:2pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">AMENDMENT NO. 2<br/>to<br/>FORM <span style="-sec-ix-hidden: hidden-fact-0">S-4</span><br/>REGISTRATION STATEMENT<br/></span><span class="BoldItalic" style="font-style:italic;font-weight:bold;">UNDER<br/>THE SECURITIES ACT OF 1933</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:0pt;text-align:center;margin-top:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:6pt;">&#8211;&#8211;&#8211;&#8211;&#8211;&#8211;&#8211;&#8211;&#8211;&#8211;&#8211;&#8211;&#8211;&#8211;&#8211;&#8211;&#8211;&#8211;&#8211;&#8211;&#8211;&#8211;&#8211;&#8211;&#8211;&#8211;</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:0pt;text-align:center;margin-top:0pt;"><ix:nonNumeric contextRef="c0" name="dei:EntityRegistrantName" id="ixv-32"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:16pt;">ARCA BIOPHARMA, INC.<br/></span></ix:nonNumeric><span class="Bold" style="font-style:normal;font-weight:bold;">(Exact name of registrant as specified in its charter)</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:0pt;text-align:center;margin-top:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:6pt;">__________________________</span></p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">	<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 32.22%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><ix:nonNumeric contextRef="c0" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="ixv-42"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:10pt;">Delaware</span></ix:nonNumeric></p>	</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 32.22%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:10pt;">2835</span></p>	</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 33.33%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:10pt;">36-3855489</span></p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 32.22%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">	<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;"><span class="Bold" style="font-style:normal;font-weight:bold;">(State or other jurisdiction of <br/>incorporation or organization)</span></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 32.22%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">	<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;"><span class="Bold" style="font-style:normal;font-weight:bold;">(Primary Standard Industrial <br/>Classification Code Number)</span></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 33.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">	<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;"><span class="Bold" style="font-style:normal;font-weight:bold;">(I.R.S.&#160;Employer <br/>Identification No.)</span></p>	</td>	</tr>	</table>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:4pt;text-align:center;margin-top:4pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">10170 Church Ranch Way, Suite 100<br/>Westminster, CO&#160;80021<br/>(720)&#160;940-2100<br/>(Address, including zip code, and telephone number, including area code, of registrant&#8217;s principal executive offices)</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:0pt;text-align:center;margin-top:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:6pt;">__________________________</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:2pt;text-align:center;margin-top:2pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Thomas A.&#160;Keuer<br/>President and Chief Operating Officer<br/>ARCA biopharma, Inc.<br/>10170 Church Ranch Way, Suite 100<br/>Westminster, CO&#160;80021<br/>(720)&#160;940</span><span class="nobreak"><span class="Bold" style="font-style:normal;font-weight:bold;">-2100</span></span><span class="Bold" style="font-style:normal;font-weight:bold;"><br/>(Name, address, including zip code, and telephone number, including area code, of agent for service)</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:0pt;text-align:center;margin-top:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:6pt;">__________________________</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:1pt;text-align:center;margin-top:1pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Copies of all communications, including communications sent to agent for service, should be sent to:</span></p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-top:2pt;vertical-align:top;width: 48.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">



						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;"><span class="Bold" style="font-style:normal;font-weight:bold;">Brent Fassett <br/>Ethan Lutske <br/>Ross Tanaka <br/>Savir S.&#160;Punia <br/>Wilson Sonsini Goodrich&#160;&amp; Rosati, P.C. <br/>1881 9</span><span class="Bold" style="font-style:normal;font-weight:bold;font-size:58%;vertical-align:super;">th</span><span class="Bold" style="font-style:normal;font-weight:bold;"> Street, Suite 110 <br/>Boulder, CO&#160;80302 <br/>(303)&#160;256</span><span class="nobreak"><span class="Bold" style="font-style:normal;font-weight:bold;">-5900</span></span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;vertical-align:top;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;"><span class="Bold" style="font-style:normal;font-weight:bold;">Ryan A.&#160;Murr, Esq. <br/>Branden C.&#160;Berns, Esq. <br/>Chris W.&#160;Trester, Esq. <br/>Gibson, Dunn&#160;&amp; Crutcher LLP <br/>One Embarcadero Center, Suite 2600 <br/>San Francisco, CA&#160;94111 <br/>(415)&#160;393</span><span class="nobreak"><span class="Bold" style="font-style:normal;font-weight:bold;">-8373</span></span></p>
					</td>
				</tr>

		</table>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:0pt;text-align:center;margin-top:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:6pt;">__________________________</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:2pt;margin-top:2pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:9pt;">Approximate date of commencement of proposed sale of the securities to the public: </span><span class="CharOverride-6" style="font-size:9pt;">As soon as practicable after the effective date of this registration statement and the satisfaction or waiver of all other conditions under the Merger Agreement described herein.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:2pt;margin-top:2pt;"><span class="CharOverride-6" style="font-size:9pt;">If the securities being registered on this Form are being offered in connection with the formation of a holding company and there is compliance with General Instruction G, check the following box </span><span class="GrepStyle" style="font-family:'Wingdings 24', sans-serif;font-size:9pt;">&#9744;</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:2pt;margin-top:2pt;"><span class="CharOverride-6" style="font-size:9pt;">If this Form is filed to register additional securities for an offering pursuant to Rule&#160;462(b)&#160;under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. </span><span class="GrepStyle" style="font-family:'Wingdings 24', sans-serif;font-size:9pt;">&#9744;</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:2pt;margin-top:2pt;"><span class="CharOverride-6" style="font-size:9pt;">If this Form is a post-effective amendment filed pursuant to Rule&#160;462(d)&#160;under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. </span><span class="GrepStyle" style="font-family:'Wingdings 24', sans-serif;font-size:9pt;">&#9744;</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:2pt;margin-top:2pt;"><span class="CharOverride-6" style="font-size:9pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange&#160;Act.</span></p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">	<tr class="No-Table-Style _idGenTableRowColumn-14" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-top:2pt;width: 3.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 18.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:9pt;">ARCA&#160;biopharma,&#160;Inc. <br/></span><span class="CharOverride-6" style="font-size:9pt;">Large&#160;accelerated&#160;filer</span></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 26.67%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="GrepStyle" style="font-family:'Wingdings 2', sans-serif;font-size:9pt;"><br/>&#163;</span></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 21.30%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="CharOverride-6" style="font-size:9pt;">Accelerated filer</span></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 25.37%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="GrepStyle" style="font-family:'Wingdings 24', sans-serif;font-size:9pt;">&#9744;</span></p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-15" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-top:2pt;vertical-align:top;width: 3.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;vertical-align:top;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;vertical-align:top;width: 18.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">	<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><ix:nonNumeric contextRef="c0" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="ixv-160"><span class="CharOverride-6" style="font-size:9pt;">Non-accelerated&#160;filer</span></ix:nonNumeric></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;vertical-align:top;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;vertical-align:top;width: 26.67%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">	<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="GrepStyle" style="font-family:'Wingdings 24', sans-serif;font-size:9pt;">&#9746;</span></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;vertical-align:top;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;vertical-align:top;width: 21.30%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">	<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="CharOverride-6" style="font-size:9pt;">Smaller&#160;reporting&#160;company</span></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;vertical-align:top;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;vertical-align:top;width: 25.37%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">	<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><ix:nonNumeric contextRef="c0" format="ixt:fixed-true" name="dei:EntitySmallBusiness" id="ixv-173"><span class="GrepStyle" style="font-family:'Wingdings 24', sans-serif;font-size:9pt;">&#9746;</span></ix:nonNumeric></p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-15" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-top:2pt;vertical-align:top;width: 3.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;vertical-align:top;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;vertical-align:top;width: 18.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;vertical-align:top;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;vertical-align:top;width: 26.67%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;vertical-align:top;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;vertical-align:top;width: 21.30%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">	<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="CharOverride-6" style="font-size:9pt;">Emerging&#160;growth&#160;company</span></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;vertical-align:top;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;vertical-align:top;width: 25.37%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">	<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:EntityEmergingGrowthCompany" id="ixv-188"><span class="GrepStyle" style="font-family:'Wingdings 24', sans-serif;font-size:9pt;">&#9744;</span></ix:nonNumeric></p>	</td>	</tr>	</table>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:4pt;margin-top:4pt;"><span class="CharOverride-6" style="font-size:9pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;7(a)(2)(B)&#160;of the Securities Act. </span><span class="GrepStyle" style="font-family:'Wingdings 24', sans-serif;font-size:9pt;">&#9744;</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:2pt;margin-top:2pt;"><span class="CharOverride-6" style="font-size:9pt;">If applicable, place an&#160;X in the box to designate the appropriate rule provision relied upon in conducting this transaction:</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:2pt;margin-top:2pt;"><span class="CharOverride-6" style="font-size:9pt;">Exchange&#160;Act Rule&#160;13e-4(i)&#160;(Cross-Border Issuer Tender Offer) </span><span class="GrepStyle" style="font-family:'Wingdings 24', sans-serif;font-size:9pt;">&#9744;</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:2pt;margin-top:2pt;"><span class="CharOverride-6" style="font-size:9pt;">Exchange&#160;Act Rule&#160;14d-1(d)&#160;(Cross-Border Third-Party Tender Offer) </span><span class="GrepStyle" style="font-family:'Wingdings 24', sans-serif;font-size:9pt;">&#9744;</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:2pt;margin-top:2pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:9pt;">The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section&#160;8(a)&#160;of the Securities Act&#160;of&#160;1933, as amended, or until the registration statement shall become&#160;effective on such date as the Securities and Exchange Commission, acting pursuant to said Section&#160;8(a), may determine.</span></p>
		<div style="border: none; border-bottom: double windowtext 6.0pt; padding: 0in 0in 4.0pt 0in; margin-left: 0in; margin-right: 0.0pt;"></div>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">&#160;</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>





	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;text-align:justify;margin-top:8pt;"><span class="CharOverride-7" style="color:#d2232a;">The information in this preliminary proxy statement/prospectus is not complete and may be changed. ARCA biopharma, Inc. may not sell the securities described in this preliminary proxy statement/prospectus until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary proxy statement/prospectus is not an offer to sell and it is not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted.</span></p>
		</div>
	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-align:center;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;color:#d2232a;">PRELIMINARY PROXY STATEMENT/PROSPECTUS <br/>SUBJECT TO COMPLETION, DATED JULY</span><span class="nobreak"><span class="Bold" style="font-style:normal;font-weight:bold;color:#d2232a;"> </span></span><span class="Bold" style="font-style:normal;font-weight:bold;color:#d2232a;">9, 2024</span></p>
		<table class="Basic-Table _idGenTablePara-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="Basic-Table _idGenTableRowColumn-19" style="height:12pt;">
					<td class="Basic-Table CellOverride-11" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;vertical-align:bottom;width: 11.54%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="Basic-Table CellOverride-12" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:bottom;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="Basic-Table CellOverride-12" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:bottom;width: 35.90%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Basic-Paragraph" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;"><img alt="" src="tarca_001.jpg" style="width:206.08px;max-width:100%;"/></p>
					</td>
					<td class="Basic-Table CellOverride-12" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:bottom;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="Basic-Table CellOverride-12" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:bottom;width: 35.90%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Basic-Paragraph" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;"><img alt="" src="toruka_logo.jpg" style="width:107.52px;max-width:100%;"/></p>
					</td>
					<td class="Basic-Table CellOverride-12" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:bottom;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="Basic-Table CellOverride-12" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:bottom;width: 12.82%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>

		</table>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-align:center;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">PROPOSED MERGER<br/>YOUR VOTE IS VERY IMPORTANT</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:0pt;text-align:center;margin-top:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">_______________________________</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:7pt;margin-top:7pt;">To the Stockholders of ARCA biopharma, Inc. and Oruka Therapeutics, Inc.,</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">ARCA biopharma, Inc., a Delaware corporation (&#8220;ARCA&#8221;), and Oruka Therapeutics, Inc., a Delaware corporation (&#8220;Oruka&#8221;), entered into an Agreement and Plan of Merger and Reorganization (the &#8220;Merger Agreement&#8221;) on April&#160;3, 2024, pursuant to which, among other matters, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Atlas Merger Sub Corp, a Delaware corporation (&#8220;First Merger Sub&#8221;), will merge with and into Oruka, with Oruka continuing as a wholly owned subsidiary of ARCA and the surviving corporation of the merger (the &#8220;First Merger&#8221;), and Oruka will merge with and into Atlas Merger Sub&#160;II, LLC, a Delaware limited liability company (&#8220;Second Merger Sub&#8221; and together with First Merger Sub, &#8220;Merger Subs&#8221;), with Second Merger Sub being the surviving entity of the merger (the &#8220;Second Merger&#8221; and, together with the First Merger, the &#8220;Merger&#8221;). After the completion of the Merger, Second Merger Sub will change its corporate name to &#8220;Oruka Therapeutics Operating Company, LLC&#8221; and ARCA will change its name to &#8220;Oruka Therapeutics, Inc.&#8221; The term &#8220;combined company&#8221; when used in the following proxy statement/prospectus refers to the post<span class="nobreak">-Merger</span> corporate structure including Oruka Therapeutics, Inc. (f/k/a ARCA biopharma, Inc.) as the parent entity and Oruka Therapeutics Operating Company, LLC as its wholly<span class="nobreak">-owned</span> subsidiary.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">At the closing of the First Merger (the &#8220;First Effective Time&#8221;), upon the terms and subject to the conditions set forth in the Merger Agreement, (i)&#160;each then<span class="nobreak">-outstanding</span> share of Oruka common stock (including shares of Oruka common stock issued in the Oruka pre<span class="nobreak">-closing</span> financing) (as defined below) and excluding shares to be canceled pursuant to the Merger Agreement and excluding dissenting shares) will be automatically converted solely into the right to receive a number of shares of ARCA common stock equal to the exchange ratio (described in more detail in the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">The Merger Agreement&#160;&#8212;&#160;Exchange Ratio</span>&#8221; beginning on page&#160;136 of the accompanying proxy statement/prospectus), (ii)&#160;each then<span class="nobreak">-outstanding</span> share of Oruka preferred stock will be converted into the right to receive a number of shares of ARCA Series&#160;B non<span class="nobreak">-voting</span> convertible preferred stock, par value $0.001 per share (&#8220;ARCA Series&#160;B Preferred Stock&#8221;), which are each convertible into 1,000<span class="nobreak"> </span>shares of ARCA common stock, equal to the exchange ratio divided by 1,000, (iii)&#160;each then<span class="nobreak">-outstanding</span> option to purchase Oruka common stock will be assumed by ARCA, subject to adjustment as set forth in the Merger Agreement and described in more detail in the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">The Merger Agreement&#160;&#8212;&#160;Oruka Options</span>&#8221; beginning on page 139 of the accompanying proxy statement/prospectus, (iv)&#160;each then<span class="nobreak">-outstanding</span> warrant to purchase shares of Oruka common stock will be converted into a warrant to purchase shares of ARCA common stock, subject to adjustment as set forth in the Merger Agreement and described in more detail in the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">The Merger Agreement&#160;&#8212;&#160;Oruka Warrants</span>&#8221; beginning on page 139 of the accompanying proxy statement/prospectus, (v)&#160;each in<span class="nobreak">-the-money</span> option to acquire shares of ARCA&#8217;s common stock that is issued and outstanding (whether vested or unvested) will be cancelled and converted into the right to receive an amount in cash equal to the excess (if any) of the volume weighted average closing price of ARCA&#8217;s common stock for the five consecutive&#160;trading days ending three (3)&#160;trading days prior to the closing of the First Merger (the &#8220;Parent Closing Price&#8221;) over the option&#8217;s exercise price and (vi)&#160;each share of ARCA common stock that is issued and outstanding at the First Effective Time will remain issued and outstanding in accordance with its terms and such shares, subject to the proposed reverse stock split, and will be unaffected by the Merger.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">Based on ARCA&#8217;s and Oruka&#8217;s capitalization as of April&#160;3, 2024 (the date the Merger Agreement was executed) and taking into account ARCA&#8217;s current cash position, each share of Oruka capital stock is currently estimated to be entitled to receive approximately 7.4631<span class="nobreak"> </span>shares of ARCA common stock. This estimated exchange ratio does not give effect to the </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">&#160;</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>


	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;text-indent:0pt;margin-top:7pt;">proposed ARCA reverse stock split and is subject to adjustment based on ARCA&#8217;s estimated net cash at the closing of the First Merger as described in more detail in the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">The Merger Agreement&#160;&#8212;&#160;Exchange Ratio</span>&#8221; beginning on page 136 of the accompanying proxy statement/prospectus.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, prior to the First Effective Time, ARCA&#8217;s board of directors expects to declare a special cash dividend (the &#8220;special cash dividend&#8221;) to stockholders of record of outstanding shares of ARCA common stock as of a record date prior to the First Effective Time, to be set by ARCA&#8217;s board of directors as close as reasonably practicable to (but not later than) the First Effective Time. The ex<span class="nobreak">-dividend</span> date in respect of such special cash dividend will be determined by The Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;). ARCA stockholders of record who continue to hold their eligible shares of ARCA common stock until market open on the ex<span class="nobreak">-dividend</span> date will be entitled to payment of the special cash dividend. The special cash dividend will be equal in the aggregate to ARCA&#8217;s reasonable, good faith approximation of the amount by which ARCA&#8217;s net cash (as determined pursuant to the Merger Agreement) is expected to exceed $5.0&#160;million. ARCA currently estimates that the aggregate amount of cash to be distributed to stockholders of record as of the record date of the special cash dividend will be approximately $20.0<span class="nobreak"> </span>million.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On April&#160;3, 2024, concurrently with the execution and delivery of the Merger Agreement, Oruka entered into a subscription agreement (the &#8220;Subscription Agreement&#8221;) with certain investors to purchase shares of Oruka common stock and Oruka pre<span class="nobreak">-funded</span>&#160;warrants for an aggregate purchase price of approximately $275.0&#160;million (which includes $25.0<span class="nobreak"> </span>million of proceeds previously received from the issuance of the Convertible Note and accrued interest on such note), referred to herein as the &#8220;Oruka pre<span class="nobreak">-closing</span>&#160;financing,&#8221; immediately prior to the closing of the Merger. The shares of Oruka common stock and Oruka pre<span class="nobreak">-funded</span>&#160;warrants that are issued in the Oruka pre<span class="nobreak">-closing</span>&#160;financing will be converted into the right to receive a number of shares of ARCA common stock and warrants to purchase shares of ARCA common stock, respectively, equal to the exchange ratio described in more detail in the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">The Merger Agreement&#160;&#8212;&#160;Exchange Ratio</span>&#8221; beginning on page&#160;136 of the accompanying proxy statement/prospectus. ARCA, Oruka and the investors participating in the Oruka pre<span class="nobreak">-closing</span> financing have also agreed to enter into a registration rights agreement (the &#8220;registration rights agreement&#8221;) at the closing of the Oruka pre<span class="nobreak">-closing</span> financing, pursuant to which, among other things, the combined company will agree to provide for the registration and resale of certain shares of ARCA common stock that are held by the investors participating in the Oruka pre<span class="nobreak">-closing</span> financing from time to time pursuant to Rule&#160;415 under the Securities Act (&#8220;Rule&#160;415&#8221;). The Oruka pre<span class="nobreak">-closing</span> financing is more fully described in the sections titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Agreements Related to the Merger&#160;&#8212;&#160;Subscription Agreement</span>&#8221; and &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Agreements Related to the Merger&#160;&#8212;&#160;Registration Rights Agreement</span>&#8221; beginning on page 153 and 155, respectively, of the accompanying proxy statement/prospectus.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Immediately after the Merger, based solely on the estimated exchange ratio as described in the accompanying proxy statement/prospectus, ARCA securityholders as of immediately prior to the Merger are expected to own approximately 2.39% of the outstanding shares of capital stock of the combined company (on a fully diluted basis), and former holders of Oruka securities (including those issued in the Oruka pre<span class="nobreak">-closing</span> financing) are expected to own approximately 97.61% of the outstanding shares of capital stock of the combined company (on a fully diluted basis), subject to certain assumptions, including, but not limited to, ARCA&#8217;s net cash as of closing being equal to $5.0&#160;million. Under certain circumstances described in more detail in the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">The Merger Agreement&#160;&#8212;&#160;Exchange Ratio</span>&#8221; beginning on page 136 of the accompanying proxy statement/prospectus, the ownership percentages may be adjusted up or down including, but not limited to, if ARCA&#8217;s net cash as of closing is less than $5.0&#160;million. ARCA currently estimates that its net cash as of closing will be approximately $5.0&#160;million, after giving effect to the special cash dividend, which is expected to be approximately $20.0<span class="nobreak"> </span>million, and the currently estimated ownership percentages reflect this projection.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Shares of ARCA common stock are currently listed on Nasdaq under the symbol &#8220;ABIO.&#8221; ARCA intends to file an initial listing application for the combined company with Nasdaq. After completion of the Merger, ARCA will be renamed &#8220;Oruka Therapeutics, Inc.&#8221; and it is expected that the common stock of the combined company will trade on Nasdaq under the symbol &#8220;ORKA.&#8221; It is a condition to the consummation of the Merger that ARCA will receive confirmation from Nasdaq that the combined company has been approved for listing on Nasdaq, but there can be no assurance such listing condition will be met or that ARCA will obtain such confirmation from Nasdaq. If such listing condition is not met or if such confirmation is not obtained, the Merger will not be consummated unless the condition is waived. The Nasdaq condition set forth in the Merger Agreement is not expected to be waived by the applicable parties. On &#160;<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>, 2024, the last&#160;trading day before the date of the accompanying proxy statement/prospectus, the closing sale price of ARCA common stock was $<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span> per share.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">&#160;</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>


	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA stockholders are cordially invited to attend the special meeting in lieu of the annual meeting of ARCA stockholders. ARCA is holding its special meeting in lieu of the annual meeting of stockholders (the &#8220;ARCA special meeting&#8221;) on<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span><span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>, at&#160;&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Mountain Time, unless postponed or adjourned to a later date, in order to obtain the stockholder approvals necessary to complete the Merger and related matters. At the ARCA special meeting, ARCA will ask its stockholders to:</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">1.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Approve (i)&#160;the issuance of shares of ARCA common stock (including the shares of ARCA common stock issuable upon conversion of ARCA Series&#160;B Preferred Stock), which will represent more than 20% of the shares of ARCA common stock outstanding immediately prior to the Merger, to stockholders of Oruka, pursuant to the terms of the Merger Agreement, a copy of which is attached as <span class="Italic" style="font-style:italic;font-weight:normal;">Annex&#160;A</span> to the accompanying proxy statement/prospectus, and (ii)&#160;the change of control of ARCA resulting from the Merger, pursuant to Nasdaq Listing Rules 5635(a)&#160;and 5635(b), respectively (the &#8220;Nasdaq Stock Issuance Proposal&#8221; or &#8220;Proposal&#160;No. 1&#8221;);</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">2.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Approve an amendment to the amended and restated certificate of incorporation of ARCA (the &#8220;ARCA Charter&#8221;) to increase the number of shares of ARCA common stock that ARCA is authorized to issue from 100,000,000<span class="nobreak"> </span>shares to&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, in the form attached as <span class="Italic" style="font-style:italic;font-weight:normal;">Annex&#160;G</span> to the accompanying proxy statement/prospectus (the &#8220;Authorized Share Increase Proposal&#8221; or &#8220;Proposal&#160;No. 2&#8221;);</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">3.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Approve an amendment to the ARCA Charter to effect a reverse stock split of ARCA&#8217;s issued and outstanding common stock at a ratio in the range between 1:&#160;&#160;&#160;&#160;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>to 1:&#160;&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>, inclusive, in the form attached as <span class="Italic" style="font-style:italic;font-weight:normal;">Annex&#160;H </span>to the accompanying proxy statement/prospectus, if deemed necessary by ARCA and Oruka, with the final ratio and effectiveness of such amendment and the abandonment of such amendment to be mutually agreed by ARCA&#8217;s board of directors and Oruka&#8217;s board of directors prior to the First Effective Time or, if the Nasdaq Stock Issuance Proposal is not approved by ARCA stockholders, determined solely by ARCA&#8217;s board of directors (the &#8220;Reverse Stock Split Proposal&#8221; or &#8220;Proposal&#160;No. 3&#8221;);</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">4.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Approve an amendment to the ARCA Charter to reflect Delaware law provisions regarding officer exculpation, in the form attached as <span class="Italic" style="font-style:italic;font-weight:normal;">Annex&#160;I</span> (the &#8220;Officer Exculpation Proposal&#8221; or &#8220;Proposal&#160;No. 4&#8221;);</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">5.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Elect the Class&#160;III director, Jacob Ma<span class="nobreak">-Weaver</span>, to ARCA&#8217;s board of directors and to hold office until ARCA&#8217;s 2027 annual meeting of stockholders and until his successor has been duly elected and qualified, or until his earlier death, resignation or removal (the &#8220;Director Election Proposal&#8221; or &#8220;Proposal&#160;No. 5&#8221;), provided that if the Merger is consummated, the approval of Proposal&#160;No. 5 will only have an effect until the completion of the Merger because the composition of ARCA&#8217;s board of directors will be reconstituted upon completion of the Merger, in accordance with the Merger Agreement;</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">6.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Ratify the appointment of KPMG LLP as ARCA&#8217;s independent registered public accounting firm for fiscal year ending December&#160;31, 2024, provided that PricewaterhouseCoopers LLP is expected to be appointed for that fiscal year if the Merger is completed (the &#8220;Auditor Ratification Proposal&#8221; or &#8220;Proposal&#160;No. 6&#8221;);</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">7.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Approve the Oruka Therapeutics, Inc. 2024 Stock Incentive Plan (the &#8220;Stock Plan Proposal&#8221; or &#8220;Proposal&#160;No. 7&#8221;);</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">8.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Approve the Oruka Therapeutics, Inc. 2024 Employee Stock Purchase Plan (the &#8220;ESPP Proposal&#8221; or &#8220;Proposal&#160;No. 8&#8221;);</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">9.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Approve, on an advisory basis, certain compensation arrangements for ARCA named executive officers that are based on or otherwise relate to the Merger (the &#8220;the Merger Compensation Proposal&#8221; or &#8220;Proposal&#160;No. 9&#8221;);</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">10.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Approve an adjournment of the ARCA special meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of the Nasdaq Stock Issuance Proposal, the Authorized Share Increase Proposal and/or the Reverse Stock Split Proposal (the &#8220;Adjournment Proposal&#8221; or &#8220;Proposal&#160;No. 10&#8221;); and</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">11.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Transact such other business as may properly come before the stockholders at the ARCA special meeting or any adjournment or postponement thereof.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">&#160;</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>


	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As described in the accompanying proxy statement/prospectus, certain ARCA stockholders who in the aggregate owned approximately 28.5% of the outstanding shares of ARCA capital stock as of May<span class="nobreak"> </span>3, 2024, and certain Oruka stockholders who in the aggregate owned approximately 90% of the outstanding shares of Oruka capital stock as of May&#160;3, 2024, are parties to stockholder support agreements with ARCA and Oruka, respectively, whereby such stockholders have agreed to vote in favor of the adoption of the Merger Agreement and the approval of the Merger and related transactions contemplated by the Merger Agreement, subject to the terms of the support agreements. Following the effectiveness of the registration statement on Form&#160;S<span class="nobreak">-4</span> of which the accompanying proxy statement/prospectus is a part and pursuant to the Merger Agreement, Oruka stockholders holding a sufficient number of shares of Oruka capital stock to adopt the Merger Agreement and approve the Merger and related transactions will be asked to execute written consents providing for such adoption and approval.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">While the combined company will not be considered a &#8220;controlled company&#8221; under the relevant listing rules of Nasdaq, it is anticipated that the combined company&#8217;s executive officers, directors and principal stockholders will, in the aggregate, beneficially own approximately <span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>% of the combined company&#8217;s outstanding shares of common stock (on a fully<span class="nobreak">-diluted</span> basis). As a result, if these stockholders were to choose to act together, they would be able to control or significantly influence all matters submitted to the combined company&#8217;s stockholders for approval, as well as the combined company&#8217;s management and affairs, though they have no agreement to do so or any expectation of entering into such an agreement.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">After careful consideration, each of ARCA&#8217;s and Oruka&#8217;s boards of directors have approved the Merger Agreement and have determined that it is advisable to consummate the Merger. ARCA&#8217;s board of directors has approved the proposals described in the accompanying proxy statement/prospectus and recommends that its stockholders vote &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">FOR</span>&#8221; the proposals described in the accompanying proxy statement/prospectus.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">More information about ARCA, Oruka, the Merger Agreement and transactions contemplated thereby and the foregoing proposals is contained in the accompanying proxy statement/prospectus. ARCA urges you to read the accompanying proxy statement/prospectus carefully and in its entirety. IN PARTICULAR, YOU SHOULD CAREFULLY CONSIDER THE MATTERS DISCUSSED UNDER &#8220;RISK FACTORS&#8221; BEGINNING ON PAGE 15 OF THE ACCOMPANYING PROXY STATEMENT/PROSPECTUS.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA and Oruka are excited about the opportunities the Merger brings to ARCA&#8217;s and Oruka&#8217;s stockholders and thank you for your consideration and continued support.</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-22" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 59.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">



						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Thomas A.&#160;Keuer</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 39.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Lawrence Klein</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 59.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Italic" style="font-style:italic;font-weight:normal;">President and Chief Operating Officer</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 39.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="Italic" style="font-style:italic;font-weight:normal;">Chief Executive Officer</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 59.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">ARCA biopharma, Inc.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 39.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Oruka Therapeutics, Inc.</p>
					</td>
				</tr>

		</table>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of the accompanying proxy&#160;statement/prospectus. Any representation to the contrary is a criminal offense.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">The accompanying proxy statement/prospectus is dated&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2024, and is first being mailed to ARCA&#8217;s stockholders on or about&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2024.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">&#160;</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>


	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA BIOPHARMA, INC.<br/>10170 Church Ranch Way, Suite 100<br/>Westminster, CO&#160;80021</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">NOTICE OF SPECIAL MEETING OF STOCKHOLDERS IN LIEU OF ANNUAL MEETING OF STOCKHOLDERS</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">To the stockholders of ARCA biopharma, Inc.:</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">NOTICE IS HEREBY GIVEN</span> that a special meeting in lieu of annual meeting of stockholders (the &#8220;ARCA special meeting&#8221;) will be held on&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;at&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;a.m. Mountain Time, unless postponed or adjourned to a later date. The ARCA special meeting will be held in person at the&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">The ARCA special meeting will be held for the following purposes:</span></p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">1.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>To approve (i)&#160;the issuance of shares of ARCA common stock (including the shares of ARCA common stock issuable upon conversion of ARCA Series&#160;B Preferred Stock), which will represent more than 20% of the shares of ARCA common stock outstanding immediately prior to the Merger, to stockholders of Oruka, pursuant to the terms of the Merger Agreement, a copy of which is attached as <span class="Italic" style="font-style:italic;font-weight:normal;">Annex&#160;A</span> to the accompanying proxy statement/prospectus, and (ii)&#160;the change of control of ARCA resulting from the Merger, pursuant to Nasdaq Listing Rules 5635(a)&#160;and 5635(b), respectively;</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">2.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>To approve an amendment to the amended and restated certificate of incorporation of ARCA (the &#8220;ARCA Charter&#8221;) to increase the number of shares of ARCA common stock that ARCA is authorized from 100,000,000 to issue to&#160;&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>, in the form attached as <span class="Italic" style="font-style:italic;font-weight:normal;">Annex&#160;G</span> to the accompanying proxy statement/prospectus;</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">3.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>To approve an amendment to the ARCA Charter to effect a reverse stock split of ARCA&#8217;s issued and outstanding common stock at a ratio in the range between 1:&#160;&#160;&#160;&#160;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>to 1:&#160;&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>, inclusive, in the form attached as <span class="Italic" style="font-style:italic;font-weight:normal;">Annex&#160;H </span>to the accompanying proxy statement/prospectus, if deemed necessary by ARCA and Oruka, with the final ratio and effectiveness of such amendment and the abandonment of such amendment to be mutually agreed by ARCA&#8217;s board of directors and Oruka&#8217;s board of directors prior to the First Effective Time or, if the Nasdaq Stock Issuance Proposal is not approved by ARCA stockholders, determined solely by ARCA&#8217;s board of directors;</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">4.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>To approve an amendment to the ARCA Charter to reflect Delaware law provisions regarding officer exculpation, in the form attached as <span class="Italic" style="font-style:italic;font-weight:normal;">Annex&#160;I </span>to the accompanying proxy statement/prospectus;</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">5.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>To elect the Class&#160;III director, Jacob Ma<span class="nobreak">-Weaver</span>, to ARCA&#8217;s board of directors and to hold office until ARCA&#8217;s 2027 annual meeting of stockholders and until his successor has been duly elected and qualified, or until his earlier death, resignation or removal, provided that if the Merger is consummated, the approval of Proposal&#160;No. 5 will only have an effect until the completion of the Merger because the composition of ARCA&#8217;s board of directors will be reconstituted upon completion of the Merger, in accordance with the Merger Agreement;</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">6.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>To ratify the appointment of KPMG LLP as ARCA&#8217;s independent registered public accounting firm for fiscal year ending December&#160;31, 2024, provided that PricewaterhouseCoopers LLP is expected to be appointed for that fiscal year if the Merger is completed;</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">7.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>To approve the Oruka Therapeutics, Inc. 2024 Stock Incentive Plan;</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">8.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>To approve the Oruka Therapeutics, Inc. 2024 Employee Stock Purchase Plan;</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">9.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>To approve, on an advisory basis, certain compensation arrangements for ARCA named executive officers that are based on or otherwise relate to the Merger;</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">&#160;</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>


	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">10.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>To approve an adjournment of the ARCA special meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of the Nasdaq Stock Issuance Proposal, the Authorized Share Increase Proposal and/or the Reverse Stock Split Proposal; and</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">11.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>To transact such other business as may properly come before the stockholders at the ARCA special meeting or any adjournment or postponement thereof.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">These proposals are collectively referred to as the &#8220;Proposals.&#8221;</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s board of directors has fixed<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span><span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>, 2024 as the record date (the &#8220;Record Date&#8221;) for the determination of stockholders entitled to notice of, and to vote at, the ARCA special meeting and any adjournment or postponement thereof. Only holders of record of shares of ARCA common stock at the close of business on the Record Date are entitled to notice of, and to vote at, the ARCA special meeting. At the close of business on the Record Date, ARCA had&#160;&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>shares of common stock outstanding and entitled to vote.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Your vote is important. The affirmative vote of a majority of the shares of ARCA common stock entitled to vote on the subject matter and present at the ARCA special meeting, assuming a quorum is present, is required for approval of Proposal&#160;No.</span><span class="nobreak"><span class="Bold" style="font-style:normal;font-weight:bold;"> </span></span><span class="Bold" style="font-style:normal;font-weight:bold;">1, Proposal&#160;No.</span><span class="nobreak"><span class="Bold" style="font-style:normal;font-weight:bold;"> </span></span><span class="Bold" style="font-style:normal;font-weight:bold;">6, Proposal&#160;No.</span><span class="nobreak"><span class="Bold" style="font-style:normal;font-weight:bold;"> </span></span><span class="Bold" style="font-style:normal;font-weight:bold;">7, Proposal&#160;No.</span><span class="nobreak"><span class="Bold" style="font-style:normal;font-weight:bold;"> </span></span><span class="Bold" style="font-style:normal;font-weight:bold;">8, Proposal&#160;No. 9 and Proposal&#160;No. 10. The affirmative vote of a majority of the votes properly cast by the holders of ARCA common stock at the ARCA special meeting, assuming a quorum is present, is required for approval of Proposal&#160;No. 2 and Proposal&#160;No. 3. The affirmative vote of a majority of the outstanding shares of ARCA common stock is required for approval of Proposal&#160;No. 4. With respect to Proposal&#160;No.</span><span class="nobreak"><span class="Bold" style="font-style:normal;font-weight:bold;"> </span></span><span class="Bold" style="font-style:normal;font-weight:bold;">5, the director is elected by a plurality of the votes properly cast at the ARCA special meeting, and the one nominee for director receiving the highest number of affirmative votes properly cast will be elected. Proposal&#160;No. 1 is conditioned on the approval of Proposal&#160;No. 2. Notwithstanding the approval of Proposal&#160;No.</span><span class="nobreak"><span class="Bold" style="font-style:normal;font-weight:bold;"> </span></span><span class="Bold" style="font-style:normal;font-weight:bold;">1, if Proposal&#160;No. 2 is not approved, the actions contemplated by Proposal&#160;No. 1 will not be effected and the Merger will not be consummated.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">All stockholders are cordially invited to attend the special meeting in person. Even if you plan to attend the ARCA special meeting, ARCA requests that you sign and return the enclosed proxy or vote by mail or online to ensure that your shares will be represented at the ARCA special meeting if you are unable to attend. You may change or revoke your proxy at any time before it is voted at the ARCA special meeting.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA&#8217;S BOARD OF DIRECTORS HAS DETERMINED AND BELIEVES THAT EACH OF THE PROPOSALS OUTLINED ABOVE IS FAIR TO, IN THE BEST INTERESTS OF, AND ADVISABLE TO ARCA AND ITS STOCKHOLDERS AND HAS APPROVED EACH SUCH PROPOSAL.&#160;ARCA&#8217;S BOARD OF DIRECTORS RECOMMENDS THAT ARCA STOCKHOLDERS VOTE &#8220;FOR&#8221; EACH SUCH PROPOSAL.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Important Notice Regarding the Availability of Proxy Materials for the Stockholders&#8217; Meeting to Be Held on<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span><span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>, 2024 at&#160;&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Mountain Time</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The proxy statement/prospectus and annual report to stockholders are available at <span class="Italic" style="font-style:italic;font-weight:normal;">www.arcabio.com.</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">By Order of ARCA&#8217;s Board of Directors,</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Thomas A.&#160;Keuer</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">President and Chief Operating Officer</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">&#160;&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>, 2024</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">&#160;</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>


	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">EXPLANATORY NOTE</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><ix:nonNumeric contextRef="c0" name="dei:AmendmentDescription" id="ixv-458">The issuances of (i)&#160;all shares of ARCA common stock in exchange for each share of Oruka common stock (including shares of Oruka common stock issued in the Oruka pre<span class="nobreak">-closing</span> financing), (ii)&#160;all shares of ARCA common stock issuable upon exercise of pre<span class="nobreak">-funded</span> warrants issued in exchange for pre<span class="nobreak">-funded</span> warrants to purchase shares of Oruka common stock sold in the Oruka pre<span class="nobreak">-closing</span> financing, and (iii)&#160;all shares of ARCA common stock issuable upon conversion of ARCA Series&#160;B Preferred Stock issued in exchange for each share of Oruka preferred stock, are intended to be covered by this registration statement on Form&#160;S<span class="nobreak">-4</span> of which the accompanying proxy statement/prospectus is a part. There is no difference between the shares of ARCA common stock that will be issued in exchange for each share of Oruka common stock issued in the pre<span class="nobreak">-closing</span> financing, the shares of ARCA common stock that will be issued in exchange for each other share of Oruka common stock, the shares of ARCA common stock that will be issuable upon the exercise of pre<span class="nobreak">-funded</span> warrants that will be issued in exchange for pre<span class="nobreak">-funded</span> warrants to purchase shares of Oruka common stock sold in the pre<span class="nobreak">-closing</span> financing and the shares of ARCA common stock that will be issuable upon conversion of ARCA Series&#160;B Preferred Stock that will be issued in exchange for each share of Oruka preferred stock.</ix:nonNumeric></p>
		<p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">REFERENCES TO ADDITIONAL INFORMATION</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The accompanying proxy statement/prospectus incorporates important business and financial information about ARCA biopharma, Inc. that is not included in or delivered with this document. You may obtain this information without charge through the Securities and Exchange Commission (&#8220;SEC&#8221;) website (<span class="Italic" style="font-style:italic;font-weight:normal;">www.sec.gov</span>) or upon your written or oral request by contacting 10170 Church Ranch Way, Suite 100, Westminster, Colorado, Attention: Corporate Secretary, or by calling (720)&#160;940<span class="nobreak">-2100</span>. ARCA also maintains a website at <span class="Italic" style="font-style:italic;font-weight:normal;">https://arcabio.com/</span>, at which you may access these materials free of charge as soon as reasonably practicable after they are electronically filed with, or furnished to, the SEC.&#160;However, the information contained in or accessible through ARCA&#8217;s website is not part of the accompanying proxy statement/prospectus or the registration statement of which the accompanying proxy statement/prospectus forms a part.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">To ensure timely delivery of these documents, any request should be made no later than<span style="width: 10px;display: inline-block;">&#160;&#160;&#160;</span><span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>, 2024 to receive them before the ARCA special meeting.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">For additional details about where you can find information about ARCA, please see the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Where You Can Find More Information</span>&#8221; beginning on page 320 of the accompanying proxy statement/prospectus.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">&#160;</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="TOC001"></a><p class="H1_TOC" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">TABLE OF CONTENTS</span></p>
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;font-variant:normal;">Page</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T27"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">QUESTIONS AND ANSWERS ABOUT THE MERGER</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">iii</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T26"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">PROSPECTUS SUMMARY</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">1</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T25"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">MARKET PRICE AND DIVIDEND INFORMATION</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">14</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T24"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">RISK FACTORS</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">15</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T23"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">88</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T22"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">THE SPECIAL MEETING IN LIEU OF ANNUAL MEETING OF ARCA STOCKHOLDERS</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">91</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T991188"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">THE MERGER</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">96</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T21"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">THE MERGER AGREEMENT</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">135</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T20"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">AGREEMENTS RELATED TO THE MERGER</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">153</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T19"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">ARCA DIRECTORS, OFFICERS AND CORPORATE GOVERNANCE</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">156</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T18"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">ADDITIONAL INFORMATION REGARDING THE BOARD OF DIRECTORS AND CORPORATE GOVERNANCE</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">159</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T17"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">ARCA EXECUTIVE COMPENSATION</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">166</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T16"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">ARCA EQUITY COMPENSATION PLAN INFORMATION</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">172</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T15"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">ORUKA EXECUTIVE COMPENSATION</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">173</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T14"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">ORUKA DIRECTOR COMPENSATION</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">175</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T9980"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">MATTERS BEING SUBMITTED TO A VOTE OF ARCA STOCKHOLDERS</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">176</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T9981"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">PROPOSAL NO. 1 &#8212; THE NASDAQ STOCK ISSUANCE PROPOSAL</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">176</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T9982"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">PROPOSAL NO. 2 &#8212; THE AUTHORIZED SHARE INCREASE PROPOSAL</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">178</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T9983"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">PROPOSAL NO. 3 &#8212; THE REVERSE STOCK SPLIT PROPOSAL</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">180</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T9984"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">PROPOSAL NO. 4 &#8212; THE OFFICER EXCULPATION PROPOSAL</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">187</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T9985"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">PROPOSAL NO. 5 &#8212; THE DIRECTOR ELECTION PROPOSAL</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">189</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T9986"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">PROPOSAL NO. 6 &#8212; THE AUDITOR RATIFICATION PROPOSAL</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">190</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T9992"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">PROPOSAL NO. 7 &#8212; THE STOCK PLAN PROPOSAL</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">191</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T9993"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">PROPOSAL NO. 8 &#8212; THE ESPP PROPOSAL</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">194</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T9994"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">PROPOSAL NO. 9 &#8212; THE MERGER COMPENSATION PROPOSAL</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">196</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T9987"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">PROPOSAL NO. 10 &#8212; THE ADJOURNMENT PROPOSAL</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">197</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T13"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">ARCA&#8217;S BUSINESS</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">198</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T12"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">ORUKA&#8217;S BUSINESS</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">214</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T9988"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">ARCA&#8217;S MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">250</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T11"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">ORUKA&#8217;S MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">261</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T10"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">MANAGEMENT FOLLOWING THE MERGER</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">273</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T9989"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS OF THE COMBINED COMPANY</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">280</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T9"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">284</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T9990"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">NOTES TO THE UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">289</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T8"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">DESCRIPTION OF ARCA CAPITAL STOCK</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">296</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T7"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">COMPARISON OF RIGHTS OF HOLDERS OF ARCA CAPITAL STOCK AND ORUKA CAPITAL STOCK</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">301</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T6"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">PRINCIPAL STOCKHOLDERS OF ARCA</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">312</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T5"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">PRINCIPAL STOCKHOLDERS OF ORUKA</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">315</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T4"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">PRINCIPAL STOCKHOLDERS OF THE COMBINED COMPANY</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">317</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T3"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">LEGAL MATTERS</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">319</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T2"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">EXPERTS</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">319</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T1"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">WHERE YOU CAN FIND MORE INFORMATION</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">320</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T9991"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">STOCKHOLDER PROPOSALS OR DIRECTOR NOMINATIONS FOR 2025 ANNUAL MEETING</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">321</span></p>
					</td>
				</tr>

		</table>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">i</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;font-variant:normal;">Page</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T111">INDEX TO FINANCIAL STATEMENTS</a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">F-1</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T100"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">Annex&#160;A AGREEMENT AND PLAN OF MERGER AND REORGANIZATION</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">A-1</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T101"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">Annex&#160;B OPINION OF LUCID CAPITAL MARKETS</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">B-1</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T102"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">Annex&#160;C FORM OF COMPANY STOCKHOLDER SUPPORT AGREEMENT</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">C-1</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T103"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">Annex&#160;D FORM OF ARCA STOCKHOLDER SUPPORT AGREEMENT</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">D-1</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T104"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">Annex&#160;E FORM OF LOCK-UP AGREEMENT</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">E-1</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T105"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">Annex&#160;F CERTIFICATE OF DESIGNATION OF SERIES B NON-VOTING CONVERTIBLE PREFERRED STOCK</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">F-1</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T106"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">Annex&#160;G CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE&#160;OF INCORPORATION OF ARCA BIOPHARMA, INC.&#160;TO REFLECT INCREASE&#160;IN AUTHORIZED SHARES</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">G-1</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T107"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">Annex&#160;H CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE&#160;OF INCORPORATION OF ARCA BIOPHARMA, INC.&#160;TO REFLECT REVERSE&#160;STOCK SPLIT</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">H-1</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T108"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">Annex&#160;I CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE&#160;OF INCORPORATION OF ARCA BIOPHARMA, INC.&#160;TO REFLECT DELAWARE&#160;LAW PROVISIONS REGARDING OFFICER EXCULPATION</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">I-1</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T109"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">Annex&#160;J Appraisal Rights (Section&#160;262 of the Delaware General Corporation&#160;Law)</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">J-1</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T110"><span class="CharOverride-2" style="font-variant:normal;text-transform:uppercase;">Annex&#160;K 2024 Oruka Therapeutics, Inc. Stock Incentive Plan</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">K-1</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T112"><span class="CharOverride-2" style="font-variant:normal;text-transform:uppercase;">Annex&#160;L 2024 Oruka Therapeutics, Inc. Employee Stock Purchase Plan</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">L-1</span></p>
					</td>
				</tr>

		</table>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;"></p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">ii</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T27"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">QUESTIONS AND ANSWERS ABOUT THE MERGER</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Except where specifically noted, the following information and all other information contained in this proxy statement/prospectus does not give effect to the proposed reverse stock split described in Proposal&#160;No.&#160;3 of this proxy statement/prospectus</span>.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">All references to Oruka&#8217;s &#8220;product candidates,&#8221; &#8220;programs,&#8221; &#8220;portfolio&#8221; and &#8220;pipeline&#8221; in this proxy statement/prospectus refer to the research programs with respect to which Oruka has the option to acquire intellectual property license rights to pursuant to those certain antibody discovery and option agreements, each dated March&#160;6, 2024 and subsequently amended and restated on March&#160;28, 2024, by and among Oruka, Paragon Therapeutics, Inc. (&#8220;Paragon&#8221;) and Paruka Holding LLC (&#8220;Paruka&#8221;) (the &#8220;Paragon Option Agreements&#8221;).</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following section provides answers to frequently asked questions about the Merger. This section, however, provides only summary information. For a more complete response to these questions and for additional information, please refer to the cross<span class="nobreak">-referenced</span> sections.</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Q:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>What is the Merger?</span></p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">A:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>On April&#160;3, 2024, ARCA, Oruka, First Merger Sub and Second Merger Sub entered into the Merger Agreement, a copy of which is attached as <span class="Italic" style="font-style:italic;font-weight:normal;">Annex&#160;A</span>.&#160;The Merger Agreement contains the terms and conditions of the proposed Merger. Pursuant to the Merger Agreement, First Merger Sub will merge with and into Oruka, with Oruka continuing as a wholly owned subsidiary of ARCA and the surviving corporation of the First Merger. Oruka will then merge with and into Second Merger Sub, with Second Merger Sub being the surviving entity of the Second Merger. This entire transaction is referred to in this proxy statement/prospectus as the Merger. In connection with the Merger, ARCA will change its corporate name to &#8220;Oruka Therapeutics, Inc.&#8221;</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-left:24pt;text-indent:0pt;margin-top:8pt;">At the First Effective Time, upon the terms and subject to the conditions set forth in the Merger Agreement, (i)&#160;each then<span class="nobreak">-outstanding</span> share of Oruka common stock (including shares of Oruka common stock issued in the Oruka pre<span class="nobreak">-closing</span> financing) (excluding shares to be canceled pursuant to the Merger Agreement and excluding dissenting shares) will be automatically converted solely into the right to receive a number of shares of ARCA common stock equal to the exchange ratio (described in more detail in the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">The Merger Agreement&#160;&#8212;&#160;Exchange Ratio</span>&#8221; beginning on page 136 of this proxy statement/prospectus), (ii)&#160;each then<span class="nobreak">-outstanding</span> share of Oruka preferred stock will be converted into the right to receive a number of shares of ARCA Series&#160;B Preferred Stock, which are each convertible into 1,000<span class="nobreak"> </span>shares of ARCA common stock, equal to the exchange ratio divided by 1,000, in accordance with the terms of the Merger Agreement, (iii)&#160;each then<span class="nobreak">-outstanding</span> option to purchase Oruka common stock will be assumed by ARCA, subject to adjustment as set forth in the Merger Agreement, and (iv)&#160;each then<span class="nobreak">-outstanding</span> warrant to purchase shares of Oruka common stock will be converted into a warrant to purchase shares of ARCA common stock, subject to adjustment as set forth in the Merger Agreement and the form of warrant.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-left:24pt;text-indent:0pt;margin-top:8pt;">Each share of ARCA common stock that is issued and outstanding at the First Effective Time will remain issued and outstanding in accordance with its terms and such shares, subject to the proposed reverse stock split, will be unaffected by the Merger. Immediately after the Merger, based solely on the estimated exchange ratio as described in this proxy statement/prospectus, ARCA securityholders as of immediately prior to the Merger are expected to own approximately 2.39% of the outstanding shares of capital stock of the combined company (on a fully<span class="nobreak">-diluted</span> basis), and former holders of Oruka securities (including those issued in the Oruka pre<span class="nobreak">-closing</span> financing) are expected to own approximately 97.61% of the outstanding shares of capital stock of the combined company (on a fully<span class="nobreak">-diluted</span> basis), subject to certain assumptions, including, but not limited to, ARCA&#8217;s net cash as of closing being equal to $5.0&#160;million. Under certain circumstances described in more detail in the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">The Merger Agreement&#160;&#8212;&#160;Exchange Ratio</span>&#8221; beginning on page 136 of this proxy statement/prospectus, the ownership percentages may be adjusted up or down including, but not limited to, if ARCA&#8217;s net cash as of closing is less than $5.0&#160;million. ARCA currently estimates that its net cash as of closing will be approximately $5.0<span class="nobreak"> </span>million, after giving effect to the special cash dividend, which is expected to be approximately $20.0<span class="nobreak"> </span>million, and the currently estimated ownership percentages reflect this projection.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-left:24pt;text-indent:0pt;margin-top:8pt;">In addition, prior to the First Effective Time, ARCA&#8217;s board of directors expects to declare the special cash dividend to stockholders of record of outstanding shares of ARCA common stock as of the record date prior to the First Effective Time, to be set by ARCA&#8217;s board of directors as close as reasonably practicable to (but not later than) the First Effective Time. The ex<span class="nobreak">-dividend</span> date in respect of such special cash dividend </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">iii</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-left:24pt;text-indent:0pt;margin-top:8pt;">will be determined by Nasdaq. ARCA stockholders of record who continue to hold their eligible shares of ARCA common stock until market open on the ex<span class="nobreak">-dividend</span> date will be entitled to payment of the special cash dividend. The special cash dividend will be equal in the aggregate to ARCA&#8217;s reasonable, good faith approximation of the amount by which ARCA&#8217;s net cash (as determined pursuant to the Merger Agreement) is expected to exceed $5.0&#160;million. ARCA currently estimates that the aggregate amount of cash to be distributed to stockholders of record as of the record date for the special cash dividend will be approximately $20.0<span class="nobreak"> </span>million.</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Q:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>Why are the two companies proposing to merge?</span></p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">A:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>ARCA and Oruka believe that combining the two companies will result in a company with a promising pipeline, a strong leadership team and substantial capital resources, focused on developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. For a more complete description of the reasons for the Merger, please see the sections titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">The Merger&#160;&#8212;&#160;ARCA&#8217;s Reasons for the Merger</span>&#8221; and &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">The Merger&#160;&#8212;&#160;Oruka&#8217;s Reasons for the Merger</span>&#8221; beginning on pages 104 and 110, respectively, of this proxy statement/prospectus.</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Q:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>What will happen to ARCA if, for any reason, the merger with Oruka does not close?</span></p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">A:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>ARCA has invested significant time and incurred, and expects to continue to incur, significant expenses related to the proposed merger with Oruka. In the event the Merger does not close, ARCA will have a limited ability to continue its current operations without obtaining additional financing. Although ARCA&#8217;s board of directors may elect, among other things, to attempt to complete another strategic transaction if the merger with Oruka does not close, ARCA&#8217;s board of directors may instead divest all or a portion of ARCA&#8217;s business or take steps necessary to liquidate or dissolve ARCA&#8217;s business and assets if a viable alternative strategic transaction is not available. If ARCA decides to dissolve and liquidate its assets, ARCA would be required to pay all of its contractual obligations, and to set aside certain reserves for potential future claims, and there can be no assurance as to the amount of and the timing of such liquidation and distribution of available cash left to distribute to stockholders after paying the obligations of ARCA and setting aside funds for reserves.</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Q:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>Why am&#160;I receiving this proxy statement/prospectus?</span></p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">A:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>You are receiving this proxy statement/prospectus because you have been identified as a stockholder of ARCA as of the applicable Record Date, and you are entitled to vote to approve the matters set forth herein. This document serves as:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>a proxy statement of ARCA used to solicit proxies for the ARCA special meeting to vote on the matters set forth herein; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>a prospectus of ARCA used to offer (i)&#160;shares of ARCA common stock issued in exchange for shares of Oruka common stock (including shares of Oruka common stock issued in the Oruka pre<span class="nobreak">-closing</span> financing), (ii)&#160;shares of ARCA common stock issuable upon exercise of pre<span class="nobreak">-funded</span> warrants issued in exchange for pre<span class="nobreak">-funded</span> warrants to purchase shares of Oruka common stock sold in the Oruka pre<span class="nobreak">-closing</span> financing, and (iii)&#160;shares of ARCA common stock issuable upon conversion of ARCA Series&#160;B Preferred Stock issued in exchange for shares of Oruka preferred stock in the Merger.</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Q:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>What is the Oruka pre</span><span class="nobreak"><span class="Bold" style="font-style:normal;font-weight:bold;">-closing</span></span><span class="Bold" style="font-style:normal;font-weight:bold;"> financing?</span></p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">A:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>On April&#160;3, 2024, concurrently with the execution and delivery of the Merger Agreement, Oruka entered into the Subscription Agreement with certain investors named therein, including, among others, Fairmount, Venrock Healthcare Capital Partners, RTW Investments, Access Biotechnology, Commodore Capital, Deep Track Capital, Perceptive Advisors, Blackstone Multi<span class="nobreak">-Asset</span> Investing, Avidity Partners, Great Point Partners LLC, Paradigm BioCapital, Braidwell LP and Redmile Group, pursuant to which such investors agreed to purchase shares of Oruka common stock and pre<span class="nobreak">-funded</span> warrants to purchase shares of Oruka common stock for an aggregate purchase price of approximately $275.0&#160;million (which includes $25.0<span class="nobreak"> </span>million of proceeds previously received from the issuance of the Convertible Note and accrued interest on such note). Shares of Oruka common stock and&#160;pre<span class="nobreak">-funded</span>&#160;warrants issued pursuant to this financing transaction will be converted into shares of ARCA common stock and&#160;pre<span class="nobreak">-funded</span>&#160;warrants to acquire shares ARCA common stock, in accordance with the exchange ratio and the Merger Agreement.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">iv</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-left:24pt;text-indent:0pt;margin-top:8pt;">Immediately after the First Merger, the shares of Oruka common stock and Oruka pre<span class="nobreak">-funded</span> warrants issued in the Oruka pre<span class="nobreak">-closing</span> financing are expected to represent approximately 58.2% of the outstanding shares of common stock of the combined company, on a fully<span class="nobreak">-diluted</span> basis. ARCA, Oruka and the investors participating in the Oruka pre<span class="nobreak">-closing</span> financing have also agreed to enter into a registration rights agreement at the closing of the Oruka pre<span class="nobreak">-closing</span> financing, pursuant to which, among other things, the combined company will agree to provide for the registration and resale of certain shares of ARCA common stock that are held by the investors participating in the Oruka pre<span class="nobreak">-closing</span> financing from time to time pursuant to Rule&#160;415. The closing of the Oruka pre<span class="nobreak">-closing</span> financing is conditioned upon the satisfaction or waiver of the conditions to the closing of the Merger as well as certain other conditions.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-left:24pt;text-indent:0pt;margin-top:8pt;">For a more complete description of the Oruka pre<span class="nobreak">-closing</span> financing, please see the sections titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Agreements Related to the Merger&#160;&#8212;&#160;Subscription Agreement</span>&#8221; and &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">&#8212;&#160;Registration Rights Agreement</span>&#8221; beginning on pages&#160;153 and 155 of this proxy statement/prospectus, respectively.</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Q:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>What proposals will be voted on at the ARCA special meeting in connection with the Merger?</span></p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">A:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>Pursuant to the terms of the Merger Agreement, the following proposals must be approved by the requisite stockholder vote at the ARCA special meeting in order for the Merger to close:</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-left:24pt;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Proposal&#160;No. 1 &#8212;&#160;The Nasdaq Stock Issuance Proposal</span> to approve (i)&#160;the issuance of shares of ARCA common stock (including the shares of ARCA common stock issuable upon conversion of ARCA Series&#160;B Preferred Stock), which will represent more than 20% of the shares of ARCA common stock outstanding immediately prior to the Merger, to stockholders of Oruka, pursuant to the terms of the Merger Agreement, a copy of which is attached as <span class="Italic" style="font-style:italic;font-weight:normal;">Annex&#160;A</span> to this proxy statement/prospectus, and (ii)&#160;the change of control of ARCA resulting from the Merger, pursuant to Nasdaq Listing Rules 5635(a)&#160;and 5635(b), respectively;</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-left:24pt;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Proposal&#160;No. 2 &#8212;&#160;Authorized Share Increase Proposal</span> to approve an amendment to the ARCA Charter to increase the number of shares of ARCA common stock that ARCA is authorized to issue from 100,000,000 to&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, in the form attached as <span class="Italic" style="font-style:italic;font-weight:normal;">Annex&#160;G</span> to this proxy statement/prospectus;</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-left:24pt;text-indent:0pt;margin-top:8pt;">Additionally, Proposal&#160;No. 2 must be approved to have an adequate number of authorized but unissued shares of ARCA common stock to complete the Merger; and</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-left:24pt;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Proposal&#160;No. 3 &#8212;&#160;Reverse Stock Split Proposal</span> to approve an amendment to the ARCA Charter to effect a reverse stock split of ARCA&#8217;s issued and outstanding common stock at a ratio in the range between 1:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to 1:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, inclusive, if deemed necessary by ARCA and Oruka, with the final ratio and effectiveness of such amendment and the abandonment of such amendment to be mutually agreed by ARCA&#8217;s board of directors and Oruka&#8217;s board of directors prior to the First Effective Time or, if the Nasdaq Stock Issuance Proposal is not approved by ARCA stockholders, determined solely by ARCA&#8217;s board of directors, the form attached as <span class="Italic" style="font-style:italic;font-weight:normal;">Annex&#160;H</span> to this proxy statement/prospectus.</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;text-indent:0pt;margin-top:8pt;">Each of Proposal&#160;No. 1 and Proposal&#160;No. 2 is a condition to completion of the Merger. The issuance of ARCA common stock, including shares of ARCA common stock issuable upon conversion of ARCA Series&#160;B Preferred Stock, and ARCA Series&#160;B Preferred Stock in connection with the Merger and the change of control of ARCA resulting from the Merger will not take place unless Proposal&#160;No. 1 and Proposal&#160;No. 2 are approved by ARCA stockholders and the Merger is consummated. ARCA&#8217;s board of directors may determine to effect the authorized share increase or the reverse stock split if one or both are approved and Proposal&#160;No. 1 is not approved by ARCA stockholders, following the special meeting.</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;text-indent:0pt;margin-top:8pt;">In addition to the requirement of obtaining ARCA stockholder approval of Proposal&#160;No. 1 and Proposal&#160;No.<span class="nobreak"> </span>2, the closing of the Merger is subject to the satisfaction or waiver of each of the other closing conditions set forth in the Merger Agreement. For a more complete description of the closing conditions under the Merger Agreement, please see the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">The Merger Agreement&#160;&#8212;&#160;Conditions to the Completion of the Merger</span>&#8221; beginning on page 148 of this proxy statement/prospectus.</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;text-indent:0pt;margin-top:8pt;">The presence, by attending in person or being represented by proxy, at the ARCA special meeting of the holders of at least one<span class="nobreak">-third</span> of the shares of ARCA common stock outstanding and entitled to vote at the ARCA special meeting is necessary to constitute a quorum at the meeting for the Proposals.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">v</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Q:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>What proposals are to be voted on at the ARCA special meeting, other than the Nasdaq Stock Issuance Proposal, the Reverse Stock Split Proposal and the Authorized Share Increase Proposal?</span></p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">A:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>At the ARCA special meeting, the holders of ARCA common stock will also be asked to consider the following proposal:</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Proposal&#160;No.&#160;4 &#8212;&#160;The Officer Exculpation Proposal</span> to approve an amendment to the ARCA Charter to reflect Delaware law provisions regarding officer exculpation, in the form attached as <span class="Italic" style="font-style:italic;font-weight:normal;">Annex&#160;I</span>;</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Proposal&#160;No.&#160;5 &#8212;&#160;The Director Election Proposal</span> to elect one (1)&#160;Class&#160;III director nominee named in the accompany proxy statement/prospectus to ARCA&#8217;s board of directors, to serve until ARCA&#8217;s 2027 annual meeting of stockholders or until his successor has been duly elected and qualified, or until his earlier death, resignation or removal;</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Proposal&#160;No.&#160;6 &#8212;&#160;The Auditor Ratification Proposal</span> to ratify the selection of KPMG LLP as ARCA&#8217;s independent registered public accounting firm for the fiscal year ending December&#160;31, 2024;</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Proposal&#160;No.&#160;7 &#8212;&#160;The Stock Plan Proposal</span> to approve the Oruka Therapeutics, Inc. 2024 Stock Incentive Plan;</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Proposal&#160;No.&#160;8 &#8212;&#160;The ESPP Proposal</span> to approve the Oruka Therapeutics, Inc. 2024 Employee Stock Purchase Plan;</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Proposal&#160;No.&#160;9 &#8212;&#160;The Merger Compensation Proposal</span> to approve, on an advisory basis, certain compensation arrangements for ARCA named executive officers that are based on or otherwise relate to the Merger; and</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Proposal&#160;No.&#160;10 &#8212;&#160;The Adjournment Proposal</span> to approve an adjournment of the ARCA special meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of the Nasdaq Stock Issuance Proposal, the Authorized Share Increase Proposal and/or the Reverse Stock Split Proposal.</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;text-indent:0pt;margin-top:8pt;">The approval of Proposal&#160;Nos.<span class="nobreak"> </span>3,<span class="nobreak"> </span>4,<span class="nobreak"> </span>5,<span class="nobreak"> </span>6,<span class="nobreak"> </span>7,<span class="nobreak"> </span>8, 9 and 10 are not a condition to the Merger. ARCA does not expect that any matter other than the Proposals will be brought before the ARCA special meeting.</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;text-indent:0pt;margin-top:8pt;">The presence, by attending in person or being represented by proxy, at the ARCA special meeting of the holders of at least one<span class="nobreak">-third</span> of the shares of ARCA common stock outstanding and entitled to vote at the ARCA special meeting is necessary to constitute a quorum at the meeting for the purpose of approving the Proposals.</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Q:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>What stockholder votes are required to approve the Proposals at the ARCA special meeting?</span></p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">A:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>The affirmative vote of a majority of the shares of ARCA common stock entitled to vote on the subject matter and present at the ARCA special meeting, assuming a quorum is present, is required for approval of Proposal&#160;Nos.<span class="nobreak"> </span>1,<span class="nobreak"> </span>6,<span class="nobreak"> </span>7,<span class="nobreak"> </span>8, 9 and 10. The affirmative vote of a majority of the votes properly cast by the holders of ARCA common stock at the ARCA special meeting, assuming a quorum is present, is required for approval of Proposal&#160;Nos. 2 and 3. The affirmative vote of a majority of the outstanding shares of ARCA common stock is required for approval of Proposal&#160;No. 4. With respect to Proposal&#160;No.&#160;5, directors are elected by a plurality of the votes properly cast at the ARCA special meeting, and the one nominee for director receiving the highest number of affirmative votes properly cast will be elected. Proposal&#160;No. 1 is conditioned on the approval of Proposal&#160;No. 2. Notwithstanding the approval of Proposal&#160;No.<span class="nobreak"> </span>1, if Proposal&#160;No. 2 is not approved, the actions contemplated by Proposal&#160;No. 1 will not be effected and the Merger will not be consummated.</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Q:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>What will Oruka stockholders, participants in Oruka&#8217;s 2024 Equity Incentive Plan, option holders and warrant holders receive in the Merger?</span></p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">A:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>Oruka stockholders will receive shares of ARCA common stock. ARCA will assume Oruka&#8217;s 2024 Equity Incentive Plan, as amended, along with issued and outstanding awards under such plan. Outstanding and unexercised options to purchase shares of Oruka common stock immediately prior to the First Effective Time will be converted into options to purchase shares of ARCA&#8217;s common stock, with necessary adjustments being made to the number of shares and exercise price underlying such options in order to reflect the economic equivalent of the prior equity award in light of the exchange ratio. Oruka warrant holders&#8217; outstanding and </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">vi</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;text-indent:0pt;margin-top:8pt;">unexercised warrants to purchase shares of Oruka common stock immediately prior to the First Effective Time will be assumed by ARCA and each outstanding and unexercised warrant will be converted into a warrant to purchase shares of ARCA&#8217;s common stock, with necessary adjustments to the number of shares and exercise price to reflect the exchange ratio. Applying the exchange ratio, the former Oruka securityholders immediately before the Merger are expected to own approximately 97.61% of the aggregate number of shares of the combined company&#8217;s capital stock following the Merger (on a fully<span class="nobreak">-diluted</span> basis), and ARCA securityholders immediately before the Merger are expected to own approximately 2.39% of the aggregate number of shares of the combined company capital stock following the Merger (on a fully<span class="nobreak">-diluted</span> basis), subject to certain assumptions, including, but not limited to, ARCA&#8217;s net cash as of closing being equal to $5.0&#160;million. Under certain circumstances further described in the Merger Agreement, the ownership percentages may be adjusted up or down including, but not limited to, if ARCA&#8217;s net cash less than $5.0&#160;million. ARCA management currently anticipates ARCA&#8217;s net cash as of closing will be approximately $5.0&#160;million, after giving effect to the special cash dividend, which is expected to be approximately $20.0<span class="nobreak"> </span>million, and the currently estimated ownership percentages reflect this projection.</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;text-indent:0pt;margin-top:8pt;">For a more complete description of the treatment of Oruka common stock, Oruka&#8217;s 2024 Equity Incentive Plan, Oruka options and Oruka warrants in the Merger, please see the sections titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">The Merger Agreement&#160;&#8212;&#160;Merger Consideration</span>&#8221;<span class="Italic" style="font-style:italic;font-weight:normal;"> </span>and<span class="Italic" style="font-style:italic;font-weight:normal;"> </span>&#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">The Merger Agreement&#160;&#8212;&#160;Exchange Ratio</span>&#8221; beginning on pages 135 and 136, respectively, of this proxy statement/prospectus. For a description of the effect of the Oruka pre<span class="nobreak">-closing</span> financing on ARCA&#8217;s and Oruka&#8217;s current securityholders, please see the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Agreements Related to the Merger&#160;&#8212;&#160;Subscription Agreement</span>&#8221; beginning on page 153 of this proxy statement/prospectus.</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Q:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>Will the common stock of the combined company trade on an exchange?</span></p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">A:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>Shares of ARCA common stock are currently listed on Nasdaq under the symbol &#8220;ABIO.&#8221; ARCA intends to file an initial listing application for the common stock of the combined company with Nasdaq. After completion of the Merger, ARCA will be renamed &#8220;Oruka Therapeutics, Inc.&#8221; and it is expected that the common stock of the combined company will trade on Nasdaq under the symbol &#8220;ORKA.&#8221; It is a condition to the consummation of the Merger that ARCA will receive confirmation from Nasdaq that the combined company has been approved for listing on Nasdaq, but there can be no assurance such listing condition will be met or that ARCA will obtain such confirmation from Nasdaq. If such listing condition is not met or if such confirmation is not obtained, the Merger will not be consummated unless the condition is waived. The Nasdaq condition set forth in the Merger Agreement is not expected to be waived by the applicable parties. </p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;text-indent:0pt;margin-top:8pt;">On<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>, 2024, the last&#160;trading day before the date of this proxy statement/prospectus, the closing sale price of ARCA common stock was $&#160;&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span> per share.</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Q:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>Who will be the directors of the combined company immediately following the Merger?</span></p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">A:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>Immediately following the Merger, the combined company&#8217;s board of directors will be composed of six members, all of whom will have been designated by Oruka.</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;text-indent:0pt;margin-top:8pt;">Effective as of the First Effective Time, ARCA&#8217;s board of directors will appoint the following Oruka designees: Lawrence Klein, Kristine Ball, Carl Dambkowski, Peter Harwin, Samarth Kulkarni and Cameron Turtle, to the board of directors of the combined company and concurrently therewith all of ARCA&#8217;s current directors will resign from their positions as directors of ARCA&#8217;s board of directors effective as of the First Effective Time. Dr.&#160;Kulkarni is expected to be appointed as Chair of the board of directors of the combined company.</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;text-indent:0pt;margin-top:8pt;">The staggered structure of three classes of directors of ARCA&#8217;s board of directors will remain in place for the combined company following the completion of the Merger. See the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Management Following the Merger</span>&#8221; for additional information.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">vii</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Q:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>Who will be the executive officers of the combined company immediately following the Merger?</span></p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">A:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>Immediately following the Merger, the executive management team of the combined company is expected to consist of the following members of the Oruka executive management team:</p>
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">



						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;text-align:left;"><span class="Bold" style="font-style:normal;font-weight:bold;">Name</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Title</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Lawrence Klein</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">President, Chief Executive Officer and Director</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Arjun Agarwal</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Senior Vice President, Finance and Treasurer</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Joana Goncalves</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Chief Medical Officer</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Paul Quinlan</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">General Counsel and Secretary</p>
					</td>
				</tr>

		</table>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Q:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>As an ARCA stockholder, how does ARCA&#8217;s board of directors recommend that&#160;I vote?</span></p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">A:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>ARCA&#8217;s board of directors, in consultation with financial and legal advisors and management, evaluated the terms of the Merger Agreement and the related transactions contemplated thereby and: (i)&#160;determined that the Merger and the related transactions contemplated by the Merger Agreement are fair to, advisable and in the best interests of ARCA and its stockholders; (ii)&#160;approved and declared advisable the Merger Agreement and the related transactions contemplated by the Merger Agreement and the Subscription Agreement, including the issuance of shares of ARCA common stock, including shares of ARCA common stock issuable upon conversion of ARCA Series&#160;B Preferred Stock, in connection with the Merger and the Oruka pre<span class="nobreak">-closing</span> financing, respectively; and (iii)&#160;recommends that ARCA&#8217;s stockholders vote &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">FOR</span>&#8221; each of the Proposals.</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Q:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>What risks should&#160;I consider in deciding whether to vote in favor of the Merger?</span></p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">A:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>You should carefully review the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Risk Factors</span>&#8221; beginning on page 15 of this proxy statement/prospectus and the documents incorporated by reference herein, which set forth certain risks and uncertainties related to the Merger, risks and uncertainties to which the combined company&#8217;s business will be subject, and risks and uncertainties to which each of ARCA and Oruka, as independent companies, are subject.</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Q:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>When do you expect the Merger to be consummated?</span></p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">A:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>The Merger is anticipated to close in the third quarter of 2024, but the exact timing cannot be predicted. For more information, please see the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">The Merger Agreement&#160;&#8212;&#160;Conditions to the Completion of the Merger</span>&#8221; beginning on page 148 of this proxy statement/prospectus.</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Q:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>What do&#160;I need to do now?</span></p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">A:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>ARCA urges you to read this proxy statement/prospectus carefully, including the annexes and the documents incorporated by reference, and to consider how the Merger affects you.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Stockholder of Record: Shares Registered in Your Name</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-left:24pt;text-indent:0pt;margin-top:8pt;">If you are a stockholder of record, you may vote in person at the ARCA special meeting, vote by proxy over the telephone, vote by proxy through the Internet or vote by proxy using a proxy card that you may request or that we may elect to deliver at a later time. Whether or not you plan to attend the meeting, we urge you to vote by proxy to ensure your vote is counted. You may still attend the meeting and vote in person even if you have already voted by proxy.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>To vote in person, come to the special meeting and we will give you a ballot when you arrive.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>To vote using the proxy card, simply complete, sign and date the proxy card that you may request or that we may elect to deliver at a later time and return it promptly in the envelope provided. If you return your signed proxy card to us before the special meeting, we will vote your shares as you direct.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>To vote over the telephone, dial toll<span class="nobreak">-free</span>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;using a touch<span class="nobreak">-tone</span> phone and follow the recorded instructions. You will be asked to provide the company number and control number found on the Notice. Your vote must be received by&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Mountain Time on&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2024 to be counted.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>To vote through the Internet, go to&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to complete an electronic proxy card. You will be asked to provide the company number and control number from the Notice. Your vote must be received by&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Mountain Time on&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2024 to be counted.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">viii</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-left:24pt;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Beneficial Owner: Shares Registered in the Name of Broker or Bank</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-left:24pt;text-indent:0pt;margin-top:8pt;">If you are a beneficial owner of shares registered in the name of your broker, bank, or other agent, you should have received a Notice containing voting instructions from that organization rather than from ARCA.&#160;Simply follow the voting instructions in the Notice to ensure that your vote is counted. You may vote by telephone or over the Internet as instructed by your broker or bank. To vote in person at the ARCA special meeting, you must obtain a valid proxy from your broker, bank, or other agent. Follow the instructions from your broker or bank included with these proxy materials, or contact your broker or bank to request a proxy form.</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Q:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>What if&#160;I return a proxy card or otherwise vote but do not make specific choices?</span></p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">A:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>If you return a signed and dated proxy card or otherwise vote without marking voting selections, your shares will be voted, as applicable, &#8220;For&#8221; the Nasdaq Stock Issuance Proposal, &#8220;For&#8221; the Authorized Share Proposal, &#8220;For&#8221; the Reverse Stock Split Proposal, &#8220;For&#8221; the Officer Exculpation<span class="Bold" style="font-style:normal;font-weight:bold;"> </span>Proposal, &#8220;For&#8221; the Director Election Proposal, &#8220;For&#8221; the Auditor Ratification Proposal, &#8220;For&#8221; the Stock Plan Proposal, &#8220;For&#8221; the ESPP Proposal, &#8220;For&#8221; the Merger Compensation Proposal, and &#8220;For&#8221; the Adjournment Proposal. If any other matter is properly presented at the meeting, your proxy holder (one of the individuals named on your proxy card) will vote your shares using his or her best judgment.</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Q:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>What happens if&#160;I do not return a proxy card or otherwise vote or provide proxy instructions, as applicable?</span></p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">A:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>If you are an ARCA stockholder, the failure to return your proxy card or otherwise vote or provide proxy instructions will reduce the aggregate number of votes required to approve Proposal&#160;Nos.<span class="nobreak"> </span>1,<span class="nobreak"> </span>6,<span class="nobreak"> </span>7,<span class="nobreak"> </span>8,<span class="nobreak"> </span>9, and 10.</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Q:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>If my ARCA shares are held in &#8220;street name&#8221; by my broker and&#160;I do not provide my broker or bank with voting instructions, what happens?</span></p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">A:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>If you are a beneficial owner of shares held in street name and you do not instruct your broker, bank or other agent how to vote your shares, your broker, bank or other agent may still be able to vote your shares in its discretion or your shares may constitute &#8220;broker non<span class="nobreak">-votes</span>.&#8221;</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-left:24pt;text-indent:0pt;margin-top:8pt;">If an ARCA stockholder does not return voting instructions to their broker on how to vote their shares of ARCA common stock, such broker may be prevented from voting, or may otherwise choose not to vote, such shares held by such broker, resulting in broker non<span class="nobreak">-votes</span> with respect to such shares. To make sure that your vote is counted, you should instruct your broker to vote your shares of ARCA common stock, following the procedures provided by your broker.</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Q:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>What are broker non</span><span class="nobreak"><span class="Bold" style="font-style:normal;font-weight:bold;">-votes</span></span><span class="Bold" style="font-style:normal;font-weight:bold;"> and do they count for determining a quorum?</span></p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">A:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>Generally, a &#8220;broker non<span class="nobreak">-vote</span>&#8221; occurs when shares held by a broker are not voted with respect to a particular proposal because the broker has not received voting instructions from its client(s)&#160;with respect to such shares on how to vote and does not have or did not exercise discretionary authority to vote on the matter.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-left:24pt;text-indent:0pt;margin-top:8pt;">Broker non<span class="nobreak">-votes</span>, if any, will be treated as shares present for the purpose of determining the presence of a quorum for the transaction of business at the ARCA special meeting. Broker non<span class="nobreak">-votes</span>, if any, will not be counted as &#8220;votes properly cast&#8221; or &#8220;shares entitled to vote&#8221; and will therefore have no effect on Proposal&#160;Nos.<span class="nobreak"> </span>1,<span class="nobreak"> </span>2,<span class="nobreak"> </span>3,<span class="nobreak"> </span>5,<span class="nobreak"> </span>6,<span class="nobreak"> </span>7,<span class="nobreak"> </span>8, 9 and<span class="nobreak"> </span>10, but will have the same effect as votes &#8220;AGAINST&#8221; Proposal&#160;No. 4.</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Q:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>May&#160;I revoke and/or change my vote after&#160;I have submitted a proxy or provided proxy instructions?</span></p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">A:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>ARCA stockholders of record, unless such stockholder&#8217;s vote is subject to a support agreement, may revoke and/or change their vote at any time before their proxy is voted at the ARCA special meeting in one of four ways:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>You may submit another properly completed proxy with a later date by mail or via the internet.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>You can provide your proxy instructions via telephone at a later date.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">ix</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>You may send a notice that you are revoking your proxy over the internet, following the instructions provided on your proxy card.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>You may attend the ARCA special meeting in person and vote during the meeting. Simply attending the ARCA special meeting will not, by itself, revoke your proxy and/or change your vote.</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Q:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>What are the material U.S.&#160;federal income tax consequences of the Merger to U.S.&#160;holders of Oruka common stock and Oruka preferred stock?</span></p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">A:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>The Merger will qualify as a &#8220;reorganization&#8221; within the meaning of Section 368(a) of the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;) for U.S. federal income tax purposes. As a result, subject to the limitations and qualifications described in the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">The Merger &#8212; Material U.S. Federal Income Tax Consequences of the Merger</span>&#8221; beginning on page 128, a U.S. holder of Oruka stock (as defined in therein) will generally not recognize any gain or loss for U.S. federal income tax purposes on the receipt of ARCA stock (as defined therein) in the Merger. For a more complete discussion of the material U.S.&#160;federal income tax consequences of the Merger, see the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">The Merger&#160;&#8212;&#160;Material U.S.&#160;Federal Income Tax Consequences of the Merger</span>&#8221; beginning on page 128.</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Q:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>What are the material U.S.&#160;federal income tax consequences of the reverse stock split to holders of ARCA common stock?</span></p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">A:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>The reverse stock split is intended to be treated as a &#8220;recapitalization&#8221; within the meaning of Section&#160;368(a)(1)(E) of the Code for U.S.&#160;federal income tax purposes. Assuming it so qualifies, a U.S.&#160;holder of ARCA common stock should not recognize gain or loss for U.S.&#160;federal income tax purposes upon the reverse stock split, except with respect to cash received in lieu of a fractional share of ARCA common stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-left:24pt;text-indent:0pt;margin-top:8pt;">Please review the information in the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Proposal&#160;No. 3 &#8212;&#160;The Reverse Stock Split Proposal&#160;&#8212;&#160;Material U.S.&#160;Federal Income Tax Consequences of the Reverse Stock Split</span>&#8221; beginning on page&#160;184 of this proxy statement/prospectus for a more complete description of the material U.S.&#160;federal income tax consequences of the reverse stock split to a U.S.&#160;holder of ARCA common stock.</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Q:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>What are the material U.S.&#160;federal income tax consequences of the special cash dividend that ARCA will declare and pay to holders of ARCA common stock?</span></p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">A:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>The U.S.&#160;federal income tax consequences of a holder&#8217;s receipt of the special cash dividend generally should be treated first as a dividend to the extent of ARCA&#8217;s current and accumulated earnings and profits, then as a non<span class="nobreak">-taxable</span> return of capital to the extent of the holder&#8217;s basis in ARCA common stock, and then as capital gain from the sale or exchange of ARCA common stock with respect to any remaining amount. ARCA currently has an accumulated deficit and expects additional losses in the current period. Thus, ARCA expects most or all of the distribution of the special cash dividend to be treated as other than a dividend for U.S.&#160;federal income tax purposes. However, there can be no assurance that it will be so treated. Please review the information in the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">The Merger&#160;&#8212;&#160;Material U.S.&#160;Federal Income Tax Considerations &#8212; Material U.S.&#160;Federal Income Tax Consequences of the Special Cash Dividend to Holders of ARCA Common Stock</span>&#8221; beginning on page 130 of this proxy statement/prospectus for a discussion of the material U.S.&#160;federal income tax consequences of the special cash dividend to holders of ARCA common stock.</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Q:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>Who can help answer my questions?</span></p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">A:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>If you are an ARCA stockholder and would like additional copies of this proxy statement/prospectus without charge or if you have questions about the Merger or related matters, including the procedures for voting your shares, you should contact:</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">x</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>






	<div class="BOXSTYLE" style="margin:0;padding:0;border-width:0;border-color:#000000;border-width:1pt;border: solid windowtext 1.0pt; padding: 10.0pt 4.0pt 10.0pt 4.0pt;">
		<a id="T26"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">PROSPECTUS SUMMARY</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">This summary highlights selected information from this proxy statement/prospectus and may not contain all of the information that is important to you. To better understand the Merger and the proposals being considered at the ARCA special meeting, you should read this entire proxy statement/prospectus carefully, including the Merger Agreement and the other annexes to which you are referred in this proxy statement/prospectus, and the documents incorporated by reference therein. For more information, please see the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Where You Can Find More Information</span>&#8221; beginning on page 320 of this proxy statement/prospectus. Except where specifically noted, the following information and all other information contained in this proxy statement/prospectus does not give effect to the proposed reverse stock split described in Proposal&#160;No.<span class="Italic" style="font-style:italic;font-weight:normal;"> </span>3 of this proxy statement/prospectus.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">The Companies</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">ARCA</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA is a biotechnology company dedicated to applying a precision medicine approach to the development and commercialization of targeted therapies for cardiovascular diseases. Precision medicine refers to the tailoring of medical treatment to the individual characteristics of patients, using genomic, non<span class="nobreak">-genomic</span> biomarker and other information that extends beyond routine diagnostic categorization. ARCA believes that when implemented correctly precision medicine can enhance therapeutic response, improve patient outcomes, and reduce healthcare costs.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s lead product candidate is Gencaro&#8482; (bucindolol hydrochloride) for the treatment of atrial fibrillation (&#8220;AF&#8221;) in patients with chronic heart failure (&#8220;HF&#8221;). Gencaro is being developed for patients who have a genotype that identifies a drug target associated with heightened efficacy.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s principal executive offices are located at 10170 Church Ranch Way, Suite 100, Westminster, CO&#160;80021, and its telephone number is (720)&#160;940<span class="nobreak">-2100</span>.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka is a biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. Oruka&#8217;s mission is to offer patients suffering from chronic skin diseases like psoriasis (&#8220;PsO&#8221;) the greatest possible freedom from their condition by achieving high rates of complete disease clearance with dosing as infrequently as one or twice a year. Oruka is advancing a proprietary portfolio of antibodies that were engineered by Paragon and target the core mechanisms underlying PsO and other dermatologic and inflammatory diseases.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka&#8217;s lead program, ORKA<span class="nobreak">-001</span>, is designed to target the p19 subunit of interleukin<span class="nobreak">-23</span> (IL<span class="nobreak">-23p19</span>) for the treatment of PsO.&#160;Oruka&#8217;s co<span class="nobreak">-lead</span> program, ORKA<span class="nobreak">-002</span>, is designed to target interleukin<span class="nobreak">-17A</span> and interleukin<span class="nobreak">-17F</span> for the treatment of PsO, psoriatic arthritis (&#8220;PsA&#8221;), and other conditions. These programs each bind their respective targets at high affinity and incorporate half<span class="nobreak">-life</span> extension technology with the aim to increase exposure and decrease dosing frequency. Oruka believes that its focused strategy, differentiated portfolio, and deep expertise position it to set a new treatment standard in large inflammatory and immunology (&#8220;I&amp;I&#8221;) markets with continued unmet need.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka&#8217;s principal executive offices are located at 855 Oak Grove Ave., Suite 100, Menlo Park, CA 94025, and its telephone number is (650)&#160;606<span class="nobreak">-7910</span>.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">First Merger Sub</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">First Merger Sub is a direct, wholly owned subsidiary of ARCA and was formed solely for the purpose of carrying out the Merger. First Merger Sub&#8217;s principal executive offices are located at 10170 Church Ranch Way, Suite 100, Westminster, CO&#160;80021, and its telephone number is (720)&#160;940<span class="nobreak">-2100</span>.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Second Merger Sub</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Second Merger Sub is a direct, wholly owned subsidiary of ARCA and was formed solely for the purpose of carrying out the Merger. Second Merger Sub&#8217;s principal executive offices are located at 10170 Church Ranch Way, Suite 100, Westminster, CO&#160;80021, and its telephone number is (720)&#160;940<span class="nobreak">-2100</span>.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">1</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>






	<div class="BOXSTYLE" style="margin:0;padding:0;border-width:0;border-color:#000000;border-width:1pt;border: solid windowtext 1.0pt; padding: 10.0pt 4.0pt 10.0pt 4.0pt;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">The Merger</span> <span class="CharOverride-1" style="font-style:normal;font-weight:normal;">(see page 96)</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Subject to the satisfaction or waiver of the conditions to closing set forth in the Merger Agreement, at the closing of the Merger, First Merger Sub will merge with and into Oruka, with Oruka continuing as a wholly owned subsidiary of ARCA and the surviving corporation of the First Merger and as part of the same overall transaction, Oruka will merge with and into Second Merger Sub, with Second Merger Sub being the surviving entity of the Second Merger.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA&#8217;s Reasons for the Merger</span><span class="CharOverride-1" style="font-style:normal;font-weight:normal;"> (see page 104)</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In reaching its decision to approve the Merger Agreement and the transactions contemplated by the Merger Agreement, ARCA&#8217;s board of directors considered a number of factors that it viewed as supporting its decision to approve the Merger Agreement, including:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>The financial condition and prospects of ARCA and the risks associated with continuing to operate ARCA on a stand<span class="nobreak">-alone</span> basis as well as the risks of accomplishing those objectives;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors&#8217; belief that, after a thorough review of strategic alternatives, including further advancing the development of its internal programs, entering into a licensing, sale or other strategic agreement related to certain assets sufficient to fund operations, combining with other potential strategic transaction candidates, and discussions with ARCA&#8217;s senior management, financial advisors and legal counsel, the Merger is more favorable to ARCA stockholders than the potential value that might have resulted from other strategic alternatives available to ARCA;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors&#8217; view that the $6.0&#160;million enterprise value ascribed to ARCA would provide the existing ARCA stockholders significant value for ARCA&#8217;s public listing and afford the ARCA stockholders a significant opportunity to participate in the potential growth of the combined company following the Merger at the negotiated exchange ratio while also receiving a cash payment on account of the special cash dividend; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors&#8217; view, following a review with ARCA&#8217;s management and advisors of Oruka&#8217;s current development and clinical trial plans, of the likelihood that the combined company would possess sufficient cash resources at the closing of the Merger to fund development of Oruka&#8217;s product candidates through upcoming value inflection points, including Oruka&#8217;s ongoing IND<span class="nobreak">-enabling</span> preclinical development work and its anticipated initiation of its Phase&#160;1 trials of ORKA<span class="nobreak">-001</span> in the first half of 2025 and Phase&#160;1 trials of ORKA<span class="nobreak">-002</span> in the second half of 2025.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Oruka&#8217;s Reasons for the Merger </span><span class="CharOverride-1" style="font-style:normal;font-weight:normal;">(see page 110)</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In the course of reaching its decision to approve the Merger and the Oruka&#160;pre<span class="nobreak">-closing</span>&#160;financing, Oruka&#8217;s board of directors held numerous meetings, consulted with Oruka&#8217;s senior management, legal counsel and financial advisors, and considered a wide variety of factors. Ultimately, Oruka&#8217;s board of directors concluded that a merger with ARCA, together with the additional financing committed from the Oruka pre<span class="nobreak">-closing</span> financing, was the best option to generate capital resources to support the advancement of Oruka&#8217;s pipeline and fund the combined organization.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Additional factors Oruka&#8217;s board of directors considered included the following:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the Merger will potentially expand the access to capital and the range of investors available as a public company to support the clinical development of Oruka&#8217;s pipeline, compared to the capital and investors Oruka could otherwise gain access to if it continued to operate as a privately<span class="nobreak">-held</span> company;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the potential benefits from increased public market awareness of Oruka and its pipeline;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the historical and current information concerning Oruka&#8217;s business, including its financial performance and condition, operations, management and preclinical and clinical data;</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">2</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>






	<div class="BOXSTYLE" style="margin:0;padding:0;border-width:0;border-color:#000000;border-width:1pt;border: solid windowtext 1.0pt; padding: 10.0pt 4.0pt 10.0pt 4.0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Oruka&#8217;s board of directors&#8217; belief that no alternatives to the Merger, together with the additional financing committed from the Oruka pre<span class="nobreak">-closing</span> financing, were reasonably likely to create greater value for Oruka stockholders, after considering the various financing and other strategic options to enhance stockholder value that were considered by the Oruka board of directors;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Oruka&#8217;s board of directors&#8217; expectation that the Merger, together with the additional financing committed from the Oruka pre<span class="nobreak">-closing</span> financing, would be a higher probability and more cost<span class="nobreak">-effective</span> means to access capital than other options considered, including an initial public offering (&#8220;IPO&#8221;);</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the expected financial position, operations, management structure and operating plans of the combined company (including the ability to support the combined company&#8217;s current and planned preclinical and clinical trials);</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the business, history, operations, financial resources, assets, technology and credibility of ARCA; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the terms and conditions of the Merger Agreement.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka&#8217;s board of directors also considered a number of uncertainties and risks in its deliberations concerning the Merger, the Oruka pre<span class="nobreak">-closing</span> financing, and the other transactions contemplated by the Merger Agreement, including the following:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the possibility that the Merger or Oruka pre<span class="nobreak">-closing</span> financing might not be completed;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>there is no adjustment to the exchange ratio if ARCA&#8217;s net cash as of closing is above $5.0&#160;million, and thus Oruka stockholders are expected to own at least approximately 97.61% of the outstanding shares of capital stock of the combined company (on a fully<span class="nobreak">-diluted</span> basis) following the completion of the Merger;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the potential effect of the $440,000 termination fee payable by Oruka;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the potential reduction of ARCA&#8217;s net cash to an amount below $5.0&#160;million prior to the closing;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the possibility that ARCA could consider certain unsolicited acquisition proposals;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the costs, time and effort involved in connection with completing the Merger, related disruptions or potential disruptions to Oruka&#8217;s business and related administrative challenges associated with combining the companies;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the additional expenses and obligations to which Oruka&#8217;s business will be subject following the Merger as a public company; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>various other risks associated with the combined organization and the Merger, including the risks described in the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Risk Factors</span>&#8221; in this proxy statement/prospectus.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Recommendation of ARCA&#8217;s Board of Directors </span><span class="CharOverride-1" style="font-style:normal;font-weight:normal;">(see page 92)</span></p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors has determined and declared that the issuance of shares of ARCA common stock, including shares of ARCA common stock issuable upon conversion of ARCA Series&#160;B Preferred Stock, pursuant to the Merger Agreement, and the change of control of ARCA resulting from the Merger, is fair to, in the best interests of, and advisable to, ARCA and its stockholders. ARCA&#8217;s board of directors recommends that ARCA stockholder vote &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">FOR</span>&#8221;<span class="Bold" style="font-style:normal;font-weight:bold;"> </span>the approval of Nasdaq Stock Issuance Proposal as described in this proxy statement/prospectus.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors has determined and declared that it is advisable and in the best interests of ARCA and its stockholders to approve the amendment to the ARCA Charter to effect the increase in authorized shares. ARCA&#8217;s board of directors recommends that ARCA stockholder vote &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">FOR</span>&#8221; the Authorized Share Increase Proposal as described in this proxy statement/prospectus.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">3</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>






	<div class="BOXSTYLE" style="margin:0;padding:0;border-width:0;border-color:#000000;border-width:1pt;border: solid windowtext 1.0pt; padding: 10.0pt 4.0pt 10.0pt 4.0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors has determined and declared that it is advisable and in the best interests of ARCA and its stockholders to approve the amendment to the ARCA Charter to effect the reverse stock split, if necessary. ARCA&#8217;s board of directors recommends that ARCA stockholder vote &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">FOR</span>&#8221;<span class="Bold" style="font-style:normal;font-weight:bold;"> </span>the Reverse Stock Split Proposal as described in this proxy statement/prospectus.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors has determined and believes that it is advisable to, and in the best interests of, ARCA and its stockholders to approve the amendment to the ARCA Charter to provide for the exculpation of officers, as described in this proxy statement/prospectus. ARCA&#8217;s board of directors recommends that ARCA stockholders vote &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">FOR</span>&#8221; the Officer Exculpation Proposal as described in this proxy statement/prospectus.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors has determined and believes that it is advisable to, and in the best interests of, ARCA and its stockholders to elect Jacob Ma<span class="nobreak">-Weaver</span> to serve on the ARCAs board of directors in the class of directors with terms expiring at ARCA&#8217;s 2027 annual meeting of stockholders. ARCA&#8217;s board of directors recommends that ARCA stockholders vote &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">FOR</span>&#8221;<span class="Bold" style="font-style:normal;font-weight:bold;"> </span>the director nominee named in the Director Election Proposal as described in this proxy statement/prospectus.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors has determined and believes that it is advisable to, and in the best interests of, ARCA and its stockholders to ratify the selection of KPMG LLP as ARCA&#8217;s independent registered public accounting firm for the fiscal year ending December<span class="nobreak">&#160;</span>31, 2024, provided that PricewaterhouseCoopers LLP is expected to be appointed for that fiscal year if the Merger is completed. ARCA&#8217;s board of directors recommends that ARCA stockholders vote &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">FOR</span>&#8221;<span class="Bold" style="font-style:normal;font-weight:bold;"> </span>the Auditor Ratification Proposal as described in this proxy statement/prospectus.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors has determined and believes it that it is advisable to, and in the best interests of, ARCA and its stockholders to approve the 2024 Stock Incentive Plan, as described in this proxy statement/prospectus. ARCA&#8217;s board of directors recommends that ARCA stockholders vote &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">FOR</span>&#8221; the Stock Plan Proposal as described in this proxy statement/prospectus.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors has determined and believes that it is advisable to, and in the best interests of, ARCA and its stockholders to approve the 2024 Employee Stock Purchase Plan, as described in this proxy statement/prospectus. ARCA&#8217;s board of directors recommends that ARCA stockholders vote &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">FOR</span>&#8221; the ESPP Proposal as described in this proxy statement/prospectus.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors has determined and believes that it is advisable to, and in the best interests of, ARCA and its stockholders to approve certain compensation arrangements for ARCA named executive officers that are based on or otherwise relate to the Merger. ARCA&#8217;s board of directors recommends that ARCA stockholders vote &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">FOR</span>&#8221; the Merger Compensation Proposal as described in this proxy statement/prospectus.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors has determined and believes that adjourning the ARCA special meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of the Nasdaq Stock Issuance Proposal, the Authorized Share Increase Proposal and/or the Reverse Stock Split Proposal is fair to, in the best interests of, and advisable to, ARCA and its stockholders and has approved and adopted the proposal. ARCA&#8217;s board of directors recommends that ARCA stockholders vote &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">FOR</span>&#8221; the Adjournment Proposal, if necessary, as described in this proxy statement/prospectus.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Interests of ARCA&#8217;s Directors and Executive Officers in the Merger </span><span class="CharOverride-1" style="font-style:normal;font-weight:normal;">(see page 121)</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In considering the recommendation of ARCA&#8217;s board of directors with respect to issuing shares of ARCA common stock, including shares of ARCA common stock issuable upon conversion of ARCA Series&#160;B Preferred Stock, in the Merger and the other matters to be acted upon by the ARCA stockholders at the ARCA special meeting, the ARCA stockholders should be aware that ARCA&#8217;s directors and executive officers have interests in the Merger that are different from, or in addition to, the interests of ARCA stockholders generally. These interests may present ARCA&#8217;s directors and executive officers with actual or potential conflicts of interest. These interests include the following:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>in connection with the Merger, each option to purchase shares of ARCA common stock held by ARCA&#8217;s executive officers and directors will accelerate and fully vest, and (i)&#160;each such option with an exercise price less than or equal to the Parent Closing Price will be cancelled and converted into the right to </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">4</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>






	<div class="BOXSTYLE" style="margin:0;padding:0;border-width:0;border-color:#000000;border-width:1pt;border: solid windowtext 1.0pt; padding: 10.0pt 4.0pt 10.0pt 4.0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-position:inside;list-style-type:none;text-indent:0pt;margin-top:8pt;">receive an amount in cash, without interest, equal to the Parent Closing Price less the exercise price of such option and (ii)&#160;each other option to acquire shares of ARCA&#8217;s common stock will be cancelled for no consideration;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>certain of ARCA&#8217;s executive officers will be eligible to receive retention bonuses and severance payments in connection with the Merger;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>certain of ARCA&#8217;s directors will be eligible to receive special committee fees in connection with the Merger;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>prior to the closing of the First Merger, ARCA expects to declare a cash dividend to the pre<span class="nobreak">-First</span> Merger ARCA stockholders equal in the aggregate to ARCA&#8217;s reasonable, good faith approximation of the amount by which ARCA&#8217;s net cash will exceed $5.0&#160;million, and any of ARCA&#8217;s directors and executive officers that are also ARCA stockholders will share in any such cash dividend proportionally to their pre<span class="nobreak">-First</span> Merger ownership of ARCA common stock (see the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Principal Stockholders of ARCA</span>&#8221; beginning on page 312 of this proxy statement/prospectus for additional information regarding ARCA&#8217;s directors&#8217; and officers&#8217; holdings of ARCA common stock; notably, Jacob Ma<span class="nobreak">-Weaver</span> and affiliated entities together hold 4,000,452<span class="nobreak"> </span>shares of ARCA common stock, representing over 27% of outstanding shares of ARCA common stock); and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>under the Merger Agreement, ARCA&#8217;s directors and executive officers are entitled to continued indemnification, expense advancement and insurance coverage.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s board of directors was aware of these potential conflicts of interest and considered them, among other matters, in reaching its decision to approve the Merger Agreement and the Merger, and to recommend that the ARCA stockholders approve the proposals to be presented to the ARCA stockholders for consideration at the ARCA special meeting as contemplated by this proxy statement/prospectus. As of<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span><span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>, 2024, the directors and executive officers of ARCA owned or controlled&#160;&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>% of the outstanding shares of ARCA common stock entitled to vote at the ARCA special meeting.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Interests of Oruka&#8217;s Directors and Executive Officers in the Merger </span><span class="CharOverride-1" style="font-style:normal;font-weight:normal;">(see page 121)</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In considering the recommendation of Oruka&#8217;s board of directors with respect to approving the Merger, stockholders should be aware that Oruka&#8217;s directors and executive officers have interests in the Merger that are different from, or in addition to, the interests of Oruka stockholders generally. These interests may present them with actual or potential conflicts of interest. These interests include the following:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>as of May<span class="nobreak">&#160;</span>13, 2024, Oruka&#8217;s current non<span class="nobreak">-employee</span> directors and executive officers beneficially owned, in the aggregate, approximately 73.5% of the shares of Oruka capital stock, which for purposes of this subsection excludes any Oruka shares issuable upon exercise or settlement of Oruka options held by such individual;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Fairmount Healthcare Fund&#160;II L.P. (&#8220;Fairmount Fund&#160;II&#8221;), an affiliate of Peter Harwin, an Oruka director, currently holds shares of Oruka capital stock and an unsecured convertible promissory note with an initial principal amount of $25.0&#160;million at an interest rate of 12% per annum (the &#8220;Convertible Note&#8221;) of Oruka and has agreed to purchase shares and pre<span class="nobreak">-funded</span> warrants in the Oruka pre<span class="nobreak">-closing</span> financing;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>in connection with the Merger, each option to purchase shares of Oruka common stock held by Oruka&#8217;s executive officers and directors, whether or not vested, will be converted into an option to purchase shares of the combined company&#8217;s common stock, on the same terms and conditions (including any vesting and acceleration provisions);</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Oruka&#8217;s directors and executive officers are expected to become directors and executive officers of the combined company upon completion of the Merger; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Oruka&#8217;s directors and executive officers are entitled to certain indemnification and liability insurance coverage pursuant to the terms of the Merger Agreement.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">5</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>






	<div class="BOXSTYLE" style="margin:0;padding:0;border-width:0;border-color:#000000;border-width:1pt;border: solid windowtext 1.0pt; padding: 10.0pt 4.0pt 10.0pt 4.0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka&#8217;s board of directors was aware of these potential conflicts of interest and considered them, among other matters, in reaching its decision to approve the Merger Agreement and the Merger, and to recommend that the Oruka stockholders approve the Merger as contemplated by this proxy statement/prospectus. As of May&#160;13, 2024, the directors and executive officers of Oruka owned or controlled 73.5% of the outstanding shares of Oruka capital stock.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Opinion of Lucid Capital Markets to the ARCA Board</span> <span class="CharOverride-1" style="font-style:normal;font-weight:normal;">(see page 112)</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On April&#160;2, 2024, Lucid Capital Markets, LLC (&#8220;Lucid&#8221;) orally rendered its opinion to ARCA&#8217;s board of directors (which was subsequently confirmed in writing by delivery of Lucid&#8217;s written opinion addressed to ARCA&#8217;s board of directors dated April&#160;2, 2024), that, as of such date and based upon and subject to the various assumptions and limitations made, and such other factors Lucid deemed relevant upon the review undertaken by Lucid in preparing its opinion, the exchange ratio proposed to be paid by ARCA pursuant to the terms of the Merger Agreement was fair, from a financial point of view, to the holders of ARCA common stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The full text of the written opinion of Lucid, dated April&#160;2, 2024, which describes the assumptions made and the qualifications and limitations upon the review undertaken by Lucid in preparing its opinion, is attached as <span class="Italic" style="font-style:italic;font-weight:normal;">Annex&#160;B</span> to this proxy statement/prospectus and is incorporated herein by reference. <span class="Bold" style="font-style:normal;font-weight:bold;">Lucid&#8217;s financial advisory services and opinion were provided for the information and assistance of ARCA&#8217;s board of directors (in their capacity as directors and not in any other capacity) in connection with and for purposes of ARCA&#8217;s board of directors&#8217; consideration of the Merger and the opinion of Lucid addressed only the fairness, from a financial point of view, as of the date thereof, to the holders of ARCA common stock of the exchange ratio proposed to be paid by ARCA pursuant to the terms of the Merger Agreement. The opinion of Lucid did not address any other term or aspect of the Merger Agreement or the Merger and does not constitute a recommendation to any stockholder of ARCA or Oruka as to whether or how such holder should vote with respect to the Merger or otherwise act with respect to the Merger or any other matter.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">The full text of the written opinion of Lucid should be read carefully in its entirety for a description of the assumptions made and qualifications and limitations upon the review undertaken by Lucid in preparing its opinion.</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">The Merger Agreement </span><span class="CharOverride-1" style="font-style:normal;font-weight:normal;">(see page 135)</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Merger Consideration </span><span class="CharOverride-1" style="font-style:normal;font-weight:normal;">(see page 135)</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">At the First Effective Time, upon the terms and subject to the conditions set forth in the Merger Agreement, (i)&#160;each then<span class="nobreak">-outstanding</span> share of Oruka common stock (including shares of Oruka common stock issued in the Oruka pre<span class="nobreak">-closing</span> financing) (excluding shares to be canceled pursuant to the Merger Agreement and excluding dissenting shares) will be automatically converted solely into the right to receive a number of shares of ARCA common stock equal to the exchange ratio (described in more detail in the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">The Merger Agreement&#160;&#8212;&#160;Exchange Ratio</span>&#8221; beginning on page 136 of this proxy statement/prospectus), (ii)&#160;each then<span class="nobreak">-outstanding</span> share of Oruka preferred stock will be converted into the right to receive a number of shares of ARCA Series&#160;B Preferred Stock, which are each convertible into 1,000<span class="nobreak"> </span>shares of ARCA common stock, equal to the exchange ratio divided by 1,000, in accordance with the terms of the Merger Agreement, (iii)&#160;each then<span class="nobreak">-outstanding</span> option to purchase Oruka common stock will be assumed by ARCA, subject to adjustment as set forth in the Merger Agreement, and (iv)&#160;each then<span class="nobreak">-outstanding</span> warrant to purchase shares of Oruka common stock will be converted into a warrant to purchase shares of ARCA common stock, subject to adjustment as set forth in the Merger Agreement and the form of warrant.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Immediately after the Merger, ARCA securityholders as of immediately prior to the Merger are expected to own approximately 2.39% of the outstanding shares of capital stock of the combined company (on a fully diluted basis), and former holders of Oruka securities are expected to own approximately 97.61% of the outstanding shares of capital stock of the combined company (on a fully<span class="nobreak">-diluted</span> basis). Under certain circumstances further described in the Merger Agreement, the ownership percentages may be adjusted up or down including, but not limited to, if ARCA&#8217;s net cash as of closing is lower than $5.0&#160;million. ARCA management currently anticipates ARCA&#8217;s net cash as of closing will be approximately $5.0&#160;million, after giving effect to the special cash dividend, which is expected to be approximately $20.0<span class="nobreak"> </span>million, and the currently estimated ownership percentages reflect this projection.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">6</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>






	<div class="BOXSTYLE" style="margin:0;padding:0;border-width:0;border-color:#000000;border-width:1pt;border: solid windowtext 1.0pt; padding: 10.0pt 4.0pt 10.0pt 4.0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, prior to the First Effective Time, ARCA expects to declare a cash dividend to the pre<span class="nobreak">-First</span> Merger ARCA stockholders equal in the aggregate to ARCA&#8217;s reasonable, good faith approximation of the amount by which ARCA&#8217;s net cash (as determined pursuant to the Merger Agreement) will exceed $5.0&#160;million. ARCA management currently anticipates that ARCA&#8217;s net cash as of closing to be approximately $5.0&#160;million, after giving effect to the special cash dividend, which is expected to be approximately $20.0<span class="nobreak"> </span>million.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka Options and Oruka&#8217;s 2024 Equity Incentive Plan</span> <span class="CharOverride-1" style="font-style:normal;font-weight:normal;">(see page 174)</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Under the terms of the Merger Agreement, ARCA will assume Oruka&#8217;s 2024 Equity Incentive Plan and each option to purchase shares of Oruka common stock that is outstanding and unexercised immediately prior to the First Effective Time, whether or not vested, will be assumed and converted into an option to purchase shares of ARCA common stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Accordingly, from and after the First Effective Time: (i)&#160;each outstanding Oruka stock option assumed by ARCA may be exercised solely for shares of ARCA common stock; (ii)&#160;the number of shares of ARCA common stock subject to each outstanding Oruka stock option assumed by ARCA will be determined by multiplying (A)&#160;the number of shares of Oruka common stock that were subject to such Oruka stock option assumed by ARCA, as in effect immediately prior to the First Effective Time, by (B)&#160;the exchange ratio, and rounding the resulting number down to the nearest whole number of shares of ARCA common stock; and (iii)&#160;the per share exercise price of each Oruka stock option assumed by ARCA will be determined by dividing (A)&#160;the per share exercise price of such Oruka stock option, as in effect immediately prior to the First Effective Time, by (B)&#160;the exchange ratio and rounding the resulting exercise price up to the nearest whole cent. Each Oruka stock option assumed by ARCA will otherwise continue in full force and effect and the term, exercisability, vesting schedule, acceleration rights and other terms and conditions of such Oruka stock option will otherwise remain unchanged.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Each Oruka stock option shall, in accordance with its terms, continue to be subject to further adjustment as appropriate to reflect any stock split, division or subdivision of shares, stock dividend, reverse stock split, consolidation of shares, reclassification, recapitalization or other similar transaction with respect to shares of ARCA common stock subsequent to the First Effective Time. In addition, the combined company&#8217;s compensation committee will succeed to the authority and responsibility of Oruka&#8217;s board of directors as administrator of the Oruka 2024 Equity Incentive Plan.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka Warrants</span> <span class="CharOverride-1" style="font-style:normal;font-weight:normal;">(see page 139)</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Under the terms of the Merger Agreement, each warrant to purchase shares of Oruka capital stock that is outstanding and unexercised immediately prior to the First Effective Time (including any pre<span class="nobreak">-funded</span> warrant issued pursuant to the Oruka pre<span class="nobreak">-closing</span>&#160;financing), whether or not vested, will be converted into a warrant to purchase shares of ARCA common stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Accordingly, from and after the First Effective Time: (i)&#160;each outstanding Oruka warrant assumed by ARCA may be exercised solely for shares of ARCA common stock; (ii)&#160;the number of shares of ARCA common stock subject to each outstanding Oruka warrant assumed by ARCA will be determined by multiplying (A)&#160;the number of shares of Oruka common stock that were subject to such Oruka warrant, as in effect immediately prior to the First Effective Time, by (B)&#160;the exchange ratio, and rounding the resulting number down to the nearest whole number of shares of ARCA common stock; and (iii)&#160;the per share exercise price of each Oruka warrant assumed by ARCA will be determined by dividing (A)&#160;the per share exercise price of such Oruka warrant, as in effect immediately prior to the First Effective Time, by (B)&#160;the exchange ratio and rounding the resulting exercise price up to the nearest whole cent. Each Oruka warrant assumed by ARCA will otherwise continue in full force and effect and the term, exercisability, vesting schedule, acceleration rights and other terms and conditions of such Oruka warrant will otherwise remain unchanged.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Each Oruka warrant shall, in accordance with its terms, continue to be subject to further adjustment as appropriate to reflect any stock split, division or subdivision of shares, stock dividend, reverse stock split, consolidation of shares, reclassification, recapitalization or other similar transaction with respect to shares of ARCA common stock subsequent to the First Effective Time.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">7</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>






	<div class="BOXSTYLE" style="margin:0;padding:0;border-width:0;border-color:#000000;border-width:1pt;border: solid windowtext 1.0pt; padding: 10.0pt 4.0pt 10.0pt 4.0pt;">
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">ARCA Common Stock and ARCA Options</span><span class="BoldItalic" style="font-style:italic;font-weight:bold;font-style:normal;font-weight:normal;"> </span><span class="CharOverride-1" style="font-style:normal;font-weight:normal;">(see page 140)</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Except as contemplated by the proposed increase in the number of authorized shares of ARCA common stock described in Proposal No. 2 of this proxy statement/prospectus and the proposed reverse stock split of issued and outstanding ARCA common stock described in Proposal&#160;No. 3 of this proxy statement/prospectus, ARCA common stock will remain unaffected by the Merger.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Under the terms of the Merger Agreement, prior to the closing of the Merger, ARCA&#8217;s board of directors will accelerate the vesting of all equity awards of ARCA then outstanding but not then vested or exercisable, and cancel each option to acquire shares of ARCA&#8217;s common stock with an exercise price per share greater than the Parent Closing Price, in each case, in accordance with the terms of the Merger Agreement. At the closing of the First Merger, (i)&#160;each option to acquire shares of ARCA&#8217;s common stock with an exercise price less than or equal to the Parent Closing Price will be cancelled and converted into the right to receive an amount in cash, without interest, equal to the Parent Closing Price less the exercise price of such option and (ii)&#160;each other option to acquire shares of ARCA common stock will be cancelled for no consideration.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Conditions to the Completion of the Merger</span> (see page 148)</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">To complete the Merger, ARCA stockholders must approve Proposal&#160;No. 1 and Proposal&#160;No. 2 and Oruka stockholders must adopt the Merger Agreement and approve the Merger and the related transactions contemplated by the Merger Agreement. Additionally, each of the other closing conditions set forth in the Merger Agreement must be satisfied or waived.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Non</span><span class="nobreak"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">-Solicitation</span></span> (see page 145)</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Merger Agreement contains&#160;non<span class="nobreak">-solicitation</span>&#160;provisions prohibiting ARCA and Oruka from soliciting a competing transaction. Each of ARCA and Oruka have agreed that, subject to certain exceptions, ARCA and Oruka and any of their respective subsidiaries will not, nor will either party or any of its subsidiaries authorize or permit any of the directors, officers, employees, agents, attorneys, accountants, investment bankers, advisors or representatives retained by it or any of its subsidiaries to, directly or indirectly:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>solicit, initiate or knowingly encourage, induce or facilitate the communication, making, submission or announcement of, any acquisition proposal or acquisition inquiry;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>furnish any non<span class="nobreak">-public</span> information with respect to it to any person in connection with or in response to an acquisition proposal or acquisition inquiry;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>engage in discussions or negotiations with any person with respect to any acquisition proposal or acquisition inquiry;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>execute or enter into any letter of intent or any contract contemplating or otherwise relating to any acquisition transaction; or</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>publicly propose to do any of the foregoing.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Board Recommendation Change</span> (see page 146)</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Neither Oruka&#8217;s board of directors nor ARCA&#8217;s board of directors may change its recommendation in favor of the Merger, except that prior to receipt by such party of its stockholder approval, such party&#8217;s board of directors may effect a change in recommendation as a result of a material development or change in circumstances (&#8220;Intervening Event&#8221;) or with respect to a superior offer that did not result from a material breach of the Merger Agreement if:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>such party&#8217;s board of directors shall have determined in good faith, based on the advice of its outside legal counsel, that the failure to effect such change in recommendation would reasonably be expected to be inconsistent with its fiduciary duties under applicable law;</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">8</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>






	<div class="BOXSTYLE" style="margin:0;padding:0;border-width:0;border-color:#000000;border-width:1pt;border: solid windowtext 1.0pt; padding: 10.0pt 4.0pt 10.0pt 4.0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>such party has provided at least four&#160;business days&#8217; prior written notice to the other party that it intends to effect a change in recommendation, and during such period has, and has caused its lead financial advisor and outside legal counsel to, negotiate with the other party in good faith to make such adjustments to the terms and conditions so that the acquisition proposal ceases to constitute a superior offer; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>if after the other party shall have delivered to such party a written offer to alter the terms or conditions of the Merger Agreement during the four<span class="nobreak">-business</span>&#160;day period referred to above, such party&#8217;s board of directors shall have determined in good faith (based on the advice of its outside legal counsel), that the failure to effect a change in recommendation would reasonably be expected to be inconsistent with its fiduciary duties under applicable law.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In the event of any material amendment to any superior offer, the party considering the superior offer would be required to provide the other party with notice of such material amendment and there would be a new three<span class="nobreak">-business</span>&#160;day period following such notification during which the parties would be obligated to comply again with the requirements described above.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In the case of an Intervening Event, the party suffering such event shall promptly notify the other party before effecting a change in recommendation. The written notice is required to state the material facts and circumstances related to the applicable Intervening Event and that such party&#8217;s board of directors intends to make a change in recommendation.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Termination of the Merger Agreement </span><span class="CharOverride-1" style="font-style:normal;font-weight:normal;">(see page 150)</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Either ARCA or Oruka may terminate the Merger Agreement under certain circumstances, which would prevent the Merger from being consummated.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Termination Fee </span><span class="CharOverride-1" style="font-style:normal;font-weight:normal;">(see page 151)</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If the Merger Agreement is terminated under certain circumstances, ARCA could be required to pay Oruka a termination fee of $440,000 or Oruka could be required to pay ARCA a termination fee of $440,000.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Support Agreements </span><span class="CharOverride-1" style="font-style:normal;font-weight:normal;">(see page 153)</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Certain Oruka stockholders holding approximately 90% of the outstanding shares of Oruka capital stock have entered into support agreements with ARCA and Oruka to vote all of their shares of Oruka capital stock in favor of the adoption and approval of the Merger Agreement and the transactions contemplated thereby and against any alternative acquisition proposals (the &#8220;Oruka Support Agreements&#8221;). Certain ARCA stockholders holding approximately 28.5% of the outstanding shares of ARCA common stock have entered into support agreements with ARCA and Oruka to vote all of their shares of ARCA common stock in favor of the Nasdaq Stock Issuance Proposal, the Authorized Share Increase Proposal and the Reverse Stock Split Proposal and against any alternative acquisition proposals (the &#8220;ARCA Support Agreements,&#8221; and, together with the Oruka Support Agreements, the &#8220;Support Agreements&#8221;).</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Lock-Up Agreements </span><span class="CharOverride-1" style="font-style:normal;font-weight:normal;">(see page 153)</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Certain of Oruka&#8217;s executive officers, directors and stockholders have entered into&#160;lock<span class="nobreak">-up</span>&#160;agreements, pursuant to which such parties have agreed not to, except in limited circumstances, offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any shares of ARCA&#8217;s common stock or any securities convertible into or exercisable or exchangeable for ARCA common stock, currently or thereafter owned, including shares of ARCA common stock issuable upon conversion of ARCA Series&#160;B Preferred Stock issued in exchange for shares of Oruka preferred stock in the Merger, but excluding, as applicable, shares purchased in the Oruka pre<span class="nobreak">-closing</span>&#160;financing (including any shares of ARCA common stock issuable upon exercise of pre<span class="nobreak">-funded</span> warrants issued in exchange for pre<span class="nobreak">-funded</span> warrants to purchase shares of Oruka common stock sold in the Oruka pre<span class="nobreak">-closing</span> financing), until 180&#160;days following the closing of the Merger.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">9</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>






	<div class="BOXSTYLE" style="margin:0;padding:0;border-width:0;border-color:#000000;border-width:1pt;border: solid windowtext 1.0pt; padding: 10.0pt 4.0pt 10.0pt 4.0pt;">
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Subscription Agreement and Registration Rights Agreement </span><span class="CharOverride-1" style="font-style:normal;font-weight:normal;">(see pages 153 and 155)</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Immediately prior to the execution and delivery of the Merger Agreement, certain new and existing investors of Oruka entered into the Subscription Agreement with Oruka, pursuant to which such investors have agreed to purchase Oruka common stock or, in lieu thereof, Oruka pre<span class="nobreak">-funded</span> warrants, representing an aggregate commitment of $275.0&#160;million (which includes $25.0<span class="nobreak"> </span>million of proceeds previously received from the issuance of the Convertible Note and accrued interest on such note), in the Oruka pre<span class="nobreak">-closing</span> financing.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The shares of Oruka common stock and Oruka pre<span class="nobreak">-funded</span> warrants that are issued in the Oruka pre<span class="nobreak">-closing</span> financing will be or will have the right to be, respectively, converted into shares of ARCA common stock in the Merger.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Subscription Agreement contains customary representations and warranties of Oruka and also contains customary representations and warranties of the purchaser parties thereto.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Subscription Agreement also contemplates ARCA, Oruka and the investors participating in the Oruka pre<span class="nobreak">-closing</span> financing entering into a registration rights agreement at the closing of the Oruka pre<span class="nobreak">-closing</span> financing, pursuant to which, among other things, the combined company will agree to provide for the registration and resale of certain shares of ARCA common stock that are held by the investors participating in the Oruka pre<span class="nobreak">-closing</span> financing from time to time pursuant to Rule&#160;415.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Management Following the Merger </span><span class="CharOverride-1" style="font-style:normal;font-weight:normal;">(see page 273)</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following table sets forth the name, age as of May&#160;3, 2024 and position of each of the individuals who are expected to serve as executives and directors of the combined company following completion of the Merger:</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">



						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;text-align:left;"><span class="Bold" style="font-style:normal;font-weight:bold;">Name</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Age</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 58.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Position</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Executive Officers</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 58.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Lawrence Klein</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">41</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 58.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">President, Chief Executive Officer and Director</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Arjun Agarwal</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">48</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 58.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Senior Vice President, Finance and Treasurer</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Joana Goncalves</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">50</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 58.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Chief Medical Officer</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Paul Quinlan</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">61</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 58.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">General Counsel and Secretary</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Non-Employee Directors</span>:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 58.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Samarth Kulkarni</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">45</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 58.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Chair and Director</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Kristine Ball</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">52</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 58.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Director</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Carl Dambkowski</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">39</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 58.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Director</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Peter Harwin</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">38</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 58.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Director</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Cameron Turtle</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">34</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 58.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Director</p>
					</td>
				</tr>

		</table>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Material U.S.&#160;Federal Income Tax Consequences of the Merger </span><span class="CharOverride-1" style="font-style:normal;font-weight:normal;">(see page 128)</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Merger will qualify as a &#8220;reorganization&#8221; within the meaning of Section 368(a) of the Code for U.S. federal income tax purposes. As a result, subject to the limitations and qualifications described in the section titled &#8220;The Merger &#8212; Material U.S. Federal Income Tax Consequences of the Merger&#8221; beginning on page 128, a U.S. holder of Oruka stock (as defined therein) will generally not recognize any gain or loss for U.S. federal income tax purposes on the receipt of ARCA stock in the Merger.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Risk Factors </span><span class="CharOverride-1" style="font-style:normal;font-weight:normal;">(see page 15)</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Both ARCA and Oruka are subject to various risks associated with their businesses and their industries. In addition, the Merger, including the possibility that the Merger may not be completed, poses a number of risks to each company and its respective securityholders, including the following risks:</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Risks Related to the Merger</span></p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Failure to complete, or delays in completing, the potential merger with Oruka could materially and adversely affect ARCA&#8217;s results of operations, business, financial results and/or common stock price.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">10</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>






	<div class="BOXSTYLE" style="margin:0;padding:0;border-width:0;border-color:#000000;border-width:1pt;border: solid windowtext 1.0pt; padding: 10.0pt 4.0pt 10.0pt 4.0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>The exchange ratio will not change or otherwise be adjusted based on the market price of ARCA common stock.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>The issuance of ARCA common stock, including shares of ARCA common stock issuable upon conversion of ARCA Series&#160;B Preferred Stock, to Oruka stockholders pursuant to the Merger Agreement and the resulting change in control from the First Merger must be approved by ARCA stockholders, and the Merger Agreement and transactions contemplated thereby must be approved by the Oruka stockholders. Failure to obtain these approvals would prevent the closing of the Merger.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>If ARCA completes the Merger, the combined company will need to raise additional capital and satisfy certain contractual obligations by issuing equity securities or additional debt or through licensing arrangements, which may cause significant dilution to the combined company&#8217;s stockholders or restrict the combined company&#8217;s operations.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s expected disposal of its historical assets and operations in connection with its proposed Merger with Oruka will make it a shell company. As a result, ARCA will be subject to more stringent reporting requirements, offering limitations and resale restrictions.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Some of ARCA and Oruka directors and executive officers have interests in the Merger that are different from yours and that may influence them to support or approve the Merger without regard to your interests.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA stockholders and Oruka stockholders may not realize a benefit from the Merger commensurate with the ownership dilution they will experience in connection with the Merger, including the conversion of Oruka common stock issued in the Oruka pre<span class="nobreak">-closing</span> financing.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Risks Related to ARCA</span></p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Failure to complete, or delays in completing, the proposed merger with Oruka could expose ARCA to other operational and financial risks;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA has a limited operating history, no history of commercializing products, has not generated any product revenue, has incurred significant operating losses since inception and anticipates continuing to incur net losses for the foreseeable future;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>If ARCA does not successfully consummate the Merger or another strategic transaction, ARCA&#8217;s board of directors may explore strategic alternatives, including, without limitation, another strategic transaction and/or pursue a dissolution and liquidation of ARCA;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>If the Merger is not consummated and should ARCA pursue additional clinical trials for its product candidates, it may not be able to raise sufficient capital on acceptable terms, or at all, to continue development of Gencaro or rNAPc2 or to otherwise continue operations and may not be able to execute any strategic transaction; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s failure to meet Nasdaq&#8217;s continued listing requirements could result in a delisting of its common stock, which could have a material adverse effect on its ability to consummate the Merger.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Risks Related to Oruka</span></p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Even if the Merger and Oruka pre<span class="nobreak">-closing</span> financing are successful, Oruka will need to raise additional capital, and if it is unable to do so when needed, that will raise substantial doubt about Oruka&#8217;s ability to continue as a going concern. If Oruka is unable to raise such capital when needed, or on acceptable terms, Oruka may be forced to delay, reduce or eliminate clinical trials, product development programs or future commercialization efforts and/or file for bankruptcy or cease operations altogether;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Oruka has never generated any revenue from product sales and may never be profitable;</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">11</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>






	<div class="BOXSTYLE" style="margin:0;padding:0;border-width:0;border-color:#000000;border-width:1pt;border: solid windowtext 1.0pt; padding: 10.0pt 4.0pt 10.0pt 4.0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Oruka is a preclinical stage biopharmaceutical company with a limited operating history on which to assess its business; it has not initiated, conducted or completed any clinical trials, has no products approved for commercial sale, has historically incurred losses, and anticipates that it will continue to incur significant losses for the foreseeable future;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Oruka&#8217;s programs are in preclinical stages of development and may fail in development or suffer delays that materially and adversely affect their commercial viability. If Oruka or its current or future collaborators are unable to complete development of or commercialize Oruka&#8217;s product candidates, or experience significant delays in doing so, Oruka&#8217;s business will be materially harmed;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Oruka is substantially dependent on the success of its two most advanced programs, ORKA<span class="nobreak">-001</span> and ORKA<span class="nobreak">-002</span>, and its anticipated clinical trials of such programs may not be successful;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Oruka currently relies on licensing arrangements with Paragon through the Paragon Option Agreements. If Oruka is unable to maintain collaborations or licensing arrangements, or if its collaborations or licensing arrangements are not successful, Oruka&#8217;s business could be negatively impacted;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>In order to successfully implement Oruka&#8217;s plans and strategies, Oruka will need to grow the size of its organization and it may experience difficulties in managing this growth;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Oruka&#8217;s ability to obtain and protect its patents and other proprietary rights is uncertain, exposing Oruka to the possible loss of competitive advantage; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>The regulatory approval processes of the U.S.&#160;Food and Drug Administration (&#8220;FDA&#8221;) and other comparable foreign regulatory authorities are lengthy, time<span class="nobreak">-consuming</span> and inherently unpredictable. If Oruka is not able to obtain, or if there are delays in obtaining, required regulatory approvals for its product candidates, Oruka will not be able to commercialize, or will be delayed in commercializing, its product candidates, and its ability to generate revenue will be materially impaired.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Risks Related to the Combined Company</span></p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>The market price of the combined company&#8217;s common stock is expected to be volatile, and the market price of the common stock may drop following the Merger;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>The combined company may incur losses for the foreseeable future and might never achieve profitability;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>The combined company will need to raise additional financing in the future to fund its operations, which may not be available to it on favorable terms or at all;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Provisions that will be in the combined company&#8217;s certificate of incorporation and bylaws and provisions under Delaware law could make an acquisition of the combined company more difficult and may prevent attempts by its stockholders to replace or remove its management;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>After completion of the Merger, the combined company&#8217;s executive officers, directors and principal stockholders will have the ability to control or significantly influence all matters submitted to the combined company&#8217;s stockholders for approval; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>The combined company will have broad discretion in the use of the cash and cash equivalents of the combined company and the proceeds from the Oruka pre<span class="nobreak">-closing</span> financing and may invest or spend the proceeds in ways with which you do not agree and in ways that may not increase the value of your investment.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">These risks and other risks are discussed in greater detail under the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Risk Factors</span>&#8221; beginning on page 15 of this proxy statement/prospectus. ARCA and Oruka both encourage you to read and consider all of these risks carefully.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">12</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>






	<div class="BOXSTYLE" style="margin:0;padding:0;border-width:0;border-color:#000000;border-width:1pt;border: solid windowtext 1.0pt; padding: 10.0pt 4.0pt 10.0pt 4.0pt;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Regulatory Approvals </span><span class="CharOverride-1" style="font-style:normal;font-weight:normal;">(see page 128)</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA and Oruka do not intend to seek any regulatory approval from antitrust authorities to consummate the transactions.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Nasdaq Stock Market Listing </span><span class="CharOverride-1" style="font-style:normal;font-weight:normal;">(see page 131)</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka intends to file an initial listing application for the combined company common stock with Nasdaq. If such application is accepted, it is anticipated that the common stock of the combined company will be listed on Nasdaq following the closing of the Merger under the trading symbol &#8220;ORKA.&#8221; It is a condition to the consummation of the Merger that ARCA will receive confirmation from Nasdaq that the combined company has been approved for listing on Nasdaq, but there can be no assurance such listing condition will be met or that ARCA will obtain such confirmation from Nasdaq. If such listing condition is not met or if such confirmation is not obtained, the Merger will not be consummated unless the condition is waived. The Nasdaq condition set forth in the Merger Agreement is not expected to be waived by the applicable parties.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Anticipated Accounting Treatment </span><span class="CharOverride-1" style="font-style:normal;font-weight:normal;">(see page 132)</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Merger is expected to be treated by ARCA as a reverse merger and will be accounted for as an in<span class="nobreak">-substance</span> reverse recapitalization of ARCA by Oruka in accordance with U.S.&#160;generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) as, at close, the transaction is, in essence, the issuance of equity for ARCA&#8217;s net asset, which primarily consist of cash and other nominal non<span class="nobreak">-operating</span> assets and liabilities. For accounting purposes, Oruka is considered to be acquiring the assets and liabilities of ARCA in this transaction based on the terms of the Merger Agreement and other factors, including: (i)&#160;Oruka&#8217;s equity holders will own a substantial majority of the voting rights in the combined company; (ii)&#160;Oruka&#8217;s largest stockholder will retain the largest interest in the combined company; (iii)&#160;Oruka will designate all of the initial members of the board of directors of the combined company; and (iv)&#160;Oruka&#8217;s executive management team will become the management of the combined company. The combined company will be named Oruka Therapeutics, Inc. and be headquartered in Menlo Park, California. Accordingly, the Merger is expected to be treated as the equivalent of Oruka issuing stock to acquire the net assets of ARCA.&#160;As a result of the Merger, the net assets of ARCA will be stated at fair value, which approximates carrying value, with no goodwill or other intangible assets recorded, and the historical results of operations prior to the Merger will be those of Oruka. The direct and incremental costs related to the transaction will be treated as a reduction of the net proceeds received within additional paid<span class="nobreak">-in-capital</span>. See the &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Unaudited Pro Forma Condensed Combined Financial Information</span>&#8221; elsewhere in this proxy statement/prospectus for additional information.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Appraisal Rights and Dissenters&#8217; Rights </span><span class="CharOverride-1" style="font-style:normal;font-weight:normal;">(see page 132)</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Holders of ARCA common stock are not entitled to appraisal rights in connection with the Merger under Delaware law. Holders of Oruka capital stock are entitled to appraisal rights in connection with the Merger under Delaware law.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Comparison of Stockholder Rights </span><span class="CharOverride-1" style="font-style:normal;font-weight:normal;">(see page 301)</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Both ARCA and Oruka are incorporated under the laws of the State of Delaware and, accordingly, the rights of the stockholders of each are currently, and will continue to be, governed by the Delaware General Corporation Law (&#8220;DGCL&#8221;). If the Merger is completed, Oruka stockholders will become ARCA stockholders, and their rights will be governed by the DGCL, the amended and restated bylaws of ARCA (the &#8220;ARCA Bylaws&#8221;) and the ARCA Charter, as may be further amended by Proposal&#160;Nos.<span class="nobreak"> </span>2, 3 and 4 if approved by the ARCA stockholders at the ARCA special meeting. The rights of ARCA stockholders contained in the ARCA Charter and ARCA Bylaws differ from the rights of Oruka stockholders under the amended and restated certificate of incorporation of Oruka (the &#8220;Oruka Charter&#8221;) and bylaws of Oruka (the &#8220;Oruka Bylaws&#8221;), as more fully described under the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Comparison of Rights of Holders of ARCA Capital Stock and Oruka Capital Stock</span>&#8221; beginning on page 301 of this proxy statement/prospectus.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">13</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T25"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">MARKET PRICE AND DIVIDEND INFORMATION</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The ARCA common stock is currently listed on The Nasdaq Capital Market under the symbol &#8220;ABIO.&#8221;</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The closing price of the ARCA common stock on April&#160;2, 2024, the last&#160;day of trading prior to the announcement of the Merger, as reported on The Nasdaq Capital Market, was $1.71 per share. The closing price of the ARCA common stock on<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span><span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>, 2024, as reported on The Nasdaq Capital Market, was $&#160;&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>per share.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Because the market price of the ARCA common stock is subject to fluctuation, the market value of the shares of the ARCA common stock that the Oruka stockholders will be entitled to receive in the Merger may increase or decrease.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka is a private company, and its shares of common stock and preferred stock are not publicly traded.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Assuming approval of Proposal&#160;Nos. 1 and 2 and successful application for initial listing with Nasdaq, following the consummation of the Merger, shares of ARCA common stock will trade on Nasdaq under ARCA&#8217;s new name, &#8220;Oruka Therapeutics, Inc.,&#8221; and new trading symbol &#8220;ORKA.&#8221;</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of&#160;<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span><span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>, 2024, the Record Date for the ARCA special meeting, there were approximately&#160;&#160;&#160;&#160;&#160;<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>registered holders of record of the ARCA common stock. As of&#160;&#160;&#160;&#160;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>, 2024, Oruka had&#160;&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>holders of record of Oruka common stock and one holder of record of Oruka preferred stock. For detailed information regarding the beneficial ownership of certain ARCA and Oruka stockholders, see the sections of this proxy statement/prospectus titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Principal Stockholders of ARCA</span>,&#8221; &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Principal Stockholders of Oruka</span>&#8221; and &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Principal Stockholders of the Combined Company</span>.&#8221;</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Dividends</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA has never declared or paid any cash dividends on the ARCA common stock and does not anticipate paying cash dividends on the ARCA common stock for the foreseeable future, except the&#160;special&#160;cash&#160;dividend&#160;that ARCA will declare and pay to the holders of record of outstanding shares of ARCA common stock as of a record date prior to the First Effective Time, to be set by ARCA&#8217;s board of directors as close as reasonably practicable to (but not later than) the anticipated closing date of the First Merger. The aggregate amount of the special cash dividend shall be up to an amount equal to ARCA&#8217;s reasonable, good faith approximation of the amount by which ARCA&#8217;s net cash (as calculated pursuant to the terms and conditions of the Merger Agreement) will exceed $5,000,000. Notwithstanding the foregoing, any determination to pay cash dividends subsequent to the Merger will be at the discretion of the combined organization&#8217;s then<span class="nobreak">-current</span> board of directors and will depend upon a number of factors, including the combined organization&#8217;s results of operations, financial condition, future prospects, contractual restrictions, restrictions imposed by applicable law and other factors the then<span class="nobreak">-current</span> board of directors deems relevant.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka has never paid or declared any cash dividends on Oruka capital stock. If the Merger does not occur, Oruka does not anticipate paying any cash dividends on the Oruka capital stock in the foreseeable future, and Oruka intends to retain all available funds and any future earnings to fund the development and expansion of its business. Any future determination to pay dividends will be at the discretion of the Oruka board of directors and will depend upon a number of factors, including its results of operations, financial condition, future prospects, contractual restrictions, and restrictions imposed by applicable laws and other factors the Oruka board of directors deems relevant.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">14</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T24"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">RISK FACTORS</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">The combined company will be faced with a market environment that cannot be predicted and that involves significant risks, many of which will be beyond its control. In addition to the other information contained or incorporated by reference in this proxy statement/prospectus, you should carefully consider the material risks described below before deciding how to vote your shares of ARCA common stock. You should also read and consider the other information in this proxy statement/prospectus. Please see the section titled &#8220;Where You Can Find More Information&#8221; beginning on page 320 of this proxy statement/prospectus for further information.</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Risks Related to the Merger</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Failure to complete, or delays in completing, the potential merger with Oruka, announced on April&#160;3, 2024, could materially and adversely affect ARCA&#8217;s results of operations, business, financial results and/or common stock price.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On April&#160;3, 2024, ARCA entered into the Merger Agreement with Oruka, pursuant to which, among other matters, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, First Merger Sub will merge with and into Oruka, with Oruka continuing as a wholly owned subsidiary of ARCA and the surviving corporation of the First Merger and as part of the same overall transaction, the surviving corporation in the First Merger will merge with and into Second Merger Sub, with Second Merger Sub continuing as a wholly owned subsidiary of ARCA and the surviving entity of the merger.&#160;Consummation of the Merger is subject to certain closing conditions, a number of which are not within ARCA&#8217;s control. Any failure to satisfy these required conditions to closing may prevent, delay or otherwise materially adversely affect the completion of the transaction. ARCA cannot predict with certainty whether or when any of the required closing conditions will be satisfied or if another uncertainty may arise and cannot assure you that it will be able to successfully consummate the Merger as currently contemplated under the Merger Agreement or at all.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s efforts to complete the Merger could cause substantial disruptions in, and create uncertainty surrounding, its business, which may materially adversely affect its results of operation and its business. Uncertainty as to whether the Merger will be completed in a timely manner or at all may affect ARCA&#8217;s ability to retain and motivate existing employees. Uncertainty as to whether the Merger will be completed in a timely manner or at all could adversely affect ARCA&#8217;s business and its relationship with collaborators, suppliers, vendors, regulators and other business partners. For example, vendors, collaborators and other counterparties may defer their decisions to work with ARCA or seek to change their existing business relationships with ARCA.&#160;Changes to, or termination of, existing business relationships could adversely affect ARCA&#8217;s results of operations and financial condition, as well as the market price of ARCA common stock. The adverse effects of the pendency of the transaction could be exacerbated by any delays in completion of the transaction or termination of the Merger Agreement.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">If the conditions to the Merger are not satisfied or waived, the Merger may not occur.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Even if the Merger is approved by the stockholders of Oruka and ARCA, specified conditions must be satisfied or, to the extent permitted by applicable law, waived to complete the Merger. These conditions are set forth in the Merger Agreement and described further in the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">The Merger Agreement</span>&#8221; of this proxy statement/prospectus. ARCA cannot assure you that all of the conditions to the consummation of the Merger will be satisfied or waived. If the conditions are not satisfied or waived, the Merger may not occur or the closing may be delayed.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">The exchange ratio will not change or otherwise be adjusted based on the market price of ARCA common stock.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Applying the exchange ratio, the former Oruka securityholders immediately before the Merger are expected to own approximately 97.61% of the aggregate number of shares of the combined company&#8217;s capital stock following the Merger (on a fully<span class="nobreak">-diluted</span> basis), and ARCA securityholders immediately before the Merger are expected to own approximately 2.39% of the aggregate number of shares of the combined company capital stock following the Merger (on a fully<span class="nobreak">-diluted</span> basis), subject to certain assumptions, including, but not limited to, ARCA&#8217;s net cash as of </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">15</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">closing being equal to $5.0&#160;million. In the event ARCA&#8217;s net cash is below $5.0&#160;million, the exchange ratio will be adjusted such that the number of shares issued to Oruka&#8217;s pre<span class="nobreak">-closing</span> securityholders will be increased, and ARCA stockholders will own a smaller percentage of the combined company following the consummation of the Merger.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Any changes in the market price of ARCA&#8217;s stock before the completion of the First Merger will not affect the number of shares Oruka stockholders will be entitled to receive pursuant to the Merger Agreement. Therefore, if before the completion of the First Merger, the market price of ARCA common stock increases from the market price on the date of the Merger Agreement, then Oruka stockholders could receive merger consideration with substantially more value for their shares of Oruka capital stock than the parties had negotiated when they established the exchange ratio. Similarly, if before the completion of the First Merger, the market price of ARCA common stock declines from the market price on the date of the Merger Agreement, then Oruka stockholders could receive merger consideration with substantially lower value. The Merger Agreement does not include a price<span class="nobreak">-based</span> termination right.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">The issuance of ARCA common stock, including the shares of ARCA common stock issuable upon conversion of ARCA Series&#160;B Preferred Stock, to Oruka stockholders pursuant to the Merger Agreement and the resulting change in control from the First Merger must be approved by ARCA stockholders, and the Merger Agreement and transactions contemplated thereby must be approved by the Oruka stockholders. Failure to obtain these approvals would prevent the closing of the Merger.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Before the Merger can be completed, ARCA stockholders must approve, among other things, the issuance of ARCA common stock, including shares of ARCA common stock issuable upon conversion of ARCA Series&#160;B Preferred Stock, to Oruka stockholders pursuant to the Merger Agreement and the resulting change in control from the First Merger, and Oruka stockholders must adopt the Merger Agreement and approve the Merger and the related transactions. Failure to obtain the required stockholder approvals may result in a material delay in, or the abandonment of, the Merger. Any delay in completing the Merger may materially adversely affect the timing and benefits that are expected to be achieved from the Merger.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">The Merger may be completed even though a material adverse effect may result from the announcement of the Merger, industry-wide changes or other causes.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In general, neither ARCA nor Oruka is obligated to complete the Merger if there is a material adverse effect affecting the other party between April&#160;3, 2024, the date of the Merger Agreement, and the closing of the Merger. However, certain types of causes are excluded from the concept of a &#8220;material adverse effect.&#8221; Such exclusions include, but are not limited to, changes in general economic or political conditions, industry<span class="nobreak">-wide</span> changes, changes resulting from the announcement of the Merger, natural disasters, pandemics, other public health events or force majeure events and changes in U.S.&#160;generally accepted accounting principles. Therefore, if any of these events were to occur and adversely affect ARCA or Oruka, the other party would still be obliged to consummate the closing of the Merger notwithstanding such material adverse effect. If any such adverse effects occur and ARCA consummates the closing of the Merger, the stock price of the combined company may suffer. This in turn may reduce the value of the Merger to the stockholders of ARCA, Oruka or both.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">If the Merger is not completed, ARCA&#8217;s stock price may decline significantly.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The market price of ARCA common stock is subject to significant fluctuations. Market prices for securities of pharmaceutical, biotechnology and other life science companies have historically been particularly volatile. In addition, the market price of ARCA common stock will likely be volatile based on whether stockholders and other investors believe that ARCA can complete the Merger or otherwise raise additional capital to support ARCA&#8217;s operations if the Merger is not consummated and another strategic transaction cannot be identified, negotiated and consummated in a timely manner, if at all. The volatility of the market price of ARCA common stock has been and may be exacerbated by low trading volume. Additional factors that may cause the market price of ARCA common stock to fluctuate include:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the entry into, or termination of, key agreements, including commercial partner agreements;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>announcements by commercial partners or competitors of new commercial products, clinical progress or lack thereof, significant contracts, commercial relationships or capital commitments;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the loss of key employees;</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">16</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>future sales of ARCA common stock;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>general and industry<span class="nobreak">-specific</span> economic conditions that may affect ARCA&#8217;s research and development expenditures; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>period<span class="nobreak">-to-period</span> fluctuations in financial results.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Moreover, the stock markets in general have experienced substantial volatility that has often been unrelated to the operating performance of individual companies. These broad market fluctuations may also adversely affect the trading price of ARCA common stock. In the past, following periods of volatility in the market price of a company&#8217;s securities, stockholders have often instituted class action securities litigation against such companies.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">If ARCA completes the Merger, the combined company will need to raise additional capital and satisfy certain contractual obligations by issuing equity securities or additional debt or through licensing arrangements, which may cause significant dilution to the combined company&#8217;s stockholders or restrict the combined company&#8217;s operations.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On April&#160;3, 2024, Oruka entered into the Subscription Agreement with certain investors, including existing investors of Oruka, pursuant to which the investors agreed to purchase, in the aggregate, $275.0&#160;million (which includes $25.0<span class="nobreak"> </span>million of proceeds previously received from the issuance of the Convertible Note and accrued interest on such note) in shares of common stock and pre<span class="nobreak">-funded</span> warrants of Oruka immediately prior to the closing of the Merger, referred to as the Oruka pre<span class="nobreak">-closing</span> financing. The closing of the Oruka pre<span class="nobreak">-closing</span> financing is conditioned upon the satisfaction or waiver of the conditions to the closing of the Merger as well as certain other conditions. The shares of Oruka common stock and pre<span class="nobreak">-funded</span> warrants issued in the Oruka pre<span class="nobreak">-closing</span> financing will result in dilution to all securityholders of the combined company (i.e., both ARCA&#8217;s pre<span class="nobreak">-Merger</span> securityholders and former Oruka securityholders). Furthermore, pursuant to the amended and restated offer letter agreement between Oruka and Lawrence Klein, Oruka is obligated to issue additional options to purchase shares of Oruka common stock in order to maintain Mr.&#160;Klein&#8217;s ownership in Oruka at approximately 5.0% on a fully<span class="nobreak">-diluted</span> basis (the &#8220;Target Ownership Percentage&#8221;) until Oruka has raised an aggregate of $200.0&#160;million (the &#8220;Covered Limit&#8221;). As a result, Oruka expects to issue Mr.&#160;Klein additional options of Oruka to maintain his ownership in Oruka at the Target Ownership Percentage concurrently with the closing of the Oruka pre<span class="nobreak">-closing</span> financing up to the Covered Limit. Such additional options granted will result in further dilution to all securityholders of the combined company.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Additional financing may not be available to the combined company when it is needed or may not be available on favorable terms. To the extent that the combined company raises additional capital by issuing equity securities, such financing will cause additional dilution to all securityholders of the combined company, including ARCA&#8217;s pre<span class="nobreak">-Merger</span> securityholders and Oruka&#8217;s former securityholders. It is also possible that the terms of any new equity securities may have preferences over the combined company&#8217;s common stock. Any debt financing the combined company enters into may involve covenants that restrict its operations. These restrictive covenants may include limitations on additional borrowing and specific restrictions on the use of the combined company&#8217;s assets, as well as prohibitions on its ability to create liens, pay dividends, redeem its stock or make investments. In addition, if the combined company raises additional funds through licensing arrangements, it may be necessary to grant licenses on terms that are not favorable to the combined company.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, as a result of ARCA&#8217;s assumption of the Paragon Option Agreements in connection with the Merger, the combined company will be subject to the obligation to grant to Paruka, on each of December&#160;31, 2024 and December&#160;31, 2025, warrants to purchase a number of shares equal to 1.00% of the outstanding shares of ARCA common stock as of the date of the grant on a fully<span class="nobreak">-diluted</span> basis, with an exercise price equal to the fair market value of the underlying shares on the grant date. Such warrants granted will result in further dilution to all securityholders of the combined company.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Transfers of the combined company&#8217;s securities utilizing Rule&#160;144 of the Securities Act may be limited.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">A significant portion of the combined company&#8217;s securities will be restricted from immediate resale. Holders should be aware that transfers of the combined company&#8217;s securities pursuant to Rule&#160;144 may be limited as Rule&#160;144 is not available, subject to certain exceptions, for the resale of securities initially issued by shell companies (other than business combination related shell companies) or issuers that have been at any time previously a shell company. ARCA&#8217;s expected disposal of its historical assets and operations in connection with the Merger with Oruka will make it a shell company. ARCA anticipates that following the consummation of the Merger, the combined </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">17</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">company will no longer be a shell company. As a result, ARCA anticipates that holders will not be able to sell their restricted combined company securities pursuant to Rule&#160;144 without registration until one year after ARCA files the Current Report on Form&#160;8<span class="nobreak">-K</span> following the closing that includes the required Form&#160;10 information that reflects that the combined company is no longer a shell company.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">ARCA&#8217;s expected disposal of its historical assets and operations in connection with its proposed Merger with Oruka will make it a shell company. As a result, ARCA will be subject to more stringent reporting requirements, offering limitations and resale restrictions.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA has two remaining ongoing development programs, Gencaro and rNAPc2, and it will dispose of (or is in the process of disposing of) its legacy technology and intellectual property, including those related to Gencaro and rNAPc2. Any such disposal of legacy technology and intellectual property will be contingent upon obtaining stockholder approval for the Merger. As such, ARCA expects to become a shell company upon consummation of the Merger, and its Merger with Oruka would be subject to the requirements applicable to shell company business combinations; provided, however, that if the Merger is not consummated, the disposal of ARCA&#8217;s legacy technology and intellectual property is not expected to occur and ARCA would therefore not expect to become a shell company. </p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The requirements applicable to shell company business combinations are as follows:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the combined company will need to file a Form&#160;8<span class="nobreak">-K</span> to report the Form&#160;10 type information after closing with the SEC reflecting its status as an entity that is not a shell company;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA is not, and the combined company will not be, eligible to use a Form&#160;S<span class="nobreak">-3</span> until 12 full calendar&#160;months after closing;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the combined company will need to wait at least 60 calendar&#160;days after closing to file a Form&#160;S<span class="nobreak">-8</span> for any equity plans or awards;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the combined company will be an &#8220;ineligible issuer&#8221; for three&#160;years following the closing, which will prevent the combined company from (i)&#160;incorporating by reference in its Form&#160;S<span class="nobreak">-1</span> filings, (ii)&#160;using a free writing prospectus, or (iii)&#160;taking advantage of well<span class="nobreak">-known</span> seasoned issuer status despite its public float;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>investors who (i)&#160;are affiliates of Oruka at the time the Merger is submitted for the vote or consent of Oruka stockholders, (ii)&#160;receive securities of the combined company in the Merger (i.e., Rule&#160;145(c)&#160;securities) and (iii)&#160;publicly offer or sell such securities, will be deemed to be engaged in a distribution of such securities, and therefore to be underwriters with respect to resales of those securities, and accordingly such securities may not be included in the Form&#160;S<span class="nobreak">-1</span> resale registration statement anticipated to be filed after the closing of the Merger unless such securities are sold only in a fixed price offering in which such investors are named as underwriters in the prospectus;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Rule&#160;144(i)(2)&#160;will limit the ability to publicly resell Rule&#160;145(c)&#160;securities per Rule&#160;145(d), as well as any other &#8220;restricted&#8221; or &#8220;control&#8221; securities of the combined company per Rule&#160;144 (i.e., holders of restricted securities and any affiliates of the public company are also affected) until one year after the Form&#160;10 information is filed with the SEC.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The foregoing SEC requirements would increase the combined company&#8217;s time and cost of raising capital, offering stock under equity plans, and complying with securities laws. Further, such requirements will add burdensome restrictions on the resale of combined company shares by affiliates of Oruka and any holders of &#8220;restricted&#8221; or &#8220;control&#8221; securities.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Some of ARCA&#8217;s and Oruka&#8217;s directors and executive officers have interests in the Merger that are different from yours and that may influence them to support or approve the Merger without regard to your interests.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Directors and executive officers of ARCA and Oruka may have interests in the Merger that are different from, or in addition to, the interests of other ARCA stockholders generally. These interests with respect to ARCA&#8217;s directors and executive officers may include, among others, retention bonus payments, extension of exercisability periods of previously issued stock option grants, severance payments if employment is terminated in a qualifying termination in connection with the Merger and rights to continued indemnification, expense advancement and insurance coverage.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">18</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Further, certain current members of Oruka&#8217;s board of directors will continue as directors of the combined company after the effective time, and, following the closing of the Merger, will be eligible to be compensated as non<span class="nobreak">-employee</span> directors of the combined company pursuant to ARCA&#8217;s non<span class="nobreak">-employee</span> director compensation policy that is expected to remain in place following the effective time.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s board of directors was aware of and considered those interests, among other matters, in reaching their decisions to approve and adopt the Merger Agreement, approve the Merger, and recommend the approval of the Merger Agreement to ARCA and Oruka stockholders. These interests, among other factors, may have influenced the directors and executive officers of each company to support or approve the Merger.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">ARCA stockholders and Oruka stockholders may not realize a benefit from the Merger commensurate with the ownership dilution they will experience in connection with the Merger, including the conversion of Oruka common stock issued in the Oruka pre-closing financing.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If the combined company is unable to realize the full strategic and financial benefits currently anticipated from the Merger, ARCA stockholders and Oruka stockholders will have experienced substantial dilution of their ownership interests without receiving any commensurate benefit, or only receiving part of the commensurate benefit to the extent the combined company is able to realize only part of the strategic and financial benefits currently anticipated from the Merger.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">ARCA securityholders will generally have a reduced ownership and voting interest in, and will exercise less influence over the management of, the combined company following the completion of the Merger as compared to their current ownership and voting interests in the respective companies.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">After the completion of the Merger, ARCA&#8217;s current stockholders will generally own a smaller percentage of the combined company than their ownership of ARCA prior to the Merger. Immediately after the Merger, ARCA securityholders as of immediately prior to the Merger are expected to own approximately 2.39% of the outstanding shares of capital stock of the combined company (on a fully<span class="nobreak">-diluted</span> basis), and former holders of Oruka securities are expected to own approximately 97.61% of the outstanding shares of capital stock of the combined company (on a fully<span class="nobreak">-diluted</span> basis), subject to certain assumptions, including, but not limited to, ARCA&#8217;s net cash as of closing being equal to $5.0&#160;million. The Chief Executive Officer of Oruka will serve as the Chief Executive Officer of the combined company following the completion of the Merger.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Certain provisions of the Merger Agreement may discourage third parties from submitting competing proposals, including proposals that may be superior to the transactions contemplated by the Merger Agreement.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">While the Merger Agreement is in effect, each party is generally prohibited from, among other things, soliciting, initiating or knowingly encouraging, inducing or facilitating the communication, making, submission or announcement of any acquisition proposal or acquisition inquiry. In addition, ARCA&#8217;s current directors and executive officers and certain significant stockholders have entered into support agreements pursuant to the terms of the Merger Agreement, and as an inducement to Oruka&#8217;s willingness to enter into the Merger Agreement, by which they have agreed to vote all of their shares of ARCA capital stock in favor of the Merger Agreement and the transactions contemplated thereby and against any competing proposals, subject to certain limited exceptions. These provisions could discourage a potential competing acquirer from considering or proposing an acquisition or merger, even if it were prepared to pay consideration with a higher value than that implied by the merger consideration in the combination.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Because the lack of a public market for Oruka common stock makes it difficult to evaluate the fair market value of its capital stock, the value of ARCA common stock to be issued to Oruka stockholders may be more or less than the fair market value of Oruka common stock.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The outstanding capital stock of Oruka is privately held and is not traded on any public market. The lack of a public market makes it difficult to determine the fair market value of Oruka capital stock. Because the percentage of ARCA&#8217;s equity to be issued to Oruka stockholders was determined based on negotiations between the parties, it is possible that the value of ARCA common stock and ARCA Series&#160;B Preferred Stock to be issued to Oruka stockholders will be more or less than the fair market value of Oruka capital stock.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">19</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Lawsuits may be filed against ARCA, Oruka, or any of the members of their respective boards of directors arising out of the Merger, which may delay or prevent the Merger.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Putative stockholder complaints, including stockholder class action complaints, and other complaints may be filed against ARCA, ARCA&#8217;s board of directors, Oruka, Oruka&#8217;s board of directors and others in connection with the transactions contemplated by the Merger Agreement. The outcome of litigation is uncertain, and ARCA or Oruka may not be successful in defending against any such future claims. Lawsuits that may be filed against ARCA, ARCA&#8217;s board of directors, Oruka, or Oruka&#8217;s board of directors could delay or prevent the Merger, divert the attention of ARCA&#8217;s and Oruka&#8217;s management and employees from their&#160;day<span class="nobreak">-to-day</span> business and otherwise adversely affect ARCA and Oruka financially.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of July<span class="nobreak"> </span>8, 2024, one complaint has been filed by a purported ARCA stockholder against ARCA and ARCA&#8217;s board of directors in connection with the proposed Merger.  On May<span class="nobreak"> </span>20, 2024, a purported stockholder filed a complaint, captioned <span class="Italic" style="font-style:italic;font-weight:normal;">Wynter v. ARCA biopharma, Inc., et al.,</span> No.: 1:24<span class="nobreak">-cv-1418-STV</span> (D. Colo.) (the &#8220;Complaint&#8221;), against ARCA and ARCA&#8217;s board of directors. The Complaint alleges that the defendants filed or caused to be filed a materially incomplete and misleading preliminary registration statement with the SEC and asserts claims under Sections 14(a) and 20(a) of the Exchange Act. The Complaint seeks an order enjoining the proposed Merger, or in the event that the proposed Merger is consummated, an order rescinding the Merger or awarding rescissory damages, as well as costs, including attorneys&#8217; and experts&#8217; fees. ARCA cannot predict the outcome of the Complaint.  ARCA believes that the allegations and claims asserted in the Complaint are without merit and intends to defend against them vigorously. Additional lawsuits arising out of the Merger may be filed.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">ARCA has never paid and, other than in connection with the Merger with Oruka, does not intend to pay any cash dividends in the foreseeable future.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA has never paid cash dividends on any of its capital stock. Pursuant to the terms of the Merger Agreement, ARCA may declare and pay a special cash dividend to ARCA stockholders of record prior to the Merger consisting of cash up to an amount equal in the aggregate of the amount by which ARCA&#8217;s net cash will exceed $5.0&#160;million. The amount of such special cash dividend is currently uncertain, pending the determination of ARCA&#8217;s outstanding obligations and net cash position as of the closing of the Merger. Other than such potential special cash dividend in connection with the closing of the Merger, ARCA does not currently anticipate declaring or paying cash dividends on its capital stock in the foreseeable future.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">If ARCA does not successfully consummate the Merger or another strategic transaction, ARCA&#8217;s board of directors may decide to pursue a dissolution and liquidation of ARCA.&#160;In such an event, the amount of cash available for distribution to ARCA stockholders will depend heavily on the timing of such liquidation as well as the amount of cash that will need to be reserved for commitments and contingent liabilities, as to which ARCA can give you no assurance.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">There can be no assurance that the Merger will be completed. If the Merger is not completed, ARCA&#8217;s board of directors may decide to pursue a dissolution and liquidation of ARCA.&#160;In such an event, the amount of cash available for distribution to ARCA stockholders will depend heavily on the timing of such decision and, ultimately, such liquidation, since the amount of cash available for distribution continues to decrease as ARCA funds its operations while pursuing the Merger. In addition, if ARCA&#8217;s board of directors were to approve and recommend, and ARCA stockholders were to approve, a dissolution and liquidation of ARCA, ARCA would be required under Delaware law to pay ARCA&#8217;s outstanding obligations, as well as to make reasonable provision for contingent and unknown obligations, prior to making any distributions in liquidation to stockholders. ARCA&#8217;s commitments and contingent liabilities may include obligations under ARCA&#8217;s employment and related agreements with certain employees that provide for severance and other payments following a termination of employment occurring for various reasons, including a change in control of ARCA, litigation against ARCA, and other various claims and legal actions arising in the ordinary course of business, and other unexpected and/or contingent liabilities. As a result of this requirement, a portion of ARCA&#8217;s assets would need to be reserved pending the resolution of such obligations.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, ARCA may be subject to litigation or other claims related to a dissolution and liquidation of ARCA.&#160;If a dissolution and liquidation were to be pursued, ARCA&#8217;s board of directors, in consultation with ARCA&#8217;s advisors, would need to evaluate these matters and make a determination about a reasonable amount to reserve. Accordingly, holders of ARCA common stock could lose all or a significant portion of their investment in the event of liquidation, dissolution or winding up of ARCA.&#160;A liquidation would be a lengthy and uncertain process with no assurance of any value ever being returned to ARCA stockholders.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">20</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">ARCA is substantially dependent on its remaining employees to facilitate the consummation of the Merger.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of April&#160;4, 2024, ARCA had only three full<span class="nobreak">-time</span> employees and one part<span class="nobreak">-time</span> employee. ARCA&#8217;s ability to successfully complete the Merger depends in large part on its ability to retain certain remaining personnel. Despite ARCA&#8217;s efforts to retain these employees, one or more employees may terminate their employment with ARCA on short notice. The loss of the services of certain employees could potentially harm ARCA&#8217;s ability to consummate the Merger and run its&#160;day<span class="nobreak">-to-day</span> business operations, as well as fulfill its reporting obligations as a public company.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Risks Related to the Proposed Reverse Stock Split</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">The reverse stock split may not increase the combined company&#8217;s stock price over the long-term.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The principal purposes of the reverse stock split are to (i)&#160;increase the&#160;per<span class="nobreak">-share</span>&#160;market price of ARCA common stock above the minimum bid price requirement under the Nasdaq rules so that the listing of ARCA and the shares of ARCA common stock being issued in the Merger on Nasdaq will be approved and (ii)&#160;increase the number of authorized and unissued shares available for future issuance in connection with the Merger, though such increase will not alone be sufficient to complete the Merger. It cannot be assured, however, that the reverse stock split will accomplish any increase in the per<span class="nobreak">-share</span> market price of ARCA common stock for any meaningful period of time. While it is expected that the reduction in the number of outstanding shares of ARCA common stock will proportionally increase the market price of ARCA common stock, it cannot be assured that the reverse stock split will increase the market price of ARCA common stock by a multiple of the reverse stock split ratio mutually agreed by ARCA and Oruka, or result in any permanent or sustained increase in the market price of ARCA common stock, which is dependent upon many factors, including ARCA&#8217;s business and financial performance, general market conditions and prospects for future success. Thus, while the stock price of ARCA common stock might meet the listing requirements for Nasdaq initially after the reverse stock split, it cannot be assured that it will continue to do so.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">The reverse stock split may decrease the liquidity of the combined company&#8217;s common stock.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Although ARCA&#8217;s board of directors believes that the anticipated increase in the market price of the combined company&#8217;s common stock resulting from the proposed reverse stock split could encourage interest in its common stock and possibly promote greater liquidity for its stockholders, such liquidity could also be adversely affected by the reduced number of shares outstanding after the reverse stock split. The reduction in the number of outstanding shares may lead to reduced trading and a smaller number of market makers for the combined company&#8217;s common stock. In addition, the reverse stock split may not result in an increase in the combined company&#8217;s stock price necessary to satisfy Nasdaq&#8217;s initial listing requirements for the combined company.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">The reverse stock split may lead to a decrease in the combined company&#8217;s overall market capitalization.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Should the market price of the combined company&#8217;s common stock decline after the reverse stock split, the percentage decline will be greater, due to the smaller number of shares outstanding, than it would have been prior to the reverse stock split. A reverse stock split is often viewed negatively by the market and, consequently, can lead to a decrease in the combined company&#8217;s overall market capitalization. If the per share market price does not increase in proportion to the reverse stock split ratio, then the value of the combined company, as measured by its stock capitalization, will be reduced. In some cases, the&#160;per<span class="nobreak">-share</span>&#160;stock price of companies that have effected reverse stock splits subsequently declined back to&#160;pre<span class="nobreak">-reverse</span>&#160;split levels, and accordingly, it cannot be assured that the total market value of the combined company&#8217;s common stock will remain the same after the reverse stock split is effected, or that the reverse stock split will not have an adverse effect on the combined company&#8217;s stock price due to the reduced number of shares outstanding after the reverse stock split.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">21</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Risks Related to ARCA</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Risks Related to ARCA&#8217;s Business and Financial Condition</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">If ARCA is not able to successfully develop, obtain FDA approval for and provide for the commercialization of Gencaro or rNAPc2 in a timely manner, it may not be able to continue its business operations.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA currently has no products that have received regulatory approval for commercial sale. The process to develop, obtain regulatory approval for and commercialize potential product candidates is long, complex and costly.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Failure to demonstrate that a product candidate, including Gencaro or rNAPc2, is safe and effective, or significant delays in demonstrating such safety and efficacy, would adversely affect ARCA&#8217;s business. Failure to obtain marketing approval of Gencaro or rNAPc2 from appropriate regulatory authorities, or significant delays in obtaining such approval, would also adversely affect ARCA&#8217;s business and could, among other things, preclude ARCA from completing a strategic transaction or obtaining additional financing necessary to continue as a going concern.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Even if approved for sale, a product candidate must be successfully commercialized to generate value. ARCA does not currently have the capital resources or management expertise to commercialize Gencaro, rNAPc2 or any of its other product candidates and, as a result, will need to complete a strategic transaction or, alternatively, raise substantial additional funds to enable commercialization of Gencaro, rNAPc2 or any of its other product candidates, if approved. Failure to successfully provide for the commercialization of Gencaro, rNAPc2 or any other product candidate, if approved, would damage ARCA&#8217;s business.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">If ARCA encounters difficulties enrolling patients in its future clinical trial of Gencaro, any potential enrollment milestones or potential regulatory approvals could be delayed or otherwise adversely affected.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA may encounter difficulty enrolling a sufficient number of patients in its clinical trials, due to circumstances which are outside its control, including other clinical trials that may limit the availability of study participants. As a result, ARCA may need to delay or terminate its trials, which would have a negative impact on its business. Delays in enrolling patients in the clinical trial would also adversely affect ARCA&#8217;s ability to meet projected enrollment milestones or timelines for completing the study and obtaining regulatory approval.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">ARCA&#8217;s clinical trials from its product candidates may not yield results that will enable ARCA to further develop its products as a therapy and obtain regulatory approvals necessary to be used as a drug.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA will receive regulatory approval for its product candidates only if it can demonstrate, in carefully designed and conducted clinical trials, that the product candidate is safe and effective. ARCA does not know whether any future clinical trials for Gencaro, rNAPc2 or any other product candidate will demonstrate sufficient safety and efficacy to obtain the requisite regulatory approvals or will result in marketable products.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The results from preclinical testing and early clinical trials may not be predictive of results from later studies. ARCA may suffer significant setbacks in advanced clinical trials, even after seeing promising results in earlier studies. Based on results at any stage of clinical trials, ARCA may decide to repeat or redesign a trial or discontinue development of one or more of ARCA&#8217;s product candidates. If ARCA fails to adequately demonstrate the safety and efficacy of its product candidates, ARCA will not be able to obtain the required regulatory approvals to commercialize those product candidates and ARCA&#8217;s business, results of operations and financial condition would be materially adversely affected.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, administering ARCA&#8217;s product candidates to humans may produce undesirable side effects. These side effects could interrupt, delay or halt clinical trials of ARCA&#8217;s product candidates, and could result in the FDA or other regulatory authorities denying approval of ARCA&#8217;s product candidates, for any or all targeted indications.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">ARCA may not achieve its projected development goals in the time frames it announces and expects.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA sets goals for, and makes public statements regarding, the timing of certain accomplishments, such as the initiation of its clinical trials, the steps for commencing and continuing its clinical trials, the disclosure of trial results, the obtainment of regulatory approval and the sale of drug products, which ARCA sometimes refers to as milestones. These milestones may not be achieved, and the actual timing of these events can vary </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">22</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">dramatically due to a number of factors such as delays or failures in ARCA&#8217;s clinical trials, disagreements with any collaborative partners, the uncertainties inherent in the regulatory approval process and manufacturing scale<span class="nobreak">-up</span>, delays in achieving manufacturing or marketing arrangements sufficient to commercialize ARCA&#8217;s products or ARCA&#8217;s inability to obtain sufficient financing in a timely manner. There can be no assurance that ARCA will make regulatory submissions or receive regulatory approvals as planned. If ARCA fails to achieve one or more of these milestones as planned, its business will be materially adversely affected.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">ARCA expects a Phase&#160;3 PRECISION-AF clinical trial will require substantially more capital, and ARCA cannot guarantee when or if it will be able to secure such additional financing.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA will need to secure additional financing in order to initiate enrollment of its Phase&#160;3 PRECISION<span class="nobreak">-AF</span> clinical trial. Even if ARCA can<span class="BoldItalic" style="font-style:italic;font-weight:bold;"> </span>begin enrolling patients, it expects to have to raise significant additional capital to continue enrollment. If ARCA is not able to obtain financing in the future or on acceptable terms, it may have to terminate the clinical trial early, which could adversely affect its business.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">ARCA will need to raise substantial additional funds through public or private equity or debt transactions and/or complete one or more strategic transactions or partnerships, to continue development of Gencaro, rNAPc2 or any of its other product candidates. If ARCA is unable to raise such financing or complete such a transaction, it may not be able to continue operations.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As a result of the expected development timeline to potentially obtain FDA approval for Gencaro or rNAPc2, if at all, the substantial additional costs associated with the development of ARCA&#8217;s product candidates, including the costs associated with clinical trials related thereto, and the substantial cost of commercializing Gencaro or rNAPc2, if approved, ARCA will need to raise substantial additional funding through public or private equity or debt transactions or a strategic combination or partnership. If ARCA is delayed in obtaining funding or are unable to complete a strategic transaction, it may discontinue its development activities on Gencaro, rNAPc2 and its other product candidates or discontinue its operations. Even if ARCA is able to fund continued development of Gencaro, rNAPc2 or any of ARCA&#8217;s other product candidates, ARCA expects that it will need to complete a strategic transaction or raise substantial additional funding through public or private equity or debt securities or partnership to successfully commercialize Gencaro, rNAPc2 or any other product candidate.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA believes its cash and cash equivalents as of March&#160;31, 2024 will be sufficient to fund its operations through the middle of fiscal year 2025. ARCA&#8217;s review of its strategic options may impact this projection. Conducting a Phase&#160;3 PRECISION<span class="nobreak">-AF</span> trial clinical trial would likely require additional financing. However, changing circumstances may cause ARCA to consume capital significantly faster or slower than currently anticipated. ARCA has based these estimates on assumptions that may prove to be wrong, and ARCA could exhaust its available financial resources sooner than it currently anticipates; therefore, ARCA may have to raise additional capital for other clinical trials. Initiating any Phase&#160;3 clinical trial of Gencaro will require additional financing. In 2020, ARCA entered into a new sales agreement with a placement agent to sell, from time to time, ARCA common stock in an &#8220;at the market offering.&#8221; As of December&#160;31, 2022, ARCA sold an aggregate of 9,928,272<span class="nobreak"> </span>shares of ARCA common stock pursuant to the terms of such sales agreement for aggregate gross proceeds of approximately $54.0&#160;million. Net proceeds received in this offering were approximately $52.2&#160;million, after deducting expenses for executing the &#8220;at the market offering&#8221; and commissions paid to the placement agent. In 2021, ARCA amended the new sales agreement and the amount available for the offering under its prospectus to its registration statement on Form&#160;S<span class="nobreak">-3</span> (No.&#160;333<span class="nobreak">-254585</span>), which expired in March&#160;2024. In April&#160;2024, ARCA terminated such sales agreement in accordance with its terms. Sales of ARCA common stock dilute the ownership interest of ARCA stockholders and may cause the price per share of ARCA common stock to decrease. Changing circumstances may cause ARCA to consume capital significantly faster or slower than it currently anticipates. ARCA has based these estimates on assumptions that may prove to be wrong, and it could exhaust its available financial resources sooner than it currently anticipates.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s liquidity, and its ability to raise additional capital or complete any strategic transaction, depends on a number of factors, including, but not limited to, the following:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the timing and outcome of the strategic review process;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the consummation of any particular strategic transactions, including the Merger;</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">23</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the costs and timing for potential additional clinical trials in order to gain possible regulatory approval for Gencaro, rNAPc2 and ARCA&#8217;s other product candidates;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the market price of ARCA&#8217;s stock and the availability and cost of additional equity capital from existing and potential new investors;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s ability to retain the listing of ARCA common stock on the Nasdaq Capital Market;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>general economic and industry conditions affecting the availability and cost of capital, including as a result of deteriorating market conditions due to investor concerns regarding inflation, adverse developments affecting the financial services industry, continued hostilities between Russia and Ukraine and Hamas&#8217; attack against Israel and the ensuing conflict;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s ability to control costs associated with its operations;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the terms and conditions of ARCA&#8217;s existing collaborative and licensing agreements.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The sale of additional equity or convertible debt securities would likely result in substantial dilution to ARCA stockholders. If ARCA raises additional funds through the incurrence of indebtedness, the obligations related to such indebtedness would be senior to rights of holders of its capital stock and could contain covenants that would restrict its operations. ARCA also cannot predict what consideration might be available, if any, to it or its stockholders, in connection with any strategic transaction. Should strategic alternatives or additional capital not be available to ARCA, or not be available on acceptable terms, ARCA may be unable to realize value from its assets and discharge its liabilities in the normal course of business which may, among other alternatives, cause ARCA to further delay, substantially reduce or discontinue operational activities to conserve its cash resources.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">ARCA has received a Special Protocol Assessment agreement from the FDA relating to its planned Phase&#160;3 program for Gencaro. This Special Protocol Assessment agreement does not guarantee approval of Gencaro or any other particular outcome from regulatory review.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In 2019, ARCA received a Special Protocol Assessment (&#8220;SPA&#8221;) agreement from the FDA for its planned Phase&#160;3 clinical trial of Gencaro. The FDA&#8217;s SPA process is designed to facilitate the FDA&#8217;s review and approval of drugs by allowing the FDA to evaluate the proposed design and size of certain clinical trials that are intended to form the primary basis for determining a drug product&#8217;s efficacy. Upon specific request by a clinical trial sponsor, the FDA will evaluate the protocol and respond to a sponsor&#8217;s questions regarding, among other things, primary efficacy endpoints, trial conduct and data analysis, within 45&#160;days of receipt of the request. The FDA ultimately assesses whether the protocol design and planned analysis of the trial are acceptable to support regulatory approval of the product candidate with respect to the effectiveness of the indication studied. All agreements and disagreements between the FDA and the sponsor regarding a SPA must be clearly documented in a SPA letter or the minutes of a meeting between the sponsor and the FDA.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">However, an SPA agreement does not guarantee approval of a product candidate, even if the trial is conducted in accordance with the protocol. Moreover, the FDA may revoke or alter ARCA&#8217;s SPA agreement in certain circumstances. In particular, a SPA agreement is not binding on the FDA if public health concerns emerge that were unrecognized at the time of the SPA agreement, other new scientific concerns regarding product safety or efficacy arise, ARCA fails to comply with the agreed upon trial protocols, or the relevant data, assumptions or information provided by ARCA in its request for the SPA change or are found to be false or omit relevant facts. In addition, even after an SPA agreement is finalized, the SPA agreement may be modified, and such modification will be deemed binding on the FDA review division, except under the circumstances described above, if the FDA and the sponsor agree in writing to modify the protocol and such modification is intended to improve the study. The FDA retains significant latitude and discretion in interpreting the terms of the SPA agreement and the data and results from any study that is the subject of the SPA agreement.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Even though ARCA obtained an agreement on its SPA, ARCA cannot assure you that its planned Phase&#160;3 clinical trial will succeed, will be deemed binding by the FDA under its SPA agreement or will result in any FDA approval for Gencaro. ARCA may also alter the design of the trial to focus on endpoints that are not covered by the SPA.&#160;Moreover, if the FDA revokes or alters its agreement under ARCA&#8217;s SPA, or interprets the data collected from </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">24</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">the clinical trial differently than ARCA does, the FDA may not deem the data sufficient to support an application for regulatory approval, which could materially adversely affect ARCA&#8217;s business, financial condition and results of operations.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">If ARCA is not able to maintain the requirements for listing on the Nasdaq Capital Market, it could be delisted, which could have a material adverse effect on its ability to consummate the Merger, raise additional funds as well as the price and liquidity of ARCA common stock.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA common stock is currently listed on the Nasdaq Capital Market. To maintain the listing of ARCA common stock on the Nasdaq Capital Market, ARCA is required to meet certain listing requirements, including, among others, (i)&#160;a minimum closing bid price of $1.00 per share, (ii)&#160;a market value of publicly held shares (excluding shares held by ARCA&#8217;s executive officers, directors and 10% or more stockholders) of at least $1&#160;million and (iii)&#160;either: (x)&#160;stockholders&#8217; equity of at least $2.5&#160;million; or (y)&#160;a total market value of listed securities of at least $35&#160;million. In addition, pursuant to the terms of the Merger Agreement ARCA is required to use commercially reasonable efforts to maintain its listing on Nasdaq until the First Merger Effective Time.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA has received three potential delisting notices from Nasdaq since 2012. In each of 2012, 2015 and 2018, ARCA received notification from Nasdaq of potential delisting of its shares from the Nasdaq Capital Market because the closing bid price of ARCA common stock had not met the minimum closing bid price of $1.00 per share during the preceding 30&#160;business days. ARCA subsequently regained compliance with Nasdaq&#8217;s minimum closing bid price requirements related to the 2012, 2015 and 2018 notices, by effecting a 1<span class="nobreak">-for-6</span> reverse split of ARCA common stock in March&#160;2013, a 1<span class="nobreak">-for-7</span> reverse split of ARCA common stock in September&#160;2015 and a 1<span class="nobreak">-for-18</span> reverse split of ARCA common stock in April&#160;2019. Despite effecting a 1<span class="nobreak">-for-18</span> reverse split of ARCA common stock in April&#160;2019, there can be no assurance that the market price per share of ARCA common stock will remain in excess of the $1.00 minimum bid price for a sustained period of time. The continuing effect of ARCA&#8217;s reverse stock split on the market price of ARCA common stock cannot be predicted with any certainty, and the history of similar stock split combinations for companies in like circumstances is varied. It is possible that the per share price of ARCA common stock after the reverse stock split will not rise in proportion to the reduction in the number of shares of common stock outstanding resulting from the reverse stock split, effectively reducing ARCA&#8217;s market capitalization, and there can be no assurance that the market price per post<span class="nobreak">-reverse</span> split share will either exceed or remain in excess of the $1.00 minimum bid price for a sustained period of time. The market price of ARCA common stock may vary based on other factors that are unrelated to the number of shares outstanding, including ARCA&#8217;s future performance.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The delisting of ARCA common stock from a national exchange may impair ARCA&#8217;s ability to consummate the Merger and could impair the liquidity and market price of the common stock. It could also materially adversely affect ARCA&#8217;s access to the capital markets, and any limitation on market liquidity or reduction in the price of the common stock as a result of that delisting could adversely affect ARCA&#8217;s ability to consummate the Merger or raise capital on terms acceptable to ARCA, or at all.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In future periods, if ARCA does not meet the minimum stockholders&#8217; equity, minimum closing bid price requirements, or any other listing requirements, it would be subject to delisting from the Nasdaq Capital Market.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of May&#160;9, 2024, the closing price of ARCA common stock was $3.37 per share, and the total market value of ARCA&#8217;s listed securities was approximately $48.9&#160;million. As of March&#160;31, 2024, ARCA had stockholders&#8217; equity of $35.1&#160;million.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">ARCA&#8217;s financial statements for the quarter ended March&#160;31, 2024 were prepared assuming that ARCA will continue as a going concern. ARCA&#8217;s management has concluded that due to ARCA&#8217;s need for additional capital, and the uncertainties surrounding ARCA&#8217;s ability to raise such funding, there may be uncertainty about ARCA&#8217;s ability to continue as a going concern in future&#160;years.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s financial statements for the quarter ended March&#160;31, 2024 were prepared assuming that ARCA will continue as a going concern. The going concern basis of presentation assumes that ARCA will continue in operation for the foreseeable future and will be able to realize its assets and discharge its liabilities and commitments in the normal course of business and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from ARCA&#8217;s inability to continue as a going concern. As of December&#160;31, 2019, ARCA&#8217;s management and independent </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">25</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">registered public accounting firm concluded that, due to ARCA&#8217;s need for additional capital and the uncertainties surrounding ARCA&#8217;s ability to raise such funding, substantial doubt existed as to ARCA&#8217;s ability to continue as a going concern for a period from one year after ARCA&#8217;s annual financial statements had been issued. ARCA believes its cash and cash equivalents as of March&#160;31, 2024 will be sufficient to fund its operations through the middle of fiscal year 2025. ARCA&#8217;s future viability beyond that point is dependent on the results of the strategic review process and ARCA&#8217;s ability to raise additional capital to fund its operations. ARCA expects to continue to incur costs and expenditures in connection with the process of evaluating strategic alternatives. There can be no assurance, however, that ARCA will be able to successfully consummate any particular strategic transaction, including the Merger Agreement. The process of continuing to evaluate these strategic options may be very costly, time<span class="nobreak">-consuming</span> and complex and ARCA has incurred, and may in the future incur, significant costs related to this continued evaluation, such as legal, accounting and advisory fees and expenses and other related charges, see discussion above regarding the Merger Agreement. Should ARCA pursue additional clinical trials for its product candidates, it will have to raise additional capital for clinical trials of Gencaro. ARCA may not be able to raise sufficient capital on acceptable terms, or at all, to continue development of Gencaro or rNAPc2 or to otherwise continue operations and may not be able to execute any strategic transaction. ARCA&#8217;s Merger Agreement discussed above may impact this projection. Conducting a Phase&#160;3 PRECISION<span class="nobreak">-AF</span> trial would likely require additional financing, subject to ARCA&#8217;s pursuits of a potential strategic transaction and the consummation of such potential transaction. However, changing circumstances may cause ARCA to consume capital significantly faster or slower than currently anticipated. ARCA has based these estimates on assumptions that may prove to be wrong, and ARCA could exhaust its available financial resources sooner than it currently anticipates; therefore, ARCA may have to raise additional capital for other clinical trials. Initiating any Phase&#160;3 clinical trial of Gencaro will require additional financing. ARCA cannot be certain that it will be able to make any other sale of ARCA common stock in any future offering to cover its future capital needs, or at all. Changing circumstances may cause ARCA to consume capital significantly faster or slower than it currently anticipates. If ARCA is delayed in completing or is unable to complete additional funding and/or a strategic transaction, it may discontinue its development activities or operations, but there are no assurances that these reductions would be sufficient to allow ARCA to continue to operate as a going concern. Therefore, even if ARCA resolves this uncertainty, its independent registered public accountants and/or management could conclude that uncertainty as to its ability to continue as a going concern could exist at a future date.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA has based these estimates on assumptions that may prove to be wrong, and ARCA could exhaust its available financial resources sooner than it currently anticipates. ARCA may be forced to reduce its operating expenses and raise additional funds to meet its working capital needs, principally through the additional sales of its securities or debt financings. However, ARCA cannot guarantee that it will be able to obtain sufficient additional funds when needed or that such funds, if available, will be obtainable on satisfactory terms. If ARCA is unable to raise sufficient additional capital or complete a strategic transaction, it may be unable to continue to fund its operations, develop Gencaro, rNAPc2 or its other product candidates, or realize value from its assets and discharge its liabilities in the normal course of business. If ARCA cannot raise sufficient funds, it may have to liquidate its assets, and might realize significantly less than the values at which they are carried on its financial statements, and stockholders may lose all or part of their investment in ARCA&#8217;s securities.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Market conditions and changing circumstances, some of which may be beyond ARCA&#8217;s control, could impair ARCA&#8217;s ability to access its existing cash, cash equivalents and investments and to timely pay key vendors and others.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Market conditions and changing circumstances, some of which may be beyond ARCA&#8217;s control, could impair ARCA&#8217;s ability to access its existing cash, cash equivalents and investments and to timely pay key vendors and others. For example, on March&#160;10, 2023, Silicon Valley Bank (SVB), where ARCA maintains certain accounts, was placed into receivership with the Federal Deposit Insurance Corporation (FDIC), which resulted in all funds held at SVB being temporarily inaccessible by SVB&#8217;s customers. If other banks and financial institutions with whom ARCA has banking relationships enter receivership or become insolvent in the future, ARCA may be unable to access, and may lose, some or all of its existing cash, cash equivalents and investments to the extent those funds are not insured or otherwise protected by the FDIC.&#160;In addition, in such circumstances, ARCA might not be able to timely pay key vendors and others. ARCA regularly maintains cash balances that are not insured or are in excess of the FDIC&#8217;s insurance limit. Any delay in ARCA&#8217;s ability to access its cash, cash equivalents and investments (or the loss of some or all of such funds) or to timely pay key vendors and others could have a material adverse effect on ARCA&#8217;s operations and cause it to need to seek additional capital sooner than planned.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">26</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">ARCA&#8217;s business could be adversely affected by the effects of health epidemics in regions where ARCA or third parties on which ARCA relies may have clinical trial sites or other business operations.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s business could be adversely affected by health epidemics in regions where ARCA may have concentrations of future clinical trial sites or other business operations.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, third<span class="nobreak">-party</span> manufacturing of ARCA&#8217;s drug product candidates and suppliers of the materials used in the production of ARCA&#8217;s drug product candidates may be impacted by significant delays or restrictions resulting from any future health epidemic which may disrupt ARCA&#8217;s supply chain or limit ARCA&#8217;s ability to manufacture drug product candidates for its clinical trials.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The ultimate impact of any future health epidemic is highly uncertain and subject to change. These effects could have a material impact on ARCA&#8217;s operations.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">If ARCA encounters difficulties enrolling patients in any future clinical trials, its future trials could be delayed or otherwise adversely affected.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If ARCA has difficulty enrolling a sufficient number of patients in any future clinical trial, ARCA may need to delay or terminate its trial, which would have a negative impact on its business. Delays in enrolling patients in any future clinical trials would also adversely affect ARCA&#8217;s ability to generate any product, milestone and royalty revenues under collaboration agreements, if any, and could impose significant additional costs on ARCA or on any future collaborators.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">For example, the development of vaccines for the SARS<span class="nobreak">-CoV-2</span> virus and the development of other therapies for COVID<span class="nobreak">-19</span> disease impacted ARCA&#8217;s ability to enroll patients in its rNAPc2 (AB201) Phase&#160;2b clinical trial and such enrollment was slower than expected.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The GENETIC<span class="nobreak">-AF</span> clinical trial required that ARCA identify and enroll a large number of patients with the condition under investigation and the trial enrolled only those patients having a specific genotype, and certain patients who have or are willing to have a Medtronic device implanted for monitoring and recording AFB data. As a result, enrollment for GENETIC<span class="nobreak">-AF</span> was slower than expected, with ARCA&#8217;s first patient enrolled in June&#160;2014 and enrollment completed in August&#160;2017. Because of the rigorous enrollment criteria, ARCA&#8217;s clinical trial timelines were delayed from ARCA&#8217;s original projections. ARCA anticipates that any future Phase&#160;3 clinical trial of Gencaro, including PRECISION<span class="nobreak">-AF</span>, may have similar enrollment criteria, and ARCA cannot guarantee that it will not have similar enrollment issues in any future clinical trials.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA may also encounter difficulty enrolling a sufficient number of patients in any future clinical trial, due to circumstances which are outside ARCA&#8217;s control, including as a result of continued hostilities between Russia and Ukraine and Hamas&#8217; attack against Israel and the ensuing conflict.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">ARCA will rely on contract research organizations to conduct substantial portions of its clinical trials, including any future clinical trial of Gencaro, rNAPc2, and as a result, ARCA will be unable to directly control the timing, conduct and expense of all aspects of its clinical trials.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA does not currently have sufficient staff with the requisite experience to conduct its clinical trials and therefore will rely on third parties to conduct certain aspects of any future clinical trials. ARCA previously contracted with a CRO to conduct components of its GENETIC<span class="nobreak">-AF</span> clinical trial and anticipate contracting with a CRO to conduct components of any future clinical trial for Gencaro and components of the clinical study of rNAPc2 or any future clinical trials for ARCA&#8217;s other product candidates. As a result, ARCA will have less control over many details and steps of any clinical trial, the timing and completion of any clinical trial, the required reporting of adverse events and the management of data developed through any clinical trial than would be the case if ARCA were relying entirely upon its own staff. Communicating with outside parties can also be challenging, potentially leading to mistakes as well as difficulties in coordinating activities. Outside parties, such as CROs, may have staffing difficulties, may undergo changes in priorities or may become financially distressed, adversely affecting their willingness or ability to conduct ARCA&#8217;s clinical trial. ARCA may experience unexpected cost increases that are beyond its control. Problems with the timeliness or quality of the work of a CRO may lead ARCA to seek to terminate the relationship and use an alternative service provider. However, making any change may be costly </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">27</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">and may delay ongoing trials, if any, and contractual restrictions may make such a change difficult or impossible. Additionally, it may be impossible to find a replacement organization that can conduct clinical trials in an acceptable manner and at an acceptable cost.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Even though ARCA anticipates relying on CROs in the future, it will likely have to devote substantial resources and rely on the expertise of ARCA&#8217;s employees to manage the work being done by the CROs. Due to ARCA&#8217;s limited experience in managing clinical trials, ARCA cannot guarantee its employees will do so effectively.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">ARCA expects to depend on existing and future collaborations with third parties for the development of some of ARCA&#8217;s product candidates. If those collaborations are not successful, ARCA may not be able to complete the development of these product candidates.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA collaborated with one or more clinical trial networks in its development program for rNAPc2. As a result, ARCA lacked direct control over certain aspects of the development program and the amount and timing of resources that these collaborators devote to the project.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA had a collaboration agreement with Medtronic that supported ARCA&#8217;s GENETIC<span class="nobreak">-AF</span> clinical trial. If ARCA&#8217;s arrangement with Medtronic, as amended, is continued as part of ARCA&#8217;s future development of Gencaro, ARCA will have limited control over the amount and timing of resources that they dedicate to the development of Gencaro. This is also likely to be true in any future collaboration with third parties and ARCA may seek additional third<span class="nobreak">-party</span> collaborators for the development of Gencaro, rNAPc2 or any other product candidates. ARCA&#8217;s ability to benefit from these arrangements will depend on its collaborators&#8217; abilities to successfully perform the functions assigned to them in these arrangements.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Collaborations involving ARCA&#8217;s product candidates pose the following risks to us:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>collaborators have significant discretion in determining the efforts and resources that they will apply to these collaborations;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>collaborators may not pursue development and commercialization of ARCA&#8217;s product candidates or may elect not to continue or renew development or commercialization programs based on clinical trial results, changes in the collaborator&#8217;s strategic focus or available funding, or external factors such as an acquisition that diverts resources or creates competing priorities;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with ARCA&#8217;s product candidates if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ARCA&#8217;s;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>collaborators may not properly maintain or defend ARCA&#8217;s intellectual property rights or may use ARCA&#8217;s proprietary information in such a way as to invite litigation that could jeopardize or invalidate its proprietary information or expose it to potential litigation;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>disputes may arise between the collaborators and ARCA that result in the delay or termination of the research, development or commercialization of ARCA&#8217;s product candidates or that result in costly litigation or arbitration that diverts management attention and resources;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>collaborations may be terminated and, if terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable product candidates;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>collaborators may elect to take over manufacturing rather than retain ARCA as manufacturer and may encounter problems in starting up or gaining approval for their manufacturing facility and so be unable to continue development of product candidates;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA may be required to undertake the expenditure of substantial operational, financial and management resources in connection with any collaboration;</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">28</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA may be required to issue equity securities to collaborators that would dilute ARCA&#8217;s existing stockholders&#8217; percentage ownership;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA may be required to assume substantial actual or contingent liabilities;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>collaborators may not commit adequate resources to the marketing and distribution of ARCA&#8217;s product candidates, limiting ARCA&#8217;s potential revenues from these products; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>collaborators may experience financial difficulties.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA faces a number of challenges in seeking additional collaborations. Collaborations are complex and any potential discussions may not result in a definitive agreement for many reasons. For example, whether ARCA reaches a definitive agreement for a collaboration will depend, among other things, upon its assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration, and the proposed collaborator&#8217;s evaluation of a number of factors, such as the design or results of ARCA&#8217;s clinical trials, the potential market for ARCA&#8217;s product candidates, the costs and complexities of manufacturing and delivering ARCA&#8217;s product candidates to patients, the potential of competing products, the existence of uncertainty with respect to ownership or the coverage of ARCA&#8217;s intellectual property, and industry and market conditions generally. If ARCA were to determine that additional collaborations for its Gencaro development are necessary and were unable to enter into such collaborations on acceptable terms, ARCA might elect to delay or scale back the development or commercialization of Gencaro in order to preserve its financial resources or to allow it adequate time to develop the required physical resources and systems and expertise itself.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Collaboration agreements may not lead to development or commercialization of ARCA&#8217;s product candidates in the most efficient manner, or at all. In addition, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators. If a present or future collaborator of ARCA were to be involved in a business combination, the continued pursuit and emphasis on ARCA&#8217;s product development or commercialization program could be delayed, diminished or terminated.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Any future clinical trial for Gencaro will require the use of a third-party diagnostic services provider to administer a genetic test needed to identify the patient receptor genotypes of clinical trial participants, and as a result, ARCA will be unable to directly control the timing, conduct and expense of the genetic test.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA anticipates that any future clinical trial of Gencaro, if any, will require a companion diagnostic test that identifies the patient&#8217;s receptor genotype. The trial would only enroll those patients with the receptor that has the potential for enhanced efficacy, the beta<span class="nobreak">-1</span> 389 Arg receptor as detected by a beta<span class="nobreak">-1</span> 389 Arg/Arg genotype. Accordingly, ARCA anticipates that any future clinical trial for Gencaro will require the use of a third<span class="nobreak">-party</span> diagnostic service to perform the genetic testing. There has been limited experience in ARCA&#8217;s industry in prospective development of companion diagnostics required to perform the required molecular profiling. ARCA entered into an agreement with LabCorp to provide the diagnostic services of the genetic test needed to support ARCA&#8217;s GENETIC<span class="nobreak">-AF</span> clinical trial. To provide those services, LabCorp obtained from the FDA an investigational device exemption (&#8220;IDE&#8221;) for the companion diagnostic test being used in ARCA&#8217;s GENETIC<span class="nobreak">-AF</span> clinical trial. ARCA would expect a similar agreement and approval would be necessary for any companion diagnostic used in any future clinical trials for Gencaro.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The FDA and similar regulatory authorities outside the United&#160;States regulate companion diagnostics. Companion diagnostics require separate or coordinated regulatory approval prior to commercialization. Changes to regulatory advice could delay ARCA&#8217;s development programs or delay or prevent eventual marketing approval for ARCA&#8217;s product candidates that may otherwise be approvable. In July&#160;2011, the FDA issued draft guidance that stated that if safe and effective use of a therapeutic depends on an <span class="Italic" style="font-style:italic;font-weight:normal;">in vitro</span> diagnostic, the FDA generally will not approve the therapeutic unless the FDA approves or clears this &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">in vitro</span> companion diagnostic device&#8221; at the same time that the FDA approves the therapeutic. The approval or clearance of the companion diagnostic would occur through the FDA&#8217;s Center for Devices and Radiological Health. In 2014, the FDA issued guidance on in vitro companion diagnostic devices. The guidance allows for flexibility by the FDA in the case of therapeutic products to treat serious conditions for which no alternative treatment exists and the benefits of using the companion diagnostic outweigh the risk, but it is unclear how this discretion may be applied by the agency with respect to the companion diagnostic test related to any Gencaro clinical trials. The FDA&#8217;s evolving position on the topic of companion </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">29</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">diagnostics could affect ARCA&#8217;s clinical development programs that utilize companion diagnostics. In particular, the FDA may limit ARCA&#8217;s ability to use retrospective data, otherwise disagree with ARCA&#8217;s approaches to trial design, biomarker qualification, clinical and analytical validity, and clinical utility, or make ARCA repeat aspects of a trial or initiate new trials.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Given ARCA&#8217;s limited experience in developing diagnostics, ARCA expects to rely primarily on third parties for the design and manufacture of the companion diagnostics for its product candidates. If ARCA, or any third parties that ARCA engages to assist it, are unable to successfully develop companion diagnostics for its product candidates that require such diagnostics, or experiences delays in doing so, the development of its product candidates may be adversely affected, its product candidates may not receive marketing approval and it may not realize the full commercial potential of any products that receive marketing approval. As a result, ARCA&#8217;s business could be materially harmed.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">ARCA will need to establish a collaborative arrangement with a third-party diagnostics services provider to obtain marketing clearance or approval of the companion genetic test for Gencaro. There is no guarantee that the FDA will grant timely clearance or approval of the genetic test, if at all, and failure to obtain such timely clearance or approval would adversely affect ARCA&#8217;s ability to market Gencaro.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The drug label ARCA intends to seek for Gencaro would identify the patient receptor genotype for which the drug is approved. Accordingly, ARCA believes developing a genetic test that is simple to administer and widely available will be critical to the successful commercialization of Gencaro. The genetic test will be subject to regulation by the FDA and by comparable agencies in various foreign countries. The process of complying with the requirements of the FDA and comparable agencies is costly, time consuming and burdensome.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Despite the time and expense expended, regulatory clearance or approval is never guaranteed. If regulatory clearance or approval is delayed, or if one or more third<span class="nobreak">-party</span> diagnostic services providers are unable to obtain FDA approval of the genetic test at all or in parallel with the approval of Gencaro, or are unable to commercialize the test successfully and in a manner that effectively supports the commercial efforts for Gencaro, or if the information concerning the differential response to Gencaro resulting from certain genetic variation is not included in the approval label for Gencaro, the commercial launch of Gencaro may be significantly and adversely affected.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Regulatory approval is required for the genetic test to be used in ARCA&#8217;s Gencaro clinical trials and to support the commercialization of the test, if approved. Delays or failures in obtaining such regulatory approval, including any required validation analyses may prevent a third-party diagnostics provider from commercializing such genetic test and will adversely affect ARCA&#8217;s business, operating results and prospects.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Before a genetic test can be used commercially, including in conjunction with Gencaro, if it is approved for marketing, the third<span class="nobreak">-party</span> diagnostics provider must obtain FDA Premarket Approval (&#8220;PMA&#8221;), for such test. The FDA may require additional validation of the genetic test ARCA used in GENETIC<span class="nobreak">-AF</span> prior to any approval of Gencaro or the genetic test or prior to the use of such test in any future clinical trials for Gencaro. ARCA anticipates the genetic test will be required as a condition to prescribing Gencaro. There is no guarantee the FDA will approve the anticipated PMA submission for the genetic test. Even if the genetic test is eventually approved, performing additional validation work necessary to support the PMA, if required, for current or future genetic test products, including one associated with Gencaro, would require additional time and expense and the outcome would be uncertain. Moreover, such delays or increased costs or failures could adversely affect ARCA&#8217;s business, operating results and prospects for commercializing the genetic test.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">If a third-party diagnostics provider responsible for the genetic test associated with Gencaro or certain of its third-party suppliers fails to comply with ongoing FDA or other foreign regulatory authority requirements, or if there are unanticipated problems with the genetic test, these products could be subject to restrictions or withdrawal from use in a trial or from the market.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Any diagnostic for which a third<span class="nobreak">-party</span> diagnostics provider obtains clearance or approval, and the manufacturing processes, reporting requirements, post<span class="nobreak">-approval</span> clinical data and promotional activities for such product, will be subject to continued regulatory review, oversight and periodic inspections by the FDA and other domestic and foreign regulatory bodies. With respect to the genetic test, to the extent applicable, any third<span class="nobreak">-party</span> diagnostics provider and certain of its suppliers will be required to comply with the FDA&#8217;s Quality System </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">30</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">Regulation (&#8220;QSR&#8221;) and International Standards Organization (&#8220;ISO&#8221;) requirements which cover the methods and documentation of the design, testing, production, control, quality assurance, labeling, packaging, storage and shipping of any product for which clearance or approval is obtained. Regulatory bodies, such as the FDA, enforce the QSR and other regulations through periodic inspections. The failure by a third<span class="nobreak">-party</span> diagnostics provider, or certain of its third<span class="nobreak">-party</span> manufacturers or suppliers, as the case may be, to comply with applicable statutes and regulations administered by the FDA and other regulatory bodies, or the failure to timely and adequately respond to any adverse inspectional observations or product safety issues, could result in, among other things, enforcement actions. If any of these actions were to occur, it could harm ARCA&#8217;s reputation and cause product sales and profitability of Gencaro, if approved, to suffer and may prevent ARCA from generating revenue or utilizing the genetic test further in any clinical trial. Even if regulatory clearance or approval is granted, such clearance or approval may be subject to limitations on the intended uses for which the product may be marketed and reduce ARCA&#8217;s potential to successfully commercialize the product and generate revenue from the product.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Future sales of Gencaro may suffer if its marketplace acceptance is negatively affected by the genetic test.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The genetic test is an important component of the commercial strategy for Gencaro in addition to being required for ARCA&#8217;s clinical trials. ARCA believes that the genetic test helps predict patient response to Gencaro, and that this aspect of the drug is important to its ability to compete effectively with current therapies. The genetic test adds an additional step in the prescribing process, an additional cost for the patient and payors, the risk that the test results may not be rapidly available and the possibility that it may not be available at all to hospitals and medical centers. Although ARCA anticipates that Gencaro, if approved in a timely manner, would be the first genetically<span class="nobreak">-targeted</span> cardiovascular drug, Gencaro will be one of a number of successful drugs in the beta<span class="nobreak">-blocker</span> class currently on the market. Prescribers may be more familiar with these other beta<span class="nobreak">-blockers</span>, and may be resistant to prescribing Gencaro as an AF therapy in patients with HF.&#160;For instance, the top<span class="nobreak">-line</span> results of ARCA&#8217;s Phase&#160;2B GENETIC<span class="nobreak">-AF</span> clinical trial indicated that Gencaro demonstrated a similar treatment benefit compared to the active comparator, metoprolol succinate (TOPROL<span class="nobreak">-XL</span>). If ARCA&#8217;s future clinical trials in Gencaro do not show that Gencaro has a clear therapeutic benefit as compared to other drugs in the beta<span class="nobreak">-blocker</span> class currently on the market, then prescribers may be unlikely to prescribe Gencaro to patients, even if approved. Any one of these factors could affect prescriber behavior, which in turn may substantially impede market acceptance of the genetic test, which could cause significant harm to Gencaro&#8217;s ability to compete, and in turn harm ARCA&#8217;s business.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Unless ARCA is able to generate sufficient product revenue, it will continue to incur losses from operations and will not achieve or maintain profitability. ARCA is&#160;years away from commercializing a product and generating product revenue.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s historical losses have had, and will continue to have, an adverse effect on ARCA stockholders&#8217; equity and working capital, among other things. ARCA is&#160;years away from commercializing a product and generating any product revenue. As a result, ARCA expects to continue to incur significant operating losses for the foreseeable future. Even if ARCA ultimately receives regulatory approval for Gencaro, rNAPc2 or ARCA&#8217;s other product candidates, sales of such products may not generate sufficient revenue for it to achieve or maintain profitability. Because of the numerous risks and uncertainties associated with developing therapeutic drugs, ARCA may experience larger than expected future losses and may never reach profitability.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">ARCA&#8217;s product candidates are subject to extensive regulation, which can be costly and time-consuming, and unsuccessful or delayed regulatory approvals could increase ARCA&#8217;s future development costs or impair ARCA&#8217;s future revenue.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The preclinical and clinical development, testing, manufacture, safety, efficacy, labeling, storage, recordkeeping, and subsequent advertising, promotion, sale, marketing, and distribution, if approved, of ARCA&#8217;s product candidates are subject to extensive regulation by the FDA and other regulatory authorities in the United&#160;States and elsewhere. These regulations also vary in important, meaningful ways from country to country. ARCA is not permitted to market a potential drug in the United&#160;States until it receives approval of a New Drug Application (&#8220;NDA&#8221;) from the FDA for such drug. ARCA has not received an NDA approval from the FDA for Gencaro, rNAPc2 or any of its other product candidates. There can be no guarantees with respect to ARCA&#8217;s product candidates that clinical studies will adequately support an NDA, that the products will receive necessary regulatory approvals, or that they will prove to be commercially successful.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">31</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">To receive regulatory approval for the commercial sale of any product candidates, ARCA must demonstrate safety and efficacy in humans to the satisfaction of regulatory authorities through preclinical studies and adequate and well<span class="nobreak">-controlled</span> clinical trials of the product candidates. This process is expensive and can take many&#160;years, and failure can occur at any stage of the testing. ARCA&#8217;s failure to adequately demonstrate the safety and efficacy of ARCA&#8217;s product candidates will prevent regulatory approval and commercialization of such products.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In 2008, ARCA submitted and the FDA accepted ARCA&#8217;s NDA filing for Gencaro for the treatment of chronic HF.&#160;In 2009, the FDA issued a Complete Response Letter in which the FDA stated that it could not approve the Gencaro NDA in its current form and specified actions required for approval of the NDA, including conducting an additional Phase&#160;3 clinical trial of Gencaro in patients with HF.&#160;ARCA completed a Phase&#160;2B clinical study of Gencaro in HF patients to assess its efficacy in reducing or preventing AF.&#160;ARCA enrolled 267 HF patients with AF in the Phase&#160;2B clinical trial. ARCA reported top<span class="nobreak">-line</span> Phase&#160;2B data in February&#160;2018. In the third quarter of 2018, ARCA submitted a SPA to the FDA for a Phase&#160;3 clinical trial. In 2019, the FDA approved ARCA&#8217;s SPA request for a Phase&#160;3 clinical trial of Gencaro. Even though the FDA approved ARCA&#8217;s SPA, this product candidate will require&#160;years of additional clinical development. Even if ARCA conducts additional studies in accordance with ARCA&#8217;s SPA agreement or further FDA guidance and submit or file a new or amended NDA, the FDA may ultimately decide that the NDA does not satisfy the criteria for approval.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In the event that ARCA or its collaborators conduct preclinical studies that do not comply with Good Laboratory Practices (&#8220;GLP&#8221;) or incorrectly design or carry out human clinical trials in accordance with Good Clinical Practices (&#8220;GCP&#8221;) or those clinical trials fail to demonstrate clinical significance, it is unlikely that ARCA will be able to obtain FDA approval for product development candidates. ARCA&#8217;s inability to successfully initiate and effectively complete clinical trials for any product candidate on schedule, or at all, will severely harm ARCA&#8217;s business. Significant delays in clinical development could materially increase product development costs or allow ARCA&#8217;s competitors to bring products to market before ARCA does, impairing ARCA&#8217;s ability to effectively commercialize any future product candidate. ARCA does not know whether planned clinical trials will begin on time, will need to be redesigned or will be completed on schedule, if at all. Clinical trials can be delayed for a variety of reasons, including:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>delays or failures in obtaining regulatory authorization to commence a trial because of safety concerns of regulators relating to ARCA&#8217;s product candidates or similar product candidates of ARCA&#8217;s competitors or failure to follow regulatory guidelines;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>delays or failures in obtaining clinical materials and manufacturing sufficient quantities of the product candidates for use in trials;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>failure of clinical materials to meet pre<span class="nobreak">-established</span> specifications at product release or during ongoing stability studies;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>delays or failures in reaching agreement on acceptable terms with prospective study sites;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>delays or failures in obtaining approval of ARCA&#8217;s clinical trial protocol from an institutional review board to conduct a clinical trial at a prospective study site;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>delays in recruiting patients to participate in a clinical trial, which may be due to the size of the patient population, eligibility criteria, protocol design, perceived risks and benefits of the drug, availability of other approved and standard of care therapies or, availability of clinical trial sites;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>other clinical trials seeking to enroll subjects with similar profile;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>failure of ARCA&#8217;s clinical trials and clinical investigators to be in compliance with GCP;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>unforeseen safety issues, including negative results from ongoing preclinical studies;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>inability to monitor patients adequately during or after treatment;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>difficulty recruiting and monitoring multiple study sites;</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">32</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>failure of ARCA&#8217;s third<span class="nobreak">-party</span> contract research organizations, clinical site organizations and other clinical trial managers, to satisfy their contractual duties, comply with regulations or meet expected deadlines; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>an insufficient number of patients who have, or are willing to have, a Medtronic device implanted for monitoring and recording AF burden data.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, any approvals ARCA may obtain may not cover all of the clinical indications for which it seeks approval or permit it to make claims of superiority over currently marketed competitive products. Also, an approval might contain significant limitations in the form of narrow indications, warnings, precautions or contraindications with respect to conditions of use. If the FDA determines that a risk evaluation and mitigation strategy, or REMS, is necessary to ensure that the benefits of the drug outweigh the risks, ARCA may be required to include as part of the NDA a proposed REMS that may include a package insert directed to patients, a plan for communication with healthcare providers, restrictions on a drug&#8217;s distribution, or a Medication Guide, to provide better information to consumers about the drug&#8217;s risks and benefits. Finally, an approval could be conditioned on ARCA&#8217;s commitment to conduct further clinical trials, which ARCA may not have the resources to conduct or which may negatively impact ARCA&#8217;s financial situation.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The manufacture and analytical testing of Gencaro and rNAPc2 is performed by third<span class="nobreak">-party</span> suppliers, who must also meet cGMP requirements and pass a pre<span class="nobreak">-approval</span> inspection of their facilities before ARCA can obtain marketing approval.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">All of ARCA&#8217;s product candidates are prone to the risks of failure inherent in drug development. The results from preclinical animal testing and early human clinical trials may not be predictive of results obtained in later human clinical trials. Further, although a new product may show promising results in preclinical or early human clinical trials, it may subsequently prove unfeasible or impossible to generate sufficient safety and efficacy data to obtain necessary regulatory approvals. The data obtained from preclinical and clinical studies are susceptible to varying interpretations that may delay, limit or prevent regulatory approval, and the FDA and other regulatory authorities in the United&#160;States and elsewhere exercise substantial discretion in the drug approval process. The numbers, size and design of preclinical studies and clinical trials that will be required for FDA or other regulatory approval will vary depending on the product candidate, the disease or condition for which the product candidate is intended to be used and the regulations and guidance documents applicable to any particular product candidate. The FDA or other regulators can delay, limit or deny approval of any product candidate for many reasons, including, but not limited to:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>side effects;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>safety and efficacy;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>defects in the design of clinical trials;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the fact that the FDA or other regulatory officials may not approve ARCA&#8217;s or ARCA&#8217;s third<span class="nobreak">-party</span> manufacturer&#8217;s processes or facilities; or</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the fact that new regulations may be enacted by the FDA or other regulators may change their approval policies or adopt new regulations requiring new or different evidence of safety and efficacy for the intended use of a product candidate.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In light of widely publicized events concerning the safety of certain drug products, regulatory authorities, members of Congress, the Government Accountability Office, medical professionals and the general public have raised concerns about potential drug safety issues. These events have resulted in the withdrawal of certain drug products, revisions to certain drug labeling that further limit use of the drug products and establishment of risk management programs that may, for instance, restrict distribution of drug products. The increased attention to drug safety issues may result in a more cautious approach by the FDA to clinical trials and approval. Data from clinical trials may receive greater scrutiny with respect to safety and the product&#8217;s risk/benefit profile, which may make the FDA or other regulatory authorities more likely to terminate clinical trials before completion, or require longer or additional clinical trials that may result in substantial additional expense, and a delay or failure in obtaining </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">33</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">approval or approval for a more limited indication than originally sought. Aside from issues concerning the quality and sufficiency of submitted preclinical and clinical data, the FDA may be constrained by limited resources from reviewing and determining the approvability of the Gencaro NDA in a timely manner.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In pursuing clinical development of Gencaro for an AF indication, ARCA will be required to amend the Gencaro HF NDA or prepare a new NDA.&#160;The FDA could approve Gencaro, but without including some or all of the prescribing information that ARCA has requested. For instance, the FDA could approve Gencaro for AF in a more limited patient population or include additional warnings in the drug&#8217;s label. This, in turn, could substantially and detrimentally impact ARCA&#8217;s ability to successfully commercialize Gencaro and effectively protect ARCA&#8217;s intellectual property rights in Gencaro.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">If ARCA&#8217;s product candidates receive regulatory approval, ARCA would be subject to ongoing regulatory obligations and restrictions, which may result in significant expenses and limit its ability to develop and commercialize other potential products.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If a product candidate of ARCA&#8217;s is approved by the FDA or by another regulatory authority, ARCA would be held to extensive regulatory requirements over product manufacturing, testing, distribution, labeling, packaging, adverse event reporting and other reporting to regulatory authorities, storage, advertising, marketing, promotion, distribution, and record keeping. Regulatory approvals may also be subject to significant limitations on the indicated uses or marketing of the product candidates. Potentially costly follow<span class="nobreak">-up</span> or post<span class="nobreak">-marketing</span> clinical studies may be required as a condition of approval to further substantiate safety or efficacy, or to investigate specific issues of interest to the regulatory authority. Previously unknown problems with the product candidate, including adverse events of unanticipated severity or frequency, may result in additional regulatory controls or restrictions on the marketing or use of the product or the need for post marketing studies, and could include suspension or withdrawal of the products from the market.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Furthermore, ARCA&#8217;s third<span class="nobreak">-party</span> manufacturers and the manufacturing facilities that they use to make ARCA&#8217;s product candidates are regulated by the FDA.&#160;Quality control and manufacturing procedures must continue to conform to cGMP after approval. Drug manufacturers and their subcontractors are required to register their facilities and products manufactured annually with the FDA and certain state agencies and are subject to periodic unannounced inspections by the FDA, state and/or other foreign authorities. Any subsequent discovery of problems with a product, or a manufacturing or laboratory facility used by ARCA or its collaborators, may result in restrictions on the product, or on the manufacturing or laboratory facility, including a withdrawal of the drug from the market or suspension of manufacturing. Any changes to an approved product, including the way it is manufactured or promoted, often require FDA approval before the product, as modified, can be marketed. ARCA and its third<span class="nobreak">-party</span> manufacturers will also be subject to ongoing FDA requirements for submission of safety and other post<span class="nobreak">-market</span> information.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The marketing and advertising of ARCA&#8217;s drug products by its collaborators or itself will be regulated by the FDA, certain state agencies or foreign regulatory authorities. Violations of these laws and regulations, including promotion of ARCA&#8217;s products for unapproved uses or failing to disclose risk information, are punishable by criminal and civil sanctions and may result in the issuance of enforcement letters or other enforcement action by the FDA, U.S.&#160;Department of Justice, state agencies, or foreign regulatory authorities that could jeopardize ARCA&#8217;s ability to market the product.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition to the FDA, state or foreign regulations, the marketing of ARCA&#8217;s drug products by itself or its collaborators will be regulated by federal, state or foreign laws pertaining to health care &#8220;fraud and abuse,&#8221; such as the federal anti<span class="nobreak">-kickback</span> law prohibiting bribes, kickbacks or other remuneration for the order or recommendation of items or services reimbursed by federal health care programs. Many states have similar laws applicable to items or services reimbursed by commercial insurers. Violations of these laws are punishable by criminal and civil sanctions, including, in some instances, imprisonment and exclusion from participation in federal and state health care programs, including the Medicare, Medicaid and Veterans Affairs healthcare programs. Because of the far<span class="nobreak">-reaching</span> nature of these laws, ARCA may be required to discontinue one or more of its practices to be in compliance with these laws. Healthcare fraud and abuse regulations are complex, and even minor irregularities can potentially give rise to claims that a statute or prohibition has been violated. Any violations of these laws, or any action against ARCA for violations of these laws, even if ARCA successfully defends against it, could have a material adverse effect on ARCA&#8217;s business, financial condition and results of operations.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">34</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA could also become subject to false claims litigation under federal statutes, which can lead to civil money penalties, restitution, criminal fines and imprisonment, and exclusion from participation in Medicare, Medicaid and other federal and state health care programs. These false claims statutes include the False Claims Act, which allows any person to bring a suit on behalf of the federal government alleging submission of false or fraudulent claims, or causing to present such false or fraudulent claims, under federal programs or contracts claims or other violations of the statute and to share in any amounts paid by the entity to the government in fines or settlement. These suits against pharmaceutical companies have increased significantly in volume and breadth in recent&#160;years. Some of these suits have been brought on the basis of certain sales practices promoting drug products for unapproved uses. This new growth in litigation has increased the risk that a pharmaceutical company will have to defend a false claim action, pay fines or restitution, or be excluded from the Medicare, Medicaid, Veterans Affairs and other federal and state healthcare programs as a result of an investigation arising out of such action. ARCA may become subject to such litigation and, if ARCA is not successful in defending against such actions, those actions may have a material adverse effect on its business, financial condition and results of operations. ARCA could also become subject to false claims litigation and consumer protection claims under state statutes, which also could lead to civil monetary penalties, restitution, criminal fines and imprisonment, and exclusion from participation in state health care programs. Of note, over the past few&#160;years there has been an increased focus on the sales and marketing practices of the pharmaceutical industry at both the federal and state level. Additionally, the law or regulatory policies governing pharmaceuticals may change. New statutory requirements may be enacted or additional regulations may be adopted that could prevent or delay regulatory approval of ARCA&#8217;s product candidates or limit ARCA&#8217;s ability to commercialize its products. ARCA cannot predict the likelihood, nature or extent of adverse government regulation that may arise from future legislation or administrative action, either in the United&#160;States or elsewhere.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If ARCA, its collaborators or its third<span class="nobreak">-party</span> manufacturers fail to comply with applicable continuing regulatory requirements, ARCA&#8217;s business could be seriously harmed because a regulatory agency may:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>issue untitled or warning letters;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>suspend or withdraw ARCA&#8217;s regulatory approval for approved products;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>seize or detain products or recommend a product recall of a drug or medical device, or issue a mandatory recall of a medical device;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>refuse to approve pending applications or supplements to approved applications filed by ARCA;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>suspend ARCA&#8217;s ongoing clinical trials;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>restrict ARCA&#8217;s operations, including costly new manufacturing requirements, or restrict the sale, marketing and/or distribution of ARCA&#8217;s products;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>seek an injunction;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>pursue criminal prosecutions;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>close the facilities of ARCA&#8217;s contract manufacturers; or</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>impose civil or criminal penalties.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Reliance on third parties to commercialize Gencaro, rNAPc2 or ARCA&#8217;s other product candidates could negatively impact ARCA&#8217;s business. If ARCA is required to establish a direct sales force in the United&#160;States and are unable to do so, its business may be harmed.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Commercialization of Gencaro, rNAPc2 or any other product candidate, if approved, particularly the establishment of a sales organization, will require substantial additional capital resources. ARCA currently intends to pursue a strategic partnership alternative for the commercialization of Gencaro or rNAPc2, if it is approved, and ARCA has suspended its efforts to build internal sales, marketing and distribution capabilities. If ARCA elects to rely on third parties to sell Gencaro, rNAPc2 and any other products, then it may receive less revenue than if it sold such products directly. In addition, ARCA may have little or no control over the sales efforts of those third parties. If ARCA is unable to complete a strategic transaction, ARCA would be unable to commercialize Gencaro, rNAPc2 </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">35</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">or any other product candidate without substantial additional capital. Even if such capital were secured, ARCA would be required to build internal sales, marketing and distribution capabilities to market Gencaro or rNAPc2 in the United&#160;States. None of ARCA&#8217;s current employees have experience in establishing and managing a sales force.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In the event ARCA is unable to sell Gencaro, rNAPc2 and other selected product candidates, either directly or through third parties via a strategic transaction, the commercialization of Gencaro or rNAPc2, if approved, may be delayed indefinitely.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">ARCA is dependent on ARCA&#8217;s key personnel.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The success of ARCA&#8217;s business is highly dependent on the principal members of ARCA&#8217;s board of directors and executive management. The loss of the services of any such individual might seriously harm ARCA&#8217;s product development, partnering and financing efforts. Recruiting and training personnel with the requisite skills is challenging and ARCA competes for talent with companies that are larger and have more financial resources.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">ARCA has no manufacturing capacity which puts it at risk of lengthy and costly delays of bringing its products to market.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA does not currently operate manufacturing facilities for clinical or commercial production of its product candidates, including their drug substance or active pharmaceutical ingredients, or API.&#160;ARCA has no experience in drug formulation or manufacturing, and it lacks the resources and the capabilities to manufacture any of its product candidates on a clinical or commercial scale. ARCA does not intend to develop facilities for the manufacture of product candidates for clinical trials or commercial purposes in the foreseeable future. ARCA has contracted with several third<span class="nobreak">-party</span> manufacturing organizations for production and analytical testing of its product candidates. These contract manufacturers may not perform as agreed or may not remain in the contract manufacturing business for the time required to successfully produce, store and distribute ARCA&#8217;s products. In addition, these manufacturers may have staffing difficulties, may experience delays due to key material or component availability, may not be able to manufacture ARCA&#8217;s products on a timely basis or may become financially distressed. In the event of errors in forecasting production quantities required to meet demand, natural disaster, equipment malfunctions or failures, technology malfunctions, strikes, lock<span class="nobreak">-outs</span> or work stoppages, regional power outages, product tampering, war or terrorist activities, actions of regulatory authorities, business failure, strike or other difficulty, ARCA may be unable to find an alternative third<span class="nobreak">-party</span> manufacturer in a timely manner and the production of its product candidates would be interrupted, resulting in delays and additional costs, which could impact ARCA&#8217;s ability to commercialize and sell its product candidates. ARCA or its contract manufacturers may also fail to achieve and maintain required manufacturing standards, which could result in patient injury or death, product recalls or withdrawals, an order by governmental authorities to halt production, delays or failures in product testing or delivery, stability testing failures, cost overruns or other problems that could seriously hurt ARCA&#8217;s business. Contract manufacturers also often encounter difficulties involving production yields, quality control and quality assurance, as well as shortages of qualified personnel. In addition, ARCA&#8217;s contract manufacturers are subject to ongoing inspections and regulation by the FDA, the U.S.&#160;Drug Enforcement Agency and corresponding foreign and state agencies and they may fail to meet these agencies&#8217; acceptable standards of compliance. If ARCA&#8217;s contract manufacturers fail to comply with applicable governmental regulations, such as quality control, quality assurance and the maintenance of records and documentation, ARCA may not be able to continue production of the API or finished product. If the safety of any API or product supplied is compromised due to failure to adhere to applicable laws or for other reasons, this may jeopardize ARCA&#8217;s regulatory approval for Gencaro, rNAPc2 and other product candidates, and ARCA may be held liable for any injuries sustained as a result. Upon the occurrence of one of the aforementioned events, the ability to switch manufacturers may be difficult for a number of reasons, including:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the number of potential manufacturers is limited and ARCA may not be able to negotiate agreements with alternative manufacturers on commercially reasonable terms, if at all;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>long lead times are often needed to manufacture drugs;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the manufacturing process is complex and may require a significant learning curve; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the FDA must approve any replacement prior to manufacturing, which requires new testing and compliance inspections.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">36</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Transitioning from a clinical development stage company will require successful completion of a number of steps, many of which are outside of ARCA&#8217;s control and, consequently, ARCA can provide no assurance of its successful and timely transition from a clinical development stage company.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA is a clinical development stage biopharmaceutical company with a limited operating history. To date ARCA has not generated any product revenue and has historically funded ARCA&#8217;s operations through investment capital. ARCA&#8217;s future growth depends on its ability to emerge from the clinical development stage and successfully commercialize or provide for the commercialization of Gencaro, rNAPc2 and ARCA&#8217;s other product candidates, which in turn will depend, among other things, on ARCA&#8217;s ability to:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>conduct additional clinical trials and develop and obtain regulatory approval for Gencaro, rNAPc2 or other product candidates;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>successfully partner a companion genetic test with the commercial launch of Gencaro or rNAPc2;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>enter into a strategic transaction enabling the continued development and commercialization of Gencaro or rNAPc2, or alternatively, raise significant additional capital to enable these activities;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>pursue additional indications for Gencaro or rNAPc2 and develop other product candidates, including other cardiovascular therapies; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>obtain commercial quantities of Gencaro, rNAPc2 or other product candidates at acceptable cost levels.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Any one of these factors or other factors discussed in this report could affect ARCA&#8217;s ability to successfully commercialize Gencaro and other product candidates, which could impact ARCA&#8217;s ability to earn sufficient revenues to transition from a clinical development stage company and continue ARCA&#8217;s business.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">If approved by the FDA, Gencaro or rNAPc2 will be entering a competitive marketplace and may not succeed.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Gencaro is a new type of beta<span class="nobreak">-blocker</span> and vasodilator being developed for AF.&#160;While ARCA anticipates that this drug, if approved, would be the first genetically<span class="nobreak">-targeted</span> cardiovascular drug, and potentially the only beta<span class="nobreak">-blocker</span> approved for AF, Gencaro will be one of a number of accepted treatments for AF.&#160;In addition, ARCA&#8217;s proposed prescribing information for Gencaro is expected to include a requirement for genetic testing of the patient to ascertain if they have the genotype that ARCA believes responds best to Gencaro. This additional step will add incremental cost and procedures to prescribing Gencaro, which could make it more difficult to compete against existing therapies.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA does not yet know what the commercial opportunity will be, if any, for rNAPc2 if it is approved for treating COVID<span class="nobreak">-19</span> disease. ARCA does not know how and to whom rNAPc2 would be marketed and what the commercial arrangements would be for its sales and reimbursement. While ARCA anticipates that rNAPc2, if approved, could potentially be used in combination with antiviral drugs and other therapies, there are other vaccines and therapies under development.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s commercial opportunity may be reduced or eliminated if competitors develop and commercialize products that are safer, more effective, have fewer side effects, are more convenient or are less expensive than Gencaro. If products with any of these properties are developed, or any of the existing products are better marketed, then prescriptions of Gencaro by physicians and patient use of Gencaro could be significantly reduced or rendered obsolete and noncompetitive. Further, public announcements regarding the development of any such competing drugs could adversely affect the market price of ARCA common stock and the value of ARCA&#8217;s assets.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Future sales of ARCA&#8217;s products may suffer if they are not accepted in the marketplace by physicians, patients and the medical community.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Gencaro, rNAPc2 or ARCA&#8217;s other product candidates may not gain market acceptance among physicians, patients and the medical community. The degree of market acceptance of Gencaro, rNAPc2 or ARCA&#8217;s other product candidates will depend on a number of factors, such as its effectiveness and tolerability, as compared with competitive drugs. For instance, if rNAPc2 is approved, by that time there may be superior alternatives in terms of vaccines and/or therapeutics that may significantly impact the relative medical benefits offered by rNAPc2. If </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">37</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">ARCA&#8217;s future clinical trials for rNAPc2 do not show that rNAPc2 has a clear therapeutic benefit as compared to other therapies or vaccines that are approved in the interim, then there may be a limited or no commercial market for rNAPc2. Also, prevalence and severity of side<span class="nobreak">-effects</span> could negatively affect market acceptance of rNAPc2. Failure to achieve market acceptance of Gencaro or rNAPc2 would significantly harm ARCA&#8217;s business.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If ARCA is unable to obtain acceptable prices or adequate reimbursement from third<span class="nobreak">-party</span> payors for Gencaro, rNAPc2, or any other product candidates that it may seek to commercialize, then ARCA&#8217;s revenues and prospects for profitability will suffer.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s or any strategic partner&#8217;s ability to commercialize Gencaro, rNAPc2, or any other product candidates that ARCA may seek to commercialize, is highly dependent on the extent to which coverage and reimbursement for these product candidates will be available from:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>governmental payors, such as Medicare and Medicaid;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>private health insurers, including managed<span class="nobreak">-care</span> organizations; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>other third<span class="nobreak">-party</span> payors.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Many patients will not be capable of paying for ARCA&#8217;s potential products themselves and will rely on third<span class="nobreak">-party</span> payors to pay for their medical needs. A primary current trend in the U.S.&#160;health care industry is toward cost containment. Large private payors, managed<span class="nobreak">-care</span> organizations, group purchasing organizations and similar organizations are exerting increasing influence on decisions regarding the use of, and reimbursement levels for, particular treatments. Such third<span class="nobreak">-party</span> payors, including Medicare, are challenging the prices charged for medical products and services, and many third<span class="nobreak">-party</span> payors limit reimbursement for newly approved health care products.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Cost<span class="nobreak">-control</span> initiatives could decrease the price ARCA might establish for products, which could result in product revenues lower than anticipated. If the prices for ARCA&#8217;s product candidates decrease, or if governmental and other third<span class="nobreak">-party</span> payors do not provide adequate coverage and reimbursement levels, then ARCA&#8217;s revenue and prospects for profitability will suffer.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Health care reform measures could materially and adversely affect ARCA&#8217;s business.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The business and financial condition of pharmaceutical and biotechnology companies are affected by the efforts of governmental and third<span class="nobreak">-party</span> payors to contain or reduce the costs of health care. The U.S.&#160;Congress has enacted legislation to reform the health care system. While ARCA anticipates that this legislation may, over time, increase the number of patients who have insurance coverage for pharmaceutical products, it also imposes cost containment measures that may adversely affect the amount of reimbursement for pharmaceutical products. These measures include increasing the minimum rebates for products covered by Medicaid programs and extending such rebates to drugs dispensed to Medicaid beneficiaries enrolled in Medicaid managed care organizations as well as expansion of the 340(B)&#160;Public Health Services drug discount program. In addition, such legislation contains a number of provisions designed to generate the revenues necessary to fund the coverage expansion, including new fees or taxes on certain health<span class="nobreak">-related</span> industries, including medical device manufacturers. Each medical device manufacturer has to pay an excise tax (or sales tax) in an amount equal to 2.3% of the price for which such manufacturer sells its medical devices. Such excise taxes may impact any potential sales of the genetic test if it is approved for marketing. On January&#160;22, 2018, legislation was enacted suspending the medical device tax in 2018 and 2019. In December&#160;2019, a permanent repeal of the medical device tax was enacted. The Gencaro Test (as defined elsewhere in this proxy statement/prospectus) is likely to be subject to this tax if this tax is reinstated in the future. In foreign jurisdictions there have been, and ARCA expects that there will continue to be, a number of legislative and regulatory proposals aimed at changing the health care system. For example, in some countries other than the United&#160;States, pricing of prescription drugs is subject to government control and ARCA expects to see continued efforts to reduce healthcare costs in international markets.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Some states are also considering legislation that would control the prices of drugs, and state Medicaid programs are increasingly requesting manufacturers to pay supplemental rebates and requiring prior authorization by the state program for use of any drug for which supplemental rebates are not being paid. Managed care organizations continue to seek price discounts and, in some cases, to impose restrictions on the coverage of particular drugs. </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">38</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">Government efforts to reduce Medicaid expenses may lead to increased use of managed care organizations by Medicaid programs. This may result in managed care organizations influencing prescription decisions for a larger segment of the population and a corresponding constraint on prices and reimbursement for drugs. It is likely that federal and state legislatures and health agencies will continue to focus on additional health care reform in the future although ARCA is unable to predict what additional legislation or regulation, if any, relating to the health care industry or third<span class="nobreak">-party</span> coverage and reimbursement may be enacted in the future or what effect such legislation or regulation would have on ARCA&#8217;s business. ARCA&#8217;s or any strategic partner&#8217;s ability to commercialize Gencaro, rNAPc2, or any other product candidates that ARCA may seek to commercialize, is highly dependent on the extent to which coverage and reimbursement for these product candidates will be available from government payors, such as Medicare and Medicaid, private health insurers, including managed care organizations, and other third<span class="nobreak">-party</span> payors, and any change in reimbursement levels could materially and adversely affect ARCA&#8217;s business. Further, the pendency or approval of future proposals or reforms could result in a decrease in ARCA&#8217;s stock price or limit ARCA&#8217;s ability to raise capital or to obtain strategic partnerships or licenses.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">ARCA&#8217;s competitors may be better positioned in the marketplace and thereby may be more successful than ARCA at developing, manufacturing and marketing approved products.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Many of ARCA&#8217;s competitors currently have significantly greater financial resources and expertise in conducting clinical trials, obtaining regulatory approvals, managing manufacturing and marketing approved products than ARCA.&#160;Other early<span class="nobreak">-stage</span> companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. In addition, these third parties compete with ARCA in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring therapies and therapy licenses complementary to ARCA&#8217;s programs or advantageous to ARCA&#8217;s business. ARCA expects that its ability to compete effectively will depend upon its ability to:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>successfully and rapidly complete clinical trials for any product candidates and obtain all requisite regulatory approvals in a cost<span class="nobreak">-effective</span> manner;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>build an adequate sales and marketing infrastructure, raise additional funding, or enter into strategic transactions enabling the commercialization of ARCA&#8217;s products;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>develop competitive formulations of ARCA&#8217;s product candidates;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>attract and retain key personnel; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>identify and obtain other product candidates on commercially reasonable terms.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">If ARCA fails to identify and license or acquire other products or product candidates, then it may be unable to expand its business, and the acquisition or licensing of other products or product candidates may put a strain on its operations and will likely require it to seek additional financing.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">One of ARCA&#8217;s strategies is to license or acquire clinical<span class="nobreak">-stage</span> products or product candidates and further develop them for commercialization. The market for licensing and acquiring products and product candidates is intensely competitive and many of ARCA&#8217;s competitors may have greater resources than ARCA does. If ARCA undertakes any additional acquisitions, whether of product candidates or other biopharmaceutical companies, the process of integrating an acquired product candidate or complementary company into ARCA&#8217;s business may put a strain on ARCA&#8217;s operations, divert personnel, financial resources and management&#8217;s attention. In 2020, ARCA&#8217;s research and development activities were dedicated to initiating the clinical trial of rNAPc2. If ARCA is not able to substantially expand ARCA&#8217;s research and development efforts, or identify, or license or acquire other products or product candidates or complete future acquisitions, then it will likely be unable expand its pipeline of product candidates. In addition, any future acquisition would give rise to additional operating costs and will likely require ARCA to seek additional financing. Future acquisitions could result in additional issuances of equity securities that would dilute the ownership of existing stockholders. Future acquisitions could also result in the incurrence of debt, contingent liabilities or the amortization of expenses related to other intangible assets, any of which could adversely affect ARCA&#8217;s operating results.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">39</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">ARCA would be subject to applicable regulatory approval requirements of the foreign countries in which it markets its products, which are costly and may prevent or delay ARCA from marketing its products in those countries.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition to regulatory requirements in the United&#160;States, ARCA would be subject to the regulatory approval requirements in each foreign country where it markets its products. In addition, ARCA might be required to identify one or more collaborators in these foreign countries to develop, seek approval for and manufacture ARCA&#8217;s products and any companion genetic test for Gencaro. If ARCA decides to pursue regulatory approvals and commercialization of its product candidates internationally, it may not be able to obtain the required foreign regulatory approvals on a timely basis, if at all, and any failure to do so may cause ARCA to incur additional costs or prevent it from marketing it products in foreign countries, which may have a material adverse effect on its business, financial condition and results of operations.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">If ARCA&#8217;s internal control over financial reporting is not considered effective, ARCA&#8217;s business and stock price could be adversely affected.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Section&#160;404 of the Sarbanes<span class="nobreak">-Oxley</span> Act&#160;of&#160;2002 requires ARCA to evaluate the effectiveness of its internal control over financial reporting as of the end of each fiscal year, and to include a management report assessing the effectiveness of its internal control over financial reporting in its annual report on Form&#160;10<span class="nobreak">-K</span> for that fiscal year. ARCA&#8217;s management, including ARCA&#8217;s principal executive officer and principal financial officer, does not expect that ARCA&#8217;s internal control over financial reporting will prevent all error and all fraud. ARCA continues to operate with a small staff for financial reporting. Though the process and design of ARCA&#8217;s internal controls over financial reporting have not been altered, the small number of staff involved in financial reporting may limit ARCA&#8217;s ability to properly segregate internal control procedures which could result in deficiencies or material weaknesses in ARCA&#8217;s internal controls in the future. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system&#8217;s objectives will be met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud involving a company have been, or will be, detected. The design of any system of controls is based in part on certain assumptions about the likelihood of future events, and ARCA cannot assure you that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become ineffective because of changes in conditions or deterioration in the degree of compliance with policies or procedures. Because of the inherent limitations in a cost<span class="nobreak">-effective</span> control system, misstatements due to error or fraud may occur and not be detected. ARCA cannot assure you that it or its independent registered public accounting firm will not identify a material weakness in ARCA&#8217;s internal control over financial reporting in the future. A material weakness in ARCA&#8217;s internal control over financial reporting would require management to consider ARCA&#8217;s internal control over financial reporting as ineffective. If ARCA&#8217;s internal control over financial reporting is not considered effective, ARCA may experience a loss of public confidence, which could have an adverse effect on its business and on the market price of ARCA common stock.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Changes in tax laws or regulations that are applied adversely to ARCA or its customers may have a material adverse effect on ARCA&#8217;s business, cash flow, financial condition or results of operations.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">New income, sales, use or other tax laws, statutes, rules, regulations or ordinances could be enacted at any time, which could affect the tax treatment of ARCA&#8217;s domestic and foreign earnings. Any new taxes could adversely affect ARCA&#8217;s domestic and international business operations, and ARCA&#8217;s business and financial performance. Further, existing tax laws, statutes, rules, regulations or ordinances could be interpreted, changed, modified or applied adversely to ARCA.&#160;For example, legislation enacted in 2017, informally titled the Tax Cuts and Jobs Act, significantly revised the Internal Revenue Code of 1986, as amended, or the Code. Future guidance from the Internal Revenue Service and other tax authorities with respect to the Tax Cuts and Jobs Act may affect ARCA, and certain aspects of the Tax Cuts and Jobs Act could be repealed or modified in future legislation. In addition, it is uncertain if and to what extent various states will conform to the Tax Cuts and Jobs Act or any newly enacted federal tax legislation. Changes in corporate tax rates, the realization of net deferred tax assets relating to ARCA&#8217;s operations, the taxation of foreign earnings, and the deductibility of expenses under the Tax Cuts and Jobs Act or future reform legislation could have a material impact on the value of ARCA&#8217;s deferred tax assets, could result in significant one<span class="nobreak">-time</span> charges, and could increase ARCA&#8217;s future U.S.&#160;tax expense.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">40</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">ARCA&#8217;s ability to use ARCA&#8217;s net operating losses to offset future taxable income may be subject to certain limitations.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of December&#160;31, 2023, ARCA had net operating loss (&#8220;NOL&#8221;) carryforwards of approximately $208.1&#160;million, and approximately $2.4&#160;million of research and development credits that may be used to offset future taxable income. ARCA had net operating loss carryforwards of $156.4&#160;million generated prior to 2018, which will expire beginning in 2025 if not utilized. Under the Tax Cuts and Jobs Act, ARCA&#8217;s U.S.&#160;federal NOLs of $51.7&#160;million incurred in tax&#160;years beginning after December&#160;31, 2017, may be carried forward indefinitely, but the deductibility of federal NOLs generated in tax&#160;years beginning after December&#160;31, 2017, is limited to 80% of taxable income. In addition, under Section&#160;382 of the Code, a corporation that undergoes an &#8220;ownership change&#8221; (as defined under Section&#160;382 of the Code and applicable Treasury Regulations) is subject to limitations on its ability to utilize its pre<span class="nobreak">-change</span> NOLs to offset future taxable income. ARCA has not determined whether it has experienced an ownership change in the past, and ARCA may experience ownership changes in the future as a result of subsequent shifts in ARCA&#8217;s stock ownership, some of which may be outside of ARCA&#8217;s control. There is also a risk that due to regulatory changes, such as suspensions on the use of NOLs or other unforeseen reasons, ARCA&#8217;s existing NOLs could expire or otherwise be unavailable to reduce future income tax liabilities, including for state tax purposes. For these reasons, ARCA may not be able to utilize a material portion of the NOLs reflected on its balance sheet, offset by a full valuation, even if it attains profitability, which could potentially result in increased future tax liability to ARCA and could adversely affect its operating results and financial condition.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Security breaches, cyber-attacks, or other disruptions or incidents could expose ARCA to liability and affect its business and reputation.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA is increasingly dependent on its information technology systems and infrastructure for its business. ARCA, its collaborators and its service providers collect, store, and transmit sensitive information including intellectual property, proprietary business information, clinical trial data and personal information in connection with ARCA&#8217;s business operations. The secure maintenance of this information is critical to ARCA&#8217;s operations and business strategy. Some of this information could be an attractive target of criminal attack by third parties with a wide range of motives and expertise, including organized criminal groups, &#8220;hacktivists,&#8221; patient groups, disgruntled current or former employees, nation<span class="nobreak">-state</span> and nation<span class="nobreak">-state</span> supported actors, and others. Cyber<span class="nobreak">-attacks</span> are of ever<span class="nobreak">-increasing</span> levels of sophistication, and despite ARCA&#8217;s security measures, ARCA&#8217;s information technology and infrastructure may be vulnerable to such attacks or may be breached, including due to employee error or malfeasance.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA has implemented information security measures to protect ARCA&#8217;s systems, proprietary information and sensitive data against the risk of inappropriate and unauthorized external use and disclosure and other types of compromise. However, despite these measures, and due to the ever<span class="nobreak">-changing</span> information cyber<span class="nobreak">-threat</span> landscape, ARCA cannot guarantee that these measures will be adequate to detect, prevent or mitigate security breaches and other incidents and ARCA may be subject to data breaches through cyber<span class="nobreak">-attacks</span>, malicious code (such as viruses and worms), phishing attacks, social engineering schemes, and insider theft or misuse. Any such breach could compromise ARCA&#8217;s networks and the information stored there could be accessed, modified, destroyed, publicly disclosed, lost or stolen. If ARCA&#8217;s systems become compromised, ARCA may not promptly discover the intrusion.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Any security breach of other incident, whether real or perceived, could cause ARCA to suffer reputational damage. Such incidents could result in costs to respond to, investigate and remedy such incidents, notification obligations to affected individuals, government agencies, credit reporting agencies and other third parties, legal claims or proceedings, and liability under ARCA&#8217;s contracts with other parties and federal and state laws that protect the privacy and security of personal information. Any one of these events could cause ARCA&#8217;s business to be materially harmed and its results of operations would be adversely impacted.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Failure to comply with data protection laws and regulations could lead to government enforcement actions (which could include civil or criminal penalties), private litigation, and/or adverse publicity and could negatively affect ARCA&#8217;s operating results and business.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA and its partners may be subject to federal, state, and foreign data protection laws and regulations (i.e., laws and regulations that address privacy and data security). In the United&#160;States, numerous federal and state laws and regulations, including state data breach notification laws, state health information privacy laws, </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">41</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">and federal and state consumer protection laws and regulations (e.g., Section&#160;5 of the FTC Act), that govern the collection, use, disclosure, and protection of health<span class="nobreak">-related</span> and other personal information could apply to ARCA&#8217;s operations or the operations of ARCA&#8217;s partners. In addition, ARCA may obtain health information from third parties (including research institutions from which ARCA obtains clinical trial data) that are subject to privacy and security requirements under the Health Insurance Portability and Accountability Act&#160;of&#160;1996, as amended, or HIPAA.&#160;Depending on the facts and circumstances, ARCA could be subject to criminal penalties if it knowingly obtains, uses or discloses individually identifiable health information maintained by a HIPAA<span class="nobreak">-covered</span> entity in a manner that is not authorized or permitted by HIPAA.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, the California Consumer Privacy Act, or the CCPA, became effective on January&#160;1, 2020. The CCPA gives California residents expanded rights to access and delete their personal information, opt out of certain personal information sharing and receive detailed information about how their personal information is used by requiring covered companies to provide new disclosures to California consumers (as that term is broadly defined) and provide such consumers new ways to opt<span class="nobreak">-out</span> of certain sales of personal information. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. Although there are limited exemptions for clinical trial data and the CCPA&#8217;s implementation standards and enforcement practices are likely to remain uncertain for the foreseeable future, the CCPA may increase ARCA&#8217;s compliance costs and potential liability. Many similar privacy laws have been proposed at the federal level and in other states.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Foreign data protection laws, including, without limitation, the European Union Directive 95/46/EC (the &#8220;Directive&#8221;) and the European Union&#8217;s General Data Protection Regulation (the &#8220;GDPR&#8221;) that became effective in May&#160;2018, and member state data protection legislation, may also apply to health<span class="nobreak">-related</span> and other personal information obtained outside of the United&#160;States. These laws impose strict obligations on the ability to process health<span class="nobreak">-related</span> and other personal information of data subjects in the European Union and the United Kingdom, including in relation to use, collection, analysis, and transfer (including cross<span class="nobreak">-border</span> transfer) of such personal information. These laws include several requirements relating to the consent of the individuals to whom the personal data relates, limitations on data processing, establishing a legal basis for processing, notification of data processing obligations or security incidents to appropriate data protection authorities or data subjects, the security and confidentiality of the personal data and various rights that data subjects may exercise.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Directive and the GDPR prohibit, without an appropriate legal basis, the transfer of personal data to countries outside of the European Economic Area, or EEA, such as the United&#160;States, which are not considered by the European Commission to provide an adequate level of data protection. Switzerland has adopted similar restrictions. Although there are legal mechanisms to allow for the transfer of personal data from the EEA and Switzerland to the United&#160;States, uncertainty about compliance with European Union data protection laws remains. For example, ongoing legal challenges in Europe to the mechanisms allowing companies to transfer personal data from the EEA to the United&#160;States could result in further limitations on the ability to transfer personal data across borders, particularly if governments are unable or unwilling to reach new or maintain existing agreements that support cross<span class="nobreak">-border</span> data transfers, such as the European Union<span class="nobreak">-U</span>.S.&#160;and Swiss<span class="nobreak">-U</span>.S.&#160;Privacy Shield framework. Additionally, other countries have passed or are considering passing laws requiring local data residency.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Under the GDPR, regulators may impose substantial fines and penalties for non<span class="nobreak">-compliance</span>. Companies that violate the GDPR can face fines of up to the greater of 20&#160;million Euros or 4% of their worldwide annual turnover (revenue). The GDPR increases ARCA&#8217;s responsibility and potential liability in relation to personal data that ARCA processes, and ARCA may be required to put in place additional mechanisms to ensure compliance with the GDPR and other EU and international data protection rules.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Compliance with U.S.&#160;and foreign privacy and security laws, rules and regulations could require ARCA to take on more onerous obligations in its contracts, require it to engage in costly compliance exercises, restrict its ability to collect, use and disclose data, or in some cases, impact its or its partners&#8217; or suppliers&#8217; ability to operate in certain jurisdictions. Each of these constantly evolving laws can be subject to varying interpretations. Failure to comply with U.S.&#160;and foreign data protection laws and regulations could result in government investigations and enforcement actions (which could include civil or criminal penalties), fines, private litigation, and/or adverse publicity and could negatively affect ARCA&#8217;s operating results and business. Moreover, patients about whom ARCA or its partners obtain information, as well as the providers who share this information with ARCA, may contractually limit ARCA&#8217;s </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">42</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">ability to use and disclose the information. Claims that ARCA has violated individuals&#8217; privacy rights, failed to comply with data protection laws, or breached its contractual obligations, even if ARCA is not found liable, could be expensive and time<span class="nobreak">-consuming</span> to defend and could result in adverse publicity that could harm ARCA&#8217;s business.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Risks Related to Intellectual Property and Other Legal Matters</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">If product liability lawsuits are successfully brought against ARCA, then ARCA will incur substantial liabilities and may be required to limit commercialization of Gencaro, rNAPc2 or other product candidates.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA faces product liability exposure related to the testing of its product candidates in human clinical trials, and may face exposure to claims by an even greater number of persons once it begins marketing and distributing ARCA&#8217;s products commercially. If ARCA cannot successfully defend against product liability claims, then it will incur substantial liabilities.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Regardless of merit or eventual outcome, liability claims may result in:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>decreased demand for ARCA&#8217;s products and product candidates;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>injury to ARCA&#8217;s reputation;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>withdrawal of clinical trial participants;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>costs of related litigation;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>substantial monetary awards to patients and others;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>loss of revenues; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the inability to commercialize ARCA&#8217;s products and product candidates.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA has obtained limited product liability insurance coverage. Such coverage, however, may not be adequate or may not continue to be available to ARCA in sufficient amounts or at an acceptable cost, or at all. ARCA may not be able to obtain commercially reasonable product liability insurance for any product candidate.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Defending against claims relating to improper handling, storage or disposal of hazardous chemicals, radioactive or biological materials could be time consuming and expensive.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s research and development of product candidates may involve the controlled use of hazardous materials, including chemicals, radioactive and biological materials. ARCA cannot eliminate the risk of accidental contamination or discharge and any resultant injury from the materials. Various laws and regulations govern the use, manufacture, storage, handling and disposal of hazardous materials. ARCA may be sued or be required to pay fines for any injury or contamination that results from its use or the use by third parties of these materials. Compliance with environmental laws and regulations may be expensive, and current or future environmental regulations may impair ARCA&#8217;s research, development and production efforts.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">The loss of any rights to market key products would significantly impair ARCA&#8217;s operating results.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s patent portfolios relating to Gencaro, including a patent that issued in 2021, are either owned by ARCA or are subject to licenses that impose no royalty obligations or milestone payments relating to the further development, approval and commercialization of Gencaro.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Termination of ARCA&#8217;s license agreements could result in the loss of its further rights to develop and commercialize Gencaro for any indication. The termination of any such license, or of any other agreement which enables ARCA to market a key product or product candidate, could significantly and adversely affect its business.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Certain intellectual property licensed by ARCA is the subject of additional licensing arrangements to which the party that has licensed rights to ARCA is subject. If such parties were to breach the terms of such licenses or such licenses were otherwise to terminate, ARCA&#8217;s and ARCA&#8217;s partners&#8217; rights to use such technology and develop and commercialize their products such as the genetic test may terminate and ARCA&#8217;s business would be materially harmed.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">43</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Third parties may own or control patents or patent applications that ARCA may be required to license to commercialize ARCA&#8217;s product candidates or that could result in litigation that would be costly and time consuming.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s or any strategic partner&#8217;s ability to commercialize Gencaro, rNAPc2 and other product candidates depends upon ARCA&#8217;s ability to develop, manufacture, market and sell these drugs without infringing the proprietary rights of third parties. A number of pharmaceutical and biotechnology companies, universities and research institutions have or may be granted patents that cover technologies similar to the technologies owned by or licensed to ARCA.&#160;ARCA may choose to seek, or be required to seek, licenses under third<span class="nobreak">-party</span> patents, which would likely require the payment of license fees or royalties or both. ARCA may also be unaware of existing patents that may be infringed by Gencaro or rNAPc2, the genetic testing ARCA intends to use in connection with Gencaro or its other product candidates. Because patent applications can take many&#160;years to issue, there may be other currently pending applications that may later result in issued patents that are infringed by Gencaro, rNAPc2 or ARCA&#8217;s other product candidates. Moreover, a license may not be available to ARCA on commercially reasonable terms, or at all.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">There is a substantial amount of litigation involving patent and other intellectual property rights in the biotechnology and biopharmaceutical industries generally. If a third party claims that ARCA is infringing on its technology, then ARCA&#8217;s business and results of operations could be harmed by a number of factors, including:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>infringement and other intellectual property claims, even if without merit, are expensive and time<span class="nobreak">-consuming</span> to litigate and can divert management&#8217;s attention from ARCA&#8217;s core business;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>monetary damage awards for past infringement can be substantial;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>a court may prohibit ARCA from selling or licensing product candidates unless the patent holder chooses to license the patent to ARCA; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>if a license is available from a patent holder, ARCA may have to pay substantial royalties.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA may also be forced to bring an infringement action if its believes that a competitor is infringing ARCA&#8217;s protected intellectual property. Any such litigation will be costly, time<span class="nobreak">-consuming</span> and divert management&#8217;s attention, and the outcome of any such litigation may not be favorable to ARCA.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">ARCA&#8217;s intellectual property rights may not preclude competitors from developing competing products and ARCA&#8217;s business may suffer.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s competitive success will depend, in part, on ARCA&#8217;s ability to obtain and maintain patent protection for its inventions, technologies and discoveries, including intellectual property that ARCA licenses. The patent positions of biotechnology companies involve complex legal and factual questions, and ARCA cannot be certain that its patents and licenses will successfully preclude others from using its technology. Consequently, ARCA cannot be certain that any of its patents will provide significant market protection or will not be circumvented or challenged and found to be unenforceable or invalid. In some cases, patent applications in the United&#160;States and certain other jurisdictions are maintained in secrecy until patents issue, and since publication of discoveries in the scientific or patent literature often lags behind actual discoveries, ARCA cannot be certain of the priority of inventions covered by pending patent applications. Moreover, ARCA may have to participate in interference proceedings declared by the U.S.&#160;Patent and Trademark Office to determine priority of invention, in opposition proceedings in a foreign patent office, or in a post<span class="nobreak">-grant</span> challenge proceeding such as an <span class="Italic" style="font-style:italic;font-weight:normal;">ex parte</span> reexamination or <span class="Italic" style="font-style:italic;font-weight:normal;">inter partes</span> review at the U.S.&#160;Patent and Trademark Office, any of which could result in substantial cost to ARCA, even if the eventual outcome is favorable. There can be no assurance that a court of competent jurisdiction would hold any claims in any issued patent to be valid and enforceable. An adverse outcome could subject ARCA to significant liabilities to third parties, require disputed rights to be licensed from third parties or require ARCA to cease using such technology.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA owns the clinical development program of rNAPc2, including Phase&#160;2b clinical trials. If rNAPc2 is successfully developed, ARCA believes it will have intellectual property protection for a specific use, including 12&#160;years of market exclusivity as an innovative biologic product under FDA law in the United&#160;States, 10&#160;years data protection exclusivity in the EU, and potentially patent protection in addition to this. However, another competitor could develop a compound with similar biological properties to rNAPc2 that may not be barred by ARCA&#8217;s exclusivity. ARCA has also filed a patent application for rNAPc2 and its use for COVID<span class="nobreak">-19</span> disease, but there is no assurance that this application will ultimately result in an issued patent.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">44</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Regardless of merit, the listing of patents in the FDA Orange Book for Gencaro may be challenged as being improperly listed. ARCA may have to defend against such claims and possible associated antitrust issues. ARCA could also incur substantial costs in seeking to enforce its proprietary rights against infringement.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">While the composition of matter patents on the compound that comprises Gencaro have expired, ARCA holds intellectual property concerning the interaction of Gencaro with the polymorphisms of the beta<span class="nobreak">-1</span> and alpha<span class="nobreak">-2C</span> receptors. ARCA has obtained patents that claim methods involving Gencaro after a patient&#8217;s receptor genotype has been determined. ARCA anticipates that any NDA for Gencaro will request a label including a claim that efficacy varies based on receptor genotype and a recommendation in the prescribing information that prospective patients be tested for their receptor genotype. ARCA believes that under applicable law, a generic bucindolol label would likely be required to include this recommendation as it pertains directly to the safe or efficacious use of the drug. Such a label may be considered as inducing infringement, carrying the same liability as direct infringement. If the label with the genotype information for Gencaro is not approved or it is approved after the relevant patents expire, or if generic labels are not required to copy the approved label, competitors could have an easier path to introduce competing products and ARCA&#8217;s business may suffer. The approved label may not contain language covered by the patents, or ARCA may be unsuccessful in enforcing them.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA also has obtained intellectual property related to the use of Gencaro for various cardiovascular indications in the genetic population it plans to study in Phase&#160;3. The approved label may not contain language covered by ARCA&#8217;s patents and it is possible the intellectual property may not preclude others from commercializing a generic version of Gencaro, which could cause ARCA&#8217;s business to suffer. Additionally, the patents may be invalidated and/or ARCA may be unsuccessful in enforcing them.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA may not be able to effectively protect its intellectual property rights in some foreign countries, as its patents are limited by jurisdiction and many countries do not offer the same level of legal protection for intellectual property as the United&#160;States.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA requires its employees, consultants, business partners and members of its scientific advisory board to execute confidentiality agreements upon the commencement of employment, consulting or business relationships with ARCA.&#160;These agreements provide that all confidential information developed or made known during the course of the relationship with ARCA be kept confidential and not disclosed to third parties except in specific circumstances. In the case of employees, the agreements provide that all inventions resulting from work performed for ARCA, utilizing the property or relating to ARCA&#8217;s business and conceived or completed by the individual during employment shall be ARCA&#8217;s exclusive property to the extent permitted by applicable law.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Third parties may breach these and other agreements with ARCA regarding its intellectual property and ARCA may not have adequate remedies for the breach. Third parties could also fail to take necessary steps to protect ARCA&#8217;s licensed intellectual property, which could seriously harm ARCA&#8217;s intellectual property position.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If ARCA is not able to protect its proprietary technology, trade secrets and know<span class="nobreak">-how</span>, then its competitors may develop competing products. Any issued patent may not be sufficient to prevent others from competing with ARCA.&#160;Further, ARCA has trade secrets relating to rNAPc2 and Gencaro, and such trade secrets may become known or independently discovered. ARCA&#8217;s issued patents and those that may issue in the future, or those licensed to ARCA, may be challenged, opposed, invalidated or circumvented, which could allow competitors to market similar products or limit the patent protection term of ARCA&#8217;s product candidates. All of these factors may affect ARCA&#8217;s competitive position.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">If the manufacture, use or sale of ARCA&#8217;s products infringe on the intellectual property rights of others, ARCA could face costly litigation, which could cause it to pay substantial damages or licensing fees and limit its ability to sell some or all of its products.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Extensive litigation regarding patents and other intellectual property rights has been common in the biopharmaceutical industry. Litigation may be necessary to assert infringement claims, enforce patent rights, protect trade secrets or know<span class="nobreak">-how</span> and determine the enforceability, scope and validity of certain proprietary rights. Litigation may even be necessary to defend disputes of inventorship or ownership of proprietary rights. The defense and prosecution of intellectual property lawsuits, U.S.&#160;Patent and Trademark Office interference proceedings, and related legal and administrative proceedings (e.g., a reexamination, <span class="Italic" style="font-style:italic;font-weight:normal;">inter partes</span> review, or post<span class="nobreak">-grant</span> review) in the United&#160;States and internationally involve complex legal and factual questions. As a result, such proceedings are costly and time<span class="nobreak">-consuming</span> to pursue, and their outcome is uncertain.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">45</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Regardless of merit or outcome, ARCA&#8217;s involvement in any litigation, interference or other administrative proceedings could cause it to incur substantial expense and could significantly divert the efforts of its technical and management personnel. Any public announcements related to litigation or interference proceedings initiated or threatened against ARCA could cause ARCA&#8217;s stock price to decline. Adverse outcomes in patent litigation may potentially subject ARCA to antitrust litigation which, regardless of the outcome, would adversely affect ARCA&#8217;s business. An adverse determination may subject ARCA to the loss of its proprietary position or to significant liabilities, or require it to seek licenses that may include substantial cost and ongoing royalties. Licenses may not be available from third parties, or may not be obtainable on satisfactory terms. An adverse determination or a failure to obtain necessary licenses may restrict or prevent ARCA from manufacturing and selling its products, if any. These outcomes could materially harm ARCA&#8217;s business, financial condition and results of operations.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Risks Related to Ownership of ARCA Common Stock and Stock Price Volatility</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">ARCA&#8217;s stock price has been and is expected to be volatile.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA common stock has in the past been, and in the future could be, subject to significant fluctuations. Market prices for securities of early<span class="nobreak">-stage</span> pharmaceutical, biotechnology and other life sciences companies have historically been particularly volatile. Some of the factors that may cause the market price of ARCA common stock to fluctuate include:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>failure to complete, or delays in completing, the Merger;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the regulatory status of Gencaro, rNAPc2 and the genetic test, and whether and when they are approved for sale, if at all, and the labeling or other conditions of use imposed by the FDA;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s ability to secure additional funding or complete a strategic transaction or to complete development of and commercialize Gencaro or rNAPc2;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>progress of any future clinical trials for Gencaro, rNAPc2 or ARCA&#8217;s other product candidate, including enrollment and any data that may become available;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the results of ARCA&#8217;s future clinical trials and any future NDAs of ARCA&#8217;s current and future product candidates;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the entry into, or termination of, key agreements, including key strategic alliance agreements;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the results and timing of regulatory reviews relating to ARCA&#8217;s product candidates;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>failure of any of ARCA&#8217;s product candidates, if approved, to achieve commercial success;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>general and industry<span class="nobreak">-specific</span> economic conditions that may affect ARCA&#8217;s research and development expenditures;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the results of clinical trials conducted by others on drugs that would compete with ARCA&#8217;s product candidates;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>issues in manufacturing or testing ARCA&#8217;s product candidates or any approved products;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the initiation of or material developments in or the conclusion of litigation to enforce or defend any of ARCA&#8217;s intellectual property rights;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the loss of key employees;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the introduction of technological innovations or new commercial products by ARCA&#8217;s competitors;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>changes in estimates or recommendations by securities analysts, if any, who cover ARCA common stock;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>future sales of ARCA common stock;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>changes in the structure of health care payment systems;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>period<span class="nobreak">-to-period</span> fluctuations in ARCA&#8217;s financial results; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s ability to retain the listing of ARCA common stock on the Nasdaq Capital Market.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">46</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Moreover, the stock markets in general have experienced substantial volatility that has often been unrelated to the operating performance of individual companies, including as a result of deteriorating market conditions due to investor concerns regarding inflation, adverse developments affecting the financial services industry, continued hostilities between Russia and Ukraine and Hamas&#8217; attack against Israel and the ensuing conflict. These broad market fluctuations may also adversely affect the trading price of ARCA common stock. In the past, following periods of volatility in the market price of a company&#8217;s securities, stockholders have often instituted class action securities litigation against those companies. Such litigation, if instituted, could result in substantial costs and diversion of management attention and resources, which could significantly harm ARCA&#8217;s profitability and reputation.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Future sales or the possibility of future sales of ARCA common stock may depress the market price of ARCA common stock.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Sales in the public market of substantial amounts of ARCA common stock could depress prevailing market prices of ARCA common stock. As of March&#160;31, 2024, approximately 14.5<span class="nobreak"> </span>million shares of common stock were outstanding, and all of these shares are freely transferable without restriction or further registration under the Securities Act&#160;of&#160;1933, as amended, or the Securities Act, except for shares held by ARCA&#8217;s directors, officers and other affiliates and unregistered shares held by non<span class="nobreak">-affiliates</span>. The sale of these additional shares, or the perception that such sales may occur, could depress the market price of ARCA common stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of March&#160;31, 2024, there were approximately 646,000<span class="nobreak"> </span>shares of ARCA common stock which may be issued upon the exercise of outstanding stock options, and ARCA anticipates that it will continue to issue stock option and restricted stock unit awards to its employees and consultants in the fiscal year ended December&#160;31, 2024 and thereafter. If and when these options are exercised, such shares will be available for sale in the open market without further registration under the Securities Act. The existence of these outstanding options may negatively affect ARCA&#8217;s ability to complete future equity financings at acceptable prices and on acceptable terms. The exercise of those options, and the prompt resale of shares of ARCA common stock received, may also result in downward pressure on the price of ARCA common stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In the absence of a significant strategic transaction, ARCA will need to raise significant additional capital to finance the research, development and commercialization of Gencaro, rNAPc2 and its other product candidate. If future securities offerings occur, they would dilute ARCA&#8217;s current stockholders&#8217; equity interests and could reduce the market price of ARCA common stock.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">ARCA does not expect to pay cash dividends, and accordingly, stockholders must rely on stock appreciation for any return on their investment.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA has never paid cash dividends on any of its capital stock. As a result, other than the potential special cash dividend described below, only appreciation of the price of ARCA common stock will provide a return to stockholders. Investors seeking cash dividends should not invest in ARCA common stock. In addition, pursuant to the terms of the Merger Agreement, ARCA may declare and pay a special cash dividend to ARCA stockholders of record prior to the closing of the Merger consisting of cash up to an amount equal in the aggregate of the amount by which ARCA&#8217;s net cash will exceed $5.0&#160;million. See, &#8220;ARCA has never paid and, other than in connection with the Merger with Oruka, do not intend to pay any cash dividends in the foreseeable future&#8221; for further discussion on the special cash dividend.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">ARCA&#8217;s business could be negatively affected as a result of actions of activist shareholders.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Responding to actions by activist shareholders could be costly and time<span class="nobreak">-consuming</span>, disrupt ARCA&#8217;s operations and divert the attention of management and ARCA&#8217;s employees. For example, in connection with the negotiation and entry into a cooperation agreement in June&#160;2022 with Cable Car Capital LLC, The Funicular Fund, LP, Funicular Funds, LP and Jacob Ma<span class="nobreak">-Weaver</span>, collectively, Cable Car, one of ARCA&#8217;s stockholders, ARCA appointed two new directors in 2022. Activist shareholders may advocate for certain governance and strategic changes at ARCA.&#160;In the event of stockholder activism, particularly with respect to matters which ARCA&#8217;s board of directors, in exercising their fiduciary duties, disagree with or have determined not to pursue, ARCA&#8217;s business could be adversely affected because responding to actions by activist stockholders can be costly and time<span class="nobreak">-consuming</span>, disrupting ARCA&#8217;s </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">47</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">operations and diverting the attention of management, and perceived uncertainties as to ARCA&#8217;s future direction may result in the loss of potential business opportunities and may make it more difficult to attract and retain qualified personnel, business partners, and customers.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Additionally, if faced with a consent solicitation or proxy contest, ARCA may not be able to respond successfully to the contest or dispute, which would be disruptive to its business. If individuals are elected to ARCA&#8217;s board of directors with a differing agenda, ARCA&#8217;s ability to effectively and timely implement its strategic plan and create additional value for ARCA stockholders may be adversely affected. In addition, ARCA&#8217;s share price could experience periods of increased volatility as a result of shareholder activism.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">ARCA has implemented anti-takeover provisions that could discourage, prevent or delay a takeover, even if the acquisition would be beneficial to ARCA stockholders.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Provisions of the ARCA Charter and ARCA Bylaws, as well as provisions of Delaware law, could make it more difficult for a third party to acquire ARCA, even if doing so would benefit ARCA stockholders. These provisions:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>establish a classified board of directors so that not all members of ARCA&#8217;s board may be elected at one time;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>authorize the issuance of up to approximately 5&#160;million additional shares of preferred stock that could be issued by ARCA&#8217;s board of directors to increase the number of outstanding shares and hinder a takeover attempt;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>limit who may call a special meeting of stockholders;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>prohibit stockholder action by written consent, thereby requiring all stockholder actions to be taken at a meeting of ARCA stockholders; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>establish advance notice requirements for nominations for election to ARCA&#8217;s board of directors or for proposing matters that can be acted upon at a stockholder meeting.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Specifically, the ARCA Charter provides that all stockholder action must be effected at a duly called meeting and not by a written consent. The ARCA Bylaws provide, however, that ARCA stockholders may call a special meeting of stockholders only upon a request of stockholders owning at least 50% of ARCA&#8217;s outstanding common stock. These provisions of the ARCA Charter and ARCA Bylaws could discourage potential acquisition proposals and could delay or prevent a change in control. ARCA designed these provisions to reduce its vulnerability to unsolicited acquisition proposals and to discourage certain tactics that may be used in proxy fights. These provisions, however, could also have the effect of discouraging others from making tender offers for ARCA&#8217;s shares. As a consequence, they also may inhibit fluctuations in the market price of ARCA&#8217;s shares that could result from actual or rumored takeover attempts. Such provisions also may have the effect of preventing changes in ARCA&#8217;s management.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA is permitted to issue shares of ARCA preferred stock without stockholder approval upon such terms as ARCA&#8217;s board of directors determines. Therefore, the rights of the holders of ARCA common stock are subject to, and may be adversely affected by, the rights of the holders of ARCA preferred stock that may be issued in the future. In addition, the issuance of preferred stock could have a dilutive effect on the holdings of ARCA&#8217;s current stockholders.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA is subject to the Delaware anti<span class="nobreak">-takeover</span> laws regulating corporate takeovers. These anti<span class="nobreak">-takeover</span> laws prevent a Delaware corporation from engaging in a merger or sale of more than 10% of its assets with any stockholder, including all affiliates and associates of the stockholder, who owns 15% or more of the corporation&#8217;s outstanding voting stock, for three&#160;years following the date that the stockholder acquired 15% or more of the corporation&#8217;s stock unless:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the board of directors approved the transaction where the stockholder acquired 15% or more of the corporation&#8217;s stock;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>after the transaction in which the stockholder acquired 15% or more of the corporation&#8217;s stock, the stockholder owned at least 85% of the corporation&#8217;s outstanding voting stock, excluding shares owned </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">48</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-position:inside;list-style-type:none;text-indent:0pt;margin-top:8pt;">by directors, officers and employee stock plans in which employee participants do not have the right to determine confidentially whether shares held under the plan will be tendered in a tender or exchange offer; or</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>on or after this date, the merger or sale is approved by the board of directors and the holders of at least two<span class="nobreak">-thirds</span> of the outstanding voting stock that is not owned by the stockholder.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The provisions of ARCA&#8217;s governing documents and current Delaware law may, collectively:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>lengthen the time required for a person or entity to acquire control of ARCA through a proxy contest for the election of a majority of ARCA&#8217;s board of directors;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>discourage bids for ARCA common stock at a premium over market price; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>generally deter efforts to obtain control of ARCA.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Risks Related to Oruka</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Risks Related to Oruka&#8217;s Financial Condition and Capital Requirements</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Even if the Merger and Oruka pre-closing financing are successful, Oruka will need to raise additional capital, and if it is unable to do so when needed, that will raise substantial doubt about Oruka&#8217;s ability to continue as a going concern.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of March&#160;31, 2024, Oruka had $27.7&#160;million of cash. Should this financing be successful, Oruka will need to raise additional capital to continue to fund its operations and service its debt obligations in the future. If Oruka is unable to raise additional capital when needed, that will raise substantial doubt about Oruka&#8217;s ability to continue as a going concern. As a result, Oruka has concluded there is substantial doubt about its ability to continue as a going concern for at least twelve months from the date its financial statement as of February<span class="nobreak"> </span>6, 2024 is available to be issued. In light of these concerns, Oruka&#8217;s independent registered public accounting firm included in its opinion on the financial statement an explanatory paragraph expressing substantial doubt about Oruka&#8217;s ability to continue as a going concern beyond twelve months from the date Oruka&#8217;s financial statement is available to be issued.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Developing Oruka&#8217;s product candidates requires a substantial amount of capital. Following the Merger and Oruka pre<span class="nobreak">-closing</span> financing, the combined company will also incur additional costs associated with operating as a public company. Oruka expects its research and development expenses to increase in connection with its ongoing activities, particularly as it advances its product candidates through clinical trials. Oruka will need to raise additional capital to fund its operations and such funding may not be available to Oruka on acceptable terms, or at all, and such funding may become even more difficult to obtain due to rising interest rates and the current downturn in the U.S.&#160;capital markets and the biotechnology sector in general. Competition for additional capital among biotechnology companies may be particularly intense during this present economic downturn. Oruka may be unable to raise capital through public offerings of its common stock and may need to turn to alternative financing arrangements. Such arrangements, if Oruka pursues them, could involve issuances of one or more types of securities, including common stock, preferred stock, convertible debt, warrants to acquire common stock or other securities. These securities could be issued at or below the then prevailing market price for Oruka common stock. In addition, if Oruka issues debt securities, the holders of the debt would have a claim to Oruka&#8217;s assets that would be superior to the rights of stockholders until the principal, accrued and unpaid interest and any premium or make<span class="nobreak">-whole</span> has been paid. Interest on any newly<span class="nobreak">-issued</span> debt securities and/or newly<span class="nobreak">-incurred</span> borrowings would increase Oruka&#8217;s operating costs and reduce its net income (or increase its net loss), and these impacts may be material. If the issuance of new securities results in diminished rights to holders of Oruka common stock, the market price of Oruka common stock could be materially and adversely affected.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka does not currently have any products approved for sale and does not generate any revenue from product sales. Accordingly, Oruka expects to rely primarily on equity and/or debt financings to fund its continued operations. Oruka&#8217;s ability to raise additional funds will depend, in part, on the success of its preclinical studies and clinical trials and other product development activities, regulatory events, its ability to identify and enter into licensing or other strategic arrangements, and other events or conditions that may affect its value or prospects, as well as factors related to financial, economic and market conditions, many of which are beyond Oruka&#8217;s control. There can be no assurances that sufficient funds will be available to Oruka when required or on acceptable terms, if at all.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">49</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If Oruka is unable to raise additional capital when required or on acceptable terms, it may be required to:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>significantly delay, scale back, or discontinue the development or commercialization of its product candidates;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>seek strategic partnerships, or amend existing partnerships, for research and development programs at an earlier stage than otherwise would be desirable or that Oruka otherwise would have sought to develop independently, or on terms that are less favorable than might otherwise be available in the future;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>dispose of technology assets, or relinquish or license on unfavorable terms, Oruka&#8217;s rights to technologies or any of its product candidates that it otherwise would seek to develop or commercialize itself;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>pursue the sale of the company to a third party at a price that may result in a loss on investment for Oruka&#8217;s stockholders; or</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>file for bankruptcy or cease operations altogether (and face any related legal proceedings).</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Any of these events could have a material adverse effect on Oruka&#8217;s business, operating results, and prospects.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Even if successful in raising new capital, Oruka could be limited in the amount of capital it raises due to investor demand restrictions placed on the amount of capital it raises or other reasons.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Additionally, any capital raising efforts are subject to significant risks and contingencies, as described in more detail under the risk factor titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Raising additional capital may cause dilution to Oruka&#8217;s stockholders, restrict its operations, or require it to relinquish rights.</span>&#8221;</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka has never generated any revenue from product sales and may never be profitable.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka has no products approved for commercialization and has never generated any revenue from product sales. Oruka&#8217;s ability to generate revenue and achieve profitability depends on its ability, alone or with strategic collaborators, to successfully complete the development of, and obtain the regulatory and marketing approvals necessary to commercialize one or more of its product candidates. Oruka does not anticipate generating revenue from product sales for the foreseeable future. Oruka&#8217;s ability to generate future revenue from product sales depends heavily on its success in many areas, including but not limited to:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>completing research and development of its product candidates;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>obtaining regulatory and marketing approvals for its product candidates for which it completes clinical trials;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>manufacturing product candidates and establishing and maintaining supply and manufacturing relationships with third parties that are commercially feasible, meet regulatory requirements and Oruka&#8217;s supply needs in sufficient quantities to meet market demand for its product candidates, if approved;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>qualifying for adequate coverage and reimbursement by government and third<span class="nobreak">-party</span> payors for any product candidates for which Oruka obtains regulatory and marketing approval;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>marketing, launching, and commercializing product candidates for which Oruka obtains regulatory and marketing approval, either directly or with a collaborator or distributor;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>gaining market acceptance of Oruka&#8217;s product candidates as treatment options;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>addressing any competing products and technological and market developments;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>implementing internal systems and infrastructure, as needed;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>protecting and enforcing Oruka&#8217;s intellectual property rights, including patents, trade secrets, and&#160;know<span class="nobreak">-how</span>;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>negotiating favorable terms in any collaboration, licensing, or other arrangements into which Oruka may enter;</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">50</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>obtaining coverage and adequate reimbursement from third<span class="nobreak">-party</span> payors and maintaining pricing for Oruka&#8217;s product candidates that supports profitability; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>attracting, hiring, and retaining qualified personnel.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Even if one or more of the product candidates that Oruka develops is approved for commercial sale, Oruka anticipates incurring significant costs associated with commercializing any approved product candidate. Oruka&#8217;s expenses could increase beyond expectations if it is required by regulatory authorities to perform clinical and other studies in addition to those that Oruka anticipates. Even if Oruka is able to generate revenues from the sale of any approved products, it may not become profitable and may need to obtain additional funding to continue operations. Oruka will also have to develop or acquire manufacturing capabilities or continue to contract with contract manufacturers in order to continue development and potential commercialization of its product candidates. For instance, if the costs of manufacturing Oruka&#8217;s drug product are not commercially feasible, Oruka will need to develop or procure its drug product in a commercially feasible manner in order to successfully commercialize a future approved product, if any. Additionally, if Oruka is not able to generate revenue from the sale of any approved products, it may never become profitable.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka is a preclinical stage biopharmaceutical company with a limited operating history on which to assess its business; it has not initiated, conducted or completed any clinical trials, has no products approved for commercial sale, has historically incurred losses, and anticipates that it will continue to incur significant losses for the foreseeable future.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka is a preclinical stage biopharmaceutical company with a limited operating history. Since February&#160;6, 2024 (inception), Oruka has incurred significant operating losses. For the period between February&#160;6, 2024 (inception) to March&#160;31, 2024, Oruka reported a net loss of $7.1&#160;million and had an accumulated deficit of $7.1&#160;million. Oruka will need to raise substantial additional capital to continue to fund its operations in the future. Failure to raise capital as and when needed, on favorable terms or at all, would have a negative impact on Oruka&#8217;s financial condition and its ability to develop its product candidates. Changing circumstances may cause Oruka to consume capital significantly faster or slower than it currently anticipates. If Oruka is unable to acquire additional capital or resources, it will be required to modify its operational plans to complete future milestones and it may be required to delay, limit, reduce or eliminate development or future commercialization efforts of product candidates and/or programs. Oruka has based these estimates on assumptions that may prove to be wrong, and it could exhaust its available financial resources sooner than it currently anticipates. Oruka may be forced to reduce its operating expenses and raise additional funds to meet its working capital needs, principally through the additional sales of its securities or debt financings or entering into strategic collaborations.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka has devoted substantially all of its financial resources to identify, acquire, and develop its product candidates, organizing and staffing its company, and providing general and administrative support for its operations. To date, Oruka has funded its operations primarily from the sale and issuance of convertible preferred and common equity securities and unsecured convertible notes. The amount of Oruka&#8217;s future net losses will depend, in part, on the rate of its future expenditures and its ability to obtain funding through equity or debt financings, strategic collaborations, or grants.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Biopharmaceutical product development is a highly speculative undertaking and involves a substantial degree of risk. Oruka expects its losses to increase as its product candidates enter more advanced clinical trials. It may be several&#160;years, if ever, before Oruka completes pivotal clinical trials or has a product candidate approved for commercialization. Oruka expects to invest significant funds into the research and development of its current programs to determine the potential to advance product candidates to regulatory approval. If Oruka obtains regulatory approval to market a product candidate, its future revenue will depend upon the size of any markets in which its product candidates may receive approval, and its ability to achieve sufficient market acceptance, pricing, coverage and adequate reimbursement from third<span class="nobreak">-party</span> payors, and adequate market share for its product candidates in those markets. Even if Oruka obtains adequate market share for its product candidates, because the potential markets in which its product candidates may ultimately receive regulatory approval could be very small, Oruka may never become profitable despite obtaining such market share and acceptance of its products.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">51</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka expects to continue to incur significant expenses and increasing operating losses for the foreseeable future and its expenses will increase substantially if and as it:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>continues the preclinical development and initiates the clinical development of its product candidates;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>continues efforts to discover and develop new product candidates;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>continues the manufacturing of its product candidates or increases volumes manufactured by third parties;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>advances its product candidates into larger, more expensive clinical trials;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>initiates additional preclinical studies or clinical trials for its product candidates;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>seeks regulatory and marketing approvals and reimbursement for its product candidates;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>establishes a sales, marketing, and distribution infrastructure to commercialize any products for which it may obtain marketing approval and market for itself;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>seeks to identify, assess, acquire, and/or develop other product candidates;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>makes milestone, royalty, or other payments under third<span class="nobreak">-party</span> license agreements;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>seeks to maintain, protect, and expand its intellectual property portfolio;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>is required to pay penalties under its registration rights agreement for failing to timely register the applicable securities;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>seeks to attract and retain skilled personnel; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>experiences any delays or encounters issues with the development and potential regulatory approval of its clinical and product candidates such as safety issues, manufacturing delays, clinical trial accrual delays, longer&#160;follow<span class="nobreak">-up</span>&#160;for planned studies or trials, additional major studies or trials, or supportive trials necessary to support marketing approval.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka has no significant experience as a company in initiating, conducting or completing clinical trials. In part because of this lack of experience, Oruka cannot be certain that its planned clinical trials will begin or be completed on time, if at all. In addition, Oruka has not yet demonstrated an ability to obtain marketing approvals, manufacture a commercial<span class="nobreak">-scale</span> product or arrange for a third party to do so on its behalf, or conduct sales, marketing and distribution activities necessary for successful product commercialization. Consequently, any predictions you make about Oruka&#8217;s future success or viability may not be as accurate as they could be if Oruka had a longer operating history. Further, the net losses Oruka incurs may fluctuate significantly from quarter to quarter and year to year, such that a&#160;period<span class="nobreak">-to-period</span>&#160;comparison of its results of operations may not be a good indication of its future performance.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Raising additional capital may cause dilution to Oruka&#8217;s stockholders, restrict its operations, or require it to relinquish rights.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Until such time, if ever, as Oruka can generate substantial revenue from the sale of its product candidates, Oruka expects to finance its cash needs through a combination of equity offerings, debt financings and license and development agreements. To the extent that Oruka raises additional capital through the sale of equity securities or convertible debt securities, the ownership interest of its stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of holders of Oruka common stock. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting Oruka&#8217;s ability to take specific actions, such as incurring additional debt, making capital expenditures, or declaring dividends.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If Oruka raises additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, it may be required to relinquish valuable rights to its research programs or product candidates or grant licenses on terms that may not be favorable to it. If Oruka is unable to raise additional </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">52</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">funds through equity or debt financings or other arrangements with third parties when needed, it may be required to delay, limit, reduce or terminate its product development or future commercialization efforts or grant rights to third parties to develop and market product candidates that Oruka would otherwise prefer to develop and market itself.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">To the extent that Oruka raises additional capital through the sale of equity, including pursuant to any sales under convertible debt or other securities convertible into equity, the ownership interest of its stockholders will be diluted, and the terms of these new securities may include liquidation or other preferences that adversely affect the rights of its stockholders. For instance, in March&#160;2024, Oruka sold an aggregate of 20,000,000<span class="nobreak"> </span>shares of Series&#160;A preferred stock and the Convertible Note to Fairmount Fund&#160;II for gross proceeds of $28.0&#160;million.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Debt financing, if available, would likely involve agreements that include covenants limiting or restricting Oruka&#8217;s ability to take specific actions, such as incurring additional debt, making capital expenditures, making additional product acquisitions, or declaring dividends. If Oruka raises additional funds through strategic collaborations or licensing arrangements with third parties, Oruka may have to relinquish valuable rights to its product candidates or future revenue streams or grant licenses on terms that are not favorable to Oruka. Oruka cannot assure that it will be able to obtain additional funding if and when necessary to fund its entire portfolio of product candidates to meet its projected plans. If Oruka is unable to obtain funding on a timely basis, it may be required to delay or discontinue one or more of its development programs or the commercialization of any product candidates or be unable to expand its operations or otherwise capitalize on potential business opportunities, which could materially harm Oruka&#8217;s business, financial condition, and results of operations.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Risks Related to Discovery, Development and Commercialization</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka faces competition from entities that have developed or may develop programs for the diseases addressed by product candidates developed by Oruka.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The development and commercialization of drugs is highly competitive. Product candidates developed by Oruka, if approved, will face significant competition and Oruka&#8217;s failure to effectively compete may prevent it from achieving significant market penetration. Oruka competes with a variety of multinational biopharmaceutical companies, specialized biotechnology companies and emerging biotechnology companies, as well as academic institutions, governmental agencies, and public and private research institutions, among others. Many of the companies with which Oruka is currently competing or will compete against in the future have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, clinical trial conduct, regulatory approvals, and marketing than Oruka does. Mergers and acquisitions in the pharmaceutical and biotechnology industry may result in even more resources being concentrated among a smaller number of Oruka&#8217;s competitors. Smaller or early<span class="nobreak">-stage</span> companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with Oruka in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites, recruiting participants for clinical trials, as well as in acquiring technologies complementary to, or necessary for, Oruka&#8217;s product candidates.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka&#8217;s competitors have developed, are developing or will develop programs and processes competitive with its programs and processes. Competitive therapeutic treatments include those that have already been approved and accepted by the medical community and any new treatments. Oruka&#8217;s success will depend partially on its ability to develop and commercialize products that have a competitive safety, efficacy, dosing and/or presentation profile. Oruka&#8217;s commercial opportunity and success will be reduced or eliminated if competing products are safer, more effective, have a more attractive dosing profile or presentation or are less expensive than the products Oruka develops, or if Oruka&#8217;s competitors develop competing products or if biosimilars enter the market more quickly than Oruka does and are able to gain market acceptance. See the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Oruka&#8217;s Business&#160;&#8212;&#160;Competition</span>&#8221; for more discussion about Oruka&#8217;s competitors.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, because of the competitive landscape for&#160;I&amp;I indications, Oruka may also face competition for clinical trial enrollment. Clinical trial enrollment will depend on many factors, including if potential clinical trial participants choose to undergo treatment with approved products or enroll in competitors&#8217; ongoing clinical trials for programs that are under development for the same indications as Oruka&#8217;s programs. An increase in the number of </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">53</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">approved products for the indications Oruka is targeting with its programs may further exacerbate this competition. Oruka&#8217;s inability to enroll a sufficient number of participants could, among other things, delay its development timeline, which may further harm its competitive position.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka&#8217;s programs are in preclinical stages of development and may fail in development or suffer delays that materially and adversely affect their commercial viability. If Oruka or its current or future collaborators are unable to complete development of or commercialize Oruka&#8217;s product candidates, or experience significant delays in doing so, Oruka&#8217;s business will be materially harmed.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka has no products on the market, and all of its programs are in preclinical stages of development and have not been tested in humans. As a result, Oruka expects it will be many&#160;years before it commercializes any product candidate, if ever. Oruka&#8217;s ability to achieve and sustain profitability depends on obtaining regulatory approvals for, and successfully commercializing, its product candidates, either alone or with third parties, and Oruka cannot guarantee you that it will ever obtain regulatory approval for any of its product candidates. Oruka has not yet demonstrated its ability to initiate or complete any clinical trials, obtain regulatory approvals, manufacture a clinical or commercial scale product or arrange for a third party to do so on its behalf, or conduct sales and marketing activities necessary for successful product commercialization. Before obtaining regulatory approval for the commercial distribution of Oruka&#8217;s product candidates, Oruka or an existing or future collaborator must conduct extensive preclinical tests and clinical trials to demonstrate the safety and efficacy in humans of Oruka&#8217;s programs and product candidates.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka or its collaborators may experience delays in initiating or completing clinical trials. Oruka or its collaborators also may experience numerous unforeseen events during, or as a result of, any clinical trials that they could conduct that could delay or prevent Oruka&#8217;s ability to receive marketing approval or commercialize its product candidates, including:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>regulators or institutional review boards (&#8220;IRBs&#8221;), the FDA or ethics committees may not authorize Oruka or its investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Oruka may experience delays in reaching, or fail to reach, agreement on acceptable terms with prospective trial sites and prospective contract research organizations (&#8220;CROs&#8221;), the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>clinical trial sites deviating from trial protocol or dropping out of a trial;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>clinical trials of any product candidates may fail to show safety or efficacy, produce negative or inconclusive results, and Oruka may decide, or regulators may require it, to conduct additional preclinical studies or clinical trials or Oruka may decide to abandon product development programs;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the number of subjects required for clinical trials of any product candidates may be larger than Oruka anticipates, especially if regulatory bodies require completion of&#160;non<span class="nobreak">-inferiority</span>&#160;or superiority trials, enrollment in these clinical trials may be slower than Oruka anticipates or subjects may drop out of these clinical trials or fail to return for post<span class="nobreak">-treatment</span>&#160;follow<span class="nobreak">-up</span>&#160;at a higher rate than Oruka anticipates;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Oruka&#8217;s third<span class="nobreak">-party</span> contractors may fail to comply with regulatory requirements or meet their contractual obligations to Oruka in a timely manner, or at all, or may deviate from the clinical trial protocol or drop out of the trial, which may require that Oruka add new clinical trial sites or investigators;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Oruka may elect to, or regulators, IRBs or ethics committees may require that Oruka or its investigators, suspend or terminate clinical research or trials for various reasons, including noncompliance with regulatory requirements or a finding that the participants in Oruka&#8217;s trials are being exposed to unacceptable health risks;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the cost of clinical trials of any of Oruka&#8217;s programs may be greater than Oruka anticipates;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the quality of Oruka&#8217;s product candidates or other materials necessary to conduct clinical trials of Oruka&#8217;s product candidates may be inadequate to initiate or complete a given clinical trial;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Oruka&#8217;s inability to manufacture sufficient quantities of its product candidates for use in clinical trials;</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">54</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>reports from clinical testing of other therapies may raise safety or efficacy concerns about Oruka&#8217;s programs;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Oruka&#8217;s failure to establish an appropriate safety profile for a product candidate based on clinical or preclinical data for such product candidates as well as data emerging from other therapies in the same class as Oruka&#8217;s product candidates; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the FDA or other regulatory authorities may require Oruka to submit additional data such as long<span class="nobreak">-term</span> toxicology studies, or impose other requirements before permitting Oruka to initiate a clinical trial.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Commencing clinical trials in the United&#160;States is subject to acceptance by the FDA of an investigational new drug application (&#8220;IND&#8221;), biologics license application (&#8220;BLA&#8221;) or similar application and finalizing the trial design based on discussions with the FDA and other regulatory authorities. In the event that the FDA requires Oruka to complete additional preclinical studies or it is required to satisfy other FDA requests prior to commencing clinical trials, the start of Oruka&#8217;s first clinical trials may be delayed. Even after Oruka receives and incorporates guidance from these regulatory authorities, the FDA or other regulatory authorities could disagree that Oruka has satisfied their requirements to commence any clinical trial or change their position on the acceptability of Oruka&#8217;s trial design or the clinical endpoints selected, which may require Oruka to complete additional preclinical studies or clinical trials, delay the enrollment of Oruka&#8217;s clinical trials or impose stricter approval conditions than Oruka currently expects. There are equivalent processes and risks applicable to clinical trial applications in other countries, including countries in the European Union (&#8220;EU&#8221;).</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka may not have the financial resources to continue development of, or to modify existing or enter into new collaborations for, a product candidate if it experiences any issues that delay or prevent regulatory approval of, or its ability to commercialize, its product candidates. Oruka or its current or future collaborators&#8217; inability to complete development of, or commercialize Oruka&#8217;s product candidates, or significant delays in doing so, could have a material and adverse effect on Oruka&#8217;s business, financial condition, results of operations and prospects.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka is substantially dependent on the success of its two most advanced programs, ORKA-001 and ORKA-002, and its anticipated clinical trials of such programs may not be successful.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka&#8217;s future success is substantially dependent on its ability to timely obtain marketing approval for, and then successfully commercialize, its two most advanced programs, ORKA<span class="nobreak">-001</span> and ORKA<span class="nobreak">-002</span>. Oruka is investing a majority of its efforts and financial resources into the research and development of these programs. Oruka anticipates initiating a Phase&#160;1 clinical trial in healthy volunteers of ORKA<span class="nobreak">-001</span> in the first half of 2025 and of ORKA<span class="nobreak">-002</span> in the second half of 2025, each subject to the filing of an IND or foreign equivalent and regulatory approval. The success of Oruka&#8217;s programs is dependent on observing a longer half<span class="nobreak">-life</span> of Oruka&#8217;s product candidates in humans than other extended half<span class="nobreak">-life</span> monoclonal antibodies (&#8220;mAbs&#8221;) currently marketed and in development as Oruka believes this longer half<span class="nobreak">-life</span> has the potential to result in a more favorable dosing schedule for Oruka&#8217;s product candidates, assuming they successfully complete clinical development and obtain marketing approval. This is based in part on the assumption that the longer half<span class="nobreak">-life</span> Oruka has observed in&#160;non<span class="nobreak">-human</span>&#160;primates (&#8220;NHPs&#8221;) will translate into an extended half<span class="nobreak">-life</span> of Oruka&#8217;s product candidates in humans. To the extent Oruka does not observe this extended half<span class="nobreak">-life</span> when it doses humans with its product candidates, it would significantly and adversely affect the clinical and commercial potential of its product candidates.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka&#8217;s programs will require additional clinical development, evaluation of clinical, preclinical and manufacturing activities, product development, marketing approval in multiple jurisdictions, substantial investment and significant marketing efforts before Oruka generates any revenues from product sales. Oruka is not permitted to market or promote these programs, or any other programs, before it receives marketing approval from the FDA and comparable foreign regulatory authorities, and Oruka may never receive such marketing approvals.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The success of Oruka&#8217;s product candidates will depend on a variety of factors. Oruka does not have complete control over many of these factors, including certain aspects of clinical development and the regulatory submission process, potential threats to Oruka&#8217;s intellectual property rights and the manufacturing, marketing, distribution and sales efforts of any current or future collaborator. Accordingly, Oruka cannot assure you that it will ever be able to generate revenue through the sale of these product candidates, even if approved. If Oruka is not successful in commercializing its ORKA<span class="nobreak">-001</span> or ORKA<span class="nobreak">-002</span> programs, or is significantly delayed in doing so, Oruka&#8217;s business will be materially harmed.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">55</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">If Oruka does not achieve its projected development goals in the time frames it announces and expects, the commercialization of Oruka&#8217;s product candidates may be delayed and its expenses may increase and, as a result, its stock price may decline.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">From time to time, Oruka estimates the timing of the anticipated accomplishment of various scientific, clinical, regulatory and other product development goals, which it sometimes refers to as milestones. These milestones may include the commencement or completion of scientific studies and clinical trials, such as the expected timing for the anticipated commencement of Oruka&#8217;s Phase&#160;1 studies, clinical trials in PsO and other target indications, as well as the submission of regulatory filings. From time to time, Oruka may publicly announce the expected timing of some of these milestones. All of these milestones are and will be based on numerous assumptions. The actual timing of these milestones can vary dramatically compared to Oruka&#8217;s estimates, in some cases for reasons beyond Oruka&#8217;s control. If Oruka does not meet these milestones as publicly announced, or at all, the commercialization of its product candidates may be delayed or never achieved and, as a result, its stock price may decline. Additionally, delays relative to Oruka&#8217;s projected timelines are likely to cause overall expenses to increase, which may require Oruka to raise additional capital sooner than expected and prior to achieving targeted development milestones.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Any drug delivery device that Oruka potentially uses to deliver its product candidates may have its own regulatory, development, supply and other risks.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka expects to deliver its product candidates via a drug delivery device, such as an injector or other delivery system. There may be unforeseen technical complications related to the development activities required to bring such a product to market, including primary container compatibility and/or dose volume requirements. Oruka&#8217;s product candidates may not be approved or may be substantially delayed in receiving approval if the devices that Oruka chooses to develop do not gain and/or maintain their own regulatory approvals or clearances. Where approval of the drug product and device is sought under a single application, the increased complexity of the review process may delay approval. In addition, some drug delivery devices are provided by single<span class="nobreak">-source</span> unaffiliated third<span class="nobreak">-party</span> companies. Oruka may be dependent on the sustained cooperation and effort of those third<span class="nobreak">-party</span> companies both to supply the devices and, in some cases, to conduct the studies required for approval or other regulatory clearance of the devices. Even if approval is obtained, Oruka may also be dependent on those third<span class="nobreak">-party</span> companies continuing to maintain such approvals or clearances once they have been received. Failure of third<span class="nobreak">-party</span> companies to supply the devices, to successfully complete studies on the devices in a timely manner, or to obtain or maintain required approvals or clearances of the devices could result in increased development costs, delays in or failure to obtain regulatory approval and delays in product candidates reaching the market or in gaining approval or clearance for expanded labels for new indications.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka&#8217;s approach to the discovery and development of its programs is unproven, and Oruka may not be successful in its efforts to build a pipeline of programs with commercial value.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka&#8217;s approach to the discovery and development of the research programs with respect to which it has the option to acquire intellectual property license rights to pursuant to the Paragon Option Agreements leverages clinically validated mechanisms of action and incorporates advanced antibody engineering to optimize half<span class="nobreak">-life</span> and other properties designed to overcome limitations of existing therapies. Oruka&#8217;s programs are purposefully designed to improve upon existing product candidates and products while maintaining the same, well<span class="nobreak">-established</span> mechanisms of action. However, the scientific research that forms the basis of Oruka&#8217;s efforts to develop programs using half<span class="nobreak">-life</span> extension technologies is ongoing and may not result in viable programs. There is limited clinical data available on product candidates utilizing half<span class="nobreak">-life</span> extension technologies, especially in&#160;I&amp;I indications, demonstrating whether they are safe or effective for long<span class="nobreak">-term</span> treatment in humans. The long<span class="nobreak">-term</span> safety and efficacy of these technologies and the extended half<span class="nobreak">-life</span> and exposure profile of Oruka&#8217;s programs compared to currently approved products is unknown.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka may ultimately discover that utilizing half<span class="nobreak">-life</span> extension technologies for its specific targets and indications and any programs resulting therefrom does not possess certain properties required for therapeutic effectiveness. Oruka currently has only preclinical data regarding the increased half<span class="nobreak">-life</span> properties of its programs and the same results may not be seen in humans. In addition, programs using half<span class="nobreak">-life</span> extension technologies may </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">56</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">demonstrate different chemical and pharmacological properties in participants than they do in laboratory studies. This technology and any programs resulting therefrom may not demonstrate the same chemical and pharmacological properties in humans and may interact with human biological systems in unforeseen, ineffective or harmful ways.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, Oruka may in the future seek to discover and develop programs that are based on novel targets and technologies that are unproven. If Oruka&#8217;s discovery activities fail to identify novel targets or technologies for drug discovery, or such targets prove to be unsuitable for treating human disease, Oruka may not be able to develop viable additional programs. Oruka and its existing or future collaborators may never receive approval to market and commercialize any product candidate. Even if Oruka or an existing or future collaborator obtains regulatory approval, the approval may be for targets, disease indications or patient populations that are not as broad as Oruka intended or desired or may require labeling that includes significant use or distribution restrictions or safety warnings. If the products resulting from the research programs with respect to which Oruka has the option to acquire intellectual property license rights to pursuant to the Paragon Option Agreements prove to be ineffective, unsafe or commercially unviable, such programs would have little, if any, value, which would have a material and adverse effect on Oruka&#8217;s business, financial condition, results of operations and prospects.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Preclinical and clinical development involves a lengthy and expensive process that is subject to delays and uncertain outcomes, and results of earlier studies and trials may not be predictive of future clinical trial results. If Oruka&#8217;s preclinical studies and clinical trials are not sufficient to support regulatory approval of any of its product candidates, Oruka may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development of such product candidate.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Before obtaining marketing approval from regulatory authorities for the sale of any product candidate, Oruka must complete preclinical studies and then conduct extensive clinical trials to demonstrate the safety and efficacy of such product candidate in humans. Oruka&#8217;s clinical trials may not be conducted as planned or completed on schedule, if at all, and failure can occur at any time during the preclinical study or clinical trial process. For example, Oruka depends on the availability of NHPs to conduct certain preclinical studies that it is required to complete prior to submitting an IND and initiating clinical development. There is currently a global shortage of NHPs available for drug development. This could cause the cost of obtaining NHPs for Oruka&#8217;s future preclinical studies to increase significantly and, if the shortage continues, could also result in delays to Oruka&#8217;s development timelines.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Furthermore, a failure of one or more clinical trials can occur at any stage of testing. The outcome of preclinical studies and early<span class="nobreak">-stage</span> clinical trials may not be predictive of the success of later clinical trials. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval of their product candidates. In addition, Oruka expects to rely on participants to provide feedback on measures such as measures of quality of life, which are subjective and inherently difficult to evaluate. These measures can be influenced by factors outside of Oruka&#8217;s control, and can vary widely from&#160;day<span class="nobreak">-to-day</span> for a particular participant, and from participant to participant and from site to site within a clinical trial.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka cannot be sure that the FDA will agree with its clinical development plan. Oruka plans to use the data from its planned Phase&#160;1 trials of its ORKA<span class="nobreak">-001</span> and ORKA<span class="nobreak">-002</span> programs in healthy volunteers to support Phase&#160;2 trials in PsO and other&#160;I&amp;I indications. If the FDA requires Oruka to conduct additional trials or enroll additional participants, Oruka&#8217;s development timelines may be delayed. Oruka cannot be sure that submission of an IND, BLA or similar application will result in the FDA or comparable foreign regulatory authorities, as applicable, allowing clinical trials to begin in a timely manner, if at all. Moreover, even if these trials begin, issues may arise that could cause regulatory authorities to suspend or terminate such clinical trials. Events that may prevent successful or timely initiation or completion of clinical trials include: inability to generate sufficient preclinical, toxicology or other&#160;<span class="Italic" style="font-style:italic;font-weight:normal;">in vivo&#160;</span>or&#160;<span class="Italic" style="font-style:italic;font-weight:normal;">in vitro&#160;</span>data to support the initiation or continuation of clinical trials; delays in reaching a consensus with regulatory authorities on study design or implementation of the clinical trials; delays or failure in obtaining regulatory authorization to commence a trial; delays in reaching agreement on acceptable terms with prospective CROs and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and clinical trial sites; delays in identifying, recruiting and training suitable clinical investigators; delays in obtaining required IRB approval at each clinical trial site; delays in manufacturing, </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">57</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">testing, releasing, validating or importing/exporting sufficient stable quantities of Oruka&#8217;s product candidates for use in clinical trials or the inability to do any of the foregoing; failure by Oruka&#8217;s CROs, other third parties or Oruka to adhere to clinical trial protocols; failure to perform in accordance with the FDA&#8217;s or any other regulatory authority&#8217;s current Good Clinical Practice requirements (&#8220;GCPs&#8221;) or applicable regulatory guidelines in other countries; changes to the clinical trial protocols; clinical sites deviating from trial protocol or dropping out of a trial; changes in regulatory requirements and guidance that require amending or submitting new clinical protocols; selection of clinical endpoints that require prolonged periods of observation or analyses of resulting data; transfer of manufacturing processes to facilities operated by a contract manufacturing organization (&#8220;CMO&#8221;) and delays or failure by Oruka&#8217;s CMOs or Oruka to make any necessary changes to such manufacturing process; and third parties being unwilling or unable to satisfy their contractual obligations to Oruka.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka could also encounter delays if a clinical trial is suspended or terminated by it, by the IRBs of the institutions in which such clinical trials are being conducted, by the Data Safety Monitoring Board, if any, for such clinical trial or by the FDA or comparable foreign regulatory authorities. Such authorities may suspend or terminate a clinical trial due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or Oruka&#8217;s clinical trial protocols, inspection of the clinical trial operations or trial site by the FDA or comparable foreign regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from the programs, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. If Oruka is required to conduct additional clinical trials or other testing of its product candidates beyond those that Oruka currently contemplates, if Oruka is unable to successfully complete clinical trials of its product candidates, if the results of these trials are not positive or are only moderately positive or if there are safety concerns, Oruka&#8217;s business and results of operations may be adversely affected and it may incur significant additional costs.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">If Oruka encounters difficulties enrolling participants in its future clinical trials, its clinical development activities could be delayed or otherwise adversely affected.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka may experience difficulties in patient participant enrollment in its future clinical trials for a variety of reasons. The timely completion of clinical trials in accordance with their protocols depends, among other things, on Oruka&#8217;s ability to enroll a sufficient number of participants who remain in the trial until its conclusion. The enrollment of participants in future trials for any of Oruka&#8217;s programs will depend on many factors, including if participants choose to enroll in clinical trials, rather than using approved products, or if Oruka&#8217;s competitors have ongoing clinical trials for programs that are under development for the same indications as its programs, and participants instead enroll in such clinical trials. Additionally, the number of participants required for clinical trials of Oruka&#8217;s programs may be larger than Oruka anticipates, especially if regulatory bodies require the completion of&#160;non<span class="nobreak">-inferiority</span>&#160;or superiority trials. Even if Oruka is able to enroll a sufficient number of participants for its future clinical trials, it may have difficulty maintaining participants in its clinical trials. Oruka&#8217;s inability to enroll or maintain a sufficient number of participants would result in significant delays in completing clinical trials or receipt of marketing approvals and increased development costs or may require Oruka to abandon one or more clinical trials altogether.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Preliminary, &#8220;topline&#8221; or interim data from Oruka&#8217;s clinical trials that it announces or publishes from time to time may change as more participant data become available and are subject to audit and verification procedures.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">From time to time, Oruka may publicly disclose preliminary or topline data from its preclinical studies and clinical trials, which are based on a preliminary analysis of then<span class="nobreak">-available</span> data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data. Oruka also makes assumptions, estimations, calculations and conclusions as part of its analyses of these data without the opportunity to fully and carefully evaluate complete data. As a result, the preliminary or topline results that Oruka reports may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated or subsequently made subject to audit and verification procedures.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Any preliminary or topline data should be viewed with caution until the final data are available. From time to time, Oruka may also disclose interim data from its preclinical studies and clinical trials. Interim data are subject to the risk that one or more of the clinical outcomes may materially change as participant enrollment continues and more participant data become available or as participants from Oruka&#8217;s clinical trials continue other treatments. Further, others, including regulatory agencies, may not accept or agree with Oruka&#8217;s assumptions, estimates, </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">58</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular product candidate, the approvability or commercialization of the particular product candidate and Oruka&#8217;s company in general. In addition, the information Oruka chooses to publicly disclose regarding a particular preclinical study or clinical trial is based on what is typically extensive information, and you or others may not agree with what Oruka determines is material or otherwise appropriate information to include in its disclosure. If the preliminary, topline or interim data that Oruka reports differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, Oruka&#8217;s ability to obtain approval for, and commercialize, its product candidates may be harmed, which could harm its business, operating results, prospects or financial condition.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka&#8217;s future clinical trials or those of its future collaborators may reveal significant adverse events or undesirable side effects not seen in Oruka&#8217;s preclinical studies and may result in a safety profile that could halt clinical development, inhibit regulatory approval or limit commercial potential or market acceptance of any of Oruka&#8217;s product candidates.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Results of Oruka&#8217;s clinical trials could reveal a high and unacceptable severity and prevalence of side effects, adverse events or unexpected characteristics. While preclinical studies in NHPs conducted with respect to Oruka&#8217;s programs have not shown any such characteristics to date, Oruka has not yet initiated any clinical trials in humans. If significant adverse events or other side effects are observed in any of Oruka&#8217;s future clinical trials, Oruka may have difficulty recruiting participants to such trials, participants may drop out of the trials, or Oruka may be required to abandon the trials or its development efforts of one or more programs altogether. Oruka, the FDA or other applicable regulatory authorities, or an IRB, may suspend any clinical trials of any program at any time for various reasons, including a belief that subjects or patients in such trials are being exposed to unacceptable health risks or adverse side effects. Some potential products developed in the biotechnology industry that initially showed therapeutic promise in early<span class="nobreak">-stage</span> studies and trials have later been found to cause side effects that prevented their further development. Other potential products have shown side effects in preclinical studies, which side effects do not present themselves in clinical trials in humans. Even if the side effects do not preclude the product candidate from obtaining or maintaining marketing approval, undesirable side effects may inhibit market acceptance of the approved product due to its tolerability versus other therapies. In addition, an extended half<span class="nobreak">-life</span> could prolong the duration of undesirable side effects, which could also inhibit market acceptance. Treatment<span class="nobreak">-emergent</span> adverse events could also affect participant recruitment or the ability of enrolled subjects to complete Oruka&#8217;s clinical trials or could result in potential product liability claims. Potential side effects associated with Oruka&#8217;s product candidates may not be appropriately recognized or managed by the treating medical staff, as toxicities resulting from Oruka&#8217;s product candidates may not be normally encountered in the general patient population and by medical personnel. Any of these occurrences could harm Oruka&#8217;s business, financial condition, results of operations and prospects significantly.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, even if Oruka successfully advances its product candidates or any future product candidates through clinical trials, such trials will only include a limited number of participants and limited duration of exposure to Oruka&#8217;s product candidates. As a result, Oruka cannot be assured that adverse effects of its product candidates will not be uncovered when a significantly larger number of participants are exposed to the product candidate after approval. Further, any clinical trials may not be sufficient to determine the effect and safety consequences of using Oruka&#8217;s product candidates over a multi<span class="nobreak">-year</span> period.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If any of the foregoing events occur or if one or more of the research programs with respect to which Oruka has the option to acquire intellectual property license rights to pursuant to the Paragon Option Agreements prove to be unsafe, Oruka&#8217;s entire pipeline could be affected, which would have a material adverse effect on its business, financial condition, results of operations and prospects.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka may expend its limited resources to pursue a particular program and fail to capitalize on programs that may be more profitable or for which there is a greater likelihood of success.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Because Oruka has limited financial and managerial resources, it focuses its research and development efforts on certain selected programs. For example, Oruka is initially focused on its most advanced programs, ORKA<span class="nobreak">-001</span> and ORKA<span class="nobreak">-002</span>. As a result, Oruka may forgo or delay pursuit of opportunities with other programs that later prove to have greater commercial potential. Oruka&#8217;s resource allocation decisions may cause it to fail to capitalize on viable commercial products or profitable market opportunities. Oruka&#8217;s spending on current and future research and development programs for specific indications may not yield any commercially viable product candidates. If Oruka </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">59</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">does not accurately evaluate the commercial potential or target market for a particular product candidate, it may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for it to retain sole development and commercialization rights to such product candidate.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Any approved products resulting from Oruka&#8217;s current programs or any future program may not achieve adequate market acceptance among clinicians, patients, healthcare third-party payors and others in the medical community necessary for commercial success and Oruka may not generate any future revenue from the sale or licensing of such products.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Even if regulatory approval is obtained for a product candidate resulting from one of Oruka&#8217;s current or future programs, they may not gain market acceptance among physicians, patients, healthcare payors or the medical community. Oruka may not generate or sustain revenue from sales of the product due to factors such as whether the product can be sold at a competitive cost and whether it will otherwise be accepted in the market. There are several approved products and product candidates in later stages of development for the treatment of PsO.&#160;However, Oruka&#8217;s programs incorporate advanced antibody engineering to optimize the half<span class="nobreak">-life</span> and formulation of antibodies; to date, no such antibody has been approved by the FDA for the treatment of PsO.&#160;Market participants with significant influence over acceptance of new treatments, such as clinicians and third<span class="nobreak">-party</span> payors, may not adopt a biologic that incorporates half<span class="nobreak">-life</span> extension for Oruka&#8217;s targeted indications, and Oruka may not be able to convince the medical community and third<span class="nobreak">-party</span> payors to accept and use, or to provide favorable reimbursement for, any programs developed by it or its existing or future collaborators. An extended half<span class="nobreak">-life</span> may make it more difficult for patients to change treatments and there is a perception that half<span class="nobreak">-life</span> extension could exacerbate side effects, each of which may adversely affect Oruka&#8217;s ability to gain market acceptance. Market acceptance of Oruka&#8217;s product candidates will depend on many factors, including factors that are not within Oruka&#8217;s control.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Sales of medical products also depend on the willingness of clinicians to prescribe the treatment. Oruka cannot predict whether clinicians, clinicians&#8217; organizations, hospitals, other healthcare providers, government agencies or private insurers will determine that its product is safe, therapeutically effective, cost effective or less burdensome as compared with competing treatments. If any of Oruka&#8217;s product candidates is approved but does not achieve an adequate level of acceptance by such parties, Oruka may not generate or derive sufficient revenue from that product candidate and may not become or remain profitable.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Certain of Oruka&#8217;s programs may compete with its other programs, which could negatively impact Oruka&#8217;s business and reduce its future revenue.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka is developing product candidates for the same indication, PsO, and may in the future develop its programs for other&#160;I&amp;I indications. Each such program targets a different mechanism of action. However, developing multiple programs for a single indication may negatively impact Oruka&#8217;s business if the programs compete with each other. For example, if multiple programs are conducting clinical trials at the same time, they could compete for the enrollment of participants. In addition, if multiple product candidates are approved for the same indication, they may compete for market share, which could limit Oruka&#8217;s future revenue.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka may conduct clinical trials for programs at sites outside the United&#160;States, and the FDA may not accept data from trials conducted in such locations.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka may choose to conduct one or more of its future clinical trials outside the United&#160;States. Although the FDA may accept data from clinical trials conducted outside the United&#160;States, acceptance of this data is subject to conditions imposed by the FDA.&#160;For example, the clinical trial must be well designed and conducted and performed by qualified investigators in accordance with ethical principles. The trial population must also adequately represent the U.S.&#160;population, and the data must be applicable to the U.S.&#160;population and U.S.&#160;medical practice in ways that the FDA deems clinically meaningful. In addition, while these clinical trials are subject to the applicable local laws, FDA acceptance of the data will depend on its determination that the trials also complied with all applicable U.S.&#160;laws and regulations. If the FDA does not accept the data from any trial that Oruka conducts outside the United&#160;States, it would likely result in the need for additional trials, which would be costly and time<span class="nobreak">-consuming</span> and would delay or permanently halt Oruka&#8217;s development of the applicable product candidates. Even if the FDA accepted such data, it could require Oruka to modify its planned clinical trials to receive clearance to initiate such trials in the United&#160;States or to continue such trials once initiated.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">60</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Further, conducting international clinical trials presents additional risks that may delay completion of Oruka&#8217;s clinical trials. These risks include the failure of enrolled participants in foreign countries to adhere to clinical protocol as a result of differences in healthcare services or cultural customs that could restrict or limit Oruka&#8217;s ability to conduct its clinical trials, the administrative burdens of conducting clinical trials under multiple sets of foreign regulations, foreign exchange fluctuations, diminished protection of intellectual property in some countries, as well as political and economic risks relevant to foreign countries.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Risks Related to Government Regulation</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">The regulatory approval processes of the FDA and other comparable foreign regulatory authorities are lengthy, time-consuming and inherently unpredictable. If Oruka is not able to obtain, or if there are delays in obtaining, required regulatory approvals for its product candidates, Oruka will not be able to commercialize, or will be delayed in commercializing, its product candidates, and its ability to generate revenue will be materially impaired.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The process of obtaining regulatory approvals, both in the United&#160;States and abroad, is unpredictable, expensive and typically takes many&#160;years following commencement of clinical trials, if approval is obtained at all, and can vary substantially based upon a variety of factors, including the type, complexity and novelty of the product candidates involved. Oruka cannot commercialize product candidates in the United&#160;States without first obtaining regulatory approval from the FDA.&#160;Similarly, Oruka cannot commercialize product candidates outside of the United&#160;States without obtaining regulatory approval from comparable foreign regulatory authorities. Before obtaining regulatory approvals for the commercial sale of Oruka&#8217;s product candidates, including its most advanced programs, ORKA<span class="nobreak">-001</span> and ORKA<span class="nobreak">-002</span>, Oruka must demonstrate through lengthy, complex and expensive preclinical studies and clinical trials that its product candidates are both safe and effective for each targeted indication. Securing regulatory approval also requires the submission of information about the drug manufacturing process to, and inspection of manufacturing facilities by, the relevant regulatory authority. Further, Oruka&#8217;s product candidates may not be effective, may be only moderately effective or may prove to have undesirable or unintended side effects, toxicities or other characteristics that may preclude Oruka&#8217;s obtaining marketing approval. The FDA and comparable foreign regulatory authorities have substantial discretion in the approval process and may refuse to accept any application or may decide that Oruka&#8217;s data are insufficient for approval and require additional preclinical, clinical or other data. Oruka&#8217;s product candidates could be delayed in receiving, or fail to receive, regulatory approval for many reasons, including: the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of Oruka&#8217;s clinical trials; Oruka may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that a product candidate is safe and effective for its proposed indication; the results of clinical trials may not meet the level of statistical significance required by the FDA or comparable foreign regulatory authorities for approval; serious and unexpected drug<span class="nobreak">-related</span> side effects may be experienced by participants in Oruka&#8217;s clinical trials or by individuals using drugs similar to Oruka&#8217;s product candidates; Oruka may be unable to demonstrate that a product candidate&#8217;s clinical and other benefits outweigh its safety risks; the FDA or comparable foreign regulatory authorities may disagree with Oruka&#8217;s interpretation of data from preclinical studies or clinical trials; the data collected from clinical trials of Oruka&#8217;s product candidates may not be acceptable or sufficient to support the submission of a BLA or other submission or to obtain regulatory approval in the United&#160;States or elsewhere, and Oruka may be required to conduct additional clinical trials; the FDA or the applicable foreign regulatory authority may disagree regarding the formulation, labeling and/or the specifications of Oruka&#8217;s product candidates; the FDA or comparable foreign regulatory authorities may fail to approve the manufacturing processes or facilities of third<span class="nobreak">-party</span> manufacturers with which Oruka contracts for clinical and commercial supplies; and the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering Oruka&#8217;s clinical data insufficient for approval.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Of the large number of drugs in development, only a small percentage successfully complete the FDA or foreign regulatory approval processes and are commercialized. The lengthy approval process as well as the unpredictability of future clinical trial results may result in Oruka&#8217;s failing to obtain regulatory approval to market its product candidates, which would significantly harm Oruka&#8217;s business, results of operations and prospects.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If Oruka were to obtain approval, regulatory authorities may approve any of Oruka&#8217;s product candidates for fewer or more limited indications than Oruka requests, including failing to approve the most commercially promising indications, may grant approval contingent on the performance of costly post<span class="nobreak">-marketing</span> clinical trials, or may approve a product candidate with a label that does not include the labeling claims necessary or desirable for </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">61</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">the successful commercialization of that product candidate. If Oruka is not able to obtain, or if there are delays in obtaining, required regulatory approvals for its product candidates, Oruka will not be able to commercialize, or will be delayed in commercializing, its product candidates and its ability to generate revenue will be materially impaired.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka may not be able to meet requirements for the chemistry, manufacturing and control of its programs.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In order to receive approval of its products by the FDA and comparable foreign regulatory authorities, Oruka must show that it and its contract manufacturing partners are able to characterize, control and manufacture its drug products safely and in accordance with regulatory requirements. This includes manufacturing the active ingredient, developing an acceptable formulation, manufacturing the drug product, performing tests to adequately characterize the formulated product, documenting a repeatable manufacturing process, and demonstrating that Oruka&#8217;s drug products meet stability requirements. Meeting these chemistry, manufacturing and control requirements is a complex task that requires specialized expertise. If Oruka is not able to meet the chemistry, manufacturing and control requirements, it may not be successful in getting its products approved.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka&#8217;s product candidates for which it intends to seek approval as biologics may face competition sooner than anticipated.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Patient Protection and Affordable Act, as amended by the Healthcare and Education Reconciliation Act (the &#8220;ACA&#8221;), includes a subtitle called the Biologics Price Competition and Innovation Act&#160;of&#160;2009 (&#8220;BPCIA&#8221;), which created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an&#160;FDA<span class="nobreak">-licensed</span>&#160;reference biological product. Under the BPCIA, an application for a highly similar or &#8220;biosimilar&#8221; product may not be submitted to the FDA until four&#160;years following the date that the reference product was first approved by the FDA.&#160;In addition, the approval of a biosimilar product may not be made effective by the FDA until 12&#160;years from the date on which the reference product was first approved. During this&#160;12<span class="nobreak">-year</span>&#160;period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing the sponsor&#8217;s own preclinical data and data from adequate and well<span class="nobreak">-controlled</span> clinical trials to demonstrate the safety, purity and potency of their product.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka believes that any of its product candidates approved as biologics under a BLA should qualify for the&#160;12<span class="nobreak">-year</span>&#160;period of exclusivity. However, there is a risk that this exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not consider Oruka&#8217;s product candidates to be reference products for competing products, potentially creating the opportunity for competition sooner than anticipated. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. Moreover, the extent to which a biosimilar, once approved, will be substituted for any reference products in a way that is similar to traditional generic substitution for&#160;non<span class="nobreak">-biological</span>&#160;products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Even if Oruka receives regulatory approval of its product candidates, Oruka will be subject to extensive ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense and Oruka may be subject to penalties if it fails to comply with regulatory requirements or experiences unanticipated problems with its product candidates.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Any regulatory approvals that Oruka may receive for its product candidates will require the submission of reports to regulatory authorities and surveillance to monitor the safety and efficacy of the product candidate, may contain significant limitations related to use restrictions for specified age groups, warnings, precautions or contraindications, and may include burdensome post<span class="nobreak">-approval</span> study or risk management requirements. For example, the FDA may require a risk evaluation and mitigation strategy (&#8220;REMS&#8221;) in order to approve Oruka&#8217;s product candidates, which could entail requirements for a medication guide, physician training and communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. In addition, if the FDA or comparable foreign regulatory authorities approve Oruka&#8217;s product candidates, its product candidates and the activities associated with their development and commercialization, including their design, testing, manufacture, safety, efficacy, recordkeeping, labeling, storage, approval, advertising, promotion, sale, distribution, import and export will be subject to comprehensive regulation by the FDA and other regulatory agencies in the United&#160;States and by comparable foreign regulatory authorities. These requirements include submissions of safety and other post<span class="nobreak">-marketing</span> information and reports, registration, as </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">62</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">well as&#160;on<span class="nobreak">-going</span>&#160;compliance with current cGMPs and GCPs for any clinical trials that Oruka conducts following approval. In addition, manufacturers of drug products and their facilities are subject to continual review and periodic, unannounced inspections by the FDA and other regulatory authorities for compliance with cGMPs.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If Oruka or a regulatory authority discovers previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facilities where the product is manufactured, a regulatory authority may impose restrictions on that product, the manufacturing facility or Oruka, including requiring recall or withdrawal of the product from the market or suspension of manufacturing, restrictions on Oruka&#8217;s ability to conduct clinical trials, including full or partial clinical holds on ongoing or planned trials, restrictions on the manufacturing process, warning or untitled letters, civil and criminal penalties, injunctions, product seizures, detentions or import bans, voluntary or mandatory publicity requirements and imposition of restrictions on operations, including costly new manufacturing requirements. The occurrence of any event or penalty described above may inhibit Oruka&#8217;s ability to commercialize its product candidates and generate revenue and could require Oruka to expend significant time and resources in response and could generate negative publicity.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka may face difficulties from healthcare legislative reform measures.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Existing regulatory policies may change, and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of Oruka&#8217;s product candidates. Oruka cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United&#160;States or abroad. If Oruka is slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if it is not able to maintain regulatory compliance, Oruka may lose any marketing approval that it may have obtained and it may not achieve or sustain profitability. See the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Oruka&#8217;s Business&#160;&#8212;&#160;Government Regulation&#160;&#8212;&#160;Healthcare Reform</span>&#8221; for a more detailed description of healthcare reform measures that may prevent or limit Oruka&#8217;s ability to generate revenue, attain profitability, or commercialize its product candidates.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka&#8217;s business operations and current and future arrangements with investigators, healthcare professionals, consultants, third-party payors, patient organizations and customers will be subject to applicable healthcare regulatory laws, which could expose Oruka to penalties.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka&#8217;s business operations and current and future arrangements with investigators, healthcare professionals, consultants, third<span class="nobreak">-party</span> payors, patient organizations and customers may expose Oruka to broadly applicable fraud and abuse and other healthcare laws and regulations. These laws may constrain the business or financial arrangements and relationships through which Oruka conducts its operations, including how Oruka researches, markets, sells and distributes its product candidates, if approved. See the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Oruka&#8217;s Business&#160;&#8212;&#160;Government Regulation&#160;&#8212;&#160;Other Healthcare Laws and Compliance Requirements</span>&#8221; for a more detailed description of the laws that may affect Oruka&#8217;s ability to operate.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Ensuring that Oruka&#8217;s internal operations and future business arrangements with third parties comply with applicable healthcare laws and regulations will involve substantial costs. If Oruka&#8217;s operations are found to be in violation of any of these laws or any other governmental laws and regulations that may apply to it, Oruka may be subject to significant penalties, including civil, criminal and administrative penalties, damages, fines, exclusion from government<span class="nobreak">-funded</span> healthcare programs, integrity oversight and reporting obligations to resolve allegations of&#160;non<span class="nobreak">-compliance</span>,&#160;disgorgement, individual imprisonment, contractual damages, reputational harm, diminished profits and the curtailment or restructuring of Oruka&#8217;s operations. Further, defending against any such actions can be costly and time<span class="nobreak">-consuming</span> and may require significant personnel resources. Therefore, even if Oruka is successful in defending against any such actions that may be brought against it, its business may be impaired.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Even if Oruka is able to commercialize any product candidates, due to unfavorable pricing regulations and/or third-party coverage and reimbursement policies, it may not be able to offer such product candidates at competitive prices which would seriously harm its business.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka intends to seek approval to market its product candidates in both the United&#160;States and in selected foreign jurisdictions. If Oruka obtains approval in one or more foreign jurisdictions for its product candidates, Oruka will be subject to rules and regulations in those jurisdictions. Oruka&#8217;s ability to successfully commercialize any product candidates that it may develop will depend in part on the extent to which reimbursement for these product </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">63</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">candidates and related treatments will be available from government health administration authorities, private health insurers and other organizations. Government authorities and other third<span class="nobreak">-party</span> payors, such as private health insurers and health maintenance organizations, decide which medications they will pay for and establish reimbursement levels. Government authorities and other third<span class="nobreak">-party</span> payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. These entities may create preferential access policies for a competitor&#8217;s product, including a branded or generic/biosimilar product, over Oruka&#8217;s products in an attempt to reduce their costs, which may reduce Oruka&#8217;s commercial opportunity. Additionally, if any of Oruka&#8217;s product candidates are approved and Oruka is found to have improperly promoted off<span class="nobreak">-label</span> uses of those product candidates, Oruka may become subject to significant liability, which would materially adversely affect its business and financial condition. See the sections titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Oruka&#8217;s Business&#160;&#8212;&#160;Government Regulation&#160;&#8212;&#160;Coverage and Reimbursement</span>&#8221; and &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Oruka&#8217;s Business&#160;&#8212;&#160;Other Government Regulation&#160;Outside of the United&#160;States&#160;&#8212;&#160;Regulation in the European Union</span>&#8221; for a more detailed description of the government regulations and third<span class="nobreak">-party</span> payor practices that may affect Oruka&#8217;s ability to commercialize its product candidates.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka is subject to U.S.&#160;and certain foreign export and import controls, sanctions, embargoes, anti-corruption laws, and anti-money laundering laws and regulations. Oruka can face criminal liability and other serious consequences for violations, which can harm its business.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka is subject to export control and import laws and regulations, including the U.S.&#160;Export Administration Regulations, U.S.&#160;Customs regulations, various economic and trade sanctions regulations administered by the U.S.&#160;Treasury Department&#8217;s Office of Foreign Assets Controls, the U.S.&#160;Foreign Corrupt Practices Act&#160;of&#160;1977, as amended, the U.S.&#160;domestic bribery statute contained in 18 U.S.C. &#167; 201, the U.S.&#160;Travel Act, the USA PATRIOT Act, and other state and national anti<span class="nobreak">-bribery</span> and anti<span class="nobreak">-money</span> laundering laws in the countries in which Oruka conducts activities. Anti<span class="nobreak">-corruption</span> laws are interpreted broadly and prohibit companies and their employees, agents, contractors, and other collaborators from authorizing, promising, offering, or providing, directly or indirectly, improper payments or anything else of value to or from recipients in the public or private sector. Oruka may engage third parties to sell its products outside the United&#160;States, to conduct clinical trials, and/or to obtain necessary permits, licenses, patent registrations, and other regulatory approvals. Oruka has direct or indirect interactions with officials and employees of government agencies or government<span class="nobreak">-affiliated</span> hospitals, universities, and other organizations. Oruka can be held liable for the corrupt or other illegal activities of its employees, agents, contractors, and other collaborators, even if Oruka does not explicitly authorize or have actual knowledge of such activities. Any violations of the laws and regulations described above may result in substantial civil and criminal fines and penalties, imprisonment, the loss of export or import privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm, and other consequences.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Governments outside the United&#160;States tend to impose strict price controls, which may adversely affect Oruka&#8217;s revenue, if any.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In some countries, particularly member states of the EU (&#8220;EU Member States&#8221;), the pricing of prescription drugs is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after receipt of marketing approval for a therapeutic. In addition, there can be considerable pressure by governments and other stakeholders on prices and reimbursement levels, including as part of cost containment measures. Political, economic and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after reimbursement has been obtained. Reference pricing used by various EU Member States and parallel distribution, or arbitrage between&#160;low<span class="nobreak">-priced</span>&#160;and high<span class="nobreak">-priced</span> EU Member States, can further reduce prices. To obtain coverage and reimbursement or pricing approvals in some countries, Oruka or current or future collaborators may be required to conduct a clinical trial or other studies that compare the cost<span class="nobreak">-effectiveness</span> of Oruka&#8217;s product candidates to other available therapies in order to obtain or maintain reimbursement or pricing approval. Publication of discounts by third<span class="nobreak">-party</span> payors or authorities may lead to further pressure on the prices or reimbursement levels within the country of publication and other countries. If reimbursement of any product candidate approved for marketing is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, Oruka&#8217;s business, financial condition, results of operations or prospects could be materially and adversely affected. Brexit could lead to legal uncertainty and potentially divergent national laws and regulations, including those related to the pricing of prescription pharmaceuticals, as the United Kingdom (&#8220;UK&#8221;) determines which EU laws to replicate or replace. If the UK were to significantly alter its regulations affecting the pricing of prescription pharmaceuticals, Oruka could face significant new costs.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">64</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">A breakthrough therapy, fast track, or other expedited designation for Oruka&#8217;s product candidates may not lead to a faster development or regulatory review or approval process, and it does not increase the likelihood that those product candidates will receive marketing approval.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka may seek a breakthrough therapy, fast track, or other designation for appropriate product candidates. Designations such as these are within the discretion of the FDA, or other comparable regulatory authorities. The receipt of a designation for a product candidate may not result in a faster development process, review or approval compared to products considered for approval under conventional FDA procedures and does not assure ultimate approval by the FDA.&#160;In addition, even if one or more of Oruka&#8217;s product candidates qualifies under one of FDA&#8217;s designation programs, the FDA may later decide that the products no longer meet the conditions for qualification or decide that the time period for FDA review or approval will not be shortened. See the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Oruka&#8217;s Business&#160;&#8212;&#160;Government Regulation&#160;&#8212;&#160;Expedited Development and Review Programs</span>&#8221; for a more detailed description of the process for seeking expedited designations such as fast track or breakthrough therapy designations.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Risks Related to Oruka&#8217;s Intellectual Property</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka&#8217;s ability to obtain and protect its patents and other proprietary rights is uncertain, exposing Oruka to the possible loss of competitive advantage.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka relies upon a combination of patents, trademarks, trade secret protection, confidentiality agreements and the Paragon Option Agreements to protect the intellectual property related to its programs and technologies and to prevent third parties from competing unfairly with it. Oruka&#8217;s success depends in large part on its ability to obtain and maintain patent protection for its platform technologies, programs and their uses, as well as its ability to operate without infringing on or violating the proprietary rights of others. Paragon has filed provisional patent applications and intends to file one or more additional provisional patent applications directed to antibodies that target IL<span class="nobreak">-23</span>, including applications covering composition of matter, pharmaceutical formulations, and methods of using such antibodies, including ORKA<span class="nobreak">-001</span>. In addition, Paragon has filed provisional patent applications and intends to file one or more additional provisional patent applications directed to antibodies that target IL<span class="nobreak">-17</span>, including applications covering composition of matter, pharmaceutical formulations, and methods of using such antibodies, including ORKA<span class="nobreak">-002</span>. However, Oruka may not be able to protect its intellectual property rights throughout the world and the legal systems in certain countries may not favor enforcement or protection of patents, trade secrets and other intellectual property. Filing, prosecuting and defending patents on programs worldwide would be expensive and Oruka&#8217;s intellectual property rights in some foreign jurisdictions can be less extensive than those in the United&#160;States; the reverse may also occur. As such, Oruka may not have patents in all countries or all major markets and may not be able to obtain patents in all jurisdictions even if it applies for them. Oruka&#8217;s competitors may operate in countries where Oruka does not have patent protection and can freely use Oruka&#8217;s technologies and discoveries in such countries to the extent such technologies and discoveries are publicly known or disclosed in countries where Oruka does have patent protection or pending patent applications.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka&#8217;s pending and future patent applications may not result in patents being issued. Any issued patents may not afford sufficient protection of Oruka&#8217;s programs or their intended uses against competitors, nor can there be any assurance that the patents issued will not be infringed, designed around, invalidated by third parties, or effectively prevent others from commercializing competitive technologies, products or programs. Even if these patents are granted, they may be difficult to enforce. Further, any issued patents that Oruka may license or own covering Oruka&#8217;s programs could be narrowed or found invalid or unenforceable if challenged in court or before administrative bodies in the United&#160;States or abroad, including the United&#160;States Patent and Trademark Office (&#8220;USPTO&#8221;). Further, if Oruka encounters delays in its clinical trials or delays in obtaining regulatory approval, the period of time during which Oruka could market its product candidates under patent protection would be reduced. Thus, the patents that Oruka may own and license may not afford Oruka any meaningful competitive advantage.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition to seeking patents for some of its technology and programs, Oruka may also rely on trade secrets, including unpatented&#160;know<span class="nobreak">-how</span>,&#160;technology and other proprietary information, to maintain its competitive position. Any disclosure, either intentional or unintentional, by Oruka&#8217;s employees, the employees of third parties with whom Oruka shares its facilities or third<span class="nobreak">-party</span> consultants and vendors that Oruka engages to perform research, clinical trials or manufacturing activities, or misappropriation by third parties (such as through a cybersecurity breach) of Oruka&#8217;s trade secrets or proprietary information could enable competitors to duplicate or surpass Oruka&#8217;s technological achievements, thus eroding Oruka&#8217;s competitive position in its market. In order to protect </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">65</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">Oruka&#8217;s proprietary technology and processes, it relies in part on confidentiality agreements with its collaborators, employees, consultants, outside scientific collaborators and sponsored researchers and other advisors. These agreements may not effectively prevent disclosure of confidential information and may not provide an adequate remedy in the event of unauthorized disclosure of confidential information. Oruka may need to share its proprietary information, including trade secrets, with future business partners, collaborators, contractors and others located in countries at heightened risk of theft of trade secrets, including through direct intrusion by private parties or state actors and those affiliated with or controlled by state actors. In addition, while Oruka undertakes efforts to protect its trade secrets and other confidential information from disclosure, others may independently discover trade secrets and proprietary information, and in such cases, Oruka may not be able to assert any trade secret rights against such party. Costly and time<span class="nobreak">-consuming</span> litigation could be necessary to enforce and determine the scope of Oruka&#8217;s proprietary rights and failure to obtain or maintain trade secret protection could adversely affect Oruka&#8217;s competitive business position.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Lastly, if Oruka&#8217;s trademarks and trade names are not registered or adequately protected, then Oruka may not be able to build name recognition in its markets of interest and its business may be adversely affected.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka may not be successful in obtaining or maintaining necessary rights to its programs through acquisitions and&#160;in-licenses.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Because Oruka&#8217;s development programs currently do and may in the future require the use of proprietary rights held by third parties, the growth of Oruka&#8217;s business may depend in part on its ability to acquire,&#160;in<span class="nobreak">-license</span>,&#160;or use these third<span class="nobreak">-party</span> proprietary rights. Oruka may be unable to acquire or&#160;in<span class="nobreak">-license</span>&#160;any compositions, methods of use, processes or other third<span class="nobreak">-party</span> intellectual property rights from third parties that it identifies as necessary for its programs. The licensing and acquisition of third<span class="nobreak">-party</span> intellectual property rights is a competitive area, and a number of more established companies may pursue strategies to license or acquire third<span class="nobreak">-party</span> intellectual property rights that Oruka may consider attractive or necessary. These established companies may have a competitive advantage over Oruka due to their size, capital resources and greater clinical development and commercialization capabilities. In addition, companies that perceive Oruka to be a competitor may be unwilling to assign or license rights to Oruka. Oruka also may be unable to license or acquire third<span class="nobreak">-party</span> intellectual property rights on terms that would allow it to make an appropriate return on Oruka&#8217;s investment or at all. If Oruka is unable to successfully obtain rights to required third<span class="nobreak">-party</span> intellectual property rights or maintain the existing intellectual property rights it does obtain, Oruka may have to abandon development of the relevant program, which could have a material adverse effect on its business, financial condition, results of operations, and prospects.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">While Oruka plans to obtain the right to control prosecution, maintenance and enforcement of the patents relating to its programs, there may be times when the filing and prosecution activities for patents and patent applications relating to Oruka&#8217;s programs are controlled by its current and future licensors or collaboration partners. If any of Oruka&#8217;s current and future licensors or collaboration partners fail to prosecute, maintain and enforce such patents and patent applications in a manner consistent with the best interests of Oruka&#8217;s business, including by payment of all applicable fees for patents covering its product candidates, Oruka could lose its rights to the intellectual property or its exclusivity with respect to those rights, its ability to develop and commercialize those product candidates may be adversely affected and it may not be able to prevent competitors from making, using and selling competing products. In addition, even where Oruka has the right to control patent prosecution of patents and patent applications it has licensed to and from third parties, Oruka may still be adversely affected or prejudiced by actions or inactions of its licensees, its future licensors and their counsel that took place prior to the date upon which Oruka assumed control over patent prosecution.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka&#8217;s future licensors may rely on third<span class="nobreak">-party</span> consultants or collaborators or on funds from third parties such that Oruka&#8217;s future licensors are not the sole and exclusive owners of the patents Oruka&#160;in<span class="nobreak">-licenses</span>.&#160;If other third parties have ownership rights to Oruka&#8217;s future&#160;in<span class="nobreak">-licensed</span>&#160;patents, they may be able to license such patents to Oruka&#8217;s competitors, and Oruka&#8217;s competitors could market competing products and technology. This could have a material adverse effect on Oruka&#8217;s competitive position, business, financial conditions, results of operations, and prospects.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">It is possible that Oruka may be unable to obtain licenses at a reasonable cost or on reasonable terms, if at all. Even if Oruka is able to obtain a license, it may be&#160;non<span class="nobreak">-exclusive</span>,&#160;thereby giving Oruka&#8217;s competitors access to the same technologies licensed to Oruka. In that event, Oruka may be required to expend significant time and resources </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">66</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">to redesign its technology, programs, or the methods for manufacturing them or to develop or license replacement technology, all of which may not be feasible on a technical or commercial basis. If Oruka is unable to do so, it may be unable to develop or commercialize the affected product candidates, which could harm its business, financial condition, results of operations, and prospects significantly. Oruka cannot provide any assurances that third<span class="nobreak">-party</span> patents do not exist which might be enforced against Oruka&#8217;s current technology, manufacturing methods, programs, or future methods or products resulting in either an injunction prohibiting Oruka&#8217;s manufacture or future sales, or, with respect to its future sales, an obligation on Oruka&#8217;s part to pay royalties and/or other forms of compensation to third parties, which could be significant.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Disputes may arise between Oruka and its future licensors regarding intellectual property subject to a license agreement, including: the scope of rights granted under the license agreement and other interpretation<span class="nobreak">-related</span> issues; whether and the extent to which Oruka&#8217;s technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement; Oruka&#8217;s right to sublicense patents and other rights to third parties; Oruka&#8217;s right to transfer or assign the license; the inventorship and ownership of inventions and&#160;know<span class="nobreak">-how</span>&#160;resulting from the joint creation or use of intellectual property by Oruka&#8217;s future licensors and it and its partners; and the priority of invention of patented technology.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka may be subject to patent infringement claims or may need to file claims to protect its intellectual property, which could result in substantial costs and liability and prevent Oruka from commercializing its potential products.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Because the intellectual property landscape in the biotechnology industry is rapidly evolving and interdisciplinary, it is difficult to conclusively assess Oruka&#8217;s freedom to operate and guarantee that Oruka can operate without infringing on or violating third<span class="nobreak">-party</span> rights. If certain of Oruka&#8217;s product candidates are ultimately granted regulatory approval, patent rights held by third parties, if found to be valid and enforceable, could be alleged to render one or more of Oruka&#8217;s product candidates infringing. If a third party successfully brings a claim against Oruka, Oruka may be required to pay substantial damages, be forced to abandon any affected product candidate and/or seek a license from the patent holder. In addition, any intellectual property claims (e.g., patent infringement or trade secret theft) brought against Oruka, whether or not successful, may cause Oruka to incur significant legal expenses and divert the attention of its management and key personnel from other business concerns. Oruka cannot be certain that patents owned or licensed by it will not be challenged by others in the course of litigation. Some of Oruka&#8217;s competitors may be able to sustain the costs of complex intellectual property litigation more effectively than Oruka can because they have substantially greater resources. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on Oruka&#8217;s ability to raise funds.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Competitors may infringe or otherwise violate Oruka&#8217;s patents, trademarks, copyrights or other intellectual property. To counter infringement or other violations, Oruka may be required to file claims, which can be expensive and time<span class="nobreak">-consuming</span>. Any such claims could provoke these parties to assert counterclaims against Oruka, including claims alleging that Oruka infringes their patents or other intellectual property rights. In addition, in a patent infringement proceeding, a court or administrative body may decide that one or more of the patents Oruka asserts is invalid or unenforceable, in whole or in part, construe the patent&#8217;s claims narrowly or refuse to prevent the other party from using the technology at issue on the grounds that Oruka&#8217;s patents do not cover the technology. Similarly, if Oruka asserts trademark infringement claims, a court or administrative body may determine that the marks Oruka has asserted are invalid or unenforceable or that the party against whom Oruka has asserted trademark infringement has superior rights to the marks in question. In such a case, Oruka could ultimately be forced to cease use of such marks. In any intellectual property litigation, even if Oruka is successful, any award of monetary damages or other remedy Oruka receives may not be commercially valuable.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Further, Oruka may be required to protect its patents through procedures created to attack the validity of a patent at the USPTO.&#160;An adverse determination in any such submission or proceeding could reduce the scope or enforceability of, or invalidate, Oruka&#8217;s patent rights, which could adversely affect Oruka&#8217;s competitive position. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in U.S.&#160;federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">67</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, if Oruka&#8217;s programs are found to infringe the intellectual property rights of third parties, these third parties may assert infringement claims against Oruka&#8217;s future licensees and other parties with whom Oruka has business relationships and Oruka may be required to indemnify those parties for any damages they suffer as a result of these claims, which may require Oruka to initiate or defend protracted and costly litigation on behalf of licensees and other parties regardless of the merits of such claims. If any of these claims succeed, Oruka may be forced to pay damages on behalf of those parties or may be required to obtain licenses for the products they use.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation or other legal proceedings relating to Oruka&#8217;s intellectual property rights, there is a risk that some of Oruka&#8217;s confidential information could be compromised by disclosure during this type of litigation or other proceedings.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka may be subject to claims that it has wrongfully hired an employee from a competitor or that its employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As is common in the biotechnology industry, in addition to Oruka&#8217;s employees, Oruka engages the services of consultants to assist it in the development of its programs. Many of these consultants, and many of Oruka&#8217;s employees, were previously employed at, or may have previously provided or may be currently providing consulting services to, other biotechnology or pharmaceutical companies including Oruka&#8217;s competitors or potential competitors. Oruka could in the future be subject to claims that it or its employees have inadvertently or otherwise used or disclosed alleged trade secrets or other confidential information of former employers or competitors. Although Oruka tries to ensure that its employees and consultants do not use the intellectual property, proprietary information,&#160;know<span class="nobreak">-how</span>&#160;or trade secrets of others in their work for Oruka, Oruka may become subject to claims that it caused an employee to breach the terms of his or her&#160;non<span class="nobreak">-competition</span>&#160;or&#160;non<span class="nobreak">-solicitation</span>&#160;agreement, or that Oruka or these individuals have, inadvertently or otherwise, used or disclosed the alleged trade secrets or other proprietary information of a former employer or competitor.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">While Oruka may litigate to defend itself against these claims, even if it is successful, litigation could result in substantial costs and could be a distraction to management. If Oruka&#8217;s defenses to these claims fail, in addition to requiring it to pay monetary damages, a court could prohibit Oruka from using technologies or features that are essential to its programs, if such technologies or features are found to incorporate or be derived from the trade secrets or other proprietary information of the former employers. Moreover, any such litigation or the threat thereof may adversely affect Oruka&#8217;s reputation, its ability to form strategic alliances or sublicense its rights to collaborators, engage with scientific advisors or hire employees or consultants, each of which would have an adverse effect on Oruka&#8217;s business, results of operations and financial condition. Even if Oruka is successful in defending against such claims, litigation could result in substantial costs and be a distraction to management.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Changes to patent laws in the United&#160;States and other jurisdictions could diminish the value of patents in general, thereby impairing Oruka&#8217;s ability to protect its products.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Changes in either the patent laws or interpretation of patent laws in the United&#160;States, including patent reform legislation such as the Leahy<span class="nobreak">-Smith</span> America Invents Act (the &#8220;Leahy<span class="nobreak">-Smith</span> Act&#8221;) could increase the uncertainties and costs surrounding the prosecution of Oruka&#8217;s owned and&#160;in<span class="nobreak">-licensed</span>&#160;patent applications and the maintenance, enforcement or defense of its owned and&#160;in<span class="nobreak">-licensed</span>&#160;issued patents. The Leahy<span class="nobreak">-Smith</span> Act includes a number of significant changes to United&#160;States patent law. These changes include provisions that affect the way patent applications are prosecuted, redefine prior art, provide more efficient and cost<span class="nobreak">-effective</span> avenues for competitors to challenge the validity of patents, and enable third<span class="nobreak">-party</span> submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent at USPTO<span class="nobreak">-administered</span> post<span class="nobreak">-grant</span> proceedings, including post<span class="nobreak">-grant</span> review, inter partes review and derivation proceedings. Assuming that other requirements for patentability are met, prior to March&#160;2013, in the United&#160;States, the first to invent the claimed invention was entitled to the patent, while outside the United&#160;States, the first to file a patent application was entitled to the patent. After March&#160;2013, under the Leahy<span class="nobreak">-Smith</span> Act, the United&#160;States transitioned to a&#160;first<span class="nobreak">-to-file</span>&#160;system in which, assuming that the other statutory requirements for patentability are met, the first inventor to file a patent application will be entitled to the patent on an invention regardless of whether a third party was the first to invent the </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">68</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">claimed invention. As such, the Leahy<span class="nobreak">-Smith</span> Act and its implementation could increase the uncertainties and costs surrounding the prosecution of Oruka&#8217;s patent applications and the enforcement or defense of its issued patents, all of which could have a material adverse effect on Oruka&#8217;s business, financial condition, results of operations and prospects.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, the patent positions of companies in the development and commercialization of biologics and pharmaceuticals are particularly uncertain. U.S.&#160;Supreme Court and U.S.&#160;Court of Appeals for the Federal Circuit rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations, including in the antibody arts. For example, the United&#160;States Supreme Court in&#160;<span class="Italic" style="font-style:italic;font-weight:normal;">Amgen, Inc. v. Sanofi</span>&#160;(<span class="Italic" style="font-style:italic;font-weight:normal;">Amgen</span>) recently held that Amgen&#8217;s patent claims to a class of antibodies functionally defined by their ability to bind a particular antigen were invalid for lack of enablement where the patent specification provided twenty<span class="nobreak">-six</span> exemplary antibodies, but the claimed class of antibodies covered a &#8220;vast number&#8221; of additional antibodies not disclosed in the specification. The Court stated that if patent claims are directed to an entire class of compositions of matter, then the patent specification must enable a person skilled in the art to make and use the entire class of compositions. This decision makes it unlikely that Oruka will be granted U.S.&#160;patents with composition of matter claims directed to antibodies functionally defined by their ability to bind a particular antigen. Even if Oruka is granted claims directed to functionally defined antibodies, it is possible that a third party may challenge Oruka&#8217;s patents, when issued, relying on the reasoning in&#160;<span class="Italic" style="font-style:italic;font-weight:normal;">Amgen</span>&#160;or other recent precedential court decisions. Additionally, there have been proposals for additional changes to the patent laws of the United&#160;States and other countries that, if adopted, could impact Oruka&#8217;s ability to enforce its proprietary technology. This combination of events has created uncertainty with respect to the validity and enforceability of patents once obtained. Depending on future actions by the U.S.&#160;Congress, the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways that could have a material adverse effect on Oruka&#8217;s patent rights and its ability to protect, defend and enforce its patent rights in the future.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Geopolitical instability in the United&#160;States and in foreign countries could increase the uncertainties and costs surrounding the prosecution or maintenance of patent applications and the maintenance, enforcement or defense of issued patents. For example, the United&#160;States and foreign government actions related to Russia&#8217;s invasion of Ukraine may limit or prevent filing, prosecution and maintenance of patent applications in Russia. Government actions may also prevent maintenance of issued patents in Russia. These actions could result in abandonment or lapse of patents or patent applications, resulting in partial or complete loss of patent rights in Russia. If such an event were to occur, it could have a material adverse effect on Oruka&#8217;s business. In addition, a decree was adopted by the Russian government in March&#160;2022 allowing Russian companies and individuals to exploit inventions owned by patentees that have citizenship or nationality in, are registered in, or have predominately primary place of business or profit<span class="nobreak">-making</span> activities in the United&#160;States and other countries that Russia has deemed unfriendly without consent or compensation. Consequently, Oruka would not be able to prevent third parties from practicing its inventions in Russia or from selling or importing products made using its inventions in and into Russia. Accordingly, Oruka&#8217;s competitive position may be impaired, and its business, financial condition, results of operations and prospects may be adversely affected.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, a European Unified Patent Court (&#8220;UPC&#8221;) entered into force on June&#160;1, 2023. The UPC is a common patent court that hears patent infringement and revocation proceedings effective for EU Member States. This could enable third parties to seek revocation of a European patent in a single proceeding at the UPC rather than through multiple proceedings in each of the jurisdictions in which the European patent is validated.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Although Oruka does not currently own any European patents or applications, if it obtains such patents and applications in the future, any such revocation and loss of patent protection could have a material adverse impact on Oruka&#8217;s business and its ability to commercialize or license its technology and products. Moreover, the controlling laws and regulations of the UPC will develop over time, and may adversely affect Oruka&#8217;s ability to enforce or defend the validity of any European patents it may obtain. Oruka may decide to opt out from the UPC any future European patent applications that it may file and any patents it may obtain. If certain formalities and requirements are not met, however, such European patents and patent applications could be challenged for&#160;non<span class="nobreak">-compliance</span>&#160;and brought under the jurisdiction of the UPC.&#160;Oruka cannot be certain that future European patents and patent applications will avoid falling under the jurisdiction of the UPC, if Oruka decides to opt out of the UPC.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">69</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Obtaining and maintaining patent protection depends on compliance with various procedural, document submissions, fee payment and other requirements imposed by governmental patent agencies, and Oruka&#8217;s patent protection could be reduced or eliminated for&#160;non-compliance&#160;with these requirements.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Periodic maintenance fees, renewal fees, annuities fees and various other governmental fees on patents and/or patent applications are due to be paid to the USPTO and foreign patent agencies in several stages over the lifetime of the patent and/or patent application. The USPTO and various foreign governmental patent agencies also require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction.&#160;Non<span class="nobreak">-compliance</span>&#160;events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits,&#160;non<span class="nobreak">-payment</span>&#160;of fees and failure to properly legalize and submit formal documents. If Oruka fails to maintain the patents and patent applications covering its programs, Oruka&#8217;s competitive position would be adversely affected.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent, which might adversely affect Oruka&#8217;s ability to develop and market its products.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka cannot guarantee that any of its patent searches or analyses, including the identification of relevant patents, the scope of patent claims or the expiration of relevant patents, are complete or thorough, nor can Oruka be certain that it has identified each and every third<span class="nobreak">-party</span> patent and pending application in the United&#160;States and abroad that is relevant to or necessary for the commercialization of its product candidates in any jurisdiction. The scope of a patent claim is determined by an interpretation of the law, the written disclosure in a patent and the patent&#8217;s prosecution history. Oruka&#8217;s interpretation of the relevance or the scope of a patent or a pending application may be incorrect. For example, Oruka may incorrectly determine that its products are not covered by a third<span class="nobreak">-party</span> patent or may incorrectly predict whether a third<span class="nobreak">-party</span>&#8217;s pending application will issue with claims of relevant scope. Oruka&#8217;s determination of the expiration date of any patent in the United&#160;States or abroad that it considers relevant may be incorrect. Oruka&#8217;s failure to identify and correctly interpret relevant patents may negatively impact its ability to develop and market its products.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, because some patent applications in the United&#160;States may be maintained in secrecy until the patents are issued, patent applications in the United&#160;States and many foreign jurisdictions are typically not published until 18&#160;months after filing, and publications in the scientific literature often lag behind actual discoveries, Oruka cannot be certain that others have not filed patent applications for technology covered by its issued patents or its pending applications, or that Oruka was the first to invent the technology. Oruka&#8217;s competitors may have filed, and may in the future file, patent applications covering products or technology similar to Oruka&#8217;s. Any such patent application may have priority over Oruka&#8217;s patent applications or patents, which could require Oruka to obtain rights to issued patents covering such technologies.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka may become subject to claims challenging the inventorship or ownership of its patents and other intellectual property.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka may be subject to claims that former employees, collaborators or other third parties have an interest in Oruka&#8217;s patents or other intellectual property as an inventor or&#160;co<span class="nobreak">-inventor</span>.&#160;The failure to name the proper inventors on a patent application can result in the patents issuing thereon being unenforceable. Inventorship disputes may arise from conflicting views regarding the contributions of different individuals named as inventors, the effects of foreign laws where foreign nationals are involved in the development of the subject matter of the patent, conflicting obligations of third parties involved in developing Oruka&#8217;s programs or as a result of questions regarding&#160;co<span class="nobreak">-ownership</span>&#160;of potential joint inventions. Litigation may be necessary to resolve these and other claims challenging inventorship and/or ownership. Alternatively, or additionally, Oruka may enter into agreements to clarify the scope of its rights in such intellectual property. If Oruka fails in defending any such claims, in addition to paying monetary damages, it may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on Oruka&#8217;s business. Even if Oruka is successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">70</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka&#8217;s future licensors may rely on third<span class="nobreak">-party</span> consultants or collaborators or on funds from third parties, such as the U.S.&#160;government, such that Oruka&#8217;s licensors would not be the sole and exclusive owners of any patents Oruka&#160;in<span class="nobreak">-licenses</span>.&#160;If other third parties have ownership rights or other rights to Oruka&#8217;s&#160;in<span class="nobreak">-licensed</span>&#160;patents, they may be able to license such patents to Oruka&#8217;s competitors, and Oruka&#8217;s competitors could market competing products and technology. This could have a material adverse effect on Oruka&#8217;s competitive position, business, financial conditions, results of operations, and prospects.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Patent terms may be inadequate to protect the competitive position of Oruka&#8217;s product candidates for an adequate amount of time.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Patents have a limited lifespan. In the United&#160;States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20&#160;years from its earliest United&#160;States&#160;non<span class="nobreak">-provisional</span>&#160;filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering Oruka&#8217;s product candidates are obtained, once the patent life has expired, Oruka may be open to competition from competitive products, including generics or biosimilars. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such product candidates might expire before or shortly after such product candidates are commercialized. As a result, Oruka&#8217;s owned and licensed patent portfolio may not provide it with sufficient rights to exclude others from commercializing products similar or identical to Oruka&#8217;s.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka&#8217;s technology licensed from various third parties may be subject to retained rights.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka&#8217;s future licensors may retain certain rights under the relevant agreements with Oruka, including the right to use the underlying technology for noncommercial academic and research use, to publish general scientific findings from research related to the technology, and to make customary scientific and scholarly disclosures of information relating to the technology. It is difficult to monitor whether Oruka&#8217;s licensors limit their use of the technology to these uses, and Oruka could incur substantial expenses to enforce its rights to its licensed technology in the event of misuse.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Risks Related to Oruka&#8217;s Reliance on Third Parties</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka currently relies on licensing arrangements with Paragon through the Paragon Option Agreements. If Oruka is unable to maintain collaborations or licensing arrangements, or if its collaborations or licensing arrangements are not successful, Oruka&#8217;s business could be negatively impacted.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka currently relies on its licensing arrangements with Paragon through the Paragon Option Agreements for a substantial portion of its discovery capabilities and&#160;in<span class="nobreak">-licenses</span>.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Collaborations or licensing arrangements that Oruka enters into may not be successful, and any success will depend heavily on the efforts and activities of such collaborators or licensors. If any of Oruka&#8217;s current or future collaborators or licensors experiences delays in performance of, or fails to perform its obligations under their agreement with Oruka, disagrees with Oruka&#8217;s interpretation of the terms of such agreement or terminates their agreement with Oruka, the research programs with respect to which Oruka has the option to acquire intellectual property license rights to pursuant to the Paragon Option Agreements and development timeline could be adversely affected. If Oruka fails to comply with any of the obligations under its collaborations or license agreements, including payment terms and diligence terms, Oruka&#8217;s collaborators or licensors may have the right to terminate such agreements, in which event Oruka may lose intellectual property rights and may not be able to develop, manufacture, market or sell the products covered by its agreements or may face other penalties under its agreements. Oruka&#8217;s collaborators and licensors may also fail to properly maintain or defend the intellectual property Oruka has licensed from them, if required by Oruka&#8217;s agreement with them, or even infringe upon, Oruka&#8217;s intellectual property rights, leading to the potential invalidation of Oruka&#8217;s intellectual property or subjecting it to litigation or arbitration, any of which would be time<span class="nobreak">-consuming</span> and expensive and could harm Oruka&#8217;s ability to commercialize its product candidates. In addition, collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with Oruka&#8217;s programs and products if the collaborators believe that the competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than Oruka&#8217;s.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">71</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As part of Oruka&#8217;s strategy, Oruka plans to evaluate additional opportunities to enhance its capabilities and expand its development pipeline or provide development or commercialization capabilities that complement Oruka&#8217;s. Oruka may not realize the benefits of such collaborations, alliances or licensing arrangements. Any of these relationships may require Oruka to incur&#160;non<span class="nobreak">-recurring</span>&#160;and other charges, increase its near and long<span class="nobreak">-term</span> expenditures, issue securities that dilute its existing stockholders or disrupt its management and business.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka may face significant competition in attracting appropriate collaborators, and more established companies may also be pursuing strategies to license or acquire third<span class="nobreak">-party</span> intellectual property rights that Oruka considers attractive. These companies may have a competitive advantage over Oruka due to their size, financial resources and greater clinical development and commercialization capabilities. In addition, companies that perceive Oruka to be a competitor may be unwilling to assign or license rights to Oruka. Whether Oruka reaches a definitive agreement for a collaboration will depend upon, among other things, its assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#8217;s evaluation of a number of factors. Collaborations are complex and time<span class="nobreak">-consuming</span> to negotiate, document and execute. In addition, consolidation among large pharmaceutical and biotechnology companies has reduced the number of potential future collaborators. Oruka may not be able to negotiate additional collaborations on a timely basis, on acceptable terms or at all. If Oruka fails to enter into collaborations and does not have sufficient funds or expertise to undertake the necessary development and commercialization activities, it may not be able to further develop its product candidates or bring them to market.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka currently relies, and plans to rely in the future, on third parties to conduct and support its preclinical studies and clinical trials. If these third parties do not properly and successfully carry out their contractual duties or meet expected deadlines, Oruka may not be able to obtain regulatory approval of or commercialize its product candidates.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka has utilized and plans to continue to utilize and depend upon independent investigators and collaborators, such as medical institutions, CROs, contract testing labs and strategic partners, to conduct and support its preclinical studies and clinical trials under agreements with Oruka. Oruka will rely heavily on these third parties over the course of its preclinical studies and clinical trials, and Oruka controls only certain aspects of their activities. As a result, Oruka will have less direct control over the conduct, timing and completion of these preclinical studies and clinical trials and the management of data developed through preclinical studies and clinical trials than would be the case if it were relying entirely upon its own staff. Nevertheless, Oruka is responsible for ensuring that each of its studies and trials is conducted in accordance with the applicable protocol, legal, regulatory and scientific standards, and its reliance on these third parties does not relieve Oruka of its regulatory responsibilities. Oruka and its third<span class="nobreak">-party</span> contractors and CROs are required to comply with GCP regulations, which are regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities for all of Oruka&#8217;s programs in clinical development. If Oruka or any of these third parties fail to comply with applicable GCP regulations, the clinical data generated in Oruka&#8217;s clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require Oruka to perform additional clinical trials before approving Oruka&#8217;s marketing applications. Oruka cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of Oruka&#8217;s clinical trials comply with GCP regulations. In addition, Oruka&#8217;s clinical trials must be conducted with products produced under cGMP regulations. Oruka&#8217;s failure to comply with these regulations may require it to repeat clinical trials, which would delay the regulatory approval process. Moreover, Oruka&#8217;s business may be implicated if any of these third parties violates federal or state fraud and abuse or false claims laws and regulations or healthcare privacy and security laws.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Any third parties conducting Oruka&#8217;s clinical trials will not be Oruka&#8217;s employees and, except for remedies available to Oruka under its agreements with such third parties, Oruka cannot control whether they devote sufficient time and resources to Oruka&#8217;s programs. These third parties may be involved in mergers, acquisitions or similar transactions and may have relationships with other commercial entities, including Oruka&#8217;s competitors, for whom they may also be conducting clinical trials or other product development activities, which could negatively affect their performance on Oruka&#8217;s behalf and the timing thereof and could lead to products that compete directly or indirectly with Oruka&#8217;s product candidates. If these third parties do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to Oruka&#8217;s clinical protocols or regulatory requirements or for other reasons, Oruka&#8217;s clinical trials may be extended, delayed or terminated and Oruka may not be able to complete development of, obtain regulatory approval of or successfully commercialize its product candidates.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">72</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, Oruka currently relies on foreign CROs and CMOs, including WuXi Biologics (Hong&#160;Kong) Limited (&#8220;WuXi&#8221;) for formulation and manufacturing of Oruka&#8217;s stage 1 clinical trial materials, and will likely continue to rely on foreign CROs and CMOs in the future. WuXi is a subsidiary or affiliate of WuXi Biologics, which is identified in the proposed U.S. legislation known as the BIOSECURE Act as a biotechnology &#8220;company of concern.&#8221; The BIOSECURE Act, if passed, would prohibit federal agencies from entering into procurement contracts with an entity that uses biotechnology equipment or services from a biotechnology company of concern. Foreign CMOs may be subject to U.S.&#160;legislation, including the proposed BIOSECURE Act, trade restrictions and other foreign regulatory requirements which could increase the cost or reduce the supply of material available to Oruka, delay the procurement or supply of such material or have an adverse effect on Oruka&#8217;s ability to secure significant commitments from governments to purchase its potential therapies.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">For example, the biopharmaceutical industry in China is strictly regulated by the Chinese government. Changes to Chinese regulations or government policies affecting biopharmaceutical companies are unpredictable and may have a material adverse effect on Oruka&#8217;s collaborators in China which could have an adverse effect on Oruka&#8217;s business, financial condition, results of operations and prospects. Evolving changes in China&#8217;s public health, economic, political, and social conditions and the uncertainty around China&#8217;s relationship with other governments, such as the United&#160;States and the UK, could also negatively impact Oruka&#8217;s ability to manufacture its product candidates for its planned clinical trials or have an adverse effect on its ability to secure government funding, which could adversely affect Oruka&#8217;s financial condition and cause it to delay its clinical development programs. Furthermore, if the BIOSECURE Act is passed and one or more of Oruka&#8217;s collaborators or vendors in China, including WuXi, is deemed to be a biotechnology company of concern, Oruka&#8217;s operations and financial condition may be negatively impacted as a result of any delays or increased costs arising from the trade restrictions and other foreign regulatory requirements affecting such collaborators. In addition, while Oruka has established relationships with CROs and CMOs outside of China, moving to those suppliers in the event of a geopolitical instability affecting Oruka&#8217;s collaborators in China could introduce delays into the development program.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka currently relies and expects to rely in the future on the use of manufacturing suites in third-party facilities or on third parties to manufacture its product candidates, and Oruka may rely on third parties to produce and process its products, if approved. Oruka&#8217;s business could be adversely affected if it is unable to use third-party manufacturing suites or if the third-party manufacturers encounter difficulties in production.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka does not currently own any facility that may be used as its clinical or commercial manufacturing and processing facility and must currently rely on CMOs to manufacture its product candidates. Oruka has not yet caused any product candidates to be manufactured on a commercial scale and may not be able to do so for any of its product candidates, if approved. Oruka currently has a sole source relationship for its supply of the ORKA<span class="nobreak">-001</span> and ORKA<span class="nobreak">-002</span> program. If there should be any disruption in such supply arrangement, including any adverse events affecting Oruka&#8217;s sole supplier, it could have a negative effect on the clinical development of Oruka&#8217;s programs and other operations while Oruka works to identify and qualify an alternate supply source. Oruka may not control the manufacturing process of, and may be completely dependent on, its contract manufacturing partners for compliance with cGMP requirements and any other regulatory requirements of the FDA or comparable foreign regulatory authorities for the manufacture of its product candidates. Beyond periodic audits, Oruka has limited control over the ability of its CMOs to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or a comparable foreign regulatory authority does not approve these facilities for the manufacture of Oruka&#8217;s product candidates or if it withdraws any approval in the future, Oruka may need to find alternative manufacturing facilities, which would require the incurrence of significant additional costs, delays, and materially adversely affect Oruka&#8217;s ability to develop, obtain regulatory approval for or market its product candidates, if approved. Similarly, Oruka&#8217;s failure, or the failure of its CMOs, to comply with applicable regulations could result in sanctions being imposed on Oruka, including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates or drugs, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of Oruka&#8217;s product candidates or drugs and harm Oruka&#8217;s business and results of operations.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Moreover, Oruka&#8217;s CMOs may experience manufacturing difficulties due to resource constraints, supply chain issues, or as a result of labor disputes or unstable political environments. If any CMOs on which Oruka will rely fail to manufacture quantities of Oruka&#8217;s product candidates at quality levels necessary to meet regulatory requirements and at a scale sufficient to meet anticipated demand at a cost that allows Oruka to achieve profitability, Oruka&#8217;s business, financial condition and prospects could be materially and adversely affected. In addition, Oruka&#8217;s CMOs </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">73</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">are responsible for transporting temperature<span class="nobreak">-controlled</span> materials that can be inadvertently degraded during transport due to several factors, rendering certain batches unsuitable for trial use for failure to meet, among others, Oruka&#8217;s integrity and purity specifications. Oruka and any of its CMOs may also face product seizure or detention or refusal to permit the import or export of products. Oruka&#8217;s business could be materially adversely affected by business disruptions to its third<span class="nobreak">-party</span> providers that could materially adversely affect its anticipated timelines, potential future revenue and financial condition and increase its costs and expenses. Each of these risks could delay or prevent the completion of Oruka&#8217;s preclinical studies and clinical trials or the approval of any of its product candidates by the FDA, result in higher costs or adversely impact commercialization of its product candidates. See the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Oruka&#8217;s Business&#160;&#8212;&#160;Manufacturing</span>&#8221; for a more detailed description of Oruka&#8217;s manufacturing plans and assumptions and the factors that may affect the success of Oruka&#8217;s programs.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Risks Related to Employee Matters, Managing Growth and Other Risks Related to Oruka&#8217;s Business</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">In order to successfully implement Oruka&#8217;s plans and strategies, Oruka will need to grow the size of its organization and it may experience difficulties in managing this growth.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka expects to experience significant growth in the number of its employees and the scope of its operations, particularly in the areas of preclinical and clinical drug development, technical operations, clinical operations, regulatory affairs and, potentially, sales and marketing. To manage Oruka&#8217;s anticipated future growth, Oruka must continue to implement and improve its managerial, operational and financial personnel and systems, expand its facilities and continue to recruit and train additional qualified personnel. Due to Oruka&#8217;s limited financial resources and the limited experience of its management team working together in managing a company with such anticipated growth, Oruka may not be able to effectively manage the expansion of its operations or recruit and train additional qualified personnel.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka is highly dependent on its key personnel and anticipates hiring new key personnel. If Oruka is not successful in attracting and retaining highly qualified personnel, it may not be able to successfully implement its business strategy.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka is a preclinical stage biotechnology company with a limited operating history, and, as of May&#160;3, 2024, it had ten full<span class="nobreak">-time</span> employees. Oruka has been and will continue to be highly dependent on the research and development, clinical and business development expertise of its executive officers, as well as the other principal members of its management, scientific and clinical team. Any of Oruka&#8217;s management team members may terminate their employment with Oruka at any time. Oruka does not maintain &#8220;key person&#8221; insurance for any of its executives or other employees.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Attracting and retaining qualified personnel will also be critical to Oruka&#8217;s success, including with respect to any strategic transaction that it may pursue. The loss of the services of Oruka&#8217;s executive officers or other key employees could impede the achievement of its research, development and commercialization objectives and seriously harm its ability to successfully implement its business strategy. Furthermore, replacing executive officers and key employees may be difficult and may take an extended period of time because of the limited number of individuals in Oruka&#8217;s industry with the breadth of skills and experience required to successfully develop, facilitate regulatory approval of and commercialize product candidates. Competition to hire from this limited pool is intense, and Oruka may be unable to hire, train, retain or motivate these key personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. Oruka also experiences competition for the hiring of scientific and clinical personnel from universities and research institutions.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, Oruka relies on consultants and advisors, including scientific and clinical advisors, to assist it in formulating its discovery and nonclinical and clinical development and commercialization strategy. Oruka&#8217;s consultants and advisors may be employed by employers other than Oruka and may have commitments under consulting or advisory contracts with other entities that may limit their availability to Oruka. If Oruka is unable to continue to attract and retain high quality personnel, its ability to pursue its growth strategy will be limited.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">74</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka&#8217;s future growth may depend, in part, on its ability to operate in foreign markets, where it would be subject to additional regulatory burdens and other risks and uncertainties.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka&#8217;s future growth may depend, in part, on its ability to develop and commercialize its product candidates in foreign markets for which it may rely on collaboration with third parties. Oruka is not permitted to market or promote any of its product candidates before it receives regulatory approval from the applicable foreign regulatory authority, and may never receive such regulatory approval for any of its product candidates. To obtain separate regulatory approval in many other countries, Oruka must comply with numerous and varying regulatory requirements of such countries regarding safety and efficacy and governing, among other things, clinical trials and commercial sales, pricing and distribution of its product candidates, and Oruka cannot predict success in these jurisdictions. If Oruka fails to comply with the regulatory requirements in international markets and receive applicable marketing approvals, its target market will be reduced and its ability to realize the full market potential of its product candidates will be harmed and its business will be adversely affected. Moreover, even if Oruka obtains approval of its product candidates and ultimately commercializes its product candidates in foreign markets, Oruka would be subject to the risks and uncertainties, including the burden of complying with complex and changing foreign regulatory, tax, accounting and legal requirements and reduced protection of intellectual property rights in some foreign countries.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka&#8217;s estimates of market opportunity and forecasts of market growth may prove to be inaccurate, and even if the markets in which Oruka competes achieve the forecasted growth, its business may not grow at similar rates, or at all.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka&#8217;s market opportunity estimates and growth forecasts are subject to significant uncertainty and are based on assumptions and estimates which may not prove to be accurate. Oruka&#8217;s estimates and forecasts relating to size and expected growth of its target market may prove to be inaccurate. Even if the markets in which Oruka competes meet Oruka&#8217;s size estimates and growth forecasts, Oruka&#8217;s business may not grow at similar rates, or at all. Oruka&#8217;s growth is subject to many factors, including its success in implementing its business strategy, which is subject to many risks and uncertainties.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka&#8217;s revenue will be dependent, in part, upon the size of the markets in the territories for which it gains regulatory approval, the accepted price for the product, the ability to obtain coverage and reimbursement and whether Oruka owns the commercial rights for that territory. If the number of Oruka&#8217;s addressable patients is not as significant as it estimates, the indication approved by regulatory authorities is narrower than it expects or the treatment population is narrowed by competition, physician choice or treatment guidelines, Oruka may not generate significant revenue from sales of such products, even if approved.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka&#8217;s employees, independent contractors, consultants, commercial collaborators, principal investigators, CROs, CMOs, suppliers and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka is exposed to the risk that its employees, independent contractors, consultants, commercial collaborators, principal investigators, CROs, CMOs, suppliers and vendors acting for or on its behalf may engage in misconduct or other improper activities. Oruka has adopted a code of conduct and ethics, but it is not always possible to identify and deter misconduct by these parties and the precautions Oruka takes to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting Oruka from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">75</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka&#8217;s internal information technology systems, or those of any of its CROs, manufacturers, other contractors or consultants, third-party service providers, or potential future collaborators, may fail or suffer security or data privacy breaches or other unauthorized or improper access to, use of, or destruction of Oruka&#8217;s proprietary or confidential data, employee data or personal data, which could result in additional costs, loss of revenue, significant liabilities, harm to Oruka&#8217;s brand and material disruption of its operations.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In the ordinary course of its business, Oruka and the third parties upon which it relies collect, receive, store, process, generate, use, transfer, disclose, make accessible, protect, secure, dispose of, transmit, and share (collectively, process) proprietary, confidential, and sensitive data, including personal data, intellectual property, trade secrets, and other sensitive data (collectively, sensitive information).</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Despite the implementation of security measures in an effort to protect systems that store Oruka&#8217;s information, given their size and complexity and the increasing amounts of information maintained on Oruka&#8217;s internal information technology systems and those of its third<span class="nobreak">-party</span> CROs, other contractors (including sites performing Oruka&#8217;s clinical trials), third<span class="nobreak">-party</span> service providers and supply chain companies, and consultants, these systems are potentially vulnerable to breakdown or other damage or interruption from service interruptions, system malfunction, natural disasters, terrorism, war and telecommunication and electrical failures, as well as security breaches from inadvertent or intentional actions by Oruka&#8217;s employees, contractors, consultants, business partners and/or other third parties, or from cyber<span class="nobreak">-attacks</span> by malicious third parties, which may compromise Oruka&#8217;s system infrastructure or lead to the loss, destruction, alteration or dissemination of, or damage to, Oruka&#8217;s data.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Some actors now engage and are expected to continue to engage in cyber<span class="nobreak">-attacks</span>, including without limitation nation<span class="nobreak">-state</span> actors for geopolitical reasons and in conjunction with military conflicts and defense activities. During times of war and other major conflicts, Oruka, and the third parties upon which it relies, may be vulnerable to a heightened risk of these attacks, including retaliatory cyber<span class="nobreak">-attacks</span>, that could materially disrupt Oruka&#8217;s systems and operations, supply chain, and ability to produce, sell and distribute its goods and services. In particular, severe ransomware attacks are becoming increasingly prevalent and can lead to significant interruptions in Oruka&#8217;s operations, ability to provide its products or services, loss of sensitive data and income, reputational harm, and diversion of funds. Extortion payments may alleviate the negative impact of a ransomware attack, but Oruka may be unwilling or unable to make such payments due to, for example, applicable laws or regulations prohibiting such payments.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">To the extent that any disruption or security breach were to result in loss, destruction, unavailability, alteration or dissemination of, or damage to, Oruka&#8217;s data or applications, or for it to be believed or reported that any of these occurred, Oruka could incur liability and reputational damage and the development and commercialization of its product candidates could be delayed. Further, Oruka&#8217;s insurance policies may not be adequate to compensate it for the potential losses arising from any such disruption in, or failure or security breach of, its systems or third<span class="nobreak">-party</span> systems where information important to Oruka&#8217;s business operations or commercial development is stored.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka&#8217;s fully<span class="nobreak">-remote</span> workforce may create additional risks for its information technology systems and data because its employees work remotely and utilize network connections, computers, and devices working at home, while in transit and in public locations. Additionally, business transactions (such as acquisitions or integrations) could expose Oruka to additional cybersecurity risks and vulnerabilities, as its systems could be negatively affected by vulnerabilities present in acquired or integrated entities&#8217; systems and technologies.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">While Oruka has implemented security measures designed to protect against security incidents, there can be no assurance that these measures will be effective. Oruka may be unable in the future to detect vulnerabilities in its information technology systems because such threats and techniques change frequently, are often sophisticated in nature, and may not be detected until after a security incident has occurred. Further, Oruka may experience delays in developing and deploying remedial measures designed to address any such identified vulnerabilities. Applicable data privacy and security obligations may require Oruka to notify relevant stakeholders of security incidents. Such disclosures are costly, and the disclosure or the failure to comply with such requirements could lead to adverse consequences.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka relies on third<span class="nobreak">-party</span> service providers and technologies to operate critical business systems to process sensitive information in a variety of contexts. Oruka&#8217;s ability to monitor these third parties&#8217; information security practices is limited, and these third parties may not have adequate information security measures in place. If Oruka&#8217;s third<span class="nobreak">-party</span> service providers experience a security incident or other interruption, Oruka could experience adverse </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">76</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">consequences. While Oruka may be entitled to damages if its third<span class="nobreak">-party</span> service providers fail to satisfy their privacy or security<span class="nobreak">-related</span> obligations to it, any award may be insufficient to cover Oruka&#8217;s damages, or Oruka may be unable to recover such award. In addition, supply<span class="nobreak">-chain</span> attacks have increased in frequency and severity, and Oruka cannot guarantee that third parties&#8217; infrastructure in its supply chain or its third<span class="nobreak">-party</span> partners&#8217; supply chains have not been compromised.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If Oruka (or a third party upon whom it relies) experiences a security incident or are perceived to have experienced a security incident, Oruka may experience adverse consequences, such as government enforcement actions (for example, investigations, fines, penalties, audits, and inspections); additional reporting requirements and/or oversight; restrictions on processing sensitive information (including personal data); litigation (including class claims); indemnification obligations; negative publicity; reputational harm; monetary fund diversions; interruptions in Oruka&#8217;s operations (including availability of data); financial loss; and other similar harms. Security incidents and attendant consequences may cause stakeholders (including investors and potential customers) to stop supporting Oruka&#8217;s platform, deter new customers from products, and negatively impact Oruka&#8217;s ability to grow and operate its business.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka&#8217;s contracts may not contain limitations of liability, and even where they do, there can be no assurance that limitations of liability in Oruka&#8217;s contracts are sufficient to protect Oruka from liabilities, damages, or claims related to its data privacy and security obligations. Oruka cannot be sure that its insurance coverage will be adequate or sufficient to protect it from or to mitigate liabilities arising out of its privacy and security practices, that such coverage will continue to be available on commercially reasonable terms or at all, or that such coverage will pay future claims.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka is subject to stringent and changing laws, regulations and standards, and contractual obligations relating to privacy, data protection, and data security. The actual or perceived failure to comply with such obligations could lead to government enforcement actions (which could include civil or criminal penalties), fines and sanctions, private litigation and/or adverse publicity and could negatively affect Oruka&#8217;s operating results and business.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka and third parties who it works with are or may become subject to numerous domestic and foreign laws, regulations, and standards relating to privacy, data protection, and data security, the scope of which is changing, subject to differing applications and interpretations, and may be inconsistent among countries, or conflict with other rules. Oruka is or may become subject to the terms of contractual obligations related to privacy, data protection and data security. Oruka&#8217;s obligations may also change or expand as its business grows. The actual or perceived failure by Oruka or third parties related to Oruka to comply with such laws, regulations and obligations could increase Oruka&#8217;s compliance and operational costs, expose it to regulatory scrutiny, actions, fines and penalties, result in reputational harm, lead to a loss of customers, result in litigation and liability, and otherwise cause a material adverse effect on its business, financial condition, and results of operations. See the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Oruka&#8217;s Business&#160;&#8212;&#160;Government Regulation&#160;&#8212;&#160;Data Privacy and Security</span>&#8221; for a more detailed description of the laws that may affect Oruka&#8217;s ability to operate.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">If Oruka fails to comply with environmental, health and safety laws and regulations, it could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of its business.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka is subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Oruka&#8217;s operations may involve the use of hazardous and flammable materials, including chemicals and biological and radioactive materials. In addition, Oruka may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair Oruka&#8217;s research, development or commercialization efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka may be subject to adverse legislative or regulatory tax changes that could negatively impact its financial condition.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The rules dealing with U.S.&#160;federal, state and local income taxation are constantly under review by persons involved in the legislative process and by the Internal Revenue Service and the U.S.&#160;Treasury Department. Changes to tax laws (which may have retroactive application) could adversely affect Oruka&#8217;s stockholders or Oruka. Oruka assesses the impact of various tax reform proposals and modifications to existing tax treaties in all jurisdictions </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">77</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">where it has operations to determine the potential effect on its business and any assumptions it has made about its future taxable income. Oruka cannot predict whether any specific proposals will be enacted, the terms of any such proposals or what effect, if any, such proposals would have on its business if they were to be enacted. For example, the United&#160;States recently enacted the Inflation Reduction Act&#160;of&#160;2022 (&#8220;IRA&#8221;), which implements, among other changes, a 1% excise tax on certain stock buybacks. In addition, beginning in 2022, the Tax Cuts and&#160;Jobs Act&#160;eliminated the previously available option to deduct research and development expenditures and requires taxpayers to amortize them generally over five&#160;years for research activities conducted in the United&#160;States and over 15&#160;years for research activities conducted outside the United&#160;States. The U.S.&#160;Congress is considering legislation that would restore the current deductibility of research and development expenditures; however, Oruka has no assurance that the provision will be repealed or otherwise modified. Such changes, among others, may adversely affect Oruka&#8217;s effective tax rate, results of operation and general business condition.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka may acquire businesses or products, or form strategic alliances, in the future, and may not realize the benefits of such acquisitions.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka may acquire additional businesses or products, form strategic alliances, or create joint ventures with third parties that it believes will complement or augment its existing business. If Oruka acquires businesses with promising markets or technologies, it may not be able to realize the benefit of acquiring such businesses if it is unable to successfully integrate them with its existing operations and company culture. Oruka may encounter numerous difficulties in developing, manufacturing and marketing any new product candidates or products resulting from a strategic alliance or acquisition that delay or prevent it from realizing their expected benefits or enhancing Oruka&#8217;s business. There is no assurance that, following any such acquisition, Oruka will achieve the synergies expected in order to justify the transaction, which could result in a material adverse effect on Oruka&#8217;s business and prospects.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka maintains its cash at financial institutions, often in balances that exceed federally-insured limits. The failure of financial institutions could adversely affect Oruka&#8217;s ability to pay its operational expenses or make other payments.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka&#8217;s cash held in&#160;non<span class="nobreak">-interest-bearing</span>&#160;and interest<span class="nobreak">-bearing</span> accounts exceeds the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;) insurance limits. If such banking institutions were to fail, Oruka could lose all or a portion of those amounts held in excess of such insurance limitations. For example, the FDIC took control of Silicon Valley Bank on March&#160;10, 2023. The Federal Reserve subsequently announced that account holders would be made whole. However, the FDIC may not make all account holders whole in the event of future bank failures. In addition, even if account holders are ultimately made whole with respect to a future bank failure, account holders&#8217; access to their accounts and assets held in their accounts may be substantially delayed. Any material loss that Oruka may experience in the future or inability for a material time period to access its cash and cash equivalents could have an adverse effect on its ability to pay its operational expenses or make other payments, which could adversely affect its business.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">General Risk Factors</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka&#8217;s estimates&#160;of market&#160;opportunity&#160;and forecasts&#160;of market&#160;growth may&#160;prove&#160;to be inaccurate,&#160;and even if the markets&#160;in which Oruka competes&#160;achieve&#160;the forecasted&#160;growth, its business&#160;may&#160;not grow at similar&#160;rates, or at all.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka&#8217;s market opportunity estimates and growth forecasts are subject to significant uncertainty and are based on assumptions and estimates which may not prove to be accurate. Oruka&#8217;s estimates and forecasts relating to size and expected growth of its target market may prove to be inaccurate. Even if the markets in which Oruka competes meet its size estimates and growth forecasts, Oruka&#8217;s business may not grow at similar rates, or at all. Oruka&#8217;s growth is subject to many factors, including its success in implementing its business strategy, which is subject to many risks and uncertainties.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka&#8217;s revenue will be dependent, in part, upon the size of the markets in the territories for which Oruka gains regulatory approval, the accepted price for the product, the ability to obtain coverage and reimbursement and whether Oruka owns the commercial rights for that territory. If the number of its addressable patients is not as </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">78</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">significant as Oruka estimates, the indication approved by regulatory authorities is narrower than Oruka expects or the treatment population is narrowed by competition, physician choice or treatment guidelines, Oruka may not generate significant revenue from sales of such products, even if approved.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka may become exposed to costly and damaging liability claims, either when testing a product candidate in the clinical or at the commercial stage, and its product liability insurance may not cover all damages from such claims.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka is exposed to potential product liability and professional indemnity risks that are inherent in the research, development, manufacturing, marketing, and use of pharmaceutical products. While Oruka currently has no products that have been approved for commercial sale, the future use of a product candidate in clinical trials, and the sale of any approved products in the future, may expose Oruka to liability claims. These claims may be made by patients that use the product, healthcare providers, pharmaceutical companies, or others selling such product. Any claims against Oruka, regardless of their merit, could be difficult and costly to defend and could materially and adversely affect the market for Oruka&#8217;s products or any prospects for commercialization of its products. Although Oruka intends to obtain product liability insurance for its future clinical trials, it is possible that any liabilities could exceed Oruka&#8217;s insurance coverage or that in the future Oruka may not be able to maintain insurance coverage at a reasonable cost or obtain insurance coverage that will be adequate to satisfy any liability that may arise. If a successful product liability claim or series of claims is brought against Oruka for uninsured liabilities or in excess of insured liabilities, Oruka&#8217;s assets may not be sufficient to cover such claims and its business operations could be impaired.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Litigation costs and the outcome of litigation could have a material adverse effect on Oruka&#8217;s business.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">From time to time&#160;Oruka&#160;may&#160;be&#160;subject&#160;to&#160;litigation&#160;claims through the ordinary course of its business operations regarding, but not limited to, employment matters, security of patient and employee personal information, contractual relations with collaborators and intellectual property rights. Litigation to defend itself against claims by third parties, or to enforce any rights that Oruka may have against third parties, may continue to be necessary, which could result in substantial costs and diversion of its resources, causing a material adverse effect on its business, financial condition, results of operations or cash flows.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka&#8217;s business could be adversely affected by economic downturns, inflation, increases in interest rates, natural disasters, public health crises, political crises, geopolitical events, or other macroeconomic conditions, which could have a material and adverse effect on its results of operations and financial condition.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The global economy, including credit and financial markets, has experienced extreme volatility and disruptions, including, among other things, diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, supply chain shortages, increases in inflation rates, higher interest rates, and uncertainty about economic stability. For example, the&#160;COVID<span class="nobreak">-19</span>&#160;pandemic resulted in widespread unemployment, economic slowdown and extreme volatility in the capital markets. The Federal Reserve has raised interest rates multiple times in response to concerns about inflation and it may raise them again. Higher interest rates, coupled with reduced government spending and volatility in financial markets, may increase economic uncertainty and affect consumer spending. Similarly, the ongoing military conflict between Russia and Ukraine and in the Middle East and rising tensions with China have created extreme volatility in the global capital markets and may have further global economic consequences, including disruptions of the global supply chain. Any such volatility and disruptions may adversely affect Oruka&#8217;s business or the third parties on whom Oruka relies. If the equity and credit markets deteriorate, including as a result of political unrest or war, it may make any necessary debt or equity financing more costly, more dilutive, or more difficult to obtain in a timely manner or on favorable terms, if at all. Increased inflation rates can adversely affect Oruka by increasing its costs, including labor and employee benefit costs.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka may in the future experience disruptions as a result of such macroeconomic conditions, including delays or difficulties in initiating or expanding clinical trials and manufacturing sufficient quantities of materials. Any one or a combination of these events could have a material and adverse effect on Oruka&#8217;s results of operations and financial condition.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">79</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Risks Related to the Combined Company</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">If any of the events described in &#8220;Risks Related to ARCA&#8221; or &#8220;Risks Related to Oruka&#8221; occur, those events could cause potential benefits of the Merger not to be realized.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Following completion of the Merger, the combined company will be susceptible to many of the risks described in the sections herein entitled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Risks Related to ARCA</span>&#8221; and &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Risks Related to Oruka</span>.&#8221; To the extent any of the events in the risks described in those sections occur, the potential benefits of the Merger may not be realized and the results of operations and financial condition of the combined company could be adversely affected in a material way. This could cause the market price of the combined company&#8217;s common stock to decline.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">The market price of the combined company&#8217;s common stock is expected to be volatile, and the market price of the common stock may drop following the Merger.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The market price of the combined company&#8217;s common stock following the Merger could be subject to significant fluctuations. Some of the factors that may cause the market price of the combined company&#8217;s common stock to fluctuate include:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>results of clinical trials and preclinical studies of the combined company&#8217;s product candidates, or those of the combined company&#8217;s competitors or the combined company&#8217;s existing or future collaborators;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>failure to meet or exceed financial and development projections the combined company may provide to the public;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>failure to meet or exceed the financial and development projections of the investment community;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>if the combined company does not achieve the perceived benefits of the Merger as rapidly or to the extent anticipated by financial or industry analysts;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>announcements of significant acquisitions, strategic collaborations, joint ventures or capital commitments by the combined company or its competitors;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>actions taken by regulatory agencies with respect to the combined company&#8217;s product candidates, clinical studies, manufacturing process or sales and marketing terms;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>disputes or other developments relating to proprietary rights, including patents, litigation matters, and the combined company&#8217;s ability to obtain patent protection for its technologies;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>additions or departures of key personnel;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>significant lawsuits, including patent or stockholder litigation;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>if securities or industry analysts do not publish research or reports about the combined company&#8217;s business, or if they issue adverse or misleading opinions regarding its business and stock;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>changes in the market valuations of similar companies;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>general market or macroeconomic conditions or market conditions in the pharmaceutical and biotechnology sectors;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>sales of securities by the combined company or its securityholders in the future;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>if the combined company fails to raise an adequate amount of capital to fund its operations or continued development of its product candidates;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>trading volume of the combined company&#8217;s common stock;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>announcements by competitors of new commercial products, clinical progress or lack thereof, significant contracts, commercial relationships or capital commitments;</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">80</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>adverse publicity relating to precision medicine product candidates, including with respect to other products in such markets;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the introduction of technological innovations or new therapies that compete with the products and services of the combined company; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>period<span class="nobreak">-to-period</span>&#160;fluctuations in the combined company&#8217;s financial results.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Moreover, the stock markets in general have experienced substantial volatility that has often been unrelated to the operating performance of individual companies. These broad market fluctuations may also adversely affect the trading price of the combined company&#8217;s common stock. In addition, a recession, depression or other sustained adverse market event could materially and adversely affect the combined company&#8217;s business and the value of its common stock. In the past, following periods of volatility in the market price of a company&#8217;s securities, stockholders have often instituted class action securities litigation against such companies. Furthermore, market volatility may lead to increased shareholder activism if the combined company experiences a market valuation that activists believe is not reflective of its intrinsic value. Activist campaigns that contest or conflict with the combined company&#8217;s strategic direction or seek changes in the composition of its board of directors could have an adverse effect on its operating results, financial condition and cash flows.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">The combined company may incur losses for the foreseeable future and may never achieve profitability.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The combined company may never become profitable, even if it is able to complete clinical development for one or more product candidates and eventually commercialize such product candidates. The combined company will need to successfully complete significant research, development, testing and regulatory compliance activities that, together with projected general and administrative expenses, is expected to result in substantial increased operating losses for at least the next several&#160;years. Even if the combined company does achieve profitability, it may not be able to sustain or increase profitability on a quarterly or annual basis.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">If the combined company fails to attract and retain management and other key personnel, it may be unable to continue to successfully develop or commercialize its product candidates or otherwise implement its business plan.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The combined company&#8217;s ability to compete in the highly competitive pharmaceuticals industry depends on its ability to attract and retain highly qualified managerial, scientific, medical, legal, sales and marketing and other personnel. The combined company will be highly dependent on its management and scientific personnel. The loss of the services of any of these individuals could impede, delay, or prevent the successful development of the combined company&#8217;s product pipeline, completion of its planned clinical trials, commercialization of its product candidates or&#160;in<span class="nobreak">-licensing</span>&#160;or acquisition of new assets and could impact negatively its ability to implement successfully its business plan. If the combined company loses the services of any of these individuals, it might not be able to find suitable replacements on a timely basis or at all, and its business could be harmed as a result. The combined company might not be able to attract or retain qualified management and other key personnel in the future due to the intense competition for qualified personnel among biotechnology, pharmaceutical and other businesses.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">The combined company will need to raise additional financing in the future to fund its operations, which may not be available to it on favorable terms or at all.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The combined company will require substantial additional funds to conduct the costly and time<span class="nobreak">-consuming</span> clinical efficacy trials necessary to pursue regulatory approval of each potential product candidate and to continue the development of ORKA<span class="nobreak">-001</span>, ORKA<span class="nobreak">-002</span> and Oruka&#8217;s other programs and future product candidates. The combined company&#8217;s future capital requirements will depend upon a number of factors, including: the number and timing of future product candidates in the pipeline; progress with and results from preclinical testing and clinical trials; the ability to manufacture sufficient drug supplies to complete preclinical and clinical trials; the costs involved in preparing, filing, acquiring, prosecuting, maintaining and enforcing patent and other intellectual property claims; and the time and costs involved in obtaining regulatory approvals and favorable reimbursement or formulary acceptance. Raising additional capital may be costly or difficult to obtain and could, for example, through the sale of common stock or securities convertible or exchangeable into common stock, significantly dilute the combined company&#8217;s stockholders&#8217; ownership interests or inhibit the combined company&#8217;s ability to achieve its business objectives. If the combined company raises additional funds through public or private equity offerings, the terms of </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">81</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">these securities may include liquidation or other preferences that adversely the rights of its common stockholders. In addition, any debt financing may subject the combined company to fixed payment obligations and covenants limiting or restricting its ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If the combined company raises additional capital through marketing and distribution arrangements or other collaborations, strategic alliances or licensing arrangements with third parties, the combined company may have to relinquish certain valuable intellectual property or other rights to its product candidates, technologies, future revenue streams or research programs or grant licenses on terms that may not be favorable to it. Even if the combined company were to obtain sufficient funding, there can be no assurance that it will be available on terms acceptable to the combined company or its stockholders.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">The combined company will incur additional costs and increased demands upon management as a result of complying with the laws and regulations affecting public companies.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The combined company will incur significant legal, accounting and other expenses as a public company that Oruka did not incur as a private company, including costs associated with public company reporting obligations under the Securities Exchange&#160;Act&#160;of&#160;1934, as amended (the &#8220;Exchange&#160;Act&#8221;). The combined company&#8217;s management team will consist of the executive officers of Oruka prior to the Merger. These executive officers and other personnel will need to devote substantial time to gaining expertise related to public company reporting requirements and compliance with applicable laws and regulations to ensure that the combined company complies with all of these requirements. Any changes the combined company makes to comply with these obligations may not be sufficient to allow it to satisfy its obligations as a public company on a timely basis, or at all. These reporting requirements, rules and regulations, coupled with the increase in potential litigation exposure associated with being a public company, could also make it more difficult for the combined company to attract and retain qualified persons to serve on the board of directors or on board committees or to serve as executive officers, or to obtain certain types of insurance, including directors&#8217; and officers&#8217; insurance, on acceptable terms.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Upon completion of the Merger, failure by the combined company to comply with the initial listing standards of Nasdaq will prevent its stock from being listed on Nasdaq.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Upon completion of the Merger, ARCA, under the new name &#8220;Oruka Therapeutics, Inc.,&#8221; will be required to meet the initial listing requirements to maintain the listing and continued trading of its shares on Nasdaq. These initial listing requirements are more difficult to achieve than the continued listing requirements. Pursuant to the Merger Agreement, ARCA agreed to use its commercially reasonable efforts to cause the shares of ARCA common stock being issued in the Merger (including any common stock issuable upon conversion of the ARCA Series&#160;B Preferred Stock) to be approved for listing on Nasdaq at or prior to the effective time of the Merger. Based on information currently available to ARCA, ARCA anticipates that its stock will be unable to meet the $4.00 minimum bid price initial listing requirement at the closing of the Merger unless it effects a reverse stock split. ARCA&#8217;s board of directors intends to effect a reverse stock split of the shares of ARCA common stock at a ratio of between 1:<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span><span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>to 1:&#160;&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>. In addition, often times a reverse stock split will not result in a trading price for the affected common stock that is proportional to the ratio of the split. Following the Merger, if the combined company is unable to satisfy Nasdaq listing requirements, Nasdaq may notify the combined company that its shares of common stock will not be listed on Nasdaq.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Upon a potential delisting from Nasdaq, if the common stock of the combined company is not then eligible for quotation on another market or exchange, trading of the shares could be conducted in the&#160;over<span class="nobreak">-the-counter</span>&#160;market or on an electronic bulletin board established for unlisted securities such as the Pink Sheets or the OTC Bulletin Board. In such event, it is likely that there would be significantly less liquidity in the trading of the common stock of the combined company; decreases in institutional and other investor demand for the shares, coverage by securities analysts, market making activity and information available concerning trading prices and volume; and fewer broker dealers willing to execute trades in the common stock of the combined company. Also, it may be difficult for the combined company to raise additional capital if the combined company&#8217;s common stock is not listed on a major exchange. The occurrence of any of these events could result in a further decline in the market price of the common stock of the combined company and could have a material adverse effect on the combined company.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">82</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Once the combined company is no longer a smaller reporting company or otherwise no longer qualifies for applicable exemptions, the combined company will be subject to additional laws and regulations affecting public companies that will increase the combined company&#8217;s costs and the demands on management and could harm the combined company&#8217;s operating results and cash flows.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The combined company will be subject to the reporting requirements of the Exchange&#160;Act, which requires, among other things, that the combined company file with the SEC, annual, quarterly and current reports with respect to the combined company&#8217;s business and financial condition as well as other disclosure and corporate governance requirements. However, as a &#8220;smaller reporting company,&#8221; as such term is defined in Rule&#160;12b<span class="nobreak">-2</span> under the Exchange&#160;Act, in at least the near term, the combined company may take advantage of exemptions from disclosure requirements, including not being required to comply with the auditor attestation requirements of Section&#160;404 of the Sarbanes<span class="nobreak">-Oxley</span> Act and reduced disclosure obligations regarding executive compensation in this proxy statement/prospectus and in the combined company&#8217;s periodic reports and proxy statements. Once the combined company is no longer a smaller reporting company or otherwise no longer qualifies for these exemptions, the combined company will be required to comply with these additional legal and regulatory requirements applicable to public companies and will incur significant legal, accounting and other expenses to do so. If the combined company is not able to comply with the requirements in a timely manner or at all, the combined company&#8217;s financial condition or the market price of the combined company&#8217;s common stock may be harmed. For example, if the combined company or its independent auditor identifies deficiencies in the combined company&#8217;s internal control over financial reporting that are deemed to be material weaknesses the combined company could face additional costs to remedy those deficiencies, the market price of the combined company&#8217;s stock could decline or the combined company could be subject to sanctions or investigations by the SEC or other regulatory authorities, which would require additional financial and management resources.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">If the combined company fails to maintain proper and effective internal controls, its ability to produce accurate financial statements on a timely basis could be impaired.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Provided the combined company continues to be listed on Nasdaq, the combined company will be subject to the reporting requirements of the Exchange&#160;Act, the Sarbanes<span class="nobreak">-Oxley</span> Act and the rules and regulations of Nasdaq. The Sarbanes<span class="nobreak">-Oxley</span> Act requires, among other things, that the combined company maintain effective disclosure controls and procedures and internal control over financial reporting. The combined company must perform system and process evaluation and testing of its internal control over financial reporting to allow management to report on the effectiveness of its internal controls over financial reporting in its Annual Report on Form&#160;10<span class="nobreak">-K</span>&#160;filing for that year, as required by Section&#160;404 of the Sarbanes<span class="nobreak">-Oxley</span> Act. As a private company, Oruka has not been required to document and test its internal controls over financial reporting nor has its management been required to certify the effectiveness of its internal controls and its auditors have not been required to opine on the effectiveness of its internal control over financial reporting. Following the Merger, the combined company will be required to incur substantial professional fees and internal costs to expand its accounting and finance functions and expend significant management efforts. The combined company may experience difficulty in meeting these reporting requirements in a timely manner.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The combined company may discover weaknesses in its system of internal financial and accounting controls and procedures that could result in a material misstatement of its financial statements. The combined company&#8217;s internal control over financial reporting will not prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system&#8217;s objectives will be met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud will be detected.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If the combined company is not able to comply with the requirements of Section&#160;404 of the Sarbanes<span class="nobreak">-Oxley</span> Act, or if it is unable to maintain proper and effective internal controls, the combined company may not be able to produce timely and accurate financial statements. If that were to happen, the market price of its common stock could decline and it could be subject to sanctions or investigations by Nasdaq, the SEC or other regulatory authorities.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">83</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">The unaudited pro forma condensed combined financial information for ARCA and Oruka included in this proxy statement/prospectus are preliminary, and the combined company&#8217;s actual financial position and operations after the Merger may differ materially from the unaudited pro forma financial information included in this proxy statement/prospectus.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The unaudited pro forma financial information for ARCA and Oruka included in this proxy statement/prospectus are presented for illustrative purposes only and is not necessarily indicative of the combined company&#8217;s actual financial condition or results of operations of future periods, or the financial condition or results of operations that would have been realized had the entities been combined during the period presented. The combined company&#8217;s actual results and financial position after the Merger may differ materially and adversely from the unaudited pro forma financial information included in this proxy statement/prospectus. The exchange ratio reflected in this proxy statement/prospectus is preliminary. The final exchange ratio could differ materially from the preliminary exchange ratio used to prepare the pro forma adjustments. For more information see the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Unaudited Pro Forma Condensed Combined Financial Information</span>&#8221; beginning on page&#160;284.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Provisions that will be in the combined company&#8217;s certificate of incorporation and bylaws and provisions under Delaware law could make an acquisition of the combined company more difficult and may prevent attempts by its stockholders to replace or remove its management.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Provisions that will be included in the combined company&#8217;s certificate of incorporation and bylaws may discourage, delay or prevent a merger, acquisition or other change in control of the combined company that stockholders may consider favorable, including transactions in which its common stockholders might otherwise receive a premium price for their shares. These provisions could also limit the price that investors might be willing to pay in the future for shares of the combined company&#8217;s common stock, thereby depressing the market price of its common stock. In addition, because the combined company&#8217;s board of directors will be responsible for appointing the members of the combined company&#8217;s management team, these provisions may frustrate or prevent any attempts by the combined company&#8217;s stockholders to replace or remove its current management by making it more difficult for stockholders to replace members of the combined company&#8217;s board of directors. Among other things, these provisions will:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>continue the use of a classified board of directors such that not all members of the combined company board of directors are elected at one time;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>allow the authorized number of the combined company&#8217;s directors to be changed only by resolution of its board of directors;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>limit the manner in which stockholders can remove directors from the combined company&#8217;s board of directors;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>provide for advance notice requirements for nominations for election to the board of directors or for proposing matters that can be acted on at stockholder meetings;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>require that stockholder actions must be effected at a duly called stockholder meeting and prohibit actions by its stockholders by written consent;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>limit who may call a special meeting of stockholders;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>authorize the combined company&#8217;s board of directors to issue preferred stock without stockholder approval, which could be used to institute a &#8220;poison pill&#8221; that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not been approved by the combined company&#8217;s board of directors; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>require the approval of the holders of at least 66 2/3% of the votes that all combined company stockholders would be entitled to cast to amend or repeal certain provisions of the combined company&#8217;s certificate of incorporation or bylaws.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">Moreover, because the combined company will be incorporated in Delaware, it is governed by the provisions of Section&#160;203 of the DGCL, which prohibits stockholders owning in excess of 15% of the outstanding combined company voting stock from merging or combining with the combined company. Although ARCA and Oruka believe these provisions collectively will provide for an opportunity to receive higher bids by requiring potential acquirors to negotiate with the combined company&#8217;s board of directors, they would apply even if the offer may be considered </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">84</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;text-indent:0pt;margin-top:6pt;">beneficial by some stockholders. In addition, these provisions may frustrate or prevent any attempts by the combined company&#8217;s stockholders to replace or remove then current management by making it more difficult for stockholders to replace members of the board of directors, which is responsible for appointing the members of management.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">ARCA and Oruka expect the combined company to amend its bylaws to provide that, unless the combined company consents in writing to the selection of an alternative forum, certain designated courts will be the sole and exclusive forum for certain legal actions between the combined company and its stockholders, which could limit its stockholders&#8217; ability to obtain a favorable judicial forum for disputes with the combined company or its directors, officers, employees or stockholders.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">ARCA and Oruka expect the combined company to amend its bylaws to provide that, unless the combined company consents in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, if the Court of Chancery does not have jurisdiction, the federal district court for the District of Delaware or other state courts of the State of Delaware) is the sole and exclusive forum for the following types of proceedings (i)&#160;any derivative action or proceeding brought on the combined company&#8217;s behalf, (ii)&#160;any action asserting a claim of or based on a breach of a fiduciary duty owed by any of the combined company&#8217;s current or former directors, officers, employees or stockholders to the combined company or its stockholders, (iii)&#160;any action asserting a claim arising pursuant to any provision of the DGCL or as to which the DGCL confers jurisdiction on the Court of Chancery of the State of Delaware or (iv)&#160;any action asserting a claim arising pursuant to any provision of the combined company&#8217;s certificate of incorporation or its bylaws (in each case, as they may be amended from time to time) or that is governed by the internal affairs doctrine, in each case subject to the Court of Chancery having personal jurisdiction over the indispensable parties named as defendants therein, which for purposes of this risk factor refers to herein as the &#8220;Delaware Forum Provision.&#8221; The Delaware Forum Provision will not apply to any causes of action arising under the Securities Act and the Exchange&#160;Act. ARCA and Oruka expect the combined company to also amend its bylaws to provide that, unless it consents in writing to an alternative forum, federal district courts of the United&#160;States will be the sole and exclusive forum for any complaint asserting a cause of action arising under the Securities Act, which for purposes of this risk factor is referred to herein as the &#8220;Federal Forum Provision.&#8221; There is uncertainty as to whether a court would enforce such a provision. In addition, the bylaws of the combined company will provide that any person or entity purchasing or otherwise acquiring any interest in shares of its capital stock is deemed to have notice of and consented to the foregoing Delaware Forum Provision and Federal Forum Provision; provided, however, that stockholders cannot and will not be deemed to have waived the combined company&#8217;s compliance with the U.S.&#160;federal securities laws and the rules and regulations thereunder.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">The Delaware Forum Provision and the Federal Forum Provision may impose additional costs on stockholders of the combined company in pursuing any such claims, particularly if the stockholders do not reside in or near the State of Delaware or were permitted to select another jurisdiction. Additionally, the forum selection clauses in the bylaws of the combined company may limit its stockholders&#8217; ability to bring a claim in a judicial forum that they find favorable for disputes with the combined company or its directors, officers, employees or stockholders, which may discourage such lawsuits against the combined company and its directors, officers, employees and stockholders even though an action, if successful, might benefit its stockholders. Alternatively, if a court were to find the Delaware Forum Provision or the Federal Forum Provision contained in the combined company&#8217;s bylaws to be inapplicable or unenforceable in an action, the combined company may incur additional costs associated with resolving such action in other jurisdictions, which could materially and adversely affect its business, financial condition and results of operations.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">ARCA and Oruka do not anticipate that the combined company will pay any cash dividends in the foreseeable future.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The current expectation is that the combined company will retain its future earnings, if any, to fund the growth of the combined company&#8217;s business as opposed to paying dividends. As a result, capital appreciation, if any, of the common stock of the combined company will be your sole source of gain, if any, for the foreseeable future.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">An active trading market for the combined company&#8217;s common stock may not develop and its stockholders may not be able to resell their shares of common stock for a profit, if at all.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Prior to the Merger, there had been no public market for shares of Oruka capital stock. An active trading market for the combined company&#8217;s shares of common stock may never develop or be sustained. If an active market for the combined company&#8217;s common stock does not develop or is not sustained, it may be difficult for the combined company&#8217;s stockholders to sell their shares at an attractive price or at all.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">85</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Future sales of shares by existing stockholders could cause the combined company&#8217;s stock price to decline.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If existing securityholders of ARCA and Oruka sell, or indicate an intention to sell, substantial amounts of the combined company&#8217;s common stock in the public market after legal restrictions on resale discussed in this proxy statement/prospectus lapse, the trading price of the common stock of the combined company could decline. Based on shares outstanding as of March&#160;31, 2024, after giving effect to the estimated exchange ratio and the shares of Oruka common stock and the Oruka&#160;pre<span class="nobreak">-funded</span>&#160;warrants to be issued in the Oruka&#160;pre<span class="nobreak">-closing</span>&#160;financing and shares expected to be issued upon completion of the Merger and prior to giving effect to the anticipated ARCA reverse stock split, the combined company is expected to have outstanding a total of approximately 357.5<span class="nobreak"> </span>million shares of common stock immediately following the completion of the Merger. Of the shares of common stock, approximately &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares are freely tradeable upon completion of the Merger and approximately&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares will be available for sale in the public market beginning 180&#160;days after the closing of the Merger as a result of the expiration of&#160;lock<span class="nobreak">-up</span>&#160;agreements between ARCA on the one hand and certain securityholders of Oruka on the other hand (and without giving effect to any restrictions on resale under securities laws). In addition, shares of common stock that are subject to outstanding options or warrants of Oruka (excluding the&#160;pre<span class="nobreak">-funded</span>&#160;warrants issued in the Oruka&#160;pre<span class="nobreak">-closing</span>&#160;financing) will become eligible for sale in the public market to the extent permitted by the provisions of various vesting agreements and Rules 144 and 701 under the Securities Act. If these shares are sold, the trading price of the combined company&#8217;s common stock could decline.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">After completion of the Merger, the combined company&#8217;s executive officers, directors and principal stockholders will have the ability to control or significantly influence all matters submitted to the combined company&#8217;s stockholders for approval.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Upon the completion of the Merger, and giving effect to the issuance of the shares of Oruka common stock and the Oruka&#160;pre<span class="nobreak">-funded</span>&#160;warrants prior to the closing of the Merger pursuant to the Oruka&#160;pre<span class="nobreak">-closing</span>&#160;financing, it is anticipated that the combined company&#8217;s executive officers, directors and principal stockholders will, in the aggregate, beneficially own approximately &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;% of the combined company&#8217;s outstanding shares of common stock (on a fully<span class="nobreak">-diluted</span> basis), subject to certain assumptions, including, but not limited to, ARCA&#8217;s net cash as of closing being $5.0&#160;million. ARCA management currently anticipates ARCA&#8217;s net cash as of closing will be approximately $5.0&#160;million, after giving effect to the special cash dividend, which is expected to be approximately $20.0<span class="nobreak"> </span>million, and the currently estimated ownership percentages reflect this projection. As a result, if these stockholders were to choose to act together, they would be able to control or significantly influence all matters submitted to the combined company&#8217;s stockholders for approval, as well as the combined company&#8217;s management and affairs. For example, these stockholders, if they choose to act together, would control or significantly influence the election of directors and approval of any merger, consolidation or sale of all or substantially all of the combined company&#8217;s assets. This concentration of voting power could delay or prevent an acquisition of the combined company on terms that other stockholders may desire.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">If equity research analysts do not publish research or reports, or publish unfavorable research or reports, about the combined company, its business or its market, its stock price and trading volume could decline.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The trading market for the combined company&#8217;s common stock will be influenced by the research and reports that equity research analysts publish about it and its business. Equity research analysts may elect to not provide research coverage of the combined company&#8217;s common stock after the completion of the Merger, and such lack of research coverage may adversely affect the market price of its common stock. In the event it does have equity research analyst coverage, the combined company will not have any control over the analysts or the content and opinions included in their reports. The price of the combined company&#8217;s common stock could decline if one or more equity research analysts downgrade its stock or issue other unfavorable commentary or research. If one or more equity research analysts ceases coverage of the combined company or fails to publish reports on it regularly, demand for its common stock could decrease, which in turn could cause its stock price or trading volume to decline.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">The combined company will have broad discretion in the use of the cash and cash equivalents of the combined company and the proceeds from the Oruka&#160;pre-closing&#160;financing and may invest or spend the proceeds in ways with which you do not agree and in ways that may not increase the value of your investment.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The combined company will have broad discretion over the use of the cash and cash equivalents of the combined company and the proceeds from the Oruka&#160;pre<span class="nobreak">-closing</span>&#160;financing. You may not agree with the combined company&#8217;s decisions, and its use of the proceeds may not yield any return on your investment. The combined </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">86</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">company&#8217;s failure to apply these resources effectively could compromise its ability to pursue its growth strategy and the combined company might not be able to yield a significant return, if any, on its investment of these net proceeds. You will not have the opportunity to influence its decisions on how to use the combined company&#8217;s cash resources.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">The combined company may be subject to adverse legislative or regulatory tax changes that could negatively impact its financial condition.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The rules dealing with U.S.&#160;federal, state and local income taxation are constantly under review by persons involved in the legislative process and by the Internal Revenue Service and the U.S.&#160;Treasury Department. Changes to tax laws (which changes may have retroactive application) could adversely affect the combined company or its stockholders. The combined company will assess the impact of various tax reform proposals and modifications to existing tax treaties in all jurisdictions where the combined company has operations to determine the potential effect on its business and any assumptions the combined company will make about its future taxable income. It cannot predict whether any specific proposals will be enacted, the terms of any such proposals or what effect, if any, such proposals would have on its business if they were to be enacted. For example, the United&#160;States recently enacted the IRA, which implements, among other changes, a 1% excise tax on certain stock buybacks. In addition, beginning in 2022, the Tax Act eliminates the currently available option to deduct research and development expenditures and requires taxpayers to amortize them generally over five&#160;years. The U.S.&#160;Congress is considering legislation that would restore the current deductibility of research and development expenditures, however, there is no assurance that the provision will be repealed or otherwise modified. Such changes, among others, may adversely affect its effective tax rate, results of operation and general business condition.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">The combined company&#8217;s ability to use NOL carryforwards and other tax attributes may be limited, including as a result of the Merger.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As discussed above, ARCA has incurred losses during its history, and the combined company does not expect to become profitable in the near future and may never achieve profitability. As of December&#160;31, 2023, ARCA had NOL carryforwards of approximately $208.1&#160;million, and approximately $2.4&#160;million of research and development credits that may be used to offset future taxable income. ARCA had operating loss carryforwards of $156.4&#160;million generated prior to 2018, which will expire beginning in 2025 if not utilized. Under current law, ARCA&#8217;s U.S.&#160;federal NOLs of $51.7&#160;million incurred in tax&#160;years beginning after December&#160;31, 2017 may be carried forward indefinitely, but the deductibility of such net operating loss carryforwards is limited to 80% of taxable income. It is uncertain if and to what extent various states will conform to federal law. In addition, under Sections&#160;382 and 383 of the Code, U.S.&#160;federal net operating loss carryforwards and other tax attributes may become subject to an annual limitation in the event of certain cumulative changes in ownership. An &#8220;ownership change&#8221; pursuant to Section&#160;382 of the Code generally occurs if one or more stockholders or groups of stockholders who own at least 5% of a company&#8217;s stock increase their ownership by more than 50 percentage points over their lowest ownership percentage within a rolling three<span class="nobreak">-year</span> period. The combined company&#8217;s ability to utilize its net operating loss carryforwards and other tax attributes to offset future taxable income or tax liabilities may be limited as a result of ownership changes, including, as discussed above, in connection with the Merger or other transactions. Similar rules may apply under state tax laws. If the combined company earns taxable income, such limitations could result in increased future income tax liability to the combined company, and the combined company&#8217;s future cash flows could be adversely affected.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Unfavorable global economic conditions could adversely affect the combined company&#8217;s business, financial condition, results of operations or cash flows.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The combined company&#8217;s results of operations could be adversely affected by general conditions in the global economy and in the global financial markets. A severe or prolonged economic downturn could result in a variety of risks to the combined company&#8217;s business, including, weakened demand for the combined company&#8217;s product candidates and the combined company&#8217;s ability to raise additional capital when needed on acceptable terms, if at all. A weak or declining economy could also strain the combined company&#8217;s suppliers, possibly resulting in supply disruption, or cause the combined company&#8217;s customers to delay making payments for its services. Any of the foregoing could harm the combined company&#8217;s business and the combined company cannot anticipate all of the ways in which the current economic climate and financial market conditions could adversely impact its business.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">87</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T23"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">This proxy statement/prospectus contains or incorporates statements that constitute forward<span class="nobreak">-looking</span> statements within the meaning of the federal securities laws in relation to ARCA, Oruka, the Merger and the other proposed transactions contemplated thereby. Any express or implied statements that do not relate to historical or current facts or matters are forward<span class="nobreak">-looking</span> statements. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward<span class="nobreak">-looking</span> statements. These forward<span class="nobreak">-looking</span> statements include, but are not limited to, express or implied statements regarding ARCA&#8217;s or Oruka&#8217;s expectations, hopes, beliefs, intentions or strategies regarding the future. In some cases, you can identify forward<span class="nobreak">-looking</span> statements by terminology such as &#8220;may,&#8221; &#8220;might,&#8221; &#8220;will,&#8221; &#8220;could,&#8221; &#8220;should,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;predicts,&#8221; &#8220;projects,&#8221; &#8220;seeks,&#8221; &#8220;target,&#8221; &#8220;endeavor,&#8221; &#8220;possible,&#8221; &#8220;potential,&#8221; &#8220;continue,&#8221; &#8220;contemplate&#8221; or the negative of these terms or other comparable terminology, but the absence of these words does not mean that a statement is not forward<span class="nobreak">-looking</span>. These forward<span class="nobreak">-looking</span> statements are based on current expectations and beliefs concerning future developments and their potential effects. There can be no assurance that future developments affecting ARCA, Oruka or the proposed transaction will be those that have been anticipated. These forward<span class="nobreak">-looking</span> statements involve a number of risks, uncertainties (some of which are beyond ARCA&#8217;s or Oruka&#8217;s control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward<span class="nobreak">-looking</span> statements. In addition to other factors and matters contained in or incorporated by reference in this document, ARCA and Oruka believe the following factors could cause actual results to differ materially from those discussed in the forward<span class="nobreak">-looking</span> statements:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the risk that the conditions to the closing of the Merger are not satisfied, including the failure to obtain stockholder approval required to complete the Merger and transactions contemplated thereby;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s and Oruka&#8217;s ability to meet expectations regarding the timing and completion of the Merger;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the risk that the Oruka pre<span class="nobreak">-closing</span> financing is not completed;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>uncertainties as to the timing and costs of the consummation of the Merger and the ability of each of ARCA and Oruka to consummate the Merger and the transactions contemplated thereby, including the Oruka pre<span class="nobreak">-closing</span> financing;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>statements regarding the special cash dividend that ARCA may pay to ARCA stockholders in connection with the completion of the Merger;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>risks related to ARCA&#8217;s continued listing on the Nasdaq until closing of the proposed Merger;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>expectations regarding the strategies, prospects, plans expectations and objectives of management of ARCA or Oruka for future operations of the combined company following the closing of the Merger;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the ability of the combined company to recognize the benefits that may be derived from the Merger, including the commercial or market opportunity of the product candidates of ARCA, Oruka and the combined company;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>risks related to ARCA&#8217;s and Oruka&#8217;s ability to correctly estimate their respective operating expenses and expenses associated with the transaction, uncertainties regarding the impact any delay in the closing of the Merger would have on the anticipated cash resources of the combined company upon closing and other events and unanticipated spending and costs that could reduce the combined company&#8217;s cash resources;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the accuracy of the parties&#8217; estimates regarding expenses, future revenue, capital requirements and needs for additional financing;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the occurrence of any event, change or other circumstance or condition that could give rise to the termination of the Merger Agreement;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the fact that under the terms of the Merger Agreement, ARCA and Oruka are restrained from soliciting other acquisition proposals during the pendency of the Merger, except in certain circumstances;</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">88</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the effect of the announcement or pendency of the Merger on ARCA&#8217;s or Oruka&#8217;s business relationships, operating results and business generally, including disruption of ARCA&#8217;s and Oruka&#8217;s management&#8217;s attention from ongoing business operations due to the Merger and potential adverse reactions or changes to business relationships resulting from the announcement or completion of the transaction;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the risk that the Merger Agreement may be terminated in circumstances that require ARCA or Oruka to pay a termination fee;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the outcome of any legal proceedings that may be instituted against ARCA, Oruka or any of their respective directors or officers related to the Merger Agreement or the transactions contemplated thereby;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the ability of ARCA and Oruka to protect their respective intellectual property rights;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>competitive responses to the Merger;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>legislative, regulatory, political and economic developments beyond the parties&#8217; control;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the initiation, timing and success of clinical trials for ARCA&#8217;s and Oruka&#8217;s product candidates;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>success in retaining, or changes required in, ARCA&#8217;s and Oruka&#8217;s officers, key employees or directors;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s public securities&#8217; potential liquidity and trading;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>regulatory actions with respect to ARCA&#8217;s and Oruka&#8217;s product candidates or their respective competitors&#8217; products and product candidates;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s and Oruka&#8217;s ability to manufacture their product candidates in conformity with the FDA&#8217;s requirements and to scale up manufacturing of their product candidates to commercial scale, if approved;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s and Oruka&#8217;s reliance on third<span class="nobreak">-party</span> contract development and manufacturer organizations to manufacture and supply product candidates;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the beneficial characteristics, and the potential safety, efficacy and therapeutic effects of ARCA&#8217;s and Oruka&#8217;s product candidates;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the expected potential benefits of strategic collaboration with third parties and ARCA&#8217;s and Oruka&#8217;s ability to attract collaborators with development, regulatory and commercialization expertise;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s and Oruka&#8217;s ability to successfully commercialize product candidates, if approved, and the rate and degree of market acceptance of such product candidates; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>developments and projections relating to ARCA&#8217;s and Oruka&#8217;s competitors or industry.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Should one or more of these risks or uncertainties materialize, or should any of ARCA&#8217;s or Oruka&#8217;s assumptions prove incorrect, actual results may vary in material respects from those projected in these forward<span class="nobreak">-looking</span> statements. There may be additional risks that ARCA or Oruka considers immaterial or which are unknown. You are urged to carefully review the disclosures ARCA and Oruka make concerning these risks and other factors that may affect ARCA&#8217;s and Oruka&#8217;s business and operating results under the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Risk Factors</span>&#8221; beginning on page 15 of this proxy statement/prospectus. Additional factors that could cause actual results to differ materially from those expressed in the forward<span class="nobreak">-looking</span> statements are discussed in reports filed with the SEC by ARCA and incorporated by reference herein. Please see the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Where You Can Find More Information</span>&#8221; beginning on page 320 of this proxy statement/prospectus. There can be no assurance that the Merger will be completed, or if it is completed, that it will be completed within the anticipated time period or that the expected benefits of the Merger will be realized.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">89</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If any of these risks or uncertainties materialize or any of these assumptions prove incorrect, the results of ARCA, Oruka or the combined company could differ materially from the forward<span class="nobreak">-looking</span> statements. Any public statements or disclosures by ARCA and Oruka following this proxy statement/prospectus that modify or impact any of the forward<span class="nobreak">-looking</span> statements contained in this proxy statement/prospectus will be deemed to modify or supersede such statements in this proxy statement/prospectus. You are cautioned not to place undue reliance on these forward<span class="nobreak">-looking</span> statements, which speak only as of the date of this document and are qualified in their entirety by reference to the cautionary statements herein. ARCA and Oruka do not intend, and undertake no obligation, to update any forward<span class="nobreak">-looking</span> information to reflect events or circumstances after the date of this document or to reflect the occurrence of unanticipated events, unless required by law to do so.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">90</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T22"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">THE SPECIAL MEETING IN LIEU OF ANNUAL MEETING OF ARCA STOCKHOLDERS</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Date, Time and Place</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The ARCA special meeting will be held on&#160;<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span><span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>, 2024, commencing at&#160;&#160;&#160;&#160;&#160;<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Mountain Time, unless postponed or adjourned to a later date. The ARCA special meeting will be held at&#160;&#160;&#160;&#160;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>. ARCA is sending this proxy statement/prospectus to its stockholders in connection with the solicitation of proxies by ARCA&#8217;s board of directors for use at the ARCA special meeting and any adjournments or postponements of the ARCA special meeting. This proxy statement/prospectus is first being furnished to ARCA stockholders on or about&#160;&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>, 2024.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Purpose of the ARCA Special Meeting</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The purposes of the ARCA special meeting are:</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">1.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Approve (i)&#160;the issuance of shares of ARCA common stock (including the shares of ARCA common stock issuable upon conversion of ARCA Series&#160;B Preferred Stock), which will represent more than 20% of the shares of ARCA common stock outstanding immediately prior to the Merger, to stockholders of Oruka, pursuant to the terms of the Merger Agreement, a copy of which is attached as <span class="Italic" style="font-style:italic;font-weight:normal;">Annex&#160;A</span> to this proxy statement/prospectus, and (ii)&#160;the change of control of ARCA resulting from the Merger, pursuant to Nasdaq Listing Rules 5635(a)&#160;and 5635(b), respectively (the &#8220;Nasdaq Stock Issuance Proposal&#8221; or &#8220;Proposal&#160;No. 1&#8221;);</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">2.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Approve an amendment to the amended and restated certificate of incorporation of ARCA (the &#8220;ARCA Charter&#8221;) to increase the number of shares of ARCA common stock that ARCA is authorized to issue from 100,000,000<span class="nobreak"> </span>shares to&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, in the form attached as <span class="Italic" style="font-style:italic;font-weight:normal;">Annex&#160;G</span> to this proxy statement/prospectus (the &#8220;Authorized Share Increase Proposal&#8221; or &#8220;Proposal&#160;No. 2&#8221;);</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">3.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Approve an amendment to the ARCA Charter to effect a reverse stock split of ARCA&#8217;s issued and outstanding common stock at a ratio in the range between 1:&#160;&#160;&#160;&#160;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>to 1:&#160;&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>, inclusive, in the form attached as <span class="Italic" style="font-style:italic;font-weight:normal;">Annex&#160;H </span>to this proxy statement/prospectus, if deemed necessary by ARCA and Oruka, with the final ratio and effectiveness of such amendment and the abandonment of such amendment to be mutually agreed by ARCA&#8217;s board of directors and Oruka&#8217;s board of directors prior to the First Effective Time or, if the Nasdaq Stock Issuance Proposal is not approved by ARCA stockholders, determined solely by ARCA&#8217;s board of directors (the &#8220;Reverse Stock Split Proposal&#8221; or &#8220;Proposal&#160;No. 3&#8221;);</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">4.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Approve an amendment to the ARCA Charter to reflect Delaware law provisions regarding officer exculpation, in the form attached as <span class="Italic" style="font-style:italic;font-weight:normal;">Annex&#160;I</span> (the &#8220;Officer Exculpation Proposal&#8221; or &#8220;Proposal&#160;No. 4&#8221;);</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">5.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Elect the Class&#160;III director, Jacob Ma<span class="nobreak">-Weaver</span>, to ARCA&#8217;s board of directors and to hold office until ARCA&#8217;s 2027 annual meeting of stockholders and until his successor has been duly elected and qualified, or until his earlier death, resignation or removal (the &#8220;Director Election Proposal&#8221; or &#8220;Proposal&#160;No. 5&#8221;), provided that if the Merger is consummated, the approval of Proposal&#160;No. 5 will only have an effect until the completion of the Merger because the composition of ARCA&#8217;s board of directors will be reconstituted upon completion of the Merger, in accordance with the Merger Agreement;</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">6.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Ratify the appointment of KPMG LLP as ARCA&#8217;s independent registered public accounting firm for fiscal year ending December&#160;31, 2024, provided that PricewaterhouseCoopers LLP is expected to be appointed for that fiscal year if the Merger is completed (the &#8220;Auditor Ratification Proposal&#8221; or &#8220;Proposal&#160;No. 6&#8221;);</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">7.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Approve the Oruka Therapeutics, Inc. 2024 Stock Incentive Plan (the &#8220;Stock Plan Proposal&#8221; or &#8220;Proposal&#160;No. 7&#8221;);</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">8.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Approve the Oruka Therapeutics, Inc. 2024 Employee Stock Purchase Plan (the &#8220;ESPP Proposal&#8221; or &#8220;Proposal&#160;No. 8&#8221;);</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">9.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Approve, on an advisory basis, certain compensation arrangements for ARCA named executive officers that are based on or otherwise relate to the Merger (the &#8220;the Merger Compensation Proposal&#8221; or &#8220;Proposal&#160;No. 9&#8221;);</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">91</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">10.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Approve an adjournment of the ARCA special meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of the Nasdaq Stock Issuance Proposal, the Authorized Share Increase Proposal and/or the Reverse Stock Split Proposal (the &#8220;Adjournment Proposal&#8221; or &#8220;Proposal&#160;No. 10&#8221;); and</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">11.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Transact such other business as may properly come before the stockholders at the ARCA special meeting or any adjournment or postponement thereof.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Each of Proposal&#160;No. 1 and Proposal&#160;No. 2 is a condition to completion of the Merger. The issuance of ARCA common stock, including shares of ARCA common stock issuable upon conversion of ARCA Series&#160;B Preferred Stock, and ARCA Series&#160;B Preferred Stock in connection with the Merger and the change of control of ARCA resulting from the Merger will not take place unless Proposal&#160;No. 1 and Proposal&#160;No. 2 are approved by ARCA stockholders and the Merger is consummated. The amendment to the ARCA Charter to increase the number of authorized shares of ARCA common stock will not take place unless Proposal&#160;No. 2 is approved by the requisite ARCA stockholders. The amendment to the ARCA Charter to effect a reverse stock split of ARCA&#8217;s issued and outstanding common stock will not take place unless Proposal&#160;No. 3 is approved by the requisite ARCA stockholders. ARCA&#8217;s board of directors may determine to effect the authorized share increase or the reverse stock split if one or both are approved and Proposal&#160;No. 1 is not approved by ARCA stockholders, following the special meeting.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Recommendation of ARCA&#8217;s Board of Directors</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">ARCA&#8217;s board of directors recommends that you vote:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors has determined and declared that the issuance of shares of ARCA common stock, including shares of ARCA common stock issuable upon conversion of ARCA Series&#160;B Preferred Stock, pursuant to the Merger Agreement is fair to, in the best interests of, and advisable to, ARCA and its stockholders. ARCA&#8217;s board of directors recommends that ARCA stockholder vote &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">FOR</span>&#8221;<span class="Bold" style="font-style:normal;font-weight:bold;"> </span>the approval of Nasdaq Stock Issuance Proposal as described in this proxy statement/prospectus.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors has determined and declared that it is advisable and in the best interests of ARCA and its stockholders to approve the amendment to the ARCA Charter to effect the increase in authorized shares. ARCA&#8217;s board of directors recommends that ARCA stockholder vote &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">FOR</span>&#8221; the Authorized Share Increase Proposal as described in this proxy statement/prospectus.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors has determined and declared that it is advisable and in the best interests of ARCA and its stockholders to approve the amendment to the ARCA Charter to effect the reverse stock split, if necessary. ARCA&#8217;s board of directors recommends that ARCA stockholder vote &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">FOR</span>&#8221;<span class="Bold" style="font-style:normal;font-weight:bold;"> </span>the Reverse Stock Split Proposal as described in this proxy statement/prospectus.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors has determined and believes that it is advisable to, and in the best interests of, ARCA and its stockholders to approve the amendment to the ARCA Charter to provide for the exculpation of officers, as described in this proxy statement/prospectus. ARCA&#8217;s board of directors recommends that ARCA stockholders vote &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">FOR</span>&#8221; the Officer Exculpation Proposal as described in this proxy statement/prospectus.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors has determined and believes that it is advisable to, and in the best interests of, ARCA and its stockholders to elect Jacob Ma<span class="nobreak">-Weaver</span> to serve on ARCA&#8217;s board of directors in the class of directors with terms expiring at ARCA&#8217;s 2027 annual meeting of stockholders, provided that if the Merger is consummated, the approval of Proposal&#160;No. 5 will only have an effect until the completion of the Merger because the composition of ARCA&#8217;s board of directors will be reconstituted upon completion of the Merger, in accordance with the Merger Agreement. ARCA&#8217;s board of directors that ARCA stockholders vote &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">FOR</span>&#8221;<span class="Bold" style="font-style:normal;font-weight:bold;"> </span>the director nominee named in the Director Election Proposal as described in this proxy statement/prospectus.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors has determined and believes that it is advisable to, and in the best interests of, ARCA and its stockholders to ratify the selection of KPMG LLP as ARCA&#8217;s independent registered public accounting firm for the fiscal year ending December<span class="nobreak">&#160;</span>31, 2024, provided that </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">92</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-position:inside;list-style-type:none;text-indent:0pt;margin-top:8pt;">PricewaterhouseCoopers LLP is expected to be appointed for that fiscal year if the Merger is completed. ARCA&#8217;s board of directors recommends that ARCA stockholders vote &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">FOR</span>&#8221;<span class="Bold" style="font-style:normal;font-weight:bold;"> </span>the Auditor Ratification Proposal as described in this proxy statement/prospectus.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors has determined and believes that it is advisable to, and in the best interests of, ARCA and its stockholders to approve the 2024 Stock Incentive Plan, as described in this proxy statement/prospectus. ARCA&#8217;s board of directors recommends that ARCA stockholders vote &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">FOR</span>&#8221; the Stock Plan Proposal as described in this proxy statement/prospectus.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors has determined and believes that it is advisable to, and in the best interests of, ARCA and its stockholders to approve the 2024 Employee Stock Purchase Plan, as described in this proxy statement/prospectus. ARCA&#8217;s board of directors recommends that ARCA stockholders vote &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">FOR</span>&#8221; the ESPP Proposal as described in this proxy statement/prospectus.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors has determined and believes that it is advisable to, and in the best interests of, ARCA and its stockholders to approve certain compensation arrangements for ARCA named executive officers that are based on or otherwise relate to the Merger. ARCA&#8217;s board of directors recommends that ARCA stockholders vote &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">FOR</span>&#8221; the Merger Compensation Proposal as described in this proxy statement/prospectus.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors has determined and believes that adjourning the ARCA special meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of the Nasdaq Stock Issuance Proposal, the Authorized Share Increase Proposal and/or the Reverse Stock Split Proposal is fair to, in the best interests of, and advisable to, ARCA and its stockholders and has approved and adopted the proposal. ARCA&#8217;s board of directors recommends that ARCA stockholders vote &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">FOR</span>&#8221; the Adjournment Proposal, if necessary, as described in this proxy statement/prospectus.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Record Date and Voting Power</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Only holders of record of ARCA common stock at the close of business on the Record Date of<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span><span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>, 2024, are entitled to notice of, and to vote at, the ARCA special meeting. At the close of business on the Record Date, there were&#160;&#160;&#160;&#160;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>registered holders of record of ARCA common stock and there were&#160;&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>shares of ARCA common stock issued and outstanding. Each share of ARCA common stock entitles the holder thereof to one vote on each matter submitted for stockholder approval.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Voting and Revocation of Proxies</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The proxy accompanying this proxy statement/prospectus is solicited on behalf of ARCA&#8217;s board of directors for use at the ARCA special meeting.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If, as of the Record Date referred to above, your shares were registered directly in your name with the transfer agent for ARCA common stock, Computershare Trust Company, N.A., then you are a stockholder of record. As a stockholder of record, you may vote in person at the ARCA special meeting or vote by proxy. Whether or not you plan to attend the ARCA special meeting, we urge you to vote by proxy over the telephone or on the Internet as instructed below or return the proxy card we may mail to you to ensure your vote is counted.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The procedures for voting are as follows:</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If you are a stockholder of record, you may vote at the ARCA special meeting. Alternatively, you may vote by proxy by using the accompanying proxy card, over the internet or by telephone. Whether or not you plan to attend the ARCA special meeting, ARCA encourages you to vote by proxy to ensure your vote is counted. Even if you have submitted a proxy before the ARCA special meeting, you may still attend the ARCA special meeting and vote. In such case, your previously submitted proxy will be disregarded.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>To vote in person, come to the ARCA special meeting and we will give you a ballot when you arrive. If you attend the ARCA special meeting and vote in person, your vote will revoke any proxy that you have previously submitted. Simply attending the ARCA special meeting will not, by itself, revoke your proxy.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">93</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>To vote using the proxy card, simply complete, sign and date the proxy card that you may request or that we may elect to deliver at a later time and return it promptly in the envelope provided. If you return your signed proxy card to us before the special meeting, we will vote your shares as you direct.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>You can vote by proxy over the telephone by calling the toll<span class="nobreak">-free</span> number found on the proxy card.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>You can vote by proxy over the internet by following the instructions provided on the proxy card.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If you are a beneficial owner of shares registered in the name of your broker, bank or other agent, you should have received a voting instruction card and voting instructions with these proxy materials from that organization rather than from ARCA.&#160;Simply complete and mail the voting instruction card to ensure that your vote is counted. To vote at the ARCA special meeting, you must obtain a valid proxy from your broker, bank or other agent. Follow the instructions from your broker, bank or other agent included with these proxy materials, or contact your broker, bank or other agent to request a proxy form.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA provides internet proxy voting to allow you to vote your shares online, with procedures designed to ensure the authenticity and correctness of your proxy vote instructions. However, please be aware that you must bear any costs associated with your internet access, such as usage charges from internet access providers and telephone companies.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If you hold shares beneficially in street name and do not provide your broker or other agent with voting instructions, your shares may constitute &#8220;broker non<span class="nobreak">-votes</span>.&#8221; A &#8220;broker non<span class="nobreak">-vote</span>&#8221; occurs when shares held by a broker are not voted with respect to a particular proposal because the broker has not received voting instructions from its client(s)&#160;with respect to such shares on how to vote and does not have or did not exercise discretionary authority to vote on the matter. Abstentions will be treated as shares present for the purpose of determining the presence of a quorum for the transaction of business at the ARCA special meeting. Abstentions will be counted towards the vote totals for each proposal, and will have the same effect of a vote &#8220;AGAINST&#8221; Proposal&#160;Nos.<span class="nobreak"> </span>1,<span class="nobreak"> </span>4,<span class="nobreak"> </span>6,<span class="nobreak"> </span>7,<span class="nobreak"> </span>8, 9 and 10. Broker non<span class="nobreak">-votes</span>, if any, will not be counted as &#8220;votes properly cast&#8221; or &#8220;shares entitled to vote&#8221; and will therefore have no effect on Proposal&#160;Nos.<span class="nobreak"> </span>1,<span class="nobreak"> </span>2,<span class="nobreak"> </span>3,<span class="nobreak"> </span>5,<span class="nobreak"> </span>6,<span class="nobreak"> </span>7,<span class="nobreak"> </span>8, 9 and<span class="nobreak"> </span>10, but will have the same effect of a vote &#8220;AGAINST&#8221; Proposal&#160;No. 4. If an ARCA stockholder does not return voting instructions to their broker on how to vote their shares of ARCA common stock, such broker may be prevented from voting, or may otherwise choose not to vote, such shares held by such broker, resulting in broker non<span class="nobreak">-votes</span> with respect to such shares. To make sure that your vote is counted, you should instruct your broker to vote your shares of ARCA common stock, following the procedures provided by your broker.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">All properly executed proxies that are not revoked will be voted at the ARCA special meeting and at any adjournments or postponements of the ARCA special meeting in accordance with the instructions contained in the proxy. <span class="Bold" style="font-style:normal;font-weight:bold;">If a holder of ARCA common stock executes and returns a proxy and does not specify otherwise, the shares represented by that proxy will be voted &#8220;FOR&#8221; all of the proposals in accordance with the recommendation of ARCA&#8217;s board of directors.</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Required Vote</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The presence at the ARCA special meeting of the holders of a majority of the shares of ARCA common stock outstanding and entitled to vote at the ARCA special meeting is necessary to constitute a quorum at the meeting. Abstentions and broker non<span class="nobreak">-votes</span>, if any, will be counted towards the presence of a quorum. The affirmative vote of a majority of the shares of ARCA common stock entitled to vote on the subject matter and present at the ARCA special meeting, assuming a quorum is present, is required for approval of Proposal&#160;Nos.<span class="nobreak"> </span>1,<span class="nobreak"> </span>6,<span class="nobreak"> </span>7,<span class="nobreak"> </span>8, 9 and 10. The affirmative vote of a majority of the votes properly cast by the holders of ARCA common stock at the ARCA special meeting, assuming a quorum is present, is required for approval of Proposal&#160;Nos. 2 and 3. The affirmative vote of a majority of the outstanding shares of ARCA common stock is required for approval of Proposal&#160;No. 4. With respect to Proposal&#160;No.&#160;5, directors are elected by a plurality of the votes properly cast at the ARCA special meeting, and the one nominee for director receiving the highest number of affirmative votes properly cast will be elected. Proposal&#160;No. 1 is conditioned on the approval of Proposal&#160;No. 2. Notwithstanding the approval of Proposal&#160;No.<span class="nobreak"> </span>1, if Proposal&#160;No. 2 is not approved, the actions contemplated by Proposal&#160;No. 1 will not be effected and the Merger will not be consummated.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">94</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Each of Proposal&#160;No. 1 and Proposal&#160;No. 2 is a condition to completion of the Merger. The issuance of ARCA common stock, including shares of ARCA common stock issuable upon conversion of ARCA Series&#160;B Preferred Stock, and ARCA Series&#160;B Preferred Stock in connection with the Merger and the change of control of ARCA resulting from the Merger will not take place unless Proposal&#160;No. 1 and Proposal&#160;No. 2 are approved by ARCA stockholders and the Merger is consummated. The amendment to the ARCA Charter to increase the number of authorized shares of ARCA common stock will not take place unless Proposal&#160;No. 2 is approved by the requisite ARCA stockholders. The amendment to the ARCA Charter to effect a reverse stock split of ARCA&#8217;s issued and outstanding common stock, if deemed necessary, will not take place unless Proposal&#160;No. 3 is approved by the requisite ARCA stockholders. ARCA&#8217;s board of directors may determine to effect the authorized share increase or the reverse stock split if one or both are approved and Proposal&#160;No. 1 is not approved by ARCA stockholders, following the special meeting.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Votes will be counted by the inspector of election appointed for the meeting, who will separately count &#8220;FOR,&#8221; &#8220;AGAINST&#8221; and &#8220;WITHHOLD&#8221; votes, abstentions and broker non<span class="nobreak">-votes</span>, if any, as applicable to each proposal. Abstentions and broker non<span class="nobreak">-votes</span>, if any, will be treated as shares present for the purpose of determining the presence of a quorum for the transaction of business at the ARCA special meeting. Abstentions will be counted towards the vote totals for each proposal, and will have the same effect of a vote &#8220;AGAINST&#8221; Proposal&#160;Nos.<span class="nobreak"> </span>1,<span class="nobreak"> </span>4,<span class="nobreak"> </span>6,<span class="nobreak"> </span>7,<span class="nobreak"> </span>8, 9 and 10. Broker non<span class="nobreak">-votes</span>, if any, will not be counted as &#8220;votes properly cast&#8221; or &#8220;shares entitled to vote&#8221; and will therefore have no effect on Proposal&#160;Nos.<span class="nobreak"> </span>1,<span class="nobreak"> </span>2,<span class="nobreak"> </span>3,<span class="nobreak"> </span>5,<span class="nobreak"> </span>6,<span class="nobreak"> </span>7,<span class="nobreak"> </span>8, 9 and<span class="nobreak"> </span>10, but will have the same effect of a vote &#8220;AGAINST&#8221; Proposal&#160;No. 4.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;text-indent:24pt;margin-top:8pt;">As of<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span><span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>, 2024, the directors and executive officers of ARCA owned or controlled&#160;&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>% of the outstanding shares of ARCA common stock entitled to vote at the ARCA special meeting. As of May<span class="nobreak"> </span>3, 2024, the ARCA stockholders that are party to a support agreement, including the directors, executive officers and certain stockholders of ARCA, owned an aggregate number of shares of ARCA common stock representing approximately 28.5% of the outstanding shares of ARCA common stock. Each stockholder that entered into a support agreement, including the directors and executive officers of ARCA, has agreed to vote all shares of ARCA common stock owned by him or her as of the Record Date in favor of the adoption of the Merger Agreement and the transactions contemplated thereby, including the Merger, the issuance of ARCA common stock, including shares of ARCA common stock issuable upon conversion of ARCA Series&#160;B Preferred Stock, to the stockholders of Oruka pursuant to the Merger Agreement and the change of control resulting from the First Merger, and against any alternative acquisition proposals.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Solicitation of Proxies</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition to solicitation by mail, the directors, officers, employees and agent of ARCA may solicit proxies from ARCA stockholders by personal interview, telephone, email, fax or otherwise. ARCA and Oruka will share equally the costs of printing and filing this proxy statement/prospectus and proxy card. Arrangements will also be made with brokerage firms and other custodians, nominees and fiduciaries who are record holders of ARCA common stock for the forwarding of solicitation materials to the beneficial owners of ARCA common stock. ARCA will reimburse these brokers, custodians, nominees and fiduciaries for the reasonable out of pocket expenses they incur in connection with the forwarding of solicitation materials. ARCA has retained<span style="width: 10px;display: inline-block;">&#160;&#160;&#160;</span><span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Other Matters</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of the date of this proxy statement/prospectus, ARCA&#8217;s board of directors does not know of any business to be presented at the ARCA special meeting other than as set forth in the notice accompanying this proxy statement/prospectus. If any other matters should properly come before the ARCA special meeting, it is intended that the shares represented by proxies will be voted with respect to such matters in accordance with the judgment of the persons voting the proxies.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">95</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T991188"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">THE MERGER</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">This section and the section titled &#8220;The Merger Agreement&#8221; beginning on page 135 of this proxy statement/prospectus describe the material aspects of the Merger and the Merger Agreement. While ARCA and Oruka believe that this description covers the material terms of the Merger and the Merger Agreement, it may not contain all of the information that is important to you. You should read carefully this entire proxy statement/prospectus for a more complete understanding of the Merger and the Merger Agreement and the other documents to which you are referred in this proxy statement/prospectus. See the section titled &#8220;Where You Can Find More Information&#8221; beginning on page 320 of this proxy statement/prospectus.</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Background of the Merger</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">ARCA&#8217;s board of directors and management regularly review ARCA&#8217;s operating and strategic plans in an effort to enhance stockholder value. This review involves, among other things, discussions of opportunities and risks associated with ARCA&#8217;s product candidates, development programs, financial condition and market, as well as a consideration of strategic alternatives available to ARCA.&#160;On March&#160;28, 2022, members of ARCA&#8217;s board of directors and management reviewed the results of ARCA&#8217;s Phase&#160;2 clinical trial of Recombinant Nematode Anticoagulant Protein c2, or rNAPc2 (AB201) (the &#8220;Clinical Trial&#8221;). The results of the Clinical Trial indicated that neither studied dose of rNAPc2 achieved statistical significance for the primary efficacy endpoint.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">In light of these results, ARCA&#8217;s board of directors initiated a process to identify and evaluate strategic alternatives available to ARCA that ultimately resulted in the execution of the Merger Agreement. The following is a summary of the background of the process undertaken by ARCA, the identification and evaluation of strategic alternatives and the negotiation of the Merger Agreement.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">On March&#160;28, 2022, ARCA&#8217;s board of directors held video conference meetings with members of ARCA&#8217;s management and a representative of its legal advisor, Cooley LLP (&#8220;Cooley&#8221;) in attendance, to review the Clinical Trial results. ARCA&#8217;s board of directors discussed strategic alternatives available to ARCA in light of the negative Clinical Trial results, including continuation of the development of ARCA&#8217;s current products, possible licensing opportunities or a sale of ARCA.&#160;Following this meeting, Mr.&#160;Conway, Chairman of ARCA&#8217;s board of directors, instructed management to provide ARCA&#8217;s board of directors with management&#8217;s assessment of the viability of continuing to develop ARCA&#8217;s current products in light of the negative Clinical Trial results.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">On March&#160;29, 2022, ARCA&#8217;s board of directors held a video conference meeting with members of ARCA&#8217;s management and a representative of Cooley in attendance to discuss a proposed product development plan prepared by ARCA&#8217;s management which included a plan to conduct a Phase&#160;3 trial for ARCA&#8217;s Gencaro product in patients with higher ejection fraction heart failure. ARCA&#8217;s board of directors instructed management to further refine ARCA&#8217;s product development plan and to explore other potential strategic alternatives to the product development plan available to ARCA.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">Following the close of markets on March&#160;31, 2022, ARCA publicly announced the Clinical Trial results.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">On April&#160;10, 2022, ARCA&#8217;s board of directors held a video conference meeting with members of ARCA&#8217;s management and a representative of Cooley in attendance to discuss a refined product development plan prepared by ARCA&#8217;s management and the strategic alternatives to that development plan including a sale of ARCA or other strategic transaction.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">Later that same&#160;day, ARCA&#8217;s board of directors held a video conference meeting without members of ARCA&#8217;s management or representatives of Cooley in attendance. ARCA&#8217;s board of directors discussed ARCA&#8217;s prospects as a stand<span class="nobreak">-alone</span> company pursuant to the refined product development plan presented by ARCA&#8217;s management earlier that same&#160;day, and the potential strategic alternatives thereto that were available to ARCA including a broad outreach to potential reverse merger counterparties or a liquidation of ARCA.&#160;It was the consensus of ARCA&#8217;s board of directors that in light of the negative Clinical Trial results, ARCA should explore and evaluate its strategic alternatives while continuing to evaluate its ability to continue on as a stand<span class="nobreak">-alone</span> enterprise. ARCA&#8217;s board of directors discussed the evaluation and retention of a financial advisor to assist ARCA&#8217;s board of directors in its exploration and evaluation of strategic alternatives.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">On April&#160;17, 2022, ARCA&#8217;s board of directors held a video conference meeting with members of ARCA&#8217;s management and a representative of Cooley in attendance. ARCA&#8217;s board of directors discussed the formation of a special committee of ARCA&#8217;s  board of directors (the &#8220;Special Committee&#8221;) for the purpose of identifying, </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">96</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;text-indent:0pt;margin-top:7pt;">considering, evaluating and making recommendations to ARCA&#8217;s board of directors regarding potential strategic alternatives. ARCA&#8217;s board of directors approved the formation the Special Committee and appointed Mr.&#160;Conway, Dr.&#160;Hove and Dr.&#160;Grais to serve on the Special Committee, with Mr.&#160;Conway serving as chair. The Special Committee was not formed for the purposes of addressing potential or actual conflicts of interest of any director or officer of ARCA.&#160;ARCA&#8217;s board of directors delegated to the Special Committee the full power and authority of ARCA&#8217;s board of directors to, among other things, identify, consider, evaluate and make recommendations to ARCA&#8217;s board of directors regarding potential strategic alternatives and proposals which may be available to ARCA and further resolved to not approve any transaction unless the Special Committee had recommended that ARCA&#8217;s board of directors approve such a transaction. It was also discussed and concluded that: (1)&#160;ARCA&#8217;s board of directors would continue to have an active role in (i)&#160;the evaluation of any acquisition proposal, (ii)&#160;any discussions with potential acquirers with respect to a potential strategic transaction and (iii)&#160;any broader review of strategic alternatives; (2)&#160;the Special Committee would update and seek input from ARCA&#8217;s board of directors as appropriate; and (3)&#160;members of ARCA&#8217;s board of directors who were not also members of the Special Committee would be invited to attend the meetings of the Special Committee. ARCA&#8217;s board of directors also discussed potential candidates to act as financial advisor to ARCA in connection with a potential strategic transaction and directed the Special Committee to interview potential candidates and engage a financial advisor in connection with a strategic transaction.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">On April&#160;18, 2022, ARCA publicly announced its initiation of a process to evaluate strategic options for maximizing stockholder value and the establishment of the Special Committee to assist in the pursuit of such a transaction.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">Between April&#160;25, 2022, and April&#160;29, 2022, the Special Committee, and members of ARCA&#8217;s management team met with representatives from five investment banking firms telephonically to assess their ability to act as ARCA&#8217;s financial advisor in connection with a review of potential strategic alternatives.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">On May&#160;2, 2022, the Special Committee held a video conference meeting with members of ARCA&#8217;s management team in attendance. The Special Committee discussed the qualifications of the financial advisors it had interviewed. After consideration of the relative qualifications and expertise of the candidates, including industry expertise, knowledge, access to potential transaction candidates, and recent transaction experience, the Special Committee approved the selection of Ladenburg Thalmann&#160;&amp; Co., Inc. (&#8220;Ladenburg&#8221;) as ARCA&#8217;s financial advisor to assist ARCA in its review of potential strategic alternatives and authorized and directed ARCA&#8217;s management to negotiate an engagement letter with Ladenburg. The Special Committee also determined that Ladenburg&#8217;s outreach should be focused on identifying potential reverse merger transaction candidates because the Special Committee believed such a transaction had the highest likelihood of presenting the highest value for stockholders in light of (i)&#160;the value that would be ascribed to ARCA&#8217;s public listing in such a transaction which would not be taken into account in a traditional merger or other similar strategic transaction and (ii)&#160;ARCA&#8217;s limited non<span class="nobreak">-cash</span> assets.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">On May&#160;4, 2022, ARCA&#8217;s board of directors held a video conference meeting with members of ARCA&#8217;s management and a representative of Cooley in attendance. ARCA&#8217;s board of directors reviewed the qualifications of the potential candidates to serve as ARCA&#8217;s financial advisor, the terms of the proposed engagement letter with Ladenburg and the Special Committee&#8217;s recommendation to appoint Ladenburg as ARCA&#8217;s financial advisor. ARCA&#8217;s board of directors approved the engagement of Ladenburg and authorized ARCA&#8217;s management to enter into an engagement letter in substantially the form presented to ARCA&#8217;s board of directors, which ARCA&#8217;s management executed later that same day.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">On May&#160;5, 2022, ARCA publicly announced it had retained Ladenburg to act as its financial advisor to explore and review a range of strategic alternatives focused on maximizing stockholder value including an acquisition, merger, business combination or other strategic transaction involving ARCA.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">On May&#160;6, 2022, the Special Committee held a video conference meeting with members of ARCA&#8217;s management team, and representatives of Cooley and Ladenburg in attendance. At this meeting, Ladenburg reviewed the process it proposed to undertake in order to identify and evaluate potential strategic alternatives and over 250 potential counterparties that it believed may be interested in pursuing a reverse merger transaction with ARCA.&#160;The Special Committee discussed the anticipated timeline for contacting and receiving and evaluating proposals from interested parties in connection with a strategic transaction. Ladenburg also reviewed its proposed selection criteria to be used by the Special Committee in identifying and evaluating potential counterparties. This criteria included an evaluation of (i)&#160;the quality of the assets owned by the potential counterparty, (ii)&#160;whether the potential counterparty had clear, proof of concept clinic data, (iii)&#160;the development stage of the potential counterparty, (iv)&#160;the </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">97</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;text-indent:0pt;margin-top:7pt;">counterparty&#8217;s product pipeline, (v)&#160;whether the counterparty was pursuing a concurrent private placement financing in order to ensure the counterparty had sufficient cash resources to reach the upcoming milestones with respect to the counterparty&#8217;s product candidates, (vi)&#160;the quality of the potential investors that would participate in such a concurrent financing, (vii)&#160;the amount of cash from ARCA required by the potential counterparty and the amount of cash ARCA would be able to distribute to its stockholders in a special dividend immediately prior to the closing of a transaction, (viii)&#160;the industry within which the counterparty was engaged, (ix)&#160;whether the counterparty was willing to ascribe any value to ARCA&#8217;s products in the proposed transaction, (x)&#160;whether the counterparty was expected to have value inflection points within 18&#160;months, (xi)&#160;the capital structure of the counterparty, (xii)&#160;whether the counterparty had sufficient infrastructure to maintain ARCA&#8217;s public listing or the ability to maintain such infrastructure, including whether the counterparty had financial statements sufficient to satisfy public company reporting standards, and (xiii)&#160;whether the relative valuations ascribed to ARCA and the potential counterparty in light of the foregoing factors was fair. Ladenburg also proposed limiting outreach efforts to companies in the pharmaceutical and biotechnology industry in light of ARCA&#8217;s enhanced ability to evaluate and assess the products, and related operational, industry, regulatory, financial, market and other risks and opportunities, of companies within those particular industries. Following a discussion, the Special Committee authorized Ladenburg to begin outreach to all of the potential counterparties presented by Ladenburg and adopted the proposed criteria for purposes of evaluating potential offers.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Beginning on May&#160;6, 2022, Ladenburg conducted a process of identifying and evaluating potential counterparties for a strategic transaction with assistance from the Special Committee and members of ARCA&#8217;s management. In its outreach efforts, members of ARCA&#8217;s board of directors, ARCA&#8217;s management, and representatives of Ladenburg, contacted over 250 companies that met the criteria adopted by the Special Committee.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">From May&#160;6, 2022 until June&#160;15, 2022, ARCA delivered bid process letters to 74 companies, received a total of 50 formal non<span class="nobreak">-binding</span> proposals (all of which were for reverse merger styled transactions) and entered into 37&#160;non<span class="nobreak">-disclosure</span> agreements to facilitate further diligence with potential counterparties which also contained a customary &#8220;standstill&#8221; restriction that would terminate upon entry into a definitive agreement for an acquisition of more than 50% of the shares of capital stock of ARCA. During that same period, the Special Committee, members of ARCA&#8217;s management and outside advisors met numerous times to consider the various non<span class="nobreak">-binding</span> proposals, and to receive updates regarding the solicitation and evaluation of the proposals. The Special Committee determined not to pursue 48 of the 50 non<span class="nobreak">-binding</span> proposals that were submitted due to, among other reasons, the failure of those potential counterparties to adequately satisfy many of the criteria adopted by the Special Committee. Of the two non<span class="nobreak">-binding</span> proposals that the Special Committee determined to pursue, the Special Committee determined to abandon one in June&#160;2022 in light of that counterparty&#8217;s early stage of development (Phase 1/Phase 2 clinical trial for its lead product candidate) and its need for all of ARCA&#8217;s cash to fund its operations. The other counterparty informed the Special Committee in December&#160;2022 that it was no longer interested in pursuing a transaction.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On June&#160;15, 2022, ARCA entered into a Cooperation Agreement with Cable Car Capital LLC, The Funicular Fund, LP, Funicular Funds, LP and Jacob Ma<span class="nobreak">-Weaver</span>. Pursuant to the Cooperation Agreement, ARCA&#8217;s board of directors appointed Jacob Ma<span class="nobreak">-Weaver</span> as a Class&#160;III director with a term expiring at ARCA&#8217;s 2024 annual meeting of stockholders, effective June&#160;15, 2022, and appointed Mr.&#160;Ma<span class="nobreak">-Weaver</span> to the Special Committee.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">From June&#160;15, 2022 until December&#160;15, 2022, at the direction of the Special Committee, ARCA&#8217;s management engaged third<span class="nobreak">-party</span> experts to examine and evaluate its ability to further develop Gencaro as a stand<span class="nobreak">-alone</span> enterprise and prepared an analysis of the potential value of ARCA&#8217;s assets in a liquidation.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On December&#160;15, 2022, ARCA&#8217;s board of directors held a video conference meeting with members of ARCA&#8217;s management and representatives of Wilson Sonsini Goodrich &amp; Rosati, P.C. (&#8220;Wilson Sonsini&#8221;) (who at such point had been engaged as ARCA&#8217;s counsel) and Ladenburg in attendance to discuss the strategic alternatives available to ARCA including having Ladenburg undertake a renewed search for new strategic transaction counterparties, pursuing a liquidation or continuing to pursue ARCA&#8217;s development plans as a stand<span class="nobreak">-alone</span> enterprise. The Special Committee determined that continuing to pursue potential strategic transactions was reasonably likely to result in a superior alternative to a liquidation and ARCA&#8217;s development plan as a stand<span class="nobreak">-alone</span> enterprise and as a result authorized and directed Ladenburg to re<span class="nobreak">-engage</span> with potential counterparties. As part of that authorization, it directed Ladenburg to broaden the scope of potential counterparties to include companies outside the pharmaceutical and biotechnology industry in order to evaluate all possible alternatives available to ARCA and determined to further refine its selection criteria to favor companies with later stage assets and/or near<span class="nobreak">-term</span> revenue as well as companies that did not require all of ARCA&#8217;s cash in order to achieve its key milestones to ensure a significant dividend of its </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">98</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">cash assets could be made as part of any such transaction. In addition, the Special Committee also determined that ARCA&#8217;s management should continue to further refine and pursue its development plan as a potential alternative if a compelling counterparty for a strategic transaction was not able to be found.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">From December&#160;15, 2022, until January&#160;5, 2023, the Special Committee and representatives of Ladenburg met on multiple occasions to review eleven potential counterparties for a strategic transaction in light of ARCA&#8217;s board of directors&#8217; revised selection criteria and ultimately refined the number of potential counterparties down to three potential counterparties that presented a reasonable likelihood of resulting in a superior alternative to the strategic alternatives the Special Committee was considering including a liquidation of ARCA or the continuation of its business as a standalone enterprise. ARCA and these three potential counterparties entered into non<span class="nobreak">-disclosure</span> agreements to facilitate their discussions which contained a customary &#8220;standstill&#8221; restriction that would terminate upon entry into a definitive agreement for an acquisition of more than 50% of the shares of capital stock of ARCA.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">From January&#160;5, 2023, until January&#160;20, 2023, the Special Committee, members of ARCA&#8217;s management and representatives of Ladenburg met with and reviewed presentations prepared by the three potential counterparties selected by the Special Committee. Following the presentations, the Special Committee determined that a potential transaction with Party A was the most attractive because (i)&#160;it had a promising late stage asset that was expected to reach near term value inflection points along with a promising early stage product candidate and (ii)&#160;it did not require all of ARCA&#8217;s cash to fund its operations. While it did not abandon the other two potential counterparties, the Special Committee focused its efforts on engaging with Party A in light of the attractiveness of that counterparty when compared to the other two potential counterparties.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">On January&#160;26, 2023, members of ARCA&#8217;s management and representatives of Ladenburg were given access to a virtual data room hosted by Party A.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">From January&#160;26, 2023, until March&#160;10, 2023, ARCA&#8217;s management and representatives of Ladenburg undertook an extensive preliminary due diligence review of Party A and engaged numerous advisors to assist ARCA in its due diligence review.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">On March&#160;10, 2023, at the direction of the Special Committee, representatives of Ladenburg delivered a draft term sheet to Party A providing for a reverse merger transaction and which ascribed an enterprise value to ARCA in the merger of $10,000,000 and an enterprise value to Party A of $75,000,000.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">From March&#160;10, 2023, until May&#160;30, 2023, the Special Committee and representatives of Party A met multiple times to negotiate the substantive economic terms of a potential reverse merger transaction including the size and type of investor for a private placement transaction contemplated to close substantially concurrently with the closing of a reverse merger transaction and the relative valuations to be ascribed to each party.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">On May&#160;30, 2023, the Special Committee held a video conference meeting with members of ARCA&#8217;s management team, and representatives of Wilson Sonsini and Ladenburg in attendance to discuss the final terms of the term sheet negotiated with Party A, which provided for a reverse merger transaction ascribing a $11,000,000 enterprise valuation to ARCA and a $60,000,000 enterprise valuation to Party A.&#160;The term sheet also, among other things, allowed ARCA to distribute to its pre<span class="nobreak">-closing</span> stockholders all of ARCA&#8217;s net cash in excess of $21,000,000 and gave ARCA&#8217;s stockholders a contingent value right representing the right to receive net proceeds of any sale of ARCA&#8217;s legacy product candidates. The term sheet also obligated each party to exclusively negotiate a transaction with one another. The Special Committee determined that it should continue to pursue a transaction with Party A on an exclusive basis in light of (i)&#160;the Special Committee&#8217;s view that each of (A)&#160;pursuing ARCA&#8217;s corporate objectives on a stand<span class="nobreak">-alone</span> basis, including the proposed development plan and (B)&#160;the liquidation of ARCA, was not reasonably likely to result in superior value to ARCA&#8217;s stockholders when compared to the proposed transaction; (ii)&#160;the Special Committee&#8217;s view that the $11&#160;million enterprise value ascribed to ARCA would give ARCA&#8217;s stockholders a significant opportunity to participate in the potential growth of the combined company following the Merger at the negotiated exchange ratio while also receiving a cash payment on account of the special cash dividend; (iii)&#160;the Special Committee&#8217;s view that the combined company was likely to possess sufficient cash resources at the closing of the Merger to fund development of Party A&#8217;s product candidates through upcoming value inflection points; (iv)&#160;ARCA&#8217;s positive preliminary due diligence performed to date and the recommendations of its advisors with respect to the viability of Party A&#8217;s assets and (v)&#160;the Special Committee&#8217;s view that the proposal from Party A was more favorable to ARCA than the potential value that might have resulted from further pursuing other strategic transactions available to ARCA in light of the extensive outreach process undertaken to date. As a result of that determination, the Special Committee authorized and directed ARCA&#8217;s management to execute and deliver the term sheet to Party A and began exclusively negotiating a potential reverse merger transaction with Party A.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">99</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Later that same day, ARCA and Party A executed the non<span class="nobreak">-binding</span> term sheet and representatives of ARCA, Party A, and each of their respective legal and financial advisors participated in a video conference meeting during which the timeline and process for the signing of definitive agreements providing for a potential business combination were discussed, including the signing of definitive agreements for a private placement in ARCA that was contemplated to close concurrently with the business combination. The participants tentatively agreed on a work plan that contemplated the execution of definitive agreements in late June or early July&#160;2023.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Between May&#160;30, 2023, and July&#160;20, 2023, representatives of ARCA and Party A engaged in exclusive negotiations regarding a potential reverse merger and conducted detailed due diligence reviews of one another.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On July&#160;20, 2023, Party A informed ARCA that its product approval had been delayed due to a request for additional information by the Office of New Drugs at the FDA.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Between July&#160;20, 2023, and August&#160;25, 2023, the Special Committee, Party A, and each of their respective legal and financial advisors participated in numerous video conference meetings to discuss the current status of Party A&#8217;s drug approval with the Office of New Drugs at the FDA.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">During that same period, the Special Committee met with members of ARCA&#8217;s management, and representatives of Wilson Sonsini and Ladenburg to review the status of Party A&#8217;s application with the Office of New Drugs at the FDA and discussed the other strategic alternatives available to ARCA if Party A&#8217;s approval continued to be delayed.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On August&#160;25, 2023, the Special Committee determined that it was no longer viable to continue to exclusively pursue a transaction with Party A in light of Party A&#8217;s ongoing financing challenges, regulatory difficulties, increased expenditures and the Special Committees determination that Party A would not be able to successfully market or obtain commitments for the private placement investment contemplated by the term sheet in light of the foregoing. On that same&#160;day, ARCA allowed its obligation to exclusively negotiate with Party A lapse without extension.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">From August&#160;25, 2023, until December&#160;7, 2023, the Special Committee continued to participate in numerous video conference meetings to discuss the current status of Party A&#8217;s drug approval with the Office of New Drugs at the FDA.&#160;At each of these meetings, Party A stated that regulatory approval was imminent.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">During this same period, the Special Committee conducted video conference meetings with members of ARCA&#8217;s management team, and representatives of Wilson Sonsini and Ladenburg in attendance to discuss the strategic alternatives available to ARCA if Party A&#8217;s regulatory approval continued to be delayed including a renewed search by Ladenburg for potential reverse merger partners or a liquidation of ARCA.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On December<span class="nobreak"> </span>7, 2023, Mr.<span class="nobreak"> </span>Ma<span class="nobreak">-Weaver</span> called Mr.<span class="nobreak"> </span>Conway and verbally proposed a potential partial tender offer for 50.1% of the shares of ARCA&#8217;s capital stock at a price per share range of $1.95 to $2.05 to be led by a stockholder affiliated with Mr.<span class="nobreak"> </span>Ma<span class="nobreak">-Weaver</span>.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Later that same day, the Special Committee conducted a video conference meeting (without Mr.<span class="nobreak"> </span>Ma<span class="nobreak">-Weaver</span> attending) with members of ARCA&#8217;s management team, and representatives of Wilson Sonsini and Ladenburg in attendance. The Special Committee further discussed the strategic alternatives available to ARCA including the proposal made by Mr.<span class="nobreak"> </span>Ma<span class="nobreak">-Weaver</span> earlier that day. The Special Committee discussed the proposal and noted that the proposal was unlikely to be attractive in light of (i)&#160;the fact that ARCA stockholders were expected to receive approximately $2.25 per share in cash if ARCA liquidated at that time based on the previous liquidation analysis prepared by ARCA&#8217;s management in June&#160;2022 and (ii)&#160;the outcomes that the Special Committee expected it could achieve in a potential strategic transaction. The Special Committee authorized Mr.&#160;Conway to continue conversations with Mr.&#160;Ma<span class="nobreak">-Weaver</span> regarding a potential tender offer in order to see if negotiations with Mr.&#160;Ma<span class="nobreak">-Weaver</span> could eventually result in a price per share that presented a superior alternative to the various strategic alternatives the Special Committee was considering and instructed ARCA&#8217;s management to prepare an updated liquidation analysis.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">From December&#160;7, 2023, until January&#160;12, 2024, the Special Committee (without Mr.&#160;Ma<span class="nobreak">-Weaver</span> attending), conducted numerous video conference meetings to discuss the strategic alternatives available to ARCA which included, a liquidation of ARCA, a renewed search by Ladenburg for potential reverse merger partners, and a tender offer by the stockholder affiliated with Mr.&#160;Ma<span class="nobreak">-Weaver</span>.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">During that same period, Mr.&#160;Conway and Mr.&#160;Ma<span class="nobreak">-Weaver</span> met multiple times to discuss and negotiate a potential tender offer by the stockholder affiliated with Mr.&#160;Ma<span class="nobreak">-Weaver</span>.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">100</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">During that same period, on December&#160;12, 2023, the Nominating and Corporate Governance Committee of ARCA&#8217;s board of directors met to discuss, among other matters, the compensation that should be paid to each of the directors serving as members of the Special Committee in light of the prolonged strategic process that the committee had undertaken and the extensive work that the Committee had performed and was expected to continue to perform. The Nominating and Corporate Governance Committee of ARCA&#8217;s board of directors determined that each member of the Special Committee would be entitled to $7,500 for each month of substantive service on the Special Committee that each such member had previously performed and would perform going forward.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On January&#160;12, 2024, the Special Committee conducted a video conference meeting with members of ARCA&#8217;s management team, and representatives of Wilson Sonsini and Ladenburg in attendance to discuss the strategic alternatives ARCA had been considering. At this meeting representatives of Ladenburg delivered a presentation comparing the potential value to ARCA&#8217;s stockholders that would result from a traditional merger, a reverse merger, a partial tender offer, or a liquidation. The Special Committee also reviewed a presentation prepared by ARCA&#8217;s management comparing the tender offer proposal made by Mr.&#160;Ma<span class="nobreak">-Weaver</span> on December<span class="nobreak"> </span>7, 2023 to the liquidation analysis that it had prepared which showed a potential value of $2.04 per share to stockholders in a liquidation. For more information regarding the liquidation analysis including the key assumptions therein, please see the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">The Merger &#8212; ARCA Liquidation Analysis</span>,&#8221; beginning on page 108 of this proxy statement/prospectus. Following those presentations, Mr.<span class="nobreak"> </span>Ma<span class="nobreak">-Weaver</span> left the meeting. The Special Committee then discussed the presentations and determined that pursuing a tender offer at the price per share offered by Mr.&#160;Ma<span class="nobreak">-Weaver</span> did not have a reasonable likelihood of resulting in a superior alternative when compared to the other strategic alternatives available to ARCA.&#160;In light of that determination, and the continuing delay of regulatory approvals for Party A, the Special Committee directed Ladenburg to renew its search for potential reverse merger partners and to focus its outreach on companies that did not require a material amount of cash to remain on ARCA&#8217;s balance sheet after the closing of a transaction. The Special Committee further instructed Mr.&#160;Conway to continue negotiating the terms and conditions of a potential tender offer by the stockholder affiliated with Mr.&#160;Ma<span class="nobreak">-Weaver</span> in parallel with Ladenburg&#8217;s renewed search and ARCA&#8217;s continued discussions with Party A.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">From January&#160;12, 2024, until February&#160;26, 2024, Ladenburg renewed its search for a potential counterparty in line with the Special Committee&#8217;s revised criteria and received non<span class="nobreak">-binding</span> proposals from eight potential counterparties interested in a reverse merger transaction.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">During that same period, Mr.&#160;Conway continued his discussions with Mr.&#160;Ma<span class="nobreak">-Weaver</span> regarding a potential tender offer and the Special Committee met multiple times to discuss the status of those discussions, and the other strategic alternatives the Special Committee was considering.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On February<span class="nobreak"> </span>15, 2024, the Special Committee (without Mr.&#160;Ma<span class="nobreak">-Weaver</span> attending) conducted a video conference meeting with members of ARCA&#8217;s management team, and representatives of Wilson Sonsini attending. As a result of the negotiations that Mr.<span class="nobreak"> </span>Conway and Mr.<span class="nobreak"> </span>Ma<span class="nobreak">-Weaver</span> had been engaging in, Mr.<span class="nobreak"> </span>Ma<span class="nobreak">-Weaver</span> increased his verbal offer to a price per share of $2.25 for 50.1% of the shares of ARCA&#8217;s capital stock. Mr.<span class="nobreak"> </span>Ma<span class="nobreak">-Weaver</span> then left the meeting. The Special Committee discussed Mr.&#160;Ma<span class="nobreak">-Weaver</span>&#8217;s offer of $2.25 per share and determined that while the price per share was higher than the most recent liquidation analysis presented at the January&#160;12, 2024, meeting, the offer was still not reasonably likely to result in a superior alternative when compared to the other strategic alternatives available to ARCA, including a reverse merger transaction which was expected to provide ARCA&#8217;s stockholders additional value for ARCA&#8217;s public listing. Mr.<span class="nobreak"> </span>Ma<span class="nobreak">-Weaver</span> then rejoined the meeting and the Special Committee informed him that his offer was not compelling in light of the other strategic alternatives available to ARCA, and that the stockholder affiliated with Mr.<span class="nobreak"> </span>Ma<span class="nobreak">-Weaver</span> needed to increase its proposal to a price of at least $2.50 per share for 100% of the shares of ARCA&#8217;s capital stock. The Special Committee directed Mr.&#160;Conway to continue negotiations with the stockholder affiliated with Mr.&#160;Ma<span class="nobreak">-Weaver</span>.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">From February<span class="nobreak"> </span>15, 2024, until February&#160;23, 2024, Mr.&#160;Conway and Mr.&#160;Ma<span class="nobreak">-Weaver</span> met multiple times to continue to discuss the potential tender offer. On February&#160;23, 2024, Mr.&#160;Ma<span class="nobreak">-Weaver</span> informed the Special Committee that the stockholder affiliated with Mr.&#160;Ma<span class="nobreak">-Weaver</span> was no longer interested in pursuing a tender offer.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On February&#160;26, 2024, the Special Committee conducted a video conference meeting with representatives of Ladenburg to review, discuss and evaluate the eight non<span class="nobreak">-binding</span> proposals it had received to date as a result of Ladenburg&#8217;s renewed outreach. The Special Committee determined that Oruka was a counterparty that merited serious consideration because (i)&#160;it required the least amount of ARCA&#8217;s cash and would therefore permit ARCA to distribute the largest amount of cash to its stockholders, (ii)&#160;the company was backed by a reputable investor </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">101</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">with a history of successful reverse merger transactions and (iii)&#160;the company already had informal commitments for a substantial private placement investment that was contemplated to close concurrently with the closing of the Merger. As a result, the Special Committee focused its efforts on pursing a transaction with Oruka while continuing to discuss a potential transaction with two of the other potential counterparties that had submitted non<span class="nobreak">-binding</span> proposals in case a transaction with Oruka did not come to fruition. The Special Committee determined that the remaining five non<span class="nobreak">-binding</span> proposals that had been submitted were not compelling in light of the quality of the counterparties&#8217; assets, the substantial cash needs of the potential counterparties, and the valuations sought by the potential counterparties.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On February&#160;28, 2024, the Special Committee conducted a video conference meeting with representatives of Ladenburg and Oruka in attendance to discuss Oruka&#8217;s fitness as a strategic transaction partner.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Later that same&#160;day, at the direction of the Special Committee, representatives of Ladenburg delivered a draft term sheet to representatives of Wedbush Securities Inc. (&#8220;Wedbush&#8221;), Oruka&#8217;s financial advisor, which proposed a reverse merger transaction ascribing a $10,000,000 enterprise valuation to ARCA and a $175,000,000 enterprise valuation of Oruka (which would be reduced to the extent the price per share in the proposed private placement financing ascribed a value to Oruka of less than $175,000,000) and setting forth certain other material terms including (1)&#160;the minimum investment amount to be received by Oruka as a result of a private placement transaction investment to close substantially concurrent with the business combination; (2)&#160;conditions to execution of any definitive agreement, (3)&#160;conditions to the closing of the business combination transaction; (4)&#160;the ability of ARCA to distribute any net cash in excess of $5,000,000 to the pre<span class="nobreak">-Merger</span> stockholders of ARCA; and (5)&#160;the exclusivity period.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On February&#160;28, 2024 and February&#160;29, 2024, the Special Committee conducted video conference meetings with representatives of Ladenburg and the other two counterparties that it was considering in attendance to discuss each counterparty&#8217;s value as a strategic transaction partner.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On February&#160;29, 2024, representatives of Wedbush delivered a revised term sheet to Ladenburg which ascribed a $6,000,000 enterprise valuation to ARCA and included proposed changes to a number of the other legal terms.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Later that same&#160;day, Mr.&#160;Conway spoke with representatives of Oruka and proposed an ascribed enterprise value of $7,500,000. Representatives of Oruka informed Mr.&#160;Conway that it was not willing to pursue a transaction at an ascribed enterprise value over $6,000,000.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Later that same&#160;day, the Special Committee held a video conference meeting with members of ARCA&#8217;s management and representatives of Wilson Sonsini and Ladenburg in attendance to discuss the revised proposal received by Oruka. The Special Committee determined that the revised proposal represented a promising strategic alternative that was worth pursuing on an exclusive basis in light of: (i)&#160;the Special Committee&#8217;s view that ARCA was not likely to accomplish its corporate objectives on a stand<span class="nobreak">-alone</span> basis in light of its financial condition and product candidates; (ii)&#160;the Special Committee&#8217;s view that the $6,000,000 enterprise value ascribed to ARCA was within the range of values ascribed in other recent reverse merger transactions (for more information regarding the range of values ascribed to recent reverse merger transactions, please see the section titled &#8220;The Merger &#8212; Opinion of Lucid &#8212; Analysis of precedent Reverse Merger Transactions,&#8221; beginning on page 118 of this proxy statement/prospectus) and would give ARCA&#8217;s stockholders a significant opportunity to participate in the potential growth of the combined company following the Merger at the negotiated exchange ratio while also receiving an immediate cash payment on account of the special cash dividend ARCA would be permitted to make; (iii)&#160;the fact that the $175,000,000 enterprise value ascribed to Oruka would be validated by independent third parties in the private placement investment and that any reduction in the valuation ascribed to Oruka by such investors would also reduce Oruka&#8217;s valuation for purposes of calculating the exchange ratio; (iv)&#160;the Special Committee&#8217;s view that as a result of the substantial private placement financing that Oruka was committing to obtain at the closing of the Merger the combined company was likely to possess sufficient cash resources to fund development of Oruka&#8217;s product candidates through upcoming value inflection points; (vi)&#160;the increased likelihood that the transaction could be consummated in a timely manner in light of the informal private placement commitments that Oruka had already obtained, and (vii)&#160;the Special Committee&#8217;s view that the proposal from Oruka was more favorable to ARCA than the potential value that might have resulted from further pursuing other strategic alternatives available to ARCA in light of the extensive outreach process undertaken to date. The Special Committee concluded the meeting by directing Ladenburg to continue negotiating the final legal terms of the term sheet and authorized ARCA&#8217;s management to execute and deliver the term sheet once the remaining legal terms had been finalized.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">102</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In the morning of March&#160;1, 2024, representatives of Ladenburg delivered an updated draft term sheet to representatives of Wedbush finalizing the remaining legal terms in the term sheet and finalizing the $6,000,000 enterprise value that Mr.&#160;Conway and representatives of Oruka had agreed to. Later that afternoon, representatives of Wedbush returned a proposed final draft term sheet which finalized the remaining legal terms.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Later that same&#160;day, at the direction of the Special Committee, ARCA&#8217;s management executed and delivered the term sheet to Oruka and began exclusively negotiating a transaction with Oruka.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On March&#160;4, 2024, the Special Committee met with representatives of ARCA&#8217;s management team, representatives of Wilson Sonsini and Ladenburg, Oruka&#8217;s management team, and representatives of Wedbush and Gibson, Dunn&#160;&amp; Crutcher LLP (&#8220;Gibson&#8221;), Oruka&#8217;s legal advisor, via video conference to discuss the timeline and process for signing definitive agreements providing for a potential business combination and a concurrent private placement financing and discussed and tentatively agreed on a work plan for such definitive agreements.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On March&#160;6, 2024, ARCA provided Oruka and its advisors with access to an online data room for purposes of conducting further business, financial, legal, tax, intellectual property, insurance and other due diligence with respect to ARCA and its business.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On March&#160;7, 2024, Oruka provided ARCA and its advisors with access to an online data room for purposes of conducting further business, financial, legal, tax, intellectual property, insurance and other due diligence with respect to Oruka and its business.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Also on March&#160;7, 2024, Oruka met with representatives of Jefferies LLC and Cowen and Company, LLC (together, the &#8220;Placement Agents&#8221;), representatives of Cooley, counsel to the Placement Agents, and Gibson, via video conference, to discuss the timeline and process for completing the concurrent private placement financing. Later that&#160;day, representatives of Gibson and Cooley met, via video conference, and tentatively agreed on a work plan for the definitive agreements related to such concurrent private placement financing.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On March&#160;11, 2024, Mr.&#160;Conway met with ARCA&#8217;s management team and representatives of Wilson Sonsini to discuss the proposed terms of a draft of the Merger Agreement prepared by representatives of Wilson Sonsini. Mr.&#160;Conway then authorized Wilson Sonsini to distribute the draft Merger Agreement to Gibson which was sent out later that same&#160;day.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Also on March&#160;11, 2024, Oruka authorized representatives of Gibson to distribute the draft form of subscription agreement for the concurrent financing and other related documents to Cooley and Wilson Sonsini, on behalf of the Placement Agents and ARCA, respectively.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On March&#160;15, 2024, the Special Committee met with representatives of Oruka and ARCA&#8217;s management team in attendance to discuss Oruka&#8217;s business and answer the Special Committee&#8217;s questions regarding the materials provided in the virtual data room.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Between March&#160;15, 2024 and April&#160;2, 2024, representatives of ARCA&#8217;s management team conducted further business and financial due diligence with respect to Oruka, its business and the market for treatment of chronic skin diseases and, over the same period of time, ARCA&#8217;s legal and financial advisors conducted due diligence with respect to Oruka and its business based on information available in the data room and written responses from Oruka&#8217;s management team, and such advisors negotiated the terms and conditions of the Merger Agreement at the direction of and in coordination with the Special Committee.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">During that same period, representatives of Wilson Sonsini and Gibson met on numerous occasions to discuss and negotiate the legal terms of the Merger Agreement, including the form of subscription agreement for the Oruka pre<span class="nobreak">-closing</span> financing attached as an exhibit thereto.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">During that same period, representatives of Oruka and its financial advisors held conversations with the representatives of the Placement Agents and prospective investors to discuss the contemplated private placement financing, addressed questions from potential investors and negotiated the terms and conditions of the definitive agreements for such a transaction, including the form of subscription agreement for the Oruka pre<span class="nobreak">-closing</span> financing.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">103</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On March&#160;19, 2024, at the direction of the Special Committee, ARCA entered into a new engagement letter with Lucid Capital Markets, LLC (&#8220;Lucid&#8221;) engaging Lucid as ARCA&#8217;s financial advisor in light of restructuring events that had occurred at Ladenburg which resulted in the financial advisors primarily responsible for this transaction moving from Ladenburg to Lucid.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On March&#160;20, 2024, at the direction of the Special Committee, ARCA terminated its engagement letter with Ladenburg.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On April&#160;2, 2024, ARCA&#8217;s board of directors held a video conference meeting with members of ARCA&#8217;s management team, and representatives of Wilson Sonsini and Lucid in attendance. At the meeting, ARCA&#8217;s board of directors was provided with an overview of the proposed Merger (including the potential benefits and the risks related thereto), the key terms of the related ancillary documents, and its fiduciary duties. ARCA&#8217;s board of directors also reviewed the proposed resolutions which would be adopted by ARCA&#8217;s board of directors in order to approve the entry into the proposed Merger and related transactions, including among other things, the form of Certificate of Designation of Preferences, Rights and Limitations of Series B Non<span class="nobreak">-Voting</span> Convertible Preferred Stock. Lucid then presented its oral opinion that, as of the date thereof, and subject to the assumptions more fully described below under the caption &#8220;The Merger&#160;&#8212;&#160;Opinion of Lucid, ARCA&#8217;s Financial Advisor, to ARCA&#8217;s board of directors,&#8221; beginning on page 112 in this proxy statement/prospectus, the Exchange Ratio is fair, from a financial point of view to the holders of ARCA common stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s board of directors&#8217; meeting was then adjourned and a meeting of the Special Committee was held via video conference with members of ARCA&#8217;s management team and representatives of Wilson Sonsini in attendance. The Special Committee then unanimously (i)&#160;determined that the transactions contemplated by the Merger Agreement including the Merger Agreement and related ancillary agreements contemplated thereunder, are fair to, advisable and in the best interests of ARCA and its stockholders and (ii)&#160;recommended that ARCA&#8217;s board of directors approve and adopt the Merger Agreement, the related ancillary agreements and the transactions contemplated by the Merger Agreement.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Special Committee meeting was then adjourned and a meeting of ARCA&#8217;s board of directors was held via video conference with members of ARCA&#8217;s management team and representatives of Wilson Sonsini in attendance. Based on the factors described below under the caption &#8220;The Merger&#160;&#8212;&#160;ARCA&#8217;s Reasons for the Merger,&#8221; ARCA&#8217;s board of directors then adopted and approved, among other resolutions, resolutions (a)&#160;determining that it is in the best interests of ARCA and its stockholders to adopt and approve the execution and delivery of the Merger Agreement and the ancillary documents thereto, (b)&#160;adopting and approving the Merger Agreement and ancillary documents thereto and approving ARCA&#8217;s execution, delivery and performance of the same and the consummation of the transactions contemplated by the Merger Agreement and the ancillary documents thereto, (c)&#160;recommending that the ARCA stockholders vote in favor of the Proposals with Dr.&#160;Bristow abstaining from voting on the passage of such resolutions.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On April&#160;3, 2024, the parties entered into the Merger Agreement and the related ancillary documents and the private placement investors executed and delivered the Subscription Agreement for the $275.0<span class="nobreak"> </span>million Oruka pre<span class="nobreak">-closing</span> financing.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Later that same&#160;day, ARCA and Oruka issued a joint press release announcing the execution and delivery of the Merger Agreement, and ARCA filed a Current Report on Form&#160;8<span class="nobreak">-K</span>, which filed as an exhibit (a)&#160;the Merger Agreement, (b)&#160;the form of Certificate of Designation of Preferences, Rights and Limitations of Series&#160;B Non<span class="nobreak">-Voting</span> Convertible Preferred Stock, (c)&#160;the form of Oruka Support Agreement, (d)&#160;the form of Oruka Subscription Agreement, (e)&#160;form of ARCA Support Agreement, (f)&#160;the form of Lock<span class="nobreak">-up</span> Agreement, (g)&#160;a joint press release, dated April&#160;3, 2024 (h)&#160;an investor presentation providing information on Oruka, and (i)&#160;a transcript of a conference call held to announce the proposed transactions.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA&#8217;s Reasons for the Merger</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">During the course of its evaluation of the Merger Agreement and the transactions contemplated by the Merger Agreement, ARCA&#8217;s board of directors and the members of its Special Committee held numerous meetings, consulted with ARCA&#8217;s senior management, ARCA&#8217;s legal counsel and financial advisors, and reviewed and </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">104</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">assessed a significant amount of information. In reaching its decision to approve the Merger Agreement and the transactions contemplated by the Merger Agreement, ARCA&#8217;s board of directors took into account the input and recommendations of the Special Committee, as well as other information presented to it during the process, and considered a number of factors that it viewed as supporting its decision to approve the Merger Agreement, including:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>The financial condition and prospects of ARCA and the risks associated with continuing to operate ARCA on a stand<span class="nobreak">-alone</span> basis in light of:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s decision, announced on May<span class="nobreak">&#160;</span>5, 2022, to initiate a process to explore strategic alternatives in light of and its subsequent decision announced in July of 2022 to reduce its workforce by 67%, which were each driven in large part by the results of ARCA&#8217;s Phase&#160;2 clinical trial of its primary product candidate Recombinant Nematode Anticoagulant Protein c2, or rNAPc2 (AB201), which found that neither studied dose of rNAPc2 achieved statistical significance for the primary efficacy endpoint;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>investor interest and value perception for possible further development of its programs, the product candidates&#8217; efficacy and safety profiles, stage of development, regulatory agencies&#8217; feedback regarding development pathways, and probability of success in relation to the requisite time and costs; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>difficulties encountered in ARCA&#8217;s related business development efforts to license, sell or otherwise partner its assets that could result in meaningful new capital or shared future development costs;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Oruka&#8217;s product pipeline and development candidates;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the recommendation of the Special Committee that ARCA&#8217;s board of directors approve the contemplated transactions;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors&#8217; view that, after a thorough review of strategic alternatives, including further advancing the development of its internal programs, entering into a licensing, sale or other strategic agreement related to certain assets sufficient to fund operations, combining with other potential strategic transaction candidates, and discussions with ARCA&#8217;s senior management, financial advisors and legal counsel, the Merger is more favorable to ARCA stockholders than the potential value that might have resulted from other strategic alternatives available to ARCA;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors&#8217; belief that the $6.0&#160;million enterprise value ascribed to ARCA would provide the existing ARCA stockholders significant value for ARCA&#8217;s public listing and afford the ARCA stockholders a significant opportunity to participate in the potential growth of the combined company following the Merger at the negotiated exchange ratio while also receiving a cash payment on account of the special cash dividend;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors&#8217; belief, after thorough discussions with ARCA&#8217;s management, financial advisors and legal counsel, that a potential liquidation and dissolution was not reasonably likely to create greater value for ARCA stockholders than the Merger based on, among other things, the need to hold back a potential meaningful amount of ARCA&#8217;s current cash balance to cover current and potential unknown future liabilities;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors&#8217; belief that, as a result of arm&#8217;s length negotiations with Oruka, terms of the Merger Agreement include the most favorable terms to ARCA in the aggregate that were achievable and consistent with other similar transactions;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors&#8217; view that Oruka&#8217;s product candidates have the potential to create meaningful value for the stockholders of the combined company and an opportunity for ARCA&#8217;s stockholders to participate in the growth of the combined company, based on the business, scientific, regulatory, </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">105</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-position:inside;list-style-type:none;text-indent:0pt;margin-top:8pt;">intellectual property, financial, accounting and legal due diligence conducted by ARCA management and advisors (which included diligence calls and a comprehensive review of Oruka&#8217;s due diligence materials) regarding:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the regulatory pathway for, and market opportunity of, Oruka&#8217;s product candidates, including in light of the stage of development of Oruka&#8217;s product candidates;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the quality and scope of the preclinical and clinical results available for Oruka as opposed to other parties with which ARCA engaged in discussions;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Oruka&#8217;s plans to explore the potential of its product candidates to treat other diseases, including through collaborations; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the likelihood of value inflection milestones prior to the time in which the combined company would need to raise additional financing;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors&#8217; consideration of the expected cash balances of the combined company as of the closing of the Merger resulting from the approximately $5.0&#160;million of net cash, after giving effect to the special cash dividend, which is expected to be approximately $20.0<span class="nobreak"> </span>million, expected to be held by ARCA upon completion of the Merger, together with the cash Oruka currently holds and the $275&#160;million of expected gross proceeds from the Oruka pre<span class="nobreak">-closing</span> financing;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors&#8217; view, following a review with ARCA&#8217;s management and advisors of Oruka&#8217;s current development and clinical trial plans, of the likelihood that the combined company would possess sufficient cash resources at the closing of the Merger to fund development of Oruka&#8217;s product candidates through upcoming value inflection points, including Oruka&#8217;s ongoing IND<span class="nobreak">-enabling</span> preclinical development work and its anticipated initiation of its Phase&#160;1 trials of ORKA<span class="nobreak">-001</span> in the first half of 2025 and Phase&#160;1 trials of ORKA<span class="nobreak">-002</span> in the second half of 2025;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the expected operations, management structure, operating plans and cash burn rate of the combined company and the expected cash resources of the combined company (including the ability to support the combined company&#8217;s current and planned clinical trials and operations);</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the ability of Oruka to take advantage of the potential benefits resulting from becoming a public reporting company listed on Nasdaq, should it be required to raise additional capital in the future through the sale of equity or debt securities;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the prospects of and risks associated with the other strategic candidates that had made proposals for a strategic transaction with ARCA based on the business, scientific, regulatory, intellectual property, financial, accounting and legal due diligence conducted by the Special Committee, ARCA&#8217;s management and its advisors;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors&#8217; view that the combined company will be led by an experienced senior management team from Oruka, many members of which have extensive experience in drug development, research and development, business and regulatory expertise; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the financial analysis reviewed by Lucid with ARCA&#8217;s board of directors as well as the oral opinion of Lucid rendered to ARCA&#8217;s board of directors on April<span class="nobreak">&#160;</span>2, 2024 (which was subsequently confirmed in writing by delivery of Lucid&#8217;s written opinion dated April<span class="nobreak">&#160;</span>2, 2024 addressed to ARCA&#8217;s board of directors), as to, as of April<span class="nobreak">&#160;</span>2, 2024, the fairness, of the exchange ratio from a financial point of view, to ARCA&#8217;s stockholders, as more fully described below under the caption &#8220;Opinion of Lucid, ARCA&#8217;s Financial Advisor, to ARCA&#8217;s Board of Directors,&#8221; beginning on page 112 in this proxy statement/prospectus.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s board of directors also reviewed the terms of the Merger Agreement and related transaction documents, including those described below, and concluded that the terms of the Merger Agreement and related transaction documents, in the aggregate, were reasonable under the circumstances:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the calculation of the exchange ratio, closing net cash and the estimated number of shares of ARCA common stock to be issued in the Merger;</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">106</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s ability to dividend all of its net cash (as determined in accordance with the terms of the Merger Agreement) in excess of $5.0&#160;million to the current ARCA stockholders;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the number and nature of the conditions to Oruka&#8217;s and ARCA&#8217;s respective obligations to complete the Merger and the likelihood that the Merger will be completed on a timely basis, including the fact that Oruka&#8217;s obligation to complete the Merger would not be conditioned on ARCA having a specified level of closing net cash, as more fully described below under the caption &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">The Merger Agreement&#160;&#8212;&#160;Conditions to the Completion of the Merger</span>,&#8221; beginning on page 148 in this proxy statement/prospectus;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the respective rights of, and limitations on, ARCA and Oruka under the Merger Agreement to consider and engage in discussions regarding unsolicited acquisition proposals under certain circumstances, and the limitations on the board of directors of each party to change its recommendation in favor of the Merger, as more fully described below under the caption &#8220;The Merger Agreement&#160;&#8212;&#160;Non<span class="nobreak">-Solicitation</span>,&#8221; beginning on page 145 in this proxy statement/prospectus;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the potential termination fee of $440,000, in the case of the fee payable by ARCA, or $440,000, in the case of the fee payable by Oruka, if the Merger Agreement is terminated in certain circumstances, as more fully described below under the caption &#8220;The Merger Agreement&#160;&#8212;&#160;Termination and Termination Fees,&#8221; beginning on page 150 in this proxy statement/prospectus;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the lock<span class="nobreak">-up</span> agreements, pursuant to which certain stockholders of Oruka and ARCA, respectively, have, subject to certain exceptions, agreed not to transfer their shares of ARCA common stock during the period of 180&#160;days following the completion of the Merger, as more fully described below under the caption &#8220;Agreements Related to the Merger&#160;&#8212;&#160;Lock<span class="nobreak">-Up</span> Agreements,&#8221; beginning on page 153 in this proxy statement/prospectus;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the support agreements, pursuant to which certain stockholders of ARCA and Oruka, respectively, have agreed, solely in their capacities as stockholders, to vote all of their shares of ARCA common stock or Oruka common stock in favor of the proposals submitted to them in connection with the Merger and against any alternative acquisition proposals, as more fully described below under the caption &#8220;Agreements Related to the Merger&#160;&#8212;&#160;Support Agreements,&#8221; beginning on page 153 in this proxy statement/prospectus; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the expectation that the Merger will qualify as a reorganization within the meaning of Section&#160;368(a)&#160;of the Code, and will constitute a &#8220;plan of reorganization&#8221; within the meaning of Treasury Regulations Section&#160;1.368<span class="nobreak">-2</span>(g)&#160;and 1.368<span class="nobreak">-3</span>(a), with the result that Oruka stockholders will generally not recognize taxable gain or loss for U.S.&#160;federal income tax purposes upon the exchange of Oruka common stock for ARCA common stock pursuant to the Merger Agreement, as more fully described below under the caption &#8220;The Merger&#160;&#8212;&#160;Material U.S.&#160;Federal Income Tax Consequences of the Merger,&#8221; beginning on page 128 in this proxy statement/prospectus.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In the course of its deliberations, and in addition to the consideration, input and recommendations of the Special Committee, ARCA&#8217;s board of directors also considered a variety of risks, uncertainties and other countervailing factors related to entering into the Merger, including:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the risk that the potential benefits of the Merger may not be fully achieved, or may not be achieved within the expected timeframe;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the risk that the future financial performance of Oruka may not meet ARCA&#8217;s board of directors&#8217; expectations due to factors both in and outside of Oruka&#8217;s control;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the risk that, while ARCA&#8217;s management team performed an extensive due diligence review of Oruka, there may have been relevant Oruka information not considered by ARCA&#8217;s management team and accordingly, ARCA may not have properly valued Oruka;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the potential effect of the $440,000 termination fee payable by ARCA upon the occurrence of certain events in deterring other potential companies from proposing an alternative acquisition proposal that may be more advantageous to ARCA&#8217;s stockholders;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s obligation to not solicit alternative acquisition proposals during the pendency of the Merger;</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">107</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the substantial expenses to be incurred by ARCA in connection with the Merger;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the possible volatility of the trading price of the ARCA common stock resulting from the announcement, pendency or completion of the Merger;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the scientific, technical, regulatory and other risks and uncertainties associated with development and commercialization of Oruka&#8217;s product candidates;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>various risks impacting the financial condition, results of operations and prospects for ARCA, including:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the risks and challenges associated with pursuing any strategic alternative to the Merger available to ARCA, including the discussions that ARCA&#8217;s management and ARCA&#8217;s board of directors of directors previously conducted with other potential transaction partners, and the time to negotiate and complete an alternative strategic transaction and anticipated cash burn;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the risks and delays associated with, and uncertain value and costs to ARCA stockholders of, liquidating ARCA, including the uncertainties of continuing cash burn while contingent liabilities are resolved, uncertainty of timing of release of cash until contingent liabilities are resolved, and the risks and costs associated with being a shell company prior to cash distribution;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the risks and challenges of attempting to continue to operate ARCA on a stand<span class="nobreak">-alone</span> basis, including, without limitation, (i)&#160;the considerable time and resources that would have been required to successfully address the uncertainties associated with its Gencaro product, (ii)&#160;the inability to finance ARCA&#8217;s continuing operations through the sale of securities in the capital markets due to, among other things, the lack of near term data catalysts and the general downturn in the U.S.&#160;capital markets for biotechnology companies and (iii)&#160;ARCA&#8217;s other product candidate profiles, stage of development, feedback from regulatory agencies regarding development pathway, and probability of success in relation to the requisite time and costs required as well as management&#8217;s related business development efforts to license, sell or otherwise partner the assets;.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the challenges of retaining or rebuilding staff with limited cash runway in light of the reductions in force that ARCA previously undertook; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the challenges of maintaining ARCA&#8217;s Nasdaq listing without completing the merger and the transactions contemplated in the Merger Agreement, including the reverse stock split; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the various other risks associated with the combined company and the Merger, including those described in the sections titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Risk Factors</span>&#8221; and &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Cautionary Note Regarding Forward</span><span class="nobreak"><span class="Italic" style="font-style:italic;font-weight:normal;">-Looking</span></span><span class="Italic" style="font-style:italic;font-weight:normal;"> Statements</span>&#8221; in this proxy statement/prospectus.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The foregoing information and factors considered by the Special Committee and ARCA&#8217;s board of directors are not intended to be exhaustive but are believed to include all of the material factors considered by the Special Committee and ARCA&#8217;s board of directors. In view of the wide variety of factors considered in connection with its evaluation of the Merger and the complexity of these matters, the Special Committee and ARCA&#8217;s board of directors did not find it useful, and did not attempt, to quantify, rank or otherwise assign relative weights to these factors. In considering the factors described above, individual members of the Special Committee and ARCA&#8217;s board of directors may have given different weight to different factors. The Special Committee and ARCA&#8217;s board of directors conducted an overall analysis of the factors described above, including thorough discussions with, and questioning of, ARCA&#8217;s management team and the legal and financial advisors of ARCA, and considered the factors overall to be favorable to, and to support, its determination.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA Liquidation Analysis</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In connection with the evaluation of the Merger by ARCA&#8217;s board of directors and the Special Committee, ARCA&#8217;s management prepared an analysis with respect to the estimated value of the liquidation or dissolution of ARCA as a potential alternative to the Merger, including for such purposes ARCA&#8217;s estimated cash position at the time of the potential dissolution or liquidation, ARCA&#8217;s estimated expenses in connection with any such liquidation or dissolution, and the amount of cash available to be distributed to ARCA&#8217;s stockholders in connection with any such proposed future dissolution or liquidation (the &#8220;Liquidation Analysis&#8221;). Although the Liquidation Analysis </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">108</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">assumes that the entirety of ARCA&#8217;s cash balance at the time of the dissolution or liquidation would be available for distribution to ARCA&#8217;s stockholders, it is unlikely that the entirety of such cash balance would be available at the time of an actual dissolution or liquidation due to the requirements of applicable law.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The inclusion of the Liquidation Analysis should not be deemed an admission or representation by ARCA or any of its officers, directors, affiliates, advisors, or other representatives with respect to the Liquidation Analysis. The Liquidation Analysis is not included to influence your views on the Merger, the Merger Agreement and the transactions contemplated thereby and is summarized in this proxy statement/prospectus solely to provide stockholders access to certain information considered by ARCA&#8217;s board of directors and the Special Committee in connection with its evaluation of the Merger, the Merger Agreement and the transactions contemplated thereby. Any estimates contained in these analyses are not necessarily indicative of actual values or predictive of future results or values, which may be significantly more or less favorable than as set forth below. In addition, analyses relating to the value of ARCA do not purport to be appraisals or reflect the prices at which shares of ARCA common stock may actually be valued or trade, either before or after the consummation of the Merger.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Liquidation Analysis was not prepared with a view toward public disclosure, nor was it prepared with a view toward compliance with published guidelines of the SEC, the guidelines established by the American Institute of Certified Public Accountants for preparation and presentation of prospective financial information, or GAAP.&#160;Neither the independent registered public accounting firm of ARCA nor any other independent accountant has audited, reviewed, compiled, examined or performed any procedures with respect to the accompanying unaudited prospective financial information for the purpose of its inclusion herein, and accordingly, neither the independent registered public accounting firm of ARCA nor any other independent accountant expresses an opinion or provides any form of assurance with respect thereto for the purpose of this proxy statement/prospectus.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The prospective financial information included in this proxy statement/prospectus has been prepared by, and is the responsibility of, ARCA management. PricewaterhouseCoopers LLP has not audited, reviewed, examined, compiled nor applied agreed<span class="nobreak">-upon</span> procedures with respect to the accompanying prospective financial information and, accordingly, PricewaterhouseCoopers LLP does not express an opinion or any other form of assurance with respect thereto. The PricewaterhouseCoopers LLP report included in this proxy statement/prospectus relates to Oruka&#8217;s financial statement. It does not extend to the prospective financial information and should not be read to do so.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Liquidation Analysis includes estimates of cash and of certain expenditures, which for the purpose of the Liquidation Analysis were not calculated in accordance with GAAP.&#160;Non<span class="nobreak">-GAAP</span>&#160;financial measures should not be viewed as a substitute for GAAP financial measures and may be different from&#160;non<span class="nobreak">-GAAP</span>&#160;financial measures used by other companies. Furthermore, there are limitations inherent in&#160;non<span class="nobreak">-GAAP</span>&#160;financial measures because they exclude charges and credits that are required to be included in a GAAP presentation. Accordingly,&#160;non<span class="nobreak">-GAAP</span>&#160;financial measures should be considered together with, and not as an alternative to, financial measures prepared in accordance with GAAP.&#160;The SEC rules, which otherwise would require a reconciliation of a&#160;non<span class="nobreak">-GAAP</span>&#160;financial measure to a GAAP financial measure, do not apply to&#160;non<span class="nobreak">-GAAP</span>&#160;financial measures provided to a board of directors or financial advisors in connection with a proposed business combination transaction such as the Merger if the disclosure is included in a document such as this proxy statement/prospectus to comply with requirements under state laws, including case law.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-indent:24pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">In light of the foregoing factors and the uncertainties inherent in estimated cash balances, stockholders are cautioned not to place undue reliance, if any, on the Liquidation Analysis.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The below summary of the Liquidation Analysis is subject to the statements above, and it represents estimates prepared by ARCA&#8217;s management of the cash which could be distributed to stockholders as permitted under applicable law pursuant to a plan of dissolution.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Key assumptions underlying the Liquidation Analysis included: (i)&#160;that the entire distribution of ARCA&#8217;s net cash would be made in June&#160;2024; (ii)&#160;that ARCA would have approximately $29.65&#160;million of net cash as June&#160;2024, after deducting costs and expenses, including legal fees, the fees payable to ARCA&#8217;s strategic financial advisor, accounting fees, employee retention bonuses, severance and benefits, insurance expenses, other transaction<span class="nobreak">-related</span> costs and other liabilities; (iii)&#160;that these costs and expenses were forecasted to total approximately $7.28&#160;million assuming the closing of a liquidation in June&#160;2024; and (iv)&#160;approximately 14.5&#160;million total shares of ARCA common stock outstanding as of December&#160;31, 2023. The analysis resulted in an estimated cash distribution per share in June&#160;2024 of $2.04 per share.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">109</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Oruka&#8217;s Reasons for the Merger</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In the course of reaching its decision to approve the Merger and the Oruka&#160;pre<span class="nobreak">-closing</span>&#160;financing, Oruka&#8217;s board of directors held numerous meetings, consulted with Oruka&#8217;s senior management, legal counsel and financial advisors, and considered a wide variety of factors. Ultimately, Oruka&#8217;s board of directors concluded that a merger with ARCA, together with the additional financing committed from the Oruka pre<span class="nobreak">-closing</span> financing, was the best option to generate capital resources to support the advancement of Oruka&#8217;s pipeline and fund the combined organization.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Additional factors Oruka&#8217;s&#160;board of directors considered included the following (which factors are not necessarily presented in any order of relative importance):</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the Merger will potentially expand the access to capital and the range of investors available as a public company to support the clinical development of Oruka&#8217;s pipeline, compared to the capital and investors Oruka could otherwise gain access to if it continued to operate as a privately<span class="nobreak">-held</span> company;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the Oruka pre<span class="nobreak">-closing</span> financing will generate capital resources to fund the combined company;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the potential benefits from increased public market awareness of Oruka and its pipeline;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the historical and current information concerning Oruka&#8217;s business, including its financial performance and condition, operations, management and preclinical and clinical data;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the competitive nature of the industry in which Oruka operates;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Oruka&#8217;s board of directors&#8217; fiduciary duties to Oruka stockholders;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Oruka&#8217;s board of directors&#8217; belief that no alternatives to the Merger, together with the additional financing committed from the Oruka pre<span class="nobreak">-closing</span> financing, were reasonably likely to create greater value for Oruka stockholders, after considering the various financing and other strategic options to enhance stockholder value that were considered by the Oruka board of directors;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Oruka&#8217;s board of directors&#8217; expectation that the Merger, together with the additional financing committed from the Oruka pre<span class="nobreak">-closing</span> financing, would be a higher probability and more cost<span class="nobreak">-effective</span> means to access capital than other options considered, including an IPO;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the expected operations, management structure and operating plans of the combined company (including the ability to support the combined company&#8217;s current and planned preclinical and clinical trials);</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the business, history, operations, financial resources, assets, technology and credibility of ARCA;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the availability of appraisal rights under the DGCL to holders of Oruka capital stock who comply with the required procedures under the DGCL, which allow such holders to seek appraisal of the fair value of their shares of Oruka capital stock as determined by the Delaware Court of Chancery;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the terms and conditions of the Merger Agreement, including the following:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the determination that the expected relative percentage ownership of ARCA stockholders and Oruka stockholders in the combined organization was appropriate, based on Oruka&#8217;s board of directors&#8217; judgment and assessment of the approximate valuations of ARCA (including the value of the net cash ARCA is expected to provide to the combined organization) and Oruka (including the value of the amount of proceeds from the Oruka pre<span class="nobreak">-closing</span> financing);</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the expectation that the Merger will be treated as a reorganization for U.S.&#160;federal income tax purposes, with the result that the Oruka stockholders will generally not recognize taxable gain or loss for U.S.&#160;federal income tax purposes with respect to the Merger;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the limited number and nature of the conditions of the obligation of ARCA to consummate the Merger;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-left:72pt;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the rights of Oruka under the Merger Agreement to consider certain unsolicited acquisition proposals under certain circumstances should Oruka receive a superior offer;</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">110</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-left:72pt;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the rights of Oruka under the Merger Agreement to effect a change in recommendation in favor of the Merger as a result of a material development or change in circumstances (i.e., applicable Intervening Events);</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the conclusion of Oruka&#8217;s board of directors that the potential termination fees payable by ARCA or Oruka to the other party, and the circumstances when such fee may be payable, were reasonable; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the belief that the other terms of the Merger Agreement, including the parties&#8217; representations, warranties and covenants, and the conditions to their respective obligations, were reasonable in light of the entire transaction;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the shares of ARCA&#8217;s common stock issued to Oruka stockholders, including shares of ARCA common stock issued in exchange for shares of Oruka common stock sold in the Oruka pre<span class="nobreak">-closing</span> financing, will be registered on a Form&#160;S<span class="nobreak">-4</span> registration statement and will become freely tradable for Oruka stockholders who are not affiliates of Oruka and who are not parties to lock<span class="nobreak">-up</span> agreements;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the support agreements, pursuant to which certain directors, officers and stockholders of Oruka and ARCA, respectively, have agreed, solely in their capacity as stockholders of Oruka and ARCA, respectively, to vote all of their shares of Oruka capital stock or ARCA common stock in favor of the adoption or approval, respectively, of the Merger Agreement;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the ability to obtain a Nasdaq listing and the change of the combined organization&#8217;s name to Oruka Therapeutics, Inc. prior to or upon the closing of the Merger; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the likelihood that the Merger will be consummated on a timely basis.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka&#8217;s board of directors also considered a number of uncertainties and risks in its deliberations concerning the Merger and the other transactions contemplated by the Merger Agreement, including the following:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the possibility that the Merger might not be completed and the potential adverse effect of the public announcement of the Merger on the reputation of Oruka&#160;and the ability of Oruka&#160;to obtain financing in the future in the event the Merger is not completed; the possibility that the Oruka&#160;pre<span class="nobreak">-closing</span> financing might not be completed or completed in accordance with the terms of the Merger Agreement and the potential adverse effect of the public announcement of the Oruka&#160;pre<span class="nobreak">-closing</span> financing on the reputation of Oruka&#160;and the ability of Oruka&#160;to obtain financing in the future in the event the Oruka&#160;pre<span class="nobreak">-closing</span> financing is not completed;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the exchange ratio used to establish the number of shares of ARCA&#8217;s common stock to be issued to Oruka&#160;stockholders in the Merger is fixed, except for adjustments due to ARCA&#8217;s net cash balances, the amount of proceeds from the Oruka&#160;pre<span class="nobreak">-closing</span> financing and outstanding capital stock at closing, and thus the relative percentage ownership of ARCA stockholders and Oruka&#160;stockholders in the combined organization immediately following the completion of the Merger is similarly fixed;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the potential reduction of ARCA&#8217;s net cash prior to the closing;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the possibility that ARCA could, under certain circumstances, consider unsolicited acquisition proposals if superior to the Merger or change its recommendation to approve the Merger upon certain events;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the risk that the Merger might not be consummated in a timely manner or at all, for a variety of reasons, such as the failure of ARCA to obtain the required stockholder vote or the failure of Oruka&#160;to close the Oruka&#160;pre<span class="nobreak">-closing</span> financing, and the potential adverse effect on the reputation of Oruka&#160;and the ability of Oruka&#160;to obtain financing in the future in the event the Merger is not completed;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the costs involved in connection with completing the Merger, the time and effort of Oruka&#160;senior management required to complete the Merger, the related disruptions or potential disruptions to Oruka&#8217;s business operations and future prospects, including its relationships with its employees, suppliers and partners and others that do business or may do business in the future with Oruka, and related administrative challenges associated with combining the companies;</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">111</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the additional expenses and obligations to which Oruka&#8217;s business will be subject to following the Merger that Oruka&#160;has not previously been subject to, and the operational changes to Oruka&#8217;s business, in each case that may result from being a public company;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the fact that the representations and warranties in the Merger Agreement do not survive the closing of the Merger and the potential risk of liabilities that may arise post<span class="nobreak">-closing</span>;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the risk that future sales of common stock by existing ARCA stockholders may cause the price of ARCA common stock to fall, thus reducing the potential value of ARCA common stock received by Oruka stockholders following the Merger; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>various other risks associated with the combined organization and the Merger, including the risks described in the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Risk Factors</span>&#8221; in this proxy statement/prospectus.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The foregoing information is not intended to be exhaustive, but is believed to include a summary of all of the material factors considered by Oruka&#8217;s&#160;board of directors in its consideration of the Merger Agreement, the Oruka&#160;pre<span class="nobreak">-closing</span>&#160;financing, and the transactions contemplated thereby. After conducting an overall analysis of these and other factors, including thorough discussions with, and questioning of, Oruka&#8217;s senior management and legal counsel, Oruka&#8217;s&#160;board of directors concluded that the benefits, advantages and opportunities of a potential transaction outweighed the uncertainties and risks described above. Based on this overall analysis of the factors described above, Oruka&#8217;s&#160;board of directors unanimously approved the Merger Agreement, the Merger, the Oruka&#160;pre<span class="nobreak">-closing</span>&#160;financing and the other transactions contemplated by the Merger Agreement.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Opinion of Lucid, ARCA&#8217;s Financial Advisor, to ARCA&#8217;s Board of Directors</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As stated above, pursuant to an engagement letter dated March&#160;19, 2024 (the &#8220;Engagement Letter&#8221;), ARCA retained Lucid to act as a financial advisor in connection with the Merger and to render Lucid&#8217;s opinion (the &#8220;Lucid Opinion&#8221;) to ARCA&#8217;s board of directors as to the fairness of the exchange ratio, from a financial point of view, to the stockholders of ARCA.&#160;On April&#160;2, 2024, at the request of ARCA&#8217;s board of directors, Lucid rendered the oral opinion, subsequently confirmed by delivery of the written opinion dated April&#160;2, 2024, to ARCA&#8217;s board of directors, that the exchange ratio was fair, from a financial point of view, to the stockholders of ARCA as of the date of the Lucid Opinion and based upon the various assumptions, qualifications and limitations set forth therein.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-indent:24pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">The full text of the Lucid Opinion is attached as Annex&#160;B to this proxy statement and is incorporated by reference. ARCA encourages its stockholders to read the Lucid Opinion in its entirety for the assumptions made, procedures followed, other matters considered and limits of the review by Lucid. The summary of the Lucid Opinion set forth herein is qualified by reference to the full text of the Lucid Opinion. Lucid provided the Lucid Opinion for the sole benefit and use by ARCA&#8217;s board of directors in its consideration of the Merger. The Lucid Opinion is not a recommendation to ARCA&#8217;s board of directors or to any stockholder as to how to vote with respect to the proposed Merger or to take any other action in connection with the Merger or otherwise.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In connection with the Lucid Opinion, Lucid took into account an assessment of general economic, market and financial conditions as well as its experience in connection with similar transactions and securities valuations generally and, among other things:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Reviewed a draft of the Merger Agreement;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Reviewed and analyzed certain publicly available financial and other information for each of ARCA and Oruka, respectively, including equity research on comparable companies and on ARCA, and certain other relevant financial and operating data furnished to Lucid by the management of each of ARCA and Oruka, respectively;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Reviewed and analyzed certain relevant historical financial and operating data concerning Oruka furnished to Lucid by the management of Oruka;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Discussed with certain members of the management of ARCA the historical and current business operations, financial condition and prospects of ARCA and Oruka;</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">112</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Reviewed and analyzed certain operating results of Oruka as compared to operating results and the reported price and trading histories of certain publicly traded companies that Lucid deemed relevant;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Reviewed and analyzed certain financial terms of the Merger Agreement as compared to the publicly available financial terms of certain selected business combinations that Lucid deemed relevant;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Reviewed and analyzed certain financial terms of completed IPOs for certain companies that Lucid deemed relevant;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Reviewed certain pro forma financial effects of the Merger;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Reviewed and analyzed certain internal financial analyses, including the cash burn model over the next year, projections as to cost and expenses and whether concurrent capital raised would sufficiently cover select programs, reports, and other information  concerning Oruka prepared by Oruka; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Reviewed and analyzed such other information and such other factors, and conducted such other financial studies, analyses and investigations, as Lucid deemed relevant for the purposes of the Lucid Opinion.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In conducting Lucid&#8217;s review and arriving at the Lucid Opinion, Lucid has, with ARCA&#8217;s consent, assumed and relied, without independent verification or investigation, upon the accuracy and completeness of all financial and other information provided to or discussed with Lucid by ARCA and Oruka, respectively (for their respective employees, representatives or affiliates), or which is publicly available or was otherwise reviewed by Lucid. Lucid has not undertaken any responsibility for the accuracy, completeness or reasonableness of, or independent verification of, such information. Lucid has relied upon, without independent verifications, the assessment of ARCA management and Oruka management as to the viability of, and risks associated with, the current and future products and services of Oruka (including without limitation, the development, testing and marketing of such products and services, the receipt of all necessary governmental and other regulatory approvals for the development, testing and marketing thereof, and the life and enforceability of all relevant patents and other intellectual and other property rights associated with such products and services). In addition, Lucid has not conducted, nor has it assumed any obligation to conduct any physical inspection of the properties or facilities of ARCA or Oruka. Furthermore, Lucid has assumed, with ARCA&#8217;s consent, that there will be no further adjustments to the exchange ratio between the date hereof and the date the final exchange ratio is determined. Lucid has, with ARCA&#8217;s consent, relied upon the assumption that all information provided to Lucid by ARCA and Oruka is accurate and complete in all material respects.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Lucid expressly disclaimed any undertaking or obligation to advise any person of any change in any fact or matter affecting the Lucid Opinion of which Lucid has become aware after the date of the Lucid Opinion. Lucid assumed there were no material changes in the assets, liabilities, financial condition, results of operations, business or prospects of ARCA or Oruka since the date of the last financial statements made available to Lucid. Lucid has not obtained any independent evaluations, valuations or appraisals of the assets or liabilities of ARCA or Oruka, nor has Lucid been furnished with such materials. Further, as ARCA&#8217;s board of directors was aware, Oruka&#8217;s management did not provide Lucid with, and Lucid did not otherwise have access to, financial forecasts regarding Oruka&#8217;s businesses, other than certain cash burn projections, and, accordingly, Lucid did not perform either a discounted cash flow analysis or any multiples<span class="nobreak">-based</span> analyses with respect to Oruka. In addition, Lucid has not evaluated the solvency or fair value of ARCA or Oruka under any state or federal laws relating to bankruptcy, insolvency or similar matters. The Lucid Opinion does not address any legal, tax or accounting matters related to the merger, as to which Lucid has assumed that ARCA and ARCA&#8217;s board of directors have received such advice from legal, regulatory, tax and accounting advisors as each has determined appropriate. The Lucid Opinion addresses only the fairness of the exchange ratio, from a financial point of view, to the ARCA stockholders. Lucid expresses no view as to any other aspect or implication of the merger or any other agreement or arrangement entered into in connection with the merger. The Lucid Opinion is necessarily based upon economic and market conditions and other circumstances as they existed and could be evaluated by Lucid on the date of the Lucid Opinion. It should be understood that although subsequent developments may affect the Lucid Opinion, Lucid does not have any obligation to update, revise or reaffirm the Lucid Opinion and Lucid expressly disclaims any responsibility to do so.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Lucid did not consider any potential legislative or regulatory changes currently being considered or recently enacted by the United&#160;States or any foreign government, or any domestic or foreign regulatory body, or any changes in accounting methods or generally accepted accounting principles that may be adopted by the Securities and Exchange Commission, the Financial Accounting Standards Board, or any similar foreign regulatory body or board.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">113</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">For purposes of rendering the Lucid Opinion, Lucid assumed in all respects material to Lucid&#8217;s analysis, that the representations and warranties of each party contained in the merger agreement were true and correct, that each party will perform all of the standards of the covenants and agreements required to be performed by it under the merger agreement and that all conditions to the consummation of the merger will be satisfied without waiver or amendment of any term or condition thereof. Lucid has assumed that the final form of the merger agreement will be substantially similar to the last draft reviewed by Lucid. Lucid has also assumed that all governmental, regulatory and other consents and approvals contemplated by the merger agreement or otherwise required for the transactions contemplated thereby will be obtained and that in the course of obtaining any of those consents no restrictions will be imposed or waivers made that would have an adverse effect on ARCA, Oruka or the contemplated benefits of the Merger. Lucid has assumed that the merger will be consummated in a manner that complies with the applicable provisions of the Securities Act&#160;of&#160;1933, as amended, the Securities Exchange&#160;Act&#160;of&#160;1934, as amended, and all other applicable federal and state statutes, rules and regulations. ARCA has informed Lucid, and Lucid has assumed, that the merger is intended to constitute a reorganization within the meaning of Section&#160;368(a)&#160;of the Code and the Treasury Regulations promulgated thereunder.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">It is understood that the Lucid Opinion is intended for the benefit and use of ARCA&#8217;s board of directors in its consideration of the financial terms of the Merger and, except as set forth in Lucid&#8217;s Engagement Letter, may not be used for any other purpose or reproduced, disseminated, quoted or referred to at any time, in any manner or for any purpose without Lucid&#8217;s prior written consent, unless pursuant to applicable law or regulations or required by other regulatory authority by the order or ruling of a court or administrative body, except that the Lucid Opinion may be included in its entirety in any filing related to the merger to be filed with the Securities and Exchange Commission and the proxy statement to be mailed to the ARCA stockholders. The Lucid Opinion does not constitute a recommendation to ARCA&#8217;s board of directors of whether or not to approve the merger or to any ARCA stockholder or any other person as to how to vote with respect to the merger or to take any other action in connection with the merger or otherwise. The Lucid Opinion does not address ARCA&#8217;s underlying business decision to proceed with the merger or the relative merits of the merger compared to other alternatives available to ARCA.&#160;Lucid expressed no opinion as to the prices or ranges of prices at which shares or the securities of any person, including ARCA, will trade at any time, including following the announcement or consummation of the merger. Lucid has not been requested to opine as to, and the Lucid Opinion does not in any manner address, the amount or nature of compensation to any of the officers, directors or employees of any party to the merger, or any class of such persons, relative to the compensation to be paid to the ARCA stockholders in connection with the merger or with respect to the fairness of any such compensation.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Lucid Opinion may not be published or otherwise used or referred to, nor shall any public reference to Lucid be made, without Lucid&#8217;s prior written consent.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Principal Financial Analyses</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following is a summary of the principal financial analyses performed by Lucid to arrive at the Lucid Opinion. Some of the summaries of financial analyses include information presented in tabular format. In order to fully understand the financial analyses, the tables must be read together with the text of each summary. The tables alone do not constitute a complete description of the financial analyses. Considering the data set forth in the tables without considering the full narrative description of the financial analyses, including the methodologies and assumptions underlying the analyses, could create a misleading or incomplete view of the financial analyses. Lucid performed certain procedures, including each of the financial analyses described below and reviewed with ARCA&#8217;s board of directors the assumptions on which such analyses were based and other factors, including the historical and projected financial results of ARCA and Oruka.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Transaction Overview as of the Date of the Lucid Opinion</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Based upon the exchange ratio of 7.4631 at the time of the signing of the merger agreement, it was estimated that at the closing: (a)&#160;Oruka equity holders as of immediately prior to the merger (including the shares issued in the approximately $275&#160;million Oruka pre<span class="nobreak">-closing</span> financing) will own approximately 97.61% of the fully<span class="nobreak">-diluted</span> shares of ARCA common stock at the closing of the merger, and (b)&#160;the ARCA equity holders as of immediately prior to the merger (excluding for this purpose the ARCA Out of the Money Options) will own approximately 2.39% of the fully<span class="nobreak">-diluted</span> shares of ARCA common stock at the closing of the merger, in each case, subject to adjustment of the exchange ratio as set forth in the merger agreement and described herein.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">114</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Pre-Financing Oruka Equity Value</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">For the purpose of the Lucid Opinion, Lucid utilized a Oruka equity value of $175.0&#160;million, which was the pre<span class="nobreak">-money</span> valuation utilized in the Oruka pre<span class="nobreak">-closing</span> financing. The post<span class="nobreak">-money</span> Oruka valuation is calculated by adding the negotiated value of $175.0&#160;million plus $275.0&#160;million raised in the pre<span class="nobreak">-closing</span> financing totaling $450.0&#160;million.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Analysis of Selected Initial Public Offering Transactions</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Lucid reviewed certain publicly available information for the IPOs of 19 dermatology/inflammation/autoimmune<span class="nobreak">-focused</span> biopharmaceutical companies that have completed an IPO since September&#160;2017 and whose lead product at the time of IPO was in a preclinical or Phase&#160;1 stage of clinical development. Although the companies referred to below were used for comparison purposes, none of these companies are directly comparable to Oruka. Accordingly, an analysis of the results of such a comparison is not purely mathematical but instead involves complex considerations and judgments concerning differences in historical and projected financial and operating characteristics of the selected companies below. These companies, which are referred to as the &#8220;Selected Precedent IPO Companies,&#8221; were:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Apogee Therapeutics</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Applied Molecular Transport</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Avidity Biosciences</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Azitra</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Biora Therapeutics</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Cabaletta Bio</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>DICE Therapeutics</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Dyne Therapeutics</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Evelo Biosciences</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Hoth Therapeutics</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Kezar Life Sciences</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Krystal Biotech</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Kymera Therapeutics</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Kyverna Therapeutics</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Morphic Holding</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Prometheus Biosciences</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Third Harmonic Bio</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Ventyx Biosciences</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Virpax Pharmaceuticals</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The total enterprise value at IPO is defined as the&#160;pre<span class="nobreak">-money</span>&#160;equity value plus indebtedness, liquidation value of preferred stock and&#160;non<span class="nobreak">-controlling</span>&#160;interest, minus cash and cash equivalents at the time of its IPO.&#160;The Selected Precedent IPO Companies had total enterprise values between $33.0&#160;million and $638.5&#160;million. Lucid derived a median total enterprise value of $315.2&#160;million for the Selected Precedent IPO Companies. Using the 25<span class="CharOverride-1" style="font-size:58%;vertical-align:super;">th</span>&#160;percentile and the 75<span class="CharOverride-1" style="font-size:58%;vertical-align:super;">th</span> percentile of the implied total enterprise values, Lucid then calculated a range of implied </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">115</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">total equity values for Oruka (by adding an estimated $2.7&#160;million in net cash at closing), which was approximately $177.4&#160;million to $504.2&#160;million. This compares to Oruka&#8217;s pre<span class="nobreak">-financing</span> equity value as per the merger agreement of $175.0&#160;million.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Selected Precedent IPO Companies</span></p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 38.78%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">



						<p class="TCH_left" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Filing Date</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 41.83%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Issuer</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 16.83%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Enterprise<br/>Value&#160;($M)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.78%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2/7/24</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 41.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Kyverna Therapeutics</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">511.5</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.78%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">7/13/23</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 41.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Apogee Therapeutics</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">384.3</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.78%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">6/15/23</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 41.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Azitra</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">58.6</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.78%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">9/14/22</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 41.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Third Harmonic Bio</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">359.8</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.78%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">10/20/21</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 41.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Ventyx Biosciences</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">466.6</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.78%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">9/14/21</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 41.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">DICE Therapeutics</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">343.5</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.78%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">3/11/21</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 41.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Prometheus Biosciences</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">442.5</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.78%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2/16/21</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 41.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Virpax Pharmaceuticals</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">33.0</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.78%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">9/17/20</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 41.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Dyne Therapeutics</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">460.4</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.78%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">8/20/20</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 41.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Kymera Therapeutics</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">526.2</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.78%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">6/19/20</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 41.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Biora Therapeutics</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">638.5</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.78%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">6/12/20</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 41.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Avidity Biosciences</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">292.2</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.78%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">6/4/20</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 41.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Applied Molecular Transport</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">260.5</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.78%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">10/24/19</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 41.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Cabaletta Bio</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">108.0</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.78%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">6/26/19</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 41.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Morphic Holding</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">154.4</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.78%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2/15/19</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 41.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Hoth Therapeutics</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">45.0</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.78%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">6/20/18</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 41.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Kezar Life Sciences</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">141.5</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.78%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">5/8/18</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 41.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Evelo Biosciences</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">315.2</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.78%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">9/19/17</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 41.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Krystal Biotech</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">45.3</p>
					</td>
				</tr>

		</table>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Analysis of Selected Publicly Traded Companies</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Based on its experience and professional judgment and using financial screening sources and databases to find companies that share similar business characteristics to Oruka within the biopharmaceutical industry, Lucid selected financial data of 13 publicly traded companies (referred to as the &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">Selected Publicly</span>&#160;<span class="Bold" style="font-style:normal;font-weight:bold;">Traded</span>&#160;<span class="Bold" style="font-style:normal;font-weight:bold;">Companies</span>&#8221;). Each of the Selected Publicly Traded Companies had a lead candidate in preclinical or Phase&#160;I stage of clinical development and focused on the dermatology/inflammation/autoimmune space. Although the companies referred to below were used for comparison purposes, none of those companies is directly comparable to Oruka. Accordingly, an analysis of the results of such a comparison is not purely mathematical but instead involves complex considerations and judgments concerning differences in historical and projected financial and operating characteristics of the selected companies below. The total enterprise values are based on closing stock prices on April&#160;1, 2024. The Selected Publicly Traded Companies were:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Aditxt</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Apogee Therapeutics</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Astria Therapeutics, Inc.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Azitra</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Cabaletta Bio</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Forte Biosciences, Inc.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Kyverna Therapeutics</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Rani Therapeutics</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">116</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Spyre Therapeutics</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Surrozen, Inc.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Tharimmune</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Third Harmonic Bio</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ZyVersa Therapeutics</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Selected Publicly Traded Companies had implied total enterprise values between negative $18.8&#160;million and $2.9&#160;billion. Lucid derived a median implied total enterprise value of $63.1&#160;million for the Selected Publicly Traded Companies. Using the 25<span class="CharOverride-1" style="font-size:58%;vertical-align:super;">th</span> percentile and the 75<span class="CharOverride-1" style="font-size:58%;vertical-align:super;">th</span> percentile of the implied total enterprise values, Lucid then calculated a range of implied total equity values for Oruka (by adding an estimated $2.7&#160;million in net cash at closing), which was approximately $5.3&#160;million to $539.2&#160;million. This compares to Oruka&#8217;s pre<span class="nobreak">-financing</span> equity value as per the merger agreement of $175.0&#160;million.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Selected Publicly Traded Companies</span></p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">



						<p class="TCH_left" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Company Name</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Enterprise <br/>Value&#160;($M)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Apogee Therapeutics</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,863.5</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Spyre Therapeutics</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">818.3</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Cabaletta Bio</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">575.1</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Kyverna Therapeutics</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">536.5</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Astria Therapeutics, Inc.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">370.5</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Third Harmonic Bio</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">91.1</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Rani Therapeutics</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">63.1</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Azitra</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4.9</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Aditxt</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4.2</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">ZyVersa Therapeutics</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2.6</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Tharimmune</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(5.5</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Forte Biosciences, Inc.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(11.4</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Surrozen, Inc.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(18.8</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>

		</table>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Analysis of Selected Precedent M&amp;A Transactions</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Lucid reviewed the financial terms, to the extent the information was publicly available, of the 9 most recent qualifying merger transactions of companies in the biopharmaceutical industry, which had a lead candidate in the preclinical or phase&#160;I stage of clinical development and focused on the dermatology/inflammation/autoimmune space (referred to as the &#8220;Selected Precedent&#160;M&amp;A Transactions&#8221;). Although the precedent transactions referred to below were used for comparison purposes, none of the target companies is directly comparable to Oruka. Accordingly, an analysis of the results of such a comparison is not purely mathematical, but instead involves complex considerations and judgments concerning differences in historical and projected financial and operating characteristics of the companies involved and other factors that could affect the merger value of such companies and Oruka to which they are being compared. Lucid reviewed the total enterprise values of the target companies (including future milestone payments). These transactions, including the date each was closed, were as follows below.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Selected Precedent M&amp;A Transactions had total implied enterprise values between $20.0&#160;million and $2.0&#160;billion. Lucid derived a median total enterprise value of $250.0&#160;million for the Selected Precedent M&amp;A Transactions. Using the 25<span class="CharOverride-1" style="font-size:58%;vertical-align:super;">th</span> percentile and the 75<span class="CharOverride-1" style="font-size:58%;vertical-align:super;">th</span> percentile of the implied total enterprise values, Lucid then calculated a range of implied total enterprise values for Oruka (by adding an estimated $2.7&#160;million in net cash at closing), which was approximately $65.0&#160;million to $1.0&#160;billion. This compares to Oruka&#8217;s pre<span class="nobreak">-financing</span> equity value as per the merger agreement of $175.0&#160;million.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">117</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Selected Precedent M&amp;A Transactions</span></p>
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 33.51%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">



						<p class="TCH_left" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Announced Date</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 25.05%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Target</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 19.95%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Acquirer</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 17.66%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Implied&#160;Enterprise</span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Value ($M)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 33.51%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">3/13/24</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 25.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">IMF Tre</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 19.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Novartis AG</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.70%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">90.0</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 33.51%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2/15/24</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 25.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Aiolos Bio</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 19.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">GSK</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.70%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,000.0</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 33.51%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">1/18/24</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 25.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Calypso Biotech</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 19.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Novartis AG</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.70%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">250.0</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 33.51%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">8/9/23</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 25.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">DICE Therapeutics</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 19.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Eli Lilly</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.70%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,028.7</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 33.51%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">12/1/21</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 25.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">ORIGIMM Biotechnology</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 19.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Sanofi</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.70%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">62.3</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 33.51%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">4/1/21</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 25.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Pandion Therapeutics</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 19.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Merck</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.70%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,850.0</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 33.51%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">3/20/21</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 25.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Rodeo Therapeutics</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 19.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Amgen</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.70%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">55.0</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 33.51%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">8/8/17</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 25.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Confluence Life Sciences</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 19.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Aclaris Therapeutics</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.70%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">20.0</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 33.51%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">1/26/17</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 25.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Delinia, Inc.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 19.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Celegene Corporation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.70%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">300.0</p>
					</td>
				</tr>

		</table>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Analysis of Precedent Reverse Merger Transactions</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Lucid reviewed the financial terms, to the extent the information was publicly available, of life sciences reverse merger transactions dating back to January&#160;2018 (referred to as the &#8220;Selected Precedent Reverse Merger Transactions&#8221;). Lucid reviewed the total premium to cash delivered to each target, along with other quantitative metrics. These transactions, including the date each was closed, are as follows:</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Selected Precedent Reverse Merger Transactions</span></p>
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-18" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">



						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;text-align:left;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Closed&#160;Date</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Surviving Company</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Public Company</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Value Delivered <br/>for Public Vehicle <br/>Net of Cash <br/>($ mm&#8217;s)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">3/21/2024</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">LENZ Therapeutics</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Graphite Bio (Nasdaq: GRPH)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">$12</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">3/14/2024</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Immunogenx</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">First Wave BioPharma (FWBI)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">15</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">3/6/2024</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Adaptive Phage Therapeutics</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Biomx (NYSEAM:&#160;PHGE)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">NA</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-19" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">12/27/2023</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Cyclo Therapeutics (Nasdaq: CYTH)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Applied Molecular Transport (Nasdaq: AMTI)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">1</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">12/18/2023</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Neurogene</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Neoleukin Therapeutics (Nasdaq: NLTX)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">14</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">11/13/2023</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Cartesian Therapeutics</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Selecta Biosciences (Nasdaq: RNAC)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">13</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">11/3/2023</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Korro Bio</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Frequency Therapeutics (Nasdaq: FREQ)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">15</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">10/31/2023</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Lung Therapeutics</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Aileron Therapeutics (Nasdaq: ALRN)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">10</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">10/16/2023</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Notable Labs</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Vascular Biogenics Ltd. (Nasdaq: VBLT)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">20</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">9/11/2023</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Dianthus Therapeutics</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Magenta Therapeutics (Nasdaq: MGTA)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">20</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">8/16/2023</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">EIP Pharma (CervoMed)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Diffusion Pharmaceuticals (Nasdaq: DFFN)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">10</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">6/29/2023</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">TeraImmune</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Baudax Bio (Nasdaq: BXRX)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">3</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">6/22/2023</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Spyre Therapeutics</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Aeglea BioTherapeutics (Nasdaq: AGLE)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">25</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">6/1/2023</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Elicio Therapeutics</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Angion Biomedica (Nasdaq: ANGN)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">7</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">4/22/2023</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">GRI Bio</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Vallon Pharmaceuticals (Nasdaq: VLON)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">29</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">3/20/2023</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">CalciMedica</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Graybug Vision (Nasdaq: GRAY)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">15</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">3/7/2023</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Carisma Therapeutics</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Sesen Bio (Nasdaq: SESN)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">15</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2/23/2023</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Enliven Therapeutics</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Imara (Nasdaq: IMRA)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">10</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">1/9/2023</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Catheter Precision, Inc.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Ra Medical Systems (NYSE: RMED)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">4</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">12/29/2022</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Disc Medicine</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Gemini Therapeutics (Nasdaq: GMTX)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">10</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">12/27/2022</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">GNI Group (Gyre Therapeutics)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Catalyst Biosciences (Nasdaq: CBIO)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">9</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">12/19/2022</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Kineta, Inc.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Yumanity Therapeutics (Nasdaq: YMTX)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">26</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">11/8/2022</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">ARS Pharmaceuticals</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Silverback Therapeutics (Nasdaq: SBTX)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">5</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">9/28/2022</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Aceragen, Inc.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Idera Pharmaceuticals (Nasdaq: IDRA)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">7</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-20" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">9/15/2022</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Lisata Therapeutics (Cend)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Caladrius Biosciences (Nasdaq: CLBS)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">25</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-20" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">8/30/2022</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Vivani Medical (Nano Precision)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Second Sight Medical (Nasdaq: EYES)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">NA</p>
					</td>
				</tr>

		</table>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">118</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-18" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">



						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;text-align:left;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Closed&#160;Date</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Surviving Company</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Public Company</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Value Delivered <br/>for Public Vehicle <br/>Net of Cash <br/>($ mm&#8217;s)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-19" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">7/5/2022</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Syros Pharmaceuticals (Nasdaq: SYRS)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Tyme Technologies (Nasdaq: TYME)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">8</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">5/16/2022</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Aprea Therapeutics, Inc.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Atrin Pharmaceuticals (NasdaqGS: APRE)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">15</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">10/24/2021</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Quoin Pharmaceuticals, Inc.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Cellect Biotechnology Ltd. (Nasdaq: APOP)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">13</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">8/26/2021</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Aadi Bioscience, Inc.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Aerpio Pharmaceuticals, Inc. (Nasdaq: ARPO)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">15</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">8/3/2021</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Decoy Biosystems, Inc.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Indaptus Therapeutics (Intec) (Nasdaq: INDP)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">10</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">7/27/2021</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Cytocom, Inc. (Statera)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Cleveland BioLabs, Inc. (Nasdaq: CBLI)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">NA</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">6/28/2021</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Tempest Therapeutics Inc.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Millendo Therapeutics, Inc. (Nasdaq: MLND)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">19</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">6/15/2021</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">ReShape Lifesciences Inc.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Obalon Therapeutics, Inc. (Nasdaq: OBLN)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">15</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-19" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">4/27/2021</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Leading BioSciences, Inc. (Palisade)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Seneca Biopharma, Inc. (Nasdaq: SNCA)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">30</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">4/16/2021</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">MyMD Pharmaceuticals, Inc.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Akers Biosciences, Inc. (Nasdaq: AKER)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">5</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">3/31/2021</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">StemoniX Inc. (Vyant Bio)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Cancer Genetics, Inc. (Nasdaq: CGIX)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">15</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">3/16/2021</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">ChemomAb Ltd.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Anchiano Therapeutics Ltd. (Nasdaq: ANCN)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">15</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2/24/2021</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Viracta Therapeutics, Inc.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Sunesis Pharmaceuticals (Nasdaq: SNSS)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">16</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">1/28/2021</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Quellis Biosciences, Inc. (Astria)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Catabasis Pharmaceuticals (Nasdaq: CATB)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">25</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">12/22/2020</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Yumanity Therapeutics Inc.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Proteostasis Therapeutics (Nasdaq: PTI)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">34</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">12/1/2020</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Petros Pharmaceuticals, Inc.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Neurotrope, Inc. (NasdaqCM: NTRP)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">4</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">11/23/2020</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">F<span class="nobreak">-star</span> Therapeutics, Limited</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Spring Bank Pharmaceuticals, Inc.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">23</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">11/5/2020</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Ocuphire Pharma, Inc.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Rexahn Pharmaceuticals (Nasdaq: REXN)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">16</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-19" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">10/27/2020</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Viridian Therapeutics, Inc.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Miragen Therapeutics, Inc. (NasdaqCM: MGEN)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">15</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">9/15/2020</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Adicet Bio, Inc.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">resTORbio, Inc. (NasdaqGS: TORC)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">8</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">9/14/2020</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Anelixis Therapeutics (Eledon)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Novus Therapeutics, Inc. (NasdaqCM: NVUS)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">5</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">7/6/2020</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Kiq Bio (Cogent)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Unum Therapeutics, Inc. (NASDAQ:&#160;UMRX)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">17</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">6/15/2020</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Forte Biosciences, Inc.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Tocagen Inc. (NasdaqGS: TOCA)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">8</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">5/28/2020</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Larimar Therapeutics, Inc.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Zafgen, Inc. (NasdaqGS: ZFGN)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">5</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">5/26/2020</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Histogen, Inc.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Conatus Pharmaceuticals (Nasdaq: CNAT)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">23</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">5/22/2020</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Qualigen, Inc.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Ritter Pharmaceuticals (Nasdaq: RTTR)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">NA</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">5/18/2020</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Timber Pharmaceuticals, Inc.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">BioPharmX Corporation (AMEX: BPMX)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">16</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">4/1/2020</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Curetis NV (Euronext: CURE)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">OpGen, Inc. (NasdaqCM: OPGN)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">7</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">1/9/2020</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Protara Therapeutics, Inc.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Proteon Therapeutics, Inc. (NASDAQ:&#160;PRTO)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">5</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-19" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">12/30/2019</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">NeuroBo Pharmaceuticals, Inc.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Gemphire Therapeutics Inc. (NASDAQ:&#160;GEMP)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">8</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">11/7/2019</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Venus Concept Ltd.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Restoration Robotics, Inc. (NASDAQ:&#160;HAIR)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">20</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">9/27/2019</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Ocugen, Inc.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Histogenics Corporation (NASDAQ:&#160;HSGX)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">NA</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">8/31/2019</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Brickell Biotech, Inc.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Vical Incorporated (NASDAQ:&#160;VICL)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">4</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">7/31/2019</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">ESSA Pharma (NASDAQ: EPIX)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Realm Therapeutics plc (NASDAQ:&#160;RLM)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">1</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">7/22/2019</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Salarius Pharmaceuticals, LLC</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Flex Pharma, Inc. (NASDAQ:&#160;FLKS)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">4</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">7/15/2019</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">NeuBase Therapeutics</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Ohr Pharmaceutical (NASDAQ:&#160;OHRP)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">7</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">6/10/2019</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Oncternal Therapeutics, Inc.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">GTx, Inc. (NASDAQ:&#160;GTXI)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">9</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-19" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">6/9/2019</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Edesa Biotech Inc.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Stellar Biotechnologies, Inc. (NASDAQ:&#160;SBOT)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">2</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-19" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">5/9/2019</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Armata Pharmaceuticals (f.k.a C3J)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Ampliphi Biosciences (NYSE:&#160;APHB)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">10</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-20" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">5/6/2019</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Adynxx, Inc.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Alliqua BioMedical, Inc. (NASDAQ:&#160;ALQA)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">3</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-19" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">4/23/2019</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Mereo BioPharma (AIM: MPH)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Oncomed Pharmaceuticals (NASDAQ:&#160;OMED)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">20</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-20" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">4/12/2019</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Immunic AG</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Vital Therapies, Inc. (NASDAQ: VTL)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">10</p>
					</td>
				</tr>

		</table>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">119</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-18" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">



						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;text-align:left;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Closed&#160;Date</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Surviving Company</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Public Company</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Value Delivered <br/>for Public Vehicle <br/>Net of Cash <br/>($ mm&#8217;s)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">3/26/2019</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Enlivex Therapeutics Ltd.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Bioblast Pharma Ltd. (NASDAQ:&#160;ORPN)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">5</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">3/18/2019</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">PDS Biotechnology Corporation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Edge Therapeutics, Inc. (NASDAQ:&#160;EDGE)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">5</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">3/13/2019</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">X4 Pharmaceuticals, Inc.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Arsanis, Inc. (NASDAQ:&#160;ASNS)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">29</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">1/24/2019</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Seelos Therapeutics, Inc.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Apricus Biosciences, Inc. (NASDAQ: APRI)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">8</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">12/7/2018</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Millendo Therapeutics, Inc.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">OvaScience, Inc. (NASDAQ:&#160;OVAS)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">5</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">10/12/2018</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Aravive Biologics, Inc.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Versartis, Inc. (NASDAQ:&#160;VSAR)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">0</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2/13/2018</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Vaxart, Inc.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Aviragen Therapeutics, Inc. (NASDAQ:&#160;AVIR)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">44</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">1/30/2018</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Innovate Biopharmaceuticals, Inc.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Monster Digital, Inc. (NASDAQ:&#160;MSDI)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">6</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">1/17/2018</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Evofem Biosciences, Inc.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Neothetics, Inc. (NASDAQ:&#160;NEOT)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">29</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-19" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">1/4/2018</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Rocket Pharmaceuticals, Ltd</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Inotek Pharmaceuticals Corp (NASDAQ:&#160;ITEK)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">5</p>
					</td>
				</tr>

		</table>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Lucid reviewed the value delivered for the public vehicle (net of cash) from the Selected Precedent Reverse Merger Transactions, which ranged from $0.0&#160;million to $44.0&#160;million. The 25<span class="Superscript" style="vertical-align:super;font-size:58%;">th</span> percentile and the 75<span class="Superscript" style="vertical-align:super;font-size:58%;">th</span> percentile for the value delivered for the public vehicle (net of cash), was $5.0&#160;million and $17.0&#160;million respectively.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The summary set forth above does not purport to be a complete description of all the analyses performed by Lucid. The preparation of a fairness opinion involves various determinations as to the most appropriate and relevant methods of financial analysis and the application of these methods to the particular circumstances. Therefore, such an opinion is not readily susceptible to partial analysis or summary description. Lucid did not attribute any particular weight to any analysis or factor considered by it, but rather made qualitative judgments as to the significance and relevance of each analysis and factor. Accordingly, notwithstanding the separate factors summarized above, Lucid believes, and advised ARCA&#8217;s board of directors, that its analyses must be considered as a whole. Selecting portions of its analyses and the factors considered by it without considering all analyses and factors could create an incomplete view of the process underlying the Lucid Opinion. In performing its analyses, Lucid made numerous assumptions with respect to industry performance, business and economic conditions and other matters, many of which are beyond the control of ARCA and Oruka. These analyses performed by Lucid are not necessarily indicative of actual values or future results, which may be significantly more or less favorable than suggested by such analyses. In addition, analyses relating to the value of businesses do not purport to be appraisals or to reflect the prices at which businesses or securities may actually be sold. Accordingly, such analyses and estimates are inherently subject to uncertainty, being based upon numerous factors or events beyond the control of the parties or their respective advisors. None of ARCA, Oruka, Lucid or any other person assumes responsibility if future results are materially different from those projected. The analyses supplied by Lucid and the Lucid Opinion were among several factors taken into consideration by ARCA&#8217;s board of directors in making its decision to enter into the merger agreement and should not be considered as determinative of such a decision.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Lucid was selected by ARCA&#8217;s board of directors to render an opinion to ARCA&#8217;s board of directors because Lucid is a nationally recognized investment banking firm and because, as part of its investment banking business, Lucid is continually engaged in the valuation of businesses and their securities in connection with mergers, negotiated underwritings, secondary distributions of listed and unlisted securities, private placements and valuations for corporate and other purposes. In addition, in the ordinary course of its business, Lucid and its affiliates may trade the equity securities of ARCA for its own account and for the accounts of their customers, and, accordingly, may at any time hold a long or short position in such securities. In the two&#160;years preceding the date hereof, Lucid has not received any fees from ARCA.&#160;In the two&#160;years preceding the date hereof, Lucid has not had a relationship with Oruka and has not received any fees from Oruka. Lucid and its affiliates may in the future seek to provide investment banking or financial advisory services to ARCA and Oruka and/or certain of their respective affiliates and expect to receive fees for the rendering of these services.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Pursuant to the Engagement Letter between Lucid and ARCA as of the time the merger agreement was approved, if the merger is consummated, Lucid will be entitled to receive a transaction fee of $800,000 payable in cash at the closing of the transaction. ARCA has also paid Lucid a fee for the Lucid Opinion of $250,000 </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">120</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">(in addition to the $800,000 transaction fee payable upon closing of the transaction) upon delivery of the Lucid Opinion. Additionally, ARCA has agreed to reimburse Lucid for its&#160;out<span class="nobreak">-of-pocket</span>&#160;expenses and has agreed to indemnify Lucid against certain liabilities, including liabilities under the federal securities laws. The terms of the fee arrangement with Lucid, which are customary in transactions of this nature, were negotiated at arm&#8217;s length between ARCA and Lucid, and ARCA&#8217;s board of directors was aware of the arrangement, including the fact that a portion of the fee payable to Lucid is contingent upon the completion of the merger.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Interests of ARCA&#8217;s Directors and Executive Officers in the Merger</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">In considering the recommendation of ARCA&#8217;s board of directors with respect to issuing shares of ARCA common stock, including shares of ARCA common stock issuable upon conversion of ARCA Series&#160;B Preferred Stock, in the Merger and the other matters to be acted upon by the ARCA stockholders at the ARCA special meeting, the ARCA stockholders should be aware that ARCA&#8217;s directors and executive officers have interests in the Merger that are different from, or in addition to, the interests of ARCA stockholders generally. These interests may present ARCA&#8217;s directors and executive officers with actual or potential conflicts of interest.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">ARCA&#8217;s board of directors was aware of these potential conflicts of interest and considered them, among other matters, in reaching its decision to approve the Merger Agreement and the Merger, and to recommend that the ARCA stockholders approve the proposals to be presented to the ARCA stockholders for consideration at the ARCA special meeting as contemplated by this proxy statement/prospectus.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:10pt;margin-top:10pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Treatment of ARCA Options</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">Under the terms of the Merger Agreement, prior to the closing of the Merger, ARCA&#8217;s board of directors will accelerate the vesting of all equity awards of ARCA then outstanding but not then vested or exercisable. At the closing of the First Merger, (i)&#160;each option to acquire shares of ARCA&#8217;s common stock with an exercise price less than or equal to the Parent Closing Price will be cancelled and converted into the right to receive an amount in cash, without interest, equal to the Parent Closing Price less the exercise price of such option and (ii)&#160;each other option to acquire shares of ARCA&#8217;s common stock will be cancelled for no consideration. The following table sets forth, for each ARCA executive officer and each member of ARCA&#8217;s board of directors the aggregate number of ARCA stock options that were unvested and vested as of May&#160;3, 2024 and the weighted<span class="nobreak">-average</span> exercise price.</p>
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-25" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 32.69%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">



						<p class="TCH_left" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Name</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Unvested<br/>ARCA<br/>Options<br/>(#)</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 16.67%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Weighted-Average<br/>Exercise&#160;Price&#160;of<br/>Unvested&#160;ARCA<br/>Options<br/>($)</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Vested&#160;ARCA<br/>Options<br/>(#)</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 17.31%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Weighted-Average<br/>Exercise&#160;Price&#160;of<br/>Vested&#160;ARCA<br/>Options<br/>($)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-26" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 32.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Executive Officers</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 16.67%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 17.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-26" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 32.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Thomas A.&#160;Keuer</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">19,443</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 16.67%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3.48</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">87,931</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 17.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4.95</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-26" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 32.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">C.&#160;Jeffrey Dekker</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">18,828</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 16.67%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2.90</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">53,872</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 17.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2.86</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-26" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 32.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Directors</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 16.67%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 17.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-26" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 32.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Linda Grais, M.D.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4,500</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 16.67%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1.64</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">20,895</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 17.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">6.06</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-26" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 32.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Robert E.&#160;Conway</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4,500</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 16.67%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1.64</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">20,895</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 17.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">6.06</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-26" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 32.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Anders Hove</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4,500</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 16.67%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1.64</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">20,499</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 17.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4.82</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-26" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 32.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Jacob Ma-Weaver</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">9,166</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 16.67%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1.96</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">14,834</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 17.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2.23</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-26" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 32.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">James Flynn</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">11,166</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 16.67%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2.05</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">6,834</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 17.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2.17</p>
					</td>
				</tr>

		</table>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:10pt;margin-top:10pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Retention Bonus Agreements</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">Each of ARCA&#8217;s current executive officers is party to a retention bonus letter, as amended from time to time, pursuant to which the ARCA executive officer will receive a retention bonus of $165,000, subject to his continued employment with ARCA in good standing through the earlier of a corporate transaction of ARCA or certain clinical development decisions. The Merger will constitute a corporate transaction of ARCA for purposes of the retention bonus letters.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">121</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:10pt;margin-top:10pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Employment Agreements</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">Each of ARCA&#8217;s current executive officers is party to an employment agreement that provides certain payments and benefits upon a termination of employment without cause by ARCA or a resignation by the officer for good reason (each as defined below) on the same&#160;day as a corporation transaction of ARCA or within 13&#160;months after a corporation transaction of ARCA.&#160;The Merger will constitute a corporate transaction of ARCA for purposes of the employment agreements. These payments and benefits include:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Severance pay equal to (i)&#160;12&#160;months of the ARCA executive officer&#8217;s base salary, payable in installments over 12&#160;months, plus (ii)&#160;a pro rata portion of any bonus compensation approved for the fiscal year in which the termination occurs, payable when bonuses for such year are otherwise paid;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Reimbursement of out<span class="nobreak">-of-pocket</span> costs to continue group health insurance benefits under COBRA for up to 12&#160;months.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, the employment agreements provides that ARCA may, in its sole discretion, pay additional severance pay of up to 12&#160;months of base salary to extend the term of the restrictive covenants applicable to the ARCA executive officer. The severance payments and benefits are subject to the ARCA executive officer&#8217;s release of claims in a form acceptable to ARCA.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">The employment agreements do not contain tax gross<span class="nobreak">-up</span> provisions with respect to excise taxes under Section&#160;4999 of the Code. Instead, the severance payments and benefits are subject to a &#8220;best<span class="nobreak">-of-net</span>&#8221; provision in the event of excess parachute payments under Section&#160;280G of the Code. In the event excise taxes under Section&#160;4999 of the Code would be imposed on payments made under the employment agreements, the ARCA executive officer will either pay the excise tax or have his payments and benefits reduced to an amount at which an excise tax no longer applies, based on which result is more favorable to the ARCA executive officer on an after<span class="nobreak">-tax</span> basis</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">For purposes of the employment agreements:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>&#8220;Cause&#8221; generally means that the ARCA executive officer has committed or engaged in: (i)&#160;willful misconduct, gross negligence, theft, fraud, or other illegal or dishonest conduct, any of which are considered to be materially harmful to ARCA; (ii)&#160;refusal, unwillingness, failure, or inability to perform material job duties or habitual absenteeism; or (iii)&#160;violation of fiduciary duty, violation of any duty of loyalty, or material breach of any material term of the employment agreement, intellectual property agreement or any other contract with ARCA</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>&#8220;Good Reason&#8221; generally means, with the ARCA executive officer&#8217;s consent: (i)&#160;geographic relocation by more than 30 miles; (ii)&#160;a decrease in base salary by more than 15%, other than a decrease resulting from a general reduction in the base salary of all ARCA executive officers; or (iii)&#160;significant detrimental reductions in the ARCA executive officer&#8217;s job responsibilities, in each case, subject to standard notice and cure provisions.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:10pt;margin-top:10pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Director Compensation</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">As discussed under &#8220;ARCA Director Compensation&#8221; below, Chairman of ARCA&#8217;s board of directors, Robert&#160;E. Conway, and other members of ARCA&#8217;s board of directors, including Linda Grais, M.D., Anders Hove, M.D. and Jacob Ma<span class="nobreak">-Weaver</span> (served from June 2022 to April 2024), served on the Special Committee beginning in 2022, pursuant to which they each received enhanced retainers totaling: $105,000 for each of Robert E.&#160;Conway, Linda Grais, M.D., Anders Hove, M.D. and $90,000 for Jacob Ma<span class="nobreak">-Weaver</span>. In April 2024, James Flynn replaced Mr.<span class="nobreak"> </span>Ma<span class="nobreak">-Weaver</span> on the Special Committee. Each member of the Special Committee will continue to be paid $7,500 per month for each month of substantive service on the Special Committee.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:10pt;margin-top:10pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Cash Dividend</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">Prior to the closing of the First Merger, ARCA expects to declare a cash dividend to the pre<span class="nobreak">-First</span> Merger ARCA stockholders equal in the aggregate to ARCA&#8217;s reasonable, good faith approximation of the amount by which ARCA&#8217;s net cash will exceed $5.0<span class="nobreak"> </span>million, and any of ARCA&#8217;s directors and executive officers that are also ARCA stockholders will share in any such cash dividend proportionally to their pre<span class="nobreak">-First</span> Merger ownership of ARCA common stock (see the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Principal Stockholders of ARCA</span>&#8221; beginning on page 312 of this </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">122</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;text-indent:0pt;margin-top:6pt;">proxy statement/prospectus for additional information regarding ARCA&#8217;s directors&#8217; and officers&#8217; holdings of ARCA common stock; notably, Jacob Ma<span class="nobreak">-Weaver</span> and affiliated entities together hold 4,000,452<span class="nobreak"> </span>shares of ARCA common stock, representing over 27% of outstanding shares of ARCA common stock).</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:10pt;margin-top:10pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Indemnification and Insurance</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">Under the Merger Agreement, ARCA&#8217;s directors and executive officers are entitled to continued indemnification, expense advancement and insurance coverage. For a discussion of the indemnification and insurance provisions related to the ARCA directors and officers under the Merger Agreement, please see the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">The Merger Agreement &#8212; Indemnification and Insurance for Directors and Officers</span>&#8221; beginning on page 147 of this proxy statement/prospectus.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:10pt;margin-top:10pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Quantification of Potential Payments and Benefits to ARCA Named Executive Officers</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">In accordance with Item&#160;402(t)&#160;of Regulation&#160;S<span class="nobreak">-K</span>, the table below sets forth the compensation that is based on or otherwise relates to the Offer and the Merger that may be paid or become payable to each of ARCA named executive officer in connection with the Merger. Please see the previous portions of this section for further information regarding this compensation.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The amounts indicated in the table below are estimates of the amounts that would be payable assuming, solely for purposes of this table, that (i)&#160;the Merger was consummated on May&#160;1, 2024, (ii)&#160;each ARCA named executive officer&#8217;s employment was terminated by ARCA without cause immediately following consummation of the Merger, (ii)&#160;the value per share of ARCA common stock on consummation of the Merger is $3.09 (which, in accordance with SEC requirements, is equal to the average closing price of a share of ARCA common stock over the first five&#160;business days following the first public announcement of the Merger on April&#160;3, 2024), and (iii)&#160;the Parent Closing Price is $3.09. The ARCA named executive officer will not receive pension, tax reimbursement or other benefits in connection with the Merger.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Some of the amounts set forth in the table would be payable solely by virtue of the consummation of the Merger. In addition to the assumptions regarding the consummation date of the Merger and the termination of employment, these estimates are based on certain other assumptions that are described in the footnotes accompanying the table below. Accordingly, the ultimate values to be received by an ARCA named executive officer in connection with the Merger may differ from the amounts set forth below.</p>
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 3pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">



						<p class="TCH_left" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Name</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Cash&#160;($)</span><span class="Bold-Superscript" style="font-style:normal;font-weight:bold;vertical-align:super;font-size:58%;">(1)</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Equity&#160;($)</span><span class="Bold-Superscript" style="font-style:normal;font-weight:bold;vertical-align:super;font-size:58%;">(2)</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Perquisites/<br/>Benefits&#160;($)</span><span class="Bold-Superscript" style="font-style:normal;font-weight:bold;vertical-align:super;font-size:58%;">(3)</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Total&#160;($)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Michael R.&#160;Bristow<span class="Superscript" style="vertical-align:super;font-size:58%;">(4)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">370,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">10,555</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">380,555</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Thomas A.&#160;Keuer</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">505,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3,889</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">40,746</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">549,635</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">C.&#160;Jeffrey Dekker</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">435,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,310</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">36,579</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">473,889</p>
					</td>
				</tr>

		</table>
		<p class="Tablefootnotef" style="margin-top: 0in;  border: none; margin-right: 0in; margin-bottom: -5pt; margin-left: 24.0pt; text-align: justify; text-justify: inter-ideograph; text-indent: -24.0pt; padding: 0in; font-size: 9.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">____________</p><p class="Tablefootnote_f" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:10pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(1)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>The cash amounts represent: (i)&#160;with respect to Mr.&#160;Bristow, the cash severance payments that are payable to him in connection with his prior termination of employment pursuant to his Separation Agreement and Release with ARCA dated April&#160;3, 2024, as described under &#8220;ARCA Executive Compensation&#160;&#8212;&#160;Narrative Disclosure to Summary Compensation Table&#160;&#8212;&#160;Employment Agreements or Arrangements&#8221; below, which are being included herein out of an abundance of caution but which will be payable notwithstanding the consummation of the Merger, and (ii)&#160;with respect to Mr.&#160;Keuer and Mr.&#160;Dekker, (A)&#160;a $165,000 retention bonus payable in connection with the closing of the Merger, which constitutes a single<span class="nobreak">-trigger</span> benefit, and (B)&#160;aggregate cash severance payments of $340,000 with respect to Mr.&#160;Keuer and $270,000 with respect to Mr.&#160;Dekker that may be payable in connection with the Merger pursuant to their respective employment agreements upon a termination by ARCA without Cause or by the ARCA named executive officer for Good Reason on or within 13&#160;months following a Corporate Transaction (as such terms are defined in the applicable employment agreement) subject to their timely execution and non<span class="nobreak">-revocation</span> of a release in favor of ARCA, which constitutes a double<span class="nobreak">-trigger</span> benefit. For more information, please see the section above captioned &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">&#8212;&#160;Employment Agreements</span>.&#8221;</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;">(2)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Represents ARCA stock options (which ARCA refers to as the &#8220;Executive Equity Awards&#8221;) that will accelerate and vest in the Merger, assuming, solely for purposes of this table, continued employment or service of each ARCA named executive officer through the Closing Date. Pursuant to the Merger Agreement, each Executive Equity Award will fully accelerate on the Closing Date and thus constitute a single<span class="nobreak">-trigger</span> benefit. No value is reflected herein for any Executive Equity Award with an exercise price in excess of $3.09, as Executive Equity Awards with values in excess of the Parent Closing Price will </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">123</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;text-indent:0pt;margin-top:0pt;">be cancelled for no consideration. The values for each Executive Equity Award with an exercise price in excess of $3.09 in the table below represent the product of (i)&#160;the difference between $3.09 and the applicable exercise price of the Executive Equity Award, multiplied by (ii)&#160;the number of shares of ARCA common stock subject to the Executive Equity Award, as applicable, that accelerate and vest in connection with the Merger:</p>
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-25" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 54.30%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">



						<p class="TCH_left" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Name</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.95%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Number&#160;of <br/>ARCA<br/>Shares&#160;Subject&#160;to<br/>Executive&#160;Equity<br/>Award (#)</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Per&#160;Share&#160;Value<br/>of&#160;Executive<br/>Equity&#160;Award <br/>($)</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.81%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Total ($)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 54.30%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Michael R.&#160;Bristow</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">13,194</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">0.80</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.81%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">10,555</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 54.30%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Thomas A.&#160;Keuer</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4,861</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">0.80</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.81%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3,889</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 54.30%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">C.&#160;Jeffrey Dekker</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,458</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">0.80</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.81%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,966</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 54.30%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">C. Jeffrey Dekker</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">11,458</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">0.03</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.81%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">344</p>
					</td>
				</tr>

		</table>
		<p class="Textfootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;margin-top:8pt;">(3)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Represents the estimated value of the premiums ARCA would be required to reimburse to Messrs. Keuer and Dekker for continued health coverage under COBRA for a period of 12&#160;months that may be payable in connection with the Merger pursuant to their respective employment agreements upon a termination by ARCA without Cause or by the ARCA named executive officer for Good Reason on or within 13&#160;months following a Corporate Transaction (as such terms are defined in the applicable employment agreement) subject to their timely execution and non<span class="nobreak">-revocation</span> of a release in favor of ARCA, which constitutes a double<span class="nobreak">-trigger</span> benefit. For more information, please see the section above captioned &#8220;&#8212;&#160;Employment Agreements.&#8221;</p>
		<p class="Textfootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(4)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Dr.&#160;Bristow, ARCA&#8217;s former President and Chief Executive Officer, terminated employment with ARCA on April&#160;3, 2024.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Interests of Oruka&#8217;s Directors and Executive Officers in the Merger</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In considering the recommendation of Oruka&#8217;s board of directors with respect to approving the Merger, stockholders should be aware that Oruka&#8217;s directors and executive officers have interests in the Merger that are different from, or in addition to, the interests of Oruka stockholders generally. These interests may present them with actual or potential conflicts of interest, and these interests, to the extent material, are described below.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka&#8217;s board of directors was aware of these potential conflicts of interest and considered them, among other matters, in reaching its decision to approve the Merger Agreement and the Merger, and to recommend that the Oruka stockholders approve the Merger as contemplated by this proxy statement/prospectus.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka Ownership Interests</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of May&#160;13, 2024, Oruka&#8217;s current non<span class="nobreak">-employee</span> directors and executive officers beneficially owned, in the aggregate approximately 73.5% of the shares of Oruka capital stock, which for purposes of this subsection excludes any Oruka shares issuable upon exercise or settlement of Oruka options held by such individual. Each of Oruka&#8217;s officers, directors and affiliated stockholders have also entered into a support agreement in connection with the Merger. For a more detailed discussion of the support agreements, please see the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Agreements Related to the Merger&#160;&#8212;&#160;Support Agreements</span>&#8221; beginning on page 153 of this proxy statement/prospectus.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As noted above, Fairmount Fund&#160;II, an affiliate of Peter Harwin, an Oruka director, Lawrence Klein, Oruka&#8217;s President and Chief Executive Officer, and Turtle Family Trust, of which Cameron Turtle, an Oruka director, is a trustee, also currently hold shares of Oruka capital stock. The table below sets forth the ownership of Oruka capital stock by Fairmount Fund&#160;II, Lawrence Klein and Turtle Family Trust as of May&#160;13, 2024. Fairmount Fund II also holds the Convertible Note and has agreed to purchase shares and pre<span class="nobreak">-funded</span> warrants in the Oruka pre<span class="nobreak">-closing</span> financing. For a more detailed discussion of these relationships, please see the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Certain Relationships and Related Party Transactions of the Combined Company&#160;&#8212;&#160;Oruka Transactions&#160;&#8212;&#160;Private Placement of Securities</span>&#8221; beginning on page 281 of this proxy statement/prospectus.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">124</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 3pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-18" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">



						<p class="TCH_left" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Stockholder</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Number&#160;of <br/>Shares of <br/>Capital Stock <br/>hel</span>d</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Fairmount Healthcare Fund&#160;II L.P.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">20,000,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">&#8203;<span class="Superscript" style="vertical-align:super;font-size:58%;">(1)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Lawrence Klein</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,491,646</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">&#8203;<span class="Superscript" style="vertical-align:super;font-size:58%;">(2)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Turtle Family Trust</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">149,164</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">&#8203;<span class="Superscript" style="vertical-align:super;font-size:58%;">(3)</span></p>
					</td>
				</tr>

		</table>
		<p class="Tablefootnotef" style="margin-top: 0in;  border: none; margin-right: 0in; margin-bottom: -5pt; margin-left: 24.0pt; text-align: justify; text-justify: inter-ideograph; text-indent: -24.0pt; padding: 0in; font-size: 9.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">____________</p><p class="Tablefootnote_f" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:10pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:10pt;">(1)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Consists of 20,000,000<span class="nobreak"> </span>shares of Oruka common stock issuable upon conversion of 20,000,000<span class="nobreak"> </span>shares of Oruka Series&#160;A Preferred Stock held by Fairmount Fund&#160;II.&#160;Fairmount Healthcare Fund&#160;II GP LLC (&#8220;Fairmount GP&#160;II&#8221;) is the general partner of Fairmount Fund&#160;II.&#160;Fairmount Funds Management LLC (&#8220;Fairmount Funds Management&#8221;), as the investment manager, along with Fairmount GP&#160;II, as the general partner, exercise voting and investment power over Fairmount Fund&#160;II.&#160;Fairmount Funds Management has voting and dispositive power over the common stock held by Fairmount Fund&#160;II, which is deemed shared with Fairmount GP&#160;II.&#160;As managing members of Fairmount Funds Management and Fairmount GP&#160;II, Peter Harwin and Tomas Kiselak may be deemed beneficial owners of any securities beneficially owned by Fairmount Funds Management. Fairmount Funds Management, Fairmount GP&#160;II, Mr.&#160;Harwin and Mr.&#160;Kiselak disclaim beneficial ownership of such shares of Oruka Series&#160;A Preferred Stock and the underlying shares of Oruka common stock except to the extent of their pecuniary interest therein. The principal business address for these persons and entities is 200&#160;Barr Harbor Drive, Suite 400, West Conshohocken, Pennsylvania 19428.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(2)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Consists of 1,491,646<span class="nobreak"> </span>shares of Oruka common stock held by Lawrence Klein. Such shares were purchased by Mr.<span class="nobreak"> </span>Klein, in anticipation of his service as Oruka&#8217;s Chief Executive Officer, at the fair market value on the purchase date. The purchased shares are subject to vesting as to 25% on February 26, 2025 and in equal monthly installments for the 36&#160;months thereafter.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(3)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Consists of 149,164<span class="nobreak"> </span>shares of Oruka common stock held by Turtle Family Trust, of which Cameron Turtle is a trustee. Such shares were purchased by Dr. Turtle, in anticipation of his service on the Oruka board of directors, at the fair market value on the purchase date. The purchased shares are subject to vesting as to 25% on March 1, 2025 and in equal monthly installments for the 36 months thereafter.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Klein Anti-Dilution Provision</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Pursuant to the amended and restated offer letter agreement between Oruka and Lawrence Klein, Oruka is obligated to issue additional options to purchase shares of Oruka common stock in order to maintain Mr.&#160;Klein&#8217;s ownership in Oruka at the Target Ownership Percentage until Oruka has raised an aggregate of the Covered Limit. As a result, Oruka expects to issue Mr.&#160;Klein additional options of Oruka to maintain his ownership in Oruka at the Target Ownership Percentage concurrently with the closing of the Oruka pre<span class="nobreak">-closing</span> financing up to the Covered Limit.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka Options</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Under the terms of the Merger Agreement, each option to purchase shares of Oruka common stock that is outstanding and unexercised immediately prior to the effective time of the First Merger under Oruka&#8217;s 2024 Equity Incentive Plan and that, following assumption by ARCA at the effective time of the First Merger, will be eligible to be registered on Form&#160;S<span class="nobreak">-8</span>, whether or not vested, will be converted into an option to purchase shares of ARCA common stock. ARCA will assume Oruka&#8217;s 2024 Equity Incentive Plan and each such outstanding option to purchase shares of Oruka common stock in accordance with the terms (as in effect as of the date of the Merger Agreement) of Oruka&#8217;s 2024 Equity Incentive Plan and the terms of the stock option agreement by which such option to purchase shares of Oruka common stock is evidenced. The table below sets forth information regarding the Oruka stock options held as of May&#160;13, 2024 by each of Oruka&#8217;s current executive officers and non<span class="nobreak">-employee</span> directors. The number of shares of common stock underlying such options and the exercise price will be adjusted appropriately to reflect the exchange ratio.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">125</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-34" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 35.47%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">



						<p class="TCH_left" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Name</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Number of</span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Vested</span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Options&#160;Held<br/>(#)</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Weighted</span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Average</span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Exercise&#160;Price</span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">of Vested</span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Options<br/>($)</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Number of</span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Unvested</span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Options&#160;Held<br/>(#)</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Weighted</span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Average</span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Exercise&#160;Price</span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">of Unvested</span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Options<br/>($)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 35.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Executive Officers</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 35.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Lawrence Klein</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 35.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Joana Goncalves</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">400,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3.89</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 35.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Arjun Agarwal</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">225,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2.90</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 35.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Paul Quinlan</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">400,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3.89</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 35.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Non-Employee Directors</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 35.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Peter Harwin</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 35.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Cameron Turtle</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 35.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Carl Dambkowski</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">125,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3.89</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 35.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Samarth Kulkarni</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">350,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2.90</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 35.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Kristine Ball</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">125,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3.89</p>
					</td>
				</tr>

		</table>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka Management Following the Merger</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As described in the section captioned &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Management Following the Merger</span>&#8221; beginning on page 273 of this proxy statement/prospectus certain of Oruka&#8217;s directors and executive officers are expected to become the directors and executive officers of the combined company upon the closing of the Merger.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Indemnification and Insurance</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">For a discussion of the indemnification and insurance provisions related to the Oruka directors and officers under the Merger Agreement, please see the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">The Merger Agreement&#160;&#8212;&#160;Indemnification and Insurance for Directors and Officers</span>&#8221; beginning on page 147 of this proxy statement/prospectus.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Form of the Merger</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Subject to the terms and conditions of the Merger Agreement, and in accordance with the DGCL, (i)&#160;at the First Effective Time, First Merger Sub will merge with and into Oruka, with Oruka continuing as a wholly owned subsidiary of ARCA and the surviving corporation of the First Merger and (ii)&#160;as part of the same overall transaction at the completion of the Second Merger (the &#8220;Second Effective Time&#8221;), Oruka will merge with and into Second Merger Sub, with Second Merger Sub being the surviving entity of the Second Merger.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Merger Consideration and Adjustment</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">At the First Effective Time, upon the terms and subject to the conditions set forth in the Merger Agreement, (i)&#160;each then<span class="nobreak">-outstanding</span> share of Oruka common stock (including shares of Oruka common stock issued in the Oruka pre<span class="nobreak">-closing</span> financing and excluding shares to be canceled pursuant to the Merger Agreement and dissenting shares) will be automatically converted solely into the right to receive a number of shares of ARCA common stock equal to the exchange ratio (described in more detail in the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">The Merger Agreement&#160;&#8212;&#160;Exchange Ratio</span>&#8221; beginning on page 136 of this proxy statement/prospectus), (ii)&#160;each then<span class="nobreak">-outstanding</span> share of Oruka preferred stock will be converted into the right to receive a number of shares of ARCA Series&#160;B Preferred Stock, which are each convertible into 1,000<span class="nobreak"> </span>shares of ARCA common stock, equal to the exchange ratio divided by 1,000, in accordance with the terms of the Merger Agreement, (iii)&#160;each then<span class="nobreak">-outstanding</span> option to purchase Oruka common stock will be assumed by ARCA, subject to adjustment based on the exchange ratio as set forth in the Merger Agreement, and (iv)&#160;each then<span class="nobreak">-outstanding</span> warrant to purchase shares of Oruka common stock will be converted into a warrant to purchase shares of ARCA common stock, subject to adjustment based on the exchange ratio as set forth in the Merger Agreement and the form of warrant.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">No fractional shares of ARCA common stock will be issued in connection with the Merger, and no certificates or scrip for any such fractional shares will be issued. Any fractional shares of ARCA common stock resulting from the conversion of shares of Oruka common stock (including shares of Oruka common stock issued in the </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">126</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">Oruka pre<span class="nobreak">-closing</span> financing) shall be issued as follows: (i)&#160;one share of ARCA common stock if the aggregate amount of fractional shares of ARCA common stock of any individual holder of Oruka capital stock if upon conversion is equal to or exceeds 0.50 or (ii)&#160;no shares of ARCA common stock if the aggregate amount of fractional shares of ARCA common stock of any individual holder of Oruka capital stock if upon conversion is less than 0.50, with no cash being paid for any fractional share eliminated by such rounding. Any fractional shares of ARCA Series&#160;B Preferred Stock that a holder of Oruka preferred stock would otherwise be entitled to receive will be aggregated with all fractional shares of ARCA preferred stock issuable to such holder and rounded up to the nearest whole share of ARCA&#8217;s convertible preferred stock.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Procedures for Exchanging Stock Certificates</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On or prior to the closing date, ARCA and Oruka will select an exchange agent and, at the First Effective Time (as defined herein), ARCA will deposit with the exchange agent evidence of book<span class="nobreak">-entry</span> shares representing the shares of ARCA common stock issuable pursuant to the terms of the Merger Agreement in exchange for shares of Oruka common stock (including shares of Oruka common stock issued in the Oruka pre<span class="nobreak">-closing</span> financing) (excluding shares to be canceled pursuant to the Merger Agreement and excluding dissenting shares) and the shares of ARCA Series&#160;B Preferred Stock issuable pursuant to the terms of the Merger Agreement in exchange for shares of Oruka preferred stock calculated in accordance with the Merger Agreement.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Promptly after the First Effective Time, the exchange agent will mail to each record holder of Oruka common stock (including shares of Oruka common stock issued in the Oruka pre<span class="nobreak">-closing</span> financing) (excluding shares to be canceled pursuant to the Merger Agreement and excluding dissenting shares) and each record holder of Oruka preferred stock who will receive ARCA Series&#160;B Preferred Stock issuable in exchange for such Oruka preferred stock pursuant to the terms, and calculated in accordance with, the Merger Agreement (i)&#160;a letter of transmittal and (ii)&#160;instructions for surrendering the record holder&#8217;s stock certificates in exchange for the merger consideration. Upon delivery to the exchange agent of a duly executed letter of transmittal in accordance with the exchange agent&#8217;s instructions and the declaration for tax withholding purposes, the surrender of the record holder&#8217;s stock certificates, if applicable, and delivery to the exchange agent of such other documents as may be reasonably required by the exchange agent or ARCA, the record holder of such stock certificates or book<span class="nobreak">-entry</span> shares, as applicable, will be entitled to receive in exchange therefor book<span class="nobreak">-entry</span> shares representing the number of whole shares of ARCA common stock or ARCA Series&#160;B Preferred Stock issuable to such holder pursuant to the Merger Agreement. The surrendered certificates representing shares of Oruka common stock or Oruka preferred stock will be canceled.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">After the First Effective Time, each certificate representing Oruka common stock or Oruka preferred stock that has not been surrendered will represent only the right to receive shares of ARCA common stock or ARCA Series&#160;B Preferred Stock, as applicable, issuable pursuant to the Merger Agreement to which the holder of any such certificate is entitled.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-indent:24pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">HOLDERS OF ORUKA COMMON STOCK OR ORUKA PREFERRED STOCK SHOULD NOT SEND IN THEIR ORUKA STOCK CERTIFICATES UNTIL THEY RECEIVE A LETTER OF TRANSMITTAL FROM THE EXCHANGE AGENT WITH INSTRUCTIONS FOR THE SURRENDER OF ORUKA STOCK CERTIFICATES.</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">First Effective Time and Second Effective Time</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Merger Agreement requires the parties to consummate the Merger as promptly as practicable (and in any event within two&#160;business days) after all of the conditions to the consummation of the Merger contained in the Merger Agreement are satisfied or waived, including the adoption of the Merger Agreement by the Oruka stockholders and the approval by the ARCA stockholders of the issuance of ARCA common stock, including shares of ARCA common stock issuable upon conversion of ARCA Series&#160;B Preferred Stock, and the other transactions proposed under the Merger Agreement, other than those conditions that by their nature are to be satisfied at the closing of the Merger. The First Merger will become effective upon the filing of a certificate of merger (the &#8220;First Certificate of Merger&#8221;) with the Secretary of State of the State of Delaware or at such later time as is agreed by ARCA and Oruka and specified in the First Certificate of Merger. The Second Merger will become effective upon the filing of a certificate of merger (the &#8220;Second Certificate of Merger&#8221;) with the Secretary of State of the State of Delaware or at such later time as is agreed by ARCA and Oruka and specified in the Second Certificate of Merger. Neither ARCA nor Oruka can predict the exact timing of the consummation of the Merger.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">127</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Regulatory Approvals</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In the United&#160;States, ARCA must comply with applicable federal and state securities laws and the rules and regulations of Nasdaq in connection with the issuance of shares of ARCA common stock, including shares of ARCA common stock issuable upon conversion of ARCA Series&#160;B Preferred Stock, to Oruka&#8217;s stockholders in connection with the transactions contemplated by the Merger Agreement and the filing of this proxy statement/prospectus with the SEC.&#160;ARCA and Oruka do not intend to seek any regulatory approval from antitrust authorities to consummate the transactions.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Material U.S.&#160;Federal Income Tax Consequences of the Merger</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following discussion is a summary of U.S.&#160;federal income tax consequences of the Merger generally applicable to a U.S.&#160;holder (as defined below) of Oruka common stock or Oruka preferred stock (&#8220;Oruka stock&#8221;). This discussion applies only to a U.S.&#160;holder that holds its Oruka stock as a capital asset for U.S.&#160;federal income tax purposes (generally, property held for investment). This discussion is a summary only and does not discuss all aspects of U.S.&#160;federal income taxation that may be relevant to U.S.&#160;holders in light of their particular circumstances or U.S.&#160;holders with special status, including:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>brokers, dealers or traders in securities, banks, insurance companies, other financial institutions or mutual funds;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>real estate investment trusts; regulated investment companies; tax<span class="nobreak">-exempt</span> organizations or governmental organizations;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>pass<span class="nobreak">-through</span> entities such as partnerships, S corporations, disregarded entities for federal income tax purposes and limited liability companies (and investors therein);</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>persons that have a functional currency other than the U.S.&#160;dollar;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>taxpayers that are subject to the mark<span class="nobreak">-to-market</span> accounting rules;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>persons who hold their Oruka stock that constitutes &#8220;qualified small business stock&#8221; under Section&#160;1202 of the Code or as &#8220;Section&#160;1244 stock&#8221; for purposes of Section&#160;1244 of the Code;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>persons that hold their Oruka stock as part of a straddle, constructive sale, hedging, conversion or other integrated or similar transaction;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>persons who exercise dissenters&#8217; rights;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>persons who acquired their shares of Oruka stock pursuant to the exercise of options or otherwise as compensation or through a tax<span class="nobreak">-qualified</span> retirement plan or through the exercise of a warrant or conversion rights under convertible instruments;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>persons who acquired their Oruka stock in a transaction subject to the gain rollover provisions of Section&#160;1045 of the Code; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>expatriates or former citizens or long<span class="nobreak">-term</span> residents of the United&#160;States.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">This discussion is based on the Code, proposed, temporary and final Treasury Regulations promulgated under the Code, and judicial and administrative interpretations thereof, all as of the date hereof and all of which are subject to change, which change could apply retroactively and could affect the tax consequences described herein. This discussion does not address (i)&#160;the tax consequences of the Merger under U.S.&#160;federal non<span class="nobreak">-income</span> tax law (including estate, gift, or other non<span class="nobreak">-income</span> taxes), (ii)&#160;the tax consequences of the Merger under state, local or non<span class="nobreak">-U</span>.S.&#160;tax laws, (iii)&#160;the impact of the alternative minimum tax provisions of the Code (including the 15% minimum tax applicable to the adjusted financial statement income of certain corporations) or the Medicare contribution tax on net investment income, (iv)&#160;the tax consequences of transactions effectuated before, subsequent to or concurrently with the Merger (whether or not any such transactions are consummated in connection with the Merger), including any transaction in which shares of Oruka stock are acquired, or (v)&#160;the tax consequences to holders of Oruka stock options, Oruka warrants or similar rights to acquire Oruka stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka has not and does not intend to seek any rulings from the Internal Revenue Service (the &#8220;IRS&#8221;) regarding the Merger. There can be no assurance that the IRS will not take positions inconsistent with the consequences discussed below or that any such positions would not be sustained by a court.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">128</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If any entity or arrangement classified as a partnership for U.S.&#160;federal income tax purposes holds Oruka stock, the tax treatment of such partnership and any person treated as a partner of such partnership will generally depend on the status and activities of the partner and the activities of the partnership. Each partnership holding any Oruka stock and each person that is treated as a partner of such partnership should consult its tax advisor as to the particular U.S.&#160;federal income tax consequences of the Merger.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As used herein, a &#8220;U.S.&#160;holder&#8221; is a beneficial owner of Oruka stock that is, for U.S.&#160;federal income tax purposes:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>an individual citizen or resident of the United&#160;States;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>a corporation (or other entity that is classified as a corporation for U.S.&#160;federal income tax purposes) that is created or organized (or treated as created or organized) in or under the laws of the United&#160;States, any state thereof, or the District of Columbia or otherwise treated as a U.S.&#160;tax resident for U.S.&#160;federal income tax purposes;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>an estate whose income is subject to U.S.&#160;federal income tax regardless of its source; or</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>a trust if (1)&#160;a U.S.&#160;court can exercise primary supervision over the administration of such trust and one or more U.S.&#160;persons have the authority to control all substantial decisions of the trust or (2)&#160;it has a valid election in place to be treated as a U.S.&#160;person.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Effects of the Merger</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In connection with the filing of this Registration Statement, Gibson, Dunn &amp; Crutcher LLP, counsel to Oruka, and Wilson Sonsini Goodrich &amp; Rosati, P.C., counsel to ARCA, will each deliver an opinion that the Merger will qualify as a &#8220;reorganization&#8221; within the meaning of Section 368(a) of the Code (the &#8220;Tax Opinions&#8221;). The Tax Opinions will be based on, among other things, certain assumptions stated in the Tax Opinions and in the Registration Statement, as well as on the accuracy, correctness and completeness of certain covenants, representations and statements made by Oruka and ARCA. If any of the assumptions, representations or statements made by Oruka or ARCA are, or become, inaccurate, incorrect or incomplete, or if Oruka or ARCA breach any of their covenants, the Tax Opinions may be invalid and the conclusions reached therein could be jeopardized. Neither ARCA nor Oruka intends to request any ruling from the IRS as to the U.S. federal income tax considerations of the Merger. Consequently, no assurance can be given that the IRS will not challenge the conclusions reflected below or in the Tax Opinions or that a court would not sustain such a challenge.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Based on the assumptions, qualifications and limitations described herein and in the Tax Opinions, the Merger will qualify as a &#8220;reorganization&#8221; within the meaning of Section 368(a) of the Code. As a result, a U.S. holder of Oruka stock generally will not recognize any gain or loss for U.S. federal income tax purposes upon receipt of ARCA common stock or ARCA Series B Preferred Stock (&#8220;ARCA stock&#8221;) in the Merger, as applicable. Each U.S.&#160;holder&#8217;s aggregate tax basis in the ARCA stock received in the Merger will equal such U.S.&#160;holder&#8217;s aggregate adjusted tax basis in the Oruka stock surrendered in the Merger. The holding period of the ARCA stock received by a U.S.&#160;holder in the Merger will include such U.S.&#160;holder&#8217;s holding period for the Oruka stock surrendered in the Merger. If a U.S.&#160;holder holds different blocks of Oruka stock (generally, Oruka stock acquired on different dates or at different prices), such U.S.&#160;holder is urged to consult his, her or its tax advisor with respect to the determination of the tax bases and/or holding periods of the shares of ARCA stock received in the Merger.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Information Reporting</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Each U.S.&#160;holder who receives ARCA stock in the Merger is required to retain permanent records pertaining to the Merger and make such records available to any authorized IRS officers and employees. Such records should specifically include information regarding the amount, basis, and fair market value of all transferred property, and relevant facts regarding any liabilities assumed or extinguished as part of such reorganization. Each U.S.&#160;holder who owned immediately before the Merger at least one percent (by vote or value) of the total outstanding stock of Oruka is required to attach a statement to its tax return for the year in which the Merger is consummated that contains the information listed in Treasury Regulation&#160;Section&#160;1.368<span class="nobreak">-3</span>(b). Such statement must include the U.S.&#160;holder&#8217;s tax basis in such U.S.&#160;holder&#8217;s Oruka stock surrendered in the Merger, the fair market value of such Oruka stock, the date of the Merger and the name and employer identification number of each of Oruka and ARCA.&#160;Each U.S.&#160;holder is urged to consult with its tax advisor to comply with these rules.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">129</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">This discussion of U.S.&#160;federal income tax considerations of the Merger is for general information purposes only and is not intended to be, and should not be construed as, tax advice. Determining the actual tax consequences of the Merger to you may be complex and will depend on your specific situation and on factors that are not within ARCA&#8217;s knowledge or control. You should consult your tax advisor with respect to the application of U.S.&#160;federal income tax laws to your specific situation as well as any tax consequences arising under the U.S.&#160;federal estate or gift tax rules or under the laws of any state, local, non</span><span class="nobreak"><span class="Bold" style="font-style:normal;font-weight:bold;">-U</span></span><span class="Bold" style="font-style:normal;font-weight:bold;">.S.&#160;or other taxing jurisdiction.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Material U.S.&#160;Federal Income Tax Consequences of the Special Cash Dividend to Holders of ARCA Common Stock</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">The following discussion is a summary of the material U.S.&#160;federal income tax considerations generally applicable to U.S.&#160;holder (as defined below) of ARCA common stock who receive the special cash dividend. This section applies only to U.S.&#160;holders that hold their ARCA common stock as capital assets for U.S.&#160;federal income tax purposes (generally, property held for investment). This discussion is a summary only and does not discuss all aspects of U.S.&#160;federal income taxation that may be relevant to U.S.&#160;holders in light of their particular circumstances or status including:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>brokers, dealers or traders in securities, banks, insurance companies, other financial institutions or mutual funds;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>real estate investment trusts; regulated investment companies; tax<span class="nobreak">-exempt</span> organizations or governmental organizations; qualified foreign pension funds (or entities wholly owned by one or more qualified foreign pension funds);</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>persons that have a functional currency other than the U.S.&#160;dollar;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>taxpayers that are subject to the mark<span class="nobreak">-to-market</span> accounting rules</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>persons who hold shares of ARCA common stock that constitute &#8220;qualified small business stock&#8221; under Section&#160;1202 of the Code or as &#8220;Section&#160;1244 stock&#8221; for purposes of Section&#160;1244 of the Code;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>persons that hold their ARCA common stock as part of a straddle, constructive sale, hedging, conversion or other integrated or similar transaction;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>persons who acquired their shares of ARCA common stock in a transaction subject to the gain rollover provisions under Section&#160;1045 of the Code;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>persons who acquired their shares of ARCA common stock pursuant to the exercise of options or otherwise as compensation or through a tax<span class="nobreak">-qualified</span> retirement plan or through the exercise of a warrant or conversion right under convertible instruments; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>expatriates or former citizens or long<span class="nobreak">-term</span> residents of the United&#160;States.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">This discussion is based on the Code, proposed, temporary and final Treasury Regulations promulgated under the Code, and judicial and administrative interpretations thereof, all as of the date hereof. All of the foregoing is subject to change, which change could apply retroactively and could affect the tax considerations described herein. This discussion does not address U.S.&#160;federal taxes other than those pertaining to U.S.&#160;federal income taxation (such as estate or gift taxes, the alternative minimum tax or the Medicare tax on investment income), nor does it address any aspects of U.S.&#160;state or local or non<span class="nobreak">-U</span>.S.&#160;taxation.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">ARCA has not and does not intend to seek any rulings from the IRS regarding the special cash dividend. There can be no assurance that the IRS will not take positions inconsistent with the considerations discussed below or that any such positions would not be sustained by a court.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">If any entity or arrangement classified as a partnership for U.S.&#160;federal income tax purposes holds ARCA common stock, the tax treatment of such partnership and any person treated as a partner of such partnership will generally depend on the status and activities of the partner and the activities of the partnership. Partnerships holding any ARCA common stock and persons that are treated as partners of such partnerships should consult their tax advisors as to the particular U.S.&#160;federal income tax consequences of the special cash dividend to them.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">As used herein, a &#8220;U.S.&#160;holder&#8221; is a beneficial owner of ARCA common stock that is, for U.S.&#160;federal income tax purposes:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>an individual who is a citizen or resident of the United&#160;States;</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">130</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>a corporation (or other entity that is treated as a corporation for U.S.&#160;federal income tax purposes) that is created or organized (or treated as created or organized) in or under the laws of the United&#160;States, any state thereof or the District of Columbia or otherwise treated as a U.S.&#160;tax resident for U.S.&#160;federal income tax purposes;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>an estate whose income is subject to U.S.&#160;federal income tax regardless of its source; or</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>a trust if (1)&#160;a U.S.&#160;court can exercise primary supervision over the administration of such trust and one or more U.S.&#160;persons (within the meaning of Section&#160;7701(a)(30)&#160;of the Code) have the authority to control all substantial decisions of the trust or (2)&#160;it has a valid election in place to be treated as a U.S.&#160;person (within the meaning of Section&#160;7701(a)(30)&#160;of the Code).</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">This discussion assumes that the distribution of the special cash dividend to holders of ARCA common stock will be treated for U.S.&#160;federal income tax purposes as a transaction that is separate and distinct from the Merger and the proposed reverse stock split. If, contrary to that assumption, the distribution of the special cash dividend to a holder of ARCA common stock were integrated for tax purposes with the proposed reverse stock split, this could affect the calculation of the extent to which the distribution constitutes a taxable dividend or capital gain.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Receipt of the Special Cash Dividend by U.S.&#160;Holders</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The distribution of the special cash dividend should be treated first as a dividend to the extent of ARCA&#8217;s current and accumulated earnings and profits, then as a non<span class="nobreak">-taxable</span> return of capital to the extent of the U.S.&#160;holder&#8217;s basis in its ARCA common stock, and then as capital gain from the sale or exchange of ARCA common stock with respect to any remaining value. Such capital gain will be long<span class="nobreak">-term</span> capital gain if the U.S.&#160;holder&#8217;s holding period in the ARCA common stock exceeds one year at the time of the special cash dividend. Preferential tax rates may apply to long<span class="nobreak">-term</span> capital gains of non<span class="nobreak">-corporate</span> U.S.&#160;holders (including individuals). ARCA currently has an accumulated deficit and expects additional losses in the current period. Thus, ARCA expects most or all of the distribution of the special cash dividend to be treated as other than a dividend for U.S.&#160;federal income tax purposes. However, there can be no assurance that it will be so treated.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Information Reporting and Backup Withholding</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">A U.S.&#160;holder of ARCA common stock may be subject to information reporting and backup withholding for U.S.&#160;federal income tax purposes with respect to the special cash dividends. Backup withholding will not apply, however, to a U.S.&#160;holder who (i)&#160;furnishes a correct taxpayer identification number and certifies the holder is not subject to backup withholding on IRS Form&#160;W<span class="nobreak">-9</span> or a substantially similar form, or (ii)&#160;certifies the holder is otherwise exempt from backup withholding. If a U.S.&#160;holder does not provide a correct taxpayer identification number on IRS Form&#160;W<span class="nobreak">-9</span> or other proper certification, the stockholder may be subject to penalties imposed by the IRS.&#160;Any amounts withheld under the backup withholding rules may be refunded or allowed as a credit against the federal income tax liability of a U.S.&#160;holder of ARCA common stock, if any, provided the required information is timely furnished to the IRS.&#160;U.S.&#160;holders should consult their tax advisors regarding their qualification for an exemption from backup withholding, the procedures for obtaining such an exemption, and in the event backup withholding is applied, to determine if any tax credit, tax refund or other tax benefit may be obtained.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Nasdaq Stock Market Listing</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Shares of ARCA common stock are currently listed on Nasdaq under the symbol &#8220;ABIO.&#8221; ARCA has agreed to use commercially reasonable efforts to (a)&#160;maintain its listing on Nasdaq until the First Effective Time and to obtain approval of the listing of the combined corporation on Nasdaq; (b)&#160;to the extent required by the rules and regulations of Nasdaq, prepare and submit to Nasdaq a notification form for the listing of the shares of ARCA common stock to be issued in connection with the Merger and transactions contemplated thereunder, and to cause such shares to be approved for listing (subject to official notice of issuance); (c)&#160;prepare and timely submit to Nasdaq a notification form for the proposed reverse stock split (if required) and to submit a copy of the amendment to the ARCA Charter effecting the proposed reverse stock split, certified by the Secretary of State of the State of Delaware, to Nasdaq on the closing date of the Merger; and (d)&#160;to the extent required by Nasdaq Marketplace Rule&#160;5110, assist Oruka in preparing and filing an initial listing application for the ARCA common stock issued to Oruka stockholders </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">131</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">(including any common stock issuable upon conversion of the ARCA Series&#160;B Preferred Stock) (the &#8220;Nasdaq Listing Application&#8221;) and to cause such Nasdaq Listing Application to be conditionally approved prior to the First Effective Time.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, under the Merger Agreement, each of ARCA&#8217;s and Oruka&#8217;s obligation to complete the Merger is subject to the satisfaction or waiver by each of the parties, at or prior to the closing of the Merger, of various conditions, including that the Nasdaq Listing Application shall have been approved.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If the Nasdaq Listing Application is approved, ARCA anticipates that the common stock of the combined company will be listed on Nasdaq following the closing of the Merger under the trading symbol &#8220;ORKA.&#8221; In order for the Nasdaq Listing Application to be accepted, among other requirements, the combined company must maintain a bid price of $4.00 or higher for a certain period of time following the proposed reverse stock split.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Anticipated Accounting Treatment</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Merger is expected to be treated by ARCA as a reverse merger and will be accounted for as an in<span class="nobreak">-substance</span> reverse recapitalization of ARCA by Oruka in accordance with U.S.&#160;GAAP as, at close, the transaction is, in essence, the issuance of equity for ARCA&#8217;s net asset, which primarily consist of cash and other nominal non<span class="nobreak">-operating</span> assets and liabilities. For accounting purposes, Oruka is considered to be acquiring the assets and liabilities of ARCA in this transaction based on the terms of the Merger Agreement and other factors, including: (i)&#160;Oruka&#8217;s equity holders will own a substantial majority of the voting rights in the combined company; (ii)&#160;Oruka&#8217;s largest stockholder will retain the largest interest in the combined company; (iii)&#160;Oruka will designate all of the initial members of the board of directors of the combined company; and (iv)&#160;Oruka&#8217;s executive management team will become the management of the combined company. The combined company will be named Oruka Therapeutics, Inc. and be headquartered in Menlo Park, California. Accordingly, the Merger is expected to be treated as the equivalent of Oruka issuing stock to acquire the net assets of ARCA.&#160;As a result of the Merger, the net assets of ARCA will be stated at fair value, which approximates carrying value, with no goodwill or other intangible assets recorded, and the historical results of operations prior to the Merger will be those of Oruka. The direct and incremental costs related to the transaction will be treated as a reduction of the net proceeds received within additional paid<span class="nobreak">-in-capital</span>. See the &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Unaudited Pro Forma Condensed Combined Financial Information</span>&#8221; elsewhere in this proxy statement/prospectus for additional information.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Appraisal Rights and Dissenters&#8217; Rights</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Under the DGCL, ARCA stockholders are not entitled to appraisal rights in connection with the Merger. Oruka stockholders are entitled to appraisal rights in connection with the Merger under Section&#160;262 of the DGCL.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The discussion below is not a complete summary regarding Oruka&#8217;s stockholders&#8217; appraisal rights under Delaware law and is qualified in its entirety by reference to the text of the relevant provisions of Delaware law, which are attached as <span class="Italic" style="font-style:italic;font-weight:normal;">Annex&#160;J</span> in this proxy statement/prospectus. Stockholders intending to exercise appraisal rights should carefully review <span class="Italic" style="font-style:italic;font-weight:normal;">Annex&#160;J</span>.&#160;Failure to follow precisely any of the statutory procedures set forth in <span class="Italic" style="font-style:italic;font-weight:normal;">Annex&#160;J</span> may result in a termination or waiver of these rights. This summary does not constitute legal or other advice, nor does it constitute a recommendation that Oruka stockholders exercise their appraisal rights under Delaware law.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Under Section&#160;262, where a merger is adopted by stockholders by written consent in lieu of a meeting of stockholders pursuant to Section&#160;228 of the DGCL, either the constituent corporation before the effective date of such merger or the surviving corporation, within ten&#160;days after the effective date of such merger, must notify each stockholder of the constituent corporation entitled to appraisal rights of the approval of such merger, the effective date of such merger and that appraisal rights are available.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If the Merger is completed, within ten&#160;days after the effective date of the Merger, Oruka will notify its stockholders that the Merger has been approved, the effective date of the Merger and that appraisal rights are available to any stockholder who has not approved the Merger. Holders of shares of Oruka capital stock who desire to exercise their appraisal rights must deliver a written demand for appraisal to Oruka within 20&#160;days after the date of mailing of that notice, and that stockholder must not have delivered a written consent approving the Merger. A demand for appraisal must reasonably inform Oruka of the identity of the stockholder and that such stockholder intends thereby to demand appraisal of the shares of Oruka capital stock held by such stockholder. Failure to deliver </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">132</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">a written consent approving the Merger will not in and of itself constitute a written demand for appraisal satisfying the requirements of Section&#160;262. All demands for appraisal should be addressed to c/o Oruka Therapeutics, Inc., 855 Oak Grove Ave., Suite 100, Menlo Park, CA 94025 and should be executed by, or on behalf of, the record holder of shares of Oruka capital stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ALL DEMANDS MUST BE RECEIVED BY ORUKA WITHIN&#160;20 DAYS AFTER THE DATE ORUKA MAILS A NOTICE TO ITS STOCKHOLDERS NOTIFYING THEM THAT THE MERGER HAS BEEN APPROVED, THE EFFECTIVE DATE OF THE MERGER AND THAT APPRAISAL RIGHTS ARE AVAILABLE TO ANY STOCKHOLDER WHO HAS NOT APPROVED THE MERGER.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If you fail to deliver a written demand for appraisal within the time period specified above, you will be entitled to receive the merger consideration for your shares of Oruka capital stock as provided for in the Merger Agreement, but you will have no appraisal rights with respect to your shares of Oruka capital stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">To be effective, a demand for appraisal by a holder of shares of Oruka capital stock must be made by, or in the name of, the registered stockholder, fully and correctly, as the stockholder&#8217;s name appears on the stockholder&#8217;s stock certificate(s). Beneficial owners who do not also hold the shares of record may not directly make appraisal demands to Oruka. The beneficial owner must, in these cases, have the registered owner, such as a broker, bank or other custodian, submit the required demand in respect of those shares. If shares are owned of record in a fiduciary capacity, such as by a trustee, guardian or custodian, execution of a demand for appraisal should be made by or for the fiduciary; and if the shares are owned of record by more than one person, as in a joint tenancy or tenancy in common, the demand should be executed by or for all joint owners. An authorized agent, including an authorized agent for two or more joint owners, may execute the demand for appraisal for a stockholder of record; however, the agent must identify the record owner or owners and expressly disclose the fact that, in executing the demand, he or she is acting as agent for the record owner. A record owner, such as a broker, who holds shares as a custodian for others, may exercise the record owner&#8217;s right of appraisal with respect to the shares held for one or more beneficial owners, while not exercising this right for other beneficial owners. In that case, the written demand should state the number of shares as to which appraisal is sought. Where no number of shares is expressly mentioned, the demand will be presumed to cover all shares held in the name of the record owner. In addition, the stockholder must continuously hold the shares of record from the date of making the demand through the effective time.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If you hold your shares of Oruka capital stock in a brokerage account or in other custodian form and you wish to exercise appraisal rights, you should consult with your bank, broker or other custodian to determine the appropriate procedures for the making of a demand for appraisal by the custodian.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">At any time within 60&#160;days after the effective time, any stockholder who has demanded an appraisal, but has neither commenced an appraisal proceeding or joined an appraisal proceeding as a named party, has the right to withdraw such stockholder&#8217;s demand and accept the terms of the Merger by delivering a written withdrawal to Oruka. If, following a demand for appraisal, you have withdrawn your demand for appraisal in accordance with Section&#160;262, you will have the right to receive the merger consideration for your shares of Oruka capital stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Within 120&#160;days after the effective date of the Merger, any stockholder who has delivered a demand for appraisal in accordance with Section&#160;262 will, upon written request to the surviving corporation, be entitled to receive a written statement setting forth the aggregate number of shares not voted in favor of the Merger Agreement and with respect to which demands for appraisal rights have been received and the aggregate number of holders of these shares. This written statement will be mailed to the requesting stockholder within 10&#160;days after the stockholder&#8217;s written request is received by the surviving corporation or within 10&#160;days after expiration of the period for delivery of demands for appraisal, whichever is later. Within 120&#160;days after the effective date of the Merger, either the surviving corporation or any stockholder who has delivered a demand for appraisal in accordance with Section&#160;262 may file a petition in the Delaware Court of Chancery demanding a determination of the fair value of the shares held by all such stockholders. Upon the filing of the petition by a stockholder, service of a copy of the petition must be made upon the surviving corporation. The surviving corporation has no obligation to file a petition in the Delaware Court of Chancery in the event there are dissenting stockholders, and ARCA, which is expected to be the surviving corporation, has no present intent to file a petition in the Delaware Court of Chancery. Accordingly, the failure of a stockholder to file a petition within the period specified could nullify the stockholder&#8217;s previously written demand for appraisal.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">133</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If a petition for appraisal is duly filed by a stockholder and a copy of the petition is delivered to the surviving corporation, the surviving corporation will then be obligated, within 20&#160;days after receiving service of a copy of the petition, to provide the Delaware Court of Chancery with a duly verified list containing the names and addresses of all stockholders who have demanded an appraisal of their shares and with whom agreements as to the value of their shares have not been reached by the surviving corporation. After notice to dissenting stockholders who demanded appraisal of their shares, the Delaware Court of Chancery is empowered to conduct a hearing upon the petition, and to determine those stockholders who have complied with Section&#160;262 and who have become entitled to the appraisal rights provided thereby. The Delaware Court of Chancery may require the stockholders who have demanded appraisal for their shares to submit their stock certificates to the Register in Chancery for notation thereon of the pendency of the appraisal proceedings; and if any stockholder fails to comply with that direction, the Delaware Court of Chancery may dismiss the proceedings as to that stockholder.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">After determination of the stockholders entitled to appraisal of their shares, the Delaware Court of Chancery will appraise the &#8220;fair value&#8221; of the shares owned by those stockholders. This value will be exclusive of any element of value arising from the accomplishment or expectation of the Merger, but may include a fair rate of interest, if any, upon the amount determined to be the fair value. When the value is determined, the Delaware Court of Chancery will direct the payment of the value, with interest thereon accrued during the pendency of the proceeding, if the Delaware Court of Chancery so determines, to the stockholders entitled to receive the same, upon surrender by the holders of the certificates representing those shares. At any time before the entry of judgment in the proceedings, the surviving corporation may pay to each stockholder entitled to appraisal an amount in cash, in which case interest shall accrue thereafter only upon the sum of (i)&#160;the difference, if any, between the amount so paid and the fair value of the shares subject to appraisal as determined by the Delaware Court of Chancery and (ii)&#160;interest theretofore accrued, unless paid at that time.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">In determining fair value and, if applicable, a fair rate of interest, the Delaware Court of Chancery is required to take into account all relevant factors. In Weinberger v. UOP, Inc., the Delaware Supreme Court discussed the factors that could be considered in determining fair value in an appraisal proceeding, stating that &#8220;proof of value by any techniques or methods which are generally considered acceptable in the financial community and otherwise admissible in court&#8221; should be considered, and that &#8220;fair price obviously requires consideration of all relevant factors involving the value of a company.&#8221;</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">Section&#160;262 provides that fair value is to be &#8220;exclusive of any element of value arising from the accomplishment or expectation of the merger.&#8221; In Cede&#160;&amp; Co. v. Technicolor, Inc., the Delaware Supreme Court stated that this exclusion is a &#8220;narrow exclusion [that] does not encompass known elements of value,&#8221; but which rather applies only to the speculative elements of value arising from such accomplishment or expectation. In Weinberger, the Delaware Supreme Court construed Section&#160;262 to mean that &#8220;elements of future value, including the nature of the enterprise, which are known or susceptible of proof as of the date of the merger and not the product of speculation, may be considered.&#8221;</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">You should be aware that the fair value of your shares as determined under Section&#160;262 could be more than, the same as, or less than the value that you are entitled to receive under the terms of the Merger Agreement.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">Costs of the appraisal proceeding may be imposed upon the surviving corporation and the stockholders participating in the appraisal proceeding by the Delaware Court of Chancery as the Court deems equitable in the circumstances. Upon the application of a stockholder, the Delaware Court of Chancery may order all or a portion of the expenses incurred by any stockholder in connection with the appraisal proceeding, including, without limitation, reasonable attorneys&#8217; fees and the fees and expenses of experts, to be charged pro rata against the value of all shares entitled to appraisal. In the absence of such a determination of assessment, each party bears its own expenses. Any stockholder who had demanded appraisal rights will not, after the effective time, be entitled to vote shares subject to that demand for any purpose or to receive payments of dividends or any other distribution with respect to those shares, other than with respect to payment as of a record date prior to the effective time; however, if no petition for appraisal is filed within 120&#160;days after the effective time, or if the stockholder delivers a written withdrawal of his or her demand for appraisal and an acceptance of the terms of the Merger within 60&#160;days after the effective time, then the right of that stockholder to appraisal will cease and that stockholder will be entitled to receive the merger consideration for shares of his or her Oruka capital stock pursuant to the Merger Agreement. Any withdrawal of a demand for appraisal made more than 60&#160;days after the effective time may only be made with the written approval of the surviving corporation. No appraisal proceeding in the Delaware Court of Chancery will be dismissed as to any stockholder without the approval of the court.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">Failure to follow the steps required by Section&#160;262 for perfecting appraisal rights may result in the loss of appraisal rights. In view of the complexity of Section&#160;262, stockholders who may wish to dissent from the Merger and pursue appraisal rights should consult their legal advisors.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">134</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T21"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">THE MERGER AGREEMENT</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">The following is a summary of the material terms of the Merger Agreement. A copy of the Merger Agreement is attached to this proxy statement/prospectus as Annex&#160;A and is incorporated by reference into this proxy statement/prospectus. The Merger Agreement has been attached to this proxy statement/prospectus to provide you with information regarding its terms. It is not intended to provide any other factual information about ARCA, Oruka, First Merger Sub or Second Merger Sub. The following description does not purport to be complete and is qualified in its entirety by reference to the Merger Agreement. You should refer to the full text of the Merger Agreement for details of the Merger and the terms and conditions of the Merger Agreement.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">The Merger Agreement contains representations and warranties that ARCA, First Merger Sub and Second Merger Sub, on the one hand, and Oruka, on the other hand, have made to one another as of specific dates. These representations and warranties have been made for the benefit of the other parties to the Merger Agreement and may be intended not as statements of fact but rather as a way of allocating the risk to one of the parties if those statements prove to be incorrect. In addition, the assertions embodied in the representations and warranties are qualified by information in confidential disclosure letters exchanged by the parties in connection with signing the Merger Agreement. While ARCA and Oruka do not believe that these disclosure letters contain information required to be publicly disclosed under the applicable securities laws, other than information that has already been so disclosed, the disclosure letters do contain information that modifies, qualifies and creates exceptions to the representations and warranties set forth in the attached Merger Agreement. Accordingly, you should not rely on the representations and warranties as current characterizations of factual information about ARCA or Oruka, because they were made as of specific dates, may be intended merely as a risk allocation mechanism between ARCA, First Merger Sub, Second Merger Sub and Oruka and are modified by the disclosure letters.</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Structure</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Subject to the terms and conditions of the Merger Agreement, and in accordance with Delaware law, at the closing of the Merger, First Merger Sub, a wholly owned subsidiary of ARCA formed by ARCA in connection with the Merger, will merge with and into Oruka, with Oruka surviving as a wholly owned subsidiary of ARCA, and immediately following such Merger, and as part of the same overall transaction, Oruka will merge with and into Second Merger Sub and with Second Merger Sub being the surviving entity of such Merger.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Completion and Effectiveness of the Merger</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Merger Agreement requires the parties to consummate the Merger as promptly as practicable (and in any event within two&#160;business days) after all of the conditions to the consummation of the Merger contained in the Merger Agreement are satisfied or waived, including the adoption of the Merger Agreement by the Oruka stockholders and the approval by the ARCA stockholders of the issuance of ARCA common stock, including shares of ARCA common stock issuable upon conversion of ARCA Series&#160;B Preferred Stock, and the other transactions proposed under the Merger Agreement, other than those conditions that by their nature are to be satisfied at the closing of the Merger. The Merger will become effective upon the filing of certificates of Merger with the Secretary of State of the State of Delaware or at such later time as is agreed by ARCA and Oruka and specified in the certificates of Merger. Neither ARCA nor Oruka can predict the exact timing of the consummation of the Merger.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Merger Consideration</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">At the First Effective Time, upon the terms and subject to the conditions set forth in the Merger Agreement, each share of Oruka common stock (including any shares of Oruka common stock issued pursuant to Oruka&#8217;s pre<span class="nobreak">-closing</span> financing) outstanding immediately prior to the First Effective Time (excluding shares to be canceled pursuant to the Merger Agreement and excluding dissenting shares) will be automatically converted solely into the right to receive a number of shares of ARCA common stock equal to the exchange ratio described in more detail below, and each share of Oruka&#8217;s preferred stock outstanding immediately prior to the First Effective Time (excluding shares to be canceled pursuant to the Merger Agreement and excluding dissenting shares) will be automatically converted solely into the right to receive a number of shares of ARCA&#8217;s convertible preferred stock equal to (x)&#160;the exchange ratio described in more details below <span class="Italic" style="font-style:italic;font-weight:normal;">divided by</span> (y)&#160;1,000. No fractional shares of ARCA common stock will be issued in connection with the Merger, and no certificates or scrip for any such fractional shares will be issued. Any fractional shares of ARCA common stock resulting from the conversion of shares of Oruka common stock (including shares of Oruka common stock issued in the Oruka pre<span class="nobreak">-closing</span> financing) shall </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">135</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">be issued as follows: (i)&#160;one share of ARCA common stock if the aggregate amount of fractional shares of ARCA common stock of any individual holder of Oruka capital stock if upon conversion is equal to or exceeds 0.50 or (ii)&#160;no shares of ARCA common stock if the aggregate amount of fractional shares of ARCA common stock of any individual holder of Oruka capital stock if upon conversion is less than 0.50, with no cash being paid for any fractional share eliminated by such rounding. Any fractional shares of ARCA Series&#160;B Preferred Stock would otherwise be entitled to receive will be aggregated with all fractional shares of ARCA preferred stock issuable to such holder and rounded up to the nearest whole share of ARCA&#8217;s convertible preferred stock.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Exchange Ratio</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The exchange ratio is calculated using a formula intended to allocate existing ARCA and Oruka securityholders a percentage of the combined company. Based on ARCA&#8217;s and Oruka&#8217;s capitalization as of April&#160;3, 2024, the date the Merger Agreement was executed, the exchange ratio was estimated to be equal to approximately 7.4631<span class="nobreak"> </span>shares of ARCA common stock. This estimate is subject to adjustment prior to closing of the First Merger for net cash as of 11:59&#160;p.m. Eastern Time on the business&#160;day prior to the anticipated closing date (and as a result, ARCA securityholders could own less, and Oruka securityholders (including, for this purpose, investors in the Oruka pre<span class="nobreak">-closing</span> financing) could own more, or vice versa, of the combined company). ARCA management currently anticipates that ARCA&#8217;s net cash as of closing will be approximately $5.0&#160;million, after giving effect to the special cash dividend, which is expected to be approximately $20.0<span class="nobreak"> </span>million.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Based on the estimates set forth above, after giving effect to the Oruka pre<span class="nobreak">-closing</span> financing, and certain other assumptions, immediately following the completion of the Merger, ARCA securityholders would own approximately 2.39% of the capital stock of the combined company post<span class="nobreak">-Merger</span>, and Oruka securityholders, including shares of Oruka common stock and Oruka warrants purchased in the Oruka pre<span class="nobreak">-closing</span> financing, would own approximately 97.61% of the capital stock of the combined company post<span class="nobreak">-Merger</span>. Under certain circumstances further described in the Merger Agreement, the ownership percentages may be adjusted up or down including, but not limited to, if ARCA&#8217;s net cash as of closing is lower than $5.0&#160;million. ARCA management currently anticipates ARCA&#8217;s net cash as of closing will be approximately $5.0&#160;million, after giving effect to the special cash dividend, which is expected to be approximately $20.0<span class="nobreak"> </span>million, and the currently estimated ownership percentages reflect this projection. There can be no assurances any of these assumptions will be accurate at closing when the final exchange ratio is determined. For more information on the Oruka pre<span class="nobreak">-closing</span> financing, please see the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Agreements Related to the Merger &#8212; Subscription Agreement</span>&#8221; beginning on page 153 in this proxy statement/prospectus.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The exchange ratio formula is the quotient obtained (rounded to four decimal places) by dividing the number of Oruka merger shares (defined below) by the Oruka outstanding shares (defined below), in which:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>&#8220;Aggregate valuation&#8221; means the sum of (i)&#160;the Oruka valuation plus (ii)&#160;the ARCA valuation.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>&#8220;Oruka allocation percentage&#8221; means the percentage (rounded to four decimal places) determined by subtracting the ARCA allocation percentage from 100%.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>&#8220;Oruka merger shares&#8221; means the product determined by multiplying (i)&#160;the post<span class="nobreak">-closing</span> ARCA shares by (ii)&#160;the Oruka allocation percentage.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>&#8220;Oruka outstanding shares&#8221; means, without duplication, the total number of shares of Oruka capital stock outstanding immediately prior to the First Effective Time, (including any shares of Oruka common stock or Oruka preferred stock that are issued in, or issuable upon the exercise or conversion of securities issued in, the Oruka pre<span class="nobreak">-closing</span> financing), expressed on a fully diluted and as<span class="nobreak">-converted-to-Oruka</span> common stock basis, assuming, without limitation or duplication, the exercise of all options and warrants to acquire Oruka&#8217;s capital stock and other rights or commitments to receive shares of Oruka common stock or Oruka preferred stock (or securities convertible or exercisable into shares of Oruka common stock or Oruka preferred stock, including the convertible promissory note convertible into Oruka common stock), whether conditional or unconditional, that are outstanding as of immediately prior to the First Effective Time. The calculation of Oruka outstanding shares:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-left:72pt;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>excludes, to avoid the double<span class="nobreak">-counting</span> of, any shares of Oruka common stock or Oruka preferred stock (or securities convertible or exercisable into shares of Oruka common stock or Oruka preferred stock, including any convertible promissory note convertible into Oruka common stock) to the extent such shares or securities are contributed as consideration in the Oruka pre<span class="nobreak">-closing</span> financing; and</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">136</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-left:72pt;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>includes to the extent not already issued prior to the First Effective Time, (i)&#160;any shares of Oruka common stock or Oruka preferred stock (or securities convertible or exercisable into shares of Oruka common stock or Oruka preferred stock) issuable to the &#8220;Paragon Entities&#8221; (as such term is defined in Oruka&#8217;s organizational documents) as a result of the contemplated transactions pursuant to Oruka&#8217;s organizational documents and (ii)&#160;any shares of Oruka common stock or Oruka preferred stock (or securities convertible or exercisable into shares of Oruka common stock or Oruka preferred stock) issuable pursuant to an offer letter set forth in the Oruka disclosure letter.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>&#8220;Oruka valuation&#8221; means (i)&#160;$175&#160;million <span class="Italic" style="font-style:italic;font-weight:normal;">plus</span> (ii)&#160;the amount of proceeds actually received by Oruka from the Oruka pre<span class="nobreak">-closing</span> financing (including in the proceeds actually received from any convertible promissory notes convertible into Oruka common stock, and any interest thereon, contributed as consideration in the Oruka pre<span class="nobreak">-closing</span> financing).</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>&#8220;ARCA allocation percentage&#8221; means the quotient (expressed as a percentage and rounded to four decimal places) determined by dividing (i)&#160;the ARCA valuation by (ii)&#160;the aggregate valuation.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>&#8220;ARCA outstanding shares&#8221; means, without duplication, (including, without limitation, the effects of any reverse split, if completed) the total number of shares of ARCA common stock outstanding immediately prior to the First Effective Time expressed on a fully<span class="nobreak">-diluted</span> basis, and assuming, without limitation or duplication, the issuance of shares of ARCA common stock in respect of all options, warrants or other rights or commitments to receive shares of ARCA common stock or ARCA preferred stock (or securities convertible or exercisable into shares of ARCA common stock or ARCA preferred stock, but excluding any ARCA convertible preferred stock issuable as a result of the Merger), whether conditional or unconditional, that are outstanding as of immediately prior to the First Effective Time other than options to acquire shares of ARCA common stock to the extent cancelled at or prior to closing under Section&#160;6.6(c)&#160;of the Merger Agreement.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>&#8220;ARCA valuation&#8221; means (i)&#160;$11,000,000, minus (ii)&#160;the amount by which ARCA net cash is less than $5,000,000 (if any).</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>&#8220;Post<span class="nobreak">-closing</span> ARCA shares&#8221; means the quotient determined by dividing (i)&#160;the ARCA outstanding shares by (ii)&#160;the ARCA allocation percentage. The estimated exchange ratio for purposes of the unaudited pro forma condensed combined financial information was derived on a fully<span class="nobreak">-diluted</span> basis as of March<span class="nobreak">&#160;</span>31, 2024 using a stipulated value of Oruka of approximately $175&#160;million (excluding the Oruka pre<span class="nobreak">-closing</span> financing) and of ARCA of approximately $11&#160;million. For more information, see &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Unaudited Pro Forma Condensed Combined Financial Information.</span>&#8221;</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Calculation of ARCA&#8217;s Net Cash</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Pursuant to the terms of the Merger Agreement, ARCA&#8217;s &#8220;net cash&#8221; means, as of 11:59&#160;p.m. Eastern Time on the last business&#160;day prior to the anticipated closing date, the sum (without duplication) of the following:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s unrestricted cash and cash equivalents and marketable securities determined, to the extent in accordance with GAAP, in a manner consistent with the manner in which such items were historically determined and in accordance with the financial statements (including any related notes) contained or incorporated by reference in ARCA&#8217;s SEC filings or ARCA&#8217;s balance sheet;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Certain ARCA prepaid expenses set forth in ARCA&#8217;s disclosure letter; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>All receivables which ARCA and Oruka may mutually agree are recoverable by or provide benefit to ARCA after the First Effective Time (if any).</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;"><span class="CharOverride-1" style="font-style:italic;font-weight:normal;text-decoration:underline;">minus</span> the sum (without duplication) of the following:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s consolidated short<span class="nobreak">-term</span> and long<span class="nobreak">-term</span> contractual obligations and liabilities accrued at the closing date, in each case determined in accordance with GAAP and, to the extent in accordance with GAAP, in a manner consistent with the manner in which such items were historically determined and in accordance with the financial statements (including any related notes) contained or incorporated by reference in the ARCA&#8217;s SEC reports and its balance sheet;</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">137</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>The aggregate amount (without duplication) of all fees and expenses incurred by ARCA prior to the First Effective Time in connection with the contemplated transactions or the sale of ARCA&#8217;s legacy business, in each case, to the extent unpaid as of the First Effective Time, including;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>any fees and expenses of legal counsel, accountants, financial advisors, investment bankers, brokers, consultants, tax advisors, and other professional advisors of ARCA in connection with the transactions contemplated by the Merger Agreement or the sale of ARCA&#8217;s legacy business;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>50% of the fees paid to the SEC in connection with filing this registration statement and any amendments and supplements thereto, with the SEC;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>50% of the fees and expenses in connection with the printing, mailing and distribution of this proxy statement and any amendments and supplements thereto;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>50% of the fees associated with the filing of Oruka&#8217;s initial listing application with Nasdaq;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>any bonus, retention payments, severance, change<span class="nobreak">-in-control</span> payments or similar payment obligations (including payments with &#8220;single<span class="nobreak">-trigger</span>&#8221; provisions triggered at and as of the consummation of the transactions contemplated hereby) that become due or payable to any director, officer, employee or consultant in connection with the consummation of the contemplated transactions or the sale of ARCA&#8217;s legacy business, together with any payroll taxes associated therewith;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the dividend by ARCA of any excess net cash (but only to the extent declared and unpaid) and all costs and expenses associated therewith; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the costs associated with obtaining the &#8220;D&amp;O tail policy&#8221; pursuant to Section&#160;6.7 of the Merger Agreement.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>All remaining rent payments and any other liabilities under ARCA&#8217;s lease obligations;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Any unpaid taxes of ARCA and its subsidiaries for tax periods (or portions thereof) ending on or before the closing date;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>All costs and expenses to be mutually agreed by ARCA and Oruka relating to the winding down of ARCA&#8217;s legacy business, including the sale, license or other disposition of any or all of ARCA&#8217;s legacy business to the extent unpaid as of the closing; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>The amounts due and payable to holders of options to acquire shares of ARCA&#8217;s common stock with an exercise price less than or equal to the Parent Closing Price that are cancelled and converted into the right to receive an amount in cash, without interest, equal to the Parent Closing Price less the exercise price of such options, in accordance with the Merger Agreement, to the extent unpaid as of the First Effective Time.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">No later than five&#160;business days prior to the anticipated closing date, (i)&#160;ARCA will deliver to Oruka a net cash schedule setting forth, in reasonable detail, ARCA&#8217;s good faith estimated calculation of its net cash and (ii)&#160;Oruka will deliver to ARCA a Oruka valuation schedule setting forth, in reasonable detail, Oruka&#8217;s good faith estimated calculations of the components of Oruka&#8217;s valuation, in each case, as of 11:59&#160;p.m. Eastern Time on the last business&#160;day prior to the anticipated closing date, prepared and certified by ARCA&#8217;s and Oruka&#8217;s chief financial officer (or if there is no chief financial officer, the principal financial and accounting officer), as the case may be, and, if requested, the relevant work papers and back<span class="nobreak">-up</span> materials used or useful in preparing the net cash schedule and Oruka valuation schedule, respectively. No later than three&#160;business days after delivery of such net cash schedule (the last&#160;day of such period referred to as the response date), Oruka will have the right to dispute any part of the net cash schedule by delivering a written notice to that effect to ARCA (referred to herein as a dispute notice). Any dispute notice will identify, in reasonable detail and, to the extent known, the nature and amounts of any proposed revisions to ARCA&#8217;s net cash calculation. No later than three&#160;business days after delivery of such Oruka valuation schedule (the last&#160;day of such period referred to as the response date), ARCA will have the right to dispute any part of such schedule by delivering a written notice to that effect to Oruka (referred to herein as an Oruka valuation dispute notice). Any dispute notice will identify, in reasonable detail and, to the extent known, the nature and amounts of any proposed revisions to Oruka&#8217;s valuation calculation.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">138</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If Oruka disputes the net cash schedule or ARCA disputes the Oruka valuation schedule, the parties shall attempt in good faith to resolve the disputed items and negotiate an agreed<span class="nobreak">-upon</span> determination of net cash and/or Oruka&#8217;s valuation, as the case may be. If the parties are unable to negotiate an agreed<span class="nobreak">-upon</span> determination of the disputed items or component thereof within three&#160;days after the delivery of the relevant dispute notice, any remaining disagreements will be referred to an independent auditor of recognized national standing mutually agreed upon by ARCA and Oruka. The determination of the amount of net cash or Oruka valuation made by such auditor shall be final and binding on ARCA and Oruka.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s net cash balance is subject to numerous factors, some of which are outside of ARCA&#8217;s control. The actual amount of net cash will depend significantly on the timing of the closing of the Merger. In addition, the closing of the Merger could be delayed if ARCA and Oruka are not able to agree upon the amount of ARCA&#8217;s net cash as of 11:59&#160;p.m. Eastern Time on the last business&#160;day prior to the anticipated closing date.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Oruka Options</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Under the terms of the Merger Agreement, each option to purchase shares of Oruka common stock that is outstanding and unexercised immediately prior to the First Effective Time, whether or not vested, will be assumed and converted into an option to purchase shares of ARCA common stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Accordingly, from and after the First Effective Time: (i)&#160;each outstanding Oruka stock option assumed by ARCA may be exercised solely for shares of ARCA common stock; (ii)&#160;the number of shares of ARCA common stock subject to each outstanding Oruka stock option assumed by ARCA will be determined by multiplying (A)&#160;the number of shares of Oruka common stock that were subject to such Oruka stock option assumed by ARCA, as in effect immediately prior to the First Effective Time, by (B)&#160;the exchange ratio, and rounding the resulting number down to the nearest whole number of shares of ARCA common stock; and (iii)&#160;the per share exercise price of each Oruka stock option assumed by will be determined by dividing (A)&#160;the per share exercise price of such Oruka stock option, as in effect immediately prior to the First Effective Time, by (B)&#160;the exchange ratio and rounding the resulting exercise price up to the nearest whole cent. Each Oruka stock option assumed by ARCA will otherwise continue in full force and effect and the term, exercisability, vesting schedule, acceleration rights and other terms and conditions of such Oruka stock option will otherwise remain unchanged.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">To the extent provided under the terms of a Oruka stock option assumed by ARCA in accordance with the terms of the Merger Agreement, such Oruka stock option shall, in accordance with its terms, be subject to further adjustment as appropriate to reflect any stock split, division or subdivision of shares, stock dividend, reverse stock split, consolidation of shares, reclassification, recapitalization or other similar transaction with respect to shares of ARCA common stock subsequent to the First Effective Time. In addition, ARCA&#8217;s board of directors or a committee thereof will succeed to the authority and responsibility of Oruka&#8217;s board of directors or any committee thereof with respect to each Oruka option assumed by ARCA in accordance with the terms of the Merger Agreement.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Oruka Warrants</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Under the terms of the Merger Agreement, each warrant to purchase shares of Oruka capital stock (including any pre<span class="nobreak">-funded</span> Oruka warrants issued pursuant to the Oruka pre<span class="nobreak">-closing</span> financing) that is outstanding and unexercised immediately prior to the First Effective Time, whether or not vested, will be converted into a warrant to purchase shares of ARCA common stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Accordingly, from and after the First Effective Time: (i)&#160;each outstanding Oruka warrant assumed by ARCA may be exercised solely for shares of ARCA common stock; (ii)&#160;the number of shares of ARCA common stock subject to each outstanding Oruka warrant assumed by ARCA will be determined by multiplying (A)&#160;the number of shares of Oruka common stock issuable upon exercise of the Oruka warrant that were subject to such Oruka warrant, as in effect immediately prior to the First Effective Time, by (B)&#160;the exchange ratio, and rounding the resulting number down to the nearest whole number of shares of ARCA common stock; and (iii)&#160;the per share exercise price for the ARCA common stock issuable upon exercise of each Oruka warrant assumed by ARCA will be determined by dividing (A)&#160;the per share exercise price of ARCA common stock subject to such Oruka warrant as in effect immediately prior to the First Effective Time, by (B)&#160;the exchange ratio and rounding the resulting exercise price up to the nearest whole cent. Each Oruka warrant assumed by ARCA will otherwise continue in full force and effect and the term, any restriction on the exercise and other provisions of such Oruka warrant will otherwise remain unchanged.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">139</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">To the extent provided under the terms of a Oruka warrant assumed by ARCA in accordance with the terms of the Merger Agreement, such Oruka warrant shall, in accordance with its terms, be subject to further adjustment as appropriate to reflect any stock split, division or subdivision of shares, stock dividend, reverse stock split, consolidation of shares, reclassification, recapitalization or other similar transaction with respect to shares of ARCA common stock subsequent to the First Effective Time. In addition, ARCA&#8217;s board of directors or a committee thereof will succeed to the authority and responsibility of Oruka&#8217;s board of directors or any committee thereof with respect to each Oruka warrant assumed by ARCA in accordance with the terms of the Merger Agreement.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA Common Stock and ARCA Options</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Except as contemplated by the proposed increase in the number of authorized shares of ARCA common stock described in Proposal No. 2 of this proxy statement/prospectus and<span class="Superscript" style="vertical-align:super;"> </span>the proposed reverse stock split of issued and outstanding ARCA common stock described in Proposal&#160;No. 3 of this proxy statement/prospectus, ARCA common stock will remain unaffected by the Merger.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Under the terms of the Merger Agreement, prior to the closing of the Merger, ARCA&#8217;s board of directors will accelerate the vesting of all equity awards of ARCA then outstanding but not then vested or exercisable, and cancel each option to acquire shares of ARCA&#8217;s common stock with an exercise price per share greater than the Parent Closing Price, in each case, in accordance with the terms of the Merger Agreement. At the closing of the First Merger, (i)&#160;each option to acquire shares of ARCA&#8217;s common stock with an exercise price less than or equal to the volume weighted average closing trading price of a share of ARCA common stock on Nasdaq for the five (5)&#160;consecutive&#160;trading days ending three (3)&#160;days immediately prior to the closing date of the First Merger (the &#8220;Parent Closing Price&#8221;) will be cancelled and converted into the right to receive an amount in cash, without interest, equal to the Parent Closing Price less the exercise price of such option and (ii)&#160;each other option to acquire shares of ARCA&#8217;s common stock will be cancelled for no consideration.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Procedures for Exchanging Oruka Stock Certificates</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Prior to the closing date of the First Merger, ARCA will select an exchange agent and, at the First Effective Time, ARCA will deposit with the exchange agent evidence of book<span class="nobreak">-entry</span> shares representing the shares of ARCA common stock and ARCA Series&#160;B Preferred Stock issuable pursuant to the terms of the Merger Agreement in exchange for shares of Oruka common stock and Oruka preferred stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Promptly after the First Effective Time, the exchange agent will mail to each record holder of Oruka common stock or Oruka preferred stock (i)&#160;a letter of transmittal and (ii)&#160;instructions for surrendering the record holder&#8217;s stock certificates in exchange for the Merger consideration. Upon delivery to the exchange agent of a duly executed letter of transmittal in accordance with the exchange agent&#8217;s instructions and the declaration for tax withholding purposes, the surrender of the record holder&#8217;s stock certificates, if applicable, and delivery to the exchange agent of such other documents as may be reasonably required by the exchange agent or ARCA, the record holder of such stock certificates or book<span class="nobreak">-entry</span> shares, as applicable, will be entitled to receive in exchange therefor book<span class="nobreak">-entry</span> shares representing the number of whole shares of ARCA common stock issuable to such holder pursuant to the Merger Agreement. The surrendered certificates representing shares of Oruka common stock or Oruka preferred stock will be canceled.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">After the First Effective Time, each certificate representing Oruka common stock or Oruka preferred stock that has not been surrendered will represent only the right to receive shares of ARCA common stock or preferred stock (as applicable) issuable pursuant to the Merger Agreement to which the holder of any such certificate is entitled.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">HOLDERS OF ORUKA COMMON STOCK OR ORUKA PREFERRED STOCK SHOULD NOT SEND IN THEIR ORUKA STOCK CERTIFICATES UNTIL THEY RECEIVE A LETTER OF TRANSMITTAL FROM THE EXCHANGE AGENT WITH INSTRUCTIONS FOR THE SURRENDER OF ORUKA STOCK CERTIFICATES.</span></p>
		</div>


		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">140</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Directors and Officers of ARCA Following the Merger</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Pursuant to the Merger Agreement, each of the directors and officers of ARCA will resign effective as of the First Effective Time and ARCA&#8217;s board of directors will thereafter consist of a total of six new directors designated by Oruka. Oruka has designated Lawrence Klein, Kristine Ball, Carl Dambkowski, Cameron Turtle, Peter Harwin, and Samarth Kulkarni to serve as members of ARCA&#8217;s board of directors.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, upon the closing of the Merger, Lawrence Klein will serve as Chief Executive Officer and President, Arjun Agarwal will serve as Senior Vice President, Finance and Treasurer, Joana Goncalves will serve as Chief Medical Officer, and Paul Quinlan will serve as General Counsel and Secretary.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Amendment of the Amended and Restated Certificate of Incorporation of ARCA</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA agreed to amend its amended and restated certificate of incorporation to (i)&#160;change ARCA&#8217;s name to &#8220;Oruka Therapeutics, Inc.&#8221;, (ii)&#160;effect the proposed reverse stock split, if needed, (iii)&#160;authorize a sufficient number of shares of common stock to issue the Merger consideration and (iv)&#160;increase the number of shares of ARCA common stock that ARCA is authorized to the amount proposed in this Proxy Statement.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Representations and Warranties</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Merger Agreement contains customary representations and warranties of ARCA, First Merger Sub and Second Merger Sub, on one hand, and Oruka, on the other hand, for a transaction of this type relating to, among other things:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>corporate organization and power, and similar corporate matters;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>due organization;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>subsidiaries;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>organizational documents;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>authority to enter into the Merger Agreement and the related agreements;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>votes required for completion of the Merger and approval of the proposals that will come before the ARCA special meeting of stockholders and that will be the subject of the Oruka stockholder approval;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>except as otherwise specifically disclosed in the Merger Agreement, the fact that the consummation of the Merger would not contravene the organizational documents, certain laws, governmental authorizations or certain contracts of the parties; result in any encumbrances on the parties&#8217; assets or require the consent of any third party;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the parties&#8217; efforts with respect to ensuring the inapplicability of Section&#160;203 of the DGCL and other similar takeover laws;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>capitalization;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>financial statements and, with respect to ARCA, documents filed with the SEC and the accuracy of information contained in those documents;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>material changes or events;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>liabilities;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>title to assets;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>real property and leaseholds;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>intellectual property;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>material contracts;</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">141</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the validity of material contracts to which the parties or their subsidiaries are a party and any violation, default or breach of such contracts;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>regulatory compliance, permits and restrictions;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>legal proceedings and orders;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>tax matters;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>employee and labor matters and benefit plans;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>environmental matters;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>insurance;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>financial advisors fees;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>certain transactions or relationships with affiliates;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>privacy and data security;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>with respect to ARCA, the valid issuance in the Merger of ARCA common stock; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>with respect to Oruka, the lack of ownership of ARCA&#8217;s common stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The representations and warranties are, in many respects, qualified by materiality and knowledge, and will not survive the Merger. The accuracy of the representations and warranties of the Company form the basis of certain of the conditions to the obligations of ARCA and Oruka to complete the Merger, subject to materiality thresholds.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Covenants; Conduct of Business Pending the Merger</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA has agreed that, except as permitted by the Merger Agreement, as required by law, or unless Oruka has provided written consent, during the period commencing on the date of the Merger Agreement and continuing until the earlier to occur of the First Effective Time and the termination of the Merger Agreement, ARCA and its subsidiaries will use commercially reasonable efforts to conduct their business and operations in the ordinary course consistent with past practices and in compliance with all applicable laws, regulations and certain material contracts. ARCA has also agreed that, subject to certain limited exceptions, without the consent of Oruka, it will not, and will not cause or permit any of its subsidiaries to, during the period commencing on the date of the Merger Agreement and continuing until the earlier to occur of the First Effective Time and the termination of the Merger Agreement:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>declare, accrue, set aside or pay any dividend or make any other distribution in respect of any shares of capital stock; or repurchase, redeem or otherwise reacquire any shares of capital stock or other securities (except for shares of ARCA common stock from terminated employees, directors or consultants of ARCA);</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>sell, issue, grant, pledge or otherwise dispose of or encumber or authorize the issuance of any capital stock or other security (except for ARCA common stock issued upon the valid exercise of outstanding ARCA options or ARCA RSUs), any option, warrant or right to acquire any capital stock or any other security or any instrument convertible into or exchangeable for any capital stock or other security;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>except as required to give effect to anything in contemplation of the closing, amend the certificate of incorporation, bylaws or other similar organizational documents of ARCA or its subsidiaries, or effect or be a party to any Merger, consolidation, share exchange, business combination, recapitalization, reclassification of shares, stock split, reverse stock split or similar transaction except as related to the transactions contemplated in the Merger Agreement;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>form any subsidiary or acquire any equity interest or other interest in any other entity or enter into any joint venture with any other entity;</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">142</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>lend money to any person or entity; incur or guarantee any indebtedness for borrowed money; guarantee any debt securities of others; or make any capital expenditure or commitment in excess of $25,000;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>adopt, establish or enter into certain agreements, plans or arrangements relating to employment or benefits matters; cause or permit any such agreement, plan or arrangement to be amended other than as required by law or in order to make amendments for purposes of Section&#160;409A of the Code; pay any bonus or make any profit<span class="nobreak">-sharing</span> or similar payment to, or increase the amount of the wages, salary, commissions, fringe benefits or other compensation or remuneration payable to, any of its directors, officers, employees or independent contractors; increase the severance or change of control benefits offered to any current or new employees, directors or consultants; or hire any officer, employee or consultant;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>acquire any material asset or sell, lease or otherwise irrevocably dispose of any of its assets or properties, or grant any encumbrance with respect to such assets or properties;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>sell, assign, transfer, license, sublicense or otherwise dispose of any material intellectual property rights of ARCA (other than pursuant to non<span class="nobreak">-exclusive</span> licenses in the ordinary course of business);</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>other than in the ordinary course of business: make, change or revoke any material tax election; file any amended income or other material tax return; adopt or change any material accounting method in respect of taxes; enter into any material tax closing agreement or settle any material tax claim or assessment; consent to any extension or waiver of the limitation period applicable to or relating to any material tax claim or assessment; or surrender any material claim for refund;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>waive, settle or compromise any pending or threatened legal proceeding against ARCA or any of its subsidiaries, other than waivers, settlements or agreements for an amount not in excess of $100,000 in the aggregate (excluding amounts to be paid under existing insurance policies or renewals thereof) and that do not impose any material restrictions on the operations or businesses of ARCA or its subsidiaries, taken as a whole, or any equitable relief on, or the admission of wrongdoing by ARCA or any of its subsidiaries;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>delay or fail to repay when due any material obligation, including accounts payable and accrued expenses;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>forgive any loans to any person, including its employees, officers, directors or affiliate;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>terminate or modify in any material respect, or fail to exercise renewal rights to, any material insurance policy;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>materially change pricing or royalties or other payments set or charged by ARCA or any of subsidiaries to its customers or licensees;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>agree to materially change pricing or royalties or other payments set or charged by persons who have licensed intellectual property to ARCA or any of subsidiaries;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>enter into, amend in a manner adverse to ARCA or terminate any of ARCA&#8217;s material contracts outside the ordinary course of business; or</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>agree, resolve or commit to do any of the foregoing.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Notwithstanding the foregoing restrictions, ARCA is expressly permitted to engage in the sale, license, transfer, disposition, divestiture or other monetization transaction (i.e., a royalty transaction) or winding down of its legacy business (including terminating its real estate leases and other contracts) and is expressly permitted to declare and pay a dividend on the shares of ARCA common stock outstanding prior to the First Effective Time (excluding for the avoidance of doubt any shares of ARCA&#8217;s common stock issuable pursuant to the Merger), up to an amount equal in the aggregate to ARCA&#8217;s reasonable, good faith approximation of the amount by which ARCA&#8217;s net cash at the First Effective Time will exceed $5.0&#160;million.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">143</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka has agreed that, except as permitted by the Merger Agreement, as required by law, or unless ARCA shall have provided its written consent, during the period commencing on the date of the Merger Agreement and continuing until the earlier to occur of the First Effective Time and the termination of the Merger Agreement, Oruka will use commercially reasonable efforts to conduct its business and operations in the ordinary course consistent with past practices and in compliance with all applicable laws, regulations and certain contracts. Oruka has also agreed that, subject to certain limited exceptions, without the consent of ARCA, it will not, and will not cause or permit its subsidiary to, during the period commencing on the date of the Merger Agreement and continuing until the earlier to occur of the First Effective Time and the termination of the Merger Agreement:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>declare, accrue, set aside or pay any dividend or make any other distribution in respect of any shares of capital stock; or repurchase, redeem or otherwise reacquire any shares of capital stock or other securities (except for shares of common stock from terminated employees, directors or consultants of Oruka);</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>except as required to give effect to anything in contemplation of the closing, amend the certificate of incorporation, bylaws or other organizational documents of Oruka or its subsidiaries, or effect or be a party to any Merger, consolidation, share exchange, business combination, recapitalization, reclassification of shares, stock split, reverse stock split or similar transaction except as related to the transactions contemplated in the Merger Agreement;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>other than in the ordinary course of its business, sell, issue, grant, pledge or otherwise dispose of or encumber or authorize any of the foregoing actions with respect to more than 25% of the shares of Oruka capital stock outstanding as of the date the Merger Agreement was signed: any capital stock or other security of Oruka or its subsidiaries (except for shares of outstanding Oruka common stock issued upon the valid exercise or settlement of Oruka options or warrants in accordance with their terms as in effect as of the date of the Merger Agreement); any option, warrant or right to acquire any capital stock or any other security; or any instrument convertible into or exchangeable for any capital stock or other security of Oruka or its subsidiaries;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>other than in the ordinary course of its business, acquire any equity interest or other interest in any other entity or enter into a joint venture with any other entity;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>lend money to any person or entity; incur or guarantee any indebtedness for borrowed money; guarantee any debt securities of others;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>acquire any material asset or sell, lease or otherwise irrevocably dispose of any of its assets or properties, or grant any encumbrance with respect to such assets or properties, except in the ordinary course of business;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>sell, assign, transfer, license, sublicense or otherwise dispose of any material intellectual property rights owned by Oruka, other than pursuant to non<span class="nobreak">-exclusive</span> licenses in the ordinary course of business;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>waive, settle or compromise any pending or threatened legal proceeding against Oruka, other than waivers, settlements or agreements (A)&#160;for an amount not in excess of $100,000 in the aggregate (excluding amounts to be paid under existing insurance policies or renewals thereof) and (B)&#160;that do not impose any material restrictions on the operations or businesses of Oruka or any equitable relief on, or the admission of wrongdoing by Oruka;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>enter into, amend in a manner adverse to Oruka or terminate any material contract outside of the ordinary course of its business; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>agree, resolve or commit to do any of the foregoing.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">144</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Non-Solicitation</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Each of ARCA and Oruka have agreed that, except as described below, ARCA and Oruka and any of their respective subsidiaries will not, nor will either party or any of its subsidiaries authorize any of the directors, officers, employees, agents, attorneys, accountants, investment bankers, advisors or representatives retained by it or any of its subsidiaries to, directly or indirectly:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>solicit, initiate or knowingly encourage, induce or facilitate the communication, making, submission or announcement of, any Acquisition Proposal or Acquisition Inquiry;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>furnish any non<span class="nobreak">-public</span> information with respect to it to any person in connection with or in response to an Acquisition Proposal or Acquisition Inquiry;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>engage in discussions or negotiations with any person with respect to any Acquisition Proposal or Acquisition Inquiry;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>execute or enter into any letter of intent or any contract contemplating or otherwise relating to an Acquisition Proposal; or</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>publicly propose to do any of the foregoing.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">An &#8220;Acquisition Inquiry&#8221; means, with respect to a party, an inquiry, indication of interest or request for non<span class="nobreak">-public</span> information (other than an inquiry, indication of interest or request for information made or submitted by Oruka, on the one hand, or ARCA on the other hand, to the other party) that would reasonably be expected to lead to an Acquisition Proposal.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">An &#8220;Acquisition Proposal&#8221; means, with respect to a party, any offer or proposal, whether written or oral (other than an offer or proposal made or submitted by or on behalf of Oruka or any of its affiliates, on the one hand, or by or on behalf of ARCA or any of its affiliates, on the other hand, to the other party) contemplating or otherwise relating to any Acquisition Transaction with such party.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">An &#8220;Acquisition Transaction&#8221; means any transaction or series of related transactions (other than a sale by ARCA of its legacy assets, the issuance of convertible notes by Oruka or the Oruka pre<span class="nobreak">-closing</span> financing) involving:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>any merger, consolidation, amalgamation, share exchange, business combination, issuance or acquisition of securities, reorganization, recapitalization, tender offer, exchange offer or similar transaction: (i)&#160;in which any individual, entity, governmental entity, or &#8220;group,&#8221; as defined under applicable securities laws, directly or indirectly acquires beneficial or record ownership of securities representing more than 20% of the outstanding securities of any class of voting securities of ARCA or Oruka or any of their respective subsidiaries or (ii)&#160;in which ARCA, Oruka or Merger Subs or any of their respective subsidiaries issues securities representing more than 20% of the outstanding securities of any class of voting securities of such party or any of its subsidiaries or issues securities convertible into more than 20% of the outstanding securities of any class of voting securities; or</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>any sale, lease, exchange, transfer, license, acquisition or disposition of any business or businesses or assets that constitute or account for 20% or more of the consolidated book value or the fair market value of the assets of ARCA or Oruka and their respective subsidiaries, as applicable, taken as a whole.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Notwithstanding the foregoing, before obtaining the applicable approvals of the ARCA stockholders or Oruka stockholders required to consummate the Merger, each party may furnish non<span class="nobreak">-public</span> information regarding such party and its subsidiaries to, and may enter into discussions or negotiations with, any third party in response to a bona fide written Acquisition Proposal, which such party&#8217;s board of directors determines in good faith, after consultation with such party&#8217;s financial advisors and outside legal counsel, constitutes or is reasonably likely to result in a Superior Offer (and is not withdrawn), if:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>such Acquisition Proposal was not obtained or made as a direct or indirect result of a breach of the Merger Agreement;</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">145</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>such party&#8217;s board of directors concludes in good faith, based on the advice of outside legal counsel, that the failure to take such action would reasonably be expected to be inconsistent with the fiduciary duties of such board of directors under applicable law;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>at least two&#160;business days prior to furnishing any non<span class="nobreak">-public</span> information or entering into discussions with a third party, such party gives the other party written notice of the identity of the third party and of that party&#8217;s intention to furnish non<span class="nobreak">-public</span> information to, or enter into discussions with, such third party;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>such party receives from the third party an executed confidentiality agreement containing provisions at least as favorable to such party as those contained in the confidentiality agreement between ARCA and Oruka; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>at least two&#160;business days prior to furnishing any non<span class="nobreak">-public</span> information to a third party, such party furnishes the same non<span class="nobreak">-public</span> information to the other party to the extent not previously furnished.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">A &#8220;Superior Offer&#8221; means an unsolicited <span class="Italic" style="font-style:italic;font-weight:normal;">bona fide</span> written Acquisition Proposal (with all references to 20% in the definition of Acquisition Transaction being treated as references to 50% for these purposes) that (a)&#160;was not obtained or made as a direct or indirect result of a breach of the Merger Agreement, (b)&#160;is on terms and conditions that the board of directors of the party receiving the offer determines in good faith, based on such matters that it deems relevant (including the likelihood of consummation thereof and the financing terms thereof), as well as any written offer by the other party to the Merger Agreement to amend the terms of the Merger Agreement, and following consultation with its outside legal counsel and financial advisors, if any, are more favorable, from a financial point of view, to that party&#8217;s stockholders than the terms of the transactions contemplated by the Merger Agreement, (c)&#160;is not subject to any financing conditions (and if financing is required, such financing is then fully committed to the third party) and (d)&#160;is reasonably capable of being completed on the terms proposed.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Merger Agreement also provides that each party will promptly (and in no event later than one business&#160;day after such party receives any such Acquisition Proposal or Acquisition Inquiry) advise the other party of the status and terms of, and keep the other party reasonably informed with respect to, any Acquisition Proposal or Acquisition Inquiry and any material modification or material proposed modification thereto.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Board Recommendation Change</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Under the Merger Agreement, subject to certain exceptions described below, both Oruka and ARCA agreed that their respective board of directors may not withhold, amend, withdraw or modify (or publicly propose to withhold, amend, withdraw or modify) the recommendation of such party&#8217;s board of directors in a manner adverse to the other party except for in limited circumstances described below.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">At any time prior to the approval of the Merger by each party&#8217;s respective stockholders, if (i)&#160;such party has received a bona fide written Acquisition Proposal that the such party&#8217;s board of directors determines, following consultation with its outside legal counsel and financial advisor, to be a Superior Offer, or (ii)&#160;a material development or change in circumstances (other than any such event, development or change to the extent related to any Acquisition Proposal, Acquisition Inquiry, Acquisition Transaction or the consequences thereof, the fact, in and of itself, that ARCA meets or exceeds internal budgets, plans or forecasts of its revenues, earnings or other financial performance or results of operations or, in the case of ARCA, any sale of ARCA&#8217;s legacy business) that affects the business, assets or operations of such party and occurs or arises after the date the Merger Agreement was executed.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In the case of a change recommendation due to a material development or change in circumstance, such party&#8217;s board of directors must first promptly notify the other party, in writing, at least four&#160;business days before making a change in its recommendation, stating the material facts and circumstances related to the applicable material development or change in circumstance and that such party&#8217;s board of directors intends to make a change in its recommendation.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In the case of a change its recommendation due to a Superior Offer, such party&#8217;s board of directors must first:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>determine in good faith, based on the advice of its outside legal counsel, that the failure to make a change in its recommendation would reasonably be expected to be inconsistent with its fiduciary duties under applicable law; and</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">146</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>negotiate with the other party in good faith to make such adjustments to the terms and conditions of the Merger Agreement so that such Acquisition Proposal ceases to constitute a Superior Offer, during the required four business&#160;day notice period and provide the other party with certain information regarding such Superior Offer.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If the other party delivers a written offer to alter the terms or conditions of the Merger Agreement during the required four business&#160;day notice period, the party considering a change in the recommendation of its board of directors must redetermine in good faith, based on the advice of its outside legal counsel and financial advisors, that the failure to make a change in its recommendation would reasonably be expected to be inconsistent with its fiduciary duties under applicable law (after taking into account such alterations of the terms and conditions of the Merger Agreement);</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Required Stockholder Approvals</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA is obligated under the Merger Agreement to take all action necessary under applicable law to call, give notice of and hold a meeting of the holders of ARCA common stock for the purpose of considering and voting to approve the Merger Agreement and the transactions contemplated thereby (including the Merger) and an amendment to the ARCA Charter as further described herein (collectively, the &#8220;Merger proposals&#8221;). The ARCA special meeting will be held as promptly as practicable after this registration statement on Form&#160;S<span class="nobreak">-4</span> is declared effective under the Securities Act, and in any event no later than 45&#160;days after the effective date of this registration statement on Form&#160;S<span class="nobreak">-4</span>.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Promptly after this registration statement on Form&#160;S<span class="nobreak">-4</span> has been declared effective, and no later than two business days thereafter, Oruka is required to obtain the approval by written consent from the holders of a majority of the outstanding shares of Oruka&#8217;s capital stock, voting as a single class on an as<span class="nobreak">-converted</span> basis and the holders of a majority of the outstanding shares of Oruka Series&#160;A preferred stock, voting as a separate class, in each case, to (x)&#160;adopt and approve the Merger Agreement and the Merger or the transactions contemplated thereby (including the Merger), (y)&#160;acknowledge that the approval given thereby is irrevocable and that such stockholders are aware of their rights to demand appraisal for their shares pursuant to Section&#160;262 of the DGCL, and that such stockholder has received and read a copy of Section&#160;262 of the DGCL and (z)&#160;acknowledge that by their approval of the Merger, they are not entitled to appraisal rights with respect to their shares in connection with the Merger and thereby waive any rights to receive payment of the fair value of their capital stock under the DGCL.&#160;Reasonably promptly following receipt of such consents, Oruka will prepare, and cause to be mailed to its stockholders who did not execute such consents, a notice in accordance with the DGCL.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Regulatory Approvals</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Each party agreed to use commercially reasonable efforts to file or otherwise submit, as soon as practicable after the date of the Merger Agreement, all applications, notices, reports and other documents reasonably required to be filed by such party with or otherwise submitted by such party to any governmental authority with respect to the transactions contemplated by the Merger Agreement, and to submit promptly any additional information requested by any such governmental authority. ARCA and Oruka do not intend to seek any regulatory approval from antitrust or other regulatory authorities to consummate the transactions.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Indemnification and Insurance for Directors and Officers</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Under the Merger Agreement, from the First Merger Effective Time through the sixth anniversary of the date on which the First Merger Effective Time occurs, ARCA and the surviving entity in the Second Merger agreed to indemnify and hold harmless each person who is now, or has been at any time prior to the date of the Merger Agreement, or who becomes prior to the First Merger Effective Time, a director or officer of ARCA or Oruka, respectively, against all claims, losses, liabilities, damages, judgments, fines and reasonable fees, costs and expenses, including attorneys&#8217; fees and disbursements, incurred in connection with any claim, action, suit, proceeding or investigation, whether civil, criminal, administrative or investigative, arising out of or pertaining to the fact that the indemnified officer or director is or was a director or officer of ARCA or of Oruka, whether asserted or claimed prior to, at or after the First Merger Effective Time. From and after the First Merger Effective Time, ARCA and the surviving corporation in the Merger will also fulfill ARCA&#8217;s and Oruka&#8217; indemnity obligations, respectively, to each person who is, has been, or who becomes prior to the First Merger Effective Time, a director or officer of ARCA or Oruka.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">147</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The certificate of formation and limited liability company agreement of the surviving entity will contain provisions no less favorable with respect to indemnification, advancement of expenses and exculpation of present and former directors and officers as those presently set forth in the ARCA Charter and ARCA Bylaws.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">From and after the First Merger Effective Time, ARCA will maintain director and officers&#8217; liability insurance policies, with an effective date as of the closing date of the First Merger, on commercially available terms and conditions and with coverage limits customary for U.S.&#160;public companies similarly situated to ARCA.&#160;In addition, ARCA will secure and purchase a six year &#8220;tail policy&#8221; on ARCA&#8217;s existing directors&#8217; and officers&#8217; liability insurance policy with an effective date as of the date of the closing of the First Merger.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Additional Agreements</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Each of ARCA and Oruka has agreed to use its reasonable best efforts to cause to be taken all actions necessary to consummate the Merger and the other transactions contemplated by the Merger Agreement. In connection therewith, each party has agreed to:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>make all filings and other submissions (if any) and give all notices (if any) required to be made and given by such party in connection with the transactions contemplated by the Merger Agreement;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>use commercially reasonable efforts to obtain each consent (if any) reasonably required to be obtained (pursuant to any applicable law or contract, or otherwise) in connection with the Merger and the other transactions contemplated by the Merger Agreement or for such contract to remain in full force and effect;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>use commercially reasonable efforts to lift any injunction prohibiting, or any other legal bar to, the transactions contemplated by the Merger Agreement; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>use commercially reasonable efforts to satisfy the conditions precedent to the consummation of the Merger Agreement.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Pursuant to the Merger Agreement, ARCA and Oruka have further agreed that:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA will use its commercially reasonable efforts to maintain its listing on Nasdaq and cause the shares of ARCA common stock (including any shares of ARCA&#8217;s common stock issuable upon conversion of the ARCA Series&#160;B Preferred Stock) being issued in the Merger to be approved for listing on Nasdaq at or prior to the First Merger Effective Time.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA will keep Oruka reasonably informed regarding any stockholder litigation against ARCA or any of its directors relating to the Merger Agreement or the transactions contemplated thereby.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-left:24pt;text-indent:0pt;margin-top:8pt;">ARCA will (i)&#160;give Oruka the opportunity to participate in, but not control, the defense, settlement or prosecution of any such litigation (to the extent that the attorney<span class="nobreak">-client</span> privilege is not undermined or otherwise adversely affected), (ii)&#160;consult with Oruka with respect to the defense, settlement and prosecution of any such litigation and (iii)&#160;consider in good faith Oruka&#8217;s advice with respect to such litigation.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Conditions to the Completion of the Merger</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following contains a description of all material conditions to the completion of the Merger.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Each party&#8217;s obligation to complete the Merger is subject to the satisfaction or, to the extent permitted by applicable law, the written waiver by each of the parties, at or prior to the closing, of various conditions, which include the following:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the registration statement on Form&#160;S<span class="nobreak">-4</span>, of which this proxy statement/prospectus is a part, must have been declared effective by the SEC in accordance with the Securities Act and must not be subject to any stop order or any proceeding seeking a stop order that has not been withdrawn; and any material state securities laws applicable to the issuance of the shares of ARCA&#8217;s capital stock in connection with the Merger or any of the other transactions contemplated by the Merger Agreement shall have been </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">148</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-position:inside;list-style-type:none;text-indent:0pt;margin-top:8pt;">complied with and no stop order (or similar order) shall have been issued or threatened in writing in respect of such shares of ARCA&#8217;s capital stock by any applicable state securities commissioner or court of competent jurisdiction;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>there must not have been issued, and remain in effect, any order preventing the consummation of the Merger or any of the other transactions contemplated by the Merger Agreement by any governmental authority of competent jurisdiction, and no law, statute, rule, regulation, ruling or decree will be in effect which has the effect of making the consummation of the Merger or any of the other transactions contemplated by the Merger Agreement illegal;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the holders of a majority of the outstanding shares of Oruka common stock, voting as a single class on an as<span class="nobreak">-converted</span> basis and the holders of a majority of the outstanding shares of Oruka Series&#160;A preferred stock, voting as a separate class, must have adopted and approved the Merger Agreement and the transactions contemplated thereby by written consent (the &#8220;Oruka stockholder approval&#8221;);</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the holders of the shares of ARCA common stock constituting a majority of the votes properly cast at the ARCA special meeting must have approved the Merger Agreement and the transactions contemplated thereby;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the initial listing application for ARCA&#8217;s common stock on Nasdaq (including any shares of ARCA&#8217;s common stock issuable upon conversion of the shares of ARCA Series&#160;B Preferred Stock) shall have been approved by Nasdaq;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the lock<span class="nobreak">-up</span> agreements executed by certain stockholders of Oruka will continue to be in full force and effect;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the ARCA Charter amendment shall have been duly filed with the Secretary of State of the State of Delaware, containing such amendments as are necessary to consummate the transactions contemplated by the Merger Agreement; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA shall have filed a Certificate of Designation with the Secretary of State of the State of Delaware designating the ARCA Series&#160;B Preferred Stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, each party&#8217;s obligation to complete the Merger is further subject to the satisfaction or waiver by that party of the following additional conditions:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the other party&#8217;s representations and warranties being true and correct as of the closing date, subject to applicable materiality qualifiers;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the other party to the Merger Agreement must have performed or complied with in all material respects all of such party&#8217;s agreements and covenants required to be performed or complied with by it under the Merger Agreement at or prior to the First Merger Effective Time;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the lack of a material adverse effect that is continuing with respect to the other party; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the other party having delivered certain certificates and other documents required under the Merger Agreement for the closing.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, the obligation of ARCA and Merger Subs to complete the Merger is further subject to the Subscription Agreement being in full force and effect and cash proceeds of not less than $175&#160;million having been received by Oruka, substantially simultaneously with the closing of the First Merger.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">149</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Termination and Termination Fees</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Termination of the Merger Agreement</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Merger Agreement may be terminated at any time before the First Merger Effective Time, whether before or after the required stockholder approvals to complete the Merger have been obtained, as set forth below:</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">(a)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>by mutual written consent of ARCA and Oruka;</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">(b)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>by either ARCA or Oruka, if the Merger has not been consummated by October&#160;3, 2024 (subject to possible extension as provided in the Merger Agreement); <span class="Italic" style="font-style:italic;font-weight:normal;">provided, however</span>, that this right to terminate the Merger Agreement will not be available to any party whose action or failure to act has been a principal cause of the failure of the Merger to occur on or before October&#160;3, 2024 and such action or failure to act constitutes a breach of the Merger Agreement; and <span class="Italic" style="font-style:italic;font-weight:normal;">provided, further</span>, that such date will be extended by 60&#160;days by either party in the event that the SEC has not declared effective the registration statement on Form&#160;S<span class="nobreak">-4</span>, of which this proxy statement/prospectus is a part, by the date which is 60&#160;days following October&#160;3, 2024;</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">(c)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>by either ARCA or Oruka, if a court of competent jurisdiction or governmental entity has issued a final and non<span class="nobreak">-appealable</span> order, decree or ruling or having the effect of permanently restrains, enjoins or otherwise prohibits the Merger or any of the transactions contemplated by the Merger Agreement;</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">(d)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>by ARCA, if the Oruka stockholder approval has not been obtained within two&#160;business days of the registration statement on Form&#160;S<span class="nobreak">-4</span>, of which this proxy statement/prospectus is a part, becoming effective; <span class="Italic" style="font-style:italic;font-weight:normal;">provided</span> that this right to terminate the Merger Agreement will not be available to ARCA once Oruka obtains such stockholder approval;</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">(e)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>by either ARCA or Oruka, if the ARCA special meeting has been held and completed and ARCA stockholders have taken a final vote on the Merger proposals set forth herein to be considered at the ARCA special meeting, and such proposals have not been approved by the ARCA stockholders; <span class="Italic" style="font-style:italic;font-weight:normal;">provided</span> that ARCA may not terminate the Merger Agreement pursuant to this provision if the failure to obtain the approval of ARCA stockholders was caused by the action or failure to act of ARCA and such action or failure to act constitutes a material breach by ARCA of the Merger Agreement;</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">(f)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>by Oruka, at any time prior to obtaining the approval by ARCA stockholders of the Merger proposals set forth herein to be considered at the ARCA special meeting, if any of the following circumstances shall occur:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA fails to include in this proxy statement/prospectus ARCA&#8217;s board of directors&#8217; recommendation that ARCA stockholders vote to approve the Merger proposals set forth herein to be considered at the ARCA special meeting;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors, or any committee thereof, makes an ARCA board recommendation change or publicly approves, endorses or recommends any Acquisition Proposal; or</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA enters into any letter of intent or similar document or any contract relating to any Acquisition Proposal, other than a confidentiality agreement permitted pursuant to the Merger Agreement;</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">(g)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>by ARCA, at any time prior to obtaining the Oruka stockholder approval, if any of the following circumstances shall occur:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Oruka&#8217;s board of directors makes a Oruka board recommendation change or publicly proposes, endorses or recommends any Acquisition Proposal; or</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-left:72pt;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Oruka enters into any letter of intent or similar document or any contract relating to any Acquisition Proposal;</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">150</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">(h)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>by Oruka, if ARCA or Merger Subs have breached any of their representations, warranties, covenants or agreements contained in the Merger Agreement or if any representation or warranty of ARCA has become inaccurate, in either case such that the conditions to the closing would not be satisfied as of time of such breach or inaccuracy; <span class="Italic" style="font-style:italic;font-weight:normal;">provided</span> that Oruka is not then in material breach of any representation, warranty covenant or agreement under the Merger Agreement; <span class="Italic" style="font-style:italic;font-weight:normal;">provided, further</span>, if such breach or inaccuracy is curable, then ARCA shall not be permitted to terminate the Merger Agreement pursuant to this paragraph as a result of a particular breach or inaccuracy until the earlier of the expiration of a 30<span class="nobreak">-day</span> period after delivery of written notice of such breach or inaccuracy from Oruka to ARCA or Merger Subs and Oruka&#8217;s intention to terminate pursuant to this paragraph (it being understood that ARCA shall not be permitted to terminate the Merger Agreement pursuant to this paragraph as a result of such particular breach or inaccuracy if such breach by ARCA or Merger Subs is cured prior to such termination becoming effective);</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">(i)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>by ARCA, if Oruka has breached any of its representations, warranties, covenants or agreements contained in the Merger Agreement or if any representation or warranty of Oruka has become inaccurate, in either case such that the conditions to the closing would not be satisfied as of time of such breach or inaccuracy; <span class="Italic" style="font-style:italic;font-weight:normal;">provided </span>that ARCA is not then in material breach of any representation, warranty covenant or agreement under the Merger Agreement; <span class="Italic" style="font-style:italic;font-weight:normal;">provided, further</span>, if such breach or inaccuracy is curable, then ARCA shall not be permitted to terminate the Merger Agreement pursuant to this paragraph as a result of a particular breach or inaccuracy until the earlier of the expiration of a 30<span class="nobreak">-day</span> period after delivery of written notice of such breach or inaccuracy from ARCA to Oruka and ARCA&#8217;s intention to terminate pursuant to this paragraph (it being understood that the Merger Agreement will not terminate pursuant to this paragraph as a result of such particular breach or inaccuracy if such breach by Oruka is cured prior to such termination becoming effective); or</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">(j)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>by ARCA (at any time prior to obtaining the ARCA stockholder approval), upon ARCA&#8217;s board of directors authorizing ARCA to enter into a definitive agreement that contemplates or otherwise relates to an Acquisition Transaction that constitutes a superior offer, subject to certain conditions.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Termination Fees Payable by ARCA</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA must pay Oruka a termination fee of $440,000 if (i)&#160;the Merger Agreement is terminated by ARCA or Oruka pursuant to clause (e)&#160;above or by Oruka pursuant to clause (f)&#160;above, (ii)&#160;at any time after the date of the Merger Agreement and prior to the ARCA special meeting, an Acquisition Proposal with respect to ARCA will have been publicly announced, disclosed or otherwise communicated to ARCA&#8217;s board of directors (and will not have been withdrawn), and (iii)&#160;in the event the Merger Agreement is terminated pursuant to clause (e)&#160;above, within 12&#160;months after the date of such termination, ARCA enters into a definitive agreement with respect to a subsequent transaction or consummates a subsequent transaction.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Termination Fees Payable by Oruka</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka must pay ARCA a termination fee of $440,000 if (i)&#160;the Merger Agreement is terminated by ARCA pursuant to clause (d)&#160;or (g)&#160;above, (ii)&#160;at any time after the date of the Merger Agreement and before obtaining the Oruka stockholder approval, an Acquisition Proposal with respect to Oruka will have been publicly announced, disclosed or otherwise communicated to Oruka&#8217;s board of directors (and will not have been withdrawn), and (iii)&#160;in the event the Merger Agreement is terminated pursuant to clause (d)&#160;above, within 12&#160;months after the date of such termination, Oruka enters into a definitive agreement with respect to a subsequent transaction or consummates a subsequent transaction.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Amendment and Waiver</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Merger Agreement may not be amended except by an instrument in writing signed on behalf of each of the parties to the Merger Agreement and authorized by such party&#8217;s boards of directors at any time, unless the Merger Agreement has been adopted and approved by any party&#8217;s stockholders, in which case no amendment which by law requires further approval by the such party&#8217;s stockholders, may be made without such further approval.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">151</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Any provision of the Merger Agreement may be waived by any party solely on that party&#8217;s behalf, without the consent of any other party. The waiver must be expressly set forth in a written instrument duly executed and delivered on behalf of such party, which will only be valid in the specific instance in which it is given. No failure or delay on the part of any party with respect to the exercise of any power, right, privilege or remedy under the Merger Agreement will operate as a waiver of such power, right, privilege or remedy. Furthermore, no single or partial exercise of any such power, right, privilege or remedy will preclude any other or further exercise thereof or of any other power, right, privilege or remedy.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">152</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T20"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">AGREEMENTS RELATED TO THE MERGER</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Support Agreements</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Certain Oruka stockholders holding approximately 90% of the outstanding shares of Oruka capital stock have entered into Oruka Support Agreements with ARCA and Oruka to vote all of their shares of Oruka capital stock in favor of the adoption and approval of the Merger Agreement and the transactions contemplated thereby and against any alternative acquisition proposals. Certain ARCA stockholders holding approximately 28.5% of the outstanding shares of ARCA common stock have entered into ARCA Support Agreements with ARCA and Oruka to vote all of their shares of ARCA common stock in favor of the Nasdaq Stock Issuance Proposal, the Authorized Share Increase Proposal and the Reverse Stock Split Proposal and against any alternative acquisition proposals.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Lock-Up Agreements</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Certain of Oruka&#8217;s executive officers, directors and stockholders have entered into&#160;lock<span class="nobreak">-up</span>&#160;agreements, pursuant to which such parties have agreed not to, except in limited circumstances, offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any shares of ARCA&#8217;s common stock or any securities convertible into or exercisable or exchangeable for ARCA common stock, currently or thereafter owned, including shares of ARCA common stock issuable upon conversion of ARCA Series&#160;B Preferred Stock issued in exchange for shares of Oruka preferred stock in the Merger, but excluding, as applicable, shares purchased by existing Oruka stockholders in the Oruka pre<span class="nobreak">-closing</span>&#160;financing (including any shares of ARCA common stock issuable upon exercise of pre<span class="nobreak">-funded</span> warrants issued in exchange for pre<span class="nobreak">-funded</span> warrants to purchase shares of Oruka common stock sold in the Oruka pre<span class="nobreak">-closing</span> financing), until 180&#160;days after the effective time.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Oruka stockholders who have executed&#160;lock<span class="nobreak">-up</span>&#160;agreements as of March&#160;31, 2024 owned, in the aggregate, approximately 90% of the shares of Oruka&#8217;s outstanding capital stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The foregoing description of the&#160;lock<span class="nobreak">-up</span>&#160;agreements does not purport to be complete and is qualified in its entirety by the full text of the form of&#160;lock<span class="nobreak">-up</span>&#160;agreement, which is attached hereto as&#160;<span class="Italic" style="font-style:italic;font-weight:normal;">Annex&#160;E</span>.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Subscription Agreement</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Concurrently with the execution and delivery of the Merger Agreement, certain new and existing investors of Oruka entered into the Subscription Agreement with Oruka, pursuant to which such investors have agreed to purchase immediately prior to the First Merger, shares of Oruka common stock or, in lieu thereof, Oruka pre<span class="nobreak">-funded</span>&#160;warrants, representing an aggregate commitment of approximately $275.0&#160;million (which includes $25.0<span class="nobreak"> </span>million of proceeds previously received from the issuance of the Convertible Note and accrued interest on such note), in the Oruka pre<span class="nobreak">-closing</span>&#160;financing. Under the Subscription Agreement, the number of shares of Oruka common stock or pre<span class="nobreak">-funded</span> warrants, as applicable, shall be determined at a purchase price per share or warrant equal to (i)&#160;a valuation for Oruka equal to approximately $175.0&#160;million, (ii)&#160;divided by the number of shares of Oruka common stock outstanding immediately prior to the First Effective Time of the Merger (but excluding the securities being issued under the Subscription Agreement). Each share of Oruka preferred stock will be converted into the right to receive a number of shares of ARCA Series&#160;B Preferred Stock, which are each convertible into 1,000<span class="nobreak"> </span>shares of ARCA common stock, calculated in accordance with the Merger Agreement.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The shares of Oruka common stock and Oruka pre<span class="nobreak">-funded</span>&#160;warrants that are issued in the Oruka pre<span class="nobreak">-closing</span>&#160;financing will be or will have the right to be, respectively, converted into shares of ARCA common stock in the Merger. Accordingly, by approving Proposal&#160;No.&#160;1 relating to the Merger, ARCA stockholders will also be approving the issuance of shares of ARCA common stock to be issued in exchange for all shares of Oruka common stock and&#160;pre<span class="nobreak">-funded</span>&#160;warrants that are sold in the Oruka pre<span class="nobreak">-closing</span>&#160;financing.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Subscription Agreement contains customary representations and warranties of Oruka and also contains customary representations and warranties of the purchaser parties thereto.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">153</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Each purchaser&#8217;s obligation to purchase shares of Oruka common stock and/or Oruka pre<span class="nobreak">-funded</span> warrants from Oruka pursuant to the Subscription Agreement is subject to the satisfaction or waiver of certain conditions, including:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Oruka&#8217;s representations and warranties in the Subscription Agreement being true and correct in all respects as of the effective date of the Subscription Agreement and true and correct in all material respects as of the closing date for the Oruka pre<span class="nobreak">-closing</span> financing, subject to certain exceptions;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Oruka having performed and complied in all material respects with all covenants, agreements, obligations and conditions required to be performed or complied with by it;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the issuance of a compliance certificate by the chief executive officer of Oruka;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>all registrations, qualifications, permits and approvals, if any, required under applicable state securities laws having been obtained;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the issuance of a secretary&#8217;s certificate by the secretary of Oruka;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the satisfaction or waiver of all conditions to the closing of the Merger set forth in the Merger Agreement (other than the condition regarding the Oruka pre<span class="nobreak">-closing</span> financing) and the closing of Merger being set to occur substantially concurrently with the closing of the Oruka pre<span class="nobreak">-closing</span> financing;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>no injunction having been issued prohibiting the consummation of the Oruka pre<span class="nobreak">-closing</span> financing;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Oruka having delivered the registration rights agreement required by the Subscription Agreement;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>this registration statement on Form&#160;S<span class="nobreak">-4</span> shall have been become effective under the Securities Act, no stop order shall be suspending the effectiveness of this registration statement and no proceeding for that purpose shall have been initiated or threatened in writing by the SEC;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the Nasdaq Listing Application shall have been approved by Nasdaq;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>no material adverse effect shall have occurred that is continuing, since the date of the Subscription Agreement;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Oruka shall receive at closing aggregate proceeds from the purchase of securities pursuant to the Subscription Agreement of not less than $175,000,000 (including in the proceeds any convertible securities contributed as consideration in accordance with the Subscription Agreement); and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>an opinion from Company counsel, dated as of the closing.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka&#8217;s obligation to sell shares of Oruka common stock to each purchaser pursuant to the Subscription Agreement is subject to the satisfaction or waiver of certain conditions, including:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the representations and warranties made by the purchasers being true and correct as of the effective date of the Subscription Agreement and true and correct in all material respects as of the closing date of the Oruka pre<span class="nobreak">-closing</span> financing, subject to certain exceptions;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>each purchaser having performed and complied with all covenants, agreements, obligations and conditions required to be performed or complied with by each purchaser;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>all registrations, qualifications, permits and approvals, if any, required under applicable state securities laws having been obtained; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the satisfaction or waiver of all conditions to the closing of the Merger set forth in the Merger Agreement (other than those conditions which are to be satisfied at the closing of the transactions contemplated by the Merger Agreement)) and the closing of Merger being set to occur substantially concurrently with the closing of the Oruka pre<span class="nobreak">-closing</span> financing.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">154</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Registration Rights Agreement</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Subscription Agreement contemplates ARCA, Oruka and the investors participating in the Oruka pre<span class="nobreak">-closing</span> financing entering into a registration rights agreement at the closing of the Oruka pre<span class="nobreak">-closing</span> financing, pursuant to which, among other things, the combined company will agree to provide for the registration and resale of certain shares of Oruka common stock that are held by the investors participating in the Oruka pre<span class="nobreak">-closing</span> financing from time to time, including the shares of ARCA common stock issued in exchange for shares of Oruka common stock sold in the Oruka pre<span class="nobreak">-closing</span> financing and ARCA pre<span class="nobreak">-funded</span> warrants assumed upon conversion of the Oruka pre<span class="nobreak">-funded</span> warrants sold in the Oruka pre<span class="nobreak">-closing</span> financing (including shares issuable upon exercise of such warrants).</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Pursuant to the registration rights agreement, the combined company will agree to prepare and file a resale registration statement covering the resale of the ARCA common stock within 45&#160;days of the closing of the merger pursuant to&#160;Rule&#160;415&#160;and to use its reasonable best efforts to keep such registration statement continuously effective under the&#160;Securities Act&#160;until the earlier of (a)&#160;the date that all registrable securities covered by such registration statement (i)&#160;have been sold, thereunder or pursuant to&#160;Rule&#160;144&#160;of the&#160;Securities Act&#160;(&#8220;Rule&#160;144&#8221;), or (ii)&#160;may be sold without volume or manner<span class="nobreak">-of-sale</span> restrictions pursuant to&#160;Rule&#160;144&#160;and without the requirement for the combined company to be in compliance with the current public information requirement under&#160;Rule&#160;144, and (b)&#160;five&#160;years after the date of the registration rights agreement.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Pursuant to the registration rights agreement, the combined company will agree that neither the combined company nor securityholders of the combined company (other than the investors participating in the Oruka pre<span class="nobreak">-closing</span> financing and party to the registration rights agreement) may have &#8220;piggyback&#8221; registration rights and that the combined company will be prohibited from filing any other registration statements until all of the registerable securities subject to the registration rights agreement are registered pursuant to an effective registration statement, subject to certain exceptions. The registration rights agreement also provides that the combined company will pay certain expenses relating to such registrations and indemnify the applicable securityholders against certain liabilities. The form of registration rights agreement is attached as Exhibit A to the Subscription Agreement filed as Exhibit 10.2 to this registration statement on Form&#160;S<span class="nobreak">-4</span> of which this proxy statement/prospectus is a part, and the foregoing description of the registration rights agreement is qualified in its entirety by reference thereto.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">155</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T19"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">ARCA DIRECTORS, OFFICERS AND CORPORATE GOVERNANCE</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following sets forth certain information, as of May&#160;3, 2024, concerning ARCA&#8217;s directors and executive officers.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s directors, executive officers and key employees as of May&#160;3, 2024 are as follows:</p>
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 3pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">



						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;text-align:left;">Name</p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">Age</p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 58.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">Position</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Thomas A.&#160;Keuer</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">65</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 58.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">President and Chief Operating Officer</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">C.&#160;Jeffrey Dekker</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">59</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 58.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Chief Financial Officer</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Dr.&#160;Linda Grais<span class="Superscript" style="vertical-align:super;font-size:58%;">(1)(2)*(3)(4)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">67</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 58.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Class&#160;I Director<span class="Superscript" style="vertical-align:super;font-size:58%;">(5)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Mr.&#160;Robert E.&#160;Conway<span class="Superscript" style="vertical-align:super;font-size:58%;">(1)*(2)(3)(4)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">70</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 58.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Class&#160;II Director<span class="Superscript" style="vertical-align:super;font-size:58%;">(5)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Dr.&#160;Anders Hove<span class="Superscript" style="vertical-align:super;font-size:58%;">(2)(3)*(4)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">58</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 58.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Class&#160;I Director<span class="Superscript" style="vertical-align:super;font-size:58%;">(5)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Mr.&#160;Jacob Ma-Weaver</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">36</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 58.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Class&#160;III Director<span class="Superscript" style="vertical-align:super;font-size:58%;">(5)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Mr.&#160;James Flynn<span class="Superscript" style="vertical-align:super;font-size:58%;">(1)(4)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">43</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 58.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Class&#160;I Director<span class="Superscript" style="vertical-align:super;font-size:58%;">(5)</span></p>
					</td>
				</tr>

		</table>
		<p class="Tablefootnotef" style="margin-top: 0in;  border: none; margin-right: 0in; margin-bottom: -5pt; margin-left: 24.0pt; text-align: justify; text-justify: inter-ideograph; text-indent: -24.0pt; padding: 0in; font-size: 9.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">____________</p><p class="Tablefootnote_f" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:10pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:10pt;">*<span style="width: 24px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Committee Chairperson</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(1)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Member of the Audit Committee of ARCA&#8217;s board of directors</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(2)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Member of the Compensation Committee of ARCA&#8217;s board of directors</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(3)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Member of the Nominating and Corporate Governance Committee of ARCA&#8217;s board of directors</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(4)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Member of the Special Committee of ARCA&#8217;s board of directors</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(5)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>See &#8220;Election of Board of Directors&#8221; below for discussion of Class&#160;I&#160;&#8212;&#160;III Director service terms.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Thomas A.&#160;Keuer</span>. Mr.&#160;Keuer has served as ARCA&#8217;s Chief Operating Officer since December&#160;2014, and ARCA&#8217;s President since April&#160;2024. Mr.&#160;Keuer served as ARCA&#8217;s Executive Vice President, Pharmaceutical Operations from 2006 to 2014. Prior to joining ARCA, Mr.&#160;Keuer served as the SVP of Operations for Insmed, Inc. from 2004 to 2006. Prior to Insmed, Mr.&#160;Keuer served as the VP of Engineering for Baxter Healthcare from 1998 to 2004. Prior to Baxter, Mr.&#160;Keuer served as the VP of Operations for Somatogen, Inc. Mr.&#160;Keuer received his M.S. in Biochemical Engineering from Rice University and received his B.S. in Chemical Engineering from the University of Texas, Austin.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">C. Jeffrey Dekker</span>. Mr.&#160;Dekker has served as ARCA&#8217;s Chief Financial Officer and Treasurer since May&#160;2021 and ARCA&#8217;s Secretary since April&#160;2023. Prior to joining ARCA, Mr.&#160;Dekker served in multiple roles of increasing responsibility at GlobeImmune, Inc. from 2006 to 2021, including President, Vice President of Finance, and Senior Director, Finance and Controller. Before joining GlobeImmune, Mr.&#160;Dekker held leadership positions in finance and accounting at private software companies since 1993, including posts ranging from Corporate Controller to Vice President at Webroot Software Inc., Requisite Technology Inc. and NxTrend Technology Inc. Earlier in his career, Mr.&#160;Dekker worked at ITT Rayonier Port Angeles Pulp Division and at KPMG in Los Angeles. He earned a B.S. in accounting from Utah State University and is a certified public accountant.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Linda Grais, M.D.</span><span class="Bold" style="font-style:normal;font-weight:bold;">&#160;</span>Dr.&#160;Grais has served as a member of ARCA&#8217;s board of directors since May&#160;2007. Dr.&#160;Grais was a director of Ocera Therapeutics, Inc., a public biopharmaceutical company, since January&#160;2008 and became President and Chief Executive Officer of Ocera in June&#160;2012, and served in that role until Ocera&#8217;s acquisition by Mallinckrodt Pharmaceuticals in December&#160;2017. Dr.&#160;Grais served as a Managing Member at InterWest Partners, a venture capital firm from May&#160;2005 until February&#160;2011. From July&#160;1998 to July&#160;2003, Dr.&#160;Grais was a founder and executive vice president of SGX Pharmaceuticals Inc., a drug discovery company. Prior to that, she was a corporate attorney at Wilson Sonsini Goodrich&#160;&amp; Rosati, where she practiced in such areas as venture financings, public offerings and strategic partnerships. Before practicing law, Dr.&#160;Grais worked as an assistant clinical professor of Internal Medicine and Critical Care at the University of California, San Francisco. Dr.&#160;Grais received a B.A. from Yale University, magna cum laude, and Phi Beta Kappa, an M.D. from Yale Medical School and a J.D. from Stanford Law School. Since September&#160;2015, Dr.&#160;Grais served on the board of PRA Health Sciences, which was acquired by ICON plc in 2021, a public contract research organization, and currently serves on the board of ICON plc. Dr.&#160;Grais also joined the board of Corvus Pharmaceuticals., a publicly traded pharmaceutical company, in January&#160;2019, and joined the board of Collective Health, a private healthcare services company, in March&#160;2023. ARCA believes Dr.&#160;Grais is an appropriate member of the Board of Directors because of her diverse training and experience as both a medical doctor and a lawyer, her experience as a founder and senior executive of a pharmaceutical company, and her experience as an investor in new life sciences companies. She also has extensive experience with and knowledge of ARCA&#8217;s business from her service on ARCA&#8217;s board of directors since 2007.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">156</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Robert E.&#160;Conway</span><span class="Bold" style="font-style:normal;font-weight:bold;"> </span>Mr.&#160;Conway was appointed to ARCA&#8217;s board of directors in September&#160;2013, and has served as the Chairman of ARCA&#8217;s board of directors since 2014. Mr.&#160;Conway served as the Chief Executive Officer and member of the board of directors of Array Biopharma, a publicly traded biopharmaceutical company, from 1999 to 2012. Prior to joining Array, Mr.&#160;Conway was the Chief Operating Officer and Executive Vice President of Hill Top Research, Inc., from 1996 to 1999. From 1979 until 1996, Mr.&#160;Conway held various executive positions for Corning Inc. including Corporate Vice President and General Manager of Corning Hazleton, Inc., a contract research organization. From 2004 to 2013, he served on the board of directors of PRA International, Inc., which was a public company for a portion of his tenure there, from 2012 to the present, he has served on the board of directors of eResearch Technology, Inc., a private company, and from 2015 to July&#160;2017, Advarra, Inc. from 2019 to August&#160;2022, and he has served on the board of directors of Nivalis Therapeutics, Inc. a public, clinical stage pharmaceutical company. In July&#160;2017, Nivalis Therapeutics, Inc. combined with Alpine Immune Sciences, Inc., a public, clinical stage pharmaceutical company, and Mr.&#160;Conway continues to serve on the board of directors following such combination. In addition, Mr.&#160;Conway is a member of the Strategic Advisory Committee of Genstar Capital, LLC and is a member of the board of directors of Signant Health. In April&#160;2023, Mr.&#160;Conway became Executive Chairman and member of the board of directors of ClinOne, Inc. Mr.&#160;Conway received a B.S. in accounting from Marquette University in 1976. ARCA believes Mr.&#160;Conway is an appropriate member of ARCA&#8217;s board of directors given his experience and expertise in the pharmaceutical industry, in pharmaceutical development and clinical trials, and in corporate finance, governance, accounting and public company compliance.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Anders Hove, M.D.</span><span class="Bold" style="font-style:normal;font-weight:bold;">&#160;</span>Dr.&#160;Hove has served as a member of ARCA&#8217;s board of directors since February&#160;2017. Dr.&#160;Hove is the manager of Acorn Bioventures, a partnership focusing on long<span class="nobreak">-term</span> investments in biotech, specialty pharma and medical device companies. Before Dr.&#160;Hove was a general partner of Venrock Associates, a venture capital firm, which he joined in 2004 and remained at through 2016. In 2008, Dr.&#160;Hove was a founder of Venrock Healthcare Capital Partners, Venrock&#8217;s public funds focused on small capitalization biotech companies and late<span class="nobreak">-stage</span> private companies. From 1996 to 2004, Dr.&#160;Hove was a fund manager at BB Biotech, an investment firm, and from 2002 to 2003 he also served as Chief Executive Officer of Bellevue Asset Management, an investment company. Dr.&#160;Hove previously held senior level positions in the medical, clinical and business operations of the pharmaceuticals division of Ciba<span class="nobreak">-Geigy</span> and Novartis. Mr.&#160;Hove was a member of the boards of directors of Anacor Pharmaceuticals, a publicly traded pharmaceutical company, from 2005 until its acquisition by Pfizer in June&#160;2016, and Edge Therapeutics, a publicly traded biotechnology company, from 2015 to 2016. In addition, Dr.&#160;Hove is a member of the board of directors of MC2 Therapeutics. He received a M.Sc. in Biotechnology Engineering from the Technical University of Denmark, an M.D. from the University of Copenhagen and an M.B.A. from INSEAD (the Institut Europ&#233;en d&#8217;Administration des Affaires). ARCA believes Dr.&#160;Hove is an appropriate member of ARCA&#8217;s board of directors, given his extensive training and experience as a medical doctor and masters of business administration, an executive in the pharmaceutical industry, and as an investor in biotechnology companies.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Jacob Ma</span><span class="nobreak"><span class="Italic" style="font-style:italic;font-weight:normal;">-Weaver</span></span> Mr.&#160;Ma<span class="nobreak">-Weaver</span> was appointed to ARCA&#8217;s board of directors in June&#160;2022. He is the Managing Member of Cable Car Capital LLC, an investment adviser he founded in 2013. Cable Car Capital LLC is the General Partner of Funicular Funds, LP, a hedge fund. From 2012 to 2013, Mr.&#160;Ma<span class="nobreak">-Weaver</span> was employed as an investment analyst at Amici Capital LLC, where he focused on healthcare. He was previously employed as an equity research associate at Dodge&#160;&amp; Cox and a corporate finance business analyst at McKinsey&#160;&amp; Company. Mr.&#160;Ma<span class="nobreak">-Weaver</span> received a Bachelor of Arts in Comparative Literature&#160;&amp; Society and Economics and a Master of Arts in Statistics from Columbia University. He is a Chartered Financial Analyst (CFA) charterholder. ARCA believes Mr.&#160;Ma<span class="nobreak">-Weaver</span> is an appropriate member of ARCA&#8217;s board of directors because of his experience as an investor in life sciences companies, an analyst for investment firms and his academic background.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">James Flynn</span> Mr.&#160;Flynn has served as a member of ARCA&#8217;s board of directors since December&#160;2022. Mr.&#160;Flynn is currently a Managing Member and Portfolio Manager of Nerium Capital LLC, an investment adviser he founded in 2021. Mr.&#160;Flynn has served as a board member for Axiom Health (a provider of software and big<span class="nobreak">-data</span> solutions to the healthcare industry) since 2022, a board member for MEI Pharma, Inc (a pharmaceutical company committed to the development of novel and differentiated cancer therapies) since 2023, and joined the board of RiceBran Technologies (an innovative specialty ingredients company) in January&#160;2024. From 2017 to 2018, Mr.&#160;Flynn worked as a therapeutics analyst at Aptigon Capital (a Citadel Company), an investment firm. Prior to that, from 2003 to 2017, Mr.&#160;Flynn served in various roles at Amici Capital, LLC, an investment firm, including healthcare portfolio manager (2008 to 2017). From 2002 to 2003, Mr.&#160;Flynn worked in the credit research/high yield group at Putnam Investments, an investment firm. Mr.&#160;Flynn earned a S.B. degree in Management Science with a concentration in Finance and a minor in Economic Science from the Massachusetts Institute of Technology (MIT). Mr.&#160;Flynn is a </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">157</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">Chartered Financial Analyst (CFA) charterholder. ARCA believes Mr.&#160;Flynn is an appropriate member of ARCA&#8217;s board of directors because of his experience as an investor in life sciences companies, an analyst for investment firms and his academic background.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Board Diversity Matrix (as of May&#160;3, 2024)</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The table below provides certain highlights of the composition of ARCA&#8217;s board members as of May&#160;3, 2024. Each of the categories listed in the table below has the meaning as it is used in Nasdaq Rule&#160;5605(f).</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-12">
					<td class="TCH" colspan="9" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 100.00%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">



						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Board Diversity Matrix as of May&#160;3, 2024</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Total&#160;Number&#160;of&#160;Directors&#160;and&#160;nominees:</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" colspan="7" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 61.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">5</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Part&#160;I:&#160;Gender Identity</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Male</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.03%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Female</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Non-Binary</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 16.88%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Did Not <br/>Disclose&#160;Gender</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Directors</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 16.88%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Part&#160;II:&#160;Demographic Background</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 16.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">African American or Black</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.03%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 16.88%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Alaskan Native or American Indian</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.03%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 16.88%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Asian</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.03%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 16.88%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Hispanic or Latinx</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.03%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 16.88%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Native Hawaiian or Pacific Islander</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.03%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 16.88%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">White</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 16.88%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Two or More Races or Ethnicities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.03%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 16.88%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">LGBTQ+</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.03%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 16.88%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-13" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Did Not Disclose Demographic Background</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.03%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 16.88%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>

		</table>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">158</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T18"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">ADDITIONAL INFORMATION REGARDING THE BOARD OF DIRECTORS AND CORPORATE GOVERNANCE</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Independence of The Board of Directors</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As required under the Nasdaq listing standards, a majority of the members of a listed company&#8217;s board of directors must qualify as &#8220;independent,&#8221; as affirmatively determined by the board of directors. ARCA&#8217;s board of directors consults with ARCA&#8217;s counsel to ensure that the board of directors&#8217; determinations are consistent with relevant securities and other laws and regulations regarding the definition of &#8220;independent,&#8221; including those set forth in pertinent listing standards of the Nasdaq, as in effect from time to time.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Consistent with these considerations, after review of all relevant identified transactions or relationships between each director, or any of his or her family members, and ARCA, its senior management and its independent registered public accounting firm, the Board of Directors has affirmatively determined that the following five directors are independent directors within the meaning of the applicable Nasdaq&#160;listing standards: Mr.&#160;Conway, Dr.&#160;Grais, Dr.&#160;Hove and Mr.&#160;Flynn. In making this determination, the Board of Directors found that none of the directors had a material or other disqualifying relationship with ARCA.&#160;Dr.&#160;Bristow, ARCA&#8217;s former President and Chief Executive Officer was not an&#160;independent director in 2023 by virtue of his employment relationship with ARCA.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Board Leadership Structure</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA has structured its board of directors in a way that ARCA believes effectively serves its objectives of corporate governance and management oversight. ARCA separates the roles of President and Chairman of the board of directors in recognition of the differences between the two roles. ARCA believes that the President should be responsible for the&#160;day<span class="nobreak">-to-day</span> leadership and performance of ARCA, while the Chairman of the board of directors should work with the President and the rest of the board of directors to set the strategic direction for ARCA and provide guidance to, and oversight of the President. The Chairman also sets the agenda for meetings of the board of directors and presides over them.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Mr.&#160;Conway, who is an independent director, was elected Chairman of the board of directors in 2014. In this capacity, Mr.&#160;Conway, among other things, calls and presides over board meetings, including meetings of the independent directors, and sets meeting agendas. In this role, Mr.&#160;Conway can effectively coordinate between the board of directors and management regarding risk management issues and the implementation of appropriate responses, and can help ensure the effective independent functioning of the board of directors in its oversight responsibilities. Accordingly, the Chairman has substantial ability to shape the work of the board of directors.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Role of the Board of Directors in Risk Oversight and Risk Management</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">One of the board of directors&#8217; key functions is informed oversight of ARCA&#8217;s risk management process. The board of directors does not have a standing risk management committee, but rather administers this oversight function directly through the board of directors as a whole, as well as through various standing committees of the board of directors that address risks inherent in their respective areas of oversight. In particular, while the board of directors is responsible for monitoring and assessing strategic risk exposure, the Audit Committee has the responsibility to consider and discuss the major financial risk exposures and the steps management has taken to monitor and control these exposures, including guidelines and policies to govern the process by which risk assessment and management is undertaken. The Audit Committee also monitors compliance with legal and regulatory requirements, in addition to oversight of the performance of ARCA&#8217;s accounting and financial reporting processes. The Nominating and Corporate Governance Committee monitors the effectiveness of the corporate governance guidelines, including whether they are successful in preventing illegal or improper liability<span class="nobreak">-creating</span> conduct. The Compensation Committee of the board of directors of ARCA (the &#8220;Compensation Committee&#8221;) assesses and monitors whether any compensation policies and programs have the potential to encourage excessive risk<span class="nobreak">-taking</span>. The entire board of directors and its committees address risk management issues from time<span class="nobreak">-to-time</span> and at least annually meet with the employees responsible for risk management in the committees&#8217; respective areas of oversight. Both the board of directors as a whole and the various standing committees receive periodic reports </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">159</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">from the employees responsible for risk management, as well as&#160;incidental reports as matters may arise. It is the responsibility of the committee chairs to report findings regarding material risk exposures to the board of directors as quickly as possible.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Meetings of The Board of Directors</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s board of directors met three times during the 2023 fiscal year. The independent members of the board of directors met separately as a group at each of the board meetings in 2023. All members of the board of directors attended at least 75% of the aggregate of (i)&#160;the total number of meetings of the board of directors held during the period for which each director served and (ii)&#160;the total number of meetings held by all committees of the board of directors of which each director was a member during the periods that they served. All of ARCA&#8217;s directors then on the board of directors attended ARCA&#8217;s 2023 annual meeting of stockholders (the &#8220;2023 Annual Meeting&#8221;) whether in person or via telephone.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Election of Board of Directors</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Directors are elected by a plurality of the votes of the holders of shares present in person or represented by proxy and entitled to vote on the election of directors at ARCA&#8217;s annual stockholders&#8217; meetings. The ARCA Charter, as amended, provides that the board of directors is divided into three classes to provide for staggered terms and that each director will serve for a term of three&#160;years or less, depending on the class to which the board of directors has assigned a director not previously elected by the stockholders. There is currently one Class&#160;III director whose term expires at the annual stockholders&#8217; meeting in 2024, three Class&#160;I directors whose terms expire at the annual stockholders&#8217; meeting in 2025 and one Class&#160;II directors whose term expires at the annual meeting in 2026. The one Class&#160;III director, Mr.&#160;Jacob Ma<span class="nobreak">-Weaver</span>, is currently scheduled for re<span class="nobreak">-election</span> to the board of directors at this 2024 special meeting in lieu of an annual stockholders&#8217; meeting, for a three<span class="nobreak">-year</span> term ending on the date of the annual meeting in 2027 or until his successor is duly elected and qualified or appointed.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s executive officers are appointed by and serve at the discretion of ARCA&#8217;s board of directors. There are no family relationships between ARCA&#8217;s directors and executive officers.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Code of Ethics</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA has adopted the ARCA biopharma, Inc. Code of Business Conduct and Ethics that applies to all officers, directors and employees. The Code of Business Conduct and Ethics is available on ARCA&#8217;s website at <span class="Italic" style="font-style:italic;font-weight:normal;">www.arcabiopharma.com</span>. If ARCA makes any substantive amendments to the Code of Business Conduct and Ethics or grants any waiver from a provision of the Code of Business Conduct and Ethics to any executive officer or director, ARCA will promptly disclose the nature of the amendment or waiver on its website and file any current report on Form&#160;8<span class="nobreak">-K</span> required by applicable law or Nasdaq listing standards.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Insider Trading Policy</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA has adopted an Insider Trading Policy that governs the purchase, sale and/or other dispositions of its securities by its directors, officers and employees, as well as their immediate family members and entities owned or controlled by them, and that is designed to promote compliance with insider trading laws, rules and regulations.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">160</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Information Regarding Committees of the Board of Directors</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;orphans:99;widows:1;margin-top:8pt;">ARCA&#8217;s board of directors has three standing committees: The Audit Committee, the Compensation Committee, and the Nominating and Corporate Governance Committee. The following table provides membership and meeting information for the fiscal year ended December&#160;31, 2023, for each of the committees of the board of directors:</p>
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 3pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-16" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">



						<p class="TCH_left" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Name</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Audit</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Compensation</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Nominating <br/>and <br/>Corporate <br/>Governance</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Dr.&#160;Michael R.&#160;Bristow</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Dr.&#160;Linda Grais</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">X</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">X*</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Dr.&#160;Raymond L.&#160;Woosley</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">X</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">X*</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Mr.&#160;Robert E.&#160;Conway</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">X*</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">X</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Mr.&#160;Dan J.&#160;Mitchell</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">X</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">X</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Dr.&#160;Anders Hove</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">X</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total meetings in fiscal 2023</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">6</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">2</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">1</p>
					</td>
				</tr>

		</table>
		<p class="Tablefootnotef" style="margin-top: 0in;  border: none; margin-right: 0in; margin-bottom: -5pt; margin-left: 24.0pt; text-align: justify; text-justify: inter-ideograph; text-indent: -24.0pt; padding: 0in; font-size: 9.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">____________</p><p class="Tablefootnote_f" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:10pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:10pt;">*<span style="width: 24px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Committee Chairperson.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In 2022, the board of directors established a Special Committee to evaluate strategic options for maximizing stockholder value. The Special Committee includes ARCA board Chairman Robert E.&#160;Conway (chair), and board members Linda Grais, M.D., Anders Hove, M.D and James Flynn (joined the Special Committee in April&#160;2024). Jacob Ma<span class="nobreak">-Weaver</span> served as a member of the Special Committee from June&#160;2022 to April&#160;2024.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Below is a description of each committee of the board of directors. Each of the committees has authority to engage legal counsel or other experts or consultants, as it deems appropriate to carry out its responsibilities.<span class="Bold-SmallCaps" style="font-style:normal;font-variant:small-caps;font-weight:bold;">&#160;</span>The board of directors has determined that each member of each committee meets the applicable Nasdaq rules and regulations regarding &#8220;independence&#8221; and that each member is free of any relationship that would impair his or her individual exercise of independent judgment regarding the Company.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Audit Committee</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Audit Committee of ARCA&#8217;s board of directors of ARCA (the &#8220;Audit Committee&#8221;) was established by the board of directors in accordance with Section&#160;3(a)(58)(A)&#160;of the Exchange&#160;Act, to oversee ARCA&#8217;s corporate accounting and financial reporting processes and audits of its financial statements. For this purpose, the Audit Committee performs several functions. The Audit Committee evaluates the performance of and assesses the qualifications of the independent registered public accounting firm; determines and approves the engagement of the independent registered public accounting firm; determines whether to retain or terminate the existing independent registered public accounting firm or to appoint and engage a new independent registered public accounting firm; reviews and approves the retention of the independent registered public accounting firm to perform any proposed permissible non<span class="nobreak">-audit</span> services; monitors the rotation of partners of the independent registered public accounting firm on ARCA&#8217;s audit engagement team as required by law; reviews and approves or rejects transactions between the company and any related persons; confers with management and the independent registered public accounting firm regarding the effectiveness of internal controls over financial reporting; establishes procedures, as required under applicable law, for the receipt, retention and treatment of complaints received by ARCA regarding accounting, internal accounting controls or auditing matters and the confidential and anonymous submission by employees of concerns regarding questionable accounting or auditing matters; and meets to review ARCA&#8217;s annual audited financial statements and quarterly financial statements with management and the independent registered public accounting firm, including a review of ARCA&#8217;s disclosures under the &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; discussion in its Annual Reports on Form&#160;10<span class="nobreak">-K</span> and Quarterly Reports on Form&#160;10<span class="nobreak">-Q</span>.&#160;The Audit Committee is currently composed of three<span class="Bold" style="font-style:normal;font-weight:bold;"> </span>directors: Mr.&#160;Conway (chair), Mr.&#160;Flynn and Dr.&#160;Grais. The Audit Committee met six times during the 2023 fiscal year. The board of directors has adopted a written charter of the Audit Committee that is available to stockholders<span class="Bold" style="font-style:normal;font-weight:bold;"> </span>on ARCA&#8217;s website at&#160;<span class="Italic" style="font-style:italic;font-weight:normal;">www.arcabio.com</span>.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">161</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s board of directors reviews the Nasdaq<span class="SmallCaps" style="font-variant:small-caps;"> </span>listing standards definition of independence for audit committee members on an annual basis and has determined that all members of the Audit Committee are independent (as independence is currently defined in Rule&#160;5605(c)(2)(A)(i)&#160;and (ii)&#160;of the Nasdaq<span class="SmallCaps" style="font-variant:small-caps;"> </span>listing standards). The board of directors has also determined that Mr.&#160;Conway qualifies as an &#8220;audit committee financial expert,&#8221; as defined in applicable SEC rules. The board of directors made a qualitative assessment of Mr.&#160;Conway&#8217;s level of knowledge and experience based on several factors, including his prior experience, business acumen and independence.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Compensation Committee</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Compensation Committee is currently composed of three directors: Mr.&#160;Conway, Dr.&#160;Grais (chair) and Dr.&#160;Hove. All members of the Compensation Committee are independent, as independence is currently defined in Rule&#160;5605(a)(2)&#160;of the Nasdaq listing standards. The Compensation Committee met two times during the 2023 fiscal year. The Compensation Committee has adopted a written charter that is available to stockholders on ARCA&#8217;s website at <span class="Italic" style="font-style:italic;font-weight:normal;">www.arcabio.com</span>.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Compensation Committee of ARCA&#8217;s board of directors acts on behalf of the board of directors to review, adopt and oversee ARCA&#8217;s compensation strategy, policies, plans and programs, including:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>overseeing succession planning for senior management of ARCA, including a review of the performance and advancement potential of current and future senior management and succession plans for each and recommending, as appropriate, the retention of potential succession candidates;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>assessing the overall compensation structure of ARCA and evaluating and recommending changes to ARCA&#8217;s compensation philosophies and strategies;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>reviewing and approving performance<span class="nobreak">-based</span> compensation plans or programs, including establishing goals and targets, applicable to the Chief Executive Officer and other members of the management team;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>administering, reviewing, and approving all executive compensation programs or plans, and all of ARCA&#8217;s incentive compensation and stock plans and awards thereunder of ARCA, including amendments to the programs, plans or awards made thereunder; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>preparing and approving the report of the Compensation Committee to be included as part of ARCA&#8217;s annual meeting proxy statement, to the extent required.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Compensation Committee Processes and Procedures</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Typically, the Compensation Committee meets, as it deems appropriate. The agenda for each meeting is usually developed by the Chair of the Compensation Committee. However, from time to time, various members of management and other employees as well as outside advisors or consultants<span class="Bold" style="font-style:normal;font-weight:bold;"> </span>may be invited by the Compensation Committee to make<span class="Bold" style="font-style:normal;font-weight:bold;"> </span>presentations, to provide financial or other<span class="Bold" style="font-style:normal;font-weight:bold;"> </span>background information or advice or to otherwise participate in Compensation Committee meetings. The Chief Executive Officer may not participate in, or be present during, any deliberations or determinations of the Compensation Committee regarding his compensation or individual performance objectives. The Compensation Committee has the sole authority to retain compensation consultants to assist in its evaluation of<span class="Bold" style="font-style:normal;font-weight:bold;"> </span>executive<span class="Bold" style="font-style:normal;font-weight:bold;"> </span>and director compensation, including the authority to approve the consultant&#8217;s reasonable fees and other retention terms. In general, the Compensation Committee has set executive compensation to be in line with peer companies identified by the Compensation Committee and to incentivize ARCA&#8217;s executive officers in achieving ARCA&#8217;s short- and long<span class="nobreak">-term</span> corporate goals.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In 2020, the Compensation and Nominating and Corporate Governance Committees of ARCA reviewed ARCA&#8217;s current employee and director compensation, including ARCA&#8217;s 2013 Equity Incentive Plan. As part of this review, the Committees considered certain changes to the ARCA&#160;2013 Equity Incentive Plan that were included in the 2020 ARCA Equity Incentive Plan. Both Committees recommended approval of the 2020 ARCA Equity Incentive Plan, and the Plan was subsequently approved by the board of directors and ARCA&#8217;s stockholders on December&#160;10, 2020.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">162</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The current compensation for the ARCA named executive officers was set by the Compensation Committee and the board of directors in 2020. On December&#160;21, 2020, the Compensation Committee approved the following base salary compensation and target bonus percentages for the ARCA named executive officers and principal financial officer for the 2021 fiscal year:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Michael R.&#160;Bristow, former President and Chief Executive Officer, $345,000 base salary and target bonus of 50% of base salary; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Thomas A.&#160;Keuer, Chief Operating Officer, $340,000 base salary and target bonus of 40% of base salary.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On May&#160;3, 2021, the Compensation Committee approved a $270,000 base salary and target bonus of 35% of base salary for C.&#160;Jeffrey Dekker, Chief Financial Officer, ARCA&#8217;s principal financial officer hired in May&#160;2021.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Historically, the Compensation Committee has made most of the significant adjustments to annual compensation, determined bonus and equity awards and established new performance objectives at one or more meetings held during the first quarter of the year. However, the Compensation Committee also considers matters related to individual compensation, such as compensation for new executive hires, as well as high<span class="nobreak">-level</span> strategic issues, such as the efficacy of ARCA&#8217;s compensation strategy, potential modifications to that strategy and new trends, plans or approaches to compensation, at various meetings throughout the year. Generally, the Compensation Committee&#8217;s process comprises two related elements: the determination of compensation levels and the establishment of performance objectives for the current year.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Compensation Committee reviews and approves the compensation of the President and the other executive officers of ARCA, including annual base salaries, annual and long<span class="nobreak">-term</span> incentive or bonus awards, employment agreements, and severance and change in control agreements/provisions, in each case as, when and if appropriate, and any special or supplemental benefits. For executives other than the President, the Compensation Committee solicits and considers evaluations and recommendations submitted to the Compensation Committee<span class="Bold" style="font-style:normal;font-weight:bold;"> </span>by the President. The Compensation Committee evaluates the performance of the President in light of Company and individual goals and objectives, and makes appropriate recommendations for improving performance. In performing the evaluation, the Chair of the Compensation Committee may solicit comments from the other non<span class="nobreak">-employee</span> members of the board of directors and lead the board of directors in an overall review of the President&#8217;s performance in an executive session of non<span class="nobreak">-employee</span> members of the board of directors. If the compensation for the President or any other executive officer is governed by an employment agreement, the Compensation Committee approves such employment agreement and any amendments thereto.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">For all executives as part of its deliberations, the Compensation Committee may review and consider, as appropriate,<span class="Bold" style="font-style:normal;font-weight:bold;"> </span>materials such as financial reports and projections, operational data, tax and accounting information, tally sheets that set forth the total compensation that may become payable to executives in various hypothetical scenarios, executive and director stock ownership information, company stock performance data, analyses of historical executive compensation levels and current Company<span class="nobreak">-wide</span> compensation levels.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Compensation Committee also considers the results of any &#8220;say<span class="nobreak">-on-pay</span>&#8221; vote of ARCA&#8217;s stockholders with regard to the compensation of ARCA&#8217;s executive officers when making compensation decisions. At the 2023 Annual Meeting, ARCA&#8217;s stockholders approved, on an advisory basis, the compensation of ARCA named executive officers as described in the proxy statement for such annual meeting, with over 81% of stockholder votes cast in favor of ARCA&#8217;s &#8220;say<span class="nobreak">-on-pay</span>&#8221; resolution. The Compensation Committee believes that this advisory vote supports that ARCA&#8217;s current compensation practices are aligned with the best interests of stockholders and anticipates taking into account the results of the advisory vote, and any future advisory votes, when making compensation decisions in the future.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Nominating and Corporate Governance Committee</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Nominating and Corporate Governance Committee of the board of directors of ARCA (the &#8220;Nominating and Corporate Governance Committee&#8221;) is responsible for identifying, reviewing and evaluating candidates to serve as directors of ARCA (consistent with criteria approved by the board of directors), reviewing and evaluating incumbent directors, recommending to the board of directors candidates for election to the board of directors , making recommendations to the board of directors regarding compensation for service on the board of directors and the committees thereof, making recommendations to the board of directors regarding the membership of the </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">163</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">committees of the board of directors, assessing the performance of the board of directors and developing a set of corporate governance principles for ARCA.&#160;The Nominating and Corporate Governance Committee is currently composed of three<span class="Bold" style="font-style:normal;font-weight:bold;"> </span>directors: Dr.&#160;Hove (chair), Mr.&#160;Conway and Dr.&#160;Grais. All members of the Nominating and Corporate Governance Committee in 2023 were independent (as independence is currently defined in Rule&#160;5605(a)(2) of the Nasdaq listing standards). The Nominating and Corporate Governance Committee met once during the 2023 fiscal year. The Nominating and Corporate Governance Committee has adopted a written charter that is available to stockholders on ARCA&#8217;s website at <span class="Italic" style="font-style:italic;font-weight:normal;">www.arcabio.com</span>.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Nominating and Corporate Governance Committee periodically reviews the compensation of non<span class="nobreak">-employee</span> Directors for service on the board of directors and committees thereof. In 2015, the Nominating and Corporate Governance Committee began a review of its Director compensation levels considering general market conditions in the life science industry, and in comparison to other clinical stage biopharmaceutical companies, and in early 2016, the Committee recommended, and the board of directors approved, revised compensation for non<span class="nobreak">-employee</span> Directors, discussed in &#8220;ARCA Director Compensation&#8221; below. Since adoption of this policy, the Nominating and Corporate Governance Committee has reviewed Director compensation on an annual basis.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In 2020, the Nominating and Corporate Governance Committee (together with the Compensation Committee) engaged a consultant to evaluate the current compensation of ARCA&#8217;s non<span class="nobreak">-employee</span> directors and make recommendations to the Nominating and Corporate Governance Committee. The changes made as a result of this evaluation are discussed in &#8220;ARCA Director Compensation&#8221; below.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The board of directors has adopted a process for identifying and evaluating director nominees, including stockholder nominees. Before recommending an individual to the board of directors for membership on the board of directors, the Nominating and Corporate Governance Committee canvasses its members and ARCA&#8217;s management team for potential candidates for the board of directors. The Nominating and Corporate Governance Committee also uses its network of contacts to identify potential candidates and, if it deems appropriate, may also engage a professional search firm. The Nominating and Corporate Governance Committee will consider stockholders&#8217; recommendations for nominees to serve as director if notice is timely received by the Secretary of ARCA.&#160;Candidates nominated by stockholders will be evaluated in the same manner as other candidates. The Nominating and Corporate Governance Committee keeps the board of directors apprised of its discussions with potential nominees, and the names of potential nominees received from its current directors, management, and stockholders, if the stockholder notice of nomination is timely made.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Although the board of directors has not adopted a fixed set of minimum qualifications for candidates for membership on the board of directors, the Nominating and Corporate Governance Committee generally considers several factors in its evaluation of a potential member, such as the candidate&#8217;s education, professional background and field of expertise including industry or academic experience in the pharmaceutical and biotechnology fields, experience in corporate governance and management, the reasonable availability of the potential member to devote time to the affairs of ARCA, as well as any other criteria deemed relevant by the board of directors or the Nominating and Corporate Governance Committee. However, the Nominating and Corporate Governance Committee retains the right to modify these qualifications from time to time. Candidates for director nominees are reviewed in the context of the current composition of the board of directors, the operating requirements of ARCA and the long<span class="nobreak">-term</span> interests of stockholders. In conducting this assessment, the Nominating and Corporate Governance Committee typically considers diversity, age, skills and such other factors as it deems appropriate given the current needs of the board of directors and ARCA, to maintain a balance of knowledge, experience and capability. The Nominating and Corporate Governance Committee believes it is essential that board of directors members come from a variety of backgrounds and experiences.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In the case of incumbent directors whose terms of office are set to expire, the Nominating and Corporate Governance Committee reviews these directors&#8217; overall contributions to ARCA and the board of directors during their terms, including level of attendance, level of participation, quality of performance and contribution to the board of directors&#8217; responsibilities and actions, and any relationships and transactions that might impair the directors&#8217; independence. In the case of new director candidates, the Nominating and Corporate Governance Committee also determines whether the nominee is independent for Nasdaq and SEC purposes, which determination is based upon applicable Nasdaq<span class="Bold" style="font-style:normal;font-weight:bold;"> </span>listing standards, applicable SEC rules and regulations and the advice of counsel, if necessary. The Nominating and Corporate Governance Committee conducts any appropriate and necessary inquiries into the </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">164</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">backgrounds and qualifications of possible candidates after considering the function and needs of the board of directors. The Nominating and Corporate Governance Committee meets to discuss and consider the candidates&#8217; qualifications and then determines whether to recommend a nominee to the board of directors by majority vote.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Stockholders who wish to recommend individuals for consideration by the Nominating and Corporate Governance Committee to become nominees for election to the board of directors may do so by delivering a written recommendation to the Nominating and Corporate Governance Committee addressed to the Corporate Secretary, between 60 and 90&#160;days before the one<span class="nobreak">-year</span> anniversary date of ARCA&#8217;s last annual meeting of stockholders. Recommendations must include the full name of the proposed nominee, a description of the proposed nominee&#8217;s business experience for at least the previous five&#160;years, complete biographical information, a description of the proposed nominee&#8217;s qualifications as a director, and a representation that the recommending stockholder is a beneficial or record owner of ARCA&#8217;s stock. Any such submission must be accompanied by the written consent of the proposed nominee to be named as a nominee and to serve as a director if elected. To date, the Nominating and Corporate Governance Committee has not rejected a timely director nominee from a stockholder.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In 2023, the Nominating and Corporate Governance Committee did not pay any fees to assist in the process of identifying or evaluating director candidates.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Anti-Hedging Prohibition</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s employees, directors and consultants are prohibited from engaging in any hedging transactions of ARCA&#8217;s securities, including through the use of financial instruments such as prepaid variable forwards, equity swaps, collars and exchange funds, as required by ARCA&#8217;s insider trading policy.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Stockholder Communications with the Board of Directors</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Stockholders who wish to communicate with ARCA&#8217;s board of directors may do so by e<span class="nobreak">-mail</span> by using the following email address: <span class="Italic" style="font-style:italic;font-weight:normal;">directors@arcabio.com</span>; or by mail by following the directions as set forth on ARCA&#8217;s website at <span class="Italic" style="font-style:italic;font-weight:normal;">www.arcabio.com</span>, under the section titled &#8220;Corporate Governance&#8221; and the subsection titled &#8220;Governance Documents&#8221;. Communications sent in accordance with this process will be transmitted by ARCA to the appropriate board members.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">165</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T17"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">ARCA EXECUTIVE COMPENSATION</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Executive Compensation</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following table shows for the fiscal&#160;years ended December&#160;31, 2023 and December&#160;31, 2022, compensation awarded to, paid to, or earned by ARCA&#8217;s principal executive officer and its two most highly compensated executive officers as of December&#160;31, 2023, collectively, the ARCA named executive officers:</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><span class="Bold-SmallCaps" style="font-style:normal;font-variant:small-caps;font-weight:bold;">Summary Compensation Table</span></p>
		<table class="No-Table-Style TableOverride-2" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 3pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-23" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-top:2pt;width: 31.12%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">



						<p class="TCH_left" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Name and Principal Position</p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 9.41%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">Year</p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 11.12%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">Salary <br/>($)<span class="Bold-Superscript" style="font-style:normal;font-weight:bold;vertical-align:super;font-size:58%;">(1)</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 7.70%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">Bonus <br/>($)<span class="Bold-Superscript" style="font-style:normal;font-weight:bold;vertical-align:super;font-size:58%;">(2)</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 9.41%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">Stock <br/>Awards <br/>($)</p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 12.62%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">All&#160;Other <br/>Compensation <br/>($)<span class="Bold-Superscript" style="font-style:normal;font-weight:bold;vertical-align:super;font-size:58%;">(3)</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 10.91%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">Total <br/>($)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 31.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Michael R.&#160;Bristow</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;">2023</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">345,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.70%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.41%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">13,800</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.91%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">358,800</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 31.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-indent:0pt;">Former President and Chief Executive Officer<span class="Superscript" style="vertical-align:super;font-size:58%;">(4)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 9.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;">2022</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 11.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">345,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 7.70%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="top">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 9.41%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="top">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 12.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">13,800</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 10.91%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">358,800</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 31.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Thomas A.&#160;Keuer</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;">2023</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">340,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.70%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">35,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.41%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">25,802</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.91%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">400,802</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 31.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-indent:0pt;">President and Chief Operating Officer</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 9.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;">2022</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 11.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">340,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 7.70%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="top">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 9.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">88,400</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 12.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">20,593</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 10.91%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">448,993</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 31.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">C.&#160;Jeffrey Dekker</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;">2023</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">270,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.70%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">35,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.41%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">18,072</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.91%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">323,072</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 31.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-indent:0pt;">Chief Financial Officer</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.70%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.91%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>

		</table>
		<p class="Tablefootnotef" style="margin-top: 0in;  border: none; margin-right: 0in; margin-bottom: -5pt; margin-left: 24.0pt; text-align: justify; text-justify: inter-ideograph; text-indent: -24.0pt; padding: 0in; font-size: 9.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">____________</p><p class="Tablefootnote_f" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:10pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:10pt;">(1)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>The amounts reported under &#8220;Salary&#8221; in the above table represent the actual amounts paid during the calendar year. Because ARCA&#8217;s actual pay dates do not always coincide with the first and last&#160;days of the year, these amounts may differ from the base salary amounts authorized by ARCA&#8217;s board of directors.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(2)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>The amounts reported under &#8220;Bonus&#8221; in the above table represent retention bonuses paid to each of Thomas A.&#160;Keuer and C.&#160;Jeffrey Dekker in December&#160;2023. These amounts were previously reported as &#8220;All Other Compensation&#8221; in ARCA&#8217;s Annual Report on Form&#160;10<span class="nobreak">-K</span> for the fiscal year ended December&#160;31, 2023.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(3)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Represents 401(k)&#160;Company match in the amount of $13,800 for Michael R.&#160;Bristow in each of 2023 and 2022, $15,000 and $13,600 for Thomas A.&#160;Keuer in 2023 and 2022, and $11,579 for C.&#160;Jeffrey Dekker in 2023, Health Savings Account contributions by ARCA in the amount of $850 for Thomas A.&#160;Keuer in 2022, and $3,960 for C.&#160;Jeffrey Dekker in 2023, group term life premiums in the amount of $9,602 and $4,989 for Thomas A.&#160;Keuer in 2023 and 2022, and $2,533 for C.&#160;Jeffrey Dekker in 2023, and cell phone reimbursements in the amount of $1,200 and $1,154 for Thomas A.&#160;Keuer in 2023 and 2022.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(4)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Dr.&#160;Bristow and ARCA mutually agreed to conclude Dr.&#160;Bristow&#8217;s employment effective April&#160;3, 2024.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Narrative Disclosure to Summary Compensation Table</span></p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Employment Agreements or Arrangements</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Michael R.&#160;Bristow, M.D., Ph.D.</span>&#160;&#160;&#160;&#160;Dr.&#160;Bristow served as ARCA&#8217;s President and Chief Executive Officer under an Employment and Retention Agreement dated as of June&#160;4, 2008, as amended. Pursuant to such employment agreement, Dr.&#160;Bristow was permitted to continue his academic work for the University of Colorado Health Sciences Center and for the Cardiovascular Institute, so long as it did not interfere with his duties as President and Chief Executive Officer of ARCA.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In connection with Dr.&#160;Bristow&#8217;s separation on April&#160;3, 2024, ARCA and Dr.&#160;Bristow entered into a separation agreement (the &#8220;Separation Agreement&#8221;) pursuant to which ARCA paid Dr.&#160;Bristow a lump sum amount equal to $370,000, less applicable tax withholding, which consisted of (i)&#160;12&#160;months of Dr.&#160;Bristow&#8217;s base salary as of the last date of his employment and (ii)&#160;a $25,000 cash payment. The separation payments were conditioned on Dr.&#160;Bristow not revoking the Separation Agreement.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA and Dr.&#160;Bristow also entered into a consulting agreement, effective April&#160;3, 2024 (the &#8220;Consulting Agreement&#8221;), pursuant to which Dr.&#160;Bristow provides certain consulting services to ARCA through the earlier of (i)&#160;the completion of services under the Consulting Agreement, (ii)&#160;a termination in accordance with the terms of the Consulting Agreement, and (iii)&#160;a change of control of ARCA (as defined in ARCA&#8217;s 2020 Equity Incentive Plan (the &#8220;2020 Plan&#8221;)). During the consulting term, Dr.&#160;Bristow will continue to vest in his outstanding equity awards.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">166</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Thomas A.&#160;Keuer.</span>&#160;&#160;&#160;&#160;Mr.&#160;Keuer serves as ARCA&#8217;s President and Chief Operating Officer under an Amended and Restated Employment Agreement that was effective as of January&#160;1, 2015.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On December&#160;8, 2022, the Compensation Committee approved a retention bonus of $100,000 for Mr.&#160;Keuer, subject to continued employment with ARCA through the earlier of a change in control of ARCA or certain clinical development decisions. On November&#160;29, 2023, the Compensation Committee approved the amendment of the retention bonus letter between ARCA and Mr.&#160;Keuer to (i)&#160;increase the aggregate amount of the retention bonus by 50%, to $150,000, and (ii)&#160;in order to assist with tax obligations associated with the vesting of certain ARCA restricted stock unit awards, provided that $35,000 of&#160;Mr.&#160;Keuer&#8217;s retention bonus was paid on December&#160;8, 2023. On April&#160;20, 2024, the board of directors of ARCA approved the second amendment of the retention bonus letter between ARCA and Mr.&#160;Keuer to increase the aggregate amount of the retention bonus by 33.33% to $200,000. The remaining portion of the retention bonus with respect to Mr.&#160;Keuer, consisting of $165,000, will become payable consistent with the original terms of the retention bonus letter and the first amendment to the retention bonus letter.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If ARCA terminates Mr.&#160;Keuer&#8217;s employment without &#8220;cause,&#8221; or if Mr.&#160;Keuer terminates his employment with &#8220;good reason&#8221; (as these terms are defined in his employment agreement), ARCA has agreed to pay Mr.&#160;Keuer a severance payment equivalent to (i)&#160;(a)&#160;12&#160;months of his base salary, if such termination occurs on the same&#160;day as or within 13&#160;months after a change of control of ARCA, or (b)&#160;six&#160;months of his base salary if such termination does not occur on the same&#160;day as or within 13&#160;months after a change of control of ARCA, (ii)&#160;a pro rata portion of any bonus compensation under any employee bonus plan that has been approved by ARCA&#8217;s board of directors payable to him for the fiscal year in which his employment terminated to be paid at the same time that such incentive bonus would have been paid had the termination not occurred, and (iii)&#160;reimbursement to cover out<span class="nobreak">-of-pocket</span> costs to continue group health insurance benefits under COBRA for (x)&#160;12&#160;months, if such termination occurs on the same&#160;day as or within 13&#160;months after a change of control of ARCA, or (y)&#160;six&#160;months if such termination does not occur on the same&#160;day as or within 13&#160;months after a change of control of ARCA, whether he elects or is eligible to receive COBRA (provided, in either event, that even if he does not elect or is not eligible to receive COBRA, he will receive the equivalent of such out<span class="nobreak">-of-pocket</span> expenses paid by him not to exceed the costs that the benefits would equal under COBRA if he were so eligible). In addition, ARCA may elect in its sole discretion, to pay additional severance equal to up to 12&#160;months of base salary, which additional payment would extend the covenants and obligations under Mr.&#160;Keuer&#8217;s Employee Intellectual Property, Confidentiality and Non<span class="nobreak">-Compete</span> Agreement for such additional period. The severance payment is conditioned on the execution by Mr.&#160;Keuer of a legal release in a form acceptable to ARCA.&#160;A termination for &#8220;cause&#8221; includes Mr.&#160;Keuer&#8217;s willful misconduct, gross negligence, theft, fraud, or other illegal or dishonest conduct, any of which are considered to be materially harmful to ARCA; refusal, unwillingness, failure, or inability to perform his material job duties or habitual absenteeism; or violation of fiduciary duty, violation of any duty of loyalty, or material breach of any material term of his employment agreement or his Employee Intellectual Property, Confidentiality and Non<span class="nobreak">-Compete</span> Agreement, or any other agreement, with ARCA. &#8220;Good reason&#8221; includes a relocation by us of Mr.&#160;Keuer&#8217;s normal work location greater than 30 miles; a decrease in current base salary by more than 15%, with certain exceptions; and ARCA&#8217;s unilateral decision to significantly and detrimentally reduce Mr.&#160;Keuer&#8217;s job responsibilities.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Effective as of April&#160;3, 2024, ARCA&#8217;s board of directors appointed Mr.&#160;Keuer to serve as ARCA&#8217;s President and principal executive officer. Mr.&#160;Keuer will not receive any additional compensation in connection with his appointment as President and principal executive officer. Mr.&#160;Keuer&#8217;s employment is expected to conclude upon closing of the Merger.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">C.&#160;Jeffrey Dekker.</span>&#160;&#160;&#160;&#160;Mr.&#160;Dekker serves as ARCA&#8217;s Chief Financial Officer under an Employment Agreement that was effective as of May&#160;10, 2021. Mr.&#160;Dekker has served as ARCA&#8217;s Secretary since April&#160;2023.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Under his employment agreement, Mr.&#160;Dekker is entitled to receive an annual base salary of $270,000, subject to annual increases if approved by ARCA&#8217;s board of directors or Compensation Committee and is eligible to receive an annual target bonus of 35% of his base salary as determined by ARCA&#8217;s board of directors or Compensation Committee in its sole discretion.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On December&#160;8, 2022, the Compensation Committee approved a retention bonus of $100,000 for Mr.&#160;Dekker, subject to continued employment with ARCA through the earlier of a change in control of ARCA or certain clinical development decisions. On November&#160;29, 2023, the Compensation Committee approved the amendment of the retention bonus letter between ARCA and Mr.&#160;Dekker to (i)&#160;increase the aggregate amount of the retention bonus by 50%, to $150,000, and (ii)&#160;in order to assist with tax obligations associated with the vesting of certain ARCA </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">167</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">restricted stock unit awards, provided that $35,000 of&#160;Mr.&#160;Dekker&#8217;s retention bonus was paid on December&#160;8, 2023. On April&#160;20, 2024, the board of directors of ARCA approved the second amendment of the retention bonus letter between ARCA and Mr.&#160;Dekker to increase the aggregate amount of the retention bonus by 33.33% to $200,000. The remaining portion of the retention bonus with respect to Mr.&#160;Dekker, consisting of $165,000, will become payable consistent with the original terms of the retention bonus letter and the first amendment to the retention bonus letter.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If ARCA terminates Mr.&#160;Dekker&#8217;s employment without &#8220;cause,&#8221; or if Mr.&#160;Dekker terminates his employment with &#8220;good reason&#8221; (as these terms are defined in his employment agreement), ARCA has agreed to pay Mr.&#160;Dekker a severance payment equivalent to (i)&#160;(a)&#160;12&#160;months of his base salary, if such termination occurs on the same&#160;day as or within 13&#160;months after a change of control of ARCA, or (b)&#160;six&#160;months of his base salary if such termination does not occur on the same&#160;day as or within 13&#160;months after a change of control of ARCA, (ii)&#160;a pro rata portion of any bonus compensation under any employee bonus plan that has been approved by ARCA&#8217;s board of directors payable to him for the fiscal year in which his employment terminated to be paid at the same time that such incentive bonus would have been paid had the termination not occurred, and (iii)&#160;reimbursement to cover out<span class="nobreak">-of-pocket</span> costs to continue group health insurance benefits under COBRA for (x)&#160;12&#160;months, if such termination occurs on the same&#160;day as or within 13&#160;months after a change of control of ARCA, or (y)&#160;six&#160;months if such termination does not occur on the same&#160;day as or within 13&#160;months after a change of control of ARCA, whether he elects or is eligible to receive COBRA (provided, in either event, that even if he does not elect or is not eligible to receive COBRA, he will receive the equivalent of such out<span class="nobreak">-of-pocket</span> expenses paid by him not to exceed the costs that the benefits would equal under COBRA if he were so eligible). In addition, ARCA may elect in its sole discretion, to pay additional severance equal to up to 12&#160;months of base salary, which additional payment would extend the covenants and obligations under Mr.&#160;Dekker&#8217;s Employee Intellectual Property, Confidentiality and Non<span class="nobreak">-Compete</span> Agreement for such additional period. The severance payment is conditioned on the execution by Mr.&#160;Dekker of a legal release in a form acceptable to ARCA.&#160;A termination for &#8220;cause&#8221; includes Mr.&#160;Dekker&#8217;s willful misconduct, gross negligence, theft, fraud, or other illegal or dishonest conduct, any of which are considered to be materially harmful to ARCA; refusal, unwillingness, failure, or inability to perform his material job duties or habitual absenteeism; or violation of fiduciary duty, violation of any duty of loyalty, or material breach of any material term of his employment agreement or his Employee Intellectual Property, Confidentiality and Non<span class="nobreak">-Compete</span> Agreement, or any other agreement, with ARCA. &#8220;Good reason&#8221; includes a relocation by us of Mr.&#160;Dekker&#8217;s normal work location greater than 30 miles; a decrease in current base salary by more than 15%, with certain exceptions; and ARCA&#8217;s unilateral decision to significantly and detrimentally reduce Mr.&#160;Dekker&#8217;s job responsibilities.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">168</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><span class="Bold-SmallCaps" style="font-style:normal;font-variant:small-caps;font-weight:bold;">Outstanding Equity Awards at Fiscal Year End</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following table shows for the fiscal year ended December&#160;31, 2023, certain information regarding outstanding equity awards at fiscal year<span class="nobreak">-end</span> for ARCA named executive officers.</p>
		<table class="No-Table-Style TableOverride-2" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 3pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-12" style="height:12pt;">
					<td class="TCH" rowspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">



						<p class="TCH_left" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Name</span></p>
					</td>
					<td class="TCH" rowspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="8" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 61.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Option Awards</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-26" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Number&#160;of <br/>Securities <br/>Underlying <br/>Unexercised<br/>Options<br/>(#) <br/>Exercisable</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Number&#160;of <br/>Securities <br/>Underlying <br/>Unexercised<br/>Options<br/>(#) <br/>Unexercisable</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Option <br/>Exercise<br/>Price<br/>($)</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Option<br/>Expiration<br/>Date</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-13" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Michael R.&#160;Bristow, Former President and Chief Executive Officer</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">408</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">245.70</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">2/26/2024</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">205</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">84.42</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">2/11/2025</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,511</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">59.40</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">6/8/2026</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,333</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">45.00</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">2/15/2027</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-13" style="background: #CCEEFF;height:12pt;">
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">142,500</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">47,500</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">&#8203;<span class="Superscript" style="vertical-align:super;font-size:58%;">(1)(4)</span></p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4.27</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">12/21/2030</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-13" style="background: #CCEEFF;height:12pt;">
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">63,334</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">31,666</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">&#8203;<span class="Superscript" style="vertical-align:super;font-size:58%;">(2)(4)</span></p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2.29</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">12/14/2031</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Thomas A.&#160;Keuer, President and Chief Operating Officer</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">83</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">245.70</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">2/26/2024</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">108</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">84.42</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">2/11/2025</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">866</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">59.40</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">6/8/2026</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,400</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">45.00</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">2/15/2027</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;">
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">52,500</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">17,500</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">&#8203;<span class="Superscript" style="vertical-align:super;font-size:58%;">(1)(4)</span></p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4.27</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">12/21/2030</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;">
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">23,334</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">11,666</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">&#8203;<span class="Superscript" style="vertical-align:super;font-size:58%;">(2)(4)</span></p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2.29</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">12/14/2031</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-13" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">C.&#160;Jeffrey Dekker, Secretary, Chief Financial Officer</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">35,521</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">19,479</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">&#8203;<span class="Superscript" style="vertical-align:super;font-size:58%;">(3)(4)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3.06</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">5/10/2031</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-13" style="background: #CCEEFF;height:12pt;">
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">11,800</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5,900</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">&#8203;<span class="Superscript" style="vertical-align:super;font-size:58%;">(2)(4)</span></p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2.29</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">12/14/2031</p>
					</td>
				</tr>

		</table>
		<p class="Tablefootnotef" style="margin-top: 0in;  border: none; margin-right: 0in; margin-bottom: -5pt; margin-left: 24.0pt; text-align: justify; text-justify: inter-ideograph; text-indent: -24.0pt; padding: 0in; font-size: 9.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">____________</p><p class="Tablefootnote_f" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:10pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:10pt;">(1)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Options vest in 48<span class="nobreak"> </span>monthly installments measured from December&#160;21, 2020.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(2)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Options vest in 36<span class="nobreak"> </span>monthly installments measured from December&#160;14, 2021.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(3)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Options vested 25% after one year, then in 36<span class="nobreak"> </span>monthly installments measured from May&#160;10, 2021.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(4)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>In the event of a change in control of ARCA, 50% of the unvested shares subject to this award shall become fully and immediately vested upon the closing date of such change in control, provided, however, that on the earlier of (i)&#160;the one<span class="nobreak">-year</span> anniversary of the closing date or (ii)&#160;involuntary termination, any options that remain unvested on such earlier date shall become fully and immediately vested. </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">169</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>






	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><span class="Bold-SmallCaps" style="font-style:normal;font-variant:small-caps;font-weight:bold;">ARCA Director Compensation</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following table shows for the fiscal year ended December&#160;31, 2023, certain information with respect to the compensation of all non<span class="nobreak">-employee</span> directors of ARCA:</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><span class="Bold-SmallCaps" style="font-style:normal;font-variant:small-caps;font-weight:bold;">Director Compensation</span><span class="Bold-Superscript" style="font-style:normal;font-weight:bold;vertical-align:super;font-size:58%;">(1)</span></p>
		<table class="No-Table-Style TableOverride-2" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 3pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-31" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 38.40%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">



						<p class="TCH_left" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Name</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.34%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Fees&#160;Earned <br/>or&#160;Paid&#160;in <br/>Cash&#160;<br/>($)</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.13%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Option <br/>Awards <br/>($)</span><span class="Bold-Superscript" style="font-style:normal;font-weight:bold;vertical-align:super;font-size:58%;">(2)</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.62%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Nonqualified <br/>Deferred <br/>Compensation <br/>Earnings&#160;<br/>($)</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.62%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">All&#160;Other <br/>Compensation <br/>($)</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.48%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Total&#160;<br/>($)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Linda Grais, M.D.<span class="Superscript" style="vertical-align:super;font-size:58%;">(3)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.34%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">162,500</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.13%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.62%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.62%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.48%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">162,500</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Raymond L.&#160;Woosley, M.D.<span class="Superscript" style="vertical-align:super;font-size:58%;">(4)(10)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.34%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">55,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.13%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.62%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.62%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.48%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">55,000</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Robert E.&#160;Conway<span class="Superscript" style="vertical-align:super;font-size:58%;">(5)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.34%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">195,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.13%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.62%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.62%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.48%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">195,000</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Dan J.&#160;Mitchell<span class="Superscript" style="vertical-align:super;font-size:58%;">(6)(10)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.34%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">52,500</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.13%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.62%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.62%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.48%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">52,500</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Anders Hove<span class="Superscript" style="vertical-align:super;font-size:58%;">(7)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.34%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">150,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.13%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.62%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.62%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.48%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">150,000</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Jacob Ma-Weaver<span class="Superscript" style="vertical-align:super;font-size:58%;">(8)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.34%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">130,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.13%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.62%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.62%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.48%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">130,000</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">James Flynn<span class="Superscript" style="vertical-align:super;font-size:58%;">(9)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.34%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">40,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.13%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.62%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.62%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.48%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">40,000</p>
					</td>
				</tr>

		</table>
		<p class="Tablefootnotef" style="margin-top: 0in;  border: none; margin-right: 0in; margin-bottom: -5pt; margin-left: 24.0pt; text-align: justify; text-justify: inter-ideograph; text-indent: -24.0pt; padding: 0in; font-size: 9.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">____________</p><p class="Tablefootnote_f" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:10pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:10pt;">(1)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Dr.&#160;Bristow, ARCA&#8217;s former President and Chief Executive Officer, was also a director during the year ended December&#160;31, 2023, but did not receive any additional compensation for his service as a director. Dr.&#160;Bristow&#8217;s compensation as an executive officer is set forth above under &#8220;Executive Compensation&#160;&#8212;&#160;Summary Compensation Table.&#8221;</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(2)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>The amounts reported under &#8220;Option Awards&#8221; in the above table reflect the grant date fair value of these awards as determined in accordance with Financial Accounting Standards Board Accounting Standards Codification Topic&#160;718, Compensation&#160;&#8212;&#160;Stock Compensation, excluding the effects of estimated forfeitures. The value of stock option awards was estimated using the Black<span class="nobreak">-Scholes</span> option<span class="nobreak">-pricing</span> model. The valuation assumptions used in the valuation of option grants may be found in Note&#160;8 to ARCA&#8217;s financial statements included in this annual report on Form&#160;10<span class="nobreak">-K</span> for the year ended December&#160;31, 2023.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(3)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>The aggregate number of shares issuable upon exercise of option awards outstanding at December&#160;31, 2023, for Dr.&#160;Grais was 19,458, all of which were fully vested. Includes $52,500 for Special Committee compensation for 2022 approved and paid in 2023, as discussed below and $52,500 for 2023 approved and paid in 2024.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(4)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>The aggregate number of shares issuable upon exercise of option awards outstanding at December&#160;31, 2023, for Dr.&#160;Woosley was 19,458, all of which were fully vested.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(5)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>The aggregate number of shares issuable upon exercise of option awards outstanding at December&#160;31, 2023, for Mr.&#160;Conway, Chairman of ARCA&#8217;s board of directors, was 19,458, all of which were fully vested. Includes $52,500 for Special Committee compensation for 2022 approved and paid in 2023, as discussed below and $52,500 for 2023 approved and paid in 2024.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(6)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>The aggregate number of shares issuable upon exercise of option awards outstanding at December&#160;31, 2023, for Mr.&#160;Mitchell was 19,577, all of which were fully vested.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(7)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>The aggregate number of shares issuable upon exercise of option awards outstanding at December&#160;31, 2023, for Dr.&#160;Hove was 18,999, all of which were fully vested. Includes $52,500 for Special Committee compensation for 2022 approved and paid in 2023, as discussed below and $52,500 for 2023 approved and paid in 2024.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(8)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>The aggregate number of shares issuable upon exercise of option awards outstanding at December&#160;31, 2023, for Mr.&#160;Ma<span class="nobreak">-Weaver</span> was 18,000, of which 12,000 shares were fully vested. Includes $37,500 for Special Committee compensation for 2022 approved and paid in 2023, as discussed below and $52,500 for 2023 approved and paid in 2024.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(9)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>The aggregate number of shares issuable upon exercise of option awards outstanding at December&#160;31, 2023, for Mr.&#160;Flynn was 12,000, of which 4,000 shares were vested.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(10)<span style="width: 12px;display: inline-block;">&#160;&#160;&#160;&#160;</span>These directors resigned from ARCA&#8217;s board of directors effective February&#160;2, 2024.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In 2021, ARCA revised its compensation plan for non<span class="nobreak">-employee</span> directors to provide that non<span class="nobreak">-employee</span> directors will be compensated for their service on ARCA&#8217;s board of directors, as follows:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Each non<span class="nobreak">-employee</span> director will receive an annual retainer fee of $40,000;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>As additional compensation for their services, each non<span class="nobreak">-employee</span> director will receive (i), upon joining ARCA&#8217;s board of directors, an initial option grant to purchase 12,000<span class="nobreak"> </span>shares of ARCA&#8217;s Common Stock under the 2020 Plan, (ii), in 2021 the members of the board of directors received a one<span class="nobreak">-time</span> retention option grant to purchase 12,000<span class="nobreak"> </span>shares of ARCA&#8217;s Common Stock under the 2020 Plan and (iii), on an annual basis as of the date of ARCA&#8217;s annual stockholder meeting, an annual option grant to purchase 6,000<span class="nobreak"> </span>shares of ARCA&#8217;s Common Stock under the 2020 Plan; provided that such non<span class="nobreak">-employee</span> director </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">170</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-position:inside;list-style-type:none;text-indent:0pt;margin-top:8pt;">has served on ARCA&#8217;s board of directors for at least six&#160;months prior to the date of grant (unless such six<span class="nobreak">-month</span> period is modified by recommendation of the Nominating and Corporate Governance Committee and approved by the Compensation Committee);</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>The Chairman of ARCA&#8217;s board of directors will receive an additional annual retainer fee of $30,000;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s Audit Committee chair will receive an additional annual retainer fee of $15,000;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>The chairs of ARCA&#8217;s Compensation Committee and Nominating and Corporate Governance Committee will each receive an additional annual retainer fee of $10,000;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Each non<span class="nobreak">-chair</span> member of ARCA&#8217;s Audit Committee will receive an additional annual retainer fee of $7,500; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Each non<span class="nobreak">-chair</span> member of ARCA&#8217;s Compensation Committee and Nominating and Corporate Governance Committees will receive an additional annual retainer fee of $5,000.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On January&#160;30, 2024, ARCA approved paying compensation to its existing non<span class="nobreak">-employee</span> directors, pursuant to ARCA&#8217;s Director Compensation Policy, by granting to Dr.&#160;Linda Grais, Dr.&#160;Anders Hove, Mr.&#160;Robert Conway, Mr.&#160;Daniel Mitchell, Dr.&#160;Raymond Woosley, Mr.&#160;James Flynn and Mr.&#160;Jacob Ma<span class="nobreak">-Weaver</span> options to purchase 6,000<span class="nobreak"> </span>shares of common stock at an exercise price of $1.64 per share, the closing price of ARCA&#8217;s common stock on January&#160;30, 2024. The options are subject to the terms and conditions of the Plan and ARCA&#8217;s standard forms of Stock Option Agreement and Option Grant Notice for the Plan. The options vest in 12 equal monthly installments beginning on January&#160;30, 2024, assuming Dr.&#160;Grais&#8217;, Dr.&#160;Hove&#8217;s, Mr.&#160;Conway&#8217;s, Mr.&#160;Mitchell&#8217;s, Dr.&#160;Woosley&#8217;s, Mr.&#160;Flynn&#8217;s and Mr.&#160;Ma<span class="nobreak">-Weaver</span>&#8217;s continued service on the Board for such periods.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In 2022, ARCA&#8217;s board of directors established a Special Committee to evaluate strategic options for maximizing stockholder value. The Special Committee includes ARCA board Chairman Robert E.&#160;Conway (chair), and board members Linda Grais, M.D., Anders Hove, M.D. and Jacob Ma<span class="nobreak">-Weaver</span>. In December&#160;2023, based on the recommendation of the Nominating and Corporate Governance Committee, the board determined that each member of the Special Committee will be paid $7,500 per month for each month of substantive service on the Special Committee. In December&#160;2023, payments for 2022 service were made to the members of the Special Committee of $52,500 to each of Robert E.&#160;Conway, Linda Grais, M.D., Anders Hove, M.D. and $37,500 to Jacob Ma<span class="nobreak">-Weaver</span> (joined the Committee in June&#160;2022). Payments for 2023 service were paid in 2024 to the members of the Special Committee consisting of $52,500 to each of Robert E.&#160;Conway, Linda Grais, M.D., Anders Hove, M.D. and Jacob Ma<span class="nobreak">-Weaver</span>. Payments for 2024 service through April&#160;2024 were paid in 2024 to the members of the Special Committee consisting of $30,000 to each of Robert E.&#160;Conway, Linda Grais, M.D., Anders Hove, M.D. and Jacob Ma<span class="nobreak">-Weaver</span>.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">171</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T16"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">ARCA EQUITY COMPENSATION PLAN INFORMATION</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following table sets forth information as of December&#160;31, 2023, for all of ARCA&#8217;s equity compensation plans:</p>
		<table class="No-Table-Style TableOverride-2" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-34" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 47.22%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">



						<p class="TCH_left" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Plan Category</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Number&#160;of <br/>Securities <br/>to&#160;be&#160;Issued&#160;Upon <br/>Exercise&#160;of <br/>Outstanding <br/>Options&#160;or&#160;Upon <br/>Vesting&#160;of <br/>Restricted&#160;Stock <br/>Unit</span>s<br/><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">(a)</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Weighted <br/>Average <br/>Exercise <br/>Price&#160;of <br/>Outstanding <br/>Options<br/>($)<br/>(b)</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 19.44%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Number&#160;of&#160;Securities <br/>Remaining <br/>Available&#160;for <br/>Future&#160;Issuance <br/>Under&#160;Equity <br/>Compensation <br/>Plans&#160;(Excluding <br/>Securities <br/>Reflected&#160;in<br/>Column(a)) <br/>(c)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-13" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 47.22%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Equity compensation plans approved by security holders</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">616,707</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4.76</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 19.44%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">459,718</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 47.22%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Equity compensation plans not approved by security holders</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 19.44%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 47.22%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">616,707</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4.76</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 19.44%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">459,718</p>
					</td>
				</tr>

		</table>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On December&#160;10, 2020, ARCA stockholders approved the ARCA biopharma, Inc. 2020 Equity Incentive Plan (the &#8220;2020 Plan&#8221;) at ARCA&#8217;s 2020 annual meeting of stockholders. The 2020 Plan is the successor to the Amended and Restated ARCA biopharma, Inc. 2013 Equity Incentive Plan (the &#8220;2013 Plan&#8221;). A description of the 2020 Plan is set forth in Note&#160;8 to ARCA&#8217;s financial statements included in this proxy statement/prospectus. The 2020 Plan only has options outstanding as of December&#160;31, 2023; no warrants or rights are outstanding under this plan; therefore, all values in the above table relate solely to the outstanding options.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On September&#160;17, 2013, ARCA stockholders approved the 2013 Plan at ARCA&#8217;s 2013 annual meeting of stockholders. On June&#160;9, 2016, ARCA stockholders approved an amendment to the 2013 Plan (as amended, the &#8220;Amended 2013 Plan&#8221;). A description of the 2013 Plan and the Amended 2013 Plan is set forth in Note&#160;8 to ARCA&#8217;s financial statements included in this proxy statement/prospectus. The Amended 2013 Plan only has options outstanding as of December&#160;31, 2023; no warrants or rights are outstanding under this plan; therefore, all values in the above table relate solely to the outstanding options.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Compensation Risks</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA believes its approach to goal setting, setting of targets with payouts at multiple levels of performance, and evaluation of performance results assist in mitigating excessive risk<span class="nobreak">-taking</span> that could harm the value or reward poor judgment by its executives. ARCA believes several features of its programs reflect sound risk management practices. ARCA believes it has allocated compensation among base salary and short and long<span class="nobreak">-term</span> compensation target opportunities in such a way as to not encourage excessive risk<span class="nobreak">-taking</span>. The multi<span class="nobreak">-year</span> vesting of equity awards properly accounts for the time horizon of risk. Furthermore, ARCA&#8217;s Compensation Committee assesses and monitors whether any of ARCA&#8217;s compensation policies and programs has the potential to encourage excessive risk<span class="nobreak">-taking</span> on an annual basis.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">172</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T15"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">ORUKA EXECUTIVE COMPENSATION</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Following completion of the Merger, certain executive officers of Oruka will become executive officers of the combined company. Because Oruka was not formed until 2024, there were no executive officers during 2023. This section sets forth the current compensatory arrangements for the following executive officers of Oruka as of March&#160;31, 2024, each of whom is expected to become an executive officer of the combined company.</p>
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">



						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;text-align:left;"><span class="Bold" style="font-style:normal;font-weight:bold;">Name</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Position</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 33.33%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Appointment Date</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Lawrence Klein</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">President and Chief Executive Officer</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 33.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">February&#160;26, 2024</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Paul Quinlan</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">General Counsel and Secretary</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 33.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">April&#160;30, 2024</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Joana Goncalves</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Chief Medical Officer</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 33.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">April&#160;18, 2024</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Arjun Agarwal</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Senior Vice President, Finance and Treasurer</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 33.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">March&#160;22, 2024</p>
					</td>
				</tr>

		</table>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Employment Agreements</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Employment Agreement with Mr.&#160;Klein</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka and Mr.&#160;Klein are party to an employment letter agreement, pursuant to which Mr.&#160;Klein receives an annual base salary of $600,000 and a target annual bonus of 50% of his base salary, pro<span class="nobreak">-rated</span> for 2024. In connection with his entry into his employment agreement, Mr.&#160;Klein purchased 1,491,646<span class="nobreak"> </span>shares of Oruka common stock at the fair market value on the purchase date, which will vest as to 25% on February&#160;26, 2025 and in equal monthly installments for the 36&#160;months thereafter. The employment agreement also provides that Mr.&#160;Klein will receive periodic grants of stock options, subject to approval by Oruka&#8217;s board of directors, sufficient to maintain Mr.&#160;Klein&#8217;s ownership at approximately 5% on a fully<span class="nobreak">-diluted</span> basis until Oruka has raised an aggregate of $200&#160;million in financing. Any such stock options will vest in equal monthly installments over 48&#160;months.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In the event of Mr.&#160;Klein&#8217;s termination by Oruka without cause prior to (or more than 12&#160;months following) a change in control of Oruka, Mr.&#160;Klein is eligible for the following severance benefits, subject to his execution and non<span class="nobreak">-revocation</span> of a release of claims: (i)&#160;severance payments equal to 12&#160;months of his base salary, (ii)&#160;any earned but unpaid bonus for the year preceding the date of termination, (iii)&#160;accelerated vesting of 30% of the unvested portion of any outstanding time<span class="nobreak">-based</span> equity awards, and (iv)&#160;Oruka<span class="nobreak">-subsidized</span> continuation coverage under Oruka&#8217;s group health plans for up to 12&#160;months. If Mr.&#160;Klein is terminated by Oruka without cause or by Mr.&#160;Klein for good reason on or within 12&#160;months following a change in control of Oruka, Mr.&#160;Klein will receive the foregoing benefits, as well as full acceleration of all outstanding time<span class="nobreak">-based</span> equity awards.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Employment Agreements with Other Executive Officers</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka and Mr.&#160;Quinlan are party to an employment letter agreement, pursuant to which Mr.&#160;Quinlan receives an annual base salary of $460,000 and a target annual bonus of 40% of his base salary, pro<span class="nobreak">-rated</span> for 2024. Mr.&#160;Quinlan&#8217;s employment agreement also provided for an initial grant of stock options to purchase 400,000<span class="nobreak"> </span>shares of Oruka common stock, which vest as to 25% on the first anniversary of his start date and in equal monthly installments for the 36&#160;months thereafter.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka and Dr. Goncalves are party to an employment letter agreement, pursuant to which Dr. Goncalves receives an annual base salary of $460,000 and a target annual bonus of 40% of her base salary, pro<span class="nobreak">-rated</span> for 2024. In connection with her appointment, Dr. Goncalves was granted stock options to purchase 400,000<span class="nobreak"> </span>shares of Oruka common stock, which vest as to 25% on the first anniversary of her start date and in equal monthly installments for the 36&#160;months thereafter. The employment agreement also provided for a $100,000 signing bonus, which is subject to pro<span class="nobreak">-rata</span> repayment if Dr. Goncalves is terminated for cause or resigns within one year following her start date.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka and Mr.&#160;Agarwal are party to an employment letter agreement, pursuant to which Mr.&#160;Agarwal receives an annual base salary of $360,000 and a target annual bonus of 35% of his base salary. Mr.&#160;Agarwal&#8217;s employment agreement also provided for an initial grant of stock options to purchase 225,000<span class="nobreak"> </span>shares of Oruka common stock, which vest as to 25% on the first anniversary of his start date and in equal monthly installments for the 36&#160;months thereafter.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">173</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The employment agreements with Messrs. Quinlan and Agarwal and Dr. Goncalves provide for the following severance benefits upon their termination by Oruka without cause prior to (or more than 12&#160;months following) a change in control of Oruka, subject to the executive&#8217;s execution and non<span class="nobreak">-revocation</span> of a release of claims: (i)&#160;severance payments equal to six&#160;months of the executive&#8217;s base salary, (ii)&#160;any earned but unpaid bonus for the year preceding the date of termination and (iii)&#160;Oruka<span class="nobreak">-subsidized</span> continuation coverage under Oruka&#8217;s group health plans for up to six&#160;months. If the executive is terminated by Oruka without cause or by the executive for good reason on or within 12&#160;months following a change in control of Oruka, the executive will receive the foregoing benefits, as well as full acceleration of all outstanding time<span class="nobreak">-based</span> equity awards.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Summary Description of Oruka&#8217;s 2024 Equity Incentive Plan</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka maintains the 2024 Equity Incentive Plan, the purpose of which is to advance the interests of Oruka&#8217;s stockholders by enhancing Oruka&#8217;s ability to attract, retain and motivate persons who are expected to make important contributions to Oruka and by providing such persons with equity ownership opportunities and performance<span class="nobreak">-based</span> incentives that are intended to better align the interests of such persons with those of Oruka&#8217;s stockholders. The 2024 Equity Incentive Plan provides for the issuance of up to 872,912<span class="nobreak"> </span>shares of Oruka common stock, which may be granted as stock options, restricted stock, restricted stock units and other stock<span class="nobreak">-based</span> awards to eligible employees, officers, directors, consultants and advisors of Oruka on such terms and conditions as approved by Oruka&#8217;s board of directors or any committee appointed by Oruka&#8217;s board of directors to administer the 2024 Equity Incentive Plan. No grants will be made under the 2024 Equity Incentive Plan following consummation of the Merger.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">174</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T14"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">ORUKA DIRECTOR COMPENSATION</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Because Oruka was not formed until 2024, there were no directors during 2023. In connection with his appointment as a member of Oruka&#8217;s board of directors, Dr.&#160;Kulkarni entered into a letter agreement, pursuant to which he received: (i)&#160;stock options to purchase 250,000<span class="nobreak"> </span>shares of Oruka common stock, which vest 25% on the first anniversary of his appointment date and in equal monthly installments for the 36&#160;months thereafter; and (ii)&#160;stock options to purchase 100,000<span class="nobreak"> </span>shares of Oruka common stock, which vest upon the first anniversary of the date Dr.&#160;Kulkarni is appointed Chairman of Oruka&#8217;s board of directors and will be forfeited if Dr.&#160;Kulkarni is not appointed Chairman of Oruka&#8217;s board of directors prior to March&#160;22, 2025. In connection with her appointment as a member of Oruka&#8217;s board of directors, Ms. Ball entered into a letter agreement, pursuant to which she received stock options to purchase 125,000<span class="nobreak"> </span>shares of Oruka common stock, which vest 25% on the first anniversary of her appointment date and in equal monthly installments for the 36&#160;months thereafter. In connection with his appointment as a member of Oruka&#8217;s board of directors, Mr.&#160;Dambkowski received stock options to purchase 125,000<span class="nobreak"> </span>shares of Oruka common stock, which vest 25% on the first anniversary of his appointment date and in equal monthly installments for the 36&#160;months thereafter.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In anticipation of his service on the Oruka board of directors, Dr.&#160;Turtle purchased 149,164<span class="nobreak"> </span>shares of Oruka common stock at the fair market value on the purchase date. The purchased shares are subject to vesting as to 25% on the first anniversary of his appointment date and in equal monthly installments for the 36&#160;months thereafter.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">It is expected that Oruka will implement cash retainers for all non<span class="nobreak">-employee</span> directors, including an annual cash retainer.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">175</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T9980"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">MATTERS BEING SUBMITTED TO A VOTE OF ARCA STOCKHOLDERS </span></p>
		<a id="T9981"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">PROPOSAL NO. 1&#160;&#8212;&#160;THE NASDAQ STOCK ISSUANCE PROPOSAL</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">General</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">At the ARCA special meeting, ARCA will ask its stockholders to approve (i)&#160;the issuance of shares of ARCA common stock, including shares of ARCA common stock issuable upon conversion of ARCA Series&#160;B Preferred Stock, to the stockholders of Oruka pursuant to the Merger Agreement, which shares of ARCA common stock will represent more than 20% of the shares of ARCA common stock outstanding immediately prior to the First Merger and (ii)&#160;the change of control of ARCA resulting from the First Merger, pursuant to Nasdaq Listing Rules&#160;5635(a)&#160;and 5635(b), respectively.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Immediately after the First Merger, ARCA securityholders as of immediately prior to the First Merger are expected to own approximately 2.39% of the outstanding shares of capital stock of the combined company (on a fully<span class="nobreak">-diluted</span> basis), and former holders of Oruka securities are expected to own approximately 97.61% of the outstanding shares of capital stock of the combined company (on a fully<span class="nobreak">-diluted</span> basis), subject to certain assumptions, including, but not limited to, ARCA&#8217;s net cash as of closing being equal to $5.0&#160;million. Under certain circumstances further described in the Merger Agreement, the ownership percentages may be adjusted up or down, including if ARCA&#8217;s net cash as of closing is lower than $5.0&#160;million. ARCA management currently anticipates ARCA&#8217;s net cash as of closing will be approximately $5.0&#160;million, after giving effect to the special cash dividend, which is expected to be approximately $20.0<span class="nobreak"> </span>million, and the currently estimated ownership percentages reflect this projection.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA will assume outstanding and unexercised options and warrants to purchase shares of Oruka common stock, and such securities will be converted into options and warrants, as applicable, to purchase shares of ARCA common stock, subject to certain adjustments.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, prior to the closing of the First Merger, ARCA expects to declare a cash dividend to the pre<span class="nobreak">-First</span> Merger ARCA stockholders equal in the aggregate to ARCA&#8217;s reasonable, good faith approximation of the amount by which ARCA&#8217;s net cash (as determined pursuant to the Merger Agreement) will exceed $5.0&#160;million.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The terms of, reasons for and other aspects of the Merger Agreement and the Merger are described in detail in the section of this proxy statement/prospectus titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">The Merger Agreement</span>.&#8221; A copy of the Merger Agreement is attached as <span class="Italic" style="font-style:italic;font-weight:normal;">Annex&#160;A</span> to this proxy statement/prospectus.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Reason for the Proposal</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Under Nasdaq Listing Rule&#160;5635(a)(1), a company listed on Nasdaq is required to obtain stockholder approval prior to the issuance of common stock, among other things, in connection with the acquisition of another company&#8217;s stock, if the number of shares of common stock to be issued is in excess of 20% of the number of shares of common stock then outstanding. The potential issuance of the shares of ARCA common stock in the Merger exceeds the 20% under the Nasdaq Listing Rules and is expected to represent approximately 97.61% of ARCA common stock on a fully<span class="nobreak">-diluted</span> basis immediately following the Merger. Accordingly, in order to ensure compliance with Nasdaq Listing Rule&#160;5635(a)(1), ARCA must obtain the approval of ARCA stockholders for the issuance of these shares of common stock in the Merger.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Under Nasdaq Listing Rule&#160;5635(b), a company listed on Nasdaq is required to obtain stockholder approval prior to an issuance of stock that will result in a &#8220;change of control&#8221; of the listed company. It is expected that Nasdaq will determine that the Merger constitutes a &#8220;change of control&#8221; of the listed company. Accordingly, in order to ensure compliance with Nasdaq Listing Rule&#160;5635(b), ARCA must obtain the approval of ARCA stockholders of the change of control resulting from the Merger.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">176</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Required Vote</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The affirmative vote of a majority of the shares of ARCA common stock entitled to vote on the subject matter and present in person or represented by proxy at the ARCA special meeting is required to approve the Nasdaq Stock Issuance Proposal. Abstentions will have the same effect as votes &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">AGAINST</span>&#8221; the Nasdaq Stock Issuance Proposal and broker non<span class="nobreak">-votes</span>, if any, will have no effect on the Nasdaq Stock Issuance Proposal.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Merger is conditioned upon the approval of the Nasdaq Stock Issuance Proposal. Notwithstanding the approval of the Nasdaq Stock Issuance Proposal, if the Merger is not consummated for any reason, the actions contemplated by the Nasdaq Stock Issuance Proposal will not be effected.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Nasdaq Stock Issuance Proposal is conditioned on the approval of the Authorized Share Increase Proposal. Notwithstanding the approval of the Nasdaq Stock Issuance Proposal, if the Authorized Share Increase Proposal is not approved, the actions contemplated by the Nasdaq Stock Issuance Proposal will not be effected and the Merger will not be consummated.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Certain ARCA stockholders have agreed to vote any shares of ARCA common stock owned by them in favor of the Nasdaq Stock Issuance Proposal. See &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Agreements Related to the Merger&#160;&#8212;&#160;Support Agreements</span>&#8221; beginning on page 153 of this proxy statement/prospectus for more information.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Unless otherwise instructed, it is the intention of the persons named in the accompanying proxy card to vote shares represented by properly executed proxy cards &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">FOR</span>&#8221; the approval of the Nasdaq Stock Issuance Proposal.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-align:center;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">THE ARCA BOARD OF DIRECTORS RECOMMENDS A VOTE &#8220;FOR&#8221; THE NASDAQ STOCK ISSUANCE PROPOSAL.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">177</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T9982"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">PROPOSAL NO. 2&#160;&#8212;&#160;THE AUTHORIZED SHARE INCREASE PROPOSAL</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">General</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">At the ARCA special meeting, ARCA will ask its stockholders to approve an amendment to the ARCA Charter to increase the number of authorized shares of ARCA common stock (the &#8220;ARCA Share Increase Amendment&#8221;). On<span style="width: 10px;display: inline-block;">&#160;&#160;&#160;</span><span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>, 2024, ARCA&#8217;s board of directors approved a proposal to amend the ARCA Charter to increase the number of authorized shares of ARCA common stock from 100,000,000<span class="nobreak"> </span>shares to&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, which would also have the effect of increasing the total number of authorized shares from 105,000,000, including ARCA preferred stock, to&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(the &#8220;ARCA Share Increase&#8221;), in the form attached as <span class="Italic" style="font-style:italic;font-weight:normal;">Annex&#160;G</span> to this proxy statement/prospectus. On the Record Date, there were&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of ARCA common stock issued and outstanding, and&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of ARCA common stock reserved for issuance. Accordingly, approximately&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of the total number of ARCA common stock currently authorized remain available for issuance or may be reserved for issuance.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Form of the ARCA Share Increase Amendment</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The ARCA Share Increase Amendment would amend and restate the first paragraph of Article&#160;IV of the ARCA Charter in its entirety as follows:</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">&#8220;The total number of shares of all classes of stock this Corporation shall have authority to issue is<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span><span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>, consisting of&#160;&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>shares of Common Stock, par value $0.001 per share, and 5,000,000<span class="nobreak"> </span>shares of Preferred Stock, par value $0.001 per share. The Preferred Stock may be issued from time to time, in one or more series, each series to be appropriately designated by a distinguishing letter or title, prior to the issue of any shares thereof.&#8221;</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Background and Reasons for the ARCA Share Increase Amendment</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The ARCA Charter currently authorizes the issuance of up to 100,000,000<span class="nobreak"> </span>shares of ARCA common stock and 5,000,000<span class="nobreak"> </span>shares of preferred stock. As of the close of business on the Record Date, there were&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of ARCA common stock issued and outstanding, and&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of ARCA common stock reserved for issuance. Accordingly, approximately&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of the total number of ARCA common stock currently authorized remain available for issuance or may be reserved for issuance.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As described in greater detail in the section of this proxy statement/prospectus titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">The Merger Agreement</span>,&#8221; pursuant to the Merger Agreement, ARCA will be required to issue shares of ARCA common stock, including shares of ARCA common stock issuable upon conversion of ARCA Series&#160;B Preferred Stock, to Oruka stockholders and to assume Oruka&#8217;s 2024 Equity Incentive Plan and outstanding options and warrants to purchase Oruka common stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The number of shares of ARCA common stock currently authorized and unissued and not reserved for issuance is not sufficient for (i)&#160;the issuance of ARCA common stock, including shares of ARCA common stock issuable upon conversion of ARCA Series&#160;B Preferred Stock, pursuant to the Merger Agreement and (ii)&#160;the assumption of Oruka&#8217;s 2024 Equity Incentive Plan and outstanding options and warrants to purchase Oruka common stock. In addition, there will not be sufficient shares of ARCA common stock available for issuance in connection with possible future acquisitions, equity and equity<span class="nobreak">-based</span> financings, possible future awards under employee benefit plans and other corporate purposes that ARCA&#8217;s board of directors may determine to be desirable. Therefore, ARCA&#8217;s board of directors has determined that the ARCA Share Increase Amendment is in the best interests of ARCA and its stockholders.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If the ARCA Share Increase Amendment is approved by stockholders, upon its effectiveness, and without giving effect to the proposed reverse stock split described in Proposal&#160;No. 3 of this proxy statement/prospectus, ARCA will have a total of&#160;<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span><span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>authorized shares of ARCA common stock, with&#160;&#160;&#160;&#160;&#160;<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>shares of ARCA common stock issued and outstanding (as of the Record Date), and&#160;&#160;&#160;&#160;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>shares reserved for issuance (as of the Record Date), leaving a balance of&#160;&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>shares of ARCA common stock authorized and unissued and not reserved for any specific purpose. The ARCA Share Increase Amendment will have no effect on the authorized shares of ARCA Preferred Stock.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">178</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Except for (i)&#160;the issuance of shares of ARCA common stock, including shares of ARCA common stock issuable upon conversion of ARCA Series&#160;B Preferred Stock, and (ii)&#160;the issuance of shares of ARCA common stock that may result from the assumption of Oruka&#8217;s 2024 Equity Incentive Plan and outstanding options and warrants to purchase Oruka common stock, each pursuant to the terms of the Merger Agreement, ARCA does not currently have any plans, proposals or arrangement to issue any of its authorized but unissued shares of common stock.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Possible Effects of the ARCA Share Increase Amendment</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If the ARCA Share Increase Amendment is approved and becomes effective, the additional authorized shares would be available for issuance at the discretion of ARCA&#8217;s board of directors and without further stockholder approval, except as may be required by law or Nasdaq rules. The additional shares of authorized ARCA common stock would have the same rights and privileges as the shares of ARCA common stock currently issued and outstanding. Holders of ARCA common stock have no preemptive rights. The ARCA Share Increase would not change the number of shares of common stock outstanding, nor will it have any immediate dilutive effect; however, the issuance of additional shares of ARCA common stock authorized by the ARCA Share Increase may, among other things, have a dilutive effect on earnings per share and on stockholders&#8217; equity and voting rights. Furthermore, future sales of substantial amounts of ARCA common stock, or the perception that these sales might occur, could adversely affect the prevailing market price of ARCA common stock or limit ARCA&#8217;s ability to raise additional capital. ARCA stockholders should recognize that, as a result of this proposal, they will own a smaller percentage of shares relative to the total authorized shares of the company than they presently own.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Appraisal or Dissenters&#8217; Rights</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Pursuant to the DGCL, stockholders are not entitled to appraisal rights or dissenter&#8217;s rights with respect to the ARCA Share Increase Amendment or the ARCA Share Increase.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Effectiveness of Amendment</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If the ARCA Share Increase Amendment is approved by the stockholders at the ARCA special meeting, it will become effective upon the filing of a certificate of amendment, a copy of which is attached as&#160;<span class="Italic" style="font-style:italic;font-weight:normal;">Annex&#160;G&#160;</span>to this proxy statement/prospectus, with the Delaware Secretary of State or such later effective date and time as specified in the certificate of amendment in accordance with Delaware law.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Copies of the ARCA Charter and the certificates of amendment to the ARCA Charter are available as exhibits to this proxy statement/prospectus.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Required Vote</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The affirmative vote of a majority of the votes properly cast for or against the Authorized Share Increase Proposal by the holders of ARCA common stock is required to approve the Authorized Share Increase Proposal. Abstentions and broker non<span class="nobreak">-votes</span>, if any, will have no effect on the Authorized Share Increase Proposal.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Nasdaq Stock Issuance Proposal and the Merger are conditioned upon the approval of the Authorized Share Increase Proposal. In order to have an adequate number of available shares to effect the Merger, the stockholders of ARCA will need to approve the Authorized Share Increase Proposal. Additionally, ARCA&#8217;s board of directors may determine to effect the Authorized Share Increase Proposal, if approved, even if the Nasdaq Stock Issuance Proposal is not approved by the ARCA stockholders.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Certain ARCA stockholders have agreed to vote any shares of ARCA common stock owned by them in favor of the Authorized Share Increase Proposal. See &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Agreements Related to the Merger&#160;&#8212;&#160;Support Agreements</span>&#8221; beginning on page 153 of this proxy statement/prospectus for more information.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Unless otherwise instructed, it is the intention of the persons named in the accompanying proxy card to vote shares represented by properly executed proxy cards &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">FOR</span>&#8221; the approval of the Authorized Share Increase Proposal.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-align:center;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">THE ARCA BOARD OF DIRECTORS RECOMMENDS A VOTE &#8220;FOR&#8221; THE AUTHORIZED SHARE INCREASE PROPOSAL.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">179</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T9983"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">PROPOSAL NO. 3&#160;&#8212;&#160;THE REVERSE STOCK SPLIT PROPOSAL</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">General</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">At the ARCA special meeting, ARCA will ask its stockholders to approve an amendment to the ARCA Charter to effect a reverse stock split of ARCA&#8217;s issued and outstanding common stock at a ratio in the range of<span style="width: 10px;display: inline-block;">&#160;&#160;&#160;</span><span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span class="nobreak">-for</span>-&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span class="nobreak">-for</span>-&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, to be determined mutually by ARCA&#8217;s board of directors and Oruka&#8217;s board of directors (the &#8220;Split Ratio&#8221;). The final Split Ratio and effectiveness of such amendment and the abandonment of such amendment will be mutually agreed by ARCA&#8217;s board of directors and Oruka&#8217;s board of directors prior to the First Effective Time, assuming this proposal is approved by ARCA&#8217;s stockholders. On&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2024, ARCA&#8217;s board of directors adopted resolutions approving the proposed certificate of amendment to the ARCA Charter in the form attached as <span class="Italic" style="font-style:italic;font-weight:normal;">Annex&#160;H</span> to this proxy statement/prospectus. If this certificate of amendment is filed with the Secretary of State of the State of Delaware, upon its effectiveness (the &#8220;reverse stock split effective time&#8221;), it will effect the reverse stock split by the Split Ratio but will not increase the par value of ARCA common stock. At the reverse stock split effective time, the issued and outstanding shares of ARCA common stock immediately prior to the reverse stock split effective time will automatically without further action on the part of ARCA be combined into a smaller number of shares in accordance with the final Split Ratio.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">By approving the Reverse Stock Split Proposal, ARCA stockholders will approve the amendment to the ARCA Charter pursuant to which any whole number of issued and outstanding shares of ARCA common stock, between and including<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span><span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>and&#160;&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>, would be combined into one share of ARCA common stock, and will authorize ARCA&#8217;s board of directors to file the certificate of amendment. As of the Record Date, 100,000,000<span class="nobreak"> </span>shares of ARCA common stock were authorized,&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of ARCA common stock were outstanding and no shares of ARCA common stock were held in treasury.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The reverse stock split will not change the number of authorized shares of ARCA common stock or preferred stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">All holders of ARCA common stock will be affected proportionately by the reverse stock split. No fractional shares of ARCA common stock will be issued as a result of the reverse stock split. Instead, ARCA stockholders who otherwise would be entitled to receive fractional shares will be entitled to receive cash as set forth below under the caption &#8220;No Fractional Shares.&#8221; Each ARCA stockholder will hold the same percentage of the outstanding ARCA common stock immediately following the reverse stock split as that ARCA stockholder did immediately prior to the reverse stock split, except to the extent that the reverse stock split results in ARCA stockholders receiving cash in lieu of fractional shares.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Reasons for the Reverse Stock Split</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s board of directors approved the proposal approving the amendment to the ARCA Charter effecting the reverse stock split for the following reasons:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors believes effecting the reverse stock split will result in an increase in the minimum bid price of ARCA common stock and reduce the risk of a delisting of ARCA common stock from Nasdaq in the future;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors believes a higher stock price may help generate investor interest in ARCA, and ultimately the combined company, and help ARCA attract and retain employees;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors believes a higher stock price may increase trading volume in ARCA common stock and facilitate future financings by the combined company;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors believes that the resulting increase in the number of authorized and unissued shares available for future issuance will be necessary for the issuance of shares to the stockholders of Oruka pursuant to the Merger Agreement, as described in the Nasdaq Stock Issuance Proposal, the issuance of shares of ARCA common stock that may result from the assumption of Oruka&#8217;s 2024 Equity Incentive Plan and outstanding options and warrants to purchase Oruka common stock, pursuant to the Merger Agreement, and ultimately the consummation of the Merger; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors believes that a range of reverse stock split ratios provides it with the most flexibility to achieve the desired results of the reverse stock split.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">180</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Requirements for Listing on Nasdaq</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA common stock is currently listed on The Nasdaq Capital Market under the symbol &#8220;ABIO.&#8221; ARCA intends to file an initial listing application pursuant to the terms of the Merger Agreement for the combined company to list the securities of the combined company on Nasdaq.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">According to the Nasdaq rules, an issuer must, in a case such as this, apply for initial inclusion following a transaction whereby the issuer combines with a non<span class="nobreak">-Nasdaq</span> entity, resulting in a change of control of the issuer and potentially allowing the non<span class="nobreak">-Nasdaq</span> entity to obtain a Nasdaq listing. Accordingly, the listing standards of Nasdaq will require ARCA to have, among other things, a $4.00 per share minimum bid price for a certain number of&#160;trading days preceding the closing of the Merger. Therefore, the reverse stock split may be necessary in order to satisfy Nasdaq requirements and consummate the Merger.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, it is a condition to the closing of the Merger that the shares of ARCA common stock to be issued in the Merger pursuant to the Merger Agreement have been approved for listing on Nasdaq.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">One of the effects of the reverse stock split will be to effectively increase the proportion of authorized shares which are unissued relative to those which are issued. This could result in ARCA&#8217;s management being able to issue more shares without further stockholder approval. The reverse stock split will not affect the number of authorized shares of ARCA capital stock, which will continue to be authorized pursuant to the ARCA Charter.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Potential Increased Investor Interest</span></p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:0pt;text-indent:24pt;margin-top:8pt;">On<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>, 2024, ARCA common stock closed at $&#160;&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>per share. An investment in ARCA common stock may not appeal to brokerage firms that are reluctant to recommend lower priced securities to their clients. Investors may also be dissuaded from purchasing lower priced stocks because the brokerage commissions, as a percentage of the total transaction, tend to be higher for such stocks. Moreover, the analysts at many brokerage firms do not monitor the trading activity or otherwise provide research coverage of lower priced stocks. Also, ARCA&#8217;s board of directors believes that most investment funds are reluctant to invest in lower priced stocks.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">There are risks associated with the reverse stock split, including that the reverse stock split may not result in an increase in the per share price of ARCA common stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA cannot predict whether the reverse stock split will increase the market price for ARCA common stock. The history of similar stock split combinations for companies in like circumstances is varied. There is no assurance that:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the market price per share of ARCA common stock after the reverse stock split will rise in proportion to the reduction in the number of shares of ARCA common stock outstanding before the reverse stock split;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the reverse stock split will result in a per share price that will attract brokers and investors who do not trade in lower priced stocks;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the reverse stock split will result in a per share price that will increase the ability of ARCA to attract and retain employees;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the market price per share will either exceed or remain in excess of the $1.00 minimum bid price as required by Nasdaq for continued listing; or</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the market price per share will achieve and maintain the $4.00 minimum bid price requirement for a sufficient period of time for the combined company&#8217;s common stock to be approved for listing by Nasdaq.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The market price of ARCA common stock will also be based on the performance of ARCA, and after the Merger, on the performance of the combined company, and other factors, some of which are unrelated to the number of shares outstanding. If the reverse stock split is effected and the market price of ARCA common stock declines, the percentage decline as an absolute number and as a percentage of the overall market capitalization of ARCA may be greater than would occur in the absence of a reverse stock split. Furthermore, the liquidity of ARCA common stock could be adversely affected by the reduced number of shares that would be outstanding after the reverse stock split.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">181</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Effects of the Reverse Stock Split</span></p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">General</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If the reverse stock split is implemented, after the reverse stock split effective time, the issued and outstanding shares of ARCA common stock immediately prior to the reverse stock split effective time will automatically, without further action on the part of ARCA, be combined into a smaller number of shares proportionately based on the Split Ratio and each ARCA stockholder will own a reduced number of shares of ARCA common stock. The reverse stock split will affect all ARCA stockholders uniformly and will not affect any stockholder&#8217;s percentage ownership interests in ARCA, except that ARCA stockholders who would have otherwise received fractional shares will receive cash in lieu of such fractional shares. After the reverse stock split, each share of ARCA common stock will have the same voting rights and rights to dividends and distributions and will be identical in all other respects to the ARCA common stock now authorized, and ARCA common stock issued pursuant to the reverse stock split will remain fully paid and non<span class="nobreak">-assessable</span>. The reverse stock split is not intended as, and will not have the effect of, a &#8220;going private transaction&#8221; covered by&#160;Rule&#160;13e<span class="nobreak">-3</span>&#160;under the&#160;Exchange&#160;Act. ARCA will continue to be subject to the periodic reporting requirements of the&#160;Exchange&#160;Act.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Effect on Shares of ARCA Common Stock</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The reverse stock split will not change the number of authorized shares of ARCA common stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">After the reverse stock split effective time, ARCA common stock would have a new committee on uniform securities identification procedures number, which is used to identify ARCA common stock. ARCA common stock is currently registered under Section&#160;12(b)&#160;of the&#160;Exchange&#160;Act&#160;and ARCA is subject to the periodic reporting and other requirements of the&#160;Exchange&#160;Act.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Effect on ARCA Preferred Stock</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The reverse stock split will not change the number of authorized shares of ARCA preferred stock.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Reduction in Stated Capital</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The reverse stock split will not affect the par value of ARCA common stock. As a result, after the reverse stock split effective time, the stated capital on ARCA&#8217;s balance sheet attributable to ARCA common stock will be reduced proportionately based on the Split Ratio, subject to a minor adjustment in respect of the treatment of fractional shares, and the additional paid<span class="nobreak">-in</span> capital account will be credited with the amount by which the stated capital is reduced. ARCA stockholders&#8217; equity, in the aggregate, will remain unchanged.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Effect on Equity Plans and Outstanding Derivative and Convertible Securities</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Proportionate adjustments will be made to the per share exercise price, the number of shares issuable upon the exercise, vesting or settlement of all outstanding options and warrants to purchase or acquire, as applicable, shares of ARCA common stock, and the number of shares reserved for issuance pursuant to ARCA&#8217;s existing equity incentive, stock option and employee stock purchase plans will be reduced proportionately based on the Split Ratio.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Procedure for Effecting Reverse Stock Split and Exchange of Stock Certificates</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If (i)&#160;the ARCA stockholders approve the Nasdaq Stock Issuance Proposal and the Reverse Stock Split Proposal, (ii)&#160;ARCA&#8217;s board of directors and Oruka&#8217;s board of directors mutually agree that a reverse stock split is necessary, and (iii)&#160;ARCA&#8217;s board of directors still believes that a reverse stock split is in the best interests of ARCA and its stockholders, ARCA will file the certificate of amendment to the ARCA Charter with the Secretary of State of the State of Delaware at such time as ARCA&#8217;s board of directors has determined to be the appropriate reverse stock split effective time at the Split Ratio. If the Reverse Stock Split Proposal is approved and the Nasdaq Stock Issuance Proposal is not approved by ARCA stockholders, ARCA&#8217;s board of directors and Oruka&#8217;s board of directors may mutually agree to delay effecting the reverse stock split without resoliciting stockholder approval or abandon effecting the reverse stock split; otherwise, ARCA&#8217;s board of directors may, in its sole discretion, delay without </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">182</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">resolicitation of stockholder approval or abandon effecting the reverse stock split. Beginning at the reverse stock split effective time, each stock certificate representing pre<span class="nobreak">-split</span> shares will be deemed for all corporate purposes to evidence ownership of post<span class="nobreak">-split</span> shares.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Beneficial Owners of Common Stock</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Upon the implementation of the reverse stock split, ARCA intends to treat shares held by stockholders in &#8220;street name&#8221; (i.e., through a bank, broker, custodian or other nominee), in the same manner as registered stockholders whose shares are registered in their names. Banks, brokers, custodians or other nominees will be instructed to effect the reverse stock split for their beneficial holders holding ARCA common stock in street name. However, these banks, brokers, custodians or other nominees may have different procedures than registered stockholders for processing the reverse stock split and making payment for fractional shares. If a stockholder holds shares of ARCA common stock with a bank, broker, custodian or other nominee and has any questions in this regard, stockholders are encouraged to contact their bank, broker, custodian or other nominee.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Registered Holders of Common Stock in Book-Entry Form</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Certain of ARCA&#8217;s registered holders of common stock hold some or all of their shares electronically in book<span class="nobreak">-entry</span> form with ARCA&#8217;s transfer agent,<span class="Italic" style="font-style:italic;font-weight:normal;">&#160;</span>Computershare Trust Company, N.A.&#160;These stockholders do not hold physical stock certificates evidencing their ownership of ARCA common stock. However, they are provided with a statement reflecting the number of<span class="Italic" style="font-style:italic;font-weight:normal;">&#160;</span>shares of ARCA common stock registered in their accounts. If a stockholder holds registered shares in book<span class="nobreak">-entry</span> form with ARCA&#8217;s transfer agent, no action needs to be taken to receive post<span class="nobreak">-reverse</span> stock split shares or payment in lieu of fractional shares, if applicable. If a stockholder is entitled to post<span class="nobreak">-reverse</span> stock split shares, a transaction statement will automatically be sent to the stockholder&#8217;s address of record indicating the number of shares of ARCA common stock held following the reverse stock split.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Registered Holders of Common Stock in Certificate Form</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As soon as practicable after the reverse stock split effective time, the ARCA stockholders will be notified that the reverse stock split has been effected. ARCA expects that the ARCA transfer agent will act as exchange agent for purposes of implementing the exchange of stock certificates. Holders of pre<span class="nobreak">-split</span> shares will be asked to surrender to the exchange agent certificates representing pre<span class="nobreak">-split</span> shares held in certificated form in exchange for certificates representing post<span class="nobreak">-split</span> shares in accordance with the procedures to be set forth in a letter of transmittal to be sent by ARCA.&#160;No new certificates will be issued to a stockholder until such stockholder has surrendered such stockholder&#8217;s outstanding certificate(s)&#160;together with the properly completed and executed letter of transmittal to the exchange agent. Any pre<span class="nobreak">-split</span> shares submitted for transfer, whether pursuant to a sale or other disposition, or otherwise, will automatically be exchanged for post<span class="nobreak">-split</span> shares.&#160;<span class="Bold" style="font-style:normal;font-weight:bold;">Stockholders should not destroy any stock certificate(s)&#160;and should not submit any certificate(s)&#160;unless and until requested to do so</span><span class="Italic" style="font-style:italic;font-weight:normal;">.</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">No Fractional Shares</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">No fractional shares will be issued in connection with the reverse stock split. Stockholders of record who otherwise would be entitled to receive fractional shares because they hold a number of pre<span class="nobreak">-split</span> shares not evenly divisible by the number of pre<span class="nobreak">-split</span> shares for which each post<span class="nobreak">-split</span> share is to be reclassified, will be entitled, upon surrender to the exchange agent of certificates representing such shares, to a cash payment in lieu thereof at a price equal to the fraction of a share to which the stockholder would otherwise be entitled multiplied by the closing price of the common stock on Nasdaq on the date of the filing of the certificate of amendment to the ARCA Charter effecting the reverse stock split. For the foregoing purposes, all shares of common stock held by a holder will be aggregated (thus resulting in no more than one fractional share per holder). The ownership of a fractional interest will not give the holder thereof any voting, dividend or other rights except to receive payment therefor as described herein.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Stockholders should be aware that, under the escheat laws of the various jurisdictions where stockholders reside, where ARCA is domiciled and where the funds will be deposited, sums due for fractional interests that are not timely claimed after the effective date of the split may be required to be paid to the designated agent for each such jurisdiction, unless correspondence has been received by ARCA or the exchange agent concerning ownership of such funds within the time permitted in such jurisdiction. Thereafter, stockholders otherwise entitled to receive such funds will have to seek to obtain them directly from the state to which they were paid.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">183</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Potential Anti-Takeover Effect</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Although the increased proportion of unissued authorized shares to issued shares could, under certain circumstances, have an anti<span class="nobreak">-takeover</span> effect, for example, by permitting issuances that would dilute the stock ownership of a person seeking to effect a change in the composition of ARCA&#8217;s board of directors or contemplating a tender offer or other transaction for the combination of ARCA with another company, the reverse stock split is not being proposed in response to any effort of which ARCA is aware to accumulate shares of ARCA common stock or obtain control of ARCA, other than in connection with the Merger, nor is it part of a plan by management to recommend a series of similar amendments to ARCA&#8217;s board of directors and stockholders. Other than the proposals being submitted to the ARCA stockholders for their consideration at the ARCA special meeting, ARCA&#8217;s board of directors does not currently contemplate recommending the<span class="Italic" style="font-style:italic;font-weight:normal;">&#160;</span>adoption of any other actions that could be construed to affect the ability of third parties to take over or change<span class="Italic" style="font-style:italic;font-weight:normal;">&#160;</span>control of ARCA.&#160;For more information, please see the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Risk Factors&#160;&#8212;&#160;Risks Related to the Combined Company</span>&#8221; beginning on page 80 of this proxy statement/prospectus.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Material U.S.&#160;Federal Income Tax Consequences of the Reverse Stock Split</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following is a discussion of material U.S.&#160;federal income tax consequences of the reverse stock split that are applicable to a U.S.&#160;holder (as defined below) of ARCA common stock. This discussion applies only to a U.S.&#160;holder that holds its ARCA common stock as a capital asset for U.S.&#160;federal income tax purposes (generally, property held for investment). This discussion is a summary only and does not discuss all aspects of U.S.&#160;federal income taxation that may be relevant to U.S.&#160;holders in light of their particular circumstances or U.S.&#160;holders with special status including:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>brokers, dealers or traders in securities, banks, insurance companies, other financial institutions or mutual funds;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>real estate investment trusts; regulated investment companies; tax<span class="nobreak">-exempt</span> organizations or governmental organizations;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>pass<span class="nobreak">-through</span> entities such as partnerships, S corporations, disregarded entities for federal income tax purposes and limited liability companies (and investors therein);</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>persons that have a functional currency other than the U.S.&#160;dollar;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>taxpayers that are subject to the mark<span class="nobreak">-to-market</span> accounting rules;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>persons who hold their shares of ARCA common stock that constitute &#8220;qualified small business stock&#8221; under Section&#160;1202 of the Code or as &#8220;Section&#160;1244 stock&#8221; for purposes of Section&#160;1244 of the Code;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>persons that hold their ARCA common stock as part of a straddle, constructive sale, hedging, conversion or other integrated or similar transaction;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>persons who acquired their shares of ARCA common stock pursuant to the exercise of options or otherwise as compensation or through a tax<span class="nobreak">-qualified</span> retirement plan or through the exercise of a warrant or conversion rights under convertible instruments;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>persons who acquired their ARCA common stock in a transaction subject to the gain rollover provisions of Section&#160;1045 of the Code; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>expatriates or former citizens or long<span class="nobreak">-term</span> residents of the United&#160;States.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">This discussion is based on the Code, proposed, temporary and final Treasury Regulations promulgated under the Code, and judicial and administrative interpretations thereof, all as of the date hereof and all of which are subject to change, which change could apply retroactively and could affect the tax consequences described herein. This discussion does not address (i)&#160;the tax consequences of the reverse stock split under U.S.&#160;federal non<span class="nobreak">-income</span> tax law (including estate, gift, or other non<span class="nobreak">-income</span> taxes), (ii)&#160;the tax consequences of the reverse stock split under state, local or non<span class="nobreak">-U</span>.S.&#160;tax laws, (iii)&#160;the impact of the alternative minimum tax provisions of the Code (including the 15% minimum tax applicable to the adjusted financial statement income of certain corporations) or the Medicare contribution tax on net investment income, or (iv)&#160;the tax consequences of transactions effectuated before, </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">184</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">subsequent to or concurrently with the reverse stock split (whether or not any such transactions are consummated in connection with the reverse stock split), including, any transaction in which shares of ARCA common stock are acquired.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We have not and do not intend to seek any rulings from the IRS regarding the reverse stock split. There can be no assurance that the IRS will not take positions inconsistent with the considerations discussed below or that any such positions would not be sustained by a court.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If any entity or arrangement classified as a partnership for U.S.&#160;federal income tax purposes holds ARCA common stock, the tax treatment of such partnership and any person treated as a partner of such partnership will generally depend on the status and activities of the partner and the activities of the partnership. Each partnership holding any ARCA common stock and each person that is treated as a partner of such partnerships is urged to consult its tax advisor as to the particular U.S.&#160;federal income tax consequences of the reverse stock split.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As used herein, a &#8220;U.S.&#160;holder&#8221; is a beneficial owner of ARCA common stock that is for U.S.&#160;federal income tax purposes:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>an individual citizen or resident of the United&#160;States;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>a corporation (or other entity that is classified as a corporation for U.S.&#160;federal income tax purposes) that is created or organized (or treated as created or organized) in or under the laws of the United&#160;States, any state thereof, or the District of Columbia or otherwise treated as a U.S.&#160;tax resident for U.S.&#160;federal income tax purposes;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>an estate whose income is subject to U.S.&#160;federal income tax regardless of its source; or</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>a trust if (1)&#160;a U.S.&#160;court can exercise primary supervision over the administration of such trust and one or more U.S.&#160;persons have the authority to control all substantial decisions of the trust or (2)&#160;it has a valid election in place to be treated as a U.S.&#160;person.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Treatment of U.S.&#160;Holders in the Reverse Stock Split</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA intends to treat the reverse stock split as a &#8220;recapitalization&#8221; within the meaning of Section&#160;368(a)&#160;of the Code. Assuming the reverse stock split so qualifies, a U.S.&#160;holder generally will not recognize gain or loss upon the reverse stock split. A U.S.&#160;holder&#8217;s aggregate tax basis in the shares of ARCA common stock received pursuant to the reverse stock split will equal the aggregate tax basis of the shares of the ARCA common stock surrendered, and such U.S.&#160;holder&#8217;s holding period in the shares of ARCA common stock received will include the holding period in the shares of ARCA common stock surrendered. Treasury Regulations provide detailed rules for allocating the tax basis and holding period of the shares of ARCA common stock surrendered for the shares of ARCA common stock received in a recapitalization pursuant to the reverse stock split. If a U.S.&#160;holder holds different blocks of ARCA common stock (generally, ARCA common stock acquired on different dates or at different prices), such U.S.&#160;holder is urged to consult its tax advisor with respect to the determination of the tax bases and/or holding periods of the shares of ARCA common stock received in the reverse stock split.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">A U.S.&#160;holder that receives cash in lieu of a fractional share of ARCA common stock pursuant to the reverse stock split will generally recognize capital gain or loss in an amount equal to the difference between the amount of cash received and the U.S.&#160;holder&#8217;s tax basis in the shares of ARCA common stock surrendered that is allocated to such fractional share of ARCA common stock. Any such gain or loss will be long<span class="nobreak">-term</span> capital gain or loss if, as of the effective time of the reverse stock split, the U.S.&#160;holder&#8217;s holding period for such fractional share exceeds one year. Long<span class="nobreak">-term</span> capital gains of certain non<span class="nobreak">-corporate</span> taxpayers, including individuals, are generally taxed at preferential rates. The deductibility of capital losses is subject to limitations.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Information Reporting and Backup Withholding</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Assuming the reverse stock split qualifies as a recapitalization within the meaning of Section&#160;368(a)&#160;of the Code, each U.S.&#160;holder who receives shares of ARCA common stock in the reverse stock split is required to retain permanent records pertaining to the reverse stock split and make such records available to any authorized IRS officers and employees. Such records should specifically include information regarding the amount, basis, and fair market value of all transferred property and relevant facts regarding any liabilities assumed or extinguished </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">185</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">as part of such reorganization. Each U.S.&#160;holder who owned immediately before the reverse stock split at least five percent (by vote or value) of the total outstanding stock of ARCA is required to attach a statement to its tax return for the year in which the reverse stock split is consummated that contains the information listed in Treasury Regulation&#160;Section&#160;1.368<span class="nobreak">-3</span>(b). Such statement must include the U.S.&#160;holder&#8217;s tax basis in such holder&#8217;s ARCA common stock surrendered in the reverse stock split, the fair market value of such stock, the date of the reverse stock split and the name and employer identification number of ARCA.&#160;Each U.S.&#160;holder is urged to consult with its tax advisor to comply with these rules.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">A U.S.&#160;holder may be subject to information reporting and backup withholding for U.S.&#160;federal income tax purposes on cash paid in lieu of fractional shares in connection with the reverse stock split. Backup withholding will not apply, however, to a U.S.&#160;holder who (i)&#160;furnishes a correct taxpayer identification number and certifies the holder is not subject to backup withholding on IRS Form&#160;W<span class="nobreak">-9</span> or a substantially similar form, or (ii)&#160;certifies the holder is otherwise exempt from backup withholding. If a U.S.&#160;holder does not provide a correct taxpayer identification number on IRS Form&#160;W<span class="nobreak">-9</span> or other proper certification, the stockholder may be subject to penalties imposed by the IRS.&#160;Any amounts withheld under the backup withholding rules may be refunded or allowed as a credit against the federal income tax liability of a U.S.&#160;holder of ARCA common stock, if any, provided the required information is timely furnished to the IRS.&#160;U.S.&#160;holders should consult their tax advisors regarding their qualification for an exemption from backup withholding, the procedures for obtaining such an exemption, and in the event backup withholding is applied, to determine if any tax credit, tax refund or other tax benefit may be obtained.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">This discussion of U.S.&#160;federal income tax considerations of the reverse stock split is for general information purposes only and is not intended to be, and should not be construed as, tax advice. Determining the actual tax consequences of the reverse stock split to you may be complex and will depend on your specific situation and on factors that are not within ARCA&#8217;s knowledge or control. You should consult your tax advisor with respect to the application of U.S.&#160;federal income tax laws to your specific situation as well as any tax consequences arising under the U.S.&#160;federal estate or gift tax rules or under the laws of any state, local, non</span><span class="nobreak"><span class="Bold" style="font-style:normal;font-weight:bold;">-U</span></span><span class="Bold" style="font-style:normal;font-weight:bold;">.S.&#160;or other taxing jurisdiction.</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Appraisal or Dissenters&#8217; Rights</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Pursuant to the DGCL, stockholders are not entitled to appraisal rights or dissenter&#8217;s rights with respect to the proposed amendment to the ARCA Charter to effect the reverse stock split.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Required Vote</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The affirmative vote of a majority of the votes properly cast for or against the Reverse Stock Split Proposal by the holders of ARCA common stock is required to approve the Reverse Stock Split Proposal. Abstentions and broker non<span class="nobreak">-votes</span>, if any, will have no effect on the Reverse Stock Split Proposal.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Merger is <span class="CharOverride-1" style="font-style:normal;font-weight:bold;text-decoration:underline;">not</span> conditioned upon the approval of the Reverse Stock Split Proposal. Additionally, ARCA&#8217;s board of directors may determine to effect the Reverse Stock Split Proposal, if approved, even if Proposal&#160;No. 1 is not approved by the ARCA stockholders.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Certain ARCA stockholders have agreed to vote any shares of ARCA common stock owned by them in favor of the Reverse Stock Split Proposal. See &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Agreements Related to the Merger&#160;&#8212;&#160;Support Agreements</span>&#8221; beginning on&#160;page 153 of this proxy statement/prospectus for more information.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Unless otherwise instructed, it is the intention of the persons named in the accompanying proxy card to vote shares represented by properly executed proxy cards &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">FOR</span>&#8221; the approval of the Reverse Stock Split Proposal.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-align:center;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">THE ARCA BOARD OF DIRECTORS RECOMMENDS A VOTE &#8220;FOR&#8221; THE REVERSE STOCK&#160;SPLIT&#160;PROPOSAL.</span></p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">186</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T9984"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">PROPOSAL NO. 4&#160;&#8212;&#160;THE OFFICER EXCULPATION PROPOSAL</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">General</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Section&#160;102(b)(7)&#160;of the DGCL was amended effective August&#160;1, 2022 to authorize exculpation of certain officers of Delaware corporations (the &#8220;Section&#160;102(b)(7)&#160;Amendment&#8221;). Specifically, the amendments extend the opportunity for Delaware corporations to exculpate their officers, in addition to their directors, for personal liability for breach of the duty of care in certain actions (the &#8220;officer exculpation&#8221;). This provision would not exculpate officers from liability for breach of the duty of loyalty, acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law, or any transaction in which the officer derived an improper personal benefit. Nor would this provision exculpate such officers from liability for claims brought by or in the right of the corporation, such as derivative claims.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s board of directors believes it is necessary to provide protection to officers to the fullest extent permitted by law in order to attract and retain top talent. Similar protection has long been afforded to directors. Accordingly, ARCA&#8217;s board of directors believes that the proposal to extend exculpation to officers is fair and in the best interests of ARCA and its stockholders.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">A copy of the proposed form of certificate of amendment to the ARCA Charter to effect the officer exculpation is attached as<span class="Italic" style="font-style:italic;font-weight:normal;"> Annex&#160;I</span> to this proxy statement/prospectus.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s board of directors may determine to effect the officer exculpation, if it is approved by the stockholders, even if the other proposals to be acted upon at the meeting are not approved, including the Nasdaq Stock Issuance Proposal, the Authorized Share Increase Proposal and the Reverse Stock Split Proposal. In addition, notwithstanding approval of this proposal by ARCA stockholders, ARCA&#8217;s board of directors may, in its sole discretion, abandon the proposed amendment and determine prior to the effectiveness of any filing with the Secretary of State of the State of Delaware not to effect the officer exculpation, as permitted under Section&#160;242(c)&#160;of the DGCL.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Reasons for the Proposal</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s board of directors desires to amend the ARCA Charter to maintain provisions consistent with the governing statutes contained in the DGCL, as it may be amended from time to time. Prior to the Section&#160;102(b)(7) Amendment, Delaware law has permitted Delaware corporations to exculpate directors from personal liability for monetary damages associated with breaches of the duty of care, but that protection did not extend to a Delaware corporation&#8217;s officers. Consequently, stockholder plaintiffs have employed a tactic of bringing certain claims that would otherwise be exculpated if brought against directors, against individual officers to avoid dismissal of such claims. The Section&#160;102(b)(7)&#160;Amendment was adopted to address inconsistent treatment between officers and directors and address rising litigation and insurance costs for stockholders.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As is currently the case with directors under the ARCA Charter, this provision would not exculpate officers from liability for breach of the duty of loyalty, acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law, or any transaction in which the officer derived an improper personal benefit. Nor would this provision exculpate such officers from liability for claims brought by or in the right of the corporation, such as derivative claims. ARCA&#8217;s board of directors believes it is necessary to provide protection to officers to the fullest extent permitted by law in order to attract and retain top talent. Similar protection has long been afforded to directors, and accordingly, ARCA&#8217;s board of directors believes that this proposal which would extend exculpation to officers, as specifically permitted by the Section&#160;102(b)(7)&#160;Amendment, is fair and in the best interests of ARCA and its stockholders.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Required Vote</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The affirmative vote of a majority of the outstanding shares of ARCA common stock is required to approve the Officer Exculpation Proposal. Abstentions and broker non<span class="nobreak">-votes</span>, if any, will have the same effect as votes &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">AGAINST</span>&#8221; the Officer Exculpation Proposal.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">187</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Merger is <span class="CharOverride-1" style="font-style:normal;font-weight:bold;text-decoration:underline;">not</span> conditioned upon the approval of the Officer Exculpation Proposal. If the Merger is not consummated for any reason, the actions contemplated by the Officer Exculpation Proposal may still be effected if the Officer Exculpation Proposal is approved.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Unless otherwise instructed, it is the intention of the persons named in the accompanying proxy card to vote shares represented by properly executed proxy cards &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">FOR</span>&#8221; the approval of the Officer Exculpation Proposal.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-align:center;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">THE ARCA BOARD OF DIRECTORS RECOMMENDS A VOTE &#8220;FOR&#8221; THE OFFICER EXCULPATION&#160;PROPOSAL.</span></p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">188</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T9985"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">PROPOSAL NO. 5&#160;&#8212;&#160;THE DIRECTOR ELECTION PROPOSAL</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">General</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s board of directors currently consists of five members. In accordance with the terms of the ARCA Charter and ARCA Bylaws, ARCA&#8217;s board of directors is divided into three classes, Class&#160;I, Class&#160;II and Class&#160;III, with members of each class serving staggered three<span class="nobreak">-year</span> terms. The members of the classes are divided as follows:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the Class&#160;I directors are James Flynn, Linda Grais, M.D. and Anders Hove, M.D., whose terms will expire at ARCA&#8217;s annual meeting of stockholders to be held in 2025;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the Class&#160;II director is Robert E.&#160;Conway, whose term will expire at ARCA&#8217;s annual meeting of stockholders to be held in 2026; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the Class&#160;III director is Jacob Ma<span class="nobreak">-Weaver</span>, whose term will expire at ARCA&#8217;s annual meeting of stockholders to be held in 2024.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Upon the expiration of the term of a class of ARCA&#8217;s board of directors, any director in that class will be eligible to be elected for a new three<span class="nobreak">-year</span> term at the annual meeting of stockholders in the year in which their term expires.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The ARCA Charter and ARCA Bylaws provide that the authorized number of directors shall not be less than two nor more than ten and may be changed only by resolution of ARCA&#8217;s board of directors. ARCA Bylaws also provide that ARCA&#8217;s directors may be removed only for cause by the affirmative vote of the holders of at least two<span class="nobreak">-thirds</span> of the voting rights of the shares of capital stock then entitled to vote in an annual election of directors, and that any vacancy on ARCA&#8217;s board of directors, including a vacancy resulting from an increase in the size of ARCA&#8217;s board of directors, may be filled only by vote of a majority of its directors then in office.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s board of directors has nominated Jacob Ma<span class="nobreak">-Waver</span> for election as a Class&#160;III director at the ARCA special meeting. Mr.&#160;Ma<span class="nobreak">-Weaver</span> is currently a director and has consented to continue to serve as a director if elected. If Mr.&#160;Ma<span class="nobreak">-Weaver</span> becomes unable or unwilling to serve, however, the proxies may be voted for a substitute nominee selected by ARCA&#8217;s board of directors.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA stockholders should understand, however, that if the Merger is consummated, the approval of the director nominee named in the Director Election Proposal will only have an effect until the completion of the Merger because the composition of ARCA&#8217;s board of directors will be reconstituted upon completion of the Merger, in accordance with the Merger Agreement. Following the Merger, the combined company&#8217;s board of directors will consist of six members designated by Oruka, including Carl Dambkowski, Peter Harwin, Lawrence Klein, Samarth&#160;Kulkarni, Cameron Turtle and Kristine Ball. All of ARCA&#8217;s current directors are expected to resign from their positions as directors of ARCA, effective as of the closing of the Merger.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Required Vote</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The nominee for Class&#160;III director who receives the most votes properly cast (also known as a plurality) will be elected. You may either vote &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">FOR</span>&#8221; the nominee or &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">WITHHOLD</span>&#8221; your vote from the nominee. Withheld votes and broker non<span class="nobreak">-votes</span>, if any, will have no effect on the Director Election Proposal.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Merger is <span class="CharOverride-1" style="font-style:normal;font-weight:bold;text-decoration:underline;">not</span> conditioned upon the election of the director nominee named in the Director Election Proposal.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Unless otherwise instructed, it is the intention of the persons named in the accompanying proxy card to vote shares represented by properly executed proxy cards &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">FOR</span>&#8221; the election of the director nominee named in the Director Election Proposal. However, if the nominee is unable to serve or for good cause will not serve as a director, the proxies will be voted for the election of such substitute nominee as ARCA&#8217;s board of directors may designate.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-align:center;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">THE ARCA BOARD OF DIRECTORS RECOMMENDS A VOTE &#8220;FOR&#8221; THE DIRECTOR NOMINEE NAMED IN THE DIRECTOR ELECTION PROPOSAL.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">189</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T9986"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">PROPOSAL NO. 6&#160;&#8212;&#160;THE AUDITOR RATIFICATION PROPOSAL</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">General</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">At the ARCA special meeting, ARCA will ask its stockholders to ratify the appointment by the audit committee of ARCA&#8217;s board of directors (the &#8220;ARCA audit committee&#8221;) of KPMG LLP as ARCA&#8217;s independent registered public accounting firm for the fiscal year ending December&#160;31, 2024, provided that PricewaterhouseCoopers LLP is expected to be appointed for the fiscal year ending December&#160;31, 2024 if the Merger is completed. KPMG LLP has served as ARCA&#8217;s independent registered public accounting firm since 2006.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The ARCA audit committee is solely responsible for selecting ARCA&#8217;s independent registered public accounting firm for the fiscal year ending December&#160;31, 2024. Stockholder approval is not required to appoint KPMG LLP as ARCA&#8217;s independent registered public accounting firm. However, ARCA&#8217;s board of directors believes that submitting the selection of KPMG LLP to ARCA stockholders for ratification is good corporate governance. If ARCA stockholders do not ratify this appointment, the ARCA audit committee will reconsider whether to retain KPMG LLP.&#160;If the selection of KPMG LLP is ratified, the ARCA audit committee, at its discretion, may direct the selection of a different independent registered public accounting firm at any time it decides that such a change would be in the best interest of ARCA and its stockholders.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">A representative of KPMG LLP is expected to be present at the ARCA special meeting and will have an opportunity to make a statement if he or she desires to do so and to respond to appropriate questions from ARCA stockholders.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Required Vote</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The affirmative vote of a majority of the shares of ARCA common stock entitled to vote on the subject matter and present in person or represented by proxy at the ARCA special meeting required to approve the Auditor Ratification Proposal. Abstentions will have the same effect as votes &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">AGAINST</span>&#8221; the Auditor Ratification Proposal and broker non<span class="nobreak">-votes</span>, if any, will have no effect on the Auditor Ratification Proposal.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Merger is <span class="CharOverride-1" style="font-style:normal;font-weight:bold;text-decoration:underline;">not</span> conditioned upon the approval of the Auditor Ratification Proposal.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Unless otherwise instructed, it is the intention of the persons named in the accompanying proxy card to vote shares represented by properly executed proxy cards &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">FOR</span>&#8221; the Auditor Ratification Proposal.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-align:center;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">THE ARCA BOARD OF DIRECTORS RECOMMENDS A VOTE &#8220;FOR&#8221; THE AUDITOR RATIFICATION PROPOSAL, PROVIDED THAT PRICEWATERHOUSECOOPERS LLP IS EXPECTED TO BE APPOINTED FOR THE FISCAL YEAR ENDING DECEMBER</span><span class="nobreak"><span class="Bold" style="font-style:normal;font-weight:bold;"> </span></span><span class="Bold" style="font-style:normal;font-weight:bold;">31, 2024 IF THE MERGER IS COMPLETED.</span></p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">190</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T9992"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">PROPOSAL NO. 7</span><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">&#160;&#8212;&#160;</span><span class="Bold" style="font-style:normal;font-weight:bold;">THE STOCK PLAN PROPOSAL</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">General</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">At the ARCA special meeting, ARCA will ask its stockholders to approve the Oruka Therapeutics, Inc. 2024 Stock Incentive Plan (the &#8220;2024 Stock Plan&#8221;) to be effective on the closing date of the Merger. The 2024 Stock Plan was approved by ARCA&#8217;s board of directors on<span style="width: 10px;display: inline-block;">&#160;&#160;&#160;</span><span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>, 2024, subject to stockholder approval. If the 2024 Stock Plan is approved by stockholders, no further awards will be granted under the 2020 Plan.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The purpose of the 2024 Stock Plan is to promote and closely align the interests of employees, officers, non<span class="nobreak">-employee</span> directors and individual consultants of the combined company and its stockholders by providing stock<span class="nobreak">-based</span> compensation and other performance<span class="nobreak">-based</span> compensation. The objectives of the 2024 Stock Plan are to attract and retain the best available employees, officers, non<span class="nobreak">-employee</span> directors and individual consultants for positions of substantial responsibility and to motivate participants to optimize the profitability and growth of the combined company through incentives that are consistent with the combined company&#8217;s goals and that link the personal interests of participants to those of the combined company&#8217;s stockholders. The 2024 Stock Plan allows for the grant of stock options, stock appreciation rights (&#8220;SARs&#8221;), restricted stock, restricted stock units (&#8220;RSUs&#8221;), other stock<span class="nobreak">-based</span> awards and incentive bonuses (collectively, &#8220;Awards&#8221;).</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Summary of the 2024 Stock Plan</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following description of the 2024 Stock Plan is not intended to be complete and is qualified in its entirety by the complete text of the 2024 Stock Plan, a copy of which is attached as <span class="Italic" style="font-style:italic;font-weight:normal;">Annex&#160;K</span> to this proxy statement. Stockholders are urged to read the 2024 Stock Plan in its entirety.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Federal Income Tax Consequences</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following is a summary of the U.S.&#160;federal income tax treatment applicable to the combined company and the participants who receive Awards under the 2024 Stock Plan based on the federal income tax laws in effect on the date of this proxy statement/prospectus. This summary is not intended to be exhaustive and does not address all matters relevant to a particular participant based on their specific circumstances. The summary expressly does not discuss the income tax laws of any state, municipality, or non<span class="nobreak">-U</span>.S.&#160;taxing jurisdiction, or the gift, estate, excise (including the rules applicable to deferred compensation under Section&#160;409A of the Code), or tax laws other than U.S.&#160;federal income tax law. Because individual circumstances may vary, all participants should consult their own tax advisor concerning the tax implications of Awards granted under the 2024 Stock Plan.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Incentive Stock Options</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Options granted under the 2024 Stock Plan may be either incentive stock options, which satisfy the requirements of Section&#160;422 of the Code, or non<span class="nobreak">-qualified</span> stock options, which are not intended to meet such requirements. No taxable income is recognized by the optionee at the time of the option grant, and no taxable income is recognized for ordinary income tax purposes at the time the option is exercised, although taxable income may arise at that time for alternative minimum tax purposes. Unless there is a &#8220;disqualifying disposition&#8221;, as described below, the optionee will recognize long<span class="nobreak">-term</span> capital gain in an amount equal to the excess of (i)&#160;the amount realized upon the sale or other disposition of the purchased shares over (ii)&#160;the exercise price paid for the shares. A disqualifying disposition occurs if the disposition is less than two&#160;years after the date of grant or less than one year after the exercise date. If there is a disqualifying disposition of the shares, then the excess of (i)&#160;the fair market value of those shares on the exercise date or (if less) the amount realized upon such sale or disposition over (ii)&#160;the exercise price paid for the shares will be taxable as ordinary income to the optionee. Any additional gain or loss recognized upon the disposition will be a capital gain or loss. If the optionee makes a disqualifying disposition of the purchased shares, then the combined company will be entitled to an income tax deduction for the taxable year in which such disposition occurs equal to the amount of ordinary income recognized by the optionee as a result of the disposition. The combined company will not be entitled to any income tax deduction if the optionee makes a qualifying disposition of the shares.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">191</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Nonqualified Stock Options</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">No taxable income is recognized by an optionee upon the grant of a non<span class="nobreak">-qualified</span> stock option. The optionee in general will recognize ordinary income, in the year in which the option is exercised, equal to the excess of the fair market value of the purchased shares on the exercise date over the exercise price paid for the shares, and the optionee will be required to satisfy the tax withholding requirements applicable to such income. The combined company will be entitled to an income tax deduction equal to the amount of ordinary income recognized by the optionee with respect to the exercised non<span class="nobreak">-qualified</span> stock option.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Stock Appreciation Rights</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">No taxable income is recognized upon receipt of a SAR.&#160;The participant will recognize ordinary income in the year in which the SAR is exercised, in an amount equal to the excess of the fair market value of the underlying shares of common stock on the exercise date over the base price in effect for the exercised right, and the participant will be required to satisfy the tax withholding requirements applicable to such income. The combined company will be entitled to an income tax deduction equal to the amount of ordinary income recognized by the participant in connection with the exercise of the SAR.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Restricted Stock Awards</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">A participant who receives unvested shares of combined company common stock will not recognize any taxable income at the time those shares are granted but will have to report as ordinary income, as and when those shares subsequently vest, an amount equal to the excess of (i)&#160;the fair market value of the shares on the vesting date over (ii)&#160;the cash consideration (if any) paid for the shares. The participant may, however, elect under Section&#160;83(b)&#160;of the Code to include as ordinary income in the year the unvested shares are issued an amount equal to the excess of (a)&#160;the fair market value of those shares on the issue date over (b)&#160;the cash consideration (if any) paid for such shares. If the Section&#160;83(b)&#160;election is made, the participant will not recognize any additional income as and when the shares subsequently vest. The combined company will be entitled to an income tax deduction equal to the amount of ordinary income recognized by the participant at the time such ordinary income is recognized by the participant.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Restricted Stock Units, Other Stock-Based Awards, Incentive Bonuses</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Generally, no taxable income is recognized upon the grant of RSUs, other stock<span class="nobreak">-based</span> awards or incentive bonuses. The participant will recognize ordinary income in the year in which the award is settled in shares or cash. The amount of that income will be equal to the fair market value of the shares on the date of issuance or the amount of the cash paid in settlement of the award, and the participant will be required to satisfy the tax withholding requirements applicable to the income. The combined company will be entitled to an income tax deduction equal to the amount of ordinary income recognized by the participant at the time the shares are issued or the cash amount is paid.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Deductibility of Executive Compensation</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Section&#160;162(m)&#160;of the Code limits the deductibility for federal income tax purposes of certain compensation paid to any &#8220;covered employee&#8221; in excess of $1&#160;million. It is expected that compensation deductions for any covered employee with respect to awards granted under the 2024 Stock Plan will be subject to the $1&#160;million annual deduction limitation. The Administrator may grant Awards under the 2024 Stock Plan or otherwise that are or may become non<span class="nobreak">-deductible</span> when it believes doing so is in the best interests of the combined company and its stockholders.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">New Plan Benefits</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA cannot currently determine the benefits or number of shares subject to Awards that may be granted in the future to eligible participants under the 2024 Stock Plan because the grant of Awards and terms of such Awards are to be determined in the sole discretion of the Administrator.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">192</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Required Vote</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The affirmative vote of a majority of the shares of ARCA common stock entitled to vote on the subject matter and present in person or represented by proxy at the ARCA special meeting required to approve the Stock Plan Proposal. Abstentions will have the same effect as votes &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">AGAINST</span>&#8221; the Stock Plan Proposal and broker non<span class="nobreak">-votes</span>, if any, will have no effect on the Stock Plan Proposal.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Merger is <span class="CharOverride-1" style="font-style:normal;font-weight:bold;text-decoration:underline;">not</span> conditioned upon the approval of the Stock Plan Proposal.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Unless otherwise instructed, it is the intention of the persons named in the accompanying proxy card to vote shares represented by properly executed proxy cards &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">FOR</span>&#8221; the Stock Plan Proposal.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-align:center;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">THE ARCA BOARD OF DIRECTORS RECOMMENDS A VOTE &#8220;FOR&#8221; THE STOCK PLAN PROPOSAL.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">193</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T9993"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">PROPOSAL NO. 8</span><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">&#160;&#8212;&#160;</span><span class="Bold" style="font-style:normal;font-weight:bold;">THE ESPP PROPOSAL</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">General</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">At the ARCA special meeting, ARCA will ask its stockholders to approve the Oruka Therapeutics, Inc. 2024 Employee Stock Purchase Plan (the &#8220;ESPP&#8221;) to be effective on the closing date of the Merger. The ESPP was approved by ARCA&#8217;s board of directors on <span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>, 2024, subject to stockholder approval.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The purpose of the ESPP is to provide employees of the combined company and its designated subsidiaries with an opportunity to purchase Common Stock through accumulated contributions. The ESPP, and the rights of participants to make purchases thereunder, is intended to qualify under Section&#160;423 of the Code; however, sub<span class="nobreak">-plans</span> that do not meet the requirements of Section&#160;423 of the Code may be established for the benefit of eligible employees of non<span class="nobreak">-U</span>.S.&#160;subsidiaries of the combined company.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Summary of the ESPP</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following description of the ESPP is not intended to be complete and is qualified in its entirety by the complete text of the ESPP, a copy of which is attached as <span class="Italic" style="font-style:italic;font-weight:normal;">Annex&#160;L</span> to this proxy statement. Stockholders are urged to read the 2024 Stock Plan in its entirety.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Federal Income Tax Consequences</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following is a brief description of the federal income tax treatment that will generally apply to the grant and exercise of rights under the ESPP, based on federal income tax laws in effect on the date of this proxy statement/prospectus. The exact federal income tax treatment of options will depend on the specific nature of any such option and the individual tax attributes of the participant. The following summary is not intended to be exhaustive and, among other considerations, does not describe gift, estate, social security, state, local or international tax consequences. In addition, if one or more sub<span class="nobreak">-plans</span> are established for employees of non<span class="nobreak">-U</span>.S.&#160;subsidiaries, the tax rules may be different than discussed below.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The ESPP is intended to qualify as an &#8220;employee stock purchase plan&#8221; under Section&#160;423 of the Code and, as a result, employees who participate in the ESPP will be afforded favorable tax treatment subject to meeting certain requirements specified by the Code. In general, there are no federal income tax consequences to a participant upon the grant of the option to purchase shares under the ESPP at the beginning of an option period or upon its exercise on the exercise date at the end of an option period. Upon the disposition of shares of common stock acquired upon exercise of an option, the participant will generally be subject to tax and the nature and amount of the tax will depend on whether the employee has satisfied the statutory holding period.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If the employee holds shares acquired under the ESPP for at least two&#160;years from the grant date of his or her option and at least one year from the date he or she acquired the shares (referred to as the &#8220;statutory holding period&#8221;), any gain on the sale of the shares will be taxed as ordinary income to the extent of the lesser of (i)&#160;the amount by which the fair market value of the shares on the grant date (i.e., the first&#160;day of the option period) exceeded the exercise price for the option, or (ii)&#160;the amount by which the fair market value of the shares on the date of sale exceeds the exercise price of the option. Any additional gain or loss will be taxed as long<span class="nobreak">-term</span> capital gain or loss.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If the participant sells or otherwise disposes of the shares before the expiration of the statutory holding period, then in the year of such &#8220;disqualifying&#8221; disposition, the participant will be required to recognize ordinary income equal to the difference between the fair market value of the shares on the date of the exercise of the option and the exercise price of the option. Any additional gain or loss will be short<span class="nobreak">-term</span> or long<span class="nobreak">-term</span> capital gain or loss depending on the length of time the employee has held the shares.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The combined company is not entitled to any deduction with respect to the difference between the fair market value of the common stock and the option exercise price if the participant satisfies the statutory holding period described above. If shares are sold before the statutory holding period is satisfied, the combined company receives a tax deduction for any ordinary income recognized by the participant.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">194</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">New Plan Benefits</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The benefits that will be received by or allocated to eligible employees under the ESPP cannot be determined at this time because the amount of payroll deductions contributed to purchase shares of combined company common stock under the ESPP is entirely within the discretion of each participant (subject to the limitations discussed above).</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Required Vote</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The affirmative vote of a majority of the shares of ARCA common stock entitled to vote on the subject matter and present in person or represented by proxy at the ARCA special meeting required to approve the ESPP Proposal. Abstentions will have the same effect as votes &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">AGAINST</span>&#8221; the ESPP Proposal and broker non<span class="nobreak">-votes</span>, if any, will have no effect on the ESPP Proposal.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Merger is <span class="CharOverride-1" style="font-style:normal;font-weight:bold;text-decoration:underline;">not</span> conditioned upon the approval of the ESPP Proposal.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Unless otherwise instructed, it is the intention of the persons named in the accompanying proxy card to vote shares represented by properly executed proxy cards &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">FOR</span>&#8221; the ESPP Proposal.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-align:center;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">THE ARCA BOARD OF DIRECTORS RECOMMENDS A VOTE &#8220;FOR&#8221; THE ESPP PROPOSAL.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">195</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<a id="T9994"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">PROPOSAL NO. 9</span><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">&#160;&#8212;&#160;</span><span class="Bold" style="font-style:normal;font-weight:bold;">THE MERGER COMPENSATION PROPOSAL</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">General</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Pursuant to Section&#160;14A of the Exchange&#160;Act and Rule&#160;14a<span class="nobreak">-21</span>(c)&#160;thereunder, ARCA is seeking non<span class="nobreak">-binding</span>, advisory stockholder approval of certain compensation arrangements for ARCA named executive officers that are based on or otherwise relate to the Merger, as disclosed pursuant to Item&#160;402(t)&#160;of Regulation&#160;S<span class="nobreak">-K</span> in the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">The Merger &#8212; Interests of ARCA&#8217;s Directors and Executive Officers in the Merger&#160;&#8212;&#160;Quantification of Potential Payments and Benefits to ARCA Named Executive Officers</span>&#8221; beginning on page 123 of this proxy statement/prospectus. At the ARCA special meeting, ARCA will therefore ask its stockholders to adopt the following resolution:</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-left:24pt;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">&#8220;RESOLVED:<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>That certain compensation arrangements for ARCA named executive officers in connection with the Merger, as disclosed pursuant to Item&#160;402(t)&#160;of Regulation&#160;S</span><span class="nobreak"><span class="Bold" style="font-style:normal;font-weight:bold;">-K</span></span><span class="Bold" style="font-style:normal;font-weight:bold;"> in the section titled &#8220;</span><span class="BoldItalic" style="font-style:italic;font-weight:bold;">The Merger &#8212; Interests of ARCA&#8217;s Directors and Executive Officers in the Merger&#160;&#8212;&#160;Quantification of Potential Payments and Benefits to ARCA Named Executive Officers</span><span class="Bold" style="font-style:normal;font-weight:bold;">&#8221; in the proxy statement/prospectus, are hereby APPROVED on a non</span><span class="nobreak"><span class="Bold" style="font-style:normal;font-weight:bold;">-binding</span></span><span class="Bold" style="font-style:normal;font-weight:bold;">, advisory basis.&#8221;</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Because the vote is advisory in nature only, it will not be binding on ARCA.&#160;Accordingly, to the extent ARCA is contractually obligated to pay the compensation, the compensation will be payable to the named executive officers, subject only to the conditions applicable thereto, if the Merger is completed, regardless of the outcome of the advisory vote.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Required Vote</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The affirmative vote of a majority of the shares of ARCA common stock entitled to vote on the subject matter and present in person or represented by proxy at the ARCA common stock is required to approve the Merger Compensation Proposal. Abstentions will have the same effect as votes &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">AGAINST</span>&#8221; the Merger Compensation Proposal and broker non<span class="nobreak">-votes</span>, if any, will have no effect on the Merger Compensation Proposal.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Merger is <span class="CharOverride-1" style="font-style:normal;font-weight:bold;text-decoration:underline;">not</span> conditioned upon the approval of the Merger Compensation Proposal.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Unless otherwise instructed, it is the intention of the persons named in the accompanying proxy card to vote shares represented by properly executed proxy cards &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">FOR</span>&#8221; the approval of the Merger Compensation Proposal.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-align:center;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">THE ARCA BOARD OF DIRECTORS RECOMMENDS A VOTE &#8220;FOR&#8221; THE MERGER COMPENSATION PROPOSAL.</span></p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">196</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<a id="T9987"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">PROPOSAL NO. 10&#160;&#8212;&#160;THE ADJOURNMENT PROPOSAL</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">General</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If ARCA fails to receive a sufficient number of votes to approve the Nasdaq Stock Issuance Proposal, the Authorized Share Increase Proposal and/or the Reverse Stock Split Proposal, ARCA may propose to adjourn the ARCA special meeting, for a period of not more than 60&#160;days, for the purpose of soliciting additional proxies to approve the Nasdaq Stock Issuance Proposal, the Authorized Share Increase Proposal and/or the Reverse Stock Split Proposal. ARCA currently does not intend to propose adjournment at the ARCA special meeting if there are sufficient votes to approve the Nasdaq Stock Issuance Proposal, the Authorized Share Increase Proposal and/or the Reverse Stock Split Proposal.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If a quorum is not present at the ARCA special meeting, under ARCA Bylaws, stockholders holding a majority of the shares present in person or by proxy and entitled to vote, or if no stockholders are present any officer entitled to preside at or act as secretary of the special meeting, will have the power to adjourn the special meeting until a quorum is present or represented.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Required Vote</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If a quorum is present, the affirmative vote of a majority of the shares of ARCA common stock entitled to vote on the subject matter and present in person or represented by proxy at the ARCA special meeting is required to approve the Adjournment Proposal. Abstentions will have the same effect as votes &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">AGAINST</span>&#8221; the Adjournment Proposal and broker non<span class="nobreak">-votes</span>, if any, will have no effect on the Adjournment Proposal.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Merger is <span class="CharOverride-1" style="font-style:normal;font-weight:bold;text-decoration:underline;">not</span> conditioned upon the approval of the Adjournment Proposal.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Unless otherwise instructed, it is the intention of the persons named in the accompanying proxy card to vote shares represented by properly executed proxy cards &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">FOR</span>&#8221; the approval of the Adjournment Proposal.</p>
		<p class="Text_flush_Center" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">THE ARCA BOARD OF DIRECTORS RECOMMENDS A VOTE &#8220;FOR&#8221; THE ADJOURNMENT PROPOSAL, IF NECESSARY.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">197</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T13"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">ARCA&#8217;S BUSINESS</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Overview</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">ARCA is a biopharmaceutical company applying a precision medicine approach to the development and commercialization of targeted therapies for cardiovascular diseases. Precision medicine refers to the tailoring of medical treatment to the individual characteristics of patients, using genomic, non<span class="nobreak">-genomic</span> biomarker and other information that extends beyond routine diagnostic categorization. ARCA believes that when implemented correctly precision medicine can enhance therapeutic response, improve patient outcomes, and reduce healthcare costs.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">In April&#160;2022, ARCA&#8217;s board of directors established a Special Committee and subsequently retained Lucid to evaluate strategic options, including transactions involving a merger, sale of all or part of ARCA&#8217;s assets, or other alternatives with the goal of maximizing stockholder value (the &#8220;Strategic Review&#8221;). ARCA and Lucid have reviewed several potential strategic transactions and continue to evaluate further potential development of ARCA&#8217;s existing assets, in order to maximize stockholder value. ARCA does not have a defined timeline for the strategic review process and the review may not result in any specific action or transaction.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">On April&#160;3, 2024, following a comprehensive review of strategic alternatives, ARCA, First Merger Sub, Second&#160;Merger Sub and Oruka entered into the Merger Agreement, pursuant to which, among other matters, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, First Merger Sub will merge with and into Oruka, with Oruka continuing as a wholly owned subsidiary of ARCA and the surviving corporation of the First Merger and as part of the same overall transaction, the surviving corporation in the First Merger will merge with and into Second Merger Sub with Second Merger Sub continuing as a wholly owned subsidiary of ARCA and the surviving entity of the Second Merger. The Merger is intended to qualify for federal income tax purposes as a tax<span class="nobreak">-free</span> reorganization under the provisions of Section&#160;368(a)&#160;of the Internal Revenue Code of 1986, as amended.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">In connection with the Merger, ARCA will dispose of (or is in the process of disposing of) its legacy technology and intellectual property, including those related to Gencaro and rNAPc2. Any such disposal of legacy technology and intellectual property will be contingent upon obtaining stockholder approval for the Merger and is expected to occur immediately prior to or concurrently with the closing of the Merger. In the event that ARCA shall enter into an agreement for any such sale or other disposition of its legacy assets at or prior to the closing of the Merger, the net proceeds received at or prior to the closing of the Merger will be included in the calculation of the net cash of ARCA as of the closing.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">ARCA&#8217;s future operations are highly dependent on the success of the Merger and there can be no assurances that the Merger will be successfully consummated. In the event that ARCA does not complete the Merger, ARCA may explore strategic alternatives, including, without limitation, another strategic transaction and/or pursue a dissolution and liquidation of ARCA.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">ARCA&#8217;s lead product candidate is Gencaro&#8482; (bucindolol hydrochloride) for the treatment of atrial fibrillation, (&#8220;AF&#8221;) in patients with chronic heart failure (&#8220;HF&#8221;). Gencaro is being developed for patients who have a genotype that identifies a drug target associated with heightened efficacy.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Gencaro&#8482; (bucindolol hydrochloride) for Atrial Fibrillation</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">Gencaro&#8482; (bucindolol hydrochloride) is a pharmacogenetically<span class="nobreak">-targeted</span> beta<span class="nobreak">-adrenergic</span> receptor antagonist with mild vasodilator properties that ARCA is developing for the treatment of atrial fibrillation in patients with heart failure. ARCA believes the pharmacology of Gencaro is unique and its efficacy can be enhanced by prescribing it to patients with a common genotypic variant that is present in approximately 50% of the North American and European general populations. This gene can be detected with a simple genetic test.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">ARCA is developing Gencaro to treat AF in patients with HF.&#160;AF is the most common form of cardiac arrhythmia, a disruption of the heart&#8217;s normal rhythm or rate. HF is a chronic condition in which the heart is unable to pump enough blood to meet the body&#8217;s needs. AF and HF commonly occur together. In HF patients, the development of AF leads to worsening symptoms, and increased risk of hospitalization and death. Current treatment options for AF in HF patients are limited, and can be invasive, costly and dangerous.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">ARCA&#8217;s development plan for Gencaro focuses on the treatment of AF in patients with higher ejection fraction HF, those who have an ejection fraction (&#8220;EF&#8221;) of 40% and higher who also have the genotype ARCA believes is optimal for Gencaro efficacy. This population of HF encompasses more than half of all HF patients in the United&#160;States and Europe. There are currently few approved or effective drug therapies to treat AF or HF in this patient population.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">198</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s development plan for Gencaro is based on ARCA&#8217;s published analysis of the Phase&#160;2b clinical trial of Gencaro for the prevention of AF in HF patients, known as GENETIC<span class="nobreak">-AF</span>.&#160;This analysis showed novel results for Gencaro in patients in the clinical trial with EF&#8217;s of 40% and higher. ARCA currently has an agreement with the FDA, known as a Special Protocol Assessment (&#8220;SPA&#8221;) for the requirements of a Gencaro Phase&#160;3 clinical trial, PRECISION<span class="nobreak">-AF</span>, that would support approval of Gencaro if successful. The Phase&#160;3 pivotal clinical trial of Gencaro conducted under an SPA will include secondary endpoints that are intended to capture some of this information, such as a reduction in the need to deploy rhythm control interventions including electrical cardioversion, catheter ablation and use of anti<span class="nobreak">-arrhythmic</span> drugs and avoidance of drug<span class="nobreak">-related</span> complications such as bradycardia. ARCA was issued a United&#160;States patent in February&#160;2021 for the use of Gencaro in a patient population identified as part of the clinical trial. ARCA believes this patent will substantially extend the patent protection for ARCA&#8217;s planned development of Gencaro into 2039. ARCA has sought or is seeking similar patent protection in other countries.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA believes that patients with HF and AF represent a major unmet medical need, and this need is most pronounced in patients with EF values of 40% and above. This EF range constitutes more than half of all chronic HF in the United&#160;States and Europe, as well as in Japan and China, and there are currently few approved, effective or guideline<span class="nobreak">-recommended</span> therapies for these patients to treat either their AF or HF.&#160;AF is a very common complication in these patients, with estimates of AF incidence ranging from 40% to 60%. Beta<span class="nobreak">-blockers</span> approved for HF are commonly used off<span class="nobreak">-label</span> to control heart rate in these patients, but they are not considered effective in preventing AF and none are approved for patients with EF &#8805; 40%. Other anti<span class="nobreak">-arrhythmic</span> drugs approved for the treatment of AF have adverse side effects and in HF patients are either contraindicated or have label warnings for use due to an increased risk of mortality. Interventional procedures for AF, such as catheter ablation and electrical cardioversion, are invasive, expensive, and often temporary; these interventions also typically require the continued use of beta blockers and other anti<span class="nobreak">-arrhythmic</span> drugs post<span class="nobreak">-intervention</span>.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA believes that Gencaro, if approved, may be a safe and more effective therapy for the treatment of higher ejection fraction HF patients with AF.&#160;ARCA believes there are several potentially important attributes that would differentiate Gencaro from existing therapies, including:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>More effective rhythm control compared to the current standard of care;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Reduction in the need for catheter ablation, electrical cardioversion, or toxic anti<span class="nobreak">-arrhythmic</span> drugs;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Maintenance of rhythm control after a successful AF catheter ablation;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Effective rate control with lower risk of treatment<span class="nobreak">-limiting</span>, adverse event producing bradycardia;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Reduction in symptoms and improvement in quality of life;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Reduced health care burden;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Foundational beta<span class="nobreak">-blocker</span> benefits for HF and unique evidence of efficacy in HF patients with AF;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>One of the only drug therapies approved and shown effective for AF in HF patients with EF &#8805; 40%, and the only one in its drug class.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA has an international patent portfolio for Gencaro in the United&#160;States, the EU, and other major markets, as well as new chemical entity status, including a new patent that ARCA believes will give it a strong intellectual property position to at least approximately 2039 in the United&#160;States; ARCA has filed applications similar to this new patent in international territories. ARCA has developed a laboratory platform for the diagnostic test that would be used to prescribe Gencaro; this platform was approved by FDA for use in the Phase&#160;2B clinical trial. ARCA retains all rights to this test platform; ARCA expects to use it in future clinical trials, and ARCA believes it could be one of multiple diagnostic platforms used for commercialization.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">rNAPc2 (AB201) for treatment of COVID-19</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Recombinant Nematode Anticoagulant Protein c2 (&#8220;rNAPc2&#8221;) (AB201), is a protein therapeutic in clinical development as a potential treatment for patients with COVID<span class="nobreak">-19</span>. Based on its unique mechanism of action, development history and the clinical evidence from the SARS<span class="nobreak">-CoV-2</span> pandemic, ARCA believes rNAPc2 has potential to be a beneficial therapy for patients with this serious viral disease. ARCA initiated a Phase&#160;2b clinical trial of rNAPc2 as a potential treatment for patients hospitalized with COVID<span class="nobreak">-19</span> in the fourth quarter of 2020 and </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">199</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">completed patient enrollment in the fourth quarter 2021. In the clinical trial, both doses of rNAPc2 demonstrated a treatment benefit for patients based on the coagulation biomarker D<span class="nobreak">-dimer</span>, however, neither dose achieved statistical significance for the primary efficacy endpoint of change in D<span class="nobreak">-dimer</span> level from Baseline to Day 8 compared to standard of care heparin.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On the secondary endpoints measuring thrombotic events and time<span class="nobreak">-to-recovery</span>, there was a numerical imbalance in favor of rNAPc2 that was non<span class="nobreak">-significant</span>. rNAPc2 was well<span class="nobreak">-tolerated</span> at both doses. There were no serious treatment<span class="nobreak">-related</span> adverse events and no dose dependent increase in adverse events was observed. There was no difference between rNAPc2 and standard<span class="nobreak">-of-care</span> heparin in major or non<span class="nobreak">-major</span> clinically relevant bleeding. ARCA currently does not plan additional clinical development of rNAPc2 unless ARCA is able to find a commercial or government partner to pay for development and commercialization or expansion into clinical trials for other disease indications.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">To support the continued development of Gencaro and rNAPc2, ARCA will need additional financing to fully fund any clinical trials, and ARCA&#8217;s general and administrative costs through the clinical trials&#8217; projected completion and potential commercialization. Considering the substantial time and costs associated with the development of Gencaro and rNAPc2 and the risk that ARCA may be unable to raise a significant amount of capital on acceptable terms, ARCA is also pursuing co<span class="nobreak">-development</span> and commercialization partnering opportunities with large pharmaceutical and/or specialty pharmaceutical companies and may pursue a strategic combination or other strategic transactions. If ARCA is unable to obtain sufficient financing or are unable to complete a strategic transaction, ARCA may discontinue its development activities on Gencaro or rNAPc2 or discontinue operations.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA believes its cash and cash equivalents as of March&#160;31, 2024 will be sufficient to fund its operations through the middle of fiscal year 2025. ARCA&#8217;s review of its strategic options may impact this projection. Conducting a Phase&#160;3 PRECISION<span class="nobreak">-AF</span> trial would likely require additional financing. However, changing circumstances may cause ARCA to consume capital significantly faster or slower than currently anticipated. ARCA has based these estimates on assumptions that may prove to be wrong, and ARCA could exhaust its available financial resources sooner than it currently anticipate; therefore, ARCA may have to raise additional capital for other clinical trials. Initiating any Phase&#160;3 clinical trial of Gencaro will require additional financing.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA&#8217;s Strategy</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s mission is to become a leading biopharmaceutical company developing precision targeted cardiovascular therapies to enhance therapeutic response, improve patient outcomes, and reduce healthcare costs. To achieve this goal, ARCA is pursuing the following strategies:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="Italic" style="font-style:italic;font-weight:normal;">Evaluate strategic options.&#160;&#160;&#160;&#160;</span>In April&#160;2022, ARCA&#8217;s board of directors established the Special Committee and, subsequently retained Ladenburg Thalmann to evaluate the Strategic Review. In March&#160;2024, ARCA terminated its engagement with Ladenburg Thalmann and retained Lucid Capital Markets to evaluate the Strategic Review. ARCA and Lucid have reviewed several potential strategic transactions and continue to evaluate further potential development of ARCA&#8217;s existing assets, in order to maximize stockholder value. ARCA does not have a defined timeline for the strategic review process and the review may not result in any specific action or transaction. Following a comprehensive review, on April<span class="nobreak">&#160;</span>3, 2024, ARCA, First Merger Sub, Second Merger Sub and Oruka, entered into Merger Agreement pursuant to which, among other matters, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, First Merger Sub will merge with and into Oruka, with Oruka continuing as a wholly owned subsidiary of ARCA and the surviving corporation of the merger and as part of the same overall transaction, the surviving corporation in the First Merger will merge with and into Second Merger Sub with Second Merger Sub continuing as a wholly owned subsidiary of ARCA and the surviving entity of the merger.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="Italic" style="font-style:italic;font-weight:normal;">Advance the development of Gencaro for the treatment of AF in HF patients.&#160;&#160;&#160;&#160;</span>ARCA is planning a Phase&#160;3 clinical trial for Gencaro as a therapy for AF in HF patients, focusing on patients with EF &#8805; 40%, a patient population for whom few approved or effective drug therapies currently exist.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;font-style:italic;font-weight:normal;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="Italic" style="font-style:italic;font-weight:normal;">Partner the development of rNAPc2.&#160;&#160;&#160;&#160;</span>ARCA plans to pursue strategic development and partnering opportunities with commercial or government partners for rNAPc2 development and commercialization or expansion into clinical trials for other disease indications.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">200</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;font-style:italic;font-weight:normal;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="Italic" style="font-style:italic;font-weight:normal;">Build a cardiovascular pipeline.&#160;&#160;&#160;&#160;</span>ARCA&#8217;s management, employees and consultants are experienced in cardiovascular research, molecular genetics and clinical development of cardiovascular therapies. ARCA is seeking to leverage this expertise to identify, acquire and develop other cardiovascular products or candidates, particularly those with potential for targeted development based on genetic or other biomarkers.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The above strategies are dependent upon ARCA&#8217;s ability to obtain additional funding through the sale of public or private equity or debt securities, the completion of a strategic transaction, or a combination thereof. If ARCA is unable to secure additional funding or complete a strategic transaction, ARCA may not be able to continue development of Gencaro or rNAPc2, or to continue operations.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Atrial Fibrillation in Heart Failure</span></p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Market Background and Opportunity</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Heart failure is a chronic condition in which the heart is unable to pump enough blood to meet the body&#8217;s needs. HF has numerous serious consequences, including severe impacts on quality of life, increased hospitalizations, loss of economic productivity, and premature death. HF is a leading cause of death in the developed world, and despite the availability of multiple effective drug classes, mortality due to HF is increasing. According to the 2020 American Heart Association (&#8220;AHA&#8221;) Heart Disease and Stroke Statistics, there were an estimated 6.2&#160;million Americans aged 20&#160;years or more with HF in 2016, projected to increase to between 8.3&#160;million and 10.7&#160;million by 2030. One of the fundamental classifications of heart failure is based on the percentage of blood in the left ventricle of the heart that is ejected with each heartbeat, known as EF.&#160;The spectrum of HF includes HF in which EF is 50% or more and is considered preserved ejection fraction, known as HFpEF; HF in which the EF is less than 40%, considered reduced ejection fraction (&#8220;HFrEF&#8221;); and HF in which the EF is at least 40%, but less than 50%, sometimes referred to as mid<span class="nobreak">-range</span> ejection fraction, known as HFmrEF.&#160;Together, HFmrEF and HFpEF, that is HF with EF &#8805; 40%, comprise more than half of all chronic HF in the United&#160;States and Europe. In 2012, the economic cost of HF in the United&#160;States was estimated to be nearly $31&#160;billion, of which two<span class="nobreak">-thirds</span>, or over $20&#160;billion, was attributable to direct medical costs.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Atrial fibrillation, the most common sustained cardiac arrhythmia, is a serious disorder in which the normally regular and coordinated contraction pattern of the heart&#8217;s two small upper chambers, or the atria, becomes irregular, rapid and uncoordinated. AF can have significant quality of life impacts and potentially serious medical consequences, including increasing the risk of stroke and other cardiovascular problems. In individuals with HF, AF contributes to the disease processes that lead to the progression of HF and worsening of clinical outcomes. AF is considered an epidemic cardiovascular disease and a major public health burden, similar to HF.&#160;The estimated number of individuals with AF globally in 2015 was 33.3&#160;million. According to AHA Heart Disease and Stroke Statistics Reports from&#160;2017<span class="nobreak">-2020</span>, the prevalence of AF in the United&#160;States was estimated to be 5.2&#160;million people in 2015. In the European Union, the prevalence of AF was estimated to be 8.8&#160;million (age 55 and over) in 2010. It is estimated that AF costs the U.S.&#160;economy about $6.0&#160;billion annually.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">AF and HF share many of the same risk factors and commonly occur together. It has been estimated that&#160;30<span class="nobreak">-60</span>% of HF patients will also develop AF, with this incidence increasing in HF patients with higher EF; ARCA estimates that&#160;40<span class="nobreak">-60</span>% of HF patients with EF &#8805; 40% will also be diagnosed with AF.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Medical Need and Current Therapy</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The goals of current medical therapy for AF are to provide anticoagulation to reduce the risk of stroke, and also either maintain sinus rhythm (known as rhythm control), or reduce the high heart rate caused by AF (known as rate control), in both cases to minimize patient symptoms and reduce the risk of further complications and disease progression. Unfortunately, the current treatment options for treating AF in patients with HF have significant limitations.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Beta<span class="nobreak">-blockers</span> are considered standard of care for the treatment of HF patients, including in patients with co<span class="nobreak">-morbid</span> AF.&#160;They are also viewed as foundational therapy to treat AF in HF patients for their ability to provide rate control. Their safety in this patient population is well established.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">201</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">However, current beta blockers approved for HF patients are only modestly effective at providing rhythm control, and none are FDA approved for this indication. Importantly, none of these drugs have been shown to be effective for treating HF in patients with EF &#8805; 40%, so they are currently used off<span class="nobreak">-label</span> in this setting. When used for rate control, these drugs can cause bradycardia, a condition in which the heart rate drops below a safe threshold, which often leads to dose reductions and potential loss of the drug&#8217;s treatment effect. Furthermore, recent evidence indicates that the mortality and other clinical benefits of these beta blockers in heart failure patients are uncertain when sustained or permanent AF is present.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Anti<span class="nobreak">-arrhythmic</span> drugs are a drug class that is often prescribed to provide rhythm control. These drugs are frequently used in patients with both HF and AF when a rate control strategy using a beta blocker fails to control the patient&#8217;s symptoms. However, these agents have significant safety issues. For example, in the United&#160;States, anti<span class="nobreak">-arrhythmic</span> drug therapy for AF used in addition to beta<span class="nobreak">-blockers</span> is generally confined to the drugs amiodarone and dofetilide, which have multiple safety and toxicity concerns. Because of these concerns, physicians treating HF patients seek to limit the use of these anti<span class="nobreak">-arrhythmic</span> drugs.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Non<span class="nobreak">-pharmacologic</span> interventions such as catheter ablation and electrical cardioversion (ECV), are also used to treat AF in patients with HF.&#160;Catheter ablation is now guideline<span class="nobreak">-recommended</span> in this patient population and its use is increasing. However, it is not a replacement for drug therapy; it is invasive, expensive and generally impermanent. Drug therapy, including beta blockers, is generally continued in patients post<span class="nobreak">-ablation</span>, both for rhythm control and for HF benefit. ECV is expensive and less permanent than ablation, but like ablation, post<span class="nobreak">-ECV</span> patients will generally remain on drug therapy to treat their AF and HF, including beta<span class="nobreak">-blockers</span>.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In light of the serious medical consequences presented by AF in the presence of HF as well as, the limitations of current therapies, ARCA believes there is an unmet need for a drug therapy that can provide greater rhythm control compared to the current standard of care; can reduce the need for toxic anti<span class="nobreak">-arrhythmic</span> drugs, catheter ablation, and electrical cardioversion; can provide effective rate control with a lower risk of treatment<span class="nobreak">-limiting</span> bradycardia; and can provide foundational beta<span class="nobreak">-blocker</span> benefits for HF.&#160;This need is particularly significant for HF patients with EF &#8805; 40%, for whom there are few approved or Class&#160;I guideline<span class="nobreak">-recommended</span> drug therapies.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Gencaro Clinical Development</span></p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">The GENETIC-AF Phase&#160;2B Clinical Trial</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">GENETIC<span class="nobreak">-AF</span> enrolled 267 patients from the United&#160;States, Canada and Europe. The primary analysis compared the evidence of safety and efficacy of Gencaro versus an active comparator, TOPROL<span class="nobreak">-XL</span>.&#160;The primary endpoint of the trial was time to first event of AF/atrial flutter (AFL) or All Cause Mortality (ACM) during a 24<span class="nobreak">-week</span> follow<span class="nobreak">-up</span> period after the establishment of sinus rhythm. Randomized patients had an EF &#8804; 55%, a history of AF in the past 6&#160;months, and the beta<span class="nobreak">-1</span> 389 arginine homozygous genotype that ARCA believes responds best to Gencaro. Laboratory Corporation of America (&#8220;LabCorp&#8221;) developed the genetic test, obtained an IDE from the FDA and provided the companion diagnostic test and services to support ARCA&#8217;s GENETIC<span class="nobreak">-AF</span> clinical trial.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">For the primary endpoint of time to AF recurrence, Gencaro demonstrated a similar treatment benefit in the overall population (p = 0.961) compared to the active comparator, TOPROL<span class="nobreak">-XL</span>.&#160;However, based on further analysis of the trial, ARCA believes it has identified a population that shows greater response to Gencaro compared to TOPROL<span class="nobreak">-XL</span> across multiple important clinical assessments, including the primary endpoint of time to AF recurrence, maintenance of normal sinus rhythm, cumulative AF burden, and AF<span class="nobreak">-related</span> clinical interventions and complications. ARCA plans to study this population in ARCA&#8217;s Phase&#160;3 clinical trial.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">These further analyses of the GENETIC<span class="nobreak">-AF</span> population (shown in the table below) demonstrated that Gencaro, as compared to metoprolol, reduced AF burden, improved maintenance of sinus rhythm and lowered the need for additional rhythm control interventions.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">202</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TCH" colspan="5" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 52.20%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">



						<p class="TCH_left" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Endpoint</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="5" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 46.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Entire GENETIC-AF Cohort</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" colspan="5" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:middle;width: 52.20%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="middle">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Time to 1</span><span class="CharOverride-3" style="font-size:58%;font-style:normal;font-weight:bold;vertical-align:super;">st</span><span class="CharOverride-2" style="font-style:normal;font-weight:bold;"> AF/AFL/ACM <br/>(Primary Endpoint)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:middle;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="middle">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:middle;width: 21.99%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="middle">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">1.01<br/>(neutral)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:middle;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="middle">&#160;</td>
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 23.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">(0.71, 1.42)<br/>p = 0.961<br/>N = 267</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TB" colspan="5" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:middle;width: 52.20%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="middle">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Cumulative 24-week AF Burden <br/>(substudy</span>)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:middle;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="middle">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:middle;width: 21.99%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="middle">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">0.64<br/>(</span><span class="Bold" style="font-style:normal;font-weight:bold;font-family:Symbol, sans-serif;font-size:9pt;font-style:normal;font-weight:normal;">&#8595;</span><span class="Bold" style="font-style:normal;font-weight:bold;">36%)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:middle;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="middle">&#160;</td>
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 23.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">(0.46, 0.86)<br/>p = 0.002<br/>N = 67</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" colspan="5" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:middle;width: 52.20%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="middle">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">AF Burden at Week 24</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:middle;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="middle">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:middle;width: 21.99%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="middle">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">0.45<br/>(</span><span class="Bold" style="font-style:normal;font-weight:bold;font-family:Symbol, sans-serif;font-size:9pt;font-style:normal;font-weight:normal;">&#8595;</span><span class="Bold" style="font-style:normal;font-weight:bold;">55%)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:middle;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="middle">&#160;</td>
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 23.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">(0.39, 0.50)<br/>p &lt; 0.001<br/>N = 67</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TB" colspan="5" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:middle;width: 52.20%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="middle">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">ECGs in Normal Sinus Rhythm</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:middle;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="middle">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:middle;width: 21.99%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="middle">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">1.39<br/>(</span><span class="Bold" style="font-style:normal;font-weight:bold;font-family:Symbol, sans-serif;font-size:9pt;font-style:normal;font-weight:normal;">&#8595;</span><span class="Bold" style="font-style:normal;font-weight:bold;">39%)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:middle;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="middle">&#160;</td>
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 23.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">(1.22, 1.58)<br/>p &lt; 0.001<br/>N = 257</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" colspan="5" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:middle;width: 52.20%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="middle">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">AF Interventions <br/>(ECVs, Ablations,&#160;&amp; Class&#160;3 AA Drugs)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:middle;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="middle">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:middle;width: 21.99%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="middle">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">0.68<br/>(</span><span class="Bold" style="font-style:normal;font-weight:bold;font-family:Symbol, sans-serif;font-size:9pt;font-style:normal;font-weight:normal;">&#8595;</span><span class="Bold" style="font-style:normal;font-weight:bold;">32%)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:middle;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="middle">&#160;</td>
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 23.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">(0.50, 0.91)<br/>p = 0.011<br/>N = 257</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-10" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:middle;width: 26.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="middle">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;margin-top:4pt;text-indent:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Bradycardia prevalence <br/></span>(Buc. vs. met., VR &lt; 60 bpm) </p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:middle;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="middle">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:middle;width: 12.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="middle">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;margin-top:8pt;text-indent:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">0.39<br/>(</span><span class="CharOverride-4" style="font-family:Symbol, sans-serif;font-size:9pt;font-style:normal;font-weight:normal;">&#8595;</span><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">61%)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:middle;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="middle">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.57%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;margin-top:6pt;text-indent:0pt;">(0.31, 0.49)<br/>P &lt; 0.001<br/>N = 256</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:middle;width: 21.99%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="middle">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;margin-top:8pt;text-indent:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Dose reductions</span> <br/>(pts. w/bradycardia vs. non-b.)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:middle;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="middle">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:middle;width: 10.99%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="middle">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;margin-top:8pt;text-indent:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">4.25<br/>(</span><span class="Bold" style="font-style:normal;font-weight:bold;font-family:Symbol, sans-serif;font-size:9pt;font-style:normal;font-weight:normal;">&#8593;</span><span class="Bold" style="font-style:normal;font-weight:bold;">4X)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:middle;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="middle">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;margin-top:4pt;text-indent:0pt;">(2.06, 9.60)<br/>P &lt; 0.001<br/>N = 257</p>
					</td>
				</tr>

		</table>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Time to first AF/AFL/ACM treatment effect = hazard ratio (95% CI). AF burden = % time in AF per&#160;day. Cumulative AF burden treatment effect = AUC ratio (i.e., AUC<span class="Subscript" style="vertical-align:sub;font-size:58%;">BUC</span>/AUC<span class="Subscript" style="vertical-align:sub;font-size:58%;">MET</span>) over 24<span class="nobreak">-week</span> follow<span class="nobreak">-up</span> period with significance assessed via null permutation. AFB at Week 24 = Instantaneous estimates of average daily AF burden at week 24 with comparison between groups expressed as the ratio of the estimates and tested for significance using a Wald test. Normal Sinus Rhythm = total number ECGs in sinus rhythm with ventricular rate&#160;&#8805;&#160;60&#160;and&#160;&#8804;&#160;100 bpm during efficacy follow<span class="nobreak">-up</span> period. AF Interventions = ECV, ablation, or guideline<span class="nobreak">-recommended</span> antiarrhythmic use during efficacy follow<span class="nobreak">-up</span> period. Treatment effect for normal sinus rhythm, AF interventions and bradycardia&#160;=&#160;prevalence rate ratio (i.e., PRR<span class="Subscript" style="vertical-align:sub;font-size:58%;">BUC</span>/PRR<span class="Subscript" style="vertical-align:sub;font-size:58%;">MET</span>) modeled to test significance using Poisson regression.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Treatment with Gencaro was associated with a 36% reduction in cumulative AF burden over 24&#160;weeks of follow<span class="nobreak">-up</span> compared to metoprolol, leading to a 55% reduction in AF burden at the end of 24&#160;weeks. Consistent with the results in the device substudy, there was a 39% increase in the prevalence of ECGs demonstrating normal sinus rhythm in the overall study population. Treatment with Gencaro also led to a 32% lower utilization of adjunctive rhythm control therapies, including electrical cardioversion, catheter ablation and antiarrhythmic drug therapy. There was also a 61% reduction in bradycardia with Gencaro versus metoprolol. The consequence of bradycardia is a reduction in beta<span class="nobreak">-blocker</span> dose, which 4.2<span class="nobreak">-fold</span> higher in patients exhibiting bradycardia than without bradycardia.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">The BEST Phase&#160;3 Heart Failure Trial</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The effect of Gencaro on heart failure endpoints in an advanced HFrEF population was evaluated in the 2,708&#160;patient, placebo<span class="nobreak">-controlled</span> Phase&#160;3 BEST clinical trial co<span class="nobreak">-sponsored</span> by the NHLBI and Department of Veterans Affairs. In addition to the parent population, BEST included a 1,040 patient DNA substudy that evaluated the effects of adrenergic receptor (&#8220;AR&#8221;) polymorphisms on Gencaro effectiveness. The BEST trial was terminated early because, after positive mortality results from two HF trials involving other beta<span class="nobreak">-blockers</span> had been reported, a substantial number of BEST trial investigators concluded that it was unethical to continue to give placebo to BEST trial participants. ARCA&#8217;s reanalysis of the BEST results in accordance with the FDA approved, pre<span class="nobreak">-specified</span> statistical analysis plans (which had not been performed by the sponsors of BEST) demonstrated a 13% risk reduction on the primary endpoint of ACM in the BEST trial with a p<span class="nobreak">-value</span> of 0.053. The risk reduction on HF clinical efficacy endpoints such as mortality and hospitalization ranged from 34% to 48% in this beta<span class="nobreak">-1</span> 389 arginine homozygous genotype. The DNA substudy revealed that Gencaro exhibited greater efficacy in patients homozygous for the beta<span class="nobreak">-1</span> 389 arginine homozygous genotype (<span class="Italic" style="font-style:italic;font-weight:normal;">ADRB1</span> Arg389Arg), encoding for receptors that exhibit higher function and greater affinity for norepinephrine compared to the patients who did not have the beta<span class="nobreak">-1</span> 389 arginine homozygous genotype (i.e., beta<span class="nobreak">-1</span> 389 Gly carriers). In the 47% of BEST trial patients with a <span class="Italic" style="font-style:italic;font-weight:normal;">ADRB1</span> Arg389Arg genotype Gencaro reduced (p &lt;0.05) the primary endpoint of mortality or heart transplantation by 43%, all<span class="nobreak">-cause</span> mortality, cardiovascular mortality, heart failure hospitalizations, heart failure progression, development of atrial </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">203</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">fibrillation, and incidence of ventricular tachycardia or ventricular fibrillation with degrees of reduction (effect sizes) ranging from 34% (heart failure progression) to 74% (atrial fibrillation). Beta<span class="nobreak">-1</span> 389 Gly carriers had no statistically significant reduction in any endpoint.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Pharmacology and Pharmacogenetics of Gencaro</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Gencaro (bucindolol hydrochloride) is a nonselective (blocks both beta<span class="nobreak">-1</span> and beta<span class="nobreak">-2</span> adrenergic receptors) beta- receptor blocking agent with mild vasodilator properties. This combination of properties initially placed Gencaro in the &#8220;3<span class="CharOverride-6" style="font-size:58%;vertical-align:super;">rd</span> Generation&#8221; category of beta<span class="nobreak">-blockers</span> that is based on the strategy of their development. When its pharmacogenetic properties were elucidated and its development became pharmacogenetically based, ARCA subsequently considered Gencaro a fourth<span class="nobreak">-generation</span> beta<span class="nobreak">-blocker</span>. The dominant beta<span class="nobreak">-receptor</span> on human heart cells is the beta<span class="nobreak">-1</span>, with smaller number of beta<span class="nobreak">-2</span> receptors present. Importantly, beta<span class="nobreak">-2</span> receptors are also present on adrenergic nerve terminals in the heart, where they regulate the release of the neurotransmitter norepinephrine (&#8220;NE&#8221;). The blocking of these receptors prevents them from binding with other molecules, primarily NE, which activates these receptors to release more NE.&#160;ARCA believes Gencaro has two unique anti<span class="nobreak">-adrenergic</span> properties not possessed by other beta<span class="nobreak">-blockers</span> currently approved for the treatment of HF: (1)&#160;it is moderately sympatholytic, i.e., by blocking beta<span class="nobreak">-2</span> receptors on adrenergic nerves it lowers adrenergic drive to a level that can be detected on measurements of central or systemic venous NE levels, and, (2)&#160;through &#8220;inverse agonism,&#8221; as it binds to a polymorphic &#8220;389 arginine&#8221; form of heart cell beta<span class="nobreak">-1</span> receptor in isolated human heart preparations it promotes the inactivation of the active<span class="nobreak">-state</span> of this receptor. These properties, as described below, were observed to interact with receptor polymorphisms in such a way that ARCA believes targeting a specific genotype of the beta<span class="nobreak">-1</span> receptor gene (known as ADRB1) could improve the therapeutic response of patients. ARCA believes Gencaro&#8217;s efficacy is enhanced in patients with the beta<span class="nobreak">-1</span> 389 arginine homozygous genotype (<span class="Italic" style="font-style:italic;font-weight:normal;">ADRB1</span> Arg389Arg), which has been shown to be present in approximately 50% of the North American and European general populations. To date no other beta<span class="nobreak">-blocker</span> has been shown to possess pharmacological sympatholysis, or beta<span class="nobreak">-1</span> AR inverse agonism in human heart preparations. ARCA believes that Gencaro&#8217;s sympatholytic and beta<span class="nobreak">-1</span> AR inverse agonist properties contribute to its enhanced lowering of HF and arrhythmia event rates in patients who have an <span class="Italic" style="font-style:italic;font-weight:normal;">ADRB1</span> Arg389Arg genotype.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Gencaro Clinical and Regulatory Strategy</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA intends to advance Phase&#160;3 clinical development of Gencaro as a therapy for HF patients with AF, focusing on HF with EF &#8805; 40%. The regulatory strategy for Gencaro is to obtain an initial approval to treat AF in a HF population with EF &#8805; 40% and &#8804; 55% and the beta<span class="nobreak">-1</span> 389 arginine homozygous genotype; the population demonstrating the greatest efficacy in the Phase&#160;2B GENETIC<span class="nobreak">-AF</span> clinical trial. Indication expansion for Gencaro will focus on genotype<span class="nobreak">-positive</span> HF patients with EF &gt;55%, which ARCA believes would substantially expand the addressable patient population, if successful. ARCA has obtained an SPA agreement with the FDA to conduct a single, 400<span class="nobreak">-patient</span> Phase&#160;3 clinical trial that, if successful at a statistical threshold of p &#8804; 0.01, may be sufficient to support an NDA for the marketing approval of Gencaro.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The clinical trial design is similar to GENETIC<span class="nobreak">-AF</span>, including the active comparator, TOPROL<span class="nobreak">-XL</span>, and the primary endpoint of time to AF or atrial flutter (&#8220;AF/AFL&#8221;) recurrence or mortality during a 6<span class="nobreak">-month</span> follow<span class="nobreak">-up</span> period. The planned clinical trial will use a standard significance criterion of p &#8804; 0.05 for the primary endpoint; however, if the primary endpoint is significant with a p<span class="nobreak">-value</span> &#8804; 0.01, then this single Phase&#160;3 clinical trial may be sufficient for regulatory approval per the SPA agreement. The NDA submission for Gencaro is eligible for expedited review in the United&#160;States under the Fast Track development program designation that was granted to Gencaro in 2015. Based on the use of this same endpoint in GENETIC<span class="nobreak">-AF</span> it is anticipated that &#8805;90% of the primary events will be due to recurrent AF/AFL.&#160;Secondary objectives will examine other important endpoints, such as AF burden and AF treatment<span class="nobreak">-related</span> interventions. The planned clinical trial will use a standard significance criterion of p&#160;&#8804;&#160;0.05 for the primary endpoint; however, if the primary endpoint is significant with a p<span class="nobreak">-value</span> &#8804; 0.01, then this single&#160;Phase&#160;3 clinical trial may be sufficient for regulatory approval per the SPA agreement.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">The Gencaro Test</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If approved, ARCA believes that Gencaro will be the first cardiovascular drug to be integrated with a companion diagnostic. This would be a test for the patient genotype approved for the drug, and could be performed by a variety of laboratory processes or platforms.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">204</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In collaboration with LabCorp, ARCA developed one such genetic test, obtained an IDE from the FDA and used this test in ARCA&#8217;s GENETIC<span class="nobreak">-AF</span> clinical trial. ARCA retains all rights to this particular test platform, and ARCA believes it could be used for commercialization. Future clinical trials of Gencaro, including PRECISION<span class="nobreak">-AF</span>, are expected to use a similar diagnostic test to identify the patient&#8217;s receptor genotype (the &#8220;Gencaro Test&#8221;). ARCA believes the Gencaro Test could be developed and commercialized through one or more diagnostic providers, by the company potentially marketing Gencaro, or a combination of approaches. ARCA also believes that point of care genetic tests, which could be performed during the patient&#8217;s visit to the physician, will be part of the commercialization strategy for Gencaro.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Development Pipeline</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s lead product candidate is Gencaro&#8482; (bucindolol hydrochloride) for the treatment of atrial fibrillation in patients with chronic heart failure.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Gencaro, is a potential treatment for HF patients with AF.&#160;Gencaro (bucindolol hydrochloride) is a pharmacogenetic<span class="nobreak">-targeted</span> beta<span class="nobreak">-adrenergic</span> receptor antagonist with mild vasodilator properties that is considered a fourth<span class="nobreak">-generation</span> beta<span class="nobreak">-blocker</span> based on its novel pharmacogenetic profile. ARCA believes the treatment of AF in HF patients with EF &#8805; 40% is an unmet medical need with a near term and straightforward regulatory pathway.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s plan is to obtain an initial approval for Gencaro to treat AF in a genotype specific HF population; HF patients with EF between 40% and 55% in patients with the genotype ARCA studied in the Phase&#160;2B GENETIC<span class="nobreak">-AF</span> clinical trial. ARCA believes that, if approved, there are additional indication expansion opportunities for Gencaro in other AF populations, including expanding the patient population to selected HF patients with EF &gt;55%. ARCA continues to evaluate the feasibility and potential timing for initiating PRECISION<span class="nobreak">-AF</span> relative to the COVID<span class="nobreak">-19</span> pandemic. ARCA may seek additional capital or a strategic partnership for the Phase&#160;3 clinical trial and potential commercialization of Gencaro.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA plans to pursue strategic development and partnering opportunities with commercial or government partners for rNAPc2 development and commercialization or expansion into clinical trials for other disease indications.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA also has exclusive pharmacogenetic and other patent rights to drug targets and candidates that have potential indications in cardiovascular disease, oncology and other therapeutic areas. ARCA may seek partners to assist it in the development of these candidates or who may license them. ARCA may also seek funds to advance the development of the compounds on ARCA&#8217;s own.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Financial Resources</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">To support the continued development of Gencaro and rNAPc2, ARCA will need additional financing to fully fund any clinical trials, and its general and administrative costs through the clinical trials&#8217; projected completion and potential commercialization. Considering the substantial time and costs associated with the development of Gencaro and rNAPc2 and the risk that ARCA may be unable to raise a significant amount of capital on acceptable terms, ARCA is also pursuing co<span class="nobreak">-development</span> and commercialization partnering opportunities with large pharmaceutical and/or specialty pharmaceutical companies and may pursue a strategic combination or other strategic transactions. If ARCA is unable to obtain sufficient financing or is unable to complete a strategic transaction, ARCA may discontinue its development activities on Gencaro or rNAPc2 or discontinue operations.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA believes ARCA&#8217;s cash and cash equivalents as of March&#160;31, 2024 will be sufficient to fund ARCA&#8217;s operations through the middle of fiscal year 2025. ARCA&#8217;s review of its strategic options may impact this projection. Conducting a Phase&#160;3 PRECISION<span class="nobreak">-AF</span> trial would likely require additional financing. However, changing circumstances may cause ARCA to consume capital significantly faster or slower than currently anticipated. ARCA has based these estimates on assumptions that may prove to be wrong, and ARCA could exhaust its available financial resources sooner than it currently anticipate; therefore, ARCA may have to raise additional capital for other clinical trials. Initiating any Phase&#160;3 clinical trial of Gencaro will require additional financing.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">205</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Licensing and Royalty Obligations</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Gencaro</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s patent portfolios relating to Gencaro, including a patent issued in 2021, are either owned by ARCA or are subject to licenses that impose no royalty obligations or milestone payments relating to the further development, approval and commercialization of Gencaro.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA is also a party to licenses for patents relating to Gencaro that are now expired. ARCA believes that there are no future milestone or royalty obligations that will be payable under these licenses.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Competition</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Gencaro</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Current HF treatments include three beta<span class="nobreak">-blockers</span> approved for HF in the United&#160;States. However, their efficacy in providing control of the arrhythmia caused by AF, or rhythm control, is only mild. It is also now acknowledged that evidence is lacking that the approved beta<span class="nobreak">-blockers</span> provide outcome benefits for patients who develop permanent AF.&#160;Furthermore, these drugs have not demonstrated efficacy for HF patients with EF &#8805; 40%, which is the focus of the Gencaro development program. Current AF treatments include pharmaceutical, procedural or device intervention. There are several antiarrhythmic drugs approved by the FDA for the treatment and/or prevention of recurrent AF.&#160;However, these drugs have safety and/or administration concerns and all but one have contraindications or label warnings regarding their prescription in patients with HF.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Drugs that are currently approved or used for the treatment or prevention of AF in HF either have not demonstrated efficacy in these patients, or have notable risks due to adverse side effects or lack sufficient efficacy. Therefore, in HF, and specifically in HF patients with EF &#8805; 40%, ARCA believes there is a substantial unmet medical need for AF therapies that are more effective and have fewer side effects than those currently available. ARCA believes that Gencaro&#8217;s treatment of AF in HF patients could provide a more effective and safer pharmacotherapy than treatments currently used in these patients.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The pharmaceutical industry is highly competitive. ARCA faces significant competition from pharmaceutical companies and biotechnology companies that are researching and selling products designed to treat cardiovascular conditions. Most of these companies have significantly greater financial, product development, manufacturing, and commercial resources than ARCA has.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If approved, some of the drugs which Gencaro would potentially compete with are generic in the United&#160;States and are used, though not approved or shown to be effective, for the treatment of AF or in HF patients with EF &#8805; 40%. Gencaro could be priced at a premium compared to some of these therapies. In addition, Gencaro, if approved, would be prescribed in conjunction with a diagnostic test, adding additional procedures to the process of prescribing Gencaro, which could make it more difficult for ARCA to compete against existing or future therapies.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Manufacturing and Product Supply</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Gencaro is a small molecule drug with an established manufacturing history. Multiple manufacturers of both the active pharmaceutical ingredients (&#8220;API&#8221;) and drug product have successfully produced Gencaro for use in clinical trials over the course of its clinical development. ARCA outsources all manufacturing and analytical testing of the Gencaro API and drug product. ARCA has selected third<span class="nobreak">-party</span> contract manufacturing organizations on the basis of their technical and regulatory expertise. ARCA&#8217;s approach with its contract manufacturing partners has been to replicate the manufacturing processes that were used to support the prior pivotal clinical trial with Gencaro, and to minimize any changes from these baseline processes, thereby reducing technical and regulatory risk. For API production, ARCA contracted with Groupe Novasep which completed the drug substance registration batches successfully. The resulting drug substance was used to manufacture the drug product used in the clinical trial material for the Phase&#160;2B clinical trial and is expected to be used in the proposed Phase&#160;3 clinical trial.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">For drug product production, ARCA has contracted with Patheon, Inc. to manufacture the Gencaro tablets. Gencaro is produced in a tablet form, utilizing standard solid oral dosage processing techniques. Six separate dosage strengths have been manufactured, with the maximum recommended dose of 100mg twice daily. Registration </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">206</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">batches were successfully completed by Patheon, Inc. and tablets from these runs were placed in cGMP storage to supply clinical trials. In addition, ARCA contracted with a separate service provider for packaging and distribution of its clinical trial materials.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Government Regulation</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Governmental authorities in the United&#160;States at the federal, state, and local levels and foreign countries extensively regulate, among other things, the research, development, testing, manufacture, labeling, promotion, advertising, marketing, distribution, sampling, and import and export of pharmaceutical and medical device products. In the United&#160;States, the FDA regulates these activities at the federal level pursuant to the Federal Food Drug and Cosmetic Act (&#8220;FDCA&#8221;) and the regulations promulgated thereunder. In Canada, Health Canada regulates these activities. In Europe, the Competent Authorities and Ethics Committees of the respective countries regulate these activities. In South America, the Health Authorities and Ethics Committees of their respective countries regulate these activities. ARCA anticipates that all of its product candidates will require regulatory approval by governmental agencies prior to commercialization. The process of obtaining approval and the subsequent process of maintaining compliance with appropriate federal, state, local and foreign statutes and regulations require the expenditure of substantial time and financial resources. In addition, these statutes, rules, regulations and policies may change and ARCA&#8217;s products may be subject to new legislation or regulations. Both before and after approval or clearance, failure to comply with the requirements of the FDA and other state and federal statutes can lead to significant penalties or could disrupt ARCA&#8217;s ability to manufacture and sell these products. In addition, the FDA could refuse to provide certificates needed to export ARCA&#8217;s products if the agency determines that ARCA is not in compliance.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Premarket Approval of Drugs</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">FDA approval is required for marketing of any new drug, dosage form, indication, or strength. The steps required before new human therapeutic drug products are marketed in the United&#160;States and foreign countries include rigorous preclinical and clinical testing and other approval requirements by regulatory agencies, such as the FDA and comparable agencies in foreign countries. There is no guarantee that products will be approved in a specific timeframe or at all.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Preclinical Phase.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span>Preclinical studies are generally conducted in the laboratory to identify potential drug candidates and to evaluate their potential efficacy and safety. These studies include laboratory evaluation of product chemistry, formulation and stability, as well as studies to evaluate short and long<span class="nobreak">-term</span> toxicity in animals. Preclinical studies are governed by numerous regulations, including but not limited to FDA&#8217;s Good Laboratory Practices.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Clinical Phase.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span>Before human clinical trials can commence, an Investigational New Drug (&#8220;IND&#8221;) application, submitted to FDA must become effective. For an IND to become effective, the applicant must submit, among other things, information on design of the proposed investigation, reports necessary to assess the safety of the drug for use in clinical investigation, and information on the chemistry and manufacturing of the drug, controls available for the drug, and primary data tabulations from animal or human studies. The clinical phase of development involves the performance of human studies, including adequate and well<span class="nobreak">-controlled</span> human clinical trials to establish the safety and efficacy of the product candidate for each proposed indication. Typically, clinical evaluation involves three sequential phases, which may overlap. During Phase&#160;1, clinical trials are conducted with a relatively small number of subjects or patients to determine the early safety profile of a product candidate, as well as dose tolerance, absorption, and the pattern of drug distribution and drug metabolism. Phase&#160;2 trials are conducted with groups of patients afflicted by a specific target disease to determine preliminary efficacy, optimal dosages and dosage tolerance and to identify possible adverse effects and safety risks. In Phase&#160;3, larger<span class="nobreak">-scale</span>, multi- center trials are conducted with patients afflicted with a specific target disease over a longer term to confirm Phase&#160;2 results and provide reliable and conclusive data supporting efficacy and safety of a drug as required by regulatory agencies for drug approval. The conduct of clinical trials is subject to extensive regulation. FDA may delay or suspend clinical trials through clinical holds.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">NDA Submission.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span>In the United&#160;States, the results of preclinical and clinical testing along with chemistry, manufacturing and controls information, are submitted to the FDA in the form of a NDA.&#160;Under the current Prescription Drug User Fee Act after submission of an NDA and payment, or waiver, of the required fee, the FDA&#8217;s goal is to review most standard NDAs within 10&#160;months from the time that a sponsor&#8217;s application is accepted as </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">207</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">filed by the FDA, which can occur within a 60<span class="nobreak">-day</span> window following the initial submission of the application. At the end of the 10&#160;months, the FDA&#8217;s goal is to issue a &#8220;complete response,&#8221; or approve the NDA.&#160;While FDA&#8217;s goal is to issue a complete response within 10&#160;months, the process may take longer than 10&#160;months, particularly if multiple review cycles are required. Gencaro has been granted Fast Track Designation which allows for a rolling review of a marketing application. A rolling review allows FDA to consider reviewing portions of an NDA before the sponsor submits the complete application.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In responding to an NDA, the FDA may grant marketing approval or deny the application if the FDA determines that the application does not satisfy the statutory and regulatory approval criteria. A denial may include a request for additional information, including additional clinical data and/or an additional Phase&#160;3 clinical trial. Data from clinical trials are not always conclusive and FDA may interpret data differently than ARCA interprets data. Under the Food and Drug Modernization Act&#160;of&#160;1997, the FDA is authorized to approve a drug based on a single adequate and well<span class="nobreak">-controlled</span> study if such study and other confirmatory data are sufficient to establish the drug&#8217;s effectiveness. However, it has long been the FDA&#8217;s general position that the standard of proof of a drug&#8217;s effectiveness generally requires at least two well<span class="nobreak">-controlled</span> and adequate Phase&#160;3 clinical studies demonstrating statistically significant results as compared to a placebo or active control (with p<span class="nobreak">-values</span> of less than 0.05) with respect to the primary endpoint or endpoints of the trial.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, in accordance with current FDA law and regulations, the FDA may refer a drug to an advisory committee for review prior to approval. Most new compounds are referred to an FDA advisory committee, which could add additional time to the review process. There is no guarantee that the advisory committee will recommend approval of a drug candidate. In some cases, FDA may require completion, within a specified time period, of additional clinical studies after approval, referred to as Phase&#160;4 clinical studies, to monitor the effect of a new product and may prevent or limit future marketing of the product based on the results of these post<span class="nobreak">-marketing</span> programs. Furthermore, prior to granting approval, the FDA generally conducts an inspection of the facilities, including outsourced facilities that will be involved in the manufacture, production, packaging, testing and control of the drug substance and finished drug product for compliance with current Good Manufacturing Practice (&#8220;cGMP&#8221;) requirements.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If the FDA approves the NDA, the sponsor is authorized to begin commercialization of the drug in accordance with the approval. Even if the FDA approves the NDA, the FDA may decide later to suspend or withdraw product approval if compliance with regulatory standards is not maintained or if safety problems are recognized after the product reaches the market. In addition, the FDA requires surveillance programs to monitor approved products that have been commercialized, and the agency has the power to require additional clinical studies, to require changes in labeling or to prevent further marketing of a product based on the results of these post<span class="nobreak">-marketing</span> programs. The FDA also has authority to request implementation of a risk evaluation and mitigation strategy (&#8220;REMS&#8221;) that could restrict distribution of Gencaro or require ARCA to provide additional risk information to prescribers. Whether or not FDA approval has been obtained, approval of a product candidate by comparable foreign regulatory authorities is necessary prior to the commencement of marketing of a product candidate in those countries. The approval procedures vary among countries and can involve additional testing. The time required to obtain approval may differ from that required for FDA approval.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Post</span><span class="nobreak"><span class="Italic" style="font-style:italic;font-weight:normal;">-approval</span></span><span class="Italic" style="font-style:italic;font-weight:normal;"> Compliance.&#160;&#160;&#160;&#160;</span>If regulatory approval for a drug or medical device is obtained, the product and the facilities manufacturing the product are subject to periodic inspection and continued regulation by regulatory authorities, including compliance with cGMP, as well as labeling, advertising, promotion, recordkeeping, and reporting requirements, including the reporting of adverse events. In addition, the FDA closely regulates the post<span class="nobreak">-approval</span> marketing and promotion of drugs, including standards and regulations for labeling, promotion to health care professionals, direct<span class="nobreak">-to-consumer</span> advertising, off<span class="nobreak">-label</span> promotion, industry<span class="nobreak">-sponsored</span> scientific and educational activities and promotional activities involving the Internet. Drugs may be marketed only for the approved indications and in accordance with the provisions of the approved labeling. Companies are responsible for compliance with such requirements and would be responsible to ensure that all contract manufacturing organizations who perform work for them also comply with such requirements. Similarly, if a drug manufacturer hires contract sales representatives or consultants to promote its products, such organizations or individuals must comply with all of the same requirements applicable to the drug manufacturer. The FDA regularly inspects companies to determine compliance with cGMPs and other post<span class="nobreak">-market</span> requirements. Failure to comply with statutory requirements and the FDA&#8217;s regulations can result in a variety of administrative or enforcement actions, including but not limited to an FDA Form&#160;483 (which is issued by the FDA at the conclusions of an inspection when an investigator has observed </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">208</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">any conditions that may constitute violations), a public warning letter, suspension or withdrawal of regulatory approvals, product recalls, product detentions, refusal to provide export certificates, seizure of products and criminal prosecution.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Drug Price Competition and Patent Term Restoration Act&#160;of&#160;1984.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span>Under the Drug Price Competition and Patent Term Restoration Act&#160;of&#160;1984, also known as the Hatch<span class="nobreak">-Waxman</span> Act, Congress created an abbreviated FDA review process for generic versions of pioneer (brand name) drug products. The Hatch<span class="nobreak">-Waxman</span> Act also provides for patent term restoration and the award, in certain circumstances, of non<span class="nobreak">-patent</span> marketing exclusivities.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Generic Drug Approval.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span>The Hatch<span class="nobreak">-Waxman</span> Act established an abbreviated FDA review process for drugs that are shown to be equivalent to approved pioneer drugs. Approval for a generic drug is obtained by filing an abbreviated NDA, or ANDA.&#160;Generic drug applications are &#8220;abbreviated&#8221; because they generally do not include clinical data to demonstrate safety and effectiveness. Instead, an ANDA applicant must establish that its product is bioequivalent to an approved drug and that it is the same as the approved drug with respect to active ingredient(s), route of administration, dosage form, strength and recommended conditions of use (labeling). The FDA will approve the generic as suitable for an ANDA if it finds that the generic does not raise questions of safety and effectiveness as compared to the pioneer drug. A drug is not eligible for ANDA approval if the FDA determines that it is not equivalent to the pioneer drug or if it is intended for a different use. Any applicant who files an ANDA seeking approval of a generic version of an approved drug listed in FDA&#8217;s Approved Drug Products with Therapeutic Equivalence Evaluations (the &#8220;Orange Book&#8221;) must certify to the FDA that (i)&#160;no patent information on the drug has been listed in the Orange Book; (ii)&#160;that each patent listed in the Orange Book for that approved drug has expired; (iii)&#160;FDA should approve the product on the date on which a listed patent expires; or (iv)&#160;that such patent is invalid, unenforceable or will not be infringed by the manufacture, use or sale of the generic drug. If the ANDA applicant makes a certification pursuant to (iv)&#160;above, or a Paragraph&#160;IV certification, and the NDA holder files an infringement suit against the ANDA applicant within 45&#160;days of receiving the Paragraph&#160;IV notification, the NDA owner is entitled to an automatic 30<span class="nobreak">-month</span> stay of FDA&#8217;s ability to approve the ANDA.&#160;This 30<span class="nobreak">-month</span> stay will end early upon any decision by a court that the patent is invalid, unenforceable or not infringed by the generic drug.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Patent Term Extension.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span>While the term of a U.S.&#160;patent is generally 20&#160;years from the earliest priority date of a patent application (excluding a provisional patent application), a U.S.&#160;patent that covers subject matter requiring regulatory approval to market is eligible for an extension of that patent term. The Hatch<span class="nobreak">-Waxman</span> Act provides for the restoration of a portion of the patent term lost during product development and FDA review of an application. Patent Term Extension (&#8220;PTE&#8221;), extends the term of an issued patent for generally (i)&#160;the length of the FDA approval process, i.e., the complete period of NDA review, and (ii)&#160;half of the time spent in clinical trials, i.e., the IND period. However, the maximum period of restoration cannot exceed five&#160;years, or restore the total remaining term of the patent to greater than 14&#160;years from the date of FDA approval of the product.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Under 35 U.S.C. &#167; 156(a), a patent covering a method of using a product is eligible for PTE if the following conditions are met:</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">1)<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>the patent has not yet expired;</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">2)<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>the patent was not previously extended;</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">3)<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>the patent owner submits an application for PTE that includes all necessary supporting information within 60&#160;days of FDA approval;</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">4)<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>the product was subject to regulatory review before its commercial marketing or use; and</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">5)<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>the drug application is for the first permitted commercial marketing of the product.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA believes that, if Gencaro is approved by the FDA, one of its U.S.&#160;patents may be eligible for PTE, which could provide up to 5&#160;years of additional patent life for that patent based on ARCA&#8217;s current clinical trial plans.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">A Supplementary Protection Certificate (&#8220;SPC&#8221;) is a form of patent term extension that is available for pharmaceutical products approved for marketing in the European Union (&#8220;EU&#8221;). ARCA obtained a patent in Europe on methods for using Gencaro that is similar to one of its U.S.&#160;patents and this EU patent is in force in certain countries in Europe, including the United Kingdom, France, Germany, Italy and Spain. ARCA believes that this </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">209</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">patent may be eligible for an SPC, if Gencaro is approved for marketing in any European country in which the patent is in force, which could provide up to five&#160;years of additional patent life. ARCA believes that its patents in other jurisdictions may also be eligible for similar term extensions.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Non</span><span class="nobreak"><span class="Italic" style="font-style:italic;font-weight:normal;">-Patent</span></span><span class="Italic" style="font-style:italic;font-weight:normal;"> Marketing Exclusivities.&#160;&#160;&#160;&#160;</span>Separate and apart from patent protection, the Hatch<span class="nobreak">-Waxman</span> Act entitles approved drugs to various periods of non<span class="nobreak">-patent</span> statutory protection, known as marketing exclusivity. The Hatch<span class="nobreak">-Waxman</span> Act provides five&#160;years of &#8220;new chemical entity&#8221; marketing exclusivity to the first applicant to gain approval of an NDA for a product that contains an active moiety not found in any other approved product. This exclusivity means that another manufacturer cannot submit an ANDA or 505(b)(2)&#160;NDA until the marketing exclusivity period ends. This exclusivity protects the entire new chemical entity franchise, including all products containing the active ingredient for any use and in any strength or dosage form, but will not prevent the submission or approval of stand<span class="nobreak">-alone</span> NDAs where the applicants have conducted their own clinical studies to demonstrate safety and effectiveness. There is an exception, however, for a competitor that seeks to challenge a patent with a Paragraph&#160;IV certification. Four&#160;years into the five<span class="nobreak">-year</span> exclusivity period, a manufacturer who alleges that one or more of the patents listed with the NDA is invalid, unenforceable or not infringed may submit an ANDA or 505(b)(2) NDA for a generic or modified version of the product.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Hatch<span class="nobreak">-Waxman</span> Act also provides three&#160;years of &#8220;new use&#8221; marketing exclusivity for the approval of NDAs, and supplements, where those applications contain the results of new clinical investigations (other than bioavailability studies) essential to the FDA&#8217;s approval of the applications. Such applications may be submitted for new indications, dosage forms, strengths, or new conditions of use of approved products. So long as the studies are essential to the FDA&#8217;s approval or were conducted by or for the applicant, this three<span class="nobreak">-year</span> exclusivity prohibits the final approval of ANDAs or 505(b)(2)&#160;NDAs for products with the specific changes associated with those studies. It does not prohibit the FDA from approving ANDAs or 505(b)(2)&#160;NDAs for other products containing the same active ingredient, without those changes.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Similar non<span class="nobreak">-patent</span> market exclusivity is provided for in the EU and other international jurisdictions. ARCA believes that, if approved in the EU, Gencaro may be eligible for ten&#160;years of market exclusivity in the EU, measured from the date of approval there.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">FDA Premarket Review of Medical Devices</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Unless an exemption applies, each medical device that a company wishes to market in the United&#160;States requires either approval of a premarket approval application (&#8220;PMA&#8221;), or clearance of a premarket notification, commonly known as a &#8220;510(k)&#8221; from the FDA.&#160;The FDA classifies medical devices into one of three classes. Devices deemed to pose lower risks are placed in either class&#160;I or&#160;II, which may require the manufacturer to submit to the FDA a 510(k)&#160;requesting permission to commercially distribute the device. Clearance of a 510(k)&#160;usually requires between three&#160;months and one year from the time of submission of the 510(k), although the process may take longer. The FDA&#8217;s 510(k)&#160;clearance procedure is less rigorous than the PMA approval procedure, but is available only to companies who can establish that their device is substantially equivalent to a legally<span class="nobreak">-marketed</span> &#8220;predicate&#8221; device that was (i)&#160;on the market prior to the enactment of the Medical Device Amendments of 1976, (ii)&#160;reclassified from Class&#160;III to Class&#160;II, or (iii)&#160;has been cleared through the 510(k)&#160;procedure. 510(k)s must typically be supported by performance data, including preclinical data, bench testing, and in some cases, clinical data. Some low risk devices are exempted from this requirement. Devices deemed by the FDA to pose the greatest risks, or for which there is no predicate, are placed in class&#160;III, and require a PMA.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">PMA Pathway.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span>Generally, a PMA must be supported by extensive data and valid scientific evidence, including, but not limited to, technical, preclinical, clinical trials, manufacturing and labeling to demonstrate to the FDA&#8217;s satisfaction a reasonable assurance of the safety and effectiveness of the device for its intended use. After a PMA is sufficiently complete, the FDA will accept the application and begin an in<span class="nobreak">-depth</span> review of the submitted information and will generally conduct a pre<span class="nobreak">-approval</span> inspection of the manufacturing facility or facilities to ensure compliance with FDA&#8217;s QSR. By statute, the FDA has 180&#160;days to review the &#8220;accepted application&#8221;, although, generally, review of the application can take between one and three&#160;years, and it may take significantly longer. The PMA application process can be expensive, and there is a substantial &#8220;user fee&#8221; that must be paid to FDA in connection with the submission of a PMA application. If the FDA&#8217;s evaluation of the PMA application or the manufacturing facility is not favorable, the FDA may deny approval of the PMA application or issue a &#8220;not approvable&#8221; letter. The FDA may also require additional clinical trials, which can delay the PMA approval process by several&#160;years. In addition, if FDA discovers that an applicant has </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">210</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">submitted false or misleading information, FDA may refuse to review submissions until certain requirements are met pursuant to its Application Integrity Policy. If the FDA approves the PMA, it may place restrictions on the device. After the PMA is approved, if significant changes are made to a device, its manufacturing or labeling, a PMA supplement containing additional information must be filed for prior FDA approval. PMA supplements often must be approved by the FDA before the modification to the device, the labeling, or the manufacturing process may be implemented. Delays in receipt of or failure to receive such clearances or approvals, the loss of previously received clearances or approvals, or the failure to comply with existing or future regulatory requirements could have a material adverse effect on ARCA&#8217;s business, financial condition and results of operations.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Clinical Trials.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span>Clinical trials are generally required to support a PMA application and are sometimes required for 510(k)&#160;clearance. These trials generally require an IDE application approved in advance by the FDA for a specified number of patients, unless the proposed study is deemed a non<span class="nobreak">-significant</span> risk study, which is eligible for an exemption from the IDE requirements. The IDE application must be supported by appropriate data, such as animal and laboratory testing results. Clinical trials may begin if the IDE application is approved by the FDA and the appropriate IRBs at the clinical trial sites. Submission of an IDE application does not give assurance that the FDA will issue the IDE.&#160;If the IDE application is approved, there can be no assurance the FDA will determine that the data derived from the trials support the safety and effectiveness of the device or warrant the continuation of clinical trials. An IDE supplement must be submitted to and approved by the FDA before a sponsor or investigator may make a change to the investigational plan in such a way that may affect its scientific soundness, study indication or the rights, safety or welfare of human subjects. The trial must also comply with the FDA&#8217;s regulations, including the requirement that informed consent be obtained from each subject. Even if a trial is completed, the results of clinical testing may not adequately demonstrate the safety and efficacy of the device or may otherwise not be sufficient to obtain FDA clearance to market the product in the United&#160;States.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">In Vitro Diagnostic Companion Diagnostic Devices.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span>The FDA has described <span class="Italic" style="font-style:italic;font-weight:normal;">in vitro</span> diagnostics (&#8220;IVD&#8221;) companion diagnostic devices as in vitro diagnostic devices that provide information that is essential for the safe and effective use of a corresponding therapeutic product. The use of an IVD companion diagnostic device with a particular therapeutic product is stipulated in the instructions for use in the labeling of both the diagnostic device and the corresponding therapeutic product, as well as in the labeling of any generic equivalents of the therapeutic product. An IVD companion diagnostic device could be used to (i)&#160;identify patients who are most likely to benefit from a particular therapeutic product; (ii)&#160;identify patients likely to be at increased risk for serious adverse reactions as a result of treatment with a particular therapeutic product; or (iii)&#160;monitor response to treatment for the purpose of adjusting treatment (e.g., schedule, dose, discontinuation) to achieve improved safety or effectiveness. Although FDA&#8217;s regulation of IVD companion diagnostic devices is evolving and implemented on a case<span class="nobreak">-by-case</span> basis, FDA&#8217;s stated policy for a novel therapeutic product is that an IVD companion diagnostic device should be developed and approved or cleared contemporaneously to support the therapeutic product&#8217;s safe and effective use. The clinical performance and clinical significance of the IVD companion diagnostic device is to be established using data from the clinical development program of the corresponding therapeutic product. FDA recognizes, however, that there may be cases where contemporaneous development may not be possible. With respect to the Gencaro Test, there is no assurance that ARCA will be able to develop and obtain approval or clearance contemporaneously with Gencaro. Failure to develop the Gencaro Test or obtain clearance or approval could delay approval of Gencaro, if FDA regards the Gencaro Test as an IVD companion diagnostic test that is essential to the safe and effective use of Gencaro.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Continuing Regulation.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span>After a device is placed on the market, numerous regulatory requirements apply to the manufacturer, or holder of a PMA approval. Unless subject to an exemption, medical devices distributed in the United&#160;States must be manufactured in compliance with the FDA&#8217;s QSRs and current good manufacturing practices. These regulations govern the manufacturing process, including design, manufacture, testing, release, packaging, distribution, documentation and purchasing, as well as complaint handling, corrective and preventative actions and internal auditing. In complying with the QSRs, manufacturers must expend significant time, money and effort. Companies are also subject to other post<span class="nobreak">-market</span> and general requirements, including but not limited to product listing and establishment registration, post<span class="nobreak">-market</span> surveillance requirements, limitations on promotion, and requirements for recordkeeping and reporting of certain adverse events, malfunctions, corrections and removals. As discussed above, FDA regularly inspects companies to assess compliance with the QSRs and other post<span class="nobreak">-market</span> requirements. Failure to comply with these requirements can result in, among other things, adverse publicity, warning letters, and potential civil and criminal penalties. As part of such arrangement, ARCA will seek to have the diagnostic company take responsibility for compliance with the FDA&#8217;s device approval and on<span class="nobreak">-going</span> regulatory requirements.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">211</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">International Marketing Approvals.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span>International sales of medical devices are subject to foreign government regulations, which vary substantially from country to country and are subject to change. The time required to obtain approval by a foreign country may be longer or shorter than that required for FDA clearance or approval, and the requirements may differ.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Other Regulatory Requirements.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span>ARCA is also subject to various federal, state and local laws, regulations and recommendations relating to safe working conditions, laboratory and manufacturing practices, the experimental use of animals and the use and disposal of hazardous or potentially hazardous substances, including radioactive compounds and infectious disease agents, used in connection with its work. The extent and character of governmental regulation that might result from future legislation or administrative action cannot be accurately predicted.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Medical Device Tax</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In March&#160;2010, the U.S.&#160;Congress adopted and President Obama signed into law comprehensive health care reform legislation. Among other initiatives, these laws impose significant new taxes on medical device makers in the form of a 2.3% excise tax on U.S.&#160;medical device sales, with certain exemptions, beginning on January&#160;1, 2013. On January&#160;22, 2018, legislation was enacted suspending the medical device tax in 2018 and 2019. In December&#160;2019, a permanent repeal of the medical device tax was enacted. The Gencaro Test is likely to be subject to this tax if this tax is reinstated in the future.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Intellectual Property</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The future success of ARCA&#8217;s business will partly depend on its ability to maintain market exclusivity for its product candidates, if approved, in the United&#160;States and important international markets, and for other products or product candidates that ARCA may acquire or develop. ARCA will rely on statutory protection, patent protection, trade secrets, know<span class="nobreak">-how</span>, and in<span class="nobreak">-licensing</span> of technology rights to maintain protection for ARCA&#8217;s products.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Gencaro</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA believes that Gencaro, if approved, will have market exclusivity in the United&#160;States and in major international markets. ARCA recently obtained a patent in the United&#160;States for the use of Gencaro for the patient population ARCA plans to study in the Phase&#160;3 pivotal trial. ARCA has filed similar patent applications in international jurisdictions. If Gencaro is approved by the FDA or international regulatory agencies based on this planned clinical development, ARCA believes that the commercialization of Gencaro will have patent protection extending into 2039.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA has an existing patent portfolio of United&#160;States and international patents covering the use of Gencaro for various cardiovascular indications in the genetic population it plans to study in Phase&#160;3, that ARCA believes will provide additional patent protection.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition to patent protection, Gencaro will qualify as a new chemical entity and if approved will have data protection in the United&#160;States and other jurisdictions in which it is approved.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA also has other patent rights in additional drug candidates having possible indications in cardiovascular disease, oncology, and other therapeutic areas; these are in both early and later stages of development. ARCA may seek collaborators to assist it in the development of these candidates or it may seek to raise funds to advance the development of the compounds on its own.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Information about ARCA&#8217;s Executive Officers</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Information relating to ARCA&#8217;s executive officers is included under &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">ARCA&#8217;s Directors, Executive Officers and Corporate Governance</span>&#8221; in the proxy statement/prospectus and such information is incorporated herein by reference.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Human Capital Management</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of March&#160;31, 2024, ARCA had 5 employees, 4 of which are full<span class="nobreak">-time</span>. None of ARCA&#8217;s employees are represented by any collective bargaining unit. ARCA believes that it maintains good relations with its employees.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">212</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Information relating to compensation of ARCA executive officers is included in &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">ARCA&#8217;s Executive Compensation</span>&#8221; of this proxy statement/prospectus and such information is incorporated herein by reference. The structure of ARCA&#8217;s compensation programs balances incentive earnings for both short<span class="nobreak">-term</span> and long<span class="nobreak">-term</span> performance. ARCA is committed to providing comprehensive benefit options and offering benefits that will allow ARCA&#8217;s employees and their families to live healthier and more secure lives. Some examples are employees are eligible for health insurance, prescription drug benefits, dental insurance, vision insurance, life insurance, disability insurance, health savings accounts, flexible spending accounts, paid and unpaid leaves, a retirement plan and life and disability/accident coverage. ARCA also offers a variety of voluntary benefits that allow employees to select the options that meet their needs, including hospital indemnity insurance, accident insurance and critical illness insurance.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA continually monitors employee turnover rates as its success depends upon retaining its highly trained personnel. ARCA believes the combination of competitive compensation and career growth and development opportunities have helped increase employee tenure and reduce voluntary turnover. The average tenure of ARCA&#8217;s employees, as of March&#160;31, 2024, was approximately eleven&#160;years and approximately 40% of ARCA&#8217;s employees, as of March&#160;31, 2024, have been employed by ARCA for more than ten&#160;years.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA&#8217;s Corporate Information</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On January&#160;27, 2009, ARCA completed a business combination between Nuvelo, Inc., a corporation originally incorporated in 1992, and its subsidiary, ARCA biopharma, Inc. Immediately following the business combinations, ARCA changed its name from Nuvelo, Inc. to ARCA biopharma, Inc. ARCA&#8217;s principal offices are located in Westminster, Colorado.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA files its annual reports on Form&#160;10<span class="nobreak">-K</span>, quarterly reports on Form&#160;10<span class="nobreak">-Q</span> and current reports on Form&#160;8<span class="nobreak">-K</span> pursuant to Section&#160;13(a)&#160;or 15(d)&#160;of the Exchange&#160;Act electronically with the SEC.&#160;The SEC maintains an Internet site that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC.&#160;The address of that site is <span class="Italic" style="font-style:italic;font-weight:normal;">http://www.sec.gov</span>.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">You may obtain a free copy of ARCA&#8217;s annual reports on Form&#160;10<span class="nobreak">-K</span>, quarterly reports on Form&#160;10<span class="nobreak">-Q</span>, current reports on Form&#160;8<span class="nobreak">-K</span> and amendments to those reports on ARCA&#8217;s website at <span class="Italic" style="font-style:italic;font-weight:normal;">http://www.arcabiopharma.com</span> on the earliest practicable date following the filing with the SEC or by contacting the Investor Relations Department at ARCA&#8217;s corporate office by calling (720)&#160;940<span class="nobreak">-2100</span>. Information found on ARCA&#8217;s website is not incorporated by reference into this report.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Properties and Facilities</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s headquarters facility consists of approximately 5,200 square feet of office space in Westminster, Colorado, of which approximately 5,200 square feet is leased until September&#160;2024, after which ARCA can continue to lease on a month<span class="nobreak">-to-month</span> basis. ARCA believes that this facility is adequate to meet its current needs.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Legal Proceedings</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">From time to time, ARCA may become involved in legal proceedings. Except for as disclosed herein, ARCA is not currently a party to or aware of any proceedings that it believes will have, individually or in the aggregate, a material adverse effect on its business, financial condition or results of operations. Regardless of outcome, litigation can have an adverse impact on ARCA because of defense and settlement costs, diversion of management resources and other factors.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of July<span class="nobreak"> </span>8, 2024, one complaint has been filed by a purported ARCA stockholder against ARCA and ARCA&#8217;s board of directors in connection with the proposed Merger.  On May<span class="nobreak"> </span>20, 2024, a purported stockholder filed a complaint, captioned Wynter v. ARCA biopharma, Inc., et al., No.: 1:24<span class="nobreak">-cv-1418-STV</span> (D. Colo.) (the &#8220;Complaint&#8221;), against ARCA and ARCA&#8217;s board of directors. The Complaint alleges that the defendants filed or caused to be filed a materially incomplete and misleading preliminary registration statement with the SEC and asserts claims under Sections 14(a) and 20(a) of the Exchange Act. The Complaint seeks an order enjoining the proposed Merger, or in the event that the proposed Merger is consummated, an order rescinding the Merger or awarding rescissory damages, as well as costs, including attorneys&#8217; and experts&#8217; fees. ARCA cannot predict the outcome of the Complaint. ARCA believes that the allegations and claims asserted in the Complaint are without merit and intends to defend against them vigorously. Additional lawsuits arising out of the Merger may be filed.</p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">213</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T12"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">ORUKA&#8217;S BUSINESS</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">All references to Oruka&#8217;s &#8220;product candidates,&#8221; &#8220;programs,&#8221; &#8220;portfolio&#8221; and &#8220;pipeline&#8221; in this proxy statement/prospectus refer to the research programs with respect to which Oruka has the option to acquire intellectual property license rights to pursuant to the Paragon Option Agreements.</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Overview</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka is a biotechnology company focused on developing novel monoclonal antibody therapeutics for PsO and other&#160;I&amp;I indications. Oruka&#8217;s name is derived from <span class="Italic" style="font-style:italic;font-weight:normal;">or</span>, for &#8220;skin,&#8221; and <span class="Italic" style="font-style:italic;font-weight:normal;">arukah</span>, for &#8220;restoration&#8221; and reflects the company&#8217;s mission to deliver therapies for chronic skin diseases that provide patients the most possible freedom from their condition. Oruka&#8217;s strategy is to apply antibody engineering and format innovations to validated modes of action, which Oruka believes will enable it to improve meaningfully upon the efficacy and dosing regimens of standard<span class="nobreak">-of-care</span> medicines while significantly reducing technical and biological risk. Oruka&#8217;s programs aim to treat and potentially modify disease by targeting mechanisms with proven efficacy and safety involved in disease pathology and the activity of pathogenic tissue<span class="nobreak">-resident</span> memory T cells (&#8220;TRMs&#8221;). Oruka&#8217;s lead program, ORKA<span class="nobreak">-001</span>, is designed to target the p19 subunit of interleukin<span class="nobreak">-23</span> (IL<span class="nobreak">-23p19</span>) for the treatment of PsO.&#160;Oruka&#8217;s co<span class="nobreak">-lead</span> program, ORKA<span class="nobreak">-002</span>, is designed to target interleukin<span class="nobreak">-17A</span> and interleukin<span class="nobreak">-17F</span> (&#8220;IL<span class="nobreak">-17A</span>/F&#8221;) for the treatment of PsO, PsA, and other conditions. These programs each bind their respective targets at high affinity and incorporate half<span class="nobreak">-life</span> extension technology with the aim to increase exposure and decrease dosing frequency. Oruka believes that its focused strategy, differentiated portfolio, and deep expertise position it to set a new treatment standard in large&#160;I&amp;I markets with continued unmet need.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Oruka&#8217;s Pipeline</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;text-align:center;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><img alt="" src="timage_001.jpg" style="width:596.48px;max-width:100%;"/></span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">ORKA-001</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ORKA<span class="nobreak">-001</span> is a high affinity, extended half<span class="nobreak">-life</span> monoclonal antibody (&#8220;mAb&#8221;) designed to target IL<span class="nobreak">-23p19</span>. IL<span class="nobreak">-23</span> is a pro<span class="nobreak">-inflammatory</span> cytokine that plays a critical role in the proliferation and development of T helper 17 (&#8220;Th17&#8221;) cells, which are the primary drivers of several autoimmune and inflammatory disorders, including PsO. IL<span class="nobreak">-23</span> is composed of two subunits: a p40 subunit that is shared with IL<span class="nobreak">-12</span> and a p19 subunit that is specific to IL<span class="nobreak">-23</span>. First<span class="nobreak">-generation</span> IL<span class="nobreak">-23</span> antibodies bound p40 and inhibited both IL<span class="nobreak">-12</span> and IL<span class="nobreak">-23</span> signaling, while more recent IL<span class="nobreak">-23</span> antibodies targeting the p19 subunit have shown improved efficacy and safety. Based on preclinical evidence, Oruka believes that ORKA<span class="nobreak">-001</span> could achieve higher response rates than established therapies in PsO while requiring less frequent dosing and maintaining the favorable safety profile of therapies targeting IL<span class="nobreak">-23p19</span>. ORKA<span class="nobreak">-001</span> is engineered with YTE half<span class="nobreak">-life</span> extension technology, a specific three amino acid change in the fragment crystallizable (&#8220;Fc&#8221;) domain to modify the pH<span class="nobreak">-dependent</span> binding to the neonatal Fc receptor (&#8220;FcRn&#8221;). As a result, it has a pharmacokinetic profile designed to support a subcutaneous (&#8220;SQ&#8221;) injection as infrequently as once or twice a year. In addition, emerging evidence suggests that IL<span class="nobreak">-23</span> blockade can modify the disease biology of PsO, possibly leading to durable remissions and preventing the development of PsA.&#160;Oruka believes that the expected characteristics of ORKA<span class="nobreak">-001</span> increase its potential to deliver these disease<span class="nobreak">-modifying</span> benefits. Oruka plans to initiate a Phase&#160;1 trial of ORKA<span class="nobreak">-001</span> in the first half of 2025 that will have the potential not only to generate important pharmacokinetic and safety data but also to demonstrate its efficacy in PsO patients.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">214</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">PsO is a chronic autoimmune skin disorder that affects an estimated 125&#160;million people worldwide with steadily increasing prevalence. It is the largest pharmaceutical market within dermatology, with annual sales of approximately $25&#160;billion in 2022, which is estimated to grow to $32&#160;billion by 2028. Around half of PsO patients have moderate or severe disease that cannot be adequately addressed by topical corticosteroids or oral therapies. The American Academy of Dermatology<span class="nobreak">-National</span> Psoriasis Foundation recommends biologics as first<span class="nobreak">-line</span> therapy for moderate<span class="nobreak">-to-severe</span> PsO.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Several classes of biologic therapies have been approved for PsO over the past 20&#160;years, resulting in progressively more complete symptom relief. Efficacy in PsO is typically measured via the psoriasis area and severity index (&#8220;PASI&#8221;) scoring system. The first biologics approved for PsO were tumor necrosis alpha (&#8220;TNF<span class="nobreak">-</span><span class="nobreak" style="font-family:Times New Roman, serif;font-style:normal;font-weight:normal;">&#945;</span>&#8221;) inhibitors such as Enbrel (etanercept), Humira (adalimumab), and Remicade (infliximab), which achieved a 90%&#160;improvement in PASI score (&#8220;PASI 90&#8221;) at 16&#160;weeks in around&#160;25&#160;&#8211;&#160;50% of patients and a 100% improvement in PASI score (&#8220;PASI 100&#8221;) in&#160;around 5&#160;&#8211;&#160;20% of patients. Stelara (ustekinumab), which targets the p40 subunit of IL<span class="nobreak">-23</span> that is shared with IL<span class="nobreak">-12</span>, was approved next and achieved efficacy on par with Humira. IL<span class="nobreak">-17A</span> inhibitors Cosentyx (secukinumab), Taltz (ixekizumab), and Siliq (brodalumab) followed and achieved responses of PASI 90 in around&#160;70% of patients and PASI 100 in&#160;around 40% of patients with some risk of certain side effects such as oral candidiasis. Most recently, IL<span class="nobreak">-23p19</span> inhibitors such as Ilumya (tildrakizumab), Tremfya (guselkumab), and Skyrizi (risankizumab) have achieved responses of PASI 90 in&#160;around 70&#160;&#8211;&#160;80% of patients and PASI 100 in around 30&#160;&#8211;&#160;50% of patients with highly tolerable profiles. Finally, IL<span class="nobreak">-17A</span>/F inhibitors such as Bimzelx (bimekizumab) have recently shown even higher response rates than IL<span class="nobreak">-23</span> inhibitors, but with slightly less tolerable profiles.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Treatment expectations in PsO have evolved progressively with this continued innovation. A 75% improvement in PASI score was previously thought to be an adequate depth of response, and weekly SQ dosing was viewed as acceptable. With each subsequent generation of innovation, patient and caregiver expectations have advanced. Today, Skyrizi, is widely viewed as the leader in PsO biologic therapy and achieves PASI 100 in&#160;40&#160;&#8211;&#160;50% of patients at the 16<span class="nobreak">-week</span> primary endpoint with maintenance dosing every three&#160;months. While this is a remarkable advancement, there is still significant unmet need. Approximately half of moderate<span class="nobreak">-to-severe</span> PsO patients do not achieve full skin clarity, and a continued desire for more convenient dosing options has driven significant interest in orally delivered medicines targeting these same pathways. However, oral therapies have yet to match the efficacy and safety profile of biologics. Oruka believes that a long<span class="nobreak">-acting</span> biologic with higher efficacy and potential for disease modification represents the next step in advancing the standard of care in PsO.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ORKA<span class="nobreak">-001</span> is expected to enter Phase&#160;1 clinical trials in the first half of 2025. Oruka plans to carry out a Phase&#160;1 program that could provide validation of half<span class="nobreak">-life</span> extension in 2025. In addition, Oruka plans to include PsO patients in its Phase&#160;1 program, which would give Oruka the opportunity to demonstrate 16<span class="nobreak">-week</span> PASI response rates by the end of 2026. Oruka then plans to proceed into Phase&#160;2/3 development. Based on recent precedent for PsO, Oruka anticipates that the entire development program from first<span class="nobreak">-in-human</span> to biologics license application (&#8220;BLA&#8221;) filing could take as little as six to seven&#160;years based on the averages for recently approved medicines. However, Oruka has no control over the length of time needed for FDA review, and this timeline could vary.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ORKA-002</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ORKA<span class="nobreak">-002</span> is a high affinity, extended half<span class="nobreak">-life</span> mAb designed to target IL<span class="nobreak">-17A</span> and IL<span class="nobreak">-17F</span> (IL<span class="nobreak">-17A</span>/F). IL<span class="nobreak">-17</span> inhibition has become central to the treatment of psoriatic diseases, including PsO and PsA, and has also shown efficacy in other&#160;I&amp;I indications, such as hidradenitis suppurativa (&#8220;HS&#8221;) and axial spondyloarthritis (&#8220;axSpA&#8221;). More recently, the importance of inhibiting the IL<span class="nobreak">-17F</span> isoform along with IL<span class="nobreak">-17A</span> has become appreciated, and dual blockade with the recently approved therapy Bimzelx (bimekizumab) has led to higher response rates in patients than blockade of IL<span class="nobreak">-17A</span> alone. ORKA<span class="nobreak">-002</span> is designed to bind IL<span class="nobreak">-17A</span>/F at similar epitopes, or binding sites, and affinity ranges as bimekizumab, but incorporates half<span class="nobreak">-life</span> extension technology that could enable more convenient dosing intervals. Oruka plans to initiate Phase&#160;1 trials of ORKA<span class="nobreak">-002</span> in the second half of 2025.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka views ORKA<span class="nobreak">-002</span> and ORKA<span class="nobreak">-001</span> as highly complementary. Patients with moderate<span class="nobreak">-to-severe</span> PsO that have purely skin manifestations are most often treated with IL<span class="nobreak">-23</span> inhibitors due to the high efficacy and tolerability of this mechanism. However, for patients who also have joint involvement, or signs and symptoms of </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">215</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">PsA, an IL<span class="nobreak">-17</span> inhibitor is typically used due to its efficacy in addressing both skin and joint symptoms. In addition, IL<span class="nobreak">-17</span> inhibitors are often used in patients with highly resistant skin symptoms that do not adequately resolve through treatment with an IL<span class="nobreak">-23</span> inhibitor. Together, ORKA<span class="nobreak">-001</span> and ORKA<span class="nobreak">-002</span> provide the potential to offer a highly compelling product profile for most patients with PsO and/or PsA, as well as the opportunity to address additional&#160;I&amp;I indications.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Additional Pipeline Programs</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka has a third mAb program, ORKA<span class="nobreak">-003</span>, designed to target an undisclosed pathway. Oruka&#8217;s strategy as a company is to remain highly focused on&#160;I&amp;I diseases, and specifically on inflammatory dermatology conditions. Oruka&#8217;s third program provides the potential for indication expansion beyond PsO and creates combination opportunities with Oruka&#8217;s more advanced programs.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Oruka&#8217;s Team, Investors, and Paragon Collaboration</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka was founded in February&#160;2024 by leading healthcare investor Fairmount Funds Management and hold options to acquire intellectual property rights with respect to certain research programs, including ORKA<span class="nobreak">-001</span> and ORKA<span class="nobreak">-002</span>, from Paragon. Fairmount Funds Management has launched other successful biotechnology companies leveraging antibody technologies generated by Paragon, including Apogee Therapeutics and Spyre Therapeutics. Oruka is led by a management team with significant experience in developing novel treatments for patients at biopharmaceutical companies such as CRISPR Therapeutics, Celgene, Novartis, and Protagonist Therapeutics. Together, Oruka&#8217;s team has a proven track record of building successful biotech organizations in high<span class="nobreak">-growth</span> environments.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Since its inception, Oruka has raised $3.0&#160;million in gross proceeds from the issuance of Series&#160;A convertible preferred stock and $25.0&#160;million in gross proceeds from the issuance of the Convertible Note. On April&#160;3, 2024, Oruka entered into a definitive merger agreement with ARCA to create a new public company focused on advancing Oruka&#8217;s pipeline of antibody therapies. In support of the Merger, Oruka has secured commitments for a $275.0&#160;million private investment (which includes $25.0<span class="nobreak"> </span>million of proceeds previously received from the issuance of the Convertible Note and accrued interest on such note) in Oruka common stock and pre<span class="nobreak">-funded</span> warrants to purchase Oruka common stock from a syndicate of premier healthcare investors led by Fairmount Funds Management and Venrock Healthcare Capital Partners, with participation from RTW Investments, Access Biotechnology, Commodore Capital, Deep Track Capital, Perceptive Advisors, Blackstone Multi<span class="nobreak">-Asset</span> Investing, Avidity Partners, Great Point Partners LLC, Paradigm BioCapital, Braidwell LP, and Redmile Group, as well as other investors, including multiple large investment management firms, that is expected to close immediately prior to completion of the Merger.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Following the exercise of its Options (defined below) under the Paragon Option Agreements and execution of the respective license agreements, Oruka will have exclusive worldwide development and commercialization rights to Oruka&#8217;s programs, with IL<span class="nobreak">-23</span> rights for all indications outside of inflammatory bowel disease (&#8220;IBD&#8221;), pursuant to such agreements, as applicable. Fairmount Funds Management founded Paragon in 2021 as the firm&#8217;s discovery engine for biologics that potentially overcome limitations of existing therapies. Paragon leverages a dedicated in<span class="nobreak">-house</span> team of scientific experts in antibody development, as well as its partnership with FairJourney Biologics, to generate unique therapeutic concepts and enable its rapid proof<span class="nobreak">-of-concept</span> validation. Oruka considers Paragon to be a related party. See the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Certain Relationships and Related Party Transactions&#160;&#8212;&#160;Oruka Transactions&#160;&#8212;&#160;Oruka&#8217;s Relationship with Paragon and Paruka</span>&#8221; for additional information.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">216</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Oruka&#8217;s Strategy</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">To achieve its goal of developing leading therapeutic antibodies for patients with inflammatory skin diseases, Oruka is applying antibody engineering to validated modes of action. Oruka believes this approach will enable it to improve meaningfully upon the efficacy and convenience of standard<span class="nobreak">-of-care</span> medicines while significantly reducing technical and biological risk. The key elements of Oruka&#8217;s strategy include:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Employ advanced antibody engineering to build biologics that could significantly improve upon existing therapies:&#160;&#160;&#160;&#160;</span>Oruka and its collaborators at Paragon have optimized a variety of parameters using a suite of antibody technologies to develop candidates with the potential to improve upon existing therapies. These parameters include extending half<span class="nobreak">-life</span> to increase exposure and reduce dosing frequency, enhancing affinity and specificity to maximize potency and safety, and optimizing developability to ensure consistency and enable convenient, high<span class="nobreak">-dose</span> formulations. Together, Oruka believes these features have the potential to translate into more efficacious and convenient medicines for patients.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Target validated mechanisms of action:&#160;&#160;&#160;&#160;</span>Oruka&#8217;s initial targets, IL<span class="nobreak">-23p19</span> and IL<span class="nobreak">-17A</span>/F, have established efficacy and safety for the treatment of PsO, PsA, and other indications. The FDA has approved four biologics in the IL<span class="nobreak">-23</span> class, including three targeting IL<span class="nobreak">-23p19</span>, and four biologics in the IL<span class="nobreak">-17</span> class, including one targeting IL<span class="nobreak">-17A</span>/F.&#160;While these therapies have advanced the standard of care in PsO and PsA, they have not addressed these diseases completely, and a significant fraction of patients do not achieve complete skin clearance. By applying Oruka&#8217;s advanced antibody engineering to these validated targets, Oruka believes it can maximize its chances of developing superior medicines for patients. In addition, the reduced technical and biological risk of these validated mechanisms may allow Oruka to progress its programs more efficiently and rapidly.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Leverage insights from earlier entrants to optimize Oruka&#8217;s approach:&#160;&#160;&#160;&#160;</span>Oruka benefits from a large body of clinical evidence generated by prior therapies targeting IL<span class="nobreak">-23</span> and IL<span class="nobreak">-17</span>. Oruka continues to extract and apply learnings from this precedent to its programs, including in development candidate selection, clinical trial design, dosing regimens, formulations and presentations, regulatory pathway, and indication prioritization. For instance, based on correlations between affinity and efficacy, Oruka has designed ORKA<span class="nobreak">-001</span> and ORKA<span class="nobreak">-002</span> to bind to similar epitopes and at similar or greater affinities as the leading antibodies in each class: risankizumab and bimekizumab, respectively, with the aim of maximizing efficacy. Also, by understanding the exposure<span class="nobreak">-response</span> relationships for efficacy and safety for other therapies, Oruka plans to select dose levels and regimens that could maximize efficacy and maintenance of response while maintaining safety.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Pursue opportunities with strong prospects of yielding meaningful new medicines as a &#8220;base case&#8221; and the potential to shift the treatment paradigm entirely as an &#8220;upside case&#8221;:&#160;&#160;&#160;&#160;</span>Oruka&#8217;s strategy seeks to maximize the potential for Oruka&#8217;s programs to reach a base case product profile that could meaningfully advance the standard of care&#160;&#8212;&#160;for instance, for ORKA<span class="nobreak">-001</span>, SQ dosing one or twice a year with equal or greater efficacy compared to today&#8217;s standard of care. At the same time, Oruka aims to deliver an upside case that dramatically improves outcomes for patients&#160;&#8212;&#160;for instance, significantly increasing rates of complete skin clearance via higher antibody exposures or offering patients durable remissions free from therapy by introducing patient<span class="nobreak">-specific</span> dosing intervals.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Build a preeminent biotechnology company focused on chronic skin disease and other&#160;I&amp;I indications:&#160;&#160;&#160;&#160;</span>Oruka is assembling a team of exceptional people and helping them reach their full potential and flourish so that together it can bring forward meaningful new medicines for patients.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka believes that pursuing the focused strategy outlined above will help it to succeed in its mission of offering patients living with PsO, PsA, and other dermatologic and inflammatory diseases the greatest possible freedom from their condition.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Targeting IL-23 and IL-17 to Treat Multiple&#160;I&amp;I Indications</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka&#8217;s programs benefit from significant advances in the understanding of the biology of&#160;I&amp;I diseases over the past four decades. ORKA<span class="nobreak">-001</span> and ORKA<span class="nobreak">-002</span> are designed to target two key cytokines that play a related role in multiple indications. IL<span class="nobreak">-23</span> is an upstream regulator of Th17 cells, a pro<span class="nobreak">-inflammatory</span> subset of T helper cells </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">217</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">characterized by their production of IL<span class="nobreak">-17</span>. IL<span class="nobreak">-23</span> has a critical role in maintaining Th17 cells in the tissue as well as activating these cells to secrete IL<span class="nobreak">-17</span>, which acts downstream to trigger inflammation and other disease symptoms. Th17 cells are involved in PsO, PsA, HS, axSpA, and many other diseases. They play a particularly central role in PsO and PsA.&#160;The diagram below depicting the immunopathogenesis of PsO provides an example of how Th17 cells can mediate disease and how blocking IL<span class="nobreak">-23</span> or IL<span class="nobreak">-17</span> can break the inflammatory cycle that drives disease.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Immunopathogenesis of PsO and the role of IL-23 and IL-17</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;"><img alt="" src="timage_002.jpg" style="width:599.04px;max-width:100%;"/></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">PsO develops when environmental triggers and a genetic predisposition combine to cause activation of an inflammatory cycle in the skin that leads to the formation of plaques and other disease manifestations. This process begins with the aberrant activation of the dendritic cells (&#8220;DCs&#8221;), specifically those producing IL<span class="nobreak">-23</span> and other cytokines like IL<span class="nobreak">-1</span><span class="nobreak" style="font-family:Times New Roman, serif;font-style:normal;font-weight:normal;">&#946;</span>, IL<span class="nobreak">-21</span>, TNF<span class="nobreak">-</span><span class="nobreak" style="font-family:Times New Roman, serif;font-style:normal;font-weight:normal;">&#945;</span>, and IL<span class="nobreak">-12</span>. These cytokines induce the differentiation of Th17 cells, as well as other cell types, such as T helper type 1 (&#8220;Th1&#8221;) cells that produce IFN<span class="CharOverride-1" style="font-family:Times New Roman, serif;font-style:normal;font-weight:normal;">&#947;</span> and TNF<span class="nobreak">-</span><span class="nobreak" style="font-family:Times New Roman, serif;font-style:normal;font-weight:normal;">&#945;</span> and T helper type 22 (&#8220;Th22&#8221;) cells that produce IL<span class="nobreak">-22</span>. IL<span class="nobreak">-23</span> plays a key role in the differentiation and activation of Th17 cells to secrete IL<span class="nobreak">-17</span>, as well as Th22 cells to produce IL<span class="nobreak">-22</span>. IL<span class="nobreak">-17</span> and these other cytokines induce keratinocyte hyperproliferation leading to plaque formation and a feedforward inflammatory response, with changes in gene expression in keratinocytes, the production of antimicrobial peptides, and neutrophil recruitment driving further inflammation. While many cytokines and cell types contribute to the pathogenesis of PsO, the IL<span class="nobreak">-23</span>/IL<span class="nobreak">-17</span> axis plays an important role, as supported by the success of therapies targeting this axis.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">While the successful treatment of PsO&#160;&#8212;&#160;for instance, with mAbs targeting IL<span class="nobreak">-23</span> or IL<span class="nobreak">-17</span> &#8212;&#160;can result in lesional skin returning to an apparently normal state, disease tends to recur at previously affected sites following cessation of therapy, suggesting a mechanism of &#8220;immunological memory&#8221; that predisposes individuals to recurrence in the same locations. Evidence suggests that pathogenic TRMs play a critical role in this memory. TRMs may arise from the Th17 cells and other cells that drove disease in the first place and remain in their resident tissue, in this case the epidermis and dermis, for long periods of time. Upon a disease trigger, these TRMs can actively produce proinflammatory cytokines, causing disease recurrence. IL<span class="nobreak">-23</span> appears to play an important role in maintaining and </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">218</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">potentiating TRMs, as indicated by the depletion of TRMs following treatment with an IL<span class="nobreak">-23</span> inhibitor but not an IL<span class="nobreak">-17</span> inhibitor, which may explain the longer remissions observed with IL<span class="nobreak">-23</span> inhibitors following withdrawal of therapy. This type of data has raised the prospect that efficient IL<span class="nobreak">-23</span> blockade could modify the disease biology of PsO, possibly leading to durable remissions.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The scientific discoveries that refined our understanding of the immunopathogenesis of PsO have led to waves of therapeutic advances, ultimately leading to today&#8217;s standard of care. Before the 1980s, PsO was not even thought of as an immunologic disease, but rather a disease of keratinocyte dysfunction, leading to treatments such as phototherapy, methotrexate, and retinoids. The discovery in the 1980s that PsO results from immune dysfunction led to the use of broad immunosuppressants like cyclosporine. From 1990 to 2008, it was believed that Th1 cells, a subpopulation of T helper cells that produce pro<span class="nobreak">-inflammatory</span> cytokines such as IFN<span class="CharOverride-1" style="font-family:Times New Roman, serif;font-style:normal;font-weight:normal;">&#947;</span> and TNF<span class="nobreak">-</span><span class="nobreak" style="font-family:Times New Roman, serif;font-style:normal;font-weight:normal;">&#945;</span>, were the predominant mediators of the disease, which led to the use of biologics targeting TNF<span class="nobreak">-</span><span class="nobreak" style="font-family:Times New Roman, serif;font-style:normal;font-weight:normal;">&#945;</span> such as Enbrel (etanercept) and Humira (adalimumab). Finally, the revelation that PsO is driven principally by Th17 cells resulted in the development of the primary therapies used today, which target IL<span class="nobreak">-23</span> and IL<span class="nobreak">-17</span>. This increasingly refined understanding of the disease has narrowed the standard of care from broad immunosuppressive agents (such as cyclosporine) to more specific immunomodulators (TNF<span class="nobreak">-</span><span class="nobreak" style="font-family:Times New Roman, serif;font-style:normal;font-weight:normal;">&#945;</span> inhibitors) to precise biologic therapies targeting the key cytokines involved in disease pathology (IL<span class="nobreak">-23</span> and IL<span class="nobreak">-17</span> inhibitors), with each new therapeutic class raising the bar on both safety and efficacy.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Biologic therapies, especially mAbs, are now mainstays in the treatment of a wide variety of&#160;I&amp;I diseases, including PsO and PsA.&#160;Each biologic approved in PsO has raised the bar on standard of care, with therapies that have improved upon efficacy and/or reduced dosing frequency achieving the most commercial success, even when launching many&#160;years after other biologics. Enbrel was first approved for PsO in 2004 with a weekly maintenance dosing schedule. Four&#160;years later, Humira was approved for PsO with an every<span class="nobreak">-other-week</span> (Q2W) dosing schedule. Stelara (ustekinumab) was approved a year later with similar Phase&#160;3 data to Humira, but with a significantly improved dosing schedule of every twelve&#160;weeks (Q12W). Several drugs for PsO have been approved since 2009 that demonstrated higher efficacy in their pivotal studies compared to Stelara, but with more burdensome dosing schedules, including Tremfya (guselkumab), which has a dosing schedule of every eight&#160;weeks (Q8W), and Cosentyx (secukinumab) and Taltz (ixekizumab), which have dosing schedules of every four&#160;weeks (Q4W). While these therapies have all become generally successful products, the most commercially successful drug in the PsO market today is Skyrizi (risankizumab), which combines Stelara&#8217;s Q12W dosing schedule with improvements in efficacy, as evidenced by higher PASI 90 and PASI 100 rates in clinical trials. In addition, Bimzelx (bimekizumab), approved by the FDA in 2023, has shown evidence of efficacy that exceeds even Skyrizi, though with a less convenient Q8W dosing schedule. Although many biologics have entered the PsO market over the past two decades, new entrants have had significant commercial success when they have improved upon efficacy and/or dosing frequency, and room remains to improve in both areas to set a new standard for the treatment of PsO.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Biologics have raised the bar on the standard of care in PsO, but leave room for improvement</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;text-align:center;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><img alt="" src="timage_003.jpg" style="width:500.48px;max-width:100%;"/></span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">219</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The biology driving PsO and PsA is well understood today, and the standard of care has progressed dramatically. Oruka believes that it is unlikely that a novel mechanism will emerge that is as safe and efficacious as targeting the IL<span class="nobreak">-23</span>/IL<span class="nobreak">-17</span> axis. Therefore, Oruka believes that innovation now should be focused on optimizing the product profile that can be offered to patients. While much effort is being directed toward daily oral formats to inhibit this axis, oral medicines have yet to match the efficacy of biologics. Oruka believes that a better biologic with a longer dosing interval and the potential for improved efficacy will present a more attractive product profile for most patients.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Overview of Psoriasis (PsO)</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">PsO is a chronic autoimmune skin disorder that affects an estimated 125&#160;million people worldwide with steadily increasing prevalence, estimated to be around&#160;2&#160;&#8211;&#160;3% of the population currently, according to the World Psoriasis Day consortium. The most common form of PsO is plaque psoriasis. Patients with chronic plaque psoriasis have well<span class="nobreak">-demarcated</span>, erythematous plaques with overlying, coarse, silvery<span class="nobreak">-scaled</span> patches. These plaques can occur anywhere on the body, though are typically found on the scalp, extensor areas of the knees and elbows, and gluteal cleft. Involvement of the palms, soles, or nails, and intertriginous areas, including the genitals, can also occur and can be particularly difficult to treat. Around half of PsO patients have moderate disease, defined as having 3% to 10% of the body surface area (&#8220;BSA&#8221;) involved, or severe disease, defined as having more than 10% BSA involvement. The chronic inflammation in PsO is associated with multiple comorbidities, including PsA, obesity, metabolic syndrome, hypertension, diabetes, and atherosclerotic cardiovascular disease.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As discussed earlier, PsO is a complex immune<span class="nobreak">-mediated</span> disease driven primarily by Th17 cells and the cytokines IL<span class="nobreak">-23</span> and IL<span class="nobreak">-17</span>. The interplay of environmental and behavioral risk factors and genetics is believed to trigger PsO.&#160;Multiple lines of evidence support a genetic component to the disease, including the observation that approximately 40% of patients with PsO and PsA have a family history of the disease and the identification of multiple susceptibility loci, many containing genes related to the regulation of the immune system, in genome<span class="nobreak">-wide</span> association studies.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Current PsO Treatments and Limitations</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">While patients with mild PsO typically rely on topical corticosteroids or oral therapies like Otezla (apremilast), these agents often do not provide an adequate response for patients with moderate<span class="nobreak">-to-severe</span> PsO.&#160;As a result, the American Academy of Dermatology<span class="nobreak">-National</span> Psoriasis Foundation recommends biologics as first<span class="nobreak">-line</span> therapy for moderate<span class="nobreak">-to-severe</span> PsO.&#160;Today, Skyrizi (risankizumab) is widely viewed as the leader in PsO biologic therapy. In Phase&#160;3 clinical trials, 43% and 58% of patients achieved PASI 100 at 16 and 52&#160;weeks, respectively, with SQ maintenance dosing every three&#160;months. Most recently, Bimzelx (bimekizumab) has shown evidence of efficacy that exceeds even Skyrizi, achieving a 64% PASI 100 rate at 16&#160;weeks in Phase&#160;3 trials. However, the increased efficacy comes with a less convenient Q8W dosing schedule and an increased risk of certain side effects, most notably oral candidiasis. While agents like Skyrizi and Bimzelx reflect the remarkable advancement in PsO treatment, there remains significant unmet need. Approximately half of moderate<span class="nobreak">-to-severe</span> PsO patients do not achieve full skin clarity, and while early signs are present, the promise of disease modifying therapy remains unrealized. Oruka believes that ORKA<span class="nobreak">-001</span> and ORKA<span class="nobreak">-002</span> could represent the next step in biologic innovation in PsO, with the potential for higher rates of complete skin clearance, more durable remissions, and markedly more convenient dosing regimens.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Overview of Psoriatic Arthritis (PsA)</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">PsA is a chronic inflammatory condition that affects both the skin and joints, and often coexists with PsO.&#160;Around a quarter to a third of patients with moderate<span class="nobreak">-to-severe</span> PsO also have PsA.&#160;Most individuals develop PsO before being diagnosed with PsA, with a median gap of seven to eight&#160;years between the diagnosis of skin and joint disease, though in up to 30% of patients with PsA, joint symptoms appear before or simultaneously with skin manifestations. Patients with PsA present with joint pain, stiffness, and swelling affecting the peripheral joints, axial skeleton, or both. Entheses, dactylitis, nail lesions, fatigue, and ocular inflammation all occur commonly. PsA can lead to irreversible joint damage, including bony fusion across a joint (ankylosis). The pathogenesis of PsA is likely to be closely related to the mechanisms that underlie PsO.&#160;Like PsO, the exact cause of PsA remains unknown, but environmental triggers, including infection and trauma, and genetic factors play a role.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">220</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Current PsA Treatments and Limitations</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Effective treatment of PsA requires a coordinated approach to address the unique combination of disease manifestations each patient has, which can include peripheral and axial arthritis, enthesitis, dactylitis, and skin and nail involvement. Many patients with milder disease symptoms will start with nonsteroidal anti<span class="nobreak">-inflammatory</span> drugs (&#8220;NSAIDs&#8221;) and/or local treatments to address specific disease manifestations. However, those with more moderate or severe disease and/or multidomain involvement will typically receive a biologic therapy targeting TNF<span class="nobreak">-</span><span class="nobreak" style="font-family:Times New Roman, serif;font-style:normal;font-weight:normal;">&#945;</span> or IL<span class="nobreak">-17</span>, or less commonly an oral Janus kinase (&#8220;JAK&#8221;) inhibitor. Comorbid conditions can also influence treatment selection. For example, an IL<span class="nobreak">-17</span> inhibitor would be preferred for a patient with significant skin involvement, but not for patients with IBD or ocular symptoms, where a TNF<span class="nobreak">-</span><span class="nobreak" style="font-family:Times New Roman, serif;font-style:normal;font-weight:normal;">&#945;</span> inhibitor would be preferred. The most common endpoint used to measure the efficacy of TNF<span class="nobreak">-</span><span class="nobreak" style="font-family:Times New Roman, serif;font-style:normal;font-weight:normal;">&#945;</span> or IL<span class="nobreak">-17</span> inhibitors in PsA is ACR response, or the proportion of patients achieving a specified percent improvement in American College of Rheumatology (&#8220;ACR&#8221;) score, which measures peripheral joint disease. Approved TNF<span class="nobreak">-</span><span class="nobreak" style="font-family:Times New Roman, serif;font-style:normal;font-weight:normal;">&#945;</span> inhibitors, including Humira (adalimumab) and Cimzia (certolizumab), achieved a placebo<span class="nobreak">-adjusted</span> ACR50 response of around&#160;30&#160;&#8211;&#160;35% at 24&#160;weeks with Q2W dosing. Approved IL<span class="nobreak">-17</span> inhibitors, including Cosentyx (secukinumab) and Taltz (ixekizumab), achieved a slightly lower placebo<span class="nobreak">-adjusted</span> ACR50 response of around&#160;25&#160;&#8211;&#160;30% at 24&#160;weeks, but with more convenient Q4W dosing. Bimzelx (bimekizumab) has not yet received approval in the United&#160;States for PsA; however, in two Phase&#160;3 clinical trials, bimekizumab achieved a placebo<span class="nobreak">-adjusted</span> ACR50 response of 34% and 37% at 16&#160;weeks with Q4W dosing. A significant fraction of patients with PsA still do not achieve a satisfactory response with available therapies, and even the most convenient regimens require monthly SQ dosing.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Overview of additional opportunities</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition to PsO and PsA, inhibition of IL<span class="nobreak">-23</span> or IL<span class="nobreak">-17</span> has demonstrated efficacy in a number of additional&#160;I&amp;I indications, including HS and axSpA.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">HS is a chronic inflammatory skin disease characterized by lesions that include deep<span class="nobreak">-seated</span> nodules and abscesses, draining tracts, and fibrotic scars that occur most commonly in intertriginous areas, such as the armpits and groin. Due to the associated pain, sensitive locations, drainage, odor, and scarring, this condition can have a particularly negative psychosocial impact on affected individuals. HS is believed to be underdiagnosed and could have a prevalence well above 1% worldwide. Treatment varies depending on severity and can include topical and systemic antibiotics, hormone therapy, immune modulators, and surgery. Humira (adalimumab) was the only FDA<span class="nobreak">-approved</span> medication for the treatment of moderate<span class="nobreak">-to-severe</span> HS from its approval in 2015 until the approval of Cosentyx (secukinumab) in October&#160;2023. However, now multiple other biologics, including Bimzelx (bimekizumab), are advancing through development and have demonstrated encouraging data in clinical trials, though a significant fraction of patients still do not achieve adequate responses.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">axSpA is a chronic inflammatory disease that primarily affects the spine and sacroiliac joints that comprise the axial skeleton. The disease causes severe pain, stiffness, and fatigue, and can have additional clinical manifestations like uveitis, enthesitis, peripheral arthritis, and PsO.&#160;Patients with axSpA may develop further structural damage in their spine, which can lead to the fusion of vertebra (spinal ankylosis), which has a massive negative impact on mobility, physical function, and quality of life. The overall prevalence of axSpA is estimated to be around 1% in the United&#160;States. Treatment of axSpA starts with physical therapy and NSAIDs. If patients do not have an adequate response to NSAIDs, a TNF<span class="nobreak">-</span><span class="nobreak" style="font-family:Times New Roman, serif;font-style:normal;font-weight:normal;">&#945;</span> inhibitor is typically used, followed by an IL<span class="nobreak">-17</span> inhibitor, such as Cosentyx (secukinumab), Taltz (ixekizumab), or Bimzelx (bimekizumab), or less frequently a JAK inhibitor. Patients often need to cycle through therapies over time due to inadequate responses or loss of response.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Oruka&#8217;s Solution: Half-Life Extension and Antibody Engineering Technologies</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka&#8217;s antibody engineering campaigns are designed to optimize multiple attributes in parallel: binding affinity, potency in a variety of assays, developability, and consistently extended serum half<span class="nobreak">-life</span> in non<span class="nobreak">-human</span> primates (&#8220;NHPs&#8221;). Half<span class="nobreak">-life</span> extension is possible by modifying the pH<span class="nobreak">-dependent</span> binding affinity of the antibody Fc domain for FcRn. A primary mechanism of elimination of antibodies from the serum is through pinocytosis and degradation in the lysosomes of cells. Throughout this process, antibodies can be recycled back into the serum by binding to FcRn while they are in endosomes. The interior of the endosome is acidic, and therefore the efficiency of this recycling process depends on the ability of the antibody Fc domain to bind to FcRn at low pH.&#160;If this low pH binding is efficient enough, antibody recycling can be favored over degradation, potentially resulting in a much longer serum half<span class="nobreak">-life</span>.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">221</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Antibody engineers have discovered methods of modifying the Fc domain to optimize the efficiency of recycling via FcRn binding. Several engineering strategies have been identified over the past two decades, with the so<span class="nobreak">-called</span> &#8220;YTE&#8221; mutations (M252Y/S254T/T256E) and &#8220;LS&#8221; mutations (M428L/N434S) being the most frequently used. Importantly, while these strategies have been known for some time, it was only relatively recently that enough clinical precedent was established to provide confidence in how these mutations perform in humans. Two products incorporating YTE modification were approved in 2023 by the FDA, Beyfortus (nirsevimab) and Evusheld (tixagevimab and cilgavimab), and several more candidates are in clinical trials. Two products using LS mutations were approved in 2021 and 2022, Xevudy (sotrovima) and Ultomiris (ravulizumab), respectively, and several more candidates are in clinical trials. Based on clinical data in humans, antibodies with YTE mutations typically have a half<span class="nobreak">-life</span> that is two to four times longer than wildtype antibodies. In addition, preclinical data in NHPs can be used to predict the approximate half<span class="nobreak">-life</span> in humans, with the human half<span class="nobreak">-life</span> equaling around 3.1&#160;times the NHP half<span class="nobreak">-life</span>.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Clinical experience with YTE-modified mAbs predicts significant half-life extension over wildtype mAbs</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;text-align:center;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><img alt="" src="timage_004.jpg" style="width:380.16px;max-width:100%;"/></span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">While this increasing body of clinical precedent serves to validate half<span class="nobreak">-life</span> extension, Oruka does not yet have clinical data showing that the introduction of these amino acid substitutions in its programs leads to a longer serum half<span class="nobreak">-life</span>. However, Oruka aims to establish this favorable pharmacokinetic profile early in the clinical development of its product candidates.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ORKA-001</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Summary</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ORKA<span class="nobreak">-001</span> is a high affinity, extended half<span class="nobreak">-life</span> mAb designed to target the p19 subunit of IL<span class="nobreak">-23</span>. Based on preclinical data generated to date, Oruka believes ORKA<span class="nobreak">-001</span> has the potential to become the leading IL<span class="nobreak">-23</span> inhibitor and achieve an optimal product profile in PsO consisting of the following:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;font-style:italic;font-weight:bold;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="BoldItalic" style="font-style:italic;font-weight:bold;">One to two maintenance doses per year.&#160;&#160;&#160;&#160;</span>Standard<span class="nobreak">-of-care</span> therapies targeting IL<span class="nobreak">-23</span> require maintenance dosing every eight to twelve&#160;weeks. Oruka engineered the Fc portion of ORKA<span class="nobreak">-001</span> to include YTE mutations to increase the half<span class="nobreak">-life</span> of ORKA<span class="nobreak">-001</span> in circulation, which may enable dosing every six to twelve&#160;months&#160;&#8212;&#160;a dosing interval made feasible by half<span class="nobreak">-life</span> extension technology. In </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">222</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-position:inside;list-style-type:none;text-indent:0pt;margin-top:8pt;">preclinical studies, serum levels from&#160;NHPs indicated an elimination half<span class="nobreak">-life</span> of 24&#160;days following SQ administration of a precursor antibody to ORKA<span class="nobreak">-001</span>. Based on published scientific literature on other antibodies incorporating YTE mutations and pharmacokinetic modeling, Oruka anticipates this half<span class="nobreak">-life</span> in NHPs to translate to a half<span class="nobreak">-life</span> in humans that could allow subcutaneous dosing every six to twelve&#160;months while maintaining high antibody exposures.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Higher PASI 100.&#160;&#160;&#160;&#160;</span>ORKA<span class="nobreak">-001</span> benefits from the robust validation of IL<span class="nobreak">-23</span> inhibition in PsO by multiple approved therapies, such as Skyrizi (risankizumab) and Tremfya (guselkumab), while leveraging insights from these therapies to improve upon their clinical profile. ORKA<span class="nobreak">-001</span> is designed to bind a similar epitope to the market<span class="nobreak">-leading</span> anti<span class="nobreak">-IL-23</span> antibody, Skyrizi, with similar or greater affinity and could achieve much higher exposures in patients due to half<span class="nobreak">-life</span> extension. Skyrizi and Tremfya both have a robust exposure<span class="nobreak">-response</span> relationship, with higher drug exposures leading to higher response rates. Published data indicates that these therapies have not saturated this exposure<span class="nobreak">-response</span> relationship, and ORKA<span class="nobreak">-001</span> could lead to higher response rates, including higher rates of complete skin clearance, or PASI 100, through increased exposure, even while having more convenient dosing with as few as one or two maintenance doses per year.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Validated IL</span><span class="nobreak"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">-23p19</span></span><span class="BoldItalic" style="font-style:italic;font-weight:bold;"> safety profile.&#160;&#160;&#160;&#160;</span>Existing commercially approved antibodies targeting IL<span class="nobreak">-23</span> provide a robust precedent for the safety of IL<span class="nobreak">-23</span> inhibition. Across thousands of patients dosed in dermatology and IBD indications, no correlations have been observed at the patient level between exposure and safety. While Oruka is not pursuing IBD, the approved Skyrizi regimen for Crohn&#8217;s disease supports the safety of high peak exposures. Peak Skyrizi exposures during the&#160;IV induction phase in Crohn&#8217;s disease are over 2.5 times higher than the peak ORKA<span class="nobreak">-001</span> exposures at dose levels Oruka currently plans to evaluate in PsO.&#160;In addition, an exposure<span class="nobreak">-response</span> analysis for Skyrizi in ulcerative colitis showed no relationship between exposures and evaluated safety endpoints in the 12<span class="nobreak">-week</span> induction or 52<span class="nobreak">-week</span> maintenance periods. In this assessment, the top quartile of average exposures spanned 176 to 342 &#181;g/mL in the induction period and 25 to 62 &#181;g/mL in the maintenance period, which are approximately 7 and 5 times higher, respectively, than the highest anticipated exposures with ORKA<span class="nobreak">-001</span> in the same periods.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Potential to offer longer term remission to some patients.&#160;&#160;&#160;&#160;</span>Emerging evidence suggests that IL<span class="nobreak">-23</span> blockade can modify the disease biology of PsO, possibly leading to durable remissions and preventing the development of PsA.&#160;Dr.&#160;Andrew Blauvelt, chair of Oruka&#8217;s Scientific Advisory Board, pioneered some of this work by using two- and four<span class="nobreak">-times</span> the approved dose levels of risankizumab to achieve best<span class="nobreak">-in-indication</span> response rates. This study, called KNOCKOUT, showed a robust depletion of TRMs following high dose IL<span class="nobreak">-23</span> inhibition, which could lead to longer<span class="nobreak">-lasting</span> remissions in some patients. Additional evidence from a study of guselkumab, called GUIDE, showed that intervention early in the disease course can lead to longer treatment<span class="nobreak">-free</span> remissions. In addition, retrospective claims data suggests that treatment with an IL<span class="nobreak">-23</span> inhibitor could help prevent progression to PsA, though this finding has yet to be confirmed by a prospective clinical trial. Given the high antibody exposures expected with ORKA<span class="nobreak">-001</span>, Oruka believes that ORKA<span class="nobreak">-001</span> could lead to durable remissions for some patients, especially those with short disease duration. Oruka plans to pursue patient<span class="nobreak">-specific</span> dosing intervals to provide each patient the greatest possible freedom from their disease.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka believes that this target profile for ORKA<span class="nobreak">-001</span> could offer improved freedom from disease to many patients affected by PsO and represent a step forward in the standard of care.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Preclinical Data</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka evaluated ORKA<span class="nobreak">-001</span> in numerous preclinical studies for several key features:</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Potency that matches or exceeds Skyrizi (risankizumab) in vitro</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka has tested the potency of ORKA<span class="nobreak">-001</span> <span class="Italic" style="font-style:italic;font-weight:normal;">in vitro</span>&#160;in multiple assays, including assays evaluating the inhibition of IL<span class="nobreak">-17</span> release from human peripheral mononuclear blood cells, in comparison to risankizumab generated recombinantly based on amino acid sequences from patent filings. Based on the results of these </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">223</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">experiments, Oruka believes ORKA<span class="nobreak">-001</span> has the potential for greater potency than risankizumab. Data from the existing commercially approved therapies targeting IL<span class="nobreak">-23</span> indicate that the potency of IL<span class="nobreak">-23</span> inhibition, in this case, measured by affinity, correlates tightly with efficacy.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:10pt;text-align:center;margin-top:10pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">The affinity of approved mAbs targeting IL-23 correlates tightly with efficacy</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;text-align:center;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><img alt="" src="timage_005.jpg" style="width:272.64px;max-width:100%;"/></span></p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Significant half-life extension in NHPs that could enable a maintenance dosing interval of once or twice a year in humans</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka assessed the impact of incorporating YTE modifications into a precursor antibody to ORKA<span class="nobreak">-001</span> in NHPs in comparison to risankizumab generated recombinantly based on amino acid sequences from patent filings. The mAb with YTE modifications had a significantly longer half<span class="nobreak">-life</span>, reaching approximately 24&#160;days with SQ administration. Based on clinical experience with YTE<span class="nobreak">-modified</span> mAbs and pharmacokinetic modeling, Oruka believes that this half<span class="nobreak">-life</span> extension could enable dosing once or twice per year, as shown in the figure below.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:10pt;text-align:center;margin-top:10pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">The incorporation of YTE mutations significantly extends half-life in NHPs, which could enable once or twice yearly dosing</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;text-align:center;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><img alt="" src="timage_006.jpg" style="width:590.08px;max-width:100%;"/></span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition to enabling less frequent dosing, an extended half<span class="nobreak">-life</span> would increase the exposure of ORKA<span class="nobreak">-001</span>, which has the potential to increase efficacy. Based on published literature, Skyrizi (risankizumab) demonstrates a clear relationship between antibody exposure and efficacy, with higher average serum antibody concentration correlating with higher PASI 90 and PASI 100 rates short<span class="nobreak">-term</span> (at 16&#160;weeks) and long<span class="nobreak">-term</span> (at 52&#160;weeks), as shown for PASI 100 in the figure below. In addition, the KNOCKOUT study, which evaluated two- and four<span class="nobreak">-times</span> higher doses of Skyrizi than the approved regimen, yielded some of the highest PASI 100 rates observed to date, reaching 67% at 16&#160;weeks. Based on Oruka&#8217;s pharmacokinetic modeling, ORKA<span class="nobreak">-001</span> could achieve four<span class="nobreak">-fold</span> higher average exposures than the approved Skyrizi regimen over the first 16&#160;weeks and over two<span class="nobreak">-fold</span> higher average exposures at steady<span class="nobreak">-state</span>, exceeding even the exposures in KNOCKOUT.&#160;Based on the exposure<span class="nobreak">-response</span> relationship observed with other IL<span class="nobreak">-23</span> inhibiting antibodies, Oruka believes that these increased exposures could result in higher efficacy.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">224</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ORKA-001 is projected to extend the exposure-response relationship established by studies of Skyrizi</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;text-align:center;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><img alt="" src="timage_007.jpg" style="width:536.32px;max-width:100%;"/></span></p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Safety in vitro and in vivo</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka has evaluated ORKA<span class="nobreak">-001</span> in several&#160;<span class="Italic" style="font-style:italic;font-weight:normal;">in vitro</span>&#160;and&#160;<span class="Italic" style="font-style:italic;font-weight:normal;">in vivo</span>&#160;preclinical studies to assess safety. In addition, Oruka has initiated a robust nonclinical program to characterize the toxicology, toxicokinetics, and anti<span class="nobreak">-drug</span> antibody profile of ORKA<span class="nobreak">-001</span> in NHPs, including a single<span class="nobreak">-dose</span> non<span class="nobreak">-GLP</span> dose<span class="nobreak">-range</span> finding study and one<span class="nobreak">-month</span> and six<span class="nobreak">-month</span> GLP toxicology studies. Collectively, this nonclinical program is designed to support the initiation of clinical trials. In addition, ORKA<span class="nobreak">-001</span> benefits from the favorable safety precedent for IL<span class="nobreak">-23</span> inhibition provided by the existing commercially approved IL<span class="nobreak">-23-targeted</span> antibodies across several indications.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Characteristics that support ease of manufacturing and potentially enable high-concentration formulations</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Finally, Oruka has assessed a variety of attributes essential for manufacturability and high<span class="nobreak">-concentration</span> formulation, including viscosity, solubility, and stability, among others. ORKA<span class="nobreak">-001</span> shows evidence of desirable properties across these characteristics, which Oruka believes will enhance its ability to manufacture ORKA<span class="nobreak">-001</span> successfully and consistently and to deliver high doses of ORKA<span class="nobreak">-001</span> subcutaneously using convenient, low<span class="nobreak">-volume</span> presentations.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Clinical Development Plans</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Based on these potential advantages and preclinical data, Oruka is advancing ORKA<span class="nobreak">-001</span> towards a Phase&#160;1 clinical trial in the first half of 2025. This trial will encompass a Phase&#160;1a single<span class="nobreak">-ascending</span> dose portion in healthy volunteers, followed by a Phase&#160;1b, multiple<span class="nobreak">-dose</span> portion in patients with moderate<span class="nobreak">-to-severe</span> PsO.&#160;Following completion of Phase&#160;1b, patients will become eligible for an open<span class="nobreak">-label</span> extension study. Initial data from the Phase&#160;1a cohort has the potential to provide key validation of both early safety and pharmacokinetics, including half<span class="nobreak">-life</span>, to support extended dosing intervals. Initial data from the Phase&#160;1b cohort has the potential to provide preliminary efficacy data in patients with PsO.&#160;Pending the results from the Phase&#160;1 clinical trial, Oruka plans to initiate a Phase&#160;2 clinical trial in PsO in 2026. Several aspects of PsO facilitate clinical development, including well<span class="nobreak">-established</span>, reproducible endpoints based on PASI scores, low placebo rates, particularly with PASI 90 and PASI 100, a rapid efficacy readout at 16&#160;weeks, and potentially rapid enrollment due to the large patient population. Oruka has not yet submitted an IND with the FDA for its Phase 1 clinical trials for ORKA<span class="nobreak">-001</span>.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ORKA-002</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Summary</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ORKA<span class="nobreak">-002</span> is a high affinity, extended half<span class="nobreak">-life</span> mAb designed to target IL<span class="nobreak">-17A</span>/F.&#160;Dual inhibition of both IL<span class="nobreak">-17A</span> and IL<span class="nobreak">-17F</span> has shown superior efficacy compared to IL<span class="nobreak">-17A</span> inhibition alone in PsO and other indications, as shown by the performance of Bimzelx (bimekizumab) compared to Cosentyx (secukinumab) and Taltz (ixekizumab) in Phase&#160;3 trials. These therapies all utilize Q8W dosing in PsO and Q4W dosing in PsA.&#160;By binding </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">225</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">IL<span class="nobreak">-17A</span>/F at similar epitopes and affinity ranges as Bimzelx while incorporating half<span class="nobreak">-life</span> extension technology to potentially enable dosing two to three times a year in PsO and PsA, Oruka believes that ORKA<span class="nobreak">-002</span> could become the leading therapy in the IL<span class="nobreak">-17</span> class.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Preclinical Data</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The preclinical program Oruka is conducting to inform development candidate selection and support clinical trial initiation for ORKA<span class="nobreak">-002</span> mirrors that for ORKA<span class="nobreak">-001</span> and spans potency, pharmacokinetics, safety, and manufacturing characteristics. Based on the results of these experiments, Oruka believes ORKA<span class="nobreak">-002</span> has the potential for comparable potency to bimekizumab, but with a significantly longer half<span class="nobreak">-life</span>, which Oruka believes could support dosing two or three times per year based on extrapolation from clinical precedent and pharmacokinetic modeling.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Clinical Development Plans</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka plans to initiate Phase&#160;1 trials of ORKA<span class="nobreak">-002</span> in the second half of 2025 following ORKA<span class="nobreak">-001</span>. As with ORKA<span class="nobreak">-001</span>, initial data on ORKA<span class="nobreak">-002</span> in healthy volunteers has the potential to provide key validation of both early safety and pharmacokinetics to support extended dosing intervals. Though clinical development of ORKA<span class="nobreak">-002</span> will initially focus on one lead indication, Oruka plans to evaluate ORKA<span class="nobreak">-002</span> in a range of indications over time. Oruka sees ORKA<span class="nobreak">-002</span> as highly complementary to ORKA<span class="nobreak">-001</span>, with the potential to provide an optimal therapy for the approximately one<span class="nobreak">-quarter</span> to one<span class="nobreak">-third</span> of moderate<span class="nobreak">-to-severe</span> PsO patients who have PsA, as well as for PsO patients with highly resistant skin symptoms that do not respond adequately to an IL<span class="nobreak">-23</span> inhibitor. Furthermore, ORKA<span class="nobreak">-002</span> could address indications beyond PsO, including PsA with limited skin involvement, HS, axSpA, and additional&#160;I&amp;I diseases. Oruka has not yet submitted an IND with the FDA for its Phase 1 clinical trials for ORKA<span class="nobreak">-002</span>.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Additional Pipeline Programs</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka has a third mAb program, ORKA<span class="nobreak">-003</span>, that targets an undisclosed pathway. A core tenet of Oruka&#8217;s strategy is to remain highly focused on&#160;I&amp;I diseases, and specifically on inflammatory dermatology conditions. ORKA<span class="nobreak">-003</span> provides the potential for indication expansion beyond PsO as well as combination opportunities with Oruka&#8217;s more advanced programs. In the future, Oruka may add additional programs to its portfolio beyond ORKA<span class="nobreak">-001</span>, ORKA<span class="nobreak">-002</span>, and ORKA<span class="nobreak">-003</span> that fit its strategic focus.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Intellectual Property</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka strives to protect the proprietary programs and technologies that it believes are important to its business, including seeking and maintaining patent protection intended to cover the composition of matter of its programs, their methods of use and manufacture, related technologies, diagnostics, and other inventions.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Paragon has filed provisional patent applications, and intends to file one or more additional provisional patent applications directed to antibodies that target IL<span class="nobreak">-23</span>, including applications covering composition of matter, pharmaceutical formulations, and methods of using such antibodies, including ORKA<span class="nobreak">-001</span>. In addition, Paragon has filed provisional patent applications, and intends to file one or more additional provisional patent applications directed to antibodies that target IL<span class="nobreak">-17</span>, including applications covering composition of matter, pharmaceutical formulations, and methods of using such antibodies, including ORKA<span class="nobreak">-002</span>. Oruka has not yet exercised its option to acquire exclusive rights to any IL<span class="nobreak">-23</span> or IL<span class="nobreak">-17</span> patent applications, but retains the right to do so. If the provisional patent applications are pursued non<span class="nobreak">-provisionally</span> and mature into one or more issued patents covering ORKA<span class="nobreak">-001</span> or ORKA<span class="nobreak">-002</span>, Oruka would expect those patents to expire in 2045, absent any applicable patent term adjustments or extensions.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Commercial</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Should any of its product candidates be approved for commercialization, Oruka intends to develop a plan to commercialize them in the United&#160;States and other key markets, through internal infrastructure and/or external partnerships in a manner that will enable Oruka to realize the full commercial value of its programs. Given its stage of development, Oruka has not yet established a commercial organization or distribution capabilities. Oruka currently holds exclusive Options (as defined below) to acquire worldwide development and commercialization rights to all of its programs.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">226</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Manufacturing</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka does not currently own or operate facilities for product manufacturing, testing, storage, and distribution. Oruka has contracted and expect to continue to contract with third parties for the manufacture and distribution of its product candidates. Because Oruka relies on contract manufacturers, it employs personnel with extensive technical, manufacturing, analytical and quality experience. Oruka&#8217;s team has deep knowledge and understanding of the regulations that govern manufacturing, documentation, quality assurance, and quality control of drug supply that are required to support Oruka&#8217;s regulatory filings.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Competition</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The biotechnology and biopharmaceutical industries are characterized by continuing technological advancement and significant competition. While Oruka believes that its programs, technology, development experience and scientific knowledge provide it with competitive advantages, Oruka faces competition from major pharmaceutical and biotechnology companies, academic institutions, governmental agencies, and public and private research institutions, among others. Any product candidates that Oruka successfully develops and commercialize will compete with existing therapies and new therapies that may become available in the future. Many of the companies with which Oruka is currently competing or will compete against in the future have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals, and marketing approved products than Oruka does. Mergers and acquisitions in the pharmaceutical and biotechnology industry may result in even more resources being concentrated among a smaller number of Oruka&#8217;s competitors. Smaller or early<span class="nobreak">-stage</span> companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with Oruka in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites, patient enrollment for clinical trials as well as in acquiring technologies complementary to, or necessary for, Oruka&#8217;s programs.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Key competitive factors affecting the success of all of Oruka&#8217;s product candidates that it develops, if approved, are likely to be efficacy, safety, convenience, presentation, price, the level of generic competition, and the availability of reimbursement from government and other third<span class="nobreak">-party</span> payors. Oruka&#8217;s competitors may also obtain FDA or other regulatory approval for their products more rapidly than Oruka may obtain approval for its products, which could result in Oruka&#8217;s competitors establishing a strong market position before Oruka is able to enter the market.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Specifically, there are several companies developing or marketing treatments that may be approved for the same indications and/or diseases as Oruka&#8217;s two most advanced programs, ORKA<span class="nobreak">-001</span> and ORKA<span class="nobreak">-002</span>, including major pharmaceutical companies. Oruka does not yet have clinical data for any of its programs and there can be no assurance that its programs will have similar or comparable results.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">There are several approved biologic therapies for the treatment of moderate<span class="nobreak">-to-severe</span> PsO.&#160;These include mAbs targeting IL<span class="nobreak">-23</span>, such as Skyrizi (risankizumab) from AbbVie, Tremfya (guselkumab) from Janssen, and Ilumya (tildrakizumab) from Sun Pharma, also marketed as Ilumetri by Almirall in Europe, which all target the p19 subunit, and Stelara (ustekinumab) from Janssen, which targets the p40 subunit; mAbs targeting IL<span class="nobreak">-17</span>, such as Bimzelx (bimekizumab) from UCB, which targets IL<span class="nobreak">-17A</span>/F, Cosentyx (secukinumab) from Novartis and Taltz (ixekizumab) from Eli Lilly, which both target IL<span class="nobreak">-17A</span>, and Siliq (brodalumab) from Ortho Dermatologics, also marketed as Kyntheum by LEO Pharma in Europe, which targets IL<span class="nobreak">-17</span> receptor A; and biologics targeting TNF<span class="nobreak">-</span><span class="nobreak" style="font-family:Times New Roman, serif;font-style:normal;font-weight:normal;">&#945;</span>, such as Humira (adalimumab) from AbbVie, Enbrel (etanercept) from Amgen, and Remicade (infliximab) from Janssen, and various biosimilar versions of each. In addition, there are several approved oral medicines in these indications, including the phosphodiesterase<span class="nobreak">-4</span> (PDE4) inhibitor Otezla (apremilast) from Amgen and the tyrosine kinase 2 (TYK2) inhibitor Sotyktu (deucravacitinib) from Bristol<span class="nobreak">-Myers</span> Squibb. Many of these therapies also are approved or in development for PsA, HS, axSpA, and other&#160;I&amp;I indications.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, Oruka is aware of several product candidates in clinical development for moderate<span class="nobreak">-to-severe</span> PsO, along with PsA, HS, axSpA, and other indications. These include the biologics picankibart from Innovent Biologics targeting IL<span class="nobreak">-23p19</span>, sonelokimab from MoonLake Immunotherapeutics targeting IL<span class="nobreak">-17A</span>/F, and izokibep from ACELYRIN targeting IL<span class="nobreak">-17A</span>.&#160;Also, there are several oral agents in development, including JNJ<span class="nobreak">-2113</span> from Janssen targeting the IL<span class="nobreak">-23</span> receptor, DC<span class="nobreak">-806</span> and DC<span class="nobreak">-853</span> from Eli Lilly targeting IL<span class="nobreak">-17A</span>, and TAK<span class="nobreak">-279</span> from Takeda and ESK<span class="nobreak">-001</span> from Alumis, both targeting TYK2.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">227</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">License Agreements</span></p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Paragon Therapeutics</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On March&#160;6, 2024, Oruka entered into the Paragon Option Agreements. Under the terms of each agreement, Paragon identifies, evaluates, and develops antibodies directed against certain mutually agreed therapeutic targets of interest to us. Each Paragon Option Agreement initially included one of two selected targets: IL<span class="nobreak">-23</span> and IL<span class="nobreak">-17A</span>/F.&#160;Under the Paragon Option Agreements, Oruka has the exclusive option to, on a research program<span class="nobreak">-by-research</span> program basis, be granted an exclusive, worldwide license to all of Paragon&#8217;s right, title, and interest in and to the intellectual property resulting from the applicable research program to develop, manufacture, and commercialize the antibodies and products directed to the selected target(s)&#160;(each, an &#8220;Option&#8221;). In the case of IL<span class="nobreak">-23</span>, Oruka&#8217;s Option excludes the therapeutic area of IBD.&#160;From time to time, Oruka can choose to add additional targets to the collaboration by mutual agreement with Paragon and Paruka. As of the date hereof, Oruka has not exercised any Options.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Pursuant to the terms of the Paragon Option Agreements, Oruka initiated certain research programs with Paragon that generally focus on a particular target (each, a &#8220;Research Program&#8221;). Each Research Program is aimed at discovering, generating, identifying, and/or characterizing antibodies directed to the respective target. For each Research Program, Oruka established or may establish in the future a research plan with Paragon that sets forth the activities that will be conducted, and the associated research budget (each, a &#8220;Research Plan&#8221;). Oruka&#8217;s exclusive option with respect to each Research Program is exercisable at Oruka&#8217;s sole discretion at any time during the period beginning on the initiation of activities under the associated Research Program and ending a specified number of&#160;days following (i)&#160;with respect to any Research Program other than ORKA<span class="nobreak">-001</span>, the delivery of the data package from Paragon related to the results of the Research Plan activities or (ii)&#160;with respect to ORKA<span class="nobreak">-001</span>, the completion of the IL<span class="nobreak">-23</span> antibody selection process described in the agreement (the &#8220;Option Period&#8221;). There is no payment due upon exercise of an Option pursuant to the Paragon Option Agreements.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Unless terminated earlier, each Paragon Option Agreement shall continue in force on a Research Program<span class="nobreak">-by-Research</span> Program basis until the earlier of: (i)&#160;the end of the Option Period for such Research Program, as applicable, if such Option is not exercised by us; (ii)&#160;the expiration of the 30<span class="nobreak">-day</span> period after Oruka exercises its Option with respect to a Research Program, subject to mutually agreed extension, during the Option Period and the parties are unable to finalize and execute a license agreement, and (iii)&#160;the expiration of the applicable Research Term (as defined under each Paragon Option Agreement) (the &#8220;Term&#8221;). Oruka may terminate any Paragon Option Agreement or any Research Program at any time for any or no reason upon 30&#160;days&#8217; prior written notice to Paragon, provided that Oruka must pay certain unpaid fees due to Paragon upon such termination, as well as any non<span class="nobreak">-cancellable</span> obligations reasonably incurred by Paragon in connection with its activities under any terminated Research Program. Paragon may terminate any Paragon Option Agreement or a Research Program immediately upon written notice to Oruka if, as a result of any action or failure to act by Oruka or its affiliates, such Research Program or all material activities under the applicable Research Plan are suspended, discontinued or otherwise delayed for a certain consecutive number of&#160;months. Each party has the right to terminate the Paragon Option Agreements or any Research Program upon (i)&#160;30&#160;days&#8217; prior written notice of the other party&#8217;s material breach that remains uncured for the 30<span class="nobreak">-day</span> period and (ii)&#160;the other party&#8217;s bankruptcy.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Upon signing of the Paragon Option Agreement for ORKA<span class="nobreak">-001</span>, a one<span class="nobreak">-time</span>, non<span class="nobreak">-refundable</span> research initiation fee of $0.8&#160;million became payable by Oruka to Paragon. This amount was recognized by Oruka as a research and development expense during the period ended March&#160;31, 2024, and paid to Paragon in April&#160;2024. Oruka is also responsible for 50% of the development costs incurred by Paragon prior to March&#160;31, 2024, provided that Oruka receives rights to at least one selected IL<span class="nobreak">-23</span> antibody. Oruka&#8217;s share of development costs incurred by Paragon prior to March&#160;31, 2024 is $5.9&#160;million. As of the date of filing of this proxy statement/prospectus, Oruka has not received rights to a selected IL<span class="nobreak">-23</span> antibody and has not paid or accrued the $5.9&#160;million of development costs incurred by Paragon prior to March&#160;31, 2024. Oruka will be responsible for 50% of the ORKA<span class="nobreak">-001</span> development costs incurred by Paragon from and after March&#160;31, 2024, through the completion of the IL<span class="nobreak">-23</span> selection process.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Under the Paragon Option Agreement for ORKA<span class="nobreak">-002</span>, Oruka was required to reimburse Paragon $3.3&#160;million for development costs related to ORKA<span class="nobreak">-002</span> incurred by Paragon through December&#160;31, 2023 and certain other development costs incurred by Paragon between January&#160;1, 2024 and March&#160;6, 2024 (the &#8220;pre<span class="nobreak">-effective</span> date development costs&#8221;). This amount was recognized as a research and development expense during the period from </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">228</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">February 6 (inception) to March<span class="nobreak"> </span>31, 2024, and accounts payable as of March<span class="nobreak"> </span>31, 2024. Oruka paid $3.3&#160;million to Paragon in April&#160;2024. Oruka is also responsible for the development costs incurred by Paragon from January&#160;1, 2024 to March&#160;31, 2024 of $0.9&#160;million, which was recognized as a research and development expense in the period ended March&#160;31, 2024. Oruka will be required to pay Paragon $0.8&#160;million for the research initiation fee related to ORKA<span class="nobreak">-002</span> within 30&#160;days following finalization of the ORKA<span class="nobreak">-002</span> research plan as well as for subsequent development costs related to ORKA<span class="nobreak">-002</span>. Oruka will be responsible for ORKA<span class="nobreak">-002</span> development costs incurred from and after March<span class="nobreak"> </span>31, 2024, through the completion of the IL<span class="nobreak">-17</span> selection process.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of the filing date of this proxy statement/prospectus, Oruka has not exercised its options with respect to ORKA<span class="nobreak">-001</span> or ORKA<span class="nobreak">-002</span>. For each of these agreements, if Oruka exercises its options, it will be required to make non<span class="nobreak">-refundable</span> milestone payments to Paragon of up to $12.0&#160;million upon the achievement of certain clinical development milestones, up to $10.0&#160;million upon the achievement of certain regulatory milestones, as well as tiered royalty payments in the low<span class="nobreak">-to-mid</span> single<span class="nobreak">-digits</span> beginning on the first commercial sale.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Additionally, as part of the Paragon Option Agreements, on each of December&#160;31, 2024 and December&#160;31, 2025, Oruka will grant Paruka warrants to purchase a number of shares equal to 1.00% of outstanding shares as of the date of the grant on a fully<span class="nobreak">-diluted</span> basis, with an exercise price equal to the fair market value of the underlying shares on the grant date.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Government Regulation</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The FDA and other regulatory authorities at federal, state and local levels, as well as in foreign countries, extensively regulate, among other things, the research, development, testing, manufacture, quality control, import, export, safety, effectiveness, labeling, packaging, storage, distribution, record keeping, approval, advertising, promotion, marketing, post<span class="nobreak">-approval</span> monitoring and post<span class="nobreak">-approval</span> reporting of biologics such as those Oruka is developing. Oruka, along with its third<span class="nobreak">-party</span> contractors, will be required to navigate the various preclinical, clinical and commercial approval requirements of the governing regulatory agencies of the countries in which Oruka wishes to conduct studies or seek approval or licensure of its product candidates.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">United&#160;States Biologics Regulation</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In the United&#160;States, biological products are subject to regulation under the FDCA, the Public Health Service Act (&#8220;PHSA&#8221;) and other federal, state, local, and foreign statutes and regulations. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, and local statutes and regulations requires the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S.&#160;requirements at any time during the product development process, approval process or following approval may subject an applicant to administrative action and judicial sanctions. The process required by the FDA before biologic product candidates may be marketed in the United&#160;States generally involves the following:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>completion of preclinical laboratory tests and animal studies performed in accordance with the FDA&#8217;s current Good Laboratory Practices (&#8220;GLP&#8221;) regulation;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>submission to the FDA of an IND, which must become effective before clinical trials may begin and must be updated annually or when significant changes are made;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>approval by an independent IRB, or ethics committee at each clinical site before the trial is commenced;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>manufacture of the proposed biologic candidate in accordance with current Good Manufacturing Practices (&#8220;cGMPs&#8221;);</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>performance of adequate and well<span class="nobreak">-controlled</span> human clinical trials in accordance with GCP requirements to establish the safety, purity and potency of the proposed biologic product candidate for its intended purpose;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>preparation of and submission to the FDA of a BLA, after completion of all pivotal clinical trials;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>satisfactory completion of an FDA Advisory Committee review, if applicable;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>a determination by the FDA within 60&#160;days of its receipt of a BLA to file the application for review;</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">229</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>satisfactory completion of an FDA pre<span class="nobreak">-approval</span> inspection of the manufacturing facility or facilities at which the proposed product is produced to assess compliance with cGMPs, and to assure that the facilities, methods and controls are adequate to preserve the biological product&#8217;s continued safety, purity and potency, and of selected clinical investigation sites to assess compliance with GCPs; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>FDA review and approval of a BLA to permit commercial marketing of the product for particular indications for use in the United&#160;States.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Preclinical and Clinical Development</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Prior to beginning any clinical trial with a product candidate, in the United&#160;States, Oruka must submit an IND to the FDA.&#160;An IND is a request for authorization from the FDA to administer an investigational new drug product to humans. The central focus of an IND submission is on the general investigational plan and the protocol or protocols for preclinical studies and clinical trials. The IND also includes results of animal and <span class="Italic" style="font-style:italic;font-weight:normal;">in vitro</span> studies assessing the toxicology, pharmacokinetics, pharmacology and pharmacodynamic characteristics of the product, chemistry, manufacturing and controls information, and any available human data or literature to support the use of the investigational product. An IND must become effective before human clinical trials may begin. The IND automatically becomes effective 30&#160;days after receipt by the FDA, unless the FDA, within the 30<span class="nobreak">-day</span> period, raises safety concerns or questions about the proposed clinical trial. In such a case, the IND may be placed on clinical hold and the IND sponsor and the FDA must resolve any outstanding concerns or questions before the clinical trial can begin. Submission of an IND therefore may or may not result in FDA authorization to begin a clinical trial.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition to the IND submission process, supervision of human gene transfer trials includes evaluation and assessment by an institutional biosafety committee (&#8220;IBC&#8221;), a local institutional committee that reviews and oversees research utilizing recombinant or synthetic nucleic acid molecules at that institution. The IBC assesses the safety of the research and identifies any potential risk to public health or the environment and such review may result in some delay before initiation of a clinical trial.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Clinical trials involve the administration of the investigational product to human subjects under the supervision of qualified investigators in accordance with GCPs, which include the requirement that all research subjects provide their informed consent for their participation in any clinical study. Clinical trials are conducted under protocols detailing, among other things, the objectives of the study, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. A separate submission to the existing IND must be made for each successive clinical trial conducted during product development and for any subsequent protocol amendments. Furthermore, an independent IRB for each site proposing to conduct the clinical trial must review and approve the plan for any clinical trial and its informed consent form before the clinical trial begins at that site, and must monitor the study until completed.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Regulatory authorities, the IRB or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the subjects are being exposed to an unacceptable health risk or that the trial is unlikely to meet its stated objectives. Some studies also include oversight by an independent group of qualified experts organized by the clinical study sponsor, known as a data safety monitoring board, which provides authorization for whether or not a study may move forward at designated check points based on access to certain data from the study and may halt the clinical trial if it determines that there is an unacceptable safety risk for subjects or other grounds, such as no demonstration of efficacy. There are also requirements governing the reporting of ongoing preclinical studies and clinical trials and clinical study results to public registries.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">For purposes of BLA approval, human clinical trials are typically conducted in three sequential phases that may overlap.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Phase&#160;1.&#160;&#160;&#160;&#160;The investigational product is initially introduced into healthy human subjects or patients with the target disease or condition. These studies are designed to test the safety, dosage tolerance, absorption, metabolism and distribution of the investigational product in humans, the side effects associated with increasing doses, and, if possible, to gain early evidence on effectiveness.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">230</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Phase&#160;2.&#160;&#160;&#160;&#160;The investigational product is administered to a limited patient population with a specified disease or condition to evaluate the preliminary efficacy, optimal dosages and dosing schedule and to identify possible adverse side effects and safety risks. Multiple Phase&#160;2 clinical trials may be conducted to obtain information prior to beginning larger and more expensive Phase&#160;3 clinical trials.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Phase&#160;3.&#160;&#160;&#160;&#160;The investigational product is administered to an expanded patient population to further evaluate dosage, to provide statistically significant evidence of clinical efficacy and to further test for safety, generally at multiple geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk/benefit ratio of the investigational product and to provide an adequate basis for product approval.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In some cases, the FDA may require, or companies may voluntarily pursue, additional clinical trials after a product is approved to gain more information about the product. These so<span class="nobreak">-called</span> Phase&#160;4 studies may be made a condition to approval of the BLA.&#160;Concurrent with clinical trials, companies may complete additional animal studies and develop additional information about the biological characteristics of the product candidate and must finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, must develop methods for testing the identity, strength, quality and purity of the final product, or for biologics, the safety, purity and potency. Additionally, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">A sponsor may choose, but is not required, to conduct a foreign clinical study under an IND.&#160;When a foreign clinical study is conducted under an IND, all IND requirements must be met unless waived. When the foreign clinical study is not conducted under an IND, the sponsor must ensure that the study complies with certain FDA regulatory requirements in order to use the study as support for an IND or application for marketing approval or licensure, including that the study was conducted in accordance with GCP, including review and approval by an independent ethics committee and use of proper procedures for obtaining informed consent from subjects, and the FDA is able to validate the data from the study through an onsite inspection if the FDA deems such inspection necessary. The GCP requirements encompass both ethical and data integrity standards for clinical studies.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">BLA Submission and Review</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Assuming successful completion of all required testing in accordance with all applicable regulatory requirements, the results of product development, nonclinical studies and clinical trials are submitted to the FDA as part of a BLA requesting approval to market the product for one or more indications. The BLA must include all relevant data available from pertinent preclinical studies and clinical trials, including negative or ambiguous results as well as positive findings, together with detailed information relating to the product&#8217;s chemistry, manufacturing, controls, and proposed labeling, among other things. Data can come from company<span class="nobreak">-sponsored</span> clinical studies intended to test the safety and effectiveness of the product, or from a number of alternative sources, including studies initiated and sponsored by investigators. The submission of a BLA requires payment of a substantial application user fee to the FDA, unless a waiver or exemption applies.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, under the Pediatric Research Equity Act (&#8220;PREA&#8221;), a BLA or supplement to a BLA must contain data to assess the safety and effectiveness of the biological product candidate for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The Food and Drug Administration Safety and Innovation Act requires that a sponsor who is planning to submit a marketing application for a biological product that includes a new active ingredient, new indication, new dosage form, new dosing regimen or new route of administration submit an initial pediatric study plan within sixty&#160;days after an end<span class="nobreak">-of-Phase</span>&#160;2 meeting or as may be agreed between the sponsor and FDA.&#160;Unless otherwise required by regulation, PREA does not apply to any biological product for an indication for which orphan designation has been granted.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Within 60&#160;days following submission of the application, the FDA reviews a BLA submitted to determine if it is substantially complete before the agency accepts it for filing. The FDA may refuse to file any BLA that it deems incomplete or not properly reviewable at the time of submission and may request additional information. In this event, the BLA must be resubmitted with the additional information. Once a BLA has been accepted for filing, the FDA&#8217;s goal is to review standard applications within ten&#160;months after the filing date, or, if the application qualifies </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">231</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">for priority review, six&#160;months after the FDA accepts the application for filing. In both standard and priority reviews, the review process may also be extended by FDA requests for additional information or clarification. The FDA reviews a BLA to determine, among other things, whether a product is safe, pure and potent and the facility in which it is manufactured, processed, packed or held meets standards designed to assure the product&#8217;s continued safety, purity and potency. The FDA may convene an advisory committee to provide clinical insight on application review questions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Before approving a BLA, the FDA will typically inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with GMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving a BLA, the FDA will typically inspect one or more clinical sites to assure compliance with GCPs. If the FDA determines that the application, manufacturing process or manufacturing facilities are not acceptable, it will outline the deficiencies in the submission and often will request additional testing or information. Notwithstanding the submission of any requested additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">After the FDA evaluates a BLA and conducts inspections of manufacturing facilities where the investigational product and/or its drug substance will be produced, the FDA may issue an approval letter or a Complete Response letter. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. A Complete Response letter will describe all of the deficiencies that the FDA has identified in the BLA, except that where the FDA determines that the data supporting the application are inadequate to support approval, the FDA may issue the Complete Response letter without first conducting required inspections, testing submitted product lots and/or reviewing proposed labeling. In issuing the Complete Response letter, the FDA may recommend actions that the applicant might take to place the BLA in condition for approval, including requests for additional information or clarification. The FDA may delay or refuse approval of a BLA if applicable regulatory criteria are not satisfied, require additional testing or information and/or require post<span class="nobreak">-marketing</span> testing and surveillance to monitor safety or efficacy of a product.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If regulatory approval of a product is granted, such approval will be granted for particular indications and may entail limitations on the indicated uses for which such product may be marketed. For example, the FDA may approve the BLA with a REMS to ensure the benefits of the product outweigh its risks. A REMS is a safety strategy to manage a known or potential serious risk associated with a product and to enable patients to have continued access to such medicines by managing their safe use, and could include medication guides, physician communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. The FDA also may condition approval on, among other things, changes to proposed labeling or the development of adequate controls and specifications. Once approved, the FDA may withdraw the product approval if compliance with pre- and post<span class="nobreak">-marketing</span> requirements is not maintained or if problems occur after the product reaches the marketplace. The FDA may require one or more Phase&#160;4 post<span class="nobreak">-market</span> studies and surveillance to further assess and monitor the product&#8217;s safety and effectiveness after commercialization, and may limit further marketing of the product based on the results of these post<span class="nobreak">-marketing</span> studies.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Expedited Development and Review Programs</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The FDA offers a number of expedited development and review programs for qualifying product candidates. The fast track program is intended to expedite or facilitate the process for reviewing new products that meet certain criteria. Specifically, new products are eligible for fast track designation if they are intended to treat a serious or life<span class="nobreak">-threatening</span> disease or condition and data demonstrate the potential to address unmet medical needs for the disease or condition. Fast track designation applies to the combination of the product and the specific indication for which it is being studied. The sponsor of a fast track product has opportunities for more frequent interactions with the review team during product development and, once a BLA is submitted, the product may be eligible for priority review. A fast track product may also be eligible for rolling review, where the FDA may consider for review sections of the BLA on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the BLA, the FDA agrees to accept sections of the BLA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the BLA.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">232</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">A product intended to treat a serious or life<span class="nobreak">-threatening</span> disease or condition may also be eligible for breakthrough therapy designation to expedite its development and review. A product can receive breakthrough therapy designation if preliminary clinical evidence indicates that the product, alone or in combination with one or more other drugs or biologics, may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The designation includes all of the fast track program features, as well as more intensive FDA interaction and guidance beginning as early as Phase&#160;1 and an organizational commitment to expedite the development and review of the product, including involvement of senior managers.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Any marketing application for a biologic submitted to the FDA for approval, including a product with a fast track designation and/or breakthrough therapy designation, may be eligible for other types of FDA programs intended to expedite the FDA review and approval process, such as priority review and accelerated approval. A product is eligible for priority review if there is evidence it has the potential to provide a significant improvement in the treatment, diagnosis or prevention of a serious disease or condition. For original BLAs, priority review designation means the FDA&#8217;s goal is to take action on the marketing application within six&#160;months of the 60<span class="nobreak">-day</span> filing date (as compared to ten&#160;months under standard review).</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Additionally, products studied for their safety and effectiveness in treating serious or life<span class="nobreak">-threatening</span> diseases or conditions may receive accelerated approval upon a determination that the product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. As a condition of accelerated approval, the FDA will generally require the sponsor to perform adequate and well<span class="nobreak">-controlled</span> post<span class="nobreak">-marketing</span> clinical studies to verify and describe the anticipated effect on irreversible morbidity or mortality or other clinical benefit. Under the Food and Drug Omnibus Reform Act&#160;of&#160;2022 the FDA may require, as appropriate, that such studies be underway prior to approval or within a specific time period after the date of approval for a product granted accelerated approval. Products receiving accelerated approval may be subject to expedited withdrawal procedures if the sponsor fails to conduct the required post<span class="nobreak">-marketing</span> studies or if such studies fail to verify the predicted clinical benefit. In addition, the FDA currently requires as a condition for accelerated approval pre<span class="nobreak">-approval</span> of promotional materials, which could adversely impact the timing of the commercial launch of the product.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Fast track designation, breakthrough therapy designation and priority review do not change the standards for approval but may expedite the development or approval process. Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Post-Approval Requirements</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Any products manufactured or distributed by Oruka pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to record<span class="nobreak">-keeping</span>, reporting of adverse experiences, periodic reporting, product sampling and distribution, and advertising and promotion of the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims, are subject to prior FDA review and approval. There also are continuing user fee requirements, under which the FDA assesses an annual program fee for each product identified in an approved BLA.&#160;Biologic manufacturers and their subcontractors are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMPs, which impose certain procedural and documentation requirements upon Oruka and its third<span class="nobreak">-party</span> manufacturers. Changes to the manufacturing process are strictly regulated, and, depending on the significance of the change, may require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMPs and impose reporting requirements upon Oruka and any third<span class="nobreak">-party</span> manufacturers that Oruka may decide to use. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain compliance with cGMPs and other aspects of regulatory compliance.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The FDA may withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">233</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post<span class="nobreak">-market</span> studies or clinical studies to assess new safety risks; or imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>restrictions on the marketing or manufacturing of a product, complete withdrawal of the product from the market or product recalls;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>fines, warning letters or holds on post<span class="nobreak">-approval</span> clinical studies;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of existing product approvals;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>product seizure or detention, or refusal of the FDA to permit the import or export of products;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>consent decrees, corporate integrity agreements, debarment or exclusion from federal healthcare programs;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>mandated modification of promotional materials and labeling and the issuance of corrective information;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the issuance of safety alerts, Dear Healthcare Provider letters, press releases and other communications containing warnings or other safety information about the product; or</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>injunctions or the imposition of civil or criminal penalties.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The FDA closely regulates the marketing, labeling, advertising and promotion of biologics. A company can make only those claims relating to safety and efficacy, purity and potency that are approved by the FDA and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off<span class="nobreak">-label</span> uses. Failure to comply with these requirements can result in, among other things, adverse publicity, warning letters, corrective advertising and potential civil and criminal penalties. Physicians may prescribe legally available products for uses that are not described in the product&#8217;s labeling and that differ from those tested by Oruka and approved by the FDA.&#160;Such off<span class="nobreak">-label</span> uses are common across medical specialties. Physicians may believe that such off<span class="nobreak">-label</span> uses are the best treatment for many patients in varied circumstances. The FDA does not regulate the behavior of physicians in their choice of treatments. The FDA does, however, restrict manufacturer&#8217;s communications on the subject of off<span class="nobreak">-label</span> use of their products.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Biosimilars and Reference Product Exclusivity</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The ACA includes a subtitle called the BPCIA, which created an abbreviated approval pathway for biological products that are highly similar, or &#8220;biosimilar,&#8221; to or interchangeable with an FDA<span class="nobreak">-approved</span> reference biological product. The FDA has issued several guidance documents outlining an approach to review and approval of biosimilars.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Biosimilarity, which requires that there be no clinically meaningful differences between the biological product and the reference product in terms of safety, purity, and potency, is generally shown through analytical studies, animal studies, and a clinical study or studies. Interchangeability requires that a product is biosimilar to the reference product and the product must demonstrate that it can be expected to produce the same clinical results as the reference product in any given patient and, for products that are administered multiple times to an individual, the biologic and the reference biologic may be alternated or switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biologic. A product shown to be biosimilar or interchangeable with an FDA<span class="nobreak">-approved</span> reference biological product may rely in part on the FDA&#8217;s previous determination of safety and effectiveness for the reference product for approval, which can potentially reduce the cost and time required to obtain approval to market the product. Complexities associated with the larger, and often more complex, structures of biological products, as well as the processes by which such products are manufactured, pose significant hurdles to implementation of the abbreviated approval pathway that are still being worked out by the FDA.&#160;In September&#160;2021, the FDA issued two guidance documents intended to inform prospective applicants and facilitate the development of proposed biosimilars and interchangeable biosimilars, as well as to describe the FDA&#8217;s interpretation of certain statutory requirements added by the BPCIA.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">234</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four&#160;years following the date that the reference product was first licensed by the FDA.&#160;In addition, the approval of a biosimilar product may not be made effective by the FDA until 12&#160;years from the date on which the reference product was first licensed. During this 12<span class="nobreak">-year</span> period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing that applicant&#8217;s own preclinical data and data from adequate and well<span class="nobreak">-controlled</span> clinical trials to demonstrate the safety, purity and potency of its product. The BPCIA also created certain exclusivity periods for biosimilars approved as interchangeable products. At this juncture, it is unclear whether products deemed &#8220;interchangeable&#8221; by the FDA will, in fact, be readily substituted by pharmacies, which are governed by state pharmacy law.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">A reference biologic is granted twelve&#160;years of exclusivity from the time of first licensure of the reference product. The first biologic product submitted under the abbreviated approval pathway that is determined to be interchangeable with the reference product has exclusivity against other biologics submitted under the abbreviated approval pathway for the lesser of (i)&#160;one year after the first commercial marketing, (ii)&#160;18&#160;months after approval if there is no legal challenge, (iii)&#160;18&#160;months after the resolution in the applicant&#8217;s favor of a lawsuit challenging the biologics&#8217; patents if an application has been submitted, or (iv)&#160;42&#160;months after the application has been approved if a lawsuit is ongoing within the 42<span class="nobreak">-month</span> period.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">A biological product can also obtain pediatric market exclusivity in the United&#160;States. Pediatric exclusivity, if granted, adds six&#160;months to existing exclusivity periods and patent terms. This six<span class="nobreak">-month</span> exclusivity, which runs from the end of other exclusivity protection or patent term, may be granted based on the voluntary completion of a pediatric study in accordance with an FDA<span class="nobreak">-issued</span> &#8220;Written Request&#8221; for such a study. The BPCIA is complex and continues to be interpreted and implemented by the FDA.&#160;In July&#160;2018, the FDA announced an action plan to encourage the development and efficient review of biosimilars, including the establishment of a new office within the agency that will focus on therapeutic biologics and biosimilars. On December&#160;20, 2020, Congress amended the PHSA as part of the COVID<span class="nobreak">-19</span> relief bill to further simplify the biosimilar review process by making it optional to show that conditions of use proposed in labeling have been previously approved for the reference product, which used to be a requirement of the application. In addition, government proposals have sought to reduce the 12<span class="nobreak">-year</span> reference product exclusivity period. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. As a result, the ultimate impact, implementation, and impact of the BPCIA is subject to significant uncertainty.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As discussed below, the Inflation Reduction Act&#160;of&#160;2022 (&#8220;IRA&#8221;) is a significant new law that intends to foster generic and biosimilar competition and to lower drug and biologic costs.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Other Healthcare Laws and Compliance Requirements</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Pharmaceutical companies are subject to additional healthcare regulation and enforcement by the federal government and by authorities in the states and foreign jurisdictions in which they conduct their business. Such laws include, without limitation: the federal Anti<span class="nobreak">-Kickback</span> Statute (&#8220;AKS&#8221;); the federal False Claims Act (&#8220;FCA&#8221;); the Health Insurance Portability and Accountability Act&#160;of&#160;1996 (&#8220;HIPAA&#8221;) and similar foreign, federal and state fraud, abuse and transparency laws.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The AKS prohibits, among other things, persons and entities from knowingly and willfully soliciting, receiving, offering or paying remuneration, to induce, or in return for, either the referral of an individual, or the purchase or recommendation of an item or service for which payment may be made under any federal healthcare program. The term remuneration has been interpreted broadly to include anything of value.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The AKS has been interpreted to apply to arrangements between pharmaceutical manufacturers on one hand, and prescribers and purchasers on the other. The government often takes the position that to violate the AKS, only one purpose of the remuneration need be to induce referrals, even if there are other legitimate purposes for the remuneration. There are a number of statutory exceptions and regulatory safe harbors protecting some common activities from AKS prosecution, but they are drawn narrowly and practices that involve remuneration, such as consulting agreements, that may be alleged to be intended to induce prescribing, purchasing or recommending may be subject to scrutiny if they do not qualify for an exception or safe harbor. Oruka&#8217;s practices may not in all cases meet all of the criteria for protection under a statutory exception or regulatory safe harbor. Failure to meet all of the requirements of a particular applicable statutory exception or regulatory safe harbor does not make the conduct per </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">235</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">se illegal under the AKS.&#160;Instead, the legality of the arrangement will be evaluated on a case<span class="nobreak">-by-case</span> basis based on a cumulative review of all of its facts and circumstances. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Civil and criminal false claims laws, including the FCA, and civil monetary penalty laws, which can be enforced through civil whistleblower or qui tam actions, prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment of federal government funds, including in federal healthcare programs, that are false or fraudulent. Pharmaceutical and other healthcare companies have been prosecuted under these laws for engaging in a variety of different types of conduct that &#8220;caused&#8221; the submission of false claims to federal healthcare programs. Under the AKS, for example, a claim resulting from a violation of the AKS is deemed to be a false or fraudulent claim for purposes of the FCA.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">HIPAA created additional federal criminal statutes that prohibit, among other things, executing a scheme to defraud any healthcare benefit program, including private third<span class="nobreak">-party</span> payors, and making false statements relating to healthcare matters. A person or entity does not need to have actual knowledge of the healthcare fraud statute implemented under HIPAA or specific intent to violate the statute in order to have committed a violation.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The FDCA addresses, among other things, the design, production, labeling, promotion, manufacturing, and testing of drugs, biologics and medical devices, and prohibits such acts as the introduction into interstate commerce of adulterated or misbranded drugs or devices. The PHSA also prohibits the introduction into interstate commerce of unlicensed or mislabeled biological products.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The U.S.&#160;federal Physician Payments Sunshine Act requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program, with specific exceptions, to annually report to the Centers for Medicaid&#160;&amp; Medicare Services (&#8220;CMS&#8221;) information related to payments or other transfers of value to various healthcare professionals including physicians, physician assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists, certified nurse<span class="nobreak">-midwives</span>, and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members. Beginning on January&#160;1, 2023, California Assembly Bill 1278 requires California physicians and surgeons to notify patients of the Open Payments database established under the federal Physician Payments Sunshine Act.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We are also subject to additional similar U.S.&#160;state and foreign law equivalents of each of the above federal laws, which, in some cases, differ from each other in significant ways, and may not have the same effect, thus complicating compliance efforts. If Oruka&#8217;s operations are found to be in violation of any of such laws or any other governmental regulations that apply, Oruka may be subject to penalties, including, without limitation, civil, criminal and administrative penalties, damages, fines, exclusion from government<span class="nobreak">-funded</span> healthcare programs, such as Medicare and Medicaid or similar programs in other countries or jurisdictions, integrity oversight and reporting obligations to resolve allegations of non<span class="nobreak">-compliance</span>, disgorgement, individual imprisonment, contractual damages, reputational harm, diminished profits and the curtailment or restructuring of Oruka&#8217;s operations.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Data Privacy and Security</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Numerous state, federal, and foreign laws govern the collection, dissemination, use, access to, confidentiality, and security of personal information, including health<span class="nobreak">-related</span> information. In the United&#160;States, numerous federal and state laws and regulations, including state data breach notification laws, state health information privacy laws, and federal and state consumer protection laws and regulations, govern the collection, use, disclosure, and protection of health<span class="nobreak">-related</span> and other personal information could apply to Oruka&#8217;s operations or the operations of Oruka&#8217;s partners. For example, HIPAA, as amended by the Health Information Technology for Economic and Clinical Health (&#8220;HITECH&#8221;), and their respective implementing regulations imposes data privacy, security, and breach notification obligations on certain health care providers, health plans, and health care clearinghouses, known as covered entities, as well as their business associates and their covered subcontractors that perform certain services that involve using, disclosing, creating, receiving, maintaining, or transmitting individually identifiable protected health information (&#8220;PHI&#8221;) for or on behalf of such covered entities. These requirements imposed by HIPAA and the HITECH Act on covered entities and business associates include entering into agreements that require business associates protect PHI provided by the covered entity against improper use or disclosure, among other things; following certain standards for the privacy of PHI, which limit the disclosure of a patient&#8217;s past, present, or future physical or mental health or condition or information about a </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">236</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">patient&#8217;s receipt of health care if the information identifies, or could reasonably be used to identify, the individual; ensuring the confidentiality, integrity, and availability of all PHI created, received, maintained, or transmitted in electronic form, to identify and protect against reasonably anticipated threats or impermissible uses or disclosures to the security and integrity of such PHI; and reporting of breaches of PHI to individuals and regulators. Entities that are found to be in violation of HIPAA may be subject to significant civil, criminal, and administrative fines and penalties and/or additional reporting and oversight obligations if required to enter into a resolution agreement and corrective action plan with the U.S.&#160;Department of Health and Human Services (&#8220;HHS&#8221;) to settle allegations of HIPAA non<span class="nobreak">-compliance</span>. A covered entity or business associate is also liable for civil money penalties for a violation that is based on an act or omission of any of its agents, which may include a downstream business associate, as determined according to the federal common law of agency. HITECH also increased the civil and criminal penalties applicable to covered entities and business associates and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce HIPAA and seek attorneys&#8217; fees and costs associated with pursuing federal civil actions. To the extent that Oruka submit electronic healthcare claims and payment transactions that do not comply with the electronic data transmission standards established under HIPAA and HITECH, payments to Oruka may be delayed or denied.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Even when HIPAA does not apply, according to the FTC, violating consumers&#8217; privacy rights or failing to take appropriate steps to keep consumers&#8217; personal information secure may constitute unfair acts or practices in or affecting commerce in violation of Section&#160;5(a)&#160;of the Federal Trade Commission Act.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, certain state laws, such as the California Consumer Privacy Act&#160;of&#160;2018 (&#8220;CCPA&#8221;), as amended by the California Privacy Rights Act&#160;of&#160;2020 (&#8220;CPRA&#8221;), govern the privacy and security of personal information, including health<span class="nobreak">-related</span> information in certain circumstances, some of which are more stringent than HIPAA and many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. The CCPA/CPRA applies to personal data of consumers, business representatives, and employees, and imposes obligations on certain businesses that do business in California, including to provide specific disclosures in privacy notices, rights to California residents in relation to their personal information. Health information falls under the CCPA/CPRA&#8217;s definition of personal information where it identifies, relates to, describes, or is reasonably capable of being associated with or could reasonably be linked with a particular consumer or household&#160;&#8212;&#160;unless it is subject to HIPAA&#160;&#8212;&#160;and is included under a new category of personal information, &#8220;sensitive personal information,&#8221; which is offered greater protection. Failure to comply with these laws, where applicable, can result in the imposition of significant civil and/or criminal penalties and private litigation. Privacy and security laws, regulations, and other obligations are constantly evolving, may conflict with each other to complicate compliance efforts, and can result in investigations, proceedings, or actions that lead to significant civil and/or criminal penalties and restrictions on data processing. Additionally, Oruka&#8217;s use of artificial intelligence and machine learning may be subject to laws and evolving regulations regarding the use of artificial intelligence/machine learning, controlling for data bias, and antidiscrimination.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, the CPRA expands the CCPA&#8217;s requirements, including by adding a new right for individuals to correct their personal information and establishing a new regulatory agency to implement and enforce the law. Other states, such as Virginia, Colorado, Connecticut and Utah, have also passed comprehensive privacy laws, and similar laws are being considered in several other states, as well as at the federal and local levels. While the laws in these states, like the CCPA, also exempt some data processed in the context of clinical trials, such developments further complicate compliance efforts, and increase legal risk and compliance costs for Oruka and the third parties upon whom Oruka relies.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Coverage and Reimbursement</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Significant uncertainty exists as to the coverage and reimbursement status of any pharmaceutical or biological product for which Oruka obtains regulatory approval. Sales of any product, if approved, depend, in part, on the extent to which such product will be covered by third<span class="nobreak">-party</span> payors, such as federal, state, and foreign government healthcare programs, commercial insurance and managed healthcare organizations, and the level of reimbursement, if any, for such product by third<span class="nobreak">-party</span> payors. Decisions regarding whether to cover any of Oruka&#8217;s product candidates, if approved, the extent of coverage and amount of reimbursement to be provided are made on a plan<span class="nobreak">-by-plan</span> basis. Further, no uniform policy for coverage and reimbursement exists in the United&#160;States, and coverage and reimbursement can differ significantly from payor to payor. Third<span class="nobreak">-party</span> payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement rates, but also have their own </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">237</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">methods and approval process apart from Medicare determinations. As a result, the coverage determination process is often a time<span class="nobreak">-consuming</span> and costly process that will require Oruka to provide scientific and clinical support for the use of Oruka&#8217;s product candidates to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Third<span class="nobreak">-party</span> payors are increasingly challenging the prices charged for medical products and services, examining the medical necessity and reviewing the cost effectiveness of pharmaceutical or biological products, medical devices and medical services, in addition to questioning safety and efficacy. Adoption of price controls and cost<span class="nobreak">-containment</span> measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit sales of any product that receives approval. Decreases in third<span class="nobreak">-party</span> reimbursement for any product or a decision by a third<span class="nobreak">-party</span> not to cover a product could reduce physician usage and patient demand for the product.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">For products administered under the supervision of a physician, obtaining coverage and adequate reimbursement may be particularly difficult because of the higher prices often associated with such drugs. Additionally, separate reimbursement for the product itself or the treatment or procedure in which the product is used may not be available, which may impact physician utilization. In addition, companion diagnostic tests require coverage and reimbursement separate and apart from the coverage and reimbursement for their companion pharmaceutical or biological products. Similar challenges to obtaining coverage and reimbursement, applicable to pharmaceutical or biological products, will apply to companion diagnostics.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, the U.S.&#160;government, state legislatures and foreign governments have continued implementing cost<span class="nobreak">-containment</span> programs, including price controls, restrictions on coverage and reimbursement and requirements for substitution of generic products. The IRA provides CMS with significant new authorities intended to curb drug costs and to encourage market competition. For the first time, CMS will be able to directly negotiate prescription drug prices and to cap out<span class="nobreak">-of-pocket</span> costs. Each year, CMS will select and negotiate a preset number of high<span class="nobreak">-spend</span> drugs and biologics that are covered under Medicare Part&#160;B and Part&#160;D that do not have generic or biosimilar competition. On August&#160;29, 2023, HHS announced the list of the first ten drugs that will be subject to price negotiations. These price negotiations will begin in 2023, although the Medicare drug price negotiation program is currently subject to legal challenges. The IRA also provides a new &#8220;inflation rebate&#8221; covering Medicare patients that took effect in 2023 and is intended to counter certain price increases in prescriptions drugs. The inflation rebate provision will require drug manufacturers to pay a rebate to the federal government if the price for a drug or biologic under Medicare Part&#160;B and Part&#160;D increases faster than the rate of inflation. To support biosimilar competition, beginning in October&#160;2022, qualifying biosimilars may receive a Medicare Part&#160;B payment increase for a period of five&#160;years. Separately, if a biologic drug for which no biosimilar exists delays a biosimilar&#8217;s market entry beyond two&#160;years, CMS will be authorized to subject the biologics manufacturer to price negotiations intended to ensure fair competition. Notwithstanding these provisions, the IRA&#8217;s impact on commercialization and competition remains largely uncertain.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Healthcare Reform</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The United&#160;States and some foreign jurisdictions are considering or have enacted a number of reform proposals to change the healthcare system. There is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality or expanding access. In the United&#160;States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by federal and state legislative initiatives, including those designed to limit the pricing, coverage, and reimbursement of pharmaceutical and biopharmaceutical products, especially under government<span class="nobreak">-funded</span> health care programs, and increased governmental control of drug pricing.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The ACA, which was enacted in March&#160;2010, substantially changed the way healthcare is financed by both governmental and private insurers in the United&#160;States, and significantly affected the pharmaceutical industry. The ACA contains a number of provisions of particular import to the pharmaceutical and biotechnology industries, including, but not limited to, those governing enrollment in federal healthcare programs, a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected, and annual fees based on pharmaceutical companies&#8217; share of sales to federal health care programs. Since its enactment, there have been judicial and Congressional challenges to certain aspects of the ACA, and Oruka expects there will be additional challenges and amendments to the ACA in </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">238</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">the future. For example, the IRA, among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces through plan year 2025. The IRA also eliminates the &#8220;donut hole&#8221; under the Medicare Part&#160;D program beginning in 2025 by significantly lowering the beneficiary maximum out<span class="nobreak">-of-pocket</span> cost and creating a new manufacturer discount program.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Other legislative changes have been proposed and adopted since the ACA was enacted, including automatic aggregate reductions of Medicare payments to providers of on average 2% per fiscal year as part of the federal budget sequestration under the Budget Control Act&#160;of&#160;2011. These reductions went into effect in April&#160;2013 and, due to subsequent legislative amendments, will remain in effect until 2032 unless additional action is taken by Congress.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, the Bipartisan Budget Act&#160;of&#160;2018, among other things, amended the Medicare Act (as amended by the ACA) to increase the point<span class="nobreak">-of-sale</span> discounts that manufacturers must agree to offer under the Medicare Part&#160;D coverage discount program from 50% to 70% off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs being covered under Medicare Part&#160;D.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Moreover, there has recently been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed and enacted federal and state measures designed to, among other things, reduce the cost of prescription drugs, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products. For example, in May&#160;2019, CMS adopted a final rule allowing Medicare Advantage Plans the option to use step therapy for Part&#160;B drugs, permitting Medicare Part&#160;D plans to apply certain utilization controls to new starts of five of the six protected class drugs, and requiring the Explanation of Benefits for Part&#160;D beneficiaries to disclose drug price increases and lower cost therapeutic alternatives, which went into effect on January&#160;1, 2021. In response to the Biden administration&#8217;s October&#160;2022 executive order, on February&#160;14, 2023, HHS released a report outlining three new models for testing by the CMS Innovation Center which will be evaluated on their ability to lower the cost of drugs, promote accessibility, and improve quality of care. It is unclear whether the models will be utilized in any health reform measures in the future. Further, on December&#160;7, 2023, the Biden administration announced an initiative to control the price of prescription drugs through the use of march<span class="nobreak">-in</span> rights under the Bayh<span class="nobreak">-Dole</span> Act. On December&#160;8, 2023, the National Institute of Standards and Technology published for comment a Draft Interagency Guidance Framework for Considering the Exercise of March<span class="nobreak">-In</span> Rights which for the first time includes the price of a product as one factor an agency can use when deciding to exercise march<span class="nobreak">-in</span> rights. While march<span class="nobreak">-in</span> rights have not previously been exercised, it is uncertain if that will continue under the new framework.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Notwithstanding the IRA, continued legislative and enforcement interest exists in the United&#160;States with respect to specialty drug pricing practices. Specifically, Oruka expects regulators to continue pushing for transparency to drug pricing, reducing the cost of prescription drugs under Medicare, reviewing the relationship between pricing and manufacturer patient programs, and reforming government program reimbursement methodologies for drugs.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Other Government Regulation&#160;Outside of the United&#160;States</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition to regulations in the United&#160;States, Oruka is subject to a variety of regulations in other jurisdictions governing, among other things, research and development, clinical trials, testing, manufacturing, safety, efficacy, quality control, labeling, packaging, storage, record keeping, distribution, reporting, export and import, advertising, marketing and other promotional practices involving biological products as well as authorization, approval as well as post<span class="nobreak">-approval</span> monitoring and reporting of Oruka&#8217;s products. Because biologically sourced raw materials are subject to unique contamination risks, their use may be restricted in some countries.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Whether or not Oruka obtains FDA approval for a product, Oruka must obtain the requisite approvals from regulatory authorities in foreign countries prior to the commencement of clinical trials or marketing of the product in those countries. Certain countries outside of the United&#160;States have a similar process that requires the submission of a clinical trial application much like the IND prior to the commencement of human clinical trials.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The requirements and process governing the conduct of clinical trials, including requirements to conduct additional clinical trials, product licensing, safety reporting, post<span class="nobreak">-authorization</span> requirements, marketing and promotion, interactions with healthcare professionals, pricing and reimbursement may vary widely from country </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">239</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">to country. No action can be taken to market any product in a country until an appropriate approval application has been approved by the regulatory authorities in that country. The current approval process varies from country to country, and the time spent in gaining approval varies from that required for FDA approval. In certain countries, the sales price of a product must also be approved. The pricing review period often begins after market approval is granted. Even if a product is approved by a regulatory authority, satisfactory prices may not be approved for such product, which would make launch of such products commercially unfeasible in such countries.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Regulation in the European Union</span></p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">European Data Laws</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The collection and use of personal health data and other personal data in the EU is governed by the provisions of the European General Data Protection Regulation (EU) 2016/679 (&#8220;GDPR&#8221;), which came into force in May&#160;2018, and related data protection laws in individual EU Member States. The GDPR imposes a number of strict obligations and restrictions on the ability to process, including collecting, analyzing and transferring, personal data of individuals, in particular with respect to health data from clinical trials and adverse event reporting. The GDPR includes requirements relating to the legal basis of the processing (such as consent of the individuals to whom the personal data relates), the information provided to the individuals prior to processing their personal data, the notification obligations to the national data protection authorities, and the security and confidentiality of the personal data. EU Member States may also impose additional requirements in relation to health, genetic and biometric data through their national legislation.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, the GDPR imposes specific restrictions on the transfer of personal data to countries outside of the European Economic Area (&#8220;EEA&#8221;) that are not considered by the European Commission (&#8220;EC&#8221;) to provide an adequate level of data protection. Appropriate safeguards are required to enable such transfers. Among the appropriate safeguards that can be used, the data exporter may use the standard contractual clauses (&#8220;SCCs&#8221;). With regard to the transfer of data from the EEA to the United&#160;States, on July&#160;10, 2023, the EC adopted its adequacy decision for the EU<span class="nobreak">-US</span> Data Privacy Framework. On the basis of the new adequacy decision, personal data can flow from the EEA to U.S.&#160;companies participating in the framework.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Failure to comply with the requirements of the GDPR and the related national data protection laws of the EU Member States may result in significant monetary fines for noncompliance of up to &#8364;20&#160;million or 4% of the annual global revenues of the noncompliant company, whichever is greater, other administrative penalties and a number of criminal offenses (punishable by uncapped fines) for organizations and, in certain cases, their directors and officers, as well as civil liability claims from individuals whose personal data was processed. Data protection authorities from the different EU Member States may still implement certain variations, enforce the GDPR and national data protection laws differently, and introduce additional national regulations and guidelines, which adds to the complexity of processing personal data in the EU.&#160;Guidance developed at both the EU level and at the national level in individual EU Member States concerning implementation and compliance practices are often updated or otherwise revised.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Furthermore, there is a growing trend towards the required public disclosure of clinical trial data in the EU, which adds to the complexity of obligations relating to processing health data from clinical trials. Such public disclosure obligations are provided in the new EU Clinical Trials Regulation&#160;No. 536/2014 (&#8220;CTR&#8221;), European Medical Agency (&#8220;EMA&#8221;) disclosure initiatives and voluntary commitments by industry. Failure to comply with these obligations could lead to government enforcement actions and significant penalties against Oruka, harm to Oruka&#8217;s reputation, and adversely impact Oruka&#8217;s business and operating results. The uncertainty regarding the interplay between different regulatory frameworks, such as the CTR and the GDPR, further adds to the complexity that Oruka faces with regard to data protection regulation. With regard to the transfer of personal data from the EEA to the UK, personal data may now freely flow from the EEA to the UK since the UK is deemed to have an adequate data protection level.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">However, the adequacy decisions include a &#8216;sunset clause&#8217; which entails that the decisions will automatically expire four&#160;years after their entry into force. Additionally, following the UK&#8217;s withdrawal from the EU and the EEA, companies also have to comply with the UK&#8217;s data protection laws (including the UK GDPR (as defined </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">240</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">in section&#160;3(10)&#160;(as supplemented by section 205(4)) of the Data Protection Act&#160;2018 (the &#8220;DPA&#160;2018&#8221;)), the DPA&#160;2018, and related data protection laws in the UK). Separate from the fines that can be imposed by the GDPR, the UK regime has the ability to fine up to the greater of &#163;17.5&#160;million or 4% of global turnover.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Following the UK&#8217;s withdrawal from the EU and the EEA, companies are subject to specific transfer rules under the UK regime; personal data may flow freely from the UK to the EEA, since the EEA is deemed to have an adequate data protection level for purposes of the UK regime. These UK international transfer rules broadly mirror the GDPR rules. On February&#160;2, 2022, the UK Secretary of State laid before the UK Parliament the international data transfer agreement (&#8220;IDTA&#8221;) and the international data transfer addendum to the EC&#8217;s standard contractual clauses for international data transfers (Addendum) and a document setting out transitional provisions. The IDTA and Addendum came into force on March&#160;21, 2022 and replaced the old SCCs for the purposes of the UK regime. However, the transitional provisions, adopted with the IDTA and the Addendum, provide that contracts concluded on or before September&#160;21, 2022 on the basis of any old SCCs continue to provide appropriate safeguards for the purpose of the UK regime until March&#160;21, 2024, provided that the processing operations that are the subject matter of the contract remain unchanged and reliance on those clauses ensures that the transfer of personal data is subject to appropriate safeguards.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">With regard to the transfer of personal data from the UK to the United&#160;States, the UK government has adopted an adequacy decision for the United&#160;States, the UK<span class="nobreak">-US</span> Data Bridge, which came into force on October&#160;12, 2023. The UK<span class="nobreak">-US</span> Data Bridge recognizes the United&#160;States as offering an adequate level of data protection where the transfer is to a U.S.&#160;company participating in the EU<span class="nobreak">-US</span> Data Privacy Framework and the UK Extension.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Drug and Biologic Development Process</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Regardless of where they are conducted, all clinical trials included in applications for marketing authorization (&#8220;MA&#8221;) for human medicines in the EU/EEA must have been carried out in accordance with EU regulations. This means that clinical trials conducted in the EU/EEA have to comply with EU clinical trial legislation but also that clinical trials conducted outside the EU/EEA have to comply with ethical principles equivalent to those set out in the EEA, including adhering to international good clinical practice and the Declaration of Helsinki. The conduct of clinical trials in the EU is governed by the CTR, which entered into force on January&#160;31, 2022. The CTR replaced the Clinical Trials Directive 2001/20/EC, (&#8220;Clinical Trials Directive&#8221;) and introduced a complete overhaul of the existing regulation of clinical trials for medicinal products in the EU.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Under the former regime, which will expire after a transition period of three&#160;years as outlined below in more detail, before a clinical trial can be initiated it must be approved in each EU member state where there is a site at which the clinical trial is to be conducted. The approval must be obtained from two separate entities: the National Competent Authority (&#8220;NCA&#8221;) and one or more Ethics Committees. NCA of the EU Member States in which the clinical trial will be conducted must authorize the conduct of the trial, and the independent Ethics Committee must grant a positive opinion in relation to the conduct of the clinical trial in the relevant EU member state before the commencement of the trial. Any substantial changes to the trial protocol or other information submitted with the clinical trial applications must be submitted to or approved by the relevant NCA and Ethics Committees. Under the current regime all suspected unexpected serious adverse reactions to the investigated drug that occur during the clinical trial must be reported to the NCA and to the Ethics Committees of the EU member state where they occur.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">A more unified procedure will apply under the new CTR.&#160;A sponsor will be able to submit a single application for approval of a clinical trial through a centralized EU clinical trials portal (the &#8220;CTIS&#8221;). One national regulatory authority (the reporting EU member state proposed by the applicant) will take the lead in validating and evaluating the application and consult and coordinate with the other concerned EU Member States. If an application is rejected, it may be amended and resubmitted through the EU clinical trials portal. If an approval is issued, the sponsor may start the clinical trial in all concerned EU Member States. However, a concerned EU member state may in limited circumstances declare an &#8220;opt<span class="nobreak">-out</span>&#8221; from an approval and prevent the clinical trial from being conducted in such member state. The CTR also aims to streamline and simplify the rules on safety reporting, and introduces enhanced transparency requirements such as mandatory submission of a summary of the clinical trial results to the EU Database. The CTR foresees a three<span class="nobreak">-year</span> transition period. EU Member States will work in CTIS immediately after the system has gone live. Since January&#160;31, 2023, submission of initial clinical trial applications via CTIS is mandatory, and by January&#160;31, 2025, all ongoing trials approved under the former Clinical Trials Directive will need to comply with the CTR and have to be transitioned to CTIS.&#160;On July&#160;19, 2023, the EC </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">241</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">published guidance concerning the steps to be taken in this transition. This guidance provides, among other things, that (i)&#160;documentation which was previously assessed will not be reassessed, (ii)&#160;templates that were developed and endorsed by the EU Clinical Trials Expert Group to provide compliance with the CTR do not need to be updated and (iii)&#160;there is no need to retrospectively create a site suitability form, which are only necessary for new trial sites.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Under both the former regime and the new CTR, national laws, regulations, and the applicable GCP and GLP standards must also be respected during the conduct of the trials, including the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use guidelines on Good Clinical Practice and the ethical principles that have their origin in the Declaration of Helsinki.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">During the development of a medicinal product, the EMA and national regulators within the EU provide the opportunity for dialogue and guidance on the development program. At the EMA level, this is usually done in the form of scientific advice, which is given by the Committee for Medicinal Products for Human Use (&#8220;CHMP&#8221;) on the recommendation of the Scientific Advice Working Party. A fee is incurred with each scientific advice procedure, but is significantly reduced for designated orphan medicines. Advice from the EMA is typically provided based on questions concerning, for example, quality (chemistry, manufacturing and controls testing), nonclinical testing and clinical studies, and pharmacovigilance plans and risk<span class="nobreak">-management</span> programs. Advice is not legally binding with regard to any future Marketing Authorization Application (&#8220;MAA&#8221;) of the product concerned.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Drug Marketing Authorization</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In the EEA, after completion of all required clinical testing, pharmaceutical products may only be placed on the market after obtaining a MA.&#160;To obtain a MA of a drug under European Union regulatory systems, an applicant can submit an MAA through, amongst others, a centralized or decentralized procedure.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">To be used or sold in the UK, a drug must have an effective MA obtained by a centralized application through EMA or a national application. National applications are governed by the Human Medicines Regulations (SI 2012/1916). Applications are made electronically through the Medicines and Healthcare products Regulatory Agency (&#8220;MHRA&#8221;) Submissions Portal. The process from application to authorizations generally takes up to 210&#160;days, excluding time taken to provide any additional information or data required by the MHRA.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On August&#160;30, 2023, the MHRA published detailed guidance on its recently announced new International Reliance Procedure (&#8220;IRP&#8221;) for MAAs. The IRP applies since January&#160;1, 2024 and replaces existing EU reliance procedures to apply for authorizations from seven international regulators (e.g., Health Canada, Swiss Medic, FDA, EMA, among others). The IRP allows medicinal products approved in other jurisdictions that meet certain criteria to undergo a fast<span class="nobreak">-tracked</span> MHRA review to obtain and/or update a MA in the UK or Great Britain.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Applicants can submit initial MAAs to the IRP but the procedure can also be used throughout the lifecycle of a product for post<span class="nobreak">-authorization</span> procedures including line extensions, variations and renewals.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Centralized Authorization Procedure</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The centralized procedure provides for the grant of a single MA that is issued by the EC following the scientific assessment of the application by the EMA that is valid for all EU Member States as well as in the three additional member states of the EEA.&#160;The centralized procedure is compulsory for certain types of medicinal products, including for medicines developed by means of certain biotechnological processes, products designated as orphan medicinal products, advanced therapy medicinal products (&#8220;ATMP&#8221;) and medicinal products with a new active substance indicated for the treatment of certain diseases (AIDS, cancer, neurodegenerative disorders, diabetes, auto<span class="nobreak">-immune</span> and viral diseases). For medicinal products containing a new active substance not yet authorized in the EEA before May&#160;20, 2004 and indicated for the treatment of other diseases, medicinal products that constitute significant therapeutic, scientific or technical innovations or for which the grant of a MA through the centralized procedure would be in the interest of public health at EU level, an applicant may voluntarily submit an application for a MA through the centralized procedure.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Under the centralized procedure, the CHMP established at the EMA, is responsible for conducting the initial assessment of a drug. The CHMP is also responsible for several post<span class="nobreak">-authorization</span> and maintenance activities, such as the assessment of modifications or extensions to an existing MA.&#160;Under the centralized procedure, the timeframe for the evaluation of an MAA by the EMA&#8217;s CHMP is, in principle, 210&#160;days from receipt of a valid MAA.&#160;However, </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">242</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">this timeline excludes clock stops, when additional written or oral information is to be provided by the applicant in response to questions asked by the CHMP, so the overall process typically takes a year or more, unless the application is eligible for an accelerated assessment. Accelerated evaluation might be granted by the CHMP in exceptional cases, when a medicinal product is expected to be of a major public health interest, particularly from the point of view of therapeutic innovation. Upon request, the CHMP can reduce the time frame to 150&#160;days if the applicant provides sufficient justification for an accelerated assessment. The CHMP will provide a positive opinion regarding the application only if it meets certain quality, safety and efficacy requirements. This opinion is then transmitted to the EC, which has the ultimate authority for granting MA within 67&#160;days after receipt of the CHMP opinion.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Decentralized Authorization Procedure</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Medicines that fall outside the mandatory scope of the centralized procedure have three routes to authorization: (i)&#160;they can be authorized under the centralized procedure if they concern a significant therapeutic, scientific or technical innovation, or if their authorization would be in the interest of public health; (ii)&#160;they can be authorized under a decentralized procedure where an applicant applies for simultaneous authorization in more than one EU member state; or (iii)&#160;they can be authorized in an EU member state in accordance with that state&#8217;s national procedures and then be authorized in other EU countries by a procedure whereby the countries concerned agree to recognize the validity of the original, national MA (mutual recognition procedure).</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The decentralized procedure permits companies to file identical MA applications for a medicinal product to the competent authorities in various EU Member States simultaneously if such medicinal product has not received marketing approval in any EU Member State before. This procedure is available for pharmaceutical products not falling within the mandatory scope of the centralized procedure. The competent authority of a single EU Member State, the reference member state, is appointed to review the application and provide an assessment report. The competent authorities of the other EU Member States, the concerned member states, are subsequently required to grant a MA for their territories on the basis of this assessment. The only exception to this is where the competent authority of an EU Member State considers that there are concerns of potential serious risk to public health, the disputed points are subject to a dispute resolution mechanism and may eventually be referred to the EC, whose decision is binding for all EU Member States.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Risk Management Plan</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">All new MAAs must include a Risk Management Plan (&#8220;RMP&#8221;) describing the risk management system that the company will put in place and documenting measures to prevent or minimize the risks associated with the product. RMPs are continually modified and updated throughout the lifetime of the medicine as new information becomes available. An updated RMP must be submitted: (i)&#160;at the request of EMA or a national competent authority, or (ii)&#160;whenever the risk<span class="nobreak">-management</span> system is modified, especially as the result of new information being received that may lead to a significant change to the benefit<span class="nobreak">-risk</span> profile or as a result of an important pharmacovigilance or risk<span class="nobreak">-minimization</span> milestone being reached. The regulatory authorities may also impose specific obligations as a condition of the MA.&#160;Since October&#160;20, 2023, all RMPs for centrally authorized products are published by the EMA, subject only to limited redactions.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">MA Validity Period</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">MAs have an initial duration of five&#160;years. After these five&#160;years, the authorization may subsequently be renewed on the basis of a reevaluation of the risk<span class="nobreak">-benefit</span> balance. Once renewed, the MA is valid for an unlimited period unless the EC or the national competent authority decides, on justified grounds relating to pharmacovigilance, to proceed with only one additional five<span class="nobreak">-year</span> renewal. Applications for renewal must be made to the EMA at least nine&#160;months before the five<span class="nobreak">-year</span> period expires.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Additionally, the holder of a MA for an ATMP must put in place and maintain a system to ensure that each individual product and its starting and raw materials, including all substances coming into contact with the cells or tissues it may contain, can be traced through the sourcing, manufacturing, packaging, storage, transport and delivery to the relevant healthcare institution where the product is used.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">243</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Any authorization which is not followed by the actual placing of the drug on the EU market (in case of centralized procedure) or on the market of the authorizing member state within three&#160;years after authorization ceases to be valid.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">For the UK, the period of three&#160;years during which the drug has not been marketed in Great Britain will be restarted from the date of conversion to a Great Britain MA.&#160;Conversion refers to the procedure by which, as of January&#160;1, 2021, MAs granted on the basis of a centralized procedure in the EU are only valid in Northern Ireland but not in Great Britain, whereas, prior EU authorizations have all been automatically converted into UK MAs effective in Great Britain only.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On the other hand, for the EU, in the case the drug has been marketed in the UK, the placing on the UK market before the end of the period starting when the UK left the EU on January&#160;31, 2020 and ending on December&#160;31, 2020 (the &#8220;Brexit Transition Period&#8221;) will be taken into account. If, after the end of the Brexit Transition Period, the drug is not placed on any other market of the remaining EU Member States, the three<span class="nobreak">-year</span> period will start running from the last date the drug was placed on the UK market before the end of the Brexit Transition Period.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Advanced Therapy Medicinal Products</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In the EU, medicinal products, including ATMPs are subject to extensive pre- and post<span class="nobreak">-market</span> regulation by regulatory authorities at both the EU and national levels. ATMPs comprise gene therapy products, somatic cell therapy products and tissue engineered products, which are genes, cells or tissues that have undergone substantial manipulation and that are administered to human beings in order to cure, diagnose or prevent diseases or regenerate, repair or replace a human tissue. Pursuant to the ATMP Regulation, the Committee on Advanced Therapies (&#8220;CAT&#8221;) is responsible in conjunction with the CHMP for the evaluation of ATMPs. The CHMP and CAT are also responsible for providing guidelines on ATMPs. These guidelines provide additional guidance on the factors that the EMA will consider in relation to the development and evaluation of ATMPs and include, among other things, the preclinical studies required to characterize ATMPs. Although such guidelines are not legally binding, compliance with them is often necessary to gain and maintain approval for product candidates.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition to the mandatory RMP, the holder of a MA for an ATMP must put in place and maintain a system to ensure that each individual product and its starting and raw materials, including all substances coming into contact with the cells or tissues it may contain, can be traced through the sourcing, manufacturing, packaging, storage, transport and delivery to the relevant healthcare institution where the product is used.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Exceptional Circumstances/Conditional Approval</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Similar to accelerated approval regulations in the United&#160;States, conditional MAs can be granted in the EU in exceptional circumstances. A conditional MA can be granted for medicinal products where, although comprehensive clinical data referring to the safety and efficacy of the medicinal product have not been supplied, a number of criteria are fulfilled: (i)&#160;the benefit/risk balance of the product is positive, (ii)&#160;it is likely that the applicant will be in a position to provide the comprehensive clinical data, (iii)&#160;unmet medical needs will be fulfilled by the grant of the MA and (iv)&#160;the benefit to public health of the immediate availability on the market of the medicinal product concerned outweighs the risk inherent in the fact that additional data are still required. A conditional MA must be renewed annually.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Data and Market Exclusivity</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As in the United&#160;States, it may be possible to obtain a period of market and / or data exclusivity in the EU that would have the effect of postponing the entry into the marketplace of a competitor&#8217;s generic, hybrid or biosimilar product (even if the pharmaceutical product has already received a MA) and prohibiting another applicant from relying on the MA holder&#8217;s pharmacological, toxicological and clinical data in support of another MA for the purposes of submitting an application, obtaining MA or placing the product on the market. New Chemical Entities (&#8220;NCEs&#8221;) approved in the EU qualify for eight&#160;years of data exclusivity and 10&#160;years of marketing exclusivity.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">An additional non<span class="nobreak">-cumulative</span> one<span class="nobreak">-year</span> period of marketing exclusivity is possible if during the data exclusivity period (the first eight&#160;years of the 10<span class="nobreak">-year</span> marketing exclusivity period), the MA holder obtains an authorization for one or more new therapeutic indications that are deemed to bring a significant clinical benefit compared to existing therapies.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">244</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The data exclusivity period begins on the date of the product&#8217;s first MA in the EU.&#160;After eight&#160;years, a generic product application may be submitted and generic companies may rely on the MA holder&#8217;s data. However, a generic product cannot launch until two&#160;years later (or a total of 10&#160;years after the first MA in the EU of the innovator product), or three&#160;years later (or a total of 11&#160;years after the first MA in the EU of the innovator product) if the MA holder obtains MA for a new indication with significant clinical benefit within the eight<span class="nobreak">-year</span> data exclusivity period. Additionally, another non<span class="nobreak">-cumulative</span> one<span class="nobreak">-year</span> period of data exclusivity can be added to the eight&#160;years of data exclusivity where an application is made for a new indication for a well<span class="nobreak">-established</span> substance, provided that significant preclinical or clinical studies were carried out in relation to the new indication.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Another year of data exclusivity may be added to the eight&#160;years, where a change of classification of a pharmaceutical product has been authorized on the basis of significant pre<span class="nobreak">-trial</span> tests or clinical trials (when examining an application by another applicant for or holder of MA for a change of classification of the same substance the competent authority will not refer to the results of those tests or trials for one year after the initial change was authorized).</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Products may not be granted data exclusivity since there is no guarantee that a product will be considered by the EU&#8217;s regulatory authorities to include an NCE.&#160;Even if a compound is considered to be an NCE and the MA applicant is able to gain the prescribed period of data exclusivity, another company nevertheless could also market another version of the medicinal product if such company can complete a full MAA with their own complete database of pharmaceutical tests, preclinical studies and clinical trials and obtain MA of its product.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On April&#160;26, 2023, the EC submitted a proposal for the reform of the European pharmaceutical legislation. The current draft envisages e.g., a shortening of the periods of data exclusivity, however, there is currently neither a final version of this draft nor a date for its entry into force.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Orphan Designation and Exclusivity</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The criteria for designating an orphan medicinal product in the EU are similar in principle to those in the U.S.&#160;The EMA grants orphan drug designation if the medicinal product is intended for the diagnosis, prevention or treatment of a life<span class="nobreak">-threatening</span> or chronically debilitating condition affecting no more than five in 10,000 persons in the EU (prevalence criterion). In addition, orphan drug designation can be granted if, for economic reasons, the medicinal product would be unlikely to be developed without incentives and if there is no other satisfactory method approved in the EU of diagnosing, preventing, or treating the condition, or if such a method exists, the proposed medicinal product is a significant benefit to patients affected by the condition. An application for orphan drug designation (which is not a MA, as not all orphan<span class="nobreak">-designated</span> medicines reach the authorization application stage) must be submitted first before an application for MA of the medicinal product is submitted. The applicant will receive a fee reduction for the MAA if the orphan drug designation has been granted, but not if the designation is still pending at the time the MA is submitted, and sponsors must submit an annual report to EMA summarizing the status of development of the medicine. Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process. Designated orphan medicines are eligible for conditional MA.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The EMA&#8217;s Committee for Orphan Medicinal Products reassesses the orphan drug designation of a product in parallel with the review for a MA; for a product to benefit from market exclusivity it must maintain its orphan drug designation at the time of MA review by the EMA and approval by the EC.&#160;Additionally, any MA granted for an orphan medicinal product must only cover the therapeutic indication(s)&#160;that are covered by the orphan drug designation. Upon the grant of a MA, orphan drug designation provides up to ten&#160;years of market exclusivity in the orphan indication.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">During the 10<span class="nobreak">-year</span> period of market exclusivity, with a limited number of exceptions, the regulatory authorities of the EU Member States and the EMA may not accept applications for MA, accept an application to extend an existing MA or grant a MA for other similar medicinal products for the same therapeutic indication. A similar medicinal product is defined as a medicinal product containing a similar active substance or substances as contained in a currently authorized orphan medicinal product, and which is intended for the same therapeutic indication. An orphan medicinal product can also obtain an additional two&#160;years of market exclusivity for an orphan<span class="nobreak">-designated</span> condition when the results of specific studies are reflected in the Summary of Product </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">245</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">Characteristics (&#8220;SmPC&#8221;) addressing the pediatric population and completed in accordance with a fully compliant Pediatric Investigation Plan (&#8220;PIP&#8221;). No extension to any supplementary protection certificate can be granted on the basis of pediatric studies for orphan indications.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The 10<span class="nobreak">-year</span> market exclusivity may be reduced to six&#160;years if, at the end of the fifth year, it is established that the product no longer meets the criteria for orphan designation, i.e., the condition prevalence or financial returns criteria under Article&#160;3 of Regulation (EC) No. 141/2000 on orphan medicinal products. When the period of orphan market exclusivity for an indication ends, the orphan drug designation for that indication expires as well. Orphan exclusivity runs in parallel with normal rules on data exclusivity and market protection. Additionally, a MA may be granted to a similar medicinal product (orphan or not) for the same or overlapping indication subject to certain requirements.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In the UK, following the post<span class="nobreak">-Brexit</span> transition period, a system for incentivizing the development of orphan medicines was introduced. Overall, the requirements for orphan designation largely replicate the requirements in the EU and the benefit of market exclusivity has been retained. Products with an orphan designation in the EU can be considered for an orphan MA in Great Britain, but a UK<span class="nobreak">-wide</span> orphan MA can only be considered in the absence of an active EU orphan designation. The MHRA will review applications for orphan designation at the time of a MA, and will offer incentives, such as market exclusivity and full or partial refunds for MA fees to encourage the development of medicines in rare diseases.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Pediatric Development</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In the EU, companies developing a new medicinal product are obligated to study their product in children and must therefore submit a PIP together with a request for agreement to the EMA.&#160;The EMA issues a decision on the PIP based on an opinion of the EMA&#8217;s Pediatric Committee. Companies must conduct pediatric clinical trials in accordance with the PIP approved by the EMA, unless a deferral (e.g., until enough information to demonstrate its effectiveness and safety in adults is available) or waiver (e.g., because the relevant disease or condition occurs only in adults) has been granted by the EMA.&#160;The MAA for the medicinal product must include the results of all pediatric clinical trials performed and details of all information collected in compliance with the approved PIP, unless a waiver or a deferral has been granted, in which case the pediatric clinical trials may be completed at a later date. Medicinal products that are granted an MA on the basis of the pediatric clinical trials conducted in accordance with the approved PIP are eligible for a six<span class="nobreak">-month</span> extension of the protection under a supplementary protection certificate (if any is in effect at the time of approval), or, in the case of orphan medicinal products, a two year extension of the orphan market exclusivity. This pediatric reward is subject to specific conditions and is not automatically available when data in compliance with the approved PIP are developed and submitted. An approved PIP is also required when a MA holder wants to add a new indication, medicinal form or route of administration for a medicine that is already authorized and covered by intellectual property rights.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In the UK, the MHRA has published guidance on the procedures for UK PIPs which, where possible, mirror the submission format and requirements of the EU system. EU PIPs remain applicable for Northern Ireland and EU PIPs agreed by the EMA prior to January&#160;1, 2021 have been adopted as UK PIPs.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">PRIME Designation</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In March&#160;2016, the EMA launched an initiative to facilitate development of product candidates in indications, often rare, for which few or no therapies currently exist. The Priority Medicines (&#8220;PRIME&#8221;) scheme is intended to encourage drug development in areas of unmet medical need and provides accelerated assessment of products representing substantial innovation reviewed under the centralized procedure. Products from small<span class="nobreak">-and</span> medium<span class="nobreak">-sized</span> enterprises may qualify for earlier entry into the PRIME scheme than larger companies on the basis of compelling non<span class="nobreak">-clinical</span> data and tolerability data from initial clinical trials. Many benefits accrue to sponsors of product candidates with PRIME designation, including but not limited to, early and proactive regulatory dialogue with the EMA, frequent discussions on clinical trial designs and other development program elements, and potentially accelerated MAA assessment once a dossier has been submitted. Importantly, once a candidate medicine has been selected for the PRIME scheme, a dedicated contact point and rapporteur from the CHMP or CAT are appointed facilitating increased understanding of the product at EMA&#8217;s Committee level. A kick<span class="nobreak">-off</span> meeting with the CHMP/CAT rapporteur initiates these relationships and includes a team of multidisciplinary experts to provide </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">246</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">guidance on the overall development plan and regulatory strategy. PRIME eligibility does not change the standards for product approval, and there is no assurance that any such designation or eligibility will result in expedited review or approval.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Post-Approval Regulation</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Similar to the United&#160;States, both MA holders and manufacturers of medicinal products are subject to comprehensive regulatory oversight by the EMA, the EC and/or the competent regulatory authorities of the EU Member States. This oversight applies both before and after grant of manufacturing licenses and MAs. It includes control of compliance with EU good manufacturing practices rules, manufacturing authorizations, pharmacovigilance rules and requirements governing advertising, promotion, sale, and distribution, recordkeeping, importing and exporting of medicinal products.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Failure by Oruka or by any of its third<span class="nobreak">-party</span> partners, including suppliers, manufacturers and distributors to comply with EU laws and the related national laws of individual EU Member States governing the conduct of clinical trials, manufacturing approval, MA of medicinal products and marketing of such products, both before and after grant of MA, statutory health insurance, bribery and anti<span class="nobreak">-corruption</span> or other applicable regulatory requirements may result in administrative, civil or criminal penalties. These penalties could include delays or refusal to authorize the conduct of clinical trials or to grant MA, product withdrawals and recalls, product seizures, suspension, withdrawal or variation of the MA, total or partial suspension of production, distribution, manufacturing or clinical trials, operating restrictions, injunctions, suspension of licenses, fines and criminal penalties.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The holder of MA for a medicinal product must also comply with EU pharmacovigilance legislation and its related regulations and guidelines, which entail many requirements for conducting pharmacovigilance, or the assessment and monitoring of the safety of medicinal products.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">These pharmacovigilance rules can impose on holders of MAs the obligation to conduct a labor intensive collection of data regarding the risks and benefits of marketed medicinal products and to engage in ongoing assessments of those risks and benefits, including the possible requirement to conduct additional clinical studies or post<span class="nobreak">-authorization</span> safety studies to obtain further information on a medicine&#8217;s safety, or to measure the effectiveness of risk<span class="nobreak">-management</span> measures, which may be time consuming and expensive and could impact Oruka&#8217;s profitability. MA holders must establish and maintain a pharmacovigilance system and appoint an individual qualified person for pharmacovigilance, who is responsible for oversight of that system. Key obligations include expedited reporting of suspected serious adverse reactions and submission of Periodic Safety Update Reports (&#8220;PSURs&#8221;) in relation to medicinal products for which they hold MAs. The EMA reviews PSURs for medicinal products authorized through the centralized procedure. If the EMA has concerns that the risk benefit profile of a product has varied, it can adopt an opinion advising that the existing MA for the product be suspended, withdrawn or varied. The agency can advise that the MA holder be obliged to conduct post<span class="nobreak">-authorization</span> Phase&#160;4 safety studies. If the EC agrees with the opinion, it can adopt a decision varying the existing MA.&#160;Failure by the MA holder to fulfill the obligations for which the EC&#8217;s decision provides can undermine the ongoing validity of the MA.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">More generally, non<span class="nobreak">-compliance</span> with pharmacovigilance obligations can lead to the variation, suspension or withdrawal of the MA for the product or imposition of financial penalties or other enforcement measures.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The manufacturing process for pharmaceutical products in the EU is highly regulated and regulators may shut down manufacturing facilities that they believe do not comply with regulations. Manufacturing requires a manufacturing authorization, and the manufacturing authorization holder must comply with various requirements set out in the applicable EU laws, regulations and guidance, including Directive 2001/83/EC, Directive 2003/94/EC, Regulation (EC) No 726/2004 and the European Commission Guidelines for Good Manufacturing Practice (&#8220;GMP&#8221;). These requirements include compliance with EU GMP standards when manufacturing pharmaceutical products and active pharmaceutical ingredients, including the manufacture of active pharmaceutical ingredients outside of the EU with the intention to import the active pharmaceutical ingredients into the EU.&#160;Similarly, the distribution of pharmaceutical products into and within the EU is subject to compliance with the applicable EU laws, regulations and guidelines, including the requirement to hold appropriate authorizations for distribution granted by the competent authorities of the EU Member States. The manufacturer or importer must have a qualified person who is responsible for certifying that each batch of product has been manufactured in accordance with GMP, before releasing the product for commercial distribution in the EU or for use in a clinical trial. Manufacturing facilities are subject to periodic inspections by the competent authorities for compliance with GMP.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">247</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Sales and Marketing Regulations</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The advertising and promotion of Oruka&#8217;s products is also subject to EU laws concerning promotion of medicinal products, interactions with physicians, misleading and comparative advertising and unfair commercial practices. In addition, other national legislation of individual EU Member States may apply to the advertising and promotion of medicinal products and may differ from one country to another. These laws require that promotional materials and advertising in relation to medicinal products comply with the product&#8217;s SmPC as approved by the competent regulatory authorities. The SmPC is the document that provides information to physicians concerning the safe and effective use of the medicinal product. It forms an intrinsic and integral part of the MA granted for the medicinal product. Promotion of a medicinal product that does not comply with the SmPC is considered to constitute off<span class="nobreak">-label</span> promotion. All advertising and promotional activities for the product must be consistent with the approved SmPC and therefore all off<span class="nobreak">-label</span> promotion is prohibited. Direct<span class="nobreak">-to-consumer</span> advertising of prescription<span class="nobreak">-only</span> medicines is also prohibited in the EU.&#160;Violations of the rules governing the promotion of medicinal products in the EU could be penalized by administrative measures, fines and imprisonment. These laws may further limit or restrict the advertising and promotion of Oruka&#8217;s products to the general public and may also impose limitations on its promotional activities with healthcare professionals.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">EU regulation with regards to dispensing, sale and purchase of medicines has generally been preserved in the UK following Brexit, through the Human Medicines Regulations 2012. However, organizations wishing to sell medicines online need to register with the MHRA.&#160;Following Brexit, the requirements to display the common logo no longer apply to UK<span class="nobreak">-based</span> online sellers, except for those established in Northern Ireland.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Anti-Corruption Legislation</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In the EU, interactions between pharmaceutical companies and physicians are also governed by strict laws, regulations, industry self<span class="nobreak">-regulation</span> codes of conduct and physicians&#8217; codes of professional conduct both at EU level and in the individual EU Member States. The provision of benefits or advantages to physicians to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order or use of medicinal products is prohibited in the EU.&#160;The provision of benefits or advantages to physicians is also governed by the national anti<span class="nobreak">-bribery</span> laws of the EU Member States. Violation of these laws could result in substantial fines and imprisonment.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Payments made to physicians in certain EU Member States also must be publicly disclosed. Moreover, agreements with physicians must often be the subject of prior notification and approval by the physician&#8217;s employer, his/her regulatory professional organization, and/or the competent authorities of the individual EU Member States. These requirements are provided in the national laws, industry codes, or professional codes of conduct, applicable in the individual EU Member States. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In the UK, the pharmaceutical sector is recognized as being particularly vulnerable to corrupt practices, some of which fall within the scope of the Bribery Act&#160;2010. Due to the Bribery Act&#160;2010&#8217;s far<span class="nobreak">-reaching</span> territorial application, the potential penalized act does not have to occur in the UK to become within its scope. If the act or omission does not take place in the UK, but the person&#8217;s act or omission would constitute an offense if carried out there and the person has a close connection with the UK, an offense will still have been committed.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Bribery Act&#160;2010 is comprised of four offenses that cover (i)&#160;individuals, companies and partnerships that give, promise or offer bribes, (ii)&#160;individuals, companies and partnerships that request, agree to receive or accept bribes, (iii)&#160;individuals, companies and partnerships that bribe foreign public officials, and (iv)&#160;companies and partnerships that fail to prevent persons acting on their behalf from paying bribes. The penalties imposed under the Bribery Act&#160;2010 depend on the offence committed, harm and culpability and penalties range from unlimited fines to imprisonment for a maximum term of ten&#160;years and in some cases both.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Regulations in the UK and Other Markets</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The UK formally left the EU on January&#160;31, 2020 and EU laws now only apply to the UK in respect of Northern Ireland as laid out in the Protocol on Ireland and Northern Ireland and as amended by the Windsor Framework sets out a long<span class="nobreak">-term</span> set of arrangements for the supply of medicines into Northern Ireland. The EU and the UK agreed on a trade and cooperation agreement (&#8220;TCA&#8221;), which includes provisions affecting the life </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">248</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">sciences sector (including on customs and tariffs). There are some specific provisions concerning pharmaceuticals, including the mutual recognition of GMP, inspections of manufacturing facilities for medicinal products and GMP issued documents. The TCA does not, however, contain wholesale mutual recognition of UK and EU pharmaceutical regulations and product standards.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The UK government has adopted the Medicines and Medical Devices Act&#160;2021 (the &#8220;MMDA&#8221;) to enable the UK&#8217;s regulatory frameworks to be updated following the UK&#8217;s departure from the EU.&#160;The MMDA introduces regulation<span class="nobreak">-making</span>, delegated powers covering the fields of human medicines, clinical trials of human medicines, veterinary medicines and medical devices. The MHRA has since been consulting on future regulations for medicines and medical devices in the UK.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">For other countries outside of the EU, such as countries in Eastern Europe, Latin America or Asia, the requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary from country to country. In all cases, again, the clinical trials must be conducted in accordance with GCPs and the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If Oruka fails to comply with applicable foreign regulatory requirements, it may be subject to, among other things, fines, suspension of clinical trials, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Employees and Human Capital Resources</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of May&#160;3, 2024, Oruka had ten full<span class="nobreak">-time</span> employees. Oruka also engages temporary employees and consultants to augment its existing workforce. None of Oruka&#8217;s employees are represented by a labor union or covered under a collective bargaining agreement. Oruka considers its relationship with its employees to be good.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka recognizes that attracting, motivating, and retaining talent at all levels is vital to continuing its success. Oruka invests in its employees through high<span class="nobreak">-quality</span> benefits, professional development opportunities, and various health and wellness initiatives and offers competitive compensation packages (base salary and incentive plans), ensuring fairness in internal compensation practices. The principal purposes of Oruka&#8217;s incentive plans (bonus and equity) are to align with the long<span class="nobreak">-term</span> interests of its stakeholders and stockholders.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Properties and Facilities</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka currently operates as a virtual company and does not maintain physical corporate offices. Oruka&#8217;s employees currently work remotely. Oruka believe these arrangements support its current needs. Oruka maintains a mailing address at 221 Crescent St., Building<span class="nobreak"> </span>23, Suite 105, Waltham, MA.&#160;In April&#160;2024, Oruka entered into a lease agreement with Oak Grove LP for office space located in Menlo Park, California. The lease begins on June&#160;15, 2024 with an initial term of 39.5&#160;months.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Legal Proceedings</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">From time to time, Oruka may become involved in legal proceedings. Oruka is not currently a party to or aware of any proceedings that it believes will have, individually or in the aggregate, a material adverse effect on its business, financial condition or results of operations. Regardless of outcome, litigation can have an adverse impact on Oruka because of defense and settlement costs, diversion of management resources and other factors.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">249</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T9988"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">ARCA&#8217;S MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">The following discussion and analysis of ARCA&#8217;s financial condition and results of operations should be read in conjunction with ARCA&#8217;s consolidated financial statements and notes thereto appearing elsewhere in this proxy statement/prospectus. Some of the information contained in this discussion and analysis or set forth elsewhere in this proxy statement/prospectus, including information with respect to ARCA&#8217;s plans and strategy for ARCA&#8217;s business, includes forward</span><span class="nobreak"><span class="Italic" style="font-style:italic;font-weight:normal;">-looking</span></span><span class="Italic" style="font-style:italic;font-weight:normal;"> statements that involve risks and uncertainties. As a result of many factors, ARCA&#8217;s actual results could differ materially from the results described in or implied by the forward</span><span class="nobreak"><span class="Italic" style="font-style:italic;font-weight:normal;">-looking</span></span><span class="Italic" style="font-style:italic;font-weight:normal;"> statements contained in the following discussion and analysis</span>.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Overview</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA is dedicated to applying a precision medicine approach to the development and commercialization of targeted therapies for cardiovascular diseases. Precision medicine refers to the tailoring of medical treatment to the individual characteristics of patients, using genomic, non<span class="nobreak">-genomic</span> biomarker and other information that extends beyond routine diagnostic categorization. ARCA believes that when implemented correctly precision medicine can enhance therapeutic response, improve patient outcomes, and reduce healthcare costs.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s lead product candidate is Gencaro&#8482; (bucindolol hydrochloride) for the treatment of atrial fibrillation (&#8220;AF&#8221;) in patients with chronic heart failure (&#8220;HF&#8221;). Gencaro is being developed for patients who have a genotype that identifies a drug target associated with heightened efficacy.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Merger Agreement</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On April&#160;3, 2024, ARCA, First Merger Sub, Second Merger Sub and Oruka entered into the Merger Agreement, pursuant to which, among other matters, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, First Merger Sub will merge with and into Oruka, with Oruka continuing as a wholly owned subsidiary of ARCA&#8217;s and the surviving corporation of the First Merger and as part of the same overall transaction, the surviving corporation in the First Merger will merge with and into Second Merger Sub with Second Merger Sub continuing as a wholly owned subsidiary of ARCA&#8217;s and the surviving entity of the Second Merger. The Merger is intended to qualify for federal income tax purposes as a tax<span class="nobreak">-free</span> reorganization under the provisions of Section&#160;368(a)&#160;of the Internal Revenue Code of 1986, as amended.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Subject to the terms and conditions of the Merger Agreement, at the closing of the First Merger, (a)&#160;each then<span class="nobreak">-outstanding</span> share of Oruka common stock (including shares of Oruka common stock issued in the financing transaction described below) will be converted solely into the right to receive a number of shares of ARCA&#8217;s common stock calculated in accordance with the Merger Agreement (the &#8220;Exchange Ratio&#8221;), (b)&#160;each then<span class="nobreak">-outstanding</span> share of Oruka preferred stock will be converted into the right to receive a number of shares of ARCA Series&#160;B Preferred Stock calculated in accordance with the Merger Agreement, (c)&#160;each then<span class="nobreak">-outstanding</span> option to purchase Oruka common stock will be assumed by ARCA, subject to adjustment as set forth in the Merger Agreement and (d)&#160;each then<span class="nobreak">-outstanding</span> warrant to purchase shares of Oruka common stock will be converted into a warrant to purchase shares of ARCA&#8217;s common stock, subject to adjustment as set forth in the Merger Agreement and form of warrant. Under the terms of the Merger Agreement, prior to the closing of the transaction, ARCA&#8217;s board of directors will accelerate the vesting of all equity awards of ARCA&#8217;s then outstanding but not then vested or exercisable, and cancel each Out of the Money Options to acquire shares of ARCA&#8217;s common stock with an exercise price per share greater than the Parent Closing Price, in each case, in accordance with the terms of the Merger Agreement. At the closing of the First Merger, each option to acquire shares of ARCA&#8217;s common stock with an exercise price less than or equal to the Parent Closing Price will be cancelled and converted into the right to receive an amount in cash, without interest, equal to the Parent Closing Price less the exercise price of such option.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Under the Exchange Ratio formula in the Merger Agreement, upon the closing of the First Merger, on a pro forma basis and based upon the number of shares of ARCA&#8217;s common stock expected to be issued in the First Merger, pre<span class="nobreak">-First</span> Merger Oruka stockholders (including Oruka stockholders issued shares of Oruka common stock and pre<span class="nobreak">-funded</span> warrants in the Oruka pre<span class="nobreak">-closing</span> financing) will own approximately 97.61% of the combined </p>
		</div>


		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">250</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">company and pre<span class="nobreak">-First</span> Merger ARCA stockholders will own approximately 2.39% of the combined company. For purposes of calculating the Exchange Ratio, (i)&#160;shares of ARCA&#8217;s common stock underlying warrants and other rights to receive shares (other than Options to acquire shares of ARCA&#8217;s common stock, to the extent cancelled at or prior to closing of the First Merger in accordance with the Merger Agreement) outstanding as of immediately prior to the closing of the First Merger will be deemed to be outstanding, and (ii)&#160;all shares of Oruka common stock underlying outstanding Oruka stock options and warrants will be deemed to be outstanding. The Exchange Ratio will be adjusted to the extent that ARCA&#8217;s net cash at closing is less than $5.0&#160;million and will be based on the amount of proceeds actually received by Oruka in the financing transaction described below, as further described in the Merger Agreement.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, prior to the First Effective Time, ARCA expects to declare a cash dividend to the pre<span class="nobreak">-First</span> Merger ARCA stockholders equal in the aggregate to ARCA&#8217;s reasonable, good faith approximation of the amount by which ARCA&#8217;s net cash (as determined pursuant to the Merger Agreement) will exceed $5.0&#160;million. ARCA management currently anticipates that ARCA&#8217;s net cash as of closing to be approximately $5.0&#160;million, after giving effect to the special cash dividend, which is expected to be approximately $20.0<span class="nobreak"> </span>million.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In connection with the Merger, ARCA is required to seek the approval of its stockholders to, among other things, (a)&#160;issue shares of ARCA&#8217;s common stock issuable in connection with the First Merger (including the shares of ARCA common stock issuable under the ARCA Series&#160;B Preferred Stock) under the rules of Nasdaq, and (b)&#160;amend its amended and restated certificate of incorporation, to (i)&#160;effect a reverse stock split of ARCA&#8217;s common stock (if deemed necessary by ARCA and Oruka), (ii)&#160;increase the number of shares of ARCA&#8217;s common stock that it is authorized to issue, and (iii)&#160;such other changes as are mutually agreeable to ARCA and Oruka (the &#8220;ARCA Voting Proposals&#8221;).</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Each of ARCA and Oruka has agreed to customary representations, warranties and covenants in the Merger Agreement, including, among others, covenants relating to (1)&#160;using commercially reasonable efforts to obtain the requisite approval of its stockholders, (2)&#160;non<span class="nobreak">-solicitation</span> of alternative acquisition proposals, (3)&#160;the conduct of their respective businesses during the period between the date of signing the Merger Agreement and the closing of the Merger, (4)&#160;ARCA using commercially reasonable efforts to maintain the existing listing of ARCA&#8217;s common stock on Nasdaq and cause the shares of ARCA&#8217;s common stock to be issued in connection with the First Merger to be approved for listing on Nasdaq prior to the closing of the First Merger, and (5)&#160;ARCA filing with the SEC and causing to become effective a registration statement to register shares of ARCA&#8217;s common stock to be issued in connection with the First Merger, except as set forth in the Merger Agreement (the &#8220;Registration Statement&#8221;).</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Consummation of the Merger is subject to certain closing conditions, including, among other things, (1)&#160;approval by ARCA&#8217;s stockholders of the ARCA Voting Proposals, (2)&#160;approval by the requisite Oruka stockholders of the adoption and approval of the Merger Agreement and the transactions contemplated thereby, (3)&#160;Nasdaq&#8217;s approval of the initial listing application to be submitted in connection with the First Merger, (4)&#160;the effectiveness of the Registration Statement, (5)&#160;the expiration of any applicable waiting periods (or extensions thereof) under the Hart Scott<span class="nobreak">-Rodino</span> Antitrust Improvements Act&#160;of&#160;1976, as amended, (6)&#160;the Subscription Agreement (described below) being in full force and effect providing for the receipt of proceeds of not less than $175,000,000 (including in the proceeds any notes contributed as consideration in the Oruka pre<span class="nobreak">-closing</span> financing described below) and (7)&#160;to the extent ARCA has declared the cash dividend described above, ARCA delivering the aggregate amount distributable to the pre<span class="nobreak">-First</span> Merger ARCA stockholders to its&#8217; transfer agent for further distribution to the pre<span class="nobreak">-First</span> Merger ARCA stockholders. Each party&#8217;s obligation to consummate the Merger is also subject to other specified customary conditions, including regarding the accuracy of the representations and warranties of the other party, subject to the applicable materiality standard, and the performance in all material respects by the other party of its obligations under the Merger Agreement required to be performed on or prior to the date of the closing of the Merger.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Merger Agreement contains certain termination rights of each of ARCA and Oruka. Upon termination of the Merger Agreement under specified circumstances, ARCA and Oruka may each be required to pay the other party a termination fee of $440,000.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Pursuant to a Certificate of Designation of Preferences, Rights and Limitations of the Series&#160;B Non<span class="nobreak">-Voting</span> Convertible Preferred Stock to be filed by ARCA with the Secretary of State of the State of Delaware (the &#8220;Certificate of Designation&#8221;) in connection with the Merger Agreement and the transactions thereunder, ARCA will establish the terms of a new series of preferred stock of ARCA designated as Series&#160;B Non<span class="nobreak">-Voting</span> Convertible </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">251</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">Preferred Stock, par value $0.001 per share (the &#8220;ARCA Series&#160;B Preferred Stock&#8221;). Holders of the ARCA Series&#160;B Preferred Stock will be entitled to receive dividends on shares of ARCA Series&#160;B Preferred Stock equal to, on an as<span class="nobreak">-if-converted-to-ARCA</span> common stock basis, and in the same form as dividends actually paid on shares of ARCA&#8217;s common stock. Except as otherwise required by the Certificate of Designation or law, the ARCA Series&#160;B Preferred Stock will not have voting rights. However, as long as any shares of ARCA Series&#160;B Preferred Stock are outstanding, ARCA will not, without the affirmative vote of the holders of a majority of the then outstanding shares of the ARCA Series&#160;B Preferred Stock, (a)&#160;alter or change adversely the powers, preferences or rights given to the ARCA Series&#160;B Preferred Stock, (b)&#160;alter or amend the Certificate of Designation, (c)&#160;amend ARCA&#8217;s certificate of incorporation, bylaws or other charter documents in any manner that adversely affects any rights of the holders of the ARCA Series&#160;B Preferred Stock, (d)&#160;file any articles of amendment, certificate of designations, preferences, limitations and relative rights of any series of Preferred Stock (as defined in the Certificate of Designation), if such action would adversely alter or change the preferences, rights, privileges or powers of, or restrictions provided for the benefit of the ARCA Series&#160;B Preferred Stock, (e)&#160;issue further shares of the ARCA Series&#160;B Preferred Stock or increase or decrease (other than by conversion) the number of authorized shares of the ARCA Series&#160;B Preferred Stock, (f)&#160;at any time while at least 30% of the originally issued ARCA Series&#160;B Preferred Stock remains issued and outstanding, consummate either (A)&#160;a Fundamental Transaction (as defined in the Certificate of Designation) or (B)&#160;any merger or consolidation of ARCA or other business combination in which ARCA&#8217;s stockholders immediately before such transaction do not hold at least a majority of the capital stock of ARCA immediately after such transaction, or (f)&#160;enter into any agreement with respect to any of the foregoing. The ARCA Series&#160;B Preferred Stock does not have a preference upon any liquidation, dissolution or winding<span class="nobreak">-up</span> of ARCA.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Following the closing of the First Merger, each share of ARCA Series&#160;B Preferred Stock then outstanding shall be convertible, at any time and from time to time, at the option of the holder of the ARCA Series&#160;B Preferred Stock, into a number of shares equal to 1,000<span class="nobreak"> </span>shares of ARCA&#8217;s common stock, subject to certain limitations, including that a holder of ARCA Series&#160;B Preferred Stock is prohibited from converting shares of ARCA Series&#160;B Preferred Stock into shares of ARCA&#8217;s common stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than a specified percentage (initially set at 9.99%) of the total number of shares of ARCA&#8217;s common stock issued and outstanding immediately after giving effect to such conversion.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">At the First Merger Effective Time (the &#8220;Effective Time&#8221;), the combined company&#8217;s board of directors is expected to consist of six (6)&#160;members, all of whom will be designated by Oruka. Upon the closing of the transaction, the combined company will be led by Oruka&#8217;s chief executive officer.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Financing Transaction</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Concurrently with the execution and delivery of the Merger Agreement, certain parties have entered into the Subscription Agreement with Oruka, pursuant to which they have agreed, subject to the terms and conditions of such agreement, to purchase immediately prior to the consummation of the First Merger, shares of Oruka common stock and pre<span class="nobreak">-funded</span> warrants to purchase shares of Oruka common stock for an aggregate purchase price of approximately $275.0&#160;million (which includes $25.0<span class="nobreak"> </span>million of proceeds previously received from the issuance of the Convertible Note and accrued interest on such note). The consummation of the transactions contemplated by such agreements is conditioned on the satisfaction or waiver of the conditions set forth in the Merger Agreement and in the Subscription Agreement. Shares of Oruka common stock and pre<span class="nobreak">-funded</span> warrants to purchase shares of Oruka common stock issued pursuant to this financing transaction will be converted into shares of ARCA common stock and pre<span class="nobreak">-funded</span> warrants to acquire shares ARCA common stock, in accordance with the exchange ratio and the Merger Agreement.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s future operations are highly dependent on the success of the Merger and there can be no assurances that the Merger will be successfully consummated. There can be no assurance that the strategic review process or any transaction relating to a specific asset, including the Merger or any asset sale, will result in ARCA pursuing such a transaction(s), or that any transaction(s), if pursued, will be completed on terms favorable to ARCA and its stockholders in the existing entity or any possible entity that results from a combination of entities. If the strategic review process is unsuccessful, ARCA&#8217;s board of directors may decide to pursue a dissolution and liquidation.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">252</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Gencaro&#8482; (bucindolol hydrochloride) for Atrial Fibrillation</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Gencaro&#8482; (bucindolol hydrochloride) is a pharmacogenetically<span class="nobreak">-targeted</span> beta<span class="nobreak">-adrenergic</span> receptor antagonist with mild vasodilator properties that ARCA is developing for the treatment of atrial fibrillation in patients with heart failure. ARCA believes the pharmacology of Gencaro is unique and its efficacy can be enhanced by prescribing it to patients with a common genotypic variant that is present in approximately 50% of the North American and European general populations. This gene can be detected with a simple genetic test.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA is developing Gencaro to treat AF in patients with chronic HF.&#160;AF is the most common form of cardiac arrhythmia, a disruption of the heart&#8217;s normal rhythm or rate. HF is a chronic condition in which the heart is unable to pump enough blood to meet the body&#8217;s needs. AF and HF commonly occur together. In HF patients, the development of AF leads to worsening symptoms, and increased risk of hospitalization and death. Current treatment options for AF in HF patients are limited, and can be invasive, costly and dangerous.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s development plan for Gencaro focuses on the treatment of AF in patients with higher ejection fraction HF, those who have an ejection fraction, or EF, of 40% and higher who also have the genotype ARCA believes is optimal for Gencaro efficacy. This population of HF encompasses more than half of all HF patients in the United&#160;States and Europe. There are currently few approved or effective drug therapies to treat AF or HF in this patient population.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s development plan for Gencaro is based on ARCA&#8217;s published analysis of the Phase&#160;2b clinical trial of Gencaro for the prevention of AF in HF patients, known as GENETIC<span class="nobreak">-AF</span>.&#160;This analysis showed novel results for Gencaro in patients in the clinical trial with EF&#8217;s of 40% and higher. ARCA currently has an agreement with the FDA, known as a Special Protocol Assessment (&#8220;SPA&#8221;), for the requirements of a Gencaro Phase&#160;3 clinical trial, PRECISION<span class="nobreak">-AF</span>, that would support approval of Gencaro if successful. The Phase&#160;3 pivotal clinical trial of Gencaro conducted under a SPA will include secondary endpoints that are intended to capture some of this information, such as a reduction in the need to deploy rhythm control interventions including electrical cardioversion, catheter ablation and use of anti<span class="nobreak">-arrhythmic</span> drugs and avoidance of drug<span class="nobreak">-related</span> complications such as bradycardia. ARCA was issued a United&#160;States patent in February&#160;2021 for the use of Gencaro in a patient population identified as part of the clinical trial. ARCA believes this patent will substantially extend the patent protection for its planned development of Gencaro into 2039. ARCA has sought or is seeking similar patent protection in other countries.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA believes that patients with HF and AF represent a major unmet medical need, and this need is most pronounced in patients with EF values of 40% and above. This EF range constitutes more than half of all chronic HF in the United&#160;States and Europe, as well as in Japan and China, and there are currently few approved, effective or guideline<span class="nobreak">-recommended</span> therapies for these patients to treat either their AF or HF.&#160;AF is a very common complication in these patients, with estimates of AF incidence ranging from 40% to 60%. Beta<span class="nobreak">-blockers</span> approved for HF are commonly used off<span class="nobreak">-label</span> to control heart rate in these patients, but they are not considered effective in preventing AF and none are approved for patients with EF &#8805; 40%. Other anti<span class="nobreak">-arrhythmic</span> drugs approved for the treatment of AF have adverse side effects and in HF patients are either contraindicated or have label warnings for use due to an increased risk of mortality. Interventional procedures for AF, such as catheter ablation and electrical cardioversion, are invasive, expensive, and often temporary; these interventions also typically require the continued use of beta blockers and other anti<span class="nobreak">-arrhythmic</span> drugs post<span class="nobreak">-intervention</span>.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA believes that Gencaro, if approved, may be a safe and more effective therapy for the treatment of higher ejection fraction HF patients with AF.&#160;ARCA believes there are several potentially important attributes that would differentiate Gencaro from existing therapies, including:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>More effective rhythm control compared to the current standard of care;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Reduction in the need for catheter ablation, electrical cardioversion, or toxic anti<span class="nobreak">-arrhythmic</span> drugs;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Maintenance of rhythm control after a successful AF catheter ablation;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Effective rate control with lower risk of treatment<span class="nobreak">-limiting</span>, adverse event producing bradycardia;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Reduction in symptoms and improvement in quality of life;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Reduced health care burden;</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">253</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Foundational beta<span class="nobreak">-blocker</span> benefits for HF and unique evidence of efficacy in HF patients with AF;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>One of the only drug therapies approved and shown effective for AF in HF patients with EF &#8805; 40%, and the only one in its drug class.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA has an international patent portfolio for Gencaro in the United&#160;States, the EU, and other major markets, as well as new chemical entity status, including a new patent that ARCA believes will give it a strong intellectual property position to at least approximately 2039 in the United&#160;States; ARCA has filed applications similar to this new patent in international territories. ARCA has developed a laboratory platform for the diagnostic test that would be used to prescribe Gencaro; this platform was approved by FDA for use in the Phase&#160;2B clinical trial. ARCA retains all rights to this test platform; ARCA expects to use it in future clinical trials, and ARCA believes it could be one of multiple diagnostic platforms used for commercialization.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">rNAPc2 (AB201) for treatment of COVID-19</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Recombinant Nematode Anticoagulant Protein c2 (&#8220;rNAPc2&#8221;) (AB201) is a protein therapeutic in clinical development as a potential treatment for patients with COVID<span class="nobreak">-19</span>. Based on its unique mechanism of action, development history and the clinical evidence from the SARS<span class="nobreak">-CoV-2</span> pandemic, ARCA believes rNAPc2 has potential to be a beneficial therapy for patients with this serious viral disease. ARCA initiated a Phase&#160;2b clinical trial of rNAPc2 as a potential treatment for patients hospitalized with COVID<span class="nobreak">-19</span> in the fourth quarter of 2020 and completed patient enrollment in the fourth quarter 2021. In the clinical trial, both doses of rNAPc2 demonstrated a treatment benefit for patients based on the coagulation biomarker D<span class="nobreak">-dimer</span>, however, neither dose achieved statistical significance for the primary efficacy endpoint of change in D<span class="nobreak">-dimer</span> level from Baseline to Day 8 compared to standard of care heparin.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On the secondary endpoints measuring thrombotic events and time<span class="nobreak">-to-recovery</span>, there was a numerical imbalance in favor of rNAPc2 that was non<span class="nobreak">-significant</span>. rNAPc2 was well<span class="nobreak">-tolerated</span> at both doses. There were no serious treatment<span class="nobreak">-related</span> adverse events and no dose dependent increase in adverse events was observed. There was no difference between rNAPc2 and standard<span class="nobreak">-of-care</span> heparin in major or non<span class="nobreak">-major</span> clinically relevant bleeding. ARCA currently does not plan additional clinical development of rNAPc2 unless ARCA is able to find a commercial or government partner to pay for development and commercialization or expansion into clinical trials for other disease indications.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">To support the continued development of Gencaro and rNAPc2, ARCA will need additional financing to fully fund any clinical trials, and ARCA&#8217;s general and administrative costs through the clinical trials&#8217; projected completion and potential commercialization. Considering the substantial time and costs associated with the development of Gencaro and rNAPc2 and the risk that ARCA may be unable to raise a significant amount of capital on acceptable terms, ARCA is also pursuing co<span class="nobreak">-development</span> and commercialization partnering opportunities with large pharmaceutical and/or specialty pharmaceutical companies and may pursue a strategic combination or other strategic transactions. If ARCA is unable to obtain sufficient financing or is unable to complete a strategic transaction, ARCA may discontinue its development activities on Gencaro or rNAPc2 or discontinue operations.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA believes its cash and cash equivalents as of March&#160;31, 2024 will be sufficient to fund ARCA&#8217;s operations through the middle of fiscal year 2025. ARCA&#8217;s future viability beyond that point is dependent on the results of the strategic review process and ARCA&#8217;s ability to raise additional capital to fund its operations. ARCA expects to continue to incur costs and expenditures in connection with the process of evaluating strategic alternatives. There can be no assurance, however, that ARCA will be able to successfully consummate any particular strategic transaction, including the Merger. The process of continuing to evaluate these strategic options may be very costly, time<span class="nobreak">-consuming</span> and complex and ARCA has incurred, and may in the future incur, significant costs related to this continued evaluation, such as legal, accounting and advisory fees and expenses and other related charges, see the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">The Merger Agreement</span>&#8221; in this proxy statement/prospectus. Should ARCA pursue additional clinical trials for its product candidates, ARCA will have to raise additional capital for clinical trials of Gencaro. ARCA may not be able to raise sufficient capital on acceptable terms, or at all, to continue development of Gencaro or rNAPc2 or to otherwise continue operations and may not be able to execute any strategic transaction. The Merger discussed above may impact this projection. Conducting a Phase&#160;3 PRECISION<span class="nobreak">-AF</span> trial would likely require additional financing, subject to ARCA&#8217;s pursuit of a potential strategic transaction and the consummation of such potential transaction. However, changing circumstances may cause ARCA to consume capital significantly faster or slower than currently anticipated. ARCA has based these estimates on assumptions that may prove to be wrong, and ARCA could exhaust its available financial resources sooner than it currently anticipates; therefore, ARCA may have to raise additional capital for other clinical trials. Initiating any Phase&#160;3 clinical trial of Gencaro will require additional financing.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">254</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In 2020, ARCA entered into a new sales agreement with a placement agent to sell, from time to time, in an &#8220;at the market offering.&#8221;</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In 2021, ARCA amended the new sales agreement and the amount available for the offering under ARCA&#8217;s prospectus to ARCA&#8217;s registration statement on Form&#160;S<span class="nobreak">-3</span> (No.&#160;333<span class="nobreak">-254585</span>), which expired in March&#160;2024. In April&#160;2024, ARCA terminated such sales agreement in accordance with its terms. No sales were made under this sales agreement in 2024 or 2023.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Results of Operations</span></p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">General and Administrative Expenses</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">General and administrative (&#8220;G&amp;A&#8221;) expenses primarily consist of personnel costs, consulting and professional fees, insurance, facilities and depreciation expenses, and various other administrative costs.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">G&amp;A expenses were $2.3&#160;million for the three&#160;months ended March&#160;31, 2024 compared to $1.4&#160;million for the corresponding period of 2023, an increase of $0.9&#160;million. During the three&#160;months ended March&#160;31, 2023, ARCA recorded $159,000 for one<span class="nobreak">-time</span> termination benefits related to the mutually agreed to conclusion of Christopher D.&#160;Ozeroff&#8217;s employment, the former Secretary, Senior Vice President and General Counsel of ARCA, effective March&#160;31, 2023. The increase for the three<span class="nobreak">-month</span> period was primarily a result of a $1.1&#160;million increase in professional fees primarily related to the Merger Agreement discussed above, offset by $0.2&#160;million lower one<span class="nobreak">-time</span> termination benefits and lower personnel costs from the reduction discussed above.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">G&amp;A expenses were $6.3&#160;million for the year ended December&#160;31, 2023, compared to $5.8&#160;million for 2022, an increase of approximately $0.4&#160;million. During the year ended December&#160;31, 2023, ARCA recorded $159,000 for one<span class="nobreak">-time</span> termination benefits related to the mutually<span class="nobreak">-agreed</span> to conclusion of Christopher D.&#160;Ozeroff&#8217;s employment, the former Secretary, Senior Vice President and General Counsel of ARCA, effective March&#160;31, 2023. During the year ended December&#160;31, 2022, ARCA recorded total restructuring charges of approximately $755,000, of which $470,000 and $285,000 were recognized in research and development and general and administrative expenses, respectively, in connection with the restructuring, all in the form of one<span class="nobreak">-time</span> termination benefits. The increase in expenses during 2023 was primarily a result of increases in professional fees and fees to the Special Committee in connection with the Strategic Review, offset by lower one<span class="nobreak">-time</span> termination benefits and lower personnel costs from the reductions discussed above.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">G&amp;A expenses in 2024 are expected to be higher than those in 2023 as ARCA incurs professional fees related to the Merger Agreement discussed above and maintains administrative activities to support its ongoing operations. ARCA does expect to incur significant costs related to ARCA&#8217;s exploration of strategic alternatives and the Merger, including legal, accounting and advisory expenses and other related charges.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">While ARCA does not believe that inflation had a material effect on its financial condition and results of operations during the periods presented, it may result in increased costs in the foreseeable future.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Research and Development Expenses</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Research and development (&#8220;R&amp;D&#8221;) expense is comprised primarily of personnel costs, clinical development, manufacturing process development, and regulatory activities and costs.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">R&amp;D expense for the three&#160;months ended March&#160;31, 2024 was $0.2&#160;million compared to $0.4&#160;million for the corresponding period of 2023, a decrease of $0.2&#160;million.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">R&amp;D personnel costs decreased approximately $0.2&#160;million for the three&#160;months ended March&#160;31, 2024, as compared to the corresponding period of 2023, due to decreased headcount.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Manufacturing process development costs for the three&#160;months ended March&#160;31, 2024 and 2023 were consistent.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">R&amp;D expense decreased $0.1&#160;million related to the unrestricted research grants with ARCA&#8217;s former President and Chief Executive Officer&#8217;s academic research laboratory at the University of Colorado. There was no expense under these arrangements for the three&#160;months ended March&#160;31, 2024. Total expense under these arrangements </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">255</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">for the three&#160;months ended March&#160;31, 2023 was $108,000. In December&#160;2023, the Company made a payment of $125,000 for the grant period July&#160;2022 through December&#160;2023 under these arrangements. In April&#160;2024, the former President and Chief Executive Officer resigned.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s research and development expenses were $1.0&#160;million for the year ended December&#160;31, 2023 as compared to $4.7&#160;million for 2022, a decrease of $3.7&#160;million.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">R&amp;D personnel costs decreased approximately $1.2&#160;million for the year ended December&#160;31, 2023, as compared to the corresponding periods of 2022, due to one<span class="nobreak">-time</span> termination benefits incurred in 2022 and decreased headcount from the July&#160;2022 personnel reduction.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Clinical expense decreased approximately $1.0&#160;million for the year ended December&#160;31, 2023, as compared to the corresponding period of 2022. Manufacturing process development costs decreased approximately $1.1&#160;million for the year ended December&#160;31, 2023, as compared to the corresponding period of 2022.&#160;The majority of clinical and manufacturing close out costs related to ARCA&#8217;s rNAPc2 (AB201) international Phase&#160;2b clinical trial were incurred in the first half of 2022, with no comparable costs for the corresponding periods of 2023.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">R&amp;D expense in 2024 is expected to be lower than 2023, as ARCA completed its rNAPc2 (AB201) international Phase&#160;2b clinical trial. Should ARCA resume clinical trials of product candidates, it expects research and development costs to increase significantly for the foreseeable future as ARCA&#8217;s product candidate development programs progress.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Interest and Other Income</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Interest and other income was $473,000 and $450,000 in the three&#160;months ended March&#160;31, 2024 and 2023, respectively. Interest income was higher due to higher interest rates in 2024 compared to the corresponding periods of 2023.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Interest and other income was $2.0&#160;million of interest income for the year ended December&#160;31, 2023 as compared to $0.7&#160;million for 2022, resulting in an increase of $1.3&#160;million. Interest income was higher due to higher interest rates in 2023 compared to the corresponding periods of 2022. ARCA expects interest income in 2024 to be lower than 2023, as ARCA continues to use its cash and cash equivalents to fund operations, assuming interest rates remain consistent with 2023.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Other Expense</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">There was no other expense for the year ended December&#160;31, 2023. Other expense was $5,000 for the year ended December&#160;31, 2022. The amounts were nominal to ARCA&#8217;s overall operations. Based on ARCA&#8217;s current capital structure, other expense is expected to be negligible in 2024.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Liquidity and Capital Resources</span></p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Cash and Cash Equivalents as of March&#160;31, 2024 and 2023</span></p>
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">March&#160;31,<br/>2024</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">December&#160;31,<br/>2023</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="5" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(in thousands)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Cash and cash equivalents</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">35,903</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">37,431</p>
					</td>
				</tr>

		</table>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of March&#160;31, 2024, ARCA had total cash and cash equivalents of $35.9&#160;million, as compared to $37.4&#160;million as of December&#160;31, 2023. The net decrease of $1.5&#160;million primarily reflects the cash used in operating activities during the three&#160;months ended March&#160;31, 2024.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Cash and Cash Equivalents as of December&#160;31, 2023 and 2022</span></p>
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="5" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">December&#160;31,</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-color:#000000;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-color:#000000;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-color:#000000;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-color:#000000;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-color:#000000;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">2022</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:none;border-bottom-width:0pt;border-left-color:#000000;border-right-color:#000000;border-top-color:#000000;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:none;border-bottom-width:0pt;border-left-color:#000000;border-right-color:#000000;border-top-color:#000000;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="5" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:none;border-bottom-width:0pt;border-left-color:#000000;border-right-color:#000000;border-top-color:#000000;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(in thousands)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-color:#000000;border-top-style:none;border-top-width:0pt;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Cash and cash equivalents</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-color:#000000;border-top-style:none;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-color:#000000;border-top-style:none;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-color:#000000;border-top-style:none;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">37,431</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-color:#000000;border-top-style:none;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-color:#000000;border-top-style:none;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-color:#000000;border-top-style:none;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">42,445</p>
					</td>
				</tr>

		</table>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">256</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of December&#160;31, 2023, ARCA had total cash and cash equivalents of approximately $37.4&#160;million, as compared to $42.4&#160;million as of December&#160;31, 2022. The net decrease of $5.0&#160;million during the year primarily reflects cash used in operating activities during the year ended December&#160;31, 2023.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Cash Flows from Operating, Investing and Financing Activities</span></p>
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Three&#160;Months Ended March&#160;31,</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">2024</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(in thousands)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net cash used in:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Operating activities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(1,528</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(1,595</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Investing activities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Financing activities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net decrease in cash and cash equivalents</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(1,528</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(1,595</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>

		</table>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Net cash used in operating activities for the three&#160;months ended March&#160;31, 2024 was consistent with the same period in 2023. This was primarily due to lower outflows related to changes in operating assets and liabilities and a higher net loss in 2024, as discussed in Results of Operations above.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">There were no investing activities in the three&#160;months ended March&#160;31, 2024 and 2023.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;orphans:99;widows:1;margin-top:8pt;">There were no financing activities in the three&#160;months ended March&#160;31, 2024 and 2023.</p>
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Years Ended December&#160;31,</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-color:#000000;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-color:#000000;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-color:#000000;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-color:#000000;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-color:#000000;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">2022</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:none;border-bottom-width:0pt;border-left-color:#000000;border-right-color:#000000;border-top-color:#000000;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:none;border-bottom-width:0pt;border-left-color:#000000;border-right-color:#000000;border-top-color:#000000;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:none;border-bottom-width:0pt;border-left-color:#000000;border-right-color:#000000;border-top-color:#000000;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(in thousands)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-style:none;border-top-color:#000000;border-top-style:none;border-top-width:0pt;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net cash provided by (used in):</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-style:none;border-top-color:#000000;border-top-style:none;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-style:none;border-top-color:#000000;border-top-style:none;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-style:none;border-top-color:#000000;border-top-style:none;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-style:none;border-top-color:#000000;border-top-style:none;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-style:none;border-top-color:#000000;border-top-style:none;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-style:none;border-top-color:#000000;border-top-style:none;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-style:none;border-top-color:#000000;border-top-style:none;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-style:none;border-top-color:#000000;border-top-style:none;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Operating activities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(5,014</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(10,912</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Investing activities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(2</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Financing activities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net increase in cash and cash equivalents</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(5,014</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(10,914</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>

		</table>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;orphans:99;widows:1;margin-top:8pt;">Net cash used in operating activities for the year ended December&#160;31, 2023 decreased approximately $5.9&#160;million compared with 2022. This was primarily due to lower outflows related to changes in operating assets and liabilities and a lower net loss in 2022, as discussed in Results of Operations above.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">There were no investing activities in the year ended December&#160;31, 2023. Net cash used in investing activities for the year ended December&#160;31, 2022 was $2,000 for the purchase of property and equipment.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">There were no financing activities in the&#160;years ended December&#160;31, 2023 or 2022.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Sources and Uses of Capital</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s primary sources of liquidity to date have been capital raised from issuances of shares of its preferred and common stock. The primary uses of ARCA&#8217;s capital resources to date have been to fund operating activities, including research, clinical development and drug manufacturing expenses, license payments, and spending on capital items.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In 2020, ARCA entered into a new sales agreement with a placement agent to sell, from time to time, in an &#8220;at the market offering.&#8221;</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In 2021, ARCA amended the new sales agreement and the amount available for the offering under its prospectus to its registration statement on Form&#160;S<span class="nobreak">-3</span> (No.&#160;333<span class="nobreak">-254585</span>), which expired in March&#160;2024. In April&#160;2024, ARCA terminated such sales agreement in accordance with its terms. No sales were made under this sales agreement in 2024 or 2023.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">257</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s ability to execute its development programs in accordance with ARCA&#8217;s projected timeline depends on a number of factors, including, but not limited to, the following:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the timing and outcome of the strategic review process;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the consummation of any particular strategic transactions, including the Merger;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the costs and timing for the potential additional clinical trials in order to gain possible regulatory approval for Gencaro, rNAPc2 or any other product candidate;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the market price of ARCA&#8217;s stock and the availability and cost of additional equity capital from existing and potential new investors;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s ability to retain the listing of its common stock on the Nasdaq Capital Market;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s ability to control costs associated with its operations;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>general economic and industry conditions affecting the availability and cost of capital, including as a result of deteriorating market conditions due to investor concerns regarding inflation, adverse developments affecting the financial services industry, continued hostilities between Russia and Ukraine and Hamas&#8217; attack against Israel and the ensuing conflict;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the terms and conditions of ARCA&#8217;s existing collaborative and licensing agreements.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA believes its cash and cash equivalents as of March&#160;31, 2024 will be sufficient to fund operations through the middle of fiscal year 2025. ARCA&#8217;s future viability beyond that point is dependent on the results of the strategic review process and its ability to raise additional capital to fund its operations. ARCA expects to continue to incur costs and expenditures in connection with the process of evaluating strategic alternatives. There can be no assurance, however, that ARCA will be able to successfully consummate any particular strategic transaction, including the Merger. The process of continuing to evaluate these strategic options may be very costly, time<span class="nobreak">-consuming</span> and complex and ARCA has incurred, and may in the future incur, significant costs related to this continued evaluation, such as legal, accounting and advisory fees and expenses and other related charges, see the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">The Merger Agreement</span>&#8221; in this proxy statement/prospectus. Should ARCA pursue additional clinical trials for its product candidates, ARCA will have to raise additional capital for clinical trials of Gencaro. ARCA may not be able to raise sufficient capital on acceptable terms, or at all, to continue development of Gencaro or rNAPc2 or to otherwise continue operations and may not be able to execute any strategic transaction. The Merger Agreement discussed above may impact this projection. Conducting a Phase&#160;3 PRECISION<span class="nobreak">-AF</span> trial would likely require additional financing, subject to ARCA&#8217;s pursuit of a potential strategic transaction and the consummation of such potential transaction. However, changing circumstances may cause ARCA to consume capital significantly faster or slower than currently anticipated. ARCA has based these estimates on assumptions that may prove to be wrong, and it could exhaust its available financial resources sooner than ARCA currently anticipates; therefore, ARCA may have to raise additional capital for other clinical trials. Initiating any Phase&#160;3 clinical trial of Gencaro will require additional financing. If ARCA resumes the development of product candidates, ARCA may not be able to raise sufficient capital on acceptable terms, or at all, to continue development and potential commercialization Gencaro or to otherwise continue operations and may not be able to execute any strategic transaction.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In April&#160;2022, ARCA established a Special Committee of ARCA&#8217;s board of directors to conduct a comprehensive review of strategic alternatives. As part of the strategic review process, ARCA explored potential strategic alternatives that included, without limitation, an acquisition, merger, business combination or other transactions. ARCA has and is continuing to explore strategic alternatives related to its product candidates and related assets, including, without limitation, licensing transactions and asset sales.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Contractual Obligations and Commitments</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In December&#160;2022, ARCA&#8217;s board of directors approved retention bonuses for certain employees, subject to continued employment with ARCA through the earlier of a change in control of ARCA or certain clinical development decisions totaling $265,000. In November&#160;2023, the retention bonuses were amended to increase </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">258</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">the aggregate amount of the retention bonus by 50% and in order to assist with tax obligations associated with the vesting of certain ARCA restricted stock unit awards in December&#160;2023, a total of $86,000 was paid in December&#160;2023. On April&#160;20, 2024, ARCA&#8217;s board of directors approved the second amendment of certain retention bonus letters between ARCA and each of Thomas A.&#160;Keuer and C.&#160;Jeffrey Dekker to increase the aggregate amount of the retention bonus with respect to each such executive to $200,000. The remaining portion of the retention bonus with respect to Thomas A.&#160;Keuer and C.&#160;Jeffrey Dekker, consisting of $165,000, will become payable consistent with the original terms of the applicable retention bonus letter and first amendment to retention bonus letter. Any payment related to the retention bonuses of Thomas A.&#160;Keuer and C.&#160;Jeffrey Dekker will be paid by ARCA via payroll within 30&#160;business days of the date of occurrence of the applicable &#8220;Payment Event Date&#8221; (as such term is otherwise defined in the applicable second amendment to the retention bonus letter). Each such retention bonus letter and first amendment to retention bonus letter will otherwise remain subject to their original terms and conditions.&#160;As of March&#160;31, 2024, the unpaid retention bonuses totaled $311,000, none of which was accrued as of March&#160;31, 2024, since there had not been a change in control or clinical development decision. In April&#160;2024, the retention bonuses were again amended to increase the aggregate amount of the retention bonus, with the unpaid retention bonus increasing to $444,000.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On August&#160;29, 2020, ARCA entered into a lease agreement for approximately 5,200 square feet of office facilities in Westminster, Colorado which serves as ARCA&#8217;s primary business office effective October&#160;1, 2020 (the &#8220;October&#160;2020 Lease&#8221;). The lease term was 42&#160;months beginning October&#160;1, 2020. In March&#160;2024, ARCA entered into an amendment to extend the lease term six (6)&#160;months through September&#160;2024. If ARCA elects to stay in the property after September&#160;2024, it will pay rent month to month equal to 125% of the base rent paid in September&#160;2024. In June&#160;2021, ARCA entered into a sublease agreement for approximately 3,000 square feet of additional office facilities in ARCA&#8217;s primary business office. The sublease term was 29&#160;months and terminated in October&#160;2023. The leases include real estate taxes and insurance, which is not a lease component and is not included in the lease obligation. In addition, common area maintenance charges are based on actual costs incurred and are a non<span class="nobreak">-lease</span> component that is not included in the lease obligation. Rent expense, which is included in general and administrative expense, for the three&#160;months ended March&#160;31, 2024 and 2023 was $22,000 and $31,000, respectively. As of March&#160;31, 2024, the lease liability was $48,000.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA has licensed worldwide rights to all preclinical and clinical data through the BEST trial for development of bucindolol. The patents that were the subject of this license are expired. If the license agreement is deemed enforceable, ARCA would incur milestone and royalty obligations upon the occurrence of certain events, including if the FDA grants marketing approval for Gencaro, upon regulatory marketing approval in Europe and Japan and based on achievement of specified product sales levels.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Critical Accounting Policies and Estimates</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">A critical accounting policy is one that is both important to the portrayal of ARCA&#8217;s financial condition and results of operation and requires management&#8217;s most difficult, subjective or complex judgments, often as a result of the need to make estimates about the effect of matters that are inherently uncertain. While ARCA&#8217;s significant accounting policies are described in Note&#160;1 of ARCA&#8217;s consolidated financial statements and notes thereto appearing elsewhere in this proxy statement/prospectus, ARCA believes the following critical accounting policy affected its most significant judgments, assumptions, and estimates used in the preparation of ARCA&#8217;s financial statements and, therefore, is important in understanding ARCA&#8217;s financial condition and results of operations. ARCA had no significant outsourcing expense activity in 2023 or 2022.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Accrued Outsourcing Expenses</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As part of the process of preparing ARCA&#8217;s financial statements, ARCA may be required to estimate accrued outsourcing expenses. This process involves identifying services that third parties have performed on ARCA&#8217;s behalf and estimating the level of service performed and the associated cost incurred for these services as of the balance sheet date. Examples of estimated accrued outsourcing expenses include contract service fees, such as fees payable to contract manufacturers in connection with the production of materials related to ARCA&#8217;s drug product, and service fees from clinical research organizations. ARCA develops estimates of liabilities using its judgment based upon the facts and circumstances known at the time.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">259</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Indemnifications</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In the ordinary course of business, ARCA enters into contractual arrangements under which it may agree to indemnify certain parties from any losses incurred relating to the services they perform on ARCA&#8217;s behalf or for losses arising from certain events as defined within the particular contract. Such indemnification obligations may not be subject to maximum loss clauses. ARCA has entered into indemnity agreements with each of ARCA&#8217;s directors, officers and certain employees. Such indemnity agreements contain provisions, which are in some respects broader than the specific indemnification provisions contained in Delaware law. ARCA also maintains an insurance policy for its directors and executive officers insuring against certain liabilities arising in their capacities as such.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">260</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T11"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">ORUKA&#8217;S MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">You should read the following discussion and analysis of Oruka&#8217;s financial condition and results of operations together with the sectioned titled &#8220;Oruka&#8217;s Business&#8221; and Oruka&#8217;s financial statements and the related notes appearing elsewhere in this proxy statement/prospectus. Some of the information contained in this discussion and analysis or set forth elsewhere in this proxy statement/prospectus, including information with respect to Oruka&#8217;s plans and strategy for its business and related financing, includes forward</span><span class="nobreak"><span class="Italic" style="font-style:italic;font-weight:normal;">-looking</span></span><span class="Italic" style="font-style:italic;font-weight:normal;"> statements that involve risks, uncertainties, and assumptions. As a result of many factors, including those factors set forth in the section titled &#8220;Risk Factors&#160;&#8212;&#160;Risks Related to Oruka,&#8221; Oruka&#8217;s actual results could differ materially from the results described in or implied by these forward</span><span class="nobreak"><span class="Italic" style="font-style:italic;font-weight:normal;">-looking</span></span><span class="Italic" style="font-style:italic;font-weight:normal;"> statements. You should carefully read the section titled &#8220;Risk Factors&#160;&#8212;&#160;Risks Related to Oruka&#8221; to gain an understanding of the factors that could cause actual results to differ materially from Oruka&#8217;s forward</span><span class="nobreak"><span class="Italic" style="font-style:italic;font-weight:normal;">-looking</span></span><span class="Italic" style="font-style:italic;font-weight:normal;"> statements. Please also see the section titled &#8220;Cautionary Note&#160;Regarding Forward</span><span class="nobreak"><span class="Italic" style="font-style:italic;font-weight:normal;">-Looking</span></span><span class="Italic" style="font-style:italic;font-weight:normal;"> Statements.&#8221;</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Overview</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka is a biotechnology company focused on developing novel monoclonal antibody therapeutics for psoriasis and other&#160;I&amp;I indications. Oruka&#8217;s name is derived from <span class="Italic" style="font-style:italic;font-weight:normal;">or</span>, for &#8220;skin,&#8221; and <span class="Italic" style="font-style:italic;font-weight:normal;">arukah</span>, for &#8220;restoration&#8221;&#8212;&#160;reflects Oruka&#8217;s mission to deliver therapies for chronic skin diseases that provide patients the most possible freedom from their condition. Oruka&#8217;s strategy is to apply antibody engineering and format innovations to validated modes of action, which Oruka believes will enable it to improve meaningfully upon the efficacy and dosing regimens of standard<span class="nobreak">-of-care</span> medicines while significantly intending to reduce technical and biological risk. Oruka&#8217;s programs aim to treat and potentially modify disease by targeting mechanisms with proven efficacy and safety involved in disease pathology and the activity of pathogenic tissue<span class="nobreak">-resident</span> memory T cells. Oruka&#8217;s lead program, ORKA<span class="nobreak">-001</span>, is designed to target the p19 subunit of interleukin<span class="nobreak">-23</span> (&#8220;IL<span class="nobreak">-23p19</span>&#8221;) for the treatment of psoriasis. Oruka&#8217;s co<span class="nobreak">-lead</span> program, ORKA<span class="nobreak">-002</span>, is designed to target interleukin<span class="nobreak">-17A</span> and interleukin<span class="nobreak">-17F</span> (&#8220;IL<span class="nobreak">-17A</span>/F&#8221;) for the treatment of PsO, PsA, and other conditions. These programs each bind their respective targets at high affinity and incorporate half<span class="nobreak">-life</span> extension technology with the aim to increase exposure and decrease dosing frequency. Oruka believes that its focused strategy, differentiated portfolio, and deep expertise position it to set a new treatment standard in large&#160;I&amp;I markets with continued unmet need.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka Therapeutics, Inc. was established and incorporated under the laws of the state of Delaware on February&#160;6, 2024. Oruka Therapeutics, Inc. was founded by Paragon and has since assembled a management team with significant experience in clinical development.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ORKA<span class="nobreak">-001</span> is a high affinity, extended half<span class="nobreak">-life</span> mAb designed to target IL<span class="nobreak">-23p19</span>. IL<span class="nobreak">-23</span> is a pro<span class="nobreak">-inflammatory</span> cytokine that plays a critical role in the proliferation and development of Th17 cells, which are the primary drivers of several autoimmune and inflammatory disorders, including PsO.&#160;IL<span class="nobreak">-23</span> is composed of two subunits: a p40 subunit that is shared with IL<span class="nobreak">-12</span> and a p19 subunit that is specific to IL<span class="nobreak">-23</span>. First<span class="nobreak">-generation</span> IL<span class="nobreak">-23</span> antibodies bound p40 and inhibited both IL<span class="nobreak">-12</span> and IL<span class="nobreak">-23</span> signaling, while more recent IL<span class="nobreak">-23</span> antibodies targeting the p19 subunit have shown improved efficacy and safety when applied by other companies. Based on preclinical evidence, Oruka believes that ORKA<span class="nobreak">-001</span> could achieve higher response rates than established therapies in PsO while requiring less frequent dosing and maintaining the favorable safety profile of therapies targeting IL<span class="nobreak">-23p19</span>. ORKA<span class="nobreak">-001</span> is engineered with YTE half<span class="nobreak">-life</span> extension technology, a specific three amino acid change in the Fc domain to modify the pH<span class="nobreak">-dependent</span> binding to the neonatal FcRn. As a result, it has a pharmacokinetic profile designed to support an SQ injection as infrequently as once or twice a year. In addition, emerging evidence suggests that IL<span class="nobreak">-23</span> blockade can modify the disease biology of PsO, possibly leading to durable remissions and preventing the development of PsA.&#160;Oruka believes that the expected characteristics of ORKA<span class="nobreak">-001</span> increase its potential to deliver these disease<span class="nobreak">-modifying</span> benefits. Oruka plans to initiate a Phase&#160;1 trial of ORKA<span class="nobreak">-001</span> in the first half of 2025 that will have the potential to not only generate important pharmacokinetic and safety data but also to demonstrate its efficacy in PsO patients.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ORKA<span class="nobreak">-002</span> is a high affinity, extended half<span class="nobreak">-life</span> mAb designed to target IL<span class="nobreak">-17A</span>/F.&#160;IL<span class="nobreak">-17</span> inhibition has become central to the treatment of psoriatic diseases, including PsO and PsA, and has also shown efficacy in other&#160;I&amp;I indications, such as HS and axSpA.&#160;More recently, the importance of inhibiting the IL<span class="nobreak">-17F</span> isoform along with IL<span class="nobreak">-17A</span> has become appreciated, and dual blockade with the recently approved therapy Bimzelx (bimekizumab) has </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">261</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">led to higher response rates in patients than blockade of IL<span class="nobreak">-17A</span> alone. ORKA<span class="nobreak">-002</span> is designed to bind IL<span class="nobreak">-17A</span>/F at similar epitopes, or binding sites, and affinity ranges as bimekizumab, but incorporates half<span class="nobreak">-life</span> extension technology that could enable more convenient dosing intervals. Oruka plans to initiate Phase&#160;1 trials of ORKA<span class="nobreak">-002</span> in the second half of 2025.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka views ORKA<span class="nobreak">-002</span> and ORKA<span class="nobreak">-001</span> as highly complementary. Patients with moderate<span class="nobreak">-to-severe</span> PsO that have purely skin manifestations are most often treated with IL<span class="nobreak">-23</span> inhibitors due to the high efficacy and tolerability of this mechanism. However, for patients who also have joint involvement, or signs and symptoms of PsA, an IL<span class="nobreak">-17</span> inhibitor is typically used due to its efficacy in addressing both skin and joint symptoms. In addition, IL<span class="nobreak">-17</span> inhibitors are often used in patients with highly resistant skin symptoms that do not adequately resolve through treatment with an IL<span class="nobreak">-23</span> inhibitor. Together, ORKA<span class="nobreak">-001</span> and ORKA<span class="nobreak">-002</span> provide the potential to offer a highly compelling product profile for most patients with PsO and/or PsA, as well as the opportunity to address additional&#160;I&amp;I indications.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka has a third mAb program, ORKA<span class="nobreak">-003</span>, designed to target an undisclosed pathway. Oruka&#8217;s strategy as a company is to remain highly focused on&#160;I&amp;I diseases, and specifically on inflammatory dermatology conditions. Oruka&#8217;s third program provides the potential for indication expansion beyond PsO and creates combination opportunities with Oruka&#8217;s more advanced programs.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Since Oruka&#8217;s inception in February&#160;2024, it has devoted substantially all of its resources to raising capital, organizing and staffing the company, business and scientific planning, conducting discovery and research activities, establishing arrangements with third parties for the manufacture of Oruka&#8217;s programs and component materials, and providing general and administrative support for these operations. Oruka does not have any programs approved for sale and have not generated any revenue from product sales. To date, Oruka has funded its operations primarily with proceeds from the issuance of its Series&#160;A convertible preferred stock and the issuance of the Convertible Note, both of which were related party transactions. Through March&#160;31, 2024, Oruka received gross proceeds of $3.0&#160;million from the issuance of its Series&#160;A convertible preferred stock and gross proceeds of $25.0&#160;million from the issuance of the Convertible Note. Under the Series A Preferred Stock and Convertible Note Purchase Agreement (the &#8220;Purchase Agreement&#8221;) pursuant to which the Convertible Note was sold, Oruka can sell up to an additional $30.0&#160;million in convertible notes. Oruka intends to sell an additional $30.0&#160;million in convertible notes but there is currently no expectation as to when that will occur.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka has incurred operating losses since inception. Oruka&#8217;s ability to generate product revenue sufficient to achieve profitability will depend heavily on the successful development and eventual commercialization of any programs Oruka may develop. Oruka generated net losses of $7.1&#160;million for the period from February&#160;6, 2024 (inception) to March&#160;31, 2024. As of March&#160;31, 2024, Oruka had an accumulated deficit of $7.1&#160;million. Oruka expects to continue to incur significantly increased expenses for the foreseeable future if and as it:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>continues its research and development and discovery<span class="nobreak">-related</span> development of its programs, ORKA<span class="nobreak">-001</span>, ORKA<span class="nobreak">-002</span>, and ORKA<span class="nobreak">-003</span>;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>submits for and receives allowance to proceed with its investigational new drug applications, or INDs, for certain of its programs in order to commence future clinical trials;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>successfully completes future preclinical studies for its pipeline;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>seeks and identifies additional research programs and product candidates and initiates discovery<span class="nobreak">-related</span> activities and preclinical studies for those programs;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>hires additional research and development and clinical personnel;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>experiences any delays, challenges, or other issues associated with the pre<span class="nobreak">-clinical</span> and clinical development of its programs, including with respect to its regulatory strategies;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>seeks marketing approvals for any programs for which it successfully completes clinical trials;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>develops, maintains and enhances a sustainable, scalable, reproducible and transferable manufacturing process for the programs it may develop;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ultimately establishes a sales, marketing and distribution infrastructure to commercialize any programs for which it may obtain marketing approval;</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">262</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>adds operational, financial and management information systems and personnel, including personnel to support its product development;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>seeks timely and successful completion of preclinical studies;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>pursues effective investigational new drug applications or comparable foreign applications that allow commencement of its planned clinical trials or future clinical trials for any programs it may develop;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>initiates enrollment and successful completion of clinical trials;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>pursues positive results from its future clinical trials that support a finding of safety and effectiveness, and an acceptable risk<span class="nobreak">-benefit</span> profile in the intended populations;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>seeks marketing approvals from applicable regulatory authorities;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>maintains, expands, enforces, defends and protects its intellectual property portfolio and other intellectual property protection or regulatory exclusivity for any products it may develop;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>seeks maintenance of a continued acceptable safety, tolerability and efficacy profile of any programs it may develop following approval;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>further acquires or in<span class="nobreak">-licenses</span> product candidates or programs, intellectual property and technologies;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>establishes and maintains any future collaborations, including making royalty, milestone or other payments thereunder;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>maintains a continued acceptable safety profile of its products following approval; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>incurs additional costs of operating as a public company, including audit, legal, regulatory and tax related services associated with maintaining compliance with an exchange listing and SEC requirements, director and officer insurance premium and investor relation cost.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Any changes in the outcome of any of these variables with respect to the development of programs that Oruka may identify could mean a significant change in the costs and timing associated with the development of such programs. For example, if the FDA or another regulatory authority were to require Oruka to conduct clinical trials beyond those that Oruka currently anticipates will be required for the completion of clinical development of a program, or if Oruka&#8217;s experiences significant delays in its clinical trials due to patient enrollment or other reasons, Oruka would be required to expend significant additional financial resources and time on the completion of clinical development. Oruka may never obtain regulatory approval for any of its programs.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka will not generate revenue from product sales unless and until it successfully initiate and complete clinical development and obtain regulatory approval for any product candidates. If Oruka obtains regulatory approval for any of its programs and do not enter into a commercialization partnership, Oruka expects to incur significant expenses related to developing Oruka&#8217;s commercialization capability to support product sales, manufacturing, marketing, and distribution.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As a result, Oruka will need substantial additional funding to support its continued operations and growth strategy. Until such a time as Oruka can generate significant revenue from product sales, if ever, it expects to finance its operations through the sale of equity, debt financings or other capital sources, including collaborations with other companies or other strategic transactions. Oruka may be unable to raise additional funds or enter into such other agreements on favorable terms, or at all. If Oruka fails to raise capital or enter into such agreements as, and when, needed, Oruka may have to significantly delay, scale back or discontinue the development and commercialization of one or more of Oruka&#8217;s programs.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Because of the numerous risks associated with product development, Oruka is unable to accurately predict the timing or amount of increased expenses or when or if Oruka will be able to achieve or maintain profitability. Even if Oruka is able to generate product sales, it may not become profitable. If Oruka fails to become profitable or are unable to sustain profitability on a continuing basis, then Oruka may be unable to continue Oruka&#8217;s operations at planned levels and be forced to reduce or terminate its operations.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">263</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka believes that the expected net proceeds from the Merger and the Oruka pre<span class="nobreak">-closing</span> financing, together with Oruka&#8217;s existing cash and sales of additional convertible notes under the Purchase Agreement, will enable Oruka to fund its operating expenses through 2027. Oruka has based this estimate on assumptions that may prove to be wrong, and Oruka could exhaust its available capital resources sooner than Oruka expects. See &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">&#8212;&#160;Liquidity and Capital Resources</span>&#8221; and &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Risk Factors&#160;&#8212;&#160;Risks Related to Oruka&#8217;s Financial Condition and Capital Requirements</span>.&#8221;</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Without giving effect to any proceeds from this Merger and the Oruka pre<span class="nobreak">-closing</span> financing, as well as any proceeds from additional borrowings under the Convertible Note, as of March&#160;31, 2024, Oruka expects that its existing cash will be sufficient to fund its operating expenses through the end of second quarter of 2024. Beyond that point, Oruka will need to raise additional capital to finance its operations, which cannot be assured. As disclosed in Oruka&#8217;s financial statements for the period February&#160;6, 2024 (inception) to March&#160;31, 2024, Oruka concluded that there is substantial doubt about its ability to continue as a going concern within one year of the date those financial statements are available to be issued. See Note&#160;1 to Oruka&#8217;s financial statements appearing at the end of this proxy statement/prospectus for additional information on its assessment.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Impact of Risk Factors on Oruka&#8217;s Operations</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Uncertainty in the global economy presents significant risks to Oruka&#8217;s business. Oruka is subject to continuing risks and uncertainties in connection with the current macroeconomic environment, including increases in inflation, rising interest rates, recent bank failures, geopolitical factors, including the ongoing conflicts between Russia and Ukraine and Israel and Gaza and the responses thereto, and supply chain disruptions. While Oruka is closely monitoring the impact of the current macroeconomic conditions on all aspects of Oruka&#8217;s business, including the impacts on its participants in future clinical trials, employees, suppliers, vendors and business partners, the ultimate extent of the impact on its business remains highly uncertain and will depend on future developments and factors that continue to evolve. Most of these developments and factors are outside Oruka&#8217;s control and could exist for an extended period of time. Oruka will continue to evaluate the nature and extent of the potential impacts to Oruka&#8217;s business, results of operations, liquidity and capital resources. For additional information, see the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Risk Factors&#160;&#8212;&#160;Risks Related to Oruka</span>.&#8221;</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Components of Results of Operations</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Revenue</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">To date, Oruka has not generated revenue from any sources, including product sales, and do not expect to generate any revenue from the sale of products in the foreseeable future. If Oruka&#8217;s development efforts for its product candidates are successful and result in regulatory approval, Oruka may generate revenue in the future from product sales or payments from future collaboration or license agreements that Oruka may enter into with third parties, or any combination thereof. Oruka cannot predict if, when, or to what extent it will generate revenue from the commercialization and sale of its product candidates. Oruka may never succeed in obtaining regulatory approval for any of its product candidates.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Operating Expenses</span></p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-left:24pt;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Research and Development</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Research and development expenses consist primarily of costs incurred in connection with the development and research of Oruka&#8217;s programs. These expenses include costs of funding research performed by third parties, including Paragon, that conduct research and development activities on Oruka&#8217;s behalf, expenses incurred in connection with continuing Oruka&#8217;s current research programs and discovery<span class="nobreak">-phase</span> development of any programs Oruka may identify, including under future agreements with third parties, such as consultants and contractors, and personnel related expenses, including salaries, bonuses, benefits, and equity<span class="nobreak">-based</span> compensation expense.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka expenses research and development costs as incurred. For the period from February&#160;6, 2024 (inception) to March&#160;31, 2024 Oruka recognized $5.0&#160;million of expenses, in connection with services provided by Paragon and Paruka under the Option Agreements, including nonrefundable research and development expense fees associated with each Research Plan on its condensed statement of operations and comprehensive loss. See &#8220;&#8212;<span class="Italic" style="font-style:italic;font-weight:normal;">&#160;Contractual Obligations and Commitments</span>&#8221; below for further details on Oruka&#8217;s research plans.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">264</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka&#8217;s primary focus since inception has been the identification and development of its pipeline programs. Oruka&#8217;s research and development expenses primarily consist of external costs, such as fees paid to Paragon under the Paragon Option Agreements. Oruka separately tracks the amount of costs incurred under the Paragon Option Agreements with Paragon between ORKA<span class="nobreak">-001</span> and ORKA<span class="nobreak">-002</span>. See &#8220;&#8212;&#160;<span class="Italic" style="font-style:italic;font-weight:normal;">Contractual Obligations and Commitments</span>&#8221; below for further details on the Paragon Option Agreements.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-left:24pt;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">General and Administrative</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">General and administrative expenses consist primarily of personnel related expenses, including salaries, bonuses, benefits, and equity<span class="nobreak">-based</span> compensation, for individuals in Oruka&#8217;s executive, finance, operations, human resources, business development and other administrative functions. Other significant general and administrative expenses include legal fees relating to corporate matters, professional fees for accounting, auditing, tax, information technology, insurance, and recruiting costs. Oruka currently operates as a virtual company. Therefore, Oruka does not incur material operating expenses for the rent, maintenance and insurance of facilities or for depreciation of fixed assets. In April&#160;2024, Oruka entered into a lease agreement with Oak Grove LP (&#8220;Oak Grove Lease&#8221;) for office space located in Menlo Park, California. The Oak Grove Lease begins on June&#160;15, 2024 with an initial term of 39.5&#160;months. Oruka&#8217;s lease payment is expected to be $1.4&#160;million over the initial lease term.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka expects that its general and administrative expenses will increase substantially for the foreseeable future as Oruka increases its headcount to support the expected growth. Oruka also expects to incur increased expenses associated with a reverse merger public transaction and becoming a public company, including increased costs of accounting, audit, legal, regulatory and tax related services associated with maintaining compliance with SEC requirements, additional director and officer insurance costs, and investor and public relations costs. Oruka also expects to incur additional intellectual property<span class="nobreak">-related</span> expenses as Oruka files patent applications to protect innovations arising from its research and development activities.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Other Expense</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Interest expense of $0.2&#160;million incurred for the period from February&#160;6, 2024 (inception) to March&#160;31, 2024 relates to the Convertible Note issued to Fairmount Fund&#160;II in March&#160;2024.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Income Taxes</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">No provision for income taxes was recorded for the period of February&#160;6, 2024 (inception) through March&#160;31, 2024. Deferred tax assets generated from Oruka&#8217;s net operating losses have been fully reserved as Oruka believes it is not more likely than not that the benefit will be realized due to its cumulative losses generated to date.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Results of Operations</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following table summarizes Oruka&#8217;s statement of operations and comprehensive loss for the period presented (in thousands):</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 3pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-12" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Period&#160;from <br/>February&#160;6, <br/>2024&#160;(Inception) <br/>to&#160;March&#160;31, <br/>2024</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Operating expenses</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Research and development<span class="Superscript" style="vertical-align:super;font-size:58%;">(1)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5,193</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">General and administrative<span class="Superscript" style="vertical-align:super;font-size:58%;">(2)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,670</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total operating expenses</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">6,863</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:10pt;">Loss from operations</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(6,863</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:10pt;">Other expense</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Interest expense<span class="Superscript" style="vertical-align:super;font-size:58%;">(3)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(214</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total other expense</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(214</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:10pt;">Net loss and comprehensive loss</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(7,077</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>

		</table>
		<p class="Tablefootnotef" style="margin-top: 0in;  border: none; margin-right: 0in; margin-bottom: -5pt; margin-left: 24.0pt; text-align: justify; text-justify: inter-ideograph; text-indent: -24.0pt; padding: 0in; font-size: 9.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">____________</p><p class="Tablefootnote_f" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:10pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:10pt;">(1)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Includes related party amount of $5,051 (see Note&#160;12 to Oruka&#8217;s unaudited condensed financial statements for the period February&#160;6, 2024 (Inception) to March&#160;31, 2024)</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">265</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(2)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Includes related party amount of $848 (see Note&#160;12 to Oruka&#8217;s unaudited condensed financial statements for the period February&#160;6, 2024 (Inception) to March&#160;31, 2024)</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(3)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Includes related party amount of $214 (see Note&#160;12 to Oruka&#8217;s unaudited condensed financial statements for the period February&#160;6, 2024 (Inception) to March&#160;31, 2024)</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Research and Development Expenses</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following table summarizes Oruka&#8217;s research and development expenses incurred for the period presented (in thousands):</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 3pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-12" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Period&#160;from <br/>February&#160;6, <br/>2024&#160;(Inception) <br/>to&#160;March&#160;31, <br/>2024</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">External research and development costs by selected target:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:20pt;">ORKA-002<span class="Superscript" style="vertical-align:super;font-size:58%;">(1)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4,155</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:20pt;">ORKA-001<span class="Superscript" style="vertical-align:super;font-size:58%;">(2)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">750</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:10pt;">Other research and development costs:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:10pt;">Personnel-related (including stock-based compensation)<span class="Superscript" style="vertical-align:super;font-size:58%;">(3)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">264</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:20pt;">Other</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">24</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:30pt;">Total research and development expenses</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5,193</p>
					</td>
				</tr>

		</table>
		<p class="Tablefootnotef" style="margin-top: 0in;  border: none; margin-right: 0in; margin-bottom: -5pt; margin-left: 24.0pt; text-align: justify; text-justify: inter-ideograph; text-indent: -24.0pt; padding: 0in; font-size: 9.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">____________</p><p class="Tablefootnote_f" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:10pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:10pt;">(1)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Includes related party amount of $4,155 for the period February&#160;6, 2024 (Inception) to March&#160;31, 2024</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(2)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Includes related party amount of $750 for the period February&#160;6, 2024 (Inception) to March&#160;31, 2024</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(3)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Includes related party amount of $146 for the period February&#160;6, 2024 (Inception) to March&#160;31, 2024</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Research and development expenses were $5.2&#160;million for the period from February&#160;6, 2024 (inception) to March&#160;31, 2024 and consisted primarily of the following:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>$4.2&#160;million of research and development expense due to Paragon for services rendered under the Paragon Option Agreement for ORKA<span class="nobreak">-002</span>;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>$0.8&#160;million of research initiation fee expense due to Paragon related to the Paragon Option Agreement for ORKA<span class="nobreak">-001</span>; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>$0.2&#160;million of personnel<span class="nobreak">-related</span> costs related to recruiting costs, salaries, benefits and other compensation<span class="nobreak">-related</span> costs, including stock<span class="nobreak">-based</span> compensation of less than $0.1&#160;million and $0.1&#160;million of personnel<span class="nobreak">-related</span> costs are amounts due to Paragon related to recruiting costs for hiring Oruka&#8217;s research and development team.</p>
		<p class="H3_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">General and Administrative Expenses</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following table summarizes Oruka&#8217;s total general and administrative expenses for the period presented (in thousands):</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 3pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-12" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Period&#160;from <br/>February&#160;6, <br/>2024&#160;(Inception) <br/>to&#160;March&#160;31, <br/>2024</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:10pt;">Personnel-related (including stock-based compensation)<span class="Superscript" style="vertical-align:super;font-size:58%;">(1)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">781</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:10pt;">Professional and consulting fees</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">444</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:10pt;">Legal fees related to patent<span class="Superscript" style="vertical-align:super;font-size:58%;">(2)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">256</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other<span class="Superscript" style="vertical-align:super;font-size:58%;">(3)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">189</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:20pt;">Total general and administrative expenses</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,670</p>
					</td>
				</tr>

		</table>
		<p class="Tablefootnotef" style="margin-top: 0in;  border: none; margin-right: 0in; margin-bottom: -5pt; margin-left: 24.0pt; text-align: justify; text-justify: inter-ideograph; text-indent: -24.0pt; padding: 0in; font-size: 9.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">____________</p><p class="Tablefootnote_f" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:10pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:10pt;">(1)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Includes related party amount of $505 for the period February&#160;6, 2024 (Inception) to March&#160;31, 2024</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(2)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Includes related party amount of $256 for the period February&#160;6, 2024 (Inception) to March&#160;31, 2024</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(3)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Includes related party amount of $87 for the period February&#160;6, 2024 (Inception) to March&#160;31, 2024</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">266</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">General and administrative expenses were $1.7&#160;million for the period from February&#160;6, 2024 (inception) to March&#160;31, 2024 and consisted primarily of the following:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>$0.8&#160;million of personnel<span class="nobreak">-related</span> costs related to recruiting costs, salaries, benefits and other compensation<span class="nobreak">-related</span> costs, including stock<span class="nobreak">-based</span> compensation of less than $0.1&#160;million and $0.5&#160;million of personnel<span class="nobreak">-related</span> costs are amounts due to Paragon related to recruiting costs for hiring Oruka&#8217;s executive team, legal, and finance and accounting functions;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>$0.4&#160;million of professional and consulting fees associated with increases in accounting, audit, and legal fees due to an increase in Oruka&#8217;s business activity and as Oruka began preparation to become a public company;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>$0.3&#160;million of legal fees due to Paragon associated with patent related activities;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>$0.1&#160;million of investor and public relations costs and fees associated with company formation; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>$0.1&#160;million of costs due to Paragon related to company formation fees.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Liquidity and Capital Resources</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Since Oruka&#8217;s inception, Oruka has incurred significant operating losses. Oruka expects to incur significant expenses and operating losses for the foreseeable future as Oruka commences the pre<span class="nobreak">-clinical</span> and clinical development of its programs and continue its early<span class="nobreak">-stage</span> research activities. Oruka has not yet commercialized any products and Oruka does not expect to generate revenue from sales of products for several&#160;years, if at all. To date, Oruka has funded its operations primarily with proceeds from the sale of its Series&#160;A convertible preferred stock and the issuance of the Convertible Note. In March&#160;2024, Oruka received $3.0&#160;million in gross proceeds from the issuance of Series&#160;A convertible preferred stock and $25.0&#160;million in gross proceeds from the issuance of the Convertible Note, both of which were related party transactions. As of March&#160;31, 2024, Oruka had cash of $27.7&#160;million.</p>
		<p class="H3_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Cash Flows</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following table summarizes Oruka&#8217;s cash flows for the period presented (in thousands):</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-12" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Period&#160;from <br/>February&#160;6, <br/>2024&#160;(Inception) <br/>to&#160;March&#160;31, <br/>2024</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net cash used in operating activities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(168</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net cash provided by financing activities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">27,911</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net increase in cash</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">27,743</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>

		</table>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-left:24pt;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Operating Activities</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">From February&#160;6, 2024 (inception) to March&#160;31, 2024, net cash used in operating activities was $0.2&#160;million and was primarily attributable to a net loss of $7.1&#160;million, offset by a $6.1&#160;million increase in related parties accounts payable and other current liabilities and a $0.8&#160;million increase in accrued expenses and other current liabilities. The increase in amounts due to related parties and accrued expenses and other current liabilities was primarily due to an increase in Oruka&#8217;s business activity, as well as vendor invoicing and payments.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-left:24pt;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Financing Activities</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">From February&#160;6, 2024 (inception) to March&#160;31, 2024, net cash provided by financing activities was $27.9&#160;million, consisting of $2.9&#160;million of net proceeds from the issuance of Oruka&#8217;s Series&#160;A convertible preferred&#160;stock and $25.0&#160;million of net proceeds from the issuance of the Convertible Note.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">267</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H3_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Funding Requirements</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">To date, Oruka has not generated any revenue from product sales. Oruka has devoted substantially all of its resources to advancing the development of its portfolio of programs, organizing and staffing, business planning, raising capital, and providing general and administrative support for these operations. Current and future programs will require significant research and development efforts, including preclinical and clinical trials, and regulatory approvals to commercialization. These efforts require significant amounts of additional capital, adequate personnel, and infrastructure. Even if Oruka&#8217;s development efforts are successful, it is uncertain when, if ever, Oruka will realize significant revenue from product sales. If Oruka obtains regulatory approval for any of its product candidates and start to generate revenue, Oruka expects to incur significant expenses related to developing its internal commercialization capability to support product sales, marketing, and distribution.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka believes its existing cash, together with the anticipated net proceeds from this Merger and the Oruka pre<span class="nobreak">-closing</span> financing, as well as issuances of additional convertible notes under the Purchase Agreement, will be sufficient to fund its operating expenses requirements through 2027. Oruka has based this estimate on assumptions that may prove to be wrong, and Oruka could exhaust its available capital resources sooner than Oruka expects. Oruka expects that it will require additional funding to advance its potential product candidates through development, regulatory approval and commercialization if any of its product candidates are approved.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Until such time, if ever, as Oruka can generate substantial product revenue, Oruka expects to finance its cash needs through a combination of equity offerings and debt financings. To the extent that Oruka raises additional capital through the sale of equity or convertible debt securities, ownership interest may be materially diluted, and the terms of such securities could include liquidation or other preferences that adversely affect your rights as a common stockholder. Debt financing, if available, may involve agreements that include restrictive covenants that limit Oruka&#8217;s ability to take specified actions, such as incurring additional debt, making capital expenditures or declaring dividends. If Oruka is unable to raise additional funds, it may be required to delay, reduce or eliminate some or all of its planned operations.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Contractual Obligations and Commitments</span></p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-left:24pt;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Paragon Option Agreements</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In March&#160;2024, Oruka entered into the Paragon Option Agreements. Under the terms of the Paragon Option Agreements, Paragon identifies, evaluates and develops antibodies directed against certain mutually agreed therapeutic targets of interest to Oruka. The Option Agreement includes two selected targets, IL<span class="nobreak">-23</span> (ORKA<span class="nobreak">-001</span>) and IL<span class="nobreak">-17A</span>/F (ORKA<span class="nobreak">-002</span>). Under each of the Paragon Option Agreements, Oruka has the exclusive option to, on a research program<span class="nobreak">-by-research</span> program basis, be granted an exclusive, worldwide license to all of Paragon&#8217;s right, title and interest in and to the intellectual property resulting from the applicable research program to develop, manufacture and commercialize the antibodies and potential products directed to the selected targets. If Oruka exercises its options, Oruka will be required to make non<span class="nobreak">-refundable</span> milestone payments to Paragon of up to $12.0&#160;million under each respective agreement upon the achievement of certain clinical development milestones, up to $10.0&#160;million under each respective agreement upon the achievement of certain regulatory milestones, as well tiered royalty payments in the low<span class="nobreak">-to-mid</span> single<span class="nobreak">-digits</span> beginning on the first commercial sale. From time to time, Oruka can choose to add additional targets to the collaboration by mutual agreement with Paragon.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Pursuant to the terms of the Paragon Option Agreements, the parties initiated certain Research Programs. Each Research Program is aimed at discovering, generating, identifying and/or characterizing antibodies directed to the respective target. For each Research Program, the parties established a Research Plan that sets forth the activities that will be conducted, and the associated research budget. Oruka and Paragon will agree on initial Research Plans that outline the services that will be performed commencing at inception of the arrangement related to IL<span class="nobreak">-17</span> and IL<span class="nobreak">-23</span>. Oruka&#8217;s exclusive option with respect to each Research Program is exercisable at Oruka&#8217;s sole discretion at any time during the period beginning on the initiation of activities under the associated Research Program and ending a specified number of&#160;days following the delivery of the data package from Paragon related to the results of the Research Plan activities. There is no payment due upon exercise of an Option pursuant to the Paragon Option Agreements.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">268</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Pursuant to the Paragon Option Agreements, on a research program<span class="nobreak">-by-research</span> program basis following the finalization of the Research Plan for each respective research program, Oruka was required to pay Paragon a nonrefundable fee in cash of $0.8&#160;million related to the research initiation fee for ORKA<span class="nobreak">-001</span>. This amount was recognized as a research and development expense during the period from February&#160;6 (inception) to March&#160;31, 2024, and paid to Paragon in April&#160;2024. Oruka is also responsible for 50% of the development costs incurred prior to March&#160;31, 2024, provided that Oruka receives rights to at least one selected IL<span class="nobreak">-23</span> antibody. Oruka&#8217;s share of development costs incurred prior to March&#160;31, 2024 is $5.9&#160;million. As of the date of issuance of Oruka&#8217;s condensed financial statements, Oruka has not received rights to a selected IL<span class="nobreak">-23</span> antibody and has not paid or accrued the $5.9&#160;million of development costs incurred prior to March&#160;31, 2024. Oruka will be responsible for 50% of the ORKA<span class="nobreak">-001</span> development costs incurred from and after March&#160;31, 2024, through the completion of the IL<span class="nobreak">-23</span> selection process.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka was also required to reimburse Paragon $3.3&#160;million for development costs related to ORKA<span class="nobreak">-002</span> incurred by Paragon through December&#160;31, 2023 and certain other development costs incurred between January&#160;1, 2024 and March&#160;6, 2024. This amount was recognized as a research and development expense during the period from February 6 (inception) to March<span class="nobreak"> </span>31, 2024, and accounts payable as of March<span class="nobreak"> </span>31, 2024. Oruka paid $3.3&#160;million to Paragon in April&#160;2024. Oruka is also responsible for the development costs incurred from January&#160;1, 2024 to March&#160;31, 2024 of $0.9&#160;million, which was recognized as a research and development expense in the period from February&#160;6 (inception) to March&#160;31, 2024. Oruka will be required to pay Paragon $0.8&#160;million for the research initiation fee related to ORKA<span class="nobreak">-002</span> within 30&#160;days following finalization of the ORKA<span class="nobreak">-002</span> Research Plan as well as for subsequent development costs related to ORKA<span class="nobreak">-002</span>. Oruka will be responsible for ORKA<span class="nobreak">-002</span> development costs incurred from and after March<span class="nobreak"> </span>31, 2024, through the completion of the IL<span class="nobreak">-17</span> selection process.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Furthermore, the Paragon Option Agreements provide for an annual equity grant of warrants to purchase 1.00% of the then outstanding shares of Oruka common stock, on a fully diluted basis, on each of December&#160;31, 2024 and December&#160;31, 2025, during the term of the Paragon Option Agreements, at the fair market value determined by Oruka&#8217;s board of directors.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka expenses the service fees as the associated costs are incurred when the underlying services are rendered. Such amounts are classified within research and development expenses in the accompanying statement of operations and comprehensive loss.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-left:24pt;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Note&#160;Payable with Related Party</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In March&#160;2024, Oruka entered into the Purchase Agreement with Fairmount Fund&#160;II, whereby Oruka issued a convertible note, with an initial principal amount of $25.0<span class="nobreak"> </span>million that can be converted into Series&#160;A Preferred Stock (or a Series&#160;of preferred shares that is identical in respect to the shares of preferred shares issued in its next equity financing) or shares of the Company&#8217;s common stock in exchange for aggregate proceeds of $25.0&#160;million. The Convertible Note accrues interest at a rate of 12.0% per annum. All unpaid interest and principal are scheduled to mature on December&#160;31, 2025 (the &#8220;Maturity Date&#8221;). Prepayment is not permitted without prior written consent of Fairmount Fund II. Pursuant to the Purchase Agreement, the Company has the right to sell and issue additional convertible notes up to an aggregate principal amount equal to $30.0<span class="nobreak"> </span>million, in addition to the $25.0<span class="nobreak"> </span>million of initial principal amount of the Convertible Note.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In connection with the proposed reverse recapitalization transaction, the Convertible Note will convert into a number of shares of common stock based on the aggregate principal amount, plus any unpaid accrued interest, divided by the conversion price, which is an amount to be determined based upon Oruka&#8217;s fully<span class="nobreak">-diluted</span> capitalization immediately prior to the reverse recapitalization transaction. In the event the proposed reverse recapitalization transaction or any other proposed corporate transactions do not close prior to Oruka&#8217;s next equity financing, the Convertible Note will convert into the series of issued convertible preferred stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of March&#160;31, 2024, the aggregate principal amount of outstanding borrowings under the Convertible Note was $25.0&#160;million and Oruka has the right to issue and sell up to an additional $30.0&#160;million in convertible notes under the Purchase Agreement.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">269</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Critical Accounting Policies and Significant Judgments and Estimates</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka&#8217;s management&#8217;s discussion and analysis of its financial condition and results of operations is based on its financial statements, which have been prepared in accordance with U.S. GAAP.&#160;The preparation of these condensed financial statements requires Oruka to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported revenues recognized and expenses incurred during the reporting periods. Oruka&#8217;s estimates are based on its historical experience and on various other factors that Oruka believes are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">While Oruka&#8217;s significant accounting policies are described in more detail in Note&#160;2 to its financial statement and condensed financial statements included elsewhere in this proxy statement/prospectus, Oruka believes the following accounting policies used in the preparation of its financial statements require the most significant judgments and estimates.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Accrued Research and Development Expenses</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As part of the process of preparing Oruka&#8217;s financial statements, Oruka is required to estimate its accrued research and development expenses. This process involves estimating the level of service performed and the associated cost incurred for the services when Oruka has not yet been invoiced or otherwise notified of actual costs. The majority of Oruka&#8217;s service providers invoice the company in arrears for services performed, on a pre<span class="nobreak">-determined</span> schedule or when contractual milestones are met; however, some require advance payments. Oruka makes estimates of its accrued expenses as of each balance sheet date in the financial statements based on facts and circumstances known to Oruka at that time. At each period end, Oruka corroborates the accuracy of these estimates with the service providers and make adjustments, if necessary. Estimated accrued research and development expenses include those related to fees paid to vendors in connection with discovery development activities and any research organizations in connection with studies and testing. Although Oruka does not expect its estimates to be materially different from amounts actually incurred, Oruka&#8217;s understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in reporting amounts that are too high or too low in any particular period.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Stock-Based Compensation</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka measures stock<span class="nobreak">-based</span> awards granted to employees, directors, and non<span class="nobreak">-employees</span> in the form of stock options to purchase shares of Oruka common stock, based on their fair value on the date of the grant using the Black<span class="nobreak">-Scholes</span> model. Oruka measures restricted common stock awards using the difference, if any, between the purchase price per share of the award and the fair value of Oruka common stock at the date of grant. Compensation expense for those awards is recognized over the requisite service period, which is generally the vesting period of the respective award for employees. Compensation expense for awards to non<span class="nobreak">-employee</span> with service<span class="nobreak">-based</span> vesting conditions is recognized in the same manner as if Oruka had paid cash in exchange for the goods or services, which is generally the over the vesting period of the award. Oruka uses the straight<span class="nobreak">-line</span> method to recognize the expense of awards with service<span class="nobreak">-based</span> vesting conditions. Oruka accounts for forfeitures as they occur.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Black<span class="nobreak">-Scholes</span> model uses inputs that are determined by the Board on the date of grant and assumptions Oruka makes for the volatility of stock<span class="nobreak">-based</span> awards, the expected term of stock<span class="nobreak">-based</span> awards, the risk<span class="nobreak">-free</span> interest rate for a period that approximates the expected term of Oruka&#8217;s stock<span class="nobreak">-based</span> awards and its expected dividend yield. Oruka has historically been a private company and lack company<span class="nobreak">-specific</span> historical and implied volatility information of Oruka&#8217;s stock. Therefore, Oruka estimates its expected stock volatility based on the historical volatility of a representative group of public companies in the biotechnology industry for a term equal to the remaining time of the expected term. The expected term of Oruka&#8217;s stock options has been determined utilizing the &#8220;simplified&#8221; method for awards that qualify as &#8220;plain<span class="nobreak">-vanilla</span>&#8221; stock options. The risk<span class="nobreak">-free</span> interest rate is determined by reference to the U.S.&#160;Treasury yield curve for time periods approximately equal to the remaining contractual term of the options on the date of measurement. Oruka has estimated a 0% dividend yield based on the expected dividend yield and the fact that Oruka has never paid, and do not expect to pay, any cash dividends in the foreseeable future.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">270</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-left:24pt;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Determination of Fair Value of Common Stock</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As there has been no public market for Oruka&#8217;s stock<span class="nobreak">-based</span> awards to date, the estimated fair value of stock<span class="nobreak">-based</span> awards has been determined by Oruka&#8217;s board of directors as of the date of grant, with input from management, and with consideration of additional objective and subjective factors that it believed were relevant. In addition, Oruka&#8217;s board of directors considered various objective and subjective factors to determine the fair value of its share<span class="nobreak">-based</span> awards as of each grant date, including:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the prices at which Oruka sold shares of Series&#160;A convertible preferred stock and preferences of the Series&#160;A convertible preferred stock relative to Oruka&#8217;s stock<span class="nobreak">-based</span> awards at the time of each grant;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the progress of Oruka&#8217;s research and development programs, including the status of discovery<span class="nobreak">-phase</span> studies for its product candidates;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Oruka&#8217;s stage of development and business strategy;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>external market conditions affecting the biotechnology industry and trends within the biotechnology industry;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Oruka&#8217;s financial position, including cash on hand, and Oruka&#8217;s historical and forecasted performance and operating results;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the lack of an active public market for Oruka common stock and its Series&#160;A convertible preferred stock;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the likelihood of achieving a liquidity event, such as the proposed reverse recapitalization transaction, or sale of Oruka in light of prevailing market conditions; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the analysis of reverse recapitalization transactions and market performance of similar companies in the biotechnology industry.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka&#8217;s common stock valuations were prepared using a hybrid method, including an option pricing method (&#8220;OPM&#8221;). The OPM treats common stock and preferred stock as call options on the total equity value&#160;of a company, with exercise prices based on the value thresholds at which the allocation among the various holders of a company&#8217;s securities changes. Under this method, the common stock has value only if the funds available for distribution to stockholders exceed the value of the preferred stock liquidation preferences at the time of the liquidity event, such as a strategic sale or a merger. The hybrid method is a probability<span class="nobreak">-weighted</span> expected return method (&#8220;PWERM&#8221;), where the equity value in one or more of the scenarios is calculated using an OPM.&#160;The PWERM is a scenario<span class="nobreak">-based</span> methodology that estimates the fair value of common stock based upon an analysis of future values for the company, assuming various outcomes. The common stock value is based on the probability<span class="nobreak">-weighted</span> present value of expected future investment returns considering each of the possible outcomes available as well as the rights of each class of stock. The future value of the common stock under each outcome is discounted back to the valuation date at an appropriate risk<span class="nobreak">-adjusted</span> discount rate and probability weighted to arrive at an indication of value for the common stock. A discount for lack of marketability of the common stock is then applied to arrive at an indication of value for the common stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The assumptions underlying these valuations represented management&#8217;s best estimate, which involved inherent uncertainties and the application of management&#8217;s judgment. As a result, if Oruka had used significantly different assumptions or estimates, the fair value of Oruka&#8217;s incentive shares and its stock<span class="nobreak">-based</span> compensation expense could have been materially different.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Once a public trading market for Oruka common stock has been established in connection with the completion of this Merger, it will no longer be necessary for Oruka&#8217;s board of directors to estimate the fair value of its stock<span class="nobreak">-based</span> awards in connection with its accounting for granted stock<span class="nobreak">-based</span> awards or other such awards Oruka may grant, as the fair value of Oruka&#8217;s common stock and share<span class="nobreak">-based</span> awards will be determined based on the quoted market price of Oruka&#8217;s common stock.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Recently Issued Accounting Pronouncements</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">A description of recently issued accounting pronouncements that may potentially impact Oruka&#8217;s financial position, results of operations or cash flows is disclosed in Note&#160;2 to Oruka&#8217;s condensed financial statements as of March&#160;31, 2024 appearing at the end of this proxy statement/prospectus.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">271</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Off-Balance Sheet Arrangements</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of March&#160;31, 2024, Oruka did not have any off<span class="nobreak">-balance</span> sheet arrangements, as defined in the rules and regulations of the SEC.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Quantitative and Qualitative Disclosures about Market Risk</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Interest Rate Risk</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Convertible Note bears interest until December&#160;2025 at a fixed rate per annum equal 12%. An immediate 10% change in the prime rate would not have a material impact on Oruka&#8217;s debt<span class="nobreak">-related</span> obligations, financial position or results of operations.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Inflation Risk</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka&#8217;s results of operations and financial condition are presented based on historical cost. While it is difficult to accurately measure the impact of inflation due to the imprecise nature of the estimates required, Oruka believes the effects of inflation, if any, on Oruka&#8217;s results of operations and financial condition have been immaterial. Oruka cannot assure you its business will not be affected in the future by inflation.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">272</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T10"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">MANAGEMENT FOLLOWING THE MERGER</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Executive Officers and Directors</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Upon the completion of the Merger, the business and affairs of the combined company will be managed under the direction of the combined company&#8217;s board of directors.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The combined company&#8217;s board of directors will initially be fixed at six members, consisting of six current Oruka board members, namely Lawrence Klein, Kristine Ball, Carl Dambkowski, Peter Harwin, Samarth Kulkarni and Cameron Turtle. The staggered structure of the current ARCA board of directors will remain in place for the combined company following the completion of the Merger.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Each executive officer of the combined company will serve at the discretion of the combined company&#8217;s board of directors and holds office until his or her successor is duly elected and qualified or until his or her earlier resignation or removal. There are no family relationships among any of the proposed combined company&#8217;s directors or executive officers.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">All of ARCA&#8217;s current directors are expected to resign from their positions as directors of ARCA, effective as of the closing of the Merger.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following table sets forth the name, age as of May&#160;3, 2024 and position of each of the individuals who are expected to serve as executives and directors of the combined company following completion of the Merger:</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">



						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;text-align:left;"><span class="Bold" style="font-style:normal;font-weight:bold;">Name</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.37%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Age</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 59.29%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Position</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Executive Officers</span>:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 7.37%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 59.29%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Lawrence Klein</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 7.37%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">41</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 59.29%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">President, Chief Executive Officer and Director</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Arjun Agarwal</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 7.37%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">48</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 59.29%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Senior Vice President, Finance and Treasurer</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Joana Goncalves</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 7.37%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">50</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 59.29%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Chief Medical Officer</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Paul Quinlan</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 7.37%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">61</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 59.29%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">General Counsel and Secretary</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Non-Employee Directors</span>:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 7.37%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 59.29%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Samarth Kulkarni</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 7.37%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">45</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 59.29%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Chair and Director</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Kristine Ball</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 7.37%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">52</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 59.29%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Director</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Carl Dambkowski</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 7.37%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">39</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 59.29%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Director</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Peter Harwin</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 7.37%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">38</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 59.29%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Director</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Cameron Turtle</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 7.37%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">34</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 59.29%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Director</p>
					</td>
				</tr>

		</table>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Executive Officers</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Lawrence Klein, Ph.D.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span>Dr.&#160;Klein has served as Chief Executive Officer of Oruka and as a member of its board of directors since February&#160;2024. Prior to joining Oruka, Dr.&#160;Klein was a Partner at Versant Venture Management, LLC, a healthcare and biotechnology venture capital firm, from January&#160;2023 to February&#160;2024, where he invested in and helped to grow early<span class="nobreak">-stage</span> biotechnology companies. Prior to Versant, Dr.&#160;Klein served in various positions at CRISPR Therapeutics AG (Nasdaq: CRSP), a biopharmaceutical company, including Chief Operating Officer from January&#160;2020 to October&#160;2022, Chief Business Officer from January&#160;2019 to January&#160;2020, Senior Vice President, Business Development and Strategy from November&#160;2017 to December&#160;2018 and as Vice President, Strategy from February&#160;2016 to November&#160;2017, where he helped to initiate and execute on several transformative partnerships, establish the strategic direction of the company, oversee important pipeline programs and led several functions, including program and portfolio management. Before joining CRISPR, Dr.&#160;Klein was an Associate Partner at McKinsey&#160;&amp; Company, a global management consulting firm, from October&#160;2014 to February&#160;2016. Dr.&#160;Klein served as a member of the board of directors of Dyne Therapeutics, Inc. (Nasdaq: DYN) from September&#160;2019 to May&#160;2023 and of Jasper Therapeutics, Inc. (Nasdaq: JSPR) from September&#160;2021 to June&#160;2023. Dr.&#160;Klein received his B.S. in biochemistry and physics from the University of Wisconsin<span class="nobreak">-Madison</span> and his Ph.D. in biophysics from Stanford University.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka believes Dr.&#160;Klein is qualified to serve as a member of the board of directors of the combined company because of his business development, operational and senior management experience in the biotechnology industry and his academic expertise and accomplishments.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">273</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Arjun Agarwal.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span>Mr.&#160;Agarwal has served as the Senior Vice President of Finance of Oruka since March&#160;2024, where he is responsible for overseeing the company&#8217;s finance and accounting functions. Prior to joining Oruka, Mr.&#160;Agarwal served as VP of Finance at Jasper Therapeutics, Inc. (Nasdaq: JSPR), a biotechnology company, from June&#160;2021 to March&#160;2024, including through multiple financings and the company&#8217;s successful transition to become a publicly traded entity. Before joining Jasper, Mr.&#160;Agarwal served as Vice President, Corporate Controller at Protagonist Therapeutics, Inc. (Nasdaq: PTGX), a biotechnology company, from August&#160;2019 to June&#160;2021, where he was responsible for overseeing the company&#8217;s finance and accounting functions. Prior to joining Protagonist, Mr.&#160;Agarwal served in various roles of increasing responsibility at McKesson Corporation (NYSE:&#160;MCK),&#160;an international healthcare services company, from 2009 to 2019. Prior to McKesson, Mr.&#160;Agarwal worked at PricewaterhouseCoopers LLP, where he managed a portfolio of audit clients. He is a graduate of Sydenham College of Commerce and Economics at Mumbai University, India. He is a Certified Public Accountant (CPA) and a Chartered Accountant accredited by the Institute of Chartered Accountants of India.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Joana Goncalves, MBChB.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span>Dr.&#160;Goncalves has served as the Chief Medical Officer of Oruka since April&#160;2024. Prior to joining Oruka, Dr.&#160;Goncalves served as Chief Medical Officer of Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company, from October&#160;2018 to April&#160;2024, where she was responsible for representing Cara Therapeutics in interactions with regulatory agencies, the investor and scientific communities and the board of directors, building multifunctional terms and developing the clinical development strategy in dermatological conditions. Prior to Cara, Dr.&#160;Goncalves held various positions at Celgene Corporation, a pharmaceutical company, which was later acquired by Bristol<span class="nobreak">-Myers</span> Squibb Company, from April&#160;2014 to October&#160;2018, where she most recently served as Vice President, Medical Affairs for Dermatology and Neurology and was instrumental in planning and executing medical support activities for a number of programs, including OTEZLA&#174; for psoriasis. Prior to Celgene, Dr.&#160;Goncalves served as Vice President, Medical Strategy and Scientific Affairs at LEO Pharma Inc., the U.S.&#160;subsidiary of LEO Pharma A/S, a global healthcare company specializing in dermatology and critical care, from February&#160;2012 to April&#160;2014. She began her pharmaceutical career at Novartis Pharmaceuticals, working on a range of products across various therapeutic areas from 2001 to 2012. Dr.&#160;Goncalves received her MBChB from the University of Cape Town, South Africa.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Paul Quinlan.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span>Mr.&#160;Quinlan has served as General Counsel of Oruka since April&#160;2024. Prior to joining Oruka, Mr.&#160;Quinlan served as General Counsel, Chief Compliance Officer and Corporate Secretary of CymaBay Therapeutics, Inc., a biopharmaceutical company, from October&#160;2020 to March&#160;2024, where he was responsible for the general supervision of the company&#8217;s legal affairs. From December&#160;2017 to February&#160;2020, he served as General Counsel and Corporate Secretary of CymaBay, where he was responsible for the general supervision of the company&#8217;s legal affairs. Prior to CymaBay, Mr.&#160;Quinlan served as General Counsel and Secretary, from 2010 to January&#160;2018, and Chief Legal Officer from 2016 to January&#160;2018, of TerraVia Holdings, Inc., a biotechnology company, where he was responsible for the general supervision of the company&#8217;s legal affairs. Prior to joining TerraVia, Mr.&#160;Quinlan served as General Counsel of Metabolex, Inc., a biopharmaceutical company, from 2005 to 2010. Prior to joining Metabolex, Mr.&#160;Quinlan held various positions at Maxygen, Inc., a biopharmaceutical company, from 2000 to 2005. Prior to Maxygen, Mr.&#160;Quinlan practiced law at Cooley LLP and Cravath, Swaine,&#160;&amp; Moore LLP.&#160;Mr.&#160;Quinlan received a law degree from Columbia Law School and an M.Sc. in Medical Biophysics from the University of Toronto.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Non-Employee Directors</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Kristine Ball.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span>Ms. Ball has served as a member of the board of directors of Oruka since May&#160;2024. Ms.&#160;Ball has served as President and Chief Executive Officer of Antiva Biosciences, Inc., a private biopharmaceutical company, since April&#160;2023. Prior to Antiva, Ms. Ball served as Chief Executive Officer of Soteria Biotherapeutics, Inc., a private biotechnology company, from September&#160;2020 to August&#160;2022. Prior to joining Soteria, Ms. Ball served as Senior Vice President, Corporate Strategy and Chief Financial Officer of Menlo Therapeutics, Inc., a Nasdaq<span class="nobreak">-listed</span> biopharmaceutical company, which later became VYNE Therapeutics Inc. (Nasdaq: VYNE), from September&#160;2017 to March&#160;2020, where she was responsible for leading all non<span class="nobreak">-R</span>&amp;D functions, including strategic planning, corporate development, commercial, human resources, legal, finance and information technology. Prior to joining Menlo, Ms. Ball served as Chief Financial Officer and Senior Vice President of Relypsa, Inc., a Nasdaq<span class="nobreak">-listed</span> pharmaceutical company, which was later acquired by Galenica Group, from November&#160;2012 to October&#160;2016. Prior to Relypsa, Ms. Ball held various other finance roles in the life sciences industry, including Senior Vice President of Finance&#160;&amp; Administration and Chief Financial Officer of KAI Pharmaceuticals, Inc., a </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">274</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">biopharmaceutical company, and Vice President of Finance at Exelixis, Inc. (Nasdaq: EXEL), a biotechnology company. Prior to that, Ms. Ball served as a senior manager in life sciences audit practice of Ernst&#160;&amp; Young LLP. Ms.&#160;Ball has previously served on the boards of directors of Atreca, Inc. (Nasdaq: BCEL), a biopharmaceutical company, from 2020 to 2024, Soteria from 2020 to 2022 and Forty Seven, Inc., a Nasdaq<span class="nobreak">-listed</span> biotechnology company, which was later acquired by Gilead Sciences, Inc., from 2018 to 2020. Ms. Ball received a B.S. from Babson College.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka believes Ms. Ball is qualified to serve as a member of the board of directors of the combined company because of her experience as an executive officer and director of life sciences companies and her background in finance, corporate development and strategic planning. </p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Carl Dambkowski, M.D.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span>Dr.&#160;Dambkowski has served as a member of the board of directors of Oruka since February&#160;2024. Dr.&#160;Dambkowski has served as the Chief Medical Officer of Apogee Therapeutics, Inc. (Nasdaq: APGE), a biotechnology company, since September&#160;2022. Prior to joining Apogee, Dr.&#160;Dambkowski served as a strategic and clinical leader for a variety of companies, including as Chief Medical Officer of QED Therapeutics, Inc., a private biotechnology company, from July&#160;2021 to September&#160;2022; Chief Strategy Officer and EVP of Operations of Origin Biosciences, Inc., a private bioecology company, from March&#160;2018 to June&#160;2021; and Chief Medical Officer of Navire Pharma, Inc., a private biotechnology company, from January&#160;2020 to September&#160;2022, where he served as the clinical lead starting prior to IND for BBP<span class="nobreak">-398</span> through the out licensing of the compound to Bristol<span class="nobreak">-Myers</span> Squibb based on initial clinical data and for low<span class="nobreak">-dose</span> infigratinib in achondroplasia through initial proof<span class="nobreak">-of-concept</span> data. He was part of the core team that brought TRUSELTIQ<span class="Superscript" style="vertical-align:super;font-size:58%;">&#174;</span> (infigratinib) and NULIBRY<span class="Superscript" style="vertical-align:super;font-size:58%;">&#174;</span> (fosdenopterin) through regulatory review and FDA approval at QED Therapeutics and Origin Biosciences, respectively. From July&#160;2016 to March&#160;2018, Dr.&#160;Dambkowski was an associate at McKinsey&#160;&amp; Company, a global management consulting firm, where he advised biotech and pharmaceutical companies across the world on a range of research and development activities. Dr.&#160;Dambkowski co<span class="nobreak">-founded</span> Novonate, Inc., a private medical device company focused on building life<span class="nobreak">-saving</span> devices for neonates, in January&#160;2015. Dr.&#160;Dambkowski has coauthored numerous peer<span class="nobreak">-reviewed</span> publications and scientific abstracts and is a named inventor on multiple published and granted patents. Dr.&#160;Dambkowski was trained as a physician at Stanford University, where he also received his M.D. with a concentration in bioengineering. He also received a B.A. (with honors) from Stanford University and an M.A. from Columbia University.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka believes Dr.&#160;Dambkowski is qualified to serve as a member of the board of directors of the combined company because of his significant experience and innovations in the biotechnology industry and his academic expertise and accomplishments.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Peter Harwin.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span>Mr.&#160;Harwin has served as a member of the board of directors of Oruka since February&#160;2024. Mr.&#160;Harwin is a Managing Member at Fairmount Funds Management, a healthcare investment firm he co<span class="nobreak">-founded</span> in April&#160;2016. Prior to Fairmount Funds Management, Mr.&#160;Harwin was a member of the investment team at Boxer Capital, LLC, an investment fund that was part of the Tavistock Group, based in San Diego. Mr.&#160;Harwin also serves as chairman of the board of directors of Cogent Biosciences, Inc. (Nasdaq: COGT) and is a member of the board of directors of Apogee Therapeutics, Inc. (Nasdaq: APGE), Viridian Therapeutics, Inc. (Nasdaq: VRDN) and Spyre Therapeutics, Inc. (Nasdaq: SYRE). Mr.&#160;Harwin received a B.B.A. from Emory University.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka believes Mr.&#160;Harwin is qualified to serve as a member of the board of directors of the combined company because his experience serving as a director of biotechnology companies and as a manager of funds specializing in the area of life sciences.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Samarth Kulkarni, Ph.D.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span>Dr.&#160;Kulkarni has served as a member of the board of directors of Oruka since February&#160;2024. Dr.&#160;Kulkarni has served as the Chief Executive Officer of CRISPR Therapeutics AG (Nasdaq: CRSP), a biopharmaceutical company, since December&#160;2017, where he has also served as a member and chair of the board of directors since June&#160;2018 and September&#160;2023, respectively. Previously, Dr.&#160;Kulkarni served as CRISPR&#8217;s President and Chief Business Officer from May&#160;2017 to November&#160;2017 and as Chief Business Officer from August&#160;2015. Prior to joining CRISPR, Dr.&#160;Kulkarni was at McKinsey&#160;&amp; Company, a global management consulting firm, from 2006 to 2015, with various titles, his most recent being Partner within the Pharmaceuticals and Biotechnology practice. Dr.&#160;Kulkarni has also served as a member of the boards of directors of Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology company, since 2019, including as lead independent director since September&#160;2023, Repare Therapeutics Inc. (Nasdaq: RPTX), a precision oncology company, since November&#160;2019 and Centessa Pharmaceuticals plc (Nasdaq: CNTA), a biotechnology company, </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">275</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">since February&#160;2021. Dr.&#160;Kulkarni received a Ph.D. in Bioengineering and Nanotechnology from the University of Washington and a B.&#160;Tech. from the Indian Institute of Technology. Dr.&#160;Kulkarni has authored several publications in leading scientific and business journals.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka believes that Dr.&#160;Kulkarni is qualified to serve as a member of the board of directors of the combined company because of his experience as a consultant and an executive in the biopharmaceutical industry and his academic expertise and accomplishments.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Cameron Turtle, D.Phil.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span>Dr.&#160;Turtle has served as a member of the board of directors of Oruka since February&#160;2024. Dr.&#160;Turtle has served as Chief Executive Officer and a member of the board of directors of Spyre Therapeutics, Inc. (formerly Aeglea BioTherapeutics, Inc.) (Nasdaq: SYRE), a biotechnology company, since November&#160;2023 and, before that, as Chief Operating Officer from June&#160;2023 to November&#160;2023. Prior to joining Spyre, Dr.&#160;Turtle was an advisor to Spyre Therapeutics, Inc., a private biotechnology company, from May&#160;2023 to June&#160;2023. Previously, he served as Venture Partner at Foresite Labs, a life sciences investment firm, from July&#160;2022 to May&#160;2023; Chief Strategy Officer of BridgeBio Pharma (Nasdaq: BBIO), a biotechnology company, from January&#160;2021 to April&#160;2022; and Chief Business Officer of Eidos Therapeutics (Nasdaq: EIDX), a biopharmaceutical company, from November&#160;2018 to January&#160;2021, where he led business development, investor relations, and multiple operational functions as the company advanced an investigational medicine for a form of heart failure. Prior to joining BridgeBio and Eidos, he was a consultant at McKinsey&#160;&amp; Company, a global management consulting firm, where he worked with pharmaceutical and medical device companies on topics including M&amp;A, growth strategy, clinical trial strategy, and sales force optimization. Dr.&#160;Turtle received his B.S. with honors in Bioengineering from the University of Washington and his D.Phil. in Cardiovascular Medicine from the University of Oxford, St. John&#8217;s College. He is the recipient of several awards, including a Rhodes Scholarship, Goldwater Scholarship, Forbes 30 Under<span class="nobreak"> </span>30, San Francisco Business Times 40 Under<span class="nobreak"> </span>40, and the Biocom Life Sciences Catalyst Award.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka believes Dr.&#160;Turtle is qualified to serve as a member of the board of directors of the combined company because of his experience as a leader in building, financing, and shaping biopharmaceutical organizations from preclinical development to late<span class="nobreak">-stage</span> clinical trials and commercialization.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Composition of the Board of Directors</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s board of directors currently consists of five members, divided into three staggered classes, with one class to be elected at each annual meeting to serve for a three<span class="nobreak">-year</span> term. The staggered structure of the board of directors will remain in place for the combined company following the completion of the Merger, with Class&#160;I directors holding terms expiring at the 2025 annual meeting of stockholders, Class&#160;II directors holding terms expiring at the 2026 annual meeting of stockholders and Class&#160;III directors holding terms expiring at the 2027 annual meeting of stockholders. It is anticipated that the incoming directors will be appointed to classes of the combined company board of directors following the completion of the Merger as follows: Carl Dambkowski and Peter Harwin are expected to be Class&#160;I directors; Cameron Turtle and Lawrence Klein are expected to be Class&#160;II directors; and Samarth Kulkarni and Kristine Ball are expected to be Class&#160;III directors.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Director Independence</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Nasdaq listing rules require a majority of a listed company&#8217;s board of directors to be comprised of independent directors who, in the opinion of the board of directors, do not have a relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director. Subject to specified exceptions, each member of a listed company&#8217;s audit, compensation and nominating committees must be independent, and audit and compensation committee members must satisfy additional independence criteria under the Exchange&#160;Act.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Based on information provided by each proposed director concerning her or his background, employment and affiliations, ARCA and Oruka expect that the combined company&#8217;s board of directors will determine that each of the directors other than Lawrence Klein, Oruka&#8217;s current President and Chief Executive Officer, who is expected to serve as President and Chief Executive Officer of the combined company, will qualify as an &#8220;independent director&#8221; as defined under applicable Nasdaq listing rules. In making these determinations, the combined company&#8217;s board of directors will consider the current and prior relationships that each director has with ARCA and Oruka and all other facts and circumstances that the company&#8217;s board of directors deems relevant in determining the independence of each proposed director, including the interests of each combined company director in the Merger, any relevant </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">276</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">related party transactions and the beneficial ownership of securities of ARCA, Oruka or the combined company by each combined company director. See also the sections titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">The Merger &#8212; Interests of Oruka&#8217;s Directors and Executive Officers in the Merger</span>,&#8221; &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Certain Relationships and Related Party Transactions of the Combined Company</span>&#8221; and &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Principal Stockholders of Oruka</span>&#8221; beginning on pages 124, 280 and 315, respectively, of this proxy statement/prospectus for additional information.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Board Leadership Structure</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Following the completion of the Merger, Dr.&#160;Kulkarni is expected to serve as Chair of the board of directors of the combined company. The combined company&#8217;s Principles of Corporate Governance will provide its board of directors with the flexibility to combine or separate the positions of Chair of the board of directors and Chief Executive Officer. Oruka believes that having these positions be separate is the appropriate leadership structure for the combined company at this time as it will help facilitate independent oversight of management by the board of directors of the combined company and allow the Chief Executive Officer to focus on strategy execution and managing the business while the Chair focuses on corporate governance and managing the combined company&#8217;s board of directors.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Committees of the Board of Directors</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Following the completion of the Merger, ARCA and Oruka anticipate that the board of directors of the combined company will establish an audit committee, a compensation committee and a nominating and corporate governance committee, each of which will operate pursuant to a charter adopted by the board of directors of the combined company. ARCA and Oruka believe that following the completion of the Merger the functioning and composition of these committees of the combined company will comply with the requirements of Nasdaq listing rules and SEC rules and regulations. The board of directors of the combined company may also establish other committees from time to time to assist the combined company and its board of directors. Each of the audit committee, compensation committee, nominating and corporate governance committee is expected to have the responsibilities described below.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Audit Committee</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Following the completion of the Merger, the initial members of the combined company&#8217;s audit committee are expected to be Kristine Ball, Carl Dambkowski and Cameron Turtle, each of whom qualifies as an independent director for audit committee purposes, as defined under the rules of the SEC and the applicable Nasdaq listing rules and has sufficient knowledge in financial and auditing matters to serve on the combined company&#8217;s audit committee. Kristine Ball is expected to chair the audit committee. Kristine Ball is an &#8220;audit committee financial expert&#8221; as defined in Item&#160;407(d)(5)(ii)&#160;of Regulation&#160;S<span class="nobreak">-K</span> promulgated under the Securities Act.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The primary responsibilities of the combined company&#8217;s audit committee will be to oversee the combined company&#8217;s accounting and financial reporting processes, including the audits of the financial statements, and the internal and external audit processes. The audit committee will also oversee the system of internal controls established by management and the combined company&#8217;s compliance with legal and regulatory requirements. The audit committee will also be responsible for the review, consideration and approval or ratification of related party transactions. The audit committee will oversee the independent auditors, including their independence and objectivity. The audit committee will be empowered to retain outside legal counsel and other advisors as it deems necessary or appropriate to assist it in fulfilling its responsibilities and to approve the fees and other retention terms of the advisors.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Compensation Committee</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Following the completion of the Merger, the initial members of the combined company&#8217;s compensation committee are expected to be Peter Harwin, Samarth Kulkarni and Kristine Ball, each of whom qualifies as an independent director, as defined under applicable Nasdaq listing rules and also meets the additional, heightened independence criteria applicable to members of the compensation committee. Peter Harwin is expected to chair the compensation committee.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">277</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:9pt;margin-top:9pt;">The primary responsibilities of the combined company&#8217;s compensation committee will be to periodically review and approve the compensation and other benefits for the combined company&#8217;s senior officers and directors. This will include reviewing and approving corporate goals and objectives relevant to the compensation of the combined company&#8217;s Chief Executive Officer and other executive officers, evaluating the performance of these officers in light of the goals and objectives and setting or recommending to the combined company&#8217;s board of directors the officers&#8217; compensation. The compensation committee will also administer and make recommendations to the combined company&#8217;s board of directors regarding equity incentive plans that are subject to the board of directors&#8217; approval and approve the grant of equity awards under the plans.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Nominating and Corporate Governance Committee</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Following the completion of the Merger, the initial members of the combined company&#8217;s nominating and corporate governance committee are expected to be Cameron Turtle, Samarth Kulkarni and Peter Harwin, each of whom qualifies as an independent director, as defined under applicable Nasdaq listing rules. Cameron Turtle is expected to be chair the nominating and corporate governance committee.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:9pt;margin-top:9pt;">The combined company&#8217;s nominating and corporate governance committee will be responsible for engaging in succession planning for the combined company&#8217;s board of directors, developing and recommending to the combined company&#8217;s board of directors criteria for identifying and evaluating qualified director candidates and making recommendations to the combined company&#8217;s board of directors regarding candidates for election or reelection to the board of directors at each annual stockholders&#8217; meeting. In addition, the nominating and corporate governance committee will be responsible for overseeing the combined company&#8217;s corporate governance matters. The nominating and corporate governance committee will also be responsible for overseeing the structure, composition and functioning of the combined company&#8217;s board of directors and its committees.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Compensation Committee Interlocks and Insider Participation</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:9pt;margin-top:9pt;">None of the expected members of the combined company&#8217;s compensation committee has at any time been one of the officers or employees of the combined company. None of the combined company&#8217;s expected executive officers currently serves, or in the past fiscal year has served, as a member of the board of directors or compensation committee of any entity that has one or more executive officers that is or are expected to serve on the combined company&#8217;s board of directors or compensation committee following the completion of the Merger.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Code of Conduct and Ethics</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Following the completion of the Merger, the combined company will adopt a Code of Conduct and Ethics that establishes the standards of ethical conduct applicable to all of the combined company&#8217;s directors, officers and employees. The full text of the combined company&#8217;s Code of Conduct and Ethics will be posted on the combined company&#8217;s website at<span style="width: 10px;display: inline-block;">&#160;&#160;&#160;</span><span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>. The Code of Conduct and Ethics is expected to address, among other matters, compliance with laws and policies, conflicts of interest, corporate opportunities, regulatory reporting, external communications, confidentiality requirements, insider trading, proper use of assets and how to report compliance concerns. The combined company intends to disclose any amendments to the Code of Conduct and Ethics, or any waivers of its requirements, on its website to the extent required by applicable rules. The combined company&#8217;s audit committee will be responsible for applying and interpreting the Code of Conduct and Ethics in situations where questions are presented to it. Information contained on, or that can be accessed through, the combined company&#8217;s website is not incorporated by reference into this proxy statement/prospectus, and you should not consider information on the combined company&#8217;s website to be part of this proxy statement/prospectus.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">278</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Director Compensation</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Prior to the Merger, Oruka did not have a formal policy to provide any cash or equity compensation to its non<span class="nobreak">-employee</span> directors for their service on its board of directors or committees of its board of directors. Oruka&#8217;s non<span class="nobreak">-employee</span> director compensation is described under &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Oruka Director Compensation</span>&#8221; in this proxy statement/prospectus. Except as described below, determinations with respect to director compensation after the closing of the Merger have not yet been made. In connection with closing of the Merger, it is expected that the board of directors of the combined company will adopt a non<span class="nobreak">-employee</span> director compensation policy designed to enable the combined company to attract and retain, on a long<span class="nobreak">-term</span> basis, highly qualified non<span class="nobreak">-employee</span> directors and align its directors&#8217; interests with those of its stockholders. Employee directors will not receive additional compensation for their services as directors. It is expected that each director who is not an employee will be paid cash and equity compensation for serving on the board of directors of the combined company, the amount and terms of which have not yet been determined. The combined company will also reimburse its non<span class="nobreak">-employee</span> directors for reasonable travel and out<span class="nobreak">-of-pocket</span> expenses incurred in connection with attending the board of director and committee meetings.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">279</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T9989"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS<br/>OF THE COMBINED COMPANY</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition to the compensation arrangements, including employment, termination of employment and change in control arrangements, with Oruka&#8217;s and ARCA&#8217;s directors and executive officers, including those discussed in the sections titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Management Following the Merger</span>,&#8221; &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Oruka Executive Compensation</span>&#8221; and &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">ARCA Executive Compensation</span>,&#8221; the following is a description of each transaction involving ARCA since January&#160;1, 2022, each transaction involving Oruka since February&#160;6, 2024 (inception) and each currently proposed transaction in which:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>either Oruka or ARCA has been or is to be a participant;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the amounts involved exceeded or will exceed the lesser of $120,000 and 1% of the average of Oruka&#8217;s or ARCA&#8217;s total assets at year<span class="nobreak">-end</span> for the last two completed fiscal&#160;years, as applicable; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>any of Oruka&#8217;s or ARCA&#8217;s directors, executive officers or holders of more than 5% of Oruka&#8217;s or ARCA&#8217;s capital stock, or an affiliate or immediate family member of the foregoing persons, had or will have a direct or indirect material interest.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">ARCA Transactions</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As a smaller reporting company, SEC rules require ARCA to disclose any transaction for the last two completed fiscal&#160;years or any currently proposed transaction in which ARCA is a participant and in which any related person has or will have a direct or indirect material interest involving an amount in excess of $120,000 or 1% of the average of ARCA&#8217;s total assets at year<span class="nobreak">-end</span> for the last two fiscal&#160;years. A related person is any executive officer, director, nominee for director or holder of 5% or more of ARCA&#8217;s common stock or an affiliate or immediate family member of any of those persons.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Other than the compensation arrangements and other arrangements disclosed above under the headings &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">ARCA Executive Compensation</span>&#8221; and &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">ARCA Director Compensation</span>&#8221; and the transactions described below, since January&#160;1, 2022, there has not been and there is not currently proposed, any transaction or series of similar transactions to which ARCA was, or will be, a party in which the amount involved exceeded, or will exceed, $120,000 (or, if less, 1% of the average of ARCA&#8217;s total assets amounts at December&#160;31, 2022 and 2023) and in which any director, executive officer, holder of 5% or more of any class of ARCA&#8217;s capital stock or any member of the immediate family of, or entities affiliated with, any of the foregoing persons, had, or will have, a direct or indirect material interest.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Transactions With ARCA&#8217;s Former President and Chief Executive Officer</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA has entered into unrestricted research grants with its former President and Chief Executive Officer&#8217;s academic research laboratory at the University of Colorado. Funding of any unrestricted research grants is contingent upon ARCA&#8217;s financial condition, and can be deferred or terminated at ARCA&#8217;s discretion. There was no expense under these arrangements for the three&#160;months ended March&#160;31, 2024. Total expense under these arrangements for the three&#160;months ended March&#160;31, 2023 was $108,000. Total expense under these arrangements for the&#160;years ended December&#160;31, 2023 and 2022 was $(91,000) and $432,000, respectively. In December&#160;2023, ARCA made a payment of $125,000 for the grant period July&#160;2022 through December&#160;2023 under these arrangements. In April&#160;2024, the President and Chief Executive Officer resigned.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Cooperation Agreement</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA is party to a Cooperation Agreement (the &#8220;Cooperation Agreement&#8221;) with Cable Car Capital LLC, The Funicular Fund, LP, Funicular Funds, LP and Jacob Ma<span class="nobreak">-Weaver</span> (collectively, &#8220;Cable Car&#8221;).</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Pursuant to the Cooperation Agreement, ARCA&#8217;s board of directors appointed Mr.&#160;Ma<span class="nobreak">-Weaver</span> as a Class&#160;III director with a term expiring at ARCA&#8217;s 2024 annual meeting of stockholders, effective June&#160;15, 2022 and appointed Mr.&#160;Ma<span class="nobreak">-Weaver</span> to the Special Committee of ARCA&#8217;s board of directors (the &#8220;First Director Appointment&#8221;).</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Additionally, under the terms of the Cooperation Agreement, ARCA and Cable Car initiated a process and subsequently identified a mutually acceptable second independent director, Mr.&#160;James Flynn, to join ARCA&#8217;s board of directors. Mr.&#160;Flynn was elected as director at the 2022 annual meeting of stockholders.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">280</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Under the terms of the Cooperation Agreement, Cable Car agreed to abide by customary standstill restrictions from the date of the Cooperation Agreement until the earlier to occur of (i)&#160;the 180<span class="CharOverride-2" style="font-size:58%;vertical-align:super;">th</span>&#160;day after the First Director Appointment is no longer serving as a director of ARCA and (ii)&#160;the 90<span class="CharOverride-2" style="font-size:58%;vertical-align:super;">th</span>&#160;day prior to the 2023 Annual Meeting (such period, the &#8220;Cooperation Period&#8221;), including that Cable Car will not, among other things, (i)&#160;seek additional representation, or the removal of an existing director, on ARCA&#8217;s board of directors, (ii)&#160;engage in any solicitation of proxies, or (iii)&#160;initiate, propose or otherwise solicit, including any solicitations of the type contemplated by Rule&#160;14a<span class="nobreak">-2</span>(b)&#160;promulgated under the Securities Exchange&#160;Act&#160;of&#160;1934 of ARCA&#8217;s stockholders for the approval of, any stockholder proposal. The Cooperation Period expired on November&#160;1, 2023, the 90<span class="Superscript" style="vertical-align:super;font-size:58%;">th</span><span class="Superscript" style="vertical-align:super;">&#160;</span>day prior to the 2023 Annual Meeting.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA and Cable Car also agreed to customary mutual non<span class="nobreak">-disparagement</span> obligations.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Policies and Procedures for Related Party Transactions</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s Audit Committee reviews and approves all related party transactions. This review covers any material transaction, arrangement or relationship, or any series of similar transactions, arrangements or relationships, in which ARCA was or will be a participant, and a related party had or will have a direct or indirect material interest, including, purchases of goods or services by or from the related party or entities in which the related party has a material interest, indebtedness, guarantees of indebtedness and employment by ARCA of a related party. In evaluating any related party transaction, ARCA&#8217;s Audit Committee considers, among&#160;other things, the relative benefits of the transaction to ARCA, what, if any, alternatives may be available from persons not affiliated to ARCA, if the terms of the transaction have been negotiated on an arm&#8217;s length basis and any other matters that ARCA&#8217;s Audit Committee may deem relevant in determining whether such related party transaction is in the best interests of ARCA and its stockholders.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Oruka Transactions</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following is a summary of each transaction or series of similar transactions since February&#160;6, 2024 (inception) or any currently proposed transaction, to which Oruka was or is a party in which:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the amounts involved exceeded or will exceed the lesser of $120,000 and 1% of Oruka&#8217;s total assets; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>any of Oruka&#8217;s directors or executive officers, any holder of 5% of any class of Oruka capital stock or an affiliate or immediate family member of the foregoing persons had or will have a direct or indirect material interest.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Compensation arrangements for Oruka named executive officers and directors are described elsewhere in this proxy statement/prospectus under &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Oruka Executive Compensation</span>&#8221; and &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Oruka Director Compensation</span>.&#8221;</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Private Placements of Securities</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Series&#160;A Preferred Stock and Convertible Note&#160;Financing</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On March&#160;6, 2024, Oruka completed a preferred stock and convertible note financing (the &#8220;Oruka Series&#160;A Financing&#8221;) and issued and sold to Fairmount Fund&#160;II (i)&#160;an aggregate of 20,000,000<span class="nobreak"> </span>shares of Series&#160;A preferred stock at a purchase price of $0.15 per share and (ii)&#160;the Convertible Note with an initial principal amount of $25,000,000 at an interest rate of 12% per annum, for aggregate gross proceeds of $28&#160;million. Fairmount Fund&#160;II is expected to contribute the aggregate principal amount and all accrued interest under the Convertible Note in exchange for Oruka common stock and Oruka pre<span class="nobreak">-funded</span> warrants in connection with Oruka&#8217;s pre<span class="nobreak">-closing</span> financing. Fairmount Funds Management is the investment manager of Fairmount. Peter Harwin, a director of Oruka, is a managing member of Fairmount Funds Management.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka Pre-Closing Financing</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On April&#160;3, 2024, in connection with the execution of the Merger Agreement, Oruka entered into the Subscription Agreement with certain investors to consummate the Oruka pre<span class="nobreak">-closing</span> financing. Pursuant to the Subscription Agreement, the investors agreed to purchase an estimated aggregate of 38,382,693<span class="nobreak"> </span>shares of Oruka common stock and 9,009,825 Oruka pre<span class="nobreak">-funded</span> warrants, at an estimated price of $5.80 per share of common stock </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">281</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">and $5.79 per warrant, respectively, for aggregate gross proceeds of approximately $275.0&#160;million (which includes $25.0<span class="nobreak"> </span>million of proceeds previously received from the issuance of the Convertible Note and accrued interest on such note). The aggregate purchase price of $275.0&#160;million is fixed, while the purchase price per share or warrant and the aggregate number of shares and warrants to be purchased is subject to change pursuant to the terms of the Subscription Agreement. Please see the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Agreements Related to the Merger&#160;&#8212;&#160;Subscription Agreement</span>.&#8221; The closing of the Oruka pre<span class="nobreak">-closing</span> financing is conditioned upon the satisfaction or waiver of the conditions to the Merger as well as certain other conditions. Three of the investors or their affiliates are, or are expected to be as of immediately following the Oruka pre<span class="nobreak">-closing</span> financing, beneficial holders of more than 5% of Oruka&#8217;s capital stock, and the table below sets forth the number of shares of Oruka common stock and Oruka pre<span class="nobreak">-funded</span> warrants expected to be purchased by such holders at the closing of the Oruka pre<span class="nobreak">-closing</span> financing (based on the currently estimated purchase price per share or warrant, as applicable).</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 3pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-11" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">



						<p class="TCH_left" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Participant</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Shares of <br/>Oruka <br/>Common Stock</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Pre-funded <br/>Warrants of <br/>Oruka</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:bold;">Total <br/>Purchase <br/>Price</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Entities affiliated with Fairmount</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4,973,597</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">8,813,325</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">80,000,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="Superscript" style="vertical-align:super;font-size:58%;">(1)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Entities affiliated with Venrock Healthcare Capital Partners</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4,973,595</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">196,500</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">30,000,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Entities affiliated with FMR LLC</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4,308,409</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">25,000,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>

		</table>
		<p class="Tablefootnotef" style="margin-top: 0in;  border: none; margin-right: 0in; margin-bottom: -5pt; margin-left: 24.0pt; text-align: justify; text-justify: inter-ideograph; text-indent: -24.0pt; padding: 0in; font-size: 9.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">____________</p><p class="Tablefootnote_f" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:10pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:10pt;">(1)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Includes $25.0<span class="nobreak"> </span>million of proceeds previously received by Oruka from the issuance of the Convertible Note and accrued interest on such note, with the remainder of the purchase price to be paid in cash.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Oruka&#8217;s Relationship with Paragon and Paruka</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka is party to a number of agreements with Paragon and Paruka. Paragon and Paruka each beneficially own more than 5% of Oruka&#8217;s capital stock through their respective holdings of Oruka common stock. Fairmount beneficially owns more than 5% of Oruka&#8217;s capital stock, has one seat on Oruka&#8217;s board of directors and beneficially owns more than 5% of Paragon. Fairmount appointed Paragon&#8217;s board of directors and has the contractual right to approve the appointment of any executive officers of Paragon, but is not the beneficial owner of Paragon&#8217;s securities. Paruka is an entity formed by Paragon as a vehicle to hold equity in Oruka in order to share profits with certain employees of Paragon.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In March&#160;2024, Oruka entered into the Paragon Option Agreements. Under the Paragon Option Agreements, Oruka has the exclusive option to, on a research program<span class="nobreak">-by-research</span> program basis, be granted an exclusive, worldwide license to all of Paragon&#8217;s right, title, and interest in and to the intellectual property resulting from the applicable research program to develop, manufacture, and commercialize the antibodies and products directed to the selected target(s).</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Upon signing of the Paragon Option Agreement for ORKA<span class="nobreak">-001</span>, a one<span class="nobreak">-time</span>, non<span class="nobreak">-refundable</span> research initiation fee of $0.8&#160;million was due from Oruka to Paragon. This amount was recognized by Oruka as a research and development expense during the period ended March&#160;31, 2024, and paid to Paragon in April&#160;2024. Oruka is also responsible for 50% of the development costs incurred prior to March&#160;31, 2024, provided that Oruka receives rights to at least one selected IL<span class="nobreak">-23</span> antibody. Oruka&#8217;s share of development costs incurred prior to March&#160;31, 2024 is $5.9&#160;million. As of the date of filing of this proxy statement/prospectus, Oruka has not received such rights and has not paid such development costs. Oruka will be responsible for 50% of the ORKA<span class="nobreak">-001</span> development costs incurred from and after March&#160;31, 2024, through the completion of the IL<span class="nobreak">-23</span> selection process.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Under the Paragon Option Agreement for ORKA<span class="nobreak">-002</span>, Oruka was required to reimburse Paragon for the pre<span class="nobreak">-effective</span> date development costs. During the period ended March&#160;31, 2024, this was recognized as a research and development expense, and Oruka paid $3.3&#160;million to Paragon in April&#160;2024. Oruka is also responsible for the development costs incurred from January&#160;1, 2024 to March&#160;31, 2024 of $0.9&#160;million, which was recognized as a research and development expense in the period ended March&#160;31, 2024. Oruka will be required to pay Paragon $0.8&#160;million for the research initiation fee related to ORKA<span class="nobreak">-002</span> within 30&#160;days following finalization of the ORKA<span class="nobreak">-002</span> research plan as well as for subsequent development costs related to ORKA<span class="nobreak">-002</span>.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">282</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of the date of filing of this proxy statement/prospectus, Oruka has not exercised its options with respect to ORKA<span class="nobreak">-001</span> or ORKA<span class="nobreak">-002</span>. For each of the Paragon Option Agreements, if Oruka exercises its options, it will be required to make non<span class="nobreak">-refundable</span> milestone payments to Paragon of up to $12.0&#160;million upon the achievement of certain clinical development milestones, up to $10.0&#160;million upon the achievement of certain regulatory milestones, as well as tiered royalty payments in the low<span class="nobreak">-to-mid</span> single<span class="nobreak">-digits</span> beginning on the first commercial sale.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Additionally, as part of the Paragon Option Agreements, on each of December&#160;31, 2024 and December&#160;31, 2025, Oruka will grant Paruka warrants to purchase a number of shares equal to 1.00% of Oruka&#8217;s outstanding shares on a fully<span class="nobreak">-diluted</span> basis as of the date of the grant, with an exercise price equal to the fair market value of the underlying shares on the grant date.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">For additional detail regarding Oruka&#8217;s arrangements with Paragon, including the Paragon Option Agreements, see the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Oruka&#8217;s Business&#160;&#8212;&#160;License Agreements</span>.&#8221;</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Other Agreements with Oruka Stockholders</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In connection with the Oruka Series&#160;A Financing, Oruka entered into investors&#8217; rights, voting and right of first refusal and co<span class="nobreak">-sale</span> agreements containing registration rights, information rights, voting rights and rights of first refusal, among other things, with certain holders of Oruka preferred stock and certain holders of Oruka common stock. These stockholder agreements will terminate upon the closing of the Merger.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Oruka Indemnification Agreements and Insurance</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka has entered into an indemnification agreement with each of its directors and officers and purchased directors&#8217; and officers&#8217; liability insurance. The indemnification agreements require Oruka to indemnify its directors and officers to the fullest extent permitted under Delaware law.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Oruka Policies for Approval of Related Party Transactions</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka does not have a formal policy regarding approval of transactions with related parties. To date, all disclosable transactions with related parties have been approved by the directors not interested in such transaction pursuant to Section&#160;144(a)(1)&#160;of the DGCL.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">283</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T9"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Defined terms included below shall have the same meaning as terms defined and included elsewhere in this proxy statement/prospectus.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On April&#160;3, 2024, Oruka entered into a Merger Agreement with ARCA and the Merger Subs, pursuant to which, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, First Merger Sub will merge with and into Oruka, with Oruka continuing as a wholly owned subsidiary of ARCA and the surviving corporation of the Merger. Immediately following the First Merger and as part of the same overall transaction, Oruka will merge with and into Second Merger Sub, with Second Merger Sub being the surviving entity of the Second Merger. The transaction is expected to be completed in the third quarter of 2024 (the &#8220;Closing Date&#8221; or the &#8220;Effective Time&#8221;) following the filed Form&#160;S<span class="nobreak">-4</span> being deemed effective by the SEC and receipt of approval by the stockholders of each of Oruka and ARCA, in the latter case pursuant to a special meeting. In connection with the Merger, Second Merger Sub will change its corporate name to &#8220;Oruka Therapeutics Operating Company, LLC&#8221; and ARCA will change its name to &#8220;Oruka Therapeutics, Inc.&#8221; ARCA following the Merger is referred to herein as the &#8220;combined company.&#8221; The combined company will be led by Oruka&#8217;s management team and will remain focused on developing biologics to optimize the treatment of inflammatory skin diseases.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In accordance with an exchange ratio determined in accordance with the terms of the Merger Agreement (the &#8220;Exchange Ratio&#8221;) (together with the Oruka pre<span class="nobreak">-closing</span> financing, the &#8220;Transactions&#8221;), immediately prior to the Effective Time, (i) each share of Oruka common stock outstanding, including outstanding and unvested Oruka restricted stock and shares of Oruka common stock issued in connection with the Subscription Agreement (both defined in Note&#160;1 of the accompanying notes), will be converted into the right to receive shares of ARCA common stock, which will be subject to the same vesting provisions as those immediately prior to the Merger, (ii) each share of Oruka Series A convertible preferred stock will be converted into the right to receive ARCA Series B convertible preferred stock, (iii) each option to purchase Oruka common stock will be converted into the right to receive an option to purchase ARCA common stock, which will be subject to the same vesting provisions as those immediately prior to the Merger, and (iv) each pre<span class="nobreak">-funded</span> warrant to purchase shares of Oruka common stock issued in connection with the Subscription Agreement will be converted into the right to receive a pre<span class="nobreak">-funded</span> warrant to purchase shares of ARCA common stock. </p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Exchange Ratio is currently estimated to be approximately 7.4631<span class="nobreak"> </span>shares of ARCA common stock for each fully<span class="nobreak">-diluted</span> share of Oruka common stock. Under the Exchange Ratio formula, the former Oruka stockholders immediately before the effective time, including those purchasing shares and pre<span class="nobreak">-funded</span> warrants in the Oruka pre<span class="nobreak">-closing</span> financing, are currently estimated to own approximately 97.6% of the outstanding common stock of the combined company on a fully<span class="nobreak">-diluted</span> basis, and the stockholders of ARCA immediately before the effective time are currently estimated to own approximately 2.4% of the outstanding common stock of the combined company on a fully<span class="nobreak">-diluted</span> basis and are subject to certain assumptions, including, but not limited to, (a)&#160;ARCA&#8217;s net cash balance (as defined in the Merger Agreement) as of the Closing being approximately $5.0&#160;million, (b)&#160;Oruka closing on approximately $275.0&#160;million in the Oruka pre<span class="nobreak">-closing</span> financing described in this proxy statement/prospectus, (c)&#160;a valuation for ARCA equal to its net cash as of the business&#160;day immediately prior to the closing date of the Merger, plus $6.0&#160;million, and (d)&#160;a valuation for Oruka equal to $175.0&#160;million, in each case as further described in the Merger Agreement.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following unaudited pro forma condensed combined financial information gives effect to the Merger, which is expected to be accounted for as a reverse recapitalization under United&#160;States Generally Accepted Accounting Principles, or U.S.&#160;GAAP.&#160;For further detail related to the accounting for the Merger, please see Notes 1 and&#160;3 below.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The unaudited pro forma condensed combined balance sheet combines the historical balance sheets of ARCA and Oruka as of March&#160;31, 2024 and depicts the accounting of the transactions prepared pursuant to the rules and regulations of Article&#160;11 of SEC Regulation&#160;S<span class="nobreak">-X</span>, as amended (&#8220;pro forma balance sheet transaction accounting adjustments&#8221;). The unaudited pro forma condensed combined statements of operations for the three&#160;months ended March&#160;31, 2024 for ARCA, the period from February&#160;6, 2024 (inception) to March&#160;31, 2024 for Oruka, and the year ended December&#160;31, 2023 for ARCA combine the historical results of ARCA and Oruka for those periods and depict the pro forma transaction accounting adjustments assuming that those adjustments were made as of January&#160;1, 2023 </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">284</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">(&#8220;pro forma statements of operations transaction accounting adjustments&#8221;). Collectively, pro forma balance sheet transaction accounting adjustments and pro forma statements of operations transaction accounting adjustments are referred to as &#8220;transaction accounting adjustments&#8221; or &#8220;pro forma adjustments&#8221;.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">These unaudited pro forma condensed combined financial information and related notes have been derived from and should be read in conjunction with:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the historical unaudited condensed financial statements of Oruka as of March<span class="nobreak">&#160;</span>31, 2024 and for the period from February<span class="nobreak">&#160;</span>6, 2024 (inception) to March<span class="nobreak">&#160;</span>31, 2024, and the related notes included elsewhere in this proxy statement/prospectus;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the historical unaudited condensed consolidated financial statements of ARCA as of and for the three&#160;months ended March<span class="nobreak">&#160;</span>31, 2024, and the related notes included elsewhere in this proxy statement/prospectus;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the historical audited consolidated financial statements of ARCA for the year ended December<span class="nobreak">&#160;</span>31, 2023, and the related notes included elsewhere in this proxy statement/prospectus; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the sections titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">ARCA&#8217;s Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span>,&#8221; &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Oruka&#8217;s Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operation</span>,&#8221; and other financial information relating to ARCA and Oruka included elsewhere in this proxy statement/prospectus.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The unaudited pro forma condensed combined financial information is based on the assumptions and pro forma adjustments that are described in the accompanying notes. The pro forma adjustments are preliminary, subject to further revision as additional information becomes available and additional analyses are performed including but not limited to additional financing, additional direct and incremental offering costs and a reverse stock split. Adjustments have been made solely for the purpose of providing unaudited pro forma condensed combined financial information. Differences between these preliminary estimates and the final accounting, expected to be completed after the Closing, may occur and these differences could have a material impact on the accompanying unaudited pro forma condensed combined financial information.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The unaudited pro forma condensed combined financial information does not give effect to the potential impact of current financial conditions, regulatory matters, operating efficiencies or other savings or expenses that may be associated with the integration of the two companies. The unaudited pro forma condensed combined financial information is not necessarily indicative of the financial position or results of operations in the future periods or the result that actually would have been realized had ARCA and Oruka been a combined organization during the specified periods. The actual results reported in periods following the Merger may differ significantly from those reflected in the unaudited condensed combined pro forma financial information presented herein for a number of reasons, including, but not limited to, differences in the assumptions used to prepare this unaudited pro forma condensed combined financial information.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">285</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">UNAUDITED PRO FORMA CONDENSED COMBINED BALANCE SHEET<br/>AS OF MARCH 31, 2024<br/></span><span class="CharOverride-1" style="font-style:normal;font-weight:normal;">(In thousands, except share amounts)</span></p>
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 18.98%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:8pt;font-style:normal;font-weight:bold;">Historical</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.92%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.73%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-10" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.35%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:8pt;">5(A)<br/>ARCA<br/></span><span class="CharOverride-2" style="font-size:8pt;font-style:normal;font-weight:bold;">biopharma, <br/>Inc.</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.49%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:8pt;">5(B)<br/>Oruka<br/>Therapeutics,<br/></span><span class="CharOverride-2" style="font-size:8pt;font-style:normal;font-weight:bold;">Inc.</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.92%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:8pt;">Transaction<br/>Accounting<br/></span><span class="CharOverride-2" style="font-size:8pt;font-style:normal;font-weight:bold;">Adjustments</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:8pt;font-style:normal;font-weight:bold;">Notes</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.73%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:8pt;">Pro&#160;Forma<br/></span><span class="CharOverride-2" style="font-size:8pt;font-style:normal;font-weight:bold;">Combined</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:9pt;">Assets</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">Current assets:</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">Cash and cash equivalents</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">35,903</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">27,743</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">(1,687</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">5(a)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">267,004</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">249,786</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">5(c)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">(19,512</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">5(d)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">(4,973</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">5(e)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">(256</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">5(h)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">(20,000</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">5(i)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Prepaid expenses and other current assets</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">767</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">(716</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">5(f)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">51</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">Total current assets</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">36,670</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">27,743</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">202,642</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">267,055</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">Operating lease right-of-use assets</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">17</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">(17</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">5(g)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">Property and equipment, net</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">7</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">(7</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">5(g)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">Other assets</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">12</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">488</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">(488</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">5(d)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">12</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">Total assets</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">36,706</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">28,231</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">202,130</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-5" style="text-decoration:underline;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">267,067</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-11" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:9pt;">Liabilities, Convertible Preferred Stock and Stockholders&#8217; Equity (Deficit)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">Current liabilities:</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">Accounts payable</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">529</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">4</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">533</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">Accrued expenses and other current liabilities</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">1,052</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">1,262</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">(21</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">5(c)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">1,326</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">(919</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">5(e)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">(48</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">5(g)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">Related party accounts payable and other current liabilities</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">5,899</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">5,899</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">Total current liabilities</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">1,581</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">7,165</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">(988</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">7,758</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">Long term liabilities:</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">Accrued interest payable, related party</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">214</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">(214</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">5(c)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">Notes payable to related parties, noncurrent</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">24,980</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">(24,980</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">5(c)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">Total liabilities</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">1,581</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">32,359</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">(26,182</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">7,758</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">Oruka convertible preferred stock</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">2,931</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">(2,931</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">5(b)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">ARCA convertible preferred stock</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">2,931</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">5(b)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">2,931</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-11" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">Stockholders&#8217; equity (deficit) </span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">ARCA common stock, $0.001 par value</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">14</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">(14</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">5(j)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">Oruka common stock, $0.0001 par value</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">1</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">0</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">5(c)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">6</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">4</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">5(c)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">Additional paid-in capital</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">225,861</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">17</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">25,214</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">5(c)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">263,449</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">249,782</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">5(c)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">(20,000</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">5(d)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">22</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">5(h)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">(20,000</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">5(i)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">(197,446</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">5(j)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">Accumulated deficit</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">(190,750</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">(7,077</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">(1,687</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">5(a)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">(7,077</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">(4,053</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">5(e)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">(716</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">5(f)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">24</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">5(g)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-12" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">(278</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">5(h)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-12" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">197,460</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">5(j)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-12" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">Total stockholders&#8217; equity (deficit)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">35,125</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">(7,059</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">228,312</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">256,378</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">Total liabilities, convertible preferred stock and stockholders&#8217; equity (deficit)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">36,706</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">28,231</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">202,130</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-5" style="text-decoration:underline;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">267,067</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>

		</table>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;text-align:center;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">See accompanying notes to the unaudited pro forma condensed combined financial information.</span></p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">286</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">UNAUDITED PRO FORMA CONDENSED COMBINED STATEMENT OF OPERATIONS<br/>FOR THE THREE MONTHS ENDED MARCH 31, 2024<br/></span><span class="CharOverride-1" style="font-style:normal;font-weight:normal;">(In thousands, except share and per share amounts)</span></p>
		<table class="No-Table-Style _idGenTablePara-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-20" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-top:2pt;width: 38.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 23.17%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">Historical</p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 10.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 4.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 12.16%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-21" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-top:2pt;width: 38.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 11.20%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">6(A) <br/>ARCA <br/>biopharma, <br/>Inc.</p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 10.81%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">6(B) <br/>Oruka <br/>Therapeutics, <br/>Inc.</p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 10.04%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">Transaction <br/>Accounting <br/>Adjustments</p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 4.83%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">Notes</p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 12.16%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">Pro&#160;Forma <br/>Combined</p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">Notes</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Operating expenses:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.11%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.07%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Research and development</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.11%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">165</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5,193</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.95%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.07%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5,358</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">General and administrative</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.11%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,317</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.72%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,670</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.95%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">263</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">6(f)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.07%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4,250</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total operating expenses</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.11%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,482</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.72%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">6,863</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-5" style="text-decoration:underline;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.95%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">263</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-5" style="text-decoration:underline;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.07%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">9,608</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Income (loss) from operations</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.11%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(2,482</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(6,863</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(263</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.07%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(9,608</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other income (expense), net</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.11%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.07%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Interest income</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.11%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">473</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.72%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.95%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.07%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">473</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Interest expense</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.11%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.72%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(214</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.95%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">214</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">6(e)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.07%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total other income (expense), net</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.11%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">473</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.72%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(214</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.95%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">214</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.07%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">473</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net loss</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.11%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(2,009</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.72%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(7,077</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.95%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(49</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.07%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(9,135</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net loss</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.11%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(2,009</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.07%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(9,135</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-23" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Weighted average common shares outstanding, basic&#160;and diluted</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.11%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">14,501,143</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.07%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">409,964,662</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">6(g)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-23" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net loss per share attributable to common stockholders, basic and diluted</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.11%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(0.14</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.07%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(0.02</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>

		</table>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-left:24pt;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">See accompanying notes to the unaudited pro forma condensed combined financial information.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">287</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">UNAUDITED PRO FORMA CONDENSED COMBINED STATEMENT OF OPERATIONS<br/>FOR THE TWELVE MONTHS ENDED DECEMBER 31, 2023<br/></span><span class="CharOverride-1" style="font-style:normal;font-weight:normal;">(In thousands, except share and per share amounts)</span></p>
		<table class="No-Table-Style _idGenTablePara-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-20" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-top:2pt;width: 41.13%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="6" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 21.64%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">Historical</p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 10.14%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 4.87%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 10.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 6.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-21" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-top:2pt;width: 41.13%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 9.55%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">6(A) <br/>ARCA <br/>biopharma, <br/>Inc.</p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 10.92%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">6(B) <br/>Oruka <br/>Therapeutics, <br/>Inc.</p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 10.14%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">Transaction <br/>Accounting <br/>Adjustments</p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 4.87%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">Notes</p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 10.33%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">Pro&#160;Forma <br/>Combined</p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 6.04%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">Notes</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 41.13%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Operating expenses:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.43%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.02%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.87%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 41.13%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Research and development</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.43%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,013</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.36%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.02%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.87%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,013</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 41.13%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">General and administrative</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.43%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">6,283</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.02%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,687</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.87%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">6(a)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">9,990</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 41.13%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.43%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.02%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">716</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.87%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">6(b)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 41.13%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.43%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.02%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(24</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.87%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">6(c)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 41.13%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.43%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.02%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">278</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.87%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">6(d)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 41.13%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.43%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.36%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.02%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,050</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.87%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">6(f)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.21%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 41.13%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total operating expenses</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.43%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">7,296</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.36%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.02%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3,707</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.87%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.21%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">11,003</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 41.13%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Income (loss) from operations</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.43%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(7,296</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.36%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.02%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(3,707</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.87%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(11,003</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 41.13%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other income (expense), net</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.43%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.02%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.87%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 41.13%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Interest income</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.43%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,957</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.02%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.87%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,957</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 41.13%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Interest expense</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.43%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.36%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.02%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.87%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.21%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 41.13%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total other income (expense), net</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.43%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,957</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.36%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.02%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.87%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.21%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,957</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 41.13%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net loss</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.43%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(5,339</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.36%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.02%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(3,707</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.87%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.21%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(9,046</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 41.13%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net loss</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.43%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(5,339</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.02%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.87%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.21%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(9,046</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-23" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 41.13%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Weighted average common shares outstanding, basic&#160;and diluted</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.43%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">14,415,877</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.02%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.87%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.21%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">409,879,396</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">6(h)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-23" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 41.13%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net loss per share attributable to common stockholders, basic and diluted</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.43%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(0.37</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.02%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.87%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.21%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(0.02</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>

		</table>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;text-align:center;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">See accompanying notes to the unaudited pro forma condensed combined financial information.</span></p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">288</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T9990"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">NOTES TO UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">1. Description of the Merger</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On April&#160;3, 2024, ARCA, Oruka, First Merger Sub, and Second Merger Sub entered into the Merger Agreement to which the First Merger Sub merges with and into Oruka, with Oruka becoming a wholly owned subsidiary of ARCA.&#160;Oruka will merge with and into the Second Merger Sub, with the Second Merger Sub being the surviving entity. Subsequent to the Second Merger, Second Merger Sub would remain a wholly owned subsidiary of ARCA and ARCA will change its name to &#8220;Oruka Therapeutics, Inc.&#8221; Subject to the terms and conditions of the Merger Agreement, at closing of the Merger (the &#8220;Closing&#8221;):</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">a)<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>each outstanding share of, and pre<span class="nobreak">-funded</span> warrant related to, Oruka common stock, including (i)&#160;outstanding and unvested Oruka Restricted Stock (defined below) will be converted into the right to receive a number of shares of, and pre<span class="nobreak">-funded</span> warrants related to, ARCA common stock, based on the Exchange Ratio;</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">b)<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>each outstanding share of Oruka Series A convertible preferred stock at closing will be exchanged into ARCA Series B convertible preferred stock, which are each convertible into 1,000<span class="nobreak"> </span>shares of ARCA common stock, equal to the Exchange Ratio divided by 1,000; and</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">c)<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>each outstanding and unexercised option to purchase shares of Oruka common stock (&#8220;Oruka options&#8221;) immediately prior to Closing will be assumed by ARCA and will be converted into an option to purchase shares of ARCA common stock which continues to vest pursuant to the original terms, with necessary adjustments to the number of shares and exercise price to reflect the Exchange Ratio.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">All Oruka restricted stock outstanding and unvested immediately prior to Closing (&#8220;Oruka Restricted Stock&#8221;) that is assumed by ARCA in the Merger will remain unvested to the same extent and will be subject to the same repurchase option, risk of forfeiture or other condition under any applicable restricted stock purchase agreement.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Under the terms of the Merger Agreement, the board of directors of ARCA will take actions to accelerate the vesting of certain outstanding options to purchase ARCA common stock held by a current employee, director or consultant of ARCA as of the closing of the Merger. The acceleration of vesting of ARCA&#8217;s options occurs either upon a change of control as defined, pursuant to the terms of the original awards, or a modification of the awards as a result of the Merger. The incremental fair value of ARCA&#8217;s options associated with the modification to accelerate vesting has been included as an adjustment to the unaudited pro forma condensed combined financial information.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Immediately following the Merger, ARCA stockholders are expected to own approximately 2.4% of the outstanding capital stock of the combined company on a fully diluted basis, former Oruka stockholders are expected to own approximately 39.3% of the outstanding capital stock of the combined company on a fully diluted basis, and investors participating in the Subscription Agreement (defined below) are expected to own approximately 58.3% of the outstanding capital stock of the combined company on a fully diluted basis. Oruka stockholders are expected to receive approximately 238,540,759<span class="nobreak"> </span>shares on a fully diluted basis in connection with the Merger, including (i) 47,510,340<span class="nobreak"> </span>shares of ARCA common stock and stock options subject to vesting terms, based on the number of shares of Oruka common stock outstanding immediately prior to the Merger, including Oruka Restricted Stock, (ii) the number of shares of, and pre<span class="nobreak">-funded</span> warrants related to, Oruka common stock issued to investors participating in the Subscription Agreement (defined below), and (iii) Oruka convertible preferred stock outstanding as of March&#160;31, 2024, which will be exchanged into shares of ARCA Series B convertible preferred stock. These estimates are subject to certain inputs, which include, but are not limited to, (a)&#160;ARCA&#8217;s net cash balance (as defined in the Merger Agreement) as of the Closing being approximately $5.0&#160;million, (b)&#160;Oruka raising approximately $275.0&#160;million in the Oruka pre<span class="nobreak">-closing</span> financing described in this proxy statement/prospectus, (c)&#160;a valuation for ARCA equal to its net cash as of the business&#160;day immediately prior </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">289</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">to the closing date of the Merger, plus $6.0&#160;million and (d)&#160;a valuation for Oruka equal to $175.0&#160;million, in each case as further described in the Merger Agreement. The following table summarizes the pro forma number of shares of common stock of the combined company outstanding following the consummation of the Transactions:</p>
		<table class="No-Table-Style TableOverride-2" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 3pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-31" style="height:12pt;">
					<td class="TCH" rowspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">



						<p class="TCH_left" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="CharOverride-6" style="font-style:normal;font-weight:bold;">Equity Capitalization Summary (fully diluted basis) <br/>Upon Consummation of the Merger</span></p>
					</td>
					<td class="TCH" rowspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="4" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-6" style="font-style:normal;font-weight:bold;">Pro&#160;Forma <br/>(Assuming&#160;ARCA&#160;Net&#160;Cash <br/>at&#160;Closing&#160;of&#160;$5.0&#160;Million)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-6" style="font-style:normal;font-weight:bold;">Number&#160;of <br/>Shares&#160;Owned</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-6" style="font-style:normal;font-weight:bold;">% <br/>Ownership</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Oruka stockholders</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">238,540,759</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">39.3</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">ARCA stockholders</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">14,501,143</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2.4</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Investors participating in the Subscription Agreement<span class="Superscript" style="vertical-align:super;font-size:58%;">(1)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">353,695,101</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">58.3</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total common stock of the combined company</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">606,737,003</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">100.0</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>

		</table>
		<p class="Tablefootnotef" style="margin-top: 0in;  border: none; margin-right: 0in; margin-bottom: -5pt; margin-left: 24.0pt; text-align: justify; text-justify: inter-ideograph; text-indent: -24.0pt; padding: 0in; font-size: 9.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">____________</p><p class="Tablefootnote_f" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:10pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:10pt;">(1)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Includes 67,241,225 pre<span class="nobreak">-funded</span> warrants related to the Subscription Agreement after reflecting the estimated Exchange Ratio.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Consummation of the Merger is subject to certain closing conditions, including, among other things, (1)&#160;approval by ARCA stockholders, (2)&#160;approval by the requisite Oruka stockholders of the adoption and approval of the Merger Agreement and the transactions contemplated thereby, (3)&#160;Nasdaq&#8217;s approval of the listing of the shares of ARCA common stock to be issued in connection with the Merger and (4)&#160;the effectiveness of a registration statement filed with the SEC in connection with the Merger.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The employment agreements for ARCA employees include entitlement to change in control payments for certain executives, and severance and retention bonus payments for certain non<span class="nobreak">-executives</span>, the aggregate of which will be treated as pre<span class="nobreak">-Merger</span> compensation expense of ARCA and will be reflected as an increase to accrued expenses of ARCA, which will be assumed by the combined company at Closing. Prior to the Closing, ARCA also (i)&#160;discontinued its research and development activities, (ii)&#160;sold its assets held for sale, and (iii)&#160;terminated and/or expired its operating leases. Additionally, ARCA&#8217;s current Directors&#160;&amp; Officers (&#8220;D&amp;O&#8221;) policy will be fully utilized at Closing.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Private Financing Transaction&#160;&#8212;&#160;Subscription Agreement</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Concurrently with the execution of the Merger Agreement, certain parties have entered into the Subscription Agreement with Oruka to purchase, prior to the consummation of the Merger, approximately 38,382,693<span class="nobreak"> </span>shares of Oruka common stock and 9,009,825 pre<span class="nobreak">-funded</span> warrants, at an estimated purchase price of $5.80 and $5.79 per share, respectively, for an aggregate purchase price of approximately $275.0&#160;million, which includes $25.0&#160;million proceeds received as of March&#160;31, 2024 from the issuance of a convertible note and accrued interest. Shares of Oruka common stock and pre<span class="nobreak">-funded</span> warrants to purchase shares of Oruka common stock issued pursuant to the Subscription Agreement will be converted into shares of ARCA common stock and pre<span class="nobreak">-funded</span> warrants to purchase shares of ARCA common ctock at Closing per the Merger Agreement.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2. Basis of Presentation</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The unaudited pro forma condensed combined financial information has been prepared in accordance with Article&#160;11 of SEC Regulation&#160;S<span class="nobreak">-X</span>, as amended. The adjustments presented in the unaudited pro forma condensed combined financial information have been identified and presented to provide relevant information necessary for an understanding of the combined company upon consummation of the Merger. The unaudited pro forma condensed combined statement of operations data for the three&#160;months ended March&#160;31, 2024 and the unaudited pro forma condensed combined statement of operations data for the year ended December&#160;31, 2023, give effect to the Merger as if it had been consummated on January&#160;1, 2023. The unaudited pro forma condensed combined balance sheet as of March&#160;31, 2024 gives effect to the Merger and combines the historical balance sheets of ARCA and Oruka as of such date.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">The unaudited pro forma condensed combined financial information is based on the assumptions and adjustments that are described in the accompanying notes. Accordingly, the pro forma adjustments are preliminary, subject to further revision as additional information becomes available and additional analyses are performed and have been made solely for the purpose of providing unaudited pro forma condensed combined financial information. Differences between these preliminary accounting conclusions and estimates and the final accounting conclusions and amounts may occur as a result of, among other reasons: (i)&#160;changes in initial assumptions in the determination of the accounting acquirer and related accounting, (ii)&#160;changes in the amount of ARCA&#8217;s net cash to be assumed at the </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">290</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;text-indent:0pt;margin-top:6pt;">Closing Date, and (iii)&#160;other changes in ARCA&#8217;s assets and liabilities, which are expected to be completed after the Closing, and these differences could have a material impact on the accompanying unaudited pro forma condensed combined financial information and the combined company&#8217;s future results of operations and financial position.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:10pt;margin-top:10pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">3. Accounting for the Merger</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">The unaudited pro forma condensed combined financial information gives effect to the Merger, which will be accounted for under U.S.&#160;GAAP as an in<span class="nobreak">-substance</span> reverse recapitalization of ARCA by Oruka, as the transaction is, in essence, the issuance of equity for ARCA&#8217;s net assets, which will primarily consist of cash and other nominal non<span class="nobreak">-operating</span> assets and liabilities. Under this method of accounting, Oruka will be considered the accounting acquirer for financial reporting purposes. This determination is based on the expectations that, immediately following the Merger:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Oruka is not a variable interest entity as it has sufficient equity at risk in order to fund its next development milestones;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Oruka stockholders will own a substantial majority of the voting rights in the combined company;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Oruka&#8217;s largest stockholder will retain the largest interest in the combined company;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Oruka will designate the initial members of the board of directors of the combined company;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Oruka&#8217;s executive management team will become the management of the combined company; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>The combined company will be renamed &#8220;Oruka Therapeutics, Inc.&#8221;</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">As a result of Oruka being the accounting acquirer, Oruka&#8217;s assets and liabilities will be recorded at their pre<span class="nobreak">-combination</span> carrying amounts. ARCA&#8217;s assets and liabilities will be measured and recognized at their fair values as of the effective time, which are expected to approximate the carrying value of the acquired cash and other non<span class="nobreak">-operating</span> assets, with no goodwill or other intangible assets recorded. Any difference between the consideration transferred and the fair value of the net assets of ARCA following the determination of the actual consideration transferred for ARCA will be reflected as an adjustment to additional paid<span class="nobreak">-in</span> capital. For periods prior to Closing, the historical financial statements of Oruka shall become the historical financial statements of the combined company.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:10pt;margin-top:10pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">4. Shares of ARCA Common Stock, Convertible Preferred Stock, Options, and Warrants Issued to Oruka Stockholders upon Closing of the Merger</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">At Closing, all outstanding shares of Oruka common stock, on a fully<span class="nobreak">-diluted</span> basis, will be exchanged for shares of ARCA common stock based on the preliminary estimated Exchange Ratio of 7.4631, determined in accordance with the terms of the Merger Agreement. The estimated number of shares of ARCA common stock that ARCA expects to issue to Oruka&#8217;s stockholders assumes ARCA&#8217;s net cash at Closing is $5.0&#160;million and is determined as follows:</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 3pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-22" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 85.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Shares of Oruka common stock outstanding as of March&#160;31, 2024<span class="Superscript" style="vertical-align:super;font-size:58%;">(1)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.30%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">9,460,019</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 85.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Shares of Oruka common stock to be issued upon conversion of Oruka convertible preferred&#160;stock</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.30%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">20,000,000</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 85.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Shares of Oruka common stock issued upon exercise of Oruka stock options<span class="Superscript" style="vertical-align:super;font-size:58%;">(2)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.30%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">698,669</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-23" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 85.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Estimated shares to purchase Oruka common stock upon exercise of Oruka&#8217;s CEO&#8217;s stock options&#160;granted immediately prior to the closing of the Merger<span class="Superscript" style="vertical-align:super;font-size:58%;">(3)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.30%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,804,003</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-23" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 85.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Estimated shares of Oruka common stock to be issued in connection with the Subscription Agreement, see Note&#160;5(c)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.30%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">38,382,693</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-23" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 85.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Estimated shares of Oruka common stock to be issued upon exercise of Oruka pre-funded warrants to be issued in connection with the Subscription Agreement,&#160;see Note&#160;5(c)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.30%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">9,009,825</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 85.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total Oruka fully diluted shares prior to the closing of the Merger</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.30%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">79,355,209</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 85.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Estimated Exchange&#160;Ratio</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.30%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">7.4631</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-23" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 85.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Estimated fully diluted shares to be issued to Oruka stockholders and Investors participating in Subscription Agreement upon closing of the Merger<span class="Superscript" style="vertical-align:super;font-size:58%;">(4)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.30%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">592,235,860</p>
					</td>
				</tr>

		</table>
		<p class="Tablefootnotef" style="margin-top: 0in;  border: none; margin-right: 0in; margin-bottom: -5pt; margin-left: 24.0pt; text-align: justify; text-justify: inter-ideograph; text-indent: -24.0pt; padding: 0in; font-size: 9.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">____________</p><p class="Tablefootnote_f" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:10pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:10pt;">(1)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Represents shares of Oruka common stock outstanding as of March&#160;31, 2024, including 3,863,361 shares of unvested Oruka Restricted Stock.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(2)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Represents the outstanding options to acquire Oruka common stock as of March&#160;31, 2024. Such stock options will become exercisable for shares of ARCA common stock following the Merger.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">291</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;">(3)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Represents stock options expected to be issued to Oruka&#8217;s Chief Executive Officer to maintain 5.0% ownership of the combined company pursuant to his employment agreement immediately prior to the Merger.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(4)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Represents the total estimated fully diluted shares to be issued to Oruka stockholders at Closing based on the preliminary estimated Exchange Ratio of 7.4631.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:7pt;margin-top:7pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">5. Adjustments to Unaudited Pro Forma Condensed Combined Balance Sheet as of March&#160;31, 2024</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">The pro forma notes and adjustments, based on preliminary estimates that could change materially as additional information is obtained, are as follows:</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:7pt;margin-top:7pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Pro forma notes:</span></p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;">5(A)&#160;&#160;Derived from the unaudited condensed consolidated balance sheet of ARCA as of March&#160;31, 2024.</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;">5(B)&#160;&#160;Derived from the unaudited condensed balance sheet of Oruka as of March&#160;31, 2024.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:7pt;margin-top:7pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Pro forma Balance Sheet Transaction Accounting Adjustments:</span></p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;">5(a)<span style="width: 10px;display: inline-block;">&#160;&#160;&#160;</span>To reflect preliminary estimated incremental compensation expense of $1.7&#160;million related to severance, retention bonuses and change in control payments resulting from pre<span class="nobreak">-existing</span> employment agreements or from approval from ARCA&#8217;s board of directors that is expected to be incurred upon closing of the Merger. The pro forma adjustment is reflected as a decrease in cash of $1.7&#160;million for the severance and retention bonuses payments made subsequent to March&#160;31, 2024 and an increase to accumulated deficit of $1.7&#160;million.</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;">5(b)&#160;&#160;To reflect the exchange of all outstanding shares of Oruka Series&#160;A convertible preferred stock, with a carrying amount of $2.9&#160;million, into ARCA Series&#160;B convertible preferred stock at closing of the Merger, with the terms of ARCA Series B convertible preferred stock resulting in classification within stockholders&#8217; equity.</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;">5(c)<span style="width: 10px;display: inline-block;">&#160;&#160;&#160;</span>To reflect the issuance of 38,382,693<span class="nobreak"> </span>shares of Oruka common stock and 9,009,825 pre<span class="nobreak">-funded</span> warrants, pursuant to the Subscription Agreement entered into concurrently with the execution of the Merger Agreement, for an aggregate purchase price of $275.0<span class="nobreak"> </span>million, which includes $25.0<span class="nobreak"> </span>million proceeds received as of March<span class="nobreak"> </span>31, 2024 from the issuance of the convertible note. The aggregate proceeds are net less than $0.1<span class="nobreak"> </span>million of debt issuance costs and include accrued interest of $0.2<span class="nobreak"> </span>million as of March<span class="nobreak"> </span>31, 2024 adjusted through accumulated deficit (see Note 6(e)), for net proceeds prior to transaction costs of $249.8<span class="nobreak"> </span>million. The proceeds received in connection with the Subscription Agreement are recorded net of transaction costs deemed to be direct and incremental costs of the equity financing in the amount of approximately $20.0<span class="nobreak"> </span>million (see Note 5(d)) for net proceeds from the Subscription Agreement post<span class="nobreak">-transaction</span> costs of $229.8<span class="nobreak"> </span>million. The issuance of shares in connection with the Subscription Agreement are recorded as the issuance of Oruka common stock at par value, with the remaining amount recorded to additional paid<span class="nobreak">-in-capital</span>. Additionally, 1,804,003 options to purchase shares of Oruka common stock will be issued to Oruka&#8217;s Chief Executive Officer to maintain 5.0% ownership of the combined company, pursuant to his employment agreement, subject to vesting conditions (see Note 6(f)).</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">&#160;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The net cash proceeds received prior to direct and incremental transaction costs from the Subscription Agreement and corresponding adjustment to additional paid<span class="nobreak">-in-capital</span> upon close of the Merger is determined as follows (in thousands):</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-22" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 85.06%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Aggregate purchase price of the Subscription Agreement</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">275,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 85.06%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net proceeds previously received from issuance of convertible note as of March&#160;31, 2024</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(24,980</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 85.06%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Debt issuance costs recorded as part of issuance of convertible note as of March&#160;31, 2024</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(20</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-23" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 85.06%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accrued interest payable as part of issuance of convertible note as of March&#160;31, 2024, see <br/>Note&#160;6(e)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.25%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(214</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-23" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 85.06%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net proceeds received prior to direct and incremental transaction costs from the Subscription Agreement upon close of the Merger</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">249,786</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 85.06%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Issuance of Oruka common stock and pre-funded warrants at par value upon close of the Merger</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.25%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(4</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-35" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 85.06%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Additional paid-in capital related to the issuance of Oruka common stock and pre-funded <br/>warrants upon close of the Merger (excluding Oruka common stock to be issued in connection with conversion of convertible note)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.25%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">249,782</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>

		</table>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">292</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">5(d)&#160;&#160;To reflect preliminary estimated transaction costs of $19.5&#160;million, not yet reflected in the historical financial statements, that are expected to be incurred by Oruka in connection with the Merger, and $0.5&#160;million reflected in the historical financial statements as deferred offering costs, such as advisory, legal and auditor fees, as a reduction in cash and a reduction in other assets in the unaudited pro forma condensed combined balance sheet. As the Merger will be accounted for as a reverse recapitalization equivalent to the issuance of equity for the net assets, primarily cash, of ARCA, these direct and incremental costs are treated as a reduction of the net proceeds received within additional paid<span class="nobreak">-in</span> capital.</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">5(e)<span style="width: 10px;display: inline-block;">&#160;&#160;&#160;</span>To reflect preliminary estimated transaction costs of $4.1&#160;million, not yet reflected in the historical financial statements and $0.9&#160;million reflected in the historical financial statements, which are expected to be incurred by ARCA in connection with the Merger, such as advisory, legal and auditor fees and including the estimated $1.7<span class="nobreak"> </span>million cost of a D&amp;O tail policy, as a reduction in cash of $5.0<span class="nobreak"> </span>million, a reduction in accrued expenses of $0.9<span class="nobreak"> </span>million, and a reduction in accumulated deficit of $4.1<span class="nobreak"> </span>million in the unaudited pro forma condensed combined balance sheet.</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">5(f)<span style="width: 10px;display: inline-block;">&#160;&#160;&#160;</span>To derecognize $0.7&#160;million of ARCA&#8217;s prepaid expenses consisting of $0.1&#160;million of prepaid expenses related to software that will not be utilized and $0.6&#160;million of prepaid insurance primarily related to the current ARCA&#8217;s D&amp;O policy that will be fully utilized at Closing.</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">5(g)&#160;&#160;To reflect the derecognition of ARCA&#8217;s operating leases that will expire prior to the closing of the Merger and the derecognition of property and equipment that will be fully depreciated prior to the closing of the Merger. The operating lease right<span class="nobreak">-of-use</span> assets and property and equipment of less than $0.1&#160;million will be derecognized.</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">5(h)&#160;&#160;To reflect the one<span class="nobreak">-time</span> stock compensation expense of $0.3&#160;million in general and administrative expense related to the acceleration of stock options pursuant to pre<span class="nobreak">-existing</span> grant agreements, which provide for such acceleration upon a change in control provision, which will be triggered by the Merger, as well as a modification to accelerate vesting of in<span class="nobreak">-the-money</span> stock options, and to reflect the one<span class="nobreak">-time</span> cash payment of $0.3&#160;million to settle in<span class="nobreak">-the-money</span> stock options per terms of the Merger Agreement.</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">5(i)<span style="width: 10px;display: inline-block;">&#160;&#160;&#160;</span>To reflect an estimate of the one<span class="nobreak">-time</span> dividend of $20.0&#160;million declared and paid on the shares of ARCA common stock outstanding prior to the Merger. The dividend will be treated as a decrease in additional paid<span class="nobreak">-in</span> capital in the unaudited pro forma condensed combined balance sheet.</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">5(j)<span style="width: 10px;display: inline-block;">&#160;&#160;&#160;</span>To reflect the recapitalization of Oruka, pursuant to the Merger Agreement, through the contribution of 238,540,759<span class="nobreak"> </span>shares of Oruka common stock, including 47,510,340<span class="nobreak"> </span>shares of Oruka Restricted Stock and Oruka stock options (see Note&#160;4), and the issuance of 286,453,876<span class="nobreak"> </span>shares of Oruka common stock and 67,241,224 pre<span class="nobreak">-funded</span> warrants and 149,262,000 preferred stock, reflecting the estimated Exchange Ratio of 7.4631 and to reflect the derecognition of the accumulated deficit of ARCA which is reversed to additional paid<span class="nobreak">-in</span> capital.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-left:24pt;margin-top:8pt;">The derecognition of accumulated deficit of ARCA of $197.5&#160;million is determined as follows (in thousands):</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-22" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accumulated deficit of ARCA as of March&#160;31, 2024</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">190,750</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-23" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Compensation expense related to ARCA severance, retention bonuses and change in control payments, see Note&#160;5(a)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,687</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Preliminary estimated transaction costs of ARCA, see Note&#160;5(e)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4,053</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Derecognition of ARCA prepaid software expenses and prepaid insurance, see Note&#160;5(f)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">716</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Derecognition of ARCA operating leases, see Note&#160;5(g)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(24</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Pre-Merger stock-based compensation expense for ARCA&#8217;s accelerated awards, see Note&#160;5(h)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">278</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total adjustment to derecognize the accumulated deficit of ARCA</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">197,460</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>

		</table>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">293</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">6. Adjustments to Unaudited Pro Forma Condensed Combined Statement of Operations</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The pro forma notes and adjustments, based on preliminary estimates that could change materially as additional information is obtained, are as follows:</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Pro forma notes:</span></p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">6(A)&#160;&#160;Derived from the unaudited condensed consolidated statement of operations and comprehensive loss of ARCA for the three&#160;months ended March&#160;31, 2024.</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">6(B)&#160;&#160;Derived from the unaudited condensed statement of operations and comprehensive loss of Oruka for the period February&#160;6, 2024 (inception) to March&#160;31, 2024.</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">6(C)&#160;&#160;Derived from the audited consolidated statement of operations and comprehensive loss of ARCA for the year ended December&#160;31, 2023.</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">6(D)&#160;&#160;Derived from the unaudited condensed statement of operations and comprehensive loss of Oruka for the year ended December&#160;31, 2023.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka and ARCA did not record any provision or benefit for income taxes during the three&#160;months ended March&#160;31, 2024 because each company expects to incur a pre<span class="nobreak">-tax</span> loss in 2024 and each company maintains a full valuation allowance on its deferred tax assets. Accordingly, no pro forma adjustments have an impact on associated income tax.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Pro forma Statements of Operations Transaction Accounting Adjustments:</span></p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">6(a)<span style="width: 10px;display: inline-block;">&#160;&#160;&#160;</span>To reflect preliminary estimated incremental compensation expense related to severance, retention bonuses and change in control payments recorded in general and administrative expenses of $1.7&#160;million, resulting from pre<span class="nobreak">-existing</span> employment agreements or from approval from ARCA&#8217;s board of directors that will be incurred upon Closing assuming that the adjustment described in Note&#160;5(a)&#160;was made on January&#160;1, 2023.</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">6(b)&#160;&#160;To reflect the derecognition of ARCA&#8217;s prepaid expenses of $0.1&#160;million related to software that will not be utilized, and prepaid insurance of $0.6&#160;million primarily related to the current ARCA D&amp;O policy that will be fully utilized at Closing, assuming the adjustment made in Note&#160;5(f)&#160;was made on January&#160;1, 2023.</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">6(c)<span style="width: 10px;display: inline-block;">&#160;&#160;&#160;</span>To reflect the derecognition of ARCA&#8217;s operating leases that will expire prior to the closing of the Merger and the derecognition of property and equipment that will be fully depreciated prior to the closing of the Merger. The operating lease right<span class="nobreak">-of-use</span> assets and property and equipment of less than $0.1&#160;million will be derecognized, assuming the adjustment made in Note&#160;5(g)&#160;was made on January&#160;1, 2023.</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">6(d)&#160;&#160;To reflect the one<span class="nobreak">-time</span> stock compensation expense of $0.3&#160;million in general and administrative expense related to the acceleration of stock options pursuant to pre<span class="nobreak">-existing</span> grant agreements which provide for such acceleration upon a change in control provision, which will be triggered by the Merger, as well as a modification to accelerate vesting of in<span class="nobreak">-the-money</span> stock options, assuming the adjustment made in Note&#160;5(h)&#160;was made on January&#160;1, 2023.</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">6(e)<span style="width: 10px;display: inline-block;">&#160;&#160;&#160;</span>To reflect Oruka&#8217;s interest expense related to its convertible note that is recorded in its historical financial statements, to be derecognized in the unaudited pro forma condensed combined statement of operations for the three&#160;months ended March&#160;31, 2024 assuming that the adjustment described in Note&#160;5(c)&#160;was made on January&#160;1, 2023.</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">6(f)<span style="width: 10px;display: inline-block;">&#160;&#160;&#160;</span>To reflect stock compensation expenses of $1.1&#160;million and $0.3<span class="nobreak"> </span>million for the year ended December<span class="nobreak"> </span>31, 2023 and the three months ended March<span class="nobreak"> </span>31, 2024, respectively, in general and administrative expense related to stock options expected to be issued to Oruka&#8217;s Chief Executive Officer to maintain 5.0% ownership pursuant to his employment agreement, assuming the adjustment was made on January&#160;1, 2023. These options vest over 4 years from the date of issuance.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">294</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">6(g)&#160;&#160;The pro forma combined basic and diluted net loss per share has been adjusted to reflect the pro forma net loss for the three&#160;months ended March&#160;31, 2024. In addition, the number of shares used in calculating the pro forma combined basic and diluted net loss per share has been adjusted to reflect the estimated total number of shares of common stock of the combined company for the respective periods. Pro forma weighted average shares outstanding includes the pre<span class="nobreak">-funded</span> warrants related to the Subscription Agreement as the exercise price is negligible and they are fully vested and exercisable. For the three&#160;months ended March&#160;31, 2024, the pro forma weighted average shares have been calculated as follows:</p>
		<table class="No-Table-Style TableOverride-2" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 3pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">March&#160;31, 2024</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">December 31, <br/>2023</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Basic and <br/>Diluted</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Basic and <br/>Diluted</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Historical weighted average number of ARCA common shares outstanding</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">14,501,143</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">14,415,877</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-35" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Estimated shares of ARCA common stock expected to be issued to Oruka stockholders upon Closing, assuming consummation of the Merger as of January&#160;1, 2023, see Note&#160;4<span class="Superscript" style="vertical-align:super;font-size:58%;">(1)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">395,463,519</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">395,463,519</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-23" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Pro forma combined weighted average number of common shares <br/>outstanding</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">409,964,662</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">409,879,396</p>
					</td>
				</tr>

		</table>
		<p class="Tablefootnotef" style="margin-top: 0in;  border: none; margin-right: 0in; margin-bottom: -5pt; margin-left: 24.0pt; text-align: justify; text-justify: inter-ideograph; text-indent: -24.0pt; padding: 0in; font-size: 9.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">____________</p><p class="Tablefootnote_f" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:10pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:10pt;">(1)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Represents the estimated shares of ARCA common stock expected to be issued to Oruka stockholders at Closing, excluding (i)&#160;the outstanding and unvested Oruka Restricted Stock and Oruka stock options at Closing that will be converted to the right to receive 28,832,649<span class="nobreak"> </span>shares of ARCA common stock and 18,677,691 stock options, respectively, after reflecting the estimated Exchange Ratio and (ii)&#160;the outstanding Oruka convertible preferred stock that will be exchanged for 149,262,000<span class="nobreak"> </span>shares of ARCA convertible preferred stock. The 28,832,649<span class="nobreak"> </span>shares of ARCA common stock and 18,677,691 stock options are subject to the same vesting conditions (see Note&#160;4).</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">295</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T8"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">DESCRIPTION OF ARCA CAPITAL STOCK</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">The following description of ARCA capital stock and provisions of the ARCA Charter and ARCA Bylaws are summaries and are qualified by reference to such charter and bylaws and applicable provisions of Delaware corporate law. Copies of these documents are filed as exhibits to the registration statement of which this proxy/prospectus forms part.</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Authorized Capital Stock</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The ARCA Charter authorizes ARCA to issue 100,000,000<span class="nobreak"> </span>shares of ARCA common stock and 5,000,000<span class="nobreak"> </span>shares of preferred stock, $0.001 par value per share (&#8220;ARCA preferred stock&#8221;).</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA Common Stock</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Voting Rights.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span>Each holder of ARCA common stock is entitled to one vote for each share on all matters submitted to a vote of the stockholders, including the election of directors; provided, however, holders of ARCA common stock may not, unless otherwise required by law, vote on any amendment to the ARCA Charter that relates solely to the terms of one or more series of ARCA preferred stock that ARCA may issue if the holders of such ARCA preferred stock are entitled to vote on such amendment. In all such matters other than the election of directors, the affirmative vote of the majority of shares present in person, by remote communication, or represented by proxy at a meeting of the stockholders and entitled to vote generally on the subject matter shall be the act of the stockholders. Directors shall be elected by a plurality of the votes of the shares present in person, by remote communication, or represented by proxy at a meeting of the stockholders and entitled to vote generally on the election of directors. ARCA&#8217;s stockholders do not have cumulative voting rights in the election of directors. Accordingly, holders of a majority of the voting shares are able to elect all of the directors to be elected at any particular time. See the section of this proxy statement/prospectus titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Description of ARCA Capital Stock &#8212; Anti</span><span class="nobreak"><span class="Italic" style="font-style:italic;font-weight:normal;">-Takeover</span></span><span class="Italic" style="font-style:italic;font-weight:normal;"> Effects of Delaware Law and Provisions of the ARCA Charter and ARCA Bylaws</span>&#8221; for a description of elections of members of ARCA&#8217;s board of directors.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Dividends.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span>Subject to preferences that may be applicable to any then outstanding ARCA preferred stock, holders of ARCA common stock are entitled to receive dividends, if any, as may be declared from time to time by ARCA&#8217;s board of directors out of legally available funds.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Liquidation.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span>In the event of ARCA&#8217;s liquidation, dissolution or winding up, holders of ARCA common stock will be entitled to share ratably in the net assets legally available for distribution to stockholders after the payment of all of ARCA&#8217;s debts and other liabilities and the satisfaction of any liquidation preference granted to the holders of any then outstanding shares of ARCA preferred stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Rights and Preferences.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span>Holders of ARCA common stock have no preemptive, conversion, subscription or other rights, and there are no redemption provisions applicable to ARCA common stock. The rights, preferences and privileges of the holders of ARCA common stock are subject to and may be adversely affected by the rights of the holders of shares of any series of ARCA preferred stock that ARCA may designate in the future.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Fully Paid and Nonassessable.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span>All outstanding shares of ARCA common stock are fully paid and nonassessable.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA Preferred Stock</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Pursuant to the ARCA Charter, ARCA&#8217;s board of directors has the authority, without further action by ARCA&#8217;s stockholders, to issue up to 5,000,000<span class="nobreak"> </span>shares of ARCA preferred stock, in one or more series, to establish from time to time the number of shares to be included in each such series, and to fix the designations, powers, preferences, privileges and relative participating, optional or special rights and the qualifications, limitations or restrictions thereof, including dividend rights, conversion rights, preemptive rights, voting rights, terms of redemption and repurchase, liquidation preferences and sinking fund terms, any or all of which may be greater than the rights of ARCA common stock. ARCA preferred stock may be convertible into ARCA common stock or other securities of ARCA, or may be exchangeable for debt securities. Conversion may be mandatory or at the holder&#8217;s option and would be at prescribed conversion rates. Because ARCA&#8217;s board of directors, without stockholder approval, can issue ARCA preferred stock with voting, conversion or other rights, ARCA preferred stock could be issued quickly </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">296</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">with terms calculated to delay or prevent a change in control of ARCA or make removal of management more difficult. Additionally, the issuance of ARCA preferred stock may have the effect of decreasing the market price of ARCA common stock and may adversely affect the voting power of holders of ARCA common stock and reduce the likelihood that ARCA&#8217;s common stockholders will receive dividend payments and payments upon liquidation.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Delaware General Corporation Law provides that the holders of any class or series of ARCA preferred stock will have the right to vote separately as a class on any proposed amendment to the ARCA Charter that would alter or change the powers, preferences or special rights of the holders of such class or series of ARCA preferred stock so as to affect them adversely. This right is in addition to any voting rights that may be provided for in the applicable certificate of designation.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Series&#160;A Convertible Preferred Stock</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s board of directors has designated 135,000 of the 5,000,000 authorized shares of preferred stock as &#8220;Series&#160;A Convertible Preferred Stock.&#8221;</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Series&#160;A Convertible Preferred Stock ranks:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>senior to all of ARCA&#8217;s common stock;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>on parity with any class or series of ARCA capital stock specifically ranking by its terms on parity with the Preferred Stock; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>junior to any class or series of ARCA capital stock specifically ranking by its terms senior to the Preferred Stock;</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">in each case, as to distributions of assets upon ARCA&#8217;s liquidation, dissolution or winding up whether voluntarily or involuntarily.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Each share of Series&#160;A Convertible Preferred Stock is convertible into 100<span class="nobreak"> </span>shares of ARCA&#8217;s common stock (subject to adjustment as provided in the related certificate of designation of preferences) at any time at the option of the holder, provided that the holder is prohibited from converting Preferred Stock into shares of ARCA&#8217;s common stock if, as a result of such conversion, the holder, together with its affiliates, would beneficially own more than 9.99% of the total number of shares of ARCA&#8217;s common stock then issued and outstanding.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In the event of ARCA&#8217;s liquidation, dissolution, or winding up, holders of Series&#160;A Convertible Preferred Stock will receive a payment equal to $0.001 per share of Series&#160;A Convertible Preferred Stock before any proceeds are distributed to the holders of ARCA&#8217;s common stock. In addition, each share of Series&#160;A Convertible Preferred Stock will be entitled to receive, on an as<span class="nobreak">-if-converted</span> basis, <span class="Italic" style="font-style:italic;font-weight:normal;">pari passu</span> with each share of ARCA&#8217;s common stock, any distributions of ARCA&#8217;s assets or surplus funds which ARCA makes upon shares of ARCA&#8217;s common stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Shares of Series&#160;A Convertible Preferred Stock have no voting rights, except as required by law.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Except for stock dividends or certain other distributions set forth in the certificate of designation, shares of Series&#160;A Convertible Preferred Stock will be entitled to receive dividends (on an as<span class="nobreak">-converted</span> basis) in the same form as dividends actually paid on shares of ARCA&#8217;s common stock when and if declared by ARCA&#8217;s board of directors.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA is not obligated to redeem or repurchase any shares of Series&#160;A Convertible Preferred Stock. Shares of Series&#160;A Convertible Preferred Stock are not otherwise entitled to any redemption rights, or mandatory sinking fund or analogous fund provisions.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">No shares of Series&#160;A Convertible Preferred Stock are currently issued and outstanding.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Series&#160;B Non-Voting Convertible Preferred Stock</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s board of directors will designate<span style="width: 10px;display: inline-block;">&#160;&#160;&#160;</span><span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>shares of ARCA preferred stock as ARCA Series&#160;B Preferred Stock through its certificate of designation in the form attached as <span class="Italic" style="font-style:italic;font-weight:normal;">Annex</span>&#160;<span class="Italic" style="font-style:italic;font-weight:normal;">F </span>(the &#8220;Certificate of Designation&#8221;). Holders of the ARCA Series&#160;B Preferred Stock will be entitled to receive dividends on shares of ARCA Series&#160;B Preferred Stock equal to, on an as<span class="nobreak">-if-converted-to-ARCA</span> common stock basis, and in the same form as dividends </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">297</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">actually paid on shares of ARCA common stock. Except as otherwise required by the Certificate of Designation or law, the ARCA Series&#160;B Preferred Stock will not have voting rights. However, as long as any shares of ARCA Series&#160;B Preferred Stock are outstanding, ARCA will not, without the affirmative vote of the holders of a majority of the then outstanding shares of the ARCA Series&#160;B Preferred Stock, (a)&#160;alter or change adversely the powers, preferences or rights given to the ARCA Series&#160;B Preferred Stock, (b)&#160;alter or amend the Certificate of Designation, (c)&#160;amend ARCA&#8217;s charter, bylaws or other charter documents in any manner that adversely affects any rights of the holders of the ARCA Series&#160;B Preferred Stock, (d)&#160;file any articles of amendment, certificate of designations, preferences, limitations and relative rights of any series of Preferred Stock (as defined in the Certificate of Designation), if such action would adversely alter or change the preferences, rights, privileges or powers of, or restrictions provided for the benefit of the ARCA Series&#160;B Preferred Stock, (e)&#160;issue further shares of the ARCA Series&#160;B Preferred Stock or increase or decrease (other than by conversion) the number of authorized shares of the ARCA Series&#160;B Preferred Stock, (f)&#160;at any time while at least 30% of the originally issued ARCA Series&#160;B Preferred Stock remains issued and outstanding, consummate either (A)&#160;a Fundamental Transaction (as defined in the Certificate of Designation) or (B)&#160;any merger or consolidation of ARCA or other business combination in which the stockholders of ARCA immediately before such transaction do not hold at least a majority of the capital stock of ARCA immediately after such transaction, or (f)&#160;enter into any agreement with respect to any of the foregoing. The ARCA Series&#160;B Preferred Stock does not have a preference upon any liquidation, dissolution or winding<span class="nobreak">-up</span> of ARCA.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Following the closing of the First Merger (as defined elsewhere in this proxy statement/prospectus), each share of ARCA Series&#160;B Preferred Stock then outstanding shall be convertible, at any time and from time to time, at the option of the holder of the ARCA Series&#160;B Preferred Stock, into a number of shares equal to 1,000<span class="nobreak"> </span>shares of ARCA common stock, subject to certain limitations, including that a holder of ARCA Series&#160;B Preferred Stock is prohibited from converting shares of ARCA Series&#160;B Preferred Stock into shares of ARCA common stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than a specified percentage (initially set at 9.99%) of the total number of shares of ARCA common stock issued and outstanding immediately after giving effect to such conversion.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Anti-Takeover Effects of Delaware Law and Provisions of the ARCA Charter and ARCA Bylaws</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Certificate of Incorporation and Bylaws</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The ARCA Charter and ARCA Bylaws include a number of provisions that may deter or impede hostile takeovers or changes of control. These provisions include:</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Issuance of Undesignated ARCA preferred stock.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span>Under the ARCA Charter, ARCA&#8217;s board of directors has the authority, without further action by the stockholders, to issue up to 5,000,000<span class="nobreak"> </span>shares of undesignated ARCA preferred stock with rights and preferences, including voting rights, designated from time to time by ARCA&#8217;s board of directors. The existence of authorized but unissued shares of ARCA preferred stock enables ARCA&#8217;s board of directors to make it more difficult or to discourage an attempt to obtain control of ARCA by means of a merger, tender offer, proxy contest or otherwise.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Classified Board.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span>The ARCA Charter provides for a classified board of directors consisting of three classes of directors, with staggered three<span class="nobreak">-year</span> terms. Only one class of directors will be elected at each annual meeting of ARCA&#8217;s stockholders, with the other classes continuing for the remainder of their respective three<span class="nobreak">-year</span> terms. This provision may have the effect of delaying a change in control of ARCA&#8217;s board of directors.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Board of Directors Vacancies.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span>The ARCA Charter and ARCA Bylaws authorize only ARCA&#8217;s board of directors to fill vacant directorships, unless ARCA&#8217;s board of directors determines by resolution that the stockholders shall fill such vacant directorships. In addition, the number of directors constituting ARCA&#8217;s board of directors may be set only by resolution adopted by a majority vote of ARCA&#8217;s entire board of directors. These provisions prevent a stockholder from increasing the size of ARCA&#8217;s board of directors and gaining control of ARCA&#8217;s board of directors by filling the resulting vacancies with its own nominees.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Stockholder Action; Special Meetings of Stockholders.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span>The ARCA Charter provides that ARCA&#8217;s stockholders may not take action by written consent, but may only take action at annual or special meetings of ARCA&#8217;s stockholders. Under the ARCA Bylaws, stockholders are not permitted to cumulate their votes for the election of directors. The ARCA Bylaws further provide that special meetings of the stockholders may be called by the chief executive officer, president, ARCA&#8217;s board of directors, or by holders of ARCA common stock who hold, </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">298</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">in the aggregate, not less than fifty percent (50%) of the outstanding shares of ARCA common stock for the purpose or purposes stated in the call of the meeting. These provisions may prevent stockholders from corporate actions as stockholders at times when they otherwise would like to do so.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Advance Notice Requirements for Stockholder Proposals and Director Nominations.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span>The ARCA Bylaws provide advance notice procedures for stockholders seeking to bring business before ARCA&#8217;s annual meeting of stockholders, or to nominate candidates for election as directors at ARCA&#8217;s annual meeting of stockholders. The ARCA Bylaws also specify certain requirements as to the form and content of a stockholder&#8217;s notice. These provisions may make it more difficult for ARCA&#8217;s stockholders to bring matters before ARCA&#8217;s annual meeting of stockholders or to nominate directors at ARCA&#8217;s annual meeting of stockholders.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">These provisions are intended to enhance the likelihood of continued stability in the composition of ARCA&#8217;s board of directors and its policies and to discourage certain types of transactions that may involve an actual or threatened acquisition of ARCA.&#160;These provisions are designed to reduce ARCA&#8217;s vulnerability to an unsolicited acquisition proposal. The provisions also are intended to discourage certain tactics that may be used in proxy fights. However, these provisions could have the effect of discouraging others from making tender offers for ARCA&#8217;s shares and, as a consequence, they may also reduce fluctuations in the market price of ARCA&#8217;s shares that could result from actual or rumored takeover attempts.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Section&#160;203 of the Delaware General Corporation Law</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA is subject to Section&#160;203 of the Delaware General Corporation Law. Section&#160;203 generally prohibits certain Delaware corporations from engaging, under certain circumstances, in a &#8220;business combination&#8221; with any &#8220;interested stockholder for a period of three&#160;years following the time that such stockholder became an interested stockholder, unless:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>prior to such time the board of directors approved either the business combination or transaction which resulted in the stockholder becoming an interested stockholder;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>upon consummation of the transaction which resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the number of shares outstanding (a)&#160;shares owned by persons who are directors and also officers and (b)&#160;employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>at or subsequent to such time the business combination is approved by the board of directors and authorized at an annual or special meeting of stockholders, and not by written consent, by the affirmative vote of at least&#160;66<span class="nobreak">-2</span>/3% of the outstanding voting stock which is not owned by the interested stockholder.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Section&#160;203 defines a business combination to include:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>any merger or consolidation involving the corporation and the interested stockholder;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>any sale, lease, exchange, mortgage, pledge, transfer or other disposition (in one transaction or a series of transactions) involving the interested stockholder of 10% or more of the assets of the corporation (or its majority<span class="nobreak">-owned</span> subsidiary);</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>subject to exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>subject to exceptions, any transaction involving the corporation that has the effect, directly or indirectly, of increasing the proportionate share of the stock or any class or series of the corporation beneficially owned by the interested stockholder; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the receipt by the interested stockholder of the benefit, directly or indirectly (except proportionately as a stockholder of such corporation), of any loans, advances, guarantees, pledges or other financial benefits, other than certain benefits set forth in Section&#160;203, provided by or through the corporation.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">299</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In general, Section&#160;203 defines an interested stockholder as any entity or person beneficially owning 15% or more of the outstanding voting stock of the corporation and any entity or person that is an affiliate or associate of such entity or person.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">A Delaware corporation may &#8220;opt out&#8221; of these provisions with an express provision in its original certificate of incorporation or an express provision in its certificate of incorporation or bylaws resulting from a stockholders&#8217; amendment approved by a majority of the outstanding voting shares. ARCA has not &#8220;opted out&#8221; of these provisions and do not plan to do so. The statute could prohibit or delay mergers or other takeover or change in control attempts and, accordingly, may discourage attempts to acquire ARCA.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Potential Effects of Authorized but Unissued Stock</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Shares of ARCA common stock and ARCA preferred stock are available for future issuance without stockholder approval. ARCA may utilize these additional shares for a variety of corporate purposes, including future public offerings to raise additional capital, to facilitate corporate acquisitions, payment as a dividend on the capital stock or as equity compensation to ARCA&#8217;s service providers under ARCA&#8217;s equity compensation plans.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The existence of unissued and unreserved ARCA common stock and ARCA preferred stock may enable ARCA&#8217;s board of directors to issue shares to persons friendly to current management or to issue ARCA preferred stock with terms that could render more difficult or discourage a third<span class="nobreak">-party</span> attempt to obtain control by means of a merger, tender offer, proxy contest or otherwise, thereby protecting the continuity of ARCA&#8217;s management. In addition, ARCA&#8217;s board of directors has the discretion to determine designations, rights, preferences, privileges and restrictions, including voting rights, dividend rights, conversion rights, redemption privileges and liquidation preferences of each series of ARCA preferred stock, all to the fullest extent permissible under the Delaware General Corporation Law and subject to any limitations set forth in the ARCA Charter. The purpose of authorizing the board of directors to issue ARCA preferred stock and to determine the rights and preferences applicable to such ARCA preferred stock is to eliminate delays associated with a stockholder vote on specific issuances. The issuance of ARCA preferred stock, while providing desirable flexibility in connection with possible financings, acquisitions and other corporate purposes, could have the effect of making it more difficult for a third party to acquire, or could discourage a third party from acquiring, a majority of ARCA&#8217;s outstanding voting stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Also, if ARCA issues additional shares of authorized, but unissued, ARCA common stock, these issuances will dilute the voting power and distribution rights of ARCA&#8217;s existing common stockholders.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Amendments to Governing Documents</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Generally, the amendment of the ARCA Charter requires approval by ARCA&#8217;s board of directors and a majority vote of stockholders, provided that the provisions of the ARCA Charter relating to (i)&#160;the requirement that all stockholder action be taken only at a duly called annual meeting or special meeting; (ii)&#160;the authority and power of ARCA&#8217;s board of directors and the procedure required to amend ARCA Bylaws; (iii)&#160;the percentage of the shares necessary to amend the ARCA Charter; (iv)&#160;the elimination of directors&#8217; personal liability for monetary damages arising from their negligence and gross negligence; and (v)&#160;indemnification of directors, officers and other persons requires approval of ARCA&#8217;s stockholders holding at least&#160;66<span class="nobreak">-2</span>/3% of ARCA&#8217;s capital stock then outstanding and entitled to vote. Any amendment to ARCA Bylaws requires the approval of either a majority of ARCA&#8217;s board of directors or approval of ARCA&#8217;s stockholders holding at least&#160;66<span class="nobreak">-2</span>/3% of ARCA&#8217;s capital stock then outstanding and entitled to vote.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Listing</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA common stock is listed on the Nasdaq Capital Market under the symbol &#8220;ABIO.&#8221;</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Transfer Agent and Registrar</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The transfer agent and registrar for ARCA common stock is Computershare Trust Company N.A.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">300</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T7"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">COMPARISON OF RIGHTS OF HOLDERS OF ARCA CAPITAL STOCK AND <br/>ORUKA CAPITAL STOCK</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If the Merger is completed, Oruka stockholders will receive shares of ARCA common stock and ARCA Series&#160;B Preferred Stock, pursuant to the terms of the Merger Agreement. Prior to or upon the closing of the Merger, assuming that Proposal&#160;Nos.<span class="nobreak"> </span>2, 3 and 4 are approved by ARCA&#8217;s stockholders, the ARCA Charter will be amended to increase the number of shares of ARCA common stock that ARCA is authorized to issue from 100,000,000 to &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, to effect the proposed reverse stock split and to reflect Delaware law provisions regarding officer exculpation, respectively, as set forth in the forms of certificates of amendment attached as <span class="Italic" style="font-style:italic;font-weight:normal;">Annex&#160;G, Annex&#160;H </span>and <span class="Italic" style="font-style:italic;font-weight:normal;">Annex&#160;I</span>,<span class="Italic" style="font-style:italic;font-weight:normal;">&#160;</span>to this proxy statement/prospectus.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA and Oruka are both incorporated under the laws of the State of Delaware. The rights of ARCA stockholders and Oruka stockholders are generally governed by the DGCL.&#160;Upon completion of the Merger, Oruka stockholders will become ARCA stockholders, and their rights will be governed by the DGCL, the ARCA Bylaws and the ARCA Charter, as amended.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The material differences between the current rights of Oruka stockholders under the Oruka Charter and Oruka Bylaws and their rights as ARCA stockholders, after the Merger, under the ARCA Charter and ARCA Bylaws, both as will be in effect immediately following the completion of the Merger and assuming that that Proposal&#160;Nos.<span class="nobreak"> </span>2, 3 and 4 are approved by ARCA&#8217;s stockholders, are summarized below. The summary below does not purport to be complete and is subject to, and qualified in its entirety by reference to, the DGCL and the governing corporate instruments that are subject to amendment in accordance with their terms. You should carefully read this entire document and the other referenced documents, including the governing corporate instruments, for a more complete understanding of the differences between being a stockholder of ARCA or Oruka before the Merger and being a stockholder of the combined company following the completion of the Merger. For more information on how to obtain these documents, see the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Where You Can Find More Information</span>&#8221; beginning on page 320 of this proxy statement/prospectus.</p>
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">



						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Oruka</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 100.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="Italic" style="font-style:italic;font-weight:normal;">Organizational Documents</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;margin-top:8pt;text-indent:0pt;">The rights of ARCA stockholders are governed by the ARCA Charter, ARCA Bylaws and the DGCL.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">The rights of Oruka stockholders are governed by the Oruka Charter, Oruka Bylaws and the DGCL.&#160;Rights of certain holders of Oruka preferred stock are governed by the Investors&#8217; Rights Agreement (the &#8220;Oruka IRA&#8221;), the Right of First Refusal and Co<span class="nobreak">-Sale</span> Agreement (the &#8220;Oruka ROFR Agreement&#8221;), and the Voting Agreement, each dated as of March&#160;6, 2024.</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 100.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-top:8pt;text-align:center;"><span class="Italic" style="font-style:italic;font-weight:normal;">Authorized Capital Stock</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;margin-top:8pt;text-indent:0pt;">ARCA is authorized to issue two classes of capital stock which are designated, respectively, &#8220;common stock&#8221; and &#8220;preferred stock.&#8221; The total number of shares that ARCA is authorized to issue is 105,000,000, of which 100,000,000<span class="nobreak"> </span>shares are common stock, par value $0.001 per share, and 5,000,000<span class="nobreak"> </span>shares are preferred stock, par value $0.001 per share.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Oruka is authorized to issue two classes of capital stock which are designated, respectively, &#8220;common stock&#8221; and &#8220;preferred stock.&#8221; The total number of shares that Oruka is authorized to issue is 85,000,000, of which 65,000,000<span class="nobreak"> </span>shares are common stock, par value $0.0001 per share, and 20,000,000<span class="nobreak"> </span>shares are preferred stock, par value $0.0001 per share. The number of authorized shares of Oruka common stock may be increased or decreased (but not below the number of shares thereof then outstanding) by (in addition to any vote of the holders of one or more series of Oruka preferred stock that may be required under the Oruka Charter) the affirmative vote of the holders of shares of Oruka capital stock representing a majority of the votes represented by all outstanding shares of Oruka capital stock entitled to vote, irrespective of the provisions of Section&#160;242(b)(2) of the DGCL.</p>
					</td>
				</tr>

		</table>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">301</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">



						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Oruka</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 100.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="Italic" style="font-style:italic;font-weight:normal;">Common Stock</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;margin-top:8pt;text-indent:0pt;">ARCA&#8217;s authorized common stock consists of 100,000,000<span class="nobreak"> </span>shares of common stock, par value $0.001 per share. </p>
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;margin-top:8pt;text-indent:0pt;">Each holder of a share of ARCA common stock is entitled to one vote for each such share held of record on the applicable record date on each matter voted on at a meeting of stockholders.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Oruka&#8217;s authorized common stock consists of 65,000,000<span class="nobreak"> </span>shares of common stock, par value $0.0001 per share. </p>
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Each holder of a share of Oruka common stock is entitled to one vote for each such share held of record on the applicable record date on each matter voted on at a meeting of stockholders (and written actions in lieu of meetings).</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 100.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-top:8pt;text-align:center;"><span class="Italic" style="font-style:italic;font-weight:normal;">Preferred Stock</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-10" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;margin-top:8pt;text-indent:0pt;">ARCA&#8217;s authorized preferred stock consists of 5,000,000<span class="nobreak"> </span>shares of preferred stock of which ARCA&#8217;s board of directors has designated 135,000<span class="nobreak"> </span>shares of preferred stock as &#8220;Series&#160;A Convertible Preferred Stock.&#8221; </p>
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;margin-top:8pt;text-indent:0pt;">No shares of ARCA Series&#160;A Convertible Preferred Stock or undesignated preferred stock are currently outstanding. ARCA&#8217;s board of directors is authorized to issue shares of undesignated preferred stock in one or more series and to fix the designations, powers, preferences and relative, participating, optional and other rights, and any qualifications, limitations and restrictions, on such shares. </p>
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;margin-top:8pt;text-indent:0pt;">In connection with the Merger, ARCA&#8217;s board of directors intends to designate shares of undesignated preferred stock as Series&#160;B Non-Voting Convertible Preferred Stock through a certificate of designation in the form attached as <span class="Italic" style="font-style:italic;font-weight:normal;">Annex&#160;F </span>(the &#8220;Certificate of Designation&#8221;). No shares of Series&#160;B Non-Voting Convertible Preferred Stock are currently authorized or outstanding. As long as any shares of Series&#160;B Non-Voting Preferred Stock are outstanding, ARCA will not, without the affirmative vote or written waiver of the holders of a majority of the then outstanding shares of the Series&#160;B Non-Voting Preferred Stock: (i)&#160;alter or change adversely the powers, preferences or rights given to the Series&#160;B Non-Voting Preferred Stock or alter or amend the Certificate of Designation, amend or repeal any provision of, or add any provision to, the ARCA Charter or ARCA Bylaws, or file any articles of amendment, certificate of designations, preferences, limitations and relative rights of any series of ARCA preferred stock, in each case if such action would adversely alter or change the preferences, rights, privileges or powers of, or restrictions provided for the benefit of the Series&#160;B Non-Voting Preferred Stock, regardless of whether any of the foregoing actions will be by means of amendment to the ARCA Charter or by merger, consolidation, recapitalization, reclassification, conversion or otherwise, (ii)&#160;issue further shares of Series&#160;B Non-Voting Preferred Stock beyond those contemplated for issuance in the Merger Agreement or increase or decrease (other than by conversion) the number of authorized shares of Series&#160;B Non-Voting Preferred Stock, (iii)&#160;at any time while at least 30% of the originally issued ARCA Series&#160;B Non-Voting Preferred Stock remains issued and outstanding, consummate either: (A)&#160;any Fundamental Transaction</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">All of Oruka&#8217;s 20,000,000<span class="nobreak"> </span>shares of preferred stock are designated as shares of &#8220;Series&#160;A Preferred Stock,&#8221; of which 20,000,000 are issued and outstanding. Each holder of a share of Oruka preferred stock is entitled to cast the number of votes equal to the number of whole shares of Oruka common stock into which the shares of preferred stock held by such holder are convertible as of the record date for determining stockholders entitled to vote on such matter.</p>
					</td>
				</tr>

		</table>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">302</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">



						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Oruka</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-11" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">(as defined in the Certificate of Designation) or (B)&#160;any merger or consolidation of ARCA with or into another entity or any stock sale to, or other business combination in which the stockholders of ARCA immediately before such transaction do not hold at least a majority on an as<span class="nobreak">-converted-to-ARCA</span> common stock basis of the capital stock of ARCA, immediately after such transaction or (iv)&#160;enter into any agreement with respect to any of the foregoing that does not explicitly require the approval contemplated herein to consummate such transaction.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 100.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;"><span class="Italic" style="font-style:italic;font-weight:normal;">Number and Qualification of Directors</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-12" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">The number of ARCA directors is not less than two (2)&#160;nor more than ten (10), the exact number determined from time to time by resolution of ARCA&#8217;s board of directors, acting by the affirmative vote of a majority of the directors. The ARCA&#8217;s board of directors currently consists of five (5)&#160;members. No decrease in the authorized number of directors constituting ARCA&#8217;s board of directors will shorten the term of any incumbent director. Directors of ARCA need not be stockholders of ARCA.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">The number of directors of Oruka is established from time to time by the board of directors. Oruka&#8217;s board of directors currently consists of six members.</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 100.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;"><span class="Italic" style="font-style:italic;font-weight:normal;">Structure of Board of Directors; Term of Directors; Election of Directors</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">ARCA&#8217;s board of directors is divided into three classes, designated as Class&#160;I, Class&#160;II and Class&#160;III, respectively. Election of directors need not be by written ballot. The term of office of the first class expired at the first annual meeting of stockholders or any special meeting in lieu thereof following January&#160;1, 2004, the term of office of the second class expired at the second annual meeting of stockholders or any special meeting in lieu thereof following January&#160;1, 2004 and the term of office of the third class expired at the third annual meeting of stockholders or any special meeting in lieu thereof following January&#160;1, 2004.&#160;At each succeeding annual meeting of stockholders, or special meeting in lieu thereof, directors are elected for a full term of three&#160;years to succeed the directors of the class whose terms expire at such annual meeting or special meeting lieu of thereof. Notwithstanding the foregoing, directors elected to each class hold office until their successors are duly elected and qualified.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Oruka directors shall be elected at the annual meeting of stockholders by such stockholders as have the right to vote on such election. Election of directors need not be by written ballot. Each director shall hold office for a term of one year and until his or her successor is elected and qualified, or until such director&#8217;s earlier resignation or removal. </p>
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">The holders of record of the shares of Oruka&#8217;s Series&#160;A Preferred Stock, voting together exclusively and as a separate class, are entitled to elect one director of Oruka. The holders of record of the shares of common stock and of any other class or series of voting stock (including the Series&#160;A Preferred Stock), exclusively and voting together as a single class on an as<span class="nobreak">-converted</span> to Common Stock basis, shall be entitled to elect the balance of the total number of directors.</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 100.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;"><span class="Italic" style="font-style:italic;font-weight:normal;">Removal of Directors</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-14" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Any director may be removed from office at any time, but only with cause and only by the affirmative vote of the holders of sixty<span class="nobreak">-six</span> and two<span class="nobreak">-third</span> percent or more of the voting power of the outstanding shares of capital stock of ARCA entitled to vote at an election of directors, unless otherwise provided under the DGCL or the ARCA Charter.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Any one or more or all of the Oruka directors may be removed, with or without cause, by the holders of a majority of shares entitled to vote at an election of directors, except that any director elected by the holders of Series&#160;A Preferred Stock may be removed without cause only by the affirmative vote of the holders of a majority of the outstanding shares of Series&#160;A Preferred Stock, together as a single class on an as<span class="nobreak">-converted</span> to common stock basis, given either at a special meeting of such stockholders duly called for that purpose or pursuant to a written consent of stockholders.</p>
					</td>
				</tr>

		</table>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">303</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">



						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Oruka</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 100.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;"><span class="Italic" style="font-style:italic;font-weight:normal;">Vacancies on the Board of Directors</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-15" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Any director may resign at any time by giving notice in writing to ARCA Chairperson of the board of directors, if one is elected, the ARCA Vice Chairperson of the board of directors, if one is elected, the Chief Executive Officer or the President. Such resignation shall be effective upon receipt, unless the resignation otherwise provides. Any vacancies and any newly created directorships resulting from any increase in the number of directors, will be filled solely and exclusively by the affirmative vote of a majority of the remaining directors then in office, even if less than a quorum, or by a sole remaining director, and not by the ARCA stockholders. Any director elected in accordance with the preceding sentence will hold office for the remainder of the full term of the director for which the vacancy was created or occurred and until such director&#8217;s successor is elected and qualified or until his or her earlier resignation, death or removal.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Any director may resign at any time upon notice given in writing or by electronic transmission to Oruka. Such resignation shall be effective upon receipt unless it is specified to be effective at some other time or upon the happening of some other event. A vacancy in any director seat not reserved for holders of Series&#160;A Preferred Stock can be filled by either (A)&#160;the vote or written consent in lieu of a meeting of the stockholders entitled elect those directors, or (B)&#160;the vote or written consent in lieu of a meeting of a majority of the remaining director(s), although less than a quorum. Vacancies and newly created directorships resulting from any increase in the authorized number of directors may be filled by a majority of the directors then in office, though less than a quorum, or by a sole remaining director, and the directors so chosen shall hold office until the next annual election and until their successors are duly elected and shall qualify, unless sooner displaced. If there are no directors in office, then an election of directors may be held in the manner provided by statute. </p>
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">If the holders of shares of Series&#160;A Preferred Stock fail to elect a sufficient number of directors to fill all directorships for which they are entitled to elect directors, then any directorship not so filled shall remain vacant until such time as the holders of the Series&#160;A Preferred Stock elect a person to fill such directorship.</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 100.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;"><span class="Italic" style="font-style:italic;font-weight:normal;">Stockholder Action by Written Consent</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-16" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">No action may be taken by the ARCA stockholders except at an annual or special meeting of the ARCA stockholders called in accordance with the ARCA Bylaws, and no action may be taken by the ARCA stockholders by written consent in lieu of a meeting.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Any action required or permitted to be taken at any annual or special meeting of stockholders may be taken without a meeting, without prior notice and without a vote, if a consent in writing, setting forth the action so taken, is signed by the holders of outstanding stock having not less than the minimum number of votes that would be necessary to authorize or take such action at a meeting at which all shares entitled to vote thereon were present and voted. Every written consent shall bear the date of signature of each stockholder who signs the consent, and no written consent shall be effective to take the corporate action referred to therein unless, within 60&#160;days of the earliest dated consent delivered to Oruka, a written consent signed by a sufficient number of stockholders to take action are delivered to Oruka.</p>
					</td>
				</tr>

		</table>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">304</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">



						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Oruka</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 100.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;"><span class="Italic" style="font-style:italic;font-weight:normal;">Quorum</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-17" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Subject to the provisions of the ARCA Bylaws, ARCA Charter and the DGCL as to the vote that is required for a specified action, the presence in person or by proxy of the holders of at least one<span class="nobreak">-third</span> of the outstanding shares of ARCA entitled to vote at any meeting of stockholders shall constitute a quorum for the transaction of business.&#160;In the absence of a quorum, stockholders holding a majority of the shares present in person or by proxy and entitled to vote, regardless of whether or not they constitute a quorum, or if no stockholders are present, any officer entitled to preside at or act as secretary of the meeting, may adjourn the meeting to another time and place.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Except as otherwise provided by the DGCL or the Oruka Charter, the holders of a majority of the voting power of all of the shares of stock entitled to vote at the meeting, present in person or by proxy, shall constitute a quorum for all purposes. Where a separate vote by a class or series is required, a majority of the voting power of the shares of such class or series present in person or represented by proxy shall constitute a quorum entitled to take action with respect to that vote on that matter. The stockholders present at a duly constituted meeting may continue to transact business until adjournment notwithstanding the withdrawal of enough stockholders to reduce the voting shares below a quorum. If a quorum shall fail to attend any meeting, the chairman of the meeting or the holders of a majority of the shares of stock entitled to vote who are present, in person or by proxy, may adjourn the meeting to another place, if any, date, or time.</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 100.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;"><span class="Italic" style="font-style:italic;font-weight:normal;">Special Meetings of Stockholders</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Special meetings of the stockholders may be called by ARCA&#8217;s board of directors, Chief Executive Officer, President, or by holders of ARCA common stock who hold, in the aggregate, not less than fifty percent (50%) of the outstanding shares of ARCA common stock for the purpose or purposes stated in the call of the meeting.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Special meetings of the stockholders, for any purpose or purposes prescribed in the notice of the meeting, may be called by Oruka&#8217;s board of directors or the Chief Executive Officer if one is elected, or the President, and shall be held at such place, date, and time as they or he or she shall fix.</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 100.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;"><span class="Italic" style="font-style:italic;font-weight:normal;">Notice of Stockholder Meetings</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Notice of all meetings of ARCA stockholders shall state the place, if any, date and hour of the meeting, and, in the case of a special meeting, the purpose or purposes for which the meeting is called, shall be given to each stockholder entitled to vote at the meeting, and unless otherwise provided in the DGCL, the ARCA Charter or the ARCA Bylaws, the notice shall be given not less than ten nor more than sixty&#160;days before the meeting to each stockholder entitled to vote at the meeting as of the record date for determining the stockholders entitled to notice of the meeting, and, if mailed, shall be deposited in the United&#160;States mail, postage prepaid, directed to the stockholder at the stockholder&#8217;s address as it appears on the records of ARCA.&#160;The notice to stockholders for any meeting will be given in accordance with Section&#160;232 of the DGCL.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Except as otherwise provided by the DGCL or the Oruka Charter, notice of the place, date, and time of all meetings of the stockholders, the means of remote communications, if any, by which stockholders and proxyholders may be deemed to be present in person and vote at such meeting, and the record date for determining the stockholders entitled to vote at the meeting, shall be given not less than 10&#160;days nor more than 60&#160;days before date of the meeting to each stockholder entitled to vote at such meeting as of the record date for determining the stockholders entitled to notice of the meeting.</p>
					</td>
				</tr>

		</table>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">305</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">



						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Oruka</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 100.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;"><span class="Italic" style="font-style:italic;font-weight:normal;">Advance Notice Requirements for Stockholder Proposals</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-18" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Nominations of persons for election to ARCA&#8217;s board of directors and the proposal of business to be considered by the stockholders may be made at an annual meeting of stockholders (i)&#160;pursuant to the corporation&#8217;s notice of meeting, (ii)&#160;by or at the direction of ARCA&#8217;s board of directors, or (iii)&#160;by any stockholder of ARCA who is a stockholder of record at the time of giving notice provided for in the ARCA Bylaws, who is entitled to vote at the meeting, who is present (in person or by proxy) at the meeting and who complies with the notice procedures set forth in the ARCA Bylaws as to such nomination or business. </p>
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">For the avoidance of doubt, the foregoing clause (ii)&#160;shall be the exclusive means for a stockholder to bring nominations or business properly before an annual meeting of stockholders (other than matters properly brought under Rule&#160;14a<span class="nobreak">-8</span> (or any successor rule) under the Exchange&#160;Act).</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Neither the Oruka Charter nor the Oruka Bylaws contain advance notice requirements for stockholder proposals.</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 100.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;"><span class="Italic" style="font-style:italic;font-weight:normal;">Amendment of Certificate of Incorporation</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-19" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">The ARCA Charter provides that it may be amended by the affirmative vote of the majority of the voting rights of all classes of capital stock entitled to vote, provided, however, that no amendment, alteration, change or repeal of any provision requiring the affirmative vote of the holders of more than a majority of the voting rights may be made unless approved by the affirmative vote of such greater number of holders. The affirmative vote of the holders of 66 2/3% of the voting rights is required to amend, repeal or adopt any provision inconsistent with the provisions of the ARCA Charter relating to: (i)&#160;the requirement that all stockholder action be taken only at a duly called annual meeting or special meeting; (ii)&#160;the authority and power of ARCA&#8217;s board of directors and the procedure required to amend the ARCA Bylaws; (iii)&#160;the percentage of the shares necessary to amend the ARCA Charter; (iv)&#160;the elimination of ARCA&#8217;s directors&#8217; personal liability for monetary damages arising from their negligence and gross negligence; and (v)&#160;indemnification of ARCA&#8217;s directors, officers and other persons.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">The Oruka Charter may be amended pursuant to Section&#160;242 of the DGCL; provided that, at any time when shares of preferred stock are outstanding, the written consent or affirmative vote of the holders of at least a majority of the outstanding shares of preferred stock, voting together as a single class on an as<span class="nobreak">-converted</span> to common stock basis (the &#8220;Requisite Holders&#8221;), is required to (i)&#160;amend, alter or repeal of any provision of the Oruka Charter in a manner that adversely affects the special rights, powers, and preferences of the preferred stock or any series thereof, (ii)&#160;create or issue any capital stock unless the same ranks junior to the preferred stock with respect to its special rights, powers and preferences or (iii)&#160;increase the authorized number of shares of preferred stock or any additional class or series of capital stock of Oruka unless the same ranks junior to the preferred stock with respect to its special rights, powers and preferences.</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 100.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;"><span class="Italic" style="font-style:italic;font-weight:normal;">Amendment of Bylaws</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-20" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Except as otherwise provided by law, the ARCA Bylaws may be amended or repealed by ARCA&#8217;s board of directors. The ARCA Bylaws may also be amended or repealed by the stockholders by the affirmative vote of not less than&#160;66<span class="nobreak">-2</span>/3% of the outstanding shares of capital stock entitled to vote, voting together as a single class.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">The Oruka Bylaws may be amended or repealed by Oruka&#8217;s board of directors or by the stockholders; provided that, at any time when shares of preferred stock are outstanding, the written consent or affirmative vote of the Requisite Holders is required to amend, alter or repeal of any provision of the Oruka Bylaws in a manner that adversely affects the special rights, powers, and preferences of the preferred stock or any series thereof.</p>
					</td>
				</tr>

		</table>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">306</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">



						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Oruka</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 100.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;"><span class="Italic" style="font-style:italic;font-weight:normal;">Limitation on Director and Officer Liability</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-21" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">To the fullest extent permitted by the DGCL, as the same exists or as may hereafter be amended, a director of ARCA shall not be personally liable to ARCA or its stockholders for monetary damages for breach of fiduciary duty as a director. Any amendment, repeal or modification of Article&#160;IX of the ARCA Charter shall not adversely affect any right or protection existing at the time of such amendment, repeal or modification with respect to any acts or omissions occurring before such amendment, repeal or modification of a person serving as a director at the time of such amendment, repeal or modification.</p>
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">To the fullest extent permitted by the DGCL, as the same exists or may hereafter be amended, an officer of ARCA shall not be personally liable to ARCA or its stockholders for monetary damages for breach of fiduciary duty as an officer. Any amendment, repeal or modification of Article XIII of the ARCA Charter shall not adversely affect any right or protection existing at the time of such amendment, repeal or modification with respect to any acts or omissions occurring before such amendment, repeal or modification of a person serving as an officer at the time of such amendment, repeal or modification.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">To the fullest extent permitted by law, a director or officer of Oruka shall not be personally liable to Oruka or its stockholders for monetary damages for breach of fiduciary duty as a director or officer. If the DGCL or any other law of the State of Delaware is amended to authorize corporate action further eliminating or limiting the personal liability of directors or officers, then the liability of a director or officer of Oruka shall be eliminated or limited to the fullest extent permitted by the DGCL as so amended. Any amendment, repeal or elimination of the foregoing provisions by the Oruka stockholders shall not adversely affect any right or protection of a director of Oruka existing at the time of, or increase the liability of any Oruka director with respect to any acts or omissions of such director occurring prior to, such amendment, repeal or elimination.</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 100.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;"><span class="Italic" style="font-style:italic;font-weight:normal;">Indemnification</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">ARCA will indemnify any person who was or is a party or is threatened to be made a party to, or otherwise becomes involved in, any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative and whether internal or external to ARCA (a &#8220;Proceeding&#8221;), by reason of the fact that the person is or was a director, officer, employee, or other agent of ARCA, or is or was serving at the request of ARCA as a director, officer, employee or agent of another foreign or domestic corporation, partnership, joint venture, trust or other enterprise (any such person, an &#8220;Agent of ARCA&#8221;). Expenses incurred by an Agent in connection with a Proceeding shall be paid by ARCA as they are incurred and in advance of the final disposition of such Proceeding, subject to certain conditions. These rights to indemnification and advancement of expenses shall not be deemed exclusive of any other rights to which a person seeking indemnification or advancement of expenses may be entitled. ARCA has the power to purchase and maintain insurance on behalf of any person who is or was an Agent of ARCA against any liability asserted against the person and incurred by the person in any such capacity, or arising out of the person&#8217;s status as such, whether or not ARCA would have the power to indemnify the person against such liability.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">To the fullest extent permitted by applicable law, Oruka is authorized to provide indemnification of (and advancement of expenses to) its directors, officers and agents (and any other persons to which the DGCL permits Oruka to provide indemnification) through Oruka Bylaw provisions, agreements with such agents or other persons, vote of stockholders or disinterested directors or otherwise, in excess of the indemnification and advancement otherwise permitted by Section&#160;145 of the DGCL.&#160;Any amendment, repeal, modification or elimination of the foregoing provisions shall not (a)&#160;adversely affect any right or protection of any director, officer or other agent of Oruka existing at the time of such amendment, repeal, modification or elimination; or (b)&#160;increase the liability of any Oruka director, officer or agent with respect to any acts or omissions of such director, officer or agent occurring prior to, such amendment, repeal, modification or elimination. The Oruka Bylaws require Oruka to indemnify, to the fullest extent permitted by Delaware law, as the same exists or may hereafter be amended, and except in certain circumstances, each person who was or is made a party to or is threatened to be made a party to or is otherwise involved in any action, suit or proceeding, whether civil, criminal, administrative or investigative (a &#8220;proceeding&#8221;), by reason of the fact that he or she is or was a director or an officer of Oruka or is or was serving at the request of Oruka as a director, officer, or trustee of another corporation or of a partnership, joint venture, trust or other enterprise, including service with respect to an employee benefit</p>
					</td>
				</tr>

		</table>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">307</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">



						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Oruka</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-23" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">plan, whether the basis of such proceeding is alleged action in an official capacity as a director, officer or trustee, or in any other capacity while serving as a director, officer or trustee (an &#8220;indemnitee&#8221;). The Oruka Bylaws also provide that an indemnitee will have the right to be paid by Oruka expenses (including attorney&#8217;s fees) incurred in defending any such proceeding in advance of its final disposition, provided, however, that, if the DGCL requires, an advancement of expenses incurred by an indemnitee in his or her capacity as a director or officer shall be made only upon delivery to Oruka of an undertaking, by or on behalf of such indemnitee, to repay all amounts so advanced if it shall ultimately be determined by final judicial decision from which there is no further right to appeal that such indemnitee is not entitled to be indemnified for such expenses. The Oruka Bylaws also provide that the rights to indemnification and advance of expenses shall not be exclusive of any other right which any person may have or hereafter acquire under any statute, the Oruka Charter, the Oruka Bylaws, agreement, vote of stockholders or disinterested directors or otherwise.</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 100.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;"><span class="Italic" style="font-style:italic;font-weight:normal;">Conversion Rights</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-24" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">ARCA does not have any outstanding shares of Series&#160;A Convertible Preferred Stock or undesignated preferred stock. When the Series&#160;B Non<span class="nobreak">-Voting</span> Convertible Preferred Stock is issued in connection with the Merger, the holders of Series&#160;B Non<span class="nobreak">-Voting</span> Convertible Preferred Stock will have the right to convert such shares into ARCA common stock at any time a ratio of 1<span class="nobreak"> </span>share of Series&#160;B Non<span class="nobreak">-Voting</span> Convertible Preferred Stock to 1000<span class="nobreak"> </span>shares of ARCA common stock.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">The Oruka Charter provides that holders of preferred stock have the right to convert such shares into shares of common stock, at the option of the holder, at any time, at a conversion rate in accordance with the terms set forth in the Oruka Charter. In addition, upon the earliest to occur of (i)&#160;immediately prior to the closing of the sale of shares of common stock to the public at a price of at least $1.00 per share (subject to appropriate adjustment for any stock dividend, stock split, combination or other similar recapitalization with respect to the common stock) in a firm<span class="nobreak">-commitment</span> underwritten public offering pursuant to an effective registration statement under the Securities Act, resulting in at least $50,000,000 of gross proceeds to Oruka and in connection with such offering the shares of Oruka common stock are listed for trading on the Nasdaq Stock Market&#8217;s National Market, the New&#160;York Stock Exchange or another exchange or marketplace approved by Oruka&#8217;s board of directors; and (ii)&#160;the date and time, or the occurrence of an event, specified by vote or written consent of the Requisite Holders, all outstanding shares of preferred stock will automatically be converted into shares of common stock, at the then effective conversion rate as calculated in accordance with the Oruka Charter.</p>
					</td>
				</tr>

		</table>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">308</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">



						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Oruka</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 100.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;"><span class="Italic" style="font-style:italic;font-weight:normal;">Right of First Refusal</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-25" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">ARCA does not have a right of first refusal in place.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Certain stockholders party to the Oruka ROFR Agreement wishing to transfer any shares of Oruka capital stock (other than any shares of preferred stock or common stock that are issued or issuable upon conversion of preferred stock) must first provide Oruka with the right to purchase such shares. In such an event, if Oruka does not elect to exercise its right of first refusal in full, certain stockholders party to the Oruka ROFR Agreement have a secondary refusal right to purchase all or any portion of such shares of Oruka capital stock which are proposed for sale or transfer and not purchased by Oruka pursuant to its right of first refusal.</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 100.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;"><span class="Italic" style="font-style:italic;font-weight:normal;">Right of Co</span><span class="nobreak"><span class="Italic" style="font-style:italic;font-weight:normal;">-Sale</span></span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-26" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">ARCA does not have a right of co<span class="nobreak">-sale</span> in place.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Certain stockholders party to the Oruka ROFR Agreement have a right of co<span class="nobreak">-sale</span> with respect to any Oruka capital stock proposed to be transferred or sold that is not either purchased by Oruka by exercise of its right of first refusal (as further described above) or by any Oruka stockholder by exercise of their secondary refusal right (as further described above), each pursuant to the Oruka ROFR Agreement.</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 100.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;"><span class="Italic" style="font-style:italic;font-weight:normal;">Preemptive Rights</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">ARCA stockholders do not have preemptive rights. Thus, if additional shares of ARCA common stock are issued, the current holders of ARCA common stock will own a proportionately smaller interest in a larger number of outstanding shares of common stock to the extent that they do not participate in the additional issuance.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Pursuant to the Oruka IRA, if Oruka proposes to offer or sell certain new equity securities, Oruka must first offer such securities to each Major Investor (as defined in the Oruka IRA, who will then have a right to purchase securities in such new offering equal to the proportion of the ownership interest of such Major Investor prior to such offering.</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 100.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;"><span class="Italic" style="font-style:italic;font-weight:normal;">Distributions to Stockholders</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-27" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Dividends upon ARCA capital stock, subject to the provisions of the ARCA Charter and applicable law, if any, may be declared by ARCA&#8217;s board of directors. Dividends may be paid in cash, in property, or in shares of the capital stock, subject to the provisions of the ARCA Charter and applicable law. ARCA&#8217;s board of directors may fix a record date for the determination of holders of ARCA capital stock entitled to receive payment of a dividend or distribution declared thereon, which record date shall not precede the date upon which the resolution fixing the record date is adopted, and which record date may not be more than 60&#160;days prior to the date fixed for the payment thereof.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Oruka shall not declare, pay or set aside any dividends (other than dividends on shares of common stock payable in shares of common stock) unless holders of preferred stock first receive, or simultaneously receive, a dividend on each outstanding share of preferred stock in an amount calculated in accordance with the Oruka Charter.</p>
					</td>
				</tr>

		</table>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">309</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">



						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Oruka</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 100.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;"><span class="Italic" style="font-style:italic;font-weight:normal;">Exclusive Forum</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-28" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">ARCA does not have an exclusive forum in place.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">The Oruka Charter provides that, unless Oruka consents in writing to the selection of an alternative forum, the Court of Chancery in the State of Delaware shall be the sole and exclusive forum for any stockholder (including a beneficial owner) to bring (i)&#160;any derivative action or proceeding brought on behalf of Oruka, (ii)&#160;any action asserting a claim of breach of fiduciary duty owed by any director, officer or other employee of Oruka to Oruka or Oruka&#8217;s stockholders, (iii)&#160;any action asserting a claim against Oruka, its directors, officers or employees arising pursuant to any provision of the DGCL, the Oruka Charter or the Oruka Bylaws or (iv)&#160;any action asserting a claim against Oruka, its directors, officers or employees governed by the internal affairs doctrine or that otherwise relates to the internal affairs of Oruka, except for, as to each of (i)&#160;through (iv)&#160;above, any claim as to which the Court of Chancery determines that there is an indispensable party not subject to the jurisdiction of the Court of Chancery (and the indispensable party does not consent to the personal jurisdiction of the Court of Chancery within ten&#160;days following such determination), which is vested in the exclusive jurisdiction of a court or forum other than the Court of Chancery, or for which the Court of Chancery does not have subject matter jurisdiction. These provisions may impose additional costs on Oruka&#8217;s stockholders in pursuing any such claims, particularly if the stockholders do not reside in or near the State of Delaware or were permitted to select another jurisdiction. Additionally, these provisions may limit Oruka&#8217;s stockholders&#8217; ability to bring a claim in a judicial forum that they find favorable for disputes with Oruka or its directors, officers or other employees, which may discourage such lawsuits against Oruka and its directors, officers and other employees even though an action, if successful, might benefit its stockholders.</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 100.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;"><span class="Italic" style="font-style:italic;font-weight:normal;">Registration Rights</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">ARCA does not have any registration rights in place.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Under the Oruka IRA, certain holders of Oruka capital stock that are party to the Oruka IRA, have certain registration rights, including the right to demand that Oruka file a registration statement, so called &#8220;demand&#8221; registration rights, or request that their shares be covered by a registration statement that Oruka is otherwise filing, so<span class="nobreak">-called</span> &#8220;piggyback&#8221; registration rights. The registration rights granted under the Oruka IRA will terminate upon the earlier of: (i)&#160;the closing of a Deemed Liquidation Event (as such term is defined in the Oruka Charter), (ii)&#160;such time after Oruka&#8217;s initial public offering when all registrable securities could be sold under Rule&#160;144 of the Securities Act or a similar exemption without limitation during a three<span class="nobreak">-month</span> period without registration or (iii)&#160;the third anniversary of Oruka&#8217;s initial public offering.</p>
					</td>
				</tr>

		</table>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">310</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">



						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Oruka</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 100.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;"><span class="Italic" style="font-style:italic;font-weight:normal;">Stock Transfer Restrictions Applicable to Stockholders</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-29" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Shares of ARCA are transferable in the manner prescribed by the DGCL.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Shares of Oruka are transferable in the manner prescribed by the DGCL, subject to additional limits on certain holders of Oruka capital stock party to the Oruka ROFR Agreement and Oruka IRA.</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 100.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;"><span class="Italic" style="font-style:italic;font-weight:normal;">Stockholder Rights Plan</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-30" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">ARCA does not have a stockholder rights plan in place.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Oruka does not have a stockholder rights plan in place.</p>
					</td>
				</tr>

		</table>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">311</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T6"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">PRINCIPAL STOCKHOLDERS OF ARCA</span></p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Security Ownership of Certain Beneficial Owners</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following table sets forth certain information regarding the ownership of ARCA common stock as of May&#160;3, 2024, by: (i)&#160;each director of ARCA, (ii)&#160;each ARCA named executive officer, (iii)&#160;all executive officers and directors of ARCA as a group and (iv)&#160;all those known by ARCA to be beneficial owners of more than five percent of its common stock. Unless otherwise noted below, the address of each beneficial owner listed on the table is c/o ARCA biopharma, Inc., 10170 Church Ranch Way, Suite 100, Westminster, Colorado, 80021.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA has determined beneficial ownership in accordance with the rules of the SEC and includes voting or investment power with respect to ARCA common stock. Except as indicated by the footnotes below, ARCA believes, based on the information furnished to it, that the persons and entities named in the table below have sole voting and investment power with respect to all shares of ARCA common stock that they beneficially own, subject to applicable community property laws. The table is based upon information supplied by officers, directors and principal stockholders of ARCA and Schedules 13G or 13D, Form&#160;4s or other ownership reports filed with the SEC.&#160;Except as contemplated by the Merger and the Merger Agreement, ARCA does not know of any arrangements, including any pledge by any person of its securities, the operation of which may at a subsequent date result in a change of control of ARCA.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In computing the number of shares of ARCA common stock beneficially owned by a person and the percentage ownership of that person, ARCA deemed outstanding shares of ARCA common stock subject to options or warrants held by that person that are currently exercisable or exercisable within 60&#160;days of May&#160;3, 2024. ARCA did not deem these shares outstanding, however, for the purpose of computing the percentage ownership of any other person.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;orphans:99;widows:1;margin-top:8pt;">The percentages below are based on 14,507,143<span class="nobreak"> </span>shares of ARCA common stock outstanding as of May&#160;3, 2024.</p>
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 3pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">



						<p class="TCH_left" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Beneficial Owner</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Shares <br/>Beneficially<br/>Owned</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Percentage<br/>Shares <br/>Beneficially<br/>Owned</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Directors and Named Executive Officers</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Michael R.&#160;Bristow, M.D., Ph.D.<span class="Superscript" style="vertical-align:super;font-size:58%;">(1)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">254,274</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1.7</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Thomas A.&#160;Keuer<span class="Superscript" style="vertical-align:super;font-size:58%;">(2)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">133,521</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">*</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">C.&#160;Jeffrey Dekker<span class="Superscript" style="vertical-align:super;font-size:58%;">(3)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">97,146</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">*</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Linda Grais, M.D.<span class="Superscript" style="vertical-align:super;font-size:58%;">(4)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">21,895</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">*</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Robert E.&#160;Conway<span class="Superscript" style="vertical-align:super;font-size:58%;">(5)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">71,895</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">*</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Anders Hove, M.D.<span class="Superscript" style="vertical-align:super;font-size:58%;">(6)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">21,499</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">*</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Jacob Ma-Weaver<span class="Superscript" style="vertical-align:super;font-size:58%;">(7)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4,016,952</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">27.7</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">James Flynn<span class="Superscript" style="vertical-align:super;font-size:58%;">(8)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">8,500</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">*</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">All current directors and executive officers as a group (7 persons)</span><span class="Superscript" style="vertical-align:super;font-size:58%;font-style:normal;font-weight:bold;">(9)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4,371,408</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">29.6</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">5% Stockholders</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Funicular Funds, LP<span class="Superscript" style="vertical-align:super;font-size:58%;">(10)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4,016,952</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">27.7</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Entities affiliated with Adage Capital<span class="Superscript" style="vertical-align:super;font-size:58%;">(11)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,200,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">8.3</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Entities affiliated with Janus Henderson<span class="Superscript" style="vertical-align:super;font-size:58%;">(12)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,080,107</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">7.5</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Entities affiliated with Allostery Investments<span class="Superscript" style="vertical-align:super;font-size:58%;">(13)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,065,016</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">7.3</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Entities affiliated with Avidity Partners<span class="Superscript" style="vertical-align:super;font-size:58%;">(14)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,000,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">6.9</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Entities affiliated with Venrock<span class="Superscript" style="vertical-align:super;font-size:58%;">(15)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">754,669</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5.2</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>

		</table>
		<p class="Tablefootnotef" style="margin-top: 0in;  border: none; margin-right: 0in; margin-bottom: -5pt; margin-left: 24.0pt; text-align: justify; text-justify: inter-ideograph; text-indent: -24.0pt; padding: 0in; font-size: 9.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">____________</p><p class="Tablefootnote_f" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:10pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:10pt;">*<span style="width: 24px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Less than 1%.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(1)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Includes the following: (i)&#160;1,109<span class="nobreak"> </span>shares owned by Investocor Trust, of which Dr.&#160;Bristow is the sole trustee; (ii)&#160;1,414<span class="nobreak"> </span>shares owned by NFS as Custodian for Michael Bristow&#8217;s IRA; and (iii)&#160;options to purchase 249,466<span class="nobreak"> </span>shares that are exercisable within 60&#160;days of May&#160;3, 2024.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(2)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Includes options to purchase 92,791<span class="nobreak"> </span>shares that are exercisable within 60&#160;days of May&#160;3, 2024.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(3)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Includes options to purchase 57,146<span class="nobreak"> </span>shares that are exercisable within 60&#160;days of May&#160;3, 2024.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">312</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(4)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Includes options to purchase 21,895<span class="nobreak"> </span>shares that are exercisable within 60&#160;days of May&#160;3, 2024.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(5)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Includes options to purchase 21,895<span class="nobreak"> </span>shares that are exercisable within 60&#160;days of May&#160;3, 2024.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(6)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Includes options to purchase 21,499<span class="nobreak"> </span>shares that are exercisable within 60&#160;days of May&#160;3, 2024.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(7)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Includes options to purchase 16,500<span class="nobreak"> </span>shares that are exercisable within 60&#160;days of May&#160;3, 2024. Also see Footnote (10)&#160;below.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(8)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Includes options to purchase 8,500<span class="nobreak"> </span>shares that are exercisable within 60&#160;days of May&#160;3, 2024.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(9)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>See Notes (2)&#160;through (8)&#160;above.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(10)<span style="width: 12px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Includes options to purchase 16,500<span class="nobreak"> </span>shares that are exercisable within 60&#160;days of May&#160;3, 2024 by Jacob Ma<span class="nobreak">-Weaver</span> and shares reported on the Form&#160;4 filed on December&#160;19, 2022 by The Funicular Funds, LP (the &#8220;Fund&#8221;) and Mr.&#160;Ma<span class="nobreak">-Weaver</span>, reporting stock ownership as of December&#160;16, 2022. The Fund, the Funicular Fund (&#8220;Funicular&#8221;), Cable Car Capital LLC (&#8220;Cable Car&#8221;) and Mr.&#160;Ma<span class="nobreak">-Weaver</span> may be deemed to be a member of a Section&#160;13(d)&#160;group that may be deemed to collectively beneficially own more than 10% of ARCA&#8217;s outstanding shares of common stock. Despite such shared beneficial ownership, the reporting persons disclaim beneficial ownership of the securities except to the extent of their pecuniary interest therein. Funicular, as a feeder fund to the Fund, may be deemed to beneficially own the securities directly owned by the Fund. Cable Car, as the general partner of the Fund, may be deemed to beneficially own the securities directly owned by the Fund. Mr.&#160;Ma<span class="nobreak">-Weaver</span>, as the Managing Member of Cable Car, may be deemed to beneficially own the securities directly owned by the Fund.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(11)<span style="width: 12px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Based solely on a Schedule&#160;13D filed on April&#160;5, 2024 reporting stock ownership as of April&#160;3, 2024 with respect to the following reporting persons: Adage Capital Management, L.P. (&#8220;ACM&#8221;), Robert Atchinson, and Phillip Gross. ACM and Messrs. Consists of 1,200,000 shares of ARCA common stock held directly by Adage Capital Partners, L.P. (&#8220;ACP&#8221;). Adage Capital Partners GP, L.L.C. (&#8220;ACPGP&#8221;) is the general partner of ACP. ACM is the investment manager of ACP. Adage Capital Advisors, L.L.C. (&#8220;ACA&#8221;) is managing member of ACPGP. Adage Capital Partners LLC (&#8220;ACPLLC&#8221;) is general partner of ACM. Messrs. Atchinson and Gross are managing members of ACA and ACPLLC. Messrs. Atchinson and Gross may be deemed to have shared voting power and dispositive power over the shares held directly by ACP. The address of each of the entities and persons listed above is 200&#160;Clarendon Street, 52<span class="CharOverride-3" style="font-size:58%;vertical-align:super;">nd</span> Floor, Boston, Massachusetts 02116.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(12)<span style="width: 12px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Based solely on a Schedule&#160;13G filed on April&#160;11, 2024 reporting stock ownership as of April&#160;3, 2024 with respect to the following reporting persons: Janus Henderson Group plc (&#8220;JHG&#8221;) and Janus Henderson Biotech Innovation Master Fund Ltd (&#8220;JHB&#8221;). JHG and JHB each reported that they hold shared voting power and shared dispositive power with respect to 1,080,107 shares of ARCA common stock. JHG has a 100% ownership stake in Janus Henderson Investors U.S.&#160;LLC (&#8220;JHIUS&#8221;), Janus Henderson Investors UK Limited and Janus Henderson Investors Australia Institutional Funds Management Limited, (each an &#8220;Asset Manager&#8221; and collectively as the &#8220;Asset Managers&#8221;). Due to the above ownership structure, holdings for the Asset Managers are aggregated for purposes of this filing. Each Asset Manager is an investment adviser registered or authorized in its relevant jurisdiction and each furnishing investment advice to various fund, individual and/or institutional clients (collectively referred to herein as &#8220;Managed Portfolios&#8221;). As a result of its role as investment adviser or sub<span class="nobreak">-adviser</span> to the Managed Portfolios, JHIUS may be deemed to be the beneficial owner of 1,080,107 shares of ARCA common stock held by such Managed Portfolios. However, JHIUS does not have the right to receive any dividends from, or the proceeds from the sale of, the securities held in the Managed Portfolios and disclaims any ownership associated with such rights. The address of JHG is 201 Bishopsgate, EC2M 3AE, United Kingdom, and the address of JHB is C/O Janus Henderson Investors US LLC, 151 Detroit Street, Denver, Colorado 80206.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(13)<span style="width: 12px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Based solely on a Schedule&#160;13G filed on April&#160;15, 2024 reporting stock ownership as of April&#160;3, 2024 with respect to the following reporting persons: Allostery Master Fund LP (&#8220;Allostery Master Fund&#8221;), Allostery Investments LP (&#8220;Allostery Investments&#8221;), Allostery Investments GP LLC (&#8220;Allostery Investments GP&#8221;), Christopher Staral, and David Modest. Allostery Master Fund, Allostery Investments LP, Allostery Investments GP, and Messrs. Staral and Modest each reported that they hold shared voting power and shared dispositive power with respect to 1,065,016 shares of ARCA common stock. Allostery Investments, as the investment manager of Allostery Master Fund, may be deemed to have beneficially owned the 1,065,016 shares beneficially owned by Allostery Master Fund. Allostery Investments GP, as the general partner of Allostery Investments, may be deemed to have beneficially owned the 1,065,016 shares beneficially owned by Allostery Investments. Messrs. Modest and Staral, as the managing members of Allostery Investments GP, may be deemed to have beneficially owned the 1,065,016 shares beneficially owned by Allostery Investment GP.&#160;The address of each of the entities and persons listed above is One Stamford Plaza, 9<span class="CharOverride-3" style="font-size:58%;vertical-align:super;">th</span> Floor, 263 Tresser Boulevard, Stamford, Connecticut 06901.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(14)<span style="width: 12px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Based solely on a Schedule&#160;13G filed on April&#160;9, 2024 reporting stock ownership as of April&#160;3, 2024 with respect to the following reporting persons: Avidity Partners Management LP, Avidity Partners Management (GP) LLC, Avidity Capital Partners Fund (GP) LP, Avidity Capital Partners (GP) LLC, Avidity Private Master Fund&#160;I LP, David Witzke, and Michael Gregory, which each reported that they hold shared voting power and shared dispositive power with respect to 1,000,000 shares of ARCA common stock. Avidity Partners Management (GP) LLC serves as the general partner of Avidity Partners Management LP. Avidity Capital Partners Fund (GP) LP serves as the general partner of Avidity Private Master Fund I LP. Avidity Capital Partners (GP) LLC serves as the general partner of Avidity Capital Partners Fund (GP) LP. Messrs. Witzke and Gregory serve as the managing members of Avidity Partners Management (GP) LLC and Avidity Capital Partners (GP) LLC. The address of each of the entities and persons listed above is 2828 N Harwood Street, Suite 1220, Dallas, Texas 75201.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">313</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(15)<span style="width: 12px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Based solely on a Schedule&#160;13G filed on April&#160;29, 2024 reporting stock ownership as of April&#160;17, 2024 with respect to the following reporting persons: Venrock Healthcare Capital Partners&#160;III, L.P., VHCP Co<span class="nobreak">-Investment</span> Holdings&#160;III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management&#160;III, LLC, VHCP Management EG, LLC, Nimish Shah, and Bong Koh, which each reported that they hold shared voting power and shared dispositive power with respect to 754,669 shares of ARCA common stock, consisting of (i)&#160;164,442 shares held by Venrock Healthcare Capital Partners&#160;III, L.P., (ii)&#160;16,450 shares held by VHCP Co<span class="nobreak">-Investment</span> Holdings&#160;III, LLC, and (iii)&#160;573,777 shares held by Venrock Healthcare Capital Partners EG, L.P.&#160;VHCP Management&#160;III, LLC is the general partner of Venrock Healthcare Capital Partners&#160;III, L.P. and the manager of VHCP Co<span class="nobreak">-Investment</span> Holdings&#160;III, LLC.&#160;VHCP Management EG, LLC is the general partner of Venrock Healthcare Capital Partners EG, L.P.&#160;Messrs. Shah and Koh are the voting members of VHCP Management&#160;III, LLC and VHCP Management EG, LLC.&#160;The address of each of the entities and persons listed above is 7&#160;Bryant Park, 23<span class="CharOverride-3" style="font-size:58%;vertical-align:super;">rd</span> Floor, New&#160;York, New&#160;York 10018.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">314</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T5"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">PRINCIPAL STOCKHOLDERS OF ORUKA</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following table sets forth certain information known to Oruka regarding beneficial ownership of Oruka capital stock on an as<span class="nobreak">-converted</span> to Oruka common stock basis as of May&#160;3, 2024 for:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>each person or group of affiliated persons, who is known by Oruka to be the beneficial owner of more than 5% of Oruka capital stock;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>each of Oruka&#8217;s directors;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>each Oruka named executive officer; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>all of Oruka&#8217;s directors and executive officers and directors as a group.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Beneficial ownership is determined in accordance with the rules of the SEC and thus represents voting or investment power with respect to Oruka&#8217;s securities. Under such rules, beneficial ownership includes any shares over which the individual has sole or shared voting power or investment power as well as any shares that the individual has the right to acquire within 60&#160;days of May&#160;3, 2024. Shares of Oruka&#160;common stock that an individual has the right to acquire within 60&#160;days of May&#160;3, 2024 are deemed to be outstanding and beneficially owned by the individual for the purpose of computing the percentage ownership of that individual, but they are not treated as outstanding for the purpose of computing the percentage ownership of any other person. To Oruka&#8217;s knowledge and subject to applicable community property rules, and except as otherwise indicated below, the persons and entities named in the table have sole voting and sole investment power with respect to all shares beneficially owned. The percentage of beneficial ownership shown prior to the Merger and Oruka&#160;pre<span class="nobreak">-closing</span>&#160;financing in the table below is based on 29,460,019<span class="nobreak"> </span>shares of Oruka&#160;common stock deemed to be outstanding as of May&#160;3, 2024, assuming the conversion of all outstanding shares of Oruka&#160;preferred stock into shares of Oruka&#160;common stock. The following table does not reflect any shares of Oruka&#160;common stock or Oruka&#160;pre<span class="nobreak">-funded</span> warrants that such holders have agreed to purchase in the Oruka&#160;pre<span class="nobreak">-closing</span>&#160;financing.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Unless otherwise indicated, the address for each beneficial owner is c/o Oruka Therapeutics, Inc., 855 Oak Grove Ave., Suite 100, Menlo Park, CA 94025.</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 3pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">



						<p class="TCH_left" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Name of Beneficial Owner</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Number&#160;of <br/>Shares <br/>Beneficially <br/>Owned</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Percentage <br/>of&#160;Shares <br/>Outstanding <br/>Beneficially <br/>Owned</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Fairmount Healthcare Fund&#160;II, L.P.<span class="Superscript" style="vertical-align:super;font-size:58%;">(1)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">20,000,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">67.9</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Paragon Therapeutics, Inc.<span class="Superscript" style="vertical-align:super;font-size:58%;">(2)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,500,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">8.5</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Paruka Holding LLC<span class="Superscript" style="vertical-align:super;font-size:58%;">(3)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,500,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">8.5</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">McKenna Capital Partners LLC<span class="Superscript" style="vertical-align:super;font-size:58%;">(4)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,491,646</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5.1</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Named Executive Officers and Directors:</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Lawrence Klein<span class="Superscript" style="vertical-align:super;font-size:58%;">(5)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,491,646</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5.1</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Arjun Agarwal</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">*</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Cameron Turtle<span class="Superscript" style="vertical-align:super;font-size:58%;">(6)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">149,164</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">*</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Samarth Kulkarni</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">*</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Peter Harwin<span class="Superscript" style="vertical-align:super;font-size:58%;">(1)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">20,000,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">67.9</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Carl Dambkowski</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">*</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Kristine Ball</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">*</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">All executive officers and directors as a group (9 persons)<span class="Superscript" style="vertical-align:super;font-size:58%;">(7)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">21,640,810</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">73.5</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>

		</table>
		<p class="Tablefootnotef" style="margin-top: 0in;  border: none; margin-right: 0in; margin-bottom: -5pt; margin-left: 24.0pt; text-align: justify; text-justify: inter-ideograph; text-indent: -24.0pt; padding: 0in; font-size: 9.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">____________</p><p class="Tablefootnote_f" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:10pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:10pt;">*<span style="width: 24px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Less than 1%.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(1)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Consists of 20,000,000<span class="nobreak"> </span>shares of Oruka common stock issuable upon conversion of 20,000,000 Oruka Series&#160;A Preferred Stock held by Fairmount Fund&#160;II.&#160;Fairmount GP&#160;II is the general partner of Fairmount Fund&#160;II.&#160;Fairmount Funds Management, as the investment manager, along with Fairmount GP&#160;II, as the general partner, exercise voting and investment power over Fairmount Fund&#160;II.&#160;Fairmount Funds Management has voting and dispositive power over the common stock held by Fairmount Fund&#160;II, which is deemed shared with Fairmount GP&#160;II.&#160;As managing members of </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">315</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;text-indent:0pt;margin-top:0pt;">Fairmount Funds Management and Fairmount GP&#160;II, Peter Harwin and Tomas Kiselak may be deemed beneficial owners of any securities beneficially owned by Fairmount Funds Management. Fairmount Funds Management, Fairmount GP&#160;II, Mr.&#160;Harwin and Mr.&#160;Kiselak disclaim beneficial ownership of such shares of Oruka Series&#160;A Preferred Stock and the underlying shares of Oruka common stock except to the extent of their pecuniary interest therein. The principal business address for these persons and entities is 200 Barr Harbor Drive, Suite 400, West Conshohocken, Pennsylvania 19428.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(2)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Consists of 2,500,000<span class="nobreak"> </span>shares of Oruka common stock held by Paragon. Paragon is managed by its board of directors, consisting of Peter Harwin, Tomas Kiselak, and Evan Thompson.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(3)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Consists of 2,500,000<span class="nobreak"> </span>shares of Oruka common stock held by Paruka. Paruka is managed by its sole manager, Evan Thompson.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(4)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Consists of 1,491,646<span class="nobreak"> </span>shares of Oruka common stock held by McKenna Capital Partners LLC (&#8220;McKenna Capital Partners&#8221;). Mark McKenna is the Chief Investment Officer and Managing Director of McKenna Capital Partners, a family office. Mr.&#160;McKenna disclaims beneficial ownership of such shares of Oruka common stock except to the extent of his pecuniary interest therein. The principal business address for these persons and entities is PO Box 9542, Rancho, Santa Fe, CA 92067.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(5)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Consists of 1,491,646<span class="nobreak"> </span>shares of Oruka common stock held by Lawrence Klein.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(6)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Consists of 149,164<span class="nobreak"> </span>shares of Oruka common stock held by Turtle Family Trust, of which Cameron Turtle is a trustee.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(7)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Consists of (i)&#160;20,000,000<span class="nobreak"> </span>shares of Oruka common stock issuable upon conversion of 20,000,000<span class="nobreak"> </span>shares of Oruka Series&#160;A Preferred Stock and (ii)&#160;1,640,810<span class="nobreak"> </span>shares of Oruka common stock.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">316</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T4"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">PRINCIPAL STOCKHOLDERS OF THE COMBINED COMPANY</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Except where specifically noted, the following information and all other information contained in this proxy statement/prospectus does not give effect to the proposed reverse stock split described in Proposal&#160;No. 3 of this proxy statement/prospectus</span>.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following table sets forth certain information regarding beneficial ownership of the combined company&#8217;s common stock immediately after consummation of the Merger, assuming the consummation of the Merger occurred on<span style="width: 10px;display: inline-block;">&#160;&#160;&#160;</span><span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>, 2024 for:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>each person or group of affiliated persons, who is expected by ARCA and Oruka to be the beneficial owner of more than 5% of the combined company&#8217;s common stock;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>each person expected to be a director of the combined company;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>each person expected to be a named executive officer of the combined company; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>all of the combined company&#8217;s excepted directors and executive officers and directors as a group.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Beneficial ownership is determined in accordance with the rules of the SEC and thus represents voting or investment power with respect to the combined company&#8217;s securities. Under such rules, beneficial ownership includes any shares over which the individual or entity has sole or shared voting power or investment power as well as any shares that the individual has the right to acquire within 60&#160;days of<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span><span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>, 2024. Shares of the combined company&#8217;s common stock that an individual or entity has the right to acquire within 60&#160;days of&#160;&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>, 2024 are deemed to be outstanding and beneficially owned by the individual or entity for the purpose of computing the percentage ownership of that individual, but they are not treated as outstanding for the purpose of computing the percentage ownership of any other person. To ARCA&#8217;s and Oruka&#8217;s knowledge and subject to applicable community property rules, and except as otherwise indicated below, the persons and entities named in the table have sole voting and sole investment power with respect to all shares beneficially owned.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The table lists applicable percentage ownership based on<span style="width: 10px;display: inline-block;">&#160;&#160;&#160;</span><span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>shares of common stock expected to be outstanding upon consummation of the merger, after giving effect to the anticipated ARCA reverse stock split and the Oruka pre<span class="nobreak">-closing</span> financing. The number of shares beneficially owned includes shares of common stock that each person has the right to acquire within 60&#160;days, including upon the exercise of stock options and warrants. These stock options and warrants shall be deemed to be outstanding for the purpose of computing the percentage of outstanding shares of the combined company&#8217;s common stock expected to be owned by such person but shall not be deemed to be outstanding for the purpose of computing the percentage of outstanding shares of the combined organization&#8217;s common stock expected to be owned by any other person.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Immediately after the Merger, ARCA securityholders as of immediately prior to the Merger are expected to own approximately 2.39% of the outstanding shares of capital stock of the combined company (on a fully<span class="nobreak">-diluted</span> basis), and former holders of Oruka securities are expected to own approximately 97.61% of the outstanding shares of capital stock of the combined company (on a fully<span class="nobreak">-diluted</span> basis), subject to certain assumptions, including, but not limited to, subject to certain assumptions, including, but not limited to, ARCA&#8217;s net cash as of closing being equal to $5.0&#160;million. ARCA management currently anticipates ARCA&#8217;s net cash as of closing will be approximately $5.0&#160;million, after giving effect to the special cash dividend, which is expected to be approximately $20.0<span class="nobreak"> </span>million, and the currently estimated ownership percentages reflect this projection. There can be no assurances any of these assumptions will be accurate at closing when the final exchange ratio is determined. The table below assumes that, based on ARCA&#8217;s and Oruka&#8217;s capitalization as of May&#160;3, 2024, the date the Merger Agreement was executed, the exchange ratio is estimated to be equal to approximately 7.4631<span class="nobreak"> </span>shares of ARCA common stock, prior to giving effect to the anticipated ARCA reverse stock split. The estimated exchange ratio was derived on a fully<span class="nobreak">-diluted</span> basis as of May&#160;3, 2024, using a stipulated value of Oruka of approximately $175.0&#160;million and of ARCA of approximately $11.0<span class="nobreak"> </span>million, assuming net cash of $5.0&#160;million as of closing. The final exchange ratio is subject to adjustment prior to closing of the Merger based upon ARCA&#8217;s net cash at closing and the aggregate proceeds from the sale of Oruka common stock and Oruka pre<span class="nobreak">-funded</span> warrants in the Oruka pre<span class="nobreak">-closing</span> financing.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">317</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;orphans:99;widows:1;margin-top:8pt;">Unless otherwise indicated, the address for each beneficial owner is c/o Oruka Therapeutics, Inc., 855 Oak Grove Ave., Suite 100, Menlo Park, CA 94025.</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 3pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">



						<p class="TCH_left" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Name of Beneficial Owner</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Number&#160;of <br/>Shares <br/>Beneficially <br/>Owned</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Percentage <br/>of&#160;Shares <br/>Outstanding <br/>Beneficially <br/>Owned</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">All executive officers and directors as a group (<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span> persons)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">%</p>
					</td>
				</tr>

		</table>
		<p class="Tablefootnotef" style="margin-top: 0in;  border: none; margin-right: 0in; margin-bottom: -5pt; margin-left: 24.0pt; text-align: justify; text-justify: inter-ideograph; text-indent: -24.0pt; padding: 0in; font-size: 9.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">____________</p><p class="Tablefootnote_f" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:10pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:10pt;">*<span style="width: 24px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Less than 1%. </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">318</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T3"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">LEGAL MATTERS</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Wilson Sonsini Goodrich&#160;&amp; Rosati, P.C. will pass upon the validity of ARCA&#8217;s common stock offered by this proxy statement/prospectus.</p>
		<a id="T2"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">EXPERTS</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The financial statements of ARCA biopharma, Inc. as of December&#160;31, 2023 and 2022 and for each of the&#160;years in the two<span class="nobreak">-year</span> period ended December&#160;31, 2023, have been included herein in reliance upon the report of KPMG LLP, independent registered public accounting firm, appearing elsewhere herein, and upon the authority of said firm as experts in accounting and auditing.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The financial statement of Oruka Therapeutics, Inc. as of February&#160;6, 2024 included in this proxy statement/prospectus has been so included in reliance on the report (which contains an explanatory paragraph relating to Oruka&#8217;s ability to continue as a going concern as described in Note&#160;1 to the financial statement) of PricewaterhouseCoopers LLP, an independent registered public accounting firm, given on the authority of said firm as experts in auditing and accounting.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">319</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T1"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">WHERE YOU CAN FIND MORE INFORMATION</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA is subject to the informational requirements of the Exchange&#160;Act and in accordance therewith, files annual, quarterly and current reports, proxy statements and other information with the SEC electronically, and the SEC maintains a website that contains ARCA&#8217;s filings as well as reports, proxy and information statements, and other information issuers file electronically with the SEC at <span class="Italic" style="font-style:italic;font-weight:normal;">www.sec.gov</span>.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA also makes available free of charge on or through its website at <span class="Italic" style="font-style:italic;font-weight:normal;">www.arcabio.com</span>, its Annual Reports on Form&#160;10<span class="nobreak">-K</span>, Quarterly Reports on Form&#160;10<span class="nobreak">-Q</span>, Current Reports on Form&#160;8<span class="nobreak">-K</span> and amendments to those reports filed or furnished pursuant to Section&#160;13(a)&#160;or 15(d)&#160;of the Exchange&#160;Act as soon as reasonably practicable after ARCA electronically files such material with or otherwise furnishes it to the SEC.&#160;The website addresses for the SEC and ARCA are inactive textual references and except as specifically incorporated by reference into this proxy statement/prospectus, information on those websites is not part of this proxy statement/prospectus.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA has filed with the SEC a registration statement on Form&#160;S<span class="nobreak">-4</span>, of which this proxy statement/prospectus is a part, under the Securities Act to register the shares of ARCA common stock (including the shares of ARCA common stock issuable upon conversion of ARCA Series&#160;B Preferred Stock) to be issued to Oruka stockholders in the Merger. The registration statement, including the attached annexes, exhibits and schedules, contains additional relevant information about ARCA and ARCA common stock. This proxy statement/prospectus does not contain all of the information set forth in the registration statement because certain parts of the registration statement are omitted in accordance with the rules and regulations of the SEC.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA has supplied all information contained in this proxy statement/prospectus relating to ARCA and Oruka has supplied all information contained in this proxy statement/prospectus relating to Oruka.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If you would like to request documents from ARCA or Oruka, please send a request in writing or by telephone to either ARCA or Oruka at the following addresses:</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">



						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">ARCA biopharma, Inc.<br/>10170 Church Ranch Way, Suite 100<br/>Westminster, CO&#160;80021<br/>Attn: Corporate Secretary<br/>Tel: (720)&#160;940-2100</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">Oruka Therapeutics, Inc.<br/>855 Oak Grove Ave., Suite 100 <br/>Menlo Park, CA 94025 <br/>Attn: Secretary<br/>Tel: (650)&#160;606<span class="nobreak">-7910</span></p>
					</td>
				</tr>

		</table>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If you are a ARCA stockholder and would like additional copies, without charge, of this proxy statement/prospectus or if you have questions about the Merger, including the procedures for voting your shares, you should contact ARCA&#8217;s proxy solicitor, <span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>, at the following address and telephone number:</p>
		<p class="Text_ind_center" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:3;margin-top:8pt;">Banks and Brokers Call:<br/>Stockholders Call Toll Free: </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">320</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<a id="T9991"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">STOCKHOLDER PROPOSALS OR DIRECTOR NOMINATIONS FOR&#160;2025 ANNUAL MEETING</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If an ARCA stockholder would like ARCA to consider including a proposal in ARCA&#8217;s proxy statement for its 2025 annual meeting pursuant to Rule&#160;14a<span class="nobreak">-8</span> of the Exchange&#160;Act, then the proposal must be received by ARCA&#8217;s corporate secretary at ARCA&#8217;s principal executive offices on or before&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2025. In addition, stockholder proposals must comply with the requirements of Rule&#160;14a<span class="nobreak">-8</span> regarding the inclusion of stockholder proposals in company<span class="nobreak">-sponsored</span> proxy materials. Proposals should be addressed to:</p>
		<p class="Text_ind_center" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:3;margin-top:8pt;">ARCA biopharma, Inc.<br/>Attention: Corporate Secretary<br/>10170 Church Ranch Way, Suite 100<br/>Westminster, Colorado, 80021</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The ARCA Bylaws also establish an advance notice procedure for stockholders who wish to present a proposal or nominate a director at an annual meeting, but do not seek to include the proposal or director nominee in ARCA&#8217;s proxy statement. In order to be properly brought before ARCA&#8217;s 2025 annual meeting, the stockholder must provide timely written notice to ARCA&#8217;s corporate secretary, at ARCA&#8217;s principal executive offices, and any such proposal or nomination must constitute a proper matter for stockholder action. The written notice must contain the information specified in the ARCA Bylaws. To be timely, a stockholder&#8217;s written notice must be received by ARCA&#8217;s corporate secretary at ARCA&#8217;s principal executive offices:</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">no earlier than<span style="width: 10px;display: inline-block;">&#160;&#160;&#160;</span><span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>, 2025, and</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">no later than<span style="width: 10px;display: inline-block;">&#160;&#160;&#160;</span><span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>, 2025.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In the event that ARCA holds its 2025 annual meeting more than 30&#160;days before, or more than 60&#160;days after, the one<span class="nobreak">-year</span> anniversary of this year&#8217;s annual meeting, then such written notice must be received by ARCA&#8217;s corporate secretary at ARCA&#8217;s principal executive offices:</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">no earlier than the 90<span class="CharOverride-3" style="font-size:58%;vertical-align:super;">th</span>&#160;day prior to the&#160;day of ARCA&#8217;s 2025 annual meeting, and</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">no later than close of business on the later of: (i)&#160;the 60<span class="CharOverride-3" style="font-size:58%;vertical-align:super;">th</span>&#160;day prior to the&#160;day of ARCA&#8217;s 2025 annual meeting or (ii)&#160;the 10<span class="CharOverride-3" style="font-size:58%;vertical-align:super;">th</span>&#160;day following the earlier of the&#160;day on which public announcement of the date of ARCA&#8217;s 2025 annual meeting is first made or notice is first given.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Availability of Bylaws</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">A copy of the ARCA Bylaws may be obtained by accessing ARCA&#8217;s filings on the SEC&#8217;s website at&#160;<span class="Italic" style="font-style:italic;font-weight:normal;">www.sec.gov</span>. You may also contact ARCA&#8217;s corporate secretary at ARCA&#8217;s principal executive offices for a copy of the relevant bylaw provisions regarding the requirements for making stockholder proposals and nominating director candidates.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Householding of Proxy Materials</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The SEC has adopted rules that permit companies and intermediaries (e.g., brokers) to satisfy the delivery requirements for proxy materials with respect to two or more stockholders sharing the same address by delivering a single set of the proxy materials addressed to those stockholders. This process, which is commonly referred to as &#8220;householding,&#8221; potentially means extra convenience for stockholders and cost savings for companies.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In connection with the ARCA special meeting, a number of brokers with account holders who are ARCA stockholders will be &#8220;householding&#8221; the proxy materials. A single set of the proxy materials will be delivered to multiple stockholders sharing an address unless contrary instructions have been received from the affected stockholders. Once you have received notice from your broker that they will be &#8220;householding&#8221; communications to your address, &#8220;householding&#8221; will continue until you are notified otherwise or until you revoke your consent. If, at any time, you no longer wish to participate in &#8220;householding&#8221; and would prefer to receive a separate set of the proxy materials, please notify your broker or ARCA.&#160;Direct your written request to Secretary, ARCA biopharma, Inc., 10170 Church Ranch Way, Suite 100, Westminster, Colorado, 80021 or contact Investor Relations at (720)&#160;940<span class="nobreak">-2100</span>. ARCA undertakes to promptly deliver a separate set of the proxy materials upon receiving your written request. Stockholders who currently receive multiple copies of the proxy materials at their addresses and would like to request &#8220;householding&#8221; of their communications should contact their brokers.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">321</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T111"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA BIOPHARMA, INC.</span></p>
		<p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">INDEX TO FINANCIAL STATEMENTS </span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Years ended December</span><span class="nobreak"><span class="Bold" style="font-style:normal;font-weight:bold;"> </span></span><span class="Bold" style="font-style:normal;font-weight:bold;">31, 2023 and 2022</span></p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 89.52%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.20%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">Page</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.52%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T201">Report of Independent Registered Public Accounting Firm, KPMG LLP</a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.20%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;">F-2</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.52%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T202">Balance Sheets as of December 31, 2023 and 2022</a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.20%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;">F-3</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.52%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T203">Statements of Operations for the years ended December 31, 2023 and 2022</a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.20%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;">F-4</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.52%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T204">Statements of Stockholders&#8217; Equity for the years ended December 31, 2023 and 2022</a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.20%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;">F-5</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.52%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T205">Statements of Cash Flows for the years ended December 31, 2023 and 2022</a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.20%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;">F-6</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.52%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T206">Notes to Financial Statements</a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.20%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;">F-7</p>
					</td>
				</tr>

		</table>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Three months ended March</span><span class="nobreak"><span class="Bold" style="font-style:normal;font-weight:bold;"> </span></span><span class="Bold" style="font-style:normal;font-weight:bold;">31, 2024 and 2023 Interim Financial Statements (Unaudited)</span></p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.52%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T207">Balance Sheets as of March 31, 2024 and December 31, 2023</a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.20%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;">F-19</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.52%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T208">Statements of Operations for the three months ended March 31, 2024 and 2023</a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.20%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;">F-20</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.52%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T209">Statements of Stockholders&#8217; Equity for the three months ended March 31, 2024 and 2023 and interim&#160;periods </a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.20%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;">F-21</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.52%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T210">Statements of Cash Flows for the three months ended March 31, 2024 and 2023</a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.20%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;">F-22</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.52%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T211">Notes to Financial Statements</a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.20%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;">F-23</p>
					</td>
				</tr>

		</table>
		<p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ORUKA THERAPEUTICS, INC.</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">As of February 6, 2024</span></p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Page</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T212">Report of Independent Registered Public Accounting Firm</a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">F-34</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T213">Balance Sheet as of February&#160;6, 2024</a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">F-35</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T214">Notes to Financial Statement</a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">F-36</p>
					</td>
				</tr>

		</table>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Period from February&#160;6, 2024 (Inception) to March&#160;31, 2024</span></p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T215">Unaudited Condensed Balance Sheets</a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">F-41</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T216">Unaudited Condensed Statement of Operations and Comprehensive Loss</a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">F-42</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T217">Unaudited Condensed Statement of Convertible Preferred Stock and Stockholders&#8217; Deficit</a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">F-43</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T218">Unaudited Condensed Statement of Cash Flows</a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">F-44</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T219">Notes to Unaudited Condensed Financial Statements</a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">F-45</p>
					</td>
				</tr>

		</table>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-1</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T201"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Report of Independent Registered Public Accounting Firm</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">To the Stockholders and Board of Directors <br/>ARCA biopharma, Inc.:</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Opinion on the Financial Statements</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">We have audited the accompanying balance sheets of ARCA biopharma, Inc. (the Company) as of December&#160;31, 2023 and December&#160;31, 2022, the related statements of operations, stockholders&#8217; equity, and cash flows for the&#160;years then ended, and the related notes (collectively, the financial statements). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December&#160;31, 2023 and December&#160;31, 2022, and the results of its operations and its cash flows for the&#160;years then ended, in conformity with U.S.&#160;generally accepted accounting principles.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Basis for Opinion</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on these financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United&#160;States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S.&#160;federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">We conducted our audits in accordance with the standards of the PCAOB.&#160;Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Critical Audit Matters</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Critical audit matters are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1)&#160;relate to accounts or disclosures that are material to the financial statements and (2)&#160;involved our especially challenging, subjective, or complex judgments. We determined that there are no critical audit matters.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">/s/ KPMG LLP </p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">We have served as the Company&#8217;s auditor since 2006.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Boulder, Colorado <br/>February&#160;1, 2024</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-2</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T202"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA BIOPHARMA, INC.<br/>BALANCE SHEETS</span></p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">As of December&#160;31,</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">2022</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(in thousands, except share and <br/>per share amounts)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-align:center;text-indent:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ASSETS</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Current assets:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Cash and cash equivalents</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" unitRef="usd" id="ixv-37766">37,431</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" unitRef="usd" id="ixv-37767">42,445</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other current assets</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsCurrent" scale="3" unitRef="usd" id="ixv-37768">161</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsCurrent" scale="3" unitRef="usd" id="ixv-37769">254</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total current assets</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" unitRef="usd" id="ixv-37770">37,592</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" unitRef="usd" id="ixv-37771">42,699</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Right-of-use asset&#160;&#8211;&#160;operating</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" unitRef="usd" id="ixv-37772">247</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" unitRef="usd" id="ixv-37773">343</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Property and equipment, net</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd" id="ixv-37774">10</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd" id="ixv-37775">25</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other assets</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" unitRef="usd" id="ixv-37776">12</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" unitRef="usd" id="ixv-37777">18</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Total assets</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" unitRef="usd" id="ixv-37778">37,861</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" unitRef="usd" id="ixv-37779">43,085</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-14" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-align:center;text-indent:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Current liabilities:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accounts payable</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="3" unitRef="usd" id="ixv-37780">362</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="3" unitRef="usd" id="ixv-37781">334</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accrued compensation and employee benefits</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-37782">100</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-37783">173</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accrued expenses and other liabilities (related party&#160;&#8211;&#160;$<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-37784">0</ix:nonFraction>&#160;and $<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-37785">216</ix:nonFraction>&#160;at December&#160;31, 2023 and 2022, respectively)</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-37786">175</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-37787">625</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total current liabilities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-37788">637</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-37789">1,132</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Operating lease liability, net of current portion</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" unitRef="usd" id="ixv-37790">204</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" unitRef="usd" id="ixv-37791">280</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Total liabilities</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" unitRef="usd" id="ixv-37792">841</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" unitRef="usd" id="ixv-37793">1,412</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Commitments and contingencies</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-1">&#160;</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-2">&#160;</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Stockholders&#8217; equity:</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Preferred stock, $<ix:nonFraction contextRef="c1" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-37794"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-37795">0.001</ix:nonFraction></ix:nonFraction>&#160;par value; <ix:nonFraction contextRef="c1" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="6" unitRef="shares" id="ixv-37796"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="6" unitRef="shares" id="ixv-37797">5</ix:nonFraction></ix:nonFraction>&#160;million shares authorized; <ix:nonFraction contextRef="c1" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" unitRef="shares" id="ixv-37798"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" unitRef="shares" id="ixv-37799"><ix:nonFraction contextRef="c1" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-37800"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-37801">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>&#160;shares&#160;issued or outstanding at December&#160;31, 2023 and 2022</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-3; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-4; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-15" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Common stock, $<ix:nonFraction contextRef="c1" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-37802"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-37803">0.001</ix:nonFraction></ix:nonFraction>&#160;par value; <ix:nonFraction contextRef="c1" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="6" unitRef="shares" id="ixv-37804"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="6" unitRef="shares" id="ixv-37805">100</ix:nonFraction></ix:nonFraction>&#160;million shares authorized at December&#160;31, 2023 and 2022; <ix:nonFraction contextRef="c1" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-37806"><ix:nonFraction contextRef="c1" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-37807">14,501,143</ix:nonFraction></ix:nonFraction>&#160;and <ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-37808"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-37809">14,410,143</ix:nonFraction></ix:nonFraction>&#160;shares issued and outstanding at December&#160;31, 2023 and 2022, respectively</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="3" unitRef="usd" id="ixv-37810">14</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="3" unitRef="usd" id="ixv-37811">14</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Additional paid-in capital</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" unitRef="usd" id="ixv-37812">225,747</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" unitRef="usd" id="ixv-37813">225,061</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accumulated deficit</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" sign="-" unitRef="usd" id="ixv-37814">188,741</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" sign="-" unitRef="usd" id="ixv-37815">183,402</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Total stockholders&#8217; equity</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-37816">37,020</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-37817">41,673</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Total liabilities and stockholders&#8217; equity</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" unitRef="usd" id="ixv-37818">37,861</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" unitRef="usd" id="ixv-37819">43,085</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>

		</table>
		<p class="Text_flush_Center" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:3;margin-top:8pt;">See accompanying Notes to Financial Statements</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-3</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<a id="T203"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA BIOPHARMA, INC.<br/>STATEMENTS OF OPERATIONS</span></p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Years Ended December&#160;31,</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">2022</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(in thousands, except share and <br/>per share amounts)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Costs and expenses:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">General and administrative</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-37820">6,283</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-37821">5,847</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Research and development (related party&#160;&#8211;&#160;$(<ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="abio:ResearchAndDevelopmentExpenseReversed" scale="3" sign="-" unitRef="usd" id="ixv-37822">91</ix:nonFraction>)&#160;and $<ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="abio:ResearchAndDevelopmentExpenseReversed" scale="3" unitRef="usd" id="ixv-37823">432</ix:nonFraction> as of the&#160;years&#160;ended December&#160;31, 2023 and 2022, respectively)</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-37824">1,013</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-37825">4,749</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total costs and expenses</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" unitRef="usd" id="ixv-37826">7,296</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" unitRef="usd" id="ixv-37827">10,596</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Loss from operations</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-37828">7,296</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-37829">10,596</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-14" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Interest and other income</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestAndOtherIncome" scale="3" unitRef="usd" id="ixv-37830">1,957</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestAndOtherIncome" scale="3" unitRef="usd" id="ixv-37831">675</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other loss</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-6; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingExpense" scale="3" unitRef="usd" id="ixv-37832">5</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net loss</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-37833">5,339</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-37834">9,926</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-14" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net loss per share:</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody-ind_2" style="-sec-ix-hidden: hidden-fact-8; -sec-ix-hidden: hidden-fact-7; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Basic and diluted</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c6" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-37835">0.37</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c7" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-37836">0.69</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Weighted average shares outstanding:</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody-ind_2" style="-sec-ix-hidden: hidden-fact-10; -sec-ix-hidden: hidden-fact-9; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Basic and diluted</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-37837">14,415,877</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-37838">14,410,143</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
				</tr>

		</table>
		<p class="Text_flush_Center" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:3;margin-top:8pt;">See accompanying Notes to Financial Statements</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-4</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<a id="T204"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA BIOPHARMA, INC.<br/>STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</span></p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 33.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="15" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 65.17%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Stockholders&#8217; Equity</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 33.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="4" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 24.36%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><br/>Common stock</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" rowspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Additional<br/>Paid-In<br/>Capital</span></p>
					</td>
					<td class="TCH" rowspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" rowspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Accumulated<br/>Deficit</span></p>
					</td>
					<td class="TCH" rowspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" rowspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.75%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Total</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 33.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Shares</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Amount</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 33.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="15" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 65.17%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(in thousands, except share and per share amounts)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 33.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Balance, December&#160;31, 2021</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-37839">14,410,143</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="Bold" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.76%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-37840">14</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="Bold" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-37841">224,505</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="Bold" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.19%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(<ix:nonFraction contextRef="c15" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-37842">173,476</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="Bold" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c16" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-37843">51,043</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 33.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Share-based compensation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.76%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-15; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c18" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" unitRef="usd" id="ixv-37844">556</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.19%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-16; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" unitRef="usd" id="ixv-37845">556</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 33.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net loss</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.76%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-17; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-18; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.19%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c19" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-37846">9,926</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.33%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-37847">9,926</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 33.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Balance, December&#160;31, 2022</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c20" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-37848">14,410,143</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.76%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c20" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-37849">14</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c21" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-37850">225,061</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.19%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(<ix:nonFraction contextRef="c22" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-37851">183,402</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-37852">41,673</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 33.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Issuance of common stock upon vesting&#160;of Restricted Stock Units</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c23" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="0" unitRef="shares" id="ixv-37853">91,000</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.76%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-19; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-style:normal;font-weight:normal;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-20; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-style:normal;font-weight:normal;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.19%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-21; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-style:normal;font-weight:normal;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-style:normal;font-weight:normal;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.33%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-22; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-style:normal;font-weight:normal;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 33.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Share-based compensation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.76%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-23; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c24" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" unitRef="usd" id="ixv-37854">686</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.19%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-24; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" unitRef="usd" id="ixv-37855">686</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 33.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net loss</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.76%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-25; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-26; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.19%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c25" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-37856">5,339</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.33%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-37857">5,339</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 33.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Balance, December&#160;31, 2023</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c26" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-37858">14,501,143</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="Bold" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.76%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c26" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-37859">14</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="Bold" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c27" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-37860">225,747</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;"><span class="Bold" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.19%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">(<ix:nonFraction contextRef="c28" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-37861">188,741</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="Bold" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.33%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-37862">37,020</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">&#160;</span></p>
					</td>
				</tr>

		</table>
		<p class="Text_flush_Center" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:3;margin-top:8pt;">See accompanying Notes to Financial Statements</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-5</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<a id="T205"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA BIOPHARMA, INC.<br/>STATEMENTS OF CASH FLOWS</span></p>
		<table class="No-Table-Style _idGenTablePara-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Years Ended December&#160;31,</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">2022</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(in thousands)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Cash flows from operating activities:</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net loss</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-37863">5,339</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-37864">9,926</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Adjustments to reconcile net loss to net cash used in operating activities:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Depreciation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepreciationAndAmortization" scale="3" unitRef="usd" id="ixv-37865">15</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepreciationAndAmortization" scale="3" unitRef="usd" id="ixv-37866">20</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Amortization of right-of-use asset&#160;&#8211;&#160;operating</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" unitRef="usd" id="ixv-37867">96</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" unitRef="usd" id="ixv-37868">94</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Share-based compensation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" unitRef="usd" id="ixv-37869">686</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" unitRef="usd" id="ixv-37870">556</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Loss from disposal of property and equipment</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-51; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" sign="-" unitRef="usd" id="ixv-37871">5</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Change in operating assets and liabilities:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other current assets</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" scale="3" sign="-" unitRef="usd" id="ixv-37872">93</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" scale="3" sign="-" unitRef="usd" id="ixv-37873">808</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other assets</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" sign="-" unitRef="usd" id="ixv-37874">6</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-52; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accounts payable</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" unitRef="usd" id="ixv-37875">28</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" sign="-" unitRef="usd" id="ixv-37876">783</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accrued compensation and employee benefits</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" scale="3" sign="-" unitRef="usd" id="ixv-37877">73</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" scale="3" sign="-" unitRef="usd" id="ixv-37878">752</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accrued expenses and other liabilities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" scale="3" sign="-" unitRef="usd" id="ixv-37879">526</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" scale="3" sign="-" unitRef="usd" id="ixv-37880">934</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Net cash used in operating activities</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" sign="-" unitRef="usd" id="ixv-37881">5,014</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" sign="-" unitRef="usd" id="ixv-37882">10,912</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Cash flows from investing activities:</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Purchase of property and equipment</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-53; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-37883">2</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Net cash used in investing activities</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-54; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" sign="-" unitRef="usd" id="ixv-37884">2</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Cash flows from financing activities:</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Net cash provided by financing activities</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-55; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-56; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Net decrease in cash and cash equivalents</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" sign="-" unitRef="usd" id="ixv-37885">5,014</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" sign="-" unitRef="usd" id="ixv-37886">10,914</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Cash and cash equivalents, beginning of year</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd" id="ixv-37887">42,445</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c16" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd" id="ixv-37888">53,359</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Cash and cash equivalents, end of year</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd" id="ixv-37889">37,431</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd" id="ixv-37890">42,445</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Supplemental cash flow information:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Interest paid</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-57; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-58; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Income tax refund received</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-59; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-60; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>

		</table>
		<p class="Text_flush_Center" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:3;margin-top:8pt;">See accompanying Notes to Financial Statements</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-6</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T206"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA BIOPHARMA, INC.<br/>NOTES TO FINANCIAL STATEMENTS</span></p>
		<ix:nonNumeric contextRef="c6" continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c6_cont_1" escape="true" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" id="ixv-20937"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(1)&#160;ARCA and Summary of Significant Accounting Policies</span></p>
		<ix:nonNumeric contextRef="c6" continuedAt="abio_DescriptionOfBusinessPolicyTextBlock-c6_cont_1" escape="true" name="abio:DescriptionOfBusinessPolicyTextBlock" id="ixv-20940"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Description of Business</span></p></ix:nonNumeric>
		<ix:continuation continuedAt="abio_DescriptionOfBusinessPolicyTextBlock-c6_cont_2" id="abio_DescriptionOfBusinessPolicyTextBlock-c6_cont_1"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA biopharma, Inc. (&#8220;ARCA&#8221;), a Delaware corporation, is headquartered in Westminster, Colorado. ARCA is a clinical<span class="nobreak">-stage</span> biopharmaceutical company applying a precision medicine approach to the development and commercialization of genetically targeted therapies for cardiovascular diseases. ARCA&#8217;s lead product candidate is Gencaro&#8482; (bucindolol hydrochloride) for the treatment of atrial fibrillation (&#8220;AF&#8221;) in patients with chronic heart failure (&#8220;HF&#8221;).</p></ix:continuation>
		<ix:continuation id="abio_DescriptionOfBusinessPolicyTextBlock-c6_cont_2"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In April&#160;2022, the Board of Directors established a Special Committee and, in May&#160;2022, retained Ladenburg Thalmann&#160;&amp; Co. Inc. to evaluate strategic options, including transactions involving a merger, sale of all or part of ARCA&#8217;s assets, or other alternatives with the goal of maximizing stockholder value. ARCA does not have a defined timeline for the strategic review process and the review may not result in any specific action or transaction.</p></ix:continuation>
		<ix:nonNumeric contextRef="c6" continuedAt="abio_LiquidityAndGoingConcernPolicyTextBlock-c6_cont_1" escape="true" name="abio:LiquidityAndGoingConcernPolicyTextBlock" id="ixv-20948"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Liquidity and Going Concern</span></p></ix:nonNumeric>
		<ix:continuation continuedAt="abio_LiquidityAndGoingConcernPolicyTextBlock-c6_cont_2" id="abio_LiquidityAndGoingConcernPolicyTextBlock-c6_cont_1"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA devotes substantially all of its efforts towards obtaining regulatory approval and raising capital necessary to fund its operations and it is subject to a number of risks associated with clinical research and development, including dependence on key individuals, the development of and regulatory approval of commercially viable products, the need to raise adequate additional financing necessary to fund the development and commercialization of its products, and competition from larger companies. ARCA has <ix:nonFraction contextRef="c6" decimals="INF" format="ixt:fixed-zero" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-37891">no</ix:nonFraction>t generated revenue to date and has incurred substantial losses and negative cash flows from operations since its inception. ARCA has historically funded its operations through issuances of common and preferred stock.</p></ix:continuation>
		<ix:continuation continuedAt="abio_LiquidityAndGoingConcernPolicyTextBlock-c6_cont_3" id="abio_LiquidityAndGoingConcernPolicyTextBlock-c6_cont_2"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA believes that its current cash and cash equivalents as of December&#160;31, 2023 will be sufficient to fund its operations through the middle of fiscal year 2025. ARCA&#8217;s review of its strategic options may impact this projection. Changing circumstances may cause ARCA to consume capital significantly faster or slower than currently anticipated. ARCA has based these estimates on assumptions that may prove to be wrong, and ARCA could exhaust its available financial resources sooner than it currently anticipates. Therefore, ARCA will have to raise additional capital for clinical trials of Gencaro. ARCA may not be able to raise sufficient capital on acceptable terms, or at all, to continue development of Gencaro or rNAPc2 or to otherwise continue operations and may not be able to execute any strategic transaction.</p></ix:continuation>
		<ix:continuation continuedAt="abio_LiquidityAndGoingConcernPolicyTextBlock-c6_cont_4" id="abio_LiquidityAndGoingConcernPolicyTextBlock-c6_cont_3"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s liquidity, and its ability to raise additional capital or complete any strategic transaction, depends on a number of factors, including, but not limited to, the following:</p></ix:continuation>
		<ix:continuation continuedAt="abio_LiquidityAndGoingConcernPolicyTextBlock-c6_cont_5" id="abio_LiquidityAndGoingConcernPolicyTextBlock-c6_cont_4"><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the costs and timing for the potential additional clinical trials in order to gain possible regulatory approval for Gencaro, rNAPc2, or any other product candidate;</p></ix:continuation>
		<ix:continuation continuedAt="abio_LiquidityAndGoingConcernPolicyTextBlock-c6_cont_6" id="abio_LiquidityAndGoingConcernPolicyTextBlock-c6_cont_5"><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the market price of ARCA&#8217;s stock and the availability and cost of additional equity capital from existing and potential new investors;</p></ix:continuation>
		<ix:continuation continuedAt="abio_LiquidityAndGoingConcernPolicyTextBlock-c6_cont_7" id="abio_LiquidityAndGoingConcernPolicyTextBlock-c6_cont_6"><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s ability to retain the listing of its common stock on the Nasdaq Capital Market;</p></ix:continuation>
		<ix:continuation continuedAt="abio_LiquidityAndGoingConcernPolicyTextBlock-c6_cont_8" id="abio_LiquidityAndGoingConcernPolicyTextBlock-c6_cont_7"><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>general economic and industry conditions affecting the availability and cost of capital, including as a result of deteriorating market conditions due to investor concerns regarding inflation, adverse developments affecting the financial services industry, continued hostilities between Russia and Ukraine and Hamas&#8217; attack against Israel and the ensuing conflict;</p></ix:continuation>
		<ix:continuation continuedAt="abio_LiquidityAndGoingConcernPolicyTextBlock-c6_cont_9" id="abio_LiquidityAndGoingConcernPolicyTextBlock-c6_cont_8"><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s ability to control costs associated with its operations;</p></ix:continuation>
		<ix:continuation continuedAt="abio_LiquidityAndGoingConcernPolicyTextBlock-c6_cont_10" id="abio_LiquidityAndGoingConcernPolicyTextBlock-c6_cont_9"><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; and</p></ix:continuation>
		<ix:continuation continuedAt="abio_LiquidityAndGoingConcernPolicyTextBlock-c6_cont_11" id="abio_LiquidityAndGoingConcernPolicyTextBlock-c6_cont_10"><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the terms and conditions of ARCA&#8217;s existing collaborative and licensing agreements.</p></ix:continuation></ix:nonNumeric>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-7</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-align:center;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA BIOPHARMA, INC.<br/>NOTES TO FINANCIAL STATEMENTS</span></p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(1)&#160;ARCA and Summary of Significant Accounting Policies</span><span class="CharOverride-1" style="font-style:normal;font-weight:normal;"> (cont.)</span></p>
		<ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c6_cont_2" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c6_cont_1"><ix:continuation id="abio_LiquidityAndGoingConcernPolicyTextBlock-c6_cont_11"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The sale of additional equity or convertible debt securities would likely result in substantial additional dilution to ARCA&#8217;s stockholders. If ARCA raises additional funds through the incurrence of indebtedness, the obligations related to such indebtedness would be senior to rights of holders of ARCA&#8217;s capital stock and could contain covenants that would restrict ARCA&#8217;s operations. ARCA also cannot predict what consideration might be available, if any, to it or its stockholders, in connection with any strategic transaction. Should strategic alternatives or additional capital not be available to ARCA, or not be available on acceptable terms, ARCA may be unable to realize value from its assets and discharge its liabilities in the normal course of business which may, among other alternatives, cause ARCA to further delay, substantially reduce or discontinue operational activities to conserve its cash resources.</p></ix:continuation>
		<ix:nonNumeric contextRef="c6" continuedAt="_BasisOfAccountingPolicyPolicyTextBlock-c6_cont_1" escape="true" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="ixv-20998"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Basis of Presentation</span></p></ix:nonNumeric>
		<ix:continuation id="_BasisOfAccountingPolicyPolicyTextBlock-c6_cont_1"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The accompanying financial statements have been prepared in accordance with U.S.&#160;generally accepted accounting principles (&#8220;GAAP&#8221;) and include all adjustments necessary for the fair presentation of ARCA&#8217;s financial position, results of operations and cash flows for the periods presented. Management has performed an evaluation of ARCA&#8217;s activities through the date of filing of the Annual Report on Form&#160;10<span class="nobreak">-K</span>.</p></ix:continuation>
		<ix:nonNumeric contextRef="c6" continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c6_cont_1" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="ixv-21004"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Recent Accounting Pronouncements</span></p></ix:nonNumeric>
		<ix:continuation id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c6_cont_1"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA reviewed all other recently issued accounting pronouncements and concluded that they were either not applicable or not expected to have a significant impact to the financial statements.</p></ix:continuation>
		<ix:nonNumeric contextRef="c6" continuedAt="_UseOfEstimates-c6_cont_1" escape="true" name="us-gaap:UseOfEstimates" id="ixv-21009"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Accounting Estimates in the Preparation of Financial Statements</span></p></ix:nonNumeric>
		<ix:continuation id="_UseOfEstimates-c6_cont_1"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The preparation of financial statements in conformity with accounting principles generally accepted in the United&#160;States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. ARCA bases estimates on various assumptions that are believed to be reasonable under the circumstances. ARCA believes significant judgment was involved in estimating the outsourcing expenses, and in estimating other accrued liabilities and income taxes. Management is continually evaluating and updating these estimates, and it is possible that these estimates will change in the future or that actual results may differ from these estimates.</p></ix:continuation>
		<ix:nonNumeric contextRef="c6" continuedAt="_CashAndCashEquivalentsPolicyTextBlock-c6_cont_1" escape="true" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="ixv-21014"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Cash Equivalents</span></p></ix:nonNumeric>
		<ix:continuation id="_CashAndCashEquivalentsPolicyTextBlock-c6_cont_1"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Cash equivalents generally consist of money market funds and debt securities with maturities of 90&#160;days or less at the time of purchase. ARCA invests its excess cash in securities with strong ratings and has established guidelines relative to diversification and maturity with the objective of maintaining safety of principal and liquidity.</p></ix:continuation>
		<ix:nonNumeric contextRef="c6" continuedAt="_ConcentrationRiskCreditRisk-c6_cont_1" escape="true" name="us-gaap:ConcentrationRiskCreditRisk" id="ixv-21019"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Concentrations of Credit Risk</span></p></ix:nonNumeric>
		<ix:continuation id="_ConcentrationRiskCreditRisk-c6_cont_1"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Financial instruments that potentially subject ARCA to significant concentrations of credit risk consist primarily of cash and cash equivalents. ARCA has <ix:nonFraction contextRef="c1" decimals="INF" format="ixt:fixed-zero" name="us-gaap:FairValueDisclosureOffbalanceSheetRisksAmountAsset" scale="0" unitRef="usd" id="ixv-37892">no</ix:nonFraction> off<span class="nobreak">-balance-sheet</span> concentrations of credit risk, such as foreign exchange contracts, option contracts, or foreign currency hedging arrangements. ARCA maintains cash and cash equivalent balances in the form of bank demand deposits and money market fund accounts with financial institutions that management believes are creditworthy. Such balances may at times exceed the insured amount.</p></ix:continuation>
		<ix:nonNumeric contextRef="c6" continuedAt="_PropertyPlantAndEquipmentPolicyTextBlock-c6_cont_1" escape="true" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="ixv-21025"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Property and Equipment</span></p></ix:nonNumeric>
		<ix:continuation continuedAt="_PropertyPlantAndEquipmentPolicyTextBlock-c6_cont_2" id="_PropertyPlantAndEquipmentPolicyTextBlock-c6_cont_1"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Property and equipment are stated at cost less accumulated depreciation and amortization. Cost includes expenditures for equipment, leasehold improvements, replacements, and renewals. Maintenance and repairs are charged to expense as incurred. When assets are sold, retired, or otherwise disposed of, the cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is reflected in operations. The cost of </p></ix:continuation></ix:continuation>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-8</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-align:center;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA BIOPHARMA, INC.<br/>NOTES TO FINANCIAL STATEMENTS</span></p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(1)&#160;ARCA and Summary of Significant Accounting Policies</span><span class="CharOverride-1" style="font-style:normal;font-weight:normal;"> (cont.)</span></p>
		<ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c6_cont_3" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c6_cont_2"><ix:continuation id="_PropertyPlantAndEquipmentPolicyTextBlock-c6_cont_2"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">property and equipment is depreciated using the straight<span class="nobreak">-line</span> method over the estimated useful lives of the related assets. Leasehold improvements are amortized over the shorter of the life of the lease or the estimated useful life of the assets.</p></ix:continuation>
		<ix:nonNumeric contextRef="c6" continuedAt="abio_ComprehensiveLossPolicyPolicyTextBlock-c6_cont_1" escape="true" name="abio:ComprehensiveLossPolicyPolicyTextBlock" id="ixv-21044"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Comprehensive Loss</span></p></ix:nonNumeric>
		<ix:continuation id="abio_ComprehensiveLossPolicyPolicyTextBlock-c6_cont_1"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Comprehensive loss is defined as the change in equity during a period from transactions and other events and/or circumstances from non<span class="nobreak">-owner</span> sources. If ARCA had comprehensive gains (losses), they would be reflected in the statement of operations and comprehensive loss and as a separate component in the statement of stockholders&#8217; equity. There were no elements of comprehensive loss during the&#160;years ended December&#160;31, 2023 and 2022.</p></ix:continuation>
		<ix:nonNumeric contextRef="c6" continuedAt="_LesseeLeasesPolicyTextBlock-c6_cont_1" escape="true" name="us-gaap:LesseeLeasesPolicyTextBlock" id="ixv-21050"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Leases</span></p></ix:nonNumeric>
		<ix:continuation continuedAt="_LesseeLeasesPolicyTextBlock-c6_cont_2" id="_LesseeLeasesPolicyTextBlock-c6_cont_1"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA determines if an arrangement is a lease at inception. Operating leases are included in right<span class="nobreak">-of-use</span> (&#8220;ROU&#8221;) asset&#160;&#8212;&#160;operating and lease obligations are included in accrued expenses and other liabilities and operating lease liability on ARCA&#8217;s December&#160;31, 2023 and 2022 balance sheets.</p></ix:continuation>
		<ix:continuation id="_LesseeLeasesPolicyTextBlock-c6_cont_2"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ROU lease assets represent ARCA&#8217;s right to use an underlying asset for the lease term and lease obligations represent ARCA&#8217;s obligation to make lease payments arising from the lease. Operating ROU lease assets are recognized at the commencement date based on the present value of lease payments over the lease term. As ARCA&#8217;s lease does not provide an implicit rate, ARCA uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. ARCA&#8217;s lease terms may include options to extend or terminate the lease when it is reasonably certain that ARCA will exercise that option. Lease expense for lease payments is recognized on a straight<span class="nobreak">-line</span> basis over the lease term.</p></ix:continuation>
		<ix:nonNumeric contextRef="c6" continuedAt="abio_AccruedOutsourcingExpensesPolicyTextBlock-c6_cont_1" escape="true" name="abio:AccruedOutsourcingExpensesPolicyTextBlock" id="ixv-21059"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Accrued Outsourcing Expenses</span></p></ix:nonNumeric>
		<ix:continuation id="abio_AccruedOutsourcingExpensesPolicyTextBlock-c6_cont_1"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As part of the process of preparing its financial statements, ARCA is required to estimate accrued outsourcing expenses. This process involves identifying services that third parties have performed on ARCA&#8217;s behalf and estimating the level of service performed and the associated cost incurred for these services as of the balance sheet date. Examples of estimated accrued outsourcing expenses include contract service fees, such as fees payable to contract manufacturers in connection with the production of materials related to ARCA&#8217;s drug product, and service fees and pass through costs from clinical research organizations. ARCA develops estimates of liabilities using its judgment based upon the facts and circumstances known at the time.</p></ix:continuation>
		<ix:nonNumeric contextRef="c6" continuedAt="_SegmentReportingPolicyPolicyTextBlock-c6_cont_1" escape="true" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="ixv-21064"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Segments</span></p></ix:nonNumeric>
		<ix:continuation id="_SegmentReportingPolicyPolicyTextBlock-c6_cont_1"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA operates in <ix:nonFraction contextRef="c6" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" unitRef="pure" id="ixv-37893">one</ix:nonFraction> segment. Management uses one measure of profitability and does not segment its business for internal reporting.</p></ix:continuation>
		<ix:nonNumeric contextRef="c6" continuedAt="_ResearchAndDevelopmentExpensePolicy-c6_cont_1" escape="true" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="ixv-21069"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Research and Development</span></p></ix:nonNumeric>
		<ix:continuation continuedAt="_ResearchAndDevelopmentExpensePolicy-c6_cont_2" id="_ResearchAndDevelopmentExpensePolicy-c6_cont_1"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Research and development costs are expensed as incurred. These consist primarily of salaries, contract services, and supplies.</p></ix:continuation>
		<ix:continuation continuedAt="_ResearchAndDevelopmentExpensePolicy-c6_cont_3" id="_ResearchAndDevelopmentExpensePolicy-c6_cont_2"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Costs, if any, related to clinical trial and drug manufacturing activities are based upon estimates of the services received and related expenses incurred by contract research organizations (&#8220;CROs&#8221;), clinical study sites, drug manufacturers, collaboration partners, laboratories, consultants, or otherwise. Related contracts vary significantly in length, and could be for a fixed amount, a variable amount based on actual costs incurred, capped at a certain limit, or for a combination of these elements. Activity levels are monitored through communications with the vendors, including detailed invoices and task completion review, analysis of expenses against budgeted amounts, and pre<span class="nobreak">-approval</span> of any changes in scope of the services to be performed. Certain significant vendors may also provide </p></ix:continuation></ix:continuation>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-9</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-align:center;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA BIOPHARMA, INC.<br/>NOTES TO FINANCIAL STATEMENTS</span></p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(1)&#160;ARCA and Summary of Significant Accounting Policies</span><span class="CharOverride-1" style="font-style:normal;font-weight:normal;"> (cont.)</span></p>
		<ix:continuation id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c6_cont_3"><ix:continuation continuedAt="_ResearchAndDevelopmentExpensePolicy-c6_cont_4" id="_ResearchAndDevelopmentExpensePolicy-c6_cont_3"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">an estimate of costs incurred but not invoiced on a periodic basis. Expenses related to the CROs and clinical studies, as well as contract drug manufacturers, are primarily based on progress made against specified milestones or targets in each period.</p></ix:continuation>
		<ix:continuation id="_ResearchAndDevelopmentExpensePolicy-c6_cont_4"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In accordance with certain research and development agreements, ARCA is obligated to make certain upfront payments upon execution of the agreement. ARCA records these upfront payments as prepaid research and development expenses, which are included in Other current assets or Other assets in the accompanying Balance Sheets. Such payments are recorded to research and development expense as services are performed. ARCA evaluates on a quarterly basis whether events and circumstances have occurred that may indicate impairment of remaining prepaid research and development expenses.</p></ix:continuation>
		<ix:nonNumeric contextRef="c6" continuedAt="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c6_cont_1" escape="true" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="ixv-21092"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Stock-Based Compensation</span></p></ix:nonNumeric>
		<ix:continuation id="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c6_cont_1"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s stock<span class="nobreak">-based</span> compensation cost recognized is based on the estimated grant date fair value. ARCA recognizes compensation costs for its stock<span class="nobreak">-based</span> awards on a straight<span class="nobreak">-line</span> basis over the requisite service period for the entire award, as adjusted for expected forfeitures.</p></ix:continuation>
		<ix:nonNumeric contextRef="c6" continuedAt="_IncomeTaxPolicyTextBlock-c6_cont_1" escape="true" name="us-gaap:IncomeTaxPolicyTextBlock" id="ixv-21100"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Income Taxes</span></p></ix:nonNumeric>
		<ix:continuation id="_IncomeTaxPolicyTextBlock-c6_cont_1"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The current benefit for income taxes represents actual or estimated amounts payable or refundable on tax returns filed or to be filed each year. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the period that includes the enactment date. The overall change in deferred tax assets and liabilities for the period measures the deferred tax expense or benefit for the period. The measurement of deferred tax assets may be reduced by a valuation allowance based on judgmental assessment of available evidence if deemed more likely than not that some or all of the deferred tax assets will not be realized.</p></ix:continuation></ix:continuation>
		<ix:nonNumeric contextRef="c6" escape="true" name="us-gaap:EarningsPerShareTextBlock" id="ixv-21105"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(2)&#160;Net Loss Per Share</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA calculates basic loss per share by dividing net loss by the weighted average common shares outstanding during the period. Diluted loss per share is computed by dividing net loss by the weighted average number of common shares outstanding during the period increased to include, if dilutive, the number of additional common shares that would have been outstanding if the potential common shares had been issued. ARCA&#8217;s potentially dilutive shares include stock options and restricted stock units.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><ix:nonNumeric contextRef="c6" continuedAt="_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock-c6_cont_1" escape="true" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="ixv-37894">Because ARCA reported a net loss for the&#160;years ended December&#160;31, 2023 and 2022, all potentially dilutive shares of ARCA common stock have been excluded from the computation of the dilutive net loss per share for all periods presented. Such potentially dilutive shares of ARCA common stock consist of the following:</ix:nonNumeric></p>
		<ix:continuation id="_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock-c6_cont_1"><table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Years Ended<br/>December&#160;31,</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2022</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Potentially dilutive securities, excluded:</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Outstanding stock options</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c62" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares" id="ixv-37895">616,707</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c63" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares" id="ixv-37896">704,960</ix:nonFraction></p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Unvested restricted stock units</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-70; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c65" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares" id="ixv-37897">91,000</ix:nonFraction></p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares" id="ixv-37898">616,707</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares" id="ixv-37899">795,960</ix:nonFraction></p>	</td>
				</tr>

		</table></ix:continuation></ix:nonNumeric>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-10</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-bottom:10pt;text-align:center;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA BIOPHARMA, INC.<br/>NOTES TO FINANCIAL STATEMENTS</span></p>
		<ix:nonNumeric contextRef="c6" escape="true" name="us-gaap:FairValueDisclosuresTextBlock" id="ixv-21170"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(3)&#160;Fair Value Disclosures</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (&#8220;exit price&#8221;). Inputs used to measure fair value are classified into the following hierarchy:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Level 1 &#8212;&#160;Unadjusted quoted prices in active markets for identical assets or liabilities. ARCA&#8217;s Level 1 assets consist of money market investments. ARCA does not have any Level 1 liabilities.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Level 2 &#8212;&#160;Unadjusted quoted prices in active markets for similar assets or liabilities; unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active; or inputs other than quoted prices that are observable for the asset or liability. ARCA&#8217;s Level 2 assets consist of corporate bonds and commercial paper securities. ARCA does not have any Level 2 liabilities.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Level 3 &#8212;&#160;Unobservable inputs for the asset or liability. ARCA does not have any Level 3 assets or liabilities.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of December&#160;31, 2023 and 2022, ARCA had $<ix:nonFraction contextRef="c66" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" unitRef="usd" id="ixv-37900">37.4</ix:nonFraction>&#160;million and $<ix:nonFraction contextRef="c67" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" unitRef="usd" id="ixv-37901">42.4</ix:nonFraction>&#160;million, respectively, of cash equivalents consisting of money market funds with original maturities of 90&#160;days or less. ARCA has the ability to liquidate these investments without restriction. ARCA determines fair value for these money market funds with Level 1 inputs through quoted market prices. There were <span style="-sec-ix-hidden: hidden-fact-73"><span style="-sec-ix-hidden: hidden-fact-74">no</span></span> transfers between any fair value hierarchy levels in 2023 or 2022.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Fair Value of Other Financial Instruments</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The carrying amount of other financial instruments, including accounts payable, approximated fair value due to their short maturities. As of December&#160;31, 2023 and 2022, ARCA did <span style="-sec-ix-hidden: hidden-fact-71"><span style="-sec-ix-hidden: hidden-fact-72">not</span></span> have any debt outstanding.</p></ix:nonNumeric>
		<ix:nonNumeric contextRef="c6" escape="true" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="ixv-21191"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(4)&#160;Property and Equipment</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><ix:nonNumeric contextRef="c6" continuedAt="_PropertyPlantAndEquipmentTextBlock-c6_cont_1" escape="true" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="ixv-37902">Property and equipment consist of the following (in thousands):</ix:nonNumeric></p>
		<ix:continuation id="_PropertyPlantAndEquipmentTextBlock-c6_cont_1"><table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">	<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Estimated<br/>Life</span></p>	</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">December&#160;31,<br/>2023</span></p>	</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">December&#160;31,<br/>2022</span></p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Computer equipment</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><ix:nonNumeric contextRef="c69" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-37903">3</ix:nonNumeric>&#160;years</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c69" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-37904">39</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c70" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-37905">39</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Lab equipment</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><ix:nonNumeric contextRef="c71" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-37906">5</ix:nonNumeric>&#160;years</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c71" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-37907">130</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c72" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-37908">130</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Furniture and fixtures</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><ix:nonNumeric contextRef="c73" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-37909">5</ix:nonNumeric>&#160;years</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c73" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-37910">37</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c74" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-37911">44</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Computer software</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><ix:nonNumeric contextRef="c75" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-37912">3</ix:nonNumeric>&#160;years</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c75" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-37913">16</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c76" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-37914">16</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-37915">222</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-37916">229</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accumulated depreciation and amortization</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-37917">212</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-37918">204</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Property and equipment, net</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd" id="ixv-37919">10</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd" id="ixv-37920">25</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	</tr>	</table></ix:continuation>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">For the&#160;years ended December&#160;31, 2023 and 2022, depreciation and amortization expense was $<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepreciationAndAmortization" scale="3" unitRef="usd" id="ixv-37921">15</ix:nonFraction>,000 and $<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepreciationAndAmortization" scale="3" unitRef="usd" id="ixv-37922">20</ix:nonFraction>,000, respectively.</p></ix:nonNumeric>
		<ix:nonNumeric contextRef="c6" escape="true" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="ixv-21351"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(5)&#160;Related Party Arrangements</span></p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Transactions with ARCA&#8217;s President and Chief Executive Officer</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA has entered into unrestricted research grants with its President and Chief Executive Officer&#8217;s academic research laboratory at the University of Colorado. Funding of any unrestricted research grants is contingent upon ARCA&#8217;s financial condition, and can be deferred or terminated at ARCA&#8217;s discretion. Total expense under these arrangements for the&#160;years ended December&#160;31, 2023 and 2022 was $(<ix:nonFraction contextRef="c77" decimals="0" format="ixt:num-dot-decimal" name="abio:ResearchAndDevelopmentExpenseReversed" scale="0" sign="-" unitRef="usd" id="ixv-37923">91,000</ix:nonFraction>) and $<ix:nonFraction contextRef="c78" decimals="0" format="ixt:num-dot-decimal" name="abio:ResearchAndDevelopmentExpenseReversed" scale="0" unitRef="usd" id="ixv-37924">432,000</ix:nonFraction>, respectively. In December&#160;2023, ARCA made a payment of $<ix:nonFraction contextRef="c79" decimals="0" format="ixt:num-dot-decimal" name="abio:PaymentOfUnrestrictedResearchGrants" scale="0" unitRef="usd" id="ixv-37925">125,000</ix:nonFraction> for the grant period July&#160;2022 through December&#160;2023 under these arrangements.</p></ix:nonNumeric>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-11</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-bottom:10pt;text-align:center;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA BIOPHARMA, INC.<br/>NOTES TO FINANCIAL STATEMENTS</span></p>
		<ix:nonNumeric contextRef="c6" continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c6_cont_1" escape="true" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="ixv-21364"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(6)&#160;Commitments and Contingencies</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA has or is subject to the following commitments and contingencies:</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Employment Agreements and Reduction of Workforce</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA maintains employment agreements with several key executive employees. The agreements may be terminated at any time by ARCA with or without cause upon written notice to the employee, and entitle the employee to wages in lieu of notice for periods not exceeding one calendar year from date of termination without cause or by the employee for good reason. Certain of these agreements also provide for payments to be made under certain conditions related to a change in control of ARCA.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In December&#160;2022, ARCA&#8217;s Board of Directors approved retention bonuses for certain employees, subject to continued employment with ARCA through the earlier of a change in control of ARCA or certain clinical development decisions totaling $<ix:nonFraction contextRef="c80" decimals="0" format="ixt:num-dot-decimal" name="abio:RetentionBonuses" scale="0" unitRef="usd" id="ixv-37926">265,000</ix:nonFraction>. In November&#160;2023, the retention bonuses were amended to increase the aggregate amount of the retention bonus by <ix:nonFraction contextRef="c81" decimals="2" format="ixt:num-dot-decimal" name="abio:PercentageOfRetentionBonuses" scale="-2" unitRef="pure" id="ixv-37927">50</ix:nonFraction>% and in order to assist with tax obligations associated with the vesting of certain Company restricted stock unit awards in December&#160;2023, a total of $<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="abio:RetentionBonusPaid" scale="0" unitRef="usd" id="ixv-37928">86,000</ix:nonFraction> was paid in December&#160;2023. As of December&#160;31, 2023, the unpaid retention bonuses totaled $<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="abio:RetentionBonuses" scale="0" unitRef="usd" id="ixv-37929">311,000</ix:nonFraction>, none of which was accrued as of December&#160;31, 2023, since there had not been a change in control or clinical development decision.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA and Christopher D.&#160;Ozeroff, the Secretary, Senior Vice President and General Counsel of ARCA mutually agreed to conclude Mr.&#160;Ozeroff&#8217;s employment effective March&#160;31, 2023. Pursuant to Mr.&#160;Ozeroff&#8217;s existing employment agreement, as previously amended, ARCA will provide Mr.&#160;Ozeroff severance benefits pursuant to the terms of his existing employment agreement with ARCA, as previously amended. The severance benefits include severance payments and reimbursement to cover out<span class="nobreak">-of-pocket</span> costs to continue group health insurance benefits under COBRA, whether he elects or is eligible to receive COBRA (provided, that even if he does not elect or is not eligible to receive COBRA, he will receive the equivalent of such out<span class="nobreak">-of-pocket</span> expenses paid by him not to exceed the costs that the benefits would equal under COBRA if he were so eligible). During the year ended December&#160;31, 2023, ARCA recorded an expense of $<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SeveranceCosts1" scale="0" unitRef="usd" id="ixv-37930">159,000</ix:nonFraction> for these severance benefits, <span style="-sec-ix-hidden: hidden-fact-75">none</span> of which remains unpaid.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In 2022, ARCA implemented a strategic reduction of the workforce by approximately <ix:nonFraction contextRef="c7" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" scale="-2" unitRef="pure" id="ixv-37931">67</ix:nonFraction>%, or <ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated" scale="0" unitRef="pure" id="ixv-37932">12</ix:nonFraction> employees. Personnel reductions were primarily focused in research and development and general and administrative functions. The restructuring was a result of ARCA&#8217;s decision to manage operating costs and expenses. During the year ended December&#160;31, 2022, ARCA recorded total restructuring charges of approximately $<ix:nonFraction contextRef="c82" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RestructuringCharges" scale="0" unitRef="usd" id="ixv-37933">755,000</ix:nonFraction>, of which $<ix:nonFraction contextRef="c83" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RestructuringCharges" scale="0" unitRef="usd" id="ixv-37934">470,000</ix:nonFraction> and $<ix:nonFraction contextRef="c84" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RestructuringCharges" scale="0" unitRef="usd" id="ixv-37935">285,000</ix:nonFraction> were recognized in research and development and general and administrative expenses, respectively, in connection with the restructuring, all in the form of one<span class="nobreak">-time</span> termination benefits, none of which remains unpaid.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Operating Lease</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On August&#160;29, 2020 ARCA entered into a lease agreement for approximately <ix:nonFraction contextRef="c85" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AreaOfRealEstateProperty" scale="0" unitRef="sqft" id="ixv-37936">5,200</ix:nonFraction> square feet of office facilities in Westminster, Colorado which serves as ARCA&#8217;s primary business office effective October&#160;1, 2020 (&#8220;October&#160;2020 Lease&#8221;). The lease term is <ix:nonNumeric contextRef="c85" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="ixv-37937">42&#160;months</ix:nonNumeric> beginning October&#160;1, 2020 and includes an <ix:nonNumeric contextRef="c86" name="us-gaap:LesseeOperatingLeaseOptionToExtend" id="ixv-21381">option to renew for an additional <ix:nonNumeric contextRef="c85" format="ixt-sec:durmonth" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="ixv-37938">36</ix:nonNumeric><span class="nobreak"> </span>month term at the then prevailing rental rate.</ix:nonNumeric> The exercise of the lease renewal option is at ARCA&#8217;s sole discretion. The amounts recorded assume ARCA will exercise its renewal option. In June&#160;2021, ARCA entered into a sublease agreement for approximately <ix:nonFraction contextRef="c87" decimals="0" format="ixt:num-dot-decimal" name="abio:AreaOfRealEstatePropertySubleaseAdditionalOfficeFacilities" scale="0" unitRef="sqft" id="ixv-37939">3,000</ix:nonFraction> square feet of additional office facilities in its primary business office (&#8220;2021 Lease&#8221;). The sublease term was <ix:nonNumeric contextRef="c88" format="ixt-sec:durwordsen" name="abio:LesseeOperatingSubleaseTermOfContract" id="ixv-37940">29&#160;months</ix:nonNumeric> and terminated in October&#160;2023. <ix:nonNumeric contextRef="c6" name="us-gaap:LesseeOperatingLeaseAssumptionsAndJudgmentsAllocationOfLeaseAndNonleaseComponent" id="ixv-21383">The leases include real estate taxes and insurance, which is not a lease component and is not included in the lease obligation. In addition, common area maintenance charges are based on actual costs incurred and are a non<span class="nobreak">-lease</span> component that is not included in the lease obligation.</ix:nonNumeric></p></ix:nonNumeric>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-12</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-align:center;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA BIOPHARMA, INC.<br/>NOTES TO FINANCIAL STATEMENTS</span></p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(6)&#160;Commitments and Contingencies</span><span class="CharOverride-1" style="font-style:normal;font-weight:normal;"> (cont.)</span></p>
		<ix:continuation id="_CommitmentsAndContingenciesDisclosureTextBlock-c6_cont_1"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><ix:nonNumeric contextRef="c6" continuedAt="_LesseeOperatingLeaseLiabilityMaturityTableTextBlock-c6_cont_1" escape="true" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="ixv-37941">Future minimum commitments due under the October&#160;2020 Lease agreement as of December&#160;31, 2023 are as follows (in thousands):</ix:nonNumeric></p>
		<ix:continuation id="_LesseeOperatingLeaseLiabilityMaturityTableTextBlock-c6_cont_1"><table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2024</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" unitRef="usd" id="ixv-37942">93</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2025</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" unitRef="usd" id="ixv-37943">96</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2026</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" unitRef="usd" id="ixv-37944">100</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2027</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" unitRef="usd" id="ixv-37945">25</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total remaining lease payments</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" unitRef="usd" id="ixv-37946">314</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Less: imputed lease interest</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" unitRef="usd" id="ixv-37947">34</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Less: Current portion</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" unitRef="usd" id="ixv-37948">76</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Operating lease liability, net of current portion</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" unitRef="usd" id="ixv-37949">204</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>

		</table></ix:continuation>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Rent expense, which is included in general and administrative expense, under these leases for the&#160;years ended December&#160;31, 2023 and 2022 was $<ix:nonFraction contextRef="c89" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseCost" scale="0" unitRef="usd" id="ixv-37950">119,000</ix:nonFraction> and $<ix:nonFraction contextRef="c90" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseCost" scale="0" unitRef="usd" id="ixv-37951">125,000</ix:nonFraction>, respectively.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of December&#160;31, 2023, the lease liability was $<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiability" scale="0" unitRef="usd" id="ixv-37952">280,000</ix:nonFraction> and the current portion is included in accrued expenses and other liabilities and the non<span class="nobreak">-current</span> portion is in operating lease liability, net of current portion in the accompanying balance sheet. Cash paid for amounts included in the measurement of lease liabilities and the operating cash flows from operating leases for the&#160;years ended December&#160;31, 2023 and 2022 were $<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasePayments" scale="0" unitRef="usd" id="ixv-37953">127,000</ix:nonFraction> and $<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasePayments" scale="0" unitRef="usd" id="ixv-37954">131,000</ix:nonFraction>, respectively. The weighted<span class="nobreak">-average</span> remaining lease term for the operating lease as of December&#160;31, 2023 is <ix:nonNumeric contextRef="c1" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="ixv-37955">3.2</ix:nonNumeric>&#160;years. The weighted<span class="nobreak">-average</span> discount rate for the operating lease is <ix:nonFraction contextRef="c1" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" unitRef="pure" id="ixv-37956">7</ix:nonFraction>%.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Patent Agreement</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In July&#160;2021, ARCA entered into a patent assignment agreement (the &#8220;Agreement&#8221;) with the University Medical Center of Johannes Gutenberg University Mainz, Germany.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Under the terms of the Agreement, ARCA received exclusive world<span class="nobreak">-wide</span> patent rights relating to the use of rNAPc2 as a potential treatment for COVID<span class="nobreak">-19</span>, and other indications, based on the research and discoveries from Univ.<span class="nobreak">-Prof</span>. Dr.&#160;Wolfram Ruf, the Scientific Director and Alexander von Humboldt Professor at the Center for Thrombosis and Hemostasis (&#8220;CTH&#8221;) of the University Medical Center Mainz, and his collaborators. ARCA has upfront and potential milestone obligations to the University Medical Center Mainz that could total approximately &#8364;<ix:nonFraction contextRef="c91" decimals="-5" format="ixt:num-dot-decimal" name="abio:PotentialUpfrontAndMilestoneObligationsAndRoyaltyObligations" scale="6" unitRef="eur" id="ixv-37957">1.6</ix:nonFraction>&#160;million and royalty obligations in the low single digit range, if rNAPc2 receives regulatory approval and is commercialized. The term of the Agreement extends to the date of expiration of the last to expire of any of the assigned patents.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Gencaro License</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA has licensed worldwide rights to all preclinical and clinical data through the BEST trial for development of bucindolol. The patents that were the subject of this license are expired. If the license agreement is deemed enforceable, ARCA would incur milestone and royalty obligations upon the occurrence of certain events, including if the FDA grants marketing approval for Gencaro, upon regulatory marketing approval in Europe and Japan and based on achievement of specified product sales levels.</p></ix:continuation>
		<ix:nonNumeric contextRef="c6" continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c6_cont_1" escape="true" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="ixv-21494"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(7)&#160;Equity Financings</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">At the Market Equity Financing</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On July&#160;22, 2020, ARCA entered into a Capital on Demand<span class="Superscript" style="vertical-align:super;font-size:58%;">TM</span> Sales Agreement (the &#8220;Sales Agreement&#8221;) with JonesTrading Institutional Services LLC, as agent (&#8220;JonesTrading&#8221;), pursuant to which ARCA may offer and sell, from time to time through JonesTrading, shares of ARCA&#8217;s common stock, par value $<ix:nonFraction contextRef="c92" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-37958">0.001</ix:nonFraction> per share (&#8220;ARCA&#160;common stock&#8221;), having an aggregate offering price of up to $<ix:nonFraction contextRef="c92" decimals="-5" format="ixt:num-dot-decimal" name="abio:CommonStockAuthorizedOfferingAmountUnderAgreementToSell" scale="6" unitRef="usd" id="ixv-37959">54.0</ix:nonFraction>&#160;million (the &#8220;Shares&#8221;).</p></ix:nonNumeric>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-13</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-align:center;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA BIOPHARMA, INC.<br/>NOTES TO FINANCIAL STATEMENTS</span></p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(7)&#160;Equity Financings</span><span class="CharOverride-1" style="font-style:normal;font-weight:normal;"> (cont.)</span></p>
		<ix:continuation id="_StockholdersEquityNoteDisclosureTextBlock-c6_cont_1"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Under the Sales Agreement, JonesTrading may sell the Shares by any method permitted by law and deemed to be an &#8220;at the market offering&#8221; as defined in Rule&#160;415 promulgated under the Securities Act&#160;of&#160;1933, as amended, including sales made directly on or through the Nasdaq Capital Market, on any other existing trading market for ARCA common stock or to or through a market maker. In addition, under the amended Sales Agreement, JonesTrading may sell the Shares by any other method permitted by law, including in negotiated transactions. ARCA may instruct JonesTrading not to sell Shares if the sales cannot be effected at or above the price designated by ARCA from time to time.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA is not obligated to make any sales of the Shares under the Sales Agreement. The offering of Shares pursuant to the Sales Agreement will terminate upon the earlier of (a)&#160;the sale of all of the Shares subject to the Sales Agreement or (b)&#160;the termination of the Sales Agreement by JonesTrading or ARCA, as permitted therein.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA paid JonesTrading a commission rate equal to <ix:nonFraction contextRef="c93" decimals="3" format="ixt:num-dot-decimal" name="abio:SellingCommissionPerAdditionalSharesSoldPercentage" scale="-2" unitRef="pure" id="ixv-37960">3.0</ix:nonFraction>% of the aggregate gross proceeds from each sale of Shares and agreed to provide JonesTrading with customary indemnification and contribution rights. ARCA will also reimburse JonesTrading for certain specified expenses in connection with entering into the Sales Agreement.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><ix:nonFraction contextRef="c94" decimals="0" format="ixt:fixed-zero" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-37961"><ix:nonFraction contextRef="c95" decimals="0" format="ixt:fixed-zero" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-37962">No</ix:nonFraction></ix:nonFraction> sales were made in 2023 or 2022.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In April&#160;2021, ARCA amended the 2020 Sales Agreement and the amount available for the offering under its prospectus to ARCA&#8217;s registration statement on Form&#160;S<span class="nobreak">-3</span> (No.&#160;333<span class="nobreak">-254585</span>). The amount available for the offering under the prospectus supplement is subject to the limitation of not selling a total value amount of shares exceeding more than one<span class="nobreak">-third</span> of ARCA&#8217;s public float in any 12<span class="nobreak">-month</span> period.</p></ix:continuation>
		<ix:nonNumeric contextRef="c6" continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c6_cont_1" escape="true" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="ixv-21521"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(8)&#160;Share-based Compensation</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Stock Plans</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s equity incentive plan, <span class="Italic" style="font-style:italic;font-weight:normal;">the 2020 Equity Incentive Plan </span>(the &#8220;Equity Plan&#8221;),<span class="Italic" style="font-style:italic;font-weight:normal;"> </span>was approved by stockholders on December&#160;10, 2020. The maximum number of shares issuable under this plan is <ix:nonFraction contextRef="c96" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" unitRef="shares" id="ixv-37963">1,167,425</ix:nonFraction><span class="nobreak"> </span>shares.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Equity Plan provides for the granting of stock options (including indexed options), restricted stock units, stock appreciation rights, restricted stock purchase rights, restricted stock bonuses, performance shares, performance units and deferred stock units. Under the Equity Plan, awards may be granted to employees, directors and consultants of ARCA, except for incentive stock options, which may be granted only to employees. As of December&#160;31, 2023, options to purchase <ix:nonFraction contextRef="c97" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-37964">601,900</ix:nonFraction><span class="nobreak"> </span>shares with a weighted average exercise price of $<ix:nonFraction contextRef="c97" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-37965">3.45</ix:nonFraction> per share were outstanding under the Equity Plan, and <ix:nonFraction contextRef="c97" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" unitRef="shares" id="ixv-37966">459,718</ix:nonFraction><span class="nobreak"> </span>shares were reserved for future awards.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In general, the Equity Plan authorizes the grant of stock options that vest at rates set by the Board of Directors or the Compensation Committee thereof. Generally, stock options granted by ARCA under the equity incentive plans become exercisable ratably for a period of <span style="-sec-ix-hidden: hidden-fact-97">three</span> to <span style="-sec-ix-hidden: hidden-fact-98">four</span>&#160;years from the date of grant and have a maximum term of <span style="-sec-ix-hidden: hidden-fact-99">ten</span>&#160;years. The exercise prices of stock options under the equity incentive plan generally meet the following criteria: the exercise price of incentive stock options must be at least <ix:nonFraction contextRef="c100" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" unitRef="pure" id="ixv-37967">100</ix:nonFraction>% of the fair market value on the grant date and exercise price of options granted to <ix:nonFraction contextRef="c98" decimals="INF" format="ixt:num-dot-decimal" name="abio:PercentageHoldingForStockOptionsExercisePrice" scale="-2" unitRef="pure" id="ixv-37968">10</ix:nonFraction>% (or greater) stockholders must be at least <ix:nonFraction contextRef="c101" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" unitRef="pure" id="ixv-37969">110</ix:nonFraction>% of the fair market value on the grant date.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In conjunction with the adoption of the Equity Plan, ARCA discontinued grants under the 2013 Plan, effective December&#160;10, 2020. As of December&#160;31, 2023, options to purchase <ix:nonFraction contextRef="c102" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-37970">14,807</ix:nonFraction><span class="nobreak"> </span>shares with a weighted average exercise price of $<ix:nonFraction contextRef="c102" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-37971">57.73</ix:nonFraction> per share were outstanding under the 2013 plan.</p></ix:nonNumeric>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-14</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-align:center;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA BIOPHARMA, INC.<br/>NOTES TO FINANCIAL STATEMENTS</span></p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(8)&#160;Share-based Compensation</span><span class="CharOverride-1" style="font-style:normal;font-weight:normal;"> (cont.)</span></p>
		<ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c6_cont_2" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c6_cont_1"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA did <ix:nonFraction contextRef="c103" decimals="INF" format="ixt:fixed-zero" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" scale="0" unitRef="shares" id="ixv-37972">no</ix:nonFraction>t grant options in 2023. ARCA granted options to purchase an aggregate of <ix:nonFraction contextRef="c104" decimals="0" format="ixt:num-dot-decimal" name="abio:PurchaseAggregateShares" scale="0" unitRef="shares" id="ixv-37973">60,000</ix:nonFraction><span class="nobreak"> </span>shares of ARCA common stock in the year ended December&#160;31, 2022. <ix:nonNumeric contextRef="c6" continuedAt="_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock-c6_cont_1" escape="true" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="ixv-21552">The fair values of employee stock options granted in the year ended December&#160;31, 2022 were estimated at the date of grant using the Black<span class="nobreak">-Scholes</span> model with the following assumptions and had the following estimated weighted average grant date fair value per share:</ix:nonNumeric></p>
		<ix:continuation id="_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock-c6_cont_1"><table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">	<tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;">	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Year Ended<br/>December&#160;31,<br/>2022</span></p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Expected term</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonNumeric contextRef="c6" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="ixv-37974">5.5</ix:nonNumeric>&#160;years</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Expected volatility</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c6" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure" id="ixv-37975">107</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Risk-free interest rate</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c6" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure" id="ixv-37976">3.56</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Expected dividend yield</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c6" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" unitRef="pure" id="ixv-37977">0</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Weighted-average grant date fair value per share</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c6" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-37978">1.87</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	</tr>	</table></ix:continuation>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><ix:nonNumeric contextRef="c6" continuedAt="_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock-c6_cont_1" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="ixv-37979">A summary of ARCA&#8217;s stock option activities for the&#160;years ended December&#160;31, 2023 and 2022, and related information as of December&#160;31, 2023, is as follows:</ix:nonNumeric></p>
		<ix:continuation id="_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock-c6_cont_1"><table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">	<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" colspan="10" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 61.11%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Options Outstanding</span></p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-17" style="height:12pt;">	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Number of<br/>Options</span></p>	</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Weighted<br/>Average<br/>Exercise<br/>Price</span></p>	</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term (in&#160;years)</span></p>	</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Aggregate<br/>Intrinsic Value<br/>(in thousands)</span></p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Options outstanding&#160;&#8211;&#160;December&#160;31,&#160;2021</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c16" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-37980">904,123</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c16" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-37981">5.59</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Granted</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c7" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" unitRef="shares" id="ixv-37982">60,000</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c7" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-37983">2.31</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Exercised</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-76; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-77; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Forfeited and cancelled</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c7" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" scale="0" unitRef="shares" id="ixv-37984">259,163</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c7" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-37985">4.74</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Options outstanding&#160;&#8211;&#160;December&#160;31,&#160;2022</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-37986">704,960</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-37987">5.62</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonNumeric contextRef="c7" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="ixv-37988">8.29</ix:nonNumeric></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" unitRef="usd" id="ixv-37989">18</ix:nonFraction></p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Granted</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-78; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-79; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Exercised</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-80; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-81; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Forfeited and cancelled</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c6" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" scale="0" unitRef="shares" id="ixv-37990">88,253</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c6" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-37991">11.68</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Options outstanding&#160;&#8211;&#160;December&#160;31,&#160;2023</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-37992">616,707</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-37993">4.76</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonNumeric contextRef="c6" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="ixv-37994">7.35</ix:nonNumeric></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-82; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Options exercisable&#160;&#8211;&#160;December&#160;31,&#160;2023</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" unitRef="shares" id="ixv-37995">463,068</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-37996">5.28</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonNumeric contextRef="c6" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="ixv-37997">7.29</ix:nonNumeric></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-83; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-18" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Options vested and expected to vest&#160;&#8211;&#160;December&#160;31,&#160;2023</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" unitRef="shares" id="ixv-37998">616,661</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-37999">4.76</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonNumeric contextRef="c6" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" id="ixv-38000">7.35</ix:nonNumeric></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-84; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>	</td>	</tr>	</table></ix:continuation>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The aggregate intrinsic value in the table above represents the total intrinsic value, based on ARCA&#8217;s closing price as of December&#160;31 of the respective year, which would have been received by the option holders had all the option holders with in<span class="nobreak">-the-money</span> options exercised as of that date. As of December&#160;31, 2023, the unrecognized compensation expense related to unvested options, excluding estimated forfeitures, was $<ix:nonFraction contextRef="c105" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="0" unitRef="usd" id="ixv-38001">367,000</ix:nonFraction> which is expected to be recognized over a weighted average period of <ix:nonNumeric contextRef="c106" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="ixv-38002">1.1</ix:nonNumeric>&#160;years. ARCA recognizes compensation costs for its share<span class="nobreak">-based</span> awards on a straight<span class="nobreak">-line</span> basis over the requisite service period for the entire award, as adjusted for expected forfeitures.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Restricted Stock Units</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA granted restricted stock units (&#8220;RSUs&#8221;) under the Equity Plan to employees during 2022. The fair value of RSU awards is the closing price of ARCA common stock on the date of the grant and is recognized as compensation expense on a straight<span class="nobreak">-line</span> basis over the respective vesting period. The stock awards granted had a requisite service period of <span style="-sec-ix-hidden: hidden-fact-100">one</span> year.</p></ix:continuation>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-15</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-align:center;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA BIOPHARMA, INC.<br/>NOTES TO FINANCIAL STATEMENTS</span></p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(8)&#160;Share-based Compensation</span><span class="CharOverride-1" style="font-style:normal;font-weight:normal;"> (cont.)</span></p>
		<ix:continuation id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c6_cont_2"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><ix:nonNumeric contextRef="c6" continuedAt="_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock-c6_cont_1" escape="true" name="us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" id="ixv-38003">A summary of RSU activity for the year ended December&#160;31, 2023 is presented below:</ix:nonNumeric></p>
		<ix:continuation id="_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock-c6_cont_1"><table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="5" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Restricted Stock Units<br/>Outstanding</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-19" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Number of<br/>Shares</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Weighted<br/>Average<br/>Grant Date<br/>Fair Value</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">RSUs outstanding&#160;&#8211;&#160;December&#160;31, 2021</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-85; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-86; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Granted</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c7" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" unitRef="shares" id="ixv-38004">91,000</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c7" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-38005">2.21</ix:nonFraction></p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Vested and released</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-87; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-88; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Forfeited and cancelled</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-89; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-90; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">RSUs outstanding&#160;&#8211;&#160;December&#160;31, 2022</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" unitRef="shares" id="ixv-38006">91,000</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-38007">2.21</ix:nonFraction></p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Granted</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-91; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-92; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Vested and released</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c6" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" unitRef="shares" id="ixv-38008">91,000</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c6" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-38009">2.21</ix:nonFraction></p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Forfeited and cancelled</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-93; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-94; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">RSUs outstanding&#160;&#8211;&#160;December&#160;31, 2023</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-95; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-96; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>

		</table></ix:continuation>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of December&#160;31, 2023, there was <ix:nonFraction contextRef="c108" decimals="INF" format="ixt:fixed-zero" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="0" unitRef="usd" id="ixv-38010">no</ix:nonFraction> unrecognized compensation cost related to unvested stock awards.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Non-cash Stock-based Compensation</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><ix:nonNumeric contextRef="c6" continuedAt="_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock-c6_cont_1" escape="true" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="ixv-22033">For the&#160;years ended December&#160;31, 2023 and 2022, ARCA recognized the following non<span class="nobreak">-cash</span>, share<span class="nobreak">-based</span> compensation expense (in thousands):</ix:nonNumeric></p>
		<ix:continuation id="_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock-c6_cont_1"><table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="5" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Years Ended<br/>December&#160;31,</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2022</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">General and administrative</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c89" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-38011">526</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c90" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-38012">423</ix:nonFraction></p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Research and development</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c109" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-38013">160</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c110" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-38014">133</ix:nonFraction></p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-38015">686</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-38016">556</ix:nonFraction></p>	</td>
				</tr>

		</table></ix:continuation>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA did not recognize any tax benefit related to employee stock<span class="nobreak">-based</span> compensation cost as a result of the full valuation allowance on its net deferred tax assets.</p></ix:continuation>
		<ix:nonNumeric contextRef="c6" escape="true" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="ixv-22096"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(9)&#160;Employee Benefit Plans</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA has a 401(k)&#160;plan and makes a <ix:nonNumeric contextRef="c6" name="us-gaap:DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans" id="ixv-38017">matching contribution equal to <ix:nonFraction contextRef="c111" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" scale="-2" unitRef="pure" id="ixv-38018">100</ix:nonFraction>% of the employee&#8217;s first <ix:nonFraction contextRef="c111" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" scale="-2" unitRef="pure" id="ixv-38019">3</ix:nonFraction>% of the employee&#8217;s contributions and <ix:nonFraction contextRef="c112" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" scale="-2" unitRef="pure" id="ixv-38020">50</ix:nonFraction>% of the employee&#8217;s next <ix:nonFraction contextRef="c112" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" scale="-2" unitRef="pure" id="ixv-38021">2</ix:nonFraction>% of contributions.</ix:nonNumeric> ARCA adopted the plan in 2006 and contributed $<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DefinedContributionPlanCostRecognized" scale="0" unitRef="usd" id="ixv-38022">56,000</ix:nonFraction> and $<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DefinedContributionPlanCostRecognized" scale="0" unitRef="usd" id="ixv-38023">96,000</ix:nonFraction> for the&#160;years ended December&#160;31, 2023 and 2022, respectively.</p></ix:nonNumeric>
		<ix:nonNumeric contextRef="c6" continuedAt="_IncomeTaxDisclosureTextBlock-c6_cont_1" escape="true" name="us-gaap:IncomeTaxDisclosureTextBlock" id="ixv-22100"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;">(<span class="Bold" style="font-style:normal;font-weight:bold;">10)&#160;Income Taxes</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Effective June&#160;1, 2005, ARCA changed from an S<span class="nobreak">-Corporation</span> to a C<span class="nobreak">-Corporation</span>. As an S<span class="nobreak">-Corporation</span>, the net operating loss carryforwards were distributed to ARCA&#8217;s stockholders; such amounts were not significant. As of December&#160;31, 2023, ARCA has net operating loss carryforwards of approximately $<ix:nonFraction contextRef="c1" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingLossCarryforwards" scale="6" unitRef="usd" id="ixv-38024">208.1</ix:nonFraction>&#160;million, and approximately $<ix:nonFraction contextRef="c113" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" unitRef="usd" id="ixv-38025">2.4</ix:nonFraction>&#160;million of research and development credits that may be used to offset future taxable income. ARCA&#8217;s net operating loss carryforwards through December&#160;31, 2017 will expire beginning <span style="-sec-ix-hidden: hidden-fact-107">2025</span> through <span style="-sec-ix-hidden: hidden-fact-108">2037</span>. <ix:nonNumeric contextRef="c6" name="us-gaap:TaxCreditCarryforwardDescription" id="ixv-38026">The net operating loss carryforwards beginning in 2018, have no expiration.</ix:nonNumeric> <ix:nonNumeric contextRef="c116" continuedAt="_TaxCreditCarryforwardLimitationsOnUse-c116_cont_1" name="us-gaap:TaxCreditCarryforwardLimitationsOnUse" id="ixv-38027">Utilization of net operating losses and tax credits, including those acquired as a result of the Merger, will be subject to an annual limitation due to ownership change limitations provided by Internal Revenue Code Section&#160;382. ARCA believes that an ownership change limitation as defined under Section&#160;382 of the U.S.&#160;Internal Revenue Code occurred as a result of its various historical financing transactions. Future utilization of the federal net operating losses and tax credit </ix:nonNumeric></p></ix:nonNumeric>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-16</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-align:center;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA BIOPHARMA, INC.<br/>NOTES TO FINANCIAL STATEMENTS</span></p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;">(<span class="Bold" style="font-style:normal;font-weight:bold;">10)&#160;Income Taxes</span><span class="CharOverride-1" style="font-style:normal;font-weight:normal;"> (cont.)</span></p>
		<ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c6_cont_2" id="_IncomeTaxDisclosureTextBlock-c6_cont_1"><ix:continuation id="_TaxCreditCarryforwardLimitationsOnUse-c116_cont_1"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">carryforwards accumulated from June&#160;2005 to the change in ownership date will be subject to annual limitations to offset future taxable income. The annual limitation may result in the expiration of the net operating losses and credits before utilization. As such, a portion of ARCA&#8217;s net operating loss carryforwards may be limited.</p></ix:continuation>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the period in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. Due primarily to ARCA&#8217;s history of operating losses, management is unable to conclude that it is more likely than not that ARCA will realize the benefits of these deductible differences, and accordingly has provided a valuation allowance against the entire net deferred tax assets and liabilities of approximately $<ix:nonFraction contextRef="c1" decimals="-5" format="ixt:num-dot-decimal" name="abio:DeferredTaxAssetsAndLiabilitiesValuationAllowance" scale="6" unitRef="usd" id="ixv-38028">55.5</ix:nonFraction>&#160;million at December&#160;31, 2023, reflecting an increase of approximately $<ix:nonFraction contextRef="c6" decimals="-5" format="ixt:num-dot-decimal" name="abio:ValuationAllowanceDeferredTaxAssetsAndLiabilitiesChangeInAmount" scale="6" unitRef="usd" id="ixv-38029">1.2</ix:nonFraction>&#160;million from December&#160;31, 2022. The deferred tax assets are primarily comprised of net operating loss carryforwards and research and experimentation credit carryforwards. As of December&#160;31, 2023, ARCA has not performed an Internal Revenue Code Section&#160;382 limitation study. Depending on the outcome of such a study, the gross amount of net operating losses recognizable in future tax periods could be limited. A limitation in the carryforwards would decrease the carrying amount of the gross amount of the net operating loss carryforwards, with a corresponding decrease in the valuation allowance recorded against these gross deferred tax assets.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><ix:nonNumeric contextRef="c6" continuedAt="_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock-c6_cont_1" escape="true" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="ixv-38030">Income tax benefit attributable to ARCA&#8217;s loss from operations before income taxes differs from the amounts computed by applying the U.S.&#160;federal statutory income tax rate of <ix:nonFraction contextRef="c6" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" unitRef="pure" id="ixv-38031"><ix:nonFraction contextRef="c7" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" unitRef="pure" id="ixv-38032">21</ix:nonFraction></ix:nonFraction>% for 2023 and 2022, as a result of the following (in thousands):</ix:nonNumeric></p>
		<ix:continuation id="_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock-c6_cont_1"><table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Years ended<br/>December&#160;31,</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2022</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">U.S.&#160;federal income tax benefit at statutory rates</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="3" sign="-" unitRef="usd" id="ixv-38033">1,121</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="3" sign="-" unitRef="usd" id="ixv-38034">2,085</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">State income tax benefit, net of federal benefit</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="3" sign="-" unitRef="usd" id="ixv-38035">192</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="3" sign="-" unitRef="usd" id="ixv-38036">357</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Research and experimentation credits</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-101; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-102; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Deferred tax asset adjustment</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="abio:IncomeTaxReconciliationAdjustmentToDeferredTaxAsset" scale="3" unitRef="usd" id="ixv-38037">47</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="abio:IncomeTaxReconciliationAdjustmentToDeferredTaxAsset" scale="3" unitRef="usd" id="ixv-38038">2</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="3" unitRef="usd" id="ixv-38039">107</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="3" unitRef="usd" id="ixv-38040">186</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Change in valuation allowance</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="3" unitRef="usd" id="ixv-38041">1,159</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="3" unitRef="usd" id="ixv-38042">2,254</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Income tax benefit</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-103; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-104; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>

		</table></ix:continuation></ix:continuation>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-17</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-align:center;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA BIOPHARMA, INC.<br/>NOTES TO FINANCIAL STATEMENTS</span></p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;">(<span class="Bold" style="font-style:normal;font-weight:bold;">10)&#160;Income Taxes</span><span class="CharOverride-1" style="font-style:normal;font-weight:normal;"> (cont.)</span></p>
		<ix:continuation id="_IncomeTaxDisclosureTextBlock-c6_cont_2"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><ix:nonNumeric contextRef="c6" continuedAt="_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock-c6_cont_1" escape="true" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="ixv-38043">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting and the amounts used for income tax purposes, as well as operating loss and tax credit carryforwards. The income tax effects of temporary differences and carryforwards that give rise to significant portions of ARCA&#8217;s net deferred tax assets and liabilities consisted of the following (in thousands):</ix:nonNumeric></p>
		<ix:continuation id="_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock-c6_cont_1"><table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">As of December&#160;31,</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2022</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Deferred tax assets:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net operating loss carryforwards</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" scale="3" unitRef="usd" id="ixv-38044">51,190</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" scale="3" unitRef="usd" id="ixv-38045">50,008</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Charitable contribution carryforwards</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsCharitableContributionCarryforwards" scale="3" unitRef="usd" id="ixv-38046">371</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsCharitableContributionCarryforwards" scale="3" unitRef="usd" id="ixv-38047">393</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Research and experimentation credits</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="3" unitRef="usd" id="ixv-38048">2,420</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="3" unitRef="usd" id="ixv-38049">2,420</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Capitalized research and development costs</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="abio:DeferredTaxAssetResearchAndDevelopment" scale="3" unitRef="usd" id="ixv-38050">951</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="abio:DeferredTaxAssetResearchAndDevelopment" scale="3" unitRef="usd" id="ixv-38051">979</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Capitalized intangibles</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" scale="3" unitRef="usd" id="ixv-38052">354</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" scale="3" unitRef="usd" id="ixv-38053">356</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Stock-based compensation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" unitRef="usd" id="ixv-38054">232</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" unitRef="usd" id="ixv-38055">205</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accrued compensation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" scale="3" unitRef="usd" id="ixv-38056">7</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" scale="3" unitRef="usd" id="ixv-38057">6</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Lease liabilities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="abio:DeferredTaxAssetsLeaseLiabilities" scale="3" unitRef="usd" id="ixv-38058">69</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="abio:DeferredTaxAssetsLeaseLiabilities" scale="3" unitRef="usd" id="ixv-38059">94</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total deferred tax assets</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" unitRef="usd" id="ixv-38060">55,594</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" unitRef="usd" id="ixv-38061">54,461</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Valuation allowance</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" unitRef="usd" id="ixv-38062">55,531</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" unitRef="usd" id="ixv-38063">54,372</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Deferred tax assets, net of valuation allowance</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsNet" scale="3" unitRef="usd" id="ixv-38064">63</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsNet" scale="3" unitRef="usd" id="ixv-38065">89</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Deferred tax liabilities:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Right-of-use asset</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="abio:DeferredTaxLiabilitiesRightOfUseAsset" scale="3" unitRef="usd" id="ixv-38066">61</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="abio:DeferredTaxLiabilitiesRightOfUseAsset" scale="3" unitRef="usd" id="ixv-38067">84</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Depreciation and amortization</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-38068">2</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-38069">5</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net deferred tax liability</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-105; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-106; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>

		</table></ix:continuation>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Since ARCA is in a loss carryforward position, it is generally subject to U.S.&#160;federal and state income tax examinations by tax authorities for all&#160;years for which a loss carryforward is available. Thus, ARCA&#8217;s open tax&#160;years extend back to <span style="-sec-ix-hidden: hidden-fact-109">2009</span>. ARCA believes that its tax filing positions and deductions related to tax periods subject to examination will be sustained upon audit and does not anticipate any adjustment will result in a material adverse effect on ARCA&#8217;s financial condition, result of operations, or cash flow. For the&#160;years ended December&#160;31, 2023 and 2022, ARCA has <ix:nonFraction contextRef="c1" decimals="INF" format="ixt:fixed-zero" name="us-gaap:LiabilityForUncertainTaxPositionsCurrent" scale="0" unitRef="usd" id="ixv-38070"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:fixed-zero" name="us-gaap:LiabilityForUncertainTaxPositionsCurrent" scale="0" unitRef="usd" id="ixv-38071">no</ix:nonFraction></ix:nonFraction> reserve for uncertain tax positions. ARCA does not expect that the total amounts of unrecognized tax benefits will significantly increase or decrease within the subsequent twelve&#160;months. In the event ARCA concludes it is subject to interest or penalties arising from uncertain tax positions, it will record interest and penalties as a component of other income and expense. <ix:nonFraction contextRef="c6" decimals="0" format="ixt:fixed-zero" name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense" scale="0" unitRef="usd" id="ixv-38072"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:fixed-zero" name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense" scale="0" unitRef="usd" id="ixv-38073">No</ix:nonFraction></ix:nonFraction> interest or penalties were recognized in the financial statements for the&#160;years ended December&#160;31, 2023 and 2022.</p></ix:continuation>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-18</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T207"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA BIOPHARMA, INC.<br/>BALANCE SHEETS<br/>(Unaudited)</span></p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">March&#160;31, <br/>2024</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">December&#160;31, <br/>2023</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(in thousands, except share and <br/>per share amounts)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-align:center;text-indent:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ASSETS</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Current assets:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Cash and cash equivalents</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" unitRef="usd" id="ixv-38074">35,903</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" unitRef="usd" id="ixv-38075">37,431</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other current assets</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsCurrent" scale="3" unitRef="usd" id="ixv-38076">767</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsCurrent" scale="3" unitRef="usd" id="ixv-38077">161</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total current assets</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" unitRef="usd" id="ixv-38078">36,670</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" unitRef="usd" id="ixv-38079">37,592</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Right-of-use asset&#160;&#8211;&#160;operating</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" unitRef="usd" id="ixv-38080">17</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" unitRef="usd" id="ixv-38081">247</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Property and equipment, net</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd" id="ixv-38082">7</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd" id="ixv-38083">10</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other assets</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" unitRef="usd" id="ixv-38084">12</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" unitRef="usd" id="ixv-38085">12</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Total assets</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" unitRef="usd" id="ixv-38086">36,706</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" unitRef="usd" id="ixv-38087">37,861</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;text-indent:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Current liabilities:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accounts payable</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="3" unitRef="usd" id="ixv-38088">529</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="3" unitRef="usd" id="ixv-38089">362</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accrued compensation and employee benefits</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-38090">84</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-38091">100</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accrued expenses and other liabilities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-38092">968</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-38093">175</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total current liabilities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-38094">1,581</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-38095">637</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Operating lease liability, net of current portion</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-5; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" unitRef="usd" id="ixv-38096">204</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Total liabilities</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" unitRef="usd" id="ixv-38097">1,581</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" unitRef="usd" id="ixv-38098">841</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Commitments and contingencies</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Stockholders&#8217; equity:</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Common stock, $<ix:nonFraction contextRef="c5" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-38099"><ix:nonFraction contextRef="c1" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-38100">0.001</ix:nonFraction></ix:nonFraction>&#160;par value; <ix:nonFraction contextRef="c5" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="6" unitRef="shares" id="ixv-38101"><ix:nonFraction contextRef="c1" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="6" unitRef="shares" id="ixv-38102">100</ix:nonFraction></ix:nonFraction>&#160;million shares authorized at March&#160;31,&#160;2024 and December&#160;31, 2023; <ix:nonFraction contextRef="c5" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-38103"><ix:nonFraction contextRef="c1" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-38104"><ix:nonFraction contextRef="c5" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-38105"><ix:nonFraction contextRef="c1" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-38106">14,501,143</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>&#160;shares issued and outstanding at March&#160;31, 2024 and December&#160;31, 2023, respectively</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="3" unitRef="usd" id="ixv-38107">14</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="3" unitRef="usd" id="ixv-38108">14</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Additional paid-in capital</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" unitRef="usd" id="ixv-38109">225,861</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" unitRef="usd" id="ixv-38110">225,747</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accumulated deficit</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" sign="-" unitRef="usd" id="ixv-38111">190,750</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" sign="-" unitRef="usd" id="ixv-38112">188,741</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Total stockholders&#8217; equity</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-38113">35,125</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-38114">37,020</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Total liabilities and stockholders&#8217; equity</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" unitRef="usd" id="ixv-38115">36,706</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" unitRef="usd" id="ixv-38116">37,861</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>

		</table>
		<p class="Text_flush_Center" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:3;margin-top:8pt;">See accompanying Notes to Financial Statements</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-19</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T208"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA BIOPHARMA, INC.<br/>STATEMENTS OF OPERATIONS<br/>(Unaudited)</span></p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-10" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">March&#160;31,</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-10" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">2024</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(in thousands, except share and <br/>per share amounts)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Costs and expenses:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">General and administrative</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-38117">2,317</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-38118">1,406</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-11" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Research and development (related party&#160;&#8211;&#160;$<ix:nonFraction contextRef="c11" decimals="-3" format="ixt:num-dot-decimal" name="abio:ResearchAndDevelopmentExpenseReversed" scale="3" unitRef="usd" id="ixv-38119">0</ix:nonFraction>&#160;and $<ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="abio:ResearchAndDevelopmentExpenseReversed" scale="3" unitRef="usd" id="ixv-38120">108</ix:nonFraction> as of March&#160;31,&#160;2024&#160;and 2023, respectively)</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-38121">165</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-38122">390</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total costs and expenses</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" unitRef="usd" id="ixv-38123">2,482</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" unitRef="usd" id="ixv-38124">1,796</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Loss from operations</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-38125">2,482</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-38126">1,796</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Interest and other income</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestAndOtherIncome" scale="3" unitRef="usd" id="ixv-38127">473</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestAndOtherIncome" scale="3" unitRef="usd" id="ixv-38128">450</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net loss</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-38129">2,009</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-38130">1,346</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net loss per share:</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody-ind_2" style="-sec-ix-hidden: hidden-fact-12; -sec-ix-hidden: hidden-fact-11; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Basic and diluted</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-38131">0.14</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c10" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-38132">0.09</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Weighted average shares outstanding:</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody-ind_2" style="-sec-ix-hidden: hidden-fact-14; -sec-ix-hidden: hidden-fact-13; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Basic and diluted</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-38133">14,501,143</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-38134">14,410,143</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
				</tr>

		</table>
		<p class="Text_flush_Center" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:3;margin-top:8pt;">See accompanying Notes to Financial Statements</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-20</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T209"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA BIOPHARMA, INC.<br/>STATEMENTS OF STOCKHOLDERS&#8217; EQUITY<br/>(Unaudited)</span></p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-10" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 33.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="15" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 65.17%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Stockholders&#8217; Equity</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 33.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="4" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 24.36%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><br/>Common stock</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" rowspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Additional <br/>Paid-In <br/>Capital</span></p>
					</td>
					<td class="TCH" rowspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" rowspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Accumulated<br/>Deficit</span></p>
					</td>
					<td class="TCH" rowspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" rowspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.75%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Total</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-10" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 33.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Shares</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Amount</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-10" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 33.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="15" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 65.17%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(in thousands, except share and per share amounts)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 33.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Balance, December&#160;31, 2022</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c20" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-38135">14,410,143</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="Bold" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.76%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c20" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-38136">14</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="Bold" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c21" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-38137">225,061</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="Bold" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.19%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(<ix:nonFraction contextRef="c22" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-38138">183,402</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="Bold" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-38139">41,673</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 33.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Share-based compensation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.76%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-27; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c30" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" unitRef="usd" id="ixv-38140">204</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.19%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-28; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" unitRef="usd" id="ixv-38141">204</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 33.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net loss</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.76%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-29; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-30; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.19%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c31" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-38142">1,346</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.33%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-38143">1,346</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 33.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Balance, March&#160;31, 2023</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c32" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-38144">14,410,143</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.76%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c32" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-38145">14</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c33" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-38146">225,265</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.19%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(<ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-38147">184,748</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c35" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-38148">40,531</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 33.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Share-based compensation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.76%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-31; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c37" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" unitRef="usd" id="ixv-38149">187</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.19%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-32; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c39" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" unitRef="usd" id="ixv-38150">187</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 33.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net loss</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.76%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-33; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-34; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.19%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c38" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-38151">1,480</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.33%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c39" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-38152">1,480</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 33.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Balance, June&#160;30, 2023</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c40" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-38153">14,410,143</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.76%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c40" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-38154">14</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c41" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-38155">225,452</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.19%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(<ix:nonFraction contextRef="c42" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-38156">186,228</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c43" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-38157">39,238</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 33.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Share-based compensation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.76%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-35; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c45" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" unitRef="usd" id="ixv-38158">154</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.19%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-36; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c47" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" unitRef="usd" id="ixv-38159">154</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 33.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net loss</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.76%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-37; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-38; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.19%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c46" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-38160">1,424</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.33%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c47" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-38161">1,424</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 33.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Balance, September&#160;30, 2023</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c48" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-38162">14,410,143</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.76%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c48" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-38163">14</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c49" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-38164">225,606</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.19%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(<ix:nonFraction contextRef="c50" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-38165">187,652</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c51" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-38166">37,968</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-11" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 33.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Issuance of common stock upon vesting&#160;of Restricted Stock Units</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c52" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="0" unitRef="shares" id="ixv-38167">91,000</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.76%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-39; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:normal;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-style:normal;font-weight:normal;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-40; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:normal;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-style:normal;font-weight:normal;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.19%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-41; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:normal;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-style:normal;font-weight:normal;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-style:normal;font-weight:normal;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.33%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-42; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:normal;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-style:normal;font-weight:normal;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 33.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Share-based compensation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.76%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-43; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c53" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" unitRef="usd" id="ixv-38168">141</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.19%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-44; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c55" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" unitRef="usd" id="ixv-38169">141</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 33.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net loss</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.76%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-45; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-46; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.19%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c54" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-38170">1,089</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.33%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c55" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-38171">1,089</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 33.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Balance, December&#160;31, 2023</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c26" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-38172">14,501,143</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.76%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c26" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-38173">14</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c27" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-38174">225,747</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.19%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(<ix:nonFraction contextRef="c28" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-38175">188,741</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-38176">37,020</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 33.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Share-based compensation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.76%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-47; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c57" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" unitRef="usd" id="ixv-38177">114</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.19%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-48; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" unitRef="usd" id="ixv-38178">114</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 33.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net loss</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.76%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-49; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-50; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.19%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c58" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-38179">2,009</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.33%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-38180">2,009</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 33.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Balance, March&#160;31, 2024</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c59" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-38181">14,501,143</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="Bold" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.76%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c59" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-38182">14</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="Bold" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c60" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-38183">225,861</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;"><span class="Bold" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.19%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">(<ix:nonFraction contextRef="c61" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-38184">190,750</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="Bold" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.33%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-38185">35,125</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">&#160;</span></p>
					</td>
				</tr>

		</table>
		<p class="Text_flush_Center" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:3;margin-top:8pt;">See accompanying Notes to Financial Statements</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-21</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T210"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA BIOPHARMA, INC.<br/>STATEMENTS OF CASH FLOWS<br/>(Unaudited)</span></p>
		<table class="No-Table-Style _idGenTablePara-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-10" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Quarter Ended March&#160;31,</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-10" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">2024</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-10" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(in thousands)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Cash flows from operating activities:</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net loss</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-38186">2,009</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-38187">1,346</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Adjustments to reconcile net loss to net cash used in operating activities:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Depreciation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepreciationAndAmortization" scale="3" unitRef="usd" id="ixv-38188">3</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepreciationAndAmortization" scale="3" unitRef="usd" id="ixv-38189">4</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Amortization of right-of-use asset&#160;&#8211;&#160;operating</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" unitRef="usd" id="ixv-38190">16</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" unitRef="usd" id="ixv-38191">25</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Share-based compensation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" unitRef="usd" id="ixv-38192">114</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" unitRef="usd" id="ixv-38193">204</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Change in operating assets and liabilities:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other current assets</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" scale="3" unitRef="usd" id="ixv-38194">606</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" scale="3" unitRef="usd" id="ixv-38195">598</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accounts payable</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" unitRef="usd" id="ixv-38196">167</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" unitRef="usd" id="ixv-38197">32</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accrued compensation and employee benefits</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" scale="3" sign="-" unitRef="usd" id="ixv-38198">16</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" scale="3" unitRef="usd" id="ixv-38199">62</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accrued expenses and other liabilities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" scale="3" unitRef="usd" id="ixv-38200">803</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" scale="3" unitRef="usd" id="ixv-38201">22</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Net cash used in operating activities</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" sign="-" unitRef="usd" id="ixv-38202">1,528</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" sign="-" unitRef="usd" id="ixv-38203">1,595</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Cash flows from investing activities:</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Net cash used in investing activities</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-61; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-62; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Cash flows from financing activities:</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Net cash provided by financing activities</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-63; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-64; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Net decrease in cash and cash equivalents</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" sign="-" unitRef="usd" id="ixv-38204">1,528</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" sign="-" unitRef="usd" id="ixv-38205">1,595</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Cash and cash equivalents, beginning of year</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd" id="ixv-38206">37,431</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd" id="ixv-38207">42,445</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Cash and cash equivalents, end of year</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd" id="ixv-38208">35,903</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c35" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd" id="ixv-38209">40,850</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Supplemental cash flow information:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Interest paid</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-65; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-66; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Income tax refund received</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-67; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-68; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Supplemental disclosure of noncash investing and financing transactions:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Leased assets and operating lease liabilities&#160;&#8211;&#160;amended lease term</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" unitRef="usd" id="ixv-38210">214</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-69; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>

		</table>
		<p class="Text_flush_Center" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:3;margin-top:8pt;">See accompanying Notes to Financial Statements</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-22</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T211"></a><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA BIOPHARMA, INC.<br/>NOTES TO FINANCIAL STATEMENTS<br/>(Unaudited)</span></p>
		<ix:nonNumeric contextRef="c0" continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_1" escape="true" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" id="ixv-24333"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(1)&#160;ARCA and Summary of Significant Accounting Policies</span></p>
		<ix:nonNumeric contextRef="c0" continuedAt="abio_DescriptionOfBusinessPolicyTextBlock-c0_cont_1" escape="true" name="abio:DescriptionOfBusinessPolicyTextBlock" id="ixv-24336"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;margin-top:8pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Description of Business</span></p></ix:nonNumeric>
		<ix:continuation continuedAt="abio_DescriptionOfBusinessPolicyTextBlock-c0_cont_2" id="abio_DescriptionOfBusinessPolicyTextBlock-c0_cont_1"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA biopharma, Inc. (&#8220;ARCA&#8221;), a Delaware corporation, is headquartered in Westminster, Colorado. ARCA is dedicated to applying a precision medicine approach to the development and commercialization of genetically targeted therapies for cardiovascular diseases. ARCA&#8217;s lead product candidate is Gencaro&#8482; (bucindolol hydrochloride) for the treatment of atrial fibrillation (&#8220;AF&#8221;) in patients with chronic heart failure (&#8220;HF&#8221;).</p></ix:continuation>
		<ix:continuation continuedAt="abio_DescriptionOfBusinessPolicyTextBlock-c0_cont_3" id="abio_DescriptionOfBusinessPolicyTextBlock-c0_cont_2"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In April&#160;2022, ARCA established a Special Committee of the board of directors (the &#8220;Board&#8221;) of ARCA to conduct a comprehensive review of strategic alternatives. As part of the strategic review process, ARCA explored potential strategic alternatives that included, without limitation, an acquisition, merger, business combination or other transactions. ARCA has and is continuing to explore strategic alternatives related to its product candidates and related assets, including, without limitation, licensing transactions and asset sales.</p></ix:continuation>
		<ix:continuation continuedAt="abio_DescriptionOfBusinessPolicyTextBlock-c0_cont_4" id="abio_DescriptionOfBusinessPolicyTextBlock-c0_cont_3"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On April&#160;3, 2024, following a comprehensive review of strategic alternatives, ARCA, Atlas Merger Sub Corp., a Delaware corporation and a wholly<span class="nobreak">-owned</span> subsidiary of ARCA (&#8220;Merger Sub&#160;I&#8221;), Atlas Merger Sub&#160;II LLC, a Delaware limited liability company and a wholly<span class="nobreak">-owned</span> subsidiary of ARCA (&#8220;Merger Sub&#160;II&#8221;) and Oruka Therapeutics, Inc., a Delaware corporation (&#8220;Oruka<span class="CharOverride-1" style="text-decoration:underline;">&#8221;</span>), entered into an Agreement and Plan of Merger and Reorganization (the &#8220;Merger Agreement&#8221;), pursuant to which, among other matters, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Merger Sub&#160;I will merge with and into Oruka, with Oruka continuing as a wholly owned subsidiary of ARCA and the surviving corporation of the merger (the &#8220;First Merger&#8221;) and as part of the same overall transaction, the surviving corporation in the First Merger will merge with and into Merger Sub&#160;II with Merger Sub&#160;II continuing as a wholly owned subsidiary of ARCA and the surviving entity of the merger (the &#8220;Second Merger&#8221; and together with the First Merger, the &#8220;Merger&#8221;). The Merger is intended to qualify for federal income tax purposes as a tax<span class="nobreak">-free</span> reorganization under the provisions of Section&#160;368(a)&#160;of the Internal Revenue Code of 1986, as amended.</p></ix:continuation>
		<ix:continuation id="abio_DescriptionOfBusinessPolicyTextBlock-c0_cont_4"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s future operations are highly dependent on the success of the Merger and there can be no assurances that the Merger will be successfully consummated. In the event that ARCA does not complete the Merger, it may explore strategic alternatives, including, without limitation, another strategic transaction and/or pursue a dissolution and liquidation of ARCA. See Note&#160;10.</p></ix:continuation>
		<ix:nonNumeric contextRef="c0" continuedAt="abio_LiquidityAndGoingConcernPolicyTextBlock-c0_cont_1" escape="true" name="abio:LiquidityAndGoingConcernPolicyTextBlock" id="ixv-24351"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Liquidity and Going Concern</span></p></ix:nonNumeric>
		<ix:continuation continuedAt="abio_LiquidityAndGoingConcernPolicyTextBlock-c0_cont_2" id="abio_LiquidityAndGoingConcernPolicyTextBlock-c0_cont_1"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA devotes substantially all of its efforts towards obtaining regulatory approval and raising capital necessary to fund its operations and it is subject to a number of risks associated with clinical research and development, including dependence on key individuals, the development of and regulatory approval of commercially viable products, the need to raise adequate additional financing necessary to fund the development and commercialization of its products, and competition from larger companies. ARCA has <ix:nonFraction contextRef="c0" decimals="INF" format="ixt:fixed-zero" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-38211">no</ix:nonFraction>t generated revenue to date and has incurred substantial losses and negative cash flows from operations since its inception. ARCA has historically funded its operations through issuances of common and preferred stock.</p></ix:continuation>
		<ix:continuation continuedAt="abio_LiquidityAndGoingConcernPolicyTextBlock-c0_cont_3" id="abio_LiquidityAndGoingConcernPolicyTextBlock-c0_cont_2"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA believes that its current cash and cash equivalents as of March&#160;31, 2024 will be sufficient to fund its operations through the middle of fiscal year 2025. The future viability of ARCA beyond that point is dependent on the results of the strategic review process and its ability to raise additional capital to fund its operations. ARCA expects to continue to incur costs and expenditures in connection with the process of evaluating strategic alternatives. There can be no assurance, however, that ARCA will be able to successfully consummate any particular strategic transaction, including the Merger Agreement. The process of continuing to evaluate these strategic options may be very costly, time<span class="nobreak">-consuming</span> and complex and ARCA has incurred, and may in the future incur, significant costs related to this continued evaluation, such as legal, accounting and advisory fees and expenses and other related charges, see Note&#160;10 regarding the Merger Agreement. Should ARCA pursue additional clinical trials for its product candidates, it will have to raise additional capital for clinical trials of Gencaro. ARCA may not be able to raise sufficient capital on acceptable terms, or at all, to continue development of Gencaro or rNAPc2 or to otherwise continue operations and may not be </p></ix:continuation></ix:nonNumeric>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-23</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-align:center;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA BIOPHARMA, INC.<br/>NOTES TO FINANCIAL STATEMENTS<br/>(Unaudited)</span></p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(1)&#160;ARCA and Summary of Significant Accounting Policies</span><span class="CharOverride-2" style="font-style:normal;font-weight:normal;"> (cont.)</span></p>
		<ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_2" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_1"><ix:continuation continuedAt="abio_LiquidityAndGoingConcernPolicyTextBlock-c0_cont_4" id="abio_LiquidityAndGoingConcernPolicyTextBlock-c0_cont_3"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">able to execute any strategic transaction. Changing circumstances may cause ARCA to consume capital significantly faster or slower than currently anticipated. ARCA has based these estimates on assumptions that may prove to be wrong, and it could exhaust its available financial resources sooner than it currently anticipates. Depending on the results of the strategic review process, ARCA may have to raise additional capital for clinical trials of Gencaro and to fund its operations. ARCA may not be able to raise sufficient capital on acceptable terms, or at all, to continue development of Gencaro or rNAPc2 or to otherwise continue operations and may not be able to execute any strategic transaction.</p></ix:continuation>
		<ix:continuation continuedAt="abio_LiquidityAndGoingConcernPolicyTextBlock-c0_cont_5" id="abio_LiquidityAndGoingConcernPolicyTextBlock-c0_cont_4"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s liquidity, and its ability to raise additional capital or complete any strategic transaction, depends on a number of factors, including, but not limited to, the following:</p></ix:continuation>
		<ix:continuation continuedAt="abio_LiquidityAndGoingConcernPolicyTextBlock-c0_cont_6" id="abio_LiquidityAndGoingConcernPolicyTextBlock-c0_cont_5"><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the timing and outcome of the strategic review process;</p></ix:continuation>
		<ix:continuation continuedAt="abio_LiquidityAndGoingConcernPolicyTextBlock-c0_cont_7" id="abio_LiquidityAndGoingConcernPolicyTextBlock-c0_cont_6"><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the consummation of any particular strategic transactions, including the Merger;</p></ix:continuation>
		<ix:continuation continuedAt="abio_LiquidityAndGoingConcernPolicyTextBlock-c0_cont_8" id="abio_LiquidityAndGoingConcernPolicyTextBlock-c0_cont_7"><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the costs and timing for the potential additional clinical trials in order to gain possible regulatory approval for Gencaro, rNAPc2, or any other product candidate;</p></ix:continuation>
		<ix:continuation continuedAt="abio_LiquidityAndGoingConcernPolicyTextBlock-c0_cont_9" id="abio_LiquidityAndGoingConcernPolicyTextBlock-c0_cont_8"><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the market price of ARCA&#8217;s stock and the availability and cost of additional equity capital from existing and potential new investors;</p></ix:continuation>
		<ix:continuation continuedAt="abio_LiquidityAndGoingConcernPolicyTextBlock-c0_cont_10" id="abio_LiquidityAndGoingConcernPolicyTextBlock-c0_cont_9"><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s ability to retain the listing of its common stock on the Nasdaq Capital Market;</p></ix:continuation>
		<ix:continuation continuedAt="abio_LiquidityAndGoingConcernPolicyTextBlock-c0_cont_11" id="abio_LiquidityAndGoingConcernPolicyTextBlock-c0_cont_10"><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>general economic and industry conditions affecting the availability and cost of capital, including as a result of deteriorating market conditions due to investor concerns regarding inflation, adverse developments affecting the financial services industry, continued hostilities between Russia and Ukraine and Hamas&#8217; attack against Israel and the ensuing conflict;</p></ix:continuation>
		<ix:continuation continuedAt="abio_LiquidityAndGoingConcernPolicyTextBlock-c0_cont_12" id="abio_LiquidityAndGoingConcernPolicyTextBlock-c0_cont_11"><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s ability to control costs associated with its operations;</p></ix:continuation>
		<ix:continuation continuedAt="abio_LiquidityAndGoingConcernPolicyTextBlock-c0_cont_13" id="abio_LiquidityAndGoingConcernPolicyTextBlock-c0_cont_12"><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; and</p></ix:continuation>
		<ix:continuation continuedAt="abio_LiquidityAndGoingConcernPolicyTextBlock-c0_cont_14" id="abio_LiquidityAndGoingConcernPolicyTextBlock-c0_cont_13"><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the terms and conditions of ARCA&#8217;s existing collaborative and licensing agreements.</p></ix:continuation>
		<ix:continuation id="abio_LiquidityAndGoingConcernPolicyTextBlock-c0_cont_14"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The sale of additional equity or convertible debt securities would likely result in substantial additional dilution to ARCA&#8217;s stockholders. If ARCA raises additional funds through the incurrence of indebtedness, the obligations related to such indebtedness would be senior to rights of holders of ARCA&#8217;s capital stock and could contain covenants that would restrict ARCA&#8217;s operations. ARCA also cannot predict what consideration might be available, if any, to it or its stockholders, in connection with any strategic transaction. Should strategic alternatives or additional capital not be available to ARCA, or not be available on acceptable terms, ARCA may be unable to realize value from its assets and discharge its liabilities in the normal course of business which may, among other alternatives, cause ARCA to further delay, substantially reduce or discontinue operational activities to conserve its cash resources.</p></ix:continuation>
		<ix:nonNumeric contextRef="c0" continuedAt="_BasisOfAccountingPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="ixv-24413"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Basis of Presentation</span></p></ix:nonNumeric>
		<ix:continuation continuedAt="_BasisOfAccountingPolicyPolicyTextBlock-c0_cont_2" id="_BasisOfAccountingPolicyPolicyTextBlock-c0_cont_1"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The accompanying unaudited financial statements of ARCA were prepared in accordance with generally accepted accounting principles for interim financial information and pursuant to Regulation&#160;S<span class="nobreak">-X</span>.&#160;Accordingly, these financial statements do not include all of the information and footnotes required by accounting principles generally accepted in the United&#160;States of America (&#8220;GAAP&#8221;) for complete financial statements. In the opinion of management, these financial statements include all normal and recurring adjustments considered necessary for a fair presentation of these interim financial statements. The results of operations for the three&#160;months ended March&#160;31, 2024 are not necessarily indicative of results expected for the full year ending December&#160;31, 2024. ARCA has generated no revenue to date and its activities have consisted of seeking regulatory approval, research and development, exploring </p></ix:continuation></ix:continuation>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-24</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-align:center;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA BIOPHARMA, INC.<br/>NOTES TO FINANCIAL STATEMENTS<br/>(Unaudited)</span></p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(1)&#160;ARCA and Summary of Significant Accounting Policies</span><span class="CharOverride-2" style="font-style:normal;font-weight:normal;"> (cont.)</span></p>
		<ix:continuation id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_2"><ix:continuation id="_BasisOfAccountingPolicyPolicyTextBlock-c0_cont_2"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">strategic alternatives for further developing and commercializing Gencaro and rNAPc2, and raising capital. These unaudited financial statements should be read in conjunction with the audited financial statements and footnotes thereto for the year ended December&#160;31, 2023 included elsewhere in this proxy statement/prospectus. Amounts presented are rounded to the nearest thousand, where indicated, except per share data and par values.</p></ix:continuation>
		<ix:nonNumeric contextRef="c0" continuedAt="_ConcentrationRiskCreditRisk-c0_cont_1" escape="true" name="us-gaap:ConcentrationRiskCreditRisk" id="ixv-24433"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Concentrations of Credit Risk</span></p></ix:nonNumeric>
		<ix:continuation id="_ConcentrationRiskCreditRisk-c0_cont_1"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Financial instruments that potentially subject ARCA to significant concentrations of credit risk consist primarily of cash and cash equivalents. ARCA has <ix:nonFraction contextRef="c5" decimals="INF" format="ixt:fixed-zero" name="us-gaap:FairValueDisclosureOffbalanceSheetRisksAmountAsset" scale="0" unitRef="usd" id="ixv-38212">no</ix:nonFraction> off<span class="nobreak">-balance-sheet</span> concentrations of credit risk, such as foreign exchange contracts, option contracts, or foreign currency hedging arrangements. ARCA maintains cash and cash equivalent balances in the form of bank demand deposits and money market fund accounts with financial institutions that management believes are creditworthy. Such balances may at times exceed the insured amount.</p></ix:continuation>
		<ix:nonNumeric contextRef="c0" continuedAt="abio_ComprehensiveLossPolicyPolicyTextBlock-c0_cont_1" escape="true" name="abio:ComprehensiveLossPolicyPolicyTextBlock" id="ixv-24439"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Comprehensive Loss</span></p></ix:nonNumeric>
		<ix:continuation id="abio_ComprehensiveLossPolicyPolicyTextBlock-c0_cont_1"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Comprehensive loss is defined as the change in equity during a period from transactions and other events and/or circumstances from non<span class="nobreak">-owner</span> sources. If ARCA had comprehensive gains (losses), they would be reflected in the statement of operations and comprehensive loss and as a separate component in the statement of stockholders&#8217; equity. There were no elements of comprehensive loss during the three&#160;months ended March&#160;31, 2024 and 2023.</p></ix:continuation>
		<ix:nonNumeric contextRef="c0" continuedAt="_LesseeLeasesPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:LesseeLeasesPolicyTextBlock" id="ixv-24445"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Leases</span></p></ix:nonNumeric>
		<ix:continuation continuedAt="_LesseeLeasesPolicyTextBlock-c0_cont_2" id="_LesseeLeasesPolicyTextBlock-c0_cont_1"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA determines if an arrangement is a lease at inception. Operating leases are included in right<span class="nobreak">-of-use</span> (&#8220;ROU&#8221;) asset&#160;&#8212;&#160;operating and lease obligations are included in accrued expenses and other liabilities and operating lease liability on ARCA&#8217;s March&#160;31, 2024 and December&#160;31, 2023 balance sheets.</p></ix:continuation>
		<ix:continuation id="_LesseeLeasesPolicyTextBlock-c0_cont_2"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ROU lease assets represent ARCA&#8217;s right to use an underlying asset for the lease term and lease obligations represent ARCA&#8217;s obligation to make lease payments arising from the lease. Operating ROU lease assets are recognized at the commencement date based on the present value of lease payments over the lease term. As ARCA&#8217;s leases do not provide an implicit rate, ARCA uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. ARCA&#8217;s lease terms may include options to extend or terminate a lease when it is reasonably certain that ARCA will exercise that option. Lease expense for lease payments is recognized on a straight<span class="nobreak">-line</span> basis over the lease term.</p></ix:continuation>
		<ix:nonNumeric contextRef="c0" continuedAt="abio_AccruedOutsourcingExpensesPolicyTextBlock-c0_cont_1" escape="true" name="abio:AccruedOutsourcingExpensesPolicyTextBlock" id="ixv-24454"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Accrued Outsourcing Expenses</span></p></ix:nonNumeric>
		<ix:continuation id="abio_AccruedOutsourcingExpensesPolicyTextBlock-c0_cont_1"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As part of the process of preparing its financial statements, ARCA is required to estimate accrued outsourcing expenses. This process involves identifying services that third parties have performed on ARCA&#8217;s behalf and estimating the level of service performed and the associated cost incurred for these services as of the balance sheet date. Examples of estimated accrued outsourcing expenses include contract service fees, such as fees payable to contract manufacturers in connection with the production of materials related to ARCA&#8217;s drug product, and service fees and pass through costs from clinical research organizations. ARCA develops estimates of liabilities using its judgment based upon the facts and circumstances known at the time.</p></ix:continuation>
		<ix:nonNumeric contextRef="c0" continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="ixv-24459"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Recent Accounting Pronouncements</span></p></ix:nonNumeric>
		<ix:continuation id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_1"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA reviewed recently issued accounting pronouncements and concluded that they were either not applicable or not expected to have a significant impact to the financial statements.</p></ix:continuation></ix:continuation>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-25</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-bottom:10pt;text-align:center;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA BIOPHARMA, INC.<br/>NOTES TO FINANCIAL STATEMENTS<br/>(Unaudited)</span></p>
		<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:EarningsPerShareTextBlock" id="ixv-24472"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(2)&#160;Net Loss Per Share</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA calculates basic loss per share by dividing net loss by the weighted average common shares outstanding during the period. Diluted loss per share is computed by dividing net loss by the weighted average number of common shares outstanding during the period increased to include, if dilutive, the number of additional common shares that would have been outstanding if the potential common shares had been issued. ARCA&#8217;s potentially dilutive shares include stock options and restricted stock units.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="ixv-38213">Because ARCA reported a net loss for the three&#160;months ended March&#160;31, 2024 and 2023, all potentially dilutive shares of ARCA common stock have been excluded from the computation of the dilutive net loss per share for all periods presented. Such potentially dilutive shares of ARCA common stock consist of the following:</ix:nonNumeric></p>
		<ix:continuation id="_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock-c0_cont_1"><table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">March&#160;31,</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2024</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Potentially dilutive securities, excluded:</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Outstanding stock options</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c117" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares" id="ixv-38214">645,845</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c118" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares" id="ixv-38215">664,857</ix:nonFraction></p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Unvested restricted stock units</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-110; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c120" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares" id="ixv-38216">91,000</ix:nonFraction></p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares" id="ixv-38217">645,845</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares" id="ixv-38218">755,857</ix:nonFraction></p>	</td>
				</tr>

		</table></ix:continuation></ix:nonNumeric>
		<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:FairValueDisclosuresTextBlock" id="ixv-24529"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(3)&#160;Fair Value Disclosures</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">There were <span style="-sec-ix-hidden: hidden-fact-111"><span style="-sec-ix-hidden: hidden-fact-112">no</span></span> marketable securities as of March&#160;31, 2024 or December&#160;31, 2023.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (&#8220;exit price&#8221;). Inputs used to measure fair value are classified into the following hierarchy:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Level 1 &#8212;&#160;Unadjusted quoted prices in active markets for identical assets or liabilities. ARCA&#8217;s Level 1 assets consist of money market investments. ARCA does not have any Level 1 liabilities.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Level 2 &#8212;&#160;Unadjusted quoted prices in active markets for similar assets or liabilities; unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active; or inputs other than quoted prices that are observable for the asset or liability. ARCA does not have any Level 2 assets or liabilities.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Level 3 &#8212;&#160;Unobservable inputs for the asset or liability. ARCA does not have any Level 3 assets or liabilities.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of March&#160;31, 2024 and December&#160;31, 2023, ARCA had $<ix:nonFraction contextRef="c121" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" unitRef="usd" id="ixv-38219">35.9</ix:nonFraction>&#160;million and $<ix:nonFraction contextRef="c66" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" unitRef="usd" id="ixv-38220">37.4</ix:nonFraction>&#160;million, respectively, of cash equivalents consisting of money market funds with original maturities of 90&#160;days or less. ARCA has the ability to liquidate these investments without restriction. ARCA determines fair value for these money market funds with Level 1 inputs through quoted market prices. There were <span style="-sec-ix-hidden: hidden-fact-113">no</span> transfers of assets between fair value hierarchy levels during the three&#160;months ended March&#160;31, 2024.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Fair Value of Other Financial Instruments</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The carrying amount of other financial instruments, including accounts payable, approximated fair value due to their short maturities.</p></ix:nonNumeric>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-26</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-bottom:10pt;text-align:center;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA BIOPHARMA, INC.<br/>NOTES TO FINANCIAL STATEMENTS<br/>(Unaudited)</span></p>
		<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="ixv-24558"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(4)&#160;Property and Equipment</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><ix:nonNumeric contextRef="c0" continuedAt="_PropertyPlantAndEquipmentTextBlock-c0_cont_1" escape="true" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="ixv-38221">Property and equipment consist of the following (in thousands):</ix:nonNumeric></p>
		<ix:continuation id="_PropertyPlantAndEquipmentTextBlock-c0_cont_1"><table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">	<tr class="No-Table-Style _idGenTableRowColumn-11" style="height:12pt;">	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Estimated<br/>Life</span></p>	</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">March&#160;31,<br/>2024</span></p>	</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">December&#160;31,<br/>2023</span></p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Computer equipment</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><ix:nonNumeric contextRef="c122" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-38222">3</ix:nonNumeric>&#160;years</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c122" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-38223">39</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c69" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-38224">39</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Lab equipment</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><ix:nonNumeric contextRef="c123" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-38225">5</ix:nonNumeric>&#160;years</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c123" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-38226">130</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c71" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-38227">130</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Furniture and fixtures</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><ix:nonNumeric contextRef="c124" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-38228">5</ix:nonNumeric>&#160;years</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c124" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-38229">37</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c73" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-38230">37</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Computer software</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><ix:nonNumeric contextRef="c125" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-38231">3</ix:nonNumeric>&#160;years</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c125" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-38232">16</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c75" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-38233">16</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-38234">222</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-38235">222</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accumulated depreciation and amortization</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-38236">215</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-38237">212</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Property and equipment, net</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd" id="ixv-38238">7</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd" id="ixv-38239">10</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	</tr>	</table></ix:continuation>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">For the three&#160;months ended March&#160;31, 2024 and 2023, depreciation and amortization expense was $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepreciationAndAmortization" scale="3" unitRef="usd" id="ixv-38240">3</ix:nonFraction>,000 and $<ix:nonFraction contextRef="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepreciationAndAmortization" scale="3" unitRef="usd" id="ixv-38241">4</ix:nonFraction>,000 respectively.</p></ix:nonNumeric>
		<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="ixv-24718"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(5)&#160;Related Party Arrangements</span></p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Transactions with ARCA&#8217;s Former President and Chief Executive Officer</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA has entered into unrestricted research grants with its former President and Chief Executive Officer&#8217;s academic research laboratory at the University of Colorado. Funding of any unrestricted research grants is contingent upon ARCA&#8217;s financial condition, and can be deferred or terminated at ARCA&#8217;s discretion. There was <ix:nonFraction contextRef="c127" decimals="0" format="ixt:fixed-zero" name="abio:ResearchAndDevelopmentExpenseReversed" scale="0" unitRef="usd" id="ixv-38242">no</ix:nonFraction> expense under these arrangements for the three&#160;months ended March&#160;31, 2024. Total expense under these arrangements for the three&#160;months ended March&#160;31, 2023 was $<ix:nonFraction contextRef="c126" decimals="0" format="ixt:num-dot-decimal" name="abio:ResearchAndDevelopmentExpenseReversed" scale="0" unitRef="usd" id="ixv-38243">108,000</ix:nonFraction>. In December&#160;2023, ARCA made a payment of $<ix:nonFraction contextRef="c77" decimals="0" format="ixt:num-dot-decimal" name="abio:PaymentOfUnrestrictedResearchGrants" scale="0" unitRef="usd" id="ixv-38244">125,000</ix:nonFraction> for the grant period July&#160;2022 through December&#160;2023 under these arrangements. In April&#160;2024, the President and Chief Executive Officer resigned, see Note&#160;10.</p></ix:nonNumeric>
		<ix:nonNumeric contextRef="c0" continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="ixv-24724"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(6)&#160;Commitments and Contingencies</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA has or is subject to the following commitments and contingencies.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Employment Agreements and Reduction of Workforce</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA maintains employment agreements with several key executive employees. The agreements may be terminated at any time by ARCA with or without cause upon written notice to the employee, and entitle the employee to wages in lieu of notice for periods not exceeding one calendar year from the date of termination without cause or by the employee for good reason. Certain of these agreements also provide for payments to be made under certain conditions related to a change in control of ARCA.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In December&#160;2022, ARCA&#8217;s Board of Directors approved retention bonuses for certain employees, subject to continued employment with ARCA through the earlier of a change in control of ARCA or certain clinical development decisions totaling $<ix:nonFraction contextRef="c80" decimals="0" format="ixt:num-dot-decimal" name="abio:RetentionBonuses" scale="0" unitRef="usd" id="ixv-38245">265,000</ix:nonFraction>. In November&#160;2023, the retention bonuses were amended to increase the aggregate amount of the retention bonus by <ix:nonFraction contextRef="c81" decimals="2" format="ixt:num-dot-decimal" name="abio:PercentageOfRetentionBonuses" scale="-2" unitRef="pure" id="ixv-38246">50</ix:nonFraction>% and in order to assist with tax obligations associated with the vesting of certain Company restricted stock unit awards in December&#160;2023, a total of $<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="abio:RetentionBonusPaid" scale="0" unitRef="usd" id="ixv-38247">86,000</ix:nonFraction> was paid in December&#160;2023. As of March&#160;31, 2024, the unpaid retention bonuses totaled $<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="abio:RetentionBonuses" scale="0" unitRef="usd" id="ixv-38248">311,000</ix:nonFraction>, none of which was accrued as of March&#160;31, 2024, since there had not been a change in control or clinical development decision. In April&#160;2024, the retention bonuses were again amended to increase the aggregate amount of the retention bonus, with the unpaid retention bonus increasing to $<ix:nonFraction contextRef="c128" decimals="0" format="ixt:num-dot-decimal" name="abio:RetentionBonuses" scale="0" unitRef="usd" id="ixv-38249">444,000</ix:nonFraction>. See Note&#160;10.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA and Christopher D.&#160;Ozeroff, the former Secretary, Senior Vice President and General Counsel of ARCA mutually agreed to conclude Mr.&#160;Ozeroff&#8217;s employment effective March&#160;31, 2023. Pursuant to Mr.&#160;Ozeroff&#8217;s existing employment agreement, as previously amended, ARCA provided Mr.&#160;Ozeroff severance benefits pursuant to the terms </p></ix:nonNumeric>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-27</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-align:center;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA BIOPHARMA, INC.<br/>NOTES TO FINANCIAL STATEMENTS<br/>(Unaudited)</span></p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(6)&#160;Commitments and Contingencies</span><span class="CharOverride-2" style="font-style:normal;font-weight:normal;"> (cont.)</span></p>
		<ix:continuation id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_1"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">of his existing employment agreement with ARCA, as previously amended. The severance benefits included severance payments and reimbursement to cover out<span class="nobreak">-of-pocket</span> costs to continue group health insurance benefits under COBRA, whether he elects or is eligible to receive COBRA.&#160;During the year ended December&#160;31, 2023, ARCA recorded an expense of $<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SeveranceCosts1" scale="0" unitRef="usd" id="ixv-38250">159,000</ix:nonFraction> for these severance benefits, <span style="-sec-ix-hidden: hidden-fact-115">none</span> of which remains unpaid.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA and Dr.&#160;Michael Bristow, former President, Chief Executive Officer and a member of the board of directors of ARCA mutually agreed to conclude Dr.&#160;Bristow&#8217;s employment and service as a director, effective April&#160;3, 2024. See Note&#160;10.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Operating Leases</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On August&#160;29, 2020 ARCA entered into a lease agreement for approximately <ix:nonFraction contextRef="c85" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AreaOfRealEstateProperty" scale="0" unitRef="sqft" id="ixv-38251">5,200</ix:nonFraction> square feet of office facilities in Westminster, Colorado which serves as its primary business office effective October&#160;1, 2020 (&#8220;October&#160;2020 Lease&#8221;). The lease term was <ix:nonNumeric contextRef="c85" format="ixt-sec:durmonth" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="ixv-38252">42</ix:nonNumeric>&#160;months beginning October&#160;1, 2020. In March&#160;2024, ARCA entered into an amendment <ix:nonNumeric contextRef="c0" name="us-gaap:LesseeOperatingLeaseOptionToExtend" id="ixv-38253">to extend the <ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend" id="ixv-38254">lease</ix:nonNumeric> term six (<ix:nonNumeric contextRef="c5" format="ixt-sec:durmonth" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="ixv-38255">6</ix:nonNumeric>)&#160;months through <ix:nonNumeric contextRef="c0" name="abio:OperatingLeasesExtendedExpiryYearsAndMonth" id="ixv-38256">September&#160;2024</ix:nonNumeric></ix:nonNumeric>. If ARCA elects to stay in the property after September&#160;2024, it will pay rent month to month equal to <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="abio:PercentageOfBaseRentToBePaidMonthly" scale="-2" unitRef="pure" id="ixv-38257">125</ix:nonFraction>% of the base rent paid in September&#160;2024. In June&#160;2021, ARCA entered into a sublease agreement for approximately <ix:nonFraction contextRef="c87" decimals="0" format="ixt:num-dot-decimal" name="abio:AreaOfRealEstatePropertySubleaseAdditionalOfficeFacilities" scale="0" unitRef="sqft" id="ixv-38258">3,000</ix:nonFraction> square feet of additional office facilities in its primary business office (&#8220;2021 Lease&#8221;). The sublease term was <ix:nonNumeric contextRef="c131" format="ixt-sec:durmonth" name="abio:LesseeOperatingSubleaseTermOfContract" id="ixv-38259">29</ix:nonNumeric>&#160;months and terminated in October&#160;2023. <ix:nonNumeric contextRef="c0" name="us-gaap:LesseeOperatingLeaseAssumptionsAndJudgmentsAllocationOfLeaseAndNonleaseComponent" id="ixv-24752">The leases include real estate taxes and insurance, which is not a lease component and is not included in the lease obligation. In addition, common area maintenance charges are based on actual costs incurred and are a non<span class="nobreak">-lease</span> component that is not included in the lease obligation.</ix:nonNumeric></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><ix:nonNumeric contextRef="c0" continuedAt="_LesseeOperatingLeaseLiabilityMaturityTableTextBlock-c0_cont_1" escape="true" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="ixv-38260">Future minimum commitments due under the October&#160;2020 Lease agreement, as amended, as of March&#160;31, 2024 are as follows (in thousands):</ix:nonNumeric></p>
		<ix:continuation id="_LesseeOperatingLeaseLiabilityMaturityTableTextBlock-c0_cont_1"><table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2024</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="3" unitRef="usd" id="ixv-38261">49</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total remaining lease payments</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" unitRef="usd" id="ixv-38262">49</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Less: imputed lease interest</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" unitRef="usd" id="ixv-38263">1</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Less: Current portion</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" unitRef="usd" id="ixv-38264">48</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Operating lease liability, net of current portion</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-114; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>

		</table></ix:continuation>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Rent expense, which is included in general and administrative expense, for the three&#160;months ended March&#160;31, 2024 and 2023 was $<ix:nonFraction contextRef="c129" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseCost" scale="0" unitRef="usd" id="ixv-38265">22,000</ix:nonFraction> and $<ix:nonFraction contextRef="c130" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseCost" scale="0" unitRef="usd" id="ixv-38266">31,000</ix:nonFraction>, respectively.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of March&#160;31, 2024, the lease liability was $<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiability" scale="0" unitRef="usd" id="ixv-38267">48,000</ix:nonFraction>, it is all current and is included in accrued expenses and other liabilities in the accompanying balance sheet. Cash paid for amounts included in the measurement of lease liabilities and the operating cash flows from operating leases for the three&#160;months ended March&#160;31, 2024 and 2023 were $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasePayments" scale="0" unitRef="usd" id="ixv-38268">23,000</ix:nonFraction> and $<ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasePayments" scale="0" unitRef="usd" id="ixv-38269">33,000</ix:nonFraction>, respectively. The weighted<span class="nobreak">-average</span> remaining lease term for the operating lease as of March&#160;31, 2024 is <ix:nonNumeric contextRef="c5" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="ixv-38270">0.5</ix:nonNumeric>&#160;years. The discount rate for the operating lease is <ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" unitRef="pure" id="ixv-38271">7</ix:nonFraction>%.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Patent Agreement</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In July&#160;2021, ARCA entered into a patent assignment agreement (the &#8220;Agreement&#8221;) with the University Medical Center of Johannes Gutenberg University Mainz, Germany.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Under the terms of the Agreement, ARCA received exclusive world<span class="nobreak">-wide</span> patent rights relating to the use of rNAPc2 as a potential treatment for COVID<span class="nobreak">-19</span>, and other indications, based on the research and discoveries from Univ.<span class="nobreak">-Prof</span>. Dr.&#160;Wolfram Ruf, the Scientific Director and Alexander von Humboldt Professor at the Center for Thrombosis and Hemostasis (&#8220;CTH&#8221;) of the University Medical Center Mainz, and his collaborators. ARCA has upfront and potential milestone obligations to the University Medical Center Mainz that could total approximately &#8364;<ix:nonFraction contextRef="c91" decimals="-5" format="ixt:num-dot-decimal" name="abio:PotentialUpfrontAndMilestoneObligationsAndRoyaltyObligations" scale="6" unitRef="eur" id="ixv-38272">1.6</ix:nonFraction>&#160;million and royalty obligations in the low single digit range, if rNAPc2 receives regulatory approval and is commercialized. The term of the Agreement extends to the date of expiration of the last to expire of any of the assigned patents.</p></ix:continuation>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-28</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-bottom:10pt;text-align:center;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA BIOPHARMA, INC.<br/>NOTES TO FINANCIAL STATEMENTS<br/>(Unaudited)</span></p>
		<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="ixv-24825"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(7)&#160;</span><span class="BoldItalic" style="font-style:italic;font-weight:bold;font-style:normal;font-weight:bold;">Equity Financings</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;margin-top:8pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">At the Market Equity Financing</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In 2020, ARCA entered into a Capital on Demand&#8482; Sales Agreement (the &#8220;Sales Agreement&#8221;) with JonesTrading Institutional Services LLC, as agent (&#8220;JonesTrading&#8221;), pursuant to which ARCA may offer and sell, from time to time through JonesTrading, shares of ARCA&#8217;s common stock, par value $<ix:nonFraction contextRef="c132" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-38273">0.001</ix:nonFraction> per share (&#8220;ARCA common stock&#8221;).</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In 2021, ARCA amended the 2020 Sales Agreement and the amount available for the offering under its prospectus to ARCA&#8217;s registration statement on Form&#160;S<span class="nobreak">-3</span> (No.&#160;333<span class="nobreak">-254585</span>), which expired in March&#160;2024. In April&#160;2024, ARCA terminated the Sales Agreement in accordance with its terms.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><ix:nonFraction contextRef="c133" decimals="INF" format="ixt:fixed-zero" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-38274"><ix:nonFraction contextRef="c134" decimals="INF" format="ixt:fixed-zero" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-38275">No</ix:nonFraction></ix:nonFraction> sales were made under the Sales Agreement in 2024 or 2023.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Merger Agreement</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">See &#8220;Financing Transaction&#8221; discussion in Note&#160;10 below.</p></ix:nonNumeric>
		<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="ixv-24839"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(8)&#160;Share-based Compensation</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;orphans:99;widows:1;margin-top:8pt;"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="ixv-24843">For the three&#160;months ended March&#160;31, 2024 and 2023, ARCA recognized the following non<span class="nobreak">-cash</span>, share<span class="nobreak">-based</span> compensation expense in the statements of operations (in thousands):</ix:nonNumeric></p>
		<ix:continuation id="_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock-c0_cont_1"><table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-11" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="5" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Three&#160;Months Ended<br/>March&#160;31,</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2024</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">General and administrative</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c129" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-38276">114</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c130" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-38277">163</ix:nonFraction></p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Research and development</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-116; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c136" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-38278">41</ix:nonFraction></p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-38279">114</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-38280">204</ix:nonFraction></p>	</td>
				</tr>

		</table></ix:continuation>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="ixv-38281">Stock option transactions for the three&#160;months ended March&#160;31, 2024 under ARCA&#8217;s stock incentive plans were as follows:</ix:nonNumeric></p>
		<ix:continuation id="_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock-c0_cont_1"><table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">	<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 46.15%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Options Outstanding</span></p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-15" style="height:12pt;">	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Number of<br/>Options</span></p>	</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Weighted<br/>Average<br/>Exercise<br/>Price</span></p>	</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term<br/>(in&#160;years)</span></p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Options outstanding&#160;&#8211;&#160;December&#160;31, 2023</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-38282">616,707</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-38283">4.76</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonNumeric contextRef="c137" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="ixv-38284">7.35</ix:nonNumeric></p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Granted</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" unitRef="shares" id="ixv-38285">42,000</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-38286">1.64</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Exercised</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-117; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-118; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Forfeited and cancelled</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" scale="0" unitRef="shares" id="ixv-38287">12,862</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-38288">17.45</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Options outstanding&#160;&#8211;&#160;March&#160;31, 2024</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c5" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-38289">645,845</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-38290">4.30</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="ixv-38291">6.82</ix:nonNumeric></p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Options exercisable&#160;&#8211;&#160;March&#160;31, 2024</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c5" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" unitRef="shares" id="ixv-38292">502,517</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-38293">4.71</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="ixv-38294">6.55</ix:nonNumeric></p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Options vested and expected to vest&#160;&#8211;&#160;March&#160;31, 2024</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c5" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" unitRef="shares" id="ixv-38295">645,816</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-38296">4.30</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" id="ixv-38297">6.82</ix:nonNumeric></p>	</td>	</tr>	</table></ix:continuation></ix:nonNumeric>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-29</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-bottom:10pt;text-align:center;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA BIOPHARMA, INC.<br/>NOTES TO FINANCIAL STATEMENTS<br/>(Unaudited)</span></p>
		<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:IncomeTaxDisclosureTextBlock" id="ixv-25053"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(9)&#160;Income Taxes</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In accordance with GAAP, a valuation allowance should be provided if it is more likely than not that some or all of ARCA&#8217;s deferred tax assets will not be realized. ARCA&#8217;s ability to realize the benefit of its deferred tax assets will depend on the generation of future taxable income. Due to the uncertainty of future profitable operations and taxable income, ARCA has recorded a full valuation allowance against its net deferred tax assets. ARCA believes its tax filing positions and deductions related to tax periods subject to examination will be sustained upon audit and, therefore, has <span style="-sec-ix-hidden: hidden-fact-119">no</span> reserve for uncertain tax positions.</p></ix:nonNumeric>
		<ix:nonNumeric contextRef="c0" continuedAt="_SubsequentEventsTextBlock-c0_cont_1" escape="true" name="us-gaap:SubsequentEventsTextBlock" id="ixv-25058"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(10)&#160;Subsequent Events</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Merger Agreement</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On April&#160;3, 2024, ARCA, Merger Sub&#160;I, Merger Sub&#160;II and Oruka, entered into the Merger Agreement, pursuant to which, among other matters, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Merger Sub&#160;I will merge with and into Oruka, with Oruka continuing as a wholly owned subsidiary of ARCA and the surviving corporation of the merger and as part of the same overall transaction, the surviving corporation in the First Merger will merge with and into Merger Sub&#160;II with Merger Sub&#160;II continuing as a wholly owned subsidiary of ARCA and the surviving entity of the merger. The Merger is intended to qualify for federal income tax purposes as a tax<span class="nobreak">-free</span> reorganization under the provisions of Section&#160;368(a)&#160;of the Internal Revenue Code of 1986, as amended.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Subject to the terms and conditions of the Merger Agreement, at the closing of the First Merger, (a)&#160;each then<span class="nobreak">-outstanding</span> share of Oruka common stock (including shares of Oruka common stock issued in the financing transaction described below) will be converted solely into the right to receive a number of shares of ARCA common stock calculated in accordance with the Merger Agreement (the &#8220;Exchange Ratio&#8221;), (b)&#160;each then<span class="nobreak">-outstanding</span> share of Oruka preferred stock will be converted into the right to receive a number of shares of Series&#160;B Preferred Stock (as defined below) of ARCA, calculated in accordance with the Merger Agreement (c)&#160;each then<span class="nobreak">-outstanding</span> option to purchase Oruka common stock will be assumed by ARCA, subject to adjustment as set forth in the Merger Agreement and (d)&#160;each then<span class="nobreak">-outstanding</span> warrant to purchase shares of Oruka common stock will be converted into a warrant to purchase shares of ARCA common stock, subject to adjustment as set forth in the Merger Agreement and form of warrant. Under the terms of the Merger Agreement, prior to the closing of the transaction, the Board will accelerate the vesting of all equity awards of ARCA then outstanding but not then vested or exercisable, and cancel each option (the &#8220;Out of the Money Options&#8221;) to acquire shares of ARCA common stock with an exercise price per share greater than the volume weighted average closing trading price of a share of ARCA common stock on The Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;) for the five (<ix:nonNumeric contextRef="c138" format="ixt-sec:durday" name="abio:NumberOfConsecutiveTradingDays" id="ixv-38298">5</ix:nonNumeric>)&#160;consecutive&#160;trading days ending three (3)&#160;days immediately prior to the closing date of the First Merger (the &#8220;Parent Closing Price&#8221;), in each case, in accordance with the terms of the Merger Agreement. At the closing of the First Merger, each option to acquire shares of ARCA common stock with an exercise price less than or equal to the Parent Closing Price will be cancelled and converted into the right to receive an amount in cash, without interest, equal to the Parent Closing Price less the exercise price of such option.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Under the Exchange Ratio formula in the Merger Agreement, upon the closing of the First Merger, on a pro forma basis and based upon the number of shares of ARCA common stock expected to be issued in the First Merger, pre<span class="nobreak">-First</span> Merger Oruka stockholders (including Oruka stockholders issued shares of Oruka common stock and pre<span class="nobreak">-funded</span> warrants in the financing transaction described below) will own approximately <ix:nonFraction contextRef="c139" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" unitRef="pure" id="ixv-38299">97.62</ix:nonFraction>% of the combined company and pre<span class="nobreak">-First</span> Merger ARCA stockholders will own approximately <ix:nonFraction contextRef="c140" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" scale="-2" unitRef="pure" id="ixv-38300">2.38</ix:nonFraction>% of the combined company. For purposes of calculating the Exchange Ratio, (i)&#160;shares of ARCA common stock underlying warrants and other rights to receive shares (other than Options to acquire shares of ARCA common stock, to the extent cancelled at or prior to closing of the First Merger in accordance with the Merger Agreement) outstanding as of immediately prior to the closing of the First Merger will be deemed to be outstanding, and (ii)&#160;all shares of Oruka common stock underlying outstanding Oruka stock options and warrants will be deemed to be outstanding. The Exchange Ratio will be </p></ix:nonNumeric>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-30</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-align:center;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA BIOPHARMA, INC.<br/>NOTES TO FINANCIAL STATEMENTS<br/>(Unaudited)</span></p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(10)&#160;Subsequent Events</span><span class="CharOverride-2" style="font-style:normal;font-weight:normal;"> (cont.)</span></p>
		<ix:continuation continuedAt="_SubsequentEventsTextBlock-c0_cont_2" id="_SubsequentEventsTextBlock-c0_cont_1"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">adjusted to the extent that ARCA&#8217;s net cash at closing is less than $<ix:nonFraction contextRef="c138" decimals="-5" format="ixt:num-dot-decimal" name="abio:ThresholdAmountOfAdjustedExchangeRatio" scale="6" unitRef="usd" id="ixv-38301">5.0</ix:nonFraction>&#160;million and will be based on the amount of proceeds actually received by Oruka in the financing transaction described below, as further described in the Merger Agreement.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, prior to the closing of the First Merger, ARCA expects to declare a cash dividend to the pre<span class="nobreak">-First</span> Merger ARCA stockholders equal in the aggregate to ARCA&#8217;s reasonable, good faith approximation of the amount by which ARCA&#8217;s net cash (as determined pursuant to the Merger Agreement) will exceed $<ix:nonFraction contextRef="c141" decimals="0" format="ixt:num-dot-decimal" name="abio:ThresholdAmountOfDeclaredCashDividend" scale="0" unitRef="usd" id="ixv-38302">5,000,000</ix:nonFraction>.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In connection with the Merger, ARCA is required to seek the approval of its stockholders to, among other things, (a)&#160;issue shares of ARCA common stock issuable in connection with the First Merger (including the shares of ARCA common stock issuable under the Series&#160;B Preferred Stock) under the rules of Nasdaq, and (b)&#160;amend its amended and restated certificate of incorporation, to (i)&#160;effect a reverse stock split of ARCA common stock (if deemed necessary by ARCA and Oruka), (ii)&#160;increase the number of shares of ARCA common stock that ARCA is authorized to issue, and (iii)&#160;such other changes as are mutually agreeable to ARCA and Oruka (the &#8220;ARCA Voting Proposals&#8221;).</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Each of ARCA and Oruka has agreed to customary representations, warranties and covenants in the Merger Agreement, including, among others, covenants relating to (1)&#160;using commercially reasonable efforts to obtain the requisite approval of its stockholders, (2)&#160;non<span class="nobreak">-solicitation</span> of alternative acquisition proposals, (3)&#160;the conduct of their respective businesses during the period between the date of signing the Merger Agreement and the closing of the Merger, (4)&#160;ARCA using commercially reasonable efforts to maintain the existing listing of the ARCA common stock on Nasdaq and cause the shares of ARCA common stock to be issued in connection with the First Merger to be approved for listing on Nasdaq prior to the closing of the First Merger, and (5)&#160;ARCA filing with the U.S.&#160;Securities and Exchange Commission (the &#8220;SEC&#8221;) and causing to become effective a registration statement to register shares of ARCA common stock to be issued in connection with the First Merger, except as set forth in the Merger Agreement (the &#8220;Registration Statement&#8221;).</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Consummation of the Merger is subject to certain closing conditions, including, among other things, (1)&#160;approval by ARCA stockholders of the ARCA Voting Proposals, (2)&#160;approval by the requisite Oruka stockholders of the adoption and approval of the Merger Agreement and the transactions contemplated thereby, (3)&#160;Nasdaq&#8217;s approval of the initial listing application to be submitted in connection with the First Merger, (4)&#160;the effectiveness of the Registration Statement, (5)&#160;the expiration of any applicable waiting periods (or extensions thereof) under the Hart Scott<span class="nobreak">-Rodino</span> Antitrust Improvements Act&#160;of&#160;1976, as amended, (6)&#160;the subscription agreements (described below) being in full force and effect providing for the receipt of proceeds of not less than $<ix:nonFraction contextRef="c142" decimals="INF" format="ixt:num-dot-decimal" name="abio:SubscriptionAgreementReceiptAmount" scale="0" unitRef="usd" id="ixv-38303">175,000,000</ix:nonFraction> (including in the proceeds any notes contributed as consideration in the financing transaction described below) and (7)&#160;to the extent ARCA has declared the cash dividend described above, ARCA delivering the aggregate amount distributable to the pre<span class="nobreak">-First</span> Merger ARCA stockholders to ARCA&#8217;s transfer agent for further distribution to the pre<span class="nobreak">-First</span> Merger ARCA stockholders. Each party&#8217;s obligation to consummate the Merger is also subject to other specified customary conditions, including regarding the accuracy of the representations and warranties of the other party, subject to the applicable materiality standard, and the performance in all material respects by the other party of its obligations under the Merger Agreement required to be performed on or prior to the date of the closing of the Merger.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Merger Agreement contains certain termination rights of each of ARCA and Oruka. Upon termination of the Merger Agreement under specified circumstances, ARCA and Oruka may each be required to pay the other party a termination fee of $<ix:nonFraction contextRef="c143" decimals="0" format="ixt:num-dot-decimal" name="abio:PaymentOfOtherPartyTerminationFee" scale="0" unitRef="usd" id="ixv-38304">440,000</ix:nonFraction>.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Pursuant to a Certificate of Designation of Preferences, Rights and Limitations of the Series&#160;B Non<span class="nobreak">-Voting</span> Convertible Preferred Stock to be filed by ARCA with the Secretary of State of the State of Delaware (the &#8220;Certificate of Designation&#8221;) in connection with the Merger Agreement and the transactions thereunder, ARCA will establish the terms of a new series of preferred stock of ARCA designated as Series&#160;B Non<span class="nobreak">-Voting</span> Convertible Preferred Stock, par value $<ix:nonFraction contextRef="c144" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-38305">0.001</ix:nonFraction> per share (the &#8220;Series&#160;B Preferred Stock&#8221;). Holders of the Series&#160;B Preferred Stock will be entitled to receive dividends on shares of Series&#160;B Preferred Stock equal to, on an as<span class="nobreak">-if-converted-to-ARCA</span> common stock </p></ix:continuation>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-31</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-align:center;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA BIOPHARMA, INC.<br/>NOTES TO FINANCIAL STATEMENTS<br/>(Unaudited)</span></p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(10)&#160;Subsequent Events</span><span class="CharOverride-2" style="font-style:normal;font-weight:normal;"> (cont.)</span></p>
		<ix:continuation continuedAt="_SubsequentEventsTextBlock-c0_cont_3" id="_SubsequentEventsTextBlock-c0_cont_2"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">basis, and in the same form as dividends actually paid on shares of the ARCA common stock. Except as otherwise required by the Certificate of Designation or law, the Series&#160;B Preferred Stock will not have voting rights. However, as long as any shares of Series&#160;B Preferred Stock are outstanding, ARCA will not, without the affirmative vote of the holders of a majority of the then outstanding shares of the Series&#160;B Preferred Stock, (a)&#160;alter or change adversely the powers, preferences or rights given to the Series&#160;B Preferred Stock, (b)&#160;alter or amend the Certificate of Designation, (c)&#160;amend its certificate of incorporation, bylaws or other charter documents in any manner that adversely affects any rights of the holders of the Series&#160;B Preferred Stock, (d)&#160;file any articles of amendment, certificate of designations, preferences, limitations and relative rights of any series of Preferred Stock (as defined in the Certificate of Designation), if such action would adversely alter or change the preferences, rights, privileges or powers of, or restrictions provided for the benefit of the Series&#160;B Preferred Stock, (e)&#160;issue further shares of the Series&#160;B Preferred Stock or increase or decrease (other than by conversion) the number of authorized shares of the Series&#160;B Preferred Stock, (f)&#160;at any time while at least <ix:nonFraction contextRef="c145" decimals="2" format="ixt:num-dot-decimal" name="abio:MinimumPercentageOfOriginallyIssuedShares" scale="-2" unitRef="pure" id="ixv-38306"><ix:nonFraction contextRef="c145" decimals="2" format="ixt:num-dot-decimal" name="abio:MinimumPercentageOfOriginallyIssuedOutstanding" scale="-2" unitRef="pure" id="ixv-38307">30</ix:nonFraction></ix:nonFraction>% of the originally issued Series&#160;B Preferred Stock remains issued and outstanding, consummate either (A)&#160;a Fundamental Transaction (as defined in the Certificate of Designation) or (B)&#160;any merger or consolidation of ARCA or other business combination in which the stockholders of ARCA immediately before such transaction do not hold at least a majority of the capital stock of ARCA immediately after such transaction, or (f)&#160;enter into any agreement with respect to any of the foregoing. The Series&#160;B Preferred Stock does not have a preference upon any liquidation, dissolution or winding<span class="nobreak">-up</span> of ARCA.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Following the closing of the First Merger, each share of Series&#160;B Preferred Stock then outstanding shall be convertible, at any time and from time to time, at the option of the holder of the Series&#160;B Preferred Stock, into a number of shares equal to <ix:nonFraction contextRef="c146" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockConvertibleSharesIssuable" scale="0" unitRef="shares" id="ixv-38308">1,000</ix:nonFraction><span class="nobreak"> </span>shares of ARCA common stock, subject to certain limitations, including that a holder of Series&#160;B Preferred Stock is prohibited from converting shares of Series&#160;B Preferred Stock into shares of ARCA common stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than a specified percentage (initially set at <ix:nonFraction contextRef="c147" decimals="4" format="ixt:num-dot-decimal" name="abio:InitiallySpecifiedPercentageForBeneficialNumberOfShares" scale="-2" unitRef="pure" id="ixv-38309">9.99</ix:nonFraction>%) of the total number of shares of ARCA common stock issued and outstanding immediately after giving effect to such conversion.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">At the effective time of the First Merger (the &#8220;First Effective Time&#8221;), the combined company&#8217;s board of directors is expected to consist of <ix:nonFraction contextRef="c148" decimals="0" format="ixt-sec:numwordsen" name="abio:ExceptedNumberOfBoardMembers" scale="0" unitRef="pure" id="ixv-38310">five</ix:nonFraction> (5)&#160;members, all of whom will be designated by Oruka. Upon the closing of the transaction, the combined company will be led by Oruka&#8217;s chief executive officer.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Financing Transaction</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Concurrently with the execution and delivery of the Merger Agreement, certain parties have entered into a subscription agreements with Oruka, pursuant to which they have agreed, subject to the terms and conditions of such agreements, to purchase immediately prior to the consummation of the First Merger, shares of Oruka common stock and pre<span class="nobreak">-funded</span> warrants to purchase shares of Oruka common stock (together, the &#8220;PIPE Securities&#8221;) for an aggregate purchase price of approximately $<ix:nonFraction contextRef="c149" decimals="-5" format="ixt:num-dot-decimal" name="abio:AggregatePurchasePrice" scale="6" unitRef="usd" id="ixv-38311">275.0</ix:nonFraction>&#160;million. The consummation of the transactions contemplated by such agreements is conditioned on the satisfaction or waiver of the conditions set forth in the Merger Agreement and in the subscription agreement. Shares of Oruka common stock and pre<span class="nobreak">-funded</span> warrants to purchase shares of Oruka common stock issued pursuant to this financing transaction will be converted into shares of ARCA common stock and pre<span class="nobreak">-funded</span> warrants to acquire shares ARCA common stock, in accordance with the Exchange Ratio and the Merger Agreement.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Separation of Michael Bristow, M.D., President, Chief Executive Officer and Director</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Effective April&#160;3, 2024, ARCA and Dr.&#160;Michael Bristow, President, Chief Executive Officer and a member of the Board mutually agreed to conclude Dr.&#160;Bristow&#8217;s employment and service as a director.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In connection with Dr.&#160;Bristow&#8217;s separation, ARCA and Dr.&#160;Bristow entered into a separation agreement (the &#8220;Separation Agreement&#8221;) on April&#160;3, 2024. Pursuant to the terms of the Separation Agreement, ARCA provided to Dr.&#160;Bristow a lump sum payment equal to (i)&#160;twelve (<ix:nonNumeric contextRef="c150" format="ixt-sec:durmonth" name="abio:NumberOfMonthsBaseSalary" id="ixv-38312">12</ix:nonNumeric>)&#160;months of Dr.&#160;Bristow&#8217;s base salary as of the last date of his employment and (ii)&#160;a cash payment of $<ix:nonFraction contextRef="c150" decimals="0" format="ixt:num-dot-decimal" name="abio:CashPayment" scale="0" unitRef="usd" id="ixv-38313">25,000</ix:nonFraction>, less applicable withholdings. The severance benefits were conditioned on the non<span class="nobreak">-revocation</span> by Dr.&#160;Bristow of a legal release of claims.</p></ix:continuation>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-32</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-align:center;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA BIOPHARMA, INC.<br/>NOTES TO FINANCIAL STATEMENTS<br/>(Unaudited)</span></p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(10)&#160;Subsequent Events</span><span class="CharOverride-2" style="font-style:normal;font-weight:normal;"> (cont.)</span></p>
		<ix:continuation id="_SubsequentEventsTextBlock-c0_cont_3"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA and Dr.&#160;Bristow entered into a consulting agreement, effective April&#160;3, 2024 (the &#8220;Consulting Agreement&#8221;), pursuant to which Dr.&#160;Bristow is providing certain consulting services provided for in the Consulting Agreement to ARCA until the earlier of (i)&#160;the completion of services under the Consulting Agreement, (ii)&#160;a termination in accordance with the terms of the Consulting Agreement, and (iii)&#160;upon a Change of Control (as defined in ARCA&#8217;s 2020 Equity Incentive Plan (the &#8220;Plan&#8221;)). Pursuant to the Consulting Agreement, Dr.&#160;Bristow provision of services under the Consulting Agreement are deemed to be a Continuous Service (as defined in the Plan) and, as a result, his equity awards under the Plan continue to vest during the term of the Consulting Agreement.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Appointment of Thomas Keuer as President</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Effective as of April&#160;3, 2024, the Board appointed Thomas A.&#160;Keuer, ARCA&#8217;s Chief Operating Officer, to serve as ARCA&#8217;s President and principal executive officer. Mr.&#160;Keuer has been with ARCA since 2006, and as its Chief Operating Officer for the last nine&#160;years, a position he will continue to serve in. Mr.&#160;Keuer will not receive any additional compensation in connection with his appointment as President and principal executive officer. Mr.&#160;Keuer&#8217;s position will end upon closing of the merger transaction with Oruka Therapeutics, Inc. as previously disclosed on a Current Report on Form&#160;8<span class="nobreak">-K</span> filed with the SEC on April&#160;3, 2024.</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Second Amendment to Retention Bonus Letter of Thomas A.&#160;Keuer and C.&#160;Jeffrey Dekker</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On April&#160;20, 2024, the board of directors of ARCA approved the second amendment of certain retention bonus letters between ARCA and each of Thomas A.&#160;Keuer and C.&#160;Jeffrey Dekker to increase the aggregate amount of the retention bonus with respect to each such executive to $<ix:nonFraction contextRef="c151" decimals="0" format="ixt:num-dot-decimal" name="abio:IncreaseOfRetentionBonusToEachExecutive" scale="0" unitRef="usd" id="ixv-38314"><ix:nonFraction contextRef="c152" decimals="0" format="ixt:num-dot-decimal" name="abio:IncreaseOfRetentionBonusToEachExecutive" scale="0" unitRef="usd" id="ixv-38315">200,000</ix:nonFraction></ix:nonFraction>. The remaining portion of the retention bonus with respect to Thomas A. Keuer and C. Jeffrey Dekker, consisting of $<ix:nonFraction contextRef="c153" decimals="0" format="ixt:num-dot-decimal" name="abio:RetentionBonuses" scale="0" unitRef="usd" id="ixv-38316">165,000</ix:nonFraction>, will become payable consistent with the original terms of the applicable retention bonus letter and first amendment to retention bonus letter. Any payment related to the retention bonuses of Thomas A. Keuer and C. Jeffrey Dekker will be paid by ARCA via payroll within&#160;30 business days of the date of occurrence of the applicable &#8220;Payment Event Date&#8221; (as such term is otherwise defined in the applicable second amendment to the retention bonus letter). Each such retention bonus letter and first amendment to retention bonus letter will otherwise remain subject to their original terms and conditions.</p></ix:continuation>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-33</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T212"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">To the Board of Directors and Stockholders of Oruka Therapeutics, Inc.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Opinion on the Financial Statement&#160;&#8212;&#160;Balance Sheet</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">We have audited the accompanying<span class="Bold" style="font-style:normal;font-weight:bold;"> </span>balance sheet of Oruka Therapeutics, Inc. (the &#8220;Company&#8221;) as of February&#160;6, 2024, including the related notes (collectively referred to as the &#8220;financial statement&#8221;). In our opinion, the<span class="Bold" style="font-style:normal;font-weight:bold;"> </span>financial statement presents fairly, in all material respects, the financial position of the Company as of February&#160;6, 2024<span class="Bold" style="font-style:normal;font-weight:bold;"> </span>in conformity with accounting principles generally accepted in the United&#160;States of America.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Substantial Doubt about the Company&#8217;s Ability to Continue as a Going Concern</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">The accompanying financial statement has been prepared assuming that the Company will continue as a going concern. As discussed in Note&#160;1 to the financial statement, the Company has not generated any revenue from product sales or other sources and has incurred significant operating losses and negative cash flows from operations since inception, which raises substantial doubt about its ability to continue as a going concern. Management&#8217;s plans in regard to these matters are also described in Note&#160;1. The financial statement does not include any adjustments that might result from the outcome of this uncertainty.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Basis for Opinion</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">The<span class="Bold" style="font-style:normal;font-weight:bold;"> </span>financial statement is the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s<span class="Bold" style="font-style:normal;font-weight:bold;"> </span>financial statement based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United&#160;States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S.&#160;federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">We conducted our audit of this financial statement in accordance with the standards of the PCAOB and in accordance with auditing standards generally accepted in the United&#160;States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the<span class="Bold" style="font-style:normal;font-weight:bold;"> </span>financial statement is free of material misstatement, whether due to error or fraud.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Our audit included performing procedures to assess the risks of material misstatement of the<span class="Bold" style="font-style:normal;font-weight:bold;"> </span>financial statement, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the<span class="Bold" style="font-style:normal;font-weight:bold;"> </span>financial statement. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the<span class="Bold" style="font-style:normal;font-weight:bold;"> </span>financial statement. We believe that our audit provides a reasonable basis for our opinion.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Critical Audit Matters</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Critical audit matters are matters arising from the current period audit of the financial statement that were communicated or required to be communicated to the audit committee and that (i)&#160;relate to accounts or disclosures that are material to the financial statement and (ii)&#160;involved our especially challenging, subjective, or complex judgments. We determined there are no critical audit matters.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-style:normal;font-weight:normal;">/s/ PricewaterhouseCoopers LLP</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Boston, Massachusetts<br/><span class="Bold" style="font-style:normal;font-weight:bold;font-style:normal;font-weight:normal;">May&#160;13, 2024</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">We have served as the Company&#8217;s auditor since 2024.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-34</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T213"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ORUKA THERAPEUTICS, INC.<br/>BALANCE SHEET<br/>(In thousands, except share amounts)</span></p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">February&#160;6, <br/>2024</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">ASSETS</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Current Assets</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Subscription receivable</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Total assets</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-style:normal;font-weight:bold;">1</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Commitments and contingencies (Note&#160;5)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">STOCKHOLDERS&#8217; EQUITY</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Series&#160;A convertible preferred stock, $0.0001 par value, 20,000,000 shares authorized, no shares issued and outstanding as of February&#160;6, 2024</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Common stock, $0.0001 par value, 65,000,000 shares authorized, 5,596,658 issued and outstanding as of February&#160;6, 2024</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Total stockholders&#8217; equity</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-style:normal;font-weight:bold;">1</span></p>
					</td>
				</tr>

		</table>
		<p class="Text_ind_center" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:3;margin-top:8pt;">The accompanying notes are an integral part of this financial statement.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-35</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T214"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ORUKA THERAPEUTICS, INC.<br/>NOTES TO FINANCIAL STATEMENT</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">1.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Nature of the Business and Basis of Presentation</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Background and Basis of Presentation</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">Oruka Therapeutics, Inc. (&#8220;Oruka&#8221; or the &#8220;Company&#8221;) was established and incorporated under the laws of the state of Delaware on February&#160;6, 2024. Oruka was founded by Paragon Therapeutics, Inc. (&#8220;Paragon&#8221;). The Company currently operates as a virtual company, and thus, does not maintain a corporate headquarters or other significant facilities. Oruka was formed to develop biologics to optimize the treatment of inflammatory skin diseases.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">The Company is subject to risks and uncertainties common to early<span class="nobreak">-stage</span> companies in the biopharmaceutical industry, including, but not limited to, completing preclinical and clinical trials, obtaining regulatory approval for product candidates, development by competitors of new technological innovations, dependence on key personnel, the ability to attract and retain qualified employees, reliance on third<span class="nobreak">-party</span> organizations, protection of proprietary technology, compliance with government regulations, product liability, uncertainty of market acceptance of products and the ability to raise additional capital to fund operations.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">The Company&#8217;s potential products will require approval from the U.S.&#160;Food and Drug Administration or comparable foreign authorities prior to the commencement of commercial sales. There can be no assurance that the Company&#8217;s potential products will receive all the required approvals. In addition, there can be no assurance that the Company&#8217;s potential products, if approved, will be accepted in the marketplace, nor can there be any assurance that any future products can be developed or manufactured at an acceptable cost and with appropriate performance characteristics, or that such products will be successfully marketed, if at all.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">The financial statement and accompanying notes have been prepared in accordance with accounting principles generally accepted in the United&#160;States of America (&#8220;U.S.&#160;GAAP&#8221;).</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Liquidity</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">The accompanying financial statement has been prepared on the basis that the Company is a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the normal course of business. As of February&#160;6, 2024, the Company had no cash.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">The Company will devote substantially all of its resources to advancing the development of its portfolio of programs, organizing and staffing the Company, business planning, raising capital, and providing general and administrative support for these operations. Current and future programs will require significant research and development efforts, including preclinical and clinical trials and regulatory approvals to commercialization. These efforts require significant amounts of additional capital, adequate personnel, and infrastructure. Even if the Company&#8217;s development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales. If the Company obtains regulatory approval for any of its product candidates and starts to generate revenue, it expects to incur significant expenses related to developing its internal commercialization capability to support product sales, marketing, and distribution.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">As a result, the Company will need substantial additional funding to support its operating activities as it advances its potential product candidates through development, seeks regulatory approval and prepares for and, if any of its product candidates are approved, proceeds to commercialization. Until such time as the Company can generate significant revenue from product sales, if ever, the Company expects to finance its operating activities through a combination of equity offerings and debt financings. Adequate funding may not be available to the Company on acceptable terms, or at all.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">If the Company is unable to obtain additional funding, the Company will assess its capital resources and may be required to delay, reduce the scope of or eliminate some or all of its planned operations, which may have a material adverse effect on the Company&#8217;s business, financial condition, results of operations and ability to operate as a going concern. The financial statement does not include any adjustments that may result if the Company is not able to continue as a going concern.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company has not generated any revenue from product sales or other sources and has incurred significant operating losses and negative cash flows from operations since inception.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-36</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ORUKA THERAPEUTICS, INC.<br/>NOTES TO FINANCIAL STATEMENT</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">In March&#160;2024, the Company received $3.0&#160;million in proceeds from the sale of Series&#160;A convertible preferred stock and $25.0&#160;million in proceeds from the sale of an unsecured convertible promissory note, both of which were related party transactions (see Note&#160;7<span class="Italic" style="font-style:italic;font-weight:normal;"> Subsequent Events</span>).</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">ARCA biopharma, Inc., a Delaware corporation (&#8220;ARCA&#8221;), and the Company entered into an Agreement and Plan of Merger and Reorganization (the &#8220;Merger Agreement&#8221;) on April&#160;3, 2024, pursuant to which, among other matters, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Atlas Merger Sub Corp, a Delaware corporation (&#8220;First Merger Sub&#8221;), will merge with and into Oruka, with Oruka continuing as a wholly owned subsidiary of ARCA and the surviving corporation of the merger (the &#8220;First Merger&#8221;), and Oruka will merge with and into Atlas Merger Sub&#160;II, LLC, a Delaware limited liability company (&#8220;Second Merger Sub&#8221; and together with First Merger Sub, &#8220;Merger Subs&#8221;), with Second Merger Sub being the surviving entity of the merger (the &#8220;Second Merger&#8221; and, together with the First Merger, the &#8220;Merger&#8221;). In connection with the Merger, Second Merger Sub will change its corporate name to &#8220;Oruka Therapeutics Operating Company, LLC&#8221; and ARCA will change its name to &#8220;Oruka Therapeutics, Inc.&#8221; ARCA following the Merger is referred to herein as the &#8220;combined company.&#8221; The combined company will be led by Oruka&#8217;s management team and will remain focused on developing biologics to optimize the treatment of inflammatory skin diseases.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">Concurrent with the execution of the Merger Agreement, the Company entered into a subscription agreement with certain investors to which the Company agreed to issue and sell to investors in a private placement financing (the &#8220;Private Placement&#8221;) shares and pre<span class="nobreak">-funded</span> warrants of the Company&#8217;s common stock at an estimated purchase price of $5.80 per share of common stock and $5.79 per warrant for gross proceeds of approximately $275.0&#160;million, which will precede the closing of the Merger Agreement transaction. Shares of the Company&#8217;s common stock and pre<span class="nobreak">-funded</span> warrants to purchase shares of the Company&#8217;s common stock issued pursuant to the Private Placement will be converted into the right to receive shares of ARCA common stock and pre<span class="nobreak">-funded</span> warrants to purchase ARCA common stock, respectively, in accordance with the exchange ratio at the effective time of the close of the transaction. The proceeds from the Private Placement are expected to advance the Company&#8217;s pipeline, business development activities, working capital, and other general corporate purposes.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">However, the agreements are subject to the satisfaction of customary closing conditions, and there are no assurances that such conditions will be achieved nor that such financing or other strategic transactions will be available on acceptable terms, or at all. If the Merger Agreement is terminated under certain circumstances, ARCA could be required to pay Oruka a termination fee of $0.4<span class="nobreak"> </span>million or Oruka could be required to pay ARCA a termination fee of $0.4<span class="nobreak"> </span>million. Based on its expectation of continuing operating losses for the foreseeable future, as of May<span class="nobreak"> </span>13, 2024, the date the Company&#8217;s financial statement is available to be issued, the Company has concluded there is substantial doubt about its ability to continue as a going concern for at least twelve&#160;months from the date the financial statement is available to be issued.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:9pt;margin-top:9pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Summary of Significant Accounting Policies</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:9pt;margin-top:9pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Subscription receivable</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">The Company accounts for any notes received in exchange for common stock as a subscription receivable, provided the note underlying the receivable is paid prior to the date the financial statement is available to be issued.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:9pt;margin-top:9pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">3.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Common Stock</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">As of February&#160;6, 2024, the Company has the authority to issue a total of 65,000,000<span class="nobreak"> </span>shares of common stock at a par value of $0.0001. As of February&#160;6, 2024, 5,596,658<span class="nobreak"> </span>shares of common stock were issued and outstanding for a nominal consideration, which was received in March&#160;2024, prior to the date the financial statement is available to be issued. Each share of common stock entitles the holder to one vote for each share of common stock held of record by such holder on all matters on which stockholders generally are entitled to vote. The holders of common stock are entitled to receive dividends, if any, as declared by the Company&#8217;s Board of Directors. Upon dissolution, liquidation or winding up of the Company, the holders of shares of common stock, subject to the rights of the holders of any outstanding series of preferred stock, shall be entitled to receive the assets of the Company available for distribution to its stockholders ratably in proportion to the number of shares held.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-37</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ORUKA THERAPEUTICS, INC.<br/>NOTES TO FINANCIAL STATEMENT</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">4.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Related Party Transactions</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company issued 5,596,658<span class="nobreak"> </span>shares of common stock, through a series of contribution agreements, to Paragon, Paruka Holding, LLC (&#8220;Paruka&#8221;), an entity formed by Paragon as a vehicle to hold equity in the Company, and Oruka Advisors LLC (&#8220;Oruka Advisors&#8221;), an entity formed by Paragon as a vehicle to hold equity in the Company, as part of its common stock subscription agreement with such entities. As of February&#160;6, 2024, Paragon, Paruka and Oruka Advisors each beneficially own approximately 44.7%, 44.7% and 10.6%, respectively, of the Company through their common stock holdings.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">5.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Commitments and Contingencies</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company may be subject to legal proceedings that arise in the ordinary course of business. As of February&#160;6, 2024, there were no material proceedings to which the Company was a party, nor did the Company have knowledge of any proceedings threatened against it.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">6.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Stock-Based Compensation</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On February&#160;6, 2024, the Company&#8217;s Board of Directors approved the 2024 Equity Incentive Plan (the &#8220;2024 Plan&#8221;), under which the Company may grant stock options, restricted stock awards, restricted stock units, or other stock<span class="nobreak">-based</span> awards to its employees, officers, directors, consultants, and advisors. The Company reserved 372,912<span class="nobreak"> </span>shares of its common stock for issuance under the 2024 Plan. As of February&#160;6, 2024, no awards had been issued under the plan.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">7.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Subsequent Events</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company evaluated all events subsequent to February&#160;6, 2024, through May<span class="nobreak"> </span>13, 2024, the date on which the financial statement was available to be issued.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Stock-Based Compensation</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In February&#160;2024, the Company&#8217;s Board of Directors authorized and granted 2,073,387 restricted stock awards at a price of $0.0001 per share to employees of the Company.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In March 2024, the Company&#8217;s Board of Directors authorized and granted 1,789,974 restricted stock awards at a price of $0.0001 per share to consultants and a director of the Company.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On March&#160;5, 2024, the Company&#8217;s Board of Directors approved an amendment to the 2024 Plan to increase the number of shares of common stock available for issuance under the 2024 Plan from 372,912 to 872,912.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On March&#160;22, 2024, the Company granted options for the purchase of an aggregate 698,669<span class="nobreak"> </span>shares of common stock, at an exercise price of $2.90 per share.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On May<span class="nobreak"> </span>7, 2024, the Company&#8217;s Board of Directors approved an amendment to the 2024 Plan to increase the number of shares of common stock available for issuance under the 2024 Plan from 872,912 to 2,063,669.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On May<span class="nobreak"> </span>7, 2024, the Company granted options for the purchase of an aggregate 1,365,000<span class="nobreak"> </span>shares of common stock, at an exercise price of $3.89 per share.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Antibody Discovery and Option Agreements</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On March&#160;6, 2024, the Company entered into an Antibody Discovery and Option Agreement with Paragon and Paruka, which was subsequently amended and restated on March&#160;28, 2024, whereby the Company was granted an exclusive, worldwide option, on a research program<span class="nobreak">-by-research</span> program basis, to all of Paragon&#8217;s right, title and interest in and to the intellectual property (&#8220;ORKA<span class="nobreak">-001</span>&#8221;) resulting from the applicable research program to develop, manufacture and commercialize products directed at the selected target (&#8220;IL<span class="nobreak">-23</span>&#8221;), with the exception of pursuing ORKA<span class="nobreak">-001</span> for the treatment of inflammatory bowel disease. Upon signing of the Antibody Discovery and Option Agreement for ORKA<span class="nobreak">-001</span>, a one<span class="nobreak">-time</span>, non<span class="nobreak">-refundable</span> research initiation fee of $0.8&#160;million was due to Paragon. This amount was recognized as a research and development expense during the period ended March&#160;31, 2024, and paid to Paragon in April&#160;2024. The Company is also responsible for 50% of the development costs incurred prior to </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-38</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ORUKA THERAPEUTICS, INC.<br/>NOTES TO FINANCIAL STATEMENT</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">March&#160;31, 2024, provided that the Company receives rights to at least one selected IL<span class="nobreak">-23</span> antibody. As of the date this financial statement is available to be issued, the Company has not received rights to a selected IL<span class="nobreak">-23</span> antibody and has not paid or accrued the $5.9&#160;million of development costs incurred prior to March&#160;31, 2024. The Company will be responsible for 50% of the ORKA<span class="nobreak">-001</span> development costs incurred from and after March&#160;31, 2024, through the completion of the IL<span class="nobreak">-23</span> selection process.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On March&#160;6, 2024, the Company also entered into an Antibody Discovery and Option Agreement with Paragon and Paruka, which was subsequently amended and restated on March&#160;28, 2024, whereby the Company was granted an exclusive, worldwide option, on a research program<span class="nobreak">-by-research</span> program basis, to all of Paragon&#8217;s right, title and interest in and to the intellectual property (&#8220;ORKA<span class="nobreak">-002</span>&#8221;) resulting from the applicable research program to develop, manufacture and commercialize products directed at the selected target (&#8220;IL<span class="nobreak">-17</span>&#8221;). The Company was also required to reimburse Paragon $3.3&#160;million for development costs related to ORKA<span class="nobreak">-002</span> incurred by Paragon through December&#160;31, 2023 and certain other development costs related to ORKA<span class="nobreak">-002</span> incurred by Paragon between January&#160;1, 2024 and March&#160;6, 2024. This amount was recognized as a research and development expenses during the period from February&#160;6 (inception) to March&#160;31, 2024 and accounts payable as of March&#160;31, 2024. The Company paid $3.3&#160;million to Paragon in April&#160;2024. The Company is also responsible for the development costs incurred by Paragon from January&#160;1, 2024 to March&#160;31, 2024 of $0.9&#160;million, which was recognized as a research and development expense in the period from February&#160;6 (inception) to March&#160;31, 2024. The Company will be required to pay Paragon $0.8&#160;million for the research initiation fee related to ORKA<span class="nobreak">-002</span> within 30&#160;days following finalization of the ORKA<span class="nobreak">-002</span> research plan as well as for subsequent development costs related to ORKA<span class="nobreak">-002</span>.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of the date of issuance of the Company&#8217;s financial statement, the Company has not exercised its options with respect to ORKA<span class="nobreak">-001</span> or ORKA<span class="nobreak">-002</span>. For each of these agreements, if the Company exercises its options, it will be required to make non<span class="nobreak">-refundable</span> milestone payments to Paragon of up to $12.0&#160;million upon the achievement of certain clinical development milestones, up to $10.0&#160;million upon the achievement of certain regulatory milestones, as well as tiered royalty payments in the low<span class="nobreak">-to-mid</span> single<span class="nobreak">-digits</span> beginning on the first commercial sale.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Additionally, as part of the Antibody Discovery and Option Agreements, on each of December&#160;31, 2024 and December&#160;31, 2025, the Company will grant Paruka warrants to purchase a number of shares equal to 1.00% of the then outstanding shares of the Company&#8217;s common stock as of the date of the grant on a fully<span class="nobreak">-diluted</span> basis, with an exercise price equal to the fair market value of the underlying shares on the grant date.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Series&#160;A Preferred Stock</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On March&#160;6, 2024, the Company issued 20,000,000<span class="nobreak"> </span>shares of Series&#160;A convertible preferred stock to Fairmount Healthcare Fund&#160;II, L.P. (&#8220;Fairmount&#8221;), a related party of the Company, at a purchase price of $0.15 per share for gross proceeds of $3.0&#160;million. The Company incurred less than $0.1&#160;million of issuance costs in connection with this transaction.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The holders of Series&#160;A convertible preferred stock are entitled to vote, together with the holders of common stock, on all matters submitted to stockholders for a vote. Each holder of outstanding shares of Series&#160;A convertible preferred stock is entitled to the number of votes equal to the number of shares of common stock into which the shares of preferred stock held by such holder are convertible as of the record date for determining stockholders entitled to vote on such matter.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Each share of Series&#160;A convertible preferred stock is convertible at the option of the holder, at any time, and without the payment of additional consideration by the holder. In addition, each share of Series&#160;A convertible preferred stock will be automatically converted into shares of common stock at the applicable conversion ratio then in effect upon either (i)&#160;the closing of a firm<span class="nobreak">-commitment</span> underwritten public offering of the Company&#8217;s common stock at a price of at least $1.00 per share resulting in at least $50.0&#160;million of gross proceeds to the Company, or (ii)&#160;the vote or written consent of the holders of a majority of the Preferred Stock, voting as a single class.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-39</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ORUKA THERAPEUTICS, INC.<br/>NOTES TO FINANCIAL STATEMENT</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">The conversion ratio of Series&#160;A convertible preferred stock is determined by dividing the Original Issue Price by the Conversion Price in effect at the time of conversion. The Original Issue Price is $0.15 per share for Series&#160;A convertible preferred stock (in each case subject to appropriate adjustment in the event of any stock split, stock dividend, combination or other similar recapitalization and other adjustments as set forth in the Company&#8217;s certificate of incorporation, as amended and restated). The Conversion Price is $0.15 per share for Series&#160;A convertible preferred stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">The Company may not declare, pay or set aside any dividends on shares of any other class or series of capital stock of the Company (other than dividends on shares of common stock) unless the holders of the Series&#160;A convertible preferred stock then outstanding first receive, or simultaneously receive, a dividend on each outstanding share of Series&#160;A convertible preferred stock in an amount at least equal to (i)&#160;in the case of a dividend being distributed to common stock or any class or series that is convertible into common stock, the equivalent dividend on an as<span class="nobreak">-converted</span> basis or (ii)&#160;in the case of a dividend on any class or series that is not convertible into common stock, a dividend equal to a dividend rate on Series&#160;A convertible preferred stock calculated based on the respective Original Issue Price of Series&#160;A convertible preferred stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company, or upon the occurrence of a Deemed Liquidation Event (as defined below), the holders of shares of Series&#160;A convertible preferred stock then outstanding are entitled to be paid out of the assets or funds of the Company available for distribution to stockholders before any payment is made to the holders of common stock. The holders of Series&#160;A convertible preferred stock are entitled to an amount equal to the greater of (i)&#160;the applicable Original Issue Price per share of Series&#160;A convertible preferred stock, plus any declared but unpaid dividends thereon, or (ii)&#160;the amount per share that would have been payable had all shares of Series&#160;A convertible preferred stock been converted into common stock immediately prior to such liquidation, dissolution, winding up or Deemed Liquidation Event. If upon any such liquidation event, the assets or funds of the Company available for distribution to stockholders are insufficient to pay the full amount to which they are entitled, then the holders of shares of Series&#160;A convertible preferred stock will share ratably in any distribution of the assets or funds available for distribution in proportion to the respective amounts which would otherwise be payable if it were paid in full.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">Unless the holders of a majority in voting power of the then outstanding shares of Series&#160;A convertible preferred stock elect otherwise, a Deemed Liquidation Event shall include a merger or consolidation (other than one in which stockholders of the Company own a majority by voting power of the outstanding shares of the surviving or acquiring corporation) or sale, lease, transfer, exclusive license or other disposition of all or substantially all of the Company&#8217;s assets.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">Series&#160;A convertible preferred stock does not have redemption rights, except for the contingent redemption upon the occurrence of a Deemed Liquidation Event.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:10pt;margin-top:10pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Convertible Notes</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">On March&#160;6, 2024, the Company entered into a Series A Preferred Stock and Convertible Note Purchase Agreement (the &#8220;Purchase Agreement&#8221;) with Fairmount, whereby the Company issued a convertible note (the &#8220;Convertible Note&#8221;), with an initial principal amount of $25.0<span class="nobreak"> </span>million, that can be converted into Series&#160;A preferred stock (or a Series&#160;of preferred shares that is identical in respect to the shares of preferred shares issued in its next equity financing) or shares of the Company&#8217;s common stock in exchange for proceeds of $25.0&#160;million. The Convertible Note will automatically convert into shares of the Company&#8217;s common stock upon the closing of a corporate transaction, including the reverse recapitalization transaction, and is otherwise due and payable at the request of the holder at any time. The Convertible Note accrues interest at a rate of 12.0% per annum. All unpaid interest and principal are scheduled to mature on December&#160;31, 2025. Prepayment is not permitted without prior written consent of Fairmount. Pursuant to the Purchase Agreement, the Company has the right to sell and issue additional convertible notes up to an aggregate principal amount equal to $30.0<span class="nobreak"> </span>million, in addition to the $25.0<span class="nobreak"> </span>million of initial principal amount of the Convertible Note.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:10pt;margin-top:10pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Oak Grove Lease</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">On April&#160;12, 2024, the Company entered into a lease agreement with Oak Grove LP (&#8220;Oak Grove Lease&#8221;) for office space located in Menlo Park, California. The lease commencement date is June&#160;15, 2024 with an initial term of 39.5&#160;months. The total lease payment is expected to be $1.4&#160;million over the initial lease term.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-40</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T215"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ORUKA THERAPEUTICS, INC.<br/>CONDENSED BALANCE SHEETS <br/>(UNAUDITED)<br/>(In thousands, except share and per share amounts)</span></p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">March&#160;31,<br/>2024</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">February&#160;6,<br/>2024</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">ASSETS</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Current assets</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Cash</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">27,743</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Subscription receivable</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total current assets</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">27,743</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other assets</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">488</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total assets</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">28,231</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS&#8217; DEFICIT</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Current liabilities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accounts payable</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accrued expenses and other current liabilities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,262</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Related party accounts payable and other current liabilities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5,899</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total current liabilities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">7,165</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Long term liabilities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accrued interest payable, related party</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">214</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Note payable to related party, noncurrent</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">24,980</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total liabilities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">32,359</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Commitments and contingencies (Note&#160;10)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Series&#160;A convertible preferred stock, $0.0001 par value; 20,000,000 shares authorized as of March&#160;31, 2024 and February&#160;6, 2024; 20,000,000 and no&#160;shares issued and outstanding as of March&#160;31, 2024 and February&#160;6, 2024, respectively; liquidation preference of $3,000 and $0 as of March&#160;31, 2024 and February&#160;6, 2024, respectively</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,931</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Stockholders&#8217; deficit:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-10" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Common stock, $0.0001 par value; 65,000,000 shares authorized, 9,460,019 and 5,596,658 shares issued and outstanding as of March&#160;31, 2024 and February 6, 2024, respectively</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Additional paid-in capital</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">17</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accumulated deficit</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(7,077</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total stockholders&#8217; deficit</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(7,059</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total liabilities, convertible preferred stock and stockholders&#8217; deficit</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">28,231</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1</p>
					</td>
				</tr>

		</table>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;text-align:center;margin-top:8pt;">The accompanying notes are an integral part of these condensed financial statements.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-41</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T216"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ORUKA THERAPEUTICS, INC.<br/>CONDENSED STATEMENT OF OPERATIONS AND COMPREHENSIVE LOSS <br/>(UNAUDITED)<br/>(In thousands, except share and per share amounts)</span></p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 3pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Period&#160;from <br/>February&#160;6,<br/>2024 <br/>(Inception)&#160;to<br/>March&#160;31, <br/>2024</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Operating expenses</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Research and development<span class="Superscript" style="vertical-align:super;font-size:58%;">(1)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5,193</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">General and administrative<span class="Superscript" style="vertical-align:super;font-size:58%;">(2)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,670</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total operating expenses</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">6,863</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Loss from operations </p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(6,863</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other expense</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Interest expense<span class="Superscript" style="vertical-align:super;font-size:58%;">(3)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(214</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total other expense</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(214</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net loss and comprehensive loss</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(7,077</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-14" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net loss per share attributable to common stockholders, basic and diluted</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(1.26</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Weighted-average common shares outstanding, basic and diluted</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5,596,658</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>

		</table>
		<p class="Tablefootnotef" style="margin-top: 0in;  border: none; margin-right: 0in; margin-bottom: -5pt; margin-left: 24.0pt; text-align: justify; text-justify: inter-ideograph; text-indent: -24.0pt; padding: 0in; font-size: 9.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">____________</p><p class="Tablefootnote_f" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:10pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:10pt;"><span class="Styles-for-Word-RTF-Imported-Lists_Word-Imported-List-Style1" style="font-family:Times New Roman, serif;font-style:normal;font-weight:normal;">(1)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Includes related party amount of $5,051 (see Note&#160;12)</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;"><span class="Styles-for-Word-RTF-Imported-Lists_Word-Imported-List-Style1" style="font-family:Times New Roman, serif;font-style:normal;font-weight:normal;">(2)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Includes related party amount of $848 (see Note&#160;12)</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;"><span class="Styles-for-Word-RTF-Imported-Lists_Word-Imported-List-Style1" style="font-family:Times New Roman, serif;font-style:normal;font-weight:normal;">(3)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Includes related party amount of $214 (see Note&#160;12)</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;text-align:center;margin-top:8pt;">The accompanying notes are an integral part of these condensed financial statements.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-42</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>






	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T217"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ORUKA THERAPEUTICS, INC.<br/>CONDENSED&#160;STATEMENT&#160;OF&#160;CONVERTIBLE&#160;PREFERRED&#160;STOCK&#160;AND&#160;STOCKHOLDERS&#8217;&#160;DEFICIT<br/>(UNAUDITED)<br/>(In thousands)</span></p>
		<table class="No-Table-Style _idGenTablePara-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-right-color:#000000;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 28.91%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-left-color:#000000;border-right-color:#000000;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.10%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="4" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-color:#000000;border-left-color:#000000;border-top-color:#000000;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 17.50%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:9pt;">Convertible<br/>Preferred Stock</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-color:#000000;border-left-color:#000000;border-right-color:#000000;border-right-width:1pt;border-top-color:#000000;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-right: windowtext 1pt none; border-right-style: solid;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-color:#000000;border-left-color:#000000;border-left-width:1pt;border-right-color:#000000;border-top-color:#000000;padding-bottom:3pt;padding-top:3pt;width: 0.55%; padding: 0in 0in 3px 0in;border-width: 0pt;border-left: windowtext 1pt none; border-left-style: solid;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-color:#000000;border-left-color:#000000;border-right-color:#000000;border-top-color:#000000;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.10%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-left-color:#000000;padding-bottom:3pt;padding-top:3pt;width: 18.60%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:9pt;">Common Stock</span></p>
					</td>
					<td class="TCH" colspan="2" rowspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 9.02%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:9pt;">Additional<br/>Paid-in<br/>Capital</span></p>
					</td>
					<td class="TCH" colspan="2" rowspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 9.58%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:9pt;">Accumulated<br/>Deficit</span></p>
					</td>
					<td class="TCH" colspan="4" rowspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 12.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:9pt;">Total<br/>Stockholders&#8217;<br/>Deficit</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-right-color:#000000;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 28.91%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;border-left-color:#000000;border-right-color:#000000;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.10%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-width:0pt;border-left-color:#000000;border-right-color:#000000;border-top-color:#000000;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 8.84%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:9pt;">Shares</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-width:0pt;border-left-color:#000000;border-right-color:#000000;border-top-color:#000000;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.10%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-width:0pt;border-left-color:#000000;border-right-color:#000000;border-top-color:#000000;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 7.55%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:9pt;">Amount</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-width:0pt;border-left-color:#000000;border-right-color:#000000;border-right-width:1pt;border-top-color:#000000;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-right: windowtext 1pt none; border-right-style: solid;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-width:0pt;border-left-color:#000000;border-left-width:1pt;border-right-color:#000000;border-top-color:#000000;padding-bottom:3pt;padding-top:3pt;width: 0.55%; padding: 0in 0in 3px 0in;border-width: 0pt;border-left: windowtext 1pt none; border-left-style: solid;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-width:0pt;border-left-color:#000000;border-right-color:#000000;border-top-color:#000000;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.10%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-left-color:#000000;padding-bottom:3pt;padding-top:3pt;width: 9.94%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:9pt;">Shares</span></p>
					</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 8.66%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:9pt;">Amount</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-23" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 28.91%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:9pt;">Balances as of February&#160;6, 2024 (inception)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.10%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-color:#000000;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 8.84%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-color:#000000;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.10%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-color:#000000;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-2" style="font-size:9pt;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-color:#000000;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 6.08%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-right-width:1pt;border-top-color:#000000;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-right: windowtext 1pt none; border-right-style: solid;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-left-width:1pt;border-top-color:#000000;border-top-width:0pt;width: 0.55%; padding: 0in 0in 3px 0in;border-width: 0pt;border-left: windowtext 1pt none; border-left-style: solid;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-color:#000000;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.10%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="No-Table-Style TB _idGenCellOverride-1" style="width: 9.94%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;"><span class="CharOverride-2" style="font-size:9pt;">5,596,658</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;"><span class="CharOverride-2" style="font-size:9pt;">$</span></p>
					</td>
					<td class="No-Table-Style TB _idGenCellOverride-1" style="width: 7.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;"><span class="CharOverride-2" style="font-size:9pt;">1</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;"><span class="CharOverride-2" style="font-size:9pt;">$</span></p>
					</td>
					<td class="No-Table-Style TB _idGenCellOverride-2" style="width: 7.55%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;"><span class="CharOverride-2" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;"><span class="CharOverride-2" style="font-size:9pt;">$</span></p>
					</td>
					<td class="No-Table-Style TB _idGenCellOverride-2" style="width: 8.10%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;"><span class="CharOverride-2" style="font-size:9pt;">$</span></p>
					</td>
					<td class="No-Table-Style TB _idGenCellOverride-2" style="width: 8.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">1</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 28.91%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;"><span class="CharOverride-2" style="font-size:9pt;">Issuance of common stock</span><span class="Superscript" style="vertical-align:super;font-size:6pt;">(1)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.10%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.84%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.10%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.08%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-right-width:1pt;padding-left:0pt;padding-right:0pt;width: 1.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-right: windowtext 1pt none; border-right-style: solid;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-left-width:1pt;width: 0.55%; padding: 0in 0in 3px 0in;border-width: 0pt;border-left: windowtext 1pt none; border-left-style: solid;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.10%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="No-Table-Style TB" style="width: 9.94%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;"><span class="CharOverride-2" style="font-size:9pt;">3,863,361</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="No-Table-Style TB" style="width: 7.18%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;"><span class="CharOverride-2" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="No-Table-Style TB" style="width: 7.55%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;"><span class="CharOverride-2" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="No-Table-Style TB" style="width: 8.10%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="No-Table-Style TB" style="width: 8.10%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-24" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 28.91%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;"><span class="CharOverride-2" style="font-size:9pt;">Issuance of Series&#160;A convertible preferred stock, net of issuance costs of $69</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.10%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.84%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">20,000,000</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.10%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.08%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">2,931</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-right-width:1pt;padding-left:0pt;padding-right:0pt;width: 1.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-right: windowtext 1pt none; border-right-style: solid;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-left-width:1pt;width: 0.55%; padding: 0in 0in 3px 0in;border-width: 0pt;border-left: windowtext 1pt none; border-left-style: solid;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.10%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="No-Table-Style TB" style="width: 9.94%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;"><span class="CharOverride-2" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="No-Table-Style TB" style="width: 7.18%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;"><span class="CharOverride-2" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="No-Table-Style TB" style="width: 7.55%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;"><span class="CharOverride-2" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="No-Table-Style TB" style="width: 8.10%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="No-Table-Style TB" style="width: 8.10%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 28.91%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;"><span class="CharOverride-2" style="font-size:9pt;">Stock-based compensation expense</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.10%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.84%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.10%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.08%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-right-width:1pt;padding-left:0pt;padding-right:0pt;width: 1.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-right: windowtext 1pt none; border-right-style: solid;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-left-width:1pt;width: 0.55%; padding: 0in 0in 3px 0in;border-width: 0pt;border-left: windowtext 1pt none; border-left-style: solid;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.10%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="No-Table-Style TB" style="width: 9.94%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;"><span class="CharOverride-2" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="No-Table-Style TB" style="width: 7.18%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;"><span class="CharOverride-2" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="No-Table-Style TB" style="width: 7.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;"><span class="CharOverride-2" style="font-size:9pt;">17</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="No-Table-Style TB" style="width: 8.10%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="No-Table-Style TB" style="width: 8.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">17</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 28.91%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;"><span class="CharOverride-2" style="font-size:9pt;">Net loss</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.10%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.84%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.10%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.08%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-right-width:1pt;padding-left:0pt;padding-right:0pt;width: 1.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-right: windowtext 1pt none; border-right-style: solid;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-left-width:1pt;width: 0.55%; padding: 0in 0in 3px 0in;border-width: 0pt;border-left: windowtext 1pt none; border-left-style: solid;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.10%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="No-Table-Style TB" style="width: 9.94%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="No-Table-Style TB" style="width: 7.18%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="No-Table-Style TB" style="width: 7.55%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#160;</p>
					</td>
					<td class="No-Table-Style TB" style="width: 8.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(7,077</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#160;</p>
					</td>
					<td class="No-Table-Style TB" style="width: 8.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(7,077</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 28.91%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:9pt;">Balances as of March&#160;31, 2024</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.10%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.84%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">20,000,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.10%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.08%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,931</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-right-width:1pt;padding-left:0pt;padding-right:0pt;width: 1.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-right: windowtext 1pt none; border-right-style: solid;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-left-width:1pt;width: 0.55%; padding: 0in 0in 3px 0in;border-width: 0pt;border-left: windowtext 1pt none; border-left-style: solid;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.10%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="No-Table-Style TB" style="width: 9.94%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">9,460,019</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">$</p>
					</td>
					<td class="No-Table-Style TB" style="width: 7.18%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">1</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">$</p>
					</td>
					<td class="No-Table-Style TB" style="width: 7.55%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">17</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">$</p>
					</td>
					<td class="No-Table-Style TB" style="width: 8.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(7,077</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">$</p>
					</td>
					<td class="No-Table-Style TB" style="width: 8.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(7,059</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</p>
					</td>
				</tr>

		</table>
		<p class="Textfootnotef" style="margin-top: 0in;  border: none; margin-right: 0in; margin-bottom: -5pt; margin-left: 24.0pt; text-align: justify; text-justify: inter-ideograph; text-indent: -24.0pt; padding: 0in; font-size: 9.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">____________</p><p class="Textfootnote_f" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:10pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:10pt;">(1)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Includes issuance of 3,863,361 restricted stock awards (see Note 7)</p>
		<p class="Text_ind_center" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:3;margin-top:8pt;">The accompanying notes are an integral part of these condensed financial statements.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-43</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T218"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ORUKA THERAPEUTICS, INC. <br/>CONDENSED STATEMENT OF CASH FLOWS<br/>(UNAUDITED)<br/>(In thousands)</span></p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">Period&#160;from<br/>February&#160;6,<br/>2024<br/>(Inception) to<br/>March&#160;31, <br/>2024</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Cash flows from operating activities:</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net loss</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(7,077</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Adjustments to reconcile net loss to net cash used in operating activities:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Stock-based compensation expense</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">85</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Non-cash interest expense</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Changes in operating assets and liabilities:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Subscription receivable</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accounts payable</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accrued expenses and other current liabilities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">773</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Related party accounts payable and other current liabilities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5,831</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accrued interest payable, related party</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">214</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net cash used in operating activities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(168</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Cash flows from financing activities:</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Proceeds from issuance of Series&#160;A convertible preferred stock, net of issuance costs paid</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,931</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Proceeds from issuance of notes payable to related parties, net of issuance costs paid</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">24,980</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net cash provided by financing activities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">27,911</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Net increase in cash</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">27,743</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Cash at beginning of period</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Cash at end of period</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">27,743</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Supplemental disclosure of non-cash financing activities:</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Deferred offering costs in accrued expenses and other current liabilities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">488</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>

		</table>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;text-align:center;margin-top:8pt;">The accompanying notes are an integral part of these condensed financial statements.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-44</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T219"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ORUKA THERAPEUTICS, INC.<br/>NOTES TO CONDENSED FINANCIAL STATEMENTS<br/>(UNAUDITED)</span></p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-left:24pt;text-indent:-24pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">1.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Nature of the Business and Basis of Presentation</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Background and Basis of Presentation</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka Therapeutics, Inc. (&#8220;Oruka&#8221; or the &#8220;Company&#8221;) was established and incorporated under the laws of the state of Delaware on February&#160;6, 2024. Oruka was founded by Paragon Therapeutics, Inc. (&#8220;Paragon&#8221;). The Company currently operates as a virtual company, and thus, does not maintain a corporate headquarters or other significant facilities. Oruka was formed to develop biologics to optimize the treatment of inflammatory skin diseases.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company is subject to risks and uncertainties common to early stage companies in biopharmaceutical industry, including, but not limited to, completing preclinical and clinical trials, obtaining regulatory approval for product candidates, development by competitors of new technological innovations, dependence on key personnel, the ability to attract and retain qualified employees, reliance on third<span class="nobreak">-party</span> organizations, protection of proprietary technology, compliance with government regulations, product liability, uncertainty of market acceptance of products and the ability to raise additional capital to fund operations.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company&#8217;s potential products require approval from the U.S.&#160;Food and Drug Administration or comparable foreign authorities prior to the commencement of commercial sales. There can be no assurance that the Company&#8217;s potential products will receive all the required approvals. In addition, there can be no assurance that the Company&#8217;s potential products, if approved, will be accepted in the marketplace, nor can there be any assurance that any future products can be developed or manufactured at an acceptable cost and with appropriate performance characteristics, or that such products will be successfully marketed, if at all.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The accompanying unaudited interim condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United&#160;States of America (&#8220;U.S.&#160;GAAP&#8221;) and pursuant to the rules and regulations of the U.S.&#160;Securities and Exchange Commission (&#8220;SEC&#8221;) regarding interim financial information. Accordingly, they do not include all of the information and notes required by U.S.&#160;GAAP for complete financial statements. These unaudited condensed financial statements include only normal and recurring adjustments the Company believes are necessary to fairly state the Company&#8217;s financial position and the results of its operations and cash flows. The results for the period from February&#160;6, 2024 (inception) to March&#160;31, 2024 are not necessarily indicative of results expected for the full fiscal year or any subsequent interim period.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Going Concern</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The accompanying condensed financial statements have been prepared on the basis that the Company is a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the normal course of business. As of March&#160;31, 2024, the Company had $27.7&#160;million in cash.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Since inception, the Company has devoted substantially all of its resources to advancing the development of its portfolio of programs, organizing and staffing the Company, business planning, raising capital, and providing general and administrative support for these operations. Current and future programs will require significant research and development efforts, including preclinical and clinical trials, and regulatory approvals to commercialization. These efforts require significant amounts of additional capital, adequate personnel, and infrastructure. Even if the Company&#8217;s development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales. If the Company obtains regulatory approval for any of its product candidates and starts to generate revenue, it expects to incur significant expenses related to developing its internal commercialization capability to support product sales, marketing, and distribution.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As a result, the Company will need substantial additional funding to support its operating activities as it advances its potential product candidates through development, seeks regulatory approval and prepares for and, if any of its product candidates are approved, proceeds to commercialization. Until such time as the Company can generate significant revenue from product sales, if ever, the Company expects to finance its operating activities through a combination of equity offerings and debt financings. Adequate funding may not be available to the Company on acceptable terms, or at all.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-45</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Note_H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;">ORUKA THERAPEUTICS, INC.<br/>NOTES TO CONDENSED FINANCIAL STATEMENTS<br/>(UNAUDITED)</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If the Company is unable to obtain additional funding, the Company will assess its capital resources and may be required to delay, reduce the scope of or eliminate some or all of its planned operations, which may have a material adverse effect on the Company&#8217;s business, financial condition, results of operations and ability to operate as a going concern.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company has not generated any revenue from product sales or other sources and has incurred significant operating losses and negative cash flows from operations since inception. The Company has incurred a net loss of $7.1&#160;million during the period from February&#160;6, 2024 (inception) to March&#160;31, 2024. As of March&#160;31, 2024, the Company had an accumulated deficit of $7.1&#160;million.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In March&#160;2024, the Company received $3.0&#160;million in gross proceeds from the issuance of Series&#160;A convertible preferred stock (&#8220;Series A Preferred Stock&#8221;) and $25.0&#160;million in gross proceeds from the issuance of a convertible note, both of which were related party transactions (see Note&#160;12).</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA biopharma, Inc., a Delaware corporation (&#8220;ARCA&#8221;), and the Company entered into an Agreement and Plan of Merger and Reorganization (the &#8220;Merger Agreement&#8221;) on April&#160;3, 2024, pursuant to which, among other matters, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Atlas Merger Sub Corp, a Delaware corporation (&#8220;First Merger Sub&#8221;), will merge with and into Oruka, with Oruka continuing as a wholly owned subsidiary of ARCA and the surviving corporation of the merger (the &#8220;First Merger&#8221;), and Oruka will merge with and into Atlas Merger Sub&#160;II, LLC, a Delaware limited liability company (&#8220;Second Merger Sub&#8221; and together with First Merger Sub, &#8220;Merger Subs&#8221;), with Second Merger Sub being the surviving entity of the merger (the &#8220;Second Merger&#8221; and, together with the First Merger, the &#8220;Merger&#8221;). In connection with the Merger, Second Merger Sub will change its corporate name to &#8220;Oruka Therapeutics Operating Company, LLC&#8221; and ARCA will change its name to &#8220;Oruka Therapeutics, Inc.&#8221; ARCA following the Merger is referred to herein as the &#8220;combined company.&#8221; The combined company will be led by Oruka&#8217;s management team and will remain focused on developing biologics to optimize the treatment of inflammatory skin diseases.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Concurrent with the execution of the Merger Agreement, the Company entered into a subscription agreement with certain investors pursuant to which the Company agreed to issue and sell to investors in a private placement financing (the &#8220;Private Placement&#8221;) shares of the Company&#8217;s common stock and pre<span class="nobreak">-funded</span> warrants to purchase shares of the Company&#8217;s common stock at an estimated purchase price of $5.80 per share of common stock and $5.79 per warrant for gross proceeds of approximately $275.0&#160;million, inclusive of $25.0&#160;million proceeds received as of March&#160;31, 2024 from the issuance of the Company&#8217;s convertible note, which will precede the closing of the Merger. Shares of the Company&#8217;s common stock and warrants to purchase shares of the Company&#8217;s common stock issued pursuant to the Private Placement will be converted into the right to receive shares of ARCA common stock and warrants to purchase shares of ARCA common stock, respectively, in accordance with the exchange ratio at the effective time of the close of the transaction. The proceeds from the Private Placement are expected to advance the Company&#8217;s pipeline, as well as for general corporate purposes, which may include capital expenditure, working capital and general and administrative expenses.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">However, the agreements are subject to the satisfaction of customary closing conditions, and there are no assurances that such conditions will be achieved nor that such financing or other strategic transactions will be available on acceptable terms, or at all. If the Merger Agreement is terminated under certain circumstances, ARCA could be required to pay Oruka a termination fee of $0.4<span class="nobreak"> </span>million or Oruka could be required to pay ARCA a termination fee of $0.4<span class="nobreak"> </span>million. Based on its expectation of continuing operating losses for the foreseeable future, and the need to raise future capital, as of May<span class="nobreak"> </span>13, 2024, the date the Company&#8217;s condensed financial statements are available to be issued, the Company has concluded there is substantial doubt about its ability to continue as a going concern for one year from the date that these condensed financial statements are available to be issued.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The accompanying condensed financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty. Accordingly, the condensed financial statements have been prepared on a basis that assumes the Company will continue as a going concern and which contemplates the realization of assets and satisfaction of liabilities and commitments in the ordinary course of business.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-46</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Note_H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;">ORUKA THERAPEUTICS, INC.<br/>NOTES TO CONDENSED FINANCIAL STATEMENTS<br/>(UNAUDITED)</p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-left:24pt;text-indent:-24pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Summary of Significant Accounting Policies</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Use of Estimates</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The preparation of the Company&#8217;s condensed financial statements in conformity with U.S.&#160;GAAP requires management to make estimates, assumptions, and judgements that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the condensed financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected within these condensed financial statements include but are not limited to research and development expenses and related prepaid or accrued costs and the valuation of stock<span class="nobreak">-based</span> compensation awards and related expenses. The Company bases its estimates on known trends and other market<span class="nobreak">-specific</span> or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates, as there are changes in circumstances, facts, and experience. Actual results may differ materially from those estimates or assumptions.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Concentrations of Credit Risk</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Financial instruments that potentially expose the Company to concentrations of credit risk primarily consist of cash. The Company maintains its cash balances at an accredited financial institution in amounts that, at times, may exceed federally insured limits. However, the Company has not experienced any losses on its deposits of cash.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company is dependent on third<span class="nobreak">-party</span> organizations to research, develop, manufacture, and process its product candidates for its development programs, including its two most advanced programs, ORKA<span class="nobreak">-001</span> and ORKA<span class="nobreak">-002</span>. The Company expects to continue to be dependent on a small number of manufacturers to supply it with its requirements for all products. The Company&#8217;s research and development programs could be adversely affected by a significant interruption in the supply of the necessary materials. A significant amount of the Company&#8217;s research and development activities are performed under its agreements with Paragon (see Note&#160;9).</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Deferred Offering Costs</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company capitalizes certain legal, professional, accounting, and other third<span class="nobreak">-party</span> fees that are directly associated with in<span class="nobreak">-process</span> equity financings as deferred offering costs until such financings are consummated. After the consummation of equity financing, these costs are recorded as a reduction of the proceeds from the offering, either as a reduction of the carrying value of the preferred stock or in stockholders&#8217; deficit as a reduction of additional paid<span class="nobreak">-in</span> capital generated as a result of the offering. Should the in<span class="nobreak">-process</span> equity financing (see Note&#160;1) be abandoned, the deferred offering costs would be expensed immediately as a charge to operating expenses in the statement of operations and comprehensive loss. As of March&#160;31, 2024, deferred offering costs of $0.5&#160;million were recorded as Other assets in the condensed balance sheet.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Debt Issuance Costs</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Debt issuance costs incurred in connection with the Company&#8217;s convertible note (see Note&#160;4) are recorded as a reduction of the carrying value of the notes payable liability on the Company&#8217;s balance sheet and are amortized to interest expense over the term of the loan using the effective interest method.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Subscription receivable</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company accounts for any notes received in exchange for common stock as a subscription receivable, provided the note underlying the receivable is paid prior to the date the financial statement is available to be issued.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Fair Value Measurements</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Certain assets and liabilities are carried at fair value under U.S.&#160;GAAP.&#160;Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-47</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Note_H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;">ORUKA THERAPEUTICS, INC.<br/>NOTES TO CONDENSED FINANCIAL STATEMENTS<br/>(UNAUDITED)</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Level&#160;1 &#8212;&#160;Quoted prices in active markets that are identical assets or liabilities.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Level&#160;2&#160;&#8212;&#160;Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Level&#160;3&#160;&#8212;&#160;Unobservable inputs that are supported by little or no market activity that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies, and similar techniques.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The carrying values of the Company&#8217;s prepaid expenses and other current assets, accounts payable and accrued expenses and other current liabilities approximate their fair values due to their relatively short maturity period. The Company accounts for its convertible note at amortized cost.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Classification of Convertible Preferred Stock</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company has classified the convertible preferred stock outside of stockholders&#8217; deficit on the Company&#8217;s condensed balance sheet because the holders of such stock have certain liquidation rights in the event of a deemed liquidation event that, in certain situations, is not solely within the control of the Company and would require the redemption of the then<span class="nobreak">-outstanding</span> convertible preferred stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company&#8217;s Series&#160;A Preferred Stock is not redeemable, except in the event of deemed liquidation (see Note&#160;5). Because the occurrence of a deemed liquidation event is not currently probable, the carrying values of the convertible preferred stock are not being accreted to their redemption values. Subsequent adjustments to the carrying values of the convertible preferred stock would be made only when a deemed liquidation event becomes probable.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Note&#160;Payable to Related Party</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company accounts for its convertible note at amortized cost. The Company considers if optional conversion features are required to be bifurcated and separately accounted for as a derivative. Costs related to the issuance of the convertible note are recorded as a debt discount, amortized over the term of the convertible note (see&#160;Note&#160;4) and are accounted as interest expense in other expenses within the condensed statements of operations and comprehensive loss using the effective interest method.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Research and Development Contract Costs Accruals</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company records the costs associated with research studies and manufacturing development as incurred. These costs are a significant component of the Company&#8217;s research and development expenses, with a substantial portion of the Company&#8217;s ongoing research and development activities conducted by third<span class="nobreak">-party</span> service providers, including contract research organizations (&#8220;CROs&#8221;) and contract manufacturing organizations (&#8220;CMOs&#8221;), and the Company&#8217;s related<span class="nobreak">-party</span> Paragon (see Note&#160;9).</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company accrues for expenses resulting from obligations under its two antibody discovery and option agreements (the &#8220;Option Agreements&#8221;) between Paragon, Paruka Holding LLC (&#8220;Paruka&#8221;), an entity formed by Paragon as a vehicle to hold equity in the Company, and the Company and agreements with CROs, CMOs, and other outside service providers for which payment flows do not match the periods over which materials or services are provided to the Company. Accruals are recorded based on estimates of services received and efforts expended pursuant to agreements established with Paragon, CROs, CMOs, and other outside service providers. These estimates are typically based on contracted amounts applied to the proportion of work performed and determined through analysis with internal personnel and external service providers as to the progress or stage of completion of </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-48</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Note_H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;">ORUKA THERAPEUTICS, INC.<br/>NOTES TO CONDENSED FINANCIAL STATEMENTS<br/>(UNAUDITED)</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">the services. The Company makes significant judgments and estimates in determining the accrual balance in each reporting period. In the event advance payments are made to Paragon, a CRO, CMO, or outside service provider, the payments will be recorded as a prepaid asset which will be expensed as the contracted services are performed. Changes in these estimates that result in material changes to the Company&#8217;s accruals could materially affect the Company&#8217;s results of operations. As of March&#160;31, 2024, the Company has not experienced any material deviations between accrued and actual research and development expenses.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Segment Information</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company operates and manages its business as a single segment for the purposes of assessing performance and making operating decisions. The Company&#8217;s chief executive officer, who is the chief operating decision maker (the &#8220;CODM&#8221;), reviews the Company&#8217;s financial information on an aggregated basis for purposes of evaluating financial performance and allocating resources.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Research and Development Costs</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Research and development costs are expensed as incurred. Research and development costs include salaries and bonuses, stock<span class="nobreak">-based</span> compensation, employee benefits, and external costs of vendors and consultants engaged to conduct research and development activities.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses on the accompanying condensed balance sheet. The prepaid amounts are expensed as the related goods are delivered or the services are performed, or when it is no longer expected that the goods will be delivered, or the services rendered. If nonrefundable advance payments represent a one<span class="nobreak">-time</span> cost for obtaining goods or services, with anticipated benefits to be utilized within a year of period end, the payment is expensed immediately.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">General and Administrative Expenses</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">General and administrative expenses consist primarily of salaries and bonuses, stock<span class="nobreak">-based</span> compensation, employee benefits, finance and administration costs, human resources costs, information technology costs, professional service fees, and other general overhead costs to support the Company&#8217;s operations.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Commitments and Contingencies</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company is subject to contingent liabilities, such as legal proceedings and claims, that arise in the ordinary course of business activities. The Company accrues for loss contingencies when losses become probable and are reasonably estimable. If the reasonable estimate of the loss is a range and no amount within the range is a better estimate, the minimum amount of the range is recorded as a liability on the balance sheet. The Company does not accrue for contingent losses that, in its judgment, are considered to be reasonably possible, but not probable; however, it discloses the range of reasonably possible losses. As of March&#160;31, 2024, no liabilities were recorded for loss contingencies (see Note&#160;10).</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Stock-Based Compensation</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company measures all stock<span class="nobreak">-based</span> awards granted to employees, directors, and non<span class="nobreak">-employees</span> in the form of stock options to purchase shares of its common stock, based on the fair value of the awards on the date of grant using the Black<span class="nobreak">-Scholes</span> option<span class="nobreak">-pricing</span> model. The Company measures restricted common stock awards (&#8220;RSAs&#8221;) using the difference, if any, between the purchase price per share of the award and the fair value of the Company&#8217;s common stock at the date of grant.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company grants stock options and restricted stock awards that are subject to either service or performance<span class="nobreak">-based</span> vesting conditions. Compensation expense for awards to employees and directors with service<span class="nobreak">-based</span> vesting conditions is recognized using the straight<span class="nobreak">-line</span> method over the requisite service period, which is generally the </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-49</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Note_H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;">ORUKA THERAPEUTICS, INC.<br/>NOTES TO CONDENSED FINANCIAL STATEMENTS<br/>(UNAUDITED)</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">vesting period of the respective award. Compensation expense for awards to non<span class="nobreak">-employees</span> with service<span class="nobreak">-based</span> vesting conditions is recognized in the same manner as if the Company had paid cash in exchange for the goods or services, which is generally over the vesting period of the award. Forfeitures are accounted for as they occur. As of each reporting date, the Company estimates the probability that specified performance criteria will be met and does not recognize compensation expense until it is probable that the performance<span class="nobreak">-based</span> vesting condition will be achieved.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company has issued stock options and RSAs with service<span class="nobreak">-based</span> vesting conditions.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company classifies stock<span class="nobreak">-based</span> compensation expense in its condensed statement of operations and comprehensive loss in the same manner in which the award recipient&#8217;s payroll costs are classified or in which the award recipient&#8217;s service payments are classified.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Net Loss per Share Attributable to Common Stockholders</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company applies the two<span class="nobreak">-class</span> method when computing net loss per share attributable to the Company&#8217;s common stockholders as the Company has issued shares that meet the definition of participating securities. The&#160;two<span class="nobreak">-class</span>&#160;method determines net loss per share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The&#160;two<span class="nobreak">-class</span>&#160;method requires loss available to common stockholders for the period to be allocated between common and participating securities based upon their respective rights to share in the undistributed earnings as if all loss for the period had been distributed. The Company considers its convertible preferred stock to be participating securities as, in the event a dividend is paid on common stock, the holders of convertible preferred stock would be entitled to receive dividends on a basis consistent with the Company&#8217;s common stockholders. There is no allocation required under the two<span class="nobreak">-class</span> method during periods of loss since the participating securities do not have a contractual obligation to share in the losses of the Company.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Basic net loss per share attributable to common stockholders is computed by dividing the net loss attributable to the Company&#8217;s common stockholders by the weighted average number of common shares outstanding for the period, excluding potentially dilutive common shares. Diluted net loss per share attributable to common stockholders is computed by adjusting net loss attributable to common stockholders to reallocate undistributed earnings based on the potential impact of dilutive securities. Diluted net loss per share attributable to common stockholders is computed by dividing the diluted net loss by the weighted average number of common shares outstanding for the period, including potential dilutive common shares. For purposes of this calculation, the Company&#8217;s outstanding convertible preferred stock, stock options to purchase common stock and unvested RSAs are considered potential dilutive common shares.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company generated a net loss for the period presented. Accordingly, basic and diluted net loss per share is the same because the inclusion of the potentially dilutive securities would be anti<span class="nobreak">-dilutive</span>.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Income Taxes</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the financial statements or in the Company&#8217;s tax returns. Deferred tax assets and liabilities are determined based on the differences between the financial statement basis and tax basis of assets and liabilities using enacted tax rates in effect for the&#160;years in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. The potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company accounts for uncertainty in income taxes recognized in the condensed financial statements by applying a two<span class="nobreak">-step</span> process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more likely than not to be sustained, the tax position is then assessed to determine </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-50</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Note_H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;">ORUKA THERAPEUTICS, INC.<br/>NOTES TO CONDENSED FINANCIAL STATEMENTS<br/>(UNAUDITED)</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">the amount of benefit to recognize in the condensed financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related net interest and penalties. The Company had accrued no amounts for interest or penalties related to uncertain tax positions as of March&#160;31, 2024.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Recently Issued Accounting Pronouncements</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In November&#160;2023, the FASB issued ASU No.&#160;2023<span class="nobreak">-07</span>, <span class="Italic" style="font-style:italic;font-weight:normal;">Segment Reporting</span> (<span class="Italic" style="font-style:italic;font-weight:normal;">Topic&#160;280</span>) (&#8220;ASU&#160;2023<span class="nobreak">-07</span>&#8221;), which enhances the segment disclosure requirements for public entities on an annual and interim basis. Under this proposal, public entities will be required to disclose significant segment expenses that are regularly provided to the CODM and included within each reported measure of segment profit or loss. Additionally, current annual disclosures about a reportable segment&#8217;s profit or loss and assets will be required on an interim basis. Entities will also be required to disclose information about the CODM&#8217;s title and position at the Company along with an explanation of how the CODM uses the reported measures of segment profit or loss in their assessment of segment performance and deciding how to allocate resources. Finally, ASU&#160;2023<span class="nobreak">-07</span> requires all segment disclosures for public entities that have only a single reportable segment. The amendments in ASU&#160;2023<span class="nobreak">-07</span> are effective for fiscal&#160;years beginning after December&#160;15, 2023, and interim periods within fiscal&#160;years beginning after December&#160;15, 2024. Early adoption is permitted. The Company is currently evaluating the impact of this standard on its condensed financial statements.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In December&#160;2023, the FASB issued ASU&#160;2023<span class="nobreak">-09</span>, <span class="Italic" style="font-style:italic;font-weight:normal;">Income Taxes (Topic&#160;740): Improvements to Income Tax Disclosures</span>. This ASU expands disclosures in an entity&#8217;s income tax rate reconciliation table and disclosures regarding taxes paid both in the U.S.&#160;and foreign jurisdictions. This update is effective beginning with the Company&#8217;s 2025 fiscal year annual reporting period. The Company is currently evaluating the impact of this standard on its condensed financial statements.</p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-left:24pt;text-indent:-24pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">3.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Accrued Expenses and Other Current Liabilities</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Accrued expenses and other current liabilities consisted of the following (in thousands):</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">March&#160;31,</span><span class="CharOverride-2" style="text-decoration:underline;"><br/></span><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">2024</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accrued professional and consulting fees</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,040</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accrued recruiting fees</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">88</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accrued employee compensation and benefits</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">78</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">56</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,262</p>
					</td>
				</tr>

		</table>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-left:24pt;text-indent:-24pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">4.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Note&#160;Payable with Related Party</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In March&#160;2024, the Company entered into a Series A Preferred Stock and Convertible Note Purchase Agreement (the &#8220;Purchase Agreement&#8221;) with Fairmount Healthcare Fund&#160;II, L.P. (&#8220;Fairmount&#8221;), whereby the Company issued a convertible note (the &#8220;Convertible Note&#8221;), with an initial principal amount of $25.0<span class="nobreak"> </span>million, that can be converted into Series&#160;A Preferred Stock (or a Series&#160;of preferred shares that is identical in respect to the shares of preferred shares issued in its next equity financing) or shares of the Company&#8217;s common stock in exchange for aggregate proceeds of $25.0&#160;million. The Convertible Note will automatically convert into shares of the Company&#8217;s common stock upon the closing of a corporate transaction, including the Private Placement, and is otherwise due and payable at the request of the holder at any time. The Convertible Note accrues interest at a rate of 12.0% per annum. All unpaid interest and principal are scheduled to mature on December&#160;31, 2025 (the &#8220;Maturity Date&#8221;). Prepayment is not permitted without prior written consent of Fairmount. Pursuant to the Purchase Agreement, the Company has the right to sell and issue additional convertible notes up to an aggregate principal amount equal to $30.0<span class="nobreak"> </span>million, in addition to the $25.0<span class="nobreak"> </span>million of initial principal amount of the Convertible </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-51</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Note_H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;">ORUKA THERAPEUTICS, INC.<br/>NOTES TO CONDENSED FINANCIAL STATEMENTS<br/>(UNAUDITED)</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">Note. The principal payment along with the accrued interest on the Convertible Note is due in full on the Maturity Date. As of March&#160;31, 2024, the Company had outstanding borrowings of $25.0&#160;million from Fairmount under its Convertible Note.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In connection with the proposed reverse recapitalization transaction, the Convertible Note will convert into a number of shares of common stock based on the aggregate principal amount, plus any unpaid accrued interest, divided by the conversion price, which is an amount to be determined based upon the Company&#8217;s fully<span class="nobreak">-diluted</span> capitalization immediately prior to the reverse recapitalization transaction. In the event the proposed reverse recapitalization transaction or any other proposed corporate transactions do not close prior to the Company&#8217;s next equity financing, the Convertible Note will convert into the next series of issued convertible preferred stock. </p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company assessed all terms and features of the Convertible Note in order to identify any potential embedded features that would require bifurcation. As part of this analysis, the Company assessed the economic characteristics and risks of the embedded features. The Company determined that the share settled redemption feature was clearly and closely related to the debt host and did not require separate accounting. The Company determined that the conversion options of the Convertible Note were not clearly and closely associated with a debt host. However, these features did not meet the definition of a derivative under ASC&#160;815, <span class="Italic" style="font-style:italic;font-weight:normal;">Derivatives and Hedging</span>, and as a result did not require separate accounting as a derivative liability.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company paid debt issuance costs of less than $0.1&#160;million in relation to the Convertible Note. The debt issuance costs are reflected as a reduction of the carrying value of Convertible Note on the condensed balance sheet and are being amortized as interest expense over the term of the Convertible Note using the effective interest method. For the period from February&#160;6, 2024 (inception) to March&#160;31, 2024, the Company recognized interest expense related to the Convertible Note of $0.2&#160;million, which includes non<span class="nobreak">-cash</span> interest expense related to the amortization of debt issuance costs of less than $0.1&#160;million. For the period from February&#160;6, 2024 (inception) to March&#160;31, 2024, the weighted average effective interest rate of the Convertible Note was approximately 12.0%.</p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-left:24pt;text-indent:-24pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">5.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Convertible Preferred Stock</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In March&#160;2024, the Company issued and sold an aggregate of 20,000,000<span class="nobreak"> </span>shares of Series&#160;A Preferred Stock to Fairmount, at a purchase price of $0.15 per share, for gross proceeds of $3.0&#160;million. The Company incurred less than $0.1&#160;million of issuance costs in connection with this transaction.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Upon the issuance of the Series&#160;A Preferred Stock, the Company assessed the embedded conversion and liquidation features of the securities as described below and determined that such features did not require the Company to separately account for these features.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of March&#160;31, 2024, convertible preferred stock consisted of the following (in thousands, except share amounts):</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-11" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 24.79%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="11" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 73.93%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">March&#160;31, 2024</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-12" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 24.79%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Preferred&#160;Stock<br/>Authorized</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Preferred Stock<br/>Issued and<br/>Outstanding</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Carrying<br/>Value</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Liquidation<br/>Preference</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Common Stock<br/>Issuable Upon<br/>Conversion</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 24.79%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Series&#160;A Preferred Stock</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">20,000,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">20,000,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,931</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">20,000,000</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 24.79%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">20,000,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">20,000,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,931</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">20,000,000</p>
					</td>
				</tr>

		</table>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The holders of the Series A Preferred Stock have the following rights and preferences:</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Voting</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The holders of Series&#160;A Preferred Stock are entitled to vote, together with the holders of common stock, on all matters submitted to stockholders for a vote. Each holder of outstanding shares of Series&#160;A Preferred Stock is entitled to the number of votes equal to the number of shares of common stock into which the shares of preferred stock held by such holder are convertible as of the record date for determining stockholders entitled to vote on such </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-52</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Note_H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;">ORUKA THERAPEUTICS, INC.<br/>NOTES TO CONDENSED FINANCIAL STATEMENTS<br/>(UNAUDITED)</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">matter. A majority vote of the holders of Series&#160;A Preferred Stock is required to liquidate or dissolve the Company, amend the certificate of incorporation or bylaws, reclassify common stock or establish another class of capital stock, create shares that would rank senior to or authorize additional shares of Preferred Stock, declare a dividend or make a distribution.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, the holders of shares of Series&#160;A Preferred Stock are entitled to elect one director of the Company. The holders of shares of common stock and any other class or series of voting stock (including Series&#160;A convertible preferred stock), exclusively and voting together as a single class, are entitled to elect the balance of the total number of directors of the Company. The Company controls the Board of Directors.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Conversion</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Each share of Series&#160;A Preferred Stock is convertible at the option of the holder, at any time, and without the payment of additional consideration by the holder. In addition, each share of Series&#160;A Preferred Stock will be automatically converted into shares of common stock at the applicable conversion ratio then in effect upon either (i)&#160;the closing of a firm<span class="nobreak">-commitment</span> underwritten public offering of the Company&#8217;s common stock at a price of at least $1.00 per share resulting in at least $50.0&#160;million of gross proceeds to the Company, net of the underwriting discount and commissions, or (ii)&#160;the vote or written consent of the holders of a majority of the outstanding shares of preferred stock, voting as a single class.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The conversion ratio of Series&#160;A Preferred Stock is determined by dividing the original issue price by the conversion price in effect at the time of conversion. The original issue price is $0.15 per share for Series&#160;A Preferred Stock (in each case subject to appropriate adjustment in the event of any stock split, stock dividend, combination or other similar recapitalization and other adjustments as set forth in the Company&#8217;s certificate of incorporation, as amended and restated). The Conversion Price is $0.15 per share for Series&#160;A convertible preferred stock. As of March&#160;31, 2024, each outstanding share of Series&#160;A Preferred Stock was convertible into common stock on a one<span class="nobreak">-for-one</span> basis.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Dividends</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company may not declare, pay or set aside any dividends on shares of any other class or series of capital stock of the Company (other than dividends on shares of common stock) unless the holders of the Series&#160;A Preferred Stock then outstanding first receive, or simultaneously receive, a dividend on each outstanding share of Series&#160;A Preferred Stock in an amount at least equal to (i)&#160;in the case of a dividend being distributed to common stock or any class or series that is convertible into common stock, the equivalent dividend on an as<span class="nobreak">-converted</span> basis or (ii)&#160;in the case of a dividend on any class or series that is not convertible into common stock, a dividend equal to a dividend rate on Series&#160;A Preferred Stock calculated based on the respective original issue price of Series&#160;A Preferred Stock. For the period from February&#160;6, 2024 (inception) through March&#160;31, 2024, no cash dividends had been declared or paid by the Company.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Liquidation</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company, or upon the occurrence of a Deemed Liquidation Event (as defined below), the holders of shares of Series&#160;A Preferred Stock then outstanding are entitled to be paid out of the assets or funds of the Company available for distribution to stockholders before any payment is made to the holders of common stock. The holders of Series&#160;A Preferred Stock are entitled to an amount equal to the greater of (i)&#160;the applicable original issue price per share of Series&#160;A Preferred Stock, plus any declared but unpaid dividends thereon, or (ii)&#160;the amount per share that would have been payable had all shares of Series&#160;A Preferred Stock been converted into common stock immediately prior to such liquidation, dissolution, winding up or Deemed Liquidation Event. If upon any such liquidation event, the assets or funds of the Company available for distribution to stockholders are insufficient to pay the full amount to which they are entitled, then the holders of shares of Series&#160;A Preferred Stock will share ratably in any distribution of the assets or funds available for distribution in proportion to the respective amounts which would otherwise be payable if it were paid in full.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-53</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Note_H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;">ORUKA THERAPEUTICS, INC.<br/>NOTES TO CONDENSED FINANCIAL STATEMENTS<br/>(UNAUDITED)</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Unless the holders of a majority in voting power of the then outstanding shares of Series&#160;A Preferred Stock elect otherwise, a Deemed Liquidation Event shall include a merger or consolidation (other than one in which stockholders of the Company own a majority by voting power of the outstanding shares of the surviving or acquiring corporation) or sale, lease, transfer, exclusive license or other disposition of all or substantially all of the Company&#8217;s assets.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Redemption</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Series&#160;A Preferred Stock does not have redemption rights, except for the contingent redemption upon the occurrence of a Deemed Liquidation Event.</p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-left:24pt;text-indent:-24pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">6.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Common Stock</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of March&#160;31, 2024, the Board of Directors authorized up to 65,000,000<span class="nobreak"> </span>shares of common stock at a $0.0001 par value. As of March&#160;31, 2024, 5,596,658<span class="nobreak"> </span>shares of common stock were issued and outstanding and 3,863,361<span class="nobreak"> </span>shares of RSAs were issued and outstanding. The voting, dividend and liquidation rights of the holders of the Company&#8217;s common stock and RSAs are subject to and qualified by the rights, powers and preferences of the holders of Series&#160;A Preferred Stock set forth above. Each share of common stock entitles the holder to one vote, together with the holders of Series&#160;A Preferred Stock, on all matters submitted to the stockholders for a vote. The holders of common stock are entitled to receive dividends, if any, as declared by the Company&#8217;s Board of Directors, subject to the preferential dividend rights of Series&#160;A Preferred Stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of March&#160;31, 2024, there are 20,698,669<span class="nobreak"> </span>shares of common stock reserved for issuance for the potential conversion of shares of Series&#160;A preferred stock into common stock, the exercise of outstanding stock options for common stock under the Company&#8217;s 2024 Equity Incentive Plan (the &#8220;2024 Plan&#8221;).</p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-left:24pt;text-indent:-24pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">7.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Stock-Based Compensation</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">2024 Equity Incentive Plan</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The 2024 Plan was adopted by the Company&#8217;s Board of Directors on February&#160;6, 2024. The 2024 Plan provides for the Company to grant stock options, restricted stock awards, restricted stock units, and other stock<span class="nobreak">-based</span> awards to employees, officers, directors, consultants, and advisors. The 2024 Plan is administered by the Board of Directors, or at the discretion of the Board of Directors, by a committee of the Board of Directors. The exercise prices, vesting and other restrictions are determined at the discretion of the Board of Directors, or its committee, if so delegated. Stock options granted under the 2024 Plan generally vest over four&#160;years, subject to the participant&#8217;s continued service, and expire after ten&#160;years, although stock options have been granted with vesting terms less than four&#160;years. Upon adoption, the 2024 Plan authorized 372,912<span class="nobreak"> </span>shares of common stock reserved for issuance under the plan. On March&#160;5, 2024, the 2024 Plan was amended to increase the number of shares of common stock reserved for issuance by 500,000<span class="nobreak"> </span>shares. As of March&#160;31, 2024, the total number of shares of common stock reserved for issuance under the 2024 Plan was 872,912, with 174,243<span class="nobreak"> </span>shares available for future grants.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Stock Option Valuation</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The fair value of each stock option grant is estimated on the grant date using the Black<span class="nobreak">-Scholes</span> option<span class="nobreak">-pricing</span> model. The Company is a private company and lacks company<span class="nobreak">-specific</span> historical and implied volatility information. Therefore, it estimates its expected stock volatility based on the historical volatility of a publicly traded set of peer companies and expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own traded stock price. For stock options with service<span class="nobreak">-based</span> vesting conditions, the expected term of the Company&#8217;s stock options has been determined utilizing the &#8220;simplified&#8221; method for awards that qualify as &#8220;plain<span class="nobreak">-vanilla</span>&#8221; stock options. The risk<span class="nobreak">-free</span> interest rate is determined by reference to the U.S.&#160;Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. The expected dividend yield is based on the fact that the Company has never paid cash dividends on common stock and does not expect to pay any cash dividends in the foreseeable future.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-54</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Note_H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;">ORUKA THERAPEUTICS, INC.<br/>NOTES TO CONDENSED FINANCIAL STATEMENTS<br/>(UNAUDITED)</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following table summarizes the weighted<span class="nobreak">-average</span> assumptions used in calculating the fair value of the awards from February&#160;6, 2024 (inception) to March&#160;31, 2024:</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-15" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 81.94%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 16.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Period from<br/>February&#160;6, 2024<br/>(Inception) to<br/>March&#160;31, 2024</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 81.94%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Expected volatility</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.06%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">103.0</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 81.94%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Expected term (in&#160;years) </p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.06%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">6.0</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 81.94%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Risk-free interest rate</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.06%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4.2</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 81.94%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Expected dividend yield</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.06%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>

		</table>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Stock Options</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following table summarizes the stock option activity for the period of February&#160;6, 2024 (inception) through March&#160;31, 2024:</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-19" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 43.16%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Number of<br/>Options</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Weighted<br/>Average<br/>Exercise<br/>Price</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term (Years)</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.89%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Aggregate<br/>Intrinsic<br/>Value</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 43.16%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Balance as of February&#160;6, 2024 (inception)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.18%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 43.16%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Granted</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">698,669</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2.90</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 43.16%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Exercised</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 43.16%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Forfeited</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 43.16%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Balance as of March&#160;31, 2024</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">698,669</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2.90</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">10.0</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.18%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 43.16%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Vested and expected to vest, March&#160;31, 2024</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">698,669</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2.90</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">10.0</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.18%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 43.16%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Exercisable, March&#160;31, 2024</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.18%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>

		</table>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The weighted average grant<span class="nobreak">-date</span> fair value of stock options granted from February&#160;6, 2024 (inception) to March&#160;31, 2024 was $2.37. As of March&#160;31, 2024, there was no aggregate intrinsic value for the outstanding options. The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the stock options and the fair value of the Company&#8217;s common stock for those stock options that had an exercise price lower than the fair value of the Company&#8217;s common stock.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Restricted Stock Awards</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In February 2024 and March&#160;2024, the Company issued 3,863,361<span class="nobreak"> </span>shares of RSAs to certain employees, directors, and consultants at a price of $0.0001 per share, the par value of the common stock. Such RSAs have service<span class="nobreak">-based</span> vesting conditions only and vest over a four<span class="nobreak">-year</span> period, during which time all unvested shares are subject to forfeiture by the Company in the event the holder&#8217;s service with the Company voluntarily or involuntarily terminates.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following table summarizes the RSAs activity for the period from February&#160;6, 2024 (inception) through March&#160;31, 2024:</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-15" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Number of<br/>RSAs</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Weighted<br/>Average<br/>Grant Date<br/>Fair Value</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Unvested balance as of February&#160;6, 2024 (inception)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Granted</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3,863,361</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Unvested balance as of March&#160;31, 2024</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3,863,361</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>

		</table>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-55</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Note_H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;">ORUKA THERAPEUTICS, INC.<br/>NOTES TO CONDENSED FINANCIAL STATEMENTS<br/>(UNAUDITED)</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Paruka Warrant Obligation</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In March&#160;2024, the Company entered into the Option Agreements with Paragon and Paruka. Under the terms of the Option Agreements, Paruka will be entitled to grants of warrants to purchase a number of shares equal to 1.00% of then outstanding shares of the Company&#8217;s stock, on a fully diluted basis, on December&#160;31, 2024 and December&#160;31, 2025, at the fair market value determined by the Board of Directors of the Company (the &#8220;Paruka Warrant Obligation&#8221;). The grant dates for the issuance of warrants are expected to be December&#160;31, 2024 and December&#160;31, 2025 as all terms of the award, including number of shares and exercise price, will be known by all parties. The service inception period for the grant precedes the grant date, with the full award being vested as of the grant date with no post<span class="nobreak">-grant</span> date service requirement. As of March&#160;31, 2024, the pro<span class="nobreak">-rated</span> estimated fair value of warrants to be granted on December&#160;31, 2024 was $0.7&#160;million. For the period February&#160;6, 2024 (inception) to March&#160;31, 2024, $0.1&#160;million was recognized as stock<span class="nobreak">-based</span> compensation expense related to the Paruka Warrant Obligation. The warrants expected to be granted to Paruka are liability<span class="nobreak">-classified</span> and after the initial recognition, the liability is adjusted to fair value at the end of each reporting period, with changes in fair value recorded in the statement of operations and comprehensive loss.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Stock-Based Compensation Expense</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following table summarizes the classification of the Company&#8217;s stock<span class="nobreak">-based</span> compensation expense in the condensed statement of operations and comprehensive loss (in thousands):</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-15" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 80.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 17.74%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Period from<br/>February&#160;6,&#160;2024<br/>(Inception) to<br/>March&#160;31, 2024</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 80.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Research and development</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 16.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">70</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 80.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">General and administrative</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 16.03%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">15</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 80.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 16.03%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">85</p>
					</td>
				</tr>

		</table>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of March&#160;31, 2024, total unrecognized compensation cost related to the unvested stock options was $1.6&#160;million, which is expected to be recognized over a weighted average period of approximately 3.40&#160;years. As of March&#160;31, 2024, total unrecognized compensation cost related to the unvested RSAs was less than $0.1&#160;million, which is expected to be recognized over a weighted average period of 3.92&#160;years. As of March&#160;31, 2024, the unrecognized compensation cost related to the Paruka Warrant Obligation was $0.6&#160;million, which is expected to be recognized over a weighted average period of 0.8&#160;years.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following table summarizes the award types of the Company&#8217;s stock<span class="nobreak">-based</span> compensation expense in the condensed statement of operations and comprehensive loss (in thousands):</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-15" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 80.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 17.74%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Period from<br/>February&#160;6, 2024<br/>(Inception) to<br/>March&#160;31, 2024</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 80.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Paruka warrant obligation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 16.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">68</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 80.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Stock options</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 16.03%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">17</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 80.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 16.03%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">85</p>
					</td>
				</tr>

		</table>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-left:24pt;text-indent:-24pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">8.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Income Taxes</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">No provision for income taxes was recorded for the period of February&#160;6, 2024 (inception) through March&#160;31, 2024. Deferred tax assets generated from the Company&#8217;s net operating losses have been fully reserved, as the Company believes it is not more likely than not that the benefit will be realized due to the Company&#8217;s cumulative losses generated to date.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-56</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Note_H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;">ORUKA THERAPEUTICS, INC.<br/>NOTES TO CONDENSED FINANCIAL STATEMENTS<br/>(UNAUDITED)</p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-left:24pt;text-indent:-24pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">9.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Paragon Option Agreements</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In March&#160;2024, the Company entered into the Option Agreements with Paragon and Paruka. Under the terms of the Option Agreements, Paragon identifies, evaluates and develops antibodies directed against certain mutually agreed therapeutic targets of interest to the Company. The Option Agreements includes two selected targets, IL<span class="nobreak">-23</span> (ORKA<span class="nobreak">-001</span>) and IL<span class="nobreak">-17</span> A/F (ORKA<span class="nobreak">-002</span>). Under the Option Agreements, the Company has the exclusive options to, on a research program<span class="nobreak">-by-research</span> program basis, be granted an exclusive, worldwide license to all of Paragon&#8217;s right, title and interest in and to the intellectual property resulting from the applicable research program to develop, manufacture and commercialize the antibodies and products directed to the selected targets (each, an &#8220;Option&#8221;), with the exception of pursuing ORKA<span class="nobreak">-001</span> for the treatment of inflammatory bowel disease. If the Company exercises its options, it will be required to make non<span class="nobreak">-refundable</span> milestone payments to Paragon of up to $12.0&#160;million under each respective agreement upon the achievement of certain clinical development milestones, up to $10.0&#160;million under each respective agreement upon the achievement of certain regulatory milestones, as well as tiered royalty payments in the low<span class="nobreak">-to-mid</span> single<span class="nobreak">-digits</span> beginning on the first commercial sale. From time to time, the Company can choose to add additional targets to the collaboration by mutual agreement with Paragon.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Pursuant to the terms of the Option Agreements, the parties initiated certain research programs that generally focus on a particular target (each, a &#8220;Research Program&#8221;). Each Research Program is aimed at discovering, generating, identifying and/or characterizing antibodies directed to the respective target. For each Research Program, the parties will establish a research plan that sets forth the activities that will be conducted, and the associated research budget (each, a &#8220;Research Plan&#8221;). The Company and Paragon will agree on initial Research Plans that outline the services that will be performed commencing at the inception of the arrangement related to ORKA<span class="nobreak">-001</span> and ORKA<span class="nobreak">-002</span>. The Company&#8217;s exclusive Option with respect to each Research Program is exercisable at its sole discretion at any time during the period beginning on the initiation of activities under the associated Research Program and ending a specified number of&#160;days following (i) with respect to any Research Program other than ORKA<span class="nobreak">-001</span>, the delivery of the data package from Paragon related to the results of the Research Plan activities, or (ii) with respect to ORKA<span class="nobreak">-001</span>, the completion of the IL<span class="nobreak">-23</span> antibody selection process described in the agreement (the &#8220;Option Period&#8221;). There is no payment due upon exercise of an Option pursuant to the Option Agreements.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Unless terminated earlier, the Option Agreements shall continue in force on a Research Program<span class="nobreak">-by-Research</span> Program basis until the earlier of: (i)&#160;the end of the Option Period for such Research Program, as applicable, if such Option is not exercised by the Company; (ii)&#160;the expiration of the 30<span class="nobreak">-day</span> period after Oruka exercises its Option with respect to such Research Program, subject to mutually agreed extension, during the Option Period and the parties are unable to finalize and execute a license agreement, and (iii) the expiration of the applicable research term (the &#8220;Term&#8221;). Upon the expiration of the Term for all then<span class="nobreak">-existing</span> Research Programs, under the Option Agreements, the Option Agreements will automatically expire in its entirety. The Company may terminate the Option Agreements or any Research Program at any time for any or no reason upon 30&#160;days&#8217; prior written notice to Paragon, provided that the Company must pay certain unpaid fees due to Paragon upon such termination, as well as any non<span class="nobreak">-cancellable</span> obligations reasonably incurred by Paragon in connection with its activities under any terminated Research Program. Each party has the right to terminate the Option Agreements or any Research Program upon (i)&#160;30&#160;days&#8217; prior written notice of the other party&#8217;s material breach that remains uncured for the 30<span class="nobreak">-day</span> period and (ii)&#160;the other party&#8217;s bankruptcy.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Pursuant to the Option Agreements, on a research program<span class="nobreak">-by-research</span> program basis following the finalization of the research plan for each respective research program, the Company was required to pay Paragon a one<span class="nobreak">-time</span>, nonrefundable research initiation fee of $0.8&#160;million. This amount was recognized as a research and development expense during the period from February&#160;6 (inception) to March&#160;31, 2024 and accounts payable as of March&#160;31, 2024, and paid to Paragon in April&#160;2024. The Company is also responsible for 50% of the development costs incurred prior to March&#160;31, 2024, provided that the Company receives rights to at least one selected IL<span class="nobreak">-23</span> antibody. Oruka&#8217;s share of development costs incurred prior to March&#160;31, 2024 is $5.9&#160;million. As of the date these condensed financial statements are available to be issued, the Company has not received rights to a selected IL<span class="nobreak">-23</span> antibody and has not paid or accrued the $5.9&#160;million of development costs incurred prior to March&#160;31, 2024. The Company will be responsible for 50% of the ORKA<span class="nobreak">-001</span> development costs incurred from and after March&#160;31, 2024, through the completion of the IL<span class="nobreak">-23</span> selection process.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-57</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Note_H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;">ORUKA THERAPEUTICS, INC.<br/>NOTES TO CONDENSED FINANCIAL STATEMENTS<br/>(UNAUDITED)</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company was also required to reimburse Paragon $3.3&#160;million for development costs related to ORKA<span class="nobreak">-002</span> incurred by Paragon through December&#160;31, 2023 and certain other development costs incurred by Paragon between January&#160;1, 2024 and March&#160;6, 2024. This amount was recognized as a research and development expense during the period from February&#160;6 (inception) to March&#160;31, 2024, and accounts payable as of March&#160;31, 2024. The Company paid $3.3&#160;million to Paragon in April&#160;2024. The Company is also responsible for the development costs incurred by Paragon from January&#160;1, 2024 to March&#160;31, 2024 of $0.9&#160;million, which was recognized as a research and development expense in the period from February&#160;6 (inception) to March&#160;31, 2024. The Company will be required to pay Paragon $0.8&#160;million for the research initiation fee related to ORKA<span class="nobreak">-002</span> within 30&#160;days following finalization of the ORKA<span class="nobreak">-002</span> research plan as well as for subsequent development costs related to ORKA<span class="nobreak">-002</span>. The Company will be responsible for ORKA<span class="nobreak">-002</span> development costs incurred from and after March&#160;31, 2024, through the completion of the IL<span class="nobreak">-17</span> selection process.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Furthermore, the Paragon Agreement provides for an annual equity grant of warrants to Paruka to purchase 1.00% of the then outstanding shares of the Company&#8217;s common stock, on a fully diluted basis, on December&#160;31, 2024 and December&#160;31, 2025, during the term of the Paragon Agreement, at the fair market value determined by the Board of Directors of the Company. The warrants are liability<span class="nobreak">-classified</span> and after the initial recognition, the liability is adjusted to fair value at the end of each reporting period, with changes in fair value recorded in the statement of operations and comprehensive loss (see Note&#160;7).</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company expenses the service fees as the associated costs are incurred when the underlying services are rendered. Such amounts are classified within research and development expenses in the accompanying statement of operations and comprehensive loss.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company concluded that the rights obtained under the Option Agreements represent an asset acquisition whereby the underlying assets comprise in<span class="nobreak">-process</span> research and development assets with no alternative future use. The Option Agreements did not qualify as a business combination because substantially all of the fair value of the assets acquired was concentrated in the exclusive license options, which represent a group of similar identifiable assets. The research initiation fee represents a one<span class="nobreak">-time</span> cost on a research program<span class="nobreak">-by</span> research program basis for accessing research services or resources with benefits that are expected to be consumed in the near term, therefore the amounts paid are expensed as part of research and development costs immediately. Amounts paid as reimbursements of on<span class="nobreak">-going</span> development cost, monthly development cost fee and additional development expenses incurred by Paragon due to work completed for selected targets prior to the effective date of the Option Agreement that associated with services being rendered under the related Research Programs is recognized as research and development expense when incurred.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">For the period from February&#160;6, 2024 (inception) to March&#160;31, 2024 the Company recognized $5.0&#160;million of expenses in connection with services provided by Paragon under the Option Agreements, including nonrefundable research and development expense fees following the finalization of a Research Plan.</p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-left:24pt;text-indent:-24pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">10.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Commitments and Contingencies</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">401(k)&#160;Plan</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company maintains a defined<span class="nobreak">-contribution</span> plan under Section&#160;401(k)&#160;of the Internal Revenue Code of 1986 (the &#8220;401(k)&#160;Plan&#8221;). The 401(k)&#160;Plan covers all employees who meet defined minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pre<span class="nobreak">-tax</span> basis. Matching contributions to the 401(k)&#160;Plan may be made at the discretion of management. For the period from February&#160;6, 2024 (inception) to March&#160;31, 2024, the Company has not recorded any expense related to 401(k)&#160;match contributions.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Indemnification Agreements</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-58</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Note_H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;">ORUKA THERAPEUTICS, INC.<br/>NOTES TO CONDENSED FINANCIAL STATEMENTS<br/>(UNAUDITED)</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">third parties. In addition, the Company has entered into indemnification agreements with each of its directors and executive officers that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or executive officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. To date, the Company has not incurred any material costs as a result of such indemnifications. The Company is not aware of any indemnification arrangements that could have a material effect on its financial position, results of operations or cash flows, and it has not accrued any liabilities related to such obligations in its condensed financial statements as of March&#160;31, 2024.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Legal Proceedings</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">From time to time, the Company may become involved in legal proceedings or other litigation relating to claims arising in the ordinary course of business. The Company accrues a liability for such matters when it is probable that future expenditures will be made and that such expenditures can be reasonably estimated. Significant judgment is required to determine both probability and estimated exposure amount. Legal fees and other costs associated with such proceedings are expensed as incurred. As of March&#160;31, 2024, the Company was not a party to any material legal proceedings or claims.</p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-left:24pt;text-indent:-24pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">11.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Net Loss per Share</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Basic and diluted net loss per share attributable to common stockholders was calculated as follows (in thousands, except share and per share amounts):</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-15" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 80.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 17.74%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Period from<br/>February&#160;6, 2024<br/>(Inception) to<br/>March&#160;31, 2024</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 80.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Numerator:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 80.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net loss</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.32%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(7,077</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 80.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Denominator:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 80.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Weighted-average common shares outstanding, basic and diluted</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.32%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5,596,658</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 80.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net loss attributable to common stockholders, basic and diluted</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.32%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(1.26</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</p>
					</td>
				</tr>

		</table>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">For the computation of basic net loss per share attributable to common stockholders, the amount of weighted<span class="nobreak">-average</span> common shares outstanding excludes all shares of unvested restricted common stock as such shares are not considered outstanding for accounting purposes until vested.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company&#8217;s potential dilutive securities have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted<span class="nobreak">-average</span> number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. The Company excluded potential common shares from the computation of diluted net loss per share attributable to common stockholders for the period presented because including them would have had an anti<span class="nobreak">-dilutive</span> effect:</p>
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-15" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 80.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 17.74%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Period from<br/>February&#160;6, 2024<br/>(Inception) to<br/>March&#160;31, 2024</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 80.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Convertible preferred stock (as converted to common stock)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 17.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">20,000,000</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 80.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Unvested restricted stock awards</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 17.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3,863,361</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 80.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Stock options to purchase common stock</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 17.74%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">698,669</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 80.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 17.74%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">24,562,030</p>
					</td>
				</tr>

		</table>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-59</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Note_H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;">ORUKA THERAPEUTICS, INC.<br/>NOTES TO CONDENSED FINANCIAL STATEMENTS<br/>(UNAUDITED)</p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-left:24pt;text-indent:-24pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">12.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Related Party Transactions</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Paragon and Paruka each currently beneficially own more than 5% of the Company&#8217;s capital stock through its common stock holdings. For the period from February&#160;6, 2024 (inception) to March&#160;31, 2024 the Company recognized $5.0&#160;million of expenses, in connection with services provided by Paragon and Paruka under the Option Agreements, including nonrefundable research and development expense fees following the finalization of a Research Plan on its condensed statement of operations and comprehensive loss. As of March&#160;31, 2024, the Company had $5.8&#160;million in amounts due to related parties pertaining to services provided by Paragon and Paruka under the Option Agreements and reimbursements of recruiting and start<span class="nobreak">-up</span> fees on its condensed balance sheet. In addition, under the terms of the Option Agreements, Paruka will be entitled to grants of warrants to purchase a number of shares equal to 1.00% of outstanding shares of the Company&#8217;s common stock, on a fully diluted basis, as of the date of the grants (see Note&#160;7). If the Company exercises its options, it will be required to make non<span class="nobreak">-refundable</span> milestone payments to Paragon of up to $12.0&#160;million under each respective agreement upon the achievement of certain clinical development milestones, up to $10.0&#160;million under each respective agreement upon the achievement of certain regulatory milestones, as well as tiered royalty payments in the low<span class="nobreak">-to-mid</span> single<span class="nobreak">-digits</span> beginning on the first commercial sale.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Fairmount Funds Management LLC (&#8220;Fairmount Funds Management&#8221;) beneficially owns more than 5% of the Company&#8217;s capital, currently has one representative appointed to the Company&#8217;s Board of Directors, and beneficially owns more than 5% of Paragon. In March&#160;2024, the Company issued and sold an aggregate of 20,000,000<span class="nobreak"> </span>shares of Series&#160;A Preferred Stock to Fairmount, an affiliated fund of Fairmount Funds Management, at a purchase price of $0.15 per share, for gross proceeds of $3.0&#160;million (see Note&#160;4). In March&#160;2024, Fairmount entered into the Purchase Agreement with the Company and holds a convertible note with an initial principal amount of $25.0&#160;million (see Note&#160;4). As of March&#160;31, 2024, the Company had $0.2&#160;million in amounts due to related parties pertaining to accrued interest related to the Company&#8217;s outstanding borrowings of $25.0&#160;million under the Purchase Agreement with Fairmount.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following is a summary of related party accounts payable and other current liabilities (in thousands):</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">March&#160;31,<br/>2024</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Paragon reimbursable Option Agreement fees</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4,983</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Paragon reimbursable recruiting and start-up fees</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">848</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Paruka Warrant Obligation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">68</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5,899</p>
					</td>
				</tr>

		</table>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;orphans:99;widows:1;margin-top:8pt;">The following is a summary of noncurrent liability, related party (in thousands):</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">March&#160;31,<br/>2024</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accrued interest payable</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">214</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Note payable</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">24,980</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">25,194</p>
					</td>
				</tr>

		</table>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-left:24pt;text-indent:-24pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">13.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Subsequent Events</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company has evaluated events and transactions occurring subsequent to March<span class="nobreak"> </span>31, 2024 through May<span class="nobreak"> </span>13, 2024, the date at which the condensed financial statements were available to be issued. In connection with the reissuance of the condensed financial statements, the Company has evaluated subsequent events through July<span class="nobreak"> </span>9, 2024, the date these condensed financial statements were available to be reissued.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oak Grove Lease</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On April&#160;12, 2024, the Company entered into a lease agreement with Oak Grove LP (&#8220;Oak Grove Lease&#8221;) for office space located in Menlo Park, California. The lease commencement date is June&#160;15, 2024 with an initial term of 39.5&#160;months. The total lease payment is expected to be $1.4&#160;million over the initial lease term.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-60</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Note_H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;">ORUKA THERAPEUTICS, INC.<br/>NOTES TO CONDENSED FINANCIAL STATEMENTS<br/>(UNAUDITED)</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Amended 2024 Stock Plan</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On May<span class="nobreak"> </span>7, 2024, the Company&#8217;s Board of Directors approved an amendment to the 2024 Plan to increase the number of shares of common stock available for issuance under the 2024 Plan from 872,912 to 2,063,669. On May&#160;7, 2024, the Company granted options for the purchase of an aggregate 1,365,000 stock options, at an exercise price of $3.89 per share.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In June 2024, pursuant to the Option Agreements with Paragon, the Company completed the selection process of its development candidate for IL<span class="nobreak">-23</span> antibody for ORKA<span class="nobreak">-001</span> program. The Company is responsible for 50% of the development costs incurred through the completion of the IL<span class="nobreak">-23</span> selection process, provided that the Company receives rights to at least one selected IL<span class="nobreak">-23</span> antibody. Oruka&#8217;s share of development costs incurred prior to March<span class="nobreak"> </span>31, 2024 is $5.9<span class="nobreak"> </span>million, which was recorded as a research and development expense during the quarter ended June<span class="nobreak"> </span>30, 2024 and accounts payable as of June<span class="nobreak"> </span>30, 2024. Amounts related to development cost incurred subsequent to March<span class="nobreak"> </span>31, 2024, have not been determined as of the reissuance date of these condensed financial statements.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On July<span class="nobreak"> </span>3, 2024, the Private Placement agreement was amended and restated, among other things, for warrants to be issued to certain of Oruka&#8217;s employees and service providers. No such warrants have been issued as of the reissuance date of these condensed financial statements.</p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-61</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T100"></a><p class="ParaOverride-1" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-align:right;widows:3;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Annex A</span></p>
		<p class="ParaOverride-2" style="margin:0;padding:0;border-width:0;margin-top:210pt;orphans:3;text-align:center;widows:3;margin-top:210pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">AGREEMENT AND PLAN OF MERGER AND REORGANIZATION</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-align:center;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">among:</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-align:center;widows:3;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">ARCA BIOPHARMA, Inc.</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">;</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-align:center;widows:3;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">ATLAS MERGER SUB CORP.</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">;</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-align:center;widows:3;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">Atlas Merger Sub II, LLC</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">; and</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-align:center;widows:3;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">ORUKA THERAPEUTICS, Inc.</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-align:center;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Dated as of April 3, 2024</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">&#160;</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>


	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:8pt;margin-top:8pt;">Table of Contents</p>
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">Annex&#160;A<br/>Page Nos.</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Section&#160;1. Definitions and Interpretative Provisions</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="Bold" style="font-style:normal;font-weight:bold;">A-2</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">1.1</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Definitions</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-2</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">1.2</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other Definitional and Interpretative Provisions</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-14</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Section&#160;2. Description of Transaction</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="Bold" style="font-style:normal;font-weight:bold;">A-15</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2.1</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">The Merger</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-15</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2.2</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Effects of the Merger</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-15</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2.3</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Closing; First Effective Time; Second Effective Time</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-15</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2.4</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Organizational Documents; Directors and Officers</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-15</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2.5</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Conversion of Company, First Merger Sub and Second Merger Sub Equity Securities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-16</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2.6</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Closing of the Company&#8217;s Transfer Books</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-17</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2.7</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Surrender of Company Capital Stock</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-18</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2.8</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Calculation of Net Cash and Company Valuation.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-19</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2.9</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Further Action</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-20</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2.10</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Intended Tax Treatment</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-20</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2.11</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Withholding</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-20</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2.12</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Appraisal Rights</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-21</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Section&#160;3. Representations and Warranties of the Company</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="Bold" style="font-style:normal;font-weight:bold;">A-21</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">3.1</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Due Organization; Subsidiaries</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-21</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">3.2</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Organizational Documents</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-22</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">3.3</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Authority; Binding Nature of Agreement</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-22</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">3.4</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Vote Required</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-22</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">3.5</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Non-Contravention; Consents</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-22</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">3.6</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Capitalization.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-23</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">3.7</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Financial Statements</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-24</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">3.8</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Absence of Changes</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-24</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">3.9</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Absence of Undisclosed Liabilities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-24</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">3.10</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Title to Assets</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-25</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">3.11</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Real Property; Leasehold</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-25</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">3.12</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Intellectual Property</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-25</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">3.13</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Agreements, Contracts and Commitments</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-27</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">3.14</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Compliance; Permits; Restrictions</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-29</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">3.15</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Legal Proceedings; Orders</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-30</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">3.16</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Tax Matters</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-31</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">3.17</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Employee and Labor Matters; Benefit Plans.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-32</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">3.18</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Environmental Matters</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-34</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">3.19</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Insurance</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-34</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">3.20</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">No Financial Advisors</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-34</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">3.21</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Transactions with Affiliates</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-34</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">3.22</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Privacy and Data Security</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-34</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">3.23</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Ownership of Parent Capital Stock</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-35</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">3.24</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">No Other Representations or Warranties</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-35</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Section&#160;4. Representations and Warranties of Parent, First Merger and Second Merger Sub</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="Bold" style="font-style:normal;font-weight:bold;">A-35</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">4.1</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Due Organization; Subsidiaries</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-35</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">4.2</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Organizational Documents</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-36</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">4.3</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Authority; Binding Nature of Agreement</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-36</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">4.4</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Vote Required</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-36</p>
					</td>
				</tr>

		</table>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-i</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">Annex&#160;A<br/>Page Nos.</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">4.5</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Non-Contravention; Consents</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-37</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">4.6</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Capitalization</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-37</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">4.7</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">SEC Filings; Financial Statements</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-38</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">4.8</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Absence of Changes</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-40</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">4.9</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Absence of Undisclosed Liabilities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-40</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">4.10</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Title to Assets</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-40</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">4.11</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Real Property; Leasehold</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-40</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">4.12</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Intellectual Property</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-40</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">4.13</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Agreements, Contracts and Commitments</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-42</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">4.14</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Compliance; Permits; Restrictions</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-44</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">4.15</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Legal Proceedings; Orders</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-46</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">4.16</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Tax Matters</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-46</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">4.17</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Employee and Labor Matters; Benefit Plans</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-47</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">4.18</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Environmental Matters</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-49</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">4.19</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Insurance</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-49</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">4.20</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Transactions with Affiliates</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-49</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">4.21</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">No Financial Advisors</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-49</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">4.22</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Valid Issuance</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-49</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">4.23</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Privacy and Data Security</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-49</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">4.24</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">No Other Representations or Warranties</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-50</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Section&#160;5. Certain Covenants of the Parties</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="Bold" style="font-style:normal;font-weight:bold;">A-50</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">5.1</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Operation of Parent&#8217;s Business</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-50</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">5.2</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Operation of the Company&#8217;s Business.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-52</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">5.3</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Access and Investigation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-53</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">5.4</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">No Solicitation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-54</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">5.5</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Notification of Certain Matters</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-55</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Section&#160;6. Additional Agreements of the Parties</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="Bold" style="font-style:normal;font-weight:bold;">A-55</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">6.1</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Registration Statement, Proxy Statement</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-55</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">6.2</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Company Stockholder Written Consent</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-57</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">6.3</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Parent Stockholder Meeting</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-58</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">6.4</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Efforts; Regulatory Approvals.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-60</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">6.5</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Company Options; Company Warrants</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-60</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">6.6</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Employee Benefits</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-61</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">6.7</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Indemnification of Officers and Directors</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-62</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">6.8</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Disclosure</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-63</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">6.9</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Listing</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-63</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">6.10</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Tax Matters</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-64</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">6.11</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Legends</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-64</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">6.12</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Officers and Directors</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-64</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">6.13</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Termination of Certain Agreements and Rights</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-65</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">6.14</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Section&#160;16 Matters</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-65</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">6.15</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Allocation Information</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-65</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">6.16</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Parent SEC Documents</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-65</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">6.17</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Wind-Down Activities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-65</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">6.18</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Obligations of Merger Subs</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-65</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">6.19</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Pre-Closing Financing Restructuring</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-65</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">6.20</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Parent Pre-Closing Dividend</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-66</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">6.21</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Parent Re-Domestication</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-66</p>
					</td>
				</tr>

		</table>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-ii</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">Annex&#160;A<br/>Page Nos.</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Section&#160;7. Conditions Precedent to Obligations of Each Party</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="Bold" style="font-style:normal;font-weight:bold;">A-66</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">7.1</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Effectiveness of Registration Statement</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-66</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">7.2</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Regulatory Approvals</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-66</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">7.3</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">No Restraints</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-66</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">7.4</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Stockholder Approval</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-66</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">7.5</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Listing</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-66</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">7.6</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Lock-Up Agreements</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-66</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">7.7</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Parent Charter Amendment</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-66</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">7.8</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Certificate of Designation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-66</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Section&#160;8. Additional Conditions Precedent to Obligations of Parent and Merger Subs</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="Bold" style="font-style:normal;font-weight:bold;">A-66</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">8.1</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accuracy of Representations</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-66</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">8.2</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Performance of Covenants</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-67</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">8.3</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Documents</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-67</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">8.4</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">No Company Material Adverse Effect</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-67</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">8.5</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Company Stockholder Written Consent</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-67</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">8.6</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Company Pre-Closing Financing</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-67</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">8.7</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Parent Pre-Closing Dividend</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-67</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Section&#160;9. Additional Conditions Precedent to Obligation of the Company</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="Bold" style="font-style:normal;font-weight:bold;">A-67</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">9.1</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accuracy of Representations</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-67</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">9.2</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Performance of Covenants</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-68</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">9.3</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Documents</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-68</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">9.4</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">No Parent Material Adverse Effect</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-68</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Section&#160;10. Termination</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="Bold" style="font-style:normal;font-weight:bold;">A-68</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">10.1</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Termination</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-68</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">10.2</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Effect of Termination</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-70</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">10.3</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Expenses; Termination Fees</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-70</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Section&#160;11. Miscellaneous Provisions</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="Bold" style="font-style:normal;font-weight:bold;">A-71</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">11.1</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Non-Survival of Representations and Warranties</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-71</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">11.2</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Amendment</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-71</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">11.3</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Waiver</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-71</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">11.4</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Entire Agreement; Counterparts; Exchanges by Electronic Transmission or Facsimile</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-71</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">11.5</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Applicable Law; Jurisdiction</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-72</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">11.6</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Assignability</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-72</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">11.7</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Notices</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-72</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">11.8</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Cooperation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-73</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">11.9</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Severability</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-73</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">11.10</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other Remedies; Specific Performance</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-73</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">11.11</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">No Third-Party Beneficiaries</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-73</p>
					</td>
				</tr>

		</table>
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Exhibits:</span></p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.54%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Exhibit&#160;A-1</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 87.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Form of Parent Stockholder Support Agreement</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.54%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Exhibit&#160;A-2</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 87.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Form of Company Stockholder Support Agreement</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.54%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Exhibit&#160;B</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 87.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Form of Lock-Up Agreement</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.54%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Exhibit&#160;C</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 87.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Form of Subscription Agreement</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-11" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 11.54%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Exhibit&#160;D-1</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 87.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">First Certificate of Merger, including certificate of incorporation of the First Step Surviving Corporation attached as Exhibit&#160;A thereto, incorporated by reference into this Agreement</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.54%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Exhibit&#160;D-2</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 87.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Second Certificate of Merger, incorporated by reference into this Agreement</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.54%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Exhibit&#160;E</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 87.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Form of Certificate of Designation</p>
					</td>
				</tr>

		</table>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-iii</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-align:center;widows:3;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">AGREEMENT AND PLAN OF MERGER AND REORGANIZATION</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:small-caps;font-weight:bold;">This Agreement and Plan of Merger and Reorganization </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(this &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Agreement</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) is made and entered into as of April 3, 2024, by and among </span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:small-caps;font-weight:bold;">ARCA biopharma, Inc.</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, a Delaware corporation (&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), </span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:small-caps;font-weight:bold;">Atlas Merger Sub Corp.</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, a Delaware corporation and wholly owned subsidiary of Parent (&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">First Merger Sub</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), </span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:small-caps;font-weight:bold;">Atlas Merger Sub II, LLC</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, a Delaware limited liability company and wholly owned subsidiary of Parent (&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Second Merger Sub</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; and, together with First Merger Sub, &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Merger Subs</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), and </span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:small-caps;font-weight:bold;">Oruka Therapeutics, Inc.</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, a Delaware corporation (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;). Certain capitalized terms used in this Agreement are defined </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;1</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-align:center;widows:3;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:small-caps;font-weight:bold;">Recitals</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">A.&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Parent and the Company intend to effect a merger of First Merger Sub with and into the Company (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">First Merger</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) in accordance with this Agreement and the DGCL.  Upon consummation of the First Merger, First Merger Sub will cease to exist and the Company will become a wholly owned subsidiary of Parent.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">B.&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Immediately following the First Merger and as part of the same overall transaction as the First Merger, the Company will merge with and into Second Merger Sub (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Second Merger</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; and, together with the First Merger, the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Merger</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), with Second Merger Sub being the surviving entity of the Second Merger.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">C.&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Parties intend that, (i) the First Merger and the Second Merger, taken together, will constitute an integrated transaction described in Rev. Rul. 2001-46, 2001-2 C.B. 321 that qualifies as a &#8220;reorganization&#8221; within the meaning of Section&#160;368(a) of the Code, and (ii) this Agreement will constitute, and is hereby adopted as, a plan of reorganization within the meaning of Treasury Regulations Sections&#160;1.368-2(g) and 1.368-3(a).</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">D.&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Transaction Committee of the Parent Board has (i) determined that the Contemplated Transactions are fair to, advisable and in the best interests of Parent and its stockholders and (ii) recommended that the Parent Board approve and adopt this Agreement.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">E.&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Parent Board has (i) determined that the Contemplated Transactions are fair to, advisable and in the best interests of Parent and its stockholders, (ii) approved and declared advisable this Agreement and the Contemplated Transactions, including the issuance of shares of Parent Capital Stock to the stockholders of the Company pursuant to the terms of this Agreement and the constructive issuance by the Company of shares of Company Common Stock to stockholders of Parent (as reflected in Rule&#160;145(a) of the Securities Act) (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Constructive Issuance</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) and (iii) determined to recommend, upon the terms and subject to the conditions set forth in this Agreement, that the stockholders of Parent vote to approve this Agreement and thereby approve the Contemplated Transactions, including the issuance of shares of Parent Capital Stock to the stockholders of the Company pursuant to the terms of this Agreement, the Constructive Issuance, and, if deemed necessary by the Parties, an amendment to Parent&#8217;s certificate of incorporation to effect the Nasdaq Reverse Split.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">F.&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The First Merger Sub Board has (i) determined that the Contemplated Transactions are fair to, advisable, and in the best interests of First Merger Sub and its sole stockholder, (ii) approved and declared advisable this Agreement and the Contemplated Transactions and (iii) determined to recommend, upon the terms and subject to the conditions set forth in this Agreement, that the stockholder of First Merger Sub votes to adopt this Agreement and thereby approve the Contemplated Transactions.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">G.&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The sole member of the Second Merger Sub has (i) determined that the Contemplated Transactions are fair to, advisable, and in the best interests of Second Merger Sub and its sole member, (ii) approved and declared advisable this Agreement and the Contemplated Transactions and (iii) determined to recommend, upon the terms and subject to the conditions set forth in this Agreement, that the sole member of Second Merger Sub votes to adopt this Agreement and thereby approve the Contemplated Transactions.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">H.&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Company Board has (i) determined that the Contemplated Transactions are fair to, advisable and in the best interests of the Company and its stockholders, (ii) approved and declared advisable this Agreement and the Contemplated Transactions and (iii) determined to recommend, upon the terms and subject to the conditions set forth in this Agreement, that the stockholders of the Company vote to adopt this Agreement and thereby approve the Contemplated Transactions.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-1</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">I.<span style="width: 10px;display: inline-block;">&#160;&#160;&#160;</span><span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Concurrently with the execution and delivery of this Agreement and as a condition and inducement to the Company&#8217;s willingness to enter into this Agreement, each of the officers, directors and stockholders set forth on </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;A</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Parent Disclosure Letter (solely in their capacity as stockholders of Parent) are executing support agreements in favor of the Company in substantially the form attached hereto as </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Exhibit&#160;A-1</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> </span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Stockholder Support Agreement</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), pursuant to which such Persons have, subject to the terms and conditions set forth therein, agreed to vote all of their shares of capital stock of Parent in favor of the approval of this Agreement and thereby approve the Contemplated Transactions, and, if deemed necessary by Parent, an amendment to Parent&#8217;s certificate of incorporation to effect the Nasdaq Reverse Split, and against any competing proposals.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">J.<span style="width: 10px;display: inline-block;">&#160;&#160;&#160;</span><span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Concurrently with the execution and delivery of this Agreement and as a condition and inducement to Parent&#8217;s willingness to enter into this Agreement, each of the officers, directors and stockholders of the Company listed on </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;A</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Company Disclosure Letter (solely in their capacity as stockholders of the Company) are executing support agreements in favor of Parent in substantially the form attached hereto as </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Exhibit&#160;A-2</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Stockholder Support Agreement</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), pursuant to which such Persons have, subject to the terms and conditions set forth therein, agreed to vote all of their shares of Company Capital Stock in favor of the adoption of this Agreement and thereby approve the Contemplated Transactions and against any competing proposals.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">K.&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Concurrently with the execution and delivery of this Agreement and as a condition and inducement to Parent&#8217;s and the Company&#8217;s willingness to enter into this Agreement, all of the stockholders of the Company or Parent listed on </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;B</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Company Disclosure Letter are executing lock-up agreements in substantially the form attached hereto as </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Exhibit&#160;B</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Lock-Up Agreement</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">,&#8221; and collectively, the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Lock-Up Agreements</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;).</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">L.&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>It is expected that within two (2) Business Days after the Registration Statement is declared effective under the Securities Act, the holders of shares of Company Capital Stock sufficient to adopt and approve this Agreement and the Merger as required under the DGCL and the Company&#8217;s certificate of incorporation and bylaws will execute and deliver an action by written consent adopting this Agreement, in form and substance reasonably acceptable to Parent, in order to obtain the Required Company Stockholder Vote.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">M.<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Concurrently with the execution and delivery of this Agreement, certain investors have executed a Subscription Agreement in the form attached hereto as </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Exhibit&#160;C</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> among the Company and the Persons named therein (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Subscription Agreement</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), pursuant to which such Persons will have agreed to purchase in the amounts set forth therein (including by contribution of Company Notes) (i) shares of Company Common Stock and (ii) pre-funded Company Warrants, in each case, immediately prior to the First Effective Time (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Pre-Closing Financing</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;).</span></p>
		<p class="ParaOverride-11" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-align:center;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:small-caps;font-weight:bold;">Agreement</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">The Parties, intending to be legally bound, agree as follows:</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;1. </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Definitions and Interpretative Provisions</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">1.1<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Definitions</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>For purposes of this Agreement (including this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;1</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">):</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Acceptable Confidentiality Agreement</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means a confidentiality agreement containing terms not materially less restrictive in the aggregate to the counterparty thereto than the terms of the Confidentiality Agreement, except such confidentiality agreement need not contain any standstill, non-solicitation or no hire provisions. Notwithstanding the foregoing, a Person who has previously entered into a confidentiality agreement with Parent relating to a potential Acquisition Proposal on terms that are not materially less restrictive than the Confidentiality Agreement with respect to the scope of coverage and restrictions on disclosure and use shall not be required to enter into a new or revised confidentiality agreement, and such existing confidentiality agreement shall be deemed to be an Acceptable Confidentiality Agreement.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Acquisition Inquiry</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means, with respect to a Party, an inquiry, indication of interest or request for non-public information (other than an inquiry, indication of interest or request for information made or submitted by the Company, on the one hand, or Parent, on the other hand, to the other Party) that would reasonably be expected to lead to an Acquisition Proposal.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-2</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Acquisition</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> </span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Proposal</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means, with respect to a Party, any offer or proposal, whether written or oral (other than an offer or proposal made or submitted by or on behalf of the Company or any of its Affiliates, on the one hand, or by or on behalf of Parent or any of its Affiliates, on the other hand, to the other Party) contemplating or otherwise relating to any Acquisition Transaction with such Party.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Acquisition</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> </span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Transaction</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any transaction or series of related transactions (other than any Parent Legacy Transaction, the issuance of Company Notes, or the Company Pre-Closing Financing) involving:</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>any merger, consolidation, amalgamation, share exchange, business combination, issuance of securities, acquisition of securities, reorganization, recapitalization, tender offer, exchange offer or other similar transaction: (i) in which a Person or &#8220;group&#8221; (as defined in the Exchange Act and the rules promulgated thereunder) of Persons directly or indirectly acquires beneficial or record ownership of securities representing more than 20% of the outstanding securities of any class of voting securities of a Party or any of its Subsidiaries or (ii) in which a Party or any of its Subsidiaries issues securities representing more than 20% of the outstanding securities of any class of voting securities of such Party or any of its Subsidiaries, or issues securities convertible into more than 20% of the outstanding securities of any class of voting securities of such Party or any of its Subsidiaries; or</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>any sale, lease, exchange, transfer, license, acquisition or disposition of any business or businesses or assets that constitute or account for 20% or more of the consolidated book value or the fair market value of the assets of a Party and its Subsidiaries, taken as a whole.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Affiliate</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; shall have the meaning given to such term in Rule&#160;145 under the Securities Act.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Affordable Care Act</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the Patient Protection and Affordable Care Act.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Anticipated Closing Date</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the anticipated Closing Date, as agreed upon by Parent and the Company.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Business</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> </span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Day</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any day other than a day on which banks in the State of New York are authorized or obligated to be closed.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Certificate of Designation</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the Certificate of Designation of Preferences, Rights and Limitations of Parent Convertible Preferred Stock in the form attached hereto as </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Exhibit&#160;E</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">COBRA</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the Consolidated Omnibus Budget Reconciliation Act of 1985, as set forth in Section&#160;4980B of the Code and Section&#160;6 of Title I of ERISA.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Code</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the Internal Revenue Code of 1986, as amended.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Associate</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any current employee, independent contractor, officer or director of the Company or any of its Subsidiaries.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Board</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the board of directors of the Company.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Capital Stock</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the Company Common Stock and the Company Preferred Stock.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Capitalization Representations</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the representations and warranties of the Company set forth in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Sections&#160;3.6(a)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">3.6(d)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Common Stock</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the common stock, $0.0001 par value per share, of the Company.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Contract</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any Contract: (a) to which the Company or any of its Subsidiaries is a Party, (b) by which the Company or any of its Subsidiaries is or may become bound or under which the Company or any of its Subsidiaries has, or may become subject to, any obligation or (c) under which the Company or any of its Subsidiaries has or may acquire any right or interest.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Employee Plan</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any Employee Plan that the Company or any of its Subsidiaries (i) sponsors, maintains, administers, or contributes to, or (ii) provides benefits under or through, or (iii) has any obligation to contribute to or provide benefits under or through, or (iv) may reasonably be expected to have any Liability, or (v) utilizes to provide benefits to or otherwise cover any current or former employee, officer, director or other service provider of the Company or any of its Subsidiaries (or their spouses, dependents, or beneficiaries).</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-3</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Fundamental Representations</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the representations and warranties of the Company set forth in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Sections&#160;3.1(a)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">3.2</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">3.3</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">3.4</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">3.5(a)(i)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">3.20</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company IP Rights</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means all Intellectual Property rights that are owned or purported to be owned by, assigned to, exclusively licensed to, or controlled by the Company or its Subsidiaries that are necessary for, or used or held for use in, the operation of the business of the Company and its Subsidiaries as presently conducted.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company IP Rights Agreement</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any Contract governing, related to or pertaining to any Company IP Rights other than any confidential information provided under confidentiality agreements.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Key Employee</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any executive officer of the Company or any of its Subsidiaries.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Material Adverse Effect</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any Effect that, considered together with all other Effects that have occurred prior to the date of determination of the occurrence of a Company Material Adverse Effect, has or would reasonably be expected to have a material adverse effect on the business, financial condition, assets, liabilities or results of operations of the Company or its Subsidiaries, taken as a whole; </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">however</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that Effects arising or resulting from the following shall not be taken into account in determining whether there has been a Company Material Adverse Effect: (a) the announcement of this Agreement or the pendency of the Contemplated Transactions, (b) the taking of any action, or the failure to take any action, by the Company that is required to comply with the terms of this Agreement, (c) any natural disaster, calamity or epidemics, pandemics or other force majeure events, or any act or threat of terrorism or war, any armed hostilities or terrorist activities (including any escalation or general worsening of any of the foregoing) anywhere in the world or any governmental or other response or reaction to any of the foregoing, (d) any change in GAAP or applicable Law or the interpretation thereof, (e) general economic or political conditions or conditions generally affecting the industries in which the Company and its Subsidiaries operate or (f) any change in the cash position of the Company and its Subsidiaries which results from operations in the Ordinary Course of Business; except in each case with respect to clauses&#160;(c), (d) and (e), to the extent disproportionately affecting the Company and its Subsidiaries, taken as a whole, relative to other similarly situated companies in the industries in which the Company and its Subsidiaries operate.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Merger Shares</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the product determined by </span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:underline;">multiplying</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> (i) the Post-Closing Parent Shares </span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:underline;">by</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> (ii) the Company Allocation Percentage, in which:</span></p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="_idGenBNMarker-1" style="display:inline-block;text-indent:0;width:24pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>&#8220;<span class="CharOverride-7" style="font-style:normal;font-weight:bold;">Aggregate Valuation</span>&#8221; means the sum of (i) the Company Valuation, <span class="CharOverride-8" style="font-style:italic;font-weight:normal;text-decoration:underline;">plus</span> (ii) the Parent Valuation.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="_idGenBNMarker-1" style="display:inline-block;text-indent:0;width:24pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>&#8220;<span class="CharOverride-7" style="font-style:normal;font-weight:bold;">Company Allocation Percentage</span>&#8221; means the percentage (rounded to four decimal places) determined by <span class="CharOverride-8" style="font-style:italic;font-weight:normal;text-decoration:underline;">subtracting</span> (i)&#160;the Parent Allocation Percentage <span class="CharOverride-8" style="font-style:italic;font-weight:normal;text-decoration:underline;">from</span> (ii)&#160;100 percent.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="_idGenBNMarker-1" style="display:inline-block;text-indent:0;width:24pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>&#8220;<span class="CharOverride-7" style="font-style:normal;font-weight:bold;">Company Equity Value</span>&#8221; means $175,000,000.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-left:72pt;margin-top:8pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>&#8220;<span class="CharOverride-7" style="font-style:normal;font-weight:bold;">Company Outstanding Shares</span>&#8221; means, without duplication, the total number of shares of Company Capital Stock outstanding immediately prior to the First Effective Time (including any shares of Company Common Stock or Company Preferred Stock that are issued in, or issuable upon the exercise or conversion of securities issued in, the Company Pre-Closing Financing), expressed on a fully diluted and as-converted-to-Company Common Stock basis assuming, without limitation or duplication the exercise of all Company Options, Company Warrants or other rights or commitments to receive shares of Company Common Stock or Company Preferred Stock (or securities convertible or exercisable into shares of Company Common Stock or Company Preferred Stock, including the Company Notes), whether conditional or unconditional, that are outstanding as of immediately prior to the First Effective Time. For the avoidance of doubt, Company Outstanding Shares shall (a) exclude, to avoid the double-counting of, any shares of Company Common Stock or Company Preferred Stock (or securities convertible or exercisable into shares of Company Common Stock or Company Preferred Stock, including any Company Notes) to the extent such shares or securities are contributed as consideration in the Company Pre-Closing Financing and (b) include (i) to the extent not already issued prior to the First Effective Time, any shares of Company Common Stock or Company Preferred Stock (or securities convertible or exercisable into shares of Company Common Stock or Company Preferred Stock) issuable to the Paragon Entities (as such term is defined in the Company&#8217;s Organizational Documents) as a result of the Contemplated Transactions pursuant to the </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-4</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-position:inside;list-style-type:none;margin-left:72pt;text-indent:0pt;margin-top:8pt;">Company&#8217;s Organizational Documents and (ii) to the extent not already issued prior to the First Effective Time, any shares of Company Common Stock or Company Preferred Stock (or securities convertible or exercisable into shares of Company Common Stock or Company Preferred Stock) issuable pursuant to the offer letter set forth in Section&#160;3.6(d) of the Company Disclosure Letter.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="_idGenBNMarker-1" style="display:inline-block;text-indent:0;width:24pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>&#8220;<span class="CharOverride-7" style="font-style:normal;font-weight:bold;">Company Valuation</span>&#8221; means the (i) Company Equity Value plus (ii) the amount of proceeds actually received by the Company from the Company Pre-Closing Financing (including in the proceeds actually received from any Company Notes, and any interest thereon, contributed as consideration in the Company Pre-Closing Financing).</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="_idGenBNMarker-1" style="display:inline-block;text-indent:0;width:24pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>&#8220;<span class="CharOverride-7" style="font-style:normal;font-weight:bold;">Exchange Ratio</span>&#8221; means the ratio (rounded to four decimal places) equal to the quotient obtained by dividing (i) the Company Merger Shares by (ii) the Company Outstanding Shares.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="_idGenBNMarker-1" style="display:inline-block;text-indent:0;width:24pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>&#8220;<span class="CharOverride-7" style="font-style:normal;font-weight:bold;">Parent Allocation Percentage</span>&#8221; means the quotient (expressed as a percentage and rounded to four decimal places) determined by <span class="CharOverride-8" style="font-style:italic;font-weight:normal;text-decoration:underline;">dividing</span> (i) the Parent Valuation <span class="CharOverride-8" style="font-style:italic;font-weight:normal;text-decoration:underline;">by</span> (ii)&#160;the Aggregate Valuation.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="_idGenBNMarker-1" style="display:inline-block;text-indent:0;width:24pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>&#8220;<span class="CharOverride-7" style="font-style:normal;font-weight:bold;">Parent Outstanding Shares</span>&#8221; means, without duplication, (including, without limitation, the effects of the Nasdaq Reverse Split, if completed) the total number of shares of Parent Common Stock outstanding immediately prior to the First Effective Time expressed on a fully-diluted basis, and assuming, without limitation or duplication, the issuance of shares of Parent Common Stock in respect of all Parent Options, warrants or other rights or commitments to receive shares of Parent Common Stock or Parent Preferred Stock (or securities convertible or exercisable into shares of Parent Common Stock or Parent Preferred Stock, but excluding any Parent Convertible Preferred Stock issuable in accordance herewith), whether conditional or unconditional, that are outstanding as of immediately prior to the First Effective Time. Notwithstanding any of the foregoing, no Parent Options, if any, shall be included in the total number of shares of Parent Common Stock outstanding for purposes of determining the Parent Outstanding Shares to the extent cancelled at or prior to Closing under <span class="CharOverride-9" style="text-decoration:underline;">Section&#160;6.6(c)</span>.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="_idGenBNMarker-1" style="display:inline-block;text-indent:0;width:24pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>&#8220;<span class="CharOverride-7" style="font-style:normal;font-weight:bold;">Parent Valuation</span>&#8221; means (i) $11,000,000, <span class="CharOverride-8" style="font-style:italic;font-weight:normal;text-decoration:underline;">minus</span> (ii) the amount by which Parent Net Cash is less than $5,000,000 (if any).</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="_idGenBNMarker-1" style="display:inline-block;text-indent:0;width:24pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>&#8220;<span class="CharOverride-7" style="font-style:normal;font-weight:bold;">Post-Closing Parent Shares</span>&#8221; mean the quotient determined by <span class="CharOverride-8" style="font-style:italic;font-weight:normal;text-decoration:underline;">dividing</span> (i) the Parent Outstanding Shares <span class="CharOverride-8" style="font-style:italic;font-weight:normal;text-decoration:underline;">by</span> (ii) the Parent Allocation Percentage.</p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Notes</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the convertible notes issued pursuant to that certain Series A Preferred Stock and Convertible Note Purchase Agreement among the Company and the purchasers party thereto, dated as of March 6, 2024, or any additional convertible promissory notes that may be issued from time to time prior to the Closing.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Options</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means options or other rights to purchase shares of Company Capital Stock issued by the Company.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Preferred Stock</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the shares of the Company&#8217;s capital stock designated as preferred stock, including the Company Series A Preferred Stock.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Registered IP</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means all Company IP Rights that are owned or exclusively licensed by the Company that are registered, filed or issued under the authority of, with or by any Governmental Authority, including all patents, registered copyrights and registered trademarks and all applications and registrations for any of the foregoing.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Series A Preferred Stock</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means a series of the Company&#8217;s preferred stock designated as Series A Preferred Stock, $0.0001 par value per share.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Stock Plans</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the Company&#8217;s Amended and Restated 2024 Equity Incentive Plan.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Triggering Event</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; shall be deemed to have occurred if, at any time prior to the adoption of this Agreement and the approval of the Contemplated Transactions by the Required Company Stockholder Vote: (a) the Company Board shall have made a Company Board Adverse Recommendation Change; (b) the Company Board or </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-5</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">any committee thereof shall have publicly proposed, endorsed or recommended any Acquisition Proposal; or (c) the Company shall have entered into any letter of intent or similar document or any Contract relating to any Acquisition Proposal.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Warrants</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means warrants to purchase shares of Company Capital Stock issued by the Company.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Confidentiality</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> </span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Agreement</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the letter agreement dated as of February 9, 2024, between the Company and Parent.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Consent</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any approval, consent, ratification, permission, waiver or authorization (including any Governmental Authorization).</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Contemplated</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> </span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Transactions</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the Merger, the Constructive Issuance and the other transactions contemplated by this Agreement (other than the Parent Legacy Transaction and Parent Charter Amendment), the Company Pre-Closing Financing and the Nasdaq Reverse Split (to the extent applicable and deemed necessary by Parent and the Company).</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Contract</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means, with respect to any Person, any written agreement, contract, subcontract, lease (whether for real or personal property), mortgage, license, or other legally binding commitment or undertaking of any nature to which such Person is a party or by which such Person or any of its assets are bound or affected under applicable Law.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">DGCL</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the General Corporation Law of the State of Delaware.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">DLLCA</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the Delaware Limited Liability Company Act.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Effect</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any effect, change, event, circumstance, or development.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Employee Plan</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means (A) an &#8220;employee benefit plan&#8221; within the meaning of Section&#160;3(3) of ERISA whether or not subject to ERISA; (B) other plan, program, policy or arrangement providing for stock options, stock purchases, equity-based compensation, bonuses (including any annual bonuses and retention bonuses) or other incentives, severance pay, deferred compensation, employment, compensation, change in control or transaction bonuses, supplemental, vacation, retirement benefits (including post-retirement health and welfare benefits), pension benefits, profit-sharing benefits, fringe benefits, life insurance benefits, perquisites, health benefits, medical benefits, dental benefits, vision benefits, and all other employee benefit plans, agreements, and arrangements, not described in (A) above; and (C) all other plans, programs, policies or arrangements providing compensation to employees, consultants and non-employee directors.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Encumbrance</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any lien, pledge, hypothecation, charge, mortgage, security interest, lease, exclusive license, option, easement, reservation, servitude, adverse title, claim, infringement, interference, option, right of first refusal, preemptive right, community property interest or restriction or encumbrance of any nature (including any restriction on the voting of any security, any restriction on the transfer of any security or other asset, any restriction on the receipt of any income derived from any asset, any restriction on the use of any asset and any restriction on the possession, exercise or transfer of any other attribute of ownership of any asset).</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Enforceability Exceptions</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the (a) Laws of general application relating to bankruptcy, insolvency and the relief of debtors and (b) rules of law governing specific performance, injunctive relief and other equitable remedies.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Entity</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any corporation (including any nonprofit corporation), partnership (including any general partnership, limited partnership or limited liability partnership), joint venture, estate, trust, company (including any company limited by shares, limited liability company or joint stock company), firm, society or other enterprise, association, organization or entity, and each of its successors.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Environmental</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> </span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Law</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any federal, state, local or foreign Law relating to pollution or protection of human health or the environment (including ambient air, surface water, ground water, land surface or subsurface strata), including any law or regulation relating to emissions, discharges, releases or threatened releases of Hazardous Materials, or otherwise relating to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-6</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">ERISA Affiliate</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means, with respect to any Entity, any other Person that would be treated as a single employer with such Entity or part of the same &#8220;controlled group&#8221; as such Entity under Sections&#160;414(b),(c),(m) or (o) of the Code.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">ERISA</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the Employee Retirement Income Security Act of 1974, as amended.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Exchange</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> </span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Act</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the Securities Exchange Act of 1934, as amended.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">First</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> </span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Merger Sub Board</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the board of directors of First Merger Sub.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Governmental Authority</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any: (a) nation, state, commonwealth, province, territory, county, municipality, district or other jurisdiction of any nature, (b) federal, state, local, municipal, foreign, supra-national or other government, (c) governmental or quasi-governmental authority of any nature (including any governmental division, department, agency, commission, bureau, instrumentality, official, ministry, fund, foundation, center, organization, unit, body or Entity and any court or other tribunal, and for the avoidance of doubt, any taxing authority) or (d) self-regulatory organization (including Nasdaq).</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Governmental Authorization</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any: (a)&#160;permit, license, certificate, franchise, permission, variance, exception, order, approval, clearance, registration, qualification or authorization issued, granted, given or otherwise made available by or under the authority of any Governmental Authority or pursuant to any Law or (b)&#160;right under any Contract with any Governmental Authority.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Hazardous Materials</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any pollutant, chemical, substance and any toxic, infectious, carcinogenic, reactive, corrosive, ignitable or flammable chemical, or chemical compound, or hazardous substance, material or waste, whether solid, liquid or gas, that is subject to regulation, control or remediation under any Environmental Law, including without limitation, crude oil or any fraction thereof, and petroleum products or by-products.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">HSR Act</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the U.S. Hart Scott-Rodino Antitrust Improvements Act of 1976, as amended.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">In the Money Parent Option</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; shall mean Parent Options with an exercise price equal to or less than the Parent Closing Price.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Intellectual Property</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means: (a) United States, foreign and international patents, patent applications, including all provisionals, nonprovisionals, substitutions, divisionals, continuations, continuations-in-part, reissues, extensions, supplementary protection certificates, reexaminations, term extensions, certificates of invention and the equivalents of any of the foregoing, statutory invention registrations, invention disclosures and inventions (collectively, &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Patents</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), (b) trademarks, service marks, trade names, domain names, corporate names, brand names, URLs, trade dress, logos and other source identifiers, including registrations and applications for registration thereof and goodwill associated therewith, (c) copyrights, including registrations and applications for registration thereof, (d) software, including all source code, object code and related documentation, (e) formulae, customer lists, trade secrets, know-how, confidential information and other proprietary rights and intellectual property, whether patentable or not, and (f) all United States and foreign rights arising under or associated with any of the foregoing.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">IRS</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the United States Internal Revenue Service.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Knowledge</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means, (i) with respect to an individual, that such individual is actually aware of the relevant fact or such individual would reasonably be expected to know such fact in the ordinary course of the performance of such individual&#8217;s employment responsibilities, (ii) with respect Parent, the Knowledge of the individuals listed on </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Schedule&#160;A</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Parent Disclosure Letter as of the date of such knowledge is imputed and (iii) with respect to any Person that is an Entity (other than Parent) the Knowledge of any executive officer of such Person as of the date such knowledge is imputed. With respect to any matters relating to Intellectual Property, such awareness or reasonable expectation to have knowledge does not require any such individual to conduct or have conducted or obtain or have obtained any freedom to operate opinions of counsel or any Intellectual Property rights clearance searches.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Law</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any federal, state, national, supra-national, foreign, local or municipal or other law, statute, constitution, principle of common law, resolution, ordinance, code, edict, decree, rule, regulation, ruling or requirement issued, enacted, adopted, promulgated, implemented or otherwise put into effect by or under the authority of any Governmental Authority (including under the authority of Nasdaq or the Financial Industry Regulatory Authority).</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-7</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Legal Proceeding</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any action, suit, litigation, arbitration, proceeding (including any civil, criminal, administrative, investigative or appellate proceeding), hearing, inquiry, audit, examination or investigation commenced, brought, conducted or heard by or before any court or other Governmental Authority or any arbitrator or arbitration panel.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Multiemployer</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> </span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Plan</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means a &#8220;multiemployer plan,&#8221; as defined in Section&#160;3(37) or 4001(a)(3) of ERISA.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Multiple Employer Plan</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means a &#8220;multiple employer plan&#8221; within the meaning of Section&#160;413(c) of the Code or Section&#160;3(40) of ERISA.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Multiple Employer Welfare Arrangement</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means a &#8220;multiple employer welfare arrangement&#8221; within the meaning of Section&#160;3(40) of ERISA.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Nasdaq Reverse Split</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means a reverse stock split of all outstanding shares of Parent Common Stock effected by Parent for the purpose of maintaining compliance with Nasdaq listing standards.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Nasdaq</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means The Nasdaq Stock Market.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Order</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any judgment, order, writ, injunction, ruling, decision or decree of (that is binding on a Party), or any plea agreement, corporate integrity agreement, resolution agreement or deferred prosecution agreement with, or any settlement under the jurisdiction of, any court or Governmental Authority.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Ordinary</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> </span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Course of Business</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means, in the case of each of the Company and Parent, such actions taken in the ordinary course of its business and consistent with its past practice or, with respect to the Company, the customary practices of a recently formed company at a similar stage of development; provided, however, that during the Pre-Closing Period, the Ordinary Course of Business of Parent shall also include actions required to effect and effecting any Parent Legacy Transaction.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Organizational Documents</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means, with respect to any Person (other than an individual), (a) the certificate or articles of association or incorporation or organization or limited partnership or limited liability company, and any joint venture, limited liability company, operating or partnership agreement and other similar documents adopted or filed in connection with the creation, formation or organization of such Person and (b) all bylaws, regulations and similar documents or agreements relating to the organization or governance of such Person, in each case, as amended or supplemented.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Out of the Money Parent Options</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; shall mean Parent Options with an exercise price greater than the Parent Closing Price.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Associate</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any current employee, independent contractor, officer or director of Parent or any of its Subsidiaries.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Balance Sheet</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the audited balance sheet of Parent as of December 31, 2023, included in Parent&#8217;s Report on Form 10-K for the year ended December 31, 2023, as filed with the SEC.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Board</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the board of directors of Parent.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Capital Stock</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the Parent Common Stock and the Parent Preferred Stock.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Capitalization Representations</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the representations and warranties of Parent and Merger Subs set forth in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Sections&#160;4.6(a)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">4.6(d)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Closing Price</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the volume weighted average closing trading price of a share of Parent Common Stock on Nasdaq for the five (5) consecutive trading days ending three (3) trading days immediately prior to the Closing Date as reported by Bloomberg L.P.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Common Stock</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the common stock, $0.001 par value per share, of Parent.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Contract</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any Contract: (a) to which Parent is a party, (b) by which Parent or any Parent IP Rights or any other asset of Parent is or may become bound or under which Parent has, or may become subject to, any obligation or (c) under which Parent has or may acquire any right or interest.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-8</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Convertible Preferred Stock</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means Parent&#8217;s non-voting convertible preferred stock, par value $0.001 per share, with the rights, preferences, powers and privileges specified in the Certificate of Designation.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Employee Plan</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any Employee Plan that Parent or any of its Subsidiaries (i) sponsors, maintains, administers, or contributes to, or (ii) provides benefits under or through, or (iii) has any obligation to contribute to or provide benefits under or through, or (iv) may reasonably be expected to have any Liability, or (v)&#160;utilizes to provide benefits to or otherwise cover any current or former employee, officer, director or other service provider of Parent or any of its Subsidiaries (or their spouses, dependents, or beneficiaries).</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Fundamental Representations</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the representations and warranties of Parent and Merger Subs set forth in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Sections&#160;4.1(a)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">4.2</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">4.3</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">4.4</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">4.5(a)(i)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">4.21</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent IP Rights Agreement</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any Contract governing, related or pertaining to any Parent IP Rights.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent IP Rights</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means all Intellectual Property owned, licensed or controlled by Parent that is necessary for, or used or held for use in, the operation of the business of Parent.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> </span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Key Employee</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means (i) an executive officer of Parent; and (ii) any employee of Parent that reports directly to the Parent Board or to an executive officer of Parent.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Legacy Business</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the business of Parent as conducted at any time prior to the date of this Agreement, including but not limited to business related to the assets listed on </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;1.1(a)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Parent Disclosure Letter.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Material Adverse Effect</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any Effect that, considered together with all other Effects that have occurred prior to the date of determination of the occurrence of the Parent Material Adverse Effect, has or would reasonably be expected to have a material adverse effect on the business, financial condition, assets, liabilities or results of operations of Parent and its Subsidiaries, taken as a whole; </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">however</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that Effects arising or resulting from the following shall not be taken into account in determining whether there has been a Parent Material Adverse Effect: (a) the announcement of this Agreement or the pendency of the Contemplated Transactions, (b) any change in the stock price or trading volume of Parent Common Stock (it being understood, however, that any Effect causing or contributing to any change in stock price or trading volume of Parent Common Stock may be taken into account in determining whether a Parent Material Adverse Effect has occurred, unless such Effects are otherwise excepted from this definition), (c) the taking of any action, or the failure to take any action, by Parent that is required to comply with the terms of this Agreement, (d) any natural disaster, calamity or epidemics, pandemics or other force majeure events, or any act or threat of terrorism or war, any armed hostilities or terrorist activities (including any escalation or general worsening of any of the foregoing) anywhere in the world, or any governmental or other response or reaction to any of the foregoing, (e) any change in GAAP or applicable Law or the interpretation thereof or (f) general economic or political conditions or conditions generally affecting the industries in which Parent or any of its Subsidiaries operates; except, in each case with respect to clauses&#160;(d), (e) and (f), to the extent materially and disproportionately affecting Parent or any of its Subsidiaries, taken as a whole, relative to other similarly situated companies in the industries in which Parent or any of its Subsidiaries operates. Notwithstanding the above, a delisting of Parent Common Stock on Nasdaq shall constitute a Parent Material Adverse Effect, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> that the Company has not refused or unreasonably delayed its consent to reasonable actions by Parent to maintain the listing of Parent Common Stock on Nasdaq.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Net Cash</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means without duplication, (i) Parent&#8217;s unrestricted cash and cash equivalents and marketable securities determined, to the extent in accordance with GAAP, in a manner consistent with the manner in which such items were historically determined and in accordance with the financial statements (including any related notes) contained or incorporated by reference in the Parent SEC Documents and the Parent Balance Sheet, </span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:underline;">plus</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> (ii) all prepaid expenses set forth on </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;1.1(b)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Parent Disclosure Letter, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">plus</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> (iii) all receivables which the parties may mutually agree (each in their sole discretion) are recoverable by or provide benefit to Parent after the First Effective Time (if any), </span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:underline;">minus</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> (iv) the sum of Parent&#8217;s consolidated short-term and long-term contractual obligations and liabilities accrued at the Closing Date, in each case determined in accordance with GAAP and, to the extent in accordance with GAAP, in a manner consistent with the manner in which such items were historically determined and in accordance with the financial statements (including any related notes) contained or incorporated by reference in the Parent SEC Documents and the Parent Balance Sheet, </span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:underline;">minus</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> (v) the aggregate amount (without duplication) </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-9</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">of all fees and expenses incurred by Parent prior to the First Effective Time in connection with the Contemplated Transactions or the Parent Legacy Transaction, including: (a) any fees and expenses of legal counsel, accountants, financial advisors, investment bankers, brokers, consultants, tax advisors, and other professional advisors of Parent in connection with the Contemplated Transactions or the Parent Legacy Transaction; (b) 50% of the fees paid to the SEC in connection with filing the Registration Statement and any amendments and supplements thereto, with the SEC; (c)&#160;50% of the fees and expenses in connection with the printing, mailing and distribution of the Proxy Statement and any amendments and supplements thereto; (d) 50% of the Nasdaq Fees; (e)&#160;any bonus, retention payments, severance, change-in-control payments or similar payment obligations (including payments with &#8220;single-trigger&#8221; provisions triggered at and as of the consummation of the transactions contemplated hereby) that become due or payable to any director, officer, employee or consultant in connection with the consummation of the Contemplated Transactions or any Parent Legacy Transaction, together with any payroll Taxes associated therewith; (f) the dividend of any excess Parent Net Cash (but only to the extent declared and unpaid) and all costs and expenses associated therewith; and (g)&#160;the costs associated with obtaining the &#8220;D&amp;O tail policy&#8221; pursuant to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.7,</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> in each case, to the extent unpaid as of the First Effective Time, </span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:underline;">minus</span><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;"> </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(vi) all remaining rent payments and any other Liabilities under Parent&#8217;s lease obligations, </span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:underline;">minus</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> (vii) any unpaid Taxes of Parent and its Subsidiaries for Tax periods (or portions thereof) ending on or before the Closing Date, </span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:underline;">minus</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> (viii) all costs and expenses to be mutually agreed by Parent and the Company relating to the winding down of Parent Legacy Business, including the sale, license or other disposition of any or all of the Parent Legacy Business to the extent unpaid as of the Closing, including any costs incurred costs incurred by Parent following the Closing pursuant to Section&#160;6.17 and </span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:underline;">minus</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> (ix) the amounts due and payable to holders of Parent Options pursuant to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.6(c)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> to the extent unpaid as of the First Effective Time; </span><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">provided, however, </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">that if any portion of the fees and expenses described in subclauses&#160;(b), (c), and (d) of clause&#160;(v) have been paid by Parent prior to the First Effective Time in an amount greater than Parent&#8217;s share of such fee and expense described in subclauses&#160;(b), (c), and (d), then (x) such portion in excess of Parent&#8217;s shares of such fee and expense described in subclauses&#160;(b), (c), and (d) shall not be deducted by reason of subclauses&#160;(b), (c), and (d) of clause&#160;(v) and (y) such portion shall be added to the calculation of Parent Net Cash.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Options</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means options or other rights to purchase shares of Parent Common Stock granted by Parent, including pursuant to any Parent Stock Plan.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Preferred Stock</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the shares of Parent&#8217;s capital stock designated as preferred stock, par value $0.001 per share of Parent, including the Parent Convertible Preferred Stock.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Registered IP</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means all Parent IP Rights that are owned or exclusively licensed by Parent that are registered, filed or issued under the authority of, with or by any Governmental Authority, including all patents, registered copyrights and registered trademarks and all applications for any of the foregoing.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Restricted Stock Units</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any equity award with respect to Parent Common Stock that represents the right to receive in the future shares of Parent Common Stock pursuant to any Parent Stock Plan.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Triggering Event</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; shall be deemed to have occurred if, prior to the approval of this Agreement and the Contemplated Transactions by Parent&#8217;s stockholders and subject to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.3(c)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">: (a) Parent shall have failed to include in the Proxy Statement the Parent Board Recommendation, (b) the Parent Board or any committee thereof shall have made a Parent Board Adverse Recommendation Change or subject to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.3(e)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, publicly proposed, endorsed or recommended any Acquisition Proposal or (c) Parent shall have entered into any letter of intent or similar document or any Contract relating to any Acquisition Proposal (other than an Acceptable Confidentiality Agreement permitted pursuant to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;5.4</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">).</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Party</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; or &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parties</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the Company, Merger Subs and Parent.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Permitted Alternative Agreement</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means a definitive agreement that contemplates or otherwise relates to an Acquisition Transaction that constitutes a Superior Offer.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Permitted Encumbrance</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means (a) any statutory liens for current Taxes not yet due and payable or for Taxes that are being contested in good faith by the appropriate proceedings and for which adequate reserves have been made on the Company Budget or the Parent Balance Sheet, as applicable, in accordance with GAAP, (b)&#160;minor non-monetary liens that have arisen in the Ordinary Course of Business and that do not (in any case or in the aggregate) materially detract from the value of the assets subject thereto or materially impair the operations of the Company or Parent, as applicable, (c)&#160;statutory liens to secure obligations to landlords, lessors or renters under </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-10</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">leases or rental agreements, (d) deposits or pledges made in connection with, or to secure payment of, workers&#8217; compensation, unemployment insurance or similar programs mandated by Law, (e) statutory liens in favor of carriers, warehousemen, mechanics and materialmen, to secure claims for labor, materials or supplies for amounts that are not yet due and payable and (f) liens arising under applicable securities Law.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Person</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any individual, Entity or Governmental Authority.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Personal Information</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any data or information that constitutes &#8220;personal information,&#8221; &#8220;personal data,&#8221; &#8220;personally identifiable information,&#8221; &#8220;protected health information,&#8221; or any analogous term under applicable Law, including any such information that identifies, relates to, describes, is linked to, is reasonably capable of being associated with, or could reasonably be linked, directly or indirectly, with any identified or identifiable individual or household.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Privacy Laws</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; mean, collectively, (i) all Laws governing privacy, data protection, data security, trans-border data flow, data loss, data theft, breach notification, data localization, sending solicited or unsolicited electronic mail or text messages, cookies or other tracking technology, or the collection, handling, use, maintenance, storage, disclosure, transfer, or other processing of Personal Information, including any such legally binding requirements set forth in regulations and agreements containing consent orders published by regulatory authorities of competent jurisdiction such as the U.S. Federal Trade Commission, U.S. Federal Communications Commission, and state data protection authorities, including HIPAA, Section&#160;5 of the Federal Trade Commission Act, the Telephone Consumer Protection Act and U.S. state consumer protection and data breach notification Laws, and (ii) any legally binding requirements of any self-regulatory organizations governing data privacy, data protection, data security, trans-border data flow, data loss, data theft, breach notification, data localization, sending solicited or unsolicited electronic mail or text messages, cookies or other tracking technology, or the collection, handling, use, maintenance, storage, disclosure, transfer, or other processing of Personal Information.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Representatives</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means with respect to a Person, such Person&#8217;s directors, officers, employees, agents, attorneys, accountants, investment bankers, advisors and other representatives.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Sarbanes-Oxley Act</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the Sarbanes-Oxley Act of 2002.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">SEC</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the United States Securities and Exchange Commission.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Securities Act</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the Securities Act of 1933, as amended.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Subsequent Transaction</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any Acquisition Transaction (with all references to 20% in the definition of Acquisition Transaction being treated as references to 50% for these purposes).</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Subsidiary</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means, with respect to an Entity, a Person if such Person directly or indirectly owns or purports to own, beneficially or of record, (a) an amount of voting securities or other interests in such Entity that is sufficient to enable such Person to elect at least a majority of the members of such entity&#8217;s board of directors or other governing body or (b) at least 50% of the outstanding equity, voting, beneficial or financial interests in such Entity.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Superior</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> </span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Offer</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means an unsolicited bona fide written Acquisition Proposal (with all references to 20% in the definition of Acquisition Transaction being treated as references to 50% for these purposes) that: (a) was not obtained or made as a direct or indirect result of a breach of this Agreement, (b) is on terms and conditions that the Parent Board or the Company Board, as applicable, determines in good faith, based on such matters that it deems relevant (including the likelihood of consummation thereof and the financing terms thereof), as well as any written offer by the other Party to this Agreement to amend the terms of this Agreement, and following consultation with its outside legal counsel and financial advisors, if any, are more favorable, from a financial point of view, to Parent&#8217;s stockholders or the Company&#8217;s stockholders, as applicable, than the terms of the Contemplated Transactions, (c) is not subject to any financing conditions (and if financing is required, such financing is then fully committed to the third party) and (d) is reasonably capable of being completed on the terms proposed.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Tax Return</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any return (including any information return), report, statement, declaration, claim or refund, estimate, schedule, notice, notification, form, election, certificate or other document or information, and any amendment or supplement to any of the foregoing, filed or required to be filed with any Governmental Authority (or provided to a payee) in connection with the determination, assessment, collection or payment of any Tax or in connection with the administration, implementation or enforcement of or compliance with any Law relating to any Tax.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-11</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Tax</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any U.S. federal, state, local, foreign or other tax, including any income tax, franchise tax, capital gains tax, gross receipts tax, value-added tax, surtax, estimated tax, employment tax, unemployment tax, national health insurance tax, environmental tax, excise tax, ad valorem tax, transfer tax, conveyance tax, stamp tax, sales tax, use tax, property tax, business tax, withholding tax, payroll tax, social security tax, customs duty, licenses tax, alternative or add-on minimum or other tax or similar charge, duty, levy, fee, tariff, impost, obligation or assessment in the nature of a tax (whether imposed directly or through withholding and whether or not disputed), and including any fine, penalty, addition to tax, interest or additional amount imposed by a Governmental Authority with respect thereto (or attributable to the nonpayment thereof).</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Treasury Regulations</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the United States Treasury regulations promulgated under the Code.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b) Each of the following terms is defined in the Section&#160;set forth opposite such term:</span></p>
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-14" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">



						<p class="TCH_left" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Terms</p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-7" style="font-style:normal;font-weight:bold;">Section</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">AAA</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">2.8(i)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Accounting Firm</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">2.8(i)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Agreement</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Preamble</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Allocation Certificate</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">6.15</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Assumed Option</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">6.5(a)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Assumed Warrant</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">6.5(b)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Capitalization Date</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">4.6(a)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Cash Determination Time</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">2.8(a)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Certificate of Merger</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">2.3</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Certifications</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">4.7(a)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Closing Date</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">2.3</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Closing</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">2.3</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Company 409A Plan</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">3.17(j)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Company Audited Financial Statements</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">6.1(e)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Company Board Adverse Recommendation Change</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">6.2(d)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Company Board Recommendation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">6.2(c)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Company Budget</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">3.7(a)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Company Disclosure Letter</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Section&#160;3</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Company Interim Financial Statements</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">6.1(e)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Company Intervening Event</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">6.2(d)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Company Material Contract</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">3.13(a)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Company Material Contracts</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">3.13(a)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Company Permits</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">3.14(b)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Company Product Candidates</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">3.14(d)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Company Real Estate Leases</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">3.11</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Company Regulatory Permits</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">3.14(d)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Company Required S-4 Information</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">6.1(d)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Company Stockholder Support Agreement</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Recital</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Company Stockholder Written Consents</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">6.2(a)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Company Termination Fee</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.3(b)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Company Valuation Calculation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">2.8(b)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Company Valuation Delivery Date</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">2.8(b)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Company Valuation Determination Time</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">2.8(b)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Company Valuation Dispute Notice</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">2.8(d)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Company Valuation Response Date</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">2.8(d)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Company Valuation Schedule</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">2.8(b)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Company</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Preamble</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Concurrent Investment</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Preamble</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Costs</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">6.7(a)</p>
					</td>
				</tr>

		</table>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-12</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-14" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">



						<p class="TCH_left" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Terms</p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-7" style="font-style:normal;font-weight:bold;">Section</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">D&amp;O Indemnified Parties</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">6.7(a)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Dispute Notice</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">2.8(c)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Dissenting Shares</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">2.12(a)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Drug/Device Regulatory Agency</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">3.14(b)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Employment-Related Laws</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">3.17(k)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">End Date</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.1(b)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Exchange Agent</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">2.7(a)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">FDA</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">3.14(b)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">FDCA</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">3.14(c)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">First Certificate of Merger</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">2.3</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">First Effective Time</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">2.3</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">First Merger</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Recital</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">First Step Surviving Corporation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">2.1</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Form S-4</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">6.1(a)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">GAAP</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">3.7(a)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Intended Tax Treatment</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">2.10</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Liability</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">3.9</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Lock-Up Agreement</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Recital</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Lock-Up Agreements</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Recital</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Merger Consideration</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">2.5(a)(ii)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Merger Subs</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Preamble</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Merger</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Recital</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Nasdaq Fees</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">6.9</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Nasdaq Listing Application</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">6.9</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Notice Period</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">6.2(d)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Ordinary Course Agreement</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">3.16(g)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Parent 409A Plan</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">4.17(j)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Parent Board Adverse Recommendation Change</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">6.3(c)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Parent Board Recommendation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">6.3(b)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Parent Charter Amendment</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">2.4(b)(ii)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Parent Disclosure Letter</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Section&#160;4</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Parent Intervening Event</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">6.3(c)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Parent Legacy Transaction</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">5.1(c)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Parent Material Contract</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">4.13(a)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Parent Material Contracts</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">4.13(a)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Parent Net Cash Calculation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">2.8(a)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Parent Net Cash Schedule</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">2.8(a)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Parent Notice Period</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">6.3(c)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Parent Permits</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">4.14(b)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Parent Pre-Closing Dividend</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">5.1(c)(ii)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Parent Pre-Closing Dividend Amount</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">5.1(c)(ii)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Parent Product Candidates</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">4.14(d)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Parent Real Estate Leases</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">4.11</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Parent Regulatory Permits</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">4.14(d)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Parent SEC Documents</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">4.7(a)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Parent Stock Plans</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">4.6(c)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Parent Stockholder Matters</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">6.3(a)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Parent Stockholder Meeting</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">6.3(a)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Parent Stockholder Support Agreement</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Recital</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Parent</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Preamble</p>
					</td>
				</tr>

		</table>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-13</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-14" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">



						<p class="TCH_left" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Terms</p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-7" style="font-style:normal;font-weight:bold;">Section</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">PHSA</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">3.14(c)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Post-Closing Welfare Plan</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">6.6(b)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Pre-Closing Period</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">5.1(a)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Privacy Policies</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">3.22</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Proxy Statement</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">6.1(a)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Registration Statement</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">6.1(a)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Required Company Stockholder Vote</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">3.4</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Required Parent Stockholder Vote</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">4.4</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Response Date</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">2.8(c)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">SEC Documents</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">6.16</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Second Certificate of Merger</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">2.3</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Second Effective Time</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">2.3</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Second Merger</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Recital</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Stockholder Notice</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">6.2(b)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Subscription Agreement</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Recital</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Surviving Entity</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">2.1</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Tax Certificates</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">6.10(c)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Transaction Litigation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">6.4(c)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">WARN Act</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">3.17(k)</p>
					</td>
				</tr>

		</table>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">1.2<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Other Definitional and Interpretative Provisions</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The words &#8220;hereof,&#8221; &#8220;herein&#8221; and &#8220;hereunder&#8221; and words of like import used in this Agreement shall refer to this Agreement as a whole and not to any particular provision of this Agreement. The captions herein are included for convenience of reference only and shall be ignored in the construction or interpretation hereof. References to Sections, Exhibits and Schedules&#160;are to Sections, Exhibits and Schedules&#160;of this Agreement unless otherwise specified. Any capitalized terms used in any Exhibit&#160;or Schedule&#160;but not otherwise defined therein shall have the meaning as defined in this Agreement. Any singular term in this Agreement shall be deemed to include the plural, and any plural term the singular, the masculine gender shall include the feminine and neuter genders; the feminine gender shall include the masculine and neuter genders; and the neuter gender shall include masculine and feminine gender. Whenever the words &#8220;include,&#8221; &#8220;includes&#8221; or &#8220;including&#8221; are used in this Agreement, they shall be deemed to be followed by the words &#8220;without limitation,&#8221; whether or not they are in fact followed by those words or words of like import. The word &#8220;or&#8221; is not exclusive. &#8220;Writing,&#8221; &#8220;written&#8221; and comparable terms refer to printing, typing and other means of reproducing words (including electronic media) in a visible form. References to any agreement or Contract (except for references to any agreements or Contracts listed on the Parent Disclosure Letter or Company Disclosure Letter) are to that agreement or Contract as amended, modified or supplemented from time to time in accordance with the terms hereof and thereof. The Exhibits to this Agreement, the Parent Disclosure Letter and the Company Disclosure Letter are integral parts of the interpretation of this Agreement, but only Exhibit&#160;D-1 (including Exhibit&#160;A to such Exhibit) and Exhibit&#160;D-2 is incorporated by reference and made a part hereof for purposes of Section&#160;251 of the DGCL. References to any Person include the successors and permitted assigns of that Person. References to any statute are to that statute and to the rules and regulations promulgated thereunder, in each case as amended, modified, re-enacted thereof, substituted, from time to time. References to &#8220;$&#8221; and &#8220;dollars&#8221; are to the currency of the United&#160;States. All accounting terms used herein will be interpreted, and all accounting determinations hereunder will be made, in accordance with GAAP unless otherwise expressly specified. References from or through any date shall mean, unless otherwise specified, from and including or through and including, respectively. All references to &#8220;days&#8221; shall be to calendar days unless otherwise indicated as a &#8220;Business Day.&#8221; Except as otherwise specifically indicated, for purposes of measuring the beginning and ending of time periods in this Agreement (including for purposes of &#8220;Business Day&#8221; and for hours in a day or Business Day), the time at which a thing, occurrence or event shall begin or end shall be deemed to occur in the Eastern time zone of the United States. The Parties agree that any rule of construction to the effect that ambiguities are to be resolved against the drafting Party shall not be applied in the construction or interpretation of this Agreement. The Parties agree that the Company Disclosure Letter or Parent Disclosure Letter shall be arranged in sections and subsections corresponding to the numbered and lettered sections and subsections contained in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;3</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> or </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;4</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, respectively. The disclosures in any section or subsection of the Company Disclosure Letter or the Parent Disclosure Letter shall qualify other sections and subsections in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;3</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> or </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;4</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, respectively, to the extent it is readily apparent from a reading of the disclosure that such disclosure is </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-14</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">applicable to such other sections and subsections. The words &#8220;delivered&#8221; or &#8220;made available&#8221; mean, with respect to any documentation, that prior to 5:00 p.m. (New York City time) on the date that is the day prior to the date of this Agreement, a copy of such material has been (a)</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">&#160;</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">posted to and continuously made available by a Party to the other Party and its Representatives in the electronic data room maintained by such disclosing Party for the purposes of the Contemplated Transactions or (b) delivered by or on behalf of a Party or its Representatives to the other Party or its Representatives via electronic mail or in hard copy form prior to the execution of this Agreement.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;2. </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Description of Transaction</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">2.1<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">The Merger</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Upon the terms and subject to the conditions set forth in this Agreement, at the First Effective Time, First Merger Sub shall be merged with and into the Company, and the separate existence of First Merger Sub shall cease. The Company will continue as the surviving corporation in the First Merger (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">First Step Surviving Corporation</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;).  Upon the terms and subject to the conditions set forth in this Agreement, at the Second Effective Time, the First Step Surviving Corporation will merge with and into Second Merger Sub, and the separate existence of the First Step Surviving Corporation shall cease.  As a result of the Second Merger, Second Merger Sub will continue as the surviving entity in the Second Merger (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Surviving Entity</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;).</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">2.2<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Effects of the Merger</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The First Merger shall have the effects set forth in this Agreement and in the applicable provisions of the DGCL. As a result of the First Merger, the Company will become a wholly owned subsidiary of Parent. The Second Merger shall have the effects set forth in this Agreement and in the applicable provisions of the DGCL and the DLLCA.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">2.3<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Closing; First Effective Time; Second Effective Time</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Unless this Agreement is earlier terminated pursuant to the provisions of </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.1</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, and subject to the satisfaction or waiver of the conditions set forth in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;7</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;8</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, the consummation of the Merger (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Closing</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) shall take place remotely, as promptly as practicable (but in no event later than the second Business Day following the satisfaction or waiver of the last to be satisfied or waived of the conditions set forth in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;7</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;8</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;9</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, other than those conditions that by their nature are to be satisfied at the Closing, but subject to the satisfaction or waiver of each of such conditions), or at such other time, date and place as Parent and the Company may mutually agree in writing. The date on which the Closing actually takes place is referred to as the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Closing Date</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.&#8221; Immediately prior to the Closing on the Closing Date, Parent shall file the Certificate of Designation with the office of the Secretary of State of the State of Delaware. At the Closing, (i) the Parties shall cause the First Merger to be consummated by executing and filing with the Secretary of State of the State of Delaware a certificate of merger with respect to the Merger, satisfying the applicable requirements of the DGCL and in form and substance attached hereto as </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Exhibit&#160;D-1</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and incorporated herein by reference (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">First Certificate of Merger</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) and (ii) the Parties shall cause the Second Merger to be consummated by executing and filing with the Secretary of State of the State of Delaware a certificate of merger with respect to the Second Merger, satisfying the applicable requirements of the DGCL and the DLLCA and in form and substance attached hereto as </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Exhibit&#160;D-2</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and incorporated herein by reference (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Second Certificate of Merger</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; and together with the First Certificate of Merger, the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Certificate of Merger</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;). The First Merger shall become effective at the time of the filing of such Certificate of Merger with the Secretary of State of the State of Delaware or at such later time as may be specified in such Certificate of Merger with the consent of Parent and the Company (the time as of which the Merger becomes effective being referred to as the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">First</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> </span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Effective Time</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;). The Second Merger shall become effective at the time of the filing of such Second Certificate of Merger with the Secretary of State of the State of Delaware or at such later time as may be specified in such Second Certificate of Merger with the consent of Parent and the Company (the time as of which the Second Merger becomes effective being referred to as the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Second Effective Time</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;).</span></p>
		<p class="ParaOverride-18" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;page-break-after:avoid;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">2.4<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Organizational Documents; Directors and Officers</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>At the First Effective Time:</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(i)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The certificate of incorporation of the First Step Surviving Corporation shall be amended and restated in the Merger to read as set forth on </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Exhibit&#160;A</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> to the Certificate of Merger, until thereafter amended as provided by the DGCL and such certificate of incorporation;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(ii)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The bylaws of the First Step Surviving Corporation shall be identical to the bylaws of the Company as in effect immediately prior to the First Effective Time, until thereafter amended as provided by the DGCL and such bylaws; and</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-15</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(iii)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>the directors and officers of the First Step Surviving Corporation, each to hold office in accordance with the certificate of incorporation and bylaws of the First Step Surviving Corporation, shall be such persons as shall be mutually agreed upon by Parent and the Company.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>At the Second Effective Time:</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(i)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The certificate of formation of the Surviving Entity shall be the certificate of formation of Second Merger Sub as in effect immediately prior to the Second Effective Time, until thereafter amended as provided by the DLLCA and such certificate of formation; provided, however, that at the Second Effective Time (as part of the Second Certificate of Merger), the certificate of formation shall be amended to (A) change the name of the Surviving Entity to &#8220;Oruka Therapeutics Operating Company, LLC,&#8221; and (B) make such other changes as are mutually agreed to by Parent and the Company;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(ii)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The limited liability company agreement of the Surviving Entity shall be amended and restated in its entirety to read identically to the limited liability company agreement of Second Merger Sub as in effect immediately prior to the Second Effective Time, until thereafter amended as provided by the DLLCA and such limited liability company agreement; provided, however, that following the Second Effective Time (but as soon thereafter as practicable), the limited liability company agreement shall be amended to change the name of the Surviving Entity to &#8220;Oruka Therapeutics Operating Company, LLC&#8221;;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(iii)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The certificate of incorporation of Parent shall be identical to the certificate of incorporation of Parent immediately prior to the Second Effective Time, until thereafter amended as provided by the DGCL and such certificate of incorporation; </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">however</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that at the Second Effective Time, Parent shall file an amendment to its certificate of incorporation to (i) change the name of Parent to &#8220;Oruka Therapeutics, Inc.&#8221;, (ii) effect the Nasdaq Reverse Split (to the extent applicable and necessary), (iii) increase the number of shares of Parent Common Stock that Parent is authorized to issue to a number mutually agreed between Parent and the Company, and (iv) make such other changes as are mutually agreeable to Parent and the Company (such amendment, the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Charter Amendment</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;);</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(iv)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The directors and officers of Parent, each to hold office in accordance with the certificate of incorporation and bylaws of Parent, shall be as set forth in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.12</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">; and</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(v)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The directors and officers of Surviving Entity, each to hold office in accordance with the certificate of formation and limited liability company agreement of Second Merger Sub, shall be as set forth in&#160;</span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.12</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#160;after giving effect to the provisions of&#160;</span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.12</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, or such other persons as shall be mutually agreed upon by Parent and the Company.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">2.5<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Conversion of Company, First Merger Sub and Second Merger Sub Equity Securities</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>At the First Effective Time, by virtue of the Merger and without any further action on the part of Parent, Merger Subs, the Company or any stockholder of the Company or Parent:</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(i)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>any shares of Company Capital Stock held as treasury stock immediately prior to the First Effective Time shall be canceled and retired and shall cease to exist, and no consideration shall be delivered in exchange therefor; and</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(ii)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>subject to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;2.5(c)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, (A) each share of Company Common Stock (including any shares of Company Common Stock issued pursuant to the Company Pre-Closing Financing) outstanding immediately prior to the First Effective Time (excluding shares of Company Capital Stock to be canceled pursuant to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;2.5(a)(i)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and excluding Dissenting Shares) shall be converted solely into the right to receive a number of shares of Parent Common Stock equal to the Exchange Ratio, and (B) each share of Company Preferred Stock outstanding immediately prior to the First Effective Time (excluding shares of Company Capital Stock to be canceled pursuant to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;2.5(a)(i)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and excluding Dissenting Shares) shall be converted solely into the right to receive a number of shares of Parent Convertible Preferred Stock equal to (x) the Exchange Ratio </span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:underline;">divided by</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> (y) 1,000 (collectively, the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Merger Consideration</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;).</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-16</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>If any shares of Company Capital Stock outstanding immediately prior to the First Effective Time are unvested or are subject to a repurchase option or a risk of forfeiture under any applicable restricted stock purchase agreement or other similar agreement with the Company, then the shares of Parent Capital Stock issued in exchange for such shares of Company Capital Stock will to the same extent be unvested and subject to the same repurchase option or risk of forfeiture, and such shares of Parent Capital Stock shall accordingly be marked with appropriate legends. The Company shall take all actions that may be necessary to ensure that, from and after the First Effective Time, Parent is entitled to exercise any such repurchase option or other right set forth in any such restricted stock purchase agreement or other agreement.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>No fractional shares of Parent Capital Stock shall be issued in connection with the Merger, and no certificates or scrip for any such fractional shares shall be issued. Any holder of Company Common Stock who would otherwise be entitled to receive a fraction of a share of Parent Common Stock (after aggregating all fractional shares of Parent Common Stock issuable to such holder) shall receive from Parent, in lieu of such fractional share and upon surrender by such holder of a letter of transmittal in accordance with </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;2.8</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and any accompanying documents as required therein: (i) one share of Parent Common Stock if the aggregate amount of fractional shares of Parent Common Stock such holder of Company Common Stock would otherwise be entitled to is equal to or exceeds 0.50; or (ii) no shares of Parent Common Stock if the aggregate amount of fractional shares of Parent Common Stock such holder of Company Common Stock would otherwise be entitled to is less than 0.50, with no cash being paid for any fractional share eliminated by such rounding. Any fractional shares of Parent Preferred Stock that a holder of Company Preferred Stock would otherwise be entitled to receive shall be aggregated with all fractional shares of Parent Preferred Stock issuable to such and any remaining fractional shares shall be, in lieu of such fractional share and upon surrender by such holder of a letter of transmittal in accordance with </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;2.8</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and any accompanying documents as required therein, rounded up to the nearest whole share of Parent Preferred Stock.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>All Company Options outstanding immediately prior to the First Effective Time shall be treated in accordance with </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.5(a)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. All Company Warrants outstanding immediately prior to the First Effective Time shall be treated in accordance with&#160;</span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.5(b)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(e)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Each share of common stock, $0.001 par value per share, of First Merger Sub issued and outstanding immediately prior to the First Effective Time shall be converted into and exchanged for one validly issued, fully paid and nonassessable share of common stock, $0.001 par value per share, of the First Step Surviving Corporation. Each book entry share of First Merger Sub evidencing ownership of any such shares shall, as of the First Effective Time, evidence ownership of such shares of common stock of the First Step Surviving Corporation.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(f)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>If, between the date of this Agreement and the First Effective Time, the outstanding Company Capital Stock or Parent Capital Stock shall have been changed into, or exchanged for, a different number of shares or a different class, by reason of any stock dividend, subdivision, reclassification, recapitalization, split (including the Nasdaq Reverse Split to the extent such split has not previously been taken into account in calculating the Exchange Ratio), combination or exchange of shares or other like change, the Exchange Ratio shall, to the extent necessary, be equitably adjusted to reflect such change to the extent necessary to provide the holders of Company Capital Stock, Company Options, Company Warrants and Parent Capital Stock with the same economic effect as contemplated by this Agreement prior to such stock dividend, subdivision, reclassification, recapitalization, split, combination or exchange of shares or other like change; </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">however</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that nothing herein will be construed to permit the Company or Parent to take any action with respect to Company Capital Stock or Parent Capital Stock, respectively, that is prohibited or not expressly permitted by the terms of this Agreement.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(g)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>At the Second Effective Time, by virtue of the Second Merger and without any action on the part of Parent, the First Step Surviving Corporation, Second Merger Sub or their respective stockholders, each share of the First Step Surviving Corporation issued and outstanding immediately prior to the Second Effective Time shall be canceled and extinguished without any conversion thereof and no payment or distribution shall be made with respect thereto.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">2.6<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Closing of the Company&#8217;s Transfer Books</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. At the First Effective Time: (a)&#160;all Company Capital Stock outstanding immediately prior to the First Effective Time shall be treated in accordance with </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;2.5(a)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, and all holders of certificates representing Company Capital Stock that were outstanding immediately prior to the First Effective Time shall cease to have any rights as stockholders of the Company and (b) the stock </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-17</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">transfer books of the Company shall be closed with respect to all Company Capital Stock outstanding immediately prior to the First Effective Time. No further transfer of any such Company Capital Stock shall be made on such stock transfer books after the First Effective Time.</span></p>
		<p class="ParaOverride-18" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;page-break-after:avoid;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">2.7<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Surrender of Company Capital Stock</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>On or prior to the Closing Date, Parent and the Company shall jointly select a reputable bank, transfer agent or trust company to act as exchange agent in the Merger (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Exchange Agent</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;). At the First Effective Time, Parent shall deposit with the Exchange Agent evidence of book-entry shares representing the shares of Parent Capital Stock issuable pursuant to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;2.5(a)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> in exchange for Company Capital Stock.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Promptly after the First Effective Time, the Parties shall cause the Exchange Agent to mail to the Persons who were record holders of shares of Company Capital Stock that were converted into the right to receive the Merger Consideration: (i) a letter of transmittal in customary form and containing such provisions as Parent may reasonably specify (including a provision confirming that delivery of physical stock certificates representing shares of Company Capital Stock, (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Stock Certificates</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) shall be effected, and risk of loss and title shall pass, only upon delivery of such Company Stock Certificates to the Exchange Agent) and (ii) instructions for effecting the surrender of Company Stock Certificates, or uncertificated shares of Company Capital Stock, in exchange for book-entry shares of Parent Capital Stock. Upon surrender of a Company Stock Certificate or other reasonable evidence of the ownership of uncertificated Company Capital Stock to the Exchange Agent for exchange, together with a duly executed letter of transmittal and such other documents as may be reasonably required by the Exchange Agent or Parent: (A) the holder of such Company Stock Certificate or uncertificated shares of Company Capital Stock shall be entitled to receive in exchange therefor book-entry shares representing the Merger Consideration (in a number of whole shares of Parent Capital Stock) that such holder has the right to receive pursuant to the provisions of </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;2.5(a)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;2.5(c)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and (B) the Company Stock Certificate or uncertificated shares of Company Capital Stock so surrendered shall be canceled. Until surrendered as contemplated by this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;2.7(b)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, each Company Stock Certificate or uncertificated shares of Company Capital Stock shall be deemed, from and after the First Effective Time, to represent only the right to receive book-entry shares of Parent Capital Stock representing the Merger Consideration. If any Company Stock Certificate shall have been lost, stolen or destroyed, Parent may, in its discretion and as a condition precedent to the delivery of any shares of Parent Capital Stock, require the owner of such lost, stolen or destroyed Company Stock Certificate to provide an applicable affidavit with respect to such Company Stock Certificate and post a bond indemnifying Parent against any claim suffered by Parent related to the lost, stolen or destroyed Company Stock Certificate or any Parent Capital Stock issued in exchange therefor as Parent may reasonably request.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>No dividends or other distributions declared or made with respect to Parent Capital Stock with a record date after the First Effective Time shall be paid to the holder of any unsurrendered Company Stock Certificate with respect to the shares of Parent Capital Stock that such holder has the right to receive in the Merger until such holder surrenders such Company Stock Certificate or uncertificated shares of Company Capital Stock or provides an affidavit of loss or destruction in lieu thereof in accordance with this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;2.7</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> (at which time such holder shall be entitled, subject to the effect of applicable abandoned property, escheat or similar Laws, to receive all such dividends and distributions, without interest).</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Any shares of Parent Capital Stock deposited with the Exchange Agent that remain undistributed to holders of Company Stock Certificates as of the date that is 180 days after the Closing Date shall be delivered to Parent upon demand, and any holders of Company Stock Certificates who have not theretofore surrendered their Company Stock Certificates or uncertificated shares of Company Capital Stock in accordance with this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;2.7</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> shall thereafter look only to Parent for satisfaction of their claims for Parent Capital Stock and any dividends or distributions with respect to shares of Parent Capital Stock.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(e)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>No Person shall be liable to any holder of any Company Stock Certificate or uncertificated shares of Company Capital Stock or to any other Person with respect to any shares of Parent Capital Stock (or dividends or distributions with respect thereto) or for any cash amounts delivered to any public official pursuant to any applicable abandoned property Law, escheat Law or similar Law.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-18</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">2.8<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Calculation of Net Cash and Company Valuation</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>No later than five (5) Business Days before the Closing, Parent will deliver to the Company a schedule (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> </span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Net Cash Schedule</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) setting forth, in reasonable detail, Parent&#8217;s good faith, estimated calculation of Parent Net Cash (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> </span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Net Cash Calculation</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) as of 11:59 p.m. on the Business Day prior to the Anticipated Closing Date (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Cash</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> </span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Determination Time</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) prepared and certified by Parent&#8217;s chief financial officer (or if there is no chief financial officer at such time, the principal financial and accounting officer for Parent). Parent shall make available to the Company (electronically to the greatest extent possible) as reasonably requested by the Company, the work papers and back-up materials used or useful in preparing the Parent Net Cash Schedule&#160;and, if reasonably requested by the Company, Parent&#8217;s internal finance personnel and its accountants and counsel at reasonable times and upon reasonable notice. The Parent Net Cash Calculation shall include Parent&#8217;s determination, as of the Cash Determination Time, of the defined terms in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;1.1(a)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> necessary to calculate the Exchange Ratio.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>No later than five (5) Business Days before the Closing, the Company will deliver to Parent a schedule (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Valuation Schedule</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) setting forth, in reasonable detail, the Company&#8217;s good faith, estimated calculations of the components of the Company Valuation (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Valuation Calculation</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) and the date of delivery of such schedule being (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Valuation Delivery Date</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) as of 11:59 p.m. on the last Business Day prior to the Anticipated Closing Date (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Valuation Determination Time</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) prepared and certified by the Company&#8217;s chief financial officer (or if there is no chief financial officer at such time, the principal financial and accounting officer for the Company). The Company shall make available to Parent, as reasonably requested by Parent, the work papers and back-up materials used or useful in preparing the Company Valuation Schedule&#160;and, if reasonably requested by Parent, the Company&#8217;s accountants and counsel at reasonable times and upon reasonable notice.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>No later than three (3) Business Days after the Cash Determination Time (the last day of such period, the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Response Date</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), the Company shall have the right to dispute any part of the Parent Net Cash Calculation by delivering a written notice to that effect to Parent (a &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Dispute Notice</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;). Any Dispute Notice shall identify in reasonable detail and to the extent known the nature and amounts of any proposed revisions to the Parent Net Cash Calculation and will be accompanied by reasonably detailed materials supporting the basis for such revisions.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>No later than three (3) Business Days after the Company Valuation Delivery Date (the last day of such period, the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Valuation Response Date</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), Parent shall have the right to dispute any part of the Company Valuation Calculation by delivering a written notice to that effect to the Company (a &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Valuation Dispute Notice</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;). Any Company Valuation Dispute Notice shall identify in reasonable detail and to the extent known the nature and amounts of any proposed revisions to the Company Valuation Calculation and will be accompanied by reasonably detailed materials supporting the basis for such revisions.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(e)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>If, on or prior to the Response Date, the Company notifies Parent in writing that it has no objections to the Parent Net Cash Calculation or, if on the Response Date, the Company fails to deliver a Dispute Notice as provided in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;2.8(c)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, then the Parent Net Cash Calculation as set forth in the Parent Net Cash Schedule&#160;shall be deemed to have been finally determined for purposes of this Agreement and to represent the Parent Net Cash at the Cash Determination Time for purposes of this Agreement.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(f)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>If, on or prior to the Company Valuation Response Date, Parent notifies the Company in writing that it has no objections to the Company Valuation Calculation or, if on the Company Valuation Response Date, Parent fails to deliver a Company Valuation Dispute Notice as provided in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;2.8(d)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, then the Company Valuation Calculation as set forth in the Company Valuation Schedule&#160;shall be deemed to have been finally determined for purposes of this Agreement and to represent the Company Valuation at the Company Valuation Determination Time for purposes of this Agreement.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(g)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>If the Company delivers a Dispute Notice on or prior to the Response Date, then Representatives of Parent and the Company shall promptly meet and attempt in good faith to resolve the disputed item(s) and negotiate an agreed-upon determination of Parent Net Cash, which agreed upon the Parent Net Cash amount shall be deemed to have been finally determined for purposes of this Agreement and to represent the Parent Net Cash at the Cash Determination Time for purposes of this Agreement.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-19</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(h)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>If Parent delivers a Company Valuation Dispute Notice on or prior to the Company Valuation Response Date, then Representatives of Parent and the Company shall promptly meet and attempt in good faith to resolve the disputed item(s) and negotiate an agreed-upon determination of the components of the Company Valuation, which agreed upon Company Valuation amount shall be deemed to have been finally determined for purposes of this Agreement and to represent the Company Valuation at the Company Valuation Determination Time for purposes of this Agreement.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(i)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>If Representatives of Parent and the Company are unable to negotiate an agreed-upon determination of Parent Net Cash as of the Cash Determination Time pursuant to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;2.8(g)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> or the components of Company Valuation as of the Company Valuation Determination Time pursuant to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;2.8(h)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> within three days after delivery of the Dispute Notice or the Company Valuation Dispute Notice, as applicable, (or such other period as Parent and the Company may mutually agree upon), then any remaining disagreements as to the calculation of Parent Net Cash or Company Valuation shall be referred to an independent auditor of recognized national standing jointly selected by Parent and the Company. If the parties are unable to select an independent auditor within five (5) days, then either Parent or the Company may thereafter request that the Boston, Massachusetts Office of the American Arbitration Association (&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">AAA</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) make such selection (either the independent auditor jointly selected by both parties or such independent auditor selected by the AAA, the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Accounting Firm</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;). Parent and the Company shall promptly deliver to the Accounting Firm the work papers and back-up materials used in preparing the Parent Net Cash Schedule&#160;and the Dispute Notice and the Company Valuation Schedule&#160;and the Company Valuation Dispute Notice, and Parent and the Company shall use commercially reasonable efforts to cause the Accounting Firm to make its determination within five&#160;(5) Business Days of accepting its selection. Parent and the Company shall be afforded the opportunity to present to the Accounting Firm any material related to the unresolved disputes and to discuss the issues with the Accounting Firm; </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">however</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that no such presentation or discussion shall occur without the presence of a Representative of each of Parent and the Company. The determination of the Accounting Firm shall be limited to the disagreements submitted to the Accounting Firm. The determination of the amount of Parent Net Cash or the components of the Company Valuation made by the Accounting Firm shall be made in writing delivered to each of Parent and the Company, shall be final and binding on Parent and the Company and shall (absent manifest error) be deemed to have been finally determined for purposes of this Agreement and to represent the Parent Net Cash at the Cash Determination Time or the components of the Company Valuation at the Company Valuation Determination Time for purposes of this Agreement. The Parties shall delay the Closing until the resolution of the matters described in this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;2.8(i)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The fees and expenses of the Accounting Firm shall be allocated between Parent and the Company in the same proportion that the disputed amount of the Parent Net Cash or the Company Valuation that was unsuccessfully disputed by such Party (as finally determined by the Accounting Firm) bears to the total disputed amount of the Parent Net Cash amount or the components of the Company Valuation. If this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;2.8(i)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> applies as to the determination of the Parent Net Cash at the Cash Determination Time or to the determination of the components of the Company Valuation at the Company Valuation Determination Time, as applicable, upon resolution of the matter in accordance with this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;2.8(i)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, the Parties shall not be required to determine Parent Net Cash or the Company Valuation again even though the Closing may occur later than the Anticipated Closing Date, except that either Parent and the Company may request a redetermination of Parent Net Cash or the Company Valuation if the Closing Date is more than thirty (30) days after the Anticipated Closing Date.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">2.9<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Further Action</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. If, at any time after the First Effective Time, any further action is determined by the Surviving Entity to be necessary or desirable to carry out the purposes of this Agreement or to vest the Surviving Entity with full right, title and possession of and to all rights and property of the Company, then the officers and directors of the Surviving Entity shall be fully authorized, and shall use their and its commercially reasonable efforts (in the name of the Company, in the name of First Merger Sub, in the name of Second Merger Sub, in the name of the Surviving Entity and otherwise) to take such action.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">2.10<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Intended Tax Treatment</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Parties acknowledge and agree that, for U.S. federal (and applicable state and local) income Tax purposes, the Merger is intended to qualify as a reorganization within the meaning of Section&#160;368(a) of the Code (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Intended Tax Treatment</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;). The Parties adopt this Agreement as a &#8220;plan of reorganization&#8221; within the meaning of Treasury Regulations Sections&#160;1.368-2(g) and 1.368-3.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">2.11<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Withholding</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Each of the Exchange Agent, Parent and the Surviving Entity shall be entitled to deduct and withhold from any consideration deliverable pursuant to this Agreement to any Person such amounts as are required to be deducted or withheld from such consideration under applicable Law; </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> that </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-20</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">the Exchange Agent, Parent and the Surviving Entity shall use commercially reasonable efforts to promptly notify such Persons of any intention to withhold any portion of such consideration and cooperate with such Persons to reduce or eliminate any such withholding to the extent permitted by applicable Law. To the extent such amounts are so deducted or withheld and remitted to the appropriate Governmental Authority, such amounts shall be treated for all purposes under this Agreement as having been paid to the Person to whom such amounts would otherwise have been paid. All payments made under this agreement that constitute compensation to employees for services for Tax purposes shall be made through the payroll of the Surviving Entity or Parent, as applicable.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">2.12<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Appraisal Rights</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Notwithstanding any provision of this Agreement to the contrary, shares of Company Capital Stock that are outstanding immediately prior to the First Effective Time and which are held by stockholders or owned by beneficial owners who have exercised and perfected appraisal rights for such shares of Company Capital Stock in accordance with the DGCL (collectively, the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Dissenting Shares</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) shall not be converted into or represent the right to receive the Merger Consideration described in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;2.5</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> attributable to such Dissenting Shares. Such stockholders or beneficial owners shall be entitled to receive payment of the fair value of such shares of Company Capital Stock held by them in accordance with the DGCL, unless and until such stockholders or beneficial owners fail to perfect or effectively withdraw or otherwise lose their appraisal rights under the DGCL. All Dissenting Shares held by stockholders or owned by beneficial owners who shall have failed to perfect or shall have effectively withdrawn or lost their right to appraisal of such shares of Company Capital Stock under the DGCL (whether occurring before, at or after the First Effective Time) shall thereupon be deemed to be converted into and to have become exchangeable for, as of the First Effective Time, the right to receive the Merger Consideration, without interest, attributable to such Dissenting Shares upon their surrender in the manner provided in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Sections&#160;2.5</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">2.7</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Company shall give Parent prompt written notice of any demands by dissenting stockholders or beneficial owners received by the Company, withdrawals of such demands and any other instruments served on the Company and any material correspondence received by the Company in connection with such demands, and Parent shall have the right to participate in all negotiations and proceedings with respect to such demands. The Company shall not, except with Parent&#8217;s prior written consent, not to be unreasonably withheld, delayed or conditioned, make any payment with respect to, or settle or offer to settle, any such demands, or approve any withdrawal of any such demands or agree to do any of the foregoing.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;3. </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Representations and Warranties of the Company</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Except as set forth in the written disclosure document delivered by the Company to Parent (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Disclosure Letter</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) concurrently with the execution of this Agreement, the Company represents and warrants to Parent and Merger Subs as follows:</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">3.1<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Due Organization; Subsidiaries</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Company is a corporation or other legal entity duly incorporated or otherwise organized, validly existing and in good standing under the Laws of the jurisdiction of its incorporation or organization and has all necessary power and authority: (i) to conduct its business in the manner in which its business is currently being conducted, (ii) to own or lease and use its property and assets in the manner in which its property and assets are currently owned or leased and used and (iii) to perform its obligations under all Contracts by which it is bound.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Company is duly licensed and qualified to do business, and is in good standing (to the extent applicable in such jurisdiction), under the Laws of all jurisdictions where the nature of its business in the manner in which its business is currently being conducted requires such licensing or qualification other than in jurisdictions where the failure to be so qualified individually or in the aggregate would not be reasonably expected to have a Company Material Adverse Effect.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Company has no Subsidiaries and the Company does not own any capital stock or membership interests of, or any equity, ownership or profit sharing interest of any nature in, or controls directly or indirectly, any other Entity. The Company is not and has never otherwise been, directly or indirectly, a party to, member of or participant in any partnership, joint venture or similar business entity. The Company has not agreed or is obligated to make, or is bound by any Contract under which it may become obligated to make, any </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-21</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">future investment in or capital contribution to any other Entity. The Company has not, at any time, been a general partner of, or has otherwise been liable for any of the debts or other obligations of, any general partnership, limited partnership or other Entity.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">3.2<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Organizational Documents</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Company has delivered to Parent accurate and complete copies of the Organizational Documents of the Company. The Company is not in breach or violation of its Organizational Documents in any material respect.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">3.3<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Authority; Binding Nature of Agreement</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Company has all necessary corporate power and authority to enter into and to perform its obligations under this Agreement and to consummate the Contemplated Transactions. The Company Board has (i) determined that the Contemplated Transactions are fair to, advisable and in the best interests of the Company and its stockholders, (ii) approved and declared advisable this Agreement and the Contemplated Transactions and (iii) determined to recommend, upon the terms and subject to the conditions set forth in this Agreement, that the stockholders of the Company vote to adopt this Agreement and thereby approve the Contemplated Transactions. This Agreement has been duly executed and delivered by the Company and assuming the due authorization, execution and delivery by Parent, First Merger Sub and Second Merger Sub, constitutes the legal, valid and binding obligation of the Company, enforceable against the Company in accordance with its terms, subject to the Enforceability Exceptions.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">3.4<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Vote Required</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The affirmative vote (or written consent) of (i)&#160;the holders of a majority of the shares of Company Capital Stock outstanding on the record date, voting as a single class on an as-converted&#160;basis, and (ii) the holders of a majority of the shares of Company Series A Preferred Stock outstanding on the record date and entitled to vote thereon, voting as a separate class, is the only vote of the holders of any class or series of Company Capital Stock necessary to adopt and approve this Agreement and approve the Contemplated Transactions (collectively, the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Required Company Stockholder Vote</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;).</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">3.5<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Non-Contravention; Consents</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Subject to obtaining the Required Company Stockholder Vote, compliance with any applicable requirements of the HSR Act (if applicable) and the filing of the Certificate of Merger and Certificate of Designation required by the DGCL or DLLCA, neither (x) the execution, delivery or performance of this Agreement by the Company, nor (y) the consummation of the Contemplated Transactions, will directly or indirectly (with or without notice or lapse of time):</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(i)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>contravene, conflict with or result in a violation of any of the provisions of the Company&#8217;s Organizational Documents;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(ii)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>contravene, conflict with or result in a material violation of, or give any Governmental Authority or other Person the right to challenge the Contemplated Transactions or to exercise any remedy or obtain any relief under, any Law or any Order by which the Company, or any of the assets owned or used by the Company, is subject;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(iii)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>contravene, conflict with or result in a material violation of any of the terms or requirements of, or give any Governmental Authority the right to revoke, withdraw, suspend, cancel, terminate or modify, any Governmental Authorization that is held by the Company or that otherwise relates to the business of the Company, or any of the assets owned, leased or used by the Company;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(iv)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>contravene, conflict with or result in a violation or breach of, or result in a default under, any provision of any Company Material Contract, or give any Person the right to: (A)&#160;declare a default or exercise any remedy under any Company Material Contract, (B) any material payment, rebate, chargeback, penalty or change in delivery schedule under any Company Material Contract, (C) accelerate the maturity or performance of any Company Material Contract or (D) cancel, terminate or modify any term of any Company Material Contract, except in the case of any nonmaterial breach, default, penalty or modification; or</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(v)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>result in the imposition or creation of any Encumbrance upon or with respect to any asset owned or used by the Company (except for Permitted Encumbrances).</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-22</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Except for (i) the Required Company Stockholder Vote, (ii) the filing of the Certificate of Merger and Certificate of Designation with the Secretary of State of the State of Delaware pursuant to the DGCL or DLLCA, (iii) compliance with any applicable requirements of the HSR Act (if applicable) and (iv)&#160;such consents, waivers, approvals, orders, authorizations, registrations, declarations and filings as may be required under applicable federal and state securities laws, the Company was not, is not, nor will be required to make any filing with or give any notice to, or to obtain any Consent from, any Person in connection with (x) the execution, delivery or performance of this Agreement or (y) the consummation of the Contemplated Transactions.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>No state takeover statute or similar Law applies or purports to apply to the Merger, this Agreement, the Company Stockholder Support Agreements or any of the Contemplated Transactions.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">3.6<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Capitalization.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The authorized capital stock of the Company consists of (i) 65,000,000 shares of Company Common Stock of which 9,460,019 shares have been issued and are outstanding as of the date hereof and (ii) 20,000,000 shares of Company Preferred Stock, of which 20,000,000 shares have been designated Series A Preferred Stock and 20,000,000 have been issued and are outstanding as of the date hereof. The Company does not hold any shares of its capital stock in its treasury. As of the date of this Agreement, the Company&#8217;s capital stock is held by the Persons and in the amounts set forth in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;3.6(a)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Company Disclosure Letter, which further sets forth for each such Person (i) the&#160;name of such Person and the number of shares held, (ii)&#160;the class and series of such shares, (iii)&#160;the number of the applicable book-entry positions representing such shares or the number of the certificate representing such shares, (iv)&#160;whether such Person is or has ever been an employee, and (v) the state of residence of such Person. Each share of Company Preferred Stock is convertible into one share of Company Common Stock. There are no declared or accrued but unpaid dividends with respect to any shares of the Company&#8217;s capital stock and the Company has never declared or paid any dividend or other distribution.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>All of the outstanding Company Capital Stock as set out in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;3.6(a)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Company Disclosure Letter have been duly authorized and validly issued, and are fully paid and nonassessable and are free of any Encumbrances other than Encumbrances set forth in the Organizational Documents or under applicable securities Laws. None of the outstanding Company Capital Stock is entitled or subject to any preemptive right, right of participation, right of maintenance or any similar right and none of the outstanding Company Capital Stock is subject to any right of first refusal in favor of the Company. Except as contemplated herein, there is no Company Contract relating to the voting or registration of, or restricting any Person from purchasing, selling, pledging or otherwise disposing of (or granting any option or similar right with respect to), any Company Capital Stock. The Company is not under any obligation, nor is it bound by any Contract pursuant to which it may become obligated, to repurchase, redeem or otherwise acquire any outstanding Company Capital Stock or other securities. </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;3.6(b)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Company Disclosure Letter accurately and completely describes all repurchase rights held by the Company with respect to Company Capital Stock (including shares issued pursuant to the exercise of stock options) and specifies which of those repurchase rights are currently exercisable.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Except for the Company Stock Plans and except as set forth on </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;3.6(c)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Company Disclosure Letter, the Company does not have any stock option plan or any other plan, program, agreement or arrangement providing for any equity-based compensation for any Person. </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;3.6(c)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Company Disclosure Letter sets forth the following information with respect to each Company Option outstanding as of the date hereof: (i) the name of the holder, (ii) the number of shares of Company Common Stock subject to such Company Option as of the date hereof, (iii) the exercise price of such Company Option, (iv) the date on which such Company Option was granted, (v) the applicable vesting schedule, including any acceleration provisions, (vi)&#160;the date on which such Company Option expires, (vii) whether such Company Option is intended to be an &#8220;incentive stock option&#8221; (as defined in the Code) or a nonqualified stock option and (viii) in the case of a Company Option, the plan pursuant to which such Company Option was granted. The Company has made available to Parent accurate and complete copies of equity incentive plans pursuant to which the Company has equity-based awards, the forms of all award agreements evidencing such equity-based awards and evidence of board and stockholder approval of the Company Stock Plans and any amendments thereto.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Except for the outstanding Company Options or as set forth on </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;3.6(d)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Company Disclosure Letter, there is no: (i) outstanding subscription, option, call, warrant or right (whether or not currently exercisable) to acquire any Company Capital Stock or other securities of the Company, (ii) outstanding security, instrument or obligation that is or may become convertible into or exchangeable for any shares of the </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-23</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">capital stock or other securities of the Company, (iii)&#160;stockholder rights plan (or similar plan commonly referred to as a &#8220;poison pill&#8221;) or Contract under which the Company is or may become obligated to sell or otherwise issue any Company Capital Stock or any other securities or (iv) condition or circumstance that may give rise to or provide a basis for the assertion of a claim by any Person to the effect that such Person is entitled to acquire or receive any shares of capital stock or other securities of the Company. There are no outstanding or authorized stock appreciation, phantom stock, profit participation or other similar rights with respect to the Company.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(e)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>All outstanding Company Capital Stock, Company Options and other securities of the Company have been issued and granted in compliance in all material respects with (i) all applicable securities laws and other applicable Law and (ii) all requirements set forth in applicable Contracts.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(f)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Company Capital Stock are uncertificated.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">3.7<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Financial Statements</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;3.7(a)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Company Disclosure Letter includes true and complete copies of the Company&#8217;s budget overview for March 2024 (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Budget</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;).</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Company maintains a system of internal accounting controls designed to provide reasonable assurance that: (i) transactions are executed in accordance with management&#8217;s general or specific authorizations, (ii) transactions are recorded as necessary to permit preparation of the financial statements of the Company in conformity with GAAP and to maintain accountability of the Company&#8217;s assets, (iii) access to the Company&#8217;s assets is permitted only in accordance with management&#8217;s general or specific authorization and (iv)&#160;the recorded accountability for the Company&#8217;s assets is compared with the existing assets at regular intervals and appropriate action is taken with respect to any differences. The Company maintains internal controls consistent with the practices of similarly situated private companies over financial reporting that provides reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;3.7(c)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Company Disclosure Letter lists, and the Company has delivered to Parent accurate and complete copies of the documentation creating or governing, all securitization transactions and &#8220;off-balance sheet arrangements&#8221; (as defined in Item 303(c) of Regulation S-K under the Exchange Act) effected by the Company.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>There have been no formal internal investigations regarding financial reporting or accounting policies and practices discussed with, reviewed by or initiated at the direction of the chief executive officer, chief financial officer or general counsel of the Company, the Company Board or any committee thereof. Neither the Company nor its independent auditors have identified (i) any significant deficiency or material weakness in the design or operation of the system of internal accounting controls utilized by the Company, (ii) any fraud, whether or not material, that involves the Company, the Company&#8217;s management or other employees who have a role in the preparation of financial statements or the internal accounting controls utilized by the Company or (iii) any claim or allegation regarding any of the foregoing.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">3.8<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Absence of Changes</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Except as set forth on </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;3.8</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Company Disclosure Letter, between the date of its incorporation and the date of this Agreement, the Company has conducted its business only in the Ordinary Course of Business (except for the execution and performance of this Agreement and the discussions, negotiations and transactions related thereto) and there has not been any (a) Company Material Adverse Effect or (b) action, event or occurrence that would have required consent of Parent pursuant to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;5.2(b)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of this Agreement had such action, event or occurrence taken place after the execution and delivery of this Agreement.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">3.9<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Absence of Undisclosed Liabilities</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Since the date of its incorporation, the Company does not have any liability, indebtedness, obligation, expense, claim, deficiency, guaranty or endorsement of any kind, whether accrued, absolute, contingent, matured, unmatured or otherwise (each a &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Liability</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), except for: (a) Liabilities disclosed, reflected or reserved against in the Company Budget, (b) normal and recurring current Liabilities that have been incurred by the Company since the date of the Company Budget in the Ordinary Course of Business (none of which relates to any breach of contract, breach of warranty, tort, infringement or violation of Law), (c) Liabilities for performance of obligations of the Company under Company Contracts, (d) Liabilities incurred in connection with the Contemplated Transactions and the Subscription Agreement, (e)&#160;Liabilities described in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;3.9</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Company Disclosure Letter and (f) those Liabilities that are not material to the Company.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-24</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">3.10<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Title to Assets</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Company owns and has good and valid title to, or, in the case of leased properties and assets, valid leasehold interests in, all tangible properties or tangible assets and equipment used or held for use in its business or operations or purported to be owned by it, including: (a) all tangible assets reflected on the Company Budget and (b) all other tangible assets reflected in the books and records of the Company as being owned by the Company. All of such assets are owned or, in the case of leased assets, leased by the Company free and clear of any Encumbrances, other than Permitted Encumbrances.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">3.11<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Real Property; Leasehold</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Company does not own and has never owned any real property, nor is the Company party to any agreement to purchase or sell any real property. The Company has made available to Parent (a) an accurate and complete list of&#160;all real properties with respect to which the Company directly or indirectly holds a valid leasehold interest as well as any other real estate that is in the possession of or leased by the Company and (b)&#160;copies of all leases under which any such real property is possessed (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> </span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Real Estate Leases</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), each of which is in full force and effect, with no existing material default thereunder by the Company or to the Company&#8217;s Knowledge, the other party thereto.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">3.12<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Intellectual Property</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;3.12(a)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Company Disclosure Letter is an accurate, true and complete listing of all Company Registered IP.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;3.12(b)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Company Disclosure Letter accurately identifies (i) all Company Contracts pursuant to which any Company IP Rights are licensed to the Company (other than (A) any non-customized software that (1) is so licensed solely in executable or object code form pursuant to a nonexclusive, internal use software license and other Intellectual Property associated with such software and (2)&#160;is not incorporated into, or material to the development, manufacturing or distribution of, any of the Company&#8217;s products or services, (B) any Intellectual Property licensed on a nonexclusive basis ancillary to the purchase or use of services, equipment, reagents or other materials, (C) any confidential information provided under confidentiality agreements and (D) agreements between Company and its employees in Company&#8217;s standard form thereof) and (ii)&#160;whether the license or licenses granted to the Company are exclusive or nonexclusive.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;3.12(c)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Company Disclosure Letter accurately identifies each Company Contract pursuant to which any Person has been granted any license or covenant not to sue under, or otherwise has received or acquired any right (whether or not currently exercisable) or interest in, any Company IP Rights (other than (i) any confidential information provided under confidentiality agreements and (ii) any Company IP Rights nonexclusively licensed to academic collaborators, suppliers or service providers for the sole purpose of enabling such academic collaborator, supplier or service providers to provide services for the Company&#8217;s benefit).</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Company is not bound by, and no Company IP Rights are subject to, any Contract containing any covenant or other provision that in any way limits or restricts the ability of the Company to use, exploit, assert or enforce any Company IP Rights anywhere in the world.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(e)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Company exclusively owns all right, title and interest to and in Company IP Rights (other than (i) Company IP Rights licensed to the Company, or co-owned rights each as identified in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;3.12(e)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Company Disclosure Letter, (ii) any non-customized software that (A) is licensed to the Company solely in executable or object code form pursuant to a nonexclusive, internal use software license and other Intellectual Property associated with such software and (B) is not incorporated into, or material to the development, manufacturing or distribution of, any of the Company&#8217;s products or services and (iii) any Intellectual Property licensed on a nonexclusive basis ancillary to the purchase or use of equipment, reagents or other materials), in each case, free and clear of any Encumbrances (other than Permitted Encumbrances). Without limiting the generality of the foregoing:</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(i)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>All documents and instruments necessary to register or apply for or renew registration of Company Registered IP have been validly executed, delivered and filed in a timely manner with the appropriate Governmental Authority.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-25</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(ii)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Each Person who is or was an employee or contractor of the Company and who is or was involved in the creation or development of any Intellectual Property for the Company has signed a valid, enforceable agreement containing a present assignment of such Intellectual Property to the Company and confidentiality provisions protecting trade secrets and confidential information of the Company.</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(iii)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>To the Knowledge of the Company, no current or former stockholder, officer, director or employee of the Company has any claim, right (whether currently exercisable, or exercisable in the future) or interest to or in any Company IP Rights purported to be owned by the Company. To the Knowledge of the Company, no employee of the Company is (a) bound by or otherwise subject to any Contract restricting him or her from performing his or her duties for the Company or (b) in breach of any Contract with any former employer or other Person concerning Company IP Rights purported to be owned by the Company or confidentiality provisions protecting trade secrets and confidential information comprising Company IP Rights purported to be owned by the Company.</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(iv)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>No funding, facilities or personnel of any Governmental Authority or any university, college, research institute or other educational institution were used, directly or indirectly, to develop or create, in whole or in part, any Company IP Rights in which the Company has an ownership interest, except for any such funding or use of facilities or personnel that does not result in such Governmental Authority or institution owning such Company IP Rights or the right to receive royalties or other remuneration for the practice of such Company IP Rights as of the date of this Agreement.</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(v)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Company has taken reasonable steps to maintain the confidentiality of and otherwise protect and enforce its rights in all proprietary information that the Company holds, or purports to hold, as confidential or a trade secret.</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(vi)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Company has not assigned or otherwise transferred ownership of, or agreed to assign or otherwise transfer ownership of, any Company IP Rights to any other Person.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(f)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Company has delivered or made available to Parent, a complete and accurate copy of all Company IP Rights Agreements. With respect to each of the Company IP Rights Agreements: (i) each such agreement is valid and binding on the Company and in full force and effect, (ii) the Company has not received any written notice of termination or cancellation under such agreement, or received any written notice of breach or default under such agreement, which breach has not been cured or waived and (iii) the Company, and to the Knowledge of the Company, no other party to any such agreement, is not in breach or default thereof in any material respect.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(g)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The manufacture, marketing, offering for sale, sale, importation, use or intended use or other disposal of any product as currently sold or under development by the Company does not violate any license or agreement between the Company and any other third party, and, to the Knowledge of the Company, does not infringe or misappropriate any valid and issued Patent right or other Intellectual Property of any other Person, which infringement or misappropriation would reasonably be expected to have a Company Material Adverse Effect. To the Knowledge of the Company, no third party is infringing upon any Patents owned by Company within the Company IP Rights, or otherwise violating any Company IP Rights Agreement.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(h)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>As of the date of this Agreement, Company is not a party to any Legal Proceeding (including, but not limited to, opposition, interference or other proceeding in any patent or other government office) contesting the validity, enforceability, claim construction, ownership or right to use, sell, offer for sale, license or dispose of any Company IP Rights. The Company has not received any written notice asserting that any Company IP Rights or the proposed use, sale, offer for sale, license or disposition of products, methods or processes claimed or covered thereunder infringes or misappropriates or violates the rights of any other Person or that the Company has otherwise infringed, misappropriated or otherwise violated any Intellectual Property of any Person. None of the Company IP Rights is subject to any outstanding order of, judgment of, decree of or agreement with any Governmental Authority that limits the ability of the Company to exploit any Company IP Rights.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-26</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(i)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Each item of Company Registered IP is and at all times has been filed and maintained in compliance in all material respects with all applicable Law and all filings, payments and other actions required to be made or taken to maintain such item of Company Registered IP in full force and effect have been made by the applicable deadline. To the Knowledge of the Company, all Company Registered IP that is issued or granted is valid and enforceable.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(j)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>To the Knowledge of the Company, no trademark (whether registered or unregistered) or trade name owned, used or applied for by the Company conflicts or interferes with any trademark (whether registered or unregistered) or trade name owned, used or applied for by any other Person. None of the goodwill associated with or inherent in any trademark (whether registered or unregistered) in which the Company has or purports to have an ownership interest has been impaired as determined by the Company in accordance with GAAP.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(k)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Except as set forth in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Sections&#160;3.12(b),</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">3.12(c)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> or </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">3.12(k)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Company Disclosure Letter or as contained in &#8220;off-the-shelf&#8221; license agreements entered into in the Ordinary Course of Business by the Company, (i) the Company is not bound by any Contract to indemnify, defend, hold harmless or reimburse any other Person with respect to any Intellectual Property infringement, misappropriation, or similar claim which is material to the Company, taken as a whole and (ii) the Company has never assumed, or agreed to discharge or otherwise take responsibility for, any existing or potential liability of another Person for infringement, misappropriation, or violation of any Intellectual Property right, which assumption, agreement or responsibility remains in force as of the date of this Agreement.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(l)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Company is not party to any Contract that, as a result of such execution, delivery and performance of this Agreement, will cause the grant of any license or other right to any Company IP Rights, result in breach of, default under or termination of such Contract with respect to any Company IP Rights, or impair the right of the Company or the Surviving Entity and its Subsidiaries to use, sell or license or enforce any Company IP Rights or portion thereof, except for the occurrence of any such grant or impairment that would not individually or in the aggregate, reasonably be expected to result in a Company Material Adverse Effect.</span></p>
		<p class="ParaOverride-18" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;page-break-after:avoid;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">3.13<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Agreements, Contracts and Commitments</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;3.13(a)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Company Disclosure Letter lists the following Company Contracts in effect as of the date of this Agreement other than the Subscription Agreement (each, a &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Material Contract</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; and collectively, the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Material Contracts</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;):</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(i)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>each Company Contract relating to any agreement of indemnification or guaranty not entered into in the Ordinary Course of Business;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(ii)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>each Company Contract containing (A) any covenant limiting the freedom of the Company or the Surviving Entity to engage in any line of business or compete with any Person, or limiting the development, manufacture or distribution of the Company&#8217;s products or services (B)&#160;any most-favored pricing arrangement, (C) any exclusivity provision or (D) any non-solicitation provision;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(iii)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>each Company Contract (A) pursuant to which any Person granted the Company an exclusive license under any Intellectual Property, or (B) pursuant to which the Company granted any Person an exclusive license under any Company IP Rights;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(iv)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>each Company Contract relating to capital expenditures and requiring payments after the date of this Agreement in excess of $100,000 pursuant to its express terms and not cancelable without penalty;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(v)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>each Company Contract containing any royalty, dividend or similar arrangement based on the revenues or profits of the Company, any of its Subsidiaries, or of a product;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(vi)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>each Company Contract relating to the disposition or acquisition of material assets or any ownership interest in any Entity, in each case, involving payments in excess of $100,000 after the date of this Agreement;</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-27</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(vii)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>each Company Contract relating to any mortgages, indentures, loans, notes or credit agreements, security agreements or other agreements or instruments relating to the borrowing of money or extension of credit in excess of $100,000 or creating any material Encumbrances with respect to any assets of the Company or any loans or debt obligations with officers or directors of the Company;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(viii)<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>each Company Contract requiring payment by or to the Company after the date of this Agreement in excess of $100,000 pursuant to its express terms relating to: (A)&#160;any distribution agreement (identifying any that contain exclusivity provisions), (B) any agreement involving provision of services or products with respect to any pre-clinical or clinical development activities of the Company, (C) any dealer, distributor, joint marketing, alliance, joint venture, cooperation, development or other agreement currently in force under which the Company has continuing obligations to develop or market any product, technology or service, or any agreement pursuant to which the Company has continuing obligations to develop any Intellectual Property that will not be owned, in whole or in part, by the Company or (D) any Contract to license any patent, trademark registration, service mark registration, trade name or copyright registration to or from any third party to manufacture or produce any product, service or technology of the Company or any Contract to sell, distribute or commercialize any products or service of the Company, in each case, except for Company Contracts entered into in the Ordinary Course of Business;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(ix)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>each Company Contract with any Person, including any financial advisor, broker, finder, investment banker or other Person, providing advisory services to the Company in connection with the Contemplated Transactions and requiring payments by Company after the date in this Agreement in excess of $100,000 pursuant to its express terms;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(x)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>each Company Contract to which the Company is a party or by which any of its assets and properties is currently bound, which involves annual obligations of payment by, or annual payments to, the Company in excess of $100,000;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(xi)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>each Company Contract entered into in settlement of any Legal Proceeding or other dispute pursuant to which the Company or any of its Subsidiaries has outstanding obligations to pay consideration in excess of $100,000;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(xii)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>any other Company Contract that is not terminable at will (with no penalty or payment) by the Company, and (A) which involves payment or receipt by the Company after the date of this Agreement under any such agreement, contract or commitment of more than $100,000 in the aggregate, or obligations after the date of this Agreement in excess of $100,000 in the aggregate or (B) that is material to the business or operations of the Company taken as a whole; or</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(xiii)<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Company Real Estate Leases.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Company has delivered or made available to Parent accurate and complete copies of all Company Material Contracts, including all amendments thereto. There are no Company Material Contracts that are not in written form. The Company has not, nor to the Company&#8217;s Knowledge, as of the date of this Agreement has any other party to a Company Material Contract, breached, violated or defaulted under, or received notice that it breached, violated or defaulted under, any of the terms or conditions of any Company Material Contract in such a manner, and, if such Company Material Contract provides for a cure period, the Company or such other party fails to have cured such breach, violation or default, so that any other party or the Company, as the case may be, is permitted to modify, cancel or terminate any such Company Material Contract, or would permit any other party to seek damages which would reasonably be expected to have a Company Material Adverse Effect. As to the Company, as of the date of this Agreement, each Company Material Contract is valid, binding, enforceable and in full force and effect, subject to the Enforceability Exceptions. No Person is renegotiating, or has a right pursuant to the terms of any Company Material Contract to change, any material amount paid or payable to the Company under any Company Material Contract or any other material term or provision of any Company Material Contract.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-28</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">3.14<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Compliance; Permits; Restrictions</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Company is, and has been in material compliance with all applicable Laws. No investigation, claim, suit, proceeding, audit, Order or other Legal Proceeding or action by any Governmental Authority is pending or, to the Knowledge of the Company, threatened against the Company. There is no agreement or Order binding upon the Company which (i) has or would reasonably be expected to have the effect of prohibiting or materially impairing any business practice of the Company, any acquisition of material property by the Company or the conduct of business by the Company as currently conducted, (ii) is reasonably likely to have an adverse effect on the Company&#8217;s ability to comply with or perform any covenant or obligation under this Agreement or (iii) is reasonably likely to have the effect of preventing, delaying, making illegal or otherwise interfering with the Contemplated Transactions.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Except for matters regarding the U.S. Food and Drug Administration (or any successor agency thereto) (&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">FDA</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) or other comparable Governmental Authority responsible for regulation of the development, testing, manufacturing, processing, storage, labeling, sale, marketing, advertising, distribution and importation or exportation of drug or medical device products (&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Drug/Device Regulatory Agency</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), the Company holds all required Governmental Authorizations for the operation of the business of the Company as currently conducted (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Permits</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;). </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;3.14(b)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Company Disclosure Letter identifies each Company Permit. The Company is in material compliance with the terms of the Company Permits. No Legal Proceeding is pending or, to the Knowledge of the Company, threatened, which seeks to revoke, substantially limit, suspend or materially modify any Company Permit. The rights and benefits of each Company Permit will be available to the Surviving Entity or its Subsidiaries, as applicable, immediately after the Second Effective Time on terms substantially identical to those enjoyed by the Company as of the date of this Agreement and immediately prior to the First Effective Time.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>There are no Legal Proceedings pending or, to the Knowledge of the Company, threatened with respect to an alleged violation by the Company of the Federal Food, Drug, and Cosmetic Act (&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">FDCA</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), the Public Health Service Act (&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">PHSA</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), FDA regulations adopted thereunder, the Controlled Substances Act or any other similar Law promulgated by a Drug/Device Regulatory Agency.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Company holds all required Governmental Authorizations issuable by any Drug/Device Regulatory Agency necessary for the conduct of the business of the Company as currently conducted, and the development, testing, manufacturing, processing, storage, labeling, sale, marketing, advertising, distribution and importation or exportation, as currently conducted, of any of its products or product candidates (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Product Candidates</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) (collectively, the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Regulatory Permits</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) and no such Company Regulatory Permit has been (i) revoked, withdrawn, suspended, cancelled or terminated or (ii) modified in any adverse manner, other than immaterial adverse modifications. </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;3.14(d)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Company Disclosure Letter identifies each Company Regulatory Permit. The Company has timely maintained and is in compliance in all material respects with the Company Regulatory Permits and has not received any written notice or correspondence or, to the Knowledge of the Company, other communication from any Drug/Device Regulatory Agency regarding (A) any material violation of or failure to comply materially with any term or requirement of any Company Regulatory Permit or (B) any revocation, withdrawal, suspension, cancellation, termination or material modification of any Company Regulatory Permit. The Company has made available to Parent all information requested by Parent in the Company&#8217;s possession or control relating to material Company Product Candidates and the development, testing, manufacturing, processing, storage, labeling, sale, marketing, advertising, distribution and importation or exportation of the Company Product Candidates, including but not limited to complete copies of the following (to the extent there are any): (x) adverse event reports; preclinical, clinical and other study reports and material study data; inspection reports, notices of adverse findings, untitled letters, warning letters, filings and letters and other written correspondence to and from any Drug/Device Regulatory Agency; and meeting minutes with any Drug/Device Regulatory Agency and (y) similar reports, material study data, notices, letters, filings, correspondence and meeting minutes with any other Governmental Authority. All such information is accurate and complete in all material respects.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(e)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>All clinical, preclinical and other studies and tests conducted by or on behalf of, or sponsored by, the Company, or in which the Company or its current products or product candidates, including the Company Product Candidates, have participated, were, and, if still pending, are being conducted in accordance in all material respects with standard medical and scientific research procedures, in accordance in all material respects </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-29</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">with the applicable protocols and in compliance in all material respects with the applicable regulations of the Drug/Device Regulatory Agencies and other applicable Law, including 21 C.F.R. Parts 11, 50, 54, 56, 58, 312 and 812. The Company has not received any written notices, correspondence or other communications from any Drug/Device Regulatory Agency, Governmental Authority, institutional review board, ethics committee or safety monitoring committee requiring, or to the Knowledge of the Company threatening to initiate, any action to place a clinical hold order on, or otherwise terminate, delay or suspend any clinical studies conducted by or on behalf of, or sponsored by, the Company or in which the Company or its current products or product candidates, including the Company Product Candidates, have participated. Further, no clinical investigator, researcher or clinical staff participating in any clinical study conducted by or, to the Knowledge of the Company, on behalf of the Company has been disqualified from participating in studies involving the Company Product Candidates, and to the Knowledge of the Company, no such administrative action to disqualify such clinical investigators, researchers or clinical staff has been threatened or is pending.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(f)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Company is not, and to the Knowledge of the Company, no contract manufacturer with respect to any Company Product Candidate, is the subject of any pending or, to the Knowledge of the Company, threatened investigation in respect of its business or products, including Company Product Candidates, by the FDA pursuant to its &#8220;Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities&#8221; Final Policy set forth in 56 Fed. Reg. 46191 (September 10, 1991) and any amendments thereto or by any other Drug/Device Regulatory Agency under a comparable policy. The Company has not, and to the Knowledge of the Company, no contract manufacturer, nor their respective officers, employees or agents, with respect to any Company Product Candidate has committed any acts, made any statement or failed to make any statement, in each case in respect of its business or products that would violate the FDA&#8217;s &#8220;Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities&#8221; Final Policy, and any amendments thereto or a comparable policy of any other Drug/Device Regulatory Agency. None of the Company, and to the Knowledge of the Company, any contract manufacturer with respect to any Company Product Candidate, or any of their respective officers, employees or agents is currently or has been debarred, convicted of any crime or is engaging or has engaged in any conduct that could result in a debarment or exclusion under (i) 21 U.S.C. Section&#160;335a or (ii) any similar applicable Law. To the Knowledge of the Company, no debarment or exclusionary claims, actions, proceedings or investigations in respect of their business or products are pending or threatened against the Company, and to the Knowledge of the Company, any contract manufacturer with respect to any Company Product Candidate, or any of their respective officers, employees or agents.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(g)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>All manufacturing operations conducted by, or to the Knowledge of the Company, for the benefit of the Company in connection with any Company Product Candidate have been and are being conducted in compliance in all material respects with applicable Laws, including the FDA&#8217;s standards for current good manufacturing practices, including applicable requirements contained in 21 C.F.R. Parts 210, 211 and 600-610 and the respective counterparts thereof promulgated by Governmental Authorities in countries outside the United States.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(h)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Neither the Company nor, to the Knowledge of the Company, any manufacturing site of a contract manufacturer or laboratory, with respect to any Company Product Candidate, (i) is subject to a Drug/Device Regulatory Agency shutdown or import or export prohibition or (ii) has received any Form FDA 483, notice of violation, warning letter, untitled letter or similar correspondence or notice from the FDA or other Drug/Device Regulatory Agency alleging or asserting noncompliance with any applicable Law, in each case, that have not been complied with or closed to the satisfaction of the relevant Drug/Device Regulatory Agency, and, to the Knowledge of the Company, neither the FDA nor any other Drug/Device Regulatory Agency is considering such action.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">3.15<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Legal Proceedings; Orders</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>There is no pending Legal Proceeding and, to the Knowledge of the Company, no Person has threatened in writing to commence any Legal Proceeding: (i) that involves the Company or any of its Subsidiaries or any Company Associate (in his or her capacity as such) or any of the material assets owned or used by the Company or any of its Subsidiaries or (ii) that challenges, or that may have the effect of preventing, delaying, making illegal or otherwise interfering with, the Contemplated Transactions.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-30</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>There is no Order to which the Company or any of its Subsidiaries, or any of the material assets owned or used by the Company or any of its Subsidiaries, is subject. To the Knowledge of the Company, no officer or Company Key Employee is subject to any Order that prohibits such officer or Company Key Employee from engaging in or continuing in any conduct, activity or practice relating to the Company or any of its Subsidiaries or any material assets owned or used by the Company or any of its Subsidiaries.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">3.16<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Tax Matters</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Company has timely filed (or caused to be timely filed) all income Tax Returns and all other material Tax Returns required to be filed by the Company under applicable Law (taking into account any applicable extensions). All such Tax Returns were true, correct and complete in all material respects. Subject to exceptions as would not be material, no claim has been made by a Governmental Authority in a jurisdiction where the Company does not file Tax Returns that the Company is subject to taxation by that jurisdiction.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>All material amounts of Taxes due and owing by the Company (whether or not shown on any Tax Return) have been timely paid (taking into account any applicable extensions).</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Company has withheld and paid to the appropriate Governmental Authority all material Taxes required to have been withheld and paid in connection with any amounts paid or owing to any employee, independent contractor, creditor, stockholder or other third party.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>There are no Encumbrances for a material amount of Taxes (other Encumbrances described in clause&#160;(a) of the definition of &#8220;Permitted Encumbrances&#8221;) upon any of the assets of the Company.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(e)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>No deficiencies for a material amount of Taxes with respect to the Company have been claimed, proposed or assessed by any Governmental Authority in writing that have not been timely paid in full. There are no pending (or, based on written notice, threatened) material audits, assessments, examinations or other actions for or relating to any liability in respect of Taxes of the Company. The Company has not granted a waiver of any statute of limitations in respect of a material amount of Taxes or an extension of time with respect to a material Tax assessment or deficiency that, in each case, is currently in effect.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(f)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Company has not been a United States real property holding corporation within the meaning of Section&#160;897(c)(2) of the Code in the last five (5) years.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(g)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Company is not a party to any Tax allocation, Tax sharing or similar agreement (including indemnity arrangements), other than customary commercial Contracts entered into in the Ordinary Course of Business the primary purpose of which does not relate to Tax (an &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Ordinary Course Agreement</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;).</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(h)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Company has not been a member of an affiliated group filing a consolidated U.S. federal income Tax Return (other than a group the common parent of which is the Company). The Company has no Liability for the Taxes of any Person under Treasury Regulations Section&#160;1.1502-6 (or any similar provision of state, local, or foreign law), as a transferee or successor, or by Contract (other than an Ordinary Course Agreement).</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(i)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Company has not distributed stock of another Person, or has had its stock distributed by another Person, in a transaction that was purported or intended to be governed in whole or in part by Section&#160;355 of the Code or Section&#160;361 of the Code.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(j)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Company has not entered into any transaction identified as a &#8220;listed transaction&#8221; for purposes of Treasury Regulations Sections&#160;1.6011-4(b)(2) or 301.6111-2(b)(2).</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(k)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Company is not aware of any facts or circumstances and has not taken or agreed to take any action, in each case, that would reasonably be expected to prevent or impede the Intended Tax Treatment.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-31</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">3.17<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Employee and Labor Matters; Benefit Plans.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Company has made available to Parent a list (on an anonymized basis) setting forth, for each Company Associate who is an employee of the Company or any of its Subsidiaries, whether full- or part-time, such employee&#8217;s annual salary (or if hourly, hourly rate), most recent annual bonus received, and current annual bonus opportunity. No Company Key Employee has indicated to the Company, or any of its Subsidiaries, that he or she intends to resign or retire as a result of the transactions contemplated by this Agreement or otherwise. The Company has made available to Parent a list (on an anonymized basis) setting forth, for each Company Associate who is an individual independent contractor engaged by the Company, such contractor&#8217;s rate of compensation.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The employment of the Company&#8217;s and each of its Subsidiaries&#8217; employees is terminable by the Company and/or its applicable Subsidiary at will. The Company has made available to Parent accurate and complete copies of all employee manuals and handbooks, to the extent currently effective and material.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Neither the Company nor any of its Subsidiaries is a party to, bound by the terms of, and does not have a duty to bargain under, any collective bargaining agreement or other Contract with a labor organization representing its employees, and there are no labor organizations representing or, to the Knowledge of the Company, purporting to represent or seeking to represent any employees of the Company.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;3.17(d)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Company Disclosure Letter lists all Company Employee Plans (other than employment arrangements which are terminable &#8220;at will&#8221; without any contractual obligation on the part of the Company or any of its Subsidiaries to make any severance, termination, change in control or similar payment and that are substantively identical to the employment arrangements made available to Parent).</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(e)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Each Company Employee Plan that is intended to be qualified under Section&#160;401(a) of the Code has received a favorable determination or opinion letter with respect to such qualified status from the IRS. To the Knowledge of the Company, nothing has occurred that would reasonably be expected to adversely affect the qualified status of any such Company Employee Plan or the exempt status of any related trust.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(f)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Each Company Employee Plan has been established, maintained and operated in compliance, in all material respects, with its terms all applicable Law, including, without limitation, the Code, ERISA and the Affordable Care Act. No Legal Proceeding (other than those relating to routine claims for benefits) is pending or, to the Knowledge of the Company, threatened with respect to any Company Employee Plan. All payments and/or contributions required to have been made with respect to all Company Employee Plans either have been made or have been accrued in accordance with the terms of the applicable Company Employee Plan and applicable Law.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(g)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Neither the Company nor any of its ERISA Affiliates maintains, contributes to or is required to contribute to, or has, in the past six (6) years, maintained, contributed to or been required to contribute to (i) any &#8220;employee benefit plan&#8221; that is or was subject to Title IV or Section&#160;302 of ERISA or Section&#160;412 of the Code, (ii) a Multiemployer Plan, (iii) any funded welfare benefit plan within the meaning of Section&#160;419 of the Code, (iv) any Multiple Employer Plan, or (v) any Multiple Employer Welfare Arrangement. Neither the Company nor any of its ERISA Affiliates has ever incurred any liability under Title IV of ERISA.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(h)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>No Company Employee Plan provides for medical or other welfare benefits to any service provider beyond termination of service or retirement, other than (1) pursuant to COBRA or an analogous state law requirement or (2) continuation coverage through the end of the month in which such termination or retirement occurs. The Company does not sponsor or maintain any self-funded medical or long-term disability benefit plan.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(i)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span> No Company Employee Plan is subject to any law of a foreign jurisdiction outside of the United States.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(j)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Each Company Employee Plan that constitutes in any part a &#8220;nonqualified deferred compensation plan&#8221; (as such term is defined under Section&#160;409A(d)(1) of the Code and the guidance thereunder) (each, a &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> </span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">409A Plan</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) has been operated and maintained in all material respects in </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-32</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">operational and documentary compliance with the requirements of Section&#160;409A of the Code and the applicable guidance thereunder. No payment to be made under any Company 409A Plan is or, when made in accordance with the terms of the Company 409A Plan, will be subject to the penalties of Section&#160;409A(a)(1) of the Code.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(k)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Company and each of its Subsidiaries is, and has been, in material compliance with all applicable federal, state and local laws, rules and regulations respecting employment, employment practices, terms and conditions of employment, worker classification, tax withholding, prohibited discrimination, retaliation and harassment, equal employment, fair employment practices, meal and rest periods, immigration status, employee and workplace safety and health, wages (including overtime wages), compensation, hours of work, &#8220;plant closings&#8221; and &#8220;mass layoffs&#8221; within the meaning of the Worker Adjustment and Retraining Act of 1988 or similar state or local law (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">WARN Act</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), labor practices or disputes, restrictive covenants, employment agreements, workers&#8217; compensation and long-term disability policies, leaves of absence and worker privacy (collectively, &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Employment-Related Laws</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), and in each case, with respect to employees of the Company and any of its Subsidiaries: (i)&#160;has withheld and reported all material amounts required by law or by agreement to be withheld and reported with respect to wages, salaries and other payments to employees, (ii)&#160;is not liable for any material amounts of arrears of wages, severance pay or any Taxes or any penalty for failure to comply with any of the foregoing and (iii)&#160;is not liable for any material payment to any trust or other fund governed by or maintained by or on behalf of any Governmental Authority, with respect to unemployment compensation benefits, social security or other benefits or obligations for employees (other than routine payments to be made in the Ordinary Course of Business). There are no material Legal Proceedings, claims, labor disputes or organizing activities, or grievances pending or, to the Knowledge of the Company, threatened or reasonably anticipated against or involving the Company or any of its Subsidiaries or any trustee of the Company or any of its Subsidiaries relating to any employee, contingent worker, director, employment agreement or Employee Plan (other than routine claims for benefits) or Employment-Related Laws. To the Knowledge of the Company, there are no material pending or threatened or reasonably anticipated claims or actions against the Company, any trustee or any trustee of any Subsidiary of the Company under any workers&#8217; compensation policy or long-term disability policy. The Company is not a party to a conciliation agreement, consent decree or other agreement or Order with any federal, state or local agency or Governmental Authority with respect to employment practices.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(l)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Neither the Company nor any of its Subsidiaries has any material liability with respect to any misclassification within the last four (4) years of: (i) any Person as an independent contractor rather than as an employee, (ii) any employee leased from another employer or (iii) any employee currently or formerly classified as exempt from overtime wages. Neither the Company nor any of its Subsidiaries has taken any action which would constitute a &#8220;plant closing&#8221; or &#8220;mass layoff&#8221; within the meaning of the WARN Act, issued any notification of a plant closing or mass layoff required by the WARN Act (nor has the Company or any of its Subsidiaries been under any requirement or obligation to issue any such notification), or incurred any liability or obligation under the WARN Act that remains unsatisfied.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(m)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>To the Company&#8217;s Knowledge, there has never been, nor has there been any threat of, any strike, slowdown, work stoppage, lockout, job action, union, organizing activity, question concerning representation or any similar activity or dispute, by or with respect to any Company Associates. No event has occurred within the past six months, and no condition or circumstance exists, that, to the Company&#8217;s Knowledge, might directly or indirectly be likely to give rise to or provide a basis for the commencement of any such strike, slowdown, work stoppage, lockout, job action, union organizing activity, question concerning representation or any similar activity or dispute.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(n)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Neither the Company nor any of its Subsidiaries is, nor has the Company nor any of its Subsidiaries been, engaged in any material unfair labor practice within the meaning of the National Labor Relations Act. There is no material Legal Proceeding, claim, labor dispute or grievance pending or, to the Knowledge of the Company, threatened or reasonably anticipated relating to any employment contract, privacy right, labor dispute, wages and hours, leave of absence, plant closing notification, workers&#8217; compensation policy, long-term disability policy, harassment, retaliation, immigration, employment statute or regulation, safety or discrimination matter involving any current or former employee of the Company or any of its Subsidiaries including charges of unfair labor practices or discrimination complaints.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-33</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(o)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>There is no contract, agreement, plan or arrangement to which the Company or any of its Subsidiaries is a party or by which it is bound to compensate any of its employees or other service providers for any income or excise taxes paid pursuant to the Code, including, but not limited to, Section&#160;4999 or Section&#160;409A of the Code.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(p)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Neither the Company nor any of its Subsidiaries is a party to any Contract that as a result of the execution and delivery of this Agreement, the stockholder approval of this Agreement, nor the consummation of the transactions contemplated hereby, could (either alone or in conjunction with any other event) result in, or cause the accelerated vesting, payment, funding or delivery of, or increase the amount or value of, any payment or benefit to any employee, officer, director or other service provider of the Company or any of its Subsidiaries.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">3.18<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Environmental Matters</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Company has complied with all applicable Environmental Laws, which compliance includes the possession by the Company of all permits and other Governmental Authorizations required under applicable Environmental Laws and compliance with the terms and conditions thereof, except for any failure to be in compliance that, individually or in the aggregate, would not result in a Company Material Adverse Effect. The Company has not received any written notice or other communication (in writing or otherwise), whether from a Governmental Authority, citizens group, employee or otherwise, that alleges that the Company is not in compliance with any Environmental Law and, to the Knowledge of the Company, there are no circumstances that may prevent or interfere with the Company&#8217;s compliance with any Environmental Law in the future, except where such failure to comply would not reasonably be expected to have a Company Material Adverse Effect. To the Knowledge of the Company: (i) no current or prior owner of any property leased or controlled by the Company has received any written notice or other communication relating to property owned or leased at any time by the Company, whether from a Governmental Authority, citizens group, employee or otherwise, that alleges that such current or prior owner or the Company is not in compliance with or violated any Environmental Law relating to such property and (ii) the Company has no material liability under any Environmental Law. The Company has made available all environmental site assessments, environmental audits and other material environmental documents in the Company&#8217;s possession or control relating to the Company, including the Company&#8217;s business and current or former facilities.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">3.19<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Insurance</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Company has delivered to Parent accurate and complete copies of all material insurance policies and all material self-insurance programs and arrangements relating to the business, assets, liabilities and operations of the Company. Each of such insurance policies is in full force and effect and the Company is in compliance in all material respects with the terms thereof. Other than customary end of policy notifications from insurance carriers, the Company has not received any notice or other communication regarding any actual or possible: (i) cancellation or invalidation of any insurance policy or (ii) refusal or denial of any coverage, reservation of rights or rejection of any material claim under any insurance policy. The Company has provided timely written notice to the appropriate insurance carrier(s) of each Legal Proceeding pending against the Company, and no such carrier has issued a denial of coverage or a reservation of rights with respect to any such Legal Proceeding, or informed the Company of its intent to do so.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">3.20<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">No Financial Advisors</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Except as set forth on </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;3.20</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Company Disclosure Letter, no broker, finder or investment banker is entitled to any brokerage fee, finder&#8217;s fee, opinion fee, success fee, transaction fee or other fee or commission in connection with the Contemplated Transactions based upon arrangements made by or on behalf of the Company.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">3.21<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Transactions with Affiliates</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;3.21</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Company Disclosure Letter describes any material transactions or relationships between, on one hand, the Company and, on the other hand, any (a)&#160;executive officer or director of the Company or any of such executive officer&#8217;s or director&#8217;s immediate family members, (b)&#160;owner of more than 5% of the voting power of the outstanding Company Capital Stock or (c)&#160;to the Knowledge of the Company, any &#8220;related person&#8221; (within the meaning of Item&#160;404 of Regulation S-K under the Securities Act) of any such officer, director or owner (other than the Company) in the case of each of (a), (b)&#160;or (c)&#160;that is of the type that would be required to be disclosed under Item&#160;404 of Regulation&#160;S-K under the Securities Act.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">3.22<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Privacy and Data Security</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Company is and has at all times been in compliance with all applicable Privacy Laws and the applicable terms of any Company Contracts governing privacy, data protection, data security, trans-border data flow, data loss, data theft, or breach notification, data localization, sending solicited or </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-34</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">unsolicited electronic mail or text messages, cookies or other tracking technology, with respect to, or the collection, handling, use, maintenance, storage, disclosure, transfer, or other processing of, Personal Information (including any such information of individuals, clinical trial participants, patients, patient family members, caregivers or advocates, physicians and other health care professionals, clinical trial investigators, researchers, pharmacists that interact with the Company in connection with the operation of the Company&#8217;s business), except, in each case, for such noncompliance as has not had, and would not reasonably be expected to have, individually or in the aggregate, a Company Material Adverse Effect. To the Knowledge of the Company, the Company (i) has implemented and maintains reasonable written policies and procedures that materially comply with applicable Privacy Laws and are designed to protect the privacy and security of Personal Information (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Privacy Policies</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) and (ii) has complied with such Privacy Policies, except for such noncompliance as has not had, and would not reasonably be expected to have, individually or in the aggregate, a Company Material Adverse Effect. To the Knowledge of the Company, no Legal Proceeding has been asserted or threatened against the Company by any Person alleging a violation of Privacy Laws, Privacy Policies, or the applicable terms of any Company Contracts governing privacy, data protection, data security, trans-border data flow, data loss, data theft, or breach notification, data localization, sending solicited or unsolicited electronic mail or text messages, cookies or other tracking technology, with respect to, or the collection, handling, use, maintenance, storage, disclosure, transfer, or other processing of, Personal Information. To the Knowledge of the Company, there have been no data security incidents or data breaches or other adverse events or incidents that have resulted in any unauthorized access to, or collection, use, disclosure, modification or destruction of, Personal Information or other data in the possession or control of the Company or any service provider acting on behalf of the Company, in each case, where such incident, breach or event resulted in a notification obligation to any Person under applicable Law or pursuant to the terms of any Company Contract.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">3.23<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Ownership of Parent Capital Stock</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. None of the Company or any of their directors, officers, or Affiliates or, to the knowledge of the Company or any of its controlled Affiliates, any employees of the Company or any of its controlled Affiliates (a) has owned any shares of Parent&#8217;s capital stock; or (b) has been an &#8220;interested stockholder&#8221; (as defined in Section&#160;203 of the DGCL) of Parent, in each case during the three years prior to the date hereof.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">3.24<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">No Other Representations or Warranties</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Company hereby acknowledges and agrees that, except for the representations and warranties contained in this Agreement, neither Parent nor any other person on behalf of Parent makes any express or implied representation or warranty with respect to Parent or with respect to any other information provided to the Company, any of its stockholders or any of their respective Affiliates in connection with the Contemplated Transactions, and (subject to the express representations and warranties of Parent set forth in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;4</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> (in each case as qualified and limited by the Parent Disclosure Letter)) none of the Company, or any of its Representatives or stockholders, has relied on any such information (including the accuracy or completeness thereof).</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;4. </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Representations and Warranties of Parent, First Merger and Second Merger Sub</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Except (i) as set forth in the written disclosure document delivered by Parent to the Company (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Disclosure Letter</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) concurrently with the execution of this Agreement or (ii) as disclosed in the Parent SEC Documents filed with the SEC prior to the date hereof and publicly available on the SEC&#8217;s Electronic Data Gathering Analysis and Retrieval system (but (A) without giving effect to any amendment thereof filed with, or furnished to the SEC on or after the date hereof and (B) excluding any disclosures contained under the heading &#8220;Risk Factors&#8221; and any disclosure of risks included in any &#8220;forward-looking statements&#8221; disclaimer or in any other section to the extent they are forward-looking statements or cautionary, predictive or forward-looking in nature), it being understood that any matter disclosed in the Parent SEC Documents shall be deemed to be disclosed in a section of the Parent Disclosure Letter only to the extent that is readily apparent from a reading of such Parent SEC Documents that is applicable to such section or subsection of the Parent Disclosure Letter, Parent, First Merger Sub and Second Merger Sub represent and warrant to the Company as follows:</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">4.1<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Due Organization; Subsidiaries</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Each of Parent, First Merger Sub and Second Merger Sub is a corporation duly incorporated or formed, as applicable, validly existing and in good standing under the Laws of the jurisdiction of its incorporation or formation, as applicable, and has all necessary corporate power and authority: (i) to conduct its business in the manner in which its business is currently being conducted, (ii) to own or lease and use its property </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-35</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">and assets in the manner in which its property and assets are currently owned or leased and used and (iii) to perform its obligations under all Contracts by which it is bound. Since the date of its incorporation, Merger Subs have not engaged in any activities other than in connection with or as contemplated by this Agreement.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Each of Parent and its Subsidiaries is licensed and qualified to do business, and is in good standing (to the extent applicable in such jurisdiction), under the Laws of all jurisdictions where the nature of its business in the manner in which its business is currently being conducted requires such licensing or qualification other than in jurisdictions where the failure to be so qualified individually or in the aggregate would not be reasonably expected to have a Parent Material Adverse Effect.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Parent has no Subsidiaries other than Merger Subs and except as set forth on </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;4.1(c)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Parent Disclosure Letter, Parent does not own any capital stock of, or any equity ownership or profit sharing interest of any nature in, or control directly or indirectly, any other Entity other than Merger Subs. Except as set forth on </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;4.1(c)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Parent Disclosure Letter, Parent is not and has not otherwise been, directly or indirectly, a party to, member of or participant in any partnership, joint venture or similar business entity. Parent has not agreed and is not obligated to make, nor is Parent bound by any Contract under which it may become obligated to make, any future investment in or capital contribution to any other Entity. Parent has not, at any time, been a general partner of, and has not otherwise been liable for any of the debts or other obligations of, any general partnership, limited partnership or other Entity.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">4.2<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Organizational Documents</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Parent has delivered to the Company accurate and complete copies of Parent&#8217;s Organizational Documents. Parent is not in breach or violation of its Organizational Documents in any material respect.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">4.3<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Authority; Binding Nature of Agreement</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Parent and each Merger Sub has all necessary corporate power and authority to enter into and to perform its obligations under this Agreement and to consummate the Contemplated Transactions. The Parent Board has: (a) determined that the Contemplated Transactions are fair to, advisable and in the best interests of Parent and its stockholders, (b) approved and declared advisable this Agreement and the Contemplated Transactions, including the issuance of shares of Parent Capital Stock to the stockholders of the Company pursuant to the terms of this Agreement and (c) determined to recommend, upon the terms and subject to the conditions set forth in this Agreement, that the stockholders of Parent vote to approve the Contemplated Transactions, and, if deemed necessary by Parent and the Company, the amendment to the certificate of incorporation of the Parent to (i) change the name of Parent to &#8220;Oruka Therapeutics, Inc.&#8221;, (ii) effect the Nasdaq Reverse Split and (iii) make such other changes as are mutually agreeable to Parent and the Company pursuant to the terms of this Agreement. The First Merger Sub Board (by unanimous written consent) has: (x)&#160;determined that the Contemplated Transactions are fair to, advisable and in the best interests of First Merger Sub and its sole stockholder, (y) deemed advisable and approved this Agreement and the Contemplated Transactions and (z)&#160;determined to recommend, upon the terms and subject to the conditions set forth in this Agreement, that the stockholder of First Merger Sub vote to adopt this Agreement and thereby approve the Contemplated Transactions.  The sole member of Second Merger Sub (by unanimous written consent) has:  (A) determined that the Contemplated Transactions are fair to, advisable, and in the best interests of Second Merger Sub and the sole member; and (B)&#160;deemed advisable and approved this Agreement and the Contemplated Transactions.  This Agreement has been duly executed and delivered by Parent and Merger Subs and, assuming the due authorization, execution and delivery by the Company and the accuracy of the representation in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;3.23</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, constitutes the legal, valid and binding obligation of Parent and Merger Subs, enforceable against each of Parent and Merger Subs in accordance with its terms, subject to the Enforceability Exceptions.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">4.4<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Vote Required</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Assuming the accuracy of the representation in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;3.23</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, the affirmative vote of a majority of the shares of Parent Common Stock properly cast at the Parent Stockholder Meeting is the only vote of the holders of any class or series of Parent&#8217;s capital stock necessary to approve this Agreement and thereby approve the Contemplated Transactions and clauses&#160;(i), (ii) and (iii) of the definition of &#8220;Parent Charter Amendment&#8221; (collectively, the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Required Parent Stockholder Vote</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;).</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-36</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-18" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;page-break-after:avoid;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">4.5<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Non-Contravention; Consents</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Subject to obtaining the Required Parent Stockholder Vote, compliance with any applicable requirements of the HSR Act (if applicable) and the filing of the Certificate of Merger and Certificate of Designation required by the DGCL or DLLCA, and assuming the accuracy of the representation in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;3.23</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, neither (x) the execution, delivery or performance of this Agreement by Parent or Merger Subs, nor (y) the consummation of the Contemplated Transactions, will directly or indirectly (with or without notice or lapse of time):</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(i)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>contravene, conflict with or result in a violation of any of the provisions of the Organizational Documents of Parent or its Subsidiaries;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(ii)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>contravene, conflict with or result in a material violation of, or give any Governmental Authority or other Person the right to challenge the Contemplated Transactions or to exercise any remedy or obtain any relief under, any Law or any Order to which Parent or its Subsidiaries or any of the assets owned or used by Parent or its Subsidiaries, is subject;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(iii)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>contravene, conflict with or result in a material violation of any of the terms or requirements of, or give any Governmental Authority the right to revoke, withdraw, suspend, cancel, terminate or modify, any Governmental Authorization that is held by Parent or its Subsidiaries or that otherwise relates to the business of Parent, or any of the assets owned, leased or used by Parent;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(iv)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>contravene, conflict with or result in a violation or breach of, or result in a default under, any provision of any Parent Material Contract, or give any Person the right to: (A)&#160;declare a default or exercise any remedy under any Parent Material Contract, (B) any material payment, rebate, chargeback, penalty or change in delivery schedule under any such Parent Material Contract, (C)&#160;accelerate the maturity or performance of any Parent Material Contract or (D) cancel, terminate or modify any term of any Parent Material Contract, except in the case of any nonmaterial breach, default, penalty or modification; or</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(v)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>result in the imposition or creation of any Encumbrance upon or with respect to any asset owned or used by Parent or its Subsidiaries (except for Permitted Encumbrances).</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Except for (i) any Consent set forth on </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;4.5(a)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Parent Disclosure Letter under any Parent Contract, (ii) the Required Parent Stockholder Vote, (iii) the filing of the Certificate of Merger and Certificate of Designation with the Secretary of State of the State of Delaware pursuant to the DGCL or DLLCA, (iv) compliance with any applicable requirements of the HSR Act (if applicable) and (v) such consents, waivers, approvals, orders, authorizations, registrations, declarations and filings as may be required under applicable federal and state securities laws, and assuming the accuracy of the representation in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;3.23</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, neither Parent nor any of its Subsidiaries was, is or will be required to make any filing with or give any notice to, or to obtain any Consent from, any Person in connection with (x) the execution, delivery or performance of this Agreement or (y) the consummation of the Contemplated Transactions.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Assuming the accuracy of the representation in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;3.23</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, the Parent Board and the First Merger Sub Board have taken and will take all actions necessary to ensure that the restrictions applicable to business combinations contained in Section&#160;203 of the DGCL are, and will be, inapplicable to the execution, delivery and performance of this Agreement and to the consummation of the Contemplated Transactions. No other state takeover statute or similar Law applies or purports to apply to the Merger, this Agreement or any of the other Contemplated Transactions.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">4.6<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Capitalization</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The authorized capital stock of Parent consists of (i)&#160;100,000,000 shares of Parent Common Stock of which 14,501,143 shares have been issued and are outstanding as of March 28, 2024 (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Capitalization Date</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) and (ii) 5,000,000 shares of Parent Preferred Stock, par value $0.001 per share, of which 135,000 have been designated Series A Convertible Preferred Stock. No shares of Parent Preferred Stock have been issued and are outstanding as of the Capitalization Date. Parent does not hold any shares of its capital stock in its treasury.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-37</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>All of the outstanding shares of Parent Common Stock have been duly authorized and validly issued, and are fully paid and nonassessable and are free of any Encumbrances other than Encumbrances set forth in the Organizational Documents or under applicable securities Laws. None of the outstanding shares of Parent Common Stock is entitled or subject to any preemptive right, right of participation, right of maintenance or any similar right and none of the outstanding shares of Parent Common Stock is subject to any right of first refusal in favor of Parent. Except as contemplated herein, there is no Parent Contract relating to the voting or registration of, or restricting any Person from purchasing, selling, pledging or otherwise disposing of (or granting any option or similar right with respect to), any shares of Parent Common Stock. Parent is not under any obligation, nor is Parent bound by any Contract pursuant to which it may become obligated, to repurchase, redeem or otherwise acquire any outstanding shares of Parent Common Stock or other securities. </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;4.6(b)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Parent Disclosure Letter accurately and completely describes all repurchase rights held by Parent with respect to shares of Parent Common Stock (including shares issued pursuant to the exercise of stock options) and specifies which of those repurchase rights are currently exercisable.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Except for the Parent 2004 Equity Incentive Plan, Parent 2013 Equity Incentive Plan and Parent 2020 Equity Incentive Plan, (each as may be amended from time to time, collectively, the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Stock Plans</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) and except as set forth on </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;4.6(c)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Parent Disclosure Letter, Parent does not have any stock option plan or any other plan, program, agreement or arrangement providing for any equity-based compensation for any Person. Parent does not have any employee stock purchase plan or similar program. </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;4.6(c)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Parent Disclosure Letter sets forth the following information with respect to each Parent Option outstanding as of the Capitalization Date, as applicable: (i) the name of the holder, (ii) the number of shares of Parent Common Stock subject to such Parent Option as of the Capitalization Date, (iii) the exercise price of such Parent Option, (iv) the date on which such Parent Option was granted, (v) the applicable vesting schedule, including any acceleration provisions, (vi) the date on which such Parent Option expires, (vii) whether such Parent Option is intended to be an &#8220;incentive stock option&#8221; (as defined in the Code) or a nonqualified stock option and (viii) in the case of a Parent Option, the plan pursuant to which such Parent Option was granted. Parent has made available to the Company accurate and complete copies of equity incentive plans pursuant to which Parent has equity-based awards, the forms of all award agreements evidencing such equity-based awards and evidence of board and stockholder approval of the Parent Stock Plans and any amendments thereto.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Except for the outstanding Parent Options or as set forth on </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;4.6(d)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Parent Disclosure Letter, there is no: (i) outstanding subscription, option, call, warrant or right (whether or not currently exercisable) to acquire any shares of the capital stock or other securities of Parent, (ii) outstanding security, instrument or obligation that is or may become convertible into or exchangeable for any shares of the capital stock or other securities of Parent, (iii) stockholder rights plan (or similar plan commonly referred to as a &#8220;poison pill&#8221;) or Contract under which Parent is or may become obligated to sell or otherwise issue any shares of its capital stock or any other securities or (iv) condition or circumstance that may give rise to or provide a basis for the assertion of a claim by any Person to the effect that such Person is entitled to acquire or receive any shares of capital stock or other securities of Parent. There are no outstanding or authorized stock appreciation, phantom stock, profit participation or other similar rights with respect to Parent.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(e)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>All outstanding shares of Parent Common Stock and Parent Options, and other securities of Parent have been issued and granted in compliance in all material respects with (i) all applicable securities laws and other applicable Law and (ii) all requirements set forth in applicable Contracts.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">4.7<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">SEC Filings; Financial Statements</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Parent has filed or furnished, as applicable, on a timely basis all forms, statements, certifications, reports and documents required to be filed or furnished by it with the SEC under the Exchange Act or the Securities Act (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent SEC Documents</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;). As of the time it was filed with the SEC (or, if amended or superseded by a filing prior to the date of this Agreement, then on the date of such filing), each of the Parent SEC Documents complied in all material respects with the applicable requirements of the Securities Act or the Exchange Act (as the case may be) and as of the time they were filed, none of the Parent SEC Documents contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading. The certifications and statements required by (i) Rule&#160;13a-14 under the Exchange Act and (ii) 18 U.S.C. &#167;1350 (Section&#160;906 of the Sarbanes-Oxley Act) relating to the Parent SEC </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-38</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Documents (collectively, the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Certifications</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) are accurate and complete and comply as to form and content with all applicable Laws. As used in this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;4.7</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, the term &#8220;file&#8221; and variations thereof shall be broadly construed to include any manner in which a document or information is furnished, supplied or otherwise made available to the SEC.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The financial statements (including any related notes) contained or incorporated by reference in the Parent SEC Documents: (i) complied as to form in all material respects with the Securities Act and the Exchange Act, as applicable, and the published rules and regulations of the SEC applicable thereto, (ii)&#160;were prepared in accordance with GAAP (except as may be indicated in the notes to such financial statements or, in the case of unaudited financial statements, as permitted by Form 10-Q of the SEC, and except that the unaudited financial statements may not contain footnotes and are subject to normal and recurring year-end adjustments that are not reasonably expected to be material in amount) applied on a consistent basis unless otherwise noted therein throughout the periods indicated and (iii) fairly present, in all material respects, the financial position of Parent as of the respective dates thereof and the results of operations and cash flows of Parent for the periods covered thereby. Other than as expressly disclosed in the Parent SEC Documents filed prior to the date hereof, there has been no material change in Parent&#8217;s accounting methods or principles that would be required to be disclosed in Parent&#8217;s financial statements in accordance with GAAP. The books of account and other financial records of Parent and each of its Subsidiaries are true and complete in all material respects.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Parent&#8217;s auditor has at all times since the date of enactment of the Sarbanes-Oxley Act been: (i) a registered public accounting firm (as defined in Section&#160;2(a)(12) of the Sarbanes-Oxley Act), (ii) to the Knowledge of Parent, &#8220;independent&#8221; with respect to Parent within the meaning of Regulation S-X under the Exchange Act and (iii) to the Knowledge of Parent, in compliance with subsections (g) through (l) of Section&#160;10A of the Exchange Act and the rules and regulations promulgated by the SEC and the Public Company Accounting Oversight Board thereunder.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Except as set forth on </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;4.7(d)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Parent Disclosure Letter, Parent has not received any comment letter from the SEC or the staff thereof or any correspondence from Nasdaq or the staff thereof relating to the delisting or maintenance of listing of the Parent Common Stock on Nasdaq. Parent has not disclosed any unresolved comments in the Parent SEC Documents.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(e)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>There have been no formal internal investigations regarding financial reporting or accounting policies and practices discussed with, reviewed by or initiated at the direction of the chief executive officer, chief financial officer or general counsel of Parent, the Parent Board or any committee thereof, other than ordinary course audits or reviews of accounting policies and practices or internal controls required by the Sarbanes-Oxley Act.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(f)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Parent is in compliance in all material respects with the applicable provisions of the Sarbanes-Oxley Act, the Exchange Act and the applicable listing and governance rules and regulations of Nasdaq.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(g)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Parent maintains a system of internal control over financial reporting (as defined in Rules&#160;13a-15(f) and 15d-15(f) of the Exchange Act) that is sufficient to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP, including policies and procedures sufficient to provide reasonable assurance (i) that Parent maintains records that in reasonable detail accurately and fairly reflect Parent&#8217;s transactions and dispositions of assets, (ii)&#160;that transactions are recorded as necessary to permit preparation of financial statements in accordance with GAAP, (iii) that receipts and expenditures are made only in accordance with the authorization policy and (iv) regarding prevention or timely detection of the unauthorized acquisition, use or disposition of Parent&#8217;s assets that could have a material effect on Parent&#8217;s financial statements. Parent has evaluated the effectiveness of Parent&#8217;s internal control over financial reporting and, to the extent required by applicable Law, presented in any applicable Parent SEC Document that is a report on Form 10-K or Form 10-Q (or any amendment thereto) its conclusions about the effectiveness of the internal control over financial reporting as of the end of the period covered by such report or amendment based on such evaluation. Parent has disclosed to Parent&#8217;s auditors and the Audit Committee of the Parent Board (and made available to the Company a summary of the significant aspects of such disclosure) (A) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting that are reasonably likely to adversely affect Parent&#8217;s ability to record, process, summarize and report financial information and (B) any fraud, whether or not material, that involves management or other employees who have a significant role in Parent&#8217;s or its </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-39</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Subsidiaries&#8217; internal control over financial reporting. Except as disclosed in the Parent SEC Documents filed prior to the date hereof, Parent&#8217;s internal control over financial reporting is effective at the reasonable assurance level and Parent has not identified any material weaknesses in the design or operation of Parent&#8217;s internal control over financial reporting.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(h)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Parent&#8217;s &#8220;disclosure controls and procedures&#8221; (as defined in Rules&#160;13a-15(e) and 15d-15(e) of the Exchange Act) are designed to ensure that all information (both financial and nonfinancial) required to be disclosed by Parent in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC, and that all such information is accumulated and communicated to Parent&#8217;s principal executive officer and principal financial officer as appropriate to allow timely decisions regarding required disclosure and to make the Certifications and such disclosure controls and procedures are effective. Parent has carried out evaluation of the effectiveness of its disclosure controls and procedures as required by Rule&#160;13a-15 of the Exchange Act.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">4.8<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Absence of Changes</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Except as set forth on </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;4.8</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Parent Disclosure Letter, between December 31, 2023 and the date of this Agreement, Parent has conducted its business only in the Ordinary Course of Business (except for the execution and performance of this Agreement and the discussions, negotiations and transactions related thereto) and there has not been any (a) Parent Material Adverse Effect or (b) action, event or occurrence that would have required consent of the Company pursuant to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;5.1(b)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of this Agreement had such action, event or occurrence taken place after the execution and delivery of this Agreement.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">4.9<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Absence of Undisclosed Liabilities</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Since December 31, 2023, neither Parent nor any of its Subsidiaries has any Liability except for: (a) Liabilities disclosed, reflected or reserved against in the Parent Balance Sheet, (b) normal and recurring current Liabilities that have been incurred by Parent or its Subsidiaries since the date of the Parent Balance Sheet in the Ordinary Course of Business (none of which relates to any breach of contract, breach of warranty, tort, infringement or violation of Law), (c) Liabilities for performance of obligations of Parent or any of its Subsidiaries under Parent Contracts, (d) Liabilities incurred in connection with the Parent Legacy Business or the Contemplated Transactions, (e) Liabilities described in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;4.9</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Parent Disclosure Letter and (f) those Liabilities that are not material to Parent.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">4.10<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Title to Assets</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Each of Parent and its Subsidiaries owns, and has good and valid title to, or, in the case of leased properties and assets, valid leasehold interests in, all tangible properties or tangible assets and equipment used or held for use in its business or operations or purported to be owned by it, including: (a)&#160;all tangible assets reflected on the Parent Balance Sheet and (b) all other tangible assets reflected in the books and records of Parent as being owned by Parent. All of such assets are owned or, in the case of leased assets, leased by Parent or any of its Subsidiaries free and clear of any Encumbrances, other than Permitted Encumbrances.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">4.11<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Real Property; Leasehold</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Neither Parent nor any of its Subsidiaries owns or has ever owned any real property, nor is Parent party to any agreement to purchase or sell any real property. Parent has made available to the Company (a) an accurate and complete list of&#160;all real properties with respect to which Parent directly or indirectly holds a valid leasehold interest as well as any other real estate that is in the possession of or leased by Parent or any of its Subsidiaries and (b)&#160;copies of all leases under which any such real property is possessed (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> </span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Real Estate Leases</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), each of which is in full force and effect, with no existing material default thereunder by Parent or its Subsidiaries or, to Parent&#8217;s Knowledge, the other party thereto.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">4.12<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Intellectual Property</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;4.12(a)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Parent Disclosure Letter is an accurate, true and complete listing of all Parent Registered IP.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;4.12(b)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Parent Disclosure Letter accurately identifies (i) all Parent Contracts pursuant to which any Parent IP Rights are licensed to Parent (other than (A) any non-customized software that (1) is so licensed solely in executable or object code form pursuant to a nonexclusive, internal use software license and other Intellectual Property associated with such software and (2) is not incorporated into, or material to the development, manufacturing, or distribution of, any of Parent products or services, (B) any Intellectual Property licensed on a nonexclusive basis ancillary to the purchase or use of services, equipment, reagents or other materials, (C) any confidential information provided under confidentiality agreements and (D) agreements between Parent and its employees in Parent&#8217;s standard form thereof) and (ii) whether the license or licenses granted to Parent are exclusive or nonexclusive.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-40</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;4.12(c)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Parent Disclosure Letter accurately identifies each Parent Contract pursuant to which any Person has been granted any license or covenant not to sue under, or otherwise has received or acquired any right (whether or not currently exercisable) or interest in, any Parent IP Rights (other than (i) any confidential information provided under confidentiality agreements and (ii) any Parent IP Rights nonexclusively licensed to academic collaborators, suppliers or service providers for the sole purpose of enabling such academic collaborator, supplier or service providers to provide services for Parent&#8217;s benefit).</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Neither Parent nor any of its Subsidiaries is bound by, and no Parent IP Rights are subject to, any Contract containing any covenant or other provision that in any way limits or restricts the ability of Parent or any of its Subsidiaries to use, exploit, assert, or enforce any Parent IP Rights anywhere in the world.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(e)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Parent or one of its Subsidiaries exclusively owns all right, title, and interest to and in the Parent IP Rights (other than (i) Parent IP Rights licensed to Parent, or co-owned rights each as identified in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;4.12(e)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Parent Disclosure Letter, (ii) any non-customized software that (A) is licensed to Parent solely in executable or object code form pursuant to a nonexclusive, internal use software license and other Intellectual Property associated with such software and (B) is not incorporated into, or material to the development, manufacturing or distribution of, any of Parent or its Subsidiaries&#8217; products or services and (iii) any Intellectual Property licensed on a nonexclusive basis ancillary to the purchase or use of equipment, reagents or other materials), in each case, free and clear of any Encumbrances (other than Permitted Encumbrances). Without limiting the generality of the foregoing:</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(i)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>All documents and instruments necessary to register or apply for or renew registration of Parent Registered IP have been validly executed, delivered, and filed in a timely manner with the appropriate Governmental Authority.</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(ii)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Each Person who is or was an employee or contractor of Parent or any of its Subsidiaries and who is or was involved in the creation or development of any Intellectual Property for Parent or any of its Subsidiaries has signed a valid, enforceable agreement containing a present assignment of such Intellectual Property to Parent or such Subsidiary and confidentiality provisions protecting trade secrets and confidential information of Parent and its Subsidiaries.</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(iii)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>To the Knowledge of Parent, no current or former stockholder, officer, director or employee of Parent or any of its Subsidiaries has any claim, right (whether currently exercisable, or exercisable in the future), or interest to or in any Parent IP Rights purported to be owned by Parent. To the Knowledge of Parent, no employee of Parent or any of its Subsidiaries is (a) bound by or otherwise subject to any Contract restricting him or her from performing his or her duties for Parent or such Subsidiary or (b) in breach of any Contract with any former employer or other Person concerning Parent IP Rights purported to be owned by Parent or such Subsidiary or confidentiality provisions protecting trade secrets and confidential information comprising Parent IP Rights purported to be owned by Parent or such Subsidiary.</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(iv)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>No funding, facilities or personnel of any Governmental Authority were used, directly or indirectly, to develop or create, in whole or in part, any Parent IP Rights in which Parent or any of its Subsidiaries has an ownership interest.</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(v)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Parent and each of its Subsidiaries has taken reasonable steps to maintain the confidentiality of and otherwise protect and enforce its rights in all proprietary information that Parent or such Subsidiary holds, or purports to hold, as confidential or a trade secret.</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(vi)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Parent or any of its Subsidiaries has not assigned or otherwise transferred ownership of, or agreed to assign or otherwise transfer ownership of, any Parent IP Rights to any other Person.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(f)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Parent has delivered, or made available to the Company, a complete and accurate copy of all material Parent IP Rights Agreements.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(g)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The manufacture, marketing, offering for sale, sale, importation, use or intended use or other disposal of any product as currently sold or under development by Parent does not violate any license or agreement between Parent or its Subsidiaries and any third party in any material respect, and, to the Knowledge </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-41</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">of Parent, does not infringe or misappropriate any valid and issued Patent right or other Intellectual Property of any other Person, which infringement or misappropriation would reasonably be expected to have a Parent Material Adverse Effect. To the Knowledge of Parent, no third party is infringing upon any Patents owned by Parent within the Parent IP Rights, or violating any Parent IP Rights Agreement.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(h)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>As of the date of this Agreement, Parent is not a party to any Legal Proceeding (including, but not limited to, opposition, interference or other proceeding in any patent or other government office) contesting the validity, ownership or right to use, sell, offer for sale, license or dispose of any Parent IP Rights. Parent has not received any written notice asserting that any Parent Registered IP or the proposed use, sale, offer for sale, license or disposition of any products, methods or processes claimed or covered thereunder infringes or misappropriates or violates the rights of any other Person or that Parent or any of its Subsidiaries have otherwise infringed, misappropriated or otherwise violated any Intellectual Property of any Person.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(i)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>To the Knowledge of Parent, no trademark (whether registered or unregistered) or trade name owned, used or applied for by Parent conflicts or interferes with any trademark (whether registered or unregistered) or trade name owned, used or applied for by any other Person except as would not have a Parent Material Adverse Effect. None of the goodwill associated with or inherent in any trademark (whether registered or unregistered) in which Parent has or purports to have an ownership interest has been impaired as determined by Parent in accordance with GAAP.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(j)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Except as may be set forth in the Contracts listed on </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;4.12(b)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">4.12(c)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> or </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">4.12(k)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Parent Disclosure Letter or as contained in &#8220;off-the-shelf&#8221; license agreements entered into in the Ordinary Course of Business by Parent, (i) Parent is not bound by any Contract to indemnify, defend, hold harmless or reimburse any other Person with respect to any Intellectual Property infringement, misappropriation or similar claim which is material to Parent taken as a whole and (ii) Parent has never assumed, or agreed to discharge or otherwise take responsibility for, any existing or potential liability of another Person for infringement, misappropriation or violation of any Intellectual Property right, which assumption, agreement or responsibility remains in force as of the date of this Agreement.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(k)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Neither Parent nor any of its Subsidiaries is party to any Contract that, as a result of such execution, delivery and performance of this Agreement, will cause the grant of any license or other right to any Parent IP Rights, result in breach of, default under or termination of such Contract with respect to any Parent IP Rights, or impair the right of Parent or the Surviving Entity and its Subsidiaries to use, sell or license or enforce any Parent IP Rights or portion thereof, except for the occurrence of any such grant or impairment that would not individually or in the aggregate, reasonably be expected to result in a Parent Material Adverse Effect.</span></p>
		<p class="ParaOverride-18" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;page-break-after:avoid;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">4.13<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Agreements, Contracts and Commitments</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;4.13</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Parent Disclosure Letter identifies each Parent Contract that is in effect as of the date of this Agreement (each, an &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Material Contract</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; and collectively, the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Material Contracts</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;):</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(i)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>each Parent Contract relating to any material bonus, deferred compensation, severance, incentive compensation, pension, profit-sharing or retirement plans, or any other employee benefit plans or arrangements;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(ii)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>each Parent Contract requiring payments by Parent after the date of this Agreement in excess of $100,000 pursuant to its express terms relating to the employment of, or the performance of employment-related services by, any Parent Associate providing employment related, consulting or independent contractor services, not terminable by Parent on thirty (30) calendar days&#8217; or less notice without liability;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(iii)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>each Parent Contract relating to any agreement or plan, including any option plan, stock appreciation right plan or stock purchase plan, any of the benefits of which will be increased or the vesting of benefits of which will be accelerated, by the occurrence of any of the Contemplated Transactions (either alone or in conjunction with any other event, such as termination of employment), or the value of any of the benefits of which will be calculated on the basis of any of the Contemplated Transactions;</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-42</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(iv)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>each Parent Contract relating to any agreement of indemnification or guaranty not entered into in the Ordinary Course of Business;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(v)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>each Parent Contract containing (A) any covenant limiting the freedom of Parent or any of its Subsidiaries to engage in any line of business or compete with any Person, or limiting the development, manufacture or distribution of the Parent&#8217;s products or services (B) any most-favored pricing arrangement, (C) any exclusivity provision or (D) any non-solicitation provision;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(vi)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>each Parent Contract (A) pursuant to which any Person granted Parent an exclusive license under any Intellectual Property, or (B) pursuant to which Parent granted any Person an exclusive license under any Parent IP Rights;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(vii)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>each Parent Contract containing any royalty, dividend or similar arrangement based on the revenues or profits of Parent, any of its Subsidiaries, or of a product;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(viii)<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>each Parent Contract relating to capital expenditures and requiring payments after the date of this Agreement in excess of $100,000 pursuant to its express terms and not cancelable without penalty;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(ix)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>each Parent Contract relating to the disposition or acquisition of material assets or any ownership interest in any Entity, in each case, involving payments in excess of $100,000 after the date of this Agreement;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(x)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>each Parent Contract entered into in settlement of any Legal Proceeding or other dispute pursuant to which Parent or any of its Subsidiaries has outstanding obligations to pay consideration in excess of $100,000;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(xi)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>each Parent Contract relating to any mortgages, indentures, loans, notes or credit agreements, security agreements or other agreements or instruments relating to the borrowing of money or extension of credit in excess of $100,000 or creating any material Encumbrances with respect to any assets of Parent or any loans or debt obligations with officers or directors of Parent;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(xii)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>each Parent Contract requiring payment by or to Parent after the date of this Agreement in excess of $100,000 pursuant to its express terms relating to: (A) any distribution agreement (identifying any that contain exclusivity provisions), (B) any agreement involving provision of services or products with respect to any pre-clinical or clinical development activities of Parent, (C) any dealer, distributor, joint marketing, alliance, joint venture, cooperation, development or other agreement currently in force under which Parent or any of its Subsidiaries has continuing obligations to develop or market any product, technology or service, or any agreement pursuant to which Parent or any of its Subsidiaries has continuing obligations to develop any Intellectual Property that will not be owned, in whole or in part, by Parent or such Subsidiary or (D) any Contract to license any patent, trademark registration, service mark registration, trade name or copyright registration to or from any third party to manufacture or produce any product, service or technology of Parent or any of its Subsidiaries or any Contract to sell, distribute or commercialize any products or service of Parent or any of its Subsidiaries, in each case, except for Parent Contracts entered into in the Ordinary Course of Business;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(xiii)<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>each Parent Contract with any Person, including any financial advisor, broker, finder, investment banker or other Person, providing advisory services to Parent in connection with the Contemplated Transactions and requiring payments by Parent after the date in this Agreement in excess of $100,000 pursuant to its express terms;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(xiv)<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>each Parent Contract to which Parent or any of its Subsidiaries is a party or by which any of their assets and properties is currently bound (other than Parent Real Estate Leases), which involves annual obligations of payment by, or annual payments to, Parent or such Subsidiary in excess of $100,000;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(xv)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>any Parent Real Estate Lease;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(xvi)<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>a Contract disclosed in or required to be disclosed in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;4.12(b)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> or </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;4.12(c)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Parent Disclosure Letter; or</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-43</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(xvii)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>any other Parent Contract (other than Parent Real Estate Leases) that is not terminable at will (with no penalty or payment) by Parent or any of its Subsidiaries, and (A) which involves payment or receipt by Parent or such Subsidiary after the date of this Agreement under any such agreement, contract or commitment of more than $100,000 in the aggregate, or obligations after the date of this Agreement in excess of $100,000 in the aggregate or (B) that is material to the business or operations of Parent and its Subsidiaries taken as a whole.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Parent has delivered or made available to the Company accurate and complete copies of all Parent Material Contracts, including all amendments thereto. There are no Parent Material Contracts that are not in written form. Parent has not nor, to Parent&#8217;s Knowledge as of the date of this Agreement, has any other party to a Parent Material Contract, breached, violated or defaulted under, or received notice that it breached, violated or defaulted under, any of the terms or conditions of any Parent Material Contract in such a manner, and, if such Parent Material Contract provides for a cure period, Parent or such other party fails to have cured such breach, violation or default, so that any other party or Parent, as the case may be, is permitted to modify, cancel or terminate any such Parent Material Contract, or would permit any other party to seek damages which would reasonably be expected to have a Parent Material Adverse Effect. As to Parent and its Subsidiaries, as of the date of this Agreement, each Parent Material Contract is valid, binding, enforceable and in full force and effect, subject to the Enforceability Exceptions. No Person is renegotiating, or has a right pursuant to the terms of any Parent Material Contract to change, any material amount paid or payable to Parent under any Parent Material Contract or any other material term or provision of any Parent Material Contract.</span></p>
		<p class="ParaOverride-18" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;page-break-after:avoid;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">4.14<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Compliance; Permits; Restrictions</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Parent and each of its Subsidiaries is, and since January 1, 2023, has been in material compliance with all applicable Laws. No investigation, claim, suit, proceeding, audit, Order or other action by any Governmental Authority is pending or, to the Knowledge of Parent, threatened against Parent or any of its Subsidiaries. There is no agreement or Order binding upon Parent or any of its Subsidiaries which (i)&#160;has or would reasonably be expected to have the effect of prohibiting or materially impairing any business practice of Parent or any of its Subsidiaries, any acquisition of material property by Parent or any of its Subsidiaries or the conduct of business by Parent or any of its Subsidiaries as currently conducted, (ii) is reasonably likely to have an adverse effect on Parent&#8217;s ability to comply with or perform any covenant or obligation under this Agreement or (iii) is reasonably likely to have the effect of preventing, delaying, making illegal or otherwise interfering with the Contemplated Transactions.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Except for matters regarding the FDA or other Drug/Device Regulatory Agency, each of Parent and its Subsidiaries holds all required Governmental Authorizations that are material to the operation of the business of Parent and Merger Subs as currently conducted (collectively, the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Permits</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;). </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;4.14(b)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Parent Disclosure Letter identifies each Parent Permit. Each of Parent and its Subsidiaries is in material compliance with the terms of the Parent Permits. No Legal Proceeding is pending or, to the Knowledge of Parent, threatened, which seeks to revoke, substantially limit, suspend or materially modify any Parent Permit. The rights and benefits of each Parent Permit, if any, will be available to Parent and Surviving Entity immediately after the Second Effective Time on terms substantially identical to those enjoyed by Parent and its Subsidiaries as of the date of this Agreement and immediately prior to the First Effective Time.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>There are no Legal Proceedings pending or, to the Knowledge of Parent, threatened with respect to an alleged violation by Parent or any of its Subsidiaries of the FDCA, PHSA, FDA regulations adopted thereunder, the Controlled Substances Act or any other similar Law promulgated by a Drug/Device Regulatory Agency.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Each of Parent and its Subsidiaries holds all required Governmental Authorizations issuable by any Drug/Device Regulatory Agency necessary for the conduct of the business of Parent and Merger Subs as currently conducted, and, as applicable, the development, testing, manufacturing, processing, storage, labeling, sale, marketing, advertising, distribution and importation or exportation, as currently conducted, of any of its product candidates (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Product Candidates</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Regulatory Permits</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) and no such Parent Regulatory Permit has been (i) revoked, withdrawn, suspended, cancelled or terminated or (ii) modified in any adverse manner other than immaterial adverse modifications. Section&#160;4.14(d) of the Parent Disclosure Letter identifies each Parent Regulatory Permit. Parent has timely maintained and is in compliance in all material respects with the Parent Regulatory Permits and neither Parent nor or any of its Subsidiaries has, since January 1, 2023, </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-44</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">received any written notice or correspondence or, to the Knowledge of Parent, other communication from any Drug/Device Regulatory Agency regarding (A) any material violation of or failure to comply materially with any term or requirement of any Parent Regulatory Permit or (B) any revocation, withdrawal, suspension, cancellation, termination or material modification of any Parent Regulatory Permit. Parent has made available to the Company all information requested by the Company in Parent&#8217;s or its Subsidiaries&#8217; possession or control relating to material Parent Product Candidates and the development, testing, manufacturing, processing, storage, labeling, sale, marketing, advertising, distribution and importation or exportation of the Parent Product Candidates, including, but not limited to, complete copies of the following (to the extent there are any): (x) adverse event reports; pre-clinical, clinical and other study reports and material study data; inspection reports, notices of adverse findings, untitled letters, warning letters, filings and letters and other written correspondence to and from any Drug/Device Regulatory Agency; and meeting minutes with any Drug/Device Regulatory Agency and (y) similar reports, material study data, notices, letters, filings, correspondence and meeting minutes with any other Governmental Authority. All such information are accurate and complete in all material respects.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(e)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>All clinical, pre-clinical and other studies and tests conducted by or on behalf of, or sponsored by, Parent or its Subsidiaries, in which Parent or its Subsidiaries or their respective product candidates, including the Parent Product Candidates, have participated were, since January 1, 2023, and, if still pending, are being conducted in accordance in all material respects with standard medical and scientific research procedures, and in compliance in all material respects with the applicable regulations of the Drug/Device Regulatory Agencies and other applicable Law, including 21 C.F.R. Parts 11, 50, 54, 56, 58, 312 and 812. Since January 1, 2023, neither Parent nor any of its Subsidiaries has received any written notices, correspondence, or other communications from any Drug/Device Regulatory Agency requiring or, to the Knowledge of Parent, any action to place a clinical hold order on, or otherwise terminate, delay or suspend any clinical studies conducted by or on behalf of, or sponsored by, Parent or any of its Subsidiaries or in which Parent or any of its Subsidiaries or its current product candidates, including the Parent Product Candidates, have participated. Further, no clinical investigator, researcher or clinical staff participating in any clinical study conducted by or, to the Knowledge of Parent, on behalf of Parent or any of its Subsidiaries has been disqualified from participating in studies involving the Parent Product Candidates, and to the Knowledge of Parent, no such administrative action to disqualify such clinical investigators, researchers or clinical staff has been threatened or is pending.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(f)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Neither Parent nor any of its Subsidiaries and, to the Knowledge of Parent, any contract manufacturer with respect to any Parent Product Candidate is the subject of any pending or, to the Knowledge of Parent, threatened investigation in respect of its business or products by the FDA pursuant to its &#8220;Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities&#8221; Final Policy set forth in 56 Fed. Reg.&#160;46191 (September 10, 1991) and any amendments thereto or by any other Drug/Device Regulatory Agency under a comparable policy. Neither Parent nor any of its Subsidiaries and, to the Knowledge of Parent, any contract manufacturer, nor their respective officers, employees or agents, with respect to any Parent Product Candidate has committed any acts, made any statement or failed to make any statement, in each case in respect of its business or products that would violate FDA&#8217;s &#8220;Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities&#8221; Final Policy, and any amendments thereto. None of Parent, any of its Subsidiaries, and to the Knowledge of Parent, any contract manufacturer with respect to any Parent Product Candidate, or any of their respective officers, employees or agents is currently or has been debarred, convicted of any crime or is engaging or has engaged in any conduct that could result in a material debarment or exclusion under (i) 21 U.S.C. Section&#160;335a or (ii) any similar applicable Law. To the Knowledge of Parent, no material debarment or exclusionary claims, actions, proceedings or investigations in respect of their business or products are pending or threatened against Parent, any of its Subsidiaries, and to the Knowledge of the Parent, any contract manufacturer with respect to any Parent Product Candidate, or any of its officers, employees or agents.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(g)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>All manufacturing operations conducted by, or to the Knowledge of Parent, for the benefit of, Parent or its Subsidiaries in connection with any Parent Product Candidate, since January 1, 2023, have been and are being conducted in compliance in all material respects with applicable Laws, including the FDA&#8217;s standards for current good manufacturing practices, including applicable requirements contained in 21 C.F.R. Parts 210 and 211, and the respective counterparts thereof promulgated by Governmental Authorities in countries outside the United States.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-45</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(h)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>None of Parent, any of its Subsidiaries, and to the Knowledge of Parent, any manufacturing site of a contract manufacturer or laboratory, with respect to any Parent Product Candidate, (i) is subject to a Drug/Device Regulatory Agency shutdown or import or export prohibition or (ii) has received any Form&#160;FDA 483, notice of violation, warning letter, untitled letter or similar correspondence or notice from the FDA or other Drug/Device Regulatory Agency alleging or asserting noncompliance with any applicable Law, in each case, that have not been complied with or closed to the satisfaction of the relevant Drug/Device Regulatory Agency, and, to the Knowledge of Parent, neither the FDA nor any other Drug/Device Regulatory Agency is considering such action.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">4.15<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Legal Proceedings; Orders</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>There is no pending Legal Proceeding and, to the Knowledge of Parent, no Person has threatened in writing to commence any Legal Proceeding: (i) that involves Parent or any of its Subsidiaries or any Parent Associate (in his or her capacity as such) or any of the material assets owned or used by Parent or any of its Subsidiaries or (ii) that challenges, or that may have the effect of preventing, delaying, making illegal or otherwise interfering with, the Contemplated Transactions.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>There is no Order to which Parent or any of its Subsidiaries, or any of the material assets owned or used by Parent or any of its Subsidiaries is subject. To the Knowledge of Parent, no officer or other Parent Key Employee or any of its Subsidiaries is subject to any Order that prohibits such officer or employee from engaging in or continuing in any conduct, activity or practice relating to the business of Parent or any of its Subsidiaries or any material assets owned or used by Parent or any of its Subsidiaries.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">4.16<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Tax Matters</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Each of Parent and each of its Subsidiaries has timely filed (or caused to be timely filed) all income Tax Returns and all other material Tax Returns required to be filed by it under applicable Law (taking into account any applicable extensions). All such Tax Returns were true, correct and complete in all material respects. Subject to exceptions as would not be material, no claim has been made by a Governmental Authority in a jurisdiction where Parent or any of its Subsidiaries does not file Tax Returns that Parent or any of its Subsidiaries is subject to taxation by that jurisdiction.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>All material amounts of Taxes due and owing by Parent or any of its Subsidiaries (whether or not shown on any Tax Return) have been timely paid (taking into account any applicable extensions).</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Each of Parent and each of its Subsidiaries has withheld and paid to the appropriate Governmental Authority all material Taxes required to have been withheld and paid in connection with any amounts paid or owing to any employee, independent contractor, creditor, stockholder or other third party.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>There are no Encumbrances for a material amount of Taxes (other Encumbrances described in clause&#160;(a) of the definition of &#8220;Permitted Encumbrances&#8221;) upon any of the assets of Parent or any of its Subsidiaries.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(e)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>No deficiencies for a material amount of Taxes with respect to Parent or any of its Subsidiaries have been claimed, proposed or assessed by any Governmental Authority in writing that have not been timely paid in full. There are no pending (or, based on written notice, threatened) material audits, assessments, examinations or other actions for or relating to any liability in respect of Taxes of Parent or any of its Subsidiaries. Neither Parent nor any of its Subsidiaries has granted a waiver of any statute of limitations in respect of a material amount of Taxes or an extension of time with respect to a material Tax assessment or deficiency that, in each case, is currently in effect.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(f)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Neither Parent nor any of its Subsidiaries is a party to any Tax allocation, Tax sharing or similar agreement (including indemnity arrangements), other than Ordinary Course Agreements.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(g)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Neither Parent nor any of its Subsidiaries has been a member of an affiliated group filing a consolidated U.S. federal income Tax Return (other than a group the common parent of which is Parent). Neither Parent nor any of its Subsidiaries has any material Liability for the Taxes of any Person (other than Parent or its Subsidiaries) under Treasury Regulations Section&#160;1.1502-6 (or any similar provision of state, local, or foreign law), as a transferee or successor, or by Contract (other than an Ordinary Course Agreement).</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-46</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(h)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Neither Parent nor any of its Subsidiaries has distributed stock of another Person, or has had its stock distributed by another Person, in a transaction that was purported or intended to be governed in whole or in part by Section&#160;355 of the Code or Section&#160;361 of the Code.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(i)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Neither Parent nor any of its Subsidiaries has entered into any transaction identified as a &#8220;listed transaction&#8221; for purposes of Treasury Regulations Sections&#160;1.6011-4(b)(2) or 301.6111-2(b)(2).</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(j)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Neither Parent nor any of its Subsidiaries is aware of any facts or circumstances or has taken or agreed to take any action, in each case, that would reasonably be expected to prevent or impede the Intended Tax Treatment.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">4.17<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Employee and Labor Matters; Benefit Plans</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Parent has made available to Company a list setting forth, for each Parent Associate who is an employee of Parent or any of its Subsidiaries, such employee&#8217;s name, employer, title, hire date, location, whether full- or part-time, whether active or on leave (and, if on leave, the expected return), whether exempt from the Fair Labor Standards Act and applicable state law, annual salary (or if hourly, hourly rate), most recent annual bonus received and current annual bonus opportunity. The Parent has made available to Company a list setting forth, for each Parent Associate who is an individual independent contractor engaged by Parent or any of its Subsidiaries, such contractor&#8217;s name, duties and rate of compensation.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The employment of Parent&#8217;s employees is terminable by Parent at will. Parent has made available to the Company accurate and complete copies of all employee manuals and handbooks, to the extent currently effective and material.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Parent is not a party to, bound by the terms of, and does not have a duty to bargain under, any collective bargaining agreement or other Contract with a labor organization representing any of its employees, and there are no labor organizations representing or, to the Knowledge of Parent, purporting to represent or seeking to represent any employees of Parent.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;4.17(d)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Parent Disclosure Letter lists all Parent Employee Plans (other than employment arrangements which are terminable &#8220;at will&#8221; without any contractual obligation on the part of Parent or any of its Subsidiaries to make any severance, termination, change in control or similar payment and that are substantively identical to the employment arrangements made available to the Company).</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(e)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Each Parent Employee Plan that is intended to be qualified under Section&#160;401(a) of the Code has received a favorable determination or opinion letter with respect to such qualified status from the IRS. To the Knowledge of Parent, nothing has occurred that would reasonably be expected to adversely affect the qualified status of any such Parent Employee Plan or the exempt status of any related trust.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(f)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Each Parent Employee Plan has been established, maintained and operated in compliance, in all material respects, with its terms all applicable Law, including, without limitation, the Code, ERISA and the Affordable Care Act. No Legal Proceeding (other than those relating to routine claims for benefits) is pending or, to the Knowledge of Parent, threatened with respect to any Parent Employee Plan. All payments and/or contributions required to have been made with respect to all Parent Employee Plans either have been made or have been accrued in accordance with the terms of the applicable Parent Employee Plan and applicable Law.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(g)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Neither Parent nor any of its ERISA Affiliates maintains, contributes to or is required to contribute to, or has, in the past six (6) years, maintained, contributed to or been required to contribute to (i) any &#8220;employee benefit plan&#8221; that is or was subject to Title IV or Section&#160;302 of ERISA or Section&#160;412 of the Code, (ii) a Multiemployer Plan, (iii) any funded welfare benefit plan within the meaning of Section&#160;419 of the Code, (iv) any Multiple Employer Plan, or (v) any Multiple Employer Welfare Arrangement. Neither Parent nor any of its ERISA Affiliates has ever incurred any liability under Title IV of ERISA.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(h)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>No Parent Employee Plan provides for medical or other welfare benefits to any service provider beyond termination of service or retirement, other than (1) pursuant to COBRA or an analogous state law requirement or (2) continuation coverage through the end of the month in which such termination or retirement occurs. Parent does not sponsor or maintain any self-funded medical or long-term disability benefit plan.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-47</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(i)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span> No Parent Employee Plan is subject to any law of a foreign jurisdiction outside of the United States.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(j)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Each Parent Employee Plan that constitutes in any part a &#8220;nonqualified deferred compensation plan&#8221; (as such term is defined under Section&#160;409A(d)(1) of the Code and the guidance thereunder) (each, a &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent 409A Plan</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) has been operated and maintained in all material respects in operational and documentary compliance with the requirements of Section&#160;409A of the Code and the applicable guidance thereunder. No payment to be made under any Parent 409A Plan is or, when made in accordance with the terms of the Parent 409A Plan, will be subject to the penalties of Section&#160;409A(a)(1) of the Code.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(k)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Parent is in material compliance with all Employment-Related Laws and in each case, with respect to the employees of Parent: (i)&#160;has withheld and reported all material amounts required by law or by agreement to be withheld and reported with respect to wages, salaries and other payments to employees, (ii)&#160;is not liable for any material amounts of arrears of wages, severance pay or any Taxes or any penalty for failure to comply with any of the foregoing and (iii)&#160;is not liable for any material payment to any trust or other fund governed by or maintained by or on behalf of any Governmental Authority, with respect to unemployment compensation benefits, social security or other benefits or obligations for employees (other than routine payments to be made in the Ordinary Course of Business). There are no material Legal Proceedings, claims, labor disputes or organizing activities, or grievances pending or, to the Knowledge of Parent, threatened or reasonably anticipated against or involving Parent or any trustee of Parent relating to any employee, contingent worker, director, employment agreement or Parent Employee Plan (other than routine claims for benefits) or Employment-Related Laws. To the Knowledge of Parent, there are no material pending or threatened or reasonably anticipated claims or actions against Parent, any Parent trustee or any trustee of any Subsidiary of Parent under any workers&#8217; compensation policy or long-term disability policy. Parent is not a party to a conciliation agreement, consent decree or other agreement or Order with any federal, state or local agency or Governmental Authority with respect to employment practices.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(l)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Parent has no material liability with respect to any misclassification within the past three (3) years of: (i) any Person as an independent contractor rather than as an employee, (ii) any employee leased from another employer or (iii) any employee currently or formerly classified as exempt from overtime wages. Parent has not taken any action which would constitute a &#8220;plant closing&#8221; or &#8220;mass layoff&#8221; within the meaning of the WARN Act, issued any notification of a plant closing or mass layoff required by the WARN Act (nor has Parent been under any requirement or obligation to issue any such notification), or incurred any liability or obligation under the WARN Act that remains unsatisfied.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(m)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>To the Knowledge of Parent, there has never been, nor has there been any threat of, any strike, slowdown, work stoppage, lockout, job action, union, organizing activity, question concerning representation or any similar activity or dispute, with respect to any Parent Associate. No event has occurred within the past six months, and no condition or circumstance exists, that, to the Knowledge of Parent, might directly or indirectly be likely to give rise to or provide a basis for the commencement of any such strike, slowdown, work stoppage, lockout, job action, union organizing activity, question concerning representation or any similar activity or dispute.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(n)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Parent is not, nor has Parent been, engaged in any material unfair labor practice within the meaning of the National Labor Relations Act. There is no material Legal Proceeding, claim, labor dispute or grievance pending or, to the Knowledge of Parent, threatened or reasonably anticipated relating to any employment contract, privacy right, labor dispute, wages and hours, leave of absence, plant closing notification, workers&#8217; compensation policy, long-term disability policy, harassment, retaliation, immigration, employment statute or regulation, safety or discrimination matter involving any current or former employee of Parent, including charges of unfair labor practices or discrimination complaints.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(o)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>There is no contract, agreement, plan or arrangement to which Parent or any of its Subsidiaries is a party or by which it is bound to compensate any of its employees or other service providers for any income or excise taxes paid pursuant to the Code, including, but not limited to, Section&#160;4999 or Section&#160;409A of the Code.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(p)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Neither Parent nor any of its Subsidiaries is a party to any Contract that as a result of the execution and delivery of this Agreement, the stockholder approval of this Agreement, nor the consummation of the transactions contemplated hereby, could (either alone or in conjunction with any other event) </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-48</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(i) result in the payment of any &#8220;parachute payment&#8221; within the meaning of Section&#160;280G of the Code or (ii) result in, or cause the accelerated vesting, payment, funding or delivery of, or increase the amount or value of, any payment or benefit to any employee, officer, director or other service provider of Parent or any of its Subsidiaries.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">4.18<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Environmental Matters</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Since January 1, 2023, Parent and each of its Subsidiaries has complied with all applicable Environmental Laws, which compliance includes the possession by Parent of all permits and other Governmental Authorizations required under applicable Environmental Laws and compliance with the terms and conditions thereof, except for any failure to be in compliance that, individually or in the aggregate, would not result in a Parent Material Adverse Effect. Neither Parent nor any of its Subsidiaries has received since January 1, 2023, any written notice or other communication (in writing or otherwise), whether from a Governmental Authority, citizens group, employee or otherwise, that alleges that Parent or any of its Subsidiaries is not in compliance with any Environmental Law, and, to the Knowledge of Parent, there are no circumstances that may prevent or interfere with Parent&#8217;s or any of its Subsidiaries&#8217; compliance with any Environmental Law in the future, except where such failure to comply would not reasonably be expected to have a Parent Material Adverse Effect. To the Knowledge of Parent: (i) no current or prior owner of any property leased or controlled by Parent or any of its Subsidiaries has received since January 1, 2023, any written notice or other communication relating to property owned or leased at any time by Parent or any of its Subsidiaries, whether from a Governmental Authority, citizens group, employee or otherwise, that alleges that such current or prior owner or Parent or any of its Subsidiaries is not in compliance with or violated any Environmental Law relating to such property and (ii) neither Parent nor any of its Subsidiaries has any material liability under any Environmental Law. Parent has made available all environmental site assessments, environmental audits and other material environmental documents in the Parent&#8217;s possession or control relating to the Parent and its Subsidiaries, including the Parent&#8217;s and its Subsidiaries&#8217; business and current or former facilities.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">4.19<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Insurance</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;"> </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Parent has delivered to the Company accurate and complete copies of all material insurance policies and all material self-insurance programs and arrangements relating to the business, assets, liabilities and operations of Parent and its Subsidiaries (including Merger Subs). Each of such insurance policies is in full force and effect and Parent and its Subsidiaries (including Merger Subs) are in compliance in all material respects with the terms thereof. Other than customary end of policy notifications from insurance carriers, since January 1, 2023, neither Parent nor any of its Subsidiaries has received any notice or other communication regarding any actual or possible: (i) cancellation or invalidation of any insurance policy or (ii) refusal or denial of any coverage, reservation of rights or rejection of any material claim under any insurance policy. Each of Parent and its Subsidiaries (including Merger Subs) has provided timely written notice to the appropriate insurance carrier(s) of each Legal Proceeding pending against Parent or such Subsidiary for which Parent or such Subsidiary has insurance coverage, and no such carrier has issued a denial of coverage or a reservation of rights with respect to any such Legal Proceeding, or informed Parent or any of its Subsidiaries of its intent to do so.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">4.20<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Transactions with Affiliates</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Except as set forth in the Parent SEC Documents filed prior to the date of this Agreement, since the date of Parent&#8217;s last proxy statement filed with the SEC, no event has occurred that would be required to be reported by Parent pursuant to Item 404 of Regulation S-K promulgated by the SEC. </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;4.20</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Parent Disclosure Letter identifies each Person who is (or who may be deemed to be) an Affiliate of Parent as of the date of this Agreement.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">4.21<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">No Financial Advisors</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Except as set forth on </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;4.21</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Parent Disclosure Letter, no broker, finder or investment banker is entitled to any brokerage fee, finder&#8217;s fee, opinion fee, success fee, transaction fee or other fee or commission in connection with the Contemplated Transactions based upon arrangements made by or on behalf of Parent.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">4.22<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Valid Issuance</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Parent Capital Stock (including any Parent Common Stock issuable upon conversion of the Parent Convertible Preferred Stock) to be issued in the Merger will, when issued in accordance with the provisions of this Agreement, be validly issued, fully paid and nonassessable. The Parent Common Stock issuable upon conversion of the Parent Convertible Preferred Stock has been duly reserved for issuance, and upon issuance in accordance with the terms of the Certificate of Designation, will be validly issued, fully paid and nonassessable.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">4.23<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Privacy and Data Security</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Parent and its Subsidiaries are and since January 1, 2023, have been in compliance with all applicable Privacy Laws and the applicable terms of any Parent Contracts governing privacy, data protection, data security, trans-border data flow, data loss, data theft, or breach notification, data </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-49</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">localization, sending solicited or unsolicited electronic mail or text messages, cookies or other tracking technology, with respect to, or the collection, handling, use, maintenance, storage, disclosure, transfer, or other processing of, Personal Information (including any such information of individuals, clinical trial participants, patients, patient family members, caregivers or advocates, physicians and other health care professionals, clinical trial investigators, researchers, pharmacists that interact with Parent or any of its Subsidiaries in connection with the operation of Parent&#8217;s and its Subsidiaries&#8217; business), except, in each case, for such noncompliance as has not had, and would not reasonably be expected to have, individually or in the aggregate, a Parent Material Adverse Effect. To the Knowledge of Parent, Parent (i) has implemented and maintains reasonable Privacy Policies that materially comply with applicable Privacy Laws and are designed to protect the privacy and security of Personal Information and (ii) has complied with such Privacy Policies, except for such noncompliance as has not had, and would not reasonably be expected to have, individually or in the aggregate, a Parent Material Adverse Effect. To the Knowledge of Parent, no Legal Proceeding has been asserted or threatened against Parent by any Person alleging a violation of Privacy Laws, Privacy Policies, or the applicable terms of any Parent Contracts governing privacy, data protection, data security, trans-border data flow, data loss, data theft, or breach notification, data localization, sending solicited or unsolicited electronic mail or text messages, cookies or other tracking technology, with respect to, or the collection, handling, use, maintenance, storage, disclosure, transfer, or other processing of, Personal Information. To the Knowledge of Parent, there have been no data security incidents or data breaches, or other adverse events or incidents that have resulted in any unauthorized access to, or collection, use, disclosure, modification or destruction of, Personal Information or other data in the possession or control of Parent or any service provider acting on behalf of Parent, in each case, where such incident, breach, or event has resulted in a notification obligation to any Person under applicable Law or pursuant to the terms of any Parent Contract.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">4.24<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">No Other Representations or Warranties</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Parent hereby acknowledges and agrees that, except for the representations and warranties contained in this Agreement, neither the Company nor any of its Subsidiaries nor any other person on behalf of the Company or its Subsidiaries makes any express or implied representation or warranty with respect to the Company or its Subsidiaries or with respect to any other information provided to Parent, Merger Subs or stockholders or any of their respective Affiliates in connection with the Contemplated Transactions, and (subject to the express representations and warranties of the Company set forth in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;3</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> (in each case as qualified and limited by the Company Disclosure Letter)) none of Parent, Merger Subs nor any of their respective Representatives or stockholders, has relied on any such information (including the accuracy or completeness thereof).</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;5. </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Certain Covenants of the Parties</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">5.1<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Operation of Parent&#8217;s Business</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Except (i) as expressly contemplated or permitted by this Agreement, (ii)&#160;as set forth in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;5.1(a)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Parent Disclosure Letter, (iii) as required by applicable Law, or (iv) unless the Company shall otherwise consent in writing (which consent shall not be unreasonably withheld, delayed or conditioned), during the period commencing on the date of this Agreement and continuing until the earlier to occur of the termination of this Agreement pursuant to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and the First Effective Time (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Pre-Closing Period</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), Parent shall, and shall cause its Subsidiaries to, use commercially reasonable efforts to (x) conduct its business and operations in the Ordinary Course of Business and in material compliance with all applicable Law and the requirements of all Contracts that constitute Parent Material Contracts and (y) continue to pay material outstanding accounts payable and other material current Liabilities (including payroll) when due and payable.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Except (i)&#160;as expressly contemplated or permitted by this Agreement, (ii)&#160;as set forth in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;5.1(b)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#160;of the Parent Disclosure Letter, (iii) as required by applicable Law, or (iv)&#160;with the prior written consent of the Company (which consent shall not be unreasonably withheld, delayed or conditioned), at all times during the Pre-Closing Period, Parent shall not, nor shall it cause or permit any of Subsidiaries to, do any of the following:</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(i)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>declare, accrue, set aside or pay any dividend or make any other distribution in respect of any shares of its capital stock or repurchase, redeem or otherwise reacquire any shares of its capital stock or other securities, (except for shares of Parent Common Stock from terminated employees, directors or consultants of Parent);</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-50</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(ii)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>except as required to give effect to anything in contemplation of the Closing, amend any of its Organizational Documents, or effect or be a party to any merger, consolidation, share exchange, business combination, recapitalization, reclassification of shares, stock split, reverse stock split or similar transaction except, for the avoidance of doubt, the Contemplated Transactions;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(iii)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>sell, issue, grant, pledge or otherwise dispose of or encumber or authorize the issuance of: (A) any capital stock or other security (except for Parent Common Stock issued upon the valid exercise or settlement of outstanding Parent Options or Parent Restricted Stock Units, as applicable), (B)&#160;any option, warrant or right to acquire any capital stock or any other security or (C) any instrument convertible into or exchangeable for any capital stock or other security;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(iv)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>form any Subsidiary or acquire any equity interest or other interest in any other Entity or enter into a joint venture with any other Entity;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(v)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>(A) lend money to any Person, (B) incur or guarantee any indebtedness for borrowed money, (C) guarantee any debt securities of others or (D) make any capital expenditure or commitment in excess of $25,000;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(vi)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>(A) adopt, establish or enter into any Parent Employee Plan, including, for the avoidance of doubt, any equity awards plans, (B) cause or permit any Parent Employee Plan to be amended other than as required by law or in order to make amendments for the purposes of compliance with Section&#160;409A of the Code, (C) pay any bonus or make any profit-sharing or similar payment to (except with respect to obligations in place on the date of this Agreement pursuant to any Parent Employee Plan disclosed to the Company), or increase the amount of the wages, salary, commissions, fringe benefits or other compensation or remuneration payable to, any of its directors, officers, employees or consultants, (D)&#160;increase the severance or change of control benefits offered to any current or new employees, directors or consultants, or (E)&#160;hire any officer, employee or consultant;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(vii)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>acquire any material asset or sell, lease, license or otherwise irrevocably dispose of any of its assets or properties, or grant any Encumbrance with respect to such assets or properties;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(viii)<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>sell, assign, transfer, license, sublicense or otherwise dispose of any material Parent IP Rights (other than pursuant to non-exclusive licenses in the Ordinary Course of Business);</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(ix)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>other than in the Ordinary Course of Business: (A) make, change or revoke any material Tax election; (B) file any amended income or other material Tax Return; (C) adopt or change any material accounting method in respect of Taxes; (D) enter into any material Tax closing agreement, settle any material Tax claim or assessment; (E) consent to any extension or waiver of the limitation period applicable to or relating to any material Tax claim or assessment; or (F) surrender any material claim for refund;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(x)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>waive, settle or compromise any pending or threatened Legal Proceeding against Parent or any of its Subsidiaries, other than waivers, settlements or agreements (A)&#160;for an amount not in excess of $100,000 in the aggregate (excluding amounts to be paid under existing insurance policies or renewals thereof) and (B) that do not impose any material restrictions on the operations or businesses of Parent or its Subsidiaries, taken as a whole, or any equitable relief on, or the admission of wrongdoing by Parent or any of its Subsidiaries;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(xi)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>delay or fail to repay when due any material obligation, including accounts payable and accrued expenses;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(xii)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>forgive any loans to any Person, including its employees, officers, directors or Affiliate;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(xiii)<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>terminate or modify in any material respect, or fail to exercise renewal rights with respect to, any material insurance policy;</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-51</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(xiv)<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>(A) materially change pricing or royalties or other payments set or charged by Parent or any of Subsidiaries to its customers or licensees or (B) agree to materially change pricing or royalties or other payments set or charged by Persons who have licensed Intellectual Property to Parent or any of Subsidiaries;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(xv)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>enter into, amend in a manner adverse to Parent or terminate any Parent Material Contract outside of the Ordinary Course of Business; or</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(xvi)<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>agree, resolve or commit to do any of the foregoing.</span></p>
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Nothing contained in this Agreement shall give the Company, directly or indirectly, the right to control or direct the operations of Parent prior to the First Effective Time. Prior to the First Effective Time, Parent shall exercise, consistent with the terms and conditions of this Agreement, complete unilateral control and supervision over its business operations.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Notwithstanding any provision herein to the contrary (including the foregoing provisions of this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;5.1</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">), Parent may:</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(i)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>engage in the sale, license, transfer, disposition, divestiture or other monetization transaction (i.e., a royalty transaction) or winding down of the Parent Legacy Business (including terminating its Parent Real Estate Leases and other Parent Contracts) or the sale, license, transfer, disposition, divestiture or other monetization transaction (i.e., a royalty transaction) or other disposition of any Parent Legacy Business (each, an &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Legacy Transaction</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;); </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">however</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that to the extent any Parent Legacy Transaction results in material obligations of Parent that will extend beyond Closing, such terms shall be reasonably acceptable to the Company and any such post-Closing obligations shall be a reduction to Parent Net Cash; and</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(ii)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>declare and pay a dividend on the shares of Parent Common Stock outstanding prior to the First Effective Time (excluding for the avoidance of doubt any shares of Parent Common Stock issuable pursuant to the Contemplated Transactions), up to an amount equal in the aggregate to Parent&#8217;s reasonable, good faith approximation of the amount by which Parent Net Cash will exceed $5,000,000 (such dividend, the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Pre-Closing Dividend</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; and such amount, the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Pre-Closing Dividend Amount</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;).</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">5.2<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Operation of the Company&#8217;s Business.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Except (i) as expressly contemplated or permitted by this Agreement or the Subscription Agreement, (ii)&#160;as set forth in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;5.2(a)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Company Disclosure Letter, (iii) as required by applicable Law, (iv) with respect to the issuance of any Company Notes, which is expressly permitted, or (v)&#160;unless Parent shall otherwise consent in writing (which consent shall not be unreasonably withheld, delayed or conditioned), during the Pre-Closing Period the Company shall, and shall cause its Subsidiaries to, use commercially reasonable efforts to conduct its business and operations in the Ordinary Course of Business and in material compliance with all applicable Law and the requirements of all Contracts that constitute Company Material Contracts.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Except (i) as expressly contemplated or permitted by this Agreement, including the Subscription Agreement, (ii)&#160;as set forth in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;5.2(b)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Company Disclosure Letter, (iii) as required by applicable Law, (iv) with respect to the issuance of any Company Notes, which is expressly permitted, or (v) with the prior written consent of Parent (which consent shall not be unreasonably withheld, delayed or conditioned), at all times during the Pre-Closing Period, the Company shall not, nor shall it cause or permit any of its Subsidiaries to, do any of the following:</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(i)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>declare, accrue, set aside or pay any dividend or make any other distribution in respect of any shares of its capital stock; or repurchase, redeem or otherwise reacquire any shares of Company Capital Stock or other securities (except for shares of Company Common Stock from terminated employees, directors or consultants of the Company);</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-52</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(ii)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>except as required to give effect to anything in contemplation of the Closing, amend any of its or its Subsidiaries&#8217; Organizational Documents, or effect or be a party to any merger, consolidation, share exchange, business combination, recapitalization, reclassification of shares, stock split, reverse stock split or similar transaction except, for the avoidance of doubt, the Contemplated Transactions;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(iii)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>other than in the Ordinary Course of Business, sell, issue grant, or authorize any of the foregoing actions with respect to more than 25% of the shares of Company Capital Stock outstanding as of the date of this Agreement: (A) any capital stock or other security of the Company or any of its Subsidiaries (except for shares of outstanding Company Common Stock issued upon the valid exercise of Company Options or Company Warrants), (B) any option, warrant or right to acquire any capital stock or any other security or (C) any instrument convertible into or exchangeable for any capital stock or other security of the Company or any of its Subsidiaries;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(iv)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>other than in the Ordinary Course of Business, acquire any equity interest or other interest in any other Entity or enter into a joint venture with any other Entity;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(v)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>(A) lend money to any Person, (B) incur or guarantee any indebtedness for borrowed money, or (C) guarantee any debt securities of others;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(vi)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>acquire any material asset or sell, lease, license or otherwise irrevocably dispose of any of its assets or properties, or grant any Encumbrance with respect to such assets or properties, except in the Ordinary Course of Business;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(vii)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>sell, assign, transfer, license, sublicense or otherwise dispose of any material Company IP Rights (other than pursuant to non-exclusive licenses in the Ordinary Course of Business);</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(viii)<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>waive, settle or compromise any pending or threatened Legal Proceeding against the Company, other than waivers, settlements or agreements (A) for an amount not in excess of $100,000 in the aggregate (excluding amounts to be paid under existing insurance policies or renewals thereof) and (B) that do not impose any material restrictions on the operations or businesses of the Company or any equitable relief on, or the admission of wrongdoing by the Company;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(ix)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>enter into, amend in a manner adverse to the Company or terminate any Company Material Contract outside of the Ordinary Course of Business; or</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(x)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>agree, resolve or commit to do any of the foregoing.</span></p>
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Nothing contained in this Agreement shall give Parent, directly or indirectly, the right to control or direct the operations of the Company prior to the First Effective Time. Prior to the First Effective Time, the Company shall exercise, consistent with the terms and conditions of this Agreement, complete unilateral control and supervision over its business operations.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">5.3<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Access and Investigation</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Subject to the terms of the Confidentiality Agreement, which the Parties agree will continue in full force following the date of this Agreement, during the Pre-Closing Period, upon reasonable notice, Parent, on the one hand, and the Company, on the other hand, shall and shall use commercially reasonable efforts to cause such Party&#8217;s Representatives to: (a) provide the other Party and such other Party&#8217;s Representatives with reasonable access during normal business hours to such Party&#8217;s Representatives, personnel, property and assets and to all existing books, records, Tax Returns, work papers and other documents and information relating to such Party and its Subsidiaries, (b) provide the other Party and such other Party&#8217;s Representatives with such copies of the existing books, records, Tax Returns, work papers, product data, and other documents and information relating to such Party and its Subsidiaries, and with such additional financial, operating and other data and information regarding such Party and its Subsidiaries as the other Party may reasonably request, (c) permit the other Party&#8217;s officers and other employees to meet, upon reasonable notice and during normal business hours, with the chief financial officer and other officers and managers of such Party responsible for such Party&#8217;s financial statements and the internal controls of such Party to discuss such matters as the other Party may deem necessary, and (d) make </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-53</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">available to the other Party copies of any material notice, report or other document filed with or sent to or received from any Governmental Authority in connection with the Contemplated Transactions. Any investigation conducted by either Parent or the Company pursuant to this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;5.3</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> shall be conducted in such manner as not to interfere unreasonably with the conduct of the business of the other Party.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Notwithstanding anything herein to the contrary in this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;5.3</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, no access or examination contemplated by this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;5.3</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> shall be permitted to the extent that it would require any Party or its Subsidiaries to waive the attorney-client privilege or attorney work product privilege, or violate any applicable Law; </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that such Party or its Subsidiary (i) shall be entitled to withhold only such information that may not be provided without causing such violation or waiver, (ii) shall provide to the other Party all related information that may be provided without causing such violation or waiver (including, to the extent permitted, redacted versions of any such information) and (iii) shall enter into such effective and appropriate joint-defense agreements or other protective arrangements as may be reasonably requested by the other Party in order that all such information may be provided to the other Party without causing such violation or waiver.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">5.4<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">No Solicitation</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Each of Parent and the Company agrees that, during the Pre-Closing Period, neither it nor any of its Subsidiaries shall, nor shall it or any of its Subsidiaries authorize or permit any of its Representatives to, directly or indirectly: (i) solicit, initiate or knowingly encourage, induce or facilitate the communication, making, submission or announcement of any Acquisition Proposal or Acquisition Inquiry, (ii)&#160;furnish any non-public information regarding such Party to any Person in connection with or in response to an Acquisition Proposal or Acquisition Inquiry, (iii) engage in discussions or negotiations with any Person with respect to any Acquisition Proposal or Acquisition Inquiry, (iv)&#160;execute or enter into any letter of intent or any Contract contemplating or otherwise relating to any Acquisition Transaction or (v) publicly propose to do any of the foregoing; </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">however</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that, notwithstanding anything contained in this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;5.4</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and subject to compliance with this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;5.4</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, prior to the approval of this Agreement by a Party&#8217;s stockholders (i.e., the Required Company Stockholder Vote, in the case of the Company and its Subsidiaries, or the Required Parent Stockholder Vote in the case of Parent), such Party may furnish non-public information regarding such Party and its Subsidiaries to, and enter into discussions or negotiations with, any Person in response to a bona fide written Acquisition Proposal by such Person which such Party&#8217;s board of directors determines in good faith, after consultation with such Party&#8217;s financial advisors and outside legal counsel, constitutes, or is reasonably likely to result in, a Superior Offer (and is not withdrawn) if: (A) such Acquisition Proposal was not obtained or made as a direct or indirect result of a breach of this Agreement, (B) the board of directors of such Party concludes in good faith based on the advice of outside legal counsel, that the failure to take such action would reasonably be expected to be inconsistent with the board of directors&#8217; fiduciary duties under applicable Law, (C) at least two&#160;(2) Business Days prior to initially furnishing any such nonpublic information to, or entering into discussions with, such Person, such Party gives the other Party written notice of the identity of such Person and of such Party&#8217;s intention to furnish nonpublic information to, or enter into discussions with, such Person, (D) such Party receives from such Person an executed Acceptable Confidentiality Agreement and (E) at least two&#160;(2) Business Days prior to furnishing any such nonpublic information to such Person, such Party furnishes such nonpublic information to the other Party (to the extent such information has not been previously furnished by such Party to the other Party). Without limiting the generality of the foregoing, each Party acknowledges and agrees that, in the event any Representative of such Party takes any action that, if taken by such Party, would constitute a breach of this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;5.4</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> by such Party, the taking of such action by such Representative shall be deemed to constitute a breach of this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;5.4</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> by such Party for purposes of this Agreement.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>If any Party or any Representative of such Party receives an Acquisition Proposal or Acquisition Inquiry at any time during the Pre-Closing Period, then such Party shall promptly (and in no event later than one&#160;(1) Business Day after such Party becomes aware of such Acquisition Proposal or Acquisition Inquiry) advise the other Party in writing of such Acquisition Proposal or Acquisition Inquiry (including the identity of the Person making or submitting such Acquisition Proposal or Acquisition Inquiry, and the terms thereof). Such Party shall keep the other Party reasonably informed with respect to the status and terms of any such Acquisition Proposal or Acquisition Inquiry and any material modification or material proposed modification thereto.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-54</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Each Party shall immediately cease and cause to be terminated any existing discussions, negotiations and communications with any Person that relate to any Acquisition Proposal or Acquisition Inquiry as of the date of this Agreement and request the destruction or return of any nonpublic information provided to such Person.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">5.5<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Notification of Certain Matters</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. During the Pre-Closing Period, each of the Company, on the one hand, and Parent, on the other hand, shall promptly notify the other (and, if in writing, furnish copies of) if any of the following occurs: (a) any notice or other communication is received from any Person alleging that the Consent of such Person is or may be required in connection with any of the Contemplated Transactions, (b)&#160;any Legal Proceeding against or involving or otherwise affecting such Party or its Subsidiaries is commenced, or, to the Knowledge of such Party, threatened against such Party or, to the Knowledge of such Party, any director or officer of such Party, (c) such Party becomes aware of any inaccuracy in any representation or warranty made by such Party in this Agreement or (d) the failure of such Party to comply with any covenant or obligation of such Party; in each case that could reasonably be expected to make the timely satisfaction of any of the conditions set forth in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;7</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;8</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> or </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;9</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, as applicable, impossible or materially less likely. No such notice shall be deemed to supplement or amend the Company Disclosure Letter or the Parent Disclosure Letter for the purpose of (x)&#160;determining the accuracy of any of the representations and warranties made by the Company in this Agreement or (y) determining whether any condition set forth in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;7</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;8</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> or </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;9</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> has been satisfied. Any failure by either Party to provide notice pursuant to this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;5.5</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> shall not be deemed to be a breach for purposes of </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;8.2</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> or </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;9.2</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, as applicable, unless such failure to provide such notice was knowing and intentional.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;6. </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Additional Agreements of the Parties</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.1<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Registration Statement, Proxy Statement</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>As promptly as practicable after the date of this Agreement, Parent, in cooperation with the Company, shall prepare and file with the SEC a registration statement on Form S-4 (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Form S-4</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), in which a proxy statement relating to the Parent Stockholder Meeting to be held in connection with the Merger (together with any amendments thereof or supplements thereto, the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Proxy Statement</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) shall be included as a part (the Proxy Statement and the Form S-4, collectively, the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Registration Statement</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), in connection with the registration under the Securities Act of the shares of Parent Common Stock (including any Parent Common Stock issuable upon conversion of the Parent Convertible Preferred Stock) to be issued by virtue of the Contemplated Transactions, other than any shares of Parent Capital Stock which are not permitted to be registered on Form S-4 pursuant to applicable Law. Parent shall use commercially reasonable efforts to (i) cause the Registration Statement to comply with applicable rules and regulations promulgated by the SEC, (ii) cause the Registration Statement to become effective as promptly as practicable, and (iii) respond promptly to any comments or requests of the SEC or its staff related to the Registration Statement. Parent shall use commercially reasonable efforts to take all actions required under any applicable federal, state, securities and other Laws in connection with the issuance of shares of Parent Capital Stock pursuant to the Contemplated Transactions (including any Parent Common Stock issuable upon conversion of the Parent Convertible Preferred Stock). Each of the Parties shall reasonably cooperate with the other Party and furnish all information concerning itself and its Affiliates, as applicable, to the other Parties that is required by law to be included in the Registration Statement as the other Parties may reasonably request in connection with such actions and the preparation of the Registration Statement and Proxy Statement.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Parent covenants and agrees that the Registration Statement (and the letter to stockholders, notice of meeting and form of proxy included therewith) will (i) comply as to form in all material respects with the requirements of applicable U.S. federal securities laws and the DGCL and DLLCA, and (ii)&#160;will not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary in order to make the statements made therein, in light of the circumstances under which they were made, not misleading. The Company covenants and agrees that the information supplied by or on behalf of the Company to Parent for inclusion in the Registration Statement (including the Company Budget) will not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary in order to make such information, in light of the circumstances under which they were made, not misleading. Notwithstanding the foregoing, neither Party makes any covenant, representation or warranty with respect to statements made in the Registration Statement (and the letter to stockholders, notice of meeting and form of proxy included therewith), if any, based on information provided by the other Party or any of its Representatives regarding such other Party or its Affiliates for inclusion therein.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-55</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Parent shall use commercially reasonable efforts to cause the Proxy Statement to be mailed to Parent&#8217;s stockholders as promptly as practicable after the Registration Statement is declared effective under the Securities Act. If at any time before the First Effective Time, (i)&#160;Parent, Merger Subs or the Company (A) become aware of any event or information that, pursuant to the Securities Act or the Exchange Act, should be disclosed in an amendment or supplement to the Registration Statement or Proxy Statement, (B) receives notice of any SEC request for an amendment or supplement to the Registration Statement or for additional information related thereto, or (C) receives SEC comments on the Registration Statement, or (ii) the information provided in the Registration Statement has become &#8220;stale&#8221; and new information should be disclosed in an amendment or supplement to the Registration Statement, as the case may be, then such Party, as the case may be, shall promptly inform the other Parties thereof and shall cooperate with such other Parties in Parent filing such amendment or supplement with the SEC (and, if appropriate, in mailing such amendment or supplement to the Parent stockholders) or otherwise addressing such SEC request or comments and each Party and shall use their commercially reasonable efforts to cause any such amendment to become effective, if required. Parent shall promptly notify the Company if it becomes aware (1) that the Registration Statement has become effective, (2) of the issuance of any stop order or suspension of the qualification or registration of the Parent Capital Stock issuable in connection with the Contemplated Transactions (including any Parent Common Stock issuable upon conversion of the Parent Convertible Preferred Stock) for offering or sale in any jurisdiction, or (3) any order of the SEC related to the Registration Statement, and shall promptly provide to the Company copies of all written correspondence between it or any of its Representatives, on the one hand, and the SEC or staff of the SEC, on the other hand, with respect to the Registration Statement and all orders of the SEC relating to the Registration Statement.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Company shall reasonably cooperate with Parent and provide, and cause its Representatives to provide, Parent and its Representatives, with all true, correct and complete information regarding the Company that is required by Law to be included in the Registration Statement or reasonably requested by Parent to be included in the Registration Statement (collectively, the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Required S-4 Information</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;). Without limiting the foregoing, the Company will use commercially reasonable efforts to cause to be delivered to Parent a consent letter of the Company&#8217;s independent accounting firm, dated no more than two (2) Business Days before the date on which the Registration Statement is filed with the SEC (and reasonably satisfactory in form and substance to Parent), that is customary in scope and substance for consent letters delivered by independent public accountants in connection with registration statements similar to the Registration Statement. The Company and its legal counsel shall be given reasonable opportunity to review and comment on the Registration Statement, including all amendments and supplements thereto, prior to the filing thereof with the SEC, and on the response to any comments of the SEC on the Registration Statement, prior to the filing thereof with the SEC. Parent may file the Registration Statement, or any amendment or supplement thereto, without the prior consent of the Company, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> that Parent has included the Company Required S-4 Information in the Registration Statement in substantially the same form as it was provided to Parent by the Company pursuant to this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.1</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">; </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">further</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that if the prior consent of the Company is not obtained then, notwithstanding anything else herein, the Company makes no covenant or representation regarding the portion of such information supplied by or on behalf of the Company to Parent for inclusion in such Registration Statement that the Company reasonably identifies prior to such filing of the Registration Statement.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(e)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>As promptly as reasonably practicable following the date of this Agreement, the Company will use commercially reasonable efforts to furnish to Parent (i) audited financial statements for each of its fiscal years required to be included in the Registration Statement, or an audited period balance sheet, as applicable (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Audited Financial Statements</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) and (ii) unaudited interim financial statements for each interim period completed prior to Closing that would be required to be included in the Registration Statement or any periodic report due prior to the Closing if the Company were subject to the periodic reporting requirements under the Securities Act or the Exchange Act (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Interim Financial Statements</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;). Each of the Company Audited Financial Statements and the Company Interim Financial Statements will be suitable for inclusion in the Registration Statement and prepared in accordance with GAAP as applied on a consistent basis during the periods involved (except in each case as described in the notes thereto) and on that basis will present fairly, in all material respects, the financial position and the results of operations, changes in stockholders&#8217; equity and cash flows of the Company as of the dates of and for the periods referred to in the Company Audited Financial Statements or the Company Interim Financial Statements, as the case may be.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-56</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.2<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Company Stockholder Written Consent</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Promptly after the Registration Statement has been declared effective under the Securities Act, and in any event no later than two (2) Business Days thereafter, the Company shall obtain the approval by written consent from Company stockholders sufficient for the Required Company Stockholder Vote in lieu of a meeting pursuant to Section&#160;228 of the DGCL, for purposes of (i)&#160;adopting and approving this Agreement and the Contemplated Transactions, (ii) acknowledging that the approval given thereby is irrevocable and that such stockholder is aware of its rights to demand appraisal for its shares pursuant to Section&#160;262 of the DGCL, and that such stockholder has received and read a copy of Section&#160;262 of the DGCL and (iii) acknowledging that by its approval of the Merger it is not entitled to appraisal rights with respect to its shares in connection with the Merger and thereby waives any rights to receive payment of the fair value of its capital stock under the DGCL (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Stockholder Written Consents</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;). Under no circumstances shall the Company assert that any other approval or consent is necessary by its stockholders to approve this Agreement and the Contemplated Transactions.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Reasonably promptly following receipt of the Required Company Stockholder Vote, and in any event no later than ten (10) days thereafter, the Company shall prepare and mail a notice (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Stockholder Notice</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) to every stockholder of the Company that did not execute the Company Stockholder Written Consent. The Stockholder Notice shall (i) be a statement to the effect that the Company Board determined that the Merger is advisable in accordance with Section&#160;251(b) of the DGCL and in the best interests of the stockholders of the Company and approved and adopted this Agreement, the Merger and the other Contemplated Transactions, (ii) provide the stockholders of the Company to whom it is sent with notice of the actions taken in the Company Stockholder Written Consent, including the adoption and approval of this Agreement, the Merger and the other Contemplated Transactions in accordance with Section&#160;228(e) of the DGCL and the certificate of incorporation and bylaws of the Company and (iii) include a description of the appraisal rights of the Company&#8217;s stockholders available under the DGCL, along with such other information as is required thereunder and pursuant to applicable Law. All materials (including any amendments thereto) submitted to the stockholders of the Company in accordance with this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.2(b)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> shall be subject to Parent&#8217;s advance review and reasonable approval.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Company agrees that, subject to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.2(d)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">: (i) the Company Board shall recommend that the Company&#8217;s stockholders vote to adopt and approve this Agreement and the Contemplated Transactions and shall use commercially reasonable efforts to solicit such approval within the time set forth in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.2(a)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> (the recommendation of the Company Board that the Company&#8217;s stockholders vote to adopt and approve this Agreement being referred to as the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Board Recommendation</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) and (ii) the Company Board Recommendation shall not be withdrawn or modified (and the Company Board shall not publicly propose to withdraw or modify the Company Board Recommendation) in a manner adverse to Parent, and no resolution by the Company Board or any committee thereof to withdraw or modify the Company Board Recommendation in a manner adverse to Parent or to adopt, approve or recommend (or publicly propose to adopt, approve or recommend) any Acquisition Proposal shall be adopted or proposed.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Notwithstanding anything to the contrary contained in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.2(c)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, and subject to compliance with </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;5.4</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.2</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, if at any time prior to approval and adoption of this Agreement by the Required Company Stockholder Vote, (i) the Company receives a bona fide written Acquisition Proposal that the Company Board determines, following consultation with its outside legal counsel and financial advisor, to be a Superior Offer, or (ii) as a result of a material development or change in circumstances (other than any such event, development or change to the extent related to (A) any Acquisition Proposal, Acquisition Inquiry, Acquisition Transaction or the consequences thereof or (B) the fact, in and of itself, that the Company meets or exceeds internal budgets, plans or forecasts of its revenues, earnings or other financial performance or results of operations) that affects the business, assets or operations of the Company that occurs or arises after the date of this Agreement (a &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Intervening Event</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), the Company Board may withhold, amend, withdraw or modify the Company Board Recommendation (or publicly propose to withhold, amend, withdraw or modify the Company Board Recommendation) in a manner adverse to Parent (collectively, a &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Board Adverse Recommendation Change</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) if, but only if, (x) in the case of a Superior Offer, following the receipt of and on account of such Superior Offer, (i) the Company Board determines in good faith, based on the advice of its outside legal counsel, that the failure to withhold, amend, withdraw or modify the Company Board Recommendation would reasonably be expected to be inconsistent with its fiduciary duties under applicable Law, (ii) the Company has, during the Notice Period (as defined below), negotiated with Parent in good faith to make such adjustments to the terms and conditions of this Agreement so that such Acquisition Proposal ceases to constitute a Superior Offer and (iii) if, Parent has delivered </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-57</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">to the Company a written offer to alter the terms or conditions of this Agreement during the Notice Period, the Company Board shall have determined in good faith, based on the advice of its outside legal counsel and financial advisor, that the failure to withhold, amend, withdraw or modify the Company Board Recommendation would reasonably be expected to be inconsistent with its fiduciary duties under applicable Law (after taking into account such alterations of the terms and conditions of this Agreement); </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> that (1) Parent receives written notice from the Company confirming that the Company Board has determined to change its recommendation at least four&#160;(4) Business Days in advance of the Company Board Adverse Recommendation Change (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Notice Period</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), which notice shall include a description in reasonable detail of the reasons for such Company Board Adverse Recommendation Change, and written copies of any relevant proposed transaction agreements with any party making a potential Superior Offer, (2) during any Notice Period, Parent shall be entitled to deliver to the Company one or more counterproposals to such Acquisition Proposal and the Company will, and cause its Representatives to, negotiate with Parent in good faith (to the extent Parent desires to negotiate) to make such adjustments in the terms and conditions of this Agreement so that the applicable Acquisition Proposal ceases to constitute a Superior Offer and (3) in the event of any material amendment to any Superior Offer (including any revision in the amount, form or mix of consideration the Company&#8217;s stockholders would receive as a result of such potential Superior Offer), the Company shall be required to provide Parent with notice of such material amendment and the Notice Period shall be extended, if applicable, to ensure that at least three (3) Business Days remain in the Notice Period following such notification during which the parties shall comply again with the requirements of this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.2(d)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and the Company Board shall not make a Company Board Adverse Recommendation Change prior to the end of such Notice Period as so extended (it being understood that there may be multiple extensions) or (y) in the case of a Company Intervening Event, the Company promptly notifies Parent, in writing, within the Notice Period before making a Company Board Adverse Recommendation Change, which notice shall state expressly the material facts and circumstances related to the applicable Company Intervening Event and that the Company Board intends to make a Company Board Adverse Recommendation Change.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(e)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Company&#8217;s obligation to solicit the consent of its stockholders to sign the Company Stockholder Written Consent in accordance with </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.2(a)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> shall not be limited or otherwise affected by the commencement, disclosure, announcement or submission of any Superior Offer or other Acquisition Proposal or Acquisition Inquiry, or by any Company Board Adverse Recommendation Change.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.3<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Parent Stockholder Meeting</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Parent shall take all action necessary under applicable Law to call, give notice of and hold a meeting of the holders of Parent Common Stock to consider and vote to approve this Agreement and thereby approve the Contemplated Transactions and the Parent Charter Amendment and, if deemed necessary by Parent the approval of the Parent Legacy Transaction (collectively, the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Stockholder Matters</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; and such meeting, the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Stockholder Meeting</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;). The Parent Stockholder Meeting shall be held as promptly as practicable after the date that the Registration Statement is declared effective under the Securities Act, and in any event, no later than 45 days after the effective date of the Registration Statement. Parent shall take reasonable measures to ensure that all proxies solicited in connection with the Parent Stockholder Meeting are solicited in compliance with all applicable Law. Notwithstanding anything to the contrary contained herein, if on the date of the Parent Stockholder Meeting, or a date preceding the date on which the Parent Stockholder Meeting is scheduled, Parent reasonably believes that (i) it will not receive proxies sufficient to obtain the Required Parent Stockholder Vote, whether or not a quorum would be present, (ii) it will not have sufficient shares of Parent Common Stock represented (whether in person or by proxy) to constitute a quorum necessary to conduct the business of the Parent Stockholder Meeting or (iii) that the failure to postpone or adjourn the Parent Stockholder Meeting would reasonably be expected to be inconsistent with its fiduciary obligations under applicable Law, Parent may postpone or adjourn, or make one or more successive postponements or adjournments of, the Parent Stockholder Meeting as long as the date of the Parent Stockholder Meeting is not postponed or adjourned more than an aggregate of 30 days in connection with any postponements or adjournments.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Parent agrees that (i) the Parent Board shall recommend that the holders of Parent Common Stock vote to approve the Parent Stockholder Matters and shall use commercially reasonable efforts to solicit such approval within the timeframe set forth in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.3(a)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> above and (ii) the Proxy Statement shall include a statement to the effect that the Parent Board recommends that Parent&#8217;s stockholders vote to approve the Parent Stockholder Matters (the recommendation of the Parent Board being referred to as the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Board Recommendation</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;).</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-58</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Notwithstanding anything to the contrary contained in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.3(b)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, and subject to compliance with </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;5.4</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.3</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, if at any time prior to approval and adoption of this Agreement by the Required Parent Stockholder Vote, (i) Parent receives a bona fide written Acquisition Proposal that the Parent Board determines, following consultation with its outside legal counsel and financial advisor, to be a Superior Offer, the Parent Board may withhold, amend, withdraw or modify the Parent Board Recommendation (or publicly propose to withhold, amend, withdraw or modify the Parent Board Recommendation) in a manner adverse to the Company or (ii) as a result of a material development or change in circumstances (other than any such event, development or change to the extent related to (A) any Acquisition Proposal, Acquisition Inquiry, Acquisition Transaction or the consequences thereof, (B) the fact, in and of itself, that Parent meets or exceeds internal budgets, plans or forecasts of its revenues, earnings or other financial performance or results of operations or (C) any Parent Legacy Transaction) that affects the business, assets or operations of Parent that occurs or arises after the date of this Agreement (a &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Intervening Event</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), (collectively, a &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Board Adverse Recommendation Change</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) if, but only if, (x) in the case of a Superior Offer, following the receipt of and on account of such Superior Offer, (i) the Parent Board determines in good faith, based on the advice of its outside legal counsel, that the failure to withhold, amend, withdraw or modify the Parent Board Recommendation would reasonably be expected to be inconsistent with its fiduciary duties under applicable Law, (ii) Parent has, and has caused its financial advisors and outside legal counsel to, during the Parent Notice Period (as defined below), negotiated with the Company in good faith to make such adjustments to the terms and conditions of this Agreement so that such Acquisition Proposal ceases to constitute a Superior Offer, and (iii) if, after the Company has delivered to Parent a written offer to alter the terms or conditions of this Agreement during the Parent Notice Period, the Parent Board shall have determined in good faith, based on the advice of its outside legal counsel and financial advisor, that the failure to withhold, amend, withdraw or modify the Parent Board Recommendation would reasonably be expected to be inconsistent with its fiduciary duties under applicable Law (after taking into account such alterations of the terms and conditions of this Agreement); </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> that (1) the Company receives written notice from Parent confirming that the Parent Board has determined to change its recommendation at least four (4) Business Days in advance of the Parent Board Adverse Recommendation Change (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> </span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Notice Period</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), which notice shall include a description in reasonable detail of the reasons for such Parent Board Adverse Recommendation Change, and written copies of any relevant proposed transaction agreements with any party making a potential Superior Offer, (2) during any Parent Notice Period, the Company shall be entitled to deliver to Parent one or more counterproposals to such Acquisition Proposal and Parent will, and cause its Representatives to, negotiate with the Company in good faith (to the extent the Company desires to negotiate) to make such adjustments in the terms and conditions of this Agreement so that the applicable Acquisition Proposal ceases to constitute a Superior Offer and (3) in the event of any material amendment to any Superior Offer (including any revision in the amount, form or mix of consideration the Parent&#8217;s stockholders would receive as a result of such potential Superior Offer), Parent shall be required to provide the Company with notice of such material amendment and the Parent Notice Period shall be extended, if applicable, to ensure that at least three (3) Business Days remain in the Parent Notice Period following such notification during which the parties shall comply again with the requirements of this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.3(c)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and the Parent Board shall not make a Parent Board Adverse Recommendation Change prior to the end of such Parent Notice Period as so extended (it being understood that there may be multiple extensions) or (y) in the case of a Parent Intervening Event, Parent promptly notifies the Company, in writing, within the Parent Notice Period before making a Parent Board Adverse Recommendation Change, which notice shall state expressly the material facts and circumstances related to the applicable Parent Intervening Event and that the Parent Board intends to make a Parent Board Adverse Recommendation Change.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Parent&#8217;s obligation to call, give notice of and hold the Parent Stockholder Meeting in accordance with </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.3(a)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> shall not be limited or otherwise affected by the commencement, disclosure, announcement or submission of any Superior Offer, Acquisition Proposal or Acquisition Inquiry, or by any Parent Board Adverse Recommendation Change.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(e)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Nothing contained in this Agreement shall prohibit Parent or the Parent Board from (i) complying with Rules&#160;14d-9 and 14e-2(a) promulgated under the Exchange Act; </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">however</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that any disclosure made by Parent or the Parent Board pursuant to Rules&#160;14d-9 and 14e-2(a) shall be limited to a statement that Parent is unable to take a position with respect to the bidder&#8217;s tender offer unless the Parent Board determines in good faith, after consultation with its outside legal counsel, that such statement would reasonably be expected to be inconsistent with its fiduciary duties under applicable Law; (ii) complying with Item 1012(a) of Regulation </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-59</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">M-A promulgated under the Exchange Act; (iii) informing any Person of the existence of the provisions contained in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;5.4</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">; or (iv) making any disclosure to the stockholders of Parent that the Parent Board (or a committee thereof), after consultation with its outside legal counsel, has determined in good faith is required by applicable Law.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.4<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Efforts; Regulatory Approvals.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Parties shall use reasonable best efforts to consummate the Contemplated Transactions. Without limiting the generality of the foregoing, each Party: (i) shall make all filings and other submissions (if any) and give all notices (if any) required to be made and given by such Party in connection with the Contemplated Transactions, (ii) shall use commercially reasonable efforts to obtain each Consent (if any) reasonably required to be obtained (pursuant to any applicable Law or Contract, or otherwise) by such Party in connection with the Contemplated Transactions or for such Contract to remain in full force and effect, (iii) shall use commercially reasonable efforts to lift any injunction prohibiting, or any other legal bar to, the Contemplated Transactions and (iv)&#160;shall use commercially reasonable efforts to satisfy the conditions precedent to the consummation of this Agreement.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Notwithstanding the generality of the foregoing, each Party shall use commercially reasonable efforts to file or otherwise submit, as soon as practicable after the date of this Agreement, all applications, notices, reports and other documents reasonably required to be filed by such Party with or otherwise submitted by such Party to any Governmental Authority with respect to the Contemplated Transactions, and to submit promptly any additional information requested by any such Governmental Authority. Without limiting the generality of the foregoing, the Parties shall prepare and file, if required, (a) the notification and report forms required to be filed under the Hart&#8211;Scott&#8211;Rodino Antitrust Improvements Act of 1976 and (b) any notification or other document required to be filed in connection with the Merger under any applicable foreign Law relating to antitrust or competition matters, no later than ten (10) Business Days after the date the Company and Parent receive notification (in writing or otherwise) from the Federal Trade Commission, the Department of Justice, any state attorney general, foreign antitrust or competition authority or other Governmental Authority that a filing is required in connection with antitrust or competition matters.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Without limiting the generality of the foregoing, Parent shall give the Company prompt written notice (email being sufficient) of any litigation against Parent and/or its directors relating to this Agreement or the Contemplated Transactions (&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Transaction Litigation</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) (including by providing copies of all pleadings with respect thereto) and keep the Company reasonably informed with respect to the status thereof. Parent will (i) give the Company the opportunity to participate in, but not control, the defense, settlement or prosecution of any Transaction Litigation (to the extent that the attorney-client privilege is not undermined or otherwise adversely affected; </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> that Parent and the Company will use commercially reasonable efforts to find alternative solutions to not undermine or adversely effect the privilege such as entering into common interest agreements, joint defense agreements or similar agreements), (ii) consult with the Company with respect to the defense, settlement and prosecution of any Transaction Litigation and (iii) consider in good faith the Company&#8217;s advice with respect to such Transaction Litigation. Parent will obtain the prior written consent of the Company (such consent not to be unreasonably withheld, conditioned or delayed) prior to settling or satisfying any such claim.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.5<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Company Options; Company Warrants</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>At the First Effective Time, Parent shall assume each Company Stock Plan and each Company Option, whether vested or unvested, that is outstanding immediately prior to the First Effective Time shall, at the First Effective Time, cease to represent a right to acquire shares of Company Common Stock and shall be converted, at the First Effective Time, into an option to purchase shares of Parent Common Stock (an &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Assumed Option</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), on the same terms and conditions (including any vesting provisions and any provisions providing for accelerated vesting upon certain events) as were applicable under such Company Option as of immediately prior to the First Effective Time, except for administrative or ministerial changes as determined by the Company Board (or, following the First Effective Time, the Parent Board or compensation committee). The number of shares of Parent Common Stock subject to each such Assumed Option shall be equal to (i) the number of shares of Company Common Stock subject to the respective Company Option immediately prior to the First Effective Time multiplied by (ii)&#160;the Exchange Ratio, rounded down, if necessary, to the nearest whole share of Parent Common Stock, and such Assumed Option shall have an exercise price per share (rounded up to the nearest whole cent) equal to (A) the exercise price per share of the Company Common Stock otherwise purchasable pursuant to the respective Company Option immediately prior to the First Effective Time divided by (B) the Exchange Ratio; </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that in the case of any Company Option </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-60</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">to which Section&#160;421 of the Code applies as of immediately prior to the First Effective Time (taking into account the effect of any accelerated vesting thereof, if applicable) by reason of its qualification under Section&#160;422 of the Code, the exercise price, the number of shares of Parent Common Stock subject to such option and the terms and conditions of exercise of such option shall be determined in a manner consistent with the requirements of Section&#160;424(a) of the Code; </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">further</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that in the case of any Assumed Option to which Section&#160;409A of the Code applies as of the First Effective Time, the exercise price, the number of shares of Parent Common Stock subject to such option and the terms and conditions of exercise of such option shall be determined in a manner consistent with the requirements of Section&#160;409A of the Code in order to avoid the imposition of any additional taxes thereunder. The Company Board shall, prior to the First Effective Time, take all actions necessary to effect the foregoing.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>At the First Effective Time, each Company Warrant (including any pre-funded Company Warrant issued pursuant to the Company Pre-Closing Financing), whether vested or unvested, that is outstanding immediately prior to the First Effective Time shall, at the First Effective Time, cease to represent a right to acquire shares of Company Capital Stock and shall be converted, at the First Effective Time, into a warrant to purchase shares of Parent Common Stock (an &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Assumed Warrant</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), on the same terms and conditions (including any vesting provisions and any provisions providing for accelerated vesting upon certain events) as were applicable under such Assumed Warrant as of immediately prior to the First Effective Time. The number of shares of Parent Common Stock subject to each such Assumed Warrant shall be equal to (i) the number of shares of the Company Common Stock subject to each Assumed Warrant immediately prior to the First Effective Time multiplied by (ii)&#160;the Exchange Ratio, rounded down, if necessary, to the nearest whole share of Parent Common Stock, and such Assumed Warrant shall have an exercise price per share (rounded up to the nearest whole cent) equal to (A) the exercise price per share of the Company Common Stock otherwise purchasable pursuant to such Assumed Warrant immediately prior to the First Effective Time divided by (B) the Exchange Ratio.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.6<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Employee Benefits</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Parent shall comply with the terms of any employment, severance, retention, change of control, or similar agreement specified on </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;4.17(d)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> or contemplated by </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;5.1(b)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Parent Disclosure Letter, subject to the provisions of such agreements.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>From and after the First Effective Time, with respect to each benefit plan maintained by Parent or the Surviving Entity that is an &#8220;employee welfare benefit plan&#8221; as defined in Section&#160;3(1) of ERISA (each, a &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Post-Closing Welfare Plan</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) in which any current or former employee of Parent is or becomes eligible to participate (including under COBRA), Parent and the Surviving Entity shall use commercially reasonable efforts to cause each such Post-Closing Welfare Plan to (i) waive all limitations as to pre-existing conditions, waiting periods, required physical examinations and exclusions with respect to participation and coverage requirements applicable under such Post-Closing Welfare Plan for such current or former Parent employee and his or her eligible dependents to the same extent that such pre-existing conditions, waiting periods, required physical examinations and exclusions would not have applied or would have been waived under the corresponding Parent Employee Plan in which such current or former Parent employee was a participant immediately prior to his or her commencement of participation in such Post-Closing Welfare Plan, and (ii) provide each such current or former Parent employee and his or her eligible dependents with credit for any co-payments and deductibles paid in the plan year that includes the First Effective Time, and prior to the date that, such current or former Parent employee commences participation in such Post-Closing Welfare Plan in satisfying any applicable co-payment or deductible requirements under such Post-Closing Welfare Plan for the applicable plan year, to the extent that such expenses were recognized for such purposes under the comparable Parent Employee Plan.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>As of immediately prior to the First Effective Time, each Parent Option that is then outstanding but not then vested or exercisable shall become immediately vested and exercisable in full. At the First Effective Time, each In the Money Parent Option that is then outstanding shall be canceled and the holder thereof shall be entitled to receive (i) an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (A) the excess of the Parent Closing Price over the exercise price per share of the Parent Common Stock underlying such Parent Option by (B) the number of shares of the Parent Common Stock underlying such Parent Option (such amount, the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Stock Option Cash Consideration</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;). Parent shall cause the Surviving Entity to pay the Parent Stock Option Cash Consideration, less applicable withholdings, at or </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-61</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">within ten (10) business days after the First Effective Time. At the First Effective Time, each Out of the Money Parent Option shall be cancelled for no consideration. Prior to the Closing, the Parent Board shall have adopted appropriate resolutions and taken all other actions necessary and appropriate to provide for the foregoing.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.7<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Indemnification of Officers and Directors</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>From the First Effective Time through the sixth anniversary of the date on which the First Effective Time occurs, each of Parent and the Surviving Entity shall indemnify and hold harmless each person who is now, or has been at any time prior to the date hereof, or who becomes prior to the First Effective Time, a director or officer of Parent or the Company, respectively (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">D&amp;O Indemnified Parties</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), against all claims, losses, liabilities, damages, judgments, fines and reasonable fees, costs and expenses, including attorneys&#8217; fees and disbursements (collectively, &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Costs</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), incurred in connection with any claim, action, suit, proceeding or investigation, whether civil, criminal, administrative or investigative, arising out of or pertaining to the fact that the D&amp;O Indemnified Party is or was a director or officer of Parent or of the Company, whether asserted or claimed prior to, at or after the First Effective Time, in each case, to the fullest extent permitted under the DGCL. Each D&amp;O Indemnified Party will be entitled to advancement of expenses incurred in the defense of any such claim, action, suit, proceeding or investigation from each of Parent and the Surviving Entity, jointly and severally, upon receipt by Parent or the Surviving Entity from the D&amp;O Indemnified Party of a request therefor; </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> that any such person to whom expenses are advanced provides an undertaking to Parent, to the extent then required by the DGCL, to repay such advances if it is ultimately determined that such person is not entitled to indemnification. Without otherwise limiting the D&amp;O Indemnified Parties&#8217; rights with regards to counsel, following the First Effective Time, the D&amp;O Indemnified Parties shall be entitled to continue to retain Wilson Sonsini Goodrich &amp; Rosati or such other counsel selected by the D&amp;O Indemnified Parties.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The certificate of incorporation and bylaws of the Surviving Entity shall contain, and Parent shall cause the certificate of incorporation and bylaws of the Surviving Entity to so contain, provisions no less favorable with respect to indemnification, advancement of expenses and exculpation of present and former directors and officers as those presently set forth in the certificate of incorporation and bylaws of Parent.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>From and after the First Effective Time, (i) the Surviving Entity shall fulfill and honor in all respects the obligations of the Company to its D&amp;O Indemnified Parties as of immediately prior to the Closing pursuant to any indemnification provisions under the Company&#8217;s Organizational Documents and pursuant to any indemnification agreements between the Company and such D&amp;O Indemnified Parties, with respect to claims arising out of matters occurring at or prior to the First Effective Time and (ii) Parent shall fulfill and honor in all respects the obligations of Parent to its D&amp;O Indemnified Parties as of immediately prior to the Closing pursuant to any indemnification provisions under Parent&#8217;s Organizational Documents and pursuant to any indemnification agreements between Parent and such D&amp;O Indemnified Parties, with respect to claims arising out of matters occurring at or prior to the First Effective Time.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>From and after the First Effective Time, Parent shall maintain directors&#8217; and officers&#8217; liability insurance policies, with an effective date as of the Closing Date, on commercially reasonable terms and conditions and with coverage limits customary for U.S. public companies similarly situated to Parent. In addition, Parent shall purchase at its sole expense, prior to the First Effective Time, a six (6) year prepaid &#8220;D&amp;O tail policy&#8221; for the non-cancelable extension of the directors&#8217; and officers&#8217; liability coverage of Parent&#8217;s existing directors&#8217; and officers&#8217; insurance policies for a claims reporting or discovery period of at least six (6) years from and after the First Effective Time with respect to any claim related to any period of time at or prior to the First Effective Time with terms, conditions, retentions and limits of liability that are no less favorable than the coverage provided under Parent&#8217;s existing policies as of the date of this Agreement, or otherwise acceptable to Parent, except that Parent will not commit or spend on such &#8220;D&amp;O Tail policy&#8221; annual premiums in excess of 250% of the annual premiums paid by Parent in its last full fiscal year prior to the date hereof for Parent&#8217;s current policies of directors&#8217; and officers&#8217; liability insurance and fiduciary liability insurance (nor, for the avoidance of doubt, shall Parent be obligated to spend any specific amount), and if such premiums for such &#8220;D&amp;O tail policy&#8221; would exceed 250% of such annual premium, then Parent shall purchase policies that provide the maximum coverage available at an annual premium equal to 250% of such annual premium. The Company shall in good faith cooperate with Parent prior to the First Effective Time with respect to the procurement of such &#8220;D&amp;O tail policy.&#8221;</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-62</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(e)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>From and after the First Effective Time, Parent shall pay all expenses, including reasonable attorneys&#8217; fees, that are incurred by the persons referred to in this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.7</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> in connection with their enforcement of the rights provided to such persons in this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.7</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(f)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The provisions of this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.7</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> are intended to be in addition to the rights otherwise available to the current and former officers and directors of Parent and the Company by Law, charter, statute, bylaw or agreement, and shall operate for the benefit of, and shall be enforceable by, each of the D&amp;O Indemnified Parties, their heirs and their Representatives.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(g)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>In the event Parent or the Surviving Entity or any of their respective successors or assigns (i) consolidates with or merges into any other Person and shall not be the continuing or surviving corporation or entity of such consolidation or merger or (ii) transfers all or substantially all of its properties and assets to any Person, then, and in each such case, proper provision shall be made so that the successors and assigns of Parent or the Surviving Entity, as the case may be, shall succeed to the obligations set forth in this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.7</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Parent shall cause the Surviving Entity to perform all of the obligations of the Surviving Entity under this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.7</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(h)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Unless directed otherwise by the Company in writing no less than three&#160;(3)&#160;Business Days before the Closing Date, Parent shall use reasonable best efforts to take all actions as are necessary to terminate any 401(k) or other plan(s) with a cash or deferred arrangement (as defined in Section&#160;401(k) of the Code), effective as of no later than the day immediately preceding the Closing Date.  Parent shall provide the Company copies of all such corporate actions or documentation related to the same at least three (3) Business Days before their adoption or approval for the Company&#8217;s reasonable review and comment.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.8<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Disclosure</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Parties shall use their commercially reasonable efforts to agree to the text of any initial press release and Parent&#8217;s Form 8-K announcing the execution and delivery of this Agreement. Without limiting any Party&#8217;s obligations under the Confidentiality Agreement, no Party shall, and no Party shall permit any of its Subsidiaries or any of its Representative to, issue any press release or make any public disclosure regarding the Contemplated Transactions unless: (a) the other Party shall have approved such press release or disclosure in writing, such approval not to be unreasonably conditioned, withheld or delayed; or (b) such Party shall have determined in good faith, upon the advice of outside legal counsel, that such disclosure is required by applicable Law and, to the extent practicable, before such press release or disclosure is issued or made, such Party advises the other Party of, and consults with the other Party regarding, the text of such press release or disclosure; </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">however</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that each of the Company and Parent may make any public statement in response to specific questions by the press, analysts, investors or those attending industry conferences or financial analyst conference calls, so long as any such statements are consistent with previous press releases, public disclosures or public statements made by the Company or Parent in compliance with this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.8</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Notwithstanding the foregoing, a Party need not consult with any other Parties in connection with such portion of any press release, public statement or filing to be issued or made pursuant to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.2(d)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> or pursuant to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.3(e)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.9<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Listing</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. At or prior to the First Effective Time, Parent shall use its commercially reasonable efforts to (a) maintain its listing on Nasdaq until the First Effective Time and to obtain approval of the listing of the combined corporation on Nasdaq, (b) to the extent required by the rules and regulations of Nasdaq, prepare and submit to Nasdaq a notification form for the listing of the shares of Parent Common Stock to be issued in connection with the Contemplated Transactions, and to cause such shares to be approved for listing (subject to official notice of issuance); (c) prepare and timely submit to Nasdaq a notification form for the Nasdaq Reverse Split (if required) and to submit a copy of the amendment to Parent&#8217;s certificate of incorporation effecting the Nasdaq Reverse Split, certified by the Secretary of State of the State of Delaware, to Nasdaq on the Closing Date; and (d) to the extent required by Nasdaq Marketplace Rule&#160;5110, assist the Company in preparing and filing an initial listing application for the Parent Common Stock on Nasdaq (including any Parent Common Stock issuable upon conversion of the Parent Convertible Preferred Stock) (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Nasdaq Listing Application</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) and to cause such Nasdaq Listing Application to be conditionally approved prior to the First Effective Time. Each Party will reasonably promptly inform the other Party of all verbal or written communications between Nasdaq and such Party or its representatives. The Parties will use commercially reasonable efforts to coordinate with respect to compliance with Nasdaq rules and regulations. The Party not filing the Nasdaq Listing Application will cooperate with the other Party as reasonably requested by such filing Party with respect to the Nasdaq Listing Application and promptly furnish to such filing Party all information concerning itself and its members that may be required or reasonably requested in connection </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-63</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">with any action contemplated by this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.9</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. All Nasdaq fees associated with any action contemplated by this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.9</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, including any fees related to the engagement of a consultant (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Nasdaq Fees</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), shall be shared equally by the Company and Parent.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.10<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Tax Matters</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Parties shall use reasonable best efforts (and each shall cause its Affiliates) to cause the Merger to qualify for the Intended Tax Treatment. No Party shall take any actions, or fail to take any action, which action or failure to act would reasonably be expected to prevent or impede the Intended Tax Treatment. The Parties shall report the Contemplated Transactions for all applicable Tax purposes in a manner that is consistent with the Intended Tax Treatment. No Party shall take any position that is inconsistent with the Intended Tax Treatment during the course of any audit, litigation or other proceeding with respect to Taxes, in each case, unless otherwise required by a determination within the meaning of Section&#160;1313(a) of the Code. The Parties shall comply with the recordkeeping and information reporting requirements imposed on them, including, but not limited to, those set forth in Treasury Regulation Section&#160;1.368-3.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Parent shall promptly notify the Company if, at any time before the First Effective Time, Parent becomes aware of any fact or circumstance that would reasonably be expected to prevent, cause a failure of, or impede the Intended Tax Treatment. The Company shall promptly notify Parent if, at any time before the First Effective Time, the Company becomes aware of any fact or circumstance that would reasonably be expected to prevent, cause a failure of, or impede the Intended Tax Treatment.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>If the SEC requires that an opinion with respect to the Intended Tax Treatment be prepared and submitted in connection with the Registration Statement and Proxy Statement, (i) the Company shall use its reasonable best efforts to cause Gibson, Dunn and Crutcher LLP (or such other nationally recognized law or accounting firm reasonably satisfactory to the Company) to furnish an opinion (as so required and subject to customary assumptions and limitations), (ii) Parent shall use its reasonable best efforts to cause Wilson Sonsini Goodrich &amp; Rosati (or such other nationally recognized law or accounting firm reasonably satisfactory to Parent) to furnish an opinion (as so required and subject to customary assumptions and limitations), and (iii) Parent and the Company shall each deliver to each of Gibson, Dunn and Crutcher LLP (or such other nationally recognized law or accounting firm reasonably satisfactory to the Company) and Wilson Sonsini Goodrich &amp; Rosati (or such other nationally recognized law or accounting firm reasonably satisfactory to Parent) a Tax certificate, dated as of the date the Registration Statement and Proxy Statement shall have been declared effective by the SEC and signed by an officer of Parent or the Company, as applicable, containing customary representations and covenants reasonably acceptable to the Company and Parent, as applicable, in each case, as reasonably necessary and appropriate to enable such advisors to render such opinions (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Tax Certificates</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;). Each of Parent and the Company shall use its commercially reasonable efforts not to take or cause to be taken any action that would cause to be untrue (or fail to take or cause not to be taken any action which would cause to be untrue) any of the Tax certifications, covenants or representations included in the Tax Certificates.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Parent and the Company shall reasonably cooperate in the preparation, execution and filing of all Tax Returns, questionnaires, applications or other documents regarding any real property transfer, sales, use, transfer, value added, stock transfer and stamp taxes, and transfer, recording, registration and other fees and similar Taxes which become payable in connection with the Merger that are required or permitted to be filed on or before the First Effective Time. Each of Parent and the Company shall pay, without deduction from any consideration or other amounts payable or otherwise deliverable pursuant to this Agreement and without reimbursement from the other party, any such Taxes or fees imposed on it by any Governmental Authority, which becomes payable in connection with the Merger.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.11<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Legends</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Parent shall be entitled to place appropriate legends on the book entries and/or certificates evidencing any shares of Parent Capital Stock to be received in the Merger by equityholders of the Company who may be considered &#8220;affiliates&#8221; of Parent for purposes of Rules&#160;144 and 145 under the Securities Act reflecting the restrictions set forth in Rules&#160;144 and 145 and to issue appropriate stop transfer instructions to the transfer agent for any such shares of Parent Capital Stock.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.12<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Officers and Directors</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Until successors are duly elected or appointed and qualified in accordance with applicable Law, the Parties shall use commercially reasonable efforts and take all necessary action so that the Persons listed on </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.12</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Parent Disclosure Letter are elected or appointed, as applicable, to </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-64</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">the positions of officers or directors of Parent and the Surviving Entity, as set forth therein, to serve in such positions effective as of the Second Effective Time. If any Person listed on </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.12</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Parent Disclosure Letter is unable or unwilling to serve as officer or director of Parent or the Surviving Entity, as set forth therein, the Party appointing such Person (as set forth on </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.12</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Parent Disclosure Letter) shall designate a successor. The Parties shall use reasonable best efforts to have each of the Persons that will serve as directors and officers of the Parent following the Closing to execute and deliver a Lock-Up Agreement prior to Closing.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.13<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Termination of Certain Agreements and Rights</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Each of Parent and the Company shall cause any stockholder agreements, voting agreements, registration rights agreements, co-sale agreements and any other similar Contracts between either Parent or the Company and any holders of Parent Common Stock or Company Capital Stock, respectively, including any such Contract granting any Person investor rights, rights of first refusal, registration rights or director registration rights, to be terminated immediately prior to the First Effective Time, without any liability being imposed on the part of Parent or the Surviving Entity.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.14<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;16 Matters</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Prior to the First Effective Time, Parent shall take all such steps as may be required to cause any acquisitions of Parent Common Stock and any options to purchase Parent Common Stock in connection with the Contemplated Transactions, by each individual who is reasonably expected to become subject to the reporting requirements of Section&#160;16(a) of the Exchange Act with respect to Parent, to be exempt under Rule&#160;16b-3 promulgated under the Exchange Act.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.15<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Allocation Information</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Company will prepare and deliver to Parent prior to the Closing a spreadsheet setting forth (as of immediately prior to the First Effective Time) (a) each holder of Company Capital Stock, (b)&#160;such holder&#8217;s name and address, (c) the number or percentage and type of Company Capital Stock held as of the Closing Date for each such holder and (d) the number of shares of Parent Capital Stock to be issued to such holder pursuant to this Agreement in respect of the Company Capital Stock held by such holder as of immediately prior to the First Effective Time (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Allocation Certificate</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;).</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.16<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Parent SEC Documents</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. From the date of this Agreement to the First Effective Time, Parent shall use commercially reasonable efforts to timely file with the SEC all registration statements, proxy statements, Certifications, reports, schedules, exhibits, forms and other documents required to be filed by Parent with the SEC under the Exchange Act or the Securities Act (&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">SEC Documents</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;). As of its filing date, or if amended after the date of this Agreement, as of the date of the last such amendment, each SEC Document filed by Parent with the SEC (a) shall comply in all material respects with the applicable requirements of the Exchange Act and the Securities Act, and (b) shall not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary in order to make the statements made therein, in light of the circumstances under which they were made, not misleading.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.17<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Wind-Down Activities</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Following the Closing, Parent shall use its commercially reasonable efforts to continue the wind-down activities of Parent associated with the Parent Legacy Business, including termination of its research and development activities set forth on Section&#160;6.17 of the Parent Disclosure Letter.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.18<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Obligations of Merger Subs</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Parent will take all action necessary to cause each Merger Sub to perform its obligations under this Agreement and to consummate the Merger on the terms and conditions set forth in this Agreement.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.19<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Pre-Closing Financing Restructuring</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. In the event the structure of the Company Pre-Closing Financing either violates applicable Law or materially and adversely effects Parent&#8217;s ability to cause the Registration Statement to become effective in a timely manner, and in any event 60 days prior to the End Date, then Parent and the Company shall, and shall use their reasonable best efforts to cause the investors in the Company Pre-Closing Financing, to cause the Company Pre-Closing Financing to be amended, modified and/or restructured such that such investment occurs as a direct acquisition of shares of Parent Common Stock substantially contemporaneously with the Closing in a manner which preserves to the extent possible, the amount of funds ultimately received by Parent and its Subsidiaries, and the number of Parent shares ultimately held by the investor in respect of such amounts as though the Company Pre-Closing Financing has been consummated by its terms.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-65</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.20<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Parent Pre-Closing Dividend</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. If Parent declares the Parent Pre-Closing Dividend, then, prior to the First Effective Time, Parent shall deposit the Parent Pre-Closing Dividend Amount with Parent&#8217;s transfer agent for further distribution to the holders of the shares of Parent Common Stock outstanding as of the record date of the Parent Pre-Closing Dividend.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.21<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Parent Re-Domestication</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The parties shall discuss in good faith whether to change the domicile of Parent prior to the First Effective Time.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;7. </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Conditions Precedent to Obligations of Each Party</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The obligations of each Party to effect the Merger and otherwise consummate the Contemplated Transactions to be consummated at the Closing are subject to the satisfaction or, to the extent permitted by applicable law, the written waiver by each of the Parties, at or prior to the Closing, of each of the following conditions:</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">7.1<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Effectiveness of Registration Statement</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Registration Statement shall have become effective in accordance with the provisions of the Securities Act, and shall not be subject to any stop order or Legal Proceeding seeking a stop order with respect to the Registration Statement that has not been withdrawn. Any material state securities laws applicable to the issuance of the shares of Parent Capital Stock in connection with the Contemplated Transactions (including any Parent Common Stock issuable upon conversion of the Parent Convertible Preferred Stock) shall have been complied with and no stop order (or similar order) shall have been issued in respect of such shares of Parent Capital Stock (including any Parent Common Stock issuable upon conversion of the Parent Convertible Preferred Stock) by any applicable state securities commissioner or court of competent jurisdiction.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">7.2<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Regulatory Approvals</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Any applicable waiting periods (or any extensions thereof) under the HSR Act (if applicable) shall have expired or otherwise been terminated.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">7.3<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">No Restraints</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. No Order preventing the consummation of the Contemplated Transactions shall have been issued by any Governmental Authority of competent jurisdiction and remain in effect and there shall not be any Law which has the effect of making the consummation of the Contemplated Transactions illegal.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">7.4<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Stockholder Approval</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. (a) Parent shall have obtained the Required Parent Stockholder Vote (but solely with respect to such items as are necessary to consummate the transactions contemplated by this Agreement) and (b) the Company shall have obtained the Required Company Stockholder Vote.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">7.5<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Listing</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Nasdaq Listing Application shall have been approved by Nasdaq.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">7.6<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Lock-Up Agreements</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Lock-Up Agreements shall be in full force and effect.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">7.7<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Parent Charter Amendment</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Parent Charter Amendment shall have been duly filed with the Secretary of State of the State of Delaware, containing such amendments as are necessary to consummate the transactions contemplated by this Agreement.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">7.8<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Certificate of Designation</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Parent shall have filed the Certificate of Designation with the Secretary of State of the State of Delaware.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;8. </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Additional Conditions Precedent to Obligations of Parent and Merger Subs</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The obligations of Parent and Merger Subs to effect the Merger and otherwise consummate the transactions to be consummated at the Closing are subject to the satisfaction or the written waiver by Parent, at or prior to the Closing, of each of the following conditions:</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">8.1<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Accuracy of Representations</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Company Fundamental Representations shall have been true and correct in all material respects as of the date of this Agreement and shall be true and correct on and as of the Closing Date with the same force and effect as if made on and as of such date (except to the extent such representations and warranties are specifically made as of a particular date, in which case such representations and warranties shall be true and correct as of such date). The Company Capitalization Representations shall have been true and correct in all respects as of the date of this Agreement and shall be true and correct on and as of the Closing Date with the same force and effect as if made on and as of such date, except, in each case, (x) for such inaccuracies which are de minimis, individually or in the aggregate, (y) for those representations and warranties which address matters only as of a particular date (which representations and warranties shall have been true and correct, subject to the qualifications as set forth in the preceding clause&#160;(x), as of such particular date). The representations and warranties of the Company contained in this Agreement (other than the Company Fundamental Representations </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-66</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">and the Company Capitalization Representations) shall have been true and correct as of the date of this Agreement and shall be true and correct on and as of the Closing Date with the same force and effect as if made on the Closing Date except (a) in each case, or in the aggregate, where the failure to be so true and correct would not reasonably be expected to have a Company Material Adverse Effect (without giving effect to any references therein to any Company Material Adverse Effect or other materiality qualifications) or (b) for those representations and warranties which address matters only as of a particular date (which representations shall have been true and correct, subject to the qualifications as set forth in the preceding clause&#160;(a), as of such particular date) (it being understood that, for purposes of determining the accuracy of such representations and warranties, any update of or modification to the Company Disclosure Letter made or purported to have been made after the date of this Agreement shall be disregarded).</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">8.2<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Performance of Covenants</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Company shall have performed or complied with in all material respects all agreements and covenants required to be performed or complied with by it under this Agreement at or prior to the First Effective Time.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">8.3<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Documents</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Parent shall have received the following documents, each of which shall be in full force and effect:</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>a certificate executed by the Chief Executive Officer or Chief Financial Officer of the Company certifying (i) that the conditions set forth in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Sections&#160;8.1</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">8.2</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">8.4</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">8.5</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">8.6</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> have been duly satisfied and (ii) that the information (other than emails and addresses) set forth in the Allocation Certificate delivered by the company in accordance with </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.15</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> is true and accurate in all respects as of the Closing Date;</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>a certificate pursuant to Treasury Regulations Sections&#160;1.1445-2(c) and 1.897-2(h), together with a form of notice to the IRS in accordance with the requirements of Treasury Regulations Section&#160;1.897-2(h), in each case, in form and substance reasonably acceptable to Parent;</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>the Company Valuation Schedule; and</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>the Allocation Certificate.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">8.4<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">No Company Material Adverse Effect</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Since the date of this Agreement, there shall not have occurred any Company Material Adverse Effect that is continuing.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">8.5<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Company Stockholder Written Consent</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Company Stockholder Written Consent executed by the stockholders of the Company shall be in full force and effect.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">8.6<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Company Pre-Closing Financing</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Subscription Agreement (as may be amended, restated or supplemented pursuant to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.19</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">) shall be in full force and effect and proceeds of not less than $175,000,000 (including in the proceeds any Company Notes contributed as consideration in the Company Pre-Closing Financing) shall have been received by the Company (or, if applicable pursuant to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.19</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, Parent or one or more of its affiliates) or will be received by the Company (or, if applicable pursuant to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.19</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, Parent or one or more of its affiliates) substantially simultaneously with the Closing in connection with the consummation of the transactions contemplated by the Subscription Agreement.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">8.7<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Parent Pre-Closing Dividend</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. If Parent declares the Parent Pre-Closing Dividend, then the Parent Pre-Closing Dividend Amount shall have been deposited by Parent with Parent&#8217;s transfer agent for further distribution to the holders of the shares of Parent Common Stock outstanding as of the record date of the Parent Pre-Closing Dividend.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;9. </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Additional Conditions Precedent to Obligation of the Company</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The obligations of the Company to effect the Merger and otherwise consummate the transactions to be consummated at the Closing are subject to the satisfaction or the written waiver by the Company, at or prior to the Closing, of each of the following conditions:</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">9.1<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Accuracy of Representations</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Parent Fundamental Representations shall have been true and correct in all material respects as of the date of this Agreement and shall be true and correct on and as of the Closing Date with the same force and effect as if made on and as of such date (except to the extent such representations and warranties are specifically made as of a particular date, in which case such representations and warranties shall be true and correct as of such date). The Parent Capitalization Representations shall have been true and correct in all respects as of the date of this Agreement and shall be true and correct on and as of the Closing </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-67</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Date with the same force and effect as if made on and as of such date, except, in each case, (x) for such inaccuracies which are de minimis, individually or in the aggregate, (y) for those representations and warranties which address matters only as of a particular date (which representations and warranties shall have been true and correct, subject to the qualifications as set forth in the preceding clause&#160;(x), as of such particular date). The representations and warranties of Parent and Merger Subs contained in this Agreement (other than the Parent Fundamental Representations and the Parent Capitalization Representations) shall have been true and correct as of the date of this Agreement and shall be true and correct on and as of the Closing Date with the same force and effect as if made on the Closing Date except (a) in each case, or in the aggregate, where the failure to be so true and correct would not reasonably be expected to have a Parent Material Adverse Effect (without giving effect to any references therein to any Parent Material Adverse Effect or other materiality qualifications) or (b) for those representations and warranties which address matters only as of a particular date (which representations shall have been true and correct, subject to the qualifications as set forth in the preceding clause&#160;(a), as of such particular date) (it being understood that, for purposes of determining the accuracy of such representations and warranties, any update of or modification to the Parent Disclosure Letter made or purported to have been made after the date of this Agreement shall be disregarded).</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">9.2<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Performance of Covenants</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Parent and Merger Subs shall have performed or complied with in all material respects all of their agreements and covenants required to be performed or complied with by each of them under this Agreement at or prior to the First Effective Time.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">9.3<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Documents</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Company shall have received the following documents, each of which shall be in full force and effect:</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>a certificate executed by an executive officer of Parent certifying that the conditions set forth in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Sections&#160;9.1</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">9.2</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">9.4</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> have been duly satisfied;</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>written resignations in forms satisfactory to the Company, dated as of the Closing Date and effective as of the Closing executed by the officers and directors of Parent who are not to continue as officers or directors of Parent pursuant to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.12</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> hereof; and</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>the Parent Net Cash Schedule.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">9.4<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">No Parent Material Adverse Effect</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Since the date of this Agreement, there shall not have occurred any Parent Material Adverse Effect that is continuing.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;10. </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Termination</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">10.1<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Termination</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. This Agreement may be terminated prior to the First Effective Time (whether before or after adoption of this Agreement by the Company&#8217;s stockholders and whether before or after approval of the Parent Stockholder Matters by Parent&#8217;s stockholders, unless otherwise specified below):</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>by mutual written consent of Parent and the Company;</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>by either Parent or the Company if the Merger shall not have been consummated by October 3, 2024 (subject to possible extension as provided in this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.1(b)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">End Date</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;); </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">however</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that the right to terminate this Agreement under this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.1(b)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> shall not be available to the Company or Parent if such Party&#8217;s (or in the case of Parent, Merger Subs&#8217;) action or failure to act has been a principal cause of the failure of the Merger to occur on or before the End Date and such action or failure to act constitutes a breach of this Agreement, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided further</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">however</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that, in the event that the SEC has not declared effective under the Securities Act the Registration Statement by the date which is sixty (60) days prior to the End Date, then either the Company or Parent shall be entitled to extend the End Date for an additional sixty (60)&#160;days;</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>by either Parent or the Company if a court of competent jurisdiction or other Governmental Authority shall have issued a final and nonappealable Order having the effect of permanently restraining, enjoining or otherwise prohibiting the Contemplated Transactions;</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>by Parent if the Required Company Stockholder Vote shall not have been obtained within two (2) Business Days of the Registration Statement becoming effective in accordance with the provisions of the Securities Act; </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">however</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that once the Required Company Stockholder Vote has been obtained, Parent may not terminate this Agreement pursuant to this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.1(d)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">;</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-68</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(e)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>by either Parent or the Company if (i) the Parent Stockholder Meeting (including any adjournments and postponements thereof) shall have been held and completed and Parent&#8217;s stockholders shall have taken a final vote on the Parent Stockholder Matters and (ii)&#160;the Parent Stockholder Matters shall not have been approved at the Parent Stockholder Meeting (or at any adjournment or postponement thereof) by the Required Parent Stockholder Vote; </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">however</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that the right to terminate this Agreement under this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.1(e)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> shall not be available to Parent where the failure to obtain the Required Parent Stockholder Vote shall have been caused by the action or failure to act of Parent and such action or failure to act constitutes a material breach by Parent of this Agreement;</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(f)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>by the Company (at any time prior to the approval of the Parent Stockholder Matters by the Required Parent Stockholder Vote) if a Parent Triggering Event shall have occurred;</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(g)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>by Parent (at any time prior to the adoption of this Agreement and the approval of the Contemplated Transactions by the Required Company Stockholder Vote) if a Company Triggering Event shall have occurred;</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(h)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>by the Company, upon a breach of any representation, warranty, covenant or agreement set forth in this Agreement by Parent or Merger Subs or if any representation or warranty of Parent or Merger Subs shall have become inaccurate, in either case, such that the conditions set forth in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;9.1</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> or </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;9.2</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> would not be satisfied as of the time of such breach or as of the time such representation or warranty shall have become inaccurate; </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that the Company is not then in material breach of any representation, warranty, covenant or agreement under this Agreement; </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided further</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that if such inaccuracy in Parent&#8217;s or Merger Subs&#8217; representations and warranties or breach by Parent or Merger Subs is curable by Parent or Merger Subs, then the Company shall not be permitted to terminate this Agreement pursuant to this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.1(h)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> as a result of such particular breach or inaccuracy until the earlier of (i) the expiration of a thirty (30) day period commencing upon delivery of written notice from the Company to Parent or Merger Subs of such breach or inaccuracy and its intention to terminate pursuant to this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.1(h)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and (ii) Parent or Merger Subs (as applicable) ceasing to exercise commercially reasonable efforts to cure such breach following delivery of written notice from the Company to Parent or Merger Subs of such breach or inaccuracy and its intention to terminate pursuant to this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.1(h)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> (it being understood that the Company shall not be permitted to terminate this Agreement pursuant to this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.1(h)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> as a result of such particular breach or inaccuracy if such breach by Parent or Merger Subs is cured prior to such termination becoming effective);</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(i)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>by Parent, upon a breach of any representation, warranty, covenant or agreement set forth in this Agreement by the Company or if any representation or warranty of the Company shall have become inaccurate, in either case, such that the conditions set forth in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;8.1</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> or </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;8.2</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> would not be satisfied as of the time of such breach or as of the time such representation or warranty shall have become inaccurate; </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> that Parent is not then in material breach of any representation, warranty, covenant or agreement under this Agreement; </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">further</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that if such inaccuracy in the Company&#8217;s representations and warranties or breach by the Company is curable by the Company then Parent shall not be permitted to terminate this Agreement pursuant to this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.1(i)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> as a result of such particular breach or inaccuracy until the earlier of (i) the expiration of a thirty&#160;(30)&#160;day period commencing upon delivery of written notice from Parent to the Company of such breach or inaccuracy and its intention to terminate pursuant to this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.1(i)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and (ii) the Company ceasing to exercise commercially reasonable efforts to cure such breach following delivery of written notice from Parent to the Company of such breach or inaccuracy and its intention to terminate pursuant to this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.1(i)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> (it being understood that Parent shall not be permitted to terminate this Agreement pursuant to this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.1(i)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> as a result of such particular breach or inaccuracy if such breach by the Company is cured prior to such termination becoming effective); or</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(j)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>by Parent (at any time prior to the approval of the Parent Stockholder Matters by the Required Parent Stockholder Vote) and following compliance with all of the requirements set forth in the proviso to this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.1(j)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, upon the Parent Board authorizing Parent to enter into a Permitted Alternative Agreement; </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">however</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that Parent shall not enter into any Permitted Alternative Agreement unless: (i) Parent shall have complied in all material respects with its obligations under </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;5.4</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.3</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, (ii) the Parent Board shall have determined in good faith, after consultation with its outside legal counsel, that the failure to enter into such Permitted Alternative Agreement would reasonably be expected to be inconsistent with its fiduciary obligations under applicable Law and (iii) Parent shall concurrently pay to the Company the Company Termination Fee in accordance with </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.3(d)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-69</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">The Party desiring to terminate this Agreement pursuant to this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.1</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> (other than pursuant to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.1(a)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">) shall give a notice of such termination to the other Party specifying the provisions hereof pursuant to which such termination is made and the basis therefor described in reasonable detail.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">10.2<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Effect of Termination</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. In the event of the termination of this Agreement as provided in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.1</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, this Agreement shall be of no further force or effect; </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">however</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that (a)&#160;this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.2</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.3</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;11</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> (other than </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;11.8)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and the related definitions of the defined terms in such sections shall survive the termination of this Agreement and shall remain in full force and effect and (b) the termination of this Agreement and the provisions of </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.3</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> shall not relieve any Party of any liability for fraud or for any willful and material breach of any representation, warranty, covenant, obligation or other provision contained in this Agreement.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">10.3<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Expenses; Termination Fees</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Except as set forth in this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.3</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.9</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> all fees and expenses incurred in connection with this Agreement and the Contemplated Transactions shall be paid by the Party incurring such expenses, whether or not the Merger is consummated.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>If (i) this Agreement is terminated by Parent or the Company pursuant to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.1(e)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> or by the Company pursuant to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.1(f)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, (ii) at any time after the date of this Agreement and prior to the Parent Stockholder Meeting, an Acquisition Proposal with respect to Parent shall have been publicly announced, disclosed or otherwise communicated to the Parent Board (and shall not have been withdrawn) and (iii)&#160;in the event this Agreement is terminated pursuant to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.1(e)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, within twelve (12) months after the date of such termination, Parent enters into a definitive agreement with respect to a Subsequent Transaction or consummates a Subsequent Transaction, then Parent shall pay to the Company, within ten (10) Business Days after termination (or, if applicable, upon such entry into a definitive agreement or consummation of a Subsequent Transaction), a nonrefundable fee in an amount equal to $440,000 (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Termination Fee</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;).</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>If this Agreement is terminated (i) by the Company pursuant to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.1(b)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> or </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.1(e)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> (when at the time this Agreement is terminated, the Company had the right to terminate this Agreement pursuant to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.1(f)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">) then Parent shall pay to the Company within five (5) Business Days of such termination, the Company Termination Fee or (ii) by Parent pursuant to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.1(j)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, then Parent shall pay to the Company, concurrent with such termination, the Company Termination Fee.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>If (i) this Agreement is terminated by Parent pursuant to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.1(d)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> or </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.1(g)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, (ii) at any time after the date of this Agreement and before obtaining the Required Company Stockholder Vote, an Acquisition Proposal with respect to the Company shall have been announced, disclosed or otherwise communicated to the Company Board (and shall not have been withdrawn) and (iii) in the event this Agreement is terminated pursuant to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.1(d)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, within twelve&#160;(12) months after the date of such termination, the Company enters into a definitive agreement with respect to a Subsequent Transaction or consummates a Subsequent Transaction, then the Company shall pay to Parent, within ten (10) Business Days after termination (or, if applicable, upon such entry into a definitive agreement or consummation of a Subsequent Transaction), a nonrefundable fee in an amount equal to $440,000.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(e)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>If either Party fails to pay when due any amount payable by it under this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.3</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, then (i) such Party shall reimburse the other Party for reasonable costs and expenses (including reasonable fees and disbursements of counsel) incurred in connection with the collection of such overdue amount and the enforcement by the other Party of its rights under this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.3</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and (ii)&#160;such Party shall pay to the other Party interest on such overdue amount (for the period commencing as of the date such overdue amount was originally required to be paid and ending on the date such overdue amount is actually paid to the other Party in full) at a rate per annum equal to the &#8220;prime rate&#8221; (as announced by Bank of America or any successor thereto) in effect on the date such overdue amount was originally required to be paid plus three percent.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(f)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Parties agree that, subject to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.2</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, the payment of the fees and expenses set forth in this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.3</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> shall be the sole and exclusive remedy of each Party following a termination of this Agreement under the circumstances described in this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.3</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, it being understood that in no event shall either Parent or the Company be required to pay the individual fees or damages payable pursuant to this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.3</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> on more than one occasion. Subject to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.2</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, following the payment of the fees and expenses set forth in </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-70</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.3</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> by a Party, (i) such Party shall have no further liability to the other Party in connection with or arising out of this Agreement or the termination thereof, any breach of this Agreement by the other Party giving rise to such termination, or the failure of the Contemplated Transactions to be consummated, (ii) no other Party or their respective Affiliates shall be entitled to bring or maintain any other claim, action or proceeding against such Party or seek to obtain any recovery, judgment or damages of any kind against such Party (or any partner, member, stockholder, director, officer, employee, Subsidiary, Affiliate, agent or other Representative of such Party) in connection with or arising out of this Agreement or the termination thereof, any breach by such Party giving rise to such termination or the failure of the Contemplated Transactions to be consummated and (iii) all other Parties and their respective Affiliates shall be precluded from any other remedy against such Party and its Affiliates, at law or in equity or otherwise, in connection with or arising out of this Agreement or the termination thereof, any breach by such Party giving rise to such termination or the failure of the Contemplated Transactions to be consummated. Each of the Parties acknowledges that (x) the agreements contained in this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.3</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> are an integral part of the Contemplated Transactions, (y) without these agreements, the Parties would not enter into this Agreement and (z)&#160;any amount payable pursuant to this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.3</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> is not a penalty, but rather is liquidated damages in a reasonable amount that will compensate the Parties in the circumstances in which such amount is payable; provided, however, that nothing in this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.3(f)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> shall limit the rights of the Parties under </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;11.10</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;11. </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Miscellaneous Provisions</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">11.1<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Non-Survival of Representations and Warranties</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The representations and warranties of the Company, Parent and Merger Subs contained in this Agreement or any certificate or instrument delivered pursuant to this Agreement shall terminate at the First Effective Time, and only the covenants that by their terms survive the First Effective Time and this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;11</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> shall survive the First Effective Time.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">11.2<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Amendment</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. This Agreement may be amended with the approval of the respective boards of directors of the Company, Merger Subs and Parent at any time (whether before or after the adoption and approval of this Agreement by the Company&#8217;s stockholders or before or after obtaining the Required Parent Stockholder Vote); </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">however</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that after any such approval of this Agreement by a Party&#8217;s stockholders, no amendment shall be made which by Law requires further approval of such stockholders without the further approval of such stockholders. This Agreement may not be amended except by an instrument in writing signed on behalf of each of the Company, Merger Subs and Parent.</span></p>
		<p class="ParaOverride-18" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;page-break-after:avoid;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">11.3<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Waiver</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Any provision hereof may be waived by the waiving Party solely on such Party&#8217;s own behalf, without the consent of any other Party. No failure on the part of any Party to exercise any power, right, privilege or remedy under this Agreement, and no delay on the part of any Party in exercising any power, right, privilege or remedy under this Agreement, shall operate as a waiver of such power, right, privilege or remedy; and no single or partial exercise of any such power, right, privilege or remedy shall preclude any other or further exercise thereof or of any other power, right, privilege or remedy.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>No Party shall be deemed to have waived any claim arising out of this Agreement, or any power, right, privilege or remedy under this Agreement, unless the waiver of such claim, power, right, privilege or remedy is expressly set forth in a written instrument duly executed and delivered on behalf of such Party and any such waiver shall not be applicable or have any effect except in the specific instance in which it is given.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">11.4<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Entire Agreement; Counterparts; Exchanges by Electronic Transmission or Facsimile</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. This Agreement and the other schedules, exhibits, certificates, instruments and agreements referred to in this Agreement constitute the entire agreement and supersede all prior agreements and understandings, both written and oral, among or between any of the Parties with respect to the subject matter hereof and thereof; </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">however</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that the Confidentiality Agreement shall not be superseded and shall remain in full force and effect in accordance with its terms; </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">further</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that only Exhibit&#160;D (including Exhibit&#160;A to such Exhibit) is incorporated by reference and made a part hereof for purposes of Section&#160;251 of the DGCL. This Agreement may be executed in several counterparts, each of which shall be deemed an original and all of which shall constitute one and the same instrument. The exchange of a fully executed Agreement (in counterparts or otherwise) by all Parties by facsimile or electronic transmission in PDF format shall be sufficient to bind the Parties to the terms and conditions of this Agreement.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-71</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">11.5<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Applicable Law; Jurisdiction</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. This Agreement shall be governed by, and construed in accordance with, the laws of the State of Delaware, regardless of the laws that might otherwise govern under applicable principles of conflicts of laws. In any action or proceeding between any of the Parties arising out of or relating to this Agreement or any of the Contemplated Transactions, each of the Parties: (a) irrevocably and unconditionally consents and submits to the exclusive jurisdiction and venue of the Court of Chancery of the State of Delaware or, to the extent such court does not have subject matter jurisdiction, the Superior Court of the State of Delaware or the United States District Court for the District of Delaware, (b) agrees that all claims in respect of such action or proceeding shall be heard and determined exclusively in accordance with clause&#160;(a) of this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;11.5</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, (c)&#160;waives any objection to laying venue in any such action or proceeding in such courts, (d) waives any objection that such courts are an inconvenient forum or do not have jurisdiction over any Party, (e) agrees that service of process upon such Party in any such action or proceeding shall be effective if notice is given in accordance with </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;11.7</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of this Agreement and (f) irrevocably and unconditionally waives the right to trial by jury.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">11.6<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Assignability</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. This Agreement shall be binding upon, and shall be enforceable by and inure solely to the benefit of, the Parties and their respective successors and permitted assigns; </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">however</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that neither this Agreement nor any of a Party&#8217;s rights or obligations hereunder may be assigned or delegated by such Party without the prior written consent of the other Party, and any attempted assignment or delegation of this Agreement or any of such rights or obligations by such Party without the other Party&#8217;s prior written consent shall be void and of no effect.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">11.7<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Notices</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. All notices and other communications hereunder shall be in writing and shall be deemed to have been duly delivered and received hereunder (a)&#160;one&#160;(1) Business Day after being sent for next Business Day delivery, fees prepaid, via a reputable international overnight courier service, (b)&#160;upon delivery in the case of delivery by hand or (c) on the date delivered in the place of delivery if sent by email or facsimile (with a written or electronic confirmation of delivery) prior to 6:00 p.m. (New York City time), otherwise on the next succeeding Business Day, in each case to the intended recipient as set forth below:</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">if to Parent or Merger Subs:</span></p>
		<p class="ParaOverride-20" style="margin:0;padding:0;border-width:0;margin-left:72pt;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">ARCA biopharma, Inc.<br/>10170 Church Ranch Way, Suite 100<br/>Westminster, CO 80021 <br/>Attention: C. Jeffrey Dekker<br/>Email: ***</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">with a copy to (which shall not constitute notice):</span></p>
		<p class="ParaOverride-20" style="margin:0;padding:0;border-width:0;margin-left:72pt;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Wilson Sonsini Goodrich &amp; Rosati<br/>1881 9</span><span class="CharOverride-11" style="font-family:Times New Roman PS Std, serif;font-size:6pt;font-style:normal;font-weight:normal;vertical-align:super;">th</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> Street, Suite 110<br/>Boulder, CO 80302<br/>Attn: Brent Fassett<br/>Email: bfassett@wsgr.com</span></p>
		<p class="ParaOverride-20" style="margin:0;padding:0;border-width:0;margin-left:72pt;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">and</span></p>
		<p class="ParaOverride-20" style="margin:0;padding:0;border-width:0;margin-left:72pt;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Wilson Sonsini Goodrich &amp; Rosati<br/>One Market Plaza, Spear Tower, Suite 3300<br/>San Francisco, CA 94105<br/>Attn: Ethan Lutske, Ross Tanaka<br/>Email: elutske@wsgr.com, rtanaka@wsgr.com</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">if to the Company:</span></p>
		<p class="ParaOverride-20" style="margin:0;padding:0;border-width:0;margin-left:72pt;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Oruka Therapeutics, Inc.<br/>221 Crescent Street, Building 23, Suite 105<br/>Waltham, Massachusetts 02453<br/>Attention: Lawrence Klein<br/>Email: ***</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-72</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">with a copy to (which shall not constitute notice):</span></p>
		<p class="ParaOverride-20" style="margin:0;padding:0;border-width:0;margin-left:72pt;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Gibson, Dunn &amp; Crutcher LLP<br/>One Embarcadero Center, Suite 2600<br/>San Francisco, CA 94111<br/>Attention: Ryan Murr, Branden Berns, Chris Trester<br/>Email: rmurr@gibsondunn.com, bberns@gibsondunn.com, ctrester@gibsondunn.com</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">11.8<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Cooperation</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Each Party agrees to cooperate fully with the other Party and to execute and deliver such further documents, certificates, agreements and instruments and to take such other actions as may be reasonably requested by the other Party to evidence or reflect the Contemplated Transactions and to carry out the intent and purposes of this Agreement.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">11.9<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Severability</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Any term or provision of this Agreement that is invalid or unenforceable in any situation in any jurisdiction shall not affect the validity or enforceability of the remaining terms and provisions of this Agreement or the validity or enforceability of the offending term or provision in any other situation or in any other jurisdiction. If a final judgment of a court of competent jurisdiction declares that any term or provision of this Agreement is invalid or unenforceable, the Parties agree that the court making such determination shall have the power to limit such term or provision, to delete specific words or phrases or to replace such term or provision with a term or provision that is valid and enforceable and that comes closest to expressing the intention of the invalid or unenforceable term or provision, and this Agreement shall be valid and enforceable as so modified. In the event such court does not exercise the power granted to it in the prior sentence, the Parties agree to replace such invalid or unenforceable term or provision with a valid and enforceable term or provision that will achieve, to the extent possible, the economic, business and other purposes of such invalid or unenforceable term or provision.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">11.10<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Other Remedies; Specific Performance</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Except as otherwise provided herein, any and all remedies herein expressly conferred upon a Party will be deemed cumulative with and not exclusive of any other remedy conferred hereby, or by law or equity upon such Party, and the exercise by a Party of any one remedy will not preclude the exercise of any other remedy. The Parties agree that irreparable damage for which monetary damages, even if available, would not be an adequate remedy, would occur in the event that any of the provisions of this Agreement were not performed in accordance with their specific terms (including failing to take such actions as are required of it hereunder to consummate this Agreement) or were otherwise breached. It is accordingly agreed that the Parties shall be entitled to an injunction or injunctions to prevent breaches of this Agreement and to enforce specifically the terms and provisions hereof in the Court of Chancery of the State of Delaware or, to the extent such court does not have subject matter jurisdiction, the Superior Court of the State of Delaware or the United States District Court for the District of Delaware, this being in addition to any other remedy to which they are entitled at law or in equity, and each of the Parties waives any bond, surety or other security that might be required of any other Party with respect thereto. Each of the Parties further agrees that it will not oppose the granting of an injunction, specific performance or other equitable relief on the basis that any other Party has an adequate remedy at law or that any award of specific performance is not an appropriate remedy for any reason at law or in equity.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">11.11<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">No Third-Party Beneficiaries</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Nothing in this Agreement, express or implied, is intended to or shall confer upon any Person (other than the Parties and the D&amp;O Indemnified Parties to the extent of their respective rights pursuant to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.7</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">) any right, benefit or remedy of any nature whatsoever under or by reason of this Agreement.</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-align:center;widows:3;margin-top:8pt;"><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">Remainder of page intentionally left blank</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-73</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:small-caps;font-weight:bold;">In Witness Whereof</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">,</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> the Parties have caused this Agreement to be executed as of the date first above written.</span></p>
		<table class="No-Table-Style _idGenTablePara-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">



					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="CharOverride-7" style="font-style:normal;font-weight:bold;">ARCA </span><span class="CharOverride-12" style="font-style:normal;font-variant:small-caps;font-weight:bold;">biopharma, Inc</span><span class="CharOverride-7" style="font-style:normal;font-weight:bold;">.</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-18" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">By:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 42.74%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">/s/ C. Jeffrey Dekker</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Name:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 42.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">C. Jeffrey Dekker</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Title:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 42.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Chief Financial Officer</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-18" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;"><span class="CharOverride-7" style="font-style:normal;font-weight:bold;">ATLAS MERGER SUB CORP.</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-18" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">By:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 42.74%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">/s/ C. Jeffrey Dekker</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Name:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 42.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">C. Jeffrey Dekker</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Title:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 42.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">President</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-18" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;"><span class="CharOverride-7" style="font-style:normal;font-weight:bold;">ATLAS MERGER SUB II, LLC</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-18" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">By:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 42.74%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">/s/ C. Jeffrey Dekker</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Name:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 42.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">C. Jeffrey Dekker</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Title:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 42.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">President</p>
					</td>
				</tr>

		</table>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-align:center;widows:3;margin-top:8pt;"><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">Signature Page to Agreement and Plan of Merger and Reorganization</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-74</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:small-caps;font-weight:bold;">In Witness Whereof</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">,</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> the Parties have caused this Agreement to be executed as of the date first above written.</span></p>
		<table class="No-Table-Style _idGenTablePara-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">



					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="CharOverride-12" style="font-style:normal;font-variant:small-caps;font-weight:bold;">Oruka Therapeutics, Inc.</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-18" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">By:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 42.74%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">/s/ Lawrence Klein</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Name:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 42.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Lawrence Klein</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Title:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 42.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Chief Executive Officer</p>
					</td>
				</tr>

		</table>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-align:center;widows:3;margin-top:8pt;"><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">Signature Page to Agreement and Plan of Merger and Reorganization</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-75</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T101"></a><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:right;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Annex&#160;B</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">OPINION OF LUCID CAPITAL MARKETS</span></p>
		<p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:14pt;">LUCID CAPITAL MARKETS, LLC</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">April&#160;2, 2024</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">ARCA biopharma, Inc.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:0pt;margin-top:0pt;">10170 Church Ranch Way, Suite 100</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:0pt;margin-top:0pt;">Westminster, CO&#160;80021</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:0pt;margin-top:0pt;">Attention: Robert E.&#160;Conway</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:0pt;margin-top:0pt;">Chairman of the Board of Directors</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Members of the Board of Directors:</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We have been advised that ARCA biopharma, Inc., a Delaware corporation (&#8220;ARCA&#8221; or &#8220;Parent&#8221;), proposes to enter into an Agreement and Plan of Merger (the &#8220;Agreement&#8221;), by and among ARCA, Atlas Merger Sub Corp., a Delaware corporation and a wholly owned subsidiary of ARCA (&#8220;Merger Sub&#8221;), and Oruka Therapeutics, Inc., a Delaware corporation (&#8220;Oruka&#8221; or the &#8220;Company&#8221;). At the Effective Time, Merger Sub will be merged with and into the Company (the &#8220;Merger&#8221;), and the separate existence of the Merger Sub will cease. The Company will continue as the surviving corporation in the Merger (the &#8220;Surviving Corporation&#8221;). Pursuant to the terms of the Agreement, upon consummation of the Merger, each share of Company Capital Stock (other than shares of Company Capital Stock held as treasury stock immediately prior to the Effective Time which shall be canceled and retired and shall cease to exist and excluding Dissenting Shares) will be converted into and become exchangeable for a number of shares of Parent Common Stock equal to the Exchange Ratio. The terms and conditions of the Merger are more fully set forth in the Agreement. Capitalized terms used but not defined herein shall have the meanings ascribed to such terms in the Agreement.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Agreement contemplates that Parent may declare and pay a dividend on the shares of Parent Common Stock outstanding prior to the Effective Time (excluding for the avoidance of doubt any shares of Parent Common Stock issuable pursuant to the Contemplated Transactions) up to an amount equal in the aggregate to Parent&#8217;s reasonable, good faith approximation of the amount by which Parent Net Cash will exceed $5,000,000 (the &#8220;Parent Pre<span class="nobreak">-Closing</span> Dividend&#8221;). The Agreement also contemplates that concurrently with the execution and delivery of the Agreement, certain investors will execute a Subscription Agreement pursuant to which such Persons will have agreed to purchase (including by contribution of Company Notes) (i)&#160;shares of Company Common Stock and (ii)&#160;pre<span class="nobreak">-funded</span> Company Warrants, in each case immediately prior to the Effective Time (the &#8220;Company Pre<span class="nobreak">-Closing</span> Financing&#8221;). It is a condition precedent to the obligations of Parent and Merger Sub to effect the Merger that proceeds of not less than $175&#160;million be received from the Company Pre<span class="nobreak">-Closing</span> Financing.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We have assumed, with your consent, that the Parent Net Cash amount is expected to be, and we have assumed, with your consent, that it will be approximately $5.0&#160;million at Closing after taking effecting the Parent Pre<span class="nobreak">-Closing</span> Dividend.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Assuming that the Parent Pre<span class="nobreak">-Closing</span> Dividend has occurred, the holders of Company Common Stock, Company Options and Company Warrants will in the aggregate hold approximately 97.6% of the fully<span class="nobreak">-diluted</span> shares of Parent Common Stock (excluding certain Parent Options) immediately following the Merger and the holders of Parent Common Stock will in the aggregate hold approximately 2.4% of the fully<span class="nobreak">-diluted</span> shares of Parent Common Stock (excluding certain Parent Options) immediately following the Merger, in each case, after accounting for the Parent Pre<span class="nobreak">-Closing</span> Dividend and the Company Pre<span class="nobreak">-Closing</span> Financing.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We have, with your consent, relied upon the assumption that all information provided to us by ARCA and Oruka is accurate and complete in all material respects. We expressly disclaim any undertaking or obligation to advise any person of any change in any fact or matter affecting our Opinion of which we become aware after the date hereof. We have assumed there were no material changes in the assets, liabilities, financial condition, results of operations, business or prospects of ARCA or Oruka since the date of the last financial statements made available to </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex B-1</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">us. We have not obtained any independent evaluations, valuations or appraisals of the assets or liabilities of ARCA or Oruka, nor have we been furnished with such materials. In addition, we have not evaluated the solvency or fair value of ARCA or Oruka under any state or federal laws relating to bankruptcy, insolvency or similar matters.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Our Opinion does not address any legal, regulatory, tax or accounting matters related to the Merger, as to which we have assumed that ARCA and the Board of Directors have received such advice from legal, tax and accounting advisors as each has determined appropriate. Our Opinion addresses only the fairness from a financial point of view of the Exchange Ratio as set forth in the Merger Agreement to the holders of Parent Common Stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We express no view as to any other aspect or implication of the Merger or any other agreement or arrangement entered into in connection with the Merger. Our Opinion is necessarily based upon economic and market conditions and other circumstances as they exist and can be evaluated by us on the date hereof. It should be understood that although subsequent developments may affect our Opinion, we do not have any obligation to update, revise or reaffirm our Opinion and we expressly disclaim any responsibility to do so.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We have not considered any potential legislative or regulatory changes currently being considered or recently enacted by the United&#160;States or any foreign government, or any domestic or foreign regulatory body, or any changes in accounting methods or generally accepted accounting principles that may be adopted by the Securities and Exchange Commission (the &#8220;SEC&#8221;), the Financial Accounting Standards Board, or any similar foreign regulatory body or board.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In your capacity as members of the Board of Directors of ARCA (the &#8220;Board of Directors&#8221;), you have requested our opinion (our &#8220;Opinion&#8221;) as to the fairness, from a financial point of view and as of the date hereof, of the Exchange Ratio as set forth in the Agreement to the holders of Parent Common Stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In connection with our Opinion, we took into account an assessment of general economic, market and financial conditions as well as our experience in connection with similar transactions and securities valuations generally and, among other things:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Reviewed a draft of the Merger Agreement;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Reviewed and analyzed certain publicly available financial and other information for each of ARCA and Oruka, respectively, including equity research on comparable companies and on ARCA, and certain other relevant financial and operating data furnished to us by the management of each of ARCA and Oruka, respectively;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Reviewed and analyzed certain relevant historical financial and operating data concerning Oruka furnished to us by the management of Oruka;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Discussed with certain members of the management of ARCA the historical and current business operations, financial condition and prospects of ARCA and Oruka;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Reviewed and analyzed certain operating results of Oruka as compared to operating results and the reported price and trading histories of certain publicly traded companies that we deemed relevant;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Reviewed and analyzed certain financial terms of the Merger Agreement as compared to the publicly available financial terms of certain selected business combinations that we deemed relevant;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Reviewed and analyzed certain financial terms of completed initial public offerings for certain companies that we deemed relevant;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Reviewed certain pro forma financial effects of the Merger;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Reviewed and analyzed certain internal financial analyses, including the cash burn model over the next year, projections as to cost and expenses and whether concurrent capital raised would sufficiently cover select programs, reports, and other information concerning Oruka prepared by Oruka; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Reviewed and analyzed such other information and such other factors, and conducted such other financial studies, analyses and investigations, as we deemed relevant for the purposes of our Opinion.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex B-2</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">For purposes of rendering our Opinion we have assumed, with your consent, that except as would not be in any way meaningful to our analysis: (i)&#160;the final form of the Agreement will not differ from the Draft Agreement that we have reviewed; (ii)&#160;the representations and warranties of each party contained in the Agreement are true and correct in all respects; (iii)&#160;each party will perform all of the covenants and agreements required to be performed by such party under the Agreement; and (iv)&#160;the transactions contemplated by the Agreement will be consummated in accordance with the terms of the Agreement, without any waiver or amendment of any term or condition thereof. We have also assumed that all governmental, regulatory and other consents and approvals contemplated by the Agreement or otherwise required for the transactions contemplated by the Agreement will be obtained and that in the course of obtaining any of those consents no restrictions will be imposed, or waivers made that would have an adverse effect on ARCA, Oruka, or the contemplated benefits of the Merger. We have assumed that the Merger will be consummated in a manner that complies with the applicable provisions of the Securities Act&#160;of&#160;1933, as amended, the Securities Exchange&#160;Act&#160;of&#160;1934, as amended, and all other applicable federal and state statutes and the rules and regulations promulgated thereunder.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">It is understood that this letter is intended for the benefit and use of the Board of Directors (in its capacity as such) in its consideration of the financial terms of the Merger and, except as set forth in our engagement letter with ARCA, dated as of March&#160;19, 2024 (the &#8220;Engagement Letter&#8221;), may not be used for any other purpose or reproduced, disseminated, quoted or referred to at any time, in any manner or for any purpose without our prior written consent, except that this Opinion may be included in its entirety in any filing related to the Merger required to be filed with the SEC and any proxy statement to be mailed to holders of Parent Common Stock. This letter does not constitute a recommendation to the Board of Directors of whether to approve the Merger or to any stockholder of ARCA or any other person as to how to vote or act with respect to the transactions contemplated by the Agreement (including the Merger) or any other matter. Our Opinion does not address ARCA&#8217;s underlying business decision to proceed with the Merger or the relative merits of the Merger compared to other alternatives available to ARCA.&#160;We express no opinion as to the prices or ranges of prices at which shares or the securities of any person, including ARCA, will trade at any time, including following the announcement or consummation of the Merger, or as to the potential effects of volatility in the credit, financial, and stock markets on ARCA, Oruka or the transactions contemplated by the Agreement. We have not been requested to opine as to, and our Opinion does not in any manner address, the amount or nature of compensation to any of the officers, directors or employees of any party to the Merger, or any class of such persons, relative to the compensation to be paid to the holders of Parent Common Stock in connection with the Merger or with respect to the fairness of any such compensation.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Lucid is an investment bank providing investment banking, brokerage, equity research, institutional sales and trading services. As part of our investment banking services, we are regularly engaged in the valuation of businesses and their securities in connection with mergers, negotiated underwritings, secondary distributions of listed and unlisted securities, private placements and valuations for corporate and other purposes. We have acted as ARCA&#8217;s financial advisor in connection with the Merger and will receive a fee for our services pursuant to the terms of our Engagement Letter, a significant portion of which is contingent upon consummation of the Merger. In addition, ARCA has agreed to reimburse our expenses and indemnify us for certain liabilities that may arise out of our engagement. We will also receive an additional fee for rendering our Opinion set forth below pursuant to the Engagement Letter, which is not contingent upon consummation of the Merger. In the two&#160;years preceding the date hereof, Lucid has not had a relationship with ARCA or its affiliates and has not received any fees from ARCA or any of its affiliates. In the two&#160;years preceding the date hereof, Lucid has not had a relationship with Oruka or any of its affiliates and has not received any fees from Oruka or any of its affiliates. Lucid and its affiliates may in the future seek to provide investment banking or financial advisory services to ARCA and Oruka and/or their respective affiliates and expect to receive fees for the rendering of these services.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In the ordinary course of business, Lucid or certain of our affiliates, as well as investment funds in which we or our affiliates may have financial interests, may acquire, hold or sell long or short positions, or trade or otherwise effect transactions in debt, equity, and other securities and financial instruments (including bank loans and other obligations) of, or investments in, ARCA, Oruka or any other party that may be involved in the Merger and/or their respective affiliates.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex B-3</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Consistent with applicable legal and regulatory requirements, Lucid has adopted policies and procedures to establish and maintain the independence of our research department and personnel. As a result, our research analysts may hold views, make statements or investment recommendations and/or publish research reports with respect to ARCA and the proposed Merger that may differ from the views of Lucid&#8217;s investment banking personnel.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Opinion set forth below was reviewed and approved by a fairness opinion committee of Lucid.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Based upon and subject to the foregoing, including the various assumptions and limitations set forth herein and such other factors that we deem relevant, it is our opinion that, as of the date hereof, the Exchange Ratio is fair, from a financial point of view, to the holders of Parent Common Stock.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Very truly yours,</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;"><img alt="" src="tlucid_sig.jpg" style="width:179.20000000000002px;max-width:100%;"/></span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;margin-top:8pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Lucid Capital Markets, LLC</span></p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex B-4</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T102"></a><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:right;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Annex&#160;C</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">FORM OF COMPANY STOCKHOLDER SUPPORT AGREEMENT</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">This Support Agreement (this &#8220;</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Agreement</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) is made and entered into as of April 3, 2024, by and among Oruka Therapeutics, Inc., a Delaware corporation (the &#8220;</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Company</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), ARCA biopharma, Inc., a Delaware corporation (&#8220;</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Parent</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), and the undersigned stockholder (the &#8220;</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Stockholder</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) of the Company. Capitalized terms used herein but not otherwise defined shall have the respective meanings ascribed to such terms in the Merger Agreement (as defined below).</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-align:center;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">RECITALS</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">WHEREAS, concurrently with the execution and delivery hereof, Parent, the Company and Atlas Merger Sub Corp., a Delaware corporation and a wholly owned subsidiary of Parent (the &#8220;</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">First Merger Sub</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), and Atlas Merger Sub II LLC, a Delaware limited liability company (the &#8220;</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Second Merger Sub</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) have entered into an Agreement and Plan of Merger and Reorganization (as such agreement may be amended or supplemented from time to time pursuant to the terms thereof, the &#8220;</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Merger Agreement</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), pursuant to which (i) the First Merger Sub will merge with and into the Company, with the Company surviving the merger as the surviving corporation and a wholly owned subsidiary of Parent and (ii) the Company will merge with and into the Second Merger Sub, with Second Merger Sub being the surviving entity of the Second Merger, upon the terms and subject to the conditions set forth in the Merger Agreement (the &#8220;</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Merger</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;).</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">WHEREAS, as of the date hereof, the Stockholder is the beneficial owner (as defined in Rule 13d-3 under the Exchange Act) of such number of shares of Company Capital Stock as indicated in </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Appendix A</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">WHEREAS, as an inducement to the willingness of Parent to enter into the Merger Agreement, Parent has required that Stockholder enter into this Agreement.</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">NOW, THEREFORE, intending to be legally bound, the parties hereby agree as follows:</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">1.<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Certain Definitions</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Capitalized terms used but not otherwise defined herein shall have the meanings ascribed thereto in the Merger Agreement. For all purposes of this Agreement, the following terms shall have the following respective meanings:</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>&#8220;</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Constructive Sale</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means, with respect to any security, a short sale with respect to such security, entering into or acquiring a derivative contract with respect to such security, entering into or acquiring a futures or forward contract to deliver such security or entering into any other hedging or other derivative transaction that has the effect of either directly or indirectly materially changing the economic benefits or risks of ownership of such security.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>&#8220;</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Shares</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means (i) all shares of Company Capital Stock beneficially owned by the Stockholder as of the date hereof, and (ii) all additional shares of Company Capital Stock acquired and beneficially owned by the Stockholder during the period commencing with the execution and delivery of this Agreement and expiring on the Closing Date.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>&#8220;</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Transfer</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; or &#8220;</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Transferred</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means, with respect to any security, the direct or indirect assignment, sale, transfer, tender, exchange, pledge or hypothecation, or the grant, creation or suffrage of a lien, security interest or encumbrance in or upon, or the gift, grant or placement in trust, or the Constructive Sale or other disposition of such security (including transfers by testamentary or intestate succession, by domestic relations order or other court order, or otherwise by operation of law) or any right, title or interest therein (including any right or power to vote to which the holder thereof may be entitled, whether such right or power is granted by proxy or otherwise), or the beneficial ownership thereof, the offer to make such a sale, transfer, Constructive Sale or other disposition, and each agreement, arrangement or understanding, whether or not in writing, to effect any of the foregoing.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex C-1</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">2.<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Transfer and Voting Restrictions</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Stockholder covenants to Parent and the Company as follows:</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Except as otherwise permitted by Section 2(c), during the period commencing with the execution and delivery of this Agreement and expiring on the Expiration Date (as defined below), the Stockholder shall not Transfer any of the Stockholder&#8217;s Shares, or publicly announce its intention to Transfer any of its Shares.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Except as otherwise permitted by this Agreement or otherwise permitted or required by order of a court of competent jurisdiction or a Governmental Authority, the Stockholder will not commit any act that would restrict the Stockholder&#8217;s legal power, authority and right to vote all of the Shares held by the Stockholder or otherwise prevent or disable the Stockholder from performing any of his, her or its obligations under this Agreement. Without limiting the generality of the foregoing, except for this Agreement, the Voting Agreement of the Company, dated as of March 6, 2024 (the &#8220;</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Voting Agreement</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) and as otherwise permitted by this Agreement, the Stockholder shall not enter into any voting agreement with any person or entity with respect to any of the Stockholder&#8217;s Shares, grant any person or entity any proxy (revocable or irrevocable) or power of attorney with respect to any of the Shares, deposit any Shares in a voting trust or otherwise enter into any agreement or arrangement with any person or entity limiting or affecting the Stockholder&#8217;s legal power, authority or right to execute and deliver the Company Stockholder Written Consent.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Notwithstanding anything else herein to the contrary, the Stockholder may, at any time, Transfer Shares (i) by will or other testamentary document or by intestacy, (ii) to such Stockholder&#8217;s Affiliates (in&#160;each case, directly or indirectly) (iii) to any member of the Stockholder&#8217;s immediate family (or, if the Stockholder is a corporation, partnership or other entity, to an immediate family member of a beneficial owner of the Shares held by the Stockholder), (iv) to any trust or other entity for the direct or indirect benefit of the Stockholder or the immediate family of the Stockholder (or, if the Stockholder is a corporation, partnership or other entity, for the direct or indirect benefit of an immediate family member of a beneficial owner of the Shares held by the Stockholder) or otherwise for estate tax or estate planning purposes, (v) in the case of a Stockholder who is not a natural person, by pro rata distributions from the Stockholder to its members, partners, or shareholders pursuant to the Stockholder&#8217;s organizational documents, (vi) purchased from the Company pursuant to the Company Pre-Closing Financing on or about the Closing Date but prior to the Closing (including any shares of the Company issued upon conversion of any pre-funded Company Warrants), and (vii) to the extent required by applicable Law; </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that in the cases of clauses (i)-(v), (x) such Transferred Shares shall continue to be bound by this Agreement and (y) the applicable direct transferee (if any) of such Transferred Shares shall have executed and delivered to Parent and the Company a support agreement substantially identical to this Agreement upon consummation of the Transfer if not already a party thereto.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Notwithstanding anything to the contrary herein, nothing in this Agreement shall obligate the Stockholder to exercise any option or any other right to acquire any shares of Company Capital Stock.</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">3.<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Agreement to Vote Shares</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Stockholder covenants to the Company as follows:</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Until the Expiration Date (as defined below), at any meeting of the stockholders of the Company, however called, and at every adjournment or postponement thereof, and on every action or approval by written consent of the stockholders of the Company, the Stockholder shall be present (in person or by proxy) and vote, or exercise its right to consent with respect to, all Shares held by the Stockholder (A) in favor of the adoption and approval of the Merger Agreement, (B) in favor of approval of the Contemplated Transactions, and (C) against any Acquisition Proposal.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>If the Stockholder is not the record holder, of Shares, the Stockholder agrees to take all actions necessary to cause the record holder and any nominees to be present (in person or by proxy) and vote all the Stockholder&#8217;s Shares in accordance with this </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 3.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>In the event of a stock split, stock dividend or distribution, or any change in the capital stock of the Company by reason of any split-up, reverse stock split, recapitalization, combination, reclassification, reincorporation, exchange of shares or the like, the term &#8220;Shares&#8221; shall be deemed to refer to and include such shares as well as all such stock dividends and distributions and any securities into which or for which any or all of such shares may be changed or exchanged or which are received in such transaction.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex C-2</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">4.<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Action in Stockholder Capacity Only</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Stockholder is entering into this Agreement solely in the Stockholder&#8217;s capacity as the beneficial owner of its Shares and not in the Stockholder&#8217;s capacity as a director or officer of the Company. Nothing herein shall limit or affect the Stockholder&#8217;s ability to act as an officer or director of the Company.</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">5.<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Irrevocable Proxy</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Stockholder hereby revokes (or agrees to cause to be revoked) any proxies that the Stockholder has heretofore granted with respect to its Shares. In the event and to the extent that the Stockholder fails to vote the Shares in accordance with </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 3</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> at any applicable meeting of the stockholders of the Company or pursuant to any applicable written consent of the stockholders of the Company, the Stockholder shall be deemed to have irrevocably granted to, and appointed, the Company, and any individual designated in writing by it, and each of them individually, as his, her or its proxy and attorney-in-fact (with full power of substitution), for and in its name, place and stead, to vote his, her or its Shares in any action by written consent of Company stockholders or at any meeting of the Company stockholders called with respect to any of the matters specified in, and in accordance and consistent with, </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 3</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of this Agreement. The Company agrees not to exercise the proxy granted herein for any purpose other than the purposes described in this Agreement. Except as otherwise provided for herein (including the next sentence), the Stockholder hereby affirms that the irrevocable proxy is coupled with an interest and may under no circumstances be revoked and that such irrevocable proxy is executed and intended to be irrevocable. Notwithstanding any other provisions of this Agreement, the irrevocable proxy granted hereunder shall automatically terminate on the Expiration Date.</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">No Solicitation</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Stockholder agrees not to directly or indirectly, including through any of its officers, directors or agents, take any action that the Company is prohibited from taking pursuant to Section 5.4 of the Merger Agreement and Section 5.4 of the Merger Agreement is hereby incorporated by reference </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">mutatis mutandis</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">7.<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Documentation and Information</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Stockholder shall permit and hereby authorizes Parent and the Company to publish and disclose in all documents and schedules filed with the SEC, and any press release or other disclosure document that Parent or the Company reasonably determines to be necessary in connection with the Merger and any of the Contemplated Transactions, a copy of this Agreement, the Stockholder&#8217;s identity and ownership of the Shares and the nature of the Stockholder&#8217;s commitments and obligations under this Agreement; provided, that, Parent and the Company provide such documents, schedules, press release or other disclosure document to the Stockholder in advance for its review and comment. Each of Parent and the Company is an intended third-party beneficiary of this </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 7</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">8.<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">No Exercise of Appraisal Rights; Waivers</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Stockholder hereby irrevocably and unconditionally (a)&#160;waives, and agrees to cause to be waived and to prevent the exercise of, any rights of appraisal, any dissenters&#8217; rights and any similar rights (including any notice requirements related thereto) relating to the Merger that Stockholder may have by virtue of, or with respect to, any Shares (including all rights under Section 262 of the DGCL) and (b) agrees that the Stockholder will not bring, commence, institute, maintain, prosecute or voluntarily aid or participate in any action, claim, suit or cause of action, in law or in equity, in any court or before any Governmental Authority, which (i) challenges the validity of or seeks to enjoin the operation of any provision of this Agreement or (ii) alleges that the execution and delivery of this Agreement by the Stockholder breaches any duty that such Stockholder has (or may be alleged to have) to the Company or to the other Company stockholders; provided, that (x) the Stockholder may defend against, contest or settle any such action, claim, suit or cause of action brought against the Stockholder that relates solely to the Stockholder&#8217;s capacity as a director, officer or securityholder of the Company and (y) the foregoing shall not limit or restrict in any manner the Stockholder from enforcing the Stockholder&#8217;s rights under this Agreement and the other agreements entered into by the Stockholder in connection herewith, or otherwise in connection with the Merger, including the Stockholder&#8217;s right to receive the Merger Consideration pursuant to the terms of the Merger Agreement.</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">9.<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Representations and Warranties of the Stockholder</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Stockholder hereby represents and warrants to Parent and the Company as follows:</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>(i) The Stockholder is the beneficial owner of the shares of Company Capital Stock indicated in </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Appendix A</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> (each of which shall be deemed to be &#8220;held&#8221; by the Stockholder for purposes of </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 3</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> unless otherwise expressly stated with respect to any shares in </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Appendix A</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">), free and clear of any and all Encumbrances (except for any Encumbrance that may be imposed pursuant to this Agreement, the Voting Agreement, the Investors&#8217; </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex C-3</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-7" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Rights Agreement of the Company, dated as of March 6, 2024 (the &#8220;</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Investors&#8217; Rights Agreement</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), the Right of First Refusal and Co-Sale Agreement of the Company, dated as of March 6, 2024 (the &#8220;</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">ROFR</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), any lock-up agreement entered into by and between the Stockholder, the Company and Parent, and Encumbrances arising under applicable securities or community property laws; and (ii) the Stockholder does not beneficially own any securities of the Company other than the shares of Company Capital Stock and rights to purchase shares of Company Capital Stock set forth in </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Appendix A</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Except as otherwise provided in this Agreement, the Stockholder has full power and authority to (i) make, enter into and carry out the terms of this Agreement and (ii) vote all of its Shares in the manner set forth in this Agreement without the consent or approval of, or any other action on the part of, any other person or entity (including any Governmental Authority). Without limiting the generality of the foregoing, except for the Voting Agreement, the Stockholder has not entered into any voting agreement (other than this Agreement) with any person with respect to any of the Stockholder&#8217;s Shares, granted any person any proxy (revocable or irrevocable) or power of attorney with respect to any of the Stockholder&#8217;s Shares, deposited any of the Stockholder&#8217;s Shares in a voting trust or entered into any arrangement or agreement with any person limiting or affecting the Stockholder&#8217;s legal power, authority or right to vote the Stockholder&#8217;s Shares on any matter.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>This Agreement has been duly and validly executed and delivered by the Stockholder and (assuming the due authorization, execution and delivery by the other parties hereto) constitutes a valid and binding agreement of the Stockholder enforceable against the Stockholder in accordance with its terms, subject to the Enforceability Exceptions. The execution and delivery of this Agreement by the Stockholder and the performance by the Stockholder of the agreements and obligations hereunder will not result in any breach or violation of or be in conflict with or constitute a default under any term of any Contract or if applicable any provision of an organizational document (including a certificate of incorporation) to or by which the Stockholder is a party or bound, or any applicable law to which the Stockholder (or any of the Stockholder&#8217;s assets) is subject or bound, except for any such breach, violation, conflict or default which, individually or in the aggregate, would not reasonably be expected to materially impair or adversely affect the Stockholder&#8217;s ability to perform its obligations under this Agreement.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The execution, delivery and performance of this Agreement by the Stockholder do not and will not require any consent, approval, authorization or permit of, action by, filing with or notification to, any Governmental Authority, except for any such consent, approval, authorization, permit, action, filing or notification the failure of which to make or obtain, individually or in the aggregate, has not and would not materially impair the Stockholder&#8217;s ability to perform its obligations under this Agreement.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(e)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Stockholder has had the opportunity to review the Merger Agreement and this Agreement with counsel of the Stockholder&#8217;s own choosing. The Stockholder has had an opportunity to review with its own tax advisors the tax consequences of the Merger and the Contemplated Transactions. The Stockholder understands that it must rely solely on its advisors and not on any statements or representations made by Parent, the Company or any of their respective agents or representatives with respect to the tax consequences of the Merger and the Contemplated Transactions. The Stockholder understands that such Stockholder (and not Parent, the Company or the Surviving Corporation) shall be responsible for such Stockholder&#8217;s tax liability that may arise as a result of the Merger or the Contemplated Transactions. The Stockholder understands and acknowledges that the Company, Parent and Merger Sub are entering into the Merger Agreement in reliance upon the Stockholder&#8217;s execution, delivery and performance of this Agreement.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(f)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>With respect to the Stockholder, as of the date hereof, there is no action, suit, investigation or proceeding pending against, or, to the knowledge of the Stockholder, threatened against, the Stockholder or any of the Stockholder&#8217;s properties or assets (including the Shares) that would reasonably be expected to prevent or materially delay or impair the ability of the Stockholder to perform its obligations hereunder or to consummate the transactions contemplated hereby.</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">10.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Certain Agreements</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Each Stockholder, by this Agreement, and with respect to such Stockholder&#8217;s Shares, severally and not jointly, hereby agrees to terminate, subject to the occurrence of, and effective immediately prior to, the Effective Time each of (a) the Voting Agreement, the Investors&#8217; Rights Agreement and the ROFR and (b)&#160;any rights under any letter agreement providing for redemption rights, put rights, purchase rights, information rights, rights to consult with and advise management, inspection rights, preemptive rights, board of directors </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex C-4</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">observer rights or rights to receive information delivered to the board of directors or other similar rights not generally available to stockholders of the Company between the Stockholder and the Company, but excluding, for the avoidance of doubt, any rights the Stockholder may have that relate to any indemnification, commercial, development or employment agreements or arrangements between such Stockholder and the Company or any subsidiary of the Company, which shall survive in accordance with their terms. Each Stockholder hereby terminates and waives all rights of first refusal, redemption rights and rights of notice of the Merger and the other transactions contemplated by the Merger Agreement, effective as of immediately prior to, and contingent upon, the Effective Time.</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">11.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Termination</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. This Agreement shall terminate and shall cease to be of any further force or effect as of the earliest of (a) such date and time as the Merger Agreement shall have been terminated pursuant to the terms thereof as in effect on the date of this Agreement (and without giving effect to any amendments thereto unless consented to by the Stockholder), (b) the Effective Time and (c) the time this Agreement is terminated upon the written agreement of the Stockholder, the Company and Parent (the &#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Expiration Date</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;); </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">, </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">however</span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">,</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> that (i) </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 12</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> shall survive the termination of this Agreement, and (ii) the termination of this Agreement shall not relieve any party hereto from any liability for any material and willful breach of this Agreement prior to the Effective Time.</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">12.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Miscellaneous Provisions</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Amendments</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. No amendment of this Agreement shall be effective against any party unless it shall be in writing and signed by each of the parties hereto.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Entire Agreement; Counterparts; Exchanges by Electronic Transmission or Facsimile</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. This Agreement constitutes the entire agreement between the parties to this Agreement and supersedes all other prior agreements, arrangements and understandings, both written and oral, among the parties with respect to the subject matter hereof. This Agreement may be executed in several counterparts, each of which shall be deemed an original and all of which shall constitute one and the same instrument. The exchange of a fully executed Agreement (in counterparts or otherwise) by all parties by facsimile or electronic transmission in PDF format shall be sufficient to bind the parties to the terms and conditions of this Agreement.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Applicable Law; Jurisdiction.</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> This Agreement shall be governed by, and construed in accordance with, the laws of the State of Delaware, regardless of the laws that might otherwise govern under applicable principles of conflicts of laws. In any action or proceeding between any of the parties arising out of or relating to this Agreement, each of the parties: (i) irrevocably and unconditionally consents and submits to the exclusive jurisdiction and venue of the Court of Chancery of the State of Delaware or, to the extent such court does not have subject matter jurisdiction, the Superior Court of the State of Delaware or the United States District Court for the District of Delaware, (ii) agrees that all claims in respect of such action or proceeding shall be heard and determined exclusively in accordance with clause (i) of this </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 12(c)</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, (iii) waives any objection to laying venue in any such action or proceeding in such courts, (iv) waives any objection that such courts are an inconvenient forum or do not have jurisdiction over any party, (v) agrees that service of process upon such party in any such action or proceeding shall be effective if notice is given in accordance with </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 12(h)</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of this Agreement and (vi)&#160;irrevocably and unconditionally waives the right to trial by jury.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Assignment</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. This Agreement shall be binding upon, and shall be enforceable by and inure solely to the benefit of, the parties and their respective successors and permitted assigns; </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">however</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that neither this Agreement nor any of a party&#8217;s rights or obligations hereunder may be assigned or delegated (except by Merger) by such party without the prior written consent of the other party, and any attempted assignment or delegation of this Agreement or any of such rights or obligations by such party without the other party&#8217;s prior written consent shall be void and of no effect.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(e)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">No Third Party Rights</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Nothing in this Agreement, express or implied, is intended to or shall confer upon any Person any right, benefit or remedy of any nature whatsoever under or by reason of this Agreement.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(f)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Severability</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Any term or provision of this Agreement that is invalid or unenforceable in any situation in any jurisdiction shall not affect the validity or enforceability of the remaining terms and provisions of this Agreement or the validity or enforceability of the offending term or provision in any other situation or in any other jurisdiction. If a final judgment of a court of competent jurisdiction declares that any term or provision of this </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex C-5</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-7" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Agreement is invalid or unenforceable, the Parties agree that the court making such determination shall have the power to limit such term or provision, to delete specific words or phrases or to replace such term or provision with a term or provision that is valid and enforceable and that comes closest to expressing the intention of the invalid or unenforceable term or provision, and this Agreement shall be valid and enforceable as so modified. In the event such court does not exercise the power granted to it in the prior sentence, the Parties agree to replace such invalid or unenforceable term or provision with a valid and enforceable term or provision that will achieve, to the extent possible, the economic, business and other purposes of such invalid or unenforceable term or provision.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(g)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Specific Performance</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:6pt;font-style:normal;font-weight:normal;vertical-align:super;"> </span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Except as otherwise provided herein, any and all remedies herein expressly conferred upon a party will be deemed cumulative with and not exclusive of any other remedy conferred hereby, or by law or equity upon such party, and the exercise by a party of any one remedy will not preclude the exercise of any other remedy. The parties agree that irreparable damage for which monetary damages, even if available, would not be an adequate remedy, would occur in the event that any of the provisions of this Agreement were not performed in accordance with their specific terms (including failing to take such actions as are required of it hereunder to consummate this Agreement) or were otherwise breached. It is accordingly agreed that the parties shall be entitled to an injunction or injunctions to prevent breaches of this Agreement and to enforce specifically the terms and provisions hereof the Court of Chancery of the State of Delaware or, to the extent such court does not have subject matter jurisdiction, the Superior Court of the State of Delaware or the United States District Court for the District of Delaware, this being in addition to any other remedy to which they are entitled at law or in equity, and each of the parties waives any bond, surety or other security that might be required of any other party with respect thereto. Each of the parties further agrees that it will not oppose the granting of an injunction, specific performance or other equitable relief on the basis that any other party has an adequate remedy at law or that any award of specific performance is not an appropriate remedy for any reason at law or in equity.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(h)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Notices</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. All notices and other communications hereunder shall be in writing and shall be deemed duly delivered (i) one (1) Business Day after being sent for next Business Day delivery, fees prepaid, via a reputable international overnight courier service, (ii) upon delivery in the case of delivery by hand or (iii) on the date delivered in the place of delivery if sent by email or facsimile (with a written or electronic confirmation of delivery) prior to 6:00 p.m. (New York City time), otherwise on the next succeeding Business Day, (A) if to the Company or Parent, to the address, electronic mail address or facsimile provided in Section 11.7 of the Merger Agreement, including to the persons designated therein to receive copies; and/or (B) if to the Stockholder, to the Stockholder&#8217;s address, electronic mail address or facsimile shown below Stockholder&#8217;s signature to this Agreement.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(i)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Confidentiality</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.  Except to the extent required by applicable Law or regulation, the Stockholder shall hold any non-public information regarding the Company, this Agreement, the Merger Agreement and the Merger in strict confidence and shall not divulge any such information to any third person until the Company and Parent have publicly disclosed their entry into the Merger Agreement and this Agreement; provided, however, that the Stockholder may disclose such information to its Affiliates, attorneys, accountants, consultants, and other advisors (provided that such Persons are subject to confidentiality obligations at least as restrictive as those contained herein).  Neither the Stockholder nor any of its Affiliates (other than the Company, whose actions shall be governed by the Merger Agreement), shall issue or cause the publication of any press release or other public announcement with respect to the Company, this Agreement, the Merger, the Merger Agreement or the other transactions contemplated hereby or thereby without the prior written consent of the Company and Parent, except as may be required by applicable Law in which circumstance such announcing party shall make reasonable efforts to consult with the Company and Parent to the extent practicable.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(j)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Interpretation</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The words &#8220;hereof,&#8221; &#8220;herein&#8221; and &#8220;hereunder&#8221; and words of like import used in this Agreement shall refer to this Agreement as a whole and not to any particular provision of this Agreement. The captions herein are included for convenience of reference only and shall be ignored in the construction or interpretation hereof. References to Sections and Appendixes are to Sections and Appendixes of this Agreement unless otherwise specified. Any capitalized terms used in any Appendix but not otherwise defined therein shall have the meaning as defined in this Agreement. Any singular term in this Agreement shall be deemed to include the plural, and any plural term the singular, the masculine gender shall include the feminine and neuter genders; the feminine gender shall include the masculine and neuter genders; and the neuter gender shall include masculine and feminine gender. Whenever the words &#8220;include,&#8221; &#8220;includes&#8221; or &#8220;including&#8221; are used in this Agreement, they shall be deemed to be followed by the words &#8220;without limitation,&#8221; whether or not they are in fact followed by those words or words of like import. The word &#8220;or&#8221; is not exclusive. &#8220;Writing,&#8221; &#8220;written&#8221; and comparable terms refer to </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex C-6</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-7" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">printing, typing and other means of reproducing words (including electronic media) in a visible form. References to any agreement or Contract are to that agreement or Contract as amended, modified or supplemented from time to time in accordance with the terms hereof and thereof. References to any Person include the successors and permitted assigns of that Person. References to any statute are to that statute and to the rules and regulations promulgated thereunder, in each case as amended, modified, re-enacted thereof, substituted, from time to time. References to &#8220;$&#8221;&#160;and&#160;&#8220;dollars&#8221; are to the currency of the United States. All accounting terms used herein will be interpreted, and all accounting determinations hereunder will be made, in accordance with GAAP unless otherwise expressly specified. References from or through any date shall mean, unless otherwise specified, from and including or through and including, respectively. All references to &#8220;days&#8221; shall be to calendar days unless otherwise indicated as a &#8220;Business Day.&#8221; Except as otherwise specifically indicated, for purposes of measuring the beginning and ending of time periods in this Agreement (including for purposes of &#8220;Business Day&#8221; and for hours in a day or Business Day), the time at which a thing, occurrence or event shall begin or end shall be deemed to occur in the Eastern time zone of the United States. The Parties agree that any rule of construction to the effect that ambiguities are to be resolved against the drafting Party shall not be applied in the construction or interpretation of this Agreement.</span></p>
		<p class="ParaOverride-9" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-align:center;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">[</span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">Remainder of Page Left Intentionally Blank</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">]</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex C-7</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">IN WITNESS WHEREOF, the undersigned have caused this Agreement to be duly executed as of the date first above written.</span></p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 35.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">



						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">COMPANY:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 63.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 35.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;"><span class="CharOverride-8" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">Oruka Therapeutics, Inc.</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 63.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 35.47%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 63.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 35.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">By:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 63.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 35.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Title:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 63.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>

		</table>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-align:center;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">[</span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">Signature Page to Company Stockholder Support Agreement</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">]</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex C-8</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 35.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">



						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="CharOverride-9" style="font-variant:normal;text-transform:uppercase;">Parent</span>:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 63.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 35.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;"><span class="CharOverride-8" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">ARCA BIOPHARMA, Inc.</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 63.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 35.47%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 63.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 35.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">By:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 63.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 35.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Title:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 63.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>

		</table>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-align:center;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">[</span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">Signature Page to Company Stockholder Support Agreement</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">]</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex C-9</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">



						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">[STOCKHOLDER],</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">in his/her capacity as the Stockholder:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Signature:&#160;_______________________________</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Address:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">_______________________</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">_______________________</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">_______________________</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>

		</table>
		<p class="ParaOverride-9" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-align:center;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">[</span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">Signature Page to Company Stockholder Support Agreement</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">]</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex C-10</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="ParaOverride-9" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-align:center;widows:2;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Appendix A</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex C-11</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T103"></a><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:right;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Annex&#160;D</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">FORM OF ARCA STOCKHOLDER SUPPORT AGREEMENT</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">This Support Agreement (this &#8220;</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Agreement</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) is made and entered into as of April 3, 2024, by and among Oruka Therapeutics, Inc., a Delaware corporation (the &#8220;</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Company</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), ARCA biopharma, Inc., a Delaware corporation (&#8220;</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Parent</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), and the undersigned stockholder (the &#8220;</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Stockholder</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) of the Parent. Capitalized terms used herein but not otherwise defined shall have the respective meanings ascribed to such terms in the Merger Agreement (as defined below).</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-align:center;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">RECITALS</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">WHEREAS, concurrently with the execution and delivery hereof, Parent, the Company and Atlas Merger Sub Corp., a Delaware corporation and a wholly owned subsidiary of Parent (the &#8220;</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">First</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Merger Sub</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), and Atlas Merger Sub II, LLC, a Delaware limited liability company (the &#8220;</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Second Merger Sub</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) have entered into an Agreement and Plan of Merger and Reorganization (as such agreement may be amended or supplemented from time to time pursuant to the terms thereof, the &#8220;</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Merger Agreement</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), pursuant to which (i) the First Merger Sub will merge with and into the Company, with the Company surviving the merger as the surviving corporation and a wholly owned subsidiary of Parent and (ii) the Company will merge with and into the Second Merger Sub, with Second Merger Sub being the surviving entity of the Second Merger, upon the terms and subject to the conditions set forth in the Merger Agreement (together, the &#8220;</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Merger</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;).</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">WHEREAS, as of the date hereof, the Stockholder is the beneficial owner (as defined in Rule 13d-3 under the Exchange Act) of such number of shares of Parent Common Stock as indicated in </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Appendix A</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">WHEREAS, as an inducement to the willingness of the Company to enter into the Merger Agreement, the Company has required that Stockholder enter into this Agreement.</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">NOW, THEREFORE, intending to be legally bound, the parties hereby agree as follows:</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">1.<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Certain Definitions</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Capitalized terms used but not otherwise defined herein shall have the meanings ascribed thereto in the Merger Agreement. For all purposes of this Agreement, the following terms shall have the following respective meanings:</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>&#8220;</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Constructive Sale</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means, with respect to any security, a short sale with respect to such security, entering into or acquiring a derivative contract with respect to such security, entering into or acquiring a futures or forward contract to deliver such security or entering into any other hedging or other derivative transaction that has the effect of either directly or indirectly materially changing the economic benefits or risks of ownership of such security.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>&#8220;</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Parent Stockholder Matters</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the approval of the Merger Agreement and the Contemplated Transactions and the Parent Charter Amendment and, if deemed necessary by Parent the approval of the Parent Legacy Transaction.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>&#8220;</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Shares</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means (i) all shares of Parent Common Stock owned, beneficially or of record, by the Stockholder as of the date hereof, and (ii) all additional shares of Parent Common Stock acquired by the Stockholder, beneficially owned or of record, during the period commencing with the execution and delivery of this Agreement and expiring on the Closing Date.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>&#8220;</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Transfer</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; or &#8220;</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Transferred</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means, with respect to any security, the direct or indirect assignment, sale, transfer, tender, exchange, pledge or hypothecation, or the grant, creation or suffrage of a lien, security interest or encumbrance in or upon, or the gift, grant or placement in trust, or the Constructive Sale or other disposition of such security (including transfers by testamentary or intestate succession, by domestic relations order or other court order, or otherwise by operation of law) or any right, title or interest therein (including any right or power to vote to which the holder thereof may be entitled, whether such right or power is granted by proxy or otherwise), or the record or beneficial ownership thereof, the offer to make such a sale, transfer, Constructive Sale or other disposition, and each agreement, arrangement or understanding, whether or not in writing, to effect any of the foregoing.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex D-1</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">2.<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Transfer and Voting Restrictions</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Stockholder covenants to Parent and the Company as follows:</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Except as otherwise permitted by Section 2(c), during the period commencing with the execution and delivery of this Agreement and expiring on the Expiration Date (as defined below), the Stockholder shall not Transfer any of the Stockholder&#8217;s Shares, or publicly announce its intention to Transfer any of its Shares.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Except as otherwise permitted by this Agreement or otherwise permitted or required by order of a court of competent jurisdiction or a Governmental Authority, the Stockholder will not commit any act that would restrict the Stockholder&#8217;s legal power, authority and right to vote all of the Shares held by the Stockholder or otherwise prevent or disable the Stockholder from performing any of his, her or its obligations under this Agreement. Without limiting the generality of the foregoing, except for this Agreement, and as otherwise permitted by this Agreement, the Stockholder shall not enter into any voting agreement with any person or entity with respect to any of the Stockholder&#8217;s Shares, grant any person or entity any proxy (revocable or irrevocable) or power of attorney with respect to any of the Shares, deposit any Shares in a voting trust or otherwise enter into any agreement or arrangement with any person or entity in each case, which has the effect of limiting or affecting the Stockholder&#8217;s legal power, authority or right to vote the Stockholder&#8217;s Shares in favor of the Parent Stockholder Matters and against any competing proposals.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Notwithstanding anything else herein to the contrary, the Stockholder may, at any time, Transfer Shares (i) by will or other testamentary document or by intestacy, (ii) to such Stockholder&#8217;s Affiliates (in each case, directly or indirectly) (iii) to any member of the Stockholder&#8217;s immediate family (or, if the Stockholder is a corporation, partnership or other entity, to an immediate family member of a beneficial owner of the Shares held by the Stockholder), (iv) to any trust or other entity for the direct or indirect benefit of the Stockholder or the immediate family of the Stockholder (or, if the Stockholder is a corporation, partnership or other entity, for the direct or indirect benefit of an immediate family member of a beneficial owner of the Shares held by the Stockholder) or otherwise for estate tax or estate planning purposes, (v) in the case of a Stockholder who is not a natural person, by pro rata distributions from the Stockholder to its members, partners, or shareholders pursuant to the Stockholder&#8217;s organizational documents, (vi) purchased from the Company on or about the Closing Date but prior to the Closing (including any shares of the Company issued upon conversion of any pre-funded Company Warrants), (vii) to the extent required by applicable Law and (viii) pursuant to the exercise of any option to purchase any Parent Common Stock, including in order to pay the exercise price of such option or satisfy taxes applicable thereto; </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that in the cases of clauses (i)-(v), (x) such Transferred Shares shall continue to be bound by this Agreement and (y) the applicable direct transferee (if any) of such Transferred Shares shall have executed and delivered to Parent and the Company a support agreement substantially identical to this Agreement upon consummation of the Transfer if not already a party thereto.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Notwithstanding anything to the contrary herein, nothing in this Agreement shall obligate the Stockholder to exercise any option or any other right to acquire any shares of Parent Common Stock.</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">3.<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Agreement to Vote Shares</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Stockholder covenants to the Company as follows:</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Until the Expiration Date (as defined below), at any meeting of the stockholders of Parent called to vote upon the Parent Stockholder Matters, however called, and at every adjournment or postponement thereof, and on every action or approval by written consent of the stockholders of Parent, the Stockholder shall be present (in person or by proxy) and vote, or exercise its right to consent with respect to, all Shares held by the Stockholder (A) in favor of the Parent Stockholder Matters, and (B) against any Acquisition Proposal.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>If the Stockholder is the beneficial owner, but not the record holder, of Shares, the Stockholder agrees to take all actions necessary to cause the record holder and any nominees to be present (in person or by proxy) and vote all the Stockholder&#8217;s Shares in accordance with this </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 3.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>In the event of a stock split, stock dividend or distribution, or any change in the capital stock of Parent by reason of any split-up, reverse stock split, recapitalization, combination, reclassification, reincorporation, exchange of shares or the like, the term &#8220;Shares&#8221; shall be deemed to refer to and include such shares as well as all such stock dividends and distributions and any securities into which or for which any or all of such shares may be changed or exchanged or which are received in such transaction.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex D-2</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">4.<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Action in Stockholder Capacity Only</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Stockholder is entering into this Agreement solely in the Stockholder&#8217;s capacity as a record holder and beneficial owner, as applicable, of its Shares and not in the Stockholder&#8217;s capacity as a director or officer of Parent. Nothing herein shall limit or affect the Stockholder&#8217;s ability to act as an officer or director of Parent.</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">5.<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Irrevocable Proxy</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Stockholder hereby revokes (or agrees to cause to be revoked) any proxies that the Stockholder has heretofore granted with respect to its Shares. In the event and to the extent that the Stockholder fails to vote the Shares in accordance with </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 3</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> at any applicable meeting of the stockholders of Parent or pursuant to any applicable written consent of the stockholders of Parent, the Stockholder shall be deemed to have irrevocably granted to, and appointed, Parent, and any individual designated in writing by it, and each of them individually, as his, her or its proxy and attorney-in-fact (with full power of substitution), for and in its name, place and stead, to vote his, her or its Shares in any action by written consent of Parent stockholders or at any meeting of Parent stockholders called with respect to any of the matters specified in, and in accordance and consistent with, </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 3</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of this Agreement. Parent agrees not to exercise the proxy granted herein for any purpose other than the purposes described in this Agreement. Except as otherwise provided for herein, the Stockholder hereby affirms that the irrevocable proxy is coupled with an interest and may under no circumstances be revoked and that such irrevocable proxy is executed and intended to be irrevocable. Notwithstanding any other provisions of this Agreement, the irrevocable proxy granted hereunder shall automatically terminate on the Expiration Date.</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">No Solicitation</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Stockholder agrees not to directly or indirectly, including through any of its officers, directors or agents, take any action that Parent is prohibited from taking pursuant to Section 5.4 of the Merger Agreement and Section 5.4 of the Merger Agreement is hereby incorporated by reference </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">mutatis mutandis</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">7.<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Documentation and Information</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Stockholder shall permit and hereby authorizes Parent and the Company to publish and disclose in all documents and schedules filed with the SEC, and any press release or other disclosure document that Parent or the Company reasonably determines to be necessary in connection with the Merger and any of the Contemplated Transactions, a copy of this Agreement, the Stockholder&#8217;s identity and ownership of the Shares and the nature of the Stockholder&#8217;s commitments and obligations under this Agreement. Each of Parent and the Company is an intended third-party beneficiary of this </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 7</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">8.<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Representations and Warranties of the Stockholder</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Stockholder hereby represents and warrants to Parent and the Company as follows:</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>(i) The Stockholder is the beneficial or record owner of the shares of Parent Common Stock indicated in </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Appendix A</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> (each of which shall be deemed to be &#8220;held&#8221; by the Stockholder for purposes of </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 3</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> unless otherwise expressly stated with respect to any shares in </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Appendix A</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">), free and clear of any and all Encumbrances (except for any Encumbrance that may be imposed pursuant to this Agreement), and Encumbrances arising under applicable securities or community property laws; and (ii) the Stockholder does not beneficially own any securities of Parent other than the shares of Parent Common Stock and rights to purchase shares of Parent Common Stock set forth in </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Appendix A</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Except as otherwise provided in this Agreement, the Stockholder has full power and authority to (i) make, enter into and carry out the terms of this Agreement and (ii) vote all of its Shares in the manner set forth in this Agreement without the consent or approval of, or any other action on the part of, any other person or entity (including any Governmental Authority). Without limiting the generality of the foregoing, the Stockholder has not entered into any voting agreement (other than this Agreement) with any person with respect to any of the Stockholder&#8217;s Shares, granted any person any proxy (revocable or irrevocable) or power of attorney with respect to any of the Stockholder&#8217;s Shares, deposited any of the Stockholder&#8217;s Shares in a voting trust or entered into any arrangement or agreement with any person limiting or affecting the Stockholder&#8217;s legal power, authority or right to vote the Stockholder&#8217;s Shares on any matter.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>This Agreement has been duly and validly executed and delivered by the Stockholder and (assuming the due authorization, execution and delivery by the other parties hereto) constitutes a valid and binding agreement of the Stockholder enforceable against the Stockholder in accordance with its terms, subject to the Enforceability Exceptions. The execution and delivery of this Agreement by the Stockholder and the performance by the Stockholder of the agreements and obligations hereunder will not result in any breach or violation of or be in conflict with or constitute a default under any term of any Contract or if applicable any provision of an organizational document (including a certificate of incorporation) to or by which the Stockholder is a party or bound, </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex D-3</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-7" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">or any applicable law to which the Stockholder (or any of the Stockholder&#8217;s assets) is subject or bound, except for any such breach, violation, conflict or default which, individually or in the aggregate, would not reasonably be expected to materially impair or adversely affect the Stockholder&#8217;s ability to perform its obligations under this Agreement.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The execution, delivery and performance of this Agreement by the Stockholder do not and will not require any consent, approval, authorization or permit of, action by, filing with or notification to, any Governmental Authority, except for any such consent, approval, authorization, permit, action, filing or notification the failure of which to make or obtain, individually or in the aggregate, has not and would not materially impair the Stockholder&#8217;s ability to perform its obligations under this Agreement.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(e)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Stockholder has had the opportunity to review the Merger Agreement and this Agreement with counsel of the Stockholder&#8217;s own choosing. The Stockholder has had an opportunity to review with its own tax advisors the tax consequences of the Merger and the Contemplated Transactions. The Stockholder understands that it must rely solely on its advisors and not on any statements or representations made by Parent, the Company or any of their respective agents or representatives with respect to the tax consequences of the Merger and the Contemplated Transactions. The Stockholder understands that such Stockholder (and not Parent, the Company or the Surviving Corporation) shall be responsible for such Stockholder&#8217;s tax liability that may arise as a result of the Merger or the Contemplated Transactions. The Stockholder understands and acknowledges that the Company, Parent and Merger Sub are entering into the Merger Agreement in reliance upon the Stockholder&#8217;s execution, delivery and performance of this Agreement.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(f)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>With respect to the Stockholder, as of the date hereof, there is no action, suit, investigation or proceeding pending against, or, to the knowledge of the Stockholder, threatened against, the Stockholder or any of the Stockholder&#8217;s properties or assets (including the Shares) that would reasonably be expected to prevent or materially delay or impair the ability of the Stockholder to perform its obligations hereunder or to consummate the transactions contemplated hereby.</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">9.<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Termination</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. This Agreement shall terminate and shall cease to be of any further force or effect as of the earliest of (a) such date and time as the Merger Agreement shall have been terminated pursuant to the terms thereof as in effect on the date of this Agreement (and without giving effect to any amendments thereto unless consented to by the Stockholder), (b) the Effective Time and (c) the time this Agreement is terminated upon the written agreement of the Stockholder, the Company and Parent (the &#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Expiration Date</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;); </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">, </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">however</span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">,</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> that (i) </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 10</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> shall survive the termination of this Agreement, and (ii) the termination of this Agreement shall not relieve any party hereto from any liability for any material and willful breach of this Agreement prior to the Effective Time.</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">10.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Miscellaneous Provisions</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Amendments</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. No amendment of this Agreement shall be effective against any party unless it shall be in writing and signed by each of the parties hereto.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Entire Agreement; Counterparts; Exchanges by Electronic Transmission or Facsimile</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. This Agreement constitutes the entire agreement between the parties to this Agreement and supersedes all other prior agreements, arrangements and understandings, both written and oral, among the parties with respect to the subject matter hereof. This Agreement may be executed in several counterparts, each of which shall be deemed an original and all of which shall constitute one and the same instrument. The exchange of a fully executed Agreement (in&#160;counterparts or otherwise) by all parties by facsimile or electronic transmission in PDF format shall be sufficient to bind the parties to the terms and conditions of this Agreement.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Applicable Law; Jurisdiction.</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> This Agreement shall be governed by, and construed in accordance with, the laws of the State of Delaware, regardless of the laws that might otherwise govern under applicable principles of conflicts of laws. In any action or proceeding between any of the parties arising out of or relating to this Agreement, each of the parties: (i) irrevocably and unconditionally consents and submits to the exclusive jurisdiction and venue of the Court of Chancery of the State of Delaware or, to the extent such court does not have subject matter jurisdiction, the Superior Court of the State of Delaware or the United States District Court for the District of Delaware, (ii) agrees that all claims in respect of such action or proceeding shall be heard and determined exclusively in accordance with clause (i) of this </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 10(c)</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, (iii) waives any objection to laying </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex D-4</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-7" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">venue in any such action or proceeding in such courts, (iv) waives any objection that such courts are an inconvenient forum or do not have jurisdiction over any party, (v) agrees that service of process upon such party in any such action or proceeding shall be effective if notice is given in accordance with </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 10(h)</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of this Agreement and (vi)&#160;irrevocably and unconditionally waives the right to trial by jury.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Assignment</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. This Agreement shall be binding upon, and shall be enforceable by and inure solely to the benefit of, the parties and their respective successors and permitted assigns; </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">however</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that neither this Agreement nor any of a party&#8217;s rights or obligations hereunder may be assigned or delegated (except by the Merger) by such party without the prior written consent of the other party, and any attempted assignment or delegation of this Agreement or any of such rights or obligations by such party without the other party&#8217;s prior written consent shall be void and of no effect.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(e)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">No Third Party Rights</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Nothing in this Agreement, express or implied, is intended to or shall confer upon any Person any right, benefit or remedy of any nature whatsoever under or by reason of this Agreement.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(f)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Severability</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Any term or provision of this Agreement that is invalid or unenforceable in any situation in any jurisdiction shall not affect the validity or enforceability of the remaining terms and provisions of this Agreement or the validity or enforceability of the offending term or provision in any other situation or in any other jurisdiction. If a final judgment of a court of competent jurisdiction declares that any term or provision of this Agreement is invalid or unenforceable, the Parties agree that the court making such determination shall have the power to limit such term or provision, to delete specific words or phrases or to replace such term or provision with a term or provision that is valid and enforceable and that comes closest to expressing the intention of the invalid or unenforceable term or provision, and this Agreement shall be valid and enforceable as so modified. In the event such court does not exercise the power granted to it in the prior sentence, the Parties agree to replace such invalid or unenforceable term or provision with a valid and enforceable term or provision that will achieve, to the extent possible, the economic, business and other purposes of such invalid or unenforceable term or provision.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(g)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Specific Performance</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:6pt;font-style:normal;font-weight:normal;vertical-align:super;"> </span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Except as otherwise provided herein, any and all remedies herein expressly conferred upon a party will be deemed cumulative with and not exclusive of any other remedy conferred hereby, or by law or equity upon such party, and the exercise by a party of any one remedy will not preclude the exercise of any other remedy. The parties agree that irreparable damage for which monetary damages, even if available, would not be an adequate remedy, would occur in the event that any of the provisions of this Agreement were not performed in accordance with their specific terms (including failing to take such actions as are required of it hereunder to consummate this Agreement) or were otherwise breached. It is accordingly agreed that the parties shall be entitled to an injunction or injunctions to prevent breaches of this Agreement and to enforce specifically the terms and provisions hereof the Court of Chancery of the State of Delaware or, to the extent such court does not have subject matter jurisdiction, the Superior Court of the State of Delaware or the United States District Court for the District of Delaware, this being in addition to any other remedy to which they are entitled at law or in equity, and each of the parties waives any bond, surety or other security that might be required of any other party with respect thereto. Each of the parties further agrees that it will not oppose the granting of an injunction, specific performance or other equitable relief on the basis that any other party has an adequate remedy at law or that any award of specific performance is not an appropriate remedy for any reason at law or in equity.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(h)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Notices</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. All notices and other communications hereunder shall be in writing and shall be deemed duly delivered (i) one (1) Business Day after being sent for next Business Day delivery, fees prepaid, via a reputable international overnight courier service, (ii) upon delivery in the case of delivery by hand or (iii) on the date delivered in the place of delivery if sent by email or facsimile (with a written or electronic confirmation of delivery) prior to 6:00 p.m. (New York City time), otherwise on the next succeeding Business Day, (A) if to the Company or Parent, to the address, electronic mail address or facsimile provided in Section 11.7 of the Merger Agreement, including to the persons designated therein to receive copies; and/or (B) if to the Stockholder, to the Stockholder&#8217;s address, electronic mail address or facsimile shown below Stockholder&#8217;s signature to this Agreement.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(i)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Confidentiality</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.  Except to the extent required by applicable Law or regulation, the Stockholder shall hold any non-public information regarding the Company, this Agreement, the Merger Agreement and the Merger in strict confidence and shall not divulge any such information to any third person until the Company and Parent have publicly disclosed their entry into the Merger Agreement and this Agreement; provided, however, that the Stockholder may disclose such information to its Affiliates, attorneys, accountants, consultants, and other advisors (provided that such Persons are subject to confidentiality obligations at least as restrictive as those contained </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex D-5</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-7" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">herein).  Neither the Stockholder nor any of its Affiliates (other than Parent, whose actions shall be governed by the Merger Agreement), shall issue or cause the publication of any press release or other public announcement with respect to Parent, this Agreement, the Merger, the Merger Agreement or the other transactions contemplated hereby or thereby without the prior written consent of the Company and Parent, except as may be required by applicable Law in which circumstance such announcing party shall make reasonable efforts to consult with the Company and Parent to the extent practicable.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(j)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Interpretation</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The words &#8220;hereof,&#8221; &#8220;herein&#8221; and &#8220;hereunder&#8221; and words of like import used in this Agreement shall refer to this Agreement as a whole and not to any particular provision of this Agreement. The captions herein are included for convenience of reference only and shall be ignored in the construction or interpretation hereof. References to Sections and Appendixes are to Sections and Appendixes of this Agreement unless otherwise specified. Any capitalized terms used in any Appendix but not otherwise defined therein shall have the meaning as defined in this Agreement. Any singular term in this Agreement shall be deemed to include the plural, and any plural term the singular, the masculine gender shall include the feminine and neuter genders; the feminine gender shall include the masculine and neuter genders; and the neuter gender shall include masculine and feminine gender. Whenever the words &#8220;include,&#8221; &#8220;includes&#8221; or &#8220;including&#8221; are used in this Agreement, they shall be deemed to be followed by the words &#8220;without limitation,&#8221; whether or not they are in fact followed by those words or words of like import. The word &#8220;or&#8221; is not exclusive. &#8220;Writing,&#8221; &#8220;written&#8221; and comparable terms refer to printing, typing and other means of reproducing words (including electronic media) in a visible form. References to any agreement or Contract are to that agreement or Contract as amended, modified or supplemented from time to time in accordance with the terms hereof and thereof. References to any Person include the successors and permitted assigns of that Person. References to any statute are to that statute and to the rules and regulations promulgated thereunder, in each case as amended, modified, re-enacted thereof, substituted, from time to time. References to &#8220;$&#8221;&#160;and&#160;&#8220;dollars&#8221; are to the currency of the United States. All accounting terms used herein will be interpreted, and all accounting determinations hereunder will be made, in accordance with GAAP unless otherwise expressly specified. References from or through any date shall mean, unless otherwise specified, from and including or through and including, respectively. All references to &#8220;days&#8221; shall be to calendar days unless otherwise indicated as a &#8220;Business Day.&#8221; Except as otherwise specifically indicated, for purposes of measuring the beginning and ending of time periods in this Agreement (including for purposes of &#8220;Business Day&#8221; and for hours in a day or Business Day), the time at which a thing, occurrence or event shall begin or end shall be deemed to occur in the Eastern time zone of the United States. The Parties agree that any rule of construction to the effect that ambiguities are to be resolved against the drafting Party shall not be applied in the construction or interpretation of this Agreement.</span></p>
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-align:center;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">[</span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">Remainder of Page Left Intentionally Blank</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">]</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex D-6</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">IN WITNESS WHEREOF, the undersigned have caused this Agreement to be duly executed as of the date first above written.</span></p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 35.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">



						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">COMPANY:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 63.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 35.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;"><span class="CharOverride-8" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">Oruka Therapeutics, Inc.</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 63.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 35.47%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 63.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 35.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">By:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 63.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 35.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Title:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 63.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>

		</table>
		<p class="ParaOverride-11" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-align:center;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">[</span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">Signature Page to Parent Stockholder Support Agreement</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">]</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex D-7</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 35.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">



						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="CharOverride-9" style="font-variant:normal;text-transform:uppercase;">Parent</span>:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 63.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 35.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;"><span class="CharOverride-8" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">arca biopharma, Inc.</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 63.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 35.47%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 63.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 35.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">By:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 63.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 35.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Title:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 63.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>

		</table>
		<p class="ParaOverride-11" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-align:center;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">[</span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">Signature Page to Parent Stockholder Support Agreement</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">]</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex D-8</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 44.23%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">



						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">[STOCKHOLDER],</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 54.49%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 44.23%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">in his/her capacity as the Stockholder:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 54.49%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 44.23%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Signature: _______________________________</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 54.49%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 44.23%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Address:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 54.49%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 44.23%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">_______________________</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 54.49%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 44.23%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">_______________________</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 54.49%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 44.23%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">_______________________</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 54.49%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>

		</table>
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-align:center;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">[</span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">Signature Page to Parent Stockholder Support Agreement</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">]</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex D-9</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-align:center;widows:2;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Appendix A</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex D-10</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T104"></a><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:right;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Annex&#160;E</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">FORM OF LOCK-UP AGREEMENT</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-align:right;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">April 3, 2024</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">ARCA biopharma, Inc.</span><span class="CharOverride-2" style="font-family:Calibri, sans-serif;"><br/></span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">10170 Church Ranch Way, Suite 100</span><span class="CharOverride-2" style="font-family:Calibri, sans-serif;"><br/></span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Westminster, CO</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Ladies and Gentlemen:</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">The undersigned signatory of this lock-up agreement (this &#8220;</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Lock-Up Agreement</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) understands that ARCA biopharma, Inc., a Delaware corporation (&#8220;</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Parent</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), has entered into an Agreement and Plan of Merger and Reorganization, dated as of April 3, 2024 (as the same may be amended from time to time, the &#8220;</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Merger Agreement</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) with Atlas Merger Sub Corp., a Delaware corporation and a wholly owned subsidiary of Parent, Atlas Merger Sub II LLC, a Delaware limited liability company and a wholly owned subsidiary of Parent, and Oruka Therapeutics, Inc., a Delaware corporation (the &#8220;</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Company</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;). Capitalized terms used but not otherwise defined herein shall have the respective meanings ascribed to such terms in the Merger Agreement.</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">As a condition and inducement to each of the parties to enter into the Merger Agreement and to consummate the transactions contemplated thereby, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the undersigned hereby irrevocably agrees that, subject to the exceptions set forth herein, without the prior written consent of Parent, the undersigned will not, during the period commencing upon the Closing and ending on the date that is 180 days after the Closing Date (the &#8220;</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Restricted Period</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;); </span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided,</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> that if a registration statement covering the shares of Company Common Stock and pre-funded Company Warrants issued and sold in connection with the Company Pre-Closing Financing (other than any shares or pre-funded Company Warrants held by affiliates of the Company) has not been declared effective by the SEC prior to the end of such 180-day period, then the Restricted Period shall end on such later date upon which such registration statement is first declared effective:</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(1)<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any shares of Parent Common Stock or any securities convertible into or exercisable or exchangeable for shares of Parent Common Stock (including without limitation, shares of Parent Common Stock or such other securities which may be deemed to be beneficially owned by the undersigned in accordance with the rules and regulations of the SEC and securities of Parent which may be issued upon exercise of an option to purchase shares of Parent Common Stock or a warrant to purchase shares of Parent Common Stock) that are currently or hereafter owned by the undersigned, except as set forth below (collectively, the &#8220;</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Undersigned&#8217;s Shares</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;);</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(2)<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>enter into any swap, short sale, hedge or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of the Undersigned&#8217;s Shares regardless of whether any such transaction described in clause (1) above or this clause (2) is to be settled by delivery of shares of Parent Common Stock or other securities, in cash or otherwise;</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(3)<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>make any demand for, or exercise any right with respect to, the registration of any shares of Parent Common Stock or any security convertible into or exercisable or exchangeable for shares of Parent Common Stock (other than such rights set forth in the Merger Agreement); or</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(4)<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>publicly disclose the intention to do any of the foregoing.</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">The restrictions and obligations contemplated by this Lock<span class="nobreak">-Up</span> Agreement shall not apply to:</p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>transfers of the Undersigned&#8217;s Shares:</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(1)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>(A) to any person related to the undersigned (or to an ultimate beneficial owner of the undersigned) by blood or adoption who is an immediate family member of the undersigned, or by marriage or domestic partnership (each, a &#8220;</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Family Member</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), or to a trust formed for the benefit of the undersigned or any of the undersigned&#8217;s Family Members, (B) to the undersigned&#8217;s estate, following the death of the undersigned, by </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex E-1</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">will, intestacy or other operation of Law, (C) as a bona fide gift or a charitable contribution, (D) by operation of Law pursuant to a qualified domestic order or in connection with a divorce settlement or (E) to any partnership, corporation or limited liability company which is controlled by or under common control with  the undersigned and/or by any such Family Member(s);</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(2)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>if the undersigned is a corporation, partnership, limited liability company or other entity, (A)&#160;to another corporation, partnership, limited liability company or other entity that is a direct or indirect affiliate (as defined under Rule 12b-2 of the Exchange Act) of the undersigned, including investment funds or other entities that controls or manages, is under common control or management with, or is controlled or managed by, the undersigned, (B) as a distribution or dividend to equity holders, current or former general or limited partners, members or managers (or to the estates of any of the foregoing), as applicable, of the undersigned (including upon the liquidation and dissolution of the undersigned pursuant to a plan of liquidation approved by the undersigned&#8217;s equity holders), (C) as a bona fide gift or a charitable contribution or otherwise to a trust or other entity for the direct or indirect benefit of an immediate family member of a beneficial owner (as defined in Rule 13d-3 of the Exchange Act) of the Undersigned&#8217;s Shares or (D) transfers or dispositions not involving a change in beneficial ownership; or</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(3)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>if the undersigned is a trust, to any grantors or beneficiaries of the trust;</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;"><span class="CharOverride-4" style="text-decoration:underline;">provided</span> that, in the case of any transfer or distribution pursuant to this clause (a), such transfer is not for value (other than transfers pursuant to 1(A), 1(E) or 2(A)) and each donee, heir, beneficiary or other transferee or distributee shall sign and deliver to Parent a lock<span class="nobreak">-up</span> agreement in the form of this Lock<span class="nobreak">-Up</span> Agreement with respect to the shares of Parent Common Stock or such other securities that have been so transferred or distributed;</p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>the exercise of an option to purchase shares of Parent Common Stock (including a net or cashless exercise of an option to purchase shares of Parent Common Stock ), and any related transfer of shares of Parent Common Stock to Parent for the purpose of paying the exercise price of such options or for paying taxes (including estimated taxes) due as a result of the exercise of such options or for paying taxes (including estimated taxes) due as a result of the exercise of such options; </span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> that, for the avoidance of doubt, the underlying shares of Parent Common Stock shall continue to be subject to the restrictions on transfer set forth in this Lock-Up Agreement;</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>transfers to Parent in connection with the net settlement of any other equity award that represents the right to receive in the future shares of Parent Common Stock, settled in shares of Parent Common Stock, to pay any tax withholding obligations; </span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> that, for the avoidance of doubt, the underlying shares of Parent Common Stock shall continue to be subject to the restrictions on transfer set forth in this Lock-Up Agreement;</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>the establishment of a trading plan pursuant to Rule 10b5-1 under the Exchange Act for the transfer of shares of Parent Common Stock; </span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> that such plan does not provide for any transfers of shares of Parent Common Stock during the Restricted Period;</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(e)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>transfers by the undersigned of shares of Parent Common Stock purchased by the undersigned on the open market or in a public offering by Parent, in each case following the Effective Time;</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(f)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>pursuant to a bona-fide third party tender offer, merger, consolidation or other similar transaction made to all holders of Parent&#8217;s capital stock involving a change of control of Parent, </span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> that in the event that such tender offer, merger, consolidation or other such transaction is not completed, the Undersigned&#8217;s Shares shall remain subject to the restrictions contained in this Lock-Up Agreement;</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(g)<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>pursuant to an order of a court or regulatory agency; or</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(h)<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>transfers by the undersigned of shares of Parent Common Stock issued pursuant to the Merger Agreement in respect of shares of the Company (including any shares of the Company issued upon exercise of any pre-funded Company Warrants), if any, purchased from the Company on or about the Closing Date but prior to the Closing.</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">and </span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, further, that, with respect to each of (b), (c), and (d) above, no filing by any party (including any donor, donee, transferor, transferee, distributor or distributee) under Section 16 of the Exchange Act or other public announcement shall be made voluntarily reporting a reduction in beneficial ownership of shares of Parent Common Stock or any securities convertible into or exercisable or exchangeable for Parent Common Stock in connection with such transfer or disposition during the Restricted Period (other than any exit filings) and if any filings under </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex E-2</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Section 16(a) of the Exchange Act, or other public filing, report or announcement reporting a reduction in beneficial ownership of shares of Parent Common Stock in connection with such transfer or distribution, shall be legally required during the Restricted Period, such filing, report or announcement shall clearly indicate in the footnotes therein, in reasonable detail, a description of the circumstances of the transfer and that the shares remain subject to the lock-up agreement.</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">For purposes of this Lock-Up Agreement, &#8220;change of control&#8221; shall mean the transfer (whether by tender offer, merger, consolidation or other similar transaction), in one transaction or a series of related transactions, to a person or group of affiliated persons, of the Company&#8217;s voting securities if, after such transfer, the Company&#8217;s stockholders as of immediately prior to such transfer do not hold a majority of the outstanding voting securities of the Company (or the surviving entity).</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Any attempted transfer in violation of this Lock-Up Agreement will be of no effect and null and void, regardless of whether the purported transferee has any actual or constructive knowledge of the transfer restrictions set forth in this Lock-Up Agreement, and will not be recorded on the share register of Parent. In furtherance of the foregoing, the undersigned agrees that Parent and any duly appointed transfer agent for the registration or transfer of the securities described herein are hereby authorized to decline to make any transfer of securities if such transfer would constitute a violation or breach of this Lock-Up Agreement. Parent may cause the legend set forth below, or a legend substantially equivalent thereto, to be placed upon any certificate(s) or other documents, ledgers or instruments evidencing the undersigned&#8217;s ownership of Parent Common Stock:</span></p>
		<p class="ParaOverride-7" style="margin:0;padding:0;border-width:0;margin-left:72pt;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">THE SHARES REPRESENTED BY THIS CERTIFICATE ARE <br/>SUBJECT TO AND MAY ONLY BE TRANSFERRED IN <br/>COMPLIANCE WITH A LOCK-UP AGREEMENT, A COPY <br/>OF WHICH IS ON FILE AT THE PRINCIPAL OFFICE OF <br/>THE COMPANY.</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">The undersigned hereby represents and warrants that the undersigned has full power and authority to enter into this Lock-Up Agreement. All authority herein conferred or agreed to be conferred and any obligations of the undersigned shall be binding upon the successors, assigns, heirs or personal representatives of the undersigned.</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">The undersigned understands that if the Merger Agreement is terminated for any reason, the undersigned shall be released from all obligations under this Lock-Up Agreement. The undersigned understands that Parent is proceeding with the transactions contemplated by the Merger Agreement in reliance upon this Lock-Up Agreement.</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Except as otherwise provided herein, any and all remedies herein expressly conferred upon a party will be deemed cumulative with and not exclusive of any other remedy conferred hereby, or by law or equity upon such party, and the exercise by a party of any one remedy will not preclude the exercise of any other remedy.  The parties agree that irreparable damage for which monetary damages, even if available, would not be an adequate remedy, would occur in the event that any of the provisions of this Lock-Up Agreement were not performed in accordance with their specific terms (including failing to take such actions as are required of it hereunder to consummate this Agreement) or were otherwise breached.  It is accordingly agreed that the parties shall be entitled to an injunction or injunctions to prevent breaches of this Lock-Up Agreement and to enforce specifically the terms and provisions hereof in any court of the United States or any state having jurisdiction, this being in addition to any other remedy to which they are entitled at law or in equity, and each of the parties waives any bond, surety or other security that might be required of any other party with respect thereto.  Each of the parties further agrees that it will not oppose the granting of an injunction, specific performance or other equitable relief on the basis that any other party has an adequate remedy at law or that any award of specific performance is not an appropriate remedy for any reason at law or in equity.</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">In the event that any holder of Parent&#8217;s securities that are subject to a substantially similar agreement entered into by such holder, other than the undersigned, is permitted by Parent to sell or otherwise transfer or dispose of shares of Parent Common Stock for value other than as permitted by this or a substantially similar agreement entered into by such holder (whether in one or multiple releases or waivers), the same percentage of shares of Parent Common Stock held by the undersigned on the date of such release or waiver as the percentage of the total number of outstanding shares of Parent Common Stock held by such holder on the date of such release or waiver that are the subject of such release or waiver shall be immediately and fully released on the same terms from any remaining restrictions set forth herein (the &#8220;</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Pro-Rata Release</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;); </span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">however</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that such Pro-Rata Release shall not be applied unless </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex E-3</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">and until permission has been granted by Parent to an equity holder or equity holders to sell or otherwise transfer or dispose of all or a portion of such equity holders shares of Parent Common Stock in an aggregate amount in excess of 1% of the number of shares of Parent Common Stock subject to a substantially similar agreement.  In the event of any Pro-Rata Release, the Company shall promptly (and in any event within two (2) business days of such release) inform each relevant holder of Parent Common Stock or warrants of the terms of such Pro-Rata Release.</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Upon the release of any of the Undersigned&#8217;s Shares from this Lock-Up Agreement, Parent will reasonably cooperate with the undersigned to facilitate the timely preparation and delivery of certificates representing the Undersigned Shares without the restrictive legend above or the withdrawal of any stop transfer instructions by virtue of this Lock-Up Agreement.</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">This Lock-Up Agreement shall be governed by, and construed in accordance with, the laws of the State of Delaware, regardless of the laws that might otherwise govern under applicable principles of conflicts of laws.  In any action or proceeding between any of the parties arising out of or relating to this Lock-Up Agreement, each of the parties: (i) irrevocably and unconditionally consents and submits to the exclusive jurisdiction and venue of the Court of Chancery of the State of Delaware or, to the extent such court does not have subject matter jurisdiction, the Superior Court of the State of Delaware or the United States District Court for the District of Delaware, (ii) agrees that all claims in respect of such action or proceeding shall be heard and determined exclusively in accordance with foregoing clause (i) of this paragraph, (iii) waives any objection to laying venue in any such action or proceeding in such courts, (iv) waives any objection that such courts are an inconvenient forum or do not have jurisdiction over any party and (v) irrevocably and unconditionally waives the right to trial by jury. This Lock-Up Agreement constitutes the entire agreement between the parties to this Lock-Up Agreement and supersedes all other prior agreements, arrangements and understandings, both written and oral, among the parties with respect to the subject matter hereof. This Lock-Up Agreement may be executed in several counterparts, each of which shall be deemed an original and all of which shall constitute one and the same instrument.  The exchange of a fully executed Lock-Up Agreement (in&#160;counterparts or otherwise) by all parties by facsimile or electronic transmission in PDF format shall be sufficient to bind the parties to the terms and conditions of this Agreement.</span></p>
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-left:1pt;margin-top:8pt;orphans:2;text-align:center;widows:2;margin-top:8pt;"><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">[SIGNATURE PAGE FOLLOWS]</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex E-4</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 32.09%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">



					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 27.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 37.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Very truly yours,</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 32.09%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 27.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:right;">Print Name of Stockholder:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 37.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 32.09%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 27.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 37.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 32.09%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 27.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 37.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Signature (for individuals):</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 32.09%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 27.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 37.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 32.09%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 27.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 37.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Signature (for entities):</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 32.09%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 27.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 3.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">By:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 33.48%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 32.09%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 27.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 3.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 33.48%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Name:</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 32.09%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 27.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 3.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 33.48%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Title:</p>
					</td>
				</tr>

		</table>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-align:center;widows:2;margin-top:8pt;"><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">[Signature Page to Lock-Up Agreement]</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex E-5</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-11" style="height:12pt;">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 38.51%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">



						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Accepted and Agreed<br/>by ARCA biopharma, Inc.:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 60.20%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 2.78%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">By:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 34.46%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 60.20%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 38.51%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Name:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 60.20%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 38.51%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Title:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 60.20%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>

		</table>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-align:center;widows:2;margin-top:8pt;"><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">[Signature Page to Lock-Up Agreement]</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex E-6</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T105"></a><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:right;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Annex&#160;F</span></p>
		<p class="ParaOverride-2" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-align:center;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">Arca biopharma, Inc.</span></p>
		<p class="ParaOverride-2" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-align:center;widows:2;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">CERTIFICATE OF DESIGNATION OF PREFERENCES,</span><span class="CharOverride-3" style="font-family:Times New Roman, serif;font-size:11pt;font-style:normal;font-weight:bold;"><br/></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">RIGHTS AND LIMITATIONS</span><span class="CharOverride-3" style="font-family:Times New Roman, serif;font-size:11pt;font-style:normal;font-weight:bold;"><br/></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">OF</span><span class="CharOverride-3" style="font-family:Times New Roman, serif;font-size:11pt;font-style:normal;font-weight:bold;"><br/></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">SERIES B NON-VOTING CONVERTIBLE PREFERRED STOCK</span></p>
		<p class="ParaOverride-2" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-align:center;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Pursuant to Section 151 of the</span><span class="CharOverride-5" style="font-family:Times New Roman, serif;font-size:11pt;font-style:normal;font-weight:normal;"><br/></span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">General Corporation Law of the State of Delaware</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">THE UNDERSIGNED DOES HEREBY CERTIFY, on behalf of ARCA biopharma, Inc., a Delaware corporation (the &#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Corporation</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), that the following resolution was duly adopted by the Board of Directors of the Corporation (the &#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Board of Directors</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), in accordance with the provisions of Section 151 of the General Corporation Law of the State of Delaware (the &#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">DGCL</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), at a meeting duly called and held on [&#8226;], 2024, which resolution provides for the creation of a series of the Corporation&#8217;s Preferred Stock, par value $0.001 per share, which is designated as &#8220;Series B Non-Voting Convertible Preferred Stock,&#8221; with the preferences, rights and limitations set forth therein relating to dividends, conversion, redemption, dissolution and distribution of assets of the Corporation.</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:36pt;widows:2;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">WHEREAS</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">:<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>the Amended and Restated Certificate of Incorporation of the Corporation (as amended from time to time, the &#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Certificate of Incorporation</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), provides for a class of its authorized stock known as Preferred Stock, consisting of 5,000,000 shares, $0.001 par value per share (the &#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Preferred Stock</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), issuable from time to time in one or more series.</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:36pt;widows:2;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">RESOLVED</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">:<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>that, pursuant to authority conferred upon the Board of Directors by the Certificate of Incorporation, (i) a series of Preferred Stock of the Corporation be, and hereby is, authorized by the Board of Directors, (ii)&#160;the Board of Directors hereby authorizes the issuance of [&#8226;] shares of &#8220;Series B Non-Voting Convertible Preferred Stock&#8221; pursuant to the terms of the Agreement and Plan of Merger and Reorganization, dated April 3, 2024, by and among the Corporation, Atlas Merger Sub Corp., a Delaware corporation and wholly owned subsidiary of the Corporation, Atlas Merger Sub II, LLC, a Delaware limited liability company and wholly owned subsidiary of Parent, and Oruka Therapeutics, Inc. (the &#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Merger Agreement</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), and (iii) the Board of Directors hereby fixes the designations, powers, preferences and relative, participating, optional or other special rights, and the qualifications, limitations or restrictions thereof, of such shares of such series of Preferred Stock, in addition to any provisions set forth in the Certificate of Incorporation that are applicable to the Preferred Stock of all classes and series, as follows:</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-align:center;text-indent:20pt;widows:2;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">TERMS OF SERIES B NON-VOTING CONVERTIBLE PREFERRED STOCK</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:72pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">1.&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Definitions</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. For the purposes hereof, the following terms shall have the following meanings:</span></p>
		<p class="ParaOverride-7" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:55pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Business Day</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the United States or any day on which banking institutions in the State of New York are authorized or required by law or other governmental action to&#160;close.</span></p>
		<p class="ParaOverride-7" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:55pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Buy-In</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; shall have the meaning set forth in </span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 6.4.3</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-7" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:55pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Closing Sale Price</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means, for any security as of any date, the last closing trade price for such security immediately prior to 4:00 p.m., New York City time, on the principal Trading Market where such security is listed or traded, as reported by Bloomberg, L.P. (or an equivalent, reliable reporting service), or if the foregoing do not apply, the last trade price of such security in the over-the-counter market on the electronic bulletin board for such security as reported by Bloomberg, L.P., or, if no last trade price is reported for such security by Bloomberg, L.P., the average of the bid prices of any market makers for such security as reported on the OTC Pink Market by OTC Markets Group, Inc. If the Closing Sale Price cannot be calculated for a security on a particular date on any of the foregoing bases, the Closing Sale Price of such security on such date shall be the fair market value as determined in good faith by the Board of Directors.</span></p>
		<p class="ParaOverride-7" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:55pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Commission</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the United States Securities and Exchange Commission.</span></p>
		<p class="ParaOverride-7" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:55pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Common Stock</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the Corporation&#8217;s common stock, par value $0.001 per share, and stock of any other class of securities into which such securities may hereafter be reclassified or changed.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex F-1</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="ParaOverride-7" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:55pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Conversion Shares</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means, collectively, the shares of Common Stock issuable upon conversion of the shares of Series B Non-Voting Preferred Stock in accordance with the terms hereof.</span></p>
		<p class="ParaOverride-7" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:55pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Exchange Act</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</span></p>
		<p class="ParaOverride-7" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:55pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Holder</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means a holder of shares of Series B Non-Voting Preferred Stock.</span></p>
		<p class="ParaOverride-7" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:55pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Person</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</span></p>
		<p class="ParaOverride-7" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:55pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Trading Day</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means a day on which the principal Trading Market is open for business.</span></p>
		<p class="ParaOverride-7" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:55pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Trading Market</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, or the New York Stock Exchange (or any successors to any of the foregoing).</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:72pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">2.&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Designation, Amount and Par Value</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The series of Preferred Stock shall be designated as the Corporation&#8217;s Series B Non-Voting Convertible Preferred Stock (the &#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Series B Non-Voting Preferred Stock</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) and the number of shares so designated shall be [&#8226;]. Each share of Series B Non-Voting Preferred Stock shall have a par value of $0.001 per share.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:72pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">3.&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Dividends</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Holders shall be entitled to receive, and the Corporation shall pay, dividends on shares of the Series B Non-Voting Preferred Stock (on an as-if-converted-to-Common-Stock basis, without regard to the Beneficial Ownership Limitation (as defined below)) equal to and in the same form, and in the same manner, as dividends (other than dividends on shares of the Common Stock payable in the form of Common Stock) actually paid on shares of the Common Stock when, as and if such dividends (other than dividends payable in the form of Common Stock) are paid on shares of the Common Stock. Other than as set forth in the previous sentence, no other dividends shall be paid on shares of Series B Non-Voting Preferred Stock, and the Corporation shall pay no dividends (other than dividends payable in the form of Common Stock) on shares of the Common Stock unless it simultaneously complies with the previous sentence.</span></p>
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:72pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">4.&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Voting Rights</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-9" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:108pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">4.1<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Except as otherwise provided herein or as otherwise required by the DGCL, the Series B Non-Voting Preferred Stock shall have no voting rights. However, as long as any shares of Series B Non-Voting Preferred Stock are outstanding, the Corporation shall not, without the affirmative vote or written waiver of the holders of a majority of the then outstanding shares of the Series B Non-Voting Preferred Stock: (i) alter or change adversely the powers, preferences or rights given to the Series B Non-Voting Preferred Stock or alter or amend this Certificate of Designation of Preferences, Rights and Limitations of Series B Non-Voting Convertible Preferred Stock (the &#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Certificate of Designation</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), amend or repeal any provision of, or add any provision to, the Certificate of Incorporation or Amended and Restated Bylaws of the Corporation, as amended, or file any articles of amendment, certificate of designations, preferences, limitations and relative rights of any series of Preferred Stock, in each case if such action would adversely alter or change the preferences, rights, privileges or powers of, or restrictions provided for the benefit of the Series B Non-Voting Preferred Stock, regardless of whether any of the foregoing actions shall be by means of amendment to the Certificate of Incorporation or by merger, consolidation, recapitalization, reclassification, conversion or otherwise, (ii) issue further shares of Series B Non-Voting Preferred Stock beyond those contemplated for issuance in the Merger Agreement or increase or decrease (other than by conversion) the number of authorized shares of Series B Non-Voting Preferred Stock, (iii) at any time while at least [&#8226;] shares of Series B Non-Voting Preferred Stock remains issued and outstanding, consummate either: (A) any Fundamental Transaction (as defined below) or (B) any merger or consolidation of the Corporation with or into another entity or any stock sale to, or other business combination in which the stockholders of the Corporation immediately before such transaction do not hold at least a majority on an as-converted-to-Common Stock basis of the capital stock of the Corporation, immediately after such transaction or (iv) enter into any agreement with respect to any of the foregoing that does not explicitly require the approval contemplated herein to consummate such transaction. Holders of shares of Common Stock acquired upon the conversion of shares of Series B Non-Voting Preferred Stock shall be entitled to the same voting rights as each other holder of Common Stock.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex F-2</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-9" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:108pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">4.2<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Any vote required or permitted under </span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 4.1</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> may be taken at a meeting of the Holders or through the execution of an action by written consent in lieu of such meeting or other written waiver by such stockholders, provided that the consent or waiver is executed by Holders representing a majority of the outstanding shares of Series B Non-Voting Preferred Stock.</span></p>
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:72pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">5.&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Rank; Liquidation</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-9" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:108pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">5.1<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Series B Non-Voting Preferred Stock shall rank on parity with the Common Stock as to distributions of assets upon liquidation, dissolution or winding up of the Corporation, whether voluntarily or involuntarily (a &#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Liquidation</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;).</span></p>
		<p class="ParaOverride-9" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:108pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">5.2<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Upon any Liquidation,  each Holder shall be entitled to receive out of the assets, whether capital or surplus, of the Corporation the same amount that a holder of Common Stock would receive if the Series B Non-Voting Preferred Stock were fully converted (disregarding for such purpose any Beneficial Ownership Limitations) to Common Stock which amounts shall be paid </span><span class="CharOverride-8" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">pari passu</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> with all holders of Common Stock, plus an additional amount equal to any dividends declared on but unpaid to such shares. If, upon any such Liquidation, the assets of the Corporation shall be insufficient to pay the Holders of shares of the Series B Non-Voting Preferred Stock the amount required under the preceding sentence, then all remaining assets of the Corporation shall be distributed ratably to the Holders and the holders of Common Stock in accordance with the respective amounts that would be payable on all such securities if all amounts payable thereon were paid in full. For the avoidance of any doubt, a Fundamental Transaction shall not be deemed a Liquidation unless the Corporation expressly declares that such Fundamental Transaction shall be treated as if it were a Liquidation.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:72pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Conversion</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-9" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:108pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.1<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Conversion at Option of Holder</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Subject to </span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 6.3</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, each share of Series B Non-Voting Preferred Stock then outstanding shall be convertible, at any time and from time to time, at the option of the Holder thereof, into a number of shares of Common Stock equal to the Conversion Ratio, subject to the Beneficial Ownership Limitation (as defined below) (each, an &#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Optional Conversion</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;). Holders shall effect conversions by providing the Corporation with the form of conversion notice attached hereto as </span><span class="CharOverride-9" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;text-decoration:underline;">Annex A</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> (a &#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Notice of Conversion</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), duly completed and executed. Provided the Corporation&#8217;s transfer agent is participating in the Depository Trust Company (&#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">DTC</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) Fast Automated Securities Transfer program, the Notice of Conversion may specify, at the Holder&#8217;s election, whether the applicable Conversion Shares shall be credited to the account of the Holder&#8217;s prime broker with DTC through its Deposit Withdrawal Agent Commission system (a &#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">DWAC Delivery</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;). The date on which an Optional Conversion shall be deemed effective (the &#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Conversion Date</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) shall be the Trading Day that the Notice of Conversion, completed and executed, is sent via email to, and received during regular business hours by, the Corporation; provided, that the original certificate(s) (if any) representing such shares of Series B Non-Voting Preferred Stock being converted, duly endorsed, and the accompanying Notice of Conversion, are received by the Corporation within two (2) Trading Days thereafter. In all other cases, the Conversion Date shall be defined as the Trading Day on which the original certificate(s) (if any) representing such shares of Series B Non-Voting Preferred Stock being converted, duly endorsed, and the accompanying Notice of Conversion, are received by the Corporation. The calculations set forth in the Notice of Conversion shall control in the absence of manifest or mathematical error.</span></p>
		<p class="ParaOverride-9" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:108pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.2<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Conversion Ratio</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The &#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Conversion Ratio</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; for each share of Series B Non-Voting Preferred Stock shall be 1,000 shares of Common Stock issuable upon the conversion (the &#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Conversion</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) of each share of Series B Non-Voting Preferred Stock (corresponding to a ratio of 1,000:1), subject to adjustment as provided herein.</span></p>
		<p class="ParaOverride-9" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:108pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.3<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Beneficial Ownership Limitation</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Notwithstanding anything herein to the contrary, the Corporation shall not effect any conversion of any share of Series B Non-Voting Preferred Stock with respect to a Holder, and a Holder shall not have the right to convert any portion of the Series B Non-Voting Preferred Stock pursuant to </span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 6.1</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, to the extent that, after giving effect to such attempted conversion set forth on an applicable Notice of Conversion with respect to the Series B Non-Voting Preferred Stock, such Holder (or any of such Holder&#8217;s affiliates or any other Person who would be a beneficial owner of Common Stock beneficially owned by the Holder for purposes of Section 13(d) or Section 16 of the Exchange Act and the applicable rules and regulations of the United States Securities and Exchange Commission (the &#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Commission</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), including any &#8220;group&#8221; of which the Holder is a member (the foregoing, &#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Attribution Parties</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;)) would beneficially own a number of shares </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex F-3</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">of Common Stock in excess of the Beneficial Ownership Limitation. For purposes of the foregoing sentence, the aggregate number of shares of Common Stock beneficially owned by such Holder and its Attribution Parties shall include the number of shares of Common Stock issuable upon conversion of the Series B Non-Voting Preferred Stock subject to the Notice of Conversion with respect to which such determination is being made, but shall exclude the number of shares of Common Stock which are issuable upon (A) conversion of the remaining, unconverted Series B Non-Voting Preferred Stock beneficially owned by such Holder or any of its Attribution Parties, and (B) exercise or conversion of the unexercised or unconverted portion of any other securities of the Corporation (including any warrants) beneficially owned by such Holder or any of its Attribution Parties that are subject to and would exceed a limitation on conversion or exercise similar to the limitation contained herein. Except as set forth in the preceding sentence, for purposes of this </span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 6.3</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the applicable rules and regulations of the Commission, and the terms &#8220;beneficial ownership&#8221; and &#8220;beneficially own&#8221; have the meanings ascribed to such terms therein. In addition, for purposes hereof, &#8220;group&#8221; has the meaning set forth in Section 13(d) of the Exchange Act and the applicable rules and regulations of the Commission. For purposes of this </span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 6.3</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, in determining the number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as stated in the most recent of the following: (A) the Corporation&#8217;s most recent periodic or annual filing with the Commission, as the case may be, (B) a more recent public announcement by the Corporation that is filed with the Commission, or (C) a more recent notice by the Corporation or the Corporation&#8217;s transfer agent to the Holder setting forth the number of shares of Common Stock then outstanding. Upon the written request of a Holder (which may be by email), the Corporation shall, within two (2) Trading Days thereof, confirm in writing to such Holder (which may be via email) the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to any actual conversion or exercise of securities of the Corporation, including shares of Series B Non-Voting Preferred Stock, by such Holder or its Attribution Parties since the date as of which such number of outstanding shares of Common Stock was last publicly reported or confirmed to the Holder. The &#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Beneficial Ownership Limitation</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; shall initially be [19.99]% of the number of shares of Common Stock outstanding as of the applicable measurement date. The Corporation shall be entitled to rely on representations made to it by the Holder in any Notice of Conversion regarding its Beneficial Ownership Limitation. Notwithstanding the foregoing, by written notice to the Corporation (which may be via email), (i) each Holder may reset the Beneficial Ownership Limitation percentage to a higher percentage applicable to such Holder, not to exceed 19.99%, which increase will not be effective until the sixty-first (61</span><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:6pt;font-style:normal;font-weight:normal;vertical-align:super;">st</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">) day after such written notice is delivered to the Corporation, and (ii) each Holder may reset the Beneficial Ownership Limitation percentage to a lower percentage effective immediately after the delivery of such notice to the Corporation. Upon such an increase by a Holder of the Beneficial Ownership Limitation pursuant to clause (i) applicable to such Holder, not to exceed 19.99%, the Beneficial Ownership Limitation may not be further amended by such Holder without first providing the minimum notice required by this </span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 6.3</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Notwithstanding the foregoing, (x) at any time following notice of a Fundamental Transaction, each Holder may waive and/or change the Beneficial Ownership Limitation applicable to such Holder effective immediately upon written notice to the Corporation and may reinstitute a Beneficial Ownership Limitation at any time thereafter effective immediately upon written notice to the Corporation (y) at any time that the beneficial ownership of shares of Common Stock of a Holder (together with any of such Holder&#8217;s Attribution Parties) is equal to or less than 9.00% of the number of shares of Common Stock outstanding as of any given date, then such Holder&#8217;s Beneficial Ownership Limitation shall automatically be set to 9.99%. The provisions of this </span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 6.3</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> shall be construed, corrected and implemented in a manner so as to effectuate the intended Beneficial Ownership Limitation herein contained and the shares of Common Stock underlying the Series B Non-Voting Preferred Stock in excess of the Beneficial Ownership Limitation shall not be deemed to be beneficially owned by the Holder for any purpose including for purposes of Section 13(d) or Rule 16a-1(a)(1) of the Exchange Act.</span></p>
		<p class="ParaOverride-9" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:108pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.4<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Mechanics of Conversion</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:144pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.4.1<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Delivery of Certificate or Electronic Issuance</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Upon Conversion not later than two (2)&#160;Trading Days after the applicable Conversion Date, or if the Holder requests the issuance of physical certificate(s), two (2)&#160;Trading Days after receipt by the Corporation of the original certificate(s) representing such shares of Series B Non-Voting Preferred Stock being converted, duly endorsed, and the accompanying Notice of Conversion (the &#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Share Delivery Date</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), the Corporation shall either: (a)&#160;deliver, or cause to be delivered, to the converting Holder a physical certificate or certificates representing the number of Conversion Shares being acquired upon the conversion of shares of Series B Non-Voting Preferred Stock, or (b)&#160;in the case of a DWAC Delivery (if so requested by the Holder), electronically transfer such Conversion Shares by crediting the account of the Holder&#8217;s </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex F-4</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">prime broker with DTC through its DWAC system. If in the case of any Notice of Conversion such certificate or certificates for the Conversion Shares are not delivered to or as directed by or, in the case of a DWAC Delivery, such shares are not electronically delivered to or as directed by, the applicable Holder by the Share Delivery Date, the applicable Holder shall be entitled to elect to rescind such Notice of Conversion by written notice to the Corporation at any time on or before its receipt of such certificate or certificates for Conversion Shares or electronic receipt of such shares, as applicable, in which event the Corporation shall promptly return to such Holder any original Series B Non-Voting Preferred Stock certificate delivered to the Corporation and such Holder shall promptly return to the Corporation any Common Stock certificates or otherwise direct the return of any shares of Common Stock delivered to the Holder through the DWAC system, representing the shares of Series B Non-Voting Preferred Stock unsuccessfully tendered for conversion to the Corporation.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:144pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.4.2<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Obligation Absolute</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Subject to </span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 6.3</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and subject to Holder&#8217;s right to rescind a Notice of Conversion pursuant to </span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 6.4.1</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, the Corporation&#8217;s obligation to issue and deliver the Conversion Shares upon conversion of Series B Non-Voting Preferred Stock in accordance with the terms hereof are absolute and unconditional, irrespective of any action or inaction by a Holder to enforce the same, any waiver or consent with respect to any provision hereof, the recovery of any judgment against any Person or any action to enforce the same, or any setoff, counterclaim, recoupment, limitation or termination, or any breach or alleged breach by such Holder or any other Person of any obligation to the Corporation or any violation or alleged violation of law by such Holder or any other Person, and irrespective of any other circumstance which might otherwise limit such obligation of the Corporation to such Holder in connection with the issuance of such Conversion Shares. Subject to </span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 6.3</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and subject to Holder&#8217;s right to rescind a Notice of Conversion pursuant to </span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 6.4.1</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, in the event a Holder shall elect to convert any or all of its Series B Non-Voting Preferred Stock, the Corporation may not refuse conversion based on any claim that such Holder or anyone associated or affiliated with such Holder has been engaged in any violation of law, agreement or for any other reason, unless an injunction from a court, on notice to Holder, restraining and/or enjoining conversion of all or part of the Series B Non-Voting Preferred Stock of such Holder shall have been sought and obtained by the Corporation, and the Corporation posts a surety bond for the benefit of such Holder in the amount of 150% of the value of the Conversion Shares into which would be converted the Series B Non-Voting Preferred Stock which is subject to such injunction, which bond shall remain in effect until the completion of arbitration/litigation of the underlying dispute and the proceeds of which shall be payable to such Holder to the extent it obtains judgment. In the absence of such injunction, the Corporation shall, subject to </span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.3</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and subject to Holder&#8217;s right to rescind a Notice of Conversion pursuant to </span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 6.4.1</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, issue Conversion Shares upon a properly noticed conversion.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:144pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.4.3<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Buy-In on Failure to Timely Deliver Certificates</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. If the Corporation fails to deliver to a Holder the applicable certificate or certificates or to effect a DWAC Delivery, as applicable, by the Share Delivery Date pursuant to </span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 6.4.1</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> (other than a failure caused by materially incorrect or incomplete information provided by Holder to the Corporation or the application of the Beneficial Ownership Limitation), and if after such Share Delivery Date such Holder is required by its brokerage firm to purchase (in an open market transaction or otherwise), or the Holder&#8217;s brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by such Holder of the Conversion Shares which such Holder was entitled to receive upon the conversion relating to such Share Delivery Date (a &#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Buy-In</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), then the Corporation shall (A) pay in cash to such Holder (in addition to any other remedies available to or elected by such Holder) the amount by which (x) such Holder&#8217;s total purchase price (including any brokerage commissions) for the shares of Common Stock so purchased exceeds (y) the product of (1) the aggregate number of shares of Common Stock that such Holder was entitled to receive from the conversion at issue multiplied by (2) the actual sale price at which the sell order giving rise to such purchase obligation was executed (including any brokerage commissions) and (B) deliver to such Holder the number of shares of Common Stock that would have been issued if the Corporation had timely complied with its delivery requirements under </span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 6.4.1</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. For example, if a Holder purchases shares of Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted conversion of shares of Series B Non-Voting Preferred Stock with respect to which the actual sale price (including any brokerage commissions) giving rise to such purchase obligation was a total of $10,000 under clause (A) of the immediately preceding sentence, the Corporation shall be required to pay such Holder $1,000. The Holder shall provide the Corporation written notice, within three (3) Trading Days after the occurrence of a Buy-In, indicating the amounts payable to such Holder in respect of such Buy-In together with applicable confirmations and other evidence reasonably requested by the Corporation. Nothing herein shall limit a Holder&#8217;s right to pursue any other remedies available to it </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex F-5</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Corporation&#8217;s failure to timely deliver certificates representing shares of Common Stock upon conversion of the shares of Series B Non-Voting Preferred Stock as required pursuant to the terms hereof.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:144pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.4.4<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Reservation of Shares Issuable Upon Conversion</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Corporation covenants that at all times it will reserve and keep available out of its authorized and unissued shares of Common Stock for the sole purpose of issuance upon conversion of the Series B Non-Voting Preferred Stock, free from preemptive rights or any other actual contingent purchase rights of Persons other than the Holders of the Series B Non-Voting Preferred Stock, not less than such aggregate number of shares of the Common Stock as shall be issuable (taking into account the adjustments of </span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 7</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">) upon the conversion of all outstanding shares of Series B Non-Voting Preferred Stock. The Corporation covenants that all shares of Common Stock that shall be so issuable shall, upon issue, be duly authorized, validly issued, fully paid and non-assessable.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:144pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.4.5<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Fractional Shares</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. No fractional shares of Common Stock shall be issued upon conversion of the Series B Non-Voting Preferred Stock, no certificates or scrip for any such fractional shares shall be issued and no cash shall be paid for any such fractional shares. Any fractional shares of Common Stock that a Holder of Series B Non-Voting Preferred Stock would otherwise be entitled to receive shall be aggregated with all fractional shares of Common Stock issuable to such Holder and any remaining fractional shares shall be rounded up to the nearest whole share.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:144pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.4.6<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Transfer Taxes</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The issuance of certificates for shares of the Common Stock upon conversion of the Series B Non-Voting Preferred Stock shall be made without charge to any Holder for any documentary stamp or similar taxes that may be payable in respect of the issue or delivery of such certificates, provided that the Corporation shall not be required to pay any tax that may be payable in respect of any transfer involved in the issuance and delivery of any such certificate upon conversion in a name other than that of the registered Holder(s) of such shares of Series B Non-Voting Preferred Stock and the Corporation shall not be required to issue or deliver such certificates unless or until the Person or Persons requesting the issuance thereof shall have paid to the Corporation the amount of such tax or shall have established to the satisfaction of the Corporation that such tax has been paid.</span></p>
		<p class="ParaOverride-9" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:108pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.5<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span> </span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Status as Stockholder</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Upon each Conversion Date, (i) the shares of Series&#160;B Non-Voting Preferred Stock being converted shall be deemed converted into shares of Common Stock and (ii)&#160;the Holder&#8217;s rights as a holder of such converted shares of Series B Non-Voting Preferred Stock shall cease and terminate, excepting only the right to receive certificates for such shares of Common Stock and to any remedies provided herein or otherwise available at law or in equity to such Holder because of a failure by the Corporation to comply with the terms of this Certificate of Designation. In all cases, the Holder shall retain all of its rights and remedies for the Corporation&#8217;s failure to convert Series B Non-Voting Preferred Stock.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:72pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">7.&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Certain Adjustments</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-9" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:108pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">7.1<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Stock Dividends and Stock Splits</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. If the Corporation, at any time while this Series B Non-Voting Preferred Stock is outstanding: (A) pays a stock dividend or otherwise makes a distribution or distributions payable in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Corporation upon conversion of this Series B Non-Voting Preferred Stock) with respect to the then outstanding shares of Common Stock; (B) subdivides outstanding shares of Common Stock into a larger number of shares; or (C) combines (including by way of a reverse stock split) outstanding shares of Common Stock into a smaller number of shares, then the Conversion Ratio shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock (excluding any treasury shares of the Corporation) outstanding immediately after such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately before such event (excluding any treasury shares of the Corporation). Any adjustment made pursuant to this </span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 7.1</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> shall become effective immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision or combination.</span></p>
		<p class="ParaOverride-9" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:108pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">7.2<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Fundamental Transaction</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. If, at any time while this Series B Non-Voting Preferred Stock is outstanding, (A) the Corporation effects any merger or consolidation of the Corporation with or into another Person or any stock sale to, or other business combination (including, without limitation, a reorganization, recapitalization, spin-off, share exchange or scheme of arrangement) with or into another Person </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex F-6</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(other than such a transaction in which the Corporation is the surviving or continuing entity and its Common Stock is not exchanged for or converted into other securities, cash or property), (B) the Corporation effects any sale, lease, transfer or exclusive license of all or substantially all of its assets in one transaction or a series of related transactions, (C) any tender offer or exchange offer (whether by the Corporation or another Person) is completed pursuant to which more than 50% of the Common Stock not held by the Corporation or such Person is exchanged for or converted into other securities, cash or property, or (D) the Corporation effects any reclassification of the Common Stock or any compulsory share exchange pursuant (other than as a result of a dividend, subdivision or combination covered by </span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 7.1</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">) to which the Common Stock is effectively converted into or exchanged for other securities, cash or property (in any such case, a &#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Fundamental Transaction</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), then, upon any subsequent conversion of this Series B Non-Voting Preferred Stock the Holders shall have the right to receive, in lieu of the right to receive Conversion Shares, for each Conversion Share that would have been issuable upon such conversion immediately prior to the occurrence of such Fundamental Transaction, the same kind and amount of securities, cash or property as it would have been entitled to receive upon the occurrence of such Fundamental Transaction if it had, immediately prior to such Fundamental Transaction, converted the Series B Non-Voting Preferred Stock immediately prior to such Fundamental Transaction (the &#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Alternate Consideration</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;). For purposes of any such subsequent conversion, the determination of the Conversion Ratio shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and the Corporation shall adjust the Conversion Ratio in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holders shall be given the same choice as to the Alternate Consideration it receives upon any conversion of this Series B Non-Voting Preferred Stock following such Fundamental Transaction. To the extent necessary to effectuate the foregoing provisions, any successor to the Corporation or surviving entity in such Fundamental Transaction shall file a new certificate of designations with the same terms and conditions and issue to the Holders new preferred stock consistent with the foregoing provisions and evidencing the Holders&#8217; right to convert such preferred stock into Alternate Consideration. The terms of any agreement to which the Corporation is a party and pursuant to which a Fundamental Transaction is effected shall include terms requiring any such successor or surviving entity to comply with the provisions of this </span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 7.2</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and insuring that this Series B Non-Voting Preferred Stock (or any such replacement security) will be similarly adjusted upon any subsequent transaction analogous to a Fundamental Transaction. The Corporation shall cause to be delivered to each Holder, at its last address as it shall appear upon the stock books of the Corporation, written notice of any Fundamental Transaction at least 20 calendar days prior to the date on which such Fundamental Transaction is expected to become effective or close. Notwithstanding anything to the contrary herein, any Parent Legacy Transaction (as defined in the Merger Agreement) shall not constitute a Fundamental Transaction.</span></p>
		<p class="ParaOverride-9" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:108pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">7.3<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Calculations</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. All calculations under this </span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 7</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> shall be made to the nearest cent or the nearest 1/100</span><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:6pt;font-style:normal;font-weight:normal;vertical-align:super;">th</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of a share, as the case may be. For purposes of this </span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 7</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be the sum of the number of shares of Common Stock (excluding any treasury shares of the Corporation) issued and outstanding.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:72pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">8.&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Redemption</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The shares of Series B Non-Voting Preferred Stock shall not be redeemable; provided, however, that the foregoing shall not limit the ability of the Corporation to purchase or otherwise deal in such shares to the extent otherwise permitted hereby and by law.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:72pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">9.&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Transfer</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. A Holder may transfer any shares of Series B Non-Voting Preferred Stock together with the accompanying rights set forth herein, held by such holder without the consent of the Corporation; provided that such transfer is in compliance with applicable securities laws. The Corporation shall in good faith (i)&#160;do and perform, or cause to be done and performed, all such further acts and things, and (ii) execute and deliver all such other agreements, certificates, instruments and documents, in each case, as any holder of Series B Non-Voting Preferred Stock may reasonably request in order to carry out the intent and accomplish the purposes of this </span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 9</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The transferee of any shares of Series B Non-Voting Preferred Stock shall be subject to the Beneficial Ownership Limitation applicable to the transferor as of the time of such transfer.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:72pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">10.<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Series B Non-Voting Preferred Stock Register</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Corporation shall maintain at its principal executive offices (or such other office or agency of the Corporation as it may designate by notice to the Holders in accordance with </span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 11</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">), a register for the Series B Non-Voting Preferred Stock, in which the Corporation shall record (i) the name, address, and electronic mail address of each holder in whose name the shares </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex F-7</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">of Series B Non-Voting Preferred Stock have been issued and (ii) the name, address, and electronic mail address of each transferee of any shares of Series B Non-Voting Preferred Stock. The Corporation may deem and treat the registered Holder of shares of Series B Non-Voting Preferred Stock as the absolute owner thereof for the purpose of any conversion thereof and for all other purposes. The Corporation shall keep the register open and available at all times during business hours for inspection by any holder of Series B Non-Voting Preferred Stock or his, her or its legal representatives.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:72pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">11.<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Notices</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Any notice required or permitted by the provisions of this Certificate of Designation to be given to a Holder of shares of Series B Non-Voting Preferred Stock shall be mailed, postage prepaid, to the post office address last shown on the records of the Corporation, or given by electronic transmission in compliance with the provisions of the DGCL, and shall be deemed sent upon such mailing or electronic transmission.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:72pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">12.<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Book-Entry; Certificates</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Series B Non-Voting Preferred Stock will be issued in book-entry form; provided that, if a Holder requests that such Holder&#8217;s shares of Series B Non-Voting Preferred Stock be issued in certificated form, the Corporation will instead issue a stock certificate to such Holder representing such Holder&#8217;s shares of Series B Non-Voting Preferred Stock. To the extent that any shares of Series B Non-Voting Preferred Stock are issued in book-entry form, references herein to &#8220;certificates&#8221; shall instead refer to the book-entry notation relating to such shares.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:72pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">13.<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Lost or Mutilated Series B Non-Voting Preferred Stock Certificate</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. If a Holder&#8217;s Series B Non-Voting Preferred Stock certificate shall be mutilated, lost, stolen or destroyed, the Corporation shall execute and deliver, in exchange and substitution for and upon cancellation of a mutilated certificate, or in lieu of or in substitution for a lost, stolen or destroyed certificate, a new certificate for the shares of Series B Non-Voting Preferred Stock so mutilated, lost, stolen or destroyed, but only upon receipt of evidence of such loss, theft or destruction of such certificate, and of the ownership hereof reasonably satisfactory to the Corporation.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:72pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">14.<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Waiver</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Any waiver by the Corporation or a Holder of a breach of any provision of this Certificate of Designation shall not operate as or be construed to be a waiver of any other breach of such provision or of any breach of any other provision of this Certificate of Designation or a waiver by any other Holders. The failure of the Corporation or a Holder to insist upon strict adherence to any term of this Certificate of Designation on one or more occasions shall not be considered a waiver or deprive that party (or any other Holder) of the right thereafter to insist upon strict adherence to that term or any other term of this Certificate of Designation. Any waiver by the Corporation or a Holder must be in writing. Notwithstanding any provision in this Certificate of Designation to the contrary, any provision contained herein and any right of the Holders of Series B Non-Voting Preferred Stock granted hereunder may be waived as to all shares of Series B Non-Voting Preferred Stock (and the Holders thereof) upon the written consent of the Holders of not less than a majority of the shares of Series B Non-Voting Preferred Stock then outstanding, provided, however, that the Beneficial Ownership Limitation applicable to a Holder, and any provisions contained herein that are related to such Beneficial Ownership Limitation, cannot be modified, waived or terminated without the consent of such Holder, provided further, that any proposed waiver that would, by its terms, have a disproportionate and materially adverse effect on any Holder shall require the consent of such Holder(s).</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:72pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">15.<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Severability</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Whenever possible, each provision hereof shall be interpreted in a manner as to be effective and valid under applicable law, but if any provision hereof is held to be prohibited by or invalid under applicable law, then such provision shall be ineffective only to the extent of such prohibition or invalidity, without invalidating or otherwise adversely affecting the remaining provisions hereof.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:72pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">16.<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Status of Converted Series B Non-Voting Preferred Stock</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. If any shares of Series B Non-Voting Preferred Stock shall be converted or redeemed by the Corporation, such shares shall, to the fullest extent permitted by applicable law, be retired and cancelled upon such acquisition, and shall not be reissued as a share of Series B Non-Voting Preferred Stock. Any share of Series B Non-Voting Preferred Stock so acquired shall, upon its retirement and cancellation, and upon the taking of any action required by applicable law, resume the status of authorized but unissued shares of preferred stock and shall no longer be designated as Series B Non-Voting Preferred Stock.</span></p>
		<p class="ParaOverride-11" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-align:center;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">[</span><span class="CharOverride-8" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">Remainder of Page Intentionally Left Blank</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">]</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex F-8</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;text-indent:24pt;margin-top:8pt;"><span class="CharOverride-11" style="font-style:normal;font-weight:bold;">IN WITNESS WHEREOF</span>, ARCA biopharma, Inc. has caused this Certificate of Designation of Preferences, Rights and Limitations of Series B Non<span class="nobreak">-Voting</span> Convertible Preferred Stock to be duly executed by its [&#8226;] on [&#8226;], 2024.</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 52.84%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">



					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 45.87%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="CharOverride-12" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">ARCA biopharma, Inc.</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:8pt;vertical-align:top;width: 52.84%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 5.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">By:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 38.65%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:8pt;vertical-align:top;width: 52.84%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 5.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Name:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 38.65%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:8pt;vertical-align:top;width: 52.84%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 5.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Title:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 38.65%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">&#160;</p>
					</td>
				</tr>

		</table>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex F-9</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-2" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-align:center;widows:2;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">ANNEX A</span></p>
		<p class="ParaOverride-2" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-align:center;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">NOTICE OF CONVERSION</span><span class="CharOverride-5" style="font-family:Times New Roman, serif;font-size:11pt;font-style:normal;font-weight:normal;"><br/><br/></span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(TO BE EXECUTED BY THE REGISTERED HOLDER IN ORDER TO CONVERT SHARES OF SERIES B NON-VOTING CONVERTIBLE PREFERRED STOCK)</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">The undersigned Holder hereby irrevocably elects to convert the number of shares of Series B Non-Voting Convertible Preferred Stock (&#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Series B Non-Voting Preferred Stock</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) indicated below, represented in book-entry form, into shares of common stock, par value $0.001 per share (the &#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Common Stock</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), of ARCA biopharma, Inc., a Delaware corporation (the &#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Corporation</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), as of the date written below. If securities are to be issued in the name of a Person other than the undersigned, the undersigned will pay all transfer taxes payable with respect thereto. Capitalized terms utilized but not defined herein shall have the meaning ascribed to such terms in that certain Certificate of Designation of Preferences, Rights and Limitations of Series B Non-Voting Convertible Preferred Stock (the &#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Certificate of Designation</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) filed by the Corporation with the Secretary of State of the State of Delaware on [&#8226;], 2024.</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">As of the date hereof, the number of shares of Common Stock beneficially owned by the undersigned Holder (together with such Holder&#8217;s Attribution Parties), including the number of shares of Common Stock issuable upon conversion of the Series B Non-Voting Preferred Stock subject to this Notice of Conversion, but excluding the number of shares of Common Stock which are issuable upon (A) conversion of the remaining, unconverted Series&#160;B Non-Voting Preferred Stock beneficially owned by such Holder or any of its Attribution Parties, and (B) exercise or conversion of the unexercised or unconverted portion of any other securities of the Corporation (including any warrants) beneficially owned by such Holder or any of its Attribution Parties that are subject to a limitation on conversion or exercise similar to the limitation contained in </span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 6.3</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Certificate of Designation, is _____. For purposes hereof, beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the applicable regulations of the Commission. In addition, for purposes hereof, &#8220;group&#8221; has the meaning set forth in Section 13(d) of the Exchange Act and the applicable regulations of the Commission.</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">CONVERSION CALCULATIONS:</span></p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 74.23%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">



						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:justify;">Date to Effect Conversion:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.27%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 24.50%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">_____________________</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 74.23%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:justify;">Number&#160;of&#160;shares&#160;of&#160;Series&#160;B&#160;Non-Voting&#160;Preferred&#160;Stock&#160;owned&#160;prior&#160;to&#160;Conversion:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.27%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 24.50%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">_____________________</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 74.23%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:justify;">Number of shares of Series B Non-Voting Preferred Stock to be Converted:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.27%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 24.50%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">_____________________</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 74.23%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:justify;">Number of shares of Common Stock to be Issued:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.27%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 24.50%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">_____________________</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 74.23%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:justify;">Address for delivery of physical certificates:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.27%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 24.50%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">_____________________</p>
					</td>
				</tr>

		</table>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" colspan="5" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 43.09%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">



						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-align:justify;text-indent:0pt;">For DWAC Delivery, please provide the following:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.29%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 55.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 3.86%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.29%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 12.86%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:justify;">Broker No.:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.29%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 23.79%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">_____________________</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.29%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 55.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 3.86%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.29%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 12.86%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:justify;">Account No.:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.29%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 23.79%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">_____________________</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.29%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 55.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>

		</table>
		<table class="No-Table-Style _idGenTablePara-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">



					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="CharOverride-13" style="font-variant:normal;text-transform:uppercase;">[HOLDER]</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:8pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">By:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 42.74%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:8pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Name:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 42.74%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:8pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Title:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 42.74%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">&#160;</p>
					</td>
				</tr>

		</table>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex F-10</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T106"></a><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:right;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Annex&#160;G</span></p>
		<p class="ParaOverride-2" style="margin:0;padding:0;border-width:0;margin-right:3pt;margin-top:8pt;orphans:2;text-align:center;widows:2;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">CERTIFICATE OF AMENDMENT</span><span class="CharOverride-1" style="font-family:Times New Roman, serif;font-size:11pt;font-style:normal;font-weight:bold;"><br/></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">TO THE<br/>AMENDED AND RESTATED CERTIFICATE OF INCORPORATION<br/>OF</span><span class="CharOverride-1" style="font-family:Times New Roman, serif;font-size:11pt;font-style:normal;font-weight:bold;"><br/></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">ARCA BIOPHARMA, INC.</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-right:3pt;margin-top:8pt;orphans:2;text-indent:36pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">ARCA biopharma, Inc., a corporation organized and existing under the laws of the State of Delaware (the &#8220;</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Corporation</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), certifies that:</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">1.&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The name of the Corporation is ARCA biopharma, Inc. The Corporation&#8217;s original Certificate of Incorporation was filed with the Secretary of State of the State of Delaware on March 16, 2004&#160;under the name &#8220;Nuvelo Merger Sub, Inc.&#8221;</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">2.&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Board of Directors (the &#8220;</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Board</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) of the Corporation duly adopted resolutions proposing to amend the Certificate of Incorporation of the Corporation (the &#8220;</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Amendment</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), declaring the Amendment to be advisable and in the best interests of the Corporation and its stockholders, and authorizing the appropriate officers of the Corporation to solicit the consent of the stockholders therefor, which resolution setting forth the proposed Amendment is as follows:</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">The first paragraph of Article IV of the Corporation&#8217;s Amended and Restated Certificate of Incorporation is hereby amended and restated in its entirety as follows:</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;The total number of shares of all classes of stock this Corporation shall have authority to issue is [&#8226;], consisting of [&#8226;] shares of Common Stock, par value $0.001 per share, and 5,000,000 shares of Preferred Stock, par value $0.001 per share. The Preferred Stock may be issued from time to time, in one or more series, each series to be appropriately designated by a distinguishing letter or title, prior to the issue of any shares thereof.&#8221;</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">3.&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>This Certificate of Amendment was duly adopted by the stockholders of the Corporation in accordance with Section 242 of the General Corporation Law of the State of Delaware.</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">4.&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>This Certificate of Amendment shall become effective on [&#8226;], 2024 at [&#8226;] [a.m./p.m.] Eastern Time.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-align:center;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">[</span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">Signature Page Follows</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">]</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex G-1</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="ParaOverride-9" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:36pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">IN WITNESS WHEREOF</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, this Certificate of Amendment is duly executed by the undersigned officer of the Corporation on ____________, 2024.</span></p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:8pt;vertical-align:top;width: 52.84%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">



					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 5.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">By:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 38.65%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:8pt;vertical-align:top;width: 52.84%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 5.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Name:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 38.65%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:8pt;vertical-align:top;width: 52.84%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 5.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Title:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 38.65%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>

		</table>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex G-2</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T107"></a><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:right;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Annex&#160;H</span></p>
		<p class="ParaOverride-2" style="margin:0;padding:0;border-width:0;margin-right:3pt;margin-top:8pt;orphans:2;text-align:center;widows:2;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">CERTIFICATE OF AMENDMENT</span><span class="CharOverride-1" style="font-family:Times New Roman, serif;font-size:11pt;font-style:normal;font-weight:bold;"><br/></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">TO THE<br/>AMENDED AND RESTATED CERTIFICATE OF INCORPORATION<br/>OF</span><span class="CharOverride-1" style="font-family:Times New Roman, serif;font-size:11pt;font-style:normal;font-weight:bold;"><br/></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">ARCA BIOPHARMA, INC.</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-right:3pt;margin-top:8pt;orphans:2;text-indent:36pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">ARCA biopharma, Inc., a corporation organized and existing under the laws of the State of Delaware (the &#8220;</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Corporation</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), certifies that:</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">1.&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The name of the Corporation is ARCA biopharma, Inc. The Corporation&#8217;s original Certificate of Incorporation was filed with the Secretary of State of the State of Delaware on March 16, 2004&#160;under the name &#8220;Nuvelo Merger Sub, Inc.&#8221;</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">2.&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Board of Directors (the &#8220;</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Board</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) of the Corporation duly adopted resolutions proposing to amend the Certificate of Incorporation of the Corporation (the &#8220;</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Amendment</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), declaring the Amendment to be advisable and in the best interests of the Corporation and its stockholders, and authorizing the appropriate officers of the Corporation to solicit the consent of the stockholders therefor, which resolution setting forth the proposed Amendment is as follows:</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Article IV of the Corporation&#8217;s Amended and Restated Certificate of Incorporation is hereby amended to add the following paragraph at the end of Article IV:</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;Upon the effectiveness of the Certificate of Amendment to the Amended and Restated Certificate of Incorporation adding this paragraph (the &#8220;</span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Effective Time</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), each [&#8226;] to [&#8226;] shares of  Common Stock issued immediately prior to the Effective Time shall automatically be combined into one (1) validly issued, fully paid and nonassessable share of Common Stock, without any further action by the Corporation or any holder thereof, the exact ratio within the [&#8226;] to [&#8226;] range to be determined by the Board of Directors of the Corporation prior to the Effective Time and publicly announced by the Corporation, subject to the treatment of fractional share interests as described below (the &#8220;</span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Reverse Stock Split</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;). No fractional shares of Common Stock shall be issued in connection with the Reverse Stock Split. Each certificate that immediately prior to the Effective Time represented shares Common Stock, as applicable (the &#8220;</span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Old Certificates</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), shall, until surrendered to the Corporation in exchange for a certificate representing such new number of shares of Common Stock, automatically represent that number of shares of Common Stock into which the shares of Common Stock represented by the Old Certificate shall have been combined, subject to the elimination of fractional share interests as described above.&#8221;</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">3.&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>On [&#8226;], 2024, the Board of Directors of the Corporation determined that each [&#8226;] shares of the Corporation&#8217;s Common Stock, par value $0.001 per share (the &#8220;</span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Common Stock</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), issued immediately prior to the Effective Time shall automatically be combined into one (1) validly issued, fully paid and nonassessable share of Common Stock. The Corporation publicly announced this ratio on [&#8226;], 2024.</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">4.&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>This Certificate of Amendment was duly adopted by the stockholders of the Corporation in accordance with Section 242 of the General Corporation Law of the State of Delaware.</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">5.&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>This Certificate of Amendment shall become effective on [&#8226;], 2024 at [&#8226;] [a.m./p.m.] Eastern Time.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-align:center;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">[</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">Signature Page Follows</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">]</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex H-1</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="ParaOverride-9" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:36pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">IN WITNESS WHEREOF</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, this Certificate of Amendment is duly executed by the undersigned officer of the Corporation on ____________, 2024.</span></p>
		<table class="No-Table-Style _idGenTablePara-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:8pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">



					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">By:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 42.74%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:8pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 42.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Name:</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 42.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Title:</p>
					</td>
				</tr>

		</table>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex H-2</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T108"></a><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:right;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Annex&#160;I</span></p>
		<p class="ParaOverride-2" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-align:center;widows:2;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">CERTIFICATE OF AMENDMENT TO THE<br/>AMENDED AND RESTATED CERTIFICATE OF INCORPORATION<br/>OF ARCA BIOPHARMA, INC.</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">ARCA biopharma, Inc. (the &#8220;</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Corporation</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the &#8220;</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">General Corporation Law</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), does hereby certify:</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:54pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">1.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>The current name of the Corporation is ARCA biopharma, Inc. The date of filing of the original Certificate of Incorporation of ARCA biopharma, Inc. with the Secretary of State of the State of Delaware was March 16, 2004 under the name Nuvelo Merger Sub, Inc.</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:54pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">2.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>The Amended and Restated Certificate of Incorporation of the Corporation was filed with the Secretary of State of the State of Delaware on March 18, 2004 (as amended, the &#8220;</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Certificate of Incorporation</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;).</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:54pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">3.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>The existing Certificate of Incorporation is hereby amended to add Article XIII to the Certificate of Incorporation to read as follows:</span></p>
		<p class="ParaOverride-2" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-align:center;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">XIII.</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;background-color:#ffffff;margin-top:8pt;orphans:2;text-indent:25pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">To the fullest extent permitted by the Delaware General Corporation Law, as the same exists or as may hereafter be amended, an officer of the Corporation shall not be personally liable to the Corporation or its stockholders for monetary damages for breach of fiduciary duty as an officer.</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;background-color:#ffffff;margin-top:8pt;orphans:2;text-indent:25pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Neither any amendment nor repeal of this Article XIII, nor the adoption of any provision of this Certificate of Incorporation inconsistent with this Article XIII, shall eliminate or reduce the effect of this Article XIII in respect of any matter occurring, or any action or proceeding accruing or arising or that, but for this Article XIII, would accrue or arise, prior to such amendment, repeal or adoption of an inconsistent provision.&#8221;</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:54pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">4.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>All other provisions of the Certificate of Incorporation shall remain in full force and effect.</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:54pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">5.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>The amendment of the Certificate of Incorporation herein certified has been duly adopted in accordance with the provisions of 242 of the General Corporation Law.</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:54pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>This Certificate of Amendment shall become effective as of _____, 2024 at _____ Eastern Time.</span></p>
		<p class="ParaOverride-2" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-align:center;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">[</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">Signature Page Follows</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">]</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex I-1</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">IN WITNESS WHEREOF</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, the Corporation has caused this Certificate of Amendment to be executed by the undersigned authorized officer of the Corporation as of this _____ day of _____, 2024.</span></p>
		<table class="No-Table-Style _idGenTablePara-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:8pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">



					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">By:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 42.74%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:8pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 42.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Name:</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 42.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Title:</p>
					</td>
				</tr>

		</table>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex I-2</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T109"></a><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:right;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Annex&#160;J</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Appraisal Rights (Section&#160;262 of the Delaware General Corporation Law)</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">&#167; 262. Appraisal rights</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">(a)&#160;Any stockholder of a corporation of this State who holds shares of stock on the date of the making of a demand pursuant to subsection (d)&#160;of this section with respect to such shares, who continuously holds such shares through the effective date of the merger, consolidation, or conversion, who has otherwise complied with subsection&#160;(d)&#160;of this section and who has neither voted in favor of the merger, consolidation or conversion nor consented thereto in writing pursuant to &#167; 228 of this title shall be entitled to an appraisal by the Court of Chancery of the fair value of the stockholder&#8217;s shares of stock under the circumstances described in subsections (b)&#160;and (c)&#160;of this section. As used in this section, the word &#8220;stockholder&#8221; means a holder of record of stock in a corporation; the words &#8220;stock&#8221; and &#8220;share&#8221; mean and include what is ordinarily meant by those words; the words &#8220;depository receipt&#8221; mean a receipt or other instrument issued by a depository representing an interest in 1 or more shares, or fractions thereof, solely of stock of a corporation, which stock is deposited with the depository; the words &#8220;beneficial owner&#8221; mean a person who is the beneficial owner of shares of stock held either in voting trust or by a nominee on behalf of such person; and the word &#8220;person&#8221; means any individual, corporation, partnership, unincorporated association or other entity.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">(b)&#160;Appraisal rights shall be available for the shares of any class or series of stock of a constituent or converting corporation in a merger, consolidation or conversion to be effected pursuant to &#167; 251 (other than a merger effected pursuant to &#167; 251(g)&#160;of this title), &#167; 252, &#167; 254, &#167; 255, &#167; 256, &#167; 257, &#167; 258, &#167; 263, &#167; 264 or &#167; 266 of this title (other than, in each case and solely with respect to a domesticated corporation, a merger, consolidation or conversion authorized pursuant to and in accordance with the provisions of &#167; 388 of this title):</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">(1)&#160;Provided, however, that no appraisal rights under this section shall be available for the shares of any class or series of stock, which stock, or depository receipts in respect thereof, at the record date fixed to determine the stockholders entitled to receive notice of the meeting of stockholders, or at the record date fixed to determine the stockholders entitled to consent pursuant to &#167; 228 of this title, to act upon the agreement of merger or consolidation or the resolution providing for conversion (or, in the case of a merger pursuant to &#167; 251(h)&#160;of this title, as of immediately prior to the execution of the agreement of merger), were either: (i)&#160;listed on a national securities exchange or (ii)&#160;held of record by more than 2,000 holders; and further provided that no appraisal rights shall be available for any shares of stock of the constituent corporation surviving a merger if the merger did not require for its approval the vote of the stockholders of the surviving corporation as provided in &#167; 251(f)&#160;of this title.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">(2)&#160;Notwithstanding paragraph (b)(1)&#160;of this section, appraisal rights under this section shall be available for the shares of any class or series of stock of a constituent or converting corporation if the holders thereof are required by the terms of an agreement of merger or consolidation, or by the terms of a resolution providing for conversion, pursuant to &#167; 251, &#167; 252, &#167; 254, &#167; 255, &#167; 256, &#167; 257, &#167; 258, &#167; 263, &#167; 264 or &#167; 266 of this title to accept for such stock anything except:</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">a. Shares of stock of the corporation surviving or resulting from such merger or consolidation, or of the converted entity if such entity is a corporation as a result of the conversion, or depository receipts in respect thereof;</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">b. Shares of stock of any other corporation, or depository receipts in respect thereof, which shares of stock (or depository receipts in respect thereof) or depository receipts at the effective date of the merger, consolidation or conversion will be either listed on a national securities exchange or held of record by more than 2,000 holders;</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">c. Cash in lieu of fractional shares or fractional depository receipts described in the foregoing paragraphs (b)(2)a. and b. of this section; or</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">d. Any combination of the shares of stock, depository receipts and cash in lieu of fractional shares or fractional depository receipts described in the foregoing paragraphs (b)(2)a., b. and c. of this section.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">(3)&#160;In the event all of the stock of a subsidiary Delaware corporation party to a merger effected under &#167; 253 or &#167; 267 of this title is not owned by the parent immediately prior to the merger, appraisal rights shall be available for the shares of the subsidiary Delaware corporation.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">(4)&#160;[Repealed.]</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex J-1</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">(c)&#160;Any corporation may provide in its certificate of incorporation that appraisal rights under this section shall be available for the shares of any class or series of its stock as a result of an amendment to its certificate of incorporation, any merger or consolidation in which the corporation is a constituent corporation, the sale of all or substantially all of the assets of the corporation or a conversion effected pursuant to &#167; 266 of this title. If the certificate of incorporation contains such a provision, the provisions of this section, including those set forth in subsections (d), (e), and (g)&#160;of this section, shall apply as nearly as is practicable.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">(d)&#160;Appraisal rights shall be perfected as follows:</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">(1)&#160;If a proposed merger, consolidation or conversion for which appraisal rights are provided under this section is to be submitted for approval at a meeting of stockholders, the corporation, not less than 20&#160;days prior to the meeting, shall notify each of its stockholders who was such on the record date for notice of such meeting (or such members who received notice in accordance with &#167; 255(c)&#160;of this title) with respect to shares for which appraisal rights are available pursuant to subsection (b)&#160;or (c)&#160;of this section that appraisal rights are available for any or all of the shares of the constituent corporations or the converting corporation, and shall include in such notice either a copy of this section (and, if 1 of the constituent corporations or the converting corporation is a nonstock corporation, a copy of &#167; 114 of this title) or information directing the stockholders to a publicly available electronic resource at which this section (and, &#167; 114 of this title, if applicable) may be accessed without subscription or cost. Each stockholder electing to demand the appraisal of such stockholder&#8217;s shares shall deliver to the corporation, before the taking of the vote on the merger, consolidation or conversion, a written demand for appraisal of such stockholder&#8217;s shares; provided that a demand may be delivered to the corporation by electronic transmission if directed to an information processing system (if any) expressly designated for that purpose in such notice. Such demand will be sufficient if it reasonably informs the corporation of the identity of the stockholder and that the stockholder intends thereby to demand the appraisal of such stockholder&#8217;s shares. A proxy or vote against the merger, consolidation or conversion shall not constitute such a demand. A stockholder electing to take such action must do so by a separate written demand as herein provided. Within 10&#160;days after the effective date of such merger, consolidation or conversion, the surviving, resulting or converted entity shall notify each stockholder of each constituent or converting corporation who has complied with this subsection and has not voted in favor of or consented to the merger, consolidation or conversion, and any beneficial owner who has demanded appraisal under paragraph (d)(3)&#160;of this section, of the date that the merger, consolidation or conversion has become effective; or</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">(2)&#160;If the merger, consolidation or conversion was approved pursuant to &#167; 228, &#167; 251(h), &#167; 253, or &#167; 267 of this title, then either a constituent or converting corporation before the effective date of the merger, consolidation or conversion, or the surviving, resulting or converted entity within 10&#160;days after such effective date, shall notify each stockholder of any class or series of stock of such constituent or converting corporation who is entitled to appraisal rights of the approval of the merger, consolidation or conversion and that appraisal rights are available for any or all shares of such class or series of stock of such constituent or converting corporation, and shall include in such notice either a copy of this section (and, if 1 of the constituent corporations or the converting corporation is a nonstock corporation, a copy of &#167; 114 of this title) or information directing the stockholders to a publicly available electronic resource at which this section (and &#167; 114 of this title, if applicable) may be accessed without subscription or cost. Such notice may, and, if given on or after the effective date of the merger, consolidation or conversion, shall, also notify such stockholders of the effective date of the merger, consolidation or conversion. Any stockholder entitled to appraisal rights may, within 20&#160;days after the date of giving such notice or, in the case of a merger approved pursuant to &#167; 251(h)&#160;of this title, within the later of the consummation of the offer contemplated by &#167; 251(h)&#160;of this title and 20&#160;days after the date of giving such notice, demand in writing from the surviving or resulting entity the appraisal of such holder&#8217;s shares; provided that a demand may be delivered to such entity by electronic transmission if directed to an information processing system (if any) expressly designated for that purpose in such notice. Such demand will be sufficient if it reasonably informs such entity of the identity of the stockholder and that the stockholder intends thereby to demand the appraisal of such holder&#8217;s shares. If such notice did not notify stockholders of the effective date of the merger, consolidation or conversion, either (i)&#160;each such constituent corporation or the converting corporation shall send a second notice before the effective date of the merger, consolidation or conversion notifying each of the holders of any class or series of stock of such constituent or converting corporation that are entitled to appraisal rights of the effective date of the merger, consolidation or conversion or (ii)&#160;the surviving, resulting or converted entity shall send such a second notice to all such holders on or within 10&#160;days after such effective date; provided, however, that if such second notice is sent more than 20&#160;days following the sending of the first notice or, in the case of a merger approved pursuant to &#167; 251(h)&#160;of this title, later than the later of the consummation of the offer contemplated by &#167; 251(h)&#160;of this title and 20&#160;days following the sending of the first notice, such second notice need </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex J-2</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">only be sent to each stockholder who is entitled to appraisal rights and who has demanded appraisal of such holder&#8217;s shares in accordance with this subsection and any beneficial owner who has demanded appraisal under paragraph (d)(3)&#160;of this section. An affidavit of the secretary or assistant secretary or of the transfer agent of the corporation or entity that is required to give either notice that such notice has been given shall, in the absence of fraud, be prima facie evidence of the facts stated therein. For purposes of determining the stockholders entitled to receive either notice, each constituent corporation or the converting corporation may fix, in advance, a record date that shall be not more than 10&#160;days prior to the date the notice is given, provided, that if the notice is given on or after the effective date of the merger, consolidation or conversion, the record date shall be such effective date. If no record date is fixed and the notice is given prior to the effective date, the record date shall be the close of business on the&#160;day next preceding the&#160;day on which the notice is given.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">(3)&#160;Notwithstanding subsection (a)&#160;of this section (but subject to this paragraph (d)(3)), a beneficial owner may, in such person&#8217;s name, demand in writing an appraisal of such beneficial owner&#8217;s shares in accordance with either paragraph (d)(1)&#160;or (2)&#160;of this section, as applicable; provided that (i)&#160;such beneficial owner continuously owns such shares through the effective date of the merger, consolidation or conversion and otherwise satisfies the requirements applicable to a stockholder under the first sentence of subsection (a)&#160;of this section and (ii)&#160;the demand made by such beneficial owner reasonably identifies the holder of record of the shares for which the demand is made, is accompanied by documentary evidence of such beneficial owner&#8217;s beneficial ownership of stock and a statement that such documentary evidence is a true and correct copy of what it purports to be, and provides an address at which such beneficial owner consents to receive notices given by the surviving, resulting or converted entity hereunder and to be set forth on the verified list required by subsection (f)&#160;of this section.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">(e)&#160;Within 120&#160;days after the effective date of the merger, consolidation or conversion, the surviving, resulting or converted entity, or any person who has complied with subsections (a)&#160;and (d)&#160;of this section hereof and who is otherwise entitled to appraisal rights, may commence an appraisal proceeding by filing a petition in the Court of Chancery demanding a determination of the value of the stock of all such stockholders. Notwithstanding the foregoing, at any time within 60&#160;days after the effective date of the merger, consolidation or conversion, any person entitled to appraisal rights who has not commenced an appraisal proceeding or joined that proceeding as a named party shall have the right to withdraw such person&#8217;s demand for appraisal and to accept the terms offered upon the merger, consolidation or conversion. Within 120&#160;days after the effective date of the merger, consolidation or conversion, any person who has complied with the requirements of subsections (a)&#160;and (d)&#160;of this section hereof, upon request given in writing (or by electronic transmission directed to an information processing system (if any) expressly designated for that purpose in the notice of appraisal), shall be entitled to receive from the surviving, resulting or converted entity a statement setting forth the aggregate number of shares not voted in favor of the merger, consolidation or conversion (or, in the case of a merger approved pursuant to &#167; 251(h)&#160;of this title, the aggregate number of shares (other than any excluded stock (as defined in &#167; 251(h)(6)d. of this title)) that were the subject of, and were not tendered into, and accepted for purchase or exchange in, the offer referred to in &#167; 251(h)(2)&#160;of this title), and, in either case, with respect to which demands for appraisal have been received and the aggregate number of stockholders or beneficial owners holding or owning such shares (provided that, where a beneficial owner makes a demand pursuant to paragraph (d)(3)&#160;of this section, the record holder of such shares shall not be considered a separate stockholder holding such shares for purposes of such aggregate number). Such statement shall be given to the person within 10&#160;days after such person&#8217;s request for such a statement is received by the surviving, resulting or converted entity or within 10&#160;days after expiration of the period for delivery of demands for appraisal under subsection (d)&#160;of this section hereof, whichever is later.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">(f)&#160;Upon the filing of any such petition by any person other than the surviving, resulting or converted entity, service of a copy thereof shall be made upon such entity, which shall within 20&#160;days after such service file in the office of the Register in Chancery in which the petition was filed a duly verified list containing the names and addresses of all persons who have demanded appraisal for their shares and with whom agreements as to the value of their shares have not been reached by such entity. If the petition shall be filed by the surviving, resulting or converted entity, the petition shall be accompanied by such a duly verified list. The Register in Chancery, if so ordered by the Court, shall give notice of the time and place fixed for the hearing of such petition by registered or certified mail to the surviving, resulting or converted entity and to the persons shown on the list at the addresses therein stated. The forms of the notices by mail and by publication shall be approved by the Court, and the costs thereof shall be borne by the surviving, resulting or converted entity.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex J-3</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">(g)&#160;At the hearing on such petition, the Court shall determine the persons who have complied with this section and who have become entitled to appraisal rights. The Court may require the persons who have demanded an appraisal for their shares and who hold stock represented by certificates to submit their certificates of stock to the Register in Chancery for notation thereon of the pendency of the appraisal proceedings; and if any person fails to comply with such direction, the Court may dismiss the proceedings as to such person. If immediately before the merger, consolidation or conversion the shares of the class or series of stock of the constituent or converting corporation as to which appraisal rights are available were listed on a national securities exchange, the Court shall dismiss the proceedings as to all holders of such shares who are otherwise entitled to appraisal rights unless (1)&#160;the total number of shares entitled to appraisal exceeds 1% of the outstanding shares of the class or series eligible for appraisal, (2)&#160;the value of the consideration provided in the merger, consolidation or conversion for such total number of shares exceeds $1&#160;million, or (3)&#160;the merger was approved pursuant to &#167; 253 or &#167; 267 of this title.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">(h)&#160;After the Court determines the persons entitled to an appraisal, the appraisal proceeding shall be conducted in accordance with the rules of the Court of Chancery, including any rules specifically governing appraisal proceedings. Through such proceeding the Court shall determine the fair value of the shares exclusive of any element of value arising from the accomplishment or expectation of the merger, consolidation or conversion, together with interest, if any, to be paid upon the amount determined to be the fair value. In determining such fair value, the Court shall take into account all relevant factors. Unless the Court in its discretion determines otherwise for good cause shown, and except as provided in this subsection, interest from the effective date of the merger, consolidation or conversion through the date of payment of the judgment shall be compounded quarterly and shall accrue at 5% over the Federal Reserve discount rate (including any surcharge) as established from time to time during the period between the effective date of the merger, consolidation or conversion and the date of payment of the judgment. At any time before the entry of judgment in the proceedings, the surviving, resulting or converted entity may pay to each person entitled to appraisal an amount in cash, in which case interest shall accrue thereafter as provided herein only upon the sum of (1)&#160;the difference, if any, between the amount so paid and the fair value of the shares as determined by the Court, and (2)&#160;interest theretofore accrued, unless paid at that time. Upon application by the surviving, resulting or converted entity or by any person entitled to participate in the appraisal proceeding, the Court may, in its discretion, proceed to trial upon the appraisal prior to the final determination of the persons entitled to an appraisal. Any person whose name appears on the list filed by the surviving, resulting or converted entity pursuant to subsection (f)&#160;of this section may participate fully in all proceedings until it is finally determined that such person is not entitled to appraisal rights under this section.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">(i)&#160;The Court shall direct the payment of the fair value of the shares, together with interest, if any, by the surviving, resulting or converted entity to the persons entitled thereto. Payment shall be so made to each such person upon such terms and conditions as the Court may order. The Court&#8217;s decree may be enforced as other decrees in the Court of Chancery may be enforced, whether such surviving, resulting or converted entity be an entity of this State or of any state.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">(j)&#160;The costs of the proceeding may be determined by the Court and taxed upon the parties as the Court deems equitable in the circumstances. Upon application of a person whose name appears on the list filed by the surviving, resulting or converted entity pursuant to subsection (f)&#160;of this section who participated in the proceeding and incurred expenses in connection therewith, the Court may order all or a portion of such expenses, including, without limitation, reasonable attorney&#8217;s fees and the fees and expenses of experts, to be charged pro rata against the value of all the shares entitled to an appraisal not dismissed pursuant to subsection (k)&#160;of this section or subject to such an award pursuant to a reservation of jurisdiction under subsection (k)&#160;of this section.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">(k)&#160;From and after the effective date of the merger, consolidation or conversion, no person who has demanded appraisal rights with respect to some or all of such person&#8217;s shares as provided in subsection (d)&#160;of this section shall be entitled to vote such shares for any purpose or to receive payment of dividends or other distributions on such shares (except dividends or other distributions payable to stockholders of record at a date which is prior to the effective date of the merger, consolidation or conversion); provided, however, that if no petition for an appraisal is filed within the time provided in subsection (e)&#160;of this section, or if a person who has made a demand for an appraisal in accordance with this section shall deliver to the surviving, resulting or converted entity a written withdrawal of such person&#8217;s demand for an appraisal in respect of some or all of such person&#8217;s shares in accordance with subsection (e)&#160;of this section, then the right of such person to an appraisal of the shares subject to the withdrawal shall cease. Notwithstanding the foregoing, no appraisal proceeding in the Court of Chancery shall be dismissed as to any person without the approval of the Court, and such approval may be conditioned upon such </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex J-4</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">terms as the Court deems just, including without limitation, a reservation of jurisdiction for any application to the Court made under subsection (j)&#160;of this section; provided, however that this provision shall not affect the right of any person who has not commenced an appraisal proceeding or joined that proceeding as a named party to withdraw such person&#8217;s demand for appraisal and to accept the terms offered upon the merger, consolidation or conversion within 60&#160;days after the effective date of the merger, consolidation or conversion, as set forth in subsection (e)&#160;of this section.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">(l)&#160;The shares or other equity interests of the surviving, resulting or converted entity to which the shares of stock subject to appraisal under this section would have otherwise converted but for an appraisal demand made in accordance with this section shall have the status of authorized but not outstanding shares of stock or other equity interests of the surviving, resulting or converted entity, unless and until the person that has demanded appraisal is no longer entitled to appraisal pursuant to this section.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex J-5</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T110"></a><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:right;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Annex&#160;K</span></p>
		<p class="ParaOverride-2" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-align:center;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">ORUKA THERAPEUTICS, INC.</span><span class="CharOverride-2" style="font-family:Times New Roman, serif;font-style:normal;font-weight:bold;"><br/></span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">2024 STOCK INCENTIVE PLAN</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:-36pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">1.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Purpose</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">The purpose of this Oruka Therapeutics, Inc. 2024 Stock Incentive Plan (the &#8220;</span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Plan</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) is to promote and closely align the interests of employees, officers, non-employee directors and other individual service providers of Oruka Therapeutics, Inc. and its stockholders by providing stock-based compensation and other performance-based compensation. The objectives of the Plan are to attract and retain the best available employees, officers, non-employee directors and other individual service providers for positions of substantial responsibility and to motivate Participants to optimize the profitability and growth of the Company through incentives that are consistent with the Company&#8217;s goals and that link the personal interests of Participants to those of the Company&#8217;s stockholders. The Plan provides for the grant of Options, Stock Appreciation Rights, Restricted Stock, Restricted Stock Units and Other Stock-Based Awards and for Incentive Bonuses, which may be paid in cash, Common Stock or a combination thereof, as determined by the Committee.</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:-36pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">2.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Definitions</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:-36pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">As used in the Plan, the following terms shall have the meanings set forth below:</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>&#8220;</span><span class="BoldItalic" style="font-style:italic;font-weight:bold;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Act</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the Securities Exchange Act of 1934, as amended.</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>&#8220;</span><span class="BoldItalic" style="font-style:italic;font-weight:bold;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Affiliate</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any entity in which the Company has a substantial direct or indirect equity interest, as determined by the Committee from time to time.</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>&#8220;</span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Award</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means an Option, Stock Appreciation Right, Restricted Stock, Restricted Stock Unit, Other Stock-Based Award or Incentive Bonus, or any combination of these, granted to a Participant pursuant to the provisions of the Plan, any of which may be subject to performance conditions.</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>&#8220;</span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Award Agreement</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means a written or electronic agreement or other instrument as may be approved from time to time by the Committee and designated as such implementing the grant of each Award. An Award Agreement may be in the form of an agreement to be executed by both the Participant and the Company (or an authorized representative of the Company) or certificates, notices or similar instruments as approved by the Committee and designated as such.</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(e)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>&#8220;</span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Beneficial Owner</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; shall have the meaning set forth in Rule 13d-3 under the Act.</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(f)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>&#8220;</span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Board</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the Board of Directors of the Company.</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(g)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>&#8220;</span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Cause</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; has the meaning set forth in the written employment, offer, services or severance agreement or letter between the Participant and the Company or an Affiliate, or in any severance plan in which the Participant participates, or if there is no such agreement or plan or no such term is defined in such agreement or plan, means a Participant&#8217;s (i) dishonest statements or acts with respect to the Company or any Affiliate, or any current or prospective customers, suppliers, vendors or other third parties with which such entity does business that results in or is reasonably anticipated to result in material harm to the Company; (ii) conviction or plea of guilty or no contest to: (A) a felony or (B) any misdemeanor involving moral turpitude, deceit, dishonesty or fraud; (iii) failure to perform in all material respects the Participant&#8217;s assigned duties and responsibilities; (iv) gross negligence, willful misconduct that results in or is reasonably anticipated to result in material harm to the Company; (v) violation of any material provision of any agreement(s) between the Participant and the Company; or (vi) material violation of any written Company policies.</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(h)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>&#8220;</span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Change in Control</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means, except as otherwise provided in an Award Agreement, the occurrence of any one of the following events:</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-left:24pt;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(i)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>any Person is or becomes the Beneficial Owner, directly or indirectly, of securities of the Company (not including the securities beneficially owned by such Person or any securities acquired directly from the Company or its Affiliates) representing 50% or more of the combined voting power of the Company&#8217;s then outstanding securities, excluding any Person who becomes such a Beneficial Owner in connection with a transaction described in </span><span class="CharOverride-8" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 2(h)(iii)(A)</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> below;</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-left:24pt;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex K-1</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-left:24pt;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(ii)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>the following individuals cease for any reason to constitute a majority of the number of directors then serving: (A) individuals who, on the Effective Date (as defined below), constitute the Board and (B)&#160;any new director (other than a director whose initial assumption of office is in connection with an actual or threatened election contest, including a consent solicitation, relating to the election of directors of the Company) whose appointment or election by the Board or nomination for election by the Company&#8217;s stockholders was approved or recommended by a vote of at least a majority of the directors then still in office who were either directors on the Effective Date or whose appointment, election or nomination for election was previously so approved or recommended;</span></p>
		<p class="ParaOverride-7" style="margin:0;padding:0;border-width:0;margin-left:24pt;margin-top:7pt;orphans:2;text-indent:24pt;widows:2;margin-top:7pt;"><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(iii)<span style="width: 10px;display: inline-block;">&#160;&#160;&#160;</span>there is consummated a merger or consolidation of the Company or any direct or indirect subsidiary of the Company with any other entity, other than (A) a merger or consolidation which would result in the holders of the voting securities of the Company outstanding immediately prior to such merger or consolidation continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or any parent thereof) at least 50% of the combined voting power of the securities of the Company or such surviving entity or any parent thereof outstanding immediately after such merger or consolidation;</span></p>
		<p class="ParaOverride-7" style="margin:0;padding:0;border-width:0;margin-left:24pt;margin-top:7pt;orphans:2;text-indent:24pt;widows:2;margin-top:7pt;"><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(iv)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>the implementation of a plan of complete liquidation or dissolution of the Company; or</span></p>
		<p class="ParaOverride-7" style="margin:0;padding:0;border-width:0;margin-left:24pt;margin-top:7pt;orphans:2;text-indent:24pt;widows:2;margin-top:7pt;"><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(v)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>there is consummated a sale or disposition by the Company of all or substantially all of the Company&#8217;s assets, other than a sale or disposition by the Company of all or substantially all of the Company&#8217;s assets to an entity, at least 50% of the combined voting power of the voting securities of which is owned by stockholders of the Company in substantially the same proportions as their ownership of the Company immediately prior to such sale.</span></p>
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:7pt;orphans:2;text-indent:24pt;widows:2;margin-top:7pt;"><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(i)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>&#8220;</span><span class="BoldItalic" style="font-style:italic;font-weight:bold;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Code</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the Internal Revenue Code of 1986, as amended from time to time, and the rulings and regulations issued thereunder.</span></p>
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:7pt;orphans:2;text-indent:24pt;widows:2;margin-top:7pt;"><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(j)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>&#8220;</span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Committee</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the Compensation Committee of the Board (or any successor committee) or such other committee as designated by the Board to administer the Plan under </span><span class="CharOverride-8" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 6</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:7pt;orphans:2;text-indent:24pt;widows:2;margin-top:7pt;"><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(k)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>&#8220;</span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Common Stock</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the common stock of the Company, $0.001 par value per share, or such other class or kind of shares or other securities as may be applicable under </span><span class="CharOverride-8" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 16</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:7pt;orphans:2;text-indent:24pt;widows:2;margin-top:7pt;"><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(l)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>&#8220;</span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Company</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means Oruka Therapeutics, Inc., a Delaware corporation, and except as utilized in the definition of Change in Control, any successor corporation.</span></p>
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:7pt;orphans:2;text-indent:24pt;widows:2;margin-top:7pt;"><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(m)<span style="width: 10px;display: inline-block;">&#160;&#160;&#160;</span>&#8220;</span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Disability</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; has the meaning set forth in a written employment, offer, services or severance agreement or letter between the Participant and the Company or an Affiliate, or in any severance plan in which the Participant participates, or if there is no such agreement or plan or no such term is defined in such agreement or plan, means the inability of the Participant to engage in any substantial gainful activity by reason of any medically determinable physical or mental impairment. A determination of Disability shall be made by the Committee on the basis of such medical evidence as the Committee deems warranted under the circumstances, and in this respect, Participants shall submit to an examination by a physician upon request by the Committee.</span></p>
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:7pt;orphans:2;text-indent:24pt;widows:2;margin-top:7pt;"><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(n)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>&#8220;</span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Dividend Equivalent</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means an amount payable in cash or Common Stock, as determined by the Committee, equal to the dividends that would have been paid to the Participant if the share of Common Stock with respect to which the Dividend Equivalent relates had been owned by the Participant.</span></p>
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:7pt;orphans:2;text-indent:24pt;widows:2;margin-top:7pt;"><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(o)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>&#8220;</span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Effective Date</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the date on which the Plan takes effect, as defined pursuant to </span><span class="CharOverride-8" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 4</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:7pt;orphans:2;text-indent:24pt;widows:2;margin-top:7pt;"><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(p)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>&#8220;</span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Eligible Person</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; any current or prospective employee, officer, non-employee director or other individual service provider of the Company or any Subsidiary; </span><span class="CharOverride-9" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">provided, however</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that Incentive Stock Options may only be granted to employees of the Company or any of its &#8220;subsidiary corporations&#8221; within the meaning of Section 424 of the Code.</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(q)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>&#8220;</span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Fair Market Value</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means as of any date, the value of the Common Stock determined as follows: (i)&#160;if the Common Stock is listed on any established stock exchange, system or market, its Fair Market Value shall be the closing price of a share of Common Stock as quoted on such exchange, system or market as reported in the Wall Street Journal or such other source as the Committee deems reliable (or, if no sale of Common Stock is reported for such date, on the next preceding date on which any sale shall have been reported); and (ii) in the absence of an </span></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex K-2</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">established market for the Common Stock, the Fair Market Value thereof shall be determined in good faith by the Committee by the reasonable application of a reasonable valuation method, taking into account factors consistent with Treas. Reg. &#167; 409A-1(b)(5)(iv)(B) as the Committee deems appropriate.</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(r)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>&#8220;</span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Incentive Bonus</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means a bonus opportunity awarded under </span><span class="CharOverride-8" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 12</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> pursuant to which a Participant may become entitled to receive an amount based on satisfaction of such performance criteria established for a specified performance period as specified in the Award Agreement.</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(s)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>&#8220;</span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Incentive Stock Option</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means an Option that is intended to qualify as an &#8220;incentive stock option&#8221; within the meaning of Section 422 of the Code.</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(t)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>&#8220;</span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Merger Agreement</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means that Agreement and Plan of Merger and Reorganization dated April 3, 2024 by and between the Company (f/k/a ARCA biopharma, Inc.) and Oruka Therapeutics Operating Company, LLC (f/k/a Oruka Therapeutics, Inc.).</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(u)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>&#8220;</span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Nonqualified Stock Option</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means an Option that is not intended to qualify as an &#8220;incentive stock option&#8221; within the meaning of Section 422 of the Code.</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(v)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>&#8220;</span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Option</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means a right to purchase a number of shares of Common Stock at such exercise price, at such times and on such other terms and conditions as are specified in or determined pursuant to an Award Agreement. Options granted pursuant to the Plan may be Incentive Stock Options or Nonqualified Stock Options.</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(w)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>&#8220;</span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Other Stock-Based Award</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means an Award granted to an Eligible Person under </span><span class="CharOverride-8" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 11</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(x)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>&#8220;</span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Outstanding Common Stock</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the sum of (i) the shares of Common Stock outstanding, (ii)&#160;the shares of Common Stock underlying unexercised pre-funded warrants, and (iii) the shares of Common Stock underlying the Company&#8217;s preferred stock, par value $<span style="width: 10px;display: inline-block;">&#160;&#160;&#160;</span><span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>(determined on an as-converted basis without regard to any limitations on such conversation).</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(y)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>&#8220;</span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Participant</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any Eligible Person to whom Awards have been granted from time to time by the Committee and any authorized transferee of such individual.</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:7.5pt;"><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(z)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>&#8220;</span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Person</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; shall have the meaning given in Section 3(a)(9) of the Act, as modified and used in </span><span class="CharOverride-8" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Sections&#160;14(d)</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and </span><span class="CharOverride-8" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">15(d)</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> thereof, except that such term shall not include (i) the Company or any of its Affiliates, (ii) a trustee or other fiduciary holding securities under an employee benefit plan of the Company or any of its Subsidiaries, (iii) an underwriter temporarily holding securities pursuant to an offering of such securities or (iv) a corporation owned, directly or indirectly, by the stockholders of the Company in substantially the same proportions as their ownership of stock of the Company.</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:7.5pt;"><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(aa)<span style="width: 10px;display: inline-block;">&#160;&#160;&#160;</span>&#8220;</span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Restricted Stock</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means an Award or issuance of Common Stock the grant, issuance, vesting and/or transferability of which is subject during specified periods of time to such conditions (including continued employment or engagement or performance conditions) and terms as the Committee deems appropriate.</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:7.5pt;"><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(bb)&#160;&#160;&#8220;</span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Restricted Stock Unit</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means an Award denominated in units of Common Stock under which the issuance of shares of such Common Stock (or cash payment in lieu thereof) is subject to such conditions (including continued employment or engagement or performance conditions) and terms as the Committee deems appropriate.</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:7.5pt;"><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(cc)<span style="width: 10px;display: inline-block;">&#160;&#160;&#160;</span>&#8220;</span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Separation from Service</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; or &#8220;</span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Separates from Service</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means a Termination of Employment that constitutes a &#8220;separation from service&#8221; within the meaning of Section 409A of the Code.</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:7.5pt;"><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(dd)&#160;&#160;&#8220;</span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Stock Appreciation Right</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; or &#8220;</span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">SAR</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means a right granted that entitles the Participant to receive, in cash or Common Stock or a combination thereof, as determined by the Committee, value equal to the excess of (i)&#160;the Fair Market Value of a specified number of shares of Common Stock at the time of exercise over (ii) the exercise price of the right, as established by the Committee on the date of grant.</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:7.5pt;"><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(ee)<span style="width: 10px;display: inline-block;">&#160;&#160;&#160;</span>&#8220;</span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Subsidiary</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any business association (including a corporation or a partnership, other than the Company) in an unbroken chain of such associations beginning with the Company if each of the associations other than the last association in the unbroken chain owns equity interests (including stock or partnership interests) possessing 50% or more of the total combined voting power of all classes of equity interests in one of the other associations in such chain.</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex K-3</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(ff)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>&#8220;</span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Substitute Awards</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means Awards granted or Common Stock issued by the Company in assumption of, or in substitution or exchange for, awards previously granted, or the right or obligation to make future awards, by a company acquired by the Company or any Subsidiary or with which the Company or any Subsidiary combines.</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(gg)&#160;&#160;&#8220;</span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Termination of Employment</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means ceasing to serve as an employee of the Company and its Subsidiaries or, with respect to a non-employee director or other service provider, ceasing to serve as such for the Company and its Subsidiaries, except that with respect to all or any Awards held by a Participant (i) the Committee may determine that a leave of absence (including as a result of a Participant&#8217;s short-term or long-term disability or other medical leave) or employment on a less than full-time basis is considered a &#8220;Termination of Employment,&#8221; (ii) the Committee may determine that a transition from employment to service with a partnership, joint venture or corporation not meeting the requirements of a Subsidiary in which the Company or a Subsidiary is a party is not considered a &#8220;Termination of Employment,&#8221; (iii) service as a member of the Board shall constitute continued service with respect to Awards granted to a Participant while he or she served as an employee, (iv) service as an employee of the Company or a Subsidiary shall constitute continued employment with respect to Awards granted to a Participant while he or she served as a member of the Board or other service provider, and (v) the Committee may determine that a transition from employment with the Company or a Subsidiary to service to the Company or a Subsidiary other than as an employee shall constitute a &#8220;Termination of Employment&#8221;. The Committee shall determine whether any corporate transaction, such as a sale or spin-off of a division or Subsidiary that employs or engages a Participant, shall be deemed to result in a Termination of Employment with the Company and its Subsidiaries for purposes of any affected Participant&#8217;s Awards, and the Committee&#8217;s decision shall be final and binding.</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:-36pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">3.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Eligibility</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Any Eligible Person is eligible for selection by the Committee to receive an Award.</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:-36pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">4.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Effective Date and Termination of Plan</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">This Plan became effective on the Closing Date (as defined in the Merger Agreement) (the&#160;&#8220;</span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Effective Date</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;). The Plan shall remain available for the grant of Awards until<span style="width: 10px;display: inline-block;">&#160;&#160;&#160;</span><span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>, 2034. Notwithstanding the foregoing, the Plan may be terminated at such earlier time as the Board may determine. Termination of the Plan will not affect the rights and obligations of the Participants and the Company arising under Awards theretofore granted.</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:-36pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">5.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Shares Subject to the Plan and to Awards</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-9" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">Aggregate Limits</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The aggregate number of shares of Common Stock issuable under the Plan shall be equal to (i)<span style="width: 10px;display: inline-block;">&#160;&#160;&#160;</span><span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>, </span><span class="CharOverride-9" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">plus</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> (ii) any shares of Common Stock added as a result of the following sentence (collectively, the &#8220;</span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Share Pool</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;). The Share Pool will automatically increase on January 1 of each year beginning in 2025 and ending with a final increase on January 1, 2034 in an amount equal to &#160;&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span> of the Outstanding Common Stock on the preceding December 31; </span><span class="CharOverride-9" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">provided, however</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that the Committee may provide that there will be no January 1 increase in the Share Pool for any such year or that the increase in the Share Pool for any such year will be a smaller number of shares of Common Stock than would otherwise occur pursuant to this sentence. The aggregate number of shares of Common Stock available for grant under this Plan and the number of shares of Common Stock subject to Awards outstanding at the time of any event described in </span><span class="CharOverride-8" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 16</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> shall be subject to adjustment as provided in </span><span class="CharOverride-8" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 16</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The shares of Common Stock issued under this Plan may be shares that are authorized and unissued or shares that were reacquired by the Company, including shares purchased in the open market or in private transactions.</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-9" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">Issuance of Shares</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. For purposes of </span><span class="CharOverride-8" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 5(a)</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, the aggregate number of shares of Common Stock issued under this Plan at any time shall equal only the number of shares of Common Stock actually issued upon exercise or settlement of an Award. Shares of Common Stock subject to Awards that have been canceled, expired, forfeited or otherwise not issued under an Award and shares of Common Stock subject to Awards settled in cash shall not count as shares of Common Stock issued under this Plan. The aggregate number of shares available for issuance under this Plan at any time shall not be reduced by (i) shares subject to Awards that have been terminated, expired unexercised, forfeited or settled in cash, (ii) shares subject to Awards that have been retained or withheld by the Company in payment or satisfaction of the exercise price, purchase price or tax withholding obligation of an Award, or (iii) shares subject to Awards that otherwise do not result in the issuance of shares in connection with payment or settlement thereof. In addition, shares that have been delivered (either actually or by attestation) to the Company in payment or satisfaction of the exercise price, purchase price or tax withholding obligation of an Award shall be available for issuance under this Plan.</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex K-4</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-9" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">Substitute Awards</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Substitute Awards shall not reduce the shares of Common Stock authorized for issuance under the Plan or authorized for grant to a Participant in any calendar year. Additionally, in the event that a company acquired by the Company or any Subsidiary, or with which the Company or any Subsidiary combines, has shares available under a pre-existing plan approved by stockholders and not adopted in contemplation of such acquisition or combination, the shares available for grant pursuant to the terms of such pre-existing plan (as adjusted, to the extent appropriate, using the exchange ratio or other adjustment or valuation ratio or formula used in such acquisition or combination to determine the consideration payable to the holders of common stock of the entities party to such acquisition or combination) may be used for Awards under the Plan and shall not reduce the shares of Common Stock authorized for issuance under the Plan; </span><span class="CharOverride-9" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">provided, however</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that Awards using such available shares (i) shall not be made after the date awards or grants could have been made under the terms of the pre-existing plan, absent the acquisition or combination, (ii) shall only be made to individuals who were not employees or service providers of the Company or its Affiliates at the time of such acquisition or combination, and (iii) shall comply with the requirements of any stock exchange or market or quotation system on which the Common Stock is traded, listed or quoted.</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-9" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">Tax Code Limits</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The aggregate number of shares of Common Stock that may be issued pursuant to the exercise of Incentive Stock Options granted under this Plan shall be equal to<span style="width: 10px;display: inline-block;">&#160;&#160;&#160;</span><span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>, which number shall be calculated and adjusted pursuant to </span><span class="CharOverride-8" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 16</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> only to the extent that such calculation or adjustment will not affect the status of any Option intended to qualify as an Incentive Stock Option under Section 422 of the Code.</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(e)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-9" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">Limits on Non-Employee Director Compensation.</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> The aggregate dollar value of equity-based (based on the grant date Fair Market Value of equity-based Awards) and cash compensation granted under this Plan or otherwise to any non-employee director shall not exceed $750,000 during any calendar year; </span><span class="CharOverride-9" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">provided, however</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that in the calendar year in which a non-employee director first joins the Board or during any calendar year in which a non-employee director is designated as Chairman of the Board or Lead Director, the maximum aggregate dollar value of equity-based and cash compensation granted to the non-employee director may be up to $1,000,000.</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:-36pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">6.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Administration of the Plan</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-9" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">Administrator of the Plan</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Plan shall be administered by the Committee. The Board shall fill vacancies on, and from time to time may remove or add members to, the Committee. The Committee shall act pursuant to a majority vote or unanimous written consent. Any power of the Committee may also be exercised by the Board, except to the extent that the grant or exercise of such authority would cause any Award or transaction to become subject to (or lose an exemption under) the short-swing profit recovery provisions of Section 16 of the Act. To the extent that any permitted action taken by the Board conflicts with action taken by the Committee, the Board action shall control. To the maximum extent permissible under applicable law, the Committee (or any successor) may by resolution delegate any or all of its authority to one or more subcommittees composed of one or more directors and/or officers of the Company, and any such subcommittee shall be treated as the Committee for all purposes under this Plan. Notwithstanding the foregoing, if the Board or the Committee (or any successor) delegates to a subcommittee comprised of one or more officers of the Company the authority to grant Awards, no such subcommittee shall designate any officer serving thereon or any officer (within the meaning of Section 16 of the Act) or non-employee director of the Company as a recipient of any Awards granted under such delegated authority. The Committee hereby delegates to and designates the [Senior Vice President] of the Company (or such other officer with similar authority), and to his or her delegates or designees, the authority to assist the Committee in the day-to-day administration of the Plan and of Awards granted under the Plan, including those powers set forth in </span><span class="CharOverride-8" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 6(b)(v)</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> through </span><span class="CharOverride-8" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">(xi)</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and to execute Award Agreements or other documents entered into under this Plan on behalf of the Committee or the Company. The Committee may further designate and delegate to one or more additional officers or employees of the Company or any Subsidiary, and/or one or more agents, authority to assist the Committee in any or all aspects of the day-to-day administration of the Plan and/or of Awards granted under the Plan.</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-9" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">Powers of Committee</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Subject to the express provisions of this Plan, the Committee shall be authorized and empowered to do all things that it determines to be necessary or appropriate in connection with the administration of this Plan, including:</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-left:24pt;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(i)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>to prescribe, amend and rescind rules and regulations relating to this Plan and to define terms not otherwise defined herein;</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-left:24pt;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(ii)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>to determine which Persons are Eligible Persons, to which of such Eligible Persons, if any, Awards shall be granted hereunder and the timing of any such Awards;</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-left:24pt;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex K-5</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-left:24pt;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(iii)<span style="width: 10px;display: inline-block;">&#160;&#160;&#160;</span>to prescribe and amend the terms of the Award Agreements, to grant Awards and determine the terms and conditions thereof;</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-left:24pt;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(iv)<span style="width: 10px;display: inline-block;">&#160;&#160;&#160;</span>to reduce the exercise price of a previously awarded Option or Stock Appreciation Right or cancel and re-grant or exchange such Option or Stock Appreciation Right for cash or a new Award with a lower (or no) exercise price with any such determination made by the Committee in its sole discretion, in each case, without stockholder approval;</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-left:24pt;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(v)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>to adopt such procedures and sub-plans as are necessary or appropriate (A) to permit or facilitate participation in this Plan by Eligible Persons who are not citizens of, or subject to taxation by, the United States or who are employed outside the United States or (B) to allow Awards to qualify for special tax treatment in a jurisdiction other than the United States; </span><span class="CharOverride-9" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">provided, however</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that Board approval will not be necessary for immaterial modifications to this Plan or any Award Agreement that are required for compliance with the laws of the relevant jurisdiction;</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-left:24pt;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(vi)<span style="width: 10px;display: inline-block;">&#160;&#160;&#160;</span>to establish and verify the extent of satisfaction of any performance goals or other conditions applicable to the grant, issuance, retention, vesting, exercisability or settlement of any Award;</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-left:24pt;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(vii)&#160;&#160;to prescribe and amend the terms of or form of any document or notice required to be delivered to the Company by Participants under this Plan;</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-left:24pt;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(viii)&#160;to determine the extent to which adjustments are required pursuant to Section 16;</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-left:24pt;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(ix)<span style="width: 10px;display: inline-block;">&#160;&#160;&#160;</span>to interpret and construe this Plan, any rules and regulations under this Plan and the terms and conditions of any Award granted hereunder, and to make exceptions to any such provisions if the Committee, in good faith, determines that it is appropriate to do so;</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-left:24pt;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(x)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>to approve corrections in the documentation or administration of any Award; and</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-left:24pt;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(xi)<span style="width: 10px;display: inline-block;">&#160;&#160;&#160;</span>to make all other determinations deemed necessary or advisable for the administration of this Plan.</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Notwithstanding anything in this Plan to the contrary, with respect to any Award that is &#8220;deferred compensation&#8221; under Section 409A of the Code, the Committee shall exercise its discretion in a manner that causes such Awards to be compliant with or exempt from the requirements of Section 409A of the Code. Without limiting the foregoing, unless expressly agreed to in writing by the Participant holding such Award, the Committee shall not take any action with respect to any Award which constitutes (x) a modification of a stock right within the meaning of Treas. Reg. &#167; 1.409A-1(b)(5)(v)(B) so as to constitute the grant of a new stock right, (y) an extension of a stock right, including the addition of a feature for the deferral of compensation within the meaning of Treas. Reg. &#167; 1.409A-1 (b)(5)(v)(C), or (z) an impermissible acceleration of a payment date or a subsequent deferral of a stock right subject to Section&#160;409A of the Code within the meaning of Treas. Reg. &#167; 1.409A-1(b)(5)(v)(E).</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">The Committee may, in its sole and absolute discretion, without amendment to the Plan but subject to the limitations otherwise set forth in </span><span class="CharOverride-11" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 20</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, waive or amend the operation of Plan provisions respecting exercise after Termination of Employment. The Committee or any member thereof may, in its sole and absolute discretion, except as otherwise provided in </span><span class="CharOverride-11" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 20</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, waive, settle or adjust any of the terms of any Award so as to avoid unanticipated consequences or address unanticipated events (including any temporary closure of an applicable stock exchange, disruption of communications or natural catastrophe).</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-9" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">Determinations by the Committee</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. All decisions, determinations and interpretations by the Committee regarding the Plan, any rules and regulations under the Plan, and the terms and conditions of, or operation of, any Award granted hereunder, shall be final and binding on all Participants, beneficiaries, heirs, assigns or other persons holding or claiming rights under the Plan or any Award. The Committee shall consider such factors as it deems relevant, in its sole and absolute discretion, to making such decisions, determinations and interpretations, including the recommendations or advice of any officer or other employee of the Company and such attorneys, consultants and accountants as it may select. Members of the Board and members of the Committee acting under the Plan shall be fully protected in relying in good faith upon the advice of counsel and shall incur no liability except for as a result of gross negligence or willful misconduct in the performance of their duties.</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex K-6</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-9" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">Subsidiary Awards</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. In the case of a grant of an Award to any Participant employed by a Subsidiary, such grant may, if the Committee so directs, be implemented by the Company issuing any subject shares of Common Stock to the Subsidiary, for such lawful consideration as the Committee may determine, upon the condition or understanding that the Subsidiary will transfer the shares of Common Stock to the Participant in accordance with the terms of the Award specified by the Committee pursuant to the provisions of the Plan. Notwithstanding any other provision hereof, such Award may be issued by and in the name of the Subsidiary and shall be deemed granted on such date as the Committee shall determine.</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:-36pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">7.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Plan Awards</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-9" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">Terms Set Forth in Award Agreement</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Awards may be granted to Eligible Persons as determined by the Committee at any time and from time to time prior to the termination of the Plan. The terms and conditions of each Award shall be set forth in an Award Agreement in a form approved by the Committee for such Award, subject to and incorporating by reference or otherwise the applicable terms and conditions of the Plan, which Award Agreement may contain such terms and conditions as specified from time to time by the Committee, provided such other terms and conditions do not conflict with the Plan. The Award Agreement for any Award (other than Restricted Stock Awards) shall include the time or times at or within which and the consideration, if any, for which any shares of Common Stock or cash, as applicable, may be acquired from the Company. The terms of Awards may vary among Participants, and the Plan does not impose upon the Committee any requirement to make Awards subject to uniform terms. Accordingly, the terms of individual Award Agreements may vary.</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-9" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">Termination of Employment</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Subject to the express provisions of the Plan, the Committee shall specify before, at, or after the time of grant of an Award the provisions governing the effect(s) upon an Award of a Participant&#8217;s Termination of Employment.</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-9" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">Rights of a Stockholder</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. A Participant shall have no rights as a stockholder with respect to shares of Common Stock covered by an Award (including voting rights) until the date the Participant becomes the holder of record of such shares of Common Stock. No adjustment shall be made for dividends or other rights for which the record date is prior to such date, except as provided in </span><span class="CharOverride-8" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Sections 10(b)</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-8" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">11(b)</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> or </span><span class="CharOverride-8" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">16</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of this Plan or as otherwise provided by the Committee.</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-9" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">No Fractional Shares</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. No fractional shares of Common Stock shall be issued pursuant to an Award or in settlement thereof.</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:-36pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">8.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Options</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-9" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">Grant, Term and Price</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The grant, issuance, retention, vesting and/or settlement of any Option shall occur at such time and be subject to such terms and conditions as determined by the Committee or under criteria established by the Committee, which may include conditions based on continued employment or engagement, passage of time, attainment of age and/or service requirements, and/or satisfaction of performance conditions. The term of an Option shall in no event be greater than 10 years; </span><span class="CharOverride-9" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">provided, however</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, the term of an Option (other than an Incentive Stock Option) shall be automatically extended if, at the time of its scheduled expiration, the Participant holding such Option is prohibited by law or the Company&#8217;s insider trading policy from exercising the Option, which extension shall expire on the 30</span><span class="CharOverride-12" style="font-family:Times New Roman PS Std, serif;font-size:6pt;font-style:normal;font-weight:normal;vertical-align:super;">th</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> day following the date such prohibition no longer applies. The Committee will establish the price at which Common Stock may be purchased upon exercise of an Option, which in no event will be less than the Fair Market Value of such shares on the date of grant; </span><span class="CharOverride-9" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">provided, however</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that the exercise price per share of Common Stock with respect to an Option that is granted as a Substitute Award may be less than the Fair Market Value of the shares of Common Stock on the date such Option is granted if such exercise price is based on a formula set forth in the terms of the options held by such optionees or in the terms of the agreement providing for such merger or other acquisition that satisfies the requirements of (i) Section 409A of the Code, if such options held by such optionees are not intended to qualify as &#8220;incentive stock options&#8221; within the meaning of Section 422 of the Code, and (ii) Section 424(a) of the Code, if such options held by such optionees are intended to qualify as &#8220;incentive stock options&#8221; within the meaning of Section 422 of the Code. The exercise price of any Option may be paid in cash to the Company or such other method as determined by the Committee, including an irrevocable commitment by a broker to pay over such amount from a sale of the shares of Common Stock issuable under an Option, the delivery of previously owned shares of Common Stock or withholding of shares of Common Stock otherwise deliverable upon exercise.</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex K-7</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-9" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">No Reload Grants</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Options shall not be granted under the Plan in consideration for, and shall not be conditioned upon the delivery of, shares of Common Stock to the Company in payment of the exercise price and/or tax withholding obligation under any other employee stock option.</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-9" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">Incentive Stock Options</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Notwithstanding anything to the contrary in this </span><span class="CharOverride-8" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 8</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, in the case of the grant of an Incentive Stock Option, if the Participant owns stock possessing more than 10% of the combined voting power of all classes of stock of the Company, the exercise price of such Option must be at least 110% of the Fair Market Value of the shares of Common Stock on the date of grant and the Option must expire within a period of not more than five years from the date of grant. Notwithstanding anything in this </span><span class="CharOverride-8" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 8</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> to the contrary, Options designated as Incentive Stock Options shall not be eligible for treatment under the Code as Incentive Stock Options (and will be deemed to be Nonqualified Stock Options) to the extent that either (i) the aggregate Fair Market Value of shares of Common Stock (determined as of the time of grant) with respect to which such Options are exercisable for the first time by the Participant during any calendar year (under all plans of the Company and any Subsidiary) exceeds $100,000, taking Options into account in the order in which they were granted, or (ii) such Options otherwise remain exercisable but are not exercised within three months (or such other period of time provided in Section 422 of the Code) of separation of service (as determined in accordance with Section 3401(c) of the Code and the regulations promulgated thereunder).</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-9" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">No Stockholder Rights</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Participants shall have no voting rights and will have no rights to receive dividends or Dividend Equivalents in respect of an Option or any shares of Common Stock subject to an Option until the Participant has become the holder of record of such shares.</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:-36pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">9.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Stock Appreciation Rights</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-9" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">General Terms</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The grant, issuance, retention, vesting and/or settlement of any Stock Appreciation Right shall occur at such time and be subject to such terms and conditions as determined by the Committee or under criteria established by the Committee, which may include conditions based on continued employment or engagement, passage of time, attainment of age and/or service requirements, and/or satisfaction of performance conditions. The term of a Stock Appreciation Right shall in no event be greater than 10 years; </span><span class="CharOverride-9" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">provided, however</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, the term of a Stock Appreciation Right shall be automatically extended if, at the time of its scheduled expiration, the Participant holding such Stock Appreciation Right is prohibited by law or the Company&#8217;s insider trading policy from exercising the Stock Appreciation Right which extension shall expire on the 30</span><span class="CharOverride-12" style="font-family:Times New Roman PS Std, serif;font-size:6pt;font-style:normal;font-weight:normal;vertical-align:super;">th</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> day following the date such prohibition no longer applies. Stock Appreciation Rights may be granted to Participants from time to time either in tandem with or as a component of Options granted under the Plan (&#8220;</span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">tandem SARs</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) or not in conjunction with other Awards (&#8220;</span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">freestanding SARs</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;). Upon exercise of a tandem SAR as to some or all of the shares covered by the grant, the related Option shall be canceled automatically to the extent of the number of shares covered by such exercise. Conversely, if the related Option is exercised as to some or all of the shares covered by the grant, the related tandem SAR, if any, shall be canceled automatically to the extent of the number of shares covered by the Option exercise. Any Stock Appreciation Right granted in tandem with an Option may be granted at the same time such Option is granted or at any time thereafter before exercise or expiration of such Option, provided that the Fair Market Value of Common Stock on the date of the SAR&#8217;s grant is not greater than the exercise price of the related Option. All freestanding SARs shall be granted subject to the same terms and conditions applicable to Options as set forth in </span><span class="CharOverride-8" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 8</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and all tandem SARs shall have the same exercise price as the Option to which they relate. Subject to the provisions of </span><span class="CharOverride-8" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 8</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and the immediately preceding sentence, the Committee may impose such other conditions or restrictions on any Stock Appreciation Right as it shall deem appropriate. Stock Appreciation Rights may be settled in Common Stock, cash, Restricted Stock or a combination thereof, as determined by the Committee and set forth in the applicable Award Agreement.</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-9" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">No Stockholder Rights</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Participants shall have no voting rights and will have no rights to receive dividends or Dividend Equivalents in respect of an Award of Stock Appreciation Rights or any shares of Common Stock subject to an Award of Stock Appreciation Rights until the Participant has become the holder of record of such shares.</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:-36pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">10.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Restricted Stock and Restricted Stock Units</span></p>
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:7pt;orphans:2;text-indent:24pt;widows:2;margin-top:7pt;"><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-9" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">Vesting and Performance Criteria</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The grant, issuance, vesting and/or settlement of any Award of Restricted Stock or Restricted Stock Units shall occur at such time and be subject to such terms and conditions as determined by the Committee or under criteria established by the Committee, which may include conditions based on continued employment or engagement, passage of time, attainment of age and/or service requirements, </span></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex K-8</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-9" style="margin:0;padding:0;border-width:0;margin-top:7pt;orphans:2;widows:2;margin-top:7pt;"><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">and/or satisfaction of performance conditions. In addition, the Committee shall have the right to grant Restricted Stock or Restricted Stock Unit Awards as the form of payment for grants or rights earned or due under other stockholder-approved compensation plans or arrangements of the Company.</span></p>
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:7pt;orphans:2;text-indent:24pt;widows:2;margin-top:7pt;"><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-9" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">Dividends and Distributions</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Participants in whose name Restricted Stock is granted shall be entitled to receive all dividends and other distributions paid with respect to those shares of Common Stock, unless determined otherwise by the Committee. The Committee will determine whether any such dividends or distributions will be automatically reinvested in additional shares of Restricted Stock and/or subject to the same restrictions on transferability as the Restricted Stock with respect to which they were distributed or whether such dividends or distributions will be paid in cash. Shares underlying Restricted Stock Units shall be entitled to dividends or distributions only to the extent provided by the Committee.</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:-36pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">11.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Other Stock-Based Awards</span></p>
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:7pt;orphans:2;text-indent:24pt;widows:2;margin-top:7pt;"><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-9" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">General Terms. </span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">The Committee is authorized, subject to limitations under applicable law, to grant to Eligible Persons such other Awards that may be denominated or payable in, valued in whole or in part by reference to, or otherwise based on, or related to, Common Stock, as deemed by the Committee to be consistent with the purposes of the Plan. The Committee shall determine the terms and conditions of such Other Stock-Based Awards. Common Stock delivered pursuant to an Other Stock-Based Award in the nature of a purchase right granted under this </span><span class="CharOverride-8" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 11</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> shall be purchased for such consideration, paid for at such times, by such methods, and in such forms, including cash, Common Stock, other Awards, or other property, as the Committee shall determine.</span></p>
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:7pt;orphans:2;text-indent:24pt;widows:2;margin-top:7pt;"><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-9" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">Dividends and Distributions</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Shares underlying Other Stock-Based Awards shall be entitled to dividends or distributions only to the extent provided by the Committee.</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:-36pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">12.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Incentive Bonuses</span></p>
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:7pt;orphans:2;text-indent:24pt;widows:2;margin-top:7pt;"><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-9" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">Vesting Criteria</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Committee shall establish the vesting conditions applicable to an Incentive Bonus, including any performance criteria and level of achievement versus such criteria that may determine the amount payable under an Incentive Bonus, which may include a target, threshold and/or maximum amount payable and any formula for determining such achievement.</span></p>
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:7pt;orphans:2;text-indent:24pt;widows:2;margin-top:7pt;"><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-9" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">Timing and Form of Payment</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Committee shall determine the timing of payment of any Incentive Bonus. Payment of the amount due under an Incentive Bonus may be made in cash or in Common Stock, as determined by the Committee.</span></p>
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:7pt;orphans:2;text-indent:24pt;widows:2;margin-top:7pt;"><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-9" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">Discretionary Adjustments</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Notwithstanding satisfaction of any performance goals, the amount paid under an Incentive Bonus on may be adjusted by the Committee on the basis of such further considerations as the Committee shall determine.</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:-36pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">13.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Performance Awards</span></p>
		<p class="ParaOverride-9" style="margin:0;padding:0;border-width:0;margin-top:7pt;orphans:2;widows:2;margin-top:7pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">The Committee may establish performance criteria and level of achievement versus such criteria that shall determine the number of shares of Common Stock, Restricted Stock Units, Other Stock-Based Awards or cash to be granted, retained, vested, issued or issuable under or in settlement of or the amount payable pursuant to an Award (any such Award, a &#8220;</span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Performance Award</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;). A Performance Award may be identified as &#8220;Performance Share,&#8221; &#8220;Performance Equity,&#8221; &#8220;Performance Unit&#8221; or other such term as chosen by the Committee.</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:-36pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">14.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Deferral of Payment</span></p>
		<p class="ParaOverride-9" style="margin:0;padding:0;border-width:0;margin-top:7pt;orphans:2;widows:2;margin-top:7pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">The Committee may, in an Award Agreement or otherwise, provide for the deferred delivery of Common Stock or cash upon settlement, vesting or other events with respect to Restricted Stock Units, Other Stock-Based Awards or in payment or satisfaction of an Incentive Bonus. Notwithstanding anything herein to the contrary, in no event will any election to defer the delivery of Common Stock or any other payment with respect to any Award be allowed if the Committee determines, in its sole discretion, that the deferral would result in the imposition of the additional tax under Section 409A(a)(1)(B) of the Code. No Award shall provide for deferral of compensation that does not comply with Section 409A of the Code. The Company, any Subsidiary or Affiliate which is in existence or hereafter comes into existence, the Board and the Committee shall have no liability to a Participant, or any other party, if an Award that is intended to be exempt from, or compliant with, Section 409A of the Code is not so exempt or compliant or for any action taken by the Board or the Committee in respect thereof.</span></p>
		<p class="ParaOverride-9" style="margin:0;padding:0;border-width:0;margin-top:7pt;orphans:2;widows:2;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex K-9</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:-36pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">15.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Conditions and Restrictions Upon Securities Subject to Awards</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">The Committee may provide that the Common Stock issued upon exercise of an Option or Stock Appreciation Right or otherwise subject to or issued under an Award shall be subject to such further agreements, restrictions, conditions or limitations as the Committee in its discretion may specify prior to the exercise of such Option or Stock Appreciation Right or the grant, vesting or settlement of such Award, including conditions on vesting or transferability, forfeiture or repurchase provisions and method of payment for the Common Stock issued upon exercise, vesting or settlement of such Award (including the actual or constructive surrender of Common Stock already owned by the Participant) or payment of taxes arising in connection with an Award. Without limiting the foregoing, such restrictions may address the timing and manner of any resales by the Participant or other subsequent transfers by the Participant of any shares of Common Stock issued under an Award, including (a) restrictions under an insider trading policy or pursuant to applicable law, (b) restrictions designed to delay and/or coordinate the timing and manner of sales by the Participant and holders of other Company equity compensation arrangements, (c) restrictions as to the use of a specified brokerage firm for such resales or other transfers and (d) provisions requiring Common Stock be sold on the open market or to the Company in order to satisfy tax withholding or other obligations.</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:-36pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">16.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Adjustment of and Changes in the Stock</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>The number and kind of shares of Common Stock available for issuance under this Plan (including under any Awards then outstanding), and the number and kind of shares of Common Stock subject to the limits set forth in </span><span class="CharOverride-8" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 5</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, shall be equitably adjusted by the Committee to reflect any reorganization, reclassification, combination of shares, stock split, reverse stock split, spin-off, dividend or distribution of securities, property or cash (other than regular, quarterly cash dividends), or any other event or transaction that affects the number or kind of shares of Outstanding Common Stock. Such adjustment may be designed to comply with Section 424 of the Code or may be designed to treat the shares of Common Stock available under the Plan and subject to Awards as if they were all outstanding on the record date for such event or transaction or to increase the number of such shares of Common Stock to reflect a deemed reinvestment in shares of Common Stock of the amount distributed to the Company&#8217;s securityholders. The terms of any outstanding Award shall also be equitably adjusted by the Committee as to price, number or kind of shares of Common Stock subject to such Award, vesting, performance criteria, and other terms to reflect the foregoing events, which adjustments need not be uniform as between different Awards or different types of Awards. No fractional shares of Common Stock shall be issued or issuable pursuant to such an adjustment.</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>In the event there shall be any other change in the number or kind of outstanding shares of Common Stock, or any stock or other securities into which such Common Stock shall have been changed, or for which it shall have been exchanged, by reason of a Change in Control, other merger, consolidation or otherwise, then the Committee shall determine the appropriate and equitable adjustment to be effected, which adjustments need not be uniform between different Awards or different types of Awards. In addition, in the event of such change described in this paragraph, the Committee may accelerate the time or times at which any Award may be exercised, consistent with and as otherwise permitted under Section 409A of the Code, and may provide for cancellation of such accelerated Awards that are not exercised within a time prescribed by the Committee in its sole discretion.</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>In the event of a Change in Control, the Committee, acting in its sole discretion without the consent or approval of any Participant, may take one or more of the following actions, which may vary among individual Participants and/or among Awards held by any individual Participant: (i) arrange for the assumption of an outstanding Award by the successor or acquiring entity (if any) of such Change in Control (or by its parents, if any), which assumption will be binding on all selected Participants; provided that the exercise price and the number and nature of shares issuable upon exercise of any such Option or Stock Appreciation Right, or any Award that is subject to Section 409A of the Code, will be adjusted appropriately pursuant to Section 424(a) of the Code; (ii) provide for the issuance of substitute awards by the successor or acquiring entity (if any) of such Change in Control (or by its parents, if any) that will substantially preserve the otherwise applicable terms of the outstanding Award as determined by the Committee in its sole discretion; (iii) accelerate vesting or waive any forfeiture conditions; (iv)&#160;accelerate the time of exercisability of an Award so that such Award may be exercised in full or in part for a limited period of time on or before a date specified by the Committee, after which specified date all unexercised Awards and all rights of Participants thereunder shall terminate; or (v) make such other adjustments to Awards then outstanding as the Committee deems appropriate to reflect such Change in Control. Notwithstanding anything herein to the contrary, in the event of a Change in Control in which the acquiring or surviving company </span></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex K-10</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">in the transaction does not assume or continue outstanding Awards or issue substitute awards upon the Change in Control, unless determined otherwise by the Committee, immediately prior to the Change in Control, all Awards that are not assumed, continued or substituted for shall be treated as follows effective immediately prior to the Change in Control: (A) in the case of an Option or Stock Appreciation Right, the Participant shall have the ability to exercise such Option or Stock Appreciation Right, including any portion of the Option or Stock Appreciation Right not previously exercisable, (B) in the case of any Award the vesting of which is in whole or in part subject to performance criteria or an Incentive Bonus, all conditions to the grant, issuance, retention, vesting or transferability of, or any other restrictions applicable to, such Award shall immediately lapse and the Participant shall have the right to receive a payment based on target level achievement or actual performance through a date determined by the Committee, and (C) in the case of outstanding Restricted Stock, Restricted Stock Units or Other Stock-Based Awards (other than those referenced in subsection (B)), all conditions to the grant, issuance, retention, vesting or transferability of, or any other restrictions applicable to, such Award shall immediately lapse. In no event shall any action be taken pursuant to this </span><span class="CharOverride-8" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 16(c)</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> that would change the payment or settlement date of an Award in a manner that would result in the imposition of any additional taxes or penalties pursuant to Section 409A of the Code.</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Notwithstanding anything in this </span><span class="CharOverride-8" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 16</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> to the contrary, in the event of a Change in Control, the Committee may provide for the cancellation and cash settlement of all outstanding Awards upon such Change in Control (including the cancellation for no consideration of any Option or Stock Appreciation Right with an exercise price that equals or exceeds the per share consideration in such transaction).</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(e)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>Notwithstanding anything in this </span><span class="CharOverride-8" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 16</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> to the contrary, an adjustment to an Option or Stock Appreciation Right under this </span><span class="CharOverride-8" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 16</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> shall be made in a manner that will not result in the grant of a new Option or Stock Appreciation Right under Section 409A of the Code.</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:-36pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">17.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Transferability</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Each Award may not be sold, transferred for value, pledged, assigned, or otherwise alienated or hypothecated by a Participant other than by will or the laws of descent and distribution, and each Option or Stock Appreciation Right shall be exercisable only by the Participant during his or her lifetime. Notwithstanding the foregoing, (a) outstanding Options may be exercised following the Participant&#8217;s death by the Participant&#8217;s beneficiaries or as permitted by the Committee and (b) as permitted by the Committee, a Participant may transfer or assign an Award as a gift to any &#8220;family member&#8221; (as such term is defined in the Registration Statement on Form S-8) (an &#8220;</span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Assignee Entity</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), provided that such Assignee Entity shall be entitled to exercise assigned Options and Stock Appreciation Rights only during the lifetime of the assigning Participant (or following the assigning Participant&#8217;s death, by the Participant&#8217;s beneficiaries or as otherwise permitted by the Committee) and provided further that such Assignee Entity shall not further sell, pledge, transfer, assign or otherwise alienate or hypothecate such Award.</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:-36pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">18.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Compliance with Laws and Regulations</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>This Plan, the grant, issuance, vesting, exercise and settlement of Awards hereunder, and the obligation of the Company to sell, issue or deliver shares of Common Stock under such Awards, shall be subject to all applicable foreign, federal, state and local laws, rules and regulations, stock exchange rules and regulations, and to such approvals by any governmental or regulatory agency as may be required. The Company shall not be required to register in a Participant&#8217;s name or deliver Common Stock prior to the completion of any registration or qualification of such shares under any foreign, federal, state or local law or any ruling or regulation of any government body which the Committee shall determine to be necessary or advisable. To the extent the Company is unable to or the Committee deems it infeasible to obtain authority from any regulatory body having jurisdiction, which authority is deemed by the Company&#8217;s counsel to be necessary to the lawful issuance and sale of any shares of Common Stock hereunder, the Company and its Subsidiaries shall be relieved of any liability with respect to the failure to issue or sell such shares of Common Stock as to which such requisite authority shall not have been obtained. No Option shall be exercisable and no Common Stock shall be issued and/or transferable under any other Award unless a registration statement with respect to the Common Stock underlying such Option is effective and current or the Company has determined, in its sole and absolute discretion, that such registration is unnecessary.</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex K-11</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>In the event an Award is granted to or held by a Participant who is employed or providing services outside the United States, the Committee may, in its sole discretion, modify the provisions of the Plan or of such Award as they pertain to such individual to comply with applicable foreign law or to recognize differences in local law, currency or tax policy. The Committee may also impose conditions on the grant, issuance, exercise, vesting, settlement or retention of Awards in order to comply with such foreign law and/or to minimize the Company&#8217;s obligations with respect to tax equalization for Participants employed outside their home country.</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:-36pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">19.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Withholding</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">To the extent required by applicable federal, state, local or foreign law, the Committee may, and/or a Participant shall, make arrangements satisfactory to the Company for the satisfaction of any withholding tax obligations that arise with respect to any Award or the issuance or sale of any shares of Common Stock. The Company shall not be required to recognize any Participant rights under an Award, to issue shares of Common Stock or to recognize the disposition of such shares of Common Stock until such obligations are satisfied. To the extent permitted or required by the Committee, these obligations may or shall be satisfied by the Company withholding cash from any compensation otherwise payable to or for the benefit of a Participant, the Company withholding a portion of the shares of Common Stock that otherwise would be issued to a Participant under such Award or any other Award held by the Participant, or by the Participant tendering to the Company cash or, if allowed by the Committee, shares of Common Stock.</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:-36pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">20.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Amendment of the Plan or Awards</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">The Board may amend, alter, suspend or terminate this Plan, and the Committee may amend or alter any Award Agreement or other document evidencing an Award made under this Plan; however, except as provided pursuant to the provisions of </span><span class="CharOverride-11" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 16</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, no such amendment shall, without the approval of the stockholders of the Company:</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>increase the maximum number of shares of Common Stock for which Awards may be granted under this Plan;</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>extend the term of this Plan;</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>change the class of Persons eligible to be Participants; or</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>otherwise amend the Plan in any manner requiring stockholder approval by law or the rules of any stock exchange or market or quotation system on which the Common Stock is traded, listed or quoted.</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">No amendment or alteration to the Plan or an Award or Award Agreement shall be made which would materially impair the rights of the holder of an Award without such holder&#8217;s consent; </span><span class="CharOverride-14" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">provided</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-14" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">however</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that no such consent shall be required if the Committee determines in its sole discretion and prior to the date of any Change in Control that such amendment or alteration either (i) is required or advisable in order for the Company, the Plan or the Award to satisfy any law or regulation or to meet the requirements of, or avoid adverse financial accounting consequences under, any accounting standard, or (ii) is not reasonably likely to significantly diminish the benefits provided under such Award, or that any such diminishment has been adequately compensated.</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:-36pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">21.<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>No Liability of Company</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">The Company, any Subsidiary or Affiliate which is in existence or hereafter comes into existence, the Board, the Committee and any delegate thereof shall not be liable to a Participant or any other person as to: (a) the non-issuance or sale of shares of Common Stock as to which the Company has been unable to obtain from any regulatory body having jurisdiction the authority deemed by the Company&#8217;s counsel to be necessary to the lawful issuance and sale of any shares of Common Stock hereunder; and (b) any tax consequence expected, but not realized, by any Participant or other person due to the receipt, vesting, exercise or settlement of any Award granted hereunder.</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:-36pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">22.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Non-Exclusivity of Plan</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Neither the adoption of this Plan by the Board nor the submission of this Plan to the stockholders of the Company for approval shall be construed as creating any limitations on the power of the Board or the Committee to adopt such other incentive arrangements as either may deem desirable, including the granting of equity awards otherwise than under this Plan, and such arrangements may be either generally applicable or applicable only in specific cases.</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex K-12</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:-36pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">23.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Governing Law</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">This Plan and any agreements or other documents hereunder shall be interpreted and construed in accordance with the laws of the State of Delaware and applicable federal law. Any reference in this Plan or in the agreement or other document evidencing any Awards to a provision of law or to a rule or regulation shall be deemed to include any successor law, rule or regulation of similar effect or applicability.</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:-36pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">24.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>No Right to Employment, Reelection or Continued Service</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Nothing in this Plan or an Award Agreement shall interfere with or limit in any way the right of the Company, its Subsidiaries and/or its Affiliates to terminate any Participant&#8217;s employment, service on the Board or service at any time or for any reason not prohibited by law, nor shall this Plan or an Award itself confer upon any Participant any right to continue his or her employment or service for any specified period of time. Neither an Award nor any benefits arising under this Plan shall constitute an employment contract with the Company, any Subsidiary and/or its Affiliates. Subject to </span><span class="CharOverride-11" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Sections 4</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and </span><span class="CharOverride-11" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">20</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, this Plan and the benefits hereunder may be terminated at any time in the sole and exclusive discretion of the Board without giving rise to any liability on the part of the Company, its Subsidiaries and/or its Affiliates.</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:-36pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">25.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Specified Employee Delay</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">To the extent any payment under this Plan is considered deferred compensation subject to the restrictions contained in Section 409A of the Code, such payment may not be made to a specified employee (as determined in accordance with a uniform policy adopted by the Company with respect to all arrangements subject to Section 409A of the Code) upon Separation from Service before the date that is six months after the specified employee&#8217;s Separation from Service (or, if earlier, the specified employee&#8217;s death). Any payment that would otherwise be made during this period of delay shall be accumulated and paid on the sixth month plus one day following the specified employee&#8217;s Separation from Service (or, if earlier, as soon as administratively practicable after the specified employee&#8217;s death).</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:-36pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">26.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>No Liability of Committee Members</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">No member of the Committee shall be personally liable by reason of any contract or other instrument executed by such member or on his or her behalf in his or her capacity as a member of the Committee nor for any mistake of judgment made in good faith, and the Company shall indemnify and hold harmless each member of the Committee and each other employee, officer or director of the Company to whom any duty or power relating to the administration or interpretation of the Plan may be allocated or delegated, against any cost or expense (including counsel fees) or liability (including any sum paid in settlement of a claim) arising out of any act or omission to act in connection with the Plan, unless arising out of such Person&#8217;s own fraud or willful bad faith; </span><span class="CharOverride-14" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">provided, however</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that approval of the Board shall be required for the payment of any amount in settlement of a claim against any such Person. The foregoing right of indemnification shall not be exclusive of any other rights of indemnification to which such Persons may be entitled under the Company&#8217;s Certificate of Incorporation and Bylaws (as each may be amended from time to time), as a matter of law, pursuant to any individual agreement or otherwise, or any power that the Company may have to indemnify them or hold them harmless.</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:-36pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">27.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Severability</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">If any provision of the Plan or any Award is or becomes or is deemed to be invalid, illegal, or unenforceable in any jurisdiction or as to any Person or Award, or would disqualify the Plan or any Award under any law deemed applicable by the Committee, such provision shall be construed or deemed amended to conform to the applicable laws, or if it cannot be construed or deemed amended without, in the determination of the Committee, materially altering the intent of the Plan or the Award, such provision shall be stricken as to such jurisdiction, Person or Award, and the remainder of the Plan and any such Award shall remain in full force and effect.</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:-36pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">28.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Unfunded Plan</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">The Plan is intended to be an unfunded plan. Participants are and shall at all times be general creditors of the Company with respect to their Awards. If the Committee or the Company chooses to set aside funds in a trust or otherwise for the payment of Awards under the Plan, such funds shall at all times be subject to the claims of the creditors of the Company in the event of its bankruptcy or insolvency.</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex K-13</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:-36pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">29.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Clawback/Recoupment</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Awards granted under this Plan will be subject to recoupment in accordance with any clawback policy that the Company adopts or is required to adopt pursuant to the listing standards of any national securities exchange or association on which the Company&#8217;s securities are listed or as is otherwise required by the Rule 10D-1 under the Exchange Act or other applicable law. In addition, the Committee may impose such other clawback, recovery or recoupment provisions in an Award Agreement as the Committee determines necessary or appropriate, including a reacquisition right in respect of previously acquired shares of Common Stock or other cash or property upon the occurrence of misconduct. No recovery of compensation under such a clawback policy will be an event giving rise to a right to resign for &#8220;good reason&#8221; or be deemed a &#8220;constructive termination&#8221; (or any similar term) as such terms are used in any agreement between any Participant and the Company.</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:-36pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">30.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Beneficiary Designation</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Participants may designate beneficiaries with respect to Awards under the Plan in accordance with the procedures determined by the Committee. In the absence of a beneficiary designation, a Participant&#8217;s estate will be the deemed beneficiary.</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:-36pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">31.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Interpretation</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Headings are given to the Sections and subsections of the Plan solely as a convenience to facilitate reference and shall not be deemed in any way material or relevant to the construction or interpretation of the Plan or any provision thereof. Words in the masculine gender shall include the feminine gender, and where appropriate, the plural shall include the singular and the singular shall include the plural. The use herein of the word &#8220;including&#8221; following any general statement, term or matter shall not be construed to limit such statement, term or matter to the specific items or matters set forth immediately following such word or to similar items or matters, whether or not non-limiting language (such as &#8220;without limitation&#8221;, &#8220;but not limited to&#8221;, or words of similar import) is used with reference thereto, but rather shall be deemed to refer to all other items or matters that could reasonably fall within the broadest possible scope of such general statement, term or matter. References herein to any agreement, instrument or other document means such agreement, instrument or other document as amended, supplemented and modified from time to time to the extent permitted by the provisions thereof and not prohibited by the Plan.</span></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex K-14</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T112"></a><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:right;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Annex&#160;L </span></p>
		<p class="ParaOverride-2" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-align:center;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">ORUKA THERAPEUTICS, INC.</span><span class="CharOverride-2" style="font-family:Times New Roman, serif;font-style:normal;font-weight:bold;"><br/></span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">2024 EMPLOYEE STOCK PURCHASE PLAN</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-left:24pt;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:-24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="color:#010000;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">1.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Purpose</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">The purpose of this Oruka Therapeutics, Inc. 2024 Employee Stock Purchase Plan (the &#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Plan</span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) is to provide employees of the Company and its Designated Subsidiaries with an opportunity to purchase Common Stock through accumulated Contributions. The Company&#8217;s intention is to have the Plan qualify as an &#8220;employee stock purchase plan&#8221; under Section 423 of the Code. The provisions of the Plan, accordingly, will be construed to extend and limit Plan participation in a uniform and nondiscriminatory basis consistent with the requirements of Section 423 of the Code.</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-left:24pt;text-indent:-24pt;margin-top:12pt;"><span class="CharOverride-7" style="color:#010000;">2.&#160;&#160;&#160;&#160;&#160;&#160;</span><span class="CharOverride-8">Definitions.</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">As used in the Plan, the following terms shall have the meanings set forth below:</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-9" style="color:#010000;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-11" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Administrator</span><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the Compensation Committee of the Board (or any successor committee), or such other committee as designated by the Board to administer the Plan under </span><span class="CharOverride-12" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 14</span><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-9" style="color:#010000;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-11" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Applicable Laws</span><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the requirements relating to the administration of equity-based awards under U.S. state corporate laws, U.S. federal and state securities laws, the Code, any stock exchange or quotation system on which the Common Stock is listed or quoted and the applicable laws of any foreign country or jurisdiction where options are, or will be, granted under the Plan.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-9" style="color:#010000;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-11" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Board</span><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the Board of Directors of the Company.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-9" style="color:#010000;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-11" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Code</span><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the Internal Revenue Code of 1986, as amended from time to time, and the rulings and regulations issued thereunder.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-9" style="color:#010000;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(e)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-11" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Common Stock</span><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the common stock of the Company, $0.001 par value per share.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-9" style="color:#010000;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(f)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-11" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Company</span><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means Oruka Therapeutics, Inc., a Delaware corporation, and any successor corporation.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-9" style="color:#010000;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(g)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-11" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Compensation</span><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means an Eligible Employee&#8217;s base salary or base hourly rate of pay before deduction for any salary deferral contributions made by the Eligible Employee to any tax-qualified or nonqualified deferred compensation plan, but excluding commissions, overtime, incentive compensation, bonuses and other forms of compensation. The Administrator, in its discretion, may, on a uniform and nondiscriminatory basis, establish a different definition of Compensation for an Offering Period.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-9" style="color:#010000;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(h)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-11" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Contributions</span><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the payroll deductions and any other additional payments that the Administrator may permit to be made by a Participant to fund the exercise of options granted pursuant to the Plan, subject to Section 423 of the Code.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-9" style="color:#010000;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(i)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-11" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Designated Subsidiary</span><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any Subsidiary that has been designated by the Administrator from time to time in its sole discretion as eligible to participate in the Plan. As of the date of adoption of the Plan, the Designated Subsidiaries consist exclusively of: Oruka Therapeutics Operating Company, LLC.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-9" style="color:#010000;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(j)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-11" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Effective Date</span><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the Closing Date (as defined in that Agreement and Plan of Merger and Reorganization dated April 3, 2024 by and between the Company (f/k/a ARCA biopharma, Inc.) and Oruka Therapeutics Operating Company, LLC (f/k/a Oruka Therapeutics, Inc.)).</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-9" style="color:#010000;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(k)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-11" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Eligible Employee</span><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any person, including an officer, who is customarily employed by the Company or a Designated Subsidiary (i) for more than 20 hours per week and (ii) for more than five months in any calendar year. For purposes of the Plan, the employment relationship shall be treated as continuing intact while the individual is on sick leave or other leave of absence approved by the Company. Where the period of leave exceeds 90 days and the individual&#8217;s right to reemployment is not guaranteed either by statute or by contract, the employment relationship shall be deemed to have terminated on the 91</span><span class="CharOverride-13" style="font-family:Times New Roman PS Std, serif;font-size:6pt;font-style:normal;font-weight:normal;vertical-align:super;">st</span><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> day of such leave. &#8220;Eligible Employee&#8221; shall not include any person who is a citizen or resident of a foreign jurisdiction if granting them an option under the Plan would violate the law of such jurisdiction, or if compliance with the laws of the jurisdiction would cause the Plan to violate Section 423 of the Code.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex L-1</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-9" style="color:#010000;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(l)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-11" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Employer</span><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the Company and each Designated Subsidiary.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-9" style="color:#010000;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(m)<span style="width: 10px;display: inline-block;">&#160;&#160;&#160;</span></span><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-11" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Enrollment Date</span><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the first Trading Day of each Offering Period.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-9" style="color:#010000;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(n)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-11" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Exchange Act</span><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the Securities Exchange Act of 1934, as amended, including the rules and regulations promulgated thereunder.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-9" style="color:#010000;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(o)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-11" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Exercise Date</span><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the last Trading Day of each Offering Period.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-9" style="color:#010000;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(p)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-11" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Fair Market Value</span><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means as of any date, the value of the Common Stock determined as follows: (i) if the Common Stock is listed on any established stock exchange, system or market, its Fair Market Value shall be the closing price for the Common Stock as quoted on such exchange, system or market as reported in the Wall Street Journal or such other source as the Administrator deems reliable (or, if no sale of Common Stock is reported for such date, on the next preceding date on which any sale shall have been reported); and (ii) in the absence of an established market for the Common Stock, the Fair Market Value thereof shall be determined in good faith by the Administrator.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-9" style="color:#010000;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(q)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-11" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">New Exercise Date</span><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means a new Exercise Date if the Administrator shortens any Offering Period then in progress.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-9" style="color:#010000;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(r)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-11" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Offering</span><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means an offer under the Plan of an option that may be exercised during an Offering Period as further described in </span><span class="CharOverride-12" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 4</span><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. For purposes of the Plan, the Administrator may designate separate Offerings under the Plan (the terms of which need not be identical) in which Eligible Employees of one or more Employers will participate, even if the dates of the applicable Offering Periods of each such Offering are identical and the provisions of the Plan will separately apply to each Offering. To the extent permitted by Treasury Regulation Section 1.423-2(a)(1), the terms of each Offering need not be identical; </span><span class="CharOverride-15" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">provided, however</span><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that the terms of the Plan and an Offering together satisfy Treasury Regulation Sections 1.423-2(a)(2) and (a)(3).</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-9" style="color:#010000;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(s)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-11" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Offering Periods</span><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the periods established by the Administrator (not to exceed 27 months) during which an option granted pursuant to the Plan may be exercised. The duration and timing of Offering Periods may be changed pursuant to </span><span class="CharOverride-12" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Sections 4</span><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-12" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">18,</span><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and </span><span class="CharOverride-12" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">19</span><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The first Offering Period shall commence on the Effective Date and end on the next December 9 or June 8 that follows the Effective Date, and subsequent Offering Periods shall be each six-month period commencing the day after the prior Offering Period ends and ending on each December 9 and June&#160;8.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-9" style="color:#010000;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(t)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-11" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Outstanding Common Stock</span><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the sum of (i) the shares of Common Stock outstanding, (ii) the shares of Common Stock underlying unexercised pre-funded warrants, and (iii) the shares of Common Stock underlying the Company&#8217;s preferred stock, par value $<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span><span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>(determined on an as-converted basis without regard to any limitations on such conversation).</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-9" style="color:#010000;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(u)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-11" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Parent</span><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means a &#8220;parent corporation,&#8221; whether now or hereafter existing, as defined in Section 424(e) of the Code.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-9" style="color:#010000;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(v)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-11" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Participant</span><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means an Eligible Employee who elects to participate in the Plan.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-9" style="color:#010000;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(w)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-11" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Purchase Period</span><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the period during an Offering Period during which shares of Common Stock may be purchased on a Participant&#8217;s behalf in accordance with the terms of the Plan. Unless the Administrator determines otherwise, during the first Offering Period, the Purchase Period will begin on the first date of such Offering Period and end on the last day of such Offering Period, and subsequent Purchase Periods shall be each six-month period commencing thereafter. Unless the Administrator determines otherwise, each Purchase Period following the first Purchase Period will be a six-month period.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-9" style="color:#010000;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(x)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-11" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Purchase Price</span><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means an amount equal to 85% of the Fair Market Value of a share of Common Stock on the Enrollment Date or on the Exercise Date, whichever is lower; </span><span class="CharOverride-15" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">provided, however</span><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that the Purchase Price may be determined for subsequent Offering Periods by the Administrator subject to compliance with Section 423 of the Code (or any other Applicable Law) or pursuant to </span><span class="CharOverride-12" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 18</span><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-9" style="color:#010000;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(y)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-11" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Subsidiary</span><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means a &#8220;subsidiary corporation,&#8221; whether now or hereafter existing, as defined in Section 424(f) of the Code.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex L-2</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-9" style="color:#010000;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(z)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-11" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Trading Day</span><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means a day on which the national stock exchange upon which the Common Stock is listed is open for trading or, if the Common Stock is not listed on a national stock exchange, a business day as determined by the Administrator in good faith.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-9" style="color:#010000;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(aa)<span style="width: 10px;display: inline-block;">&#160;&#160;&#160;</span></span><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-11" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Treasury Regulations</span><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the Treasury regulations of the Code. Reference to a specific Treasury Regulation or Section of the Code shall include such Treasury Regulation or Section, any valid regulation promulgated under such Section, and any comparable provision of any future legislation or regulation amending, supplementing or superseding such Section or regulation.</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-left:24pt;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:-24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="color:#010000;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">3.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Eligibility.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-9" style="color:#010000;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-15" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">Offering Periods</span><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Any Eligible Employee on a given Enrollment Date will be eligible to participate in the Plan if he or she was employed by the Company for at least 30 calendar days immediately preceding the Enrollment Date, subject to the requirements of </span><span class="CharOverride-12" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 5</span><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">; </span><span class="CharOverride-15" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">provided, however</span><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that an Eligible Employee who commences employment with the Company or a Designated Subsidiary following such 30-day period will be eligible to participate in the Plan at the beginning of the next Purchase Period to occur that is at least 30 calendar days following the commencement of his or her employment with the Company or a Designated Subsidiary. Eligible Employees who do not elect to participate in the Plan on a given Enrollment Date may elect to participate in the Plan at the beginning of any subsequent Purchase Period, as determined by the Administrator.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-9" style="color:#010000;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-15" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">Non-U.S. Employees</span><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Employees who are citizens or residents of a non-U.S. jurisdiction (without regard to whether they also are citizens or residents of the United States or resident aliens (within the meaning of Section 7701(b)(1)(A) of the Code)) may be excluded from participation in the Plan or an Offering if the participation of such employees is prohibited under the laws of the applicable jurisdiction or if complying with the laws of the applicable jurisdiction would cause the Plan or an Offering to violate Section 423 of the Code. In addition, as provided in </span><span class="CharOverride-12" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 14</span><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, the Administrator may establish one or more sub-plans of the Plan (which may, but are not required to, comply with the requirements of Section 423 of the Code) to provide benefits to employees of Designated Subsidiaries located outside the United States in a manner that complies with local law. Any such sub-plan will be a component of the Plan and will not be a separate plan.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-9" style="color:#010000;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-15" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">Limitations</span><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Any provisions of the Plan to the contrary notwithstanding, no Eligible Employee will be granted an option under the Plan (i) to the extent that, immediately after the grant, such Eligible Employee (or any other person whose stock would be attributed to such Eligible Employee pursuant to Section 424(d) of the Code) would own capital stock of the Company or any Parent or Subsidiary of the Company and/or hold outstanding options to purchase such stock possessing 5% or more of the total combined voting power or value of all classes of the capital stock of the Company or of any Parent or Subsidiary of the Company, or (ii) to the extent that his or her rights to purchase stock under all employee stock purchase plans (as defined in Section 423 of the Code) of the Company or any Parent or Subsidiary of the Company accrues at a rate that exceeds $25,000 worth of stock (determined at the Fair Market Value of the stock at the time such option is granted) for each calendar year in which such option is outstanding at any time, as determined in accordance with Section 423 of the Code and the regulations thereunder.</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-left:24pt;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:-24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="color:#010000;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">4.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Offering Periods</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">The Plan will be implemented by consecutive Offering Periods with new Offering Periods commencing at such times as determined by the Administrator. The Administrator will have the power to change the duration of Offering Periods (including the commencement dates thereof) without stockholder approval.</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-left:24pt;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:-24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="color:#010000;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">5.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Participation</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">An Eligible Employee may participate in the Plan by (i) submitting to the Company&#8217;s Finance department (or its delegate), on or before a date determined by the Administrator prior to an applicable Enrollment Date, a properly completed subscription agreement authorizing Contributions in the form provided by the Administrator for such purpose, or (ii) following an electronic or other enrollment procedure determined by the Administrator.</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-left:24pt;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:-24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="color:#010000;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">6.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Contributions</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-9" style="color:#010000;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">At the time a Participant enrolls in the Plan pursuant to </span><span class="CharOverride-12" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 5</span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, such Participant will elect to have payroll deductions made on each pay day or other Contributions (to the extent permitted by the Administrator) made during the Offering Period (or portion thereof) in an amount equal to at least 1% but not exceeding 15% of the </span></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex L-3</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Compensation (or such other percentage of Compensation as determined by the Administrator in its sole discretion, prior to the commencement of an applicable Offering Period), that the Participant receives on each pay day during the Offering Period; </span><span class="CharOverride-15" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">provided, however</span><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that should a pay day occur on an Exercise Date, a Participant will have any payroll deductions made on such day applied to his or her notional account under the subsequent Purchase Period or Offering Period. The minimum permissible projected Contribution by any Participant for an Offering Period shall be $500. The maximum permissible Contribution by any Participant for all Offering Periods during any calendar year shall be $25,000. The Administrator, in its sole discretion and to the extent permitted by Section 423 of the Code, may permit all Participants in a specified Offering to contribute amounts to the Plan through payment by cash, check, or other means set forth in the subscription agreement prior to each Exercise Date of each Purchase Period. A Participant&#8217;s subscription agreement will remain in effect for successive Offering Periods unless terminated as provided in </span><span class="CharOverride-12" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 10</span><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-9" style="color:#010000;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Payroll deductions for a Participant will commence on the first pay day following the Enrollment Date (or such later date on which a Participant enrolls in the Plan pursuant to </span><span class="CharOverride-12" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 5</span><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">) and will end on the last pay day prior to the Exercise Date of such Purchase Period to which such authorization is applicable, unless sooner terminated by the Participant as provided in </span><span class="CharOverride-12" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 10</span><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">; </span><span class="CharOverride-15" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">provided, however</span><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that with respect to the first Offering Period, payroll deduction for a Participant will not commence until such time as determined by the Administrator.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-9" style="color:#010000;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">All Contributions made for a Participant will be credited to his or her notional account under the Plan and payroll deductions will be made in whole percentages only. Except to the extent permitted by the Administrator pursuant to </span><span class="CharOverride-12" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 6(a)</span><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, a Participant may not make any additional payments into such notional account.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-9" style="color:#010000;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">A Participant may discontinue his or her participation in the Plan as provided in </span><span class="CharOverride-12" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 10</span><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Participants shall not be permitted to increase or to otherwise decrease their rates of Contributions during a Purchase Period unless otherwise determined by the Administrator in its sole discretion; </span><span class="CharOverride-15" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">provided, however</span><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that Participants shall be permitted to increase or decrease their rates of Contributions effective as of the beginning of each Purchase Period.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-9" style="color:#010000;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(e)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Notwithstanding the foregoing, to the extent necessary to comply with Section 423(b)(8) of the Code, a Participant&#8217;s Contributions may be decreased to 0% at any time during a Purchase Period. Subject to Section 423(b)(8) of the Code, Contributions will recommence at the rate originally elected by the Participant effective as of the beginning of the first Purchase Period scheduled to end in the following calendar year, unless terminated by the Participant as provided in </span><span class="CharOverride-12" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 10</span><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-9" style="color:#010000;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(f)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">At the time the option under the Plan is exercised, in whole or in part, or at the time some or all of the Common Stock issued under the Plan is disposed of (or any other time that a taxable event related to the Plan occurs), the Participant must make adequate provision for the Company&#8217;s or Employer&#8217;s federal, state, local, or any other tax liability payable to any authority including taxes imposed by jurisdictions outside of the United States, national insurance, social security, or other tax withholding obligations, if any, that arise upon the exercise of the option or the disposition of the Common Stock (or any other time that a taxable event related to the Plan occurs). At any time, the Company or the Employer may, but will not be obligated to, withhold from the Participant&#8217;s compensation the amount necessary for the Company or the Employer to meet applicable withholding obligations, including any withholding required to make available to the Company or the Employer any tax deductions or benefits attributable to sale or early disposition of Common Stock by the Eligible Employee. In addition, the Company or the Employer may, but will not be obligated to, withhold from the proceeds of the sale of Common Stock or any other method of withholding the Company or the Employer deems appropriate to the extent permitted by Treasury Regulation Section 1.423-2(f).</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-left:24pt;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:-24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="color:#010000;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">7.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Grant of Option</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">On the Enrollment Date of each Offering Period, each Eligible Employee participating in such Offering Period (or any Purchase Period within such Offering Period) will be granted an option to purchase on each Exercise Date during such Offering Period (at the applicable Purchase Price) up to a number of shares of Common Stock determined by dividing (i) such Eligible Employee&#8217;s Contributions accumulated prior to such Exercise Date and retained in the Eligible Employee&#8217;s notional account as of the Exercise Date by (ii) the applicable Purchase Price; </span><span class="CharOverride-16" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">provided, however</span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that in no event will an Eligible Employee be permitted to purchase during each Purchase Period more than 5,000 shares of Common Stock (subject to any adjustment pursuant to </span><span class="CharOverride-17" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 18</span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">); </span><span class="CharOverride-16" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">provided, further</span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that such purchase will be subject to the limitations set forth in </span><span class="CharOverride-17" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Sections 3(c)</span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and </span><span class="CharOverride-17" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">13</span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Eligible Employee may accept the grant of such option by electing to participate in the Plan in accordance with the requirements of </span><span class="CharOverride-17" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 5</span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. </span></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex L-4</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">The Administrator may, for future Offering Periods, increase or decrease, in its absolute discretion, the maximum number of shares of Common Stock that an Eligible Employee may purchase during each Purchase Period of an Offering Period. Exercise of the option will occur as provided in </span><span class="CharOverride-17" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 8</span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, unless the Participant has withdrawn pursuant to </span><span class="CharOverride-17" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 10</span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The option will expire on the last day of the Offering Period.</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-left:24pt;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:-24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="color:#010000;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">8.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Exercise of Option</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-9" style="color:#010000;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Unless a Participant withdraws from the Plan as provided in </span><span class="CharOverride-12" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 10</span><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, such Participant&#8217;s option for the purchase of shares of Common Stock will be exercised automatically on the Exercise Date, and the maximum number of full shares subject to the option will be purchased for such Participant at the applicable Purchase Price with the accumulated Contributions from his or her notional account. No fractional shares of Common Stock will be purchased; unless determined by the Administrator, any Contributions accumulated in a Participant&#8217;s notional account that are not sufficient to purchase a full share will be retained in the Participant&#8217;s notional account for the subsequent Purchase Period or Offering Period, subject to earlier withdrawal by the Participant as provided in </span><span class="CharOverride-12" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 10</span><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Any other funds left over in a Participant&#8217;s notional account after the Exercise Date will be returned to the Participant (without interest thereon, except as otherwise required under local laws, as further set forth in </span><span class="CharOverride-12" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 12</span><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">). During a Participant&#8217;s lifetime, a Participant&#8217;s option to purchase shares hereunder is exercisable only by him or her.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-9" style="color:#010000;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">If the Administrator determines that, on a given Exercise Date, the number of shares of Common Stock with respect to which options are to be exercised may exceed (i) the number of shares of Common Stock that were available for sale under the Plan on the Enrollment Date of the applicable Offering Period, or (ii) the number of shares of Common Stock available for sale under the Plan on such Exercise Date, the Administrator may in its sole discretion (x) provide that the Company will make a pro rata allocation of the shares of Common Stock available for purchase on such Enrollment Date or Exercise Date, as applicable, in as uniform a manner as will be practicable and as it will determine in its sole discretion to be equitable among all Participants exercising options to purchase Common Stock on such Exercise Date, and continue all Offering Periods then in effect, or (y) provide that the Company will make a pro rata allocation of the shares available for purchase on such Enrollment Date or Exercise Date, as applicable, in as uniform a manner as will be practicable and as it will determine in its sole discretion to be equitable among all Participants exercising options to purchase Common Stock on such Exercise Date, and terminate any or all Offering Periods then in effect pursuant to </span><span class="CharOverride-12" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 19</span><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Company may make a pro rata allocation of the shares available on the Enrollment Date of any applicable Offering Period pursuant to the preceding sentence, notwithstanding any authorization of additional shares for issuance under the Plan by the Company&#8217;s stockholders subsequent to such Enrollment Date.</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-left:24pt;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:-24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="color:#010000;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">9.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Delivery</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">As soon as reasonably practicable after each Exercise Date on which a purchase of shares of Common Stock occurs, the Company will arrange the delivery to each Participant of the shares purchased upon exercise of his or her option in a form determined by the Administrator (in its sole discretion) and pursuant to rules established by the Administrator. The Company may permit or require that shares be deposited directly with a broker designated by the Company or to a designated agent of the Company, and the Company may utilize electronic or automated methods of share transfer. The Company may require that shares be retained with such broker or agent for a designated period of time and/or may establish other procedures to permit tracking of disqualifying dispositions of such shares. No Participant will have any voting, dividend, or other stockholder rights with respect to shares of Common Stock subject to any option granted under the Plan until such shares have been purchased and delivered to the Participant as provided in this </span><span class="CharOverride-17" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 9</span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-left:24pt;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:-24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="color:#010000;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">10.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Withdrawal</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">A Participant may withdraw all, but not less than all, the Contributions credited to his or her notional account and not yet used to exercise his or her option under the Plan at any time by (a) submitting to the Company&#8217;s Finance department (or its delegate) a written notice of withdrawal in the form determined by the Administrator for such purpose, or (b) following an electronic or other withdrawal procedure determined by the Administrator. All the Participant&#8217;s Contributions credited to his or her notional account will be paid to such Participant as soon as reasonably practicable after receipt of notice of withdrawal and such Participant&#8217;s option for the Offering Period will be automatically terminated, and no further Contributions for the purchase of shares will be made for such Offering Period. If a Participant withdraws from an Offering Period, Contributions will not resume at the beginning of the succeeding Offering Period, unless the Participant re-enrolls in the Plan in accordance with the provisions of </span><span class="CharOverride-17" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 5</span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex L-5</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-left:24pt;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:-24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="color:#010000;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">11.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Termination of Employment</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Upon a Participant&#8217;s ceasing to be an Eligible Employee, for any reason, he or she will be deemed to have elected to withdraw from the Plan and the Contributions credited to such Participant&#8217;s notional account during the Offering Period but not yet used to purchase shares of Common Stock under the Plan will be returned to such Participant or, in the case of his or her death, to the person or persons entitled thereto under </span><span class="CharOverride-17" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 15</span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, and such Participant&#8217;s option will be automatically terminated. In no event may a Participant be granted an option under the Plan following his or her termination of employment unless such Participant subsequently becomes an Eligible Employee again.</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-left:24pt;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:-24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="color:#010000;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">12.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Interest</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">No interest will accrue on the Contributions of a Participant in the Plan, except as may be required by Applicable Law, as determined by the Company, and if so required by the laws of a particular jurisdiction, shall apply to all Participants in the relevant Offering except to the extent otherwise permitted by Treasury Regulation Section 1.423-2(f).</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-left:24pt;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:-24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="color:#010000;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">13.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Stock</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-9" style="color:#010000;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Subject to adjustment upon changes in capitalization of the Company as provided in </span><span class="CharOverride-12" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 18</span><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> hereof, the maximum number of shares of Common Stock that will be made available for sale under the Plan shall be equal to (i)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>shares, </span><span class="CharOverride-15" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">plus</span><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> (ii) any shares of Common Stock added as a result of the following sentence (collectively, the &#8220;</span><span class="CharOverride-11" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Share Pool</span><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;). The Share Pool will automatically increase on January 1 of each year beginning in 2025 and ending with a final increase on January 1, 2034 in an amount equal to &#160;&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span> of the Outstanding Common Stock on the preceding December 31; </span><span class="CharOverride-15" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">provided, however</span><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that the Committee may provide that there will be no January 1 increase in the Share Pool for any such year or that the increase in the Share Pool for any such year will be a smaller number of shares of Common Stock than would otherwise occur pursuant to this sentence.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-9" style="color:#010000;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Until the shares are issued (as evidenced by the appropriate entry on the books of the Company or of a duly authorized transfer agent of the Company), a Participant will only have the rights of an unsecured creditor with respect to such shares, and no right to vote or receive dividends or any other rights as a stockholder will exist with respect to such shares.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-9" style="color:#010000;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Shares of Common Stock to be delivered to a Participant under the Plan will be registered in the name of the Participant or in the name of the Participant and his or her spouse.</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-left:24pt;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:-24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="color:#010000;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">14.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Administration</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">The Plan shall be administered by the Administrator. The Board shall fill vacancies on, and from time to time may remove or add members to, the Administrator. Any power of the Administrator may also be exercised by the Board. The Administrator will have full and exclusive discretionary authority to construe, interpret, and apply the terms of the Plan, to designate separate Offerings under the Plan, to determine eligibility, to adjudicate all disputed claims filed under the Plan, and to establish such procedures that it deems necessary for the administration of the Plan (including, without limitation, to adopt such procedures and sub-plans as are necessary or appropriate to permit the participation in the Plan by employees who are foreign nationals or employed outside the United States, the terms of which sub-plans may take precedence over other provisions of this Plan, with the exception of </span><span class="CharOverride-17" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 13(a)</span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, but unless otherwise superseded by the terms of such sub-plan, the provisions of this Plan shall govern the operation of such sub-plan). Unless otherwise determined by the Administrator, the employees eligible to participate in each sub-plan will participate in a separate Offering. Without limiting the generality of the foregoing, the Administrator is specifically authorized to adopt rules and procedures regarding eligibility to participate, the definition of Compensation, handling of Contributions, making of Contributions to the Plan (including, without limitation, in forms other than payroll deductions), establishment of bank or trust accounts to hold Contributions, payment of interest, conversion of local currency, obligations to pay payroll tax, determination of beneficiary designation requirements, withholding procedures, and handling of stock certificates that vary with applicable local requirements. The Administrator also is authorized to determine that, to the extent permitted by Treasury Regulation Section 1.423-2(f), the terms of an option granted under the Plan or an Offering to citizens or residents of a non-U.S. </span></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex L-6</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">jurisdiction will be less favorable than the terms of options granted under the Plan or the same Offering to employees resident solely in the United States. The Administrator hereby delegates to and designates the [Senior Vice President] of the Company (or such other officer with similar authority), and to his or her delegates or designates, the authority to assist the Administrator in the day-to-day administration of the Plan. The Administrator may also delegate some or all of its responsibilities to one or more other persons (which may include Company personnel) and, to the extent there has been any such delegation, any reference in the Plan to the Administrator shall include the delegate of the Administrator. Every finding, decision, and determination made by the Administrator will, to the full extent permitted by Applicable Laws, be final and binding upon all parties.</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-left:24pt;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:-24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="color:#010000;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">15.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Designation of Beneficiary</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-9" style="color:#010000;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">If permitted by the Administrator, a Participant may file a designation of a beneficiary who is to receive any shares of Common Stock and cash, if any, from the Participant&#8217;s notional account under the Plan in the event of such Participant&#8217;s death subsequent to an Exercise Date on which the option is exercised but prior to delivery to such Participant of such shares and cash. In addition, if permitted by the Administrator, a Participant may file a designation of a beneficiary who is to receive any cash from the Participant&#8217;s notional account under the Plan in the event of such Participant&#8217;s death prior to exercise of the option. If a Participant is married and the designated beneficiary is not the spouse, spousal consent will be required for such designation to be effective.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-9" style="color:#010000;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Such designation of beneficiary may be changed by the Participant at any time by notice in a form determined by the Administrator. In the event of the death of a Participant and in the absence of a beneficiary validly designated under the Plan who is living at the time of such Participant&#8217;s death, the Company will deliver such shares and/or cash to the executor or administrator of the estate of the Participant, or if no such executor or administrator has been appointed (to the knowledge of the Company), the Company, in its discretion, may deliver such shares and/or cash to the spouse or to any one or more dependents or relatives of the Participant, or if no spouse, dependent, or relative is known to the Company, then to such other person as the Company may designate.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-9" style="color:#010000;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">All beneficiary designations will be in such form and manner as the Administrator may designate from time to time. Notwithstanding </span><span class="CharOverride-12" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Sections 15(a)</span><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and </span><span class="CharOverride-12" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">15(b)</span><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, the Company and/or the Administrator may decide not to permit such designations by Participants in non-U.S. jurisdictions to the extent permitted by Treasury Regulation Section 1.423-2(f).</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-left:24pt;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:-24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="color:#010000;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">16.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Transferability</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Neither Contributions credited to a Participant&#8217;s notional account nor any rights with regard to the exercise of an option or to receive shares of Common Stock under the Plan may be assigned, transferred, pledged, or otherwise disposed of in any way (other than by will, the laws of descent and distribution or as provided in </span><span class="CharOverride-17" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 15</span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">) by the Participant. Any such attempt at assignment, transfer, pledge, or other disposition will be without effect, except that the Company may treat such act as an election to withdraw funds from an Offering Period in accordance with Section 10 hereof.</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-left:24pt;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:-24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="color:#010000;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">17.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Use of Funds</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">The Company may use all Contributions received or held by it under the Plan for any corporate purpose, and the Company will not be obligated to segregate such Contributions except under Offerings in which applicable local law requires that Contributions to the Plan by Participants be segregated from the Company&#8217;s general corporate funds and/or deposited with an independent third party for Participants in non-U.S. jurisdictions. Until shares of Common Stock are issued, Participants will only have the rights of an unsecured creditor with respect to such shares.</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-left:24pt;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:-24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="color:#010000;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">18.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Adjustments, Dissolution, Liquidation, Merger or Other Corporate Transaction</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-9" style="color:#010000;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-15" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">Adjustments</span><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. In the event that any dividend or other distribution (whether in the form of cash, Common Stock, other securities, or other property), recapitalization, stock split, reverse stock split, reorganization, merger, consolidation, split-up, spin-off, combination, repurchase, or exchange of Common Stock or other securities of the Company, or other change in the corporate structure of the Company affecting the Common Stock occurs, the Administrator, in order to prevent dilution or enlargement of the benefits or potential benefits intended to be made </span></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex L-7</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">available under the Plan, will, in such manner as it may deem equitable, adjust the number and class of Common Stock that may be delivered under the Plan, the Purchase Price per share and the number of shares of Common Stock covered by each option under the Plan that has not yet been exercised, and the numerical limits of </span><span class="CharOverride-12" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Sections 7</span><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and </span><span class="CharOverride-12" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">13</span><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-9" style="color:#010000;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-15" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">Dissolution or Liquidation</span><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. In the event of the proposed dissolution or liquidation of the Company, any Offering Period then in progress will be shortened by setting a New Exercise Date, and will terminate immediately prior to the consummation of such proposed dissolution or liquidation, unless provided otherwise by the Administrator. The New Exercise Date will be before the date of the Company&#8217;s proposed dissolution or liquidation. The Administrator will notify each Participant in writing or electronically, prior to the New Exercise Date, that the Exercise Date for the Participant&#8217;s option has been changed to the New Exercise Date and that the Participant&#8217;s option will be exercised automatically on the New Exercise Date, unless prior to such date the Participant has withdrawn from the Offering Period as provided in </span><span class="CharOverride-12" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 10</span><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-9" style="color:#010000;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-15" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">Merger or Other Corporate Transaction</span><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. In the event of a merger, sale, or other similar corporate transaction involving the Company, each outstanding option will be assumed or an equivalent option substituted by the successor corporation or a Parent or Subsidiary of the successor corporation. If the successor corporation refuses to assume or substitute for the option, the Offering Period with respect to which such option relates will be shortened by setting a New Exercise Date on which such Offering Period shall end. The New Exercise Date will occur before the date of the Company&#8217;s proposed merger, sale, or other similar corporate transaction. The Administrator will notify each Participant in writing or electronically prior to the New Exercise Date, that the Exercise Date for the Participant&#8217;s option has been changed to the New Exercise Date and that the Participant&#8217;s option will be exercised automatically on the New Exercise Date, unless prior to such date the Participant has withdrawn from the Offering Period as provided in </span><span class="CharOverride-12" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 10</span><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-left:24pt;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:-24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="color:#010000;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">19.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Amendment or Termination</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-9" style="color:#010000;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">The Administrator, in its sole discretion, may amend, suspend, or terminate the Plan, or any part thereof, at any time and for any reason. If the Plan is terminated, the Administrator, in its discretion, may elect to terminate all outstanding Offering Periods either immediately or upon completion of the purchase of shares of Common Stock on the next Exercise Date (which may be sooner than originally scheduled, if determined by the Administrator in its discretion), or may elect to permit Offering Periods to expire in accordance with their terms (and subject to any adjustment pursuant to </span><span class="CharOverride-12" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 18</span><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">). If the Offering Periods are terminated prior to expiration, all amounts then credited to Participants&#8217; notional accounts that have not been used to purchase shares of Common Stock will be returned to the Participants (without interest thereon, except as otherwise required under local laws, as further set forth in </span><span class="CharOverride-12" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 12</span><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">) as soon as administratively practicable.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-9" style="color:#010000;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Without stockholder consent and without limiting </span><span class="CharOverride-12" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 19(a)</span><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, the Administrator will be entitled to change the Offering Periods or Purchase Periods, designate separate Offerings, limit the frequency and/or number of changes in the amount withheld during an Offering Period, establish the exchange ratio applicable to amounts withheld in a currency other than U.S. dollars, permit payroll withholding in excess of the amount designated by a Participant in order to adjust for delays or mistakes in the Company&#8217;s processing of properly completed withholding elections, establish reasonable waiting and adjustment periods and/or accounting and crediting procedures to ensure that amounts applied toward the purchase of Common Stock for each Participant properly correspond with Contribution amounts, and establish such other limitations or procedures as the Administrator determines in its sole discretion advisable that are consistent with the Plan.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-9" style="color:#010000;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">In the event the Administrator determines that the ongoing operation of the Plan may result in unfavorable financial accounting consequences, the Administrator may, in its discretion and, to the extent necessary or desirable, modify, amend, or terminate the Plan to reduce or eliminate such accounting consequence including, but not limited to:</span></p>
		<p class="ParaOverride-7" style="margin:0;padding:0;border-width:0;margin-left:24pt;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-9" style="color:#010000;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(i)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">amending the Plan to conform with the safe harbor definition under the Financial Accounting Standards Board Accounting Standards Codification Topic 718 (or any successor thereto), including with respect to an Offering Period underway at the time;</span></p>
		<p class="ParaOverride-7" style="margin:0;padding:0;border-width:0;margin-left:24pt;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex L-8</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-7" style="margin:0;padding:0;border-width:0;margin-left:24pt;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-9" style="color:#010000;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(ii)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">altering the Purchase Price for any Offering Period or Purchase Period including an Offering Period or Purchase Period underway at the time of the change in Purchase Price;</span></p>
		<p class="ParaOverride-7" style="margin:0;padding:0;border-width:0;margin-left:24pt;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-9" style="color:#010000;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(iii)<span style="width: 10px;display: inline-block;">&#160;&#160;&#160;</span></span><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">shortening any Offering Period or Purchase Period by setting a New Exercise Date, including an Offering Period or Purchase Period underway at the time of the Administrator action;</span></p>
		<p class="ParaOverride-7" style="margin:0;padding:0;border-width:0;margin-left:24pt;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-9" style="color:#010000;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(iv)<span style="width: 10px;display: inline-block;">&#160;&#160;&#160;</span></span><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">reducing the maximum percentage of Compensation a Participant may elect to set aside as Contributions; and</span></p>
		<p class="ParaOverride-7" style="margin:0;padding:0;border-width:0;margin-left:24pt;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-9" style="color:#010000;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(v)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">reducing the maximum number of shares of Common Stock a Participant may purchase during any Offering Period or Purchase Period.</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Such modifications or amendments will not require stockholder approval or the consent of any Participants.</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-left:24pt;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:-24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="color:#010000;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">20.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Notices</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">All notices or other communications by a Participant to the Company under or in connection with the Plan will be deemed to have been duly given when received in the form and manner specified by the Company at the location, or by the person, designated by the Company for the receipt thereof.</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-left:24pt;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:-24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="color:#010000;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">21.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Conditions Upon Issuance of Shares</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-9" style="color:#010000;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Shares of Common Stock will not be issued with respect to an option unless the exercise of such option and the issuance and delivery of such shares pursuant thereto will comply with all applicable provisions of law, domestic or foreign, including the Securities Act of 1933, as amended, the Exchange Act, the rules and regulations promulgated thereunder, and the requirements of any stock exchange upon which the shares may then be listed, and will be further subject to the approval of counsel for the Company with respect to such compliance.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-9" style="color:#010000;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">As a condition to the exercise of an option, the Company may require the person exercising such option to represent and warrant at the time of any such exercise that the shares are being purchased only for investment and without any present intention to sell or distribute such shares if, in the opinion of counsel for the Company, such a representation is required by any of the aforementioned applicable provisions of Applicable Law.</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-left:24pt;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:-24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="color:#010000;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">22.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Term of Plan</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">The Plan will become effective upon the earlier to occur of its adoption by the Board or its approval by the stockholders of the Company. It will continue in effect until terminated pursuant to </span><span class="CharOverride-17" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 19</span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-left:24pt;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:-24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="color:#010000;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">23.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Stockholder Approval</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">The Plan will be subject to approval by the stockholders of the Company within 12 months after the date the Plan is adopted by the Board. Such stockholder approval will be obtained in the manner and to the degree required under Applicable Laws.</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-left:24pt;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:-24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="color:#010000;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">24.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Governing Law</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">This Plan and any agreements or other documents hereunder shall be interpreted and construed in accordance with the laws of the State of Delaware and applicable federal law. Any reference in this Plan or in any agreements or other documents hereunder to a provision of law or to a rule or regulation shall be deemed to include any successor law, rule, or regulation of similar effect or applicability.</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex L-9</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-left:24pt;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:-24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="color:#010000;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">25.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Severability</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">If any provision of the Plan is or becomes or is deemed to be invalid, illegal, or unenforceable for any reason in any jurisdiction or as to any Participant, such invalidity, illegality, or unenforceability shall not affect the remaining parts of the Plan, and the Plan shall be construed and enforced as to such jurisdiction or Participant as if the invalid, illegal, or unenforceable provision had not been included.</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-left:24pt;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:-24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="color:#010000;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">26.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Interpretation</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Headings are given to the Sections and subsections of the Plan solely as a convenience to facilitate reference and shall not be deemed in any way material or relevant to the construction or interpretation of the Plan or any provision thereof. Words in the masculine gender shall include the feminine gender, and where appropriate, the plural shall include the singular and the singular shall include the plural. The use herein of the word &#8220;including&#8221; following any general statement, term, or matter shall not be construed to limit such statement, term, or matter to the specific items or matters set forth immediately following such word or to similar items or matters, whether or not non-limiting language (such as &#8220;without limitation&#8221;, &#8220;but not limited to&#8221;, or words of similar import) is used with reference thereto, but rather shall be deemed to refer to all other items or matters that could reasonably fall within the broadest possible scope of such general statement, term, or matter. References herein to any agreement, instrument, or other document means such agreement, instrument, or other document as amended, supplemented, and modified from time to time to the extent permitted by the provisions thereof and not prohibited by the Plan.</span></p>
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-align:center;text-indent:24pt;widows:2;margin-top:8pt;"></p>
		<p class="ParaOverride-9" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-align:center;text-indent:24pt;widows:2;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex L-10</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-2" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-align:center;widows:2;margin-top:8pt;"><span class="CharOverride-20" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;text-decoration:underline;">EXHIBIT A</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;text-align:center;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ORUKA THERAPEUTICS, INC.</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:0pt;text-align:center;margin-top:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2024 EMPLOYEE STOCK PURCHASE PLAN</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;text-align:center;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">SUBSCRIPTION AGREEMENT</span></p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;vertical-align:top;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"></p>



					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;vertical-align:top;width: 41.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;vertical-align:top;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;vertical-align:top;width: 36.11%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 41.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:justify;">Original Application</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:justify;">Offering&#160;Date:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 36.11%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 41.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-top:8pt;text-align:justify;">Change in Payroll Deduction Rate</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 36.11%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>

		</table>
		<p class="ParaOverride-16" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">1.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>hereby elects to participate in the Oruka Therapeutics, Inc. 2024 Employee Stock Purchase Plan (the &#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Plan</span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) and subscribes to purchase shares of the Company&#8217;s Common Stock in accordance with this Subscription Agreement and the Plan. Capitalized terms used but not defined in this Subscription Agreement have the meanings provided under the Plan.</span></p>
		<p class="ParaOverride-16" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">2.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>I hereby authorize payroll deductions from each paycheck in the amount of ____% of my Compensation on each payday (from 1% to 15%) during the Offering Period in accordance with the Plan, commencing with the next Offering Period; </span><span class="CharOverride-16" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">provided, however</span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that, in no event may more than $25,000 of Common Stock be purchased under the Plan in any calendar year. The minimum permissible projected Contribution for the Offering Period is $500. (Please note that no fractional percentages are permitted.)</span></p>
		<p class="ParaOverride-16" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">3.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>I understand that the payroll deductions will be accumulated for the purchase of shares of Common Stock at the applicable Purchase Price determined in accordance with the Plan. I understand that if I do not withdraw from an Offering Period, any accumulated payroll deductions will be used to automatically exercise my option and purchase Common Stock under the Plan.</span></p>
		<p class="ParaOverride-16" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">4.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>I have received a copy of the complete Plan and its accompanying prospectus. I understand that my participation in the Plan is in all respects subject to the terms of the Plan.</span></p>
		<p class="ParaOverride-16" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">5.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Shares of Common Stock purchased for me under the Plan should be issued in the name(s) of&#160;&#160;&#160;&#160;(Eligible Employee or Eligible Employee and Spouse only).</span></p>
		<p class="ParaOverride-16" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>I understand that if I dispose of any shares received by me pursuant to the Plan within two years after the Offering Date (the first day of the Offering Period during which I purchased such shares), I will be treated for federal income tax purposes as having received ordinary income at the time of such disposition in an amount equal to the excess of the fair market value of the shares at the time such shares were purchased by me over the price that I paid for the shares. The Company may, but will not be obligated to, withhold from my compensation the amount necessary to meet any applicable withholding obligation including any withholding necessary to make available to the Company any tax deductions or benefits attributable to sale or early disposition of Common Stock by me. If I dispose of such shares at any time after the expiration of the two-year holding period, I understand that I will be treated for federal income tax purposes as having received income only at the time of such disposition, and that such income will be taxed as ordinary income only to the extent of an amount equal to the lesser of (a) the excess of the fair market value of the shares at the time of such disposition over the Purchase Price which I paid for the shares, or (b) 15% of the fair market value of the shares on the first day of the Offering Period. The remainder of the gain, if any, recognized on such disposition will be taxed as capital gain.</span></p>
		<p class="ParaOverride-16" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">7.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>I hereby agree to be bound by the terms of the Plan. The effectiveness of this Subscription Agreement is dependent upon my eligibility to participate in the Plan.</span></p>
		<table class="No-Table-Style _idGenTablePara-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Employee&#8217;s Social Security #:</p>



					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Employee&#8217;s Address:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">&#160;</p>
					</td>
				</tr>

		</table>
		<p class="ParaOverride-9" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-align:center;text-indent:24pt;widows:2;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex L-11</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">I UNDERSTAND THAT THIS SUBSCRIPTION AGREEMENT WILL REMAIN IN EFFECT THROUGHOUT SUCCESSIVE OFFERING PERIODS UNLESS TERMINATED BY ME.</span></p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-15" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-width:1pt;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 44.02%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"></p>



					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 3.85%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 5.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Date:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 42.74%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-16" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:1pt;padding-left:0pt;vertical-align:top;width: 44.02%; padding: 0in 0in 3px 0in;border-width: 0pt;border-top: windowtext 1pt none; border-top-style: solid;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Signature</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 3.85%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 5.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 42.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>

		</table>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex L-12</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;text-align:center;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">EXHIBIT B</span></p>
		<p class="ParaOverride-2" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-align:center;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">ORUKA THERAPEUTICS, INC.</span><span class="CharOverride-2" style="font-family:Times New Roman, serif;font-style:normal;font-weight:bold;"><br/></span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">2024 EMPLOYEE STOCK PURCHASE PLAN</span></p>
		<p class="ParaOverride-2" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-align:center;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">NOTICE OF WITHDRAWAL</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">The undersigned Participant in the Offering Period of the Oruka Therapeutics, Inc. 2024 Employee Stock Purchase Plan that began on ______________, ______ (the &#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Offering Date</span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) hereby notifies the Company that he or she hereby withdraws from the Offering Period. He or she hereby directs the Company to pay to the undersigned as soon as reasonably practicable all the payroll deductions credited to his or her notional account with respect to such Offering Period. The undersigned understands and agrees that his or her option for such Offering Period will be automatically terminated. The undersigned understands further that no further payroll deductions will be made for the purchase of shares in the current Offering Period and the undersigned will be eligible to participate in succeeding Offering Periods only by delivering to the Company a new Subscription Agreement.</span></p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Participant&#8217;s Name:</p>



					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Participant&#8217;s Address:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">&#160;</p>
					</td>
				</tr>

		</table>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-15" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-width:1pt;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 44.02%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"></p>



					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 3.85%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 5.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Date:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 42.74%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-16" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:1pt;padding-left:0pt;vertical-align:top;width: 44.02%; padding: 0in 0in 3px 0in;border-width: 0pt;border-top: windowtext 1pt none; border-top-style: solid;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Signature</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 3.85%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 5.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 42.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>

		</table>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex L-13</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">PART&#160;II <br/>INFORMATION NOT REQUIRED IN PROXY STATEMENT/PROSPECTUS</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-left:48pt;text-indent:-48pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Item&#160;20.<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>Indemnification of Directors and Officers</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Delaware</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA and Oruka are corporations under the DGCL.&#160;Section&#160;145(a)&#160;of the DGCL provides that a corporation may indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding (other than an action by or in the right of the corporation) by reason of the fact that such person is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorneys&#8217; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with such action, suit or proceeding if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding, had no reasonable cause to believe such person&#8217;s conduct was unlawful.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Section&#160;145(b)&#160;of the DGCL provides that a corporation may indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action or suit by or in the right of the corporation to procure a judgment in its favor by reason of the fact that the person is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise against expenses (including attorneys&#8217; fees) actually and reasonably incurred by the person in connection with the defense or settlement of such action or suit if the person acted in good faith and in a manner the person reasonably believed to be in or not opposed to the best interests of the corporation and except that no indemnification shall be made in respect of any claim, issue or matter as to which such person shall have been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery of the State of Delaware or the court in which such action or suit was brought shall determine upon application that, despite the adjudication of liability but in view of all the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the Court of Chancery of the State of Delaware or such other court shall deem proper.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Section&#160;145 of the DGCL further provides that to the extent a director or officer of a corporation has been successful on the merits or otherwise in the defense of any action, suit or proceeding referred to in subsections (a)&#160;and (b)&#160;of Section&#160;145, or in defense of any claim, issue or matter therein, such person shall be indemnified against expenses (including attorneys&#8217; fees) actually and reasonably incurred by such person in connection therewith; that indemnification provided for by Section&#160;145 shall not be deemed exclusive of any other rights to which the indemnified party may be entitled; and the indemnification provided for by Section&#160;145 shall, unless otherwise provided when authorized or ratified, continue as to a person who has ceased to be a director, officer, employee or agent and shall inure to the benefit of such person&#8217;s heirs, executors and administrators. Section&#160;145 also empowers the corporation to purchase and maintain insurance on behalf of any person who is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise against any liability asserted against such person and incurred by such person in any such capacity, or arising out of his status as such, whether or not the corporation would have the power to indemnify such person against such liabilities under Section&#160;145.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Section&#160;102(b)(7)&#160;of the DGCL provides that a corporation&#8217;s certificate of incorporation may contain a provision eliminating or limiting the personal liability of a director to the corporation or its stockholders for monetary damages for breach of fiduciary duty as a director, provided that such provision shall not eliminate or limit the liability of a director (i)&#160;for any breach of the director&#8217;s duty of loyalty to the corporation or its stockholders, (ii)&#160;for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (iii)&#160;under Section&#160;174 of the DGCL, or (iv)&#160;for any transaction from which the director derived an improper personal benefit.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">II-1</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H5" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">ARCA</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The ARCA Charter contains provisions that eliminate, to the maximum extent permitted by the DGCL, the personal liability of directors for monetary damages for breach of fiduciary duty as a director. Please see Proposal&#160;No. 4 for details regarding the proposed amendment to the ARCA Charter to eliminate, to the maximum extent permitted by the DGCL, the personal liability of officers for monetary damages for breach of fiduciary duty as an officer. The ARCA Charter and ARCA Bylaws provide that ARCA shall indemnify its directors and executive officers and may indemnify its employees and other agents to the fullest extent permitted by the DGCL.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA has entered into indemnification agreements with its directors and executive officers, in addition to the indemnification provided for in the ARCA Charter and ARCA Bylaws, and it intends to enter into indemnification agreements with any new directors and executive officers in the future.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA has purchased and intends to maintain insurance on behalf of any person who is or was a director or officer against any loss arising from any claim asserted against him or her incurred by him or her in any such capacity, subject to certain exclusions.</p>
		<p class="H5" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Oruka</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Oruka Charter contains provisions that limit or eliminate the personal liability of Oruka&#8217;s directors or officers to the fullest extent permitted by the DGCL, as it now exists or may in the future be amended. These limitations of liability do not alter director or officer liability under the federal securities laws and do not affect the availability of equitable remedies such as an injunction or rescission. In addition, the Oruka Bylaws provide that:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Oruka will indemnify its directors and officers to the fullest extent permitted by the DGCL, as it now exists or may in the future be amended; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Oruka will advance expenses, including attorneys&#8217; fees, to its directors and officers in connection with legal proceedings relating to their service for or on behalf of Oruka, subject to limited exceptions.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka has entered into indemnification agreements with its directors and executive officers. These agreements provide that Oruka will indemnify each of its directors and executive officers to the fullest extent permitted by Delaware law. Oruka will advance expenses, including attorneys&#8217; fees (but excluding judgments, fines and settlement amounts), to each indemnified director or executive officer in connection with any proceeding in which indemnification is available and Oruka will indemnify its directors and officers for any action or proceeding arising out of that person&#8217;s services as a director or officer brought on behalf of Oruka or in furtherance of Oruka&#8217;s rights. Additionally, certain of Oruka&#8217;s directors may have certain rights to indemnification, advancement of expenses or insurance provided by their affiliates or other third parties, which indemnification relates to and might apply to the same proceedings arising out of such director&#8217;s services as a director referenced herein. Nonetheless, Oruka has agreed in the indemnification agreements that Oruka&#8217;s obligations to those same directors are primary and any obligation of such affiliates or other third parties to advance expenses or to provide indemnification for the expenses or liabilities incurred by those directors are secondary.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka also intends to maintain general liability insurance which covers certain liabilities of its directors and officers arising out of claims based on acts or omissions in their capacities as directors or officers, including liabilities under the&#160;Securities Act.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-left:48pt;text-indent:-48pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Item&#160;21.<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>Exhibits and Financial Statement Schedules</span></p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:24pt;margin-top:8pt;">(a)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>Exhibit Index</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">A list of exhibits filed with this registration statement on Form&#160;S<span class="nobreak">-4</span> is set forth on the Exhibit Index and is incorporated herein by reference.</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:24pt;margin-top:8pt;">(b)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Financial Statements</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The financial statements filed with this registration statement on Form&#160;S<span class="nobreak">-4</span> are set forth on the Financial Statement Index and are incorporated herein by reference.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">II-2</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-left:48pt;text-indent:-48pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Item&#160;22.<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>Undertakings</span></p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:24pt;margin-top:8pt;">(a)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>The undersigned registrant hereby undertakes:</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">(1)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>To file, during any period in which offers or sales are being made, a post<span class="nobreak">-effective</span> amendment to this registration statement:</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;">(i)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>To include any prospectus required by Section&#160;10(a)(3)&#160;of the Securities Act;</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;">(ii)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post<span class="nobreak">-effective</span> amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule&#160;424(b)&#160;if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the &#8220;Filing Fee Table&#8221; table in the effective registration statement; and</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;">(iii)<span style="width: 10px;display: inline-block;">&#160;&#160;&#160;</span>To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-left:72pt;text-indent:0pt;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Provided, however</span>, that paragraphs (a)(1)(i)&#160;and (a)(1)(ii)&#160;herein do not apply if the information required to be included in a post<span class="nobreak">-effective</span> amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to Section&#160;13 or Section&#160;15(d)&#160;of the Exchange&#160;Act (15 U.S.C. 78m or 78o(d)) that are incorporated by reference in the registration statement.</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">(2)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>That, for the purpose of determining any liability under the Securities Act, each such post<span class="nobreak">-effective</span> amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">(3)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>To remove from registration by means of a post<span class="nobreak">-effective</span> amendment any of the securities being registered which remain unsold at the termination of the offering.</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">(4)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the registrant&#8217;s annual report pursuant to Section&#160;13(a)&#160;or Section&#160;15(d)&#160;of the Exchange&#160;Act (and, where applicable, each filing of an employee benefit plan&#8217;s annual report pursuant to Section&#160;15(d)&#160;of the Exchange&#160;Act) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">(5)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>The undersigned registrant hereby undertakes as follows: that prior to any public reoffering of the securities registered hereunder through use of a prospectus which is a part of this registration statement, by any person or party who is deemed to be an underwriter within the meaning of Rule&#160;145(c), the issuer undertakes that such reoffering prospectus will contain the information called for by the applicable registration form with respect to reofferings by persons who may be deemed underwriters, in addition to the information called for by the other items of the applicable form.</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">(6)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>The registrant undertakes that every prospectus: (i)&#160;that is filed pursuant to paragraph (a)(5)&#160;immediately preceding, or (ii)&#160;that purports to meet the requirements of Section&#160;10(a)(3)&#160;of the Act and is used in connection with an offering of securities subject to Rule&#160;415, will be filed as a part of an amendment to the registration statement and will not be used until such amendment is effective, and that, for purposes of determining any liability under the Securities Act&#160;of&#160;1933, each such post<span class="nobreak">-effective</span> amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">II-3</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">(7)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>The undersigned registrant hereby undertakes to respond to requests for information that is incorporated by reference into the prospectus pursuant to Item&#160;4, 10(b),<span class="nobreak"> </span>11, or 13 of this form, within one business&#160;day of receipt of such request, and to send the incorporated documents by first class mail or other equally prompt means. This includes information contained in documents filed subsequent to the effective date of the registration statement through the date of responding to the request.</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">(8)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>The undersigned registrant hereby undertakes to supply by means of a post<span class="nobreak">-effective</span> amendment all information concerning a transaction, and the company being acquired involved therein, that was not the subject of and included in the registration statement when it became effective.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.</p>
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;border-left-style:solid;border-right-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">



						<p class="TCH_left" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Exhibit <br/>Number</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-left-style:solid;border-right-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;border-left-style:solid;border-right-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><br/>Description</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-width:0pt;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">2.1&#8224;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000119312524085437/d794675dex21.htm">Agreement and Plan of Merger and Reorganization, dated as of April&#160;3, 2024, by and among ARCA biopharma, Inc., Atlas Merger Sub Corp., Atlas Merger Sub&#160;II, LLC, and Oruka Therapeutics, Inc. (included as Annex&#160;A to the proxy statement/prospectus and incorporated herein by reference).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">3.1</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000119312509064819/dex31.htm">Amended and Restated Certificate of Incorporation of ARCA biopharma, Inc., as amended (incorporated by reference to Exhibit 3.1 to ARCA biopharma, Inc.&#8217;s Form&#160;10-K filed on March&#160;27, 2009).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">3.1(a)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000119312513090814/d498361dex51.htm">Certificate of Amendment to Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 5.1 of ARCA biopharma, Inc.&#8217;s Form&#160;8-K filed on March&#160;5, 2013).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">3.1(b)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000156459015007723/abio-ex31_74.htm">Certificate of Amendment to Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 of ARCA biopharma, Inc.&#8217;s Form&#160;8-K filed on September&#160;3, 2015).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">3.1(c)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000156459019010715/abio-ex31_7.htm">Certificate of Amendment to Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 of ARCA biopharma, Inc.&#8217;s Form&#160;8-K filed on April&#160;3, 2019).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">3.2</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/0000907654/000156459021034792/abio-ex31_47.htm">Bylaws of ARCA biopharma, Inc., as currently in effect (incorporated by reference to Exhibit 3.1 of ARCA biopharma, Inc.&#8217;s Form&#160;8-K filed on June&#160;28, 2021).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">3.3</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000119312513233692/d507513dex31b.htm">Form of Certificate of Designation of Preferences, Rights and Limitations of Series&#160;A Convertible Preferred Stock of the Registrant (previously filed with the SEC as an Exhibit and incorporated herein by reference from ARCA biopharma, Inc.&#8217;s Form&#160;S-1, filed on March&#160;25, 2013, File No.&#160;333-187508).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">3.4</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000119312524085437/d794675dex31.htm">Form of Certificate of Designation of Preferences, Rights and Limitations of Series&#160;B Non-Voting Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 of ARCA biopharma, Inc.&#8217;s Form&#160;8-K filed on April&#160;3, 2024).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">3.5***</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024042529/ea020512201ex3-5_arcabio.htm">Amended and Restated Certificate of Incorporation of Oruka Therapeutics, Inc.</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">3.6***</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024042529/ea020512201ex3-6_arcabio.htm">Bylaws of Oruka Therapeutics, Inc, as currently in effect.</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">4.1</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000119312509013220/dex41.htm">Form of Common Stock Certificate (incorporated by reference to Exhibit 4.1 of ARCA biopharma, Inc.&#8217;s Form&#160;8-K filed on January&#160;29, 2009).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">4.2</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000156459019017210/abio-ex42_106.htm">Form of Common Stock Certificate (incorporated by reference to Exhibit 4.2 of ARCA biopharma, Inc.&#8217;s Form&#160;10-Q filed on May&#160;8, 2019).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">4.3***</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024042529/ea020512201ex4-3_arcabio.htm">Investor Rights Agreement, dated March&#160;6, 2024, by and among Oruka Therapeutics, Inc. and certain parties thereto.</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">5.1**</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Opinion of Wilson Sonsini Goodrich&#160;&amp; Rosati, P.C.</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">8.1*</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="ea020512204ex8-1_arca.htm">Form of Tax Opinion of Wilson Sonsini Goodrich &amp; Rosati, P.C.</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">8.2*</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="ea020512204ex8-2_arca.htm">Form of Tax Opinion of Gibson, Dunn &amp; Crutcher LLP</a></p>
					</td>
				</tr>

		</table>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">II-4</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;border-left-style:solid;border-right-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">



						<p class="TCH_left" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Exhibit <br/>Number</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-left-style:solid;border-right-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;border-left-style:solid;border-right-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><br/>Description</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-width:0pt;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.1</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000119312524085437/d794675dex101.htm">Form of Oruka Support Agreement (incorporated by reference to Exhibit 10.1 to ARCA biopharma, Inc&#8217;s Form&#160;8-K filed on April&#160;3, 2024).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.2&#8224;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000119312524085437/d794675dex102.htm">Form of Oruka Subscription Agreement (incorporated by reference to Exhibit 10.2 to ARCA biopharma, Inc&#8217;s Form&#160;8-K filed on April&#160;3, 2024).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.3</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000119312524085437/d794675dex103.htm">Form of ACRA Support Agreement (incorporated by reference to Exhibit 10.3 to ARCA biopharma, Inc&#8217;s Form&#160;8-K filed on April&#160;3, 2024).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.4</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000119312524085437/d794675dex104.htm">Form of Lock-Up Agreement (incorporated by reference to Exhibit 10.4 to ARCA biopharma, Inc&#8217;s Form&#160;8-K filed on April&#160;3, 2024).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.5</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000095017024041846/abio-ex10_1.htm">Separation Agreement and Release, by and between ARCA and Michael Bristow, dated as of April&#160;3, 2024 (incorporated by reference to Exhibit 10.1 of ARCA biopharma, Inc.&#8217;s Form&#160;8-K filed on April&#160;4, 2024).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.6&#8224;&#8224;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000095017024041846/abio-ex10_2.htm">Consulting Agreement, by and between ARCA and Michael Bristow, dated as of April&#160;3, 2024 (incorporated by reference to Exhibit 10.2 of ARCA biopharma, Inc.&#8217;s Form&#160;8-K filed on April&#160;4, 2024).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.7#</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000095017022026298/abio-ex10_1.htm">Memorandum Regarding Cash Retention Bonus between ARCA biopharma, Inc. and Thomas A, Keuer dated December&#160;8, 2022 (incorporated by reference to Exhibit 10.1 of ARCA biopharma, Inc.&#8217;s Form&#160;8-K filed on December&#160;9, 2022).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.8#</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000095017023067790/abio-ex10_1.htm">Amendment to Retention Bonus Letter, dated December&#160;4, 2023, by and among ARCA biopharma, Inc. and Thomas A.&#160;Keuer (incorporated by reference to Exhibit 10.1 of ARCA biopharma, Inc.&#8217;s Form&#160;8-K filed on December&#160;4, 2023).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.9#</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000095017024046918/abio-ex10_1.htm">Second Amendment to Retention Bonus Letter, dated April&#160;22, 2024, by and between ARCA biopharma, Inc. and Thomas A.&#160;Keuer (incorporated by reference to Exhibit 10.1 of ARCA biopharma, Inc.&#8217;s Form&#160;8-K filed on April&#160;23, 2024).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.10#</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000095017022026298/abio-ex10_2.htm">Memorandum Regarding Cash Retention Bonus between ARCA biopharma, Inc. and C.&#160;Jeffrey Dekker dated December&#160;8, 2022 (incorporated by reference to Exhibit 10.2 of ARCA biopharma, Inc.&#8217;s Form&#160;8-K filed on December&#160;9, 2022).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.11#</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000095017023067790/abio-ex10_2.htm">Amendment to Retention Bonus Letter, dated December&#160;4, 2023, by and among ARCA biopharma, Inc. and C.&#160;Jeffrey Dekker (incorporated by reference to Exhibit 10.2 of ARCA biopharma, Inc.&#8217;s Form&#160;8-K filed on December&#160;4, 2023).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.12#</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000095017024046918/abio-ex10_2.htm">Second Amendment to Retention Bonus Letter, dated April&#160;22, 2024, by and between ARCA biopharma, Inc. and C.&#160;Jeffrey Dekker (incorporated by reference to Exhibit 10.2 of ARCA biopharma, Inc.&#8217;s Form&#160;8-K filed on April&#160;23, 2024).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.13</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000156459020042033/abio-ex101_7.htm">Office Lease Agreement, effective August&#160;7, 2020, between ARCA biopharma, Inc. and Potens Partners&#160;LLC (incorporated by reference to Exhibit 10.1 of ARCA biopharma, Inc.&#8217;s Form&#160;8-K filed on August&#160;31, 2020).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.14</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000095017024035373/abio-ex10_1.htm">First Amendment to Office Lease Agreement, dated March&#160;19, 2024, by and between ARCA biopharma, Inc. and Lotus Church Ranch, LLC (incorporated by reference to Exhibit 10.1 of ARCA biopharma, Inc.&#8217;s Form&#160;8-K filed on March&#160;22, 2024).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.15#</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000119312513374827/d601298dex101.htm">ARCA biopharma, Inc. 2013 Equity Incentive Plan (incorporated by reference to Exhibit 10.1 of ARCA biopharma, Inc.&#8217;s Form&#160;8-K filed on September&#160;23, 2013).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.16#</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000119312513374827/d601298dex102.htm">Form of Stock Option Agreement and Option Grant Notice under 2013 Equity Incentive Plan (Standard) (incorporated by reference to Exhibit 10.2 of ARCA biopharma, Inc.&#8217;s Form&#160;8-K filed on September&#160;23, 2013).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.17#</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000119312513374827/d601298dex103.htm">Form of Stock Option Agreement and Option Grant Notice under 2013 Equity Incentive Plan (Officer) (incorporated by reference to Exhibit 10.3 of ARCA biopharma, Inc.&#8217;s Form&#160;8-K filed on September&#160;23, 2013).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.18#</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000119312513374827/d601298dex104.htm">Form of Stock Option Agreement and Option Grant Notice under 2013 Equity Incentive Plan (Director) (incorporated by reference to Exhibit 10.4 of ARCA biopharma, Inc.&#8217;s Form&#160;8-K filed on September&#160;23, 2013).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.19#</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000119312513374827/d601298dex105.htm">Form of Restricted Stock Unit Award Agreement and Notice of Grant Award under 2013 Equity Incentive Plan (Standard) (incorporated by reference to Exhibit 10.5 of ARCA biopharma, Inc.&#8217;s Form&#160;8-K filed on September&#160;23, 2013).</a></p>
					</td>
				</tr>

		</table>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">II-5</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;border-left-style:solid;border-right-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">



						<p class="TCH_left" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Exhibit <br/>Number</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-left-style:solid;border-right-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;border-left-style:solid;border-right-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><br/>Description</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-width:0pt;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.20#</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000119312513374827/d601298dex106.htm">Form of Restricted Stock Unit Award Agreement and Notice of Grant Award under 2013 Equity Incentive Plan (Officer) (incorporated by reference to Exhibit 10.6 of ARCA biopharma, Inc.&#8217;s Form&#160;8-K filed on September&#160;23, 2013).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.21#</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000156459020056751/abio-ex101_7.htm">ARCA biopharma, Inc. 2020 Equity Incentive Plan (incorporated by reference to Exhibit 10.1 of ARCA biopharma, Inc.&#8217;s Form&#160;8-K filed on December&#160;10, 2020).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.22#</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000156459020058225/abio-ex101_6.htm">Form of Stock Option Agreement and Option Grant Notice under 2020 Equity Incentive Plan (Standard) (incorporated by reference to Exhibit 10.1 of ARCA biopharma, Inc.&#8217;s Form&#160;8-K filed on December&#160;23, 2020).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.23#</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000156459020058225/abio-ex102_11.htm">Form of Stock Option Agreement and Option Grant Notice under 2020 Equity Incentive Plan (Officer) (incorporated by reference to Exhibit 10.2 of ARCA biopharma, Inc.&#8217;s Form&#160;8-K filed on December&#160;23, 2020).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.24#</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000156459020058225/abio-ex103_7.htm">Form of Stock Option Agreement and Option Grant Notice under 2020 Equity Incentive Plan (Director) (incorporated by reference to Exhibit 10.3 of ARCA biopharma, Inc.&#8217;s Form&#160;8-K filed on December&#160;23, 2020).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.25#</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000156459020058225/abio-ex104_8.htm">Form of Restricted Stock Unit Award Agreement Notice of Grant Award under 2020 Equity Incentive Plan (Standard) (incorporated by reference to Exhibit 10.4 of ARCA biopharma, Inc.&#8217;s Form&#160;8-K filed on December&#160;23, 2020).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.26#</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000156459020058225/abio-ex105_9.htm">Form of Restricted Stock Unit Award Agreement Notice of Grant Award under 2020 Equity Incentive Plan (Officer) (incorporated by reference to Exhibit 10.5 of ARCA biopharma, Inc.&#8217;s Form&#160;8-K filed on December&#160;23, 2020).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.27&#167;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000119312509113082/dex101.htm">License and Sublicense Agreement, dated October&#160;28, 2003, by and between ARCA Discovery, Inc. and CPEC, L.L.C. (incorporated by reference to Exhibit 10.1 of ARCA biopharma, Inc.&#8217;s Form&#160;10-Q filed on May&#160;15, 2009).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.28&#167;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000119312509113082/dex102.htm">Amendment to License and Sublicense Agreement, dated February&#160;22, 2006, by and between ARCA Discovery, Inc. and CPEC, L.L.C. (incorporated by reference to Exhibit 10.2 of ARCA biopharma, Inc.&#8217;s Form&#160;10-Q filed on May&#160;15, 2009).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.29</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000119312509064819/dex1046.htm">Assignment and Assumption Agreement, dated January&#160;26, 2009, by and between ARCA biopharma, Inc. and ARCA biopharma Colorado, Inc. (incorporated by reference to Exhibit 10.46 of ARCA biopharma, Inc.&#8217;s Form&#160;10-K filed on March&#160;27, 2009).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.30</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000119312509064819/dex1048.htm">Assignment and Assumption Agreement, dated January&#160;26, 2009, by and between ARCA biopharma, Inc. and ARCA biopharma Colorado, Inc. (incorporated by reference to Exhibit 10.48 of ARCA biopharma, Inc.&#8217;s Form&#160;10-K filed on March&#160;27, 2009).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.31</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000119312509064819/dex1052.htm">Form of Indemnification Agreement between ARCA biopharma, Inc. and its directors and officers (incorporated by reference to Exhibit 10.52 of ARCA biopharma, Inc.&#8217;s Form&#160;10-K filed on March&#160;27, 2009).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.32&#167;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000119312511223373/dex105.htm">Amended and Restated Exclusive License Agreement, dated August&#160;12, 2011, by and between the Regents of the University of Colorado and ARCA biopharma, Inc (incorporated by reference to Exhibit 10.5 of ARCA biopharma, Inc.&#8217;s Form&#160;10-Q filed on August&#160;15, 2011).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.33#</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000119312509064819/dex1043.htm">Amended and Restated Employment and Retention Agreement, dated June&#160;4, 2008, by and between ARCA biopharma, Inc. and Michael R.&#160;Bristow (incorporated by reference to Exhibit 10.43 of ARCA biopharma, Inc.&#8217;s Form&#160;10-K filed on March&#160;27, 2009).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.34#</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000156459013000333/abio-ex10_20130629569.htm">Amendment Agreement by and between ARCA biopharma, Inc. and Michael R.&#160;Bristow, effective as of June&#160;13, 2013 (incorporated by reference to Exhibit 10.6 of ARCA biopharma, Inc.&#8217;s Form&#160;10-Q filed August&#160;13, 2013).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.35#</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000119312514457143/d842508dex102.htm">Amended and Restated Employment Agreement, dated December&#160;29, 2014, by and between ARCA biopharma, Inc. and Thomas A.&#160;Keuer (incorporated by reference to Exhibit 10.2 of ARCA biopharma, Inc.&#8217;s Form&#160;8-K/A filed on December&#160;30, 2014).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.36#</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000156459021026534/abio-ex102_75.htm">Employment Agreement, dated April&#160;21, 2021, by and between ARCA biopharma, Inc. and C.&#160;Jeff Dekker (incorporated by reference to Exhibit 10.2 of ARCA biopharma, Inc.&#8217;s Form&#160;10-Q filed on May&#160;11, 2021).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.37&#167;&#167;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000156459021040795/abio-ex103_140.htm">Assignment Agreement for Patent Rights, dated July&#160;1, 2021, by and between ARCA biopharma, Inc. and University Medical Center of the Johannes Gutenberg University Mainz (incorporated by reference to Exhibit 10.3 of ARCA biopharma, Inc.&#8217;s Form&#160;10-Q filed on August&#160;4, 2021).</a></p>
					</td>
				</tr>

		</table>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">II-6</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;border-left-style:solid;border-right-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">



						<p class="TCH_left" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Exhibit <br/>Number</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-left-style:solid;border-right-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;border-left-style:solid;border-right-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><br/>Description</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-width:0pt;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.38*#</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="#T110">Oruka Therapeutics, Inc. 2024 Stock Incentive Plan (included as <span class="Italic" style="font-style:italic;font-weight:normal;">Annex&#160;K </span>to the proxy statement/prospectus and incorporated herein by reference)</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.39*#</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="#T112">Oruka Therapeutics, Inc. 2024 Employee Stock Purchase Plan (included as <span class="Italic" style="font-style:italic;font-weight:normal;">Annex&#160;L </span>to the proxy statement/prospectus and incorporated herein by reference)</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.40***#</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024042529/ea020512201ex10-40_arcabio.htm">Amended and Restated Oruka Therapeutics, Inc. 2024 Equity Incentive Plan, as amended by the First Amendment dated May 7, 2024</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.41***</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024042529/ea020512201ex10-41_arcabio.htm">Form of Restricted Stock Notice and Restricted Stock Purchase Agreement of Oruka Therapeutics, Inc.</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.42***#</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024042529/ea020512201ex10-42_arcabio.htm">Form of Stock Option Agreement under Oruka Therapeutics, Inc. 2024 Equity Incentive Plan</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.43***#</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024042529/ea020512201ex10-43_arcabio.htm">Amended and Restated Director Offer Letter, dated March&#160;22, 2024, between Oruka Therapeutics, Inc. and Samarth Kulkarni</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.44***#</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024042529/ea020512201ex10-44_arcabio.htm">Director Offer Letter, dated April&#160;24, 2024, between Oruka Therapeutics, Inc. and Kristine Ball</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.45***</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024042529/ea020512201ex10-45_arcabio.htm">Form of Indemnification Agreement between Oruka Therapeutics, Inc. and its directors and officers</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.46***#</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024042529/ea020512201ex10-46_arcabio.htm">Amended and Restated Employment Offer Letter, dated February&#160;14, 2024, by and between Oruka Therapeutics, Inc. and Lawrence Klein</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.47***#</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024042529/ea020512201ex10-47_arcabio.htm">Employment Offer Letter, dated March&#160;11, 2024, by and between Oruka Therapeutics, Inc. and Arjun Agarwal</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.48***#</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024042529/ea020512201ex10-48_arcabio.htm">Employment Offer Letter, dated March&#160;15, 2024, by and between Oruka Therapeutics, Inc. and Joana Goncalves</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.49***#</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024042529/ea020512201ex10-49_arcabio.htm">Employment Offer Letter, dated April&#160;12, 2024, by and between Oruka Therapeutics, Inc. and Paul Quinlan</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.50***&#8224;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024053881/ea020512202ex10-50_arcabio.htm">Amended and Restated Antibody Discovery and Option Agreement (IL-17), dated March&#160;28, 2024, by and among Paragon Therapeutics, Inc., Paruka Holding LLC and Oruka Therapeutics, Inc.</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.51***&#8224;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024053881/ea020512202ex10-51_arcabio.htm">Amended and Restated Antibody Discovery and Option Agreement (IL-23), dated March&#160;28, 2024, by and among Paragon Therapeutics, Inc., Paruka Holding LLC and Oruka Therapeutics, Inc.</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">21.1***</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024042529/ea020512201ex21-1_arcabio.htm">List of Subsidiaries of ARCA biopharma, Inc.</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">23.1*</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="ea020512204ex23-1_arca.htm">Consent of KPMG LLP, independent registered public accounting firm of ARCA biopharma, Inc.</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">23.2*</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="ea020512204ex23-2_arca.htm">Consent of PricewaterhouseCoopers LLP, independent registered public accounting firm of Oruka Therapeutics, Inc.</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">23.3**</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Consent of Wilson Sonsini Goodrich&#160;&amp; Rosati, P.C. (included in Exhibit 5.1).</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">24.1***</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024042529/ea0205122-01.htm#T555">Power of Attorney (included in the signature page hereto).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">99.1**</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Form of ARCA biopharma, Inc. proxy card.</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">99.2***</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024053881/ea0205122-02.htm#T106">Proposed form of Certificate of Amendment of Certificate of Incorporation of ARCA biopharma, Inc.&#160;&#8212;&#160;Increase in Authorized Shares (included as Annex&#160;G to the proxy statement/prospectus and incorporated herein by reference).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">99.3***</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024053881/ea0205122-02.htm#T107">Proposed form of Certificate of Amendment of Certificate of Incorporation of ARCA biopharma, Inc.&#160;&#8212;&#160;Reverse Stock Split (included as Annex&#160;H to the proxy statement/prospectus and incorporated herein by reference).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">99.4***</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024053881/ea0205122-02.htm#T108">Proposed form of Certificate of Amendment of Certificate of Incorporation of ARCA biopharma, Inc.&#160;&#8212;&#160;Officer Exculpation (included as Annex&#160;I to the proxy statement/prospectus and incorporated herein by reference).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">99.5***</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024042529/ea020512201ex99-5_arcabio.htm">Consent of Lucid Capital Markets, LLC.</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">99.6***</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024042529/ea020512201ex99-6_arcabio.htm">Consent of Lawrence Klein to serve as a director of ARCA biopharma, Inc., to be renamed Oruka Therapeutics, Inc. </a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">99.7***</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024042529/ea020512201ex99-7_arcabio.htm">Consent of Kristine Ball to serve as a director of ARCA biopharma, Inc., to be renamed Oruka Therapeutics, Inc. </a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">99.8***</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024042529/ea020512201ex99-8_arcabio.htm">Consent of Carl Dambkowski to serve as a director of ARCA biopharma, Inc., to be renamed Oruka Therapeutics, Inc. </a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">99.9***</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024042529/ea020512201ex99-9_arcabio.htm">Consent of Peter Harwin to serve as a director of ARCA biopharma, Inc., to be renamed Oruka Therapeutics, Inc. </a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">99.10***</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024042529/ea020512201ex99-10_arcabio.htm">Consent of Samarth Kulkarni to serve as a director of ARCA biopharma, Inc., to be renamed Oruka Therapeutics, Inc. </a></p>
					</td>
				</tr>

		</table>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">II-7</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 3pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;border-left-style:solid;border-right-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">



						<p class="TCH_left" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Exhibit <br/>Number</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-left-style:solid;border-right-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;border-left-style:solid;border-right-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><br/>Description</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-width:0pt;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">99.11***</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024042529/ea020512201ex99-11_arcabio.htm">Consent of Cameron Turtle to serve as a director of ARCA biopharma, Inc., to be renamed Oruka Therapeutics, Inc. </a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">101.INS*</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">XBRL Instance Document.</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">101.SCH*</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">XBRL Taxonomy Extension Schema.</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">101.CAL*</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">XBRL Taxonomy Extension Calculation Linkbase.</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">101.DEF*</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">XBRL Taxonomy Extension Definition Linkbase.</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">101.LAB*</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">XBRL Taxonomy Extension Label Linkbase.</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">101.PRE*</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">XBRL Taxonomy Extension Presentation Linkbase.</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">107**</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Filing Fee Table.</p>
					</td>
				</tr>

		</table>
		<p class="Tablefootnotef" style="margin-top: 0in;  border: none; margin-right: 0in; margin-bottom: -5pt; margin-left: 24.0pt; text-align: justify; text-justify: inter-ideograph; text-indent: -24.0pt; padding: 0in; font-size: 9.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">____________</p><p class="Tablefootnote_f" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:10pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:10pt;">*<span style="width: 24px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Filed herewith.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">**<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>To be filed by amendment.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">***<span style="width: 12px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Previously filed.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">#<span style="width: 24px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Indicates management contract or compensatory plan or arrangement.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">&#8224;<span style="width: 24px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Exhibits and/or schedules have been omitted pursuant to Item&#160;601(a)(5)&#160;of Regulation&#160;S<span class="nobreak">-K</span>.&#160;The registrant hereby undertakes to furnish supplementally copies of any of the omitted exhibits and schedules upon request by the SEC; provided, however, that the registrant may request confidential treatment pursuant to Rule&#160;24b<span class="nobreak">-2</span> under the Exchange&#160;Act for any exhibits or schedules so furnished. Certain portions of this exhibit (indicated by &#8220;[***]&#8221;) have been omitted because they are both (i)&#160;not material and (ii)&#160;would be competitively harmful if publicly disclosed.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">&#8224;&#8224;<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Certain portions of this exhibit (indicated by &#8220;[***]&#8221;) have been omitted because they are both (i)&#160;not material and (ii)&#160;would be competitively harmful if publicly disclosed.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">&#167;<span style="width: 24px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Confidential treatment has been granted as to portions of the exhibit. Confidential materials omitted and filed separately with the SEC.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">&#167;&#167;<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Schedules have been omitted from this filing pursuant to Item&#160;601(b)(2)&#160;of Regulation&#160;S<span class="nobreak">-K</span>.&#160;ARCA agrees to furnish supplementally a copy of any omitted schedule to the SEC upon its request; provided, however, that the Company may request confidential treatment pursuant to Rule&#160;24b<span class="nobreak">-2</span> of the Exchange&#160;Act for any schedule so furnished. Certain portions of the exhibit, identified by the mark, &#8220;*,&#8221; have been omitted because such portions contained information that is both (i)&#160;not material and (ii)&#160;would likely cause competitive harm if publicly disclosed.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">II-8</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">SIGNATURES</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Pursuant to the requirements of the Securities Act, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized in the City of Westminster, State of Colorado, on July<span class="nobreak"> </span>9, 2024.</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">ARCA BIOPHARMA, INC.</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-11" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 6.84%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">By:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 41.88%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">/s/ Thomas A.&#160;Keuer</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.84%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Name:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 41.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Thomas A.&#160;Keuer</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.84%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Title:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 41.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">President and Chief Operating Officer</p>
					</td>
				</tr>

		</table>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Pursuant to the requirements of the Securities Act this registration statement has been signed by the following persons in the capacities and on the dates indicated.</p>
		<table class="No-Table-Style TableOverride-2" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-15" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 26.65%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">



						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;text-align:left;"><span class="Bold" style="font-style:normal;font-weight:bold;">Signature</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 47.76%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Title</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 23.03%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Date</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-11" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;width: 26.65%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">/s/ Thomas A.&#160;Keuer</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 47.76%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;">President and Chief Operating Officer </p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 23.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;">July<span class="nobreak"> </span>9, 2024</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 26.65%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Thomas A. Keuer</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 47.76%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;"><span class="Italic" style="font-style:italic;font-weight:normal;">(Principal Executive Officer)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 23.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-11" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;width: 26.65%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">/s/ C.&#160;Jeffrey Dekker</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 47.76%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;">Chief Financial Officer </p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 23.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;">July<span class="nobreak"> </span>9, 2024</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 26.65%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">C. Jeffrey Dekker</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 47.76%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">(<span class="Italic" style="font-style:italic;font-weight:normal;">Principal Financial Officer and <br/>Principal Accounting Officer</span>)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 23.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-11" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;width: 26.65%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">/s/ *</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 47.76%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;">Director</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 23.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;">July<span class="nobreak"> </span>9, 2024</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 26.65%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Linda Grais</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 47.76%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 23.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-11" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;width: 26.65%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">/s/ *</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 47.76%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;">Director</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 23.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;">July<span class="nobreak"> </span>9, 2024</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 26.65%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Robert Conway</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 47.76%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 23.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-11" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;width: 26.65%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">/s/ *</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 47.76%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;">Director</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 23.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;">July<span class="nobreak"> </span>9, 2024</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 26.65%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Anders Hove</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 47.76%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 23.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-11" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;width: 26.65%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">/s/ *</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 47.76%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;">Director</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 23.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;">July<span class="nobreak"> </span>9, 2024</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 26.65%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Jacob Ma<span class="nobreak">-Weaver</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 47.76%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 23.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-11" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;width: 26.65%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">/s/ *</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 47.76%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;">Director</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 23.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;">July<span class="nobreak"> </span>9, 2024</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 26.65%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">James Flynn</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 47.76%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 23.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>

		</table>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 4.06%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">*&#160;By:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 29.91%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">/s/ Thomas A.&#160;Keuer</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 63.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="No-Table-Style TB" style="width: 4.06%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 29.91%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Thomas A.&#160;Keuer</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 63.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="No-Table-Style TB" style="width: 4.06%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 29.91%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Attorney<span class="nobreak">-in-Fact</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 63.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>

		</table>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">II-9</p>



</div><div style="display: none"><ix:header>
<ix:hidden>
<ix:nonNumeric contextRef="c0" id="hidden-fact-0" name="dei:DocumentType">S-4/A</ix:nonNumeric>
<ix:nonFraction contextRef="c1" id="hidden-fact-1" name="us-gaap:CommitmentsAndContingencies" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c2" id="hidden-fact-2" name="us-gaap:CommitmentsAndContingencies" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c1" id="hidden-fact-3" name="us-gaap:PreferredStockValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c2" id="hidden-fact-4" name="us-gaap:PreferredStockValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c5" id="hidden-fact-5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c6" id="hidden-fact-6" name="us-gaap:OtherNonoperatingExpense" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c6" decimals="2" id="hidden-fact-7" name="us-gaap:EarningsPerShareDiluted" sign="-" unitRef="usdPershares">0.37</ix:nonFraction>
<ix:nonFraction contextRef="c7" decimals="2" id="hidden-fact-8" name="us-gaap:EarningsPerShareDiluted" sign="-" unitRef="usdPershares">0.69</ix:nonFraction>
<ix:nonFraction contextRef="c7" decimals="0" id="hidden-fact-9" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="shares">14410143</ix:nonFraction>
<ix:nonFraction contextRef="c6" decimals="0" id="hidden-fact-10" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="shares">14415877</ix:nonFraction>
<ix:nonFraction contextRef="c10" decimals="2" id="hidden-fact-11" name="us-gaap:EarningsPerShareDiluted" sign="-" unitRef="usdPershares">0.09</ix:nonFraction>
<ix:nonFraction contextRef="c0" decimals="2" id="hidden-fact-12" name="us-gaap:EarningsPerShareDiluted" sign="-" unitRef="usdPershares">0.14</ix:nonFraction>
<ix:nonFraction contextRef="c10" decimals="0" id="hidden-fact-13" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="shares">14410143</ix:nonFraction>
<ix:nonFraction contextRef="c0" decimals="0" id="hidden-fact-14" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="shares">14501143</ix:nonFraction>
<ix:nonFraction contextRef="c17" id="hidden-fact-15" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c19" id="hidden-fact-16" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c17" id="hidden-fact-17" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c18" id="hidden-fact-18" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c23" id="hidden-fact-19" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c24" id="hidden-fact-20" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c25" id="hidden-fact-21" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c6" id="hidden-fact-22" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c23" id="hidden-fact-23" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c25" id="hidden-fact-24" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c23" id="hidden-fact-25" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c24" id="hidden-fact-26" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c29" id="hidden-fact-27" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c31" id="hidden-fact-28" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c29" id="hidden-fact-29" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c30" id="hidden-fact-30" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c36" id="hidden-fact-31" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c38" id="hidden-fact-32" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c36" id="hidden-fact-33" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c37" id="hidden-fact-34" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c44" id="hidden-fact-35" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c46" id="hidden-fact-36" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c44" id="hidden-fact-37" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c45" id="hidden-fact-38" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c52" id="hidden-fact-39" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c53" id="hidden-fact-40" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c54" id="hidden-fact-41" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c55" id="hidden-fact-42" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c52" id="hidden-fact-43" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c54" id="hidden-fact-44" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c52" id="hidden-fact-45" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c53" id="hidden-fact-46" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c56" id="hidden-fact-47" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c58" id="hidden-fact-48" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c56" id="hidden-fact-49" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c57" id="hidden-fact-50" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c6" id="hidden-fact-51" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c7" id="hidden-fact-52" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c6" id="hidden-fact-53" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c6" id="hidden-fact-54" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c6" id="hidden-fact-55" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c7" id="hidden-fact-56" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c6" id="hidden-fact-57" name="us-gaap:InterestPaidNet" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c7" id="hidden-fact-58" name="us-gaap:InterestPaidNet" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c6" id="hidden-fact-59" name="us-gaap:ProceedsFromIncomeTaxRefunds" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c7" id="hidden-fact-60" name="us-gaap:ProceedsFromIncomeTaxRefunds" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-61" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c10" id="hidden-fact-62" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-63" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c10" id="hidden-fact-64" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-65" name="us-gaap:InterestPaidNet" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c10" id="hidden-fact-66" name="us-gaap:InterestPaidNet" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-67" name="us-gaap:ProceedsFromIncomeTaxRefunds" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c10" id="hidden-fact-68" name="us-gaap:ProceedsFromIncomeTaxRefunds" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c10" id="hidden-fact-69" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c64" id="hidden-fact-70" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c1" id="hidden-fact-71" name="us-gaap:DebtLongtermAndShorttermCombinedAmount" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c2" id="hidden-fact-72" name="us-gaap:DebtLongtermAndShorttermCombinedAmount" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c6" id="hidden-fact-73" name="abio:FairValueAssetsBetweenHierarchyLevelsTransfersAmount" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c68" id="hidden-fact-74" name="abio:FairValueAssetsBetweenHierarchyLevelsTransfersAmount" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c1" id="hidden-fact-75" name="us-gaap:RestructuringReserveCurrent" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c7" id="hidden-fact-76" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c7" id="hidden-fact-77" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="usdPershares" xsi:nil="true"/>
<ix:nonFraction contextRef="c6" id="hidden-fact-78" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c6" id="hidden-fact-79" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="usdPershares" xsi:nil="true"/>
<ix:nonFraction contextRef="c6" id="hidden-fact-80" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c6" id="hidden-fact-81" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="usdPershares" xsi:nil="true"/>
<ix:nonFraction contextRef="c1" id="hidden-fact-82" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c1" id="hidden-fact-83" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c1" id="hidden-fact-84" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c16" id="hidden-fact-85" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c16" id="hidden-fact-86" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="usdPershares" xsi:nil="true"/>
<ix:nonFraction contextRef="c7" id="hidden-fact-87" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c7" id="hidden-fact-88" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" unitRef="usdPershares" xsi:nil="true"/>
<ix:nonFraction contextRef="c7" id="hidden-fact-89" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c7" id="hidden-fact-90" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" unitRef="usdPershares" xsi:nil="true"/>
<ix:nonFraction contextRef="c6" id="hidden-fact-91" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c6" id="hidden-fact-92" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="usdPershares" xsi:nil="true"/>
<ix:nonFraction contextRef="c6" id="hidden-fact-93" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c6" id="hidden-fact-94" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" unitRef="usdPershares" xsi:nil="true"/>
<ix:nonFraction contextRef="c1" id="hidden-fact-95" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c1" id="hidden-fact-96" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="usdPershares" xsi:nil="true"/>
<ix:nonNumeric contextRef="c98" id="hidden-fact-97" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">P3Y</ix:nonNumeric>
<ix:nonNumeric contextRef="c99" id="hidden-fact-98" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">P4Y</ix:nonNumeric>
<ix:nonNumeric contextRef="c6" id="hidden-fact-99" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">P10Y</ix:nonNumeric>
<ix:nonNumeric contextRef="c107" id="hidden-fact-100" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1">P1Y</ix:nonNumeric>
<ix:nonFraction contextRef="c6" id="hidden-fact-101" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c7" id="hidden-fact-102" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c6" id="hidden-fact-103" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c7" id="hidden-fact-104" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c1" id="hidden-fact-105" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c2" id="hidden-fact-106" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" unitRef="usd" xsi:nil="true"/>
<ix:nonNumeric contextRef="c114" id="hidden-fact-107" name="abio:OperatingLossCarryforwardsExpirationYear">2025</ix:nonNumeric>
<ix:nonNumeric contextRef="c115" id="hidden-fact-108" name="abio:OperatingLossCarryforwardsExpirationYear">2037</ix:nonNumeric>
<ix:nonNumeric contextRef="c6" id="hidden-fact-109" name="us-gaap:OpenTaxYear">2009</ix:nonNumeric>
<ix:nonFraction contextRef="c119" id="hidden-fact-110" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c5" id="hidden-fact-111" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c1" id="hidden-fact-112" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-113" name="abio:FairValueAssetsBetweenHierarchyLevelsTransfersAmount" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c5" id="hidden-fact-114" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c1" id="hidden-fact-115" name="us-gaap:RestructuringReserveCurrent" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c135" id="hidden-fact-116" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-117" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-118" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="usdPershares" xsi:nil="true"/>
<ix:nonFraction contextRef="c5" id="hidden-fact-119" name="us-gaap:LiabilityForUncertainTaxPositionsCurrent" unitRef="usd" xsi:nil="true"/>
<ix:nonNumeric contextRef="c0" name="dei:AmendmentFlag" id="ixv-38439">true</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:EntityCentralIndexKey" id="ixv-38440">0000907654</ix:nonNumeric>
</ix:hidden>
<ix:references><link:schemaRef xlink:href="abio-20240331.xsd" xlink:type="simple"/></ix:references>
<ix:resources xmlns="http://www.xbrl.org/2003/instance"><xbrli:context xmlns="" id="c0">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c1">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c2">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c3">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c4">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c5">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c6">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c7">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c8">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c9">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c10">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c11">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c12">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c13">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c14">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c15">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c16">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c17">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c18">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c19">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c20">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c21">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c22">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c23">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c24">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c25">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c26">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c27">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c28">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c29">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c30">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c31">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c32">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c33">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c34">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c35">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c36">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c37">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c38">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c39">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c40">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c41">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c42">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c43">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c44">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-07-01</xbrli:startDate>
    <xbrli:endDate>2023-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c45">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-07-01</xbrli:startDate>
    <xbrli:endDate>2023-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c46">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-07-01</xbrli:startDate>
    <xbrli:endDate>2023-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c47">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-07-01</xbrli:startDate>
    <xbrli:endDate>2023-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c48">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c49">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c50">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c51">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c52">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-10-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c53">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-10-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c54">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-10-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c55">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-10-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c56">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c57">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c58">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c59">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c60">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c61">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c62">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c63">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c64">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c65">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c66">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c67">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c68">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-12-31</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c69">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c70">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c71">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c72">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c73">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c74">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c75">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrYwqBFvPJwgls7iB/C7qgJlieUnn0NA5OCi94KNojOhCKLtgRf7Lh8PNXaX7qyF9a6SJv7mHT4i4TG0zLkQ0ch6DUlOii5J7LMDGl2/JapjDY9mloXuib5mHVGZ5CeGApH//7xHOalGUmL15AlWw6rbn9qzGZe/F/uh8urYvQsY+tuMobOgKRuTaSu3qacAf3U+DL7e4ELcmLOJtDmP4OEM] CSR-->
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c76">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c77">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c78">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c79">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-12-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c80">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">abio:ClinicalDevelopmentDecisionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c81">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-11-30</xbrli:startDate>
    <xbrli:endDate>2023-11-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c82">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c83">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c84">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c85">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-08-29</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c86">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-08-28</xbrli:startDate>
    <xbrli:endDate>2020-08-29</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c87">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c88">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-10-31</xbrli:startDate>
    <xbrli:endDate>2023-10-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c89">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c90">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c91">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abio:UniversityMedicalCenterOfJohannesGutenbergUniversityMainzMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abio:PatentAssignmentAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-07-01</xbrli:startDate>
    <xbrli:endDate>2021-07-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c92">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abio:CapitalOnDemandSalesAgreementMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="dei:LegalEntityAxis">abio:JonesTradingInstitutionalServicesLLCMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-07-22</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c93">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="dei:LegalEntityAxis">abio:JonesTradingInstitutionalServicesLLCMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-07-22</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c94">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abio:NewCapitalOnDemandSalesAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c95">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abio:NewCapitalOnDemandSalesAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c96">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">abio:TwoThousandAndTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-10</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c97">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">abio:TwoThousandAndTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c98">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c99">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c100">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">abio:IncentiveStockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c101">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">abio:IncentiveStockOptionMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:PrincipalOwnerMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c102">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">abio:TwoThousandAndThirteenPlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c103">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">abio:TwoThousandAndTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c104">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">abio:TwoThousandAndTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c105">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c106">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c107">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c108">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c109">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c110">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c111">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">abio:FirstThreePercentPayContributionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c112">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">abio:NextTwoPercentPayContributionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c113">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c114">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:EarliestTaxYearMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2017-01-01</xbrli:startDate>
    <xbrli:endDate>2017-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c115">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:LatestTaxYearMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2017-01-01</xbrli:startDate>
    <xbrli:endDate>2017-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c116">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c117">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c118">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c119">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c120">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c121">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c122">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c123">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c124">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c125">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c126">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c127">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c128">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-04-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c129">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c130">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c131">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-06-01</xbrli:startDate>
    <xbrli:endDate>2021-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c132">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abio:CapitalOnDemandSalesAgreementMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="dei:LegalEntityAxis">abio:JonesTradingInstitutionalServicesLLCMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c133">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abio:NewCapitalOnDemandSalesAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c134">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abio:NewCapitalOnDemandSalesAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c135">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c136">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c137">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-12-31</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c138">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="dei:LegalEntityAxis">abio:ArcaBiopharmaIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-03</xbrli:startDate>
    <xbrli:endDate>2024-04-03</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c139">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">abio:ArcaBiopharmaIncAndOrukaTherapeuticsIncMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-04-03</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c140">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">abio:ArcaBiopharmaIncAndOrukaTherapeuticsIncMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="dei:LegalEntityAxis">abio:ArcaBiopharmaIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-04-03</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c141">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-03</xbrli:startDate>
    <xbrli:endDate>2024-04-03</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c142">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abio:MergerAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-04-03</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c143">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">abio:ArcaBiopharmaIncAndOrukaTherapeuticsIncMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abio:MergerAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-04-03</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c144">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abio:MergerAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-04-03</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c145">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-04-03</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c146">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abio:FirstMergerMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="dei:LegalEntityAxis">abio:ArcaBiopharmaIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-04-03</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c147">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="dei:LegalEntityAxis">abio:ArcaBiopharmaIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-03</xbrli:startDate>
    <xbrli:endDate>2024-04-03</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c148">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abio:FirstMergerMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="dei:LegalEntityAxis">abio:OrukaTherapeuticsIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-03</xbrli:startDate>
    <xbrli:endDate>2024-04-03</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c149">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abio:CommonStockAndPreFundedWarrantsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="dei:LegalEntityAxis">abio:OrukaTherapeuticsIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-03</xbrli:startDate>
    <xbrli:endDate>2024-04-03</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c150">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abio:SeperationAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-03</xbrli:startDate>
    <xbrli:endDate>2024-04-03</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c151">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:PresidentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abio:SecondAmendmentOfCertainRetentionBonusLettersMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-20</xbrli:startDate>
    <xbrli:endDate>2024-04-20</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c152">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abio:SecondAmendmentOfCertainRetentionBonusLettersMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-20</xbrli:startDate>
    <xbrli:endDate>2024-04-20</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c153">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">abio:ThomasAKeuerAndCJeffreyDekkerMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-04-20</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:unit xmlns="" id="usd">
  <xbrli:measure>iso4217:USD</xbrli:measure>
</xbrli:unit><xbrli:unit xmlns="" id="usdPershares">
  <xbrli:divide>
    <xbrli:unitNumerator>
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unitNumerator>
    <xbrli:unitDenominator>
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unitDenominator>
  </xbrli:divide>
</xbrli:unit><xbrli:unit xmlns="" id="shares">
  <xbrli:measure>xbrli:shares</xbrli:measure>
</xbrli:unit><xbrli:unit xmlns="" id="pure">
  <xbrli:measure>xbrli:pure</xbrli:measure>
</xbrli:unit><xbrli:unit xmlns="" id="sqft">
  <xbrli:measure>utr:sqft</xbrli:measure>
</xbrli:unit><xbrli:unit xmlns="" id="eur">
  <xbrli:measure>iso4217:EUR</xbrli:measure>
</xbrli:unit></ix:resources></ix:header>

</div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-8.1
<SEQUENCE>2
<FILENAME>ea020512204ex8-1_arca.htm
<DESCRIPTION>FORM OF TAX OPINION OF WILSON SONSINI GOODRICH & ROSATI, P.C.
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin-top: 0; margin-bottom: 0"><B>Exhibit 8.1</B></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 72%"><IMG SRC="ex8-1_001.jpg" ALT=""></TD><TD STYLE="text-align: justify; width: 28%"><P STYLE="margin-top: 0; margin-bottom: 0">Wilson Sonsini Goodrich &amp; Rosati</P>
                                                                        <P STYLE="margin-top: 0; margin-bottom: 0">Professional Corporation</P>
                                                                        <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
                                                                        <P STYLE="margin-top: 0; margin-bottom: 0">701 5th Ave #5100</P>
                                                                        <P STYLE="margin-top: 0; margin-bottom: 0">Seattle, WA 98104</P>
                                                                        <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
                                                                        <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-variant: small-caps">o</FONT>: 206.883.2500</P></TD>
</TR></TABLE>

<P STYLE="text-align: right; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">[DATE]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">ARCA biopharma, Inc.<BR>
10170 Church Ranch Way, Suite 100<BR>
Westminster, CO 80021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in"><B>RE: U.S. Federal Income Tax Consequences
of the Merger</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">We have acted as counsel
to ARCA biopharma, Inc., a Delaware corporation (&ldquo;<U>Parent</U>&rdquo;) in connection with that certain registration statement
on Form S-4 (Registration No. 333-279387), initially filed with the Securities and Exchange Commission on [&#9679;], 2024 (the &ldquo;<U>Registration
Statement</U>&rdquo;), including the proxy statement/prospectus forming a part thereof (the &ldquo;<U>Proxy Statement/Prospectus</U>&rdquo;),
and the agreement and plan of merger and reorganization (the &ldquo;<U>Agreement</U>&rdquo;), dated as of April 3, 2024, by and among
Parent, Atlas Merger Sub Corp., a Delaware corporation and a wholly owned subsidiary of Parent (&ldquo;<U>First Merger Sub</U>&rdquo;),
Atlas Merger Sub II, LLC, a Delaware limited liability company and a wholly owned subsidiary of Parent (&ldquo;<U>Second Merger Sub</U>&rdquo;
and, together with First Merger Sub, &ldquo;<U>Merger Subs</U>&rdquo;), and Oruka Therapeutics, Inc., a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;),
pursuant to which (1) First Merger Sub will merge with and into the Company (the &ldquo;<U>First Merger</U>&rdquo;), with the Company
continuing as a wholly owned subsidiary of Parent and the surviving corporation of the First Merger and the outstanding shares of Company
capital stock being converted into the right to receive shares of Parent; and (2) following confirmation of the effectiveness of the
First Merger, the Company will merge with and into Second Merger Sub (the &ldquo;<U>Second Merger</U>&rdquo; and, together with the First
Merger, the &ldquo;<U>Merger</U>&rdquo;), with Second Merger Sub being the surviving entity of the merger.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>1
</SUP></FONT>This opinion is being delivered in connection with the Registration Statement and the Proxy Statement/Prospectus, pursuant
to Section 6.10(c) of the Agreement, concerning certain U.S. federal income tax matters. Capitalized terms used herein but not defined
shall have the meanings set forth in the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">In preparing the opinion
set forth below, we have examined and reviewed originals or copies, certified or otherwise identified to our satisfaction, of the Agreement,
including the exhibits thereto, the Registration Statement and the Proxy Statement/Prospectus, the representation letters of Parent and
the Company (each a &ldquo;<U>Representation Party</U>&rdquo; and together, the &ldquo;<U>Representation Parties</U>&rdquo;) delivered
to us for purposes of this opinion (the &ldquo;<U>Representation Letters</U>&rdquo;) and such other documents, certificates and records
as we have deemed necessary or appropriate as a basis for our opinion. In our examination, we have assumed the genuineness of all signatures,
the legal capacity of natural persons, the authenticity of all documents submitted to us as originals, the conformity to original documents
of all documents submitted to us as certified, conformed, photostatic or electronic copies, and the authenticity of the originals of
such latter documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><SUP>1</SUP></FONT></TD><TD STYLE="text-align: left">Except as otherwise provided, all &ldquo;Section&rdquo; references
contained herein refer to sections of the Internal Revenue Code of 1986, as amended (the &ldquo;<U>Code</U>&rdquo;), and to the Treasury
Regulations promulgated thereunder.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">In rendering our opinion,
we have relied upon statements, representations, warranties and covenants of officers and other representatives of the Representation
Parties, and we have assumed that such statements, representations, warranties and covenants, including those set forth in the Representation
Letters, are and will continue to be true, correct and complete (and, to the extent relevant, complied with) through the Merger Effective
Time without regard to any qualification as to knowledge, belief, intent, or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">In rendering our opinion,
we have assumed, without any independent investigation or examination thereof, that (i) the Merger will be consummated in the manner
described in the Agreement and will be effective under applicable state law, and that none of the terms or conditions contained therein
will be waived or modified and (ii) the Agreement, the Registration Statement, the Proxy Statement/Prospectus and the Representation
Letters accurately and completely reflect the facts relating to the Merger. Our opinion assumes and is expressly conditioned on, among
other things, the initial and continuing accuracy of the facts, information, covenants, representations and warranties set forth in the
documents referred to above, including those set forth in the Representation Letters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Our opinion is based on the
Code, Treasury Regulations promulgated thereunder, judicial decisions, published positions of the Internal Revenue Service (the &ldquo;<U>Service</U>&rdquo;),
and such other authorities as we have considered relevant, all as in effect on the date of this opinion and all of which are subject
to change or differing interpretations, possibly with retroactive effect. A change in the authorities upon which our opinion is based
could affect the conclusions expressed herein. Moreover, there can be no assurance that positions contrary to our opinion will not be
taken by the Service or, if challenged, by a court.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Based upon the foregoing
we are of the opinion that, for U.S. federal income tax purposes, the Merger will qualify as a &ldquo;reorganization&rdquo; within the
meaning of Section 368(a) of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Except as expressly set forth
above, we express no other opinion. We are furnishing this opinion solely to you in connection with the Merger, and this opinion is not
to be relied upon by any other person or for any other purpose without our prior written consent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">This opinion is expressed
as of the date hereof, and we are under no obligation to supplement or revise our opinion to reflect any legal developments, any factual
matters arising subsequent to the date hereof, or the impact of any information, document, certificate, record, statement, representation,
covenant, or assumption relied upon herein that becomes incorrect or untrue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 60%"></TD><TD STYLE="text-align: justify; width: 40%">Very truly yours</TD>
</TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify">&nbsp;</TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: justify"><FONT STYLE="text-decoration: none">Wilson Sonsini Goodrich
&amp; Rosati, P.C.</FONT></TD></TR>
     </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">-2-</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-8.2
<SEQUENCE>3
<FILENAME>ea020512204ex8-2_arca.htm
<DESCRIPTION>FORM OF TAX OPINION OF GIBSON, DUNN & CRUTCHER LLP
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 8.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 75%; text-align: left"><IMG SRC="ex8-2_001.jpg" ALT=""></TD><TD STYLE="text-align: justify; width: 25%">Gibson, Dunn &amp; Crutcher LLP</TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>
                                                                        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in">200 Park Avenue<BR>
New York, NY 10166-0193</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in">Tel 212.351.4000</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in">gibsondunn.com</P>

</TD></TR>
     </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM OF OPINION AS TO TAX MATTERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">[DATE], 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Oruka Therapeutics, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">221 Crescent Street, Building 23, Suite 105</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Waltham, Massachusetts 02453</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">We have acted as U.S. tax
counsel to Oruka Therapeutics, Inc., a corporation incorporated pursuant to the laws of Delaware (&ldquo;<U>Company</U>&rdquo;), in connection
with the proposed merger of Atlas Merger Sub Corp. (&ldquo;<U>First Merger Sub</U>&rdquo;), a newly-formed corporation incorporated pursuant
to the laws of Delaware and a direct, wholly-owned subsidiary of ARCA Biopharma, Inc., a corporation incorporated pursuant to the laws
of Delaware (&ldquo;<U>Parent</U>&rdquo;), with and into the Company, with the Company as the surviving corporation (the &ldquo;<U>First
Merger</U>&rdquo;), and the subsequent merger of Atlas Merger Sub II, LLC (&ldquo;<U>Second Merger Sub</U>&rdquo; and, together with the
First Merger Sub, &ldquo;<U>Merger Subs</U>&rdquo;), a newly-formed Delaware limited liability company and a direct, wholly-owned subsidiary
of Parent, with Second Merger Sub being the surviving entity of the merger (the &ldquo;<U>Second Merger</U>&rdquo; and, together with
the First Merger, the &ldquo;<U>Merger</U>&rdquo;) pursuant to the Agreement and Plan of Merger among Company, Parent, and Merger Subs
dated as of April 3, 2024 (the &ldquo;<U>Merger Agreement</U>&rdquo;). At your request, and in connection with the filing of the Form
S-4 (Registration No. 333-279387) (including the proxy statement/prospectus contained therein, the &ldquo;<U>Registration Statemen</U>t&rdquo;),
we are rendering our opinion concerning the qualification of the Merger as a &ldquo;reorganization&rdquo; within the meaning of section
368(a) of the Code.<FONT STYLE="font-size: 10pt"><SUP>1</SUP></FONT> Capitalized terms used but not defined in this letter shall have
the meanings ascribed to them in the Merger Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">In rendering our opinion,
we have examined the Merger Agreement, the Registration Statement, (as amended or supplemented through the date of this letter), and such
other documents as we have deemed necessary or appropriate for purposes of our opinion. In addition, we have assumed that (i) the Merger
will be consummated in accordance with the provisions of the Merger Agreement and as described in the Registration Statement, (ii) no
transaction, covenant, or condition described in the Registration Statement and affecting this opinion will be waived by any party, (iii)
the statements concerning the Merger and the parties set forth in the Merger Agreement are true, complete, and correct, (iv) the Registration
Statement is true, complete, and correct, (v) the statements and representations made by Parent and the Company in their respective officer&rsquo;s
certificates dated as of the date of this letter and delivered to us for purposes of this opinion (the &ldquo;<U>Officer&rsquo;s Certificates</U>&rdquo;)
are true, complete and correct as of the date of this letter and will remain true, complete and correct at all times up to and including
the Closing Date, (vi) any such statements and representations made in the Officer&rsquo;s Certificates that are qualified by knowledge,
belief, materiality, or comparable qualification are and will be true, complete, and correct without such qualification, and (vii) Parent,
the Company, and their respective subsidiaries will treat the Merger for U.S. federal income tax purposes in a manner consistent with
the opinion set forth below. If any of the above-described assumptions are untrue for any reason, our opinion as expressed below may be
adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt"><SUP>1</SUP></FONT></TD><TD STYLE="text-align: left">Unless otherwise indicated, all &ldquo;section&rdquo; references
are to the Internal Revenue Code of 1986 (the &ldquo;Code&rdquo;), as in effect as of the date of this Opinion.</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Abu
Dhabi &ndash; Beijing &ndash; Brussels &ndash; Century City &ndash; Dallas &ndash; Denver &ndash; Dubai &ndash; Frankfurt &ndash; Hong
Kong &ndash; Houston &ndash; London &ndash; Los Angeles<BR>
Munich &ndash; New York &ndash; Orange County &ndash; Palo Alto &ndash; Paris &ndash; Riyadh &ndash; San Francisco &ndash; Singapore
&ndash; Washington, D.C.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0pt"><IMG SRC="ex8-2_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Oruka Therapeutics, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">[DATE], 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Page 2</FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Based upon and subject to
the foregoing, we are of the opinion that, under currently applicable U.S. federal income tax law, the Merger will qualify as a reorganization
within the meaning of section 368(a) of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">We express no opinion on any
issue relating to the tax consequences of the Merger contemplated by the Registration Statement other than the opinion set forth above.
Our opinion is based on current provisions of the Code, Treasury regulations promulgated under the Code, published pronouncements of the
Internal Revenue Service, and case law, any of which may be changed at any time with retroactive effect. Any change in applicable laws
or the facts and circumstances surrounding the Merger, or any inaccuracy in the statements, facts, assumptions, or representations upon
which we have relied, may affect the continuing validity of our opinion as set forth in this letter. We assume no responsibility to inform
Parent of any such change or inaccuracy that may occur or come to our attention.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">We are furnishing this opinion
in connection with the filing of the Registration Statement, and this opinion is not to be relied upon for any other purpose without our
prior written consent. We hereby consent to the filing of this opinion with the Securities and Exchange Commission as an exhibit to the
Registration Statement and to the references in the Registration Statement to us. In giving such consent, we do not admit that we are
in the category of persons whose consent is required under Section 7 of the Securities Act of 1933, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Very truly yours,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>ea020512204ex23-1_arca.htm
<DESCRIPTION>CONSENT OF KPMG LLP, INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM OF ARCA BIOPHARMA, INC
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 23.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>



<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 8%"><IMG SRC="ex23-1_001.jpg" ALT=""></TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 44%; font-size: 10pt"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-style: normal; font-weight: normal"></FONT></P>
                                            <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
                                            <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
                                            <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-style: normal; font-weight: normal">KPMG LLP<BR> 1023 Walnut Street<BR> Boulder, Colorado, CO 80302</FONT></P></TD>
    <TD STYLE="width: 26%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 17%; font-size: 10pt">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Consent of Independent Registered Public Accounting
Firm</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-weight: normal">We consent to the use of our report
dated February&nbsp;1,&nbsp;2024, with respect to the financial statements of ARCA biopharma Inc., included herein, and to the reference
to our firm under the heading &ldquo;Experts&rdquo; in the prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 20%">&nbsp;</TD>
    <TD STYLE="width: 20%">&nbsp;</TD>
    <TD STYLE="width: 20%; text-align: center"><IMG SRC="ex23-1_002.jpg" ALT=""></TD>
    <TD STYLE="width: 20%">&nbsp;</TD>
    <TD STYLE="width: 20%">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-weight: normal">Boulder, Colorado<BR>
July 9,&nbsp;2024</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 25%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 75%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">KPMG LLP, a Delaware limited liability
    partnership and a member firm of<BR> the KPMG global organization of independent member firms affiliated with<BR>
 KPMG International
    Limited, a private English company limited by guarantee.</FONT></TD></TR>
  </TABLE>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>5
<FILENAME>ea020512204ex23-2_arca.htm
<DESCRIPTION>CONSENT OF PRICEWATERHOUSECOOPERS LLP, INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM OF ORUKA THERAPEUTICS, INC
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0pt"><B>Exhibit 23.2</B></P>

<P STYLE="margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">We hereby consent to the use in this Registration Statement on Form
S-4 of ARCA biopharma, Inc. of our report dated May 13, 2024 relating to the financial statement of Oruka Therapeutics, Inc., which appears
in this Registration Statement. We also consent to the reference to us under the heading &ldquo;Experts&rdquo; in such Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ PricewaterhouseCoopers LLP<BR>
Boston, Massachusetts <B><BR>
</B>July 9, 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>ex8-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex8-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  R 'X# 2(  A$! Q$!_\0
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M7P#X%B\&6,YDN/M5_=$&>;&!@=%'?')Y[UO:[KVG>'-+?4-3G$4"G XR6;L
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M5-FX+E-$XJK+G^7H<?J-HGPY^+NG-I1:+3M2V![<'@*[;67Z X8>E=1\;?\
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94DUG;R.0F6>)23\H[D445:^-F4DO9(__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>ex8-2_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex8-2_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  1 *P# 2(  A$! Q$!_\0
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MD=B2/RJKH&GQZOIJ:EJZ+=SW!9E64;DC7. %4\#I65I&DRW%CX@TJVF,MCN
MMG8_*7!)P#^"Y_"M7P?J")I:Z7=L(;VU9D:.3Y21G((_/'_ZZFI%PA+E=Y76
MO6UM/^".G)2G'F5E9Z=+W_JQ3NY7\*^)+*.W=_[,O3M,!8E8SG!*YZ8R#^8]
M*B\06EW:>(Q<Z."LL-O]IDB!)$GS$'CZ=OZU8UN+_A(?$FG6MHPDALV,EQ*O
M*KDCY<^OR_K[&M(W$(\;[#*F[[!MQN'7S.GU]JI3<>65KRY7?SUTO\A."ES1
MOIS*WZV^8@U"R\2>&;B9 ,K$Q9"?FB<*?\@U=\/PQPZ#8[%P9($D<_WF*@DU
MS?B+2KC1;B;6-)7]S*I2[@'3!ZMCT_D?:NHT48T+3QZ6T?\ Z"*YZT8JDG!^
MZW]VFQM2<G4:FO>2^_7<YSQG"G]H:0PW S3^7)AB-RY7@_F:UKWP]!]F=]-:
M6SNE7,;Q2, 3V!&<$5D^-IXH[W1M\BC9<;VYZ*"O)K=U'7;&QLVE6XBEE*_N
MHHV#,[=@ *MNI[.ER>?YD)4_:5.;R_(QM/U;_A(/!]\]V@-Q;QN&(XR0I(8>
MA_PJSX'C7_A'8K@C,LC-O<G).&(%0>'-!N;/PS>0W VW-XK?(>-H*X /OR?S
MI/!6H6\.C&PGD6&XMY'#1R':<$YSS]<?A5UE%PJ*GLI+\ORN32<E.FZF]G_7
MK8MQZ=:'Q==*805^R+)M).-S,P)Q]!7/QW%WX<U>\OH5>325NFMY8@22G (/
M/^]Q^7>NGTZ1+W7;^_B(:V6*.W24'Y7*EF8@^@W8S4.B/:WQUJW8QRH][)N3
M(.Y=JC/TX-3&HXWYE=6BFOZV94J:E;E=G=V?]=!FOI9ZC8Z?=QD2+)=0H)%)
M&Y&;!'ZU3\4Z4[7>G#2_W%XY?:58@-L7('IVP*S;G3[WP_JUIIZ,9-*N;V%X
MBW)C8.#CZ_SKI-6N88O$6B+)*BD/+G+ 8S&0,_B0*M7IN/([JTFO^"B7:HI<
MZL[I/_@":'K$'B"P>WNHPMU'\MQ PQR.X'IG\C4/AS2;*71D>:W65S+*-S_,
M2 [*.OL!47B/19X[A==TCY;Z'F1%'$J_3N<?F*N^$9?/\-6\N,%WE8CT)D8U
ME.RI.=)V3:T[/7\.QI"[J*%17:3U[K3^F+XK_P"0!/7%>"O^0@W^?6BBNC#?
M[K,Y\1_O,3<UK_D,77_ ?_011J?^O@_Z]X_Y444H;1]/T0Y;R]?U9>\*_?FK
M)^(?^LL_\]Z**5+_ 'Q?UT'5_P!U?]=3K-"_Y =G_P!<Q7)_$/K:T45GA?\
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'_&OG^A__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>ex23-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex23-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  E %X# 2(  A$! Q$!_\0
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#O__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>ex23-1_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex23-1_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  < (0# 2(  A$! Q$!_\0
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MT.FV]MIG[0WPA;6]8U&.*%9/L^BP^)[>XEN[EW64VUC9! TC)!$J)M7@H/\
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MMXEU+X@+^S5X/35K'58--M? ?[-VK:&?'-_8W:^)]7\3:SX;UM;K1$L8;SQ
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MP]H<TEO?:WXRO?A7I/A./4I-4O+"QLH?#^HZMK^L6<27-XP!_4S17\R6D_\
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EV]AI.B:)I-O::;I6FV5NB06EC8VT%M;Q*L<42* **Z&B@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>tarca_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tarca_001.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
M     ! !+     $  0$L     0 !_^X $T%D;V)E &0      04  DE$_]L
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M3FSU5-C-S_,#M6HQLLGBJ9NJNGY*.6I@ DCF2DW!V/F*.LHRSHIBJJ;&XUP
M28,A>S>_=>ZNLZR_E5?R^>J:"&BP?Q;ZRW')&O[V0[-Q4O:U?5RE0'FF?L2H
MW)31,Y%]$$4,*']"+[]U[HRJ_&'XUHJHGQYZ-1$4*JKU-L%555%E55&  55
ML /I[]U[H'.QOY<?P3[5IJZGWA\5.EO+DDD2LRNUMF8W8&X)FD1XS.=R;"3;
M6>6J"OQ**@2*0MCZ5M[KW5,_RC_X3H; S%%D]Q_$CL_,;.SJ)4U4'6W:D_\
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M9))U&'$T,"$\ E;@ <#Y[/?+FB?G+W?YBYAG(/BWT\<9%:>#;M]/;\2<B*)
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MR'R594A(E9D! 9XQKL'M?:ILK<^\_%K79H:&.,=MQ?R'X(( <A6IW2TPH)7
M9T)[[F.1KP;)LE);QOB8YC@7\3R>I'DOK2OD"".]<Q5;FR;5TU/34-)3PK0X
MC$4,8BQV%Q4+R/2XVAB %HHO*S.[7EGE=Y9"TCLQA+GC=;KF?<FO)XT@AC7P
M[>",!8K:!22D,:@# J26/<[%G8EF)Z%FTVL>W0"%&+LQU.[&K.YI5F/SI@<
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M2P ]XA<[K/S'SC?75NAD>:=DC"@DLJ'PXP !4DJHZEC92FW;1#'(=(1 6)P
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M?NO=>]^Z]U[W[KW6LGCTN;_U:W^M]/?S4;>FJ3K/J8T7I=XR/D$_X $?F_\
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M%CS!O5I&+$/H,54^$%L&E"37APZ8=T;WZYZHBEIL3A\7)G0C 8O"4U)!4AB
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MHWMVSU;%_+V&GIG=(_IVEF__ 'E-E>^J']W_ (]G-S_Z75Q_V@[=UCE[U_\
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M98)71@58@^Z]U]-3K/L#;W;'76Q.S]I5(J]L=A[/VYO7 5 96:3$;FQ%)F*
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M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=:17\_KY._Z8?EMCND\%6K4;.^-V!?
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MM9D<ID:D*\=!CQD,C+55<[#13P*\C>E3[]U[JU7_ *!_/Y@?_*ETU_Z,IO\
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M:_\ 1E-_]C_OW7NO?] _G\P/_E2Z:_\ 1E-_]C_OW7NO?] _G\P/_E2Z:_\
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MJ%)9UYM 7-'MQ=M%)?\ )%[#O]HHU'Z8TNXT\C/8M29?.I574 $DCH<;=O\
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MQ??NO=6*?RJ/D6?C/\Y.EMXUU8:/:>[\S_HHWVS&T!VOV'+3X9*NK;R1Z:3
M[D_AV4D-S84/T;Z'W7NOH>>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ^5?[]U[KWOW7NOH;?RC_P#MW)\5O_#%RW_O;;I]^Z]U8U[]U[I(=@;#VGVE
ML?=O7&^\-2[AV;OC;V5VON;"UBDP9'#9FCEH:ZG+*5DAE,,Q,<J%9(9 KHRN
MJD>Z]U\YCYQ_$O=GPL^1N^>D=QFLK\1CJA<WU]NBJA$2[QZ^S$DTNW,ZC1Q0
MT[UL<<;T=>L2B.')4E1&MU0$^Z]T47W[KW6PY_(A_F /TUV<OQ'[0S9CZO[A
MS:R]9Y')UJ)1[)[6KA'3Q86-ZIE%-ANQRD=,L:/I3,K3E(]5942>_=>ZW-/?
MNO=>]^Z]U[W[KW7O?NO=:P7_  I+Z7J,ALOXZ?(+'P,T6V=P;GZGW1)' TI,
M&ZZ*#=6T)I9D8?:TU#4[8RT9+*5>6MC 96 $GNO=:EGOW7NAR^,O;U3T%\AN
ME.Z*=YPG6G9NSMVY&*GC666MP6*S='-N+%K&UM:Y? _<TK %6TS'2RM9A[KW
M7TTL?7T65H*'*8VIAK<=DJ.FKZ"LIW$D%715D*5%+4P..'AG@D5U/Y4CW[KW
M4SW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=$(_F9_)Z/XF?#3MSLRBKQ1;TR^)/7766ET6I?L#?
M$%5C,36T:R21K+/MG'K5YIDO=H<;)8,?2?=>ZT._AUT%7_*#Y.]+=%44<STV
M_M\8RCW%+ TL<U#LO%B7/;YR44L,4K1SX[:&+K9HR0%,J*"R@ZA[KW7TKL;C
MJ##XZ@Q&+I(*#&8NBI<=CJ&EC$5-14%#!'34E)3Q+98X*>GB5$4<!0![]U[J
M;[]U[KWOW7NO>_=>Z+1\Q^A*#Y/?%_NSHRLBIY*K?NQ,M1[<FJ5UPX_>N+5,
M[L7+.HDA+)BMX8NAJ&4.FM(RI(!/OW7NOFGUE'5XZKJL?D*6IH:^AJ9Z.MHJ
MR"6FJZ.KII6AJ:6JIIE2:GJ:>9&1T=0R,"" 1[]U[J;@,[F-K9W"[FV]D*C$
MY_;N6QV=P>4I&"U6-S&(K(<AC<A3,RLJU%'6TZ2(2" RCCW[KW7TP_C!W=B/
MDA\>^G^\L*(XZ7LK8F#W%5TD3K(N+STE,*3<^#9T)5I<#N2EJZ)R.-<!]^Z]
MT._OW7NO>_=>Z][]U[K6#B?1(K?XV/\ K'W\S*-I:O6?Y%13H1L3E:&@,<E+
M0Q5=2H1A4955J8(Y0H.N'&#_ "231(2"M2:J*0 $H.1[E'8M[VS;@KV-L)Y@
M!^I<T=5:G%+<?IX8G$IF5@ 2@J1T175M--42N54UPF"?M?C_ +SI(]3QZ7$F
MY<QFC3'*9&JK$I4,5'3R26HZ"$DG[;'T,82CQU,I^D4$:1K^ /8_;FG>M\:,
M[M=23K$*1H32.)?X(8EHD:>BHJJ/(=%:V%K:AOIHPA;+$#N8^K,<L?F23TI,
M?4_I(/\ 3\G_ (BW]/8LVZZ! %>D,T=>EK0U7Z2#_2W^W_V'L;V%U4#/11+'
M3H\O06P8,=CO])6[/%0TT4,DV"2O98(8*;21+G9S,55$D4E:;58:;R &\;>\
MS?9'DB*PV_\ UP.9:0H%+6XD(552F;EM7"HQ'7RJXXJ>HDYSWI[B?]P[;5V)
MI)IR2?*,4_XU^SU'4O???;5TDV(V8[TU'=HI\ZZE*NI'T(QT;#520GG]QAYF
M^JA+7*KG/WK-X[[7RDQ2+(:X(H[^OA _"O\ 2/<?(+Q+6S\F^"!<[J*MQ$?D
M/],?,_(8^WH6NOJ-=Y];T<&]::DW/0Y1JQ#29VCILE#44$-1)2PI5Q5<4BU1
MU0LP>0,Q##GZ>Y/Y)M5YMY BM^;XTW&&Z$BM'<QI*KQ!B@6174AZZ2:M4D'C
MT&MZE_=>^L^U,;=X].8V*D,0"2I!%.(P.B_9CXO_ !JW5N:LP.(.>VOG8I)#
M/1[8RU2M*TD*++4I ,W0YW&Q&  J\<>@(=0501Q >\_=D^[IS1O\VS;4MQM=
M\&)9;*=U2JT9PBW"7$*T&"JJ*9  (P-+;G_GS;K!+RY\.XA(%&E0:J' KH:-
MC7R)K7&>N-5\.NC-G4SYK/;@W]4XV QQ/#7Y?&M TDTBK& F$VS1US.Y&GTN
M  23:UPV_P!T/V4Y2B.[[W?;G/;I12LUQ%I)8BG^XUI%(3Y8:E"2>%1N/W/Y
MOW1Q:64-NLC5-51JT S_ &DK+_+HQW6.QNL=KX>"OZZP.,H*6O@TMDXTEJ<M
M4HCD/!6Y*O>HR;F*92&B>32C V ]Y#^W7)?MSRQM*7?(%C#;Q3J 95!:9P">
MV6:0M*U#7M9B :T Z V_[MO^X730[Y,[LA^$T"#YJJT7(\P,] )E.T]W[.WO
MGEJ:Z3*4]/E:JFFQE:Q%)+20SNE,:540"@=J<JRM$HU$@NK\CW#&Y>Y'-'*O
M.%ZMQ,;B-)G1H9#1"BL0FB@[#IH05&:U8-T,K?E[;-TVF$QH(V* AU^+41G5
MZY\C^5.ABEKMG]Z;1K,;1U2T^3A05"4]2$_B6$R"J5AJ3$"?/12,^AGC)5XV
M(NK\+*<MYRK[R<KS;?:2:)U&H*U/%MY1A7(!RAX$J:,I(J&P PL.Y\H;FEQ*
MNJ,FE173(OF*^1\Z'@1YCC7ENS'Y+;N7R&#R].]+D,=4/!4Q-R"P&I)8FL!+
M!-&P>-Q<.C!AP?>"7,]AN&P;I/L^ZH8IX&*LI_:&!\U((*D8((/4V[?<6]];
M)=VK:HW%0?\ )]HX$>1QT&V0JOJ >?SR?]A[CG<+JM3T>01^?2)K:QXY%EBD
M>*6)UDBDC<I(DB$,CHZZ65U8 @@@@\^P)?W\D,@FA8HZ$,K*:%2#4$$&H(\B
M/MZ-HHE<%6%0<$>1KQZ8LWNJNRA;^.%,U(0 U=6W.7X5D#',)IKJF2.-K(*E
MJB);*-!  ]AO?.<+_= 1OX6_/#Q9?]R0!45^I6DC$ ]OBF5!0=A ITJMMNAM
MO]PZQ ?A7X/LT?"/GITD^O0692:(MIA,FEE6XD"AE;2/(+J2&4-P&L+C\#W#
MF[S0/-_BQ;305U4J&ID @Y%>!QCR'0CMD95[Z5^7^S_J^?5NO\O/_F2VY_\
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M)(TBWC!&A1#6^I6_O<E@HD (R:^EK52@U2S?^8X_<"-6NQ3?E"H'4 +N*J*
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M[!5'VDTZLY^//P=./J*+>'=4%//402156-V%%-%5TL<L;:XIMSU5.\E-6:7
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MY7+&HIZ6F"%654J-1$;,P]U[HZ/QLS_<79%=NGMS?M5+@=C[LBIJ;KKKQJ9
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M&&2E#65D@IF )6=A[]U[H\'<79%!U+UMNK?E<J2MA<<W\-I') R&:K'6CPU
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*OW7NO>_=>Z__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>toruka_logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 toruka_logo.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
M     ! !+     $  0$L     0 !_^X $T%D;V)E &0      04  DE$_]L
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MLOE\[73. LN2KJO)5+R.=*JC5$LTA)+6 '^L/<C06MI91Z+:WCBB X(H4?R
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M[-]JV+=-ZD*;?;%E'Q.<(OVL<5^0J?ET%^9><N7.4H%FWS<5C=A6.):M(_\
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M!J&A$:@:I"#CR6N"P..C%S?"%/M!X.QG->!=C-M<"DD-F] 5,ZTT(N1ZKO\
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MN]P;KW1D@ J*#+4U4Y"I'&HTPTU)31* !Z(:>!/[*+P+%6PV3;M(TPV$"?D
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MQ]WD\6VV6%R(M(EFIYDDZ%/V4K3Y@^74]^P/*MO]+?\ -MU"#<F0VUJ6_"H
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M6B=HJ6B6P8TP9I);Z9?& R/&_,W/L*Q26.Q.6E/:UQP"CST5R3_2X#B*X(R
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M)-19&GC5Y9WPRRF2>ER"BY6G#&&4#3&J-8/('+//ERL\5COD@>%B%6<@!E/
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MW[KW7O?NO=>]^Z]U[W[KW56WR_R4M9VRM$TC-#B-LXBDBBNVB-JF2LR,K!2
MODD^\%V%R0J@GT@"=?;N%8]@,H7NDG=B?L 4?X.L,??F[>XYW2W+DQP6<2*O
MD"Q=R:>IU"I^0].C1?$+ TF-ZI&8B1/O-QYS)U55/I_=,6.E_A=)3,U@3%":
M61U'(#3,?S[ ON'=23;]].Q/APQ*JCRJPU$_::@?D.IF]B=M@M.2%OD4?47=
MQ(\C>=$;PU7[!I)'S8^O1I_8$ZFCKWOW7NL4\$%5#+35,,513SQO#/!/&DL,
MT,BE)(I8I R21R(2&4@@@V/NRLR,KHQ#@U!&""/,'UZI)''+&\4J!HF!5E8
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MDLI-69_<>:J8*2F@IX2[NS,(J/'8ZB@73%"A;3'&B_4DF[%B94M+3;]DL!#
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M_=.4+=-JW"W-YLJGL7522('B$8U!3ST&F>#*.C5I\Q.IS1_<M2[N2?\ ./\
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M'@SCU8\54_M/R%*X_>XWO/%LLDVR\J-'-N2U6:Z/='$>!5!P>0>9-54XHQJ
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M_LY0"S+3^,^:?TCD'C4<(M]W_;'9;/;[CFO97ALW0CQ[8E4CDKYPC 64_P
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M,AHL+!+$VJ\$QQ%+135,!#6*RLX8?6]O;5CRIR_M[K+;;:GBC(9RSD'U&LD
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MSD;X_+8]X:V@KZ*:4054 E8T>6Q-8%AE:%I824<!)(Y$*L%=642[MFYV&^V
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ME*B1FD>;%O78)GD8$&21<)5X^.5R6N=8:YY-S[/[3FSF*R4)!NDF@8 DTO\
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MD*,D T!ITJ^G^V,QU-N9<M1*U;B*X14VX,,9"D>0HD<LLL)OHBR-'K9H)""
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MRDTLF1Q]?BI3)$;^2DFGB@,FGZAXR1;D&WLWM[S;]QC;Z6ZAGCIW!&5Q0^1
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M%MNVWQ!+'<%=V1115F0CQ*4P X96IZZJ8X#U\,MUSY/9^X]IU,QD.V,I3UE
MKGU18[/)4.U/'SZHHLA032'\JT_)L5'L)^Y.WK!N-G?HM!/&5>GFR4R?F58#
M\NI-^[]O<EYL&Z[)-)4V<X>,'RCF#'2/D)$8_P"V^SKA\S]U3X[:6VMITTK1
MC<N4JJ_(*C6\M#@4I6BIY0#S%+7U\4HN.7IQ_3WOVVL%FW"]W!UKX"!$KY-)
M6I'S"J1^?5?O!;U):;%M&QQ.1]9,TDH'FD.DA3\B[J?M7H$?B5UQ0[NWAD=S
MYJDCK,7LZ&DEI*:HC62GGSU>\IH99$>Z3+CH:62738Z93$Q(L 1/[@;S+M^W
M0V-M(5GN20S#B(UIJ'RU$@?94=1U[&\I6V^;[=[UN$(DL[ *8T855IG)T$UP
M?#"DT\F*GRR?KM'K[%]F;-RFVLC%']Q)$]3A:UE!DQF:ABD%#6QM^I4#N4E
M(\D+NMQ>_N)]CW>?9-Q@O86.@'3(O\2$]RG_  CT(!ZR<YRY6LN;]@O=GNT7
MQ2I>WD/&.4 Z''GQ-&]5)'GU3[M3/Y'8F\<-GX%EAR&V\S#434]PDCBEG\5?
M02$W 6JI_)"_^TN?>1-_:0[KMMS:,089HB WVBJM^1H1U@;LFYW?+',&W[FB
MLMU9W 9TX$Z6I(A_TRU4_;U=_3SQ55/!54[K+!4PQ3PR*;K)%,BR1NI_*NC
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M%F]%%3_+K1( J30?/H)?]FT^*O\ WDS\??\ T<W7/_V2>WOH[S_E$E_WEO\
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MM' BO0FM[B*YC$D1QYCS!]#T=3V5]/\ 5 ?_  ID_P"W3G:O_B3ND_\ WO\
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M>.-W2G@;L7#TRS3LH*PQ-4U$<89K O(J_5@",^0#_P BBQ_TLG_5MNB[=?\
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M8RR)3-#()>5=_?E_<UN&!:S<:)T'$KY,/FIR/7(J*UZ17UH+N H,2#*D^O\
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M-3U%%#V7N6JEKXT7R0U>*Q^,JT=EF4+!?N+O*7VYQ;=;O6"U!#^GB'XA\](
M'R.H="G9[8Q0&9QW/D?Z7R_;_@IUM.^X[Z-^B^_+3_LE7Y,_^*^]S?\ ON=R
M>U-G_N9:?\U5_P"/#JDG]G)_I3_@Z^.3[ROZ 76_+_PD:_[),^4W_BQ.)_\
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MOK8-&OPXPR]Z+(*$N*]KBN./25_V<+J7_CANW_SS4G_UU]K_ /6ZY@_BM_\
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MW91S[,=KVB_WFX^FL("\@%6/!5'JQ.!_A/D#T0\Q\T;)RG8?O'?+P10$Z44
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M:[_W6GV8>V?_ "4-S_YHK_Q[HB^\/_R0N7_^>MO^K9Z.3C/^+;C_ /J!I/\
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MJQJ104()/1FMU]/];[TAIHLYM3%,U)44\\-504T6,K0D$RS/2/5T*P3R454
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MB>A&I'4,IHP#"JD&A (\Q7HLOS"_YE+!_P"';AO_ '$ROL;>W7_*P-_SSO\
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MSVEU(%8NN@&XL;_T]RI[:AFBYA5/C*Q ?;2:G6-?W@FC2ZY$>:G@B2Y+5%<
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M_P!Y#;_O(3D?_E5MK_YN?]7I.L%?>3_IY',?_4/_ -HL'0!^Q9U&/5V75/\
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M']RQUC'U:/\ #W_F4L__ (=N9_\ <3%>X+]Q?^5@7_GG3_"_69_L-_RHS?\
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0O]*/\'6?W7ISKWOW7NO_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>timage_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 timage_001.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
M     ! !+     $  0$L     0 !_^X $T%D;V)E &0      04  DE$_]L
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M\^GR' R0/R_V>NM47_'*#_J4_P#U\]^I\A^S_9ZU5O4?L/7M47_'*#_J4_\
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M_P"'W'_.3_8Z]_PS#EO^]I?\U7_TJ67_ .MWOW]9A_RB6?\ S@_Z&Z]^Y/\
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M_P#.#_H;KW[D_P"'W'_.3_8Z]_PS#EO^]I?\U7_TJ67_ .MWOW]9A_RB6?\
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M_P#K=[]_68?\HEG_ ,X/^ANO?N3_ (?<?\Y/]CKW_#,.6_[VE_S5?_2I9?\
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M_P"'W'_.3_8Z]_PS#EO^]I?\U7_TJ67_ .MWOW]9A_RB6?\ S@_Z&Z]^Y/\
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M_P#.#_H;KW[D_P"'W'_.3_8Z]_PS#EO^]I?\U7_TJ67_ .MWOW]9A_RB6?\
MS@_Z&Z]^Y/\ A]Q_SD_V.O?\,PY;_O:7_-5_]*EE_P#K=[]_68?\HEG_ ,X/
M^ANO?N3_ (?<?\Y/]CKW_#,.6_[VE_S5?_2I9?\ ZW>_?UF'_*)9_P#.#_H;
MKW[D_P"'W'_.3_8Z]_PS#EO^]I?\U7_TJ67_ .MWOW]9A_RB6?\ S@_Z&Z]^
MY/\ A]Q_SD_V.O?\,PY;_O:7_-5_]*EE_P#K=[]_68?\HEG_ ,X/^ANO?N3_
M (?<?\Y/]CKW_#,.6_[VE_S5?_2I9?\ ZW>_?UF'_*)9_P#.#_H;KW[D_P"'
MW'_.3_8Z]_PS#EO^]I?\U7_TJ67_ .MWOW]9A_RB6?\ S@_Z&Z]^Y/\ A]Q_
MSD_V.O?\,PY;_O:7_-5_]*EE_P#K=[]_68?\HEG_ ,X/^ANO?N3_ (?<?\Y/
M]CKW_#,.6_[VE_S5?_2I9?\ ZW>_?UF'_*)9_P#.#_H;KW[D_P"'W'_.3_8Z
M]_PS#EO^]I?\U7_TJ67_ .MWOW]9A_RB6?\ S@_Z&Z]^Y/\ A]Q_SD_V.O?\
M,PY;_O:7_-5_]*EE_P#K=[]_68?\HEG_ ,X/^ANO?N3_ (?<?\Y/]CKW_#,.
M6_[VE_S5?_2I9?\ ZW>_?UF'_*)9_P#.#_H;KW[D_P"'W'_.3_8Z]_PS#EO^
M]I?\U7_TJ67_ .MWOW]9A_RB6?\ S@_Z&Z]^Y/\ A]Q_SD_V.O?\,PY;_O:7
M_-5_]*EE_P#K=[]_68?\HEG_ ,X/^ANO?N3_ (?<?\Y/]CKW_#,.6_[VE_S5
M?_2I9?\ ZW>_?UF'_*)9_P#.#_H;KW[D_P"'W'_.3_8Z]_PS#EO^]I?\U7_T
MJ67_ .MWOW]9A_RB6?\ S@_Z&Z]^Y/\ A]Q_SD_V.O?\,PY;_O:7_-5_]*EE
M_P#K=[]_68?\HEG_ ,X/^ANO?N3_ (?<?\Y/]CKW_#,.6_[VE_S5?_2I9?\
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M_P"'W'_.3_8Z]_PS#EO^]I?\U7_TJ67_ .MWOW]9A_RB6?\ S@_Z&Z]^Y/\
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M_P#.#_H;KW[D_P"'W'_.3_8Z]_PS#EO^]I?\U7_TJ67_ .MWOW]9A_RB6?\
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M_P#K=[]_68?\HEG_ ,X/^ANO?N3_ (?<?\Y/]CKW_#,.6_[VE_S5?_2I9?\
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M_P"'W'_.3_8Z]_PS#EO^]I?\U7_TJ67_ .MWOW]9A_RB6?\ S@_Z&Z]^Y/\
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MKA?CV<;1NL>X>/KM;0>%;R2K2$99*4!J3C.:4/SZ+MPV]K3PM,TYURI&:R'
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MS>A^(H>K+M"0$!&-!Y9Z'? [PZUZZV=)%D&JLQDHR*9*VKQ[B&SMR0OU#@<
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M$,*O\NF7Y5O9R?$9CQ&=1K^0_P !Z:DW1&!H:ED*Z52RU ?D7Y%U'YYM]/\
M>_;XW%%X&GRJ#_EZ)[CDJX#X7!]:KY_,#K#/N57)\<,G/!+NI^IO] IX_H+_
M /%/>FWFN#D=*/ZFS@9C(-,YK^S%>H?]X9T6RK&&XYTL3_7D$V]U.Z*!Q_U?
MSZO'R9--DHWV4'V?Y.L!SU0VHZ8$+_JTTX-[&_!))!N/=!O /'_!T9CD>4#
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MJH1_7@$W_/\ 3VT&M9<#!/KCJT?[[M:YU 4S354?L!ZZ:GI[DQV((_424/\
MMM3#Z>_+9POP/YUZU)O&ZPCO*8\BM?\  O\ EQUV(8R0MS>_Y('_ !K_ 'GV
MXMDE:9_;\_LZ=?FR=5UT7[2C&N/DU./S/^?@]-&CE2[:E-B5-QS_ +[^GM))
M:(AI4]&>W<Q2WL9<HM!7CQQ\OS]>L)B%AZY.>;@J+_[Q[9: +YGHPCW*65NU
M$..-"1_)NN/C1+DM)P#:P#6_WW^Q]TT*N37^1Z5BXN7 (6/CD$L/\A_9_/RZ
MQ:X^?7(OT'Z?Z?T]M%E]3^P>72B$3OQ1#2OXC_/ _P!CKVN ?61Q_CI _P"(
MM[]5!YG]@ZOX-VPPD=?],Q'^"OV]=-/3@7U2D _0Z1P/Z_0_[S[\98QQU?R'
M7FLKUL*(A\P'/'\Q7KA]U!Q=7/\ KL/^*^Z?41CR8_F/\W7GVJ^(^.-?M1J?
M\?/^#J9!)#(X41NX(XU'_B01[6VS1R-A2<'B1_G'04W.2YM$/B2(F14J#3A\
MU;B>I9\ X\2(P!L3J/U_Y"/X_P /9D88@*@ 4]?^+Z"PW>Y=M/B2-4X*!:'^
M5?S(ZQB72WI56MQ_FPXY_P "/; <@]H4_8!T8R.DJTN&N%.>);_""<4^74E9
MYFLX\7IN?\V@^G]>+D#_ !]NB1_1>D;0V!%#),?MK3UKGKD,G.KO+XJ1FOI8
MO!&PY_PMI_WCZ^[M?.HJ54_/IF#:K.[H!/(N*Z3\ZUIQ'4M<W6QQ$Z: I,-!
M5^#9;_V%<! 0?PH_PYY&OKGI6JBOS_XOI*_*]9-*&5E'F%:A7Y5 \_L]16G4
M/^+ .6$- K"Q814X8_UX^A'T_P!?VTNY@&E%X9I_L?YNCB3D^H%9):D@=W:*
M?[;/^3[>LSYB>J4M^T!J];K%ZF(O]226O;B_]/K?ZE5%N/B"N/V4Z)K_ )8:
MWET1AWJ*U)K_ (!Z^O[.NJ>NJ4/[2E06%K'3<CG_ 'C_ %_:F"_=\*//[/\
M#TDN>7UMT)F)4YX L/*G#^9].E'23QUA,DU/(2H%S*"RZG%[E@1;\V_XW[7H
MP(J1GH(31BV- 016G$AL'B*5_/J8M?DZ:XH*:B@:[ ^.B=BP:W)9B0PX^A(
M_')-JLTS833^?2F.&QD4&>212#D"E#Q\S7Y>73^D/9510J%QU3!C@PJ%JI<2
ME+&#4HNG3+.H!+IR K7L+@$"X9\"5CDC\@?\IZ>:/;8E[%<D<2SC/V45?\)Z
M2^1Q>X&G\>1R9,LP2RU&1UW50;%2CLND?2P^AN ."/;4EA)*<M3Y</\  >CB
MQY@L+5"!;5%/B.EO(\=0Q7_5Z=>?9<5-3T[39-FK9T9F@CII)8U%B #*I8DW
M'T$?^L?;";,H^(L3Z]*XO<1E8K!%"B< I&?/@0>/&E0!U-QNU=O3TZ2>#=&3
MKRY5XJ*@CIH;AK*/))(S!6%M3:0%O_MG8]HA#=P8_P"K[>D]USO?/E'11CB!
M48\SI(\J\/MKTHDZ]J9 /%LZIA8!9"V3W!# I62]F0*8RPO;D,W/ Y('M6FV
MP_P'\_\ B^B>?G^=R!)='@/AX4]?A7_5]O34VR\FK%/X3AZ<+* [R9$U"BY9
M1^6)6Z_@FYY^AL+#;AY*OYC/^#I)-S7J_M)IF'$!3@@_[;J6_7N6^R%0M9@
M5F6(QP4Y8@MS^MH]&HFXMJ!_WD"_[KKQT^OP]-+S4D8[3)3AE@#3YT_U>G3_
M +>ZCR.8ILI5SYB&D@Q0B><KX:4DRZFTH)'C+N41VTQH_"DD<'WHVBQ8_P %
M!TFN>:":%%).:D]U1Y9U']OITHJ;I';\E0D<NZ)7AEIX7-1"L4WB>0K=)8XR
M[AU!(*!M:M]0;$>V)+>-/BU?M_V1TJ7G&XDHD:Q\!\**23CB#6O ^73C6_'S
M%8>N-/N'<G\"H3%%+_$JRG8KIGU:&\,4<U6/)I.B]-R002MC9M[>&F 3_J^W
MI?%SC?6S"I0>?PY\_*E//_4>@@K.O:%JRKBI*NOJ8J:8I!,<8Z+*+>I]3:$5
M5:PY !N2.+7HNU13C4:C^72U^=KB0@,H:F 4%3^?<#7(\_F?FB)J.3%KJGI(
M9%DE>.)F<?[JO<Z4(8_4<DV-K"X]IVB2V. .EJ7$VZ937PR 34U^ULYI2@X^
M6*]-L.3FI6#(Q4*PDTLB.K%3_:!N""/ZCVDDOU3U_ET:Q\O37/85(-.)U"E#
M44_+%.'4:OS0JIIY_'2Q2S&[^ >-0!8"R@VX'^-_ZGV@FW-14K2OKT<V/)DS
MXFU!0>T >HSFGJ/3IJ?((B']U23=F'X_Q_K[0G<](X@UXCRZ/DY/\4$LC=OP
M$&C8'^E'^7J.^6!&G6= ]6GZ"[?4\<>V)-SU8_U'I98\K&/.DDC@2<@5^S]O
M40Y*']0,I)^@O]#_ +<W]I3>+Y5_;T(UV-@*$1T\\<1^P4Z@RY6-@0/-?_@V
M@?[&WM.]Z&]?VTZNFPT.=%/*H)/\^'4!JT,"=#V^EVD(_P!X]I&FKG/[>C2#
M;=# :E]:  ?Y.HLN2*@+XDO^206/^W/_ !KW1[@@<!T9#;6/!J_F?\G4%ZYV
MM^@?A0;&W^M86]L-,3Z=*4VH5JQS\J_\7U!FJW)]5KD<D#VRTG2L;=$M./\
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M4G>HI7]-F5A3@:@UIC (XX(]TV*/;;^!4%8I9$&DFM*.H89X@@CCZD=73?S
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MBJ3C$#2?;ZD\ALIL+O3[$(=T&W:R1XZ0Z].>YE6M*_/A7\^F+;FPS["=Z\(
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MIZ52\L]34U#QPP0QJ"6=W55 N2![LB&0A5!).  *DG\NJ22+$I9B  *DDT
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MTBC) ],FG02YI]X+K8]XEVBUV]KJ1-&GPY',DFJ!)C1$A<]H8UH3@$X\D/\
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M>S>DMD]H4^[Y:TU69VAFJK%8B+(4D])#%3KG&I#"ACG<I634\5FC=I$%=_R
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MT;.W/PK7[#UZ'FG<67NEU?(J/E\O\O7!*7'N8]=-5,E],P@%V]7U87])(O\
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MHZXB.I8%5I5%N=107XL?=A%(XHJ?RZ8GW2VA7493Z#.,FG7$P5=CJ10"!?\
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MLQV+@JS*YBHIRS/1T]1(E-#2TSGR)#3B:41RU#P1"#:^7WV':;OQO[22&4L
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M+(%/AD49U4UTC2%51QK3NXFG$A)N\PY:M=%K$0&)&H&H0L*:C742>%*X\JC
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M_P!@;9V1_*SV%\9,E\;?COLRAV5N/#YS*SXRJAW5A=C?<4F#H]NP8V2OI*#
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MH# UU 9U.W2KF3EZ#9XD>)G)9M)U%2*4)\E7TZVNOYVG??\ +BZ&Z]Z)RO\
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M/D:MVU6!<96"[%8S0R,S232:;6^P+8;[;WML*V]RLCJ0.U7:%VI\@P[EX>8
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MJ*BHJ:F::>>:65Y9II))9'9W8F2-\OI=RY9AGG8N[S$LQ\_U9AY8  % !@
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MV?,CNGYC?!NO^8?QTQ/QVS>"W[M.CV3BL5/+4#)4M9NG$O5U#M+D,AS!,D2
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MM]3[(?;7_DK1_P"DD_XX>AA[X_\ *N7'^G@_ZO)T>3^6Q_V0#\.O_%>.KO\
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M*GY'^762"#[@L'JHH1J _<9P/I]> 5_I_P 1[O#$9OQ ?;7_ (KIK<]T7:J
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M= WKWOW7NN<?ZU_U_>CPZ=@^,?:.OJQ?R\?^R /@U_XIY\9O_>*PGO'/>O\
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MWFC>*VM&44O;^!N68(!)&91*28PZZP/%F-2M:C!!X<".G=IVB[CY[O;MH91
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MJJZMFT_Q;*O!)E<J3)45$S@35*(7!=%]B_D'?!+NDUU?3(&>!@7D9(P6UQ
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MY(94@J?])DTWC=U(5]#4VE]#6-CP;6/LI'N5NH_&G_.-/\W0C/L=RX1_8/\
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M50035>3W!BL+#2XZC@RE7-,L%-45$Q5%A5V0PRE^R6NT<ERM=->I.WAE56,
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M4^U]WT\E9-2XRFJIXZ5)ZFGC:5HQ&))8T+!G4&1O;*]AL+Z1YY$C4P, SLJ
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MKI)I6AI7C0]8X?=]V.]V;Z_ZRWG@U_2Z/&BDBU:?J:Z=:K6FH5IPJ*\>G_\
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M&?S%/^]/'?\ _P"@_OG_ .P7VG_J+MG_ $=(/VQ?];^E_P#KN;[_ -,_>?\
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MWB<O'DNPY*RF?&9&LI(:.O2HHR)XS!-('A/E4E/5[E#G&_@N=JV^..2-V2-
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MNV[W=R7C[C FO22JM$U B*G'QLFB^G'RZBGDSG7?.5=N@VR/8[R3P]0$CB=
MS22/(21]+115SQ; XGSZ.9_+$^#/R@S7RQ[/_F1_.?;U!LKMO?%-E:;8'74
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M/F259]PN70AE::0JRD$$%S0@C!!]>A3R3;R6NSV,4JLCI:6ZNC@JRL(E!!!
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M_+7H11\CVR*M&<4X49EIFO!2.LJ;ORS:0BJ--@&CC%^/]8?T]N+S#<B@4_L
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MWJI[<?F3U(^V>WHB4I-W9KE54#%/,5\O6GY],;YC(5TB(@FE)L$33Z;"_ '
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MOREAP+_7@?3GV@: H.!_9TL&\)</H1XZUH!7SK\J]2,32BHG 9)/#S=@2/\
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MZ?AWB:4T:)>/$*Q'^#KC'%$3>/**6<<))(OX^EO7[TJ@_C_P?Y^E9OP@J\9
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M?[P/^M'7OK=E_P"4>;_>C_UNZ]_LS'_"97_O71\V?_1N5?\ ]M'W[]W\P_\
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MO]Z/_6[KW^S,?\)E?^]='S9_]&Y5_P#VT??OW?S#_P I4'^\#_K1U[ZW9?\
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M@.GO!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
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MJI-@/4P_'^MQ[U5?/IY&!'G_ *ORZX%D;C0+?46-_I[]CRZL6'GUR &EB$N
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MRSQG0LHBDB6_X+(5-KBQ(O[-1= *5"DL,5S3\P1T426?B.&=@(VKVDH2?+#
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MSZ?)1UD+I/X[$:5FAU#2"WY+*&2W%'!H/-#1C^1_S=)-U4S2$"> AN[PIDJ
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M6GYL7/\ JSU"AJ8IBS38/'T"60>/[1Y+VL#;R%[-_KM]/I;GW19*\44?D?\
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M&0J"19RI%[ <CW?6PSU9E*GRZSKD:LL 9VN2H_V!]^60];5R#UF-3,?U3/\
M[%OZ^[ZCTH$I'K^WK(I!!4ZR+<6)_P")][J/3IRB_P +?SZE1QH?HKGC_CH3
M]/>Z _\ %];\ 'SZD+(J#1X&)!MJ(O\ [S[L"!UHL4Q0G[.LGW-N/&1_OO\
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MSX!F]Q9S'U&.J$@&H.]%B*&OFDGEL(S4R4\*&0I5+$_9PZFU>0X_,^G\Z_\
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M_P _7OI)?X'_ -Y/^;KW\5Q?_.RH/_.R/_H[W[ZN+^-/]Z'^?KWTDO\  _\
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MN+_YV5!_YV1_]'>_?5Q?QI_O0_S]>^DE_@?_ 'D_YNO?Q7%_\[*@_P#.R/\
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MG7_>?>BGS'53,U?AZY>%?J&4@?7ZC_BM_>P/]6>K+.?->N:P!E)U*--^%/\
MK?X>[!0WG3KQN*<1_AZ[\&@\2*PM8C5?Z_TX]Z*4X'JOCU\O]7\NO%$%KW']
M2"/^*^_ KYGJID8^76:-(A>[BQXX]1Y_PN/][]W0KZ]4(9\ ?MZ\7B%_4Q !
M&HC3P/\ #G_>_=V=0.JFW<^0_(GKK4FH%0;7!'!_XK[3^( :]4^G8=9/-8W
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M$1!^68#VUU9G$2EF-  223@ 9)ZW-=G]>?"S^1S\=-H=B=M8*DWY\E=Z44E
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MU:,F+*;>SN+6J>FH,HLB1Q??0EJF.DEE%/*\-5%*KK(MZ P)%,$?Y..#\_\
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MU9N@,/6/#BOXW4]:8OLC"9#=<=,$24G^%QU9AFJ1$S-]G#6R5NI&B%.9],3
M]>?=N:7P]; 5IK*'1_G_ #I_+H3-R?>K'KTJ3_ &&K_-_/JE2AVON;)[FH]E
M8S;N=R.\<CG:?:^/VE0XBHJ\G/DZNH6DBQT-!'&U5+7RU3+"E.L1E:4B,(7-
MO8N,R!/$+#335JJ-.FE:UX4IFO"G0:\)BVBAU5TZ:'56M*4XUKBGKU=7E_\
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M]U6H)5])=NG.%CM,GA2,6<89475I^TU _($D>?2W;^6+O<4\10%4Y!<TU?8
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M=4DC692C %6!!!X$$4(_/J^[86Y4WELK:NZET!L_@,7DYDC^B2U4*M-'^?\
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M@-0RVJB$TT*30$L0!/\ [:^TS7[1;ANH06[J&A@+ M<:D+*30X73W@5U&E2
MHR8SHK-Y;<?4FR,YG*Z?)Y;(XJ6>NKJDAGD?[B9=3$ "^E0/I]![EOVWW&?=
M]CL[FY<R2R1:G=N+'4V32G49>X-A#M>\W5O;H$C20!$7@HT*<?MZ+YTAV3OC
M<GR*[7VEG-QUV2VYA$WTV)Q,ZQB. XS.TE-!H*QJ_P"U!(Z"['@\W-C[BGVX
MYPW+>.;=SL+F=Y+>'ZSPHB%TIX=Y%&M**#A6(R?//4D\_<K;?M?+&WWMO"J3
MR_2>)("VI_$M))&K4D98 \.G_P"7V_=X;"VUM"MV?GJS U5?G:VEK)J,(3)'
M'3ZU5M:.+!N?I[-??GFB_P"5K*UEV^9H6>=E8KI.I?#)IW ^8Z+?97EVRYCN
M[F.]A694A5E#5P2]*X(\NGONSM/>VQNL-I56SL96Y7=6Z*&B5\K'BI,JM&D=
M+%)45+HD;Q^=WD01B0:#=V*MHTDT]QN<]RY:V>W?;HGEN;A4'B")I1$HC#,Y
M 4C420%#8R30Z:$OY#Y1L.8-VN$OI$CMX&8B,R",R$R,JH"2#I !+%<\!45K
MT V\]P_)?H6GVQO7=N^L;NW%Y?(P4&3V]*JS(LLD3SFG=OM82FJ..4"6!QI9
M>0RV#1AS%NW.'M@EON-_>QW44LBQRP$"@8J7T5\-2*A6HR$4(X$<9$V+;.5?
M<1I["RM)+:2-"\<P)!*A@FH#Q&K0LO:XR#Q!X&?[L[,K-K](5^^]M5+X[*Y2
M@V[)M^:6&.9HVSTM.URDBR1L\=,\K6*,+K_L?<R^XW-\FR<N2;G9MHD=(# 2
M%)4S,F:,&!(1B:$$5'43\A<JQ[OOZ;?=+KC1YA, 6 80J_FI4T+ #!!H>BY[
M=I/FIN?!8;<6-WSA1C\[BZ',4 JH<5!)X,E&LL3.G\+.DLC VN?<2[3;^XF\
MVL5W#>PZ)HTE34ML&T2*&6H^F-,'J3MSGY$VFXEM9;277%(\;Z3<%=2,5-#]
M0*T(Z/YCEK$Q] F0=9*]*.E6ND6UFF5%$K"P L7U'@ ?T ]Y0VH=8D$IJX5=
M9]6H*\*>?6.=R4:1S&*)J;2/1:FGKY=3/;_3'7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=4L?SB/^/K_E0_\ C67XF_\ N37^Q/RSPN_^>.?_ )]Z)-ZXP?\ /1'_
M )>OFY?((_\ &>.X_P#Q*'8/_NVJ?<BVHI;Q?Z1?\ ZCBX_M9?\ FJ_^$]!'
M_P C]N=,]=EF/U8G_7-_?NM4IUU[]UOKWOW7NN&L?X^[Z#U[KQ<#CGW<0D^G
M7NNO)_A_O/M]8P!D#KW7@UR?P+?2]O=9% '#KW7BQL 6N!]!JU6_WCVU$ >O
M=<-1_J?]O[>:,$=>IUL5?R^?Y*N'[8ZJQ?R:^8N^<EUAU-E<4VZMO;+Q^0IM
MM5=3AD3RQYG.9BN#P8?&U$0,D<:P^:2G99VJ*8,H;4&V"8:Y#I7CY"H]:G '
M^'Y=1CS1[A-M\_T6WQB68'2S$%@'X:55<LWKF@.*'--BW:_;'P!^3FU(?BM0
M]N=*_(C%P[?H,+_<#.;UH=^UF0I]J+&D-2KSRO49&LI?!',*R%WG5U%4)0W[
MGLX!AF41$AA0"AXFGS\S_/SZB:>QW79Y#?F*6 EBVM5**I<Y! PH-::3CRIY
M=%ZR/Q(_EM_RXYXN_,5\;MXUNZ*&6IEVO5[;VCO;Y"5M)4TB-,OV*3OF,;@Z
MJP(AK:N>B(/I%6.?;+P06/?I..'$_P"'%?2O1K%OF\<W#Z7QT"GXM310 @XS
M32S#U50?]+UC^"GRC^<'RL[X[-[%WOT0_3_PRJ\%287KG$]BT[X'<*UV)DJ'
MCR-$C4:5.4;+15"C("4)CZ81TR8^IEEAJ_O-6=Q+<N6(HGE7_)Z_/R_9G?,^
MR;;L=K'#'-XEV&)<H0R%3Q!S1=-.W\1R6%"-(1_(GXJ_R/MU=L9K%=H[DZ+Z
MV[>R>7GAW)C]J]XMU[)%7US^5Q7XRERJ87'5;R3%V\M#"[E[R:O3:LL5J&R0
MI^1P/\('2W:MZYDB@!B262( :=4.NH'H=.MA^9^71 N\/@]V[_* W]MWYU?#
M7=]=VWTOBM&&[$VKNN**LK:? [IDA+PY&KQT45-D<%6R1TNFOAIZ>:BJ_LY3
M#,@:8,S1-94D0U'^?UI@@^N/RQT)-NYB@YYB;;K]/"E-2A6H!=:Y4,20PSVD
MFHKGRZ-7D/EG_)9_F,8S$;H^3&#V[U]VK38V#'UT/9/\5Z_S%-'0^1DA3=6
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MB>]BZ4>73@MR< =8'K@QL58V^FIN.?\ 6_XK[VUWJ%*#[>MK;D?+K$9$))'
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MQH. 0JQ"^?XL@GB21P  !2?Y[W\G?=_3?SAZ[WG\:MFI+U'\Z.TL+L[9V&H
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M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZNR_P"$Z?\
MV^1^'G_EP7_OK-[^PGSQ_P DN?\ YM_]7H^A%RG_ ,E"+_;_ /5M^KB]W?\
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M;@L=%3U\\[R2E99*BJ>'RU=1KFE*KXXHQ[RM<[9:*+2SD#N>YCI8,Y R350
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M'R.>LGP2_P"/0WU_X<F/_P#<7WK[L_\ R3KS_GI7_JT.M?>$_P!SK3_F@_\
MU</1[/>2W6/G14/DUM3;>W>CNRJS!X3&XRLSV7P65S5;2TJQS5516YJEFDDG
MEL9)"9)'(#,0MR% ''N#_>39+3:N6MPDMH8XVFEAEE95 :21[N)BS-Q)J2<G
M%<4ZF+VIWBZW/F"Q2XE>188Y8XE9B5C1;610%' 8 &!4TS7H0?C?_P R/Z[_
M .U++_[DS^Q9[3?\JY8?\T/^?VZ#7NA_R7[W_FJ/^.)T0?:&T-Z;T^1/;^+V
M+O.HV-EZ?,;_ ,A49:GDFB:2FBSD4;TQ,#*]GEEA?DV_;'YM[Q>Y?V+<>8>;
M=UAVV[:RE66^=I5U5:,7BJ4[2#DLK>G;UD5O>]6.Q<L[;-N%J+N,QV:+&VDA
M7-HS!NX$8"L/7NZX?(WKCL_9.$VY5[\[-J]^4=;E:JGH*.IGJI1!*D.II )W
M9;LGIN.?]A[][N\I;SR[:P2;GN+WJ/*RHC:^QM!.KN8CACK?M?S/M._7$R;=
M8+:,L:L[*$[U+4IV@<#GJS.@SN)VSU[BL_G:Z#&XC%;6Q-77UM0VE41*:+^E
MRS,2%55!9F(506(!S&@W*#:-LCN;EUCBCMXV=VX* B_\4 ,DT !)ZQ4N-OFW
M7<I+>W0O))/(J(O$DNW_ !9)P!DXZ(Q4R[J^8>_:..GHZS;_ $SLZO+2U4ZF
M.2H9K:P&%UDR%3'8*BDI20MJ8EW GQHF>]]_=T141X-HM'J6;!D/GG@97& !
MB)#4FI ?(&)+3V2VYBS+-N=RE HR$'E\Q&IR2<RL* 4!T&F[TZG_ -)NQL7M
M"AW)0[.H,5E:+(AZBA^ZB>/'4\T$4'_ B#QHGF#7]7*J+?GW-?N5R-_7/;8[
M".X6U2.5)*E-:LJ(Z*OQI0#4#Y\!CJ(_;_G'^J>X27LD#7+R1NE ^E@SNKEO
M@>I.FGEQ/10^XNC&^/VWL'V5L/?FZ1N&@S&.Q==/6S0KK\\3Z&A$<:6B4PA6
M@E,Z/&VDG2I#0/S_ .VQ]K;2+>-KO;D3I+'&Y=D[@5(&G2H[1I */K!4T.!0
MS1R3[@#W'N9=JW&TM_!>-Y$"!L485#:F.3JJ'700PJ!4U%@G7^Y)MX;&VCNF
MIA2FJ=P;=Q&5JH(@0B2UD"/*J7)/C$A;3<WTVO[REY6W=M_VVUO7 5IX(I64
M< SH&(%?*I-/EUC?S'M:[)N%S:*2RPS21J3Q*JY )^=*5^?2O]GW1+U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW5$_;O_"C[^5)T;VQV?TI
MV+W+OS%]@]/]A[UZMWUC*/I3<^5AILSU_DJG$Y."*JI\<\%3'#6TDZ++&[1R
M* Z,5(/MLR@=>Z'3XD?SP?Y9/S:['QO3W0_R2QU=VKG PV]L/?&SL[UK6Y.2
M.*>=Z?%OG,;0T>2JTAIY9&IZ:JEGT#5XR+VVL@;'7NK9/=^O=>]^Z]T6+Y7?
M,SXQ_![K1^W/E/W!M?J'9#UC8O%U><:>NK<G6+$\_P!CA\50PU64R];X8W<P
MTE'-(L:M(X6-6859@O'KW5>F&_G\_P NQ\[M?&=B;@[TZ V]OJOI\=L?LWY"
M_''=_4FT\L]5#+41/3[@R6,6A@@>&+6):IZ>,*RL6"ZBM?%'7NKG,?D*#+T%
M#E<574>3Q>3HZ;(8W)8^I2MIZBGK462&>":-FCEAEC961U8JRD,I((/MSKW4
MSW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=4L?SB/^/K_ )4/_C67XF_^Y-?[$_+/"[_YXY_^?>B3>N,'_/1'_EZ^;E\@
M?^9\=Q_^)0[!_P#=M4^Y%MO["+_2+_QT=1Q<?VLO_-5_\)Z"(FPO[>5=1ITS
MUT'!-N?=S$5%<=>ZY>VNO=>]^Z]U'^ES_0'CVI(_%Y>G6^N*O=UO_JKG_6]M
M&0]:ZS!0Q0<#4Q'^\_\ %/;#W#*:=*%&.'^#_-UXH56]P>2I %[?GD_T]W=R
M1Y],MQZXZ3;5^+V_U_; E*'IR-01T*O1&T<+V!WATSL/<C^/;V]^U^O-HY^3
MSM2::+<F7HZ*J/E0AX[032>M2"OU!N/;\=WJ.DXJ0/+SZ1[E(UM;R2IQ2-V
MIQ*J2/\ !ULR_P#"C?MC>FU-L?&_H';-74[?ZQW73;OW7N7$XDFAI\C+LJ3%
MTV(HIDC"(]'BQ42S+3DM&9GIYB@>F@=37=9A'I0X%*_*O#^7^7J'O::P2X:X
MNGHTBE54G)4,&+'[6X$\: ^IZU5<9E,AALAC\SB,A78G+XBMI,GBLKC*MZ"I
MI:F@=98*BGGB=)8)X955XY$8,C ,I! /LA>93P)_GU-AAU*0P# @@@BM0?(U
MXCK8J^)O\^/Y?T&%I=@;SZ!'RSS6%H8O!F]IS5^V-PR4U/I4R91L;B<W2U;
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M[[-[BR^2SN9K?!'3>:KR\SU%1+XX4CAC\DTCMI2-46]E55  .(HUA4(HH%
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MW/M?R/L<W+6TVUA.4:2&/0YC)*$ZB<%E4TSY@=(N<MYBYAW2XO8 P25]2AP
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MWOW7NJ6/YQ'_ !]?\J'_ ,:R_$W_ -R:_P!B?EGA=_\ /'/_ ,^]$F]<8/\
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MKWOW7NO>_=>Z][]U[KWOW7NO>_=>ZO Z!VXVU>G.O\3(ACG; Q9:I1A9EDW
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MJ-B 1["?./O1+RWNTNU6E@]XT2HSLDK!JNBN>U8), .M37B:8Z$W*GM)%O\
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MJ(./Y=-]9Q]!_K#V8)PZ9?CUW[<3CTV_#K)%^L?[[\^WNDC\>G"/]8_UP?\
M;$>W(QY];CP:_,?X>G,#UH/I]?\ >/;RBIZLPU=3E&I5'XN2?]A?V]U9QVC[
M?\_4V("Y('U ]^Z8;)ZF)$SNJ)RQL #]/\3_ *P'U]O@>734CA*UZR3)#&^C
M4SD$:F_WW_%?>^J1LSBO#J+[]T_U[W[KW7O?NO=>]^Z]U[W[KW0[_'#HCOSY
M$]J8?8'QIV;N;>_;-)35F\,)C-H5\6*KZ=-IA:J7(054U32+3M0E4D$@G1T8
M*4.H#V@W&^@V^(O<L%0G2:@L#JKB@!X_9TLL+.:]D"P EQW"A"D4(S4D<.KW
M*'YY_P M?^:5-M;;'\T7IW-_'7Y39*AP.S&^?WQ[KH\=1Y&2A^TI:.NWO@*B
M.:F1/MZ:"GJ*EZ3)+#"9#328BF"BG!9V7<>6M3;<XEARWT\@J1Q^$XKZX*DF
M@(;H5#=;+?:+>H8Y,#QD-!Q''C3T[@P KD=*;X_? 'Y,?$;^9SV;L?M#:O37
MRNV;\#^K<9OG ]K_ "G[DJNI>L-IX?<])!+LS=>2>O@W"*%:!*>IB@PGV=1%
M!7TDDL4K18^&M+-_O5ON>WJT1>![F0JR0QAY9"I[EP8ZUU ZJU(-*9(Z>L]K
MGL+PB33*L"!E:60I&@/PM^.E-)%*4%*U% >K!-N;S[[[G^$?\U2M^9W\Q#X<
M?S"M@[0^'_8^9VYUIT;M]=X4FS=X9.$G8NXJ;.ML[:E+B98<I1U:4M!%!.[S
M04U5#,A@F#$KQP6EY9BUMKBV8S("\I*F1:@.-.IJX(J00*$@CAT9J\US:W)N
M)X9P(G(6,!@AH2IK1?,8!!. 0>/1$\5\GMX_RO/Y'/PPBZCV_@-O?(_YK]_=
MW_(;%;TWAM:FWK)@L?L!8MKQY_$TF4CK<73Y6JPTFW4H7FI9$BIZJKJ8J<5;
M"HC.7VU>9=XG\4DPVZ)&0ITU)[M)I0TU:ZD>E*TIT5I?-L.V1>& )9F9P2*T
M'#4*U%=.F@^=:<>C ?S,OY@7RB^/-'_+BVKU&-L8?^9)WK\,NB]P?(?Y%CK'
M;M?O>L3?DK)@]HTU=64%3C*%9,V<PU:U,B/*ZTWK@@/C9!L&R6U^;J274;2*
M:3PH]3A,9+$ AL+I^9^=.EN\[K/9B"., 7,D:>(^E=6<!:D:<MJ^0^5>CK]H
M?'[HCM7^;G\W?DUVW'TED,G_ "ZOAY\;ZC<:]X4\NU-DY+MSL7"U5?@-S[QK
M*"EK2V(Q5+#3+4&/#UP5FIG11)0)&Y5;WD]KMD%NFL"ZGEH8Z,_@J55E45&6
M).*K6A'!NC&:VBN+^69M!-O"F'[5\1M3!F-#@ #-#2M>*]%%@[RRG:74?S(V
M'_,__FK?RV_E)TEOOXZ]EY'J'9'4.X9-S[CVGV%@XUJ]K9'9U$VPMMFF2E05
M<(ABJJJIJ'%)3)%(LM0S&360MY('VVSNXI4D74TBD(Z'#!CK;CBOPK0FOE0O
M6Y,R2I?7-L\;(VD(P+(W$:1I'#R^(U IY]::/N7.HVZWV?@I5X+J?XY_RF/Y
M=.16*MI?GQ\*/GGV!OFDKH%J8JN3N7!-N+"4]5 ::6*2EDP\N5IQJ5RWV\41
M20RZ6A#>E>[N+R^7!MYX5%,4"L4J#6M:JO#UKBG4L[4R6T%K:-D3PRMG-2P#
MT(IPHS<?2F>J\/Y-'1&-^-?7GQ[WQG<?2M\JOYJ7;F-Z/Z2P>8@GBFV_T9LS
M)05W:>ZS"T$-135FY</CLC1XR96ECD5L95PR"FEK"I]S=>G<I)(P3X-HA>0B
MG=<.-,:\2.UF%1@CO'&G11RU:_0)&YIXMRP5 ?*%>YSP!R :<0:H>%>AC[?[
M4V9L+<_\Y;^<WB]I[;[![YV)\O<=\&OB?4[YPU+GZ+:M?LG'83;5;O.&BF6H
MHZBM.%AI6QSRT^M%@>%VTUE2GM+;V\EPMCM+,5C>$W$NDY<,SR!3P],^537-
M!T_-,D!N]Q50TB2>"FK@I540L*?;]M!2HJ>BD=;?)OO#^9-_*E_FAYSYZ;JI
M>U1\7Z;HGLCX]=U;FVMA=LY3#;JW5EJRBJ,#C\O3XVEII:?*Q14=,]"B><K7
MO'$RM54YC-+G;H>7]SM!8@J9=:RQAF8%!3N())Q4FIQ5:TP>BZWO9-YL+DW9
M#"/2T;E54A\X!  \@*#-&(KD=&L_E\? /M[X]?RJ.S^R.N-V=)]5?-W^8?M&
MGVQL[.]X=JT?4\^T^H<P[B>JQE2:J2K_ (IN2%151O!"C0B?'23>.>@,;E>_
M;[#?;DB2!WM[9JD1KKURC.0:"@-%-:@@&GQ=&6S[1+:6+LA5)YA@N2NA#PX5
M(-*D<""17AT6'^>K\?=V]<? W^4!FMRYG8^ZLYU)U+O[XN[[W+UYO"EWOB)*
MG8T>$.#CQ^1HT$55 :2@RI))5XRJQR1K(']F?)=^EQ>WH4,/$<3*&%" 6:M1
M7CWC_/T7\U6;06MK4@^&OA,0:BNE:4QP[#_FZI[_ )871.Z^_P#YF]5;=VUT
M1L[Y&8W9LV2[.WUUMV5OG_1MM5\)LV+R5%?NG-_;U@H\!05<M%)5H:.H6K6U
M"T$JU)1A5S+?+8V;L9&B+4171=;ZF\E%5R0#0U%.(-0.@[L-H;RY4!%D"U9E
M9M*T'F30X!(Q0UX$4KUN _#?M+O_ +[^4/;>#^2?\Q;^7G\E?B/-UAW/N3>7
MP*^/$<?<V)HMET.-KH8Z),BNQMN46-H=MSU>'A->]=6#(Q&6)E\LT,@BS=;>
M"QMXS!;744P9 +B6L9,E0<#6]2:$T%"M :G/4A[?-->3N)9[>2,AOT(R).SA
MDZ5-!49-0:G QU1%_)3[LZFZHZD^4VPY_D!MGX$_+#O9]DXSXU?-_LS84.Y\
M##0[)J14;HVDN2RE/)BL!]Y%44HJZSS0M:KII9'>6BHH)1ES=:274\3B,W,,
M0/BVZ,0^I@=+$+W'Y8_"1BIZ"_+4Z00R+K$$DA&B9U!4JI%0-7;]OVCC3I)_
MSL-X?*VBP_QNZ1^>?3>P=P_)?8.'W#GMN?/GKG=E/E\=VGLK<TS/1T<<6.P6
M(I:D8.H$*>6I85L)#3?9P1Y0SUCW*$-L6EFLI&$34!MG6C1./.I9CD5I3!X5
M)7#7,TLX6.*Z13(M2)U/;(IXBFE<@TK7((J  V:N_B%M+Y44V^\I\C_BKMG/
MY/<OPZQU/\C-U[LPTM.D.WL9L.0ULN1R*3U%.*G'E*:9*BF42?<P&6!HI$D9
M2(]VFM2@MKE@!<?I**$EBU!C!H02*$\#0]$>V17 8SVXJ8?U&-0  *G.14$
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M,8%8ZB2P->T5)K@ABP%:_L/1Q^R^Z>C/YA/\NSY__'W^5A-O?J7>'2?8=?\
M(#M/;[8],9N;Y!;3RB25&Z]Q95:2C;+3U%=EGK9(L<)C)]K38K'5%-1P5\>.
MI"FVLYMAOK6;<M+JZB-"35;=AA0*F@TU%3PRS DBO1C/=1[Q:7$=C565B[ "
MC3 Y)P*G50XXF@!H#3K3:V-O;=/6F]MG=C[&S-1MW>VP-U;?WML[<%(D<LM#
ME=J5<-?CZR)9DDB:2EJX(9%#QLA*@,K"X,M3PK<HT;BJLI5AZJPH1CY'J-X9
M6@=70T92&!]"#4<?F.MTC^8+\X^I_BA\;=C_ ,P7H3JBDZW_ )B'\WOX[[%.
M8WE*5RAV5@=O8;$Q;FR>%<Z#3U>7FJL4E+,L,(K9*>FR,\;38\PM$>Q[-+N=
MPUC,Y>ULY7[>&MBS!01^1KQH"P!&JO4E;MN<=A"MW$@6>YC6AXZ1I!.<<*@?
M,T)! IU6[_PG@DV/U55_S'OG)VS/O:;9?QJ^)%7@,]4;(:AGS0E[LKYI3/BO
MXFZ4SYUX-L5<5&U1**;RSM]R=)! @Y[#W M;.,*#+-BM0!H 45I^']3-!7&.
MB;E K";BZ<L?#CS2A)#58\?/LQG[>A-^%7Q7_DB=^[=[[[2^/'5WSW^2_;'Q
MGZ^F[:'P]^1W:>Q]@3[NQ.$EBDJJ_#OLS#FHR46/E2*"MIC7:O'5*JT=5-/3
M1LFWO<]WL3''.UO$DK:/'B61@A-10ZR:8R"!7&#@]/[1M^VW>MXEFD:,:O"D
M* M3-0%I7.,FF<C(ZZ_EL_([??\ -&_GJ[&^6G;>*V_L?:7Q_P"J]Z]CXS86
M I?N\9MG:74V$JL7A<9!5,M.["DS.?IZV:KG4!ZF241QP0O!!![?[!.6]F-M
M&2QED52YP6=CJ)IGR330>6<FM=;->-OFYB=^T1HQ"\:*!I KCS>M3]GI2MGX
MH?$K=W\V?YL]]]K;IS%3U+\?7W]V?\EOE/WEDH(*>BVI@-SY6OSM7$*B6U ,
MS7>::*DB)<($GK&AEIJ.92?;GNR\KV<40H\VA(HD%>YE4+7UTBGVG Q6H)[#
M;3O]U)(:I%K9W;T!):@\JY^P<<\#'_FC_P P3:7R>RVP?C9\7,!)UE\ OBW
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M?2O6,*9F#%9@Y+-;CB7R4L<D"-3O(LB\?94<<TGDEO:61DCBU'09,:_='?\
M_72W"WY<V<"41S>)-<#,:LJE"01_H<8<ZFX,Q"K4TU9 >W.R?ZW%C/OVZDQ&
M2+1%"<2,"0X!!_&Y4:5XJH+-05TK/YEXR'"=*;%PU.[R4^(W=M_&0/)^IDH,
M3D8E+?XE4%_8@^\+:+M_+MG M2L=U!&">)"6MPH_P=$?L;=-?;]=SM@R6TSD
M#@"]Q Q_P])W8_:GR:QVRMGX_ =-8W*8*AVMM^CPN3>&H+5-)34D*4TY*UR
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M\O7S>?D#_P ST[DXOJ[2[!&H+_J<K4_\5]R-:?[C1_Z5?\'4:7(_6E_YJO\
M\>/0.?3C_C7N_5*]<BP5#8'4;_0>U2'2M>M4KUC6!G4D$ !;<_XCCWKP]>?S
MZOXNG\\=8 "MU(8_GA/Z?[;VCFC\3JXEQY==BQ^E^/J"+>TKQF/IZE>O6/\
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M(3)#42?Q:C>.2F_A= ].T>/E,_VHF::D2C7QV4=FQF#$*!6GD*_9Q^0]?7%
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M(WO;PWC_ $I\6NJFLZ-5>/I\_@X_MZ#?JS^<ON#=?;7S6SGSRZ>Q7R:Z>_F
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MAM[X[G:>!^)'4FPNE]J=(?Z7?XH:W#;)I,_1M&=Q1[8HDHC61[AJ[JNWY4C
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M[KWOW7NLD44L\L<$$<DTTTB10PQ(9&=I#9551<LS$@  7)X'N\<;2L%4$L2
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M?\]$?^7KYO/?P8]Z=R6) 7M/L#_W:U7N1+3_ ''B_P!(/\ ZC6\Q/*/^&/\
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MYW-_YQ4O_1OOW_ S[;_RF7/^\Q?] ]>_X(2^_P"42#_>Y/\ /U[_ &1/9O\
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M]+[T_#_5\NGX?B7[1_EZ^J]_+Q_[( ^#7_BGGQF_]XK">\<]Z_W,G_YK2_\
M'VZG3;?]QXO^::?\='1P_99TMZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZI8_G$?\ 'U_RH?\ QK+\3?\
MW)K_ &)^6>%W_P \<_\ S[T2;UQ@_P">B/\ R]?-Z^0*#_3CW(;GCM+L$_U_
MY>U5_P 5]R1;9M8?](/\ ZC.?$\W_-1_^/-T#NH\<_06'O?5*==$D_D_[>WO
MW7B.I$,",IGE(T@V]3?G_6^ONZCSZ:=])H >L%2 6U*ME(%A;^GY_K[\*''3
MR-3J+[65'6^IE% :FI2!.6D(1>;\G_B!^>/I[VJ^*1QZU+(4'2S:C@*?812B
M&EI1JKIG8*68@DCC\D<#DA0/IR;F'ABFE<4^+Y](*L[5&#P/H?\ !7I-5TD;
M%O B0TP(6,#@FWU)/U)/Y]H995)H* >7#I2M":C'3'I^IN>?^1^TS1J<]*3C
MKQCN.+DW//U]MX7C_J_EUY6T]9(X9'.D$EN-(4D$D_CZ?GW5E+TT@'[<C_ .
MK>,%R>L]1134Q17-YF17>(FY75R ?]JM:_\ 3Z>_2VQ"BH ^S'6EF#Y Q\^G
M?;&Z=R[#W+@MX;1S&2VWNG;.4HLW@<]B:HTE325>/D$D$\,BV*NCJ#_0_0@@
MD>V!;UX<?*G'&?7JLBI<J8W4,K AE.001D9ZVU_YI&2_V:7^3AT'\G-XXZE7
ML/&P])=B5M?B<>:>*.MWS3)A<Y%$NMS38ZKK*U950NUFAID+$@'V;;@/J;='
M/$$9_(@_M(K^SJ$>2H_W+S!<649/AGQ4 )\D.M?M( (_,GK4)M_4B_\ 3GV2
MBW9L^O4YDD=;C7\C+=VXODO\&N^?CIVY-4[LZ_VODLCU?MZ;,RR5S1X'L/"R
M+4897>_^38YC*].HDO"E2L2".**$ _VT-)&\3\. ^6H$4'V4K^?4!^Y$*;1N
M,%Y!19&[V \WC<$,?F:T/K3[>@L_GD;]ZYZ!^(7QI^!FRLQ!79S#Q;"KIJ"H
M=)ZRGVQU3B:C#T%96A2/#/E\CH:-])\II*VWTO[U?C0B1#RH:_8*?SK7I7[=
MV\NYWMSN<@H&U@<:%Y'#D#Y*!3\QT-&"V)A_YK/\FSKGKS86;IY>Y.E=O;*Q
M&/HLQ7K)+'O#I'&-B%I\B[3GQC<V#GG:"HEETI_$8JF47BEB#R+]3  .*TQP
MX"G\Q^5>BZ6Z/)>_R32C]*8N2:?Z'*P<D8_ PR!F@('$=/7Q>ZQ7^4C_ "O^
MW>T^Y)J2@[?W]B<AO2OVC7U,4#19W/8X8[:^U$D1)7GJ8I"LE85640/+6LH:
M"G:1O(/I(F9J MP'[:?X:GT_*O7MWO/Z\[S#!;@F*,A=0SVJVIW^0\E]>WS-
M.BA_\)Z>Z]D9? ?(?X>[UFQ\53O\MV#MC&5=2(WR]/D,;_!]R44:,H#R4U%3
M8Z8(KL[PO42: D#M[0[5("7B8_%P'Y4/\L_MZ/O=3;I(S!N$5?T^QB/PG5J0
M_MJ*^M!YCHW'\UK)Y_X#?RN>J^A>B\KE,-09+/[&Z"RN]*#_ '$5K4"XG+9;
M+57DI@@@KMP56+D-24*ZXZFK /JO[4;D#:VZQKYFA/"N"3^T_P"4=$7(X7F?
M>I;NY )"O,J'(!U*BC/$(&QZ$+UI=A2;_P"'^-_83D<=9"A2>'6VG_(:I,-T
M]\'/E_\ )NMP])3Y;%;EW?+49S*%:2.;%].;4I\W'"9VLT=)%59.N,K@A-5[
MDM"0HGV=/!A=Z9S_ "%?\O4&>YK-N.Y6ED":$+@>32RZ*_,T44_V>M6;M+LW
M>G<G8.\^TNQ<]6[DWMOS.UNXMPYG(3-*\L]:Q.A 25A@AC"100I:."%(X8E6
M-%4!R\D:60ZCP/\ /\NIKL;./;HDBA4*JJ%"CR '^7^?'H/+_P!!;_'VG!KT
MKU$>76=2;?6]QS_L/;L>>MDXKUR%N"3_ +#W9F\NO!J]9(V36@=A&C,H9W)(
M )Y/ )_W@^[0#4<\*]>)U#'IU*J:L: E*"B@6N&L6']>+>U<E\*:5!'ETF@M
M-)U/0^?3&5)+7O?Z_3^OU]E[Y(/[>C$,/+KP7\:[?X>[&(-FO3JBHK7KER+"
MQ;_&]O;$EL2<'KQD"8ZY!K:@0>5_XF__ !'MDVK>77A,.L@(NMOHM_K_ (^[
MQV["M?EU220$=9DD3](:Y^OT]OK P/3#/7RZSJR6_K<\@#\ ?C_D7NQB*]5K
MUE">L<'38?4?U]U )/#IEV'$'K-=186*V(MQ_O?M8B"G3/#\^LJ6)'Y'/O86
MO 'INO630 1]?Z_[;W:%Z"AZHXJ>LA!_ -OQQ[,.F^N]#?ZEC_K#WNG2*3XC
MUD0&UB"#?Z6]JXOA'5.L\8L;_G^AX]N<>D\K >?ETX)Q_KD*?]O[>7JL8-*]
M3H.7OS8C_>K^W%X]/<:'IS0\#\VY]O=6-"/V_P"'J=&>3;_ C_8>]@TZ9ZRF
MU^/H>?;_ !ZT.NO?NM]>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]US3
MA@;7 ^M_\??NJMPZY1KZKGD V'^O_ON??NJLV.O,6,C <>JQX_IQ_P 1[]UZ
M@ SUTS7(4<@&]_Z_\:]^Z\!3/7 _[Q^/?NKCKKW[K?7:FQ_J/H??NM$5ZS!A
M#>PU.;BY%[#_  _Q_P ??NFZ>)]G6#W[IWKWOW7NLR_HC_Y;G_>E]Z?X?]7R
MZ?A^)?M'7U7_ .7C_P!D ?!K_P 4\^,W_O%83WCGO7^YD_\ S6E_X^W4Z;;_
M +CQ?\TT_P".CHX?LLZ6]>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=4L?SB/^/K_E0_^-9?B;_[DU_L3\L\
M+O\ YXY_^?>B3>N,'_/1'_EZ^;UW]_S/3N+\!NT>P+_ZW\6JN?<G64=;:''X
M%]?0=1E>&D\Q_P"&-G_;-T$Q10+V7GZ<6_WF]O;DD.D8!_GTG#U\^HYC8?T)
M_%C_ %]L!#Z']G3X(/4JGB.DR2$"-.2"WU(_ ']3[LJ>9Z8DD%=(XG'V=19B
M9B6"V!-@+?T]UUBO3Z#3UB,5OJ&'^OQ[WK/7JUZR1N875X6:-U-U8-8_T][2
M1TZ\>_CGK(:B8)I4NR%M<B%C8GZ7(O8V_J1>WO9E<5X_/IO0I_+'7 R%VU'B
M_%C]!;VV3JSU8#KL1*RMRJ-I-B3P;?B]O=P_6]76  JI_)O_ *_O5#)U;I58
MR*&AI*C*U #.%$-&A< E_HQT@_XV'!M^J_'LW@00)4_ETAFK*=(_;TS.WW<T
ME7,+ZKEK^D:@ +6/]+?2WLMF9G:IX?Y>E"KX8TY/4*0M*6U  FPTV^FGVTCA
M#4]/)V];5/\ *"^5O0WR(^*^=_EH?)JMHJ:MJ,;NC;VQ(MPY$446?P6Z:J2N
M%!CZVH8B'<."R-1++11 K(($I)*)7:BF$9I:W$<RF)L \. XY_;7(ZAGGO9K
MK:[Y=XL@<%3)I%=#*--2!^!E%&_.I[AT$N[?^$W/<R=B"EV)\A>L:CJ:>NJ&
M_C>[<5E:+<5)2NTABC_A5'23XS(U$:>)7D_C-$DC:G6*(6C][.W/7!6GY@_L
MH?\ #TKA]V;4Q5D@D$E/A4H4)_TQ8$ _Z4T^?6Q#\(_C5T=\->L9?C5U-N;'
M[CW/M4X_>W:=955U(V<K*_?/GAILOEJ&G=GH*>MCQ,]/CXV71]O0F-9)Y(9I
MG,+>)8!I!J>)^T_X/E_J/46<R;O<[_,+R=2J-5(@ = 5*5"DCN(U58^I\A0#
MY_GR)[B[![^[O[*[;[3DK1OC>6Z\KD,OCZX2(<<(9##!B8XY522&#%4\<5)%
M&R*R)"JL-0-R L7.HY)R>LF=NLH]MMXX(?@10%^?J?M)R3YD]6<_R(NY-\]?
M_._:76^ EJZC9W>&WMV[<W[B(D\L97:&&RF;QF0*V(66AJJ1HQ)<:8:JH47U
MZ2NLCI8?.H/SQ_J/[>@A[C6$=UMKRM\4)5D/IJ=4(_,-P]0/3H;_ /A1%VSO
MG._*+KSIFJR%33]=[$ZLP^\,-@U+10SY7>597Q5F2E XGD6GH::FB)!$(281
MZ3--JM?5<G^CC]HK_J^SHO\ :VR2*R>=0/$DD*D^>E *#Y#)/SK\AU15UKO?
M?'5^_MH=D=;YBOV_OO9.=QVX]M9C%D^6GJL:XDC)4W62%[,LL;AHY8F>*56C
M=E)9%;DM4<:BA'K_ #ZDB[CCN8VAF4,KJ592<$$?E_JSU]#[O7JKJKYB_&C$
M=.=^-!MA.\]K;;K\9CERT&(RM%G8:.'+Q28;SL3-D,5-&TAB"2K)#'-'/')3
M/,K'\T:W<862@U $?(TKCK%S;;V?EZ]:XM:MX+,":$J8]17NIP#>N*&A&:=:
MY<?_  FW[M/8;4$OR*ZK3J;SW7=$>#R\NXC%Y!Z3@3"F-$GBOZO[R$:O[-CP
M1'8&)XK3USP^S_)7\^I;_P!=^V$51!+XE/AJFBO^GK7_ (Q^71E?YE/R&Z!_
ME]_""'^7-\=,Q2Y3L7=.S6V1NF.G>GR-5CL-GC?<66W%+ L<"YS<Z2542P"-
M75*B2=8Z>"*E61;=.MK'X$9S^(^GV_,^GD/3'1-RCMEUS1N7[WO!2-6UI6H#
M,/A" _A3!KYD4R2U-1(EAP>?Q_7Z>R4VZGC_ *OY=3MXG7>ASJ"QW*AF(O\
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MZD>VWB(..MZ_7KCXEMRXO_@"?>EB:M>'6]?7,AG%@Y.DW"G@#_6'T'NTGB$
M=56@ZX%6TA&U79E^GJ'^V_K;WY(F;XJ]6+5X=9WI66)92-*LQ5"Q%SQ?4!];
M<VO]/;OT_G3IM)*D@9IQ].LQH)HZ=*J5"(I5/A.G3JM;GG\7][-OI&K]G3 O
M%D?0*$@Y^71BJ+YF_,+%XR+!XWY7_);&8>" TD.*H.]-TTE,D1%C$E/'E5A6
M/22-(2UOQ;VQ'+(#2K4'E4TZ2/L-A(=9MX"W&IAC+$^M=->CJ_RG_G[!\/\
MY+[AW!V[E<UE^L^\:&CV_P!I[AJ)9\W6TE925+SX[<$Y=VGK!12U%8E2/W)C
M3U,TD:R3(D;K;>4V[5/#@:>A\_RI_AZ(.=>6_P"L%H$A $D)U1C@"*4*>@J
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MZS#]$7_+8?[T?;;_ .7_ "=/0_$OV_YNOJ6? ??6'POPI_E_;1JZ7-29//\
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M8\,"IY!]^Z\7IT(N0S]%C=O5.Y9XJYZ"EQ;9>2&GHWGJ#$L?ETK H\C2Z>-
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M#KY\E].GU?3W[JNL=+O>6\L7L;$+FLO3Y>JI&K(:(1X7%RY>;7.KL#XH07T
M(;M:P-OZ^_=6)ITW[&[$P?8$.1FPM'GZ1,9)315 SN$GPI8U0<KXQ,JF0 (;
MD?3B_P!??NM!M727W+WCM':N<K\!D<9O.>MQTD4<\N,VC5Y& F6-)!XYHT*2
M#2XN0>#<?4>_=:+@="+E=QT.(VY4;HJH<A)CZ;'QY*2"DH7J:DQRA6"K3J#(
MTEF%U N#?^GOW5JTZ1VR>V]M;]RM1A\-0;II:JFQ\N2DDSFVJG#1&.&2*(JL
MLRA6D+3*0H-R Q^BGW[K0:O7M[=M[:V%E:?#YF@W35553CXLE')@]M5.9B$<
MTDL05I85*K(&A8E2;@%3]&'OW7BU.ECBMQT.7VY3[HI8<A'CZG'R9*."KH7I
MJD1Q!F*M3L!(LEE-E(N3;^OOW6ZUZ#[:W=NTMW9ZAV]C,9O*GKLA]UX)LKM.
MKQE./M(9)V\D\J!$ND3!;GEB%')'OW6@]>E!OKLC ]>_PO\ C='N&K_B_P!]
M]M_ <%/F]/V'AU^7P*WBOYTTZOU6:WZ3[]UXMIZ>-H;MQN]<-'G<33Y2FHY*
MBHIEBS&-DQ4^JF-F)AE <*3]#:Q_'OW6P:](#_3KL_\ O!_=K^%[U^__ (S_
M  /S?W0K/M_-Y_M]7GT>/PZ^?)?3I]7T]^ZKK'2[WEO+%[&Q"YK+T^7JJ1JR
M&B$>%Q<N7FUSJ[ ^*$%] "&[6L#;^OOW5B:=-^QNQ,'V!#D9L+1Y^D3&24T5
M0,[A)\*6-4'*^,3*ID "&Y'TXO\ 7W[K0;5TE]R]X[1VKG*_ 9'&;SGK<=)%
M'/+C-HU>1@)EC20>.:-"D@TN+D'@W'U'OW6BX'0BY_<E!MS;]7N2NAR$U!14
M\%3+#CZ%ZZH*SLB*$@0&1V!<7 %P+G\>_=6)H*])+9':VW-_5]7CL-0;GI)Z
M*C^]E?.;<J,-&4UK'9'F4*[W<>D<VN?Q[]UH-7J/O/M_;&QLNF%S&/W755;T
M<-<),+MFIR\.B=G4 RPJ4#@QFZWN!8_GW[KQ:G2UQ6XZ'+[<I]T4L.0CQ]3C
MY,E'!5T+TU2(X@S%6IV D62RFRD7)M_7W[K=:]!]M;NW:6[L]0[>QF,WE3UV
M0^Z\$V5VG5XRG'VD,D[>2>5 B72)@MSRQ"CDCW[K0>O2@WUV1@>O?X7_ !NC
MW#5_Q?[[[;^ X*?-Z?L/#K\O@5O%?SIIU?JLUOTGW[KQ;3T\;0W;C=ZX:/.X
MFGRE-1R5%13+%F,;)BI]5,;,3#* X4GZ&UC^/?NM@UZ#^D[UV?6;@IMMQ8O>
MJU]5F(<''-+M"LBIQ-/.( S3E/&L(<W,A.D+ZOI[]UK6.EQO;>V)V%BJ?,9F
MFS-52U.0BQL<>#Q,N9E$DT<LH9HH066,+"P+$6!*CZL/?NMDTZC['W_A=_TE
M=686DSM)%CZB.FF7.X:;#.6D76#&DP!=;?4C@'CW[KP->DGN7O':.U<Y7X#(
MXS><];CI(HYY<9M&KR,!,L:2#QS1H4D&EQ<@\&X^H]^ZJ7 Z$7/[DH-N;?J]
MR5T.0FH**G@J98<?0O75!6=D10D" R.P+BX N!<_CW[JQ-!7I);([6VYOZOJ
M\=AJ#<])/14?WLKYS;E1AHRFM8[(\RA7>[CTCFUS^/?NM!J]1]Y]O[8V-ETP
MN8Q^ZZJK>CAKA)A=LU.7AT3LZ@&6%2@<&,W6]P+'\^_=>+4Z6M+N2@K-LQ[K
MBAR"XV7#MFU@EH7BJO"L1FTFF(\@FTBWCMJU>GZ^_=;KBO2"VGW1M3>6;IL!
MBL;N^FK:J.HECER^U:K%P 4J-(VJ:50BDJIL">38#W[K0>O3QOGLW =?2XV+
M-46XZMLI'4R4YP6 J,T%%(4#>4PJPC)\BZ0?KS;Z>_=>+4Z?-H;MQN]<-'G<
M33Y2FHY*BHIEBS&-DQ4^JF-F)AE <*3]#:Q_'OW6P:]!_2=Z[/K-P4VVXL7O
M5:^JS$.#CFEVA614XFGG$ 9IRGC6$.;F0G2%]7T]^ZUK'2XWMO;$["Q5/F,S
M39FJI:G(18V./!XF7,RB2:.64,T4(++&%A8%B+ E1]6'OW6R:=1]C[_PN_Z2
MNK,+29VDBQ]1'33+G<--AG+2+K!C28 NMOJ1P#Q[]UX&O2/W!WKL_;>9R."K
M\7O6:LQE0::HEQVT*RO@9@ ;QS1H4D6Q'(-O?NM%P.A(W3N2@VC@:[<.3AR-
M10X_[7SPXJ@DR=0?NYHX%\<$0+O9Y5+6'"@L> ??NMDTZ2^Q^T=O;_JJZDPM
M#N6DEQ]/%4SMG=O5&%0K*VD"-IE4.UQR!R!S[]UH-7J'O/M_;&QLNF%S&/W7
M55;T<-<),+MFIR\.B=G4 RPJ4#@QFZWN!8_GW[KQ:G2UI=R4%9MF/=<4.07&
MRX=LVL$M"\55X5B,VDTQ'D$VD6\=M6KT_7W[K=<5Z06T^Z-J;RS=-@,5C=WT
MU;51U$L<N7VK58N "E1I&U32J$4E5-@3R; >_=:#UZ>-\]FX#KZ7&Q9JBW'5
MME(ZF2G."P%1F@HI"@;RF%6$9/D72#]>;?3W[KQ:G2@VGNC';RP=-G\7!DJ>
MBJY*F..++X^3%S@TLC1MJAE =064V)'(L1P??NM@UZ#S%=Z[/S&=HMO4N+WK
M'6UV03&PS5>T*RE@$DCZ SSL@1([_5B;6Y]^ZJ'!Z6>]]]8?8./I,EF:7-U=
M/65@H8DP>'FS,@<H\EWCA!94TH?4>+V'U/OW5BU.L>Q]_P"%W_25U9A:3.TD
M6/J(Z:9<[AIL,Y:1=8,:3 %UM]2. >/?NO UZ1^X.]=G[;S.1P5?B]ZS5F,J
M#35$N.VA65\#, #>.:-"DBV(Y!M[]UHN!T)&Z=R4&T<#7;AR<.1J*''_ &OG
MAQ5!)DZ@_=S1P+XX(@7>SRJ6L.%!8\ ^_=;)ITE]C]H[>W_55U)A:'<M)+CZ
M>*IG;.[>J,*A65M($;3*H=KCD#D#GW[K0:O3?O#N/:VR<R^#RV.W;4UB4\%2
M9<-M>JRT.FH!*@31*4+"W(O<?GW[KQ:G2X_O)0?W5_O?X<C_  S^[_\ >3[?
M["3[OP?;?=:/M;>7[CQ\>*VK7Z+7]^ZW7SZ0^S^X]K;VS*8/$X[=M-6/3SU(
MES.UZK$PZ:< L#-*H0,;\"]S^/?NM!J].F^>S<!U]+C8LU1;CJVRD=3)3G!8
M"HS044A0-Y3"K",GR+I!^O-OI[]UXM3I0;3W1CMY8.FS^+@R5/15<E3''%E\
M?)BYP:61HVU0R@.H+*;$CD6(X/OW6P:]!YBN]=GYC.T6WJ7%[UCK:[()C89J
MO:%92P"21] 9YV0(D=_JQ-K<^_=5#@]+/>^^L/L''TF2S-+FZNGK*P4,28/#
MS9F0.4>2[QP@LJ:4/J/%[#ZGW[JQ:G7MD;ZP^_L?5Y+#4N;I*>CK#0RIG,/-
MAI"X1)+I', S)I<>H<7N/J/?NO!J](S*]Z[/P^=K=O56+WK)6T.0?&S34FT*
MRJ@,D;Z"R3JA1X[_ $8&UN??NJEP.A#W9NC';-P=3G\I!DJBBI)*:.2+$8^3
M*3DU4BQKIAB!=@&87(' N3P/?NK$TZ3^QNS<!V#+DHL+1;CI&Q<=-)4'.X"H
MPH859<+XC,JB0CQMJ ^G%_K[]UH-7IKWAW'M;9.9?!Y;';MJ:Q*>"I,N&VO5
M9:'34 E0)HE*%A;D7N/S[]UXM3I<?WDH/[J_WO\ #D?X9_=_^\GV_P!A)]WX
M/MONM'VMO+]QX^/%;5K]%K^_=;KY](?9_<>UM[9E,'B<=NVFK'IYZD2YG:]5
MB8=-. 6!FE4(&-^!>Y_'OW6@U>G#?':.WM@55#29JAW+5RY"GEJ8&P6WJC-(
M%B;21(T*L$:YX!Y(Y]^Z\6ITJ-K;DH-W8&AW#C(<C3T.0^Z\$.5H),94#[2:
M2!O)!* Z7>)BMQRI##@CW[K8->@WV_WKL_<F9QV"H,7O6&LR=0*:GER.T*R@
M@5B";R32($C6P/)-O?NM!P>EIO??6'V#CZ3)9FES=73UE8*&),'AYLS('*/)
M=XX065-*'U'B]A]3[]ULM3KVR-]8??V/J\EAJ7-TE/1UAH94SF'FPTA<(DET
MCF 9DTN/4.+W'U'OW7@U>D9E>]=GX?.UNWJK%[UDK:'(/C9IJ3:%950&2-]!
M9)U0H\=_HP-K<^_=5+@="'NS=&.V;@ZG/Y2#)5%%224T<D6(Q\F4G)JI%C73
M#$"[ ,PN0.!<G@>_=6)ITG]C=FX#L&7)186BW'2-BXZ:2H.=P%1A0PJRX7Q&
M95$A'C;4!].+_7W[K0:O3/NSNC:FS<W4X#*XW=]36TL=/+)+B-JU64@(JD61
M=,T2E&(5A< \&X/OW7B].E[5;DH*/;,FZY8<@V-BPZYMH(J%Y:KPM$)M(I@/
M(9M)MX[:M7I^OOW6ZXKTBMF=O[8WSEWPN'Q^ZZ6K2CFKC)FMLU.(AT0,BD"6
M90A<F066]R+G\>_=:#5ZF;X[1V]L"JH:3-4.Y:N7(4\M3 V"V]49I L3:2)&
MA5@C7/ /)'/OW7BU.E1M;<E!N[ T.X<9#D:>AR'W7@ARM!)C*@?:320-Y()0
M'2[Q,5N.5(8<$>_=;!KT&^W^]=G[DS..P5!B]ZPUF3J!34\N1VA64$"L03>2
M:1 D:V!Y)M[]UH.#TL-\;_PNP*2AK,U29VKBR%1)30K@L--F7#1KK)D2$$HM
MOH3P3Q[]ULFG4C9.]L3OW%5&8PU-F:6EILA+C9(\YB9<-*9(8XI2RQ3 ,T96
M90& L2&'U4^_=>!KTAZOO79]'N"IVW+B]ZM7TN8FP<DT6T*R6G,T$Y@++.$\
M;0EQ<2 Z2OJ^GOW6M8Z$3=FZ,=LW!U.?RD&2J**DDIHY(L1CY,I.352+&NF&
M(%V 9A<@<"Y/ ]^ZV33I/[&[-P'8,N2BPM%N.D;%QTTE0<[@*C"AA5EPOB,R
MJ)"/&VH#Z<7^OOW6@U>F?=G=&U-FYNIP&5QN[ZFMI8Z>627$;5JLI 15(LBZ
M9HE*,0K"X!X-P??NO%Z=+VJW)04>V9-URPY!L;%AUS;014+RU7A:(3:13 >0
MS:3;QVU:O3]??NMUQ7I%;,[?VQOG+OA</C]UTM6E'-7&3-;9J<1#H@9%($LR
MA"Y,@LM[D7/X]^ZT&KU(WOVMMS8-?28[,T&YZN>MH_O8GP>W*C,QA-;1V=X5
M*H]T/I/-K'\^_=>+4Z5N W)0;CV_2;DH8<A#05M//4Q0Y"A>AJ L#.C!X' D
M1B4-@1<BQ_/OW6P:BO0=;:[QVCNK.4& QV,WG!6Y&26."7)[1J\= #%&\A\D
MTB!(QI0V)/)L/J??NJAP>E9OC?\ A=@4E#69JDSM7%D*B2FA7!8:;,N&C763
M(D()1;?0G@GCW[JQ-.I&R=[8G?N*J,QAJ;,TM+39"7&R1YS$RX:4R0QQ2EEB
MF 9HRLR@,!8D,/JI]^Z\#7I#U?>NSZ/<%3MN7%[U:OI<Q-@Y)HMH5DM.9H)S
M 66<)XVA+BXD!TE?5]/?NM:QT(&[]VXW96&DSN6I\I4T<=13TS18?&R96?54
MFRD0Q N5!^IM8?GW[K9-.F?8O9&!["_BG\$H]PTG\(^Q^Y_CV"GPFK[_ ,VC
MQ>=5\MO ^K3^FZW_ %#W[K0;5TG]T]V[2VCGJ[;V3QF\JBNQ_P!KYYL5M.KR
M=.?NX8YU\<\2%'LDJAK'A@5/(/OW7B].A!RNXZ'$;<J-T54.0DQ]-CX\E)!2
M4+U-28Y0K!5IU!D:2S"Z@7!O_3W[K=:=(K9G;^V-\Y=\+A\?NNEJTHYJXR9K
M;-3B(=$#(I EF4(7)D%EO<BY_'OW6@U>I&]^UMN;!KZ3'9F@W/5SUM'][$^#
MVY49F,)K:.SO"I5'NA])YM8_GW[KQ:G2MP&Y*#<>WZ3<E##D(:"MIYZF*'(4
M+T-0%@9T8/ X$B,2AL"+D6/Y]^ZV#45Z#K;7>.T=U9R@P&.QF\X*W(R2QP2Y
M/:-7CH 8HWD/DFD0)&-*&Q)Y-A]3[]U4.#TJ-\]B8/K^''39JCS]6F3DJ8J<
M8+"3YHJ:4(6\@A5C&"'%B?KS;Z>_=;+:>G#9N\L7OG$-FL13Y>EI%K)J(QYK
M%RXB;7 J,3XI@'T$.+-:Q-_Z>_=;!KTA/].NS_[P?W:_A>]?O_XS_ _-_="L
M^W\WG^WU>?1X_#KY\E].GU?3W[JNL=+_ '?NW&[*PTF=RU/E*FCCJ*>F:+#X
MV3*SZJDV4B&(%RH/U-K#\^_=6)ITS[%[(P/87\4_@E'N&D_A'V/W/\>P4^$U
M??\ FT>+SJOEMX'U:?TW6_ZA[]UH-JZI]_FWY^BSG9G\L_;5'%7Q5^ROYJ'P
M\S&5FK**2DII(LI7/%&M'4,/'52JU;$71#= )"?T'V).7) GU(->ZTG _P!Y
M#9_9T4;NNOP:?AN(B?VT_P O7SO^]7'^F/MM88E+MVCV&COP#_Q=ZP&Q^MO<
MP;5BUB_TB_X.HLN4;Q9"QK^K+3_>VZ"2DA+DJM,YF-D3TW%A8?07-[_X>UZB
MOSZ84(N2/VCJ+68\Q269AY#_ +K_ ,1]1_3VT]OJS_+JGAZQ5.'I2G^&G4)J
M61.6C*BU[WOQ_M_;/@],G4O'K(*"4P"HTDQO(\:6_J@4_P#10][%K7/E_J^?
M3BH6P...G?%X!ZN)JN>\-,NH+_JF('T6]P/J+D_3\<\>WH[.N6Z9G<AM!^+T
M^5?.G4_.+24=/'248BEF.EIGC_"_4(.+V_K<W_K[=F"PB@H>F8HS&=3?D#G\
MS3_5Z=(XQ,>>%%P; ?X?CD_GVDHK9IT\90W C_)UQ\37MKM_@5'O>@'@/Y]7
M%2*UZ\8)!]6/(N/1[UH \O\ #U5GTX)_EUUXW _+<_@>VI !P%.MJX]>O:'_
M -2W'^%O;?Y'\@3_ (.K@UX>7653.L;*K,(V(+()!8E?H2M_J/ZV]V(*BO\
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M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZSC]$7_+4_\
M$>]/\/\ J^73T'Q+]O7U7OY>/_9 'P:_\4\^,W_O%83WCGO7^YD__-:7_C[=
M3KMO^X\7_--/^.CHX?LLZ6]>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=4L?SB/^/K_E0_\ C67XF_\ N37^
MQ/RSPN_^>.?_ )]Z)-ZXP?\ /1'_ )>OGT=O4NOM;M%M$9U=E]A-J()_Y>]6
M/]3_ *WN<MG359P'UC7_  #J)KT%IY 3_HDA'^]G[.@]^PU(;JJ#2/P>;GZ<
M<#Z>S+PJ=)'_ $LC/4ZC^WH_(!&LY !19'(LPO9OI^/Z >WHV6.OGZ5ZI-'X
MZT5M)X&@&1Z=,^0%373/),5;DE=%]*@?T^E@/:64-*:GI/#:_3X ('Y_SKTU
MM1O]6&K4 ;@>VO"Z5^&/7KPIW^@U6']+_P#%/=-!^?5:CK-#1^37;E0+&XMR
M?Z>W%2O6R]/+JS7^3?VKMKHC^9[\,>P]WU=/1;?B[<IMFY"MG.F*F':>/KMK
M15,SZE$<%-/F8Y9'/IC1&=O2#[#O-UFUSMLZ)QT!J?)&#G^2GH[Y>E$%[$S5
M U$?86!4?S(ZWA/^%)WQ8WG\E_Y;N;S/7V,R.=W-\<^R-N]\U&W\4GGGK,-A
M:#*X?.&.*Q\G\.QV9ER+@$/X:*4)K<B-X@Y%W)-NOU\0@+(IC+'R)(8?M*@>
MF<^O4A<TV+7MH= )9&#@#SI4'^1)I\NOFCJE^=1XXM[R"P?RZA]FT]9- 'T)
M]T(IU0O7KZ(W_"6;XS[XZ:^#.^^X=\XRNP?^S+]H1[KV+C<A"]-)-MO9E"F-
MH,H8I$22-,G7R99X#8I-2)3543-%4(3!?N'?)=WPC0U\) C'RUDEB,>E0#Z&
MH\NI9Y-M7M[0NXIXC%E&1VT !SZT)'J*'K5G_P"%"7<V&[P_FL_(N7;V0I,O
M@>K5V7TQ1UU'6BN3[OK[$TT6<IR5U)%)1;BGS%+)&#Z9(6U6D+*)&Y$L3;;;
M'J!!D+24(IAC0?;55!!]#T">;KM9[UZ4(0*E:UR!4_806((^77T6>B<+M+<?
MP>Z;VYOU:1MBY[XI]>87>BU^2?"P'$Y3:%'!D1/61S4\E)":-YM<R3QM$MW6
M1"H80/<$I.Q7B)#3[0QIU+L0!C%>&D5_9U3]!_*'_P"$Y2U$+Q;/^/<LZS1-
M%&_S@W=4AF5@54QOV.RR FP*LI#?0@@V]B=N:]Y89=_^<,8_F(^B,;#MP_"O
M_.1R/V:^K4L7UK\.?Y9/QY[3[$ZLZ.V]U%U5L;;E9O[L&GZ7ZWESN7R%/@(N
M:FH2@AJ,KEY*>$D^6IG>.FA$DTTL%-'+*@?::YWJ95D<N[$*ID? J>%6- .C
M81P[;&S*H50"Q"+G'R45)Z^;S_.#_F>[P_FC?(?&;\7!5^Q>DNK,7D]K]']>
M92:&IK*6ES,L,N2R^4DAUPG,9N2EHS41Q2O!3PTU+31O,89*FHG7EGEL<O0E
M20TCD&1A6F*T KY"IS0$DGY 1/O?,)W>4%5HBBBAB <Y)- <G'F>'6TK_P )
M%]QT57\.OD[M,3*^7PGR7@W!6P^4,RTVYMK82FI6*?55>7$5@!^A*M;])]Q[
M[D@F[B)_WR!^QW_S]#/DIP]L_ ?JG@:_A7K6Z_X4;]=;@V7_ #=?DOD\[2M!
M0=BX[J+?VTZJUA4XZHVCA<6TJ_X19/%9&G/]6@8C@CV->1YUFVV,#BA=6^W6
M6_P,.@YS.AAO')'Q!6'V:0O^%3U1TM*AOR;BWX _XCV, M>B$2^HZ^H?_P )
MRNO<[U[_ "D/C>FX:&LQM9O3)]K=@4='71B)_L-R;HRIQLZCZ^&MH(:>JB)_
M5%,C?0CWC]SI,LVY3:34#2OYJB@C\B".I7Y<0QV<>H4KJ/Y,Q(_:"#U\Y3YK
M9?'9WYK_ "YW=AJA:O%Y_P"4W?FX,5-8$24^4W9EJF![J6!#QNA%F(_Q(]S=
MLB>':0>HBBJ/L1>HPW.,-<3?.20_M8]?4V_E4L6_EH_ MF^K?$OH=C^.3MS'
M^X Y@-;^X_YKR_\ 'SU+6TXM8?\ FE'_ ,='5>G?_P#PHF^&?1/SPV7\0*FL
MCW+L2')939_>OR)QF71\%L_<4TD4%!CK)'+_ !2FH9Q/'G:J.5(<8[(@:HEI
MZZ*F-K3DV[N[0W0%#@QQT[G7S(]/Z(XL/]K4ON.8X+>X$!.,AGKVHV* _P"4
M\%\_.D7^?#_*%P'\R7HF'N?I+%8=_EUU!M>:LZZRM#)3TXWKM^/R5TFT:JMU
M+%))(TLU1A)YI?!!62RPM)!39"IJ(M<J<Q-LLVB0GP7/>,G0>&L >GXJ<1Y$
M@=>W_9AND55'ZBCM..X<=)^7IZ'Y$U^9_58G*[<R65V[E\778G+XZNJL3F<3
ME:.3'55+4XZ1HJBEJ8)E26">&9'22-T#HZE6 8$>YWC966JD$, 00:@@Y!!'
MD>HKDB$9 :H*X-<9'&O^;K?N_P"$I/PG_P!'O0G8?S6WAA5I]R]T5E7UIU54
M55/:6/;&TJP/F*V%B@*Q9G/P1P$!C<8='Y#W,3^XV\_42)9(>V+O>AP9&&*^
M7:IQZ:B.A]R?MGAA[MLF2BI@=L:\:&E>YLG-#1>C1?S=/Y%':?\ -0^06V.V
M:[Y@87JK8O7^P*#8VP>M9NFZC>(HS+/+6Y7(RUB;FQB2U>3JY45R*1=-/34L
M9+&,L2;ESFJ/E^)D\$NS-5F\334 4 IH;AG]O1EO.PMN\BN9-(5:!=%<DY-=
M0XX_9UW_ "B/Y%/:O\J[Y!;K[8H_F%A^UM@]A=?5VQM]]8TW3E1LM:N2"HAK
M<3DTK'W-E$2KQ=3',B7I#>"KJHPRF2_OW,G-:<PQ*AAT,C:E;7JP10BFA>./
MV#JVS;&VTNS>)J#"A71IR#@UU'AG]O14?^%7?P5A[)Z.ZS^<^SL-%)N[HBMI
M>LNV*JFIHEEJ-H[UK#_":NHD\?FE3![CJ/#$@DTHN9J)2NE&8&?MYNO@3M:.
M>V4:E^3J/MIW+Q\R0!T7<Y66N$7"BK1X:@R4)^S-#^0!)ZT'C3JITA2!8GCG
MZ#_8#W,M.HO:4MUR-/ I!1F(\<98E/S:S?4_0-?G_>!]/>P .'6HY6!J?7A\
MNN!IU.HA3Q<DGD?[UQ[T5KUOQ&)ZX>+_ !/^P&K_ (GW4K3JA<@_ZAU[Q$6^
MMCP/Q[W2G'JX)\^N7B (# V) Y_Q_I_C[KTV[<*'@0>I7ABTZ;WOS8<'_;\G
M_>/;U 1TH64D=<#!$#Q?_8G_ (U[UH'7M1/7*.FC<G4XC 5B+B][6L.%/)_U
MQ[TJUZHS$<!7K@(T4 W(LQ_!M_K_ -3[]0#CTXI X]1S$W'T-_Z7_P"*>Z4I
MUO6>N/C:YY4_T O?_>O?J=>#EN ZS*I(MQ<<'VZHQ3IX#UZYB,?4_7_#WO2.
MO&OK_AZ[T@?@G_;>]TZU0^H_GUQ1%8D#CGC_ &/MH^@ZI(?GUGCB!O<-Q;^S
M?_B/=XQ7C7K<1KY]<F15'U)_VDKI]V=0.O2C''SZ\JKZ2;\GZ?7W32!TF8]<
MN%%_]8>_#C0=,D5ZQEB?R;?[;W?KU.N/OW6^O>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>ZSC]$7_ "U/_$>]/\/^KY=/P?$/],.OJO?R\?\ L@#X-?\ BGGQF_\
M>*PGO'/>O]S)_P#FM+_Q]NITVW_<>+_FFG_'1T</V6=+>O>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NJ6/YQ
M'_'U_P J'_QK+\3?_<FO]B?EGA=_\\<__/O1)O7&#_GHC_R]?/X[<J&/:G9J
MQC]/96_P2([GG,5=_P#>O<[[*U+* >D2C^0ZB6\ DN)*UQ)+^W6>D/2SQ!B)
MH@R7O8,8S_K7L;?[;V;(17(K_+HMO;5Y5_3;2?F*CIX@P])DHY:J$FE6)2QD
MG<E0>;7(!M?_  7^GM5'9"X4NO;3.>'1))?2;8R+,0[.:*J ACZT%?+CD_GT
MVRXJ98S(KTTHLS,$E$A_VWMEK=E%:J1]O1S%?JYTT(_TP8?X1TUM 0!Z; ?C
M0%X_VWM.4^72_4I].LJQ*BL?!$Q) 4D'C_6LRC_;W]^  \NF"4<X/#B !G]H
M/7HZ<.XM&%#?7C2/^-?[?WL(.G7=817\\9/4FHQB@#Q-2RL55F$<M_Q]"'^I
M'^TC_8GW:2#TI^WHK^K5S4AUK_$M/\ /\^OH6?R5?YX'6ORLZ[V?\8_E7NW#
M['^4VU<+CMJ8C/;OKDH,=V+24,24T-73U=2L=-'NB10BUN/DD#UTA-70+*KU
M--18^\X<E3;.[7$"DP$UQ4F*N:$<=/HWV YI68.6N:(=T18I'7Q:4XX>GF,
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M<AK^\A]MNDW2WCN(_AD4-3C0^8\L@U'Y=0GN-K)83/ W%"17A4>1\^(H?SZ
M*2ANY"H1<V'I^G^\_7VL,?20-I&3UQ2@:_(_3?D_3_7_ -?W[P^JM)Z'K/\
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M^@.O?ZV6P?\ *%#_ ,:_Z"Z]_LQ?=O\ S\7/?[>'_KS[]_KN\R?\I\W[(_\
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M:6>)U-FCD4V!N NVZ_CW2%9XJZ'K2HH<$J?Y@])+ZS?;Y6ADIJ6E:&HR ?\
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MMU%U8,."#[U7KW3I@]V[5W.KMMK<VWMPK$&,C8/-4V6"Z2 =1IY)+6+*#?\
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MK!2M32M3Z_93H*P[E<;J\;PQ7$:/3N94:.A\SW5H/E^SHN?27QORO>,?;DF
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M8X]?/7[,[,W_ -R[_P!V]I]I[MS>^^Q-]YNLW%N[=VXJQJ^LKJRO:\DLLAL
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MS?2D6SME=6[?I-B5^;AHMRXNMKIX\6U=+5Y4T,-,[O)$A6GA$C/9=1%8-O\
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M,%!55,5=45DT2QV@2G@US3&2G/\ F_FVTN;-K>W?Q&DH"5! 10P8DD@5K2@
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MAYZRAS+1)AM..\\XW%%4!%4S2112RFPAD]AGFC8KC:K" 2L'T2RU8$D#Q A
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M5HH@"%!AJ!&I II 8T&..>G;+<MIAG,L1(DD)!-)<EV!/Q=HJ?LIT\?-S^6
MNY_^%!?P2^0V V?49#JGO3*#MSM.MH8Y_LJ3=/Q0QR9(3UTH+TT$69@H]II'
M  GWTZ5S,DFJID]UVOF'PMEN+=F =*)&#2I28T( IY=Y)\J@8QUN_P!E\3=(
M9PI*M5G.:!HQVDFOGVT XT/SZH;[N[]_V9'_ (4J[ ["IJZLK<%B?YE_QEZK
MVN:B;R1#'],[TVUM6*2C022)%25LF(FK$"Z=9J6FD19I9![&EC9?0[ R&E6M
M9G-/,R([YX9 ('Y4X#H+7EU]7O"MF@N(T%?+0ZJ:?(D$_GZ]7+_\*6/Y@GS+
M^''R%^.>UOC+W[O+J#;V\.F<WN#<N*VW#03Q5=;1YRHIHZB05E'5$2+  GI*
M@@"X-A["?(>R6N[1S&XC#E64+4L* @U^$CTZ$?-V[7&VO&('TZ@U<*:T(I\0
M/KUI]?)WYN?*KYFU&S*OY/\ =&Y^XJGKV#/4VS)]RTU# U!'N9J1J](C14E+
MJ6I:@I"P?58QC3INUY2VW9K;:-7TR!-=-5"QKIK3XB?4]1_?;I/N>GQWU::Z
M<**5I7X0/0=%7]F?1?U[W[KW6=?T1?X2G_B/>FX?G_FZ?@^(?Z8=;P7Q/_[)
M9^-7_B .F_\ WG<;[X?^Z_\ RM.\_P#2UW#_ +2YNNOWMQ_RKVU_]*ZR_P"T
M:+H?_8 Z&?7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U9W\%LT:G9.\\ TNLXG<U+D
MTC+ZBB9NF6, "]U4O1.1P!JU$<W]YF_=IW'QMMN[4FOA7"R 5X+-&!P\@3$Q
M]*U\Z]8G_>"L/"O[6Y IXD#1UIQ,3D_MI*/RI\NCR^\D^L?^O>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NM-.7X08KYO_ /"B;^;1M/*_)?Y>_&B/9'4WQ(W#%G?B'W+'TUDL
MFU?U[L.F-)EZJ3$Y85M#$/W(XA''IE]>H_3VQIU,?RZ]U:UL3_A/Y\2<;O?:
M>]>_._/G5\XX=A;BQ.[]E[%^:7R5E[?VUCLIA?-X:Q<+2XC"TU8Y$S*\=9]S
M Z#QM$4>59+B(?,]>Z%_^:=\>>NODK7_ !)V'B/F+1_#+YH;5[;W%V9\(=X0
MKC,[79/.;5PTE/GJ"';61DC&X<8F,KZ=J^*)AX0U.)_)!.]-4^<5IFA\NO=$
M0WO\L?YE/P*[=^,&._FC=6?#?Y8_'[M_Y.]9_'KJ3Y,=$8JJVEO#;&ZNQXJ\
MX[*9#;>;IGHA)(,:\TO\*%+]M'!.4K*B1Z:F]U+%?BS\^O=*'^:\E'\;OYKG
M\G3^8/V _P#"^@MC[I[P^,O:N]I_(])M^O[UVWE,/MBLR)CB;[7'U%3F,@9:
MIV$,(IOWC&"I;;]K ]>ZV.J6JIJZFIJVBJ8*RCK((:JDJZ69:B*6*H4/')'(
MA*/&Z$,K*2""""0?;O7NM=C:V]Y?EO\ \*+ZK<G4U12;HZ9_EZ_"K<G4W:^^
ML5$9Z*G[#[AS4TTNVUKKB*KJHL4].SI )%I9\?D(*B5)QX5:!U-CR'7NMB[V
M[U[KWOW7NM-.7X08KYO_ /"B;^;1M/*_)?Y>_&B/9'4WQ(W#%G?B'W+'TUDL
MFU?U[L.F-)EZJ3$Y85M#$/W(XA''IE]>H_3VQIU,?RZ]U:UL3_A/Y\2<;O?:
M>]>_._/G5\XX=A;BQ.[]E[%^:7R5E[?VUCLIA?-X:Q<+2XC"TU8Y$S*\=9]S
M Z#QM$4>59+B(?,]>Z%_^:=\>>NODK7_ !)V'B/F+1_#+YH;5[;W%V9\(=X0
MKC,[79/.;5PTE/GJ"';61DC&X<8F,KZ=J^*)AX0U.)_)!.]-4^<5IFA\NO=$
M0WO\L?YE/P*[=^,&._FC=6?#?Y8_'[M_Y.]9_'KJ3Y,=$8JJVEO#;&ZNQXJ\
MX[*9#;>;IGHA)(,:\TO\*%+]M'!.4K*B1Z:F]U+%?BS\^O=)K^<$WR/^;'\Q
M;X5_ GX>4?1.>WO\3*&'^9%V=2?)-]STFQURFTLG#@]C4F:J-I139=Y(I*O)
MSFBC6-:I*VG$LW@\T3^>K$ ?;U[HL_\ -?Z8_GV;BZ,V;\L>\1_*NID_EU]B
MX[YE[7R7Q=JNWJ7=Q/6D$KY*B W-"V-JL#+1M]WE*7[NBEGAH5"50"F&;3AB
M*FF,XKU[K:T^-W>VR_D_T#T[\A^O)WGV9W-UUM3L/ "4%988MS4D52U+.K*I
M6IHY7D@F4J"LL;K^/;RG4*]>Z&OWOKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW5+'\XC_ (^O^5#_ .-9?B;_ .Y-?[$_+/"[_P">.?\ Y]Z)-ZXP?\]$
M?^7K2/WN*=MV[YADQ<;LW8&^7%;Y%-]>6KCZE\#6/J(%V-K#WFGR3"K[+9U
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MQ>.3PQ#3J6D#O]79FY]TV[;(-IC\*W70E2:59LGCEB3Y>O5[V_EW%_$F;4U
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M@ZA6BUQXFFI9B0L2]Q-?AFWV[]O8)H#O>\L([*+O57J/%TFFIO/1JP%%3(<
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M)I?MZ6@J?&^KS&&I:.=Z/ZJ@?27* @"W!TEFD*F@IC_8Z*[W?MPWN9-+'34
M@8P?7)KY?YJ=$YWW38>JR.9JZ:@\;2S!883+-6I$IN +LJE]*6%S)]1?DFP)
MKB(?;_L=2YR])-$%+DA:<-)!-3FI_+_5GHO^0VS55)62DGHZ>0%K1QF2-K<6
M5@P(#$D_0W(X]DL\3D]M?]G/4FP;K;QJ"P!'IQS09Z1]3%N["O9\EDH-8*PC
M[F1$D5/JH(<!E]1LHN.3Q[*W$UOZTZ$=M<V]Z R(AKY\&%/3/#IG_B68DE6"
MI%,)0B^&:JDDL#$+K8M)I6Q _LVN![:UDGAD^=./1@4C4"C/C[*8]/V=*%-F
M;LRM.*AI4J*:0AXTI)&J$5%^IM$K*H!M]3<<7M[N+9IQQ S7I)/N<<.*,3^=
M/\W37-U[D5<>=,@A*:B/M'_U0N+L1]+@?7C^A^OO;6&D5KUN'?Z8"T'K2M//
MU^SRZYTO7AJ=<<M754#!/U5-$VC5ZN'9'+*H('(0G_>O=GVS4./'Y]73F[Z3
MAY<** ?\IZ;Y>MLY%*PA;'5D?(1X\A'&#;_EMXV_IR4'_$^RX;=1J<?3H[BY
MTC"=QIC\5//[<U!IUQBZWW6[F/[?'LPMQ_&*52/K];S #Z'ZD?2WMU-LE/ =
M,'G*U1#K(\L^7'CTK<)T%O;+U4=+14='4U,Z,(*:GR]))*S @ >-)W?EC^ >
M>+7^GOW0\7]IV]$TON!:0$>&[-3^%:'_ %>O1D-O_ KLZID1LW%A\"S+3RO3
M[@R3T$R+,K,&FIX8JBIA@M'+>:2)([*3K 5K/I:(M*=W#AGRKT4W?.X856JU
MS1J@DDD<"!3(-?(4/07[SQ&U.F,D^/H8*3=6:,"_Y=3YBBR-)"QNI"M0561$
MGJ4_[OII@I!**38>6Y2 FBT/S&*];@5]]0-*_:150#0T\JT(R/3%/\ -579N
MY!-)/C8L1A9)ETLV.Q<8D_;^A6:83SQL+\:)5M_A[127[,:4'[.A3:[3'"!2
MM .%2?\ +Q_/_9AX/>.8;<-)D<YG<O.!()*FHGK):IRB&]K-(-08A18M;Z7X
M%O;UG>&W>I_V.O;EM,4T&D*M<Y(J:&GG6HX=>W+FY,[D'KY:/%6<6B^WQ4%-
M<?0,_CC#O)SZFD=F)^I(]ZN2)VU #\QTQM\)L8] 9P/Z+L *?F.N]NT>6KLE
M34M!"JRRR@1^&-4 Y%VN!Z550;D_3Z^W+=&SPP/(?['5-QFBTAB26)H*NQJ?
MS;_-TNJS=N9P>49,!,6^V:T%5=[L8F]3*T;*2"18$GZ7/YX5)?&(T%,=!^#:
MXKY2)%IJX@$C'0CX'O'?F1EIZ#*Y"HAQS2/]Q-CZ-7J 9 R%M3!V9>3Z4D3^
MIYM[-X-RD<:2<'^7GT%]QY,V^WK+%$NM02*FE:X/G3S/$9]>ALI,GF*"EIJ&
MNK<=241=JN.NGH:7%5#?<HI<J\4(K)R/KHNX0^E;$D%>* :C0XKT!I0TVI$#
MKFE*$K^WR'3XN^-BT>#KJ7R[ORF>J8C'29$9>/#4],="B1EIC%42U;&Q"M]W
M3Z;@LC?I'FFUX! 'V=,Q[<\=&,8U5K6A_/C^7S'IT#%9AHLA4(]+F9?6VLRY
M: 5 Y'ZB4,K%F-A?GVQ)9B0U\^A'%OLEDNET'F:"N/RSYG_.>A6Q(SV!H?M<
M/5[<HH6A$CY48R@>I5[ %H:BHI!4169F!)D0-9E/]/:PV* "@\NB"?F%T8G6
MS&M=/'S(I\N/R'2*_NCNG)92)X,Y5Y$23$BHHJRAQ$2ES^O2D3E3S>Z@'Z"Y
ML#[2M:2,<$]&HYALHXR98@"3Q.,B@\S_ #Z4#]@=E[5CK]KX93N<U;14]3/G
MY,3DW>6*Z 02&#[^ 78@%*R-I  Q )]L3>(C$!:T\^EEO9[?=IXDI6,&A %5
MIC]A_P W'K$_9/RLVA205T'6;8VE,SS19FLZK&96]20BZ*[(4M<R6460K*K
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M@VI)3SR25K%YG:1,NK$R,Q+<\D\^\7O^!TNA.UR-W<2NS,\BVS*[,Y)8DK=
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M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U2Q_.(_X^O\
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M:Y!S%%N5I"C;C*DMN9%#QQ4C9N)%3X8QCA7C3[0LV22QN96%E&T<PC8J\E7
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MT/@?&/2T<NFE>G,9IRJ&+246VIO+[>O=)O\ X4*?$;XO?'C^5)N+MOH;X_\
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M]0HS<!@TX>N.(ST)&5W)G=XTJ18K([',,Y$+93:FX<9LMZAB39YYLE@J"5E
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M>.J%UK'6XT1X"4*ZE6 ^U42#4I(L)3=2;W!(*D3$\!2O34MIK%7H//U/\_\
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MN^RB01L&!)H&-:#]N#T N[=E9#;]<:#+T&;P56H,TE!EJ&2!EU E;+,(7*D
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M7Y&O^$?YNL$T40Y635R+WCM_Q)]MN@/G_+_9Z6-<NH (I^?^P.HIC3ZZP/\
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M[&W<OE:.:#'9S^"5N-@HLNV*JY(JE:.HE6GJ&B$4UXG8%=;[7N4<BM)?:U#
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ME_Z!Z]_LH/>?_//8O_T(Z+_K][]_K!<R?[YB_P"<\?\ GZ]_KU<O_P"_I/\
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M_GZ]_KU<O_[^D_YP2_\ 0/7O]E![S_YY[%_^A'1?]?O?O]8+F3_?,7_.>/\
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M^L%S)_OF+_G/'_GZ]_KU<O\ ^_I/^<$O_0/7O]E![S_YY[%_^A'1?]?O?O\
M6"YD_P!\Q?\ .>/_ #]>_P!>KE__ '])_P X)?\ H'KW^R@]Y_\ //8O_P!"
M.B_Z_>_?ZP7,G^^8O^<\?^?KW^O5R_\ [^D_YP2_] ]>_P!E![S_ .>>Q?\
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M+>'<2-#$&HJ036G^H?+I;4,^U,C/$JUHPU6Y<L,A3Z8"]UMHG4U!&K43Z@A
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M'*6_WKGVE>,^G^3H^@W=&SJK^P_X.F^2E86-P/KQ>_U_K?VPR=&K7WBBE/\
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MN*@ BN,_X:]*C?H@H0Q-?,?ZOM].E/38ZHTJL&M"(Q9E;2;D7/T^HU6M[H$
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M2E:I8^0RU])%(&D<Q1EH[",-ROI(G(34P+&A P!7K(?9=DB2$/,""56N1J;
MR0:T)\_GT7GO[?NP^J-P-AM^?'C:U&'8R8["U6Y:Z')5<4CR+%)2RTUVKHW:
M+2DT2>+R>FRL2OM=MQEGC)9\#U"U'\O7HDWDVUNX0VY?57B[J>('%6 _U?;T
M4_>G9N5@RQCVQL?:PPU7!#6XG!&'-91J:-HEUQ2#(UKA987DDX$" J20JEM
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M>_=>ZI8_G$?\?7_*A_\ &LOQ-_\ <FO]B?EGA=_\\<__ #[T2;UQ@_YZ(_\
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M_/\ #^9_R=*XOP?Z;KZKO\O'_L@#X-?^*>?&;_WBL)[QRWK_ ',G_P":TO\
MQ]NIPVW_ ''B_P"::?\ '1T</V6=+>O>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NJ6/YQ'_'U_RH?_&LOQ-_
M]R:_V)^6>%W_ ,\<_P#S[T2;UQ@_YZ(_\O50_P >:3,R=<4T]/2Y(_[GM\I2
M+1J\08G<&4 8M$-2C6/RP)L.0.1+^TRZ;2'S[!_DZQAYI@,VX7!_X:?\O0]Q
M;5WWFA&,@L&-MK2*KR5<L,JB:R:8YYW:HD+$@Z$#7(U%1:WLP>50*\.@XUFP
MX="?MOJO*83&U6<W)@OXQAH;^6$5AQS,Q'U57C2HE%B;L8T4<'R>TDMTC\".
ME,=C137TST7SL;J+J2MI*_)T,4^R*XR5%6T*UM%6(DFGUHBU*R5\VHO?UU(.
MKE?3Z NL-WE1@H.*CSZ".Z\MP7 )%!Q)'K0=5[[NZXB>MDEI\[,,? \],DGK
M@EF6G<&.0(TA$;F(&PL23<646/N0;#>I(%JH!ZB3<^5$>7B0/*GET'%9LET3
M[?'5]6P><.TJVC9C)8%BQ":-*WL02?4.#ZB%XW<2X)Z#G]5F5_\ %^-:U/'C
MT:3XW;<W!1=C4]169S!6R-.T&7JMXU1H:<TZI&#Y9GUD,D<:11B-&541$"E0
M%]A_>YTEC.A<_+J4.2MFN8[@F=J@K05X G_-U9%O[XL[7H-N3[\V#NR@WKB6
M9JG)#;^5HRU(S1JQ,8F59JF,L1ZDB\HYM&03:/OWO)8L$92:GS\NI#39EADI
MBG!J4K7[/\O31L;HS&;SP.1EJL+"V,BAECJ\ODJ&FJ98I*<.\9021L\2F1A<
M"RF_J/T]KKB^>,ZE8GAY]*CLT.DC2/M(SQZ#23J'KNB:JHEP%'DIU9E=\A3K
M40E(KV"KI&HN"06T&]S8JK&WAO$OJ0?MZ2?N2WK0HI\^ ^SH1-B[0VOCZ6FV
M[D>NMNU]!/5QRTJ5@CT 2<*"A:5RQE==!T-ZC9PWU9)->/(:^?1I%M\ 73H%
M/LZ'/"]8=-;@P,U#N#J[9&+R331TV-W'!M2CIZ@ZRBW9GAB9I)2;W*DEFMR+
M*4S;A.APS=5'+]L#J"+\\#J/M[XZ];1Y#,22[7Q4?\/QM3+1O#3?9PR$#4DQ
M=F$8]*,#J](U6LK+QYMVGDQ4G[3TU-M-M:91!4GR'Y]5I=JU_=,E?DUH,9AQ
MC/NV;&1XO!44U3&M-(V@,X+5B ,RZE\]@5/"J!86;/)#IK(>X]1WS!!N$K%8
M@-'1&]QU&[$J",S!-]S#)K6O@@JHXR\H%R?.UM0!*D!N"A%]-_8WM);8CB.H
MCO;2^1F5@U36E*]-V'&\<UEL128?'-DJW(5E+C<=!!&$\DDW^:B"(#J8@W5;
M&PUE@"#97<3VZC4Q!P>/ITU8VNXW#A%5JU'[>C2]E#O_ *NI]GT^X]U4%9NG
M<%-5551L2D6@S5710T'@\2U"PT@U_P"?,<B4TC^.560N6+6"]I)97C-4:1Y-
MZ=2?O$>Z[;#%I.MQ3]/CY=2,/LW=G:F-DE[1V=@4%.-%#+Y:B.K)F%R4:GJ?
M+3JR:7* QWX#(I LGN-P@VUO\6=C]O3MCR]=[XE+U-/[?]7Y]*W'_";K_)4\
M%=/4[FHJG(&;[;&8K(4\D48A.FP^YHGJ= ,9U,T@L/S:UF!SM,F,>G[.G?\
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MLEM:?#0RT6'K]O8Z:5I%_B%1G*3-U).DE?'- 7IHRRLI6RI^?RUR:17.L=P
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M8&QJ'*5YQM51-B5J:HTCOD(IE: &ZDRB:1"=%B?VU '-A?2%=O.W6C:J>/0
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MO?NO=91^B'_J)_Z)]T?A^?\ D'3\/%?],/\  >OJP?R\?^R /@U_XIY\9O\
MWBL)[QUWK_<R?_FM+_Q]NITVW_<>+_FFG_'1T</V6=+>O>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NJ6/YQ'
M_'U_RH?_ !K+\3?_ ')K_8GY9X7?_/'/_P ^]$F]<8/^>B/_ "]5J_'3(=;4
MW2VWJ?=':O4V$)S/8#5N'S&_,51U\#Q;CRX59J-ZCSQ,2 P#JMU-PMB#[$L3
ML0*BO:GV\#U&NZ6OB32\?[2M:?+I:PY/H"OJG>L[HZSCI@DB^:'>>+@;4K>@
M '(!F%F<GBXX!-S;V[J;^'^?1;]!JXU/RI_L=/U//\62K&?O'93R*R"!*;>V
M"46LP9BK58 TW'+,;VXM]/?F9Z</Y]>&W*. 8'[#TY4N4^+]*\E.O>>RVC=K
M**G?> DL(RQ^J5-F+6X]2_4#VT-0_"?V]._1?,_L/^;IKK<G\<%ET4O>&RI%
MD*IZ=[X%#;7=M1-7,A8@D<CBP/U]NAV]/Y]:-B.%3^S_ &.FYIOCO)H$/>6R
M%8%C)]QOK RLVG@"ZU<85K_4@$ _V6'NVIOX3TQ^[!Z-_/J?CO\ 9:^9*KN+
M9<,D?FC:&;>^W+W56$12+^)A/$S:2"0K"]R+CFNIOX3^WJ_[N \C^P]+2BI/
MC&B([?(_K.GBU)(T$V_\ T@!MZ6*9(D*ED'Z?I?DW]LMJ)^$_MZ=%H *4;]A
M_P W2PILA\<,=XI*?Y/]:SPQE46FQ^^<2X'E.D$C[QFN 2+ A%!+,"!<O(:#
M*GI2L908#?LZ&K;V_OC-68J6DR?R+ZL2LI&C'FG[&P-.QUI86'\0<L%! )(4
M:B;<?1J123A?Y]::-CY$?[4_YNLU5O[XR8YX@WR8Z@$;)8LO:.$D>Y&JY$>2
M LOTL+7/NGAGTZTJ./7]A_S=(W+]P_&'2RQ=Y;#K2UB3#V#A%UV8'4X?(V)-
M@+$VL.5XM[V(F\A3J]&'K^P]1L=\@_C!BF=GW]UUDJA:@2P-/V1@Z5 H8^,/
MX:PAW72NHA0I(^B D&WA-\NM,&/K^P]*&7Y<=%0N/X5O_IK&(BZ$GD[ PTL@
M*M>Y*U1U!KO<\7! %Q[]X+_+JH1AG_)UVWRPZSJH];]Z]64FFT<2T_8>(NO]
M3I^Y52--U!/]DFWUX]X+>?5@K'_HG_8Z$#:GR>Z>BAC.3^1'6+I/51)!3'LK
M!TB1QEO4=,56B@DMR;#\WN#;W7P/D>ME&IP/^\GIPW)W[T%E,K+CL;WSTQ2X
M;'(E?55O^DG"LTDD0\A#,:P22,K"R(O#$  \\-Z'&=-.D6AS^%OV'_-TE,I\
MB.H\^*-,%WEU#"7,WW#UG9N"QJP>:P>5VER+*[LJW6[MI'!'Y]VHW\)Z]X;_
M ,+?[R>D5F^YOC7A\#D:#+=_]%[ARKTU1%38BB[.H*RECDD5PC5%5135!9$U
MAQ%$I9B"#+"?6MA#7-#7JS%B*:3@>A_S=$\K=\?'ZM$PIN^^J3.4&EZW<%-2
MPFXX"2I42S6(/U:DB_KI47TJ%C91\/\ /I/):-*/,?*G0;;DRW7=-2>>F[1Z
MBS5+$XD2;"=E87*, 02&-.*M*R*P)YDIE'UN0?;R K@KT@>P<&@!/Y'H&:W?
M_6[2K(.Q=BBRS!F.ZZ%C9 -(LL[, "> ;7!_/-EB-I\CTEDMI%- I_9TF:[L
MCKW]V!-^;&8AGTRQ[FH) /H2$U3\J"O^Q^G]/:Z)ZUJ*=-M X\C^P],B=C;*
MC9PO86S-#-+K0;GH=).GAC:8GU?\1[NW=Y],R0N."Y^SJ7C^U]EXQHG@[$VA
M!H=E,2;HHC=5/(8&6UR2;<F_U(/T+3)7TZU%%+J^$_LZ6"]R=5Y6+Q9C=FPF
M82!QIW'CX;E4LA#^<E=-CZ3_ (<GVE:(D_YNE/TY)[A_+KBV3Z>W' L-)W!U
M]M^IF:.G-+D\[0E&(2[-Y8YBB!@#I9K&]S<$#WX3F'&D]4EVXRB@!_9Z]!MD
MSM#'HP/8?74RV*2BGWM1%77U#6@%2ZWT ZOTBX92&//LPM]P#\5_.O1;)LDZ
M\/\  >D6^Y-E4S1Q'>FT(KMH#G=V/L+@ $$U&E18?@<_2W!]KQ<CY=(OHY@V
MFA^VG61-V["A(6JWKM&R.)8#'N>D?1R2;H*@JS%=7U%^1_K%,64^?\^G6LI/
M,']AZ=Z??6Q)9EE&]]F^D!_5N2@4W!'TU3>F^FY_VWNKD4ZV+>4?A/[#TKJ+
M?VP%A.C?>R"X_:17W90I<. ' *SWL1^#:XX]L$>AZ,+>WD*BJG]GS/RZ?J;L
M#K<JY_T@[.IWN[%ANN@;4I*DG2:C\ '^MQQ[;(/2Q;=Q^$_LZ>,9V?LFAG6N
MA[0V+%-$-4-1C-V4N,JD1=++J(JT8NI#'T$AC8 V)]M.M>(KT_'$Z'@?V=&4
MZH^3?6N*SD$6]>QMG5^ ".7GH>Q*3#5RLY95UR"K8U"(5+$ +PWJ 3Z(9;?T
MQ]IZ,U#..%/7'_%=&XG[-^(&Y(:=J[MOK.H^YGGF1JOL3"53_LJP\AG$T<JW
M9=48LC -?2NI]*9X&'"G[>KBQ8T(K^P]81NSX=8^.M2C[-ZPF=8S*:^O[,P^
M2 ,BLVF.-JP"ZA#;2VH&P!N;EHQR)_Q?5KBRD7U_WD])N3LSX[XEC(O??5IH
MXF$OVXWKC)EM$&-F1LG*A8WM<(.0 />I'G [1U5-OD.36GG@]5Y]S]R];9/.
M92?"=N83/4CU$BP25NZ:2 E)/4415JN(4/I34J.RA6L"?9O:1,ZC70=)BIAJ
M ,$4X=$TW)V#M6:4.N]MM/XY3I(W!2$G\#U">]Q_C<>S:)!'Z=%UP#Y _LZ"
M?);DVM/K\.Y]OD_0'^-4Q_5<_P"K](YO<?ZWM9',%\^D4D+OP!_8>@ZR>?VW
M&9%_O%@)7_U?\5IC:_U'IE/^/M3K0^?2?Z=AY?RZ1];EMN-J(S^%8,JG]O+T
MZ_IM]3K/'^M[<%P ,=7^GH,CI+UF8P1:4KF\2022&7*0%OQ^=8'X][\4,*U_
MGUHQ%<4_ETFJO,X98RJY/%O9E+,N0BU>G@ G7S]3^+>U"2(1QZ9:%SP'24J\
MQB=$FC)4'J4:-5="?]>]F/M])E7SZ:^GD' =)FLR=!("HK\:IN5(2NC/T_Q+
M>W5G0\3UHPR?B'21K:VB)(6NHR!JO_E2?G_6;W=98SP:G51"PX#I,U-72C41
M5TQ&EA_GUXL/]?Z^]ET_B'5Q"YX<>DO/54W]FIA!7Z+Y%-^?^)]U,JG\0/3R
M0/Z],]35QF_[BV;\*_\ 3\V!]M-)4]&<(H,J?V=,<LM.7;U_DFX-OK[9+J//
MHP313AUC\E)_JA_R=[UK'7M0_P!1Z]Y*3_5#_D[W[6.O:A_J/7O)2?ZH?\G>
M_:QU[4/]1Z]Y*3_5#_D[W[6.O:A_J/7O)2?ZH?\ )WOVL=>U#_4>O>2D_P!4
M/^3O?M8Z]J'^H]>\E)_JA_R=[]K'7M0_U'KWDI/]4/\ D[W[6.O:A_J/7O)2
M?ZH?\G>_:QU[4/\ 4>O>2D_U0_Y.]^UCKVH?ZCU[R4G^J'_)WOVL=>U#_4>O
M>2D_U0_Y.]^UCKVH?ZCU[R4G^J'_ "=[]K'7M0_U'KWDI/\ 5#_D[W[6.O:A
M_J/7O)2?ZH?\G>_:QU[4/]1Z]Y*3_5#_ ).]^UCKVH?ZCU[R4G^J'_)WOVL=
M>U#_ %'KWDI/]4/^3O?M8Z]J'^H]>\E)_JA_R=[]K'7M0_U'KWDI/]4/^3O?
MM8Z]J'^H]>\E)_JA_P G>_:QU[4/]1Z]Y*3_ %0_Y.]^UCKVH?ZCU[R4G^J'
M_)WOVL=>U#_4>O>2D_U0_P"3O?M8Z]J'^H]>\E)_JA_R=[]K'7M0_P!1Z]Y*
M3_5#_D[W[6.O:A_J/7O)2?ZH?\G>_:QU[4/]1Z]Y*3_5#_D[W[6.O:A_J/7O
M)2?ZH?\ )WOVL=>U#_4>O>2D_P!4/^3O?M8Z]J'^H]>\E)_JA_R=[]K'7M0_
MU'KWDI/]4/\ D[W[6.O:A_J/7O)2?ZH?\G>_:QU[4/\ 4>O>2D_U0_Y.]^UC
MKVH?ZCU[R4G^J'_)WOVL=>U#_4>O>2D_U0_Y.]^UCKVH?ZCU[R4G^J'_ "=[
M]K'7M0_U'KDLL.N-8R#<-QS^?S_K^],PZ<B?O4>I_P O7T"?AI_.U_EB=4?$
M#XI]6[^^37\!WWUM\;>C-@[UP7^ACL'*?99?9VU\7CLE2?=46TZFCJ?MJRFF
MC\L%1+#)IUQ2.A5C"VZ<J7]Q<S2)%56ED93KC%0SD@Y<'@?/J8+'?;2&&-&>
MA5$!&E\$* >"]&2_X?T_E+_]Y8?^P*[+_P#L-]H?ZG;E_OG_ *J1?]!]*OZP
MV?\ OS_C#_\ 0/7O^']/Y2__ 'EA_P"P*[+_ /L-]^_J=N7^^?\ JI%_T'U[
M^L-G_OS_ (P__0/7O^']/Y2__>6'_L"NR_\ [#??OZG;E_OG_JI%_P!!]>_K
M#9_[\_XP_P#T#U[_ (?T_E+_ />6'_L"NR__ +#??OZG;E_OG_JI%_T'U[^L
M-G_OS_C#_P#0/7O^']/Y2_\ WEA_[ KLO_[#??OZG;E_OG_JI%_T'U[^L-G_
M +\_XP__ $#U[_A_3^4O_P!Y8?\ L"NR_P#[#??OZG;E_OG_ *J1?]!]>_K#
M9_[\_P",/_T#U[_A_3^4O_WEA_[ KLO_ .PWW[^IVY?[Y_ZJ1?\ 0?7OZPV?
M^_/^,/\ ] ]>_P"']/Y2_P#WEA_[ KLO_P"PWW[^IVY?[Y_ZJ1?]!]>_K#9_
M[\_XP_\ T#U[_A_3^4O_ -Y8?^P*[+_^PWW[^IVY?[Y_ZJ1?]!]>_K#9_P"_
M/^,/_P! ]>_X?T_E+_\ >6'_ + KLO\ ^PWW[^IVY?[Y_P"JD7_0?7OZPV?^
M_/\ C#_] ]>_X?T_E+_]Y8?^P*[+_P#L-]^_J=N7^^?^JD7_ $'U[^L-G_OS
M_C#_ /0/7O\ A_3^4O\ ]Y8?^P*[+_\ L-]^_J=N7^^?^JD7_0?7OZPV?^_/
M^,/_ - ]>_X?T_E+_P#>6'_L"NR__L-]^_J=N7^^?^JD7_0?7OZPV?\ OS_C
M#_\ 0/7O^']/Y2__ 'EA_P"P*[+_ /L-]^_J=N7^^?\ JI%_T'U[^L-G_OS_
M (P__0/7O^']/Y2__>6'_L"NR_\ [#??OZG;E_OG_JI%_P!!]>_K#9_[\_XP
M_P#T#U[_ (?T_E+_ />6'_L"NR__ +#??OZG;E_OG_JI%_T'U[^L-G_OS_C#
M_P#0/7O^']/Y2_\ WEA_[ KLO_[#??OZG;E_OG_JI%_T'U[^L-G_ +\_XP__
M $#U[_A_3^4O_P!Y8?\ L"NR_P#[#??OZG;E_OG_ *J1?]!]>_K#9_[\_P",
M/_T#U[_A_3^4O_WEA_[ KLO_ .PWW[^IVY?[Y_ZJ1?\ 0?7OZPV?^_/^,/\
M] ]>_P"']/Y2_P#WEA_[ KLO_P"PWW[^IVY?[Y_ZJ1?]!]>_K#9_[\_XP_\
MT#U[_A_3^4O_ -Y8?^P*[+_^PWW[^IVY?[Y_ZJ1?]!]>_K#9_P"_/^,/_P!
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M />6'_L"NR__ +#??OZG;E_OG_JI%_T'U[^L-G_OS_C#_P#0/7O^']/Y2_\
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MPWW[^IVY?[Y_ZJ1?]!]>_K#9_P"_/^,/_P! ]>_X?T_E+_\ >6'_ + KLO\
M^PWW[^IVY?[Y_P"JD7_0?7OZPV?^_/\ C#_] ]>_X?T_E+_]Y8?^P*[+_P#L
M-]^_J=N7^^?^JD7_ $'U[^L-G_OS_C#_ /0/7O\ A_3^4O\ ]Y8?^P*[+_\
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M?^_/^,/_ - ]>_X?T_E+_P#>6'_L"NR__L-]^_J=N7^^?^JD7_0?7OZPV?\
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M_P! ]>_X?T_E+_\ >6'_ + KLO\ ^PWW[^IVY?[Y_P"JD7_0?7OZPV?^_/\
MC#_] ]>_X?T_E+_]Y8?^P*[+_P#L-]^_J=N7^^?^JD7_ $'U[^L-G_OS_C#_
M /0/7O\ A_3^4O\ ]Y8?^P*[+_\ L-]^_J=N7^^?^JD7_0?7OZPV?^_/^,/_
M - ]>_X?T_E+_P#>6'_L"NR__L-]^_J=N7^^?^JD7_0?7OZPV?\ OS_C#_\
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MX?T_E+_]Y8?^P*[+_P#L-]^_J=N7^^?^JD7_ $'U[^L-G_OS_C#_ /0/7O\
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M -Y8?^P*[+_^PWW[^IVY?[Y_ZJ1?]!]>_K#9_P"_/^,/_P! ]>_X?T_E+_\
M>6'_ + KLO\ ^PWW[^IVY?[Y_P"JD7_0?7OZPV?^_/\ C#_] ]>_X?T_E+_]
MY8?^P*[+_P#L-]^_J=N7^^?^JD7_ $'U[^L-G_OS_C#_ /0/7O\ A_3^4O\
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M[ KLO_[#??OZG;E_OG_JI%_T'U[^L-G_ +\_XP__ $#U[_A_3^4O_P!Y8?\
ML"NR_P#[#??OZG;E_OG_ *J1?]!]>_K#9_[\_P",/_T#U[_A_3^4O_WEA_[
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M /L-]^_J=N7^^?\ JI%_T'U[^L-G_OS_ (P__0/7O^']/Y2__>6'_L"NR_\
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M_(9[W]9-_OQ_]Z;_ #]:\%/X1^P==?[)Y\2/^\6_CI_Z)/;7_P!;/?OK)O\
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M.O?[)]\2?^\7/CI^1_S)+;/Y_P#(9[W];-_OQ_\ >V_S]>\)3Y#]@Z[_ -E
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MGQU_]$GMK_ZV>_?73_[\?_>V_P _7O!3^$?L'7?^R??$K_O%WX[?^B4VU_\
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M7_UL]^^OG_WY)_O;?Y^O>"G\(_8.O?[*!\2_^\7?CK_Z)/;7_P!;/?OKY_\
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M #Z/K'_T L5_]2>_>,_\1_:>O:!Z#]G7O]"?3/\ SZ/K'_T L5_]2>_>,_\
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M>@_9U[_0GTS_ ,^CZQ_] +%?_4GOWC/_ !']IZ]H'H/V=>_T)],_\^CZQ_\
M0"Q7_P!2>_>,_P#$?VGKV@>@_9U[_0GTS_SZ/K'_ - +%?\ U)[]XS_Q']IZ
M]H'H/V=>_P!"?3/_ #Z/K'_T L5_]2>_>,_\1_:>O:!Z#]G7O]"?3/\ SZ/K
M'_T L5_]2>_>,_\ $?VGKV@>@_9U[_0GTS_SZ/K'_P! +%?_ %)[]XS_ ,1_
M:>O:!Z#]G7O]"?3/_/H^L?\ T L5_P#4GOWC/_$?VGKV@>@_9U[_ $)],_\
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M#]G7O]"?3/\ SZ/K'_T L5_]2>_>,_\ $?VGKV@>@_9U[_0GTS_SZ/K'_P!
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MC/\ Q']IZ]H'H/V=>_T)],_\^CZQ_P#0"Q7_ -2>_>,_\1_:>O:!Z#]G7O\
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M/V=>_P!"?3/_ #Z/K'_T L5_]2>_>,_\1_:>O:!Z#]G7O]"?3/\ SZ/K'_T
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M']IZ]H'H/V=>_P!"?3/_ #Z/K'_T L5_]2>_>,_\1_:>O:!Z#]G7O]"?3/\
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M)],_\^CZQ_\ 0"Q7_P!2>_>,_P#$?VGKV@>@_9U[_0GTS_SZ/K'_ - +%?\
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MH^L?_0"Q7_U)[]XS_P 1_:>O:!Z#]G7O]"?3/_/H^L?_ $ L5_\ 4GOWC/\
MQ']IZ]H'H/V="=[;ZMU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=:XO\ZK^;YW__ "Q/E3\!MN]?==;>[1Z([6PO
M?G8'R?VLF'DK-SIM/I2/!5>9RVV:A:V!4J-O8*NR^6J(6I)UE@H',K4U.D]1
M'[KW5E/S<^8\G6G\L7Y!?.?XP;EV9OC^[/Q@W%WYTKNNH@.Y,'DXUQ0R>)JY
M(H9J=JFBJ8WC9D6>-RI*ZD8<>Z]T9K9?<VWZ#XU['[[[FWALSK[;TG3>SNS.
MQ][[JS5)LO XJ/)8BER&0K:RNR%1%1X['P/+(S23U*QQ(/6]A?W[KW33T[\P
MOB9\A]O[MW9T+\G.@.Z-K[!CFFWSN+JWM_;^_*+#1T\'W,DF5J<9D*F''QI3
MWE9YWC41@N3I!(]U[HC_ /*__FI]>_S&-Q?-':M!E^FL%NWXU?,#NGI'8NQ-
MC=LT._<OG^O^KX\!1XOLJ2F1H:E\)N;+Y#))2UE/1?PT"-*2*JJIHI9I/=>Z
M.9FOF[\,MN=R4OQVW!\L_C9A._*VN@Q=+TKEN[]M8_=3U52CR14JX"7))E/N
M9(T9DB^U\C*+JI!%_=>Z&'L_MCJ[I+9>7[([E['V)U/U[M^(39S?/9&[:#9&
M(HU-[&IR.2J*:DAU6-M<P+'@7/OW7NDQTC\C?C[\E]LU>\_CIWEU%WQM''U[
MXK(;FZ=[&Q'9-#3U48)--456'K*R&"H %_&[J^GU6L;^_=>Z576W:O5_<VUH
M=\]/]D;"[6V349+,X:#>'6V\,=OK%/6;<JI:'(4B9#%U%52-4T%;!-3U$0F+
MP3QO%*JR(RCW7NB<_P Q[YW4/P*Z0V]O#!]<9;O+O?N7LS:/0?Q@^/\ M_+0
M8.MWEOKL*1XL3C#75-XL=C85CEJ:^L=&2GIHF-B[Q@^Z]T30==_\*&*?;*]H
MGY+_ ,N/([_BIDW!+\4U^/.ZZ3;4C"TK[>C[%.Z3FUE,=X$R#8#Q^?3(\0AO
M;W7NC0_!/^9CU1\M_B=O'Y'=FT^&^+6X>@-Y[_ZA^8?7_:^^<7CJ;K7>744P
MIMRX[+YZ>:FQPQ=.S1U%-7S- DE++&TJ0S++%'[KW1F!\S?B!_%>W,$?E1\=
M$S'0&"BW3WKC)>Z]MQ3;,QDZHZY'=,;9(-@* K)&345H@B&M;N-0O[KW0J[V
M[9ZKZTZ[R?;W8_9G7_7_ %/A<519[,=H;VWGCMJ;=I*')M"E-6U.;KZF#&P4
ME0]1 L<SU*QR-)&%8EUO[KW1&^R/E5V9MK^:-\4OB/@Y=LS=.=T?%+Y&]T[I
MFDQ9JLDV5ZLRVUJ+$FBKUG$<5%)!FZIID\#F1EA9)$ <2>Z]T=_#]P=2[BWY
MO/JO;_:/76<[/ZXQN&S/8?7&'WMC,GGL#1[C$IQU7FL/!4OD,735X@F-/+4T
M\23B-S$S:6M[KW0(;:^?'P:WGVJW1FT/F1\7-U=SK6SXT]4[=[[VMFMP_=4Q
M024HQ%-E)*YJI#(@:$0&4&]U]+6]U[HVGOW7NJFJC^8'%UO_ #%/F#T;\@.R
M^H.H_B[\??BG\:NY\9OOL'+T6PDI<OV]F-T8_(+DL]DZZ"B:F:/"T@I8=$;^
M5Y!JE+QJGNO=6-]6=S=0=Y[)HNR^E>U.NNW>NLB9EH-]]9;UQN^L/,:=5>18
M\EBZFJHV>)70NHFU("-0%_?NO= KMKY\?!K>?:K=&;0^9'Q<W5W.M;/C3U3M
MWOO:V:W#]U3%!)2C$4V4DKFJD,B!H1 90;W7TM;W7NA2[K^0_0?QLVM%OCY#
M]V=3]%;,J*Z+&4^ZNW^P\3UQCY:F<J$IXJO+U=)!).Q9;1JY;F]K>_=>Z?NJ
M^WNI^]-E8OLGI3LWK_M[KS.>7^#;ZZRWCC]]XBJ,! D6#(XNHJJ25HV-G59B
M4/# 'CW[KW2URF5Q>#QM=F<WDJ##XC%TL]=D\KE*R/'TU/!3*7DFGGF9(H8H
MU!+.[!5 )) ]^Z]T6;J+YS_"OY ;UR76_17RY^-'<O8.'2HDR>R.K>\=L[]R
ML*TC2),S4&+R=55:86AD$A$1"6]1%Q?W7NEAV/\ *;XR=//OB+MCY$='=:5'
M66!VYNGL:DWYVO@MIS8'&[QDJX</7YB"NKX)<=29>:@KHZ&6=(TJY*>>.G,C
MQ.%]U[I8=4=Q]1][[,Q_8W2':/7G</7V5>2+&[XZOWGCM^XB=X0K/'%D<74U
M5(\D8="Z"74NH:@+^_=>Z7];6T>-HZO(Y&KIJ#'T%-/6UU=6SI2PPPTJ&26:
M:60JD<4:*S,S,%5022 /?NO=%JZ/^;7PU^36>S.U?CC\L/C?WYN7;U''D,Y@
M.FN[=M]F5E+3RLZ+434V&R5;*E.SHP$I3QDCAOI[]U[I2=C_ "H^,73LN]*?
MMKY%=&=95/6^%VUN3L*DW]VQ@=HS8+';TDJX</79B&OKX)<;1Y:6@KTHIJA(
MXZIZ:H6!G,,@7W7NI>/^2GQ_SW3%9\A]K]W]/;EZ/I<//FAV_B>S<-6;5,$6
ME1(^XH:N7%11&62*,N:@A7=5(U$*?=>ZIM^)7\V;=7\P?^6UU)\K^H>V_A'\
M;.]]P?(':^T.X>MNYNZ8<CB]I87+]G9;;M%MJOF1!DJ?>^\-G8^GGV[%68VB
M7*9*J@DIX$HY54>Z]U=MVYW1T]T!L;)=G=[=J]<=+];X:>@I<MO[M;>V-Z^P
MU-+E95IZ6&;)Y:II**.:JJ'2*&-I@\LC+'&&=@#[KW3'U-\COCYWUL*L[4Z0
M[SZA[@ZSQSY*/)=@]9=CX??&%IFPP<U:U&3QM94T<!I5C=I1),IC4%FL!?W[
MKW08Y#Y]?!?%9OKG;F2^9GQ6H<]W!@L9NCJC$U7R!VI#/N7&YM%DH<A@HVRP
M.5HJ]'5J6>F\D=2#>!I+'W[KW1M??NO=5!_,;^;/U5\1OY@7P+^%V[-T=%X+
M;GR@F[^J>[>S>PNY<;L^78,'6NTAE]ITU;0U,D,%)4;YSM9046/FKZV!:@I)
M3T=/55%1&\'NO='L[Y^8WQ(^+-3MVB^3'R?^/OQ\KMWP5]5M.@[I[BV_UC49
M.+%-&E5-CX,SD*.6LAI7FA6:2)'2)I(U<J74'W7NAXV_N' ;LPF*W-M7.8?<
MVV\[0T^3PFX-OY.',T-935:AXJBEJZ9Y(*B"52"DD<C(PY!(]^Z]U)RF5Q>#
MQM=F<WDJ##XC%TL]=D\KE*R/'TU/!3*7DFGGF9(H8HU!+.[!5 )) ]^Z]T6;
MJ+YS_"OY ;UR76_17RY^-'<O8.'2HDR>R.K>\=L[]RL*TC2),S4&+R=55:86
MAD$A$1"6]1%Q?W7NE!WK\N_BE\7C@5^2GR7Z#^/S[I,PVU'W3V]@.L6R IK^
M5J)<UD*)JE(B+.T894/#$$CW[KW0Q46]=G9+:4._L=NW;-?L6IPW]XZ?>M%G
MJ6JQ,F.$9F^_3))*U&U%X09/.)C%H]6K3S[]U[HN6P_GO\&>T\7+G.M/F9\5
M>P,+#O?:G6CYC9GR"VGN6E_O%OR=:7!8(5%'EIHFR^;JF6''TBN9ZV4B.F25
M^/?NO=#[0]E]<Y3?VX.J<9O_ &3D>T=I[?P>[-T];4.ZJ"KS^,Q6YI*B'&Y/
M(8>.=LC1X_(34E4E-434R0SO#*L3NT;@>Z]TELYVWL7)5/</7NQ^U^JCW%U5
MLNFS^\-JUV],?4U>U1NV@K*G;^2W5C89I:_#8JO%)//#-54L:5%/!/)!Y%C>
MWNO= ?\ 'CY$XRB^-7QHW3\GODC\3<YVEVYLF&H/873W:%!'L3>.7Q>*J\WE
MJCKVMR4U)-F\13XFAKJY6BC>2.@IIJJ8+%%)(/=>Z6V.^:?P\R_2E;\D\7\J
MOCID/CQCLC5XC(=YTG=.W)]HP5E XCFI)MQ+D3B8ZN.0A6A:K$@8J--V%_=>
MZ7O2_?\ T5\C]H#L#X^=S=6=X[&-=58P[PZCW]BNQ,8*FB8I-3M78BJJZ99X
MF!#1F0./R/?NO="Y[]U[HKV:^;OPRVYW)2_';<'RS^-F$[\K:Z#%TO2N6[OV
MUC]U/55*/)%2K@)<DF4^YDC1F2+[7R,HNJD$7]U[H5]S=S=/[*W_ ->=4;R[
M7ZUVEVEV[_>'_11UKN;?6+P.?W/_ '1IUJ\M_=[#555%D<U_"Z5UFJ_LZ:;[
M:(B2;0A!]^Z]U)R/;756'[(VYTWE^S>OL7V_O';^7W9M'JK([SQM#N3*XK ,
M$K\GC<'+4KE*['T3D+45$-*\,+$"1U/OW7N@@S/S<^&>W>XZ?X[[@^6?QKP?
M?E76P8VEZ5R_>&V<=NN2JJE9XJ5<!-DTRAJI$5F2'[7R,HU!2.??NO=%^[-^
M4O:.T_YI?Q6^(&).W/\ 1%W%\5ODAW'N_P"YQ#3909?JC+[7H<6*2M$ZI!2-
M#FZLSQFG=I'2(J\85P_NO='KV%V7USVKA:O<G5^_]D]D;=H-P;AVG7Y[86ZJ
M#>%%!E=I5<M!E<9-58Z>H@CR&,KH9J>KIVD$U-/&\,R)(K*/=>Z3^ [XZ.W7
MUG6=T[6[FZHW+TYCSN 5_;. [$Q&8VS!_=*LGQ^5\V>IZR3%Q?PS(4M335>J
MJ'V]1#+#-HDC=1[KW2,Z(^7GQ2^4?\=_V6KY+]"?(!MK^#^\L?3';F![,?'B
MJMXFK4PU?6/2K+>R-(JAC<*20??NO= U\7?D7-4;$Q5-\E?D]\-]Y]E=B?(G
MN_J[J.KZ([2H:C%9E-GYC)C&;3H5KI*6HR>^\'A*+1N#'TD4TE-705@"B&*Z
M^Z]T;G>G97776XVPW8F_ME;"7>^[L/U_LQMZ;JH=K#+Y[<7D_A^$Q9KIX/O\
MO7>&;[>C@\E1-H?QQMI:WNO=!7WO\O/BE\7/X%_LROR7Z$^/[;H\_P#=J/N?
MMS ]9OD!2W\K429FOHWJEBM9VC5@IL&()'OW7NAQV_N' ;LPF*W-M7.8?<VV
M\[0T^3PFX-OY.',T-935:AXJBEJZ9Y(*B"52"DD<C(PY!(]^Z]TGJGL_K2C[
M&QG3U7V'L:E[;S6T\CO[#=6U.[:"#<=7@L/51457FJ7"-4#)SXFEK9X*>:L2
ME:GCFDCB>17=5/NO=8<1VOU;N#L+=_4F![*V!F^UNO<7M_-[^ZRQ&\<=DMPX
M.BW:CR8JLS&%AJ7R6,I<G''(U)+4TT<=0JLT+.%)'NO=>V]VOU;NY^P(]J=E
M; W._4^XLAM#M--O;QQV:.VLMB:2"OJL7N 4U3*<-D::@JJ6IEIJSPS1P313
M.@CD1C[KW00='_-KX:_)K/9G:OQQ^6'QO[\W+MZCCR&<P'37=NV^S*REIY6=
M%J)J;#9*ME2G9T8"4IXR1PWT]^Z]T]=I_+;XK=&?WN7NCY*]"=32; HMFY+?
M4'8_;V V7+AJ?L6>KIMOSY6+(Y"GDQ\.<J*"OCQ[SJBUCTU0M.9#!*%]U[HJ
M7P,^7F^_D]WI_,6V=G\ILS-]>?&WY,;0ZSZ3S6SJ5"M9MW<^Q-M[ICJZFNBJ
M:B#)O/4YJ8PU,.B)Z;PZ58ZI']U[J/\ -K^9-\?^D>BOFS0=/?)?XTY[YB_&
M_P"+?R#[@P70]7VE@MQ[@I<OU9M#(9^C3+;4ILK%FC3QRQ4<E1"8XG,#@ED5
MP_OW7NA*_EX?+K#_ "P^+'QJWENGL'J[+_([>?Q0^-/>_>76NR<_1+7X*I[U
MVQ1YF"JJMOI6U63PN+R=0U<<<:I=,T4+B*6;QNWOW7NC8;*[7ZM[)R6^L-UU
MV5L#?V7ZOW95;"[+Q6RMXX[=53MW.T,<<T^%SL%#4SRXC+0PRQ.]'5+%4(CH
MS1A6!/NO=%4[)^0U7NS>7Q!RWQM^3/P[GZI[$[]WGU]V=_>SL^BRV0WA2[.Q
M><BK]M=92XQZRDRN]<3N#&'^(41G5J:CI,DLH2>#2GNO=#)W%\N?BI\>-R;.
MV;WY\E>A.D]W=AR^'8>U^V.W<!U[D,RPFAIC_"Z/+5])45P%1401$PQN!)(B
M$ZF4'W7NB.?RH_FOV]\TI/YB[]L#9GVWQ?\ YG7RD^)/5<FS,/)B4DVCU <,
M<-+D&DJZL5N3=<A,9ZE#%'*-!6%+&_NO='(V?\W?AEV'VUD.A-@_+/XV;V[P
MQ4N0@R74&TN[]M;BW+!)B2@JXI<)29*;(I+2EU$R&GU1$V<*0;>Z]T:'W[KW
M1:M[_,WX@=:9%\1V)\J/CIL;+0]E4W351B]V]U[;V]41;NK*.DR,6UYH*K)1
M2P[@?'U]!5#'NJU7V]33S^+Q31,WNO=)[X[[][/W7VI\N\+V!VY\;^PMK]?=
MT8O;G5VUNE-S-F]P[1P\VW<772X;LNG:-%Q>ZY*ZIJ:J&!693BI:*4G4[$^Z
M]UBQG\P/X'9JK[,H,1\U?B;DZSI>BR&3[?@H?D3M&J.UJ;#SM2UE1N'1ER,/
M!1U2-#4259B6"8&*4I(-/OW7NBZ=Y?-G<'4'\R#XU_'S-;MZWVI\:NQ?B!\E
M?D%V5O/=T]/B!15/4.4VM2XZL_CU3604-!B12YNJ>I,JE6*PN)8U5Q)[KW1S
M.HOE1\9._P#9.=[*Z,^0W2/</7NUHZF7=.]NLNTL)O?%8M:*.6:8Y*NQM=4T
MU (H8)I'^XDCTHCN;*I(]U[H@G\LK^:[UG_,)S'S:P?]X.DMJ[@^+ORX[OZ<
MVCM#:/;^/WIDLUUUU/#@:;']G5,6NGG& W%E:[)BGKH:,8Q5B2ECJZF:&6>3
MW7NCK]1_-KX;=_[VS76O1?RP^-_<O8FW$K9,]L3JWNW;>_<Q2)CI&BJ'GQN+
MR5561QT\J,DC&'2C"S$&WOW7NC&Y?+XG;^)RF>SV4QV$P>$QU;E\UFLO6QXV
MDI*3&QM-4U554S,D-/3T\*/)))(ZHB*S,P4$^_=>ZUS/Y=O\SOM;^83\W/E5
ME-N?-CX7;1^*?QF^0_>W5VV_BO@L5B-W[]WQL/J'$4E'!VS2;K7>&JFV=D=P
M9>AJXLI2[?J<9+! ]$M1&[^<^Z]U=ULWY??$_L7?NV.J^OODW\?]]]E[VV!C
M^UMF; V;W%M[<^8R^V,M"*FEW%C,=0Y">KK\)4TQ$T5;!%)3R0GRI(8_5[]U
M[IARGSG^%.$[G_V7',_+OXRXKY C*TV";I#(=Z;8H]V+7UE.M5#0OMZ3)KE8
MZV:E=)D@:E$KQ.DBH5=2?=>Z%/?/>W2'6&7&W^R^Y.JNO,\=F[A[&&$WSV'B
M-I5?]WMHS4M/EL]]MD*RGF_@V,J*ZBBJZW1]M325$"32HTL8;W7N@MPWSF^%
MNXNF<W\BL#\M/C=E^@]M5DF-W%W-C^Z]N56V*"IC<QFEK,VF1..IJIG&E89*
MA9')4(IU+?W7NADZK[<ZK[SV/A>S>ENR=B=M]<[CBEEP&^^MMV4&]L16+ Q2
M3[;(XV>II)FBD5D=5E)1P4<!@0/=>ZK._GE_-KN?^7C_ "VNZ/E;T!%LZ;M'
M8.XNH\9@HM^X*7<>+,6]MU8C#5OGI(*NAED84==,8R*E=,@5CJ *GW7N@LW%
ML#_A05M3:V1WAM?Y2_RW.V,]A,5-G*#K'-_%S>?7M/FWI(C,<9_'*??5?)CI
M:H QQ5!HWC20HTH$>KW[KW1O_P"6M\_=G?S!O@5TO\VQB*3J_';^VSGI]]X'
M+Y=31X/+;#R%;A]P0C(5*TRR8V#(8ZJ>GJ)5C+4K1/($8L![KW0P=1?.?X5_
M(#>N2ZWZ*^7/QH[E[!PZ5$F3V1U;WCMG?N5A6D:1)F:@Q>3JJK3"T,@D(B(2
MWJ(N+^Z]TY[W^9OQ ZTR+XCL3Y4?'38V6A[*INFJC%[M[KVWMZHBW=64=)D8
MMKS0562BEAW ^/KZ"J&/=5JOMZFGG\7BFB9O=>ZR][?,;XD_%V3%0_)/Y.]
M=!U.=5WP='W%V_@.N)ZU8@Q9J2#+U])-4JH5KF-& (M>]A[]U[H:-G;WV7V'
MM?$[XV!N_:^^=E9^C&1P6[]G9^DW-BZVG:X$])D**:>DJ820?7',R\'GCW[K
MW1;,9_,#^!V:J^S*#$?-7XFY.LZ7HLAD^WX*'Y$[1JCM:FP\[4M94;AT9<C#
MP4=4C0U$E68E@F!BE*2#3[]U[H:^U>[^F.B=@5O:_=O;?6?3_5V.;&)7=C=G
M[ZQ>P\%$V:D2&B23+92JI:%7K)I(XX%,^J:1U2(,S 'W7NH?2_?_ $5\C]H#
ML#X^=S=6=X[&-=58P[PZCW]BNQ,8*FB8I-3M78BJJZ99XF!#1F0./R/?NO=!
M1O#Y\?!GKZAVYE-]?,KXL;/QF[]T;AV3M;);D^0&U,-3Y#,;0KI\7E\91S5&
M5CBGKL5DZ:HHZV%&+TM7&]-.(YE*>_=>Z--C<ECLSCJ#+XBOHLKB<K14N2Q>
M4QM4E=3U-/7(LL$\$\3-%-#-$RNCHQ5U(9200??NO=5S?*S8/\TS-]A9+<'Q
M$^37Q*ZJZCI=K4!@V=W1\=,[VCF&R=$DSULYRV-W7@Z>.DJ/V1'#]C(\>EW,
MKAQ&GNO=56_RH_D3_.J_F.?%7H+YJUWR5^#NQ.M>T-T[L&;ZN7XM;BJ\P,9U
MQN[)[<R<$&97>QI*>KR"8:I>GF.-F2G,T;/%-H9&]U[H^/27\S+9^$[A_F08
M?YD]X=!=$=4?&'Y=[7Z#Z>W1V+NS%]3P5%'G=D;=W&U/69#,9&&#(Y,UN7JM
M)B\96F1+Q>B25O=>ZM8VWV#L+>6S*#L?:&]]H;KZ\RF*FSV,W[MO<M%G<+4T
M-.',E;!E*6:6AFI$$<A:9)S& K78:3;W7N@7Z9^:'P_^1FZ-P[(^/WRH^.W>
M&\MI1M/N?:O4G<^W>Q,C01I))"9*NCQ&1JZB"(2Q2(7:,*&4B]_?NO=.?:?R
MV^*W1G][E[H^2O0G4TFP*+9N2WU!V/V]@-ERX:G[%GJZ;;\^5BR.0IY,?#G*
MB@KX\>\ZHM8]-4+3F0P2A?=>ZS]K_*SXO]$;+P'8_=OR,Z+ZBZ_W9!056U=[
M]E]L8+9&)RD642.6FDQN0R5?34M?'412QR1M!+('C974E2#[]U[I4=:][=)=
MR]>IVUU'V_UCV?U;)2U5<.QM@;[Q>[\&(J&/S5#OE:"JGHD%/%ZY=4P\2\R:
M;'W[KW02O\\?@_'N/KC9[_,7XN#=7<.&Q.X^IMO#OS:K5FY\?GHA/05V @&5
M,F7I*Z$AZ::E66.=2&B9P1?W7NC&[MW?M+8&VLWO3?>Z-N[*V=MJ@FRNX]V;
MMS=-MO&8^EIA>2IK:^LEAI:6GC'ZI)951?R1[]U[H(NB/E=\7_E'0YS)?&KY
M%]'_ " H-LU45#N.KZ8[4P?9D=!-.BR1QUK8:NK!2O(C*RB33J!N+^_=>Z$G
M:W9?7.^<UOC;>R=_[)WAN+K'<$.T^R<#M;=5!N"MV]E:FD@KX\9G*6DGFGQ.
M0DH:FFJ%IZJ.*9H)8I@ACD5C[KW56O\ -2_FV=2_ +X4?(/Y']6[LZ([U[9Z
M:WOA>HJ3IM^Z,923G=U=E\#C\KA:^GQTM;DER^V<;GZ?+9#$B"*M6B56F:CB
MF6I7W7NC+=B?(:KWGN'X2[M^,_R9^'=;TGW7V_FL3NK*;G[/HLU/V!@:'!YB
M9<9U+68MZW'[@W-3Y:@CFJ(HZDQICJ;(-J\D(T^Z]T,7>OR[^*7Q>.!7Y*?)
M?H/X_/NDS#;4?=/;V ZQ;("FOY6HES60HFJ4B(L[1AE0\,02/?NO="G/V5US
M2[#;M.IW_LJGZQ3!KN9^QI]U4,.!&-= XR!R[3C'BA*$,)_N/$5(.NWOW7N@
MKZ(^7GQ2^4?\=_V6KY+]"?(!MK^#^\L?3';F![,?'BJMXFK4PU?6/2K+>R-(
MJAC<*20??NO=&)]^Z]U5?_.O^9';O\O_ /ED?)CY<=$0;0J>UNIEZ<&U8=]X
M6;<.*/\ ?WL#:NV*TU5'3U=#+,5QV:K&BM5(%F$;L'52C>Z]T=FJ^1/36R\3
MM:'MCN3J;KS=68ZJF[9JL)O3L#$;.J3@\ E F9SR4F0K()AA,959&CBJJS2:
M:F>H@CFE1I8PWNO=3.CODI\=_DWMRLW?\<N]>H.^=K8ZK6@R6X.GNQ\1V/24
ML[Z],%5/B*RKCIIV\;D1R,KD*2!8'W[KW2/[7^:OPZZ'WU@NK^[_ )6_'#I[
MLG<XHFV[L#L_NS;>P\S6C)R+#3-38S*9*EK)5J971(2L)$KD*A9N/?NO=&6@
MG@JH(:FFFBJ*:HBCGIZB"02HZ2@,CHZDJR,I!!!((-Q[]U[K+[]U[I&=A]C;
M ZCV3N3LGM/>^T>M^O=G8V3,;KWSOS<M%L_#XVEB95-17Y/(STU#1PZW1?)-
M.B:F4:KD>_=>ZH<_D:_/WY'?S,L'N?Y3=B_*CXK93KS/4_9$5+\#NI]DTB[\
MZU7^^-;BMH5^]<Z-U9')*,K@]OY2:&&IV[2)7BKBK*:?Q0F$^Z]U;=L;YS_"
MGL[M;)=$];?+OXR]@=UX>LS6.RO4NRN]-L;HW)3U.VY?M\C3386AR<^02HQ\
MX,=3$:?R02*R2JC*P'NO="-V7\A^@>EYZNE[@[PZBZKJZ#8^X>SJRB[%[(P^
MRYX]M[1J*.DRN?>'(UE-*,+C:K(8^"JK='VT$U33Q2R+)/$K>Z]TK^O.QNON
MW-D[;[*ZJWQM'LKKO>.-CS&T]][#W'1[NP^3I)695J:#)4$T]'5PET==<4S+
MJ5EO<$#W7N@B[V^8WQ)^+LF*A^2?R=Z Z#J<ZKO@Z/N+M_ =<3UJQ!BS4D&7
MKZ2:I50K7,:, 1:][#W[KW0"?/[Y=5O2G\MSY/?,GXT;MZ\W[E.M.A]W]H]7
M;KHZVGW_ +;R%1@83)3R>7'58@R%"[J5;PUBZA<+(I%Q[KW06P_,;N(_/WX(
M?&MFVLW7/R)^#7</R$[#8X-AD/[P;"FV?%1?8U0G"4U"XS]:983!(6*PZ9$"
MN)/=>ZLRWSOO8_6&S]Q=A=E[RVIUYL'9^*JL[NW?&^=Q4>TL/BZ&A&J:LR.3
MKYJ>BH:6%>7EFG2-!RS >_=>Z!O&_,7XDYGM]?C[B/D_\?,IWL]*E;'TUC^X
M]O5FZ'BD5'5TP,>0;)NK(Z,+4QNI#?3GW[KW2M[+^0_0/2\]72]P=X=1=5U=
M!L?</9U91=B]D8?9<\>V]HU%'297/O#D:RFE&%QM5D,?!55NC[:":IIXI9%D
MGB5O=>Z8\S\KOB]MSI#'?)C</R.Z*P/QSS%)C*[$]\YGMG XO9U5%FI_M:-Z
M;<L]>F'G%75$00A*QC+-^R@:3T^_=>Z472_?_17R/V@.P/CYW-U9WCL8UU5C
M#O#J/?V*[$Q@J:)BDU.U=B*JKIEGB8$-&9 X_(]^Z]TC=Y?,3XD]==MX'H'L
M#Y0?'K9'>FZ$H9-N=-;M[EV[MW=-<N5\@I&I<!5Y&'*S"K,4H@*TI\Q1Q%K*
ML![KW2I@^1GQ\J=E8WLJF[VZ:J.NLSON+JW$;^@[/PDN$J]S3YIMN)MRFRJU
MQH9\Z^X4?%K0).U6<BK40B^Y!B]^Z]TF=K?,#XF;WVYV7O'9OR=^/NZ=H]+Y
MRJVUV_NG =Q[>RV-VMD*(N):+<5=!D7I<-4QF.0&.KEA8:&X]+6]U[K'T3\Q
M/B7\HILU3_&SY.= ]_5.VPC;@I>F^WL!V3+1+($*O518>OJY((V\B .ZA23I
M!U @>Z]U"[)^:_PYZ<QF[,QVQ\K?CEUOC-A[RAZYWO6;V[JVYMI<1N&HHZ7(
M)@<G]WDHC0YEL?74=4**8)4_:SQ5'B\,BN?=>Z]V1\U_AQT[BNO,[VQ\K?CC
MUM@^VQ3OU9F=\]U[<VO2;CCJ](CFPE16Y*&'*4[%T_>IWDB&I;N-2W]U[H5N
MQNX>I>GMAY#M/MGL_K[K'K+%4D-?D^P^P-Y8[9^$@AJ%UQRRY3(5%/1(DJ\H
M3/9Q^F_OW7ND]TC\C?C[\E]LU>\_CIWEU%WQM''U[XK(;FZ=[&Q'9-#3U48)
M--456'K*R&"H %_&[J^GU6L;^_=>Z&?W[KW2&W-V?UILO<VPME;Q[#V-M/>7
M:F3RV$ZPVEN;=M!@<GN2MP%&^0KJ3 T%541568JJ*@CDJ9XJ2*9X:=6FD58U
M+#W7NL-5VOU;0]EXKI>M[*V!1]Q9W:=?OW!]3U6\<=3[EK,%BJA:.JS5)@GJ
M1E*C$TU6RP2UD=*U/',1&\@<A??NO=%4^77R&J]KX*?9G1'R9^'?6/>.SNU?
MCE3=E8;Y'=GT6%BQVVNV=PQ4?V4]#3O/D:+<.[L?#DJ;:JU%+'%D<HB11NZ+
M*![KW1;?F-_-GZJ^(W\P+X%_"[=FZ.B\%MSY03=_5/=O9O87<N-V?+L&#K7:
M0R^TZ:MH:F2&"DJ-\YVLH*+'S5]; M04DIZ.GJJBHC>#W7NHG27\S+9^$[A_
MF08?YD]X=!=$=4?&'Y=[7Z#Z>W1V+NS%]3P5%'G=D;=W&U/69#,9&&#(Y,UN
M7JM)B\96F1+Q>B25O=>ZMBV=O39W8FV,+O;K_=FV=];,W'1KD=O;NV=G:7<^
M+KZ=F91/15]%+/254)96 >*5EN"+W!]^Z]U5E_-Y^;?<WP@VC\$<STO!LR:M
M^2'\R[XO?$OL$[SP<V=6/:O;]/N6;+28Y8:RC^VRH;$4H@J)/-'&#)J@<L"O
MNO=-WRD^<G=?3G\WG^5U\(MI0[+DZ6^8>R_ESF^V9<Q@9JS,QU'2&S<AG\,<
M17I60Q4:M6TL:U(DI*@2Q:E3QL=8]U[JX/W[KW24WYNVEV#L?>>^Z[&YK,T6
MRMJ;BW;68C;F,ES61JXMN4<U9)34%'"K35=;.D)2"&-2\LK*B@LP'OW7NJ"*
M'O'^>=OWXO57S[P#?"SJ;;LNP\MWIMOX"]F],[QJ-R_W1Q<#Y2##;BW_ /WF
MH),9O:NPD+NZ)M!*2CKI(Z>>+2DVGW7NC+;]_F"?(?NWX?\ P7[;^ O05;N/
ML_\ F!G8']W]R=H;5S&Y]E]48O<N%DS.;W'V#4X PL:?#I#+1T,(KJ1,MD&A
MABG <(_NO=)?J;Y9_-OX[_S!.B?@1\Y=Q="=]8WY<]3]Q]B=!=[_ !^ZOS_4
M%;C<OT/#29#<.WMV;9K<ONNABQDV*K%EQV83.TX>H04,U,\]1$WOW7NKM/?N
MO=%$W?\ -GXHP18W:&WOEY\6,=V=V33=DX+IW%9SO+;?^Y;.==RUF-RD%+3Q
MY&2HKS@,S1STV4BIX99:2:GJ*>:-9XGC'NO=<?C[WA)C/ACU=WS\I._/B_EZ
MB+JK$[R[<^0O4?85+3]3U#O$9*S-8#<>3DHZ7^[+?6"JJ)(P8P"[7N3[KW2I
MZW^9GQ"[BI=E5O4WRG^.O9=-V3N;-;+Z[EV)W5MO=8SV8VW13Y+(8G#BAR4Y
MR63H<=2U-744M.))X:6*2HD1849Q[KW1#.DOYF6S\)W#_,@P_P R>\.@NB.J
M/C#\N]K]!]/;H[%W9B^IX*BCSNR-N[C:GK,AF,C#!D<F:W+U6DQ>,K3(EXO1
M)*WNO=&M^7/SBZF^,WPA[E^:V%W?U=V+M#8?3V_.Q^M"G:>-PV&WGD]M8FOR
M&+P&(W!%]_2U%7G*FA:EIA2Q5<LDA(AAE=='OW7NHGPE^</5GRN^#72/S%KN
MR.F<;CMV=*=<;W[NJ]K=C8[)X#9FYLSMW%Y7<^V\IDGK9(\55;;K\@]-54U?
M/'5TI55JT20D>_=>Z%SHCY>?%+Y1_P =_P!EJ^2_0GR ;:_@_O+'TQVY@>S'
MQXJK>)JU,-7UCTJRWLC2*H8W"DD'W[KW0K=A]C; ZCV3N3LGM/>^T>M^O=G8
MV3,;KWSOS<M%L_#XVEB95-17Y/(STU#1PZW1?)-.B:F4:KD>_=>ZH2_DA?S"
MOD#_ #(-K[R^6_:WRS^)LO5E=CNSZB3X.]:;1HJ/>W5U/2[NKL=M3*[ZW$^Z
MZ^O@AR&W]NY:H2.KV_1Q5R54=;3U A@,1]U[JX+H_P";7PU^36>S.U?CC\L/
MC?WYN7;U''D,Y@.FN[=M]F5E+3RLZ+434V&R5;*E.SHP$I3QDCAOI[]U[IZ[
M3^6WQ6Z,_O<O='R5Z$ZFDV!1;-R6^H.Q^WL!LN7#4_8L]73;?GRL61R%/)CX
M<Y44%?'CWG5%K'IJA:<R&"4+[KW0YXC+XG<&)Q>>P.4QV;P>;QU%E\+FL16Q
MY*DJZ3)1K-355+4PL\-13U$+I)')&[(Z,K*Q4@^_=>Z+/V[\Z/A3T!O+'==]
MZ?+KXS].;_RYI1C=D=G]Y;9V+EIA6O''"RX[)Y.FJ]$CRH%8PA3?@V!M[KW1
M>?YFWRYW_P#%WXR=:]S]%9'9V6R&]_D[\3.K$RF4HUW3CJC =Y;TP^ R512&
MGJ(HWF;&Y&22DG69HUD\<A65+HWNO=3NLOE+VCNS^:7\J?B!ECMS_1%T[\5O
MC?W'M#[;$-#E#E^U\ONBAR@JZTSLD](L.$I#!&*=&C=Y2SR!D">Z]T-OSJ^5
MVU_A%\2._P#Y0;F?:E7)U!U5O[>VU=I;NWM3[ AW)FMKX>NR6,VS2Y&HBJ"N
M1S<]&*:GCAI*B=W?]JGE8:3[KW58>$_FT9KM?KG^2SVOU7N_HROPGSL[$VUL
MOY74&U,]2[ZH]IY.7J6OWUN+;,-?#D7.#S.V\W31TM9#7EJJEA#QU4$<Q#I[
MKW5MG2ORV^*_R2R&YL3\>?DET/WIE=F5$U-N[%]0]MX'L:IQCT\@A;[Z#$5]
M7+2KY65 TB*K,0%)N/?NO=8N]_EY\4OBY_ O]F5^2_0GQ_;='G_NU'W/VY@>
MLWR I;^5J),S7T;U2Q6L[1JP4V#$$CW[KW0C9GMWJC;G6E=W1N'L[KS!=.XS
M;C;PR7;&9WIC<7MJGQ"()3E)\[/4IBXL<(R'-2U4(=/JUVY]^Z]TEMD_)7XZ
M]E]A;]ZEZZ[YZ<WYVGU9245?V7UQL[LO#;ESFWX,D$:";,XJCK)J[&Q2B2/2
M]1!&IU*+W87]U[H-]M?/CX-;S[5;HS:'S(^+FZNYUK9\:>J=N]][6S6X?NJ8
MH)*48BFRDE<U4AD0-"(#*#>Z^EK>Z]TNNQ_E1\8NG9=Z4_;7R*Z,ZRJ>M\+M
MK<G85)O[MC [1FP6.WI)5PX>NS$-?7P2XVCRTM!7I135"1QU3TU0L#.89 ON
MO=+KK#MCJ[NW9>([(Z:['V)VQU[N"(S8/?/6^[:#>^(K%%KFFR.-J*FDFTW%
M]$Q*G@V/OW7N@>S7S=^&6W.Y*7X[;@^6?QLPG?E;708NEZ5RW=^VL?NIZJI1
MY(J5<!+DDRGW,D:,R1?:^1E%U4@B_NO=#7NGLOKG8V:V/MO>V_\ 9.S]Q=G;
M@FVGUM@=T[JH-OUNX<K34D]?)C,'2U<\,^6R$=#35-0U/2QRS+!%+,4$<;,/
M=>ZX;C[/ZTV=NO8.P]W=A[&VKOGM:NSN+ZNV9N/=M!@\MN6IVO1-D<G3X#'5
M51%69B?'8]'JJJ.DAF>GIU:>4)$"WOW7NJEN@OYN77?R0^<W\QGX3;:WY\;]
MIY'XJ[3Z:;X\;SG[LQN=FW_7[TVEGMQ[QR<5&KHLF)V#44F+I<K'CXZYL?:H
MEKYXS-%!#[KW5A7Q.W[O3=WQ5Z9['[F[1Z#[.WMF>L\3N?L'MOXY[E_CO7.4
MJ7A::KRNULK.(ON-NLH+05$@6\2ZG/!/OW7NN73/S/\ A_\ (S<VX-E?'[Y4
M?'7O#>.U$>7<VU.H^Z=N=BY*@2.1X6DJZ+$9*KJ8(A+&Z:WC":E*ZKBWOW7N
MAPWK5Y''[-W;7X?*8/!Y:BVSGJO%YK<\_P!KC:.IIJ65X*K(2V;QT-/*JR3M
MI.F)7-C:WOW7NBM?'/Y"4$7QP^,6X?DO\C?BCN+MKN79]&(-]],]FT/]Q]ZY
MNCQE5F,E)UU5Y&:EGSN,BQM'65D?AC>5:&GFJ95$<4D@]U[H1^E?EM\5_DED
M-S8GX\_)+H?O3*[,J)J;=V+ZA[;P/8U3C'IY!"WWT&(KZN6E7RLJ!I$568@*
M3<>_=>ZX]Q?+GXJ?'C<FSMF]^?)7H3I/=W8<OAV'M?MCMW =>Y#,L)H:8_PN
MCRU?25%<!45$$1,,;@22(A.IE!]U[JF?XX_S$_E?\CNK?GEN"/MKX?=,YWXV
M?SH]]_"3KO=_=]9-U_MJMZYV/N+;%$N*-6T^0_B._P#.8[+5E-B&010UN4>C
MB\2(6U>Z]U>UVIV]U/T7LK*=D]U]F]?]0]>8/Q?QG?79N\<?L3$4IG)$:SY'
M*5%+21-(PLBM,"YX4$\>_=>Z9>G/D#T/\B=G-V'T#W3U3W=L)*JJH)-Z=2]A
M8GL3%)/0DB:!Z_$U=72I-"0=<;2ATMZ@/?NO=!3MKY\?!K>?:K=&;0^9'Q<W
M5W.M;/C3U3MWOO:V:W#]U3%!)2C$4V4DKFJD,B!H1 90;W7TM;W7NB;_ #&_
MFS]5?$;^8%\"_A=NS='1>"VY\H)N_JGNWLWL+N7&[/EV#!UKM(9?:=-6T-3)
M#!25&^<[64%%CYJ^M@6H*24]'3U5141O![KW1Q_CKOSM'=O:WRZP6_>VOCCV
M+MG8'=.*VUU9M3I/<K9S<6T<14;>Q==+ANRZ9HT&,W7+7U-350P*S*V+EH92
M=<C$^Z]U-RGSG^%.$[G_ -EQS/R[^,N*^0(RM-@FZ0R'>FV*/=BU]93K50T+
M[>DR:Y6.MFI729(&I1*\3I(J%74GW7NA3WSWMTAUAEQM_LON3JKKS/'9NX>Q
MAA-\]AXC:57_ '>VC-2T^6SWVV0K*>;^#8RHKJ**KK='VU-)40)-*C2QAO=>
MZ:>CODI\=_DWMRLW?\<N]>H.^=K8ZK6@R6X.GNQ\1V/24L[Z],%5/B*RKCII
MV\;D1R,KD*2!8'W[KW2$W7\Y?A7L3MJDZ$WO\N?C/L_O"OJZ*@H^H-S]Y[9P
M.Y9*C)%A3TZX2JR<61-14%&$4?V^N0\(I)%_=>Z--[]U[H$>\_DO\<_C!MW%
M;N^27?73?0&UL[EQ@,%N'N?LS#=945=7F)Y_LJ*IS5;11556((I93#$SR")'
MD*Z$9A[KW2IV+V_U/VAUY0=N=:]G=?\ 8'564Q4^=QO96R]XX[<^!GHJ9#)+
M5Q9>BJ)J!Z>*-69Y!4:4 )8BQ]^Z]UEPG;/5>YNLZ;NG;?9G7^X.G*W:L^^Z
M/MG";SQV5VS+@Z6!ZJ7,Q9Z"IDQ<F*CIHY)FJUJC3K$K2&0(I(]U[JK7^8K_
M #>NF/A)@?@CN;;.^/C[O_:WS+^5?QTZNJ][YCO#%8G%8/K'MN>IGS/:U-44
M\TM-D]M8S&4;:,D:VGQ,3U,-3/6/$A@F]U[H^';/S4^'G0VW=E;O[N^57QTZ
MBVIV3CJ/,==[D[)[IVYLNASU'D8!54]7AJK(Y&GAR=)/3,LJ34SR1O&RNK%6
M!/NO=-'R1[@R:_#SM;NKXW]W?&O:^53JW+[OZJ[Y[KWS!'U922QQZZ3,;BS]
M U3 NVE()GJ8'<".Y1KV(]U[I=;L[[ZIZ)Z7V_VS\D^[NF>L-HI@]IIN/M3>
M&_\ &;'VK-D,Y# B/19;*U%%1M3Y"JD_R,&0-,KH$4DV]^Z]U6QUY_,@S7<7
M\X[;'P^ZAWUTWVA\/]V_RM?]G+V[V!U[64^\I\AN4]GR[0#T>X\?D:G&U&&_
MA:\P1TY<5 +F>UX_?NO=6!=L_-?X<]"[YP76'>'RM^./3_9.Y_L#MW8'9W=>
MV]BYJM&4E2&E:FQF3R5-6RK4S2(D3+"1(QTH2??NO=&7@G@JH(:FFFBJ*:HB
MCGIZB"02HZ2@,CHZDJR,I!!!((-Q[]U[H.>W.Z.GN@-C9+L[O;M7KCI?K?#3
MT%+EM_=K;VQO7V&II<K*M/2PS9/+5-)11S550Z10QM,'ED98XPSL ?=>Z3O5
MWR6^.G=_7>3[>Z:[YZ;[6ZIPB9>3-=E===EX;>6!HEP"N]<U9EL?6U%#2BCC
MBD><RSKXD4N^E1?W[KW5&?\ +>_F6=R?S'OG7\G?[D?,SX<X/XS?'?Y)=V]/
M[*^(VT\#B]]]B=@;*ZMQ='CZ+M/';EAW<TR;3RVY,SCZBGR-'MVKQT\4+4*3
MI)()S[KW1Z?YU_S([=_E_P#\LCY,?+CHB#:%3VMU,O3@VK#OO"S;AQ1_O[V!
MM7;%::JCIZNAEF*X[-5C16JD"S"-V#JI1O=>Z+I_-R^=7RR^,.T/Y:F"^+&9
MZGVWV5\XOF1T;\6\YN;M?8=7OS%8R/N>E\*9*/'4>5Q,[&BKY89605?KA5XA
M9F5U]U[H&_EI\E?YS'\L;J6J^9/R(W_\'OEW\7>JMQ[-;Y%]==6],[EZ)WO3
M;:W5E:3#2Y7:-?D-WYC"UF4H:S(4<AI:Z-8YXA(BLCD2I[KW0H?S(_FK\V=G
M?._^63\+OA/O7H[KI_G3M3Y-Y_.[[[RZIR79<6/_ -".W*3<]$T-#09S!SI]
MU2+6P.AE)$DD3DJ(V5_=>Z0_R'^2?\Z'^6WM"3Y0_)-_AE\V_B%L.IQE5\C<
M7T+UONOHCL3:NWZJMHZ>LW5@J6OS6Y<+GZ+"TLU54UU),\$Q2*,I)# :FJIO
M=>ZO_P!D;SVSV/LO:'8>RLM2Y_9N_-KX#>>TL[1-KAK<9NBDBKJ"KA;\Q5-+
M/%(A_*L/?NO=*CW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=:WW\Q;$XO/?
M\*!?Y"&#S>.HLOA<SUY_-#Q.7Q.2I4K::JI<CU/5PU%/40R*T<T$\3NCHRE7
M5BK @D>_=>ZJY^:N7R_\I/XV?S+/Y479.2RLGPX^37Q<^2?<_P#*V["S]4L]
M/A*J>BJ,AO'I.IJW(D$^(J:ELA@A*&::EF:-JB6JJ8H(O=>Z/9\T,13][?)_
M_A-W\*^Y,%2[K^'O>&T^YNS>X^O]PQBIP.ZMP_'GJ#'YO9>*SU-)_DN0H:3)
MS/,,?4K)!7/*%>&3P@#W7NA4_FA])]8?&[YR?R<._/C3U#LK9G=7:?S6PWPX
M[3PW7.(H]BP[LZB[;P.4.\*'<N.H(Z>DW#B-K4U!!E*>*LIITI9HU,/CD>,C
MW7NBI_RV*^J^/OP1_P"%)??/16R-LXWNWI?^8U_-^EZBRF%V;!/64G^C_:FW
M<K@\12I20I5-BZ7)TM-+'CXG6'6@T(K6(]U[H _B/\;?D?VO_*!V'UB_\G3X
M0=K=8_)3XYX[M'L#Y,=D_.O'X#=>Y\WV7A8\K5=F;@JZGJ_(9;';I2KF2OUR
M[EFJ<7)!'3)7!:56'NO=';[)^*7S#[N^)'\FC<]9V7\/OD/\S_AZ-S[PRWQ^
M[U[7IMV;)[G:CVQ6[7FRU%F,?'D1F<]@<4L>2I<@*&6"*KFJ:BJDA92']U[H
M3?Y=W:G61_F6[PQ?R*_EH[^_EB?S(.YOBW]U7X+;/:.*[(ZS['VCUSFX_/DJ
M2NV=-3[4RF[\-(] DD]5BGRE'CV%&E=]LQ6I]U[J^GHWH'I3XS=>8[J7X^]7
M[+Z=ZQQ%?ELGBMA]?X.';F+IJC/5#U59+!1TZK#$U34R222:5 9V+6N3[]U[
MJD/^=!//UG\U_P"1K\G=\9U<)\<NI/FMV!USVQ65F+-504&=^0FV8L-LC-Y.
ML".N,H<?D*+(T[U,Q2GB:N2666/QJP]U[K899E52S$*J@LS,;  ?4D_@#W[K
MW6E)F<O0=H? W_A5Q\B^O_\ *^B.VNY^VMN]7;CI86BH,W6=0;.Q^&W/F<5(
M56.NQ];E64)60ZX:AXY-,CM&]O=>ZL"^7WPE^+_Q/_D'?+_*=)=+]=[-[ W9
M_+M-'VAVYB=H4%%NS>54N#@K:G)[MW!' N4W!D:W(U%55RS5M5,WGGD92H:W
MOW7NN?\ PH.EHG_X3==ZQSY&BHA6]2?"O[&6I:1EFDI^P>N*I((O#'*S2SI
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M?B)</1C.QS9"DQSXFDCIQ7S+3PA ??NO=3/YJ-.W0?RZ_E1?/Z@6HHL5UO\
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MH-^4^U)<-U]M/,2Y;;4&2@J8L-FLA5R8_P"YKJ5(ZJ1,;0)Y0L"CW[KW5?\
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M[8M-N+-U]7C]^[HV_!MVLGR\=5E,?C<)BJ"DBH<;YXTQX.J%(Y"7/NO=74_
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M "7_ ),$WQ0Z1SYW-_?CY 2_/S8'<Z[?7%8?(5N/8[:PV*ILEDADLK34./\
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MK<6W<Q@RZP97!5U?09.FI:MJ:>KI9O)0S1S4E34021E9+CW7NO?)#^7KT/\
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M<R];[BZ^-'C5Q#4N&FDIJ^@J<578Q(Z7(8^OH*NDKX!HJ8W)+^_=>ZY?&/\
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M*BV-A3N*2:I6EI9:? Q;GKL%CZZ=ZJFPN0W!5XIY0J5])74X,!]U[HQ/=O\
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MY:OQM^4/Q$[FK,[UKVS\S_@I'MKL'K_-5VVIJG'9WM'!XK,XFM5#25]'*/\
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M/QJV0G9F^-S)BFI_XIDZ2@FK<;CJ'!82"JCJ,ADLCE:.C@@#%99) (C[KW2
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M.RN!ZTP]='(V+K>P,Q797'0XF?.RQF/&XVDCK\Q5"]2N/%"DM4GNO=$LV?\
M+_XS_&2'^<C\B&RGRYWWCOBQW5%N?Y';4WG6X#<]+0UN%V)MW)'&]1T/\3H(
MZ;;TN-J::=Z?*5U)(V5EK9-:Q2*Q]U[IAS/\^GXM;7IME=D[NZ*^9>T/A_O_
M ''MO:>W?GMN;HR/$]3&KW55K14=94Y63,?QZFVY45+K'!GGV]_!ZHD/25D]
M.\4\GNO='<^8_P _NG/AC)U;M?<NV.U^Z.[.]LSD<%T?\</CSLL=C;VW1)A$
MBER5918]ZN@H:'"XB*>"3(93(Y*CQ]''(C35*E@#[KW0+=9?S4NMNUHN_=@#
MX_?+'J[Y4] ; QW9.Z?AYV/UAB\5V)7;?W)524&-W#M:*#/5VTMU8B6J1EDJ
M<?N>HBI9%,%;X)V2)_=>ZI^_E]?/O=?RD_X3L=S=V_/.O^;M)4;0ZJ^0>?[>
M^4W65/M?9>Y-VX_(;YWJXK^HLFN13'QY':='14V(*5V+Q$-!54L<--#)1B"H
M?W7NKJN^?YA?0GPWZX^-6W:O;_>W>/:O?>V,)C_CU\=>G=EIVCV7NNGP^,HI
MJJODH(ZJBQE)2XREJ*:3+92NR5'C:9G+-46('OW7NI'QO_F<]%=]YKOK8>\=
MD]U?%'N7XQ[+I.SN[NE/E/LJEV'G,3M3()6RT^ZZ6IQ63SVW\[MR2/'U1:LQ
M>;K%IV"1U:P2RQ(_NO=%<_X??^.N)VWL/NCL'XU_-KJ?X9]GYK:>)V1\Z^Q>
ME\;B.M9X-^M#'@LWD6@W'5;PV_MO,33PQTN4RNTZ.D+2P&1XEGC+>Z]U=ZK*
MRAE(96 964W!!^A!_(/OW7NN_?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=:TO\VC"=M?S /YB'PG_ )9_QX[7Q74>2^/F-/\ ,R[S[(SG759V
MQB<35=99./$]7X_*8"++;?Q^:-9N*2NJFQU7F40I%3U<M//"@AG]U[HK7\S'
MX_\ \Q[X3;@^+G\WOO/YM[$^6U-_+X[;PL._=D]<?#0?'W*-UA\@,CC-M=@J
MU7B-]9V/,QQT<E%+%3U>-,=&XDR"5$*0U$53[KW1R>K_ )-_&G:G_"@GY&'=
M_9&QMOY/Y!_RX_B#5]";NW%708>BSE)2Y;=^8K<=C,M5F*G-9D<?+0Y"&A$P
MFK*:AJ*F.-TH)3'[KW35U;O/:GR&_FC_ ,WOY ]"9W&;TZ)Z]^ O67Q6[#[$
MVG5C)8++=F[0_O5G:_'TF0@U4>4KML8')45)6O#+)]I),M,S!]:+[KW20_EF
M_/KX(=:_\)Z.J=S[T[CZKV]M3I#XE9/KGN?8F7R]'B,K#N08VICK<+-@'9<C
M49+=-96QSX^-:1WR\>1IJNF$T=6CM[KW1?>N>F-[=:?&W_A*;U1WMMVIIM\;
M2^1N+R>9VSN:G+U.,J*/K7>N=PE-40RC5!685/X:H0@&GFIU46,8M[KW1@?Y
M^&T.PJ+YE_R8.]4^1.X/B5T9UWWA\C^N-^_)C$;>P^\J;96Z.[MJ8^BV3DLC
MC-S8_);62GR51C<KBQD<G3&+'"MDEC>*1ED'NO=)[<G6NT\I_,:_EP]==T_S
M?N^_G'WYLWLC<WR#Z6Z?Z]Z$ZGGI,-C\#AY:/,9S>N8Z_P +AZW;>U\QBZVH
MHX9ZVK,-?*&2F@J)(&">Z]T@/YF?=>_OY47S3^8.^NH,+E\I4?S@/B9A-M=!
M8/&_>UZ?[,OU36XGKS!0TE,\BXVDDSNV]YXNOJ'%12FH?",\OE*EU]U[HPG=
M/Q=VI\*LI_PFZ^*VS!%)AND/E95;)J,E'&D1R&1HNHMZ29C+2B..)#/ELM+6
MUDI$2WDG8Z1]/?NO=)?K+Y+?(/YE?(/^8AC=D?.'HS^5)TY\4OEOV'T7N_9F
M"Z'V-E^T=V'KJDHGJ>Q]PY[?E54X?&XG<@>?^'U VI5/)34K?Y6&B,DGNO=$
M,^!^?QFY_P"2M_PIIS&&[4W=WEC,_P!^?S/=WX'N+?5!2T&6W;A]T]182KQ&
MZ:J/'04N-T9^@\=;"]'1TU))!+'+34E)3O%3Q^Z]T9KN#?.RM\_\)XOY3;[*
MW?MC=Z[2W5_)-V-NH[8SU+G?X9F]MY/K5,CA\A]K++]GE*%W05%+-HGA++Y$
M74+^Z]T:+XK;GVY\:OY]W\W?%?)'>VW=BYOY@=:?!3LOXEY;?N7@V[!N+;/4
M&V,WM_=6.P57720P2U6&S4U(M30P2-,R)]ZT6B[^_=>Z#[8&[=O?(W^<7_-2
M^0OQWWE0;R^/'4O\L+;?Q2[EW9M&E_B6WLUVQ2Y3+;@BIZ3/0AL?E<GM#;"R
MT-<E-43&DDKEIJCQR1JI]U[ISZ'QF/Q/_"2W.4N-I(**GE_DS_(W)R0TZ"-6
MJ,UUQNBLJYB!_NRHJIYI7/\ :=V)^OOW7NB@]8[ ^.7:G5/\E[:6#^:'<W\M
M_P#F/?\ #/'2K?'CY);?H<'-M+=>U4P&W)LELK*46XY4Q>[ZG&Y<199L&E30
MU1IDEJ3.8M#1^Z]U:%_*H^2ORFW)\J/FM\-_DGVMT'\PJWXT[?Z/S]'\XN@]
MA4?7#;@J=_T55%+MC?&+Q4]7@Z/=^*CQRSFGH*MTAI)8_*L9>.*/W7NKB>EN
M]NF/D?L#'=J]!=I;$[DZTR];E<=BM^];;FI-WXBIGP<[TM9%!7T4LU-,]-4Q
MR12!9#I=2IY!]^Z]U0C_ ,*0MC[1[.VI_*%ZV[ V]C-W;#["_G;_  CV/O;:
MF;IQ5T>3Q&[*;=E!DL?5Q'B6EK:*HFAE0\,CL/S[]U[JRCK+^4'_ "Q.F.P-
MH]J]4?!WX\=?=D;!SE%N79F]=J["I\1D<;7XYM4-525,1#Q2H?R#8@E6!4D'
MW7NJZ]T?]Q6W7'_C#2N_]_3GO?NO=%8_DW? #X0?*[<?\X7?_P F/B=\?^^-
M\8/^=[\]]G8?=O:O5N(WMD:;%44^W:V''0U=?2S31T4597ULR0A]"RSS. &D
M8GW7NA?SWQ#^+?Q)_P"% '\M##_&#X^=0] XK>?Q-^;V3W;C^I=AX[8T62J,
M32XB*EFK4Q\$ J)*>.:58V<$H'8+;4;^Z]UL0;8[YZ6WKVKV5T9M'M/8FY>Y
M.FZ3:]=VQUAA-RTN1SFW(=[4D==AY,SCHI&J<>F3HI8YZ8S1IYHF#I=>??NO
M=%/_ )MO_;JS^93_ .*%?+K_ -X'/^_=>ZI0VU_V3U_PD7_ZBOCQ_P# UY?W
M[KW1^.D<1BYO^% WSPSTM!2R9K&_R[_AOB,?E'A#3PTN;W1O2:LIXY+:EBJ9
M<?0O(H-F:"(GE![]U[HB4W6&S-X_*7YW=B?RS?YK^\?Y;?>^RODOFLS\V/B]
M\C>O]H=B;(R^YJ;%4DM7NZ';&Y*Z@R6(PV\::*C8[CI,C/%4QTM5]I%"R(T/
MNO=%9_F(?*3LWYB_\)/>_NZ.V=B==;,WDV]NM=C5M=TS15%!LS<D/6_>FU\)
M#N_:<54B3KM_<0I/NJ4LNE];/%^TT8]^Z]U>7\H>A?YA?RYWQMSNC^7O_./V
MC\8_CKEMC8[$8_9FT/B)U[\K,=D\MAJ_))DL[3;KRN0$S"?5!1O21,T-/)1/
M9A+)*J^Z]T"63VWV!LW^<M_*SVCVQV,.X>T=K_RO_E7M[L?MI=ITFPQN?/8;
M)];TV6W",'0,]#AQF:^.HJ_LJ=V@I?-X(B413[]U[I<?R"<9CZ#X<]V55'20
M4U1FOYAO\P#)Y::) C5%1%V9G*-9I3_:D6EI*:($_P!B-!^/?NO=5I_R2.D?
MF+WM_P )[/@1MKX7?-B+X,[_ ,3V1\C\YNCLB3X];=^1W\6P\?8_8=.V$&)W
M+-!246NMGI*K[N)S,/MO"%*3.1[KW0O_ ,QSH/Y5]2_RR]L]=_.3YATOSSWS
MNC^9E\&:^B[&F^/NWOCO%2;:S'8&R*%=LR8/;D]10UJ15E/E:IJR1Q-**_[=
MAXZ>,GW7NAY_X4'_ /%F_DV_^-Z_Y>?_ %JWI[]U[I1[2[4ZXZ>_X4 ?+K&=
MK[WVQUK/VU_+Q^*>1ZSFWWFZ?:=/G8^O]T;UBS*XNIKY((*V7'/74_FCBD:1
M%+,5THQ'NO=%"^"W<'6'??\ ,V_X4O\ ;'3>Z,5OKKO<747PDP^%WWMS,P;@
MQ.7GZ[ZQWIM?)U.)K*9!3U%%3Y7"UU'KCGJ$>>FF99BI$<?NO=8,'B,7C_\
MA('/145!2TU))_*UW#EWIXX0$-5D\74U]14:;6\LM;-).S?7RL7^OOW7NAY_
MFNTM-1?R9?B1145/!24=)VW_ "K:6DI*6):>***GWKL9(XXXT 5(T4 *H
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M)ZGL?<.>WY55.'QN)W('G_A]0-J53R4U*W^5AHC))[KW58WQAW#B]R_R,/\
MA2KF</VKNWO'%Y_YA?-S=V [CWW0TF/RV[</NO:&R*K#[IJH\?!2XW3N"A,=
M;"]'1TU))!+')2TE+3O%3Q^Z]U<5_.'V]@J;^3S\9=N0X?'# X[NS^6'AZ'$
M/1I+3Q4L.]MF4BTZQ.K((A2LT6FUC&2ANI(/NO=#A_-E_P"RK?Y(7_C2A?\
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M0O\ \#CF_?NO=.DW6&S-X_*7YW=B?RS?YK^\?Y;?>^RODOFLS\V/B]\C>O\
M:'8FR,ON:FQ5)+5[NAVQN2NH,EB,-O&FBHV.XZ3(SQ5,=+5?:10LB-#[KW06
M=Y_)+?GS>_D5_&CL_O#KKK+;6?S?\Q7XH=99X=28^>DV1NNBV-W?B\!_>C:]
M/5HD_P#=S<\-*]13ZETR*[M'^RT8]^Z]U9Q_-OH:&M^5W\CXUE'2U9A_F64\
ML)J:=)]#4_7V[ZB-EU Z62>""12.5DC1Q9D4CW7NI7R-_P"W]W\M'_Q2GYZ?
M^YVQO?NO=</^%'G4O:_=7\F;YH;*Z:H,OF=W4^W.N][5^WL%%+/5Y#"=<[OP
M&>S]/#'"&EE:/#XZLJ#$BLTZP& *WDL?=>Z#7^;1\Y?A)V1_)?\ D#6]>=O=
M9]DXOY3?'RNZ?^,?7^Q,M2;OS6X]V]J4*T&TL#A=N8YZG)S9BBR<U+)-21TA
MFQ_VLSSI%]L^GW7NBW]L[(W_ -9_S*_^$G/6_:^8EW%VEU]\=OG;LCLK<$\0
MA>NS^U.@MJ4&9K'0$A'JLC3U,A4$@%K>_=>ZVEIY?##--XY9?%%)+XH$\CMX
MP3I1>-3-:P%^3[]U[K4G^*'RP[H^8?Q0WA\TMX?S-.G?Y5'QBQ.]N\'R'Q0^
M/_1'7&'WCM"DV#G\KCI:?>>XM]KN%HMT96.DCR#T]%M*CED>L@=&D,RQ#W7N
MJZ>DL+N>#_A.G_)^[8R<VY*CJGXD_P WO9W?GS &7Q];#64^Q=C=W=BP9VOS
MU!$*N1XL;5Y?%UF0AGF>*GT-42REZ56]^Z]UM@?(CY^?"G$[X^%?6UMA?+#L
MSY-]];1Q?QUV3UA6[7[2R.-DBH*^LJ^S(EJJX1XW ;2Q2U,];EJ:3[J&"9DH
MTGE<PM[KW54/\FO?&RQU7_/^ZR.[MLCLB'^;7_-.WQ+L YVE&:7"RX[;6/7+
MG%^7[X8PU\;TWW7@\'G!AU^3T^_=>Z(STQ40]0[,_P"$D'RX[<SE)MKXG=1]
M3=Y]7]H;TW!**3![<W3W]UF,1L:OS-3*5I*&GK\O :>.NJ7CAHY(P3(AFY]U
M[JT+^:1V9L'Y&_/3^2[\=OC?V9MK>/R*V#\X=O\ RQWM_HZGAWW-M[J7K;"9
M5-X56=J<>U1#@\7NR.HI<32R54L*UL[VI_+)!I]^Z]T/'\K/&8^+YP?SRLQ'
M20)E*_YX]=XRLKU0"62GQ/5VTI::%V^IC@DK:MD'X,KG^T??NO= )_(\WKM#
MK7"_SY.Q.P-RX39FP]A_SQOYD.\MZ[OW+D8L/CL5B=LQ[?K<CD:^KG9(::CH
MJ2&:::5W"1QHS,0 3[]U[K8&Z\[$V)VUL?:O9G6.[MO;^Z]WQA*'<FSMZ;3R
MD6;QF4Q^3024];0UD#/#4TTZ$,DB.592""1[]U[K6._G)=!]>?)_^=I_(JZ,
M[57=C;"WSM3^86,Z-C;\S/665!VWL6GR](U)G-OUV-R]"RUM!3%S3UL?EB#P
M2ZX99(V]U[JRKK'^19_+5ZR[9V'W>_3>]>UNR.J\BF:ZQS'R$[]WY\@:?;]?
M'/3U*Y#%XO=VX\OBJ>OCJ:.DECJ#1-+#+!#+"T<D:N/=>ZJE[A^)GQ]^9'_"
MH_=O7?R4V''VIU_U_P#RKMB]VT/6VXJT5>U\OEMJ;^@PE%'NC R124NXJ&D7
M<L]5!2U3&F2K@BDEAG "K[KW0S?%3>&8_DI_.JA_EJ=M9G)'^75\P]S9C=O\
MM3M?<[C[39&\=RUTU1FNC\CDWF<_;3555#+MQJGQR2/40TR2UM365 HO=>ZV
M%-L=\]+;U[5[*Z,VCVGL3<O<G3=)M>N[8ZPPFY:7(YS;D.]J2.NP\F9QT4C5
M./3)T4L<],9HT\T3!TNO/OW7NB _SR?^W07\Q3_Q5CL[_P!PS[]U[JNWYU?-
MSX5=K_\ "?K/X_J?L_K;>R_)7XH;.^.'QOZDVMFJ/)9W*;XWKC*';^ VGC]N
MPR/D5S>$S0C%52?:K)C_ +*>2<1)3NZ^Z]T)5+L#-[0_F[_R>]G]CF#-=@=8
M_P JSY*87.9:734,,[@?]'6'R=9$X)&N8RUZ%@3=)G -F]^Z]U)RTOA_X5/8
MJ;QRR^+^0?4R^*!/([>/ORL.E%XU,UK 7Y/OW7NB<?%#Y8=T?,/XH;P^:6\/
MYFG3O\JCXQ8G>W>#Y#XH?'_HCKC#[QVA2;!S^5QTM/O/<6^UW"T6Z,K'21Y!
MZ>BVE1RR/60.C2&98A[KW1'>@L519[_A+E\%=J;IIJW-Q5'\R#J[;.\<7N_'
M-!53_P 0^5&36LILK23/.4J)X9R*F)Y9+,[HSN02?=>ZV OY_P!C,?FO@_UO
MA\M209#%Y;YX_ ;&9*@JD$L4]/7]H[=BFAD4\-')&[*P_()'OW7NHG\V^AH:
MWY7?R/C64=+5F'^993RPFIITGT-3]?;OJ(V74#I9)X()%(Y62-'%F12/=>ZR
M_).7P_SZ/Y:TWCEE\7PD^>\OB@3R.WCK-CG2B\:F:U@+\GW[KW5<OQ0^6'='
MS#^*&\/FEO#^9IT[_*H^,6)WMW@^0^*'Q_Z(ZXP^\=H4FP<_E<=+3[SW%OM=
MPM%NC*QTD>0>GHMI4<LCUD#HTAF6(>Z]U73TEA=SP?\ "=/^3]VQDYMR5'5/
MQ)_F][.[\^8 R^/K8:RGV+L;N[L6#.U^>H(A5R/%C:O+XNLR$,\SQ4^AJB64
MO2JWOW7NMJ[Y0?//X;TNX?B!U7C*S87R?[>^4W=&W\%\9=L]856UNULCAJML
M9D:J;M**.JKO'CL!LW'">IK<K3R?<Q02M'1I/+(T+>Z]U77_ ,)\.^.COB__
M "J,3T'\C>WNM>G>]_ACV+\I=N?+[;'9N]L?M')8#)+V#NO/#*99<E405,U!
M68'(8Z:GR+(8:J,$12OXR![KW51M7LCL7=/\B'M3>FRMU9WK+9_RY_GE8/O'
MX79W+;$DQLVU=C]N=S[<IMGY6FP>06D>>D.1IJW.TL,HBCJ(:N-5;PNKGW7N
MK@_Y<M!-_*D^</9_\LGO3==7OK#?,W,[H^6GQ"^7/8RT%/NGLK.QT])%V%L_
M>63IJ>F7,[PV_*M/744K^N3%5,<*(BI3Q>_=>Z*#\@?^R4/^%:?_ (EC-_\
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MGQNXMH[PP=-N3&5]/(0Q@K*&LBFI:F(LJG1)$RW -K@>_=>Z!'X_?#3XE?%
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M=?\ 7.UJ'96%QL5=435<T=!B\;!345)'+55$\SK% @:61Y""SL3[KW0#]M_
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M:ZCZ#V/BNLNC^L=A=0]=X/R'$;'ZUVG0[*Q5.TUM;Q4..@IZ99)-*ZW\>IR
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M;R+9;;N.[>ZXQ/8$>/J9%T//0C)TM2:262.Z2-$4,B$H^I21[]U[J9LOXO\
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F7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>timage_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 timage_002.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
M     ! !+     $  0$L     0 !_^X $T%D;V)E &0      04  DE$_]L
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M5R/QW[<GZ=S^W_DS1[_R\=?/LW?LL>/KLW2X@XIH)*G$USY)E@^]$:R"-0Q
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M5V!'EVI&ERRU=/7"@3!MC&)"9QLTPQYIC(+5)%Y/&!)[H8E_*E?*M?\ B_\
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M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K0?\ YH_\@O\
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M<?)_^5GT3\@^MOE!)L!-R=E=J8K?NU4Z^W/6[HA2'&8*EH)'J :*CB=?N-(
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M_P F_P#&_;GA]>ZD>W.O=1_!_M?_ ";_ ,;]M^'U[J1[<Z]U'\'^U_\ )O\
MQOVWX?7NO>#_ &O_ )-_XW[]X?7NH_MOKW4CP?[7_P F_P#&_;GA]>ZC^V^O
M=>]^Z]U(\'^U_P#)O_&_;GA]>ZX^"E_HO_4P_P#%?>Z+U[KEX/\ :_\ DW_C
M?O7A]>ZD>W.O=1?!2_T7_J8?^*^Z47KW7+P?[7_R;_QOWKP^O=2/;G7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>ZK^^?WSSZ5_ES_'W+?)CO^#><O6^&W'M+9TJ==8"'<F0%;O.:.."
M04=3+%%%I9Y&]<HN !_:O[K%$(Q4U-<=7)8&@H*9-?D:>7V]4A_]!AW\H_\
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M//\ [1_R=_QKVYXG7NO>?_:/^3O^->_>)U[J/[;Z]U[W[KW6?[@_Z@?\E_\
M&O;?U7^JG^SUO'7#SP?UC_ZEM_Q3WKQ(/4?SZ]3K)Y_]H_Y._P"->U/B=:ZD
M>W.O=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M)?-9(T%,+6NU_>F>@Z;C34>BR[N[ABQ#5MN+_CW;7IZNXU4Z,QMVK6NV]@<O
M?TU=!09$_P#(="%/^\@^VE; /^KATZXHQ'Y?SZ57MSIOKWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][+^O=<-8_Q]W^J/\ J_XOKW4;R?X?[S[2
M=>Z]Y/\ #_>??NO=8_N8_P"O^]_\4]^Z<\/K#]Y_M*_\E>_:_G_/I_Z4_P"K
M_BNO>=/Z-_MA_P 5]^ZIU[[S_:5_Y*]^U_/^?5_I3_J_XKKWWG^TK_R5[]K^
M?\^O?2G_ %?\5U[[S_:5_P"2O?M?S_GU[Z4_ZO\ BNO?>?[2O_)7OVOY_P ^
MO?2G_5_Q77O.G]&_VP_XK[]U3KWWG^TK_P E>_:_G_/J_P!*?]7_ !777WH_
MHG_)?OW37A?;UW]Y_M*_\E>_:_G_ #Z=^E/^K_BNO>=/Z-_MA_Q7W[JG7O.G
M]&_VP_XK[]U[KJ>8V_ L#JOR!_QO_C7MX3_2GJ@&>N1F4?AO]M_QOVQ!_C/3
MA6G7-/TC_8^VH>'34G3+H_RKZ+IT?ZC_ 'W^]^W=,/\ J/\ L]6^F-*T_P!7
M[.G;SI_1O]L/^*^]]6Z]YT_HW^V'_%??NO=>\Z?T;_;#_BOOW7NO>=/Z-_MA
M_P 5]^Z]U[SI_1O]L/\ BOOW7NO>=/Z-_MA_Q7W[KW7O.G]&_P!L/^*^_=>Z
M]YT_HW^V'_%??NO=>\Z?T;_;#_BOOW7NO>=/Z-_MA_Q7W[KW7O.G]&_VP_XK
M[]U[KWG3^C?[8?\ %??NO=>\Z?T;_;#_ (K[]U[KOR?Y7ILFG3_O'^M]?]]]
M/>OT./5J'3UBED70"2OZN>?]?_'VH,4U/T>'S_V>FA. <_ZOY])C*9G#82 U
MF2S-!B:0B^FORO\ ";6/Y%C[)-PW6#:E_P <N/I_YUZ5I:,QHJU/0</W1B*^
M4T^S=L[HWE,+)]]08_\ AE(0?^FV<*1^?Q_O'L+2>Z%G=?HV=;H_ZOMZ-8>7
M7CRY"#YY_P W3?\ ?]MYL!Y?[I;*I@ .!_>BK(Y-^2;_ )]H9MQWS<CV?HP]
M."RLK/,P+']G^&G3-F-O0TE/][OSM/<%- WT R-'M>DYM_QQ8V'^P]D5[<PP
M8O\ <O\ FST8VTY_XB68^VG^?H/FV]B]U0>#K_;FZ\M?Z;LSVXJO%4E*1<^;
MGB?BY]DWT#;K_P DRW_U?RZ]]5$W]JP^P"I_P_Y.C;[6QV2P6W\/B<KFER^0
MIJ$+75U<034ZK\W/T !_VWXL3[G3E^RFMX?UN@E.ZR,2 ?R\NEGY_P#:/^3O
M^->S7ZEO]5/\W2+K']W_ ,V_^3_^->W/#Z<\/J9[;Z;Z][,.O=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO= GV74^&DKQS];W_VP]W)H*=:(X'JGGOC
M>E?1O5B*J_-?<V_K^/\ >O=&ZN'ZN9Z:E2KZBZPK)N?-UWLRO((O^O$TE_\
MH;WLY1:^@/\ +JIJ)7 _B;_#T+/O77NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NF_P!I^O=>]^Z]TX>U'7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NHU1]4_P!9_P#B
M/:.Z_P W^7K?EU%-62+!(S_B2#[H;LVX_6/2GZ4?ZO\ BNI7W!_U _Y+_P"-
M>[_5?ZJ?[/2;'7#[O_FW_P G_P#&O?O#ZOX?63S_ .T?\G?\:]J/$Z;ZQ^3_
M  _WGV5]>ZCRO_0*/\2/I_QOW4OIZ4"+7U&GG3@?7ZV'/^W/MO\ QCY]7"G_
M %5Z[\LG^J_W@?\ %/;>L=*] ZQB83\#_#Z^VB9SUH+HZ:?,O^^_Y%[=UCKW
MU77.[_Z@?\E_\:]T^HA_U#KWU74MI2/JEA;GU?T_V'ND-Y!<?V/3E*=</*?\
M?^2O;OU!_P"&?ZOSZ<T#KEY7_P!2?]M_QKVD_>4'3=#UWY_]H_Y._P"->W?'
M/IUN@]>N'W%-_A_U+_XU[OXPZKUQ$M%4@^#2#R?S?_8^[F05Z\%(&>LW']#_
M +?_ (U[WK'3/C#J-[9\?Y?SZ44'KUGGJ#!]5LW^O?\ WKWOQNM  ]=05OW
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M/^J6WM!/[A[?!Q\7K0Y=NSY ?G_L]>_TZ]>_\[NO_P#07JO_ *C]V_UQK/\
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M>E)C?_5>"W^]>R"7W&K_ &'3B\LA?B)/^E4_YCTEZCMG-5Y;[WM_8VWPP_X
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MRM/V<.FBMH-^RF^:Z=V'GQ?G[#<5&GT']:VG]E\^T;A;?VUIT^M]:'X;MO\
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M44]3*#;CE3<'^@_VW'L[V#F.+>\>?^4=%=W8FRXY!R"#@CH2?N_^;?\ R?\
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MM>$/]0Z]YO\ :%]^\4_ZCU[PA_J'7'[A?]2O^V]^\4_ZCU;Z?K#]VW_'./\
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M/Y?[/4:7=6!B6U3G\#2F_P!5RR$_[RZ^_#?XE_XO_8ZK]&?X3^SI/UW9FQZ
M?Y9O' (1] N0!_WH6_WGVDFYIVVWXS_Y?\/3B[3>'\/^K^?26F[KVE+ 5Q=9
M7[BJ+ *<!MBKR=N?]3Z;_P"W]ARZ]Q]O'Z,'?TNM]BNOQ8_/_-U%CW_OO(QV
MP?6V=@('-=NVNI<9<?ZQO>WM#+SUN%Y@6GA]+OW!:V?Q7=?D!7_/TQY.+?59
M:3>78^W]EXY0;4&UA_#;_P"M6UH_)_IQ[)KO=+V_^*XI]F.GECC7%NA;YM0_
MRX_RZ3,4G2..G$T/\0[#S9^H_P LWW4\?\DW]E_C;,/[;Q)NM4G(\E_8/\_2
MQI]T[WR*M!M7KBOHZ=02:_=2_P!UZ4#^O@MYO9G#<7L\/@[; 88>F6D1#WL*
M_+)_GTO>M]KY#;>'K8LY64%5793.97<%?]@"M-_N4!!L"!];?ZWT]CWE:RFM
MX?U_7_-T3[A*)350<  >O0A>Q/TFZF5?^Z_^0_\ B/;<?3<?4'_+_P#F][MC
MY=6Q\NN7NW5NI'OW2?K)]W_S;_Y/_P"->V_#Z<\/J-35#7_4&N/Z6O;_ (G_
M 'UO;?U!'#_5_+KS+3KC7Y&CHK?<UR4EQ< +>_\ Q/O4E[!;_/KRH7X=(>HW
MWM:E!^]WEM^CN;#_ '(T;_\ $$^RJ;?[2W_T>OY#I4EA=-^$_P _\_4=NS-E
MS<P;UP /_:U?_>K?ZWMO^M>V'_B0>JBTD_A_ETMZ7)4U;1F>G_RZEY^HY%K<
M?[S[.H;R#<?]GIAE*]2O.G]&_P!L/^*^T_373;64V.R=*V/KZ6AJJ>H4'[+A
M;V%_SP;#_6_P]UO;&'>/T9AT\EP8LJ?Y] ]7]4#"SF7K[<>0V6.2<>?]RN+/
M^M1_6_\ K^PE<<G^'FRN/!Z-H-X$0_575_(],&;PG857"*3=&P]B=@4^D$UM
M!D5QE5<?U-7S<?X'V$-WY?W C_';>.__ .:/'U_T4]&,5W:@U1V3Y'A_(=(A
M<+#BRWVFP^ZMJ3_ZG:&X/XK2_GZWJ?8>G6\V\?H07-M\_J8/\W1B;@,:,\;#
MT*D'_-_+J.<GN^#_ (#YGY#6_I7;6I<I[+?W[>_\I!_WK_9ZT%C/X8O]X_V.
ML35?8TUO%5]\5A^ESC<5C.1^1?C\'VTU[N$_#ZGHPACLQQ$?^K[>HPVKV;E^
M9L1V56@CZ[I[7I,=_C_F<;[13V5_>?VWU/\ SD_S]+$N[2RX:*?T4/\ AZZI
M>DMSU50[UU/UKB66Y/\ $15[YJK?X"LJ+>VUY)N9Q\<?Y?ZCU6'?[=/] 8_/
M '\NGV+K2FPM/?,]OC$P'^S@L9B-K"WLU_J7:V_^C_Y?\O28[O</@)^VO^8]
M--9!T#2@#,=BY_<%K\5F\JO)#_;T8M[1"';K7I0O[RGX*!]@ _P]1(ZSI-%!
MP_5V>W3:X+#9U78#_7K#_P 1[6_7;<3B#QO]7RZOX&Y#+.%_,=.L$N%F'^XO
MXS(QM;5G6Q.,^G^'_&_:,W]L_P#8[-XW_.#_ ##KRV]S;\;[]@/4.MQ&3EX@
M^.'7%-3<W-=N"F;_ &Y%./\ B/;&E9_^6=;0_G_L].J\R_\ $R1O]J?\@Z"W
M.5F!PZ^"MZPZKIJG_G2X3>=8*L?X_P"1V'^\>R/<MWMMLF^G-O\ Y1_AZM'M
M]P@\<2/]I4#_  CI5K2;0@I]N4E%L??5+O'*8,YP[4H=[5>,^VI3<#S3V!N?
M];\6]F]S"EO"?&M[GO\ ^7G_ &.F(6N6-=::1BI7SX>O74V#BF!;)]==S7L!
M_P ?C293_>Q[(Y=KL9O[9+G_ )R_['2Y;F7_ )2H_P#>"/\ G[IH.S>LIN*W
MK+N6U_\ CE;_ 'L^TT>P;'%_9P7/[1_FZ41[C>P?V+Q_L/\ T%U(I=K=/4G,
M/4W;%5S]#C+?3_8^U'T&Q0?Z!+^WJK;ING\<8^T?[(Z4$9ZRHOU=+;[-P?\
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MYRFXJS)_]:_^*>WV&[W']M;_ .K]O556Q7\;'\A_T#TW5^V>TLW3Z,FG4;P
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M[,XY.?[.2#_[TWMK]Y0>G7OIW]/Y=8O[T;;_ .=OM[_S[4O_ !7W[]YP?/\
M;U?Z-OG^P]28\[@IB+97''Z_IS-OI_AK'O?[V@].M&U<>1_9TX1UU).EJ<_>
M$6))LW^]@#\_T]NPWL SP_GTP4;K-Z_]I_WGVI^H'S_U?GU7'SZ]Z_\ :?\
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M/7OIQZ?S_P!GKWW2?T/OVL]>^G'I_/\ V>NONE_U/^\_\:]OTZU]+U[[I?\
M4_[S_P :]^IU[Z7KWW2_ZG_>?^->_4Z]]+U[[I?]3_O/_&O?J=>^EZS>3_#_
M 'GVFZOUUYJ;_5'_ )(_XU[MCY]5S\NN'FI-5KL?^G?_ !KVBS:&O6LGTZXF
M0,H\5C]+'Z>Z&]^GQT^5KQZZ\JVM45@-B+VLO]?K[40'ZKB>JD!. ZY>985-
MQ?\ '^O?_??U]^M[@W!IUYEQ7K+Y/\/]Y]O=5Z]Y/\/]Y]^Z]UCB9#:S?[<_
M[P?>OJ!_J_XOJS1XZD>?_#_>/^-^VOJ_L_U?GTUH'43SO3F^H7/XM?VK,WKT
MQ]*/7_5^WKA]P/\ CHO^\^T_A?+_ %?LZO\ 3KUSU4G^I/\ O/NGBCU/2GZ8
M_+_5^?6?R?X?[S[KU;P^O>3_  _WGVHZ;Z]Y/\/]Y]^Z]U[R?X?[S[]U[K%]
MTG]#[MX/S'^K\NO> /0=>^Y']!_R5_QKVE^I_P!7^H]:H.HGFJIQJ8?9_P!2
M0#_ON/:6>^@_U8_P=.*M/G_/K%(8Z=09Z[\GA44?\4_WKVI6X>XQTFI/QI_@
MZ1.=[1V'AU%#/EFK,C:WV.!7^+50X'YAL+^R#=.:;;;_ (<?9QZ7VNW74AJ1
M4?/ATD/](>]<J##M?8C45(05;(;\R?\ #KW-[_96X_V'L/MSC>W&+6 =&,>T
M(N;EC_M17K$V'[-R?[V=[!.WZ9>30;7VR,6/]A-6\_[Q[*Y4W"7-S<&#[/\
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MJ#_RHT%7M@?^J52!_O'M%#R:\'!+?I8=WD(_W(NQ^S_*.H?^C[/XTFVPZ_\
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MB%%%UMNBJIE +UN2%)M>EYO]/O*L"W^N/97_ *X<'_*/)T__ %?;^-1_,_R
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M[_8>ZTZWX!^?\NB^]CXK=D.6HLS1UV[*K:1H0N0Q^TLG_#*JEL/^!A_Y7?\
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M@O\ Q#>TG]:[ ?\ $G_CW^;IX;+=^2-^Q?\ /TWR=P]=D '>V#Y_Y48ZH?\
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MKG_DH3^-_J^SHRM[2X7_ '%0CY_\6>G##[RV7B8/L]B;2K<^5'+;5VUJ'/\
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M/_/U:3F!#_Q#@_U?LZQMT+AY5O6;R[(R9 MZ]PJ?]MS[5?ZV<)_MKNX/\O\
M(?\ !UIN9BO"U0?E_P 5U/A^.?6# ,U-F\F;_3);AK#_ -"V_P!Z]ZA]J]L/
M^_>D9Y@F_H_L_P!GITH^C.JL:"L.T<'657T!R$A_%_I8&_\ MO9O#R!M-O\
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M@'1A;[;=77PH?V'_ "]%:W#EMH[?SE5NCJK?NU,3D<L@.X-I5N2_R6J/%R"
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M;_8R*/L'4\8/.[?I_-#L_I;9GU_R[/;D_B=[_P!+DB_^P]L&T_=W%$L_\/\
MU5Z]]>+O_B1=M]@I_DZ;JGL3.0CQ1=O]74Q _P" &U-NUNY?K^?T@#VT=V(_
MXE";IT6ZOQM)OM)I_@/4$;\W%)_F.Q\Y5W_Y4NF[C_H;VW^_+H_V-U+_ ,XQ
M_FZ?&WVH_P"(T?\ O9_S]8SO/=P/.^=ZU/U_3TT/][!'M)/N=R_]M/=?\X^M
MBSMX?PP_DY'^0=8VW[O&/_,[ZK"/ZUO3E6/]Z;W9=]N1_HUU_P!DZ_Y1UHVM
MJWX8ORD/^0]2!W'OJE_:,^!RA!^C[,W!C#S_ *WOW]9[FW_!^P_\5TI'+ULV
M3-3_ 'FO^7K$OR)W-2?\7+:%!5\W'V&0JT_^1WM/_K@7UCPMO]7[>M_U:MSP
MN.IL'R1\U@=FX^G/'-=O5L9_Q/\ Q'M[_74GFX)_(]-/R@#_ ,23^P'_  UZ
M=U[5WKFJ>JK<+2]88K^%T.1K:X'>0W-4V_I]E#<?3_#VHDYLN;JV[?I?^<E*
M_M/2.7EVVM9Z3F<UQPH!^8'0>XK='<F\:>DJXNQ.NMKT]4"!:MI#4\_BRJ>?
M8*M+C<-[G[+HQ'YFG^7H^%EMUA_96K-]BL?\G3Z.ONU<KQ-WE0UGXM19!C_Q
M'LS_ '/?#_EH2?MCZ2"^M1CZ2GY=>'4O;,\_^1]S+5'ZF\E6/^*^UIY:O_\
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M_!_L]*#=6Y_XA#_JK_FZQ?P#?\7_  '[DR-_Z9';=.H_WF_NWU-U;_\ $O\
M.J].":U/_$/]AD/^;K#+2]CQ'U=P8_@D?\>Y3GZ?ZU_=_P!X7/\ REQ?\9_S
M=.B6U;_B'_*3_/TP5^2W#3>FL[NH:7^G^X[$2?Z_]HV]IY]S1/[;<O!_YP?Y
M.E4<-M<<+.OYM_EKTBJK,;0K+_Q7LC?V?J/J*# B_P!/^H,_[U[*I&MI_C?Z
MGHRMX;E?["V"CYG_ &.L4.)VM,1-BNL=X9X$<5^=QJK?_P [:AO][]IQ#;VX
M_P!P)#_V4?Y.E1:X/&2T7Y C_-UDJ]Y#$@10;;ZZVZ> :%=R7JK_ -?!14_T
M]W_>\UG_ &,:]6_=WU?&YFZBKOWL7(F^*PN/^WL!;'8VKN/]C-[3MO\ NH^!
M#TKAV:U_T>X_P?Y!UU_'>XUGN])7T=N-5!MRCR'^V]O-N6_'XNJSV&V ?HX_
M,CK/1;AW+-6TE)DM^YO;]357H*(9_KVEQ@J;?CR7('X_H!_3V[9ROJ\#ZHP_
MD/\ #TC:SMQ%J%K$<U/>30_9TK<Y2[JV_C_XEFNUEIJ<?ZG9U,?^)]B*YVB?
M:/UOWD?V1]%5O,DG:+1/][;_ #](P;LSP^N_=PU5-^<A_HI)I?\ ;D^RR3<[
MPGX_&_X=X0_S=&LL"T_W&I\M9K_AZXKNB:J%YNR-J'_I@S^RFQG_ !7V6F3_
M )>O^<W5/I O"U;\F/3!E(L/F!X*O>/5!!/-?0[>;&U5+_U!$B_^]^TOT]M<
MS5-U;P_\W.G$AN(QBV<_:2?\/0_Q]B=?FGHX?[]4)/U)^_Y/^Q(_WL^Y8L^;
M;&PA_M[?_G*>@LVWW+$]I_WGCT'79NZ]L9&@PTU'N;'9:#%5_P!_G<!09*PJ
M:4VM;\7A_P!X]A;FCFFSN(:?5'H]VO9[]2?\6IC'#'3;C\QAL90464V+V2:,
MWYV_G\G_ !2DY_ZS0G_8>R';-[^DAI9W72FYV2]NSWVO[,=*_#=[X05'\-W-
M]C@*\VO6T&2&3I:G\6\X%R#Q];_Z_L3V//\ 9_V-Y].G_-S_ (O_ %>713<<
ML-Q6I^1%*="5_?\ V=("3N+"TOTL%R=&WL71;UM,'ZPGB'VR=%D>SW5*:6/V
M _[/7?\ ??:W_/2[:_\ /_3>[_UCVW_E,7^73G[JW#_E%E_8?\_7#^^NV/\
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M"=W$U.9!R(%=09*K^YI:8?6C^]_K$;?GV*N7^0G2'P9O\ORQT77>^S7![?\
M)2O'IQ.S=V8__CW-]Y!@_P"JAW7C?XG_ ,5_WKVLGY-GVT_XO/\ X?\ *.F!
M?I)_;KQ\Q_Q?4.MH=_U($68V1LG>@('^7T&1&,^G]=8)_P!M[+C;;MYV]J?V
M_P"0CI0)K4CM>1?Y_P#'@>F"IQCCB?H<@6/UR5*/K_L?9)-LKS_VUI_U4_V.
MEPNH1PN_Y'_/URCP^2E!^UZ6H?\ 7KLE1K]/]>_MV':+:#^Q'3)>'\3_ +.G
M>FH-TP<T75FU:2>_!;(BUO\ 7--[,?#W7_?%MX/_ #4_V>D_^+#\;_LZFQ+V
M=#Q1;#VE]3R-P!O_ (W]TBAF_P"4"V_YRW'^?JI:P/XV_8O7,Y#M6+B;;FQ%
M_P /X^!_\;>[S336W&"R_P"RK_9ZNL%@?Q/_ +P?\O7"/,=E_C#;$_Q_W/D_
M[Q[+IIKFY_Y1O^<HZT8;8?Q?[S_L=2Y(>UY?KM[8K?Z^1J_S^/\ @,/9A]/?
MW(_W MO^<EQ_GZ<\6U3B[_L7IDJ]L[YJ?VJW:?4QX!'WOW0^O]/\F']/::3:
M)N'T]M_SD/\ GZV9+ <'<_8%Z8ZO:F;@)^^VSTI26^H6OJ_^CC[+1L;G\%E_
MO7^STM^MA_Y2+S_G%TS2[9A']GI#&#Z<-5$_[8'BW'MG]VRGX#:?SZ>\33_8
M_4'_ 'G_ #CJ33[;C_W3O#IZE^O%#CS_ -?_ &M^CK_Q.M$_WCI(9+S^&X/[
M?\W2FI<*]'=1W!@\73D6_P!P6+Q6._V'(_XGVZ;.0_\ $L?RZKXDO_*(3]NH
M_P"$=29<?M;Z9GNW/5?YXW'1XS_B?;OTVWG^WN^FO#N5^&T _*O2?E/1"DF;
M,[AW746M_P 7*KR7T^G^9'U]N?[K;/JW^[*Z]!^73G0YC;E,0VT>EZWRZ>:W
M(XNCVR+G_EM_7_'VI3>(+84M[?\ GTFGVYW-;B04]!GI2ON/MIE/@Q6U,%2'
MC_<CDZK*_P"POP#^/:^?<]RN3W^%'^W_ &>MC;=N4?KEF_WG_8Z9ZG+;P%_X
MGVMM_;U[_P"X_'XVC'(_PFM[)Y+US\%WT];[?;+_ &%J?S/2=J*_ $ Y3NS/
MU?X_W'9&D;Z_X1$?CV62[A;D]^X]&0V6X']A:#]AZ;)I^L[<;DWW6'ZB^2RU
MOZ?D?C_7]Z^JMK_X^'5FLKI?[;3_ "ZQQML P<)V.?Q>@ERX''_('O2[5M\?
MX+GCZ?[/1<8Q;G$Z?F?]CK.C[4'_  'K.W*7\_Y"<J/=1<00?V,=YT8&%SQN
M+,_;3_9ZXBJQ4))@W'W71BUN<=5C\_X6][_>LT'_ !(DZ;^E)\K3]HZSC<-?
M3>G&[\W^HM<?>]<G)?\ %#[I->7@S#/)^?518*WQ+:_DW^QT,NQLKN/,[9IJ
MS<U*M-DZA@.&&*-5QQ>UK<?3W*W+NZ&.#]?SX8Z#&YVZVS47R_ET6[OB(T&X
M36;JRN>QFUJK'XR@P&<P=?\ PNEIJG_IL'^-K^P%S3%-?75?]!Z$&S&EO04J
M.(/&G55'=<^^L$U34#)'?>);T^&L.K(BW'XO]?\ ;>S;;[RZAB[8=72&ZVQ6
M_ML=6>=8X>HRO6W6]53]!8*0S[*V?6-79S<G_ P?:TX\]C]-5KV_Q]A&2%[G
MOAVVOSS_ )^G(#!;$PF](R< #'\NA5I=N[@C4SP=%==TP'%SN;_I(?[U[0/M
M[P?\1(?Y_P"?JDU_;^=Y/^P?YNE&F5W?@Z=IZCH;9_\ D@Y-!749M<#_ %_\
M/K[<FWZYY:_W-VV/\^DHVZWOSVWC=,^7W<O;.TMV;;VWA:S ;DQ;8ZOK* Z2
M:JF^[-X%FA :]C?ZGB_T%_:B[>'FZPI9)TTK?N6Y5GN*C.?0TXY_P_/IOVS@
MNN=R4Y&U=Q;LV%N&F#+7;?H-Q#%U--4D 6^SG-C<W_(_I;V&]FV#:KJ;3-?&
MTF_+_#CK=Y=W<P\8JKJ?E4$="7%C>]]KKY\+N7![_P 9R?L,]CSC*KU?UEB^
MO^ /^V]CNN^;9_Q(^IST7%K&]XJ4/J#C^?\ EZD?Z8\]B;T^]^K=UXSTV;(8
M+_?S4X_I8BP _P!O?V8P>XD\7^YEOTG/+RW68W!^1Q_@_P W3S3_ ""ZRJ 5
MJ=QOC)K_ $R&-K,9]?\ "_\ Q)]F4'N;8#IMN5+L9I7[*?Y:=.,7>O5%N=]X
M,'^U:,C_ %OS[,/Z^[5_O\_LZ9.P7G\/\^N4OR!ZHB^N[J-C^+1>V?\ 7(VK
M_?YZU_5N[_A'[>F1OD/U\_&%HMW[A8GZX3;E5E;?[#5_K>R^;W0VKS\7_!_A
MKTH_JU=^>D?GU"J.YMSY :-O=1;NGT_1\XW]V#_O1_WOV6R^Z)_T"#JXY?0?
M%(/RH>DM7]C]JMI6>MZFV73*+VS6Y?XH?]B;G\_[[Z>R&X]S=SN?^4*'_J(Z
M60;+$.'B,?D*?YND'/OBJE!_C/R"HUXN,?L3;C6-[?7E?9 >9YYYO^2E_@_S
M='2[6*8LN'\1?_(3TTK7;&R'IK=W]T[J7^F/2J%O]>[>V)I5W0_KSR3?SZ<$
MEQ9_"J+UE^PZJ%Q_HX[:RMA]*_'U7^QO:I'^]>VAMVU1_P!M:7'^#IKZZ\N?
M^)2#[#7_ "#IR^RZ=\'_ #*#?]M7U_N_5^[_ $NVT_W$N?\ 5_M^M?735_W+
M3_5^?4":/H\$^39_9>!^GUHLJ/K_ +!N#[OX6S)QM+E/]7_-0=-'QY^%TC?R
M_P _6>ERG75)4?[][NO?NU+ V.>3_)3_ .=5/<>]B6V@_6@W+P>E/T5T<-9J
M?LZ5N/W=OR@U2X/MSJO>E(+?Y!GM.)J3_A^U8_[U_7V90\[7NWYM[^UF_:?\
M/16=IC<TGCG6OI2G2J@[8W] A&2ZN_BM.QL*_9^X:3*C_8CZ_P"\CV?#W3N8
M?]R;>+_:U_S]--L5K<']!R*?[_Z=3WOMM5(S6$WI@N+@9';]8O\ O'/_ !']
M?9I;^[NUI_;HW[:],/R;)<CLN(?]7Y'IX3OOJT<KN.2D-S_P/QM6_P!/]<?\
M3[-![J;5P^H/[!TR>4[P?A!_VQ_R]>G^0?5D8NVXWJO^U=C*M/\ B/;,WNMM
M0X3_ ,AUH<J7A'PC\STQ57R#V_(1_ ]M[LRH": #C?X73 ?Z]R3_ +$>T4WN
MU;_Z#W_LZ>7E*X_$0/VGI/Y'MKL*K6^/VAM':ZD6-;NS>-$_TM^( /\ >;^R
M27W3W"ZQ EL/^:TO_%=.+RJT>6A8_P"E4_Y.DW5;GW)-'X\[WUL?;]*+D4.U
M:*FE//UY-S_MS[)KSF*ZW'^VW*VMO^;G^;I4FV.GPV;-7UK_ )3TGJ@]*RU/
MFW#VENW=<]OU?Q&K%-Q^"(@?][]H=5M_Q,O_ !L^D?2H17?X8POYYZE4.2Z/
MI3; =;9S<%3>W&SJW+?[Q6@'V:6:6=O_ &-K_J_;TTVV3-\5T /]-_L#I02X
MC>N\J>KQVW^HMJ[*Q=6/X?\ QS=<=']T;?G[2!=5_P#6_P!A?VH7:+SFK-M:
M^##]O26:9-NQ'=%F^5?^*_;T/..ZOVS%M'#;2S=%C]P0X:@-%>M:QYY_%V'^
MQ''X]R'9\CV5O9>#/W]!U]S<R%E[:GI!3='T^-+3]>[SSFR:H^K^'T.2.5I+
M?XTDUN1_L?8=;VOA@F\>RG_P5_E7I9!N^H:9%!^9'4.2/O7"U.BHI=B]@0N+
MZER(VW5?[T1?_8'VU+L^_P"U'QIOUOS_ -GI9XFUWHH-2_E7_..L4_8.Z([#
M<'2>Z/QS1Q4F5/\ M[#V4R[X_P#Q-L)?\'^3JWT]M^"11]M?\XZ;Y>S]J_\
M*1U-N87^A79(7_>B/=!NEG_OBX_[)NGA8N/QC_>A_FZX1]E;88_Y!T]OF_\
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M;B\' _D /\O3HO=74>%/V5%N*A"#C[' 8NW]/^.)O_MC_L?;HYTL-L_L:_\
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M^/75E-/Y:.DS#5'_ (<0_/\ AI'^^Y]V7VWV\XG+?L'3,W->X'_?7[#TH?\
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M:/8V3M]3C]G50^O^/'/MY>=/^4?ZG_G&/]GI//L94=Y0?G_Q73G3=F[ID_X
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M?HMM86M!0VU<U].I-'O7/T0$4>5V/NFG87M0;B_AI_V/E)^O^Q]HI;_P_/\
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MF_N\6X6P_L(/^J/3_P!#<CB__5;_ &.H\1VK+S2]6YVI ^I&S+_7_7M[O]5
M/^(DG^K\STF <<;H?[U_Q74ZEAGEO_"^GP0./]R I,9_MK 7Y]OZIO\ 0;4]
M6\8>=W_AZ=4'8%)3\T>T]ET_U!-LB3_A_J?]]_C[UX5Q'_OO_G+_ ,6>D_\
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M!4'[5ITH8MY;^JM@?Q<49RV97('[$#'?PS[FE_YV?@_XGV)3N4ES8?I?ZO\
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M?]<>U@]NX_\ 1]S'\^DYY@@_#9_M/_%]9TZ(VA(OFSVY]]Y[_4_?[NK" /\
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ME63_ )2?^J_1/-NV[VW\/\NGBGVA\9(_\UN\_P"QW)_V#]F\/)/)MQ_Q(/\
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M!]4*%M-#4^?^K\NAN]R)T5= #V%VK0;&SHP57AS6J,>M<6H\E_"R=7//^O\
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M_P!OP/8>N+'F:W^ -^W_ #]+H+GE]Q^N*?;U ,??%/\ \76IWP0> ,+D-O\
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M*Y^?;F#^VM;C_LI/2A-MMFP+H5^0ITQTW<68SD_@PO7%=E;?3[#(4G^2D?\
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MK4Y^IKMQ!?I_7[(K]/9S!8WE?T;#P?\ FXG^7HMFFB_%*6_('_)TYC%?(;(
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MP7^Z-L4(^G+8ZB//^W]F Y?L+C_BNF_JK@<2?]Z/^?J?%$8.:;'_ &'^-_\
MB/\ ??GVL-G]-UK46'KU-LO^KO\ ZX]U@EG/_$?K>.->L9E-S<"W(Y;\_P"%
M_=Q<0G^WZ;-Q\NL']+LH'Y%C_P ;]WA$'_*1_+IXV_R_GUAEL3?@7_H+_2_^
M]W]J)YIIO[']:G3(_P 3X]-V9RV(P6/^]S57C\5CJ0^BOR UDVYL./\ B/\
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M/^\@C_>?8GM+ZPM^%OT5M979XN#_ +8C_!T_#MS9L%A)A-U8CB_^Y#956/\
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MBVX@/KS^&'LJFY _WS?];7F?^)5)^P_Y^F>HZF[5Q(/\ [;K:NUO^![?6_\
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MT_PU>_#DS:I_^(O^'_-UL[M=CA=?X/\ /TP5?2?4]6 :?:5'3'^M _\ "O\
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M>BD[N'_/KJ$C^@JN;_ZU_;PGWW_5C_)U6E@/XCUP:'NACQN/K&F/ ]./J?\
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MF*VSMK"_M8[;U!B[V]5#C=7U_P!C[.[2WMK'I$;JX;S_ &]*.)JF 6)'^O\
M[X>UO@?+_!TE$/V_RZSPO4"WJ M^?K]?]A[]6O6OH1_JIUSM5_X_\DC_ (I[
M<T_,=-_3_/\ P=3(I7^G']/]]?VY],.F1'7U_E_GZETGW(^OT%_J2/Z_B_\
MC[,(K+ICP0O3W"S?FLL+7N&O_P 1;VL3;4_WQT63O#_J/4C3Y3=K*?\ '%_\
M2=/M=#9P_@_U9Z1LU/[#_#U,%!2@_P"3T>,)/)OBR?\ ??GV:V&T/TFN&F_U
M'IQ\LUO!JL1QJU#_ %O9W9V#V\W#I(8IJ:JC[<?X>I,,X M_0_7^G_&O]A_L
M/>IA,)OUKCKP \AUG#5,-,5!%Q>PN?Q_CQ_O7NTTD/$]-+;@X_S]0JG<6(I2
M9Z[,X&EXL+9/Z#V@_?-E;_\ $BV_GT\MJS8"O^P?Y:=)Z??NP(U!J=W[2N#<
M 5]$?][4^V)^:=IM_P#1X_\ 5]G5DVF[/X6_GTSR]M]4T@(GWA@6_IZ&_'T^
MG_%/I[)WYIV2X^,1].0;/>'^P!'4)NZ>L@/V-RT=5;Z&U:IY_P!<GV\.<=I@
M_L1T^-@O"/\ BNL3]W=<0<KF<F00/^796'_HH>VYO<+:>M#EZ\/&G\NHO^G;
MK;_G:UW_ *#-=_Q7W3_7*LOG_+_/UK^KLOH/]Z/^;KK_ $[]:'Z;D8?X?PJL
M8?[P_MJ7W%L!TH_JM=_ZCUFF[PZSFN/[X4%N;WQ.HC_;@^T\/N)M7^__ .7_
M !73@Y8NQY?\:_V.L.2[.ZJSU.M%*?[P */\A_NU694C_DJ_NMQS%L>Y_P#$
M?QO]7VCJUOM5[9<#0>M:?X1T%62JJ_!STL^QJ3=NR]FY6M^PSU?G,7_DM+39
M0_\  RB\_$/^\>PO=S?N?]>"PEC@FX=*&'B]LC*SC- ?,>1_U?ET*F,PO4^/
M_P MGR^W\OD;EAD,_N?^*51^GXE'U_U_8CVS;>78/UDN.B^26^8TA4C\L=+!
M=\]>X^#T[PVE2FXN5KZ1?]>^KV(FYAY?V_X)_P"0Z2#;-SD_MU;^?^6G2?J^
M].N*4 3[MH*NW _AZ_Q3_>2 ?]X]D]Q[F;5_H,Y_P]/V^PW7\/\ .G3'-WYA
M";X#;N^<]5'B^/VV!_O0'M/%[E>.?T/V]*UY=;\>D?M/^$=-O^D_L_(#_<-T
M_6&E_!S^0;&CG_8CWZ;G'>+CX-M_8.K'8MM'^Y%YUFCS'R%R*C7MO8^ I3;G
M(5M_]L.?K_K>R[Z[F6Z_L?\ -T]]-M,7$L?G2O\ @ZE+M[ORL_X$;[VEBA]+
M4%$#]/\ 8?\ $^S(6',=P?UKC^8_ZU](S=V"\$8_;7_+UFBV)V:]OONXJX7'
M_+NV[2&W'Y^GMZ'D3=MRP^Y2'_>.O'=[116"SZ['6^[/]W=Q;]_V'V9_WJ2_
MM6>1=S\]R_P]7&[)Y6:]3AU=N&;_ #':N^C_ -/*0?[R3[U_4>__ .4O^75?
MW_ .-H/VG_H'J(W6F^HA_D7<6[$/)/WV.I0/]Y(_K[33<IWP/^Y?5AOUN>-H
M/RS_ )NH@VGW/2C_ '%]H82K!X_W/[?4?[V3[3P[3O-M_8W&O_FM7_-UIK[:
MVXQD?Z4C_(>LRY;O/$$FNVWM'=E+QS@LC_":H7_ *VM?VK6XYIM\/!;_ &?Z
MDZI-;[>]? 9A\R#3^?627N"NH.-V]<;LV_IX^_7'_P 5I?\ ;16_ _U_>_Z[
M3[5_N98=-#85O?@D!_//^'I\P?<>P,L/VMQT5)4_3^'9 ?P@#G^O//\ K^UT
M7N!87F3/&G5&Y9NK3RK_ *OGT(M#6X_**10U>-JC>^G'Y6_^\$_\3[$=G=P;
MK_8W$?1:RFRX@C[17IKK=J;8R/\ Q=<-0U-K$_Q#&T*?X_BW^]>VY=GLJ_K0
M=;69UX$_M)_R=)"3J;KN46AVECZ6]P/L\I6XG_>2H]E\W)>V'_B/_J_GTJ7>
M)1^,_F ?\%.N9Z?VRO[,5?NRD/UM0[AJQ_O(%@/95+R)MESY=*/WS(/-?S%/
M\O3%7]![/KEO55F[ZDD#Z9-;<?XFWU_UO:$^U=A>'NN/Y=/Q<RW-I_8A?V],
M,GQJVE!S1Y?<%(+?\O$4>3_K_0GGV0W'M;8'_B1_J_;T;6_.-T>*C^8_R=(3
M)TM-L;*T>,V[N38>XZJKKL=06KMD40_A?\3^E9-6TG'/^OQ[#D-S#RY_B>VW
M$5Y\_P#KU7I@2G<1K=67C2A.:?(G_#T/.W^ML-2_:Y3,E=V[AM<Y[<!*C\_Y
MF"Y,/X_'^/T^DL;#R9;;?^M/W_\ 5GHBEW&X;M7M \AQ_P '2NRNX,+AZ<29
M++X_#P$#TU^4)_XC_B?];V<7>Y;?LG2--NN;LX!K\@!T&F1[ZZSQ2^!=Q&JJ
M?ZX_$A?]O_QH^PO<^Z>U6'D9O]7V]'UORC>.<@#\_P#8Z2%1\F-JZ#38[#9S
M+7Y]>.!^G^O_ +T?8?F]TXI_[&#I>O)I'$CK!3][5M>?\CZKW76'ZW+$_P#&
MO;R\]3?\H@Z?AY9 _P")74Z+M?=4LX\/3VZK66XL;?[U[O;<[3?\HO\ AZO/
ML2#C=@?LZ])VGN-?\[U)O<\6_63_ +;GV:Q<W7H_XCR?SZ8&T1MP=3^S_/UB
MD[HQ=(H&6VAO?%&]AJVWI_Q_'_%/=)^=1#_;P'\NED>QM3L*GKE'W;U[5>F3
M+U])QS_$,8/Q_K>U-I[@V ]>M'8KKY=.4'8FRJ\VH=V8+_6_B1'/^Q/M9#SI
MMT__ !(ZJVUNOX3THXLYB*N#3%D\%56YM09.P_W@^S.*YL_[:HZ:^C;@5(ZS
M>4SM>F%O3:_^^_Q/]?:C_<CJ_ ]1I8IX1ZC=2US_ +#_ (W[5"+Z?I3;YX]0
M98YPQY%Q]#]!R/:6+RZ6 UZ@2,MN*6,_ZYM[?-P_I_@ZL#-\OY]1IOM]/[.B
M^H6T>ZGQ?E_J^SI[KTOGMZ1;_4W^O^Q_P]Z^KB^?2FG4;RU47+*K?D6X^G^]
M^Z_HS^O7CUW)43H.!<W_ +1(_P")'M*;VTM^G? U_P"K_9Z:I]P8BEO]WE:*
MD^E_]R>G_B1[:-]:0<>K_1EN /\ J_9TPOOG @?Y-4U^3)^HH<?5Y/\ 3_L#
M[9/,=I!Q/Y\>GQ:-Y"GY@?Y.N)W2'_X [3W14?CU8\8SZ_TN/:+^L,UU_90,
M?LZN=OT\6B'VFO\ AZ]_>#/2_P# 78];Q]/O<G2)_O=_:F+<KP?V'^?_ "=-
MB!3\1_9C_*>DM6;5W#FJ\UD&*H]L55S]_7T.2JO\I_K:P46Y_/LCO[*^WK^V
M_P O^4GI9;7%O9>9/[,?LIUZ'KW,K_G<M@ZO_&NQRY,<_3ZD>V[?EFXC_1\?
M_5^SK<^YP7.0I_E_EZ4=-A]XTE/XH-P4=)3GZ?8;;'^Q_/L\M-IN+'_1Y/\
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M?9>G/>W</'_YP_+ID;%)J) \SQ^WH3G[HZ[BY7=M"OT_LUO_ !7WY_<':_\
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M'IK*GZ?ZU/[-(?=+;+?S/\NDYY<O3_H!_P![_P!GK')\G>A(?IO;JJJ_%_\
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M -_+^T_Y^FZGIJK\)19F'QY+$465I1Q:N*K]?]=6/^\^TEUL\,O]O#&?V?Y
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MVRBK ^MF-O\ >3_7V=1;E!<9/2.X!QU/Y_/U]O&&O]AC[/\ 9ZOU[W3Z>?\
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MNTEA80'_ !F8G[6D_P"M@Z:.Y27(_P 6A(_YLI_E3ID_T9]/?I.'P%14$_\
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M/]T>WF'H[1QDW^-3LS'_ .M_:B?Z>S"VVC=!_P 2A_J_+HLGFM/^48_[T?\
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M]YG8_C^OM0OMQ:2&NA?!]/J9Z?\ 'Z],/O%W,*ZB3ZZ4_P W4:/I+J"']_\
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M_"?]Z_Z&Z@5&%[/_ -T[TI1_Y+5.?_C<^TGT>Z_\I!_8/\W2P3VO\)_WIO\
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MRCINDS_85:=5!B:F@I[<BLAIS_T/ Q_WGVF.Z[A/B&%_V)_T#T\+*T_W\O\
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MR@4J!Z_#TX4F1Q- /-/U'D7^@NY'_710/K[?M[V>T_T _L7_ *!Z;N+(7/\
MQ)'\_P#/THX=]FF4BAZ]W!2"_*C%I_C;^P?Z^S'^LBV__$$C_>/^@>BP[1,V
M#<C^?^?J?)VK71W\>SL_"/H15Z6^GUY=7]MCG)O.%O\ C/\ T#UX\OI_O]1^
MW_H+J/'V76R@3(^-H1^!5UK_ .'^JQY_WGWJWYQOC_Q!;_C'_6GI-/LJ>4X_
M*O\ T%UPR'9>XJ;&BL@R&V)S2D@4:9T$K_K:L61_O'^'MZXYFG)^)O\ C/\
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MD'"W3^?^?JPW!CQ\7]K_ .?KI<70D_N8C%"WY;'47TM_K>[S<MV?]C%##]@
M_P W5S?GB/%_WI_^@NNOX1B_^=/B+?7_ (ME%]/]M[I_5JS_ +']#JOU;>DO
M[6_Z"ZD_P7&CC^#X@6_ZMU$/;4W+]E_OE?\ LF_V.O?6-Z2_[T_^?KO^"XT\
M?P?#DV_YUU$/=8=DLS_H0_[(1_T#ULW;?\-_WIO\_77\&QG_ #J<-_YP4/M1
M^YMK_H_]D/\ L=>^J?TE_P!Z?_/U&?%XM3SB<1=?[7\/HKF_M[^K]E<>2_\
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M^UO^@NN_X1C/^=1AO_/=0^V_W-MG]'_LFZ]]2WI+_O3_ .?KO^#XW_G3X?\
M\]M#[?\ W)MG]'_LF/6OJ7])?]Z?_/UW_ L3_P Z;#?^<-'[I_5[:_\ E'3_
M (U_GZU^\&_X;_O3?]!=>;"8J/\ 3A\./K?3CJ+W7]Q;9!_H"_\ .+J_U;-_
MOW_>F_S]=?P7#_\ .KV[_P">_'_\4]O?N;;/Z/\ V3=,?5'TE_WI_P#/UW_"
M,3_SIL5_Y[:/VU_5_;/6#_G&.K?6-Z2?M;_/UD_@V*_YT^&_\]U#[5_U:VOT
M@_U?GU;ZMO27_>F_Z"ZD_P "Q7_.HP__ )[Z/W[^KFU>B?\ 9,>F/JW])?\
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M/B/_ #UT/_%/;_[FVWU7_LGZ]]7_ $9?]Z;_ *"ZX?P7$_\ .KVW_P"<./\
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M@A-4*4G_ !_-[_U%O9==[-?0?K0YZ6K=6V1D?/'3G+N?*TMQF=N5],=(/W]
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MWO5?[QQ[N.33_P I%UU;]YD?A@_8/\_6/_1#M+_E8W-_Z&M5_P 4]J?ZD_\
M#Y>M_O,^D/\ O(_S]9CUAAJ?_@'FMZTGXMCMRU8_Q_WW/M..1_\ E[;_ %?E
MTZVXL.-M!^S_ (OK*O7F21?\B[![-HV^ECE:+)CG_6<_X^]#D_P>&Y2=,'=Q
M3NM$_F/\/7!]E;NBYI^R\\PYO_$,=2#_ (D\?[;W0[5>VV/WG<]*%WE&_P"(
M@_(GICW!MKM4XG,0XSL4Y:J^Q_R"@..&+-C^?->]^/:3=-EWR?\ L;C_  ]/
M6=W95!,=/GC_ #GI*[9SVU-GTXAS/7>>VMD>?OL_7;<_B_U_ZN4-K'_;_P"'
MLLMMSL=JQ>V__-[ATON+>XOS5'!'H#_DZ7S=K[!D_3N&A8$C_@?]X?K_ *Y'
ML[LN<]J_T+IH\NW2^1_*G4:I[.V"HLV[J(<_IH$'X_PY'^^_I[6?UKL(C^M^
MMUH;)=0# I]M/]GIJD[.V$Q).Y#5'C_@#C:M;_[$'WZ;G7;QTK&R71\OVD=-
MY[.V4O\ F!G*L\B]#MVL7Z_ZQ/MN3G6V/^C]++?9+@>0_;U@D[+VB>31;N'X
MXV_6?\4]IOZVVW^__P#!TJ_<USY ?[T>L<G9.SE-I5K:,_G[_&5G_%;^VOZV
MVA_T<_RZ4?N2_' #^77F[!V5+8C<9I3_ $^A_P!ZM[40<QVT_P#H_6SL]P,Z
M:]<CO':,UQ!N3' _C_<E;_B?^)]K(=UL?GUL[?<^G\NLD68Q,@_9S..JP. #
MD_Z_\4]K8KE+C_1_]7[.J?3W \OY?YNI:3XZ;_@&>?J"MQ]/;AEI_H_3RGU'
M7I//;TG^NGVW%X4_2CAPZB%#"#Y&&H\\7L/]];VZ\Y\^MV\&.HLDD' )4CZ_
MD^[-XO\ O_I97U'27KL-A\J :NDH:OFP(_WW];_GVS<;/XW'I5;W-.F.39F*
MBXH:JMQEQ<K0Y*P_/^O[+H^6_I^E\.XD^A_+K$V JXP/%N?.G_#R7_Z*_P!;
M\>T_[G8?\2NGCN2^=N.HXVY7#@;KS-6/SI^T'_$>VSM9_P!_G_5^?55O0/PC
M\O\ BNI/]TA_N[<.;/\ Y$[?[V/>SMI_W_\ ZOV]:^MT\!_J_9UCDVGC1S+E
M-P6_K_% /^)]Z_<*_P"__P"73B[A-Y+_ (.N#;3B/_ /<&<(Y^M>#_Q/^^_/
MNPV%_P#?_P#/ILWTO$J/V=%J^7=/FZ+XW=UP?Q6DRM*=@;C;_+,;I-_*%;_>
MS^/K_K7]VN+*[MXS6:HJ/7U^SH1\DW"_O2WQ0YI0^=/MZUW>K.^>P=B=8[OZ
M=ZN@R-+E^VLK0P5^;P-_XH:;[?Q?PW%(.?/57Y'Y^GT^H?BN9[:)@QXT!'D:
M$\?EGK+CF;E2RW"]M[W=*^!#4CU\O\W'H\7\J+(=*8[L+>V-W5CZ&#ML4>O9
M>8S/^:&,Y_B%-C_^57(%3_E#?B"_X)/M=MNXM&Q=>)%!Q^+_ (KA\J^?49>^
M]E>WD%O>V%?H:_*G#''R_G6GE7JX'OGN_'=*]+=@=F*J9^MVSC*],/1TE?Q/
MD6_R3'J0/]2+WY]B2]W6*56?S-!7^7[ .L>-FY6/-%[;V0P*U./+B?S)ZI,Z
M;Z-[A^<%%N/M[LWY'9'9SQ9>LP&W*>HK:AVJ*BC!:8+0QUM**#'T@^OAX%Q8
M>R"$FZ#,7 X$EJ$_ZJ?EUD!S-N5G[>S6]C!M_C>H Q_LG\Z]&*^!GR4[*P';
M>[/BSW1GJ[?=1@3G*39.96N.?J%JMCW,E,M23_E5)/2*1")_\+6]JANYMB8;
MC]0'%.-#\OE_+H->Y7(<#V-ON=C^CJH3C34'Y8H<YQ7\Z=%.WGO+OO<7S4[(
MZ\ZMWEN?![@WMO/<&P\)356;J8J3&P91"M34&,?\!5IJ4\V%@/:=EN;N4+!,
M:UI@Y.:4J>AMMG+6S;=RZ+V^AK11-6@I4+QQ^WJQ?H;XC_(?XR[([RRU)V50
M]D;ZW%AL:G7^%GS>22@:9VL34KE%0>FJ M?\BWLQ7:[N0%!<C(H=)XY^P=1;
MS-[@[)SE/;PP[?\ 2QPDU)&12OH>BBT_P@[LW?0YS?\ \J_E%)U5NJ6KKS1'
M*[I7.QU5):YJ_*,I04\=*3Q>Y/UXO8%B7;KMS66<4Q\623]N>A-<<\;;8_H[
M+8''&@X?+UK^7V]<?Y=^_NP-Y;U[7Z!S>^<QFMO2;!W<-KY:KKJJN%#4T=1]
MD*NFDD_RD4M1<U-A:_%_Z>T^W;==7<G]OQXTX<*]&GN?MT5G8V^ZPV_@Y'13
M#\?MZ4WRZJOCU_I)K_[YC>;X+_27:I\_W*XS[CR_\K7U]'LO>Q,ESX>*UI3-
M/B_;_*O4@V7.D-SRZ;[Z<^#Q\J\.'&E?SI\Z='2^>VT=W]%_'7XS;1_O[F<A
MN/!UN6V]EMQTF:J:*JR0^R4B5P9KZ=+ #_ >UF\6:+#'2G GU S_ ).HM]IS
M9\U7VXF:$D&E!05P/L\\<>A=^24F4Q_\NSJW>=!G<[C]QU&#Z;JZW/4E=4FK
M/WM&GD!E^GIL+"_MV_V\K;@",&K''VUZ).0XX;KFCZ*:&J4\N.".BV?'OXX_
M(+Y<]-XK)YGO?<&T]B;4K:W$;,Q<%=4U\M?4T0)J:ROG^^](%_#>Q_H/\=[1
ML\LL#,*1C/'A7& *?9T+N>]TV7D3=?IX8,X]*TJ:5_GT_P#\O3?O9N$[]W'\
M=]X;YR^1VQBQO!VHJG.5-:,=7[%K"LK4@D-@DFEOI];^TVW12&Z6+5IJ:'TR
M/]CI+[B6>V7&RG>H+<$CS^5?\Q_;TC-R]@=]_.[OO/=,=9[YRVV.J,359UU:
M2LJ:"E&*VY.:<93))0 U-75U+C_)H=)-^!Q[?VV&^W%Q$D_$XJ33_+_EXT'2
MV+:=DY$VS]Z;I;B6;&!2IQ6@K3J-VQUE\DOY=FX]M[SVQVMD]X;4W+5G$U2R
MUE1]O]PMP:#(X^KEJ+FI!_9F(((-P?>MQM;_ &F-98Y])(-"OIY^F//I3RSN
M6S>ZGU$)MPE,T(&#ZCH[7R<^9>Y=H_%[K/M3KVO-'G>\J*FH-LBHH@/X2(*<
M3Y&13;F6F:W@/X%S]>?;UXM[:VZ35P2:_P"U_P!DCJ..3N3K?>-TN()A_8?/
M^+A_@S7S]>BB[-^!GR&[@ZH7O+-=W[B3L#<F&.]\!M-\QD7>JIJ^]33M+7&<
MB.KJK$B]-S_7ZVI^[+[<8#)XH^5<L?GT+MTYYV;:+X6,,!\'_1* 4'I_J'_%
M&!ZPZN^6F^?BUW!L;N6BWOL7=E)B::OZJW/7[@?&Y.IJ<>PJ8Z2J%).+\,81
M<#S&?BY'N]ILEU!&U9?F%/#&32H\Q_,]$?,^^\OC>K::Q_L:@3T.:'%?VY/R
M!ZZ_E;]EYG?VWNQ.J-Y;CW1F]P[3RF/W1A?XYGZH2B"M/AECL"+?:U[*?Q^?
M:.WL/KM35H0, >H_;QQUOWDL8K::WOH(*0S8-1@= 5U_D-Q?*'^87EJ;";EW
M1'U?LG/5M=5TU)FZJ6$8GK4?;Q'5<-_N4K% _%BUOK[;AM3<3FA%*DU^1_V/
M\/0CWJ.SY6Y1@\:"EU-_J^5>BN]R]&[OV7\NL9TM7;\J\QNG.9[9JTN^_P#*
M//!_?A5:D/)^Y_R(./\ 8^TMSMD,-P58@GAYT/#Y?//4G\F\XV6Y<NFXAMB(
M8<TQY?G3-/7AZ=6+_(OL;L3X+_%S9G4-#OB+=7:V[MP;B@._ZV^0GIL>:A:B
MIJ%^ZY\Q:0TT/ XO8\\"!Q':Q^'%/WMDZ?3R\O/UX\>H0Y-V6#GS>_KC;GZ*
M"GZ)Q4^F/3]F>BS/\1^V8.H*7Y"'Y1U\?:9VX.SSM(;JJ?)R?NO'_$/OK_Q$
M1>JWVHA_.KVG'B*NI+A?6GXO3]O_ !5>AC<\U6ESO9V6#;R(*^!6G^K'^KAU
M8Y_+Z^5F3[^ZJS2=A5]&^_-E56-Q69R,C#'FII<C3&2@J2;6,RD6^GT/]?;]
MON4;DK)<D<:?X/Y'J)_<SV_/*VZ4@M_MX8-<C\^C]QY;$5%/9<W0@?X90?[V
M1[62[[;)^/\ ET OI;BWX6_4CSX=^)ZS''_ &_U_US?VS^\$N/\ 0.K:9U\_
M\'^?IGFP>T*J\T]'@B"?JI_VW^'^\>TS6]OY=.Q7%P/7I,Y&GI\/-X<7E<]4
MU]5?[*@H,E_$;6^EQ,![03=G^X_2H'ZD?XP,>?EU.H*;>LEC6UE!2V'%\=_%
M:G_>![I;Q;G<=4G^F'^K'3K_  3*U8\62W%7>#^E%C#BR?\ 7:W^\>SR+8;O
M_?\ C\O\'2$W:\0/\/3[2[4P5+:H:C^[F(O]_7#^*?[$^]V^RRP?VO\ AZ2S
M[@3Y]/L<0CU?8_Y%8D -Q_O%O:Z$PP?V4'18:GB>G:EDR##_ (&+_4V4?X^U
M?UL0\Y/V],:*^G\NI\?W\HYK!]?[*V_WW^W]L^-%Y>)TSIT^G6?7+_RLX_\
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MX.N:;L[FJ0/M-I>DFP/]V;#^G]/:R'>.9[C_ $GRZN;6R3B?Y_[/3G3Y+Y!
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M]F4/(,W^C78Z2'F +\%H.G*/IC9X_P Z<[E1^37[EJU'U_Q'_$^UR<C6L?\
MJ/3,N]7-SY ?LZ=:;JOKJ@7]G:> 0C\US_Q7_>"#[.[/EC;[/_0*]:;?+N+\
M1'Y4_P ->EI08K"8ZG\-#1X^DIEO<X_%'Z<^S7Z" _ZO]GI";LDUK7[2?\G3
MO*Q*BY_/^ _!]U@VR#K5:?/J!)C\;+?[FBQM_P"H-O\ >.#[]-M\)Z<U$>9_
METRU.T-H58_RS;. JR+7_P!Q]$?K_L?99^Y+.Y.8(^GA>NO G\R?\O2=J>J^
MNIA_QZ%%2?B]$/X7]?\ D(6_V'M+-R=MES_;_P O]1Z?7<)5&&K]HK_@ITUK
MU-M< _PZOW9MUCS?'[EJ[?[:W_$^TG]3;:#^PZO^\KH\:'IFJNJMY:;;>[AW
M534__.OKGH\J/\?HQ'LFN^3K_P#T'<NEB[];CX[05]1U%IM@]O4HU)V\_P#2
MU;MXCZ?UO[K%L6]V^/J^J_O*R?\ XBC^?^;I0?;]NX:+]C+;4WB+"V/R&,_N
MQ5&_YMQ;_?6]F,$.^6@Q_C'^'I&6L;HTHT7S&1_EZ@Y/MO([?%+3;HV)GL74
M5.JAQXO29*E%2?I^_P#7\#\\^T]WST=H^.WN?]GI1'LHF_W'93YX)!I^1ZF4
MVZ>Q<^/]^YL[ 8BD_-?GMR<7_P 8:*WT_P!;WN'G*]WS^Q^FZ::PCL?C+'Y!
M<?X#USEVGV/5QJ<UV*,8@!TT&U=NT>+X/]#6\G_>?9@NT7]Y_;7'@_\ - ?\
M5U0;C:VGPI7_ $[?YJ]<H^IL567.6W%OS<%3]?\ +MS!@ /\8A[4?U-\?XYY
M>M?OXK_N.J ?(?\ %#KF.G=@,+G#Y"K4?7^(;FK$^G_()]M?U-VF/JPW^\N/
M,?LZR?Z(>OR+KM*AJQ>W&1K?^*>WOZD6739WZ0\&I^0Z>\?USLBB_>IMGX*E
M(YM)CKG^O-BOM=8<G[>OZ_Z7\_\ 9ZK<;K=7!I4_RZ6D<-/1TOV],?LJ,WN;
MWO;V?06?@=%]:FIZF>Z:QU?4?3J(S>"Q%N 0+&UN1_K^]Q/UNX-1US]O_4'Y
M?ZOSZ1=8ZA6]9NO]GD#_ %O;(G'_ "C]*@/GUR_UR.?]A[<N)I[G_B/^P=.@
M >?7O\H_VG_D[VU^C\_Y=;Z].S7MZ>!]3S:__$^W1<F#/2#Z;_5_J'7("R_G
M]3?7_8>[VL_U(Z<NNH)"\U$^0L+'@@ <_P!1_L??GO7MSCCU: 7!\NFVIW7M
MR@(,^YL#2BUS_N1HQ_O!4'Z^R*?FVPMO[:>V_ETK6PN9> 8_;J_R]-3=A=>1
MV,V\=I_^?"D7_>Q[1_ULV?\ Y2S^SI3^X]R_Y16_:?\ /TV5'9O7)-AOW:A_
MX+7V_P!Z]T'-NS)QNH_V=/+M6YV__$4]8)>SNKXA8;\PM^;WK_\ D?MF;G:P
M_P!_VW_.3J_T-WQTG_+T&>_=Z;(W'AUH<1N*MJMQ4E?C:_ KM_&5N2JA58L6
MA/\ KDW/_&_8.YDYLMMQ/^+_ *TW_">E-K87,/\ ;@!<UK@9ZF4N\>SHZ>D&
M=ZQKJJI-#:M>BW%2-_L+ VO[M#O^Z"+QIX.C>2RM34(X&?,5Z[FW3V=*/\DZ
MLHJ0?TKMZD?7_8W]HGW+<KD_[B1?LZ]!;;<H_P!RR?R'^;ID?)]UM.?'M+KB
MDO\ BLW#5N>?]8GVDG7?#_H=O_@'\ST:Q?NU>-R_Y '_  #J#4R]VR@$0]94
MQ/U&O*_]%/?V5.V__P %J/\ 5\ATLA;:!_HUP?S'^?IL;(=TTXO)MSKBHM?T
MT-?5^TACWP?@@_U?GTL#;<W_ !);^0Z@R;V[*H@#DNKQ4CZC^ZVX*3)?Z_$P
M)]ICOE];?VUK_J_GU86MLXJMU3[01_DZX4_<>SII_M,^N0V=7FW^0;HQU5C/
M^LW^9]VAYIB_T7_/_@Z>.UM2HS]E.A"I<IAJG]W&9?!9<G_E2R=)?_;G_7]G
MZW5O<0^/"].BJ99P:&V/\^H]=N[;&/\ ^+CN'!8L7/ R%(W!_P!<>T%[S!;V
MOQ]*+?;[BZ_L >@^J>Y]CB?P8K*YO=U2?QM?;]77VO\ [<'_ &W^\^T[\PI/
M_N/!7_5\STO@V:Y _6I'\B0/\ /6$[R["RAO@.M6I8/H:W>V?_AM_P#7HH?;
M0W/< /TH/\O^;JQM5KW.?]J!_L]9OX-V]67%9N[:F"LI_P @PFWOXI_L?W@?
M;9_>ER?CT?RZ;$MHG_$<GYD]>&R-Y36-7VYO@@7XH:#$XO\ Z+]O?U6EG_6_
M>#_\9_S]:^M7@+4'\SU(CZ^W!QX.V=_TO'!:@Q0^G_5,?;3;/??\I,W\_P#H
M+IR#<8/*UA_;_L=)RMZ:W%/F:3<C=L[C_B]*O^15O]VZ7&U/ M;Z_2Q_/LB_
MJ'X<WC2W-U_QCI2-Z$ZE?I8:4R*DC_!T^10=WXZ'1#N#9&X*>UA79W;U7C*G
M_;4=O][]GOT^Y0?V/ZO_ #6_XKI'X-J36A'V''[*]=)2]T5Q/ESVQ\(/KIQV
MW*K)?];P#[<ECWFX_MH+?\S)_L];,5JO#4?V#_*.LW]Q^Q*\+/DNW,^3;@X3
M;U+BR?\ 8ZK^Z?U>-Q_;;A.G_.'JG[SMTP+4?F3UPDV#F;>>J[<[&J2+ '^)
M4N._WNG'^]^ZS<KG_HX/_P 8_P YZ?2\BI_N*H_G_FZPG9V9^E%V-NWC\?Y)
ME/\ >CS[3P[*UOQN9/\ 5^?3IW& _P#$8=8_X'V'3?\  /?M%5<_7.;<*G_;
M_C_;^[PV=]YW5/SZ>-Q:D9MC^1IU/6#M]OVJ2KZXJK7/WU=05BVM_K$CVI1;
MVV/^A_R_R](YYK5LG4/E7_9Z"_<NZ>WZ'>%+LRNW7L#;'W-#]Z<V,> #?CPQ
M>:P-7;\>PANF[;KXOA>/%_J_+\NC6QCVYEU:9C\B?]GATO:#J.#.0>?=^]]T
M[RF _P"=C_#*;_J31W_WOV<[9RQ"Y_6G^H_G_AZ+;B]-M\*A1TK*/K/KS%?\
M6S:>$-_J3CCE?^MMN?8EM]@LHN,/@]%EQO\ <-YD_P O\'2IAQ.(IO\ ,8BA
MM_08P V]K1%#!F'_  ])S?%O7J?I!X(2EN+W:W_$@^U,*H#_ )NM-/<'TZE&
M18K_ .7K?^C$6]N>,.KTZZ\O!L?]?C_??7W5'Z]#!7KAYQ_J4_V_MW0.JZ!U
MPD/FM3S@"Y_ O_C_ ,3_ $]U&(?"Z?IGI$9/K38>8_=R.TL)55('_ W[ XO_
M !N?""?]Y]E-WL%O<>9Z>3<;A30$_9Q_P])L=1XBFF(P.7WOMD6O_D&?K!_K
MCPSW/LBGY0(_L?\ )_L=+!N6L9TM^6/\O4J+8W8E -6.[9S8@^A_C6W:7*_[
M8FWMF'9C_H$_^3_/TG-U;M\2BORK_F'78I>YX+&+=NQ\WS_R\=O5.,_Z%]FI
ML-\M>%?R_P!D#I,+G;9.((_,?Y">L#9OOF+_ )A#8V6_K_#\A5GZ?['VT)=_
MC_XBV_[/]GI01LUS_P 26Z]_?'O<?OS=7X,?G_(-Q7^O^L;^]IS#NUOPM8_V
M=,S[=MQ_XE'I3TF_NU%XJ^E\C2W^IH=QD'_>![.X^:M]G^+;O\/^ST3WFR;<
M/["[_EU-PO?>WLE7?PVIVWOFFS%+]<?08T9/_;^&Q_V_MO:_<RWN?[&#^?3-
MWR]<VV25IYUQTLZ;L#<=5^_B.K=V/I-@,[]GCK6_/Z>/8O',=Z/@L.B"6R0"
MD\@/V9_RGIP.X.SYP/!UMM^DM_RO;D%_^L+#VN@W7>9?[&TK^1_V.DAM-MMO
M^)?[/]GK,*#M^N73/FMI[5  '^X/&5>2)_U_O0!?G\>[/!OEUPM^F939Q_Q-
M]ND?X*=)NIZ&@R66_CV>W?GZO,< U^"QE)M?^O\ QR/U_P!]_7V30^V,.X_K
M33^#TH7F,QC2%!'S))_F.E0NP]\8<"+"=CYXTY_Y0,]C:/+<?ZW/U_/L_7EF
M]L/[&_Z02WT<F605]1_GQUG6B[C%_%N/:N3M^,GMNLQ7^]"WY]ZBCW6VZ\+J
MS/$$?G7_ "]8QG^TL8O^Y38N W%2W/\ Q9-QJXO_ *U;>P]J/WENMD?U[?\
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M6,JT:HJV'YLQ%P1S8G_7^@]E,_N+8=.KLETV3CSS3'6<[^W?4K;$]6[KJ?\
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MORZW]7:_[[/^]?[/7?\ !^V?^?C8/_T!_P#C7M?]/N'_ "D=5^IM?X&_WO\
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M3TV-WMU_'4-!E*S/XJ<_IH,[MZKQ?T_PM;Z_X>W$]P+*W_MO\'^ST]!LDG
M?:#4_P"#J5#VUUE5?YC=]$O/ R*%O^(X_P!Y]O)SUM6X',YZ=GVB[7&FGV?\
M5TL:++XC,4QGPVYJ+*L/Q1909C_C?L\L]\AN_P"P_P O20QFUPRD#YT_SGK(
M^-Q\MQ/1X\&_YQ)(-_\ ;W]^G%GN'2@3LGKTVG"T,)_8H,:;W '\)/\ L/S_
M *WNGT'^^8.GOJ#YG_5^WK#44E/3@3&CQ](0+DL1_P 0 /;9:%#^M_J_;TI
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M?E/O;^ UW\!I:K96ZJK;K_8:KT(R@T1?N_UI0?>MLB,<@I/I/F:^>G/1A[U
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MX'$]H'^H]55]S5&[?A1\N>T<OMBD.+H-][4WAD-N@>FG^U[*I#8#_M7Y1O\
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MLX3'X5JX#_@2<;86Y_I;VNY<V$[-;P0S?@K_ (2?\O6[NZ%W<,W\1K]F /\
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MD*4-<^@4F,-O\0/\?=9[.::'^W_GTIBD$I^']E3T$\=#@I<S28W)YB@RN/\
MS75P_P"!57_U'?Z_L$[?;VEO<?XWT(VN&^GJO'H9:?#8"&F'AQ&/N;V'^M_K
MB]O]C[D6&&Q_T'HC\>X\SUW]MC8?\S1+_L&]K0['_??^K\^G#-.1_J_S=9_'
M!_RJ'_DE?=_"A].M:C_%UFCCIOJI!XL=1M[;\+Z?_8Z;Z[\#_P!5_P!N?^*>
M]]7UCKW@?^J_[<_\4]^Z]K'7#0?\/;GBCJ_2!WYM' =A;6W%LO=5.*[ ;HI8
M]O96DH*_^&Z8*WZ6EAX)!/UYO_6WMM9"O;<5_P!1_P!CJEG-^[B)[?CY5%>
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M0: /VFKJ<1 _TM;_ %OR?=;D+<2UN"@7Y'_BQT]LO,N]\KRULO/R(-/V'/\
M/H&=D_#_ .,G4.7_ (_L?9$&Z-[TMFPM?E:^HW>L'^*"H\@I2/\ $?['V3[@
MUC$*"(G_  ?LH/Y]'^Y\Y[KO9K<'2/.F#^VO^#]O1AOX1F:W%+@ZO:M-FL!4
MT?V-;1[HH*5?N67\S FWT_P]ENUO<7O]E /V=$ES=6]=52#\B?\ BNBC5_\
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MOG=5;]IUYG<AIR&0N/\ @,HL>?S[ 'NER=-MW+UQ/XXPPQZY'1_RQNH?<;8
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MN':E23^K/8P2?C_;_P"Q]B*W]R]O?^V_ET67/+%U!P(/^K\^EYB=Y;6S-/\
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MKH'7NLNL?X^Z:#U[J)44=%4_\"Z2BJ?\?I]/=0Q'2CIFFV9M9AYH,2:90?\
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MC[$_093_ 'J_MIMW3TZ3RQS]2/+3_P#.\QO_ )]3[1_O=/3^75-$_7+73_\
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M^(HE)M],;?\ XGZ^V)HI/+IX/#Z]-<>VZ&CYAK,_2V/_ "@;CJ[\V_WWU]E
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MZ.[5@O'_ %<>D1IAI+>;$UM-4&WZL?\ [[Z>R>%YO]\=''BCUZQ??0'ZB_\
M@,=?_BONTTAZ<\3K+&E?5?\  /$5U4/Z#&_\1[5VB=,M-3SZ5F!P$^.KZS)Y
M;52"J^M!0?7G_#^GL1[9!-8C$_[>F[F</BG2H+4Q%R#P2&O]?I_O7L^2:G2&
M%:#KWE%^=(O^-/\ O?NWTR3_ /%]*OJ+@?\ %=0I*:AEMYJ3'U?^/\,M]?\
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M7FGW0U76XV@I<>;4&7EIO\S%8$_["UO]YU-1P*\!@=).:=F_=%Y/#"#Y^O\
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M]R33_P!)/^/+T0/9/]8J_(_X.C)^YKZ"71=NTY1#NQB./\AQEOS^"/\ ??\
M%/<!^ZT.J]@G_P!7D.ASR@>RGV_Y>@<K=RX"CJ##-5,*C_E1Q]LI;_;D?3W%
M<O,45IT/%VXW/3*^^J&UX,37U2W_ -[_ !8#V5?U@\?JPV,]1_[]S_\ //Y#
M_P ^9]I_W\?7I7^Y_LZR0[Z@_P"4S$U])3_FM_XNGU_U_;J;]2;IF;9_V]+1
M)A*>?^ ]O8L^I_T;HO$'EUD]?^T_[S[0?3?4=4\(ITT5VW<1D:CS3TA\]_\
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M\KY]W3=K.[/GUJ:-K;J'+'EMRD&?[[;^&L#PO^557_7GVX8KR;^QZW54X_\
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MH]X8K_,5AK\5_45V,_AG^]>S8;S#T7&T8_/\^GBFR>(J_P!^BK:&KX-[Y/\
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M/TS]45X4Z[.Q]LQVAHZ48D@6_P BR56?][]M'88;?^RSUOZHGCUE_@N=A/\
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M -B:[I?)"*-4CC0&G'\CTS86DCD$"II2M >'VD>?^'HW_P V?Y;?\P[N2O\
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M>5?7SX9ZN=[9F^$^P_Y(GQ%Z$_F<9^IV#T7V_P#'3H_84^9DVU696OP^XZS
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M8+<_+]G1=/?>72HHMO;<H/IBJ&E_/^7_ /8:WLV@M(H/[8_ZORZ*I[DMT\5
MV=+>"K&U!]0-(I!_O7^O[,X[>TN/7^?17-.PZYP8[8O^>H\M_"Q_TQ;C]F,%
MI:>?^#HJN&;I1TN+KI;3X7?0JZ<?4UQI,F>/\+_\1[76]A"/[*>G3-PGJO\
MAZ<Q_?.D(_XL65X)Y^\Q?_%/9PD6Y-PZ+)F3Y_X>N4><SD-Q-MO^E_L,D,I[
MK^])K;^V@ZI].IX'K/\ WLIX?^!N'SE+;\C' ?7_ %Q[T.8H9O[:#K7[M,_
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M.HXVW_&_;LT_@],^ #PZ;JG='EM#!1?:?]-]> ?]YM[+I=S_ -7^H])_IO\
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M2<04FU*J_'^0D8S_ 'WX]G2K>0?Z!TBEF3U/649G/1?Y[:%>;?\ *ADCE/\
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MPCJ+2T-.W[LQ^Y%_I_Q<O;\ A?\ MO\ -TW<1&W/2MI:.&[?Y)0_I/\ OO\
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MVI']AU+44,7$/V'^L./9G:[;#T_';'K$\U/"+6H/]M[5?3Q>IZ?\.O\ J/\
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M<'Z;IOEQ&'E'[]&14?G_ &'^W_'M%+M</30N/MZXQXN>F'^XO,5Q-C>@K?\
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MBM*C[?3_  =+WX7]?3;M^0=')55/\/CZWPV2W5)1A;U%2L=-]J0/\?\ *_\
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MCV_E6VWG,Q1?QC_<?]Q_#Z4U7^%A+]34?@<G@>PSR5RPO,=X;8"@,<GS"T!
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M&(Q1_=JVI/H#;_C?MF*6*";INA(Z;(\[3S'_ "*BKJSZ_P#+L_XI[=EOH?\
M4>E'TO7'^)5__/-5G_JI_P 4]I/K?]5>K?2C_57_ #=9?XQ7_P#/-U_^\_\
M%??OK?\ 57IWZ<>HZPG*5WT_NYGQ?^I]J1>^!U[Z<>HZY?Q#/3W^WVV3;F]?
MD=7ND]W=S=.A0.NK[DFY@.WZ3_']/NW^/_/K7^+=-CX',3S_ '%;E\?4FE-_
MX><9_DO/M-^ZKF[Q-^WJX>"VX=</[H-YO,N7KZ;D?\ "1_Q!^GM5#L2?ZAU<
MW4/V_P"K\^LJX.NI18[CKP 3_A_O/MU]LF_W_P!:AN!Z=<AC<M]8-R B_P!?
MX91C_BOM1]++;_Z/U:H/E_J_;UC-/G_S5T%4?Z_PN_M3X,O3YH>N1GST5O\
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M1'ZOK_Q6_M2D*/'0 _;3_4.D,6SWEO;F8\*5.?+_  _RZ&V69H5 G)O?ZG_
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M=2O\EE_QM_0D?7_8^U?U\7KTW]/Z=1:G)8^#_/UEB?RIY]IY;JO3P-!3J/\
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M!5+]E4\KDL?457^M_G1]/];V%+?<6?EX6J(Y'U ;B*888_ET(M$,_,6J>?\
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MR;HS=1O;Y"?"O*?PG+5D@ZKV1EFH?X?4^HXMLA++P!=A:D'('(Y^OL_OFO\
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M/\_7:=.9X"X['K?\;[;I!_O1/M4_MS-_O_Q.O0\Z*."_S/46JZNW_1V-'N/
MY7Z<9#&?PKZ_3BWM#-R+?P?CZ7+S?:G_ (CGI*Y.EW?@[C<.T*\4]'_RGX*^
M3I?^OQ^O]?89FY?N;/\ MNGEW:VO,J?V]-5-N7;DUHOXO04E3<?Y!7_[BQ^?
MZ>R>%OI^C)K4GUZEKD:&4VAJZ ?4V_B1 ]J8;B%_[:?I1:6YN/+KJ?.8JFIQ
M429>AI+V!'\2Y]T6:&/_ $?_ *I],S(T/ETWTVY**M/@PM%GMP?X8'&U9/\
MMO;NMW_L:3=,>)!;?%0?;3I14V W_7@BEV<:2PO?/Y#^%<?[&U_9W;<NW^X_
MZ!T7W._6L?XO\O2FI^L.Q:HG[_<>"Q) N?L,=_%:OC\V ]G\'MI>W'^CQ)T@
M;F:-?)OSQT_TG1F/F/\ N8W)N_+<?G(C$_3_ )8EK^S.S]KK;;_[>?7TA?FF
MX/P@#]AZ5F-Z=ZYQD_GCV?0U=2>1]^_\5_VPJ+#_ 'U_8JM>5=I0]%MSOUW<
MC)I\^'^?I<18#;T=.(X<)COM[@77'T-O]C<_\1[7_P!7K,8$$?\ SBST7F\<
MFM3_ +TW2%W+U'M7<*??4=+_ '>S L<?G<$?X94FX_I8'_8GV'=ZY"MMPP.C
M&SW^XCJ":CSKZ?ZO7H(<AL;?^WQ_P!H=ZXWBV0Q_^XZJ%^>80?\ 7_K]/K[
MTO)E_M_P="^QYBM9/[>H/SZ1\VX\51U/V6;%?@*D'F@SF-_A?T]@:UOY$^HA
MF@\%^CF)H;FA!K]G4V/+XF4CPY>@_P!8Y+^GM2ER8/CZ]- 3_8==R92@B_SV
M9H/\.+?7W072^1ZMHG/E_/IN&Y\%*?!C?OL__A@L969/Z_[[^GO?UZ?[?_FG
MU8-%Y_Y.E#1T&]\G?^$[#W!3'D'(9W)G%_T^I-@/9@FU;K=_V-ACHMGW>TMN
M+CIYINONSIK>5=J4G/U'W>6O_K6O[,(>0[_</^(_@])SS3:IYD_LZRR]>=GQ
M<P5FTJT#\ U9_P!]^/9G%[6[E;_Z/;/TR>98V\FZ;*C;79%!_E$FVZ#+@<?[
M@,F/^(Y_WCVAO.5MVV__ $#_ *J=/+S!:/P:GVBG2<K,_#CJBVX,/G]OU7ZO
M]SV-_P DY_PXM[#UR]S'V>!HZ,()(+G]8&OV=.,$E/5P&>CK*"JI[CC'FW^^
M_'N\5W]/U8CUZSA[5'[U_P#>OK[TC^%UN>87767U<?FFN?\ >K>[IMLU?&Z:
M@8</]7#K%_E%UX)_I:]N?=KFTM9QTN@,XZ0V=I<1A9_OL76C 9D_2AQYO]U_
MC]D#P/9=^Z'_ -!_P=+Q;3MQR.NX]TY"*@HY:S;M?B2#SD!C1_M_^*>SJTM[
MG_1H.M_NRW. >HT.6H*\_M9C[H_3D\?[U[5I*G^^.CB*QA'G^W'4@W%FX//^
M]^UGC>/TL4 =,U=MO'S?Y117I*GZ6/LIDV:*3'3GU/TW35_=JN_W3F+_ ./\
M-(]I_P!T3>G\^J?O->IO]U,C_P [@?\ GK_XU[0_23>G\^E'CCY_ZORZXP[6
MIY2/O:NOJ_Z _P"XKV^FU>/_ &V.DDU^!PZ56.P<- ?#C*2_%N.?I_O'M9!M
M\,'15/?%NGP8^HL3./L^1;C^GNZ7GT_17/> ]<:R7$XJ"V3K*"EY Y!]LS7G
M@=-BZ+?ZCU&ILR<ASAMN9W<-K_\  #'5H_WHG_#VXJ37'#I-<;F$%6('S-.G
MR/!=C50)H]B-26N?]S]?28KZ?T^GM3#L6[7'_$'_ *J=(COUH@KKK]@)_P '
M3!E>M-_U0\R[.VH)_P#E?Q^2X-O]?V6WW(VZC_0#_P Y.EUMS#:G@Q_,=,=+
M/F-L0G%[YHZ_%5!%A79#%WIN/ZUG^^_/MJVL;G;#^MT81;I;WF4S]ASTHHS!
M+^_3G[MK?3'BW^]^SGZZ"X_U?['3PMR//KL./^4:_)_/^/\ K^_$^)_J_P!C
MKWC&VZ:<QC8,M3^&;Z&]C_OA[8GM_J.E,-Q3[>D7-M[.16\ H:H?T'/_ !7V
M4/LLHXSQ]'L-^*<.HG\-RX'^48AO_/G;Z?[X>_?3W/KT[]1;]<!A\]*.,-]M
MQ^,E[3^#+/T^)>IT&W:V7_@;68^DIOR<?;_C7M1%8TZJ;VO^H=3XZG$8K_(<
M7_E521S]A_N5/LSAEA@Z34)Z\1E\A;[@_P )IP?J1_E?/^V//M3XTT_^K'7B
M .LE-B<?%8S$5=18WKZ\V'/M?]#X']MT[]17ICJL[D)9ZV'&4=Z<\G^(?[W[
M*FW>"+I7!:FYX]-3U.86_FK*\7_V'U_PM[L;D7'ETN^GT]<-%5?]^MK[?UM?
M_BO^/MOZ8=/"+_5_J/4/QC_E;R/^^_V/M[PATSJ_U9ZD8RHR'\0\,%6*NQO7
M$_3^GM3:^-UXTZ6_L[Z2]8M!_P /=- ZOK/6.2EIYO\ /TJDF_)_WU_=X;6(
M=/'[:]0I,502\"BH#Q]#_P :_P /?I;:+KP/GU0G\Z::$?,K:, -XIL%U:A/
M^'\2DO\ [S?WZ>U^G)*^K'_C/60GMW<:MAG@G^7\FZLZ[M^66R?C_OO:FQMX
M-GZW(;GQ6/RE'7T>)HQ3TYR%0:#URBUS93Q<C\>VI1-#3 QQZB#EOE";FF&X
MFA_!7^7^KY]!+NW^9AT5@-TU&U*:@W5N.EQ=4*/(Y_;-'25L!T_3TR@:A?\
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M68BN#0K0D9S\^I.V=Q[VZ_[T^&NXLUNC-I0]B]=;*PV7I17?P^GT9.KGI/\
M@+_P$T@&CGY'/UM^?9%R:]WL^Y;3XN+>Y;4HI7MU4-3C/#]O2Z>T@W2PW(4_
M6@J/MH ?\XZ,'L+L3L?8/SBWSU!O_>>9SNS.PJ.279-/72%Z>F$U**W&_9WO
MI6PJ*>PX_P!L+25LG,FY;/S/<;9>2R,9ZB$U)+DDF(T\L4'\^@?=[';7NP6]
MU;@:[?\ MO*E,-_GZ!;XR;XRVS=J?,_;F9R?\1K]G3;LW5A&S*C)?;93%?Q:
M$5@O?G[RFI.?^1$ <D[V-EM]XMY@,J.'G+D?ZO\ !T*^=XOK;G;+A?QFA^S]
M,_ZOMZ [:.^NU-Q5_P /4S?8>\*BOSV_LT$KO[P59J9J5LKCZ,FI/UEY%6/S
MQ[ O+O.>Z?O"*83/19DT^BUR:9^RG'H2;IRY8;.]^ /]!X?D>CH=>]A[_P"[
M?G!G8]J[IRV#ZAZBDR-%EJ3!_MTN16(?:?Y2/]W-7Y <\'TTOTL/<]<K[W=\
MQ\ZM/8U,$+5K#P510_M_V.HPWK:(-AY=@\< R3C&KC4_/\_Y]%?VYN'?^]]A
M?.6MBWMO,IC,CC\U0C^/U0$ H<O,:L-_KXY?IQ]!_3W&-M>[GO%MN]T9')J"
MX_C[CQSCTQ]O0\OK:VVV^V>"@T>&16G# _R]-E)O?=&5K/A9F*'<V8PE=FJ*
MNV;F&P=?_#&J,D,P<355=28?\Y/,GV?)_I[CBZWB>/P5LP(0*%2@. "#@5\Q
M7CT<[580$;@;X:O.A^RM/V]#'\4>W:GKGHWY.Y'/3+DMT]7U%76XZKS2?Q&H
MOEM5-'%+5W\O_%QTGZ'^O'N>/9WGD<J[7O$C#_&I%0^* ?BKI-/M(_/H \Y;
M+^]]PVV4_"Q-1BA\_P#!T'_8G</;60^)^P=VY_=20=@]H]IY2B_O1AL%2;=R
M-3A,2LPBHYG0*3!]Y>WX'T]@WF/FR]W/9Q-=*&FEN&)9E)DJ!DU6A/"HIQ_G
MT(MOV&QM=WN(;+^Q@A%!7 ))\CP/KT/?4N5W3LOYX;@V/F,]F:G&=@[$I*NC
MI*VMO3?</AZ>NHFBI ?#%]I]MD+<<>Q7[>-/RUS2MI?4K- 5A &:2@&I-?.O
M\N@IS%#;[KLIN(."RUK]AH>I/Q_WGV95[F^4'QV[(WEFLYG\-B]VYS;.<K,B
M6J?) I -&?R&$]+46'%O9WRQS%>7 WGEF[F(E(NI(QQ&L<?V\?Y>75=_VJV6
M+;=RMU%*P@T'X3PK_@ZK@^:.\)9?Y$OS]Q^2JC59#;VR-R[9H4JS]\:==T5&
M/U $_3]-7_M_8_\ NJ[J);1TGXF[J,4SIK_DZ)O=VVEM]S6>7S1J_8/^+ZK^
M_P"$N6;RM/T;M6G_ +P5-%@Z;OKO"7*XUJT+31T4.#IA([1<W8*HL;<6'L1>
M\?,]Q9^XL:K+(L2P>,:#B:2#_!U78;""ZY4E\85*/0?[RG^7K94^/F^NPNT-
M[]W]LS;AR%+UE@<%N/"X7:^H_;6-&TL*C\>6D'^''W'^O[CGVUW?=.:+W=-T
MM[C_ !%+6Y*']M.EO->TVMC;[;:E:W$[*;G]O5>OR-K]Y9W^5=\H]Q9#=6Y:
MIZ;%]B+6_?Y"I85-/DMM2F6)K\'_ "RJO8G\GV&O8Z\OMR@^M,TE#N8%/+^U
M_/B./1ASK#;QW$4( J(6SBN >J$O^$O]5NN3X_\ R0P.W,_GL179O=N[HUBQ
M6;,2/+!LW[P!VB^MQ2GCV//O6;GNB[O:?02S ?1R^)IFF2HJ@_#QX^?1=R+#
M;OMCF0#%U'QS0ZOG\^MJS9GR RO77P>RFZ\'4T=)V VZ\ALG#YVIQU+]SYZ^
MIU1U<M^:HTF.8@<7Y%[Z1[CKD[W);EKDGQK?_<[ZD$T]*9I4?+'\^C?F7EV'
M=N8?!CK]/HX>7I^7SZ0O9/8':+3_  LQ=9D_!N_LI<?NS?1P^!I<8<V<KEJ=
M:'^(PJ!K/V@'U_J3_K!_FB\OMWAVD,!XURN:DU%6IWTXG/GBF>(Z,MKM[&SB
MW.:*M(#2#T ""M/3/\^EO\::S>H[@^7?00WAF/XN^,WK5;-S5=7_ ,1J,=5P
MU=1!YJ43#ZD5=+>UOI?\>SOVOEG,N\;1*/U_II1&!7)@/V^8_P /17S4EO#;
M;9=T&G4I/^E8>?V?['2#Z\[0WYV/\./DCUSO7/9O(;_ZLI:J45E<]ZFHQIJU
M\]'5D@EM)HZ^  G\_P"'-=MY@GYHY8W';)Q2XM=) XT]1Y>O1O)L]EM6_;=<
MVX'@7%0?MI@]-N^^Y-V4'P4Z,RNVMW9?%[TEW3+LP[FQY*9+[7;9J2(?./5;
MT47!_P!A^?8<W/F:4<J[>8P/&CNIB<XX8IY_ZJ=+['88)^:KJ&6G@%0:>1)I
MY?MZ4/4?9^X,!\EOD%N_=^Z,SG<;L+J7,5F9HJVOO3M4XZEQ">#[0?LD>8U7
M%O:7VU]P)=JW"2>]F'AO;D8J8V-:#U]0  *D],<S[ LFWV]O;BGZPI_,^77/
MJG=O=>?^,WR>[UWAOS<B0;KHZK'['PYK_L*:@.H1,<2+_P"1Z?,*,  <7]CW
ME7=-X/*^\;EXVF! %1C4U8G)3/D,4'D/,UZ)-VV^T7>=ML8%&HFO 5X5%?7(
MK4^>>@2W9GM_[?\ C?\ $CL?(;HW-5QP[RWL,K15E?4FGGA7*CQ?=#_E*_R6
M&J'[_P".!]/<4[K<7EIMEA*TW8S7(7S((*G'VFHQY="_:[2"+<-QMX0,!,_:
M#7]F.L/8^6W9_?OYC8C&;GW-!CL=387<N)HZ'<%50!J;'9?'!2@B(N!25?'L
M+[EN]V9Y18S.D.IP]<U!H!7(I0U/ET:;990006$TX_6I2N,8)_GT8OL/Y([J
MV'\->@LAUW54>![)[,I*7"SY&@Q]-]S;:[&"K/C()^[K)317L;_CWD1NGN7/
ML?+M@MD1XTI;QR*TH.'#R_R=1U%RI!NF_7?U )ACH17YBN*_Z@>N6\<KOW*?
M+CJSJ6#.+@DINNDJ=SXC:F.I<73#-Y+$5]1D\AX%LIGN3<\?T]@3FSZ[==W%
MI"L?CF +*3'B@XC_  ?9TNV%K?;=IN+GB/%)&?*HIGI)_'?<':.[?BU\CNO,
M-O#==+OOKJOER>"W#_$?O,A]L-53642U<Q!!;[2JX!N;V'UM[-N1[B^DV?<D
MA4?56ZU*C XT/F<=5YFLK%-QVXG^PDT+]IQ3%.F'L'M#<'<?P'H=QUF:JJG=
MNQ.Q\'A-SUWWX-14K1J?M)JL?6Y,U(+_ $)!/)]H>9.8Y^:>5;6:XHSV]RPE
MJ":@@@'\N(].C;:-MM]BYKN(8!2&=*CY<,#]G2_[U[>WU-A_A?-M#<M9@L[V
M)2;3KMT5] VFIR3%L?0WK;?6*XJ_]>_/O?/_ #$8+#:;F$:"UHQR>%#0?S('
M2+EC:8!<;E!,.P/08X5&K_5_@Z1?3O=63VG@?FGVCE\]5[CB@RV-Q^S<-N>O
M.3ISDLQ5Y&*D:**JORJW/^P^GM-[=\\3['87MS<4E)4>&WD9B:U(SC2?+]G6
M^:.7X)9]N2"H%233& !BH_U<>H_Q<J=_57<V"W%V1FZ[<FX]R=$9+<N+KLVY
M:I@QV0R=J0W/_!21S]/9#[>&\.]FZ=0!<.0"#JJVD#TX5!(^WHTY@@@M]O(V
MWRE'C#AU9+&Q"FQ_/O*OP3T JAN/74JB?_/CGZ?6WNOT4/\ J'3-6'ETG*W:
M&V<A?S8F@%1;_EWW_P!]_O/LIEV&WO\ ^QZ7?57"])/(X+;6UOWJ+=U?@:G_
M )4 /XJ?]OP/87O(XMJ_L<S=+5)D.1CK!B=W;REXAQ S]/S>N.-_AGT]N6FY
MW?KU=K1!THOX_NW_ )Y)?_/D?9W^])O]!@Z0?2K_ !==>7?=408*/!;?Y_I_
M$_\ 7_K]?;FO<KC^Q_R#KW@H./6*IVYNJKXK=\_VA_P QQ/_ !3^OM##L%Y<
M/^M-U;ZM!-@="+MS:U1%UCV)C/[P5K5%3D]M-_$/]2(ZF)K_ .OQ;_8^Y-VK
M8?\ D.WT/C_CM\>0_P :7H,SW8_?D1TC\7_'3T=CWE1U#W4&L_X&Q_\ +$>R
M?>>)^T?X.EEIP_U?+ING(>_/'Y/_ ! Y^GLK\2G2@6OSZYL;G\_T^MOI[TMW
M]/TLZ[O4?T'^\_\ %?=O&;IOM_U5ZQ>VNG.O>W= Z;TGUZ][I_S1ZU_J^76"
M7R78MI^VX!*V_P +V_/O4Q>XFMX3P^?#ID>,"?7\N@ H=L82'N.KI_M?N<92
MX'&;LH<>6O34N4RU6*,RBQ!)^IX'TOP;>XULMH2WYFGAA_WWT?2[E.UL*D@U
MI7SH!7HQD,2D<)I L;7O?_'W)]O#/ ?UKCHE)'7<P\_"V('UMQ_O?M/#%!7/
M6@*#KN#^W_R#_P 3[<;P/]7^QUL]<+UW]4_V_NW@#T/6J#T'7+_(?\/KQ;W>
M'Q_]!K^76FKYTZ:Y8:.K4&HH,;66)Y#?\3S_ (>T<L4=S_;0=>_QE.!/29K.
MNMBY.XK-I8#^O_%N_P"C1_Q'L@NN3=JNA_8=+K?<;JVX-_,?[/2=_P!#76%O
M/_=LV^M_XI7?]&^V?ZA;3_OCI5^_[SU'[.DWNKHW:%5AZP[>I6Q>;H[?P^O/
M^Y6__(/U'!_V'L.\P^VUA]'XT'^K'2FRYBNE:CTI^SI8]0U--)L/;S45(*8T
M=!_#ZZ@^A^ZQMO+;_7()_P!C;\>Q/RFEG+96_@?/HOW*4W#MJ]<'T!H/\/0G
M?Y9_:M_MK?[W[%@@GM\9Z+\>76'WOKW3A[3]>Z][]U[KWOW7NNKC^H_V_O?T
MY_U?\5U[K'K/]1_R1_TE[5:_]7^H=)_IE_U5_P _4'Q'ZEKD#ZVM]?\ 7]LF
M3_?/3WTW7IB%T_EAQ8\\'_>?;47C7/\ ;?!_Q?7KGH$\0IV'OT[>I[':N^?X
ME6XVA'/VN4Q1_P LA'_49^/ZW]@BR5^5]S_=L]Q^C<_V/1B\,-S%K [D.3Z@
M^>?3_)T.PM;_ "JUN;6_XU_L/K[',/C](#\NHLOWM_Q:W-OI_P C]O4A'_$C
MKW4N>H\(! N?^*\?[W[2#P;;^VZW2O1=LMO;<.YLM5X?98Q^*QV(R'V-;NRN
MQO\ %/\ *K#BBA)/UM_R+W'FX\TQW,_@6=QT(]OVJ",:G&3G2#3'SZ;/[MYB
M2TTO9&^S/8<4&5/^]"X]EPL=PN/UOK[G_G)_L]&ICMA@(G^K\NN7]ZMW; J!
M59G+?WJVF*VU<#C-.3I;_P"[A_QUAX_K_O!]TL]_O-I[9CKS^?2.]VM)1XJC
M2:8_A\\8Z,O!5TTM-]S3V^T!X_XI_A_OOK[ER*\AW"''02*D&AX]2_=>O=>]
M^Z]TQY6I%+CZ^9B1_N,RAN/ZBWM'N\WTT-/M'3R)K(^1!Z#WIVF6+KC;Y/\
MP(% Q'/_ #M2!_Q ]H-@B^GA\;I1O!U2$>O^0_[/0G>S_P#T#_5Z=(_/\O\
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M_23_ %Q_O8]D5YP/2D= 5U.1-B]]2#_E)[&WK;_8GV$N5O[7_5Z="7=<&G]
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M%;;G6^RMO4%%%3;<H1]KC^:VOQH-5_K6*@WX_P!Z'^/L8;9R7MEA#!XT'?\
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M;YH;(IJO_)IVP75A:W/ZLE+_ +P+^U4EE.S%3QR/Y =9%>W5Y!<[#<3CY?\
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M?Z_3VS#IC1F(^' _97I3[H[_ 'O[Z\$W%:T;%?7Y=%]_E>#[7O[MS%P\4?\
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M[5_8.F[(24-+V?\ .X5XO!A.K=RX.A_%BM=C<;"1_C["4*?327OB_%IT_F2
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M0FW_ %:\B+_[S[R(N=F^@W?;5A_T&#_".HUVF3Q-ONISFL[?X>C(DI87N/\
M'CW-DS=$(BZS>TW3G6'P@?2P_P!9?:7<KDS_ .X?6EE'GT%6,-#MS*U@W91_
M[F*JOM_':_\ W*6MQ>WL&IN4,,WZO[.CB)2P[>A4IJT9"#S458U53#_G77/L
M86DUM<=%K>./]1ZY:T_U)_Y)]K]$/3?@_P"K_4.N6L?@L/\ 6 ]L&&;_ $&?
MJ]0.(Z[_ ,HL+?7_ (W_ +W[50^#KZU_HN>A P/W']Q]]?IM_&<'?_7U4]O]
MA]?8UVKPOZO7W_-:W_ZOKT')_P#DMQ_8W_'3T;+WDKU$_3)6_0W_ $Z4^G]?
M\+\^PUNW#]'\Z<.EUK7Y_P"7H =[[OS#9[^Y.T*N@HLD*#[W/YZNM_DM+]/K
M_P KO^^X_$8<V\V>'#^[+/\ MNA)86(G'B/6GD!Y_P"QTC?[A4$RB;,[DW7G
M\D1Q6U^XJS%#_;P@^'_;^PY^[YI3X,W1_P"(+7@ /E3KI<'G]N?Y;LG<F>'V
MAL,#GLE_%*6J'^-O^ ?^QM[3I=3<N?\ )-ZI+ +[,@'V@=#ULW<F/WEMC&9F
MC"T1K*#U4?U^UTZ?/"?]M_O M;W+/+^Y?U@A$W0-O83;L5_GZ_\ %=++V;=-
M]>]I^O=>]^Z]T#N*_?[KW@/H#L/;9^O_ $TU!]@VQSNUQ_J\^E\F+)/],?\
M >AB]CKI!U@FM=;W_/T_V'M@>/\ Z!UL=)W-[BV_M^G-7FLO0XNGN>,ADBWU
M_P!I))]I]XW2S@@K>=.16C,:*#]H%/\ ">D''W/UE-4W&YZ2_/-JP?\ $?\
M$>PQ_7FSN9O ,_Z/2X[7(HX&OY?YNA#QF4PV7QQK,75T%5!6<?Q#'*!_Q5O]
MN?R?8GAOX1_N&?&Z0-:L#FHIY=.7M_IOIP]^Z]U[VHZ]U%_Y3_\ D'VSY?GU
M7R_+H'>I"((-^4/U^R[.W(;_ .P;_BGL)\E?V$__ #4'2_>.\HP\T'\^AD]B
MZ/I-)U']M]-]=BQ/J)YY]W\>:V@_0ZV0//K-/>RWM?U6_P!X]ZA\#KW46+5Q
M;(DDGZ 7X_V-O;8F^H_WWUXCY=2_!_M?_)O_ !OW>$_3=>KUY;?ZG^GX_P"1
M>_0^-<<.KOU(]ZZ;ZCS\%#_K_P#$>]P#ZG]#KU:= QW(DU-@L-N>  U.T\[M
MG/M;FU*U7^Z#_O'L*<YKX:?6_P"^?]GI;MDO@1%/)J@_;0?Y.A>AF\R\?UYY
MM_K\>Q5$/J8?'Z9:B=9]7^TM_MO=O%^SK?42IA_R04WT '-C_6P_XGW23_%X
MI^DMID]%FZ[C%'MK^&3@BHQ.0R5!G>?^4HUG'^\7]PSRU+]/#X7_  SJ0C0F
MOJ,=+[V(_#ZKK'3!N,P2X#<D$UOMQM_(VO\ X4@'LJWH>!9S];M221^7^'H4
M>NA5'K[9OW%_N/X'CM!_ZHC]?]L/8_Y2/^ZR"#H![B1XC'[>E][.NJ=1'^G^
MQ]J8>G(^F#=/_'OY7_PW<U_[A#V4[S_N'<?ZO+K4/]H/],/^/=,/5?\ QX.S
M_P#M1XS_ 'L>T7+/^X=O_J]>E&X?&WV]"1[$723KWLOZ]T6[/C7V_EIJH"U)
MM3&#!CZ<92J_RS_>?^)]QGO5-PW4P]#'9R5LP1YG/V &G^3I0^U-Q-X'3DYK
M3K O_ H_ZR^WI(/J(.O3'/43J,&++]I8V*W\/7=..KJ'\_\ %XI?W[?UX'O?
M(L_TWU'^KUZ+.9 6T5XZ2#^T=#U[D3HEZ;OR?]8?\3[9N_[#K8X]-;_I_P"0
M_P#B?:?<?['\O\W2E./0(=-_\>IE_P#P[-Q_^Y?L$\L?Z/T)K_XU^Q?\!Z7E
M1_9_Y:/_ ,3[-I_\@Z4Q</\ 5\^F&M_SO_((_P![7V7GA_J^?2^#H/-]8"'=
MFVMP;<FXASM *(:N.5!]D]_9_O"W\$?ZL]'%A<?2W 8\>/\ +HM.ULW-/ <%
MFM-+N_:X^QS5"1?Z7O60\6_RS_B?Q[@BZNOW;-X)\_\ #U)\8^H&J&E#TJG^
MWMYOQ?@C^O\ Q3_>/;:!_P#B^O3^,.D1)?>?8.UL!C#]Q0;9SG]Z-SUK"WVW
M\,N:2D_WW_$>WMA@^IO:S?ZN'5;\_1VQIYB@^WHU$GX_V/N:^@%UD]^Z4=>]
M^Z]UCC_/^P]^Z3] YT@/^,<4T7_*KF\_8#C]-7?V%^5C^A;_ .KR'1MO(_QD
M_8/\O0VRL8O5Q]+?[?\ Y%[%7]OT3@ZN@$[\>:7:6&I21_#\IO? T&<8?\JW
MW1X_Q^GL(>X1^@@/V$_G3H_Y=%9_R_U?X.FRM.FAK ;?\6]?]]_L/<765O\
M4GH7-#3^70.P2<'Z\$6_P_WW/L[@DIT*8!3KE'*(=P[=J%XFJJ_(T)_V''^]
M'V]M>93UJ]H >AYV6_DS])^+T.3/^\J/^(]R#MN6_P!7SZ O,?\ 8?G_ )1T
M./\ N[_D'V)I?B_/_)T!QUQ]I>G^L1_0/]?_ (K[L_'IB?@.@<ZI(EJ^TI^.
M>Q,I^/\ IC@_XK["7+7&Y_TH_P /1ONG"U^P_P"#H:?P/]<_\1[&4_$=%$'
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M]M!_@Z8N-A1O@;/E7S_/H6\'G,?N7'T>8PU9]WCJP$45>W%K#_8<>QQMU_\
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MDY5JM)"A2(V5N+#\W]E.XV4EW<F9%.DUH*$CA3C_ "ZGWVQYHVC:^7YX+ZY
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M9[@7 ,'C*:U%",9_U?;T5[^5=T]VUU75=M_Z4^L]\;!&<I]H+BCN?&MC//\
MPR.H>98BRBY  O\ T]H]EV^XLXV+(::?,$<3\^AK[Q\Q6',4L'T-R)*'-"#2
M@^70?;TZ0[EKOYFF#[-I^JM[5/6-/V5M"JJ]_#&-_"S38W&1QF436"D:1?\
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MF(CZ_;*PO_K ^T\GBK&&^GH&' ^HQ_@ZFKV7WD7 GVN2Y''RX9\\?X>EU_+
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M[LI^U-D15VR\EC]L[?P]%EU/^4W6EM5FXX_Y2C!_K#V+O<SW5DYRW7]Z0Q^
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MYK9F>PBU#G5/3EP/"PO]*>IL(#^1!]/9+[=\XP\CRB06PD54$(2M!WC-/*H
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M0O>QA'TEDZD>V^F^@T[&W34;1V_Y8*3[O-Y>N."P%"#_ ,I&6O\ G\\_F_\
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M4=1IKV:PL>./]M[8,M#T^/ET%>%'BW]N^"$_Y-54&V\C8<\C\_ZW)]A+:/\
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M^CPO"Z,_W4>.!^T]3(-V8RKE$56U=BIS_P KN.!''^QY]O6^_JQ\$]-S6$T
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MV=4+[N^&/SY^0>X\+CN\-[[6DVYA:D7RTN>I7^WILCZI*JEH,?20?<U!_P
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MX=7UYO[-[C[H]BNV^#XZ^/IIXE.W212G[//CY\<]%D/O+??7_6Z>W^&N>/\
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ML/\ W,P]62E;75_.4^V7GP41Y/''XXX_V+PV.YW?!@Z9-U:P9!J1P X5^?\
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M.A:NUP6N37_/TO<114^/H:&BAL:>D'\/M]/U?\;]C>QM/T>BRY;/3PYM5?\
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M;FU%M2G[>E#5_P#1/_%?9D./6X.'Y]-OM_I[KJ/]%7_P0^T\G]O!]O59_/\
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MSOL4.^VCU%3'4H?5O,'ABGSX]'^U7<T,^AN!QU] _P"-'?\ L;Y0=#=0=_\
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M]6U:G*GRX'Y<?\!ST<3WOK752_;^3H<+\Z*2HR-6:1/]EVB7[X#3R<B>;?[
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M_P#<.WZ<:PME^-P/]+D_SK7]G4&?KO.;G_?[.W+_ !3&AR3M/ ,,;C!;_E<
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MM2VT0_U?[/3>@_LZ!Q^H9L)/]QUENO-[.;22<+_Q\N-L?Z4E9Q[#\NP';O\
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MKK*(?,BB_P"3[4QX)/2>X%<==3UE/0@35IH:2FY%ZQK'_BG_ !3VHDO(;?\
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M\ @U)YM8_@_TY_I;V#.;=G_></C0_P"@_K]/[=+K>A&#VFGE3K#M+L_;&ZL
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MT>TO5NJK^TJ2GJOG>\$UJH?[+4I/WO\ CDF_WDW_ *?7W@/[J64,_N$1-P,
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M<B;6G_(>O3X'XH/3_?R]!J:<_ON//\7_ !T]'#]Y,]1/T"N\(^QVR!K=L5N
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MUT?9D?SZ=AO[2T^!<_,T_P  /^#IRH.HMDK,9ZVCR.XZ@@VK\YD:W)_3^A
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M>(#_ '+[ #&W]<76?3Z_U7_B/8-(\#>8*?[[QTO6I@J?XL_G_P 7T+L']O\
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M5OLZXZW_ *'_ 'CWJ65_]&Z3CP?+J4(0;FH/'XY_XGVS%>0V_5M->H,P\/\
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M%_<NYL=U[MG+;YW5+%@MI[:P\F=RF1K>*818Y=3NOX_RC^Q_Q/N6)[E54LV
M 2?L_P!1QT1V]J2:#-?Y]7\_\)G^I-S==_RWL9V)N_!?P?+_ "B[T[A^1>-Q
M];0>&JCPF]\C11XI&2WI5H87F!-@%G!6XL3A!SEN37^XW$B'+3ESY=KDD#[*
M>?Y^?0\MK;PE _A4+^8_V.C6_P RC^7=O7YU[]^ V^MG=E;<Z_IOA_\ *G$]
M][HH=P82NW-_%J+;R@+C<:E+-$L$L80QF5O&CZU;6K*I!"&\'3GX3_F_S=/
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MD>?3[2=?[0Q9MB=HX&E_U\=?_>N1[=AY;M;?]:G^'JAW2Y<4+&GVCI5PP"G
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MY+RX59%!J?3J'L3)=S;@VUB=P+6[2:ERV/:N^PK\75GZ?\L!]?I_QOVWR_\
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MC^[8>DY<G)./0CJ45^M\?]#_ ,=/^D/:_1]/TF\"O @=85I2#^^X/^ 6UO\
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MGR1Z.02>;7]T\8=)^@6[-RV/QV*JJW(5E!C*:FM;[XW_ -;Z?[Z_MM[A+?\
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MU_7Y3#X%A@MLRO,/(AS&[YXY,A4F2(R%)9*HHP##W(7[\N=@MDCJ8G\Z5%>
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M1I^WS^P'TZ=M"-:D^M?V'_/T7#8]1]YM'%30W6G-"V/*FU[8HB"_%QS?^O\
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M)S!2LDI^AN-0X_X+J_WKV9*Z.<5_.G1=-<16WE^RG^4CH7MM]>T__ S)R!@
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M^^M[=ELH0*=;%P0:])"79&)GF\])?#5( '^1VQ=_\?0"?96^U?5?V1 ^VO\
MDKT_^\=/&O\ +_8ZB08'<].I:EW1)-!^5SV/6_\ L"K'W4;7N$']C<#\Z_Y
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MNK^R\-%Y*3.X7<6.M;15QU./J[#_ *AX)UMQ_JO8&W'V]W7;G_Q21!]HD/\
M@C/0FMN<H[N;N!'^\X_XUT];>ER\O7_8,)V[7PY:FRFW<>,;*D_BF9ZB%/)$
MIB\NA S,UH_T@_B_L2;5:[A^XKZ+6OU.NWHU&I_;+_1K_+HON+Y/WI%<>7<?
M*OPGYTZ.?[R2ZBWINJOJ/^"?\1[#NY?V_P"S_!TJMN _+J![*>EW4?P?[7_R
M;_QOW[KW018!E/<.^HN;5FT]MUUB?]4*@?[P3["=D*;K/T83'_$D^TCK/V9N
MC+[=VOYL83_&<O7XS!4)! M5Y0 DC_??\5]J.;+[Z.'QNO;';"[:A\L_LZ0&
M'V?B,->=R,MFJS_@?GLA_N5JJJK/XM?_ 'W^O[ ]CM)D_6FZ%4<GTV. ].%!
MT]U%#C\A#X:RDH*RFOS_ !'&$?[T3[5_NN&3JWU)GSGIKV"_]T]['9E)SM3<
M./;(8*A//VM5B2?O(3?^MO\ D?NW*%Q]#>?1=%6[0!T\0\1Y^HZ,-].3[E6'
M_&.@T<YZ</;/5>O>_=>Z"+N&FCJ^N-Q" G[NBHA7D$?\ZGC_ 'W_ !'L,<Z0
M']T^-T8;*VF[ ]?\O0B8BI_B6/HZSD?=X_$Y#_;'4?8FMA6#]G^4=(+D:21\
MR/\ +T\^U/6NH_G_ -H_Y._XU[]U[H'-X]CUM-E%VQM+$T&7SY4-D&KC>EQ?
MX_RPK]?\"#_K>P9S%S!-9_HV5-?1OMM@+H:G) ^7%O\ +TCI)NSYE,TV_,?2
M@"XH*';=&?\ >)_S[!9O-UN3XWC]"$;?:KBA_,D]3:3L#>NS;U&[*/'[BVXQ
MU9#/X+''%U=+?_E=H^!^?9DO-\VT_P"YF(>BB;:$E^"H/D"20>A]@K*62FH*
MFG'_  /90./]O_7\^Y0\7ZC^PZ#V:D'RZ<O;O7NO>_=>ZCS?V%']3_Q'M)-_
MO_K8Z"/J<Z:??\#7!H=][EN1S] 1_P 3["W*7Z'CP]+-T/PGU4?X>A4]BSI%
MUX<_3W:\_P 7SU8=!5VUG<OC<!146%KA25^[<]CL%0UM@?M!E+&<$\'Z^PAS
MW?S;7#^C^/HPV:V6Z:K<%%3\Z<.D[AMN8G;=-]IC*,?;,!_E]@U55$V)GGGX
M%O82L=N\.+H5QN8N)S^T#Y=.,L7WM.()P/MOZV_VWLS>PL]P_P!S(.F(+@C@
M>DYL11M7>U9MBD%MN[@P+9V@H3S]I4XSF;^OY'^]>TG++S6EY]%_SAZ+M[@$
M::_,&A^SHS/N6N@UU[VGZ]U[W[KW7O?NO=>]^Z]T"G9421[AZPRB<T\&^1]?
M^KO1W'_17L)<S]MY;_;7_!T:;7WHZ^J4_9J'0H_V_P#D'_B?8]_T'HCZ>O9?
MTHZZ!O\ X$?4>]SP4Z]TR9#&8[,4M91Y*B^[I*NQK\?7&PM;@@C_ %OP?;=Y
M#!N$/@S=.QL4H5/V$9Z"Q^C]F)/_ +BFS^W8+7-#A=Q5F-I>/\;?[[\>PN_(
M]E(>'^K^?1E!S!);K4D5]2N?\/2PVSU]M;:%CAZ-:>HK3_EU?6J,E550(_X[
MEC]?S8?TX]F6U\LV6V?V$!_/_8Z1W=_)??$0?LP!^WI;&*P"E_R#;3[/X/[;
MQQTEKBG6#VSUKIP]^Z]TV5@^V_RH7^HN;?T_XK[9NYJXZL.['06]-Q?[\*F_
M'WE;N3(_\D5H_P"*>P]R=_N%<=+=\:DA^P?Y>AE]B?I!TV3_ .97_@__ !7V
M_!Q/2CJ*3JN?Z*O^]GV@6'Z;Q_\ AW^QT[ ?]7[>BQ;MVEF]G9W+9_9U*-P;
M=SY%=G=JX\@U5-4GC[ND_P #_OOP?<1;UL/[@F_0Z&FS[N)E"N:$8#'\7R_/
MS'0>5?8NW(2/-29NFJ/^5 [;JA5?[ \?D^R.\W-+G^V_P]#%3$/3^7^3IOH-
MO[DWUG,3F,SB:_;^T,#7?Q"@H:_BJR=3QX3-#;_(X?\ 86]ZV?8YMR'^,?V/
M5I-Q6S!%N>X_RZ'B8\C_ ((WX_Q]R6TL,$/@]%, )STSO]?]A[3=&<' ],LQ
M,%-63V'W5OJ/\;?\5]HA$/&S_P ,Z4?9PZ!+I6TNWMV9&&]\WV%O"O'/]:KZ
M?[Q["?*'Z]G-7_E('^ 'H\W@4<#T4?SZ&%/I_L?8AZ1=,^>Q<&X,)E,%7_\
M ;.462I*R_\ U<[?X_TO[:W*P.XP>#Y_ZCUJV<6DP(X#(Z*_M#+5&/!V+N/_
M "7<VV/\B'W@_P"!5,/^ E7#^/\ C7T]PO>_[KIO#E_S4ZD2TF^J%1P/^'I>
M!J<_OS\_T ;\#_;^T,URMOCIT03'I!5;'>V^MJ;5PRI4_P .SF.W1NBLH?\
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M6#WC0 _\%N?][]AZ[FTW]M#]G^7HRMN[;[KY$?Y^ALUC_:/8RJ>B3Z<?ZO\
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M\GKWI_L=2'L?*X7]:?CZ5X]!L7(E\LMK 6'%SS[3>$*]#DC%.D#N.HFKLJ,
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M/]/]Z]R5'%"/+HAN"1_J^SJ9#^H_\%/YM_3WLPPC_BNFM1Z [Y,'_C W=/\
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MDO3K!^@_\&/^]#VUU[H'-UR^+L[JROXM5#<6WR/\11B:_P#O(]AC</\ DIV
M_P":G2RU6D4@^P_S/0Q'Z#_6_P")/L4Q?\2/M'^3HM_S'_+U/]UZKU$L?Z)_
MMO=?"^WI1TW5E!#D:6MHJ]A74M62>?3];_T^EO;E_#!N$/3=LY2A'ET!,NQ]
MW[4"Q;2_A^X=N\_P_ ;@_P!Q%72D?405IM?_ &'T^O!]Q6G*=YRQ-XUG^MT?
M0;VDXH_:?49'[.L/VO;&1_8H]MT6W[6_W(;@R7\4/_4F(_\ $>VI;3>]W_1^
MG\'I=^]K./.NOV="9LC9--M''UFFL7*YK*UOW^=SM<=(JJK\6 _I_O?^\#G8
M^7#LG]C_ &_SZ#DVZ?6GT4"@ Z$SV)ND73?[3]>Z][M#_C'5AC/0'[USD5'V
M9LZ>M(J?X3M+<61-!:]OXI]M"1;\W^GL'7\GBWL'0@VC:CN4;:<5(%>/#I$Y
MO<.2SU2!7"U-IXH"+6_VWL\D+L]>I!VO98-M@_R],[ BUS?_ &-_=RFGH]ZX
M^_=>Z0F1B--N&CF _8RW^0,!S_E1^G^MS?\ VWL';NOAW'1C;3_3P="IA]H6
M%'-E2%OS_#R/]?\ 'MV&]Z"%_O\ 7[>E^!X*>DA TM2?J;_6_P!ZX]EIG2T\
M>;H)TGN/M\^N^DT%72;PW02?M=U;KR5?0+;_ )1,8117_P!A[,O;VW\<3S?Q
M_P"S_GZ(=]G"E5]%I^9H?\G0S^Q]XOV=%5#Z_P ^O>]W_P#J_EUH\/\ 5\^@
MKW:?N.S^J(+?1=R9'G_J$)_XCV%M^_Y*=O\ ETMA/Z3G\OY]"I[$W3'7O=O%
M^SIJA]?Y]%IH8_XCO;?>9J&U9&ESO\"H&^GVM**3@V_VWY]P[&L.X7D\.Y=#
M6TA*(@'I4_,U'2W,U[4]OI_C_3_?6^OLQA3SZU]1Y4ZB3Q"IIJNCG_RNGJ=6
M/R'(_ Y_I_7WZ^VF&[-.E-NWCT/ID=.'2L\S[*-+4$+_  C(9+#4'%KTN+JB
M(;_[!O8@]OKS7MGC3_ZLUZ"^]I]/)CS(_,TIT,1FMZ=-C^/5?_B/8PA_QC]?
MHHIUZ3_@,_\ TZ_XCVEW3^PZ\OQ#\^@=Z<'AVED:7Z_PK=6]L< /\*J__$_U
M]A[E<_H"'YG_ "=&>[_&?FJ_Y>A:^O(]C";_ !?HM&,]>]VZKTS[@W%AMK8:
MMS&<K#2XZFX7(+8GD?3\CV6;MO4.UP^--TZEJUZP5>/IT#\?9.]\W^[M[;M!
MBL<0%_B&Z\D34V_Z@X+ ?[[ZGV +GG+<O^(4'9T((-C1?C8D_(8_;_L]9#V%
MV)A/^+KL_;V6I+<KM'( 57^OX9OZ?ZWN\'.VY_VUS!^CTRVS1,:6[&OSX="G
MMC=6'WEAFR6&K0("%%RH_P D(!^OT!X_Q^GL:;5O5GS!_8_\5T37=HUN:-_T
M5TL?9GTSU[VW+QZ]T'W953]IL3?LMK@8/(#_ )*HE'^]>RGFD_3P'_5\^E>T
MC5(A/^K/4G:5,:7:FRX-/ P./Y^G(HC_ ,1[>Y>7Z:P@ZK>2![EOD2/Y@=*F
M864<D^H?4_Z_LV\+[.M=1O=>O=-C_3_8^Z/PZ,.D)E^Q]EXFH-%E-R4#3CC[
M C_>^#_O?L/W&]V=G_;3]*;?;'N^ _U?SZB8OL/9^>J/#CMRT-74F_\ N/L5
MN3S8&?GV[#ONU7?]C/TJ;:[FU&1_J_+I52RU!XIQ_MQ[.Q9P3\;CIHDCRZQ-
MS;_8_7CZ>ZFEN,]*P-74/W3I_J//_8_Y"_XCW[KW39*;L"/]2/\ B??A/TM:
MGGT@>PZ/^(;+W!  ;G!"OY_K8G_#\#V2[V/'A,W2O;6TL!\_\Y_R=/6 E^[P
M6)FL/\JQ^._WD#_B?==H/Z,'SI_EZO<<3\JG^74_Q4W^IC_V_P#QOV<>)TSX
MP]>N/@IO]I_Y*]TKUOQ_G_@Z]X*;_:?^2O?J]>\?Y_X.O>"F_P!I_P"2O?J]
M>\?Y_P"#H-]]P^2HVWA)1?'Y7(,:XC_JUTEOJ?I?V#^<9O[ ]&NV+IJ?//\
M,]3/#;_'_#_6_P!\?S_L/:1K>&QA@Z-IYSUB*@?52/\ 7/\ QOVK%QX_& =-
M"X'SZ:,5'_#]]+%!;_?P8/(??%3?_*L;^1[1['N-+S]O3&X#5'^8I^?0MPP@
MT^J_ %K7Y_XC_>_8\F3RZ(3/Y]=Z?]J7_;^[:#U[Z@?ZO^+ZZT#_ &CW3KWU
M _U?\7TA=\J)CMO% \Y3=>-&HG_G6_O$<?[#\>PSS/=&W\#I3"X)-?(?X>EY
M'%3?@V'YYO\ [[_;>Q7>6OT$W@G_ 'WTF^HU"O6+P4W^T_\ )7MNO6O'^?\
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M%3]O17]3T$6?ZJ4Y>JS.TLQ7;5R.4(:LQ]&/\EJB/S-#86/^]7]@.]Y(G?\
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MYZP_C_*+\<@?[W_L/K[<EA^H_P 3Z\#3NZ;=DF2E[4W-1PV\&5VA09^O%_\
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MJD D?WN<\'D'_@'[1M[9;=YWJ_[P/\_3D_O5S<O#9Z_[=/\ H'J1MSY>?/\
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M8Z9Z!_80\G;_ &_/?_@$-O8_G_&DM?W'/+ _W<771ON?_),M/]7H>ALB_P"
M+?ZQ_P"(]RB?BZ#'3HGU_P!A[\G'JC\.@!^2W_9.7=/_ (C3>'_N,OL!>Y?_
M "1+G_2K_P >'1QRK_R4[7[1_EZG?%?_ +)VZ1_\1EMC_P!Q1[-_8C_E4[+_
M $Q_R]%'./\ R59/M_R+T:7W,?09Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>ZB30I4H::I&I6LWI-KV]TXX/6P:=?-<W1MF/^7/\
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MPIZU_GUOK?RV_C#)\,_@G\8_C)6S4E5G.I>H]OX?=(QY26F_B^1:7*9V2%I
M0WDS-77,#S?0IX%Q[PNW.\%_<22CB!0_;2IZ'B+12WD2*?E@=6%>V^M=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U7'7_P#;
MQ2L_\5G/_N=[Q$Y@_P"GA_\ 4/\ ]8>I9M/^58'_ #7'_'AT>3WD'T!NF_W[
MKW4_@<"W]?Z^T<P^GZM\77"HTW>VJ_I^O^P]O#Q_E_+I.*=<O(O^I_WW^W]Z
M\;_5_J/5OJ?]7^H==4X;T$?[5]"?\?;_ (TW3E!^?7/VGZ]U[VHZ]UDB_P S
M5?\ 41'_ -#K[,?] ZHW$?G_ (.E)[/^B+J)43 +]/H/Q_L/^*C_ 'GV1[A_
ME_R]+;8=0O/_ +1_R=_QKV4>(?\ 5_Q?2S'2 [&W!18#9>X,G5U@I V"R@HU
M/U-4P8W''^K(%OZ7_/LFYGW"&PAG_P!GY=/[=&SLH'KG[,]1.KYZ ==;2^SJ
MQ50?P/&WY_WWYXM^?;7);UVR@^/JV[S4D-?7^5!T)(F$PT@6!_/U^G/^%_8C
M/^,'I-2G47Q'_'_DGW7K7@?/^77+2/ZI_P DGV[])_R\?ZOV=-_3?ZO]1Z[)
M)_Q_US[I###T_P#/J?\ XGZ^W)Y^J=0/:?Q?MZMCY]>]N0_XQUX8SUG/T_RN
MW^%Q_P 4_P!A]?:8S_;U4D>70+=<U/\ "MP=D;0G84D]+GCG<?\ ]0VZK6_U
MK36]@[EZ[^FFN(>C>_'B*CC/E^8_U'H8O8XZ*.LHL+DWX^HM_7W<PF#I1USG
M_L?\A?\ $>ZB;Z;I@=-<F-IZ@?O4>-K#]=-Q_6QO<'Z6]L3V-E?_ *TUOTX+
MHK@&G3G% *>YIOH00>?\?\./=X8OI^FFSQZP?3@>U,W^,=6&<=3^&'MK_<;J
MO7?M_KW3/[UX)]#TGZ VCS$6/[WW%C0;/G]CX\J1_P K.-' _P!?23_L?<5V
M^Y?3[F8?ET(98BT"_)B?R/\ L=&!UKQ];&_-_P"G^P]RW/'3'1"UQ7J3[0].
M]=6']!_MO>_J#_J_XOKW6.*S-8<W!_-OI;_#VI\3QN'3!N!]G[>HGM/X/T_2
MFE>'7O;?B_;U['SZ][MU7J3<_P!3_M_=_#'^K_BNG/#ZS^Z=-]!-GNRJ.FR%
M9M[:U"-V;L:UJ.A_X#4OX_RRM%O#Q]>>/\/89W+FV&V_0A[WZ5Q;<7 9NU?Y
MG\L]-FWNMZBIRM'NWL*K.X-Q4BC(4%#KU8S%A/\ E3B^I/ _/XY]ZVSE^>OC
MS_K4_9_J^73LM\ -$?:.!_B)_9_/H9/#_:U_X_I_XW[%'@_Z#T@KU$^U']1_
MO/M[QNF_I>@ZSG5F%J\B<OMZLK]I[B/'WV"74/4.140 ^$7^GU]AO<>4X9_[
M#]'I='N1 HU&'S_R=,\>5[8P#:<GMS![VQX57^_P5=_#:CG_ *8YQ8G_  '/
MM!]9NVS_ */T_C_TZGIXI939#%#Z$ C_ %?GU+B[AP5,JG<.*W;M,,"-6>VW
M6'@_TG@)/^\'VY_7B#_1J_ZOV=>;;'8=A5OL('^&O3NG</6$@M_>[;[?].[#
M_>?=?ZY6?J?\/2?]UR_P_P QURD[4ZVB/W W=@_\0V1/^]6]O3<T;?!U<;3>
M'%#3[!TVR=O[/E+4^%I-P;BGL6O@MM5>5Y%^;&Q_WGV5_P"N!#<?V'_5KKW[
MF=<M0?:W33_&^T]PVI\-M&AVK JW-?NW(G)57^)%%1FX_P!Y'M_^L.Z[Q^A!
M;^#_ ,.\_P#5^73WT5I#EVU?)10?S/\ EZG4'5./JYAE=[9C);UR-KZ:\_Y+
M;^D-&"?Z_@^W8>5X;C]:\[WZ;:[*80:1\O\ /PZ%."DI:$FG@M]I:Y/U^E_8
MK,(MS^CTBJ6X\?3KJJB\]U) ](//^N?;<EIX_5+4\>@BK>I\-2S5F:V9FLAL
MO,U2G(LN"6]+:P/[^+'[-N1]>/K[#\W+AM_]P^SHW7=B:*X##AG)_;Y_LZ:3
MN7LO:1MN?:%#NK'TI;_<]L0Z:GFQ_=QH'/%N.!_Q*%[^]L/UYH/SZ<@MHY,*
MQ'R:M#^?^;IUQ/:&Q-RRBAI-Q45)D#Q_!,A;&U/_ %)G'^]'VOM.:X=P_2Q]
MG2UK%XQD'[>(_P '2BJ9002;?:Z?J01_A_L;^ULD/T_2N \3TU5<OB(#"Y/X
M'']?]?V7SS?3U_U>G2R$>706[EWWM/;!,V<SV%Q=S:U;D?Q_K?@_[#V07VYV
MEAT(K6P9^ /023=PMF9A#LC96Z]X  DUIQO]VL9].;5E638_[;V5)S5+/_N/
M!7H\AVK2/\9;P_MR?V=)^6F[JW2J0UE7M;K7&DW"X5#N&J_U_*;4G^\CVBG:
M]OS_ +Z_/_-7HR2.UM@"*W'V@C^1H>N=)T]@(JVDK]RY;-=@Y>GO_EVY\A_$
M:6E^G_*&+4M_KQ?_ !]I_P"K2_Z/^IT\V\S$4@ B!KPX_P"?INR/3]%0S_Q+
MKK=&:Z^R%2?^ -"?XECJG3]/)C9_JQ_YL'C_ !]M?U?\'^P_;_L]/Q[R3_N0
M W^'\N/^$=0T[ WSM#3%V'M;^)X^FN/[Z;+ R=/]!Q5X[_@726N+_P"\>VI-
MXO;7]&?_ %?ZOGUN2PMKHUMS3Y,/\!\_Y]"+MO?&U]W0_=[<RE!DX+7'V7_
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M& K;_P"O<$_[T?95S1_N/<_G^RO2C;C2Y2OJ/\'2EVK()=M[8F!_Y<.,//\
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M\]D^#XF]<2'FWR7Z30?["HR7/^\^Q3RPOZK_ .D;_CK]0][V-3:[?_GMM?\
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M7_%=)/"^?^K]O6:HI_N+<\^[].\.@NRG5F GKSF<!65^T<V"?\NP0_A0L?\
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M=:](?/8.AH\?5SU=7792OM]A05M=DK_\7/Z6Y_XCVDWC;? B\4_;T)K6X)(
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M.X?+B?RZ%:"H\_T'J_WWU^OL41#ZCI(1IZQ^3_#_ 'GW7J_A]<VFU"VFW/\
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M_P"7_-U)\1_U1_V__&O=M$O_  OIOQQZ=0O#2?U;_DGV]UKJ7]L/]2/^2_\
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M?] DO\OC_G]7S0_]'C3?_6_W[L_B/\NO>(W\(_:>N?\ T"/_ ,OC_G]7S/\
M_1W4_P#];O?NS^(_RZ]XC?PC]IZX_P#0)%_+\_Y^[\U__1X4G_U#[WI7U/[!
MUOQ#Z#]IZZ_Z!)?Y?'_/ZOFA_P"CQIO_ *W^]=G\1_EUKQ&_A'[3UW_T"6?R
M[_\ G]OS5_\ 1Z4G_P!;_>NWU_P?YNG:G^'^9ZBG_A(Y_+QUI*.Y_F()2M_O
MSW!$6C_(TO\ PST<_P!3_O'O=%]3_+IOQ6_A'[3U._Z!)/Y>?_/Z_FC_ .CT
MIO\ ZV>]Z5]3^P=:\1OX1^T]<?\ H$?_ )?'_/ZOF?\ ^CNI_P#ZW>]=G\1_
MEU[Q&_A'[3UA_P"@2+^7Q_S^OYG_ /H[Z7_ZW^_=G\1_EU[Q&_A'[3US_P"@
M27^7Q_S^KYH?^CQIO_K?[]V?Q'^77O$;^$?M/7/_ *!'_P"7Q_S^KYG_ /H[
MJ?\ ^MWOW9_$?Y=>\1OX1^T]8?\ H$B_E\?\_K^9_P#Z.^E_^M_OW9_$?Y=>
M\1OX1^T](#L#_A*ATKLS Y'<7P^^7ORTZ@[ZQRMDNNM[9WL^7*TD591$:(:V
M*CC@JC$Q/JJ(D9$X.GZ6T"!E2:^7^K_+UMAGN&/.AJ?Y_P"#H\'\@GY[]W?,
M?XZ]L]:_*%5KODS\/>W,OT7VQNUZ4QQYZ3$*ZX_,5DNES)D)(X9(*F1;(8XD
MG!+B2]&36M#Q'^7_ "_Y.O?$U12AK@>H]/EFO6PQ[MUKKWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZK=J_\ MX36?^*RC_W:#WA]N_\ T\K_
M )M'_JSU+5M_RK/^V_Y_'1ZO>0/0-Z][]U[H'>[L'/F^N,O3T/-12,-P8_Z@
MZ<9>;Z?['V$N=K+]Y[4$_&G2WE^X^DN_'/G@])+;>6H-P8'$9J+]66H"O_))
MM[!FT7WU\)F_WST*-QMO#.GIW]G'2+KF$MQ_6YN>?\?KS_3VD*3/W_P?K=>\
M$7'Z'Y=)OID-D-V]H;G@_P" ]178W!4%_P _PT\?U]M^W5O]1>7UW_O[IOF>
M?2B+YBI/[.C$^Y7Z"?3C'_FZG_@\?^]K[-5_L3^7^'I]OB'Y_P#'>EO[%?08
MZ9I?HO\ K#_B?8<W'^WZ66G#\NL'M%TLZC3S4E,14U-@/QQ_OO\ #VEEE\#K
M5"<#I 3]G;!Q]0(:W=V#-3?D_P 1/_$$C_>?9,.8MLM_[>X_U?RZ7_NF1LA&
M'[/\YZ4^+W!B,[3>;"5=!EJ;3P*#*Z/]XX%O9K8[U97_ /8=)+FU:/XJC[1_
MFZ<@2#<>[S0_4=:!_;US;Z_3DFUK_P!/:A;OP.FA:^I_U?MZC>0+/8DZ2MR;
MVX%_Q_7VQ-X,)_6M^G2/ '0/X..GS/;6\<M(J$;5H=L8#"+:WVPRJ^2LM]!<
M6_/T'L(6^VZ]YG^71A<,;6!1QK4GY^G0V><'^Q<?\&_I_L/8NI-;]%U.L'M7
MUKIP]^Z]U[W[KW7O?NO=-_M/U[J1/_8_Y"_XCVHZ]T'>X.N=L;GG.4FI/X3F
MM7^X_/8 G%57(X_>_)_V-_\ 'V%MUY?AW _/I3:7[PXXCS!STGDV1V)26@HN
MTUJ*<6;3G-N4N2J^?Z6Y/^^X]EJ\OWI_XD5^W/2R;<HOX"#_ $20/Y4K^SI&
M[^V[N[$[1RV=K>U,Y65-+0@$8_[3%TIN?\#?_>/9/O>V36\-/J)>E%A<HST"
M ?X:]"#MWK/8%(E)DSASF,S<D5NX#_%*OC^HF-O\;^SK9>6;*XAMYIND=W?R
M:BM:#Y>?0IPQ"+CGZ_G_ 'U_8NBLC;?V/2)WU]<_/_M'_)W_ !KVKZ;ZP&_Y
MO_L?;/@PC^QZN.I_M[JG3?[+^O=2/:SP^G/$ZQ_0CD7L%^GOT473'U7RZQ^V
M)9:=/$T^WJ1/_8_Y"_XCVI$,'5:5ZZ3^U_K@W]Z$/^C0=7?H'.X'%)BL1N"!
M+':F[MMY!OS>E^[M,/\ > /81YRB_1^MZ7;;DZ#^)37[:4Z&&*3S?IN>;?T^
MG^O[%<,_U,/C=(9%T=<K"F^G(_P]-M/^W_K[U];X'5 -70#=S7K:G8FT]0;'
M;AS;9#.74#[FEQA\_A)'/Y^G^'N/?<>/PYK> _Z-3SZ/.5X?'#/_  B@^1ZE
M>$P?Y.5 I/I_#[_\3Q[1[=8_NB'P8>CAKD.:D=2)IC$.;FXXTD?["_\ OO\
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M6_\ M^/;-]/]-#XW^KC3IZ"'Z@@?ZN%>B:X+'G?-2>Q=W?[DZ[)WK\+0UO\
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M7O?NO=1Y_P"Q_P A?\1[;DZ]U21_/7_[)4ZU_P#%E>E/_<FL]B#8_P#<A_\
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MWM2DE*:J8FVD150)/-OJ/:#<]@GVQJN=3>BT)/YBH_8>A9R-[M;5S[&4M*Q
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MM->6YG_MNDP@"^=.@%S/4]71UM9F=@9H;5J:E175^";'#)XNKNI!(B L"?Z
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MH_,<01T&+;.[2QZK%29?:6?IOJ*W)X^KQ=5_K$?U_P!O[!ESR]NT']A/;?\
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M(;_&P!UOLDNQ7M["/]%X'Y9/^7H46F[?ONW0FG ^=14D 4(^SHT,;S<WXO\
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M^73A[KU3H&.V+0[>VS7_ $-'OS;WU_PK#?V%N=O[+_J)Z6[,:,1_1)Z%:/\
MX%-_K+_O9]B^V_LA^71=#P/^KSZ<?;/3G3?[?_W&ZMQZX93(TV(Q]96R@?:T
M>/\ OU/^OJM_O(]H[N7]W_K]4C!E/SK3HK-#C*G?II-S;T_B%9#5I]]@-IW(
MI:6E''TX\TU_]Z^GN(ELGYFA\;>9^AO"D%M58A]I\Z]*G^Z>T?!_Q[N$(_[5
MG_&O^-^W8K':J>#-_N-TY]7'Q!->DJZMUG4TNX-O,:/;OWV-H,]@?U4OVN4_
MY38/K^/]];VA:W3E";QO'U]4GBANQI(]2#YUZ-E$+,1_B"/]L?<T64_U$'0*
M;J1[5]5Z!7<=_P#2?U7#*+_Y'OI@/]C3D>P-OG^Y-O7_ %<>C.P_W%D_+_!T
M*G_*5_R%_P 1['_E^?\ EZ1>7Y=.WM#TSU[W[KW7O?NO=-]K?Z_M[ZOZCJWV
M=..O_7_Y.]V_6Z;T_P"K'3;P?]];W?\ 6@_U<.G<'J0G%[#Z$<'_ !]I/%^H
MX];DZD^U'3?7O:?KW7O?NO=1I8A>X%_K<7_U^1_OO]A[IX'CP^!UL'H&NL&%
M!/OS;+<4N W;D30!OQ2Y7_++7L/]2/Q_L/R GRG<_33W$$WX.ENX0:PC>H%?
MMX=#"/T'_7_XI[&T_$=,]-&Y:22NP&:H80?N:J@R6/QMC_QUHK?ZW+7'LJWT
M3FRGZ9@H''#U/^]= -L*I@DVCB_!_P HE :*O!'_ "EXOF8>XLV#,/ZWQ]#@
M88_RZ5?(/]2?]A]/9C_8=5Z0_8L<']P<IY>*?[,$?[S_ %_QO[1\Q _07'\?
MZ?5X#^F*>IZ,7C8:C^&T7GO]W_#++S;ZD$?[V/S[D_:Z_1V_C] .Z[F-/]7#
MI_\ 9KUOKWM/U[H&M\VF[ ZJA Y^^W-7G_6^SO["6^?\E*W_ -7IT:68_3?\
MAT*R_P# V3_@B_[W[&:<1]H_P=$\/ _ZO/J?[9Z<Z;_=H8?(=7Z+UN=DH.UZ
M:MDL:;/;5_AU%;^S_#:N_/\ L+'_ &/N(=\3Q]__ %O]]="O9IOT?F&_PCI2
MDVY/LWC'U'#I^<TI3KB/U'_8_P#$>ZQ?VO[.K]!YM[_B^]J3P'_)?XAMF_\
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M<S&.I<)MVF7*]D[]RB T&!@',=-26M]UFZFQ@IJ4_O\ ^P!(D[VQY6ON:[J
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MLIK$?XC:C^C_ ,7T(?TJ/]=N?]A]/][]GD7^,#I\XZP5=-334];#]/NV./\
MZ?U^O^/M#N4/U\/@S=.6)"FOSZ"/$5$\W3V'\_'VIRN/ _[5=6"?][_WCV*>
M0)II[/H,<Q "0]5+?(+]&5MSQ];?XGV.8;F*SQ+T53"O5S/5&^=H83ISJ>DS
M.[<!BZL=:]>C[.NR&KC^$T_']1>W^P^GL-7G.-C;D#[,9\AT;K8W+H2%\VR
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M[W[KW7O?NO=1Y_['_(7_ !'MN3KW5+/\WF.*KVC\3<1F !M++_,CJ&DW8?\
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M7NF_W[I/UV#;_&_'O4OZ_7N'7IIJ6'_@0/\ )+<*?\?;,LG[O_W-_P!0Z?\
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M!-N<W@WO0<O[);90Z<*\/0_YO4=#'Y^/4H_Y*_XU[D'_ )H]%-.FG)[DP^*
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M'_PIU_E=] [^W#UIM63N_P"1%9M7+_P;);LZNV[C(MO&7"7$DF-R&3J';+K
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MJL<_,4_+K!+[ZNZP;ISL2#J\&WMH?L\P/+R-?SZO3I_J_P#K)_Q/L>VO^?\
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M7VX_ET;;?NUOOL_^/VO@'A^ATV;=[4[5S6U\9N&3JFFRF(S5&*VBK=L9Z U
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MJVF>05)J#=V0%[@#V2;=?FYF8<*4_P !Z/K[:TAMEEJ3J!P> [E_(<3U7O\
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MD43U%3)D0TQH:!CI;3J (T@<  @+8GL)P]T1\_\ !TKOH3#&*DGMXD_,>O1
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MOL/\Y'_=93HPVW$J_F/Y5_R=+K"N9L+B)C_RF4&'4?[[_#GV;;3_ &5O^?\
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MCGD!'==@-_-XTW^'HXM;C2FA?7-?/I0UN*PV7H1096DHJBEK+!:#(XRW^O\
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M+ GZ^TDVV;AN1_6G_P"</1DMWM]F.T5_TV*_ET];=Z^VGM B;#8&@ILA4?\
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M;VO^0+#_  %_9#N-QY]++44_U?9TWZQ_C[+O!Z,/#ZQ>Z_[D]5X=<V%@ ?\
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MW-NY?N=V;B0E0;"EIJ5B/#C(#J YN?P?^()3L.PF#_=G_HTW5KB<4$8^$?\
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M&YN/Q<?7\'WC!?[Q>;>[^#/UDCMNWQR00$J0?5>/2A@[6I\?/X-YX:OVK4$
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M?ZO+I7;6K?XEM[;V0XO5X/'9$\_ZJE/_ !7VNVV6L%?]6/\ BNJW2TGI\_\
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MW(^EC_OO]]_7\>[K;UX].23:>'7OMU_U'_)W_&_=NJ]9T^G^Q]^GZ]UF5UC
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MAG$BBY^M4H)^@]Q;[B[5,D<-_ I C71Y_ K!HZ^E:D5]6'6=?W)^=K:&_O\
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M?O:+\^&W_(O;>R?3[/N?[SF_L>DUR;BZC\,$ZAD4-*_(]+'M VQ=9S<<Z?\
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ME3B9]8I<C31;8U24)<*)PI)4M<<CW6I'F?VCK5$/$#YX/"GV]7]P?V_^0?\
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M#9K%FP\M;CN:BX)I7A7S\_/R/1GS!S9M>TS&! S4XFN.-#\-34>E.B]_&?\
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M["[3ZRZ/QO:_4461W3T]M<;LS\NX*-9TH:=J98*XI15:M.X;TD&QTL1;V/\
MD_;FVE3;MC/I4\.@#SUN$6Z2F>,>7F:"E?L.?7'1/,5MWXI;8_X3+_*7#_"W
M?6]^R?C?1_'OY+_W-WCV_MO^ZV;J*BLKW.3 I#%1OXHI=;$BF;D_4<#V(GN2
M+SPU^&GG\Z?YN@T$C:S"-AB:XSPU&O 4R3Z=%S_X1;K?XN_-)H14T;COC8X\
ME*2S#_?LN3R3^?:R;B?R_P"?NDD']D/M;/\ O/3_ /R1-D_R9NO/EY\H]Z?!
M/Y#?)?LOL[!]&]A9OMS!]Q=:RXG%TFW\;F*.?,20,<+1R-5I51J8PLI' ']
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MXG_?'W9.A!.:]-FX\O!A(!X:7[JOJ?\ @#0D_P"^MQ[]?;C^[^J64!N_D/\
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M@-[CWFG8-KM+:Y"A(Y I\)?$JS4 T]A4MGA2M/ECK-3V5^\)[A;M>[?96_\
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M_P#'AT=\J_\ )3M?],/\!Z>OBI_V3ETQ_P"(SV3_ .XA]GOL?_RJVW_Z=O\
MCQZ(N<?^2K=?9T:#W,709Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[JNC>?P"ZCWY\\NEOYAV9SN_(.Y^C^I-S=-[4P>.RT-
M/A)L1NC[Z.I%;1-1ZA6_[EZ@E%J0KDH%7T@C;%6 J<CR_;_GZ\KLKEJ8)K7-
M?+_-QZ(/WM_(%^.W='R:[N^5&*^37S8Z6[([ZS.%SG8T/0'=E9US1USXS'TM
M!"BQXJ(2-%$M%=!4$JAN /JY]XBLQ-:?LZ\T150"H-,5-?+_ %>71@_A3_*8
MV=\+NV:[MG!?+#YP=SUN3VIE-HR[8^0/R(R79& #9>02?=G&5@\BUHMJ1FL%
M<AQ9@+V60 _$3]M/\_5-)44*@<.''!ZN,]TZOU7]\Z/A)U3\^^HMJ].=NY?=
M>$VWLWM'K+N+#5NQ<S2;?JY<CUQ525% /'-#4HM%)KG5?R&]0NJG5N*195TG
M'GC\^JT*MJ !J*9K\C_DZ/3)CUDIC0EEL<7_  _41?\ L@7_ -:P]M$5Q\NG
M-6:_.O1(?@9\&.J?@!TK6=%]05^[<]MVMW[V%V9/F=[Y:DS.3DRW8M<U;D(H
MZB""F50@71S^06O8D*], JT&?/\ E3Y=-1,2VIA3%*"M.-?GYGI'9O\ E\=0
M;F_F#[9_F*[GSO8.Y>YMB=.Y7ISKW;5?G::LVUMZER2RQUM5C*'[=IX,I6+7
MR,9#.$ E==6HJ/=25(XY_ETX'97U4%*_G_JQ^SJP3(8[&Y6CJ<3D:6AK,;5T
M+8^NI*[U+44N0 4W/U%V#"UN3>Q4V/MO!Q_J/5@Q7(X\?SZI7^%?\D/XL_!;
MNK8W:_6.]>],]2]3T?;_ /HAZXWMO&+.[9VBW>]3"VXI</11T5+(D]73TU/2
MDB,,J-K9?W&LXLBJ:U)XTK3JC1,4H0!6F<U]?\GGT;_Y8_ KJKY<=K_$KMKL
M/*[VH=Q_$/MJI[@ZXH-JY:DQ])4Y6=?'X<HC4[/)1Z:<>I;,RZARSF]O&4E3
MZ'Y>M?7Y=:\,D,* ZOM]*?Y>K#/=>M]>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW5<%7_V\5JO_ !6I?_=BGO#SFK_E
M?C_S2_Y]ZE>U_P"58_V__/XZ'7I'_CTLM_X?6X?^A3[DWD[A_P W>@_S!\7^
MU'^$=#%['T_11TX>T_2CIO\ ;G_-;I/T W93K'V9UT)Q_DK4.Y?LM0M_E37N
M/<4\T>/<7?@S="_ET QO3US^P=/UQXK?4\D\'^GLP\#ZC^VZ9K3AUQ_V M_K
M _7_ &/NMK^A_8]+6SQZZ;[>QMR3JL2?Z@_3VPL/;/XW^KATSMG]N*=(&BT_
M[+3E[_Y@9:/3?_E5_B]+>WLNLY?^0=/_ *9?^TJ+I.X_W<K]G\]+='D]Y.=1
MOTQ9;]*?\$;_ 'H>R+<?B/\ ICTLL^!^S_-U$]EG1ITW0?\  G_8I_Q'O<G]
MA/\ ZO/IL^7V?Y.BR[$YH-R4<_\ P(I-V;C^_P#Q]*OS?\1[A?9?\7AGLYO[
M;H9<;-6'"@I^SI<!?3P1^3>WLTB'T^.K'/4+)?;_ ,'S$%:?\G&/RG\0_'-^
M/Q[U=RPP0^-U9:UITL.J9:@=<;1$PN!@L6>/ZZ_8SY,/T&VP03=!#<Z&1B.A
M+_HK'CZ@CV)IX/,=4ZR^VNO=>]^Z]U[W[KW1?-YRC=^Z!LNRG;NW1C\YNUK<
MU54?^ =$#;@&PJ+?\:]PYSE?_O.;Z.#HZV^WUC6:U-0/D.-?\G[.EOS<@'V3
MPPPV\/1MQZR>[]>Z][3]>Z][]U[KWOW7NO>]6_#_ %?+KW06W.S=W<_\>YO7
M(6_ZA<I_O/\ P-_WWT]DEG_NHF_6_'TI/ZJ_-?Y@]"E[.[?A_J^72;KWO?7N
MO>_=>ZBS5%-14_FFJEI:>EM<D?\ &N?>A-#!_;'K>DD\*UZ#Z7M/:<,XAH:N
MORS'FV$QU9D_]OR?]]_C[(+CF&'[/]7SZ4P;6S#A^TC_ &>N%'V/LJKG\,U4
MV+J?Z9O'5>,^O^]>U4/,L/\ 8_ZOY=5>R8"HJ?\ 2D5_G3_#T(D(IY*<5$!N
M!>P/')]F!?ZCICQB#3IISE$<OA\OC9O^4FAR5!P+_2X_V/X]O7L/U\/@=;MS
MI.KYC_+TR[ K!D-F;<K9N+X/'*?_ "%\?\1[)]HF^OAZ>G30Q^W_ (\.EN_T
M_P!C[.H>'2?H-=Z[DK\::7"X:R[ARHR'V)KC:EI:7%DVK1]+<6YY_P!;Z>PY
MS!NGT@Z5V5K]2232F.'$DUP>D$-I4%41+F:NNS^0M;[ZNR7]?Z0>P3-=_4="
M81:<"@'I3KDNT:".TM <ABZKD_?8')_PP_\ $^]+,=O_ +'J\UOKP?V$=.D&
MY\]M3C,WW!A 1_E]"?\ *J7^GFA]GVU<Q3'^VZ*I]N#_  X^W@>AAI,C!D*"
MBK:(?=4U5_EPX_"_\4O[&RR_40]!^=2I^P4Z0PD_BW9=9-:]-M/ _8_3_E*R
MO/\ UI/]?9/%_NPO/!/X.E*C3&/F:_E6O0DBUQ:_Y_XG_C?LYQ/^MTQPZY^[
M]:Z][]U[KWOW7NO>_=>Z][]U[IGJJFFI*>MGGYIJ,CGZ\&_U_P!C[3I_B'ZT
MW5H*M@=!1UW15&4_B^_ZP#[C=5</L;G_ (#8S&_YGG\_X^R#8[;ZG];HTFN-
M!T>GV9)KT(\D?TY]FJMJZ9Z@5$ 7ZV_/^'^\_P"V]M2VVKCT9I/TS5< /^:-
M[DV_QM[*KBWIPZ,8)O7I*9/%>:GJH)R*JGJS_E_WX(X'_&K>RZ>#Z\_K=&-O
M/3(_+H*XJ;<O6$_WNU:6OSNSSS7[(;_@32_]JCZ7'Y^W]GNU[_+M'Z!^'_#T
M[<6PO>.#Y'_/T+FWMR8/=>).8P=6*J@46*_6IIK#_,S"Y/E_U_\ >?<R;+NT
M.Y1=$<D9M#1O]@_X>G"JIZB8'P#_ "0\#\?3_7_XCW=[$#JT%QT%>Y>K^O=Q
M5_WV:V7A,E6_VJP4 CJ?Z?T]DM]L%E=8/\J_Y^C^QWBXL\PMCYTI_@Z"WMSX
M]U&^/C5\C.F^D8L'UQV-VYT;V!L':&<IV7%_:YC=F'\%$C5!](%D>,GCZ\_G
MV*>2MJ@L'(\R,5_;_/\ R] WG?<I[F$,2: _YQY>G7SO/A/\R^SOY'^YNS>B
M/ES_ "R>K>TX<_O&!=X3=[]<_P +W#",9#)22PX'<-?CLAALAA)2#+%ITB;7
M9)RI#>Y::1A4 #\QP_U?9U"D34IJ)IDC2:5_ST_9QZV#OY#W<7\CWN+YC;C[
M'^*O5G<GQ5^:V]\?V+6X?I_?G8DV2VO7XO>#S/E<3M6&@"X?(4U"(?-34%7$
MND(%C>0>0!/<M)2J8/EYC_!_AZ46P77W4(\S2A^WB1]I'#RZK5_X4</(_P#P
MH(^+<8OX/X5\+0P_Q&X4'^]CWMAX:$?T?^?1UX'QW'VG_CYZV+_^%.*E_P"3
M7\IVEX;_ $G_ !V%_P#R=\7_ ,:]A[:?[:6O0QYI_LK;[#U7Q_)OZ9[2^27_
M  F0^270G2^6;"=I]J[U^1FVMCRS5RXB.IK)*K#2C%&8E57^+!?LM3.%8U84
MGDCV>7,Y+JH\R?/_ $O[>@O;1@"9C_"/+_3_ +.M?KX*?S%MR?R>\-O#XK?,
MG^59U-VCC<QNW-UN]*GNGK(;*WPBY&G6DEHOXIF<5DJ#)XQ&4BG 41>,EA(1
M:ZX$9! /V\?]CHKJ<$,1Z4.#_G_;UL??\)ZM]?R3>P.\]^9_X)[2[A^/WRMW
MAL[<$F[.E.Y=^U>9H:G;.1R'WM;#MOPL,5E*3!Z0#9(JND51,%DC74"W<;;Z
MA*+6OSH<4^0Z,+"X%M+5J$8R*@U_:1QZIMPNR<'_ #./^%/_ &EL+Y14K[OZ
MQVKVGVU@CUOFJD+33X'XY8BOEP^V)+*CMB:B:@NR*X:2Y9BI(]LW-Q)8VA:$
M5(&!\NGK:W2ZN=,AQZ_.@%:8\S7]H\^MC+YD?R&/@5\[-S]<[NINN\U\6:OK
MFFK\-N=?BWL[#[-&X**K19,;'6&2*3&T4N&D420U+1,THOY.!;W'.V<]W,E3
M<*.'$#AG_4.I W3D6SLJ+"_'A4T)Q\QGUQGJCG_A5;VOO/8G5/\ +E^%V$SG
M8%5L/;7564W_ )8[ZKOOLKGJ[:M0VT\)69Z5+)79*CH,2Y.I2&>=F5>?8]V'
M=#N2";]GY8_EPZ N][:-M=HJ^>:?8#_EKT$'<?R]_DD;T_EV2?$GKW^77W_M
M+M_ =8Q#8'>-)TW0+N ;XQ^.5H\K7[@_XN%535V11_OKJ"],28XD=1[$"LAS
M3/K7SZ(6+Z:U%*\*8I]M>/5D?_":_MCLG/\ \H'^9CT3ONFW!%C.C]E]MY3K
M:/<6)K*,T>.[3V1EZBNH:(U/I54R]"TO'">1FMR3[3S1>."/0$_ZOV=*8I-
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M).^;G_B=]D_^\A/[$$O]L/L_RGHEA_LOS;_ G59W_"46&CJ_YG/S5QN3QO\
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MKO9GL?\ Q*_TK?\ '6ZB?W@_Y)UM_P ]=O\ ]78>K04_S,'^L?>*&Z_[EO\
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MVK\B-Z546;RE;O/+;3,;8O"[2H*S&TU<\DN29IDH:,U+A2&=_P E:((+;]5
M!G+5Q4_/_53IJ:2YOSX<I).GM!&:#- *9X>?' ZM3_DC]/\ S-VC_(=WKU?T
MQD<C\8?F%6]N]U;AZAJNWMCF%14QUF(?[6>CS=-XH8,Y3FJHTJ]/ID0,^OE
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MV_6K:4H<?9GA3]G3)MC<M?'EO[I;N_R3<5)?^'Y#_E%RE*?]WP_\5][M+_\
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M^9H=XZ"LUB82*\/4<#TOB00..?8CEE-L>F.O7 46 YO[<A'U)Z]US\'^U_\
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M"G\^@:KNS)LO+_#^O\/_ !]::Z5F=KY"N+I01S:UC6,.;'Z\7]QONO/?T_\
M8]&MKL]/C-*\ .)Z@&C["K"9JSLIJ:IN;T&!H*2W'_+:W^VM[#LVZ7_^KCT9
M^!:C 7\R?^+/7?W7:.$!GHMST.ZH"/\ @%GL<,:1_K34@/\ OOQ[\.8;^#K9
ML[5\$4/J#7_"/\G28ZHKI3@,OC<Q3#%Y?%YW(FMH1S<9:TWU_P!A[!W+UX;A
M.CC<E'U (-00,^7^K/0L0?H/_!C_ +T/8AZ2OQZS>_=4Z][]U[KWOW7NO>_=
M>ZX/]/\ 8^[0\.O=<4CL "+?T -_>O&'5V:O09[OI:_!Y"CWUBJ.U1B:%J#/
M8_\ Y6L7]?\ U3_XW[)[RT\";QNJ1D.-'D34?(\?Y\>A H*VFJZ>DFHB*F"K
MH!74  M_DW%O][_WWU]F5E*9X?\ 5PZV13B:9H?]-CK#F_\ BT9?P7\_\.R5
MO]MS[2[M3P/V]6CXBO#'^ ] WM&W]V,1X?K]CC?][]QE+QZ%Z<<]*OVWU7J/
M[]THZ]+'YH?#.?\ )JS@?X7_ .*^V)\4Z97J9UE/Y=F4L,PYQ1R.$)^M_P"'
M5?\ QKW)_+)-Q9_ZO6O07W1?U#]M3^8I_DZ@[1KZ8;[[$PQO]S]_B\^O^QI1
M_P 5]L;9>GQIX/M_EUZ[MZ(C?*G[2!T*807"\V_Z-_Y%[.H?['\NF-9Z!.C!
MBW%OFBJ/^!)S5#7'C\Y:D'_&_<;[Q_N1_J^?0BLO[!3Y4(_F.E 7'^Z2+VOR
M?]]_A]?9;"E/7I69APZY^]=>Z2FX,A-#]GAL:/N]PY1?\AH3Q:__ "FS?XPV
M_K[<6#ZGK8(7)X#SZ4VX*4;(Z[K*"BL:FFH?L37_ /33E/V3_MO^*>QR\/T%
MGX/04MF\5ZGSR!\ATN,'208C$8C&PGBEH<;0C_>!_P 2?9QMT/Z/5)&J23ZD
M_P J=2:BMIL?3U596G[2FIJ'[[( &WTN?]C_ *WM^\O3;]4$&JE*$DT'0&$U
MV]=.3S1KJ/"U1M@L%0FUJ4W_ 'JWZW,UO<;;CN\U_P .A+960B]*^I]>IAV1
MMJQE_A-$:G^A;\_Z_P!;6]E @/\ HW2G0?*O48;6HJ,^?#5N?Q53_3'Y+3]?
M]O\ [W[5Q2/;_P"_.J^%">-#TI]O[LRF-KJ3;VZO\I_BOIP.>H./N;?[IE'X
MK/\ >/8GVG>C!GCT47UF,E<4X@^7^QT*SJ546^I:WL:32:>BU./03[(C_C^>
MW'OJ4#[:K/\  =J7X_R3&_4\_P#':;_B?83V[_=A-]9_JKTKF_24(,TRWY]"
MPJ"$7/(L>1_M_P#7O[&$OZ_ZW22NK'6'0?\ #VUX/3O4&6G7^I_H0?\ ??\
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M:6ZJ[?6/(.G9N]<GKJ?J/^+=EC^?^6]Q_B3[#EY]?"*G_5_J_+H4;5:6!PP
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MCC2GF,_X>AJDW!G:P>:KR]?4_P#D0TKS_MO]]_O GN=SDFR2?\O1#;[!;6F
M*?EU@R6<S^6I_M:C+5M5%_:-7D=9_'Y^OMN3=9+W#DD>53UZUV>VL\P 5^0_
MV.L]/F<SAAXZ3+5D$ -EN0I%O\;<C_>O::RO[F,]A(]>K2;5;W(K, 3U4+_-
MO[D_G ]>8'J&K_E;]983MR;<F)WOMWN:>JVU1[ER6 EDT_P7(8N3+9?'FG+4
MC3>.1(YCJ!/)/$C;+('CUL36GI_L>G42<RV[6\_@1@  U&:>0^=.-:\>J\/Y
M#'\F/N+X7;P[U^9_SGQ>%H?D/V7MC*[3V+L>IW10[LRF,I]_U/W&Y=PYFKIE
M:.FRV1!=(U1N4>0,H)'NV^7:L/!/$^1^?_%]-\N[//-=J%]:DUKPS2OG4C-/
M+K88H-K[3P,U5+MO;U#C:<W'^14'-0!_O=_<70[?'"WV=9*6LI,5">/SX=!O
MO#M6+$UC83;%'0YO/7M7D@XVFIOI_P "I;DD\>S68JAT@]"+:^6YKH&9L#]I
M/V=(*+??8[S&=<IM:DMS]G1;?'Y_YNF>_OQG;H0CD^W'K^W_ &.N67^0TNV<
M7E<-O[9M5]EDZ')45#O+;)&0Q]/4Y,?6JA-JK'_7_/W^OT]E7,!5[2<-YQ_Z
MO\'06W#DJ;4#;GAD@\2/\O1SNMLS1;EV-M_+T=30U,%1@\:OWM&#D?\ BU?[
M V//U_K[A6UBT" 2>IZC?=H?W=.1,//[!G\CT+4,-P..+W ^G/\ OK_[SS[,
MTMJ=$\UQ7IZBBMP+"P_WW^Q]JR=>!T6DZ>G:&(<$\VN?:B#I)*W4SVLZ2=.'
MOW2?KWOW7NFRHKJ:CM--4T5+]?J!_O'(]M37L-OTZL);%"?MZZIIZ>K%X*TL
M/S8^W?K8+CIM[<KTR;CVSC]S4/V5:1_DH_B%!7T'_ JEJC_NZ"WU%A[07FS?
MO>'_ %<.JH/"-1]F>!Z3& W%ETRPVENTDYJVG'Y#_E%RE*/]Y\__ "(^TNW;
ME]%_B<W3[Q" :UX?S4])JMQ^0V)45<7VGW6U:KF@KZ#D8R_X_K]F./81W&PF
M@Z.;&Y$M#P/H?/[?GTYT63QV0@,U'5X^JIQS_N/_ ,/S[)(9S/Z]&9AK\OV=
M.,LHAISY_P#BE_;O@U..G>/2,J:BHW9]W@-J?Y3!5V_CN<_Y1:2E_/\ KUG^
MM_L?\%UG9:ICXW2*]<6@!;CY#SKTL-^18W%8':%% #24"[MVW0?TN,9>_P#O
M7L2\Q0FPLH#_ ,,_U?X>B';?U'8GB ?YG_8Z[[# Q\VS\_?_ "?%UIH:\#G_
M (NEK\?[?VSSAFOV_P"4].[+DLOJ*C]@'4GV$?"^SH14/K_/KWNO3O7O=9?\
MO3:\3TDMR_7;EOI_?S;7\/O_ +#_ 'W^V]NVO]O^72.;_)GH??<N]!?KWOW7
MND/OC,SX3 UD]" ,E6$4&!(%S]SD_J>?:'<;RL/^KY=.Q1ZC3]OY5Z==N8>G
MV]AZ+"Q<_P ,H?H/\?\ D7^V]WVV#P8?&Z\[ZS7U/^?I0J +VO\ XW]J1-]1
MTUPZ\&N+V_-K>_3'Z?KW'KNX_J/]O[:^H/\ J_XOKW77I"_X>W/]R>O=<O=^
MO=>]^Z]U[VHZ]TAMXYZ?"8JU%>KS.5KQ08&AM?\ RGV2[C=]/(@8_(#)]1G_
M #=3=LX"GV]BJ3&6-4:6WWU=;BJJLG_GIO\ 6M_O'M3MUI]!#U21S(2?S ]
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M<W/L&<R<@P[A+XUG^C_J].C*+<FC 5AJ'IYC\R3TS1]8[NF;5E.Q\@M.%X;
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M=P_\RJ[%_P#$?[S_ /=//[G.7_<:3_FD_7)SES_DI6O_ #UP_P"'K3G^#/\
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MN!Z6V^<G7G T>-QG.X=U?PW!T'%OM?XI_GYOI]/#_A_Q3W(^^7?U,,$'09B
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MO]A_9=&4)V^\_P!R 5/GIX?S'^3J10=X;7BFH\?OJDS/6V4:Y^TW)CO\F/\
M@,A%_DA_U[^U$&\0O_N;_J_R_P NJ3;0T K;48<:C_-_L]#)2U=-4PB2BR S
M4!!"5M!E;4W_ %AY]FRPVY_XDD^O'HCF,X('T_A^@/'IS!73J-ZPD_4O;_'_
M 'GW;3X'5_!ZXQ.!>] G^Q'_ !7_ (I[H9(?]7_%=4\ C_5_L]<ON%_Y4?\
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M;^QN/V],FZLV^)*'U5O^*_P=8VWMOS!V.Y]BY&II2;_?[2R7\5'/X\-_K?\
MVKW[^L6X;?\ HS6!?_AW^JO5C;VLF4< ^A'_ !73UA^U]C9:;['^,'$Y  @4
M.?MBJH_[&<%?S^1[-X><MO\ ]'[.D+[==KPR/D*CI?I-22V^V6UOJ#Q]?]:W
M^'LZMKS]X']#JEN*#/6?]FWZ_P#'Z?X?UM_Q'M3]1/\ V'T_^KCUKZD<:_YN
MD)O$!<<I_(_V'U_WJWMB[\&.'I0A^J..J"^[=P9.EK=^[:VS3?Q.K&]MPUQS
M?_*/3TV1/%OP)3_QP_'N);/<9+5_"BX=""YM_JH 3Z = +_+7I&H?YIE''5U
MU3E9Y_C3O2KR>1RG(Y:BM>_X!M?_  ]Y+;+++-L<9_X8?\G6*<=![@70S7Z%
M/L^,];;GM/U,_7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW25S?_%GR_\ VK\E_P!#-[I/_9'_ &W2BP_W)7[5
MZTL_AA_S*;.?^).[*_\ =U4^\9=H_P!Q_P#FXO\ U:7KN-S5\5O_ ,\P_P"/
M='"_Y1O;_G^?09Z#_J'_ +>I? W_ *A>X?\ W6S>S;8?^2E:_P#-5_\ !)T%
M/=7_ *=WOW^E7_M(MNMICN'_ )E5V+_XC_>?_NGG]SG+_N-)_P TGZY.<N?\
ME*U_YZX?\/6G'\&O^R;=D?\ :PW5_P"[FO\ >.>W_P"XZ_\ -S_"G7;WGS_<
MU/\ FC:_]6UZ.,?U+_L?;L?06?ATR?%/_M[=\:/_ !"G;W_0K^SWE3_DK?\
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M'Z@#[/\ )T4@]S?Z9O\ CQZ%,2\$!;_X$V]NRVG3?63VWT8=-65K?L<-F*T
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M//\ <C]'KVBG4[VYTFZX/]/]C[M#PZ]T&^X-[3T>0_@N&Q'\5S--_P #[_\
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MV:SG_MK>V_P?Y>KI<LO!B/D#7_".@^FZBPM->;;&9SVU:@ W7!9'7_U@XO\
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MQ2X4DUU9^RH!]?G\NK2_>NO=)RMK<?AL?59#(538S'XQEKJRLKE 72 !^ +
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M7^G^/M1",=1]PZNH_D0T]8W2/R&RL9C.(R_RDWF<-K_K004L=2?];0Y_U_\
M8>XQ]Q%2XN01P-/^.CK/C[JHN%V.8O\ \I$Y'V>,_P#EZOZ]@3K)CKWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZJP[&W7!L[Y[U]?)1_>2U7
MQK%#0T:\?JR=_H+\&QX_IQ[P:]P-[.R\^5' 0#^:]3?LVW?7\MT]9J_L/0EI
M/O7>U?2[CHZ/.U>:Q=??!_3&8NET\_\ 68#^GL237.[;PFNS_MO]7^7HM\&T
MMX3 U "*GU/_ !71@=I[[P^YH!0@G$9JEN,A@,AS5'_D?N7=BWV&_P#T9O\
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M]ND@4>U!C[5541]!DZSZW/\ RK_[U[@;=K3]_P#X/LZ&%C)X!HMP23Q-<#[
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MLKT0#<=5C-\Y#S8W;]#MC95-S14%#CQC:G(\#_@7_P <H?Z?[ZR"VL+25O\
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MI0>:;0?A/[1_GZ:,WTYN?*46BL['K*S):;MC_P"'_P +QE3_ $AF\ L00/\
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MRF%JZ#+8^J)!KZ+CZ#_;_4_GV-[2\AW#]:'HG9&B)!J#Z$XZ<?9QU;KBTJP
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MI\9*#_P))O<QV(X/IN?];W&/,NWW'+LW[QAA+K-\SBO^#H]VJY&D(30@]OS
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M>S,9G]U9;&;N>BI-P5@AJLSE*VHGU2^$.U1.(E2$ ,L2QKI]TDC+"E&_XO\
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M/6L!\1/F#U=TK_,>[6^46^(-]+U=O:;NJKVY/A-J-7Y!AO+(T=?0'[-K7O&
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M."$RE6>(M'.>/;]24^$YXG-.F6%6TZ@0."BE<@^A)_U9Z5O</\OKMCI?YO\
M_">/8_4^R-Z]F]-?!_:6\]@=A]MT./22DH*7$;67'TE;E65W^T2NJB=/HO8V
M6]M1;./RXFF.KZU8KFFJM!7/E3[>'5K7\V'^7UMG^99\)NT_B]E,G!MS/U;R
M;NZJW.*RJ^WQ^Y-N/Y,/45L<#EJFBEFGD@J49'5%,C!=<8*ZB<2I3S&1UYZZ
M@?(@ ]('^3-VS\JNP?B+LS8OS2^/6^.C?D)T",3T_NJJW1BX<)C-Q4VV()*+
M&;GP3P!8)XZJA58JF&.'Q1U2>AM+V1QP2F001C(I]G^SU02 /52#JJ<$')X_
MD>/[>KBO:3JW5)/\]%K_ !-ZT'_@2/37'U/J&4/X]G6V2>$EU\E?_ W^;J*?
M=T5VZV_YZH/^KD?1U\AE\KNR:2FQTL.(VQ35PH_N*B,35%55)<W@5@1XB23_
M %]X(<S\P,-RNA"*Y_V.LL^6[6!K"W8UU:?4T '_ !?4"GP%9BN,3NBMIIS8
M@34=!7_[PJCV'HFNO]^+_O(_S="#Z>%N(_FU>E'1;TRV-ECH=Z_824LS&BQ>
MZL+=J521_P I0)LAN/Q;V(=JYE%QB;%,>7^3HHN+*@JGGD@\<_GTT]EO_D58
M1:]_]]_O7L;V$,UY^MT324MC3JE+Y#?YZI_X,/8J@_M.BJXX=7^]%?\ ,D^H
M?_$5=<?^ZF'V/8_\W^3I OQM_IC_ (3T+/O73_43\#_63_>_;DW]C^WI$/BZ
M#+M*TIV%0?056_<=S_3^%W'^]>P-SWF:"+_AD?\ D/1ULYIJ^2_X:]"]#_;N
M/I:_^PY_XI['<<7@?H]%C&N>@.^27_9/7=?_ (B;>'_N*GN-?=/_ )5[<?\
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M^_OT>E,,6LZO+C4^8^7H.GW:6!@V]B/ ?\KR-6!7YZN/_*5597_D?LQM+/\
M=$/]/I#))XK?+R'R'2>WIN.O@GH]L;>J_M,U54(K:^O-O\EI?I_U.^GLBYCW
M?Z,>##_+HSVS;_JJEABM!4<37I-8K!8_&6EHJ334U7UKZ[_<I5<?ZP_'^O[
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M)L<"*C[#Q_P]"'YKD>CG\>JW_$>Q!--]/TC(IU[S_P"T?\G?\:]UZUUU^/\
M++?X?[[_ &WU]J.M?9T67-8O(];YC+3T>'KLML3*5PR!./'\3J<75K;S\&]J
M._X/]+'\WAK?MDFY8O/K/]!Z%6VW@N% )[OV5_V>N";TV;+!YH-W8,4WUM_$
M3_Q7W;]_PW'^.4_U?LZ.OI&7MH?]7Y]-\4%3VC74>,QE'7_W-I*_^(9_/5V-
M_AOW/\+X^RHC:YX_XWQS[;MK2;F>?]'^QZ+-SN!:C--7I6M*^?ET:2&, &G/
MT_K^KZ\_X?3W+T-EX,/069JYZS?]>_>O]!_/_)UOH&*ESMSM^DJ+$TN]L#_#
MR!Q:JVM:<_Z]J&W^W]@_<3^[[VWZ5*/$C/J#_A_V>AK@_M_\@_\ $^Q]<_Y/
M\O1=Y=1_;?6NN,T0F!IB6!O<-;CVU>6D]SG\'5@P'099'I_KK(3?>+MO[2IX
MO]ED:[&?]:%/L-WW)NV7.8>E"[G*F":_:/\ BNE%MO8NT=KB^%Q&/@321]^Q
MU57J'U\UCQ]?H?:FTY:LK/\ 0ZH]])>Y)/V>7^?I%[AW_D)<A6[8V32&JR-)
M89[.9#U8K%6^M@?\],.?V_\ #Z_6P;WOF_Z?_$K/HPL]I_&^ > 'Q'I,T^R:
M"IG_ (KN#^(;LS5A_E^=-_\ U3_Y0Q;V $MIKJ;QKSHZA'TPHF!\O\_ ]*G^
M 8'[?]W"X\_UU8VC'T_WCV]>6=D/['I2':O^RW26K=B;8-2*W%T=?M_(@ FO
MP'^XRQ_J?^1^TL-AZ];"G@2#_/I'YJ;=&V]U;=SVY2,_AZ.AR."KL[1<U5)3
M9+Z?Q3^EB?\ ;^R_<[VYM[VW\?\ U#JUM';2(RH*&H-#P)%#CY?9T-T=33S*
M# 0;7'^M?V?1M0=4*D<>@_WM_P  :W_6?W>/A^?^7JC_ .K]G52WR&_55_['
M_B?9[8_%TD_T7]O^ ]%;_EO_ /;TS&_^*Z[U_P"MU-[R1VK_ ))"?:/\'6+%
MG_RNUS_S1?\ X]UMC>T_4Q]>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]TW^T_7NG#VHZ]TGLM-XZ2OJ:D+]I1:"!?3>UKF_\
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M'^^Y]NP[Q<V__$CJGT5L_%1]H)_V.LZ;E[9HA:;$[4SL'UOC\C58H_\ %/\
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M+ ?CV)H;WZC^P\^D&D@T(I3I%]H9_)83:=9_"Q_N9RU=C,!@BIY^[REH>/\
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MG]F.P?\ )2M/^:C?]9.@O[J?].[W_P#TB_\ :1;=;4'<?_,J^R/_  P-Z?\
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MF UW6#\^C>Q%+1ORZ%)/H/\ @I_WKW(=Y_;]$]KT!OR4_P"R>.Z?_$3[P_\
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MI0?L)_PGKNF[,P_W'AW!19#:U35_7[X_Y+_A^]Q[6P[^;GATD^B*<"#3]O\
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M6YLH9_[;^9Z=5R#CH#<EUKF-K?=5_7U91?PYV-=7[1SWJI00#8T<_'V0M?\
MPXN3]/</[Y[:_1_K[>?]7GT*K7?Q>4%W6O#4./Y^O2,EW;AXYA!OK;5?M3('
MZ/G<:<K2\?0BMM<_[U[C^YA.WG]>WZ.K>Y)'801\C0_LI3K%'N_K6DOX,M@?
MN+$#[#'6JN?\>3_O'MGQ(3_RC]+=$GH?VX_P=%X[E[IW75Y'&=9=4TE=M?/[
MGP?]Z,UO/-4!4XW"&J-']Y24G_.QK;#P$6^MOKR!!L.WM?2^(O0IY9Y>@O\
M_&+BAI@*#Q-.%?/I"[,V=M[9.+^SP5*3-55BUM9F<@/XE4Y&IR!/FJLA5V'E
MEN3]?Z?X^Y;*?2Q:(O\ 5^?4D%#"3$:\.&12GH/\_2OT'_#VW4=+M8ZR^V]!
MZ:Z][IU[J//_ &/^0O\ B/;D?7NH_MSKW4CP?[7_ ,F_\;]M^)U[J+)'_L;_
M .^_V_MOI1U$T'_#W[KW7I(5'U8?TY/^^_WKVUX)/2P3>IZ26=K,7@<7E,[E
M*G[;%8VB^[K*T<_Y/COI?_&Y/X_WCWHK7'2J"8X X^7V]!/USMS)UR93L/<%
M*M-G-[&]%AJX\X[#4'_%OI?H!_2>H/\ O%_;$:=*FO@.T>7GZL>/IZ_SZ$V>
MBAD!X%O\>/;:6_2V*XKTRU%%Z?K?_#Z^]F"O1C#<=-LV,@>Y-,+VX]/MJ9*]
M/Q3T/37/C>/V&6E_Q'_(O:4P=+5N?]6.HLF+_P"!=@?/5 ?[P./>])ZOX_IU
M#Z<W/-\?^QL%3QU ;IWL_+#;6<P@(,&'R^2XI,A2&_[5+7?[OYM;Z_CVNA:*
M%@K\#C/ ']G^SU&?N'R_^_(#/ .Z(:APJP]..?\  #0^?5@':O;G7_3^#3.[
MSSWA-OLJ7#8-AD,ED*D6!I,?2&PJG/\ 4_[&WOT,R)-K?]G4'[;M5SOE(+85
M^9X#[?/JL7>^?[=[GW#_ 'FW!FJGJW *0-M;8PQIJS,4].!;_*<B;M2U<H _
MS)Y_I[#5_LO[UN?J)*^?A5S3TX4ZR:Y2V"'8K;Z>4 G%?P@GA7@<=)L=.;"D
ME:KKL+6;CK^3][N^NJLY4?\ JS_C_A[6VL3VO^K_ &!T*[>*& <?V#_9Z=5Z
MQV*1?^Y.T1S]1A*5?^('M2"YZ7'<IX?,C[/^*ZF_Z--A3_M2;(V:8>>/X'3?
M]'>Z@ _A/\^JG=9U&)Z_+_4>H6.ZYFV?6'-]39[-=5[AMJ^]VSD;4'!^E5B[
M_830_P"'T_P]U1 OQ]!G==GL]Z'ZX!'I3_!GCT>WX]]^9'?>1'5W9%/0X/M#
M'4G\7/V=ACLSCK$_Q7%6 /\ U%TGTB'(_(!K!+]0=#_'UCESARB.6@;BWS;\
M/F#Z'_)TBOEUOK+YK<&-^/FV<E5XXYG"C<O9>7PUFGI\/86H(BMR)<U^1:_@
ML""./=WU+$ I^W_-\\9Z-?:[9(-R!W"< TPH-*$^OG2AQPKQXXZ!_&;<Q>$H
MJ;'8:FHL=0XW_(J2CH_5]N3_ *Y^OM"3XV>I^^MK@YZ4<= )?\Z/I_7W15IT
MS-< <.G"&F$7JXY^EO;ZI7CTBGGZDQ0$W("_TO\ [[_BGMX/3J@EKQK_ *OS
MZF1QZ+\W)]ZZ3_!T'.\<!NS'$;RZ]I*.ISM/_P 7O;%7_P O&F_UA]*L?\:_
MU_!*9Z:%VK=K</48H?RX?ZATN^N-[[?[)PK9;!U-JBF'V>9PU<;U&/J#?_):
MN&UK?[Z]_HLDN.'^JG1'/520?R/KT(_O6@]4ZRI]/]C[=Z3]28HA8$CC\#^O
M^)]NDUP.D_7!/K_L/=^D_13,DOE[5[:%4/W@VTZ*DO\ \JWVG_$BWLDO9<]2
M9RR/T%],G_#T\>T70DZXA@>!?W;POLZNP(X]<-!_P]O=6UCIQZID_P",L;R$
M9'VXV9M,5O\ U%"IKO#_ ,3[?@C[O]5>@+S@/\7'K4_X.EM))]CWW\<JRGXJ
M1W+64@O_ ,J^0Q]<*OWK;)98[D=1MSL/J-H?_2U_,<.K<(<K6T[7J""!^+?U
M_P ;^Q9#?3'K%P[8.E31U]+7\TPL0+^JWX_WG_>/9M!X'2(J5X]3?9ATEZ][
M]U[IP]J.O=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]TV^O_:?]Y]HOIQ\_]7Y=
M6Q\^I7@_VO\ Y-_XW[I],W^JG^?JO06]D[*DW1@Z&7"U*4NX=OU:YS!U@ 9?
MN+$V(Y!\]_\ $?[ ^PWSER_^_(JC_-T:[1>_0M1L@X/09;?W339B:JQ]72C%
M[@QJ7SF#KB#4TP-B+'Z?8\\>X&2']SP^!/\ VU>AQ&NK(.",'R/#^?2'W%&-
MM;TK*N?_ (LNZ5QP^^'--39/&W')-OSR>?<;;];?3S^./+H_VR<2H ?*N,5*
MFM/V_P"'IY_8_P!HN/\ B?9/FYZ/.LWNO2?KHS?T87O;D?['^GM/>_XMTZAK
MTE<?3_WQSM(:,&JVK@*T5^0R'UIJJJQGUA_/]?\ ?<>Q#MNV?7=%&XW_ (:Y
MP2*#A45_S=#E_L/S8^Y3F_Q?H.TU<>@ZS6<KLMD*O;.TA_N2_P"7]G;?Y+B_
MK_KC^)_[#_C09O+W]X?V/^K^72I8PE"W#R'F>/IY?+I4X#;=#MFA^RHB.5O7
MUX%ZJIJ3]9I?Z\>UMKMOT_56D,AS]H] .E+[->F^N&@?X^V?&'7NN?NO7NO>
M_=>Z][]U[K@_T_V/NT/#KW39D\G!AL?596LM]O24&3KE-_Q?_8^T>Z7?T?'I
MNW7ZN@'J/V<?\'2+ZQPQQ^VFRE<;Y'==8<[7WXYR=K<?B_M%MUGX$'^KATKN
M'+-0< /YCH0^/ZG_ &W_ !OV9^)TSX/7O\I_U47_ "3_ -(^U/U737A#KCH3
M_'_;?\;]^UCIWP>NO)4@_J7_ &Y/MG5]1QZWX0ZAU5#3U?[,M%CZS^A!T^Z_
MN>&?IL.5SGH/YJ4]<5U'NC"?Y)A?OK;NP5"-5**7*<?>0C\@6_V_]/;FRO\
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M/S'^7IN;@?\ 2G_".BM?S=ZR"C[/_P"$WL]764=+#2_+GKNLK*NLJ_LJ> '
M8%BTTPOH50&+-^ I/Y]M)^'\O\G3["OE\OMRW6SL_<_4<BF&#M#KG_8;TQ#
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M&Z K??7NX<7F6[,ZMM3;PIK?QG;0-L=N*FO>]5:W^Y#^L_\ L?K8^W6B]/\
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MW>=!UOB$VZ,K-C8FAHON"H%ETLQ"I9>2?I<^]F1/PC^?^<]:4.OQ&OY >6>
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M^QT:+V:] WI =C;NFV=MX38VD_B.Y\[6_P &V7A@ 349')'^@L;P_P# B?\
MQ_V_MI_]7V]6B4$^E!4G& /]6.LNPMI0[*V]38AC]S7#^(9K<V;O_P ",EDA
M_E=7S^1]/^(O[W%Y?SZ==BQJ?E0=++Q?[3_O/_&_;?6^N+H&%CP1]#[;(T9'
M2CK!I'^'_)'_ !OW[1_JK_L=>\?K')"JBX_'/X'NND].>-\^HOV8_P ?]O\
M\;]WT?ZO]1Z5^.?3K%]E_OM/_&O?M)]>O>.?3HOO?\=/4;?VOM-;C_2#O/ [
M<)M?_)_NONJK^OY/MJX?U\NE^W3Y)'D*G_!_DZ&TT5/2?L04=[\\"W_%?>_
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M15$_\M_?F59,-U>WN)[,UMS0?E3I"?Z!NJ8K2# 9CQ7M]BN[\G]M_K_Y^_\
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M/ZV_XGVEW"\^GA_I]6M1J/\ J^73SUQ0STVT<1!-_P IE"<@1]?Q[/>5+/\
M=]GT5W[AF^PT_P '2SF_X!M_P=/^(]B5./2#J73_ /%OR'_+2F_WL>UX_P!Q
M/S_R]>/^Y0^S_)T('LWZ#_04;I_XOP_[5P_WL^X=]QO]S(/^:?0OV#X3]O\
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MO]7KTZ)M=M_I6_D1_J_9T,$RF&"WYX/^W]O@X_/IB'CTGO&)?]M^?\/=)O\
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M?::V_AHH/X]GC]/\E!_R*#Z?CV!N<=R\?_5_J\NC?9%T@G\A]M<G]O4T6/\
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M.I?M3TUU[VGZ4=:@_P#+QJ),A_.^^0\T+&>GESGR5!J_];,T'/\ L+#W"')
M"[],?/PY#^5#UU\^\C=5]C=EM_0[?]O^XZ=;=7G3^C?[8?\ %?<W]<@^I'G3
M^C?[8?\ %??NO=3)I@ 0#Q]"1^?\![NS5P.O=8?;O2?J+]['3@*$)X'Z@/\
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M^P>RW<P_%;9/GIA0$^7#'5TZ?S.>U8]QFJJ>O]GKM.UAAQ7U1R(I[6O]W?\
MSUO\/K^/>4']3B$^,Z_3S_XOKY__ /@CKGQ_]QT\#UKBOV4Z-3W1\[=L=>;)
MZ]W-M#;K[LR_:6&_C>$PU?7#'TU+CCQ]W5J!I:]B.1<\_2PN4V?+K7^M2]=
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M;0PT\0\,-'CJ2EN!>W_(N?9C%%X'2$D_\7USF/U^XYY.G_>?]X]O7UYX$/\
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M!NP?6A_:.A=L.1^W_#T#7:,TQVT,- 3_ +GJ_&X(<<\W_KQ^/<0<R7)MX?\
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MYWZ+9I_/I ]V>;_1/OJ*("_]V:X@?],_'F_WB_MJZ^''^H=.[=3ZA:^O\Z=
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M63)W$@4%#6N<5_P="5T1\8-K]O?%_OCMF7<"4N7V#62?P2,T/,-/MNF^ZK+
M<#[X7-_\/\>&=[WN2&XA!/QT_(4_R]''(7MI9<Q\MW^XT'Z&L#A^&O#'J.B[
M=6=;1;Z[%Z(Q>Z:@X[9W:.[SMP5?T_8HJFU58GC@'P?X>UV]7WAVMPB&I50*
M_GU'7*O*_P#6O>MHGN?TXYI'8+\])(_P'HZ?\POIVC'RJV]MGK-_XMOCLS%8
M$5>VSS]M/C56DI?W?Z5<5*/K8\_T^I9RIO(AMI&ERBLN/GP'[>IG^\1R6^Z[
MQ:;?MQTW-Q$U&XT4&I_PT_/H(>AOCWM;?_7'RBW!OO/#:DW4.'6A%61_$?!4
M/5<2#Z'G[7[7_>?Q[?Y@W-'EAD!KW?SS_FIT&>2_;^WWBPW%]Q4)]'&5K7\(
M -?Y_P NBZ]<]:YWL'=O66TZ?_<-+VIEQ1XC,5M#8>JT-55'_J$_WWT]G&\;
MNBPN1Q4Q@'J/>5^1;CF;<+6-^%PI9A3/ =&8^6'Q>AZ?[ZVQUEL*L&37>&(H
M*[#8D#_*()Z >(1?0?\  KQ5?@X_V_LHVK>#=0*&SJ H/.O#_)U)GNE[<#9M
MUL[.VP*GA\A_F/6;H_XOX?M_XR]W=I29^/';LZ_S!^TC/$$%/M^F^ZJC(/S]
M^.?KQ_M_;&[[X(+F%83@D?D //JO(/MC^^>6]PW&\ \9-6?LQC]E?SIT5[:V
MS*R7_1CN/?$%93]=[PWW_"JW+4(_Y4*J#[\\_P!/8ADW>*>9T4$,5 K^>>HP
MY9Y.O0EG<;H08!,32F*YI_/_ &>EEV9U.=O=J=M[1ZWJTWSL?JRJR&6S6486
M,%#>G \A%Q;_ '1]3R>/:#:-Y\/3'+5)F-:_T1T:\R^WE[!O,\6S:9]O@3,9
MK4.:4I\J>1X5'0T;D^+^ Q'P:V+\F(M^BJW+D,LAJH?L1]O4T^0J'I*6FM?B
M6ET$E_H;\?3DNCWUH]PDC$?86(TYX$TIT,-U]LH)^1[7>3=_XRD2N)L4)TUK
M3A0U_P!GJN3OG!9C;6&VE!G*?P5AW?UGE:2E'/[&Y:II(?\ B/8K@,>X^-X8
M\@?RX]1)'%=<O[GMIN\_JHIIZO5?\)_9UO?T'_ 8_P"M)[Q]F^'_ %?/KK7;
M\?\ 5\NG/VUT_P!>]^Z]T O:?_%KJO\ @S?]#>VO+_5Z]7''_5Z=49?(F"";
M^*4U13"II5^_H:PC_:3P?=;I(KV*HZW;3E>KK.D*.CH>F.HX*4 45+U/UXYY
MO<OB8&O_ +<G_>O8.N/A'^KRZ$$1H[?Z9O\ CW0I^T_2SKL?YD_ZW_%/>_.W
MZ0G_ ')/V=!KLF$'/[[G/U&?M_3\^POL7]M/T:W/!?RZ$'V)^BCJ1[]T8=>]
M^Z]TT9FI%)B,W6P6M14&44'_ &)/^]>R_=9O A^MZ36JZB%]3_GZ#7:],*7;
M]';_ (%59&0R%_\ JZ\?\1_O/L&[)9_4?K='MXW'_5Z]*'V=W''_ %?/IOK!
M8R_L6O?FWU^OMV&+5TGZ;<:11=@47VYL-PX&V0O_ -6N]_\ B/\ ;>R"Q'TE
M_HZ5W)^JM?']#_A_U4Z%GW(/19U[W[KW7O?ND_0 ]WYZ?#;%RZP_\",N114%
M[?3*F_\ MSQ[C;W"W#Z"S_TY/1_R^FMOLZ?-F8(X';&W,7"/^+7C\<;$_P"K
MOY_]X]AKE*#Z"Q\+Y]*[ZX\2X/S_ ,O2R]KNDO7O?NO=>]^Z]U[W[KW7O?NO
M=<?]W?\ (7OW5O/\^B0?.G_F1#_^'WU[_P"[1_<->_/_ "2%_P":X_XXW0O]
MO/\ DHS?Z4_X4Z.S_9I?^U>?^A1[E/;/["W_ .:?^7H(R\6^T_Y>I2?H'^Q_
MWKV87?\ ;'_FE'_EZ>/'KC[MTFZ!3L66NW/E\1U?M^J%)4YYFR&ZZZ@7_@+C
M/I_7_=_L/;GXVY7L%G#^/^V].C.T(M$,C?A^$?/HP.,QE#A,?287%47VN/I<
M?BZ#'4+<_P"2FY+?XF_^P_WCW/\ 8;5^YT\&'SX] 2.Y,MQ5CG/Y'IVJ:6FK
M*405#"LIB?\ EX<_3_;'W::+]X'];^?^H]*5.GATAY^N\,LQFPU;7[?J22-%
M#D[_ ./-_89N=@LWX8Z66]ZT HV?M'4$1]CXD@05F"W#3$7M7*<55?Z_%B/;
M?T4UK_8_[/6]4=UZC[*TZDQ;MW12<93860!!^F/RG\5_XD_[W[<.Z;E!_;]>
M-HA^%OVTZR#LC$0G_+*7<.)(X K\:"/]Y]W_ '_#_HW37T+#@:_RZYQ=D;.'
MUS)/^ Q8%O:P<Q6O^_\ _#U?]UW/I_/_ &.LY[!V9,/^+OC^#]2OMK^L5O\
M[_ZV-NN1Y=8O](.S/^=RO_GKK/\ BOOW]9K;_?\ UKZ*Y]/Y_P"QUA7L/;XN
M:.BS]80.;XP$?[SS[8GWV$?[/32;6PXT'Y]<4WWD)!_N+V=GZN_'^Y G$?[U
M[3_OR'TZ?_=?JU/V?YNF;)_WWSE/71948':>.O\ Y>*\_P 5J_M!]+W_ .)]
ML;A>;G<0_K];LO#C^&K>E,"M/V?MZB;4W;!@O\AR=9756W6M08+/:;_2_P#Q
MK_BGNNU7EY_H]='3UY%J^&E<$CU_U>O0PQRTU0?N*:_UY'X_WCV,X?!Z(S4=
M8O>^M=2/?NC#KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZQ_\H/\ OOZ>U7G^?1?U
M-I_^+?7_ .O3_P#0X]KA_N*?M_R]>;_<H?ZO(]+_ -G'0?Z"G=7_ !?Q_P!J
ML?[V/<*^Z']K;]"[E_X#_J\^@?['QV0JL#292BI/NLAM^O&=&//_ "D_PS_6
MYM_OOZ>XIY@@^I@_U<.A78SA&(KQP/ETF\=D:#(X\5U)6?=T]5Q]/]];W&T5
MSX_]OT+FDIP'4R;Z"U_S_C[5M:3'^QZ<E(\^N"_I-Q;D?BW]?>K:&:XZW :=
M)S*039O+8?;$!O45M>,A7GBU+2XO_'_'D^U]O8_43^#T6[C<"-:_ZB3_ )^A
MVFF,H'!%SP/\/<D_\D^'H)@ GI.93>.!Q<_V7WARN2M;^!8(?Q6J/U_XU[3Q
M#ZC^QZ>4$^5/F<#]@_R]9,)L?+;MK:3.;XH_X5A*3(+7X#:835>I^OWN3N5!
MO:PI[_[US)O*O)!N/[?H+[GNZQ"B9/ GY>@Z,E#"+ D>CFPO>]_R?<T6]O\
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MOWG[BVK>=LCG_>F4?X%ZJZJL?C.P?DA4;6HQ]MMS=7R"^T"@@?Y/D\EX@/\
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M4$<"_P#9K&>C,5%)4?[+3C*Z6QKNR/D#7FD-OQBZ!?\ ZL]Y>6S(QU#RB/\
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MO[*+RX6[M+EOXWD)^VA/^'J2=FVBVLN8=F@'_$:SMPOE0=JX_(=+GOBHE/\
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MX_Q'N4[!*0V__-/H*SPUJ?GUE,P)O?\ UQ;_ (U[,YH#U917J(9/4*BXYO\
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M>@/V_P!?X>!_K_[#Z^S;]U'P?!KTT+FAKFOKTC)MM9G;A^YVA6DTHO?;]?\
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MUN->C*VL2>/\ND;65E37$?<DFUN?Z?\ %/I[#ESN=.C2WV[TZPJ";_ZXO?\
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MN./]N?:6\B(AGK_JSTHCH&!'J#^T=->P<C#E=E;<JX5^[84.-N/I_P 6H_\
M&A[+MFF_Q/IJ]C[S_JXTZ6Z?3_8^SV;AU3KG[KU[K"T@A7S&Y/YOQ]?Z^Z2S
M>/GJU-7;T'W]Y,CN/(#&;%H_[P5/(R&=)/\ "J7@_P#*;_K<_P"3?[#V[:V%
M[NDW@V?26XF2R%7Q\O,_EY_GTYU'5./HZ4Y_>=8-[;EIA_D2UA_R6EN1_P
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M>Z][]U[IO]I^O=,-7N*EIAHI@M;4?2PL+?\ $?[[Z^RBYW<Q#&.C&VL?JO\
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M4&#]!_X,?]Z'N[\>B_J/*?\ )[?D$_\ $^[&4]6T]%XW>1#VMU?+_AN*@_\
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M'GVB-J'X8_.H_P '0SL/<+<+;XM)_P!K0_MKU%'Q"H"#J[J[LI?\6SE+^?\
MJA^ONWTGSZ6?ZX%[_ O[/]GJ;!\+>G'F\^\:W?'9[T8)-)O/>-36XWF_(IK0
MQ<?Z_O:V<#_/_5\NBZ^Y\W"YX +CR K_ (3T9S$8+#[:Q5'A-OXF@P>(QJAJ
M+"X'&?PNFIK<W,/-_K_7ZGWM52/#^7EZ=!":>>[[I\DXU')(_P!7ITY-,">
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M2?CQN*GW'\\/G%N7"76@S>UODW7T(^G^XZLWAA1;_84A]XN>W/;S6]/]^/\
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M)_48BX4>=(Z,3^6/V]*#OG<&'ZZ^='639JK^WPO1O26!JZFML!_Q;,%,8?\
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MVVH_4;9X'5KL4:OSZ>O9ATUTX>#_ &O_ )-_XW[3]>ZA\?\  /\ VK]7^/\
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M (%@/^('LGEW;3PQ_J^?2M+,MTBZS+U5?>[#3?Z"W'^P'L.7-_T:6]K3IL]
MN3JM_L/93*_C]+A!3KKWOIKKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NN&L?X^_=>ZE^?_ &C_ )._XU[]TYXG4?S_ .T?\G?\:]J.D_A]>\_^T?\
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MSB@TIC \OA'2C^)':>^^M.^NOJS:57;^^6:Q^T-QX<'^("HI\GP0?^H;_/\
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MM(;K]$T\;\O]0Z1Y@X5^7'C\AY_X.M0G^??\R?CMVQW!\%>K*3Y"]0[O^-M
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M7^;KT?D?LZ8]GR^7;^(%N%QLH_VY/LMV7^RZ=E%#TH/9MTBZ][]THZS?V_\
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M?\F&L!?M;CZVY_(^A#]]O=UN+HSR5T>;&IIZ=.;'[:['R]!<06MJJ"<U(4
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M]%W=;/'KOQ+_ %;_ %[_ /&O>IO!GZW0CK&!>_-[\<>[0P^!TF)KUZP_H/\
M;>]>!UZIZY^!/ZM_MQ_Q3VUK/3_7'VMZ3]9*B$@W.DW%K<V(_P"*^T4I\?I4
MIITE-G$?P&QY-'D,EC[?7]5:/99LW]CTIO/B_9_@Z4P^@_UA[.(.BT\>N_?N
MG^O>U'2?K'44IKJ>NQ\YYK/QQ^.?^('LOO(?J.E*G3^70;X:JJ/M_P"%UO\
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MZ]_?.3_E2/\ MS_Q3W[]_?,_ZOSZ]^Z_MZ]_?.3_ )4C_MS_ ,4]^_?WS/\
MJ_/KW[K^WKW]\Y/^5(_[<_\ %/?OW]\S_J_/KW[K^WKA_>]O^5)O^2V]V_K
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M*O&]RTBZ696JD5-!7R-:?S/5Y5P1X9) )HP K3%/]1IY>?6Q\_\ F_\ D/\
MXCVM3AT32_Y.I/N_5>H=+_P(;_@H_P!Z/NA^+IR+AU3)_.[.GXJ=;2#Z'Y.=
M.V_\ZZP_\3[/.7Y? G<'_?+_ /'6ZB#WK&K:K;_I9V?_ &DP]7.P;J_8\)H?
MHI2P-@>?][_WW]?<57V_F.3K)&PV\7,%:]2_[YR?\J1_VY_XI[2_O[YG_5^?
M2S]U_;U[^^<G_*D?]N?^*>_?O[YG_5^?7OW7]O0&=F;R,F*K3]G8:CPO'^/M
MT;^2//JIVJAZI'^0^Y)YI,G#]K^1_P O"_\ K^U:[_JBZK!MU.KF^F]P[GJ.
MGNM/L</CW5>N]FQEJ_)'FV)IP!:_YL/\+>X]W#=)A*/LZ/;:T74W^F/#[>A%
MBW)N&DXRN'!I['_+J#_?6'M/#OXM^E!M=7^;I68S*X[)4QGHJYJVFL3ZA_Q/
M^%O9Q#<F7Y=%?T_T7^;J7K'^/LT\4]-Z#U+]M]+>NA]!_K#WZ#^VZ;\OV?Y.
MD5B ,GG\SE3;[:D_W[^.^I^G^>_P_P"1^R*S_7O/&'3[?"%/VGI;>SWI)UCX
MGXN;W_J!]![T8J=.ZQUUXZ3_ )UP_P"2#[MX</IU32WJ?Y=-%=G\?A_^!U<Y
MXM_#;ZO\?]X]EMY?PP=6%J6_SXZ9?[ZXW_E4W";_ -,6#_Q'M%#OQ@\NE'[L
MKYC]O^QTY8S<6'R]J>@KF6I'/\-)_P"(MS_M_:R'=.F&M:'Y=*/Z?XD_[[_;
M>S3_ '(ZK\'7?NO3O7O?ND_33D*3SCC\F_)_K[37]IXW'IRU;3T4_-X[+]/9
MVLW7A*7^*[$RM>1G,'0^K[;_ )O1<_[S[@/F?9YN6I_&A_W&_P!&Z&6W2#>5
MTGXO(]#AA,O0[AH!F<96?>4]7;[&XOS;Z?X_4^SE]QA>& 0]4G4VA(/3IQ];
M_FW^Q_UO:Z9JO3I+XU8*] 'U(;?)OY'7XMM;I_\ ]PZVWL'\@@7/-%Q_SS-_
MA'2O>33:[7_3=&T?])_V'O(:T_LORZ P^+HBW\RCL/8/67P(^8^:["WKM?9>
M*S_QM[TV=A,OO+/4^ IZO,;PVKE4QN/A:H\<C5=2W,$ 7Z G@7(.=DVB2XNH
MYX#JDTFM3QQY?,^0STGN)HH8@H'F#0#@*_;3'F>HO\JZ9*K^6W_+X^UJ:&5(
M_B1T2@JZ2M_B!6H;;6*!5DM8'5<%;FW%^/JFWL23[DHN>.D:?LIU6W%(7^W/
M1%/Y/G96R*_N/^;EL&AW;LBOWFO\U?Y([REVQ#N"GK<E'C9\=MVF7-04#3"I
MEH#,C0>=-0_#,I(U'6^VM]+)&L\0-N WB"HJ&H/*H/"G2>SN85=3FNE0/(&O
MEP/5]'U'T]@KP?IYOT>CVM1GKWN_5NB@]DQ_\Y3=(?6W^C_M[G_JKI/^*^X&
MY_@IS#M\T/JO^$]"G9VKMEW_ *8?X!TX[MI:[9FZ\3F=D$4>X-T9HT.1P9/^
M2U6DF\W^L.#[?GN?W+>_H_ETY!"+U#XG "M?/HPM!GZ:MO3Y ?9U0_M#_#\?
M[S[FVVWGQX>@I<VU.G::_P"1]/I_L?\ 8>SB!_V])&N*</\ 5_+K)]NW^H_Y
M._XW[OK'6^N/NW7NO>T_2CKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z3]!_D6XLU
M0D ?>WR./_/LKM/T.'5LD G\^E=I_P!J;_;^S?QCZ],:#UC\Z?T;_;#_ (K[
M]H/5.H_G3^C?[8?\5]J-!Z3]9O=.O=<O.G]&_P!L/^*^VM!Z4=<?;O2?KWM1
MU[K!<_U/^W]H_%'2O0>IOK_VG_>?;GC]5H>L/OW2;J;#_P  ZS_7I_\ H;V8
MC_<3\_\ +U=_]RE^P_\ '>A#]B?H.=!;N[_B[?\ D-;V"]^_MOR'^#H]VSX1
M]O29]D?2OJ1[]U[J/[]U[J1[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZC^_=>ZD>_=>Z][]U[KWOWB_/I1UEN_
M]!_OO]C[WXW3.@]8O>NJ]>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW35E28<=76M] ?\ >_=FP>C#;C0?GTF+)_5O]X_XK[II/I_J
M_9T?^#_J_P!1ZX^=/Z-_MA_Q7VYH/3'3?FJ\T6.K2?I5'^'ZA_A?_B/^1^V5
M/AI3HXVRQ^HN.@X 4?OSC@?V?\?=7/KT.IJ 8ZP\?Y_C_??X_P!/=.GNA*Z\
MQ[?<5M;]"1_#L>"?Z\?G\CVH4?CZCGFB^I^AT*7X/^N/^)]W7B/]7KT"+7KK
MW3JG7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]UWQ_4_[;_C?N^L]7^EZZ]TZIU']^Z]U,\?^/^\>[ZSU?Z7J
M'[IU3J1[]U[KWOW7NO>_=>Z][]U[J/[]U[J1[]U[J/[]U[KWOW7NI'OW7NO>
M_=>ZQ^/_ !_WCW?6>K_2]8_=.J=3/'_C_O'N^L]7^EZA^Z=4Z][]U[KWOW7N
MI'OW7NO>_=>Z][]U[KWOW7NH_OW7NI'OW7NO>_=>ZC^_=>Z][]U[J1[]U[J/
M[]U[J1[]U[H/]V "@JQ?Z?0_[#V^9>O)QKU4S\CS^]5"7Z_3_>#[6)-V=-RK
M^KT4/^7C&?\ ATZPL"OQVWLW/'Z13'_B/<PV4U=C0_,=8Q67^,\\W(_X0_\
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MZY_U5'#K;\WKU!UWVEDMAY7??7NSMX9?J[<)WIUKD<]M6@RE;A,MC8WC&5Q
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MW!(L!];?\3S_ +?VF:"&XZ?GA*]-D?\ N)W31^#_ (#9@_85X_U_Q^/;,?\
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M:SU[6?\ #W[KVL]>UG_#W[KVL]>UG_#VHZIU$][A_P 9F\#I.<"O7O:;Q_\
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M/_'_ 'CW[P^O=>\?^/\ O'OWA]>Z]X_\?]X]^\/KW7O'_C_O'OWA]>Z]X_\
M'_>/?O#Z]UC]M]>ZR>/_ !_WCVYX?7NO>/\ Q_WCW[P^O=>\?^/^\>_>'U[K
MWC_Q_P!X]^\/KW7O'_C_ +Q[]X?7NO>/_'_>/?O#Z]U[Q_X_[Q[]X?7NO>/_
M !_WCW[P^O=>\?\ C_O'OWA]>Z]X_P#'_>/?O#Z]U[Q_X_[Q[]X?7NO>/_'_
M 'CW[P^O=>\?^/\ O'OWA]>Z]X_\?]X]^\/KW7O'_C_O'OWA]>Z]X_\ '_>/
M?O#Z]U[Q_P"/^\>_>'U[KWC_ ,?]X]^\/KW7O'_C_O'OWA]>Z]X_\?\ >/?O
M#Z]U[Q_X_P"\>_>'U[KWC_Q_WCW[P^O=>\?^/^\>_>'U[KWC_P ?]X]^\/KW
M7O'_ (_[Q[]X?7NO>/\ Q_WCW[P^O=>\?^/^\>_>'U[KWC_Q_P!X]^\/KW7O
M'_C_ +Q[]X?7NO>/_'_>/?O#Z]U[Q_X_[Q[]X?7NO>/_ !_WCW[P^O=>\?\
MC_O'OWA]>Z]X_P#'_>/?O#Z]U[Q_X_[Q[]X?7NO>/_'_ 'CW[P^O=>\?^/\
MO'OWA]>Z]X_\?]X]^\/KW7O'_C_O'OWA]>Z]X_\ '_>/?O#Z]U[Q_P"/^\>_
M>'U[K'[;Z]UD\?\ C_O'MSP^O=>\?^/^\>_>'U[KWC_Q_P!X]^\/KW7O'_C_
M +Q[]X?7NO>/_'_>/?O#Z]U[Q_X_[Q[]X?7NO>/_ !_WCW[P^O=>\?\ C_O'
MOWA]>Z]X_P#'_>/?O#Z]U[Q_X_[Q[]X?7NO>/_'_ 'CW[P^O=>\?^/\ O'OW
MA]>Z]X_\?]X]^\/KW7O'_C_O'OWA]>Z]X_\ '_>/?O#Z]U[Q_P"/^\>_>'U[
MK'[;Z]U[W[KW2%WB?\BKK?X#_>#[>BAIUI&R*]5(?)#_ ($5?_!Q_P 1[5P_
M!U8_VW13/Y=G_;TQ/_%:]Y?]"TGN8K'_ )(Z?;'_ (1UBSMW_*XW/_-&Y_X_
MUM&>TG4J]>]^Z]U[W[KW4&F0"?[D\6]']3]/=&XUZ<B;%/\ 5Y=55?RK_P"7
MGN3^73UGWUL;/=FXGM!NZ/DQVG\A<=6X7;C8E*6DWS'3J,9(6J*@^8:58NNI
M5]04L&O[U'6A%0:DG'2N9P6#"HH*9\O\/5I%=1BLQ]91,/M/O*#*8\ G\Y;Z
M6M?_ )'[T1C]O\^F0U#]E/Y=5K?RL?@AG_Y=GQ:K^@,]V5#V95UO<O:O; W!
MA-NR;6ID7LFM>L6F996E8O&FE2. &;2OZ?=(EK5*UJ:XKY^73UQ(&C# 4QIS
M\ND_W]_+YS7<_P#,Z^&7\P:A[*H]O8/XI;%[*Z_GZNKMG5DM1EO[ZTE9")Z:
MM%0XI5@6LNS- -.@$:FN"S"FM%C_ (05H:^?3[2Z"[$<3JKBGI_J'2E_F@_R
M[>I/YF7Q9R?26^LC/M#>F SD&]>GNV\/ ^0K]K;DPX,<&24QLDWVLL2_;UC*
MZDI:3U%% L4#X/'B#Z?ZO/Y]4@8HFH9!I4'S_P!5<?+JN3YG_P G_P"=WSH^
M/OPNZ7[6^>FRLQF?C=Y=S]HSYWI:7,8SL+/[:J[;=R^X,$]:T%<U'ARJ5-)4
M1313SM-.=33!_>G$<2J-0Q4GTJ?]CIV"1G9B%.?D/\^!6O\ L=#-M3X:_P [
MW;N1V9'F?YN/3V3V)MG+;<&3V1A_A'L["Z\5B7(GQ%,]'1(M!YJ "%2&544A
M+@'VY''Y4&/Z*^7Y=-SD$_VK&OS;/YZO\_5^GM3T5]88/T'_ (,?]Z'NB<.K
MOQZJ<^1%".F_EC!O^I;[;8GR$PN/V]FLL/\ @/2[AVA9:7S@7M]U3J#;_$_T
M]L>'1M1X?Y1_GZ-(KC2=/F2:#^B>A#<FF-7+6 TL%+1??5M;7'_@-[:\'_5Z
M=+^/#_B^F;X7X>?L?L?MOY*S4R#;-?14'3G6@K1?[K'8.J49"OM^(JFJ"F]O
MJ2/:D ZB?*E!7TKGHI9O$56\ZEF^VF.K+_;W1?TX>_=>Z][]U[H!J63^YW8N
M:PLP_P!QN]B,]@3_ $JC_P #8./Z\_[Q[33QU!!\\C[>CNRG\&0'S7!^SI=5
ME;!C:>MKJZ]'!2&V06W]?]]]/:>-*9/1A--JQZ])CJ^GGR$&9WK6THI:G=>1
M_B&/4$'_ ";%<P_[W_L?:M!X=5]>'V#H/%OJ*2^@S^?0S>WNDO5:G\SOXV=Y
M_*OX1=T](_&KM/<?37>&<H<?F.N-XX7=57M)/XCL^O3()B*O)T8DGIZ#-QEZ
M$@#QZD2]E%U9:0O5E-#_ )O]6*]+H0K((V%1YCTK_JR>.>J-.].G?YLW\V'#
M?%+X:_(SX.T7Q+ZBZ6[NZK[5^3WR W?VKBNP4W)_HO\ -%*NRJ/%L*VI3+Q2
MR,SSNRK)+&Q8JATLZBRBBT I4^M.E$:^$S*[5)J N< G_5]GV]6.)\'N\^_?
MYUNY/FO\C]@[;I_BW\;OCM_HC^(N$R>XJ7> R^9WKJ;<6X:W%AI%Q[A):Z%Q
M4)^XAIF/D:SBG@'31Q@"@X&O^KCTY]0&[T.6-32HI]G^#Y]&5_F'_P OWJ3Y
MJ?#'OWXW8GK;KK:V[^P.O<O2]=[DQ^UZ/%C';BQ3?Q+!2O4TT %,(\K34YJ/
M]3!)>XY/M]K80J5 %?(\,\>D\%TTK!F)(\\UP?E^=>JFMY_!O^9=\A?C7_)&
MQO:O6&!Q_=/P=^46V\GW\@[/PTU]M=>TJ8K'[AI)XY/\LJ*['4L9-.DDLY,2
ML%/EY8$:ZJ$"JGNSY?ZATND?5&I!PX[30_Q9_P /\^K9?YL?\N_87\R[XN[F
MZ<S-;0[2[,V]7-V%T!V9 WV57M_=^#_;H:Z.>+_*/LJL?Y/7,)=:(%D4.R)?
M2QB--->'#_5_JSTF^I)>M#0TK_J^7^#TZIW^2/7/_"@;OO\ EC=9?%).GMI[
M;^151N'_ $<?);M/;7R+P>)K-R[%VO0Q^%L7E@\DF)R.[3YJ7*.%<H:36H5:
MXHVPNL! ,\":C(_;_J_/JZ,L0+ZL<0-)P?V?L_.G0F_%X_SB?AMU1M'H/XX_
MR6?A[U?U)M"=(,?@\1\THLE/53Q3?Y;E\C6?8M497*32-JJ*VIU%VTA@51$3
M00R#2:4K_$!G]O3US,%)9%;53^$G[!PQ^0KULMT$E5)CJ6?(TOVV1-#COOJ#
M_BY::CZ@<?4@_FX_']+^UXX9^6./1&U*X_XOI2^]]-]8(_\ @4__  2/_>_=
M!\73J\!_J]>J9/YX_P#V2IUG_P"+)='_ /N76>S[8?[5O^:;_P#'&ZB#WL_Y
M)-O_ ,]]E_VDP]6VK_FJ'_@[_P#$^X(O_CD_U>G64FU_[CVWV#K+[1]/=>D0
M!1=OS_3VYX?6P*] -VI_Q9JK_7]Z@X?ZOGTV?BZI5[__ ,YD?^#_ /$>S!/]
M7\^F_+J\SIC_ )E)U1_XB[KK_P!U%-[++GX?R'^3I9^-O],W^'H4'_7_ + _
M\1[JG#IRXX_L_P '314<9G;$']<B*\C_ 'KV7WA^HN>EU +<_LZ7WL5=$'7O
M?NE'4/*_\6.N_P"U?F/:>]_LI_M/^3K=K\8ZA;<_X]W#?]0#>T6S_P!C!_J]
M.G+OB?\ 3?Y.GGV:]-=<'^G^Q]^Z]TP;PA$^WZPT]B:33D#S<<W_ -C^?95O
M<=,=.VDXKU"BJ?O*>CGIQ8UI _WOVCL_[+I8>I3_ %_V'M3TR_'KA*?!SR>2
M/K_7GVG'^C].4X==;*B\>%\]_P#@;D,DO]?U ?[S[>Y=_P!P_P ^DTOQT^SI
M4^SKIGKWOW7NO>_=>ZY>!/ZM_MQ_Q3VUK/7NH,M)YG-B?H3_ +<_\5]L79J/
MRZ9 _P /0:;KZUP&Z29LC1D5%+_Q;Z^@_P!Q=40/^;QX_I[#.[<G1;Q^L_1_
M%O9AQ-_GZ+GT[A-P8/Y!?(&AI\HN<JZ;:_4'_%^O]T=='7&X_P ?]C_M_<$\
MC<J/MO-EQ##/_%_DZ$^][M;WEE;$B@)/#[>C$[S[;VYU7M?+]A]IUV,V'LO9
MM!)N#=V]]TY*@P6&H::+]OSU%=5!RBNU@H4%C?CZW&1=C<S33>%%PX_MZ <]
ML&% 17_-_@ZT-_CS\:^]?EYW+\O^B/Y?O8/4FZ?B]M_Y";QSM;\X,CN*IH&P
M>([VFJMSUE'C-J&G3*9C<^-6:HHX*A(%QVO0P<('<98S>\D7*6VBV,$OBE"0
MPT:0"!BG"H]:^6.@(W+W[VE4N,GRQ_DKZ_ZCUNT?%OJ+ISXA="=5_'#IW$9&
M/8_5NS\=M7$TKXL+7UDFMGJLC4BY)J\SDC]S5M<JS*JA;6]XIWN_2O>B5Q21
MA0#H:#8RL)B/^'%!_F'#K5 _F"_R\ODA\$:;Y0]^_$S9&Q>SOA3E<;V7W')M
M3=._:3KS+]6Y/-AJG*4=(E;+%'F]LY"O9:NAI8=,R3N:-U<E6.27MC[QR-:O
M8W$4I9!5 PH5-#7)K5>';09KG/0-W/8%AG65OB^6:^=>''J^C^3/N3IS)_R\
MOC?UM\:>_NO>Z]N]0=;[>V]N[<6S<BT]71;AS\DF9K:/)XHJN0PL!J*JL*?=
M6_2Q4FW$(<W6>X7MY(TIJLBA10_G_E/0KVF:WMD)<9)\\B@%/\@QQ'5L5'LF
MFK*CS9NNK\LMO^7A91_O9/L+;=RA/!^M-T8-N@I1:#H'MW8G'TGR)ZFIJ&U+
M2TG77:A!M:P%51_['_C7N.N<]O@',>W3?,?X#T;[9?D[5=USD=& ,)AI?\G^
MH/\ 0#\7/ ]RE*XZ+1/3J,DC0J >&TWTC@?T_P"*^[[IND!CMT3I$\C"<PP?
MZO/K+Y*>XGY^O]/Z?7\_7V\\,-_T[<&G47_)9_IQ_7_B/:*:/]^?HWEO;=G5
MA.+/*D]8OMO"?\GKA1G^NJQ_WW^P]Z\7ZC];KPQCKCYLC!R"P)_K_A[KUH$?
M/J5]R?Z)_P E?\:]KO&/5,=>FJO$#>PL/S^/^-^TPN-'2GQ?IL=<#5$@@7-[
M_P"\6_WWX]O/=PW/ZW3-N"N.N_NZF>U.U_\ "WU]MQ>-;_\ */UK!]>N!H!,
M?W[UHY!-[>Z)XT'Z,W2B"A-1U,CC\/\ @1[TS5Z2=89(_-<$>[X4=>X=8(J;
MP_\  <FC_P ?K[]@=6U5X]9/O*C_ )2+W'UO_C_L?>_&Z\QZR^W_ !CU7KAY
M!_0^[S-]!^CU<7&K/67_ (#57] ?][!_WBWMG^PA_P!7E_L=>\^N7D_P_P!Y
M]L>'U3K$#?VHBEIU[J3[<\?KW7*G_4G_ "%_Q/MS\/\ J]>D_3O!+_D=<"?K
M-"18_P"UK]?:@3?XF3^7\^JD#ZG_ %>G0C^QIT0]!ENG_BZM_P!JP_[V/8-W
MC^V_/H]VSX1]O3)[*>E?7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=)_/@0X8$W!)&KF_P!"/Z>T\O'_ %>G1OM'^7I#>0?U'_)/_&O>O$^?
M0L\'[/\ 5^76*U+!]2?]CS[OXE?3IKP!T%LM5]WDJVHLOJ8\?XJ/^-^V%?Q$
M'Y=2#!!]-#TX3_C_ &'_ !/ND'7CPZFX:E%7F:* C_@9D5-O]A[6>'XB8Z*=
MUG^D@Z,&/\W'_P &/_$^_1]0Y-QZ</;G3/7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW0<[Q
M_P" 59S?_:K6_P!X]O0O6O5EASU4O\CS_E-7Q_OA;V]'^NG6A_;]%%_EX6_X
M=#9+_P#<N'88_P!M]M[EJQD_W3(?^:?^3K%K;O\ E<+G_FC<_P#'^MI#VSU*
MG7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW6'SI_1O\ ;#_BONFL=7T'K-[O
MU3KWOW7NO>_=>Z][]U[KWOW7N@N[(ZWV7V]M/)[%WW@:',;<SC!ZNCJFT-<
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MJO9OISU(J]PZ+!OW(4\7R%ZNJ1>J V/V*25_QK*+_B/<+\WW\-QOMKX'J/\
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M[)-%FMO$:"GV3D^7IU:VY0N-.NY=-+4-2W&OY#CBAKGH3NH_D+L?M_;N6SF
MH\UA1M2JK\-O7";HHACZC'5&.4D-5D?7@6M?\&]O8BY/]QK+G"WGN(O\5^G
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MRL7VG^2U-92..+_YJ16_V O[6BU_Q,])3<GZD?ZAT+7L;=!WH+]U_P#%V?\
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M3?\ C?OW7O$Z]X/]K_Y-_P"-^_=>\3KW@_VO_DW_ (W[]U[Q.O>#_:_^3?\
MC?OW7O$Z]X/]K_Y-_P"-^_=>\3KW@_VO_DW_ (W[]U[Q.O>#_:_^3?\ C?OW
M7O$Z]X/]K_Y-_P"-^_=>\3KW@_VO_DW_ (W[]U[Q.O>#_:_^3?\ C?OW7O$Z
M]X/]K_Y-_P"-^_=>\3KW@_VO_DW_ (W[]U[Q.O>#_:_^3?\ C?OW7O$Z]X/]
MK_Y-_P"-^_=>\3KW@_VO_DW_ (W[]U[Q.O>#_:_^3?\ C?OW7O$Z]X/]K_Y-
M_P"-^_=>\3KW@_VO_DW_ (W[]U[Q.O>#_:_^3?\ C?OW7O$Z]X/]K_Y-_P"-
M^_=>\3KW@_VO_DW_ (W[]U[Q.O>#_:_^3?\ C?OW7O$Z]X/]K_Y-_P"-^_=>
M\3KW@_VO_DW_ (W[]U[Q.O>#_:_^3?\ C?OW7O$Z]X/]K_Y-_P"-^_=>\3KW
M@_VO_DW_ (W[]U[Q.O>#_:_^3?\ C?OW7O$Z]X/]K_Y-_P"-^_=>\3KW@_VO
M_DW_ (W[]U[Q.O>#_:_^3?\ C?OW7O$Z]X/]K_Y-_P"-^_=>\3KW@_VO_DW_
M (W[]U[Q.O>#_:_^3?\ C?OW7O$Z]X/]K_Y-_P"-^_=>\3KW@_VO_DW_ (W[
M]U[Q.O>#_:_^3?\ C?OW7O$Z]X/]K_Y-_P"-^_=>\3KW@_VO_DW_ (W[]U[Q
M.O>#_:_^3?\ C?OW7O$Z]X/]K_Y-_P"-^_=>\3KW@_VO_DW_ (W[]U[Q.O>#
M_:_^3?\ C?OW7O$Z]X/]K_Y-_P"-^_=>\3KW@_VO_DW_ (W[]U[Q.O>#_:_^
M3?\ C?OW7O$Z]X/]K_Y-_P"-^_=>\3KW@_VO_DW_ (W[]U[Q.O>#_:_^3?\
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MPM>W)^MK_P#$^U2KYGIKJ;[2=&'7O>KO^P_U>O3:\3TF-K/X:>NH2=7VM?\
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M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZC226]*_3\^TUQ<4ZNJUZJG[_\
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M )R-_P!;.D\QW(?A_P /^?KE3]\_*J2(B'N6DM^+;;QG_P!C_P!?>WV'9O\
ME&_XVY_ZS=*88Y_]_-_O?^QUZ3O+Y1"X/<=%;ZF^V\"?][V_[VVQ;5_RC?\
M&I/^MO35?^&M_O7^QUSC[S^4)Y'<E)Q_3;F,_P#L?]IOZN[./^(S_P#.9_\
MMHZV5G/^C-_O7_0O4>3N[Y1F_P#QG*@///\ OVL<1_[S7MS^K>SC_B.__.63
M_K?TU2X_WZW^]?['74?>_P KYASW1C_K_:VMA/\ ['#[M_5W9J?[C'_>V_ZV
M].^+-_OYO]Z'^;ICSORA^<VVHOOMK9;J'L<@6JJ#>.!FIZL?@>-\8F$A-O\
MJ)(]U_JCL%V/!87$/KHD+$#_ &YF_P '55FN6.:C[.'^$]'R^,'RMVE\CL#4
MXAWJ=K]J;2I:%=^;!SM"VW:^DDCL/N(H)ZJKFEQG-C/'52./[3BXO&G,G+<O
M+LQ)#&W(JDC$%01\Z*/SI^?2N%VNJ'!J<$>?^ST<*- ][W_V'L,VRUH?]7EU
MYVICJ7[4]-]>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW4?\
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MFHY?N9HYZ^JI[7J556TBQ+$GV*]RW+;]BN'L8]NCD\$A6EF)\63)\\TX>?\
MEZ2HTLA*^.#^S.!Z@_M_P="+U)EOE%V'L#N3IGL3-5/6O=O7.>Q^U=J_(K&[
M->MQ>;H$9JB'.XZ@K%6BJ:HTP%/.ZB[)4"_-_9'ND.W02P7-M^I!(E6M_$Q&
M..EL^=/+AQ]**D@E0A@*@Y*US_L?GY@^O1<NXJ#YE]3]I?&[K2/YN9;/0?(7
M>>6V2N57J#!4'\(^U1;R-2_\I5M5^/\ ;^QAL4^S[K9W5T=O_P!Q8_$_M9.[
M'IY]$=W9WL08BXI3/D:XKQ_+H^/1_6G>77F3W'7]O?)ZI[VQ>7P]/28VDJ=B
M46R_X1/1%?N,@9:;]0GAN.#S?GW'VXW]K?E$M+;P:@4[R^OSX@_Y>C6*&:WM
MO&GGH0?]7ET17J3Y?]K[B^2.'W5N7,2K\5N^NS.S^B^F,4U/ PH,IU[]N:#(
M"K(\C)FZJ236;^K4?8^WGE6S@L##%07MO!!<S>?;+BG^UI0=%UI/.LM)_A J
M3\OV?(_R_,[/;73WR+W]O:&OZL^564Z0V^V,H,34;5I>M\3ODK7?< 2UOWM4
M?N6\S7.H\_CV"=JW:SV] +NR^HQ35K>/_#Y#AY^O1A/#+=+^A<>&>-?7]HZ(
ME\<:7YE?(.#N0R_-3+;*_P!$G;6>ZC]?3^"SWWPQ.N^1X_X#:]/^9_/L=\S3
M;3L/@4V_7X\0F_M93IK^'ATBVZWEEI6XK4>5!T9WLC_9N\OO'JCX\]8[E?:%
M/3]?_P!X.X?EON+9<-53Y*NH@P-)@\7I,$67F4!P%(=VY)'L,;5^Z4AGOKE
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M *S_ +#_ 'OW"^Z?[D]9-[?_ &'^KUZC^T?2[J1/_8_Y"_XCW[IN/H$^T_\
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M^\>_>">O=>\?^/\ O'OW@GKW7O'_ (_[Q[]X)Z]U[Q_X_P"\>_>">O=>\?\
MC_O'OW@GKW7O'_C_ +Q[]X)Z]U[Q_P"/^\>_>">O=>\?^/\ O'OW@GKW6/W[
MP3U[K)X_\?\ >/?O!/7NO>/_ !_WCW[P3U[KWC_Q_P!X]^\$]>Z]X_\ '_>/
M?O!/7NO>/_'_ 'CW[P3U[KWC_P ?]X]^\$]>Z]X_\?\ >/?O!/7NO>/_ !_W
MCW[P3U[KWC_Q_P!X]^\$]>Z]X_\ '_>/?O!/7NO>/_'_ 'CW[P3U[KWC_P ?
M]X]^\$]>Z]X_\?\ >/?O!/7NL?OW@GKW63Q_X_[Q[]X)Z]U[Q_X_[Q[]X)Z]
MUC]^\$]>ZR>/_'_>/?O!/7NO>/\ Q_WCW[P3U[KWC_Q_WCW[P3U[KWC_ ,?]
MX]^\$]>Z]X_\?]X]^\$]>Z]X_P#'_>/?O!/7NO>/_'_>/?O!/7NL?OW@GKW6
M3Q_X_P"\>_>">O=>\?\ C_O'OW@GKW7O'_C_ +Q[]X)Z]U[Q_P"/^\>_>">O
M=>\?^/\ O'OW@GKW7O'_ (_[Q[]X)Z]U[Q_X_P"\>_>">O=8_?O!/7NO>_>"
M>O=>]^\$]>Z][]X)Z]UD\?\ C_O'OW@GKW7O'_C_ +Q[]X)Z]U[Q_P"/^\>_
M>">O=>\?^/\ O'OW@GKW7O'_ (_[Q[]X)Z]U[Q_X_P"\>_>">O=>\?\ C_O'
MOW@GKW7O'_C_ +Q[]X)Z]U[Q_P"/^\>_>">O=>\?^/\ O'OW@GKW7O'_ (_[
MQ[]X)Z]U[Q_X_P"\>_>">O=)/>0\.WJ[_@N*((X_ ]I)<Q_GT?\ +69_V_X1
MT#MO]I7_ 'W^P]I:GJ2? Z"G)3^>MJ%N+DD#_6^O^VN;>W=7=T.+*']$#IQV
MW_P//^O_ -%'WYOBZ2[M_N/^70C8"E^XW!AX!S_E_P#O/^^O[=5O$7H&;Y,+
M:#'1D%B$-K<'G_B/=D/43W)ZX>/_ !_WCVKZ2=8_?O Z]U\XO_A9"D2?S!?B
MTDL'IJ/B+CU*_P"+[_W?SQ_K?[S;V)=C%(1^7^7HJOO[9OM/^ =7OUG_  D]
M_E/;WZUI_P" P_)'9&X]R[2Q&2H=T0=SC<AQU=FZ(212-1UV,2@JTA.H#4ZH
MPXU6X-+C=_!ETTQ^76Q9*,XXGU!H#UKL_P N3L#O7^1E_/"R?P.WKOFHKND^
MP^SJ#I'LFDFK8J?$9G%]BP1R;)WM!CRL\-/F8$J<;*2$$DJ.]*]]:^UEZHNX
M2WRKTQ;G3("/R^VE?\E#Y=;W?\P#^8W\5_Y;75@[.^3N_P#(;>&?R>8Q/7'7
MNTL2NX,_N3(4CK'51XFA5A'Y*1W199JE_LJ>X=U=S;V'K;;6N!4_R_U?ZO+H
MVN+^)?A_GP'^K\C3CU1OTO\ \*\_Y>?9/8M)LKL?K/O[H[;.9K(,;C.UMX8W
M$;NH***6H^V^XR\.#KI:ZD72Q)GI!-'&.69R"/9I+L2-'IZ1Q[FZYJ/LX?Y?
M\-.K[?F=\W^HOA)\1=Z_-/?6-W)V5T_L^@Z]KQ%U++19NLSE'V37XK%T%?B&
MR%7CL;6Q@91U'^7,PI=(8J/4">PM=$OTYX<<>G2CZHL?&IG/EP^7V]4I[W_X
M5A?RX=I?'WK_ +?H]K]\9W??9\VYEPWQXHJ3!4^X<31;0S$F*.2W)51Y5\-B
M5R<$#24!-34U;Q1M(J( A)@=A?Q*UQ\^F/JVK0T^VF?YD>GJ*]'>_EC?SQOA
MU_-)RF7V!U10[WZQ[BV;B'W?6=0]EX6@I\C4XF"44E1E<)68R23'5]%0B>G8
MH"*A$;4\3B_M+>;08<CIV#<4)SG/'(I3UR?\G27_ )EW\_GX/_RRM\#I_?W^
MD#N?O-*"/);CZTZABQ\\NWTR5#%+3-G\AD:J''TSU@G4CQFIK3<:AX]*F]MM
M<TGQ=>.X1K0K@8\JU_(4_+_!UJT?SW_YR?Q&_FL? 'I.AZ+KMV[)[.ZY^1CY
MC>'3W:N+HJ3/I0U>%JA_&:.7'SUF.R.)6\:NR3QNC"\L6D7!WM>VBS7''-?S
MI_FZ+KV\,Q-<C%/RK_G&<UZV'OC)_,'ZK_ED?\)^_P"7I\G.Z=D=C]@;'?J_
MIGK@X?K#'XJLRJU>Y6RTL99LK78RF^V$,+E5,K,2"M^?:&\V\7LU3Y?[/2JU
MNS"A ^7\PHZ!CLC_ (5I?R^=F4'3[;8Z?^0O96?[/V5B=WY;:VS\1M[&UNW5
MW)75%-!@ZZ5,XJ5V>T6E-+2(R#5"34AB;.G:J<,_R_XO^72A;^.F<?E7T_9_
M/HM_\Y7LG^416_S'_BAD?F=TS\YLM\EMW]*?&K<'7<_4VZ<#M+"X[%YG=F5;
M;M#GZ#(Y9YX<OC,D:M<B$!!*?H5K2'UO;RP0 1^E1PX=)+F>/QL$&C$&NKC6
MOD>BD_\ "M[^8E-F=];3_ES==9?N'9>;ZLK6WOWO%'F8\3M?=%'V1@\9-M^A
MM1Y(Y#+R8E99U*U]$$'E(4N P-]FL0P\7S/\NM7EWJ&C]F,^?_%XQU9]_+!_
MF>_$?YG?RGN^/C?6]<=X8W9_PH_E[U^T/DQ'%/@L)-F<)1[0R]-F6V34PY0Z
M*PP4V1^S%4*($  A[6=N6T$4X/J/]C_+U:*8R1UQ\0'#U_XK_!TK?^$T>X_Y
M:.X]@_*=OY<O7/RJZZV\F[.OH.U(OE/N;;V:EJI_X?6M0?PA,+75H4?YPS!H
MS=?RHL"UO<4LHHG#\OG]G7MO1&IKIQ/ &OEZU\NA\_F ?\*/_@'\ ^SLWT9E
M#V3WKW1M:2?&]AX/IV#'ST.WLG"S"3&YC,Y:II4_B4/C?7%2^66G/I12_I]L
MC9Y!'I)S_EZ>>]+>@'V5-#_(?9TY?R[?^%$GP-_F+=GT'1VVCO\ Z'[LW#5/
M%LC8_<L>,I:7<XQY\J4>&SN+J9J<Y&<DE*&I:%V,>FG11^V4<NPR1<#_ *OR
MZO#N)>OG^61^1K7CGB>M@5A5Q?7G\<BWT_QXO[)_$Z-S/7HHOS"^9'QZ^"G1
M>X>^_DKOJ'K[8&+JFPT%0I?-9?)Y#(QF2'#8C'TFDY#)S1JS'2X6,7)-@?9M
M;;;+<9;_ %'HKN)O"-%(\B?3^7\@.M<3'_\ "Q?^7W5;V@P^2^/WRCQFSGK?
ML/[XR4NVI:VDB7T_=##TV4+L;W&A*@3WN2FGU QCV)0>DOUK$<<^E#_GK_+K
M97Z?^4WQZ[[Z!Q'R?ZS[:VUN3H?<&R<AO3_2:<F^+I*.CPAMD8<Q'("V*.)%
M_OTJM3T@(8EU*GV43;5<12UXCUZ71WL0%*9QCU^SU^7#Y]:Z7>/_  KR_ES]
M9=D9;8^P^J^_N^=LX.JDQS]D[/QN!VQA:Z*DE<&JP\>7K8\CD-3K=7J8:1)!
M^A58D>S=-DU<?\W2=]Q1N/\ @K4_M%/V'UZO/^!7\Q3XL?S(NI1V]\7]]U^9
MI<-F*?:O86SMT8YL)N+;M=5+K3'Y;':W(CKF!6DG!^RJR-"N9 4""[VMK<5'
MY];6ZBDP1GR]#_F_U4KUI5?RPO\ N+:^5/\ XL9\]/\ W;9CV>[E_N,?S_R]
M%L/]I^S_ "=-O\T[_N+)ZC_\2I\(/_>;P'M3;?[CC[!_@Z]<_%_J]6Z^C-51
M?[D,AP0#E!]?\/I_MO83N_/[#T?69J/]7IUA\?\ C_O'M#UKKWC_ ,?]X]O>
M">O=>\?^/^\>_>">O=>\?^/^\>_>">O=>\?^/^\>_>">O=>\?^/^\>_>">O=
M>\?^/^\>_>">O=>\?^/^\>_>">O=8_?O!/7NLGC_ ,?]X]^\$]>Z]X_\?]X]
M^\$]>Z]X_P#'_>/?O!/7NL?OW@GKW63Q_P"/^\>_>">O=>\?^/\ O'OW@GKW
M7O'_ (_[Q[]X)Z]UC]^\$]>ZR>/_ !_WCW[P3U[KWC_Q_P!X]^\$]>Z]X_\
M'_>/?O!/7NO>/_'_ 'CW[P3U[KWC_P ?]X]^\$]>Z]X_\?\ >/?O!/7NO>/_
M !_WCW[P3U[K'[]X)Z]UD\?^/^\>_>">O=>\?^/^\>_>">O=>\?^/^\>_>">
MO=>\?^/^\>_>">O=>\?^/^\>_>">O=>\?^/^\>_>">O=>\?^/^\>_>">O=>\
M?^/^\>_>">O=>\?^/^\>_>">O=>\?^/^\>_>">O=>\?^/^\>_>">O=>\?^/^
M\>_>">O=>\?^/^\>_>">O=8_?O!/7NO>_>">O=9/'_C_ +Q[]X)Z]U[Q_P"/
M^\>_>">O=>\?^/\ O'OW@GKW7O'_ (_[Q[]X)Z]U[Q_X_P"\>_>">O=>\?\
MC_O'OW@GKW7O'_C_ +Q[]X)Z]U[Q_P"/^\>_>">O=>\?^/\ O'OW@GKW6/W;
MP.O=9/'_ (_[Q[]U[H.MXQ'P5H_I;Z_X#W<Y!Z:CXCJI7Y%QG[BJ_P!]_3WN
M'XORZ=M_[8?9T47^7W_V],H__%;-[?\ 6VG]S#9?\DR+[5ZQCV__ )6ZZ_YH
MO_Q[K:-]HNI,Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>ZC^T_7NJ@_GNU>WRH^*C3'_(6V5W%1X8?]-^JFO?_ *IC'[F;V]0_NV_
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M\\WW#_YR8C_ZO][_ '5<?ZA_L]:^HC]5_G_FZY?\.-]2?\Z3N+_SCQ1_^/\
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M51VKDXX:+$A33F%:@1F=7N+B_LQ) ?C7\O\ 8Z8'B.1V:?EGC4_ZJ?+H=/\
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M<5QTH6, \>D;'\<GY/VK?[:_^\>V)).K&V^WKW^RX5?_ "J?[Q[KXG6OIO\
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MCH:-9-=5+18^.-*ER!X7(4@S8H,4'[*5^W_4.DRJ7-?7YUH/EDG_  GJ[_\
MF9_"SY6;F_D(]F?$'&[H[?\ F_\ *U<1TN=P[EKU&2S>Y,C0;ZV_F<S_  XS
M& F@Q"3&.-&=V:CI2Y#/^DMCF+3TST^R*$U8 SY@>7$^6<_[/2L_X38?&KOS
MXE_RX:#J3Y&]7[MZ>["3OCL+<<FS]V1+!71T6:K*$I5B! Y :-"-6FQM=1_1
M!N4VN>F1_P 5TMMX_$B[:$Z3P(.:G'Y]4U?#O^7E\V^N_P#A3#O_ .7V[OC;
MVEMCXW5?='RDW%CNZLMC*.+#2T>[-JYRGQ4RN]0%*U51+&E]9!#$+ROK,WW
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M(8 5-O\ IF^WC^G_  4>Q3_7/8;GB;N/]C^7V'K0$\&>S^7^&O6/_9:/GO\
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M?W2HO^5$?[8>[:1_J!ZWXC>O7O[I47_*B/\ ;#W[2/\ 4#U[Q&]>O?W2HO\
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MDU+#S?2"/Q]!_P ;]H'DZGK:K>E>DWK/^'M!T=]*';7[N3!_P_UOH;>UMO\
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M^Z]U[W[KW3?[]U[IP]^Z]U[W[KW4?_=_^^_U/MO\7^KTZ>\OS_R]4L_SP?\
MLE'K7_Q9;IS_ -SLG[$&Q<'_ -(__'&ZA[WN_P"25;?\]UG_ -I,/5R-/_P&
M/^NWN&KS^TZRCV__ '&_+K+[8Z4=>]I^E'7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U']^Z3]
M2/?NE'4?W[I/U[W[KW4CW[I1U[W[KW6+0?\ #W[IK0>LOOW3O7O?NO=>]^Z]
MU']J.B_HIWRZ_P"+%L+_ *C=Q?\ N+[>A^']O^ =;/Q'[!_AZ-)A/^+)MO\
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M.8N%*$5SZ=+?J#MCKSO?J[9W;G4FY\=O_K3L?;..WALO=^V684-91YD%;$,
MT5I(W721=2+'WZXM_H\_Y.O0RFY-#C[/]1Z%FQ_H?]M[9\(=*]9ZC>W.DG7+
M[=O]1_R=_P ;]W\%>O=9O=.E'4?VHZ3]2;'^A_VWM'X0Z5ZSTE8MQ[??/U6U
MZ;.8FLW7A<1C\G6[;&0+5]+05UA1RS4?Y:L:P(_Q']?;OTW2<7!XTQZTX_\
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MZ]U[W[KW2#WG_P  :S_??VO=H^'Y=,2\1_J\QU4-\C_^!-3_ *X]NGAU=/\
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MZ; ON&-H$=""H53Y' ;[>C#FCF2#G6&WMMM*SO/+'0U!!\'CP^0_;^=(TWR
MV5\7_P"8KW?/V/3YNCV77]#=-8"KWICZ.HK8L5/0RS_:O7?:J_VU+7:6(F"F
MYL/H3[VY:;Q"M:&1A7.#0<:=-V^^0\O[].DI&H6L+?:"T@_R?X?3H0^IMXX?
MY<?.W!=]=9T]=6=(_'SJ[=VT&W]DJ.HQT&<S6\JAE%)C14W-33P)(/W3]/H;
M K[HY>-ZQ\7J*G%:U'^7HWVJ\@YJW3ZN&G@VT=,<,T/^3_5GHJFSM]=L[/\
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M#^5O-!4=9?)35<:_F'W11"_'#.&/^]>Z$\/]*?\  .A%[=8M)OE/_P _,/\
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M$_JW^W'_ !3W[6>O=9O=.O=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=8?
MG]6_VX_XI[OK/7NLWNG7NO>_=>Z][]U[K#X$_JW^W'_%/=]9Z]U[P)_5O]N/
M^*>_:SU[KW@3^K?[<?\ %/?M9Z]U[P)_5O\ ;C_BGOVL]>Z]X$_JW^W'_%/?
MM9Z]U[P)_5O]N/\ BGOVL]>Z]X$_JW^W'_%/;O7NLWM/U[KWOW7NL/@3^K?[
M<?\ %/=]9Z]U[P)_5O\ ;C_BGOVL]>ZS>Z=>Z][]U[KWOW7NL/@3^K?[<?\
M%/=]9Z]UF]TZ]UA\"?U;_;C_ (I[OK/7NLWNG7NO>_=>ZP^!/ZM_MQ_Q3W?6
M>O=9O=.O=>]^Z]T&O:O&SJZ>_(R&*(_\[B/::Z-1^WH5<G8OOSZ)+4R:ZBK
MXTA1[*I)]6>LF[< 4'4;6?\ #W;Q.K]"'U(@J-\X>"UP&L./Z#VIMGUGH'<^
MGZ:P/1X%_P" _P#MO]['LWCZQLN?]7\NLG@3^K?[<?\ %/>M9Z;ZS>Z=>Z][
M]U[KYZ/\^FH_TI_\*1_@IUSN 3P;9VR_Q%P5%55K#[62EKMS29R7PE;_ +6N
MJ*-_A:_)/L46?]@!\NBN9@9ZCS-3]M3_ )NMF3_A2L"G\F+YSK?ZT?5?^\;Y
MVK[+K(4G/2ZY-85^S_)U6]_PCA;R?RW/D)_C\N-T\_7].U]KGV[O,6H5^?\
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MO_E&(GKT#T++XP&,=N%47*@AW[ZZ$+!#Y])[523C&?6GE\N@L^9?_<8KL_\
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MKW7O?NO=8? G]6_VX_XI[OK/7NLWNG7NL/@3^K?[<?\ %/=]9Z]U[P)_5O\
M;C_BGOVL]>Z]X$_JW^W'_%/?M9Z]U[P)_5O]N/\ BGOVL]>Z]X$_JW^W'_%/
M?M9Z]U[P)_5O]N/^*>_:SU[KW@3^K?[<?\4]^UGKW7O G]6_VX_XI[]K/7NL
MWNG7NL/@3^K?[<?\4]WUGKW7O G]6_VX_P"*>_:SU[KW@3^K?[<?\4]^UGKW
M6;W3KW7O?NO=>]^Z]U[W[KW6'P)_5O\ ;C_BGN^L]>ZS>Z=>ZP^!/ZM_MQ_Q
M3W?6>O=9O=.O=8? G]6_VX_XI[OK/7NO>!/ZM_MQ_P 4]^UGKW6;W3KW6'P)
M_5O]N/\ BGN^L]>Z]X$_JW^W'_%/?M9Z]U[P)_5O]N/^*>_:SU[KW@3^K?[<
M?\4]^UGKW7O G]6_VX_XI[]K/7NO>!/ZM_MQ_P 4]^UGKW7O G]6_P!N/^*>
M_:SU[K-[IU[K#X$_JW^W'_%/=]9Z]UF]TZ]UA\"?U;_;C_BGN^L]>ZS>Z=>Z
MP^!/ZM_MQ_Q3W?6>O=>\"?U;_;C_ (I[]K/7NO>!/ZM_MQ_Q3W[6>O=9O=.O
M=>]^Z]UA\"?U;_;C_BGN^L]>Z1.\?^ *_P#!5_WOWY/]7\^MR\1_J\QU45\B
MXS)451'(O^1_A[?$6I>O6_\ C,PZ)K_+YDO_ #5H1]=/QGWJQ'TX$U-_O/'N
M4K1O"VB,_,?Y.L7=LG^JYYN1_P N[_S?K:$\=5_JT_ZEGV@HW4O:1Z?ZOV]!
MAN_JCK3L5::GWUUMMO<])3 _9S;NP%-DF_'T,I!_VRB_^]UC:5\AQ0>JUZ9N
M=NM+H_J0'\C3I5X7;.)VC1TN.VQMJBV[04I_R.BP5 <537/]1#_Q4?U]V(4#
MNDU?8/\ 9/3\5J;3^R@T?;GJNK(]%?(7O/Y%;%W7WVG7N$Z1Z%W3GNQ^I-K;
M(KZJMR6?R<1,>*K\R:MF%.U%$IU D'[FX(L=0W3PWD6.FIR5:E:GTKT$-PV)
MM^N;:>[J8[4^- 33M)!4T_:?^+ZLQ^R!I?\ * :S[O22 OUN/]Z%O?JXSFO0
MO\(5KPZ:L7A*#$8T4-'28^EIS<_Y%C/X6QX_)X-K?X>VF80OK_V.M*ABA\$Y
M_/'6''[:PV'T_P $VS1XNIJ"!6FAQU+0_=D?T!#'\_XGW9 YS))3UP.JQV\4
M/]C;U_U?ET2/;70&\<?\X^\^\,[0X*JZK[#ZDV/LO%2"O_B=89MNSUD=4)*0
M<^-6G;5?C^A)!L^S-I4I0Z6'SK^706AY?7]ZSWDQ-)H\C[*_X:]'CH<-C\33
M-'BJ04=.OIH:+'L+_P!>;"W^/^W]I7D=_CQZ ="J.SA@/Z.?MX=<,=M_#XF%
M8J/$4%-3UG^6Y#[)AS?^E@+D_C_>/>VD=Q0 4XFG6X[6&#S/R_U5ZATVS=O4
M%--CX]L;:I**I#"NQZT%*!5!OK<#B_\ 2XX][8/(*:V_8/\ -U2WLHK;_0(_
MY]//\(H/M_X!]K0?P^_V/\/_ (6/MM6JWT^GUXO]/;>L?'BG#@:?MZ?\(_V.
M:_;Y=0L5A\?@H_ML+3T>,I2!>CI/]QA/^N% N/\ 8>]@_P"_*?9TW:H;(_H_
M['7L1M^@Q*G[2BQ])]U_EM<*$_PR]4 /Z$'GG_>_:EY=?D/4^6>O16O@'_5P
MZE4V"QV(I3%14M#24QY/V*_PO_>O^*^]:0_RZJUL8#FO6'&X.@P>.-)C*.AI
M*8^FV/\ ]Q7T_P!@3_MS[\QU"@'[,=;B3P34G]N>E%[WTWU[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]UA\"?U;_ &X_XI[IH'5]9ZS>[]4Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NL/@3^K?[<?\ %/=- ZOK/6;W?JG7O?NO=>]^Z]U2E_.[
M>_Q0V"/K;Y.=.?7^AK*S_BGL[Y?3QIG/_"W'_&&ZB/WLQM5N/^7ZR_E<P]7*
MK_P$_P"0A_Q'N([S^TZR;V__ ''/4CVQTIZP^!/ZM_MQ_P 4]M:SU[KW@3^K
M?[<?\4]^UGKW7O G]6_VX_XI[]K/7NO>!/ZM_MQ_Q3V[U[KW@3^K?[<?\4]M
M:SU[KW@3^K?[<?\ %/?M9Z]UF]TZ]UA\"?U;_;C_ (I[OK/7NLWNG7NL/@3^
MK?[<?\4]WUGKW7O G]6_VX_XI[]K/7NO>!/ZM_MQ_P 4]^UGKW7O G]6_P!N
M/^*>_:SU[K-[IU[K#X$_JW^W'_%/=]9Z]U[P)_5O]N/^*>_:SU[KW@3^K?[<
M?\4]^UGKW7O G]6_VX_XI[]K/7NO>!/ZM_MQ_P 4]^UGKW7O G]6_P!N/^*>
M_:SU[KW@3^K?[<?\4]N]>Z]X$_JW^W'_ !3VUK/7NO>!/ZM_MQ_Q3W[6>O=9
MO=.O=8? G]6_VX_XI[OK/7NO>!/ZM_MQ_P 4]N]>Z*/\MHK879__ %';E/\
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M#\5NGOB_UW-3OM/JG!"/(;MR%%2XRIS-7DR<EG=P5BM_FQD:]&8*+D*BK=@
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MA_LF'6W_ #[3!_\ 4E?^C?=OZX77^_)/VG_/U;_6(V#_ )0;7_>$_P W7?\
MLF'6G_/M<)_U(7_BGOW]<+K_ 'Y)^T_Y^O?ZQ&P?\H-K_O"?YNO?[)AUI_S[
M7"?]2%_XI[]_7"Z_WY)^T_Y^O?ZQ&P?\H-K_ +PG^;KC_LE?5G_/M,%_U(3_
M (I[W_7*[_WY)^T_Y^J?ZPNP?\H%I_SCC_S=<O\ 9,NL_P#GVN"_ZDK[U_7"
MZ_WY)^T_Y^K_ .L1L'_*#:_[PG^;KO\ V3#K+_GV>%_ZEC_BGNG]<;K_ 'Y)
M_O1_S]5_UA]A_P"4&U_YQQ_YNN_]DSZU_P"?9X3_ )(7_HWWO^N5U_OQ_P#>
MCU[_ %A]A_Y0;7_G''_FZ]_LF?6O_/L\)_R0O_1OOW]<KK_?C_[T>O?ZP^P_
M\H-K_P XX_\ -UQ_V3#K3_GVN$_ZD+_Q3W;^N%U_OR3]I_S]6_UB-@_Y0;7_
M 'A/\W7+_9,^M?\ GV>$_P"2%_Z-]U_KE=?[\?\ WH]5_P!8?8?^4&U_YQQ_
MYNO?[)GUK_S[/"?\D+_T;[]_7*Z_WX_^]'KW^L/L/_*#:_\ ../_ #==Q_#'
MK9;:>M,&HO\ V4 _XCVZO.=TW&1S^9Z?M_8C84PMC:C[$0?Y.@\[:^*NR-M]
M4=I[DQVQ,+19/"[ WWFJ&OB4$4M5B,-4R@-P.3S]1[6VG,T\LB*)'J!C)Q_/
MHFY@]H=JL[*YE:SMR&/<"B]U?7'1=?@5T;BNY?C=BM][\VX-U;AGW?O7''-9
M$ @4N*J4:*_^N6]G/-.^3;??> DA'0*]H?;?;N9-I2XNK59"14U )/<:']E.
MCF/\->N/)QUMA;_2YL?^(]A*/FNZ_P!^/^T]2:?938N/T=M_O"_YNN/^R8=:
M?\^UPG_4A?\ BGMS^N%U_OR3]I_S]-_ZQ&P?\H-K_O"?YNNO]DQZN_Y]M@_^
MI,?_ !3WO^N5W_OR3]I_S]:_UA=A_P"4"T_YQI_FZ[_V3#K3_GVN$_ZD+_Q3
MWK^N%U_OR3]I_P _6_\ 6(V#_E!M?]X3_-UE_P!DTZW_ .?987_DC_C7NO\
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M+K_?DG[3_GZ]_K$;!_R@VO\ O"?YNI0^&?59OY>LL'^+^E?=1SA<_P"_9/\
M>CU7_6'V$\;&T_YQI_FZ&'8/P3Z$RT]-!G>H]M5],>+58J!_K_1;?C_>O>OZ
MWWPS%(_[3_GZ>'L5L-*&RM:#R\-"!^T=6-=5_P MOX2";'Y:M^,>PY<I15>.
MJJ.NK9ZP?Y3CN3;_ "EA^ 1<$#CCVE?G"\M_@O6Q\R>/Y]/P>RNREM4VU6M:
M@U\*.M12AKIKBF/3RZMLB'G!J!];<_['_>/84EP.I@ZQ^V^O=2/?NO=>]^Z]
MU[W[KW4?W[KW4CW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U']^Z]U(]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW4?W[KW10_F#_ ,>]LS_J.W-_[B+[?A^'\NFOQ'\O\/1L-M_\
M6+;7_AN[7_\ <%O;,_ =7@XG[6_P].GO75NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MH_OW7NI'OW7NO>_=>Z][]U[KM_\ @1_L#_O8]J-NXG\^M7?E]G0C^QAT0=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW2/S7_ I?\ EFO^]#V&MU_M_P!G^#I?9?#^
M1Z9_99T8]>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=1_?NO=2/?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW4?W[KW4CW[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=1_?NO=2/?NO=>]^Z]U[W[KW7O?NO=>]^Z]T#W=
MW_,L<M_VL:'_ -S&]M7'Q?LZ&'M[_P E?_5\^B#22?O_ )O[).LLA_J_/K']
MPW^K_P"3?^->_=5Z'GX\2_[_ *!^@_@61^O^%O:G;A^L/]7D>HI]VA_B'YCH
M\/\ RG?[[^OLY\OSZQUZR>Z]>Z][]U[J/[]U[KWOW7NN&@?X^V_"/5]9ZE^W
M.J=>]^Z]U[W[KW7O?NO=>]^Z]U']^Z]UDC_/^P]I^O=8_:CKW4CW[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW4?W[KW
M4CW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=1_?NO=2/?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW4?W[KW7O?NO=2/?NO=>]^Z]U[W
M[KW7O?NO=1_?NO=2/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW4?W[KW4CW[K
MW7O?NO=>]^Z]U[W[KW37D*8S-]N1^/\ >_\ D7NP&*]>Z!+=?7\-=8S47UL0
M![N@Z;D@*]!#4](8JJ'%+;_'Z_7_ &'NWB]5!8>O4/\ T#8W_E5'^V_XW[8T
M?(_R_P W3E#Z]>_T#8W_ )51_MO^-^_:/D?Y?YNO4/KU[_0-C?\ E5'^V_XW
M[]H^1_E_FZ]0^O7O] V-_P"54?[;_C?OVCY'^7^;KU#Z]>_T#8W_ )51_MO^
M-^_:/D?Y?YNO4/KU[_0-C?\ E5'^V_XW[]H^1_E_FZ]0^O7O] V-_P"54?[;
M_C?OVCY'^7^;KU#Z]>_T#8W_ )51_MO^-^_:/D?Y?YNO4/KU[_0-C?\ E5'^
MV_XW[]H^1_E_FZ]0^O7O] V-_P"54?[;_C?OVCY'^7^;KU#Z]>_T#8W_ )51
M_MO^-^_:/D?Y?YNO4/KUE_T$XTV_R5C_ (7'MV&"O6M)]>L?^@?'?\JW^^_V
M_O7TWV_RZWH/K_J_;US_ -!6._Y5C_M_?OIOM_EU[0?7_5^WKA_H'QW_ "K?
M[[_;^_?3?;_+KV@^O^K]O7#_ $#XS]0I#_K?7_B?>H4ITV8_3H#_ )-=*8RF
M^.'R-J'I=)I.C.VJM2!_J-N5S\<?U]B#8;2EY%_IF/\ QD] WG9RVV7P/_*.
M!_,=$;_DS]28[/\ P8PLKTNBJ@[F[/0\?4*(CS_K6)]B;W"MM&X_D?\  .HX
M^[=<&?8H_FQ/[7>O5K7^@K&_\JG^\_[X7]QW])V_RZGW6?!ZQ_Z!<=_SK#_O
MO]C[KI_U?ZATWI^8ZY_Z"<;_ ,JO^]>ZZ?M_U?EU?2?7KA_H&QO_ "JC_;?\
M;]ZT?(_R_P W6Z'UZX_Z!,;_ ,JY_P!O[OI_U?ZAU30>N?\ H+QO_*FW^V'O
M6A/G^W_8ZO2X]1^S_9ZY?Z"<;_RJ_P"]>]:?M_U?EUK2?7KW^@G&_P#*K_O7
MOVG[?]7Y=>TGUZ]_H)QO_*K_ +U[]I^W_5^77M)]>O?Z"<;_ ,JO^]>_:?M_
MU?EU[2?7KW^@G&_\JO\ O7OVG[?]7Y=>TGUZX?Z!L;_RJC_;?\;]ZT?(_P O
M\W6Z'UZ]_H&QO_*J/]M_QOW[1\C_ "_S=>H?7KW^@;&_\JH_VW_&_?M'R/\
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M]Y_M*_\ )7OVD>O7NO?>?[2O_)7OVD>O7NO?>?[2O_)7OVD>O7NO?>?[2O\
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M*R_YPO\ ]M746/I[^=.P\L'RV^+56.3=.KZLC_>[>Z:]G\;^Q>OVC_H#I_\
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MK7L__P J_;?8G^$=']]AKJ2.O>_=>Z][]U[KWOW7NO>_=>Z][]U[J#4?J?\
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M/\JL!\3OY:$N&K<K19RJI=S=B56W4WM29*JI 8ZTQ"K26EI=NX$:O/5Z;32
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M2/+SP. X]:YF]_D&G:G6V<Z8V/U!W!F.V-Q;9I-L#8E'LZIKJF"HS ,/[U(
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M?_\ DD7W_- ?Y>@ _EC_ /9 ?Q/_ /$28/\ ZVR^R_G+^W;_ $I_P'JOL_\
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MI"PU(^H(TU"_XV]ES[>DV6S]G^;'2A)C;]KBG^FI_AZ'/J7^</V=M&N_NO\
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MQ^+[#VW7Y7<'7<6*H</2./NS457A%C#^H?U/] .;>XCN]VM[T&&)G)4I4%2
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M/2LU#D>YOM##NW=C,N5I]M&P4HAL5K,Z;$%C<48X7U$Z11M^WB04/Q>9]/\
M9_P=%%W=%.^/X?(>O^8?X>B$="_R\=]=M5'^EKY2;BW5BH=T^3.#:]76G([I
MR88\UF6J9[_P]2;DL]YS]=/Y]B:.S@A[F/'-*Y/V^G1 7E?L8#&*_A'V>O\
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M_+G)MG=<Q75I&1I59!&&!TU&BF"3PS0&O$CKI5[J^[^^O[/[7?PW-U,%N4;
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MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]I^O= -\F?\ LFSY'_\
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M[)M(C)8Q<,@T*GH2V=W+97?TDHIJP0.'EPQ3S'IY^G5SL/\ RL%5^I-@"/\
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M_P!?VDFW8O\ Z)7[3T(+/DC;[;_B. /D*]"30]/=58O]FCZYVI3L#]'QYO\
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M@]J=GY/'5<6(^ZVO!CQ/#+44^MX%62C=650VDV!%O9E9;9)S!RZ;6W.F6!P
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M_P"IK,7^/]=?>GY7MCG]X)_U7_S=:A]W[\_\LF__ "-O_P!M ZY_\.6]_?\
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MI"H_XY0EK'G^GU_'LKG9MS'BWD]!Y4X=/1106AKQ/S)J>GWGC_>1:_\ OO\
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M)+QUM4T-*?B)+<,%RQIPT\.KL=L;,VGL/ 4^W-GX[#[8V_BCJI<1BJ.DH*>
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M/^.MU<O\/_\ LDOXQ?\ B"NN_P#W B]PGSQ_R5;[[)?^.KU('+_^XT'^G/\
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M1_?ND_4CW[I1U[W[KW4>7^U_L/\ B/;\/^K^72%^/6NK_P *(O\ F6'Q<_\
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M/^K_ (KKW7O?OIS_ *O^*Z]U[W[Z<_ZO^*Z]U[W[Z<_ZO^*Z]U[W[Z<_ZO\
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MVOIS_J_XKI)U[W[Z<_ZO^*Z]U[W[Z<_ZO^*Z]U[W[Z<_ZO\ BNO=>]^^G/\
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MOIS_ *O^*Z]U[W[Z<_ZO^*Z]U[W[Z<_ZO^*Z]U[W[Z<_ZO\ BNO=>]^^G/\
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M21\_C\>ZW4'BJ)AP)!_(^72FUF\*JGC0C\QP/6T+*1!5$TW_  %N0/\ C?L
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MS6D/D7DR\YOETVD-*U\1:FK?X<?/H-<U<WP<OP$L:* *D@8_V?Y=:[,G:?\
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M 'Z_^]#_ *!Z3VY_^$^&7IL=Y=D?)_;%7EZ<'R#=?7,N&I5O]-5;233/%?\
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MCU[V57[?H:ZAVYD-ZXN#.U<-)67:4+]TP#!221Z21^/9OMF^7FW_ -BH:GJ
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M_6]N?]X]N/=S0?\ -'JD%N&^WJA7^?\ ; QN:^.O1W9<E-1+D=N=J5>U/N4
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MTFXL+<6,B;5.F^6<EM,::,J1Y-Y_EP\_,]8F>ZGU?M7OEGO^UJ&^J(69"/B
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MOW7NO>_=>ZP^!/ZM_MQ_Q3W?6>O=9O=.O=>]^Z]UA@_0?^#'_>A[4=>Z@/\
M7_8>T3\>O=9?=.E'7O?NO=>]^Z]U[W[KW7*E8?<X[CZD?[[_ 'GWXSUZ:T]:
MT76?_;W;L3_Q+?='_6N?W)6T?!^9_P '0,W+XA_I5_R=7=^WND_7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW1</D?\ )#:/QNVE2YS.4L>X-VY^,8[KSKS'
M"U9DZL<%FM_P#QU'])IAZF;@?X/JHC%3Q_"/]7ETZ P:@X>9_P!7GU4U68K?
M7<>ZSVK\@LJVY]TD$;7V:3;"X2F3D4E+2#A$%^% L/\ 7]T:I.I\GT\AU1%5
MAI3 \SYG[3T)GMOI[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N@ZW
M?UCM_=LM-E_\LVUNRC*/@M\X,_99*#3_ %$-N;_F][_TY]N-*&]0?7SZHL6G
M&"/Y=&2Z0^:>[^O\IB.J_E=5M5XFMU46UN_*3]RFJ]5[?WE/)=!?_/WUJ+?4
M>W&J"%/Y-_GZI0-W'CYK_F].K68I/+!YH!]W3U?%!_#Q_7VGZ]3_ %'KE[]U
M7KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z!+Y%=>'M;H?M/8XIC45&<VK69/":3]<EBB*W'C_8H6 _U_:@#2C2>HQ]
MO$=.!=$BGYY^S@>B:_R5NSXY*#N7I/+57[U-7XWLG9U*W #93_<7EK<<EF>A
M_P!@/81WJTJ"_P"=/Y="'9W *O\ :#_A'5Z_L*]'?7O?NO=>]^Z]U[W[KW7O
M?NO=1_?ND_4CW[I1U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=8KGFGY_!O_ +?_ 'GV[/B$_GTR./Y]%IS9M\GEO^.M<=_O%6#_
M ,1[DW8YO VX'_AG^7J"^9!7F;_J&/\ @Z'Y5J&'A-==>0P(X_WGC^GMV.H[
MZ]":X(_L*?Y^J7T7_L>9+&;7'PVPR\?XB7V*V?\ W4#_ )K2?\?7J X[?_D?
M2?\ 2JM?YK/T9S^9](:?X%?)RI'/VVS#_P G2TI_XCV5<LK6X7_:_P"$=#CW
M@;1L%XWI%*?V(>JK?C1ELA_+OW[\<MSYNIK1\-/G)LO8%7EZRKKBU-M'?<=/
M"6DF%]7V]>0QX NI:US2\'M^C<RQE5S)$%)_I# ^S]OK\NHCY*EC]JOW; XT
MV&YLRH*_[CW)&H**FI#T- *T8>6K!OOF[222?S)OY5:N+QR[N[!U6'_'3'V%
M_P#8CVQRY<Q1;;?>-_:U-?\ >1T+O<&T:\YNV%UX#QJ_F"/\G\^@S^47:_77
M3O\ -V^/W87;F^,'UML7%_%O,4=;NC+U#XF"EGR%7D!#$ !>Y8CC@_T^A(>V
MVT:3;&2*/4-0_GK_ ,_19S7N]KM/.5K<;A=+;ULI1W$**Z[<TJU!D XKG3@&
MAZ/KM_\ F._!/=.XL1@L'\KNI\KGLWDZ'!X"CI\SD8YYYZ_]F.,LR"UN.2W^
MN;W/L-C9]S@2GA/Y#S\_RZE*RY[V'<KC2NXV18C@'0DT'D-6?R'1[U/C_P
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MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW74M13TL'FK/\
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MP][FY/3X$F!^?7E]T)MN_7FL9%^1 _S]#5M;>6W]WXDYS;%:,I3$@ /Q]?\
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M>+_:?]Y_XW[]XX].O:#UBT'_  ]VT'JO77BJ?Z-[UG_4>O=>\53_ $;W[/\
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M_P NBW2?+6I^D.Q<>+#\;C8?]%>U1A^7^K]G3 N3ZG]G6+_9MLG_ ,\+C?\
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MS<GI/UJ<=HQONG^=YEJ>4>NA[NV^OTX_W';8(M]?\/\ >?>2>P*4V**+U7_
M!USLYD5;KW#N:5[)5_FL@_R];&[_ %!'TL.+_P"P]@=Z?V/61\%:5ZYO]?\
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M%D]5_8?\_1>.[.P\%V=F-MUV&H:^BI\5C5QU>*YM=[59Y_WGVJMU%ITEG<R
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MI43UU?D0%K<C4_[54.B@?T^E^/:*\F25O&\Z$D^I/'HZY2V"WY:VD;=&-*J
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M2 &P<U)+#@"!CJS'X@H*CXJ?&2>8V7_0CU\/]@,1"/\ >_8?WZ#PY92?Z/\
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MT5%_N-I@!_O7'M29:_VO[>@M'$L0"H H& H   ^0'^;J1S;_ )"_XGW3PO\
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MU=5_A,/^4+_7/M7<3>O5D33A<GU\O]GHWV!V]@-M4#8O;V'Q^)QVGEW.H_\
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ML3R$CPF_%WDTT-0XIVZL''5W/?U;BLULS;65PU7]W!N'<>U*^AKKW-53$?\
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M_8:_Y>L$OO:;2++<++>#7_%D=J#S+)^7\-./GGRZNFZTW/2;]ZWZZWS3_P#
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M_P!,+DA_Q/MVR_0N#]G5[G,0_P!,.M7/X*)#)_PD5[E4PHT?^A/Y*"H8JO\
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M:.COEF3]V[E!6H^7H1BF/L_GT_[ ^&';O8&T\%O+;DO7]5A-S4OWV&_B6?\
ML:@P*!>RO 0!_@./<C\L?=ZYMYRM(+^R=LU'^Y8]?/-?Y]''-/O[RMRU?&RD
M@4&,BM+=?0>@Z4__  WSWI_RL=9_^A"?^O'L_P#^!AYM_P"4EO\ LL_V>B;_
M ()/E7_?'_9H?\W7?_#?/>?_ !SZ^_\ 0@7_ *\>V?\ @7N<_P#E);_LM/\
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M_+D< -?I$5#Z5B!B:E>&5/5B4GX_V/L,R=2K'U#]N=-]>]^Z]U[W[KW62/\
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M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZB/]/\
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M *E <>9I6GJ*=**AV+D.A/CA%L_)Y*FKM_[PS^1SNY\C3,&\V2W'.E14+?\
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MS%?\_P#+KF5S)(OM+[AQBX/Z<[%5&DD"*>@H".!\2/4?*CDFE*];-IM##?\
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M]-_("$S[[V^N+W?2D'']A[27^ZN=A'U(9G]-;_KU!!_H?Q[5.R/\0H?4<?\
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MC;H7HC8WQVZSV[U7L6%6H, 1D*_/5JA*G,9/*)IJJ^K4L;1U*^E0.+ ?XGV
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MC>6"PFY\%797Y'SXR;["NI_+2_LM.KK-IL0" ;$6'(N3;MSARG:321-:%1&
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MR1H>58.IX/(XOSQ[CC<-JEL;D!C4'((].A?9WO[P@,L(H0:']G2OX_H?]O\
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M?R([/^5/Q=D[3[AR>ULCO"@[JW]M&,X# 1[>I?X;MBO@2G#4L2KK"22D+=>
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M[]U[KWOW7NO>_=>Z][]U[J/[]THZD>_=)^O>_=>Z][]U[KWOW7NNOR/]8_\
M$>W).KGX>NC^I?\ 8^VXO+K<?7+W[IOJ;'55,'^8KCQ;B]_^->_5GZL=)_U#
MH,.Q^H>INV<?'0]G=>[!WY05>@B;.82FKJP!?H/OT83 F_M3!N%PO$5ZH]K%
M)\)(_D.JF.^OY/&S-R?<9CXW[P;:&:*"M?8._7_BV, 8V_R3)@??4(YX#).?
M]J]B?;]Y$/Q8/SX=(+BR,WP"H]1QZ),.ROGY\)!2X#L?;V<R^S*#G''?4?\
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M]:V+D9E^1XE:GT\L_;G@:;<G]6W%H@ BDQ$H I0>@_F/EC@.EA\>/&O\Y/\
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M[J?^5W(?[?\ XW[IX\W6M*_ZO^*Z:ZZCH<M!X<K1X[*TU_U5^*H<P>>?P?\
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M6NS=\[Q[1VKL3;&#W[V<^+??>]\%B7Q^3S7\*.J'[YOI>X&O0!<DWOQ[<O\
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M):0^2#5<W>X)8EE)/LU//VXQ^+]',611VU48'RQPZ3#EVTM_[>%JFM:$<?\
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MO_QKW[Q.O57KW/\ 0?[?_C7OWB=>JO7N?Z#_ &__ !KW[Q.O57KW/]!_M_\
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MI%:5_F.MB\( -"!P!H0/\QZ##L#Y1?&GJ7<5+LWL_P"175&PMTS\T. W'O\
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MG?\ &O?NO>'U[S_[1_R=_P :]^Z]X?7O/_M'_)W_ !KW[KWA]>\_^T?\G?\
M&O?NO>'U[S_[1_R=_P :]^Z]X?7O/_M'_)W_ !KW[KWA]>\_^T?\G?\ &O?N
MO>'U[S_[1_R=_P :]^Z]X?7O/_M'_)W_ !KW[KWA]>\_^T?\G?\ &O?NO>'U
M[S_[1_R=_P :]^Z]X?7O/_M'_)W_ !KW[KWA]>\_^T?\G?\ &O?NO>'U[S_[
M1_R=_P :]^Z]X?7O/_M'_)W_ !KW[KWA]>\_^T?\G?\ &O?NO>'U[S_[1_R=
M_P :]^Z]X?7O/_M'_)W_ !KW[KWA]>\_^T?\G?\ &O?NO>'U[S_[1_R=_P :
M]^Z]X?7O/_M'_)W_ !KW[KWA]>\_^T?\G?\ &O?NO>'U[S_[1_R=_P :]^Z]
MX?7O/_M'_)W_ !KW[KWA]>\_^T?\G?\ &O?NO>'U[S_[1_R=_P :]^Z]X?7O
M/_M'_)W_ !KW[KWA]>\_^T?\G?\ &O?NO>'U[S_[1_R=_P :]^Z]X?7O/_M'
M_)W_ !KW[KWA]>\_^T?\G?\ &O?NO>'U[S_[1_R=_P :]^Z]X?7O/_M'_)W_
M !KW[KWA]>\_^T?\G?\ &O?NO>'U[S_[1_R=_P :]^Z]X?7O/_M'_)W_ !KW
M[KWA]>\_^T?\G?\ &O?NO>'U[S_[1_R=_P :]^Z]X?7O/_M'_)W_ !KW[KWA
M]>\_^T?\G?\ &O?NO>'U[S_[1_R=_P :]^Z]X?7O/_M'_)W_ !KW[KWA]>\_
M^T?\G?\ &O?NO>'U[S_[1_R=_P :]^Z]X?7O/_M'_)W_ !KW[KWA]>\_^T?\
MG?\ &O?NO>'U[S_[1_R=_P :]^Z]X?6%9%)8V/X]^E\^O2=4G?S&(J>7^8A_
M*'GGAHYY:3MS=HA\;6&E*O&V_K_O7N=.3,[+<_Z>3_)U'G-@'[QL_L_GX;#_
M  =7APR_[DUN;#^)@?U]PQ.?U>I ]>J-_P"6A/B\-\M/YQF:R$M'CZ:@^1U)
MD:RNRG(48S^-S2R50YYO]1_4^YIYZM6NK"QMT'B_HC/V-QZC'E2:&VO+V>;U
M&,_[[CX?GTI7_FY56Z:/+;UZ<^#/RN[LZ'PU=DFK.[<#CL=CJ*KI]K\U-3C:
M"6&:NR%,!RX>IX'ZM/(]EK^VV86>ZAMY!QB50 :>@0@D<?\ 4.C27G4SU$<-
MQI/#ABOVL#^8&3PKUQ^8'SUV?O\ _EM[C[OZ I>V=QXKO/:F\.O\+O+K[ UN
M-DV9DC3>2LGW01Z,*M%*H@>I5R)%8Z3:]Z\K\EK)O+17(A/:@#*N9#G+9Q3S
M]>K[[S)]#MOUL1';5J'@1\OV>?#H0O@'\M-D5OPHH]V]B;6[%ZBVI\:^K]E8
MO=_8W;N%.'H\[3PXR1I\IAJH!CE\?*X U #SAE'+&YISYR=-%N4%O:21$2J
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M=,=C_:4.3.SH:6BD&1Q\V02I\;%9EF8ED;1JX O;V_M-C?WFW37<([7=BY]
M./26ZNX5NHH96&D>7\1QG@:5QTF^Z_YDO5/2/=N\/CM-UIV]OSN';.VMHY7:
M^R.O<&=TU.[JK?$22C'8%0K$BACD$M?-4HT4,(<(NH ,]MW(3W=O^\%D8Q:0
MP4"M:CR^SB:\.F[_ )KBCE%G# HJ3DXH Q%3FGEY4\JTKTW] ?S'L?VOWM1_
M&ONCX[]P_%;NRKPU7N#9>S>SI:6MAS-%0JS21T>2IZ>E>&9PITMITFS"][ U
MW+E$;58&[M"94XR*1AE\Z&IKTW:<TF>;Z.6(1#U%*^7I4>?#CD?;T8;J7Y7;
M+[H[P^1G1&W\-O"@W5\9<K@L7N[+9W$T<N+R$^<X4XN, &%BXNOJ-QR/9)?\
MKS;3!'=+7PIR P/#NR*=']MO4%]=B*H_3!X5U8 X_P NL^1^5VQL9\Q=L_#6
MIP^[O[^;TZMR/:]-G:".E3;WV&*N1!-<?>/6^)&4D$68 @D$ :3EB:YLA=FN
MHKJ'I3ATW^](+>[-MB@.GY\0/LIT5_?O\TOKO:?:_:GQ]Z^Z+[V[I[^Z[W>=
ML4/7.RL!!'-GG>F-779A9A))%186F(<K)6+*P!4VTWT""U]OH[B)GO)!'"/Q
MOQ(XUJ< ?/HL?FAGE6.$J&(K]@/ =(+:?\WKK?.T>Y=M9GX]]^;6^3FW]VQ;
M*'Q'BPJ[KSN5R=;"U210RR::1,<94 K*V:'RTUSH# V!HWMO<V<6N(Q#;P::
MZ5:M/+-*>I\O\*.+G2%CX'A W5*UX8J/3]@H:>OR&GXL_P P/#_)#LW>/Q\W
M[TEV%\;>_P#9F&I=[UW6G:$D>03)X>J :2:EKJ.*""60HZ,H>(JPYN;^R7F7
MD>WY9M4W2!XKA914J]#4'@5(%#_JX]&FR<SM?3>#,=(K2HQ3CQR?0^>/V=)C
MN/\ F2[<VCVWNGH/X]?'3N;YA]J]9,J=F8_J=TQV$Q%55'3+3Y'*UOW$DE<D
MEU*$(MQ8-?@7V3DC7 MU?7D<#S_%IU@"OS)_/_9'1?>\UG;UGBLH/%'D.W4?
M0=Q %?MK_AZ$CXB?S!-J?*;L?>_3&7ZJ[&^.W>O7^(I=PYOK#LRGIJ*44-34
MI')74513Q00SS*&!TM#R#?D D4YTY N-DM8]T,D4\>"S*M"5/F",4^VG1I8[
MS]5+X(.H'A3/KCS]/*O53'QE^75'\8?DU_,LVEM/IKLCY!=Q=D?+'/[AVIUO
MU1C(#42T.VH*M*O)Y/)U*3T./QX$QB*O$W!8DK8,)(W_ )<?F+;[.9Y8EM_!
MJ54<10"M30 ?X:] 38][%M>WU2%T@')KQ1> J,X]?*O5M7Q(^=VP/E+N/>W6
MDW7V^NAN^>O**CKM]]/=FP&GR"4]6?W*VFO&)<C2(-!8LJL 054BY,5\R<DW
M7+=LUVKL\9%69L, ?,>HZ&&P<RP[M2&6 $5P1P^RN:?:">'5@,4G]>/]?F_^
MP'L"S)#%_8]"WQS=<>L'G_VC_D[_ (U[KU7P^O>?_:/^3O\ C7OW7O#Z]Y_]
MH_Y._P"->_=>\/KWG_VC_D[_ (U[]U[P^O>?_:/^3O\ C7OW7O#Z]Y_]H_Y.
M_P"->_=>\/KWG_VC_D[_ (U[]U[P^O>?_:/^3O\ C7OW7O#ZR>3_  _WGVHZ
M;Z)S\TOF/UM\*.G&[9WU25.;R.0JI-M]<=>X>V%FRF7IU_<C(",*:DIBRBKJ
M0;PL0J\^Q1RAR7+SO<&VEX#%!Q)IP_SG_BNBK?-VAVF+QA]I)S0'_5@=4\[/
M^;_\ZKO?;*=U=,_%G8$75D]$),7C#M+^(SY&D4Z+4HR>8I\CD[,I!F2!K$'F
M]_<R-RARQ9/]+=7*!3D!J5(_.,$]1=%S3OUZ/&AMB&]"WGZ5&!^?1S/Y>O\
M- I?ESN/</2/;6S8>K/D1M>BR-?6[:1:H8K+)MQ2:[P)47JZ3(8]0[2X^9BC
M@-<K^ 1SC[?/LZSWL8K$H[%\O#'P_L]/]0&?+?,PO)A97>6Q7.17S^8^?ET
M_P O/YH7RSZ=^9^Z/B7\?^E.L.S*RCI]G/M*/(4^8J\]D:C(8J.OJ"S0U-/
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MD7F%PS!00;GD<<>[<V\G)M,_TEB IJ:TX4'GTURQS$-UB%W=U-5J >.6(H*
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M^R2S7<=VGTL_PDDT'V4I^VO1'=\XRM-/#:$C%: A>/ $FOEY</V8.-_+L_F
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MO/\ [1_R=_QKW[KWA]>\_P#M'_)W_&O?NO>'U[S_ .T?\G?\:]^Z]X?7O/\
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MQP7)T2@%&+ .;<'<FX[9S'-+>2SB,J*!M84@>A'G3HO%O>[72TAA)3S%"?\
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MU[W[KW4CS_[1_P G?\:]^Z;\/J/[]TYU[W[KW7O?NO=>]^Z]U(\_^T?\G?\
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M0_RM?EGWMC?CYL#L;L#9V^<]D4P77U9VWU__ *.<3N"ID:3P)B:R.JE=35Z
M*;[X4;7( 1-1]VN-H,8JM?G\OY_/K?UL>:T-"?(Y'YCRZ.1\E/YG?PJ^'?>'
M5?QN^17;5/UKVSVQMV'<^Q:?+;2RLV-:CJZRLQT>3K<H(OM,:C+CIKWD72;@
M_4CW2TVX7(SP]?+JKW[197/R/'A]E/Y]!M\#/YPGPQ_F1;][@Z]^,&:[&R]5
MTA2G.;JW/O;KX[.PM52"L>DCR>+S<;R 1S)&C 5B4LA4@Z"K#WJ?;OI!^7RZ
M<CNVF].(&*\<GS^SRZ)]W'_PIO\ Y3O3/8F:ZTF[)[7[/JL#F),/N?>_3'6*
M[PVS1QK4&#_*,M)DL:U:+JR_<113$_4?CWO]RL17_-_J/6OW@@]/L.K_ "5
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M]%L$]B=S]>4N>RTF*V[VAV=U#+A]M51CG$%ONZ7)5]1%&ILIJY*"-P&_<4D
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M=8CI"DV U?0\#Z@D*>U,\6W[DL\_Q%1Y?T@>A)SU8'=-N^FMSQ#C\RIZ4_\
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M#IMA7SZR63_4?\FM_P 4]TT#_?'2KP8/]5>N"QTRW/*G\6/T_P!@?=$22/\
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M0*8 ^8Q_S\>O1H\_!F;[:M3[*+CIE_X4U8CN?;G\LK^3YM[Y'48Q?>6"J:O
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M8JHX"GDZC[)=TV^."WI\OYX_S]+[2:5IJK4G53)KZGS_ -+U(P7\WGY'Y/\
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MZ>_EK;2Z7P$E71Y+Y0=TX3:>5GIY( LF!V#C_P".5T9'UM45*8V#Z7.BRVX
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MZ_#+%_*VM^<]+T'MM?E;EZB6OJNYX,I6"LEJY*-,,?\ <<*H4)E_A$$-S?\
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M#^2N0R>Y-_X%?XE@X:?/QXN<3K54=]3Z:*M) -^#;F_LO]MK"XEM=QM)Z17
M.4&0-0QD=*><;R"VGL[L5\$BF>/PLHP?M Z2O\Z;Y/=';H^)%7U%LGL#:/8>
M]M]]@[*W)3X;K_,4N[DHL)@LA-4SY7(-2>FAAD:4 QRDV-K?0V4^W6V75E>F
M5V!*0** UP#6IX=5YTW&/<;,PQ*0.&0:YIZ]+_YX>2;Y+?R:(9((&?\ TKT@
MI4FL!+4&AVZK$G^@8"]_^->W.5R)+/<'CFJQKQR*Z1CI)N_Z\MI4<*_X)/\
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MT/[:IM_\GV]2/:#JW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=8?
MG]6_VX_XI[>\8];KUF]L]:Z1VX-R87:.!S.YMT9O&8/;VV<=F\_N+<.4J334
M-#18.D$E?7EUN6:*(J%&FY) M?ZK+?\ 5ZI/6VH #4^717OA+\E<Y\R^AL%\
MAJSKN?K+9?8.Y-XU_2=!F<M!EJO-;"Q-;''MS=N5:-B,2=SCR5@H0FF2C^V-
MS&%)=EM9ATU',%/&N.-?7..'EGY=&VQ>5PN5H34XG(X7(T-S_E^&RE#E;$?X
M0&_U_P /:4VA/3OU/R_PC_".G2W IH+ <DW_ ,?;4</U'^K[>K38_P!7V=,
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M!\O7H]'P-^<V.^:6RN]-]Y?:6-ZFH^I?F)W3\7,?#F=W)DQEY.IJZ.!<BO\
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M=@_'ON;8NS-M8^?QOE\MF<'54]##&ZWT.CHQMSJ(_!]EUKFX@^P]&-V:1 G
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M4GY9VXQ>!7C@D@9&<4I^T]!F/Y3W\MI$+3?#?J744J E6M5EB_[Q]1"BM*\
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M=8N*<?GZ_P"O>_M/T[U1?\BWU?\ "@K^6Q<_]R:?+PW/^*5O_%?8L;_<9?\
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M/^XV@QQ)O1DGF_%S?V374WU'2VW%!_JXYZF8W_B[8[_M9'_B/=8^MW/#\O\
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M7^(2#S*^F72TJI9Z;<#.,Y^W/^'K26H.%&D?( <?LI_,=)GYS=3[ZZS^$_\
M, SF\]@=W?S1-N=Q5^-W/#\.MR;_ *#8O\&VU52T463Q.R,GC=O9"MI4V[!*
MV4C$5!65X:DC2,*_K/K:<1T!P/7.,\?/U^759H]1&GB ?3)P*>7'YUX\>M7;
M*=9]=_.K<7P9^-OQB^2W\P/YE;UVIW-U)N;-;)[QK]SIM[X\[7Z^JJ.MSC9Q
ML]LC:.-W=614]*V*IZN?/4,M/&I\--4.T:*;QR$\?3 K@5QC_#44'2'1H)-
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MQ6,4"4O123$!B)K!5TF5S[DI-:W-O# (H9/Q(0:\13@*<>D\7*5)?%FF&NF
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M"L+L_P!I34[EK<W8D+8'VOYPLUAF@M;3CI;)^7^3HIY1OUO;8WLH P,#S))
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M][]U[KWOW7NO>_=>Z][]U[KWOW7N@NW-_P 7/_R&#_>A["F\\.CS;?\ *?\
M#TT>R+I9U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=)G=,1&S=Y?FVS]S_X6_R.J]GO+LO^[*T^P_X#
MTBWPTL;G_3#_ (\.JE/Y&#C_ &0#:QXY[<[B/T_K)#8>QK[K+]-=)]K?X?\
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M_#:HU L,**CR/F<_LIY=%QV7<)[N&Z<D8\Q4DG[/L \A3@,9?.P_BA\\MO\
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M_C[]]+U[ZKKAZ/\ :O\ >/?M!ZOXQZ]Z/]J_WCW[0>O>,>LWN_@GIGK#Z/\
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M_P!J_P!X]^T'J_C'KCHC_HW^W]^^EZI]5U[1'_1O]O[]]+U[ZKKEZ/\ :O\
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M-'_RJ0_[Q_T=[]X<'H/Y]>UGKWV-'_RJ0_[Q_P!'>_>'!Z#^?7M9Z]]C1_\
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M^C_Y5%_VR_\ %??OIV_U'K53UQ^QH_\ E4A_WC_H[W[PX/0?SZWK/7OL:/\
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MSUZAZ]_$?\(_^2_?M9Z]0]=?>M_RH/\ [<?\4]J-(]>M=2O.NC[G^S;1:_\
ML;W]L:O/\NO=1OXC_A'_ ,E^]:SUNAZ]_$?\(_\ DOW[6>O4/7#[T?T3_DOV
MHUGI/0]3_/\ [1_R=_QKVQXG3_6/[R/^G^]_\4]^\3KW7OO(_P"G^]_\4]^\
M3KW4SVYU[K6Q_G0_SD^Q/Y5O>/Q!PN)ZNV;V'TYVY7;KKNZ:C)/6Y#<-)B=H
M5V,AE? FFG2G6I6.O>5WJ4F82( PTCVHAC+(HIBF>->/E3HJOMU&W2G-#P'
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M0S,0> %<<:^G2OZU%A\;&HD"N--*<:UI3YUI\^!ZKNR/\W;^:+T[U+AOF_\
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M%^7GPT^'M3L+<VXM[?+L]E9#&;GH\G0XC%XFCZU@AFR,M0Y1VK)D^Y4B$K&
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M9TU\H=U?-S??Q>['SV/IY7P-9NS; PV,&7R&''B@R5*8JN&L%%)&4-7Y=*:
M -JBP5(-"68&G"M >D5Z\]TEN.)"AAJ%#I.H>1:AIG)('"M<]#G_ #*?C7\B
M/Y1>3^+ORQ^(OSJ^4G9_>7:O>F$^/G9R_*3L4]K;?W75=I4DU-1UM7A8TH*9
M(,=DJD,T#,3&D:I$P,&HJ(@)E)HU2:-7(-10>GG]O#IR^5[6:)ED!&FJT)72
M :D\#DJI H!QK\NE5_,R^*7=_P#*SZWZ/_F#=9?/[YD=G?('!?(+IK8_<%/W
M+VC_ !W:^[Z#?F62&OH7VU D=-BL8@J$6EH_-,L5,Q7Z+Y&J -+$,20P#5X&
MO^K@>E$RR6S1%E%-#,M*XH*UX@5QD@>OGPW+<)DEK\=19&("F@KJ#&9(+8<G
M*V-C_L"/]O[0R-4 C& ?VUZ.8EH2.-"1^RG0$[Z^.?1O9V_.K.SM_P#6.PM\
M=D]'Y3.;@ZKW3N/;%'D,O@ZW,Q*M1+A:YF2/'?=1H'(TFS L"&%Q90R4Q4C(
M]?7R_P O57\.:H!H#Z''IZ>GIUK9_P UCY$5W\U/M'&_R9_@N\6]Z[);ZP&Y
M?FUW[1(<GM'KW ;/J15RX@UY01UF?D:-E-.)0L+!:.[N=%&[' 8V\3CPU'\(
M_/S/^Q]G1;N4TNZ*8145!"J,,3Z\#05'IG/"A($G+;3Q%-_PI4^'NT33+/@N
MB/Y96Y*'K?@/'%!#+78V-H[$W*Q5C1WO]0#]?=RT0A/#MU 'Y5ZT7<WL8'!X
ME9O]-7'^$]*+_A4 DFW_ (6?&;L7%H3OG8_\P7XQ5NW:Y1::"H9LBS",KP"9
M*:,_X%1SP?;5M+V@>=1_/I[<;8/JD/#O/[!CJ\&HZI^,_5O8?9'RXR6R>KMC
M=C[AZ_3;?:O>&2Q-+C,G6X'9.EUBSF:=VT8JB6AB5FJ8R4T <&-;ME"Q(-!C
M)^7V_EZ9Z6ATA <5.:@?/[/S]>M<_8O86>_G@?S2OCUWUTGA,OA?Y<O\M/>6
MZ,[M[O;/8?\ AY[([#W!#) (< 'C _A6,1J+3*]R="O*4>L@B#C5C 90?DWJ
MW''\O]1Z0&;]YRNC'M *E?X5!'\ZCC7R\ZU&P)N';WQ%^$^+[_\ E-G,/U+T
M90;UG7LOY$=Q)AZ?;K9>HQ@,9R6:KP[#*5LEY%A0Q@O(S$#6P#-*I8$+0>I_
MXNOY=&#RK 0TE6/ *.->'E3[#U1/\#JGLW^:M_-#'\V>NV#N/K#X3=#=:;O^
M/OPUAWOB&QV;WO4[@KF.9W?]K_RC8N-UFT,@*:]$*F3P53!5(Y%*^0TKZG.3
M_J_GT50)]2_B @H[:W_HT&/LXFH-3P^$U'6UYZ:9?ZJ?^0;:?]O>]_9?\'1U
MUK[?S2?Y=_RB[B[X^.'\P#^7UVILWKKY??&G:.Z=F8_:W:%(\FV-V;<W8\C'
M$54ZH9:5GE\L=Y"$D2=064KRLA:,'350%X5X$'R/\_\ 5Q+[RT:0&6+46<U8
M+E@0,'-*T_GGSH5(OV%_-X^>WQSVON+;W\WO^4-N#(_'BOA3:?;/<_0&3HNT
M]I5.(RU,*2NK<EBJ@5E)545FND,^0A!-PKJ6 ]Z6(3#M!IYD'4/]G[/7I*EY
M+$?\8%3Y!P%:M?0$@"E"23PJ/+)C?GG\\-L]%?RU?B\?Y5-3UY@$^;78767Q
MP^).5VK@$PN*VQ1;]G,57DZ3$F E:W#NHI%I2C>.IDDFOJTQKN./L&NE1@<,
M5XG[>E%]<_1DUX29;U)& ,XI3]GH>'04?(C^3MW%\7OC3O[Y/_&[^9/\Y9?F
MST_L3.]OY??'8G:DNX]O;QJMATARV7QV2VO+!]H^*KQ%(L*-5521ZRCK4A;J
M]X_B$@NU0*DDU!IGSS_AKTU](+9!)&@R: #%*X'J!^0Q_+HB7;_S7^5'S^[9
M_D)[XZ$[:W7\6]W?,#J7NK!]ES;:>?.T6.J<)-7;>W=F:+&:HZ.JR='%C,U4
M8=JE5:DD 9R&'E][';5P=.H9]0,@^G1;>7))MXV[@I;212A(*D5X\16E//.1
M4$:_G+\<NT_Y-G:OPG^5?QL^9_R\[+Q/97RTZMZ*[\ZO^3'=4G:V*WE2]C$T
M!R=0T5#2QK610"1FX>5-2.CPL!?RRB8&C,06"L":UKTKN8Y+>2-E10=!96%:
MII!. 3YTI_/Y$S?RKJ^ZOYFG\UG??\M_;/?/9WQ[^)7Q,Z,VMV?W^.@]S'9V
MY-YY?L1GAH,(<HX,6/Q%/1Z2PN\4E@QBNZ"+2%5%*D*HJ:>?3]XLEY(*BK.Q
M"UKBF?+U]0:_X>BF_)#XY_)/^7__ #*/Y1'4W7GS#^2G9'Q&[8^59IL3UKVY
MV%6;QR6 R6*QABJ<-_%XQ#_$MKY6AE2:+'5,9^UFCG9HAY2\EC26-M+$JS$4
M/R4G_5P_SM:'BF"$ ,L=:CUU #Y^9X_*GE3=-]D_1YUK?_\ "F7L3-8[X"[)
MZ&VYD)\=7_+?Y-]&_'C+S8\ZI7PF]<HLF0ID'!26<4\2W ]6DW^I'LSA!<5_
MB8 ](KUA$/"K32K,#0>0)KD'R'1X_P"9-LS$=:?RE_F!L#;U#3XK;VUOA[O?
M:6#H,<=4='2;6P#TD<1-A=KC23;GZDDW)I X>8 >0(_8.JW,1B@F;U6O[:GK
M7=[B[&[ ZL_X26?$[>W6VZ\WL?=N#Z^Z3K,9N':N4K,351!=RR,-4U/9Q3R2
M(B2>JP901S8^VTBK)7^BO_'3TAW&410@&N7;T)S*!PQTNOGW\)?D3\;?@;G?
MYI>9_F&?+C.?.3JG;VPN\,Z/](XQFP].X:O%/E]G8?9\486AP:)6(D<3.$8J
M9)+B=559'*')!#54!CD<,8_U?LZU+92B$ 2+5BRCXJ5I0$T(^T>=?,Y!=/DA
M\+OD?OW^6UFOYI'9?\PKY9XGYIT'1U-\I]J4'6O9;[-Z[VVU3C*7*)MC"[1A
MM+38W[-VIVD_B1J9)C'57(#)[],WA2"( UH&Q0 5H<#C^P],3.ZV9N)I!Q((
MK5C0$'NI0D>I4^M*8ZA?S!_EC\N>X?CA_P )^.V.F.SZKK+OGY0=F['HLYFJ
M2"1<)6YW<.&PE$U;D\$&6CR=*M6]164M%*2H9PH320HK'Q*DT)/^;JVXS-+'
M;RQBJA:@>>03C[/GZ4XT/2,_F5_&'Y$?RAJSXJ_*SXB_.KY1=I=V=N=Z;<^/
M7:<?RI[!/:NW=U579@EIZ2LJL(D-!":?&Y.H#I"3=$C58F!AU>[0D3(30U)T
MD&A#:L?X?6O5KFSD2:)ED&!5<D%:&I_:!3 '&ORZ5O\ ,V^)O=W\K+K'J;^8
M7U=_,!^879WR'VY\@>D]@]OQ]K]DME]K;LQO865$.0H7VW#'!2XW$Q&HB:DH
MA43>*"33I4#R&B2*P! ;54 UX'_+T_)MSQ,S&0:2A( K44\^-*^IIZ^=*'Z[
M/[*WY+_PHT^%NSL?OC>E!UONW^7MVSOC+[ 3=.0EQ,M9'5U;0U4F,U"F:I21
M(F"JI!9$(-[@M2$E2,@$,:5^WI\HIN4>@U*8U!^1U5_XZ/G^T]0/YS_8G8&Q
M/GO_ ")<#LO?6\-L8#L/YR5N)WYCML[DK\1!FZ)CM:/[')?;N/OX?&TD>A@V
ME'9=/((8M*D. 2*L0?*N.G[PJLQ)&5H1]NJG#AY]%1['V1\H/EA_/N^:WQ"V
MA\M>[>@?C^/CAT;OOMFEZPW8<9GC14L./%-1;3R'^9VJ<K6U<?\ $ZV.'[EZ
M5OM%"@MJ6Q/J( ) TJ33[/+_ %?[)9I=I7!4,Q9@./EG/KQ\J$4XY%%IT+U]
MVS_+%_G6_'+X9=??);OCN;XD?,_HCM_?%3UW\@]_R=@U^V,[L.CRF0^YQ606
M-%_RG^%QQJL<":E?QL954.6P"ZC230*30G@:'T^SJZLEE<LC*!XCBA .1V@U
MJ:^8Q\R?0 GF_/F;T+\_/F_\P=L?.W^93N3X8?$OXS]D93I3H7X\]9]M1=-5
M.]9L*TE+E]WY_)1T[S5E%+44EX:9O(+S".,AE_=WH+L#2BG 4'/V^?58KAKJ
M:2)I:M&*EFP 17 R*_E^SCT9_P#EC?.7"]:?S.G_ )>?5OSRS'\Q#XG]W=/;
MD[9^/>^-Z[YC[!W5L/-;*:6IRNT,EG-,#92A;$TDU5 ATF)$C,8C<2*?31KX
M14C!6H]5I\_L_P!7ETHM+IFE_3?60VECY/J)IZY_U$>9W!_:3HVZU6/YN&QM
MI]F?SC_Y-/6F_L!0[MV3OK$?)K:.Z=M9.0S4E91YG%44=13!P=2DZC8A@1=2
M+<>UENY179<@\?/SZ"F_6T5Y>6<<N""2/R6O^3I$?RR-];P_E,?.7<7\F;Y
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M)O9+T(NM7OY"H/\ H*;^$2 <?[(+W2H_V*;D]KBM:#^@W^ =$P/^-@_\-3_
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MZ#4(723ZJ?7U'#K8M'A)E64!*U#+7(I\)!KYCU R>.*$^Z:V%VO_ #S/D_\
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MZ-IY+M[XS=W?(*;MO'=FX2OR5'19:,T4^,HI:'/K37J?NXF)*QEH]&A=;0+
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M= _&7-S8CL;<^!J/!-NS=U56C%BNP4:K-)C*="2T3+9HQ*\CN"5 *56B\ "
M&/J?/_-_/I!<:YC0B6C_ !&C$J/3A^WC4?F#>3\2/YDF=[E[/ZX^/V*_E0_S
M'_BWM2JQ];B,/O[N[XPP=;[+VY2[;QDC0TTU=#D9$HX)G@6"DN%Y=5%F(4IM
M>HBKGT\L?L/1K#*NDHL-/.IJ"3_MA\^KM(8Y INCCU'ZJ1_3VCH>EO6M!_,,
MV!_,0^)_\Q/K?^9+\5>N.Y/EOT+N#J8=)?(SXC==[NR,]92@27IMR;=V\$6F
MEK_5J,U/2/+&\+F4(L]W61 !06(/D5U"OV_[/1=.KQ3-X0H 258"M?D?6O\
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MINJ\/M.OR6X9LPVUL?228EL4(CD?XLE0CPM#XM2Z&0K< >W7(ED#UX ?Y/\
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MC;3;T-+&H1M0M)(I!6HIQ4XK]GD>KVRFRF#QQ4+X<=U.!-:C I3^8X\ =;X
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M!= X;MS8.0VK+5;,ZIA(R&7HH<I#'4.^1$--&U5$&BFN3<A6O>YNPY5A^$!
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M+!8O<(PB&HEW/MQLA%'/4T.5G82U-0NJEFK'G-,RQ/XT;N9 U"HH1C!K^?\
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MW7/T+T;D*Q8<KMO^&X[+IC:K*SW6;'Y2JK)H4C\BI/$^JI(02JS7UJAK@C)
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M..S*[XW8;I/M?*TR2TDF4R>YXZ&FAK*?$53Q&:.A9;&9A8M]LA+<DJ5- -/
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M\OG**)'TK#=="&(3(@CG+>ULSQR:@6%#D&@)7Y4.?^*Z+K6!K%@8HZ$&A%2
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M/2*)DL%)-22:::8S6F:')X;I-(K*A#*RG^C"WY/LO04Z.^J6OY]W5';'=?\
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MDPU&H4&A&14CU'^KCU>*P$]O-XOQ3  BN=(P < G'G@X'KT'VPLS_,5^(/\
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M?*GMCY7_ !GR/3L^\(1'"M'M3;F(W93IF(ZN1(W27(PH)#+,94TK%J.@5&D
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M3@*>AKY=$@_F#?RZ_E_F?YA?</Q+Z%Z:[1JO@W_-5[>^-W=OR+[=VQMG+Y;
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97NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>timage_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 timage_003.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
M     ! !+     $  0$L     0 !_^X $T%D;V)E &0      04  DE$_]L
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M7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\
M0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI
M_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^
M?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_
M]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B
M?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3
MW[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW
M7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\
M0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI
M_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^
M?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_
M]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B
M?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3
MW[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW
M7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\
M0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI
M_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^
M?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_
M]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B
M?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3
MW[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW
M7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\
M0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI
M_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^
M?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_
M]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B
M?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3
MW[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW
M7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\
M0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI
M_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^
M?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_
M]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B
M?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3
MW[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW
M7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\
M0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI
M_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^
M?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_
M]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B
M?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3
MW[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW
M7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\
M0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI
M_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^
M?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_
M]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B
M?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3
MW[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW
M7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\
M0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI
M_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^
M?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_
M]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B
M?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3
MW[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW
M7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\
M0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI
M_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^
M?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_
M]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B
M?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3
MW[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW
M7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\
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M=>]^Z]T0#^;%_P!NLOYEG_B@'S(_]]UN/W[KW5;7_"53_MQY\3O_  YOD?\
M^_)W7[]U[K8D]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]UI8?\ "B3_ +?<?\)S_P#Q:WJ__P!^WUS[
M]U[K=/\ ?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW54O\ ,+^7?SC^
M&.[MC]K]-_"K)?-#XCP;7K(^_,+TYG1'VAMJNI)ZF5,S@<#*'BW-BOL?$M11
MQ(*E9560300^5_?NO=5\_+_Y/_'W^?+_ "U^\.C?Y>G;VS][?(&GRW6N\\Y\
M5.ULG)U%NBM7JK=6-S.7V?N/#5\]'6TE+E:?%U=')5Q//CO,51JO06=?=>ZJ
M'3X?_*[Y?]@]&=/;!_X3>_'[^6%EMF?(GHOLO='S4PN\=N8VIVUB^J-P46;R
M38Q\5@,36Y6?(T^/DIHXZ>IKP\DT9=5!^[A]U[K?8]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW1 /YL7_ &ZR_F6?^* ?,C_WW6X_?NO=5M?\
M)5/^W'GQ._\ #F^1_P#[\G=?OW7NMB3W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UT6 ^I]["D]:+ ==:U_K_O'O>@
M]:UCKVM?Z_[Q[]H/7M8Z]K7^O^\>_:#U[6.O:U_K_O'OV@]>UCKVM?Z_[Q[]
MH/7M8Z]K7^O^\>_:#U[6.O:U_K_O'OV@]>UCKVM?Z_[Q[]H/7M8Z]K7^O^\>
M_:#U[6.O:U_K_O'OV@]>UCKVM?Z_[Q[]H/7M8Z]K7^O^\>_:#U[6.O:U_K_O
M'OV@]>UCKVM?Z_[Q[]H/7M8Z]K7^O^\>_:#U[6.O:U_K_O'OV@]>UCKVM?Z_
M[Q[]H/7M8Z]K7^O^\>_:#U[6.O:U_K_O'OV@]>UCKVM?Z_[Q[]H/7M8Z]K7^
MO^\>_:#U[6.O:U_K_O'OV@]>UCKVM?Z_[Q[]H/7M8Z]K7^O^\>_:#U[6.O:U
M_K_O'OV@]>UCKVM?Z_[Q[]H/7M8Z]K7^O^\>_:#U[6.O:U_K_O'OV@]>UCKV
MM?Z_[Q[]H/7M8Z]K7^O^\>_:#U[6.O:U_K_O'OV@]>UCKVM?Z_[Q[]H/7M8Z
M]K7^O^\>_:#U[6.O:U_K_O'OV@]>UCKVM?Z_[Q[]H/7M8Z]K7^O^\>_:#U[6
M.O:U_K_O'OV@]>UCKVM?Z_[Q[]H/7M8Z]K7^O^\>_:#U[6.O:U_K_O'OV@]>
MUCKVM?Z_[Q[]H/7M8Z]K7^O^\>_:#U[6.O:U_K_O'OV@]>UCKVM?Z_[Q[]H/
M7M8Z]K7^O^\>_:#U[6.O:U_K_O'OV@]>UCKVM?Z_[Q[]H/7M8Z]K7^O^\>_:
M#U[6.O:U_K_O'OV@]>UCKVM?Z_[Q[]H/7M8Z]K7^O^\>_:#U[6.O:U_K_O'O
MV@]>UCKVM?Z_[Q[]H/7M8Z]K7^O^\>_:#U[6.O:U_K_O'OV@]>UCKVM?Z_[Q
M[]H/7M8Z]K7^O^\>_:#U[6.O:U_K_O'OV@]>UCKVM?Z_[Q[]H/7M8Z]K7^O^
M\>_:#U[6.O:U_K_O'OV@]>UCKVM?Z_[Q[]H/7M8Z]K7^O^\>_:#U[6.O:U_K
M_O'OV@]>UCKVM?Z_[Q[]H/7M8Z]K7^O^\>_:#U[6.O:U_K_O'OV@]>UCKVM?
MZ_[Q[]H/7M8Z]K7^O^\>_:#U[6.O:U_K_O'OV@]>UCKVM?Z_[Q[]H/7M8Z]K
M7^O^\>_:#U[6.O:U_K_O'OV@]>UCKVM?Z_[Q[]H/7M8Z]K7^O^\>_:#U[6.M
M+'_A1&0?YW'_  G/M_WE;U?_ ._;ZY]Z(IUL&O6ZA[UUOKWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>ZIE_F=_S,/D#\3^T^A_BK\*/AQEOFM\NOD!M7L+L
M;$[&;?%)UYAL!M?KIZ2EJ\WEZ^JLL@FR-?3P0PM4T<)"3:ZV.4TT-1[KW5,.
MV.L=I?S6?E[D?C/_ #1/Y;6Z?Y7_ /,FHNF\C\C?C]\N/BUVM!C<[E,7MK(1
M8:JJ8MRX'[JBK<EB:S(1L:?(5>2=(=5C0N\)E]U[H^.TMT_SQOY:&[MM;.[A
MPF%_F\_#&LW'B=OKWILJ"/K?NG9N-R53)",AN?"#[FDW918V%XGJ)Z;[JKDC
M22HJ:VG4:/?NO=;(_OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ(!_-B_[=9?S+/\ Q0#YD?\ ONMQ^_=>ZK:_X2J?]N//B=_X<WR/_P#?D[K]
M^Z]UL2>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NH=3+XV4?U6_P#ON/;\2ZATGF:AZC_<_P"/^^_VWMWP^F=9Z]]S
M_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]
MM[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7
MM9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S
M_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]
MM[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7
MM9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S
M_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]
MM[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7
MM9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S
M_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]
MM[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7
MM9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S
M_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]
MM[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7
MM9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S
M_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]
MM[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7
MM9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S
M_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]
MM[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7
MM9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S
M_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]
MM[]X?7M9ZTN_^%#<GD_G;_\ "=$_D?*[J[_W[?7/MF5=-.E$+5KUNL>V>GNO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[JA'^;1\7/A'\LN_P#XW[+["^?.
M_OY?/SLVKM/=5?\ 'GLOJ7N,=,;DS6V]VU#09?"4DU5/0T^;A-=C(YVI:.OC
MR$!0,2*:I=9?=>Z$O^7=_)GV7\(>[=S_ "H[%^77RO\ G/\ )/<G7%1U)@^V
M?E'V94[X."VQD\A!E:S'X2GJ)ZN6-LC64M&\\T^0J;+"%I$I%J*S[KW7NKHF
M954LQ"JH+,S&P 'U)/X ]^Z]T7C87RU^,_:G<F]/C[UAWCUKV-W'UMMV#=/8
MNP]B;JI=VU> HZN>&FA_C)H))X<94SR5$9CIJB6.I="95B,8+^_=>Z,1[]U[
MH!/E7VINOHOXO?)'NW8>S:GL7?'3O0?</:FS>OJ..>6;.Y7KW;V1R^.PT2TL
M%34M)E*RCAIE$--+*6E CCD>RGW7NM8WXP?"BN^6_P#+%PW\S#M?^:/\U\?\
MM>T.I*SY-2]^;&^3^1V-LWK[*;<I#7#:E%L:CDI]G1[:P4M!)09>BK,=++4,
M^1"U$'EA\/NO=&$D_F\?)#$_\)T^J?YA^1V2B?,CN+8VV^I^O,'D\-#A(LGO
MG>>\*K86$W-'C:OPT\E%E$IUW)!3J!35%+(@C*TL@=?=>Z:/DM_*T^0WQ'^&
MN^?F-T%_,$^=N\OYA?QRV)NSY*[OW5O[NS.]J;4[(KMFT%9G-Q[+R'63U$>V
MAM_*TR5=#AZ2@Q\510M'CRDE5+"?+[KW5]?PU^1F*^7GQ/\ CG\H,-BI<#0]
M]=-=?=HG 3-Y&Q\^[L;3U=7CR]V$GV-5)-!K#$/X]0)!]^Z]T97W[KW1 /YL
M7_;K+^99_P"* ?,C_P!]UN/W[KW5;7_"53_MQY\3O_#F^1__ +\G=?OW7NMB
M3W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]TT9&0)*@()O'_P 2?:B&I'2&Z?21]G3?YQ_J3_M_;U#Z])?%^?7O./\
M4G_;^_4/KU[Q?GU[SC_4G_;^_4/KU[Q?GU[SC_4G_;^_4/KU[Q?GU[SC_4G_
M &_OU#Z]>\7Y]>\X_P!2?]O[]0^O7O%^?7O./]2?]O[]0^O7O%^?7O./]2?]
MO[]0^O7O%^?7O./]2?\ ;^_4/KU[Q?GU[SC_ %)_V_OU#Z]>\7Y]>\X_U)_V
M_OU#Z]>\7Y]>\X_U)_V_OU#Z]>\7Y]>\X_U)_P!O[]0^O7O%^?7O./\ 4G_;
M^_4/KU[Q?GU[SC_4G_;^_4/KU[Q?GU[SC_4G_;^_4/KU[Q?GU[SC_4G_ &_O
MU#Z]>\7Y]>\X_P!2?]O[]0^O7O%^?7O./]2?]O[]0^O7O%^?7O./]2?]O[]0
M^O7O%^?7O./]2?\ ;^_4/KU[Q?GU[SC_ %)_V_OU#Z]>\7Y]>\X_U)_V_OU#
MZ]>\7Y]>\X_U)_V_OU#Z]>\7Y]>\X_U)_P!O[]0^O7O%^?7O./\ 4G_;^_4/
MKU[Q?GU[SC_4G_;^_4/KU[Q?GU[SC_4G_;^_4/KU[Q?GU[SC_4G_ &_OU#Z]
M>\7Y]>\X_P!2?]O[]0^O7O%^?7O./]2?]O[]0^O7O%^?7O./]2?]O[]0^O7O
M%^?7O./]2?\ ;^_4/KU[Q?GU[SC_ %)_V_OU#Z]>\7Y]>\X_U)_V_OU#Z]>\
M7Y]>\X_U)_V_OU#Z]>\7Y]>\X_U)_P!O[]0^O7O%^?7O./\ 4G_;^_4/KU[Q
M?GU[SC_4G_;^_4/KU[Q?GU[SC_4G_;^_4/KU[Q?GU[SC_4G_ &_OU#Z]>\7Y
M]>\X_P!2?]O[]0^O7O%^?7O./]2?]O[]0^O7O%^?7O./]2?]O[]0^O7O%^?7
MO./]2?\ ;^_4/KU[Q?GU[SC_ %)_V_OU#Z]>\7Y]>\X_U)_V_OU#Z]>\7Y]>
M\X_U)_V_OU#Z]>\7Y]>\X_U)_P!O[]0^O7O%^?7O./\ 4G_;^_4/KU[Q?GU[
MSC_4G_;^_4/KU[Q?GU[SC_4G_;^_4/KU[Q?GU[SC_4G_ &_OU#Z]>\7Y]>\X
M_P!2?]O[]0^O7O%^?7O./]2?]O[]0^O7O%^?7O./]2?]O[]0^O7O%^?7O./]
M2?\ ;^_4/KU[Q?GU[SC_ %)_V_OU#Z]>\7Y]>\X_U)_V_OU#Z]>\7Y]>\X_U
M)_V_OU#Z]>\7Y]>\X_U)_P!O[]0^O7O%^?7O./\ 4G_;^_4/KU[Q?GU[SC_4
MG_;^_4/KU[Q?GU[SC_4G_;^_4/KU[Q?GU[SC_4G_ &_OU#Z]>\7Y]>\X_P!2
M?]O[]0^O7O%^?7O./]2?]O[]0^O7O%^?7O./]2?]O[]0^O7O%^?7O./]2?\
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M\Y_U(_V_OWA?+KWC'KWG/^I'^W]^\+Y=>\8]>\Y_U(_V_OWA?+KWC'KWG/\
MJ1_M_?O"^77O&/7O.?\ 4C_;^_>%\NO>,>O><_ZD?[?W[POEU[QCU[SG_4C_
M &_OWA?+KWC'KWG/^I'^W]^\+Y=>\8]>\Y_U(_V_OWA?+KWC'KWG/^I'^W]^
M\+Y=>\8]>\Y_U(_V_OWA?+KWC'KWG/\ J1_M_?O"^77O&/7O.?\ 4C_;^_>%
M\NO>,>O><_ZD?[?W[POEU[QCU[SG_4C_ &_OWA?+KWC'KWG/^I'^W]^\+Y=>
M\8]>\Y_U(_V_OWA?+KWC'KWG/^I'^W]^\+Y=>\8]>\Y_U(_V_OWA?+KWC'KW
MG/\ J1_M_?O"^77O&/7O.?\ 4C_;^_>%\NO>,>O><_ZD?[?W[POEU[QCU[SG
M_4C_ &_OWA?+KWC'KWG/^I'^W]^\+Y=>\8]>\Y_U(_V_OWA?+KWC'KWG/^I'
M^W]^\+Y=>\8]>\Y_U(_V_OWA?+KWC'KWG/\ J1_M_?O"^77O&/7O.?\ 4C_;
M^_>%\NO>,>O><_ZD?[?W[POEU[QCU[SG_4C_ &_OWA?+KWC'KWG/^I'^W]^\
M+Y=>\8]>\Y_U(_V_OWA?+KWC'KWG/^I'^W]^\+Y=>\8]>\Y_U(_V_OWA?+KW
MC'KWG/\ J1_M_?O"^77O&/7O.?\ 4C_;^_>%\NO>,>O><_ZD?[?W[POEU[QC
MUIY?S[WU_P [+_A.]?BWRRZHX_\ *M==^RK<ETE?S_R="/8GUJ_VC_+UO#>R
MSH_Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NM,S_A5-EY^Q._?Y47PX[Q
M^06XOC/\!ODAVSO=ODKV)CA%1XUZG:=?M:+'/EZV=&I*:/%PY*H>GFKBV+Q\
MU7_&:^GJ(\8A@]U[I'_S(OC3UA\Z/YT'PK^"7S*^1&^=M_RZ=J?!F/?_ ,>8
MZ7?.+V?B.P^P-G5\F'RU%'N**"+%5VZ),0U-/6K2QK5TU%!''104,>5,T_NO
M=%1^2OQ)^)?\FS^<5_*E;^53W=NVC[*[_P"^]H=6?(KXH4/9%9VS3MLO=N9Q
M6#JLGDC#425U-2U])DLR4ILK/4QBJHH\I0)!_#)[^Z]U]!'W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=$ _FQ?]NLOYEG_B@'S(_]]UN/W[KW
M5;7_  E4_P"W'GQ._P##F^1__OR=U^_=>ZV)/?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW05;]DTY&C'%OL@?I_P W
M']GVU+5#_IO\@Z"',3Z95_TO^4](7S#_  _VQ]FF@]![Q?GU[S#_  _VQ]^T
M'KWB_/KWF'^'^V/OV@]>\7Y]>\P_P_VQ]^T'KWB_/KWF'^'^V/OV@]>\7Y]>
M\P_P_P!L??M!Z]XOSZ]YA_A_MC[]H/7O%^?7O,/\/]L??M!Z]XOSZ]YA_A_M
MC[]H/7O%^?7O,/\ #_;'W[0>O>+\^O>8?X?[8^_:#U[Q?GU[S#_#_;'W[0>O
M>+\^O>8?X?[8^_:#U[Q?GU[S#_#_ &Q]^T'KWB_/KWF'^'^V/OV@]>\7Y]>\
MP_P_VQ]^T'KWB_/KWF'^'^V/OV@]>\7Y]>\P_P /]L??M!Z]XOSZ]YA_A_MC
M[]H/7O%^?7O,/\/]L??M!Z]XOSZ]YA_A_MC[]H/7O%^?7O,/\/\ ;'W[0>O>
M+\^O>8?X?[8^_:#U[Q?GU[S#_#_;'W[0>O>+\^O>8?X?[8^_:#U[Q?GU[S#_
M  _VQ]^T'KWB_/KWF'^'^V/OV@]>\7Y]>\P_P_VQ]^T'KWB_/KWF'^'^V/OV
M@]>\7Y]>\P_P_P!L??M!Z]XOSZ]YA_A_MC[]H/7O%^?7O,/\/]L??M!Z]XOS
MZ]YA_A_MC[]H/7O%^?7O,/\ #_;'W[0>O>+\^O>8?X?[8^_:#U[Q?GU[S#_#
M_;'W[0>O>+\^O>8?X?[8^_:#U[Q?GU[S#_#_ &Q]^T'KWB_/KWF'^'^V/OV@
M]>\7Y]>\P_P_VQ]^T'KWB_/KWF'^'^V/OV@]>\7Y]>\P_P /]L??M!Z]XOSZ
M]YA_A_MC[]H/7O%^?7O,/\/]L??M!Z]XOSZ]YA_A_MC[]H/7O%^?7O,/\/\
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M]H/7O&'7ON&_U?\ R;_QKW[0>O>,.O?<-_J_^3?^->_:#U[QAU[[AO\ 5_\
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M7OV@]>\8=>^X;_5_\F_\:]^T'KWC#KWW#?ZO_DW_ (U[]H/7O&'7ON&_U?\
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M1'_S3_Y^;H)=;?U_WCV(- Z!?7M;?U_WCW[0.O=>UM_7_>/?M Z]U[6W]?\
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M&U<1UUBOBGV%A>N\;)M>FRU'MRLZ\VY4U&ULI04#&&-:C;V0H:"JIO'+ ZO
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M#VY64G4ORMS&Y]^=-;PFH7IXEW9M:C%!DH8Y]&BJI<G282*ED'D+TU92TBA
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M^+_SQZ!WC@>CMIY+%[>W1VM#-GL'L^GW/2XK&9.GW7C)L8*C&Y'^#TE+5RK
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M5D&,R&.KXY8H3+X//#4/H6NCN(N80T[).N8V0!3Z')H:>>:_M'D>K,*8]/\
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MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW6FO\
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MU;34]91U$%725<$532U5-*L\<L<ZADDC=25='4@JP)!!!!M[#?5.JH_YG?\
M-BZP_EOX79-#)M&D[H[<WOD?+2]3T._(MDU%'A88YO-FZ^K&,S4E+ U2D4%-
M&V/O5.9C'(%II?9KM>UMN;$ Z5 RU*Y].(S^?5M.*_L^?^K_ #='T^-/<O\
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MEAAQTL;>Z]U]$WW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=$
M_FQ?]NLOYEG_ (H!\R/_ 'W6X_?NO=5M?\)5/^W'GQ._\.;Y'_\ OR=U^_=>
MZV)/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW1>NX/^+WC/^U4/^MTGL7\N_V3?Z;_ "#J,^=_]R(_^:?_ #\W02>Q
M#T"^O>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NDKOO:5!O[8^\MB95Y(\7O7
M:FX=I9*2*^I:?<='-1S,NED;4(YF(LZF_P!"/K[V#0UZVK:2#Z&O6JE_+S_F
M"[9_E++V1_+H_F X7<W7E5U7OG<>Y>M.TMN[;JMV8K(XG=TJU:EH*%:BO>FK
MYFEK:&J@I9E*5$U)6I1U5&5E%-_8-N]+FWHVH ,M0"K 4\Z#&/\ "*@]78#_
M #?,5_/H>M^?S</DO\].U9/C9_)^V3#'4XW&+F]_?)SM[ P8^@Q-&Y2-9Z/&
MY."L@I(1/(L8>NQM75U3B5*7%%(C4E.FTQV"^)>&E3VQJ06:A\SZ?8?,9!QU
MX ?[.:</VU_U9\DINKY9_P X/^5A6[:WY\]EZZ^87Q@W#GJ/!;JWYU)2TM-D
MMNS9(CPK%4QX+:;I)*1)XER6*DHZB4+2)D*266&]UM+3="5MM4;@85_A;C7S
M8U_/AY')ZT*$9_EQ'^2G0K?)O_A0O\/Y>B-UXWXQUN_.SN^M\[>R6U=@[0J>
MN,IA(\=E-Q0-2TM5E):I:>*ICIII5<4]!/4S5$BK"IC5S,C,'+\Y<>* B#+-
MJ7X1QI0GR]13UZVH /&OI0')_ET1+^6?\V:S^3E5[U^$O\Q'8^\NK,=N^IP/
M?NP=UXW'OO>/'C?F+I*6LHZN#'R5,ST+28I8@]!%4"#*09&&9#J,R+]RL_WS
M2XM:-2J,/A-5.#FE<$<?*GV#Q&,G_**>G[:_ZN.?^9;\XJO^</)M'X/?RZ]A
M[S[5I-O5F4[UW[N[)4@V-%D(MA8ZK@IJ*DI\H]+-'1+-DT5I:X4OFR+T-/#&
M01*VMMLOW,?J+JB_@4#N-6\\5& #ZXK\J^ P:'CQ^ST_;3_56AX/BQ_PH4^)
ML/1^W,!\L)M^=0]_]>8:FV=O_;"==Y3/0Y/)[7A6EGJ\<]%#4&B-7+$3+29#
M[22DJ3+ 6EBC6ID17/+\P>L(#H<JP9>!X5J1Y>8P?Y=:8 GT^6<?X>JFL]\X
M/DCN;YHO_.ZVY\>]UM\.NM=WXGX\Q09.JH**KFVWDZ"IQ4T4EIIF^]:KR3U+
M5,(DH*?*5%-C#63!9"306,2P_0EQXK5D\RH8>7YJ//RJ:<!U8</E2GS.>/Y'
M_5QZN.[?_P"%'?P=VWU5+N+I>#L3MGMK*X\1[<ZMKME5NSA2U]7$3"N;R=4A
MHDIH9M*2_P .FR$KMZ8593Y5*8N7;AFHX"+YL6!%/L!K^VGVCJH45XU^RN?Y
M=!%C<7_PI/[*VQC?D!C^P_COUG'-C'W%C?B]6[?Q.-R-1!-JGCH9XJ[;N5^W
MGJHA&BQUF]H*B %5DDI9_,0YJVV.J4E;/]IZ?9D?S7K9 !IC^=/]7V8Z$SH#
M_A0]\:Y]MY?:GS2V[NSXW_('K[(Y/:G8&UL9L[*[SQ53E=NS24E:N.-##65V
M/E%3#*LE'7(/M7O$*RJ"F8TGY?FJ&AI(C %6J%-#G(8C^7\N'6BH'G^7_%=
MU\-]Q;@_FJ?S9*?^8IMW8>XMD?&#XH]=5_4'6F8W(T5#69W*34N;2&&HAA,Z
M&=/[VY6OGCAJ66DC7'PS3.TS([MX/W7:?2L07D8.P'!1CS]>T?S^1ZV5 %?R
M'S^?V>7^H@;0OL-]-]>]^Z]U[W[KW6IU_P *B>[=SXC9_P 8_C[BJJHH]L;U
MRN^.SMX)!520BLEV8*"@Q%/*B%4E@A?)9"9DD##RK3R*%:($BKE: .[R'BH
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M/D4:E @K<3&3+.K1E5UOK4W)=>Q+;WC"0=OB5('\!(;%*>1ZL2"?V9/K3/\
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M:@BIH9C&TL0JIEN(;,;\MV;23>-2BH#GR+$4I^PU_P"+Z\!09\^'[>/\J?\
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MJ>FECAJYH#!+HBEHZJ%]B.8;:JDJZ\5![2WS%>!I@GA\Z&KGP\.!\\X^6/\
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MD9SM^\M9*8V42(?PGR^S!P?,4_9GJZM3UKZC_5GI-?R^_P"1]M7XF]WGY/\
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MT_EQZ\S:C^0'[ !T83^9_P#R\/\ AR'IK8G4G^E__0S_ ')[-I.QO[P?Z/\
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MP_(=;./=5=UAC.H>SJ_NR7!0]0TNQ-TR]F2;FTF@_@:T<W\2%4'X:)J7R@J
M68D*H+$#V'(PS, M:U%*<:^5.J+6N.M>W_A,ATK2;9^*G;O>62VM#0[C[/[@
MK]K8/=%13C[BMV_L/'8X(M/(5U"B7.5>7C8"2SSP.&4>)&(AYGFUSA <*HJ/
M1B2?\%.O'  _/_)T(O\ PI+JNK9/@_M'!;FCH*SMG+=U;17I>@AB^YR9J$BJ
M1F7IXX[S_9-C&>*8Z3$U1)1HP,S069Y=U"YJ,*%8OY#33_/3K:@D'\A^=?\
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ME<Y-EJW$0UE89&$-358_.T]#6TMF2-7JMLU,Z*BO+)4R^H'O[ZCG6EQ"CL:
MN.UB!3T!-?L('E0#JX85'_%_L!Z"'J_!K_-<R/9_\NS^9CMN38/SK^'$;9[9
M/?'6C4F'R5=C)Y,?#5Y!8?$V.J(JPU&$J9XXJ6*DKZ2LIJNDAQ]3 )0Y(QVK
M3<VIK%*""K D Y[3GRS0UK@BI''9[?Y<#_,?Y?\ 4 7KYZ_R8OGQL[H[,[YC
M^;G9?SBV+U/JWGD>C^SLONJAD.(VW"\]3+BZ"HW5G*>KJZ6GC8-3T\U'4R0>
M3[*0U/BIY%=CO5NS@&)8B<>(NG!./-10?//S%.M UX>?EZ_LZ:/CUVKTK0_S
M!OY77R+^%>U:3I3'?+?868ZE^1'QYVE5&HQ^.DV)(V!KA)#X0\E-(:6FK8JA
MHT-2V-BR,VBJFJW9NXC<6\\4QU&)E9'/'O/V^8\O*OV=.'/'@0?Y"H\O(X_V
M.C>=0].]?_/;^=;\[)_E9BJ;L'"?&/9E%UUU#U%NL"JQB8O+1'%2UWV,BI]Q
M#&E56UJ:D=$K<O'5HXEAI'5++,UE91"+M,A9G8<:JPIGR_+T^9K4]HQY4_F*
MGH*/Y;_;O97Q?Z0_GC=,=79W*YWK_P"$F4[FW!\=LYF'?+G'5F,&^J)9;G73
MO!*NV<7D6@C6.+SBKF8$U;NJC<X5NGM7;XI0@>E!6NC/V]Q'Y >75?R\SZ_L
M_P!7KU5GCNL>L^UOAC\3?C9U#UQC.]OY@WS[[.WKW=NOM7/Y^89+;5%L;<FX
M\%%')6SF"H:&MI,1FZBO^\\U. F3K[5$C8ZHB,S*\-Q),Y*0PJ$"@8.I1@ 8
MXD'U^$&GE89%/7_BZFN<<,?.GSNSV3_(![M["Q6R]N_-+^8WWAW!UGMP8ZME
MZ2P&5SF2QD%12Z1X<?D]QYW(TU-!'&K1"2/;$4K(UT,!4!B=]^2.I@@1&\FH
M*T_)1G\R/D>J:J$\3_*OV\>D7@]^_+GYO=H[Q^$/\L+<N/\ A9\&OAW5R=6Y
MKN[!I529+)U>(^YIS'05L>FOEFJJZ&KF2.EKX)Y8B<GDL@9:JGISKPX;)%FN
M099)!J"5H ":U-/4?*G$4Q4.'''CPX5\N !QC_BNCN?%[^2/LSK?M_;GR)^6
M_P BNU/G#W5LJHQ^0V-ENU*NO3&8FJQ=1]W2U7VV0S&=R&1J**H_<I_N,G]H
MDI:8T1F$;Q);K>6E4QQ(L2-\00"I^T@#^0&,''3>N@_S_P"3TZO+]DW5.O>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>ZU*?YX/_ &^M_P"$]G_BVW47_OV>O?84YC^)/L;_  CJ1>1O@E_T
MR?X&ZWMO8:Z'?7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW1&.Z/Y
M8W\NSY$[HFWQW?\ "/XO]E[VJA&M;O/='2^!K,O4K%KT+59):)*VJ13(Y"RS
MN 3<"_OW7NI'2/\ +1_EZ_&W<R[VZ(^%/QBZMWM$K)3;UVETQ@<?F8$<H6CI
MLK]DV0I8G:.-FCAJ$1F5692R@CW7NCO^_=>Z][]U[JD/_A2!N;>>TOY)GSXR
MNQ*&JR&;J^O=@[9KH*2CJ:YUPV]=[;8PVXYRE*Z2K%2[>K\I-)(Q\,4<;2U"
MM3I*I]U[HM?0_P 4?YN_R)^(_5_R&H/YDF1^(7:6[NHNO=Y]!?$_K+H?:>>Z
MZVC@QAZ.IVUM?>%3G<=7[EW%E9Z+[=,UD(JVCA@GEEBH\>T--&LONO=$K^5O
MS6WE_,(_DC_%CM;Y#[.H>K^S*7^9U\7OC_\ *W9VVZF2HQ4.9ZD[/CPV?DIQ
M>I0T%;]M2UPIC+614L\@I4J*S[=*B7W7NMH[YHXW$9GX=?+'#[@H,;E<#E?C
M1WMC<WB\Q2Q5U)4TE=M;*Q5-/503JT,U--"SI*DBE'0LK J2/?NO=$E_D,SY
M:H_DZ_R\I,TM2M8OQQVG!"*JG^V;[2FEJ8Z A=*7C-"E,8WM^Y'I>[:M1]U[
MJW#W[KW6DM_-,_GP?-G(]2?S&OB'/_)"^4U#U37=<_+SXWS?+"7<F[6V]#MZ
MJQFX=L-V&T!ZA3&G#1XUCF"AW*M-]L-)R8B_RKW[KW5HO_"53_MQY\3O_#F^
M1_\ [\G=?OW7NMB3W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]TA?]&77O\ ?H]F_P!SMO\ ]_S0#&_W
MM_AL?WOA"&.WFM?7XCX_)_G/%^UJ\?I]A[^J>V?O'][_ $L'UOA^%]5X:^-H
MX4UTKPQ7C3%:8Z-_W]>_2?0>/)]/JU^#J/AZJUX?;FG"N:5STNO8AZ*.O>_=
M>Z][]U[H-^U>O?\ 29M:CP$>8;;]=B][=;[[Q.82A&2\57UON#&9^!'A,L!D
M@JWQWVTX$R$P32 ,"?>QCK1ST4[#_P O'JK&PXV#(=E=X[IAV['MVAV?'N;=
M.(K%PV/V[3Y^)<9CT@P-,@I*J?<==43M.L]27CI((:B&AI8:1;:^JZ.E_FOA
M5T[N6BW#B=QS[NS>#W9+MO\ O%A*W*4B4]7!MS8U?U\*.0PT$4ZTU9@<C4M4
M:)ED-5IDBDAB!A.M1_U?MZWI'2.@^ O7LS[/K]S]K=W;XW/U[3Y^/8F\]RY;
M;<62Q$V:RFQ,M#6438S:^-I8ZK'U'7V(2%C2,M1#5Y6/))7_ '[LN]?R'^JO
M^?KVG_5_J^SIO@_EV=204.X<2O8W>383=G260^/FY,&V\,:*6JVSD:3-TS4A
M1<(K4[K+N#)5>J!XE>K:.65)!$B#WB'_ "]:T#I2[4^"W6FUZ'>]--O[N+=F
M0[#QO9-!NO<>\MTX_-Y&ID[6VIL[:&6JS4_PB(?<F@V3C)X;QF&*JFJ[1&E:
MFI:;1>OY?YR?\O6PM.D5V5_+7Z1[0[(J.S\QO3N'$9O(;LP&[,SCMO;@PU+1
M5S;8QFPL=0T4Z5& JJE*"&3KG;U:5@JH99:LU(FFDI'BI8+"0CT_U5_S]:*
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M\3FTDCR%+CL]08R@Q:5XE_>%75T^/:O<2'R(*Q4E"RJX#F^72W4_932@""G
MTKP^5304\AUY_P"?G]I_U?MZNN]D_5.O>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K4I_G@_]OK?^
M$]G_ (MMU%_[]GKWV%.8_B3[&_PCJ1>1O@E_TR?X&ZWMO8:Z'?7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]T1[Y\?S%/BE_+3Z83O'Y7]@2[0VUDLNNW-H
M;?PF*EW)G=P9-HVF_A^%QD%GJ9DA1I)99)(:6G0!ZBHB5E+>Z]UJ^9W_ (6Y
M?#FGRABVS\,ODQE\+?BOSNY]K;=JO\XX_P" =/6Y2+_-"-O^!WZV9/HHD?W7
MNK7?Y:'_  I)_E]_S,NU:3H+98[,Z*[US461GV9U[W?B<;C4W&,5#]S40X+*
MXK)Y.@J:Z*G663[.>2EJY(XIGIX9DB=E]U[K8']^Z]U[W[KW1>OEG\<-F_+_
M .,O>WQ>[!K<EB]G]\=7[OZRS6:PJQ-6X]=T4<E/%DJ(3I) U9CIVBJ8!+&T
M9EB02*R7!]U[JC;IKL_^>3\.?CEMSX24_P#+SVM\L.S^GMLX;I7HKYM8;Y-[
M9V=L3,X#!"+$;>W1O? YZO;>M#DL/AXX9LM1P0U4F1GIV6EG0U(D7W7NE[B?
MY(V0K/Y*&\?Y;.\^WQD/D'V%-N'O3<G?>-\V.I8^WLSN5=[PY>F6DAHZA,-2
MY^"DHR5IXYWH$>58XZAE5/=>Z"3NO=G\\GYF_%;=7\O;>O\ +[Z_^/\ V+W1
MLG-_'[Y%_.7+?(K;6\^MX]K;AB?"[GW1L_:N+KY=Z5M9N7!SU$F.Q=;%3RT,
ME44K9-5/);W7NM@+XW=$[,^+_P ?NE?CEUVE0NQ^C>K]D=6;7DK&USS4FR,=
M3X^*IJ6NVNJJA 9IFN=4KNU^??NO=#5[]U[H@'\V+_MUE_,L_P#% /F1_P"^
MZW'[]U[JMK_A*I_VX\^)W_AS?(__ -^3NOW[KW6Q)[]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z+UW!_Q>\9_VJA_U
MND]B_EW^R;_3?Y!U&?._^Y$?_-/_ )^;H)/8AZ!?7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW22WSL+8_9VU<QL;L?:&VM][,W#2M1
M9S:N[L)3[AQ]7$_]B>DJHY8) #8BZ$J0&%B ?=D<H05)!&01@CK8-.BA]<_R
MRO@%U/N^EW[L+XH=/8;=N/JUR&+S%3MS^/M1U",S)/0Q9&2K@HIHV8E'@BC:
M.PT%=*V4R7\\HTM(Y'H6-#]N<]6\0_+\@!_@'5)6T<)\U/Y(G<7=.!ZM^+V[
M/EO\"^YNQ*[L39M'U4E95YK:E5DH41HJF*AH,K/2O24-/3T4S5-#]G71TE%+
M#74D[34WLY=H=Y12\@CE1=)U_"X!]2>.:^N3BF>K8;]OEQ'Y8QZ>G0>?(3:_
M\Q'^>MFML=??[+MG?A%\4^LZK-[WI<_W?CZ_[O,[C@QM12XJ7P5-%B:VM$D=
M;+3Q_94+4=%#/733UM74)34C/6TEOL57UB61@!1#V@5SG(\OMX8IGK1 &/GQ
M\_V5^?KT,G5?\S+^8S\-M@8GXV?)C^6QWAW7V9UGA*39NRNS^KQDLAB]RT^%
MA>#'/4UF-P&=HJB84U/%Y:JCJI9)0&>:B@G5PZ>3;;:Z;7%,B*34JY 9>&!4
MBO'Y>E3QZL1JR:_ED'_!3_5CRZ&7X$?![OSY"?(OO'^8+_,EZRVWB<_W+L>H
MZMZZ^,^ZL73;CH\7MG))2QR?Q3&5HK%I@M%2I2Q4M0RU#O49&IK:>*6>(!F]
MO(X8UM[<DA6UF3(+/\N%*?Y!3A4Z9M/#[/6@KZ^=?V?X!91LG^6#_+[ZZWG2
M=@[/^)73>+W9CJT9'&9&;;?\7BI*A6UI/245;)44-++$]FB>*F1HB 8RI ]E
M[[A/(-+2.0>(+'/\^J^(?E^0 /\ (='P]H^J=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M:E/\\'_M];_PGL_\6VZB_P#?L]>^PIS'\2?8W^$=2+R-\$O^F3_ W6]M[#70
M[Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NM0'_A4!T]V/M;M[^6Y_,:JO
MCC'\N?BU\'][]@9/Y*=+3H^0ABQ^Y:K;U=!E*ZB,-7 V(9<-**JHFI9*2&:F
MHDR,<E%,^CW7N@XVW_PL6_E&4.'IJ*J^&WRWV\:2".&DQ&V^GNLJZCB54'[<
M;MO_ !VA%?4H I0-(#6!.D>Z]U7KN3Y6];_\*"?YKO\ +:W%_+S^".Z.GJGX
M?]]=>]U_([Y1[TPF-VK7Q;8VIN/%[B3'9I]K29''K'%+A,FV$^^RD]74Y*KD
MAHEH(9,C-+[KW7T3_?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MT0#^;%_VZR_F6?\ B@'S(_\ ?=;C]^Z]U6U_PE4_[<>?$[_PYOD?_P"_)W7[
M]U[K8D]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=%^[=C+YK&$?\ZL#_K+)[%G+[A(V_TW^0=1ISLM;B/_ )I_\_-T
M$WA;_??\C]GWC#H&:#U[PM_OO^1^_>,.O:#U[PM_OO\ D?OWC#KV@]>\+?[[
M_D?OWC#KV@]>\+?[[_D?OWC#KV@]>\+?[[_D?OWC#KV@]>\+?[[_ )'[]XPZ
M]H/7O"W^^_Y'[]XPZ]H/7O"W^^_Y'[]XPZ]H/7O"W^^_Y'[]XPZ]H/7O"W^^
M_P"1^_>,.O:#U[PM_OO^1^_>,.O:#U[PM_OO^1^_>,.O:#U[PM_OO^1^_>,.
MO:#U[PM_OO\ D?OWC#KV@]>\+?[[_D?OWC#KV@]>\+?[[_D?OWC#KV@]>\+?
M[[_D?OWC#KV@]>\+?[[_ )'[]XPZ]H/7O"W^^_Y'[]XPZ]H/7O"W^^_Y'[]X
MPZ]H/7O"W^^_Y'[]XPZ]H/7O"W^^_P"1^_>,.O:#U[PM_OO^1^_>,.O:#U[P
MM_OO^1^_>,.O:#U[PM_OO^1^_>,.O:#U[PM_OO\ D?OWC#KV@]>\+?[[_D?O
MWC#KV@]>\+?[[_D?OWC#KV@]>\+?[[_D?OWC#KV@]>\+?[[_ )'[]XPZ]H/7
MO"W^^_Y'[]XPZ]H/7O"W^^_Y'[]XPZ]H/7O"W^^_Y'[]XPZ]H/7O"W^^_P"1
M^_>,.O:#U[PM_OO^1^_>,.O:#U[PM_OO^1^_>,.O:#U[PM_OO^1^_>,.O:#U
M[PM_OO\ D?OWC#KV@]>\+?[[_D?OWC#KV@]>\+?[[_D?OWC#KV@]>\+?[[_D
M?OWC#KV@]>\+?[[_ )'[]XPZ]H/7O"W^^_Y'[]XPZ]H/7O"W^^_Y'[]XPZ]H
M/7O"W^^_Y'[]XPZ]H/7O"W^^_P"1^_>,.O:#U[PM_OO^1^_>,.O:#U[PM_OO
M^1^_>,.O:#U[PM_OO^1^_>,.O:#U[PM_OO\ D?OWC#KV@]>\+?[[_D?OWC#K
MV@]>\+?[[_D?OWC#KV@]>\+?[[_D?OWC#KV@]>\+?[[_ )'[]XPZ]H/7O"W^
M^_Y'[]XPZ]H/7O"W^^_Y'[]XPZ]H/7O"W^^_Y'[]XPZ]H/7O"W^^_P"1^_>,
M.O:#U[PM_OO^1^_>,.O:#U[PM_OO^1^_>,.O:#U[PM_OO^1^_>,.O:#U[PM_
MOO\ D?OWC#KV@]>\+?[[_D?OWC#KV@]>\+?[[_D?OWC#KV@]>\+?[[_D?OWC
M#KV@]>\+?[[_ )'[]XPZ]H/7O"W^^_Y'[]XPZ]H/7O"W^^_Y'[]XPZ]H/7O"
MW^^_Y'[]XPZ]H/7O"W^^_P"1^_>,.O:#U[PM_OO^1^_>,.O:#U[PM_OO^1^_
M>,.O:#U[PM_OO^1^_>,.O:#U[PM_OO\ D?OWC#KV@]:DW\\1"G\ZW_A/7?\
M/RVZC_WCMGKSV%^87ULGV-_DZD3D<427_3+_ (#UO9^P[T.NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[JJ+^;'_-T^._\I;J/9^]>WL'N?LSL?MS-9+;'
M2W1NPVIUS&XZK#K3'(3&6I)CHL3COO:%*JJ\,[K+54T,5-/+,J>_=>ZU4-R?
MSPOGSOC+G=>!_P"$R6/R6*RZ15(R&Y/C%O3?U95("5CD_BT/7U!'.!3+#&K?
M:D70L/25C3W7NK2?Y9?_  HXZX[0^1NQO@7\N?@MN?\ EE]R=E56/Q'2V$S=
M%/@MOYBNRLOV&)Q$M!DMO;7R.$K\O6034.,/V5325E7$M$M1%520P/[KW6V'
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NB ?S8O\ MUE_,L_\
M4 ^9'_ONMQ^_=>ZK:_X2J?\ ;CSXG?\ AS?(_P#]^3NOW[KW6Q)[]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z!#M"+
MR9?'G^F-'_6V3V)MD_LV_P!-_D'4?<WJ3,G^D_Y^/09?;?X?[[_;^SKH):#U
M[[;_  _WW^W]^Z]H/7OMO\/]]_M_?NO:#U[[;_#_ 'W^W]^Z]H/7OMO\/]]_
MM_?NO:#U[[;_  _WW^W]^Z]H/7OMO\/]]_M_?NO:#U[[;_#_ 'W^W]^Z]H/7
MOMO\/]]_M_?NO:#U[[;_  _WW^W]^Z]H/7OMO\/]]_M_?NO:#U[[;_#_ 'W^
MW]^Z]H/7OMO\/]]_M_?NO:#U[[;_  _WW^W]^Z]H/7OMO\/]]_M_?NO:#U[[
M;_#_ 'W^W]^Z]H/7OMO\/]]_M_?NO:#U[[;_  _WW^W]^Z]H/7OMO\/]]_M_
M?NO:#U[[;_#_ 'W^W]^Z]H/7OMO\/]]_M_?NO:#U[[;_  _WW^W]^Z]H/7OM
MO\/]]_M_?NO:#U[[;_#_ 'W^W]^Z]H/7OMO\/]]_M_?NO:#U[[;_  _WW^W]
M^Z]H/7OMO\/]]_M_?NO:#U[[;_#_ 'W^W]^Z]H/7OMO\/]]_M_?NO:#U[[;_
M  _WW^W]^Z]H/7OMO\/]]_M_?NO:#U[[;_#_ 'W^W]^Z]H/7OMO\/]]_M_?N
MO:#U[[;_  _WW^W]^Z]H/7OMO\/]]_M_?NO:#U[[;_#_ 'W^W]^Z]H/7OMO\
M/]]_M_?NO:#U[[;_  _WW^W]^Z]H/7OMO\/]]_M_?NO:#U[[;_#_ 'W^W]^Z
M]H/7OMO\/]]_M_?NO:#U[[;_  _WW^W]^Z]H/7OMO\/]]_M_?NO:#U[[;_#_
M 'W^W]^Z]H/7OMO\/]]_M_?NO:#U[[;_  _WW^W]^Z]H/7OMO\/]]_M_?NO:
M#U[[;_#_ 'W^W]^Z]H/7OMO\/]]_M_?NO:#U[[;_  _WW^W]^Z]H/7OMO\/]
M]_M_?NO:#U[[;_#_ 'W^W]^Z]H/7OMO\/]]_M_?NO:#U[[;_  _WW^W]^Z]H
M/7OMO\/]]_M_?NO:#U[[;_#_ 'W^W]^Z]H/7OMO\/]]_M_?NO:#U[[;_  _W
MW^W]^Z]H/7OMO\/]]_M_?NO:#U[[;_#_ 'W^W]^Z]H/7OMO\/]]_M_?NO:#U
M[[;_  _WW^W]^Z]H/7OMO\/]]_M_?NO:#U[[;_#_ 'W^W]^Z]H/7OMO\/]]_
MM_?NO:#U[[;_  _WW^W]^Z]H/7OMO\/]]_M_?NO:#U[[;_#_ 'W^W]^Z]H/7
MOMO\/]]_M_?NO:#U[[;_  _WW^W]^Z]H/7OMO\/]]_M_?NO:#U[[;_#_ 'W^
MW]^Z]H/7OMO\/]]_M_?NO:#U[[;_  _WW^W]^Z]H/7OMO\/]]_M_?NO:#UJ+
M?ST8_'_.N_X3SC^ORUZD_P#?L]>>P[OGQ)]A_P G0\Y/%$E_TR_X#UO2^R'H
M9=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW6KU_P *&?AY\Q]Q=H? W^9C
M\).KL3\B>S/Y>6\=W;GW%\=*[;DNZZW.8W.SXFNBKL1C:<BLR=5CY,7.C4M&
M&R.J>GJ\<C5%*4?W7NJ_!_PK7^:.W'J,-O?^13WI!N2C\25=..T]U[6:)I(D
M<>2BJ^GZR=->H.H:8'0RBY_6?=>Z#';.\?YE/_"A[Y\_R^NR.Q/Y?&1^"OQ=
M^"'<VU_D+F^W>PMLYBNR&4%%D\1FY,-A\]N#$;9DRRYM]MT5.E)B\<\-$TR9
M+)O.L5%$WNO=;ZWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z(
M!_-B_P"W67\RS_Q0#YD?^^ZW'[]U[JMK_A*I_P!N//B=_P"'-\C_ /WY.Z_?
MNO=;$GOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[H(.Q(]>3H3>UJ"WTO\ [L?V(=G^!O\ 3?Y!T"N9E!E3_2?Y3T'W
M@_VO_DW_ (W[-^@UH'7O!_M?_)O_ !OW[KV@=>\'^U_\F_\ &_?NO:!U[P?[
M7_R;_P ;]^Z]H'7O!_M?_)O_ !OW[KV@=>\'^U_\F_\ &_?NO:!U[P?[7_R;
M_P ;]^Z]H'7O!_M?_)O_ !OW[KV@=>\'^U_\F_\ &_?NO:!U[P?[7_R;_P ;
M]^Z]H'7O!_M?_)O_ !OW[KV@=>\'^U_\F_\ &_?NO:!U[P?[7_R;_P ;]^Z]
MH'7O!_M?_)O_ !OW[KV@=>\'^U_\F_\ &_?NO:!U[P?[7_R;_P ;]^Z]H'7O
M!_M?_)O_ !OW[KV@=>\'^U_\F_\ &_?NO:!U[P?[7_R;_P ;]^Z]H'7O!_M?
M_)O_ !OW[KV@=>\'^U_\F_\ &_?NO:!U[P?[7_R;_P ;]^Z]H'7O!_M?_)O_
M !OW[KV@=>\'^U_\F_\ &_?NO:!U[P?[7_R;_P ;]^Z]H'7O!_M?_)O_ !OW
M[KV@=>\'^U_\F_\ &_?NO:!U[P?[7_R;_P ;]^Z]H'7O!_M?_)O_ !OW[KV@
M=>\'^U_\F_\ &_?NO:!U[P?[7_R;_P ;]^Z]H'7O!_M?_)O_ !OW[KV@=>\'
M^U_\F_\ &_?NO:!U[P?[7_R;_P ;]^Z]H'7O!_M?_)O_ !OW[KV@=>\'^U_\
MF_\ &_?NO:!U[P?[7_R;_P ;]^Z]H'7O!_M?_)O_ !OW[KV@=>\'^U_\F_\
M&_?NO:!U[P?[7_R;_P ;]^Z]H'7O!_M?_)O_ !OW[KV@=>\'^U_\F_\ &_?N
MO:!U[P?[7_R;_P ;]^Z]H'7O!_M?_)O_ !OW[KV@=>\'^U_\F_\ &_?NO:!U
M[P?[7_R;_P ;]^Z]H'7O!_M?_)O_ !OW[KV@=>\'^U_\F_\ &_?NO:!U[P?[
M7_R;_P ;]^Z]H'7O!_M?_)O_ !OW[KV@=>\'^U_\F_\ &_?NO:!U[P?[7_R;
M_P ;]^Z]H'7O!_M?_)O_ !OW[KV@=>\'^U_\F_\ &_?NO:!U[P?[7_R;_P ;
M]^Z]H'7O!_M?_)O_ !OW[KV@=>\'^U_\F_\ &_?NO:!U[P?[7_R;_P ;]^Z]
MH'7O!_M?_)O_ !OW[KV@=>\'^U_\F_\ &_?NO:!U[P?[7_R;_P ;]^Z]H'7O
M!_M?_)O_ !OW[KV@=>\'^U_\F_\ &_?NO:!U[P?[7_R;_P ;]^Z]H'7O!_M?
M_)O_ !OW[KV@=>\'^U_\F_\ &_?NO:!U[P?[7_R;_P ;]^Z]H'7O!_M?_)O_
M !OW[KV@=>\'^U_\F_\ &_?NO:!U[P?[7_R;_P ;]^Z]H'7O!_M?_)O_ !OW
M[KV@=>\'^U_\F_\ &_?NO:!U[P?[7_R;_P ;]^Z]H'7O!_M?_)O_ !OW[KV@
M=>\'^U_\F_\ &_?NO:!UJ#_SW4T?SL/^$\8O>_RTZF_%O^:L]=^R'>>*_8?\
MG0PY7%%D^U?\!ZWF/9+T*NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[JJ/
M^8Y_.9^%7\K#<?5VV/ECE.RL5D>X<)N7/;*?8NP9-Z12P;2GI*>N$[15,34\
MD<E;3:0R6</=22K >Z]U6Q_T%[?R</\ GK?D+_Z(JK_^K??NO="ATA_PJ7_E
M1?(/NGJ#H/KK<_>E1V#W?VAL#J#8D&7Z9J<72/F>RLM287%I5535;+34[5U;
M ))2I$:%G(-K>_=>ZV,_?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]T0#^;%_VZR_F6?^* ?,C_ -]UN/W[KW5;7_"53_MQY\3O_#F^1_\ [\G=
M?OW7NMB3W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]T%^^8P^1I"?\ E2 _Y/?V=;8VE#]O^0=!+F%=4J_Z7_*>D3X5
M_P!]_P C]F7B=$'A]>\*_P"^_P"1^_>)U[P^O>%?]]_R/W[Q.O>'U[PK_OO^
M1^_>)U[P^O>%?]]_R/W[Q.O>'U[PK_OO^1^_>)U[P^O>%?\ ??\ (_?O$Z]X
M?7O"O^^_Y'[]XG7O#Z]X5_WW_(_?O$Z]X?7O"O\ OO\ D?OWB=>\/KWA7_??
M\C]^\3KWA]>\*_[[_D?OWB=>\/KWA7_??\C]^\3KWA]>\*_[[_D?OWB=>\/K
MWA7_ 'W_ "/W[Q.O>'U[PK_OO^1^_>)U[P^O>%?]]_R/W[Q.O>'U[PK_ +[_
M )'[]XG7O#Z]X5_WW_(_?O$Z]X?7O"O^^_Y'[]XG7O#Z]X5_WW_(_?O$Z]X?
M7O"O^^_Y'[]XG7O#Z]X5_P!]_P C]^\3KWA]>\*_[[_D?OWB=>\/KWA7_??\
MC]^\3KWA]>\*_P"^_P"1^_>)U[P^O>%?]]_R/W[Q.O>'U[PK_OO^1^_>)U[P
M^O>%?]]_R/W[Q.O>'U[PK_OO^1^_>)U[P^O>%?\ ??\ (_?O$Z]X?7O"O^^_
MY'[]XG7O#Z]X5_WW_(_?O$Z]X?7O"O\ OO\ D?OWB=>\/KWA7_??\C]^\3KW
MA]>\*_[[_D?OWB=>\/KWA7_??\C]^\3KWA]>\*_[[_D?OWB=>\/KWA7_ 'W_
M "/W[Q.O>'U[PK_OO^1^_>)U[P^O>%?]]_R/W[Q.O>'U[PK_ +[_ )'[]XG7
MO#Z]X5_WW_(_?O$Z]X?7O"O^^_Y'[]XG7O#Z]X5_WW_(_?O$Z]X?7O"O^^_Y
M'[]XG7O#Z]X5_P!]_P C]^\3KWA]>\*_[[_D?OWB=>\/KWA7_??\C]^\3KWA
M]>\*_P"^_P"1^_>)U[P^O>%?]]_R/W[Q.O>'U[PK_OO^1^_>)U[P^O>%?]]_
MR/W[Q.O>'U[PK_OO^1^_>)U[P^O>%?\ ??\ (_?O$Z]X?7O"O^^_Y'[]XG7O
M#Z]X5_WW_(_?O$Z]X?7O"O\ OO\ D?OWB=>\/KWA7_??\C]^\3KWA]>\*_[[
M_D?OWB=>\/KWA7_??\C]^\3KWA]>\*_[[_D?OWB=>\/KWA7_ 'W_ "/W[Q.O
M>'U[PK_OO^1^_>)U[P^O>%?]]_R/W[Q.O>'U[PK_ +[_ )'[]XG7O#Z]X5_W
MW_(_?O$Z]X?7O"O^^_Y'[]XG7O#Z]X5_WW_(_?O$Z]X?7O"O^^_Y'[]XG7O#
MZ]X5_P!]_P C]^\3KWA]>\*_[[_D?OWB=>\/KWA7_??\C]^\3KWA]>\*_P"^
M_P"1^_>)U[P^O>%?]]_R/W[Q.O>'UI\_SZ4"?SL?^$\%OS\L^J/]X[:Z[]D^
MYG45^P_Y.A3RZNE7^U?\!ZWC/97T(^O>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[JO3^9/_ "U?C;_,Z^.F[>C>^-FX:HSTN&RDG5/;$&-A&?V?G'C)HLIB
M,AH-3%"M2L7WE'Y/MJ^G#05$;JP*^Z]U5Y_)_P#Y..Q^LOB%@NGOYF/\M/\
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M]4^G7O!'7OM%_I_O/_&_?JGTZ]X(Z]]HO]/]Y_XW[]4^G7O!'7OM%_I_O/\
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M_C?OU#Z]>\/KWB_VG_>?^-^_4/KU[P^O>+_:?]Y_XW[]0^O7O#Z]XO\ :?\
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M[?W[Q?GU[P3U[[;_  _WW^W]^\7Y]>\$]>^V_P /]]_M_?O%^?7O!/7OMO\
M#_??[?W[Q?GU[P3U[[;_  _WW^W]^\7Y]>\$]>^V_P /]]_M_?O%^?7O!/7O
MMO\ #_??[?W[Q?GU[P3U[[;_  _WW^W]^\7Y]>\$]>^V_P /]]_M_?O%^?7O
M!/7OMO\ #_??[?W[Q?GU[P3U[[;_  _WW^W]^\7Y]>\$]>^V_P /]]_M_?O%
M^?7O!/7OMO\ #_??[?W[Q?GU[P3U[[;_  _WW^W]^\7Y]>\$]>^V_P /]]_M
M_?O%^?7O!/7OMO\ #_??[?W[Q?GU[P3U[[;_  _WW^W]^\7Y]>\$]>^V_P /
M]]_M_?O%^?7O!/7OMO\ #_??[?W[Q?GU[P3U[[;_  _WW^W]^\7Y]>\$]>^V
M_P /]]_M_?O%^?7O!/7OMO\ #_??[?W[Q?GU[P3U[[;_  _WW^W]^\7Y]>\$
M]>^V_P /]]_M_?O%^?7O!/7OMO\ #_??[?W[Q?GU[P3U[[;_  _WW^W]^\7Y
M]>\$]>^V_P /]]_M_?O%^?7O!/7OMO\ #_??[?W[Q?GU[P3U[[;_  _WW^W]
M^\7Y]>\$]>^V_P /]]_M_?O%^?7O!/7OMO\ #_??[?W[Q?GU[P3U[[;_  _W
MW^W]^\7Y]>\$]>^V_P /]]_M_?O%^?7O!/7OMO\ #_??[?W[Q?GU[P3U[[;_
M  _WW^W]^\7Y]>\$]:6__"A^/Q_SM_\ A.@/Z_*[J\_^Q;ZY]MNVKIZ--'6Z
MI[;Z<Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NL4\\%+!-4U,T5/34\4D
M]143R")$2(%G=W8A515!))(  N??NO=4.?.O_A2-_*N^"XSVW<IWA%\B>W,'
M45F-FZA^,PI>S*V&MQ]2M)4TF2S:U5-M;$3T4QD^ZIZK-I6Q+#,J4DLZ+"_N
MO=4_?%/^=)_.N_FX?*GX^Y#X;_"Z/X]_R],/\BNH).^>VLGCX-SU61V;@-UQ
MR[PHQO/<R8O U3U&WJ*KII\?M["396DJ&,:UVNIIBONO=;M/OW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z(!_-B_[=9?S+/_% /F1_[[K<?OW7
MNJVO^$JG_;CSXG?^'-\C_P#WY.Z_?NO=;$GOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NM+#_A1)_P!O
MN/\ A.?_ .+6]7_^_;ZY]^Z]UNG^_=>Z][]U[KWOW7NO>_=>Z][]U[I'[PW[
MM/85-1UF[,K_  FFKYWIJ23[&IKM;QKK*VIH9F6R\W8 ?XW][ KUHFG2!_V8
MWIG_ )[+_P!=[*__ %#[WH/6M8Z]_LQO3/\ SV7_ *[V5_\ J'W[0>O:QTJ=
MH]L=?[[R4^(VIG_XKD::ADR4U/\ PJMH=,,,D43/KJ::%#9YHQ8,6YN!8$C1
M4CK88'H1?>NM]>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW6GW
M_P *MOA9_,\^66SNAJOX08?M[L7I#:&U^RZ#Y$=/=5]F288Y:;+S8R?%5=;M
M!<E1C=:TL%'6Q(L='6U,+3Z8H-$LK#W7NM>_X(_)G^0'\:^FNW>HOEA_+][>
MZ#^=.)Z@WAMQM_?*S 5_R3AAW4<56##3T.-.'QTFS\J]3-0UD4J=?4DE&\B
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M=J4">*S@D#230'$;V\^\A[A<\"RW)>3S^Z;ZXAB2Y2_42QQ2S+%XY1X_$>)
MQ?Q/!2-U!8.J]P,WL3Y4;HW9\[>Z/B=5;9P-+M7K'K3%;XQNZ*>:H;(5,]?3
M[3F:&=&<TPB4[AJ "D8:T4=SRUX^WGVVM]LY,L.9EFD,UW=O;M"0OAHJM>K4
M$#57_%EXFG<?EU+/+/OC=;][F;MR(]K$D&W;?'>I=!W,LC/'MCZ64C2 /KV%
M0:]B^IZ/#[A_K)#KWOW7NDAOK'5V5VY44N*EQR9J*OPF7P<.6F:GIYZW;E;3
MY*EIII$#21QU,M(L;R)'(T2L9%BE*>-E^VRK#*&?5H*NKE15E21&C+ &@)4-
M6A(J<5%:@OW2)IX2L>G6&1T#DJK/&ZR*I(!(#%*$@,0#72U*$F._ME]V=U0Y
MKJJHQ^9Z-Z$W'D9<QV=N;<>3Q W!4PYJ8SY/:^"EQ67RD HLG5RR--DJCP&.
M&62D@BJ5/IE38-RVGE IN2LFX;C&--I#&DQMHV1:)<3":"%BT87MB75J8!V9
M*4,'<W;+OWN&'V8I)M6T3'5N%S+) +V:-VU26EO]/<7"JLQ8B6X<H4C)BB20
MMKC:'^+&2Z:S<FY_A)VYM_K"7(U,,N<Z+W]6S[QV+FIM/C#)#'4/EMOULK%2
M]302.7T)'X-'I][N.?FYJB\+F>T>Z*@B._A40WT0K6C'2(YD&:+(!2I.JO3V
MU^U,7(4YFY.NTL8W8&7:YF:?;9FH16--?B6TC$BKPG2U!JC;I+_P+YO[SW%1
M0Y7JW9_7>XAE%W!G>TJ_?V,WAMY:]*2?&T%3C\93A,Y58[;-)/655!AJN@IE
MGRTU/75684154=0$;U-IMD8V]P\JFJI&8GCE5:@G435-3X4NK-100$RM)IVB
MXN)=)O81&0!XGAR*Z,?,*Q 8#YL@(KYYK8OLW:U!LC:6VMG8N:LJ<?M?!8O
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M2VHA#'[W5]R]QY%V;9;7;Q"OUFSPK/*T0>5HQ!&@0,2**/$9AZ,:CSK?[O\
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MS&&E@BIXC45$E7)I@4*NN65GEE>P%W=V=C<LQ))]X;R.96+&E2230!14YP
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M6C_/GJC9O9'\O[Y@=.YR@-)LK<GQ/[OV@]+B4AIWHZ;^ZN1BII*'RQ3P0U%
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MXR;[RB-12R2I1@XFE=\<9312U+35;Q^>34M@U.JE:]=CX7;<;9Z;1J]_[IR
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MOW7NO>_=>Z][]U[KWOW7NO>_=>ZUDOG1_P!E6]P?]K7 ?^Z;'>SBU_LQ^?\
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M.PLOU^FT-J]>[<V3112Y&&DADR(J-Q5M34R.M#)62(6,9CFA'E6:-Q(XY 7
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MS9>#(04;XE(T#/5+DZ2HF#4VAHYFA3SA8$DD35EE]/DP(/V4ZW>835P*D$=
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MV+U'NC$4&;WQ/@:*BJ>R\%NC.S4\]7#A\A-)%1P[9DBC=:0&:2=2XA5"2SX
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M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UI8?\
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M-X(F8/+XD(9]*G2INUA[]U[KV2R>.PV/K,MF,A18K%XZFEK,ADLE5QT-/!#
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MG!JJJ62Q1'\0=858CRS%(EY;B2O:?VWO/=#>8-NMT8Q:T:[F .F"W#5=BU"
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MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZTL/^%$G_ &^X_P"$Y_\
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MN1JVKGR>#V)E\_6[1Q<T59)-+31P8=(*-G(I(8%2)8_=>ZM_]^Z]U[W[KW1
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M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NM+#_A1)_P!ON/\
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M\@NU=W=P[Y@PM-NK>M3CJK+P;>HY:"C5L914U!'X(9IZF5 8:6,MJG:[:B+
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M4\NC)NP1&=@Q5%9B$0R&RB_"J"S'^@ )/T O[3R.(E+&M "30%C0"N H))]
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MH%E$NK4"P*I&=>.UM1"U!8$ZB>E<]ZC>&891&B@52C5K7/!:'\S3B?/J^?\
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M:2RQQHJJ&"@#@7+$M/(9#5C7J0>5.3MNY*MVMMMB\*-G,C#6[EG("U)=F/
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M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW6EA_P *)/\
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MGVT=LTN\QUO0[MHJG-'$UL,-1#DACDF-4:*6"H@D67QZ&21'!TL#[\'#</\
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M\DZZ_P">D?\ 5I>JN/>#W60W7O?NO=&;^&G_ &5!TU_X=?\ \:U'N;ONX?\
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M"M-G)%W-GJO<HJDRN#IL,U%D<9F*M:C'U=)!3STDM/33(YGB\K>Z]T&/5_\
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M%6%'57HR,IP11@Q[@5 ::_:/W*MN2?&M[U7,4Q5U>,!BCJ-)JI(J&%,@U!'
M@U%:W_#=7RG_ .>0P/\ Z&>-_P#JCWA__P "#SI_OFU_[*H_\W4[_P"OER]_
MOZ7_ )P2?YNO?\-U?*?_ )Y# _\ H9XW_P"J/?O^!!YT_P!\VO\ V51_YNO?
MZ^7+W^_I?^<$G^;HUOQ&^!79_7O;&W^S>TY<'AJ':!K*_%X'&91<Q5559/#-
M3P^5X5-/#3PB0S$B=W9@B: &<K.'L-]UW>.3=]AWK>G@C6U#M%##(97DE='B
M&LZ0JJH8MAB2=(H!7J.O<OWCV_?-MDV_;A([3:5>1TT*J!E8T!-2QIIX  5-
M>%;A_>?'6,77O?NO=4$?S$.G.RNW/FIBLQA>J>L/YAW5'7_Q>HL;O+X!R_*V
M+HK>6R\KNK.9J5.RL/A)IJ?!YJHW?04]-AZ*ISF0Q;T!PM9_!\BIK<A&/=>Z
M+)TEO#8ORSWI_+8^&3;Y^6-=\2JG9?\ ,%R7;77?R6WXS[US&_?BENK;^W:;
MJ?>>ZMNU5,=RXC8@S6X3% ,C6C+46*Q]1D:[*&">=O=>Z"_YUKGOC!BOYN7Q
M'^,79^\^ONH\'\5?@)\@]CT6.W3F=XOUCO7M_M#*[3R=%M\Y+)R'&8S)X7;6
M&RG\%CJ8:-GDF:%(HZJIU>Z]T;SMKX,=2==_S-/@STQLC<_=>"ZD^2'QN^:N
M;^46QCWMO#)1=DUGQ\R'4]5MRMW;4U&;DJJW(15^YJR6HJHY8IJJG$F-F9\;
M55-))[KW17NQ.S.W_B'\.?YPO3WQRW=O';^T^E/YD/Q]Z"Z:J)][5\E3U]LK
MY1T/2T^ZH<+N')39"NP5'CFWQN*3'5<M2\."DJ5J:98H:6*!?=>Z,_UQT?W)
M\;?EQ\,\_L7IKJKX3;8WEV#N_K3N?:&?_F$5O:Y[;Q6:VSF*XI3[7S=!C#N;
ML7"9BBQ^6AR<9J,J,='ETEE:FEDC;W7NCM_SC^_NP.D/@QV%MGHVAS&<^3?R
MBR^ ^(WQBVSMEJ'^*5F\>^FEQ<=3CQDJJBH1-@<*,SF6DJ:J*E@BQSS5<U/2
MQS3Q^Z]U4QM+>/<GPI^9O\N;M'/?R]NU_@]\6?\ 1-MK^5GW+N[?_;74F_<;
M64>9:GGZ;K*F/86^-S9&DJL1NZDR%"U55X^.G9-Q3B3(1RF."K]U[H9.P.H?
MF1VW_.K^<5'\0OF5M/X>Y'"_#3X)5.^<ON;XMXWY-MG(*O*]HK04U/!DMS[<
MBPXHI$JGD=14/4>6-;PB$^7W7NC/?(?HKYT;4_E\_(KK7O#^9EU1O3NSLW=?
M6>!ZH[DS_6U#\"L.E-EL_@Z>IZZERF!W#G<C25W8L2U^ ILMCZM,M23Y>%L;
M3R54$0E]U[H*?@%#M3HKYRQ=,;U^*O>?\OWN;M/XY[IS6(Z1VG\A,/W_ -$]
MBP=5Y';Z9G=V$,+2YG$[PVV<M048FJL9M^6NQU?**VFR$L%-)3^Z]T>OYE"C
M[8^27P(^+,CX2MH,OV_N'Y>=CX*O@>OFDV[\.J:DK\/-%%'*BPF'M'</7,RS
M3H\1%/(B*9BA7W7NCF]W[IV'L;I?MW>O:=+D:WK':'6._=S]CTF'P];N*KDP
M.!Q5559A*;'XR.7)5\[8Z*I$=/21/53M:*G1YF13[KW5$'6WQI^7?0?Q6VCV
MI_+0_F(=?=Z?".DZ8I=Z=1?%GYS]3XG?FVH]B)C(ZZ@V_B>S]K-AMU8O'4N"
M1L?$<O2YY*>)8_N%+PU#5'NO=!%\BOF;N[YPR?R@=B?&SXA]A=X;>W%UUU=_
M-.[_ /C+L3<.Q]E38G:NR**"GZSPM?D-YY[;.W8,;+V)6PU]*@JEDKX=L,:2
MEFIQ4_;^Z]TJ/AOVSVQU7WM_-!^)G>?QRWI\1\'\C.ONR_Y@7Q7ZE[#WILG>
MU0(]X8QL+VW1T-?L7<.YL+)"N\XZ3.BG_B,55$<[4M)0Q1!*FJ]U[I%_RO?B
MI_-HW=_+D^#FYNIOYM_6G3W66<^+/261V)U=5_RV=N]D38'%U& H31XR;/UG
M8='4YB>FATK)5O1TYG?4X@A4B-?=>Z/+_,OZF[A[0["^%&T=KUG3ORG.QL7V
MSNSN'X$]C=^_[+-6]J14E#@,?!OO%04,=:F4&Q*R6N_W%9*!L M7GJ*>HJ::
MLHJ"8^Z]T)G\I#=?7<O6OR ZBV;M;Y.]/;CZ0^065VYV'\7?D]V!B>UZGJVN
MW;@L)GJ/:NT-Q8>KRT%?L6;&Y"ER>+C?<&2>D:OJ*:.2FIHZ>CI_=>Z!KKGI
M38OST^</\R&D^6U-N7?F*^+O;G4/2?Q\ZDJ]WYO:.*VSM[/==;;W3)NZ@H,5
MDZ-),_N3/9O,A,TP-5%#CXJ:DE@%/(@]U[JKON>EB[[_ )5WQ[@[4W+N/N&/
MH#^=/LCXI]4=JYK>>;JLCG=C=>?)NGV/BJ_(93^(+/FZ^JVYBJ.G?)SR25+2
M0FH65*QII6]U[K90^6.'I>K_ ("?); ;%GR^"HNO/A_W)A]G5*Y^NR%?11;2
MV7DH<?(,I5U,^3GJZ=*>$_=35<E4\B^:29Y27/NO=4<5/QXPGQ\^*/\ )Z^8
MVT-Y]D5WRQW9\@?Y76R.Y.\<[V/N/+5V\\+\K<KM;:N]L'EZ&IS,^-. JJ/<
M$SX_&&FDI,4U-2?91QO")3[KW0R?'+XX=7?//J7YI_)/Y=;GWZO=U!\HOFOU
M-@]\0]G[DZ[JNG=O]#;GS.W-L4FTXL3EZ1-L34. QF-S5550*M1D9ZMZJJEJ
M(I4!]U[HJ?PC ^4GSH_DT_)_N[&UV6[K[?\ Y//9/=>_]PIG<QAUR.XMHY[J
M6GQN8:BCKTID6H@<U$D"0BCJGF\LL,OH(]U[J9U]LCO?YKGYQ=R=G_'67L_>
MNW_EM\N.D]C=Y57SRS7QNRW4&&Z.W#6X#;]+L_"T6,E3:-7B\1CL;F:G(Q5U
M-/EZBJ>MJW^VG0>_=>ZV%/@INKLG>_PV^,NZ>XM^=;=I]IY?IC8<V_NSNG]V
MT>^]K[BRD-#%%5YW!YC'LU#D<?EI8S51SP6B?RG0JCTCW7NC7^_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NB ?S
M8O\ MUE_,L_\4 ^9'_ONMQ^_=>ZK:_X2J?\ ;CSXG?\ AS?(_P#]^3NOW[KW
M6Q)[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[K2P_P"%$G_;[C_A.?\ ^+6]7_\ OV^N??NO=;I_OW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z)U\
MD_@;\:_E=N3;.^.UMN[\QO8>T<2^V\)V7T[W9O3X^;D7$3U/W<N$J<[L7/[>
MR=?A9:DO*:*JJ9J=)G:>&..HM*/=>Z:]Q_RZ?AMN3HS8_P =&Z7Q^V^L^K\_
MF-X=7G8.Y\WU[G]MYW<39"3([AP>[L+DJ'=6-W!DI<ME'KLC%F15U[5=3][+
M4"HF#^Z]U'V]_+B^'6W>C>Q?CQ%U369GKWN/*[6W!W)7[I[&W1NC<^[LELML
M8^,R.Y-ZUV:FW?EJNC.&QJQ//FV$4,(IHU2F+0GW7NC%[CZ1ZPW;V_U=WUN#
M;'\0[8Z8VKVCLGK7=?\ &LA2_P -QG=#X"3<M-]C!5QXVL_B3[7P1\E51SRT
M_P!M:ED@$U1Y?=>Z1:_$KXY-1?)+%U_5.WL_A?E]N%]T_)';^[):O>.-W56R
M[=Q.TW:MQN5J:RAIX'V_@\72-34E/3TS>#SF(U,DLTGNO= O\??Y:?Q"^,_9
M,';W6^R-[Y;L7#X7+;6V-N;M[O#>_?4NTL/G1$E9A]F)O;<.>AVECJN*""*>
M/%QTK5$$4-/.\L$$,<?NO=&([(^._3_;O8G1?:W8NTY=R;X^->[=S;[Z7R,N
MYLOCZ7$9C=V%J]O5N1DQ5'7T^)RU5_"*^M@IVR-#5_9F:2:C\$[&7W[KW7OD
M-\=NF_E9U)N?HSOS9<6_>L-WRX*JS6WSF\EMB85&U\A2Y;&5E%E<-68[+XO(
M8_)45)4TU715]/4P31(\4JD>_=>Z*]WC_*R^%/R)[;R'>_9^Q>UG[9S&R]I=
M>YO>?7ORN[;Z6FK\1L1JQ\129"#9>^=OT=>:)\C7,DU13R3EIY&>5BQ/OW7N
MG+8'\L;X8]<[$[<ZQQO7O8&[]@=Z83";>[-VIW1\D.S?D'25M-MR>6JH?M$W
MYO'<APU1354QF6HQK4=1YHX)3*9*:G:+W7NE+\<OY?7Q=^+6\:[L?K#:N^LQ
MV56;=R6RZ?LCN?N[>WR'W!08'*U5+6SX#$9C?FX=Q5^'PDM50T4LM'13P0SR
MT\,U0LTT:R>_=>Z,B.K-F#MB3NQL?42]AMUY#U9!E9LA-)%!A4R4F6EIZ>E+
M_;PR5=<T+U$JQB284U*CL5@C ]U[I?RQ13Q203QQS0S1O%-#*@D5UD!#*RD$
M,K D$$6(X/OW7NJJ)/Y)G\MUMRY[+TW1^YL3M#=67K]P;HZ&P/?'8& ZNR-=
ME6E>JGJ^L*/=$&Q)8JDS2F:D_@(H)7=Y)*5I9)';W7NCR;'^,W1W6W<?8O?N
MR=B4^![6[4V-U?UEO'<4.<R=5 VWNF4R";:P^,Q-16S8; 8_'#*U[&'%X^C2
MIDE\M6)Y4C=/=>Z;^V_BET'WEV)U;VSV=L,YWL?I?%=F8'KC=N/W5FMIU5#C
MNX\6,/N;&SG#Y+'QY3&9:@2)9:2O2IIEFA@JXHHZN"&>/W7NB+[>_D;_ ,N+
M:."P^U]J;!^1^V-L[>QU'A\!MW;W\PGY$86@H:3'HL5/2T=)3=JQ4]-301JJ
M1Q1QJB* JJ  /?NO=&?[3_E_?%WN3JKJ?J'>^T]\RX3HG&QXOIO>F"[PWQMC
M>^W46CBH))*#L''[BI]\//64D$,==)49^=LBJ*,A]U[]U[H5/CO\8>D/BIL[
M*[(Z-V8^U<7N3<E3O3>.6RVY,MOO.9_-UM+2T4V:W%N/<%=E,_N#+S4=#10-
M69#)5$YA@AB#B.)%7W7N@F^0'\OCXM_)7?\ C^U>Q=I[WPW95-C,)MW+[ZZ>
M[HWGT%E,YAMO3U-128+<M9LG/X"7<>%IY:RK,5+D6J8X///]OXO-+K]U[I;Y
M_P"&/QAW'TMU;\=*SJ#;N-Z1Z5W7U1O;JWKC:=77[&Q^&R?2&5I,YMBHIEPM
M7CY67&Y6AIJAH999(*MU85L=0DDJO[KW0Y[\V1M?LS8^\^M][XS^-[+[!VIN
M+9&[\-][48W[O%[KHYJ#(4OW%)+3U=/]Q25$J>2&>.5-6J.1'"L/=>Z"G</Q
M:Z(W5UATYTUGMB_?];= [KZ+WOU)MS^\^9I?X3E/C5D,;E-DU7WD.0CKZ_\
M@M=B,=+XZVJJ(JSQ:*^.JCDE1_=>Z+]W#_*\^%7>G9&Y>S^P.L=QG,=A222]
MO;9V=W#O/K?:^^W?'Q8H/OS:.WL_C-L[QD_AT$%,[Y7%53STT4=-4M-3(L0]
MU[H8NQ?AE\;>T^R.@>W-U]<FG[#^+[RITCN+9>[\[UFV(HYY<=.^'FI]MY/$
MTF8V[)-B,7(V'R5/68MFI8=5(0MC[KW0(=V_RK?A#\@NQMS=G=B=8;HASG8D
MM)+W%@^O^Z-[=3;=W]]A31T4(W_MC:^X<1M_>@%%%'2R?Q;&U1J:-1159GH_
MV/?NO='[P>#PVV<+A]M[<Q.-P.WMO8O'X/ X+#T4>-HZ*BQ,204M)2TT*I#3
MTU-!&D<4:(J(BJJ@* /?NO=.GOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[H@'\V+_MUE_,L_P#% /F1_P"^ZW'[
M]U[JMK_A*I_VX\^)W_AS?(__ -^3NOW[KW6Q)[]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K2P_X42?]
MON/^$Y__ (M;U?\ ^_;ZY]^Z]UNG^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[H@'\V+_MUE_,L_\4 ^9'_ONMQ^_=>ZK:_X2J?]N//B=_X<WR/_
M /?D[K]^Z]UL2>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>ZTL/^%$G_ &^X_P"$Y_\ XM;U?_[]OKGW
M[KW6Z?[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NJSOD]_,=K.@OE-M#X?=<?$/Y%?*SN7=G0&8^2C8KI+);'P\%!MC [
MBI]KU=15S[SW;M>(RQ96MQZ>.%Y6*U", 0LA3W7NN'6G\SO86[L3\E\3V5T/
MW[\<^]?BGT=6_(SLGXZ]RXC PYZKV>(<Y+0YS;V3P.>SFV<W05\V R%)Y(<U
MJIJQ/!5I"&C=_=>Z/?T_V3B>YNI.K>X,#0Y'%X/M;KG9'9.&QF7$:U=/2;ZQ
ME+E*>"J$,DL(J(8:I$D\<KIK#:69;$^Z]T(OOW7N@Z[@[)Q/3/4G:7<&>H<C
ME,'U3USO?LG,XS$"-JNHI-BXRJRE1!2B:2*$U$T-*Z1^25$UE=3*MR/=>Z]T
M_P!DXGN;J3JWN# T.1Q>#[6ZYV1V3AL9EQ&M73TF^L92Y2G@JA#)+"*B&&J1
M)/'*Z:PVEF6Q/NO=!S\B/DGM3XW_ .@O^]6"W#G/]/7R+ZR^-FV_[OK3-]GE
MNTOOOLZZN^YG@MCJ?[&3S&+R3>I=$3\V]U[HQ?OW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[H-^H]]YKLOKW;^]MQ=;;TZBS&:_BWWG7G
M82T29C'_ ,-KJFDC^\&.JZZC'W<4"5,7CJG_ &)H]>E]2+[KW0D>_=>Z][]U
M[KWOW7N@+^-7?&WODYTGLGOC9^/J*#9?8\><S&R9JBN@R/\ $,+2Y.MH\3FH
M9J8M"]'GL?34^1I=+M_DU5#J.K5;W7NAT]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=$ _FQ?]NLOYEG_ (H!\R/_ 'W6X_?NO=5M?\)5/^W'GQ._
M\.;Y'_\ OR=U^_=>ZV)/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=:6'_"B3_M]Q_PG/_\ %K>K_P#W
M[?7/OW7NMT_W[KW7O?NO=>]^Z]U[W[KW7O?NO=:\7\[_ +W[+VIG>H>H-H[L
MS^U=KYG;68WIN>';^5FQ#9*;[S[.D@JWIWCDEIJ003.(F<Q-)(LC(7BB98&]
MY-[N;5X+6)V1&1I'TL5UG5I -*5 H33A4UX@==5/[N;VTV??+;=-^O[:"YN(
M;B*TMS/$DHMU\+Q79 X8*[ZU4N!J"J5! =@=?W_2)V!_SW6\?_0FK?\ K_[@
MS]XW'^_9/][;_/UU$_JGM7_*%:?]D\/_ $!U[_2)V!_SW6\?_0FK?^O_ +]^
M\;C_ '[)_O;?Y^O?U3VK_E"M/^R>'_H#JQ?^5O\ (/MS;7R_ZPV:F^=SY39W
M9.0R>V=V[8S&<J<E1U"28^KEIZD0SR21QU='4PPR1S(JR:0\.OQ2R*P_]M=^
MNX-UAA\1VCE+(Z,Q93V,0:$FA! H>/$<">L3_OG^UFQ;MR'N.X&SMX[JP2.X
MMKB*&..5")XD=-2*I,<B.RLA)6NEZ:D4C<(]Y6]<%^O>_=>ZUT_E/UWWOV9_
M/VZIP/QZ^1G^RQ[TI/Y/_:F7R>_?]$.&[I^[Q<'=&U(9L1_"\Y/3TE/]Q5U%
M%4?=(YE3[7PJNB>0CW7NB_\ 8NW^U_CM\HOY@76/RK[:VM\Q/D#\E?Y0'R1W
MUUU\D<)U]!TOD]G]??'Z.HH4Z\K]G8[(Y3$PXS)9[=M;F4S<$\,V1R354$U.
MD%/10TONO=+RER'7_<@^!WQ]I>A_D)\W.PM@_P KSX]]B[@^,^,[;P_373VV
M:+?6+IZ;"[RWO/ELOBSGMRYFNP53C,3#3XW/R8FFIZNM6AHC4_<5'NO=%1Z
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M&#_[&O?NO=>_X:V_X4O_ />]38__ **&#_[&O?NO=>_X:V_X4O\ _>]38_\
MZ*&#_P"QKW[KW7O^&MO^%+__ 'O4V/\ ^BA@_P#L:]^Z]U[_ (:V_P"%+_\
MWO4V/_Z*&#_[&O?NO=>_X:V_X4O_ />]38__ **&#_[&O?NO=>_X:V_X4O\
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M4V/_ .BA@_\ L:]^Z]U[_AK;_A2__P![U-C_ /HH8/\ [&O?NO=>_P"&MO\
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M .QKW[KW7O\ AK;_ (4O_P#>]38__HH8/_L:]^Z]U[_AK;_A2_\ ][U-C_\
MHH8/_L:]^Z]U[_AK;_A2_P#][U-C_P#HH8/_ +&O?NO=>_X:V_X4O_\ >]38
M_P#Z*&#_ .QKW[KW7O\ AK;_ (4O_P#>]38__HH8/_L:]^Z]U[_AK;_A2_\
M][U-C_\ HH8/_L:]^Z]U[_AK;_A2_P#][U-C_P#HH8/_ +&O?NO=>_X:V_X4
MO_\ >]38_P#Z*&#_ .QKW[KW7O\ AK;_ (4O_P#>]38__HH8/_L:]^Z]U[_A
MK;_A2_\ ][U-C_\ HH8/_L:]^Z]U[_AK;_A2_P#][U-C_P#HH8/_ +&O?NO=
M>_X:V_X4O_\ >]38_P#Z*&#_ .QKW[KW7O\ AK;_ (4O_P#>]38__HH8/_L:
M]^Z]U[_AK;_A2_\ ][U-C_\ HH8/_L:]^Z]U[_AK;_A2_P#][U-C_P#HH8/_
M +&O?NO=>_X:V_X4O_\ >]38_P#Z*&#_ .QKW[KW7O\ AK;_ (4O_P#>]38_
M_HH8/_L:]^Z]U[_AK;_A2_\ ][U-C_\ HH8/_L:]^Z]U[_AK;_A2_P#][U-C
M_P#HH8/_ +&O?NO=>_X:V_X4O_\ >]38_P#Z*&#_ .QKW[KW7O\ AK;_ (4O
M_P#>]38__HH8/_L:]^Z]U[_AK;_A2_\ ][U-C_\ HH8/_L:]^Z]U[_AK;_A2
M_P#][U-C_P#HH8/_ +&O?NO=>_X:V_X4O_\ >]38_P#Z*&#_ .QKW[KW7O\
MAK;_ (4O_P#>]38__HH8/_L:]^Z]U[_AK;_A2_\ ][U-C_\ HH8/_L:]^Z]U
M[_AK;_A2_P#][U-C_P#HH8/_ +&O?NO=>_X:V_X4O_\ >]38_P#Z*&#_ .QK
MW[KW7O\ AK;_ (4O_P#>]38__HH8/_L:]^Z]U[_AK;_A2_\ ][U-C_\ HH8/
M_L:]^Z]U[_AK;_A2_P#][U-C_P#HH8/_ +&O?NO=>_X:V_X4O_\ >]38_P#Z
M*&#_ .QKW[KW7O\ AK;_ (4O_P#>]38__HH8/_L:]^Z]U[_AK;_A2_\ ][U-
MC_\ HH8/_L:]^Z]U[_AK;_A2_P#][U-C_P#HH8/_ +&O?NO=>_X:V_X4O_\
M>]38_P#Z*&#_ .QKW[KW7O\ AK;_ (4O_P#>]38__HH8/_L:]^Z]U[_AK;_A
M2_\ ][U-C_\ HH8/_L:]^Z]U[_AK;_A2_P#][U-C_P#HH8/_ +&O?NO=>_X:
MV_X4O_\ >]38_P#Z*&#_ .QKW[KW7O\ AK;_ (4O_P#>]38__HH8/_L:]^Z]
MU[_AK;_A2_\ ][U-C_\ HH8/_L:]^Z]U[_AK;_A2_P#][U-C_P#HH8/_ +&O
M?NO=>_X:V_X4O_\ >]38_P#Z*&#_ .QKW[KW7O\ AK;_ (4O_P#>]38__HH8
M/_L:]^Z]U[_AK;_A2_\ ][U-C_\ HH8/_L:]^Z]U[_AK;_A2_P#][U-C_P#H
MH8/_ +&O?NO=>_X:V_X4O_\ >]38_P#Z*&#_ .QKW[KW7O\ AK;_ (4O_P#>
M]38__HH8/_L:]^Z]U[_AK;_A2_\ ][U-C_\ HH8/_L:]^Z]U[_AK;_A2_P#]
M[U-C_P#HH8/_ +&O?NO=>_X:V_X4O_\ >]38_P#Z*&#_ .QKW[KW7O\ AK;_
M (4O_P#>]38__HH8/_L:]^Z]U5]W%_+V_F*[8_G;?R/-I_S%/GKA_EGF,_W;
MOCMGJW<& V4FWVP<'Q1DPG8&0QDL8Q^-65-Q5.-H*?R6=H5#N.0%/NO=?0;]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW12_EE\,.F_F-MG"8+L^'.8W*[6JJJJVMO'
M:=;#09*A&0\7W4"M4T]7334M7X(?+'+3/RBM&T<@U^POS1RC:<V1JER&#(24
MD0@.M:5&0P(-!4$?90YZG'V/^\%O_L'>37.S&&2.Y55N;6Y1GMYM&K0Q$;Q.
MKIK;2RN/B(8,IIU7Y_PQ5\:_^?K]X_\ GPP'_P!8O8$_UEMO_P!_W'[8O^M?
M64?_ "<GYO\ ^C;L_P#SCO?^VSKW_#%7QK_Y^OWC_P"?# ?_ %B]^_UEMO\
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M;B^+WPBZDZ/RF;IZWN"'8>3W3VWOM*!*-LKV+VK+5;AWCN":-$%WKMV9;)5
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M$T./Q^%A>HJZVLJIV2&GIJ:".2221W"HBEF( ]^Z]U4!M+_A0!_*YWCNW:6
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M=7<N!_F4?S1_YH7P:[?^=E=A".I.I*'Y,;6J]@=#XO,*Q?";)QC9B:GDW)-
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M+TM9!!/"9*=C%-&DJ:716'NO="!!!!2P0TU-#%3TU/%'!3T\$8B1$B 5$1%
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MTDN+HMOT>WLYONEBGQ[)E0^7W-OXSU4E+#YZRGI:V#T_=&-_=>ZJ3^1W;_\
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M-.VXYZ62MI*.*AHF$./7$K65M>V1R50M-1Q^Z]TT_P T/^6?\\^K?YG75_\
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KZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>timage_004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 timage_004.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
M     ! !+     $  0$L     0 !_^X $T%D;V)E &0      04  DE$_]L
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MZ]U[W[KW7O?NO=>]^Z]TL=H516HJ*,GT2Q^9!^!)$0K6'^*OS_P7W[KW2_\
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T$N<).6KK
MDG]\CG^@50!_O'OW7NFGW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UF@-G:W'[-2/]O3R@^_
M=>Z5F\6/GHE_ AE8?Z[.H/\ T*/?NO=(WW[KW7O?NO=>]^Z]T57Y(_-WXJ_$
M&?:U/\ENY-O=0'>\.3FVE4;IH-QB@SXPSTJ9:''9/'86OIWFIOOX&G@\HD19
MXW9 LB$NQPO-\ )^S/26ZO8;( S.J \"QH#^WHS.'R^*W#B,7G\%D:+,83.8
MZAR^'RV-J8JS'93%9*FBK<?D:"K@9TEAGAF26*1&*LK!@2#[:Z4@UZ<??NM]
M%*VI\[/B1OOOW.?%S9/>&U=W=^[9KL[CMR=:[:I\]F\QM^KVPO\ OXTS57C<
M/4T5*M"]H*N6>J1(IR('83$1ETPNJZR#0\#Y'I*E]#)(85=2XXJ#5A]H\N/1
M:_\ AZ_^5;_WFKU-_P D[L_^QKV[]%-_ W[#TC_?UE_O^+_>U_S]>_X>O_E6
M_P#>:O4W_).[/_L:]^^BF_@;]AZ]^_K+_?\ %_O:_P"?IYVY_.-_ED;OW#@=
MI[9^876&:W'N?,XO;NW\/11;KDK<MF\U708W%8VDC.W%#2SSU,<48N+LX'O1
MLY5%2C?LZLF]6DC!5FC))  #BI)P!QZ'/Y'?/CX>_$7<.WMJ?)+OG9O4>X=U
MX:;<.W<9N=,WY\MAJ>NEQL]?2OC<3D$*)/"T;!F# CZ6();C@>;X%)IQH*]*
M+K<(+*@FD5*\-1 K3TKT7/\ X>O_ )5O_>:O4W_).[/_ +&O;OT4W\#?L/27
M]_67^_XO][7_ #]>_P"'K_Y5O_>:O4W_ "3NS_[&O?OHIOX&_8>O?OZR_P!_
MQ?[VO^?JS#;FX<-NW;V"W7MROBRNWMS8;%[AP63@65(,CALU0P9+%U\*3QQ.
M$F@J4D4.JL W(!X]I3CHU!KD=//OW6^O>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NBV;2^8'QIWUW[O+XM[2[<VWF_D#U[C:W+[TZMI
M8LNFX]O8S'G""KKJ[[C&PT_C3^\=#ZDG?4*J,K<'VX865=9!H>!\NDRWD3R&
M$.I=14H"-0&,D?F/V]>[P^8'QI^-NZ^L]C=X]N;;ZYW=W)DIL1U?@<W%EY:[
M>F3@R6%P\U#AEQN-KE:1:G<5##I=D]52EN#<>2%I 2H) XT\NO3WD5LRK(ZJ
M7-%!(!8X%!Z\1^WH=MS[GVYLK;F=WAO#.XG;&U=L8FOSVX]QYZOIL5A<'A<5
M325N2RN5R5;)#%!3P10M)++(RJJJ23;W0"N!TH9@HJ< <3U5;UY_/-_EC]K=
MP;=Z-Z]^0E?NG?V[=UKLS;<.,ZB[FEP>8SLDTM/"*7<)V"M)]H[Q$C(/(M*(
M_P!]YEIP90L?;YHUULM!]H_S]$D',=E<RB&.34Y)  5Z$BOGII3'&M.CR?''
MY;?''Y=;>W!NSXV]L;<[;VYM7,Q;=W!F-LQY5:+&9N:AAR4>-GDRF.QY,O@J
M(Y2$#65U)M<>TTD+0FC C[>C.VO(KU2T3JX!H2I!%>-,?;T8OVWTIZ][]U[K
MWOW7NO>_=>Z][]U[KWOW7NFC"9_!;EH3E-N9G%Y_&"NRF,_B6&KZ7)X\Y'"9
M*KPN:H5K:*6>,S4=;05%'51ABT4\$D,@62-U'J4ZT#7AT ?3GS ^-/R![ [/
MZKZ:[<VWO_L'I?)56([3VOA8LN*_9.3H\WD=N5-#F7KL;21+(M;B*JGTQR27
M:![7 )]N/"T8!8$ \"?/I/#>17+,D;JQ0T8 @E34BA].!_9T9/VWTIZ][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z:,SG\%MVGI:O<&9Q>$I:[*8K!T-1EJ^
MEQ\5;F\]D*?$X+"T;U<L0EJZVKJXJ6CIH]4DTTJ11JSLJGU*]:)IQZ=_?NM]
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW1;,%\P/C3N;Y#;E^*&![<VWE/D3L[&R9
M?='5--%ESN/"8R+&8?,O75S/C4IEC^US]%*&%0;BI0"[&WMPPL%UD'2>!\ND
MRWD3R&$.I=14I4:@,9(_,?MZ,G[;Z4]>]^Z]U[W[KW7O?NO=>]^Z]TCNPNP-
MF]4;%W=V9V)GZ/:NQ-A;>RN[-X;ER(G:@P.W,'1RY#+Y:M%+#42>*"&!Y)-"
M.=*FP/NRJ7-!DG@.J22+"I=B  "23P &23TENC^]NH_DEUOA>WNC=]8CLCK7
M<51EZ7";OP2UJXO)5&!RM9@\O'3_ ,0I**4F"KQ\T#DQ@:HS:XY][>-HC1@0
M?0]4@N$NE#QL&4UHP-0:&G'[1TCNFOEM\<?D)O;M7KGICMC;?8&]^C\S_=[M
MC;F%3*+7[&S?\6SF"_AN9^^QU'&)/N]M5\%HGD&JE?FP!.WA:, L" >%?/JD
M-Y%<LRQNK%#1@""5.10^G _LZ,7[;Z4]>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T][<8KF:/\ HQF4
M_P"(:GE_XFQ]^Z]T*OOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z"3.?\ %VK_ /EN?^A5]^Z]TU>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NLT'Z
MV_Y8U'_N/+[]U[I5[Q_X$T?_ "PD_P"MGOW7ND=[]U[KWOW7NO>_=>Z(5_,E
M^"6Q/YAWQ6WST%NO['%;H>/^]'4F^:FD%3/L#M##TU2-NYQ2JM(:2<5$N.RL
M,9#2T59.B%9?&Z*+6X-JX<?F/4>G1;NVV)NT#0O3.5:E=+>1'#\_45'GU2A_
MPGM^<>^]LU^_?Y3?RPIZO:??'QJK=R4/4U+N%VCR.5V?MW(RKNKK4U,S,E3/
M@I)_O\++!)(M5AZ@FG'VV/$DB_<[<&DZ?"W'Y$_ZOV]![E7<77587&)(<+@B
MJ"@_E44X54@BN3U9!_.C_F/T'\O?XK9*?9V0IY_DEW5%E-@]";?AFIY<IC\M
M44T=-G>S7QLD-8TM+MV+(Q3QJ8)(YJ^>AI7TI.SHEL;7ZI\_",L?E_L_[/1M
MO^[C:8*KF1^V-?,L<5H*D@5K\S05%1T%'\BO^6;5_"+H2O[C[IH*ZK^7/R5@
MHMV=I5^XIYJ_/['VY5RRYC!]=3U55453_?F6NDR6XI]0EGKIQ!,TBT,#^[[A
M=_4M1::5PM/\/3/+>S?NN(O)4S2T:0DU(.33B>%34^9KFE*&2_X90_E6_P#>
M%74W_)6[/_LE]L_6S?QM^T]+?W#9?[XB_P!X7_-UK$]2_!GXEYW_ (4;=U?$
MK+]';0KOCCMS:N5KL)U+,V8&V<=5P] ["W1%/"4RB5)*Y#*U%4 U0PURGBU@
M#>6X<6BN&.HG)KGBW0-M=MMWWF:$QH4$8(32-(.F,\/S/[>MH_;G\G+^61M#
M<.!W9MGX>]887<>V,SB]Q;?S%%+NN.MQ.;PM=!DL5DJ20[C8++!/31RQFQLR
M ^R<WDK"A=OV]#1-EM(V#+#&""""$%01D'AUK_?\*%-I;<W]_-2_E8;%WCB:
M;/;1WKD^M]I;IP5;Y?L\UMS<?R,Q&'SF)J_#)$_BJ::LEADT.K:7-B#S[,]K
M)6*4CB!_D;H*\V1K+>6:L 07H0>!!>,$=7T?\,H?RK?^\*NIO^2MV?\ V2^R
MWZV;^-OVGH4?N&R_WQ%_O"_YNO?\,H?RK?\ O"KJ;_DK=G_V2^_?6S?QM^T]
M>_<-E_OB+_>%_P W5F&W-O8;:6WL%M3;E!%BMO;9PV+V]@L9 TKP8[#86A@Q
MN+H(7GDE<I#!3)&I=F8A>23S[2G/1J!3 Z>??NM]%AA^:'Q7E[=[5Z'D[RV)
M0]L=&[*K>Q^WMHY?(3867KS8F-@VS59#=FY\MEZ:AH*:A@BWEC))9VJM*I6(
MQLH8J[X+A0U#0X!I@G_4.DHO83(T6M=:C4RU%5&,D>0R/V]%'PO\[W^53N#L
M4=6XSYE]=G=+UZ8V.KK\%V)A]BSU<CP1QK3]IYC9E!M>1&:H4+-'F&C)O9O2
MUGVL)E744-/Y_LX_RZ+X^8K*63PEF0M^>DUIP:FDG/ 'HUWR:^;WQ/\ AOMK
M&;K^2W>6RNJ\7G(9JC;]-E)Z_,[DW)3TX0U%1MG9NUJ#.YC)1Q^5/(]#0U"K
MK6Y%Q=B*!YS1 2>E]Y?PV"ZYG5!\SD^>!Q)^0!/29^*W\PWX7?-DY.'XP_(#
M9_9^5PM-)6Y7;$=+N+:.]:''1U/V;Y6?8N_<)M;,BC\I5/N_L?"2Z6?UK>TU
MM);_ !J1_@_:,=-V.Z6^Y"L#JU.(%0P\L@@$</,9Z.5--#30RU%1+%!3P123
M3SS2+%###$I>6665RJJJJI+,2  +GVQTOZJJ[*_G@?RJNIMW5&Q]W_,;8DVX
M*2IEHZK^Y&V.S>T<'2U4%4U'/!4[MZPV-O#$QLDB$.&K1I U&R\^UB6$T@J%
M-/G0?X:5Z);CF*RM7T/,M:TQ5J&M,E00/SIT??I'Y!]'_)39D/8?0?:NQNV]
MF2SO2/GMC;AH,[345='?R8[*PTLK3454H%VI:N.&4 ABEB"4SQM$:,"#Z''1
MI!<1W2ZXV5E/FI!'\NEYO/>NS^N=JY_?78&ZMN['V5M7&U&9W-N[=N9QVWMM
M;?Q-(NNJR69S>6J*2FIH(Q^J6:1%']?=54L:#)/D.KNZQ*68@ "I)-  /,D\
M.JU=J_SMOY5V\^QTZJP/S)Z[;=LM?_#*>?+8/L+;6RJNM,T%/'#1=G[EV;B-
MLS^1ZA%B>'+NLG.@MI:RIK"95U%#3^?[./13'S#92R>$LR%OSTFM,!B-).>
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M8U1"K6(QXU%7#"X4-0T. :8)_P!0Z3B]A:1H@ZZU%66HJHQDCR&1^WHFL?\
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MD43K*ET)<M[,IKK;\R2/V="638;*12AAB (I4(H;\B "#\Z] 9_*(^$/S*^
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MDRTN5O(DE7@ZAA7B*BM#QR.M>C_A6-_V0[\??_%K<+_[Z'MGV:[)_:M_I?\
M*.@AS[_N(G_-9?\ CDG1A>S_ /A0W_+J^)^,V-U3DLYV=W?O+;&SMJ83=]/T
M%M;;.ZL/M7,T&W:"&OQ62W/O#?&P<;45%/+$T%1%C:JO:&56BE".CJK$6V2W
M%6  'D6Q7]@)Z,;[FNSVXZ"Q=A@B,!M/VDE1BE"*U'IU9?\ "G^8Q\2OY@.V
M\OG?C9V7%N+*;9CI)=W[#S^/J=L]A;2CKBR4E3F=KY&TC4TCHT25]&]72-(I
M19RX(]I)[9[8T<4]/0]&VW[I!NBZH'#4XC@P^T&A'#'KY=+7Y>_-KXU_!;K:
M'M+Y*]C46QL!D*\XG;F-AHZW.;LWAF%$328O:FU\3#55=;)$LZ25,B1B&GC8
M25$D4?J]ZA@>X.E!4]7OMPAVU/$F8*M:>9))\@!4G\O+/#JG':O_  J1_EH;
MAW6VW<OA?DWL7$+/41#?FZNK-JUFU'CAJ4@CJEH]D]E[QSGCF1C/&#A@X12'
M1)+1E>VSS 5[3\@<C]M!_/H.Q\[V+N5/B*!7N*=ISY:2S9XY ^=#CJ_?J;MO
MK/O;KW;/:_3V]MO]B=<[RH6R&VMW[8KDR&(RM-%434=0(IE"LDL,]-)!402K
M'+#+$\4J)(C*"QD*&A%"/+H5Q2K.H="&4BH(-01T(ONO3G7O?NO=)O>7_'H;
MJ_\ #;SG_NLJO>QQZT>'6E#_ ,)_?GW\6?@-\$/D7OGY+=D4^THL_P#)2&CV
MCM3%T%9N/?6\ZREZQV@]7#MO:^+CFGDC@$J?<5DYIZ6$R(LT\;21AC_=+=[F
M50@KV_Y3U'7*.Y0[99.\[!1XQ XDDZ$X 5)ZN+^.G_"DG^6W\A.PL5UO59#N
M/HC*9_(8_$X#.]\;,VI@=GY3*9)ZB*GHI=R[$[ [%@QX#Q)&]1ESCJ<-/'^\
M1K*(9]JE@&K!'GI)-/V@?RZ/K#F^SOW$8+(20%\0 !B?FK,!^=.(I7JZ;NKM
M[9_0?3_97>._7R(V+U1L?<?86[)<+1C)Y1=N;6Q51F<K+C:#S0>>404KM'&'
M74; 'GV@C0R,%'$F@^T]".>=;9&D?"JI9CQH *GH/?B3\K.J/FKT3M3Y%=)R
M[AFZXWG6;EH<)+NG#?P#-/-M3<>4VKEC4XO[JL,:BKP\PC)D.I0&L ?=IH6@
M8JW$?Y<]-65['N$0FB-5:M#0C@2#@YXCH,/G1_,(^/7\O#8^R^P_D5-O2GVU
MOS=<^S,%-LO;*[HJOXY!B*O.&*MI!D:!HXVIZ&4K(-8NNDV)%[6]L]R2$%2!
M7C3IG<=SAVI!).2%)T@@$YH3Y ^AZ$/Y2_+KJ+X??'G._)SN.3<L'6&W/[H?
MQ27;>$&=ST?]]\[B-NX3Q8A:REUWJ<W LMI?0I9N0/=886G;0O'/\NG;V]CV
M^(S2FBBE30GB0!@?,]5T_(G_ (4"_P NGXX[9ZWS&;W?O_L7<W9G6O77;.-Z
MQZIVIB]P;]VUL_M+:^'WGM)M^#.[HVOAL/7R8S.TU9+BJK,+6+#*DH@:.6!Y
M5<.V2S$@"E"14\*BH^=>'ET47O--G9*K%BQ958(@JU& (K4@#!!HQ!IT-/P]
M_G)? _YI;)[&WGL#LZHZ[?J':D^^^SMJ]VTN+V!N;9NR*-":_=]<T>;S>,J<
M=2M:*KJL=DJU*>22))C&9X/(U/926Y 8<304S7I5MV^VVYHSQO32*N&[2@I6
MIKB@]02/GT2;.?\ "GW^61A^Q3L:F/R#W#M]*W[.7MK!]68ANNHT4RAZX4N6
MWQB=S20 Q :H=N2,VM2B,MR%*[1,RUH!\B<_YOY]%DG.=C')X>IB/-PM4''Y
MZCP\E(SQZO?ZC[<ZW[XZWVAV]U#N_$;\ZXWYB(LYM7=6#E>6@RE!*\D+$+-'
M#+%-%+#)!4TT\<<L,L;Q2HDB,H+64H:'!'$=">*59U#H05(J".!'57OS&_GJ
M_P O7X5;VSO5^_-_[J[)[3VLPAW-U[TIM:/>66V_6EWC?$YG<&7R^UL!3U\9
MC/W&/DS"U,''FBCU)J5V^WRW(U*,>I-/]GHEW'F2TVQBDCDN!4HH+'[*\ ?D
M2/V= 3T+_P *5?Y9W=^\*'9N9SO;G0%3E*V#'XW/]];*VY@=GSU-2K^,UVZ-
MA[Z[%I,;"&4))5Y9Z"!"P9Y50,P=EVF:(5H&_P!*:_R(!Z26?.%E>'26:,UH
M/$  _:"RC\R.KK.Z>X-F]"]/=D]Y[[ER!V'U5L;<78FZI\'1KE<E_=K:^*J,
MUE)L90B> 5$O@I7:.,2+K-@#S[01H9&"CB30?:>A)/.MLC2/A54LQXT %3U5
MCV%_/P_EU=;?'GJSY$YK?F],ACNZ<9O',];]6X/:$=;W'G,7L?>FZ>O\MDJ[
M:L^9HZ/%TTV5V=6TU#59?)T,-04O'(=$OC5IMTKN4ID4J:X%:'C^?1+/S-9P
M0K.7)5]6@ '4VDD&@-*9%*F@^?4'X<?S^?Y?'S/[%Q'4FUMP]C=/=D;GRL>$
MV5M?OC:V"VJ=[96H-%%0XW;NX-H[OW[B#554M9X*.BK,A25,\L;1PPNS1>3=
MQMLML-1H1YD9I^T ]4VSFBTW1M"%E<\%< %N' @L/RK7!Q3JZ[V@Z$77O?NO
M=9H/UM_RQJ/_ ''E]^Z]TJ]X_P# FC_Y82?];/?NO=([W[KW7O?NO=>]^Z]U
M[W[KW1"OYIG_ &[:^=G_ (JEWE_[[W.^U-G_ &J?Z9?\/19O7^X<_P#S1D_X
MX>B&_P#";'_MU%U'_P")%[K_ /?C9KVIW;^W/V#_  #HLY/_ .2?']K_ /5Q
MNKY_9;T)NO>_=>ZT\.C_ /N+!^0O_AE9G_X&+K/V=S?[A)_IO\K= 2S_ .2[
M/_S3'_'(NMP_V2=#OK3P_GR?]O?_ .41_P"'KTY_\$_M_P!G>V?V,W^E_P"?
M6Z G-/\ N=9?\U!_U<CZW#_9)T.^O>_=>Z][]U[KWOW7NM2/XS_]Q4OS,_\
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MHX''4,-4Z22UF2VYV9'EHHH?*JIC:M2[%%+;O?UK>-UX+@_;2G^3_!UK8?\
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M7G7,+3C(15$NJ>EG?3(H$ND:%07;1,P\$$"F:UX_F3T(MGBNXHR+QU=]6"H
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M08^?<>@QN>WQS;S''2BRH'D X/IU-0CA0^&M1Y\>.>MLKY6?%?HGLWX;=R=
M93JSK^DZY?J+>-#MO;=!M+"X_"[,R6+VM5/M?.[6QN.I*2.@JL54XZDJ:&:D
M$+Q/2QE&&D>R2*5D<,":UX]#R[M([F%HG4%2I%*8^5/2G$4X'AU3!_PEXR^[
M-X_RPNV-L-N>KQ\FW/D]V[LO8N36EIJI]FT.5ZGZ<W3')0TK" 3"'+[PK\B$
MF<ZI)V4L$TA3'>5"S ^J@G]I'^3H+\CR-)9%2?AE95^0*JW^%B?SZ&SX<_&3
M^77_ "5&[*?O7Y@],;B[][:WK6;IF[,[PS.R-H=Q0[0EI\?]CMBAP]?NO<>3
MEC%94561R65@$'WDU<C5"*L$&EF:67<*:5-%%**#0?ZO\G1A8V=IRX&URKJD
M8L7E90[<,5-":5J?F>JHO^% 7\P'^5?\N_C8VR^G-][8[>^4^R]\[2RNQ=Z[
M4ZZWC2/A,'4/!#O/%S=HY3:V%HZW'56,J09<?3UU;":JEIF>-:BD0Q+MKMIH
M'J00I!K4CYTQQX_ZJ=![FS=;"^@*(ZO*I4H5#&E2*T8#205XBI%0/,"EQ&;S
MF9W+_P )RZW.[@RE=FLUDOY50J,EELG4RUN1R-3_ ++ND;U=?6SL\DTSZ 9)
MI&9W:[.S,22A "W5!_OW_G[H0.YDV@LQ))M*DG)),7$]$]_X3%_#KIK$_#MO
MEEGMH;=W9W+V3V!OC;V#W;GL11Y7*;"V!L[*082#:NU:C(05#4(J\E15V2KI
M:4Q&<SPI)?P"[V[S,9"GD*8]33B?\'2'DNQCCM%GI5V+#4>*J&(T@^0J-5/4
MUZ![_A4YTSL;K[8WQ8^7G7VU\=LOO3#=WQ[*G[,VQ3T6&SN0I(MM9C?>UFS4
MM)%')65.-K]GFHQE5-K:G\DZ!K2@>W=F<N6C)[2M:?L'^7I+SQ$L,<5R@ D6
M0 ..-*,P^VA6HKPSZGK;?V[6SY+;^"R-45-3D,-C*VH**$0SU5%!/,40?0:I
M#8?CV2''0[&>GGWKK?6:#];?\L:C_P!QY??NO=*O>/\ P)H_^6$G_6SW[KW2
M.]^Z]U[W[KW7O?NO=>]^Z]T ORFZ0_V9?XV][?'K^\_]RO\ 37U1OGK'^]_\
M%_O'_=G^^FWJ_ _QS^ ?Q; _>_;?>^7[;[VD\FG3Y4OJ#L,G@NK<:$&GV'I+
M>VWUD+Q5IK1DK2M-0(K2HK2OKT W\MCX1?\ #>GQ1VC\8?\ 2;_I>_NKN/>N
M?_OO_<O^X'W_ /?#<=;N#[3^[7][-Z^+[?[SP^3^(2>33JTI?2'+NX^J<O2E
M:8K7@*>@Z3;/MW[IMU@U:].KNIIKJ8MPJ?7UZ/G[3=&?7O?NO=4\;'_E.?W,
M_FP=A_S/_P#3[_$O[^82MP_^@_\ T6?9_P *^[ZQVSUQ]Q_I+_TCU7GT_P!W
M/O-']WX;^;PZAH\K+GO-<(AIP-:U^9\J?/UZ(8=D\&_>]UUUKIT:>&$%=6K/
MP^GGU</[0]'W5&'\U;^3%D_YEG</3'<6$^5-?\=,STSM*?;N)7%]2U&_<G/D
MSNB3=%!N3';@I.VNN)<?/2RE!"(HY75XQ(LJD  PLKX6@8%=6JGG3U^1]>@W
MOO+YWEXW64QF.M"%U&I(-0=2TI3HBW_0.9\M_P#O=?\ (S_T7?9G_P!U][5?
MO6/_ 'RO[1_T#T5_U4NO^4Z7]C_];NO?] YGRW_[W7_(S_T7?9G_ -U][]^]
M8_\ ?*_M'_0/7OZJ77_*=+^Q_P#K=ULA_&/I_.?'_P"/O4/2NYNQLMV[N'K/
M8V%VEF>S\[15F.S.^\CBX/%5;FR=%D,_NJ>.>J<F219<C6M<F\KGGV4S.)&+
M 4J:T]/\'0PM(3;Q)&S%RJA2QXL0*5-2>/'B>AU]M]*.JD>L_P"5G_HZ_FI]
MS?S,_P#3I_&/]+FRYMH?Z$_]&/\ #_[O^7:77>UOXC_I(_TA5WW=O[@^?P_P
M"F_X%Z-?[6N1<]YKA$-.!K6OS/E3Y^O1%!LO@WTE[KKK0+HT\,(*ZM6?@]!Q
MZ/'\NN@?]FH^,G>/QR_O9_<3_3/USN+8']\?X#_>?^[?\?I&I?XM_=[^,[>^
M\\6K5X/OJ75]/(OU]IH)?!</2M"#3[.C.^MOK(7AK36C+6E::@16E17CZ]!/
M_+E^&/\ PW_\2.NOBS_I(_TM?W R6^LA_?K^Y_\ </\ BW]]-\;@WGX?[L?W
MIWGX/MOX[]MJ_B,WD\7DLFK0KEW<?52%Z4K3%:\!3T'2;:-N_=5NL&K5IU=U
M--=3%N%3Z^O0#?.#^6)_LY?RV^#7RE_TW_Z./]DP[&V[O_\ N+_HU_OA_I)_
M@'9>Q^Q/X3_>?^_^U_X/Y?[F?9^?^'Y73]SY?&WC\3N6UY].CI2NL4K6E,$>
MA]>DVZ;-^\IX)M>GP7U4TUU=R-2NH4^'T/'H\'R:^,O3/R^Z9W;T-WSM*#>'
M7F\((1649FDHLIB<I12>?$[CVYEH/W:+(T4MI::IB-P;HX>)Y(W312M"P930
MCHTNK6.]C,4H#*PH0?\ 5@CR/EU01M3^1Q\\/CQB\GUA\/?YO?;G5W0.0JIF
MQ6PMS;%JLSE]F4=5+'-5Q[?RN-WM24T,\DC2SR3X>CVZ)';U)J+2$Q:_BE[I
M(@6]02 ?]7Y]!F+EVZLQHM[MUC\E9%<K@#!)'\@/\O1]OY<G\G/HSX ;CW%W
M'7[VWE\B_E'O>CJ:;=_?O9H495?XMX9MR1[0PLE;F9*!<E/$9:RIK<CEJZ4,
M8GK#$61D]U>M<T6@51P4<.C+:=BCVLF34TDK?%(YJQX8'&@J*\2?4F@Z-;\[
M/@?T-_,*Z1K.DN]\7D?LJ>O&?V7O/;E1!0[QZ^W9%2ST=/N+;=;54U9"6,52
M\-32U,,T%1$Y21-01T9M[AK9M2_[!'H>ENY;;%NL1BF%0<@CBI]0?7_BCCJE
M_ _R.OGQ2[4IOCYG/YQW=\OQ0IY#CIMEX':&9QF_:K92OH79%-NBK[(R3TM&
MU,?M33FHJZ%$]/\ #GA_8]KC?Q5U>$NK[>W]G#HA7E^Z \(WDGA5X!0)*5J!
MKJ3_ )*8I3HV?PH_DF=9_!/YR[[^6'3O:/VW6VY.FX^G]K] /U_/'4[5I_X?
MU?!7;ER/:M3V#DY,K5UE7UY49"LUX*C,D^6D;6/'^ZU/N!N(A&PR#4M7CQ\J
M?/I5MW+B;9=-<1M160((POPTT9U:C4G14XR3Q]1/_F*_RL_]G[[S^&W='^G3
M_1/_ +*3O2MW?_=K_1C_ '[_ -('WF\.N=U_P[^,?Z0MF_PK3_<#[?S?:Y*_
MW>O0/%HDK:WGTRNM*ZA3C2F"/0^O3VZ[+^\YH)=>GP7U4TZM7<AI74*?#Z'C
MT8O^8U\,?^' /B1V+\6?])'^B7^_^2V+D/[]?W/_ +^?PG^Y>^-O[S\/]V/[
MT[,\_P!S_ OMM7\1A\?E\EGTZ&:M+CZ60/2M*XK3B*>AZ5;OMW[UMV@U:=6G
MNIJII8-PJ/3UZ%?XY= ?[+_\5>GOC+_>W^]O^B?I;:G4']]OX#_ ?X__ '8V
MI2[8_O#_ ';_ (SF?M?/]MY_M/OZG1JT>9[:RW++XKEZ4J2:?::]*;.V^DA2
M&M="*E:4KI %:5-.'KT2_P#E,?RQ/^&N>I.SNK/]-_\ IR_TC]C0;_\ X[_H
MU_T9_P &\.V<3MW^$_PS^_\ V#]Q?^%^;S_<0?KT>/TZBHOKSZQ@U*4%.-?/
M[!T6[#LW[CB:+7KU.6KITTJ%%*:F].F_^8]_*&Z5_F"97:/:E)O7=OQW^4'6
M\,46P?D-UE&HW#3QX]ZBLP-!NS&P5^$FR%/CJR?[NAEI<CC*VG?4L%;''(Z-
MZUO6MJB@93Q4\.M[ML4>ZD/J:.5:Z9$PPXX/"HJ:\0>-"*FI!=P_R-OFI\C*
M+"=;?.#^;-V[W5\?,)7T-96]:;6V0VV<EO,8BJBJ,4VY,YD]V96"6>-HA,E3
MDZ'.R1RJ'C82 2A0+^.',485O4DFG1<_+MQ> )=W3R1U!**BQZJ&HJ034?+U
MH:U'5TN7^!_Q>S'PZG^![]:T%'\:WV+'L.EV;1SS&LQM-35:9BAW-1YJM^]G
M.<@RL29M,M.9IVR"_=2F20MJ0"X</XE>ZM:]'S;="T'TQ4>'I"Z?D.&>-1QK
MQKGCU2CU7_)#^?GQ8I,EUI\/_P";EOKJSH*JS59F,3LK<73U!NO(;9?(L\U:
M,?!5[MDH%EFEE:6IEQT.&CGE8S/ ).28/N$4_=)$"WJ&(Z#UOR[=6 \.VNV2
M.M0K1JY%>.21YYP /SST^]T?\)LNENYNE]PX?<?R7[9W7\LMY]@[8WYO#YC]
MP8Z?M7=V4I\#C,YB:S8V/V0^\]JQ4>$JH\ZTP@&5EG2:DI#)4SPTL$"5BW1H
MF!  4"F@8'VUSG''_/U>]Y2BO(B&=S*Q!\9^]L$X JH"T)%!0<.-!U=WF/C=
MB^Q_B1/\4>\=PGL#&;FZ.@Z6[&W?MS$2;"GW.LFT(MK9;=>$PK9G=1Q51,\9
MK:> UM>L$NE2\J+8EXDT/K7%#45S3^6>A&]L)X3%+W:DTN15:U%#3)(K]IIZ
M]4Y?R\?Y(?>?\OWY&[/[!V[_ ##-^[[^.^T:O?\ /+\;*S8^XL'M7=$&\]L9
MO"4)RM&G;N5P]/7T59DJ3)ODZ;#&2>;'*HCA2=Q&876X+=)0Q@,:=U?3\OY5
MZ#NT\N2[3*&6X=HAJ_2*FE&K3\9 (-#4**_*IZ-M\!OY6?\ LCOR>^:'R/\
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M+#N[;FP:$5F;R,U.L$24>Z>L&Q-:?+:EIZ^GKJEHX7/L\ ^JM J\4.1Y^?\
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MR_E<9;N'^:=\>/YC\'<^.P.-Z+V5A=H3]22[%J<C7;E.*'9JOD(MZ)NNCCI
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M;%I$5:&JQS>.28%RS(\:JWNVME95 [A0UK\QC(]>BK<-GBW*2*5RP,+:ETD
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M>^27\HSX_?*OXA_'_P"&7:_:/R&J>O/CC5[6JME[TQ.Z^O(.T<VNS=F9S86
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M4]2E?41R+?7WH@CCU96#<"#]G2U]ZZMU[W[KW718*+L0HNJW) %V(51S^22
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MJ*N\T_V]09(S"8Y$=SN'U":-"@5Q3R'[//'"G1UM?+?[MF\<S2.Q6CZB:.U
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M+99 TDGP+Q^9]/\ 5ZCJ_,.ZR6QCM;:GC3&@/'0M::B,GUS2E Q\J= CA_\
MA,-T[N'#XK?/=/S4^8.\?E"F,HZG)=N8?>NUEP]'NV&F21*S%4>Z]F[DW#)2
MTU2\AA,FY8)G2QU0,39S][,*JJ(%]*?[('\NDJ\G1L1))/<-( .\. :_*JD@
M9.*]2_Y5'RT^5'QR^>';?\GOYQ]GS=TY[9^ ;<?QH[FS;5"9_=.WL3MBCWDF
MW'RF;85N7@K-N5+Y6'SSY&IQM1B,G0O65=/'$U+Z\@26,3Q"@)HP]#_D_EY8
MZWLE_/:W3[?=/K*@-$Y%"ZTX9XFF?,@AZL:= Y_, [,[9^?/\X[&_P JG(?)
M7=GQ0^-_7FR\)GMQR;'W$FU-U=Y;OS/6.'[,EQ>(R+STZ5]0U+O"&@HL;5?<
M4L0Q5=6&FJ)UC1;6\:V\'C:0[$TSD**^8_+^8Z9W*>3<]P%CXCPHJ:B5.EI&
M(K0'S !X4\FJ#0$3.]?^$Z=1\5.K-U]S_P L/Y.?+K;WR7V3#0;EV[M+,]A[
M-AI>R?X)715#[6@K]B;*ZN\54T,M0U(N1>NI)I/\FGCCBGDE3:;IX[!9E0KP
M)H:BOYGJLG*/[OC9[*699!0@%ETN5R 0%4&O 5QG.*];#'P3W'\GMT?%#IS(
M_,O8;==?)6GV]487M+"'+[2S0R66P.5R&'Q^\/N=D5^1QL3YRAHJ7+3T<#J*
M::LDIPH$8N67"HKD(:K7!X?X?3AT*]N>:2%#<+HDIW*""*@TK@D9XT\JT\NC
M;^V>EO6F%_-^[;^5^Q?YZOQCVO\ $O=N0Q7:N^_CQM+KS8.-R%;5UFRL/NON
M&L[^ZI?L#+[7J'J,=/)@J;<QS4<U=254,;XN*2>*:*(QL>V4<;6S,X&&K7SH
M-)I7CGA^?0 WRYN$W2*.!B"T5 *]H+>*NHKP.D=V1G2.AL^17_";Y!T_OKO^
MF^;_ ,GNS/G#LW8.:WK0=D[WW3BX]K[GWKMO$56<;%4;2T-7N+#TU9+'44U)
M4'<U6:3[E96654>.1N/=*'1H0(3D 9I^VA/Y=*KKE'6#-X\S3A31RP U4/HI
M*J23@' /1<?Y;C?//^>)T?1]4=\_*GL/J#XM_&7&4VP-^[PZLK*6C[J^4&^L
MZV3R.'Q6]]UU4\UJ;;^#&.BJY*NBJ4K7G6:H6NJYY)Z!R[6+;GJJAF;(#<%'
M#\ZFOV=)-EFNN9H:2R-'''VLT9 >5^.3F@44J .XDY\@&'S+^+F^_P#A.SWO
M\8OD=\2OD!W+NKX[=C[[J<'VEU9OG(XRMJ,PVWWQ61S^"W#!MV@VA@LLF8PD
M]1'C9I<;0U-%4XXRI.P9&A<AF&ZAD=0& JI'^HGB?Y])KZR;D]XYX)':%GTR
M1L0:^9(II%2!C@00,D&@WHZ^OH\70UN3R-5#18_'4E37U]94R+%3TE'20O45
M55/*Q 5(TC9W8\  GV'NI)ZU)OY+T-?_ #!?YI7SI_FF;GI*NIV/M#(574WQ
M^;(H[0T-/N&F3 X5L='6:)J6KQ>RMMTL-?&(8%>3=4SVUM( <WX^EA2'S^)O
M]7^KAT".7C^];VXOLZ1^E%G%,5P<C !\OB/$UZ1_S(K5_E7?S_\ I3Y:0F+"
M]#?.G$1[7[3J9C2PXK&U&;K-L[%[3JBQCQHAAQV2I=K;TKI7FJ':2HG/(981
M:#_&[5D\XS4?9D_/YC]G3=^?W+NT<_X+@>&WR/:ORH*Z">/XOEUN*>R3H=]?
M/<^&G0_RS^57\T3^9#\=/CWW7N3X[=4[V^0G<&X?E+VQLU)J7>-/UMM+O;?]
M/AMD;2S5,8)8,AFZW<CQQPQU-+KBI9IY6FIJ6>DJ1-<R1Q0QLXU$*-(/"M!D
M_9_J]1%NUV]S>7UU%"YC0RL977X](=Z*I\BU3GRI6N*&S#Y2_P AC<?P/Z?[
M ^7'\MCY;?*3;O>O46%R/:&[<%O3=NW\PW9VVMHTM=N'=&/H6V#L79QJ:]8(
MYZNFQV6I,W!7NC4CHK5 F5'%N0N&"3(NDX%!2G#U/#UX='%WRP^UH]Q933"0
M5<AB&\2E210**MDTJ#4X\ZB\7^4G\ZI?YA7PHZ^[TST6)H^S<7D,MUKW)C,(
MOBQM'V3M%*)ZZNI*/4WVT65Q^4QV:BI;L(%R0A#.(]1+[RW^ED*>7$?8?]5.
MA'L>YC=K99L:N#@>3CCYFE>('H1U9=[2]&_6AE_-W_EQ[)ZT_F=_!?9U!W?W
MYG*;YS_)8U6Z\GG]VXFJRO41[&^0>QL760]+3PX"G7&)0+OF:3'+4K6^-Z2G
M+:]#!A'87.J&0Z5[5\A\5%/'UX=1GS'M8BO+<>)*?&E-:O7PZNGP8[::L<>
M].MQ+X2_$#;?P@Z2CZ0VKV7VEVQBHMUY_=G][NX<[0;BWI)4[@6A6;'S9/'8
MO#QM3P?8**=?""H8@D^R*>7QVU4 ^0%!U(%C9BQC$89WI7N<ZF-37)H/R^71
MN_;/2SKWOW7NO>_=>Z][]U[KWOW7NM-?_A4EF=Y[=^0?\L;<'7- ^4["P6<[
M5S.P\9'0-E9,CO/&;VZ(K=KT"8M"#4F:N@@C$ YD+:/S[/=G *2ZL"@J?E1N
MH_YU9TFM#&*N'8J/5@T5!Y>?1I,?_P )RC\A]M8;MWYY?-GY1[^^8N7I1N'-
M[HV3N_9Z]=]?;GK94R<6"VAB-Q;%S-8U)BY@D:28VNP4$C0!Z:EHTT(K'[S\
M*JQ(@7AD&I'SSTO/*9O0LEW/,THS564*K8^$:,4H,BE:5H.'37_*>^4WRG^+
M?S\[:_D]?-GM*M[EK,#B*W<OQN[:W)4Y2JSVX*#';=I=\T^#H\OG7J:RNH<E
MMNHGRD<%355KXRKQ%=0)4SH!XMWL*31B>,4J:,/0_P"K_",=:V2^GL[I]ONG
MUD#5$YP66E:9R<9\Z$,-1ITB*S>F]OY=?_"BN@VUN'=&Z#\:/Y@VWDAVQC<S
MFLN^S-M[Q['J8X8*/"4V2:IH16Q;]VF*84U&U*U-0[HAOZ'2.?81;FU) &I#
MFG$CY_D?Y=:>YDVS=@C,3%<+V@DA5?A05J*DKP%/C'RKLH?*KOW;WQ:^-_=G
MR(W2GGP_4'7&Y][-0 QB3,Y+%8Z5L#M^G$M31*9LC7O34,"M-$#)4*-:WN"N
M*,RL%'F0/V]"N[N5LXGE;@BEC3B:"N.&>J6/^$X?6/:-5\5NROF!W?N7<^Z.
MQ/EWVKN#<^)GW'EL_61T/7NTLMF,9128K#Y:K>FH$K\]7Y^K H((DFI11$O(
MD<*Q+MS*JXC0"B@#%,GYT_9GH/\ *B2R6YN)F8M,Q8 EJ*M30 $D ')%.((X
MT'6Q-[+>A1T'&YNG.HMZ[MVOO_>75?7&[=]['JZ&OV5O7<VQ]L9[=NT*_&-D
MVQM;M?<F5Q=768^:G.:K#!)230M&:N;21Y7U6#$"@)SQ^?3;1*Y#, 2IJ"0"
M0:$5'I@D?F>HW='='6'QYZPWCW+W+O'$;#ZWV'B)LUN7<N:F,=-24T96.&FI
MH8UDEJ:NIED2GHZ.G26>HGE2&%'D=5/D0R$*HJ3UJ:9;=2[D*JBI)X =:K7\
MH3;G8?\ ,=_FI_(S^<%NO9&4V9TG@(,SUYT)2[G$=57S9R79V(ZQQ]%@I(Y'
MA1\7M6EJFS\M)JA^_P ^T4,D[&J=3B^(M(5@!JU:M3]N?]7D/ET"=@5MXO9-
MQ92(Z:(@V3P"DCTH :TQ5B*FAZV]?9+T.^O>_=>ZUGOYGG;O8W\QSY5;7_DX
M_%7<66P^SL?6XC>_\P+N/ /"N-V5UWCI:7(_Z+HZ]TG$U6_GI9JBDC%ILA-0
M4,K^"++I":6BBU3QWI7A&I\SZ_8/]5#3H)[Q*^ZS#;X2P7#7#K3M3R3[6_P4
MP1JH3S^<EU)L#H;YU_R).FNK-OTNU^O>MNPMB;3VG@J072BQ6*[\Z6AC:>8C
M5-43-JGJJB2[S32R2R%G=B5.WL7BF)R2"3^QNB[F2)8+JP1  JR  #@ 'BZV
MU^YNI-G][]6;ZZ@W[#D)=J=@;=R&W<M+A\E5X7.8]:R(BFS& S5!)%/1U]%,
ML=5154+!XIH4<?IM[)$8H01Y?GT.98Q,I0UH00:$@Y]"*$'T(R.M63^63\DN
MWOY77SJ[-_E2?.7L:JS^PM_9=M\?&/NK>67KIZ'(29S[E, \F9S==5?:8W<M
M+AW@:FEF:.@SN/J*-9)/N'E)M=PK=1B>,4IAP,4_U?X/SZ!VSWDNU736%TQ;
M5W0NQJ2IK@G\O/@016A'0?U6_>U?Y^?\SK^ZG6>].P]C?RWOB#/)%NC<FQ]U
M[DV=#VH7R>FHJ4R&%EQ4QR.[YL9]KC%9M>/PE#-5QM!5S.DU]"[=#5@#(_ ,
M =(_U?S^SIH32<RWM(V=;:'#,C,OB-C%01Q^5:*":C4.MQO&8V@PV.Q^(Q5)
M!08S%45)C<;0TR".FHJ"A@CI:.DIXQPJ1QQ*B*/H ![).AT,=%(^?_QYRGRG
M^'7?O26V\ID,%O?=.P<I6=;YW%97)X/(8GLK;7CW+L*HCR^&J:2JAADRF)IJ
M:M\3_N4L\T3I)'(\;O6\GA.&(J <@TR//CTCW"V-Y"\:DJ64Z6!(*MQ!J"#Q
M^>1@XZJ\_P"$X?ROSWR!^"E9U3V'E\QD^VOBSV#F^M=T'<U1)/NB;:N?JJS=
M.QJ[,BJ;[D-%]QDL(OW2B0G!L&+,&/M7ND(BEJM-+ $4X=$O*=^]Y:Z9"Q>-
MBC:OBQD5\\ TSFH->@/_ .%#_<_9^^-Q?"C^6_\ 'S<NXL!VU\H^W\+N/<==
MM&LKJ;+8G9E%E#LO;#Y8X>IIZI,7-D<S7Y:LF#0QI'M>1Y95B22SFVQJ-<K@
M$(O ^9/^JGY])^:;F1C#:0LRO-(*LO$(,'@0?.N*84U-.IG\]CY*=H?![XX_
M"KX:_&[L.KZ/Q_?N4J>H,[W]69FLH<CU]UGUAC.NMJY&>NW@T[U=%49 [_@R
M&1S<<_W@AQE6ZS"65I1K;H5G9G8:M(J%]3GR_+_!UOF>_>PBB@B8Q^*P0R^2
M** FM10YK7T#&H.>FBG_ .$POQDRF*INQ<-\S_F%5]\UV*BRE#W=3[XZ_P C
MBJO<D^.$$&Y::BI=CQYF2E>-E58TW896A.D5=C?W;][.!IT)I_AH:?X:?RZ;
M_J9#J\7QKCQ/X]:UK2G'17ACCPZ.O_)BQ/\ ,NZ[Z_[AZ1_F&X'<F;HNL=VT
M&/Z$[QW5O3;&Z\WV-M)),WA,SBJK[7+UN<DI:-L!1Y'&9+/1+4U$.9:)V'VR
M+[3WQB8AHO,=RT.#_J_P=&6PK>0J\5V*Z&I'(6!,BY&0"3B@-3DUSD$FZOVA
MZ/\ KWOW7NO>_=>Z][]U[IYV_P#\7BB_X/)_UHE]^Z]T*_OW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z"3.?\ %VK_ /EN?^A5]^Z]
MTU>_=>Z][]U[IMS.9P^W<5D<]N#+8W!8/$4<^0RV9S-=2XS%8N@I8S+4UV1R
M-;+!#!#&JEI)9755 N2![]2O6B:<>M6KXH_->7>'_"@OYL4G9WR:PE?T#L#X
MQ[HVCTO'G^S-OT'4F&2IWS\8,O/2;/8Y2DQ$M=42OD9)ZJ,RU<RPNLDCI %C
M-YH MJA R6R:9X-_FZ!UG?O+O$T;.2BQ=JU[1_9'APK4G/'RX=;3M#7463HJ
M/)8VLI<ACLA2T]=05]#415=%7457$E12UE'54[R1RQ2QR*\<B,RLK @D'V4=
M#+J5[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>ZK^_F@=X_(+X^?"KM_?_Q8ZSWMVGWW-1XO:W7N'V'LC-]A9C;M
M?N;(P8[)[_GVS@<1G)98<%0/59%3-324_G@A2H_:=_:FTC660*YH/,G'#[?7
MAT6[O<RVEN\D*%W  50"34D"M "32M?RZIS^ 7\@'XQ]H_'C9??W\PG;?:'?
M/R=^06WJ#M??C=@=B]H[(R>Q:G>]!!F<7MVNH-L;FVQDI<O1TM5",JV;FJ9%
MJ_+#X(4B$077&Y/&Q6(A54T% #6GGD'CT'MNY6@N8EFO TDL@#N69U*E@#IH
MI'#AGS]!0 N/3F W%_)J_G>=3_"+I+L#?&Z?B!\R]KX7=Z=1[NSCYFGV#D-_
M9CL/:^$KL5-.D*?>XG+]<F-:]8UJ:K$SK3ULE74Q)4>W92+ZW,K !E-*@<>'
M^?\ S=)K53L&YK:1,QBF0MH8U"&KG'^\T]2#DD@=;C?LCZ'G7O?NO=4$_P Q
MS^=7B^A^P<Q\+_A=UQNSY)?/'+SMM.BVIA-IYFLVGU=N+*XZ@JL;7[B$M+3R
M9BJC@R\5='18\24:I$[9"MI471(8VUAXH\20A4]3Q/V?ZOV]!K=N8!:O]-;H
M99R,*!VH32A8XQFOV<2H(/59W_":*L[>K?FE_,WD[_S64W#W?33[3QG;.7S.
M3I\QD:OL##]C=C8G=0GR5%)+3RB.LHI8HS3'P!$58 (@@"S=@HCCT"BYH/D0
M.B7DXRM<7?C'5(&0.>-6!D!_+&/*G#K;[WCO[8O7>,AS78&]-I[%PU161XZG
MRV\=QX?;&,GR$T4T\5##7YNLH8FF9*:1UB5RQ6-B!938C KPZ'S,%XFGV].V
M"S^"W1B,?N';.:Q.XL!EJ=:O%YS!9&CR^(R5*Y*K4X_)8^:HAFC)4@/&[#CZ
M^]4IUX&O#I*[M[8ZLV#DL;AM]]E]?[*R^9C$N'Q6[=Y;=VYDLK$T_P!JLF-H
M<QDJ.6=3+^V#$KC5Z?KQ[V%)ZT7"\2!^?0@>]=6Z ?Y3?]DQ?(W_ ,0/V]_[
M[[</NR<1]HZ;F^!OL/\ @Z^=)_)N^;79_P#+=[<V;W]NO';AE^&'?F_\Q\?^
MX*NE@:KPT6X]F8G9^YCN2FC (3*[;I^RJ#(I'=9*J@JZZ"(.US&*]QMUN@5'
MQJ-0^8-<?R_;]O40<L;D^T,)'KX$CF-O17 4AC7AAO7(KQTCKZ86'R^*W#B,
M7G\%D:+,83.8ZAR^'RV-J8JS'93%9*FBK<?D:"K@9TEAGAF26*1&*LK!@2#[
M"74Q UZU)?YF/_<2E_*\_P#$3=)?^_N^2_LZMO\ <.3_ $W_ $!T!MS_ .2W
M;?\ -+_K=U8)_P *3O\ MU%VY_XD7I3_ -^-A?:?:?[<?8?\!Z-.</\ DGR?
M:G_5Q>CY?RL_^W;7P3_\52Z-_P#?>X+VFO/[5_\ 3-_AZ,]E_P!PX/\ FC'_
M ,<'1]?:;HSZT\/Y#?\ V]__ )N__AZ]Q_\ P3^X/9WN?]C#_I?^?5Z G*W^
MYU[_ ,U#_P!7).D/_P *,NOMO=M_S-OY9/56[EK7VIV:FR.OMSICJK[+(/M[
M>?R QVW,TM!6>.7PS&FR4HBETMH:S6-K>[;4Q2*5AQ J/M /37-\*W%W:1OE
M6?21PPSQ@_X>K+?^@8G^5]_SJ>^/_1NO_P#8[[2?O:?U'[!_FZ./ZG;?_OL_
M[V_^?JJ'^:7_ "=<5_*NZRQ'\P?^7AW5W%UIFNG-W[,I=\87-[LI\E68[$[H
MW!CMMXC/[:SE!A<:]1 ^8K<;1Y; YA*^DK(*URY$41I)UUE?&];PI@&!K0T\
MZ?YJY&>B'?=A78X_K+)FC*%=0U$@J6 \P:Y(J"=)'EZ[5W\O;Y/2?,SX6?'?
MY+5<-!39OL[8$%5NVFQ44T.*I=^;:R>2V9V!38R&H9W2FCS>W*]($9G*HJC6
M]M1)KF'P)&3T/\O+^70XVR\&X6\<PIWJ":9 ;@1^1!'1QY98X8Y)II$AAA1Y
M99976..*.-2[R2.Y 55 )))  'MCI=UJM]X?->7,?\**/AGL6/Y-82H^*FS>
MH]^;CDQ>.[,V_!TY0;YW%\?OD-0UN5W%7X[*18VHR+2PX^"F?)3320-*D=/X
M_.RR&\4 ^D=J=U0*TS2J_P"?H&WE^_[W@B#GP_#9BH-%+%9>-./ 4KP\N/6T
M=M[<>WMVX:@W'M3.X;<VWLK$T^,SNWLI0YK#9&!)9('FH,IC9ZF"9 \3(6C=
M@&4CZ@^RBE.AB#7(Z>??NM]>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UF@_6W_+&H_]QY??NO=*O>/_
M  )H_P#EA)_UL]^Z]TCO?NO=>]^Z]U[W[KW5'/\ PHT_[=(?(K_PY.B__?X]
M?^S':O[=?]M_QT]!KF__ ))\O_-O_JXG0=;8_P"X:2I_\9C;N_\ ?39KW8_[
ME_\ -S_G[JH_Y(__ %"?]8NE)_PFQ_[=1=1_^)%[K_\ ?C9KWK=O[<_8/\ Z
MWR?_ ,D^/[7_ .KC=%+_ .%8\,3?"+X]3F*,SQ_*G%0QS%%,L<4_4G:;S1)(
M1<*YIXRR@V)12?H+/[)_:-_I?\HZ+N??]Q$_YK+_ ,<?J'_PJ*Q67K/Y;7QH
MR5'1U=3BL/\ (OKF3,U%.CR4^/%;TIVI1XZIKE2^A&E<P),X"B25(]0>5%;V
MS$"9OFII^T=;YZ4M9H0#02J3\AH<9_,T^T];(WQYSNW]T= ]'[EVID:#+[7W
M!U!UKFMN97%2)+C,E@LILW"UN)KL?)& IAE@FC>(J -+#V4R#2Q!]3T,H7$B
M*RD$$ @C(((J".DGV]\N?C;T'V#U?U5W'V]M7K[L+NFKEH.K-L9]Z^*NWKD(
MLCC<.,?AY:>AJ(3425>8I:6G@DEC>:6=(XE=S;WM(6D!*@D#B1Y=-37D5NRI
M(ZJSFB@D L<"@]3D?MZUL/FS_P!Q0/\ +\_\0OL__K7\E?9O;_[AO_IO^@>@
M?N'_ "7+?_FD?\$W6UAOVCR>1V+O3'X4E<S7[3W'1XD@,Q&3JL/604!"I',3
M^ZZ<!&/^!^GLE7CT.&R#U\_?^1__ "__ )%?,?JGO.NZ*_F;=[?""LZ][*Q&
M)WGU7U32]@&'/G+;;CFPN]L['M'OSJ55GD?'5V.1:B@J' QQ GM>-!/N%VD#
M#5&KU%033U^:GJ)^6MFGOXG,=S)!I<J475QH,FDB9\N'EU=7GOY&7STIL%FJ
MC='_  H%^7=/MJGQ.1FW%/GJ7N6+!0X**CF?+2YJ7(?-):=:1:=9#4M.1&(P
MQ?TW]H!N47^^$_E_T!T(CRO=^=_-_P ;_P"MW1LOY;'QPZ:_E!?!KY+[U3Y8
M;9^574&&RN[/D-F][]>[2P6#I<93;;ZZPU%DMN8N+!=E]F15]75Q;6@^VO70
M7DF2,1BY=DUW.;^1:+I.%I6OG]@]>C39]O3EVVDU2:U!:0L%I0!17 9J_#_L
M=5Y_'GO3^>+_ #@H<UWG\?\ NOJGX'?$M-Y9O;>TPFV<7NO>6?BPU13)4/15
M>3V=N.ORLU$Q^WK*L5VVJ*2?S110N8V6-3+';V/:ZEVH*YH!_J_/HLM+G<=_
M'C0NEO#5@O:'=J$"IK4<0>!'I0\>BK?S@?Y:?R)Z ^#>^OD+\K?YE_?WRKWO
M%OSK7![:ZRS55EMK=-P5V<S%%C:I:;9N7WINV"IJJ>CHJJMBDH*7#^N-I9(G
M*R/(_8W:22JB1JHH<\6X$\?^+Z+^8=GFM[22:>YEE:J47X(\LH^"I%?/%,YI
MZ['GPHPG3&Z_Y07Q*V9\@VV4>H-[?#;IG:.]J3L#+8[";7R6)SG6^%I9<?69
M+)UE D3O>\#I-'*DBJ\3+(JL"JZ)6=RM:AR13[>A?M:))8PJX!4PQ@@\""@Q
MGJF'._\ "=GL'83Q=V?RH/YC.].LL'O7&4&]ME8VNWEN"GVMN?$9>%,[M*NQ
MO=72V3"9/"U%)60_9S3;?RJS4[+(T]2LANO&YANV>,-3!-*$>N#Y_LZ#IY5:
M$>)M]R\8/>%U$HU<KE3E?F0U1Z^>3X[_ ,Q_^:9\#/F]T1\)/YIM%M;M'8WR
M#W!@MG=>=R8>FVZV;CKMVYS'[5VUN'";JV908*GRF.ILM7Q4.:H<YB:;)PI4
MK5^<0I#'6>EM8;F-I(*@KDJ?3\_LKQ/7K7=[[;+F.VOPC+(=*R+Q+&E. &*D
M*054YK6@R73^<GU%O;MG^?G\3NN<+WONCXP9CM3IGK#;_77?6TH,P=P;$RU5
MG^Y<5C3@'P^ZNOJEJFLRL38VU-F:9U_B0.MK^%GK"18[5B0&HV5/G\/R/^#R
MZ1<PVKW6ZPHCM$6CHL@K4$>(<4*Y\L'SZL"_X8K_ )B/_?0!\T?_ #A[Q_\
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M,G-5U,6/R-#N6CJ8Z6>>I>FE::F,]0(1/(@OK7Z233Q'$'Y="+8-V_?-N)2
M&!*N!6@84.*^1!!\Z5I4TZM)]H^CKK4C^;/_ '% _P OS_Q"^S_^M?R5]G=O
M_N&_^F_Z!Z VX?\ )<M_^:1_P3=;2_<'_,I>T?\ Q'6]O_>:R?LF3B/M'0W?
M@?L/6M;_ ,).?^R'?D%_XM;FO_?0]3>S?>_[5?\ 2_Y3T"N0O]Q'_P":S?\
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MCJ7-97QA")LQB)L9F9#H4%ZYP+Z3[*+Z#Z>4KY<1]A_U4Z&?+^X_O.T20FK
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MRR6MVH66,!NWS7%:Y85%0:@T(.!@UV*O99T*NO>_=>Z][]U[KWOW7NGG;_\
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M_BB2YO=I&8 $F@X#R'3*6\<;,ZJH9J:F %6I@5/$T\O3K6$_D&?]O//YS_\
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MFDHZ1?"E)+F.VC,<-26^)CC%/+A_J]>G;;;+K<KE+J^"((ZF*%2&H:\6.17
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M)R&?Z[W[@L33_=Y7-;+W3B<92^6"#[G(9'!UU'14_GJ9(8TUR3*NN1T47NQ
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MGD?=S$%5)%% X.*UH0:8^7IQZIMEX\DLUM(=30E*/0+J61-0K0TU"AK0 '%
M.K7O:/HYZUHOY]O\M/Y-?S#.X_@G1]*;%FSG6^R\MO\ V_W=OJGW9USA9^M=
ML;\W3U-%-N2';^]=X[9J\L]/083)5BTV,AK'8T@C*AY8U<VVV[2U5]1R0-(H
M<D ^G0.YIV:;=Y+<1K5%9A(P*@JK%,]Q%< \ >'4&+O3_A17\<=I3_'P?#OI
MCY:;FV]1P;;ZX^5>,WOB,9BMQ86BH8J/'YS?^U\MO_9TD^4 56GFJA@%9U/D
M6J.NHFJ(K64ZM90>:D5_80.'[>G6N=VM%,?@I,1A90X0'R!96(SYFA \AZ]&
M*_E,_P K'M?XT=E=O_-WYL;^H>U/F_\ (1\O'N&HQ=;_ !C;W7&W,YE:7+9/
M$8[*O24:3UU6V-HX)!10PT6/I*.''8\-3*TDM+V\$P$<8HB\/4GY_P"KY]*-
MCV5[)Y+FX8/-*>XBI55KP!.?3Y   #%3=)VGUMM3N/K/L'J7?6.BRVS.S-E[
MFV'NK&S*'2LP&Z\-68/*PC5]&,-:^AA8JUF!! /M K%"".(-1T(98UF4HPJ&
M!!!X$$4/6D!_PGN^'FYMU?S%>SMQ;^W ^_NOOY:]+V+U3UQEB*Q-NKOW=W8'
M8N&QE3MJFCJ9:?[>5*S=F<:*26I,<]=3R\L(I$/]SN (AI%#)1F]: #_ &/V
M'J..4]N8W;ER66U+QQFA U,S5(S3A6H-?B'H.M[SV'NI*Z][]U[K4>_GT?!W
M^:1\Y/D]UC3=!] 0]I_%[IC:F%K]MXVO[;Z@VCMS=/8V9KILAOBOW#MK=G;F
MS<E(?MZ>BQ*R_;TQ6"*;[:4>>21CK;9X;=&UM1CC@20*>5 ?]5.@+S3M]]N,
MT8AC#Q( U"RA6>N=0+K44 'YG.>G;"]J?\*H-MX?%;>V]\*/C%@L!@L=18C"
MX7$9KXW8[%8C%8ZGCI,?C<;CZ3Y00Q00010I'%%&BJBJ%4  #W[P[+^-O^-?
M] ];%YOHP+>']J_];NC@_"#M+_A05N/Y0]8X;YO_ !MZ6V#\7JS^^G^D[=NT
ML[TQ6;@Q/V_7F[*O9?\ #Z;:??>]<@WGW#!B::7[?&5-HYG+^.,/+&S<1VJH
M3&S%L4!KZC^B/+I?MMSNTDRBYAC6/.IE*U'::<)6\Z#@>M@KV5]"KKWOW7NO
M>_=>ZUVOYNWP4^5/R@^=O\LCN7HSJW^_'6WQZ[.P6X>X-R?WWZYVU_=##T7<
M766ZJFL_@^\-W[?K\AIH-O5D_CQ=+6N?#H"F1T1C2QN4ACD5C0L*#!S@CR'S
MZ"F_[;/>W-K)$NI8Y-3FJC2-<9\R"<*>%>KI?E)O'O78G0_8NX?C-U(_=O>\
M6!J*+K'8,FX]E[5Q55NK(C[+&YC<F8WWNS9=$N,QSS"MKH$KDJ)XH3# /)(&
M4OB568!C0>9R<?E7H17<DD4;-$FMP.U:@5/EEB !Z_+A4]4Y?R5/Y7?;7QFR
M7;/S*^<(DSGSE[_S>>&;3+9G:N[*OKG:];F)ZW*^/<6T:[+XZ3)[BJ%2JK3C
MZJ2GIZ.GHJ.!82M4C+K^[6:D<>$7AQS_ *OV\?7H@Y=V:2RUW%R=4\OQ5H=(
MKP!'KYTQ@ #&0L_F,_RW_EIUU\^.F_YF?\K_ &-2;M[;JLS'0?([I]=];)ZY
MPV^Z"EHHJ6MS==5;YW#M>@GI-P8VG;$9V".=YTJHJ+)T\#U7W%3%>UN4>,PS
M&@XJU":'\J_ZJCIG=]JGANDOK-=3_#*FI5#K3B22/L\\Z33'6Q]M'+9G/;5V
MYF]Q;5R.QL_EL)C,CF]F9?(X/,9/:F5K*.&?(;>K\MMC)9C'5,M)*[0/44-5
M402%-<;LI!]E9%#T+5-14BGR]/V=*+WKK?5!O\^;^7GWC\S.K^@NU/B1M^3,
M_*KXU]IPYW8Z4.Z]N;)R\NTMP-05F:GQFXMX;FVOBXJO&9;:^$RM(U5/K1:>
MH6G(>5DE,=NN5@8J_P +"A_U 5]1^?08YGVJ7<(TDMQ^M$X9,@<2*_$0O$ Y
M]*#CT9K^3'\'\[\"/@EUWU-V!@J+ ]S[JRVX.SNZJ2DJ\1DVI=\;HJHZ>CP4
MV7P63S5'5-B<-BL7BWGI*N>"22DDEA;3)[:O[CZF4L.' ?8/\_'I9R]MIVJU
M2)@ ^6?A\39I@FM!1:US3H,?YR7\K[=7\P/9'4G8/1>]\?UM\I_C5N.MW3U%
MN3+U-;C\+F(*^JPN4K-O9'+8Z"KEH:F&NVSC\AB<C]O4BGF@DC:-4JI)HK6-
MW],2&%5848?ZOMZ;W[9CNJHT;:)8FU1L>%<&AX^8&:&E/M!*!A?FA_PHIVKL
M\]<[C_EA]6;_ .V**BJ<1C^X*/L[9V-V1EZFE2:DH=R9O;5!VI%2/)*:?[B=
M(<QAHY"_[<%*KK&'_I[4FHD('H5-?VT_R?MZ0C<-V12IM49\@.)5"'T.DM6G
MRJ*_+HPW\IG^65WE\=^W.^/G1\W-Y[=WM\S/DM'6X_-X_:DD=9M[KK:N4S6.
MSN6P\62IH:6EGJZR;!8R(QT41IJ*FQL-/3SS*\K%J[NUE58XP0B\*\2?4]*]
MEVB2UDDN;EE::7CI':JC@!@'R%?L'&E2\?,?$_SB*G^9/\9*_P"*<N37X 09
M/H$_(9*?-_'&DHVQ\/;N4D[M\V.W_7P[ND!VN:;6,-$S,/317JM0][MS!X+:
M_C[M/Q>F.&./KU3<AN/UD7T_]AV>)_9_QG5\7=\-.'Y9ZO']EW0EZ][]U[KW
MOW7NGG;_ /Q>*+_@\G_6B7W[KW0K^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[H),Y_P 7:O\ ^6Y_Z%7W[KW35[]U[KWOW7NO>_=>
MZU1_@5_W$W?S-?\ Q7/<W_O5_$#V=7/^X<?^F_Z#Z ^W_P#)<N?^:0_ZP=;7
M'LEZ''7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UK@_*+^4?_ #+>Z_D+V[VOU;_-
MV[QZ1Z[WWO3*;@V=U-MO?7?M%@]AX*J9%HL!C:/;O;6!H8HXUCU>.EHX(U+$
M*O%R:07T42!6B5B.)(&?Y'H)[AL%U=S-)'=R1JQ%$771< >4@'E7AT O_#'W
M\VO_ +WE?(S_ -&)\EO_ +>/M[]XP?[Y7]B_] ](_P"J][_RG2_]5/\ K;U8
M+_+<_ES_ #C^(?>6ZNR?DQ_,>[8^8&Q,WU1G-CXGK3?>ZNWLYB,'NW);OV+G
MJ#?--2;_ .Q]WT:U--1[:KZ!)(J9)@F3D5951I$=+=W<<Z@)&$-:U%.%#C '
M1KM&S7&W2EY;EY@5*A6U4!)4U[G;.".'GU=G[+^A'TQS;9V[4;BH=WU&#Q,^
MZ<9B:[!8W<4U!32YK'87*5-'693%T&1DC:6&"IEQU/)411,JRM3Q%PQC33NO
M6J"M>H^[MF[0[ V[E-H;\VKMO>VT\W3M29K:^[L'C-R;=R](_P"NERF$S-+6
MTU1&?RDL3@_T]^!IPZ\RAQ0BH]#PZ*-U]_+6^ '56\\5V)UY\._CUM/>V!JS
MD,#N3%]8[87)8+(:M<>1PDDU#,M)41G_ #,].L<D=R(V4$^WWNI9!1F8CT)/
M2"':K6W8.D4:L.!"*"/S ZA_S!_GSUM_+EZ.QG??:_7_ &OV!M')[]PO7C4_
M4^&VWF*_"97/XG/Y;'Y;<S;FW5M6&DQK?W>DI/NEDF/W532P>.\X8;M;8W;:
M5(!I7/G_ "/5-UW1-HB\:179=04Z "16N34B@Q2OJ0//HT73W:6U.\.I^MNY
M-BUT>1V=VEL;:V_]M5<<BR>3#;KPU'FJ%)2H73+&E8(YHV"LDB,C*K*0&'4H
M2#Q!H>E\4JSJ'4U# $$>8(J.M3C_ (55Q;4PV:^!6Z]BBKI?E3%OC>R[$JMK
M4574;NJ=KX2IV9D,64./65GGI=Q5E <+"\;R--4U?VWTG!.=F!.L'X-.?]7V
M5Z _/!""W9*^,)/TZ DT%*XR"=6F@X^GGUM_8EJ]L5C&RJ+'E&Q]&V2C0QE(
MZ\TT9K$0Q/(EA)J TLP_H2/9(>AX.G#W[KW7O?NO=:D?\@S_ +>>?SG_ /Q-
M&Y__ ((/N?V=[G_8P_Z7_GU>@-RM_N9??\U?^?Y>MMMF"@LQ"JH+,S$ * +D
MDGZ >R3H<]:''\U'(]E_SR_GME^BO@OU]@-Y[8^$G6G9E'F^VZL-AJ/>V;IJ
MN&JSV'3=GVU3'-3567V_'@MDTCA4JJN:NR"S1XV:>KIQ%94VV/7(?C(H!QIZ
M_P \_EU&>^J_-%UX%J!2 /J=J@%B0"*T/FM%]3J(P*]7Z?R$_G=LWY1_$; =
M#U^W,?UIWO\ $+"8/J/L?K2GQ<.W5?!;?A?![6WMB<!:*6%*E,:U)EX98XY(
M,I35(D18YJ=I"W<;8P/6M0V0?]GH5<M;HNX0:"NAXJ(Z4I2F 0.(&*4/ @CR
MKU>I[+^A%T _RF_[)B^1O_B!^WO_ 'WVX?=DXC[1TW-\#?8?\'5 G_"4/_MW
M=W-_XNCV)_[X[XZ>S;>_[4?Z0?X6Z!O(?^X;_P#-9O\ CD?6/_A03\!]]97&
M[-_F=?$Z3+;8^3/Q7DP^>WO7;3BIES.<Z]VE6#*8O?4,#P2"IK]JR*9*B.5)
MEJ,5)/',DD=)%$U-MN54F*2FEO7R/^STHYIVMY56\MZB:'/;2K+Y_;3)IFHJ
M*&O51,'SLVO_ #$?YS/\H+Y!X6B7";ICZOZ<V%VYM5"&BVKVQM?M_P"0<^Y\
M=12+)-JHJJ'+T>7QI9S(*+)4XF"3B1%7-;&UMI4/\50?4'1T'XMS7=]TM9EQ
M6*C+6NEAXU1_E'R(-!UL#?\ "D[_ +=1=N?^)%Z4_P#?C87V7;3_ &X^P_X#
MT*.</^2?)]J?]7%Z/E_*S_[=M?!/_P 52Z-_]][@O::\_M7_ -,W^'HSV7_<
M.#_FC'_QP='U]INC/K3P_D-_]O?_ .;O_P"'KW'_ /!/[@]G>Y_V,/\ I?\
MGU>@)RM_N=>_\U#_ -7).H?\_;'8_,?S;OY2^(R]!193%93=/4V.R>,R-+!7
M8_(X^N^3&"IJV@KZ*I26.:&:.5HY8I%975BK @D>_;9_8S?Z7_GUNM<TBM[9
M?\U!_P!7(^MJ/_96?C%_WCET/_Z*'K[_ .Q[V3:SZG]O0X\%/X1^P="3M#K[
M877U&^.V%LC:&R,?)S)0[0VUAMM4<EI9IAKI<-142'UU$C\K^IV/U8WT23QZ
MNJA> I]G2O\ >NM]>]^Z]UJC]W?]Q7/P]_\ %<]S_P#P.WRE]G47^X3_ .F'
M^%>@/>_\EV#_ )I'_CLW6UQ[)>AQU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=9H/UM_RQJ/\
MW'E]^Z]TJ]X_\":/_EA)_P!;/?NO=([W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=4N_P#=Q%_YA=_^?B]F'_$7_F[_ ,^=!O\ Y;'_
M %!_]9NAIH'E[I_FQY^I)>HVE\&_BECL#!ID$M)#W5\OMT1YW*Z@#ICJJ#9_
M3N/N@U2>'<2N_CC>+SI_@B\NYOS 4?Y2W\NC(5ENSQI'&/L+2MG\U$8_)_VR
M/F'\VM^;2W]3?#_X7;)Q/=?S<W?@*?-_P[-U$T/4GQRV=DZFCI(.VOD1G<>S
M34="$K#/C<-3+)79 HOCB\<D9E]#"&[G-%K^9^0_U4'[ =7MZZ'P;<!Y2*@&
MH1!PU.1D#T RWE@$@6_@S\-\9\.^LL]BLOOC,]P=W]M;MK^T_D7WEN6&"FSW
M:W:V=13ELLE!3@1T&*I!_D>%Q<1*4M*BI=I&D=]3S>,U0* 84#R'^KC\^G=O
MLOHDH6+NQ+.YH"[GB:#@/(#R4 >71UO;'2[KWOW7NO>_=>Z][]U[JA#^9U\C
M_P"<9M+LC<_0?P0^)6'W]LCL+8V*I]H?(VBB1LSL3-YRAJ,;N:CFDW%O7&8.
MFR-!-"U309#*PQ4J+4Q:X)VA=G,+2. ]TK4H?AH<C[0.@[O-U?QDQVD(;4N)
M-2C234'#$9'$$XSP-.C8_P HS^7]#_+G^'NUNG,U48C+=L;HRE7V+W3G\*6F
MQU9OS.4M%2'"8JNFA@DGH<118^EQM/*R1B5H):D1QF=D#5[<_52%O+@/LZ5[
M'M8VBW6+!;XG(\V/'R&!P'R ZL^]I.C?KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NGG;_P#Q>*+_ (/)_P!:)??N
MO="O[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N@DSG
M_%VK_P#EN?\ H5??NO=-7OW7NO>_=>Z][]U[K5X^9G\H/^89COY@O8OSW_EL
M?)?KGJ[=/<^!BQF^*#L2JJL;F<%++AMLX?-XC&1R=:]D8O*8FN?:%'7@5D--
M/35"JJ+($293>WOHC$(IE) -13\^.1Z] W<MANQ=M=V4JHSKI</Y4"C'8XH=
M(XBH(XFN+C.S?DIVA\2_C5T5!V=UIO+Y._+?=VT]F; ;KSX\82NRU#V1WE0[
M.H&WSG(=Q9?%X&EP&UQ7P5-=4YK,0T:4U*ZV@DG*4[EZQB5C0A5J<MY#RX<3
M]G^#H1R7,EK$A=3)(0H*QC!>F:%J +@FK$8QQ(! '^3Q\B/DM\C.NOF9E?E;
MD<1+VGU9_,&[[Z/?;6VWIJC:?7>)Z[VEU-!)U]M+(00125F-Q^2R.2^WK:EI
MII_,9'<AE57KV%82FC@45JGB:D](=AO9KU9C-34EP\8"\%"A, T!.:Y.3\N
M%;<G<'8VX_YA^[-B[+R>Z,IUM\3_ (9UG9?8?6^VJF*.+LCN7OK=V1I^J=MU
M\(6[U5!A.FLS-0K-J429R-T4$.2T$ CJ>+-0'T"@5_;J'[.EIF9[DH":)%J9
M:"C&1B%SQJ!&V//4/3HLG6W0?\T7N_IQOD5VG\Z-[_%GOW=N.K=[;1^-VU^I
MNGJOHCIFC6&>?;O7G95!O3:68SN;E\<,39NNFS5-)$\\R17$,9]NM)%&=(0,
M.&HDAC\QF@^6/MKTDBMKN=/$>9HW.1&%C,:>BFJEFI^(AA7-*8H<W^65\M<[
M\Y/@WT'\G-U;?I-L[M[!P.?HMWXS%TU528)MV;%WEN/K[<N3VY#655?(N/K:
MW:TU721-4U+0I,())7EB<^V[N#Z:1D]#C[#D?X>E&S7_ .\[:.<BA89'EJ4E
M33)Q4&F>'1\?:;HSZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[H#/D
MK\<^J_EGTAV#\?>Z<#_>'KOLC#?PG,TL4BT^1H*FGJ8,CAMP8.M:.;[?(8ZM
MHX*VAJ K:)H$)5EU*7(I6A8,IH1TGNK6.]C:*4:E84(_U>8X@^1SUKJ]1_R]
M_P">5_+UQV:Z9^$GR?\ CCW-\:%K<I4==;?[[H,G0;EV$F5K:ROJ&I,7_=G(
MI2.TE49)(:7.5E#+,SSBA@:6129O<V]UW2*RMYZ:4/[?]7S/06M]LW+:AX5M
M+%)$/A$P8,@J<=HSQ]:>@'0T?#S^2[W1EOE11_/;^:EWO@/E)\B]OR8RKZXV
M+MF"LGZLZ[R> KZNKVSDXVK\'M*"5,6TPK,5AL=@\90TE?+-6L:VI83BD]^H
M3PH057S/F?\ 5Y^OR&.G;#EZ0S_5WSB64?"H'8E":4K2M.(P*&IR>[JTC^9-
MT%\A_DW\0.R.FOBOVE2],=W;ER>PZK:O8=9O??'75/A:7;^^MO9[<<+;MZYP
MV?R],:O'8ZJI M-2R"4S>*4K$[L$EI*D,@9Q4"M10'R/KT<[Q;37EN\<#:'.
MG2VIEI1@3E03D CIS_ET=&=^_&SX;=.]*_*#LRF[B[SV7_I"_OQV-1[SWIV#
M3[B_O'VGOC=FV?'N_L+$8+,5?VF'SN/H#]Y21>(TI@BU01QNVKN199"R"BFE
M!0#R \NM[1;36=ND<[:Y!JU-J9JU9B,L 30$#/1VO:?HRZHV_EC_ ,LWOCX7
M?,;^8'\A.T=V]1Y[9?RN[!S.[.N\9L'/;RRFZ,-CLAVEV!O>&'>E%N+86UJ2
MGG%)NNGC9:&MR*B5)%#E LCF-Y=K<1QJH-5%#6GH!C)].@WLNSR[=<7,KE2)
MGU*%)) U.<U4?Q#@3T=?^8]U9\Q.\OC!O+IGX5[PZLZV['[,C;:FYNR.S=W;
MUVG+M'8&0@ECW*VR)MD=>[_J&R]?%_N/CJ'%$:2&HEJ()ONDA*)K5HT<-)4@
M9H #4_.I&.C+=HKB>!H[8JKMC4S,ND'B1I5C7TX4XUQ3I _RJOY<NR_Y;'QC
MQ'5%#/C-Q]L;LJ8=W]Y]A8XU4U-NK?4U)%2_P_ SY&EH:A,)B88Q18J%X*<L
M!+5RPQU-747M>71NWU' X >@Z:V7:$V: 1+DGN=OXF(%?L&* >GSJ>B+]^?R
MF/D;L;^9MLW^8U_+OWIT?U]6[D%3)\E.JNV\_O[:FW.Q*G*5-+2[R.*_N'L#
M?221[CHU6JKDJ8Z7[;,4,.53[F>9A HCO%:$Q2@FGPD4Q^TC_BNBZYV66.^6
M\M2BUQ,KEJ,,<**<D#Y"H!S4];"L1D,<9F1(YBB&5(I&FC20J"Z1RO%"64&X
M#%$)'.D?3V6]"CH-^Z-FY3L;IWMCKW"3T%+FM]]:;[V;B*K*RU$&+ILIN?:V
M5PE!/DIJ2EKI4ITEKD:9HH)G" E4<V4[4T->J.NI2/4$=5A?R2OY?/<W\MKX
MJ=@=&]Y;FZQW7NW=?R#W5VOCLCU1F=U9S;L.W<YUQU1M"DHJVKW?LO8M2M:M
M3L6K>2-*22(120LLS.SI&NW&Z6[<,M0 H&:>I/D3Z]$'+.T2;- T4I4DR%^P
MDBA51YA<]O5O]91TF1I*K'Y"EIJZ@KJ:>CK:*L@BJ:2LI*F)H:FEJJ:9722.
M1'9'1U*LI(((/M!T(NM3_87_  G>[+Z%_FG]?_++H;?/2^-^*&S.Y\7VIC^N
M,]F=\X[L[:V*F2>KS6RMNXG'[ S6)JJ:CJ:IXL3)/FJ1C3"-)@KQEY#E]S$L
M!C8'52E<4-"..>@3#RHUIN"W,101 EM&0RDJ00!0BE349%!BF,W,_P W'X9]
MH?/?X2[Z^-O3^>V%MO?.Y]U]>9V@RO964W#A]IPTFTMV8_.Y&.LKMK[7WC6+
M(\-(RP!*&12Y 9D6[!#8W MI [5H*\..1^71]OVWONEJ\$94,VFA8D##!O($
M^7IT9?X7],;H^.GQ(^-G0N]J_ 93>'3G2?7'6^Y\EM6JR-=MJNSFS]K8W!Y.
MKP59EL7@ZJ6D>6C9H)*BCI9&0@O$ANH:N)!*[,.!).?F>EFWV[6EO'$U"4C1
M33A55 -*@8QT9GVSTLZH6_EH?RM_D!\-/G?\ZOE!V?O#IW.[ ^3NX=_9;86(
MV%N#>N4WAB*;=7<>4["QZ;OQ^X>OMKT5.Z45:D4PHLAD )P54O':0F-Y=K<1
MQJH-5%#6GH!C)].@ULVS2[=<W$SE2)G+*%)) U.V:J/XO(GKW\R_^5O\@/F7
M\[_@K\H.L-X=.X+8'QBW#L'+;]Q&_=P;UQ>\,O3;5[CQ?8603:&/V]U]NBBJ
M'>BHGBA%;D,>#.0K%([R#UG=K;QR*P-6%!2GH1G(]>O;SLTNXW-O,A4"%PS!
MB02-2-BBG^'S(ZOI]EW0EZ][]U[KWOW7NO>_=>ZUT/YIG\IKY==^?,7J'Y\_
M KOC975/??7FT*#9=;2]A560Q=/CTQ/]Z*6BW)M/*46R]^4\[U-%N^JQ^2Q>
M3H! \(UK*YD:'V:6=ZD2&*525)KCCY?,>G04WO8Y[NX2[M)%21!I[N%.[([6
MSW$$$4IZ4R=W!]_?*+X7_#/I'#_*_:>X?F)\Y=UY'<NRJ#:OQHPE1E:3L[=D
MNXMQY;;%;E<_6;5V/C=O8V@P,N.&XLU6T5'24\D,S4\=06ABD3-&DTAT'2G'
MN\OV5KGAQ/KY]&L4\]E;IXX\6;X2(AAC4T-3I QEB:"N!Q *8_D\?(CY+?(S
MKKYF97Y6Y'$2]I]6?S!N^^CWVUMMZ:HVGUWB>N]I=302=?;2R$$$4E9C<?DL
MCDOMZVI:::?S&1W(956U["L)31P**U3Q-2>F-AO9KU9C-34EP\8"\%"A, T!
M.:Y.3\N %;<G<'8VX_YA^[-B[+R>Z,IUM\3_ (9UG9?8?6^VJF*.+LCN7OK=
MV1I^J=MU\(6[U5!A.FLS-0K-J429R-T4$.2T$ CJ>+-0'T"@5_;J'[.EIF9[
MDH":)%J9:"C&1B%SQJ!&V//4/3HLG6W0?\T7N_IQOD5VG\Z-[_%GOW=N.K=[
M;1^-VU^INGJOHCIFC6&>?;O7G95!O3:68SN;E\<,39NNFS5-)$\\R17$,9]N
MM)%&=(0,.&HDAC\QF@^6/MKTDBMKN=/$>9HW.1&%C,:>BFJEFI^(AA7-*8H<
MW^65\M<[\Y/@WT'\G-U;?I-L[M[!P.?HMWXS%TU528)MV;%WEN/K[<N3VY#6
M55?(N/K:W:TU721-4U+0I,())7EB<^V[N#Z:1D]#C[#D?X>E&S7_ .\[:.<B
MA89'EJ4E33)Q4&F>'1\?:;HSZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>ZS0?K;_EC4?\ N/+[]U[I5[Q_X$T?_+"3_K9[]U[I'>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[HL7^RH==_P"S
MF_[/+_&=Z?Z6?]EB_P!E0_N]_$<'_H[_ -'?^E7_ $O_ ,9_A/\ =S^)?QK^
M)?L?<?Q?[;[;T?9^7][V]XY\/P\4U:OG6E.D/T"?4_55;7X7A4QITZM=>%:U
M^=*>72BZ7^/FV.E=T=_;SQ.:S^X]S?(ON.K[CWKE=Q/C7FHJT;,V?U_M[:>$
M&-H* )BL3BMD4=/11S>::[2O)*[/Q5Y"X /X10?M)_R]/PVZPEV'%VU-]NE5
M_P "CJM'</\ )(ZWRG<_=O>VU?GC_,UZ@WO\@M[5>^NR5Z5^3&UNM,1EJ]JJ
MODP>)--M_J"&::@PU/D'H,-!6U%6U+2JL2R'U,RM=P*J%*1D**"JDG^9Z))>
M75DD>43W*%VU,$D"CT& GD,"M33SZ.?\1/A3_LI%9ONL_P!FU^;7R;_OU3;=
MIOM?EWWS_IHH]G?W>ES,OGV)!_=7;?\ #I:[^,Z<BUYO,M+3BR^+U,3W'CT[
M46G\*TK]N>C#;]M_=^K]6:753^U?7II7A@4K7/V#H[7M/T9=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]T\[?\ ^+Q1?\'D_P"M$OOW7NA7]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW029S_B[5_P#RW/\
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MO_=5S_QM%\Z/_F7>S#</]#_YI)_EZ#?+G_$K_GLG_P"?>AI_EF/+V7A/E/\
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ME@G42Q05$<\$2"[MC:.4.?,'U'0AV?=$WB 3(*>3*34JPXC_ "@XJ"#0<.K
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M=85"I<W:J, "8  ?(!.K8OCETA_LNO4>W.I?]+W>7>O]W:G.U/\ I,^1N_\
M_2=VYG?XYG,AG/!N/>?\)PGW45'_ !#[.A7[9/%30117;1J*&63Q6U4 ^2B@
MZ/K.V^CC$>MWI7ND;4YJ2<F@K2M!\J=#C[;Z4]>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=%!Z4^&>P?CYM/Y5
M;9ZTWGV-2U'RT[[[Q^26\MPYO(;8R67V9V5WQC<5C]P_Z/Q1;4Q$$&.QS86"
M?%4V2BR<R.&^XJ:E2 K\LYFTUIVJ%%/0=(+/;TLA($+?JR/*U:&C/2M* 8QB
MM?MZ4VV_BWLO9OQ&Q'PXV=N??>S=AX/HJGZ$Q&]=JY3$XWLS$X&'9HV8^[,3
MG*G!Y&CASK1EZT5AQTD:U3F406LONK2EGUFA-:YX<:^5.G4M5BA$"$J F@$?
M$ !I!%0<CY@YZK$V!_(AZ_ZHVEB-@=6_S(OYN/6NQ-OI51X'96P/F%A-G;2P
MD=;6U.2K8\1MO;O4&.HZ99JFLFJ)1#"@>25W:[,Q*UMR+FICB)]2E3_AZ(H^
M5UA4*ES=JHP )@ !\@$ZMB^.72'^RZ]1[<ZE_P!+W>7>O]W:G.U/^DSY&[__
M -)W;F=_CF<R&<\&X]Y_PG"?=14?\0^SH5^V3Q4T$45VT:BAED\5M5 /DHH.
MCZSMOHXQ'K=Z5[I&U.:DG)H*TK0?*G0X^V^E/7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW6>G!:1@.3X*H_P"P6FF8_P"\#W[KW2JW
MC_P)H_\ EA)_UL]^Z]TCO?NO=>]^Z]U[W[KW50O\]OHD]]_RM_E#BZ181FNL
MMKT7>V&J)J8U(I1T]DJ?>.Z&C5;,CS8"AR]*LBD:#/J:Z!E*W;I/#F4^II^W
M'^7HBYFMOJK&9:THNOU^ A_Y@4Z</Y&7=*=X?RM?B=F9-2Y+86QZGI;*P,2W
M@?I[-9'86%L]S<2XK"X^H']/-I_'OVX1^',X]37]N?\ +U;ENX%S8PL/) G^
M\=G_ #[U6%\,:7$_//\ GV_S"?D#F11;EZM^*?6=1\8-H4=112M'!D<X*SJS
M)O13RK;P58VKOUVD%C*F5O&3%?VIN!]/;(OFY+G_ %?81T4[<PW'=+B6H*PH
M(0*'B2:_L*L/F#CYYO\ A.ED\Q\=^X/YC_\ +9W3)7"H^/W>M;OK9$F7F093
M,X*?(U?6N?S1I!'3H*>HI-J;6R,,U/&(Y/XL7TH&37O=*2B.4?B6AH/,?\73
M\NJ\I@V;W%F:_I256IJ2K5I\N"@X_BX#I)_SSJ2;Y=_S-OY7/\O+'SIE,)6;
MB';/:FVVUBAGVCN/=44.9K*YQ$ZO/1[9ZGW-+! &!"UAUZ5F1_>]O_1BEE^6
MD'Y_\61U3F3_ !^\M;,$$:O$=2,%1^7HKBGSSY=;9:(D:)'&BQQQJJ(B*%1$
M4!51%4   "P ]D_0VZH[_P"%&G_;I#Y%?^')T7_[_'K_ -F.U?VZ_P"V_P".
MGH-<W_\ )/E_YM_]7$Z'W^2A_P!NK?A5_P"(F;_WK-R^V+W^V?\ TQ_P]+]A
M_P!PH/\ FDG_ !T=6D^TO1MU[W[KW6O]_*C_ )@_R6^6GS>_F/\ 1W<NX-MY
M3K[XS]C9W:_5E!A=I8C U]'C*+MSL3:%-_&<I0QB6LD6BVO2IKD(NVMR"6%C
M*\M%@CC9:U85-?L!_P O0:V3=I=PN+F*332%]*T!!IJ<9R?X1Z= E_,K_G"=
M_P#P1_FB=2=%XC KV1T)N7H.EW55]1;=VMB9^P-^=M[SINYMI];;?PV[9HY*
MJD@J]RX;;<=3X8YV2 5!CAF9A"[EK8+<0EZT(-*^5!0G^5>DV[<P2;;?1P4#
M(R5H!WESK50#4#+!1GU/28WUB_\ A4AN/ U'?>W-^?%WK>DI\=#NF#XB[8PO
M7N>WA/1TSRY@[/J,GO#J_=R35\L++05"P[\I2S):GDAF.OWM#9CM(<^6O@/2
MN#^? ]-3)O<GZJM"@ KX(R3YZ22AS^$D.!Z4X]'Z_DO?S0<]_,DZ8[$':NT<
M'L+Y"=#;GQ&T^TMN[?3)4>+RE%G:"KDV[O&EP>8DJ*K&M5U6!RU%58Z2>I\,
MV.=A(%E6*--?6GTC"AJK"H/1IR_O)WB)BZZ)$;2Z^A]:'(!H<'@01FG5S?M#
MT?\ 6K1_PK&_[(=^/O\ XM;A?_?0]L^SG9/[5O\ 2_Y1T".??]Q$_P":R_\
M').F#J;M?^?O_, ZFVEV]\.,Q\??@S\=J3#8[#=3T?<6,H,_V7VYMC 8J#$4
M^]*EMP],=R0I2U\E(TM(ZT.#B8$&"6LIM%9/IH[:U8K)J=O/3\(/IQ!Q_JSU
M=;G=-WC$MKX<$9^'Q,R.OK\#@ ^6*^A((),9_+W_ )K'R>E^8>;_ ):O\S/K
M/;G7?R:BH:RMZO[(V;2G&[0[7AQV,JLXL1I(9ZJBD_B6.Q]3D,5E<:\%/,:6
M>AFI:2MB\+-7-F@C$T1)7@0>*_ZO\W$=*]KWN9K@V=X@24 E67X) /2ORR/L
M-0I%.K(_YE?\PWK+^6U\<LCW=OO%U&\-S9?)+M+JKK7'U\.,K]^[YJJ.IK*>
MBGR<L55]EC:2*F>JRE?X*@PPI:*&:HD@@D2VEL;MP@QYD^@Z-=WW5-G@,SY\
ME6M"S'@/\I.: $T/#JF#8D__  IQ^7&T</W_ +,[5^+7P^V?NV@7<FT>D=Y;
M-PD6Y:W;E>TN0PCY"CW+TEWEDJ.2HIC$@CR>:Q4X616E@IV+:%Y^DA)4AG/#
M4.%?ED?Y>@^IWJ^"RJ880<B-@=5*X#51\T]"ISD \#!_ '^;5\B*KY:Y3^7#
M_,UZGP'3_P I5AEFZRW]M&%J'8G;*1TU=E8*3[=LCDJ425]%2-48?)XNH>DK
M&@GI)8**MA$,[-S9*(_%B-5\P>*_;_J]./2S;-\E>X-G>($E JK+\$@SPK\L
MC)K1JZ2*=5._\*@,/\X::;;N6[6W7U'D/AA7=TT$?QZVQMVFF3M;#[G7JAAN
M"HWQ4';=#&U,T\67-.%R-4=$L-U!!T+]F\.N-6O3W<--*^7GT0<\"YT#68_!
M\1= &KQ-6@\?*GQ</EU<;VA@?YC>"_E:_P S&/\ F*[UZ,WGNJH^-W:[]:3]
M&TD]+BJ';Z=7;J7.Q9T5.TMJ.:AZEH3&=$PT+PRFX)?'X7CQ^%JIJ6NJE:U^
M70CN1="QN/JS&6\.2GAZJ:=!XZJ&M:]4G?R@OD7_ #/NU_AAMOX>_P M3KKK
MW8 ZKSG8&5[@^6W>"P5.T,#N#L#<^5W!MG9_7^-J<3NBFGKX**KCJJOS83.L
MI=/-2TT#0RUAA?Q1)+XDQ)K2BKQ-!Y\,?GT&N7KR\N+-;>R55*:M<LGP@LQ8
M!:5JU#4U! \QD5-CD_YDO\V[^55\CNFM@_S4LIU-W]\?.[\XU!'W1L' [;P*
M;9HHJ_#8K<%9M_+[,V-U<ADP*5\.3K<9FMN^6IIZMA350TCP,_2P7JDP55E_
M"<U_F?\ #^72\;M?['*B7^B2.0T\5:#2309P@H.)JM:$D$TIUM[JP8!E(96
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M?]D._'W_ ,6MPO\ [Z'MGV<[)_:M_I?\HZ!'/O\ N(G_ #67_CDG3;UYW/\
MSYOG[U7LSLWX/Q]'?"'XVT6W\+C.J\IW9087-=J]Q8';^&3#MNNKI-P=9=RT
MM/0Y">G,U"8L7B8RBQM#5UE.?NIM&.WM6*RZG;ST_"/YJ:]._4[GNZ"2TT01
MFFDR9D<4XTTR  ^6*XK6AZ%+^69_-+^8M5\VMV?RP_YE>U-IT/R'PN'RM7L/
MLO:^/QN!_OU6[;VQ#N^>GR6.V\L.'K(LO@H*G/XW)8JEQ<:I!)3RT:2$)"W=
MV:>&)H2=)X@\17_53/[3T[L^]7!N&LKU5$H%5=<"0 ?S)%6P .((!%.AN_FQ
M_/SY'?$CY??RS>G.F,[MO%;(^4/;PV9VQ29K:F+S]?7X3_2?TSM;1ALC7(TE
M%)]IO>O7R17.ID:UT'NEE:K.DC-6JBHI]A/^3I1O>[2[?<6T4>FDSZ6J"334
M@QD?Q'UZOI]EW0EZU_OC-_,'^2W9O\[[Y:?!;=NX-MU?Q^ZAZYW+NC9>'I=I
M8BAW'39.@'33TGWVYZ>-*BHC3^_%<-#_ %!CU$E+DREM%2W645J30^GG_FZ#
M5KNTLVY2VATZ$34* ZJTCXFO](^70&?S,OYPWR%^!_\ ,^ZIZ,V_MV#LWHS<
M?0%/NJ7IW";=Q@WUV!V_O*E[GVGUIMW%;T:DKJNAIJS<V&VW'5-!3U;QP"H:
M."=V$+N6E@MQ"7)((:E?( 4)-/L)Z2;OS!+MMZD"J&1HZZ:'4SG6% / 58**
MT-*GH,^\MS_\*=-B];;E^7F0WM\8=G;,V9M*L[%W/\3]D;7V;NK=&$VQAJ*7
M,YN@K&SG76Y*NLJ:*C:22K@QF_II7^S9:77(RI+:,6;'1WU)IK.!_AX?:.FK
MEMZ0&X!A"JI8P@%C0 FGPDEA_1< D8^;ETA_.2^>_P#,RZYV5U3_ "[^B.OM
MH_(O";,3,_*WNKM2L;_0CTQD*S)YK";3I]C4-6N5J:VKW ,!/DJ:"IH\K]I&
M?MO#7B"KJZ;4MA':&LK'37M"\6_S4KU>TYAGWI MFBAPH,K2$Z(R20 *5+$T
M)'D!2M34 -<K_,5_F[_RKODWT?L+^:3N?I_O_P"/'>VX$Q"=P;%P6TMN4.V*
M2+(XK$;BKL%G]K[#ZA\4V"7+4N4KZ+/8+_**6H;[:I!5V@<^E@O$8P55E'PG
M-?YG_#^6>DPW6_V29$ORDD<AIXJT&DX&31!0<34<"2":$=;)'S?^7?7WP6^,
MG9OR8[)I:[*X38..HH\9MO%NL>5W=NS/Y&EP>U-KT$SQS+$:NMKXDFJ61UIX
M!+4.K)$P)5!";APB\3T+MPODVV%IY*Z5'EQ))H!^9('IZXZU_P#JOL+_ (4?
M?S!NNMN?([I#LOXE_"WJ/L!*C</6FT]U;;I\GN+<&QZV>0[>S54VZ.F?D!4/
M#40:98*R3^#?=K:IBI8Z>:$$R9;2V8HP=R,'R%?VC_+T%XY=XW6-98F@A5NY
M0:EM)X5JCC(SBGV#AUBZ+_F@?S*_AC\[>EO@K_-9P/6N^\)W[D]N;?Z_^06P
M<3C\.]5D=Y9.JVUM7-X^?9>$V_BJ^A;/24V%RU#58+ UE"LJU\A--XOO/26<
M4\9E@)[:DJ?]7IGSKPX]>MM[O-ONDM;]4(DH$E2H!)QY"A[J BBZ:UX4Z/-_
M/O\ GA\AOY?WQCZD[3^-^;VY@]V[O[XQVP,W/N;:^-W713;<JNOM^[BEAAHL
MFI6.7[G;U,PE7G2&7Z-[8VVU6[<JU:!:X^T#_+T8\T;M+L\"R1::F0*=0)%"
MK'R(].BM3=[?SVOYC&,E[P^!TW1_PH^+67K9ZOI?(]WT.W<UVUV_LZFCGAHM
MWY2@R_6G==+1TV39Q-30K08P)XU$=550?Y3.ZL=O:G3+J=O,#@#Z<1D?LZ22
MS[GNH\2T,<,9RC/EW6G&FEP :X! ;'SZ>?Y9W\TOYF5'S;W'_+'_ )E^S]I8
MKO\ QF R]=L/LS;U!CMOS;ZR.W=NTNZOM*[&[<2/"5T&8P=-79S'Y/$P8R-1
M3/324:R-H@U=V<?A^-"3IKD'RK_JIG]IKU;9]YN#<&RO542 55Q@2 #]A)%6
MJ*<"* CHR?\ -;_F8]U_&OMCX_\ PE^%W7VW.QOF;\G%I\EMG^^:R3;4V#LZ
MJSE=@J'<-?CDKL6M3+638#,%))ZF.FHX<345-0LRJD+LVEHLJM)(2$7C3B3Z
M#I9O.[R6DD=M;*K32\ Q[54<2:$'R-/L/&E"2_?>W/\ A3]\?-I[M[YS/R(^
M(/R#P6SL%E]WY;H?;FR\'499\1CX&S>1H,-!C^@.H:ZMFHJ>FDABIJ?=<M1.
M 4B-5.T;%0&LY*+1UX=W^?)_P=%ICWNWU2%X)  3X=#]M!1$-?(5;[<YZMP_
ME4_S#<%_,I^+%!WG!MNEV/OG;VZ\QUUVILBAJZROQN WGAJ/&9>.?"5]?34T
ML]!7X[.T-=3L1)XFGDI6EDEIY'**\M3:/I.?,'U'1YLN[)O, E44-2K+_"PH
M>/F*$$'Y^M>K*/:7HWZ][]U[KWOW7NGG;_\ Q>*+_@\G_6B7W[KW0K^_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[H/=VT31U45:H_;
MJ$$<A_I-$+"Y_P 4 M_P4^_=>Z2/OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[I]PU$TL.3K&
M'[=+CJU5/]9I::5+#_64L3_KCW[KW3IO'_@31_\ +"3_ *V>_=>Z1WOW7NO>
M_=>Z][]U[IDW+MW$[OVYN#:>?I$K\%NC"97;N:H9 #'68G-4$^-R5)(&##3)
M#4NAN#P?>P:=:(U"G6H;_)2^0-1\#?C7_.%Z)WW_ !6KS7P$W]V+VMCZ')J*
M=]PO3[<W5LH8[$T53*RP_=9'INA>Q*PLV;BD5F#NP.MPC^I>)Q3]0 ?G7_9_
MET!N7+D;7%=PMJ/T[NPKQ*4-*<..@GR'=7S/1]/^$TW2V8V1_+_R?>>\)LE7
M[Y^5_<^_^V,ME\S"R9:OPN&R!V%B):N>9C+.*FLVYE<K'42!?(,IK4%"LCIM
MU<-+I%*( HI^W^5:=&7*$#):>*]=4SO(U13B:5\L$+7\\8Z+)WC0S_#3_A3!
M\>>U*&FAP_7OSVZH38>[,C+,_P!KEMYUF"K>OUPM"AG7PU(S6PMC5DP\;QR_
MQ#T_O2NT3T9\:T92<HU1]A_XL_\ %=([A38[S'(  L\95B3Q91Y9P>U/D:^M
M>G;X)1CY@?\ "@_^81\GYJU,SLWXA;63H#8B5%&P.#W1(4ZHDEQ$SQ@+!*=@
M[XE,A),IRA:,^$V&K@>!;1I2A<EC_J^PC]G5ML;Z_=;B:M1"JQ**<"3G]C*W
MVUQCK:>]E'0RZHY_X4:?]ND/D5_X<G1?_O\ 'K_V8[5_;K_MO^.GH-<W_P#)
M/E_YM_\ 5Q.A]_DH?]NK?A5_XB9O_>LW+[8O?[9_],?\/2_8?]PH/^:2?\='
M5I/M+T;=>]^Z]UJ1_P @S_MYY_.?_P#$T;G_ /@@^Y_9WN?]C#_I?^?5Z W*
MW^YE]_S5_P"?Y>FWYW8?%YS_ (4\?R]Z++T--D:2#JGK;,0T]5&)8H\IM[*?
M(?/X.N53])*6MQE/4PM_9DA5AR/?K?\ W#?_ $W_ $#UK<0#OEO7_?7^ 3'K
M;N]DG0ZZU./^$^5#%C/Y@/\ .KQL#2/!C^_::AA>8JTK14G=7R1@C:5D2,%B
M(P6(51?Z >SK=,Q0_P"E_P B] ?E7%Y??\U?^?Y>ML?V2]#CK5H_X5C?]D._
M'W_Q:W"_^^A[9]G.R?VK?Z7_ "CH$<^_[B)_S67_ (Y)ULR=<;9P&R^O-A[.
MVI3T5)M;:>S-K[9VU2XVE6AQU-@,#@Z'%X:GH*)500PI3TL:Q1  (H"VX]D[
M&IZ&J*%  X 4'6J9_/NI(MF_S1_Y.O:&S$BH>S<CV=MS;M5D:!&ARM?A=J]\
M=85>V,373T\L3S4K3;ZS,(IV(5EJZA#=9&'LZVWNAE!X4K^=#_F'0(YG_3OK
M)UPQDTDC!*ZX\5].XX^9]>L/_"B+'T.^/GY_)_ZOW?'%FNO-R=L1X_<&U<FD
M53@LE0[K[HZ5V]N..OH*E)(I5JJ&(4THE5U,=U(LS ^VOMBE8<0N#Y\&ZUS8
M!)=62-E6E[E/ ]\8R.!P2/S/6W6JA0%4!54!550 % %@ !] /9)T.NM1;_A0
M924^UOYCO\GCL7;:IBM]U/:E'BY\_1%*;)R8_:?=W361VU335<<;2&*GGW7D
MFC5M:C[F4!?4P)UM@U13 _P_Y&Z W-!T7MDPP?$(J.--<>/YG]O2R_X5G_\
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MP?\ [K*7V3GCT-APZ4GO76^M13^6=_W$I?S0_P#Q$W=O_O[OC1[.KG_<./\
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ML?'2Q@K'410E;FTNU2U)%"O$-4 4XUR>JVG-UHR*KZDD^$QZ')##%!I7.>'
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M/RR_[BD_@+_XKLO_ +R'RO\ 9Q!_N$_^F_RKT";_ /Y+EO\ \TC_ ()NA_\
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M_P"*>_=>Z]_!\I_RH57_ %*;_BGOW7NO?P?*?\J%5_U*;_BGOW7NO?P?*?\
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MG_X*OHWV8;5_;K_MO^.GH-\W?\DZ7_FW_P!74Z,A_)M_[=8_ _\ \5OZ]_\
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MO=>_@>6_Y4)_]LO_ $=[]U[KW\#RW_*A/_ME_P"CO?NO=>_@>6_Y4)_]LO\
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M"?\ VR_]'>_=>Z]_ \M_RH3_ .V7_H[W[KW7OX'EO^5"?_;+_P!'>_=>Z]_
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MR?\ RWG_ ."KZ-]F&U?VZ_[;_CIZ#?-W_).E_P";?_5U.C(?R;?^W6/P/_\
M%;^O?_=:?;%Y_:O_ *9O\/1ALG^X<'_-*/\ XZ.K+O:;HTZ][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>ZH!_X5'?\ ;BCYS?\ ELW_ ,&'\???NO=?(%]^Z]U]J?\ D>_]
MNA?Y=7_BJ75'_N@A]^Z]U:C[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z36\_^//W9_X;6=_]U=5[]UH\.M>+_A*Y_P!NJL;_ .+"=Q?]
M"[6]F6[?VY^P?X!T&.3O^2?']K_\?/6R%[+>A1U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>)MR> .23^/?NO=)S(;FH*/4D!^\G'&F)@(5/
M^US6(_Y)#?XV]H)]P2+ [C\N'[>E\&WO+D]H^?']G2(K\UD,@2)9BD)_Y1X;
MQQ6_HPN2WT_M$_X>R>:[>?B<>@X='$-HD' 5/J>/33[3=*>O>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZET==54$@EI9FC-QJ6
M]XY /Q(AX/\ L?I^/;L4S0FJFG^#IJ6%9A1A7_#T(&*W)35VF&ITTM4;  G]
MF5CQ^V[?0G_4M_L"?9W;7ZS8;!_D>B2YL&ARN1_,=*7V8=%_7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=:F?_"D[^:-\/J?XD?(C^7=M_?==OWY,;YJ>J*7)X+8V-@S6U^LZC9?<VP.
MRLM1]E;MER%%2TE8:/8]33C&4/\ $JZ&IJ*=:NFIH9&G0YVFT<R"6E%%<GSP
M1C]OV= CG'>(%MWM-59&T=HSIHP;N/ 87AQR,4->A?\ Y"7\WOX7=K_'3XQ?
M!%]X9SKKY)=8]7X/KRDVIV/B:3"87L[*;8H(ONY^L-UT&4R]%6M*LUX,;728
MW)2F&8PT4D41E+6XV4D3-(1522:CRJ?/_53Y]*N6M^M[N*.V!*R(BKI84U:5
M )4Y!^S#8)I3K9M]E?0MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZH!_X5'?]N*/G-_Y
M;-_\&'\???NO=?(%]^Z]U]J?^1[_ -NA?Y=7_BJ75'_N@A]^Z]U:C[]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z36\_\ CS]V?^&UG?\
MW5U7OW6CPZUXO^$KG_;JK&_^+"=Q?]"[6]F6[?VY^P?X!T&.3O\ DGQ_:_\
MQ\];(7LMZ%'7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=,N2SU#CKHS
M>>H%_P#)XB"5/_-U^0O^\G_ ^TEQ>)!CB?0?Y?3I7;V;W&> ]3_D]>D#D<Y7
M9$E9)/% 2;4\)*H1_P W#>[?['C^@'LDGO'GXF@]!_JST=06:09&3ZG_ %8Z
M9_:7I7U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=*C$;DFH],%9JJ*4657^LT(_&DD^I1_0\C\'
M\>S&UOS%VOD?S'1==6 E[DP?Y'H0X)X:F))H)%EB<75U-P?ZC_ C\@\CV>HX
MD%5-1T1.AC-&%#UE]VZKU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW15_G-VYN7H+X7_+#N[9D22[OZF^.O<G86U1(',,6XMI
M[ SV:PM54*@),4-321S2@6NB,+CZAV%/%=5]6 _::=)+^X-I!)*!4HCL!ZZ5
M)_R=?&_R^7RVX,MD\]GLGD<WG,WD:W+YG,Y>MJ<EELOELE4RUF1R>3R-9+--
M45%1-,\LTTKN[N[,S%B3['0 44'6/CN9"68DDDDDFI).223Y]<L-F<QMS,8K
M<.WLKDL%G\%DJ',X/.8:NJL7F,-F,7515V-RN*R5#+!-3U-/- DT$\+H\;HK
MHP8 ^_$!A0]>1S&0RD@@@@@T((R""//K[)GPK[;W#W[\//BMWCNVE-'NKN#X
MZ]+]F;F@$:Q1#<&]^NMN[CS$M(B6'V\E1D9)*<V6\3H2JDZ0!9D\)V7T8C]A
MIUD)8W!NX(Y2*:T1Z>FI0?\ +T9KVUTJZ][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NJ ?\ A4=_
MVXH^<W_ELW_P8?Q]]^Z]U\@7W[KW7VI_Y'O_ &Z%_EU?^*I=4?\ N@A]^Z]U
M:C[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z36\_^//W9
M_P"&UG?_ '5U7OW6CPZUXO\ A*Y_VZJQO_BPG<7_ $+M;V9;M_;G[!_@'08Y
M._Y)\?VO_P ?/6R%[+>A1U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=1:NMIJ&(S54
MJQ)^ >7<_P"I1!<D_P"M[;EE6$58TZ<BB:8T45Z0.3W/4U>J*CU4D!N"X/\
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MX'Y=1QN/),=O!))$TC."610*C37"T +$T\Z_EUL"?RZO^$[7SC^67:&U:WY
M=3[]^*WQWQ^9AJNPMT=M8"NV-V3F,)CJPC([:V!UMN2FH\O_ !&N$/@@R.2H
M:6AIXY35AZHQQTE2KN]TCA!"'4WE3('VG_-]F.B79^4;F]=6F4QQ@@MJJ'8
MFH"\16E*FF#45X=?3.VQMK![,VUM[9^V,;38;;6U,'B=M;>P]&GCH\5@\%04
M^+Q.-I(Q^F*"GI8XHU_"J!["ASU,(&D4'3Y[]UOKWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZH!
M_P"%1W_;BCYS?^6S?_!A_'WW[KW7R!??NO=?:G_D>_\ ;H7^75_XJEU1_P"Z
M"'W[KW5J/OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[I-;
MS_X\_=G_ (;6=_\ =75>_=:/#K7B_P"$KG_;JK&_^+"=Q?\ 0NUO9ENW]N?L
M'^ =!CD[_DGQ_:__ !\];(7LMZ%'7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=)?+;EIZ/5!
M1Z:FI%P6O>"%@;'401J/^ /^N?Q[+KG<%B[5R?Y#HQMMO:7N; _F>@_JJNHK
M)6FJ96ED;\L>%'^I118 ?X #V222M*:L:]'<<2Q"BBG4?VWTYU[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW4NBK:B@G6>F<HXX8'E)$N"4D
M7\@V_P"*<^W8IF@-5/\ L]-30K.-+?\ %="EB\I!E(!+$=,JV$T)-VC8_P"]
MJ?P?^)N/8CMKE;E:CCYCTZ#EQ;M;M0\/(^O3G[4=)^O>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z(+MS^9O\&^R?DINWX4]2?)_J3>_P M]N;=S&5C
MZHQ^2RE=!+DL519&HJL(F[J+''"U>0H?X=)+E<-092?(T<*-+44T26;W[KW6
MA-MS^0O_ #Q/YO'S6W7V%_,VS^YNE=I8#<TN/WCVEV3EL5GJ.AVS'4U2C9OQ
M6ZNVUEJK'M0G[&/P/$V*QB+,:V>HJZUGAJ?=>ZWQ?Y=_\KCX<?RPNK8NN/BY
MUE18?,Y+%XRA[#[AW+'09KN3MFKQAEEBR&_MZQT%"\L:S5,T]/BZ**BQM(TS
M_:4< =K^Z]U8=[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NJ ?\ A4=_VXH^
M<W_ELW_P8?Q]]^Z]U\@7W[KW7VI_Y'O_ &Z%_EU?^*I=4?\ N@A]^Z]U:C[]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z36\_^//W9_P"&
MUG?_ '5U7OW6CPZUXO\ A*Y_VZJQO_BPG<7_ $+M;V9;M_;G[!_@'08Y._Y)
M\?VO_P ?/6R%[+>A1U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=8:BI@I8FGJ)%BB3ZLQ_/X51]23^ +D^Z
M22"(58T'5TC,AHHJ>@[R^XYZ[7!2ZJ>D-U8\":8?G603I'^T@_ZY/T]D=U?F
M;M7 _F>CRUL!%W-D_P ATF?9=T8]>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U*HZR>AG2HIWTNOU'U5U/ZD=?R#_O
MN?;D4K0MJ7CTU-"LRZ6_XKH5<9DH<G3+/%Z7%EFB)NT4EN5/TN#_ &3^?]>X
M]B6WG%PM1^8]#T&[B V[4/Y'U'3C[?Z8Z][]U[KWOW7NO>_=>Z][]U[I$=F=
MC;-Z>ZW[ [;[&S=-MGKWJW9&Z^QM][DK YH]O[-V1@:_<VY\W5B)78Q4E#C)
MYY-*DZ8S8$^_=>Z^:M_,I_X4:_.?^;%V0OPN_EB==]L]7=3;[R<^U<?B>OJ2
MJR7R9[\HZT&BG_O)D-L&K&V,(R3%ZG'8NK.F$/)DLH],STT/NO=7>?R"O^$R
M.2^!W9/7/SE^9.^%RGRAVGCL[5=<=*[ R:3[#ZCJ-X[6R^T\I6[ZW3%&&W!G
M%QFX:JE%+0F+&4<LLC+-DV%/40^Z]UN2>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>ZH!_P"%1W_;BCYS?^6S?_!A_'WW[KW7R!??NO=?:G_D
M>_\ ;H7^75_XJEU1_P"Z"'W[KW5J/OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[I-;S_X\_=G_ (;6=_\ =75>_=:/#K7B_P"$KG_;JK&_
M^+"=Q?\ 0NUO9ENW]N?L'^ =!CD[_DGQ_:__ !\];(7LMZ%'7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=-63R]+B
MX[RG7,PO%3H1Y'_&IOKI7_$_["_M-<7*VPSQ\AY]*+>V:X..'F?+H-,ADJK)
M3>6H?TB_BA6XBB4_A5_K_4GD_P"V]A^>X:X-6_(>0Z$,%NMN*+^9\STW^V.G
M^O>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NI^.R$V-J5J(3<?IEC)LLL9-RC?7_ %P?P?;T$YMVU#\Q
MZCIBX@%PND_D?0]"Q254-;3QU,#:HY!<7_4I'#(XN;$'@^Q-'()5#+P/09DC
M,3%6XCJ3[<ZIU[W[KW7O?NO=:RW\X+_A3-\3_P"7(NY^F.D#A?E)\OZ&-J&?
M8NWLPW^B[JG)O-)3/+VYOK%K4H:VE\4DC;:Q32US,B15DF,2>.I]^Z]U6M_P
MG"^4G\Z'^8U\F^W?D+\M]V;B["_EY;YV'V1M;<>*WYM#;&#Z;S>]LA746/PN
MT.C=MKA:5ZF#&+#68_+/2O54@I_/!DYI\A)&??NO=;5GP^_EH_!+X"U.]LA\
M0_C3U_TME^Q<A/D-X;@PW\=SVYLHD]5)7#"P;GWEF=R9"CQ$4LS/2X2BJ:;'
MTY/[%+& +>Z]T>;W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW4/(9"@Q-#59/*UU'C,;0P255=D,A4PT=#1TT*EY:BJJZEXXXXU NSNP ')/
MOW7NJX>P/YR/\J;J_)YC";S_ )A7Q)HLUM^IK*'-X?$]V;)W7E<9D,=.:7(8
MNLQVTLIG)DJX)5:*:E*>9'1D9 RL![KW4KK7^<)_*Q[>RF,P6P/Y@7Q.RV=S
M311XG!5_=6RML9O)3S"4QTE%A]U93"5,DY$+'[=8C(.+KR+^Z]U8GCLECLQ0
MTN4Q%?193&5T*U%%D<=505U#60/^B>EJZ:26.1#;AD8@_P!??NO=3??NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW5 /_"H[_MQ1\YO_+9O_@P_C[[]
MU[KY OOW7NOM3_R/?^W0O\NK_P 52ZH_]T$/OW7NK4??NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW2:WG_ ,>?NS_PVL[_ .ZNJ]^ZT>'6
MO%_PE<_[=58W_P 6$[B_Z%VM[,MV_MS]@_P#H,<G?\D^/[7_ ./GK9"]EO0H
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M3>:W!%CPU/3Z9JPCD7O'3W_,ECRW]%_V)_Q07=\(.U<M_(=+[2Q,_<V%_F?L
MZ#B::6HE>:>1I97-V=C<D_\ $#^@'L@=S(:DU/1^B",444'6+W7JW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=$'[F^9F5ZW["SNQ\/L6DKX]O24M-4Y#,9&JI9
M:RHJ**EKC)3T=/2^B("J C9G?R !QI# >X)YQ]XY.6MPEL8K4/X6D%WD*EBR
MJ^ %-!W8R:\<=35RG[3Q\P6,=Y+<,OBZB%1 P4!BN26R<9P*<.@M_P"' ]V?
M\^\V[_Y]\E_UY]AC_7_N/^4./_G*W_0'0D_UC[;_ )2I?^<:?Y^E[UC\W<QO
M3?FV-H9;8%%3TVY<O1X5*S#Y.LJ*JAGKYE@@K)*6>D<20HS@S^J/1'JDN=.D
MGO+/O7+O=_#9R6@432+'JCD9F4L: T*9 _%D4%3Y4Z)>8O:"+:+*:ZBN6)B1
MI-+HH#!14BH;!/X<&IH/.O5AOO(#J"^B1]^_+7)=0[Z?96(V92Y=Z3&T-?69
M+*9"HI(YGR$9FCBH8*:![HBV#2,_+ZE"C1=H7Y\]UWY0OOHH[824179W<J"7
MK0* IJ !DUXU%,9E[DGVQCYIL_JY9RE7951%#$:<5))&3Z4X4-<X!'_AP/=G
M_/O-N_\ GWR7_7GV"O\ 7_N/^4./_G*W_0'0P_UC[;_E*E_YQI_GZ6G7?SDS
M.Z][[8VOENOZ&&DW)FL=@A4XC*5<U;23Y2KAHJ>J%-44S+*B-,#(@9#IN0UQ
MI)SR][WR;M>PVLMH )I$BU)(692[!0:%14 G.1BI\J$IWWV=BVRSFN8KEBT4
M;24=%"L$4L14'!(&#G/[>K%O>0G4#]>]^Z]U[W[KW3]@<N<;4:)6/V<[ 3#D
M^-OHLZC_  ^C6^H_J0/:VRNOIVH?A/'Y?/I%>VOU"U'Q#A\_ET*((8!E(((!
M!!N"#R""/8C!KT'"*= Q\@?D7T;\5>J]R]V_(KM'9W4'5FT:=)LYO'>V7I\3
MC8I9W$-#C*%)"9JROJY76"BQ]''/4U,KK%!%)(RJ?=>ZUY.G/YWOQK_GE-\S
M?Y;GP]RO?'QY[=WA\;^Y8.GOD3NW!4&(PN3I8UI]E/N_!T^U=W/G,6X;<U)7
MT\52E#5_:/*UZ:LB6G/NO=5^_P K#_A'EU]TSNN'MS^9MO'8OR#SV!RE/5;-
M^/W5-?NMNETJ<5DFJJ7.]D[KSV(V;D]QQSB" C;ZXW&T(421US9.&=J>+W7N
MMV[ ;?P.U,)B=L[7PF(VWMO X^EQ."V_@,;1X?"87%4,*4]#C,3BL=#304U/
M#'&J10PQHB*H50 +>_=>Z=_?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=4^_SI_YE^__ .6+\8=G=C]-]"9/Y&=X]T]N8GHOIWKZB3,5="-Z
M9K:>[MXKF<UA-L4M7ELG!3T>S*K1C,8L4U1*\:>>"/7*ONO=:<VXOY5O_"F/
M^=O5T>^/FIV')T!TUN++X[-XOK?O7=E7U7L_;VW<K6PYZ%=O_%_K+$9NN2MQ
M$%0D-*F\J*@R;20)#5U_F6:=?=>Z-9UM_P (=,?'505?<'\Q.MK*+P3K4X'K
M;XX08RJ-0T:_;30;MW1W#ED"(]]<380EQ:TD9]^Z]U+[)_X0Z8">?[KJ#^8G
MF,72K1PQ_P $[)^.%%GIY\@)*EJBK_O3MCN';:Q0LK0HE/\ P>9E*NYF8,J)
M[KW18]K?R8/^%)_\G;/2;Z^ O=>.[TZ[Q.:$M3UMT_V4^2VWN/!R3C,UU=O'
MXV=WTNW,3/-/)CQ23G OE,I']XWV=0JO/,GNO=;9'\D/^9]W?_,CZ<[<I?D_
M\<,G\:/DI\9MZ;8ZQ[EVC7XW<VUX<KN3/;63<U-FJ7K_ 'O14^:V]Y:=DE?%
MY&:M9!,K)421LI]^Z]U=Q[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NJ ?^
M%1W_ &XH^<W_ );-_P#!A_'WW[KW7R!??NO=?:G_ )'O_;H7^75_XJEU1_[H
M(??NO=6H^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NDUO
M/_CS]V?^&UG?_=75>_=:/#K7B_X2N?\ ;JK&_P#BPG<7_0NUO9ENW]N?L'^
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MZ][]U[J@'_A4=_VXH^<W_ELW_P &'\???NO=?(%]^Z]U]J?^1[_VZ%_EU?\
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MRG_RN?\ U&7G^"?K*[F?_E4_^H2U_P ,/5RGO,#K%'KWOW7NJ:^I/^RRH_\
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M/<;[AM]IO>\QP<N)*J$QZ2=9TN#5I!K)8(N#5CBA/"G4@6%[=;/M+S;^\;.
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M+C<'C*2NFHZB./,)A(:W(5L:1I4YXQ@4L/NO= [_ ,(E/^R%/EO_ .+:1?\
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M3(4,<B,5='JX$=&'!5E:0$$?T/MHSHIH64?F.G1 ["H5OV'KA_%L5_SL\?\
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MZJ!^2_\ V5C2?]K+KG_K3B/>)?N/_P K;'_I[/\ PIUE'[>_\JR_^ENO^?\
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M]U[W[KW3?EO^+5D_^U?6_P#N-)[9N/[-O]*W^ ]/6_\ :+_IE_PCJIWX#_\
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M([.S$DCN9"6/$]'B((P%' ="M[KU;KWOW7NO>_=>ZI][$_[+AQ__ (EKJ_\
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MCH,?-5204<LD6E89&'NO=4:?] 5/\K+_ )_Y\_\ _P!&G\=?_N5??NO=>_Z
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MEEU14;?43XK&X[(]?;IHLKO39L,,-/33U$.,CQ-%#*X6*NJ 96?W7NFG8_\
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MO59.658(*<Y!:=*J>0VCAHZJI6&&9V/"K%(Y)( N2![#=ISQM%]*(8KN!G)
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M4QV%H*K*9:MIL=CJ*(S5595RI#3PQBPN\CD"Y) 4#DD@ $D#W>*)IF"H"2>
M&3U22585+.0 .). .B'=K_)K)YPU."Z^>HP^'N\,^X"&@S&23])- I"M21'D
MAO\ /,+&\7J4CK:N6U@H]Q1F\E_"OV^I_E]O0%W7F1IJI;U5>!;\1^ST'\_L
MZ*2[O([R2.TDDC,[N[%G=V)9G=F))))N2?8K IT%2:Y/7'W[K77O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]T8SH[O&KZ]JX]O[@DGK-EUDY_#S5&WJB9[O6T2#46@8MJJ*=?\
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MO]*W^ ]/6_\ :+_IE_PCJIWX#_\ ,X=R?^(US'_O4;.]XH^PW_)8F_YXY/\
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MOKC=NWLO3;CP^0[8WQ@:^1,]7TM114Q;#8F48M'BD2>KRT$OBC:NMQU55.'
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M7XA?"S^9O\-Z_J_LWY#;)ZMZ?S_9^U]QUG>'7.[.J(_NMS[5J,G51;=@WIN
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MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZK,^?'\UCXP?
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M=?1XZE5E1JFOJH*.G#N;(AFJ'C6Y_ OS[]U[IC_OOLO_ )Z_:_\ Y_\ $_\
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M+^<K_P \'T+_ .CXVW_]1>_=>Z]_T")?SE?^>#Z%_P#1\;;_ /J+W[KW7O\
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M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z$':-'XZ::M8>JH?QQW_XY1$ZB/\
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MOW7NO>_=>Z][]U[KWOW7NO>_=>Z36\_^//W9_P"&UG?_ '5U7OW6CPZUXO\
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M6QLAU_V5L%MT24T%-,QI:7);NQ\=7)J18HZDRO\ MH[)[KW6F_\ *7^?KO\
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M(SX6@6*-@+,WFC(!X8'GVQ'RKLLYT)*"QP LZDD_(9Z>?F;>(06>$@#))@D
M 'J:CJP[^7S_ #*JWY.[GFZ@[9P.!V[V<,579C;>;VV]328+>=-C ]1D\:N&
MR%36RTM?3TP^ZM'4SQSQ13N$@\05PMS5R@-D03P,S1U (:FI">&0 ""?D*8&
M:]"/EGFK]\L89E"R $@K72X'&@-2"!Y5-<G'#I5?S0OE1W#\7-I]2Y?J'+XG
M$UN[=Q;FQN:;*X+'9R.>EQN-QE52+#'D(I!&5>I>Y6UP;'Z#VGY-V2#>Y9$G
M#$*H(TFF2:=*>:]XFV:%'ATU9])U"HII)]1Z=&#^ W<V^^_OC!L?M'LFNHLC
MN[.Y/>5-D*K'XVEQ-(\.&W=F</0+'0T:)&NF"BC#$#D@D\GV5\S;?'M5[)!%
M72NBE34]R*QS]IZ,.7K^3<[1)Y::FU5H*##LH]?(=$__ )AW\RIOC_D4ZBZ*
MJ\'F.V(I89]Y9^K@AS.)V%3JR2QX,T3WAGRE2O,L<A9::(^M#+(OC/\ E3E#
M][CQ[C4L7!0,%SZC^B/7S.!Y]$G,W-8VD^#!I:7BU<A!\Z4R?3R&3Y=6%_R1
MJCYJ_(!<E\F_D'N_%83JF/'SX?KG:./V%M_$9K?5;DE_RG<U=D7Q[RTF+@A0
M?:K!XYJLU"3+(E*!]T!/=,[?M6FQM%9I*ZI'+DJ@'!0!2IKQK@4I2O =^V(O
MMTU7MUI5*:8U"4+5_$22:"G"F34&M..QM[A7J8NM+7Y]?SZ?EGU]\N^[NN?C
M/N[8N.Z?ZXW;-L'!-E=@8;<-=DLSM&FI\)O3*/E<M ))(I<S25XI2@\9ITB9
M"X;6V2W*'M)87^W07%\)/%E3Q"%DT@*YJ@H ?PD$^=21UCKS9[KWUAN$UO9>
M%X43>&"R$DLN'XE?Q5 \J"H)KUL>_P KCYCS?.'X==>=Q9ZJQTO9./GR>P^W
M*7&QT=-!2]@;8DB6KJEQU&Q6E3)4-909>*GTH(TKU11I4$PQSSRW_5;<I+50
M?#P\)-<QMPR>.D@J3ZJ>I?Y+YB',^WQW)IXF4E IB1<' )I448 YH1U8;["'
M0KZ][]U[H,^YNV]E="]4=@]S=C9!\7LCK3:F8W?N2KAA-35?P_#TKU+4M!2J
M5,U54.JT]+""#)+*B#EO:W;K"7=9X[:$5>5U11P%6-,GR'J?(=)+^]CVV"2X
MF-$C1G8\:*HJ<#B?0>?6FON#^=#_ #9?F5V)O&@^#O7V0VGM;:B56X$VQU9T
M_@NX-WXS:$9EIZ*;?>=WKMS>=*U3.RDH*&AQWDE'A@20JVO)&+VTY>Y7A1MV
ME#N_;625HD+\3H$91J#S+$CS-*BF/$ON+OW,\TB[3%H1.ZB1K(X3@-9D#+4\
M0% .*"M"38K_ "H?YW&_?D7W*GQ/^8FW<'MKMW.5F6QW7>]L#@:W:<&7W'@:
M6JJLOU_OW;%7/4)09;3CJIJ2IA%)%))%]D],E28FJ ;S_P"U\6R6O[PVUV>$
M!3(K,&(5B '1@!J7(!&2*ZJE:Z1=R)[ER[U<G;]Q0).2PC95902H)9'4DZ6%
M"0< TTD TU;"?<W;>RNA>J.P>YNQL@^+V1UIM3,;OW)5PPFIJOX?AZ5ZEJ6@
MI5*F:JJ'5:>EA!!DEE1!RWN(-NL)=UGCMH15Y75%' 58TR?(>I\AU+-_>Q[;
M!)<3&B1HSL>-%45.!Q/H//K37W!_.A_FR_,KL3>-!\'>OLAM/:VU$JMP)MCJ
MSI_!=P;OQFT(S+3T4V^\[O7;F\Z5JF=E)04-#CO)*/# DA5M>2,7MIR]RO"C
M;M*'=^VLDK1(7XG0(RC4'F6)'F:5%,>)?<7?N9YI%VF+0B=U$C61PG :S(&6
MIX@* <4%:$FQ7^5#_.XW[\B^Y4^)_P Q-NX/;7;N<K,MCNN][8' UNTX,ON/
M TM559?K_?NV*N>H2@RVG'534E3"*2*22+[)Z9*DQ-4 WG_VOBV2U_>&VNSP
M@*9%9@Q"L0 Z, -2Y (R1754K72+N1/<N7>KD[?N*!)R6$;*K*"5!+(ZDG2P
MH2#@&FD@&FK9?]PGU,G6MQ_.<_G)S?&B&@^/OP^[)Q2_(J'/TM9V5O/%X7:V
M]L3U?M^ABDE?:4L.Z,7G\7+G,A-)$)X&IJEJ*GBE$HAJ)H"LT>V?MM^_B;S<
M8S]-I(C0LR&9CBHTE6T+ZU&IJ 5 ;J'_ '(]P_W$HM+"0?4D@NP"N(E&:'4&
M74WI0T6I-"5K8%_)V^1?<GRH^#.Q>XN^=X_W[['S.\.QL5DMQ_W>VKMC[F@P
M.ZZ[&8F#^$;-P>WJ!/%!"J:HZ56:UW+-<^PA[C;/;;#NTMM:)X<2K$574S4+
M1JQR[,<D^O0K]OMVN-\VJ*YNGUR,T@9M*K73(RC"!1P \NK1?8&Z&O7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]TK]I
M4/EJ9:YQZ*8&.*_T,T@]1'_!5/\ R</9IMD.IBY\L#[3T5[G-I4(//)^SH0?
M9YT1]>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=(7L;=76>TMJUU5VYN38NV=D96^ R=3V-F-OX;:N2&5@GB;"UTVYJBFI)
MON8DE4TTA;R*&&D@'W[KW6LG_,R_E'_RA/F%\:\IU)\5]S_RQ_ACVUD]^;6W
M,.[-C;8Z$QN7QV P\]?59O;E%3[&S>T:A8<@9XHFACJH(E1>58*J'W7NA?\
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MK4J\<+&G"I>,GU\^B2_R;NZ>H^G_ /9C?]*?9.R^O?[Q?Z(?X%_>_<.-P/\
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M\R_Z _\ #QWK_P"Z3"^PC[;?V\W_ #37_CW0J]P?]QXO^:G_ #Z>BL[ ^?\
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MZAS-)!45%)@/DWM:/)&*">H%'2Y7K'M6F@KZRH4.(HA/#%3^24@-+4QH#J8
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M4@5.11"&-3G>S]XK=9.=:V/_  IU_P"R.^B?_%EL9_[Z[LKW-?L9_P E.?\
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M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[H/MW4I2J@JU'IGB\;D?\=83P2?\58
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MQ^18?X".L$/QYZ<@8NFS(6)4K:;,[CJ5L2#<)49B50>/J!?_ &Y]V/,%X?\
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MW]NW^D/_ !Y>@?SM_N*G_-5?^.2=7-_RH?\ MV3\ O\ Q4/H#_WVFW?99?\
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M )IQ?\>?HTWQP_YD9UC_ .&O2?\ 6R;W*7M]_P D2R_YYT_P=1QS[_R6;O\
MYK-_DZ&SV,>@CU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UJQ?\ "NO_ +=N=)?^+O\
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MT=P=H[KC/^?HZG"8%6ZUV:9Y'+@C1DJ&954VO%9?0"/>V[4'^KY]:&3U9/\
M*_XH?&C:OQH[VW+MKHGJW!;@P75N\LIALSB]FX6BR.,R-%A:J>DK:*K@I4>.
M6-T#(ZD$$7'MI6-1D\>KD"G5?G\HGH_I[MO:7=E7V?UILO?U5A=Q[.IL1/NO
M;^.S4N-@K,9G):J&C>N@F,:R- C.%M<J+_3VY,Q!%.J(*]7U[$ZZV'U?@SMG
MKK:.W]D[>-;49(X7;6,I<1C?OZM(4J:S[2CCB3R2"G0.UKG2+_3VP37IVE.H
M';F^)>LNJ>SNR8<='F)NONO=Z;XBQ,M2U%%E)=I[;R6>CQTE8D-28EG- (C*
M(Y"H;5I:UCX"IIUHXZJ.V5_-LWAV7MFHQW77QBW)OGN23,58I=B[0K\]N3&X
M[9U%1XN23=N:R..VH9_755STL=-% %7Q&26>/5$DKQAIQ..JZZ]<.L?YQ&.E
MBWE@.[.G,WMGL3 1R4>W-N;.7*5L^ZMV19!,3-LJLQ&7HUJ<36I._+3O4"T<
MJ%5G2*&?QA]#UH/Z]1H/YL79VP.R\'MKY'?&3*]4;5W$V/K(I:J3<N/W5A=N
MY+QI'GOL-PX6A3*1PL7%0D"43*5>.WFB:)O>#48->O:_7J[N&:*HABJ()$E@
MGC2:&6-@R2Q2J'CD1A]0P8$'_'VQTYUK!]C;>R?\QO\ F![_ -KX+*S4FTML
M8#=>"PF:A:-XL7MKKG&UV.Q&27RI.&I<CN;)Q2N JMXLF;%6&KVJ!\)>FOB/
M1E?Y./;^0P68[8^,&[C44.3QU95;XVYC*]IEGH,EC9Z;;>_<'XY-2HR/'0SK
M I7U)4O9KL1685H>MH?+H/OYP]?3XKY)] Y2K+K28W8]!7U112[BGH]^Y*HF
M*(/J=,9L/S[]#D'K3\>AOWW_ #5>[,'3Q=D[>^(6[(>@:NK2+";[WM#NG"KN
M*BGFI4Q]>N?H\#5XJC^Z$C+ BR9!'=M,<TIBD4Z$0.*YZMK^75F_QV^2W7GR
M1ZD@[<VE/+BL7325]#NG$YB2G6OVCF<1315F4QV5EA=HRJ0U$=3%,I D@F22
MRDE%:9=)IU8&O5<]3_,][A[3W7NS$_%#XLYWM;:^TZN&FGW95R9RK>L@EJ72
MGKZG$83&Q)0+5I2SFCAGK99F1?*R*5DA5SP@.)IU377AT,WQ4_F*Q]U]K5_0
M?;G5V1Z8[=@.43&XJMK:J>BRE;AX)*_(8&JHLKCL564&0CIHGGCBD2=)D@D8
M21MXXWT\>D5X];#5ZLX]M=7Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NOEF_P ]G^93W)\V_F5V_P!;U&Z\YB_CAT%V7NOK7JOJZEJYZ';M
M36;#RU;M7,]D;BQE//XZ[+96KQ]544U35*STE'/%2Q".TQE%NVVBP1AJ=S"I
M/H#P _+C\^H9YIWF2_N'B!(CC8H%X E30DT.<C%> I@&M:F.B._.X?C+VAMC
MN;HGL#<?6O9&T*V.LP^Y-M9":AJ&C66*6IQ64@1O%6X^J$(CK<?5)-3U$9,<
MT;H2/:Z:%9UTL*CH@LKZ7;Y!+$Q5A^PCT/J#Z=?7"_ER_+./YS?"/XZ_*@XV
MGP^4[5V.\VZ\510U<&-Q^_MH9[,[ [%I,1'77E%$F>VKD5HC(TA, C.M[ZV!
M=S";>0H?(_RXC^74[;7?#<K=)QC6M2/1@:$9 X$$?/HZ_MCI?U[W[KW7O?NO
M=>]^Z]U[W[KW2;WAO+:/7FUL]OC?NY]O[+V9M;&5.:W+NS=68H,!MS 8BB0R
MU>3S.:RE12T]-!&HN\LTB*/R??NO=4&=!?\ "E7^7G\J/GSMSX!=%2=M[NS>
M_:W<FV-C?(&AVGB:;IS/[PV[M[.[AJZ#%G,9JFS;4LD6 GCH<G)A335$QCM_
MDSBI/NO=43_'W_A'CWIV3\N.Q.W_ .9M\M\'VYUA4[ZJ]T_?=3YW>59W%\AW
MFS-54_<=E9S>VVZ%-IPU5+!3"NIL75Y^H43S4M'6THIX*Y_=>ZW@_CW\<.B/
MBCU;M[I7XY=5;+Z=ZOVQ&RXK:&Q\+2X?'FJF"?>Y?)R0J9J[(53()*W(ULM1
M55$EY)Y9');W[KW0V>_=>Z][]U[KWOW7NO>_=>Z3^=PJ9.+RPZ4K(E.AN )E
M'/BD/_0I_'^L>$-Y:?4"H^(?S^72VSNS;FA^$\?E\^@Q='C=HY%9'1BKHP(9
M6!L00?8>92IH>/0B5@PJ.'7'WKK?7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=%.B^4M!/WX>EXMJSM1
MKEIMO'<O\2"S#,T]+)/,?X2U"!X!+$T&K[C4;>0 CT>XL3W.CDW[]RB TUF+
MQM>?$"ECV:?AJ--=5?.GEU)C>W#ILG[W,PKH$OA:,>&6H.[5\5#6FFGE\^C8
M^Y3ZC/KWOW7NO>_=>ZK9_F 9O#U$'7V"I\I03YG'UN=K*_%PU4,M?0TM72XM
M*6>LI4=GB64QMXRX75I;3>QMCG[^WL+I:P*ZF17D9D# LJE5 )'$ T-*\:&G
M#J?O9"SE1KF9D81LL:JY!"LP9B0#P)%<TX8KT:;XP9S#9;I/8=-C,I05]3A\
M'38_+4U)50SU&,K4DG)I:^"-V>%R!J59 I(]0N.?<H^VM[#=[+:K$ZN8XD1P
MK E' R& R#\CY9X=1Q[B6<MKN]RTB,H>0LA92 ZXRI."/L^SHP'L=] CKWOW
M7NDEOS=U+L+9NY=Y5M+-6TVW,35Y-Z.G98YJMH$_:IDD<$)K<JI<@Z0;V-K$
MJWO=5V.SFO'!988VD*CBVD5H*^OKY=&>R[8V]7<5HA"F5U0,>"U.3\Z#-//H
M)_CUWS%WKA<_7MMQ]MU^WLA2TE53+D1E*6HAKX9IJ2>"I-)0N&_R=UD1H["P
M8,=150K[?\]#GF"63P3"T3A677K!#"H(.E?0@BGYYP)N>>2SR;-''XOBK*I8
M'3H(*D @C4P\Q0U_+&3"^Q_T!NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[K5B_X5U_]NW.DO\ Q=_K;_WPWR4]GW+W
M]NW^D/\ QY>@?SM_N*G_ #57_CDG5S?\J'_MV3\ O_%0^@/_ 'VFW?99?_V\
MG^G;_">C_:/]Q(?^:4?_ !T=6!>TG1CU[W[KW7O?NO=>]^Z]U[W[KW7)59V5
M$5G=B%55!9F)X 51<D^]@5P.M$TR>EOB-KVT5.3']&2D^O\ B#.P/_)@_P!B
M?Q[-[7;OQ2?DO^?_ #=$]UN->V/_ 'K_ #=+9555"J JJ %50 J@<  #Z>S<
M"G1037KOWOKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UK$_\ "N#H?M/N[^43G\MUB,I5TW0O
M?'7'?'9V%Q/W3S9GJS;VV.Q=E;@-734T\0EI<75[_P ?GZKS+*D<6(:<J&B6
M1/=>Z#'^13_*A_DZ]\?RPOB[VVWQCZ!^1?8F\-@XVJ[PWUV#AZ3L/=&/[IC5
MCV!L_(QYFKR Q(Q59,U)38^"&D4TL=/4%',WED]U[JWK_AD7^43_ -ZZ/B7_
M .B?VO\ _4GOW7NCG?'7XL_'/XC;)RG6_P 8^ENN^BMA9O=-;O?+[1ZTVW0;
M7P61W?DL3A,#7[CJ\?CHXD>KFHMM8^FDF(U&.CB4\(/?NO=#Y[]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZH!_P"%1W_;BCYS?^6S?_!A_'WW[KW7
MR!??NO=?:G_D>_\ ;H7^75_XJEU1_P"Z"'W[KW5J/OW7NO>_=>ZU[?YSFS:[
M;'9?0_=^!6:AR%5B,CM>;,TI -%F-DYJ#<^V9G1E*^8_WBJFC<ABRTNEO3&H
M]J(34$=-OTP?!C(S_*W^8YV+\BLACI(,5MK&;BWCCTE9I(Z66JH*'K?96.G#
MDGRC&U,LZ @JK41L;JE]R=BTZTN37I+_ "DW-6_#3^9'N;M?&>>/&[TV=F-[
M4U%20^-ZQM[['S^UZB-R"@>^X\1)6"0%0&12U]#$^4:UIUX]IZ,+_).Z]DAV
MUW=VS5H[G,YW;^P<7.Z_3^!44VXL_:5B2WD;<6/U?0 Q?DGBLYX#K:#JSOYG
M?]DF_(O_ ,0]OO\ ]T%9[:3B/M'5SPZK-_DB_P#'D]__ /AT[%_]U.X?;L_$
M=4CZO+]L=.= %\K?^R7/DG_X@+N+_P!]WN+W9.(^T=:/#JJ;^2)040VQ\@LF
M*:'^(29[8% ]9H!J#10X_<]1'3"0\A \[.5%KDW-["SL_EU2/H&=JX3&Y;^=
M/54-92PO2Q=D;QS:1>&$H,EANGLYN.AJM#QNNM:RACFUVU:AJ!#V8;_T/_5Z
M]>_%TO\ ^>'20)5_&>N5+5-33=P4DTESZH**7K&:G33>WI:OE-_]J_P]^@\_
MRZ])U8I\G.\!T!\)*S>])5?:[ER'7.U]F[**.J5']Z]UX&FQM!5TNJ6*[T,3
M5&2(!)TT;<&UBU&NH]68T'5"'PA[_P"U?B_#O#=NQ/CGG.TY.P:;%X^#<YQV
M[!0T6+P%9DQ5T&)J<+@ZZ*4354O^5-Y#9Z-$LI1KJ) &Q4#IM<>72/D[YWQU
MQ\QL1\ILGU;F.J9,UOS^]V5V=+CLQCZ?)8[*008[L>GQDV5HL.T[9!,C63.Q
M4A)JQ2^JUVV!5:5KUZM#7HXO\WO);=W#WI\=\P:V*LVEG.L,5DCD8&F$%5MW
M);PR%4:V%XU$FAZ:;R*5 :QX%_=(>!ZV_'J\OY#X[:U1\:>Y\=DH,7_=).F=
M]*82T4.*AQE)L[)2T3T\D+1K&D0AC>!XF4H45D((!]IUXCIP\.JBOY*M%6YO
M9WR@V_E?N7VGD9^NZ*&)2(HC6Y7%]@46X_MYT 82M3)0!S?T@(18DW?G\NJ1
M]!*/AU\\/B?NW=^0^(N_UWOM*7)1?=C9>X-J5.5>EIEEEPZ[YZZW:7HY:Z)*
MET7[>*ONKLRZ$=D7>M7X]:TE>'0X?%;^85VE!\@\5T=\H>I,!M7?&]\UC-K-
MN^DVA)L+>\.YLI%3TNW8]XXJN*I60US-3P4\T"TND31LBS1E0*O$*5'6PWD>
MKU_;'3G7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U\KG^>G_
M "ZNWOA'\U^X]ZY/:V<K/C]W[V?NSLOJ#M"*@J9]KU$F_P#*9/>65ZXR&8CB
M:&GS.&GJJRE^RGD6:>DI8ZU%:.4E1=MMTL\87\2@ CY#%?\ 5Y]0OS5M$FWW
M+24)CD8LK<15NXJ<8-:T]1ZYI4YTWTMVO\A>R-K=0=); W+V9V5O3)4^*VYM
M':F.DR&2K:B>5(FJ:AAHBI:. /Y:ROJY(*:EA5YZF:*%'D5?)*L(U,0!\^@_
M:VDEZXCB4LQ\@/RJ?09R3@>?7UR/Y;'Q-F^#?P9^.'Q:KJ^FRF=ZNV-,N\*^
MAJ9ZS&5&_P#>FX<WV%V&V'J:J.*1Z$9S=N06B9TC/@$?H3](!-S-]1(S^I_E
MP'\NIXVNQ&VVZ0#.E<GU8FI.?4DGH\/MCHPZ][]U[KWOW7NO>_=>Z2.\MW0[
M3VMO/<--CZO<^1V=M7,[G?:>":*IW%EQB\76Y*EQ6.HM1;[BM-$8*4, 'D8
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M (<(RO\ SZW'_P#H65/_ -8/8]_X(&3_ )05_P"R@_\ 6GH$?ZQL?_*8W_.
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M;-U_Y3;O_LHF_P"@^L4_2?3D\,T#]5==(DT4D3-!LO;E/,JR(49H:B#&QNC
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MKW\8RG_*_5?]36_XK[]U[KW\8RG_ "OU7_4UO^*^_=>Z]_&,I_ROU7_4UO\
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MXJJI,@8J:D6HCHZC RAXJN1/=>ZV8?A_\$OB+\!NO*GJWXA=%;.Z3V?D*_\
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M]Q3_ -!'+K4?["99#_O/M*^VQMPJ/L/^>O2I-RD7C0_:/\U.FR79I^L%</\
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M.\U!M3:E!,ZZG;2)*NKD @I( T\[!0 U;>W:Y;2O^P!ZGIS<MRBVJ(RRF@'
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M,L*/55"4$\\LCL(Z>FIIZF4B*%S[2V]NURVE>/\ (#U/1QN.XQ;7$9I30#
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M%OS%=6T:QI83:54*,OP H/\ 0>J]?YHGR#_F$?S%LC\<][;8_DX?-;XY=O\
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MG:V*P1EYZ@_A .3C_5]G3;[_ ";A<I!84=0?UI"IT@5I@U'H:>1Q0TKT-O\
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MOW7NO>_=>Z][]U[J@'_A4=_VXH^<W_ELW_P8?Q]]^Z]U\@7W[KW7VI_Y'O\
MVZ%_EU?^*I=4?^Z"'W[KW1[]XY3[_)&FC:]/0:H18\/47'W#_P"P("#_ (+_
M (^_=>Z2/OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[HI?R"_P"/EPO_ &HQ_P"Y]7[=3ATT_'H _=^J=&U^/O\
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M^]B]?]-]3]Y;*K.M-H4&\<[GNQ\7L*EVX]-DLS%A:+$0U.V=^[DJA73O))-
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M !=*_P#ZBI?^AC[]U[IM]^Z]U[W[KW7O?NO=:;O_  J+V$>U?D5_+ ZO%?\
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M=5/Y)122!&:.WIM<$@$G1&E-%!)]!T,I[B.T77(P51Q)-!G'1,?^'K_Y5O\
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MX_%UMN>R3H<]:HGQ-_[BD_GU_P"*[-_[R'Q0]G4_^X2?Z;_*W0'L/^2Y<?\
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M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=4 _\
M"H[_ +<4?.;_ ,MF_P#@P_C[[]U[KY OOW7NOL7_ ,EW_MU!_+]_\5>ZN_\
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M>_=>Z2^3WKM3#5DF/RN<H:&MB6-I*>=V61%E19(R0$/U5@1[L%)ZT6 Z;_\
M25L3_GJ,7_U-?_KW[]H/6M8Z4^*R^-S=(M?B:R&OHV=XUJ("6C,D9LZ@D#D$
M\^]$4ZV#7IQ]ZZWU[W[KW71 (((!!!!!%P0>""#[]U[JD[Y<]";^^"7<VS?E
MQT+#)1;*RN8CGSN)IXW_ (5M;<.5,K9;:68HX2/]PF:@9UA-],,Q>%3"RT6I
M2C>(-)Z:8:<CJ]+X[=][*^2?56W>TMD5"BERD9H\YA9)HY<CM7<U)'%_&-MY
M54"$2P-*KQN50302Q5"#QRH2PRZ33IP&O0X>Z];Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MH(<Q_P 72O\ ^HJ7_H8^_=>Z;??NO=>]^Z]U[W[KW5=OS0_EF]#_ #H[6^-'
M<';6[>W-N[F^*^YZK=G7M#UUGMFXC!9C(U>Y-E[HDAWE3;EV%NZHJ(!4;%I$
M5:&JQS>.28%RS(\:JWNVME95 [A0UK\QC(]>BK<-GBW*2*5RP,+:ETD $U4Y
MJI_A'"GGU8E[2]&O5?/7G\MKHWK3Y[]O?S%,%NOM>K[L[IV8=C;IVOELYM"?
MJV@Q)QO7N+^XP&$H]BT&6BJ?'UM0G749NJ35+.?'9HQ$J>[9XA$0* U!S7S^
M?S].BJ+:(H;M[P%M;KI()&FE%&!IK7L'GZ]!?_, _D]?$S^8=N';O8W9*[ZZ
MU[KVG046+P?<O4.<H=O;O?&XNN;)8C'YV#*XG-T5<E'-)(]).]-'5P>0K#4H
M@"BUM>O:@@4(/%3D>G3>Z;%!NQ#R:E=::9$.EQ0U^8^RHQ4TIT7?J[_A/[\6
M,-NK [L^1W<GR>^:YVI7QY3:^S?DIVG4[GZVQ&2CDUFMDVA04=":PR!$2>FK
MJNHI)D4I-32(Q7VX^Y.?@"IZE10_MZ30\M0J:S/+/0U"S.74'(K3 /'SKT<'
MXT?RO_C]\2OE3W[\K^E]S]K8//\ R/\ XQ)V!U149;8K]+4M=F-QT^ZGR6U]
MNT'7F.RU%+3UHJGI$.<FAB3(U,0B,9B6)B6Z:9%1J=O YK3]M/Y>72VTVB*R
MGDGC+ R_$G;HJ/,#36O'S\S\J._7G\MKHWK3Y[]O?S%,%NOM>K[L[IV8=C;I
MVOELYM"?JV@Q)QO7N+^XP&$H]BT&6BJ?'UM0G749NJ35+.?'9HQ%M[MGB$1
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MCIH7@R=/25V;R/DE>]3'1TL-H,B]DX]5?AU;/[>Z9Z6'7_\ Q^^U?^UYC_\
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MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U0#_P *CO\
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M\(CTZIK'4N+^:S\5H,E0X_<2=J[,BKW*QY+=/7.1I*&-5=$DE=*"KR52R)Y
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M](T+6O\ EB. /\3;W[KW2YP^V%@9:G(Z))5(:.F!U1QD<AI6'#'_  ''^O\
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MBIVAB2>F,E.#.MW1I(Q0JSPPU9J'2?#%!Q\^J#NST;O^8> OPM[[50 !M7&
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M -&^_=>Z]_",7_SKZ3_J1'_T;[]U[KW\(Q?_ #KZ3_J1'_T;[]U[KW\(Q?\
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M9TF2G6:2<3.Z^[APK5'#JI4D=*_YV?%+Y"_)7:?5>P^L=\[#P.S-LP2U6_\
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M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW5
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MRB[EDD,#!5U)]T]3=B3ZM2WXL/=>ZV%_?NO=?!\_V:+Y,_\ >17>O_HW-_\
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MW[KW7O\ 9HODS_WD5WK_ .C<W_\ _9![]U[KW^S1?)G_ +R*[U_]&YO_ /\
ML@]^Z]TSYKY!=];EI8Z'<7=W;N?HHJA*N*CS79.\\K2Q54<<L*5,=/79J=%D
M5)W0. " ["]B??NO=)C_ $E]C_\ /?[V_P#0JSO_ -7^_=>Z7D7R>^2D,<<,
M/R&[RAAA1(HHHNV=_1QQ1QJ$2.-$SX"JH      ]^Z]US_V:+Y,_]Y%=Z_\
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M]Y%=Z_\ HW-__P#V0>_=>Z]_LT7R9_[R*[U_]&YO_P#^R#W[KW7O]FB^3/\
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M;F__ /[(/?NO=>_V:+Y,_P#>17>O_HW-_P#_ -D'OW7NO?[-%\F?^\BN]?\
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M[]U[KW_0$'\9O^\Z>]?_ $6&P/\ Z[>_=>Z]_P! 0?QF_P"\Z>]?_18; _\
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M"#^,W_>=/>O_ *+#8'_UV]^Z]U[_ * @_C-_WG3WK_Z+#8'_ -=O?NO=>_Z
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M!69#!8_LOL+;VS*W,T%)4LD<LU+'FFGBCD(5F0*Q )]^Z]UO\?\ 0$'\9O\
MO.GO7_T6&P/_ *[>_=>Z]_T!!_&;_O.GO7_T6&P/_KM[]U[KW_0$'\9O^\Z>
M]?\ T6&P/_KM[]U[KW_0$'\9O^\Z>]?_ $6&P/\ Z[>_=>Z]_P! 0?QF_P"\
MZ>]?_18; _\ KM[]U[KW_0$'\9O^\Z>]?_18; _^NWOW7NO?] 0?QF_[SI[U
M_P#18; _^NWOW7NO?] 0?QF_[SI[U_\ 18; _P#KM[]U[KW_ $!!_&;_ +SI
M[U_]%AL#_P"NWOW7NO?] 0?QF_[SI[U_]%AL#_Z[>_=>Z]_T!!_&;_O.GO7_
M -%AL#_Z[>_=>Z]_T!!_&;_O.GO7_P!%AL#_ .NWOW7NO?\ 0$'\9O\ O.GO
M7_T6&P/_ *[>_=>Z]_T!!_&;_O.GO7_T6&P/_KM[]U[KW_0$'\9O^\Z>]?\
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MUL#:75?5>TL)L+KG86$H]M[,V9MNC3'8#;. QR>*@P^'H(O3#3PKZ8HELJJ
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M[&QU5?/'222/+4U-)24T4;U%94T].CRCW7NM>/(?\*O\MLNA/;W;7\GCY_\
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MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K1W^)&%P_\
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M&DK:3S*$EIR?=>ZR_/S$8K^91_PJP^(?PH[$^RWM\?/A!U=1=B[YZTS5*T.
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M87<G^D]J*(I][48"BWGC.LTJY(XF>3[2CKI*J41LD$$TK1QO[KW5E'_":_\
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MSG_@KO\ ]G9__5']^Z]UJV_SF_YI'_#NORQV[\H?]!G^R^?P#I/:'3W]Q_\
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M/B]C[ZVKF*RA7-X:ODRK?<4E$] B)41H(YF#'0"C>Z]UIJ?'SX-=U=O_ ,V
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M\*N-J?)+X,_S+.L_D[TEW5VKL+87R8VMB.S=KXO"=A[F7;>"[OZ1KMO8+?\
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MY-CXZI7*4,0Q^:BCR+5 J:*FJ4IY14U<T/NO=7H?\)QOAC\E?@9_+4V[\?\
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M1R)55<55*I:GE@]U[JE?X4]?_P#"OKKGHO9GP"Z[ZSV=T3U=M_"5.R-H]_\
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MK:&R]F_S1>LML;3VKMS#4D5!A]O[;VYA/E]0T=#14D$"0TU)2PQ111HJ(JJ
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M_6^05ZN@ADQ5?M;:W>O<%3,TBOYR),.T12E8,XD\4<GNO=;3?\B3_A.CL/\
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4=>]^Z]U[W[KW7O?NO=>]^Z]U_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>timage_005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 timage_005.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
M     ! !+     $  0$L     0 !_^X $T%D;V)E &0      04  DE$_]L
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M<_V'N_ ;?A\N*QD^>RGR!HSD9H# \P-&DB,L,2P>Z]TC_BM\O?CS_)4^:_\
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M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZIV_X4"?]N9_Y@W_ (@JI_\
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M .0]%MZV4RG4.;GS&YL3N?:^7W?14KT>-R&+SN(\=3*(Y98A(*NF]U[JSO\
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M0OO#?/75/L+K/?VV<IN?)S^#<L*Y(8MEW13U3253P9BJ:G]U[HR>T?Y</>&
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MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U3M_P *!/\
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M_)7[IS,N V]\X]C[2R<>D@]O[.[0Z8PTL;@VDBW7V?LC:VTCZ@04->)5M<J
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M;L_^4'\]-S;2^/G1^UMR8;I*HJ\1N#;G4^P\)G,55#<^VXQ4XW+8S 4M?0U
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M)7RXJ/(4+Y2"$5,^-2K@:OAIR8P)Y:-9#41PDS)9BH7UCGD>_=>Z]D,GC<3
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MO;G77;F4[MSU958W+56Q^V-Y;CV]M R0YBDT4=-BZ\U\=HQDX7J)G,_NO=;
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M:SMCI7J7L^KZCW+C]Y]4U78?7&SMZU/6.\<3)22XK=G7L^Y,-DI=E[EQDM!
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MY2_RT_YD'\N#:/R+V'@<OF=R_';YP;M^*>:K=@Y^;$4./R;[>F[<RF$J-O'
M;_V-6TV3QM!-D:J3"YRDKL9YYI9T6/W7NMKK_AD7^43_ -ZZ/B7_ .B?VO\
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MW<N)CJMH4:?>U%!]M7UL%8V32IBGIP9O%22I3I-$\C*CEELJ,PJ.M%@#0]&
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M=>]^Z]U[W[KW7O?NO=>]^Z]UI)_\+7<=V+4_';X'9%J7)57QPQ7R"WX_=/\
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M<A645=(:6KIHC[KW0V]\Y?\ E =C?\)TNB?E1UW3_$CHO^9#TG@^@<;MC/\
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M3<FP=UP8[(Y+,Q9"@AW%M3)8G+Q45?$H6:)9@DJBS CW[KW0,?\ "L266?\
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M52U/24M%CJ34\T\A2-$0LQ !M[KW2DSWR7[U_G[_ "/W5\?_ (*=X[^^./\
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MM7K#:N/S%3NO<&;K=[;LW-5;.V_G\@M!CH:.DAQ\60GFDE1'%-.1[KW5I_\
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M3?<U4E_'34_F=/-426]*+=C^![]U[J9[]U[J&V1QZ5R8MJ^C7)RTYJX\<U5
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M7NJ&_B?_ "$L)\X?C/UQ\Q?YD?R1^7>^OGI\@=FGNO!]F;5[MW+U^_Q/';^
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M_L?8_4&[.R]D;8[1[-QF?S'7&PMP;DQ6&W1O['[4J,/2[EFV;B,C4T]5N63
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MV^%WRW^!/R)^,_P!["@^6G>'R*^-?9]/6X?:N&W;M':O1O1<VSI:GN;O?O\
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MX6GP> KQ644<\$M-B*LZ%II\;4U7NO=6;?S(OYHM'\ OEI\/.I?DSU9LZE^
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M%+59'*_$[XH56!Q5=%.DVYMQ4_\ ?;/TE9 8Z[%QT]09'G+:O=>Z:=D_-/\
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M X=J2&?X0]E3314S8^G,$4TR_(V-998XB S!5#$7L/?NO=/W^@_^?+_WGU\
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MO9?_ -TA[]U[KW^@_P#GR_\ >?7P _\ 2'>R_P#[I#W[KW7O]!_\^7_O/KX
M?^D.]E__ '2'OW7NO?Z#_P"?+_WGU\ /_2'>R_\ [I#W[KW7O]!_\^7_ +SZ
M^ '_ *0[V7_]TA[]U[KW^@_^?+_WGU\ /_2'>R__ +I#W[KW7O\ 0?\ SY?^
M\^O@!_Z0[V7_ /=(>_=>Z)C\8M_?SUOD+W'\V.JZ3YK_  >PD_Q'[\PO2F0R
M.7^&6\<A0[FJLMU1L;LY<O@*7%]XXBMQ..BI]ZI3-!6SU\YE@9Q,$8(ONO='
M._T'_P ^7_O/KX ?^D.]E_\ W2'OW7NO?Z#_ .?+_P!Y]? #_P!(=[+_ /ND
M/?NO=>_T'_SY?^\^O@!_Z0[V7_\ =(>_=>Z]_H/_ )\O_>?7P _](=[+_P#N
MD/?NO=>_T'_SY?\ O/KX ?\ I#O9?_W2'OW7NO?Z#_Y\O_>?7P _](=[+_\
MND/?NO=>_P!!_P#/E_[SZ^ '_I#O9?\ ]TA[]U[KW^@_^?+_ -Y]? #_ -(=
M[+_^Z0]^Z]U[_0?_ #Y?^\^O@!_Z0[V7_P#=(>_=>Z]_H/\ Y\O_ 'GU\ /_
M $AWLO\ ^Z0]^Z]U[_0?_/E_[SZ^ '_I#O9?_P!TA[]U[KW^@_\ GR_]Y]?
M#_TAWLO_ .Z0]^Z]U[_0?_/E_P"\^O@!_P"D.]E__=(>_=>Z]_H/_GR_]Y]?
M #_TAWLO_P"Z0]^Z]U[_ $'_ ,^7_O/KX ?^D.]E_P#W2'OW7NO?Z#_Y\O\
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M -Y]? #_ -(=[+_^Z0]^Z]U[_0?_ #Y?^\^O@!_Z0[V7_P#=(>_=>Z]_H/\
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MNO>_=>ZUMO\ A61_VY0[]_\ $E_'K_W\.U??NO=7_=+_ /,G>I__ !&FQ/\
MWEL5[]U[HE7PA^37\O3Y+=R_,N;X?8/KRA[VZD[1I.K/F'F,/T]1]6]G9??F
M!S.^:3%KV!DJS;F W=OS'T&XZ#<<-!DJPU5&]8F0^VE9C.3[KW5$_P#PL&PT
ML_Q>^ ^9ZKIHA\M(OY@G7&&^/]=AEHHNP%ER'7G9-554VUJRI53'$>RZ#9SN
M&D6 5HI&<?0CW7NA1[.J:OI;_A6!\6]U=D)#CL5\J_Y:FY^I.O<] D\>W\EV
MCLC<.\]Y;IVO15,HGD6>EQ.T8Y(Q4_;ZSE*2)6>:14?W7NK7?YW/9&W^K/Y1
MG\Q3<>Y,WC\#0Y?XE]R=;T=7DIZ>GAJMP=O;1R'56V,) U20DF0W#N'>5-0T
MT:WD>>H0)ZB/?NO=)?\ D,]-S=#?R?/@%U]586MV]73]#XSL?)8C(BN2OI,K
MW9G\_P!T94U<&2EEK*2HJ<CV!+,T#:!3F3QJD:(L:^Z]U;E[]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>ZHZ^<O\GC<_<WR>H_GQ\#OEINK^7S\WY]JT^Q>QNR]K=?;<[0Z\[VVC008^
MAP]'V[U?N2KH<%N'/8'%XRGI:3)5 JU^UI*6*:FE-)224_NO=,_PS_DW]B=?
M?+/'?/W^8=\T]W?S"OEYLO;64V;TMG,MUAM'IKJ7HW;V;HFH\O5;'ZNVI4Y'
M#1[RK(JVNB_B=,,93BGKI :)JE5JA[KW5[OOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[JNC^95_++Z"
M_F?=.;:ZQ[ER&]-D[HZUWC3=D=*]S=8YJ3;W9/4785'324D&XMM9%0T%3#+$
MR&>CJ%>&26""=?'4TU-/%[KW53.[_P"2A_-0^16R)/CE\R/Y[W:?:GQ)S%%_
M!.P-B]7_ !3ZEZ;[7[*VL$E63;><[AH<SGMQ?8Y)UB^_7+G<E-D*?R4U13RI
M(7'NO=7T]9?$'XX]1_%K"_"W9G5>VH?C-ANL<AT^W5>6IFSN!SNPLWC*W%;G
MQ6ZOXL]54[FGW?#DZN3+U-8\M1D:FKFFG=Y)68^Z]U0I@_Y&?\PWXU8?<W1'
M\O+^='V7\9OAEG\CN"LVUTGOWXY; [XWAU!CMS5M769';G7/;&YMP8S=^/PU
M+)5$TC4%1A:J)RTDDLM2TE3)[KW5Q/\ +E_EW='?RS_CS3]!]+5.Y=SSY?=&
M:[#[1[5W]5TF3['[>[,W+X!G=[;TRM)2TD515R4])#2TL*KIIJ2GC4M+*99Y
M?=>Z/M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[JK7Y4_RU/\ 9F?YA'\OWYW_ .FG^Y/^R*_Z6?\ C%?^CG^\G^E+
M_2C@X\+_ ,?Q_?S ?W(_@?C\G_%GR_W-]/[7ZO?NO=6D.B2H\<B+)'(K))&Z
MAT='!5D=6!5E938@\$>_=>ZUK<C_ "-OE=\9NR>T<Q_*+_F<;D^ /17=FZJ_
M>V\_C'G/CUUU\@NK]E;KR\<4>7R?3-/ONK$.P,96 '104M)%+3(D4,=8*>"F
MA@]U[JPG^6-_*UZ__EQ[<[6W#6]H[V^2GRC^2&YZ+?/R8^4?9U-2TN\NT-T4
M4-3]K0XO%0564;:6Q<569&LGH<4U?D989*N3R5<RK"L7NO= +\Y?Y/&Y^YOD
M]1_/CX'?+3=7\OGYOS[5I]B]C=E[6Z^VYVAUYWMM&@@Q]#AZ/MWJ_<E70X+<
M.>P.+QE/2TF2J!5K]K24L4U-*:2DDI_=>Z9_AG_)O[$Z^^6>.^?O\P[YI[N_
MF%?+S9>VLILWI;.9;K#:/374O1NWLW1-1Y>JV/U=M2IR.&CWE615M=%_$Z88
MRG%/72 T35*K5#W7NKW??NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW5;?\V3^7M_PZ'\*-_\ P\_TN_Z#O[\[FZ]W%_I$_N#_
M *3/X7_</>.*W9]G_='^^O7_ -[_ !7^&?;^3^)P^#7KTR6T'W7NC_[+V[_=
M#9VT]I_>?Q'^Z^V<%MW^(?;_ &GWW\$Q=+C?O/M?/4_;?<_;:_'Y)-&JVIK7
M/NO=45?*7^2=OC+?+'>_SQ_EM_-S?W\NWY2=P"@@[[J,9U[M[O#ICNB"AI8(
MDR.XNH]Z92@V[0[H:JQ]+4/5LE;223+4RFC%56U%4WNO=1OC5_))W^?E?US\
MZ?YF_P X]^?S&/DATA%71] 8G)=:;1Z1Z$Z9K*W[.4;HP74>S*FMP>2WS15T
M$D\&0C7&TOF-//-135F/H:NG]U[HZG\S#^6'U)_,GZ]Z_H=P[QW=TAWWT3NY
M>POC5\GNL?%#V=TCO;RXZ:MJ,1(U10-E]L;@;#T?\4Q35-,M4]%331S05%-!
M-'[KW58E3_(O^:'RJW1UKA_YL'\U_>7S9^-'5&Z<3O7&_&K97QUZX^/6V^Q]
MR;<JJ>; OV[N/9==+4[OV\D"SQ5=%54=573+4$P9&E8,TGNO=;,5)24M!2TU
M#0TU/145%3PTE'1TD,=-2TE+31K#3TU-3PJD,%/!"@1$0!54   #W[KW4CW[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=:+W\BG^8A\W/D1_/>^;_P :^[ODKV=V
M9T5UK@?E]-L7K/=.7AK=N;<FV'\DMB;/VA+11K2153R8';.2GHX&EED/CE);
M4WJ]^Z]T.?\ PHB_X4$[I^/6X(?Y>/\ +DS\^ZOE]N_+XO:_9/877E/4[KW'
MU#ELOD:&DP?5G7F+QE%D$SG=N[:VICIWBA6JEQ,<@@$#5]0GVWNO=7 ?R4_B
MW_,,Z8Z!7LO^9Q\H^T.[ODCVE3465BZKW'NS^)[1^/VUIX(IZ79U5'AI(=O[
MK[)JI+39G(".:FQ\O^0T$DL<<U96^Z]U==[]U[KWOW7NO>_=>ZT\_FU\N.]_
MY@/_  H&^+?\K+XW=L=F]8?'OXAY6'NOYFYWJ??63V-4]@U^W,#C-^YS9&Z,
MK@JO$YG+;'I*"NPNT)*"&HG@DR^Z*QZFG8T,,U/[KW6WO6YW!XRH@H\EF<5C
MZNI"M3TM;D:2DJ*@.YB0P03S1RRAY05&D&["WU]^Z]TGLQV7USMW<.,VCN#?
M^R<'NO-%5P^V,QNK!8S<.69[:%QF%K:^#)5Y?4+"*)[W]^Z]TAODUGLSM;XW
M?(+<^W<E5X;<&W.D.U\]@LQ02M!78K,XC8>?R&,R5%.OJAJZ&MITEC<<JZ@^
M_=>Z^4M\5_Y]/\VGKWN7XY=]=Z?,+OG?/Q;Q/R.V5M[M>GW!44^>VCN';> R
MVU=P=E;.RU!AL8F4-=5=>9J2>EA&B6KLYIO*U/.J>Z]U]'+^=U\Q\G\*/Y5G
MRR^1.PMS9'![]7KFBV-U!N?:TM%+EL9V!W#F\/UUL_=F!JJAFH/)M2;=/\<$
MUV*P8]WB6201H_NO=:0W\CK^:C_-5[A_G ?#'X\_*#Y<=W[VZY[&_C^Y-R]<
M[OS>*J</N7:NY/C!O7M[KNOKHJ"A1I*/(X^JQ&7IU\BL T8D4$,@]U[J_;^?
M%\DOD)_*H_F&_P OW^9/L_M'M*N^)'8>4G^.7RPZ &^-P5_5N1BHVJ,LN[L3
MUM4/58&E["RO7F0R%525])$E0:S9]+&Q5*BH%1[KW6VCMW<&%W;M_!;JVWD:
M;,;=W-AL9N# 9>C8O293"YFB@R.+R-*[*K/35U#4QRH2 2K#CW[KW3Q[]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z^-
MMB?G1\BO@7_,_P#YD&]OBC0/+WQW?V+\KOC1L/.4.,J,]N39^0[,^3>+R;[B
MV/MRGHZX[@WZ\.T3C\/ T;K%7U\=0(YF@6"7W7NCQ?R4]W_\-5?SMMM;0_FJ
M]#R;4[<[/QT&V,9V;W4:W<V\^DNTN]$Q>;V;V]!GJ?-Y[;E;%V&,S+A,YGY%
MJZ[$ME*AI:ZA2GS$4ONO=?5G]^Z]U[W[KW7O?NO=1,A74V,H*W)5CF.DQ])4
MUU5(J-(R4U)"\\[A$#.Y6*,FP!)_'OW7NM ;_A'SE(/DG\\/YK_S0W;@::#L
MC>*;;S;5;2392?!#Y+]P=H]H[VP]-F*B**:>*MS/7]!KD=4DJ/LU8@68>_=>
MZ0G_  L<S78&V_Y@G\M;<74TM5!VI@.O*G-=9S4-%C\G6P]@8KNS&UVS):3'
M9:FK,5D*J/<<%,8X*F&6GE<!9$9"5/NO=&4^:O\ PDAVSN#XI]U_)G-_,?Y(
M]V_S&*;KC.=P[[W5V%D=DYGJ7M7LC;N".Y-T[8H=NKLVF[$PM'G:?&S8K#54
MVYZQ<>33NU-)!']K[]U[H6_^$['\QOMSYI_RBOG]T=WUO/+]C]D_#WJW>>%Q
M&^=QU.7RFZ\QT_VMU#V16]?4.[-PY66K;<>;V_GM@[AHHJKS&H_A<5''.FN,
M3U/NO=:HGQP^-_\ IL_X3X?S!NS:"CR=7N#XL_.#XT]PTR8FF^[FFV[G]EYK
MI[=D%="L$\XPM#1=DQ96JDCT& 8M99'6!);^Z]U:A_.$_F#;A^;'\D_^1]\>
M-E9#<6]NY/D97T/]_:2AFI\=4[J[!^,=$WQ@&)W%3--C89ZS?_:>ZY<G1QM&
M*!I:-*GT::=O?NO=*KIGI3;OQM_X6(?'_P"/>T:=:;;/2&R>@^J,)$LTU03C
M]@_R@-E;8@GEJJ@M4U=14KC/++-*3+-([.Y+,3[]U[K9#_X5F=<8;>_\E3O?
M=&3Q%!D:_IWL[X^]B;>K:NEIIZG Y;*]N[8ZEJ,IBYIW6:BK*C!=H5M$\D(:
M1J:KEC(\;N1[KW1DO^$XO<V6[R_DN?!C<N<@D@R>T.O=R=,D-*)XY<3T;V+O
M'J7:T\$MD;QR[1V?0%D95,4FJ,:E57?W7NKO/?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7S8?^$]G7^Q]\_P#"EKYR
MY#>6T]O[IK.NJSYQ]@;$J,]BZ3*/M+?%'\F]J[9H]V8'[R*48[<%%@=TY&FA
MJHP)H8ZN30RDW]^Z]U=/_P *T/Y4?^S7_%RB^<O3&T(LC\@_B?AJC_2%3X>@
MA.?[%^-YJ*C(;@II9$,<^3KNH<E539ZCC8LR8R?++$KS211M[KW2^_X31_SH
M-M_+GX19_IGY(;[J/]F'^#O74E;OC<6=;,YK.=C?'C:M!,,!VK--_N6SFZMQ
M[5Q= ,5N%HQ4U]14Q4U6ZO+D /?NO='4V_\ \*<?Y&NYLWC<!C?G9AJ:NRU5
M'1TL^X.B/E'M+"1327TODMR[JZ0PNW,+2BWJGK*J"!/[3CW[KW5XNT]V;7WY
MMG ;TV3N+";NVANK$T.>VSNC;64HLWM_<&$RE/'5X[+X;+XZ:HH,ECJZEE62
M*:&1XY$8$$CW[KW3ED\?!EL;D,55&04V3H:O'U!B8)*(*R"2FF,;E7"R".0V
M)! /X]^Z]UH*?\(Y,%4?'_YD_P V;XG[IRT3[YV0_7F"R-"&GH6R=1T#VGW-
MUMNG+1XAS,%BH,QO*F0EY2]-]XJ#5Y&(]U[H(O\ A9W7[OQ7SG_EX93KZ/)2
M[]QO4N:K]D18?&_QG+R;OH^X*.HVU'BL.:6N&5R3YF.$04W@F\\NE-#ZM)]U
M[JS+Y+?\*SOA)5_ ;M>AV]BNTMK_ #UW!U+N[K6;XU;KZOWEC#UAWAE\+D-F
MY67=^\*ZDPFV)=I[%W+-+63PPY"+,U%/3"G--3U3LL/NO=%W_P"$Q'PI[#Z%
M_E'_ ,QOY5]B8;-;:3YC]5[CBZVP^9I_LVR?5?275/;]/A-^T5%/0P5\%#O+
M<W9F8CIY9)7AK:'&TU3 HAE26;W7N@1_X2I] X[Y5?RJ/YOGQLRCS0TW>51+
MUA%5TQ@%7CLCO#HW<N'P^6HS5)+2BMQ&6JH*J$RJT8EB74"MQ[]U[J@3^0#T
M)OGY3_S>O@WTSO\ HMSYC9/QFWWN?M_,;3S=36X^CZUH>F:O/]L""KPM5)2S
MT"9+NZGQ=)7TOB,E34UHBJ5,(8)[KW5^.[_^XYFD_P##HV1_\*MP'OW7NK[_
M /A5SO/'[7_DC?)G!UM53T]3V/O?XZ[,Q,,Q025^0H>^^O>PY*6D#RQLU0F*
MV'53D*)&\4+G2%!9?=>Z&_\ X3<]09GI;^2O\'-O9^7R9/=NQ]X]O@!0D<6&
M[G[0WOV?M2*,7+<;2W30%R2=4I8BP(4>Z]U>-[]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z+CUO\.OB-TYV5N/N;J'X
ML?''JON#>,>=AW=VOUOTAUEL?LK=,.Z<O3;@W-%N/?6V-L8O=&<CW'GJ*&MK
MUJ:J45E7$DTNN158>Z]T86MHJ/)4=7CLC24U?CZ^FGHJZAK8(JJCK:.JB>"J
MI*NEG22"IIJF"1DDC=61T8@@@^_=>ZK3[;^!?P9^/O0GR5[&Z%^&'Q/Z1["I
M?C7WOBJ7?G4/QUZ@ZUWG38O*]9[CARF-I]T;,V=A<W#09*%0D\*SB.90 X(]
M^Z]U3C_PF]^+_P ;?D5_(4ZHVKWWTWU=V)MW=V7^36!W/5;TV7MO,UO\&E[B
MWY \Z9C(X^;(T%1BX5$M-4131RTDD221,CHK#W7NLG_".'LKL3??\I_=6WM[
MU^3R. ZF^6/:/7_5LN12J*4.Q*C874N_JC#XZIJ"R5./H=\;WS+IXSHA:=H@
M!X[>_=>ZVO\ W[KW6E7\M>LJG^45_P *2?CI_,'IH$QGQ'_F935OQ^[ISC4[
M&@V'W-OS&8K!9&CF./HZ.GQ&+W#O7:^T]XO5U<E;+5,NX"5B2"*1/=>Z"'_A
M4ET3W?VG_,P_E<[IZQZ;[5['VSLK'[>GWEN/8?7F[MWX+:4"=_8;(O-N;+[>
MQ&1Q^!B7'TDLY:JDB AB=_TJ2/=>ZVX.SOY</P"[I[5IN\NV_AC\9NQ^WZ:K
MH:]NQMX],;"SVZZ^OQCQR8VMS>5R&$FGW!5XYHD^WDKC4/"$4(5"BWNO=&[K
MMOX'*8&LVKD\)B,CMC(XBHV_D-N5V-HZO UV!JZ-\=5X2LP]1#)CZG$5./D:
M"2F>-H7A8H5*DCW[KW03=(?&/XV?&7%YW!_&[X]]'_'S"[HKZ;*[EQ'2'4^P
MNJ,7N+*45.U)1Y+.X_8> P%)EJ^DI',44U0DDD<9*J0./?NO=)[K;X;?$+IK
MLC/]R=0?%7XW=4]O[KBSL.Z>U>MNC>L=C=D;EAW1E*?.;EBS^^=L;7Q>Y\S%
MN+-4D597+454@JZJ))9=<BAA[KW4V;XC_%*H[S'R@J/C'\>I_DLLL$Z_(>;I
M?K>7O-9Z7:L>Q*:8=M/MIM_"6GV1$F&1OXA=,4HI!:G C]^Z]UJJ_P#"C?&;
MA_F8?.?^73_)1Z>>LJ,AE-ZR?*7Y,[FQ<&2G7J7K2EQV7VCB]RU]4N*KL%05
MN/V)5;JJ(!6%EFR-=B*4^,U\7F]U[K<%V-LO;76VR=G==[+Q=/@]G;"VMM_9
M>T\)2(L=)A]M;6Q-)@\%BZ6-0JI3X_%T,4*   *@'OW7NE3[]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MN@[[>V&W:?4W:'6*Y08-NQNN]Z[#7--1')+AVW?MK)[?&4..%50FO&/.1\OA
M\\/ET:=:7U#W7NM5'H[_ (3C?S#^B.A:/XD; _GL]E; ^+$K;CH\]UAUE\2-
MN;1R]3M_?&5KLMOS&X+?K=Y9#=6 K]SR96K'W?W%0M,U06\,D:^%O=>ZV.?@
MO\*.D?Y>?Q?ZR^)WQ]Q^8INN^M:&O"97<V13+[NW?N7/9*JSFZ]Z[NRL5-14
MU9N#<V=KIJF5::GIJ&D1DIJ.GIZ2"""/W7NC<^_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
'KWOW7NO_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>timage_006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 timage_006.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
M     ! !+     $  0$L     0 !_^X $T%D;V)E &0      04  DE$_]L
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MDO6][ ]C?6EJ!X5O Z!JU,C&.74Q(P:D8(X\>! $>3VTJW5K<7!/B32JQ6E
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MZWF2.Q-T$*.-(*2!L$N%/\)(S4''^3H#?A%_,^_FQ_+[<O07?^9^*?2G4O\
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MF/R&U\SBQD6E2G>NPV8I*#)P4\[P3+%4&E-/,8W$4KZ3[;W+9[G:&"W$92O
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M0?B !"YI4XI4,[YN9LK0S1$$L%T,!J7N(SBHX$D$XK09K0G9Z^^>_P 7LO\
M$;&_+W<?<%#M7H[&8^/';A[)[*V_ENM%.0QDB4%3&N/SN/QN5FGJ<C>*ECCH
M&>L=D%(DNM+D[[5.+CZ94U2>2H1)Y5XH6&!DYQY]&"WT1B\8MI3^)P4\Z<&
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MIGCGT\Z=+K^8;\V=]_S!?^$[_=_R8WG\?:OX[T>ZNR.I,5L_;]9OAM]#,8[
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MZ"7/U5&D=)4YJ2*F5JZ6!%ADJ3*\2A"H]Q+=3&YE>0A1J9FHHHHU$FB@\!G
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MJFQT5"NY<M%3T\$=?59"HR6(FJE%'&DM14*XCCT*@&5P/\=CA9 LDFV&)$&
MLAU=HU'%*%1FOD>@U!_N,\JL61+\2.W$L@TY[1GB"<?/K;]_FX=R=/XS^5'\
MN=[YG>&TLALOLWXV[RV]UQEUS%-4TN9R?96*DI=M?PJ0.R5TL];54E1!X=9*
M(9A9$9ECCENWD?<8%4&JS(6%#4!6!:OI0 UZ&6\RJMG*Q(H8V ->)92!^TD4
MZIF^3='3Y'^7K_PF;Q]6GEI*_P"3O\M"CJH[VU1U6UJ5'6_XNK$>Q18XOMU_
MYH7G_'^B*Z%;6P_YJVO_ !SH\'_"B.""JZ+^ --4PQ5%-4?S5_BK!44\\8F2
M1)L/O971T8%61E)!!!!!L>/95R8:277_ #Q3_P"%.C#F/A;_ //5%_S]US_X
M4VJK?RGNS"RJQ3M;I5D)%[$YN(7']#8D?ZQ(_/OW(?\ R4X_]+)_QQNO<U_[
M@R?:G_'UZ8-V?]Q#/<?_ (QBSW_O=TGOR_\ )#'_ #W?]8>O'_DJG_GD_P"L
MO0M?\)P*6GI_Y/WQBEAB2.2NS??=55NHYDD3L'<\ =O\1%#$O^LH]M\\_P#)
M4F_YM_\ 5I.K<K?[@1?[?_JX_56GQLGF;^6)_P *0:9I',$7RL^?<\<1/I5Z
MC!TZNP']66*,'_@H_I[.[[_<_:_^:%G_ ,?/19:_[B7_ /S5N?\ CHZ&3;'2
M_P ._E1T_P#R<^A-U=\]Z?%/Y\T'\O/J#?/QD[MZ;KZS8\\^*DVO0+DL-'F'
M1,;F)U;'U4[XN&KBR$4!EDUQ4U6PG33W-SM\U[,L<<UN;EUE20!@&UMI)%=2
M\:!N%<9(PHBAANX[6-G>.40(8V0E21H74 ::3PRN33-*=#9UIW+_ #&/@#_,
M"^'OPF^3?RDV1\\^IOF)!VA2;9W54]9P=;[ZVNW6N-6L-=608Z>J6?&S,R'R
M5E97M,D>0*SP&C'D2SVMEN]G/=V\36[0>'5=9DC<.Q'%@"#]F.&,X>BGN=ON
M8K>:03++KHV@(RE #Y$@C^?SQTMOY:M?0#Y"?SX\::VD&1_V<'=53]@:E!-X
MYL!D DGBU:]#&&4!M-B4>Q]+61;V#X%D?^$?]97Z5[:?U;G_ )K?]8TZ:?Y'
MG96.^/\ _(*V9WJVV,AN:/JW8?R^[?RVVL @^^R[==[IWE7&CI[A@:NKI\;%
M31$BP.B_ /M;S? ;O>7BJ%UM"@+&@75'&*GY"M3TCY=E^GVU)*$Z5E:@R31W
M-!\\=,/Q,Q'\Q+Y]_'#:OS)[ _F9[;^(G1?9F(W'O+%](_%_I'9\-)MG$8S(
MUZS');[W(*W(P5\$5.YK@Z&.FD1R[AQ*/==R-EL\S6J6QF=&TF29Y.XT'!(R
MH KPR21TY9"YW&-9VF\-7%0D:IVBIXLX8DTXX !Z*Y_)ER6'RO\ +A_G15VV
M=[;@['VM7=\_,C);<W]NJL6NR6=H\AL2!Z;-Y"5(::.7(9:G$-34R+31!Y7)
M$:"R*NYM4K=V890A%O "@J I#M514DT' 5)Z2<ND-!<D,6'CRT8TJPTKG%!G
MCT&GR9KZ"N_X2;=2BBK:2L-+LSX_TU2*6I2H\<D'8=+%)&^ACH=)(Y$938AE
M92+@@*MK!',C5_WY/_U;?I/?FNRK_P TX?\ CR=6%?&',X_J'^?W\Z=L]L96
MCP6?^4/QC^,N\?C9+GI_M_XSB.O,'C<3F\=B)IPJ-4PY2AK9'HH9"\J4<]5X
MV$,C(2WZ_4[/;M&,0RS++2F&<ZE)IY$8J?L].C2U/@[C.'/]HD;1\<J@*L!]
MAS3YUZG?S@,SBNR?G3_)G^/77E;2YCO?"_-?:O?N9P^'J/)D,1L;KN6CK-Q5
MU;X09:.AKZ*DJ2BR,B5@H9D&H1.5]RVO@6M[/(/T_IVB!-*&1R-(%>)!SCAQ
M].O;T?%FMHD/?XPD\\(@.KAPK6GSX=/W\N>EIW_G+_SSJUHD-73Y;X4TL,Y'
MJ6.LVIF'E0?X.T$)/_!1[KO/_)*V_P#ZB?\ JX.O;;_N?>?\V/\ JV>FZ.>:
M+_A3//''(Z)4_P JP05"J;!T7?"2!6_J!)&C?ZZ@^]_\L'_J-_ZP]:_Y:O\
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MGO.(MH6MXS-,B)"OA") Z$ T!!\1,T X5Q0UST5<MF>19G$<;,TC>)K8HP-
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M)-*>0(UP&T+JM>PO;W'!Z&'6HE_+YPNU.R/^%&W\SJM^0^%VWGNUMGXG<_\
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M2I!"J*5K@#C7/3>W!Q>7'B%"VB+5H4J*]_&K,:TIDGA3HVW_  F_VY@\9_*
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MON^FYC69:FDCIY(IIZ>?!FOD:!7!EE@@ ((! BY7NEANA%+_ &<ZM!)P^&3
M-34"C4-?+HGWN!I(-:?'$1*G'BF:4!%:BHI\^BM]<=O;8_FC_P TWXX]C;"J
MUS?Q]^!WQ%VO\DC31UK2PMV5\SL3#+M['Y.E,:(*G"[5C>KB,CK/25T,T>B,
MF=2OFMFV+;Y$D%)+B8Q<!B.W/=0_-R!C!ITFCG7=+M&0U2*(2<3EYAVU%/)
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M5Q\.+IZ..."*E2G$$<*K$L810H9:5W8N6)8DL6))8L34DGC6N:].+&J*%
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MBG6&EFJ/OEJ8:QI9*P92+)VKTK'F>H^^45+.TMR0BNZ3K<"[UGQ0VK6<FO\
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M,[LS-_O$U^4K1%CQ&D8TI'FO:/6O$DDGS/3EIM\=H&I5F?+LYU,^*9/IZ 4
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MX(+=OW:3;?%T!3XT3Q-JJ:*_$BA&?MJ/ETLO+!+WP]1(\.19%I3BO &H./\
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M_P X9/\ H'KW[VM?]_1?\Y$_S]>_X<L_ER_]Y_?"?_TJK8O_ -?O?OW!??\
M*-/_ ,X9/^@>O?O:U_W]%_SD3_/U[_ARS^7+_P!Y_?"?_P!*JV+_ /7[W[]P
M7W_*-/\ \X9/^@>O?O:U_P!_1?\ .1/\_7O^'+/Y<O\ WG]\)_\ TJK8O_U^
M]^_<%]_RC3_\X9/^@>O?O:U_W]%_SD3_ #]>_P"'+/Y<O_>?WPG_ /2JMB__
M %^]^_<%]_RC3_\ .&3_ *!Z]^]K7_?T7_.1/\_7O^'+/Y<O_>?WPG_]*JV+
M_P#7[W[]P7W_ "C3_P#.&3_H'KW[VM?]_1?\Y$_S]>_X<L_ER_\ >?WPG_\
M2JMB_P#U^]^_<%]_RC3_ /.&3_H'KW[VM?\ ?T7_ #D3_/U[_ARS^7+_ -Y_
M?"?_ -*JV+_]?O?OW!??\HT__.&3_H'KW[VM?]_1?\Y$_P _7O\ ARS^7+_W
MG]\)_P#TJK8O_P!?O?OW!??\HT__ #AD_P"@>O?O:U_W]%_SD3_/U[_ARS^7
M+_WG]\)__2JMB_\ U^]^_<%]_P HT_\ SAD_Z!Z]^]K7_?T7_.1/\_7O^'+/
MY<O_ 'G]\)__ $JK8O\ ]?O?OW!??\HT_P#SAD_Z!Z]^]K7_ ']%_P Y$_S]
M>_X<L_ER_P#>?WPG_P#2JMB__7[W[]P7W_*-/_SAD_Z!Z]^]K7_?T7_.1/\
M/U[_ (<L_ER_]Y_?"?\ ]*JV+_\ 7[W[]P7W_*-/_P X9/\ H'KW[VM?]_1?
M\Y$_S]>_X<L_ER_]Y_?"?_TJK8O_ -?O?OW!??\ *-/_ ,X9/^@>O?O:U_W]
M%_SD3_/U[_ARS^7+_P!Y_?"?_P!*JV+_ /7[W[]P7W_*-/\ \X9/^@>O?O:U
M_P!_1?\ .1/\_7O^'+/Y<O\ WG]\)_\ TJK8O_U^]^_<%]_RC3_\X9/^@>O?
MO:U_W]%_SD3_ #]>_P"'+/Y<O_>?WPG_ /2JMB__ %^]^_<%]_RC3_\ .&3_
M *!Z]^]K7_?T7_.1/\_7O^'+/Y<O_>?WPG_]*JV+_P#7[W[]P7W_ "C3_P#.
M&3_H'KW[VM?]_1?\Y$_S]>_X<L_ER_\ >?WPG_\ 2JMB_P#U^]^_<%]_RC3_
M /.&3_H'KW[VM?\ ?T7_ #D3_/U[_ARS^7+_ -Y_?"?_ -*JV+_]?O?OW!??
M\HT__.&3_H'KW[VM?]_1?\Y$_P _7O\ ARS^7+_WG]\)_P#TJK8O_P!?O?OW
M!??\HT__ #AD_P"@>O?O:U_W]%_SD3_/U[_ARS^7+_WG]\)__2JMB_\ U^]^
M_<%]_P HT_\ SAD_Z!Z]^]K7_?T7_.1/\_7O^'+/Y<O_ 'G]\)__ $JK8O\
M]?O?OW!??\HT_P#SAD_Z!Z]^]K7_ ']%_P Y$_S]>_X<L_ER_P#>?WPG_P#2
MJMB__7[W[]P7W_*-/_SAD_Z!Z]^]K7_?T7_.1/\ /U[_ (<L_ER_]Y_?"?\
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M_P X9/\ H'KW[VM?]_1?\Y$_S]>_X<L_ER_]Y_?"?_TJK8O_ -?O?OW!??\
M*-/_ ,X9/^@>O?O:U_W]%_SD3_/U[_ARS^7+_P!Y_?"?_P!*JV+_ /7[W[]P
M7W_*-/\ \X9/^@>O?O:U_P!_1?\ .1/\_7O^'+/Y<O\ WG]\)_\ TJK8O_U^
M]^_<%]_RC3_\X9/^@>O?O:U_W]%_SD3_ #]>_P"'+/Y<O_>?WPG_ /2JMB__
M %^]^_<%]_RC3_\ .&3_ *!Z]^]K7_?T7_.1/\_7O^'+/Y<O_>?WPG_]*JV+
M_P#7[W[]P7W_ "C3_P#.&3_H'KW[VM?]_1?\Y$_S]>_X<L_ER_\ >?WPG_\
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M>_X<L_ER_P#>?WPG_P#2JMB__7[W[]P7W_*-/_SAD_Z!Z]^]K7_?T7_.1/\
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M_<%]_P HT_\ SAD_Z!Z]^]K7_?T7_.1/\_7O^'+/Y<O_ 'G]\)__ $JK8O\
M]?O?OW!??\HT_P#SAD_Z!Z]^]K7_ ']%_P Y$_S]>_X<L_ER_P#>?WPG_P#2
MJMB__7[W[]P7W_*-/_SAD_Z!Z]^]K7_?T7_.1/\ /U[_ (<L_ER_]Y_?"?\
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M_P"\/?\ V8+M/_[-_?OZ\;I_O_\ ZIP_]:^O?U6L/]]?\;D_Z#Z]_P! ZO\
M)P_[P]_]F"[3_P#LW]^_KQNG^_\ _JG#_P!:^O?U6L/]]?\ &Y/^@^O?] ZO
M\G#_ +P]_P#9@NT__LW]^_KQNG^__P#JG#_UKZ]_5:P_WU_QN3_H/KW_ $#J
M_P G#_O#W_V8+M/_ .S?W[^O&Z?[_P#^J</_ %KZ]_5:P_WU_P ;D_Z#Z]_T
M#J_R</\ O#W_ -F"[3_^S?W[^O&Z?[__ .J</_6OKW]5K#_?7_&Y/^@^O?\
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MP_\ 6OKW]5K#_?7_ !N3_H/KW_0.K_)P_P"\/?\ V8+M/_[-_?OZ\;I_O_\
MZIP_]:^O?U6L/]]?\;D_Z#Z]_P! ZO\ )P_[P]_]F"[3_P#LW]^_KQNG^_\
M_JG#_P!:^O?U6L/]]?\ &Y/^@^O?] ZO\G#_ +P]_P#9@NT__LW]^_KQNG^_
M_P#JG#_UKZ]_5:P_WU_QN3_H/KW_ $#J_P G#_O#W_V8+M/_ .S?W[^O&Z?[
M_P#^J</_ %KZ]_5:P_WU_P ;D_Z#Z]_T#J_R</\ O#W_ -F"[3_^S?W[^O&Z
M?[__ .J</_6OKW]5K#_?7_&Y/^@^O?\ 0.K_ "</^\/?_9@NT_\ [-_?OZ\;
MI_O_ /ZIP_\ 6OKW]5K#_?7_ !N3_H/KW_0.K_)P_P"\/?\ V8+M/_[-_?OZ
M\;I_O_\ ZIP_]:^O?U6L/]]?\;D_Z#Z]_P! ZO\ )P_[P]_]F"[3_P#LW]^_
MKQNG^_\ _JG#_P!:^O?U6L/]]?\ &Y/^@^O?] ZO\G#_ +P]_P#9@NT__LW]
M^_KQNG^__P#JG#_UKZ]_5:P_WU_QN3_H/KW_ $#J_P G#_O#W_V8+M/_ .S?
MW[^O&Z?[_P#^J</_ %KZ]_5:P_WU_P ;D_Z#Z]_T#J_R</\ O#W_ -F"[3_^
MS?W[^O&Z?[__ .J</_6OKW]5K#_?7_&Y/^@^O?\ 0.K_ "</^\/?_9@NT_\
M[-_?OZ\;I_O_ /ZIP_\ 6OKW]5K#_?7_ !N3_H/KW_0.K_)P_P"\/?\ V8+M
M/_[-_?OZ\;I_O_\ ZIP_]:^O?U6L/]]?\;D_Z#Z]_P! ZO\ )P_[P]_]F"[3
M_P#LW]^_KQNG^_\ _JG#_P!:^O?U6L/]]?\ &Y/^@^O?] ZO\G#_ +P]_P#9
M@NT__LW]^_KQNG^__P#JG#_UKZ]_5:P_WU_QN3_H/KW_ $#J_P G#_O#W_V8
M+M/_ .S?W[^O&Z?[_P#^J</_ %KZ]_5:P_WU_P ;D_Z#Z]_T#J_R</\ O#W_
M -F"[3_^S?W[^O&Z?[__ .J</_6OKW]5K#_?7_&Y/^@^O?\ 0.K_ "</^\/?
M_9@NT_\ [-_?OZ\;I_O_ /ZIP_\ 6OKW]5K#_?7_ !N3_H/KW_0.K_)P_P"\
M/?\ V8+M/_[-_?OZ\;I_O_\ ZIP_]:^O?U6L/]]?\;D_Z#Z]_P! ZO\ )P_[
MP]_]F"[3_P#LW]^_KQNG^_\ _JG#_P!:^O?U6L/]]?\ &Y/^@^O?] ZO\G#_
M +P]_P#9@NT__LW]^_KQNG^__P#JG#_UKZ]_5:P_WU_QN3_H/KW_ $#J_P G
M#_O#W_V8+M/_ .S?W[^O&Z?[_P#^J</_ %KZ]_5:P_WU_P ;D_Z#Z]_T#J_R
M</\ O#W_ -F"[3_^S?W[^O&Z?[__ .J</_6OKW]5K#_?7_&Y/^@^O?\ 0.K_
M "</^\/?_9@NT_\ [-_?OZ\;I_O_ /ZIP_\ 6OKW]5K#_?7_ !N3_H/KW_0.
MK_)P_P"\/?\ V8+M/_[-_?OZ\;I_O_\ ZIP_]:^O?U6L/]]?\;D_Z#Z]_P!
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MZ#Z]_P! ZO\ )P_[P]_]F"[3_P#LW]^_KQNG^_\ _JG#_P!:^O?U6L/]]?\
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MKW]5K#_?7_&Y/^@^O?\ 0.K_ "</^\/?_9@NT_\ [-_?OZ\;I_O_ /ZIP_\
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MR\W/_.7_ &.O?] ZW_@TG^8I_P"C7_XW[]_7+_ESL_\ G#_L]>_JY_R\W/\
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M *-?_C?OW]<O^7.S_P"</^SU[^KG_+S<_P#.7_8Z]_T#K?\ @TG^8I_Z-?\
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M )<[/_G#_L]>_JY_R\W/_.7_ &.O?] ZW_@TG^8I_P"C7_XW[]_7+_ESL_\
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M_F*?^C7_ .-^_?UR_P"7.S_YP_[/7OZN?\O-S_SE_P!CKW_0.M_X-)_F*?\
MHU_^-^_?UR_Y<[/_ )P_[/7OZN?\O-S_ ,Y?]CKW_0.M_P"#2?YBG_HU_P#C
M?OW]<O\ ESL_^</^SU[^KG_+S<_\Y?\ 8Z]_T#K?^#2?YBG_ *-?_C?OW]<O
M^7.S_P"</^SU[^KG_+S<_P#.7_8Z]_T#K?\ @TG^8I_Z-?\ XW[]_7+_ )<[
M/_G#_L]>_JY_R\W/_.7_ &.O?] ZW_@TG^8I_P"C7_XW[]_7+_ESL_\ G#_L
M]>_JY_R\W/\ SE_V.O?] ZW_ (-)_F*?^C7_ .-^_?UR_P"7.S_YP_[/7OZN
M?\O-S_SE_P!CKW_0.M_X-)_F*?\ HU_^-^_?UR_Y<[/_ )P_[/7OZN?\O-S_
M ,Y?]CKW_0.M_P"#2?YBG_HU_P#C?OW]<O\ ESL_^</^SU[^KG_+S<_\Y?\
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MO?\ 0--N7_O:K\R/^I]1_P#9%[]_78?\H=K_ +QU[^K1_P"4FX_YR?['7O\
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M-N7_ +VJ_,C_ *GU'_V1>_?UV'_*':_[QU[^K1_Y2;C_ )R?['7O^@:;<O\
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MDW'_ #D_V.O?] TVY?\ O:K\R/\ J?4?_9%[]_78?\H=K_O'7OZM'_E)N/\
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MH_\ *3<?\Y/]CKW_ $#3;E_[VJ_,C_J?4?\ V1>_?UV'_*':_P"\=>_JT?\
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M)4ZE5KM(.>>9#<R6TS<7M8R3ZDEF/#_3=!?E>,0)/&O!;B0 ?(!0/\'6S/[
MW0HZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>ZU^_P#A37LN#=/\IWL[.34T<\G6W:G2F]*65X]9ADKLY#MTR(?&
M^AC%GY([ZH_2[+K.KQN,>0I"FYQC^)9 ?GV,W_/O0<YK758N?0H?^-J/\O5T
M/QVWS2]G_'[HOLNAJ8*RB[#Z<ZQWS1U=+,M1'+%NW"4-?')'(A9'1TJ RLK%
M2"""0?85NHC!*Z,*%692#Q!!(Z/X9!*BL,@@$$<""*]#'[8Z<Z][]U[K64_D
M[XQ>J/YMG\]#ID3SI3;@[GV-W+C,;-)&$B3=>5W9F93!$AB6.(1[KHXQHIS^
MU' LDA*(9!US+)]5MNWRD"HCDC)'F$T(/^.D_:33H+[*G@7MY&"::T>A]7#,
M?\/[ .MFOV!>A1U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=1*FOH*.2EBK*VDI)
M:Z84U%'4U*0--(?I'$&8&1S_ *E03_A[]U[KNMKJ+&TTM;D:REH*.'1YJNMJ
M$I8D\C!%U2.51=3,H%SR2 .3[]U[K+!/!500U---%44U1%'/3U$$@E1TE 9'
M1U)5D92"""00;CW[KW46DRN+R$]934&2H*VIQTO@R%/25D=2\#W9=$R(S-$^
MI'%F -U8?@^_=>ZG^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NJQ/YT&QJ7L/^5?\X\!64T%5%C^BMP[Y
M2*HA6=1+UA-3;E@D"N" \,^)CD1K:D=592& (/>6)3#N%N0:?JJN/1CI/[0:
M=%>]QB2SF!S^FQSZJ-0_81U/_DX[T@W]_*X^#&<IJF.JCH?CWLG9;2Q2>4"3
MK:-]NRQD^26S0RXIXV&H:64KHCMXUKS+&8MPN ?]_.?]Z8M_EZWLK:[2$_\
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M-#2ZY*>&.HCD;(30!YE]U[IWZ_\ YBW>&VN]NE.E/G#\*:_XATWRBSN<V?\
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M'\/K<XQ'^;NJI)=92I'/*P6XL=P@/$PB0?\ -O6W^'3T&-\)ANK24<!*4/\
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M #KW%_\ 7CW[P^4/XMR_ZH_] ]>U<R>EA_U6_P _7OX__P *-?\ GB/Y<_\
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M\&<]2YR/&OH,].*3Y"25"52I_G(UIH8W8.#98XWXT(1[KW4O^0,V<KOYRO\
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MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NB3?S _Y?\ \=/YE?QMW/\
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MT>=P&0V]456.R..J)46KIY-8FBJ(XIT]U[I#_'GX&=TTGR9P?S,^<GR2VO\
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MU[KWOW7NO>_=>Z][]U[K2P_X6V_]D._$+_Q:VM_]Y#.>_=>ZV<OYAOS4VY\
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MUN7>,2'-R3T$.WJ;[=J6.F4M75F3EEIXJ6.);U%1/$B?K'OW7NCE?R^OF_\
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MA\&\W+A<J^273&LCQ[.W=C98ZDM(_CAEC<(J*S>Z]U4WTA35FS*_X ?SOJC
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M%>EH=V3U-'D:*'Z&1<?N7#Y:25M-U>NC!-F4"5?>&Q22YM]SA_L[N!3J]64
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MW?BX:2CI*FJB&>J6B\"3S2CW7NCG_P X#XR=V]_?$C;>1^).S<%NSY5?%[Y
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M\=),Z/!)3&26/W7NB ;)ZU_FZ[]^6?\ +_[:_F?=&=O[_P#AQ\<^ZLMN#I'
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M%DUI+U$?NO=63]Q;QW=_*_\ B;\&NJ?CKT>.^=B[1[?^&'P<W''7[YI]DUN
MVAO66BV%3;R2!X*RJW%D*7,R8".;'4D3U$HKIZ^>6*CHZRIB]U[HZ/R4^.G5
M/RVZ,['^./>.$R&X^INV,)%MW?.!Q>X:[:L]71QU,%68%R&,J*6NIU>6FC#F
M*="Z:HV)1F!]U[K7C_F%?R"^OL]UW\>,;\2]N_*'L'/XOYD?&3,=IXG>GSU[
M"RE-C.N]O9P5.Z\O01;M[ @HH,EC:&*(TLM!JR\+$OBU%2J.GNO=6Z?)OMC>
MO\O;H7XH[?\ C_TCF.^]GS?)'XM?$W=46\.XZE\SMW:?;V5BVC!NV3(9HY;.
M[SR>/S59@*>6E#SUU0E9-D*J>.DHZRIB]U[JQGW[KW6O=L#IGY[_ ,I[L/O;
M:GQ;^-5)\X_@!W=VWNSNOK7K+K7L[ =5=D]09WM&66MW+B:2@WC48_;.Z-CS
MY<BIQT=-EJ>OH9:J=9Z:6G1YW]U[H@VQ.M?YNF^OE[_+\[C_ )GO27<F^/A]
M\<>W\[D.C=O]<XW8W879E%OK>L-!MS9F\N^<=L6O?!OA,1%7Y.<9+;5,O\,D
M*56>HZ:G:L=/=>ZO*_G0_';N/Y9?RO\ Y>_';X_[/_O_ -Q=H[!P6$V+L_\
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MA*?W[KW5K_;_ &M_,OZY[4Z0^2^Q?CONSNCXY[Z^-='M_OOX";;W9UYC=_;
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MM'N*+!8C-Y^JKGEQM/\ PJGQU 5J5:MDK*JA2BC^\]U[H..O?YQN:ZW^._\
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MQ5LV.VI'DMI8FJKJ-MQ34]9CZE,.)X4^Z\-;#,8M0BD60J??NO=:2GRB[O\
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M*DI2M, HW6V-[@SJ4.O>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZI
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MV(IV"-0I(22H /NO=',_GY&E3XE?'JHC%&=TTG\R#^7W4[ 2:H%/4-F$[(Q
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M"39N>JXX<S#DJ%*:>&JD3$-#/5RPYI)4HX9EN]W&S;9%%#XY2VN[=I));%U
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M^3$@?\=/6S3[ W0HZ][]U[K63_GFQY+KSY\_R-_D#0?:P8S;WRXJ>M=V5M2
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M(/+&R(M84J)51M:!'1+^-2Q .>9.=I]RMWM$18XIYWNG'Q-JDDU!=5!A=(R
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M1^(DQ.6IF$U/4J(LO/JAE6ZR+X:FG>X)&F1#]&'N8_=Y3&U@C"C+:*"#@@U
MS^8/4>\@,)%NW4U4W3D$9!% <?MZV@?<.=2%U[W[KW7O?NO=:]/\_?X7;I['
MZDV=\Z.@ON\+\D/AE44^]#F<&$CKJK:N!JADZB6-G]$E3M2L1LK K77[8Y.,
M)-++%&96]K>8H[.X?;+NAMKP>&0U=(D(TCAP#CL/#.DU '0$YYVA[F%;VVJ)
M[8ZU(I4H#4C/'334!FH!%#JZLF_EN_-?;'SV^)_7?>F+EQM+O)J0;4[>VMCY
ME/\ "-TX".-,E3^+7(\-+6:XJZB5V+FAJJ<N2^L '\W<N2<K7TEJ]=(.J)B/
MCB;X3\R.#4_$".A#R_O*;[:I<+2I%'4'X7'$?Y17B"#Y]'P]AGHZZ][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7N@>^0'>G7WQGZ7['[Y[4R-1B]@]8;:J]S;@GHZ;[RHD6$K%3TE)#J02UE?
M5RP4U.C.BM/+&K.BDL%^V;;+N]Q':P"KR,%4<!4^9/D ,D^@Z2WMY'M\3S2F
MBHI9C\A_E].J9?Y<_P#/NZP^=/>@^/N].D\E\=-[;FQ4^4ZFJ,EV-'OZBW$^
M.CFJ*JA,S8/ /CZ\TD334J".JBJECG031RI#'42'S?[7S\KVWU<<PN$4Z9=*
M:#$30 _&]14T)P02,9P$.7>>(M\F\!XS"Y&J/4VH2#CCM6AIFF:BN<=7]^XM
MZ'/7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T77Y?\ _9)?RB_\5U[L_P#>:R?OW7NO
MEZ_\)X<Y15'R;^$>VH_-_$L3\Y\OG*LM&!'X-PX?9=/3Z6O<OY,74ZAI%AH-
MSJ-IHY/A9>5]TD\F;2/6J*A/_'QU'6_S*V^6$?FJNQ^QM0'_ !P]?64]POU(
MO7O?NO=>]^Z]T'_:_5^R^Z^L]^]1=C8A,[L7LG:><V7NO%._B,U%N"G>FG$<
M@]4,Z+)JBE6SQ2*DB$,H(565Y)M\R3PG2\;*ZGT934=,W%NEW&T4@JKJ58>H
M(H>M6C^5!VENW^6/\]NZOY37R#W/,_7>^]U_WG^,6[,QY5@JLAG CXM*9M'@
MIUW=A_$)8P_@@SE"]%"SU%3(TDU\]64?.>UP[_:*/$1=%TBTJ N"3FIT-P.2
M8V!- N(TY6N&Y:OI-HG8Z&)>W8U-0:FG"@U ?(:PP%217;7]P5U*/7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW3'N?<^W-D[;W!O'>.>P^UMI;4PN4W'N?<VX<C%AZ#'8_
M"0/4UE;6U=0\<%-24M/'))++(ZI&BLS,%!/OW7NJFY?Y_7\FR&66%_YA'0)>
M*1XF,65KYT)C)!*R1X]D=;CAE8J1R"1S[]U[JU#KSL#9G;&P-C=I]<[AH-W=
M>]E[.VSV!L/=>*9GI<GAMY44&1Q>0IBZHYIZVAJ8)HRR*2CBX!X]^Z]TL/?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW1!?YHIS2? 7Y,3X:LH*"*CV'%7[HJL
MG-'3P+M^@R%%-N/S23$0I <&F0\NNZF+6O!8$:;AU=*5%>M8;^7_ (KM6K[>
MV#N'9PRPZD@[P^+M/V=7P-)_"IQ4]B;:.$A9@?MI:\5^F6GM>58%JBEHVENT
MH/2F0BGSS3]G6[G[>Z1]>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=(?L+K7
M87;&V:K9_8VU,/N_;E7)'.V.S%-YO%-3W,552S*5GHZR!CJAJ8)8YX7L\4B,
M ?>B*];!IT6L8'Y"?'8F7:-;G?DYTY3LSR[*W1EHCV#A( 2S##YRK>&EW=2P
MK<)2926#)6L%RE6VF'W[AU;#?+_!T,W7W?77G;&U-Q;EZUK*[=N2VI%70[AZ
M^CI!MW<M#D:&.1OX-D</F9,;/BLI+)$T4:5S4T+-9_,(/WO?JUZJ5IT#5+\O
MLQ6;UR/7D/Q+^47][\1MO ;OR>(>'KQ3!C=T5>1H:&K>7_2'X2D]5B<B@59&
MD7PL7159"WJ]6T^=1_/_ #='+][ZIU[W[KW7O?NO=>]^Z]U6W_-/^,VU?EM\
M9*7IS>6+[QR>%K>RMK;B9?C_ +;Q6Y\W%+@*?(-')+!F:NCHTH#Y"LDGD+AV
MB55.HE17R;O<G+]Z+F(PZ@C+^L6"=U!^#-?3HDY@VM-XMC;R:]+,I/AZ=7::
M_BQY=50?R>/Y8N+^)GR I.XLYLCY<[:[$EQG=NRQ%V5L[:]#M2/ UN;JQM^J
MFKL=E:C(KEJ[;]#AY9XEIWBCKIZB$$1(K@<>X'/#\PVWTP:V:,&&2L9E\3Q!
M&-8HPII#LP'GI /08Y2Y43993/28.1*E'T%-'B=I[<ZBJJ3\R<#RV@_<.=2%
MU!R6,QN:Q]9B<QCZ'+8O(4\E+7XW)4D==3SQ3"SQS0RJ\<L;#@JRD$?4>[*Q
M0U!((X$8(ZT17!Z)CE/Y=_Q16O?.=;[ R7QVW*^7_CDFX_B[O3,?'.:6I9(H
MY7K*7:5;B\7DTJ$@C$\5;05,4W)D1F9F)\O-%Z129Q.-.BEPB7%%]%,H<K2N
M"I!'D>BP[-;KF-?".K6?!9HJMZMX94-6F0P(/F.FN/H[YM=<Z9NL?F9C>WL?
M3SQR?W/^5_2N'RDLL$95124VZ>OQLJJH6,>LFIK<#FI6DTDIIU W.X[?=?VM
MJ8C2@:VE<"OJ4G\;5]BM&.JK:74'P3ZQ6I$T:DT] T7A4^UE<]$X[Z_G)8?X
M/]@T/4GSAZ3EVSO*KV_1[KI<Y\?>RL1V7C:K$Y*JJ*.ERD>/W0=C[A2*:>CK
M$>*GQU>8I*>6-9IF0GV?[5R#)S+$9]ND+(&TTFB>-M8 )6L8F3%1EF6H(-!T
M5;AS5'LSB.\4*Q&K].1& 6I -',3YH<*K4((J>C%_&O^;O\  'Y21^+8O?NU
MMI9J7)IB,?M;MZNI^K<E75!A$[QXVFRM1",BT2L!(*:24H2MQ9T+%>\<B[KL
M?]M Y &HM&/$5030:BE0*^5:=+-NYGL=T \*5:DD!6.AB0*F@:A- ?+JR>GJ
M(*N"&JI9H:FFJ88ZBGJ*>031R1S ,CHZDJZ.I!!!((((-O82(I@]'_67WKKW
M7O?NO=>]^Z]U6/W3U'OW%?(;X];7PGRN^4F$VYW5O3N!=T87';UP8AI8=O;;
MR.;HJ7&&7;<LM-!3U<,:*'DF<PJ$9V-W(HL;R-K:9FMX"T:1Z6*O4DNJDFD@
M!)!]./17/"PD0"20!BU0"M/A)\U/#JQG:N"?;&V\)MZ7.Y_<\F&QM)CI-Q;J
MK(\ADJUJ5 IJ:Z>&&GBEJ9B-4C)!&A8G2BBP ;E?Q6+4"U)-%P!7R%2<=&2K
MI %2:>9XGI_]M]6Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NM9G^9%3T'6O\^_^3/W,Y@HZK?>
M"[3Z4FK@?%)(ICRF.IJ=G6179&FWW*J*0%)F<>L,R <;(S3;/?1>2F%P/++"
MI_8@_9T&-S4)N-H_F1*M?/"X_FQ_;ULS>P/T)^O>_=>ZKS_FT[6BWC_+)^>&
M)FB29*3XM]P[I"2*C /L7#U.;C>S\:HWQZLI_4" 5]5O9SRZVB_MS_PZ,?M<
M#_+T7;P*VDW_ #2D_DIZ"[^1OO\ B[)_E/\ PHS\52:K^%=65FP)682*4?JW
M-93;1B(E=W'C&)"KR$90K1JL;(H?YK@-ON-PI\Y"WY/1Q_)NF=AE$UG"1_ %
M_->T_P QU:[[#_1OU[W[KW7O?NO=,6Y]T[9V3M_+[MWGN/!;1VKM^AFR>>W-
MN?+T^ Q]#34XO)45E;5R14U-!&.6DDD55_)'OW7NJ0>U/^%+O\E#J/<TFTLU
M\V=N;KRL$9EJ:KJOK?>/:^,0$V4+FL!M^OPU0S$-Z8*^5E NX0,A?W7NCQ?$
M?^:1_+Z^=ACI?BI\K>J>UL_)1#(-L:GRLVT]RI"=5Y9=L9VGQ>X(D70VIFQH
M5;7)L03[KW1^??NO=>]^Z]U[W[KW1"L5_,A^,VX?YA&8_EG[7S&?W3\D=I](
M9#O;?SX"BHJW ;=H:.KQ5/%ALS7G()60;CK*?,X^MBHX\9,BT4J35$\#2P1R
M^Z]UG^4/\P#K;XT=D;/Z-QO5'R!^2_R$WQL_)]C8;H;XQ;!HM[Y^';>&K8<=
M4;@RM1FLQMS;F$Q?WLQAADR&>IGJY8YHJ..HEB=![KW0G?%/Y>=._,39&XMW
M]4U.Y<7E=A;USG6G:O6'8NW)=D;MV?N/;K+]U@]S8*I9JC&UPB>&>$ZI(*JE
MFAJ:6::"19#[KW1H/?NO=:6'_"VW_LAWXA?^+6UO_O(9SW[KW1NO^$K:L/B]
M\F&TG2>^\2H:W!*[>H"0#_47%_\ 7'N;/?'_ )*%O_SS_P#61^HS]KO]PI?^
M:Y_ZMIUM*^X3ZDSKWOW7NO>_=>ZP5--35M-44=93P5=)5P2TU52U,2SQRQSJ
M5>.1&!5T=20RD$$$@BWO8-,CKQ%>M/S&5%?_ "%?YITV$K):R@_EY?-RM:IH
M*B:7_(=M2M56#6+(D;[(R.06*5CK=]NUL<K-45B:4GQU'NALFL4.X60H0/BE
M6GYD^(%J/^&*10!NHI0_U&W,J<6=T:@X"Q/7\@ I-/+L(R2IZW!:>H@JX(:J
MEFAJ::IACJ*>HIY!-')', R.CJ2KHZD$$$@@@@V]P&13!ZE;K+[UU[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NM
M;O\ X4X]HYW;?PGZPZAVY43?>=Y=][>Q>7Q-)$U1-D,;LFAK,G]K'$A+R'^-
M_P !D 5&)=$4<L+R][,6:2[G)<2<(('8,30*S%4J3_I2_4>^Y-P\=@L29,LR
M(0!4D %Z#YZE7H(/YR'\O*?I#X@?%#Y._&BDDP?;_P#+FVYU;MJNW)AZ-#D*
MO;6T6HS3Y6H9(Y'JI\!N&-<@0Q\24]=E9Y+J+>UOMYS7^\;^YL;TZHMQ:0Z2
M>T2O7 ]-:G3C-0@\NF.;]A^CM(;JU%)+,)0\28DIQ]=)[LXIJ]>K^_A+\H=M
M?,OXM=.?([;*04D?8FU8:G<.%AD,O\,S>'DDH,YC"6LY6BRM-5QQ.RJ981',
M!HD4F+N8ME?EZ]ELY.,;D _Q(>Y6_-2#\N'0WVC<DW>VCN4X.M:>AX$?D01T
M:CV2]&77O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=5+_ "B_GI?RG?AYG:_:7=WS
M3ZNIMZXG)G"Y?9'7$64[KR]#5JAD>GR5%L['YR3%21H"7^]^W"M:,D2.B-[K
MW3;\:OY]/\H[Y99JAVMU#\V>KXMW9/)KAL;M+L^ERW2.0JJJ0%HX:&+>&.P:
M9!Y5 *?:23@L?'<2AHQ[KW5O".DJ))&ZR1R*KQR(P=65Q<$$<$$<@CW[KW7+
MW[KW7O?NO= /W[\GN@?BYA-E[A^0':>U^K\7V-V+M;J/8,FXIY3+F=R[TD>/
M&8;&TM/%/55E;5&.5M$<+".*.2:4I%&[K[KW2K[C[HZG^/76VZNX>\.PMI]6
M=7[(Q_\ $]U;YWKF(L'CZ*)G6-/+/,R@R32O''%$@:6:5TBB1Y'53[KW0'?&
MKY\?#_Y?YW>6T_CKWIM;L/>/7T457O'9'V>1VEG:&EGF-/'D'PF=HL9E9,5+
M4*8DKHZ-Z-Y?VUG+D#W[KW1OO?NO=%U^7_\ V27\HO\ Q77NS_WFLG[]U[KY
M?G_"9^":'YY?$^21"B57?^Y)Z=B0=2+MB6(L+?\ -R-QS_3^GN;^78V3DV_)
M&&G)'S'^++_A4C\NHQW9PW,MJ!Y0T/R-)S_@(Z^L;[A#J3NO>_=>Z][]U[KW
MOW7NJ*/YZ'\N_)?+;H6@[XZ7HJVD^4GQB@KMY;)KMNM44V3S.%QI^^R&$I6H
MD:KERU/+3QUN&T R)6))3P&,U\DBR7[:<V+L%V;:YH;6YHD@8 JK'M#'5C3D
MJ_D5-2#I Z!7.O+YW>W$T-1/!5XR"02!0E13SP"OHP J 3T._P#)^_F(XC^8
M+\7L9G<_D:%._>J4Q6S.\\#$T<$DE8T+?8;AAID(,>/W#%!-(A"*B5<-;3)=
M:<,Q9S]RB_*5Z8U!\"2KP,<U6N5)_B2H!^14^?2[E3F%.8;8/4>*E%E7T;UI
M_"U*C\QQ!ZM@]@?H3]>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW1!/YJFQJ'LO\ EK_.G8>1@W[4
MTVY_BSW1C!3=6[.3L3<4LKX.L:GCPV DK<8N;R$DZQ+%0_Q*D-4Q\"U,#.)4
M]U[K4TZ*^='\L+:O2_5>V.T_^$M'?$_9&W-@;5P.^*O"_P KO9'8]+/E,11P
MT]94PY[<%%1YS*I4S1O+]Q7TRU4A<F<O)=V]U[K=8^,VX=H;M^-_Q^W7U[U9
MDNB]@[FZ1ZIW#L?I+,;0I>OJO9V'S6!H*G&;5JL!0VHL'4[>HI8*"7'T_P"Q
M1O3M31?MQK[]U[H;O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW5;7\X[_ +=.
M_P R'_Q2;Y*?^\GE/?NO=4X_R&OC]OSMO^77L1MN=L8_KK;& [%Z7SM)B%ZZ
MI]UROD^H,5M+<F,D-1+D*/Q4<=6U*&IUB(=1*-8U\&&\(%NI56@ <@ #  H*
M?9TQ8N3!&3DF-237C4?X>MGW8.%WM@L&]%O[>])O_.M7U$ZYRBVG%LR-8)%C
M$=.*.&JK%)C99&,AFNVNU@%'LOZ4'I;>_=:Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[HNW=O0&V^R%EWS@'S&R.[=N86NBV-VEL3(KMS,Q211R/3
MX^KG,4U-E</-.0):#(4M51L&+>$2!771%>K!J?YNM17JCY2?*3:/RZQ/8^ZN
MQM\T_87]^:'$=J4^\JZHI:=<905\O\6QN9Q\P6FH<1C89J]C":>*'&#7-3K3
MO$KJT":]*F4%:?LZW8L3E\3G\909O!93'9K#92EAKL9E\36Q9*EJ8:@:HYH*
MB%GBFB=2"KHY4CD$^WND?3C[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>ZT9O^%./5O9NZ_FYUEO':_7.^]R;0POQ'V'CLQNK ;0R&8QM
M)41;RWU*\%374]/)2P3+%4TSE'E5@LL;$6D4G)GV7W&WM=MDCDEC1VNG(1G5
M6(\* 5 )!(P?V'J$O<JPGN;U'CCD91 H+*C,H/B2FA(! .1^WJSG_A.#TADJ
M#X2]][#[XZAKJ*FS/R3RF2;9G;FP)*=*NEEVMMN!:@X[,T@6>G9XYXP_A9"R
MR(#=6 !'O!N:3[G#+:RJU+91KBD!H?%E-*H<'(/[.A1[<V,EO8R)/&RDS,=,
MB%:CPXQ6C 8P>K=)_P"7AT+M]YZOH?+=L_$_)24E12P_[+1V77=?8B-JB264
M3-L^?^([&J9HY)F*-4;9FT*%C4"-0GN/QS/<R_[DB.Y%03]0@=S3%/$&F4 ^
M=''KQZ&'[GB0?HEH:*5'A,55:^>C,9(\JH?V=>_T=?/_ *XLVROD5TY\BL-3
MTE2JX#Y#]2-UKGYY097B9]V[#GI\(@]4<94=<_I349"[$^_&ZVV[^."6!B>,
M$OB1@8P(Y@7)\ZF;\NO+!=P4TRI(H7A(FERWJ7C(4#Y"+\^NJCY>]K==QEOD
M!\+N_MI44%)33U>\^BX:/Y48-6DD,4B+2[89-\$1L8V+ML=4$;-([(D4C+Y=
MDAN_]QKJ%B20$F)MGH!6I,GZ0^SQ:UQYBOGW%[<5FAD  !+1CQEJ32@"5D-/
M])2F?(T%#J_YH?%;N/)S[>V#WIL"MWE1I2OE.N=P94[$W50_>!#&F2VIGDQF
MY,;*WDC_ &ZK%PN"P4J"0/:2]V&\V]0\L+A"2!(!KB:AH=,B:D;AQ5B.GK;<
M[>[)5)%+  E"=,BU%1J1J,OV$ ]4/?*_^?9\/^OOF-L;;&9ZW^2=37_#_NCY
M"[![+FQFS]KS0UU90XW+[0>3!-+O&%ZFF.30RAJJ.B?[:SF,2_L^Y/V3VIW&
M]L3*DEL!<PPR1U>6H#%9>ZD)H:8Q7/G3/0'W'W!LK2Y,3).3#)(C46.A*ZDQ
M608KZTQUL:],]I;?[RZ?ZI[KVG1YG';5[@ZUV+VEMG'[BIX*3(08_L#%TN6H
MH:Z*FJ*NFBK(J:KC69(JN:-9 P2610',2[C8OMEQ+;2$%HI'B8K4J6C8J2*@
M&E1BH!IY#H?6=TM]#'.E0LB*Z@TJ ZAA6A(K0YR>A)]H^E/7O?NO=>]^Z]TF
MMX;/VUO_ &QFMF;PQ,&=VQN*B?'9K#U3R1QU$$A#-$YB>-]#%1<!Q<<'@D>W
M89FMV#H:,#4'T/5702 J<@\1U6AT#\1/CA2?*/Y3+#U3@A'U9OWHJOZ\ADK*
MZ>/$33;3Q>5=Z.-ZMHTUY$FH8%2&D)+ WM[$^X[Q<M:P5D/>DH?AW#Q&7./3
M'V=%EO9Q"63M&&6G'':#CJU3V$^C7KWOW7NO>_=>Z][]U[H)>U^HJ+MJDPU)
M6;^[:V&,+4U=3'4]4=C5_7DU1]XJ*4K)*%U-5&F@&-7OH8L5MJ-U=I>&T)(2
M-J_[\0.!]E>'34L(F\V'^E8C_!T3S^6EM+<&;^+OQN^06]>X>\>Q]^=M?'CK
MO<N\*7L/LZOW7B6K]VXZ@R%75TF+J":>CG\X81M&!HC=XQZ6]G_-[I!?7-K%
M'$B17$J)H0*P5'90">)QZ]%.P%I[2"9V9F>&-FJ:@LR@DTX#/IU8[["O1WU[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]UK,?\ "AW&4NT^T?Y/_P BYE,<G37SYV=C!7>62,11;GR.
MW,[*" )(_4=G1MJ-/(RZ#H%BZN.>39"T=[".#VKFGS4%1_Q\]!?F.,![63S6
MX0 _)B"?^.#K9G]@;H4=>]^Z]T'?;^TQOWJ;M#8S1M,N\^N][;3:)->IAN+&
M5-&5'C(>[>:PTD-_0W]N0OX;JWH0?V'JKC4"/EU1)_PE^WY3[O\ Y5FU]O0S
MQS2=6=W]Q[#JXT-S%)D:JEW.(W_:CLQBW'$_ZY?2X]8_S<8PY_A,6Y.Q_&D;
M#Y@*$_PJ>@YRE('LD _"S@_(ZBW^!AUL/^P7T)>O>_=>Z][]U[H@/S5_EI_&
M'^83G.J)OE=1]C]B=>]1SYG)XSHNB[1S6S-E9K)92?'SP93=&&PU50MGJS%?
MP\1T(J*KP1155;')#,M2P7W7NEYUU_+U^!?4> &U^LOA=\5]CX$S_=SX_;O0
M>U\>)YS&D1J*ITQ?EJZEHHHT,TSO*RHJER% 'NO=40=2_%_^5E_-%^97\ROX
MPYS^6MU3\;.P?Y>'<G3E-B?D_P#'3=:]1[NW!G>RY-SY*'<U-/L_!;5J<+D\
M76[;$X^ZR.:%1/4"9RDD ,GNO=;/NS=N?W/VAM7:7\;S^YO[K;;P>W/[Q[KR
M'\6RF0_@E+%3??9*JT1_<U]7XO+42Z%\DS.^D7M[]U[I2>_=>ZKR_F2?-N@^
M%W2&.GVY7;)D^0O>6XO]#_QFV[V#NBBV?A)=T9FGDD.;W%D:Z:&"@VEM*B2;
M,9RI)9DH:5XH4DJ9X(W]U[JACXN0_%?XT_SK?C!AML?*OJON'^+?RS>^Z_NW
MY%U_;V"S7]\^UNT.T=LU.;R.2R$&0DH8LWFYS2)18N*1?M<='C\?10)24U-&
MONO=6(?!NLRVYOY[7\]BNW+%43OUGUU_*SZ]ZXJJM9;4^!W7L+=&X<C3TIE9
ME^WGW!)5R/X=,9F1]2F42,?=>ZR_"^>?#_SV/YSVU\4KT.VLUU!_+MW[E<92
M2""D?-U.V,]02Y)J<$+]_645/3Q33J@:5*:)9F8QQ6]U[JO[MW_A1W_,#ZW[
M8[/Z[VY_PGM^8W8NWMA=A[UV7@NP<)NO>T5'G:/:V2J:&ES-(L'1]= M+E((
M$J8A'75"!)5"3RK:1O=>ZUU?Y]W\VWY3?S#.F?C;UUWU_*L[_P#@-@-B_(2B
MWKA>P.W<WN+*4>;K),56T)PU*F9ZXV7"M2L-3)4WCKJA]$3#P!;R*OVK_<J'
M_FK'_P ?'22__L)/^:;_ /'3UM.?\)9?^R*^^O\ Q:+,?^\GM7W+'OA_R4X?
M^>5?^KLO0 ]KO]P9/^:[?]6X^MF[W#'4E=>]^Z]U[W[KW7O?NO=$7_F*_"+9
M'S[^+^]^C=SQT5#NCP2[GZFWC4PF1L'N?$P3+CJVZ^LTLWEDI:R,<R4D\RK:
M01N@EY3YDEY6O4NHZD Z9$K3Q(R1J7^51Z, >B;?]FCWVV:W>E3E&I70X!HW
M\\^H)'GU5Q_(3^:N[]R;0WW_ "[?DE)4X/Y(_#ZLR.TL%C]PU48K<CMK;=7)
MCWH%)E9JFIVC51I1LR*(SCI<<T;2Z)Y -/=#EV*"2/=K+-M> .2H-%D8!ORU
M@Z@*UU!Q04'0:Y'WAY4?;[G$]L=.:59 :"GF=/ FG J:DD];%_N)NA]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M6K/_ #QHI>UOYCW\H'X_Z'K\;5]MT.X,YB/'Y(FH]W[PVK1U=1-&ZK%,L-!@
MZXV,CLJ"0!$\G[DU>VK"RVC=[DX/@Z5;SJ(IJ >8JSK^=/3$;<Z*USN.W0K4
M_JEB/*@>(D_D W\_7K9NWULK;/9.R=X==[TQ5-G=G[\VOG]F[JPM;$LT-7CM
MS4LM%6TTJ,&5HYZ:>1&!4@@\CW#=M</:2++&2KHRNK#!#*001\P1U(LT2SHR
M. 58%6!R""*$'[1UJY_R4.P=S?!GYI_*C^4?W/E*I(8=WYKL3X]9++3A%KS0
MTJ5,Z4NIE#-N+:@QF7BBA@5(FHLCY+3.5]S5[C6J<S[=;;_;@5*+%<A1\)K0
M$X/PO5*DU(*4QU&O)T[;'>3[1,30,9("3\2\2!PXK1J**5#UZVMO<']2=U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]T7;Y5_&K:/R\Z.W9\?M_P"[NS]F[&WY4[=3=]=U
M!ONKZVS59C\)D:7(5.'_ (Q0%:RGQN:2E-%D4A='J*">HIA(@E+#W7NBW= _
MRB/Y8OQCQ6.QO37P8^-F!J<9BDPL.ZL_UACNPMPR4X"ZTJ=R;BBRN>J_,55I
M3-D7,K*IDU%5M[KW1)_F'UE_)KW/\YOBY_+G^0_\N_J[??>7S!ZW[2S?6?8^
MW>@]H8.AQ>(ZGQ.?SF0H\ENN@R.&WABI'AQF2-$F.HZA%JID<R4Y>29/=>ZM
M,^'?Q#ZR^#W2]!\?>F<WV5D>JMN9K(UVPL!V9O\ K^R)MNXZMCITAV]B<AE)
M)JZ/ XXP-]E32SR_;K(T:N4"@>Z]T:;W[KW2<WAN_:_7^T]S;[WMGL9M;9VS
M<#EMT;JW+FJI:&CH,=@8)*JLK*J9R%B@IJ>*21V)L%4GW[KW6H#_ #']J;H^
M973?3_\ ,Y[CQ6\=L[1'S=^"^ROY?73.Y]>$_@&P]U]I[87(]BYC%*RNF[>S
M8$IY8HJU/N,1@(Z.C\5/55>03W[KW5F7\TRKB[(_F<_R&_B=NNDBRW5/:7?_
M ,O/D-O# 5[&LH*[+?#CK==P;42MQ[ 05J4^6RYJ8C*Q6":".012-;3[KW3E
M_,Y-!U/_ #'_ .2A\@MKT>5H.Q=V?)KM'XD[LR6VZ2*:3+;,[JV?D*NIQ>7C
M(4UF/QF:P^,R,3/(?X?HJJF!#([ ^Z]TB_YL?_"B3XY?RD/D5LOXX=O]$]V=
MG[EWKTKMWNZAS_6]1@H:&&AW)G=QX&*CE&4R-'4?=QU&VZF1BL1C\<L5F+:P
MONO=4X=X?\+,?A9VETKV_P!98KXG_*'&Y3L;J[?^Q,;D<A6[3-/!4;OQ-7CX
M9IQ'FGD,,4E0K/I1FT@Z038>_=>ZI+_X3#TT4_SY^'*5,$<T?^D;MNIC6>(2
M+JI=H;@>.10P(U1RQJRL.5=0001[G?;*KR1<'A60_L\>$?['44WF>:(?])_U
MADZ^JI[@CJ5NO>_=>Z][]U[KWOW7NO>_=>ZT_?F%M/>_\D/^9'A?G7T_M2JK
M/A5\G<E_=CN78&V##0TU#7YLM59?%P4FD04\Z34QSF$>T2&05V*62GI?(TL]
M\O31>Y&SG:KA@+RV!>!VR648%3QIG0X]-#T8C$4[O&_)FXC<(E)MIR%F4?A8
MY)I3Y:E/F=2U6HZVU=A;ZVCV?LG:?8VP<]0;HV1OK;N(W7M/<6+E\U/6X_.P
M)4TM3$U@=,L,B&S ,INK ,"!!=S;26<C12J5=&*LI%"K*:$'[#U*4,RW"+(A
M#*P#*1D$$5!'V]*WVQTYU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW17_FQ\CX?A_\1?DA\HI]NR[N'0O3
MF_.SX=KQ3BE^_FVI035,%(TI*^**:=(UD<'4J%F4%@ ?=>ZUA]V8G_A1=U;\
M3<U_-@S_ /,?Z"W)3[1Z6G^6F\/@A%T+C*/9C;,Q6*7<V2V]1[F6&;+&L@VX
ME0T+HPJI*I%IURS^3[D^Z]UM,?%#OW$?*KXP_'KY,8'#UVW</W]TOUKW!0;>
MR;))44$?86(I,I]E,T;-&\M(:DQ,R,58IJ4D$>_=>Z,![]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>ZK:_G'?]NG?YD/\ XI-\E/\ WD\I[]U[HHG_  G.I8*?
M^6YM-X4"&JWA3U$P'T+KM#:$5P/H/1&GT_(O]2?9MO\ _N?<_P#->7^3GI%M
MG^XD'_-&/_CHZO@]E/2WKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z@96?(4V+R51B*"'*9:GH*R?&8RIKOX9'4U$4;-#!)4^*?[=)I J-+X
M9/&"7T/;2?=>Z(3B\-\CJ+Y![P[MD^,FP].[NJ.O^M7HE[HQ_P!S%)M'+;CK
MZJMDJ?X!>5*VGS5'"8](:U&NIF70J5SU:H(IT)68^->8Z]RF1WG\4]T8[J3-
MY">;(YWJG,T$F4Z^SL\@NSU&&IVCFVW73-RV0PK4[.Y,E;29"P3WNE.'6]5>
M/^STI.O/DCCLQNFEZK[=VS4]']TU%/'+C]D[FS%-D:'.K9]=1M'-Q&.EW!3I
MXV+Q+%!7TZE35T,%Q?U>M%?/HR_O?5>O>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z"W=_1O2?8.7_O!O[I[JW>^>^U@H?XWN_K[$[EK/#3%C'#]S6T
MD\WBC+MI37I6YL!<^U<-_/;#3')(HXT5V45^P$=-/ DAJRJ3ZD _X>GO9/67
M6_6E/7TG7'7VR.OZ7*30U&3IMD[3H-JQU,E.I6.2=*"G@69T5F"LX)4$@$ ^
MVY[J6Z(,KL].&IBU/VD];2)8OA 'V #_  =+?VQTYU[W[KW7O?NO=!AV=TCT
MUW7B_P""=Q=3=;=JX@0O F-[%V/C-Z0HLAN1&F1IJA8^>;J 0UF!! /M79[A
M/M[:X))(V]8W9#^U2.F+BUBNETRHK@\0RAA^P@]:1GRK_P"$]?R@J/EKEJ'K
MK>GQEVWL?Y(=W=ZY7H_ 5.\=U1G#8/&ME-R4%#F0NT*G[>:FPB14]J>>N7[A
M=!E:/]\Y)['[N6$5@@F2Y9X(85E8)%W/18R5_6%:MG(7'E7'4+;I[=W<UT[Q
MO %EED9 6DJJDLP!I&:4&,5SUL\?'_JW^8W\5^A>CNJJ>K^)7R1QG5G57677
M]9MPU6Y_C_D:*'9.$I<9+1XW/FEWC0;D-.U(B4]75[?P!JT/EGAHW!C:$]WO
MMJWN[GN/\9@\6260-2.<,7D+"JUA*"AR \E#PU=2=MUK?;9;Q0_HRZ$C0BKQ
M4"H%-&I)K-1BJI4<:="L_P Z#L(B+Y)?&/Y+=!0Q9"3%5>]4V$G>VT_(I(2I
M3-]>U&Y*RCQD]KI5Y?"XI4!'W*4YN @_J]]1FUN+>;MU:=?@R#Y:9Q$"P_A1
MGKY5Z6?O3PO[:*6/NT@Z?$4_.L1<A?FX6GG3HPG47R8^//?D=8W2W=?6/9M1
MC)WI,QC-G;SH,S74,T88M!D,?%,:Z@J$",6BJ*>*1;&ZBQ]EE]M-UME/J(I(
M]0JI=&4,#Y@D4(^8J.EEM?0WE?"D1])HVE@2I'D:'!^1ST.'LOZ5=!GW/VQM
M3H?J7LCNG?7\3_N7U7LK<6_MU'#48R-7]AM>EDK*HTT!DB$TPAB?0GD74;"X
MO[6;?8R;G/';Q4URNL:U-!J8A14^63TGNKE+*)YI,*BL[$"M%45./L'5 ?Q7
M_G@_"+??S"[/VW@G[=_B/RO[A^/>Q^J#6[ CIXS75N(Q&U$_B3#(L:.'^*L+
MN%DM#^Y;^S[DW>?;/=+2Q21UCI;Q3/+20$A0S2&F,]O^;H&V'.^WW-P8T=JR
MO&J=C"I(51Y8SZ];)'N)NAUU[W[KW7O?NO=>]^Z]U[W[KW1&?Y8__;NWX1?^
M*N]*?^Z"A]B7G+_DKWO_ #U3_P#5QNB7EO\ Y)]M_P T(O\ CB]'F]AKHZZ]
M[]U[KWOW7NO>_=>Z)-\F/DUW)\?:[%UN*^.%!V'L3<'8O3G56W]UKW31[3J)
M\SW5G<5MK&I)BY<+6/3TD.9R]/'-,:EB(5>81D *3[:-HAW2JF;0ZQS2E?#+
M#1#&\K9##)5#04XT%>BV_OFL0&T:E+QH"& .J5UC&*<*L*_+RZ,KUCN#L3<N
MW'R'9_75!UAN5<G54R;;QN^(>P(FIHTB:*J%?!18]096:13$:<,FB^I@P]E-
MU''&U(G+K3XBNC/I2I_P]+HF9AW#2?2M?\@Z$3VGZ<Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>ZUPO^%2FPQNK^6-3;NBDJ8*WJ'Y'=2[]I*FD
MD$+*<E3YG;1#/XI'\>K<"/9)(CY4B?R$)XY!O[?S^'N 2@(DC=#7T #_ //G
MSQ7H,<W1:[,O4@HZ,*>M=/\ S]^VG6P;UYNB#?&P-C;UII8IZ;=^S]L[HIYX
M'21'3<%%!5HZ-&SQLK+,""KLI'*DBQ]@N1=#$>A(_9T)E.H5Z6'NG6^O>_=>
MZUF_^$WD%!L&B_F=?'K'P04--TU\_.P8*7&4L,--%3P5J28.%(XH2B1QJNUR
MBJM-%& @$98 I&..=BTQM)6J2]I'4FI).2>/^FZ#'+0$8N$7 6YDH!P P!_@
MZV9/8'Z$_7O?NO=>]^Z]U4Y_-@_F*]]?R[=A=2;OZ%^ 7;WS\S'8^[\]MO/;
M0ZARV9Q53M^FP]%'51Y*L.&V5O65X*J5_"HDI:9 XXE<G1[]U[JCW_H)R_F,
M_P#?-]\U_P#T,-]?_:%]^Z]T*/\ PF]RWR,[:^9'\Z?Y:]__ !%[L^'O^S4=
MA_$W?FTM@=P[3SN'M_#8NS(J^DQV5S6W]M_QS^'_ '%$:B6'&Q>+[F$21IY(
MR_NO=;:GOW7NO>_=>Z+E\A_B!\6?EO0;8Q7R@^/G47?V,V569/(;1H.VMB8_
M?,.-GS*0QU<U%'D()UIY:B.GA61D +*B@FP]^Z]U4O%_(D^+6W?YE_4'RBV#
M\5_ACM+XM=<_&C<VTZOJK%=8T6*RW^D]]W8K-X+>-)C8-O?PHMBL7CW@BKWS
M,==32,8Z>G,4LLA]U[H??D!\2_EKU=\T=U?/GX#R="[NWCW/TQL?I/Y*?'KY
M"YC*]>8O<*]65U;4;5W7A-VX#$9RNQF>Q-+EJZBJ:>KQ-51UE L*(8*B)'/N
MO="O\ _B%VOT?N'Y*_)7Y2;GZ]WA\P?F3OS:N[.X*CJ6/(2;4V[A.L,4N"V;
MLK;%3F88,S68C X[[J:2JJJ>F:KR%?6U(I(/)9O=>ZLA]^Z]UIK?\+-U5_B?
M\%4=5='^:>.5E8:@0VV\N""#P01[-=B :^MP?]_P_P#5Q>D&ZFEK,1_OJ3_C
MAZ.S_P );885^ G<=0L48GE^8&^X9)P@#LD&R]@LBLUM15&DD*@FP+,1^HWD
M_P![S_NUB_YY$_ZO3] ;VO\ ^2?)_P ]#_\ 5N+K90]PWU)'7O?NO=>]^Z]U
M[W[KW7O?NO=:P'\[7XG=D?'[MCKK^;_\0:(X[M/I3,8&;O\ PF+H6DCR>+H0
ME#3YVNAIVCFJ:3[!FQ&<4$L^+E@G+014=1,9G]N-\AW6"3E_<#6*<'P&)^"0
M]VD5X$GO3^F"*$O3J..<MLDV^5-WLQ^I$1XR@?&F!4T]!AL?#FHT]7I_"OY=
M]9?.'X[;$^0G5U4$QNYJ-J+<VVJB=9:S YS%A4RF%KE%BLU).;QN45:FE>GJ
MX@8:B-C&?,6PS\M7;VDX[D.&'PNARK#Y$?L-0<@]#3:-UBWJW2XA/:PR#Q5A
M@@_,'\CQ%00>C6>R3HSZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>ZU:/F2&[ _X4H_R_\ :+2FJI-E]*XG*B@LU;'%4X&+
MLC<CS>!F5(IVC@I"TB\JD4,AU>,+[FOE\"WY-OY*4+3TKP)!-L@%?3)Q\SZ]
M1INS&3F2T2N!"2!Y TG)-/7 _8/3K:7]PIU)?6LU_P *!?C?OS9$O1'\T7X\
MP28_N#XI;IVS2;_K*")V,V!AR2U.%R%9'#)%)4T>,RT\M'6Q DST&4<3$4M,
M^F8_:K=XKGQ]DO#6&[5M%:8DTT(%:@%E *GR9%ID]1USYM\D(BW2V'ZMNPU4
MKF.M<TH2 <$5^%FKCJ]?XD?)C8GS!^.O5GR)Z[E"X#LC;5/DZG$O.M1/B\E2
MEJ?*XBJ*<?<XO(Q5-.Y "OXQ*EXW1C&6^;/+L%W+:3?%&Q%<T8<585\F!!'R
M/0VVS<8]UMTN(OA=0?*H/F#2N0:@_,=&.]E/2_KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z+=\
MO_E%L#X4_&?N/Y5=IX?>.?Z]Z1VC-O/=>&Z_Q]%E<S44L$\,!CQ]/D<ABJ&6
MHUSH0LV1@2P/KO8'W7NM9/\ Z#5OY67_ #X/Y_\ _HK.NO\ [:OOW7NB6=.?
MS<_C=_-T_P"%(G\I#LGXW;)[OV3@^H^K/E_L?<E)W?MO [;JYZO,]:=@U\4E
M#'@=R[EADIUAX=I9X7#\"-E]7OW7NM]#W[KW7O?NO= =\E/CIU3\MNC.Q_CC
MWCA,AN/J;MC"1;=WS@<7N&NVK/5T<=3!5F!<AC*BEKJ=7EIHPYBG0NFJ-B49
M@?=>ZU\/YA7\@#J?<G0NQ\#\4,%\I-][\QOR(^-60RNVMX?/'L'+T%+M# [N
MQ4VZJVGIMW[[3$15>,V_'62TKP?[D(9$5L8/NUB]^Z]T=;YA_P O'?6U]F_
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M"/4F]>]^Z]U[W[KW7O?NO=$9_F _\RGZ:_\ %YOY?/\ [^K8WL2\J_[D2_\
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M=<[;JLIB=F;3E29:/$8[/T])7P9?(LB5<$#QBAEUM)&?=>ZK;I/E!OWX>_\
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MZ]U[W[KW7O?NO=$YZ+ ;Y1?.96 96WAT.&4BX(.PL5<$>SF__P!Q;7_2R_\
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MN+L]ML6ZR6UHFB-5C(74S4+(I.79CQ/KT/>3]QFW7;XYYVU.Q>K45:T=@,*
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M6MI>Z"3B*'.@D>:^1_$M&]0%7*G,8WZ"C]L\?;*G @C&H ^1IP\C4>53<![
M70JZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K5T_E>K1[
MR_GH_P V7L&.^6GVS'N_KF/-HSQ+3B+=F*HIZ Q@I&[++ME(];1,P^T;2]G<
MR3/SF6M>6=JA. WZNGU[&8']DM>/XOD*1URZ$N-[OY1DKHC!]. 8?MC _+[>
MMHOW#'4B]>]^Z]U[W[KW6IQ_-+Z([2_EE_,[:/\ -U^)VWWK=@;IS\>'^5G7
MF.5Z6CDEW-+!'D)ZP0JRPXS=H2-I*AHF6CS\5/7-Y9:N*-9RY)W.#G+;GY?O
MVHZC5:2'B"H) SQ*5-!YQEE%*#J,.9K*7ER\7=[5:J>VY0>8-*GY5H*GR8 D
M&IZV4?C5\CNJ?EETMLCOCIC<,.X=C;XQBU=,Q*I54-5#Z*S%Y*!6<TN2Q\X>
M*HB+&S+J1GC9':']WVF?8[A[6Y4JZ&A'D1Y$'S!&0?,=2'87\6YPK/"VI'%0
M?\(/H0<$>1Z';V6]+.O>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7N@ ^3GRCZ(^&_4&:[\^2>_J3K#J#;>:VA@=P
M[WR&(R&:IZ*??>5H\)C#4Q8RDK:J.GFR5?2123_;F&G5S/4/%3QR2I[KW5 O
MR5_E^_!/^=C\D=M_+WHC^;GVABMT[)V'2=5;8V_\-OD3MR2/"H6DK,@R4\+5
M>6Q63S"2TS5R 4YJ(::D,D3")&/NO=&*^%G\BK_9-_DQUK\D/^'*/YAW?W^C
MG^^7_&).\^YO[V;5RW][]OY7 _[E,?X4^X^P_BGWM-ZAHJZ>GD_L6]^Z]U??
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[HNOR__ .R2_E%_XKKW9_[S
M63]^Z]UH-?\ "2+%/-\P-GS4B010XOXP=J96K7_-W%9E</ S* +,[U%6K->U
M[LU[\&=^8PL7)ED *5DCX>I\=B?S-2?GU%6R$OS)=$FM(VX^@,('[!U]&_W!
M'4J]>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=-><PF'W-A<QMO<.,H<W@-P
M8O(83.8;)TR5M-5T>6B>"II:B&0,DL%1!(Z2(P*LC%2"#[NCM$P9200001@@
MC((^8ZTRAP0<@X(/F.M.[?N+W_\ \)Z_GV.S]J8W<FZ?Y<7RMSE319G;.-,E
M>,%*&6JDH$!6.FBS>VS-4RX<2R!\GA144K325$%54T\_6K1^[&U>"Y5=QM%&
MECCQ5X5.:T:@UG@LE#@-0Q-.'Y OO%74;.X8U4#$3<<4%,9TCBR C)6O6WUL
M7?&T>S-F;6[#V#N#%[KV5O7 XS<VUMR86J6MI:VAS$2STU1!*A(9)(W4_P!0
M;@@$$"!+FW>TD:*52KHQ5E84*L#0@@^8ZE:&9;A Z$,K %2#4$$5!!'2K]L]
M.=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T5OY
MN[XWCUK\0/DKO[8'6^S^XMX;3Z7W_FL'U5V!5T]#@]Q24>.G+X;*RU=12TPH
M,A%Y(9A+.B,CE3<-8^Z]UKQ;<W)_PFP_F/?"OX,'Y4;Y_E^=8S=3=4[-W1M7
MH+)?+_']-UW760WOCZ/(;BV,?)N3;6:J\1CLJ'II:6J@-+(U,DT4* H??NO=
M;0?54G64W5W6\O2M5LNNZ;EV#L^3J6MZWK:/([=FVR^.IS@9<#48YY,?/A9,
M4:1J&2FD:G>F,30LT94GW7NE][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZU=
M/YV^Q_YXV?Z@^>E/U+V-_+OB^ &Z.D]V;:Q^Q=XP[PI^UJS"[DVQ!CLSBJ6>
M/!G;7]XLIF)\C#B V56%O-1)-*CF0+[AUL"O5G?\FO=VU\K\"NG]F8S<.'K]
MV; .^Z'>NW:3(1SUF+ESNZL_7T2UL"L9(15T<T<L3,NF12=))5@%5]*LTSLI
MJ"Q(/550H "*8ZM0]I>M]>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW2&[ ZWVAVAA8-O[UH*[)
M8FFR$.4BIZ#<.1VVPGITDC1C-C*NCG=0DT@T-*4)()4D*1[K8-.@]ZY^,?2?
M4N8I\[U[M*NV]D*4Y9X0F],]DJ<-G7EDK':CK,G44;R5$LTLCNT!8RNTM_(=
M7O0%.O$UZ7_8_5_7W;NV:G9_96T\/O#;M2Z3_8Y:GU-#-#?Q55'4(4J:&M@)
MU15-/-%/"UFBD1@#[\17KP-.BV_P;Y#?'61'VM49OY-]+P,QFVCG:^%>PL#3
M(LC?[BLK4R4]'N^DA&E5IJ^2#*!0!'6ULEHO?N'5L-\O\'0_]6]R=<]RXBLR
MVP-PQY-\15G&;DP-?1U&!R^(K$%WH<SAZZ*GR6+K%^OBJ::-F6SIJC96/@:]
M5(IT)_O?6NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[K#44U/6024U7!#54TRZ)J>HB6='!_#(P*L/\"/>P:9'7J5Z9
MX=K;8IYHJBGVY@8)X)$F@GAQ%/$Z/$0RLK+&&5E8 @@W!Y'NYE8^9_:>JZ1Z
M#I^]M]6Z][]U[KWOW7NO>_=>Z][]U[HC/\L?_MW;\(O_ !5WI3_W04/L2\Y?
M\E>]_P">J?\ ZN-T2\M_\D^V_P":$7_'%Z/-[#71UTT9W;^ W1BZK";FPF(W
M%A:Z-HJW$9W&PY>EF1P599:>H22*12K$$,A!!(^A]W21HCJ4D$<"#0C]G6F4
M,*$5'H>B8C^77\7MO54V4Z6VUNOXNYJ?(OE9*[XN;_RW1U&\\R0Q2M5;<PU5
M%M+(B6.G@5EK=OU*VCC( 9%(/FYIO+C%RXN!33_C"+,P )- [@R+DGX6'$^O
M16FRVT%/!7PJ$M2$F-22*95"%;'\0/ >G6#_ $3_ #LZW%,>MOE'UWWAAJ&D
MJ:?^ZGR@ZB3#Y.H$(8TBKO'8<^&CI9.(XYJBHV7DW=0TIC:4DGPO-NNJ^+;O
M$211K>6JKZUCF#EOD!*E#YTZV8+J&FB57 K42IW-Z4>,J%^9*-7[>JA_Y@WQ
M<V=WYOWIO?GS!_EZ9/$=N[X^0OP]Z0S7R#ZN^2==V%LAMN[D[.P6$R.&G@BS
M&SL[CCE\!E*Z"&K;82313U01*Z*>*&H$@<I;[+M*30[?? PK!=S""6W5)C(M
MJ[AAV3(=+H"1XV0/A()'00YAVF/<3'+=VWZADMXS(DQ:,(UPBE?BB;N5SGP\
M$_%4 ]7X?'/XU=)_$OJ[&],?'[9?]P.M</D\QF,=MO\ O'EMU>.IS\[5-7)]
MYFZ_)5[^69F;2U4RK]$55X]QCN^\7.^SFYNWUR, "VE5J%  PBJ. ].AMM^W
M0[5$((%THM:+5FI4DG+$GB?7J-\I\KVQ@_CGW1F.C:?:]3VOC.O=Q5NS(]Y9
M>MP..6H@A+2RSUF.22MIWAI1/)"\*%A.L?XN?:6S$;2H):A-0U:0":?($@']
MO2B<L$8I350TJ2!7YD ]5-_\)S=Y?(/?7\L_JS<7=%1M[.[9R6X.V<CU?OD[
MLRNZ]T9Q<AOW>$NXJS=TF20K'7IGC51TIAJ:CS4:QS3R"9VC02\[PPV^X.L(
MI0)J4*JHOZ:4"T\J4)P,U%/,D?+$LDUFC2&M2]&)+,>]JUKYUQQ.*?8+VIZJ
MFIC M34P4[54ZTM*L\RQ&25U9A'&&(UR%4<A1<D*3:P/L(TZ$/6?W[KW5>_S
M;_F"8[X99#9F HOB]\L_E%NC=V*R^YJO!_%WJ*;LS^"XC!21PSY+.3I/#'CX
MI)9"M.&OY3'*2T:QEO9QM6T'=-7ZL,06F9I @)/D,$GY^GY]%U_N L:?IRR$
MUQ&FJ@'F>%/\O0']$?S2_C-_,=K-\?&GXS;E^0>QNW,GUEOJ#?FXJWIVMVGD
M>L:B2GEQJR9.JRE//A(-S4N0E*T5,LU;"U333%]:0,CJ;W8+C9 L\ZQLA8:?
MU%82CCC2VK21Q.,$<"1TS;;K#N9:*)G# '5V$%#PSJ6FJOEG@?3JCOO#X1?%
MCX[_ "__ ):_PV_E^Q;CW3_,,ZT^1VU.[?DE\@,-F,C6Y:BV%2F:IW-6]@UL
M534T=-+FHJJE*T91(FIF>D:"./-4\-6*K3=KB\M;JYO*"V:(Q11T 3Q30((U
M/\-.(R*5R5)!%<V$-O/;PVW]LL@DD?)?PQ4L78?Q5X'!K3 /1U?YYW?O:??_
M %[\F/A+\9LVN)VGT#\<MY_(KYX=JX^OD"XS&8'%SY7:O6E.U-;5F=Y5=/!4
M9&!YXO'A%<NL\51+ Q9RG:QV<L-U.*F258[="/B)8*TAKY)7M-,O2GPGI;O\
MSW$<D$1H$C9Y6!X +J5!3S:F1Y)Q^(=6T?RIO^W:'P,_\5.Z+_\ >>H?8?YA
M_P!S[C_FO+_Q\]&VT?[B0_\ -*/_ (Z.J_Z_^8M\YODQW9\Q-L?"7XZ] [Z^
M,7PRW'O?I[MK<';O8N9VANS>FY-MTLR97&[$;'TM9C,?/CYH*A8VRM ]'7(U
M/(E?3^5D0U.RVMA#$UW)(LLZK(@1%9$0G!>K G5_1-5H:@](EW*>[E<0(ACB
M8HY9BK,XXA: _#\\&HH1T '\G[M+O_I_^0KT5N_XT=/;6[G[4/87;.'H,-OS
ML;&=7;?Q-'E-_P"X$K=Q9[)9&KI&?%XF$:Y*:C:2NJ&>-(([>22-?S5!#<;Q
M*L[E$TH254NQ(A0A0!YDXJ2 .)/2/8))(MMC,2AVJP +:1F5JDG. ,X!/H.E
M9T3_ #<?F9NWMSY1?$S<NV_@E\@_DIU#\5][?)/K#=WPM[(SF\]BY7(;#K*2
MFJ=A9?\ BU?]_1[BG:=H2ZY"-:2H:$3P&-BWMF^Y=MHHHKI&GCA>98F$Z 2
M,-7B#3AEI\LTQTY:[Q,[O PB>58S(/"<E"0::#JRK5^?0U9#^<+NG>GP_P#Y
M;_;W0O7>Q]Z=_?/_ +@V?TQ3]=Y')5DN,P-;CC64>^\BRQ3TV0EH=LY*D7B2
M:,"FFCFEG":9'1GEP0W-U%*Q5+9&?53+#&@>8!?4.E0WCQ88)(UU-,RKIK\.
M"6/STT/1;MY?SI?E9NSY1?(#IOHG"_R_.OX?CGW'NKJ ]$?,7NK/=-=G=BR[
M:E6FBR&S:RHCH-E8^#*S"5J..MKZF5HM#.%62)Y5\?+-O%;1S3&X;Q8UD$D$
M:R0Q5)J'SJ)'G2E#Z](VWJ:29HXQ"-#E"DKE))* 4*X( /E6M1Z=;*VS\KFL
M[M/;.:W)M\[3W#EL!B,CG=L'+4^>_A]9601R5-$*ZD9Z6L6FF9XUGB;QRA1(
MM@U@"' 4D U%<'A7H3C(STH_=>M]>]^Z]U[W[KW7O?NO=>]^Z]UK,_R$JRIV
M7\M?YVGQ]KJ6IH&Z^^;N1WGB8JEK":DWOFMZT<,T:LOFT/1X3'RAWD8/'/$5
M .LL.>;D$EM83@@AK8)]AC"U_FQ'Y'H,<OL4FNXB*%9R_P"3UI_):_GULS>P
M-T)^O>_=>ZUE/YY'WO7G\P+^1EWU1?91T6$^6M=UKNB6I_7]IO;.[$3]O_,K
M=,?_ !PZI*H(DAB/C9#-['7*FF>SW"!JU, D%/\ A8<_X2OEPKT%]^U17-I*
M*4$I0U_X9I'^ '\Z<>MFOV!>A1U[W[KW7O?NO=>]^Z]UHT?-W^='_(U[9[I[
MLZ;^3?\ )V[M[Q['Z'RV_P#"[\WC0_'/8SY2FQNS:QJ>NSL>=I=T8[<='MZ<
M&&KBK)IJ>/PU$%0WC,JGW[KW3/\ RPOYW?\ )A^&6Z$HNG^EOYF_QH^._P @
M\GM#KO"[M^16<D[6ZDVO5;2ERWV[8NIK=Z;BR&%CD:HJ*>N>A-8 E-"U3#%#
M235$?NO=;U4$\%5!#4TTT5135$4<]/402"5'24!D='4E61E((()!!N/?NO=9
M??NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW6H-_P *^_\ LGGX"?\ BYLO_O'Y
M[V,.0/\ DM6?_-9?\!Z#G-W_ "3+C_FF?\G5I_\ PGN_[=3_ !^_\.+NS_WM
M<][-O=C_ )+MQ]D/_5B/I!R!_P DF'[9?^KK]75>XYZ&77O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=:KG\W3X6=G?#+NK'?S>O@5%4;;WAM'-QYCY
M+]>8+'/4X^NI:\B/([AGQ\%A+BLI%^SN*)44*6&;5H:A*RL2;>0N8H>8K8\O
M[I1D<4MI&-&1AE5!/F#_ &?_ #CRI"]1GS7L\FSS?OBQJ'4@SH/A=, F@\J?
M'_O>&!)OF^$'S1ZA^>'06U^]>I,C&D>0C7&;VV755L51DMMYRE136X?))&0R
MR1,PDIY3&BU=*\-5&H24 1AS)R[<<L736MP,C*, =,B'@R_(^?H:@Y!Z&^S;
MQ#OD"SPFH.&'XD8<5(\B/YBA&".C>^R'HUZ][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>ZU;/Y&Z?Q?\ F1_SG]SU3,N0?OW-HT<-DB/\>WYOVHF.
MDAFNKTL83UV + AB01-GN8=&S[.HX?3C^4%N/\O49\D9W'<C_P /_P ,L_6T
MG[A/J3.O>_=>Z][]U[I,[SV9M3L7:6Y=A;[V]B=V[,WCA,EMO=.V<]1)D:.O
MH,O$T%32U,$@*20S1.RL"/H>+&Q]O6]P]JZRQ,5="&5E-&5@:@@C@0>FY8EG
M4HX#*P(92*@@BA!!\CUJ$[0S/9O_  GB^;F1V/NP;FWI_+2^4NZ7R&W]P)')
MD/[NU3,(XZA@6E/\>V[2M#!D44HV:Q4<-9$CU-+'2TT]7$<7NSMHE32FY6J4
M9<#Q5X^@[6-2ODCDJ:!M1BJ%G]O[WPVJUE<-56_WTYQFI/ 4K7+**BI4CK<"
MVWN/ ;PV]@MV[4S6+W'M?<^'QNX-N;APE;'DJ.NH<S"E125E)40L\4]-4P21
MR1R(Q5T8,I((/N Y8F@8HX*LI*LI!!!!H00>!!XCJ5T<2 ,I!!%01D$'S'3U
M[;ZMU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=0<GB\9FJ"JQ69QU#EL76Q^&MQN3I(Z^"9"0=$L,JO'(MP#9E(X]^Z]
MUI6?SJ.Q?Y _Q-^36(^.WR2_E.=B[@[?WSBMM=G[6[<^%_7F%Z8JJW+[CKY]
M"4>7V]NC9V2R.Y(:Y8I:B-J:I+R55+))Y))EM[KW5>GQ<_GF?#SXF]\4.^NM
M>Y/Y]DGQRZUW?)#W9\;_ )$0;'^2&UL8N<HJ[!4N/ER.8W3#N7:D=/F&AJ4B
M_BDDLM52R0>*9G,8]U[K?M^+GR?Z2^9G0_7GR5^.V\Z??W4':&+J\GM3<<-)
M-C78XVJGH*VEJJ2ICBJ:.NH*^EJ::I@EC62*:)T8<7/NO=#_ ._=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NBZ_+__ +)+^47_ (KKW9_[S63]^Z]UH<?\)$P1
M\M*.X(_YQ![&//\ CN/:WN=N:?\ E3K#_FK'_P =GZBK8?\ E8[O_FF__'H>
MOHH^X)ZE7KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N@.^1_QVZJ^5
MO3.^.B.Y]NP[CV'OO%2X^MBLB55%4)ZJ3)XV=TD^TR>.J D]-,$;1(@U*\9=
M&,=IW6?9+A+JV8K(AJ#Y'U!'F",$>8Z1W]C%N<+03*&1Q0C_  $>A!R#Y'K5
MH^%GR1[4_D>_*+(_R\/FCDJG)?$_L3<DVX>@^]9XQ1XW%KN2J$0RX,DLJT>"
MK*@VS5&:@G#U_EK@'IZB:HJ9LYBVB'W+LAN^W "ZC4+<6XRS:1P&!5@/@-.]
M>WXET]1IL^XR<DW/[NO"?IW),$QPHJ<U]!4]W\+9/:U>MP.GJ(*N"&JI9H:F
MFJ88ZBGJ*>031R1S ,CHZDJZ.I!!!((((-O<!D4P>I7ZR^]=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZHC_GT_P P-?A;\2NR]FY;
MX;=Q?)K!=\=$]U[>I]R;=Z_3L+KW#56/Q9CDI>T$I,YA\QC-M5,-9')430,!
M-1QUBI-'+#S[KW6KIG.[?Y66?^-]?+U-_P )I?EGE?DGF^FVDZ^W+EOA[F<C
ML.HWGDL,#CJ^9<?O"7*U.U)<P\4Q2G_RJ6A.F)UE97'NO=;VOP*Q6^,%\'_A
M]@>R^K\'TCV!@OC'T7@]X].;9H9<7CMJY##[9QE-4[>H:2>KKYZ2EP\D34L4
M$E=420)$(GGE9"[>Z]T;+W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UK=?S5>
MKOYH&XS\E]^;X[!^($'\L_J?"4O<FU-N86KW1CNT:>'86#IWRLF;5MO2X"OI
M8*Q\[4QP09A'-.E(P\M2OA]N)'X_8H)=F4+0@#-12E,DDBAJ*9XUQX2>"=;$
M!0#JQ]AK6OE0UP?RIEV_DC?&CMG;V5SWR>RU;3X+JS?&RLKLS;.&:H6MESK0
MY2(RY#Q13D446,J\9-#&\\7FD,DRQ(L+&21E%TUK]G\^GYVKCK8O]VZ8Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z /M3X[;([,S%'OBAJLUUM
MV]AJ7[7;O<?7D\6%SM/&M]-)5O)#-29K%$DZ\?DJ6JI&!)6))-,BZ(KU8-3H
M+E[T[.Z)F3%_*;;M#7;'BM%1_)GK3%U#X(*.%?=V!U560VE(?0'JXYZ[$EB7
MDJ:%/VU]6G6].KA^SIN^6%)E*OI[=O>/6G>O8^WCB=FXVLVU'UWNG&2X&K62
MK336@-CJW[IIXZDCR)5Z&58](&GGQZT./1F>N^OZKK^CR-'4]A]B]A?Q"IAJ
M4JNQ,O1YB:F\2%#'324F/H-,3\%E</ZA==-VOOJO0B^_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7N@E[7[QZUZ2I,-7=D9?,8BES]35TF+DQ.RLYO(O)0JCR+(N$QN1>GLL
MBD&54#\A"Q5K*[2QEOB1& :9-65?^/,.FI9U@RU<^@)_P ]$F_E:]O;'R?Q#
M^+71Z3;HQO:?6_QIZQQV]MI[DZ]W#M.2@J-M8O'4-= ]3E,71T4LU/52*C)%
M4R,>64,BLP$?.=JXW&ZN!I,<ES*4971@P9V8'M8FA'1/RY(%LK>(A@ZPQAE9
M64@A%!&0,@]69^PCT>]>]^Z]U[W[KW7O?NO=$9_F _\ ,I^FO_%YOY?/_OZM
MC>Q+RK_N1+_SQW__ &A3]$N_?V*?\]-I_P!I4/1YO8:Z.NDUO/;YW;L[=FU5
MJQ0-N;;6=V^M<T/W(A.9I9:82F/4GD$?DU:=:ZK6U"]_=D;20?0@]:85%.M;
MOJ#X(?.SXM_RG/DE\1^^NZ.K=F]2] ]==T;NZAW3\6:_++N?>&"K:+L3=&X<
M#O.NW!C8TPU!D<WE\$T<F#2GKS04U9CGJ8_-]Y,--QWBUW*_CNH4<O(4$BRA
M2B,/#52FD]U IPXI7-/(!JQVZ>QM7@D9=*AM#1DAF4ZR0U1C)'PFOS\R8/XQ
M4D':'6/\DKJ>JJZW';>ZF_EY;7^66[<Y2Y1,8,9687J_;77VUZ@^4M$\X;?&
MY*VG:6"2*&7&>9A=%!1;JW@SWSBE6N&B I6H,KR'[*&-0?,ZJ<*]*MO'B0VJ
MT-!"KUK0 B-4%?6NLD>6/LZ#C^5MUOT)G?EWNKNOX99A\3\8]C].[SZ-R&^=
MQ=FQ;NW-WWN^'<5#)ENQ,Q0K5K5S4FVY\74T5+FJZ@27*2U]3)1)#16,[N^2
MRQP"&Z%92ZR:=.E;=-+4C&*#5K#%5PM!6K5"UVU$DD\2#^S"LFJM3,U5!8YS
MITD!C4M4TH*%MBS2+EK#40%+6Y(6]A?^@N?]N?81Z/N@K[GQW:D_4O:D'Q^E
MV+B.\<QLO<4'6>8["-32X.'<,]"]/BJW-/04==62T5'.('E6.DED>.(1* ""
MK]L8Q(GC:O###6%IJTUS2M!6G"O34P?0WATU4.G56FJF*TS2O'K6N^ O\LW^
M='\'MY9_+8?LO^6[N1>Y>U\9OKY)]K[AK=_[U[!W'1U%<DV2A3,UVT:6%I(J
M>2N>BIV$-*M7,\\H\DTTK#G>=ZVK=4 TW2^'&5A0>$(D-,8#$Y--1R2/L'07
MVS;;^P:I-N=;AI'/B&1A7.: 8' 8 _;T<CYT?R"?A5\I<=\E.U]J=8Q4'R][
MAP>]<[M3L?=7;>[\;A:?=^9I)$QN1K\?0U=;21T$%8('ECBPTZ^-3:GD)TDL
MV?G"[VTQ1%SX",NI D9)355@"0#4BOF/M'2W<N7;>^\1]/ZK T8LX&JE 2 :
M4&/+\NCI_P L#X'[3_EW_$?8W0^%Q^(IM[9!,5OOO3*;<W+EMT8S+;YK\)AL
M3GLKC)<PD%5!CZO^#4OA@6BI(D5-0I8G=P2S?]X?>[EIF)*U*Q@A05CU,R@Z
M?,:LFI/S/2W:=N7:X%C4 '!>A)!?2 2*^1I\OLZ(?MS^7?\ /OXS_(GYA1_#
MCMGXVXWXM?.O?FY^UMZU?;N'W!7[PZ[W'OE9!FLAMFBQHCQ>>$GW54U%#6Y"
MGA1UHUF5$I)3D3*;>+3<((?J4E\:!1&N@KX<B*30-7*D8R :Y]<)(MOGM)9/
M!9/#E8N=0;6CD"I'DP-.!I3\LE_G_DM?*RG_ )2'QC^$=/V1T'DNXOCM\DZO
MOW<NU,OD=P9OK??=!3[@W%F*?:N<F;#X_)2T$ZY:CDF6?!2P&>G:+2 T=;"8
M-S1;MN<UWID"2Q>&K#2)8B41=:Y(J-)I1A@\?+I&NQ2BRCMRR:HWUD9,<@#,
MVDX!H:BN#D<//HP70OP=^0'Q\^>DO\QOY'9[X/\ 2O2FWOAIN7I?>'7/2LN4
MZ[PFQ:/&Y>GSD51'69/$T>*RN.B6FJ9\ADZF3"B'SF..B:"E6>8ON-TBNK+Z
M"!9G<W D5GHQD)4I2@)*G(HH+USG-.ED5E)!<_5RF-5$)0JM0$HP;B0 1QJ:
M+3&//JO3^3]\>-H=L?S5OE=V_P!5;[I^U?@S\,NPNY<A\2*VBIX:O T&[_EL
M<?5[@BVS5Q11PST.'QE)7TA"-)&$DH*N$JU0TLQUS'>-;;=#%(ACN)U3QQD,
M8X-2IJ!\S@^60?E0LV>W$]Y+(K!X8F;PN! >6C/I(].'V'[:FL^;O\L#YY_)
MO='R%VKN+ _RY/DUL?MZJR]/TC\@N^^NJOK'L[JG%YY'@&,H:O9VVR,^,'"8
M9<=45.39YZV-IJZ,TSBC4OVG?;3;Q$ZFYB9*>)'&P:*<KD$ZG&FO!A0BG#/2
MS<-KGO"ZL(75O@=UH\510THIU4XC(->/5[7Q5Z/E^-/QLZ,^/TV[\EO^;IOJ
M[9O7<N\\M$::?)-M:BBI6JC"99C!&YC/BB,TABB"1^1].HA2^NOK9I)M(76[
M-I' :B33H^MH?IHUCJ3I4+4\304KT/WM)T_U[W[KW7O?NO=>]^Z]U[W[KW6L
MO_+_ ,E2=?\ _"AW^;[TY&AII=\]9=4]QI31QV1A14>T*N>5C$QA#M+OE6]0
M,K>1CZ6$H(YWB(R[+8R^2M*A^UF:G_5L]!?;I FYW4?F5B8?8JK7_CXZV:/8
M&Z%'7O?NO=:SO_"H=\EL[XD_%3O7#8VIR>0Z0^</5VZI$IIVI#' ,)N.I#//
MIECITDR&/QT(D:FE*R2QZ0065QSR$JSW,T#&GBVTB#SR2OEBN*GB.'07YK8P
MPQR@5\.9'/E@!O\ +0?GULM4E53UU+35M)()J6LIX:JFF4%0\=0H=& (! 92
M#R ?Z^P.13H4=2/>NO=>]^Z]U[W[KW6CIT;_ #I\)_(WW-\NOCA_,C^%ORO7
MM_>OS"[^[?Q'R6ZUVA@=S4':-#V#DFR&W\K5YO.Y[;\56:3"O24=/]I6Y$45
M#!!1204E335%)%[KW17.P,S\U^U_Y9W\S3*8?^7IVC0=<_S>/GYUULKX,?#:
MOV=+%EME3YBGRF<W3VA5XR7'LN-Q^7RNW,'*)&@QU'3YR2?*QU8I)!53^Z]U
MOU=0[5RVQ>INK]DY^O;*YW9W7>R=JYK)L_D-35[>QM-25,Y;G49IH7>]^;W]
M^Z]T(GOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K4,_X5Z0^?X^? 9 VG3\QZ
MV:]K_P# ?9>X9+?['3;V,_;Q/$WNT'_#:_L5C_DZ#7.+:-LN#_PNG[2!_EZM
M;_X3^4 H_P"4[\9:@2F0Y7(=XU[*5TZ#'V#NFET@W.H$4P:_'ZK6XN3'W6:N
M_7/R$(_[-XC_ )>D?((IM,'_ #=_ZO2=7,>X[Z&/7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=0\CCL?E\?78G+4-'E,7E*.IQV2QN1IDK:>HIZU&B
MF@GAE5HYH9HV9'1U*LI*L""1[LK%"""00:@C!!'6B*X/6GA\ANJM_P#\@+YO
M8KY=] ;7S>Z?@+W]D*?:/:O6^/K&J#AI:V66IDPR^4I#'/16FK=MU,\HU**O
M%5$T:%YZF?MIO8O=3;3M]VX6_@!>&1A_:  "IIDUP) !7X7 -"!$^X6S\AWO
MUENA:TFHLJ+^ U/#@!3BE<<4.FH/6VMU'VUUYWMUKLSM[JC<^/WEUYV!@J/<
M6UMQ8TL(YZ:M%[/'(J34]1"X>*>"6-)H)DDAF1)491!-]92[;,\$ZE)$8JRG
MB"/]6",$9'4I6UREY&LL9#*P#*1P(/0B^TO3_7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]UJU?\)[":[Y7_SC,I6'[G(R]][#,E;-ZY":_<G:LDUW//[L
MD:,W]2H)^GN;/=7MV[9P.'T[X^R*UZC/D3-[N1_X>/\ JY/UM*^X3ZDSKWOW
M7NO>_=>Z][]U[HMORT^*O4GS.Z+WGT%W-A5R>UMUT@DH,G3JJ5^&R=%=J#,X
MN<C53U]!,0RD'1-&9::H62FGFB<VV/>[CEZY2ZMFHZ'\F4\58>8(P?VBA /2
M#<]MBW:%H)A56'Y@^1'H0<CK7$_EM?*'MS^5G\I<A_*B^<NX:0]793(O6_%_
MN?).<;C(H]Q3SO11I554@$>W\_,LL<2/(S8O,":B=WBE9Z>7.<-FM^=K(;]M
MBD2 4NH1EJJ!4T RR\2?Q)1J @UC_EW<9N6;G]TWS50_[C2G ()-%J3P/ #\
M+=M2"O6V;[@WJ3^O>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NM37^8K\S-Y?RH/YP.?^<_R7^*7>'R)^''9GPRV
M3U!U9W1T[MRCWI4=9Y/:N>J*_<^)2+(UN.QF(&X99Z2KK'JLE0/7JE$M+/5+
M15D--[KW18NE?YF&_P#YZ?S$<[_-7^(_PO[\V#\)_B1_+^^3%#\AMQ[_ -I4
M>"R_>4V$HLSDMJ;"QJ8J?,XFOS-!NBC@..-/796:DU9.GJ13I50Q3^Z]U<Y_
MPG5Z5[;Z1_E=]8X_N;J[)=';H[([/[T[IQ/2V6QBX*;:V$[1W1D,EA<4,>(:
M>3'Q?P]X:F*FE@BF@CJ%CEA@<-!'[KW5Y?OW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[HNOR__ .R2_E%_XKKW9_[S63]^Z]UHK?\ "12@^\^6514>7Q_PKX2;
MPK]'CU^3R;FV/2Z+ZAHM]SJO8_ITVYN)[YR:G*&W_-X!_P!49C_DZB;EH5YB
MO/\ 2R_]78NOH9^X$ZEGKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z(A_,0^!'5W\PKX^9SI[?8@P>[,>E9G.INRHJ!*RKVYG1%IAJ5!TO/C
M:HK'%D*198_NJ;A9(JB.GGA$W*?,\_*=VMS%E<"6.M!(GF#Z'S4T-#FA%027
M?MDBW^W:"3!XH]*E'\C_ )Q45%17JE;^4_\ /'M3XC=RU'\I7^83)5;8WQLK
M(1[;^.'9>X*KR45?13?\6K '(,NFHQV0@'DP%9)+8J?X/)XIXZ6F$B<\\KP;
M[;?O_::-&XU7,2_$C_B:GJ#_ &@_VXJI) 0Y8WR7;)_W3N%0ZXAD/"1?(5^8
M':?]J:,*':8]PKU)/7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW1,/YB_<^2^.OP,^8'?&(V%MKM#)]1?'?M7L&CV#O3&MF,-DWVOB*JJ
M$&7I%5FJ<4HC,E7%Z==.DBF2($R+[KW5"76'7_\ PK$WQUMU_O3:OR6_E$;0
MVMNW9>U]R[9VJVV=RC^&X_.44%314(&+Z^R6-"TM-+%&!2Y"IIP% BGE32Y]
MU[K9LZ0HNW,;TMU!COD!E]H;@[YH.K]@47=N>Z^BFAP%=NZEQ-)'N2LP:5-+
M0U"8>IS*ULE&LM%3R"F:,/!$UXU]U[H4/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW6L%_.E^3?\ -JPO57SSZ=V)_+.V7O/X.3=&;WP%=\P:CY5;0P60AVUG
MMI1R;CSPV349-,\\V!GJ<I$E(*/S5?VBO"C+/'=?M7^Y4/\ S5C_ ./CI)?_
M -A)_P TW_XZ>K<?Y4JR)\ /CPLJ%'&+WWZ3_0[JSND_[%;'_8^T!-23\S_A
MZ72<?V?X.K#/?NJ=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]UQ95=61U5T=2KHPU AN""#P01[]U[K71_FH=C4'Q$S>#ZS^/U'D-D4G=N
MWLUN;L_95+6+)L^:#[N.&">@V])"\.)R]164LLL]3C9J 2"/_*8JIZAGC;8T
MX=/QKKX^71_/@+_,5VI\L-H4N*["?;?7O=<&6J\,=M02SXZ@SGVL,,_W. >N
M>3SRJDP$]"M9455-997O#-$YLK5ZI)'HZLT]VZ;Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NB,_S ?^93]-?^+S?R^?_?U;&]B7
ME7_<B7_GCO\ _M"GZ)=^_L4_YZ;3_M*AZ/-[#71UU[W[KW37G,'A=SX7,;;W
M)A\7N';NX<7D,'G\!G,?%EJ*NHLM$]/54=92U"205-+4P221RQ21M')&S(ZE
M20=JQ0@@T(R".(/6B PH>D1ANF.HMNQQ0;?ZQV%A*.GZSP'3%-C<3M.AQU)#
MM#:PJ1C=L0T<,"4L. H5K*E8:!(5IHTD*+&$LH=>XDD)+,Q)8N2222QXM4^9
M\SQZHL2H**   %    4<!]@\AT'O5/P[^(_1&YY=[='_ !9^.736\IL558*;
M=O5/2&V>O,F]#7O%+/1M7XC&4=4U+-)! [Q&7QNT<;,I**0HN=SN;U=$TLLB
MUK1Y'85R*T8D5R>F8+&"V.J.-$-*55%4T]*@#TZ,;[0]*NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NFO.8/"[GPN8VWN3#XO<.W=PXO(8//X#.8^++45=1
M9:)Z>JHZREJ$D@J:6I@DDCEBDC:.2-F1U*D@[5BA!!H1D$<0>M$!A0])WK[K
M3KGJ3:]#LCJK8&R>LMEXN_\ #-H=?;5H-F8NGNJJ?!C\;!34D-U1!Z(1PH'T
M ]WFF>X8O(Q9CDLQ))^TFIZK'&L0"J  ,    ?D.EM[;ZOU[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]UK0=>_93?\*D^]?[M&!IZ3^7]B/]((F:.5EF9MF^
M#Q>!=4;_ &\N#N*@ZBA<J=#0+[&\M1R^E?\ E+.G[-#?Y:\.@RE/WLU/^4;/
M^]C_ &.ME_V".A-U[W[KW6OI_P *<6Q:_P J'L05XI35OVWTLN$-1HUBJ&74
MN8-2EO+]D*P'00WC,ESHU C'D.O[SCI_#)7[-#?Y>@[S7_N#)]J?\?7J\#I=
M<HO3O4ZYP.N:7K38BY=91(&%4,72_<!A-^Z&$NN^OUW_ %<W]A*:FMJ<*FG[
M>A G ?8.A+]M]6Z][]U[KWOW7NM8?M;K_P#X5='L/L>KZA[Q_EJCJYMZ[NGZ
MPQ>Y\3D?XRNWWKZAL+#D679_VO\ $EQQIEJ"M28_,'TR%;,?=>Z$S^1?\S/Y
MC?R"[B_F*?'O^9GN/IF'N_XB[XZ2V7CNM.M=NP82NQ\6\*#/Y*ISM5/0QOC<
MC@]QT9P;XF6.NDJ%^WK!5TM'KA\_NO=;%GOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NM1/_ (5V?\R ^!'_ (N!E_\ WAMR>QO[;_\ )<M/^:C?]6WZ
M"_.G_)+N/](/^/KU;)_()_[=*_$__P KM_[\O>7M7[J_\EZZ_P";'_:/#TGY
M!_Y),'_-W_J])U<1[CWH8=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW0;]O]1=<]]=9[RZ?[;VMCMZ==;^PM1@=T;<R:L(YX)R&5DDC9)J>I
MIY4CF@GBD2:">..:%TD16"NQOI=MF2>!BDB,&5AQ!'^'Y@X(P<=,7-M'>1M%
M*H9&!#*>!!ZU*]A;P[L_X3N_+*3JGL^KW+V?_+1^0^ZJFOV;O,03Y:HVY(SL
MIJ1!"HCAW!BH'A7+TL$(7,T,<=?11BIB^S@G:ZMK;W:L?'@"Q[E @$B8 F ^
M9_"Q^ GX&.ACI(;J+()YO;ZZ\*6KV,K'0^28B<T^T?B'XAW+D,O6WSL_>&UN
MP=J;<WUL?<&)W7LW=^$QFY-K[FP-:F2HJ^@S,*3TM72SQ%HY8)X71T938@CW
M <\#VKM%(I5T)5E8$,K T((/ @]2M%*LZAT(96 *L#4$$5!!'$'I1^VNG.O>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>ZU?/^$T[0U^-_F$9^@,59B,O\C<*V,S5
M(144U4B1YJ8&"I2\4ZB*IAD&AV 65&^DBDS)[O QM8(U0RV@JIP0<#(/#A3\
MNH]Y 82"[9:$&Z<@C((XX/GQZV@_<-]2%U[W[KW7O?NO=>]^Z]U[W[KW5:/\
MS[^6YUK_ #&>B:K9N6CQ>VNYMFPUV6Z5[3FI+RXS(2H"^/KI8XWJ)L!E2D:5
MD"AM++%5Q(T]-$",.3.<)^4+H2I5HGH)HJX=?4>09?PG[0<$CH.\R<NQ<Q0>
M&^'6ICD\U;_*I_$//CQ (K:_E*?S+.QMH]A5_P#+#_F%R2[)^3/4E93[%ZNW
MMNW(,[[I@H$M2XBNKY2T-9EC2?;R8O("<KFZ-XK%JU5DKQ=SUR?#-$-ZVGOM
M9JO(B@?HL3D@#@M:AEIV''PD4(>5N89(Y#MFX=L\=%1B3^JH&,GB:9K^(9X@
M];*?N(>I Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NJ'_YBF _X4#9'Y#?<_P M+>WP\P'QO_N+ME)*#OJD6;-?WA62
MK_BCQ-'B*T_P]H30^+7-J\@FLH31?W7NB ?%3Y@?SWNH?YM7Q$^%W\SW>_Q.
MQ?47R*V/WCO3;]=UAMF%QNR7K7;.2F."P&2I:-*NDSF+RTV&KZJ*NI:*GEQT
M<X@JIYWBIYO=>ZVW_?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=%U^7_
M /V27\HO_%=>[/\ WFLG[]U[K1K_ .$A<;1?*O/*UKGX'[GD%C?B;=_7CC_8
MV8>Y[YV4IRCMP/\ ';G]MO.?\O42\KMJYAO2/X9A^R:(=?0>]P)U+77O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW53'\V+^5YLS^8OU
M%3RX:?';/^2G6E!7S]+]C5M144=-JJ'2>;!YHTR2R/B:Z2)2LRT\L^/G/W-.
MKJU33U(YY&YTDY1N*D%[>0@3Q@ D@5&I:T[A7A4!A@^1 8YHY;3F&&@[9DJ8
MGJ11L&AI7!H*X)'$?,E?\G_^:'V%N/>N1_EQ_/&+-[4^7O4]36[1VCN/>/[5
M3NF#:M.SOC\C,X!GW!34,(J(*W7*N;HC]X)7G!EJQ%S]R7%!&-XVNCV<U&8+
MPA+&F*<%)Q3&ANT@8Z)^5.97F<[=?56YCJH+?Z*%_P"?J9_I#N'GUL=^XDZ'
M_7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T"_R.ZXINX>@.Z>J
MJ[LK=?35!V+U?O?9M?VSL7/+M?,[;I]PXZHI9\WB\DY5*"NQL4CSPU#'3"Z"
M1N%/OW7NM&?I;XN_RIY<#VOL?HS_ (4C_P R_;_4_P 1,%U_3;_RVSN[,WLK
M8.V<;OO<&/VI@TQN5CPE%MN?&RYO*45,LF,FFHX%<RO(D"/(ONO=;U/0VQ(.
MK>C>F.LJ;L+=';=-UUU/UUL2G[6WOG!N?-;G3:.'H\>FX<QDE)7(93-+3BLJ
MJD$B>>:24'U^_=>Z%?W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UK_P#\Y#^:
M)\ -E_%OY\?#3=/RCZWPGRAK/CGVAU[2],5LE<F7?-;]VJ\^'QZJ*-J?SY"+
M(T+Q?OZ2)D)87-E^U?[E0_\ -6/_ (^.DE__ &$G_--_^.GH_P!_*R=7^!'Q
M[*FX&)WLA/\ C'N?-J1_L"#[+DX=+I/B/5@7NW5.O>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[JN?^91\:.I.[.BL[OC?&#J9=X]6
MXF:MV=N3%5S8ZI@7)U5*E12RV#15-++PWCDC;0XU1%"SZJL*CJZ,5..ATV+\
M,?C?L#I:'H'&=:XG*]<+DJC/U-%N,MF*R?*5:HKYAJ]RM5!E56*(155/)#+3
M+'$M,85BC5=Z1PZT7)->DDF%^17QQ1GVQ69OY1],TDC%=GYVMIX.Q,#1QJ"(
M\7F*B2"BWI3P6;3!DI*7*E=*C(U\FF,^X=;PWR_P=#]U1W3UKW7@ZC.==;FI
MLR,;4G';APE1#)B<MAZR._DH,SB:I(<ABJZ,@AH:FGC<@:E#(58^!KU4@CH4
M_>^M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=$9_F _P#,I^FO
M_%YOY?/_ +^K8WL2\J_[D2_\\=__ -H4_1+OW]BG_/3:?]I4/1YO8:Z.NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K6;_EW45)V
M)_PH#_G&]Q+&M14;&V9U-TU%7,DFJ-9:;;]#/ &?Q@*TFQH[CQ,#XE,<F@:I
M!QO+F+9K&/R9IG(^8<T_X^?V]!C;4#[C=/Y@1*#\BHK_ ,='[.MF3V!^A/U[
MW[KW6LU_PJ"@K][_ !<^(70N,R-9CJGN_P"<O6.VIOLIO$9H?X+N"A$<BM+#
M!-%'6Y:BF$<S>/S10R%D,88#GD)Q;W$\Y /AVTCBOD05/Y8!&/(GH+\U(9HH
MHJD!YT4T]"&_RT.?,#K9?IZ>&E@@I::)(*>FACIZ>")="HD*A450. JJ  /P
M/8&Z%'6;W[KW7O?NO=!/N[OCI7K_ +"V-U/OOM?K[97979^.S^4ZWV1NS=E%
MMW)9^':KTD>2.&IJN:&3)O0-749GCIQ))$LR.Z!#J]^Z]UKQ=I?R^_\ A1UN
M?L;L;.==?SH^J]A]=;AWMN_*[$V1+\=\%E)L+A,M75$V+Q35\FT6J*F7'4,D
M%.:AI3)(T?D+EC?W[KW1#\'_ "EOYU?P9I>]N^)OYZ/QBZ,C[<W/+V9\@N[.
MU.I\$LV6K<;!(L-3F]S[LP534"BQ='Y(J*D:O2BQ]->"B@IX1H]^Z]UN7=9Y
MC^\/6_7V?&X*+=@SFR-J9@;JQH84^3_B5!3S?Q" -% PAK-?F2\,9TN+HA](
M]U[I;^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NM1O_A7%&LG0GP*5Q<#Y<;B
MD'-N8M@[G9?^3E'L=^V2AM]M ?XG/[(I#_DZ"?/#%=JN*?PH/VR(.KEOY)F+
MH,/_ "M/A_28VF2DIYMB[FRDD2%F!J,YN7-UM7+ZB3>:JJ)I#S8%B  + ,>X
MLC2[W=EC4^+3\E55 _( #I3RC&L6V6X44'A@_FU6)_,DGJT[V"^A'U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T _R7^-O4ORUZ8WG
MT/W7MR/<>Q=Z4(@J%0K!64-53'71Y3&5)1S29*@FTR02A2 04D62%Y(W,MHW
M>?8[A+JV;3(AJ#Y$>8(\P1@CI'N%A%N<+03+J1A0C_ 1Z$<0?(]:N_QW[T[]
M_D,?)S$?#/Y9[@JM_P#P*[:S62K^D^Y9DE=-O)5U \M?3QKYWI:>*>HA&=Q%
MRM-++_%*!F2649"9]VVVU]T+-MQL%"7T0'CP#_1<?E4T!T-Q--#9H1&]A>S\
MCW"V=VVJUD)\&4_Z'\CZ#.1P'Q#%1UMZ8[(X_+X^ARV)KJ/*8O*4=-D<;DL=
M4I6T]13UJ++#/!-$S1S0S1LKHZ,592&4D$'W!#*4)!!!!H0<$$=2F#7(ZF>Z
M];Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NHU;608^CJZ^J8I2T-+/65+A2Y$=,A=R +DD*IX
M N?Q[VHU&@\^M$TZU??^$KM#41_%'Y(Y)D I*OY"TM# ^L$F3'[;Q,DH*_4!
M5JH;$BQN;?0^YJ]\6'[Q@'_+L#^V63_-U&GM</\ $I?^:Y_ZMQ];1?N%.I,Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NJ:OYN/\ *CVC_, Z^B[ Z^^SV1\NNL,2
M9.K.P(9_X4N6AQLCU<>V\W.EF^UDG:1Z"KN)<;5R&9&^WEJX9Y!Y#YYDY4E,
M4M9+24TEB.=-10NH/G3##@ZX.0I 1YJY63?XQ)&=%Q&*QR#%:9"L1FE>!XJ<
MCS!+U_*&_FM;S[>W36_ GYOXS([ ^:?5HR6W<=6[FHQAYMVQ[2A9ZJGJX3I2
M/<]%1Q//+XP8<E2(U?3FZR@FO/O(T>WQC=-L(DLI:-VFOA%C0?/03@5RK=C9
MI5#RIS0]XYL+X:+J.HSCQ HK4>6JF2!@CN7%:;#7N*>AYU[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T&W;'<?5'1&SINQ.ZNQ=F]4[!
MI<QM[ UN]^P-P4VU,335>[*Z#&XV&JR-;)#24OWF0JJ:GC::9$:66--6I@#[
MKW5./SS^+/\ .-^1/=]%V5_+U_F@=8_&'X[5W7^V*"AZ_K^I\+VB:O*TLE6]
M=FHLI5;?RI,%;%-2QI''6-&!!K4*9&'OW7NJI,__ "3?Y]N0[\VY\M]W?SE^
MD\KW?USLG-[*V5V/NSH7'Y:+;>)SY9LJ,'CJ[;LN#P$V2C/CKJVBQ]/5U<"I
M!55$L$:1K[KW6Q!_*]RG;M9\6J?"]]_,GJ_YW]P;)[+[(V;OSY!]008VEPU3
M68FO,@PHBP]'18V*NV_!/#0U:0QL4J(G2=A4K,B>Z]U8E[]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z+K\O\ _LDOY1?^*Z]V?^\UD_?NO=:6'_"0*@HI.W>S
M<G)2P/D:/XC;2H*6M:(&6.'(YG"25$2/;4L<STM,SJ#9C$A/Z1:<.?W(Y<VE
M:FA2,D>1(@ !_*II]IZC#E! =WW%J"HD8 ^8!E8D?G05^P=;[/N#^I/Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[JE+^;Q_*
MKH?F_M+&]U](3_W$^:73U)0U_6.]L;F'VPV9AV]4&NI\+6UL15J:KIZ@R38F
MO$D;T=6P#S)3R.T<B\A<\-RS(;>X'B6<U1+&0&TZAI+ 'C489>#+Y5 Z!_-?
M*Z[X@EA.BXCH8Y :$T-0I(SQRIXJ<CS!"/\ E'?S<\IW_EJCX7?-"EEZR^;?
M6DM;M<?WFH1MH[R.V%9*H-32"-*/=M(D3O742*L=6BO74""(5%-1K^?.0UVI
M1N6VGQ;*6C J=7@ZN )XE"<*QR#VOFA9)RKS6U^QLKT>'=1X((IXM/,>6JF2
M!@CN7%0NP3[BOH=]>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T3+^8KT
M-O[Y1_ [Y?\ QRZLR.-Q78W=OQW[6ZTV759FODQ5$V1W;AZJDIJ>MJ8ED>GH
MZR2003R".0)%([-'(H*-[KW6D#ENYODAE=[]G='X7^0MWU@]X]J_RMNKOY8F
M'ZAJ>H(*7JRF[&Z_W+O'*2;K_O2(Z/!3[?BAS5'5TE4N6CJ_NZ,I_$8]$>2/
MNO=;U/PAZ5W=\;_AM\5/C[O[<2[MWQTG\>.GNJ]W[DCGEJ8ZS);$P%!C*V:&
M29Y)7@-132"(NY8QA;V^@]U[HT7OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[J
MIS^;STAT%)_+S_F ]L;@Z9ZJK]\8_P"*/>.XZGL"JZYQ-9G%FP.V*PPU:91J
M,Y#[JFB@C$,@J!)&$0(RZ5LNVR9+>YBDD^!98V:G\(8$\/D.DM]&TT$B)\3(
MX7[2I _GT,7\K, ? GX]@  ?PC>AL!;EMS9LD_[$^R].'2V3XCU8#[MU3KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z(]\W.T=MX
M[J;L/JE<3V5F=\;FVE0U6%Q^T^FMW[UI9EGK4TJ<KA\'78F*4?;3%HI*Y)$
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M+"MI\;L.B^05?EZ>BI*L!%H:>6@K,$II(H0(@LE,[-$J+([D%F]U[H<>B?\
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M5!;W7NMQ3X(57=U;\)?B)5_)49$?(2I^-/2,W=AS*11US;IDVWCCG'KUI_\
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M>CZO+_E,?]NU_A;_ .(%V9_UJ;V3\\?\EB\_YZ)/^/'HTY9_Y)UM_P T(_\
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MM%,H=&P585!\_P!HX@\0<CK4U[ ZC^8'_">[N?)=U]!-NCY!_P N'?.9H_\
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MML;<F#WAL[=6*HLYMK=.VLI#F\?7T6102055'5T[R05$$R,&1T=E(/!]P=/
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M#Z12G^0'^7H!^X[4VQOG)&/YD_Y.MCK^6]0)COY>_P ':=)&D63XE?'JO+,
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MW<NZDJ)8:C*/0P5607"X>@I*[(U_VE)-524]*U/31M43Q>_=>ZI(_EN_S/\
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MJ6C3)U&' 6JGVY45D<+5#K(LHEQDQ&2I#'*&CG@B-6X2YP]OKGEC]>,^/:L
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M&ABK^A=S['2:>>.F5I>S7@VW!"&E>-2]1-EHXD4,7=W5(U=V5&/>68C-N%N
M*_JHV,X4ZC^P"O17O<@CM)B33]-A^;#2/VDTZS_R;ME0[!_E;?!G!04XI4K_
M (_;-WJT8C6*[]DK)N*22R11 F:3*M(3I);5J9Y&)D:O,LAEW"X)_P!_./\
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M_P E:]_YZ[G_ *O/T)N7O^2?;?\ //#_ -6UZ.)[#W1QU[W[KW7O?NO=%O\
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M?\*TK_22@_ 3C8Y^&/\ ,(^+7SRV@VY.@.Q:/+9W&8^AK-X]:YQ/X'N3!/6
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M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZU4O\
MA5D/^<<OB7_A\@=RD_\ H+Y'W+7LO_R6#_SSR?\ 'H^H]]S/^2</^:R?\=?K
M)M/KG+?S$ODOU5\=-S[CW'M[J3XS_%O8F$R/\#>&22DR.)VWA*3*-$)8Y:6*
MOFW+504\NM96DI<?I&G1>*,-U(ENYB.'BR$?[V>I"L_T8$]=*_X!T:KX2]Y=
MD?"7Y%9#^7U\FMP-7[/KJNG3H??>0#4]*G\8>0XZ&GDG8LN)SAU10Q>60463
M1Z-20\KQH%[33I]QK&H?GU?_ .W.F.O>_=>ZH?\ E"'W+_.>^'V#F/\ DF"Z
MZP.0@@J)#/%Y<=/O+*-,D=@L<S&&%=0N;Q1L390%H?BZ>7X#]O\ FZO@]WZ9
MZ][]U[HLORX^,6SOEGTKN+JG=(AHLA,!F-D[H-/YY<1F:%'%)6QCAFB8/)#4
M1@CRTTLJ JY5UT17JRMH->JS_P"6Y\I-]]6;[R/\O7Y21G!]B=>RSXCJG.Y*
ML#I6TM*@FBP@J'TBI0TC+48F<$B>D(I@$:*G22JFF#TY(M>X=7E>[],]>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW5'/\]3-3R=&=([!HEDF
MK]V=SC+4E)$IO*=NXBNI E].FYES,0 +BY(-CINM'Z>@X_EU=3M?!4^U]L[=
MVU2*BTFW<%B,%2K&NE1'B:>.G0*+"RA8Q86^GN_3/5-/\TWXU;UP6:VE\]?C
MV9<5VQTM+CJ[?R8V R2UF+PI ILJ8@=-3_#(C)3UT31L*C&2$2L(:,H]&'F.
MGHF_"?/JQ3XA_)_:/RUZ4VYVIMK[>@RLB+B-];6CJ?N9,1FJ.-#5T;$V=H&U
MK+32,JF6FDC<JK%D6P->FW72:=&?][ZKU[W[KW7O?NO=>]^Z]U7M\Q?Y7'PK
M^<5'65'='46*I-^U"H:?N'K](ME[KB>)'CC,V4IX6&4BB1VT4^2IZVF4D.L(
M=5915R_SIN/+)_Q64Z/.)^^(\*]IX$TXK1O*O1%N_+=GO8_7C!;R=>UQQ_$,
MD9X&HKFG5%V8_EX_S>?Y6@SNZ/Y=_P A:GY'= 8JKJ\U_LO>[J%<MDA3&0LT
M$6VZP24%74*CWFGP.1QV0K6C_;HP66'W)<?-FP<[43=[?Z>=J#ZB,T6OJ6&1
MPH ZN!7+#CT"VV#=N606VZ;QHAGP),M3T%: TX]I0FG \.C/?'?_ (4<?'W,
M9P=7_-GJ?LCX>=NXF6FQFY3FMOU^Y<'#5N(^*J(4<&Y<*\PDCE$-3A9HH(F/
MEKF"B1R;=O:*\B3Q]MECO(34J495<@<:=Q1J$$=K5)_#Y=&.W^X5L[>%>H]M
M(* AP2H)X9H&&"#W* /7SZ/5_,7[=ZL[L_E5_,;??3_8NRNS]FU_0V]$I=S;
M$W+2;HHF=84+1&>CEE1)DN-<;%9$/#J#Q["_*=C-M^^6D4Z/&XN(JJZE6'</
M(@='V_7,=WMEP\3*ZF"2C*0P/8?,=(G^03_VZ5^)_P#Y7;_WY>\O:[W5_P"2
M]=?\V/\ M'AZ0\@_\DF#_F[_ -7I.KB/<>]##JB[^>9DZG*=:?'/JS'NKY7?
M7;]=D\=1&0_N2X#'_P .1M"L78))GXU)6!RNL#4I8+)1^GH>)/RZN^PF(HMO
MX;$8''1K#C\)BZ#$4$*J$"0XV)(8E    5$46 L/Q[OTSUKP]YX/-_RL/FIA
MOD/L3&9.H^+W?N1J,=V#MK'*TD-%4U\CU.0H(DNL*STCE\EB%9D+1BJH4TPQ
M2NS9[37I0OZJT\QUL*[8W-@-Z;<P>[MJ9>AS^V=S8F@SF!S6-F%1!54F3C6:
M">)Q^I)(W5A]#S8@&X]N=)^GSW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW5$O\[BJFW-1?$KI:EFD6?L?M;-50CBLQ5\<F,Q,#
MD7X;5GY ET-[/8BQ!H_3T.*GT'5YM-C:"DQT&(IZ2%,92T46-@H2GDC$$,8B
M6+2UPR",!;&]QP;^[],]:Y^XZ/)_RDOFY2[JP\&5;X>?(N;PYB@@A:IAQ169
MVDIHPMRU5MF>H-1270R3XN>6F1I9Q-*C?P'I1_:K\QUL78K*8W.8O&YO#5]'
ME</F*"CRF*RF/J%JZ>IILA&LT%1!*A9)89HG1T=2592""0?;G2?J?[]U[K!4
MTU-6TU11UE/!5TE7!+355+4Q+/'+'.I5XY$8%71U)#*0002"+>]@TR.O$5ZH
MI^8?_"?GX9_([*UG8'3_ /%_B5V^9Y,I2;BZDHXOX!)D$8RPU=5MDO300213
MZ'!Q5;BV)&IBSG4)+Y?]U-QV=1#/2ZAX%)JEM/ @/DY&.X.!Z= K=^1+/<F\
M6*L$O$/%@:N()7 XYJNDGUZKU?M[^>'_ "@:.).Y]MT'SU^(^VLC(M3ON')U
MV\,MC\5&9GO)F@IW1@=$*QEI<SB\KBJ3BDIJC3H8"OZ#EGGX_P"+,;"Z8"D9
M"K&SXX+\#>@",C'XBO$=$7U6]\J >,HNX 35Q4R!<\3\0]3J#@<-7GU:]\3/
MYZ/\OOY5C&84]G_Z".Q,A)!2KL'O84^RS+/42>&.*BS0GGP%:T\ND0QC))52
M:T!I4<E% ^_>VF[;#5C%XT8J?$@JX  J25H'6GF2M,'-,]";:>==OW>@63PW
M.-$M$-2:  U*DGR )/RZN$IZB"K@AJJ6:&IIJF&.HIZBGD$T<D<P#(Z.I*NC
MJ0002"""#;V 2*8/0LZR^]=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NBZ_+_ /[)+^47_BNO=G_O-9/W
M[KW6C#_+8[VSO67\KON/J_9]?54>ZN^_D?@-K31XYW6JFP>$VGC)<M# (P9'
M^ZJ*K%TLBC]<-3)'8Z[>Y>]Y32XL_P#GC3_CS= #VS6L%P?2Y?\ XZG5VG;W
MPX[I_EC4'5/RP^/N\<[N*#;>+VOB_D)MNJ8-2M4U?B%;YXJ>R5&V,C5-]MH?
M7/03FGJ(JAW9)::'"NG/4D!Q+@_EUL%?'KOG8OR4ZEVIV]U[5M+A-RT?^5XV
MH=&JL;74MEK,96JA(2JHY;JUCID0I-&6BDC=G :],,NDTZ&KWOJO1</F)EY<
M%\3?DQE:=Y8JJEZ'[8%)-!;5'-48.NBAD%^/VY71C_@/H?I[T>'5DXC[>B:?
MR9,3_#OA!MVL\<J?Q[L+L++:I""'\-4E#JCXX0?9:>?[08_0^])PZM+\75K7
MNW3?7O?NO=4=_P R#XH=@=?[_P 3_,!^*@EQ'9_7DD>9[0P6)IA)]]38^)HI
M,VE,+?<_Y"7ILM3V(JJ,^;2K1U+348>8Z>C8$:3U85\,OEYL7YB=34>^MM^'
M$;LQ/VV+[&V.TYFFQ&2="VE694:>@JPK24LX6SIJC;3/%-&E@:]4=-!IT;KW
MOJG7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U0C_ #9V._?E
M3_+_ .F4>>6+*;]CJLA00R.H=-Z[AV_C8Y7"R+_FHZ"KTN=)C5I"' 9K-ODC
MI^+ )ZON]N=,=4:?S4_CONSK[<>U?Y@_0,TN#[+ZJR&#;L<8^!I354=*R4='
MEY(D'[ZT\4BT.0C8%)L=(ODTQ4TNNC#S'3T35[3U:%\6?D=LOY3=,;4[7V?6
M4IFR-%3T6[\##*6EP^:IHHSD,9.KVD'@E:\+LH$].T4Z7213[L#7IMETFG1B
M?>^J]>]^Z]U[W[KW7O?NO=%<^3/PK^+GS#VV^V?D5TSM#L6%(&@QN>K*1L7F
MJ"^JS8[.4+TV6HM)8G3%5K&_TD1U)4G.S<PWO+\GB6<SQGS -5;_ $RFJG\P
M>B[<=IMMV31<1JX\JC(^PBA!^8(ZU[MZ?R0_FQ\)MSU_9_\ *6^7V[L513U*
MY'*](]G[A@QAKFA66R/,:1MI;@:P@BACRN&H_"FIS6LP%Y6@]R=NYD00[_:*
MQ HL\2FJ\/Z0=?,G2Q!X:.@%)R9>;*WB;3<,HK4PRGM/\BIX "J@T_'TZ=<_
MS_>]OC7O#$]/_P U3X<[XZ=W%*E3"G:&P<#4XV&L^UF1#5QX#)R/39&BCBEC
M-16XG<52GD'[-&1*L<=+OVLMMYC-QL5VDZBGZ4A&I:C@6 !!)!H'1<>>*FT'
M/<VVN(=VMVA8U_40$H?L!K4 $5*LV?(<.M@GXV_,?XQ?+S;C[G^.?<^R^SZ*
MFB@ER>-Q%<U#E: 5"JR#)86MCI<OCBP8 ?<448+!E4DJUHJW?8+S87\.\A>(
MYIJ':U,=K"JL/F">AYM^ZVVZIKMY%<8K0Y%17(.0?D0#T9?V4=&'7O?NO= 9
M\GMVOL/XW]^;RAD,=5MKISLG,4#*V@FIHL/6/2J&\<H5GJ!$H8QL%)NP(!]Z
M/6U%33JO;^2;LY=N_#>IW"T9$V_NV-Y[@$S&Y:'%0T&'1%]"61)<;.0-3^IG
M.H7T)5.'3DQJW2Y_F>_#*I^2/5])V3UM25,/?_34,N:V75XB5J2KR=!2O]S4
MXA)(V5_NHY%^YQ[ EXZI6BC*?=R/[VPKUZ)])SPZ4_\ +<^:5'\L.H(L1NNM
MB@[QZRI:+!]CXNH*T\]>D0\-/GXH@J#QUQ0BI5$ IZP2(52*2GU^5J]:D30?
MEU8Y[MTWU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW5"&P(U[/_GE=G9>=?NJ7I[KZKDQ )9A :#;>'PDQY6W_ S.UI'"@,X(
M)8 M3\73YPGV]71=R]2[.[UZPWGU-OVB-;M?>V&GQ.0$>D2PN2LE/5TS,K".
MJHZE(IX7*D+)&I((N#8BO3(-,]4@? 'N7>OPI^06Z/Y?'R,R#1X'(9^2IZ2W
M?6%J:B,^7>1Z=*9I68)C-R"TE.HD_P FR0EI7#35$GBHITXZ><:QJ'Y];!GM
MSICKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[HC7\S5\A'_+T^:$N+J^K*&L@^-_;$XJ>\*!,ILX1P8BI><;FI
MY::LAFPCP+(M6DE-)&82PD&C41[KW6I!\3?GY_PDMS_QZZ*W#\G>D?B+UW\D
M'ZOZ[K.\=IK\"-XY?'4V\5QM*VXH<>,1M#<6,GQ"Y@58I5.0G#TIC$A9BZCW
M7NMWSISL?KKN+J'JOMSI_)T^;ZE[3ZWV/V/U=F:3#56W(JO;F^,92Y/"546.
MKJ:BK:".HQE52R+3U%'!/ &$4L,4BLB^Z]T)'OW7NO>_=>Z][]U[H'/D)M3M
MS?72':6S.A>S:/I;N7=&R\U@NM^VZ_;-/O.+;>5R<1BILR<36))2Y)L>S&9*
M:9?',ZJCE5)8>Z]UJH?R7OC_ )#XN_\ "@+^<)TEFNW^R._MP[6^/OQ8R^ZN
MY>V\D,IN#<.8[ V]M'<>7R-:ZDI#')D\O5K2TR,T='1K3TD;,D*L?=>ZV*/G
MW\\]J?R^^KMI=J;N^/\ \J/D70[OW]2]?TVT/B5U33=NYZCEJL=D,C_$LACZ
MG,85*?$1ICFA>H%0Y6HGIH_&1(67W7NM=#YJ_P Z;XH_+GJC<.V<]_*Q_FK8
M#LB':6Z=M]3]M]Q_$"@VM@MHY'>200KF,KE(-\51H,72U$%)/5SFBJ/%%"7$
M3V*LIM'*R* 2 64&GF*_[/57X'J_?^6!TGT]LCXL]+=I[&Z]Q&U]^=F=1;-?
M?^Y::!XJO*34B%I)9]4LB:)*GR2KH5 P920. *W$C.Q!)(!-*];IU9%[8ZWU
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=%7^#G_9'/QB_\0?UQ_P"ZNG]Z
M'#JS\3]IZ-1[WU7KWOW7ND#V/U=U]V[MN;:?9&T\/NW!2R+4PTV4IM4E-41
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MKZJ2=VO^W*Y2K+7IR-].#PZ#C^7I_,&G[:9OCE\DYGV;\H-EUE5MPT^X*'^
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M;LI#"(UGEKLUMC(QIY'5JF10/$<?N[E3G#-O*UA.WX'HL>KB31B4-:T"K(G
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M'+)LCL?&4<<F3Q$TA#,JLVG[G'U! %12.XCE%G0Q3I%-'HBO5T<IPZJ/Z_\
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MI-1C,UCH<K3R:?IKAG22-K?BZGW9':,U4D'U!H?Y=:90PH<_;U5G\F?Y)_\
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M[TOU'M3H?J_9_4>QVRK[4V1CIL9AGS=8N0JVCGJ)JEVGF2*%'<RSR&XB4 6
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M5-73QPO#M3M;=^$ID:)/&LL5&F<:EBDTA;A(0CL-;HSO(SG-O[I;[;J%%SJ
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M]BQ[]U[KW_;6'_X)-_\ 8L>_=>Z]_P!M8?\ X)-_]BQ[]U[KW_;6'_X)-_\
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M?_@DW_V+'OW7NO?]M8?_ ()-_P#8L>_=>Z]_VUA_^"3?_8L>_=>Z]_VUA_\
M@DW_ -BQ[]U[KW_;6'_X)-_]BQ[]U[KW_;6'_P""3?\ V+'OW7NO?]M8?_@D
MW_V+'OW7NB19GYS_ /"F+#?S"=J?RZ:J#^4M_IUW9\8*GY48VII\#V*^T_[N
M4V?R6WF2?)-6#+IFOOL94$0)0&F\'C<S:V9![KW1W?\ MK#_ /!)O_L6/?NO
M=>_[:P__  2;_P"Q8]^Z]U[_ +:P_P#P2;_[%CW[KW7O^VL/_P $F_\ L6/?
MNO=>_P"VL/\ \$F_^Q8]^Z]U[_MK#_\ !)O_ +%CW[KW7O\ MK#_ /!)O_L6
M/?NO=$B^8?SG_P"%,7PRW3\2=K=K0?REI\C\O_D_UU\5^K_]'^![%S4";C[*
MJ$IL>^>?(UE))1X59&'GGI%GJ46YCA<V]^Z]T=W_ +:P_P#P2;_[%CW[KW7O
M^VL/_P $F_\ L6/?NO=>_P"VL/\ \$F_^Q8]^Z]U[_MK#_\ !)O_ +%CW[KW
M7O\ MK#_ /!)O_L6/?NO=>_[:P__  2;_P"Q8]^Z]U[_ +:P_P#P2;_[%CW[
MKW10?GG\R/\ A3?_ "__ (H=J_+GNR#^474]8]2_W&_O-#U?A>R-PYUO[^;D
MP^V:+[&CRM70T$ULAF:0S>6J313B5TU2*B-[KW1G]J;@_P"%6V[-K;:W3C?^
M&6/X=N7 8;<%!]_'VK#/X,S3QU,7F2,M&DOCD76%8J&N%)%O?NO=/_\ VUA_
M^"3?_8L>_=>Z]_VUA_\ @DW_ -BQ[]U[KW_;6'_X)-_]BQ[]U[KW_;6'_P""
M3?\ V+'OW7NO?]M8?_@DW_V+'OW7NO?]M8?_ ()-_P#8L>_=>Z1?9&]?^%5O
M6O7>_>QL^/Y+YP6P-E[IWKFAAX.TZJL^TVK0SUU3]K%.R0R5/A@?Q+(ZHSZ0
M[!23[]U[JWW^5=\G.QOF9_+T^*?RA[<I]LTG9/<_64&[MWT^S<9-AL8M6];6
M4Q%'2U%56S0Q&.G0Z6JI#JN=5B /=>ZL!]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW4:LK*?'T=
M77UDGAI*&FGK*J70TFF.F4N[:5#,VE5)L%)/X!/O8%>O=:U/_"7PY7>/Q+^5
M7?6;Q\V-K^]OF_VENZ*&:H%7J@_@^WJAG61%A20)D:_(PEA30EFA8Z I0 <<
M^JL%S# IKX5O&AQ3(+?Y*'B>/07Y48S0R2D4\29W'G@Z?\M1P'#K9?\ 8&Z%
M'7O?NO=:S?\ ,>J:7L?^?G_)IZ;$D=35[%V[VMW1/0*P+QQF'+9"&=E6,R!&
M?8LQ4LY0F%K!+.S#C95,6SWTGDQA0'RJ&%1^QQ^WH,;DP?<;1/,"5J>="N/^
M.G]G6S)[ _0GZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NJ%?Y&"9$;G_G52;D,?]ZF_GF?-E)!*\)J?X*F,V4=N:UB
M/%/_  UAX"PN1K#$R+);W7NIG\EN.LB[I_G;IXO%AS_-_P"]9:,('1#53[8V
M>]:0MA%K932LY4EV+ O_ &"?=>ZK4[B[[_X6$XWMSM/'=.?"7XQ9_J*@[&WO
M1=5YW+;KZSAJZW;=+DZI,'5U*5';E%4)45.,6EDD$M'!('8AX8FNB^Z]U4)_
M,M^;_P#/5Z6VOU+O?^<;\4NLNO\ I)]T[BVYU?-TWN79%56U6Z<K0I4:*K^!
M[ZW94+2Q8FBKS^Y301EV7]UG"H7$TFH8D BE0*^8/F1Z>O6PQ0U K^=/\AZL
MU_V8C_A:C_W@?\4O_0PZM_\ MS>V^M=>_P!F(_X6H_\ >!_Q2_\ 0PZM_P#M
MS>_=>Z]_LQ'_  M1_P"\#_BE_P"AAU;_ /;F]^Z]U[_9B/\ A:C_ -X'_%+_
M -##JW_[<WOW7NO?[,1_PM1_[P/^*7_H8=6__;F]^Z]U[_9B/^%J/_>!_P 4
MO_0PZM_^W-[]U[KW^S$?\+4?^\#_ (I?^AAU;_\ ;F]^Z]U[_9B/^%J/_>!_
MQ2_]##JW_P"W-[]U[KW^S$?\+4?^\#_BE_Z&'5O_ -N;W[KW7O\ 9B/^%J/_
M '@?\4O_ $,.K?\ [<WOW7NO?[,1_P +4?\ O _XI?\ H8=6_P#VYO?NO=>_
MV8C_ (6H_P#>!_Q2_P#0PZM_^W-[]U[KW^S$?\+4?^\#_BE_Z&'5O_VYO?NO
M=>_V8C_A:C_W@?\ %+_T,.K?_MS>_=>Z]_LQ'_"U'_O _P"*7_H8=6__ &YO
M?NO=>_V8C_A:C_W@?\4O_0PZM_\ MS>_=>Z]_LQ'_"U'_O _XI?^AAU;_P#;
MF]^Z]U[_ &8C_A:C_P!X'_%+_P!##JW_ .W-[]U[KW^S$?\ "U'_ +P/^*7_
M *&'5O\ ]N;W[KW7O]F(_P"%J/\ W@?\4O\ T,.K?_MS>_=>Z]_LQ'_"U'_O
M _XI?^AAU;_]N;W[KW7O]F(_X6H_]X'_ !2_]##JW_[<WOW7NO?[,1_PM1_[
MP/\ BE_Z&'5O_P!N;W[KW7O]F(_X6H_]X'_%+_T,.K?_ +<WOW7NO?[,1_PM
M1_[P/^*7_H8=6_\ VYO?NO=>_P!F(_X6H_\ >!_Q2_\ 0PZM_P#MS>_=>Z]_
MLQ'_  M1_P"\#_BE_P"AAU;_ /;F]^Z]U[_9B/\ A:C_ -X'_%+_ -##JW_[
M<WOW7NO?[,1_PM1_[P/^*7_H8=6__;F]^Z]T%?>/ST_X6!_&_J'L7OGNCX:_
M%+9G5'4VU,MO?L#=7\6Z]W%_#\7@XS+557V.)[;KLE5>*,$^.FHYIF^B1L>/
M?NO=)3XN?S*_^%;?S1Z)V-\E_C1\2/BEV5TEV5_>;^Y6]?N=B[.^]_N=F,A@
M,E_N-S_:N*R]-]ME\57P?OT$7D\7EBUPO'(_NO=#_P#[,1_PM1_[P/\ BE_Z
M&'5O_P!N;W[KW7O]F(_X6H_]X'_%+_T,.K?_ +<WOW7NO?[,1_PM1_[P/^*7
M_H8=6_\ VYO?NO=>_P!F(_X6H_\ >!_Q2_\ 0PZM_P#MS>_=>Z]_LQ'_  M1
M_P"\#_BE_P"AAU;_ /;F]^Z]U[_9B/\ A:C_ -X'_%+_ -##JW_[<WOW7NO?
M[,1_PM1_[P/^*7_H8=6__;F]^Z]U[_9B/^%J/_>!_P 4O_0PZM_^W-[]U[KW
M^S$?\+4?^\#_ (I?^AAU;_\ ;F]^Z]U[_9B/^%J/_>!_Q2_]##JW_P"W-[]U
M[KW^S$?\+4?^\#_BE_Z&'5O_ -N;W[KW7O\ 9B/^%J/_ '@?\4O_ $,.K?\
M[<WOW7NO?[,1_P +4?\ O _XI?\ H8=6_P#VYO?NO=>_V8C_ (6H_P#>!_Q2
M_P#0PZM_^W-[]U[KW^S$?\+4?^\#_BE_Z&'5O_VYO?NO=>_V8C_A:C_W@?\
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M;W[KW7O]F(_X6H_]X'_%+_T,.K?_ +<WOW7NO?[,1_PM1_[P/^*7_H8=6_\
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M^_=>Z]_LJO\ PLY_[V6_";_T ]E?_<_^_=>Z]_LJO_"SG_O9;\)O_0#V5_\
M<_\ OW7NO?[*K_PLY_[V6_";_P! /97_ -S_ ._=>Z]_LJO_  LY_P"]EOPF
M_P#0#V5_]S_[]U[KW^RJ_P#"SG_O9;\)O_0#V5_]S_[]U[KW^RJ_\+.?^]EO
MPF_] /97_P!S_P"_=>Z]_LJO_"SG_O9;\)O_ $ ]E?\ W/\ []U[KW^RJ_\
M"SG_ +V6_";_ - /97_W/_OW7NO?[*K_ ,+.?^]EOPF_] /97_W/_OW7NO?[
M*K_PLY_[V6_";_T ]E?_ '/_ +]U[KW^RJ_\+.?^]EOPF_\ 0#V5_P#<_P#O
MW7NO?[*K_P +.?\ O9;\)O\ T ]E?_<_^_=>Z]_LJO\ PLY_[V6_";_T ]E?
M_<_^_=>Z]_LJO_"SG_O9;\)O_0#V5_\ <_\ OW7NO?[*K_PLY_[V6_";_P!
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M*79>ZMG[IVBTAQFY=K9N!7EQF7HUFJ(P_CEAF@FGIJF&>GFEB;W7N@'^-_\
M+>VETMW5!\F.W/D'\A_F7\B\+LG)=:[ [3^2V>P5<=I8'.2129*@VIA-LX#;
M>!Q$^8:"'^(Y 8^7)5J(L,U8:91"/=>ZL>]^Z]T77Y?_ /9)?RB_\5U[L_\
M>:R?OW7NM8S_ (14_P#;K+OS_P 7_P"T_P#WW757OW7NMOWW[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UIV_\))?^ZN7_ (O56_\ R;]^
MZ]UN)>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NM.W^3I
M_P!Q(/\ /D_\AW_N^H??NO=;B7OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7N@1[\^2WQ\^+&R5[(^27=/671FQ),E3X:GW5VCO*
MAV91SUE4K/%1TTM=-"*FKD2.1EAB#R%59@NE21[KW2IZG[>ZJ[WV%@.T^E.Q
MMD]L=;;I@EJ=N;[Z\W-1[NQ-:D#M%(:>NH99Z>1HI4>.11)JC=61PK*0/=>Z
M$7W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T@,KVKUOA.R-H]/9;>VW*#M/?N
MW-U[OV=L"?)QKE<CBMC24$.7R--1W,ST6/FRF/CFFTB-9*B)-6IP/?NO=!3\
MB?F3\3_B-2;;KOE!\C>F>@J?>-5446U#VOV%C-E/DI*/1Y_LHJZHAEJ4I_)&
M9G1&2$,ID90PO[KW0[;5W7M??6VL%O/96X\%N_:&Z,519W;6Z=LY:#.X[(46
M3C66GJZ*MI9):>JIIXF5XY8Y&1U(*D@^_=>Z?_?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]T2W>/\Q[X ]>=S'X[[[^:'QCV?WFF:QNVY^JMQ]U[?P^;@R69\'V>-J:
M&>O26ER-7]U3>"EE"3S>6/QQMK6_NO=#)WY\EOCY\6-DKV1\DNZ>LNC-B29*
MGPU/NKM'>5#LRCGK*I6>*CII:Z:$5-7(D<C+#$'D*JS!=*DCW7NE3U/V]U5W
MOL+ =I]*=C;)[8ZVW3!+4[<WWUYN:CW=B:U(':*0T]=0RST\C12H\<BB35&Z
MLCA64@>Z]T(OOW7NO>_=>Z][]U[KWOW7NO>_=>Z*Y\C/FY\/OB'-M:E^47R:
MZ0Z"K=[BM?9^/[6['Q>RZG)1XQHDJIZ*FK:F*>HIJ5YX5FF2,Q0M(@D=2Z@^
MZ]T,S=J=8KUN>XSV-L7_ $1KM8[X/:2[MH&V[_!1!]U_%QFA4'&G&?;?N_="
MI\'C]>O3S[]U[H)_CM\R?B?\N:3<E=\7_D;TSW[3[.JJ>BW6>J.PL9O5\;)6
M:_!][%0U$TM,E1XY#"[HJ3!6,;,%-O=>Z,K[]U[KWOW7NO>_=>Z][]U[KWOW
M7NNF954LQ"JH+,S&P 'U)/X ]^Z]T&/5W=?47=NR7[)Z@[*V3V5U]'E=RX-M
M[;+W'2[@Q7W>S:N>@RL KJ:22F9\?6TU1#/:0B.2-U8W4^_=>Z!_H[YV_"[Y
M,[VW1UM\>?E5T#W7O_9<-14[GV=UEVIAMY9&DAHY1!-4/24-7-,]+%.RQO,B
MM$DA",X8@'W7NC7^_=>Z][]U[KWOW7NO>_=>Z][]U[I#]D]F=>=-[%W-V?VS
MO?:W6_7.R\:^8W=OG>V<I]M8K&4D;*AJ:ZNJY(J:FA#NBZY)%6[ 7N1[]U[H
MM72G\Q;X$_)+?=+U?\??F/\ &SNKL>NQV2R])L;J_N+!;VRLE+AT\E54K0X^
MMGJ#!3QD-(_CTH"-1%Q[]U[IYW5\]/A/L;O/&?&3>7RP^/FU_D)F:O&X_&]-
M9WMC"XS<4E5FE5J*D_ADU8M2E96J\9IZ=T6:<,IB1PPO[KW1M/?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]UQ=TB1Y)'6..-6>21V"*JH+DDG@ #DD^_=>Z*)U!_,!^
M#?R![1S/2?1ORY^.O;?;F CRTV3ZZZ\[<PF[,NL> 8)7R145%6335,5$[ 5#
MPK(L)XD*^_=>ZG=X_.WX7?&;>VU^MOD-\JN@>E-_[TAIZG;&SNS>U,-LW(U<
M-9*8(:A*2NJX9DI99U:-)G58GD!17+ @>Z]T:J">"J@AJ:::*HIJB*.>GJ()
M!*CI* R.CJ2K(RD$$$@@W'OW7NLOOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NJG?YYO8,'6G\I[YJ9Z:4
MQ'+]8X[KZ ("S._:6<Q6VPBJLL3$6RK%O40J!W9)$5D80\J6YN=QMU'E('_)
M 7/_ !WHHWZ80V<Q/FA7\V[1_,]"W_*=V>-C?RSO@G@?MQ2O-\7NG]RST_B$
M!67>^'ILU-K0 6D,N0<O<:M9;5ZK^TW,,GBW]P1G]:3/R#D?Y.G]I71:P@X_
M23_CHZL']D_1AU[W[KW6LW_+AIJ7L?\ GY_SENY#''4U>Q=N]4]+P5[*"\<9
MAQ./F@5FD,@1GV+"&"H4)A6Y2R*PXWIC%L]C'Y,9G(\JAC0_L<_MZ#&VJ'W&
M[?S B6OG0KG_ (Z/V=;,GL#]"?KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z)7\V_Y>'P[_F,[
M&VAUO\RNH/\ 3'LO8>ZWWOM/#?Z0-T]>_:922CGH&JON-JYO!U<]Z2IFC\<T
M\D/JU>/6%8>Z]T=3W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=!
M7WCTGUC\D.H>Q>ANZ-L_WSZH[9VIEMD=@;5_C.0V[_$,7G(S%54OWV)JZ')4
MOEC)'DIJR&9?JDBGGW[KW24^+GQ<Z)^%W1.QOC1\:-C?Z->DNM?[S?W*V5_>
M;,;Q^R_OCF,AG\E_N2S^0RN7J?N<OE:^?]^OE\?E\46B%(XT]U[H?_?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T3OXD_ /XD_!7_2[_LJW4_\
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M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T!FQ?C'\=NL>U.Q>\>NND.K=C]R=O?\
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M;-;#W+V#42R! [GLW<F:W!&6,?!"09*&-+^H1H@;U ^UO-MQ]3N4[>CZ/]X
M3_GWI/R_"(+*)1YIJ_WLE_\ +U;I[#G1QU[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=$!^3_\
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MMOX*NS&*&"R]9AL9597"+.M2*.IJ($>>E$BV604\I:/4!9M-QP??NO=:'/\
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MCN/K^#^\>W'N%=HW3.XG'LLBHS(0&"M:Q]U[K2 ZW[R@_FB?$O\ X3-_RO\
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M,K@,30XV?';4I):&2"CKLB))JV0+4B*G#5/NO=2_YBW_  G7[2^9/\Z;H/\
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MV7MFAW_E-J4_66RMNR[PH#2XW"4C8/;QS=3A<=*\TDF0K,=5Y"8RD+!'%'%
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>=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>timage_007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 timage_007.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
M     ! !+     $  0$L     0 !_^X $T%D;V)E &0      04  DE$_]L
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MZFE5*EJ9Y*<RDTQ8A)&4:K!C:Y3;A9-MT[P.02C%216A(]*TZ>M+D7<2RJ"
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M]U[K%//#30S5-3-%3T]/%)////((D1(@6=W=B%554$DD@ "Y]^Z]UJW?)/\
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M=9ZJ0Q4=-Y%-141!EN86.US[EJ\%"P0%G;\*@ G)X# -!Q/D#TDN;Z*SH)&
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MN&C4Z43+N16@J0!Y5)I@5' GRZ5[OO";1$'859L*M:5-,^N!YGYCUZI/S?\
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M^(X8XPV %)."3@ 9J#/?=X?;?#CA4-)*:+J^$9 SD<:@#('F3BA)#VG\N_\
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MJ.@ZBI]O9C'_ ,/-30O5;?GP&4KL?-))>E6HR^,F"QQ2Z?-'2RD:TBD\:[D
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M5584V8F-/49Z"!O&\M#D8ZI4:&H#)[KW1#JW*9S"?'+M'_A-)MW)?8;WW?\
MSLJ?H3;VWMM;C*9O&?'?<^1I^R7W(KUS3O6BD:E:HFEFB=/!*T=1%+,JK4^Z
M]U:+_.]Z=:G_ )R/\CK''O+L?X@]2YO9G>/0FQ/D%U?74>-KML;B?&246'QU
M!5YFDK</35.;GR6!Q9$T3R34U1,$ >-)%]U[H\'R=_EF[TZB^.W=O9/R7_GJ
M_P R'$?'[:/6.\LGW'5YZLV5E:5MO?8S19.FDHJ;9LU57M6TTCT\=)3P2U%7
M)*E-3Q232HC>Z]U5U_,_^/75O7__  D]V/LKX6=F=L?(+XT;&WIU[VCL[LGL
M?9V2V=G:_:.[^P<GD7JJW%56&PE9'C*+*YZ,TLD^+@A./CIJJ)I*<0S/[KW5
MN73W\LSN3M_JCK?M3JG^>Y_,DW)UIV'L?;&\=AYS";EV!6TE3B=P4<-30R0R
MQ;3=&0T\B"P8Z2"IL01[]U[JOGI?I'X<=>? O_A29V#\6/F]W]\V-^;U^-_R
M@V1\L=W]R[*DPM%3[XZKV!V1%+-A\S#MC 8;/U%<N4JVK*G&55=#)"N/J'D6
M.>E>?W7NJGOC)_+K^2OQ&_EN_!+^?=\<.T>ROD-\EOC_ (B+?F^>A=PY(C #
MHJU=B<ALS!TK"JGI4P=$<ED*B2%635D*_)1435M'"\WNO=;JF<^<'P0^17\L
MC<?S/[,SF/W9\%.S>D,CDNV?N-HY+L@4^#W(/X-G\-F<)M^CRV3-7BJR>IH<
MG%%2.U#)#/),8HH))D]U[JCOJG^1=VIU[UWM#Y _R-OYQ_R.Z Z=[,VY+V;U
M)T_VC*G>O6TF+[&/\<HJ>BQ]28J*@@2:H53/7[9S&316F2KEFJGJ7F]U[JRO
M^1/_ #!OD9\\^@?D!C_EG@NNZ?O_ .)/RB[#^+78&]>I"R[=W-4;"@HI3EZ*
M(LT44C2U,T4G@(IIT2&K@BIUJ?MH?=>Z*)_,(JH-U?\ "E+^1OLO;Z?Q3<VP
MNG_F)V3O2BH]$\F.P6X]KY^AQ^1K51FDI:.IKL/D*>&69$BEJ%\$+O,2@]U[
MK9]]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T7+Y>]O[[^/\
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M6DB@H85C@1(!65^1FCIHZJBCM(Y'R_L=K]!)N-TK2A"0L2DJ#2@J2*'BWV
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M_+DWONA((<+W'_+E[@Z:Z\K6B\A.X>O:WL;<F1C=W58Z=3A\E"D;K(SR23>
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M 'OW7N@X[CZLVGWEU'VCTKOR@@RFR.W>O-Y]9[OQM3"*B.?&;ZQU3C*Z)D)
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M*J:FB_334\"V4((.?[^S4Q'1)0D!W#%P/M#"M/F"?4GI7/RE:7+"3N2M*JA
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M$_N!=T;PHX(V?+.B'436M>YB"<GB#Q/1.O*5N2OB/*ZK@*S]H%*4P 1Y<".
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MO_/U[^]/_"J7_GV_P?\ _.[&?_7_ -^T<O\ \5W_ ,8_Z!Z]JW?TMO\ C?\
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M ,^W^#__ )W8S_Z_^_:.7_XKO_C'_0/7M6[^EM_QO_/U[^]/_"J7_GV_P?\
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M_P!?_?M'+_\ %=_\8_Z!Z]JW?TMO^-_Y^O?WI_X52_\ /M_@_P#^=V,_^O\
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M /SNQG_U_P#?M'+_ /%=_P#&/^@>O:MW]+;_ (W_ )^O?WI_X52_\^W^#_\
MYW8S_P"O_OVCE_\ BN_^,?\ 0/7M6[^EM_QO_/U[^]/_  JE_P"?;_!__P [
ML9_]?_?M'+_\5W_QC_H'KVK=_2V_XW_GZ]_>G_A5+_S[?X/_ /G=C/\ Z_\
MOVCE_P#BN_\ C'_0/7M6[^EM_P ;_P _7O[T_P#"J7_GV_P?_P#.[&?_ %_]
M^T<O_P 5W_QC_H'KVK=_2V_XW_GZ]_>G_A5+_P ^W^#_ /YW8S_Z_P#OVCE_
M^*[_ .,?] ]>U;OZ6W_&_P#/U[^]/_"J7_GV_P '_P#SNQG_ -?_ '[1R_\
MQ7?_ !C_ *!Z]JW?TMO^-_Y^O?WI_P"%4O\ S[?X/_\ G=C/_K_[]HY?_BN_
M^,?] ]>U;OZ6W_&_\_7O[T_\*I?^?;_!_P#\[L9_]?\ W[1R_P#Q7?\ QC_H
M'KVK=_2V_P"-_P"?KW]Z?^%4O_/M_@__ .=V,_\ K_[]HY?_ (KO_C'_ $#U
M[5N_I;?\;_S]>_O3_P *I?\ GV_P?_\ .[&?_7_W[1R__%=_\8_Z!Z]JW?TM
MO^-_Y^O?WI_X52_\^W^#_P#YW8S_ .O_ +]HY?\ XKO_ (Q_T#U[5N_I;?\
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M ._:.7_XKO\ XQ_T#U[5N_I;?\;_ ,_7O[T_\*I?^?;_  ?_ /.[&?\ U_\
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M]?\ W[1R_P#Q7?\ QC_H'KVK=_2V_P"-_P"?KW]Z?^%4O_/M_@__ .=V,_\
MK_[]HY?_ (KO_C'_ $#U[5N_I;?\;_S]>_O3_P *I?\ GV_P?_\ .[&?_7_W
M[1R__%=_\8_Z!Z]JW?TMO^-_Y^O?WI_X52_\^W^#_P#YW8S_ .O_ +]HY?\
MXKO_ (Q_T#U[5N_I;?\ &_\ /U[^]/\ PJE_Y]O\'_\ SNQG_P!?_?M'+_\
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M /SNQG_U_P#?M'+_ /%=_P#&/^@>O:MW]+;_ (W_ )^O?WI_X52_\^W^#_\
MYW8S_P"O_OVCE_\ BN_^,?\ 0/7M6[^EM_QO_/U[^]/_  JE_P"?;_!__P [
ML9_]?_?M'+_\5W_QC_H'KVK=_2V_XW_GZ]_>G_A5+_S[?X/_ /G=C/\ Z_\
MOVCE_P#BN_\ C'_0/7M6[^EM_P ;_P _7O[T_P#"J7_GV_P?_P#.[&?_ %_]
M^T<O_P 5W_QC_H'KVK=_2V_XW_GZ]_>G_A5+_P ^W^#_ /YW8S_Z_P#OVCE_
M^*[_ .,?] ]>U;OZ6W_&_P#/U[^]/_"J7_GV_P '_P#SNQG_ -?_ '[1R_\
MQ7?_ !C_ *!Z]JW?TMO^-_Y^O?WI_P"%4O\ S[?X/_\ G=C/_K_[]HY?_BN_
M^,?] ]>U;OZ6W_&_\_7O[T_\*I?^?;_!_P#\[L9_]?\ W[1R_P#Q7?\ QC_H
M'KVK=_2V_P"-_P"?KW]Z?^%4O_/M_@__ .=V,_\ K_[]HY?_ (KO_C'_ $#U
M[5N_I;?\;_S]>_O3_P *I?\ GV_P?_\ .[&?_7_W[1R__%=_\8_Z!Z]JW?TM
MO^-_Y^O?WI_X52_\^W^#_P#YW8S_ .O_ +]HY?\ XKO_ (Q_T#U[5N_I;?\
M&_\ /U[^]/\ PJE_Y]O\'_\ SNQG_P!?_?M'+_\ %=_\8_Z!Z]JW?TMO^-_Y
M^O?WI_X52_\ /M_@_P#^=V,_^O\ []HY?_BN_P#C'_0/7M6[^EM_QO\ S];0
M'L#]";KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NBG4?S=
M^->3^8E7\#<1V'29GY.8OJ"N[QSVP\11RY%<9@*&OHL<TF2KHE:DH:Z2?(T3
M1T<LJU+P2K.L9B.KW[KW2F^4WRR^/WPLZ@S7>GR5[&Q?6O7.&JJ+%KD:REJ<
MM5U^1RI9:+$XC%T$-3DLOEJYU98*2DI9IY-+,$T([+[KW19?B_\ S8OAE\L^
MW9^@>O\ ='9.R.[?[L2;TPW5O?G2.[>@,QF,33$K45^#IMV8C%?QB&D(O.*5
MY)(D(D9!&"X]U[H9OF#\[OC'\%=J[3W/\B]^U6WJGL/<D.SNM-C;4VIE>QMT
M;FRDI351;?VU@:/(9G*2P)(CSM#2-' K*9736@;W7ND;\0?YDWQ,^;^X>P-B
M]([QW71]H=61XZLW[U!VUUEN'I3=F.HLN%^TR3[?W1C<7D9L94,VA:J&&2%9
M/VY&1V56]U[H^/OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[H(^^.]NJ/C-U#O[O;N_>6)V#U=UIMW(;GW=N?,SB&.&GH
M$+:(D_74550^F*G@C5I9YG2*)6=U!]U[K/T7W1L'Y&],]6=^=5Y&LR_6G<NP
MMK]E;"RN0QDV%GJ<1O*CBK\?/+25*1U%-)+33QL8I461"=+J&! ]U[JNWO;^
M=G\ /C_V?V3U'N+>_:F_]U=+>&/NJLZ+^/F]N\\1L^>59'>CW)F]KX/)8K&5
MU/%%(\]/)5>:G52)D1P4'NO=6.]0=Q]7=^]8;,[HZ:WSM_L7JSL+ TNY=F[W
MVU6"KHJZBJP2LL;D*\;(0R21R(DL,BO%*B2(RCW7NJL=V?S]/Y9VT-S[JQ%5
MVMV3G=E[%WK_ */=[=\[+^/.^MZ];8K*0S14]3#5[\Q> JMMB&AGF1*FHCKY
M*>(W)E*J6'NO=7!8#/X/=6#PVY]LY?&[@VYN+%T&;P.=P];'D:2LH\I$L]-5
M4M1$SQ3T\\+H\<B,5=6#*2#[]U[IV]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=%]
M^4_7'=';O0^^NM_CYWM4?&?M;=AVMC\'WC1;+H^P:K T4>:QTV=EH<5D'CHI
MLE6;?BRE'1RRMII:JHAJ[,8 I]U[K5O^#?PEZK^!'_"E9>E>KL_V-OB7,_R?
M\[V7V9VGW!O*HW]NK=^[-V]I4L>7W+N#*5&GSY&O6BI581111(D4:JEPSM[K
MW5@/S?VB._?Y\G\I?J#=\57ENL>@NB?EE\OWVG/61S8NMW)1#%[9P60R&.G7
MQ5%1@*N>"HH9E#ST\TKF+Q1/4F3W7NI7_"@S!5&RNI_@]\PMDQRXKN#XF?S$
M?B[GML[LQH@IZHX/M',':FX\!4U$B/*<-GH<I21U<* ^4QQ!U,7D!]U[J+LS
M:([N_P"%*'>N]=ZQ5>9P_P */Y<W3VU.H\1D*R.OQ^+S/R'W%D<EDL]1T<JZ
MJ/,56.HZN@>I@75)2J(ZB4JM-''[KW4K^9M@JCJ7^:Y_)*^4&PHY<+NS??=?
M='PU[6KL<(*5,_M7M?;#Y2AQN7;0T]7%A\CB:FNH4_1'.7<E9!$R^Z]UL#^_
M=>Z][]U[JN#L_P#F[_RV^F.P=W]5=H_+3KG9G8>PLY6;;W?M7+4F7^YH:['G
M3-3S>+&R1%T-N4D92+$$@W]G%OR_>W2"2.&1E85#!:@CHOEW6V@8H\J*PX@L
M 1T8OXT_,+XT?,3;VX]U_&;MW;7;VWMHYF#;VY,KMJ*KBCI*VJ@6ICIY/NZ:
MF8NT#*_I4BQ^M^/:.]V^?;F"SHR$BH#"A(X5_ETHM[N*[!:)E8 T)4U%>/\
MEZ,I[1]*.O>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZUDOYZ7\M[*=^]"?S
M ?EE\DODIV=V1U)T3\5^W=]_$/X>8!8]A;+VIG]M=?*LNZMRM0O][O?<:;BI
MLE78V2L>.#&0U"TR13)Y+^Z]T?/^7%O.OZX_D7_$#L/%1+-E-A_RU.L-YXV%
MG$8>HVOU]3UT*EBD@4-) HN8V ^ND_0^Z]T''_"=CIG%=8_R@_BEEJR*IR^]
M._ML[F^0W;.[=PS19?)[AS7=&7R&7DR&7K;R2Y"<XZHH:<25$DDY@AC6=C*'
M]^Z]U3[AM[;U^'7\OO\ X4_=!=;9+-;:V=\:^_>]JOX_T>,R@PLNTL5\MMOT
M>2:@P,M$BOC:+#RYB6KH%BD62.25G#15#/+[]U[K9+^#GQ0ZLZG_ )<'QP^)
ME5LO#U_7=+\7MA;#WUMC*8^DGAR\NY=OTXW'-DHZ=?M:FHS%=55TU4Z@K)+,
M[@D$'W[KW1%_^$X^7WE3_P M/$]/;TS.7W!/\6OD7\F_B]MS*Y^ICJZUL+U!
MN[(4N*IZAX56.^/I9DI(U0LB001)&1&J*ONO=7P>_=>Z+K\D_EI\<_A_M'";
M]^2W:VWNHMG[DW'%M'!Y[<D57+#49*:EJ:U*1/M*:I<2M2T=3(-2!=,;<WL"
MLLMOFW%BD",[ 5(45(%0*_S'2>XNH[0:I65030%C05XT_ET5K8?\XS^67V=O
MG9G6NPOE_P!:;FWUV'NO;NQME[;H*;+K/D,MNRLAH,=0PF7&1QB6KK*B&)-;
MJNIQJ8"Y]KI>7+Z!2[P2!5!9B5P !4D_8.DJ;Q:RL%66,DD  ,*DG '5E_LE
MZ,NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NM;'_ +NQO_,*/_S5O?NO=*O^:#NVF^&O\TS^5]_,4[*J
MO[O?%>FVSWY\,?D;V?5+6G';.?N:GIJ[966S4M-!)3T.&K=R4ZTM36UDJ4E*
M DDK(0CCW7ND-_.1[WZN^;.[/@+_ "W?B]V+LGN_MSNKYF]%=Y]IT?5VZ(]\
MP;3ZLZ"R$N;W#NG.5F$:OI,7$]7%CX*%:UXUK)?*L :2)2/=>Z4_:/8^WO@5
M_/\ 3W-W]N#&=<?&S^8I\+]F=)[,[AW76SXC 4G:?0^=EJ*+:^5R<L:8;%39
M;;554S4+UE7&:BH_R>G;6[HWNO=-7RN[=V/\^/YQG\L#X\_&;=^W.W]N_!W<
MG:WS*^6N_>OLR=U87:JUNW_X-L/"U>6QHJL/_&L[D9ZQC0O4BJCI=$X58I')
M]U[K9*]^Z]U[W[KW1"^P_P"5W_+S[9WON?LKLOX?]';VW[O7+U6?W7NS<.SH
MLA6U];6F\M34S.=4DKFUR?\  #@>S6#?+RV01QSRJHP%5V  ^0!Z0R[9;3L7
M>*-F/$E%)/YD=4M_\)=MOX7 =:?S :7#8VEQM/0_,C+[?I(:5/&L=%@<>%HZ
M91^(J99I0@_ 8^Q-SW(TDEL6))-K&23YDEJG\^B7E=!&LX44 N'  \@ M.MI
MCV!.A1U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW5;'\Y'_ +=.?S(?_%*/
MDC_[RF3]^Z]T@?Y8FR(^S?Y)?PGZWFJ?LXNP?Y=73^R):NY'B7=>PZ2@:2X#
M$:!4%N%)X^A]^Z]T2'^1_P#.7H7H[^71M[XL_+;N3K'X\?)#^7<=^=#_ "4Z
MW[<WM#L&MQ$'7^5RD^%S4$6?>AJ:_!9;;'V%32UM+%)22D2PT[?M:![KW11_
MC3\;^T/Y@_\ +5_GN=\;2VSF,4O\TKN3OS?GQ!P^X*+(8"JSNTNML1!C>OLI
M+2U]*E52+NBIQEHP8V0Q,CQVA9/?NO=64?#G^<A\)*'^5_UI\B.Z>_NO.N=S
M]$=%[=V?\C>J=U;F3#;PP6^>J<32XK<6UI-L9)X=R3YF7-TTD-! :!IZ\3TT
MD(E$ZL?=>Z4G_"?;IGM7J/\ EH=;YWN[;%=L?M'Y$=D]U?*;=&R<I'505.)7
MO?<==F,;25,5;%#5PU!Q#X^:2.9/+&\K)(=8;W[KW5U_OW7N@*[]^,?Q^^4V
MV,1LOY%=1[)[CVG@,]'NC#;?WUB$S5+39&*GJ*1:R*)SI6H6FJJF,-]0DCC^
MT?:JTOIK!B\#LC$4)0E214&F/+ Z8N+:.Z&F55< UHP!%>%<_;UJ=_S5OB'\
M8_BA_-!_D:4OQNZ0Z]Z7IM\?+K951NZ'8."CPBY%]O\ 8?6JT3503_.-3+65
M0CO^D2O_ %]R/RUN-QN&W[AX\CR:8#IUL6I6.:M*^M!T#-[LXK2[L_"14K**
MZ5 K1XZ5I]O6YS[B[H==>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=!K_ *&>G_\ 2S_I[_T4=:_Z=/[D
M_P"C3_31_<7%_P![/[N?=_?_ -W_ .\?VO\ &/X)]]_E'V/WGVOG_>\7D]7O
MW7NE1NW:&TM_[:S>R]][7V[O79VY:";%;CVGNW"4VY,9D*6I%I*:MH*R*:EJ
MJ>0?JCEB9&_(/OW7N@/Z ^&_Q+^*0SH^,WQIZ+Z"?<YC.Y*CJ'JW"]?S5XAT
M:$K)\91TTU3'&44JDCLBL-2J&))]U[H2^V.GNIN^-CYCK+NWK/87;O76?1$S
M6QNRMI4&]L35>*^AIJ#(P5%,\D9),;F/7&WJ1E8 ^_=>Z3/17QI^/'Q?VO5;
M)^.'1O4O1&T:^N;)Y#;O4G7^+Z_I*FI<L?N*F'%TM,M3.-; 22AF53I!"@#W
M[KW0V^_=>Z][]U[KWOW7NM7_ /X3&_\ ,N_YAG_B\&[O_<&'V..=_CM?^>2/
M_"W09Y:X7'_/3)_S[UM >P/T)NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ36\MF;/[%VGN38/8.U-M;[V+O+"9+;6[]E[RP5+N?$Y7&YF)H*S'Y+'5T4]
M'7457 [QS03PO%+&S(ZLI(]^Z]U[9NS-G]=;3VWL'K[:FVMB;%V;A,;MK:&R
M]FX*EVQB<5C<-$L%'C\;CJ&*"CH:*D@1(X8((4BBC54154 >_=>Z+WW/\%_A
M;\C-ZX+LCO[XF_'/NCL';24L.#WKVATUM_?&4IXZ&1)8(5KLC05%0T$,D:M'
M&TC1H;Z5&IK^Z]T9Z@H*'%4-%B\714F-QF-I*:@QV.H*9*."G@HT6.&&&&-5
MCBABC551%4*J@*H  'OW7NBK;K^!'P?WWW#3_(/>OQ!^-&[>\J6KILA%VWN/
MI+;F9W#]S1!Q!5/E:C'25DE7"'/CG>5I4LNAQH33[KW1M/?NO=>]^Z]U[W[K
MW6JG_/9_[>D_R"O_ !;3!_\ OQ.K/<B<G?\ )/W'_FA_UCFZ!W,G^Y=E_P U
M?^?XNMJSW'?0QZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NM7__ (3&_P#,N_YAG_B\&[O_ '!A]CCG?X[7_GDC_P +=!GE
MKA<?\],G_/O6T![ _0FZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZU4_Y[/\ V])_D%?^+:8/
M_P!^)U9[D3D[_DG[C_S0_P"L<W0.YD_W+LO^:O\ S_%UM6>X[Z&/7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UJ_P#_  F-
M_P"9=_S#/_%X-W?^X,/L<<[_ !VO_/)'_A;H,\M<+C_GID_Y]ZV@/8'Z$W7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW6JG_/9_P"WI/\ (*_\6TP?_OQ.K/<B<G?\D_<?^:'_
M %CFZ!W,G^Y=E_S5_P"?XNMJSW'?0QZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z;VJF#,
M+_1B/I_3_8>U(A!'2)IR#2O\NN/W;?U_WC_C7O?@CK7U!]?Y?['7ONV_K_O'
M_&O?O!'7OJ#Z_P O]CKWW;?U_P!X_P"->_>".O?4'U_E_L=>^[;^O^\?\:]^
M\$=>^H/K_+_8Z]]VW]?]X_XU[]X(Z]]0?7^7^QU[[MOZ_P"\?\:]^\$=>^H/
MK_+_ &.O?=M_7_>/^->_>".O?4'U_E_L=>^[;^O^\?\ &O?O!'7OJ#Z_R_V.
MO?=M_7_>/^->_>".O?4'U_E_L=>^[;^O^\?\:]^\$=>^H/K_ "_V.O?=M_7_
M 'C_ (U[]X(Z]]0?7^7^QU[[MOZ_[Q_QKW[P1U[Z@^O\O]CKWW;?U_WC_C7O
MW@CKWU!]?Y?['7ONV_K_ +Q_QKW[P1U[Z@^O\O\ 8Z]]VW]?]X_XU[]X(Z]]
M0?7^7^QU[[MOZ_[Q_P :]^\$=>^H/K_+_8Z]]VW]?]X_XU[]X(Z]]0?7^7^Q
MU[[MOZ_[Q_QKW[P1U[Z@^O\ +_8Z]]VW]?\ >/\ C7OW@CKWU!]?Y?['7ONV
M_K_O'_&O?O!'7OJ#Z_R_V.I%/,92P)O8 _3_ (U[;D0)T]#(7KU*]L]*.O>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NM7_P#X3&_\R[_F&?\ B\&[O_<&'V..=_CM?^>2
M/_"W09Y:X7'_ #TR?\^];0'L#]";KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K53_ )[/_;TG
M^05_XMI@_P#WXG5GN1.3O^2?N/\ S0_ZQS= [F3_ '+LO^:O_/\ %UM6>X[Z
M&/7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW2'J*H+43@GD32@\?T8_X>S1$&D?8.B&26C'
M[3_AZP_=K_7_ 'C_ (U[MH'5/&Z]]VO]?]X_XU[]H'7O&Z]]VO\ 7_>/^->_
M:!U[QNO?=K_7_>/^->_:!U[QNO?=K_7_ 'C_ (U[]H'7O&Z]]VO]?]X_XU[]
MH'7O&Z]]VO\ 7_>/^->_:!U[QNO?=K_7_>/^->_:!U[QNO?=K_7_ 'C_ (U[
M]H'7O&Z]]VO]?]X_XU[]H'7O&Z]]VO\ 7_>/^->_:!U[QNO?=K_7_>/^->_:
M!U[QNO?=K_7_ 'C_ (U[]H'7O&Z]]VO]?]X_XU[]H'7O&Z]]VO\ 7_>/^->_
M:!U[QNO?=K_7_>/^->_:!U[QNO?=K_7_ 'C_ (U[]H'7O&Z]]VO]?]X_XU[]
MH'7O&Z]]VO\ 7_>/^->_:!U[QNO?=K_7_>/^->_:!U[QNGO"3"66>QOIC7\?
MU/\ K#VEN@ !TNL7UD_9TH_:/HSZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZU?_ /A,
M;_S+O^89_P"+P;N_]P8?8XYW^.U_YY(_\+=!GEKA<?\ /3)_S[UM >P/T)NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NM5/\ GL_]O2?Y!7_BVF#_ /?B=6>Y$Y._Y)^X_P#-
M#_K'-T#N9/\ <NR_YJ_\_P 76U9[COH8]>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO= K7U
M[K7UJ@FRU=2OU_H[?X>Q'%$2H^P>0].@/<7)61A_2;_"?EU$_B#_ -3_ +?_
M (U[<\(_Z@.F?JCZ?ZOV=>_B#_U/^W_XU[]X1_U =>^J/I_J_9U[^(/_ %/^
MW_XU[]X1_P!0'7OJCZ?ZOV=>_B#_ -3_ +?_ (U[]X1_U =>^J/I_J_9U[^(
M/_4_[?\ XU[]X1_U =>^J/I_J_9U[^(/_4_[?_C7OWA'_4!U[ZH^G^K]G7OX
M@_\ 4_[?_C7OWA'_ % =>^J/I_J_9U[^(/\ U/\ M_\ C7OWA'_4!U[ZH^G^
MK]G7OX@_]3_M_P#C7OWA'_4!U[ZH^G^K]G7OX@_]3_M_^->_>$?]0'7OJCZ?
MZOV=>_B#_P!3_M_^->_>$?\ 4!U[ZH^G^K]G7OX@_P#4_P"W_P"->_>$?]0'
M7OJCZ?ZOV=>_B#_U/^W_ .->_>$?]0'7OJCZ?ZOV=>_B#_U/^W_XU[]X1_U
M=>^J/I_J_9U[^(/_ %/^W_XU[]X1_P!0'7OJCZ?ZOV=>_B#_ -3_ +?_ (U[
M]X1_U =>^J/I_J_9U[^(/_4_[?\ XU[]X1_U =>^J/I_J_9U[^(/_4_[?_C7
MOWA'_4!U[ZH^G^K]G7OX@_\ 4_[?_C7OWA'_ % =>^J/I_J_9U[^(/\ U/\
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M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T3W.54JYK, '@93(
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MV=NK;>).4SW8D5,-KX>KU%4>5(VF,XC*/+X'ECCTH5+NRV8+S[T%J>MEJ#I
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MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW1-,[_Q>\S_ -K7(?\
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MI=MP3?7Z\R*#<?CZ>_?3W3?Z*!]B _X>O?6[>O"V9O\ 32L/\'7?]RMYR?\
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MZ]UJI_SV?^WI/\@K_P 6TP?_ +\3JSW(G)W_ "3]Q_YH?]8YN@=S)_N79?\
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MZ-MXC.XG+461^.^_-L]J/+5P4;['Q52N%9W=C#*4:6>(1JE@_AB9)+,ZR("
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M_P!7_%=>^_7_ 'W_ "+W[POEU[ZL?ZO^*Z]]^O\ OO\ D7OWA?+KWU8_U?\
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M"8N;9K3>&WBW&AVN9)]&JHTRNS-&305!#%2:"HS0'I+_ !KZ _V7G:>=VO\
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M1]K\2.(:K*0:4+ZOPG[1HL9)LS#?*+>=#UQ)K@7;C8ZI8I2R?JI0(\M' 8V
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MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=:J?\]G_MZ3_(*_\
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MG7OIO]7^H]>^Q_VG_D[_ (W[]XG7OIO]7^H]"#U]3^&LR!M8&FB'UO\ VO\
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MO=>]^Z]U[W[KW7O?NO=:J?\ /9_[>D_R"O\ Q;3!_P#OQ.K/<B<G?\D_<?\
MFA_UCFZ!W,G^Y=E_S5_Y_BZVK/<=]#'KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[I ;\[/V1UK2056[\Y!C6J]?V5"D;U=3/X[!C%3Q*\A120"Y 120&8$CW
ML"O6B:=!I%\J>EIL?+7)N*N\\<@B3$'!5?W4C.;*(D$1B;5_7S #Z,02 =Z#
MUK6.H/\ I3[BWGZ>N>H:G"T$K:8]R=FU0PR@-]'_ (?&RU#K;D-'+*#_ $('
M/J <3UK43PZ]_H8[&WAZ^T>X,W-2R->7;6P8EVU1Z?S&\^@25,9^G[E/JM_;
MO8KO4!P'7M)/$]+K:W0W4NT'2?%;+Q<];&RNN0S*OG9@Z\AT:K:81/\ XQJG
MNI8GK84#H70 H"J     !8 #\#WKJW7?OW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[I*34@,TIYYD<_[
M<G_'V8HY 'V#HF>"I)^9ZQ_9C_'_ &__ !OW;6>J_3]>^S'^/^W_ .-^_:SU
M[Z?KWV8_Q_V__&_?M9Z]]/U[[,?X_P"W_P"-^_:SU[Z?KWV8_P ?]O\ \;]^
MUGKWT_7OLQ_C_M_^-^_:SU[Z?KWV8_Q_V_\ QOW[6>O?3]>^S'^/^W_XW[]K
M/7OI^O?9C_'_ &__ !OW[6>O?3]>^S'^/^W_ .-^_:SU[Z?KWV8_Q_V__&_?
MM9Z]]/U[[,?X_P"W_P"-^_:SU[Z?KWV8_P ?]O\ \;]^UGKWT_7OLQ_C_M_^
M-^_:SU[Z?KWV8_Q_V_\ QOW[6>O?3]>^S'^/^W_XW[]K/7OI^O?9C_'_ &__
M !OW[6>O?3]>^S'^/^W_ .-^_:SU[Z?KWV8_Q_V__&_?M9Z]]/U[[,?X_P"W
M_P"-^_:SU[Z?IUQ4 BDE(ORBC_>?:>X:H'2RSCT$]/7M)TOZ][]U[KWOW7NJ
M/?YF'P*[Q^2?R4Z.^07P1^>6$^%OSIZ9ZFWIL)XLUM3#]FTVX>O^PLC#620U
MV R*53I3PYW$ZHZIL95TSNKJ8UF@BD7W7NH'\O3^6'\PNH?E1N#YS?S&OG2_
MS2^2*=,9;X]=8T^V.N,?U;MK;.V<_F:3.Y%Z?'8REQM'-DZ^MHX0\J8FG981
MXI)*A4A\/NO=7F3P054$U-4PQ5%-41205%//&)4=)05='1@59&4D$$$$&Q]^
MZ]TQ+N_:;;J.Q5W/M]M[+A)=RMM!<Q3MDQCH)H:=Z]J 2?=+1K/401F8Q>/7
M(B:M3 >_=>Z47OW7NO>_=>Z0_979?7_3>P-W]J=K;QV[U]UQL' Y#<^\]Z[L
MRD6&QV-H,6ADGJJNIF98XXT4?UNS$(H9F53[KW55'6G\^;^6]V=O3J;:%-V)
MVUL&@[ZSE!MKI+LKN;XV;_Z;V;NFNS<9GQ=/B=U[DV]CL*[Y> >2A,U7"M1J
MCC0^:6*-_=>ZL$^4WRR^/WPLZ@S7>GR5[&Q?6O7.&JJ+%KD:REJ<M5U^1RI9
M:+$XC%T$-3DLOEJYU98*2DI9IY-+,$T([+[KW19?B_\ S8OAE\L^W9^@>O\
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M+D88^1^.7'MLSH.++^T=/K9S/P1S]BL?\G4&;>&TX+^;<^WT*C44.8I]5O\
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M-A]PY/&U,&%RM132T]5%408_)/35$D;TLRR+&5:*0$H?=>ZT_MT_S]_YMO\
M*_R-1L3^;I_+,J.P]JX21,;1?+/XR5]3@=MY=$MXJQJEZ3,;8JJNM5D<T_\
M$<!407TRXR%[Q+[KW2N;_A:[_+3&#%0GQO\ G*VY?M$<XEME;!2A\YMJC_B
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M3*\24>#I:8*4M8J$B4 BPM;Z6'OU3UZ@Z?H:>"F4I3P0P(6+E(8UB!) %[*
M+V ]ZZWUF]^Z]U[W[KW0-]MT_G_N_P $Z/XK_P G?;?XC^GL1; Y7Q*?T?\
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MW,F&WA@M\]4XFEQ6XMK2;8R3P[DGS,N;II(:" T#3UXGII(1*)U8^Z]TI/\
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MOW[@Y,_Z.%U^P_\ ;'U[][<S_P#*';_M'_;3U[_9P?\ A2K_ -ZY_B]_U/\
M_P!,OOW[@Y,_Z.%U^P_]L?7OWMS/_P H=O\ M'_;3U[_ &<'_A2K_P!ZY_B]
M_P!3_P#],OOW[@Y,_P"CA=?L/_;'U[][<S_\H=O^T?\ ;3U[_9P?^%*O_>N?
MXO?]3_\ ],OOW[@Y,_Z.%U^P_P#;'U[][<S_ /*';_M'_;3U[_9P?^%*O_>N
M?XO?]3__ -,OOW[@Y,_Z.%U^P_\ ;'U[][<S_P#*';_M'_;3U[_9P?\ A2K_
M -ZY_B]_U/\ _P!,OOW[@Y,_Z.%U^P_]L?7OWMS/_P H=O\ M'_;3U[_ &<'
M_A2K_P!ZY_B]_P!3_P#],OOW[@Y,_P"CA=?L/_;'U[][<S_\H=O^T?\ ;3U[
M_9P?^%*O_>N?XO?]3_\ ],OOW[@Y,_Z.%U^P_P#;'U[][<S_ /*';_M'_;3U
M[_9P?^%*O_>N?XO?]3__ -,OOW[@Y,_Z.%U^P_\ ;'U[][<S_P#*';_M'_;3
MU[_9P?\ A2K_ -ZY_B]_U/\ _P!,OOW[@Y,_Z.%U^P_]L?7OWMS/_P H=O\
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M[]K/7OI^O?9C_'_;_P#&_?M9Z]]/U[[,?X_[?_C?OVL]>^GZ]]F/\?\ ;_\
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M:VS]M0G*9O:V6Z,V5N5):>@5I9Q]GU[EL=N653&K:OMI=8 &FQ^ONO=;3/\
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MOOWC'KW@CKWVT?\ 3_>_^*^_>,>O>".O?;1_T_WO_BOOWC'KW@CKWVT?]/\
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MO>_=>Z][]U[KWOW7NM5/^>S_ -O2?Y!7_BVF#_\ ?B=6>Y$Y._Y)^X_\T/\
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MJ839_P#*D^+&T-A]9E)J:OFQE)C\WC!3YGL7.X'.K$<SD:R:K2&#&SS&:O\
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MYRW!;6;R%+R99QKH&:)E\4!M..W]('U(KCAT2\M33[WO<T]RJ!K:(PG14J)
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M>-I7E::94D5F2AD(#J"2"=:TK3X:4] /MEC--OMU=2*X1(TBB+(P5JA*E6(
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MF-YYA303U>1J?\HK:J=ZFMJI7G8.JH<\V\WS<V21ET2*.%-$44==""N>.*D
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MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=:J?\]G_MZ3_(*_\
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MXFE1;C4T>H+<:K$CWX@CKP8'H2)ZB"EADJ*J>&FIXEURSSR+"BC^K,Q"J/\
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MIK'IL[225=48'K9!3Y;'UE.SU$\PD4LY^9>;]GMMWL]2QPDQ2VX-4AR "
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M/F9^/JI&<TIRXG[PWN^O5KH4" &F&8:%-#\O"X>C XQ4"_YCOQ(^/&QOFO\
MRJ_@=\:>JMD[ QN\.XAW-V\]-%+E\UE<=C\KC8EK<QF<C)5Y;+/%B\3NYHQ5
MUTWDE+*#$"Q9?RCOES<[;NFZ7LDCE(/ B\D4N&PJK15&IH_A H/+I+S%MD,-
M[M]C;(B!IC-)YLPCTFK,:EB5#Y8DD^?6W7[@KJ5.O>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NM/C_A2ENKY/?*+Y6?RZ?Y.GQ\[@EZ0VM\UI]]9[NO<\%75
MTJ5^)Q3?;+1Y)*"H@J<CB*+&4>X:F3$L\=/E:K[.&>:-8O)'[KW5>O\ //VI
MV3F.ROY-'_";KI+MW=F:V?0; Z VUW%N.FQG\)DR]+CZF':>WLMEJ5:MH9:?
M;6%V_GLW)CON)*='-+-ZYJ:E:+W7NDIV%\!9O^$W'\W7^4]G?B?W[VSV+U#\
MZ>T&Z([8V'V154%+/5P0Y[:VWLQ]Y)B*6@Q]?1I!OS'5V,BEQ:S4==0.QJY4
MJ+1>Z]U]#SW[KW7O?NO=>]^Z]T4[YM_+[KOX-?'/>_R#[$H<UN-<']AM_877
M.TZ7^)9[>&ZMTR?:;=VCMZB6\E;FL]D7BIZ>*-&8 O*5*1O[]U[K4SD^*W;7
M2/\ .Y_D7]\_*O<2;N^;/S%W+\]NVODE7T4O^XS;PH.NZ6':_7.WHDEEACV]
MU_BJJ2@@D4EZVK>NR$KL]79?=>ZML^;^T1W[_/D_E+]0;OBJ\MUCT%T3\LOE
M^^TYZR.;%UNY*(8O;."R&0QTZ^*HJ,!5SP5%#,H>>GFE<Q>*)ZDR>Z]U*_X4
M&8*HV5U/\'OF%LF.7%=P?$S^8C\7<]MG=F-$%/5'!]HY@[4W'@*FHD1Y3AL]
M#E*2.KA0'RF.(.IB\@/NO=; _OW7NO>_=>Z(7V'_ #1/Y>?4V]]S]:]E_,#H
M[9._=E9>JP&Z]I[AWC%CZV@K:(VEIJF%QJCE0VN#_@1P?9K!L=Y<H)(X)64Y
M#*C$$?(@=(9=SMH&*/+&K#B"Z@C\B>J9/^$O.4Q^<ZG^?6:Q%7!D,5E_FCN+
M*8ROIG\D<]/D,;3RPS1M_:26-U93^01[$O/2&.2V5A0BUC!!X@@L#T2\KN'2
M=@:@W$A!'F"%ZVC_ &!>A1U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U3S\FLAE*_NG>*91Y3_  Z:@Q^.ADO:.EBIHI(@@_"2>1I?
M\6D9OJ?;R\.F6X]!WUM7Y/&=@[*K<-+-#DH]T82.E: G4QJ:B.)H[#]2RH[(
MR_1E8J>"?>SUH8Z$SY']BYW>?9.Y<355E2F!VIFJ_ 8K#B8B%&P\C4\U08P=
M+33RI(VLC4$*I?2H'O2B@ZVQJ>D7U=GMQP;CQ>S\9NG/[=PN^,WA-OY[^!U+
M1.T62J8H6=% :TJJU@RC45NG*LRG9ZT.K>=B];[.ZXQ@QFU,/!0AE K,A(!/
M5U+#ZO45##R2$GD+<(M[(BCCVR37IX"G2TG@AJ89J:IABJ*>HBD@G@GC$J.D
MH*LCJP*LK*2""""#8^]=;Z X_&CI,Y;^+G9%+YO)YOLQD:Q:37>]_M!4>#3_
M ,V]'CM_8]VU'JND=#A3T]/200TM)!#34M-%'!3TU/$L,<:1 *J(B@*JJ
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M^SHRFU-H;<V1AJ; ;7Q5-B<93#B*!;M(Y #2S2->2:9K#4[L6/ O8 "I->K
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M*WHGL3O#"[@S/9&Z^N,IM&#+&MKL1@*V3$:U$SXK;N.W!.^1R-EIHY*N$1S
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M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW6JG_/9_P"WI/\
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M3@\KD,9F*P4\,XIJ6DW-O;;R3U10+'(D:.X9% +.7-DGFY0GC@ ,UU(S1J"
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MYKC XD=,\T\U)RTB=AED<G3&&T]JBK,3I:@&/+.?('H\GQ+^0%#\JOC7TO\
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MU.W,-D\<,!1;:V>^2?!;6CR]!#XX:N65,A3T[/$M+3*?=>Z:OG;\5]@?,/\
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M38P4=-3'+22U@D;/U<8JY#*U))"D5,DN3>XVVFX_>J63?O J%):2MN&"!-8
M:I.GMII&!\5:GJ/(N2[U8?W>UT/H]1("H!,5+%M!-* 5S7-22*4QU8Q\Z_Y6
MNW/D9\?/CMUM\>MU8SX_=C_#?<&V-R?&7=;X89NAQIVQ%2Q+05T9629H*E\?
MCJEZ@1S2&KI(IIHJE6ECD"/+/.C[/=3S72&XCNU=+E-15G#DDD$>8J1]A(!&
M"!%OG+2[E;Q10,(7MV1X&"A@I3 !!\L#\P":\"%GQ>_EG_)#,?*G;'SA_F3]
M^;*[\[SZPV[)MGI7875>%EQ.T=M:ONHSDU,^.PS5U<T=5-+&K8:'PU<IG::I
M>GHFIEV]<X6<=BVV;/ \,$C!II)2&FEI0A30L%4$>3&H'E5M23;.7;F2Z6^W
M*59)44K$D8(BCK4$BM"Q(/F!0GSHM#E_S,OCEW/\M_ACVU\=>A]Q[&VGOGL\
M[2Q,V<["RM?AL='B\;F*'(9.%IL;BLS5"2LI:-J<*M$0RRN&=/K[#_)N[6VQ
M;C#=W2N\<19M,8!;5H8*:,R##$'CY>?1MS+M\^ZV4MO;LJO( M7)"Z=0+#"L
M<K4<//H:?B)T=)\:/B[T!T%55M!D\GU+U-LC9.>RN*\GVM7D\-00IE*NE\T<
M4PIJK(_=2Q"2-7$;J'&H'V7;[N7[XO9[H @2RR2 'B%9B0#3S H.EVU67[MM
MHK>M?#C1"1P)50"?S.>C%^RGI?U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]TG]V;6P.^=J[FV3NFA
M_BFV-X;?S.UMQXS[J:B^XH-P4TE)60>:GDAJ(?-3S2)KBE21+ZD=6 (]U[JB
M'_H%Q_D4?]X,_P#LS/<7_P!L'W[KW7O^@7'^11_W@S_[,SW%_P#;!]^Z]U9_
M\*O@5\3OY=O5F?Z4^'75/^A_K+='8&5[2SNVO[\[E[ \^=S>.Q6)JJ[[W=.8
MS>0B\N/PF+B\,=6E.OAUI$LDDKR>Z]T;_P!^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=:J?\]G_MZ3_(*_\ %M,'_P"_$ZL]R)R=_P D
M_<?^:'_6.;H'<R?[EV7_ #5_Y_BZVK/<=]#'KWOW7NO>_=>Z][]U[KWOW7NB
MO=O5];V9O+$=$[>J98:!Q3;@[1R=*UC38^G:.2&B#<@351,;6_&J$D,AD NN
M,]4;..C*X^@HL504>,QU-%1X_'TL%%14D"Z$BBIE"1HH_"JH 'NG5^IGOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NM7[_A2-G<[V'+_ "_?A_LB''93>_=_R+&=PN'SC-_#7KL<:#:^%3)J
MBO(::LJ]VU*$I&Y$4=1<7*!IH]GXEM?K]PD)"06Q5BOQT:LA*^50(?,C)'49
M>X\AG^CLT +RW *AO@JM$ ;SH3+Y#A7H%/YGV(R'\ISJ2FS/67R+[>W9\S/G
MUEDV)VE\H.T]R/7UF+VYUU-_$MPS;:H\7C&.W*-Z[<6+IXH*.&>6AH0%QR+4
MQQRA=R33GNXTSV\2VEBIDCMH5H&DD 5 Y9P78B,DEF[F'<=)(Z3\TO\ U4@U
M13.;FZ8(\\K%BJ(2S%0JD*H+THJX![14#H@'<'>/P%^)6:^-/R _EE?,#OON
M3Y68/MG9F-^0F-SU!OJD_P!(&"FI*A\G4Y2#<F QM#4M45M-!0Q4$58[>/):
MDB>6F6JA%FW[/NN^)<VF]6MO#;&&0VY'@4MI*C2%,3L0 "6+$?AR:$@AV[W3
M;]K>"XVNXGEG\5!.#XQ,\="#J$B@$XHH'#5@8!%L7\]&H[TP?R-Z W=VWU_W
MYVK_ "O,#L#+MWKL+X^[DK]LM59B<9L5LFYZC'RP^.C@I_X%+"U;-#2/3Q5M
M-#4TL]1-+[ GMHMK+:3QP201;FTB_3R7"JP"@I3P]0;N)U# +5*FA Z%O.[7
M$=Q$\J2R6(1O'2$L&+4>NO25[0-)R0,,"14=&7_DS-\.4P'?':?PV^4/?.YN
MB:2FQ$><^+'=,S2Q]<24]''4P30_>?=U1,T-+DD2HH\E+0SPWII7J:G'"5"7
MW"&XJ\,.Y6T"3]Q%S" #< L1G11>-,%0PXX#=&O*#6;I))8S2M%VCP9"2(2%
M&!K!:E/1BOD.'55/\H'X*;2_F7X[YU?)#OK>_;6+ZH[G^0>YJ&JZKZ^WU4;&
MI<KG:UI=SS9+<+T9/\7?"P;JA3'4\XDI8I*JME>.4R@ =>X/,DO)S6-E;)$9
M8+=#XSH)"JC].B!A1=1BJS :C1144R$>3MFCYD%W=3-)X<T[CPE8I4GOJY4@
MM024"DZ15C0UPI/@[\V.Y?A-\$_YM.*&[-P]G;=^&'<.'ZO^,.\-Y5S[F R.
M_LUDMHPP10SS"*+%8F2BQ&8>DCE6G_RJI$4>J4K(QS'RW;<R[GM1"I$U[#XM
MRB#11402DX![F!9 2*U45/3VS;Y/LEC?ZBTBVLIC@=SJ))8Q@'(PITL<\&-!
MY=*:'^6!MS<O\KS<O\QOO?O_ +\W#\V,C\<]S?+G9_<G^E6OHWPS9##2[FP6
M!H8M9T09"C:GIZA@ZRK-6S"D:GC2&-&3SBT&]KL]M!;K9"Y2T>#PE(DI((F=
MB14D'N'E@:JFI+G]7!-M1W*>:9KKP&N$E\1@4JGB!5 - *8/VFE, "!WK\WN
MS^S?^$V=#VYVCF&K.V.XX*3H"JW16)XY,TN(WO5X>LKG "":LK]MX'(?<NMP
M]4*B6P%T";;.68+'G'Z6$?I1-XX4?@_1$JCSP'< ?*G3U]OLMWRT;B0CQ)%\
M(D_B_5,9/EDJ"<>?12OF/\#(?C/_ "<^AOD+VWW)W36_*';$?1IZEP\6]I=L
MX'9O]\I%KAMK#8+'M'1T]9C,1+D)JO)*[Y"JRD=15&I$,GA4[Y=YF&]<Q36M
MO#"+60S^*3&'>8*#WL[@M1F"T3"*I TUR2W>MD;:]ECGFEE^HC$/AT<HL52!
MI54(6JJ2"^6)J:TP+!_YKM-\\6^(?\O3(XRC[J[,ZOPFWNN\I_,"Q70>6K<!
MNO/RT^+VR:Q99\4)ZR''5Y_O-KD2.:EIZN6GGJT=8H&4)\BMM1OKX.88Y&\0
M6!N K0QU,E*ZQ0L.RE<D @9-.A#S6-P%K:E/$= 4-V(=2RN $K32:@'NK0X)
M%< GK)_)B/P#WWWEN3>_P([Z^2?5N)P_72/V!\#NTLB^5Q:K7SSPR9^*>NJ,
MQ%6105\]$T<M!E#4TLMQ5ND&2^U._<1=VM(%CW6"WD9I#HO8U <T [.P)3%<
M.N1PRM>M<FOM]Q(7VZ69%5!KM7)*K4GN[]6:^:M]O'JKZ+YJ_"G^81\F?DMO
MS^9]\J^Q=B?'+ YU=J?%/XY[&I=[2XJ7&4U34A<_D!M?;V0IVK(X*:AGUU,@
MJ:BKJYM2QT='2P$;_P!6-SY5LK:/9;5&N677=7#^!K#$#L7QI 0,D&@I0#-2
MW05._P!AOUS.VYSL( VB"!/%T%0?C;PDS6@(J2:DXH%ZMW_X3T_(3/\ 9&UO
MF3T72]E;X[IZ4^.?=M#0_'3M7?JUDE9D-H[UGST6-I_)7T])61A*7 TU<:2:
MEADH_P")>+PP)H@B 7NOLZ6,EI<F..&:X@K<0QTHLR!-1HI(H2^D$$AM!-2:
MDBSV_P!S:\CN(=<DL<,Q$,KUJT3:M(J0#4!:D$5&H# H!L9>XDZD/KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NM7_ /X3&_\ ,N_YAG_B
M\&[O_<&'V..=_CM?^>2/_"W09Y:X7'_/3)_S[UM >P/T)NO>_=>Z][]U[KWO
MW7NO>_=>Z*7N:KF^06_/[A8B6;_11L;(156_,O QCCRE?2/>+&02*09(8V4Z
MV4@<-(#=:9GN.W[>J'N/RZ-=3T\%)3P4E+#%34M-#%3TU/!&(DCCA4*B(J@!
M550  !8 6'NG5^LWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>ZI%^:/\ (D^-WR]^6%-\W-M=^?+WX:_)BNVI2;(WYVG\
M,>WZ?IW*;EQV.IJ6@IAE:Q\1D:G[N#&T5+1":":)9:6"GAJHJA::G\7NO=")
M\*/Y*_Q,_E__ "I[6^67QSW=\@\;NKNOK>CZ^[*Z_P![]F4_8>W<I40U&-K:
MC<]7-E<14;LJMU9')8^:LJZR?=,L4M3D,@XIE6=$B]U[KW>?\D_X8?(7^8_T
MW_,_["7L>3OCI>BV2N)V1CLE@1LO,9'KALB^"SN>QM7MRLS-5FL4];1M3S4^
MX*6.-L7C&$-X)?/[KW1H/GM_+[^,/\R?H;(?'GY3[*GW1LZ3*TNY-M9W!U_\
M"SNWLO0))%!E\#DQ',:*M2&:>)P\,U/402205,$\+M&?=>ZKY^(W_"?_ .,'
MQE^1FS/E9V'W]\Q/FMW7U5COX=TON'YB]SKVG!L\.DZ//@Z:+&X_14%9W\9G
MEGBIV"RTT,,X\I]U[HY^1_EI=%9/^9)@?YHT^[.VD[_V[T=-T#1;0ASN'79S
M8:<UI-3+CVP+9ILG_ETUI%W L'"?Y/PVKW7N@5_F,_R9?C=_,;[/Z9[_ -S]
MD?(#XW_);H:BEP?7WR*^+>_J?K;=D.)>6LJ$Q4N1GQV1;[6EJ\A7U%*\ @J:
M:6IJA'.(JJHBE]U[H/OCQ_(7^)GQG^8/4GSJV)W'\P-P_([KK8>=V-OW>G:?
M=M/VI+V6VXZ"NQM5F.PJK.X.NRN0RQI*NF2(XO)XFD@7'8Y(:1$IRLGNO=:L
MORYD_D\X+^8W\IMW_P T3X7?./\ EL[T.]^P,;GZCH3M#-;BZX^0^.W3(AJ,
MCD$P>U*"JQJ[F@AARM5287<%/25%343OE:^HR J+>Z]U;!_PE?\ B9O/8"_S
M0/E)G.A-T_'SX^_-/Y!X%_C;TMV7L7^Y-?3;+Z_R._*RE$F(E+PQXI:/>E)C
M840-3LV/J1#)-3F-S[KW1F=[_P#"6WX,Y[<N_*+KOO[YQ_'_ ..O:N\!O;LO
MX;=)]^1[7ZRRU7/+#)5PR8.HQ%;,E%5Q4U+!XC5NU-!#'%124T<5.L'NO=;!
M'2?2_67QUZEZ^Z,Z:VGC]C=6]6[7QFSMC[4Q>MH:.@Q*:(TURL\TTKG4\LLD
MCRS2N\LKM([,?=>Z%'W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW6JG_ #V?
M^WI/\@K_ ,6TP?\ [\3JSW(G)W_)/W'_ )H?]8YN@=S)_N79?\U?^?XNMJSW
M'?0QZ][]U[KWOW7NO>_=>Z0O96^L?UQLS-;LKPLAH*?1CZ,MI-15U'HIX%MS
M^Y(1J(!*H&?Z*?>P*]:)ITB^B]B9#:NV:K/[GUS;\WY6-N;=E3.+2(]7=X*,
MW_2M*CFZ?19'D4'2%MMC7K2BG0W>Z]6Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[JH'Y ? 3NWO3^:M\3
M_F1D-U=7Q_&_XU;"K<<FQZS(Y&3<TV?J(]R3"OIJ,81\8837U^!)>3.*R1T+
M/'")3^X/=KYGMMMV.ZV\))]1<R*=8"^&(U,>"==:X?@OXLGT"=_L4][NMO>%
MD\&!&&@UUF1@X)';2F5XM^' Z%C^95_+ZB^>?7W68VKV1-TSWKT'V%1=H](=
MJ18--P)09&E,+S4E73,\4IHZN6DH9B\4H>&II*6<QU$<3TTR'D_FK^K$LFN/
MQH9XVBFB+%=2GS!%:$5(R.!88)J%?,>P_OV- K^%+%(LL4@4-I9?4&E0?MX@
M'(%"#_2/QB_FI;I[IV%V#\R_FMUWC>N>KZBL>EZC^)V KMO4^\=8A\<F[*[)
MX['/"DCQ S4]-3SJJ:THYJ5IGE"S<]VV2&W>+;[24R2 5ENG#&'C41JAH?DS
M'[0:=)[&PW-YEDO+B,(A-(X$($E:4+E\C_2K_O76#NCX@_S(ME?)+LSY"_"K
MYC;3S.W>U<91TN4^-WS&J-R[QVCA)XW4RR[:J,:]?/B*8,9I8::FQ\"*TLD,
MS3PF+P7V[?=HN;2.TW*T<&(DBYM/#29P?)PX ?TJ36@%*&NJE[M6XPW$EQ97
M"D2 #P+C6T2D>:%35<>0%":UKC24+-?#RK_E7?R]/YGGR([ [3P^^?D;\F]H
M[LK][[QVEMT;*PF/R?8M1D,5AZ' XXLRQ+'G-WU,P?Q0JQ>"%*>..G4,?1[_
M /UXW7;;..(I;V[(J1LVMRB:6<NU!6J1"OI0FM2>BE]I_JK87MTT@,TRN[.!
MH4.VH(%4DTHTF/4FGIT6;^7%\!_YF/7/P<ZXSWPQ^5?477&T?ESM.E['[0VM
MVWL^KEKML5&YVJ*.'/[,KZ#'Y,S9&KVM%@]4-8D,?W$(DCGC_;:,ZYPYIV>_
MW25=QMI7:U8Q1-#( )0A!T2AB*+KU]RYH:4-.BOEK8=QLK",V4\:BX59)!(A
M)C+CXHR*U.G3VL*$BM16G5LG4O\ )SZ)Z\_EV=A? ;,[BS&Y1W$DNYNTNWEH
MUI,A6;M$M%5T6<I*1Y9EIZ?$5>,QOVM&U0X>" I42RRU%3-(!K_W NKO=TW5
M55#%18HJU58@""A.*Z@S:CC)-    *K3E&"WVYMO8EA)4R28#-(2#J\^! H#
M7@*DY))*G\JO^:/O[HW:WP4[A^;O2=#\)]GP[8VU_&>M=D9&'?V:VSM.2!J/
M;U?%44%)C:.CIX8DCB*Y>K-H*?[O[V,20L(SSOLMK=-NEO9S&\<N^F613;QR
MM6KK2K,234@A:5.G2:$$PY7W.>W%A-<QBV4*NJ-")GC7\!KVJ*8!!:H U5R"
M9+^8C_*DW1\D_CC\.?B!\<<AUSU_T#\?NQ-O9K>N-W[N;,4=?+A]M8]\3"N,
M>@PV5^_RTU)DLU+-+55%('J)$<RGRR-&3\I<\+LMY=[A=>(\\\3JA14*^([!
MZM5EHM57 !QY8Z,>8N5CNEM;V<&A8HI$+!F8'PT4K0$*Q+48Y)&?/H3/YK7\
MOOM3Y\;8^+/5'7^7ZPV]U%UGW;B>P^XL?O7.Y;#5E3B<+3IC8:/ PX[#96GJ
M:DXRNS2VJJBD1'-.JRE9)6C1\C\TP\K/<SR"0RR6[10E%4@.QU58LZD ,J\
MQXX]5/-.PR;\L$2: B3+)('+"J*"** K5)#'C0?/I1_+#XB?-W,_(?;7R@^$
M_P O5V#F</LV7:6<^-7>]1F]S]89,QQ^..KAQV.GE&%J)E6 5$M+C&J#)$DT
M4\>J>*=C8]]VV.T:RW&U\16<.MS!H2Y3U%6'>/0$@9-?(AW=-JO7N!=65QH(
M0J8)=30/Z&BD%3ZL 3@>504?\$/Y;G9O2OR@[O\ G=\JNR>N^P/E%WKMNCVI
MD,/TQMBIVKM+!4.C%"KCH16"&KR,\XPF,C%1-1P2Z(I99O-/5S2!3S-S?#N-
ME#M=C')':P,7!F8/+(Q+T+:11::V[02,^@'3&R<NR6=U+?W3H]Q,H4B-2L:
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M8>CB-!425$Z4UZ?(4,D:OY7$>[[DR\L[:UNTT31W9"Q>#XC$.:41@T:T<FH
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MFE@_@-=D\=2T,%=-*E=424RPX^D:.2BR,%3#YT/MKGGEVQL[*VO]O,L4=R[
M6TQ-5X]P!+4&!6K'XE()!PYRKO-W<W,]G>".22!5K/%32U:=IPN<G@H&&! H
M*E7_ )(_RNZ)ZM^/G\QOY[?('?VS-C[F[2^2^Y]X[QP59N.F?,5,='0ON*AH
ML?22O'6Y&>ORFZLM342QPEJFH215 *OI/O<K8[J[O-OVJU5Y!%:HB$*=-=1C
M9CQ"@+$I8DT XFG1/R/NL$%M>;A.RQZ[AW>I%:4#@>1.9"% %2> KT7[^7]V
MAD\)_+A_G;?S$<KX=K[U^06\]_;=Q]?/5>1:/*[NIZN:F6DJ)@B3RIF^R($C
M/@7S3Q0JRN;1J:\VV(EWC9]G'ZB01Q5 &656 :H%2.RWJ<X%3\^D'+MYX>V[
MEN?P/,\I4DX!()4"HH>^:@QDX^75GW\I?X[YWXV?R:,]V1U/M.A;Y,=V]*]R
M]W8S(4CM-59'+5^/RO\ <.C6I;3+% N.IL&5IXV2**JGJ9%!DEDED!7/V[IO
M7,/A3N?IX9HH#@=J*RB4T'$ZBYJ<D4'   3\G;<VV;.'B4&:2-YN)[F8$Q@D
M\.T*"!@&ISQ-27\IWL[Y8]-?!OLO?G2G:7\IC;75^=WIO;<O=]5\M]V=AG?0
MJH((Z)H,Y38)S3RT=100QR8VGIHY34+52,JO6U%0I'W/MIMM_NB0W4>Z-*J1
MI"+5+?P=/$:-8K@DAB>!%/A Z"/*-Q?VU@TMN]@(R[O*;AIO%U<#KTF@P 0!
MQ!!XD]7T?R(_CQN/XX?!.FV[F.WNMNZ\'OGMC>?96P-W]2U.8KL$F&S5'B*
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MOW7NO>_=>Z][]U[KWOW7NO>_=>Z)'\R?@=U)\X\G\9)^Y,YO<;;^,7R(V?\
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M[O7/5U539?>KHVN.ORI#?;XYB."D'K$BW_$ZM9A&1<=HZH>XTZ-4 % 50
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M=Q.,P&W\5C<'@L+04F*PV%P]#%C*2DI<?&L4%-2TT"I#3T\$2*D<:(J(H"J
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MW/[=_BF6P?\ 'L+E<+_&L#/'2UU'_%()(/NJ*6:*>*.KI_)Y(6>"1%D52R.
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M3944D\#W[KW6E7M[YV?#+^=-VY/W#_,+^=7QV^./\N7J?LJ>7X]_R[]V_(/
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MAQ.X:27/Y.HI&<M3P1TU;%2$K2EZVD@1GE&^YTVW>Y1>M?[C:]J>)91-)1F
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M^\=SWRRRS1P>&0.WPG8EC_I@!7.10=>V/:)C.+B:TM+95':D:1O-KJ1J\15
M44\A4^M.K[_<9=#?KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZU4_Y[/\
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M*G/'K9?_ .'5OY:/_>>GQ+_]'QMS_P"N'L'?U>O_ /E'G_YQ/_FZ$7[WM/\
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M]^][3_?T7_.1?\_7O^'5OY:/_>>GQ+_]'QMS_P"N'OW]7K__ )1Y_P#G$_\
MFZ]^][3_ ']%_P Y%_S]>_X=6_EH_P#>>GQ+_P#1\;<_^N'OW]7K_P#Y1Y_^
M<3_YNO?O>T_W]%_SD7_/U[_AU;^6C_WGI\2__1\;<_\ KA[]_5Z__P"4>?\
MYQ/_ )NO?O>T_P!_1?\ .1?\_7O^'5OY:/\ WGI\2_\ T?&W/_KA[]_5Z_\
M^4>?_G$_^;KW[WM/]_1?\Y%_S]>_X=6_EH_]YZ?$O_T?&W/_ *X>_?U>O_\
ME'G_ .<3_P";KW[WM/\ ?T7_ #D7_/U[_AU;^6C_ -YZ?$O_ -'QMS_ZX>_?
MU>O_ /E'G_YQ/_FZ]^][3_?T7_.1?\_7O^'5OY:/_>>GQ+_]'QMS_P"N'OW]
M7K__ )1Y_P#G$_\ FZ]^][3_ ']%_P Y%_S]>_X=6_EH_P#>>GQ+_P#1\;<_
M^N'OW]7K_P#Y1Y_^<3_YNO?O>T_W]%_SD7_/U[_AU;^6C_WGI\2__1\;<_\
MKA[]_5Z__P"4>?\ YQ/_ )NO?O>T_P!_1?\ .1?\_7O^'5OY:/\ WGI\2_\
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M_1\;<_\ KA[]_5Z__P"4>?\ YQ/_ )NO?O>T_P!_1?\ .1?\_7O^'5OY:/\
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M /.)_P#-U[][VG^_HO\ G(O^?KW_  ZM_+1_[ST^)?\ Z/C;G_UP]^_J]?\
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M -</?OZO7_\ RCS_ /.)_P#-U[][VG^_HO\ G(O^?KW_  ZM_+1_[ST^)?\
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M>_>]I_OZ+_G(O^?KW_#JW\M'_O/3XE_^CXVY_P#7#W[^KU__ ,H\_P#SB?\
MS=>_>]I_OZ+_ )R+_GZ]_P .K?RT?^\]/B7_ .CXVY_]</?OZO7_ /RCS_\
M.)_\W7OWO:?[^B_YR+_GZ]_PZM_+1_[ST^)?_H^-N?\ UP]^_J]?_P#*//\
M\XG_ ,W7OWO:?[^B_P"<B_Y^O?\ #JW\M'_O/3XE_P#H^-N?_7#W[^KU_P#\
MH\__ #B?_-U[][VG^_HO^<B_Y^O?\.K?RT?^\]/B7_Z/C;G_ -</?OZO7_\
MRCS_ /.)_P#-U[][VG^_HO\ G(O^?KW_  ZM_+1_[ST^)?\ Z/C;G_UP]^_J
M]?\ _*//_P XG_S=>_>]I_OZ+_G(O^?KW_#JW\M'_O/3XE_^CXVY_P#7#W[^
MKU__ ,H\_P#SB?\ S=>_>]I_OZ+_ )R+_GZ]_P .K?RT?^\]/B7_ .CXVY_]
M</?OZO7_ /RCS_\ .)_\W7OWO:?[^B_YR+_GZ]_PZM_+1_[ST^)?_H^-N?\
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M1_[ST^)?_H^-N?\ UP]^_J]?_P#*//\ \XG_ ,W7OWO:?[^B_P"<B_Y^O?\
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MY^O?\.K?RT?^\]/B7_Z/C;G_ -</?OZO7_\ RCS_ /.)_P#-U[][VG^_HO\
MG(O^?KW_  ZM_+1_[ST^)?\ Z/C;G_UP]^_J]?\ _*//_P XG_S=>_>]I_OZ
M+_G(O^?KW_#JW\M'_O/3XE_^CXVY_P#7#W[^KU__ ,H\_P#SB?\ S=>_>]I_
MOZ+_ )R+_GZF8_\ FC?RX,OD*'%8OYT?%7(Y/)UE-C\=CZ+O';U5-//6NL<,
M,,:5Y>2661E5%4$LQ  )/NK;#?("S6\P %23&X  \SCK:[K:N0!-$230 .I)
M)_/H^'LIZ,.O>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>ZUW/YH.[:;X:_S3/Y7W\Q3LJJ_N]\5Z;;/?GPQ^1O9]4M:<=LY^YJ
M>FKME9;-2TT$E/0X:MW)3K2U-;62I24H"22LA"./=>Z0W\Y'O?J[YL[L^ O\
MMWXO=B[)[O[<[J^9O17>?:='U=NB/?,&T^K.@LA+F]P[ISE9A&KZ3%Q/5Q8^
M"A6M>-:R7RK &DB4CW7NMESW[KW7O?NO=5-]R?R-OY6WR [2WUW3V[\7_P"]
MO9G96X:W=6]=R_Z:^Q,#][7Y @S3_9XS=U%CZ;60/1!2Q1C^R@]B.SYMW"PB
M6&*72BBBCPXS05KQ*$^?F>B:YY?L[QS))'5FXG6XKBG ,!Y=:[O\C+^5A\$?
MFILGY@9'Y-](57:%9T]\H]P]8=;25';6]]K+B\%CJ2*2''QQX/<F,CG1&-Q)
M.DLQX!D( 'L8\T<QWFUM!]/($\2W21Z1QG4[$U.4/^;H/;+LMM?B7QE+:)G1
M*N_:HI088=7K?] ZO\G#_O#W_P!F"[3_ /LW]A?^O&Z?[_\ ^J</_6OHZ_JM
M8?[Z_P"-R?\ 0?7O^@=7^3A_WA[_ .S!=I__ &;^_?UXW3_?_P#U3A_ZU]>_
MJM8?[Z_XW)_T'U[_ *!U?Y.'_>'O_LP7:?\ ]F_OW]>-T_W_ /\ 5.'_ *U]
M>_JM8?[Z_P"-R?\ 0?7O^@=7^3A_WA[_ .S!=I__ &;^_?UXW3_?_P#U3A_Z
MU]>_JM8?[Z_XW)_T'U[_ *!U?Y.'_>'O_LP7:?\ ]F_OW]>-T_W_ /\ 5.'_
M *U]>_JM8?[Z_P"-R?\ 0?7O^@=7^3A_WA[_ .S!=I__ &;^_?UXW3_?_P#U
M3A_ZU]>_JM8?[Z_XW)_T'U[_ *!U?Y.'_>'O_LP7:?\ ]F_OW]>-T_W_ /\
M5.'_ *U]>_JM8?[Z_P"-R?\ 0?7O^@=7^3A_WA[_ .S!=I__ &;^_?UXW3_?
M_P#U3A_ZU]>_JM8?[Z_XW)_T'U[_ *!U?Y.'_>'O_LP7:?\ ]F_OW]>-T_W_
M /\ 5.'_ *U]>_JM8?[Z_P"-R?\ 0?7O^@=7^3A_WA[_ .S!=I__ &;^_?UX
MW3_?_P#U3A_ZU]>_JM8?[Z_XW)_T'U[_ *!U?Y.'_>'O_LP7:?\ ]F_OW]>-
MT_W_ /\ 5.'_ *U]>_JM8?[Z_P"-R?\ 0?7O^@=7^3A_WA[_ .S!=I__ &;^
M_?UXW3_?_P#U3A_ZU]>_JM8?[Z_XW)_T'U[_ *!U?Y.'_>'O_LP7:?\ ]F_O
MW]>-T_W_ /\ 5.'_ *U]>_JM8?[Z_P"-R?\ 0?7O^@=7^3A_WA[_ .S!=I__
M &;^_?UXW3_?_P#U3A_ZU]>_JM8?[Z_XW)_T'U[_ *!U?Y.'_>'O_LP7:?\
M]F_OW]>-T_W_ /\ 5.'_ *U]>_JM8?[Z_P"-R?\ 0?7O^@=7^3A_WA[_ .S!
M=I__ &;^_?UXW3_?_P#U3A_ZU]>_JM8?[Z_XW)_T'U[_ *!U?Y.'_>'O_LP7
M:?\ ]F_OW]>-T_W_ /\ 5.'_ *U]>_JM8?[Z_P"-R?\ 0?7O^@=7^3A_WA[_
M .S!=I__ &;^_?UXW3_?_P#U3A_ZU]>_JM8?[Z_XW)_T'U[_ *!U?Y.'_>'O
M_LP7:?\ ]F_OW]>-T_W_ /\ 5.'_ *U]>_JM8?[Z_P"-R?\ 0?7O^@=7^3A_
MWA[_ .S!=I__ &;^_?UXW3_?_P#U3A_ZU]>_JM8?[Z_XW)_T'U[_ *!U?Y.'
M_>'O_LP7:?\ ]F_OW]>-T_W_ /\ 5.'_ *U]>_JM8?[Z_P"-R?\ 0?7O^@=7
M^3A_WA[_ .S!=I__ &;^_?UXW3_?_P#U3A_ZU]>_JM8?[Z_XW)_T'U[_ *!U
M?Y.'_>'O_LP7:?\ ]F_OW]>-T_W_ /\ 5.'_ *U]>_JM8?[Z_P"-R?\ 0?2%
M[1_X3W?R@MN=9]B[APWQ%^SS&"V)N[,XJK_T^=GU'BJ<7CZB>"3QR[U>)]$J
M*VET96M9E()'N\?.^Z,P!FXD?Z'%Z_\ -/JK<KV !_2_XW)_T'U4I_(3_E$_
MR\OFE\"*3NGY+_'S_25V9+W%V/M5]R_Z6-\;.O08%<>:2#[/ ;EQ6/'B,\OK
M^U\C:O6[6%A)S?S1?;7?-#!+I0*A T1MDK4Y9"?Y]$W+VQ6E]:K)*FIB6J=3
MC@Q' ,!U=+_T#J_R</\ O#W_ -F"[3_^S?V&/Z\;I_O_ /ZIP_\ 6OH[_JM8
M?[Z_XW)_T'U[_H'5_DX?]X>_^S!=I_\ V;^_?UXW3_?_ /U3A_ZU]>_JM8?[
MZ_XW)_T'U[_H'5_DX?\ >'O_ +,%VG_]F_OW]>-T_P!__P#5.'_K7U[^JUA_
MOK_C<G_0?7O^@=7^3A_WA[_[,%VG_P#9O[]_7C=/]_\ _5.'_K7U[^JUA_OK
M_C<G_0?7O^@=7^3A_P!X>_\ LP7:?_V;^_?UXW3_ '__ -4X?^M?7OZK6'^^
MO^-R?]!]>_Z!U?Y.'_>'O_LP7:?_ -F_OW]>-T_W_P#]4X?^M?7OZK6'^^O^
M-R?]!]>_Z!U?Y.'_ 'A[_P"S!=I__9O[]_7C=/\ ?_\ U3A_ZU]>_JM8?[Z_
MXW)_T'U[_H'5_DX?]X>_^S!=I_\ V;^_?UXW3_?_ /U3A_ZU]>_JM8?[Z_XW
M)_T'U[_H'5_DX?\ >'O_ +,%VG_]F_OW]>-T_P!__P#5.'_K7U[^JUA_OK_C
M<G_0?7O^@=7^3A_WA[_[,%VG_P#9O[]_7C=/]_\ _5.'_K7U[^JUA_OK_C<G
M_0?7O^@=7^3A_P!X>_\ LP7:?_V;^_?UXW3_ '__ -4X?^M?7OZK6'^^O^-R
M?]!]>_Z!U?Y.'_>'O_LP7:?_ -F_OW]>-T_W_P#]4X?^M?7OZK6'^^O^-R?]
M!]>_Z!U?Y.'_ 'A[_P"S!=I__9O[]_7C=/\ ?_\ U3A_ZU]>_JM8?[Z_XW)_
MT'U[_H'5_DX?]X>_^S!=I_\ V;^_?UXW3_?_ /U3A_ZU]>_JM8?[Z_XW)_T'
MU[_H'5_DX?\ >'O_ +,%VG_]F_OW]>-T_P!__P#5.'_K7U[^JUA_OK_C<G_0
M?7O^@=7^3A_WA[_[,%VG_P#9O[]_7C=/]_\ _5.'_K7U[^JUA_OK_C<G_0?7
MO^@=7^3A_P!X>_\ LP7:?_V;^_?UXW3_ '__ -4X?^M?7OZK6'^^O^-R?]!]
M>_Z!U?Y.'_>'O_LP7:?_ -F_OW]>-T_W_P#]4X?^M?7OZK6'^^O^-R?]!]>_
MZ!U?Y.'_ 'A[_P"S!=I__9O[]_7C=/\ ?_\ U3A_ZU]>_JM8?[Z_XW)_T'U[
M_H'5_DX?]X>_^S!=I_\ V;^_?UXW3_?_ /U3A_ZU]>_JM8?[Z_XW)_T'U[_H
M'5_DX?\ >'O_ +,%VG_]F_OW]>-T_P!__P#5.'_K7U[^JUA_OK_C<G_0?7O^
M@=7^3A_WA[_[,%VG_P#9O[]_7C=/]_\ _5.'_K7U[^JUA_OK_C<G_0?7O^@=
M7^3A_P!X>_\ LP7:?_V;^_?UXW3_ '__ -4X?^M?7OZK6'^^O^-R?]!]$C_F
M2_R-/Y6G07P,^5W='4OQ>_NGV7UKTON[=FR=R?Z;.Q<[]ED,7"&@J/L\GNZL
MQ]3H;G1/2RQM_:0^S39><-QN[R&*2:JO*BL/#B%06 (J$!_9TAW+ERRM[>61
M(Z,L;$'7(:$*2.+$=)C^59_)$_E@?)'^7O\ %OO'NGXR?WS[1[&Z^J,YO+='
M^FCL+;OWE4F4R%.)?LL3NRAQU/:&")=,%)$GIOIU$DWW[F_<;*\FBBEHB2,%
M'AQ&@'S*$_M/6MKY<L[FVCD>.K,BDG6XJ2/DP'5@?_0.K_)P_P"\/?\ V8+M
M/_[-_91_7C=/]_\ _5.'_K7TO_JM8?[Z_P"-R?\ 0?7O^@=7^3A_WA[_ .S!
M=I__ &;^_?UXW3_?_P#U3A_ZU]>_JM8?[Z_XW)_T'U[_ *!U?Y.'_>'O_LP7
M:?\ ]F_OW]>-T_W_ /\ 5.'_ *U]>_JM8?[Z_P"-R?\ 0?7O^@=7^3A_WA[_
M .S!=I__ &;^_?UXW3_?_P#U3A_ZU]>_JM8?[Z_XW)_T'U[_ *!U?Y.'_>'O
M_LP7:?\ ]F_OW]>-T_W_ /\ 5.'_ *U]>_JM8?[Z_P"-R?\ 0?7O^@=7^3A_
MWA[_ .S!=I__ &;^_?UXW3_?_P#U3A_ZU]>_JM8?[Z_XW)_T'U[_ *!U?Y.'
M_>'O_LP7:?\ ]F_OW]>-T_W_ /\ 5.'_ *U]>_JM8?[Z_P"-R?\ 0?7O^@=7
M^3A_WA[_ .S!=I__ &;^_?UXW3_?_P#U3A_ZU]>_JM8?[Z_XW)_T'U[_ *!U
M?Y.'_>'O_LP7:?\ ]F_OW]>-T_W_ /\ 5.'_ *U]>_JM8?[Z_P"-R?\ 0?7O
M^@=7^3A_WA[_ .S!=I__ &;^_?UXW3_?_P#U3A_ZU]>_JM8?[Z_XW)_T'U[_
M *!U?Y.'_>'O_LP7:?\ ]F_OW]>-T_W_ /\ 5.'_ *U]>_JM8?[Z_P"-R?\
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M3A_ZU]>_JM8?[Z_XW)_T'U[_ *!U?Y.'_>'O_LP7:?\ ]F_OW]>-T_W_ /\
M5.'_ *U]>_JM8?[Z_P"-R?\ 0?5+7\^S^43_ "\OA;\"*ONGXT?'S_1KV9%W
M%UQM5-R_Z6-\;QM09Y<@:N#[//[ERN//E,$7K^U\BZ?0ZW-Q/RAS1?;I?+#/
M+J0JY(T1KD+495 ?Y]$G,.Q6EC:M)$FE@5H=3GBP' L1U;7U=_PGN_E!;CZS
MZZW#F?B+]YF,[L3:.9RM7_I\[/I_+4Y3'T\\\GCBWJD2:Y79M*(JK>RJ  /8
M;DYWW16($W G_0XO7_FGT<KRO8$#]+_C<G_0?2Z_Z!U?Y.'_ 'A[_P"S!=I_
M_9O[I_7C=/\ ?_\ U3A_ZU]6_JM8?[Z_XW)_T'U[_H'5_DX?]X>_^S!=I_\
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ML,T(_"1ZGK3Z_FQ?RLO@A\9OGM_*)Z5Z0Z+.R>LOE'\AL3L3O;;([/WEN/\
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MP_\ 6OKW]5K#_?7_ !N3_H/KW_0.K_)P_P"\/?\ V8+M/_[-_?OZ\;I_O_\
MZIP_]:^O?U6L/]]?\;D_Z#Z]_P! ZO\ )P_[P]_]F"[3_P#LW]^_KQNG^_\
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M>?V=!JYV:VCW.*W"?IM&69=3Y-)#QU5_"//K8!_Z!U?Y.'_>'O\ [,%VG_\
M9O[!G]>-T_W_ /\ 5.'_ *U]"7^JUA_OK_C<G_0?7O\ H'5_DX?]X>_^S!=I
M_P#V;^_?UXW3_?\ _P!4X?\ K7U[^JUA_OK_ (W)_P!!]>_Z!U?Y.'_>'O\
M[,%VG_\ 9O[]_7C=/]__ /5.'_K7U[^JUA_OK_C<G_0?7O\ H'5_DX?]X>_^
MS!=I_P#V;^_?UXW3_?\ _P!4X?\ K7U[^JUA_OK_ (W)_P!!]>_Z!U?Y.'_>
M'O\ [,%VG_\ 9O[]_7C=/]__ /5.'_K7U[^JUA_OK_C<G_0?7O\ H'5_DX?]
MX>_^S!=I_P#V;^_?UXW3_?\ _P!4X?\ K7U[^JUA_OK_ (W)_P!!]>_Z!U?Y
M.'_>'O\ [,%VG_\ 9O[]_7C=/]__ /5.'_K7U[^JUA_OK_C<G_0?7O\ H'5_
MDX?]X>_^S!=I_P#V;^_?UXW3_?\ _P!4X?\ K7U[^JUA_OK_ (W)_P!!]>_Z
M!U?Y.'_>'O\ [,%VG_\ 9O[]_7C=/]__ /5.'_K7U[^JUA_OK_C<G_0?7O\
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MU[^JUA_OK_C<G_0?7O\ H'5_DX?]X>_^S!=I_P#V;^_?UXW3_?\ _P!4X?\
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M .S!=I__ &;^PK_7C=/]_P#_ %3A_P"M?1[_ %6L/]]?\;D_Z#Z]_P! ZO\
M)P_[P]_]F"[3_P#LW]^_KQNG^_\ _JG#_P!:^O?U6L/]]?\ &Y/^@^O?] ZO
M\G#_ +P]_P#9@NT__LW]^_KQNG^__P#JG#_UKZ]_5:P_WU_QN3_H/KW_ $#J
M_P G#_O#W_V8+M/_ .S?W[^O&Z?[_P#^J</_ %KZ]_5:P_WU_P ;D_Z#Z]_T
M#J_R</\ O#W_ -F"[3_^S?W[^O&Z?[__ .J</_6OKW]5K#_?7_&Y/^@^O?\
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MW3@[I$CR2.L<<:L\DCL$5507))/  '))]^Z]TF?[[[+_ .>OVO\ ^?\ I/\
MK][]U[I14]33UD$-523PU5-41K+!44\JSQNKBX9'4E64CZ$$@^_=>ZS>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NM=[^;+3
M;A^7O\P3^6Y_*KR>XJ_$?&3NW$=[_);YD[:PF8K=M5NZ]M=(45,-N;5DKJ-H
MF?"97.R3KE*-9 T\0BD\D/VZB?W7N@,_F"_%3H7^3[V9\(OY@/P+ZLVK\=*0
M_+3I[XO_ "RZSZV,VUMO;UZX[XFJL9.^0PU.):2JSNWLH**JQU0L"2J[R/(\
MJQB)O=>ZVE/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=5R_P PC<G\Q>IQ77'3/\NSKWJ^FWAW"F\Z3L3Y5]S;E6/
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MI0[I6CP6YL3%4U-528*NSV.D2!\;1QTD/AE^YD299:1*3W7NDU_+M^)?2/\
M-Y[&^=/SZ_F!==;0^3<%1\O>[_C#\3NONPHJG.[=V5UIT96P8VB_A>#JF%-C
M\[FJP3SY*K$?GFEB$Z&G^XDA7W7NC'?RH/XK\1?GM_,7_E0XC*Y3*_'+HS']
M*?)GX>8S-YZJW'5;7VIWI0O_ ![9R3U0DECQ&%W%&W\+A>HD>.GDD)=@^F+W
M7NMA3W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U0;M_^3ST!G^X/EG\N/YM63Z7^7^]>U>V,W-T]D.W#4P;0ZVZRH*>E_@&T
ML/BL]6_PG%5U(\5;)75M/&C5;6J&?S35;2>Z]T'O_"?'<51*G\P_KGI#=>X>
MQOY:_5'RSJ-L?R]>P,_E*_.4[8B>DJ)=X[<VM7UM)"N2V+M;."FI<)5PU55'
M*CU*B>01B:;W7N@1_EV_$OI'^;SV-\Z?GU_,"ZZVA\FX*CY>]W_&'XG=?=A1
M5.=V[LKK3HRM@QM%_"\'5,*;'YW-5@GGR56(_/-+$)T-/]Q)"ONO=&._E0?Q
M7XB_/;^8O_*AQ&5RF5^.71F/Z4^3/P\QF;SU5N.JVOM3O2A?^/;.2>J$DL>(
MPNXHV_A<+U$CQT\DA+L'TQ>Z]UL*>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[HC_\RSY)[@^'WP!^7WR8V?\
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MZVFQ\6XJS"8_(8W(;<EEJRD$<F3QF1J31NT\"C(0TBRSI3M/J]U[JD#XY?\
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M7>_16Z\5F,^:M9:W#;WV=0YM:_:^3HI8*7+;=R.$DI:P179V2:54]U[HQ_\
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MXZHZ ZQW'W;VWA=_['W/U/E,3LS:?W/W^[QB-TX3#93(;7A^TG*Y6BHZF@F
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M@M[]U[JLC8'\T3+=V]%?/GNSK#M7XH;?V-\<?G'U?\;^E.W]_P",W/D=I9#
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MDJ8XIJ>(43"5A+$CHMPZJP('NO=41;O_ )BOSH[!V_\ RUJKXVX_XN[,RO\
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MTYG_ (]1YSK3:N^*SYJ[FKMC;'P&;Q><K]V93967@W;0E*]AELK!+B73*P>
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MMZ6EBBQ"R)7YJ16JJAH9:6F]U[K%G.QOYTG4^$P??6]NL_B%WOM"HS>R!O\
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MSU#9_)XVC6AK:2K6J93,L/NO=5![P^)GRDS'P![6V3COCEWC/O&L_P"$Q_\
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MQN^=[;]WULZOQN"7.D8I\%/)M^*5Y:Z&:6."CCA@IQ-D9:RA]U[IKZ3^<O\
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M[?P]/692JHZK"_=335,%7%[KW1M?@Q\R/DON?Y<8?H/=F5^5?R4Z.W]U%O\
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MO.5NXZC;F:7&U,./QF.6LAG3W7N@+_F(]6[_ $^6G\V7>>X^VH=TT&W-S?R
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M4;6@V3N[&;9ZN3^"U=-19.KQKUF9J):FGIZS%RX])JOW7NB^=R_('Y(?.O\
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MSNW:.]JFCK\6?O=EX38E7B<=#2T5'/'B:S"X.$S1U-14S---.1.L92-/=>Z
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M9WG(L^XZBDR=1M:MWUM.GW54JT^8IMN[OQ4%542U-3&D%15U4LWNO=*/N_\
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%W7NO_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>tlucid_sig.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tlucid_sig.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
M     ! !+     $  0$L     0 !_^X $T%D;V)E &2      04  DE$_]L
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MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW5&7\S'_ (4)_P O3^61E*_KO?\
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MR@PF"P6-H<-A<-BJ2#'XO$8G&4L5%C<9C:"ECBI:*@H*.!(H88U6..- J@
M>_=>Z+?\M_A9\6_G9U7-TO\ +/IC:7='7K5QRV/QFXXJZDRNV\Y]E5XU=Q;-
MW7@JW%;KV9N*/'U\T"U^*K:2J\,SQERCLI]U[JK[I?\ X3/?R6^D=V0[SP_P
MXPF_LQ2-(:.D[HWYV/V]M.G21H6,<VP=\[JR^Q,LJF'TM7XVK=0S -9B/?NO
M=&Z^??\ ,L^$/\I/I#&;I[[W5A-F0?P:OI.G^@^N\?A6[&[#_@,4$1P?6G7U
M+48FDIL/CIJNG@J,A4-0X3&&HB%34PF2,/[KW6E[N/\ G7_S\?YQV[-Y4_\
M+3ZRC^*/QEZ_R50V\NT<54[-Q6)V1@*.D%3D\MW1\G>W8*':.&J,+M^O7,5>
M+VW!192"C4/'#6Z4>3W7NG;_ (3]?S:OYSG<7S3V%\%*;?NU_G)T)U[V'NRM
M[[[N[,RVY=V9O;_24.2H=NY/?> ^06;,&[-QT5'68YZ_9M'F*&JR&=J<FU'4
M-!2%)L3[KW7T(^P^Q=A=2;(W1V7VCO+;/7O7NR<+7[CW?O7>.:Q^WML;;P6+
MIWJLAE<SF<I/34%!14E/&S.\CJ !_7W[KW7SH/YLG\Y#Y$_SU_D%MC^5U_*F
MPV\:WX^;WW!1XK/[JCH,[M+-]_"E>FJ,GNC?<5904^9ZX^/&RK-63T^0ABJJ
MV.%:FOA1_!0)[KW6Q%\(_CY_*3_X32=%OC?D%\H^GL!\E.Q-NIF.W^T]YUD5
M3VQON/"T5)DJ[;/5O56VZ?<795-UEA*NH1Z+'4%!5U5=/-%+4M/4R0HGNO=7
MZ?&?Y1?'_P"8_3VU^_?C)VGMGN#J3>$<IPN[MLR5L2I54VC[[#9W"9>CQFX]
MJ;FQ;2JM9BLK1T62HG8+/!&Q ]^Z]U6+_.E_G8](_P H/J'"5^6Q%-VQ\D.S
M8JP=/=%TV:&(?(46/F@@RV^=]9:GILA4[8V+B))Q&D@@>IRE9_DU*MDJ9Z7W
M7NH/\C#YX?S _P"8O\=,U\E?F5\<NG>A.N]V9)#\>,AUY-OW%9_M#;*5F2&0
MW;7;)WKF-V38G9T,2TU+C,J<HKYV>*IJH:*"B-)+4>Z]U<)N7K+JW<K5N0WA
MU]L#/O-2319*NW+M/;N5:6AT2FHCK:G*4$YDI/'(Y<2,4TLU^"??NO=?.]_G
MG?S==E_.O>V._E,?RA^F=B=D[;WSNO']<;U[*ZKZQVK45O<VY,3FXY*/KKHR
MJ@PL%/0]8X;)8=:NNW93/#29*GIO-25289)*NM]U[K9!_D3_ /"?SIS^5QU[
MA>W.XL7MGM7YU;MQ"S;N[#:+^+;=Z<H\E##)/UQU M8@A@^R"^+);A$4>0RL
MWD6-H:(I3^_=>ZN)^:OSE^,O\OKI#/=_?*7LK#]?;*Q:55+@\=+44DV\>P]S
MPXZLR='L7K;;$M52UF[]YY6GH9&AI("%CC1YZB2"FBFGC]U[K1Y[9_X40?SA
M/YM';&Y.@_Y+7QLW3UEL[$"GJ:W>E-A-E[F[>@PTU1/)CLOV+V'ONJ;HGH['
MYU<;-%%3R3R3.\<B0968@JONO=%4_E]?S9?Y\W5_S_JOY?W7'=^Q/YB^^]R]
MYXB3>D&_]ZYCN'KK%P8J*KR';M#M'OIEH,AU[UI@(,O-!E*FAIZ[#XFNP<2X
M6EFA8T^3]U[KZ2?>7=?6WQQZ>[([W[@W+1[0ZQZGVAFM[[TW#7.BQ8_"8.D>
MJG$".\9J\C6.JT])3J?)4U4L<2 NZ@^Z]U\@GY\?S$*S^=#_ #%\+V-\GNWJ
MGXT?%JES.2VML(97&;DWUC>@>C,2*[.5M71;'VHN5FW+VQO>EQ<?WIH8A_%,
MY-24SS)14T#0>Z]UL4_'CX:_(G^=1UYUM\5_A[L#>W\L[^0CTIFX99-T9ZBD
MI^]_G%N&#Q_Q_L/. _:1=CYS<0#:*B>2IVA@ZR5I97S-=CZ?&T?NO=;H_2O1
MOPG_ )4WQ4?:77^.ZX^,OQOZFP\V?W?N[<V9H,)25%3'3P093?'9&^<]415F
MY=V9IH8TEK*V>6HF;Q4\ $:P0K[KW3W\)/F3LOYW]-U?R"ZMV#VCM#I_,;VS
MV!ZAW5VGM@;+J^[=A8:BPQI.Z=E[7JZN7<N+ZXW5F:RNI,0V9IL;DJR+&M5&
MDCIYZ=I/=>Z$GY,?)CI#X?=(;^^17R*W]A^MNI.ML.^7W+N7+N[,S,ZT^-PF
M$QM.LN1W!NC<&1ECH\9C*..:MR%;-'!!&\C@>_=>Z^=#W+\C_FM_PK*^>FVO
MC/T5C-X=$_ /J?*0;KSPRE,E9BNN=J*E; .VN[7Q&1?![D[@WA]O/CMK;>IZ
MRHAII9)$IW-/#ELH/=>Z-O\ \*2^^.COY7?P:Z,_DA?!FCQ^Q:#?F Q^_?D;
M58:I4;OR'7N-KZ=L1'OS,49AJLEN[O+>V(DR68FE8/)C,.M+XUH*R.+W[KW1
M)?Y1WR8^-'\A7X4;O^=_=F"PW:W\P/YJ;<@QOQ.^.E!E<<NYMG?&>AK:IJ'L
M[LFO^P&8ZPV1W!OO#353L#6S9S%X+$M01?N5LE/[KW5COQK^*>Z=LXO?/_"B
M;_A1KNBNR^Y,!!1;P^+?Q)WG M'0[9KZI!6]6XJFZIR,TM'@,Y4U,4*[4V48
MC/0RK)F\_P"3(">2#W7NM?;&0_.__A4/_-(1\@9<'@ZZJ2IR$<59DZ[JGXC?
M&[%Y&)9J7'2S4XBK<W+2V2(B""JW3N:H\DBTT#2-2>Z]U]#'L_Y%_P L[_A.
M;\'.MNK,YG*79.TMH[9R%/UAU'MPXK.]]?(+=U#%2ONO=-+@?N,2<YN'<>=J
MXILUG:UZ#"4$]9%'+/2Q&GA]^Z]UJC[C_G7_ ,_'^<=NS>5/_+3ZRC^*/QEZ
M_P E4-O+M'%5.S<5B=D8"CI!4Y/+=T?)WMV"AVCAJC"[?KUS%7B]MP464@HU
M#QPUNE'D]U[IV_X3]?S:OYSG<7S3V%\%*;?NU_G)T)U[V'NRM[[[N[,RVY=V
M9O;_ $E#DJ';N3WW@/D%FS!NS<=%1UF.>OV;1YBAJLAG:G)M1U#04A2;$^Z]
MUMM?SV-V?+CK_P#EC?(SL+X6=LX'I3M_8&+Q&\\GOO-;AVOM*LI.M-O9**O[
M"Q^U-T;R0[>P6[\E@HFCHI99()Y#JAIIHZJ6!A[KW6@%\"_^%8?\R?X?;4H>
MM^V9=K?-/K_&2R-C*SOC)[F'<F*II)*1SC8.Y,77SY7<%$#'4.LFX:'.UZR5
M%EJ1!%' /=>ZL:S/_"X'Y SP1+M_X$=.XRJ$VJ:;,]R[USL$D&AP8XJ:BV?M
MV2&;R%3K,KKI!&BYN/=>ZW/?Y3OS\J/YE_PBZN^5^1ZFW+TQGMV2YG!;EV;G
M<?F(<.^>VY4I2UF>Z^SF8H* [QZ]SB2QS8_)0"2/49:61S4TLZK[KW5 _P#P
MI$_X4.Q?"W&[A^#GPKW9CJ_Y8;CP[T?;G:>%JZ>OA^-N#RU.57!XIXO-3GNK
M,X^7RQJY)V_221U$B_<RTXC]U[JB;^5KTY\*OY20VK_,1_F[97(=@_,OLN#'
M;[^('P+P& J.R?DKBFW/6Y&HP7?/:&S<OE*"BVWO7?\ 7PN^VTW)-2?9*16>
M67+3)38_W7NK$OE#_P *_?F+\>N]=D;3WC_+#H^B=B9,X??N0V'WWO'>=-WW
MNOI+/RYFDV]FZ"BI\'M#%]6;IW"*!:V&/)XS.P11(T(6>.:*N]^Z]UN*=H?/
M?XU=$?#_ &_\WN_-ZOTITIN'K39_9-*.Q,7D<!O<+OG:M)NS;^Q8]B5E-%NF
MK[-JZ:K%,,!%2MDA6H\31*T;Z?=>ZTV-X_S_ #^;+_.'^0^=^+7\D_IR'H[K
MW$R+4YWOS>^(P>;WMA-HFJACBWKV/N?<F.W)UETS@,J]'41TV/IZ',YVJ%UH
MZB2H4Q1^Z]T#O\N+YW_S,.E/YX_7GP07Y_YG^:9UYO[/T>VOE++)D]Q[VZ=V
M+7/MR:L[4R'56Y]RR9%\'0=&-1*7K<0N*PF7K8YZ"2B6>8,/=>ZWI/D:_P -
M.@>I=\=\_)':O1VT.K>M**7>NZ]X[UV+M&II,;-12%Z6KIDJ<-4U>0W+6U\R
MPT$%,DM=5UDR10*\LBJ?=>Z^;U\B.Q?DK_PJ1_F$;8Z"^'?36V.E/BCTUD,E
M68;<$VQ\)B:/K78&8K*7'[@[L[OW#@**"IR&[]X4^)CCPVUZ:K9"\24E-J9:
M_(^_=>Z^A?\ RXOY9GQ;_E?]$8GI/XX;.AIZV>FH:KLKM7-P4]5V1V[NR&EB
MAK-S;QS876D,DR,:/%TQBQF,B;QT\*W=W]U[HNW\V'^<]\>?Y8&TL7M6>CJN
M]_F#V='2XSH7XF=>SMD^P=Z;@SU4</M?);II,5!D\IM+9>2SSK2P3_:SU^6J
M ]/C*6KF280^Z]U\P[^=*W\SO(_+# [X_FLT==MOO[M[JC$]M;(ZZDR^UY\/
MUKTSGM[[]VQM':.WML;.S6>Q.P\90979>15<945$N:*A:C*22U\\\K^Z]U]3
M#^1[MF;:?\H7^75BYUK4>J^*75.YE%?)').8=Z8"'>-,T;1)&HHGI\\K4RD:
MDIBBL2P)/NO='0WO\I>ANO.]>EOC-N?L7"4W?/R EW:W675U%))E=VY/#[&V
M3NC?NY]V9?%8Y*FHVSLO'X?:53 ,OD!34$V3EIZ**5ZJ>.(^Z]T8'W[KW7O?
MNO=>]^Z]T0[^8[_,-Z#_ )97Q?WI\E^^LU"M-BH9</UUL"DK:>#=O;O9-71U
M,^W.O=GTLHDDEKLE)3M+657CD@Q>-AGK9[0P/[]U[KY&?9_8GS7_ )Z7\Q-<
MNV.K^R?D-\B=VT.V-C;,H*FN&S>LMD8]I1B-MXDU!J:?9_6'7>$,U97U)54U
M?=Y"H\E74SR2^Z]U]93^5'_+4ZG_ )6'Q"V3\;>O#0Y[=KK%NONWM"+'?P_(
M=J]L9*AI(-P;EEBEDJ*NCP-$M,E#AJ%Y9/L<93Q(S/,TTLGNO=64,RJI9B%5
M069F("JH%R23P ![]U[KYR'\W[YY]]_S\_YA.Q?Y0W\OC<E>_P 9]M=@5F)W
M_O#%-7)LOM+<NR:Q:G>G<._:V@ DR/2?30QDSX&%G2CS.4"5<2U-3-A6A]U[
MH^WR1_FC?R[?^$UWQCF_E]_RY\!MGO\ ^8]+C_NNR-RUM1#E<#B>SJVA:AK>
MQ_D;O#!&E;<N\*>:"]%LK%U%.^.H%BIY),93M"T_NO=$M_E _P I;N/^:IVG
M6_SF_P"=5OFKW/T6\IWAUOLSMO)46!PG<.+VY65530;BW9CJY\=M_K_XJ[/J
M1*<;A(TI*3<CAY)$7#ESF/=>Z-]_."_X5H]4=2;<W5\;/Y5]1C.P>R4QB;;E
M^4RXG'3=/]9H%>BG'4&W,K1RTO9.X\120A*.NJ:1=L4[O'+$N4C5H??NO=!/
M_P )I?Y(W^S 5E+_ #??YB5!F.V]W=B;HRN_/CKL3M>FK<S_ 'DS$N7JI*OY
M+]ETNY8GFW77Y7+Q23;1AJ4DH?$%S2^=I,9+3>Z]ULQ_S!?Y+/Q#_F2=I;2[
M7^7_ &!\D=S;,ZWV[+28GHG$]V3;+^/>/K(G$]=OR?;.,P<&>QV[YL:DE+4Y
M"FS5*KT<C!TNJ.GNO=4A?)W^=K\3/Y?6T-T?R]?Y"_QQZV[>[4ZYVWO/=._=
MX[%HZ2C^,O1."V9MJ3*[^[6[ [%JJZDI.V,WM2AIH6R^9R.9BPE-("M?F9*F
M$T$GNO=:CW\OCXG?*K_A0'_,TBQW?'<6]>SZ=)H^P?DSWYGGR-<<#T]MS-4]
M,^"VC&]!BL7M>JW9-6C%[8Q$-+04E :EYXZ-8*2>(>Z]U]63<&\/AQ_+(^+6
MWH=U[HZQ^+OQAZ/VQB]H[;7-9&BV[M_%4%'$8\=A,/3.QR.Y=U9NIUR""FCJ
M\IE:Z6233-/([-[KW6A-_-X_X5&=Q_.>ME^%'\K?;?9G7&P^RMUXWKF7MZD6
MKPWR![VK,WF:C;.-V7UE@<+43Y/KO:6_:^LHQ"WF3<^3BE2FFCQJR55'-[KW
M6?ISXW_ K_A-3UAM_P"2GSVI]G_+;^;5O/:E%NWHKX=8K(8O(;;^. R=,Z8K
M/;PJ4?.45)EDKTE^YW764S@-32TFW:2:6FJ<E4>Z]TF?Y2_PS^57_"D#YM[B
M_F ?S*]T9??'Q3Z5W*:)-L,M5@-A[PW7%54F=PWQUZGVK2N*3;W5FV,;-#4;
MGJ8YGR-5$]+#4U%;75]570>Z]UN9?S(/YSGP#_E)[(I-N]K[QQ^7[2H]M4*=
M=?%KJ-<3D>R*K#P4=11;;:KP4$]-B>M=BD8LT\&1RKTE,4A=*..IDC,/OW7N
MJ-OC]\=_YCO_  HWRV([^_F15&Y_B#_*K;*46?ZN^"VP<EG-K[E^1$>%K)*W
M![E["W*]/M[>62V@:]H9X,U7QTT=?]E'/@\7CUE3*R>Z]UN+=;];; Z>V%M+
MJWJO9NW.O>N=AX*@VSLW9.T<31X/;>VL#C(1!0XO$8J@BAI:2E@C'T5;LQ+,
M2S$GW7NOBL[]@[7_ )LG\TG>T'7E17;K[$^:7ROW,NR:S*15!7&;>WKO6N.W
MJS)Q+2TM10[9Z_Z_2&2<>",T>+QK>A?'I'NO=?8P^$7P_P"I_@7\6NG/BETO
M0&GV3U'M.CPARU33T4&:WEN2<M7;NW[N=\?34E+4[FWKN.IJ<C6ND:1K+.4C
M5(DC1?=>Z-4[I$CR2.L<<:L\DCL$1$0%F=V8A555%R3P![]U[K6R_F:_\*=/
M@C\$Y<UU;TQE(/F=\H(*B7"TO6G3N<I,AL':VY!5Y'%'&]B]K8V/+X2@RN/S
M..:FJL+B(\MG(:ADCGIJ8.)1[KW1:^Q_YGG>'\J'X+9#YU?S.MS83?O\S3YH
MX:F_V7[X8[=K<[MSKGI78N*IJ>KV[L+%;&&1RZ;0Q6TY-P+G.Q,[/)+FLME:
MFBP<N1K#C<6T/NO=:R_PS^%&_P#^;UN_M?\ G+?SH_DM4]5_!O8&YHZ;?'86
M[:F;:-9W-_=F1J6@Z2Z'AC2"FVSU[B,Q40X75@J>KK:W)2U&+Q<<N;DJJND]
MU[I/?.O^:#W/_-H[/ZC_ )37\J;J(?'_ .$%9N3&]8=.] ;'Q='L[)]T5%'4
MQY([Z[@EQHE3![(P$6*J,R<:)&AI*6*HR67EK*M4-'[KW6UIU[V1_+"_X2E?
M"3$=0[^W[2]H_*_?F-I-X=A;;V'CL16=X=\]A&BGDIIJB@C9(NNNG=JO6S4F
M"FSU5%3TU"9&C:NR-1.*CW7NM-+^9]_,R_F'_P WGOW!?'C>N(W#M[,Y;=M/
MMG87P<ZRS533[%ZRR4TN+R]*O:-6N7QJ[Z[SQ'V\L>XI]U0T=)U]#25D,U/C
M:ULG38CW7NCP_"3MOM/XQ8R+^7'_ "'>OL3\E?GYW%18I/F3_,>PN&Q^YNN^
MOTJ<>LE=U_\ 'K=V:QU-MS;/2/7F25@^^-QA*;.Y.*62AQ\TT^->#W7NDK_,
MH_E_?!;^5C\>][1?/3O+=W\PW^<A\D]DI/A]JXWM/?46Q_CKE\[AZK&S]U;_
M -SIEJ/?^_I]IR2HV"_O3,HW578^F4X2+&#(R1>Z]U<M_P )D'RW\L#^3[\S
M/YB/RVS.;V5\?=^;CQ_:/6&R,V:7$R9S$;"P55LRAW+M&DR5%0U4VX._][YR
M@VYAUDJ)8<F^*H'ID1)_+/[KW50W\KWXH]S?\*4/YJW;?S8^9*UE3\<.M-QX
M3=/9^ $V8EVW48Q?O4Z?^+'7]<YI8*/;]#C\;Y\R\&B8T$51/,BUN62=O=>Z
M^B)\K/FE\-?Y;G2N.WQ\CNTM@]#]:8#&0;=V+M=$AAR^;AP&,2''[.ZNZZP,
M$N<W%/C<72I'%18NCDCI*= 7\42ZA[KW7SF?YN__  J#^3W\Q.GSWQE^'&W=
MZ?&SXT[UJX-L5L&,JF;Y(]XXW*^"B.T]U97:.0R5-M+;NY*N8TU3MW;]3529
M2!VI*ROK*2HFHV]U[K:M_P"$WO\ (SQ/\MSI6@^27R'VOCJCYR=U;9)S,-0Z
M9(] ]<9MZ6OH>J\/4 M2)O+)4]-3U&Z*VG'IJR<;!++2TK5%9[KW0Z?S=_\
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MXQAP'FDV_05<DC@9.:*EK8?=>ZW+D1(D2.-%CCC54CC10B(B *J(J@*JJHL
M. /?NO=<O?NO=?+F^%U?\7OY'G_"BKY,5GSQQ]1UEU?U,/D+/\=]Q;?ZWW+N
M;$X.#MK)T%;TWN3;VW-K8*NRE+A\KT7N7*8E9<?2ST]!5U+TI<)')(GNO=7>
M?+#_ (6I_$K8T>>P/P]^-W;'?>X:.>*DQ.]NTZS%=-]95RNFN;,4%!32;P[%
MRM'3Z@BTU;C<%/,X>[QJJM)[KW6HS\T/YY7\U[^:3E5ZFW=VIN;&;-W[*NVZ
M+XQ_%K ;AV7L[>4F5BJZ&3;5=MW 9'<'8G:%/F(ZYHSC,WE<U3R,J%(0RJ??
MNO=;8?\ PGE_X3-97XW[IV/\[?YA&!@'=>$BIMP]%?&VJ>"KINHLU(U3]KV%
MVM-1555C\WV#34+Q28G#*S4N!ED:>K$N22G3'>Z]UI@_S?\ Y]=B_P QKYZ=
MY=][SKLU#M2CW;F=A=,;+RT%=C1U_P!1;/RM9BMHX+^!Y"GHZO#YK(T\+9+,
M)-#'4-EZRH\@6RHGNO=;4G1?P5^8G\P/XP[O^?G\T#K2NZI^!/P;^+W9G8GP
M)_E@]883*;,VMO"'JSJ+<&=V7G\KU\,O'N"3 1X_$PT]))F:E=P;QJWL[4F#
M;PY7W7NM4S^5KVO\^>N?D!G=M?RT=FY3/?*[N;8%?U;M_=&TMG4>[NP]B;+R
MF>P&8WED=G5.Y)*C8NPAEX\-2T>2W+E*0R8K'R2?;5E TTDS>Z]U8)\ZNM-D
M?RF8LGL_L3N1_EE_.?[>Q$6;[R[<GWGE=^;>^"F,W#01S0T^T]X962;/;O\
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M'6[XW[F&J=P9T4\D[FFI3+'CZ!7*4E/!&='OW7N@@[D_DN?RO_D+\G*GY?\
M=GP]ZP[*[SR6/H*'/YC=(W!7[/W;/BXH:7'YK>O59S2=8;SW%3X^!*4U^4Q%
M74S4L<<<KR+##X_=>ZLZHJ*CQM'28['4E-08^@IH**AH:*"*EHZ*CI8D@I:2
MDI8$C@IJ:F@C5(XT541%   'OW7NBF='? /X5_&KLC??</0_QBZ;ZN[5[,RF
M6S&]NP]J[+Q=)O#,UF>K)\CFD7/RQ3Y'%X_*5]3)-/1T<E/222,6:(GGW[KW
M1O/?NO=$ ^:'\K+^7_\ S"YL)7?,+XR[)[BSNV\?'A\'N^7);OV-OW&X6*O?
M*1X.F[!ZTW)LW>PP29"62441KS2ZYI3X_P!V35[KW0W_ !H^'WQ<^&^SZW8/
MQ:Z&ZQZ)VIE,BV7S.-ZZVMCL%+G\LT,--_%-QY2&-LON+(I2T\<*3UL]1*D,
M:1JP154>Z]T8JIE>"GGGBIIJR6&&66.CIFIUJ*IXT9TIH&K)Z6D6:=AI0RRQ
MQAB-3*MR/=>ZU%_G3_)%_F-?SIOD'0;X^=7R8V!\3_B'UWGJH=(?%/I5\IW%
MO3&8)XYJ:KW=V!GZZ+9G74/<6YJ?2DV1@;<='BZ61J6DC\:RO5^Z]U?9_+L_
MEE_$W^6#TQ!T[\8-C?PR3(18Z?L/L[<C4F6[2[8SV/IVA7/[[W/#1T0JF22:
M9Z7'TD-+BL<)Y%I*:%78'W7NK O?NO=%V^5OQ3Z*^;'0^^OC7\D=DP]@=1=B
M4V/AW%M]\CD\-5K58?*4><P>7Q&:PM70Y;#YG"9G'P5--44\R.DD8!U(65O=
M>Z$+I_J/KKH3JW8'2W4FUL;LGK/J_:F&V5LC:N(B,5!A-NX&BBH<?1Q:BTL\
MOBBU2S2,\T\S-)(S.[,?=>ZU$/\ A:3\9M]=H?"OXV?(K:&,W#F\-\:NX=U8
MSL2BQ,TTF+P>S>Y]OX:@CWQGL8DZQSP8;=FP\7C8ZKQ224G\:?E(I9F]^Z]U
M8_\ \)7L[0Y?^1K\/,?2.6J-KYGY)8+*+=?VZZH^47<NYHT%B2 <9N*G;FQ]
M7]+>_=>Z.7@?Y)_\K/;OR>W5\PZ+X9=3UG?6[MV4^_J_<.>I\UN7:^+W[!7+
MEGWQM7K'/YC)=9;1W=59N-,A)D,;B*:J_B*FK5UJ7DE?W7NK.\OB,7N#$Y3
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D[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>20
<FILENAME>abio-20240331.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Tue Jul 09 21:08:03 UTC 2024 -->
<xs:schema elementFormDefault="qualified" xmlns:srt-types="http://fasb.org/srt-types/2024" targetNamespace="http://www.arcabiopharma.com/20240331" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:abio="http://www.arcabiopharma.com/20240331" xmlns:dtr="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="abio-20240331_lab.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="abio-20240331_pre.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="abio-20240331_def.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="abio-20240331_cal.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef"/>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet" id="abio_r_ConsolidatedBalanceSheet">
        <link:definition>001 - Statement - Balance Sheets (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet_Parentheticals" id="abio_r_ConsolidatedBalanceSheet_Parentheticals">
        <link:definition>002 - Statement - Balance Sheets (Unaudited) (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement" id="abio_r_ConsolidatedIncomeStatement">
        <link:definition>003 - Statement - Statements of Operations (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement_Parentheticals" id="abio_r_ConsolidatedIncomeStatement_Parentheticals">
        <link:definition>004 - Statement - Statements of Operations (Unaudited) (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/ShareholdersEquityType2or3" id="abio_r_ShareholdersEquityType2or3">
        <link:definition>005 - Statement - Statements of Stockholders&#8217; Equity (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/ConsolidatedCashFlow" id="abio_r_ConsolidatedCashFlow">
        <link:definition>006 - Statement - Statements of Cash Flows (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/ARCAandSummaryofSignificantAccountingPolicies" id="abio_r_ARCAandSummaryofSignificantAccountingPolicies">
        <link:definition>007 - Disclosure - ARCA and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/NetLossPerShare" id="abio_r_NetLossPerShare">
        <link:definition>008 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/FairValueDisclosures" id="abio_r_FairValueDisclosures">
        <link:definition>009 - Disclosure - Fair Value Disclosures</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/PropertyandEquipment" id="abio_r_PropertyandEquipment">
        <link:definition>010 - Disclosure - Property and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/RelatedPartyArrangements" id="abio_r_RelatedPartyArrangements">
        <link:definition>011 - Disclosure - Related Party Arrangements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/CommitmentsandContingencies" id="abio_r_CommitmentsandContingencies">
        <link:definition>012 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/EquityFinancings" id="abio_r_EquityFinancings">
        <link:definition>013 - Disclosure - Equity Financings</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/SharebasedCompensation" id="abio_r_SharebasedCompensation">
        <link:definition>014 - Disclosure - Share-based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/EmployeeBenefitPlans" id="abio_r_EmployeeBenefitPlans">
        <link:definition>015 - Disclosure - Employee Benefit Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/IncomeTaxes" id="abio_r_IncomeTaxes">
        <link:definition>016 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/SubsequentEvents" id="abio_r_SubsequentEvents">
        <link:definition>017 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/AccountingPoliciesByPolicy" id="abio_r_AccountingPoliciesByPolicy">
        <link:definition>996000 - Disclosure - Accounting Policies, by Policy (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/NetLossPerShareTables" id="abio_r_NetLossPerShareTables">
        <link:definition>996001 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/PropertyandEquipmentTables" id="abio_r_PropertyandEquipmentTables">
        <link:definition>996002 - Disclosure - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/CommitmentsandContingenciesTables" id="abio_r_CommitmentsandContingenciesTables">
        <link:definition>996003 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/SharebasedCompensationTables" id="abio_r_SharebasedCompensationTables">
        <link:definition>996004 - Disclosure - Share-based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/IncomeTaxesTables" id="abio_r_IncomeTaxesTables">
        <link:definition>996005 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/ARCAandSummaryofSignificantAccountingPoliciesDetails" id="abio_r_ARCAandSummaryofSignificantAccountingPoliciesDetails">
        <link:definition>996006 - Disclosure - ARCA and Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/ScheduleofPotentiallyDilutiveSharesofCommonStockTable" id="abio_r_ScheduleofPotentiallyDilutiveSharesofCommonStockTable">
        <link:definition>996007 - Disclosure - Net Loss Per Share (Details) - Schedule of Potentially Dilutive Shares of Common Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/FairValueDisclosuresDetails" id="abio_r_FairValueDisclosuresDetails">
        <link:definition>996008 - Disclosure - Fair Value Disclosures (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/PropertyandEquipmentDetails" id="abio_r_PropertyandEquipmentDetails">
        <link:definition>996009 - Disclosure - Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable" id="abio_r_ScheduleofPropertyandEquipmentTable">
        <link:definition>996010 - Disclosure - Property and Equipment (Details) - Schedule of Property and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/RelatedPartyArrangementsDetails" id="abio_r_RelatedPartyArrangementsDetails">
        <link:definition>996011 - Disclosure - Related Party Arrangements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails" id="abio_r_CommitmentsandContingenciesDetails">
        <link:definition>996012 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable" id="abio_r_ScheduleofFutureMinimumCommitmentsDueTable">
        <link:definition>996013 - Disclosure - Commitments and Contingencies (Details) - Schedule of Future Minimum Commitments Due</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrYwqBFvPJwgls7iB/C7qgJlieUnn0NA5OCi94KNojOhCKLtgRf7Lh8PNXaX7qyF9a6SJv7mHT4i4TG0zLkQ0ch6DUlOii5J7LMDGl2/JapjDY9mloXuib5mHVGZ5CeGApH//7xHOalGUmL15AlWw6rbn9qzGZe/F/uh8urYvQsY+tuMobOgKRuT/ucAjluB8mb6+hIaiE3s6A==] CSR-->
      <link:roleType roleURI="http://www.arcabiopharma.com/role/EquityFinancingsDetails" id="abio_r_EquityFinancingsDetails">
        <link:definition>996014 - Disclosure - Equity Financings (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/SharebasedCompensationDetails" id="abio_r_SharebasedCompensationDetails">
        <link:definition>996015 - Disclosure - Share-based Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/ScheduleofEstimatedWeightedAverageGrantDateFairValuePerShareTable" id="abio_r_ScheduleofEstimatedWeightedAverageGrantDateFairValuePerShareTable">
        <link:definition>996016 - Disclosure - Share-based Compensation (Details) - Schedule of Estimated Weighted Average Grant Date Fair Value Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable" id="abio_r_ScheduleofStockOptionActivitiesTable">
        <link:definition>996017 - Disclosure - Share-based Compensation (Details) - Schedule of Stock Option Activities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/ScheduleofRSUActivityTable" id="abio_r_ScheduleofRSUActivityTable">
        <link:definition>996018 - Disclosure - Share-based Compensation (Details) - Schedule of RSU Activity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/ScheduleofNoncashSharebasedCompensationExpenseTable" id="abio_r_ScheduleofNoncashSharebasedCompensationExpenseTable">
        <link:definition>996019 - Disclosure - Share-based Compensation (Details) - Schedule of Non-cash, Share-based Compensation Expense</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/EmployeeBenefitPlansDetails" id="abio_r_EmployeeBenefitPlansDetails">
        <link:definition>996020 - Disclosure - Employee Benefit Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/IncomeTaxesDetails" id="abio_r_IncomeTaxesDetails">
        <link:definition>996021 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/ScheduleofIncomeTaxBenefitAttributabletoOurLossfromOperationsTable" id="abio_r_ScheduleofIncomeTaxBenefitAttributabletoOurLossfromOperationsTable">
        <link:definition>996022 - Disclosure - Income Taxes (Details) - Schedule of Income Tax Benefit Attributable to Our Loss from Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable" id="abio_r_ScheduleofNetdeferredtaxassetsandliabilitiesTable">
        <link:definition>996023 - Disclosure - Income Taxes (Details) - Schedule of Net deferred tax assets and liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/ScheduleofPotentiallyDilutiveSharesofCommonStockTable0" id="abio_r_ScheduleofPotentiallyDilutiveSharesofCommonStockTable0">
        <link:definition>996024 - Disclosure - Net Loss Per Share (Details) - Schedule of Potentially Dilutive Shares of Common Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable0" id="abio_r_ScheduleofPropertyandEquipmentTable0">
        <link:definition>996025 - Disclosure - Property and Equipment (Details) - Schedule of Property and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable0" id="abio_r_ScheduleofFutureMinimumCommitmentsDueTable0">
        <link:definition>996026 - Disclosure - Commitments and Contingencies (Details) - Schedule of Future Minimum Commitments Due</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/ScheduleofNoncashSharebasedCompensationExpenseTable0" id="abio_r_ScheduleofNoncashSharebasedCompensationExpenseTable0">
        <link:definition>996027 - Disclosure - Share-based Compensation (Details) - Schedule of Non-cash, Share-based Compensation Expense</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable0" id="abio_r_ScheduleofStockOptionActivitiesTable0">
        <link:definition>996028 - Disclosure - Share-based Compensation (Details) - Schedule of Stock Option Activities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/SubsequentEventsDetails" id="abio_r_SubsequentEventsDetails">
        <link:definition>996029 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-types/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://fasb.org/srt-types/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/sic/2024" schemaLocation="https://xbrl.sec.gov/sic/2024/sic-2024.xsd"/>
  <xs:element name="ScheduleOfPotentiallyDilutiveSharesOfCommonStockAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_ScheduleOfPotentiallyDilutiveSharesOfCommonStockAbstract"/>
  <xs:element name="ScheduleOfPropertyAndEquipmentAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_ScheduleOfPropertyAndEquipmentAbstract"/>
  <xs:element name="ScheduleOfFutureMinimumCommitmentsDueAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_ScheduleOfFutureMinimumCommitmentsDueAbstract"/>
  <xs:element name="ScheduleOfEstimatedWeightedAverageGrantDateFairValuePerShareAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_ScheduleOfEstimatedWeightedAverageGrantDateFairValuePerShareAbstract"/>
  <xs:element name="ScheduleOfStockOptionActivitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_ScheduleOfStockOptionActivitiesAbstract"/>
  <xs:element name="ScheduleOfRsuActivityAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_ScheduleOfRsuActivityAbstract"/>
  <xs:element name="ScheduleOfNonCashShareBasedCompensationExpenseAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_ScheduleOfNonCashShareBasedCompensationExpenseAbstract"/>
  <xs:element name="ScheduleOfIncomeTaxBenefitAttributableToOurLossFromOperationsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_ScheduleOfIncomeTaxBenefitAttributableToOurLossFromOperationsAbstract"/>
  <xs:element name="ScheduleOfNetDeferredTaxAssetsAndLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_ScheduleOfNetDeferredTaxAssetsAndLiabilitiesAbstract"/>
  <xs:element name="UnlabeledAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_UnlabeledAbstract"/>
  <xs:element name="UnlabeledAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_UnlabeledAbstract0"/>
  <xs:element name="UnlabeledAbstract1" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_UnlabeledAbstract1"/>
  <xs:element name="UnlabeledAbstract2" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_UnlabeledAbstract2"/>
  <xs:element name="CostsAndExpensesAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_CostsAndExpensesAbstract0"/>
  <xs:element name="UnlabeledAbstract3" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_UnlabeledAbstract3"/>
  <xs:element name="UnlabeledAbstract4" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_UnlabeledAbstract4"/>
  <xs:element name="PotentiallyDilutiveSecuritiesExcludedAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_PotentiallyDilutiveSecuritiesExcludedAbstract"/>
  <xs:element name="DeferredTaxAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_DeferredTaxAssetsAbstract"/>
  <xs:element name="PotentiallyDilutiveSecuritiesExcludedAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_PotentiallyDilutiveSecuritiesExcludedAbstract0"/>
  <xs:element name="ResearchAndDevelopmentExpenseReversed" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="abio_ResearchAndDevelopmentExpenseReversed"/>
  <xs:element name="DescriptionOfBusinessPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_DescriptionOfBusinessPolicyTextBlock"/>
  <xs:element name="LiquidityAndGoingConcernPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_LiquidityAndGoingConcernPolicyTextBlock"/>
  <xs:element name="ComprehensiveLossPolicyPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_ComprehensiveLossPolicyPolicyTextBlock"/>
  <xs:element name="AccruedOutsourcingExpensesPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_AccruedOutsourcingExpensesPolicyTextBlock"/>
  <xs:element name="IncomeTaxReconciliationAdjustmentToDeferredTaxAsset" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="abio_IncomeTaxReconciliationAdjustmentToDeferredTaxAsset"/>
  <xs:element name="DeferredTaxAssetResearchAndDevelopment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="abio_DeferredTaxAssetResearchAndDevelopment"/>
  <xs:element name="DeferredTaxAssetsLeaseLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="abio_DeferredTaxAssetsLeaseLiabilities"/>
  <xs:element name="DeferredTaxLiabilitiesRightOfUseAsset" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abio_DeferredTaxLiabilitiesRightOfUseAsset"/>
  <xs:element name="FairValueDisclosuresDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="abio_FairValueDisclosuresDetailsTable"/>
  <xs:element name="FairValueDisclosuresDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_FairValueDisclosuresDetailsLineItems"/>
  <xs:element name="FairValueAssetsBetweenHierarchyLevelsTransfersAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abio_FairValueAssetsBetweenHierarchyLevelsTransfersAmount"/>
  <xs:element name="RelatedPartyArrangementsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="abio_RelatedPartyArrangementsDetailsTable"/>
  <xs:element name="PaymentOfUnrestrictedResearchGrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abio_PaymentOfUnrestrictedResearchGrants"/>
  <xs:element name="CommitmentsandContingenciesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="abio_CommitmentsandContingenciesDetailsTable"/>
  <xs:element name="CommitmentsandContingenciesDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_CommitmentsandContingenciesDetailsLineItems"/>
  <xs:element name="RetentionBonuses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abio_RetentionBonuses"/>
  <xs:element name="PercentageOfRetentionBonuses" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_PercentageOfRetentionBonuses"/>
  <xs:element name="RetentionBonusPaid" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="abio_RetentionBonusPaid"/>
  <xs:element name="AreaOfRealEstatePropertySubleaseAdditionalOfficeFacilities" type="dtr:areaItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="abio_AreaOfRealEstatePropertySubleaseAdditionalOfficeFacilities"/>
  <xs:element name="LesseeOperatingSubleaseTermOfContract" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_LesseeOperatingSubleaseTermOfContract"/>
  <xs:element name="PotentialUpfrontAndMilestoneObligationsAndRoyaltyObligations" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abio_PotentialUpfrontAndMilestoneObligationsAndRoyaltyObligations"/>
  <xs:element name="OperatingLeasesExtendedExpiryYearsAndMonth" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_OperatingLeasesExtendedExpiryYearsAndMonth"/>
  <xs:element name="PercentageOfBaseRentToBePaidMonthly" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_PercentageOfBaseRentToBePaidMonthly"/>
  <xs:element name="EquityFinancingsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="abio_EquityFinancingsDetailsTable"/>
  <xs:element name="EquityFinancingsDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_EquityFinancingsDetailsLineItems"/>
  <xs:element name="CommonStockAuthorizedOfferingAmountUnderAgreementToSell" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abio_CommonStockAuthorizedOfferingAmountUnderAgreementToSell"/>
  <xs:element name="SellingCommissionPerAdditionalSharesSoldPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="abio_SellingCommissionPerAdditionalSharesSoldPercentage"/>
  <xs:element name="SharebasedCompensationDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="abio_SharebasedCompensationDetailsTable"/>
  <xs:element name="SharebasedCompensationDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_SharebasedCompensationDetailsLineItems"/>
  <xs:element name="PercentageHoldingForStockOptionsExercisePrice" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_PercentageHoldingForStockOptionsExercisePrice"/>
  <xs:element name="PurchaseAggregateShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_PurchaseAggregateShares"/>
  <xs:element name="EmployeeBenefitPlansDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="abio_EmployeeBenefitPlansDetailsTable"/>
  <xs:element name="EmployeeBenefitPlansDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_EmployeeBenefitPlansDetailsLineItems"/>
  <xs:element name="IncomeTaxesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="abio_IncomeTaxesDetailsTable"/>
  <xs:element name="IncomeTaxesDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_IncomeTaxesDetailsLineItems"/>
  <xs:element name="OperatingLossCarryforwardsExpirationYear" type="xbrli:gYearItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_OperatingLossCarryforwardsExpirationYear"/>
  <xs:element name="DeferredTaxAssetsAndLiabilitiesValuationAllowance" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abio_DeferredTaxAssetsAndLiabilitiesValuationAllowance"/>
  <xs:element name="ValuationAllowanceDeferredTaxAssetsAndLiabilitiesChangeInAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abio_ValuationAllowanceDeferredTaxAssetsAndLiabilitiesChangeInAmount"/>
  <xs:element name="SubsequentEventsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="abio_SubsequentEventsDetailsTable"/>
  <xs:element name="SubsequentEventsDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_SubsequentEventsDetailsLineItems"/>
  <xs:element name="NumberOfConsecutiveTradingDays" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_NumberOfConsecutiveTradingDays"/>
  <xs:element name="ThresholdAmountOfAdjustedExchangeRatio" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="abio_ThresholdAmountOfAdjustedExchangeRatio"/>
  <xs:element name="ThresholdAmountOfDeclaredCashDividend" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="abio_ThresholdAmountOfDeclaredCashDividend"/>
  <xs:element name="SubscriptionAgreementReceiptAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abio_SubscriptionAgreementReceiptAmount"/>
  <xs:element name="PaymentOfOtherPartyTerminationFee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abio_PaymentOfOtherPartyTerminationFee"/>
  <xs:element name="MinimumPercentageOfOriginallyIssuedShares" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="abio_MinimumPercentageOfOriginallyIssuedShares"/>
  <xs:element name="MinimumPercentageOfOriginallyIssuedOutstanding" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="abio_MinimumPercentageOfOriginallyIssuedOutstanding"/>
  <xs:element name="InitiallySpecifiedPercentageForBeneficialNumberOfShares" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_InitiallySpecifiedPercentageForBeneficialNumberOfShares"/>
  <xs:element name="ExceptedNumberOfBoardMembers" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_ExceptedNumberOfBoardMembers"/>
  <xs:element name="AggregatePurchasePrice" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abio_AggregatePurchasePrice"/>
  <xs:element name="NumberOfMonthsBaseSalary" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_NumberOfMonthsBaseSalary"/>
  <xs:element name="CashPayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abio_CashPayment"/>
  <xs:element name="IncreaseOfRetentionBonusToEachExecutive" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abio_IncreaseOfRetentionBonusToEachExecutive"/>
  <xs:element name="ArcaBiopharmaIncAndOrukaTherapeuticsIncMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_ArcaBiopharmaIncAndOrukaTherapeuticsIncMember"/>
  <xs:element name="ArcaBiopharmaIncMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_ArcaBiopharmaIncMember"/>
  <xs:element name="CapitalOnDemandSalesAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_CapitalOnDemandSalesAgreementMember"/>
  <xs:element name="ClinicalDevelopmentDecisionMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_ClinicalDevelopmentDecisionMember"/>
  <xs:element name="CommonStockAndPreFundedWarrantsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_CommonStockAndPreFundedWarrantsMember"/>
  <xs:element name="FirstMergerMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_FirstMergerMember"/>
  <xs:element name="FirstThreePercentPayContributionMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_FirstThreePercentPayContributionMember"/>
  <xs:element name="IncentiveStockOptionMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_IncentiveStockOptionMember"/>
  <xs:element name="JonesTradingInstitutionalServicesLLCMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_JonesTradingInstitutionalServicesLLCMember"/>
  <xs:element name="MergerAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_MergerAgreementMember"/>
  <xs:element name="NewCapitalOnDemandSalesAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_NewCapitalOnDemandSalesAgreementMember"/>
  <xs:element name="NextTwoPercentPayContributionMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_NextTwoPercentPayContributionMember"/>
  <xs:element name="OrukaTherapeuticsIncMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_OrukaTherapeuticsIncMember"/>
  <xs:element name="PatentAssignmentAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_PatentAssignmentAgreementMember"/>
  <xs:element name="SecondAmendmentOfCertainRetentionBonusLettersMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_SecondAmendmentOfCertainRetentionBonusLettersMember"/>
  <xs:element name="SeperationAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_SeperationAgreementMember"/>
  <xs:element name="ThomasAKeuerAndCJeffreyDekkerMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_ThomasAKeuerAndCJeffreyDekkerMember"/>
  <xs:element name="TwoThousandAndThirteenPlanMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_TwoThousandAndThirteenPlanMember"/>
  <xs:element name="TwoThousandAndTwentyEquityIncentivePlanMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_TwoThousandAndTwentyEquityIncentivePlanMember"/>
  <xs:element name="UniversityMedicalCenterOfJohannesGutenbergUniversityMainzMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_UniversityMedicalCenterOfJohannesGutenbergUniversityMainzMember"/>
  <xs:element name="WeightedAverageSharesOutstandingAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_WeightedAverageSharesOutstandingAbstract"/>
  <xs:element name="DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_DocumentAndEntityInformationAbstract"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>21
<FILENAME>abio-20240331_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Tue Jul 09 21:08:03 UTC 2024 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ConsolidatedBalanceSheet" roleURI="http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ConsolidatedIncomeStatement" roleURI="http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ConsolidatedCashFlow" roleURI="http://www.arcabiopharma.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ScheduleofFutureMinimumCommitmentsDueTable" roleURI="http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ScheduleofIncomeTaxBenefitAttributabletoOurLossfromOperationsTable" roleURI="http://www.arcabiopharma.com/role/ScheduleofIncomeTaxBenefitAttributabletoOurLossfromOperationsTable"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ScheduleofNetdeferredtaxassetsandliabilitiesTable" roleURI="http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ScheduleofFutureMinimumCommitmentsDueTable0" roleURI="http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable0"/>
  <calculationLink xlink:role="http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="1" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestAndOtherIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestAndOtherIncome"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_InterestAndOtherIncome" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OtherNonoperatingExpense" order="3" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.arcabiopharma.com/role/ConsolidatedCashFlow" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationAndAmortization" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrYwqBFvPJwgls7iB/C7qgJlieUnn0NA5OCi94KNojOhCKLtgRf7Lh8PNXaX7qyF9a6SJv7mHT4i4TG0zLkQ0ch6DUlOii5J7LMDGl2/JapjDY9mloXuib5mHVGZ5CeGApH//7xHOalGUmL15AlWw6rbn9qzGZe/F/uh8urYvQsY+tuMobOgKRuTNzsMDAV3cq7/ACF7RqoXp0MiGqxUm4QZ] CSR-->
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="8" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets" order="9" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" order="10" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="1" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="4" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.arcabiopharma.com/role/ScheduleofIncomeTaxBenefitAttributabletoOurLossfromOperationsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="abio_IncomeTaxReconciliationAdjustmentToDeferredTaxAsset" xlink:href="abio-20240331.xsd#abio_IncomeTaxReconciliationAdjustmentToDeferredTaxAsset"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="abio_IncomeTaxReconciliationAdjustmentToDeferredTaxAsset" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" order="6" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="abio_DeferredTaxAssetResearchAndDevelopment" xlink:href="abio-20240331.xsd#abio_DeferredTaxAssetResearchAndDevelopment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="abio_DeferredTaxAssetResearchAndDevelopment" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="abio_DeferredTaxAssetsLeaseLiabilities" xlink:href="abio-20240331.xsd#abio_DeferredTaxAssetsLeaseLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="abio_DeferredTaxAssetsLeaseLiabilities" order="8" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsNet" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="abio_DeferredTaxLiabilitiesRightOfUseAsset" xlink:href="abio-20240331.xsd#abio_DeferredTaxLiabilitiesRightOfUseAsset"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="abio_DeferredTaxLiabilitiesRightOfUseAsset" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" order="3" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" order="1" weight="1"/>
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>22
<FILENAME>abio-20240331_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Tue Jul 09 21:08:03 UTC 2024 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ConsolidatedBalanceSheet" roleURI="http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ConsolidatedIncomeStatement" roleURI="http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ConsolidatedIncomeStatement_Parentheticals" roleURI="http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ShareholdersEquityType2or3" roleURI="http://www.arcabiopharma.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ConsolidatedCashFlow" roleURI="http://www.arcabiopharma.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ARCAandSummaryofSignificantAccountingPolicies" roleURI="http://www.arcabiopharma.com/role/ARCAandSummaryofSignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_NetLossPerShare" roleURI="http://www.arcabiopharma.com/role/NetLossPerShare"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_FairValueDisclosures" roleURI="http://www.arcabiopharma.com/role/FairValueDisclosures"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_PropertyandEquipment" roleURI="http://www.arcabiopharma.com/role/PropertyandEquipment"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_RelatedPartyArrangements" roleURI="http://www.arcabiopharma.com/role/RelatedPartyArrangements"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_CommitmentsandContingencies" roleURI="http://www.arcabiopharma.com/role/CommitmentsandContingencies"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_EquityFinancings" roleURI="http://www.arcabiopharma.com/role/EquityFinancings"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_SharebasedCompensation" roleURI="http://www.arcabiopharma.com/role/SharebasedCompensation"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_EmployeeBenefitPlans" roleURI="http://www.arcabiopharma.com/role/EmployeeBenefitPlans"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_IncomeTaxes" roleURI="http://www.arcabiopharma.com/role/IncomeTaxes"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_SubsequentEvents" roleURI="http://www.arcabiopharma.com/role/SubsequentEvents"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_AccountingPoliciesByPolicy" roleURI="http://www.arcabiopharma.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_NetLossPerShareTables" roleURI="http://www.arcabiopharma.com/role/NetLossPerShareTables"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_PropertyandEquipmentTables" roleURI="http://www.arcabiopharma.com/role/PropertyandEquipmentTables"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_CommitmentsandContingenciesTables" roleURI="http://www.arcabiopharma.com/role/CommitmentsandContingenciesTables"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_SharebasedCompensationTables" roleURI="http://www.arcabiopharma.com/role/SharebasedCompensationTables"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_IncomeTaxesTables" roleURI="http://www.arcabiopharma.com/role/IncomeTaxesTables"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ScheduleofPotentiallyDilutiveSharesofCommonStockTable" roleURI="http://www.arcabiopharma.com/role/ScheduleofPotentiallyDilutiveSharesofCommonStockTable"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ScheduleofPropertyandEquipmentTable" roleURI="http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ScheduleofFutureMinimumCommitmentsDueTable" roleURI="http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ScheduleofEstimatedWeightedAverageGrantDateFairValuePerShareTable" roleURI="http://www.arcabiopharma.com/role/ScheduleofEstimatedWeightedAverageGrantDateFairValuePerShareTable"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ScheduleofStockOptionActivitiesTable" roleURI="http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ScheduleofRSUActivityTable" roleURI="http://www.arcabiopharma.com/role/ScheduleofRSUActivityTable"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ScheduleofNoncashSharebasedCompensationExpenseTable" roleURI="http://www.arcabiopharma.com/role/ScheduleofNoncashSharebasedCompensationExpenseTable"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ScheduleofIncomeTaxBenefitAttributabletoOurLossfromOperationsTable" roleURI="http://www.arcabiopharma.com/role/ScheduleofIncomeTaxBenefitAttributabletoOurLossfromOperationsTable"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ScheduleofNetdeferredtaxassetsandliabilitiesTable" roleURI="http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ScheduleofPotentiallyDilutiveSharesofCommonStockTable0" roleURI="http://www.arcabiopharma.com/role/ScheduleofPotentiallyDilutiveSharesofCommonStockTable0"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ScheduleofPropertyandEquipmentTable0" roleURI="http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable0"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ScheduleofFutureMinimumCommitmentsDueTable0" roleURI="http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable0"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ScheduleofNoncashSharebasedCompensationExpenseTable0" roleURI="http://www.arcabiopharma.com/role/ScheduleofNoncashSharebasedCompensationExpenseTable0"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ScheduleofStockOptionActivitiesTable0" roleURI="http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable0"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ARCAandSummaryofSignificantAccountingPoliciesDetails" roleURI="http://www.arcabiopharma.com/role/ARCAandSummaryofSignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_FairValueDisclosuresDetails" roleURI="http://www.arcabiopharma.com/role/FairValueDisclosuresDetails"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_PropertyandEquipmentDetails" roleURI="http://www.arcabiopharma.com/role/PropertyandEquipmentDetails"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_RelatedPartyArrangementsDetails" roleURI="http://www.arcabiopharma.com/role/RelatedPartyArrangementsDetails"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_CommitmentsandContingenciesDetails" roleURI="http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_EquityFinancingsDetails" roleURI="http://www.arcabiopharma.com/role/EquityFinancingsDetails"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_SharebasedCompensationDetails" roleURI="http://www.arcabiopharma.com/role/SharebasedCompensationDetails"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_EmployeeBenefitPlansDetails" roleURI="http://www.arcabiopharma.com/role/EmployeeBenefitPlansDetails"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_IncomeTaxesDetails" roleURI="http://www.arcabiopharma.com/role/IncomeTaxesDetails"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_SubsequentEventsDetails" roleURI="http://www.arcabiopharma.com/role/SubsequentEventsDetails"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#DocumentAndEntityInformation" roleURI="http://www.arcabiopharma.com/role/DocumentAndEntityInformation"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all"/>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_Assets" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_Liabilities" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_StockholdersEquity" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="10" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet_Parentheticals" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="9" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_CostsAndExpensesAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestAndOtherIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestAndOtherIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_InterestAndOtherIncome" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherNonoperatingExpense" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareAbstract" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_WeightedAverageSharesOutstandingAbstract" xlink:href="abio-20240331.xsd#abio_WeightedAverageSharesOutstandingAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="abio_WeightedAverageSharesOutstandingAbstract" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_WeightedAverageSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement_Parentheticals" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_ResearchAndDevelopmentExpenseReversed" xlink:href="abio-20240331.xsd#abio_ResearchAndDevelopmentExpenseReversed"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="abio_ResearchAndDevelopmentExpenseReversed" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/ShareholdersEquityType2or3" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/ConsolidatedCashFlow" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationAndAmortization" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIncomeTaxRefunds" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIncomeTaxRefunds"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_ProceedsFromIncomeTaxRefunds" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/ARCAandSummaryofSignificantAccountingPolicies" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/NetLossPerShare" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/FairValueDisclosures" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/PropertyandEquipment" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/RelatedPartyArrangements" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/CommitmentsandContingencies" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/EquityFinancings" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/SharebasedCompensation" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/EmployeeBenefitPlans" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/IncomeTaxes" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/SubsequentEvents" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/AccountingPoliciesByPolicy" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="abio_DescriptionOfBusinessPolicyTextBlock" xlink:href="abio-20240331.xsd#abio_DescriptionOfBusinessPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="abio_DescriptionOfBusinessPolicyTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_LiquidityAndGoingConcernPolicyTextBlock" xlink:href="abio-20240331.xsd#abio_LiquidityAndGoingConcernPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="abio_LiquidityAndGoingConcernPolicyTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_ComprehensiveLossPolicyPolicyTextBlock" xlink:href="abio-20240331.xsd#abio_ComprehensiveLossPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="abio_ComprehensiveLossPolicyPolicyTextBlock" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_AccruedOutsourcingExpensesPolicyTextBlock" xlink:href="abio-20240331.xsd#abio_AccruedOutsourcingExpensesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="abio_AccruedOutsourcingExpensesPolicyTextBlock" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="14" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/NetLossPerShareTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/PropertyandEquipmentTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/CommitmentsandContingenciesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/SharebasedCompensationTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/IncomeTaxesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/ScheduleofPotentiallyDilutiveSharesofCommonStockTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_StockOptionMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_PotentiallyDilutiveSecuritiesExcludedAbstract" xlink:href="abio-20240331.xsd#abio_PotentiallyDilutiveSecuritiesExcludedAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="abio_PotentiallyDilutiveSecuritiesExcludedAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_PotentiallyDilutiveSecuritiesExcludedAbstract" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="abio_ScheduleOfFutureMinimumCommitmentsDueAbstract" xlink:href="abio-20240331.xsd#abio_ScheduleOfFutureMinimumCommitmentsDueAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfFutureMinimumCommitmentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfFutureMinimumCommitmentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfFutureMinimumCommitmentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfFutureMinimumCommitmentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfFutureMinimumCommitmentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfFutureMinimumCommitmentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfFutureMinimumCommitmentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfFutureMinimumCommitmentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/ScheduleofEstimatedWeightedAverageGrantDateFairValuePerShareTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="abio_ScheduleOfEstimatedWeightedAverageGrantDateFairValuePerShareAbstract" xlink:href="abio-20240331.xsd#abio_ScheduleOfEstimatedWeightedAverageGrantDateFairValuePerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfEstimatedWeightedAverageGrantDateFairValuePerShareAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfEstimatedWeightedAverageGrantDateFairValuePerShareAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfEstimatedWeightedAverageGrantDateFairValuePerShareAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfEstimatedWeightedAverageGrantDateFairValuePerShareAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfEstimatedWeightedAverageGrantDateFairValuePerShareAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:href="abio-20240331.xsd#abio_ScheduleOfStockOptionActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" order="17" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/ScheduleofRSUActivityTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="abio_ScheduleOfRsuActivityAbstract" xlink:href="abio-20240331.xsd#abio_ScheduleOfRsuActivityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfRsuActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfRsuActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfRsuActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfRsuActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfRsuActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfRsuActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfRsuActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfRsuActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/ScheduleofNoncashSharebasedCompensationExpenseTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/ScheduleofIncomeTaxBenefitAttributabletoOurLossfromOperationsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="abio_ScheduleOfIncomeTaxBenefitAttributableToOurLossFromOperationsAbstract" xlink:href="abio-20240331.xsd#abio_ScheduleOfIncomeTaxBenefitAttributableToOurLossFromOperationsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfIncomeTaxBenefitAttributableToOurLossFromOperationsAbstract" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfIncomeTaxBenefitAttributableToOurLossFromOperationsAbstract" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfIncomeTaxBenefitAttributableToOurLossFromOperationsAbstract" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_IncomeTaxReconciliationAdjustmentToDeferredTaxAsset" xlink:href="abio-20240331.xsd#abio_IncomeTaxReconciliationAdjustmentToDeferredTaxAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfIncomeTaxBenefitAttributableToOurLossFromOperationsAbstract" xlink:to="abio_IncomeTaxReconciliationAdjustmentToDeferredTaxAsset" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfIncomeTaxBenefitAttributableToOurLossFromOperationsAbstract" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfIncomeTaxBenefitAttributableToOurLossFromOperationsAbstract" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfIncomeTaxBenefitAttributableToOurLossFromOperationsAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="abio_ScheduleOfNetDeferredTaxAssetsAndLiabilitiesAbstract" xlink:href="abio-20240331.xsd#abio_ScheduleOfNetDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="abio_DeferredTaxAssetsAbstract" xlink:href="abio-20240331.xsd#abio_DeferredTaxAssetsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfNetDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="abio_DeferredTaxAssetsAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_DeferredTaxAssetResearchAndDevelopment" xlink:href="abio-20240331.xsd#abio_DeferredTaxAssetResearchAndDevelopment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_DeferredTaxAssetsAbstract" xlink:to="abio_DeferredTaxAssetResearchAndDevelopment" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_DeferredTaxAssetsLeaseLiabilities" xlink:href="abio-20240331.xsd#abio_DeferredTaxAssetsLeaseLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_DeferredTaxAssetsAbstract" xlink:to="abio_DeferredTaxAssetsLeaseLiabilities" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfNetDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfNetDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfNetDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfNetDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_DeferredTaxLiabilitiesRightOfUseAsset" xlink:href="abio-20240331.xsd#abio_DeferredTaxLiabilitiesRightOfUseAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="abio_DeferredTaxLiabilitiesRightOfUseAsset" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrYwqBFvPJwgls7iB/C7qgJlieUnn0NA5OCi94KNojOhCKLtgRf7Lh8PNXaX7qyF9a6SJv7mHT4i4TG0zLkQ0ch6DUlOii5J7LMDGl2/JapjDY9mloXuib5mHVGZ5CeGApH//7xHOalGUmL15AlWw6rbn9qzGZe/F/uh8urYvQsY+tuMobOgKRuTEmtSFmjbcEWobL12t2ANOZvUW/BHOQbz] CSR-->
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfNetDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/ScheduleofPotentiallyDilutiveSharesofCommonStockTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_StockOptionMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_PotentiallyDilutiveSecuritiesExcludedAbstract0" xlink:href="abio-20240331.xsd#abio_PotentiallyDilutiveSecuritiesExcludedAbstract0"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="abio_PotentiallyDilutiveSecuritiesExcludedAbstract0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_PotentiallyDilutiveSecuritiesExcludedAbstract0" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="abio_ScheduleOfFutureMinimumCommitmentsDueAbstract" xlink:href="abio-20240331.xsd#abio_ScheduleOfFutureMinimumCommitmentsDueAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfFutureMinimumCommitmentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/ScheduleofNoncashSharebasedCompensationExpenseTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:href="abio-20240331.xsd#abio_ScheduleOfStockOptionActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" order="14" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/ARCAandSummaryofSignificantAccountingPoliciesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_Revenues" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosureOffbalanceSheetRisksAmountAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosureOffbalanceSheetRisksAmountAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueDisclosureOffbalanceSheetRisksAmountAsset" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NumberOfOperatingSegments" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/FairValueDisclosuresDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="abio_FairValueDisclosuresDetailsLineItems" xlink:href="abio-20240331.xsd#abio_FairValueDisclosuresDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="abio_FairValueDisclosuresDetailsTable" xlink:href="abio-20240331.xsd#abio_FairValueDisclosuresDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="abio_FairValueDisclosuresDetailsLineItems" xlink:to="abio_FairValueDisclosuresDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abio_FairValueDisclosuresDetailsTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abio_FairValueDisclosuresDetailsTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abio_FairValueDisclosuresDetailsTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_MoneyMarketFundsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_FairValueDisclosuresDetailsLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_FairValueAssetsBetweenHierarchyLevelsTransfersAmount" xlink:href="abio-20240331.xsd#abio_FairValueAssetsBetweenHierarchyLevelsTransfersAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_FairValueDisclosuresDetailsLineItems" xlink:to="abio_FairValueAssetsBetweenHierarchyLevelsTransfersAmount" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtLongtermAndShorttermCombinedAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_FairValueDisclosuresDetailsLineItems" xlink:to="us-gaap_DebtLongtermAndShorttermCombinedAmount" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_FairValueDisclosuresDetailsLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/PropertyandEquipmentDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_DepreciationAndAmortization" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/RelatedPartyArrangementsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <loc xlink:type="locator" xlink:label="abio_RelatedPartyArrangementsDetailsTable" xlink:href="abio-20240331.xsd#abio_RelatedPartyArrangementsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="abio_RelatedPartyArrangementsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abio_RelatedPartyArrangementsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ChiefExecutiveOfficerMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ChiefExecutiveOfficerMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="srt_ChiefExecutiveOfficerMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_ResearchAndDevelopmentExpenseReversed" xlink:href="abio-20240331.xsd#abio_ResearchAndDevelopmentExpenseReversed"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="abio_ResearchAndDevelopmentExpenseReversed" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_PaymentOfUnrestrictedResearchGrants" xlink:href="abio-20240331.xsd#abio_PaymentOfUnrestrictedResearchGrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="abio_PaymentOfUnrestrictedResearchGrants" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="abio_CommitmentsandContingenciesDetailsLineItems" xlink:href="abio-20240331.xsd#abio_CommitmentsandContingenciesDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="abio_CommitmentsandContingenciesDetailsTable" xlink:href="abio-20240331.xsd#abio_CommitmentsandContingenciesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="abio_CommitmentsandContingenciesDetailsLineItems" xlink:to="abio_CommitmentsandContingenciesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abio_CommitmentsandContingenciesDetailsTable" xlink:to="srt_CounterpartyNameAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abio_CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestructuringCostAndReserveAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abio_CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_RestructuringCostAndReserveAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfRestructuringDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_TypeOfRestructuringDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfRestructuringDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_TypeOfRestructuringDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abio_CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abio_CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_ClinicalDevelopmentDecisionMember" xlink:href="abio-20240331.xsd#abio_ClinicalDevelopmentDecisionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="abio_ClinicalDevelopmentDecisionMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_UniversityMedicalCenterOfJohannesGutenbergUniversityMainzMember" xlink:href="abio-20240331.xsd#abio_UniversityMedicalCenterOfJohannesGutenbergUniversityMainzMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="abio_UniversityMedicalCenterOfJohannesGutenbergUniversityMainzMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OneTimeTerminationBenefitsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OneTimeTerminationBenefitsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="us-gaap_OneTimeTerminationBenefitsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_PatentAssignmentAgreementMember" xlink:href="abio-20240331.xsd#abio_PatentAssignmentAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="abio_PatentAssignmentAgreementMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_RetentionBonuses" xlink:href="abio-20240331.xsd#abio_RetentionBonuses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsandContingenciesDetailsLineItems" xlink:to="abio_RetentionBonuses" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_PercentageOfRetentionBonuses" xlink:href="abio-20240331.xsd#abio_PercentageOfRetentionBonuses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsandContingenciesDetailsLineItems" xlink:to="abio_PercentageOfRetentionBonuses" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_RetentionBonusPaid" xlink:href="abio-20240331.xsd#abio_RetentionBonusPaid"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsandContingenciesDetailsLineItems" xlink:to="abio_RetentionBonusPaid" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeveranceCosts1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeveranceCosts1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_SeveranceCosts1" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestructuringReserveCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserveCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_RestructuringReserveCurrent" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestructuringCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_RestructuringCharges" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AreaOfRealEstateProperty" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_AreaOfRealEstateProperty" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_AreaOfRealEstatePropertySubleaseAdditionalOfficeFacilities" xlink:href="abio-20240331.xsd#abio_AreaOfRealEstatePropertySubleaseAdditionalOfficeFacilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsandContingenciesDetailsLineItems" xlink:to="abio_AreaOfRealEstatePropertySubleaseAdditionalOfficeFacilities" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_LesseeOperatingSubleaseTermOfContract" xlink:href="abio-20240331.xsd#abio_LesseeOperatingSubleaseTermOfContract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsandContingenciesDetailsLineItems" xlink:to="abio_LesseeOperatingSubleaseTermOfContract" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseAssumptionsAndJudgmentsAllocationOfLeaseAndNonleaseComponent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseAssumptionsAndJudgmentsAllocationOfLeaseAndNonleaseComponent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseAssumptionsAndJudgmentsAllocationOfLeaseAndNonleaseComponent" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_OperatingLeaseCost" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_OperatingLeaseLiability" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_OperatingLeasePayments" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_PotentialUpfrontAndMilestoneObligationsAndRoyaltyObligations" xlink:href="abio-20240331.xsd#abio_PotentialUpfrontAndMilestoneObligationsAndRoyaltyObligations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsandContingenciesDetailsLineItems" xlink:to="abio_PotentialUpfrontAndMilestoneObligationsAndRoyaltyObligations" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_OperatingLeasesExtendedExpiryYearsAndMonth" xlink:href="abio-20240331.xsd#abio_OperatingLeasesExtendedExpiryYearsAndMonth"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsandContingenciesDetailsLineItems" xlink:to="abio_OperatingLeasesExtendedExpiryYearsAndMonth" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_PercentageOfBaseRentToBePaidMonthly" xlink:href="abio-20240331.xsd#abio_PercentageOfBaseRentToBePaidMonthly"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsandContingenciesDetailsLineItems" xlink:to="abio_PercentageOfBaseRentToBePaidMonthly" order="24" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/EquityFinancingsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="abio_EquityFinancingsDetailsLineItems" xlink:href="abio-20240331.xsd#abio_EquityFinancingsDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="abio_EquityFinancingsDetailsTable" xlink:href="abio-20240331.xsd#abio_EquityFinancingsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="abio_EquityFinancingsDetailsLineItems" xlink:to="abio_EquityFinancingsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abio_EquityFinancingsDetailsTable" xlink:to="dei_LegalEntityAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityDomain_0" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abio_EquityFinancingsDetailsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_CapitalOnDemandSalesAgreementMember" xlink:href="abio-20240331.xsd#abio_CapitalOnDemandSalesAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="abio_CapitalOnDemandSalesAgreementMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_NewCapitalOnDemandSalesAgreementMember" xlink:href="abio-20240331.xsd#abio_NewCapitalOnDemandSalesAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="abio_NewCapitalOnDemandSalesAgreementMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_JonesTradingInstitutionalServicesLLCMember" xlink:href="abio-20240331.xsd#abio_JonesTradingInstitutionalServicesLLCMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="abio_JonesTradingInstitutionalServicesLLCMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_EquityFinancingsDetailsLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_CommonStockAuthorizedOfferingAmountUnderAgreementToSell" xlink:href="abio-20240331.xsd#abio_CommonStockAuthorizedOfferingAmountUnderAgreementToSell"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_EquityFinancingsDetailsLineItems" xlink:to="abio_CommonStockAuthorizedOfferingAmountUnderAgreementToSell" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_SellingCommissionPerAdditionalSharesSoldPercentage" xlink:href="abio-20240331.xsd#abio_SellingCommissionPerAdditionalSharesSoldPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_EquityFinancingsDetailsLineItems" xlink:to="abio_SellingCommissionPerAdditionalSharesSoldPercentage" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_EquityFinancingsDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/SharebasedCompensationDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="abio_SharebasedCompensationDetailsLineItems" xlink:href="abio-20240331.xsd#abio_SharebasedCompensationDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="abio_SharebasedCompensationDetailsTable" xlink:href="abio-20240331.xsd#abio_SharebasedCompensationDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="abio_SharebasedCompensationDetailsLineItems" xlink:to="abio_SharebasedCompensationDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abio_SharebasedCompensationDetailsTable" xlink:to="us-gaap_PlanNameAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abio_SharebasedCompensationDetailsTable" xlink:to="srt_RangeAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abio_SharebasedCompensationDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abio_SharebasedCompensationDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_IncentiveStockOptionMember" xlink:href="abio-20240331.xsd#abio_IncentiveStockOptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="abio_IncentiveStockOptionMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_TwoThousandAndTwentyEquityIncentivePlanMember" xlink:href="abio-20240331.xsd#abio_TwoThousandAndTwentyEquityIncentivePlanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="abio_TwoThousandAndTwentyEquityIncentivePlanMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_TwoThousandAndThirteenPlanMember" xlink:href="abio-20240331.xsd#abio_TwoThousandAndThirteenPlanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="abio_TwoThousandAndThirteenPlanMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrincipalOwnerMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrincipalOwnerMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_PrincipalOwnerMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_SharebasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_SharebasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_SharebasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_SharebasedCompensationDetailsLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_SharebasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_SharebasedCompensationDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_SharebasedCompensationDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_PercentageHoldingForStockOptionsExercisePrice" xlink:href="abio-20240331.xsd#abio_PercentageHoldingForStockOptionsExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_SharebasedCompensationDetailsLineItems" xlink:to="abio_PercentageHoldingForStockOptionsExercisePrice" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_SharebasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_PurchaseAggregateShares" xlink:href="abio-20240331.xsd#abio_PurchaseAggregateShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_SharebasedCompensationDetailsLineItems" xlink:to="abio_PurchaseAggregateShares" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_SharebasedCompensationDetailsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_SharebasedCompensationDetailsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_SharebasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_SharebasedCompensationDetailsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" order="14" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/EmployeeBenefitPlansDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="abio_EmployeeBenefitPlansDetailsLineItems" xlink:href="abio-20240331.xsd#abio_EmployeeBenefitPlansDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="abio_EmployeeBenefitPlansDetailsTable" xlink:href="abio-20240331.xsd#abio_EmployeeBenefitPlansDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="abio_EmployeeBenefitPlansDetailsLineItems" xlink:to="abio_EmployeeBenefitPlansDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetirementPlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanNameAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abio_EmployeeBenefitPlansDetailsTable" xlink:to="us-gaap_RetirementPlanNameAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetirementPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RetirementPlanNameAxis" xlink:to="us-gaap_RetirementPlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetirementPlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RetirementPlanNameAxis" xlink:to="us-gaap_RetirementPlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_FirstThreePercentPayContributionMember" xlink:href="abio-20240331.xsd#abio_FirstThreePercentPayContributionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RetirementPlanNameDomain" xlink:to="abio_FirstThreePercentPayContributionMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_NextTwoPercentPayContributionMember" xlink:href="abio-20240331.xsd#abio_NextTwoPercentPayContributionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RetirementPlanNameDomain" xlink:to="abio_NextTwoPercentPayContributionMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_EmployeeBenefitPlansDetailsLineItems" xlink:to="us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_EmployeeBenefitPlansDetailsLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_EmployeeBenefitPlansDetailsLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanCostRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_EmployeeBenefitPlansDetailsLineItems" xlink:to="us-gaap_DefinedContributionPlanCostRecognized" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/IncomeTaxesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="abio_IncomeTaxesDetailsLineItems" xlink:href="abio-20240331.xsd#abio_IncomeTaxesDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="abio_IncomeTaxesDetailsTable" xlink:href="abio-20240331.xsd#abio_IncomeTaxesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="abio_IncomeTaxesDetailsLineItems" xlink:to="abio_IncomeTaxesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxPeriodAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abio_IncomeTaxesDetailsTable" xlink:to="us-gaap_TaxPeriodAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxPeriodDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abio_IncomeTaxesDetailsTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarliestTaxYearMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarliestTaxYearMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_EarliestTaxYearMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LatestTaxYearMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LatestTaxYearMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_LatestTaxYearMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_IncomeTaxesDetailsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_IncomeTaxesDetailsLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_OperatingLossCarryforwardsExpirationYear" xlink:href="abio-20240331.xsd#abio_OperatingLossCarryforwardsExpirationYear"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_IncomeTaxesDetailsLineItems" xlink:to="abio_OperatingLossCarryforwardsExpirationYear" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_IncomeTaxesDetailsLineItems" xlink:to="us-gaap_TaxCreditCarryforwardDescription" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardLimitationsOnUse" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardLimitationsOnUse"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_IncomeTaxesDetailsLineItems" xlink:to="us-gaap_TaxCreditCarryforwardLimitationsOnUse" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_DeferredTaxAssetsAndLiabilitiesValuationAllowance" xlink:href="abio-20240331.xsd#abio_DeferredTaxAssetsAndLiabilitiesValuationAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_IncomeTaxesDetailsLineItems" xlink:to="abio_DeferredTaxAssetsAndLiabilitiesValuationAllowance" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_ValuationAllowanceDeferredTaxAssetsAndLiabilitiesChangeInAmount" xlink:href="abio-20240331.xsd#abio_ValuationAllowanceDeferredTaxAssetsAndLiabilitiesChangeInAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_IncomeTaxesDetailsLineItems" xlink:to="abio_ValuationAllowanceDeferredTaxAssetsAndLiabilitiesChangeInAmount" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_IncomeTaxesDetailsLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OpenTaxYear" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OpenTaxYear"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_IncomeTaxesDetailsLineItems" xlink:to="us-gaap_OpenTaxYear" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilityForUncertainTaxPositionsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_IncomeTaxesDetailsLineItems" xlink:to="us-gaap_LiabilityForUncertainTaxPositionsCurrent" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_IncomeTaxesDetailsLineItems" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" order="11" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/SubsequentEventsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="abio_SubsequentEventsDetailsLineItems" xlink:href="abio-20240331.xsd#abio_SubsequentEventsDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="abio_SubsequentEventsDetailsTable" xlink:href="abio-20240331.xsd#abio_SubsequentEventsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="abio_SubsequentEventsDetailsLineItems" xlink:to="abio_SubsequentEventsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abio_SubsequentEventsDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abio_SubsequentEventsDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abio_SubsequentEventsDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abio_SubsequentEventsDetailsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abio_SubsequentEventsDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abio_SubsequentEventsDetailsTable" xlink:to="dei_LegalEntityAxis" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityDomain_0" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abio_SubsequentEventsDetailsTable" xlink:to="srt_RangeAxis" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abio_SubsequentEventsDetailsTable" xlink:to="srt_OwnershipAxis" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipDomain_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_MergerAgreementMember" xlink:href="abio-20240331.xsd#abio_MergerAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="abio_MergerAgreementMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_FirstMergerMember" xlink:href="abio-20240331.xsd#abio_FirstMergerMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="abio_FirstMergerMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_SeperationAgreementMember" xlink:href="abio-20240331.xsd#abio_SeperationAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="abio_SeperationAgreementMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_SecondAmendmentOfCertainRetentionBonusLettersMember" xlink:href="abio-20240331.xsd#abio_SecondAmendmentOfCertainRetentionBonusLettersMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="abio_SecondAmendmentOfCertainRetentionBonusLettersMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_CommonStockAndPreFundedWarrantsMember" xlink:href="abio-20240331.xsd#abio_CommonStockAndPreFundedWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="abio_CommonStockAndPreFundedWarrantsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_PresidentMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_PresidentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_PresidentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ChiefFinancialOfficerMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ChiefFinancialOfficerMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefFinancialOfficerMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_ThomasAKeuerAndCJeffreyDekkerMember" xlink:href="abio-20240331.xsd#abio_ThomasAKeuerAndCJeffreyDekkerMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="abio_ThomasAKeuerAndCJeffreyDekkerMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_ArcaBiopharmaIncMember" xlink:href="abio-20240331.xsd#abio_ArcaBiopharmaIncMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="abio_ArcaBiopharmaIncMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_OrukaTherapeuticsIncMember" xlink:href="abio-20240331.xsd#abio_OrukaTherapeuticsIncMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="abio_OrukaTherapeuticsIncMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_ArcaBiopharmaIncAndOrukaTherapeuticsIncMember" xlink:href="abio-20240331.xsd#abio_ArcaBiopharmaIncAndOrukaTherapeuticsIncMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="abio_ArcaBiopharmaIncAndOrukaTherapeuticsIncMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_NumberOfConsecutiveTradingDays" xlink:href="abio-20240331.xsd#abio_NumberOfConsecutiveTradingDays"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_SubsequentEventsDetailsLineItems" xlink:to="abio_NumberOfConsecutiveTradingDays" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_SubsequentEventsDetailsLineItems" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_SubsequentEventsDetailsLineItems" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_ThresholdAmountOfAdjustedExchangeRatio" xlink:href="abio-20240331.xsd#abio_ThresholdAmountOfAdjustedExchangeRatio"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_SubsequentEventsDetailsLineItems" xlink:to="abio_ThresholdAmountOfAdjustedExchangeRatio" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_ThresholdAmountOfDeclaredCashDividend" xlink:href="abio-20240331.xsd#abio_ThresholdAmountOfDeclaredCashDividend"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_SubsequentEventsDetailsLineItems" xlink:to="abio_ThresholdAmountOfDeclaredCashDividend" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_SubscriptionAgreementReceiptAmount" xlink:href="abio-20240331.xsd#abio_SubscriptionAgreementReceiptAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_SubsequentEventsDetailsLineItems" xlink:to="abio_SubscriptionAgreementReceiptAmount" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_PaymentOfOtherPartyTerminationFee" xlink:href="abio-20240331.xsd#abio_PaymentOfOtherPartyTerminationFee"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_SubsequentEventsDetailsLineItems" xlink:to="abio_PaymentOfOtherPartyTerminationFee" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_SubsequentEventsDetailsLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_MinimumPercentageOfOriginallyIssuedShares" xlink:href="abio-20240331.xsd#abio_MinimumPercentageOfOriginallyIssuedShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_SubsequentEventsDetailsLineItems" xlink:to="abio_MinimumPercentageOfOriginallyIssuedShares" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_MinimumPercentageOfOriginallyIssuedOutstanding" xlink:href="abio-20240331.xsd#abio_MinimumPercentageOfOriginallyIssuedOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_SubsequentEventsDetailsLineItems" xlink:to="abio_MinimumPercentageOfOriginallyIssuedOutstanding" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockConvertibleSharesIssuable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_SubsequentEventsDetailsLineItems" xlink:to="us-gaap_PreferredStockConvertibleSharesIssuable" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_InitiallySpecifiedPercentageForBeneficialNumberOfShares" xlink:href="abio-20240331.xsd#abio_InitiallySpecifiedPercentageForBeneficialNumberOfShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_SubsequentEventsDetailsLineItems" xlink:to="abio_InitiallySpecifiedPercentageForBeneficialNumberOfShares" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_ExceptedNumberOfBoardMembers" xlink:href="abio-20240331.xsd#abio_ExceptedNumberOfBoardMembers"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_SubsequentEventsDetailsLineItems" xlink:to="abio_ExceptedNumberOfBoardMembers" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_AggregatePurchasePrice" xlink:href="abio-20240331.xsd#abio_AggregatePurchasePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_SubsequentEventsDetailsLineItems" xlink:to="abio_AggregatePurchasePrice" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_NumberOfMonthsBaseSalary" xlink:href="abio-20240331.xsd#abio_NumberOfMonthsBaseSalary"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_SubsequentEventsDetailsLineItems" xlink:to="abio_NumberOfMonthsBaseSalary" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_CashPayment" xlink:href="abio-20240331.xsd#abio_CashPayment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_SubsequentEventsDetailsLineItems" xlink:to="abio_CashPayment" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_IncreaseOfRetentionBonusToEachExecutive" xlink:href="abio-20240331.xsd#abio_IncreaseOfRetentionBonusToEachExecutive"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_SubsequentEventsDetailsLineItems" xlink:to="abio_IncreaseOfRetentionBonusToEachExecutive" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_RetentionBonuses" xlink:href="abio-20240331.xsd#abio_RetentionBonuses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_SubsequentEventsDetailsLineItems" xlink:to="abio_RetentionBonuses" order="18" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/DocumentAndEntityInformation" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationLineItems"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentDescription" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentDescription" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="9" xbrldt:closed="true"/>
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>23
<FILENAME>abio-20240331_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Tue Jul 09 21:08:03 UTC 2024 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xml:lang="en-US">Related Party Transaction [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders&#8217; equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl0" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl1" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related and Nonrelated Parties [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total costs and expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Loss from operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl0" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl0" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl1" xml:lang="en-US">Common stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used in investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Net decrease in cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash and cash equivalents, beginning of year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0" xml:lang="en-US">Cash and cash equivalents, end of year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">ARCA and Summary of Significant Accounting Policies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">Net Loss Per Share [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareAbstract_lbl0" xml:lang="en-US">Net loss per share:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="abio_ScheduleOfPotentiallyDilutiveSharesOfCommonStockAbstract" xlink:href="abio-20240331.xsd#abio_ScheduleOfPotentiallyDilutiveSharesOfCommonStockAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_ScheduleOfPotentiallyDilutiveSharesOfCommonStockAbstract_lbl" xml:lang="en-US">Schedule of Potentially Dilutive Shares of Common Stock [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ScheduleOfPotentiallyDilutiveSharesOfCommonStockAbstract" xlink:to="abio_ScheduleOfPotentiallyDilutiveSharesOfCommonStockAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US">Fair Value Disclosures [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Property and Equipment [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl0" xml:lang="en-US">Property and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Arrangements [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_ScheduleOfFutureMinimumCommitmentsDueAbstract" xlink:href="abio-20240331.xsd#abio_ScheduleOfFutureMinimumCommitmentsDueAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_ScheduleOfFutureMinimumCommitmentsDueAbstract_lbl" xml:lang="en-US">Schedule of Future Minimum Commitments Due [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ScheduleOfFutureMinimumCommitmentsDueAbstract" xlink:to="abio_ScheduleOfFutureMinimumCommitmentsDueAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total remaining lease payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity Financings [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_ScheduleOfEstimatedWeightedAverageGrantDateFairValuePerShareAbstract" xlink:href="abio-20240331.xsd#abio_ScheduleOfEstimatedWeightedAverageGrantDateFairValuePerShareAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_ScheduleOfEstimatedWeightedAverageGrantDateFairValuePerShareAbstract_lbl" xml:lang="en-US">Schedule of Estimated Weighted Average Grant Date Fair Value Per Share [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ScheduleOfEstimatedWeightedAverageGrantDateFairValuePerShareAbstract" xlink:to="abio_ScheduleOfEstimatedWeightedAverageGrantDateFairValuePerShareAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Number of Options, Options outstanding, ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl0" xml:lang="en-US">Purchase options shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Options outstanding, ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Weighted average exercise price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Options outstanding, ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_ScheduleOfRsuActivityAbstract" xlink:href="abio-20240331.xsd#abio_ScheduleOfRsuActivityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_ScheduleOfRsuActivityAbstract_lbl" xml:lang="en-US">Schedule of RSU Activity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ScheduleOfRsuActivityAbstract" xlink:to="abio_ScheduleOfRsuActivityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Number of Shares, RSUs outstanding, beginning of period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl0" xml:lang="en-US">Number of Shares, RSUs outstanding, ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Grant Date Date Fair Value, RSUs outstanding, beginning of period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Weighted Average Grant Date Date Fair Value, RSUs outstanding, ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Statement of Income Location, Balance [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xml:lang="en-US">Employee Benefit Plans [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Taxes [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_ScheduleOfIncomeTaxBenefitAttributableToOurLossFromOperationsAbstract" xlink:href="abio-20240331.xsd#abio_ScheduleOfIncomeTaxBenefitAttributableToOurLossFromOperationsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_ScheduleOfIncomeTaxBenefitAttributableToOurLossFromOperationsAbstract_lbl" xml:lang="en-US">Schedule Of Income Tax Benefit Attributable To Our Loss From Operations Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ScheduleOfIncomeTaxBenefitAttributableToOurLossFromOperationsAbstract" xlink:to="abio_ScheduleOfIncomeTaxBenefitAttributableToOurLossFromOperationsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Total deferred tax assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:href="abio-20240331.xsd#abio_ScheduleOfStockOptionActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_ScheduleOfStockOptionActivitiesAbstract_lbl" xml:lang="en-US">Schedule of Stock Option Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:to="abio_ScheduleOfStockOptionActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentDescription" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US">Other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Right-of-use asset &#8211; operating</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US">Other assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_UnlabeledAbstract" xlink:href="abio-20240331.xsd#abio_UnlabeledAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_UnlabeledAbstract_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_UnlabeledAbstract" xlink:to="abio_UnlabeledAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued compensation and employee benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses and other liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl0" xml:lang="en-US">Accrued expenses and other liabilities - related party (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating lease liability, net of current portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders&#8217; equity:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred stock, $0.001 par value; 5 million shares authorized; no shares issued or outstanding at December 31, 2023 and 2022</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Additional paid-in capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_UnlabeledAbstract0" xlink:href="abio-20240331.xsd#abio_UnlabeledAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_UnlabeledAbstract0_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_UnlabeledAbstract0" xlink:to="abio_UnlabeledAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostsAndExpensesAbstract_lbl" xml:lang="en-US">Costs and expenses:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostsAndExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_ResearchAndDevelopmentExpenseReversed" xlink:href="abio-20240331.xsd#abio_ResearchAndDevelopmentExpenseReversed"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_ResearchAndDevelopmentExpenseReversed_lbl" xml:lang="en-US">Related party expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ResearchAndDevelopmentExpenseReversed" xlink:to="abio_ResearchAndDevelopmentExpenseReversed_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_UnlabeledAbstract1" xlink:href="abio-20240331.xsd#abio_UnlabeledAbstract1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_UnlabeledAbstract1_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_UnlabeledAbstract1" xlink:to="abio_UnlabeledAbstract1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestAndOtherIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestAndOtherIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestAndOtherIncome_lbl" xml:lang="en-US">Interest and other income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestAndOtherIncome" xlink:to="us-gaap_InterestAndOtherIncome_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_UnlabeledAbstract2" xlink:href="abio-20240331.xsd#abio_UnlabeledAbstract2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_UnlabeledAbstract2_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_UnlabeledAbstract2" xlink:to="abio_UnlabeledAbstract2_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Basic (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_WeightedAverageSharesOutstandingAbstract" xlink:href="abio-20240331.xsd#abio_WeightedAverageSharesOutstandingAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_WeightedAverageSharesOutstandingAbstract_lbl" xml:lang="en-US">Weighted average shares outstanding:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_WeightedAverageSharesOutstandingAbstract" xlink:to="abio_WeightedAverageSharesOutstandingAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Basic (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_CostsAndExpensesAbstract0" xlink:href="abio-20240331.xsd#abio_CostsAndExpensesAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_CostsAndExpensesAbstract0_lbl" xml:lang="en-US">Costs and expenses:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_CostsAndExpensesAbstract0" xlink:to="abio_CostsAndExpensesAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_UnlabeledAbstract3" xlink:href="abio-20240331.xsd#abio_UnlabeledAbstract3"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_UnlabeledAbstract3_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_UnlabeledAbstract3" xlink:to="abio_UnlabeledAbstract3_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_UnlabeledAbstract4" xlink:href="abio-20240331.xsd#abio_UnlabeledAbstract4"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_UnlabeledAbstract4_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_UnlabeledAbstract4" xlink:to="abio_UnlabeledAbstract4_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Share-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xml:lang="en-US">Issuance of common stock upon vesting of Restricted Stock Units</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xml:lang="en-US">Issuance of common stock upon vesting of Restricted Stock Units (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xml:lang="en-US">Depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DepreciationAndAmortization_lbl0" xml:lang="en-US">Depreciation and amortization expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xml:lang="en-US">Amortization of right-of-use asset &#8211; operating</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Change in operating assets and liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl" xml:lang="en-US">Accrued compensation and employee benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xml:lang="en-US">Accrued expenses and other liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from investing activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from financing activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental cash flow information:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIncomeTaxRefunds" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIncomeTaxRefunds"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIncomeTaxRefunds_lbl" xml:lang="en-US">Income tax refund received</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIncomeTaxRefunds" xlink:to="us-gaap_ProceedsFromIncomeTaxRefunds_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US">Supplemental disclosure of noncash investing and financing transactions:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US">Leased assets and operating lease liabilities &#8211; amended lease term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherNonoperatingExpense_lbl" xml:lang="en-US">Other loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingExpense" xlink:to="us-gaap_OtherNonoperatingExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xml:lang="en-US">Loss from disposal of property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl" xml:lang="en-US">Other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xml:lang="en-US">Other assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchase of property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Interest paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyMember_lbl" xml:lang="en-US">Related Party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyMember" xlink:to="us-gaap_RelatedPartyMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-In Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated Deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">ARCA and Summary of Significant Accounting Policies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">Net Loss Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">Schedule of Potentially Dilutive Shares of Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_PotentiallyDilutiveSecuritiesExcludedAbstract" xlink:href="abio-20240331.xsd#abio_PotentiallyDilutiveSecuritiesExcludedAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_PotentiallyDilutiveSecuritiesExcludedAbstract_lbl" xml:lang="en-US">Potentially dilutive securities, excluded:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_PotentiallyDilutiveSecuritiesExcludedAbstract" xlink:to="abio_PotentiallyDilutiveSecuritiesExcludedAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Potentially dilutive securities, excluded</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US">Fair Value Disclosures</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">Property and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Schedule of Property and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Property and Equipment, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Estimated Life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">Related Party Arrangements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Schedule of Future Minimum Commitments Due</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">2024</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">2025</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">2026</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US">2027</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Equity Financings</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">Share-based Compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of Estimated Weighted Average Grant Date Fair Value Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Expected volatility</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk-free interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Expected dividend yield</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted-average grant date fair value per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Stock Option Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Number of Options, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Number of Options, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Forfeited and cancelled</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Term (in years) Options outstanding, ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Number of Options, Options exercisable, ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Options exercisable, ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Term (in years), Options exercisable, ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Options exercisable, ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US">Number of Options, Options vested and expected to vest, ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Options vested and expected to vest, ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Term (in years), Options vested and expected to vest, ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Options vested and expected to vest, ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of RSU Activity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Number of Shares, RSUs outstanding, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Grant Date Date Fair Value, RSUs outstanding, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Grant Date Date Fair Value, RSUs outstanding, Vested and released</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US">Number of Shares, RSUs outstanding, Forfeited and cancelled</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Grant Date Date Fair Value, RSUs outstanding, Forfeited and cancelled</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US">Schedule of Non-cash, Share-based Compensation Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Total expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xml:lang="en-US">Employee Benefit Plans</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of Income Tax Benefit Attributable to Our Loss from Operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">U.S. federal income tax benefit at statutory rates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">State income tax benefit, net of federal benefit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_IncomeTaxReconciliationAdjustmentToDeferredTaxAsset" xlink:href="abio-20240331.xsd#abio_IncomeTaxReconciliationAdjustmentToDeferredTaxAsset"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_IncomeTaxReconciliationAdjustmentToDeferredTaxAsset_lbl" xml:lang="en-US">Deferred tax asset adjustment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_IncomeTaxReconciliationAdjustmentToDeferredTaxAsset" xlink:to="abio_IncomeTaxReconciliationAdjustmentToDeferredTaxAsset_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xml:lang="en-US">Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Change in valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income tax benefit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Net deferred tax assets and liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_DeferredTaxAssetsAbstract" xlink:href="abio-20240331.xsd#abio_DeferredTaxAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_DeferredTaxAssetsAbstract_lbl" xml:lang="en-US">Deferred tax assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_DeferredTaxAssetsAbstract" xlink:to="abio_DeferredTaxAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_lbl" xml:lang="en-US">Net operating loss carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards_lbl" xml:lang="en-US">Charitable contribution carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US">Research and experimentation credits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_DeferredTaxAssetResearchAndDevelopment" xlink:href="abio-20240331.xsd#abio_DeferredTaxAssetResearchAndDevelopment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_DeferredTaxAssetResearchAndDevelopment_lbl" xml:lang="en-US">Capitalized research and development costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_DeferredTaxAssetResearchAndDevelopment" xlink:to="abio_DeferredTaxAssetResearchAndDevelopment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xml:lang="en-US">Capitalized intangibles</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US">Stock-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_lbl" xml:lang="en-US">Accrued compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_DeferredTaxAssetsLeaseLiabilities" xlink:href="abio-20240331.xsd#abio_DeferredTaxAssetsLeaseLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_DeferredTaxAssetsLeaseLiabilities_lbl" xml:lang="en-US">Lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_DeferredTaxAssetsLeaseLiabilities" xlink:to="abio_DeferredTaxAssetsLeaseLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Deferred tax assets, net of valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xml:lang="en-US">Deferred tax liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US">Net deferred tax liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_PotentiallyDilutiveSecuritiesExcludedAbstract0" xlink:href="abio-20240331.xsd#abio_PotentiallyDilutiveSecuritiesExcludedAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_PotentiallyDilutiveSecuritiesExcludedAbstract0_lbl" xml:lang="en-US">Potentially dilutive securities, excluded:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_PotentiallyDilutiveSecuritiesExcludedAbstract0" xlink:to="abio_PotentiallyDilutiveSecuritiesExcludedAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xml:lang="en-US">2024</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Accumulated depreciation and amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Less: imputed lease interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Less: Current portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xml:lang="en-US">Number of Options, Forfeited and cancelled</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US">Number of Shares, RSUs outstanding, Vested and released</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl" xml:lang="en-US">Research and experimentation credits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_DeferredTaxLiabilitiesRightOfUseAsset" xlink:href="abio-20240331.xsd#abio_DeferredTaxLiabilitiesRightOfUseAsset"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="abio_DeferredTaxLiabilitiesRightOfUseAsset_lbl" xml:lang="en-US">Right-of-use asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_DeferredTaxLiabilitiesRightOfUseAsset" xlink:to="abio_DeferredTaxLiabilitiesRightOfUseAsset_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xml:lang="en-US">Depreciation and amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US">Outstanding stock options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US">Unvested restricted stock units</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl0" xml:lang="en-US">Restricted Stock Units</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xml:lang="en-US">Computer equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ComputerEquipmentMember_lbl0" xml:lang="en-US">Computer Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquipmentMember_lbl" xml:lang="en-US">Lab equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EquipmentMember_lbl0" xml:lang="en-US">Lab Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US">Furniture and fixtures</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl0" xml:lang="en-US">Furniture and Fixtures</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_lbl" xml:lang="en-US">Computer software</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:to="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_lbl0" xml:lang="en-US">Computer Software</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:to="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General and Administrative</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl0" xml:lang="en-US">General and Administrative Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and Development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl0" xml:lang="en-US">Research and development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xml:lang="en-US">Asset Class [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xml:lang="en-US">Measurement Frequency [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestructuringCostAndReserveAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringCostAndReserveAxis_lbl" xml:lang="en-US">Restructuring Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_RestructuringCostAndReserveAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CounterpartyNameAxis_lbl" xml:lang="en-US">Counterparty Name [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetirementPlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanNameAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetirementPlanNameAxis_lbl" xml:lang="en-US">Retirement Plan Name [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetirementPlanNameAxis" xlink:to="us-gaap_RetirementPlanNameAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xml:lang="en-US">Tax Credit Carryforward [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxPeriodAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxPeriodAxis_lbl" xml:lang="en-US">Tax Period [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_OwnershipAxis_lbl" xml:lang="en-US">Ownership [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title and Position [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosureOffbalanceSheetRisksAmountAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosureOffbalanceSheetRisksAmountAsset"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueDisclosureOffbalanceSheetRisksAmountAsset_lbl" xml:lang="en-US">Off-balance-sheet concentrations of credit risk</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosureOffbalanceSheetRisksAmountAsset" xlink:to="us-gaap_FairValueDisclosureOffbalanceSheetRisksAmountAsset_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US">Number of segment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xml:lang="en-US">Cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_FairValueAssetsBetweenHierarchyLevelsTransfersAmount" xlink:href="abio-20240331.xsd#abio_FairValueAssetsBetweenHierarchyLevelsTransfersAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_FairValueAssetsBetweenHierarchyLevelsTransfersAmount_lbl" xml:lang="en-US">Fair value hierarchy</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_FairValueAssetsBetweenHierarchyLevelsTransfersAmount" xlink:to="abio_FairValueAssetsBetweenHierarchyLevelsTransfersAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtLongtermAndShorttermCombinedAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtLongtermAndShorttermCombinedAmount_lbl" xml:lang="en-US">Debt outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:to="us-gaap_DebtLongtermAndShorttermCombinedAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xml:lang="en-US">Marketable securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_PaymentOfUnrestrictedResearchGrants" xlink:href="abio-20240331.xsd#abio_PaymentOfUnrestrictedResearchGrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_PaymentOfUnrestrictedResearchGrants_lbl" xml:lang="en-US">Payment of unrestricted research grants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_PaymentOfUnrestrictedResearchGrants" xlink:to="abio_PaymentOfUnrestrictedResearchGrants_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_RetentionBonuses" xlink:href="abio-20240331.xsd#abio_RetentionBonuses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_RetentionBonuses_lbl" xml:lang="en-US">Amount of retention bonuses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_RetentionBonuses" xlink:to="abio_RetentionBonuses_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="abio_RetentionBonuses_lbl0" xml:lang="en-US">Retention bonuses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_RetentionBonuses" xlink:to="abio_RetentionBonuses_lbl0"/>
    <loc xlink:type="locator" xlink:label="abio_PercentageOfRetentionBonuses" xlink:href="abio-20240331.xsd#abio_PercentageOfRetentionBonuses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_PercentageOfRetentionBonuses_lbl" xml:lang="en-US">Percentage of retention bonuses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_PercentageOfRetentionBonuses" xlink:to="abio_PercentageOfRetentionBonuses_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_RetentionBonusPaid" xlink:href="abio-20240331.xsd#abio_RetentionBonusPaid"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_RetentionBonusPaid_lbl" xml:lang="en-US">Retention bonus paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_RetentionBonusPaid" xlink:to="abio_RetentionBonusPaid_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeveranceCosts1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeveranceCosts1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SeveranceCosts1_lbl" xml:lang="en-US">Severance expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeveranceCosts1" xlink:to="us-gaap_SeveranceCosts1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestructuringReserveCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserveCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestructuringReserveCurrent_lbl" xml:lang="en-US">Remains unpaid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringReserveCurrent" xlink:to="us-gaap_RestructuringReserveCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_lbl" xml:lang="en-US">Workforce reduction percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_lbl" xml:lang="en-US">Number of employees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestructuringCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestructuringCharges_lbl" xml:lang="en-US">Restructuring charges</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCharges" xlink:to="us-gaap_RestructuringCharges_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AreaOfRealEstateProperty" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AreaOfRealEstateProperty_lbl" xml:lang="en-US">Square feet (in Square Feet)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AreaOfRealEstateProperty" xlink:to="us-gaap_AreaOfRealEstateProperty_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xml:lang="en-US">Lease term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xml:lang="en-US">Lease renewal option</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xml:lang="en-US">Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_AreaOfRealEstatePropertySubleaseAdditionalOfficeFacilities" xlink:href="abio-20240331.xsd#abio_AreaOfRealEstatePropertySubleaseAdditionalOfficeFacilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_AreaOfRealEstatePropertySubleaseAdditionalOfficeFacilities_lbl" xml:lang="en-US">Square feet office facilities (in Square Feet)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_AreaOfRealEstatePropertySubleaseAdditionalOfficeFacilities" xlink:to="abio_AreaOfRealEstatePropertySubleaseAdditionalOfficeFacilities_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_LesseeOperatingSubleaseTermOfContract" xlink:href="abio-20240331.xsd#abio_LesseeOperatingSubleaseTermOfContract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_LesseeOperatingSubleaseTermOfContract_lbl" xml:lang="en-US">Sublease term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_LesseeOperatingSubleaseTermOfContract" xlink:to="abio_LesseeOperatingSubleaseTermOfContract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseAssumptionsAndJudgmentsAllocationOfLeaseAndNonleaseComponent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseAssumptionsAndJudgmentsAllocationOfLeaseAndNonleaseComponent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseAssumptionsAndJudgmentsAllocationOfLeaseAndNonleaseComponent_lbl" xml:lang="en-US">Lessee operating lease description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseAssumptionsAndJudgmentsAllocationOfLeaseAndNonleaseComponent" xlink:to="us-gaap_LesseeOperatingLeaseAssumptionsAndJudgmentsAllocationOfLeaseAndNonleaseComponent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US">Rent expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Lease liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Operating leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Weighted-average discount rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_PotentialUpfrontAndMilestoneObligationsAndRoyaltyObligations" xlink:href="abio-20240331.xsd#abio_PotentialUpfrontAndMilestoneObligationsAndRoyaltyObligations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_PotentialUpfrontAndMilestoneObligationsAndRoyaltyObligations_lbl" xml:lang="en-US">Royalty obligations (in Euro)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_PotentialUpfrontAndMilestoneObligationsAndRoyaltyObligations" xlink:to="abio_PotentialUpfrontAndMilestoneObligationsAndRoyaltyObligations_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Weighted-average remaining lease term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xml:lang="en-US">Indicates (true false) whether lessee has option to extend operating lease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_OperatingLeasesExtendedExpiryYearsAndMonth" xlink:href="abio-20240331.xsd#abio_OperatingLeasesExtendedExpiryYearsAndMonth"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_OperatingLeasesExtendedExpiryYearsAndMonth_lbl" xml:lang="en-US">Additional operating lease term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_OperatingLeasesExtendedExpiryYearsAndMonth" xlink:to="abio_OperatingLeasesExtendedExpiryYearsAndMonth_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_PercentageOfBaseRentToBePaidMonthly" xlink:href="abio-20240331.xsd#abio_PercentageOfBaseRentToBePaidMonthly"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_PercentageOfBaseRentToBePaidMonthly_lbl" xml:lang="en-US">Percentage Of Base Rent To Be Paid Monthly</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_PercentageOfBaseRentToBePaidMonthly" xlink:to="abio_PercentageOfBaseRentToBePaidMonthly_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_CommonStockAuthorizedOfferingAmountUnderAgreementToSell" xlink:href="abio-20240331.xsd#abio_CommonStockAuthorizedOfferingAmountUnderAgreementToSell"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_CommonStockAuthorizedOfferingAmountUnderAgreementToSell_lbl" xml:lang="en-US">Aggregate offering price (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_CommonStockAuthorizedOfferingAmountUnderAgreementToSell" xlink:to="abio_CommonStockAuthorizedOfferingAmountUnderAgreementToSell_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_SellingCommissionPerAdditionalSharesSoldPercentage" xlink:href="abio-20240331.xsd#abio_SellingCommissionPerAdditionalSharesSoldPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_SellingCommissionPerAdditionalSharesSoldPercentage_lbl" xml:lang="en-US">Percentage of commission rate equal</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_SellingCommissionPerAdditionalSharesSoldPercentage" xlink:to="abio_SellingCommissionPerAdditionalSharesSoldPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Sale of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US">Number of shares issuable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Reserved shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US">Stock options award, vesting period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US">Stock options award, expiration</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xml:lang="en-US">Percentage of exercise price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_PercentageHoldingForStockOptionsExercisePrice" xlink:href="abio-20240331.xsd#abio_PercentageHoldingForStockOptionsExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_PercentageHoldingForStockOptionsExercisePrice_lbl" xml:lang="en-US">Exercise price per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_PercentageHoldingForStockOptionsExercisePrice" xlink:to="abio_PercentageHoldingForStockOptionsExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xml:lang="en-US">Options granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_PurchaseAggregateShares" xlink:href="abio-20240331.xsd#abio_PurchaseAggregateShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_PurchaseAggregateShares_lbl" xml:lang="en-US">Purchase aggregate shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_PurchaseAggregateShares" xlink:to="abio_PurchaseAggregateShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US">Unrecognized compensation expense (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Weighted average period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl" xml:lang="en-US">Stock awards granted service period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xml:lang="en-US">Unrecognized compensation cost (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans_lbl" xml:lang="en-US">Matching contribution</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans" xlink:to="us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xml:lang="en-US">Employee&#8217;s contribution percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl" xml:lang="en-US">Equal contribution percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanCostRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_lbl" xml:lang="en-US">Company&apos;s contribution (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanCostRecognized" xlink:to="us-gaap_DefinedContributionPlanCostRecognized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xml:lang="en-US">Research and experimentation credits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_OperatingLossCarryforwardsExpirationYear" xlink:href="abio-20240331.xsd#abio_OperatingLossCarryforwardsExpirationYear"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_OperatingLossCarryforwardsExpirationYear_lbl" xml:lang="en-US">Operating loss carryforwards expiration year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_OperatingLossCarryforwardsExpirationYear" xlink:to="abio_OperatingLossCarryforwardsExpirationYear_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TaxCreditCarryforwardDescription_lbl" xml:lang="en-US">Operating loss carryforwards, limitations on use</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardDescription" xlink:to="us-gaap_TaxCreditCarryforwardDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardLimitationsOnUse" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardLimitationsOnUse"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TaxCreditCarryforwardLimitationsOnUse_lbl" xml:lang="en-US">Tax credit carryforward, limitations on use</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardLimitationsOnUse" xlink:to="us-gaap_TaxCreditCarryforwardLimitationsOnUse_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_DeferredTaxAssetsAndLiabilitiesValuationAllowance" xlink:href="abio-20240331.xsd#abio_DeferredTaxAssetsAndLiabilitiesValuationAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_DeferredTaxAssetsAndLiabilitiesValuationAllowance_lbl" xml:lang="en-US">Valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_DeferredTaxAssetsAndLiabilitiesValuationAllowance" xlink:to="abio_DeferredTaxAssetsAndLiabilitiesValuationAllowance_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_ValuationAllowanceDeferredTaxAssetsAndLiabilitiesChangeInAmount" xlink:href="abio-20240331.xsd#abio_ValuationAllowanceDeferredTaxAssetsAndLiabilitiesChangeInAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_ValuationAllowanceDeferredTaxAssetsAndLiabilitiesChangeInAmount_lbl" xml:lang="en-US">Increase in net deferred tax assets and liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ValuationAllowanceDeferredTaxAssetsAndLiabilitiesChangeInAmount" xlink:to="abio_ValuationAllowanceDeferredTaxAssetsAndLiabilitiesChangeInAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Federal statutory income tax rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OpenTaxYear" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OpenTaxYear"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OpenTaxYear_lbl" xml:lang="en-US">Open Tax Year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OpenTaxYear" xlink:to="us-gaap_OpenTaxYear_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilityForUncertainTaxPositionsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilityForUncertainTaxPositionsCurrent_lbl" xml:lang="en-US">Reserve for uncertain tax positions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:to="us-gaap_LiabilityForUncertainTaxPositionsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_lbl" xml:lang="en-US">Interest or penalties recognized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_NumberOfConsecutiveTradingDays" xlink:href="abio-20240331.xsd#abio_NumberOfConsecutiveTradingDays"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_NumberOfConsecutiveTradingDays_lbl" xml:lang="en-US">Number of consecutive trading days</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_NumberOfConsecutiveTradingDays" xlink:to="abio_NumberOfConsecutiveTradingDays_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl" xml:lang="en-US">Percentage of ownership interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_lbl" xml:lang="en-US">Percentage of noncontrolling ownership interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_ThresholdAmountOfAdjustedExchangeRatio" xlink:href="abio-20240331.xsd#abio_ThresholdAmountOfAdjustedExchangeRatio"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_ThresholdAmountOfAdjustedExchangeRatio_lbl" xml:lang="en-US">Adjusted exchange ratio</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ThresholdAmountOfAdjustedExchangeRatio" xlink:to="abio_ThresholdAmountOfAdjustedExchangeRatio_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_ThresholdAmountOfDeclaredCashDividend" xlink:href="abio-20240331.xsd#abio_ThresholdAmountOfDeclaredCashDividend"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_ThresholdAmountOfDeclaredCashDividend_lbl" xml:lang="en-US">Declared cash dividend</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ThresholdAmountOfDeclaredCashDividend" xlink:to="abio_ThresholdAmountOfDeclaredCashDividend_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_SubscriptionAgreementReceiptAmount" xlink:href="abio-20240331.xsd#abio_SubscriptionAgreementReceiptAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_SubscriptionAgreementReceiptAmount_lbl" xml:lang="en-US">Subscription agreement receipt amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_SubscriptionAgreementReceiptAmount" xlink:to="abio_SubscriptionAgreementReceiptAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_PaymentOfOtherPartyTerminationFee" xlink:href="abio-20240331.xsd#abio_PaymentOfOtherPartyTerminationFee"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_PaymentOfOtherPartyTerminationFee_lbl" xml:lang="en-US">Payment of other party termination fee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_PaymentOfOtherPartyTerminationFee" xlink:to="abio_PaymentOfOtherPartyTerminationFee_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_MinimumPercentageOfOriginallyIssuedShares" xlink:href="abio-20240331.xsd#abio_MinimumPercentageOfOriginallyIssuedShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_MinimumPercentageOfOriginallyIssuedShares_lbl" xml:lang="en-US">Minimum percentage of originally issued outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_MinimumPercentageOfOriginallyIssuedShares" xlink:to="abio_MinimumPercentageOfOriginallyIssuedShares_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_MinimumPercentageOfOriginallyIssuedOutstanding" xlink:href="abio-20240331.xsd#abio_MinimumPercentageOfOriginallyIssuedOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_MinimumPercentageOfOriginallyIssuedOutstanding_lbl" xml:lang="en-US">Minimum percentage of originally issued outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_MinimumPercentageOfOriginallyIssuedOutstanding" xlink:to="abio_MinimumPercentageOfOriginallyIssuedOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockConvertibleSharesIssuable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable_lbl" xml:lang="en-US">Preferred stock convertible shares issuable (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockConvertibleSharesIssuable" xlink:to="us-gaap_PreferredStockConvertibleSharesIssuable_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_InitiallySpecifiedPercentageForBeneficialNumberOfShares" xlink:href="abio-20240331.xsd#abio_InitiallySpecifiedPercentageForBeneficialNumberOfShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_InitiallySpecifiedPercentageForBeneficialNumberOfShares_lbl" xml:lang="en-US">Initially specified percentage for beneficial number of shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_InitiallySpecifiedPercentageForBeneficialNumberOfShares" xlink:to="abio_InitiallySpecifiedPercentageForBeneficialNumberOfShares_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_ExceptedNumberOfBoardMembers" xlink:href="abio-20240331.xsd#abio_ExceptedNumberOfBoardMembers"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_ExceptedNumberOfBoardMembers_lbl" xml:lang="en-US">Excepted number of board members</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ExceptedNumberOfBoardMembers" xlink:to="abio_ExceptedNumberOfBoardMembers_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_AggregatePurchasePrice" xlink:href="abio-20240331.xsd#abio_AggregatePurchasePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_AggregatePurchasePrice_lbl" xml:lang="en-US">Aggregate purchase price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_AggregatePurchasePrice" xlink:to="abio_AggregatePurchasePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_NumberOfMonthsBaseSalary" xlink:href="abio-20240331.xsd#abio_NumberOfMonthsBaseSalary"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_NumberOfMonthsBaseSalary_lbl" xml:lang="en-US">Number of months base salary</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_NumberOfMonthsBaseSalary" xlink:to="abio_NumberOfMonthsBaseSalary_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_CashPayment" xlink:href="abio-20240331.xsd#abio_CashPayment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_CashPayment_lbl" xml:lang="en-US">Cash payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_CashPayment" xlink:to="abio_CashPayment_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_IncreaseOfRetentionBonusToEachExecutive" xlink:href="abio-20240331.xsd#abio_IncreaseOfRetentionBonusToEachExecutive"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_IncreaseOfRetentionBonusToEachExecutive_lbl" xml:lang="en-US">Increase of retention bonus to each executive</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_IncreaseOfRetentionBonusToEachExecutive" xlink:to="abio_IncreaseOfRetentionBonusToEachExecutive_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_DescriptionOfBusinessPolicyTextBlock" xlink:href="abio-20240331.xsd#abio_DescriptionOfBusinessPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_DescriptionOfBusinessPolicyTextBlock_lbl" xml:lang="en-US">Description of Business</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_DescriptionOfBusinessPolicyTextBlock" xlink:to="abio_DescriptionOfBusinessPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_LiquidityAndGoingConcernPolicyTextBlock" xlink:href="abio-20240331.xsd#abio_LiquidityAndGoingConcernPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_LiquidityAndGoingConcernPolicyTextBlock_lbl" xml:lang="en-US">Liquidity and Going Concern</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_LiquidityAndGoingConcernPolicyTextBlock" xlink:to="abio_LiquidityAndGoingConcernPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of Presentation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recent Accounting Pronouncements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Accounting Estimates in the Preparation of Financial Statements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentrations of Credit Risk</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_ComprehensiveLossPolicyPolicyTextBlock" xlink:href="abio-20240331.xsd#abio_ComprehensiveLossPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_ComprehensiveLossPolicyPolicyTextBlock_lbl" xml:lang="en-US">Comprehensive Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ComprehensiveLossPolicyPolicyTextBlock" xlink:to="abio_ComprehensiveLossPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">Leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_AccruedOutsourcingExpensesPolicyTextBlock" xlink:href="abio-20240331.xsd#abio_AccruedOutsourcingExpensesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_AccruedOutsourcingExpensesPolicyTextBlock_lbl" xml:lang="en-US">Accrued Outsourcing Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_AccruedOutsourcingExpensesPolicyTextBlock" xlink:to="abio_AccruedOutsourcingExpensesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Segments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Stock-Based Compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xml:lang="en-US">Money Market Funds [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_MoneyMarketFundsMember_lbl0" xml:lang="en-US">Money Market Funds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl0" xml:lang="en-US">Level 1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US">Fair Value, Recurring [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl0" xml:lang="en-US">Fair Value Measurements, Recurring</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="srt_ChiefExecutiveOfficerMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ChiefExecutiveOfficerMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ChiefExecutiveOfficerMember_lbl" xml:lang="en-US">Chief Executive Officer</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefExecutiveOfficerMember" xlink:to="srt_ChiefExecutiveOfficerMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="srt_ChiefExecutiveOfficerMember_lbl0" xml:lang="en-US">Chief Executive Officer [Member]</label>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrYwqBFvPJwgls7iB/C7qgJlieUnn0NA5OCi94KNojOhCKLtgRf7Lh8PNXaX7qyF9a6SJv7mHT4i4TG0zLkQ0ch6DUlOii5J7LMDGl2/JapjDY9mloXuib5mHVGZ5CeGApH//7xHOalGUmL15AlWw6rbn9qzGZe/F/uh8urYvQsY+tuMobOgKRuTNzsMDAV3cq5ZvgtfzCEQWF5CvK02P2Yf] CSR-->
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefExecutiveOfficerMember" xlink:to="srt_ChiefExecutiveOfficerMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="abio_ClinicalDevelopmentDecisionMember" xlink:href="abio-20240331.xsd#abio_ClinicalDevelopmentDecisionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_ClinicalDevelopmentDecisionMember_lbl" xml:lang="en-US">Clinical Development Decision [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ClinicalDevelopmentDecisionMember" xlink:to="abio_ClinicalDevelopmentDecisionMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="abio_ClinicalDevelopmentDecisionMember_lbl0" xml:lang="en-US">Clinical development decisions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ClinicalDevelopmentDecisionMember" xlink:to="abio_ClinicalDevelopmentDecisionMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OneTimeTerminationBenefitsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OneTimeTerminationBenefitsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OneTimeTerminationBenefitsMember_lbl" xml:lang="en-US">One-time Termination Benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OneTimeTerminationBenefitsMember" xlink:to="us-gaap_OneTimeTerminationBenefitsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_UniversityMedicalCenterOfJohannesGutenbergUniversityMainzMember" xlink:href="abio-20240331.xsd#abio_UniversityMedicalCenterOfJohannesGutenbergUniversityMainzMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_UniversityMedicalCenterOfJohannesGutenbergUniversityMainzMember_lbl" xml:lang="en-US">University Medical Center of Johannes Gutenberg University Mainz</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_UniversityMedicalCenterOfJohannesGutenbergUniversityMainzMember" xlink:to="abio_UniversityMedicalCenterOfJohannesGutenbergUniversityMainzMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="abio_UniversityMedicalCenterOfJohannesGutenbergUniversityMainzMember_lbl0" xml:lang="en-US">University Medical Center Of Johannes Gutenberg University Mainz</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_UniversityMedicalCenterOfJohannesGutenbergUniversityMainzMember" xlink:to="abio_UniversityMedicalCenterOfJohannesGutenbergUniversityMainzMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="abio_PatentAssignmentAgreementMember" xlink:href="abio-20240331.xsd#abio_PatentAssignmentAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_PatentAssignmentAgreementMember_lbl" xml:lang="en-US">Patent Assignment Agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_PatentAssignmentAgreementMember" xlink:to="abio_PatentAssignmentAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SubsequentEventMember_lbl0" xml:lang="en-US">Subsequent Event [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="abio_CapitalOnDemandSalesAgreementMember" xlink:href="abio-20240331.xsd#abio_CapitalOnDemandSalesAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_CapitalOnDemandSalesAgreementMember_lbl" xml:lang="en-US">Sales Agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_CapitalOnDemandSalesAgreementMember" xlink:to="abio_CapitalOnDemandSalesAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_JonesTradingInstitutionalServicesLLCMember" xlink:href="abio-20240331.xsd#abio_JonesTradingInstitutionalServicesLLCMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_JonesTradingInstitutionalServicesLLCMember_lbl" xml:lang="en-US">Jones Trading</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_JonesTradingInstitutionalServicesLLCMember" xlink:to="abio_JonesTradingInstitutionalServicesLLCMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_NewCapitalOnDemandSalesAgreementMember" xlink:href="abio-20240331.xsd#abio_NewCapitalOnDemandSalesAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_NewCapitalOnDemandSalesAgreementMember_lbl" xml:lang="en-US">2020 Sales Agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_NewCapitalOnDemandSalesAgreementMember" xlink:to="abio_NewCapitalOnDemandSalesAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_TwoThousandAndTwentyEquityIncentivePlanMember" xlink:href="abio-20240331.xsd#abio_TwoThousandAndTwentyEquityIncentivePlanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_TwoThousandAndTwentyEquityIncentivePlanMember_lbl" xml:lang="en-US">2020 Equity Incentive Plan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_TwoThousandAndTwentyEquityIncentivePlanMember" xlink:to="abio_TwoThousandAndTwentyEquityIncentivePlanMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="srt_MinimumMember_lbl0" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_IncentiveStockOptionMember" xlink:href="abio-20240331.xsd#abio_IncentiveStockOptionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_IncentiveStockOptionMember_lbl" xml:lang="en-US">Incentive Stock Option</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_IncentiveStockOptionMember" xlink:to="abio_IncentiveStockOptionMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrincipalOwnerMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrincipalOwnerMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrincipalOwnerMember_lbl" xml:lang="en-US">Stockholders</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrincipalOwnerMember" xlink:to="us-gaap_PrincipalOwnerMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_TwoThousandAndThirteenPlanMember" xlink:href="abio-20240331.xsd#abio_TwoThousandAndThirteenPlanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_TwoThousandAndThirteenPlanMember_lbl" xml:lang="en-US">2013 Plan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_TwoThousandAndThirteenPlanMember" xlink:to="abio_TwoThousandAndThirteenPlanMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Employee Stock Option</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_FirstThreePercentPayContributionMember" xlink:href="abio-20240331.xsd#abio_FirstThreePercentPayContributionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_FirstThreePercentPayContributionMember_lbl" xml:lang="en-US">First 3% of pay contributed</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_FirstThreePercentPayContributionMember" xlink:to="abio_FirstThreePercentPayContributionMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_NextTwoPercentPayContributionMember" xlink:href="abio-20240331.xsd#abio_NextTwoPercentPayContributionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_NextTwoPercentPayContributionMember_lbl" xml:lang="en-US">Next 2% of pay contributed</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_NextTwoPercentPayContributionMember" xlink:to="abio_NextTwoPercentPayContributionMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchMember_lbl" xml:lang="en-US">Research Tax Credit Carryforward</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchMember" xlink:to="us-gaap_ResearchMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarliestTaxYearMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarliestTaxYearMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarliestTaxYearMember_lbl" xml:lang="en-US">Earliest Tax Year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarliestTaxYearMember" xlink:to="us-gaap_EarliestTaxYearMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LatestTaxYearMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LatestTaxYearMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LatestTaxYearMember_lbl" xml:lang="en-US">Latest Tax Year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LatestTaxYearMember" xlink:to="us-gaap_LatestTaxYearMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_ArcaBiopharmaIncMember" xlink:href="abio-20240331.xsd#abio_ArcaBiopharmaIncMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_ArcaBiopharmaIncMember_lbl" xml:lang="en-US">ARCA</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ArcaBiopharmaIncMember" xlink:to="abio_ArcaBiopharmaIncMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_ArcaBiopharmaIncAndOrukaTherapeuticsIncMember" xlink:href="abio-20240331.xsd#abio_ArcaBiopharmaIncAndOrukaTherapeuticsIncMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_ArcaBiopharmaIncAndOrukaTherapeuticsIncMember_lbl" xml:lang="en-US">ARCA and Oruka</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ArcaBiopharmaIncAndOrukaTherapeuticsIncMember" xlink:to="abio_ArcaBiopharmaIncAndOrukaTherapeuticsIncMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_MergerAgreementMember" xlink:href="abio-20240331.xsd#abio_MergerAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_MergerAgreementMember_lbl" xml:lang="en-US">Merger Agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_MergerAgreementMember" xlink:to="abio_MergerAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xml:lang="en-US">Series B Preferred Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesBPreferredStockMember" xlink:to="us-gaap_SeriesBPreferredStockMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_FirstMergerMember" xlink:href="abio-20240331.xsd#abio_FirstMergerMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_FirstMergerMember_lbl" xml:lang="en-US">First Merger</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_FirstMergerMember" xlink:to="abio_FirstMergerMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_OrukaTherapeuticsIncMember" xlink:href="abio-20240331.xsd#abio_OrukaTherapeuticsIncMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_OrukaTherapeuticsIncMember_lbl" xml:lang="en-US">Oruka Therapeutics Inc</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_OrukaTherapeuticsIncMember" xlink:to="abio_OrukaTherapeuticsIncMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_CommonStockAndPreFundedWarrantsMember" xlink:href="abio-20240331.xsd#abio_CommonStockAndPreFundedWarrantsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_CommonStockAndPreFundedWarrantsMember_lbl" xml:lang="en-US">Common Stock and Pre Funded Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_CommonStockAndPreFundedWarrantsMember" xlink:to="abio_CommonStockAndPreFundedWarrantsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_SeperationAgreementMember" xlink:href="abio-20240331.xsd#abio_SeperationAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_SeperationAgreementMember_lbl" xml:lang="en-US">Seperation Agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_SeperationAgreementMember" xlink:to="abio_SeperationAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_PresidentMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_PresidentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_PresidentMember_lbl" xml:lang="en-US">Thomas A. Keuer</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_PresidentMember" xlink:to="srt_PresidentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_SecondAmendmentOfCertainRetentionBonusLettersMember" xlink:href="abio-20240331.xsd#abio_SecondAmendmentOfCertainRetentionBonusLettersMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_SecondAmendmentOfCertainRetentionBonusLettersMember_lbl" xml:lang="en-US">Second Amendment of Certain Retention Bonus Letters</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_SecondAmendmentOfCertainRetentionBonusLettersMember" xlink:to="abio_SecondAmendmentOfCertainRetentionBonusLettersMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ChiefFinancialOfficerMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ChiefFinancialOfficerMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ChiefFinancialOfficerMember_lbl" xml:lang="en-US">C. Jeffrey Dekker</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefFinancialOfficerMember" xlink:to="srt_ChiefFinancialOfficerMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_ThomasAKeuerAndCJeffreyDekkerMember" xlink:href="abio-20240331.xsd#abio_ThomasAKeuerAndCJeffreyDekkerMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_ThomasAKeuerAndCJeffreyDekkerMember_lbl" xml:lang="en-US">Thomas A. Keuer and C. Jeffrey Dekker [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ThomasAKeuerAndCJeffreyDekkerMember" xlink:to="abio_ThomasAKeuerAndCJeffreyDekkerMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xml:lang="en-US">Related Party Transaction [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyTransactionDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US">Related and Nonrelated Parties [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US">Antidilutive Securities, Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US">Antidilutive Security, Excluded EPS Calculation [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Schedule of Property and Equipment [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US">Statement of Income Location, Balance [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xml:lang="en-US">Measurement Frequency [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xml:lang="en-US">Asset Class [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_FairValueDisclosuresDetailsTable" xlink:href="abio-20240331.xsd#abio_FairValueDisclosuresDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_FairValueDisclosuresDetailsTable_lbl" xml:lang="en-US">Fair Value Disclosures (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_FairValueDisclosuresDetailsTable" xlink:to="abio_FairValueDisclosuresDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_FairValueDisclosuresDetailsLineItems" xlink:href="abio-20240331.xsd#abio_FairValueDisclosuresDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_FairValueDisclosuresDetailsLineItems_lbl" xml:lang="en-US">Fair Value Disclosures (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_FairValueDisclosuresDetailsLineItems" xlink:to="abio_FairValueDisclosuresDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_RelatedPartyArrangementsDetailsTable" xlink:href="abio-20240331.xsd#abio_RelatedPartyArrangementsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_RelatedPartyArrangementsDetailsTable_lbl" xml:lang="en-US">Related Party Arrangements (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_RelatedPartyArrangementsDetailsTable" xlink:to="abio_RelatedPartyArrangementsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US">Related Party Arrangements [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US">Subsequent Event Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xml:lang="en-US">Counterparty Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfRestructuringDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfRestructuringDomain_lbl" xml:lang="en-US">Type of Restructuring [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="us-gaap_TypeOfRestructuringDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_CommitmentsandContingenciesDetailsTable" xlink:href="abio-20240331.xsd#abio_CommitmentsandContingenciesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_CommitmentsandContingenciesDetailsTable_lbl" xml:lang="en-US">Commitments and Contingencies (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_CommitmentsandContingenciesDetailsTable" xlink:to="abio_CommitmentsandContingenciesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_CommitmentsandContingenciesDetailsLineItems" xlink:href="abio-20240331.xsd#abio_CommitmentsandContingenciesDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_CommitmentsandContingenciesDetailsLineItems_lbl" xml:lang="en-US">Commitments and Contingencies (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_CommitmentsandContingenciesDetailsLineItems" xlink:to="abio_CommitmentsandContingenciesDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityDomain_lbl" xml:lang="en-US">Entity [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_EquityFinancingsDetailsTable" xlink:href="abio-20240331.xsd#abio_EquityFinancingsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_EquityFinancingsDetailsTable_lbl" xml:lang="en-US">Equity Financings (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_EquityFinancingsDetailsTable" xlink:to="abio_EquityFinancingsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_EquityFinancingsDetailsLineItems" xlink:href="abio-20240331.xsd#abio_EquityFinancingsDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_EquityFinancingsDetailsLineItems_lbl" xml:lang="en-US">Equity Financings (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_EquityFinancingsDetailsLineItems" xlink:to="abio_EquityFinancingsDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US">Award Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US">Plan Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US">Statistical Measurement [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_SharebasedCompensationDetailsTable" xlink:href="abio-20240331.xsd#abio_SharebasedCompensationDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_SharebasedCompensationDetailsTable_lbl" xml:lang="en-US">Share-based Compensation (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_SharebasedCompensationDetailsTable" xlink:to="abio_SharebasedCompensationDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_SharebasedCompensationDetailsLineItems" xlink:href="abio-20240331.xsd#abio_SharebasedCompensationDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_SharebasedCompensationDetailsLineItems_lbl" xml:lang="en-US">Share-based Compensation (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_SharebasedCompensationDetailsLineItems" xlink:to="abio_SharebasedCompensationDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetirementPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetirementPlanNameDomain_lbl" xml:lang="en-US">Retirement Plan Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetirementPlanNameDomain" xlink:to="us-gaap_RetirementPlanNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_EmployeeBenefitPlansDetailsTable" xlink:href="abio-20240331.xsd#abio_EmployeeBenefitPlansDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_EmployeeBenefitPlansDetailsTable_lbl" xml:lang="en-US">Employee Benefit Plans (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_EmployeeBenefitPlansDetailsTable" xlink:to="abio_EmployeeBenefitPlansDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_EmployeeBenefitPlansDetailsLineItems" xlink:href="abio-20240331.xsd#abio_EmployeeBenefitPlansDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_EmployeeBenefitPlansDetailsLineItems_lbl" xml:lang="en-US">Employee Benefit Plans (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_EmployeeBenefitPlansDetailsLineItems" xlink:to="abio_EmployeeBenefitPlansDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxPeriodDomain_lbl" xml:lang="en-US">Tax Period [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_TaxPeriodDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_IncomeTaxesDetailsTable" xlink:href="abio-20240331.xsd#abio_IncomeTaxesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_IncomeTaxesDetailsTable_lbl" xml:lang="en-US">Income Taxes (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_IncomeTaxesDetailsTable" xlink:to="abio_IncomeTaxesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_IncomeTaxesDetailsLineItems" xlink:href="abio-20240331.xsd#abio_IncomeTaxesDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_IncomeTaxesDetailsLineItems_lbl" xml:lang="en-US">Income Taxes (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_IncomeTaxesDetailsLineItems" xlink:to="abio_IncomeTaxesDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US">Class of Stock [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US">Title and Position [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_OwnershipDomain_lbl" xml:lang="en-US">Ownership [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OwnershipDomain" xlink:to="srt_OwnershipDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_SubsequentEventsDetailsTable" xlink:href="abio-20240331.xsd#abio_SubsequentEventsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_SubsequentEventsDetailsTable_lbl" xml:lang="en-US">Subsequent Events (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_SubsequentEventsDetailsTable" xlink:to="abio_SubsequentEventsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_SubsequentEventsDetailsLineItems" xlink:href="abio-20240331.xsd#abio_SubsequentEventsDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_SubsequentEventsDetailsLineItems_lbl" xml:lang="en-US">Subsequent Events (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_SubsequentEventsDetailsLineItems" xlink:to="abio_SubsequentEventsDetailsLineItems_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_AccruedOutsourcingExpensesPolicyTextBlock_lbl0" xml:lang="en-US">Accrued outsourcing expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_AccruedOutsourcingExpensesPolicyTextBlock" xlink:to="abio_AccruedOutsourcingExpensesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_AggregatePurchasePrice_lbl0" xml:lang="en-US">Aggregate purchase price.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_AggregatePurchasePrice" xlink:to="abio_AggregatePurchasePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_AreaOfRealEstatePropertySubleaseAdditionalOfficeFacilities_lbl0" xml:lang="en-US">Area of real estate property sublease additional office facilities.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_AreaOfRealEstatePropertySubleaseAdditionalOfficeFacilities" xlink:to="abio_AreaOfRealEstatePropertySubleaseAdditionalOfficeFacilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_CashPayment_lbl0" xml:lang="en-US">Cash payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_CashPayment" xlink:to="abio_CashPayment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_CommonStockAuthorizedOfferingAmountUnderAgreementToSell_lbl0" xml:lang="en-US">Common stock, authorized offering amount under agreement to sell.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_CommonStockAuthorizedOfferingAmountUnderAgreementToSell" xlink:to="abio_CommonStockAuthorizedOfferingAmountUnderAgreementToSell_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_ComprehensiveLossPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Comprehensive loss policy.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ComprehensiveLossPolicyPolicyTextBlock" xlink:to="abio_ComprehensiveLossPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_DeferredTaxAssetResearchAndDevelopment_lbl0" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from research and development costs.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_DeferredTaxAssetResearchAndDevelopment" xlink:to="abio_DeferredTaxAssetResearchAndDevelopment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_DeferredTaxAssetsAndLiabilitiesValuationAllowance_lbl0" xml:lang="en-US">Deferred tax assets and liabilities valuation allowance.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_DeferredTaxAssetsAndLiabilitiesValuationAllowance" xlink:to="abio_DeferredTaxAssetsAndLiabilitiesValuationAllowance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_DeferredTaxAssetsLeaseLiabilities_lbl0" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from lease liabilities.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_DeferredTaxAssetsLeaseLiabilities" xlink:to="abio_DeferredTaxAssetsLeaseLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_DeferredTaxLiabilitiesRightOfUseAsset_lbl0" xml:lang="en-US">Amount of deferred tax liability attributable to taxable temporary differences from right of use assets.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_DeferredTaxLiabilitiesRightOfUseAsset" xlink:to="abio_DeferredTaxLiabilitiesRightOfUseAsset_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_DescriptionOfBusinessPolicyTextBlock_lbl0" xml:lang="en-US">Description of business.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_DescriptionOfBusinessPolicyTextBlock" xlink:to="abio_DescriptionOfBusinessPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_ExceptedNumberOfBoardMembers_lbl0" xml:lang="en-US">Excepted Number of Board Members</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ExceptedNumberOfBoardMembers" xlink:to="abio_ExceptedNumberOfBoardMembers_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_FairValueAssetsBetweenHierarchyLevelsTransfersAmount_lbl0" xml:lang="en-US">Fair value assets between hierarchy levels transfers amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_FairValueAssetsBetweenHierarchyLevelsTransfersAmount" xlink:to="abio_FairValueAssetsBetweenHierarchyLevelsTransfersAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_IncomeTaxReconciliationAdjustmentToDeferredTaxAsset_lbl0" xml:lang="en-US">Adjustment of the carrying value of deferred tax assets during the year.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_IncomeTaxReconciliationAdjustmentToDeferredTaxAsset" xlink:to="abio_IncomeTaxReconciliationAdjustmentToDeferredTaxAsset_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_IncreaseOfRetentionBonusToEachExecutive_lbl0" xml:lang="en-US">Increase of retention bonus to each executive.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_IncreaseOfRetentionBonusToEachExecutive" xlink:to="abio_IncreaseOfRetentionBonusToEachExecutive_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_InitiallySpecifiedPercentageForBeneficialNumberOfShares_lbl0" xml:lang="en-US">Initially specified percentage for beneficial number of shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_InitiallySpecifiedPercentageForBeneficialNumberOfShares" xlink:to="abio_InitiallySpecifiedPercentageForBeneficialNumberOfShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_LesseeOperatingSubleaseTermOfContract_lbl0" xml:lang="en-US">Lessee operating sublease term of contract.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_LesseeOperatingSubleaseTermOfContract" xlink:to="abio_LesseeOperatingSubleaseTermOfContract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_LiquidityAndGoingConcernPolicyTextBlock_lbl0" xml:lang="en-US">Liquidity and going concern.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_LiquidityAndGoingConcernPolicyTextBlock" xlink:to="abio_LiquidityAndGoingConcernPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_MinimumPercentageOfOriginallyIssuedOutstanding_lbl0" xml:lang="en-US">Minimum percentage of originally issued outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_MinimumPercentageOfOriginallyIssuedOutstanding" xlink:to="abio_MinimumPercentageOfOriginallyIssuedOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_MinimumPercentageOfOriginallyIssuedShares_lbl0" xml:lang="en-US">Minimum percentage of originally issued shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_MinimumPercentageOfOriginallyIssuedShares" xlink:to="abio_MinimumPercentageOfOriginallyIssuedShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_NumberOfConsecutiveTradingDays_lbl0" xml:lang="en-US">Number of consecutive trading days.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_NumberOfConsecutiveTradingDays" xlink:to="abio_NumberOfConsecutiveTradingDays_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_NumberOfMonthsBaseSalary_lbl0" xml:lang="en-US">Number of months base salary</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_NumberOfMonthsBaseSalary" xlink:to="abio_NumberOfMonthsBaseSalary_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_OperatingLossCarryforwardsExpirationYear_lbl0" xml:lang="en-US">Operating loss carryforwards expiration year.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_OperatingLossCarryforwardsExpirationYear" xlink:to="abio_OperatingLossCarryforwardsExpirationYear_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_PaymentOfOtherPartyTerminationFee_lbl0" xml:lang="en-US">Payment of other party termination fee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_PaymentOfOtherPartyTerminationFee" xlink:to="abio_PaymentOfOtherPartyTerminationFee_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_PaymentOfUnrestrictedResearchGrants_lbl0" xml:lang="en-US">Payment of unrestricted research grants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_PaymentOfUnrestrictedResearchGrants" xlink:to="abio_PaymentOfUnrestrictedResearchGrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_PercentageHoldingForStockOptionsExercisePrice_lbl0" xml:lang="en-US">Minimum ownership percentage for 110% fair market value on the grant date.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_PercentageHoldingForStockOptionsExercisePrice" xlink:to="abio_PercentageHoldingForStockOptionsExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_PercentageOfBaseRentToBePaidMonthly_lbl0" xml:lang="en-US">Percentage of base rent to be paid monthly.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_PercentageOfBaseRentToBePaidMonthly" xlink:to="abio_PercentageOfBaseRentToBePaidMonthly_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_PercentageOfRetentionBonuses_lbl0" xml:lang="en-US">Percentage of retention bonuses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_PercentageOfRetentionBonuses" xlink:to="abio_PercentageOfRetentionBonuses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_PotentialUpfrontAndMilestoneObligationsAndRoyaltyObligations_lbl0" xml:lang="en-US">Potential upfront and milestone obligations and royalty obligations.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_PotentialUpfrontAndMilestoneObligationsAndRoyaltyObligations" xlink:to="abio_PotentialUpfrontAndMilestoneObligationsAndRoyaltyObligations_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_PurchaseAggregateShares_lbl0" xml:lang="en-US">Purchase aggregate shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_PurchaseAggregateShares" xlink:to="abio_PurchaseAggregateShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_ResearchAndDevelopmentExpenseReversed_lbl0" xml:lang="en-US">Research and development expense (reversed).</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ResearchAndDevelopmentExpenseReversed" xlink:to="abio_ResearchAndDevelopmentExpenseReversed_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_RetentionBonusPaid_lbl0" xml:lang="en-US">Retention bonus paid.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_RetentionBonusPaid" xlink:to="abio_RetentionBonusPaid_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_RetentionBonuses_lbl1" xml:lang="en-US">Retention bonuses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_RetentionBonuses" xlink:to="abio_RetentionBonuses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_SellingCommissionPerAdditionalSharesSoldPercentage_lbl0" xml:lang="en-US">Selling commission per additional shares sold percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_SellingCommissionPerAdditionalSharesSoldPercentage" xlink:to="abio_SellingCommissionPerAdditionalSharesSoldPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_SubscriptionAgreementReceiptAmount_lbl0" xml:lang="en-US">Subscription agreement receipt amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_SubscriptionAgreementReceiptAmount" xlink:to="abio_SubscriptionAgreementReceiptAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_ThresholdAmountOfAdjustedExchangeRatio_lbl0" xml:lang="en-US">Threshold amount of adjusted exchange ratio.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ThresholdAmountOfAdjustedExchangeRatio" xlink:to="abio_ThresholdAmountOfAdjustedExchangeRatio_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_ThresholdAmountOfDeclaredCashDividend_lbl0" xml:lang="en-US">Threshold amount of declared cash dividend.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ThresholdAmountOfDeclaredCashDividend" xlink:to="abio_ThresholdAmountOfDeclaredCashDividend_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_ValuationAllowanceDeferredTaxAssetsAndLiabilitiesChangeInAmount_lbl0" xml:lang="en-US">Valuation allowance deferred tax assets and liabilities change in amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ValuationAllowanceDeferredTaxAssetsAndLiabilitiesChangeInAmount" xlink:to="abio_ValuationAllowanceDeferredTaxAssetsAndLiabilitiesChangeInAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_ArcaBiopharmaIncAndOrukaTherapeuticsIncMember_lbl0" xml:lang="en-US">Arca Biopharma Inc and Oruka Therapeutics Inc</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ArcaBiopharmaIncAndOrukaTherapeuticsIncMember" xlink:to="abio_ArcaBiopharmaIncAndOrukaTherapeuticsIncMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_ArcaBiopharmaIncMember_lbl0" xml:lang="en-US">ARCA biopharma inc member.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ArcaBiopharmaIncMember" xlink:to="abio_ArcaBiopharmaIncMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_CapitalOnDemandSalesAgreementMember_lbl0" xml:lang="en-US">Capital on demand sales agreement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_CapitalOnDemandSalesAgreementMember" xlink:to="abio_CapitalOnDemandSalesAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_ClinicalDevelopmentDecisionMember_lbl1" xml:lang="en-US">Clinical Development Decision Member.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ClinicalDevelopmentDecisionMember" xlink:to="abio_ClinicalDevelopmentDecisionMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_CommonStockAndPreFundedWarrantsMember_lbl0" xml:lang="en-US">Common stock and pre funded warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_CommonStockAndPreFundedWarrantsMember" xlink:to="abio_CommonStockAndPreFundedWarrantsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_FirstMergerMember_lbl0" xml:lang="en-US">First Merge</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_FirstMergerMember" xlink:to="abio_FirstMergerMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_FirstThreePercentPayContributionMember_lbl0" xml:lang="en-US">First three percent pay contribution.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_FirstThreePercentPayContributionMember" xlink:to="abio_FirstThreePercentPayContributionMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_IncentiveStockOptionMember_lbl0" xml:lang="en-US">Incentive stock option.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_IncentiveStockOptionMember" xlink:to="abio_IncentiveStockOptionMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_JonesTradingInstitutionalServicesLLCMember_lbl0" xml:lang="en-US">JonesTrading Institutional Services LLC.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_JonesTradingInstitutionalServicesLLCMember" xlink:to="abio_JonesTradingInstitutionalServicesLLCMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_MergerAgreementMember_lbl0" xml:lang="en-US">Merger agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_MergerAgreementMember" xlink:to="abio_MergerAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_NewCapitalOnDemandSalesAgreementMember_lbl0" xml:lang="en-US">New Capital on Demand Sales Agreement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_NewCapitalOnDemandSalesAgreementMember" xlink:to="abio_NewCapitalOnDemandSalesAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_NextTwoPercentPayContributionMember_lbl0" xml:lang="en-US">Next two percent pay contribution.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_NextTwoPercentPayContributionMember" xlink:to="abio_NextTwoPercentPayContributionMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_OrukaTherapeuticsIncMember_lbl0" xml:lang="en-US">Oruka therapeutics inc member.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_OrukaTherapeuticsIncMember" xlink:to="abio_OrukaTherapeuticsIncMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_PatentAssignmentAgreementMember_lbl0" xml:lang="en-US">Patent assignment agreement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_PatentAssignmentAgreementMember" xlink:to="abio_PatentAssignmentAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_SecondAmendmentOfCertainRetentionBonusLettersMember_lbl0" xml:lang="en-US">Second amendment of certain retention bonus letters.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_SecondAmendmentOfCertainRetentionBonusLettersMember" xlink:to="abio_SecondAmendmentOfCertainRetentionBonusLettersMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_SeperationAgreementMember_lbl0" xml:lang="en-US">Seperation agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_SeperationAgreementMember" xlink:to="abio_SeperationAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_ThomasAKeuerAndCJeffreyDekkerMember_lbl0" xml:lang="en-US">Thomas A. Keuer and C. Jeffrey Dekker.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ThomasAKeuerAndCJeffreyDekkerMember" xlink:to="abio_ThomasAKeuerAndCJeffreyDekkerMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_TwoThousandAndThirteenPlanMember_lbl0" xml:lang="en-US">Two thousand and thirteen plan.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_TwoThousandAndThirteenPlanMember" xlink:to="abio_TwoThousandAndThirteenPlanMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_TwoThousandAndTwentyEquityIncentivePlanMember_lbl0" xml:lang="en-US">Two thousand and twenty equity incentive plan.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_TwoThousandAndTwentyEquityIncentivePlanMember" xlink:to="abio_TwoThousandAndTwentyEquityIncentivePlanMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_UniversityMedicalCenterOfJohannesGutenbergUniversityMainzMember_lbl1" xml:lang="en-US">University medical center of Johannes Gutenberg university Mainz.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_UniversityMedicalCenterOfJohannesGutenbergUniversityMainzMember" xlink:to="abio_UniversityMedicalCenterOfJohannesGutenbergUniversityMainzMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl0" xml:lang="en-US">Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl0" xml:lang="en-US">Deferred Tax Assets, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl0" xml:lang="en-US">Entity Small Business</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_AccruedOutsourcingExpensesPolicyTextBlock_lbl1" xml:lang="en-US">Accrued Outsourcing Expenses Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_AccruedOutsourcingExpensesPolicyTextBlock" xlink:to="abio_AccruedOutsourcingExpensesPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl0" xml:lang="en-US">Earnings Per Share, Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl0" xml:lang="en-US">Operating Loss Carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl0" xml:lang="en-US">Retained Earnings [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl0" xml:lang="en-US">Series B Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesBPreferredStockMember" xlink:to="us-gaap_SeriesBPreferredStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable_lbl0" xml:lang="en-US">Preferred Stock, Convertible, Shares Issuable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockConvertibleSharesIssuable" xlink:to="us-gaap_PreferredStockConvertibleSharesIssuable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AreaOfRealEstateProperty_lbl0" xml:lang="en-US">Area of Real Estate Property</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AreaOfRealEstateProperty" xlink:to="us-gaap_AreaOfRealEstateProperty_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_ExceptedNumberOfBoardMembers_lbl1" xml:lang="en-US">Excepted Number Of Board Members</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ExceptedNumberOfBoardMembers" xlink:to="abio_ExceptedNumberOfBoardMembers_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OpenTaxYear_lbl0" xml:lang="en-US">Open Tax Year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OpenTaxYear" xlink:to="us-gaap_OpenTaxYear_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_JonesTradingInstitutionalServicesLLCMember_lbl1" xml:lang="en-US">Jones Trading Institutional Services LLCMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_JonesTradingInstitutionalServicesLLCMember" xlink:to="abio_JonesTradingInstitutionalServicesLLCMember_lbl1"/>
    <loc xlink:type="locator" xlink:label="abio_ScheduleOfPropertyAndEquipmentAbstract" xlink:href="abio-20240331.xsd#abio_ScheduleOfPropertyAndEquipmentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_ScheduleOfPropertyAndEquipmentAbstract_lbl" xml:lang="en-US">Schedule Of Property And Equipment Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ScheduleOfPropertyAndEquipmentAbstract" xlink:to="abio_ScheduleOfPropertyAndEquipmentAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl0" xml:lang="en-US">Other Assets, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl0" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl0" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl0" xml:lang="en-US">Preferred Stock, Shares Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_lbl0" xml:lang="en-US">Restructuring and Related Cost, Number of Positions Eliminated, Period Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl0" xml:lang="en-US">Deferred Tax Assets, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl0" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl1" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl2" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_TwoThousandAndTwentyEquityIncentivePlanMember_lbl1" xml:lang="en-US">Two Thousand And Twenty Equity Incentive Plan Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_TwoThousandAndTwentyEquityIncentivePlanMember" xlink:to="abio_TwoThousandAndTwentyEquityIncentivePlanMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseAssumptionsAndJudgmentsAllocationOfLeaseAndNonleaseComponent_lbl0" xml:lang="en-US">Lessee, Operating Lease, Assumptions and Judgments, Allocation of Lease and Nonlease Component</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseAssumptionsAndJudgmentsAllocationOfLeaseAndNonleaseComponent" xlink:to="us-gaap_LesseeOperatingLeaseAssumptionsAndJudgmentsAllocationOfLeaseAndNonleaseComponent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_TwoThousandAndThirteenPlanMember_lbl1" xml:lang="en-US">Two Thousand And Thirteen Plan Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_TwoThousandAndThirteenPlanMember" xlink:to="abio_TwoThousandAndThirteenPlanMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl0" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl0" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl0" xml:lang="en-US">Preferred Stock, Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl0" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl0" xml:lang="en-US">Preferred Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl1" xml:lang="en-US">Property, Plant and Equipment, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostsAndExpensesAbstract_lbl0" xml:lang="en-US">Costs and Expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostsAndExpensesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl0" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl0" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_ThresholdAmountOfDeclaredCashDividend_lbl1" xml:lang="en-US">Threshold Amount Of Declared Cash Dividend</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ThresholdAmountOfDeclaredCashDividend" xlink:to="abio_ThresholdAmountOfDeclaredCashDividend_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl0" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtLongtermAndShorttermCombinedAmount_lbl0" xml:lang="en-US">Debt, Long-Term and Short-Term, Combined Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:to="us-gaap_DebtLongtermAndShorttermCombinedAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarliestTaxYearMember_lbl0" xml:lang="en-US">Earliest Tax Year [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarliestTaxYearMember" xlink:to="us-gaap_EarliestTaxYearMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl0" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl0" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_NewCapitalOnDemandSalesAgreementMember_lbl1" xml:lang="en-US">New Capital On Demand Sales Agreement Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_NewCapitalOnDemandSalesAgreementMember" xlink:to="abio_NewCapitalOnDemandSalesAgreementMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl0" xml:lang="en-US">Operating Lease, Liability, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl1" xml:lang="en-US">Other Accrued Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl0" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl0" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl0" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl0" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_PatentAssignmentAgreementMember_lbl1" xml:lang="en-US">Patent Assignment Agreement Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_PatentAssignmentAgreementMember" xlink:to="abio_PatentAssignmentAgreementMember_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl0" xml:lang="en-US">Amendment Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_LiquidityAndGoingConcernPolicyTextBlock_lbl1" xml:lang="en-US">Liquidity And Going Concern Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_LiquidityAndGoingConcernPolicyTextBlock" xlink:to="abio_LiquidityAndGoingConcernPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationAndAmortization_lbl1" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_CapitalOnDemandSalesAgreementMember_lbl1" xml:lang="en-US">Capital On Demand Sales Agreement Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_CapitalOnDemandSalesAgreementMember" xlink:to="abio_CapitalOnDemandSalesAgreementMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl0" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_UnlabeledAbstract3_lbl0" xml:lang="en-US">Unlabeled Abstract3</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_UnlabeledAbstract3" xlink:to="abio_UnlabeledAbstract3_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_ThomasAKeuerAndCJeffreyDekkerMember_lbl1" xml:lang="en-US">Thomas AKeuer And CJeffrey Dekker Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ThomasAKeuerAndCJeffreyDekkerMember" xlink:to="abio_ThomasAKeuerAndCJeffreyDekkerMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_UnlabeledAbstract2_lbl0" xml:lang="en-US">Unlabeled Abstract2</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_UnlabeledAbstract2" xlink:to="abio_UnlabeledAbstract2_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_UnlabeledAbstract4_lbl0" xml:lang="en-US">Unlabeled Abstract4</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_UnlabeledAbstract4" xlink:to="abio_UnlabeledAbstract4_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl0" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_UnlabeledAbstract1_lbl0" xml:lang="en-US">Unlabeled Abstract1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_UnlabeledAbstract1" xlink:to="abio_UnlabeledAbstract1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_UnlabeledAbstract0_lbl0" xml:lang="en-US">Unlabeled Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_UnlabeledAbstract0" xlink:to="abio_UnlabeledAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl0" xml:lang="en-US">Property, Plant and Equipment, Useful Life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl0" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl0" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ChiefExecutiveOfficerMember_lbl1" xml:lang="en-US">Chief Executive Officer [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefExecutiveOfficerMember" xlink:to="srt_ChiefExecutiveOfficerMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl0" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_lbl1" xml:lang="en-US">Software and Software Development Costs [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:to="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIncomeTaxRefunds_lbl0" xml:lang="en-US">Proceeds from Income Tax Refunds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIncomeTaxRefunds" xlink:to="us-gaap_ProceedsFromIncomeTaxRefunds_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeveranceCosts1_lbl0" xml:lang="en-US">Severance Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeveranceCosts1" xlink:to="us-gaap_SeveranceCosts1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_OperatingLeasesExtendedExpiryYearsAndMonth_lbl0" xml:lang="en-US">Operating Leases Extended Expiry Years And Month</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_OperatingLeasesExtendedExpiryYearsAndMonth" xlink:to="abio_OperatingLeasesExtendedExpiryYearsAndMonth_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionMember_lbl0" xml:lang="en-US">Equity Option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl0" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Periodic Reduction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl1" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_CashPayment_lbl1" xml:lang="en-US">Cash Payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_CashPayment" xlink:to="abio_CashPayment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl2" xml:lang="en-US">Equity, Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComputerEquipmentMember_lbl1" xml:lang="en-US">Computer Equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_ArcaBiopharmaIncMember_lbl1" xml:lang="en-US">Arca Biopharma Inc Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ArcaBiopharmaIncMember" xlink:to="abio_ArcaBiopharmaIncMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl1" xml:lang="en-US">Furniture and Fixtures [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_PaymentOfUnrestrictedResearchGrants_lbl1" xml:lang="en-US">Payment Of Unrestricted Research Grants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_PaymentOfUnrestrictedResearchGrants" xlink:to="abio_PaymentOfUnrestrictedResearchGrants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_FirstThreePercentPayContributionMember_lbl1" xml:lang="en-US">First Three Percent Pay Contribution Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_FirstThreePercentPayContributionMember" xlink:to="abio_FirstThreePercentPayContributionMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardDescription_lbl0" xml:lang="en-US">Tax Credit Carryforward, Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardDescription" xlink:to="us-gaap_TaxCreditCarryforwardDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl0" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl0" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl0" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_FairValueAssetsBetweenHierarchyLevelsTransfersAmount_lbl1" xml:lang="en-US">Fair Value Assets Between Hierarchy Levels Transfers Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_FairValueAssetsBetweenHierarchyLevelsTransfersAmount" xlink:to="abio_FairValueAssetsBetweenHierarchyLevelsTransfersAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl0" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_UnlabeledAbstract_lbl0" xml:lang="en-US">Unlabeled Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_UnlabeledAbstract" xlink:to="abio_UnlabeledAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_MinimumPercentageOfOriginallyIssuedShares_lbl1" xml:lang="en-US">Minimum Percentage Of Originally Issued Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_MinimumPercentageOfOriginallyIssuedShares" xlink:to="abio_MinimumPercentageOfOriginallyIssuedShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosureOffbalanceSheetRisksAmountAsset_lbl0" xml:lang="en-US">Fair Value Disclosure, off-Balance-Sheet Risks, Amount, Asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosureOffbalanceSheetRisksAmountAsset" xlink:to="us-gaap_FairValueDisclosureOffbalanceSheetRisksAmountAsset_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl0" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_RetentionBonusPaid_lbl1" xml:lang="en-US">Retention Bonus Paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_RetentionBonusPaid" xlink:to="abio_RetentionBonusPaid_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl0" xml:lang="en-US">Equity [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_PercentageOfBaseRentToBePaidMonthly_lbl1" xml:lang="en-US">Percentage Of Base Rent To Be Paid Monthly</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_PercentageOfBaseRentToBePaidMonthly" xlink:to="abio_PercentageOfBaseRentToBePaidMonthly_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl0" xml:lang="en-US">Operating Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_lbl0" xml:lang="en-US">Defined Contribution Plan, Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanCostRecognized" xlink:to="us-gaap_DefinedContributionPlanCostRecognized_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_lbl0" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_SellingCommissionPerAdditionalSharesSoldPercentage_lbl1" xml:lang="en-US">Selling Commission Per Additional Shares Sold Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_SellingCommissionPerAdditionalSharesSoldPercentage" xlink:to="abio_SellingCommissionPerAdditionalSharesSoldPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl0" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_MinimumPercentageOfOriginallyIssuedOutstanding_lbl1" xml:lang="en-US">Minimum Percentage Of Originally Issued Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_MinimumPercentageOfOriginallyIssuedOutstanding" xlink:to="abio_MinimumPercentageOfOriginallyIssuedOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl0" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_PercentageOfRetentionBonuses_lbl1" xml:lang="en-US">Percentage Of Retention Bonuses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_PercentageOfRetentionBonuses" xlink:to="abio_PercentageOfRetentionBonuses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_WeightedAverageSharesOutstandingAbstract_lbl0" xml:lang="en-US">Weighted Average Shares Outstanding Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_WeightedAverageSharesOutstandingAbstract" xlink:to="abio_WeightedAverageSharesOutstandingAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_lbl0" xml:lang="en-US">Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_DeferredTaxAssetsAbstract_lbl0" xml:lang="en-US">Deferred Tax Assets Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_DeferredTaxAssetsAbstract" xlink:to="abio_DeferredTaxAssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_IncreaseOfRetentionBonusToEachExecutive_lbl1" xml:lang="en-US">Increase Of Retention Bonus To Each Executive</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_IncreaseOfRetentionBonusToEachExecutive" xlink:to="abio_IncreaseOfRetentionBonusToEachExecutive_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringCharges_lbl0" xml:lang="en-US">Restructuring Charges</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCharges" xlink:to="us-gaap_RestructuringCharges_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_CommonStockAndPreFundedWarrantsMember_lbl1" xml:lang="en-US">Common Stock And Pre Funded Warrants Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_CommonStockAndPreFundedWarrantsMember" xlink:to="abio_CommonStockAndPreFundedWarrantsMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl0" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Employees&apos; Gross Pay</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl0"/>
    <loc xlink:type="locator" xlink:label="abio_ScheduleOfNetDeferredTaxAssetsAndLiabilitiesAbstract" xlink:href="abio-20240331.xsd#abio_ScheduleOfNetDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_ScheduleOfNetDeferredTaxAssetsAndLiabilitiesAbstract_lbl" xml:lang="en-US">Schedule Of Net Deferred Tax Assets And Liabilities Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ScheduleOfNetDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="abio_ScheduleOfNetDeferredTaxAssetsAndLiabilitiesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfOperatingSegments_lbl0" xml:lang="en-US">Number of Operating Segments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_ValuationAllowanceDeferredTaxAssetsAndLiabilitiesChangeInAmount_lbl1" xml:lang="en-US">Valuation Allowance Deferred Tax Assets And Liabilities Change In Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ValuationAllowanceDeferredTaxAssetsAndLiabilitiesChangeInAmount" xlink:to="abio_ValuationAllowanceDeferredTaxAssetsAndLiabilitiesChangeInAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl0" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl0" xml:lang="en-US">Commitments and Contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_FirstMergerMember_lbl1" xml:lang="en-US">First Merger Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_FirstMergerMember" xlink:to="abio_FirstMergerMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl0" xml:lang="en-US">Common Stock, Value, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_PotentiallyDilutiveSecuritiesExcludedAbstract_lbl0" xml:lang="en-US">Potentially Dilutive Securities Excluded Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_PotentiallyDilutiveSecuritiesExcludedAbstract" xlink:to="abio_PotentiallyDilutiveSecuritiesExcludedAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_PaymentOfOtherPartyTerminationFee_lbl1" xml:lang="en-US">Payment Of Other Party Termination Fee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_PaymentOfOtherPartyTerminationFee" xlink:to="abio_PaymentOfOtherPartyTerminationFee_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_ClinicalDevelopmentDecisionMember_lbl2" xml:lang="en-US">Clinical Development Decision Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ClinicalDevelopmentDecisionMember" xlink:to="abio_ClinicalDevelopmentDecisionMember_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl0" xml:lang="en-US">Lessee, Leases [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl0" xml:lang="en-US">Operating Lease, Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_SeperationAgreementMember_lbl1" xml:lang="en-US">Seperation Agreement Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_SeperationAgreementMember" xlink:to="abio_SeperationAgreementMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_ThresholdAmountOfAdjustedExchangeRatio_lbl1" xml:lang="en-US">Threshold Amount Of Adjusted Exchange Ratio</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ThresholdAmountOfAdjustedExchangeRatio" xlink:to="abio_ThresholdAmountOfAdjustedExchangeRatio_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingExpense_lbl0" xml:lang="en-US">Other Nonoperating Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingExpense" xlink:to="us-gaap_OtherNonoperatingExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">Statement of Stockholders&apos; Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquipmentMember_lbl1" xml:lang="en-US">Equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl1" xml:lang="en-US">Research and Development Expense [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl0" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl0" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_MergerAgreementMember_lbl1" xml:lang="en-US">Merger Agreement Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_MergerAgreementMember" xlink:to="abio_MergerAgreementMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_ArcaBiopharmaIncAndOrukaTherapeuticsIncMember_lbl1" xml:lang="en-US">Arca Biopharma Inc And Oruka Therapeutics Inc Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ArcaBiopharmaIncAndOrukaTherapeuticsIncMember" xlink:to="abio_ArcaBiopharmaIncAndOrukaTherapeuticsIncMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl0" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchMember_lbl0" xml:lang="en-US">Research Tax Credit Carryforward [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchMember" xlink:to="us-gaap_ResearchMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LatestTaxYearMember_lbl0" xml:lang="en-US">Latest Tax Year [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LatestTaxYearMember" xlink:to="us-gaap_LatestTaxYearMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl0" xml:lang="en-US">Earnings Per Share, Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_RetentionBonuses_lbl2" xml:lang="en-US">Retention Bonuses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_RetentionBonuses" xlink:to="abio_RetentionBonuses_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl0" xml:lang="en-US">Debt Securities, Available-for-Sale</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_NumberOfMonthsBaseSalary_lbl1" xml:lang="en-US">Number Of Months Base Salary</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_NumberOfMonthsBaseSalary" xlink:to="abio_NumberOfMonthsBaseSalary_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_lbl0" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl0" xml:lang="en-US">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl0" xml:lang="en-US">Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl0" xml:lang="en-US">Research and Development Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrincipalOwnerMember_lbl0" xml:lang="en-US">Principal Owner [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrincipalOwnerMember" xlink:to="us-gaap_PrincipalOwnerMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_CostsAndExpensesAbstract0_lbl0" xml:lang="en-US">Costs And Expenses Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_CostsAndExpensesAbstract0" xlink:to="abio_CostsAndExpensesAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_PercentageHoldingForStockOptionsExercisePrice_lbl1" xml:lang="en-US">Percentage Holding For Stock Options Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_PercentageHoldingForStockOptionsExercisePrice" xlink:to="abio_PercentageHoldingForStockOptionsExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl0" xml:lang="en-US">Subsequent Events [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl0" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_DeferredTaxLiabilitiesRightOfUseAsset_lbl1" xml:lang="en-US">Deferred Tax Liabilities Right Of Use Asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_DeferredTaxLiabilitiesRightOfUseAsset" xlink:to="abio_DeferredTaxLiabilitiesRightOfUseAsset_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_lbl0" xml:lang="en-US">Income Tax Examination, Penalties and Interest Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl0" xml:lang="en-US">Additional Paid in Capital, Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_ResearchAndDevelopmentExpenseReversed_lbl1" xml:lang="en-US">Research And Development Expense Reversed</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ResearchAndDevelopmentExpenseReversed" xlink:to="abio_ResearchAndDevelopmentExpenseReversed_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_DeferredTaxAssetsAndLiabilitiesValuationAllowance_lbl1" xml:lang="en-US">Deferred Tax Assets And Liabilities Valuation Allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_DeferredTaxAssetsAndLiabilitiesValuationAllowance" xlink:to="abio_DeferredTaxAssetsAndLiabilitiesValuationAllowance_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl0" xml:lang="en-US">Lessee, Operating Lease, Option to Extend</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl1" xml:lang="en-US">Fair Value, Recurring [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_OrukaTherapeuticsIncMember_lbl1" xml:lang="en-US">Oruka Therapeutics Inc Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_OrukaTherapeuticsIncMember" xlink:to="abio_OrukaTherapeuticsIncMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_PotentialUpfrontAndMilestoneObligationsAndRoyaltyObligations_lbl1" xml:lang="en-US">Potential Upfront And Milestone Obligations And Royalty Obligations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_PotentialUpfrontAndMilestoneObligationsAndRoyaltyObligations" xlink:to="abio_PotentialUpfrontAndMilestoneObligationsAndRoyaltyObligations_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans_lbl0" xml:lang="en-US">Defined Contribution Plan, Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans" xlink:to="us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl0" xml:lang="en-US">Accounts Payable, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_NextTwoPercentPayContributionMember_lbl1" xml:lang="en-US">Next Two Percent Pay Contribution Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_NextTwoPercentPayContributionMember" xlink:to="abio_NextTwoPercentPayContributionMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl0" xml:lang="en-US">Property, Plant and Equipment, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl0" xml:lang="en-US">Lessee, Operating Lease, Existence of Option to Extend [true false]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl0" xml:lang="en-US">Employee-related Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl0" xml:lang="en-US">Subsidiary, Ownership Percentage, Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl1" xml:lang="en-US">Subsequent Event [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl0" xml:lang="en-US">Increase (Decrease) in Employee Related Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl0" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl0" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_AggregatePurchasePrice_lbl1" xml:lang="en-US">Aggregate Purchase Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_AggregatePurchasePrice" xlink:to="abio_AggregatePurchasePrice_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ChiefFinancialOfficerMember_lbl0" xml:lang="en-US">Chief Financial Officer [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefFinancialOfficerMember" xlink:to="srt_ChiefFinancialOfficerMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_PresidentMember_lbl0" xml:lang="en-US">President [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_PresidentMember" xlink:to="srt_PresidentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_CommonStockAuthorizedOfferingAmountUnderAgreementToSell_lbl1" xml:lang="en-US">Common Stock Authorized Offering Amount Under Agreement To Sell</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_CommonStockAuthorizedOfferingAmountUnderAgreementToSell" xlink:to="abio_CommonStockAuthorizedOfferingAmountUnderAgreementToSell_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl0" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl0" xml:lang="en-US">Operating Income (Loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl0" xml:lang="en-US">Operating Lease, Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl0" xml:lang="en-US">Deferred Tax Liabilities, Gross [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="abio_ScheduleOfNonCashShareBasedCompensationExpenseAbstract" xlink:href="abio-20240331.xsd#abio_ScheduleOfNonCashShareBasedCompensationExpenseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_ScheduleOfNonCashShareBasedCompensationExpenseAbstract_lbl" xml:lang="en-US">Schedule Of Non Cash Share Based Compensation Expense Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ScheduleOfNonCashShareBasedCompensationExpenseAbstract" xlink:to="abio_ScheduleOfNonCashShareBasedCompensationExpenseAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_NumberOfConsecutiveTradingDays_lbl1" xml:lang="en-US">Number Of Consecutive Trading Days</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_NumberOfConsecutiveTradingDays" xlink:to="abio_NumberOfConsecutiveTradingDays_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl0" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_AreaOfRealEstatePropertySubleaseAdditionalOfficeFacilities_lbl1" xml:lang="en-US">Area Of Real Estate Property Sublease Additional Office Facilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_AreaOfRealEstatePropertySubleaseAdditionalOfficeFacilities" xlink:to="abio_AreaOfRealEstatePropertySubleaseAdditionalOfficeFacilities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_DeferredTaxAssetsLeaseLiabilities_lbl1" xml:lang="en-US">Deferred Tax Assets Lease Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_DeferredTaxAssetsLeaseLiabilities" xlink:to="abio_DeferredTaxAssetsLeaseLiabilities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl0" xml:lang="en-US">Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl0" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_OperatingLossCarryforwardsExpirationYear_lbl1" xml:lang="en-US">Operating Loss Carryforwards Expiration Year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_OperatingLossCarryforwardsExpirationYear" xlink:to="abio_OperatingLossCarryforwardsExpirationYear_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl0" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl0" xml:lang="en-US">Operating Lease, Liability, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl0" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MoneyMarketFundsMember_lbl1" xml:lang="en-US">Money Market Funds [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl0" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OneTimeTerminationBenefitsMember_lbl0" xml:lang="en-US">One-time Termination Benefits [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OneTimeTerminationBenefitsMember" xlink:to="us-gaap_OneTimeTerminationBenefitsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl0" xml:lang="en-US">Liabilities, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsCurrent_lbl0" xml:lang="en-US">Other Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_IncentiveStockOptionMember_lbl1" xml:lang="en-US">Incentive Stock Option Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_IncentiveStockOptionMember" xlink:to="abio_IncentiveStockOptionMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl1" xml:lang="en-US">General and Administrative Expense [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl0" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl0" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_DescriptionOfBusinessPolicyTextBlock_lbl1" xml:lang="en-US">Description Of Business Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_DescriptionOfBusinessPolicyTextBlock" xlink:to="abio_DescriptionOfBusinessPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl0" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl0" xml:lang="en-US">Earnings Per Share [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl0" xml:lang="en-US">Revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl1" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseCost_lbl0" xml:lang="en-US">Operating Lease, Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_DeferredTaxAssetResearchAndDevelopment_lbl1" xml:lang="en-US">Deferred Tax Asset Research And Development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_DeferredTaxAssetResearchAndDevelopment" xlink:to="abio_DeferredTaxAssetResearchAndDevelopment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl0" xml:lang="en-US">General and Administrative Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_UniversityMedicalCenterOfJohannesGutenbergUniversityMainzMember_lbl2" xml:lang="en-US">University Medical Center Of Johannes Gutenberg University Mainz Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_UniversityMedicalCenterOfJohannesGutenbergUniversityMainzMember" xlink:to="abio_UniversityMedicalCenterOfJohannesGutenbergUniversityMainzMember_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl0" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_PurchaseAggregateShares_lbl1" xml:lang="en-US">Purchase Aggregate Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_PurchaseAggregateShares" xlink:to="abio_PurchaseAggregateShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl0" xml:lang="en-US">Common Stock, Shares, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl0" xml:lang="en-US">Entity Emerging Growth Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringReserveCurrent_lbl0" xml:lang="en-US">Restructuring Reserve, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringReserveCurrent" xlink:to="us-gaap_RestructuringReserveCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl0" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl0" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl0" xml:lang="en-US">Retirement Benefits [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl0" xml:lang="en-US">Tax Credit Carryforward, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl0" xml:lang="en-US">Fair Value Disclosures [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_lbl0" xml:lang="en-US">Subsidiary, Ownership Percentage, Noncontrolling Owner</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyMember_lbl0" xml:lang="en-US">Related Party [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyMember" xlink:to="us-gaap_RelatedPartyMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl1" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilityForUncertainTaxPositionsCurrent_lbl0" xml:lang="en-US">Liability for Uncertainty in Income Taxes, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:to="us-gaap_LiabilityForUncertainTaxPositionsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl0" xml:lang="en-US">Assets, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_InitiallySpecifiedPercentageForBeneficialNumberOfShares_lbl1" xml:lang="en-US">Initially Specified Percentage For Beneficial Number Of Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_InitiallySpecifiedPercentageForBeneficialNumberOfShares" xlink:to="abio_InitiallySpecifiedPercentageForBeneficialNumberOfShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl0" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Match</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl0" xml:lang="en-US">Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl0" xml:lang="en-US">Increase (Decrease) in Accounts Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_SecondAmendmentOfCertainRetentionBonusLettersMember_lbl1" xml:lang="en-US">Second Amendment Of Certain Retention Bonus Letters Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_SecondAmendmentOfCertainRetentionBonusLettersMember" xlink:to="abio_SecondAmendmentOfCertainRetentionBonusLettersMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl0" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_ComprehensiveLossPolicyPolicyTextBlock_lbl1" xml:lang="en-US">Comprehensive Loss Policy Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ComprehensiveLossPolicyPolicyTextBlock" xlink:to="abio_ComprehensiveLossPolicyPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl0" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl0" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_IncomeTaxReconciliationAdjustmentToDeferredTaxAsset_lbl1" xml:lang="en-US">Income Tax Reconciliation Adjustment To Deferred Tax Asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_IncomeTaxReconciliationAdjustmentToDeferredTaxAsset" xlink:to="abio_IncomeTaxReconciliationAdjustmentToDeferredTaxAsset_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl0" xml:lang="en-US">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl0" xml:lang="en-US">Preferred Stock, Value, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_LesseeOperatingSubleaseTermOfContract_lbl1" xml:lang="en-US">Lessee Operating Sublease Term Of Contract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_LesseeOperatingSubleaseTermOfContract" xlink:to="abio_LesseeOperatingSubleaseTermOfContract_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_SubscriptionAgreementReceiptAmount_lbl1" xml:lang="en-US">Subscription Agreement Receipt Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_SubscriptionAgreementReceiptAmount" xlink:to="abio_SubscriptionAgreementReceiptAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl0" xml:lang="en-US">Liabilities and Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_lbl0" xml:lang="en-US">Restructuring and Related Cost, Number of Positions Eliminated</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl0" xml:lang="en-US">Deferred Tax Assets, Goodwill and Intangible Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards_lbl0" xml:lang="en-US">Deferred Tax Assets, Charitable Contribution Carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestAndOtherIncome_lbl0" xml:lang="en-US">Interest and Other Income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestAndOtherIncome" xlink:to="us-gaap_InterestAndOtherIncome_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl0" xml:lang="en-US">Increase (Decrease) in Other Current Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl0" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardLimitationsOnUse_lbl0" xml:lang="en-US">Tax Credit Carryforward, Limitations on Use</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardLimitationsOnUse" xlink:to="us-gaap_TaxCreditCarryforwardLimitationsOnUse_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl0" xml:lang="en-US">Operating Lease, Right-of-Use Asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl0" xml:lang="en-US">Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_PotentiallyDilutiveSecuritiesExcludedAbstract0_lbl0" xml:lang="en-US">Potentially Dilutive Securities Excluded Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_PotentiallyDilutiveSecuritiesExcludedAbstract0" xlink:to="abio_PotentiallyDilutiveSecuritiesExcludedAbstract0_lbl0"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>24
<FILENAME>abio-20240331_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Tue Jul 09 21:08:03 UTC 2024 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ConsolidatedBalanceSheet" roleURI="http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ConsolidatedIncomeStatement" roleURI="http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ConsolidatedIncomeStatement_Parentheticals" roleURI="http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ShareholdersEquityType2or3" roleURI="http://www.arcabiopharma.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ConsolidatedCashFlow" roleURI="http://www.arcabiopharma.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ARCAandSummaryofSignificantAccountingPolicies" roleURI="http://www.arcabiopharma.com/role/ARCAandSummaryofSignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_NetLossPerShare" roleURI="http://www.arcabiopharma.com/role/NetLossPerShare"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_FairValueDisclosures" roleURI="http://www.arcabiopharma.com/role/FairValueDisclosures"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_PropertyandEquipment" roleURI="http://www.arcabiopharma.com/role/PropertyandEquipment"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_RelatedPartyArrangements" roleURI="http://www.arcabiopharma.com/role/RelatedPartyArrangements"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_CommitmentsandContingencies" roleURI="http://www.arcabiopharma.com/role/CommitmentsandContingencies"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_EquityFinancings" roleURI="http://www.arcabiopharma.com/role/EquityFinancings"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_SharebasedCompensation" roleURI="http://www.arcabiopharma.com/role/SharebasedCompensation"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_EmployeeBenefitPlans" roleURI="http://www.arcabiopharma.com/role/EmployeeBenefitPlans"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_IncomeTaxes" roleURI="http://www.arcabiopharma.com/role/IncomeTaxes"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_SubsequentEvents" roleURI="http://www.arcabiopharma.com/role/SubsequentEvents"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_AccountingPoliciesByPolicy" roleURI="http://www.arcabiopharma.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_NetLossPerShareTables" roleURI="http://www.arcabiopharma.com/role/NetLossPerShareTables"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_PropertyandEquipmentTables" roleURI="http://www.arcabiopharma.com/role/PropertyandEquipmentTables"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_CommitmentsandContingenciesTables" roleURI="http://www.arcabiopharma.com/role/CommitmentsandContingenciesTables"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_SharebasedCompensationTables" roleURI="http://www.arcabiopharma.com/role/SharebasedCompensationTables"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_IncomeTaxesTables" roleURI="http://www.arcabiopharma.com/role/IncomeTaxesTables"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ScheduleofPotentiallyDilutiveSharesofCommonStockTable" roleURI="http://www.arcabiopharma.com/role/ScheduleofPotentiallyDilutiveSharesofCommonStockTable"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ScheduleofPropertyandEquipmentTable" roleURI="http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ScheduleofFutureMinimumCommitmentsDueTable" roleURI="http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ScheduleofEstimatedWeightedAverageGrantDateFairValuePerShareTable" roleURI="http://www.arcabiopharma.com/role/ScheduleofEstimatedWeightedAverageGrantDateFairValuePerShareTable"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ScheduleofStockOptionActivitiesTable" roleURI="http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ScheduleofRSUActivityTable" roleURI="http://www.arcabiopharma.com/role/ScheduleofRSUActivityTable"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ScheduleofNoncashSharebasedCompensationExpenseTable" roleURI="http://www.arcabiopharma.com/role/ScheduleofNoncashSharebasedCompensationExpenseTable"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ScheduleofIncomeTaxBenefitAttributabletoOurLossfromOperationsTable" roleURI="http://www.arcabiopharma.com/role/ScheduleofIncomeTaxBenefitAttributabletoOurLossfromOperationsTable"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ScheduleofNetdeferredtaxassetsandliabilitiesTable" roleURI="http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ScheduleofPotentiallyDilutiveSharesofCommonStockTable0" roleURI="http://www.arcabiopharma.com/role/ScheduleofPotentiallyDilutiveSharesofCommonStockTable0"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ScheduleofPropertyandEquipmentTable0" roleURI="http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable0"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ScheduleofFutureMinimumCommitmentsDueTable0" roleURI="http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable0"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ScheduleofNoncashSharebasedCompensationExpenseTable0" roleURI="http://www.arcabiopharma.com/role/ScheduleofNoncashSharebasedCompensationExpenseTable0"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ScheduleofStockOptionActivitiesTable0" roleURI="http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable0"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ARCAandSummaryofSignificantAccountingPoliciesDetails" roleURI="http://www.arcabiopharma.com/role/ARCAandSummaryofSignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_FairValueDisclosuresDetails" roleURI="http://www.arcabiopharma.com/role/FairValueDisclosuresDetails"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_PropertyandEquipmentDetails" roleURI="http://www.arcabiopharma.com/role/PropertyandEquipmentDetails"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_RelatedPartyArrangementsDetails" roleURI="http://www.arcabiopharma.com/role/RelatedPartyArrangementsDetails"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_CommitmentsandContingenciesDetails" roleURI="http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_EquityFinancingsDetails" roleURI="http://www.arcabiopharma.com/role/EquityFinancingsDetails"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_SharebasedCompensationDetails" roleURI="http://www.arcabiopharma.com/role/SharebasedCompensationDetails"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_EmployeeBenefitPlansDetails" roleURI="http://www.arcabiopharma.com/role/EmployeeBenefitPlansDetails"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_IncomeTaxesDetails" roleURI="http://www.arcabiopharma.com/role/IncomeTaxesDetails"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_SubsequentEventsDetails" roleURI="http://www.arcabiopharma.com/role/SubsequentEventsDetails"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#DocumentAndEntityInformation" roleURI="http://www.arcabiopharma.com/role/DocumentAndEntityInformation"/>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_Assets" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_Liabilities" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_StockholdersEquity" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet_Parentheticals" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_CostsAndExpensesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestAndOtherIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestAndOtherIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_InterestAndOtherIncome" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherNonoperatingExpense" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WeightedAverageSharesOutstandingAbstract" xlink:href="abio-20240331.xsd#abio_WeightedAverageSharesOutstandingAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="WeightedAverageSharesOutstandingAbstract" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WeightedAverageSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement_Parentheticals" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ResearchAndDevelopmentExpenseReversed" xlink:href="abio-20240331.xsd#abio_ResearchAndDevelopmentExpenseReversed"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="ResearchAndDevelopmentExpenseReversed" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/ShareholdersEquityType2or3" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_RetainedEarningsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="3.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_0" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding_0" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/ConsolidatedCashFlow" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationAndAmortization" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIncomeTaxRefunds" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIncomeTaxRefunds"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_ProceedsFromIncomeTaxRefunds" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/ARCAandSummaryofSignificantAccountingPolicies" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/NetLossPerShare" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/FairValueDisclosures" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/PropertyandEquipment" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/RelatedPartyArrangements" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/CommitmentsandContingencies" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/EquityFinancings" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/SharebasedCompensation" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/EmployeeBenefitPlans" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/IncomeTaxes" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/SubsequentEvents" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/AccountingPoliciesByPolicy" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="DescriptionOfBusinessPolicyTextBlock" xlink:href="abio-20240331.xsd#abio_DescriptionOfBusinessPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="DescriptionOfBusinessPolicyTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LiquidityAndGoingConcernPolicyTextBlock" xlink:href="abio-20240331.xsd#abio_LiquidityAndGoingConcernPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="LiquidityAndGoingConcernPolicyTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ComprehensiveLossPolicyPolicyTextBlock" xlink:href="abio-20240331.xsd#abio_ComprehensiveLossPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ComprehensiveLossPolicyPolicyTextBlock" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AccruedOutsourcingExpensesPolicyTextBlock" xlink:href="abio-20240331.xsd#abio_AccruedOutsourcingExpensesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="AccruedOutsourcingExpensesPolicyTextBlock" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/NetLossPerShareTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/PropertyandEquipmentTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/CommitmentsandContingenciesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/SharebasedCompensationTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/IncomeTaxesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/ScheduleofPotentiallyDilutiveSharesofCommonStockTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfPotentiallyDilutiveSharesOfCommonStockAbstract" xlink:href="abio-20240331.xsd#abio_ScheduleOfPotentiallyDilutiveSharesOfCommonStockAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPotentiallyDilutiveSharesOfCommonStockAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_StockOptionMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="PotentiallyDilutiveSecuritiesExcludedAbstract" xlink:href="abio-20240331.xsd#abio_PotentiallyDilutiveSecuritiesExcludedAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="PotentiallyDilutiveSecuritiesExcludedAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PotentiallyDilutiveSecuritiesExcludedAbstract" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfPropertyAndEquipmentAbstract" xlink:href="abio-20240331.xsd#abio_ScheduleOfPropertyAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_ComputerEquipmentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_EquipmentMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_FurnitureAndFixturesMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfFutureMinimumCommitmentsDueAbstract" xlink:href="abio-20240331.xsd#abio_ScheduleOfFutureMinimumCommitmentsDueAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFutureMinimumCommitmentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFutureMinimumCommitmentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFutureMinimumCommitmentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFutureMinimumCommitmentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFutureMinimumCommitmentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFutureMinimumCommitmentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFutureMinimumCommitmentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFutureMinimumCommitmentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/ScheduleofEstimatedWeightedAverageGrantDateFairValuePerShareTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfEstimatedWeightedAverageGrantDateFairValuePerShareAbstract" xlink:href="abio-20240331.xsd#abio_ScheduleOfEstimatedWeightedAverageGrantDateFairValuePerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEstimatedWeightedAverageGrantDateFairValuePerShareAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEstimatedWeightedAverageGrantDateFairValuePerShareAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEstimatedWeightedAverageGrantDateFairValuePerShareAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEstimatedWeightedAverageGrantDateFairValuePerShareAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEstimatedWeightedAverageGrantDateFairValuePerShareAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfStockOptionActivitiesAbstract" xlink:href="abio-20240331.xsd#abio_ScheduleOfStockOptionActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" order="16.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/ScheduleofRSUActivityTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfRsuActivityAbstract" xlink:href="abio-20240331.xsd#abio_ScheduleOfRsuActivityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRsuActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRsuActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRsuActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRsuActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRsuActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRsuActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRsuActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRsuActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRsuActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRsuActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/ScheduleofNoncashSharebasedCompensationExpenseTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfNonCashShareBasedCompensationExpenseAbstract" xlink:href="abio-20240331.xsd#abio_ScheduleOfNonCashShareBasedCompensationExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfNonCashShareBasedCompensationExpenseAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/ScheduleofIncomeTaxBenefitAttributabletoOurLossfromOperationsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfIncomeTaxBenefitAttributableToOurLossFromOperationsAbstract" xlink:href="abio-20240331.xsd#abio_ScheduleOfIncomeTaxBenefitAttributableToOurLossFromOperationsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIncomeTaxBenefitAttributableToOurLossFromOperationsAbstract" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIncomeTaxBenefitAttributableToOurLossFromOperationsAbstract" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIncomeTaxBenefitAttributableToOurLossFromOperationsAbstract" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="IncomeTaxReconciliationAdjustmentToDeferredTaxAsset" xlink:href="abio-20240331.xsd#abio_IncomeTaxReconciliationAdjustmentToDeferredTaxAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIncomeTaxBenefitAttributableToOurLossFromOperationsAbstract" xlink:to="IncomeTaxReconciliationAdjustmentToDeferredTaxAsset" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIncomeTaxBenefitAttributableToOurLossFromOperationsAbstract" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIncomeTaxBenefitAttributableToOurLossFromOperationsAbstract" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIncomeTaxBenefitAttributableToOurLossFromOperationsAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfNetDeferredTaxAssetsAndLiabilitiesAbstract" xlink:href="abio-20240331.xsd#abio_ScheduleOfNetDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="DeferredTaxAssetsAbstract" xlink:href="abio-20240331.xsd#abio_DeferredTaxAssetsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfNetDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="DeferredTaxAssetsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DeferredTaxAssetResearchAndDevelopment" xlink:href="abio-20240331.xsd#abio_DeferredTaxAssetResearchAndDevelopment"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrYwqBFvPJwgls7iB/C7qgJlieUnn0NA5OCi94KNojOhCKLtgRf7Lh8PNXaX7qyF9a6SJv7mHT4i4TG0zLkQ0ch6DUlOii5J7LMDGl2/JapjDY9mloXuib5mHVGZ5CeGApH//7xHOalGUmL15AlWw6rbn9qzGZe/F/uh8urYvQsY+tuMobOgKRuTv5i2Woj/UuMiToo3V7tucu2qjqPo8nZg] CSR-->
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsAbstract" xlink:to="DeferredTaxAssetResearchAndDevelopment" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DeferredTaxAssetsLeaseLiabilities" xlink:href="abio-20240331.xsd#abio_DeferredTaxAssetsLeaseLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsAbstract" xlink:to="DeferredTaxAssetsLeaseLiabilities" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfNetDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfNetDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfNetDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfNetDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DeferredTaxLiabilitiesRightOfUseAsset" xlink:href="abio-20240331.xsd#abio_DeferredTaxLiabilitiesRightOfUseAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="DeferredTaxLiabilitiesRightOfUseAsset" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfNetDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/ScheduleofPotentiallyDilutiveSharesofCommonStockTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfPotentiallyDilutiveSharesOfCommonStockAbstract" xlink:href="abio-20240331.xsd#abio_ScheduleOfPotentiallyDilutiveSharesOfCommonStockAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPotentiallyDilutiveSharesOfCommonStockAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_StockOptionMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="PotentiallyDilutiveSecuritiesExcludedAbstract0" xlink:href="abio-20240331.xsd#abio_PotentiallyDilutiveSecuritiesExcludedAbstract0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="PotentiallyDilutiveSecuritiesExcludedAbstract0" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PotentiallyDilutiveSecuritiesExcludedAbstract0" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfPropertyAndEquipmentAbstract" xlink:href="abio-20240331.xsd#abio_ScheduleOfPropertyAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_ComputerEquipmentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_EquipmentMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_FurnitureAndFixturesMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfFutureMinimumCommitmentsDueAbstract" xlink:href="abio-20240331.xsd#abio_ScheduleOfFutureMinimumCommitmentsDueAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFutureMinimumCommitmentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/ScheduleofNoncashSharebasedCompensationExpenseTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfNonCashShareBasedCompensationExpenseAbstract" xlink:href="abio-20240331.xsd#abio_ScheduleOfNonCashShareBasedCompensationExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfNonCashShareBasedCompensationExpenseAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfStockOptionActivitiesAbstract" xlink:href="abio-20240331.xsd#abio_ScheduleOfStockOptionActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" order="13.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/ARCAandSummaryofSignificantAccountingPoliciesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_Revenues" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosureOffbalanceSheetRisksAmountAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosureOffbalanceSheetRisksAmountAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueDisclosureOffbalanceSheetRisksAmountAsset" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NumberOfOperatingSegments" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/FairValueDisclosuresDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:label="FairValueDisclosuresDetailsTable" xlink:href="abio-20240331.xsd#abio_FairValueDisclosuresDetailsTable"/>
    <loc xlink:type="locator" xlink:label="FairValueDisclosuresDetailsLineItems" xlink:href="abio-20240331.xsd#abio_FairValueDisclosuresDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="FairValueDisclosuresDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresDetailsTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_MoneyMarketFundsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresDetailsTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresDetailsTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel1Member" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresDetailsTable" xlink:to="FairValueDisclosuresDetailsLineItems" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresDetailsLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FairValueAssetsBetweenHierarchyLevelsTransfersAmount" xlink:href="abio-20240331.xsd#abio_FairValueAssetsBetweenHierarchyLevelsTransfersAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresDetailsLineItems" xlink:to="FairValueAssetsBetweenHierarchyLevelsTransfersAmount" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtLongtermAndShorttermCombinedAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresDetailsLineItems" xlink:to="us-gaap_DebtLongtermAndShorttermCombinedAmount" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresDetailsLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/PropertyandEquipmentDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_DepreciationAndAmortization" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/RelatedPartyArrangementsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="RelatedPartyArrangementsDetailsTable" xlink:href="abio-20240331.xsd#abio_RelatedPartyArrangementsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="RelatedPartyArrangementsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyArrangementsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ChiefExecutiveOfficerMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ChiefExecutiveOfficerMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="srt_ChiefExecutiveOfficerMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyArrangementsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ResearchAndDevelopmentExpenseReversed" xlink:href="abio-20240331.xsd#abio_ResearchAndDevelopmentExpenseReversed"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="ResearchAndDevelopmentExpenseReversed" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PaymentOfUnrestrictedResearchGrants" xlink:href="abio-20240331.xsd#abio_PaymentOfUnrestrictedResearchGrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="PaymentOfUnrestrictedResearchGrants" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="CommitmentsandContingenciesDetailsTable" xlink:href="abio-20240331.xsd#abio_CommitmentsandContingenciesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="CommitmentsandContingenciesDetailsLineItems" xlink:href="abio-20240331.xsd#abio_CommitmentsandContingenciesDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="CommitmentsandContingenciesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsTable" xlink:to="srt_CounterpartyNameAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="UniversityMedicalCenterOfJohannesGutenbergUniversityMainzMember" xlink:href="abio-20240331.xsd#abio_UniversityMedicalCenterOfJohannesGutenbergUniversityMainzMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="UniversityMedicalCenterOfJohannesGutenbergUniversityMainzMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestructuringCostAndReserveAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_RestructuringCostAndReserveAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfRestructuringDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_TypeOfRestructuringDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OneTimeTerminationBenefitsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OneTimeTerminationBenefitsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_OneTimeTerminationBenefitsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ClinicalDevelopmentDecisionMember" xlink:href="abio-20240331.xsd#abio_ClinicalDevelopmentDecisionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="ClinicalDevelopmentDecisionMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="PatentAssignmentAgreementMember" xlink:href="abio-20240331.xsd#abio_PatentAssignmentAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="PatentAssignmentAgreementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsTable" xlink:to="CommitmentsandContingenciesDetailsLineItems" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="RetentionBonuses" xlink:href="abio-20240331.xsd#abio_RetentionBonuses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="RetentionBonuses" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfRetentionBonuses" xlink:href="abio-20240331.xsd#abio_PercentageOfRetentionBonuses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="PercentageOfRetentionBonuses" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RetentionBonusPaid" xlink:href="abio-20240331.xsd#abio_RetentionBonusPaid"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="RetentionBonusPaid" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeveranceCosts1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeveranceCosts1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_SeveranceCosts1" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestructuringReserveCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserveCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_RestructuringReserveCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestructuringCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_RestructuringCharges" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AreaOfRealEstateProperty" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_AreaOfRealEstateProperty" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AreaOfRealEstatePropertySubleaseAdditionalOfficeFacilities" xlink:href="abio-20240331.xsd#abio_AreaOfRealEstatePropertySubleaseAdditionalOfficeFacilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="AreaOfRealEstatePropertySubleaseAdditionalOfficeFacilities" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LesseeOperatingSubleaseTermOfContract" xlink:href="abio-20240331.xsd#abio_LesseeOperatingSubleaseTermOfContract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="LesseeOperatingSubleaseTermOfContract" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseAssumptionsAndJudgmentsAllocationOfLeaseAndNonleaseComponent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseAssumptionsAndJudgmentsAllocationOfLeaseAndNonleaseComponent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseAssumptionsAndJudgmentsAllocationOfLeaseAndNonleaseComponent" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_OperatingLeaseCost" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_OperatingLeaseLiability" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_OperatingLeasePayments" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PotentialUpfrontAndMilestoneObligationsAndRoyaltyObligations" xlink:href="abio-20240331.xsd#abio_PotentialUpfrontAndMilestoneObligationsAndRoyaltyObligations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="PotentialUpfrontAndMilestoneObligationsAndRoyaltyObligations" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OperatingLeasesExtendedExpiryYearsAndMonth" xlink:href="abio-20240331.xsd#abio_OperatingLeasesExtendedExpiryYearsAndMonth"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="OperatingLeasesExtendedExpiryYearsAndMonth" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfBaseRentToBePaidMonthly" xlink:href="abio-20240331.xsd#abio_PercentageOfBaseRentToBePaidMonthly"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="PercentageOfBaseRentToBePaidMonthly" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/EquityFinancingsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <loc xlink:type="locator" xlink:label="EquityFinancingsDetailsTable" xlink:href="abio-20240331.xsd#abio_EquityFinancingsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="EquityFinancingsDetailsLineItems" xlink:href="abio-20240331.xsd#abio_EquityFinancingsDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="EquityFinancingsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityFinancingsDetailsTable" xlink:to="dei_LegalEntityAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="JonesTradingInstitutionalServicesLLCMember" xlink:href="abio-20240331.xsd#abio_JonesTradingInstitutionalServicesLLCMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="JonesTradingInstitutionalServicesLLCMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityFinancingsDetailsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="CapitalOnDemandSalesAgreementMember" xlink:href="abio-20240331.xsd#abio_CapitalOnDemandSalesAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="CapitalOnDemandSalesAgreementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NewCapitalOnDemandSalesAgreementMember" xlink:href="abio-20240331.xsd#abio_NewCapitalOnDemandSalesAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="NewCapitalOnDemandSalesAgreementMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityFinancingsDetailsTable" xlink:to="EquityFinancingsDetailsLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityFinancingsDetailsLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CommonStockAuthorizedOfferingAmountUnderAgreementToSell" xlink:href="abio-20240331.xsd#abio_CommonStockAuthorizedOfferingAmountUnderAgreementToSell"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityFinancingsDetailsLineItems" xlink:to="CommonStockAuthorizedOfferingAmountUnderAgreementToSell" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SellingCommissionPerAdditionalSharesSoldPercentage" xlink:href="abio-20240331.xsd#abio_SellingCommissionPerAdditionalSharesSoldPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityFinancingsDetailsLineItems" xlink:to="SellingCommissionPerAdditionalSharesSoldPercentage" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityFinancingsDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/SharebasedCompensationDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="SharebasedCompensationDetailsTable" xlink:href="abio-20240331.xsd#abio_SharebasedCompensationDetailsTable"/>
    <loc xlink:type="locator" xlink:label="SharebasedCompensationDetailsLineItems" xlink:href="abio-20240331.xsd#abio_SharebasedCompensationDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="SharebasedCompensationDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SharebasedCompensationDetailsTable" xlink:to="us-gaap_PlanNameAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="TwoThousandAndTwentyEquityIncentivePlanMember" xlink:href="abio-20240331.xsd#abio_TwoThousandAndTwentyEquityIncentivePlanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="TwoThousandAndTwentyEquityIncentivePlanMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TwoThousandAndThirteenPlanMember" xlink:href="abio-20240331.xsd#abio_TwoThousandAndThirteenPlanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="TwoThousandAndThirteenPlanMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SharebasedCompensationDetailsTable" xlink:to="srt_RangeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SharebasedCompensationDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="IncentiveStockOptionMember" xlink:href="abio-20240331.xsd#abio_IncentiveStockOptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="IncentiveStockOptionMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SharebasedCompensationDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrincipalOwnerMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrincipalOwnerMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_PrincipalOwnerMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SharebasedCompensationDetailsTable" xlink:to="SharebasedCompensationDetailsLineItems" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SharebasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SharebasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SharebasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SharebasedCompensationDetailsLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SharebasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SharebasedCompensationDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SharebasedCompensationDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageHoldingForStockOptionsExercisePrice" xlink:href="abio-20240331.xsd#abio_PercentageHoldingForStockOptionsExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SharebasedCompensationDetailsLineItems" xlink:to="PercentageHoldingForStockOptionsExercisePrice" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SharebasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PurchaseAggregateShares" xlink:href="abio-20240331.xsd#abio_PurchaseAggregateShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SharebasedCompensationDetailsLineItems" xlink:to="PurchaseAggregateShares" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SharebasedCompensationDetailsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SharebasedCompensationDetailsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SharebasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SharebasedCompensationDetailsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/EmployeeBenefitPlansDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="EmployeeBenefitPlansDetailsTable" xlink:href="abio-20240331.xsd#abio_EmployeeBenefitPlansDetailsTable"/>
    <loc xlink:type="locator" xlink:label="EmployeeBenefitPlansDetailsLineItems" xlink:href="abio-20240331.xsd#abio_EmployeeBenefitPlansDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="EmployeeBenefitPlansDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetirementPlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanNameAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EmployeeBenefitPlansDetailsTable" xlink:to="us-gaap_RetirementPlanNameAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetirementPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RetirementPlanNameAxis" xlink:to="us-gaap_RetirementPlanNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="FirstThreePercentPayContributionMember" xlink:href="abio-20240331.xsd#abio_FirstThreePercentPayContributionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RetirementPlanNameAxis" xlink:to="FirstThreePercentPayContributionMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NextTwoPercentPayContributionMember" xlink:href="abio-20240331.xsd#abio_NextTwoPercentPayContributionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RetirementPlanNameAxis" xlink:to="NextTwoPercentPayContributionMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EmployeeBenefitPlansDetailsTable" xlink:to="EmployeeBenefitPlansDetailsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EmployeeBenefitPlansDetailsLineItems" xlink:to="us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EmployeeBenefitPlansDetailsLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EmployeeBenefitPlansDetailsLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanCostRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EmployeeBenefitPlansDetailsLineItems" xlink:to="us-gaap_DefinedContributionPlanCostRecognized" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/IncomeTaxesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="IncomeTaxesDetailsTable" xlink:href="abio-20240331.xsd#abio_IncomeTaxesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="IncomeTaxesDetailsLineItems" xlink:href="abio-20240331.xsd#abio_IncomeTaxesDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="IncomeTaxesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxPeriodAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsTable" xlink:to="us-gaap_TaxPeriodAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarliestTaxYearMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarliestTaxYearMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_EarliestTaxYearMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LatestTaxYearMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LatestTaxYearMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_LatestTaxYearMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_ResearchMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsTable" xlink:to="IncomeTaxesDetailsLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OperatingLossCarryforwardsExpirationYear" xlink:href="abio-20240331.xsd#abio_OperatingLossCarryforwardsExpirationYear"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsLineItems" xlink:to="OperatingLossCarryforwardsExpirationYear" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsLineItems" xlink:to="us-gaap_TaxCreditCarryforwardDescription" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardLimitationsOnUse" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardLimitationsOnUse"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsLineItems" xlink:to="us-gaap_TaxCreditCarryforwardLimitationsOnUse" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DeferredTaxAssetsAndLiabilitiesValuationAllowance" xlink:href="abio-20240331.xsd#abio_DeferredTaxAssetsAndLiabilitiesValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsLineItems" xlink:to="DeferredTaxAssetsAndLiabilitiesValuationAllowance" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ValuationAllowanceDeferredTaxAssetsAndLiabilitiesChangeInAmount" xlink:href="abio-20240331.xsd#abio_ValuationAllowanceDeferredTaxAssetsAndLiabilitiesChangeInAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsLineItems" xlink:to="ValuationAllowanceDeferredTaxAssetsAndLiabilitiesChangeInAmount" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OpenTaxYear" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OpenTaxYear"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsLineItems" xlink:to="us-gaap_OpenTaxYear" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilityForUncertainTaxPositionsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsLineItems" xlink:to="us-gaap_LiabilityForUncertainTaxPositionsCurrent" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsLineItems" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/SubsequentEventsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="SubsequentEventsDetailsTable" xlink:href="abio-20240331.xsd#abio_SubsequentEventsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="SubsequentEventsDetailsLineItems" xlink:href="abio-20240331.xsd#abio_SubsequentEventsDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="SubsequentEventsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesBPreferredStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_PresidentMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_PresidentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_PresidentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_ChiefFinancialOfficerMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ChiefFinancialOfficerMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_ChiefFinancialOfficerMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ThomasAKeuerAndCJeffreyDekkerMember" xlink:href="abio-20240331.xsd#abio_ThomasAKeuerAndCJeffreyDekkerMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="ThomasAKeuerAndCJeffreyDekkerMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="MergerAgreementMember" xlink:href="abio-20240331.xsd#abio_MergerAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="MergerAgreementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FirstMergerMember" xlink:href="abio-20240331.xsd#abio_FirstMergerMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="FirstMergerMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SeperationAgreementMember" xlink:href="abio-20240331.xsd#abio_SeperationAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="SeperationAgreementMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SecondAmendmentOfCertainRetentionBonusLettersMember" xlink:href="abio-20240331.xsd#abio_SecondAmendmentOfCertainRetentionBonusLettersMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="SecondAmendmentOfCertainRetentionBonusLettersMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CommonStockAndPreFundedWarrantsMember" xlink:href="abio-20240331.xsd#abio_CommonStockAndPreFundedWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="CommonStockAndPreFundedWarrantsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="dei_LegalEntityAxis" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ArcaBiopharmaIncMember" xlink:href="abio-20240331.xsd#abio_ArcaBiopharmaIncMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="ArcaBiopharmaIncMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OrukaTherapeuticsIncMember" xlink:href="abio-20240331.xsd#abio_OrukaTherapeuticsIncMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="OrukaTherapeuticsIncMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="srt_RangeAxis" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="srt_OwnershipAxis" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ArcaBiopharmaIncAndOrukaTherapeuticsIncMember" xlink:href="abio-20240331.xsd#abio_ArcaBiopharmaIncAndOrukaTherapeuticsIncMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="ArcaBiopharmaIncAndOrukaTherapeuticsIncMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="SubsequentEventsDetailsLineItems" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="NumberOfConsecutiveTradingDays" xlink:href="abio-20240331.xsd#abio_NumberOfConsecutiveTradingDays"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="NumberOfConsecutiveTradingDays" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ThresholdAmountOfAdjustedExchangeRatio" xlink:href="abio-20240331.xsd#abio_ThresholdAmountOfAdjustedExchangeRatio"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="ThresholdAmountOfAdjustedExchangeRatio" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ThresholdAmountOfDeclaredCashDividend" xlink:href="abio-20240331.xsd#abio_ThresholdAmountOfDeclaredCashDividend"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="ThresholdAmountOfDeclaredCashDividend" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SubscriptionAgreementReceiptAmount" xlink:href="abio-20240331.xsd#abio_SubscriptionAgreementReceiptAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="SubscriptionAgreementReceiptAmount" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PaymentOfOtherPartyTerminationFee" xlink:href="abio-20240331.xsd#abio_PaymentOfOtherPartyTerminationFee"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="PaymentOfOtherPartyTerminationFee" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MinimumPercentageOfOriginallyIssuedShares" xlink:href="abio-20240331.xsd#abio_MinimumPercentageOfOriginallyIssuedShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="MinimumPercentageOfOriginallyIssuedShares" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MinimumPercentageOfOriginallyIssuedOutstanding" xlink:href="abio-20240331.xsd#abio_MinimumPercentageOfOriginallyIssuedOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="MinimumPercentageOfOriginallyIssuedOutstanding" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockConvertibleSharesIssuable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="us-gaap_PreferredStockConvertibleSharesIssuable" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InitiallySpecifiedPercentageForBeneficialNumberOfShares" xlink:href="abio-20240331.xsd#abio_InitiallySpecifiedPercentageForBeneficialNumberOfShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="InitiallySpecifiedPercentageForBeneficialNumberOfShares" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExceptedNumberOfBoardMembers" xlink:href="abio-20240331.xsd#abio_ExceptedNumberOfBoardMembers"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="ExceptedNumberOfBoardMembers" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AggregatePurchasePrice" xlink:href="abio-20240331.xsd#abio_AggregatePurchasePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="AggregatePurchasePrice" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfMonthsBaseSalary" xlink:href="abio-20240331.xsd#abio_NumberOfMonthsBaseSalary"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="NumberOfMonthsBaseSalary" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CashPayment" xlink:href="abio-20240331.xsd#abio_CashPayment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="CashPayment" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IncreaseOfRetentionBonusToEachExecutive" xlink:href="abio-20240331.xsd#abio_IncreaseOfRetentionBonusToEachExecutive"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="IncreaseOfRetentionBonusToEachExecutive" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RetentionBonuses" xlink:href="abio-20240331.xsd#abio_RetentionBonuses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="RetentionBonuses" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/DocumentAndEntityInformation" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="DocumentAndEntityInformationAbstract" xlink:href="abio-20240331.xsd#abio_DocumentAndEntityInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentInformationTable" order="1.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" order="1.0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentDescription" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentDescription" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>74
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M0=5 Y3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%
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M/K,HZ3-S03@.^\Q<4#14-O%.6^!Q<7'8F5\B \B',,%]-BXJ\ON=#'*%?3)
M9Z<S\+C0^+IMPJA@YI#6$7IN&AH2RX[J6DB;HB#-T3'@:H# (N5J$.(%_4@
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MEFW;>#NK#>4-+O)V*1J\DXIWTLF[$FF*/\__H\TG?3ISU4L57E(U$*<5XG0
M8J_FG9[%[#I.6\>M>BO#/LH&WZSBFPWG>[]#9^?/X8\=U_5')VA]A6&;T'>=
MNK !YCIOBQ=G.-J%CBQ+]@#LK0Q;E9V(M?69VXEX7ZX9UF;-T,K3Z1_ZBOFI
MU<*?5:V9W=NZS/TE"[/N40<G?KX^.WTUM$@\-SB9679M$V"V;+C&WK),$0X;
M=#DW$[3+XR[H>*+%KM@7/ F-NXSB,,&=(T@CP/L;(?3KB=EJ5'O1Y0]02P,$
M%     @ B8OI6-;=!;E?!   \A(  !@   !X;"]W;W)K<VAE971S+W-H965T
M-"YX;6RM6&UOVS80_BN$5@P)T$:BWFQEMH'&<K<"[1HDS?J9D6A+J"1Z)&UG
M_WY'2I%MB1:R0?D0B]1S#_7<'<DC9P?&?XJ,4HE>RJ(2<RN3<GMKVR+):$G$
M#=O2"MZL&2^)A";?V&++*4FU45G8KN.$=DGRREK,=-\]7\S83A9Y1>\Y$KNR
M)/R?.UJPP]S"UFO'0[[)I.JP%[,MV=!'*I^V]QQ:=LN2YB6M1,XJQ.EZ;GW$
MMROL*P.-^"NG!W'RC)249\9^JL;G=&XYZHMH01.I* C\[.F2%H5B@N_XNR&U
MVC&5X>GS*_LG+1[$/!-!EZSXD:<RFUM3"Z5T37:%?&"'/V@C*%!\"2N$_H\.
M-39T+93LA&1E8PQ?4.95_4M>&D><& "/V<!M#-RN@7_!P&L,O*Y!>,' ;PS\
MMXX0- 9:NEUKUXZ+B22+&6<'Q!4:V-2#]KZV!G_EE4J41\GA;0YV<O$HB:00
M>"D06Z-O6\J)"J! 5T\5V:6YI.DU^H">'F-T]>X:O4-YA;YG;"=(E8J9+>$3
M%)&=-,/=U<.Y%X;ST%=6R4R@5972U& ?#]MC=X# !NVM ]Q7!]RY@XQ?";]!
M'GZ/7,?U#1^T?+NY9](S;![39-!\]79S=\ 97IL-GN;S+O MF8!$@- B^@)+
MD:#BUA3CFL0WDZBE[59L24+G%JQ=@O(]M1:__H)#YS>3?\<DB\<D6XU$=A8)
MOXV$/\2^^)U6,!4+'0N2PL3/A513<T]- :FY LVEMH;]PO7P9&;O3QW=!V'?
M"<]!<1\4NE/O'+3J@X*I?QSN3'#0"@X&!3^ "PE/,JTXI7O8PK9J73+)K9G"
M4R5AT%';QWB1TQ%KX'%P5VP?Y$_\R"PV;,6&@V*_,PFQ37JSS20V[(WO^E.W
MH[8/PI.H&]L^:.)V02L#DQ.<H,[T3EJ]DT&]7Y@0:,U9B5B[PYBT3GJ#?S"(
M-: ,:@TH@UP3UV6]TU;O=%#OYTI26!.D#BZ3&>6P;R:L-$[>J2'!.DFX-&""
M;C;W,3@*.HO J@\*)X%9;-2*C0;%?M/Z"@BQ2=V@[7_=*\8DB_\'&3)M$U$_
MA2YX%#O'JLP9].F?<$2XY-'&-#B;)8X3=5+&!,.>WYTF)EC@>1VVE0D61>Z%
M>8)/RD\\6'&\"D6P+B"1$4Z-%4?#,E(:C<H6C\JV&HOM/![N,1[N8.+=$9$G
MZ JJ_)@5!>$G@;DV!J:FFY[FA7.#_6XR&F'=G(W-,*^[B)EAX30Z^[N0FL=:
M& \7PS_T(9-"_;6'/6M#:R_ .6DGA82%/:\VYEP=M3P>E2T>E6TU%MMY@(XE
M,AZND8^Y^J@C8TY0O[\MPMZ)L=_=8XU('RK"+C*^@ RFDUZFOH&S5F^?G.%+
MRC?Z\D1 C;BK9'V :WO;"YJ/^EJBTW^';Y?8T!^K"QU]9W"DKV^#X R[R>'(
M7] U#.7<3&"5Y_4%2]V0;*MO$)Z9E*S4CQDE*>4* ._7C,G7AAJ@O>9:_ M0
M2P,$%     @ B8OI6"2<_5OM @  H D  !@   !X;"]W;W)K<VAE971S+W-H
M965T-2YX;6RM5EUOFS 4_2L6JZ966L-GR,<2I"5DVAZJ1<VZ/;MP$U !,]LD
M[;^?;0@CA*!H:AX"-N><ZW.OP7=V(/2%10 <O:9)QN9:Q'D^U7461)!B-B Y
M9.+)EM 4<S&D.YWE%'"H2&FB6X;AZBF.,\V;J;DU]6:DX$F<P9HB5J0IIF\+
M2,AAKIG:<>(QWD5<3NC>+,<[V !_RM=4C/1:)8Q3R%A,,D1A.]>^F-.5*_$*
M\"N& VO<(^GDF9 7.?@>SC5#+@@2"+A4P.*RAR4DB102R_A3:6IU2$ELWA_5
MORKOPLLS9K DR>\XY-%<&VLHA"TN$OY(#M^@\C.4>@%)F/I'AQ([FF@H*!@G
M:446*TCCK+SBURH/#8+0Z298%<%J$YP+!+LBV&V">X'@5 3GV@C#BJ"LZZ5W
ME3@?<^S-*#D@*M%"3=ZH["NVR%><R7VRX50\C06/>QN..8BZ<X;(%OW(@6)9
M0(9NGS)<A#&'\ [=KC$5D AX'."$W:%[]+3QT>W-';I!<89^1J1@. O93.=B
M35)9#ZKXBS*^=2&^C1Z(4&9HE840=O#]?KYI]0CH(AEU1JQC1A96K^(#I@-D
MFY^095A.QX*6U]/M+C_]=!^"7OKJ>KK5DPR[WAZVTG,NZ<5)P3OKLBB)8T64
M7Z.]=V\,3)&Q?3-9G2AC<HKR.U'VZ!2UZD2YX\G)K^:<^'5JO\[_^BV);B.Z
MZ0P-TW3LEN4NH&,:9T"_&S@<C]K&KU \<3NLW0Y[W3Y"(M[^$(G7F[]U>>ZE
MRR-LRG(<P%P39Q0#N@?-^_C!=(W/7>_->XKY[RFV>B>QDQJX=0W<JVJ0RQH@
M>!4- (.N6I0RP\8F,%H;[QQA&N/6GCO'W$_,UG8[QSBVU=II>N/(28'NU%G/
M4$"*C)>?EWJV;B>^J%.T-;\PITNS8]X7[4?9+?R3+WL7\87=Q>*$2F K0AF#
MD5@I+?N!<L!)K@Z\9\+%\:EN(]%" 94 \7Q+"#\.9("Z*?/^ E!+ P04
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MB::VF40+QF0A'A:W0@:;$S)XA)#!(X6,PDXM9!1!-4(&MT(&_QXA@T<+&?T
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M3P  &    'AL+W=O<FMS:&5E=',O<VAE970X+GAM;.U<;6\;1Y+^*P,M$"0
M1<FRD\W%+X L9[/!Q6O#2BX''.Y#<Z9)=CR<8;IG)'-__3U/5?=,#T7*SFWN
M<)?5%XD<]DMUO3Y5U>2SV]:_#VMKN^+#IF["\Y-UUVV_.3L+Y=IN3)BW6]O@
MDV7K-Z;#6[\Z"UMO3263-O79Q?GY5V<;XYJ3%\_DV5O_XEG;=[5K[%M?A'ZS
M,7[WTM;M[?.31R?IP3NW6G=\</;BV=:L[+7M?MJ^]7AW-JQ2N8UM@FN;PMOE
M\Y/+1]]</>%X&?!OSMZ&['7!DRS:]CW??%\]/SDG0;:V9<<5#/[=V"M;UUP(
M9/P:USP9MN3$_'5:_2]R=IQE88*]:NN?7=6MGY]\?5)4=FGZNGO7WO[5QO-\
MR?7*M@[RM[C5L5\]/BG*/G3M)DX&!1O7Z'_S(?(AF_#U^9$)%W'"Q:=.>!PG
M/):#*F5RK%>F,R^>^?:V\!R-U?A">".S<1K74(K7G<>G#O.Z%Y?OKBX+TU3%
MM8JQ:)?%M5LU;NE*TW3%95FV?=.Y9E6\;6M7.AN>G778F-//RKC)2]WDXL@F
MCXO7;=.M0_%M4]GJP/RK^^<_NKAG@3.<>#CV13KVRXM[5WQM_+QX_&A67)Q?
M/#E$T/W37]ERF/[X'G(>#U)X+.L]_OVD4/S'Y2)T'F;PGX<$HOL].;P?7<,W
M86M*^_P$MA^LO[$G+S[[TZ.OSI\>8L;OM-B$-4\&UCRY;_7?2T'OW^3S1U\4
M_QT9O+*A]&XK#@G#7_8!"X>@:RU<NUT;N)I9\7T#??G\LS]]?7%Q_I0?RLM'
M3[^8%0:+U.;6>%N4K=^VWG"U6>%"L897_K4WOK/>5H5KBI]MZ. # A[,"C@N
M#*[:N>Z&\3 -D-IA;-<69KNM=R36%)!*Z<3M;C@")/)3WYIRS9'=VF+J#1SZ
M%NZY$QZ4[69C?>E,[?YNTO%6MK$==JCK7=$9O[*RU=IZLR4S$%**TOC*M3<F
ME'UM?%&Y8.%C@]+(0S_Z\]-0U#@8J&JKONPPI:E<!;)YA.]L@R5:C'SR]<73
MXO-%#W(KG+0NUKO*M^4:AW:5_4)V(^4=8E<G=(-"TWF07"S=PKNZ5L('MO\E
M,9VLW.)#3 IPM]VZ*->^;5Q)CONN6!I7]Y!'FOG78>8<DBPNMUB<EG\Q4]9#
M*F91.SCA"MR^WEKR#?+9;%S764O"2.FB!7/XIG(02-?Z4'S.YW&7E_QX(!'#
M9&W(IVP;892A5"#+-6/HC44,O6&8Q$CZ@<ZN< !30S<:P]!(I@><TW>)@'%8
MG H1E%#7=(P/6S 79]BV'5C#,QQ>&(N9#DPLZQXJ-Q,6 B 4M<.!H_H:1NA?
M>ZB=OH<VK:BUBV0B.,O"-5&W?-%2CR!,TP0C 3[J3+$V0332<0K-KZ=2@RV1
MW&,T>EA5- 4',=_1-ETUC3(AV Z,T$-AA\.G@MF3^20@HU16DA6*8&HR_DW2
MDL<:8690UQJ 2>WQMXE1I8._70U6O!8^PD<MH&!^.S_F0)2FXG;=TEI/V]L&
MIXS_HI(5ITL/[9Q8YK+OJ/D B;H,SH:W:V AK%)98,=*3*U1A>I+ZD_2KT@;
M=Z8T+9E=+&S1M.1.#XZ527FRX;>P5(Z*BRU[$@Q1"ZZ$;,3F.!XNJNETNFA&
MU6*UINV$GS6<4;8J)-D!)NT^HB4?%;AI5#''Z9G@>=(SZ.ZV]Z&'3Z6["VW=
M#_RO'2R@&OPGJ9X7U^#YWV!AQ:/S>?&#C'#=3L9_UU)!KEKPR3?QD/:FI;*&
M'M'>B%6"/?C#!:G8=@E/B/]="Q6H((M%!^S.=;Q=P0G#S^S4W=_ H$7GC1,5
M+N&V.SQK+/G.B =;6?:T-:R7JX \H@6"BE_@NB2^%$V_68 UH,.[\#Y0QBT\
M'\U)G2JB+*-%05!@/((-%\HB3<;]0;=*2^5Z;W?XK'(WKNI-#3'MQRCZ>C'?
MNT?$1V/T J]N')RS30X@KM58=0WD!2176<39CB\J\5<20QKH*TF[RY]/CIB9
MYPFS-&R+("H#EK[=%+41*^!STSB;NSWJ-F.N%YYZZC_4#$1(M.1J' 4>]IYN
M.U.1HF[ACE1RC5V)LD/>85TLX86"[IQ)&/H QI-:OA \D]&Q=DA#? S\9("]
MHR(= FB_6D-'0J]F'L40+0'^;FF5RJXMW\?%%[9V=@PH6%*.TG1*J_"++R =
M!]%*O#:R]&O1IP3@,Q^R7!*9-=TQ74Z$4H0;5U6UA.>E"U34'=24"WXY+W[$
MY]$94H%<31M-07EA=ZVH :C>PF8[15][WA%JCUPR?"SZ1O/"_[A+II:#-B9;
M/7RJ^1# 89PA8@:&2M$641 \"9WNQ6&P+9Z-\N;8)B;58K<D-M$&VBTX#^.@
M)1S#&3\>\_:S8MW>0L)^EOGM)"PQ2]!WQ/&#UIW %Z=8\J +SEU(%E,N5XAL
M-$T59'::/0RA9Y/($7(1M5M5%X80D(H3[(2#]0XG<1M;G"JA$M#C.>P'6_:1
M[H/$SHNKM6E6XGN=+_L-S96VPEU*TP>;8SZL;@>YAS$1H0T:I@"$30'F3-R$
M=9/M,#S@C*7;:O0<S)C5CBJ>%)#5;00%T4 AKLTVV8?1P$EO*L?"\6^!CE>S
M% >0!M74HC4H5JLU-T#,PH;H-=7IM[WGZ4+;-HE&3C] )G3HE9@/>?/;S">"
M5Y*\-DKQ4>N1#"5%)4D59/F8="APN<_ N F=<J:\NE?F=])>4J*B+]61UF]
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M:FMVT=2\&KGR.FV5G_C.8<0R;-E"W?Y.:6I93KP*.":,E$J#)@X1EB?R-/1
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MY.3ZDHE1F=K%D]3\H8GVT$1[:*+]]B;:W:3[]^^C3=.DX:J#5N,.=5M2#(O
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M*#)R28S*E%0_?5H.05B@R<C0+>RF9H<YA+HQMA$D1OZN"YD6(8Y*W(%>K=
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MDV5X._8#9QP%[(3Y9^YP=%"O+6=%PY$S!@LI%7HL<L=!Q\YK1>))QO>QC[S
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MJ^>>C?KU.:M],;*TEY,3:8S,[>.<Q\ ](L#Z5$K3OM &W?7VS3]02P,$%
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MK'N?/7:XTY,UZKF?/$[Q4MJV/3MO-]S&;4__#V\GXQ/3<T[_1V!)T*AW.0A
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M96^5%9>W5JD5_?ZQ%I>-U94X#Y:>B,OKUY>3[D90$.^'W]X+69?BHVV_R(D
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M2R71O^D&7%\8X[LOQ""]8/KJ/U!+ P04    " ")B^E8$&6>AL 6  #(60
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M]+;E(OV@NI10%WT?I<8%$!+^R[YD,K7P,<+Z&&%]C+!^[PCK.<Z$I2\5[_Z
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M)(.<-:6YEJN/T-DSLGRI++7[DE4K&XT\DC;:R*H#HP85%VW+'CH_; ".@Q<
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M;#/>K/"/ &CG@.M+I>QFX#;H_UK,?@!02P,$%     @ B8OI6,80=V3F!0
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MD)SP*!QP$8CH"%[4.1IYO.@YCOZ]6%IG,"/^.>1J S0Z#$15<FHKF<!Y#\O
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MLCXFN9)+E2NGX&#2'S?2!6HO8_%>H$O#YPT=$ED$3.($35(Z05%I@S=8F]J
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MJL')!/N::0;.YL/IR@]Y2^UP9/3+-<[H8$@ _V=:N^T'&>BF_OG_4$L#!!0
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MQI2IEXFOC01+Y),NW4V;+GPD781N!=>E0N]X!MD ?CF.GX0C!+ZIO6] >&S
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MYHM8(HJ_8%?6>@Z(<B%96H+5"%*:[7_Q8VE$ P!')P!^"?#[ H(2$/0%C$K
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ME*5\_Y5@OR/9MGAO?L>D9&FQN2$X)EP7J/-KQN3SCGX57WVK6?X/4$L#!!0
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MT6S*I< 3NZ-U40%%MWJSCP8G(WD'W2AK[=K>D3 +";.1, <)<Y$P#PGSD;
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MPQG-Q K\]WF:LN<OHH+'-/M:;N;E_P!02P,$%     @ B8OI6/S:K\E0 P
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M#8UCM]S2^X?*&M#W5$ISVEB"^D6-?@-02P,$%     @ B8OI6 ?"F^J:!0
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M'',4Q>P#N */8GDNMC$&9 D>.0E_@K\VF="M#'/$(\R$U+?'.7C_[@-X!PS
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MI'D!GX^$T*N)<5#VM_$?4$L#!!0    ( (F+Z5C^V W'DP,  +H0   9
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M2!!F@7Z_X5P]#LP&=6<:_P102P,$%     @ B8OI6#@$*<9Y!@  \B0  !D
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M \6R1 _ ]W/.U>:+GJ"^YC3Y%U!+ P04    " ")B^E8 PQG07 #  "V"@
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M-H#W&\[5ZXT^$=4GX.A?4$L#!!0    ( (F+Z5B,K4J+<@,  -$0   9
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MNH6X? (X6X)/OW*Z49,JP5M$)*:)> <NP$+=:\L\(8"MP)'R"_!]@<#;-^_
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M [H#*_KY)S=T?M%)8Y(L-DF6&"([$3'H10S&V*-/1(B"H%5*^QUM\1.%ES]
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M;FV## X$WMQXDXW\0UY/2OPZG>U!3?^QU&P/#0 $46^#7H *!:AJ%$O-MM7
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M:%^N@:7 ]0[J\V55R><-_6B*W;-+IO\"4$L#!!0    ( (F+Z5C=@SC#40,
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M-._!G?=1L'Y/!<U_#X>_ 5!+ P04    " ")B^E8EXJ[',     3 @  "P
M %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">, ?0(8@S9?$6!/D!5J(/V!(%BD6=
MOZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]$%)I6M6X 4BV)8]ISI%"KM0L'C6'
MTD!$VV-#L%HL/D N&6:WO606IW.D5XA<UYVE/=LO3T%O@*\Z3'%":4A+,P[P
MS=)_,O?S##5%Y4HCE5L:>-/E_G;@2=&A(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T
M>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0    ( (F+Z5B,.-ET&@0
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M"JHO.+S%]I++<F&8_^AVV8MCOS.V;J2<8]M7]5GS:O\R?/\B_\,O4$L#!!0
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MD56AR*I09%4HLBH46=5_ROINS/*O_\"U][3697/(9]UOSNDG4$L! A0#%
M  @ B8OI6 =!36*!    L0   !               ( !     &1O8U!R;W!S
M+V%P<"YX;6Q02P$"% ,4    " ")B^E8W4C_#O     K @  $0
M    @ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    " ")B^E8F5R<
M(Q &  "<)P  $P              @ '. 0  >&PO=&AE;64O=&AE;64Q+GAM
M;%!+ 0(4 Q0    ( (F+Z5C"B>/!5P0  ,X.   8              " @0\(
M  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4    " ")B^E8/$U+
M5J0%   R&0  &               @(&<#   >&PO=V]R:W-H965T<R]S:&5E
M=#(N>&UL4$L! A0#%     @ B8OI6$]Y][QV P  EPX  !@
M ("!=A(  'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( (F+
MZ5C6W06Y7P0  /(2   8              " @2(6  !X;"]W;W)K<VAE971S
M+W-H965T-"YX;6Q02P$"% ,4    " ")B^E8))S]6^T"  "@"0  &
M        @(&W&@  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%
M  @ B8OI6'$#! '^!@  >3,  !@              ("!VAT  'AL+W=O<FMS
M:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( (F+Z5@8=.I[\08  &<H   8
M              " @0XE  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"
M% ,4    " ")B^E8DM0*4W45   E3P  &               @($U+   >&PO
M=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ B8OI6*9S0XCJ P
MKPT  !@              ("!X$$  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM
M;%!+ 0(4 Q0    ( (F+Z5@E*0 S&P0  !H-   9              " @0!&
M  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ B8OI6#\U
MC(4R P  F@D  !D              ("!4DH  'AL+W=O<FMS:&5E=',O<VAE
M970Q,2YX;6Q02P$"% ,4    " ")B^E8]G D,JL#  "_"P  &0
M    @(&[30  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    (
M (F+Z5BIQ31SL L  *<H   9              " @9U1  !X;"]W;W)K<VAE
M971S+W-H965T,3,N>&UL4$L! A0#%     @ B8OI6(XG_26P!0  -@\  !D
M             ("!A%T  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"
M% ,4    " ")B^E8 "(#0.L'  #J%@  &0              @(%K8P  >&PO
M=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( (F+Z5@H-9Z.DP(
M /X%   9              " @8UK  !X;"]W;W)K<VAE971S+W-H965T,38N
M>&UL4$L! A0#%     @ B8OI6-]ZD!BE"   FQ<  !D              ("!
M5VX  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4    " ")B^E8
M,XQISFX.  !L*@  &0              @($S=P  >&PO=V]R:W-H965T<R]S
M:&5E=#$X+GAM;%!+ 0(4 Q0    ( (F+Z5@099Z&P!8  ,A9   9
M      " @=B%  !X;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%
M  @ B8OI6/*O^VQC P  N0D  !D              ("!SYP  'AL+W=O<FMS
M:&5E=',O<VAE970R,"YX;6Q02P$"% ,4    " ")B^E8E,Q(WO "  "J"
M&0              @(%IH   >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+
M 0(4 Q0    ( (F+Z5CF.JO#(0,  &8(   9              " @9"C  !X
M;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @ B8OI6,80=V3F
M!0  M!(  !D              ("!Z*8  'AL+W=O<FMS:&5E=',O<VAE970R
M,RYX;6Q02P$"% ,4    " ")B^E8OK?)I_P$   !#   &0
M@($%K0  >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( (F+
MZ5B4R$R"FP(  &D'   9              " @3BR  !X;"]W;W)K<VAE971S
M+W-H965T,C4N>&UL4$L! A0#%     @ B8OI6(RM2HMR P  T1   !D
M         ("!"K4  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4
M    " ")B^E8UM1"M"X#   1#0  &0              @(&SN   >&PO=V]R
M:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( (F+Z5AA34WJE@(  ,T'
M   9              " @1B\  !X;"]W;W)K<VAE971S+W-H965T,C@N>&UL
M4$L! A0#%     @ B8OI6/51,(\I!   MQD  !D              ("!Y;X
M 'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4    " ")B^E8-?B&
MB/<"  #1"@  &0              @(%%PP  >&PO=V]R:W-H965T<R]S:&5E
M=#,P+GAM;%!+ 0(4 Q0    ( (F+Z5B%PF+@$0T  &Z:   9
M  " @7/&  !X;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%     @
MB8OI6/S:K\E0 P  60T  !D              ("!N],  'AL+W=O<FMS:&5E
M=',O<VAE970S,BYX;6Q02P$"% ,4    " ")B^E8+$88.F($  #_'@  &0
M            @(%"UP  >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4
M Q0    ( (F+Z5A"4;15C@<  +-(   9              " @=O;  !X;"]W
M;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @ B8OI6%'%60_@ @
M70<  !D              ("!H.,  'AL+W=O<FMS:&5E=',O<VAE970S-2YX
M;6Q02P$"% ,4    " ")B^E8!\*;ZIH%  #X(   &0              @(&W
MY@  >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( (F+Z5B<
M%,RW;@,  .L.   9              " @8CL  !X;"]W;W)K<VAE971S+W-H
M965T,S<N>&UL4$L! A0#%     @ B8OI6/[8#<>3 P  NA   !D
M     ("!+?   'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"% ,4
M" ")B^E8'Q.K/F,#  "E#@  &0              @('W\P  >&PO=V]R:W-H
M965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    ( (F+Z5@X!"G&>08  /(D   9
M              " @9'W  !X;"]W;W)K<VAE971S+W-H965T-# N>&UL4$L!
M A0#%     @ B8OI6 ,,9T%P P  M@H  !D              ("!0?X  'AL
M+W=O<FMS:&5E=',O<VAE970T,2YX;6Q02P$"% ,4    " ")B^E8_U1IA <$
M   -#P  &0              @('H 0$ >&PO=V]R:W-H965T<R]S:&5E=#0R
M+GAM;%!+ 0(4 Q0    ( (F+Z5B,K4J+<@,  -$0   9              "
M@28& 0!X;"]W;W)K<VAE971S+W-H965T-#,N>&UL4$L! A0#%     @ B8OI
M6*XNH[,J!   MQD  !D              ("!SPD! 'AL+W=O<FMS:&5E=',O
M<VAE970T-"YX;6Q02P$"% ,4    " ")B^E8Z8P<V?L"  !&"@  &0
M        @($P#@$ >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4 Q0
M   ( (F+Z5C^V W'DP,  +H0   9              " @6(1 0!X;"]W;W)K
M<VAE971S+W-H965T-#8N>&UL4$L! A0#%     @ B8OI6/9)BP<-!0  WAL
M !D              ("!+!4! 'AL+W=O<FMS:&5E=',O<VAE970T-RYX;6Q0
M2P$"% ,4    " ")B^E8&NO0D2\(  #'1   &0              @(%P&@$
M>&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4 Q0    ( (F+Z5C=@SC#
M40,  $H4   -              "  =8B 0!X;"]S='EL97,N>&UL4$L! A0#
M%     @ B8OI6)>*NQS     $P(   L              ( !4B8! %]R96QS
M+RYR96QS4$L! A0#%     @ B8OI6(PXV70:!   3"    \
M ( !.R<! 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( (F+Z5B2+*"6N $
M .<<   :              "  8(K 0!X;"]?<F5L<R]W;W)K8F]O:RYX;6PN
M<F5L<U!+ 0(4 Q0    ( (F+Z5B,3^J/N@$  .X<   3              "
M 7(M 0!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     X #@ /P\  %TO 0
!  $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>82
<FILENAME>0001213900-24-060183-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-24-060183-xbrl.zip
M4$L#!!0    ( (>+Z5@:FM\+Y!$  'NY   1    86)I;RTR,#(T,#,S,2YX
M<V3M76USV[@1_GZ_@G5G.NFTCF0YCF,W3D>6;,>.'+F2?)=<IW,#D9"$A"(5
M +2E_/HN0%*B2 *$9,7':_G),HF79_$L%KL+"'K[S_G4M1XP9<3WSO8.7M;W
M+.S9OD.\\=G>?7^_V6]=7^_]\YUE_?3V3_O[UA7V,$4<.]9P8;7\Z:QO$VM
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M8_H GAKK=%KED&\#I"H=#16Y9 8_'Y3.0<:/?X!US!"E)A.+YWSPZ)?9FIA
M5*[5Y?48"]Q#989-.---QLC8D]>PE4L?B^!I#T79ON<TX8D3YN%:F'(08#U\
MZ&#.(7@OA[3;0-:.0'R;4LE850/3;(, 3M;\@ .PNI[3NL&C$<6+-O[ZM2Q>
MEPE$M7R//M0/Q)=-H.Y@0BC'V!.G-$HB7!$^U>J=JO@(;Q;A>="EZU-:*0O
M*LF\]XBXFP*JW6)'!$XM>"<24#?^!'G@$%T%,*&AB7&B) C[O1RC\%3X:N\@
M==UC=-OI*E%>GFMFC)'J3J=H+N\NCZ1&*,7LEC=EAU?Y2H+_"U!+ P04
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M>CKKG3^QN\Z;ODQ&8]FPH T)Y3./P6)FR8J'2<LT)1&RMF[&H7B%^6O<98\
M]@S\C+@*QL!$[J%!.N0$R\IVL8O$30A84DN"2WWF<83W!:7EXVL2#H0#[S/[
MECU65'E](K]#AO$ :&JH;\Z=>87)]U%]P5X?)@Q!2="^M2G @/!#2[>J.Q<D
M&7:!D(QSMU#T1=A(/%MWYWU -MKRJC1.'?S$9!MRPNU?"(^W4)!?6XA3SR]7
M#<*BQ#)Y].-S/V(TAFRFFUF7\&SV+1"4=9:.I'$6$D/PK] >R;1C\KAN]UM
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M[O%-(A<SS+ -&DU20$.>7* #>7\3,DV5?E#OUTWX15^'29XM$QQ^00$HW_:
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MWK+CO.7T:-UH2-];&G,;X!%G-;?2L9<D9_#,YD:"[/ RF@42S..;<E:S'=Z
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M.VW^J^X_6W>M1]9KHO.,Q$&7$2JM3F ?.IP]<+CNI]6![SK4!7N*;</@+'Y
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M3F)6KY'MIF?S9KLR=N&R4>);-*I<6Z##T1$98ZM-&>Y1'2[4&>N*C5OKSHY
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MU0VE"=R:EA?/+]OXM[?G=[>NG_7$?&C4O6XO9DA'' KMM$A3/%DY8?$<MNS
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M0JVK5[<<NDJY4>2NDOQ-+W53-"?HF<R!#ZL;(RT]=X3H&/>I70K\5)*Q9H.
M487K8X971705KL9."E"9<4YBMD=+(FOG61YNZ&,;?#17X6KS4TG"#E8_1G30
M'9?#-KU)IS.SZWBB'OQ4 HW0(DTA=X@^L3B610.FRR*25"@S*%0I9+7!B>B?
M)O3Q"<?P]#2]?&I.;CO750^]COBG$@@]D!M@7/MFS+A_&"ZE22/S)(0KG&48
M2_("WWLYN(!V=U#&<"J)-<' MM@:X*AP:[DHH*L,>A_&X:;8(%ZLSPK'3Z4#
MY(*795/"323050 [(>\',M_=$XX>\7NRP]9C7WR,T9B5:'<@*I%O((1K%3Q4
M!)0%N(\\TTOQS]A+[YX21\);S6[_@5\30[FP_M&EL]*0RR;RR1/"\!53:RHB
MB6/?]/7GM^[,U$91+IC_,>/SOXO9QL)9DV. ;U-GP@O"?H<22J=WX2'015(N
MHM\Z#6,RY;6I@-:T&-8\=9U$ 6$1>,3RW8<DQ]/[!-3GM6U\*F,F\Y72,:BN
M]>0XB%J;P:WNI,JT,#<M]Q"7JV;#;.H?.TVR/-MW<ZE3?B>2S:'8N-"@ W%6
MZ/]S*FS[[J(1VCC"TFB6-@+US%5P'97:FH)V_*6;<+FECF&(2&'I!UE6;-CO
M)O6$C8R<DQ;OHRY!P8>V?RW["4,!-/+#XI$<YP\8O4LAT^:,_!%Q,5(S2468
M1A#% =BCL6)8V[?[P^Y@W-O2R6[_"8]D'1G&(0:%R*!/]QU.-V_&WH+3(>JB
MT?QDJY'98^4WS=J*;C;8Y"+7:G\W':6-LXV$7?G::+640Q=:/R;DH*8WI!NB
M6Z?8@!-C;+^.^?2+ZMN0C_77,]B6=B2ROSWE^!P8X+L:%<6;,/MTD6)<E>29
M^TX5XCN7AJTCKDD6<T,^?;4BWZ*PJOF4DJ]=/Z19$\G)MJJ4!Z8-.J;0(V<A
M]!2)@[EO4B&^+WR3BM;4=Y8&Y;=H%^+(>3*8-9&<_#QM\<#V)BUOP]1QD%W&
MUS@-DZ#R*Y1N!?I'<"K4*YG+EC7$WKK/W^[Z))NY&O?**[U%#]1;%("W: 7>
MHD?J+=KB%&6 #?I#&*.S)(J\--O_]DNWB?QNY'P4/3" F>9/'R*7&(\W[Q(K
M&WI-&_LX D+6M^]@E!6\NA0(8E#0HMU ;B8.6S/9Z7/2&E!SP)88=0-/D4(V
M!89.GD;&7X>L[%(!=>Y@'Y5#C]A;B/,N9!,*VW2'4C,I;II-E@TY)L^?<>J'
M&;Y.0]^Z,3HBYC.\28ZWNAXSM'ZTK 8A.DJP<>>X;<<77ZWM/#*73&^=<%1?
MDELMN<@6*=0;I-.Q F#\.5[-&$P1YJ6'@(LW26TLU4^Y>L@,PL",)*$5#Z9/
MJ,F>"OMV687&BSRF])!W]91O;86FIY5@ [[$\\I(E$<]LO2Y93U$H,3T(DE7
M.(1$1LA6/7_>ABF%,$LU,.E:YJ@5IERPJ9(H)X7VK7& ?(_LYRCB5,8<-8:-
M33#F%78X8P?I$Y-(J!+S99%G.1$,8O <X'B#-UX(]08A)1Y*<A9>!"%2;^<2
M SA@!2\I.-!\F:H:HP: . @(0-!GF!WVTNS+RNQ'R1Z1(X3I?]&]%X%>F<7;
MK)O-,$ITXD!6N[))2FT&?G)V2YR9G='&[Z4]PK96H'Y)K[8MWH.8Y;:=0O[&
M/.+%+'#W$L3A\X),?E6L7^*+D>+:3.UXG8W\LC>Q;>M=AW'V<W)ZD909!;-)
MUAFP@A=HJ!LL<U1#_65H"C<[84PKW93/KF[Z'+Z7!*TPSD*?1GG-6$\<(OJR
MU<'!:F2][!X>4MK2&M7?LUQ:35O^9>]LB8A.M(%%G'%UF_X19Z!*J!N1Y24F
M\"O.*3#+2[8RVB\G'5!S9?IW\D<*F?KE<9W*F]!?=]W17Z!UKRO48YKW6OQS
MD5&HC.<+NN@/7,Q+<] -6^Y0EX"A'OD\%8EM[\$(K!_H11Q@ VDC_U*<#2,N
MS)DO<A;+G\@W\=)4UBQX,<4M:&1)F2YHWTP-<Y>\^F+=O.V]#,-)81V?B<W4
MOU)SQ\F__85+?3M8,)$4.3U& NJ')&:\OR'_3^PN\A.-Z?X8A[GMW%,37-RE
MG1I@JY!Q>G/[L4HTW3D_W\>0$G&6J2GQ'(05L!JXES'!LZ AT\M\C=.[M1<+
MTWKF<FKJHOURO(^:*^OU/K),EB/8>@=!?"\BZ6UDN1WE>#-AD0L'HR:>+Z8$
MR^CKFF%.K*VUJ][SN3*_![5^_]U5B]V*+I/PWW8%J-Y%L)O#YZ>8=-?U.2DF
MS;5/HYA^W'L"4AQ!(Y(76ZUCJDUD1TV92,/LU%2=8_?BKD=MS#\G5=-:W8!;
MTN>41VDNT':4@IAO<]WVD/;Y^9@F6HOZC-PI.NN>QB;ITS"?G6%BLG^L*B!U
M81CBUJG=Q>>;;93L,+[%Z6/H8\GR(@J._+1<W6 _>8C#W\CJJ)JDW9RF?\$8
M&T_[6F2JI2@\?7Q(XE>^EZV/F*TA:$&&X)DLSF;3,FDBL10_F4S!D &;LYP)
M!V)$2DZ-O-,4)W41F*2&FF0;W"6Y%]&7=_)-YM0IJ,=77E0U*& <#'--0("8
MQP$]F*Z)2*<X#U-VJ.$8K\(\F[Z3J3$:MI^K31&5M1XH=1 JAZ)K\F?'S4Z'
MB@0OPH/(9?XV?1G[R0;?><_32V[G5"[T9A="$BED0Q 9P^M*-]*GPCI>PGJ7
M.T)+T?/5"D,(!:XG@TX68 [$?AB%5!M;"NDQ0,5%*N, ?!4,V[V\UGISD>=I
M>%_D  H"[99%BJZ2+$,@7:AL!)[$,ZDT;RY0$E/6C,JFB8?[61HSU+\N+9.2
M-XO\ @>$_M%M[N4%@;IK8#F5/AX%-_LNZE'QE^RECU_=?H56;" *V6;*R6:Z
M+S>3EZ.L@D?[E;FUH"<1-^$9,AK-#1W($D1@(DQLJ"LR.*J_P6,W9-"=?3:;
M0X:A["B!SP5R?X1BG,/Y4FV-\O>S,8GTI$)!PCL)IRG#WGV8R.99!/\JLAQL
M_KOD#*]PFN* ?+3(,IPWA1B@4,D\_OKK-U0ZC>':NAJ:(BB1SNHS*ID>?(B\
M&HH3/3R4LR"(@XAD;,)+)J1WT?VLEO1H:U;KSFA%Q"2"23]S'+JBR5 %%2A<
M_  WKF2:TS6\%%W&A_*=P<-.[6E^@I<X.]*H@Y!M)]MPE"4BS""0HY]V 61/
M(%XU9J;'O('D*(B]+BU'\,4UK>BII/Q@EBD\</"VH"2^35RZG6^<'>K21]'#
M+:%D"98Y@M.M)9E@IX;$CHAHRT!+_C8]+)RZVK1057D^)I9GT#)&,QHR$NWA
MSL.C9B0M8F>:/AUU_6C4&&Y/<Y_1+'>E"Y%\M$49[,9$^7Z3?>_N6M/+A?KR
MTKU.0X=/"VCIJ8X?P'E]ZJ7I;I6D$$B4W1;W_\(^N2+MFSZ,K/4&(F/?'30,
M85F$+OB *C@H@C<$GX?D^ 8TCL3PFF\$*HXE_<0J34/ZAD-+?L"##MBJ/ I3
MR[P*"C.0= 4TY7>@<B3RN:'S%G(-P>@4;56RC270Y(=3\N\P;TQQ@S-,J+&>
M6I9[9I^!&'=C*)'@ZL]U=94T!-<-N\[[%)SC$!I#.>@47052F7CL#^>I !*C
M]PP_XBC9 FV-;%()*)M!,1IXR=2EMR4*(X*H3Y3R@A?LAQ)%FN5NWD@->"BU
M:#OH8AHIT)+B=TD2/(511.:X)%LV?@BA)@_]T]3:L&MJZZYX'>P4)#.LA[A]
MJC?A=Z?6ZR/+ $^]2,-6ORM=6HU(\#BH A;%\;@0#F[A1!^,HGM9'V$5TJ?]
MQ/]4)CKXW)#YF0-C25J?S3 *H9WLLMGL)2=AO.;HRHH6^GY:?";;8ESA-WNQ
M$#L%KZ#  ^<M-G/FMJ XMYE;*$FDC'XF?!YP;A5+>2-W\0H7/9HM_.$P^&E\
M'?<!3_(@T/<"*L)#_3F@CL/K?*2?@\+Z@-7.X0]XM&L4)XWB!Z,QA4@TF8,W
MSFZ,5 2+4TC?NX[S4&.F1)YDZQ]-*7$36-!/![.-'6BDK:>:^'2\$ 4BZ=K-
M2SN)6=FIJ 3KUX_\H6?I=9+C. ^)XMZ=A5$!R2FWV"]2"OO\V8^*  >5"!\K
MF4F:(*W&_^KA)A$L#@@*2B@HJ\$<(5P"<J;#!K"VMK(,2&4<3G2%B5CC_8,F
M;\_MRCH=&>LS$.!TN;H(,]^+?L;>V$W/!B#BXO9ICJY$M($@3K7C<$G@%>=
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ML$XN,#(.-6X:PB4:RH2H2S2YYTTB']US6<]&Z41'5C"U;*X-&8#EX%)\BOC
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MO"YMJZ'F^F!8#>WK049:;C:GF8+U,%2/<UK\0Y$]7(W9_M6;Q^\5]QG^M8#
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M!Z[Z)01W^U9I@2TF:I#%]FE[%?Y:A &Y*"[BX%U"D#L%"J2QXGVD'DZ=2P\
M /D,@DN327%5;4;I4,.%>GT?QN&FV.QUP'*U)-?U, 85<9EEY>M[3KA!L)=Q
MK83":U*RNY(:$ HI)!J74()RR$R]-;=X:D(R!W:/ IK=1Z4J4YT?C<HK-6'E
MX?%GF8O5*4ST1E;:8N12!8)UYNVDK-M[#?S].+B#PD 4D)'N3KSN%;58I$(
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M0:[(")T)8G?K,,TQCJ$U9 ^?B#67EP,ID_)R*-J2[]PRJ&=);>XHT<#V=?0
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MONFMB77+!KYZ>_SVF^.OOW[SU7,6_$X'E$TI4T,)J"=2N.5@./ZJX8B,1S4
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M<_EB1*3O7;O= O/O<?K0[$HOJR7/OIQ+S7@>[Y8.DJS,9BK<%%;,60A=R^/
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M;*[X1IRQ._@4]N*(?.O D1^[H5C6,/T"9M]P.*:WA=+B,IY";B/VTS$+0^F
ML:]OTT,'.P X"^UFT*+@_DG7'.$IN(1>&=#&;3TAY($BS% NY@Q*,,-,C8BD
M]XLOR2 A!)="G[B6*+N0JU9L++C!M= X!D/KF@"S%&1.>@L$(8G@ ?8T>!"Q
M#&/+-U):Y%JR^+BOZWK/-Y=[2#Q4'G#IPJRQ5D_GC(P<>I9YC<0^DBC>8X6$
MJ^/31$WZ;7\M"_[V-:O^R9NK?;&IPP6Y\FFF'F?R^>2)U&%&L'4)L4P: [))
M#\NBR3?Y3@;4VT;.7WZN=_L-WUP)/N$#VS>9PG Z;($^JG61^RZG4S8S;V,@
M5N:\3_8[ZO6,#W8V2A2O/+D\T:_Z3*M&FGI<\(=<:'Z\,GCK6DVOP]YG,>Y3
MDX,*W(YD9FC2\J18SE!]*TH:I!BO/<B-(0T+ QZ93<:BGQUL.8:83P%E?41+
M)R?^>PU84T6=KR40*DD/L$[(WKY_1@C39Y&L-XY_QG4DU=ID1HORTPU9QS+3
MR"2U]3$1TZ25]Z:/GLL>)@DS/J\+@,R!^[U5U\,:LAW1Z1"<'BW/STDO2C7$
M]#MI%R7_[Z_*!E>6USE/7/D/IE_73]][5^E1B.1.FAGE79ET76)C.N%"(&2M
ME?FVUZUB0+8\'[;#AMH7:Z>Y:MJIV^FX;8H'K*ZT'65/*\.P[766!2.L2/Q=
M6!A5M@-HH(VP.F32!ARY>@.$[Q@]6"$P=8;;TI YV&)1/&++/$(XI-4&-DH"
M%1#M-M-X8')']0Z\HP^%&<67CA0 MM0GD6G**)6O'Z_\8[#5<R]N%>C"K#(N
M#_HO)P]F#?,^'-Z*E1]I)V,'+__SOLX+7M>K<I>OWSH;#T^7M6,A/]J,9FJX
M<V\G;3$1PV'/+(@72WIL']@XLDPM[#3SH?G <)D2I@G,#;VGRQ[J1(L4"J'*
M$Z6RV5:NTD:H'TK53]+^'2Z$F[+Y7]ZT"EU+20TZ+/>9K(W;R=A*+NG;AXVB
M2$,3S[H1SS7LC3>LG=(<TLB2R1O;CXD7_Y=I?VA%%-69;C;=KT>W/'Q/[I(3
M+MI)W2PGWTR4QM;H&#<:HL8LIQ1'\9@ <T2<^!<XR+I]-M-77Q^V:7V?A:TC
MQ4Y[W&!+3JA_0J_K8N_'MS=_3[KR9A+8RG09H#6R[L0]4>5K<4?(H-!CD3?U
MW?UCV$_9#M+!,#F,?1 #ZX]8XE@2@0<8PU=A4!*$F[IKX8&"'.UN@H>3!X)[
MTQ_V&+5,DOJ$NN4Q!A-E66PNQ6>Y*RV"?UP1M061D2U('1(IH>#CF$0<0_&R
M(=5>!N((OB]E.+PRXZC*A'C*/$WD.@Y7@_MZM9N_VSX%4_7+^H@D=L3R-4_U
M.S_,4M,\Z3),TC?/L!'>APUET-94P4 +&7U&8TECU95;]5#MP'0GK<<XM0A/
M:OB$UXD2?D$HHV+/U\(,^\HW^3K; <@U3.V_2V&&%;S^?=_P0DSVV7DRRXM_
MM]KK?R(;JWV8:;I,$880ER'-+&WF/@_4>]EOU(K-D7+I:3PGD7,J@)E55MU6
M$BI@(WU[QL\4 SDC6R2RLF)JO'+;MAZW^0#1^)C$/OQHV=#!-9DF2[;KDCI;
M?/:%[2;5-IA2 Y+U3/ PT/N2@HRF^D+4'%3E7MQ7H48LF!J3U(/DX6-@X_=9
MIC&N6^BB+]_$<2EL_-^K\D?S E=P5@PUGC!CF!K$]*CD4$TH+^X*1+&=P,.W
M7S>R4A5,^.H['Z@MZ QA>@Q69)#*KX>SX_7JA;@GQJ8X:#TJ7>E06*X+HF11
MQ,A&K2KJT1+112'SZM&*,HHMV"@9$3ID#XQ/8QM<0IVHSE9PFU3XUK#G-NA9
M9IWV()I\THMG).?8HDX27IJ2;=P4=*OZ6P E<:M^4[_)[/U1Y=H!8]TM,!*Z
MAX-FU;XP7#"0M%[@%!)$[?@SK!'M5;SB19W+OL'R3%N5XF[B35XI+X2N31Z!
M6W1G![.V6'L^)213V<46_SC1$?O 4;A]E3CH6TI/5P($<RS%2@88PA9KD'_*
MH]WF.K6[8[AVH\U=<Q#!_!]7BC4)\H6M2H0@"/6IKWE15C*OI.&"=G/[H^!5
M_9*_KG@%9:I"3?C\!EH?I#67.T'B63WBO5SW3W6^R;/J;<$L,=92DWF+#C7U
M4%+-:K(,L.4]4J"4GZ0N EIE%3A:0\ D^DDF'YU%\5M_[KC9B7-(JV_<\*;;
MG!%M8\2;;O=)MFR:*G_:-U+!;$H0?KH$!I073.0(L\3U*@;0[ZJL'@4_59/E
MA;@*A:XBFP4,(3K8\4S<F,Q2$/\MC/P6HI(C< \)L5^&N,66:IRD:(.Z.+:;
MO#</,L2DT2%;"'JO)&G(*6I,D;/Y Y*B[#G53:73-J"DF]BBFR(*U'";+E/:
M+[B#23*$S'0 O3(;4":4"6Q9 MQ2QK:O"_'-9[O=V_TK7^?;7!;R:X5%G _*
MMEN+)[KA>#].BR;'+#U'"81F7*PER=H>?@=Q->);[AA)]&)O1TGT/37+<ER&
M0[E!I$V=1^2&O:>DFW%2/VDJSI0%[]P=XQIM"%.2_VLO7O[E.R2JG:O)AN\U
MI-^@9Q*^SAKV<::>GTU/C8$UZVS#$,_$OL)+<187\#T4RN@2VWPE)*[K:JNO
M6;-^$=N]\W=UFM]NY1\#S4^!,'-',B"]8(8X,]0[#RW,?0EA"OE$2COC:/E@
M&^!$0B>U3/KPF6,P0Q/?.?W)A^S"0Q9IK8!^!'JY7H/ONA8W$OA$1L;GS6BF
MAR?O)1'F+BXHCXJ$L&[G'IJ3;)9"0=CHQDC*BW#'&_&? /5;%OOZ#]XTO!K
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MJCAL.WS_T<$^7^3$GSD>FBS9,MG"PNVUY\1OW'?97H!0;=+DD#X76R$K XV
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MK)O8( ]8^0@O E:AL?K;UBO&U:7!=T,-.P#'W&O9NP)IR;[V5WRCCQU"MLN
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MU'@<$;YZDZ]5!YCZZBC4BK*6=5#SEUO+5#P&B,1<KG%II]_K@.)X#(F'Q1,
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M>$/\;CHVO(F!,[S']RK[^]4W\A6YC.BMO&6I9TT>/W<_\.RRSX?E&_?V/?Q
M T</!EYJ&?2PZ]V\AQ_>!P]3CD_7]BK[>_%"+-\]J%4_Y+]7JU3VW\LGHA?N
MBYZMPK..;3G\][/N1?QXD/]\_.C[0-V7$<"-XR(K>Y7:7K66&&0/-IT:2!W"
MO'&JAWN5X\1FX<EO<W:*/P\,GZO'?2]>^\CP!_0D?)DZ]-#?NS&,Z>R#\H?L
MPW@/?N[3]$OZ\:(+A>6>O(=?U8/X@YF!$OG<T7OQ8_)1:]YU.WY@.,/H$.[M
M.0__?@%'%C^9/=Z[?7JT>G)R\IY^C1[U\YZ#(:OO?[^\Z W'?&+LS:S$MU9_
MJW@]B,!O$)&Y8?[R4V %-O^%_?1>?/CG3Q,>&&SH.@%W  H"?A^\IS>(F.SQ
MOT/K]N<W#?'[7A^N[LU[>.L]C?;/GP:N^?#+3Z9UR_S@P>8_OYD8WHWEG%8^
M3@T3"1E\&KB>R;V].\L,QO G3K'W5^@'UNAA+_"LR2F;ALXP" F:/S(Y JM\
M9&H,5JU,@X]O5IQ(_'M4J4SO/T:#,B,,7!CJG_^@P8:VX</9_6F90&$[@[_X
M,.CA^!T@RYYE\CW J:4G3/])*_[G/_[QTU3-\J6VPF C./*]D3&Q[(?3OC7A
M/FOS.]9U)X;#KGJL%Y@EYG//&HDG?>O_^"D=D_@3ISEUD$;8XIM;P[,,)TA]
M=\>MFW%P.G!M4Y[0WL - G<"\\N_;3X*XK\\>C[Z,W"GI]4:S.EZP , =$].
M8$,W?&\ _.7;GC$*N'=JW+J6F?QZP(%V\5.Z" (&P[9NG%.<2?QM.28 F[A!
M]\X_K28?&\)/W)M9 0"'/X6CD4=]!EN*#KO@1)*[?_-+W6<CRP8&>V<%8Q:,
M.>OQ8>A9@05';S@F:]X/88\W'-GOQ/*1:3/X?^">#^RD1!SSI_>XAE]^>C_5
M%[^>BT_,AUM,O$4KRO[^9"AHNV6VO[^_5_MPLG_\(7.?">HC[NR4.:[#/S)Y
M@_((F>F& YL#(#FP"UPR.RKCZF)Z5K$<^M\!?H^?%-D3QY[Z1AP]JY3E!M_#
M,C1X;1J\9LG,6N"+7;=;_>8YZ_7K_6;OIX'W_I=>LW'=;?5;S1ZKM\]9\_?&
MEWK[<Y,U.I>7K5ZOU6G38U\-?PP7&KA.B9V7&V4@.(<')YKB/'.0B$_TB ;[
ML_#_]%5O\*IKBZYZ/3+&9;-]#O_KLW8'$)CP.G#IGT^=[B43P\L141/<L^[W
MQI8)"S]EXE^XO&&P5WGS2V\O$C?P_6[S<ZO7[];[0"\$=<%YZ"?U6';MK0 V
M.\S;@46_Y.W@NGW>[-*H_2]-EB1=C3[K?&+5D_U]#:@OC";]SP_'M6KUXS/[
M1X/A#H"A=0];==KA!,YH*,P,]T&7CWY^,ZR\88XQ@5LPN77:= (K>.CR&\M'
MZU;0AE_>,,O\^8UU?[NW7UL;1%<%2->[C3H[:W6NOM2[E_42:[4;Y12Q?)]:
M^5,)_]OF/9!MVB]S1\R+]LD,G_E3/K1&%JB>H!%8@<] S_3@.-]I"-X!"/XN
MPEU@H (I9VV[>WW\>X\L4]'\XH)9M0*:X8^1#CIT;=N8^OR4J4_J)U AI_?,
M=VW+9#]4*I7H%3D0::C*3E8EO53^ RN')7GYZV'"=D;?=-V[AFN'$V?O(%KF
M6)R'--+ .*8:I]_X\B:M3TNHD:=*2_V8_D6LM0ICR>_QMA,6-_DMP=?LUW"M
M>6/CU_&S$I,4!!\DOB(@WD]\(> X^8V2%6^Y%UA#PY;@)09+#X23R;/?KY5K
MM1]S# 3[<&5H#)B]JHS-(6%L@-/)LTO(G0L(^/B&W=+*\.CQ5[R::=[-;(;"
MG&R%P.#%)#$ZHB_5'/*"9&0Q=9%THH"^+.1XPFN#7(T\/:=^8 1\ZKFWR!JX
M,\L26\X0%NUZ9!SOX=,--W0"[Z'AF@D.>;!&#BD(WSFWC3O#XT4,$2C5/WYZ
M'YBO':7S-E/)3E"9F2"!_-5RM;H:[M^-K8#OP;T,.9H@[SQCFH/0__-#]:CR
M4=]1#MDMO M-B%\&(4[+F>N4Y"1YK!WO'R:$-DT*-2E\%G>T BG<+^_O:U*H
M2>$B4KA_M+=_?'AX<'R20Q#?!][*RN/A,LKC60'FSJ#<ROA9B(C[JR/B_O*(
MF'D,WGZ"4!*C$HR3QB. $C(O[*8-27[U6"O2.M!IM4"4)SN%WI)6QUR/N<&8
M>^ROT+-\TQH&%& R8F26M))J(#WKW1B.]7_T][OY@LASQY2Y$\[A8\4(M6XQ
M@W"L2,9X[L?_I)/6I.M%DZXKSX(=/, Q&HYI>"9K.6;H!W!$MJ!;#1S:&@%P
M$.%"HQ5KAY-!VKNAB98F6KM$M%;7?#31>CY$JU7NEGME ?G-R=1V'T#J(FK5
MPNEC:M5VRWE42J@T[^E2M6-V[8Y9-'?,=<P>/%V'??-+M5+]4&&-<>@-QZQK
M./#?K\9#B?5"H)GH5!5!E]P/)IAIP;T2:W0$S!Q7*K4J_?SV0ZWR3GQY<E#9
MJZG7WM9-T^.^7V(@M]LAWC_[/PO !-A?B8+) V[SZ=AU.'.(&R:?-. 0Y:.I
M6 &*:_GPT6=3#QZVIL!C^3T?AH%UBU$% +;<US$#KS9F(,5Q_AS9H3_>S2M_
M(LLY3MQY;0-,9W_[<:'],9RSS^J2*?W*0^X1(;D"*F+A\HAH-,86'['.%#-!
MD5!T".?%DQ30%.5BED 0'XJ I@T0NKR 4L>EXW[R40@BJB [/W!UM1'%!C"@
M#$CO^N@R0!A<"\ 6HL4MW(,FO9KT:M*[/M);773CU?P;?TQ8>\.=8IH?HK5M
M XY/)J$CM8 4L4C_ K<")"!P9VD!7-C8#6V3#;AZZ'370_S^^4]8UC]6]=4<
M%_AJ:*P7:5*08]?FV7,*?+ )&\/!<?GXY$DVAG_*"\O2'VULV"%CPYF'V/\)
MWN9!((P,S0"VP"["P/_&Q3==U_=9WW",;X;XHF?<6AY3-HHKH#CRAZ^6[;L.
MZP'QL1R+?79=T[.&8_'<_QB3Z4>X.!^H4XE=88Z@D "/CZOL9!W"5 P A\<_
M9H';#Z=T8L%X/7(;0)['>1!)JM6*V,X9$M:TF+I?J8G?WNY7]J6<6CL\VJB<
M>G@R(Z<*RHX(B8:BUTT!8SOK\C1QTQ9N?2.KWL@A"!Z5IW$IS:)VG$5U'^!M
M97JX##V@K$W_;\D[SCP#U\ :\O<S[J%$'#_0&'N6S[[*G_N@79,)(7[@LS7P
M*6<]=)PDGVIX83#$>(>+BROQ9 >T[N9D@$6EX/)=UJ -*OI?.ZI4%'=TV"=8
MU]#RARZP@;HR3%2K5<D&#JJ'D@WLG^QOE T<[W_87\P&R&> XIIV&V@#P9^P
MC]V\\-TT#]30X5-DG%VO*38=#/KFE_ITZKGWU@0#M$R*TAJ1#8 [0SY!R1[^
MAB>FKL]-YALV/8"U@_RX=E#@TC?3<&!;PU.61XT:8\.+*DX=91:<6(T/NCV(
M_P:Z@(PA\FRT(=#ITAQ\-.)#<@>IQ09CH,[*A41.3<HXFBB3,JT5?O"QK( ,
M+;LS8 1/&4-$4-K0=4Q+&#U"N!4QW27W;N!C_0;D=!K1Y/[0LP9P%O .MYRR
M1H.=0(,EX:LU [L#CE8O 3]PHR86O"*0^H15)PV/RR=< #Q/)# #I#A<P%)4
M22NJ54A Q<: :M*:!HM\4( (H\'(^*5M864[\;ZH?&FSE@,@'(J!/Y<8B [#
M;W)PVW;O<+R!>Y^+7I\]/DT;UI+ ].^O\"ZNQV>U@W\#$,&][>7%AJ,N<?+A
MX*"PLH"&ZIV%:@6REJKR!E19@35ZA8BV 90E8!_-N88C0!NA:QIZ?F@(@V\W
MM+F0+P^.:F\'4M:,*6.B=%Q]&!1#*T*^#8O(>:F(:@N_E.(SW/!L"_Z,*7_!
M:[@;0>RI!('84UFCBT:7!>AB,)!N@KT8P " '%/ %&%2,5Z8&B\T7KP8O  !
M>(A2]>!!@BT,^XW=C3D)R A#B;(NA#@VS OX,AQR6Q;O1HSQ,-(@]UO,D-O+
M_<&'(X>/,,/4]8*$[%1"@1T@&3=XPVX\]PY$)OE;&3"'T\),/K(<*;X#@F @
M6:WRL6AY]'/UHWILX0/%BU,/(CK+APO6JIX$ 3*F(=7:8*^F,%J57Q4_ 2'(
M*A<[YU!=U95:7:IHRFLR62N,57'93PC+CC-*7VRL^].< -\I UL??O+PGQ(4
MD)<SK7TM3S NK]N6V%6>BCA,4_R-L9JLL%3GDO+)!7)S,5Z"8XLOB&V_['PK
M301?RN'7CLI''S01W$TBN+P./%\%)FJ'Z+#_4=,E39>>P^'7JN7]1\?":+JT
M6;JTK <U:\O0Q$<3G^=P^+7#\KX6BG:4^&S0,?"4,EK55U5':SUI&4^N_*"I
MV6[&?NO+6.4RGIR<I%G-^EC-:A7%.94-)^$6W94WKO>05U?\$S[0D _$=<0!
M7QXG6;?3KLL\N^-2!<0U:FHZ^6PNXTFF2DTGGXU(?J2-E)IHO93+>)(=4Q.M
M[V_$[(EX*P'_4="5^%.&4VERI<G5"[F,)UD^-;GZ7KKHZ<BZY^9>X(5\5ODD
M"G86^I;#?3^A?'[8WY885ZR+:DNKMK0^FV/6W.VY7\:3+:WZY#4://O+>+HA
M39^\1H-G?QG:-+-+NLXC3#--F=TF$$"DN&G#C"96+_$RM&%FEXC5JH:9D6'[
M.9891< ^$^EJ"**5L- <'V\K]FV1A2:OD)K.G%]CYCQ^G_GST14EX)V"Q&^L
MKIV;6&^-LCGU8\-GW.9##-YV7*HW$?HBP1WVPV$[)L,G?<IT9U.X-=>D @]4
M4^@!)Z>20EASR(%;=C%G_=;R*1C<P8*"AHWY\&[H4!J[+[N:8;DM]]8R,\4N
M>J+,D> ?']X:[][6WKT]DS4O9-9ZNG:%KBOQ8K!CG?56C.G4%K7<2FQJ@Z@"
M$"J@Z'<LB(!PA$51 .1,[L,R$5GP2P.KTTWA1.%O+[2Y %,?@=_CM@7@&D[A
MLRC*96+M+ !J*NY":"(JOF7KTFMPV6EPF2F#D:R7L<_W#MY:D@*];7BN[^^=
MT16QEN^'\$^?4RV>#A:Z>:>ID0:O5<#KP-RK1D6=TN#5'UN>N7=E>,&#AK'7
M"F-/K9#0S\A[W.,@$U*],7]N)5/\(QR.9=53C_[UL4SJQ'C %BP.'W+?QT:U
MQ$-M^-8*_&RY5)3Z[*S0Z8^Q""H&,C.#C4*/BCW%)=#NQA;,ZT_YD-I&VO:#
M6!:NUPCF+EJ,3'4O1077 0<Y-5G$U:(R40"?<37,E,QY##+G'&E3_22Q]V1_
MOX1G0HOG)E6.FMUR[B+%RL0X\?)2IV[XV15@T2=%3AAHDA/+1]$$UB $D:0H
M[1N6.;NW$MV?R>%P)I;#LP6?3.LV;:%!"X\3U6Y2&,5,-\3*4'< X*!Y *BS
MHS)B[*SEX@"_)]L%2V)AZAN!B:Q"0P "O(=ET'+$AQ3]Z7:_O$C2LPY[ABS0
M/;>P-]74NJ<:7/(#W5IF0F;8=\:#/W/O556Z*[H[7#N,)&X_<Y^)*XX&2#^9
M@(7$/IC<"(LO)7HQ>:.,KA1NE"[TJ@?7N=?E-Z%MP+M#UW9A(P,0_K]]C$V2
MNKO8.NUDM>QD@+T&&WMH)/NAWVE4*E7@051%#NAI TUH3N#_]-X0%(?^3U =
M>1\B%J@S^ L(%XDSD8!57>&"TG].9?,L?>MKZRF7>.ROT ^LT4,.(!3*RA^B
M4Q=(^H-9J^W7#"FN6$Y<V]J2M;&GJ'P#PT)Y \O'/\3\]#W\C<)"$/I8(A*M
M6&2;XLA!@5]*>44P3;/,\KIZTD/XIL^%_) L6AQ78%]Q-0LE 5'L-2KIO9C1
MXP8C8:&,&L*J1Z.J+Y.$@)O%F:Q _8RT?6B1+)%\<A ^X K]U+F@*.4\L+_@
M;]^T9'ER*CF.FQ'O8OL^+.$OAY^BU!$$< T9N4-R_.]$";0Z\P1U9H'\D=9P
M<BC#JAI.EF1<=9L7K<M6N][]@UUU.[__P7K]>K]YV6SWW\/?O:MFHW_=DVUN
MKL_^ W^R?H<U.I=7%\U^J],NL7-X_IS]Y_KBC\WUM<DN.U+BU]#8+3OV28G5
M*K6#><5<SPS?&HHHW&3\[97A&0G\4C[B[]0LLV"1B2#ADV5;92:':@#=BXE)
M=0L^Z7QOLCK=:OGPX*EU2*+.E?E=V8JW7]NB2WZ.CWS^"95KQQLND_/"3FS_
ML'SRY,):,WWFQ)D@C;B! WV9LO-WZ39G34#>LH.?W\"1>L.?WP38L.U/4)[*
M?TUO,M2X5CDJ5XZG][#H>WF^56PH^.;]PFZ9SQNF-1705.!U40'7"[\9?]KN
MC9M#!ZJ5#^7#FJ8#F@XL/K%:^;CV5#J0/9[Y_3>U7OW<]&K4I#M7G1YHPI?-
M[N=FES3F/SK77?9;I]]DK1[[K0DZ=NORJM/MU]O](@^Q;KWZ3%JOSFNVNKCC
MJC:?/]Y\GICL0QJ1/PBOO>AOV@O<X3?L[,@]:C*4:[I& VX'!076'W/@;#P$
M1N"+'TLZ?&.3X1NY=Y=W2=AOZIS;QAVV]QS"$EWI"W@K6SB)1A;4K^E=:?Z5
M+AJ*7HS'(L)!OHO 19M^W%D69[FRR<ROVL[B5UWN>C>&8_V?'!8!40Z=;4ZK
M9L&PA?K4LVS9'UR8'TNI< 2*ZH#%3USL;4HA'Q,C@+7Y8K]^2)9^U=JWN($N
M_IIHG>MS:C@7C%589W:1)58/ /;5][UPP!IP; O/\9/E^4'BK?A([RS;9AAZ
MS57LLSQ>.OJ2^%+<'R8-6$Y(_A1L7W8'V&P_,/?.X;1EWS(M=-PHY([Z!X?>
MK75K4=^O>&ER]Q.QIN3-)!>;!T>%2\Z>C>R>TBJQBXM&ZHS0R81AXK9E#"S;
M"AZB7K/JQ'H<[V7VR,2NW!O1U8WFSQYN*0-B\)6?/' 1II,>7?;)31^7*-4X
MYZ12PR066,JL$%])KK+$9A!!+;#,ZE&[:.EZ3-R6>GUV_70ITL>'L5/JJCFE
MD" F)%$Z10M89XI%(7''#17T#Q>6/'""I^P4"P<61$:-@^Y8C!12S\/N!A:"
M;J;%W-V8.Y@X8"HDC%M/SG%)>GR$C$TU\W;](-_OLB?.3$HCB6,2W8M#;'+L
M#.T0V5<AW61O1^^_O3=R>>@[%6HU!4 '<B6!*)\,%QP]#H$G+#"\8".$]VH?
M,?J7-9O>/IL6C5"'MNM;U&U[!N-S"&PS"M3#$XX)%.4$!!)9_#Q^MAK'B@+.
MN3$D4N04 5084$8-;"$"JS%2:]B/XD"3"04=@"@)XT9X0H_Y!<]9&-D>(;-X
M8.KQ@D7(,U0+D'D_SLT[]M;P1:-,&&S @2*\H[/A]YE58(@!G!'&9&;;W^8=
M4&80$Y;+97H1C?=.T#T8$H$&0TE$&"E< MI)D/6Z-H<OB 52@ 9"J6A@/>34
MD3?1_#8^*B(>J9/B?X>&K=;)5<0&\6OV-A4Y,@$@QL!+P[+5P?JRJ3M0&]RV
M!+74*;<"@/9AGE9GT2]Y>"G":&:%-00HG*-:^RC^B"),NKA>>7^*I@\X((Q#
MN.%0@*!*B#A2R(*!M$0 Y]/Y=PC/ZP/H*;$-%&G%#:BKCB_W4;?: ]+(?;'(
M,PQZ+5C@K1LDUB8GM0:4*91:6 FY"5K10L[^52E7*E4,?Y&[2<K]F:FOHF%(
M_4M(0107C6_3(2:GIAU72Y5*)7_5*MA@#B27YH*R:8E<O<&#F(:N] EWZDX%
MX+N(ZS"3S_/(4(3%0(XF8G9<=RE)7 T3 ] $55B"MA+IV'6\%$?1H3/R%Z$E
MJ^Z?K(B1>'NWC[\\4 <\29VCVYO+3@I0U%@P4@Z,OHJ+_RI.94,WG[IXJ^C:
M8<P].'?^,(NQQO#OT/*R%T7[^/#13]\\96Q8OA(H\ X2 ,7>JE;?M]Q'L*#T
M"?$YYN%"++#EZTN1>0?M#"'V#(>M&?YXAK9QWP<<P"3JAW?J"&\QI@CT8[HZ
MG WFP5-6(N+4LX9\_G8Q,9K4'UP%K!2C)5%<%"<>>(:05XP''W0,4VBO  WL
M[?Z[G$=@0M>+!,@E!=4KH<(TY.-7N.C83G,KU51QF]$F^#WWAI;/Y1[QG-_>
MILA[Q(1G1: %=VP$B06G!6AQQ1Z?&)93]'I.P@ZJ64E!6RW/+V6E;LSE=5$M
M]3CL'(D+K=B?VE8@S",*R$+'H*4)+A,3$*V:;5\U.S/PRM"FF$2T2!N/4<^8
M$LV5EDI#T*(9.Z1 #U-E>,\PACN#$  P%:D.V:J,;P+TB-I1[8(,TH<>81G1
M%H PTNQ*+(TIDA&*14:*E7H7M ^@<]:$^N8)_8?,#K;X,R)EF(]^3X_!&Q_*
M!T?[U4?+>#)B/)XW*^6Y7,1IW^#4(M!<H5(Z4CN%$1<Z)4NG9.F4K!WQ+CXY
M)4MG83R+"Y_+4^>$B@@>&TE&Q"1RQ"/A(O(+-*Y!+HN.&8O#)7,T%IM9#7_G
M];+5#&5L=1N9%C,WBA*"#+9 1C1-*:NEE*L\Y:24ANV!:W@FWJH)NN\P<#T4
M&O'R?%$  :[-0P,CU2T >8^@7YC-4)M*:&BY3T0J&N;E9<(^8#Y7S)U4C.99
MI84H;*@W2?9=8L-"#$53BK2TS=L]S(%8364*X)9\UP&>@BF(Z+2GRDLXWMM!
M&)!(:1O"16HX[PI74":'([\OL$FHLU(F"=J6A869"(O(J!NJTA$S5Z TO:CV
M 6EZ.&';\$WC;V%N99>&]PT. #UZRD@K?D]X>_&\"R[I;NPJIS_M'Y_ _5H>
MXP"T9*V==W,B9W0B%N%.N<.D9VFU4U&;3:H44^-!5/80E"GWE,0-S#] 84N1
ME-FX ;)Y0[J5FP:9""8 L&Y<K!IG4.1!I- D?.326@/W(8S<J8$B7B*\2='M
M+?(2O:-L6<)1<0!H]X%/_SHL5P19!TIIPRKDC<XJ9E'%D>0^Y5IAY;0H@3,F
MIO=:@U#.5  < BU%0G",F//N(S:!I_3 ?]5 ])ZO!JJ]:<:R><;2R0]_ CH0
MPU045"),#62P((NTC8%-4<3*K"]8F!'285P4.P 2D[#)&I$I(Q7HDGQD-F2+
MUC/D7D"V-S*ZNB(88SF;?AP<4>P8'H58%2<2E_!PI,7?)U,IVFDCO(JFC>RL
M69C_D$5<M!];9,5&5S L]5^UPR7Q L>'T9$@4 K]K>6&/LPB[2Y K3QW0C>"
M=DFR/<H;:B3\;FU7%AD ,<\3'G.\)C\NGP2LC[\KL<BGARP!GK <%7*2BL19
MUL>N6L%*1WM)B:+69,)-2YS7/.NQM&T*8K_)6R;ZB8+14R(*,KM=E\=W9J/Q
MJI=U1TG) R:R'Q8X4%^4AO/84("R]-^*^U?!CC'UF1J8Q6)-17C5$\-/V-A
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MWGG&]-F2D&JBL=2&?$&S?D6:-/(&845+V+W/L# ;JIB_\A CLZ<*;-\'YFN
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M-MOG<C\B?3<YUV^=?E/9M#YUNJHG6<Z,&NR?"]BWE,$"Q2PTQG6C1 $B:K=
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MO^?>T!*19<43CT(L<:;FO:.DK<!/K#YU.BN/$[A8;D^D \X]+M^UGWQ8487
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M]=4SW6;O^J)/CW2NFEURZVNI04L-6FK0%&TK4L/A1C+VCK0-0$L(NXA/:1O
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M:"  I/JD?CHEG"+D8#]4*I7HE00;8PD<#%A%_H.+_.=CM*&#I>V<C2\%PH6
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MC V?WG*GA%;PJS'\.[0 4RW@%K:-$Q@V80FHX@\,SHP[@"6>B!:!YZ>AYX<
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MID%H/A4#R'>49?G#]/XC4-ZI;8!R;3G(4_8&MDL*M""21?^5D/!U; 3,\A.
M_K]%E$I#QF8@H[ZAJ^T 'YIZEI1E]Q6OQ#22DF*2GRS/#^3%LUXX(-+3XR!Y
MF\EO2:LD"5E2&_E;Q.=*0-^&[O0!Y60A>@!,&4$ /!]YN,_6(;$E6H4J85OF
MO^2L2&D/ K1A^1-!5W%KEB"S,N@UT@X4H;]*23MYFYTYMCL+Q,D)_BTD,9R)
M#DN>,WTII#%<E^6$R)K@7 PX+A?U)/<.%1T4@2S30@X"JZ.,'QP*5^&'WJUU
MBZ\-XZ!<M8?D@LIR(EH3_.CD+FSFDN4B9R]_P''2]!(P'"AX4+.GWI&,$I\
M?D<F $-P8$M*L0A)L((EA%[#3W'@%NF$CF3HM-SX9P'98M=#P&'8L072JSHL
MSAP0*7%>*;(5.3BEQ*8%M4T):C$I3IFI8M*<((U! KJ;I-.C=H]G66+A%)69
M%'(#^OR5T/L3N.[S $4J@!C+*4#JM]8[04Y(4T'$*1"G0# $:'7PSB-Y:HQ1
M\X ."L<GH(I(,\-;RQG:(6D3])A?\)SE^Z&R=7#YP-3C!8L8VJZ?6,#(<@QG
M"%^ 7L+O,_/!<0PXJK!#;L,,TP7TC8XR'@28D(_8'(WW3B 9#(D @$*I,/7
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M2<&[1<Z54&32$)B,.!P;%!"CG"W&P+(Q0#*Y/(I&% H-JI$B@%-D[F"J@3M
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M1V03^*2Y8GJL9PH=1$S.X\FWY=5NR<W-NJPUB#]G$#^<!?%S:89E35N:;W(
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M"UV]1ML)H0$]X<F&!%[*L'!&F-K?>9AT^+W%O=F2BS]*;O,V@D4AYA.^D8@
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MI]5V+8I22:_*S//?IZG-10[$3O+,P$5>-RT;@XXZ*QG=APE20X'VD?.NKLU
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M9?D\E[Z"18=%%VL#(91BH=>,4::(WV7>7M52&4+A/<L?HFQKN:7BWF'X2)U
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MR"\* -HX&Q4B2,S!N!D]V35J@4\*L91O4VL[@L!?CUN"*8E CX9B@I<89"%
M?_<J.=KP7B>4EQ?AA=?Y!:F6"8F..M&(<WF[&%&,?'AC/G3!LQFH_@7U%J)U
M83H5,\-*W,F7J$M@A!*)V0X)-5ZKX9=(CP= C_U5EQ4<S.=*I,L<)2Q);++2
M)1S5@V:<:YKTTK=L$. *Z-4/XA"56Q< Q"_=!^$)Q E@:RD-<EV]:)D?R EB
M89EJU;,ME?T1.#U6]M^DLO\T5O;'ROX[J^R/*CFJY)NJY%VA@Y'*&!JSY==%
MB"=EBM#_D!"8)LQMC'<#DV\X846^XIR0D 00J?;RVOPP/UMM2GY,M,1DEY'
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M2E)JE&]JA0[T. ETTU/1S"@,5H'KFN6C=Q?*!LVT-*XTW8I&;D79\%G)AE?
ML/<K!TZB'-BC"325BFV<),BV<[UTR8Y9]2!/I)'#W@UI:*')WOKZ\>-CG#SK
M!-#D7;@O9-M-HA@Y>#%RUJW75=TZ*FON69(\BI)D?Y+DA4B'D49:_%]R>L(9
MK\<[!KR. 0M3O(LRF 9<H!&J4HZJR,/NM9+!E1<5QJ$1>]&TDVU_5K\(B%J!
M#9B J>69-)8MO.1D^R]%+&8,O$ZA@88[SR@<65(_V&B O4D>X(VE:H=7/N0M
M4[QSE)B3&79,CQ_,Z=.C)SN.9HB,<%\',WQ2_UA^54VF?A<\J-<-XCO/7?\W
M._#/'3#/&0%ZO#88/A9^QYS7>P'3X?N=$9A.<-'-CXI'P@].*I6CPKO#<JMS
MQI2V<:*I$^97DWMO(8"H&0]=,_X"I/;-/]=1,W[1FG$P38-;'E!VN-9B;[ &
MR)I06O=%+(>L,:,V$>+NUD%P6WFBPT?"9[_=!OTPCNUW;A,&4V6+7^%-S##R
MGB<@J8!UH3/L$6TTXNG:+@U4"?0)_I?+X]<&=]:_R #CIPXB?_IBON,Y(T+;
MJU*!&R* BP'B?AJVB)""7C"(/Z8K*XH&3_56<Z_J50"6I$O%FWLOL$@Y1E])
M189H5OPGQU#I[X74,0?W3;U)J%7-1@0G0W%V>9:ZX?';M2@J2GQ(MZ89,;@R
M@SC,>DICESD3SH^@ 4V>\LS^G-.-%O$[1+"WDQ7D9U9W^^74B/ %OS>S[ADO
M6>+3J;F9.;;,_/I60QOZ@R2NOD<68 JNO>;XB69JOZY]GRM/@&Q :-QLPQ)_
MP$57MGF1G#P]MNFQQDN,3<+$16SG6&5ZUU6FW\<JTUAE&K&=OU0?Z*R;804$
M6WEA& 4D D^7PZ_>\^2-O60E&W25: DG3YY$EVF/:8FI*33B,DD03FK\-E-!
MN-3F++ 8B&:_?,H9BI9QF0B$R=A/0?0*;S=!DA28H9],NE'N[@$$EF>\C9AL
M59VR<Z4[-NO1"]EENXW;B:G#E6)#%Y8 :\""))D'*= [R=>GWSTY$NL.R+'
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MG[T=06FHL\C-D9MOIVV]@!)05:;7FM[1](=*B,M$Y]M+++QO6F1&;.S+K"
MVGW_C^<3430P>DT$C8)NVZX\E2M3BW'C5&$VR.;!NBA09>61EQYSX;G()I%-
M;L$FHCP*C-P4.8/ C3>$L3GZ3M7JG!B(F\>0D<QG;[DZR79[-E-1V)7*2^EF
M,XJ*0I:(5C?1C(:ZSF31KO8;TGMA:<JD$N(L'/!5J<^ID 1-5S#"T4B.#!89
M[&8%'@B_B'".U+/BE4?E:(&1W=6SL0HEA1"FTD$WH]F7\[JZ9!6&AIKH+Q]\
M4_2+*9@R)AIVV^1S;/G69)P!!:IS[A  _L2[MLM([I'<[\")\M)TTI:/) FF
M3(ON#14IJ9;%-#9<4DT>UH0#I;:J!FV$6]^PVI#>YY1KPI%>F2>D]YB1"$&S
M$-(I5^:N=9M3/QH9<^BTQ3JA2-NW ORH*<] <3>#+8$4.V<L38&2\*"RJXI+
M^'ZJN_/D>;8"XY[$.HKG!X(Q_.JGYP(,_-#C XK_U1S8@AV&30T>WK7+2AK[
MT<0I='G>+C=IT@)!3J7ZJ5S(2_:3?BB76FR_KES7.LOGE(P+K3:TH(S=QIQL
MC#%"Z^ N3NON\Q54?2O54=G8QFTO5?0U7E@-&$0H:!TF?$!+X/ZU7F%^.OD<
MZX0Y6662F3:/.1*>0,,07RR66WU^Y5:,,BZH$R\XSAZKKZ)NN*5N6/6@QK:"
MF_3:;ATX!= G2)J+"J@UQVR*05&:N+N["9KY&1A/'A"RJP6+!GTD[!L3]@"Y
MB"$9,#6W,QW':1'<<2GY4?-E#O^P=3^D=2-Y1O*\._+<7J3J2EP%YD (%:Y=
M=&(,^O#,#@'+V*$7*B^,,9I3)F$!YD_M2D5=CTPD[$C8-R+L=^ BY0T%MUV)
M]$P;FIVV*W!(&HVYX9A@.8?]E3@YR>+9IE"7C0G$F&< X8-L_@ELY$MR)]6E
M!3C_B#(<Q#8X<DP-4[8-(U;9\*)-B!O01=4BR&/+,'5M#Q4..57#/G(%=:U7
MB.B#5U%XD@*ED9<B+]VLP0LWP()/. +>AL[HH<;U4:W2'NX5F.0EIF^+D**)
M8ZFG"^_?ZUA <-4JJ&PJ?)0K1>AQP"\U);!7>>NYKE>#65Q89"R@PQCVC-QS
M]R86$?>LKA1!*LYK9B[14 @6:A2%:I;$*?0/C @"35+8?TJ3&*>70JLZ:QQH
MULW[F40;Y>6%;K@B"TM!PL? VK$ GK/<;/AMJ@[[EB@"BCEMB9KR=1:@CHLK
M80NP_P9O"6_8T08(\!P^%)78,%X8IV3=QZ!". 89@&4CZO(WV2C-O&L:CA3#
MH6)8-\ETBY5[; E-3P0,Z.Y:X4@[/,V?S2:$NF4RX!/FDIS"UY^P 1Z6BZ3T
M5_B;AF-U. HQ1&:<X9PP4"5 ?'@3)&*RL!2G(S 5D.-[HJ)A)K0;-H<=HA1U
M'#$3^W'NO!_G-/;CQ'Z<.^O'B0-'#V?@J$OP/K<)WCC\^?.1*#MLJC[T<R4V
M;TM&= 5[HS]*\^^P1(+,=RQS;FN<ZN%7+PQQ3/S1(''&\ &S/&/C\!B:Y WG
M)W\1M)M[Y?Q')Y'S]\?Y4@5$G$[\2N 3JI1NPL)"(0&[%S)@W68$!ZY]D+,F
M/YO)B J.J-7!OPVV2Q(.![8L,IR(WRUA9PX'=YV**I@8.JZ7)X0)!8<9\]'!
M0)Y?"/*)9SIM5L (QB_$GH\CX\:]YI52DV4>CD@143<(0_*[N&$0-(#]@GZQ
MR&OY!<E16;3_[N%[8@/F3.LR[-.T.%3FM7'R:"L%7',X3JQ\IQ92\!FIEPL/
MP_S*O8DMAM(R0"98MM1Y,KC*Q-+=40_O+L5F<O-\,7(GN82?Q!@R'O"_JQ?S
M8?2ZLL 2?SD"]ZQ+!7N<'248Y))]==\WL A$75GV!A>X25:RE%[Q!M_4S*L2
M<D8#?*UJU'E1J1VP4GONB9?G\WG5E42A'S!*1&=^OYKM-&JVO<8)/>C-'A>W
M%!=TP^T4#^UA3+Z50]@R\E QL8BTQ:M10TZ$J:4K<:Y-H-K<&,0^0U*9)@XS
M=066810Q/:K.2$B3!G4%QURZ2AW%HC;-NAB=FC)5B,-CBH_QI\G?GS]_YTJ0
ML2BV)2VHT[Y!#ON$Z+H)UCO#X_E[?PJBS!W#+0AP%1&)FH8KF8(*6 N<1RY
MP7E#_<<V4\ 1V[)"'"T4Z%/[:.$0;$VS&^!42+<T2MSD%9Z)MQ-=C<CRMLXX
M;VQ,U!( I;QK8Q6,W]@>#VD(N(N_5\$@4BD,68PK$O?."XX+>QC&/R0/\H=\
MO&%[A>QUD'"L+A%UTD=16ZG?T-?:F&=?5(Q;*;T5X_4$S^"9XP\M@(DP@>(E
M&XW!8@8OVFO,O)VM3PD>P[?*-"9&T1]T\6EK;:[T:D9SY/CC$83H"?N/LJ#P
MQ(OQS;1Y7E=Q (>F5H;!YS@#B2LQ[?<33V)[8M+^+-5*&S\:+JS5FD _X,Q?
ME_,CKM+0R5*K[/<.+ 8B2=C!-[HL*NRS_)@F+T!  (^5N3HB+54CH12;P!::
M%FF*+2&7B7/C8,S\0+:D$5*$N(#?W#*QI7L1.]Y L['D^O!W;N!9RRMJ$3>A
MYK29$1%DOG[*5PQOK^IZ@RLSEZ#@ WOUO*HRIGR9!XQ4I\IS:@:2AP)AH&+,
M7#6M-_*-ETTK\X#S0#PQ8''?N,1M7%:<W*0MX\-FZI/DX)SQ8 G%I:'G![7G
MOHRP]W1'HQA*T'<12JK\E22E> 89;0%J U?;ME9Y-B$I0?&)9A%1>92<:3[6
MN\ML_;-4(++P/=[5%<K<E<*0,^CBADOMF2%>V8D=K\M%)79]+Q.FBT9?DF]B
M1.MT^HLUKMN&W-TUVMJ';&L#@ZL<)S&^9VU$K5(YVA98^B*RV7P9#>\OQO#^
MV<R"'9N';5KV=2F9=]1"EE*<W3(]]VRDG/$H\9XIJ >"_>J>>K=/C)+G<"4/
M=7W5><,J]LRS9?<@;!X=Q_CU'H7-CU@+TTM?,:J7J8VF *$)[U)YM-A=9ZW4
M45O&AENDXG][%K>("/E5..X:?&*%QBQ&60W.2NHB!S[<W0SLVO,***QTX4/[
MY+^S:P]6E"OH_D5=6D_^I[^_^,4X\11A#5T!"_&7CHVK]'V<P8Q+:S;GM7E3
M8[8.5@N+X"T!'P>V-#.CB%N)I9C=I8<\\*Q/^N!'^C[HAL9+Z#ODOA8]"M58
M#.ZN)HO?/ L6\8Y&RJF"_9)?J^9HW!XV#'Z:)H_H.8\QV&P#YO(Z(^,^6^\+
ML#[9(Z69=NP(.%(8_AC/FF+6QB'V7XQ6X>V"C,5UI8_NSB,'Z.AW=..WM@78
M._KGP9_(VH(3<8<X]:OP&/G$L#> D4_ NY_7^2Q@NGNKM0L%_7N[A7T+Y(48
M YS,=((B^'QGL1Y(]JM4ZT6@ZUA8=]>%=8]B8=VA%=8%577_SC/0X&]GOX$(
M.,-M&K$DKUQH)W_:@CB5Y!D<^.D36",NP+D<U[GY9^ERC(F3*WH<5Y$G6WV.
M;YX7!2B(9I<KL&LC: 44%<2XU0_=>JWKN6HT///-\_?_>/DA>??^]8N7R?-?
M?TI^>OU?KW]Z"?]X_>NKM^_?//_P^NVOT9G8:\IP&++(&P]#T967>%4%QHZ0
M,BG/\@FJ2)[_^/JMJ2*)Q[F?XS3U/@&TQO",$=02+A'/ OR&T^/3QZFXC$W+
M'V>*\VQ2(A1D$5195HACYF>.3)9$85@?#/)=A),FEW#IUR='WYTD:YQ@"O:Y
MEG3355]CK'_LY-$-^L>"&,G]]Z.9';_F7HW<;V3!CX[O<,'!LMTQ18;>0[!'
MSU77F$3M$#)G5'8W'9EE5-M8=."BR9Q@[R:VGX]D-AYG,WU+6YHW'6D)8LVF
MUB\L,Q.4%>XIK+!!C?\=Z6A_1:\\K2._H&%NG,9WD'&.#,+\!?6$ZX7FF>Y!
M3F/=S8I\#D8":H@Q]+AXE'??N= P[*%K1X 3&\8)DQ,ZN5/&WK50O8.JYG[5
MLU?#G/8KB2>K?5./>(;R@V0$48A7I,PF8Z^HZI**2=(P_#:L*4E-R K?#7^U
MNX8Y4N8^*!/.?]HF.;FY$;7--+NMI=,SQY"HWU.!3?(3BDE3^3\6(D^EW/R2
M0$-=>4^QV?'(L?>XB<DZ^3:U/D>W#26VE[GAPJ%)17^4>"=XQ57?HV%LAC)F
M?[3).[J#DG3O:\JJU++C8Y?W]"C7<7*G/F51;)T/MITIRLEQ5: N-4ZS5U01
M"6M9YFM2U(PBW4\'AMFN1NJB)"G17"&D?_>)BW<65>:LET[$M9N3-W)]'\_U
MIU3[^F0?S]X"V3JIL&*YQ<&46_R47^09MH_%2.5^&W;=A%[P'@M5\[@_+!/E
M27]8;Y^9PS&EZB,E6<#F6:4%"-QVR,"-J"3WJK>9A@E%6'_L5\"O696(Y<!_
MX ,DP"9/X;]ZS6?RCNR!J8T)O(VJ(P22:A$''*W@+;:XHL^5^65&K^V']5[E
M==,F+VED&SKQ2(NI%%QC!YGTC[AY,\."=7@&M5MP:$LU%0[)0> \+!*>&ZC)
M!]BNAP=0$%X-O'OY4 *+_OPHC@)FDNEW*V3'@V.%ZOP<]246V*^P)<(&-L1<
M"PX4MX=C%MV:*N-*\RO]>X>3JJKP!>T;4#5+E6%E=^M7<WO>D-P(]HA+O@<]
M([22![A!JIAW7$:][FIL.&EM/36U5@BN#1<!3W9:/&1*06J#.WW])#T^/L;_
M/TI^K5ITY2Q1&$*ED?(IL0L8'O H'.TN+9U(9#WBQ]8+V!?MEM>K'I?0D(>8
MU>\B\(>XV,V *Z::8"3U8%I@Q@C,5!OQ_#,X2$2#3,H.6RGPTF'7R166-%HY
MGQK,+:I^E^-(#<BJL9B:E&'P% ;;J :_K?.YW,#_"X'VJX8K<KQ.2@2H'/3,
M,#'<9I\R(!(JU]<X,"1&9_86:'-ZBG13Y>FK<3TU4L+;+WJS"JN:P\FG%KAB
M4HU-:\2Q@F&#'CRBRYQCX77-2W\4BE*'((R(PXW,P]T8)M&JQJJBQD(2D[SH
MC1K5GX"(&Q$?_L!?<$K=K48EEGN]G3+)H(G=B43)V_N3&:;:;;?<:"8$Q^2K
M3@B%B(H6B[?NJGCK<2S>.K3BK3^@>NMQK-[ZPJJWWK\^^T?RZOF+#V_?G\70
MQ]YLRCL(16YMX :S0=IOP>21 @%=7N1U57+;.(8EYECO0T T,E9-:O+IR[R\
MJ(H+.#A_8#KAKZ;87TY%1.P1FV?.]*:2O+, B(.]ZYI_C;-I6J!=8-PU'5#R
MTNMYF2%8VP+'O\VOTF6;$HQLLZ2Y !8EUF')<K4$3T@3+%E7ZC\#X_4RX?-%
MVSXGBW")(TPKA"30#)2\)1)SE/RW>[PJFC$XV_$=V/UJ1\F[@LHL>J'_7EC_
M7Y2\PF6\ /IZ!<28O,'W\;J8M_0&G!Y?)9& ,3+3UQ+V,8^+CQCE/I@H]^B@
M.79&)T\O#@L\K&&!K\ SEVE IF,NY7"$F6YIYDA(-CM95V@[<I); GV@%\B;
M3&W-9]8K'WUD<K9FRHH=+$FQ@(S @/ O"BOWXZNC+K3Q_WUGVEP*-_UK58>!
M;2J+FQ0KT2JY^TC7. 60HB-;EC+:8=#8(03Y5.4'P,E*2#&0CKJ&U(9,#DFE
MDLG6-I)B W)I%@(^@J-3$:NN=B%H&S_?"7Z7!GF%Y*R;L:U"7"#&42EO).MV
M[V#:7BGLAD5VE\L*J1^3];1FT.<YCH VEH!I!6VZ^B*_8,S H(.QG^A@1FH(
M<\^F-]0*[(,+0LCR45C2+;>6MP]N/?F>9QIWT-L2>>?!YW?P_E1 :E&=6/8(
M',^+:93)L-K5E$.8K)$[_S0(Y@D>CQ0Q"NY,()2L34K!1R=$F=ZHFY;0S60<
ML$=HN QYO#<M*F6):U%]+G&*FR\F^R)2TA6]$3_>(<N,!#'+Q2;GXY%M:#$+
MI8F%D#.6B*!9VAUV:Q]LED,SHK?-Q=9>P,^9(^WX\I:')V)'JI:1*+0<0MV4
M.0WD'[B)7R;]YTH2Q>CV(),-R?MM*'@B&O:CU]X^$"QV5EU,=^PI*^\PQQ8H
M81O?V/#/:"Z>%M:S^XAN6=[4W5K"W"6+^3GA1P6$!A15@_&1V?'7SD)P,PVW
ML=14O-X60+N4PS^]YZJ&]1)STD@&U$(1$)8AC2PO<"5ER9S'Y,B,,F+_>*.T
M3$X%9_M4+9=IZT]2F(O$7VVTOJ?E\>EL-]7,!MD=(R0P/#BL1V/9 W)?S5#;
M4+:DZ3!90=H;Q&!&GUE$=3]U86^-"@XKW+@V3G]2N'KOU\$#@@'SB%99"R8M
MCP_&:(  /:"/WA@!?5G5 M9,,A2')R'<.](M\,^YEM_8K;>+\]^W<7<P>HI^
MC$\@&]M/556+=.?MKG("X^ANN NC*2<@CDN-&;IFM(-D)"A!Y12\!.1GS%,9
MC8&),5W.-R/*2-:.?2"?%-#FS 1DN,R@[VN,*K3AEHT*^#BA_N"=SM<#ZSOT
M HSA%9@7C#(=(#Z:2624\(ZNW?ZT^DN0MFCOA89V'TVFCPLD4$0"^Y)R]14=
MKT<)*QR8T3,M4T,?L$(TX=8H!=IV+-N=&C3R<1N#Y%<3D!X2VV[D<ZH(M-%=
M%["\7S27#R-+Z54D7WE8VH3E[2'.#OEQ"WS_J M@X.6'#'XCED[,4 7/7YII
MUA=CS611T!^8H/] /"LV$QDC;F*!?!HXO.C^9;]UA"<0H$GO-DRB]-^?3P<2
M=V-*)L/C34V-V IX67I--' R^"]&$>2KE<YR:H(R^;&>ZO=1G G?VV^<2K[_
M[NC;D[_8@EI;V>NB-V&[\O3H\*"\+>QDE-4\H"(O"D%,U%AF>='!4FV-I6KR
MYF'JL,WN^NU/CQY]?XN7O]>7'@FTH;99K27"9BOC>!(+E7;GJYS?-9VHA>9Z
M](@@%HO0[KH([4DL0CNT(K3]U:!%^^#.[(. %M;MD B,^3[3%*8T331?/SDZ
MYK@8[&1!&8O7;.U11F1"'^2-U-8,?IZ.V",NJV#,2IJO90%+!GH3YT&P[@W'
M95QY GM?X9L%&&23S#<.!D I,LX$SKS W@!=H^##:IHI?7Y5 (:8[-B'88P&
MEL1X\VG'Q1(5&V&>&3B,?P[SL.3$NQS@@(*OB<'3;RX;A%,)7H.6F&+(Y\JK
M3:_FN%G&:!SR;_@CWDB_P6^8FL<NJ+$WY["S>=>5R3-Q^9QRR/9>N@ES'_B&
MC( D+9RY7ZHWUAV#W8D<!)?\PE(A\LAYU>84ZJ;L*GR_21"B>%;DS5)G(P+K
M*#D#DQCL%03-OH_MQCXC3"X<SFZ#_-(R"8?3"X/@F^UA8@]",TC1?$HB4^3
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M:JE.,_4CVJ81W=QRV#S FI5[;2BP*YOHMW'M/ =$RJ*CI:8'=C!Z->28#30
MW_"(;@4G_MSMFP,]4NQK3$],&!EMX$8D:&.(_3"01C_^\N_504LB!&_G'WZS
M!EV/._,#(D+"V?K?H4W[ Z)B;15=CY^Z+._^I-<WUP'!F'4%,%=/>]EM_(JK
M9[_=&V*U_ ^E>TJPN:E[<K0'Y*,&X6><D@!-#,E2U]3 (2TPWH5#-.!(DI$D
MKT"2OMO6H# =DAFY8:BN=)N3( 5!B3,5_"OK"JQ\0JR#M9&K"1\!=3;T8ZRX
M8M<>2=RW&0S '?5MV=N%;4_X=%%]>$W>1HH_%(KOK[JL2OU9L@%*9G""B;91
M!-M>RF<1_C!6GMYUY>FWL?(T5IY&?17UU8WUE4 %-ZJ8R*Y'\^@ R.USI"R3
M0&*,GZTI(NG?G9LTD<TY^8VD)N@R 5:@53U?2G>M _S&Z@"\!=!X0T-W(C5'
M:KX)-:_A3*ML@G[;ZAOY7@C8CV!C/', +!>KZ/>0AT"(T>HB3$!RH#;(<%,&
M  5%3;F!+( ,\B+-)(&6U$8(5A_'DKNR#E$K)7:..6)=$PBI5+?!DG%Z0,?!
M!TX^&!"!65VIS,20 ]HA@8>0K>.%46Y:]B3,RFM33=ZT_I1-IE=2^=XK3O0:
MJ$'+JTO!I&'>@C:3-R@OFQ8D+P_748CEPPD!+WV#Y03G HUTKO 'G'9V.Q1S
MM9]!KM:0'>6AFD'J?QP.NM32/S*5GB(01D'!LWA[E9MC(65 Q">S#56!2EL8
MDK*?)*S]VV=ZUG+Q8DWE9/!:NJ2J!5776 DB 7,']25 8EZTD?J6/?#HR=;P
ML!RAMI,VMO_*)>!BVOH/AQGEVI$!SN@9*(EYG5-+>A]MU%"K3=WZZ1<+SN42
MNZ85: 2@E*ND[964J"&V@2OGH(RPZJ@,>_C3Y.O3[_H]C<D#OIUD'ANX!BX9
MMV<2(3KS4TRRUQ7._:+VQ8N\ZIIB8]ISO!HUOYH;_WY!I=AMCN&27Q&JG++%
M\WG=\4YJ9 =,@9/0+^&*A_@VV\>#3]A@.._'->M<$B^W7I>5CY<0C*&;J%FR
M1>(XN,T?='/E!DXQ^LISSEGWGG/3FV$2WKI%6N8'D7US58#:;>_MX[@9*C:H
M=^8&_#J#+K9;'Y5TS.;E[?:'E(NK7?=%-4(4]=MJIVK1'N1'^BBE@K'0UYQ>
M4H!8/G@00>=MP3-Y>)2\8C2H%143]OL/U I1\3([L(FLS@J+Y1)0NZV?Q;4%
MK XHZQ=UR>,*_E%HK-X?+Z:E(_"59;6V-&,$SO:31WJI,Z['6R%N)%+0&X.O
M2P]W:LX.&,[M4ML>3 D(J;\D-\(121[@KDFE[ <0]F#1OK5/?&<[HJ58]F&"
MM9V%G07=L&&2T=1&"X\"+_WUZ?'Q0+AZCWJ!+@?\[A>LJS4WIX'72LC2ZA1J
M76C<QH?[-'8.=M/][<5*R?&]Q&5M>74J*K:XMZ2Z1B3#C3F1IUZR(O#VY(CK
MDD?>[AP%@<[Z+&Q TF[(RM'7WD?'NE<F90G 8+!A7XZ=W#=A,G-C<]Y2D1F8
M&@SL-GH'H( %.$0UWPYGF()*"G#]+"S#X"G$U,V8N['-A4C90NDI&?8+?-?B
M9@3J6X=WIFI"U E1/+T+CY+7M-\485A734.6FMT\'@];<3DX%FH,72L\'W+Y
MUW8@3D- \=L=G#!$P6UBX)6Y_1T].[+!&S;!5]141K. X/L+79()04NW/A;V
MB7FNE 1;[+##X)=\/VX*IXX(<2RK0 R#4*@Y?D+.J82MP_F)8HXA:>P"#H-#
MU>AJ>D87Z+YE/LOMK? =/-QF0:LN<EU2[X,WDQ)-5IRX2#]A94P,]-'X#^37
M]DI8\PGK9\@F/'!SE].<MZ:TLM0(NHY(_+!L$NSR(\U;1+1EN_B0QSV>'A<1
M49#OIP7+D8=R1LL <\0ALADZ?Z=J=8XC9GM.L2 REZ6@FUI#8W>0:*;[<SA<
MU,<1%OP#GDT.-'RL%8AJ6-)/0($(:2+^_ D[],2YHU\]29TOXMN[:@B-8J&'
M3HZ.CRV*WO4FH_<;R?A5;F3JIF::!N@_K'QKM,1N[3KQ 0N5UR:T&W30T(P#
M!F(TRRZ])>$BQ6:S^[,O2RU&>P\LVON!QC5N.<.1%$'287KA?Y"^WG>%9J8[
M>?S8W.+,7?E\;A6(]"7&".@>C?@@R(V-(9YTO\I!&YEM#"(3'+3!-_Q&82/-
MSR()9"PAVO>7JC;&YTV(S(^7A&06$A2*W_![:6NQ#L8H *G^A&V@,G1;L _X
M94@ON'7D92YX1!+0 L>B6>K"R_LE#PP2!@)IF!D-_)(","19Q=X/'])X'+RM
M:4,AXYO;6EJRT[%QQH_2JN >FZ-0B5OT!,R:5XTJS%!TUQ$E5BIW)'F=0=M4
MNC^PBF<^D1G:CJ_&FR@O;W55,+J>Z1#!76.)[5V7V'X72VQCB6TT-O8 [AH4
M!U1)496H2= R&"@-/Y8^KD$"Q$H3030#X?!F+6$Q>H;*P &]DFV!B@[\/APU
ME5/_*^HHSB14I4XV6M4);2.O<Y$74B#Q@N/NR7M-#;CPJU=PBGSCIQ.^WS]L
MC#W4CQ*OEP'9DN -4)[<O4^.@Q'/$C%;%)R)F(R;DHUDSJ1_(-%M.W2W[?Z,
M/OS=NJ[@/CJ[OO4W8.21J ^!J"*; NWAL'=B&*1WH6X)/5(J%#_VP[>2+$4K
MW0_21J=ROX,;*9_:7B)8,&8M>;K[>87_ZU=K4ZNG6L%A@DJ?J[KB\_OU^;OY
M:2JC )E"F'+)0GA +I$I&Z!"%6Z_XVLXD?F0Z+30YVH.+E((#X&%* 7*OXZ[
M38'<VTT(#%HU'KI>-;(Z3F)0DLAGJFL\T)NB2!A#N!]4V\&@?12<&X'JL[ZH
MQ=QK:!EF/+)+,<\TL-U F5K,Q$D/RTQ@'.%MX[KW0K0^7_I3M5#U!L\><WW!
M>< W P,.^&9IL+)8M>T HQ!P+F__ [%WG<.0FP<C5$+H(W[YUH _>9=/;_91
M$@7.?N!G;D>"E))2C9A9383IB$TC-VX&WU[\C/X 2(EKF/Z$N$\N ]X]L.OQ
M- /CGAT/XQ[8&-W9RQ?&Y*>"0LH7J[9K*-]7F@'I+',E-AJR36P*C!QQ(XX@
MU<DTY0%ECK,(.>UIHF$S<I'=5&_C$?W9!+<\,MS"GOC)*:54$W!L=)DI2?NN
M8$N63<@DD; C8=^3J+]4Z &W8(:JIDV^/>Y18X:3JT.!/:8?IBC^J0L-U90'
MDEHM>-62.V N59U%L)M(WW=-WQA8+4WQ,WQMQ#6G*0T4,;NIM9;0*<9%F_$P
MINF\HIL'@R &(ZLPM?P@?\BW!'\=CJZ2[LO9)K$5B1@;0"-G-Q>=N"+F@H<4
M/,C-_3LN=X.G:IU<8F"8.B_-<&0"88.KS>6M^DC79Q?*#M["(K^))W\LJ\O2
MU7.JAIH[> ^-=9;I9ITC>B"&W!CE>%%4JHU,'9GZ1DSM^LHNEY7C)/)^%\@"
ME$]Q ]?M. ;="\0TW4SFJ)MPU 6V>U4\M$F O(<#+WSV,L.>0G#7\5Q$,%I=
M&G7\M,R3!W.YJ[O;0S(W/09E#BHVTD-#N+)8JH8Q/+_RVP@YK*VU8R9T>:[.
M#59IAIF??-:9Z-G@%F+H2J2([T!%=RA&.$L%KEFM&Q,^XI"U[  &'_MW0RSR
M&IFYV/0?Y]?,2S+(-E5=0P+:J+F7U[)#X;U\F]D1M%0R,6"FV\NZLL!@2W_)
M2'$-T$12E<6&-W61?]*9;4&7T'Y>BG*@&WAMD1B 4RLN[@EVUH6%14Y'81F%
MY8V$99#W!5GYX%0$B0 \@P#D/CU7K6]%#.+3P$6[9!2B,O0NRAX&[0$T7H!J
MQ\3@<@EL8VE5]CL90F2^N()D[3__L9&N7N&NES+W.9APH#<]O4&LQY:*>00I
M%T*T(!P+G3T<3Y</HEM^8 M4#LL;/Z85VP/V%%S'&W'RCB.)7JB=LR)F$N?V
MVDVR(QC\NR$# 9M."*"8.[*\E"[7S9-@#QS;5'Z_6G/Y.@^%]/!%U&5CVVJE
MB2M<+_(NT$(RZX ,R@:3-F/=/*[2<U@FPB7SLS[MN]Y;O,ICH-MP;BRU./A2
MBS.DH4&SS* C+P,:9#AY_$Y_@B.FEC2@>3!Y#)*. 4EH>D:O;9S*\@5YN3+Q
M:E-U<D>+EP9RL^C(#8;?KWS0_ZH>FR;G532IFJP[O*E;2:R=V)^T_6D7D9C^
M(C=0T'9D7I-T*'[A-9W3/"@&'S'W@8>Q[3&<]FC')9DN2_>KOF\3\,5.+O#Z
M,H,IDM3NB)6AN-19578-=D-**1!U 9L)D-(29<PR#_C*JY*74GUIF^3^->IQ
MPM9?+$$@6!/S!*Q$8&!G<H; &C'H^\8EQ+ZK?$$ZR0?FWUXT3^4D2'J-3'9J
M\Y(1,3*]XK8,;LLC5$-J/;Y09E(6US(T':\4&UMK(,>CB#H=2^+ONB3^:2R)
MCR7Q4=W?O;JWCHJ%NY,B\15U*SNWPNK/684V&A4[&D7*T!2B/#!FX+Z:<ON=
MQ\US_E #HW=&[E4Z46W>*Q,T85(_72\C7$%7*6F\*ZMR(O!H!B68^./N5?M%
M^8%1<?V'N&6B7L8QEW-7_^(7 7+]*NIQ\#_GNK<UX>[%>,2>JHNW<@,&S:BS
ME'!,>-(8B$)"=J/0NK54PRGE*]7R@-$<NS%QK#0?<E[C@,&\,;!8QH/BL9Y3
MH[O3$4\KE>ITFE<CI3"VK'=BNJRA]8D)X@/K.WPG&6"6^DZ".(>9U,[N]C<(
M7L'PX"YO,L8K#CY>,73FIJ;32UX)UE_ 1H.7(]/8^[/6>0(3^2*M=EZ.@RAS
M\!!++54$#G]Y%UB(7Y=/U?((C"R^WA@@W3BJH$$M\U :8UQC?R S4YE=S-Z9
M0FU#9X1=@N5[;KXD82E:3'4APR9Q6'9^?K)'G>E(^&*"XHDRM\*#6TIF>0W*
MP0?B\T,@'%+#'#?#1VU"+I%WH"@,)4'=M3@]S3."!K\Q;1<6^VQ\8_O;2D_Q
M[WTWVQLE_F<B\7N0/$3K;NHY4;V2H=N91]5(&Q>5 !@+@B\"BN+G(LD%@H@R
M_2[Z;%'AX"C5N1GO/@'^U > (&CQ07,2H=3B+VH+P \<:)RFK6NV45&)3#(:
MG$.=CZI@7P:\JQB9..7>N&]SO$-)[:@7CAY;%F W"KCYV@&>3OF2A,32%^ F
MN![ 19L^N]<>GK3SGT,5TX=E)/MY$HC:T'2MP[XS?)< $_?TZ-'W.T#'#*BE
M!+2G,(YOA#;V,/6QC+W$9@!K;,IZMK_*]]\=?7ORQ[[+"-:/@[;SD=O39 8Z
M'"U@@R2$*9(P\J!;6&ZSE*,V-N9,"ZHH@[%]W0=G9T3M%\M<+Y*7UNEZRTZ7
MVUDB<I 5%]H@DF_YR2W$:E3A!Z_"7PBE4JML8Z"A1R,&*P();>95APDAN":O
M,QYO#R=#QIM4;\IL:)S.RY7-U$8;S"ZP'[KT,K7_4E+-"C)O^CMAU;<8=C,S
MUL?6&/7M_O3MOY9YH<<IA;OH.8B9<IP'Z82\!Z=;#4*MF/YAA*E=<MD\9K;F
M5"*?"B :$170"!:Z<]TJ6(5$DW(1&)IRR4+-,5?+/S%>3U?:].>*2NM3IMNF
MD7D'_@!J UJLYK]W.5=,6MJE:[W/\Q+K@38]8-Q1DV-G>(P"C,*:/I3><$12
M,$_$A-#<&/8!^K_%8IZ(+I:9-&_21MI889@M0 4".T?]SO EK<%--!G>=;9Q
M0TB,2V 'D%"%-X)[6M>WCWD:Z.U<0+LGY93I!IR6'E1"/>.V?3,N2ASIH= :
M4>M&;3LH/Q,O]<3HG"K8/(&IDG5%A08RN8N?1!148TP5):@)*@L!\S+8SP]H
M#0&9Q4+$OA:L(T!$"W@MC$E9/P9QG<TME8N"J60)4@2>R>BM8K-BD@)V*'?B
M=66B</X=Q-WQVMRCFC]X-?^C9HQY/#G,OO,P-JFH7<F\N*H>BWLBYDZ#U(5E
M/OD< 7J1Y9%T,';43@$"4Z#'YUSVT.WW0SAC3O1)G-7(G&'H&*XA))^JYLB
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MIA"(?$Y&2I( 3L9E'M.\1+5'O;E>G,>(MV<]"GAX1ZASSY9FY:=SC,X]'<%
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M,#R_K$A1; C#)T:*@Z^L62XLF\ZQ1FV'IO"3J_R4%&/SGV2KU";. C\KYJQ
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M*'7%]5Q_.C86N&P+X"<VPEAO%[(/$I8>PU(>EB,-5!81WM*V\$5G;I]1^>%
M-.;9)J'Y0^NR,$?,T57.$]!-TY;B!21+X3UL&RYY@91>,.?Y&P/ 6Y).&J7W
MQ#=B?IN^91+T6<"8H:.T!TRH;6/C'W=\7@S)3Y?EPJ$U0X42*<)FT\0+T*6M
MJ]V^[(,&#-);\<VK]Q1.7D[ F0&&0FAD.Q^Q9HK<E[BCM40^X$N_KH.@V$$<
MUM'MU_WG"?:?EZD[4]:W374[(?F=Z6L@\"7K H#+C%KXR^YMQYJ[?YR\NV_^
M^G\/'_1[@PP.__!WQ*K@Y^./4@VPGP$U]4?0!IU]T9]]&9,&3_>N?W?/RTYV
MH*U?H*X?>>5A&O_7?^+E/__#U_P;^1*_G<WS+X[OOO9S<*SRTQ^]S2#M_KMM
MU5 .DB%&E___X.#2_Z0;H*" 3/^/G_C6J2I;X3AAKRROJN?,P>OT9*#]+*<.
M']YY)O[\UZO=KG;[\^U6@S\A%D[()47NA/7(-2MW?PBJM3M'JB:XN&5/HX:X
MVEM:XBJT,W>2D*&+LI\3 "O1A&>VA,AHU/B$L5\N,+WMF]W 1<%(_:<D\ 3]
MIII9%>1%M;1)^43&+(3T9 '2%Z*4UC6,1_$FA7E %,VTH+&PN2[;==D^TK+E
MA/XDV2CU7:*W21C^J.F4"&='ZT@66@:NO>/T8RJ?^]6-4&^ZW#,D\+V]\QKF
M1#V6]X0^O(U\P_0%>-M#%56+II<>T9 [2J:M"VA=0(^P@*0S*_(- UG")U+&
M%*E,YCF-GS,U5/'7>)=W$<B(8E@=_FL*[Y\Y,<O]Y.#J5-S#WJ4D)$>X/U*Z
ME.Q+<@))6!MA2EA++"]ACUK_ ;=LL$1O0++099U?T,T!JP\(FY[A:#RBM$]X
M793KHGQ,9[1%W[DA?>,5N7=C^D7_J:O@9@Y\C*'R=]K0&PANJ++!V_7G_3'7
M0U&^K$GC7<,TJ6_?Y8$NO+X%0A4YHVM;E:;=XY^N.4*YX]^.U_RM?T^!+W?I
M+N1A4DJ"J=>BF$*\R;J<UN7TH.6$JPY*3N+?6>="F\CT? EY8#)I:3>1$&K2
MVBU>FJ@S48-!=G\(=UFP.+J_@ [-FJ/>OFTI)#]IY&7E(WM:2M)Q&$*R=36M
MJ^EG'DY6R"H@;X'6+PA!%?^460%5U&7."MAA^^>\RWYHJ29RR8JB$A-8C7:4
MNYBNJ=7@5X-_)&^,<WA(00/^I[T9AHO+?_=&>YI;1[X:@[XZRSG5!DKCV'YY
M5%Q\25T.W((Q$'LRVA0)-W-$,D,Z6!C7G][=_RLJ(7/KPXQ@PZ@HN2Z8#W+!
MC$==-[7[3:XBR^T=.18:CK-I'2E,420DF04Z8AL#Z19ZE2(_.2^AX.W$E/.,
M "6U<MCCZ^N5KGGMX7CL'HXOUQZ.M8=C/2O7L_+1STHB3R%5A?YDQ<O(K;-.
M*N4"N,.V*"M(NZ:0?X5@6QDI!8/Y8Q:[(MH FKN:Q3M65_ #,.__299,$H5I
M[XJT6''!%-8)=\XHNJTVN-K@(U93D$0J03GIK1+5"8,W:X3= -I8VJA"_?7E
M=K@P@9LQ#GH*Q QUC<"<:<"[6L+\&K=<S7TU]T=*5\6&O!@W6^J)%:G]5)TB
M^YR:,PV'FI*2<,8"C0>TY5@F7)MO!^G)I(&-&]/>"5?.R>PR6&9@0M-,/0F=
MFCQ\X;Q%,'XB-JSL&^&: 9$'W3,A?[V[<93=%.F1?'=#C[1XJ7%GC.E*R- 5
M@DX029="=S>+5"]05^TZTV(W#V),NUY#IZM0X!""0QJY5>50KH9J=--1LXH9
M8!;:L68^-[=UD'$U2*WX3@4C&?E?N'@((+1('P"A.3E&)J U&D-XEWP@3>F%
MYDX?GJNNUR<G^Q .F?TH74S'FZM0.;RD<0#E&>']&X^06/DBNI,/LTP2>Y M
MQQ;DOV0%R"DQYV?D*"GU$'-LI'EFA_PZ12/["V .F0C-%8,_KT^2'1R+7#+#
M=56=H@@PD0Y1GRJ7K01@M+@.@RZ$4D@E&&$TE3K C7(9 UT^)N%9'I$4(EDA
M,+UVD_3HDP4GLH&A_A *TITW&[?9@LYPTG"T4##3@1..A+!.#1B^0(CC1NK#
M"8X7WCLZ1C;6>P)YC_2D$T LX9(ZWIPZLNMTH78G;Q&'T:+%G5VU7T^DI^X=
M,FSMX:0@CJ6^>11$@T H#N"(<@&!R]P4A"W$:JO0RYAJX6#A4!O)%GB-/.DF
MB3LNE$;]'XR<TF$K (U.SACF:_9S[-_4SGE'?D>+^N!]IE*[3.A&B=*JZ-47
MEO4T['>S9/384G)>23Q=,]_2"0O;#FA J'5+;SOW)+JM:\,F5<E+X8$\^"?K
MRFZB5:*OXM+&@HF61>:="/3H=#<B5A_*^BL-PX=/PW 1_:%01C(.'38FA-@Y
M8WRYQ=6;07Y=@VIWIZQI7:!-HU.A(#/!R9;3$8MO I].: _)8"J5.CD.PN6-
MQ7O$JE!6<W)2QG!\U,)!F$)^QR_)HXJOV.&O% Y/'"2=8T$_1WPNI$V)->>Z
MQ?L=SA@PF263EK-%\A$0;-+$%B/;).$HN3MGV(FQ7V0!1L3]AM95+B/'3#?R
MG+$:77T#:NR"C\=\=^+]?NOZ?$GM0MO./_WRJ\V+]CK>!JR5+JI4Y^]SE=_C
M2O%Q7^R$^Q^L5>_[?MYCE[FDO7ZZ!9'7:IK4[<+U8Z:W11Y$QP[$/$G1**Z0
MX(&X-QN*3!#5C@ S<W;5)4EN.Z[P]T/CG7<4CG'M?5G1($6@RB\L%8[/)PP2
M?\VW4(=G-YV;F<C5G]F59S8QLP<+]\3C,$_\S8Z&]'QD$%D8<+-%J*=2""PX
M#B-*]3"0K& E"O?..S/DDGQ$&;1/OG[][9_H7\^^_CAP*BPO:^:L4AW#1WE*
M/EUHM3.G$3FB+&X07Q,=2@K."ORV,1#<"]'#[-!UO/<0"RO[Q7H8/8V*#)MJ
M$=YV2Z@/O\7Z377P%J_$O,+\"\O\>XT=AE.S;WHA>*-?S5LMY?3.["7^'?A-
M$+\FOUVXAXFC.8Y%S8YZ:H6L*G7P_5VD(=A_:G]:T*ICMY\3"JG2YY2OJ./.
M$\D]'*F4T3,[]! 251.HXKV))1PE"#VC<M[6Z26(0?$UM%ZJ4Y!O>9:%[81*
MXW[\K;>(S?7@+TG$Z<2UT]-L\6F_WW3YGK4@ J&</8@@-$7!H60H.1E3;Y(M
MX[T\<3']__6??G'?EMX)G1YF\3%"9BHJJ? $L&G9\0TU,82'_92_QJW6/G G
M%("/!V4+_07&/[N-\1XNN_6&B1O\E!\T121<#NF01X_&+E:P'7V@7+*'B[N_
MN&.[W= &^G&Y5["[EYQZ@SU^Z_BTA"W\E!=E4S77M-W^A41%R=P@*#0QLF!>
MW!Y%DW)N-CI^H/ S2I_Q=KY'6E8(?81@D6Y41UIT?N+PVF.;9>//!;088XN&
M8I%)<.+2++!2-PG=-?V"EC(E9".7NU )D>^ U,/U\C3[O8Y,@_V:LGN;;;8#
MJ?^4T &D=[6Y:>[8_@SCA^  "*4?U=#]MEWOIGG@\V<\47L+E, ?F.IB3G0+
M_C9Z_4[I<;1 J?R8?M?'HUFW;N7W7K&ACXT-_6K%AJ[8T-57_^7YO:T?S:[M
MG.IM."]FG5QR5@9(B_U[T7-_74MF$NL]>@JD4'%6>QX^IS\7;7XA[_/,.+_^
MY*38<H8L@7PC+KR3&T"E?JHO^[.X;,@!%PV-/<FCH'@0'I9A GEUXAH(-6B7
M6CH-WZ('QU\)#?#6:;V?:$VL;% D1*'Z/P(5,)FL6GY/%JC^N02[^ 5DW&+F
M+#T3K%C2>H:MF9C#?2CI[U3."4E%8DO"-$@/CO:UG7/28^%\@:490\F4$G,D
M7Q4465U]G4LD"RY*R,[T&97=8^I_CO#CO8>D7=@2B*-6GTP<\Q;(#'<<$U.M
MLR ]@:Z9U4I>N)?ZQQ.Y^.S<+QC2LW/80F8B;X)#].:;Q&\BA)Y59?($*9##
MB'^'65BZR0PQ<C!$4\B4A-@A)SG1BJCLV\-:1_PMU!%#>4UE[GT4YE=:V=VD
M^*Y;-R4?7BHC=O-U1,X7&S,ST7]KT@+C329)=]M<J=0 2DCQC35K]<"F9[O&
M)RQ$=3I_5WLOKCP1>H&/T'U>5@/7]>59:.,X>UW.78R7_J+W()BFF U>*Y1/
MF!0NV@%XDJVK1" <4471!26RI.K%E%H7U;U-WJ;7VY2=YLF*N5J<T&%U]F@?
M5=\Y\=DAA7WDH]%6Z@%.\Z.#R07B1ZVC0_F9TRF<CXE'ZEE(F:2[[!CTBMU
MH95)0>.G)O.%\6RE1-+28"@_),I[,":DNO FX7A0UWQ;:H;-3]..].,XC<.B
M*JFT9BL0)UG'>LO9^W5"NI)Q[G+7U-T0]!2W@U\V-?0G5A?W"9;=MZX[EB*]
M06_#@C:X:QQ^DJEKS.^S. 0@[Q?/@8+<SDM^& !1<!?WB:[$SZA@Q\.O&WFP
M<GC$5/G\^2-G#P=@<)8!**^BW=O?!K $D0>EO!"&_DZ0TUV?>M$,K?7[BTA*
MT<YB='FTM-SIR:R>I1([FXU19Q'?M$Q@?I7M7!LHH=&FX-K0,],=&[QP/U[=
M7]GI)-H+E)=5=$,GB-8!$YFQ$B\K-W.M-9D=WL^3$8Z>HLJ'&@K2$3LK'KO!
M),HL37WXU<G]X)W<GV;JJ:6!=&C4FYZNS*\RBS:8KTIPS27B,%(K&U$:10<S
M. '?<I")ZA$[FG0T\F9!02><S9G:\%BU/#R7,/0Q15A>G3J)++6PN^R_![>=
MUYYYB#"0=*<B;P,D[F<=78T9,R7] *6.-$W@$HK*6=65GO $_H;EQ4?.I9"G
M#MPEH^^?! Z#L3$3RS]%/H0/)HO:X\JA&KBT'TGP)TT\[W^\&N,\#'Z@YC#]
MT3N!'#^]T&6N2*,?OWNA2*.,!L*1&U"@6DL4+C.!%\;^$+.*Y@YI\M9UF[@4
MAQ30'%BO,^?X9FY'(DB&_,[ [,*3O ?*: [OM^#9A]V$8+FA%JU=)3Z4V,(6
M[HW)33AND0]Q#,7&OR0$$H>2&MMFM^6K#0DNEC,OHNP"4J4Z!:O+%*TWZKXS
M;Y4$$2.::[2#^T&1,>L\L/GLAK9-VP"2L<0>J;A:X%9Z@VAV990P"ZN%H\D9
MZYOXQ%K8;X:>Q,(#'BTT7UUMOO,+NB&M:\YLAH-%1;P+:2*S9\WN@DS%Q1LX
M3]+HW)@!8*^NTX?M.KU>;A8P&['X[R1U.^M,+=@]08#$L9?TN;T7EF%5(GZ"
MD79!JO&D^G\L[HM]!:TWU&NJ&809/-\IR128. 4KCF,FLQD=)T+V:6XP[>R/
M6? D$V)4A9$!\E<JVOP.N#GX5=C *>P*A;: I.5S;'6#GK!#H4XZ86+&[D$P
M=K,XV$'IYM,/L2<Y[=V5C!?@UJW#6<0[K37?H[_1PJ#TZA/8,TK1NE$?&CEB
MB.:^#/4_.C+$KK.Y!%]L5#.+S(<4I;O+B#2SHV96N@T@;(6?3C\!1R<K8905
MY'5;^+.,)IX2[=-%O/6703KP_\S R48+LY'&Y)YBG$ =F\7*XX/?):44TPTK
M;E(3CVFT7XTAB_^-,K[?E=Y0O^PY6-I*6;C"TAX"2_OTDQ66ML+25F_AEX>E
M_12+7IIR^.\W/X7F)IP;KVN!:].A^Z;W?\O;HMO\T%[GM68'0V?4FQ_"CY/Z
M%OLDNZ"^>W#>N2TX^BJ:W8!O)<D*A8])XUS0\V'H&'?/9@PI [-TUPWDI&2<
M-^=?^-TDOZ9_=OXP!F<'M<[<E,>CZ/T:5(EQG18K+MHZ=K7Y:7S$I^0J_KS,
M-@YEA!WG"_RL&J\AUAJ[T!DPYW-PDD?K]]0X^;,<@6PI<KGD@I8IG.*"X$)D
M^MC4(,!%B&SL1A@R?'3 D  &*T#$N8B%X(C'3_VMB6N5:<[)H!P$V<"%#V8$
MJ4X2[06,OF0,S'0CEMFB"I:'T$=M TTZWLRHX0)2AI+V$.*B>=H@>?W<BJ?O
M\S7;'!LYTB+B7"KQ G6+ %\E]P B*<UE>+]ZZ#4[[MVZ?(CQG!]GY4)*8^_C
M8X%HC/N20Y:)LD8H:07N=\VR,S\4 CMN A)7GECB,#4,1)W+CP2=!$GLC;L7
M-15V28V3(# 8*//2S'Y-JU[1U2>T822OX9I>3S591*_="-B@LR<7XB"6E2.$
M;V.)-6^,ZYM6+?7:N)9,I O3&.)F^=::6?K@,TNO.&W*"VU4>I655/+&RF9T
M]#ZM4_HD@KVBXG^=2X5:R[&ZVZU$#[\>C&J<ED=+^ %)#*#P<)0U=4+]%@KQ
MHEI[2H!69>0-XJ*L2844TP;42:M8"J<*X,!DD#>N.N)T=]YOZ V.:P)+T'P-
M702/QHD(];4$V!6?%M0H?8+P4P%%"Z^@<UU+"MP4&+!/:1ZU*%B9-Q8(_"%_
M5,R#+<A(!BD;?1UY_Y"CU0>E<RX_$;6=-O_%F9+&/,[R*]X8>0X_RB+!EP5^
MO:;KM/N146J]_:'Y 2-<_+3<-!VI!/&A>\"+P&@I)L9+K+R;"^]NGJAB[DR6
MU"J[,,I'%:HEY.F4K7\RF6!4C1:\MQX,4WYO">DTR.#Y$[-CO@>\]2QEP]@Z
M1A&E]($&9H??!.ZL,QP>1!WJVIC(RX&X9DM1 '_(%J, 2N_?M0%T3B@FVJ_*
MO UY*%0.R;.X_]:=W#L+C@VEN #.%P.?*0.*@/2+5V+-S+F1L*?\Y=45]WN_
MHKI4UW/4(3V;"V,"G:K.Q1+;XH\WWGF65O)O'L@,09*FN]A>'LD O7_*NU1A
MJ")B]ZVTVPKND'. 5.;D5B"!(WI7+4/DUGA+K9J*#(-Z_S<?_>V''W_ZX:\+
MP_U__RK#_3BT5(3'7JCZHBBM@V]H 7;<PFN>ZH9+N]3?:UN2]6'R+GD>2=C^
M A9,K[\.!F7,>*BCZ&OX.#Q 0EWIQ"LVZ%H$"K6+P8)JG2<-9/&N_H8W^6V)
ME\2^+9YR:&OQ30*UN1^.W^E=H<.WWLDLGER#=]R5XPW+>D<A2CQJYN#A<G@H
M&2:/:AK::)EV=8,_>#?X[\SVP'!SO&M&;88(QZB::P0D00\%MW3:!.DODG %
M2T+5=)U2D =]I2["M(A_8G=#@LN$RA'AV238O=)1\69Z(NZ)'&JQLZBP?"Y$
M,X2Q.N[5&W]:VK6P*WA_U>]Z=#B(?1 MYDU>9-$RK"WA8_$?.<7#/JM24<ZJ
MC(B("5VO:8GS6O0?YY([CV5B-OVH9C;M7;.=D-,U8[?BB&[1E:3)L0;\GXZ6
M*9^X,0W#2+#*>YR:)Z.^NFXSQ^>3X)';[U_\N'N^&8<R/%-S-- A:K;%VNB<
MS^T>(55"/9&4O+M_ _C&\3$EIYEW95V+/@T$"+R=1,IGU(_'. _3O&(="_(=
ME/DX);(G-E=16.37A2"/?1MY%^J',MZ?B,I'XUZ/O0_]V+N/,RIODSPD%?.[
MDDA\-<L=W"E&JHJ.,H6@_J7]+G3U9&*G)OI2EJMYKBWU"Q4L-^MGV\[?@*7S
MWF!>MK/?7P^_7R45Y9WZA!YACAC"U,9,:2:36D5F:#MC24SJ8$#GH'/OK7/'
M8&J($/PQ2(D5')Q]V6GAC3$WO']G%@P]EJ(951<NX.&^8,7<6PFRS'<2V<V0
MWA$:M>K<'9!SE*3J7%I]JKH&#3H4]8=<&"+>'(T,6($ 6N@9CU8_B6[HG\$I
MH+/L"%KJ7CBA-,ZR2AB4<UL<K+]B6>' "Z>QA5OGM&2^Q25><%DMJ<)^_VU
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MW#'ZJ> 9+#;ZSTU30)^$KW':_-AB P<7CZ9T_OS7'T-*AQNBFU:DI**0IU^
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M+].;SG$+4(=O;&([3RS$+X-^$B9JYI68RFU@=R#NK YH21TAZ*M8X]A/L[^
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M+=6\T*=%*BB)1;"TB7<46#?9G\&AD)%HH$C-(YF''#63@I2_,M6HT+8]T=2
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MC7)MS6 $;<G9G9D-BH9I/NB!N2DW/G8N^1V"R$C"QW$7K=O[ZW.6<3N4Q(1
MMZYX'D81=1I.^R=F? <U+NKB=!61_U,[N7_HN=VC<WXZQR^29>I&;Y([N&H5
MN5)&H KKDH K@V/&.G[JKB&JJMU-K OPAE"=_ "M6FF D1&@RS]#SRI9=1/Z
M\@/DB"U"9XI00NQ6F<=*-J>XGPBA:_JF>X#G%&.2<L<DOSRSPZZLK&LSQF,W
M8WR^-F.LS1BK'_/+L[*>=UD"S^1Y/^-J\R?I%:3S3KV/.R!AD3AJ<?"GAXOU
MF7_686^ZX"<.R+*[?;7YGMI#Q^D']H\VSI^4S<DIS!^L>VU)DA'^BL%/T[$1
MP[TT7T1??\5@/DTC/KG.!!N>NCR+SAW;>T?^880"F7 P &[59V,B+^K&&#F1
MMV6^[%*]I[<<_62)] @'S:S(;E_"CKW[N"8L/O2$A9HB2YE2/#=J?7[KM'FK
M=M4:R3\M#X]TWDSV_Y!G\:_NQ@^X.J5OD'E6RAHM(Y65BDFOTN1^>X!J">T=
MC70EN7=40[EU1A*%I4RJIHM=;LHO(<*O=**"=/*V+$ T?" EG!3 /=\080BL
M,XWH]<B25B#_7Q)*@B-SUPYE.'")ZYS:0=1((ZL:'=Y=B?:=MV55T73M;M!/
M6%_K[Z5[Z'!T/9^(&[]8,(UTE=A'Q^UD:(/P+PKL<;6P"!!O0VQ9BJF,=??[
M3>Q^R._4S0@W <]MAR8<[O8Z#J#*[M'.1+V%WN9A0_W-27K("'Y!9R M".IQ
M)3IST[(3/<!U&WWBKNZB<=S*&!.+#*0YPV.)K< *RAOF''FC@=QGKKEKQ$I3
MMJ+XQ '*CCGPB;=]VCQWC7:N -EY\>-K(>^R]IKZ^LQ>Z-^/H;(?D2,S!^"F
M(B8CWAU5$D(Y/:?Q2BAN<O2U]+ X<_*EV>K\GYPD=L.+X+RN)0(?37W*Z^B$
M@7)\W^0EB:C3Z%T-+0IK@;T?1M4Y1YXW-[9=Q3ROEG6](TO;/_'QXLKOWR#%
M3)0Q(<YC-9;#N=N\.O%;%^[JY3G6ON_YTG,0Y_1605RGZ!?V=L3-+/IAZPX
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M):G:BSHMU>]$M7QH:]XL^,DR$+FC $0_[8&P!E:C7JJXK<G2#R"6^BV&32!
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M'OD5<UE+$U[*\2][.2F':&><'NB\>-#2QVT-A!ME/:!_)X(R/ RY.VVBTJV
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MI82Y:<08RV]/IE+G9G8<I%: -GC$*GE7=HR(1N-Z%5&G^T@U7/A@H:%;[W)
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M1!UA[H+4 W>V.8-5\2ID^:[!1MB[Z:0;8=5Y*K;"L1+X3C)RX9B_\T8'$^?
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ML(Q;RQVHFQ)7$G:@FF4&+#Y%5B6BGQ.HN<+?S"V5NKD.)*[_<-,W;+TC]Z6
M,AFD!T9=YMJJE&$6YQ3M1G'!Q9GB63N(0!VF?3L+6*[TJWT PBLX0 ;C%<";
MOL/GB6!?V'9_(O37ZALW/1VP^-+5HX2[",(MHZ('+$F!,4K^F_2R,'%+SYB[
M##+^U;SIR7=G<=Y(%P.7QA)$V9D *L-]GAKN\RK#?3+<)_M;SP#WB5F<(J=D
MTN/C(A;N0 @^_!X]2EU33EH?U!%1OXVSH05$EMBMOPOD#6=(.R,CIXRB%^.S
M!98'*ZZ[<[$XMT4T51'@(LQ9Z-. Q(6X%*Y1Q=CTKZ&';%>U6W/$6W'8J2.
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M<*3A-1E5-J9L3(\Q)JY<1<B;D%:M'A1+YHS3<[)L^EXB;4R<)PUKWX6.=M+
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M70/EULUD#6HG"=T\\OF7U=7U58&"F,$0%Q\700Q'X;YX:O[)K^Z Y.-F/'@
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M2 8/@41,(";UX/[1NV<JO)B8:E(XP]!?%RPX7$OR<_//4RUJ;7ZMKJNV<D=
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M;X] >M<N;JQ5E.%X6C?D+:-T5]\PHZ-4)N*+E(>._!WR%IQS] VY'9UJO^B
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M^-"3QE"Q&94@_##4?R@G'=STK@<XE](SM =G/_09_-#(G0E.J?:+2HMP57U
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M41#!S%?+EL.4+IQ%]C0VJ8W<E)A,"6)UW71K&H,SL]&9O!]S*#@%SSV^6*W
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M#"[58 'MG^HE,)R T%=\FYF,Q#RJ"ZR+<>?6/?J676SF8[=;86<8ST>A. X
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ME-RV3'& 2F=\;V#"#-$+T9?1K\X0ST0G7<7\DXF*N^=/WMVQ\CD;$*UYH)B
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MW73M3<UDDZE#YA$/S94!M'(!54=JJRP_Y655G./0"\2I/JQ/_5"I;1>Q G+
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MSV%?]E6\/W O5K(Y)*S]?&Z\[',C>!1>OO@2 20UF$!:0>4LR9"^;PEMP7O
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M Y;S]^,X?\=B6%F?OJ8-H!?,%JYH6[(T;#"XP.O53-:9X.-. 3P=>BJH;ET
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M]91S#L@']VN2P52)=-]%0MFSL#NU:)FWU*3;5%JPNEBQ75C=%MC>^X;M?;'
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M&*$C_L:%*>WTT[$E0TYDV'VXA"FNHXM&3-:<W.=$%6). Y2C3"&]-09@7_,
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M2)H2_#$N(3RX-,,[P37)])(]'2#Z7;8);Q<S98+Z3%,9"X'7 MQZW\"M_UB
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M)8>D(XUU1JR.4FS+GX>B5W!*KVRYDZB0,:'7N+3(DH8KNVZ4=R-(S9(F>D)
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MC>Q4I&)?U,2_,I%;F9^\3$E&C)E;DX25@:*'7PP/:*9-S#QG5B"*PMEFMLX
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MAP:'5 M=BB^@2X@M\WQ@XNF2UW).H5(8DE^U"<8V#*%OGBYK( 8(=FHPB8I
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M'SYL@I]R;^*Q"5H"IPW7DURK:39XETS9<RJI(*H& DC;3-G*>-@+";RA ',
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MT6.=L#O21&DK9W$\-E7=V].4Q#+^\*ME/%%K*=2Y<:<EL6O9HRV394@=9LZ
M/0P<>]"R*:39EW]/VITXS0(T=^%+!V \Q%>K%Y-8B6Q<:"+^N@A,?U "T_^1
MDK_^Q\>B-YU()4BMKN!'9MJJ"4/ &'FR?*BX!*OPP)*?N@AY-J4$),0-4G--
MX_FRKI=U_1[6-2.LN*$!927*%$2)C+.&.2Y2AO*Q6[/E1,KU"5#>_7!>^'=9
MQ\LZ?A_K.#J<TM]@CF_B?A F0KR9N'HM!_,(%V19M\NZ?1_K5@$Z"!"H<6T#
MU&.5M>KA\[JA_* TLU'+S%X3>@R&GF;(W"$@:([,OL7P)T5X,1%XL5&>C"36
M5&3@LM;_+WOOVMLVEJ4+_Q5A4/TB =0>VTDJJ2Y@ %<JJ4Y/*@F2]#3FTP$E
M438[%*GBQ8[ZU[_KNB_D)B79LN+T;."<Z8HED9N;:Z_KLYX59?T@LJYM0-VD
MALXY8&3Y3$&][/ FDT6+8UJQ37 1$D_-"O+8(KU4*%T'?[NID".6\BY8VHB2
M'27[<-['S57)Z3D,]1(>XX%@69%34,RN.$;9B[)WD A.X[:]$Y78OX# 71FE
M4ZE^)30HO%=?1\ND/>WL-.!&K4XJ UIJF036959C&2_+<ZWO.27JF[+Z0FTI
M=H"=D&69R7249+%$>U<EW")/91PAIM<-5C0W)1NF23-9=W%U_'82P\&Z+2D:
M</S1WL2C&X_N01VBU)O?BO]6IP6/@-)@_/CCY/P_G_Q)OX(#&W3V%8'Q.]E$
MS_DQ?(@$_\BE48O(-4J>:\&9_G6*6!-AQ'>2Z5LK,&.U,[@RE\XB]/]>ZZ#!
M@_ [7+,DEI>QBI9;+57B&*J8:GU=J3:93,;J3E]&O'Z!\],G*C>__O;RK9H.
M==8[[CFH?>G(3+_.I9OO[)F1=M162)TO'"'^XN$H,+>^H<W' JS,6^-O>Y.'
M>CR*DXL<;=[E51=I-DMSH3CO53MI@!C;'B'P=V)Y$/HU=B^UA?2R:V'U"L0$
M:3>S1<U)4AFMZ]@YMF]BHHOT$AX.C]7@ZD?,%97%-G+ZD;-D0^26RK)1"AY)
M9MUR61DN'&DE8U_!H?L*GL:^@MA7$.W]H>W]R&A5MO^SM"!*(3 L2#)=KM*Q
M.:C?#%W2(/?Y_<%+0J91D%'U'E =#]D7\:@/&X_:<>60 F%DE"\'052F9I@?
MMY&22X=!UE2'E0SQVM1*E8!99D&U,>Y:"S7$,PZFG=I:J9L MJI=34W Q=WH
M"<^R:)DSDMURNE"9IT(&,0>K:7Y/,JN7$.HZS8/+])+@FI6 PCU"?GZ'$YO=
M[Y@):):I24:I)<[,VG^V"]8Z=HT81K=-6@^[LDKSYIQ2.[4-5$U>;F3$6V?(
M;$39?IOH\OLY8_BUEWBHR!NZPE)KI9S_\%HE<6'@Y(]*._VE_[-%F7*7$"46
M_]E66;W(YL:$3I8IR!3.!LEXUC<?9S/\X%?]LWM'@P^F5A-5 $,+?(R&:ZM6
MH+58CAN=<$A<'RD>@'KR*'O,X3J/0"=2(4( SS5W8[^-TR): @QO@5+/TJLD
M7T[AXN[5Y9)P-%/F]2 (749L)9@CTE%6$':#R((6H@3P,ENTH$APUUN<TGW#
MR0<[L6$D*R7^!-?!5T22NX]BV6?2-3WL3D\+&J%F FP[#0U_8+PN-VM"3)VT
M$%;,YN]P&I:X1%?X]+WL(><E#CZ[/NBR;YTD=!3#(\P#H0C,02BF,B-FHZD*
M'<3+T!V94XO_^]CPDP12589/(EDNDPRV;E'.X1@6!)^W=^N2S/4W$PX];02-
M*H7K^:_@6OK<L&FP)@9>-(<RN)Y& R[P>1;I$AXBH3E^"%C/"K6]!-DP;8E+
M[D*#.WQ!"M&&7.:E""?_4$?H2-W%O-O7I =,7\2)5F&P36WH2Y;OA=-%\I(I
M<\CI:)$/D8;@0&67-J_'PG?2S;%M,QK84;"SY2#BC:"=")N%L*8V>O?O!3:V
M\=KI\.SADID)Q<ARXA\HY?O9<3-WE@P*9J28-R0>K^6)1Z0#.PBQP4J<2APX
M)"HH)0N5B#WCO&**[7SS5*8Y67W0#RWUY0T!H+T\*E<V4,'0.:-Y5UB\V. 6
M@$S5DM^US2N<.-4!CG3<B>:N</I(J(M!Q@J9>4&6UE<+A9F.!5JH./'G;%"K
M]++$VPP>(OS=P#[_K \(CN25$K#W&WWF24&'L' 8F&9I=Z4W278]0+7I-L=X
M@[=)K$\^G0AQH:S2F3YEFNV:0=9+TE@DK;&D<WRG>U1_ZXL;$#\RH=D*54B?
MC+K;'38XKZY@+T"/&IU\\A+ #2)+-\<D,';.+VUE7Z^Z*'6P(Q[SC$XVT_L/
M>2A$R@1J@$9\+WB\=T[L;S(2S[7 8%_,<^6;J1Y9V 0;)<!:V]I2A&]12[AE
M.X?"L\IUFB@H[H3"RA.'HR2P6=Z$S/<9(ZL)\9L7^<WAP[=$17F9((YC/%VP
MY;[X->]U4\%)JFO4E<OF "0#;HZ5OF6;3TU/("8K^_M,!3HUW?A2LZ4U0L+8
M19O9C!T-"8B&3@8V^20ZR6(\O#$^"%5,G6$ -.A0#"+](2O<AQX4+V82[1U(
M4*CE/*.$D$X/*7-R/MG8SG6X0_\8=%(Y@QP+/)"'72N9.3(-#QPI%F'BB9@*
M_=Y2H:*![1#HR3#3-/MDR4;"@/H*% "Z+SAK21MV2Z0*87GGYMV8D3LR2ZPD
M.CB4$B:4>MM;K5+*VA)]*_=<@Q4NN)TVHYF84U*LK2C6RZJ\::ZV=^R:T44U
MH2"4OR39H.(RTB,TUJQ2IL8I1R04(F>-E:!E[#-54P.T38GDS!BA\4P)_ $:
M.'M5FR(+"'#4:0]<I[%9O;;S>Z7#?VC$[/ P&E2&"_!3\G(=K(J$*$918D#.
M7%*$WK!NR@(0)WC6L-015B]JQV.R@F0H#ARY.P3O54J,6(0'+LP$)T>"["ME
MF^DE#4!WW5KZ!F2%1 RS 482,26.'GK-7BEQU";FMK<2=E.W<.XA?&?F/OO-
M;1XL\?=/!Z5S$#-0R2,(%4=ECT6DLXVPL\/"SIY%V%F$G47G[:$Y;Z\YWJB3
MG$VAF(@9LA]FM45SFW0X)3%V8&1B.R>T4Z5RLD>/ZZBC!^P[Y*K"QDDH=U(1
MZ";P> #F6"7FOHR4AO2V\S?<(3O)"B>8[$<+IKD*W]%C5E+&3&&MJ,J4GA^)
M(E Z*5G:UO5NA*!YLL9R-=Y(W<+NW,;M\:LW3>!D\HO"(M1Q=#HA$MJ$WY-J
M?L7EG"=GT\GYZ?G3J3S:94;90FZ44S<8IPZL**G8H1K5VD'/]W67K5^BC_BN
M$+$/3(+ W$&Z\$9EW215Q65O3I]B#Z))N>YT41QS!D_5&<!%&4MI")<'X'1(
MNO!OU:XIV8OS1EUN2.&EY7YR"1J"VV?39@N69D3$5K7V+];K/&L&4KV9OR:J
MX7GO$_[:<!<8=81]I?>4;R9/GCT_>1;>CHGLPPK)],IB*+[(5JMTD?'5EM[8
MJZ&M.)F\7W;$P2?:\Y>X;S/<^/_5F &) *L4KX\'BE,TVU^@M[)[69@FF9+K
M),M-]88T1E#36&;;LQ>G?*4%N-H.+[)(=?=I;(Y,/P$)RA0TL^1+83_BP&%I
MU]XY22ZK5$A%%!Q*,BS((208NZ(=Q,JW8$H#6ISU@OZ(B@_TLT=<L.8&XM[I
MP2,PH&89^M"I0C_N0 @&1-N,YW60.^ZI*M=FYHI1/N89'A%T8R&'X2[Z[-":
M[+$*V1Q!^RD8XVR[G*F*_XH6U*F9!MOUT/4HP6Q=RY!&1SCP/7ZDVO_9TZ?T
MK^>G9X, %9U371ME0:\#Y&7<&.Y@MWUK&-.R#]VSOR"%-J2=MXP;M]/K;6G9
M(4-DTUR@\<T[_<UX4LB<DH6VY7A#L>M-82=._V7>TD!$HF848B30(!9DL'N^
M2[I&J(4[QAK'BS7^OK9(Y %Y0Z$)NG&HK@D557:]G/MT>M=N/CIL\EV [6$L
MB39ONY[K8&WP,(=QJN8IN02C<IG@J$3;BI8CCKNX)P?R3UL-C.L<#/@4CPB'
MOFQAJ0,[SL0E^IIY]/CCJ>N#J/^$4Q=7:P%E&*9NV(^6N6$)6T0J9TK.F%EG
MD39<<N<X3\5EEN+__>'9B3B2XOD+L-9IGI.R,&$^],W7.]W"N+?>&^K=<C3,
M5 8D#S3@M-UUHK/.K<Y/3P9&+W<"'F<4D7E<&^%:-AGPA3#!#'M3ZY0/$\__
M,U7HF%N2SHQ/XTFWX(WF5R6"Z-"MI6>^)&RLUW'OE N/;X<(-4]#3I-P0TV(
M8YQ<?X;'\SB1]&N"FG4:V G=H,W@5O N[/#HY+(Z+3R^FG')40@P):H=D;E8
ME3 -!.06XY=ROIO-&>$1R >)]NTLF[I.>6YMAFYH@0)C0BVEF5B7-^3AL%_:
MY?[?;>X$FBWPS06BH7T_G8HSM@-&*,)WX/-BRA/>>4/1;8K9.)"#)-\@A$^P
M5A2EU5?V"TRW@V.[*?VIG[>%Q8,&OYO,,+0."=74 _$I3)3CPJG%-$@01DI3
MPK+K,F]7:2_4BF[L$2%<=P*Q6/8>T:@FX'<$<J%"Q$IG4&)5%%G2LL9 8E2T
M3B:OAGY+L^9S<0)X8C=W<YBOTN!RA![OE05PTF2CGK[@F3F[WK\G+J\'?<5K
MK'89#D)6BK0\; I!*2CB'-A(<]>!7+!IZZ"+2(.KG8/.F6;95B,,5!B1 8I9
M(3->O/DVF=$5/(_LKBD7-/*8%=318B.*[J:XQ!RMHVH(7H(<@VSA7.6&=T1W
MK-K(1#NZ'"62=KK=/$T0P;]-G*CW,\ER[A@S2IC/ :(D&VELJ1!6ODA7-+].
M=&=X5W 6?&K\6-CTMBJ\ F57U>+;\S6M5YF,UOUA6_?/@Z>7QRQ69;*@,F&5
M*AP?)5%:_$@H*<#"C#K^!XHT>+/I2 G3A#32>^VPU/O9 (W[0T4P[BO W"XY
MP^NT>TWLC\0:!+46L#AORM:@PS$9S+I?OD=F0Z&0H';H(- EX7%:>EK"W/)-
MX_RS;X #WT-,C94YBJ#>)FUU,OE?$$<5.);'[2QXH%BYPC$UCHOSA&:=>ME-
MEB(W'E6F2)/#UG2EV!^ &MGQ(DSQT##%'R-,,<(4HU6\LU4<H<-C(>A:"XP-
M6D[H"N$%Y3FQT1)[AFJ/8UR<?+@$&+E,/'VGV$B5&_ZK]$HQ;]ZEM9/][D]J
M?.TTEXA1<O.E8IZ<EBCNW+)F2DP<+*N@4)8-'1M1/]@DT(;/3VMSL=3CJS84
M[W*%(\)H#O66&#+A_!9O7 QLOL_ 1CH_G#*6)$P0)IG5.;.G4,A.?! E!/!-
M\E7&O^EH(3HH!=;]^.1D<''I,@[T%L<PX;AA I-Z+-(D-[38/4:0J?"0H>+*
MRSF\+N1KPMQ%\E5&(E=,&MUP-8>Q055ZG<%^SY2VA114F5];8)0K1J2DZEJF
M*]/';Y2EZ2.FVEI$&E77)F'M<9=\Q@"T!?G[-472"7;57ZH<EB26S"8EG?#R
M$8HXZ4%0J1 5<3.2-/'CDST6^0UF"G?A NL$#%XPAB4F8;B30^$ L7#%%;[G
ME0SM2G+>G%6Y8.8LIE\I+<0:?]+ 1A 4"XO-N4](52-K3S7 ^GY%+;K:R,]I
M*:Q+8=Z/HB5#2BZE73$ZML6WX-C)*7&/9#MY,KNDE4W3,0H44R6@?)U,WC3*
M?@-Q(SZ%Y1U"KA&L*L-6.!NDV>^TH%EF CFC\II4#"DM;'^ 0$!*@=-#69/:
M^1J7+QFDVWENK7QJ,=C>O5\V#9%((1T\5ZKY5RSZ'R],6A%_34B\*<+=S;1C
M$6'XX^3L3PC?1B\$10 1L0K7I-3CK-W,(+CH$OQ:'"I\\_ST_)R7^!DN@:Q=
M*6(1BH0G2[@5=8MS930ER\JBG3=^B4$:"U?:C8X:OJT,A1!-O" Y7R<;Z12$
MYZL:F6"SFERF!:H?1(A@@F()9Y-W;@,WD9-E50 X[I<5O1"JUQ*!/3Z<43*$
M#S)#9RJ:0)ZZSR9/D8D7YY8-QI['(V\2PJRBI'-0)<7<8518^]1J-!H<QVRD
M"Y^]BH\X"M"GUBHK[_7#OX(5#!1-XZ>R$B' 38BN@P%1O,E6GEU3'-VV[\]M
MLP@&&XV@P_[N_5M0IE6U@<7?)-6"SZ%,3@<YP6[<;$:$0^+X"1C) 2J%,.C2
M(1#]MJ/Y;1>UTXH$-O0Z9; 8V7"B#T+2O[Q$]V*R:"NF3*\G5QFJO,UT. (U
M3>%*Q%@JYIR9"Y3'"'],/%UBM[7&P%WKR?R*)J7H;T@,"5!%9%YS(E'WFI2>
MF =8!.2TUP+SP_GIBY.S+ORLV^P!7SMYZGUI5*7/T<-HG-*&,]*L7"YKK,2'
MO12S=-&L:'1*U*3=I_CA[-F/W26Q_D6[;_"@YZ=G+]3ZDZ&@-H^T9["?H>^!
M;ZMM8(O_A?;B[^1YJST#C[<#(^RS_<%V\]J>G9T\]Y=F1 G?>/+5L;W.4K@<
M'WJK9\_-/!G8B"RE8BKN!3;XI1#[90T1>,T$Q-*SON2#80)C=%_!VEK4Y.3%
M*6,^^XZD2V/);MZ"B2S1^^,>"?6]:X?>$\EUT0E']AO9,MC6CBO% 8^,/*IE
M$UZ<TSV>O#"SCUZ6"SBJ_7>P]1FW:&HZH6Z8CJ:]:'&IN#.)6XMDU +B.V4K
MYNVJE1A,HR)D$5.P)/%;"%^H15 JD2OSA+HP96_N$^Z!\^RN1S<'V:J[B *?
M<K#"U%F[YJY@#W=Y53)H6.>A\7"H9* %V*U/9I6# \6)$NP#PHX].W5PH1,:
M^U";RAC\+ <G#^NG 10IQ<W$[U>5><[]0U4Z5.C"$Z108;A&5B["06+0D/-)
M)W5^>ZG9HM$(I8 !<\9WSGHN0=</Z J&#VY. O8J(Y*]0G">II0GN'=#@-Z
M!UW+" /PAN'N.5@=3EJ0_TN)6ND8HR2%1OK:A]0W<LAL57<>60(^>URTSUR>
M,2N,%"UTTVP2Q.S49@BC.VQS;?J9KTJITR4(FZX <\$=+Q\T??3-'[IO_G<'
MX729ES/,G(#(EZML;F.L>I_\4H]6+<C.&([U2)U:V8KN^K=%8YA7&7Y7(R<?
MC9;&[(X8B77W!&VCD!WG$RLPC'-$[CUX.]=I)2.=RKP$!;ZPLHI@/@?79A5B
M0OY2*IF2K/XR."0A(+B.>;B!O4[QVP[D;O0JL$C*-LVQ;V=!KMI6[>KHYRK)
M.HS'PN=U@X.GBC1=R.R)^3Q=<\A#&427M@TV#9>-6\;H/>IYD5V7(XUD]5CT
MVT8A6[>8;Z:4SAJ,>#;+-[++XNK3%XBKMVK7?,3I,&\OP[7@ *TDM\;]"3)!
M:YULN+E7\8TUI]91'.PT#4MO/I?\9[7:[04/AYB&S=P0CCK=&(0M0XR9&7!A
MZ"R-ZLPIO*,;=(5Y3*\Z92<#7HXL8Q&^<VCXSO,(WWEH\)TCXG>22;: -W[^
M!!:)*[#N^3X7/^++/YQ['M(G.WKGNRB44?_\SQ=Y_C)9UR$/?9^-H!50S(DY
MG[^ W848'V(^N.?+B[]_?O/^W<7'_YV\>__YU>3CJ]\N/O[ZYMUOD]?O/_X#
M_O//;]^__V_\]Z?/%Y]?_?[JW>=/T<D^HI,]3L<EC/[<"V<'F]?VVP:O4M1-
MUK1-JNG*@31.7I9?+%[9O8YD@ZB9*$T*IZU_:,1*AN0W6J,L*64[9=3TU$V+
MJ%/%N1&N3J<++TG"C4$X:4A*R54ZV[!3EWY=5]H-B'-@TD7OX<T\CIQ2*:64
M##+$?)0VKXPCAN@ZVJ-,W$RWVZU.)I5*])U5T1PC&?,D[=DU,7:G<#9Y(:8D
MCH2R< S^I4'OTO"97S-X';Z55?-VA5B5N9>HHGM3*BG?<*W+Z=6_TQ-^)BC>
M;<5)NKHX48[KZ!(%C+]8I%RHZ/F\2@!\66#YAN/!$,9327N-FT-#[Y>T2\+#
M)^-$",N8I>[E2<"9,AW?*<T71N4)O\9>DCFR^>%1SI:;6^\%(H,(E )>UZ6
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M<U?9XV^CI$=)OXVD]WAX';IR04QBF\76C(R3:F$6UD4+AF+3'_D6QP@<?(S
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M^K"6O"^\$-VCNL'>@RWK)I<1EW$"&I$9!.=)K09J7:776=G68(OL0G@9VM@
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MDI6LX?\HX()\S+9:"UY2FPAL@@._RFSYR>2/MJQ:RY33R+PN06C945VC==#
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MEA*@5&+!??>KMS\23=8M@3"THPJ?3$/&T00N/&R[HLW7#<M,L#G%_Z[T!&)
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M7V4KEIBKK';>&+XK9\Y5MRZQ[][S0D1VC@!0!KV9+OC-J7;1EG=.VSF*!:-
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M3%$2V),1(__!&,6+2S1?UMP'[O6R+/-T,R6459WFBA'L7F/J^1HASV"ZLVM
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MP\;_EKAZ:I(FWH6OT[!3'5HVIR."#P3_CU-F.FP2$V)@$ZG7?E.V%>6KS(0
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M[*B\'MZP7!!/#3SVKZ3%6F(HV-06\1+Y=BCHB'7XX'7X4,>DW-)]F1>RZ$]
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M+ 0LA$>(:FEJE;B!VHJL[#X.N*^?3L5<W%5CI?7<3 >5IK'O%4&K^4W,D0R
MR3T\N8^1GTK*UT9>+6OQ>EWR069 U9Q$J#-ER-S$"GGP"C'=$%1"GLKGFX\D
M+-\S-K!OHC35[#QUMZ%(O-@?B/Q@4*)C2*F?!O2I?._.ZXJLCE*2N%?7&=R7
M?ZG3IT;_C%?Z>]4[-N\333?OOE:/]A..\GR;%0>"VB;JDR']]$>DGU[(G,U8
M7$8JTEVT']/Q;)]Y[%#% 0><93(FT.5(5Y/\Z92_)8^'7JEOZ"["LC[.9,)=
M=?CD?WYDI"@!8!H*5]MTW*UKL<YN-9>Z-7D0I?S4!^XYJ&_7;#PL3Y'E!2L&
MLY:S;]J<R#USU=P@NI(EY.A'-Y@EODFB2T2IV8D62G751G&478XYDNIE22*?
MRAB@!O1G)A(>B?+_YON5+T9U^9I*O_3F'64^U^=<'0M6C12;JEDXI\)H<B@/
M/66A<C%EZ8?2^?A"?)Q_(]>.[CJ]+)NYP"MW0&)L.6]-"4^)($LDFZO8W.5W
M?>.,9MZ?*-ZIMWJ'-ZA8.2S^_>KVO6G9B]CYL6<G:@[(CWHP9G9[)=#<VZM!
MS:O('WY7V*^[\+PY+^(MO4"=75SVKHW^YZD?:L@Z)F>49%E)J'F?5^C?'U[Y
M222;Q%2_\M:HZSNCKKD/ 9/YU"9S/U'N2HXGY1.=)",17AJX)?>2+<%0?OO$
MC;VQ6N?=O:;3Z_0VG>>\>+6_=5A<=RROTZ[2"Z4?1$08&^E&4FE4KYU45=DI
MFCJX2F7J-@?G@P,1W5$FT<C[Y;H5:>TL#TT]4>NM&=:"5M8=7LF[EW']?--/
M=S%=M:FB;N4WF9)'(K<IKWQQW32WF3^TR@/0I58_A\X^\<! _=93$FXZ>;Q%
MVLJ%]+7%03>U@)5T-.A'7,15BX;W%P<)WR],R3B0G$=^/%%@S$=NR![-S&M>
MQ]RU*<REJE2A;IRW2[/IE*IH5Y)]N<@U"_B[Q,B3I4?-HS0_5^9>:HZJH)T?
M7C2$A? FFTQU"8X_,UI<(]\K1;=D&5+]>R)D6K#2RECX(0S6XQFL!2Q[= LF
M60.Q9[F-6:\HY(>Y:>IZ8U6O>9^PZ)O2^+=*"1>YG^JPG<A:R3&YD,;!B<6(
M=(2<PY;24_HQRF+I;C(/J.BR1#5W6#<@Q1I4[9=T)O.AY!9'H;;D*0\9SXN^
M(2JZP[GLRA$C_I***FW)53M?/;Q?0=I'(Y<C:/$QX#(?6AQ;L1S4:F IZ!4T
M)X(<3F^4?DO_JFO(UXG#O#Y7"#"NO'P7#JGI6E4W(?OM)$R]]X)6R)(=->F4
MMSU0Y6=R1ZYR\IDR,./H.B]04%=56Z5[L@W.4SOY+^Y7(6^HYE:3DILM)Q<N
MX&]?^XEHP>GZ84[74?VL5+2KF7M&$=>94,T(Y?D1$F*U<8.NZ.Z0%H;1Q/>X
M3US\5:@54!C/4M$I4K1KP2Q3@0[OAL:^7)$U"J//8%1YFRSE(;PL5KRXU"NB
MJ"]/WVGRH1>F\XKYC4E=$ARF13#Y0<'D,VF*Y*GQ84S20"D5*-@3*1@WQ^$(
MW'^Y":8^ J&R)QC75.<W+NA54-4\[ED..[-?(G,S<E9BCL_-5P4J@J2<JIK*
M_ W!')LC@S)A(Y9/S!,MU1-#7=Y(UAG4X]1[+2(0',B<'V/>*)2<%:)661SZ
MR5C%NY7!T4&X4IR5!G^7E\"RP[)[@F67*[+J "I;R]ZHTZ72(&J+^ZY*+K\-
M+;9 BW^:M,-W:J,K3YK7.CT1?'(]Y]A5-51'E>CCDL)+?-?-EVM.&C3KW'QU
M7,"<.UA$;[3Y0*K^XZ?J]Y"JCU1]V$S8S"=R!PMG3V6XEZN])IHI*4]O\9LF
M#R$6G-,AFVISIJ7\.'8E^](V5V=PSC,__A:/)2=A<@]+N91##CX,<W<5?J0%
M:^+G4__"S[NE>EEU+12%RI;$+_*[F0<EI,>R>V_N;JH<37-.!HH/Q?^+%;\H
M\'=T^EGUJLU+J "AH:A/KJBY?Q#S*4":H9*6J@(><P -E8/*/0$V<EI[',[%
M13E_6"3SAR946<(L#IU)-!2!S#=6Q10Y_6(FW%BFC/PAO'RG6-;,2-1N<N7<
M[/58R*T&#KCJV)0I/!B[O@QZR6ZS2<8-('R38,9/5-X%/^DR=B=)4[ODND72
MXD;*8E!W2E>XY4Q[G%/"^GKD]25K22TJH\Q]*/Z4'W10S;[D.8GJQ<6R3%):
MBD)^5ZU/E2867O')A[SE%RVZ6H\ESW.:9C&G "7U^5)(X?E1*3SF2$PUZ5BG
MS$E5BF/_2AZ!2)>G^(Q=;O/&^P-SU6O#1)[(D$E]6C=C/I\T5%^/^,@2C78J
MY)"=*YX/G:7JR+3IDEHUBQQ7UR.X=KV95ECE1)MT9CY\<MNV=I&))SM_#*N;
M'/D.VTV;Q<YSK<O5SG>ELD?E,^570J;,%<VQ7C3Y=U6I@7,O%ZDM_]E-BOPV
M/2O*8.A4QES\,H]/%F'D-+I0YM'QJ#@?4%=6RS,LM?":<Y*+2SWZM"R;:A*6
M3=!(%ZLK2;8\)#73<M9NGVY38;B2%R;E/W=>2AG/\H=Y4ON57U21:Y9.+,V=
MUU1/,@:_6N**UX/)#8NO?*_<3NEYX8B8MRF2J-5-2ZUTZ0-1-*Y1^6RZ+H 4
M6NW#3!TO3_C3U"AS2+\F"6>K7K+K$?+=*YH=R[T,@O!9WK,IR:?[#D.22=]&
M9'Q-X(]T=3*>64^4BO/Q@'(TG[HR5%]99*D(V#/**B/DC$]2S9EI=CQ_@G:Y
M1%ZT'$(J4_BD.:?QN;%JTJ^Q_)CS9G.XF95*HR@W4'Y?_F4ZGB5R:](/U>HM
M,F;U<'VU:,D\F@(-1B=-&[R6\SZ+^0TG!,GEP>DAW(B*YOB K&:FBK*$$>_U
MJ_S74HENK=]SQPP&(KWF"BSY$0$UC?DLRL]D=K*O*L94KO;Y*)YJCRO*2'+C
MD$M+>BY;6[T-:\<RG%V"JC(U74)2*BIX+@MHTOWR0ZH:97$2^4>X!VJVB"V1
MU/G,)9O(P/7-LC*F1B):/+?*Y*DGE<M-RRA1ZXI_*UJ+\V^R DMDLOC9-@HO
M+Y98352GZY6I+%:8[E#I7G-322F*F\_*&!4WX* 7GI M*0LE,^6*_%S!!9.Z
M4I66VE2%9GDSIYS64*YHN)C*4+33].5I@KD7(.U.*[ZW/IJACD:4? 6SO.8]
M E4\5<]9V?2*(M^Y6<Y]UFW_B/RR#3%- :40^&_E8C7S[U! L%[IC$U%YE*!
M\T;628Z>DC#<=N* G2$YV_/GJDN^P)">JXI42=S1(RD.:&M2HK]5N%:J2Z/'
M=E86LBIDSHO)<Q-9Y_*2QI3S]X4Z5JP9)DO<+>I.%_&*4E2BJ5/+94\7NB4G
M4%;'1BK$,.H(7UD#N0 Y>YZC)GS+41!=EPY9QW**)Z2"/J%GLN24LSPKEG=5
M-0QN_HR&-FTWV%VM/OHH2\(54$-RQZ6Q)'^X6K\E5W)5)%R=&7%5E>*1&,K,
M_\"]-I5$&0#(N+GA5ZY5ZLG4TO(33#:_/OQ3=ZYE& E]LF4X9/R2SY0'[<GJ
MNM^DM-19!-F 1Y\B,B5$M;6=Z"/D;JFFVH*!=XI*Z*95YTTZ+/4L+V&C*CT/
MV<]1)P7U$ M_3@U7\K!BO/I0J0QMR;16'D]ARY4/.(W9O:H3CI8)K^ PF#WF
M:="%LD &CK09D9/B*&J9F.-#^K2/4CZF&V3]"X91F@FCX_J"?*.0/^9"71H"
M9$J0+*8B"V#4GE.9W'@B2KO;OFJ\9]P=<S:EY#M7#J3DOFZE^+TNY*UK)VD*
M+&OFR_(=^3(RE,[4R[[!C!VE3C(V=Y!+BD1NF@JZ 1.3RW'I3&R9 :A"3<K2
M+J?S^?)1L+C@16=3'EY3$M)$:.8XXE.W2XZH+G,FDCJ>2@\81H0I</-^F)MG
MC$[>J$&Z;GF1D(";A>M&.U&%;AIO29-I61-2MN\I#F3*"SSU1Q&Z7JE,QK]"
M[@2AHIGGJ6H9KI[-[T:O4R*\3?.G(7E]1&(]:3WTUTHC&D3#6?[=DC-7QGM!
M:V0HGU4ZZN5Q<R11 5K"4(([-J=%9;Z![I%<O,5Y<8B,=?W08.=!-)GXLD2,
M8O6E0A+%(\ZYX1&9"5U$(A^Y,7)+WI"_)LU+"]6JD0+[Z"FP&TB!10HLS.WC
MF]OW' 4H;7VIHB:U,8_F7+Q"1\-,$*R(6!CNG_,.0PI+!4IN*6]KSL=Q:P99
M045'#7001/O?A<LMHR9IG)F 7<S\1C^N=",9U31$ME1V+LF-7M[$G=B=:R+)
M^7.22MN+@3#W4K;7UQL>]4-405 =DBSYZ:8AFFG4LT@S\@+9],=$5GPPT?YK
MEXO)2!/-M1+,+@7;:R9?JF6K.;NB@^JM99RQ",Q*\53'4!)U4:Z;Q<;^6%"X
M!_IM9)Q(G2B^<9-(-J^NC(*E4]Y5:%8V$PI.HP+ >G[R/8:ZVF<+;U"NT5!,
MJ-F>N+5^7RZ!4BQ+#SYOUYAQPR$.O,FOJ T.7=N#^QSEHP^Y'$F2QKY^GKDU
M<4Y9CT)NN?$<ZP";?(I* =%4J*:]D3J_JB(<^J6J<M&%^>;+<=R@%W.:N-!5
M2K>3DM^7X7+?1'%DN&XJ&30;$QD'4U4*]=-+WNJ^ERK?.QJ9.E@;&S+>(=6;
M=R_FKC"^K?IZW?6;U>NENO#"5YR]&)B)^\BM'AD,XO^?I7+?- M,P4&EBSQ^
M76Q&[O"$&@1TN;:"859V7N:E*4O9%-4S6:BISX^4]4\J95M9E#GVN;J<(PLB
ME06W^%TWMG>?NR_,^\NO'D1#D6^^7/!F:D:+Z*QX!YZ.219<%NHM 0Q$]T>D
M.\CBJ//ADMI"2;F6&(R:K\=S>]&R&^OQW)P!+P/#NE6O6R[-1;>LVOF%"G5-
MR5!U*SK9<7A4B9EIST-1<K7;R@ME2"Q53#@QGG_[,XM20]M'Y%6JU>*J/5-N
M6]4T^S=%4SOS&/, 8S"KXU4=24T)MGQ/,0L##CU6RO850!&XUZ68@]FCR,W(
M8%:S!YYQF58.)6F3)%>*O"P+]%IVI=50P<-JQR@50- 3L$1)="# -T58YXM9
MF0TN/U"'=VKBRMJCH:^4JTC?'DO( 6:^6I>ZW\25-UP>D+TA6#Z'B/>N"#7*
M\RE)JGS#N:Z<DW*U)Y;/_/"J$5Z]=7BWDE*3!U>2FM14DKK+ED)%'!)7@AG/
M=K[A-Q2>-+T\(MTNN^ZIRCW7T37ZN.0IZ"]5CH2I-PIDNJQ**ZKL I8*,%9#
M[QS@R\L>%BDS\OR86E(J5"9[>\O/V/61FQZF-[FN4%:HJ/9]U425\W252R3=
M%WG@;!X^S/>JU?H)3B(N.FR\QN4^^OPVI]QJU"4ES=$YF@3UGD5:RY(9K<*9
MGM]JPW/29S?5G31Y.D28%+O=85Y&+N(T8<&9E)5":7E.6"XQ28_F]IE,S))=
M@")+2,I6)I-I%<D)3'44S(Y<?_G*OUW]ZY95>6-(AB5Y3.5'PW?Y057A%PV0
MMO,R<U#NL%>(5I8L&'&U09^,577NF6FF5"EF:+;N=>W%>QCRFI*AFS]8!\J]
M#YY.!RI%0^LBT$]?Y/IA[1].U78&^9VEK0B= X#:B3^XQX,Q?)S]-E^-=)I/
MU.)QF&H,K*@]S6G:HC9)N^6<<Z*4B;W)1VGK77-[TS*BFL4G8X<Z(.@.,KTS
M17^662+*O^;./AD'IS3),E:W[DB/C/RPSY(XDRR1.*;JQ$:7RH/,[9,IJBK#
MBEI.RC_3U[M!1)9>-^*JN+!Y(J%J.3"MYV!F4"T.NTNR9OP168NIPK]*PS;(
MZ,U=)"O!AAQ:E=;Z3H^>/^*D-BBC(+HT1*!<%;?D:RJOR=Q$I15X)$CY^D08
M J%J L@L[EP<,@'C!CGH8K6YGI4.">I"O)5J;[JP6OW=2NT>!D)E+ V+&.5B
MIFD-KZCFF7+6BO%+9?I,GL3$,6F5KW%+"X^%ND0Z,4N4:XV6TOFJ^:HU=F[#
M3CMG?VGL6\P<5\*^EZDS];!+34UX9\QD'&DM?;<LMP9&\(<9P;?5HO5SN>DT
M.3NMS>V-KC%HLEVZL6#TO%*#Q?G]AB9O#'&N*&>)3'2HE?FGNI/N\_+*R:.W
M*G*OBU8:MJ2TQ9\0_G$>'5DUY?16PPW/J["BB;)/8%5LGLD(R#<Y$KK+L][.
MEGHLJ48@%=0<!KU38QJ#4.'E"\6OH^MP[A%[.ZWM[M]R2&:3O.360S\@2YGG
M@QJ>7]=VKRJ]JNP5P7X^T/+,Z>?#1$JJD$<'9,'E) \KYG?^G!6E<\GZSV@!
M2]NP5":]UL;>CQ5)N:=ML]QLMSC749]MN1#T7;J]69C6N:8-*(>'7*!'RP7:
M1"X0<H'@X]KFXY[&XN7[O#^=<B(.E<']PJ<OX,O^T*0N&;8QVZLUU,)D<V6I
M'_C_E1T *GYG?F+F67=GJ]6IN(A-S7>OU5F"&WS%"3M#QG?)3W45#]7>Q$-=
M3A5WN:$K>>7YZBG%*,B1(\+M97FVD-(W.:)07$:I.@]\DR2<*5D=Z4//_T&7
M:]$O>/]7(\^,EQK]\&QSJS-W=W3#LKA]XWZIS^BY*?EWQ-U.W< Y55L<GT<C
M%:$K1080\O[1ITSBA:ICBT4OYGM/\&J6M?%H=KM[1'GXCQP9G;7IJX&KMX?;
M/$*BEEFX;.&/(B\KG7T<^!$)@6[F"4)'3Q[EK13<D_E^17T^NB4-0Q_3/>>3
M(ES_7/<,['1W=#DIAG\.NII:!O/Q"[['M:L.I#!*>00Y\NGTJJ=CHHHZD8[S
M.B[5;K/Y1ND45\O9-\>\S%:P&GDY8T>%6V54-$\%4ID$/J=5F"QDWA0,C<U*
M*NTYZ$H5A95%K_(&'L4!T?WR\57.C9QK^5N*H:I8;7D NO<8C8,).DWC6/!<
M\JO*3M9ADK(@_?"*SWXF>BZ^55.J5'3\CVQXJ?*%2T6VAOY([VM*<=\AY%OM
MQ$"</.;32C1:&E7^3GE5T4)04M+2-I;E9ZPVB[&22:6,N&[EF2/6*1^2DD>S
M64<.\KN8!NT\D>@[A>)@#RH.MC^-+H5@#8W=J02\!*H$57J8*DUE"9B3B(!+
M;@1+GXIK'T*EH%(/4JDK?\@<^*T?)9YLX@AT@BH]3)7^ZZ>Q"^V!]CQ$>PB
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M&J\G]P+= .0/P #R9RELV.<Z@_R!_*VV!F]LM#K8# 0?7%<O<*_=W6GW:I?
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MK]W= NN#CP?6M^Y(\#%*QZ@" TP [UL!Q+#/:P;O ^];;0W>W,(&(*C@^CJ
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M]V_S^?!)-A4QB30=:YUVZ'<.1?B!2NSDY^P\\7-TRM<M<V62->FK-!0W\++
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M"V?DAV[H^6[@T',G2=-)(_DYW90GC'_TPQ&_+$^6<^TFSC0;T.P',\>]<OV
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M$D@.0@SH9_/P-A$"@H>'$!" X-0-A]S!'/E!@ 5$@  +&A9.1.Q]!0X !Q
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MX\-/_X=#KP ,.\7]@(@* .-I >,#*3"K-/=7=IY_<I.A^^<KY\/9Z<<7@ Y
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M=0XV_A?N-Q#$'G&#S]N'()-IX$_'/A/ZQ/-%Z)$XGG_ZS_FA)O'[IQ_? D6
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M\P[C:9FX0>,M,YZ-_N%5-!*3Q;I3P W@AC7B!GNW#C<^B2@=BZ4;\)\./U^
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MM0HAFP<2N36ET@AJ@J@&76[W@CB=Q?-$(.3VE=R0XV0!=2M.=M$[3(RDP\(
MTQ?)G\G2/ F(,Y%X;T3^X4IE5'"*P#<1$S*R.T2DNC;@^]Z/"7K-B)_[+S0G
MYF2D:&JHO^O1.'C+I.)XY>]6<<"4[0[-PW5RA4K_D$D?/#!.E3+2.W6E$W*@
M!W8JOVX"W3)9*@CT+J%RYU*Y?ZFOCDW:5AX&#]EH\(:;#G4W\U0B8VJ:=QB
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M&20/-1]5JTZ&$G16PDC^W<"L[E)8B[//@+/ V56?*'BFP-G'P=DOMP(F'%,
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M'*3E#WR=!Y8Q^*TFFDY4V*QJJ0W5<(F8?MW?3FUF4[@;OY,:^M(-_3Q_WD%
M%WD27X>"EK49^[XOAKMY@^@Z( 0)?/M#47]2EC1>@:0;5WE1$DTL44/I]RSQ
MX7):K09@(=MYXMO9:&"EPH1G9M'D$VE=!B>5S^ RQK9YF7^6HQP!W^#CV!YJ
MNPL7R,XBOS #FD8TA,$^!5K! R^G1A%2ERA]22?Q7Q1[1+.D$9315%UH;OI(
M5.?14--3SP#25]&DR&<#U!K@22086E^5<V^^9(EZ_0F?@_0L5)HN"'"_='^
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MTP6VCZ:G.F>2H/>LPM]I?  OLG!6& \O^6JNQEVWW.Y8P(O(!2*W.[>RM'L
M9$U]V^KO4M]Z41/K$AC#UKC1FS>\/EP5>ZJ/\HPB53C[][FTM)JB^HK7E6XW
ML.KQE+@+;P,^ 39.C\B9H/<Y-@+G$EM\9XU%QLOO_[7THC8_GR29RL;PP9J\
ML42;-25K%3?\#AGC$6RB@D6>N*\WG=6)3WY41;5P/<^V<>=1/AN1OQD;GH/,
MZV"BO&_NCSL>^E@D%WC]/J9J;$7A*5R: NQ;?37;W7^VMPG;[>@F^C9T$PW=
M1*_53?11Z";Z_7837=$7\4[[(!Y\41O$O6>A#>+ZB2]R#,\.A@<'7[MQ0FB#
M>)MM$(] ;;3<8G^S0-)I8VB'?C+?8#\9X-IXJO_GA_WO[= V.)S'PX,-3^?F
M660'?PRL\39ZRWP)M^SJEGAJ?1?TYY%X'HBQ\D=3G0IOC0,0SZW7"EY#X0FU
M@G=1*]BXRGZE?,HQAF]=;UST=OAQ^,T7 *Q\X99J$O=]SS?8WH/ADPWW]QI5
M 7"5@&/KZN&]Y2C;5QZPOSO8W:7__^99R";<XNF&-2Y=W**E[:Y0;^FK<"&V
MX$*T1?,/%)?8/?!C,:?U7!>8WS9O'#$MFBOQ$6<+'P-[_.&?.WNWW&DQJ*]!
M?=TJ]=6/% <9$S32H)%N$Y/8-@&,2%"/GN\-GCSJ1(/Z7JDY**3?Z7VX;85T
M/[3^#DKJ]ZZD=N0N!N$3--6@J6X3I]@VR0R:ZJ/G@[TGWWZO[Z"GAMOPM?74
M@ZOUU%XP(_S(P'E,6B?.N<B43&PS-)G@KLY+?OAXWLY*WG_$&<=N8O*?H$XD
MDX5\*'^]X!+;ATFL\W,@^JE\+5L=/30CN7?)2VY^_F6YS?]V_@_WM&>__MW>
ML.W(I_ER^!.ZFG>*@++'4@-C +<(@7*$Q=H"$N $]SKK6B+YS5(A43Z;Y9F4
M ?G%C6,JS#&U+==]P2D0@99:D4.LJIKH BL4.?W'%$9V5Q\)PLO5>1&_?(S>
MOCV*=J2:IOG!+Q_-,U)T\@"+K;#D12 4X-(5%?P+)[SF)/#+,GJG,J 8JG'I
M?G7[,3.! =9*,<C#A2ZK&0,JX%-83I9BN3V5978MPOZV-?M!4XEZD5=848-U
M/\X+YODEKA'.\]JKQ)(L9W"DW[Q,J!K.&1TGY]'4ZA,V!;D)@@AH!-LB^HG[
MMT F>ECRIN%T9AJ3SLKE(_3FCY/NWE.W4I +W*C_]&^PG:GZ9,#)9'Y-?;*4
MU1%25K; PBXI<^JH85[> 7=N[2HY][M!SZ3?&?PC9][V,S-U+$]+53);GK44
M U)!\F97UF X$,9;NL #6,E4].>QGE<M!!&N.TN*: Z[EB6J6#0X%(@UH9.,
MJQKG19*-DSG,>U27P"?+$M%2"OPO%G$+L@4L"*O9J*0\J_@0@*3V=W<%(TH5
M=, @Q*)718)EI*<U:*/1(V!IT1_X5F2FTWP*,]89DD26E8OT0L'<HKWGC_:?
M==3Z>L(S8(?=)';8_IT)SB8&<7VY:7B<'P$= HTUMPLXI+:%K/0TW-;5[Y2Z
M9+K<H#?#+3 @2 17H(N+!-X%G,JO7.ZO569HE0GP$U1EP2@RX)!<&FO+;&-5
M:;E^=L*F]+;0+M@@"AB2""7^M8\P#%GT6H^*&J_T_A.J GXLTBC2?R$($>$B
MIGCA2S#14J[EE\L<'3QIH4/"MA&MA?MWE_?O=K%*O?LGGI4OOWV;E.%[)?=7
M7=17Q=!6[U]Q&7.WR'P9ENGN[N [!3\"YK;Y_8O6N'J_/MI.S*0OK(CU4).Z
MW"FW#YITO=I_QF8X!,)\^"I)&?#U(Z+>E0VB:\ JN7VLDH\^-'&D$-0,H4O@
M_J%N2S ,.4( 1JE&,#4'F6>DJTNM#3@(_J(3H 0Y5SZ"V1GH&S3:M8401 5?
M0(<Z@#-ZS'Y$+X[1>,N!)X$>CC 2C2V!+V^@B:SUD-BI,DL[@\T ;M;@=GT$
MBQ06QGC059+*XVA'%BHI:5L<3"<+17%!"$9ODQG" Q^6!$-<UFEE-D!_1AB(
MLEF[/]6NK;#K=E>(?/MZRQGG68//8C&4!#G$+.2Z0"-1/3?DX^]%0*Z[)\AU
M3'2![=X9V_V=X.;QQC""NMS -OSD(-($MS87K-4UV2-A4B*OJ"O@X%EL/&!U
M9IQNH%S-9CI.&(YN7B1Y8?T=P.P9F1X1V<W,7B=%69GY,5B^;\,A=E)T_%>=
M5(OH389\!X?XF*I,_"\*5N,@RP,?G,T]7'MA8U>_?P <+$W1PZ5A\PF&">9.
M30'.04DG!H1&'1"&P*GU,+1G0O'HT],$& K; +89*:@(XV?>PX[ERL+49:N/
MA);CGLC0(/?#<+1RO=GN$160Y\L]TDW) B7-> P75:&(ME* *1 A_5'AIMT7
M<"S\-G8D79L\'RP# 5Y)!BV*YYG)2AS58B%&$"]ZTX66D;Y *+2QCE="C3D(
M_D@\8/PD@KKLH+GZF(@]L&$X8]T)C6@0)SN0(U=W..@%HN0E952X3"Y1NQ?>
M+KCNSF872WL.U@$/UY_H@6E=Q1@%1%T'(2OA.^81!'H[2<F"HQ_#.62@612X
M>ZOPK4X"OE7 M[H6OM7C@&\5\*VZTGKIWQTO,TZ_V\2[XO]<&_#JX-':Y7#?
M'RA/7V[RP>/AHZ=?&\TE %YM*^#5>S73 >GJ&T2Z^KX.:H,#>31\_N1K\\,.
M9ACXX':B6X$V9_AC[\ 'FPQ,*XGU."?K+WO!IF:"^<[_)'RL*U^WX3K^AQPR
M]WP1XF:5)"B=QO26G;^MRA[^SGEB$%[WY* V$EZ;]G /PNN[%%Y_T%_WGNT?
M<HOA>[Z*8_$6V[8)X_N^HGP2?4MJ!2L3/P9E(B@3]_V@@B4<E(E@"7>OX_?L
MXAL26L$6#N+KFSNH#0XDM"D(XBO8PO=M%=^D+?QM*19K6,,!0.Y& >2ND:01
M .3N D!NJ5!@8V;GE^66ZZKH]YW25[YP2[7M^[[GM^KZ^<[V,M#OEM/OIG'0
M[VPO _UN.?T&_AOH=\OV_%9];U?O9>B2$^S';\U^#%UR H.^)PI&&R'X&NC+
M]Y97;!OH,H,L[^V_#!PC<(RM-:D#QP@<8ZM).G",H&,$CA$X1N 86[*]F[N-
M L>X)QPC9(0$C][WX-'[[UQE*OHES^ H+W09A&<0GD'=WD)F<:^$Y_=*TH%C
M!)=>X!B!8P2.L27;>Q-Y28%#W!V'>"1-&@.'"!QB6UUX@4-\30YQ,'SV_);\
M=<$W%WQS6^6;.RS^K+/H\%P5ERH-,C'(Q*W5FH.=O4TR,MC9@6,$SUS@&(%C
M!(ZQK=L;/'/WBT/L[S\.GKG (8)G+G"(/@XQ?-[)'D(F7?#6?0_>NH^J3J/_
M6R=9JD)E;!"3VZM(!]-[F\1F,+T#QPC.NL Q L<('&-;MS<XZ^X7APAI=(%#
M!&==X! AC2XXYH)C[@M!S]_GV</CV3S-%UI'KY)"CZO\^P$^#R)V6[8W8.P&
M4KTGVQO@S .IWI/M#5PUD.H]V=XM!2D/R1G!!MQZ&_"CAN&B7U5Q&6#+ \O>
M8NTBA%JWR4T:0JV!8VR[Z1PX1N 86TW2@6,$'2-PC, Q L?8DNW=4D=2<!H%
MI]%6.8V.U$P7>1:=U465ZL"@ X,.*MT6\HJ@TMT#D@X<([B- L<('"-PC"W9
MWJ!C!([QC9%TX!A;YC8*'..><(R0!A8\>M^'1Z](HU=J-OH$GWQ*@O ,PC.H
MVUO(+.Z5\/Q>23IPC.#2"QPC<(S ,;9D>P-,S_WB$'L!4SMPB"UWX04.$6!Z
MOHU;$7QSV^V;.U7PRFH:_5:GGU21!>=<$(O;JS@'4WN;Q&0PM0/'",ZYP#$"
MQP@<8UNW-SCG[A>'.'@<,+0#APC.N< A0L.[X+#;LLNP%0Z[WXJDK)),1S^K
M- UR,LC)K=6D@^V]37(SV-Z!8P1O7> 8@6,$CK&MVQN\=?>+0X14NL A@K<N
M<(CKIM+];_H'NN/PT^9 ?CVXXR-(\.#'5QX!]2;;X  \]Q"Y$,T)/'_><007
M>1)?QT>T? 3V?1U]V-[06KNZL;F[X'=C^U#4GU3T3F4PN1F\,GJ=IVE^"><1
M55,=O=/%N2[\YFS.]8*I_ANF^JU<*^]4GSF'NG]S;K_]1XW7[Z#]OA_^>5A&
ML2['13+2<03L#P^AU.,JR>&HU1S_"U^@ K\/4L.E@(U.7_;FAW^N=_+TOKV7
MT4C#;#-\!*:#BX_VGQY$^01^D931O,@_+^#]JJ(!?X*_RSG,O2ZC,8@'!<N!
M1XGBR )Y^A(6:QH 1BJ+(_U9C^LJN=#PX"2!'\''A8:/<1A8=Y7#%,;Y3-,4
MK_PM34Q'\(-1@ML&_X#5+*)ZGO/.CM.\I-5,G#4/E^@\<*TMXUIOX$6S+(%C
M5G0S\/S?9&5=J&RL [>Z,V[U.B\B!?>P'-=EB0<A%RGI.)_$G _RB8L$'R^C
M0J=*+C;^CJ61?Z_M;:YAT,*YI]'A>:&)TPRB>:I5B9Q2>QRS2JKT1MGE6<?;
M68,7GPK_L9(^(]CZIO$I??=!UG@EN]U[]'0-=MO!P?:WD^J_"0ZV6?];N#,S
M7^ $AG5G#.NT'OT)5\3P&WC3C&_@.,_BI"*>Y)V-RV28BT5J/(9-IYM\F513
M>OC5+T=O!]%.\H#OOZKHT]=)45;1\62"[ @4$SR1@7PJP\.$8)0TC6;X-P_(
M[X$I$CL<\(?,&F&:59+5R!(43#RZG(+2MHCR2U1ORGI4)G&BB@6NX?#DZ)"&
M(H98%Q?)!?X,YC[/"V9+LE)O0OB+G<0N!-B,*BKS9*E ]<K!UE<PXPJX6:F8
MT<J"4<%*M3OVJ<:=-8/OX$?"C>4;?W>$\ST8R'I[M\8?%W91MFGI<V"B1J5M
M-@&.,ZD6G7,,O'.+>:<<ZQ%<TP1VO1&NA_&?=5GA-0W,].YLU55<SMI8#8\M
M?>;KL-Q25Z@5P?T5DW>9^5K>JM68>&[FT5*6T])^^.?#O*Y )\KP2(46HG**
M5J2Q/9%+S6!R996//\&XV3BM\6E^K.QY+BG+NC')^8%YH7LF(8:EF< DR4!>
M$-<F2[7U1C)KP;P'D8+JZKPNRAH(Q6Q4>S-H$%"Z2V1C=I0'S"QA(#S7F2)W
M+,@&V&9TSJ)\R%,-'Q#_Q'&)D/ EH(IJ/#D59?5L!*^"+6@V@P2)MQ?ZKUJE
M9G:P&J [8-!T':,=SWTQ SJ+8@VV?]KV9GPMW?S8S/<$YWNUQGWP9 V-^\'
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M%6CN>C3G=2C>L1Y#45Z,4&UK+>Z/UF:,#YKA1$;CZ[@X _[8H;(F*[R[GGF
MOJ2\<!S.5#'?>RT&;&Y74G;-3F9QU;U"?W3"[L6C/*UGHT3Y\6Q/D_C=<U?:
M&[GVXL,-#3?TNE)!"J@N"<A,:"LIW?#'2A)D%QBUW %:1SVWS.MBK%\"N0>J
M#%1Y/;G!,!?))-K9LX#R#1F2WY(<K#9=9UXD,PPLEO4<?;:<>WDA?-R-$$H;
M2(Y($)8&F9J4K$P=CIO7F-P+JCFA<01V8R&@&U61IQ0XQ!!)A? <"ANDC/V
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M.8>K"J2"[;=EVB6#/%IH(,]"D0VUF?)41&6VC ^;J4_BO&-6ZC#](R_I_1)
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M=)*-V-]_,8Q^__#1),=[;SRMYYB8+V\6: 5MZ)Y!KSCKQ.0\.6!F2>\64.U
MIY8U(#^_!5D5@0??(TB2D48C+M>O]'B:)>BDIZ0:#:PK+AUXA'.=8?L@ _3&
MD^*8)9GWB?'W&DP@C+'6&5;4650T:OR$#;W+,I'?4#MP(WB;9*_F'4ZEH"NP
M!3US9'R)<G!E*Z@H9E/[T.#-%WEJJS$LOU$6^DNF%.[ZG=_U)=-*K"2Y&R[A
MFS8=0ABWI7EQN-K%C3W2L726^"\UF[^$&SW$BW]&=XB\CFLP ,%,DY)CB@?0
M_ 50UZPJ4T617SI?_K_XB_^OP:;0&1$MR*I/&>(&RJI+N^R!F3FJCGRCX7H0
M> 4UJBI9G#LM[ZC'"^SCTE#^#G)RX*HM;'''E?M!)4^D_RV1 $P-F]Q[;,"=
MVZ2N,((ARJ6++8W>E$JB&Z)LZ0*81ZE=[!?>.,R5K$OD:(DX+)E5*JOIN:$_
M!SD 3T$4-O(Z8'C8["*:J]+&JV%J@;U\-?;RKR;M#.O<B YMU;^O?;K9*+ZF
MV8-09>6V38$>6%N" %FQBY FIX1R+2QZ/^;.M(&SC$'BX%JOPA\-JNG=T],1
M04.N<'69VV]Z0*Z.7%M#R,>"0=Q]PHNF#H-9_\O6L('8)R9**!".(-"Z6MPX
M*<;UC,&)W6B^VPFI'2Y>RRO'@.N*<3Y51+U;&T&+@B/C7M+4IRTVRJD/N=")
M'=>M_UI1P"Z'' 1@FLR22ABSTZE- ?$5F5Y8C+*)%I\Y,0;SAYTB3!G_753L
M5T#V#ISBG)IJY"A?E==]LU$QF_3L3N-<<L]A0B/"9K9(-1T9&HB+6I9.;PA*
M1(2Y8)D.8IN0.B SQN*(K@24N,M?;&O*N#YYL"(5LY59A<E0'38[>W"=0#_,
M1=";(T9H-;Q.'$:TP[;CKLF?X3Q@KUOX<JE XW,9N-W!VP\:SQ2+=V6RV&-.
M(79P8_T5.Q4=R82R,GK#7ASQNEPWL8CW$[.KER%() Y6=F=^8MY70IM$V].5
M1,1IIL9B$\+JDRB;)>-6QE]H"SF6@%T\KPU1U5BCHZD3!>;:19=-YJBS&UV)
M[2ZV5J<@I;OB;W!/<A9E(S4E3VMM&;-"U+E-.I-E8^9PVXT=>\)L[_-N,7!U
M_I+99(F3")QT!R21L$W#8]U)D?$>E(Z[5SJ6L1>97^BYX\("V;FDH2+M@M R
MC1Z7@: \T$0<-,W+TJ_-,DB)(*<(9=(2 Z)T?18(I>7<\*58);[+U(E(>+@Q
MS!TL+;JL*U OO3;1C,YH&D6ORB(+2$DAB^QZ662/0A;9MF61W6$:F8J2&$Y\
M'Z9$,V@0Z3<9_ X/_^80Z;L8RIJ ].MPE)60] \/T_1(S<NKH.FOV@B: ;5N
MP(+%%_4<Q"'&/!&JP0&&^>7D^/C=\?NS %=_9SF$-X #C>E33=T;>=$-E+/Q
MVF*Q!X:G5CO2HD,OW6^IE@>'-GCA9$.L;FP!JK4#47UHL,V3S"CSK*XU<.84
M=KP2*_RL:VH-9.D&$W2R&+F&C](S;/L-!]P=W0JT=Z  5@8.GF$P^55FG,9<
MQZ!;[??S0(P=,"JX(((LM('T'Y7UG-8C-.! C<QAKYH/>='-&<>Z'!?)G,:T
M$1%R+!25[7TJ2/770I1?)@W'@TQ/FR<15,4#H%\Z&JY.JBC#S7_&^)F8*AF8
MQ33+7.'M#;SI?O&F)8J0S%\G;4@:%U$^J2H*[/YE0I]\6Y:N"3ZZ=$\&!J8'
M43*FE"5A&\4VW]'UY&\I<Y1\$4#.^".5"<!]:>)9F.-$[C%F/=2H;N6LF])%
M&M@4XS/>AKTF_!II+=MW[6AHXTDWW(;P@\J&HW$L$(%1,-)I8ISD,U,+<;[F
M8V5Q4HJD_&26:_++9!J)A>MI!B<\9F$JQ+HQR:T#/P/=L@5OB)Z-\EA8#;UQ
M]8:AJZ9A3Z.%QS+9\3UAW!B$/F(X&/0# 'NKN(G &$[SO,F%LLM9=IIC;[86
M'*7#Y/X@]!3IY6JZG EDTTBGB;YHPF:E[IJ+D'9+C#3I-0A>4H_@NCC(-K$3
MZ6HR>H#SC.N"&_6EZM+WZKK#TX10_JD4+G^\8-HK\V9\P5!9GFV<=TZ81IS!
M$4ZH[;$Y&V'1U.R+=EW/^3QM^>S*8_;:7]!:C:CN4$3<<CT',P,/HL!>&_EZ
ME 4'0FF,%<4IX(X -_^/L@)FM8Q&42RL8Z2Y[SB\<Q%AOCW?[2XN,5BZL#--
M4^;N:'CYS(7$-$:-M)N4,YLFV,WO!LO,SB%1<G/CI/C,[$58/O)>\1DZBVU-
M9['3JJC'F+X15)T[4W5._<;PFVBD VF<N%2N[O=<,NW NQO&+]]WA>YBS#SD
M5'SLBIK$B1AUQ)Z09SE=>E>V%QMPZ(."2%*319,VZ"F2G"XM>FS8A=6(U?.0
M]<]@+@A$A#5OUE"A&&Z#D4'A%I3.-L!#^%P7E&/IMI;TVE9T3;J;&YHJI=97
M(VU$?K.RIN^!,\?0<'&+V>(16[0F7>38!!<S7;;N9N";7Z./>&.UV+1D5QGG
M^D1R3 EXH/$"D(TQFU>L(\U131,5>,=P5DQKO6#@%H9BN,S9JS2JRX0( $//
M#R3V[#1>=MBWL'8[B:4J(Z,+-X;+LCU6:(&>1RW+-%2+V]F7U!5K>?QF'-'/
MNKI(&I0;$W661Y?;6,K8;@-S>HCQ1/E9=V)-GL#28SP([CCE:<$^8-:%VX/]
M%&A<E[SG/T<?R06$)LTIO\7,6DR4AI'3V<Y;1LZR!'5,&S9 W7-#:X1W(2E,
M8JLJC$W:',<J">NY#=VFV$V.0KV,WN+5.,'?3J((/0FB!CN'LRP\K9P\6?N'
M50(P?T)ZZ1#V#N=$*,*]I++D1I+[BGV#-6+RU#IG-03.Q'@\-$:6-TD@&>*/
MQ(G4ING/!**:S)Q-ZK\4021NL4@4>CQR<X*"\+M+)$>\**R[6WV$PNI. 6IC
M2Y2^D>'PN"7?R#*+Y"K'J2J:[NT^#]]Q$9\7RX"";7ZO8R\CS.]?"PRCIQ>[
ML%?3<%1*G[+S!U%>5Y@\RP$3QQSPT@J[-BO:H3H/5TI)$ ,%6]J::*^CM!G$
MQ5V@\1[8S"\\<^1S8U/5!9(. U%EGFIJDF:<66T(1[4,@]<I2C6ZRVP2I;@F
M([J;$K<9,2NG]#D.C'";81:C'>?LGHK(77[7][KC=D-D-*I<:6^./8B=STZ%
M[IHG4DKGYQL(@7 Z+TIW<V=V%C*AO<'N[B[E,TX*UI=4NI*XS)[*_;W"Y.<J
MG9:^4$04.[3YR*21++_>?Q.GAJXY24ZE\RK.?(UR)6O:Z=)8^UF8\$M^X#I<
MBXN] _!:2)F[\92YQR%E;MM2Y@+PVKTX\0T;#S82497B?2Y?-,@<&.FV&E6'
M\T/*V"RNL*!T8(!P/8DGE=<P193UJ'8T'5$Z6PQ,EAPM2=DH+%1-C$4-9;0[
M?+R+?S?X'2#05WIRMF0Q3<4G+D'""ZB,J'(J#GD"&3%J2'MRD<:2M<PDB9&6
M4L!*\,)<I8VL=%9%EQ1);J 9>FINK/IJ=E+""Z@M]+^ZK81:QQI!C\$:'/P_
M6@[51AHE.].*H%DPXM(BV754WN"KV6)?S;$Q/$[0\ A>FCL-4;2L/N!/8(T2
M5 '>OY*QP#&>"A]Y>9V2JH$C)(P,W_+02I;.POKOL=((M4GL'=,4"8THK&!P
M5J*?%7K$\\R_VG;4YK(SIY6<%<DW.03S/F7N=C"(]G?W'TF"3RNPTMCJEZJT
MG<0&78X)>@#6-U,-,K<51Q2*^$S?@;W^=/CHR<%>MYD5"5FO$"^"'F=>1JVA
M')"K^,^ZK&C.UH?1\N=[D7)"9-052Q7>G;V]%X^?\^[,A[-A=*P0QS%CMX>X
MY$S4R%8M^AX3S!ZBNG,\,GD[;>Z.A+"5V+@#"<NT:( 1$; ,&:7@8 6U[#BE
MVIPHB!G+7"&,L9L+V"=&[OE"*[>9$CHYJ-Z6,%Y18F-J9#>A/ACR H&5 #ES
M[B;G4U$C1;-+3J9FTSS1/Q6SC5:J>C3UX^.A5) "%TL9II0B>><2K"?GE8O5
M0EA+.+PIENY'F&^]:A_,NM74*W,()9YWP)PM(R2F)$S!]8=+6]H5Y'#=2\'W
M$IUCRC;V@I_6,\YJ'/2DM#15GUTXE9W\X-)>/I\6]X<'S_]N[YZG5/=<R @8
M0]6S3B_W8073Z8X)=WC8FA$DI9)8$\B-\LO];H/>37G^=/AD[Y9V91C]3D%H
M<^@>XD<TJ8N*D00<GW!W,(9BW=0U<9K,'8E?FN1/%F2LW&/] Z[3X?68J8VY
MK 3+09R*<!76X:!H6R'D,QM72YQS78[]C3'K)@6A66ZCT'0?%1A/*0.V<IG0
MG^Q'IU2!@D(A."/L.@U<H6 :H?H>TV3(X1;-7HUA F1W5\T^&J@()/^T0QEM
M0):&T6O3W=--2LZ_]+8!NT+DB5(+SJN$#,3L%7"Q&PAV'#8 ZR<Z-=JD<XF(
MYO9?8EY>4\-D?R4SM]!M&J0%Y>O#0RA\HKW'!WPK5Q>)!=']5>PJ:T%QZM=?
M=5XE!(\WDKRJ'>/S( P'ZKHWACN: GVJ,08-L>$?,@F+8V<C@$S[@H(B<FLG
MUA,&P<5@W0,_K<H-CG8_WP  OU@BF)_?_GNVU<2"/13XAP]!_%$>P0M<,C!8
M][MJ,=<OL Y@)74]>M:X5>^.P!YN4G\VJE-0N5K\R&[C#\PSG@@/DX?X=*+]
MI_//+V$/@,@6+^#,4Z"!AR,P[#_1[PC1<NW_M9Z;AE/MOCRT[E:$O%(, L(\
M#"$<I<=\!V TDZK]$=R#NG2<O3;SSSZQS-H"I09*79]2):^PJ4!J-*)EBG5<
M65=R;A^2O*Q'52'-URT1=[Z5DP3V=G?_'D@[D/:7D[:G(720M*#5^N0ZPX25
M>;I <O7X\PK+LJ5LL^7/>@:,Z//P%;<N4'V@^B^G^F5EUR/]!@@TKBV8*;LQ
MJAS]*UV9=EW!WFMG' XVRD^UR>OM>"HYFC$L:M._&#O2JU_@  ?<L(1Q-EO9
M9TU=M3/(%[G7!^C&H)YEY,M4A(J!EDR*$1<I?.L;U"1$ O4]I!F8\;T=&:DR
MP5 "NAQZD%W)T=0^WF8?&(4UGR]52C,"XI@;;'7&GQR'(/M)!8PNYZ;R2<46
MOQ,]O][I[F!V8G,\;JB;<B)H*0+96^77>TF[5L>/I^<("YD7"_3.^=\UM9+>
M>QZ@+TO3IMA\;D5 OW7F?#!H*->]0NQOV^@B<26+"5\*3?<Q@6#7;H%P:<\Z
MRS/MS?+I?E=2TST009S_+4VF*.N" ]%Y#3>FE]_5E"=NN%P^&7R!/+AKCH$S
M_5*.T10'4$-K;B0N$_-6@]P":Q()]9F3VWSXWR\,PE [P@ 6&C*?;SSS^4G(
M? Z9ST'7"+K&S>D:TOFS;$E/0D,3X"M3U;B.+2K.F>W6/!YX^<.X'#'Z/ZI"
MG<//CS%Q.6F,_1T$AD-] IU;'%F>&$ #W[++BW.525XAPJKEXYJ,N =N?IM3
M'E[IV5SBN5YU?V\%:=\+6NTH[\T!N"M5:'0A"":C:BV7[PIR7!M^*_CZMH!%
MWD?FY_GZ>D*,EJ?]N/?TL9>@<Q-5K!B8M/6KGF^[*3"15AQPQ0E6CQI4DCN(
M?.P\>5L2>EVCQ?4C^BV#N]Y+K[O":"O7L=H$OHH*8_P&SH-;M=$>!)X1>,87
MI2;T1EZ7@V,V86>G\6>K5DV#6[FT7BS8)O3L]*<U+(?,U')*1;@*X2I\\56X
M7J1LYXJ>>F21D)%1F@+* MNE8<XE#%-1>J_!9(\?7!%YZRC*O#;21U=DJD<&
M2;S*R" 3<J+HU89A)Q>5;&6Y:F:;T_D!JD$3G8+Q-XXZ=>Q@T5VA>6TS8NU7
M<+IW@Y6"Q"$_[D<OL79'ASG&J;1W'GER4=KR!OK91 Y7[8QOLS/(3,J0;7FQ
M7.K5T6GVR?#)SMC4<Z_;"#:(AR >-A0/5QM7!-I#_Q\!2UQ*UQ1S"/09KG%@
M-#Y38.%5QO_XV P%8Y#0"-I^H.$OHN&/U\E76V$(K*W)=V3;+ZGT_:8()S4T
M!3O+=06F*M;BGM:9 G%:2>MA*I4A.8AM?^.F1$P,Z1;(_R5U-B_(17 MM4CD
MYSM5C*?=/_,.Z6"/"[5MK3FL="[EY[9)LB1Q3-I%4$ON' >\[<NJ@BFA1^1U
MQWOW6I5E7:5) ZHINKD"HM_ML7Z$8WU-QWIDC_7('.MK>ZQOFKD,W;NP]S*@
M86PO&L:1G[_D52.^!V%Y!,(R8&3<62W7QQ;:X\H^<0/_N.3N&Q6G94VO#\H
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MSKR;I,G@S=MB;QZ=ZA'3^RG1.U(9?1K25NY:=AQ_'NLY<=HN$&=;!))DXX(
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MY]F(S9<3)*@IT-4,_:1E/9:_!YU%+2SIK9[&/IC&++SE\7'@R.A.(O@&E6*
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MU5)6%%>[_^.^O:G7OQZ^'0VOH1,EDI$TCSPWSN=TVZO&Y4CB_QDZ(@Z'-L5
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M:E5[MYNEJ 54"JBTOCU#H?F.'4F"!))Y8]VW)*68TIHFN,G=<J:-AY-!$PM
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M()^,L& /1=4QA/*['02)X0K.R:3!39G3A44*LE<D,(,F@X5[KZ39#N(_:\-
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M*-FW2\D^2J)%'SF#OXJ7Z^@_/S8(I>)/YT5>9\DOT5\.#X^.WKQY<95.]&H
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MD<SY=Y750,#=O#\3$HQUK&8MPN#Z5S2RHV4<;B6 9W\'PN<DV'VFI0UUKZ:
MLTC9(\3%E%]SYZ)B)C&(W^,%G$8*JEW\J<B3JB.7$L%<$IB7C\R_C'<J4T0/
MQ0B Q :]4O_2)0ROBBK3V#%=11>PWQJIK)HC? %A+F9,-/S[>29;> /DTC_
MO;V=Z T^_/<ZE2^MA-E\ ^\#P>Z]WPG&\0DW;KJWD\XX][G5Z:__=^E0[-TG
M17U..BH:O!;VQCUNC/<   !"(4\:.^Z@@#P Z23F^B^3EG 5I\AR,Q/]FN=)
M8>*IJ+AJ-G\!% LMKZ/H$F!0TX#S0H$J'?-]EW4\Q3[RBIK,VX-E3@=7 <<M
M8)I/)B2M<GOZLL*UG,/W<[D7X):EX[4R!=YEJBZ7SU&8"8X%_RU-B60;,!XV
M@0@P+_*)+DM&(0*!#+Y]IQ,<4AA\81A9#I$!PE$LR\^'0'E@-9E1H^@4)GI3
MX)[@R)> T(GJR(T.1$+Y?RKU1QQ%,W6>P474,]A3G8@4\G%J8-.5BOZAYG.%
MWQ$E\X:@9<-"3^-IGJ?,%J._NV> PV6PRB1ZJR[EF9WHE!#_5,^K-OX\6SI*
MP9\\HP-P=.OCR8&H43"FT3!:B2  L,'PA'A<P'N Q,>'']Y'\S1&:&!IS)&F
M& 41N$D4ZX!?P\MY<0YBS?^0+L4'$-<%R!55NN"EE$M+L>,OG3K@ TN=L([6
M&R )7=1E%W<\F@F3P;H2Y/T#E!/I7)ML[CWG]?9/F))Y"="8#XVF$IENVFBC
M8AHJ6_.\PX/Q)6KD)&B),AJ/H[-IPS _!Q"'"7#\6<OBN6S;(DI?EV3Z!!P&
MJH$0J?$$6*!E.@0:+MTS8A6($%-B;@QY24[LB"$/\'&! AX.U7ZK3=E*%J\;
M @?3J\'SQC=Z1LS@@. 0<'8XJ0P$*$!).$<!R49,!I"'S1-$((L&,40#28-9
MO0$O#>X*)OJ4Y9>I3LY[K,$UT$&@'(Q:4]U8\P JK\?AB;%; ?('.&R.Y'"B
MY-N3N^Z3^W#C<:[3*/>7"/;W.<+_RQ\45=*9$$#A4BW*3E-C>!?>X);&D;=V
M&(FC3ZX.DND\R6$R]* ?(R,;\>-;[(OK!KCL/?NQ7RV9I'4Y_29!ZHX4$P=2
M^SU:B8JFA9[\GT=_.?MPN+N[]^@E>7^8R,.=9E7YMQ\41VW!__[7WP#![6UP
M#L>'\1] #RBKXP,0V@+$N<=[-[B>]D>;VQ%4T<U61?M+I=Z*.AI9SV;1&ISE
ML/D\Q\"[!$7^J_@3<-!EB?")\-Z67DM1%QADA1!R;=V6/0;=979'[5<P<0UM
M0:9G&EQ)4<"8KZS*VR?2K="'K3?@N3@X]OO,ESC#:&D;EZT-+'MX< -#/A=<
M^&\F3:.S?!Z=B"AL]7B[)K)FXMI$N=Q[_M-S44#QU^45D:D143&O2T_,:BR.
MZ*DX1/T%EDFFNL9\V-@*N]9!V 80,=A=RNHT7X@=YC?U/ZFN\JPQ0JP6\64O
MC:<'X6VJA[2.UE6C"B*Z&PZE4CNIIX8TB@;=,&T9OLP+Z^I%DR10;=1)*U1@
M1]9ZO+?/6C+KW&0OAK\]-%BY-FUOT3.'>H89D?Q;TJV=]UG73K#WTR@Z2. B
M"]4V<.\1F![4YW59.?U@W\K*UU[K>X.1XF6/$<F=WZA1G4&3!KFX'X%VX*VE
MI:\8'EX;D[)$DO=!.D?EFRWGGE;9-F==<RE\"EV40& T60T,#@Z.SF;%T4Q
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M:H3^(F4<-(5_'^-TH"M\+Q+(Y@L;W\OQ/MGY\8;G&P2,(&#<EX#Q3J4ZT,1
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MR#!1GA9V9#^,([M^$Q:8D*+9^',J%IXQ!LO&'\; 6^)L%OD;AE,1 "KBN(8
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M%>S,T@RDT.P+\<O*\%02&B5QJ#P05,U!5%$TP2WER#BS$;%B"-9C/7B0/\"
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M!(,H;YVI.HYA3'>ZSF:/W*0X=%B_Q[,ET!F.MGV^=+5-?9Y&-ZJU6N[YK7=
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M$QF0(1%*]#G@L?HUH%;++Z6=V )#'=S43X;%14%*I0A#381</HSS9S:>/W/
M^3.</\,JV/WGSU15XHHQ1XZO1*7'VLY0'&(IRJKRXT,O+]JUP*Q8+P-#*D^M
M]N"5SJ*5/1.Y<E*9CY:@8:T>$15N5+ ;C$K1[$_OHS?N+U5.&#T ;$-LP8:X
M+OF81Y&X\Y-1>>^*8(CVMVD242J>]JVL:)!'YL1?[K-8,G<:(P.#" 0QOAA/
M7-XJABE2?<J^^[5"C: 1#F))4</\.+NY/G?B.S"%]$["&X_:],R3MG+G#T![
M$&I[E-\D;.KPA#E.QA^"S0+1(X%J(;+<3  VP'-,E9X<,ZZ3JTK@8IS1B2 J
MQ*M!!6PR],+G'CA032DC3N\$Z,[Z/-;$=@I5+RLZ>YK6UI:K@CJNIW@T/$GU
MW6 LXOG-(<Q1K1+./5&', , #_0ZWL3N9$1NR-(YS=7&4T4H#!$;\M&F&AYZ
MM8KQF]-9E3"@'41 #Y0NM&!J,."U2)QXMK3^/%]+G.'I4G0F47D$=8*==J0O
MZ<"5RFK)XT-YLAH,7%<\J9NJ+FRN#M31_,P7NDQY'IUR2_$IXBXY %$1$86M
MFT^"7OI8_D4/@U?H0$K5"VG\1=8R,J!O+:^DM\[F@JS7'1NFZH2?CG86#0PT
M.5(P'CU.5BP>X;LF%&\%(OF@W^X>]#N#?7SY00YN</.^Q-'([U-,@,_T;2]
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M6B^A=3*"B_-3(^I(MN6W%ZHI7[EA44\U+.JIH^UU7W6=2C<B] Y0D,41Y#G
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M7^O)BY?F239%GHIBK\6)^MZF$T&$ G1"9/+E&HCDY96\R0(W/A5>%$0PN7X
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MAP@^^:DWDD&PH2#!$1\P8(G+@8(=0YW=D[B'3Z/*$0/$CBPOQPGV&R_8AF?
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M9J!/ZJ>XZH0V4@M<!>J5'^A6RF21JU:38-/7O&*0Q3@--/M1U2._A4?3L7I
MT2"R.$8E.%>;(E1DT4=P(XO.EVFIF=2\J2L'Q"<W]D8E[P,,VK2QO!M%8_2D
MR.\3*C**VI=>++=F71N7:_4V4P5,FO#6#K>9XBY3JW>9ZG5;[<.'KLU<WV6*
MRS.O(YYG\XE^M)V*.Y9<KI[+U>_Y1BV_(3L!B8R'.]M?ZDN4^*@8,B@R*.[Y
M1JT BKU6K\>@R*#8 (IGDTGDARF%A]ZYZ3R-<>V#M8=/MV)@Y3*X^P>TE8*S
MX#EU; 5$0RZ"/Q%%]]9;MA.E!/]P[V*)4>%_!M(/'WT:^MP7SI$RS?2]:4V
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MKUF<!M(^079PXG2.#K9U?DPYGHK7ZR>CR\L*6IES#<MG>3!E[RMEI^56X.@
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MMAD&,PLSRSTRBRM&L,RF>(FF=<P_!Z-\(FXH5)PB6\#%*59-T15QC7JG_"/
M2+KI@"EMH!PL.B%3741/5$5TTQ2U/<T^E.5L*@HGS ', ;O! 44T)';)++N-
M BR];PR;&4DP=#TL38+\HHNM% 6UC65=90TF=R;WK9*[9;NC_H-T755^:MU]
MI2J[VK%2+JBE:3XOI&3<+B'8_$F"@5%C(]34*M1&1_7DE2H6N+BIAUMI7K+X
ML--LU:>]JYJXQ++4R>801JS.N)2+*Y[BY0Q'#P]'U5&'42B?'D:Y>:)9O9L1
M*9B2.&YAIQ.5 J%C[^,(ST4'\KM?U ISO1$^7)7ZPXX2*I&%7)5SG-)<O9N/
M3VSZ^,1QFX]//-WC$QS.V,5P!I6Y4.>144O]PWCO0JU&<C1CJ]&,F4(D14%:
MU(XD%4.UZDZ<J\*?XI,J*EI$;Y/I&/;8!&_/WGZ\S(.U]!XZ6CPH4G;(%^Q3
M453CP74GH EX2F%>J49Y;N]4C7Z\&Y^N1BAA;O#&4F70\N4Y%7(6Q3;HSW14
M-9ML5V=VB$+0"H[%.$M2ZJKM8C1;ZB3SA#*'J1=KH$Q>0U"4QD=5_HL@F2OH
M();.1;W#_F;:4Z1?HHE!UY]TYY3/*0&52G:8.B4S'P<Z,DHU&()I'.6GS_7K
MJ%1T1,?M56*\G6NPVKMQ^:(^>7==LX::IRIM:_'9AMO()*:S]S P?9>.UQ!&
M*[;5I5[J"RN[XN>#5KMM54^>#>=06R!*SL/QY1X/?6Y#._P&H'AB(I,G!V8)
ML#&Q#NL4+%]J3-<4=-+5OPMOB&_5K4D 7I+A-"<U6Q[AEN16N[1?RVBPA4*4
M=EM'59+"+6H7&8BH)8O"US;7M119J5+:=:7O7]@!DRK!]"E-V(3XAU0UNZ*]
M,*5L@5(NPSR92Y9;3C3&H/M6=2?_%EUTY2,8>79>?>ZESC@'@,L]L^4BY-A$
MO;A(78)@A0J5+H=N@N EYPQLJ:N[I/0EB2DTG?*&*50K)T^N6]P$01WHFIMM
M:M6(7RK;5.M[IHT@S9$>AF+-#S/3/-1Z1)6;[ 073C;;8>OLB]%'\HHX _A-
M!Z0_ZH!TDX'V>=?]USOOCBX1UZ0&$FN0<%N>9?OH8J6#24 '$4$ __S01T]R
M/134WE"G4ICRR+,#1SU15^&30/((8U0X$W.%L4:H<8_'B*A!YJ4:TK"SQ1B3
M^ 1H[*@\H)X[L,U+A7L^V!0!]J'&8XZ:BU3)03=(U-%?BHH-4)G ,)>.0:$8
M*#\9AXM>>\_-M, J1HIC@<>H9M24 #Z;\JP:9%CV#RC/4G6YAU'HJ/S0E*56
MKVN)3T##4=ZV!015,,4&S12? UNYNEB#B%83UM=/M3ENU'M\Z2U55XVMY'(=
M4: .HB[,'*9RJQX(PZY9 -A46+?%IV?+T0T*45BD,,S0"S&SJ>H*RI.N>3-K
M=5LY)X-'J6*5W8?-DY+(\ZE@81YOJLV<+QH!SDV7-^P^-QVQL&2;DQ&9&K;F
MFW1#W+%)+ <^Z*QW(ZG=#W-TW))>/[9;'R' U1RO1HT9]'2 #CI0GOBP)VY<
M>K!R#;DJ<P ?H_R%OCJ4'/C? (;]V,O&Z%/Q\--$X(8H&T"218 ']#"'(:8L
M"*14SM?>'9VKH>;@;H;W9RB[0*WZY.EANHAK8E43U#:$\\-*@TSY3&>2EN8>
M3+1R;M36- V $_.8#=9F@V4.'<P(=5(3U$ESG1^M=-E$UP PJCJ>A=1:+6JR
MLD$[9 )F GXH BYI.Z9AHP%D3,;B P!,MUO4/U1Q))_4=#S1C/D#,5#>&"D/
MB>^[I\N)X4-^[F#T<#9FZ%K]4/IYK$XIWLKI/#"AEU.!E=F8CIF.-T_')I,5
MP1,)F."3Z/:@GFZM:+*.>R?9<.A[Z 3$A_L1N:JH;E93RDKNV:J)7=;&'G,&
M8;_$EJJYC!<V5%;DH[V\?8JC1+F#B3I?A,6MZO1 8:29!CGU=S0?^U.Y&4.7
MO*"P2]AL,6^6J&*7<;D#R*PI9S<>_]@<4_7-X5]]7F6&DVI792 ]Y-[$,?,R
M;FK]!;FO0=_I4]7#?'BT.O6.;7(8PU+K=^M@I?^_^:$+&H1."+D!.E!K#"]1
ME4VHCW;>UJ*?2-.7O+YN2JG-M\JE 88?V#I7.31BRJ=46W07+7_4H>;![%8H
M'<\\H%3M:9XY/R^/GML0<![]>GGT'<ZCYSSZ9Q]Z6]YKN^#L8\_46*GL;JF!
MME7=<.G:0!\.=G,K?Y!M-]5!X@?V<KWRR=PJX('ZGC=HM_YX$I =A_W1YL=/
M=K(&L[-"$69GI2K,,X4,;>MFIHA\<YF^Z"XD-;M!_:TOA3TWNU%G-J(],%L/
M+PM]M*)0 S=E9JUL2&KJ6%R>V^"VQ7$'')J,_$E>F26OO%<4[ZNK!:CB"$J3
MIS3B(@-&UT8<-)52+-5.M$KX49K.;!T_<3:/4!VU&W/BA$4#X+Q\XFU$/@;B
M6A4>T;\"D8#^ 1H&9=/ YP,_26._GUG'ZTUQ2F1')$MR9N/6$T'"B"<DO>PL
MT=)XPNC.+JU+#ZT[LT2\5DTZG>-8)V?D,,-3%Q/7'^CRN4TG+N!//$< JIA&
MYV8RU&U=U5$GJL?IE,DM7US37GF(ARCTF:F;2/53]&_I]$&1K67.45%^%)F.
MRIMUE052_=;IR8;1]_)^B'A=?EQ+_7GQ79U247^=>5@K.6^24LGO33+2+LWR
M*F^6[V&71X0#*D-GG:50*DG3:V;U$58M=U&U1%R_+@/RN>(]TC%977D45:39
M<;R-A+:5E,@:X5PH$*X(86DI\3=-I40FU>J-G82LQ.XP/U ;1Z!H94@#BC[,
M80X06EFB?,+ZEFEM%Y+YAX5C>8/'A5$\*2%S+;7L(OG4?=Y_H7Z=*QC4+[F<
MAS<L%CN%ZYL%T*,40$0*7_(J]RQY]EOR+.Q7P*RX8ZQX9:> 4H^M@:D#P7RX
M.WQHG>Q<V%*L:!2QCGLK431@SH9&E4.M?3>@:'4RDC*E%#3T"YB3K<U=+(PS
M:%D7DV-K!R[F8V#.Q>"OK#CUI9T,^4$H# &;5H4S#A2G:&JH#Z+#5^@A:+"M
M_=#483 K@?W),JOMH8<G%THG6-PQ7="?:NVK9CG]Q*Q$:]:9I!=92*IVZ.2Q
MZYL;T,"HK9'MY,A"!<X#1MF=1]E"X=&5++%^I6Z#:?F0WTER$/DZ+^D\"F^Q
M\14RUW6N_#,L;PV6O]A@9:%/T0UGC*GC_X^];VUNV\JR_7S_!:IG<DNN0AB]
M[-CMF:Z292G6M&/[2DYZYM,4"!Z2B$& C8=D]:^_^W5>($!1LD3+\;EUIY.(
M)' >^^RS'VNO;?T7B<"JSZI*N0PR2T6OKK8\Q/I0W%IJ8TF!0_E9'"%*G;@G
M*NRITW"Z@DPO#+'>AO(4M69*KA-7D#(-$[PV7M\Y3VO+E6%C16>E<6J&^=6-
MT'KWA?HL4#96:@AJ9@K76!>3,.\K910$O2R?F#DLZ;#<]28)K 2/F95 1RY(
MG$Y,TXF^CI,H(MK;Y_:P^-FQ;0T85.-64ZP[F81]3(;'RXRY_3_7LT@;9;.^
MS^A.IE]X+^VE_;;5ABYW(/6C":=8,\)0-AT+:#_26QU6WH'4-&NO,9>KZU2D
MUM!4P=1I;1\[69T;VV7V=B6Z2^]E) J@1"6EJ.%>N6D5YL0M;IJA<]J)C%N4
M$K@F\04;9,.E!MQ5[QK+NDYXO([@6MIN$$I)^'4;B?>L_I>+8G*](HXEMK^!
MOV_2B(?1 -11/$LS88!;91 B8X!;NM_\V)<VEWWS+&$"Y*Z0=&+;7BQL &$B
M.@J>AQYEX((.&-9[Q[#N!PQKP+ &,^^+S3Q/%OI(J<P=8ZHPOOBB&46O%+RD
MH'S?,,5+-U;)@"<NQ7#,G4HMT4,M&L;;#$%G:@= V^UP.T%>2/9O$\+*5.!G
MXK/!(073@#F@%.&C4A<[!HL!'S>;OS$$[AY]X.Z5*A06^8%,OZ>-9G478#)?
MP>7\3<?)#(#7Z[_3"XOLTI-3DD ?^+G*R:SWW-;,-*FNX<NJB0IPGS1*;R<;
MJ1'&\ZJRG2&1-"BY3[%03,11VL*C)K#HA@P-7 CT>-03$\TGZ"5L:8'ZLG:Q
M%5U<:6WH09G1S'R1GY15-+0:]"<,HM:CJ)UAU"OCL%HN*V!^;2H5@\KFE];T
MI857CNV!T$/%?PXTW,9_,8LXBMZ45TJ3SM6*%F_C<5,[143(3#(8:T55MQ;V
M0G5_0VN)HZ?OUO7:AM]4"OR)+H[DVA3Z]F!QS["*T+WX\!_U#=W<F]O("_=Z
MI)K)Z^B?+8:#,<Q+.T\YI!GX8'$GX(*1YR(M6^39HUU%F&?"VXI;M^&[P[7T
MZ*^E<ROI;VR?-_=>0E%Y59:??CPIFNHZ.H7%"U?5UJZJ8Z'$%U5@0B>.AG+Z
M\WF* O\N]=UL?_+UEE5:O:@<-'55%EP,@OL\AGT>L#H5[KZV.@E%2(K(&Q2A
MT:=X'<VPW]T]5#QYA P@E<NV01L9%=3'"O0.2BK7MK\;'8WXVQ_I2O 4FO S
MT8HLY]<UU1FLF/RUML5%M\-*>39Y#T3"O8>N(^;>(;[2B=;3E+:G*P!<WMQQ
M8$P^[+Z7:=WET7?W"QQA^#9R;T/).-ZWJ!#O(:.'X-Y@"POCNLDG50B;+M6X
MK'&+Y"(VCI%S'^L5J<QU[)3)]  \LJF3WNQ9%B0VP)X:.5^.7S*HN--RQ(K+
M:KD6%5@XP?>^6B30LY5PYR #<87[/"%T;U?LUAH99-#:MB@WT0B$^_W;OM^=
MU&>XX+>,^,<\!\(6L&@2E0 IG3O [7HJ"G7'WQ(W%W75.N9C]!&H=XGF;!%<
MF?HL!7CZQ\P:Y^EOS834X#24SJSS1^0SZ7@7R)[QN;5B44XF?O5.'KER>[<P
M7%)_8D5=4R&"]/CQ7LU#]6R!+XC_D?:$8^4\;\(7(9.;\3N)J6SXC;<* %+1
M)/5PDE[/DHEU'5LNT%.T(\V<.0-SU31\&]"&8JF(D-S+52.Y2C&MWI5<5.*.
MVH0!N,*2ZX*=RQ),BRQW...U:9'4=C_0LNA\P=QH+DC)>?%.K3$#Y8P)G]U)
M+U4%]R42'\$,)5.K/JNTQ?\8G/2J2&"+@.M;[G[=CJGDA@._^J#$AIC:13C!
M4B6YLHXS4I@)U5OL\>#' _: 'BZ_[)918[?[PIV!-Q>NRJGG5("$QO9$U>!<
M7-NJZ=[=PXUQ?L1K1[_I^W9;Y&C<</-S%"LLYE&UA)[ RJ]+?75]N5$]&J3%
M"$;.XS)R0"V=6BN>2U&#";,U$P:6?X":P.NDEI9%H:2QXII6#:/(TRC6D4&"
M!,N*8$C/7$],NXFKPW':HEQS'"!Q7*';*7A45##N C0PLAO4!*L6IK:[/A.U
M-V/]*1UY*T6._BA?V3!__#I9>['9 KU",0.$;[*",(XT:);P-2VN*UU@1#O1
M]:MQFQ0"QA"BQF1_H*GM+:LWB&GT>!;PD5OMX#"!, N?V7IWTQ?831-6Q'+E
MZ=Y_AF)0N! =UGG=AT]C?"<.0FV:Y4[GP%OAWS9(4)\*GR>>.V%R$-,XIA"=
M]<E7W7&87Q*YY"ACIZ)C$NTT\[;V^XL6)?>&HYQ&6:R>"T*:\R.?,&&%%_!*
MW!]H%*$M)9IE LJ409E-A]N;*4%B0_]A31RA!M%D*$YL1V2HD>:=$2']ZK3*
MQACEA#]F12A"WX(^[[/H4-8(KXEN8.QT=(8-FF,F-$^N#,48+D@)POA'6V4U
M-F6AE!-UT_4]5) GD(Y8/M+5W)-RD:59+F8[?T:'AIHR67 %6<JHUNH6.TNU
MJIMEL\!7TZ.+:/IAS]$[R),,X1G6U;9NM:L1O'ZQAG&:%2XQPX@N %F%U::S
M:#U?!I>@TG07 Q>0+%FXV+#XK"P8 F)\<,/YH[&BHC>Z#FL)OZH(\.(=7*;^
MD>7"/KQ<UX:XUR4B9\D[P9QJ=V#2B8:6I),4M/JW[\;UWF@(@L @5^J3TWD8
MGK$0M"=V8\9^9J:VS;L KJ,KW'9<WT!6&H">]P_T/ A SP#T# 5<CZB R[25
M/8)__/@Q^41]):64*[CSV\M(Y%A?,6,_+#,M?OWNUZ;#]2J%A^Y+;?Y !.?:
M9DP%T."UPHN%L@BK-YMLP/%M1"*T[\O66LQFUN<$0[TQVDMBX9 /)+4X'E'Z
M)"/>>.-E=GT>^'V-GA=8+N3+&4Q;HDE,Q)["\+($:U?P&3VE+=*8!&M3.1V;
M4']5BA9@)L5X2&X^V&\ X3/6,\*@X!\9DO^A_(Y4(7$#<=K,FHU -D!KLK_0
M=8/9ELS[R=:8-LO%_L=$/>Q<BST"UC=WJ[35A].NRMQ2B<H\Y]1;LS<PI-L;
M%%0;','X-1EI0E6\N-%.6W2OX6Y"QY>'I1LU&L^]7BDL'JBU<HW?4?3>CEBG
M&+"VJY;UM#%_-S"P@AUDP 7,%]V>BG?3S:HA#05JP(52[#[?--!)*?$HR[%E
M94S9-9&@Q'U#39*)%%V+U\_[FHC#1V?.=#? 63>53A%9E*C3CPH\%9@@;K3N
MCPQ'GMHWT.&APW??4^C(IN1$,$Y#H9.LH+8:[+2!AL$J\EJ)]A"A%6](P+[W
M,,#SK/X4G7*+#MV8!F1@7_K3G%/GVW._2\>QIN851)1A]&2\\=A41B#+&U+5
M/M^5)2>VWL_7%GKR$_PW$:*T?84%P6)Z+!;3K]BH!-7%;Z,++;<*]4H>G14I
M O\^)I_1TJXQ2T;7X.TYX(.!]2 <319;A3<K5;FVU)\=MVBQNK%3V=B,-[:!
MC4U[-K;OXC>Q+XMIX\B]?;H$<'<HXCHE-3)6,+XG@PS;&*:S8Z8GXR@P)]+_
M;!H%XPFQMK>G_VQ-R02A2*H%J+!^"0RN9&?&U/C(:<[I?[A1!,16.8W=GZR.
MG=:_;A<+JE<OA/O;7*SR38K.)\)%#8NR;EA\KW-?>1TUS-6EI/R[*R/=H4$V
M+4"7KL 4(Q>=EM'>@EB<#QA-VG1 +=[6MMUYZ!^]#'WO[M+WSA333%22*_9?
MJ,$M2ZSED(UU^4U6Z,;EIO.Y-O5!I\ '&1V3&NPE(8!'*XO8"CAT''J-!EF]
MDZS"?/-(<1;!*GL0U[9NZI<(8&_96'8^-#+Z$G7V$)3],[A2)MM>5C/X!?>-
M(^&=H6]24 %A[G\:1#F(\IU$>0EC&PJ <;&HB7]A&BXCP"&V;JS):I!(%BC>
M"U-OCO*(F?B:B_W@&)B?4L)TC5V%IE">+8B=,L^TJVZ.#EB,7B_TAK/T3X+T
M!^F_F_13[%5"1T)C#Z:!3NASE"N]=@.(Z/98FW@"?E52!?D+\G>W9L_)YV5R
MK2H',=+I+0"S&JI[:\H?%]1B5FMHJ:RCMC=MKH)1$,3RR]0B0F )O.K5\?9F
M7R3X+MZ6TM%I!&%R,1#U;HO&;8W-EH4*4$>+>YMS[.[K*--Q.>&BXEH_MO/5
MPT/_>=T:H-6O.T\.IR2<DGLP'NPQZ8TUVG1BC5&-"2:/)47%$$ LS(FCN9K,
M*!.7$H4V1VAUHA;QA;.*'$OD5Y94HY.^#:(<1/F+%;ZP;F^B]+OM#0U].'Q;
M$WR[565X$-"94R"PC8BVI20:#HN86T1;.LC0R3V5.#OO/*<[CD33BPL@0I\J
MP84+2L0AK&=^(<K=A_,4SM-]GZ=>LJD.*8/O LP0TU)A @^1"43X4?/1ZEHV
MNX=//<L&XRE!A(,(WT6$%7BF#=%;DPY'6 HJ2MB.?RE6ZWE9S(9<4V5(':3H
MPG:_BWXK,+['[R2"[A[81X !/  ,8"41[76>0(T1&Z1>'"&JJZPP2XU!5\RH
MY=%'!&>V\"<&NO,-#S]9M#E7A=E"'7X<_O2/=L*\>_@?R621%=B5F;O%4,G,
M$MG;-8:+:KIBR7]KD:'Z&%/N-='T4@P8[$1-&+>E&TD*A))A88@;P*Z0354F
M9'5+]ET^M2"Q%;S#2F'82E[?9/ U)8[79> V  I>P]6,_W W: ZEZP.'[\J3
M*QB 3LI+KBJ.9MFTB5W>O(V?J.HG;B.#N\U)1@'ZB:EVA]__FVYKK1=!)E7'
M;@L#X=1,;"^M) =Y*EBV4- 6[8(S#-ZM:8(*SA+AW_:>_N#]RD>PT/.IE8Z:
M.!EF2Z$D&0TI:&4DJDV)/-%%5;\J9$BJ%.-4I3LYO8_HJ!HW:\B/I"W;R2YO
M6GQK0]0"(F[I5+(&B0.%?:ALNO_*IL-0V10JFX+!]O 4]F#CL+HG,X>C&1:'
MOX[C(MK19$!TZ3+A#;?!<:\,N9,(G-C<BD2#6*+E)HWIZ:X_"\]A8VQ=+(D0
MH^(J!W]@"_[ /Q1GO%D>)IJTE#G'32TU[F75(D=%;>NGS\XOA,EY+?L$U79'
M*5;/*&+<K#5@SY"[X9,,P0.57VB7GS"E6+E2-\SX)M+G5;,8"UPCB-G&2AP)
MM\^[,K1/R#8&9ES"R&/DN4#RZ1Y^R2!V#]%_C:J^$!)T35D]C,Y*796EDV%\
MM@,QN@4ZFV'?/;TAM>'L==QE*7%>1 YF<:T+\^C+G0'U_H[DV ##D3""B$@*
M0SG0,L")7$_&0XDOHI]J.OT.?0/?,XI.DLZ;-9$]CKI'LR(9'?U$)H3G SE\
M-IP8=OR,VLI2LR/E"Z'JR4>:@&/%R5G=3M2BR>^CH""<RNW0@K:UB6X@2[!D
MVKOP?YUBIS(&IZ<"%;6N@09D]>8'.-00A)CUG6+65-]+%%"(\9=8-=XQ.@8]
M'((.J;X@<W>3.3?(%^V8V*H8.%KY=2T;]T<;*\8G]G%R=^/KN X *=FH9,9<
MZGW?>8+.6%DY<7J72&OU6,3"IYHP@P''YB6.^1K#^!G'7H_+O%V,L\1/]WL6
MQF]>+-><R(TG'TYH.*%WO16D5H=[4XEL9;6;-5HK@NSKYM+H@'O%ME6J7H*X
M!ZD,4GFW>X/*Q;#YQ\Z>9J=VQ) B$A0\,6BF994M,!];M^#)<3J+V2HX,V43
MJ]+@D@-\^)*$'%$"T1+-A'V-1JHP@1X^APEVFFO=APO9*H@KM!UC63!1)DU4
MZF?3^#68I=J7N0C%?Q)=PAY.N/F/! -A-5.E6Z[T7Q$\K-#PX]%S87]T0REV
M_][86O-  /'5G?O>7I)#N0(ZB>+]5TH8$J3.5'O_#LOG0B6%,!A[8+2#9\]W
M$M$%3LI]%!W5=;M8U\ZP+B,-^*1^12O<#C;&9D+'R#PT0PN7T7*$3H+;NM6=
M-WOCTT<KC[9]C331,=W_XZ3.C"RO[W<E/*I=9&S?/&GP0E,]5[VOU)2PYI6&
MNLE[K=/8@B$WI/H')Z?#A:!DLW)RJWG1F#G58[F8;_<L9["C04 1LCC#+=,D
MQ,M+U4RZKW'I=)>R*T5M)_VQK"S>VK$8ZK.-UH$PF]W3L<FN2WNO%9GFF+5M
M$4I&QL H7/:1GG"OQILB*,D\;Z*!?$GC-2+-4D+V] K,1G%?2LP@IYN#6(6-
M0U*\PFMS*WO%5;X_E55GNWJ$??WZAW#Q5[Q1!@AW9']J9NEWNMXEJUSP&U44
M#.I->P=8U:_9?+PK $\J_/\%5D;Z30'T,4B1XK^Y0AYLTL/\541QX22,R.GD
MS*!:O=5-X6H>'=01Y::;1R'#]2:+QDV#Z/O>S#5S^88XW?[50RBF.9I^'["U
M_:O7KE1'4:/F[9\NLO9C>T;T7:Y54HVBM[>?3.TB\H8AASHBYZ(>N3C7 3<X
M\66T36"(5A 1)3E!_;JL%.M7=)4J[BKVD=3B!(N]+ &A'B4NM:H[$0GB0> ;
M,?A!C]X/.K/$C6#+$',M)60GT:LD_=0NHW_ /2ER'UR?+>8U;W VC*?!?L^*
M27=W3R?FI/O*18DU0>:>7'=%#-LX$752MYTA$#^/<150@$G!O7^QA5&-?\%/
MA%=XT./C_O'254'_-KD$X]NP]\$-XU O(VRGG$[!>!3V6F2 +:\5:KH+]R'2
MSH/8XJ:F\3.[#P[7:0=-Q%=PS+<I>S33)*N(#$$U&%%JN;8/+CC=\*X2SFBB
MXL-?&!*\:8(D>O8-.!=-+L,;#S+">1(0+/A&F]5S^._0!R*@I>\=+?TTH*4#
M6CK<] ^/EG8X%^1:<PGS!$37>SDCE&D290NX$[#\D1J?3DMI"M5[?S81,G7#
M34-]Q52%FB/:&5-;,DJZT(WUQ$1"2N+O<QK-"H/]U)#?N[=[TC0XUL2I-,*>
M!Q*'@;N_K2QQ/WI)%G"]QGYP@=Z:O*4A;XG[,-B[&7."''+IB=8)6, K0QZ!
M133@9!V([;LS?B*6@IW4@M)A3FQQ,T^;=K?SA?7^]K!AQ7YKKZUA&P;'MB1Q
M3<6;#A<4R4*Y)A+L#@HM=_G#Y;4M'!U"^'[I[(O'4?RM&Y2CSQ=+IRP 1D=1
MU! >^SKA,6%F=OQ[W_QU/<8Q>XQ7UF.\!?@9GB8M,K.)&X%;[5%ZFQZIKU:'
M9'(O5%4;PQ&\PE_& X3<J%E-2>P45!8:V8*$JFA))-PR<#ZH3I?;8ZK:I![X
M4$@K9[VR/>L'ST&?Y116G$?PCP$%]<*2KQ)/M\EYPUG2C#NX;U*2J2<T-#*G
MBQU1NW(-Q>H A]("IJI8YT0V7J\[S9BA:^Q&.<U(J1M%HQO8#$KT4H%TD4N5
M+;C=B_1(A8'(M#!2R=X=\X@39[H%H_7L'.=^#+$Y$C>SKX;1TBL#IP.]CDJ7
MXGV<V^PY))92M.Q=[3XW/$:$!G6ZD2V8R"F1"]H]Q@BJYV:/6L!-OPR[!*N$
MZN(D:XW./"&..J]]]Q@^E*A%:O&#C!-9<'N4 2'C/81II&K2ZB[ W#/']-IU
MG\.>M]R6V(&XZ=L@#%P3'_^$CK[._2A9-X;ZT_;$8K#@'CKMA_ R)R"YX:_G
M,84ZL*U<5E_8%:3+@W!#LX)N_=8:"TI*!B3 [ATTY[83"@>Y!1CEH/NE2C)\
M[A9^V;Y 21V;4Y:J4?1:)-=$H5*BBK]5[XLRNBY;+<9D@JG/W%86;TM;$@3?
MJDQ4#"X6+-2GSA;\\92;\41>'UD)17H]FCX5Y56N)C.EVWU593Z*_@?&T%$J
M],*;\K;"=]!LLH^$&^;Y]L\$%+QB$@^C!=Q5A%-$?;.M\E]]G< V40BR:</:
M@ZZ#7@2S02H+PT1,R1Z)M??>?5\H^H:EHN\EMW^<F;ZK&G&)O(ZY0\F#T"CI
MT31*.EHNJR2KF>/D=5;7%$BLY=!&Y\0\%Y) 6[OA/G1 !:]_.7[;Z3:M=:S;
M:SHQVRA<@;";$[V;1@/+9WWJU'0]--T O79]Q^"&42MPT_%Q8TA+..R/YK"?
M:T?@]]) !\*AWDY7LV0ZS<@DO%02:D6W;I'\P0!V,=3PDUJ<6FQ829%:*HKR
M_,4>C'+T0?IN:D?6-*?OS==VPK9+=!C5C<\>14=CXCA@#@Z,_U KI#50%9J1
MR)KU3\G$%$H'K5'*0?RU?7^0UNU(*_>813'QMA6O@9XDTP;*A]X_P4P[F=Q_
M)9,82U3@A7"9&2Q464RHR@?Y^30@FJ4SR=>T:'0E=,)/L)C3=5UBT?VQ80#_
M>EOW'A9E/C8@+QAQP+_HC]DX?E>.HCWM[NDOZ_.YT@8W"/<6A/M8L'6K38BY
MI<JL4JP224>3F[:NC_-5839T@=&G*=S[U69R>J'4/?;%/<*!<Q/G3O=;/LJZ
MN,OIE7O1+C&2']F?KFF,*Z5.V!UW[^G!!NUQZ=KJ]@D.(KX%$?^MX.I/$\[/
MA+H?%17'JCAM*A>YX6V1\CK, II0*O9IH:;)TAK],QHEE3TA<CHJM81_H+=!
MQ\$8,.JS2MN&X4[RT[I7ZF]OS)Z^/^_(ZZWOBB"-#X-U& 97]:$?OC2H^^:$
M-?.K]T?GKZ/WI]'KL_.3XX_OSR\B^.?[7W\]>??Z(CJ*?G__\43+'@B/EAK\
M_?G)[R?G%R?1Q<?WQW\7[?CA[=E'_M</Y^\_O+\X>MN-9P5JT@"VNS>PW;,
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MU%N@;S7"H0H=!8)@A#X"V^\C$(0N= \8[![00P$<VMF' ,"#!0 .0@#@^PT
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MIDL^/:W*A7.VM/6!Q@?\"L7!,0/,0PP;M?DY_7!.5V5-6!J-)[1(QYU*M[C
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M# B8HZ:C&X45%$AWHA6XZ<Q$J\/&I;8:.^U7G3UBPTJ 3&:\@T-CU5JHA@4
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M9!V/[9IX<?2I**\*S$S\<O+NY./9\8"G?'0J'K(8[G3-FL'5\Q(1-@5<>[D
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M7;WH E]NN8\$*U-%(O<2BZ^G3#%)N: 9PT; KS4,GF/UF[5:,H/V0X&"W;7
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M'GIQ)S5TVR#SP;*Y[YMM76RR$XL\GB>5T1S[?3')X7X^)V+Y^^%&W*F?FLG
M(?N^#E;?9':[+]A=>8%S!/=&^\]O=P*OYEFC?H0=2>%4%>55E2Q[CI6F#1S<
MJ* -;]Z<PV>CI_M?6S_V*,>@%^]N\3N[?*^JLD'>2B=_<US.RVJ=ZH1_J_YV
M%ZOGA3VPAB/LK]&_'1^?G)R>OKS)$GJUP=%?.;.W/N"#)_G@]B?Y8/.3W/D:
M][3\ FO''D=^5-]Q1 *O;]9AHB<_K!N^RB&\MVLC0?=JL'R4\*3.GPP_^*#S
M8%SEIW 1;_":CHS5[1)4SE_^5C<WOO26L\',V='IVY^.CG^-_F-<_?2WG0\2
MDM6&V9--+;-7W_A!7_O"-??X6GUPWZ:75A%K3:]O?2>^=-'W]T8O7@0E_-B4
ML&>G+3O.93].Z7;*;&^TN\=*K%!M4R5YT%W?HNXRIN/!-[XKFSN!^P>C_:=W
MU5C#7ES06 ^ML79V1S_OQ7!4#O>?D.HQ$ 'ZKW?P7_O/?GX@URRX8<$-^Z;.
MTSVZ8<<6ZK%_2$ ]S)F_HIRY>#+8UA-A&6($//G36P'?ZH7_72]Z<%8>I:IZ
M<&=E=_3LD/547TSGML]S]^_B>C%&+%$-*_3C+>+N/0VPGKYX^O(^AO>7OQT\
M^^&[\<:^53T<'*_@>'TKVA<<K\-G,;A:SY^YCM?N[KYQO![,[PHIL>"+??-'
M[!Y],>MX)4WT#W3%]@_#7?^X[_KO>M&#S_4H5=(6?*[#I]^1S_7T:?"Y'KL>
M#CY7\+F^%>T+/M?!"_2YGNYJG^O_YLU+<KOV'M[M"BY6<+&^J1-UG]C?XU^(
MV_8=ESU?4.WG.15TAAO^<=_PW_6B!T_K46JF+4#Q#EY\1Y[6P8O@:3UV/1P\
MK>!I?2O:=P<.R3[""I\^7^-I[3\-&:[@?H5CMI4,UYE'",6VS<GQ[TBK+(S#
M=<Q7T/]-%LN7+C_N071T1(SG=3 2'KF1\%TO>G#6'J4>VP84\?GWY*SM!V?M
ML>OAX*P%9^U;T;X[F!##M-B+/0^*N/=PGMK>[FVR8G^N [3>A'DV.OPYF#"/
M_1 YKS^\V:+Y$L_ME6V_@@UT8*N)V9Y.IA@!.Z_:=!1=UB-D8AW%T>_G'&QY
MMAN-EXLG43 2'JF1\'TO^O[H60@Z?4N:[OG#:KK=M2DW[\F'_I.WYZQ]R?R>
M[06W+6CD1^&J[8'%?V<K,[AJ7T'W/AORW [VT',[?,&>VX?^--NSH'"^+IGL
M=["\(3+_IU(X&QA[MX]<ORYKQ2U"*-^H&Y*PU;=LP(.]^LGI-TH^;5'"^HT"
M^4DPF1[CHN\&O1;TVM\.1_O?0EW>P3TE( __.SBR02L_"F,>]&]P9+\E_=N?
M+MG9'^T^BZ,7HV>[:QW9-5E(:OY&/9M"&\*';D/H-3%V&-AM,U(UG:JT@3V;
M)_\"6SZB-KK1SHNG/T3'9T]&MC\@?.4';IF)S29/L?\PZ[9)<CV*CGL:8O:]
MY>BW8_V*;*1&,?[!N^0NVG&=5MG2MDM:H:@?.[N)-/=_^=LK> C?<S_=R_-^
M/?FHN1RI/>M#-&Z^RIIY5,,(,FQVC:E";E^J)M$E>%1%BRUA5;5H&\)\XDZ\
M<FA/8"W/BAK[GR:%PB[*JH;-P5[<V) MP9ZR,Q5-$C@:SH[ [Z_D]_1^[@Z9
MU66!'9SAHR)"-/82'O=Y6?%HL!GV7,FN20=+^S)J  W_*5T@O0FU=49MK_^1
MY/RE45]9(<RD*1OX8]$NQK#6N@+1:SM)HT50;)6EV ,0AR,-3JEU]=.7_!_/
M=OF?,"SGTT/Y=&^7,JVZ(;?I,WZKG:,SX8-T_Q,&_7L<)8+/C;$=^*S-)BK/
M"C78#Q86'P['Q/:$A<W,DHIGG*41MA+_PI%^[)Y W*/>CK;4YKO;B=9Q\7D!
M_Y/_X>2W<1_\$_WA_/Q>3_2]/,\]T8L2-D8:*F.O[AZ9_5!F-1Z*2LWP%.#Y
M"VUSMW!?&7&E\ZZ[15^!"H(E+].,>MS29TET\.P'&Z)"A='7E%FK;Y9;U'VD
M'S<\1D/-<W.5X ;CGY/HZ=/..#QU2]H2CA*\U!O%")MFUEG=F-F2DE5UFS>U
M[O,[4=A /M+\PC'^L5*\'M'!BQ^PR34,NE;Z!\[!A!>2)K7M@7'$/6>_VX><
M.TS;WL.N%O&V)<GK,I*#!,/9_X$; T=MD^79O[AO,=Y%DS_:@IN6=QH#XVR2
M9::\;MUP-%/4\C!*TCPXK)J4:IK #["CN-:SI*,Z2G-2M3-Y,)@E'^UZX6"3
MZ-E>9[/<**8W.WPMK)'==GH:CKU6_VSU$KL_SW!7_(>K)AD0LG%>II]4I25M
M4M8JCL"E3.?1X6A_X$<@MN:RF,.AA;6 MRQA,;#[*MS9\VR<T3Z[XVK@%-/<
MRK9Q/UA5:6\.MZS,,KCWL_2AE1E!%M<Y4Y=E-KF+.EOMQV9>UPE5G=%$^Z(W
M[A)T@T$H<*].+C[Z_=S?J*1JHE,P[5H0[H_8U-V/\H0[ZF%;NVMC"LZ_UA9P
MWN>T+5/9%B5=K4B7P](EDTNT+R;1F]/JY-1M[8[:";5V2Y>;*./]^.?=YV)L
M\?&.HV6>I&I<#N@&4:JY-2<]H2$Q2L$>)<W:H-" +AMX5KT$+0>+91XUOJ91
MO7OS]M49:=W7"BY&OA-@%7Y'M0S;$!U-8?X57&YGA6D(3W86WDUPD\+7[<QC
M'A2K?G0THKUX]W!7Z[/H];LC<_5Q8WN[3(W9!?9W)O!L!3N5@@).U;(!,W<'
M3/_]_=V71^?T+WLOG\"[\^L%BDQ6+VK<,[U]_"BXH@JP]EC1T]AXG7"'8(*+
MK*!WPSZ#4S56:=*BTB9I@T?7&=UQ\'P\T<VUN<RG5;F(FJL2MIX?B#)Q6>:7
MJ*A+O*LVN"A,#FZ>@%V.CEJEEO J!<<QX66BF]"X4; JSA3@A>BSS1)8F1HO
M,5ES6M:LH2FVA6KF+!XEW=%@)%#X8(;S$NG#_W:>BU*0I1F,#)."1^?'1[C8
M>S^_!.M")4627X.-H[U&^IUCXB1I"KJ'S&YC 9V^/HJ2)=RXES@SL&<&152E
M8+1;$:W13Z[)#XC,BV'0()4[?*_BRA5EPZL''A*H@P4L@<BVR'RM%^Z)8SFQ
M<!Z Z9#5GYPKOM16%W>RTV<>'X%1%CG+KB2QZ;H<F!2*M](3@H?LCG:?'K X
MKKX9I,F<9^,?6K53MS!EV%4KCWANYV6]I!M'[#,XM3-TW5%$#PY_P-T]?/X#
MCQS6;XU<ZK:$T<'S%Q$I2?!UX?F+\E_7,PQ(S!0L]O52\?B]PPQ6JDIR+7[F
M$++Y G^>H<$),FRFY5HYSBO0F\45OH]A1COW<&$?O3Y_9=YX5,W@I?"_3V+8
ME[0D\Q:'K%54+5J-YZTMNBE9RV+=ZI5(8"4*W$1QX-42IK&<5S@9UTMA12LK
M=34OHTG&0C]/X S?WUJQJ[_ILWX!?0E;7&6@QY[0Y8 C.?SYAXZ6LB/G<_)@
M.V)GHH6/CA:LX0X3(.#)>S)XN.V9@MW@>[_!^P_5#8?K4*L<'OP NCG/ARYL
MO#[TR,P38^WU)#4'NIQ/? NC<Y3K[N>@0W7P(D9/4N7E4E_8":^WMA=_FF27
M')@WEN/Y^4,W9OXZ1N.V.C-CR@M36_!_\B\-9K\Z+P3QN$JNZTX7;?@M_()[
M:$?.V#&+1L_QID?IL\A?C^XW:5GXB\X\(IE(9#?%_-#=T8BV%':4-O3#!6SG
MC^=JAN+Y$@LH2Y@(N.3I)SAO^[L'_5[(-&_K^9]2I![(#S$BM;_JA/Q'$LTK
M-?W/O_S;Q_?'N[M[X)9@0@V/]C%,#'7H?_R4L#\(_^___ <<<+T;7.?W?OP'
M6+Q4^6=P\GNWV![_/Y=2$A@\S_OS/+O)UQ4AF&;C*LNU+X76 KA2L(\2FG*S
M)4V2SG4X"*XL]R/W*7SO3C#HS7DD:W#NB,^+JUX_(;N1S!EM..X,7CY/T"[Y
M&;\BMX[[1K &7MW!B!!;WC7ZX5,;R&_\.%Q2V/N[)^IU\#BC7@3BN9>8UXL7
M7R7HA8"E6UEM EOZ,$]@,?!BF;'7HO\ 5IN"S:Z=R$N(?&TM\J5-Y9UQF\(O
M,"8>S:\G59G.P00 Q?.$0^ %ALASCJ? ES%^ 9YD"9IE$W^!\H[#W]LWWUL-
M^8!>PE_^:&- ]')*0L],^@+V=Q*!>0W^6([A$-152\P@*HK\9!@>68PQUB,)
M#/MYA#Y81KJ&PB$3XSZ(JR\AIX/A6K1GG:.@4Y0K.4QX):QY9>(;O^!L:4P2
MSL)\B)J5X)I@'F+S !*'?&!'$LSN2PB#PQRS:PG59)7K,8RB?\P5*%)PS);^
M2737Y@I3+2H'V9APQ 0OI*;V7 \,FBU4]RFTH#2<F$)(%"B@)$N#.A_S9'!.
MG=5.P#QMJV8^,..962H3O]PT$</!BDF)L3X:[^#OM(R9<$T1S5M4%7P1IBK'
M.%^]J<\="R $U$(._KX-XFUR%FQ  4$;M&-G"XP.)KB":_WTGF<DL(^4+I.'
MX=2<TU8@2$#'0W.3JZ1I8PH+Q0#^@%$>=!$:)9G-G!*5$@HL5%N5Y#,OL@8#
M')V8A@[>OCO1P5O>&7.@^3E4I>#,_9*B!_#!@BT3.,84=:&UY5#KH@35U.:8
M=&37'A$R[TYT\BU!M47(EN[CF]), GQR!;\9<7"=1':L\@Q>7QL9G6/0^*J,
MVB(#2:8TY< 6V+4U\ U[JC!VLRPU,FA\??N <=I6%9\D'5<U<3,+T(+E?'/Z
MUVAG[PG/*2,5@4@)U MH6UTOEDDS+_-K.+!Q)/&?:[LAMY.Q'I&J,0Y-&>3:
M_6Q2X35"*>8<-0GK+[#QX(V@6QJX9UB-+6!KP/1<D C ?-"YK<#<1%32==TH
MS Z#?& <Z]T)/ZLFLSF.=O9EVLV\*MO97.MQC)I7L-_)K"RR>A%KS9O06%&X
M:AZ932RDY@YP8FCZ=QAQQJ%9%;'1E6BN,SAJ65WFI%Y=90.2OTQ8X]'(8)L7
MI<@P_$AD6JXS_!O]93"T#D:U&X6F2+ > QW#6CDB&N-R3!1B<L8HHJ#LKV*^
M#4I0X]4E1R8)703OY;-HIN2G9!#V17'KZ"J1G(]_NAI84M4PK$Q2 *D-YLGL
M;K6F>%E$.Y^*\JK B5"\\ E<.BU8"=F"#@R?%<(4J+8A@X.R!?1"';,<1;UZ
MP*1#;"P;_KV8<S+0C6N;%,CCCV;K?$K-N91ZCHL'>SQ6YLY KPO5S6?""8("
M>;K[@]Z?=W SS:.CA4*8!\>Y3UJ4)_@/OKMS)TV(5ED9H4V!'M^FZL^FR[J#
M%&UJC!#P,BB'8C5<G=4$X=MD(X[.HXZ6P*D/'<ZND+CY#R,IGJJ]R1X>'DCC
M7B.4'<[&;4.J%,TR(X.D<N5*?7/*F!J-ITDBNE()Y5?[TCHO.:< @WKX,'UP
MVA^]TZ[MGF.=DT1!XBAQ@T[*A7@8P6'?FL-.N@;O76VG, ;%!X:8''(G161\
M+73I!5!'AB/H"/_..CJ-X8.4D;.<F*:_GYQ&@LV.#G=_D#2V%0CC<N)#C1]-
M RW'3<*P&7&XQ71E: )9K0Q8AJ&]\<$TJR\F0108.($U";)^3_?L2\X1V@'X
M<$O\D%.X=>-EL_$#9QOV7T6_G+P[^7AV/#"@HU-CSGL8'DRF3N _Z=WJ,WP#
M0Z[>DEYE8&;2_N#FZ($/O$?#6/3;5C8;UW;6O(1UU&: ?Z-=D>'DX%'@ZJ=Q
M\9K#4<:P,"4K-,['101E4S0 4_C*M,WEML0KG"6"H@K1Q8<CN.(JI2PD52-'
M&+B"D5^T#V$'<A6##.P.S99'T N8ZF"E\*;N# _AO8F'.P'W08&=D1/<=VF$
M#BD:XVB1(&@(?H]B0!.'T=;M$OUTG-8[&+]VS. H?Q(S5PN^/9(!BKXEF%]'
M!,#'@2>ABJHS6#=,JY2;'EL7X6P=,(%NH#Z,HX_O/YR_?SOPH/]^:QZDCU(?
M,*&1@B]0CB!).M^2MQ1B,8 XJ@,SH#CPA"A"@%DC!VZ@2T^2Z-G F$#1-?,[
M%3_Q78!H"3S2G64F?86U+W2VB@E6I7DE&N!H-OB88N64/34'J+LX+T%Y7X&"
MJN@,]RX?[:M-(-T&JN4?] :#I>0TLP9:JU=6M0(CA,PU:10 +!T-W%-_O)*H
M.D#E+K)Z1?NCMPD'($.%BW\'7:PF!+*JU&4&1UXNH]\*_",/\J(A<[^%@\*O
M/$W@^OH(WOLGSTJ@)%^RD(/!=Q!Y-(@FA$^*AEU_)TB^O[OW=!2]<D//K8X*
MXH)A=-CN2+'QK<CQ*KQQ$(S8:&B9F $OK.]IMOU2[C2*P8"P*P[P2;1,BB4E
MPG>A\%;!GY64-L_HIL.?JL^@0L$T8+<TTT%7B\.+#1#/*0N!$WQT:J-O@Q%F
MBO28*;KE6?=Y@GH*Y1[M6>+A/>2!"I[F8_<T4?*U2OD(AG7P*+=F%9U-'7#V
M<"C+J%4\7EQ\WD$U<ID610Q1K\TJM[*/K**"O*DLF14E6M>2FF7W8HRJC7PJ
MHZ/$ES#QSY5<![Z1C:=4/\/#@"<1;I9J* 6:)R 8K"[@,6CO(QZF0H7;X$_J
MT1KHY-L G0S0R3M!)P\#=#) )\.]]0#W5H&'3;2ZB1.^3<;',!:YR<2S(<=$
ML=6N42YXU<1>#.KL]8G4=>F:);A8VIK\#HQAXMV$I>!N0=1=(WPTNDKAR[&.
M.8]H66LN]\ B)ZK!8IPGOE=?4GS;^;<T^$GF^J/AXO5(1!15FIE:@E%TVC8(
MX_2'XN+NW(#&A_.3X[.+L_?O;HZ"(+8$7=!47$/Q4B2>8J][G@FFJG![L^FU
M>\L[)68VB2MI3P>%Y=J(%D72M5I\6]*NCA4'MAGL$M$F,TX )86#)LH=/)H>
M"%FJ8UU=QB8-EM6CAN&PJ WRF37%H$T7?D:63)+.E<X>$C;'M[M, "C%!7;%
MMM9AVAZK1R(\?2M[F=598PJ*YM<U^%))$1O##F5.N]0KXM,;V@^.U:-WK%X[
ML9T/V9+9:X)SM<UTG3F 2#&">H1R&2FH($)58F#%P@4.G^^_7(?&[85Y]8#P
M5V$H*>@W4/Q^15G(.VP/9!TSE-I<%\X>#N1@)52Y*4B[ \$=N+D9;N7P  RG
M3%=1C.9VQJ)(@:3<A, VZ&0']?MP:%^+@49$3%$BO+ 'X3S-<M5G.'CGBO/1
MO?E2)Q=-0>JH+1:JB> *)MNJ4#;T42BRXJH%61UXCZ)@PI9?$3F?C6(B0@C\
MWW FMZV8,>9^,TS!3<&L0!:,M6H0C!Z(X66O%&E^/HUH0"1#+WS0/)VA] W8
MZ)97Y'XP!ZN1/TH%V- @\U01D%Q80(B#H@>I4%+^N\7U4[6?N2HDJW+D+H[/
M%47 @HX-ZZ(Q,,-.I2A$O#((99 9:<X+VES--<(Q3)74V3@S- J.7@;71<KZ
M60B:6WE$$25Y!.&,;SI^__O9ZR%4R@N31H5!(*!9!HXYCQIY'9W53A.J#F>7
M0@QR5&=PH8.^K.?9TM@'Z](I_FQ73?T 2]@^I(M931#*VE9UJYS==;.SM'.\
MVP3,\@Z:9O^4W23"2F1:*SBQ*T+"J;-W1Q_2_95']XA"Y9QK\$?+E? !/H[/
M]"2KA;=.ZX0ZR,^VY(<""(BJ4I]!D];$[M.Q>G"'>:<PFXX(8!-SXM0-&8;,
M$FJ\$['>"!9L=8:SQ<32V$D$L2#$8(0Y!9_\:A=RGR#/85?=&3E%<&.-;(H$
M!##DB2Z>D<MYG+&"+"*(&1\&_K!".#\6#CGOH'6B%TW;#H2R_P44YBGINV4G
M^%=>]5"(A@C((XN G&+9'RG$<U6#TY&J.@1 MH>YLWA(/DQLCDT&H<F@*?AV
MDA ^12?)G7(,H2GO*=.U3EN,O.)Q)E* S@45FZ)5789"U1 3,/$RQO029J^F
M&D.. #<K.,%:SCQZCG^PZ8EJ(5>&U&F-/26TL!-E(K,NM1O!^_CRQ3%T.7%[
ME-+J4AG\(#&*V1(KP<VT!67#$ N59!*<MT">9 ':30+-8EX2C1OX^?PS\%QK
MV8Q,2%?)2,'9#-(-.F-VJ\!7+8SUYDR.=Y*^R>C6X W\"2L T=-*<C#?.Y\+
MUD"8S'$1Q*ARC68O(J]-&/LQU;$FJ0"SSJ9F_G8QQ55T44E&+-%U<+\KTN(/
MP7E';#<,;D]#U->MM2:(*2^/PW1H#;JR\GZ.$9A@B&W7$#,NM&<JI$D]%\,*
M_D7]L\V(TYD./!Z]7Y,JG8N[MA='^[O$YL]Y&1]=3GK.-T/,+GL:C+O5$#,V
MB 0<BVN,0\&3GZZ0.A)H%+Z(XF;%LUSR0U$H,SA1:2.Y2=:!6K,1)PN!BCV?
M<W-W60".E,O*LT]86%CA"OF1!G.V1M$;#55,YT)9DV95VBY0I\+M3@,F)C8^
M5%Q 4+<+932<H__PZDAJQ%*C2F&V:V)7=FJL+035*5_@.".;H$ZC!JPXA7<M
M]8: +B8-Q$6GA(ZZJLIBYF1R.8VG/L]AS UM0G*99#GICJFQ7BIMO41U619Z
ME)C\[1GH2P[7H%@[JH4) \TUL!I8L,Y<Y_[#FA03"<%;=EU\P;FC2(;7[F;@
MJPN@JWL'73T-H*L NOK+F_W'N==_"E?\=ET+WU(TAB^/":SJ-=GM[\<YTE<[
M[6A#..6QAU,"1]O7355RZ!8=Y2E<SF4MV28.A?0 ^1+]DPS,4DX:@@^P)["]
MC(R]\JI@P#Q9BIA=JBA(@>H9'RNQ5)W)7_Q_]MZUN6TCVQK^*ZAYSSQE5]&*
M)-N)G;SGK9)OB<_DXK&<R7L^G0+)IH08!#@ *(GY]<]>^](7$)0HQU;L4_@R
MXX@DT&AT[]Z7M==:04JZ(C]2]W$=]C%#YXJ2'&+@Z%;Y1KA[XD%R\0W%?Y<P
MDDU"I75'+6(L2]T]TX!7V4&>9I,L!@0+LK8&%Z$L%JRDJKY$%8E"@/D@64JH
M+%>(;QFE&M80LAL#ZTR:$CUT<<.^AV]OI/5IXQQ(T8]^P>?B%SROERO7%1'2
M9_0 1@]@-,6I*7ZN#<P_1 W&K8GL,$/%M<PG??; I(_NAU>[V\6C5)L0B";B
M'0R(ER* :+\9$5U@FN(LG'@6KQ@)GZK%,2*RKH";+THZ&UYW_L#!F4'1//U?
MZ>9GUOOM+I0+F[Z&8%\**BK)YQ_K%E.AJ/ZL7G?D<& 6*[= !DX/MTAT0SP5
MUF_-*VDG5WSF*W%FEIQLD\,'!?56\FU@>TQD9R+ASP'49PHN-*2_DHXJY<LB
MZ7$8:-^'>*_UO \MF;1@,I&&R/E:J155HC!N3C?9/78,W876T;94^MKH)6Q\
M'\TV9EDK.,KNJ<Y=W*BO,QLOOW16VWSA!+B%"\7EO+IB+237J. INFNFZX[[
M.OBGO/CR&,) 5RAS\DFRR[RI:$W!GSD#ID'J=06/5 1*!Z'5/[P:/=([,(,O
M^/5[MW* !)5>I.^ ZJ%Y^ZO-8WLU!KIAKXJ-;(,2#YLS^Q$[GRB^ML8ZD<^%
MMP]UWZ!JUK#5BBLZ=@/=8)*PYX%)@<#@I-Q==#,8>;N#&[N6T>%QT7D K(PI
M@[$P_<XPS]P)Y=741'(*S[UPJ)4D#\@EB>X<X6'T=JR8L1=3X@T ;*F5F-G.
MAP8'T]!X])/1G,G0@BD,X^,5L_5^QQU]1XQ,O>(]_7!-NX\Y5:&>Q6SA&B1<
MV!):Y%P'BU ,LQ!(2!/GM9B :5%W;G9>"3HM?.;7/!A/49*UC&7KRA+_UNZ=
M5OEQ5*"+D> ]$!S890J%#_Q4MS%>S=].3K*D%FGB8+[N-_$=0TFNA%;0FF:A
MXW:_22]C$M4*>=E;S7)<TW?-I]'"J51_3;P7\>=\?53,6=1!*@M9U1.M\[,A
M_VHWJ9/0NTKS+UPEA@#@*(O/Q9C0U]O+R7 _F5"-W7S:'/CG")VH-%1@M4"C
M1P?NLE@O$S&[:$):%TZ;1%UT$N4QX\F\##?QU-0%>WN_F[Z>MMSTFHXGF2SF
MN )M+J]K?4NLL(*(/(3<(&GDC7MNE_E[H'.L2QB'^+J4/JZ .9 7F9^AR1N2
M@* 4%&R0)KG"XX\YJL\W1_53;&I%NT8M\NEZM2I']MN[EZL1AQ:Z&E[[03#L
MLO\K '+(XRS:<S=/CTKR*5HTV]&A3!NV6)4N^MR)5"SKVD2,CEL>"AW2<S&*
MGG_QS6M/OH@5PH.Q@UN.><\Q6F[TDTC]9"&1"YNS/C_#A7*:D>5IA%</"8HA
MCE_UCNIU9\<_S]#6^F4M7:4W=6J4TIP"/<_6<T38)]^ U9T7S7PG$VO3;7R[
M&0?=LZXWFKHY(U?H#XO#Y8B;YD%@N$#K)'EJGGXZZI<$Z433%:WK =J,74%6
M T_6\-U]KX%GE&>^P%6)S(!3UM;D!YXX2LH/3D_=F/95R?,0<!87-5!56U1^
MW7DX51BZ6V?(7RQI.PN$&;@VUWHVDI;GA'OWPQ"T(V^Z$5TTSE7LFBF$I@?9
M*YQ.]&+U?0;8J4V/@8Z_;^KU"IS^Y,VZE3_X!,(Z]\Z,A90SYH .Z9=IWH':
M(EGR1A4-H6@,M?=[UJK6B8SV8[B5[:4H6-MF"00!HJ+8MALC!YK@0*09$9<8
M?TIA$M U"IWSZ[!NHT=]!U8?ZS99!%L+&/NWOXC?Y/02\8W7U>Q@:%WY.B5R
M$Q#[B$X7;Z"YN5>^D0D!#YT"9?$'UG @X@1,CFP9K''=YF=^EX9-^>\UG-S3
MXHK>)-,#._LJ;1M7G77G&@ZR&8J&.I^$1H!E?E4LR:%N',=Z%=3>Y[6<"4>'
MATNZV24RM_.\P(Y[&V_*D=QNQ%E^=)SEUR/.<L19CD?>I]<%-I>*/<XDE AN
M&7F"Z9G'KJ4<;K$KV:PKO9 *7B+H^/ZG-QD"(YQ(ZLR66[UTO2S-H.^8AP,.
M0F$XCHPZ38NJL_?YF44B<QQ0T##2JDP2V:1NW9@D^9R3)-\'I@$5"+H&TC,:
MC(^?&?'SC]AFW9W73:'RMCO3QIWRH$ 0LIRPZHF3@+2LL?]$3Y'_@#%"*&.&
M7M$&UZ6A =%](>U:H@HZ03,IHGIM]4<I?2*-J5I/F:15#,T^Q.4,N@C7XOG/
M(GHH6NASEM-M]>M*LSA)+,@$8@.KTE=$A+N?_TEQ7BWTAMO-I+X0JL '*_*P
MN1N>O(D'-]BSF[AHU**93K!*77(K:EYY(L97^NFKNIYGJ'#SB)[7[9))&TXH
MW+$DTZL7DN3P6:8NJ"]Q_@33M2[/5"N!+#SC(?DQGN=5/L\GV0\N+\E*RW]>
M,WC^D2CXR;,*4H_1&='J8IT_>M&S%E]@W5?G 2J05'0FBF+K)E:0W;[C:;T.
M,H)R8QWQOG<MFEO?5P@T?.^<E0'+TDZD+<Z^-FUL&U(BH-/X+-F39Q1=8B"2
M&Y("0;]1_%U:AI .XT0RR%Y[D%..?["DK]M/V#$H)+O"!S,N03?''/3WO.SW
M>*/C@[45E^(U9L^,02!Y@BHG(NIZ,=S6/M# V',CY(78#2?DG["2;WQ3Z; O
M"YY ;N_D#)EOH0SP>*O/>LD(#V*OZ+PH$1&7OND[NL5!]DS4S#$!DB2%N8ZT
MFM 3238,$SHQ^D3?VKT)0;I.D->LC=F$K<L<[X G1S>_GVUH9S)-)'RPJ+Q-
M\TR[H!"*$RE!D>%KUJNNE_I40JM>NL-*V(9QB U<\B)XI')]BCF0D08ED:(M
M9C# "\Z-M@P:D;29FM;A]Z!J(KSZ-ZSM"XUIVV.&,4>QDBMYMF0'?+U'GR<,
M^$]Z"XFW-Y2F^/3.WH>I>[ZA)<ZG<'82R9DQ1&MT^^XN-0K#8O-?>.LL<"[O
M)3%';+5A$RB:&9I[E(QF@$(RJ,T2DG(<M9U;1==5 XDKB2!N3.@4)VE%<UZ&
M$'+J.] +V^ZE(55IINL&ZHRKQLUB&=(0)6H%*]A7/R&)*9YNDG-:C^.@Y13;
M:=5P0YK%G]M%M3U,@\6R"<O.UCD+9#DQ;GXBK$O%PS$XJ>R)(G%4+AJH9+&^
M&QR/L:QP!WOGXQA!OPZY2G0@%]6KR)O(CAZNKKZCXWI5YIMOZ>6CCB=(=+J$
M*77U_]<;4?Z_^$9"_]D&<)#BAIB)(VRU2.\FYMP/1$6\6R.75BN1,4DFD,_^
M^QX+:R#+;F/*\38DV[71O?5R)DQFGO2Y6R)PVS ":6G<GD*0JTX,B]!?PFM!
MQ5GO$ ^P/;?HKJ2H<Q?=,3D<GFFDOB(7LF,@;5X52TYI[9Q:]MXEKU:MR5.'
M%8H\QKC)$OAR^#!EL2RTF$BF)*A$(+;[,<S)&R3,BMD0[F?<YY_C/G]^)YO\
MF9RM<J[V82"(#*3J-^,D#;GN%SCYI!^2OH>7SOD#2Q>\_OE%R!:L!-0@21+(
M2G9AG69+\,Y,'7? >&R@X 5PHY]?2'4\_7QB33>EA"A\$;GT<!ZHJ+#5U114
M)KWJ-1RUV%[$CX4H$,$%P@W$N+D8LQSX!SFQM0\D@E@.8FEZ5^7D4#H<!A28
M55+BL 2I$NXPL?ZEA*AG2Y/,%!3)NG()V4>SG(L7^\--!/R^U?2(T^7'O<)Z
MP[WC)A]ZF+HTPG*5_N XG[Z77"SI Y^3,V1Q)ZSJ#GNICU8&@OCA]0A#;""K
M^$UPLLU.BO!R>YH'+%L*B$[TWLT)I2G8K*3C81)N&YTCT?.C\TWS((5-EY='
M00X 1KS,5P?9"WF-$9;C:++U4-Q6X@]2K6<8G3,=L@(YH]-@BJ[YA:471$?.
M@++@4[4X5](D>8/?ROPH]SR[Y-L3DYQY7-KOZM)ITB&?MF0]PPI6@FRZ%6\C
M7OQ)0<4CN):.WE1-KVIYD*!BKGGN,V" ! QK#Y8O%K37.]/6"PYL#N)8S_^;
M/#^Y[3@4*Y82U64Q86JQI4=+B.NA(8E_7O-'(L^E;5GSUGIKK.LD^"/2@\-I
MC1BT,Q$>P6;'D@<[FO-R1DL@E!YHO?R:"1J8%BN [9@81O+E[*PX5000;K)%
M0?],WHL I33QI>D7S*2$)!RA5,;SR_9%T6?,H+[MI\EJXZ60Q\'<8$C$FU.^
MJX&4&B5580=39&_?0,LU9-I\:2!REP[DH &_(6VG#<>9ZQ;IPVW+HB1V_N]0
M7Q]=I2_$58)N]:G7K?Y4KM(-A1G;/@+EOR%O@/UH$CD^*MD&S?HS/W(<)L:4
M$OPI2R-H%(:ORNZCB=&NUE^]"+<UO+Z)VTO9B?N5EF'VBDXW%( D%1VI@7,^
MAR7"A1%^(^4TT%_G!3?,^A*,Y8.<\PE>'Y><U9(U8M0KDT NT:GD<6UT ^G[
MH(<Y.I3!LT)\P!.H/#T73,CPD7M3-S$0U[Q.AFPSJ2RZ0]KKX&@C[=\(1_LP
M.-HW(QQMA*.-?L&GAZ,A@HDI'GQS',U7/:-3S4Z-//OZ<!=#>.Z;0RZA:G9)
M&[\LZTLC23?]I?38BW(.XE:>",@"CJ1^G)Y4UYYZS(E&@]2,B6?I!H* CC(W
MT00*9^97RN%+EPMG^6_G".9NN/S6=8</U4G2A@A?N4.;H<4+Z.3M_R#HQ((>
M8"'!"YJ:]#R?;6:EYC/-%0@X=]_U<L9EBWGV*J?3_UT#BH(7G)U185U^MSE>
MC@0'%!/7T@\=N*/SJ-R4OJ#^E_5"<)*4FIG!@?(I=]D@D.%^(._F:-F)\PSB
M9*C7U6IKE-&K1W<> X8[$6&6-3U7\C=Y7P%+@%7,RRM='AY303?9]#>U@0;P
M^SYBH/_5>>T$/M#2?[>J*2QPBEKS>$/H''*V&56*Y4E#$)SIQM<O<MXMT [F
MY1[KG46^?YQ<"U3:OB\/8;GQTU3Q5Z[K)\I>X&?L70\EI[BKFQVW. . I[3)
M9M8>"GHZ&0!ZDYT2700N /^EEK]UD(60A'%HN""'(3_5]'=KT$,L(L.N%YI"
M>_KTF_"NX>(+2NL/B87,9&KJP2LS0H"B.N-,SH<F)9'A9(O'Y5OYKU !UIR*
MO'1Y$4V?2#_-7F* WH3['#<MNY@$J^C89G+ *.V"_:-%)496=2M4%'[-^IA*
MBF  =UE*9OBV46E/+3<#"DL'&]U=UK>;+M$\T<D>7G]6^PK\-]KCU*%O70AH
M8DB23U&U28-_+JCR*<M2Y(;"$X*P>Y(XVS%J)'B]-@^FIY0D/WV7(H/']R5&
M5W!?:-J7)#N=_RJ8W?A_>_C5V*IWA^=!P),5K"-#$QA B);P@+DH\\L^NC ]
M-RC,X(2IJ)/58D4OBA:;>F:X3]&S$\_"0RM#XI*I5X!6"3)>X@S1I6W%5H+[
MV+IT2OE SQ4;<<E[U)IET=NSYW8M*(3/K^V'4#BIMO5%)Z3/V_H2 6>WF49C
M)L6.,%V"S S*1)/@AFM.&D^,@:]HC=9S3A,-G5V^#IY@("?IM+6Q(7FT]>,)
M@Q!K\N*U,B;F31ZIDNGB?+(7Z1%^+F;)0AW=4\'&,*:XG.3/DU[*3T&.].9W
M6!I_Q8@&$+1Y].H2+C^_GMB#B5V7L%"W$!BMB,<*!#D$+8M\!E1#KRKG6_7G
MT1>RA-M6JUT>UY% Y>-.6-]9,TDP43UVQE[CM4)TA2DA:;)=,-(TQ1#;]F5
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MQO8VZ.+0&!B/SL.YA\#'FS]7H]ZV)^K3,ZL6&--9G@-/NS&8YN P#"\FF8L
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M<"07RQ8.]9NJ6,)T2,8'A#<P-J8?J08!I8KTK8M]10)%J4OZPQCN<PR$N]&
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MB7\X#0E/^.Q7\#%Q[,TW99TW%)[P3^WK^=7IZB0@DWX*:#RD3?# AO*8.8D
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MZVJ&5G$ASU()\<6Z'*1QA*$K&8E_)HWB1M9H7\07K)N3NT1T'/$#GZS(Q75
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MQ6IZ5'=5M(;?L?/4[J_1 F A])+$R./<V3'+YW2LA;YL>,-@;)O!16>J)M4
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M^;(:MOA47U;K-D\O]69@#B-ZS9D<8V(RX+QW_,6"O$*$\J?5MFQS;D1;/!\
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M!VDK(J]M+(*1S]=;FGE6L&9^8DF2X1'_,8#[B>/B>C7QWL+IM=SKFCHUFL]
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MY_32:6TF9/:OGY_Z?@0L#D:0T0M4H'2COV;3@[T74&VQ;?PV*_^PI7W$2R=
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M>@_M0#H2CF-&:5DR40K%(DCGCX;OW]RVR.L@>S6%^>=2JUH>3;).K[/8@I2
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MZ2>\HU!?Y:H&GD@\&?7P<OZ3X+:9K2GZ11.12D1KJ6N,- O4:9GUW%S5>,7
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M8(K4CG7%2BFWE]*'*8+B('>B!Z9WV%RKM=JQ<N#*,)JJUC<R2,:IC7Y]A**
M);NN?)%$-[PB34U2+8CP*9Y<>_O"&2ZO7HUAL%#X^5!-A;Y&#T7&QS32509"
M1>&EX%W'"66[%N?P1+IW'/;/GMS*RLC*5>2/<2\L2[P[@493>3<0J"4(C0%N
MXHW*,TV]SZ0M:WRG!*8EZ<.\I9$"8&-I$Y1>/NJ.L4^'F^BD+"RN'!UL,VOK
M#/WZ_-"O[V;HUPS]FKVU+\_:2IY-64E1.I;0R14(E9JN+_)UID7S"]5ZTSQ\
M=.BD,H)&"CC>TG/ 4H1T(!X)U)?[/_%?-4Y?YM E#44Q^NJP';1](!9T]*P#
MB =NHC@^H_;24XVWF.@'T=8^GF#LL='!*7EU\C/IN1&#5<7Z(OAXG:8,X 28
M.!R[(XFK6/*ISZLO7%'4C[D&II^#(S='(5\^"CD[[ K?<$)'&_V1$AF7 %^<
MG6:Z@/!ER#9P"5;:R??ZG=B-@>4M*;-UZ'^2K])GNKXJEI+Y9NVMDL*-K58P
MF2Y%,@33"8(8?W=AU4[D".  XV^<"FAI3$.GW 7+POZ(BKD^\T:R!%8ZF\CM
M;6C/=ZGD]DUD6%GLH9#)98[_?%@/%:N5C[*3D<; 72NF+'V54,(.C^/IE-Z
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MD8@04 X,Z)E&ZNLR[!CD,V])I <,37O[S$E?+D=RJ\JGEZ@&'X)R,DE_9#$
M$IE>H1!I)7GG+K;.M[2*Z!^JW#&BX8YC/F+_D*Z(6/;)!(75&\.)@A'YT\XU
MAO)7.%S0QLJ!O##5@DJ 3)GC%&^XM1)88JFY!KUC,C87-L>-M.Q<:5'3^.4V
MM&#JHZV.MCR"=5^7W4732H+5YX@0(]'HFEK^8)*\ _=:Z@S3P 9Y2<ACY.@_
M< PM./?*/ICYQ6J %U(9/3JSY@U.\N?8(IW!G%\[F/,9>F[/D2)82=7^3;'B
MOM@9M'EG!]VO X5O\#SY] IPOFQ\CG5J ;7$3I9#PV R!.0\*<50AOZ(#$U
M:-KH&S8 &]'WYO*,7+?3]\ST,9RK@>&('K1/(8DE/6*8U-,VJ^LNP<T7TXU=
M<)#UH0_!BU.TM7XX\BGN%E^REJVX?M95*(>X?$A&GD0&.UWL\C&>XH,1,!IE
M6R1HC.E1'7DC_ H RJ^:CMNY-:'01XGKCYG4F"F?>E4XF:IU!%(==1DTF/._
M&=MN9 )K=M]?^,0UY]@X;K!.) 4$AS@PCN9ML;JL$8P*;N8Y36:SU<: ,XN
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MN'.G8N"@N^FZDNLMG:21XI$<A,U#8&;\G1<6IK&+1,_S9)Q:VJAW*] //+&
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MVFN(A6EJ(WQ>LAQ8,%$A%V/B=B8YM6GO#COV(LA[E$\QT^D,/_OJX6=G"&7
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MPHE>HX1,34' RJ\9^MK=1W;'6U3LXZ'/M*&WW+0VPD2=8;)CG!62I3,N#A2
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M<0M<QZ-OCPR>I:LDX>/2@LL:TAQ,!O/P#5QT;LB(5+>KO&VAA0Z/#_=>@6R
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M&^>;N$ T#;E5VDA;P:T(^6@PTH9X$$J(WHE:CVXG/MG2&7394*$YS>XM9!.
M4['C?-U$%6H L%%)_PO?(%#LG;$F(<S1J;6IA0WWZUF:.P!%'38$IN0Y3%LG
M %@*Y9#OH(\?1;HEDMVCIS/^Q&A>I7_/M!XM1#1[)>XJ?3-S&8UU 0E:AEV-
M1B97X]X]-.PU6!?@LMR5M396>?SXQ+W&+\/(/,BKS@7FE;Q>E[T9\U2$D9\L
M3NN]UY *?/ A)"K%X/3-JJD"2"D!_S.?1I\D'8Y3:G1AC<2O@8"ZG>@3U0?#
M^\0$3[SJN"6M4U3S!7 SNH%;,)C868C<0&2/;3ATH=^"#,0JZ3 HZRN0&5U(
M#AM>)I_!S8KNX.BHQX]H3R6=&[$3P@9O::SQ,[B5.KTY]W+KV<+?@84_%9LR
M /=3*'_(>C =*:'W3=DCR970Z/1TP>2VT* =B6K+0F?[6E]41=(EO0D+G\&I
MAQ;>FD1R+MJVN3"['GB/H)IJ087M"S=G;U^^B9#XW^KB 'B9M 7+=R/QU'A)
M!DYKW:#Z''5_7QX93>3\!P99,9:T*M=Y8"M1KMPR-@>$:=#^'$8@R[\; )QX
M(YA-$<.C6$N9@U'+V,N-=J:'ZY; 8IGN6=D;H941[6O/6#1$CH3VZ!2[^X2.
M[++K!NMCL&4@*%NH54P;[UPX28\^3<CWYNG'DG>"F]"U3,]N5;:K80MCOF)2
M<3C>7(;0%='LCFH'#";?8MHR?'3[YQ3&&6E0FW@D_KP1ZKM B,%F?M#1"><0
MAV'0V"8]#64++TCA=X#-;O0LX#H'SIH#/IW$UW;2/0D?9X*?-_3;%F4$W@)C
M1JANV&ZU'#+QH(K+"R;]=\XL044O/AG,45=PUR*[>T=F'?Z?I:<.?,6)9C3>
M9YRUHHG%]EZ46\0%+(H=D4JJY,K9QPMX2Q5Y&J;'-Q48/<Y&<R >Y3A43P_R
MJS+7,;BYE!="%F+J-M])_-_4%XT@:Z7]T0[^8>Q@'X_+>"+JPC3>4X2401HM
M%%[Z>HE\!>-6P_U;TM[SXZB]9R8]FJ%2GQTJ]7"&2LU0J=F!__)0J4C)?V%-
M0*Y9AT_*OMA95D-8D#BN1J8C'!F:^0V7T(IS-TV;R^'BO5(1688NR+7.99K.
MCL6>%@,W=NFAUF@<:;_.Z&)V-3K4=Y7* B)14[1)5Q.SI:^;UCGI$^T<SRD6
M)J_T)_)U=[XV[QJ5DJ-TW?"@[+1%TZ[V+.&&-+@P.DLEU4WX=%N0:\9Q.!W;
M4$=A+)8EF[JA[ VWA3,_M,>@6:6FC]<%ZCC<@(C60\C5L".";\]U\KO+>H9N
MN23U&?)>&@IGKG$NOV8*Z5 ^B4DR)P+VT]DY__JG7\X#K*=+:;.42 /)&)=\
MF<C");P>C'Q)BA1G4"@I!7'U<]Z";OE?(=_.*AZ\1U[[2(&U=!)1;/G=SUQD
M^AVRX:%A$=')3RB$A.UV/BZ$3)1A>!N+G\H-!A2(7Y2!9>E8Y61>]U]^W3^+
MJ\UQGTM\>%"*T7#AU6G:(NMD(V!18T$KHJ^0 $8L.]1J Q<4S57-Q5"$AMB(
M.4J'8L*IB],^W)X1%ID<8)!"Z09N;5DC"+2F?J@ @4-G!74(1DCFZRM:IV9\
M<=255R(UR6= R&!C>*_"LY];&2K=$J%,]O.K\Y"V;RQ9+:GH=5C3^.V;.))3
M'LGB[Q3B8O8A9+6G!X10/>=9:L[S:J:9JQH'CQ'3=AG748&X2J1N14I-R.U$
M=TT;<+'$8NGXQ 83H:>O&.39[W?:,12@9TO6F:(G8@%2[3<T/R/C.P5%,V/
MO[>Z++9H7M^/:/,M&Z:*84*M?S_C_O@0CJM4%7_4?MGUPSKPW^S$;M$ +\I*
MW!;6*>.<5]F].Y*1H)'05L+ZLKR$R8>$^> #OA>F(8CPE"+E,FH#!%)'M*4
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M#NG(-;;WI"\>,H#=)XR":GQT@O$<\_Z[@_WW&WE?PP7M+ZW/)*QF> M.S5)
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M;O;[G5SJ\!3V%00'N6<HE179Z#&E!00P?;WDLD0GF^B 6ZC,9(U1%*SSJ48
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MBWK^'?\E(N^Y=UH)$EP&:+@YEE-KNC>T&:=,/SESD^$/<L5R5'2\?4KFB6\
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MI:XLD"9>%\EW!C"!FA/[,<I5F(I,FW@#\:=93K@YUE ],_P7W4F-8^N[=R.
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ME+@RB6=3#TTQ8BE_5LAWNXJ)Q573TH#5QL/SM*?1N[:JV[@PZ#$*+5H>*:D
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M1:JXR&IXK3KBUF]Q5,.IA#O J5SB,S)HZ4W@YA%GPB@)>4".!R;CZPH,<SP
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M25O5 ^)Y34M%LN=9(46 _K%VL&B-17L2<J<X+QG/UT'P$+J87\<B=S:B0;S
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M1/"HJ%DH^%^E%-OW2WCS11TI>$H:O8ZK9,&_/]R?1 =[!T?195Q'25G46=W
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M:>R ^AE*,&DY8MK IH\O92' B"TY+8<,+Y@?-CE!'5;1Q:L.'HV*>35NRRP
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M?6V?B(=D2?:J[%!89H+$)5X9=G'!?<)T1$V/#3$!AHXP\*X;1CX+:H(B'2S
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MY82D,=:=3 3)2.-!=41A&HOT*QPWM Z:2$UV)8>]NUS1@;N+<JRY L%P% Q
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M.A8 *=SA,Y .U-00W7JZ(Y2.$7*;=0V6Q*U8S?KT:GD6YEENM69Z9QIRX]"
MU<\C-5.U'+\\$3E_W>:U:E>AJ,/DT'O/?3$E5:3W>>K4R&EEK4!E4F1I+,$$
MMK5 ]9+X*J^4BO%8[\!7 3,;VBI2?5Y^7+*D!XO3IU515G]MQZJ>;_H(>R_T
MP)0M5LE8I%S%-:.K90IR_DFW&$?&JW2[6KKO151@F^*O;)9=9&$YU6)K5(L#
MW82-Z/*D(M&+=8E?]V[Y%&TZ_=9/<:/;*F=YPL%SI_O=FN[7T?ROWCVPEL^
M'HB.S()&>-%._/FB,R1-+++5CM#.;ZCJ().>YDY5?-((*#L2KR;P2&%U7^B
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M2T?0OJM<(1PRE7R@T/Q, 5NKSJ-A7ZTQ,NL,^FL=/UZK$?C%#;YU+_ N!4(
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M<86)2%^Y^[$%]Z,M"AXXA%!GB7U7EM@B2\\BC.:.EY+^_9U98\[PVIKMW3Z
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MB?IW&65JSI3BE)C;@A5IPRPAI),&<F+PIQJ:DX X,:J3C1X5JK,4G\C+<5[
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MXKR/\S1AH,T9F"TJ&WIO:OO&T*6:KPQH#>AGCX$O^9I7:J8AL\/%9E% ^F8
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M1N=<9AHQX:^*^XS1#44C^EE& 0X.H?4?(I]_IB0=S0\)+GN!A HG2"%K7IC
MT P1T;=D8!J:("(JA!$"=YA2R-PF.%XE_T*(PA ?0W#P=7.!N]O@D_^<1;%J
M9DW:8&N5M%L8:9>A]R,/LFC,S O#V>@/\2-R1E<AEA'98=T,44)J*[F7U$S#
M38YS=<Z%+0DC+2VR],NR^NU/\&]R@9<FI])<,V(H)O6D:T4:4[YH<]D^=FZ
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M3=8S**O(;WH6BR NAJ 5G+I4M\GZ.&E#]AQU=M[RJ^^B09_115JX'?"_B1)
M57:I@C*)6J7SO-U&.XM+L#^FLRA9E+:F5J^'(+;*51!)FP>U_/VV7:3O"-BR
M</UC,0TWE%,#0\2,UJ0L\;+I*%F4]STSR2HN8_(^*3F)>)6^K+Q)""3^1:OT
M7;-KF+\;2F9? .3-L!J1V%M&*@YMK/@J<A OV7)'^S@ZPXEKNYI<\MB%6S[H
MF8G #@5Z,E90@B8$K!A-?^LPHP2%O7%M=BQ:X(,F5)\D>=C&&*HMD<6<-7@M
M*<^:2YV8L!)R@19<4K!),\W2<D&NG'(,JJNL.:K*,\916JA@EJ1Q.L4EA&"U
M@BW#ITSG9S)56;S-_8B0G@@*2IAU[<#9^[$.#1AUB&#^\;2LNU;BJOZC]0O)
M%LYIV]'G(JG"FLW;$A1I$N<<39;(>.7110P3[SGK,]B2./;EJ/70M3GRJBYU
M8Z*\P4,,[KC>50Q'2B R(]5KR:2-S4#/1+CB=DLHS;YQ0.<]!V2[=NR:,+WI
M#?XE.A_E7%DW2E7."F_GQ\;5JU-ES_VTM+J@!B-/7C;T+I%.(7U*4MM;P'6U
M [**2>4P6.26>@W4KAB/A!KP.! MES!V[0EC3W=<PIA+&'/EA]M>?OA&Y*Q1
MPK 4R/N']B0<L ^!G'7.,W>; <:"L@N,GH?@F:R0SKGTG! ?KF0E%+I_(:DB
M1FNINY(V';1+,5VC*%X"7"WS4(HAR<+D"$>5.L?Z#WU/[9Q#565)6#GU*;$X
M<B\EU&%1_[.6"145.C\#AE24!Q6K,W*2'54I^LTH2L="]%30TM&)5Q?.(*VV
MJ\.=AW8.^?XV,0&K@"';V7S4ID_BB]8U?OWNS_E67^$8;#A^\.$BS>D\7F#=
M!NRV_5VQ7*@7&+Q;>><?/5O9%?:&KOW#"^Y][8#'91RKHL'0S3;>8ZOKR4M^
M1G[$I^.-GBZ^O(0] !,.]+8H03??PW&<DF[&=M/Z_S5\G_[@A >&0"C$5<G6
M"6BJH>6;7Z,?NE>U0K=;2PDC6'\ .QYY1<\)N\FUJ5[=GY?NOKC[<OG[DDXS
MR1"JTV=O'D/5M;=J;6N%Z$GD2'Y"#WDO,'IDTE@D\P"UANX.AX[ '8%?BL";
M#!>!XQO0G4C<IL<T-8I6TZ4C.$=PER(X;*])C9[%$K)BLUPGHGEECZ>>O*L9
M^40%FJG_QXY('9%> U>L,C/UD=ARG?' $["=D]!JOVR>;@32< _A$;35):?.
M-]4^IF.T5+\X^G7T>VFUE6*^W)C%9X=%CPNJD6HDT>>U[3='I(Y(+T^DT6<5
M1[,TE:("[(;';9"XA37&^0EVINKQ? FL(,S/DN[<4K21P/@([,%%']B^&M_:
M4DE>XG5P].WH^[+T;1>"KT.KNJ*"Z-#6#]"9'P$)^=FZ.2TN[>[6@0%J@I1;
M!=.94DC"U.=S%K'OS9;C+ HEH\?6*&%OI;D=NFJ),7'6SWW)[?EX_+Z"#L0\
M'?@ C2*_R-O"O.6OA=]0T]IZ7DR1%A4@- 4O#&BDKU/'))YCVKZ))[F6%<-Q
MCV(&*NPLC4/+STSW(8:KQ53OPS2G\@A'6O#W6%1DO](J(@L0.!')GG-PK:;.
M<+_T+DI%6;4%&-+2">1842.( "4:D#XR?E\CL ,7*+)H7&JX07I>STE]":1K
M<Q79D?K>VNZRV/+E]"JO>,,US;*O1\+YVLL"RAK++4Q.FZMLJC(^[QKI$)P<
MBL0QU]WWN13YGE5.<Y._E*FBS)(FD1W_\_#$D)G@GW*PT:(19$'87@?A M(J
MO3T/5(*'2OG60&U8W5-4I)\@P5I0%/0J7H9^<AVO/T^8N1Z% :U*JU88K@/R
MCR#V" R]8M*<5,6/52FLAOXIUY6!#R0Z6!;PI71*;#, 50/S$-5EPW.2!,=J
M*>;@9+)1@BG:TH(3C[**8^)4[3[;H YPRP$];^L.-/$PN&>0CJ/0-$U,F9=K
M;Y9^0VT+K#[(\D+*#D3?=YDP&#S\2E+Y#,/D(#*UX.34/^ S^,F*;$0N/ZSV
M3+^",Q*9#9I]]_0.$X1;EE%LMV#,WC *3!B:UV71@%G8T-NO7H$_T,862V[]
MGJXMB6AW$^[G?94I./%^.UGU=GJ[!27/1;*6D#>9R%0CV4((&F-^K&90IDJ$
M"[VQ$&7&=:!E(JU_:A@XTOQ=4T7'\!HB@MJ)^>) &M1+60B7PL*5J!6@-H!3
M#"L=]%4HF5=C'YF$' P2/M8NA+7#MT%7D1!<KCBT\(VZRF;=);@-'9?\D]I[
M!)I):-G*/5XDDTAD=\?NJ*G6PM5N. ,<\CWI.@/,ZR'\U@0+AD'GR[!^VI26
M=V11=:3TV* ,/=DY&Z89=*Q#ROXU% Q.3!=8;CJZAEP0=9 _U'4U2YU8Y7?I
M."NL$<I=VC +2;<J:F$3BRKS[S)E9L?6*E4ZKIQ%1V&W@R3<%DC"$X5L'+CK
M$2,BV\B$69JD*)GFG)3L,DEO*Y-4D+$6FCMF^I!T PH+?JIV2&P0(<-8I)A*
MSH(S C,F*'K1;:KP5C<P(0*J8;1K$L-\M28?IP)WU0#JVJ1QJ=W=K]D%:K%0
MC,DC)C06VF@YT0_;Y7"475G,]9?%[+JR&%<6XY26[5%:/DXF#U\+I-8I06KM
M8P?#J=-4MJ=_@R!C12&5NI)!3^U )I->6X0.U&2_TKGZUKF2^1.J"9DD$@3+
MREA<#QFQ;]%8)!G]\,#9'EM\C?^.O:HBJ>'',_P[UK/+O]\8 &@-0?R>+<X3
M] ?W7'&'&+9EB&%'&B/@!!TQJX[.<><;\6.W>N","6O38#>@&1DW6MA1^SIJ
MF#>)OF"DD#KPZ&YY@L2P._IQZ.U;3:9 T?Y1@K05##(&/NGQ<_+K5J+ .':U
M==KJ>Q6J<1\"DB!#:E&1CF%[F/4/.NQ:-& [+5N'.'@'^,>$A;KC'5\SQ:7;
M,42)S5T]+CCO1:)BQGELI40C@/#08]SXJ&"?TF2"<* $A\*PM 3[(H MQ$XT
MI\ .CYHLPM+@RT3869DR5!+IS3FIE4E7D,V=Z.Z*ZA#RVO 5S%^+/6VV)55
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M]*!B:3*H"$O)!+!9 P>Q&Q>SF_=)X;!O"H>OI6#87#<_/(N0;.462_UKA_U
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M9V_A02R<7:=)KU.*;T\IUFY,BE92U 4X:)G@=<LBRA'"^@H_ ^Y#R$22OR2
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MN!KHI'XA!$'Z-\PGL_?-55B(BV4OU!0NGIFAUV[T3GYE48$01$R?\_]V6+Q
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M2:22#X6.SE]5GEP*3/16XZR_<P^)6;T#5YF4CV(ZE\O;N87B%2O#_$\ A *
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M\X-H%,P9D*]?"]:1N^?QP_&9;3D^TU7?[9#E,LWB:["&3K[[G'W"^.+\=@#
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M'.9:TX#H+_HI^M-;SN"<BHU?FLUF_!5YH13)<L8/C:;\/P8(YE+9@_I+GE)
MD?_FUGNZ]-S9>/+F+'[81S%&<A+P:]'%1C&M7B8N.N,_Y' +!Y+]BWCL%EU0
M_I[-^12*Y6_YW)__-4W)1==FOTX^*U$>H:N;^A4'6"?U"X&Q]&_8K&?ORZM)
MAY8K$2,NEKU04\0AS R];J-[\BMSL()AF*OC_^TPUTMN;]YJ1ZQJ@R[-QHY=
M^T@P)1_CW\(1AIN&>]'+-/,W:,[=(&685J/5+6:7IT=2LV\(Z$."X\1[\JWI
M EM%"]%+#45 9F3Q[Z-^W8Q6P#BGC;/38M;)Z50*OLAI,3]&DI4%-!,[IV7E
M6$@UNP!T_R7,-UT$L]THA[.]"(=.-NMP7W%'RLI'*_QS>\$NTNGR<<GJB8_Q
M]F?6(X,Z-T+AP2FR ^,L,PXQ9'M;7?&B(>HU^!J+BGH9:GV#=!N=K=4W!K\J
M*(%?6<>O]#ME(X9^\L\W67%H-;'D<)@E!Y#>6J2W\D' A I:L@@3=GI8@ZC)
M&D31O8OLXL31>>_XXK78F;B]O%AO)V*KE8Z!X]& T5]-@]^-G4B+-0_0=]4M
MN;YQSAK=,] WZ'M-^GXGZ)MGB/&?,B=^[X'1P>!8=:B8T7:YF@VRKBU9IPZ+
M%Y([+@'8 TVG2B7 UG71V_6RWBZW5T#;VM)V>1S*SUT%>]:%/2& =['M!B;5
MEDFW%<!??"\^"'ML[4'T7LIJK16<O?$>;Y)5/K"&WQ]\DO*CM\8OEY=75Q\^
M_/[2MN^[)90RQP6%B6,I0W2*,T3G1898=NWF@BN5N<\[#_J!-WI6LT)FC6HH
M?N7=UMC-GY32DCPNP%\:UL_XE+\( GO]4%-W.&QTP\6.=0EJ#J*"=#=+R1;H
M%5SK6\\"H+*RJ2RCJ::Y(M 7 L3N KTA&"UW5%/%&:U4Z/0:G=9.,[LPVJ43
M52Y.6Q&8\3^!U\!K.B -2DU)LRA(@& T,%KMH'/2Z!9,'@91'9JHH-3 :Q5$
M&I2:DF91D #!:&"TVD&GUS@M>-0,B.K01 6E!EZK(-*@U)0T2ZD6V/F))+J/
M-D"@I%D45 %PZW#KM8-.KW%2L*P91'5HHD*X EXK+4L:&='+N1$9T2IB;3,L
M7<KN219/@'X+L8!(1TL+(-+1@Z40Z2@&'20[ZT=4B'3 :T :1)GJ%H H WF!
MO)#7K/AH0Y2!U\!K$&7UL !$&<@+Y(449L5'&Z(,O 9>@RBK@P60K8SY7B\+
M( B!LX:S1F*RXJ.-( 2\IEAB,HYO7HWI_24KL_GRK:4M"MN'1^&&*<M6\&A8
M$YK>[ ?[GYE#]BK2*:A.<$ TI($%]AD-?>//PS^J+77MOO,$O_#:C2?RE+<9
MK[T"?QTH?QE(V1=2-D-&IV>>-3N 1]4B6"!,%81A10X"6F,+0$#K35H0T'KG
MF@,I:KOW=M_L=R&@(:"!, AH]1 & 7UH"QQ(0!-NK>%W.WP#]H*2UAY&910(
M #*:./SCEGERV@=.*BRI 34UO=-KH XR6T,+E%'FL82TAH0\VZ_40D#IV6AB
MC)9QU694U#NVP$9@(STM@%TSJ"G$^IO&^MO7X0 I:H?X[9.^V6QV@8\*Q_B
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M0>.>4L&WBW(BZ%U$'/I8  TPT2@.LNQ ]2@@JDJ(8/ :>*U"2(,H.[0%(,I
M7B"O ]4[@*@@RL!KX#6UD 91=F@+((^^,OLK8"^DX ,G.TK!/VNA@W+EU#2
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MQ4YUDMDK!W<Q*S:G"'04L@ "'3B:FDFY[2!3O'(&!'5H@H)P!I\!81!AJEH
MYS:#O<!>FV"GC*XG8*JJJ3$0&XA->ZA!EAW: I!E8"^PUV:+9-LG](.I(,M
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M5WRTE0X7P6O:\1I.,B\5O\@LAXZNMP6@H^%OH*.16:[X:$-'@]? :Q!E];
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MA*W,\.XSL/S&[\\_JBUQJ-:[<;XK\BO01ZDIL9C+^^M#VCKI8?;J$<X# +L
M0$W"> A 9887 E!OSH  7#6_R\@UQES>G__KF:VS#N8O)&!](0 )" FH'\6
M,R !U9S?Q=.X\X; W#ZL/SQMM]IPB!"%M08!1"%$(1+F-1Q*S%0-G"&\&\(7
M->=W&>GQF,O[7,'N]$XQ?Q&LU!<""%8@ 5%V@$.ZTS9"*8+2I0@TCVW?<GDE
M@C4:.Q,G"-G9W3]LT#AH7%6EF%.%11MBK"$TBUYR_NG;\NG7EZ0SU]:7S:!&
ME<=9\:*(+4$!3%4-4VVST^H#4DJ[KO+62  >."3H:HV'5SUR@@8 C54-9\5K
M3:"K@:EL_;-YTF\"4DJ[+NAJ1<$#AP1=77=R@@8 C54-9\4+>*"K@:GL>O4)
MBLK5=EQ0U8I"!^X(JEJWRJ,EU#"DV<ZRG"J4[5MZJI@8HV7\<'1^<GS_&F0
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M3.!][IZ?G/8Q?Q%^UQ<"X'#H/MU2?9?P@^B;6BF"*#WF7MU;]NC\Y-AZ#3(
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M $FB/-6 .\ ="DYN)$2"AG497IP'J7?.#.CW,'F0F,"E3>!V_Q2S5X\@'
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MW\UBYZ?2Y>P@E$EXX&YPMT[R$'H/>D^A2;V7@U(Q@<MKE&*>]7#R!V+V&D,
M' [=IQ_%(-41J8X*3FZD.H*&=1E>A-^0;A6;U,53'7$BM5H3&B=2(R"O/0C
MZE""R#C5<"@Q4S5PAO!N\&X*3>J]G+:)"8PM0Z5)&1&*1A  AT/W(<T7QVGN
M0+,@I;?$E%YYGB:(&D2MJA;,Z;XGFM/>$YO=1FL:KI*!@><ZHW6D9-%+SC]]
M6S[]^J)SYMKZ<ACTIO(X*YYFO"4H=H:IS?=?@3%LO=;.F96W+@+XP$5!:6L\
MO.J1$Y0V:*QJ."N>T*VJT@:F@"DU, 5I &D &@.-:8ZSXL4&JDH#+,(I@S$L
MPJGOS+ (IRQ\X**@M%$YH>%08J;6SHTB)H3#K1K.BA=S("8$QA 3:N_,$!,J
M"Q^X*"AMU*K@2/KIWNI7VMKR=Z<Y/7S]RIT76J[AA8^V+T^E-XYE*<MKTYC8
M(=@<;%Y?J8EU$XC2JN&L.@4MP!3.Y5 "4BJZ+JR2* H>."3HZKJ3$S0 :*QJ
M.*M.^0KV(Y7!&/8CH16@%: 5=.<Q: 74LP!CT IU=V98E5,6/G!14-JH9]%P
M*#%3:^=&$1/"X58-9]6I9P&FD)>A!*14=%V( !4%#QP2=#6J5]!I92N#+.9J
M;5F:7_G0-2K7=FBX7A" FD'-]=6-[UQK^-UH-WITO9$W(_9><L7HCW-/W]HD
M/&L3>NG&=OA&6Q)336KFR>_H_!6H39GR%."L*C@[.C_NF9W.&<"EM&,K=4$$
M,-J#NWH-1$&)UY>P#J40P&@0X'N W*'K6,J#UU:YJ8 ;<E,A&[0=7L@&1$30
M#X?)8SIL;0MP5A6<'9T?=\Q^$QE-:CLV+."I#2,LX$&)H\Y%_Z'$3*V=:X66
MK:X31LPX5:;V!3BK"LXH9CPSF]T3@$MIQX:846T8(6:$$D=E#/JZS%LMBNM1
M+8-J&;5F)N@:^A(!7?65*!9.IJB6 <Y0+5-'QX:%$[5AA(43*'&-"&N]X46<
M7G:<GJ&P:8Y>ICB.J)2Z%/ $:!@T#!H&#1\TO1\\L5.>V%& "%H!K4"25&5X
MD8:-F:K+\*JWZ(I=CNHNSV(W,:WMD88-G"$-NS:.#;N):L,(NXE0XDC#YFG8
M'30H0,JUBHM]1^?_X8]KCPR+#$K7,X;>>.Q-C.#1\FE\O%D8A-:$#:=I#*S
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MH0G:L'1"NULGM&/IA+9IG= >L!5:X$4AG/@+F"-.H$+VV="8Q.J0?=KXR8+
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M53#-BP(]@WG9'T>%=LL%_(16KUP/HJ_;Y5HW&?G,6%^SX(*O#!P.D-0HO4'
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M*R3:BN6VT:LH6.M7L$SL<D#Q.#:>W71 =C-P\B YB>Z0Q^C=C!1%?Z[AZZ2
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M*%C5V1H_VXUD!M,) 8VO@R@F[0YS<X9E46:.?]/T.JM)>N)B6!V@,7:G7EF
ML/T?I?F/Z1""/;5Y6IQ]BGNNF-]5A8 F&\AM5J9G,2G[<33@;!<JM,?2AB"J
MOT%W[Z96:\-@@.4-5"GE5!K:P@8TC34J-%G;!J3(2TV)8ZT3."DU6/=43*E,
M1"6Y==O6T_U5=JWKPG! X)B<VEOO3](R$"4<B>[Q0&TL:_WJ;(,ZO!UE E0*
MAVB:["UV?9#RN7_=(AU]N ^@J0Q);=+:$"Y%$L93[EE!*(Z(:P$[0(3*J;#\
M<'<#0.J$5:\W(0J<[97G2F'L&YZ%'?$V3'J;FGA;=T.]^S72HQS%3/4IA[Y
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ML6'*(H:B#P_V>;F+J4,%>5#TK#^FS\FC\IP\)![]W>(G,2@@^_M[^S]9+]X
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M0MT_\FL&5WV"N1I@:4WK#/5W#S%%"_7:/LMB%&4=D^2O'F*.&I3WO+ M@@9
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MUE;CP:P9=H]J*RWW-R5F(!48KZ"2 "8VUIBMK>RL5?N) 28&F#";M1I@;['
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MHXLMVNO*_L"Y2M'%\IZAAB<(>P"TW.>%:BV:'A\I..NZ8%V18BE$V["#6N)
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MIGRAMKBFQ '_1.WI=B^T>AP+].3-DM^T)]OC:E3::XR7+-:#\7P"+<J*;,X
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M330_J:.44%QKD>:A?*&O10[(C*Y5![\GM_CO1'>7N\-_)W?H1OH^]?O'KPQ
M>QZD:ST-#0JPN,UGI*)*P[AEI[@//<?R^\K_\?R0Y(POOM%MY:+!-MX9[Z-R
MTYZHM=[UXM]F@AQW;=?MN&A@/L'CG6H6:9A!U.I7=]]3DC"AYQH#55-3[A/F
ML7NG=)^>/>IG$@^;_*T$C@D8*GH,[% GHJ);G4@_:7FJ ,2)FJYQBT=R(TV5
MJ<A"'"HHYRWAJ'E>NH&UZ@QX'XV4W&52'M?3;:R?1]_B; ;W-<^[/(9\RKWD
M!8J&[;.YX5Z+Y%$'VIHLMC4-X,H8N'C#1&O/N$6*MA*\"5LWKK<W,_2VF:@]
M+;7>8GEMXX:;]RGI* ON A>)]JAW:4?SE'B#0[>;F]VM4+P;-5-^[5(VTTJ+
MXT[5W+<PZE.MKKXA(9&^?N53<:44@[=8;OCK[Z.NB\K8]Y+](7WON!MKM$&K
MV^[I1G[3YS?=!%IMT 2!83*<$8N2/[D%O?S9M^ZLB!_Y_)EN33_:P^KQ=DW$
MX6SYR!B8UDWCS@V#""UBV$C/!P]O_EKU7*FU.7JF:D,?H><80Y(!HQ2)E17O
MNDV5J3MI&B&!1=RPE<4@X9PSOL- YPZL()"3!#218R^T(\3SU':#[A(:W9;1
M%2"S19#QR1^T+99D$I:TE$1"M-C^;GH?-A%AK7#9/$3=&Y*RC0[>]^+9#<63
M&]H]85L_I,;[OT+I!P0Y9JBYGVHVJCNP>GIUR$&SB981R$NFB<EW:*6?/+US
M39=R/)S@<-AW'75G:2E_;>Q.3,353KQKV^Z3VO*.Z=:'O#5[T_^LW.VMUMC?
M\U83E]&WXY3QYG'EJ+YJRCC=9T8W-E(")39_<L)^82$C!V>Q7FY[1A9F(JRN
M>EC4JK6CJNCV0X_XYS5Q@[[XI_&<:NNHKOHG0<6 >!/=C+S4R\@AK5;K-?5Q
M)PA(Y[JQ9\24U).!X3VK3V^E_4&\.ZI7(Q?RI%D]J/.=<1YKCI9M^MR+4KQ]
M/_0R>[I;9(56/K*E06TFHA46S+*.\LX.R$U'L5F9$0IFYC:GU0U[IC6H%2D$
MFX9;AZT8MPZKAS-<^:.36O75/D S3^> )6?$DMG]-31Y36TT*&\H1:!36P&F
M.[1XFX"]8_;_]9YT>8&].&;'EGZJR@I3Y%JYTGHG8;2Q,;EY0?<P92_THLW*
M1U=Q<;J1%^W'E-5=_;X:L7+1S& \+!,-BYBQ:04N/6%;1ZO+,WT!'65*7 E'
MM2_\,--#_%.K.%1@I0#V% TX-9P?>A%./?<'[ZYUR=O_H/M&IC?=^,_BEI9/
M?/$D\0:<DD*^TJ;SE>I5Y"OE.E_IU/ M\X#7Y."+9PR6(:QC.4DG)R=(2]JU
MM*0;DJ??OUY^^WQV+:ZN+Z\N;SK?;L3EM?A\?GW6O:4?+BZ_GU^H_*0;\>7R
M6E.$.G/KSL7%'WR2ZNSL]OSB-V0O;9,!TTR\H+XIVJL^T_G8OM5323DQ+368
M40Y=W^#PP%2JF428F+)RG$VMMDYB$@,I%8=-)Q=<AW:<R=TT9GA1QW$BPZP<
M@S+_V8E9LQ[@(/0Y-B8\:4KK40?E)\Y]Q;M2?NS=,6N=>"MZ>6MHO*Q@Y$<)
M*7I9EJ7)L_Y?Y>RW*N2[)MY'>6R=XM?S]?N9[F"83H>:3#M;:G8]^6!XB?NA
M5CT.Y$X?@N6H 1C.\XQ;^T.2(9J>7G)Z1DE)G,KA5\15<K/(C[D;)6EP.!B>
MP=8\@YD[P9V 20))PNR=W%4VBYD+&CVW+/1V,;!_*T>+U"J?/MO&DZ_3[FA-
MB Y:?I_M@M%[5%D CAL0QHVV(!2<C^5D//5=@AWZ%F'XD-15916,T)<N=UQ:
M:Q85(ZGSQOC*3QDS!V5Q%W*(4N5$^%+^X%M&IX_&(9UND-Q)W5W*U^R0@E(E
M)5&B"=],I>+=J43"( +P\9M,,5IEG0B3PD$%P'2[1XO'2>+&0.QQ3H43SU\4
M9I]G<LK+V!R=*DMXJU/BILPVXW5D&4C/K"!4\Z]?FG&7DW\FUE(8*KU/Y]5,
MO$!\*Y58\B)!1>>_Q5D!8[)%=U/3K>>%QIU^8O*JTYZ6H<F>;4P ,AL#&8<@
MQ?!L2V69&<ZT'4?>Y%ABQS'V#J;<J;'<G9;:P6004 H'J=F*U-A&L!,R@W2G
M;;BQVN+(1^8=ZF"*3I4C^^+/]#L';.A5V:]&52]<SWCV(P909BLZNN(P?85Z
M%<T 7$<N4"6 'FQQ'BP;J#A&Q)^/SCV_)!>.-NJPB;LGK1,V40G2R?BICRYY
M7<EAT,;$KAW/5^OX'Y-9"GXX5-'OH!_)72*RO.*N%YV%&/UULO3-5)X+B[=]
MBT?SS.<]:'WN0I_LD>_'-0;T->[]!_'.BM(-^,^'^90>QM!W5GJ@M4P'.@HO
M*VL0Z5BZQ(L:N!,=HXBK.CB.&Y*;&]?5X._V&$$7>4.+3WQX!,H#@_P^Y7DI
MH$[^KDI$O"0!7^OY5)[-A3M.3E:/=\Q+^%D@VO%:E"/]KJ5V1Y\QU)5':,VU
MRXH@Q/:.-7!"S7.L>NDMJ0&I*[$=]RXZ;T!LQS")IOBL>E./'$<X>7/6'6TK
M) =#(WJ>R>E@\2\W5.-5VVA3\V_6#3'P3HTQ-E?)F:0[GB^]_>2K=*+QW?NQ
M0 #?9F#\X,^F;^3SKE*\@407)9ML)GU@,3)..5((/,L-GGWEPD:\J,H"<\DC
MW@/]'D=9 &Q;W6'G Z!\FLKHN4,^7Z</TBD?E7C,P JBH)D5':]3U<X'LF<9
M?$Y2O).5ATJ9MZ<Y.TN=C^3"EO[]L^8ITF;/\OFEAD_$UG10T),J#U%QN2<W
M<7''MO(YFS YZ6D,D@ <@V_T.!W\91"VI3J8&,'1Y#/3H;OH#'/Z4:/#D0SI
MY8B567$-3CLZ-NWI[],<,DK6JQ_[*0$OJ[_5/HJAJ\)2ZO3U0-(Z$X &GJ&/
MH-+L<ASC1=A"%<]PB:7YQJ,R'WQ%LA[8NMG.U@TMD:.+"HQ"USHE@4,*8\YH
ME"&J7*,H85%]):JD)M+Q*,.3+S(;?%T+ECC%%%F*16F**%=$9P%YC^\=J8F6
MVT%H!];0GJ%E*LJF]2MT;/Z'J8/'U(!#HUYHZO3@40W)9.M''=Y3YYKO[VGZ
MZ"_CRG7)(I]D&B=?BQP4]6V5/JPG4D,2W>YYD2EB#0VY+(,>';VFNE7T*N5Y
M7U5W3ZK[<?D[.\G"YK&I$-*HF@,IY.@:3S[26/6S.*2E0WKW91U)?%;Q)9T'
MS?ZTZSQP+DL<EC38C21J%:@PX9P1CA*_APJ ]-E)-7T,>Y(K&0;S!"$Y1*G>
MYWELFEU]3#*J1O%9<2M]0;S5%Q^YU+4VXKC@M'A\6;P::2^+>6%VH>!.4]5S
MPDF?:=ZUC(]WTZR.G\>:L=>I3VE%/%@-5)4="%0)%Q41)D@-[,1^+#:+NH2
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M@#D%%2^2A05(Y-MD[JMP8\\P9T !*@Y<V05= "?)/=0 .X =>11N; _F#"C
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M[7KS"+Y>AH8C,V<-N@H[ VY:].D%-P5F[)I0HV!<460WNP,WZW/31JG=:#;
M3<%-H:LX08,( R(,5QZ'#X)GU:*&N],,!W1=63@R /V"RU8DRPM3FD]3NJ]"
MC7!"460WLW!";%VO;)JNCM,[BPWLQ:(>6[/4KE7AL,%A@Z;"RH"9%A-B@!G
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M#?\<;OAWZ0D/<J)C*I]$\]5FOVT9=Y:-[JEPXHIG>]%1*-\=A?95N-$]-6=
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MHTW^I7@JA'CS0OQNBR<(YC#6!;)2#DOMHV,<=2TV=X4*;UJ%)S=F2^WW.%*
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M_/\GG@;Z!PG?]()0>]* )0 &Q%ZWL8?9*Z@TLXPYI=5L]*>A8P^X^-Y _S@
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M$F/YMGV$/,[O:2%&5MX31('H(U/>DT+,6P".->G\X>+Q/(7PB%J4=XDH W-
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M8-61<OK"6MNNB1RMQ(UQ#SQ\C^+!&'F1\A86/ :%P^+5R9T^:*[@0Y0^VG5
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MX'V@#W4$X@U!="\*@.>"M^^*@/E<OGC>BG8_4/&HXK8\"9,D)<<!_OTS@:.
M[1QC'  LC#_%/[TC9$L05?P"]G=R2Z:$F<@@X5#4]3^((=#4^-LVFP71\U]W
MK3F]T&>M6JOUW$8A?]<[\C=N';3)UD$@"(XU9^/28D6W R#,EZS8?-C+NVJ-
MR>66MU@R?*?WTZ5[*R3*5@!R3J5D%A_KUDQ>IH0ID_$>]1Y9"(5UB:'@4R2O
MX&UWC])YD%\I"+)4R<CC9J7;:2TH7GS0W+<1[?+L$L2LC%ZB&O&T!J*RQ,^S
MX=A>>XZ]QL;:-HRU$T9;;*SMDSIE_5A._7BH1,T6VK[0[HM;:/^1AG_WZ"UG
MF&&YWC8;9FR8,?-NW3#CX!H;:_M@K+49>+&QMD\JEG5F.77FH1(U&VO[0KOE
M,-:&OI3+F6O'E6ZCX$@6VVMLKQTD_W(@C6VS@[+-3AEGL6U65G4ZI3JWT%E[
MU4?.CKZI1[^\WHX<V=A;N;5/*OM0^6QU<_&97+%#IF)V.@0+]K,7^<L9L%@5
M;K;K.=NO956XFS-_F>_WQ_+E2"5;PZ6WAN]T/5JL% 1KIFOTQ%7E&6"RG5Q6
MM<TQS/W1IH=*U!S#W!?:?7$+<#G+KXU-G8[9]./0);,MAR[WSUC#7?V^OQZ,
M9AE,-M0H[["A3H3U<97!9E-)Y2!D\,4&VSXIVS6T)["/@0W:CO96BNR3&CU4
MZMZRY<9$O'DB?O,R-MP?+K9-P$8)TKKX:<*E/6J;L)Q!=PH&'=MS^VW/,3-O
MO]+86P[2L=W'=M\[<8XM.MQ0C#T?505C-C;XRJJ-7V\F*VM\MD'+:(/N>THK
M\]4^F<5S#&*-4):S?\\JW5,NG;,_&G>SJ:S,[_MK.;.5S*FLI4IE31N/JYBH
M$RNDJG!5DU63;6>VG5F3JT=^Q(Z8HED[@>=9'K;NG?/$^,>9T3?6L9U+VHGO
M5:AZ;L=1(NMYF_S%G+6OZ<!S;.8KSS57,9L[6,>"X\;[HVTW:C<SI^\N@YCZ
MSU.+2M6:/MO_DKM-;[VWZPW::_+G6+J!K I@-',H[$#8KNE$EK3@@[B7+LA4
MA]H%&Q9V3@U"E+$/,KTQZ9N*=B%*7FQ]2E^H_9](PP^$=/&1\SJFPN/A0U,\
M&H'XQT(%<=;):HCZ,Q3$N1>D&J&^0".<U"O=1J-3K1<4MJ.A+QYQI[[[$3=@
MQ,V3PA%7A2^#L31Q$YU);::I-[/:%EBMMZ!?<)5Z#D_Y59;@A,:FR"I!2LO1
M5A/PT5E]/C?@;*:\0=-BQ3!-/X*/6H:H=N0>W.@G*V#K;_%I\(I<7W+7H\VI
M=(_T>W2+\?SKA+>JTTI0IV:)P_-&\, )WMLW',,UI0B&4H8U<6X$0X _MD5"
MSJ!TQ/SD\ DC>&'DJU[1\)[\^[-32\=HXH,'U#%ZX'NCZ=$_1ZA*7SY!2^U-
MT5)\ZFXY4FJAF#I=5[">OLR@L<0I+/(2LE7<P0XKL26M.11L "('<1-3\'2U
M )!)HWCG9PAZ81=RX(%%S=L;N?4Z"J3YSHI\)*O%:_5O/9V>&O=-/%[Z\0Y&
MV\BOUDFEVZHUIYN>9XAXG56*LX(%#$S.79YT!980H,UGT,_4FGS2H[N!P7V3
MOIFU/(^:&=(:@XC(KU:[TCV=H:I_SBKIWUL[5LXVIN.:3RKGON=8:ZMF"G?%
MNKG3*5#.#QY8A&MHYUDS)7E?I9LCN8\P@4N::[+ <U8A.^-*]QOL-=!C[]Z7
M)/4UI3*ZV@6ZNG3%OR)GHH0*"#\0@;V;\QZH1SRYATHY](0!6IOV"/8!7D*J
MV8BW2[Q! ?)_OYPUF_7WR2;2WXWW;\6C'0Y)Q/SA@F3W P1H7Z6%CA1Q3F]!
M0?PO#^;MPN[\%L&+0"+?YZX'.?F_JO@-1"0@"\;=.Z&,/V+;E!0IJ4O\(]EA
M32@^J%#8* 2D@.,"-&\?/=^9IXW@?8DJTD1%,P[@08[20$!P^*((U!"\T[_J
M?3.;J*^!"CV\P0;*">%Q(5$?:K#SZS\O/\UY8:.C7U?-(&58 2! U!!!%5!J
M ,/W%/H$$ *:%:QYO)AT)1 AHDX"EDB3M3DO^N9[ _VJFOCDUQ1+_=MS!KXQ
M$C?10!DKMZ:-<Q@ J/ADP^*%"(7A73U'_C1HR1]@*+]'(Y2.H<"GRB# BT*Z
M7_,,3OMN"&/J>X&M,/'O<@1&KH%_OM'L>'[W>\*(>O_FLZ'F,GS4$)YA>HYC
M ,\8,$) &K390]B&: Q+@0( KDLW!-A(!J'GPI[U@=S4VL9;^<0[X1J8'.A]
M!X ]%7XRQF/?^PGH(00LB+*EU3Y^O]A3D/=^GRP%2<"F\-Y]B^?PAYI8S[6^
MQI.Y3N<"7]]X$\,))YDO$VS2SD 3B?42L\CD%%!O;3:;3!$(+)R#L\'E]-4+
M<DNHK2(P;D0 W.%(H,I[&^&;>R^KPDXX1#,B,M)]Y."N3=0Z/F@G%.WI"$"D
M"9,%:68I^$@P>9JY@9MA5:QD!RT$BW 16)VV3R.+;P$V"/$J^H6N 1$=_ZCT
M!7"78O6 T5CIT=AOTC4-WQ-?;!/]"PS&=NGJBF6LHQ;?4JH4=6:L)1&-.8X8
M [<[8#R:FK>3/X!1#6 ]WXON%>SZ>'%[!^H2933J#$N">>V-8^]*/S(QJ.1X
MCA(&FD^51";G!SXCB/K_!4VEN-I.AB<,7VJ^!UERJ>5!_%LB2N &"S\"1'!A
M"*;$J(5&#X\D]&V,,F94R#Q9&(VUEO9,Y7XR2>"8T@]!CPB8&HR]JCU*""5L
M-:;/GWKB'@0F3 S6_(<DF)'(1EP63?55]8J,!"VX'MYT$?E@,=,X_V4@T^&G
M!$<8YM"&L<1KC%X-T/<H!7W/BF = ] 9L(JX%4HD%H=P%K@@0-_HR\%T!B7W
M_3;TS!]#8&'0LQ=_112[#<F<=CQTIR&_?G3@FB.S_1UOQ6-O$K37&#@W]+'0
M4]Y,7_J!J:YK-HX[QR"&4N%>THC@JQ#N16)]WEPKW3>G;Q7>4'LI/MNNX0+O
MWP?S)#QKYI)IYIXR +Z21!+3^\B*>H>*^CKG-6F2V[A>[#DY-\:XI:@7/DE8
MO[QA?!N-0;Z:OCT.D^V9RC,)\)+,.I^<_1,+Y'Z-K>A;4B:]0G?,U&]YI\R_
M0-4&=[Y!FO+2#4([C%#WP&!OI?\ >CP07[Z<5\GVOJ='Z\=F[XR?617CR \B
MV&7$*"HB3NLQ,M <&$AEY@;2<:K*F Z!L,B^H'\U9,D^&FAL"!"#7 _X*'Q5
MX_2],F-@/0-44?!>P\<LE>BI0$VGF341+Z\^K^2V/J=WDE;\9OC7_FT(4,GZ
M$]_[3?JW.-!Y,1#X74TD;Q:>5;KU6KW>F(W?P(:KJ2<KKJ:/U):=>[KV0^.!
M, J CWO8[7MEKL&BX[=C@ \$E*(QKO<JJ[2*(9U9H5X4#CT?;<QK/0A5?(1\
M2@DYWGFW0 V%-O1,Y*A3Z9X<UV;#1GDC.D?[M.3Q$J4P*Q-*H20:RWY0Z32)
MR+RY^?U5RLI-Y#&9)-X6:[YW N;W4^!_^D.(:6]3+P0[YM&8!%/99^\HO50?
MW,R,'9Y4H^?DID=Y<R*_'M-7TK*H"S/S$'HB(MV4Y,;LC@K:4MA1VM!OM["=
M1S=D'L"])AA.,)$^IM2"3/Y\U&@=LOYM;D[_)C35G%6^'PPQ]%%(_')W?0[R
M$Y0A6I0HX,Y1DE&!>$,A(?C?WSX AR?8RPAL\PCWY A$R$BNL">5@]W7K>&J
M)^1*/@OS;!-F$"&2CY?7WW[OW7SM5<7EU7GM0]__M7MU?7=Q*^ZNQ>?+J][5
M^67OB[B]Z]U=?+VXNKN=AZW1(O[.1NXB"OAO!+AR,'G"5-+C:TQM^:Y,W^SS
MSP$V7 ,$]VU+'C66?)/^JM(5;Q!,U=Y.4<R4=X>0S5HNFRX+H!T%/:=,IVK>
M7$*C!DT9=:FR4OH3"GV,)&!?"S'\R ZQ%"Y\[QB/*J"H_*  POOH/8RAJ@[M
M*5]C@MLU=$7SRY(#VU4I<C>1H_/8CALGZ%$<10["?2M-)@;SS8Q\E2S7,T-U
MM3=0_S8ZK98RZ4:4 I=UERJ_Y,BP,,B$L4EG@G8KY0BE'N4K([",OQ+#5ODC
MJN3XQ,@/!5CE3SM0P=QDP6ANZ&LE&9PU8^@%7O8U1GS]R/@A_1I8IP(I&GDG
MDS0=3V']O5*#G;-C.4>R*UQY[X4VK31,R@V4 1)'1O$E-MC0/OIW<Z]W/;*(
M:03Z[=HMK9;;-%R\! A"PL:;^'R@!PSX]KT'Y7]7!IPE,9AFZ '26V?L:,Z-
MV%V@Q@YH;W6 0K$UTBM1EMI;'0;5VQ[-$RXJ]I+8ZW"7OB/K4BFX3SS:2-9(
MMT@7:7Q$&KYCJ\R:-X;6?C'%48@6;LN/+0[QS'D1D..;?N9!\3LS@>#I6X!&
M<WR@.9]D3\IJR(#2=IEN=T>WE(&=VQJ#Q+$=!+B=E!<J_XHPR\9;G 7::65]
M1<N=."17$?I]X,7GR5N_2;^G!;SA*)*\!62D4T!A'9;, FW7,6=VUDWTSR0C
M(7&/W?M>$* "-:6T='Z/-,QAPB2:,^C\#E(U,3C& #$<FUL_<J>:@'2!T'S4
M Y8<N9CBHQB$ K2P;K[=)P>KCN5JS4$\# OH"6"$41\X?NKIJ#/C$&<:2TSR
M_VW:%%>J_:&AD"VEU%8Q/S.[[83=%C//\8(<_(']4UI'_Y.^5QB7O0R"2%J?
M(MQDX!';LQ2QPO+33\7I^ 5.Z';CJ5&>E&&4S4KWRBLX5CSM.%=:E_(6",5B
MK3=,Z <.PN,<3/:[RBGN 61U9I**8[R.$@DC9C.8(3[:H\X&">/!L!WR[27G
M%&*,I+"4'9($IW,C$27'Y.)$(.GUH4LR-4#J*S#CBL^PKFIXMW/2.5MQ?.W-
ME:=S.5NMUIR+FR?')V<G^HZW"LXM.P<%\),Y!-%X["2),U.PS+$!-B6H"]%G
MH#0IJ'"5.:D"8?K=F'RBE)C\B5J.K"&/DGI@%J!CYDPG'-J^%<]_.O@VC@#P
MFGC<"LP46QE]C>:<)X&-%PZ3?%^2 1M*>$G])-<#P!&H#.E!-YA&+"T\[QF0
MN/F(:3GQ,:65TV">^9IL<LQ)L\'),>5,CCG3I@WMY)%*Y,KN-N?([$F.#.$.
M\<V!H7-"S(X-RT1#2.5GMUVTW?! R!CVHRIR&[S2YB;N]00X:%?^9?(*W'*A
MMSR;!: OQ)^3;(D-#"1^%1XU5XFARBL79'SZ*N4G>\"T45>90@H@C(R?]B@:
M"3"4^\I7HY4UF,01(888(  0P"5\\E1FI_V<#)=4C65%7\^GDP:HUCY.9C1=
M[]'PK2N:P/5 H?LT]V-I>(]GF:N-]FGUN'DRB_(+D46\ >IQ#.QWPN5(M1F&
MBITAR?EZE62M79C:M3]6J=MOLKYT2_[$3&GUTULZ^1T"XD-_H+H+J26HZC^0
MOX!BC8SKI."6<>2;0SRZ//>*ON=&@81? (<26ZC2!$@_^>_H[3I> U#=SP^K
M)M(@468QJL) 7@@H$M#72Z%\1G(T=KR)Q-=8^LA7$#N%@L@)*3%=P^PJ0?6Q
MBI2D$C2WF''!F:DW>:XSR;VN)A;7SHCW!MU:\>HMEB^G+R)?KM4XKZ,0;#@7
M:4A)G*7ERW&EVZXWJIV"L@/+2!?E5#.2@_9"'ZF'K<+#5(%,,^R>R*T[7?_8
M_ 97;^K,_86>Q3><Q&HYC&TJ47 \*[0S*8SDC?'2MV?,WCS[ $-LD?HRV8DZ
M<JG4U8T$B0[:^[/G?XY"L//0-85B8&GJ:E>ZQR>=ZFGC;$WJP@7R]3"([P<T
M$"U06+?MRFFE*W95IVE3&#&D"5(M-ZOBZ,S4 V@=C-]B%"6 !:4X&)W#\F S
M21HG*D KS2P_"PJ)A*&4*C+F#6IX-@F'Y4RJ4R^,!7\<#4X9JQ"!!Z L3&^4
MB"V"F#!.^'>B*O)H#PV.4E&NIBXL<7)D_SP:VA8LY3NA_@5J,L,CX$J Y;Y,
M3G5CT&CIF\\JW8$7^?K>;'T>%=K.'#U5JTZGDT'^4HJ PL_Q =;EW]J!(4MW
M]J4*E^>E>C"[T4^L<TQ'#N:"2)7:,? <QWND6D6^C<$9XYUZP(P&F:/SQ2@*
M*$D : M+M(1/U&>IUY^MJOM/*YO^M++YIG$$Z1+RF"5)\RM5<VGCF>D"=9W$
M\0:&[<=)(LKGJ4/?BDR(:)!69A=XFGN>#'*>K;.2ZFAY$K[\'4Q"V'U0,K08
M6B<7:]XG5N8,5Z9@8=X !]]C603IO\W;H:N23F._2:>#)0>?1SJL<W>E<X'T
M_ANYF=@UA7\LQ:3QCN5P(JDZJLRAPP'QT=Y4+#?KC9:^6N54H3B=YXK9L(W4
MJ#_KF-&+&4FG6*GSN'I6GRVBM5,;:6K]7H&1=-JH=$].:Z>M-:TDHF8$%JN<
M8?K"9YCX#--Z9YB.#UGY\1FFU[FO?(:)SS#M\QFF93,4=GZ4:3M9.4V%H#:8
MY<,GIW:06F[93_CP&_760NMH04;INM!>N?E5+NJEJ_)0ES:*FI6N.YMX&L8N
MX'%2HP^M19W0G<3C"DS'J0(-3RW6HA3AA8XG_;Y>_*Y;/;<EI]W"@%EAF>ZE
M;$$=R\P?\M*%#-'1NJCX>K.VL/;V;.$K<RBMR)$Z_6!V^S/^-JS6H<@&J&&D
MOB/<M7IUK(V^-9<EB$T"[F(W%?FG:$'CJ.Z<&,"RJZL,30D*;63HHV:S3O8H
MH*-[&+5 LV!.;B>L@>?(.,]*C#Q+.JD/)_5X&^FTM?O>FKHB'<Z,^R#CSDT7
M)+6;WTV;PXM/W&Z+5KH?J!5/<<?:1,G$?:#J8*/],[$9J<[J. #;+?X4__2.
MS$^R(\4OP(S)+9D642)CKH:BKO]YC[W85NN@VTA3&?,M='/=NLY3KT)1TZB"
MCG-ZL(WQ^HV\"IZ]L+_7\7CE_EXXU1?HMZO:.AWX"L_K^U:J-K$S>P3,BG*/
MCKT=UGZML"\GM=:*&_/,EG>+>U*>;]LGVMF)E;N%]G3+N$3SG2B?9\_^!W'*
M!>(4\ES,8!7Z%O%*QOJ,A27VOUN_/WP? ,V][T6N]4[\<GY^<?'Y\_L%"N_5
MM:?<K/KB1O&;:Q1_\7.LRC]@0DN6X%\1.2Y\8?D4_;XO]S:;TRZWLK.-8O'-
M=-'>2HLR=XM]A3)CJ\W5F6)?M)/Y/!_?DOWUUDXV^VS8/M7NS7AW8OT[VXGO
M]+C2/:F=+.C$QZRW$?WQ[.[DS+POHVZ>9Y.Q_<7V5XGLKP</.]%AMV,6ZVQP
ME5IAKJ0!@4$,\X<,C_963NR#*CQ,:MZRY<6DNS43;(FN]CM*PE]DE/V9Z&1L
M#;[D4:#3$SPK57"@X>#9M?36&C/\IAE^&@M7NO_DJ!I;=:_=JKNQ@Q]' U]B
M,5!LS!:HL_FL MBR*[5R96W)EETIJ)DMN[TCW>4MN^.7L^Q0,7\&O7RIU?(J
M=ET;RTZ=M-FP8\..^7VKAAT;<6S$O;P1EX3F+!L+CKJ6F-C2L5C<LQ%7:D7*
MFI&-N%)0,QMQ>T>Z>Q6>^Z3U\BI&W&FE6W"^_.!9E2VX@V-V#LVQ57> 5EU<
M8O%HR6(/K!O8W"NUUN7S".70GO]@2<$GX?:#>$MHY^D"2+]15>VX8MI4.63Z
M\1,HZL0H7+$F,E:QKYUQ:N8>VG_,^UL_2/<KE1.;TR67ZUCNH&?[^L4'L](V
M6U"NAVT(['"RN8*#J[TI+W\[E6Y/!-$(YC^9:?&<+3$H#/4T.VWSEVW3LZ#6
M8(NJ_6$1']7<RU<U6X7M*BU&#U_8?,$.\ )5)S!X?JF_M7=F87D_09\+ZNS&
M KV4Y?[:7.UO%>]1Z[367E$M<[6_/?-VY*KZ->J\,?,VIMVH-59DABD\RF7]
M7F=9/ZU01::/SH8*^#662DEC<;I1A;5(4A[6,L_S.NR)-FL>VGZML"^M6IMK
MU+(RFU5FJG\>V*=4C%:KM@)UQH*1!>/>[-<*^W)<:]19,+)@G!&,<2R(Y*(.
M"-'GN$DF_4&=,EE<O@9Q>5A[Q"*21>361.2-'!FVBWX1_ M[?6+D.S(<^AM+
MSXHWMIN)L+QE$?H:1"@CSB7VA=O%L#@M;GD;]S$D*7D)0M-V ]L4E'E$W[VA
M!GA>%!BN52@S.8E^ TGT&PJ#<A+]YI+HXY"+EX9<E!ZB;([&>_7'3(:%^M"L
M-QNO-.-NX0O+AQ'V?;DY-?D5IB<N[D[<7MC)><O9R9D(L_+3+]O;^*Q>Z7;J
MQ]5&L\7)QYQ\?,#<_:IK([#Z?]4BAF4&G[0K"3TW:ZT.P]GR$^]*<':W1^TR
M8';JG%T<4:5@ZFI'[,X:U+2N<R@HES5^627DZE'2PUE&IMJR4NV.<.K>ZO<2
M>+]S<&,\!05>OXV[ C&OGN3\A$S@JL(<.MMOX5'I4A$+R56$&41PK(N= XN<
M Z<O&>K*%^+YS?>"8.E@5[/2;=>K]3H76N58UR%S-]L!K.GW0)JP>&#QP+$L
MIMA-PM4-A[*"YY2-?$XXJU7I GDV&,BR4N?(U7XM(Q/HGJ/.O57<)? S<Y!J
M3X-4?.:+ U=E%"B5I,X&AZX86I0H=#5MSJ[G&S@*I'ED_SP:VA90_SNA_@4)
M8(9'I^VD O+>2(SR^0[H9&B3 0='@ Z*Z!EDL\(LO31A\<#B8;\B0#M ?:>,
M^ACUL08L_<IRN(0)M-PKR^&2LGLW.5RRI^$2#HUP:.2EA4>E^]GS!]+&-H/8
M<M T7%,Z#@=*&%24*5 RY3)>M6KM,V^?'6E3CW09TSUR9 .8U#!_R/!H;V55
M^<SS-^4]@*1E:N3+H.=:%S_'MD]/2+(\ESZ.=%SI-D\ZU4:;:^]MP#AYIAS8
M43"+!<9N2G&]90YBC'- LFGWL(>%%X?;7CS<MN^V S/1_I\!>ZZ]L,%382>5
M[G'M])C-"09#'.;<KV5D BT-6N<P)X<YRTK,)0MS\JDP#GV64: \OQ-8DV4-
M0Y+R!$DY$[Z$7H7F?O;\:E>ZI_7C:J?-=1#Y%-PA,S<;%:SH]T":L'@H1TX!
MM_?BDHA[0KRK -?7T-WK%+M[M9N,9UFW[U7@BV7A#F4AF,FP".9,9D!&^N'!
MZW=6Y$^DX1=*OO[3DJ^_LN2[D2/#=N'[<Q@9BJ[(<.ZD/VKFA=Q9I7M6:R8M
M#/5T6,:QC&/[A<4>VR\["I\R\9;+?CEJO90!<PG:VG8#V_S3<*+49&GE39:\
M$N]4NHVSA78*'SSFZ/N^1]^YF2!#T]+%T'=0F^N,:W-Q;:YR65\<B]X3HN=8
M-"O,TDL3%@\L'O8K +T#U-=AU,>HCS5@Z5>6CRHR@99[9?FH8ME]FWQ4<9>Q
M-CZJR,&25RY0N($=0XL##9><U=EP9L.Y7.B9PR5[0O0,LEEAEEZ:L'A@\<#A
MDBG4UV#4QZB/-6#I5Y;#)4R@Y5Y9#I>4W;O)X9(]#9=P:(1#(R\M/+B!'8.*
M/0B43+F,]ZX)!?>CVG4#N_:K:&#7J5>Z9V?5Y@GWK]N ;?),,<#]Z_987G#_
M.H8XARV;N/76W@HO=N&L'VW;=].!F6@W!6_:!]&_KM.H=,'^;B^NCW.8LH71
M$(<Y2[V,3*"E@>L<YN0P9UF)N61A3CX5QJ'/,@J4YS>P:[&L84CR6H.D'QV0
MVZ)9.X%[+2\"X3[G[OC'F9$V5O-T-/=6F.V9IZ.QESWU.LU*M]UH5T_KI^R[
MV(=XPX9BH2P6.(K J&5O5K9\<HB!S-Y*+&ZP4<(0*//3WO+3*H;!*^A9V&E5
MNL>UTS;;"XR ]BK6R14,7KIG87MO>A9VCBO=TUKKA'L6LHPKK97'A5O*(O;8
MI-I(Q'P'-5R:7,-E*S5<^- V9RZ\ELP%J8QC)%;.7&!T6(Z5Y<R%O1%FY5/8
MY<U<N$AE[8J9"R>5[G&[5:WSJ8O]B!ARYD+IQ )G+C!J.3@YQ$!F;R46N]DX
M<X'YZ1 R%S)FP08S%]J5[@GH>K87& %QY@++PE)F+LR7?/,R%QIY(7>*F0O-
M#F<NL(PKK97'F0ME$7ML4NU+YD*+,Q=*D[G0..-"#)S.L"?I# \RB O1RY]C
M:>(?H4=?<WH#0\ARK.SJZ0V,%\ON,MQU+L&?).A4L4<2<W<>?K5^<80S51RA
MW6ZPRW [1M\6<@28YSE1@/7_WJTLNY#V53RP"VDC47DFWK+CV=V&P)]&LQN,
MC'?X3#^K?(Z,LX@L<61\98&X3,#\K%ZO\U%_%GUL[; T9&OG507,CSE@OL6
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M7UV%BTPG0CH7\(,]H@L':6LR6",8TS\6.R'J)UDW1'TE-\3%:.QX$REOI?\
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M:Q+*%8M52:=3H$L>/-M:1YG,ZO?D?6#99[?X(TS@DN::+/"<5<C.N-*] 38
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MX2HUE: JI"8_RVR80^G;Z&8O]'Q.*4^DQ)P#'_MJP[. @#6 50ZVW%W+1WF
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M#*>H="!@^6<!=(0:GC6*"'#RG_*/W@C,%."G_:KK>O&54IA'*V%LK.G9/UP
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MU5"GK:K38C=Z7UYTV2F>[PN?-'JM;K/=,N ,*V.!4=PH*1# KL(]J#LXP3T
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MAVB<\_K=[WP4O1P TL#W=3*DA;*?!>[Y[ZZ?,.<\)IF\";]9OOL?<:(ZB;!
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M_>W_B3C2ZL_M^1'H/KD\T-@?!>C7B"S(4XEUK@1NE^@;_=V:I[\[6T=A-*7
M#6Z"/1:$SN!OUY+$.,ME01OL201"XSG&[BX \-J=O3D[/0,GK7J[L2-(ZP#Q
MT=2>-YVST/DH/#'J(8?@ZB3"):X< :,X+IBW$WPW$OW\U>[/(ZMYB[V4;[@8
M?+,82N_ '\1.BRUU!Y;:V:U<JCEA8D]G#"(WZCO_S(*)67<'3S_*;H<56S*3
M<F@+C\>Q'YB'=QKTHH7$$HH-$)N"M(!PSJ-445^[]4@ JRQ)T3^&G?_S)!J-
M_)1F"J1TH@62YXLJU+KMM?[$W__9G@^$EQNU@(4[.XR%ZXF%]Q06M@Y74JY]
MO(R-7@(;@>@".)%DO;_ NG4 'Z%\&41!$-TC'/%*)^;9)]:<-EVZ]31=7@73
M+66]*-8['8V#2"K9XUO '_E)7HE^)C4M:-__1/%WF+(GF G7S80C%\P2^!_
MP?RLW/RLR"1)$)8!V/PN)@ XM:*7/Q# B(C/[1^-W D"_2*X1[LBA6-P>A.)
MPFAH$ #XWRA+P3S($,BB/7$?^VDJ0B>,4L 26B[H%TIK M[DIX$H?(-/WL-&
M@9$2.H$O,J0N-0C") F.$OP(%N()(8V>4#B(P<*^&SL3P&;.((Y&-' ?9H]C
MZ*4@P1;G"Z/"@@J3P#?=1A%:3FZ"YLN)B'&/:2")LRQF")+(&<?1'2 J.4>)
M&1-<"VPB856)T3PUC#&K$GB#=._ LZ[C#1&\.?*)-(X"?"%N];2D9(9Z!H:J
M,CDZC:)5^R%RXSZ>RT<_!I47Q4 !8SQ^,K13)&H@L5X4 FU)XTV?NF&WAJTO
M#2BV^==XB0SN)_IT8V")F&S\V;3B6*_T C_$,"(8/\92(T,H(>)+T0)%!IIO
M/1VT'FTJJOWX(+=C,5,)"QKO59M*9-*<PUZ7K4+<GNG=OT>G TR'[&38:S_T
MD*.ER'%O@8=O43RXHRB35F3%,"@<YN].(0#>6<*V%* P07;?BHO!S)W:[EA;
M-0;;I;A7>UM'N]/;]#/)5Y17,9F&(%N2Q$\47:7N#R?J 8.X4@3!=Q$&/6"/
MY/>P"7=@["IWDJ8E -]C5 &68RE)P8:BZ3GN/; %2>TJH]V5I/:PH?YXIX2]
M?Y>NOZ '8G_KZ&"OVBI''\H8!JI>4],Y3G Y%9X=28U92#^>)DK:"?%0'&MW
MK2QWL'74;;<K]Z%!P7E<ZOW0]X:T+:[GQ2BQW-E;D "O$9\!!P[=/BGLG@!$
M4"FYXOF2:K8G8Q;/WR+%/I'S&SD[5!^F'A49!=[QD,/M8*U'>KAUM+.S,T.*
M7E<Y=!A?K 6P2Y=;#.(X&@-[.!^;\A0NT+$]&#24!4WQ@VN!'G0WGC3@S] '
M/ODW(N&B_^X/$1*X/P%:3D2. T99FKE!,)%@M:_ AA=D@$>_QL6W&GAC@1 Q
M&,B(=96+N>E<9G&2H<,2QIT]W ]?*I(JXZ2! F0<BSL_RA*<I^17Y>-5D+H_
M-;BR9E"^]&#I XRWC*W)D+,<X'[BS')3_M+W[X[^7J#WJZO/KY+05Y%5Y%$
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M<NKV7/:VCJ[%."W&/7?*LRO_&XA/ 15E&\#!@UR9(+?CR8]-<5.4O4[%&QK
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MT:<,'A,." M_E(T*6?O]S+J;-B5#%(XNQ?1-(']F@I#DBT3=%$B<=T3;498
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MQ.0Z_1O+\QP28?V_ =*$Q0/''VI"SXQG-X-XZ^OL?QC-KC &L,<7-5CE<PR
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MRBU"I>.,W!2&2!HTJJ6_<#!TRB4#%0H!E7+O^G?P$U#<^"W(^;[2CJ!*4><
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MQN= 8>1!%I.MEG\WPTW$7KRUY=KV941Y?N2FZ",CM2U]:F1J TT'&(1P)?\
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M ]*?H1>O(B 3<['Q&.\PQ  7G+,1B6&<8>(<>ZF^("#_VS[<+UP$@$7L68O
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M0$7+!'S?1!EF='MM*@=U5NUSZ0 SKVD4*B//KJM6<=>B:"RLOC#CPL6?WVF
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MA&(OT==R57(=F#>>P#M:,;U63@"?!AE?>CM^-,C(FC'+5%-58A &AW& *S+
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M8F536[9'GBL^] 5Z(<)"WG4N_/-X!J8B"< E1</>#&0BQ@^$B'7.RY1@Q/1
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MW%5KS;92*Y79:..LU/;.FXN2ZG,OC]TJC;1JJ_5-X/M%-C>G[AG;S1;6RY\
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MG^1^,F,5=*_E]3J]U]Z+ !Z98M[?RU7%Y*:3R=(7KM*[\Q%,@R=TYPO-N9L
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M:84C_D:9&+I8P-D[K-2F=4K'(V;LE>^C^B1="S_HG,/3!_$*H-@ONA#U"*0
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M4AF7=PZ#D*NJ2@NUO<_X.;SQ;FZ%NW*6I/(JJQ#+,"Q[$4LMQ9_MT;P ;G?
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M%2;-U\-J3']*W4S_J]N#NC9++9:1 54RF7QGKG!A/I5,I=)0PL5:<LN;@EY
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M_W"I4->6H\.G@SH_!PZB=(QJP=S[Q]SOQI-BX:/%U%($6V;-&1O-,6\0[\,
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M=&F/C,E)D"XBE5&B;,%?@)DTJ)%1X<=<W:IU(QN=['O[K,VR^QS5ASR9>;,
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MRP#^6V8L WS3.(XU,0^Q8^B0IK;AD$F-^)H@J)X71#D7(/=GFJ4[%^E*':E
M?P!-X1OR%JQ]T2"Z3J:3&XUG2^I)?<C@"CPO,]:4G5'L0D+1/8H'><KBAE89
MH#= HXEECX8[VL$$WWBU8ESG(5)B]<\T%A! /,0I@,#<!MCR )"B95Q8]+-6
M1F:(^,"]?P5F.1@#P@&C3H+_\J?SNHB^'8?X><\\]5'5;:=\5\0Z@?"!$P;I
MN"1M0S_B:R(W(D!5RP ?7Q30M^G/AOMBI7Z.NVJQ',1'TS0>,"CLNOU\N/Q2
MX;WE :B&I+6V1_R87DKTB5 SLQE+B^CMQ7F&)H.6?#3%L[)Q$,UPNHG2,C4:
MT&UG6HP[ H^.A"59%\P5G/88JXE /,%**E3IX%;W*)0D30'$EC3P<1>U .?^
M&R0[2<N DZ$ 36/X&=$Q4;06?(R73!QUF"."NK[I.:ZLB4S?C(,3N57]'.C/
M[8D&QO)07]_#_=/DS6*P+,NYH3]+G484+X*7<T?&/<^M'J,.SI[GE0##-#%4
M(=PMR$(-ZJ&?(3L8_,!^)*2O&>RK]$5AK<ZRIQ(6.E<#^FP"9Z@YQ!J;Q$X7
MH7(Q<@530+..F5;]:-)N$@^P'0V8&(,DZ!>C10NAY\XJU@C'M;XE\DP4>_V-
M;D!>?%(\[$!@1!!K>$\KG'V.F8M\?0#Y^CWB9D0TP)IP&5 V!&6OM<#N3L=H
M$ &/!W&54W<6V,= L<RL$N!B$^VT8J)]<TTTX!U9$+*AP;L!U/D-R9[9@3-"
MU]FDJ3\'XDKS6H&',ZVME06B=L0/ZN_KF)7!5CO,6W/?]T2RS@9^3H.D-/=S
MI[-(L?5GUA3E3?(XX1.J[BW;,PLX^H(3I7G_+_U$U?T .(!M<+#]DL/&RW=E
MY+/1 G ^<AZ1=,"YQ8 19%3JJ=Z#/,.![<8VM@R"Y3S<3O#2J[^9.ML64:[$
M6L[A@X*C?#<FR_QJ^""!F0:4C]4BVT[]#%)4JLS=5Z\/+:KK_!-UCB?4.(#L
MP%A%:RV<\1:)%A""J+^!+)V5E9:)/RNH;,'2>*0Z,>:*Y)%^"/X#O!9.FJ+]
MAY>UTRF$I585< 0[/'B5!!D@ Z(WSBXOS-D6AZB'Y*W2FH[=< [6%O!RJSSG
MT=0/@+X4*IZYNPR_GU#4')'PSK$?<<7%5O@ 9]BC[568X46M>ZI/"7^=H1Z6
M4V0;B-/Z[[!+611I@4:4@W"8TT7H#@M&5[UFK;8C+13^*&+4)*)N"#NZ&LNY
M5H:11G568&A+5OO#MG4):KEX>WCE"+E$3= ;"2>%^W%2"M;A24S$#HNK>WO?
MCWXD^30;S$0^/X+]6\.F[M(YZG9[(Y<+28 2]RT;AJ-XWN]4W4O9(<.9+X6#
M#EF,]>/#819YAY#[60T86$GAN2M>Z!@C(T5$]-QV#=2^,N3*:(A/XAS].3H-
M1S<A1$95K%:9-V@[TLU;16045')VRMDZ<5VB#@^P&0QP*RE>!-MEBULUDCL7
MF;##>X'[[0,+"8M82EGPX&'#-"8  3,-\!4(M=W.WZV!XQP2^SVF!9MEYE2_
M_672 RY5!9@,1)1$'C9X(@1&GB&,"]_S&E9+FQ6FHJ_@&/45.,,-]X]7\WRW
M_:Z"'_NI8_@1NT_=]H-($Q'['TTC0E:<_$L_"(WNU$=K*,W1"5(-<Z"2J:]G
MZ%[/C>Z$4,*L2JB!@F@P2'*.0,T?\!875D:LPMN^$+%6\X8LV0T1%E$)*<RU
M2&@RX6YL%<\9P\LRR$XE@TPRR&Z60?9&,L@D@^SQ@2H99&MDD(E)<R]-I5UC
M0&NGA460J&#2![M'61WW^4Y[IZS$H*(QKS>L&H@QX95:=X+1)SZ#CH91B)*^
ML<,Y%]HEP@;R$OW%6;:OLBO,HO___*BP$EQ#P%%N]@I]JRFV2FM-8Z6L*Y)F
M.@_%.S!CKK%?' #0P6MO?X%YP.9C67LVO>QO! P=6;D=(!8IX?46]9S]:R]M
MD=&\-@VAPRTHNQ\=-T*="V&U=<N.!L>7R![^?@I'ICC3K=G :G;-:KM^'&.F
M2,];;,R(3+L_F?8E3U 48+U3RXS((/JSCCKC*TFU!Q_^'V%N$=)M-N.$1 2S
M[O5JDLXP0(0DG0.N^,!"NNU.85YC[ /S&M+,YQ Z>406SF' K ;TTV,',>TV
MY)*N81#F2"\Z/Q+^4BO[6$S5_FFW%&2BT([>Q-Q%M$Q*Q<@/$K3#?J@,2XQS
MY./L92]B;Y]BG"X!2WVF3)<XJ1Z.2==>FD_U9GX_".%2%P4;\ -*,W#3,9@F
MBXR&T+!W#F50DIM9F(31$#/GF<G02?@(^FPZ.JD]H],XH5Q/9OPZC1+@&5U0
MEI+[?5L3J&7%NL,N4N#@:'TP=-Z\%.I_8(U6R_K4S3/BF)F.*#G9,"P?? H=
M:AEQA22=T40>@$!(:6 V6PF?3!3^00W;WAG&VU@WY#\5B&UD\G4:B<W?1+V.
M]D_O6POG!,,>&,,&,9<$.%YW[46.^VB5P!^6A+61'2%:1!D)(:P-!NB#$$H#
M#I]B)H_FO@X.ZB)B G] JNP"[JJUCCDEKHJ!>D%BA1%FV</M15S8.\HIN3W'
MW._ZHH@A6!/H\/X/2-!@-&/UNY^G</B4-MG7,6C0XP8^+$3Z8H9.<TZ1X)Q^
M*X68]YID!=X970J1I)_2G<.;N<XX,(D))@O/9$387'2V$9R;]K!MUA3?D :
MY'YBBTZT%86OY-,NULOU:NFJ83*>W;5>>'!>^:Z$!RFZ +>,2&$?LAP*_@P?
MQJ"M* U;7>2M4RV1355F@,'5IOFDN-9(8<8MZ $D=!.B'X;+Q)B> 'VS$(5D
M_)2"U'B]"_%-Z^(3>%- <]_:WGYIP;3P.^B(/C"_15A^$3MY)=77M#Q0L[(Q
M*E:5OQ @2=LH<M 7L.5Y^U7G7%S%R0]C&NA _UPAAPWB$)Z.1CHP2_&L!;G3
M&CZ%<"+H6<#V%0.<A8_#8(RM-9=<@TI2V4*^UCXFX6>.+G+E(>R6<N>).I=$
M7>^)>G]))?YK(/]\MUJN@IJQHX!4DW<LTMGPLD,%2S.VN%@.,75!@L BS",%
M;7GN@U_.YYU'3RDVWL1BXVZGMMJXNW.#:F,M$( &)D&F$P, X0XH6?8""PH6
M=^#YNO/ B!/@$(+!AB#.XAA@=Q64.**SUB&&>PMEQ/C_V?O2IS:2I._/[_X5
M%=K9)R!"L )\X&%6$1CC69[%A@#/3KSOEXU2=TFJ<:M;TX<P^]>_F5E5?:G%
M87.TZ-R(62.ICSKR^&56'J\&.QM?;3 <,CRGAS^+M8-AC2F%-DJ0W&,T;U;Y
M=6#:L1YEIC^2#6Y#U[%1&9=&Q9@-+6^N\ZV&9(%@\M!"86C[4>036MIYM_^F
M$JA<IXQJEE+]5T%Y7@G9' I06W2-NN9J&HF94JF;DY@!W)]E,X$Y)B@TG.O
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MF^@#&VN-O38"MQTFDQUD*9TYN!SR<KSV%.B"!"T&H\D ZQ*F1KR8J(4$#T=
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M->TBN"G".X07FZLEH@9-R9@PJ=#3<_BKR+K^:7<)LS6,_#Z@9;"]^V.@17H
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M#@2-EZ73*-;I]8%X#]? LHG/,LUBA3$=AY-8*:XNPH*"P7+'!<43@V7V+S.
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M6A!CD<67J8[]K7,9I]?BO0H50&4-$^, 918/#)([+1[N#Y+_0G\@"L9OBZT
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M"@!$8;I<&*IOXG!+:^VRP JFAU?_9QQDR?1%DE8Y7V_WX1@_)ZW=AM0_*::
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MZD+!SW.X!_V(P%8SL(0,Y^X._I9G46=I[D0NW0B_4E8>$C9^6$1IPQ5&:=>
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MDP-J*ZIX5PF2J6[MJ*Y2DJW5U+>RVDXM-JEL<S)!KBM!VN@@ &HVGD2VK:C
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MI48XU7[2&/V##P%AF&'!8U\G$H,?0/#* #;?%*Y3<Z"-F?9@]/!*\V=QR \
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M>:T,NJ7LQ9#HO]3VUA7"+,GM*(\YI'?=E1+8ZETWJ_>SPM((R;1%)%XU<U%
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MSKPF>S-T-@RYH?C7W V%P+_07$#GC(P$NE@F5_'="AYL*V5P\O0&7+HESAW
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M^GB3@U4!*KE/BMR= BR+I(GKX#S*DS0!;U%UH>I"U87[+1Q(%VHN4?7C_K*
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M:ZOZ/=I>#4-.4SK<%8;\0_I1=:%2^Z2H79O:5?VI^E.!T.E2B+6I757BWG(
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MKXJXP?E1JAE5,ZIFW&^Q\'3V_*';$U^HCZA*<)K4;I5@7<0?@W<9/$I5H*I
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MG%*#K^,H Z( BP0O&*X*W#<J.$C86)6;_0@J)<<+7T6W,WO7URR%HY&7@H?
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M,)R4P%$A6E6+!--&BK!/'DV!-F%:[$C"M M)-B&QZ-($XYX[PEYE> %L_8+
MV^Q!55PIEK3(A2X$QEFG#?3Q4GG\/CR>?F'IC.P]OP7_H;H_(Z>XKPC290FK
M>R/K&T34ORHH4NFZW-5XP]+GTR2OA4)8"J"A !J/#*#QK0)H*("&JK1QE3:N
MTTZ>/Z!.$Q'/B$J^=UJ(=[JM=@NYG@:4TE61V9^O@]7=:!?CT^^G6<-6M9(*
M6Q'L:T56L.O3[=3C)$&#/9R@ ,?C<NH(;R#,^==QA$?CB.H)[Z0GC/G^CA?<
M;Z+U,'/O^/6PP7@[NWE-S_6]#&=7PC#FS;E5OG0_#$$XWB"VOJ 4;6K_#@[P
MB0BDW6VL'G5"!2YW[3X-8@BP"0=GAT%\A9BM]-L\:A,N@]-H<8W?ELW'"+,Y
M9;0R#7@Q5? 6Y&U4LTP6S /8F-#/A1_\> A&YD?C%U7RLTE*8PZF+Z"QZ&6=
M>%;?>/*^,4UC@&/,TFB>9DA#L75K6]S^NWA_7<0+L9#0A2X-TR;%O)Q7G3F(
MJ"T7,1T1LL6"UTN3;O_%&J&")=)H%Q5<Z^J6V&G_$'&RS?:-299'E"HB5%0
M3-63V";LW:FH'HN';7F#1V7,[0.UNQ%=MR\XH;CZCC0BB92=U,;=:3Z.]2W
MTXGB27#CJ"M0HQM9#:W$=-1*E)MODN!A\$L>V]Z+D&N>W4@$$_P:54GT>_ >
MM[:"EUB!@@D.NHC07CTQ#[O"L2]1B=,A2*CA<DN$(N*UT1P!*A."8V&P1EDG
MJ) EO,]%#;*-]\Z*$# ^F_JJ*'ER&>Q)5374:!39^_4-T[FI;Q#8<]PT#:7
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M$][#4D[,"D[=Z\GIOIV7#%^09GOB)>-[GMZ6_3M$)7^&AOL)G?R@(VI4%Z@
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M(R/FP$,AK9[U P%WDW$8=*SM$4JH[- M0<;N3=_:B(OM01/B$EYW<"X#AL]
M@D0<%UOYEU8T)O,2Z#X2Y."2F4VZ.WTCWB/PNT@:*\VNL,HG[":1HB7XG=AE
MFR9BP5EAY]/KL/1P^ 3K/]3^D%E:GL0PVS#\QALI0*+6;CQV[<8+K=W0VHV>
MQ7WRT!;W;O1O/]7^;>IN/7?8BB]ELCE(OO=V"!]HZ0EU\*D/.:'>[2YF"<>Z
M6K2[O#6%//3.-2"=; ER,DPB3Z&=BEDU:1UZR.OP(/ AX:.W9>+GR\;"P)SG
MLOA(:_"MR1FPP-E;3'"HKVBV'4VFO43DG0Y N/5A*8#8Q>WA!=M),S3AP+<U
MV2E H"=!&-S*/\ [2-LVPZ9?I?/48AC9(\#:" (9L:E)%V[SI\P-RMO7%3NO
M;#'"L+Z@Y@EE-)_#;X_KAS?]#)!<C]XMH3R1*^!>.DL_XFQ[#V4Q$O_'OG8^
MZM1;=P,= "3 6P<**8@XW>[ 3MA3[/Y^UWLI\W V+K!_(-A*P Y-8H 'Z5_+
MZ"/-$,")C%QGXT/*,[8F7G!W"E<EXH2B:J_;4A#@E1JK"#'Z72:V\?,?LXM9
M\%-1,/;NJ[*Y!&=^F>9M?<Q!X8+Z&%,G1#.3Q[<V1'88'$RM]_^G5V<3,A%L
MDW^K&)#[@1E0U:S1  Y0+3-T>"6Y47X';J=C5Z9Y^*V[]*>,IZ!_5S786AAT
MR**YR?@C&GGA5[^A'*M3_D&W,!##*^U\)*Z;]?Y<! G2#M(9Z#HIST,I[LJ7
M)D<E2.S__8I7R6YJC:4L9T3=$Z2?;MR2AF"2X>(@PL=HZ=^2MG+(7S:39>FH
M37,MMM"'P<&4L3[$69C@V<UV PFUCROT%!76=';S;EPA*5K&[$\GG,R4T<W#
MT'BO]3Y!)Z+K/U6HC!R$@8G_^::[+3C"L'S%<'G7Q4=#L6LL]ZC9:B;8!ORP
M6DGOJ&=2<]:@$]3UWUP&"]%T27BD;2(=V2DN+)CWDFZC0!18W3OH.,4HN?.G
M<+(>:@589^;7$0"U@5R1I &VUR/-D/%,V]Y];S[9V.;G<8J4R7\K;H> Y7<F
MS%B7M2M:E6F;B?LI+<%]ZJY)3=H-)FW\Y9W\-B';Y[_/=YR'K0>H7,TE?-5F
M^_K>)=_N)X/55AF9T2'9T*&@#59+,*SBX RA+J:F-']Z=3Y%*YFMG'<->+YQ
M\+.),CB6"RE[G^0^OOOY8IK["%Z0YS> 0$Z*5=T92Q<Z3[Y$/+>$A'C-76QG
M_3RBA2C "39@U"^;[))\?PQE!1MM:16?&\1G\C7K;.[G0^#@'C(%)'JY\="#
MW*#KB5TEBV$4[OZ>AXQYGIKG&ZY=KAW?R$6\?A>/G18<8PUO0F,?I^U6R7K/
MW7HG*.^"@]W!I/289;HNJZ 1=2N-!BMO\RN8)F"7!5T9L*:2,KK)G:>"G\I8
M>2X5<_5,B82Q#]E]27F:!4D"":O;TB\/Y!7L=U<W8Z^B7S/48K6S#G?RYW"X
M!X0RK('$27OHL[9S]7BV^+W&Z_FK&[*5RP#>-4:8JA)+CKHF,F%Y"__!A7.7
M36Y!/ETGZ6;UV(;A+2RD>\/.: [L3047'+>\S1MY+G\[[4S*NT25^_THZ[E7
M:N#Q2^3=6'2:9=\HL_Q;<0*4&=BVU_I3$[Q",Y\1[US"D"[6%_L"&:0YC8Z@
M6^.;@OIG&U2N2<=3;ZL"AS1;(,F8+=X./L2R+7Y;I_6F:8$,PE.#=?MESL,I
MXV-ETW4'F/M ^(" ,FKV'\@!A\<=?A\<?#IL$Z"86H1]I3ET+S'7:-OUP[9Q
MOYUR6=5-<FLOERF;<@S\%:P_>HF8'BMI(95K0V%<+K>4AR\XCPU?-AB:0CV3
MD92"3VZBDA#8W <R?),>*A]Z"[/BH2<4*"Z0;,GBC)2]-'2^ 7!*4_O3"3>+
M!VK3N3UT7I=[[Y$-<IL1#EXO[+_!QB7QNX^GI&;!&; ?3QGU>! ;+D=K\->)
M;74&-SB#Y@L[@WBD+8-ZW-KCT=0*/X.P_6TVB/%+,#!FKJ)L0<-UL*#^_V?O
MS;K<-I*MT;^"AW/7(M>"ZE25!EOMI[(L]Z>OW;:OY#Y]7T$RR8(% FP,5>+Y
M]3=CRHS$P$&NDE V'MRM(D$,B<S(&';L#;5+)/I=[./6CEGV2UAR%IDCJ2/A
MDC9HQTP?(B  \YXN4Z"2 .?4E$;U$=20ZN:T88QV;6'@S/XQ0PG,PPX)=F;:
MG=W506'<JF5*;M(2CC9):9\>]X<542"=>($)CCW!L1\9COUZ@F-/<.QP+WX0
MD:UQ;[PNE%0@4&N?Z\(NDTI:B\Z*2=6)= Z>?>M#OI_LM4PJ%:!2]<9W?16]
MN?CQXOT%A#[VTE=7<?3RTO[WPO[WRO[W;1P]O[K&<WU[==W;@W@H)N[ZCAJ_
MY />ZD1W.!YP+&.D[$MKC'5P+.]2^W(7A=U$X\C4UE6HN&N\-G@35;(V-12[
M\]2>G[9J^=IQQ\2*66TH@'?U/XX!K>\#O5Y&L*;"#V4=+W"=?02#PJ4%H7U)
M34')>4I>B^&5U&%(U7K$=\I)Q+'Z?'=J!-[41?1C4\*SH_*[>S8/G(8\BO@\
M!(Y6 Y"LU^ILB)_(NX.T;P_1*9D9-8@=MC/,5UJ'^C^-M=Z8<,0IW+D3>4.>
MPN[8^*"3?.S>)*F:** EX(C=?'.WQGV>O<-:Z7&M>@;6/:FJ<L/$<#7R*10[
M$(JM1Z*Z>OJ<<BP;BK.N/*A>VIG!V(<,YY5^6<[>?2ZH(NB?@!4E-\)5,<VQ
M(49*FZ-#2XVQ&%#E;G-[<=WGQS)I[#3XEQV6QM@I87_'-+%KW^OZ(Q$!?%^F
M"U,R/\H[1L'_W:[,!EDE1?OLQQ2VJ%]!? 9(SQ!974-&Q&ZY@ .Y@'WO(GKQ
MZNKU533[8';VDO:\UC^/HZO7KZ^HJH*[2X=K@!FK?"+F<(:(&X$UF'B']S7
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M%+$IBV;'Q#2$_,2J.WZ',A1KYM'MY#,E"L&5G/"):F24W&[M]K$C[B>W -,
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M@FL-+><_8-]+*3J@9'-N5*Z9GDGEJW_3F>P%AI#-#C+I'1;BG@X7[7E,!O6
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M,/TL5F_X.9Y2O=<5A^QP(NH=N(%M[@X">]*%#JZ#._"QFSEGVN!^WWTMCA/
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M&83]=W8/9_LQ*KOZ\^E!!IC7B!L.#502:7U21SZ@.?E1VUIC0(^[%S?;"X0
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M[(346$]I6$@'^K)FBAGZD5-GIR7,YHB%PS4)8+CX!#Q;8 GZ\6SSB^C?]N5
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MJEN3K45TRL'!?0,9YL$8QWT*/;?;-&+=K\ 1BT/<! @7/+'=]O)TO0>,Z=I
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MZ2)+-PEE@$%!(T%9D0HD-<B=[YV1TX0[:\*-K-ZQ+<H:PM0JCF@88?N,HZS
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MQDRR!!4*QQB,=5GD6P*:94IMBLD!$F?NRZ156)]Z!M5&1F4ZM"P )Y-%JE(
MG1M%T ;:*%8U9L60E+F?!G]'"5<6?DP@487MLFFQZF2-]*BM[<SRC*WPJQ4=
M1$\;:X8V][!V;16>Q5J?SI40D'8+]<N@69%806-DZG(BXE!9*5;(OD=X-\UW
M9;RU'GZG]GBB@:*3]DV)RIB/=AIM 9<@K8 /0[-_HQ/9?08W/F$BZV1FSURH
M1"9XD;*P8: 7C*+<T;JQBU?(MU;,4!)K15&X@[?R0R+'(\96F)% &RR@Z+1"
MS>Z-G?@)B_:4M-BD&57ER=4,/S*G 5IY"TC;.,15)-NB@?)EDJ[8>1 CQZ?J
MX+&[YPX8"?Q&:>^+:W6^1GWH/!.]UV?0>[V8Z+TP"P3;,8$-OH.59$V1#>/?
MBW*O76,C2@E-7M^(J+W4[C&H%9IRG%0!@4OT?Y.\@9#G*HZN+Z^?QXI./??F
M;^DF)%=[P;T#WODE&MB?DGLR^U3(Y? E%A7NJDGK6*EPV.M;+]%^]$NYTK5>
M*LH*L>Z IBYN^0P*+7N4SQ2^I[Y%.5U@#$XV0-UZ@FR$N*@8IH:4"W2WO'.2
MN,WQZB"Y"([YAZGM3W(9D+:$Z,&@F%<6M^DB%281>36 )$(F2RFWNUAN!]O0
MZ1 .<O_[\>,[ >F<$H4+CP+XJ W=^Z)#JWSH]X'X'I\%O&3D)$:/P@U;EGXT
MV5X+!"3L5<G Y>VP0!P6\"%@5N^=B@&3P81MED% SOY#*P:'X#H]>F_MMXG$
M%+@8;'R6[/%?V^0CBM1D&8*J SIED9&  XX#&R:K/*)8_*W'0]DE50- %_(R
MY4IZ:'_\X<9;P1_*9O/?/QA$7U$FO :TR\W&Y,M][.SZH<P,JBRCD7:%Q3YK
M^K^"SY-HNYT7<KD@QX/B$D7!#?S3E!M[YW / ZLWFCT9WCUVN$;D8@G9WL73
MK&&^&%LM^//8.VE>7$1O3UB Q.TYZ#X%D:ZZ%YYZZ$IU^FH^R_$1I!"D+2HB
MJ+XK/AJ,YJ&YIB87 COZX<-JQRVMRK^@I(J.=F4H?O-:73 ,FB6I.W*8<T*E
M9L<(I=.0:C@[W.'I=FO'P-Y1IG/S=IY9\\+Y$^BZAMF"';<XM.$3TDM=BFT#
M$3:3_U[L X&@WG=YE)H5?Z7N<%>FA-5'TYZ6UNT,[W':G ]LSLLOKS#M,]+M
M1?=9L4:W2P&V8K.Q7_GDYVF>])K=@S<W<?3K__E@_Q=<A9*\ JH0K8I='4CM
MQ5X?";;<%9ZRIEZCFW:"2SK7;00'7OZVR3;H2T(,=M@3F2;Q@4F\^M(>YL,[
MA:!5*QR4,%\.3H8H-U"$A$3"NAO^_2'/D>L5D#-V"8>XRSS#6IV:@@;_9'U*
M_'=E[SB!I+'==$Q&'Z'NI>[R@?BQ3ND'8>\3FGFG+$^M@$IH?NCV/1,@O!)1
MF%]"8^L*%2]G8W:&^7;?N-L=D2<G?O&H1U"ME?%&%DP4$=3'.C?N4X,@B46.
M)#B8=KM;E<E][OQ'Y+W%"ES&'*%2A%MQLF1.3F5*"%=,/7'>AHJ4D0*46-?*
MU7?D(/PQT:)9;[D;<(!FYN=Y^9VG#LK-M7T'X!$GJ4B1D:PW-9XX)S_%'=_[
M_^P,5-[['YP<]":Z6D6'.^_BH6SN!,:<P)B/#,9\,8$Q)S!FZ/4_2%5[W"[^
M(65V!.B4I!ZX8BGZP]$C;7> %VQRH?MTW<.'/6^?29:.?;?M!&*(T(^<I!GL
M@+[TH;(\7IN:H0X<)6BNET'/@/&%2)!F_8(EN\3B&B29^ :D#,'.@714:TYN
MA;G0N_RQ.PAVZ2,8-[LSISG2_A,KNGU.4W'0JP],.[4C:$%O[;["O;\KJ@KB
M#'J&)47? :.(>ZY!UQKW_M%%-NT<9>>V%>XOMG%>C: \S"AB,3/N Q(B:6F1
M942O,A.1!J!6J2F7@2D9^QKF?XMFG^:^K@=E,SNNJ S^7<#^$'ON!W@B3G#4
MS6HOQ^/G[CW05_81DN^ !F;'7<-\;,RKF=!(?/4U%7_MEPUD)L&]S="=M)_<
M)R6R!+H/UFF&*22X*'^H;DQL1LM28+YH=>+B)T6CK<$W'-E%U-1:9?ZPX4"L
M]'[N4D#NN7L&R U&W'F\N/T$!V^)GKV_M'\1W=BEB2&(7I\X#WIQJ4-N]I2:
M.I":,E\X-07OU*_0@*TE7*6I&$!K[RI5.23J&TB9FMLD6XM\"TKS(C$PM#?[
M7&HO.46[EWL LY"6,H<@5=]-U6B$\Q&3B#5_0(VFRW2'D>^] ;*8@3C-87)K
MJ(UPTCG&N;\P<#D_'C#KEW;-K4X(-9$_S;H'$50G9,BK94JA[Q*.-DEIAP8W
MDQ41;#$,]*QX5H&!='::+?TA0R2OG2%  :A(C_?U5?3FXL>+][C3VTM?V;%[
M>6G_>V'_>V7_^S:.GE]=X[F^O;J^B#[TCW1/;'V(TN: G]<Q?;$OX@>N7'6Z
M+R=,%,<<1D+K"->,7;5@>/W^AZKC!:&K\C@$DKAD#"-/",9-A3^$OLA)9%%^
M]E(\ !#J69.'CJY=;O6!5^5%]&-3PM# #N<?W>/8X$7(*B&LFAJ?9+U69\,B
M;=X=PWU[!(_$ FIX3^1=PJ2<M=[_:6QLB5DUG'"=6Y,WZCFWCHP7VN,#]RHI
MPV1EIQ33'P$.R\U,=U.,O>\=X4H/<=4SQNX9594-IH4KSTT[_H$=?_U55 ?/
MT%O'S>^8M7.-=8H]JSRD6-Z9SS!?X!+2R, AY6=4> .8*RPLN0-^.MU/YTBU
M.+J$ FZ;'8A+%S^626-'XE_V01MC7[R]&O-4KGV#P8_4:O6]C=Y,N:<E^HX!
M@W^WZZ]!FCM1//W16GH;<8+P 1 F(0BM!O_:[IG1CV#_["YTP9GS5U>OKZ+9
M![.SU[4GCZ[L]GKU^O45E0=PR^FT=#'GC??M#^]PW("!SH5=FK#/[_#F+J(O
M,F%B/&_'U1/BS-AI4!*-VL8@G^A9LXR(\+;<E,0;-895*VY"DA<K.1GN74H^
MMKX/>=5.G6=*S9[[RF#.N1S&EYEK\8$I _"FO/.Z!OMY']\PQ&I_/6]JA!1.
MW-M$N[%9)*"?BAW!=C%@[8L,SK),B3PPK4B(A2'=\%L29G%5,2FB,[DF@<9!
M3Q(/\ XY7DVF%)-O.K@R5.NL]_ROBP\7;UK%LN?/7R:N)(=S3Y0, C_\(OKM
ML!-PY$;  <=> 'BE!%#6_0#L$2J;6K4F.[V5WNF>8%^BF/!AS/]GS#+O'#W&
M3".@W(')-3DU!YR:S5=(8P0)6-THK_W[./+@O][E(@ 9$3F&(.I 9J*'TO#P
M#!OLZ[DS9)K0,O<G%DZ.^5O-/^T03&\XDH.@3F()XS9%L6H-J#2LA(WD.K'@
M"A*5, W3;;=S ]=7E_B4UY DD*2ZLNE+:!,UY0X/QEV)&FPT_*TW1^E>B/T]
M!:=-#23T>(%_Y9CQQKVTLWBGROM4>7_HROO+J?(^5=XG;\!Z [=?V!MXT  F
MW 6KE)H,D@%WT^ZA6;* OINBW)\7FL88"J25IG(X@O*.JMNFMJ\>B\)4(_;E
M8=^3REJ+$$5TDN8_VK=$@P>ICQ??/H\=3F+M(0KM^FFGPHJ)9HY..N@*.2.F
M/<_KJ"-L/D</P--;8K8T+_).TS-$LYWZA"8^QS -'2WBL#?B44E7 *8VD=B3
M)T5E'[Y:<[Z40X[29.8.LD-'.@&/9D&DU"$#XE(J)XQ*6CF!'9R5F.7%VSPQ
M++E^:$/T-"@L7DX4%M@$V.FD^8[ZY\>$?IX"[!%15VC:!<GG='H@CYL\1SV$
M<&V=LL?JK0@S@O9%SIH;[:O\#;=)8ND2!L&3RI1J[[VIJF()_8#V7/9>4OP>
M"\/)+EFB-%6%1G4>YAZ[FGWW7.QJJJ!5\?"=X$Y,2<-;V-_R#:N)XF? GO4H
MG 2^]6PB)1@[*8%>;\1L<KKF0?SPD]9[I4>3S9PT51HA=/9_F'WTEM.HIUU*
M'&9^?E@;XM)63&WGKR496G(R7>(^=8!/5CX*4_>Q:$\1G:EPLG2DYKKM<<=M
MS1\?]LF7.^3+O9I\.?3E?DL^04VPGKRW)[.;?&GOK:<!>9" 3#72K;'X/0,#
MFC25T[_0W\X9L&]=-A/!3'QOZJ9DZ2;XJL74J ]IR6K0U:Q=3!T39!#.1[.:
MG1T0)P.099/7[;#?R7]6<P58UE<%H&<$977&!R[K$V'+,$RR+1G'IPF>(I7S
M61A/?LB0M23=^K(S@@RP>7^(/@WJQK\W95JM4BXIH2-P?--9%8;X=F$8@P?&
MC?.<+1YWO>238T+ $^B;FM;VB#S%&SU9B6(5_10[!6!:-(3*ITZ.DWR]F9UR
M-:,I84)5MYA@)+_)3ZRYJEFR14!FUW-7Z327QL.V<NX^ 5'EK<FHSQK?/CO,
M]EV7Q:[$$'O U 5&EB:KWA#\Y.I>9*#H+I-?"(9ISG,0(?$!J55C'WQ>NR0^
MH M)+!K^5=5V+ &DK<,8I1(ZS=D1D:L$#$&!=#=1H[?IIYUI9%F,X"<K4RT!
M3D=S+ .OARYF73;',V76:>Y8.!FP]ZOC.=?G<P0.2$>J0O(A!?'/#P+_FI/M
M2[=+_5S@ZX<6'6R-.3+%VN6_4_H%Q.RAZP@(1;"D6)3B"EC%Z8-#++PJG=HM
M>NG=F@GE6](/DN&=H1QL@A?/6_TU&G(]5T, W,%(A@]WNB6$KOF42 ]QU284
MID'$CF:?=(%GRU(A@PW1AC2T)RV=<U#+L)]M[+)%6'!TGX HAV!" ?/;4.$7
M.V=[49 'Y@%>UGL]: 4 9=HI#X>!DA]#5F.@B4<>>;NZ&6!=X2L2+IBLQQ-N
MO5#BM;PH<%IDF>OAA[\K.WQ<(7< 84=_./-@/7@UVQQ]K[($?09<G?-8T_FT
MQ;X=C^*T#XT)[WJF72-@:;2EQA$T:E&RAA9QK )MRJ+9<<<X(5L0>H?? 2X]
M6AO[VI*>/$^@+9;PB8A?;KNUAF[')GHMFE]2JYN?;9N#E/I/;F\0O*[;%;S4
M>9_P60^&=\[9IM^ ';RQ4_^]:I$-\/A7%U<O+Z^?O<*4F,;C![HCV" 21[!&
M,RS% ,PMW>11EMS/B2HOJJ'NMK8[KJ'^SB5P110D2+38]TNW'5J=G3!Z K1.
M@-:'!K2^F@"M$Z!UVNZ_!J#UO*W2T0>!NAODLFA?Y'(\[HU.ZNLV(3):.D[_
M$D/,\#=8GJ@]9H2[&>UI=DT)F%/N_(:)NG*%G0T&J8SR 2E*IA@ QQ:N$O:\
MO7PI29(WQ0H/#;]_=:6_G[S2 ],T'7M\0SV5-:I?4KT &,[4_'(TH"ORFSC;
MEJ7("*:.E"Y7< =Q+E;D#1YRZBKQZEY=7ET] QV$V34"OIY?VL^N[&?7]-DT
MR0Y,LM_'/LD@B+Z'Q!8'!VO4,(6B=EHNFZV0K[,])-G<@D-H*FA(ZS=-M5Y8
M^3')*$;O,4[?<$_:.S&4$%'!5$4YX@GV<PCV\\T$^T'8C\/205GL)^@Y$130
M=]'WW+SZ:Y9,:H1/Q9!^!4CW85I.1\D9P7X+_"28GD>.$FJ4UM3<'E-M?3PT
MNKD'99XF<H=8'?F-ZU#.DZUQ'?C  @-]1W%TFY:D^4*I%NY28N@"U#2>(:33
M^IC/(-?NOTN8.0*ILC(#I9&9$+S))S$37K(!+PGQX,]A/MG[J55#4Y*6O @_
MN(;J&X86*> #YH8@$03]07D#%$I)!@D=R"C9Z]\630D"7/3_$9 JVJMNBZK&
MKBVLR>//%D7>!)U<*]>['1Q1[, M;W(D</P";QP8.._258/)PKXZN^/0. 6+
MPE/"_[HU*59-+01U):O_ ([+Y%4RX91&AE."R4>+6#B+6_2]GF,#F*"(!H\5
M3@2/4J,XU3ELPKW,I)[H%D HSDA!(V>2T72R;W6U*(J/E6MH8?9;7V,S3C5*
M\]9.<VY$>":>)RDA(WTI+;;6L<D=I;2(O5%#L$-2LC*\-3)8?EO8(4U2INT1
MRAE1391OL8*BM4<I@>(2^@16HAYA^_4FR5G2!PA^@68/.WRT/73+PG%E^#I]
M]S15>)YCK&F<MN&JN_LI%B6,^=CY7".I5 U^FO0C D0]B>BE+0KS#0S3> *5
MH_HTX!^17!<?XL(QC+F"PIW:]73AG4NBL)35;L<9+M[J)*T%9J-HZH#G"GPL
M)7Z,V5BB3SVM32D@M3-VC!,DR55\_S'T)]K;9< E<N8KD,$NV3N%12=2ZW0=
M04FVK>MH!L?BX#8^)>#&A(%[JT* 8-9S4V[5SO][WELJM(=K__)*82LQY1]R
M5$3KY*X@+LJ5:8E16#\N3S%FPT79AE-A\."OCBBNR@=M[]Y_.-;-6-_"%HBR
M\$OT_%:GI?M8D0 %4;&!%Z[1N1-!ES5# \K8!HXVPU\A7 Z3X$TU;<#C@WD-
M+Q.'R#'VC5H#7MT"S+.E6D;\=6W>MWBP/8FY9L#*DSL+1PWRM<=N1_%XQMBM
MP#AZ^_[=AQO'S7:S7@.A/9SF#=CX&V@#[A-!UKL>J?AJ4&=IKV>?C[DF,9T@
MFL3SS]-//L2O$XPY]8+QAH41WG]S6[#(K QU'^#&U+G,X+[/98G6[PO]B8U)
MRZ:C%-"O/*U>8.]4:J67@ QTL@1/!:9'B^Q&<'B5,P$H7<!3DQPUHJ/5,]0?
M@/$L5:_0/) 7".F[]%,T>S6/]B8I*VU@].E7?'J<FH,70,X-N'5V3UW.1&@R
M[=BY&JRX ?:L]TG05?@;I&ZC=__3K>I?7L.HT(BTOWQQ=:W]@YCY<*-_-EF=
M2EX8UP-^Q7>Z;M %N3?9FN@T_8WB8N.1VIH$@W9[@=9%7[<O>D<GQLON['.\
M#2\-Q!Z#A_R;;^/&.[W'$)"=Z8'5<D"E6S-.OD@(DV<8HQMC'L_)(HP)R5/T
M&W)$D*ZXHT3D8%SZJ#6)*]GJ[*,C01C_&E;QOD"1'N4FK]UAV&11,TEK /N>
M7<T#VOLWOWS__H;;%I(\R8I-T52^>A&JS]EY?ST7C@VZZ!(@/\D&JMQVU]_0
MS@82)D))8@^^]3(CZ &W?'M_I^1[5R[MZQ)TK&P"1XMQXV')UL]X_:NQS(I\
M\PSU\^RKE46C[<($HIU M(\-HOUF M%.(-IIZ_UJZ,1H: ?N\D[!1H=]?=+
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ML*-.1>\$0%E_PL(5\WLJ":>@F>:"<6PK@:^E=FF]?N77))6C?[E-5A2,G J
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M.B;A M\'Y$JXUO^-I1Y 3HXQ7T7$ 7;)?A3[QXX()+<K[I)2K@$Q>(</B;Z
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MB>473H7;F0\3P;=+$_*%7R-D?M-<9AJ^;-@-6A1;SI[T2=4\R7;9$?7*>EZ
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M9PB&.S@Y[D)J>B1L3@\ABQ_3J"/OG0\L/J&C&DVSE)\5PIMRW(XIW5CL#=X
MKW#%FZ4 KOX+W@7.6\S;C? '\"9E5:BUWDNQF8W1MT_,&3%+,G*&.+XN9I'G
MP0TR*FV>[:"&)E3[?G-QY,'CR/IU#P(+S"[>^P -M5Q 0Y;?[5 GMN%1&NA
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M$3OO+UZ^&UMF=#\8!QNVH?SZUZ3ZI!I87IC_#[ K6>(]/3DYCBE)R@P6;H*
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M5):Q[?;1&1LG9.QT+-R!*NA%6W%6!JW<;-;J1D'XE$[]^&;C"UM:ZYZC-@O
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M'RB=1^B_28O7+EF#+[R#MQ:,D&_CK94Z<[K]&!FC7I\=0_:%87V"Y8QY>RX
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MK.J<B!C1I$M5CFT?R(+2I332+7U1E4MO\]@ 2==$ZVD99]2XM;&G5$8I$LW
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MFV*Y?G][]C'Z]?6'7UY_B#[^XZ?H_-V']P$4%93.ODWM_BB=,/\A2+$O>B:
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M>6&AOI1/0I3T&O!&Z[X\,XEXC:)#&T&J7P*D2G6$AODKW0J^!".1BIZVY/'
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M%H\2550P05MGI[)5+VMNH]DBF[0G%9@YS+^^5-XFDEH_R+DVZ6>H)U#-7S(
MN-IEZ@A6[AK. LV'3!<WRYVY.F65M,V),V_3J>4M:(+^/**V\P6TG9=]#MN,
M9:1,254ZPEBD0:I/X1$?_ )?I<FBJ3^ DG(&7&& X::Z#B2$8!?1P9P9%=<
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M9DL9=.3]!745B.B&:/)O4E7\$KFK.W$ZCEOT^,RL0-H6# -P*%,V@8$\#LJ
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M=,5OKF=!D#2Q3=*QY^:-\=S@+:Z4#G/Y=?:!7-N4G:)\S*V7A4+&*E7%Q4
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MH-R,UNK*=@+HM]45Y[,;U!SY4PQ,%Q,F;9<]=LLT)ODPL^[0 (F7]^N^I**
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M+]/4_=F*-ID"4^(+@4.57F$VI*8<;N$%7(+AO!]2+[>[O.1%:Z8VJ0"1;?;
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M@M8!CX_%XX!+EETW U8(T,(8/6@X+_+]A[,K^L8(X@TL78T:Q!HX0X[?7A>
M']D7#*W[N&$%13SX3\NZQ8_/X%TC>]C*'HK('@+V0$)E.<?(!QZA75Q)8!(S
M7,P;F6#$*\F2\*T*8*0(3&3/!EIG*9LI2XKS89P<_E42($F330GVC<(!5I<;
M-'!R6JL4O\$'G,&],%#>* Z<4HA]N6PPQQE879:46E6ILZ0T!?G;CDVJO%\O
M8(!<H8,&OL$(IAM:+V%D>@!^!:=97.#HS&GZMK-7CJQFSQH#-@"LE.<VL(9
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MMS1NNJ1OI_J:RAD%>:F:J=(H6"0>V*T 8-".$5.%?/HY*CM7@8CX!?-LX[R
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M%(X2G1T.57J%>$M--=S""[,$PWD_I%[V87G)B]9,;5*17=H]L'P0S82L!,H
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ML[^?79Z<_NP=G9W^'0_BNT_'<N;.C]][%V!?_&W3!-?SAR:C=KD^5WE1@8I
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MLH*Q&!(LT,8)','5G&QWAH9PAFZ?G0PP*->4TR*=Z];I1FA-E2=[N?-\YV!
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MP9E@&> 59<F*^O@N5?OV/IIG15QF^2UX.U51HBQ$1!)O:VC[]O[R:(#;Y'W
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MOP6GKT.[&Y-V/8,HL&(3=E"K60[C0LZ+0\Z=/=%/*N1\#OR:7^M@FD2 3A3
M<*-#<U ^SF7#[$5O)$6\7W92\?]@_)7T[+AD>*J<7I<SIU^B:&Y9>"A5I H!
MM,LTRV%%H920B8/;<Z1UR")+(@UM@+=2=4!WQZ'VO0D*-HHXS+&28,[B"VG1
M&)QB$ #Q1@PQ*0Z-^OI$2J8*SPK?FD!DL=;"J%E7@Z0P5-/"8 L+UP9<IW*
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MNF.W/*$;>0@2J9OG$4L@C"8VD!,WRA,$$BYC%@4$,1(4XSP>6;A.?#>%_(1
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MH]/HX.H,W[S+LR]1[IUF.\[4<>)FD^B_?[#SZAO=,R=N'E#<K!%F<5SNI,Q
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M)K&5C*57N9=W=<;Q'8WCA[*-+RS*PY6T/W3+*S@+J2<1N06*?.4#2YL.]T_
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M"!NZ0(DVC6UEGW4*P,FNKFLG+\Q6@HB+ZX7%L*PX8UZ7DH5;CJUU,1W;WZO
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MU+)O"Y,-^C;6)TF%L_&]HTQXAV3?2DT5S\CC5-_=YXB1W_E[)]N[LZ'_E1M
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M3MT>"X'-#9>W79B]W$H\#VKE<BYV[)-:>#F<ZMY<7K_&>(F= "F >CRZDG_
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M! NS!(2U<=/'U<D?F/<:9_,H"V30X.\Q =)Q<F1_?;/ \_4]!9XWU).YO]?
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MTB8+CXQ5511.*LRQ>CU;((+@B/[#:#4*^]!W'60T#+Y*7C*1.V,%;*GF8_0
M"4IQK.4U3$K@W6L@$;"7^M.;U\_3Y\^?"Z%\+]"?XYR;Q3F<" GFT#?NCY%%
MK/.Z:9$I0/>[@';MR&NY_I(YM'DU^3DWUS2)G9<<>,1[3>@_F6SE=B E,#;9
MIWS3;0Y=\?N7*Q]-P\.4&'X+'_O3*:Q%^-_<3'/+9IIOOF@SS=EJDY<VT*M[
MW5?SZ?Z4VV?\LJCJH54Q@??0Z\^$HCF/VX19:@)'TQ<TV\D:/.?+#. QR K$
MN9>^CB 8M]ILJDM#OO>*>4"LD:_2H;O$9!C9,LP89_:2_ZQJH,VYK%J\:E=F
M9;ZIK-<.XE"MP9QU@VKFT#CO>$C[@.^L:"H,.YW0*C\Z/JOG&>I'%JI[M0Y"
M7\I140+5CI' V,NL S%XH21*1.*&H1 M#,(>' $,]PC9@O!K<(.-"BQ$\!6(
MA1IL4K%N 4AKV1,%F)T9R=Y(@Z</VI20G9WN_F/!$+>0SF[QR.3A9< DJV<&
M)GAM]T#;<,?%P <5X[7_'G_0,::T=56X@<B1RP/"<31-KDH9VZV]*29,B^PJ
M6CXX88R@!S;MJN;T."S IBJ(.&YE"CK-I:("Z4Q2'?,OS<X^$M(RRZU]*4NY
M2X,'?(7>[3KXE)SGC8@85>MUONRG.5,GI4E*9.KB?CNV]NQEIR5\R#6/V6$;
M>WBO:]J/\\CUN78.9<8:VGW!>&$NZGQ@,D:>G9+,>IYI#PFM2UF-3HKSY%@H
M#J]/.65ZR-IP?*_^?+1?NR'8#TBW-4)D%A&C4;O8,M_F#FBXB[F1Z+W@T\@,
MKORCQ[8.AK_817-=KOQ3TSKXWQ],F=L!_0_DT7^QRSJ'L___Q .$MXAWIJJ7
MS 9NU<:&G^#&NJ$<I]+]"VO(?A.^X@<"'C@.PD"=L??^[#EF3XUH%>5"";^S
M'LBS%1C:46^)&M+7P],G'])P=7MS0(>!44>X)"SN]N+!M2=\<[0X/KJ<$LS7
MSFQ==><7#V,>CS[EDYH\WD/VI%XZT(+G$VE\#7I5+3OZ%<*XL,YLO]C+: "9
MB;5\Z[[G$E(DQJ8$SKQU5].]E-%<^;,O.M\RAV-0=KO6Q;M!L4Z-6I C3U_U
MW)!*_2'F0IW&&;+-N9L>;$3HR-UO1^;,Z]-L5OF%3@NN:N&JFY#M.(DI.<RG
M;0T\GZ$7[VQ#[/CZ("YL#0.)W"NT, !3(694<(?.&>.=MQZ\TE 0DI0&_#YF
M,U;HFB%L.3H# WO2#=,=VG\Y:-]]\YFY+-Q>CV8CCC!1W#I)8M\OK"ILF[56
MV1Y!M$K@=SG\MP,I)/K-.=?+&OMO^!<Q]4;MO163:#' !%+JJF6!^;7 L<W+
M[^;W?_C['UD M[#$ 4J-<N9$(MA@1VG$+-@@R(X^)@F-_D=RC'K2$)VY<%10
M^.*E$6HE*!Z.OUSP2U^>YNJ8>S/FWHQ)]6:\GGLSYMZ,^<0<.C'ODKU+^TF4
MJD57J8>DC2/\-$YG<LRMT>&L5EVNM!XV-V-.\Q2<Z!N_O-L7KB#Q?2W,3*O*
M(/C:NC>,\P)2]1'16 0G8_LX.]7/5+V(P<;H!!UPJ;5(KB,I?6DGDU8?TUT5
M6.$ZPOSU<?P$]!GQN&0]TM41P-VCB[:A'M1#[&D).7"[$PRAJ^WOD8;+CL20
M"DC5M;I_A/M*[#N:U_+!:WED*=_.W<?^'6FHJ99V>=<<W#7=XAG@_ALL8]1[
M(OZC,VSGIG(@-L=D2V!EA[]MI3G*BTXZ"N8>53DU!63<$["T9N]?!E,:V.VD
M2IYM]BEC!G/*<?Q>(@/ AU9*$7(ASDVND"V**+L&/GWT_3$KPE17KK7>(SB1
M-1VT= %RG'VBHAL"0U'<X)]=G3>KG+O5VT!W,[C5#!"[&4",2\%L*SP*-T@_
M8>/19F/GMX;WLZE6^3I?<E8B2$9HL1]_'B>.,(F;/JB7"3M"<NQF<CFL(KMR
MIWIM"G,)9EJ__=F<W<"<W;$OYK2GT7I=PM!V&K8 &8J(5H)!#-#+AR_ZO(+&
M)%> 4:Z7 A1PZA7/Z-2UO*5 '@( ;SC_+@VV3:5RPBKYIIAWAI?CO'!NLG#R
M0._M$#^<.S9ESJ6T1I7\%KP?M_DIO>W)3"*B$GMJ!13H43EN?I$W>I%.Q#YN
MCQ6LD>07?3-&$]IJ#?GR<(WY-=P@1OITMX88];KMCFPE?FW:NC.ZW /[:+B*
M,$8/.A@/:P/:3R<[M H*=Q) 3WP"%^6HPED>5<\QC#FO*NL.9-8!2(,2&%?%
M\B9PA*EZUE3SZCM\]8TLOEM&-41; %)H-=F$QF&-V/2K-J^X,.E/95A"\[L\
M_%W>L4N'.Q>!EPQ242F)1I3FPK!T=0GNEE*.V5-W/@SD\01DD6(DJ-T 6/X/
MXW5VA!",BUB>GJ"J,\9D'QNAO5^9M7TFLPIZ7D0\,^J ?/[V3+= #D,87.8*
MTD\^\T3AN)V5TC"7-N*I&UU#9/].PCL6("1L]F;;,C)]@ )@;(0GR3\XP55
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M?^![>CW')1:)*:%+L:["]"9H5>Z$>@Q(IUC=2 2J()@+1,FIG!PN:[W5_,8
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MJZHK5G"SKG ,D]BFF<M<X?GG44- [$WGI=;-.<J.CTZ/C[X/*!E12I4&3DZ
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MFARUT1EM Y.\QY+Z!(F-T@A+02F@<-C#;-@N!)"][I8TK*<]0LBPMW@C4<,
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M"&-?.U3$_#NM"R1XABS<-HWSR(<FIF_?2'Q%%_%S#3O 3#@2+[1JF>(+NPC
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M]A"+\*63Y RC1(8Y.QXF2<HQ(T)V*,+#B_U!6.Q@&C :#[#.L*H2Y?3<LW,
M2K)@UA,SDA!C\0"$4PY< .)GZSK: X.;N[0CA5F6.5R[K05Y]07"-69&L>_[
M/0+'85$!]2EJ<7"V%TX:8A?^0-T&LZV1,EG(G]8KBL6U,+0LL-O)=E0L RXE
MTJMLYPMA4227]IM7&<(,OW<).>*0=;"R*"OC,DE&O6QN(9%PST5X\GM.BHL
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MMQIE20,J#7W8&%+C\71VT,"."BXW"ZEA+8;J2"+5ABD8ET*0#W)^@?0;5/K
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MI@E/_@X?A:?]!<F<9\MXH&6\F"WC_5I&908F-U-!A&#-6UT5A;=MC7-&F,^
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M [?@=ZL2<4D(_9)B4D,\3PK$GJ($I9A_\!3=(RE^J6A9-2[81M_3_16:A]T
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MYKNSM^@"TN2C4GQCGYG^ZI;EV$3P*K*'&<%2,_L@YWTJ*UYF8]H](1YT^/W
MR%S[Z""QEYU4Q1I%ZV9W9^]I?B_C[\5U!B4B'G3]^WG #?RG;Z=TGE!N5!8U
M&*W/6-/CUAGA7*/6.7B+!/D6(?$&2IG8X1!)I>G6BG^Y82F2 1X=[#/H0LF(
M""4PXJ'0N:>5\]HGC8[?',@Q?+XY+WRG"=.W3R,O_,X4UB^K=S/"FSO4B*D+
MSB<HE=HMO"AVX>F%@?40:Z3G=CL@6T?-16G_$,_JVLLI\=MQ/)4Z2@_-G\_!
M8>>4[II2:3/1BP.'',_JZY@+CH;/9&)5T_:R[@H0JQ?QV;VJ4MJ^,V$H*C-C
M&H$!C_14V,R,K4#V@BO[UV4K[=)9LJBKC]@TXR1D0TO*M ^9_H0U5'[JG("A
M)$'UP+HV+^SJB01;.*4*,09V]S3N%2?V"<O&'BC]9QQY,I?0P^=!F\Z/!#?"
M@1*YD1K_UM7,B4*+1"4CW5_,MS@E&7*#:)KM&)<?N:G:ODV@ZL_7J VM6JX:
MA\:CL6)N=9S EU0G4P+RFW*EFOZT?!?+/\;!W,CVB##8O&ZEJR$Z0!6QF&0R
M8' +8TJU+^ E\X8:3GM%.<P6]LW#JG-?[\O=8YE[]D?N\J ^?3[HD'S11-)]
M.2'_<*6%V0T9(YR2\@L$0*G34V'4#E1EX==TAND:U:$<>& <X8([TR8=,X<X
M'Z+O0,24>8I@!-JBLKN2B+.'WU4-73XE#GEII)N6*U%:GNTZ5V98H&UQ@#Z;
MNN'A^FP)\!6.U>D^[R6Y9$J6>XWKZ 0[R'M%@80M^D&#TPJKX=#*=!Q$RR##
MXK/G6TEYK;G"4%3H'2]X!PR,[FWV@(,_KO<#&?I@PT%&&]@-]J[=QC':]"AI
MD,>=$@2]*XX@ZFKS;(CL>:21(91O?UB^R*3:&+["N?)O<\_$W#,QI9Z)UW//
MQ-PS,4=?GQ=]G3[>Z.LW=LVX=D$-'.".S\$8HV.WU1CL:FF]; YQP.4=Z(-)
M61IJQQYYFEQ@0;6Y\%@LH/UA[Q_R5L*4"% 'B?HB"*[+5XZ%$:/>>R^HV"/V
M*5&F#@ICS%"<N(LBPR&X62]L82TJ^-(RZ^6L5R9K+QR+YM;4#=%_T;^:Q*[4
MO$4&2, OV8_1$!Z6MWPZ)7<Y/2@ O"[00T(NQ^6!7=_!6Q]DJ8F6CP_-U8)H
M0X-EG,%R6BOQ O/54\"Q 54I%(R'NM:R\RPOY]3EW1Z>+Q[OX?DC(V3GLU*H
MD#UHF,J9RV7=.4Q&>&!5<:9&I40TU)AIC1W.>+%+SCR*XZ?L*AW6D@GJ>_G:
MQF_!-:C9[HK'01P3$$$%+)@I\XP#; 3KL$/2AD0Z49A+> AWBIHA)1 /FY[)
M_+ZZ87KY> T3>F,S2/LPD/93Z/%3].Z*T0S!(M:A+T' R%JR9;9%JJQ_!1 [
M 3,\["Z?ZUON[_%U8+-%M?X<NH6@#G(]1MSI9 #_= 'O_R@_YF4ZL.I?WA;B
M-KH;Z)G2::F>%%TSJ66!W0&PU\8@]:L5:0)G6)TJ')C)ATH"5DV.K!DM2%FA
MV-%*@R#NA;=/XX]\^J5?@9Q3B)WZI:J**;T&G*;3[XX)R^7'R#YM$/%ZAI4R
M^:^L[("=^]1QPJ(:MZ\<6JOYXOF+U^B1&D(0,YIMG1.7^L#%4ON=EZ^P2%@*
M$[C;S /;[5YWM:.IZ%H'BHZQ]B&8^IW]!]JYEZ>S!-)-F2#Y.,;(@4EVHIX0
MU3)<5FI%NJ7% 8M:U9*BQ,0)KEBLPO/M;O1%EQ5*&CON F ,!QQJ97)5=<5*
M14=$\1,B\O/&V;:Y__! U_9Q]Q_^CLA/W05B5R:K?1S90](@)'7IXWW-K6]?
M:.UH$195];&)_=VJIMS JBM\EP=DFAGJ.P@G/HXU*(FR"EIH,;V/R0("PQ+U
M55>B7H:]+F7PJ[J/DO785H>?P6O 'R\KZM%"5,^E<4#<)I0CX'NBZZ"!N4Q!
ME#=]"6 - IXWW&$;[BE(\7X8,>055;,4QCK<":/%H7.[^O K?,24V<:UTX:5
MHNL^ 9M#U0J:;=4U<V_4'>?-7CW>O)D"<<["%P'S9)A,R'B>3#T*@(4O?5]E
M]8J_M8;M?IDMLW*9HUPV'654VD9EIHK^2STSF^J21+U6T&P#/F2#TCQ#4%M[
MR&VMRUZ+1>@WOV=%$Y$$\*!QA#38\%N^RP7)>#!B^[0LNH;.6&F% N?::VNA
MIF-I+]%A6[2='AOWM/2@7$*P-X)"A7,VJ-IAO^C:?.RKVF:HGRBUA"8RG?QY
M:9PV6,=$V:]4$GPK&YZVU%T.>[*#0H-=1+F]L7T1O28:;H*J5!\1@:55&Q'J
M,[2L4M27HLJ"K:,?#]K(6&**I)6 7,;3U?.8JVW;NR<5HA?/K$TIR7<!YB1W
M:U@>H5J2-#I=F#UBS$ OSA7?!M3E\*J _K+S[W3-\ SACZV<%AI<(Q)""]XH
MM0#Z(</::Z&'F>)?S,L@E8_KTE((7PQQZ&TX##!5D7A"'QBHX>4AZO#WB6L
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M 1T4"O4[I*?CI3(;Q1G)Y(G6\%0=K(5XPJF<V<*)W;Q<*7[S8;"!K^3WP U
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M;TT;8=Z+RJZ3ML"?G:_$)L[-*U)_/$]3G!+_VGSS3(,H,KS4!B;(>HH2T];
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M"Q61IM*156J;'-%44AU:Q*XH@)=#:QLETUJQ&!XLP&H;*K%:8K *8R(Q6*4
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M&)[LW1.=^P071FG/)H.6,QN_>,NGX^3/E4N^Z:L1RL+].I@WQ%ZR*10U;3K
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M)"WS)5X=("UA,#[AT7O7\7Z^#:T!&YKP?NV>_SX(L"D(@CMXR&&]T=!W[_E
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M+$_0WVE&Q.;Q%/X&8NQ)!$%HKZGPSAS';Q;\3*J^F\SGU7=02P,$%     @
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M/_1.-=GN[FYCY\7+W?T76Q&VD%8BP<[92,80)FPBH)]!IG$OV/GL=C#AR5C
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M9?Y\LEAEH ^5?VKT!9(ZN$P=UV6F]M;P1(P^=,MREGJ:!/6_A%\UQ8+#KR5
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MG+[#P=ACROVTR'?9/$F$KM>&P@RT["]N="MSVYQ",1%BKOQ0TQ##^/U8^+@
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M4P ^BO542SPSTS1[=-R8'^R<8_DDK,BH;H = L%5CQSQAG:-S.Q!*7D!*F$
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MHQ<^ZB<(C9W&(UCX:@<_(9Z^Q\G/0_6^33]'\;]/H9^Q_!=02P,$%     @
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M-R&@>" ?LK[HKDOQ=A.#1<:W3F$28M+MJ*@5['0HUBS8(KDNYYX*+'VDA.L
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M?4<6#_^QX>3#4^>XJ9<\]I+X-%&H09_@EKEJKY*0&XZA%@]RQC[893?B[TU
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M71-6TR#V;N7]*R2A+8=3[^JX:>?&'#"&XF+*4XGQ(#TSYNQUDKJ]I48Y>>Z
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M>)!C#9@A9(?0MU:?<Y9;7O]D&?M)V[/PYB?MS63L\;94WR4J@"S:\>1XC&B
M24[ 3_&1LK[98MR/!'E[/&K5NAX10Q6T(-[W:'<PW)&\/S.55M"X6\OQ:1[I
M'>S MF1!!( &0R:]9[Y!,%X9.RGUO2F)__*\KH[N)P C?WT1V+,R&9RP4[S[
M% VK4)S8NTGW^_1?%Y[-QAJ.'6Z=WG^^LXO:%\2UGK8]C9Q_]TOM5<HB0_G
MRIO-&I_9;-X8<4KCL^GY4O. U/627##A=Q_69^?X$/K%6]4>7K'[#!2=[/FA
MM *>T&_+DUMKN(F7M2FH_FWS<9K'R\72RHJJ:J3 YE'YE J)5P'6UOTHT[AP
MPF]%X,-"'6BW$/($N+OK UW!K[4]'BUV7$S9/0&@T,V.^R*X8=G=3M8[ L5U
M$ F4Y#$VT,YAS3\@\ 5U3:MO5SDH1BTK_6+WX6%C$))(TF,YSLXMN0_T]&2P
ME7PV9]S$4?P-;V(JNK?V"W+[-QFMJQ90^7I3BADMB[RMFZT2L/&TZ$(30];@
MM$[I3O/S!PN>D*4?Z$$*=$(-YXW0E;>,XA3!-03)W3-=AI']*C)\885AU1G4
MD1W5!W#3U)[\!,!KZ7M[KKK9H.!12#S%)!1?^<<+&LE,G>O)IAM_#.OS,/H$
MEO+BOC[(*\T!C3:[^,!IT:["_\?,0+OZ/^(799 <8%S1,%;L,F.U#Z3\@H2I
M11*T7L+AXT.2M9(60M"XDAE-%=-3)V1&+$#;0""OSF7 ]1NKA6W?C.G0Q<'M
M),#^"0!3!0G >->=!2J\73/%G&Q;Y?E*!NQA=8,;-S .,EG2PN*2_DU'=0[[
M4G4D8A.]&76M/7H3L9\#1K//R*?Q'_)B[P;]>K/;TW8U<76+D3.][%;EK^!F
M*AM^E-$E%BI]4_BXN* 3.HKEIVHO.)Q"\LOIZD@GFDY,4>W]S\.-Z1A5U1F5
MWT)SS?.Z_TX.#857=[DDN; N6.Z Z.MB[;IEA^]DK4F)0^3=1OS8J/WPIZ:+
MJ?[8P[&<%ASB=#C<*IBIX3P!>%LH"?(G:#QZEJ]D99KU6VN*K%S;;"3=--3J
MF(DCW2G\N-OZD9_1Z^S_,O3R+U5W?X%^?X4I8()OJ[[NR6&*=;;X?[)_(YL4
M19#!8.4]9JHHFKKD?! 4V 6U<)0.RT&]E@F3+%%PK83?^NQPD8^&=;NS#A.'
M.-D75\7814<3R?AU2BPPS%OE)5?RU'IAU-52GJE9A;D5=/>EE$O,$C*DOM="
MN()[-&:P:SO#N_UG/QWF[[3ZJ H7%Y /=P7T$@)Z @!Y3V'%\ %WM*5IPKSM
M.IX 6>D>3P U>/!DMPDZ[4U'=O8$V&7U."[KH&&"\'CNCMG8%EN:!UAS=KJS
M)0/5(PL>/&*I"B M2;;![#34#5&ATO?PX%TK? E:DJ%T%UL.]YJW7Q/W2WM%
MU$XJHM*:?7$YL8>GU!OT3SW*ER#"Y9J>$]]<[PI&3'*BU0((;7UE7JG\A//Q
M_S-=R)!P%N%^"?+8,;<Z8K[X!"B>]=5[D9^9W-BW\>O""=9U?_'H-Z"K^V<O
M\_/D$P ?^L(?N '<-'V(YRY&DOPT%95\>_<"96Q-"V38,]:$9A>?*STGA)7A
M-B=0XML?&99C606^M^;@REGK_:@Z>1"WSZS)_RCH&&(D-9.O%SH4XX6<XM4K
M[E>-G?1KHIP:W$W?C2!3!0L+D& 4S0P@.GEHL'LOWC4KUOF."<1*<<%YIYDW
M5^4]AE2U@3V5W&^VPHHKH5'PL3W>3GE2-=ASG\+&^84%54"W%OKHUJK#M;UB
M>'= S3)NGMQ&<.9GO'SRQ_R[J@/2Y9O#D>7:#E.1:?)GP'4!'-J>D8-6'0Z6
M-Y[HM:L0NH?;.RP4+N-[!^E^9#PPE5AR1?KRBJYP</#"\N40DISAYFG"JO>H
M2//UX0I1Q@[^Y7'+ ]<6"[)E1O&5$S'TH^K&'P0Y,(?8K.2#4UM?NW.KQO!,
M9O^K=*]]L@6>>3758XT]YL[MW]_X.U;\0Z*P;GT SM?7 "7%CXPMUG,D:/CI
M:_K"5?Z\,T\ JHZII8XZ!VO R1Z?BZ7GF\GS:"=MR1/=_4Y!D.&A0T752"'L
M8\2E,O-W07XGO[Y]GAC0@,BS[G\P6/J-NO8$$$[!PQ'BX):IH->4C\H.TVD^
MN/]AN4^?@U3P$UR<^#D /_G -$D3%?E*>)#,J7GI) ]RE##$>5),R**=T:^N
M)"3-N2\5P&BYZ"6E+B+[]A> 0?J!OT:_JHKM1V10^ +?>XI^5;%HJ6JC0ZV#
MDIV$68UIB4$-K5-#*D&Y5ZXO;,5#VD/.3VF/'S1I(,Y!YTQG^:)FFY*Q44W$
M7F%--/+6;&)1V21=GHW-*Z;+V33X=9K3[PG5R%B_*=T17^JU$.6ZX&]GT=7*
M-95ZA\3)F>C>MC&$UQ7_0DUY/]L7-,5#CNBONX0VUCYL/ROS$,*H<?)&Y3/G
M60Q(\DN,7X(_@JSI)?]\T^]9<RT>_D]0+AC"]3/,V8W^L9>YW1TSQ,0A2:W2
M/4)<)141)TX91\KWYHN9F>!K$?*''OEQ:<0*G$'EZ9C!7P&O-E[Q(;K1B:A/
M\Q,&,+SJY[K<?Q$7G[0;@_7@4''?%^UTLDMG52&I<3@.B@%-B]X[@F9)-^T6
M1;/&\DJ<_K[FG_T,H0Z? #U^O6DM:W-Y/DZQ!F6@.]^TRY4#*IA_E,WCIM51
M[&DQR!'!\)^S, \S_Y*%N?895<C%_+=QG6R.K3'/-6$N5V0[C_*M#^T\9=P:
MAHZ=DH(!U,,6>!22==<'4@;D=43)+NJ3)NM7S-O%!I)S<!7/:U?3X".P+>EG
M<@VCP=P[;K\[&@ DY?0P:0MM=G@@UJ40%TKD,_:)1A.@1]2INU1.*+YLC=R'
MZ[H2]2= -@CX@PQ:[#H'BRA\!HD@N$[^O[ZJ/G<^M[[KYLMP)">I[>'/@R;9
MR %1"/?:8*A?T=IU3)S76<K4?5V(GK4X25]:6/%[./ZCFJ")&)ELL?#A,F[%
MLVVP>W@"H S>$3UN'Q@LW7:E]]^Q9Y@T4AQE1,L*U@XQVI8=;80[;Y[]H0T+
M?7\-.\O5*=YRG$T3+@$O_LW[5/P_&I_SBG_\N^2&*3\!KD\4PU9OC;<[;NJ7
MX5:P*@[A92D"XTL"*<37XM_)_XC"&<!3JW=;3P!F)@NEK:V[K^,/YNB&NB?I
MS9,W$I-=JK=.$$:/'0850?.K[LVU\$[1>@\WWT+4O>D^7%(-*3EKC1HY>)6/
MT_.BY[&=H6W![F_]5A^PVMR))P=4ZZM?)KL\H[)&;V_FW6IV%7',O44^ >O(
MXO-:-#"R:XR*ICB22G$<(M6SU.19R%^?=)^6ER^0=,YZ_7"!4%5^P-$-1(B)
M&F+H4BNP=KI#]4G.&=I@-$F*JT\YIN%28_^TQ@YGO.1P_,<UL1QZ J "%LB6
M'7:0XY9>IO)J5C>'E#6$9O*J %N2B?!,*G2D\Z4H.:;%\7JE3D882ZW#?[Y7
M>[:;Q73/C]+$@(;>;!%QW(6[E3/D[(2Q]"VT)5="8Y/>H(Q.EZZH6:GA>=:)
M*>O6Y(6^T);,V.27O.N&IP$K_G](W%QLPNRS:/L&L=))"C*ZY\KL>P[IIPKO
M[S:,+R_6W;G,7 E*:[&9)CM5%1MYRLQ5ZC--4<K#+%\@%HPUWWQD57L"4"NF
M+_?,IF'5U==3E>YS]YG8R=%>0&).2"[GTX>,/' 1^>2$Q-UYURTXXS1,#DQ2
ME%I(,.'HDAPT#LP:QH*I-=L\ 2140=? OR'#__1B+N2\Z$X9VG#K-9.U'][
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M8WY1^X$VCC9;P1I Y, U5NE"Y2# /\G-:3F*]ZDWVX]!(AN$4C1O]02H\FX
MN=:[51%U$3"Y.@_OARZIA5//$V_):)4F<!6HX^7U-F=FZN.^P=1^F4@7V[[^
M\'FL??#4PGH'XG)YM&UW:H)45JY);0GZ?8EKF1G'S/BQUB3>AXS-=FG&ZDI
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M#C>#V&L4!E&<C0_\K O1X4\ P@:-G=)?&Y@^-KO&<6)"I/-#:F6,TJA,=?2
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M+VZ?GOY57-)!]Z5_\25:'1P<)?W[T\2=,M;O[0?S!&QI_JQA;>MZ:Y:1!F3
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M2+@/;>W],X]<WC!CZP8+\GSSB%*8N:7X38>\HJ$&XV%??Q^PP2X.UB$>?OZ
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M2# K]F*YJP-9+SF6(A ')'P.5D!%F@U+J0LAM8W(L>_9L10#4HZJ+000G (
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MS'@BC]Q_(DT8!2E_?VN\MKQ\B%H+C3"*% +'3+*5\XG0(;_TPE:-!)+9,<J
MXR=?2KZ_\>-A\BA;/>JYGV%,8*FD6+BPWVVZ56JI0GF]LFW0-=$_*]F?F9>J
M^,!%<K*0*K#CW>X@D[?F%<I+)YE71$=9K7@I\@;-XNSX$9 D4M*X..RP$"]>
M9VQ$HDS?Z\-%H7MG\0/NAI/*I!H;2]?WMQ/24_1EEF?HWNI+BK+MSU'2?ITU
M-[;P O+=AN;>?O7X2%E";DW8_XPR0#.-GQ[]6KRD.0+UB9)\(0T_6M)RJ3D
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M;PU?2K/QEFNP[!Z3 6N3K&E(%N;W&E1&::+G]I50OASS^H-3+=+S'N2V[E"
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M?!Y1.F!HKO6U^OS3KKH%_99^%X@1=%Q%&,V(T,\2QH'T Y+V@D\WJL6+'H\
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MAF6.]O'*9'VNQ\<7Z8/+EX#$,YORK"TFZESWR)-UYB=C"L+W-A@)S+9-G9?
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M*4,CQN\!W%%QK6_?#46=([RD.UA'9WZ(R*Q=V<F5:'OUI=>A5R=/12N868/
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M!H-;Y^81D1J>CS0:8O,ZN9^NN&;AU%] \H-06&?-M8U5#WV[==BV;/A/J4X
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M2L<HG)0\'M#-Q+7ZG<H^0L)JI^LDBK!A&.P_4:SE_U;%_B=AX9O]1U\\@&C
M [G8_QP63QS#_FV;I?_89FK77WE_;R[[WTS4\)],M)NI@P8CBV!_C"#XGXS@
M6+X+L?LG=BO?E<U%>O^12O)_5+*VHI(1%0[;U8.-X?[]_N67+LB\:#Y=Q0,Z
MU%@U-Q3D/_GM>&\N%_3X'6RB_H\.O\(*CR^=9898$MZ:5DQ /8:U]RZ=P%I
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MI&E^%NZZG5#XX-[B@4.HK\MFHQ3K75S!=U)K]@FIROT>WS#L2CK#8'7H6KH
M]'2=ULW[84Y0']9RI+1O($$S/AJI[9^YOD<PHB^>6T LC/H\$>S'\EN5BP7N
MQ=(N#>L82UE_+=<N>B+ O[>'LT3Z,LTUSHK>'.4G7>72P]T*PC6TL"[X9]:6
M-'"K:XU"AZ=!#5M(KRVAGT4E%$WD2:6/+;A<;%D JC95;94U;!7;R9><B^F\
MPKB?QI.T8<,V1D574A0Y4]_IWC16=Q]9_?%3XK&LC?_G/=VCD 6%4!FY&UV0
M9=:'NJYS@PZ<[GHF.LQT+6(:/7%O30?EB1W:UH*PR@VT'KIW'<9Y7QO:@M^(
MZVPJ#V9"?I_V<327.)4\+[XWH?<Y7TS@>DE0EK]SMFMW5"V;ZM9\YM>$8=SP
MI8,KA7FU+FP<J4744+Y;13<V4L4%*N0Y59<+06:$5.V@B1^X:OYXR \C#!;\
MTBE%W\&$K- -- 3)U-UY)>A-UU!841I"3>-C,^$':]C"P+I0Z E+GEDTV-X#
M<Z3_P?K3)VR&I9T>G\0/G7=Q%'.S.Z?NK)H%Q-=5=<L$7550GGWU9J^C)4FQ
MF?LG35(,NZLI1,/Z:Q-#%Z<]#UD\%&_$4)3D&5[V#/6EM#3*B"JS3,2");SO
M\U)KU L%F,"E]+D$!VL<OSXRWO(&'07!YQ'$/])BF*8** 8'?4.:3%-VF;@8
M4;-=I*?N[J6_9:K%MX\HZ/K.P49._=6F=8]7"R?$L&5@UTR9CQ5Q)7S2"4,<
M-*H"V1%6!6<"JDX94FW-?7X/GFE/[._H'7GG4(R\"(+G%J$O>TRP=]3/![I"
M'^@%KH)&+3K7S7:<CLC6YC-UO-MY,4&[U?M^&KQ+7"Z;5[R/B4A#6RV%A6H'
MH@<']7[F9M!D_5#+Z1=H6Y7GNB:;7(=M.CD>)G%'9H!6=CZTS@DRAQB$+]^@
M=L><1%)GFB0P0J_30"U9I ,3J*1=^"VQFOW:QG@@I.\<_9*UL;(;^CWS<JQ*
MRZLY5N"0)5;X<""H1N$;PF;I!OWLYUB<&U.Z7R*MU:-K6K1X(S*6W Q@"NE!
MT,BCX+;:<[UAD)&LF)7AFA;5.'_1K,)S?]DE-:_;JR_$1'7T4F\9.UC@^"(<
M%#D0@<'HRF<[[ E[RV9PMZ08CL@ _4+Y@9\5PA9UGLBMH2W+4_^6QR/833I%
M-KT'CX\,%;@E!\&9^JI\OVW33?2,K8>??0QJ$B<&N41]>.%!*KT-?A#EF+0N
ME&C[QNK=5F"%#*PK1H9,U^YPM'(^'!,7&A>DTM'$3C@7G69"]!;*-IBW$,\I
M)X\FV(92W[7\#O#GAG@0C R%5VIZ?RS:LN^1!M-PW_Y&H^R'<\X+A$(2^D!R
M,I,-[J9W(2E$&"R;R1'Q^[I439[!1+>C2M17E'-J14564])K)F.XO)5^ $G8
MJ+$[KO/'D.FKV/51$%1(YBKG7#ERNS?<8)9$WCGI]MN\=1C'T:[X.])]>6G/
M/O3*+]M%)=5_#-MJ7X9C[C)J4<GQD 4MR_@8#95UZ//%#GJ;.V ?FV& NI&U
M^<A(4O+C"SP0Z&W]X@S$0!8GDXM,>(3+[BL++TRLQL1[)?2AW1Q7/*"%W]-I
M%^?E:2AJ6@GX5X&ZXV7EC?>G'&\<E>.SUZB&PD=%UE#1<D2X^?D#19F1&-E'
M&%;ZQ]M]&N++"8&:Q@%3>, HFU6I*.G#0S[I& *.JZRD"UA%. 2:O8;"^6=E
MJ*2,E\$Z<-?>,0C[DBM4%?7P46<.MNVN(&Q%:J+)8[J7IMPNTZP/,N['@]_E
M 1.XRJ'<4+,>G1+%HB-%PE8341Y9'Y!0#=?A[:K4Z'67I\%TG3>>2K4=5%_6
MASH"W-G/'W?B--GJLO# /3P@K)BL[GEW_"A/S=Z;Z6957[;H\7?^"V]2M0CI
MD/CK)8:=$MAV81QQ WJDWG13P;$T\O5E !=PSKMD$]AFE*D.&F9\LH?,K%C4
M3NK;\-TV2KVIRV5!*5JLD76/$!E]G=;)PQ56V:QBZ]U/=^F%_1WONL7$A!LL
MM0\HGNI7@QZ\_WU+TFYSRDA'X$U!;SM AH;9O^=N@<Z.I;I&1LGG^ZM>MJ,D
ML&\[B-""U%2QE]'TW)9:-4QE<D^]HJZ3W^Z=@@3_7&&^8?IG"FO.7>AK% \3
M4H%0C%++<N&!9(S87K TW\F1ZLU,^:^'TB$W E&"L:5%G+O>/_  U-NS(J2M
M:^*&X8BN8F2FB-Y>]_+[BVMTWS1]7WS7?^:XFIO \HB*WEKOAB6=P"K[KHIN
M")P[\9$$ W'@54^;[[F-%&]J["&QVYV=!S/%_EZ0ZX"8)U17&6.9J5U?K^RV
MXL3'[SFCEYY^7>@^J$W-T6<I[6N_E2>$&!"[JS?05!?)]?[BAF4#9I'<-JZ#
MP&!P(D@O 5?Y>ZMHUGF3L*3@36"?X8".%&P&SL,J>O=F0A[?6/55' 4>&(7!
MFQEY-ZD/+L=@ W7>"A%-J0IW7.7(UKC8WDKB[#=!F0>UI#'&>1FZ;:-+!K]P
M??.R=\6*B+8RWD\[)^JI^N(!93I(G:]S60FEL]I ?O2GVH;=K2/8JDPU)UQX
M/O/XQ.6YC3635"&!/$XKP4"W^@X>L'#KJ71#\LS=<8UAN)>3+J;*:1[H#('
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M9MH2?ZI,!O ,+9B0D.4HX^$!=4)=]ZE!(E'URO3>:25@Z:G5$\,.\:A??B#
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M\@)X>X?Q=Z4\^.>)V-;W41/FP<E(,M:,K@]7:2,6TI^8DS=FJ3[2%)I4JUD
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MT[M7@4WQ\NK&_"#47=^*N!V;IY47P,:ONSO+F]CS(['N6<H>:P<#K>O%!N^
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M)_$!%I6QW"]?>[_Y]PJ&6I6B&C742MIC:7]]<5S>V..6L'5;"L(A)S(!1N@
M)/J@LO8[RXO+<G^'*RVD]OOZ.=6MLK(R]YN]92)=ZOBV5^G]M)Q:WXX46*?2
M3"/RTCU_ZR@J"KT+5F5405[GU6U\'=+TVTPEA.(U^%]OI]1/WS":L$.='2.K
MAKW7M!WUM&6XY47I6TYR^8 BH09%*E6P.%J^YG%^+L5_?V.7I_A# Q?IVI%
M %'F=QD(H(4'WO]8UWL*]]Q# -G>M&O-/0A & <!I%30\CE#R*!=!%]"-/Q@
MG>0R"AQR_;\:3)!FK?$6LO #FDC)6+GDXZ9Y%^TB7SR%;;(<S MTC*PP!/EW
MZ2R&WHV]^"SYQD]DDO4J&IP_.,LB32Z01QVM5!">CP"^EN"BM#SRU>#=5*]@
MJ&!GOPDB<8 UV\_:>P>,(-M4^EXCP4NO4UXUG"W29AYR4GP['PY_RW*+.3!R
M#T8O>'%--=#9N-O3W.@I3;$W/3&VPG)%G0A1#M;Z"0-]N.$4B$M83FW]L-JA
M\3=:*%'5EKCYO4!DTOU%8=?"@[]?(^' 9_AX5CRT?<_/A;(@$4Q6#J#QY%:@
M^J]X7_7<$$IJ1Y=ZX=\)&,7E.RA/#\@V4QC9PV]4,FQ5&.&6X\0(("C_P(/M
MY/I7[/0/2WFP*@(@IJ1H$A8#%PZA0N0)NE3K_QT@4Q0CLR? "3I.V#UOINJ:
M1#'FCX6]R:U7='T*9R^818P_7%SW,#F=F,XK:HSX<:&C+,]>?P7)/F=AI5?W
M),;+:HO=:-WK L3G^T?VNUA3(^5Q[#Q(E("*UTMA_TEV(>_=.P77&&I)73I!
MFW:IUA=*;'"! DJ2!3_0FG#CLH92:Q#>U8R WN]3%WO&:)W\U#-ZFO[YZ!<7
M18PN>]->)2:XA -RP]K[]S\HH)-(Y[ ;I9NPJ )^[DN*XRN!4- Y-2ZW0E*A
MUL\X(T(BT;$2KL$:<N;WD4;32/"%]24F%>F>4.C^Q>N:[ZWMO#P;FM395L)\
M(UK=2;AK\VB*"&#-_DFXP'H2X^I8RY;>51V*!'-; /_&GR8\O,JDQ*YZP/9Y
M5[UQXZ9=+;55/,\C+(^JK5I)8,[[\LC?Z^9:-T1<-$53@$VJZ#O7MIA(?B6U
M0#**5I)DRXR*<22%.X[,9D3V6!'#*ENNH93Z/M>O=+?^'FU3,-Y+% 2P *IR
MM$\U>ZZ%6T.'%A#Q%_;8^3R4W\_;*@H"^#.QHHH5\&NGTV]H#F@7!^ /^2&%
M 4CT[=Y]PMP1W<G3H#P>!#"_M>S\>60(9ED,]=#94WM'ZQ4K)3"&ITZ%V2/#
M1QRV=0GG0P">MYY3*0P5!K5CP26/]UEDZW*&KC_X58N3X=G'?F5S9CE#QT7>
M;!^'T-DE"(1D>3:>[>;AFQ$Q\C#1@46Q9U\"F8%W4E05"94)7(P0M_05$"@M
M,A[<6FH[JW?^,C 4\A0=J-PN-X^*C3GTFP \TX*/!ZCEAW/#_D&"\>I9"X8M
M=%_O:TX=4"( ZZSMBI@'\:VGIB8H?>2$HJ<O^$% LDO1!_TE_>??\B]6L+,W
M244=E6=\ BO#VI$H%,ZEY9F[O]CK(7U"TF$^*.SL+$(+&LUB+3G!#2I6BA.7
M\]"^ :7D^.^,G0EXCC%9?I,O@V<@[8E]!U'[,7HG1:ZH%9R2&9%G4,FRULMJ
MOT[.=\%BJ>-V&B_,>L=<H]9-\MTUXP543IG[Y[?Z9YQ<GJ)>ZL'-Q@F[RB&B
M.=Z7FK 7KDA>6,2:1SU8]FQ-O6C@OA*4*RJ8,;=F_.JF\XSUE/$7<B5FB5^F
MK=D_D(45'K+^*\-XRP^+1B,3KC_ALI_'F**O9[4)#8J(Y?&&FX9XSN>@%DC3
MD?&R%U4_-?!(S'PY>)^8KV&MB_Y9^_I /A!4B[%TC.[@XWGUTV+X\F77V*.P
M7#+JIFRZIZDFI@BJS;<D;DK?&MBAB.EZ-[W,E[O[1[?OL>CC]#GJLL[2A?$@
M$NSB67&D^X>2Y16,?HG'6I8'ZVFF6WEMN@\27V3)1E\@"4FESS\2'?1FV^Q9
MAI!QGR7&Q?83>!:V<?#JAR(G%!],"OD8OIEUHB0D[S0^=C5V&]?_0I5DGJ#)
MR$S!OQ7;#6(/Z6PJ&[?SWG>V_=$[NXWI0L<NS1=146E@=R@>79F5%,5&>UV-
M4XG#6CO@Y!$5IGJ\L#!:@J2"G>0-K)\05-['+?R>-WQ%47T%,6SEH_^S^FET
MR7XV;56QA3ZD[KO9MO>HM6U16W6\12HLW?/7-#[K.%+&0J0A9\]52,Z[BP.%
M.OI;XD%C,?5S3.P%*TFT!R%O68>*R[35!'DR338AVGIQ<V_^G5*(4J$:/1AG
MB(81+>N%Z=@[1[L1[H1,;LJGT'P6=N-(6V.B-$,;1GE,C:UQ!% SL]:QM!K#
M[I#"TL [X:!41E;4R5LQ"&,"/FL((0"GO,Q\3-GKQD#)F&T?!T)+=8.8M(O]
M/I<5WKL\(%&DM*42+8U4J&P(/W= 86ZGYY;.#$^W YI^B-4DHH9A=JZYW0CG
MS,TO".O#B\(B;P.'4.8,_D+'D"-@6)PV2$WIJ!6=A;_)9S*O20L/-[.D?8E'
MC#1$>%DBY 1_(5^>\=6NHR.E<M*!5-M5-B8O]&% N;[1C$='Z)NPY*?BN$M=
MPO-+214<FV^6Q4691 7HVAKF"PVWNL2)X*WLE+WI<'M,LY_:QC___MXM'M][
MS,I$R:AJ:&WCB,^F:KA?=E#\M=QPK3-JYYL8@\6N]COT7%&3%HV(BZ9$O:#=
M>;@?]5=P4YV\_J(#"D A-%\0;Z_M_BY?02Y$K3<' >"\;(9YNQIQZ<>\O]E\
M47NPZ2E4IXQY]J,T[Z1O1*EZ[$!%/\%-\_[)86)B/>25VS^6*6CR"#?D!6G2
MC 8;RQ!,'<)P_,_[U>$ADS.N4")W8& F6=B%TFB.LQC=KU^@!8J#8QZVWE6,
MO+](_>G8%]=<>E#E!BGD:<VL(!EEG*Y>)EC"#/'X8*MF'KBBR"R01IE86J:6
M7YDJ,8"&\3M/LFCI8]S5UI+LB51\^=:QJK&H^M3-;$ULKV9XB:+-A340]\B,
M794-4U;8OU)(>04N=ZW[\Q;4B!P'7U_Z:%J,\3BF#L.^O (YX7<[S&,(]0[J
MP"$Q.W,?!$)<@!^XZ%<LBO +1_@:?)\V%XIT 48 V/JV'\@^*QF&9LI5D:HW
M9DK&>XE$,G5 "UGYX<DU_SD6:DS&S]O0OJ$'@(J)6 KSX5XPB3;;VUXZ/8&0
MHH4+:;N4B*ZRJ0[@I4^97RZE7A'4(9EC-#$\Q3PZ+NN%/FKKYV?K^14_&8\5
MH^=+H4.4D:E@&.:8".#(NHOB&+3LH_*#(BP ME>@?F($L) Z;#M1R:C"LD13
M=B!':O;7A<FNPR/":K *939!1C:<8@V,4;U-L4N>T4A/&-!,OLY"""9Z +$'
M=6DW*VV6OB76^,%O453PV.'?ZWF54F$#II K'2"NPOE2Q $?O&6( =-F6Q6Q
M.G5[8X+*+O>533%?KRGE]Y:+B^X^_7 CUG7F''J30;BAR$$=VVVTG<DZ%-\?
M+[,=[U<OGZX^=OD<8O7/[.-2$\Y)T]]*[P)#L61\$W0Z:K4%7T4*F)%%C^V$
MJ\>WHD4MY38BJ&T*$BYI$4!HP9.L^O7W5T(+-J)'?D!3_>14&+(3 M"^/,C2
M1IMF9_7J:FSU0\O6\7LHNVYC>*2I@Q\R(8#D* 0P(;BB?!+Z*(4 ,M:O(\'O
M8D%3"&!W_LGL0+_:6Q#^3O0\95M$?=MB"Y;=YD-2[WW9</1@1-:Q0%),];MX
MX(2M*2&%&C<#JZ'1B+J,TLHY+C0BV:*<4Q97ZH@S65J"[N2A6:SQX)7.$D]T
M:>+,SQ=J?P:32&4HU0O!MO6+"A#NW-^"HB[S\B^5\,4JL%]\MIWU?RR"6Y+P
MP9*?):EKIZ;9.P8K8? J5-X7?-=5<W_)T/Q<K3Y.K[0ZLLC \M%=9J8QKBG(
MC$SBWVG(IPM:[DWK+\XS0CCHO)W&?J'6;>==]?%$\H -'JL2 /L=KXP9L!-O
MW^>EN/Z]$<?W%:L)+CJK[ERQB [>@.=U3=>E^3)H),;O,>T..H\ QD=<-,C
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M:4\TSZ^"C*:K"X(F1VI1^.>CO+%\8OA.3MR7MH,:I0D"%M1;S%J2<9F*P^7
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MGX\ _']EC,%O?Y?:_/AB1XKE0V/?'3OV<*Z2(/D/:)<< QCL0>MN9TP^EI]
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M 2;8 MM:A3QY1#<'PJZO-5YGVCC=HRF\"10MRKV+NZ4:QE[,VF2\O7DOU12
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M0][)92<4$9U0Y9D%UVE-8KD<3.5(_Q;[1QCL<GQKH@=,FU;^#!J6@?GBZ 0
MY:<Q_!5ER()LS<9TZ .2"2\IZ8]LGTRU#*)]@S?,T;3L$G'I6]\A  8! :'5
M'Z;U!!Z9U4 .OM0.\TCA5%AA%%*O:G*1"AHO>S9F>$78E1D^AB*IJYR43%?!
MYN  N-C\BY\>JMN.U$^*D7E:I5+@(5<[2DA <_ZCD9OJ?3/Q\30Z<"/"6>EW
M,]^33M)D,VJ**+L8!P=T1FZ<T[#FH,R(L(P4%B0VN4 6GHK"C"TH.W@ SK:"
M,\.O3A.9),2Y(5F>%^%6KGED,T&BQDZ38%F@.;&' W+BCX.75S81_[!P^P?+
M&_Z7DL4S5A0%^4FC2BS-8+R7!C_/N3@]*DBT^XS>;RE 5*9H$ZV%OJA1 "V%
M!QX@\1CT2YV[S,2#F:;F$<E4;*VSOD:Y#Y+0G#%AGE^*_!GWWFZ>4\=>LY?S
MX:VJS)-,MW?8# PG^WE%(#+N=@BLENQIYBC7\@_4CW0B-)7S2\$TQW@< :B?
MY[6C(A(0.Y>$K_B!#[1#;#(1@+!*3:YV)EH;C02[UQ'4QA=\=W(4N=R/OG8'
M#8WN-;MYN3LS7HF*'V:ZJ4/&05M&RV4W!],D5 KP2\$HUNJ%=OZ'%>CSV2I)
M3C4M\G"@N/LZXVW5LUA-D[*6V,XA,KP0WK?>UFS@ "KM]CB<J2I  #;XQ,;U
M-[K_B-VZ(0!+3:<<U\KP5+$E#P1 !@&XB&O6>H2_?^Z'/R, 1 A G!5ZQJ-Q
M(YP[!@$(%J7FR+KUS_GD+M,!JUUU,D*?^=!)Q5Z]K6=[?G!1-]^FC!/J7]BN
M?Q+($?O@X>WKIUM1:AB(%R!#U=AR\G3*XNXY:>UH3Z2]_HV?V-3)_I2LN8>!
M/S.)([$,7)HVQ"7#$RAK+@VYJ*@Z'JW$0(["6":ADR9D(7LE@J&"BQ/2G/C:
M,F'A?7:X:%XM7=QG!*!G;7"I4^Q*>Q/=X9;/[+%]857_,NX%$<V<.GN>1"LX
M;@4<$MHY/PD76RVK]&@::MXV\-2/;):6I/KP[$<RTP.+L]?0VQHRF09T-Q(T
M-##KZ0! :X%<8?==*!"Z(D67"1R.'OH0])'QIS+27#\"T!LCZN6O =M:!U$U
MUPQ0O="J?+N5F0>:D]WIK]P[:I=CI\::R@EE;0HJRI&POEGE\NRYFS["A*@#
M=K*M1>4$3_WLS$]:.SSO+%A68E20:GHGCO:FHK*\9/GYHO\LAX2B-Z:FT-T'
M71_^"02 /N%^7[UX:O(J_:.\.[>HF8[T'>KLD0I96V*+:O,#^I^N1W*RHW4H
M-I^WENU[44U4EA2?:VAX/X5@OI[>R;"ME.NX+-Y)N6^'OLO+=L>*R(_#E[8H
M;_1VSJ<+DX9:<>JMZI'[;<7S6!@VUB24?Y>FZK!%(MV/ S$:[V'_[DY! ,R]
M& >-)L86[LYZ%9\787H=C.;V$U7:DJI2&J2<8FOE#IU9>L#;WKT+PEDN<Y?Z
M09:R>8SE'.92W;+#&%AA2M$NBD+ZGUCG(![[/PL1,V6V0&QQ86Q7*4&VQ4\A
M(AF9Z P;;)K.."R1!SP\=/0N: UHG;K\#Q\1@!^9<XX7ES2>-]BB'/>%9ZV"
M3O>I3V%XEG++Q6"E:0'EK5?)DP<D_2Y?31M>(Q71<E$]Y)B_N7XP#HWQ5>M*
M6>A[;K3;T]LKK$$V8QPL![W+5E0V_@X/*!8NVYDS><'ZR3V%!@0@78JJ[W[C
MHM#>TM-K(+;L[T"KM,PG\2S/&M>=6HUZLUK(4&3P$F<ZJR*1E/STS+ _I &N
MNU%J_2T"Y5?NJ%-=:DL+S6B?K&I\4+R2_^+,&, G\UIF?&6P/1VOQQB++)67
M+'PC3N)JT_\GEU5WJM<5^#XXYUZ7_W(.;M>NP-#B*T;<C/9W:37IW?JPXZCT
M'Q4-!B5N@K22G@I'K$!)IZ_QOZ2525&2)"E%/G;R2M%J:! [/95Z4:XOG!2A
MLX&K\XH^;4I70\@O7OD/YZ,%6TZ.>T+T QC.3]X4\;Y&E0&X;^-OBU^BY5T[
M/K0[O;19[2[*LU^,PR>UJZZ>CN>+NN.!^T?/W<GC9Z)3/*1ZZ#[[MM:_DULB
MO?? 1?%T?1^4)[!YIOLXO<OQ&6[5A3L&VO*;S4TJ,1S[8PO'W_%L[2(-#TH+
M<D>*I#E]XZI[6U+8FA,VR\085H4M<#&I:76E#.NY'IHXVVT_I]ON%U)PN48
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MM=YW'\AQV612F2P<5&1HV2J/BX*48 3F;4NIWUPSWR2_:)(>VHLF'0I<:TY
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M"K>CG@15>EHI^&O=WSUE!TI:.I-;57,FFC:7G"P_!Z0M0LQ^0PF(I4*A^IY
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MK@05<JWSJPI4S.^JL_H-J]17"O>,C)/&T2DB3LU<#23LDTNDAP$(P%RK0;M
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M=QX\+J(#7F3M!?6Y5.&D0:QVUJB$9)D)?>%'IF<N<>K-_TW'U-II!\D>D4(
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M%3"4]:]<DY;YS\C!GI)GP%%[]S-@%N3S][VGN!V:[_4CAZ&OYM%^47VDZT"
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MIQ@9&)0D0J9D=*2CW.:ZWH]_,<(<P](T1,S9/NORFI@Q6!$ W '@[,U+^''
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M4Q$OYV.K9O%>6K!!PCO&%\>-HFW1>4,F32D7(Z'2O<J6$E."= Z_YE4OKA
M1KTLU+)C%VRX@,;#P>"#%LELB<S.6&*;8M+TYE6Y;<PU.CS\'NEO^DTS_@6.
M? 9\"'A[P_/E-EY=E)_'S*0E;&7\=D$LD8%Q)=I574N8,4F7JG3\9"U?[P.S
MJ*0"#N\E+@:!P[?A;\NM!BNG'!)),_6<32XO;#1+*S&J6)7?URBXJW>["N:N
M.WF2Q(V@G#DJ16?LR-9BU%;R.=!DA,5""U.P"/F ;VO<8+L>BV9>:#\4:E>@
M<=V;_HGMT$?.&HXI!__X1E?](GJ;BKV<DLSZ)O=9K4(Q,K^2?'(.!]KDH3JO
MUCM574?K*WZJT 1\3TV]5.I(2@]:WP%3X<,Z9<PF5WEJ012@]:]==)4LQF!G
M#I>X.*=+^*I^]&<_BON29B]/9.YF+ZG-/W%M_0>W&SL#RB&0@LK"P1_)ZEJJ
M\])XDMP22AC?7:5JJU^98#4(6Z1^7F/]JW=LBAE'15$(N"ACL/V_X%XJ?D_K
M%(I1JZ(N*>GHX&4<_4F#@BU"&1+\5A2:@_"XCG<[[3GP.'=K_M3Z-ZGM'6%6
MM?#KY;E["B.;[+GQDMIG3,QW'%3(P0>$@!D//&7!A;FR$O.OS.-TU@.UU:16
M,>'8ES=K;$ [:ID]<]:")>OPX&3U'^?DTN6-62V^G7&>J[5%P59!E")7S([3
M'S ]PIQ+1$\)Z<:_Q'T%[5_ NP4>&WSU*Q">?AR<6O"@PXC;IT_FEE/SDI*Z
MB64KW#.[[)F"YAJ*F-R:ACC*@GCN'-Q'Y:.2V$DRB(T2'AHWEN9BCI/%^V#;
MA.MR+<L9T7PZ+A2>+5,]E3G6.^G$LSN2*H>SSQ-[%2KF\\6C47NAZ)9&ZPID
MLL33$34B6H#+9\"OU[!L1\4*D+:#\E[L<K97MUUY.O+3K7]%QR7O@]YAS\@N
M)-Y)XV18Z]5.MGY!Q=K[63$1FPV=Q!O",N ).T_48XPB]NG4&]/1BQ*)KPNY
MD<:B1I$E=^H9^^I.^$/\OWQ18FC9T80ZRDU42]LK4E@X]#+_'()I>_;6E\!8
MG[3-/<^&B3/V89B;-SH/ZV-A1*^N.$Q=KEWG-*/D.I9R96P;YF^:7>>TN=1&
M,%*"N1*7@9Y4![E6T7Y)O Z2E(%XXG*VO'B 77J,%R&YP)FF%YNV/L0[J919
M^T_-1D:\22:O^%%U@Y,P7VLN9]0R6J-C$ :"1WM*.N--P!R;^W;=K9OJGE:C
MRP(']0)BC19G9*MUEYU.>!GA'WH:4E,NMQOP4NIF+*AS$V>\5]"+M4/3-&E>
M.5D9_/<+"0FC)0<"3Y+3.Z[S,6)YUPF<$9)"F1Y5YWDI2Z305]QJSJ)7T+J>
M;]J7-2<GH9?*'U:,";[8U3_253RN%/9X[[5L:ME7Y]XY]+2K2=O7"%[K9,FE
M%0]I<\M4%23.4?I4,9BADW&@$5Q2\(H*E0=?:L3)2*7:$*D;6*44F#%*TDOG
MJW^;X;X+694?\[WR:1%EGEHG<Y5^(1@F$*27E%A16.<@-]@U,(BDXK@#RX>+
MPI@NV;8IY+7\;-<%-NUOGP$*6^SSJ4^^P1L>CQ@*" &VJ/QHZGCWN-JX-(-F
M5$548%.%KEF!;4'D3IK#>VF#O.\K#EYQ;._(&=@K$HW%7UC_S,]227"_Z)W@
MS^X:V\L9 J^:"QC,#+A@.4MD;ETDE+\)EZ^$EJ/*GU,&:JL*O9/;W#^!#UUV
MZ>O/^#CM1:^TDY^/V$-KTA,V;DCD/;+XCNP85L(44K(U'!PD+3PYN*@%*5D5
MOTFX!]'OYI187H3M$'PET8I5A<[JS6I'#F;41L&KI@@?R\8=L&9RXMR<M?LX
M;+)_7C"4:<6_R+++\FXJVRG] C(>(?A]9^O'<;_WW?*T0[WUD:"=)Q;_N'II
MTX?,SK3^7H]=7A157QS8M$.C8E&1Y1&[)$TBBM.:QH<G_NUI'/OLSG8!)C,K
M8JNN6P$,%.&:0 W8% [+G;QTF*0]B27;0VF4L[3N1>LCUA1+0D?MM)49M,G2
M6">HXU'K^7_4P W/%X_CP/?VC2POE]HMR&2N!+062IS-IH>,.]\7VK;EC7^7
M*EB/<M:L9U.:C%VBR*M>+;4OM.@4XM&.:8S/5X*UI(C,3DVI?ON4>DBAU,ZH
M]:9>#%[_-FDI"83R#&B!@UMOJ8.9HEWI*^V,A7FO_@CY^S2?WGQ.W)D1]B B
M,G!Y9'KDWP/6 E@4*ON31!+>*H-.NI;7RL?=Z:8"P;WSU.<>GH9)J"^30NN0
MKC -8I(12MG[CS^S"KY"VQ%+3G=5SP!ER\M(&TUU!'F\@WD3GC E%UZ)S15I
MP.:O+IZ:MWJ^E"72M">'];_72)8,R -"$-PG%#,&PEQ1%Y=_]H4N9Y"J=) #
MMR4#Q,LYM]VPTZ2*&4?\9:2IX$OQD(,5K[HV@S^@R1(M>&_K^(I$A9KT#A19
M;1Y3I']QUNP-Z**GK&D")XX2\2L.;CU,MIVK"Q5T3VT8L9Y/VX4*#C*#^O+*
MR)>Q!;ZYKRVB ZKPRA++)R__T_*RM5&3]H*VRF@4F0\.;MJ$2C?J*V9M[S#R
M8VVZ:<9M9AI$P=1Z6 &+, ]AA0"QB,KYG$^4#<7V_6Z#A2)_9>#";:4^40TF
M<"B7$[98>,^7-OE%_?I'3[H+NGI4%/$W;=C-+W=;M]<B \L[;XU E<GW=LM!
M/13*-_$],C68&'-SVN3&>V24['IKVE <4910K?(W0E*ON&\@2LX:NSD),,;7
M$.(L+13C)S>P%;:!TAR>O=_P,X#[RX?O2\?;6HGO"/E^CQ)B4%!Y(,&T2_9)
M/)WT<,^G%_?2 "*2[Q4 ;L.6[B:.6#R8]P='QY(V7L[.XL08%BH!:XOE5UY[
MBJUR(VRS^>9Z4AZ\$(!6D7*N8'PY45#JJ!5G,^LR#1O7L2[4CM%*[-4#U ;(
MB/3[RA1\OK/*PRG/.TSI=V$\6:-WDJ9/C1I9Y*S\\/ZERZ&(_C'DC0EY<E5H
M16:$='\%2HZ:946AH,M@NP]/#_+%<61-YN3/9@@$LCIUB?EK8YW>R"\0P(YG
MX#>W& @5TMJL+105#$O3N7=B(;/ JQK^A#) #?#F>3GT$._A4*FSJ$LX4DX]
M=O4,0).Z<,-+7<9&XX\%J-6BTW:[\PWE\'_^,E1&X$%1E8UUCO@6O;F"XSYU
M\0S0OO?_HO?H[D$C,13VXO/L?=#E]2548(_-=>=/V:S=$PBDCK@[">NAHRM9
MN(W&SJ?A3$[.RX3<?W'T2Q6<"7W#J@-=< ?7$>P_ _0?9>[D3N*OW$O,<G'*
M,2#8KK+D;1 *UM*?9PS3Q.'S/V8\ @+R_[[&."<*]@;3D@&_,K]S=.O@JHI7
M! >"/W[Q2B9++I")E62NBS3'D=R3"E=+[GL=G?H,>#=T_VC@8/7UA10_<_.:
MPYE.Q(&8*-77<E =CE&!SSZ'M07_ L<68-Y2/VE3^1!L\]VSYM4$KU_;8LE[
M<3R)J".Y4-I\6]N95%#CXFQ%XASG5R212S)&PZ_F<)\''5^-9(*R2:(AC5S)
MUE.@:@"C9OP8X0ADZ8M?25Q#@YZ?/Q!375<P4ED94_"E5^(>D)$V</RX?PEI
M1/#U(V_8;NB4S-]G.%E^Y];6I-M=^/'AQK8$0%B62'W05\V]M%^(5 F,4%+*
MI!\&,U)HWH3%BC4DCJ;-L5W?1MGY(QN*4E"K(]Y^32/M(]]1&=8HKQ!JXD,>
MR<@53H&4*5X2$4P=F>'BO5!9W-]<;KOMTPZ"-\X>^MM0D2&+0K(.AR??%X'8
ME!K5M/O+)'K3N('L[YDM7,QD3:^;[WL>*>R.[SX0V#E3?(9UO#XCX6KE]M96
M_^0\WK^X*PQF:RS(MIJ:^NRBFQ6EJJC0EN55Z6:H7[ KP>#VH J6_82Q*+B&
MD&GX>2N06HZ+?%7#'P6+&S4LW#)WY?Y(ZBO#_))=;W=VK'RU\=Z#?T9SV_7:
MPP&AT'%1STDE0_W67)6ZNRX=*4.*]<>?N6Z(C1-K"AP3 3F8O^4U),TLQ+QD
M%D$CM5&B<.!_;?'%F"^/DK$DU8"S\2T;S7#=4]$U*-YTP7O,-EV5>A( #O2@
ME?SL&I$G\P&UFXS/5)E3[;J$L^]82&3<D1$EB.'B^N-,92:^7FO3Y3")LG#^
M3P'LA=G)ROX$U*@S+R[CX\%OWRY OY\!#'_<&B[[=SD-1RWL-7%QB1M5-4WU
M_$,FXV6(UZK5AOOE*>/%'BC;:3>SLU\_ ^IN*7*/Y=84&7[X=1 YZ*NVFHTS
M[GZKN_>K".G#>P9@O6U7LZQ4B$C!=97GQ'PU([L')TDH]NYM!2D)M]Y9U^;F
M2Y5VZU8\I91='FKNS[Y-\QW!ENZ?0B$W4/0 #S8>SM7'3"X,%W9WT1?M)C.1
M("&8B).? ;04MYO:N\T=WQ!5V$+H6["W4>H^*[=;^H3?U43N\5.Y$52<RNEC
MDP5L>"TMWUX3E5A.R&.H^2^(<P-] S)D5ORBB;]/<DWW]U<XT,L9-#!0^GYJ
M; CCKL)(W%=$>^AA,PH2@+!O;,AH#W@CDP\7*#JN2;Y^P9"\JR1#Z7.=L482
MEY966D425QE5F,97'"$;H<M04?SBQ\?WQ6X?FX\MXG;=3,'6IW>X2G.0C),?
M?Q8_[_%9%<^FH:&@YPW8NFR5B'!OB6L2<@N^-V<6L]9S78G@L3%8C?_307#U
M))3^>DTM%3X)8YA:(,O\P-_\QB<P$[YL\ P0+A+2&#!42Q9K$VXVU*)[<K8'
M]U.4M>BI.>/G06'7=6(QHAP:(7VJA/"*N,+(/35NB0='V9=:%&<$K2U?P\<I
M5A&3RO>::%2!%E'.1_2U$2E7@2\;?<<0%$<4AZ<_30^.CN85=(3QE-CC02O\
M3EF5L4KE=!3*TUOS3K=T3T>K6%2+3<\ MJOKFV*U1%E480^$.UKI0NU7<G(!
M*%H@:"-\Y^@$%#TS1>A"^ A>.B)8 Y94BW.ZNE?  X1SC[:U:\(L?K/?QK57
MI]PVCO8H]U+D>;[!TN/H245[Z/Y5I%S\TL/"$F"LV@BN>]A<=<JM1G<%C?25
M_QZ<AK[_Z.B8-@-:HAAY!IB>=MF'O?QJ?@+E!.A@,C\#D@ '\1Y"]MK'\(=8
M9H>1=QS1N:!=OT>;\#S%>MA!Z2%VO.H#N([\:#Y$NUHD]6_TW^Q8QCN"!!SY
M_W>'G_U/&I:LC NH-SNF 3=C^KFOWPL]UMB0N1.%3SW>Z3-B&1Z!;Z0W.Q:"
M%DF287^#_6;'.O^9NC\;K*?'HX:Z5OAI_G\PL^9_SO"_K'O _XJ+^6?X9_B_
M;:@PA_6#AQ;AY>"+ZAX<\!UMSU)>FK?A,V"2]!EP=2:1O4@(.B@$7=X4$IA]
M7O:E;J@X.!_#XS$[*__N*G<[PS%?HM7[ TEZ9N$NA;2Y/</ST3M;'B52Y&6W
M67=1M<)^K5:<X<*IRS:38/$\@UX2N%!1L(<UF:L=./<Y.-4,Y9QJEP3!]Q!_
M2[<4MP%'KGF?=^CW\*%K;PLH)1#9_%9HJ"U ) A>?S2W?*"7<:I58/'&OH+P
M]?4S0',,&8&_\_"HZ^9R8U;,"_H0?WE-L6JO[910Z?VV&?2.__#J-Z;PYW =
MOWEA!M6M\#L\E4EZ9RCN6IT@R^JE#"A;?\503>TKTA4WY"3_SY9]H1<626OB
M^51IHC*C+6VNQJ0"WFG*D9NFX@>F:D:9F0![R5I[Z>M;=7<)XTCE)5F8.^/J
M5I+Q]2=RO6RY13PT@ :%4:.ZL)RM&\LGJ5Q-)/2X$E2NKSU;8NLZ#"#H,V#;
M_EA=Z4C#6;K@! 2%/XC[.%BUXGH385U0LK;1C4_%&X=7CW,^.#*Z7 1JX">R
M_6BEO4,[.KDEL,!H,C\I>Q0"@CKFDJ@ZK&B;1%SME%FXMN9&;3,.^Z,3J@HJ
M<JW#X_2L'M5?5PC6ADWUQ8E+#U,M.,HGR!8]ZN)W5T51-('3X4($LDCMD)GE
M=9.H2$75,-YPT&_@PPZ9>=7:A5J'?XVE_%B!1,/WXK_5^,LWDC77=S:MO0Z2
MD4N)_4DV"&+W5L<]V3MLQ5V704SWP?JAJF.AU.O?7X*,NZ'K&LH<VL)Y\AK*
M-*+R@)=IBZ8F@+_A]L%7%L2I**=! 0(9JWPQI&C%[_TN6N/]@CZ?&$,K]*W?
M$[_R2.=1)5<>KL-A2T,!(N\H!'RW>&M(^\C<SO44 F_^(TE!O4I50S3 JYII
MDW6NQC^:W<.\(L88^PFI*,8X_B;\^G;["G,X7_T1 +GG-U.2;I TZ=.JG./D
MYCQ(VYGMDH*O<R>*-,_C-<LJOU?_882]]2))+,QROI?N"G%Q\@PXPMPB&Q^Z
MI-C_4^+?O)(9[6W]%CQ-WE2.2.5W<-A,RN!R'1(,C>SD,LVXLC-:Z:%^-%H6
MN.D/K  N[O)K8K4*^$GKA>+B57;&/'5T[)&?_E+#_RAD@#1?:"4?7>6OD<#B
M!&5#]-SS/.YO84I*^?.K^= Y9%JKRO+>KV3"<'+)O)[N1OB:PN@$DRRC>(#/
M@%KHWV)"/]Z)W+RM!/WI/WE>-GLUFX9;L@""+4-]/".]9]3V#/ C&X RE%N@
MY(A,#]T_ X)#02<]B[?+FZ_];,.?RJ%'(]U(^6WMI+P*SP"GG"]>1>M-TX)J
ME#(Q"A-8<?E]9E"D!OE=>8J)Q<2;6[A )8:&\U86F%IU!ATF;#T7*QE-7&_=
MIRU<45 %NUG7TG?0&OZ,^U%M3L9C3%6Q2M7.X$%+(^:%Y$2"VS4B]XQEOGA(
M*PLG21IR0L;NT.AXRTC]GFGP8^7/%". MCBI\^0CF; YC\%2=1P%4_2(ZO3N
M1[<^U=AO)H<[)M>U9,1B"4:NKTB'QQU@G\C7]3-F8I)4X%/@KQC7:7<FZ2Z1
MA6VAR\8H+&.!PNXLRGD8VE/N+&=Y"=F-3749$^T=U"M7K!^I5?<K#BV*<]Z8
M!JE-HHS7#Q,F!4;T"J*HX'G<.#&,(=^F4>P*(=EWU49;F%V@_]'KD(G]XV\+
M1%D\IANC+H0).BAJUC*.&II R3&^?@.WHC(KMM7_==R53S3D!:$!$A17[D(A
MMISB6R/H)A\QR=X*:]@BS"L2O\^S%>Q7E*O[LP]3)\HF'SFMF>7]%J%[VGT,
M^'B919QXN"(%YE2J\L#%3\0I,3=5VMI^^0-6&;:5>( @^%J2GU]MVWAWC3NN
MI:?2<'\P,SBD$$F%=@TE#B> ZZ_T%,>1WQ%>UV!="KU$O?FU54H8U:DQG8.D
MK#Q )GT\#%'U(B7,9!I9Y<YD'-<*31[)+(D**U)M^Y#&'S7W03(,0DGW@%76
ME*X:;MO_5POD725/5=G(OB-RE).FIZ2/P>2J4<(S+_%KD!XK98R2;@K@S_ +
MX.84H(P;EYP(2IY#[?YNO/I>9+,_W^=\Y_&+,6G$RG>3$[G *BV@,UZAN1"?
M64FQY(6F14RB;9ID63AY##</G*PIT+L=@ #]'*W.I.Z3534B1KN$R+!5 [-*
M2:S415!JG']'O6!T5PT%;8>+T3C9]DI+PCGQFW6*&=5J^3'""O62#@LV/-[;
MH"X&4^LL!HKT-(ZT)_%J##9?_T:#?4%:]M7U$>Q199(8=7V-GWZKJ0CF/#R<
M4M3O5).RBDW%7J-BAGP$)(E%-V*C3LYM7OJ'TVU4^KK DN?B6WR_4*DE>UFU
M:ZJP*[,;L^D%^+-WFW\PI*)"+Z'MQ5$N_0E'^@''NL]^9+8[I..K> :@B44+
MY4Y:QH5J6GLCJ%P.DG-+6=_ZS,EJ&THJ5HB_ZMXS4C;>$66:O*=P+,E,W_;0
M@T/=9DA^N;34H_5&27-/.B:&'"4?#.8PU O8O?HJKQ-PF#J%BU=7AISD;CM_
M31K YF@OE*MSHC4*5DFCWF= D >NEK7QS)1FX$KJ11V:_7@J?G>Y=75H2,Z>
M6AR-3W](G<IU&%P@U?RD94HH+&HBG$YPZ]PRK/SGCS)S%L4Y>? [1^CE??J9
M4"_R%I/FUIZV$865/W^(82MC^3A$/S48F5#]=QB^E\G@T%#EZ.Y[5N07:$TX
M#J>,$Y2/N-IPNJ*:GJS?::KO1>0645=E#.#A2+>Y6=_,"\M$5:R&)ZO4I&[8
M7N0+<GP/P.,QA^DB\J:[(\FPWVX;/+SW>P9\0)!_E6WG38@8U_H=TXP7F3\H
M3SS3TP>/5V"1O'.3O5U*8!T7DXH#:6\/J;920Q>? <8K+T/ZA>IG;Y\!*=<^
M^"<.]FC1[F3Q%81;/\J-QZZ.<'9<(PJ2 IE-#C',9_^*#"18/<5LO$-S\0\-
M6N%?>8:;3L!&I5?7513G_VD^_2E_ L^5_<'/Q-;TM7%>R=!]_-W"G3C*W#TH
M79ELTJ[L=A3]]^NI^-6^TLJ(!C\B^MT7B^K;ID.S\8KQPC/##>2,8--#AQ ]
M@+M".PK8&M/E]GH1B--:\]M5)_M![@FT =H0*J%7DOD#74]BE_ 8&B?/'Q,9
MY+B09$M/+F8P'9I"L)PTOOV(&? K37^MAG$/Y/0H)&Z@:(?NT9>_A.>Z(G9U
M0[NII-R"R.P"+1VI&4H5VYC8>K]9W%O@18S&ZXT/^@!,"U@UWOV@#$9J77SP
M+9^E((690X3;95ZORFED:>6:93[RQV\G+G7V4T;VR'K?L%,L]%TY71#<B3$,
M46P=3;A0;/''KT8] P:>NER[&%0+&0RG#+/$1PXNB%-;*=0,5@_/YLF-H?".
M,A\0-O*4\U,9S,1C1L-[5D/VG2=/8\WU)ASK8".HU!IK=6\AB^5S6Q:6F/05
MF7B2SVK8G'!/4?P#_L;J9XCR#.?5(W@9RH2.OLMW\$!Q7W"[J5\)4Z]^^_52
ME"(YX*_>@J*%J\K4WYW6+!K];U;5_I>&6A=$\U]GW(A_FQ.R0V%]!!V ?P<?
M!PIC@K=S_:R> 1M,Z&>D=Y [#C"LA@WNWY'3LGE'S@8KS;N8GNZ[U9W9^-_I
M9OX9_G]F@*:!ODG#_<&CX<\ XK$+GF> J]U3).QSZ";\8O(9('PMV^42@OA"
M_;=VU'MU:QIQ&_\YDR&DT5/IJ?W2!M2:5DWP#'C]Y+]+WB_:]#5QD.OJ&N#Q
MTC%8W$? CI+ 19$;6?X=_&C6BDE /TY6G8Q;D3Z-^DV014<#S[RN#&7\+<7.
MS2VPM<M:$CL1M@,G0^9AB7O=SOWK72S#CQ!X!-1D>%Y#QC+S>])'_ISA]AXX
M[EO_2OW6!*C]4W=>*K_]<=KM16I,"JFO7SS$X\L>=2.3SP< 1U[1,T 4T=,Y
MO!NWEP\23ESEDG.79C>C?XOJ%D\I_"M[I3 1EXB^(N^/:-)WK )XL#UH*<_F
MN\Z4)>X3!#$I-8;$_:0KG?:!%[($ZIT+264K&U!&ZF&,5$L. *V (=<]K9@(
M2*CT<CG%N?N<OJ"+5MSF811'KG 9G.OPI]^ Q74!#E*\6E3DW8N,QB]H* T;
M_4_*LZI[D),=]].V2)<#,7#OM(4O+CN?N1>KHKMWAVA9NE=Z&BA=MC6;RKY"
M>M?*KCXN$^().C'*@S0\J;6B3HXHBWECUHK+%L?3)IA@R1'#'[XN?<^6 V:3
M:+RLJONH'X) 7L6TY+:=[B&]S;OR*/J^)/T@[X*?#]H,/(C/A.AR\*9EO3B2
M5$77TK@I5T+[S092=_)M;V1N?O4SMZAJZ7281%X>QSR0^^IFZ!Y-03DFBW",
ML%);IH?!]$?/8M#UP<K+P/S?X,_R+\_3L0K(^1<"M7_U,-Y0X\@QTB$E*6/Q
MF,@\ QR&#E9;$NYKLF8K3V>[JFE"Z)UY3>+/KVL>O<F]K?\P6 [/R:5SS=6/
MJ-(]K&@?(7H:M210@.:Z)3)XP(!?(2VKH7T_9L;'"-\ ;#"HL/T&;.W^"#Z\
MNV4SV.6Q4^:8$I>.&VPR'BBSV5G %/\:Q]O?,!@K8)#-&:JI]=D$K3&:K-V"
MN$13Y*,HM],Y_ 'IBHT_)_9'U.<\E?*I%!69_$M@5,Q,>/S;#%].)X><YLYD
MIV/XD_"IIYRW;=&0$F,:PPI]S!2+@0Q#Y5=UKJB&GY,DJ"CL*!26 AVKO?3Z
MGJR"O0,@]JGH%)ZQB?V!TNX8_<,BIIGB6K?B9T#Y8C%?4)STO;JT*J:.*<EL
M_S/ WU/0YJ60:>PSH.P@WGJ [)H8@G4(#NXB+YD=0)N3EBT:7A3%T= >:=IN
M@UV0?O&L6>:S?6F\[0T=137W_J46K.!9]QM;.E7M#N7=$QAM]:@Y'72 "Y')
M_N;P6V6R/%F!X:TTA3BB\GJ1=BE0ZC(9@#%:'; SZ ^>U@T]9GO*QIJ G,V<
MZ*$JY:W.0(XZ^) DOAX0(X'&0.D4Z8HSV^S../LY"[W2)W.#BZV+4!!HZX1Z
M98"@'VQ*1M@W[C:.A,'!)!4[B/46)<;G>I[17#PUA(:FYJE]YQF C""?;HOJ
MJGF4.;SWBBSALDZ/QZZ6ON??(57%\;Z,TAU"!T;?/^@OGLGE(T#GX+P2*SAE
MU: ((L+I 0W"FT; !)>B;.T:>TGZ#!@VOA!^,J3-ZIE__'+M&]K((M:ZK'"S
M,J:61LTMPRHSTQCT#,#Y>R"&UOM2?^_<7O??X;<26EMP79U#^7\!:U)U:(UR
M[ENYY;X:7_B+'R+:[ERH\P:Q'IUNORB3+K"(.*PVS6D):M_Z/-R$252)^"U_
M$252+J@*4T=T?6]]!IB>%+XB<D%<@R9GBECR3W6,FK>IP>>A9:HH]2^0'5^E
M2IX*6HDQ8VVAA.0";GPMAM$>Z![^^KQ45WR4B"PL 0UNF_<;BMNN8"NER8%W
MP\W?=%7Z:N">.OAXH);%P]B!^V?<FWY$+\+XTOW8ZST$5Q+%>80.1D_1=-/?
M*R!/-3HM==YD4B1?;:Q7,"?*R.6JM[^@[BC=D=4*-U:::&.DI.T&#_N8WWHP
MVEQ4**HR>R0(IORDP2Z.)9&;2?2,\=YJ&,S?V$UR&$%;7Y]Z0W&K?$Q&E3$Z
M8&U@2P=$+I%.',^D.T:^/$+Q83:;JHWYJS7LAF73%)*IF .R&?NQR:PF/#^;
MFN734ZY#<-_][,G38E\3V!<!("(J0$ZZ+CK0;Z?*)*)2(:<<>-BSXJ@,-GLV
MMKPRUVG*ZB18D,XA@A@H*JKRKY[=0YKK/#%B750M=O7*%$J?V _Q>],;_7X,
M)W+'&LWQ[75MZ?$8[6D#"Q:,3(QO3&)5Q!4E\305-36^U!ZB,@=S.%!7&2"E
M^#4R45JD1VRI&Y\_W& JG['.7,G4V-O&%C>^^OG-+#3%KTH]1(617H:H\R&>
MLV6EE%Z R6Z_K*A162K3=J)9K=6DY='^%D3$ /I=.;B6*Y2XKJMLZ]Y81SU?
M\5=/=(*X=,]LR07DD.\7N!-M;@?!PB'WOS=&B$5QVVV7:D]PW3V.C%AY78DQ
M3:+?.IP4)VU)$0W#>& =^,79 I^T\,#2$9!+6W5XEU38FRYN"\X]:XX1N>2J
M7QTK?&3B7WYV]E*VS_S<_P18^TCU>UXB'VJR.0E?9VGW]=EA<J*IY\J_ER&E
M_[B=:[Q%1$:DV*5<[W9/!/WS:<!T;'9D=SAFT&?MU:Z:EF945CIQ,&5 BYDX
MTKVI2\LJ*0$[U$3T:E[5^-P#Q>WE2:=#\KV8S+*M>\0\(5;K-L@:4LHY4V<F
M+-2"6C1AU4I.Y\(6)_,+(]-UZE/A5I%WI6V!N\D;B7?45:\OL<@W,X^+<"W1
MGIBXP9E_<E>S8)4\++@NP\%MUH%H=$+EH)^"5S,8D,\>?3(TO4YDQ]-9'JF5
MVC9BB8.D=3<3<%UL ZP"4T0]OO 8.8EVA58B)KN>^NU.06B9D"-/!.I>:&.=
M4"^8C7;^X/&+HV'$,C%S_RJGSWXKK?EK$9BL<X\Y8WO4)YFQ(1H:0P/+Z1Q9
M,6BOOX2S6$D:GJ994B,Q^:P>#HP\[L/^'U/W>.?ZX&6+#ZKSZH9*+S&<*XB>
MPKJ0^/QB);D2BM1&, U49>8'2GV0K#Q_,[V8#C6D#.Y/=AOX<4O>EKE-]=WO
M_AGP[8;6(<USIK39Q-R,RP0Y:(C85IF<##W[L]/"*4NGL"?;%O^'H3FE.7>8
M#'R4?MG<QY;:!RD48+)HV;CT%JE-J!ZD3MZ8;Q8B#.;?&>T1#A3L SLU&;$D
M9V8T!KL/E0.6"Z=LA?/8&&?S?Q4Y]PF>R5B"B:&AN^]J-.<#OFV,=P1^(@6W
MD(_2]+QU7T3&Z]/PH!*MCTCA1S+XB&?]!_P3'65W+G[\)E!MVR)H14:S+"&I
M@3%#9'XB*@[MT??1FEFAG>@IQVA;OJT$50<%=P[+1=A R0[F/L+*)S]\H:3Q
MNCE-K041:+3S=+ B3E#PI]^8P:3$>\H94J:H%AZMU;Z="'XIV0G^KK_ZLFHZ
M6"4!4);+ZX%V2JTFXX[HV>?&NLM^+ !!R^0$&>-!JTIMQ-G9/D@/E]A8MVN^
MTP%=OR%E5Q!#HLG9T6? [%'9$:*U(WF6C3BN[GMH[>OW3KXXIUTJ2'MS6OB?
M[DXA"X-+9TD]YUGT%]?LNSWI3A-Z,3'N[B/&JE@.FE2"HU$T[A2'HO;5#Q'$
MDD$/6&5U[U9A(:-0K+N_$5V/GS!Z/1VANO\,^ *ZZ:S(.QX'_[0$GQE2? )?
M._YG*/KT'60=WO<,8% !?\=ZF%[L;K7\*^]]>C;BGQR/-O\+_.P?_@__A__#
M_^'_\/_OX$GP_XP;&;,E!J=+3R0X]3X#Y%.-GYK\_YS\GTZ9W_F^'(TARF(7
M]U=\Z7=T;^1#S_9+.CO2J[R,^]E2C$D>BK8=#XYR$ML"V&Z<S*^?I/;6!.QJ
MKW1&]7)2 R<M%'1Q$B9,6];:1N56\K;QA+]D6*:?TB[NF@C-+:B.'KF10N@]
MWW<,%^B)R)B]#!+1*\;Z,+6_(1 >J\ :%:I1V/!>#)LKV&,W2$19C.T!$^$+
MOOL&P@)=BTT^ Q;.;!!E_YES-?$,X--&!!Z>O;QZ@E' =T#7%$;/ -&>22?$
M5?C6 2)"]QGPL'ZVJ=X"[K;Z6Z55/0-$//[!_^!_\#_X'_P/_@?_@__!_^!_
M\#_X'_P/_@?_@__!_^!_\#_X'_P/_@?_@__!_^#_ ];,A@\^-,)J3%K1?@#/
MP"EYI%X#CG:P(#_PS^OJ58&*DA^T)+Y:DUH?,ZL;FG'!_I&%+@RY&;8<P<QA
M&Y.W#,<Z!MZJ<DW-*=T52)6><V^GQ?SBTR4%JKTH^VJF$!TVA>^D)M!/N2E8
MF[E/>(*%YTY>VA1A(I)Y8*:,KU]PW'SS%]V!^X\],F$5AR-LRN[15)5^GP$O
M@S$%=0&,,B"2+XO%!NI,"2CG-;V-4JK2%$<0\HE4J'?\'L(H>H42_#H+C*=\
MCR5WS'63"/S%6.#PP3XVKK3FY3- 'R:<=XS4NK-<4N! UWF)4=K3DH-]6B^Q
MBTQB5=@-K$3;1:)HR9&K+LTJ>%.RXR%<B(>"'%\^\S*UY][E!+;EA5<#3G\D
MP]$W$&_%*="A4!/':B+%@5VGIMOONC9RS#*SIUFJU*A$2 Y-I3&"T(Z<+&-;
M99U];1ZE8393L;#@U]8IPV?J^^_*P<E^WQ\\HTT/*BCQ-*5TMM7'1T@(AZYO
M $?WH#S;=+-<=BVJW/S%\&6CZ,TL!W3Z.*0!Y%@Z06&JO+&R!_SBKQE[PU4-
MD.G4Y 0^\I0>NH='CA9V">M)/;^(9P#@#ZA=T<<Y;_O\G1KCO!0N[,429&RQ
MQ!'+77W[\WM6#L:DX'T?.]O#\/WQ#:(=([[66;C3\?:LI[SYRM?S7X5H!WM3
M;FY[1^N#E/$?]>:LWXE-?%/5E^'=&;KZ(^UPU79W[*PV;:Y5V9!3K.#PQKC_
MDN-C>I@.OAPT>^UUW2OT9L0WWW=ZIVJGHX/<@* ?$(K[1=5?9Z.?UNJ! 5QQ
M_8GED:+45%W=Q+-H<^=_N*UM*VQ+_$IH,&BX9D15Q54%U.5T"8L*8FED@\1O
M ,ZB;0_!%"GMKI:OOGL3LS_2*\.^D.H7\UC7+S<UO),+5S/#O;'21)Z<.I]\
M\4Y]C]V]G>IRVH*C3L(RBU\OTN*=+CJE@(W:@Q!_#7$2VAQ) FGN-N&W8"+X
M@"+!U2#8Y(_'-0'#^])REFC3<=L:)G)";GZ[O$\P'_>022?F#34EJI*"HD!!
M9VE1A:;1JO*$CK#"A38",YTE@SP+;?UOC7E;%!^4XEM^&3:N=B:29<Q F/#G
ME1/SR3^'YRDLY=SD_F2^V+%=B5'LKTV!ZD(&HNM8G,[_\Y\BA<WO=9KFVA"Y
MBQ^0*XB4?BNKGE,EZN@18$XUTR;DCW3%Y=\UA!I*G:]E$@U8:LJ/.Z$E*S*[
M5-V+J'I(Z"PEO"R47%I+D@6VK<;,6&;D75['":NMVFN\(XX5Q%0J,/#)RU-N
MLSUIS9@T3Z=ELF&@JRPUJ,:EK_D8KV*;6HKEWAWH9WL)4 RBS@8Y,?.\Q]3$
M*\T'Y? B-*&MRFZMO=2 T*BZB)DJ VM6;A:WP9""$#?-;<^) %^*EOZVDW8:
MB^D=FXVL+\S%YV(+,;M6.2B1-7S6)BF2Y8BT.N%)H$8+31O2>9"*HI#L,X!.
M)%J']0Z"=+J4^1)2#IXYW]Y6D4H<U@9%#),^Y5"5<UQ8 J/2^ EP,D$:M(H*
MU8ZB/>2IF%:S ?X2%Z<)&]&%N"Q8HSU0^(/GE:5_.4FD([7U@.P;5-'\%ZFT
MS:"O*E]4S$O7!T(GU045C*RI$X1VAONIW[**3/F9/$C/15\*%?<T96+UV_1U
MY#6&R]\^C:ZX%1\.BH8U4W"J*^2Q[<W05ME:B7_0&Y'K6A_*XGXR>/#@-UC9
M7"8?W5VU)(*07E <D*%3K=64H 0K?N269GCJ,*.^)2;/'MR$7#8(^:L"#(N2
M2@E%=BX>Q]%O\_YL-$&N* X.[UD+Y#Z^"X%2)SP#6"@1&]^,7R?JF>.^T_#Q
M" 8B&%#&2@=W1'G:/M5C(O#AC^XKP_B!X,&@9P";-L\TSIHY-<)FN.=7%_M(
MQ-@0'4SZPN+3SLFT+GCU@^_F$]@FMBEPEV<7M/U@-Q E&O;5KTKT&4 L)*?
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M>AQG"AJHWH4<RDTUW.IT T?L=*@(A<=2L^#=AJ5R-&VI7+!VH5V.=S&4LF0
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M&DA1!!,[J#+FMG)R&$.,V# WEX-IDWG/2?3HJ#[V"$. +&S,:^G)6-9E:MS
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MF ST0DY!N*/2[SZ6SU^MX^^,,QN*^$O8S:EA/%'-(B;<SI*!3.#C2"FC;C#
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M4K6I2^.-]96+DQP[RI1?9@/#S<S0-,CO$O1K,O#2@\"N[,>J;N;S>WS X66
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M>2IO+1\[//SJ;JX7J(\'M$$&(C=85G6MK*T;+@J?&(CG40LZ.S]%1LN_[_A
M82#L<T!Z=EY .<^?D%A\0MF^C_&KS:LKJGY_-[@GUG;HM2F-'[RQN\?T8UG2
MH4S&X7E3%%_I9*#,-86/\6IV8.A6ASK*$"Z^4WE 5]R7Y\9BQMYO>96D'HF
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M'W.=^J^^B\:486'!9]U%&]43\O[1'-D\IX@DIIJF,JL%I3F,#SOH/>5FG\P
M+5!7PCX5FZIQN_P)1%,2BE%DJ_R8'F!MBF_RJO_5P(<XQBJ!1FU\K-5\);Z^
M[ZM<,I#3HEW]_B]EL'J34YDA<9F2CK]FTV.N*1>$<('X1^ I=$(80VI8W\J]
M2L,C$NKC(NQR9614>(N)R=\[-ZWKY;6 IYW$E#48U1_)HV3TR2LL*[, VK_F
MH?7ZYR)#X]95XQA&3DR9CRRXF4FE(.';IK2O#5V,:_I-?Z :5URA_%]FFN:8
MS.R$;:X]68>2VYA9P<I;34?'S02B]W.1+Q5G'ZH7/4SDKV,U'/"7 WY_.BAQ
M8;(JR?=IL&6/DV4)$ Y3Z]XNU';;6<IH<GV)I/Y;O:&)F0?\#!#_O6L]O5XM
MO9(:#5'LI@&;%?!<PZ&C4]H%F35($Q3@[;GQ::'8VMEZ:0,L1'^CY_.7D^A0
MY<S2P2D4 )!5,'=/6<JIHB\1?IY/0N'4Q!5B73I$J,9+/#4)%^7$Z=K\[XS,
M5NY&M\/G!Q\Q!:5+YI.X@R+X/H6X&4UBZ>BVX40'OG ADH2AQ0JI3_&N@_#^
M2>&S96I8S)])B[.1J"9^T>FD=S*++OQ&VH,G."JL?)2]S'Q1%.83%_?/OR*V
MIGOZD:RIL3_&KM.06:"()^%3(UQ&8;!T6P^8WA+$_*#\-MR-Z/:KS:#!9]X#
M*]!W$&^[J,\ TA#"GW>;,6D_ :7VPK9U-Y9U]5M)H%;TMUD0U>J.X7S[T;3H
MJC,BNB27_;6<7H[G$N?25/.H:&PW]?$B^%YS27+KJO]M&/E4_;.O3/+KWE\]
MO+1CI QA3J%.,.<G>Q_8(OQ9G@2J8J/]A"2$&K];]22>8OP7H@>&*0^,*LA5
MNM,+%( #]Q$D6=Y<$^_$P!D>&1\_"K!_Z?NT206I0/1/B?12Q^GNXY/[2/X$
M%(# ]['YM25QR-)Q7HJ414[$2!*C  PHP!5D *0)10%P7%  6)4;)Y)6.1D%
M6!:^%[V^0,JO7KC^<] \O&D6\8@:TVV19 ?&G&85 6+_**9/^NA@?4"/N//R
MI)?PD84^%X;Y^LB7S<\;PNJJISJH1=S9]=.7#B*RL[OLA_"?F)R1LP7C/5=.
MZ)L:FYIB-ZA1+Y9#SESXNR$_-BS0Q^\?2_]035B7>5*NI$A9^P3"N3,V<)/&
MN#3.?A27PX=>W6\F\1Z3U/H>DJ*-_J@O]H@#=<;#CW;BJYC!PWJL/3@T8UE,
M2C^V[$E:0:.E6\A<!57'&[:Q5K5^:N'9R7&MX2>M&C/3$K2]V<DZ 0_Q ?8S
MNNPE5=_>XOMA.?S>R<0*.L46 SIK_+C>G?"BD(_4!I+K59_W$GW;Z2R9V1O=
M)GH8>9P  L(-Z/G5K2Q6SVU8_"T*4+VVI(O_>P*1U"@<$%V+/GUY^Y&?7FN:
M75F*65'B>[*F6VY(3IF6DBC':7*>9.^L-VDH6RJG(^X(O6FVH>;WSU-=F_[R
MA:\TQ!N98<O'-W^3&[)-F)K#M"PP.&(!6;RDHCP&A&SIC\8-<3W,KO*C?- =
M55%K\Y.VPRA97;RI&IE(I_B86.]A8V?XT:6)XG5(FBX/G)<T84)=-.>'ND9:
M-;H8=Y_^45MNJF4C"5%<%D=)6O(45R] O2"I@C6-?2<BB:C[6;&O7NE'U2<$
MOO*BV#B6/RI^&&U5Y$;_VVV__^H-%0_',!3@6A%$V7$&<%E%7C2N^H!NC)%:
M&3O(Y)901/[P[">Q1A0@R=L6!<AW34'D2H^A (=H8Z/_D:(F_ZV C7A8492/
M][R5C^2\5Y189D&7Y@6%KLK?4H $LGTI1 OF&O<,+X\[KNL='X9OD*L\G6YB
M+D#S&P8-!I$D2+RRQ<0!O*+/:G.</T8%\N_>W)9#AK&#62;_R9\(<-3?(63;
ML[Z.' L@FA<N(;F_7P41OC7'#-VT 7$TS0Z)Z,YS'K,-0V2LZ3#@)=4X$"XI
M^&7YM>>XP/]*F-&0.J:UI53D7%%@6A_=3QZV4>SUYGMA>:R$/.'BW^R^T>*-
MO.(?GKP?I7-M6P!VS^B(A5I^-,5\W88WB)7<_,+3^*.=%>8RGW>D3AM7*U-
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MO94%)D$^?X@[?+0TUOAD\WY2&UXK"SYD4!*+KTO,T)6Y"+:9J[OJP_O5).C
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M"3=8L"8<D@R\.^GW0EI8_GN"]%\*K%6%W=WKC2QJ=+,852FG73_%!>29VU
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M9SZK'N;6E%+!N!+&>T+Q5IL?[N#I:U\?R)QC!7P^R=$<MY?WZ91^<B:,;J$
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MC:+#B^"JH=%C2HSE<JQ76!N+9\O[PLHL[\\O]FBVZ/3U^UF<Y);]"U^4R*$
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M\,G2<J<3]UV#>::6REX]X2:0@+LZ/2*0TE9W%,#89V=N63.P;]/&C=-M_:8
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MVO*,:>KF]MXFWF'SAG<JCX7M(;W2;D<))8*0;R8VBN+\MJBR*A"2_UO;WBN
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MF-*^/O5U'.PLZ]WN06X)-\92N^G[Z 72OF 8T)B:_&2BV^P9M8W3RY[BB4_
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M/E$R1&YUVMWRR7U3LXKQH2G$3Y)9[<S3?U= ^&)NR_3;LL/#'Q@-=$-TJ7X
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MXTKHGTAVA-44<SG;^/YH[&!]O6S8S:UN3S@$'% :U\DH-<#Y^V;-8Z/>9-D
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M/(3[/W1V?Y#T7X[N89+_$6'3ZOL9[KL7V'5"CF!>'>DK+\8M8%Y\#NLHQDT
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M0N0'@@^1:S6:S, 2#MRRK2 J22M%#HZ]CE@.0 IE[P]60GH!!N>C>Y9 GQ<
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M'_D]"524,.G]89M 3!Q#$Z+R+H.2@\'%T_74U#$@%59.NB-A5[>Q31AMVBF
M-/+[=2')M;61S9&4R$'7J@[%X9B.'WOZR)MOE"I(M+R#;G#><IUI58_W.]CY
M8!BLTC>'DKMTP#2_L'QL1/FIFS0V:3[J\._!@$;W,/!I6.Y=B]I9Q@O 1*38
M:2E/-.\7^T0!1%U?D1E/GEZ]>!Y>/B>Q6GS[/N4]. TMC8&C]A5K:CD!]M/X
MR6M$S!CQ.T*U'D+GWG!"U<$X&3*N)*W?>II(W0  X#Z))9B;2 9 "' &>$0Y
M[GW2BP(*,%PRW!AUZOX#KA\;U%=S_R;9&31D3>4\!5YVG^, ?BZ4@J2=[,,K
M/+O,_TW3*"$9@V()Y9'%9XOORXD!3CEKC<V:X]['AVSCW%^6R9[*"I_YZUM_
M7/\0Q 9J?'NF-7'JV!*KKNL!#X'7#,4^Z8N2R>X!=V*=HX:1C7!QI8Z,]T&V
MZ#QG<R;B-]P<16SYG$:?I"FL?D?@N&LZ]QPH/,0LP@83G)T"I]=U;>Y._(I$
M#FN;5])U_OC@?JH^9V-4\)%+9O->IM>-#*P!&OS$EJ4:<.W<1)T_NPW  +_3
M_^%2E\AL6*3S-6JMY#42>[]F1! &)FQBW)//0-]!T#4\J@.KM<:97VZSA*.9
M0XJQM#>XA?^@HND"^D&QO<U3/ 3(J7VTGA$38 \WT)"US"8>M?Q1R2F*9":L
M;UJF@E$^#))K5KQ';-:Z"1ZTZ1.WM#9W-$;*E^?&GXA84/>CN*-LVI7 Q17[
MS&NA/B#'#Y&H8'#P[)Z2;$3O!_76?R..8UR G6YS?>#]8 ZS>]<&[H2N-3<5
MGNJRL;5K+0/%$LA\92\7U3^3/;&9EJ#NTD8J1"&*B)F481V-A4FWNX4[%EX"
MEN>Q\^.V[L/!C?GE4<I2Y2$'827G&XRM;76-+8T)VE MV[@(KB:BJ GA4@T9
M=$RY<MP**ZC>[>\ ^GO/GN6,(S9A</3ZH-76$%E8'BE)Y(.2JA2M+*K",7[A
M":A.LKB.\SK9$V&N9?! GRE74ORK<:XLJ;C0FOW.W:/>C>C^?;U XNPGX^\-
M9+9S^CI1-AHJX#R!C;;A>\3E:@#[ G>1);;VUYUZ@VC&*_4AAM>0<[KA]H D
M"C?@3O)=LJS\%L2=E*=ZG?(%\.P.Q@HT7.Y.E!,*%^@>MQTMQ$ !Y0Y2'#EB
M][-!YK0_^KG5@2H'?L/NCK[(RC?(8/3_QL!%0K]L42OT+@N>D#)BETSS'G;.
M8JUUAIQ=:6P)>6X,?KP*+%+ 5I9EY$0PJIHLA9QC6;>!N):[&]DI(?C!WK')
M8$S)GAGJ6K!20)?1Y!*OP9<=7$!'/S:H;];+[*YXI,)S=/D!CJYDYIK*1ED)
M/KAH$0K]TZC$*,# JB3";AB4EJOI9JXV!0@03W9=%'6+JEJU(:J:HX@M;, B
M_-%H'FZJ&O5<\Y"(W.VR.9/"[1K#9KBQ-N+2TN[:T3_!8:9$(!L7^?Y.;M-4
M[FU?C!(U5G%%Z8GQ0NFP1H3^4X3\?E6AJJ8<?^-L0VV0XAO\,5R@6(!* [57
MJ7F&YSJ5Q0P]8+*K=\\&"Y?Y>\GV[$8 O7S31(>I:"S/ZXW^/$; HPOIP=19
M.U@=[M1MZ<5)]?;=CZJIU[/8$K2?B4A%(_!H(P0^R>MN">":)\CKSH>+IN;Q
MCW6:G!C/ZD]XQPY@37RD^X7JE_96317]SX*B$"JZ #\:T_+)?8[;F6F#CWD2
M;2FOO&TL_2$V\%84H+75;QI<@$*-?Z>\Y=MQN.:7G+A=>,(6$>Y":$R/'D_V
ME%)14O;:1Y<Q<;#&Y):N/C*?GAMK*=NXS:I]#VO@8@+&]SF1KN2*O^)&\F=J
M4/8?XK]2]"8^X&,+1:/X^<9(@5=RE=;#P0(*,?T QF<,Y%\TM%M'7?%*:T8I
MG9[^PE$I:ND58QJJ5D)$2HR^8U)JFE$H[@>UYD%)FP7%$'U4%J[6V,:.T,5X
MGXZ6$.>U$Q3!*#[YN(D/LIM_>%E5@SB[L;492BT(24JJ/Z'O(;3)&:,W?"U:
M\3GL+S_5T>K],.<QU<=&BRM!)LN<GLOUV][W=#Q=;/&2T_&TX.3WV[;E-!RB
M!Q*Z'ZLV'RYD%XFHDW]DC #2L5P"X@?[#XW("JC\],XX$8\^;G7G;'E7BVH+
M02RQ]#^<>_P\7HU*Z:-IZ.,(?-5I$0NSJ%]9/8-I\#0VS_+S,.2Z<Q40G^5B
M2N$D?>M?"%J!93Z%_J_OD?*_1\/_N/>@SR/R"X!OKD6XLVKV!+_D_5-FI0I<
M9RW*!K$MAT@"]4!L7"7U31[+7@"7V],B-]L(@;-G]0Y7#B*<[Q"G&ZIYVMG&
M8\UJW04T#X8W  ,W!'V,[\7M_O41@BMGBO(KH!(2*IG]]@G4=!=M#5>N8AQ*
M,8JD+GQX"N8\91\T.SS2J?X'$=*G492Z0DFB>X1@)%WP Q:L*MDPNE+5^W;K
MIU)4#WP-5'O_T5]V2ON;U(+ND1Z=][R]HN%P8#L"_>8?>UB.6".)#UDLJ'[M
M6>Z#=WT;,4%ON'8DV 79N#PE"$VJWY]-D"$Y&NM$>0'P5B=MX-8M(5J.0G-/
M.L);[RD9^2DYVP[WAF='XB:G"&EKZJ4XM%);GT8P"_/B2@OCX GJ$S3:6DV+
M=4NUFL,( C:,1W_$U/ZT9-JCZ%!JRD!SA6,92.^U.N$KO[+77X7WZ8>CP2R/
M-M=#50CLF\#I$U L)(;YZ]F*+8<C<[GO72'OK0AVO_NE8GQHL.]@H53$0'O^
ME)%PE#;?&UUH41ZF#:J04.\D]ZS_9W_ZA31X6+7N=:UK0_N$^\4*]=PG8++4
MQU)UPECV-4AO3+8UQE&^: *"$']&?+LUI0RAXF]?<(RH@5XS898[SY^M."[W
M=Z<)7:*ND:RL4;$J\[/CB7^VD_C91F:$E*8PYP^,3M-H@-\&3LL&@OX>! 2<
M:DTN9(LGC?AHT+JGILZ)_ZY:OD'+.6RMB2YY0+^,_ OR\'*:X*Q=(H76'RE
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MX\VU/PU=&TNU\4F( .S/QNN8 3P=5+A9 A=AD469XH%:B_J!DS_H_5;[O%\
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M"T_PD*&5&<-EU?N\E="R#"RF[1Q',0>5N!$-3:4/44VO^M1O#HD+WR8N4+3
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MJ*XL<:^Q)XO0F#;-AV>]-DJ!3[6JEW^[+>Y'1#SXK\M=X-G<,TF"82&%=&=
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MRMNDGIO0D0'+RS1L">44V,B]\$DE8>KC]O7N\8X* Q^;?/JVNT5K9#D:Q9N
M\^4QC+M)@_K@/1&ZN,!\35=ZV6.#TB4MW5=LK^GR:4*Z;TT\JFG7A&"EE3M
M,R=DQ<'1 TC33R52(-J/-];.4I1(?N]LSLI44MKF7.8=LGJ4P&5F4P%-OODX
M&CB$V=:LO=9EUOUX%<&HF6LA3BY3G/9>-6ZGNZNKDS6\8T66$5)86G2OHG6
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M#L\!L$HDY=;[,_!_'ZJM3&;>P1LE+ZEN_GVEITZC_X.]MPZ**]SV!9L0(($
M$=PU.$208-V0! WN3@*!(,$E6-,$ @0([NXT[NX$#P$2W)U T[@UT#:=<^Y4
MO7JOIN:^FIJZ9^:>_ZA5N_;>WUK?^LG:>S<@HKXN6.N-(HKVRK)!3/V[4VAZ
M%M3;D<XH<O#DP^:AIX\--RR5W:]SHD]'V,;0@U(^)D!=E &Y$RT!7BD7J_B#
M.3FLI(1VM*8FZDGP)'UR)="K)RCFFW$[;>K\E"X__\&F\5=UR,P*2W]6.7O8
M_4?JSXN@^:J8H:Q1G#+8<8/L4 JAZ?>?8P'XP$4L@"<9=/04\DN:"0OHN0O&
M KAC(!W#&/^._^GXH]7CYP==IZENF#-J-/YLU]J73BP@01&TLH4%@,RP@/?J
MUEC N%M+UUEX,B82<71%>[EZK=*"!7A'8#[#5X]?FD-^<# ?N4*RJR"U7'60
MG9:EU>O^-UB /!*!NH=T0A698 'M_5B S,71%:M0U_9#<D0+:'RV:_[1?-?9
MTJ$3:J,0"\@'(S&$X":,MB!DQ0(+R/%!H.XGKYZ&$2&7LG?@J_MA^ZO7AY_$
M,"Y:6,#O3O3_M$1?S)TW1]>O@]"'ZF<71Y>O+YU0",ET+.!%"61WU1\+^)SM
M@%O32#8BI6N7J0,+N,V)0.7)8A!<US<())NO&,8W$Y>2#)VN<Z<N2/=X(Q;P
MPVH<^=/\G!R7@,"'2(PF"Q;@&X]"^Z)CI7'GE1[[@P6,\9K?B*UVK7U8A&P_
MVT'_$;HAJH+\.]/_SO2_,_WO3/__)].6:UFCS9U72UOF,=PE"NA'_]-]1*_\
MQP)]< LDD[8Z&2F_:2Q\EO(-K&<)HHNE\G7^F3C97P:_W(WM5\>["1@FCU<O
M&)(5B_,66S#-CLM0=:)_\V)=:DNR O*%0-=<N32DB(0I'V./ 'G\V7KR$\[
M]>U)X-=56)BU-9+$MM+][ZCW@^;.OX)1_W?@_YV 3@UJ [0)Q^B KF;,P[J0
M\>;[ZB-2@EC 3A3D&I&G"O_&?/:;^=KGNA,5&,-T>,@]\[OD -AS3_TQ%M!?
MVC&LMX/28SZ/P (8&>6UHV>3,78@E-?Y_8$%)C%WT;#/$VHQ(VCR6?C!4 ;[
M+;_6]Y6Y:AFUAD;E!37U.0)2O%K<LJW%:Q!9WP 0TTI[\_-?9(QBI*W?[8!"
MYMDJ0@4B"49]"]]7%L/+)G*CFAGE9PEQSF3F,B^_2JO#PLJ,'YI=)88%?+T<
M#Y#VF:.$-VB7!7B+,F"4-M&AC= (*/YD.>SV1(WBK#;@3?;WST[:$+G+3 &1
M\,F*5/WQ2LX[1($+JJFAD^B3RZ6D]\=P"XT7'GWB5.PG@Y,WODIK*:1^-VY]
M)P3DY&<>6;8KA8E+5;DO;S/%W,(072TNA'$DZ>:NJZ6'$(2T^HVJCY??CG-"
M^V?]^O)[L)"S;&8""R#%P11D$+BTB_K4O_I'J8EU1&OB'<QS;O_GY7RZWWJ=
M3LJTHLW6V.1DH9Y6J"3-),:<0+BF+;?4NWA[NT^TK<"5*]B9EQ!?JYFIT^/Z
M&Q806JR= NYJJVX56Y2TY4@Z[KUMQ<6E)*P%O5*B6'_Y@O2J:KL*E>AO2'>0
M>9+>:.-,C_'3_O.T'FR[G"B9SDFA:?AM-'B9DE8Y+<T@8J"!N*8@-I"R,%">
M_."BIKY5.*S8+P"T]?%<G^N%&U6ODI#%5&*NT'T-R*)<P2V_]DZ%O/D)\/(2
M\U!;RS-S&J":Y1[2>*/)=D;W2""L2]2#_KEVZCWWQ-1[8,KWX:WU%6S;)X05
M:9D_/81KQQZ3FF31%BQP/!T281T#?>?;V<+9K BQ)<]%B.M!\$'J Y.^6Q(M
MJ.\UE -*"OCBM\F_.SHO,F,>[:PB$0_F=0R!,8.'F>,I.66J5?$KR"!HL765
M-WZ!AZ1C:1WYMXB1I[IQ0G7*=B'GK3\XG-CZC;GLUOS:$B QY".,]T=<1HT_
MRC_DM-(\(8C2FSQ]2QN]H\?,^W8!\G0%=?WH.*+TQK(&*.0![!OV\X-7_ [%
M E1IEN2$G944FBR>3FIM<KL<:PL Q1[I/;82OT.G4%!,T10@,T%+:?;C,KR(
M13A*&/-J"V@Y/ODS**%Q1,TRR^:H ,(D!WS L7WZYJ&J83#PD8R<5Q9E)NJR
M-;D<F;T9.NCT!W]&&*#KF-*H1\V7=%\N(IVSL4WHD:@Y@79L<'<B_&E\7\)>
M[K>:"OM!WGIGGL_ M?!U:_/^Z,:\_$MW@<N-2WN2LLA22U.Z.3)6,[$[W7YI
M#>?]7AG1F0HMC>JG61@-R3?MHI?DU,;+C+!&4<^]P6FKXI#RI+V#)=^MZH2&
M;BDWH*3#^NNX!MZ?:3-1Q=!PGQ;SQ5@L(*RGV"HM%>GEWX/"K$0(Y<9G-LTT
M>K+1D/  4#R/""R CE=5,>Q?-2>22\0P?->#6  _V=#"<GK$8)./QRB5 JE^
MIK#+A'Q;E^UF)Y*@N80*[Z%6?W*X7%0M=]*+GKC6.YOW:6:7\=";>/<DDUEN
MTMZBRKHQ7GM-C:$QGU)6'OK=592P4X<]UXR9C<KB,T&)B%2]CL \6CS9M-11
M7>YZ*G; !"QR+(U'1E>?TA)#GFU8Q=-=("-X:,5T2DQ,Y1@E%,LJ6+)*!&_W
M4;2IM@9.-*W37.N'H4*O?.XC"UN5R\A6'X#*5M;\66AXA>:,H ?X9:88DU5^
M_U=^?\91L?NDZ)ET2\;C,Z$6N\M9Q8R+)Z%<PEY;RA(__:8B*<ZOPXG35)_K
MCW*4,0)?&NZ6+%0^Y7?G*_^0=)#1S$3;3?3UVN]D<*?WUZV6-LNZ[8*F<%J:
MY=*09/7>.$6[*4J6=1E*7CQA87XS2?R2KA@N^4M'>]\CGAO"9*\#OT@/3TN+
M3;$QRYJGO_38?M1I \<&9K:??CN)V;,!!:?DQ2NC:X&?#VH_'BPT4)[?CD65
M(5^X.SAXCTH6W.)X9/.6>S^,GK*?K)%X]:!,&_Y;XIKS=!&"4U,.UTU 0A3+
MPD7Z\QP;.Y?%B#KD(W<-02KQ$U_E/(+"XG1F$J,@O*ABBM.)WTLS^GK$(B>:
M7VD-*4=[';^\NI.'.M&0&GV!AW&2(/MB+-I/SO(:6;2UL,-2;E-4_^%VS-U"
MTV!9*0J[X0H?9KNN1/W3X*OHR.]K_H:?E*T1 ];Q5P&.0P>KY[X<< 9[AMK-
MXV:>8GO6P6O-'\)GND\\GZ:E\I<R.;3.3.'Q?3B GM)B/N0E[)@B(9SE+'GX
M:D,7DUN&>W?';(CF)]BW%,Y\K]Q.)//+,%(0@<B&R-*Q8;G8?HLF_Y7%:1HI
M0F*CW?.1)!%:FQ %US^Z*31;2>(6L;,CTN_+Z'KY7 ]C%KE"/X(D'JAGN:HO
MHFX,ZUW)UCM-23JV(_%NY[X=.P>1WH?)7> #98BG[#Z;Z^O'EI1459665%56
M%*?5=K;6>I8DV98:M,>-L"=Y<\3.IZ:FU#WEB%.ZU*@-FMHJI=!X>P\@U1H"
M#((?_>R^]K#S6(W6:,&T^^8(PTU=HY(,4[[^BB-:,UK=Q#0U;007=<.@S09>
M%P\U+#PUUL/3GW--HB KX(*X)\U  W0FKWRE0@J\\)X./?/ER@A'7II[H3$M
MO,T8?MA0I5?ALT\2A+F%!1RQ_!VII&C(2&$!39BLP[*R"LG)\D(')ZC4R>$(
M4[S)>4:'NB'[*U>''NH.=)?:2KK JQD=*J>+1$4L (P97(Q-8TI)F:F'BS7P
M#18$:%PL!*')+[LVP%UF6<5[,C?1%X-MO<?GD5<7V0LK)3BI4*#EIU#"K?"5
MY&R<>1_<Q9RL&C_+\8^Q%[1TN!=Z!QB$=L$@#J;6)]S%I<6U_:%8P$-P:X:/
MAK]@Q@9F',GLY%&T?GT!!.5@ 8:XZ\R_./\-[W+RZ/Q7>H/I_SHPUO5G PM(
M.L"<=YZC0-.GL"M_3J3"M<]-%42(&<E"'F1^!<VF[4*$?_<=E(:C?V9C['$R
MG]D1JMJ$'HS V$)1[N[.Z"3WIO_JA?P[\-\Y\+_[KPC@6\3DYYM+(3M1$_N/
MT)#M UTL@!+!86P]PWP>A,(O'O-3%T--0:[.W,GVI-S.J9@0TSRSK^.O00<'
M1\M>406O;CU+W697%+T0VT$[5;45G\&@X,<!3-4Z <9:%0F?WSG!KC&=*&Z7
MR:&I/:&&1$:GD@0-NK2$S^*V=^3^H+*O/E]OPH[L.GD8?*9J*1CY%Z)N9;^C
MR*,STBQM_?"V,"50<?-4 3^.@ASZ^ \335%B/U H6Y%W#,<(Y+@%$OBHZBO1
M4QVSO5*Y8]"]E@Y6 FFI[RS06FG9<!,EDR54W"T>5/'Q+]K)OF:N'Z7+."_8
MK*(Y?-$B)H4&-P5O8JJV9Q/K+^)>O'<K>&@<R:IT._[JQA\\G= A'."_%'U,
M5K%), R7EJ.8ZJ<<_?->WRNLQ=0D +)088\%J$.[WGQ\&1X _.E1F *4&1R'
M@FM:/PGV+C4+K->[T0HTM7J.:46(?1ZWL(OD5.4T \IR/.IEFRO++P;]0M]A
MB3WX[&3&X%<R2'NQ5\MK4A(Y]:R:-6'KOKR\SZ+Y=<'[KOE"C!HCT:F;UV:)
M?O5)]7FRA=[LALN?+&[XI]%G[]QB7[<N35J6POGT=%\>6(>DDCS$NW1H)B]I
M4I"2I45]!=6'8\9RF92C$4)/3 SEU4/\= #9'!*S!RRW0,]\IAZO3N&,G!HX
M+L+SX\V%>)R"<22$76"YN?,-BNXH.RJS141M'XZNBANZ\%])?\Z?.,I$5'U<
M*R!/:WJ$48VRY)LLCCLN5.X+?)'W!1]=+QS;KMX;<&UW6P.<4+4S173XFJ?>
M\8F9K%QLVQRY6&3//7_K>F ]TH<$E"6/AF=]O@H^@:Y9__@I:YK1VU]=5I13
M[)Y5F_W10^UQ/KFLH1%%]+UKOZB0R/-LGH**I@G,A;\PVVNI8OM+8HC$;*'_
M\N)(R\K2H2LQX0P1'75L;PQ0F0#T]-?OP+D4R)\Z5+K$3I4HE6.6V1;,M*.V
MAN:&O]]GF-^WM\ E\JN17T3]SH"8*)GW G&8U41VGT5)@AF/!3D;6@5 QJ?B
MO,:#&MPVBRALE4KN&A;./R\25(+>,)0SQ$9W][)8!WSN<[\X\2W7O\81+!]F
M^0"XE187U(2XY&+MX+N,!*MH"!LN7;ZP;.R<4GK Z;UG$5.>&*RGB3]B](..
MV#.V/0C&9FUW:XGH 'IE!P;Q7ARLG-V<M?<2-#_F'C)])5VZD(EY-0SV]1N5
MX(8<9V7!YVG]B(8@H6TS'_UT)5%-;P^^69DJ1IZ>7]]S.@8/R]$]"SC5UM2V
M++I3.7;<\3KMELS! =DT"^>&Y8DS<R+YZ?C!+G)9M57Q)_T7731P@/TXTR@&
MLQ!^\\L[*G+PS&AX!X,/X<LJVS6+^+']9(J6'S.PRU]YCN-N%\H*F>:,1F,!
MW:VB.RR52Y0&+:1*+ULW2\H -U4'\END%:T#G=9?CBOO@NJQ@ 1WN:%U[VR?
MI,.M6R_;?X2R,"J'/^]C^>ASO\/6DR(=YV:O5N?4%!C?<VMY>31FG](5]+HC
M>L:3L8#'<.?SA.N/>MO+IU,?G@7;LJ=33Z9K98LQ//:L4U"BU%-K_K'V9=HW
M[E=,'CA3BL84EH$%L)J?7A#ZIHTV'^HER:3=;V92Y6_E.Q/65+_TF4ZO;Q/S
M^<3U]@@XL6]RX;BULG@F:=S<1/:!];GRZ;A1WZZ,DL';D">QLL1&+U@5U\/T
MA'7Q1H;I#,GRN[$ T$A)Y<"8="M'."5Q:>[+:!:B:T@V4] (%B#K='*907=>
MI<ED^D'+X:)C$+0OW<;D,_^BRB2XF0,GCQ#63H+M=!WO(^.-B-[1/>?^X*H(
MR%('9"."#G^1*DCQS89-/85-E:;5Y'!R<^<8K9<;0,P$#DR2OZ?I/-B>L!$0
MSE1_M3-)J_7&#'&#!E7-SOMN!2%]GMZ3:CTV'VC#;0":(.L.B;R\!G@RV_?^
MKH'+R[ZDO@RF]O=WHUH(&W-DMR$;3EC @X-XNQ53+Q6)H3NMB[M-.-T6W3;H
M^+WAVD.)X[9'*H?Z!-T._/SRIKO[O%?:KW6L/ G3)!4  OB#MLSV+?BF[6<T
MLFIZ)M]=,,\NRW <PY+?]3'5F<H%A\]%_%5]%BQ0E6/4S8\D#G\%X"55.QZL
M]2)>YC884H5T\@S>Y?;)#\^JO0\!+)X,UI&EPSM(,871-[TKL D>(/O,:\(9
MEB!(84=9Q#JC=OE)!#T&DKNYF.&CSH>WLST9Z()I(88L(KU]RM].=*@%)7>)
MLJ/W,$MFTM(#H5!A*?+1EDN$GC#[)6XOE?S.4NWJCKYDNB25^%!>-+NYZXT+
M,]5+P%=;5_^+!FLFDR&$L_APR GBL'1)8IONIM(;, >IPB"S_??*Y^ _#8:Z
M7?9J-F]<<$4Z6O8)N'<Q*3*D.42(P'2=5/G#N[6EG4%'S-'^>YN5?S]L7TAG
MW@.&KK;^IH0_>4>Z+R+>W$)=C060G^!8W1_6ZI7]P4 :"?W[)?QAG=!N-,8X
M&U&(@%Y!_D_%:HXC\.U-+. ]WC&.IBC.-L4P)P;J7CL=D)9X+&#4%K)Y, 5K
MQ *:3R"CPEA 5%04<^U8TO_R<?E_];CRWX'_1H'_]&RZXQ,"-:ZV@2(\8.KN
MNEGM+VU!<!DJ&-NX7%'/_O*@-:-3?XH%A(A"%L5DG\K=NC3SSS!&_[F\W(J!
MT1!=GV=(^]U$6;Y#WT498 'F'V\#0R_=KU@N>+/8"X99;PEO!:YJ@0 0[<,?
M61^*.&+T%3=<+CVH+*PY ^<>O15 2\\:5*GG3,ZP4W;FAMZ@?%?J9LO,:N7_
M4.L'IXEI>[R= 4VN3"BHM?M>[92'Y+U-TVEC=7!EM;3P3V:[%,44F*U<6KF8
M@8#IOZ"G@R;W@A<U-U &:(*.1K7RB[<2^Z_+*W[DVXIR'#M<=70L@8RG9P#$
M)2@<?U8=Z3SS<$PT&,K-+2C^,048HW@E']S-B?GF'H019:#W+SO97[E]GU-]
M>X*VC&<"Y*0RMOI).-&-9*_%_D8^!] 0?=XTL3)B;>U9LHXQ2^"]LE13UR@0
MX'&0N?51>!$&751<)U57YW(RUL$"N(42.TA/V3<Z/UW;^*55Y!55% \<1G;4
ML"V)/Y"C@A"TVA544M#<+(2P,?8&#DV]$:"0*0^\71 79EI<]"#-:$GA64HZ
MX'CMQ<[E+'OQAZQ+^XK*ZT\1+,XZPP7ZK[@GM8C6K"B<QJ#-[@\/5Z]4Q]VX
M+(A-PTZIR^TDTGSV0C!B;2Z&1@+]2LH'K.&@=1WW^,UG(@^@86;JF\)*['8>
MX:PVZ/V#<1-*Z!_R?9SX)U=>1UA/]1NRQ"BI!RM3<*&?OI4!P52!X(^OCJ,W
M]17\1."T_B(>HG\&#Z7'&]1 OIZ95KH>[!_X^!#C670?.XU",N=W>>"6?>/J
MT9')"HN_4F:4MD)L,[ZO< ;8$D+#D.I70/,]:;F,X;:EHS.2X:E2$2T6O%^4
M/!H%41LBNM$EIQ3X.]>G7,UM1%UM7;5M3O5;%?2;WH[ME:^$HBL?L@[>>?^D
M)RQ*7)<CY)ZNE(N6'#U;+0=ON0B^ZZW^L?PX5Y_AS-8?THTK+UBO'LB89Y<@
ME8:![R\^@(8B6L3&S5%'"Z9. 4F5^1\^A:PLM[GY;["I\UMYAM#SI ^\)YX+
M3@HIC<U_:&(;4IHK=P'C*X]*8I8(.AN\B3[893T4^?+)V/['*@6G(7D15(?]
MC+1WBEPM! NXTJ3^>)1Q]$.P'996'JP*,MU7*^\]NB=*^D;NWK7IMJ$YI;6R
MQHLL.6AN4='7F->LCQ_ GJN6SDZ[0O*C%_@P575Y6(#]QS@^KDR9$XZ8$J"/
M!C%YS#!( A6JHSO3MNKGX8]98(R=N0Y'=W5>JGUB;+Z<L:123\HJH]M0'-;V
MB*.NXZ]IMMD.R^+1S??4,J1L$= <R/OB@P4 "R*:-ULB<U-?\97H:3G+,B??
MU,W^0G;XE)5V6J!L^MQW_(7IWTF.VSNTHJS%77]9/*LWG+-9'^E_3#_6-QK3
MKTJO:'&7=_B>FX*4J[;4C\$S^2:7X+@@C=M^D7Q1-6X.'=G)548;,Q5K=;=L
ME%,N* ^A@)7FW%Q:J-'V(!9PM^EP<LY!5FBHLDRMZ&SYTVLOJ?:VK_U;3/&?
MGQ0)*VUTE2&'Y*OVYXY?>Q)RA4_.2@''3_7/]HRQ %/D.\K7#Z\2KNS2^#!9
M#5C -W]36O,_VJ?T.9#DU>]W(,EB@RK]@MHUG]1&'6);+:$^?I%ZDJ198DN&
M#OW\) PD&4LP3ITW@$A3K3RE&0DOMD)#JF6)A<$U>;>K:.CB&3#KU23C(]>H
M>8]1^N0CWQ[%Z89"._PG5R_QK[0).]]K<S2(/.0,)<H>O+CQY13=\_K[^:&'
MI%?FI]RQG)JE8FLV+$"F/<[[QGA!\Q:(^'Q;Y@P>%VN!M^6L #H!+CR%<57I
M>'L,80&=38T!4+T*G\M@R+0]^1YXM8^GMZ)TMLH9&+@ZNVQOUF'66HW)0L^4
MS,KIH'4>H1V.//:FV2OY _ *_/V#EH-B9P:\+M8RZ$_0XHBC^Q=%^.6=E$U3
MF!=,2PI<17,P>-SWK_LR4BYNX[.+?6D>&[8S<J\N\./:27P[^ 9+AZ88K30Y
MNVN:FZY\&V/\;M3>#QHFFD:SH&6DD,4].4@)F]@9YR\&/L&5N/4QV]UVOX"U
MSI9W'XLXJXM*^1JN\YPR/E-B=#,58\$(#-Y@ENYC :5=^Q<O#;RQ@*#RH7XG
MITFT=#,[5$6,J:6D+1#<_C"H:#%4ZX&^OAA:RCP:V@%50CTYR,I@U\7,@@H@
MZDZ?HY+O!/-,S4WK!C"88-11^BNS1!7R$6EI_F"U\.];6$ Y9 [YJ:+=B-0G
ME8;Z)GM/'%'--TG@$],(C$=[ 9>T59C2V$(KO]8TM5T<MO[OT:&K5L[]$1=G
M1]+.+/2TXAFC5^Q;@-1#1_4+Q&$[WAD\NLO#\?_)B*CZXQU4'"D6,(,X;%"^
MB!_"(USB%F7>@'"MMA:%>_SRF-!7:A&S(,7=#45)%92L><ELC7GTT.D""WAW
MM&R6^/?Z_YSGXCM!NSSR^&8%9"J^;C&1=WF4:LQ6 M'3_[A<'1=O@*O?SQDL
M / H^Z)CNIGYPL?]'+\9G%]5B@6<XJ1L+>!*! L(]S[!,9Q7.5>[^TK7TC 6
M\*>^Z^1RSV,1LN35]2<-,JB@0#[_X8W/O\IP[=^!_X:!4@.,"_,)K@-XF5'V
M0GVKZ.&J2Z[M+&K(V2 (A?S]^&* _'HW&M7AMRWY(USL2&T]"PQD79 .5!"E
MTQ?2QGDP-:%#@T4"APW0,8X@ 'M<2R2TUE!R2BS QA4T?>E^;T:EX>'>:YUO
MI-RE M]7X\>GD)X*4[:H5G5'XGL71$H<<Y!VI%.AQ*!):@& <RQ3_Q86H'[2
M-+D2L!>A'+\S^\ %#6Q"FY]T?9K(RC0V]<IJ!59-CW9FF"] [D"*S[?=C^'U
MD1Q>L\H"R_K:]'AE4>!K@0LQIDI50HEDO83CUA[5)S%L@:?<##4W<[@S.RTI
M*/-BP"(/TS)-94]*MFIP#8KK5*1E#Z.Y)KSF?LU%+&1/H7&%C4QBI<NL^2II
MJ;GKZA889F$W&VH\._N,MC\HOF")9XW\(O27;WT6*\!#-P?^66_B08-IJG]6
M+F;Q9G$U[K%3>(=!@Y=')LS0PE!QHKQ?HX9:RER#V=C-'BW==HYQA]7'%7Q.
M<SF'/\U)DW O3;P3K@M\!%4K,\Z"4"/JG KLT)E/A*@4?G$KBE^[6Q1W6J.^
M]V^R]6SZZZ.2!MZM!4R\"L\Y4IU44HE]8/E0>S#10$^:(Y)5P*F_HX:A%E^Y
M@2A154(12?HEU+ IH(DNQ9)?O<)]-K\,!<7X]QQC 5N=ZTN,;8FC5C?C[38V
MEUB [2%=V(?1F0D]+9WVJX,>\4^V< **!LHP+9"KI;JV<&QY/)L\W&%;]$"[
M]S,T]PQ5@F'Z*CZ;A*,*JL^L *6[TS1K=PJ)?8@#>+8U^&3-*JFWDT]?P9V2
MZ?]T;57U=5[,M]D_6DS4=I(:8#.26TYW;"R3>'VV_2152N7GVY!&^3AOEB<Z
MK&D*-H4AS]ATM0SA$ODLL^+K2!E0W0@*()V\Q..IV%^($C1BS7ERX$P(L/)Y
M[UPA_R+059[Y&Q9 "L19J<>F8>T8I4]8@).&X^'XD,,-BH#,I9CZKITM+2\]
M44/UN*ZTJN<;=GZ*#:-0L)&F#$4"%N Z8:KI()DQ=8V'4=<^ZR?:F6!<]&_?
M@5&-S;#%$MZ;%KFV\[SU64X5L 'Y"L,'N9Z#^HYV8B>0],T^5;6/JMKRK=YU
M?1G5FJK^XVK@8F#DW?@'UGL-*TJ+HYM-4Y9H+GK=-B+--TXQ(;]H9=RC83,U
M= TI^XPQM7=:.@*W9JZE/><0G*;E+?>RE\^E+!3A&0,(]^P27XVC@AL_*1T1
MFTU=OUFF?_-I?SE2GVFK>&'.S_Y@25?KW5 JO63"L#I--#5]7H><1'>91.3#
MJ3L-["LO_$0DBHFR_#HG"(!@&L>5K<ZU$'KN#,FUYU8)V>NZ%<:_9IE"2]<Q
MKMD_Q?!.H4V7_KV[RSW:FE.FE)JF0#X?RWL))*E+NA7W2X8MM^K=B/E]M'L)
M*!JUCA B#ZA"#$P*VIK)_,WW<-8$^M)?;ALZG_,A$Z)GIZOFSE)!@1I5 L5L
M2)3/ VU0@_$,<Z'75J=6U0?JEU"*Y:/62+&OD-9VYGX_,]!EIFA3O8.S\J]X
M]7HL(#LW<%]4H@$L3-<\VQ/5@'0_-[(KY>4K+;4O*^4J*R\K3BJMK"RU+HXS
MY+(X5>*(,LS<LC!,#>.(4^JJ5V"0D-2456LK@(KH/NW.U1_J\;A/T,61'GL.
MP(#;G(B^VD"RC6)_$$=E\HT*2#G)*?I%%]^U>R$1F ZCXC"&G8.BO"_S7*N)
M!?W!SZF@(DX[D_2O9[JXT/[ K&&K,AT,6$B/T>6D:?8SIN4ROE"$T1GA0%2E
MXS'RAGFP0^.BXE4504O#P<%O/'%8'=?\[&N#Q645%:G6YABFMHE58V8/7OUH
MG.3<O05A.J^7UBW;GGF'.?4&+FL0D17W94F[@K1QI\U5]:E+BZKM [_$*=F"
M533$]YWF)'EOR:W^E).KG95?&NZIXUH *B+8.?"RW<?F8F0A\T-10U8M[Z,K
M'&YU-;@$J9PO*IE?=383U-'[DX.BH0W*/).O9TL )) P>]]5U>=ID^4GQ>?9
M!R2KZ-"V64:;%FE%W18N%&G7"OJ:P*=XS^=Q+HSZQFQEFIM12';#>5Q+YBT>
MKUPT0Y"O;P7/I)N\K?;44-AO5BDW&$XC01PG,DU3L@IS:LQW'7H0U;83KGQ3
M 5Y$9SV(UJD+4R#X X%J%8X2HIOLS1B%4?:S1$U435>+*Y^E;8@]>I?_RV:8
M__<!P\UJXL&]NW)80$PX%C" GH[$0V>OP19]X+1GS%OPO0Y4.V0_ $@*V<CR
ML\8"5OCN'C&*52&>0:XKA%"X9FY<13 )71=EG_S^W7MI.+'RK\3P_P[\-POL
M)8$R%%!@R(]0+(!NY$0,QW3VZ+#K#\&KJ)-Q+ !XKM3A$H3Q8<<"A,S%!3%9
M\H=JJT5R.G('CM\YBCFZD(EE+5PW9BCS$YRPHXE0+ ;A)%E0<>TA,[&2DI1U
M_,[5W#GQKGVLQ4<'+(#^<B<$+*%H1;0]^]HXD%]A=OF%1V=S(M&>-*Z[9H(Q
MV4= W-U=_OT#-+DR!-6;43#Y\N[K>98X%=6-[^FE1ZW<B\E*_O9C\2F(/A"E
MZE/MYP+__!(R%7W1 :_ D8V>!/R5[[3$9>ZL /,L^@@C<C2U5WZ.!>A?M_YA
M;_H= $H_^_ODP:X+M#CS)702VBXJ03?_WJ<ECL[(H*^!["<%LVX@"=KP&@O
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MO>C+]6U%EW(."V@X&PU?\/"6<$,X#TI<[8012\?IDEKVWH+&@)%5U-"7@J]
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MWU<4)#$7+I@4I,.[L#=--I=TDL?D*%,X7LW-XE)/@\6,T'D$ABQO),&)ZN5
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M1?,SND1[VEMU=+CK'#\"3##>T0'3O4.D]L@HN@XELL<I-7JOY%D,QTM:$RQ
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M\+4N2_^0?-.ZRN9ZUO+U/Z'2\+\%)M]?F!&!E [\!M:1" P05+,CEDV1N/E
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M:X('?C%V(-9J](99KA6%.NXY)ZE3ATZS0)GO?1S9WN86!"TTYA19@59O+<W
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M?O,"^@,?6"%R'"<1GXBBS[$_!*M@P&J7! IUMD=35IL=44$$K!5([W[.Y:+
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M7&9(BD(WRH*D<.[CD0-N#XN?&(@B,0#%H/D*\,:K3LFOQC465_,11#@/<AB
MO1*X/P+5LA;9H78)OB [_NM.$U29^T0?&8O^E1.>I:7;F?(+E435KKXQY:8#
M&VWMMC 32&99G]2O3]\']">#B8J6R.^>PFTJ&G%!U'5O+C\XL!E&>:LG]!?
MY/?7EPMS1D.6\HRV:55L98QUPT.)S'@D[B=IT^9-KEK0 M9O>=40_O+UY]E"
M!HTU=^/+UJ[I\KU/V*CRV)842LO(@E;E8WD8G>*L"$Y>O>J,\G=U(]I+/F,/
M2,V(L36.X\G:*#$W8GO] Y&P"I25,*PGK7@;$ <U^@KFRSK&+NW,(#_'OGU:
MNZJSA $\O['N*?2 9L?PC;=X_YKITN((M^"?=;6X]GA17_?8K6&I(2W1O@_5
M3&WL>!]S,%$_\K:"3X.ZU=>%:8!(E8*6Z&9 _PUGA6:NW&2&'BEW:4> 7,C
M_-$N"BSA'-/YBZ&U%5+(!QPQ<O7>)J^J;O^4UN_%+R%S7AN^<<2Q;34\QDF@
M)Z/7YC6M-X//0&$PE_,19H/Z$D,/23J!C[Q/-HL8XFP1Z+;L([!][P?FCO;-
MF+K;*KCC_0U8JE=@&)/E6&ZX.%#KW!:;,QL;R'.EM9WO'"VK[I#9O-Y&#6XW
MIAD>$2*0ZA!ZUSK=0YN"O-(A&7G95F\N6@)/4LJU1RJ\,CQ1E9:AZ50N3+11
M&PYMW-?/GK,#O!0"^.1@CXI(XSU.QXGJ<A\?X3Z4Z+39LO:F$'#7Z'3Q__.3
MN QYI4/7&TCR'RAD#<Q_@[0#KTOLH8%7 2U!1!'@8EIGW#,0>LAZ0P]-3YB)
M :QZ4Y^$HP\P@.'I-@Q@:MX% ZAO;CFX:02>5SF"+RMK_][;M  ?OHA2_D]N
M/:\'GO#O5[F::>43T^*!O&[JBAP>W#Z<%9:S,V $]\.^*;,UTG4.3*\I/-1L
M8X\BR(JF,X;^W+HE]0X]Y:GAOW 4[41X?NE8/[1(:\S,]"!5>]$;[8N3_!0
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MGDYKA0LIR":;1FYN>(O/F:,)EZGV1,^'X_/WH;9_2/@6/8GU_[J&T'.*HH+
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MG^OIMMK]E;'8F6ZU;"4?>V]>TH!M_HIO/X.Z15WV86JSB,.[!JLA0,*[O*\
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MHJ  ;6?&</T@W]49 L838ZE$DQV6G"'TV)K@W7^\FE<]_*WHE<0]"?#6ICJ
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MX<K7#F-=).F:J6'37=K/.<E\W(6EGE7;\P_L]US94J!\T-#Y03;=EHFX>$\
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M3Q<R+P#=E>DPDGWQ7IFB>R_'QV:1N1X"@GU$R9-QR@N@AH\7-/GPZ#,H/@8
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MDKRRHJPLJ]RLK+PT':^?0"C)!I21'"-J.T,W1!%KJ(18):E (X2"*KA;$[V
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MWGJ+![Z)SVONS)GMA]:X\D#C%5]Q/C-LZ4:82YR.^OFU,(DWN3'J<>.61;0
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M)/E\3H@AU@TCI#E06;+7!/T\%P3"J(^C> V"IL"[!V)&/HVOOSNVI^[#6:*
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M0R.\BB2^%S*U><%_])UK?!0L_*'>64R(DVF 8%RFO#(R-S%0 Q D?*S%CU6
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MK:UM"K1RBHJ"Z#PMLJST5? (ZFHP<Z#H'9]_=EI0 9AD?P,\LQI+]0*0@&D
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MN][[ L8:5AA=6G^Z675(RWM-+V/A!\&N:3CTVSQ"6XT76F20K.(QUR>6O^T
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M2PA[%U-I^-E_=!S\^#AQ@)J+KX^=3O1Y;##V#$+ZDF1D)!C.(!Q[*[%[DOH
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MO? P2_N]^[[!*=+^:0,,1/;:;D(#QUL77I.-;]4T\I[[&F/;3N4+*FAVRW\
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M=,3C'^\:RWWT:H0^/K(\_$U^^GZP>IA] W^XF&M_Q-QM/[AIAY:^X86V&:,
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MM\!N]7]*%>C_ ?Y?!_[/,Y@I.8O5FO;P%IV-BG@/AS"1$A43M/:(&7^(CUH
MX"XB\$EDR;S^;< B=2)T%;1U$"MVO2+_1N!8 N-!SN0@@T",RDO.M*Z+Z/6U
M&C(/5[),)@5< 9TN_8F1OA0@_&MGKEJ>QFAK'U2[O/RF12T#'R-)V--E[MZ;
M5=F<V)6PMS38<L,X>/:%Z[L)::0(W*M"AN%;M'2951K2!';TY,OMMNUY1IQ+
MR05,*T[-)P(#:_H_X$+E8IJ["P;_W$I<Z6<)JVX(O%L"TBUSKBW)C751A,>
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MS.\]C4I<RSI<P?5VR,WR?$]B>Z=?\YF:1J=3NK0^?&ONO0D5!NK"NA:BTC0
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M0T<&M;7OK+=?S9KM[7[[T14P0J.@;9TO67@FD\T)+#2F4&3;Q]ZJEPL)9:Q
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MUW^Y7W1S8KQ=+^I9'!Y(6 /O,2G,G5?1.%JPZ@?6]LO5.BA%<SX=A'$[%?)
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M3^C)BPY<0=:5"ENGCBDCK=2JY9;59@G]L-*DM,\.N^8>7HS5I?M1*GGU]4A
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M<W0)_,6J7YQF\NO4PMY9C*AI')@>1,2M?&SK*O;9]VQB"_?OJ\FDSFGDH1/
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MR#T*LG>C;'\^>B%<CO);2E(DS6TPM\5 &AGJ(Z"NXQ%PX.*E+&R'CB^G#XM
M9D8H-9Z[OY[8-%F9A?Y6H?P-?:N+@@G+>D,R SJZN^X+$2;3YY,6,6)D"R0
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M4>7JQT<!+(%.KB"A)7-^,,.T'F>AAEC)M4=&]7%<!V*1,,#1F@ZL6'=J_Q0
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M7[U<?0&;$RB&.X-6_"H2E9LY]VB^('NGVZ)!CNA?#C;\:%L0A3IK*:RNFYB
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MZ:LPH:6$R$P7-\F_>[D!O@5[\I0]B,$NQ) =;V?G?KK<1UL_L#\"5,:"KF>
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M$8"7O"+Y -K70\AV(!PWS@8> 7XNEU=GZ*)? GK^+_;>,ZJIM0L7C7U;D*V
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M4?]A 0]J&_%[R6'35/C4 8?8/WG-_5?8_N&P6AE6;Q5636"A"U0M_K_8$'X
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M.MO?PWKV\CGAV^*A;3K*@+B)GJ:*[)9X([Y]E-';H,Z-,#E4:&IX7R"EQH_
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M)ILS /LV=>H"Q6WBS&.71099$>%=G7UK;5#:V^V%P1D^5H^,N9:K<P0@9E(
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M':_FN!L^&ND:%#QMP5:=_EG24_+AXNJEDR1((RP/W8<!4#&:W<T*GV8 1!F
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ME)V0DB$I^;96*B:5>/-=_?T_NY9*NJ+V*<A 8IDI]8$QO)]ZX3<:"1U"4I_
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M+ALXCMJI%CO!#, BYF@5_0">3-7ZC6S"Q+SW7<%,@_;>0Y?\9@C;QU,%">%
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MDR[2I LH2,VC"(@TZ4U >B?2 D(@1U"0+KT3 >F])9! HB*$CO020J3W0()
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MVO54V1%/ZNFW[E!QDZI]-,#4U+\<,*AXJSB07;1:(JB\.J IM$;PCVCZ9.P
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MF5UELE6OK.AQ$:RM2)8SROA4CS$V[U9[75VG_WQ1/CN1'FZVN/^=$N0QVP7
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MJQ<E#71L%X5$GYF;'M*@E"2]]A B(1[X 7C0!4HA2GG.#\.$<22@IOVD.T<
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MXP(O>E67)[F4]$Q./E1_T-8^E9:5=;%+YO-V 3^LZKAKN+)+B-K<3X3*:/B
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M\<;IUX2'Z=IDT'*[^+-@XL0HU*L'DF F@Q9<K\[_X64WF?LU)EKJ7)BX9I;
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M^E&;/&EIMK<+Q*Z[7^QS<FN-#=7/'#0021!56*T;GYXV>&08(NY8&,[)0,_
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M,X-SR3'C^3T(_'(=E!HD7D/MV5L(]Y[)_8N-I/\0\K;HQ^9L'4_EU!5X>BT
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M)566Z7_XJ,1I67%70/AR-.+GUZ+^F0&056SQAVMX_+(BI>-9H,\)<QV<FB)
M-VE4P?]=)'Y*,<*NCRP0;!-J0B",WN[U&I+6D32<(M5%E+<=8LTHFTFGB6^]
MNR4F4G7G>C_@==9%$W+U!>0Y.@/)7N33;I8CL;?B )X;1NA>3TJGV:_@;"]*
MTC1>OK73>6+9PV?[^^I6$%]I!F05$^+,[!Q_>>N*FKP"I_Z4PQ/3'KIJTMN,
M7^3?K?L\F@1FWTIQ=,2\JZD<RS=$JY1<?#\B(6IKQ_:EWWR,^:#+*.U3$WSX
MBO&#9(5$O7OG3)H94':MZF"T5C;_%;85(ERO:*G;V)RU,++!5T7@(CZ+J5-+
MZO6*<RL?@(C(;O]+8%9A>3T%2S$WYGJD#>SA>))H^F3O!?D*_*)YIZ=P*-8&
M?ACP&AP>7*"^3.>.0"0"_86W<P_J_[.05M$5P>5<?7@&M-L),]1-&#1@,'T.
MJO>KQ<LGVIN)&LX!BY\[D_.'9@.O/6G)WR2$ 5\M!%EG_5?T2OV@(R8X-ODL
M9[A\$#?'DXGSC(-$RIM>9>2%P?6OA::[PK84M9UIFVJ)$&_IF=9.-Q,O558C
M=4[KB9A0;;#JU/4)G3?Q:0H/M9F++*QMZ3G_+(3NWH61:F[H]8-1^U!%6E=C
M\"F3*&Z7>CCH2;FI T6QA%EZNQIRZ0C+F#_-&>?3,;^I>G5 %W3;;:U WM51
MQX3Q"?IN5/7!\LU90&RS3-Y9)TBK 6*#<F.<!$[3:JIPDR-(6.*SRD*]9#NE
M>:^D5G_H'[:Q_#NU/:5JHCK1Z(J<+813_Z,H=45$ Q!583/?PN\<.75/[R;O
MS>5G$^26#L0]39HC?"G/,XU<+A=\O;65<&0@]V9H!H0WG;$($A-%_<HJYK[N
MQL>8["C@0+?^[K9GRZ%=->Z4J0&R'OZ)F(_&IVW287SA2B0)J&HD \Q@D^7<
M.0O([XW/3=.S,V;PH(&E3(4F^OZC-'Z*;F7_2/ESAK+PD1;0$NQ=[E,XE,L_
MLU;[8_\LB9B P?M0P?@D,JITGA5/:T]^\+51H%>)BTV*N0VI\_SS;(DENEM(
MG)<>".!_4*AH$RZ+\R!3>Z8#)@TFQOQ#-2@7OWYR'5]::5E=/W[26!NL9?L/
M2$M>X0DDB[LX55:/\\W7ZFJDC=ZYJPQ*F;0N5;MNE#5+C*A6":A#T)EA\V0D
M*MN#GJ&>;[CS94;W]8)-%9Z/CSELU9N;FNE*@A[_4>G]YT*6;FKDR&?Z'YS=
M7?Q4]UIM?Y:6_(UZRO2F$ #T;_(Q7;[3NZL$@34O+#RL6.Y^,C'^F,!S1!<4
M/;KBK5V\Z9A'E&&>2D'ZOL0:KDWS@0D #ZX&('O-[HW#N5L2(_CY0,.J-D2,
MAC_$=1O 7\8S+PF79(6J3DWM!,8/!@>M_DR^GYYK/?'$AMLBA8Y(7O]7\Q+L
MN_9$_L,DLC =Z9/)R=@/J^\4M2-L!B;^VM[C-F@">#FY"7Y ?5)<2'[G*\QJ
MKB4_M3W.8XQ-OQE8()OXB6Y#/H1PC]V;]M89X!4DT'QIL[_CRQJU*NJ:P0R?
M54>PO[=733OV+O&O+K<6_Q56VY0\@3?)*;R&$N(&QE?C<VA7+[4S"N+AFW:)
M KSAQAO/^%*VE8J#,]IV8Z0J+)<0OSS@)])A9F9/Y=D5!&UXW*.1;]\LGU\:
M^RP6Z<E$3U$3597!'A4'[) EW%#)0?]+.#OXVU'L-?0!WFV,4@T"&D*]N=A4
MF(.=T@W%:XZ"W__W/T'P00D6(7W*% 4@MMCO7VQ3%PAU(_$M&Z<F2 IXNN#,
MO9W\?V(N.">CM_TA"RC]+X2<ZLU[^J7SRHQ'?=!T[(+G-OI$)*$SZ"+VWIRM
M@;<+(GF:$K]1HV55T+>$?=PXN8)^RQUTVS.:[\(C=Q7=RO+XHKOYW^-*=41*
MZ18''VXNL8UMGC*EGC*Q M?]![!N52< []HQ2GM9C^,$_I>'K.TID\?TAC7Z
M-_6ATV&BY=Q51Y0?MP2,L]KOG6KX8D5Z\:4M(3%Z3DLZ96)\XR5EC),D9]"[
MJN" *;!3_1)5\M?'$$#S$H'(<;,Y&^;%^I-IZ)<2\_A$MYQ-: 43:'KF,DI,
M=W]-@#'?YE'*OM$ID[AG&%@RC'U[@79'SU;;]#R8#Z3Q.2F:,\W@:==R&I\/
M4U5)A9AFRVU&\VY)2"J9OWP(7F" ],N'X G\[[]"<<=Y6>1@TKOD2B)(.;':
MF\M2*A0PR>O80GY3FB98YFY^I>J!XVU&%8!+K?VH1B/KQ<0P!"N$/WDA<+&9
M^NVS!7.;I?>5+6.'9;$UI,F_6<QO?/0DS)@,WUE?HS',KOIWR@)F :.15?3=
MGX;=E[>P:)0?D[C:R\)\[6[R_3/7!?_ELA Q^<#$B(OBS-\N2_SC-(VM=8ZQ
M0Q5HNP)OR!\L4$[Z>(1@08)&1@G/$TLD<56KBKNDDMSBPK/-:(X?N5'L*<]0
M4;J)R-+RX+B5I#(Z9TQ4)Z^KMRS:U"1\5&K^1+#M\86'?R\,@->&P*#NO,?.
M"X-3$Q:0E8'O8J@/6:&@T+<*(/D-TZ=;^F,&@MJ#0%&Z\B9:T;'?X2=V9H5
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M,&Q:?TJ']=-2I$CECI7@QK?'\0=<%O0@J5P(TYHZ3FGT;8^8!4/PK>LOOV.
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MC[2[SV8H4XQB27R5![;PD]0B.TQ<'Z;SPV2E_Y^UR/Y_^,,IX?\ 4$L#!!0
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M ST1BB)54V7ZB+2116?C-@8@Q16Z?1[NK]03U7IW5I&3!5N81OMD%DXL.GI
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M5,Q>J\UKM8$3UCQ-\Q99![\Y4YEA^@(J8AOL)[30)A$P]B)XR^BGKRI=M+#
MM$N&P5%>%SP'2[']E(4' Y]J-1K4>1]<M=H9M :_T19MKZ_;@A0#GUCF<5N<
M@D!D^79D5P$S_ <@HU!^3-J)"D,?J+H^6BIE/C93M<]C(L^,N]?LLWDYA^3>
MM#V:S[[6:2U%%QB4/56V>O0E^G#E68-+KT708M@5M_>I^29M1>R+&?8??;?*
M"8%(_O)-=5"2"SM\6+Y%9_<&RIB.ZO>[%)\<)'#.C]5J1?'!94597I&!F^F%
MN9-LKS7%M,+]9L1LIW7R"X_)<1[/(V7U=>T&/S]DCE;\]]9):R),P*.AL1(>
MX2!O0X8:^RFG>X@_LMQ0O!;$IE9CX7C,Y[A=JNX=V;>V4*=F^:\>Z*I!UG6=
M1"0('^\)%&$A9^$-;<L)HXKH'\6C7-]KOP\S@&9\E3=M3X\B[=R;.OS]\OOM
M#@L1CGX-\;29U<H%;:N=[^5\#S3LDVG_=%Y22F?>9?EJZ3BU.\G3G]UY(>,1
M4H#F?8G0PDUE]Z4.$A#NFVL(Z+9?0+<)_^JWG@5MVH>+9?8/E4M.'*R65J@0
MR5TS"<Z/DHL;")01/'M/+2-7]/2A;X$7L3H%PBZ+5,Q0F=NNSH$+[+U*MJ0&
MSE?#+<X37/0E9G1ON+4X-$D-(.5E>"PW)A6'-RS^J)V1\'V]F)032*Q$GVJY
MKZ,3Q,NIM+;65:NHIS^>?J%8-L(XQH!_J>O26>..DT@)-UTC65;^RG&(OP Y
M?8143.TCU5&/^#I2SMAZ/]Y.T,EJ=/VB6&H]1#9(?)3Z*L?VO<E*I]?AM,YV
MN0-IW;ODL[DTC_#3T29[;@30G_LR $2)I0WYDE*ZMU<G&$>V'6[,&@/M?$]
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MD!]Z%K5%&*O:_+M&>#]1!F!,-[:@M6Y$,X"(&AJZE4I>SD#.,8#@^6$OJ)U
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M#I71AG"PM1C/(- $V@HG$MEUOV+9QK<ZU RJUK$T<'2M(F*@6.!6M#'G_\X
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M<D%3$X]712-03H*#DC9[HG>!PW!0V9: 2:#/1AN;JD[FKD>4G7\,D^GA@<A
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MK?PJC;7X;Q-U7%L!OV56<<6&DMZU^H]V]\Y%,%'8^Q]6D_SW5DM,AMX2-'6
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MGEY&U:B @4P65R#2H21*J'I[U#SM)F(M$_RIL%2-QE@B$6Y#\P-"G72HM6Z
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MW+F^_, ZP,(LT]U)E?(-3>V*F;_BA-/YAA6O=2ABM06M"ZP#NV)"&\*@?GB
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M__AF""-TMANDVC&<OBL3,7E67&UW/V-MR?M^/^SWZV^(+,R8K+[KU<AHZ2O
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M'S:]E54!XM>DYR=5FMVEWX^T(ZUXQ4*H;NVZ['4N*,:?,^<^4L%(?1.BO7/
MH+<'0[H1 47LM9U'W;QM]=/W*_O+7&_9B$N9 >=SNYQZ;O:$9]/&#**\Q<=V
M+B/T_*X%[YBVI>!H[%L!]':2*II_MJ;XH7(M+FD,(HO"GW_S+MII:U0>;69
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M+BUF4=P$_:>QTD]3)*-\TO7R$-2ZJ%&:VS45% F8*ZD#)AC>V2_/X:A*(M@
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MPM8+S\)34<H@>.7C-5X9"9B)SW,[+CV]#!Q8\XP^53?'AH9Z&]TKU\TG(DZ
M/D6.OS.?@Z%1>6)C?\?0NQ/?=O]EKV]=Y<:;.4_AB^9CV KX=N)\W'\]GC?Z
M#8G(%VO_C)WI;]C-I>WOOKH0?+/Q1:H:%>903QF:3"<7#>"ZJU(PDFL%';<J
MRA=6^-#_TUQUX= U$C&7!37'<'][@9&?^7*>U E=1I<NXNFK4;8<>D B[/C4
M^LW*=?]"-?26SNW*K#\;9,JAR]T$H[W/^HX@U&0-H^\X#9,+]XGED6K4;>I
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MM[.3772ND+8@I+FU&L\8G"CK";U.3 'V63"/5,7LZ2I__-Q0269+3-U?O=D
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M2*/:]SW)/^,#I4XG5(_9A^SA7<*!(YAP8,:E@&@>KC.5#_D&\MJ,<@6C[X>
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M:K:=Q&Q=EW.%O@IZGE'+&, /TAQ8TX71O55<%^][@^.[Q @Q8V64.OHA7'*
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M- /(=M8,1UU$DJMF)_SSJ?K*^1^W7:=W]9Q;VO&.3%[EX%D_E'._T/)WA'#
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MP:G%,A<]Y>!E@@AC6\\OP_?K46/]VD0)@Y49];%+L>\V,&WLZ='/_11K6)?
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MN#7@5V,5 <I(,W?+&PL#IM#NI-)H%-BFSXPU]$Q_CT.\!:[ @1U4^/<HG^D
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MCYJY>E;6LS_G_:[KM\(N1(WZ.',@=KL:A9U!(U#EHI>X&1CE898L=U:S;;]
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M)U;LN&:@LE8YL[C=6T'NT/DYZ_^F>LRFZ6#078=PLO%V>[+T$?A9Z8#^I9$
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MEY'DJ"'8.'$#K'(.Z&SBK)$)W@)7,%/\9_[$GL_/^NT&BULJ2'+M1>1D/UF
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MN@L\YYV7$$/L2-,JG1BMK2JK(?Y[OMU^M#X.7F=99M)2PXZ)3G'237Z#&96
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M)CV_5:E@RT+S];,8EFM(TDS[S0<@0:D7C+!<\U3"$I1#7Z-&9>^X9K2?!],
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M VH-]9M0K@>_F#EU^91L_FN[1;;V&[+<_NL*6!1+@02;&1( X5^>!;%K=IR
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MHPDY\4B8 \>EV!5LW8Y4UP24*^NW[Z3#;)[P?8>$"QVE*D/3!)\/4%YI,!?
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M+>43Q(D,T7]^"RH(D!]R6[3+VJ?(;/+\&N$>_[LS-SF")<WZ7QT*,BH4)>P
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MA'=K,&0PY,0._#\_GI"+P*ID^N;T$R@!I-/Z:&-KO_;"($-=D27Q=++!)BA
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M,>->88_KI<WM[Q5_W&T]";QLC77$U>=([-6HX7F@WO)*)F8_A."-T4V(4&T
M;(I[2.G+=&@OW'C5 ^OMVK.M>=/<>^]_@\&7P;;G)P]Z0+^(TZDPNX ;F?OE
M=0]T6C#!V"\I\5Q7J'KXAK9IC+-_J=$.8<:T.)JW-/J?!:32A9M@L.^^[/)Y
M=2-;MM4#+V.M+L@79![GD=^:.L;H"Y_?A)O$+==J0-49@30<1;H\MD"].R>W
MPP3LTP?ZFS685:)M9D_&YJ+!?OMVID"HK1@Q4L$P$D?H%QX$.RCL48-?E-LJ
M[7&>Q)]2(H,YD0>SSC]D_+)?KC_.REXO9X_KQ#+A0SJ(84=*RUY0DH,P<J5N
MYKXW5MN?ZASZ]4"L;J9UTQ('MN]ZA>>J1[EY81#S7)*Y]4#PE<W(;-S85*]%
M9E8:<2+I^5U\]S8T",16QE#J,]348+6K%!%%D0$X!"?MCT\K^AXX$U,/-JP_
MD*.GP?QG+#&7KL$QA^EJ*Y+\%_\YL$V#6=+TKT6,;P7X);-#T:5<!@M/ H.C
M%X0-F=ZOV$G +W[,UK8GK_$R.C207A]:&I:(&'L]:<[M$2%>LE>D0*1KJ;"9
M@! FI*,,_O@:#29S0O\@,D^P\TCGN^&]ZP_>MEF>]<Y>_7.)3H<&$Q[XK=L;
M8>2SKA$#ABU?T,ZBX19]9)L*F]7+\M,X;95M_#K7!F^&!N/,2BEI8WKEP!CV
MI :#)921F%X^3L0GZ(MO-_4.WQN*+^810[ZYP=%=JU"<Q(N&LQW4H=KAU5?_
M*DQ2C!PO NF2>=RY!@%E#8*!)824!5Y4=\\G9AK,&3(CIW].; Y<E8\.NLQ^
MBZ."_^G:0Z<'R;0AJTU7VC.^!L^NLR\ [OPZ!\8,8.574=(4-WG&(TMED:2?
M,O-C"B$WQ=5RUR_& K5E4?SSX3C6=\\+YI2%M'%1-;@8(F\!NDL[BOO]]%!3
M=+0Y(,'<< I%CNJZLT^4AE\_))9'_0AD_;Z&[PW9"[)TD/%A((C[@-9<9DAF
MX3TF8BNJ1E91.EZ='[6NKO90YS44"O/[OS-'<>I?\-/Y(*L8J6FC$(=#@VJ6
M-A6:6YU/[F ;7LU!.%Z=&52>RU60.+YKJ9P@7%EIO8PZ(9K,]2]7!]>_2#">
MV!\X7R!6[;/38&IO.G/4W"D9B13YDW_]WP50D<U>O1E,Z&"B;"KK0SP;>4X;
M+'H\K6I-)NW<[M7]^(HN2LA@&MA.5^/T4A=O#[]SOE;F17*Y:A)P"I$%#->W
M[(F"3PRF7=LB6"[ZUFOY^<UR>FNDZWIL?U10(T[6IMZEFYA%5X]^^/XB?,WK
M>U",LLBW2CY3*CB9WM9N\R:9WM_8<&K'TU14?7F"/]0;$]^,=B*"0-&/5F-B
M5W$&E,G[;<D:DT8_?9%P:>3UQ^&7QG8V=D]2:\A\W;5?>T0P-D<_LRTS@#>U
M:IP,-,8]];I:44$+WG[L^F,[@';XFI\:W%H45!R,S1X7'@_.ZPD^H<$TO/P,
M-!G\R&D3CN _ /9]1+T/#'HNM3L3?VQG7&*R:"[9,Z_0JZS0?.;)Y VF[@W3
MJ?['&X6(VU-"MHC\.1]4;B 8.8+N)L9!_LF+)]=.21SJ]%V72)BQKE/(ZOA/
M5!%2-&WX-SXP+!W\*MH1'" ( JI"-UF_$/M&1'6W[I;B)X,RG>'^#E2R-:E^
M$YUE/FB.G9+KW?I!+A#U121D?5AE\_7*.S!V1B':*8+V=[T><_X_FKX[K(FM
M^SJ*BM="KE<!KPBQ8P.L('54+J(B!&PH+2HJ4@/2P61$5!2$B"@H"%&1+D1I
MH4=$B(@0I4,@H;<DA):>F7S#^WN^?W@>4F8R9Y^]]EKG[+,W\8 E3"G*U BM
M,+D"_VF+-?O6>^1FB'[0J@911PPP:R"LFBM !/=N(7O^]N%6_TIG\G=V<<"X
M5EO/[VXP<,;^BW1XMW(71*)&Z?#(_$B8TI2K/\(3DWBFP5 _$S/_:P"8[S=?
MK = Z[L,3F&X BP%/P3P+2E@<!!=/G\,+1<A<;*>(!.IDJ51,M-P#E-,DOWA
M/$NQQY\&06_O&2)Y9NDS"!A97 +K#HLK-M#($,@% 6S]VNX.>QFOI-@C:@!$
MIRM#3W6F9^]"43*^9$',FCZUO!%ZN)":DEFZ3H&Z?^Q>W%X%:O[#C\XAQF(\
M>"),Y+_Z- UT3_ZI_*&,Z44 ,/!IJ0JG 15$O^4VB5HAEO.HIS&<^R!=&KX[
MY25U)="W9QH<WSIYK$]'8_B2_)'1U#VJUU#L'!-84C% E3L="!Q6O:1 G?<,
M+8/3!"N@2B\V,U@NO3IX]6>XM=E_%T&]><%R68RZQ5$=-3?OZ3Z;LX5LU^,'
M\UYA!/?W2)D]H:*S[(89MSG8>>/:Q('HG//H?XQ\$PJG]I[V4G;"5Q5_5[6+
M;RC=^W*=!!H"*:UU$'B[L>6 $WB=#5.2+/QYHT1].QB#R.$;]X*]IA^V.2;7
M<KEWU#SV;U_+N.PM.?P3A;@".FM!R(@L\QD79,T :0#9)L_!HM:*G&8TB,$.
M:=OZ,U,(;EF;P:3ILW7P=_-5,T!W^+F^]#4A[HOE@5(!K9E.A-XOUT)DT)XL
ML5$JQB9PQ$J!TGJT_ Q<\N;L+\HX]%$C_&#4*_WXQ=W6GZG:!.F,I&U.27YT
MTL*ZJW+;DCM!E]MH@HV])^ %RY+G<]!]N:J\EN,67F[BDS*G#,5EQ>90MRC5
MEW[>,M_X_B.&OYQ&*=E3= 6] ,P$I#FS!A#>DHC0%)6/8) ^6SZ_$9"+[!2H
M/S 3ZJ<J4):(:'8.H_'P\X(5UADEZ*/&^"70TK>$31BAUGM8,*U 57S:@2B_
M209+I"]67TQ!3,K<&U?:?>GXOZ6WVW60__VZ%*@P*M52SQ%4O@S)_$;]L0)"
M]8F4+/TU7PFE&EM/(PKEON'>7U<P<[9"%T,L'N@!4[(4*+!?3HN?.B0XI74P
M2Z-,U'F X!W'7@T+_&&S-FSCC-Y?HXN%Y#FN]VX8/\"48"5G..E=5[N!YJ!,
M^0=,Q','$TJ7W (HI>LR5FPMX]#]L0,7Y!5<GL^O"*"Q\NSCFM?SL'-A=@(T
M0A:3?5*S_$D#B!%R$<C.QI=RR#R$T%6[2@0]]4*YO7(PUZ'&4LD'$<BE0UG]
MB4VO%T_"6U 7R6W6NQ>-"I02J1EDM.)]!2VR_H36KE&J6=_WBW9LKN>,L<_G
M2V"IZE)670II_S1S7-B%#&^+[BMO9FSJ(W<O(J$NJ\*GB-%Z'JJ"JFM02^NM
MSN^&2\?E%E!*]]V/S+!):0Q9T@@S3A?@ZZR'0]SED[!*IE6G_T]4/K>F_I,2
M9'-JF#PCS)/F"S!,Y^8V6K7[MU8,PFK5L5Z2?/E9FG$9=EQ66YZW70H^Q0EH
M9D)#,PVBF;9\9'(K*^7G??DC\*>1+V+"U+L77_6T;X<[27@A&RNB>=P>X56!
M[P+M:,[D@Q*5M]>FH*AU4&K40XQ5(GW]@A3$$:,2/PTL>CX=1@)G46?L/'6Q
M7D-S&UFD[?$=<+TU4$.;+_B 7^S[].D*6+-]\F"?[F)^RL%VC[2J;@$X7NJ#
M7MP&T8:CM28,'7TP$YIF!N'OQT#RF1RCE&N^6YG:ZR4Z%@GY]6 UI71LU+I*
M$,@N@#R%$;#->VSGOC,*E)JFJ&9&C:;M]RP? _SNG!0F2+/M9:OC4B$11?;?
M97FVI3B,+C>F'A@YHI%TQR?7<S6H]7YC!47XSQ]?L[3)T!4\]P80,X[P[66=
M]D0+8AVIVZ_U!K4"J.0)'=N\=72.*S]3)6A-(I;VEPU#",Y?Y[ZI;HANKDGV
M!#LG.E6N2KN)&3; 09C2T\8,>J5I 4AT6]F!!@9%O'HMQM:Q-[K@9^K_.O5Z
M%UEAOG\E9&77 31_ Z]=O^D\*3[=?KKO.54=&+M.->N!)L'@F1,#"^PVA][;
M01W"P(>\@MI<.WW+PN6[%:A7:S15-R*^5+Z(.C(,'N;U%1P>5J!TWQHGLLI6
MR[ RY6QVWRKX/]DP <'-$W)+L?WB"4":[@]P='N&K<\6>#F4:IETK7T)R&\1
M2_L<M4$QNP)&3'AJ=G32GH\Z^#XL=M>/7R>^._*/9<$IL5L7*[V)9!6NW_S:
MTN\JS< M'\PZ^K_@ZGM4:5B)[4> ;R_RH[)5UB_F%"Q,T$I-CD,EG-):?ON8
M#O\4N)E7LBB W$36,X,V:<:/\HCK96&1.U7D3_S+@O)/PU%XI461!_,7*M\M
M9B<#<W$%:]_/78>9<OJGNV=H'VC&-IX$P[QZLBA%YOFM7]EJ20G>;K'[<*V(
M$/$+Z._[5\X4/Y&#4=0JSYBXMVT^AW&CK?XZ]_M[5D6?_97AHO*Q]0'P8/W%
M/<A$P33S(8OJ)&=NUV]BL>&D1[_CS9OW9MO>5I+W6?F]8;Y:H)\&P.-@="^;
M!Z5D3H:BA;\#ONNO%CLLUKL@[1(R7= 'F_[\?9GM!IO,>H:[BI[9@MZMLUXA
M%Q!@MIVL20^3[-H0\LPBZ+S?W>\'ZDE".8B[ WPZZ 2Z(N&^(B"ZQ,@GS>7'
M)\R7,Z3ZW8 + ) F>3OJ?"LGST/+*;88+_X9VH#-8OXQ=F*\_W$M :@GC;8F
ME#FN.;E/+ITR?9,"./-=P(QJ'%:R&N'H?C[ %, -Z.K*0N+&RQ37NY;?'5EE
MD-D[##(WQ"2/:SW4$U\%N()2XG:)4F=  ]Z#J.$WN/>^W-[U&T+?'+944QE2
M&MFZI+XR%,.$?2)H\2G4SZ5Z_PE=QIB"*^=\7+VXSPIPFLZQ H<P9=3]VR6?
MWH57%?G8?C_]=8>2+.S@"%3 #.[W'D@YFK\O_AMM9"(-U"/.\E7$O9H477%_
M",2P>_#+U7V"<W<AH'UIXII7AY6FHM'O5^Y'8V9W;QI"5 9)L-9BN6=:%&OD
M;EI'8\*3[?_F9";?=Q=>>*<T0FJQ:<KD.@6?D=_X:?)JH9PQ</3J,U7,[-3;
M1+O86)4#33E/=GVS!>Q@ZNB*QJ/3W?4ZC4H_R8.#,J-_O(F]/:E%HLRQY40B
M;F2J.4S9]=ZC>FZ(LK^PO#]E>-M0D>'FUQX>V0??6VXHSMSN;H46^1H1GOCH
MB)::N$^[QREK9^.":WJKPJXR@]#G[#71_WA7E=PR8-TT\/&?OV8Y\X4N1;P+
M_L;JC;J3#$83HV-_/CN9+C>]&773>QX[UD@0.)_&S*4F:,_3MT?P_WBM!$K)
MB-S#IC;XU\DUCYWGG=MP*H'[Y8BRHY^$NB"?Y]:&$G<#O[=/;F9&F+EE/<EQ
M'Y2QY[:>OL/%CL_RVFX-!/PHZVC_<FE8II>_7_5:2IH>GE[RQR&$IIN+C9TW
MM4Q\?PV/JN9Y@@5ZT[_%O8AR3Z9'P!2;O!0_>>\/ZB\G3(-U3A&B;+*IVC/-
MG,K#KV#KLZ_?NURO:TVX^7G94^X9N%3HZ!?^C_5"A>_:)?/#)\,2O*LKI&DN
MQCUEJ@K4O9DYBMCHBKPM1W)!C=4=B/MWN>7LST\%QWUF8S<VF&%*<$7*_&J'
M !Q'(H5-IZ_NH*ZT3;Y7';9_Q%&GP+U@Q3AV_R88')%+CT X71$"-L;+PS='
MT%1:D9_*OD\>!YXF(Q*9J,=@.8C@K-Z,AQ/3E'%AV@/UQYALL[5[YF3*<Q-6
MLGC58T?5TO67CL\J4!K"22BTPFT#)^I5P=ZCCN2L+D@DX],K0CXS8=)%B6#8
M+GX]>8FLGKKP68'RIE?'G!4XF_\.U$H7$X[_;2U4Q06 7W$0PL"J9=;Z'0*0
M>:*C!-);"B:=2>Y_^N"'0SOH"1\QRV-#^)OV]_+60+K.S5%G&O533^F'NQ:R
M V]8S@@;+]U N,TU(HU+2%*@+MWNO3Z+J&0]J\<C.VH7DX:W<M9JZ>F]O0^J
M>'4>>C@O/UGI!ZX?EC(3($+["=W1NJQ;;QWN_6<_LJ>-(C4\#'[]54VX:J"O
MM)A;MX[WIIRH ?)N3[ZOZ&HJ,*<(VR\.>;"',%W/7D')P!X'K7CK,/849M;9
MWC+\7EY#(*UQ[:M9NAO7SC&),:U2$Q.(?P:%)*X\&-YE=>3*U)63N1?#'CVA
MC?=XR0BO$I:OCI W+T&B1MC+\N $G^#JPN$ @PU_[+"_HKOFZ"J?-F&GU?;Z
M_;>[^R)3VHFFB,.+2Q/U32W)PWKM27D]"VRWE<Q D=+48K5(.X8,$QA;VL3@
MO5_<R@K;J'O[!\#(6NE_S.-$F'6ET\MQTMQ^O(GL<JPK'*E\KG[9\-.IFXZ4
MS3$C,H=>O#QQ2H$"<.^%UV63.C2KKXN7N-AMPPJ42YO5Q-^;\"(]<\%0';R/
MUQW,,4LV#D<+C>Y]^.4Z1?O587N)1-^,F"_---FRTH( DUIW,1<DH)XP[.Y\
MQR*+\[FLE3](2+T^KX>(%W5J,?@-3+*?J0$'.,K/%:@<S)R]W).9AK8._)F^
M=879_.4.6SM2+8H(4A#:A[MUV'I!@>H5?%%Y'R&OP!/XU,N]'C!BU+/[ UVP
M\%.SGSZ&#UJZM+]CW.0XERCO\+?HL>.+Y2->X-_ZJCF<6SPL:C)ZE2IC5.L=
M[D%+11V9O6X2XA^8B(1NPBQMEFZH0+T3N$&:?'9GN!Y6FJ6-!*B[3F$(,X*)
M6=K7!A6H4:R^+I'6/U5(F')Q_8(P4R+885,MBQL>E5F>C[K&8WQ\95@  OU2
MQ Z_:SC0]=[W\(\FF;)$FB4(XDKT9%TRS7,DHC>NWCD<G=&RMVB6Q^8X9S%@
MOP62M)( YP:V!9G]C'E:V)"4!O8%7I,RY81)PV0V9+>03'@P'B6QM-'I#E?!
M]<.SUPTQO<ZX0;Q/@:C$Z7980*)WZ:3ODL4Z0B4I',K40.[CZ.C(P(N3M.YK
MI7\:'=B(HL'=3(GM[%CLF?OP<_F_^69MK>INT[_BVE7;0W5(%8_-"FC\B=UW
M_!Y".28$<CNN&TR2Y)?2>.\2A&T92:6V+O+]9BQ32Z[6[^\ERM.\:H'%!<\4
M'C-<3<7_(4+$_MSUUAZ5A67[2+A&KD>QW3SGGLOHW^V(ZEU30LN@B(4>?=TY
MZE/?E,\,][JY*.?AINZM&/LI<+LR,LSE_7FJ"KD7<8"HPBG9\;+<ZT/J^I]'
M(-/[O?2[9>0&=<S@Q,\O=;8_5+#KZ*:K8J*X#JXRS8QX-1\SF99E27ZI3XX"
M]8\4>[0^@Z%AU]Z>4IZ^Z3KW[4XL9,GC@-\Q[LL;(!CA7+ ?^*7-3(4IUQ:2
MY@7;]K(X"61^W'>$^6.DEOUP5O@";"[O/[@@-!?3\$X[W_&<HE3[LRQBOF!F
MKS,_(O+=M' ;:QKXHT!U2 (ZO-4?V/,09$ ?[PKU>O:18,@42%2^LGHB+3_[
M5UC9@RH9^ID81]*D&$[[JC7E)<JZ7I8V%*KUT+7IB61AWZC&PH/I[N/1>T$
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MS%YAI0-^>*$97</+^!PRO^\@WM<SD3AF70?8.@K3'B:'A86$/(B./@C=.8@
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M5UCF\J,7D'AC4$T<^/\?$_%?8695&!)!G2R^&ACG^H#R@8^+B$Z9_A>8&#=
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MEW;)8\(/.A=,'[=U>A:MJ1U'K&UW_,4:X+X=-:TZ@.@8J\T[VN/CSTJUHG6
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M&9!(",O(=UH)OKZ1KX5OZ X=!+,'38.%6H/_[,$%6,F@^37BRM@+3 "OM%P
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MCI)44AQLPE(^($OF>@H]&NT5>9'60KVAKH,OAJC+SK5\S.,HZ7=.)L&KZAZ
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MQ4O./.34O\P^C1Z4XEH)0T_3&Z=27]%WQ] _;-.*3+2X2$K-3>2N>K[O.CA
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M+QOLL?V*G?+<P*^-)BK4% ;G Q<;X89;[^!AJE@]39.V<KV.IL4]/6!ZXA+
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M4X(<]"RU:I8^F4BE#"/@SL:LG.Q6<OAYT#!$KYJM=:ZDN$5_M%ZTSRGP<A/
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MM0AB_'@F-#NZE\D&#JA09T&.XD)^,+,])*')$<_$8)%?UK)@O^#A+I:SW^[
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MS$N^-I=)BBJ23\V22.=!%5! )<41$L5G:.F1V3N+@NRLT:/VYI730,L4,)#
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M1?X3#1JHS=X_47MHL7:/Z_@XWY*6CO <-SU5JC#=PADQZ1ES-;1$.SY+%7-
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M[9*-UA[<P[&%E;XW*EC][)>;\NTV_.N.:I%(#PCDW7Z&>Y3.F4<26]IEL#=
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M?X /_FX^%/+09CSOB2MK6M%H5F/\(\/.K@-)!0P!C/W@/_:&05[9:G*2;=/
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MA(&=U87+S?J7S>+(#HT((11P7!?,&?0--GLN?.+ILII>,+I+\AB8(3']'96
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M^,>.!VM)@+X0+S-(M.TSR&2-N^"SOXX(^8OTN5J7UX%OW2G#JQDJ7)6SC;F
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M\'X5^(PA)I>D:S\8STM%'MJ1)(1.@-2+2-DP_$YY&<?/7!:YCS[MSX]6><@
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MCIR9MR!H7$M,>L?0R+E#3[Z%Y]73RGO&XI0/U]42_HLHP48*%_X@NO!<D,F
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M?#U&;Y5K]L_1&=//'?NOA@G24*/()>3C+-IUR?$]NK-[%G\-.$LAA]OL@<X
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MVA! +HKFKB**<BF&"Q&D>_D!Y6C1,G.3B\W\Q;YY5ORE,B/U)A)'$JO<SI)
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MN4<\Q(EH?\V:D.YD<O4$L<8Z5(N CB$8+0@:LOR8D2I'&3W#SK6!(RZ]Q!P
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MG4O;VPK#$A=V(C-#7/-LOL?$FS""> 3/3"(%BH@ S#RO&P+-FS13C2WR+/U
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MJ-?=\:-@AV.4/5ZM:]?YLLW[%IHO<IYW]%1)GZ?T!4(UW89Z%SK:;1V^4<<
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M4C&$^V_423&L$G;S:)"9D+Q\.I /:F(E8>+R)JU5?HW@FLUM<E1XR 4F5VL
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MPT7-[3H9=>S:PFKWX348JJ,M,]HJ_,^2%J)S];)K4"!=]82GA]@!$BBKB[@
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M:=#!?>PXQ$N%_$A)+^9S;9!V //%T$%EXO#:DA4KF(1QJTB&9T*N38A=*[E
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MPUT%\'R3!@G-"U/X3L:1HB*<0.:#+.7G;&3Z8Q74KT:\B1)M[W@L($99\-]
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M$L/2^2"$G)T7W64IHV.<,#KE\>_7KI,U@D=>S$#*]B^,9\?_42\H%"QK$-*
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M4*=57)WT)[_9OA5T_["XI)6 .\8#[)Q 15"7Q'7N_Z7, /(9$JVP6?@9D"=
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M0,J%NX"+*YLKA#3*=N3&$J@WZ,/G9:.>5,K1D S6W><KVWB.)7*+AP.O[SX
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M0(J745@ 3+E30DBO8]>Y&!B*4ZLG3S )1.4 99NGOAME8Q.0AIY.DP4G1B
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M+-5#$O3,OA&H#NT=QG_B[A@0$_W^4&>?DLL?S?([8R 2PJOIL&7X&/0A^OO
M+J^OMV,*OH9O^7Q'!"EJKQPF%C"\W<6\MPM5#PG4E-]KD*1)#BF*K4ZTK*GF
MTSRM;RG+_CL3&_MA.43FZZ<U >R!),%Z1(_,4^DD?<6O&&I65 O'*G;,N4'I
M>&[%:?[?WJLKDC,:SR5?7NU*:'Q?+MC[;,U-AM_&IQ:9U5B/"_\:&)P&CJ_)
MEWX]U><^$3 4CBDW/,HN?1@>-HI NC?K0LOY),^6> &N[%]NHPQ?W@7YA*"
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M69FPKY&FD-BW5=!@> 2NA#[YI+5>,$HM3S_]L. ?0=/*R$)B*N=L&K1M(P]
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MAX837)^Y-Y2%7;AX[&V^WDU,-'4 7"(LF?**.NK>D#N'I W$(7DJPKRWI<5
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MY$'M;C]WF,TVS"WKW5L^MW*'C#Z67'/NBZX2B,G%/BX/D+SY*4?#V"B^M\H
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M1\.@Z6L:>)PH>Q%KV@6]W/P8[,I8N\(8ZCCF*RB4. Z:@"Z2(2E:T@;& !'
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M&U"$S/U;YS@4=RHSH I=[3XH3#)21R]29R^4RY ,">FHBH8XN"Q=  ZM0KC
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MV#C[&_*U@LK>/9))]3O\!<647A>+?SY%T*5DF8C6YQ"L-64_ :XM@YL)NLJ
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M7$RFL)FP5#"%%MM5M2?SQP#'\>,OIN!,,V+J1)^W% ESNP+6]^. AIY+Q]F
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MX_+^ZO'3;K.A-0QMPU_=Z#$=6"M9H+13!&F5K4:1IDW6\M<Y8Q<Z 9=<]*5
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M1LU=][E8C)\C][IR5Q9.!UX]<TAK:#DLOR; )KC^XYG;?^)P-#!5S9C(1WK
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M%#XHAPZ&]YFG*AOJB""H>741Q,7+:UB0=5T$25@ =F2)U37PC>_!::/.WEX
MKDG^ AKZX7\4.M6:7)^((%+9@IOWVD%BEX\PK&NHM0KP(H?TG0.,RKH7HPC7
M@;4S23G0M=HX4!U@CW&$-F\$0*&@IKM.E:\H!HC]9V1W"U-,Y:V%L-?Q3+;7
M?NI.Z*S232H4L<+2HC]& J4DAP7D'R)F;KEK6"Q@JB2SZVM9"T[)0?JF,DO[
M62^M+*4>%?]Z9I2QK$92Y3E1X4^/]6/7E.N,)"?"R4)!W;;L3R ? VO<J+E7
MA 6?Z85WJ7]360QHEA\M<7AVEJ9<,*BX=':3SSV@-;B*V"N+Y,0OZ8H7;7 Y
M]<LVXHJ?_X-_I$81OXGC<Y'\U?K':L:MK I_8UW]RNA+\6HD%28#'*0,J2Y3
MVHE\%+#B5WPQ*C$$R,9SX4[HWJ]F[D-*,;!_^$CX@- 9"+% K09M'(YU:+%#
M0I02.E=&5?D#W CS7L?RCS5RR=YT:3H6=\#2$=/TR5&/OUD&1J_+*)OY4G6G
M$U0-['D]5:8@;?=$)M8@)%& ()2VP5XM+FX;?18I@NSN7$),$.E_,G1%D" P
MO2^*\J0*)&5NZVE'_P-OEF$!$44:I7S)$S5GA#&'LV^>I55FR1W3I3':!L0W
M2N23:F!:R$ B9<!D*%; "U#@F\&?^S+.BB4K;'SN=WA.I6F;:V%&\Y+^"^E\
MQD?Y$2R9MQM"Y$,?V1I\D<:RJ8N 9J[/-\/F'Q*3$$DNLSX9&LT'_H@@]]&C
M6E'G)OHSQ\=FGC/%ZG.!-##TC5W\!AWM'9DTEY_/%<-"ZN<OE=%+0[XR3, &
MT_I'*\=+^@>PYH$7U*I+%YTW0/ 06&>7,L>U@06OS[N#PM/?OVSQ$1::,%_Y
MLEF' Y(N*S0M#2L0D+&D58DH4-T,'([^)8*4&(U$I*@+O\GK#_2$KYPFS&!G
MR"P9-U;_OT&'1YG[; QX^<BWXDAO#>L"2M@>,KI>V+58 ;&=K$$P_9H%<\9S
M:ZQ(5>S)7O!QH*8$-N=NU)Z*=;"9)X+4$\JV<PJ)_"!-F->FN9<5U=O>%W*W
MX:SBCYIK;28>LLOC2!SS CF=M6BF=1,M3RIX8 4[U$N<V ==(T2+ W.$P&X4
M"*8 .?[XS3,S_8=.)UA*3+=.D'A<E8W3F9:QP@C!-1A!F%Z@@3/8)X)\>]Z#
M+@M;#'45[!@[=\("5A;[!;9X<A_?W=O]'14\ D0(A :Z.. GH!\=AQ_N/;39
M>5C!%59[HN"DSSKUSZU*0?R=4U5BL 4I0^>GQ2 LE#("$Z1.?_2%EP]PG\Q%
M'BW7P]^[;+-?B#]8<$&GJ7OXQD$A;.HT8=8(:P$41DR='*FM9D@N. &1?A.=
M2O6R53R"E1MG%V?P+$VNYI0(0BKV>T=TKJV,/JDLW<E]I$M;0*-'5I%LH^'7
M2U[A3"TO@2>+MO=NFNEC^&Z@.>36^ 4MUZ7#SAEM-' R'#2.DY2U]6*6* ((
M4EFKA0=E"48%&/_ZI9M)9=+L0[CHCI=6S'&G#V+U9Z7A#/(76&R5EPT^/="<
MII!I,P=!@B]7(!9((HCL4E>#=,@3 :]AJ4;2PLVH[E&Z<WL]-DYR0"!9$_2+
M=9%H%'.GZ,?0[5O\T"(:B6RS501Y9GO>O0B %HL%?5AGJ2/I@Z=8Q]&+9.#9
M5!6!.@*[";3N\1 >65*,DP_[4LS@7OPN$=N!7:K34A1!:M^F"F>$Q%+M=G*G
M"')D4!_@N./9[R6'K$)H^V4J.(<TL",)%ZQVR:P(<>+'?H+&L^T/@PU"V6#O
ME5U350"29_CXF^6.' V&*K38C_]RGHY]WQQ&OW*P==+3RR']-R"7ST,P?\,&
MV$6:)KI (<Q<=VW@_C/PNQOH]#*9M_EZF>SB9;D9,H@Q5[44YLS5?S+<>"?B
MQON?LZDNG@PKHE+SG B2/S-0LVWLW&/^MZ!G8C+%AV@36(W]84;$/F#",/S:
MBMX'-9!/,NO/WH&=Z-QH"]%5*_F__:Y<E&/\5:@UG)L0HL1H=NH<C[ KG$X9
M.JA4J+5"Y/R=..*/6)&1>*YZU.HDC#3'G!$N#+J&3)\+@(OC09*]EQ<J_J+D
M7I\>=>'?[)/M>=C[]]2N[X<"52P;  ]4S@@QQ5160Q"TD"E4$LO>?T 5[DZ_
MF2CZFZUA^[4"_N17IE_*%Y+$0+>[TBHN3[QT5_2$&QD8+G3'B*I3JW7A7Q?2
M8G*,#N5T-F,2]>6=C0!K7P\W8C;5"HU=D'FJ^ER:-&O<;:SO._ D1SYB7@BC
ML8B5]VM39O#*F:@!^[EW(09>""[O1ICO9J2G,9*MR*^]?=D'Q+-#2CMQ;>#P
M1DG5/GK!MLNUK^Z>#>HV>SXXKV[<-)?)_Y9E\X>V9I0]P)/QN55[1$^!*>NG
MHE>0ZKQEU7TG=Y/3^X>&BOLNKL\^=GLKZ/H'PU8\P4^P&)KK>J"-/,-E=4\,
M5\,N:H#KJ!'=ETQ<C@YLJ4'H%[G1-)9:Z9P4[U]Z0O]QGN.69Q9?N!)"#G^!
M_\C#Z\YLH[<:6<,UW;C]1>08=;F^OC4S18%(K[DCN?!D#H;0FP2N5!%*<__!
M7RUN[PG!,4 ^#\4(@FEU?CEB$/( .TM<P#ZT]JM>]TLO@A^1$V_;N^@;4.YV
M"JB^6'FWH6>V(\Z(RO"38?I5+IST5$3(?>SX(P;_BC 7Z#IF83$^V62]+@P8
M%$%@)@[BD"T/NX^=!MJ[6E7G %8$OXM]U"!$#2.@3BX<*!]%%E@!9$/6[3$Q
MML3R.;9\?9IX?WX1 Q,G]R' ](['2+;F7MKM[2X#C08FPLKD)G6%#N8AX:=6
M1!!C8&[#H7<E>1ZV<8Z\.-<078(JH?79==)G#RW+_^8^204\7/+J>[U#9X9L
M^^W[LYJLPD813&B-PJ!>ZO*6[N] WU07)FE_<B962XO2C<0EI<L#6R#"$D70
M*/WW RY+]_Q<TZ&WNKIU53 S"J@Z5F/::O&R/A>U;&\L='L*@S^B2/)C-VS8
M/R//[_C!U]>IZ5Q'R?D?\)>EUEC^G_>.IBL][1;U 'L 3)H8&XVFDN9V,OP4
MIVNP]V=4&3;TN] 4@>U-%XO3."%P5@\D#@P]G&Y%^G8G5B[[>,QTG1]$*6-<
MNR:<!U/Q(;2RZK8QF,>?QPH^?0_FT#15\ P$YCJ(\*$,N)>OB&>NNUXLMR6O
M)CD4E(H@U8=O[N@E1UQ2@MFXNM]J3*1'T:TW30P*HC0O@%6H?:.>%J!DKSD8
MT7TWM>W H><7!?GD>KW,2OL;JFV PDB??!#(7-(O>$,#/9^3*@NY3T>!B1IS
MWYJ[%@81&T5XI\>+!S\=/_LAU'S;:0G6OG/D]QMOZHP:M;VZ!N7]+JT=VGI]
M(SOPA+>$-LW*!R0-Q22W?IUK!+"FID@R2!WZ&8J8YS)-]+BP5G(OHO[+=97K
M!V:$XD<F_M65@<T;6CL1\9HTK=U7-9*F8N/BGK-5.FSKDY*968 D)%8N>Z*_
M,:T(6Y_*2-R\<EI_QV?2<GWI,0/8&%*8:(8L_;G[@)KI)A'$3P%(DN%@VHF?
MD9R F3)T 70))@^4]/2L4G?4[?E&:0;#3JP:UI7FB2#NM:<#0#/SE(CSD>=J
M\'.LE/%54+G]\(S#>1'DJG='Y&1I2.\.3"QI<<YWFZ\R$WQ\)FB^ 23'?-4E
M\$90NXV_V:\;Z6$$/"U=#J0K5QC5B]_PU4@DBT,^T"0D<QH)@DS6\BZ:.$QI
M,?S?W4W<\@_]4Y,,JPO*R39:X,_+<$00'M'5?K^_0)4+8#.GK8L#=(\ R=Z+
MVPT&@;T$H90/R* ;?!L@_  Q"$I/9DDM>H?)I/X]IXGA&S<.:F-'=([8KRL1
M[B2(]X]8L2WKLFV$R)<TP2,D-P-J:M%&?7.<#^<K.8/"Y;ROL!>L)F#66V_;
M5<Q!V%@$GUIY5031(;'W0QFIOR+S(_=!]X6OR8F'>IM8*\36J+V\$/&TBW[#
MF?D>+;ZCIXEWT49L%)9#7,_0(G@'SOQ( ;(CLL>3CN?9^$-MO\]9/A]2<$'^
M67A2'H1RR:,(JDM5UHFCMZ'K\B<]@\48RCT7D?R9((1*9"MS/\T7A>:^"TM3
MD7VT+)VT,PU(_IS_4\U:V#OJ;JZA-2.(+NW7/;+*%&!7-$ \8A$H)#")"X7(
MU0"U:)6W F*O49BI$E8 90?VMW70N8N;![ <IEB>%J=KK7 6-)$IL.ZZ\$+=
M+LTRV<V&1E 6NB/YG&-?!<%@6ZBN_8NLI0-"TD-31B<-LR) Z49\\%R"7?V-
MCJF(;%R5F7)*S.Z=[+/G@<0_:( T)#@/4C+%0D2?E3,?,4&:6Q=##3U*6'N2
M[.!_5U@7V*BU+H*T5!+X*+%86\;3M19^]-5KUG*<$OS?1RH@A#0ADCTVLKL-
M*%GHPUVK:ZQECW4],ZLZ/3CO@+'9_)QC@R#?DHSMA,'95+BSL//C/3&RC+3P
M24Z5I2C:8*9 $'&%\11YLE( =6$G\E$/7^R@$:?4C\.[S%G\$S .E3SX]!I'
MTUWX&+TK4SH_D>Q-2V(QYV!)/\D/IC,+7HH@.YJM;X:]VNHOHX)E0Y<CRK8.
MH3'"7QL)P%)>E+D57S:S__0A@64E?/?0;4D!;CP8MOA8!#'@/QD5RK!'3_8H
M1##FAB/\[N7A+=P;CUXTN#F _0.LPCE$;X?ERD"A:GI?\J*P3HWF?+P.!@'S
M00 W,)0;I\8S[UG^J^SIG5NRG?;E"?TP&QJ&U3DP'+NW"34^^W=8VQ,'P!F$
MKS&/TT[='CD1*[W]*)ZYY;D'&J"@M!^/R0J4-FOJN2V1[G@$[A]MP*ZUC1DE
MK+:CK400!!MLP>L]]H155LU_U0U]!A^$=81<ZF6SFS,_7/KX_&/>@6T1DE$%
M+5CV$8IP8?CZ^<I^@"/%JGFJ5#JSZC(3_;5ED$\\*9_LX=\1K&G"CQE%+/?C
M: O?RYLVBME--+DHGP_ X+R8PZE<MG5F[]SH>K*MEN0=0%C=:;$@EF</:RK9
MV[ZY>E1F0U9@<^UO"D[Q-RVG(D\) S'!(&U7-'NHH/[3US[O79O$<EDFN35#
M)GSD8%3WZ\P69W7MOJ#?I1+JJ4 AV 1.I>4_717KH+VS>H&'+IO@*5,]+VCB
M18_2.66.%!+-<YD+?]>!GQ%K0>R$=AU2)ZZ&M#1V8(AL8X1M_<]XX?^RA53X
M">N#<@_ST?'^-2QE8"WD@B8>3V8T;]@$&PV'GQ%!HED9:[.'A^#"<2J%Z-N%
MJ?K10UNMM7CQK8+;=+O3XSDZF(=&+BJ4P'5743XH@9+6A^TN-HP67!OS%$H>
M3>3E]YP,)6(ME"GS=2;LR;3S4',68JF3*PFJC%IC+/S^ITWQ0G?$S;J<.9/;
MDP*Q=!I).SYO0)RF""/X@VSL*I!/QOOO"_O.FX,NW$5=-RB.3MSI%TY=*[AP
MQN>6F@B2K'SQQ3F! Z@Z9"L\<G7#T[ZFP^(/FZ7B27YW8_\_\;'L#X([JN#.
MB^- ,;O,DY#Z0TP#.@L=+:1DR<D52%*6X=E.GJ3@(% ']5L8O9?# YJ!503*
M(.0.U/S^B2#B.(SW*QP(F5M2NLY92I]+RF 2!>$;?=XG_Y [&PJ,Z#U%5;]K
M+HD7F8T(,F:8_(V%=YHU^KW'N/H)"[L6E7A><0\"U[4*KADFP_^2]:N7S;W&
MES'MI/JN0\2B$K9*=+5J=#+TD!IP8O7]5UY=TG(%'A/><,?T1,2D@@R>.3/L
M]O<J#Q>9\7PNSC#YQ3O@[,$0Z"Q<+!P781.&R>!TA/#6G,F&O:H??Y^'=-(.
M2W-)_B86[ _P:#4L3?4'2;E,+$=(0AK%"&8WK_4<E@\0H*OPC82&#1=@[$C0
MV](/(LB0L^!JPHYY!0=PJPM,O*X',(\Y%*3\"1;*(88XSYH/@*IMLWV14K/I
MR;4)$:2+0:^K7%.BL(C=-<QYJXQ6'$8*^EL$(8@@42B[LVOM0L+U9\J.5W73
M]TA.$L5C-1-!&@VY46K]TXHA7[$)"$74PE?P*EGP:=8P/WZLZFXE@M]I$]EP
M4^F'H>YE=?,,E:T/MRO;?"XZVHAABX<O\S U0<O+AZ46:Y_O,^X1BYTA%3P7
MBXK4@*('E%VM->#[A"\3VFM&1-==L;5\M(#*K:@+V#_V@V4Q-;L8,)+W\&X_
M-5F5X)8[KUZX;VA'C2"</-C3Z$%.&@^#-6+W.HX?OZG^'2(-,SK+#W&H7!RI
MI4<E_AHX +.]QHK.E+EXCN6+BL^BC2G]Y=CM$*]F7;67B.\8C/!U74887KGA
M5W^TV4RGZ,2KA\\."!SF%DV._(7T;#*0E^"N+BBQQYPCO.I?\.0!=Y]90]@C
M]%@%9IW35XNI0/&+:J!:UC.-XR@)_=2DCW#J#[CYRYRU&7FM!<Y?%^$"3_XV
MKR=!A+/G^N"$"*[D'<(2_)0#O?9X?8G 1M")HQMZTD>%UN_H2]A10P<KVZ1X
M7Z]UMUD/./]KUE_[GF)GU8[IPL;#(B<Q\YC7!M'Z/]O#?86C*%8?'^V29S1O
M3F&<&7_/Q]_7,NY?'JUU2#Y=C56(/U<2(_E+75N.N57S(8$;TP^+783M)%QX
M^B'67:'YQ=-3YY3/T_JO+.NB5&MW2V'P/#?:OC4YZU_RX9C8V=^"HPLR"1=(
MWQC4?U#IM:&>2CB$8TS;]5+UTS:W!T_?V?E6FQ$Y3KX_Z\+COBJ\I[7NBZQP
M4Z/=/*YS+@N-F%^;E>Z\D$VII /5!2*(/7HSTACL;.W\/("K:2VSYGY:UOQQ
M03*X>]$3\R @S5&3@?'L$T&D=C_X MA1(__=%TZ"Q796>GD-%5W>M>DM+!'.
M#3'X-K8H&P<^BV7MBR ;W34:2X!JU!MQ !M!<N24'HE>XO M(Q?_9>3C-TWE
M5Z7^"=4'<&?[G'.3IDUW\#1L8>G&)<J]WL>[K\O]MC/\'HMQ@B+7#(]-.GF4
MCNKB1VJQCW^G*)(C]LQ,L5DRZFMF,\06P]92-M[2__7X+._&0XM/1;9YKX@1
MJ^T+ZJ?]3(2D[G#P7DF"S'Q8#]7W6V+%BTT&FR>P\\(T@V"S1*ZFK $CM>W1
M-R 9.]37ZS7B9 TE%'_P9)L'*@?$2V$RVA]=-7!IO')=>BK!*DSCN,J<\-S$
M6$=6M$<67,'P8MR8QB]RHE#;_OF+;3([@/BBO5X[]Y6]!<*3)B:'Q;))II X
M%I;07GP9)L9GQ^_O9=;$@@1G?_?JA;T&9V\EG,7"O_0 &TVH"\HI_X3SE?,&
MY&CDHE@P!V7-LO:WR B2Y1'X/B+(/@ZZKA_YOW-6KQN2@ F%FR 0+2/\A7S@
M4%Y_'CK/G#.OW\2'_0ZQ11G.UA88;0$+P1&@T9"?I?3P7\A6R^71QRE^G7%-
MUE.Y*=&$%+2,))PLI,W1=9:&:'Z+LG/\$(NHNO1(0<<#&VNA#)7F)P1(:X9Q
MX'BM" +XE7&>S=OL[\TY8V7[R&/73;(3\V^@Q5CE!7*IM=A1!"'RW%$KQI]Q
MZR&[_]%%9 FO4NEUZ8TR9.;-IKH;&\T(//2113?#5$001_&]]J.A!$&=*H(A
M1A'<*QZ&19R0K-2"=<'Z9L@JS^<.E$I_:6T50=11A.,G@\<Q'.(#%)2G)^B=
M:_\U&9:V?;<(XHG!90*5;,# "';MP,$%)8O3$2J-#^6V(M8'7&#_B[+WCFJJ
M>]=%8T6EZ6<'(2HJH@*B HI"1$1$!*2)@A 5$:D1:1)(%H**BA 1!04A*+V&
M'GKD0XCT$GJ  *$%"#6]K)SPV_OL<<ZXX]XQ[K\I*RMS/?,I<\WUOAD\*AFN
MW_U\@&B5E94U2Q.<M9 S&=B%V0^C"S,_D'[3/O1G?".TX?A0=O&B,"CK#KI8
M!-D"6W*B5*K/V8J5(#3I7Q$DA(E=(BB16V98C$0.ICC;:N']EGT(]&-]\5N#
M!.J%!T"SEA%HM*!;W# V8MJ=H2G9^\I#-6YZT%ZM[$R-G_H(/9'P6QRPS9?7
M6T?OK19?> SJRBC,(+'*._6852NC&*22@"J\HB_:&#\C9-:$'YE*V4PA^Y8O
MVH@_*V%Y>"#A&9 $'K'M$"P8S0C#\;9?FFC'R-]I-I&-$QK#$[.SKB_QL 74
M=S4*XP=2O9R@[:#+K2C+1Q/,.?VEG_2[_2_,JB[BN#&Z640!J97-;S@'-*!>
MU;2&_QY:U.OJ#(\UYQ?@9_N"[XH@15XT0' CR$4$\9:HQK&L0!LR@I$A4,ZT
M321,9OFPF+?AK=H32P K8RT2-!OA]CM85>"531A;30BGJG"%*[T'9C.U%NS#
M]M%NNL<:4_WXG4.+GRIK?ML7:L5^KDF5VL _#U<+14*>[MW;D7CZP^.*2[,9
M :]A.K5' %WSKP3-RB"N+]NE529S$?JQYA+ILH]*'YFTI?#(WF]VMW7OWK#)
M^MMFH7*V+<)7X]VF4*]6F.S&WC,;-/>,H23^\GQ)V2>^G-FPM=HH!QD]WQLG
M>,REK,E/XI\[\8)J1)"8#F3PDSGA2"G[R?W1P05TQQ"9O\&4U?,P3]I1*_2#
M1/R5: NS.^:9\X<W,5B=6TLT]U*)&1N/.-SZT*,)\<;1<1TI.46@1+#*?$W3
MFU&4S\IYJO^?$;[YT=($]V!/F7CR@2LU>ZTG]WP.+0N7L_O^"W;M:F'A/CT<
MND<_<Q/7>V[!Z>CK'V"S.#5)<MO\]C\.F%FMYGXEC5PN>>& &4I\WV,>/AAT
MWK/:TP9^K_>"REA&8-*!Z>A_5!),6K+%!+)AJ3GMU:8K9_6Z^L)>V^1O-33;
MJC_;'GQFJ KS2'"=DU: S]<IWEY=9M38'DV^G.%A:\3VU/\T:&^_Z^/?[LI&
M>8,YM/5P&',' G'H)/7W0T&XS8,JI-LEZ'G';"H7$>RZ=$9B305\#E,-XF?A
MO;K-1NB+^'ETZ+!\.E*N+G9 Z&EP?,]NZJU>$VICDZ:"U"M5.84G*F>2V(>/
M7=[I\V^U"AS[5Z;FP(;H/5%[+VAJ9K2\,=;5 OX- 2^P"4W@1TXT7F=33H"1
M^Z+J]S7"SR!U_\>LUI[CF6>#;O?7&AQKLK62--I\\N^%S"U7/9UK#G/=YB#M
MP97DY,C(9QHS&.8NQ[R6*6AC4@;7IUL7LT*I*FM9U*ND*V!CR-QF8R>2.K<7
MZ9:YXW.]<F2FA:WQB5_[S$>>-]^*WUHGP07"L[\>>PLM$$'"LO5 :P!:^V A
MZ2U77Y "!OEY"48=#O;=HPO["% ]R\O4U6]ME/[+(W:OSLYV]90Z*\(EI;I*
MH4DG/L?="<F6>J:X.!1R^/G/-EB'H$:GZ%2LW*RTH:$/B%-:G=W(21F&M5IQ
MU18&T#+LN#H@&JZCI^6WU>"(T4K$)/N/0\E(Q.<L\OWX-7O,OUZ>%2:3N)3L
M1H<0[_&H Z$W1MT>'F.G*1YNCCVD 6<"(4Q+^L'N RH7,B]0N=B6O;/V'&X/
MY0KP;69-CD:9EEB-2]>FU"$B8#O+^L;_%7ARNJJT7W<O20_&CW8E-\VP_:3W
M?/IPQ4V=?-ZBSXJ[/2IV4Y;B+]S([('(JYF')!(!E[4,>R-DW+6#">\/0<8G
M;X[_!@IT:C%?41;*@8*'2XL_?F;NZF/UWV9Y_?[3F(.R"8K;;FLD)X+D9<-8
M?["SNNEE";_/$(Y*3.MDA%./QDP:HMMK@P );05'JV2M]+\MW:8F@XG;!FN_
MTG7SQ*Y\OY29E=/=-N,+5B10;J7X\-&I^\:0L"7M2_*^IO5>;[Y%/MK[ &*X
MC9BH05O]RPT-N.QM%R41/LBU;4D#$"PP"+'H@"/I'BS+J;*?PB%LZ\LJ,=E:
M=9=V#+@7&=V:]A%[_\D#/,FXS\8O-TY&0_3FVP1=LNJ_?4.Z"W3VE?2N>3R4
M?4#B^ME+;B\O3#YD>H70 N+P>:VP+\15ICA4JW:\/Z"7W33EJHUYL70[TO99
M -NIT>#'*'UXMK$ZRT8N\R3UM.FUUXFG,H?TO\:-RB$24A97FQ?=7MS[;'S&
MU%PNWF53R"K1(.AE]>;,WV,2+?UT/90]ILCQQRQD$4P<4!#V7I[/N&QP$-/&
M)#SSR*LKU/8_53)[ZX,"Z>:G/>_?Y"EOB(O:5G[(?F@ 2YL\I[AY YBO>[^G
M6?^0/H[+XS*\DHHHV!:CJFQP2W#J7QOI8G,;6X=E_N13TUKBWJJRKR:N/__T
MWHT@6<XLTYZEO9W$#E]_NC$ZRH8?U+&]0@1Y?RGE5\C/J.-[E(W79/3\]HP]
M-](/(N^TM0,?!D)9.OO9:M-$O\7!%D1B[YE[JAEE!:LN+[[+C:J\OC?5LTC
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M6!@NB "5!IF1#&U@@ 'W]O L9ZI1L&UY1'QZ.)/W1$ZF$J2LKQCM7K(402J
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M%=0GWO;458PIBK_FQ%TG ]WW2[LOT#9VQ#,3UB<$*\:8\9^>/"-.F782''Y
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M-%<QK^@\3MN&CD94J^XI]@Z>Y'6CGIS6<E]GYTZ_WHT*5 !YCK>.@+6+&@J
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M=COOI#'W84:$*ZPOF#^-ORM>)_PSGUEYI'SM]U$=+: 0'6UQH%94.+CDBXS
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M"Y\FEI&@;V0+AO:F"XG@XS2)S5R:J=T:V]TXE#:CI3O.9)^35IIUH0+E)J3
M9"XIX$QOC_XFK+]J6M#E5N)_3<BT(5$.H4E;P6]!GA:4CL?4!MH2ZT(PGORS
M[M[S&_%&P^*DIF.MMXA-)7%Z>-*R"W^58'+77M3EEQK-:G;M2O],NMAFY',(
M&5[>>&C 0^M3DE#)*["^R<_@ Q)/>QFB5_/)!0G^)OAA/QL_'Q[1:DXWZUX;
MI7::D8<@BMO@[OR(U+3MQ2U)$R*]O]PC;^Y.-_A4<]_B[384\;O&$,^5TE5,
M?G9 C?ZT>N%\;4ONN2--K4G9J>/&G0&;-:J>4O8S[<S*RVDYQZR<+]2\ZH*B
M/_NE0MV^X^4>3WM+A_ FFBB/G"\9<%@H(8"PY^_N$YB7RL(QQK[>N[;,+"*[
MCE\6,G#\F0G3T]+_F35D!I:"G;5_B*G??4'(TPWI5MDWHZLXR9,PV!7LT$BI
M. H.'\2135WZ_FDP"+[_05_$B)I(I]9*118:['Z2!85!*>I'[CMA^N\].=]4
MCV"I#%BKCR3^F05!A##5TCU76B\%YV;D*0L^B'-<::DY6W(,]5^BH$_-</LJ
M!>JN\60B>L8*Z3YZ+Q(5/(%V<:!MT"8?\U9?FS:P&A@T#//718B BUC?VN-+
ML,-QH57+[S=)<%F>!.V;Z@)';%RO[ 1S);_ 0>*C/:K9'6"T3'V#XV"CT2W6
M" =T\VAX/-"]-DP-(2"5YVI=QN\#MEGGL N@,+YPS,"#7*575PV'=!1WW5/9
M5+I?4SB6',EJ=!8MTB =-/5]D-4Y TIOJPP'J71[ I2!4'AU4W54S56TQ9\0
MT#F+PUB #&'5ABJRH!S7NFC>(GQ1>CPYQN--R,_BXPO<VT: 7BP0:5K8DP>
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MA?RH?6\))&<A#8Q7H!R"KRM02:>4U02E*JG+2?53Y/8N!\HKW(A3UP4:8?B
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M13%1$G,$Z)@(4-HM0SP^ A4N'X[93PQ/IIF\@&G<G=E&6C:PX3$JFLDSL6'
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M9&L8.M;T*T<5J]TQTE/W&X?OX*ZOR,-R\S0HP>4!LY,99:&I@?/#![7I<6-
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MMH^:4:_FKUKP'.)0YT%RJM@FZH9SG,J=(-KT9-3H3/FI)DWIY^L_4ICVY\A
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METK IK;P%U5^<:-]DIR6M+LWJZOPVIHP/^?WBQ6F5)<"T,-";E<(, 6,%,Y
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M"/;7MSC^G_=1$J0D]L"%&%7#OXFC&@VODL!^PKC4S5(ZVQ=+(G*F1$;+93U
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M\8[WS9QC#-HW"#V/YI##A*0BP?+DR] 9$U>NSN22U-IGC@>#UAF?]9E,S#1
MER#:C>;),Q#><[IB_#\;/# ,PZ8K_I[SYI9JOUOH[DKX&K\:%?X153=-EB#4
MG84.O3C?"?9IY&S%_1W*%JN71B#EQ[G1JH5+W+>5_0DOB#CKV;B?'[9W_M3R
MR":/:DL0X;%/>F\ QBV3).?![QL'OS/9HX\C&GM2-UYGOD"F9^F7?='=5K\V
M='-I-;=NSN_Z&M79XS!JQ@\?:1!E>\K!<?IY[DJP#]J4LQR><JMAA#T6^D\E
M2\/$ 0<S#VD&K CE#CO[2V0;JX"6'2-0LB!,P(A!AD0<&JP$:,+#PJK0$]>I
M.(&^*M#XZ;0$<>I&@ 2!4M*Y+D&\,4&+K092-DH0%4]$I@+]'VP81%7"R(*/
M<&!D=O<2?NHGAOZ?Y0#\EPN')0AMZDP4=!T8+5P!H,4^8F#\/R)%2#\T]X'"
M+&I$Z6Y.;ZJM>-^2ZU:N8U$)3):<>TN4Z60^1A!:+B\#BY(_V? DHR4("F<^
M-9@)RG%?,:$N?RK':'9G"@H.4C+V,8<8K'<2A%'.Z0G5!Q*$;G[UG'HR@^^Y
M$/E11$F_$S@W\+,--]<DD N=U+*V=W4C9^BVJ[PR7:^5\D6_^)EZW>,YP1K6
M%5-ROE%;=Z1U6.^CX/":6W PAOJ7]P21E[;2L>N,=LPX@=!-NQF<7>#<[">:
M<P2M^DL^!(V?2*2H/TG**!X-D#E]XLV;77%N=B4G+@SOZ,JLL;4^,:5K*X"
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MX0%1W*20N-(M7)KO.:_8,BLM[B(*=>M5O/S(M \VU];K:,?;@:/%("[!R_I
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M^X^T7/?#8E];QF7GH$8,6PP@0Y)WF/IVO$I%I6<MJ?$G<K*=,L.2(%*$0!5
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MX<S!-E,$14Q?N^E+'A[Z^G(KW\^:FYN;0FY[LIY$6=N*]NQ9G:PQ-^JH*P?
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M4%-94R9C[P\D"37>9M#;;O[,J[3FMP._NB7OI$LMM :F*NMM 1YM0+'R[,A
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M6?WN.N;A[ CM>O[SG?LT00(5>S-RMBAP\N)79&8>13PZ-4T/**9OKT#@C-\
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MWUY\B3N /X+K!6H\J8W.7O&._I'F]W42&DV>K=DN%0U9^*;D_E"%XN ]+$F
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M;8Z"+S"]\X+Y7HG!P'\5!>66&^6Y,[DU82_49?0V\-,4L:WZ^U&HK5M8:OH
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MC@P<^X +X 'O:TCQE];I^$^I4B3(CA0N[;A]J)XY4.!=41EX^UR9N72WXD$
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M/B9Y1U%[3T.T /EI /![36T2<YU:[$&?\/$#@_H-%F]\+"\M0Y\(%SFNE?G
MPDI;Y$O0LKOQ5U:6T-[S4*E1UTTQGYV!+FYHJ5L?(H'HM-JU$4P#N5U\+_!I
M*1##W"$DJ,' L\O1-#R??Q0LD0A&C)K9R8W1MM>"]]6\DXF84<OW[^J"\IZM
MSG[F0<S[,.M\JGV*\$!?-$,*)JD(D>Y/-EM;T![R7]OW^DUX V41U)S2Z-;;
M> IB-?I2-L8:A_#SN38F$O@@=D[2E^+<7,K:M279+XV&0$W >]QH5/OD>"!+
M8OCO+Z7F22"2[!)!L?QB[33OM$/@Q#UX0% +L#<'1F5LU2N0Q'R9M(HKF"<M
M'O/*HPA/)&=V&-/ZUW*O/VQ4W%50[P!7-")%^'+,N5.#<1&XH00/+E$)">-:
MU5H>=*MR)F9]N203N<Z#V*9,[H'E@\%D$%]ACQB8EW)] V*M,@-<TM5$25$D
MNIY:!P_R$>/#@RQ="( $Y/(@9RP;0$?T2GBXGS;XP 1#QO_Q]V?PM=?SB1X8
M(^P5 9QD7Z.?!HU=J[@*\^A$_'2V-QV(2]58<IA7_+\>1?X0YM35*MFA# .=
M26JV.*DT OU@\_U*^A'_],C ZS55UW*:3E1423SLVA;PCPYA8_\:EQ-@0;#>
M%CGS2!@8G!==@LIVM 68:VZ[L+A[(=TKZI+36CVG4AJ_'Z6G'_AV2"9H]'#V
MSQN4O!YV\5C-TR2]3>GP9EM\^Y=WPQM]%HPW^D:KX)G;1*,<5FJ+XJV@H"!R
M[_V6Z@;VKQ%-M=/5;S&/4DK_'\[>,ZRI+FH3#J)B!2NH"%%1L2$V0%J.R(/8
M("HB"D)4$*2&WD)R%%14D @H* A!>A%"#STJ0D2DEP AA"(U=$A/3B8\,^_,
M]U[7S'?-O#_@!SGDG+/W6NN^[[WW6NO)(ZDO*G_=@^J#^&ESL8F.6G(MW._K
MK,9:ZN1TL;B>D]1?\F)8 '7:_-'[T]'" ^3Y6M.D1/^BROX36BRSBVY#[?Z3
M-Z2 4=9(JWIY44]"0<3O\:4N[[)J<OA^)G/J9?*]M\^E7- Y3T]H#V*V_[,^
MC!5(<?UQ*+3L':S>T\E_0T"TI=3USU)=R^!A8C@F-H^_E(^[Z&NOF8&>P[_;
MO6%O3/^/O^LT=C55OR#-I[V7SKJ3W7BDHF=RTV9\64J\7W39]1L;')/@DUY,
MIDW%=D[07V *1V>9=98T[E:NTCCSS !I!+-]?9#'"KSQ [8Z I$$;^$2'CRV
M_,MZ5WV5/?=?R>";)/?AJKL<YO1S@P?@B.,%5L'O_DXBZQ-\Y?EYQB&4O8M@
MC^#'@$?O"8X8YEZU\=<IU^\C8SLZA*H\/NMTS]56SX&TD1$Q[/GRD3G7K ]3
MGV_\<474T9_O$?IL7MO93/,4-9E91<B-0QLARN2T21/&NRI2[FUI"Q0&C;@/
M"2M4\]_;G+JW)4BURE:&Q_,F9M"K&Y\FI<;J4[VMDC]+I<Y<%<,6OT"(K2+]
MU_L&2-;D23&L3HAD!568=OMZRJ=, CIFO(C/^^:J4];7#-$$(\ZW/9J]UM_^
MP0A97CD$X @',O@:50P]L*B;<N)^A-QZ^%&9>^2.N7MB6/,P40PSF")RB27;
M!&$/T:-:PJ&ID ^S8M@0L/01C$_GZ=8G5OF7$N[/O?V6(E!5$IZ,%KV*&YE$
M4PI[RW^[U@H4 \ NMC>#!1K73P&U @](MHR'&??NSSW<P0PTO^4FPTE.%<.J
MM Z*8;DB; ;0;=TH^D'BHT>[GY(*AZ^)82'"D"SXQ,43KY?F](<JM:R1U&F<
M&,8U5VL1]DHB6T=?/,)P0:(B"O1B 39:#+M3T=O_"VJZB+<!AB8#7C+IL25O
M:NA]_I8!4' 1UUT#Q11IH/CW<D7&!<I=#1A<FPB_-%$SYUT1>X(RO1?XWAJR
M*85R;VM-KOLOX&^)JA!1RCXE3Y@MQB< !"-[8.&-D-S0SNAI3'8+4W>U*Q0@
M O4;0YH 1K?HI6R8(Y6A8O*^$L4V>B9H!O7B;<:@H5D,W9XFAMG QQ.?5ZH5
M-O48;^I\$)'QJ/*:;)?,SNK,1455]7NV['LCV3%B&'+Q6,O2/G@#FT[6PQJS
M6_WUM3U*M[[?'YHYPN,OGS!6.S>:??3%M^'N<3Q;B)'_6FH&D8UBOH4KISF)
M88YH]L#,L"CAV)1%Q?+_*NN+YMP#&[NJR(AW^FD1D%JAUDX%>NZABR/UAG ;
MJTGS-Z(E"G5>1AC6JZYILKF&,>(-]5TN7Y48A+ ^/^W:$#& L=V:F&I5<RL$
MJ0DW%(SS<?J,#^@O-:'U4Y6Y1?_\5/[PTRID>G9W34IZ&0N@!Q+_5W#\CP(U
M*U'RPBJAG&\<.F.J7^?:K!JOV/>3BD8,I3WOG85R=JZYEQBF:0P@&U9!#6CM
MN-\, 9H=Z*LK$_]4*,1/3U2%URS_8FLZ!,X$ 7U#BSTG'DLIEH O(!E!QNN:
ME'Y$_#2##!4VR[6M2,PCH:XWUQEKRSQMN7JO-/W:F2]^,7^)O]O#I()35%T?
MS4JM@N!$>(*%!)F*_6(7#2%=@*+*)W>9?HW)MWJ\8Y/',.AP3<\-OO5YQL*C
MK"-91YNXR=*B4 F250EHEH$K9:"=U9D2ASJ/9\'9]1!3+ERG8$[??]N580X?
MG]%!6ZQC*9GE\?+YLB"UE,!3J/P': VUF=KLHZ_AALA;3_[M.)7Y5@S3&A$M
M<!Q+:=I#DW6/UJ4?"=Q4$?'1=E[[5<Z%G%]O>]]1+'!N'H0B!<$3[$MM-R#S
M90"9 8R)80X9<\S, -^1I1%(]D4SD 50(8F<460?7D@GI"8\^C?C[O^$5&LQ
M$EIH1'+RQ8W%Y+>#Z^D/0M \H]^WP!B&"+1;G UY+'(C[BRORNYH%*[NR%A/
MDI]@))F$?_WEJA\GM6,G5>W];P:3E9^<O'?IH1BV8QOZ<T/ 'PDTO\;AC>3C
M'WW3K8SGR;$#(_$]NE>#.PQ>4[HZ%<6P6#=IX:V<>)PJ23#'$GW GK@%A3-H
MWH_LG$&@]X:<648?QCZ3>XB&P>5)1 3E9@@TCYV8\07G&2R<M:O;KZ65Y@K(
M*WOQ-M^..#NR$QWT"YOO4/9'?/GU.>TH2=@+C_3BL3MC.EYY]R([2G-N'7ZW
M5N59A^$DE.V=T,>[3[HSGON)EJ)0Y%EAXN.Z#CI^[<I[K1+W<38(>+0(P(S*
MZ?NUHOOQWU<"7?R'S'ZJ3)G]Y_7P:9ZW?<&G$PC+8/S1MSF448\2DPSXNR14
MBP#.80S-HHO['Q($RL%_S\1M,5@&IGUBG!?01#B2C: [9B@=)V7P:YH_3?V5
M?L;]MW;:UIF#'R<&^BU2V9>L-LZKI3/F5$4C??YO'2&B:>SW\?; Y)NI\(F4
M,!0?K#,N]MONKZ3X[33/>^N<\N\^JU,?S]X[+7R47A^Z/D3Z:%26*O1Q>'AX
M9%Z&*Y!CH&,F%[R];(OOV\#;=BD[A"Y-J,=KTP2MVY_^;/.)69L\.$;2AE2B
M^):M;=$"8*Z<?<'*G0Y>8K2(; A_)X9W:8HRSG*V_EW)&:REWK8^72(<4:U@
MGK4.^PB3LBI?1-4=K?D,1BU<619B/*F/GH/E2G0]O\/G24G*(4+NQ/6D),K#
MR9_^%5=W'960[GU)E"F^Q%- )*5D>",&Q8&GC\5A/K>@:)TC"$*F,R$MGIX6
M&)%PBK7MDA@6,>0_/F$L:*G^)(8QZ&='Y&*7)O3IU@$%''\QS.ON-Z?=-UI'
M,V.YN$N?)89AO5M0B" O D]("//"_N0%?P\)#.D'GBH9..G;O%H9GO(37@0,
M3FZV*-*5LVW?0T_H+2D/,E+G>7R?$_HMP$5/EM0%4M,9[GT9HSG@@E4"R@V(
MO43#S:!K6B# >5 9_J7#GCYCVM7D&F0_%)WM6/@QO&M7;G(N;??$Y@O5T/L/
MJ&FPM@_CYM!_$.JU8$M!X+R/\TRH4^Z:SK+A=>\ZEG9,+OOIW<!SM/-UM7;?
M;%$OJA&(QMXOZG]4/?7[?"U$'.VXZ8+08I_(6,K@\?_JUCJ S2D@7IC1B_2)
MCY,(.(8J&[^T/#BJ^P7B0ZBQJ>?@D&F7>76:,..)GRSMYRS?Q>)^4"+S[?<*
M1=5GV?5](:K7(G]2SKWT#!#TRC/FT91R*YIH5G%L_Z..JWO$L.BE+Z($ \2(
MR]F[#5&RYZ7-H"\W!8&GR//Q S^LQX69-2<?^I[4<OE[)) 6R*ZG3/>5GV6&
MG:_XY;>Z/&GIGQ_3O$W6GK_W,"P>!*R=]=(ONN*]T1VRUFJDWJ#=2Y"I2 Q.
M[13#@I-8%N ?P%D,^Y'(M_ 1EL_-Q"[*>+F"H2(,83J"TN?U"&-!9+6[A&M<
MK_\PN>!J(KR][DG<EE2SS-71C^$&3>&.'C"#=VMD<8R$0&F&=<NF9;TKQ%HV
M?&CD#7^9*?Q"CI-IRAN'S,G-UZHQE=6D4#>V V6VA$:80+J[[9&0>AG$.$TW
M2J=\ M<=]>'9G>#=TW_TKWS%8>F^"XI,Y0L;.GG1D.%HU]I!.RE3J1..!M=A
M7J;:RCY3<4"DUA_E,FX(DBY*J23'@*Y"SK02_?/WH=/5H<7L&<W%=%JGR?6.
MT=.+HEE5M3UVA5%_.LYNV47)L,G9.N.Q_W:G]*2--$\Y3.5$^^83QMN?1?,Z
M<;CJ36*8DB>]P%C(T5$8TZI#CDJXF>TP_NI<XG3/CGA&3AJSHFQBH3CA:>N0
M'^;2@Y142MN#[-'LJ/RZ$?.,&_>NM*L/!AEE#N'96)W*PU=+_<?>"X5BV/!2
M*UX,VQ!/VQ'?R*-Z#]0V7'WP8\ZT3!);BCW'XE([=%MG@T9NF>PIT[JX_SUV
M7<EK(2:=+*LCAAD+GTHL@7@0<; 882?'I<DMLB00-O\%?$'>SF?P='W3CQ-U
M-N8$0JCP\H$,,<RP]VU&Z9%\EO?:^Y_/!Y9$5"3$513D."8:W'+:3'^WDM%Y
MF(YSLW_XX[T8)C7!%SA?=HVQC,[<JRQ=#N[_R;(1PQK)%:2YZ^"/ZX@'<V_Q
M[[[6H3=75U?2[&?N-ZE((0[C\YWSBW=K/7NE$Q1)[<RYO^4:80+[^=IF*XMF
MPN!$U("E&?42L?A-!]O'@O K9\SO5M")*;?69GLQ[(."JY#!T']=2=NIZN9J
M76!<Z5'\\;/1@5^^TQ=)Z]\'RY]HTG\ .UO_[=<78Y+0W+++0!!$CIQ\<8GH
MO%,@ Q_3D2?'K.* *#$,P.7/D?'@>NA*D#VWBZ%4\*%OMPVQ'Z-ZG/UQ<TEO
MY_7R7<>/[?_R,DK/=>V%:KN-1]9?+ZCO"U.M/NNLH4P>$L/")B>&#K[S"H\S
M>YKKSX\H$L/T:KXRU21A;,/1"9/0$C[3UM4UFI#+?8%*Z/F86W#E[4]S<[?/
M/Z.HHFZ=CU_/I-FUG_Y(R$M&\Z\L?S4'U5GN@D#/0V_I3E>4,X!7>"#60F(W
M&T)[=&6^DJ.[Q_NP:"I-Y6MIKM9O*/E7I^M ==]=4>0_K)UG[ RO/WFR:])5
MYZG*Y;VP=1L?8=;7TK=* %/FZMR74_7'KLP,(_\$+E_0&2GV4S4%?UP8I5LI
M[K=X.Z#]9O-2OIG:I2#TE;!I?:''IP=?Y7B_^W;;/3,>]9'5KMSV/8^KZ8^[
MKV/NZ/V0M._&@_$_"?_(]:S7WP2?CT5% /(>8ABL2$2O"21_Y>!=.*J!:-$S
M5 5&SOFF6Y0'1D?GF%.0TC:[Y)C$-T?ETS+X4X_^G%]-SQ7#,*YI3DG;L(ZU
M2\1K 5X/\#Y ]F68LG*)RJ]@?W<>RXTL#T1I2;#X)?P01_T/[CG%]Z5*B><]
M-=X.1;123ZL8YG>J6"EJ3V!"325NW1[_B2'TD?2KV4DA;.G@?L&)FG[5\J+,
MW6*8JMSBLFWQ3&LM-HV<X.D_TMC8^$*GJ)?<0N)31-."MPH2M[ @FMGME;N'
M+>GXS_5Z0IL);62:')=(]C&Q_?J:;RR ^Y@J.9F68T@FK%7DTZ]_#.<</\N[
MNLEUO1CVK*N+/'LR?F&9CP6_+<U6OA#>@/"RT;E9(Q)9%LI;WA7DVVAF5WJ\
M]98Y&#73/S"<E#K"O,ZR<;H!3M:)8CU=EQ7D.3<"ZJ4F(71IXL:P@!:^FI1P
MH>U55H/9R)>SU]>$MHMA5!&SIQ[>V?+/VI8I$WV=S<>=L\]H' A PJPN"SVF
MVS#\G5:]6$V9^\-"\#N6FM-(82^/N6H,2IC'OZU0>BB7*[9JFG9K/SCNM(<[
M>$53#'N?!W1#51CK77FH)/53<X$>,D*+:_06<H&59XJ@.BS9NK:"'-H7NN8B
MT /&>$!&ZU:R($F%LHYC9=I> GAW?-()334P^@41WMA(347.GX FUF(YGP1Q
MMM_ZSA\?7O#5P_/#@3E@9%83V\?Y!%AR4LK4VFL%IPFWCF%Q;;SEXOI''MS,
M3;M^ZVRX:ELW 0Y7K91U"=0UA$W2+;G4I<G6#?[E9?+R!>.T 3VZA1JUNB/[
M?]\;7:5R;6;;C%K=.;U.\QO8%PKCT$FRQ"-W(G[[!03Z'HN1;B\15MP8?E*W
M%O'FE>CH:>X@N!;* P;T/UD:7';FL6YU 9\@Z_,8KVR?/RMM<)9'Z&DQU9@\
M$9P*F< 7D+B%-,E=PT1R*M!F#$CBC"B\EWRJ?"J@PX-;A#$\<:K?!^N0&F-H
MZQK^:ON=H87A'":G$Y@]#A4OS(AA7[Z(E.-N6 @I^*4I50[H]= 5T</XQ#<]
M<9K'G U\N%)O%D\LD9\IGY8(8!9\;/)EX97\WW)_'JRTIOB@:Y$_=8QIVDW?
MX> VNU\,DQ_KR([*[@<CY3)8[+.CLSZB(?Y9;R-,\>HYLYOC3"%?(0EB"$/$
ML.VS%R=(6<H=K-E@1%]84W=E]3-^ZZ;8O;C"FEKA7Y#^6.<4S>,89,NS$":<
MS,^S_S%\&%C\9!!Z$Q((M=FNQ6+88_2_28Y^(6J+JD+"^*31=&,Z?V59)%Y4
M(");C+0>+:N R-QJF]D>G\YSY7&%V_4-WXEA3S_="AA9&)787JB 6B;X%'!Y
M3H%PK[3_"3!'0(1/<[:\V69T;E'EU63$%5W$C]WLG;!;)S7<KIZ^ JD2)-3Z
ML9U;#3#QO8U#M30;ABY5'_4EH$93&V_-8F<L#,WCDG7<ST])!=Z_9P7FGY5C
M#S3QD._3WSPL'P#+ 0EZ\$5N.Y*E,UJZ*O;\QSA,8]JT5JJE>F]@^\0>[?*I
MC;Q64_ ;3=&VM,1S,_(CN(YZ<)6VO)Z*-DIV!]OVRQLYR:3] A80=1X+DA#1
MF$P^F8JQZ/ZW/UP26'YT+#J/H_[LQ371A\209Y ))VP,&+[< 97D3JNWH$8T
MX5_:7OZZ4+&'W.G8\5CM^D[O3O,MJ!ER*)R#SQCG"S9(OKQG^=C#Q J)"T:
MFRD M:\'M-G#LI%1KE;1P@LW]Z#<D'00]&V9%\.8+!&#R&7T.'R4Z#[W(#A^
M*C 5F%6DOHQN2X,H*Z^W==8]5@#26H_GV?3]#]=@I_QWMY!6>M=JYI:8W;!%
MKQ-#XOKM!>N:WZ-ZSDK$B'Q</Y[E/NF3V9VG;R"&K9^P+(.($*,G_MYD8KK
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M^V8U:^32)I@8)F=E%>0T=5W]GV6X^7+Z^4,:FO4]& ?'[\RNO/0-)CX'HQL
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MJ9G7^=^@)I>KS6YH%>JL:]CKLR$0UQP1NS@$H<H'&J"+96+8RN9<K9/;0-2
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MC8Y)"JNX?2W?:<JQ16A9>'=J+D,XQ=P@AE6O*,OGO&+L/^="&],4[[^/1OA
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M0J?%PF;1:UZ)5F*2$H2NUG_.(6=G5O^!;"2<XQ>>47'_<3\63<@WT+IN3PE
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M:9@][/H(HVV%6__C#A7@\T3N#_\YF"Z<=!K\BK&6NWJ;6[K^K02R\?B3<(G
MG'GA63;2.,6P&L.Y>R#MNSWOCQ]X*+S_XS]??&/TWTT8>[>HK&1GPPZ?V[-W
M^S?(FJ)NV/7YFK!8VZ!UM-D7\)_%J<(B524,UVG]\=+BE.[J[F%0"6.!4BGT
M.^RZ&'>LV&.L#-,RN,5JFFS^X770>=/!(SKW(G?I[&]+]KH#>'PY-R+V9//!
M+ &ZQV! .ZLNF]VM,)C;@2/<MFAX";W,2MP9&P#LX%Y=Q2RT#'^ON>BA8.E*
MG9>L:_X:92"EW7N8^;GXU.?&>\WF)RP^9#"UA5QVO*BUKA;:[OYQ$[7[0@S,
M*'@*2KK<DT'XFS(9W+0'RPI>UIHL^#O23>:$9! 2)4_5K,2(1%:Z*U3<,ZX;
M>9C0HJCUI'-LEG(F A'JWS,0_NJ)[I&PK3\Q,:/,Z9R+MOE@FX!_<GR++MYX
M9J7,^^K-_06XJ Z:SR ;U%[^P;X#3M7<-'IU<HVLC6KA;<E%N&<3#EUKQ ;4
M[SAMV-L<#2RA,IG7/ W9< 90V]VU;G^HJYW[LQ&R=-1=\4NI"H8OMT&B6<M@
M,8<ZJ2'LP8U?X)8A)X.FJ=#,\%6_%T]EJNK#19HBL.M_NH.0]SQ8*)$+MR2N
M/);8+/WI?6%F4E8CT*;+8J<9MK]:RE?V,>$.6SB3E[ZVA9+J_I%OEI\.K;_)
M!EI#FY/XL'R1$UU +].US1BRGIZK6;P)@3.49<5MI.2^JTJ.\_Y6!O(Q&?WF
M3CM*EV+5.Z)4?-FD(.('(^<HS84*\>"TTG.=R75O@W?&[(2I&M(R/[M979FU
M9LSH_%\<ADB"\V"#];+D8$2!IZ4"P%B6YL.634SX,%_ VXT@<.P_ AR(LX,Z
M?*-=P"DSZS7RE+H(6@41%X(V@APY4B]P#/($ZH4=/I">D8AB"E!$^,;7GUV=
M*>M@4_MXH2,A6Z#[X>ODPC_B\!MTHL7:':@#6ET8 +JAE$ZKE AP:<NL>I68
MI5]NC3"4 PT) %D]DSJL,'GYH;^8I'.Z+?: \%I!8P3(X'+._AAY_'V-#S/I
M[TPKD_,69<" VDYCN2YJA>W>A,42B#I7?P->P'D\GRSWXGL%5"\(Y;B[]WL]
M"*\(T2Q=[=O9WW+35]N-;;+GRI]<(EL7<)WZPCOM46/+28NS^#M:6GJ,M:E-
M@(,9*.GH[@1B.612?T 4(A6@K,XE;[3&RB&E]186W$#_\U0C@V=/&,$6R3:%
MH#/2O/Q5Z^8CTJJ5.,R[JLQJ[\M@#B23GL7PQ/T&)@2KNR$1F& >'Q8-+M'O
M%_8ER@%_PC=:R/XXDJ_LD9+/AV6ZNH((JI^]SNASZO!+/DR(1)_AX=?!/W[N
MD#U]H=#O92I/^;])G\[413&5 ;"H2=_&<;DV*BG?($H)$?\<'-$M:F1DN@(M
MW9U+=;783*)FJ:[>J(.ME./4*N?<9V"\]HO(G3;%I1$F&ZR1;"CPP>S3 +72
M>CB!1>V"0&C?IIF',? S>%9_R'[QX+#/3@VG,%?53PX.*#H?)@M,0.0A$%T]
M1".A#PZ^G !;:MX<G![0S->V!&(+[CXN+:[0+ILBJPPD"X4=W YZ21/&42"=
M5WK5]25B< A4 PM)$]?]SPDW,Q%3$1S?7U(6C^Y"M<:=^UU:IW(0R\(#\LE!
M$VMJ8 _U]RQ6=ZK3_#G=Z$:D(";-NDL]-^S<)BQ<4V1=)QV\L2AG9TI:(($P
M7IVM'_002Y.V5A#F:>6SB^49.E']W5V>?;GAY_&+F9DR1, I8A+.$.?8/*I<
M1@8JL:M]O5@UJ52QD[& +5(+66AW4_WI\D98)592)?P*! 9#Y$V02\.K>P#/
M9=67UP3S/>Y)VR+@V^][2_84_?OSX=+P..K(OX_J:#8%'N*H?8Q8VON(;H%P
M=Y]!6+JZ<!\(+/[[ NL0J64KF3+1^:XJ\N<:<7[V1IA(6-M,7YRI$TF7F+^F
MM+;1K(IFE^U)'-20NC\K\5]CJ7*24.B5$.$!(^B*7/I"Q;\?.^A+M/H_'YLP
MU \?4]Y=HR]P6*?D1B$"';%R@A8_6(R"WQ_,?*+A0Y%L_O/5N+.VXZ[P$$G/
M<0:[DNC#YF@7FO*V2O%,J205KRL;K>TV;C<BF%C;HT0=3^RP__V$=M7&?__)
MJT?5*1/3/X>TP-$1#$E>=P16[\R;?9Z(GE&!9?9=H72M2FSSXV[_-NAI!VTU
M0"7$;%=#G_\7CWJ*UZJ-2TDKLYXPDLPF4R#T.2;<F::Z^V/].,3QM#U'3 ]V
MF+AE0,/@[H"CA_$<Q++DU*X:]T"[,D@CL K3N7(SL:,^HY70EGJA.@7WP<M!
MM=9SN^"G33B?TAX+B!>* 359#S5(!5_T.!G\1..>S$QXT9.K\HX+9GS86&%W
M[_CJH>-CE[W'0K,%2+9QXT&C65'#*=CK@. G:'/WXFTRCNZCP#D2YY]Q''Z5
M*TW@F$0V1S6.,*MN@;"*HXC=N))Y4(H-YM%V1Y5,=%17=(?'/\.VP-<OBH,_
M.+F%'ND5&3=WVH<.U_4K^.R1*8P)2[D9A*"[.D6@V&A(8[3&T2=L5/"HG9NX
ME9^]WK\V/R?YM)>F()7!PJ2L_E+::"*4-[8DFO(0^$ZY=*VS^^+$ P(=SYD
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MJ2E)*K5;)7,T9#/*C0\[NE$@:'G^UV/Z;,\+^)Z(JK3E)V_=2K\$2JL;A8G
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MT#LWK_J=Q8?E!&L;,K^S/G'91ZJSY_)3_K6G)L"'_PI\@Q!<9SUA"WB:,)_
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MK/_NPP&7"40F,E^856GA N'[J^Q3NY2#<ANZAYY>[I=GRAC*KVF@,F?8 FL
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MZD?^YLO.U:8</DN?DXZH\\FB)'W]D/V_:'OSJ":ZMUNP%)'7,2HB*D)45$1
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M:73\*L_81.F28I2.NV8%_;L-VM5#MNU]YIT\6?R;UJD?!^RPTE=+X#B259<
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M=;N" I^R.:45^OROI876]!94$E40WD692)C58MGR</\WBTVRK9%+P5=84]S
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M((J39%+V(_W-9:>H=4= C%CL@D^T:RQ)X>!,&SGX^'^C.)$DR)ZCW$+0!X5
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M\W$$LA?M) TIQEQ]Q(Y8(K)A%X<Z\"R'G2-<092F8''P@:K<JQFBS@D!OB<
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M6_4&IF?$@_"!MWUZY1(4?[.6F25E<$?I?(%Q&JUK\(4&[OVN#U?N;$E\&S:
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M]-&(WN0<(?78@Q.\FTY%TQUCFK:FD ]86(5$,!B9?Z>O4)L)#X)_E%X^Y<=
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M7V&\$0C'A8<4&3BH*T2A85FGY(/S/4"C5_]ATG9L)\&XNXE^@S#!7VO%3]:
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MURO*@K53E9\W6>@N^GP&<^&%&;];H$-8P0N!&:<MBJ+^9HMQ7A'_'^.27O
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M\'$2O(K9_X8+"6@QYT*JD1_AZQZ<[)"4Z&H38'N:R#<R]H<+X3%?1)9 DKO
M).P'@,[^0#+T",XZ$=G54EC8YEQKS_LO%[*_V80+N>NXL?\PSZ7:L"V7UVI1
M/[Q'M9E"=,K?X('<D .!\0_5IB/'5%=C4<*V02N-)9<23"&M/7*LL/S+@NR<
M%T]XR%W%]J30DCIA/MH3-EH4TL8Z??U^W4_YONC"S8SM!!XB)_H9ZL?$+BO;
M%:87Y#;+'#CN?NBV0\CR:6H$>IM4<C\!5KNF#D6+OBXEEFMC6C=W?Q88S#!#
M;;'_;15!%U?QBS[KE,!#](%KM>+O,XN;>I$#NCNL%/J.":!KF P>!CV!E\Q1
M[5F-1<.C_"[,;N2GQ0BA+^GMW6=&'99:2U28+!3\UF\I J:>PH48"2V"+6-S
M4X%//!?_.8BQ=XU&PEJO,*!&*J;^9TK/UDKC\U+F^QJY>O?]QG.7!&:[6ZPM
MX7IP>O]GM#-<#_$3*QY+H8M[&(?$!(J9*J6S:[16\IW)T69U959]3FLO?%2@
M,U5X.IP%I8EVT%B77W(N>>>4O#@+YT&<$^J6NDIO'0AGP\O;4'V />%*H\9]
MVN#]_[XDU[\+#^:Y$#\NI!6Z*4H7A$L>"K?N^=KTE ZWZHPO^O;'N-?,;%XF
MVE\YNZG7=D,3!_=#^4<@<-A-3J"'^=]*?$[W#EH?%X+.2DDMO> 5BZ6%K+0_
MC.="3NZ.W[;F0AKI& 0-;(Y>NRT%6["D0*/L-B.\=Y"O4Q@QI1@WX-!%*[!G
M+#E(-!/<_<%_4\VH8 $^O&.;[@KS*2R&W0D"J(+#A A'\,0NE/1,2'?@\=+3
M=7>FTC/;[5P6K@TQOVEAODTOP(@<^/S0>"]9I)&:L9 :^TWB3/B"H9HGS;._
M9JJW$&(E1/E/$F@LRY[3RCFE1MBWN2 [&K3D:4.T=#02::QY9V31A!J96CG(
MA;R_O[<"TP0[P8NX[''2]=P66$\#$P\6 J7]*ZNW]^=MX"99"FQF;*4R?$,M
M<G3.JYS55%.6'\+CTX]S,^AM?AV/Y[FM56 *1S.-BET5W36N,<_$(2SKDA_T
MAKTRALY3%_02WZ%&;;B0>\F"=!RF%#E+6N-"5G&-A/.^$SX[GK&$-:I<7"\%
M@O%0O0_9K6?VK1+3H!:\I:8VI/?C=R,S)"0%Y6DXV[EEVSFQ0MJTWG-9V??^
M7_B0ZI&MI=/A)7HL%"7>=@[$C;4;W0-R"(M4FL6YL6!$#SI3;NP+^K<4+8DR
M^6;%O?,-)K-I/5[+-+KCV8FW47X3_$4FFA\'&CB:F<.S:(5Q=^^7-] Z)UEB
M=V2@1V9X8O74%5LXO985*P9;&#OZ?/DU@*:)DE!%>MU*_8<)*$J4!8 ?\+LS
M<<\6]'UR!$$-U?Q5E^)ZI645=,ITQ[/NME".A8SZ*.Q ;-JON*M3%["%3@NP
M@7\-WPD&')3-0HE[6\CZ"[\[+N6@K%(05BKT.(^/R%9.C$2!;<M1/7=7$*8^
MME^\J0SS6368:7YU2NL_^:_(7S1/0&4]!.NA:)9+-:%039K?!IGV]@-5K/'1
M("VD)^MWE__2P-:V$\\[!BWF#^<SEX_R9(^,HI/X+=U>+N3WLF;*YHKEZLRX
MYC!B&BB(8# %/2)W9:>XVE:FQ[R%/5W[^%]+YVXTL;J4>.^0S 49LX?'IB_E
M0K!CIE'CT"Q\F08]$59P>%O#U:U< 9OS%;_#,,S*;QS3.AA-J(>-%C\???
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MMMDE#/Y'08$[P;P_+LC L2!20YW-,]UE7HLH]IT@22[$4Y '"4^!65,B%T*
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MDF1QIA=,-N>2NU]MH)W1K4M-MW+3,?C!K85)EM2")2&B0N3_DHE0H"T?W>*
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M"GB;OX_-MW00+>!N^7@>'%M>T][P'.:_G#&K)A2MU]43@D@V@/*#1_&'MO-
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M1KT'?^#N+6PQ^: O^S"L.8-RXN[Q_CUI]\:'$]Y>O#$Q?/HYPM_"XIL(UW!
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M4RE@=^U7[DY#ZW#VGL#G02VRUT_:>1D&/>CR0QL1-'X1NB#A-X?AU4Y2;6$
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MZ,V5O*'(!/HI@8)$B@"=IG2A#:Q?C7;O=B!N(#IC5MNE49S7&QS>'I+X[N;
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MX+/-^+!L)5'@N<U$>G<)P$2)>^6,QY&,,]2W_WS&]9^=S,OGD4\71L?J@"?
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M([Y Y03+]C&6^87.?;DD2LSY)U=IR?C,>92#OG\YG8.B.RTHE$+.-UV ROT
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M.G?I5I#\XAIQ3(X Q@![1?2NNFEJZ8,8.W0.BQBUT@QH38!YYT-ML)18"C)
M@K"Z4F R=Q/DR:F^5$+/LFEOX6P6B>'>J$MAYS#=W[H$XIO%*=KB]1(72?D*
MU]=C%G@51I*71(3'!EFN$BH^9%#019\PYL<X=@P 1!]AE"=+)@0<@-9NKJK^
M2C9?)_8_M')NZ%S4OTF#JPZ6(T"M#9U]7$#V V[/7$D4I6N8E@>J+S:H>H P
M^QGU<B"V65X&#RZ[>UX:_DY8;@.2/SO__CV93 ?5>E/GPR4'IA-+T5&%>V4C
M\:I5B?JR&&=15A FL#P"US]<ZX@V9B4%DT6H(.O)N_?%K6W%35RKUPMGN(8
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M7V2<%8B87TEMG8SK=(?9&\UE&0A((>G_M8'UW .$+R#$OD-B[TI3$1PE,K)
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MIK<J6OB */WH_94B2 %)L2[:72:,#UL&ZGV?:%M2S5EB0>.<I[E_>/:X6%V
M$L4KH<C1/NL'8G+N$3_(3:!&!'%<_.@>+:;N\NHD[6,+V<L6/*CJJA_"P]*T
M,V1*!G5?G4_1M!9[EU0?FF&+_QI/%(K%52T&<\#=+E>S8::.-RRIK<)K;[R,
M0^)YU4:7-97O> ;WKZ(]FH_?RY0!)4KV.FWF\GI7[GBX4823J*&28HR+-D]#
MN-MN=5O>+NMI'T&9XBM[8K%_WL#+>N+*G:'KCO?%T;D28!WA?]0"4444HYF?
MR#CQ@WQ=B\6I_G83CV[XK/-Z7U:Q] "H6+( _IZI1$GZ[W<A_E[\:T-JQ*Q
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MI])8[5OVI6GI9$'2\5KM<A'DGEY6O&=Q]G10A"-B_#EI#;*L5W,H_;I*GZS
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M+_=Z7,Q%R#L4R5BOP>8QRB:WRQ2K#]15V\H_P#;[->M5DMR6=@PD[CSN(X)
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M(EJW@'+AH2*(Y>G%330H&[XSK%++0T[H$++="=RLS(>R2?<QJ 6$\RV_EH$
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M-7$*>/^1A9':CPGFD^J/'8[<M48*-#\>_XQ@J;/K*MM.[%P__B*VO[K'%Q-
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MW[[=,KJ!4LN$K[!I'834"1*IE9.="NO>/WN)A&02QM]XY(A'[&=4100W?<5
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M"'CNX/;:C,KS&OR0<J$;=D: '$_]C@QT)#$JO.\-$IVT]O>Z=MA_ZL'N)DR
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M?KH3 5E$X/GO)< ,F^&$=!*\_-?K5_WK99U:]3&7Q4B=MILW3;(RNS+36!(
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MKS]U#T%,.E&S("OI.R%[:"KL$.NM6-@&+$3HZUXRY"!#3MO&"U-(&KI_:E"
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MY2"F1\1GX5 F ?*1OUVP ^(.$I(8 X<3D]-5:0W>:6.K;C&F6BS?&2FW![Q
M#AS2RR>7[H6=G#YP0H#K#61!\F Z\B^3@W5+*W\$9B8$58/&"W,;A+6GVXZ
MM:<K 4Y[(L16+/1YF#5" (&.7)C<S0SRFS%4>+26<$F^5720\9">L-^?)%X!
MVX=ROCVXB]R4 3O+B%CWSSFZ(B<BUH,\8>^3[)>!;,)?5&#[6P4@K((%&^C&
M0SD<-B+5.3%+)'A.;HA-3<W5QO8BF\'G0T@DVXI9Q'PV0 KH>S^'[@8;VR4
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M$,&R3HG(JCC;+6?T8DV?+"_S:XIG3YE/0S[;0U9#?\N:L@U35/63RK0E/09
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M_HGC_WD:Y*<IB7P%8=H,"?#"GBCBWI  O5>TK4:1HN7(:=LIA3XX@68H%4J
M263'+",VO\5S OH8A$E1D!(2%;A7%54H4N+A_MCL[SZ)3[IL?=KL,P]6?"R
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M+QWI CV@=.N^/-[U_O@2!<7#K@L]L&,8FHFW(=Z$7:!=EG\]Z?5.;5^(,M&
M*E:22RU/ZB?<E[!TXS5#CH&/5NY+JQ;HH'&-$\ P[PCNAQU6%=K9867/722J
M7E!^K@FQBGC/D_F8E7XZPN(1%Y^<N,>*[/'A3%BG\HD2# M%G+*.'KAL.U03
MG;;^K,]R_I3U\K1;N+CP=J*$<*^E=AF++2NNOFUVIK]#TO@EXTNFYM3Y2=M=
M9^Z([0M?KO"67<:<)9 %+E*_6CYD_1L1: RJI_,YKB&S9N6L&&\_%+%,%\14
MW5%%CN>M3M]YX9S%W?3<]W6-(@^Z>U)>NNTI8)V%C,P:>"D=6"/HW)CDAX3
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M.1]P8T._M++E@RCJI]C')_'__U[']3?*_W.=_T<W.G25;U7UYJFQYEG(&CZ
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MIOH1Y:[TF;F!XP=.;Q-9+?#9_BZYHQV:> WPU$S'4X&X<%P$QH7#!S)FA-_
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M[D,PO:X 7/HW$G86FR%T=>PRE?<P$!8J131.SAS R'=#)#+T%^&CMC2)PA7
M1;UZC$2S&V$ ,B/)? 5@@^KGL)IF?N*A MCAS_NCV+!*_B0VPM^(#>Z/$B_D
M/87X<V!"L?S8)UR'P(GYSG\],>E?3:P)^T>YX6$^R0WYSW*#C 7>Q @CBI5C
M"4"X!">LJ8 3-7"2<E=8CA8QG#\IJ3VBI,@X>*6.QL@G-D(I(<YPUB>1@?6:
M4/^0-ISZ:TC\3Y <?H6$$+)>]  AY#:$D"C$T7+ZJ8A!8+LP?I%A!7 'H>$?
M4?I%%7A_1LGEKRG#^X4R&;\Q&'^?-,<1.*9=;HABFBN-19CR8KEP6"A&3(':
M.)_*T?B3=(('8L5QHYJ[.&+U>BI&S$M6D_L[2D>>?V)9CMSE.6;BA#PD-1'&
M&BN .N.$41HYE^ITOKJB_6(J)MQISV'M\QWLX)\.G+GCY#+V..7@;$]=]U:A
M$<ZD>6U,2WMVFLV"FCFO[\2@V#2;@$*C"K> DQZ3C]YOQ)U."X[HWMN@>2K6
MK?> EYI]/QI&9M,,%:MY/5$ J-ZF@PA5\^1;0#8X9!P70C0?AAIE!=W#[0;_
MXX-HRB>HOHZ#:=J"$&?(6$KVLS%![!,M_P4R%5]H>)5 !JHAD2DP2'X#Z8Y,
MG!6P9(=S&;!Z(48!>#DR-XUH.,_6XF)')@9Y3HY?J5HFHR#\S_^)4 "OLA$%
M5P!SN!QE[>BH5">_Y;B%?GL^BYP?L0IZE:  'KK#$\8A%#27ZB8.=#HS F-Z
M-39)5PU4_O=*@/X&J?]B*3'ENECLH_R8"X&<#0:,0[L6(=XG55G54-#8,CS@
M]NZ[RX5X:M\ <=N@ KAI4A;/2$_@J(9##9_*_F!Y@70'B3?\+'!1P:0WT5=^
M4 #5(<LA04<3-_^)_WQ<;L'Y<<%$ -B[32[D"P)ZQ7RB\0FA\U_$[B!F/!IV
M/DSN.S*"R0E<%C9C@13"EAFX^>F?3]UP^WI$P+FNU.Q%3M_\T%( :JX[I;7?
MQVZZWDS4J8>;9GI;W=U?LC3#RYLC0/$O^N7 -H_5'DKG?M0U]<=4ZUS3=0KH
MM_"H;=QZ>K6!_^RAA4;K*FQFLS[(WVX\F_S,M&Q>_&.G2X&F2TOB.L@K]315
M48+ 0)U9"S=&AH&D!,(%XR,Y-#Z**W]X0;[Z*4>7*(,ZC*49_CR4"'%W2M)I
M(71\80%;>]B^FJP +'#\0.'L&Z;C&ICPBZAKF&7K4=_I.QFX!(6P-"Y&-$>I
MSEK7^[1U8L0.:[K@0XQWSWNC@^D;-OLD[%NS<;[)O9W!0S3/AU0WTK[A9'63
MHV"%3+*2]<Y7?-)2]@)6\XC)[MA2!$G7MV<]<FX2JQ[9=3<L1WLL)WQ&T"G6
MK1?K:RMF=]!H;@=-4D/2O,H7S\4Q:_6V<VQVQ")!]DK$'!O8>R-.#24DGL3K
M?)KVIX-^!'!4 5SX9#"T%< EQOQ&.42#UR@E,V82G*P <@6LJX$E+YL@3W^K
ME[X*8!+4 95Q)N 21&9"?P&(\,_USR;GU#AU B/X!4(B5T6&IW1JDM,GNONA
M 2J7*+-G1MLF4R<JX5'D3TK"B?G#Q;\ ">2TF__FV^22/T^L"?W;()KWN;CW
MJP;1_\%H?BGEI'8D2<Z1A\AN2%F.MKL:CP>45&>\:VA:<$:'KH_@+V#K!;8F
M@(VTU#*6 EAPOF2T:G%N=XOH7(Z=SN!ISEFZ+ XA'X@>D4CG'>;9G[_Y;*LZ
MB+5Y*^7F,JD?M IR+M_HM)L6TNL<3!*82\@P/E<5CM>5JW.Q_/<\N5B+"_8/
MZ,#/"U5EL0Y0-6+JJYK0 DL)$^F(@LTP@3 %#<L@9AV1']ZJ 'IG,^6]4%43
M*-@?6(AT48/C:<JM!RKG 4LZAFZ%Z/4@9R82)[R?FB3K1H_[T^41)CD*@.1V
M50'<FP_?$:(Y#QA2A+$=1 ?$C>-#$,6!^A=#?9P0Z4H-#P5@4J^J  [8(SVQ
MG&N,7V V4IN6(Y[GOCI&B( Q<%( +UR:2.-<+Q)_*=05(Y=[%2#QE)D4C01@
MDC?G4&/![O (J0^)2A_[)\FD1[7D^S"B)"IT=!V5=8]0CT1@<)8Z@C""4)&6
MN* ;KL <@NC9I5##5>7N".M7RK!)"#+0)UR(LG8D[3A1F:X ^EL_4MGF4@;_
M->=/W9 (9P[2;Q99^AJ*RE0 +>LYNF+!!8SDH7)?4>[]:7KP!(()U(1R^82)
MF(82%_#^2!WJK]1Q_CUU6$,_\\DRJ9&6["YU HN@DDEE$>&)0*&D; A$\%4
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M[[Q!!#F'2<>Q7AG9GF"X @#86Z24HPL%J^!S:&X ^5 .?"6+.I8"C\,B3%O
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MJE5)CMA=CN[=0:V7&5^O\WQ1L:V@LQ_%MI53"QLFX/!!F-Q2PQEE;\>IE!+
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M_/5(S1<L$_VKA[]^W0?Y@@N57^6&8_B__>3:OTX:RK).1D&RYW4%0*'+.A1
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M6=3=GQ]DGXPAFX$1GZ+R=K5,ZY13AP8]DLKJP1>>MR7_<Z[QU7?+_Y5\(9V
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MP=*CJP?3L'=IT.R/EWU+\[M;SM59'A-J&C@>V;5=FQ;BG#_B.+)5 5R@4!1
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MDUV[!Y6#H[1Y%E:5I^OW->W I(Z1-4$*MTJ[B;<@=;5D[8^K)Q<DO:UQ'?U
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MV59+@LN2-\SH0F+?NS!^K[K9BP*FUMRV']TR'.)&O3O1NOVU?'B[TS"3%AM
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M=H_93[,#< ?.G;4"6T\[J<.6 MDAP8B,:NB/S0S/FRH+06^S%Q\8'NK=\4Y
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M)-11S&2DEO)(6E7*7$AHEGG/XXAN-X&^GJ7%7$23G,>6H9KM%NP2_%J+ GA
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M)>Q3[';)NU'\WWK0VWTO,Z]I!-9<HOX!KJIE_3!9:V"/W%V;!DU[VZ7HZU,
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M=RB+Y<B:7:!3JM[A([>BICL%143G*A$9U)@:JARSZ7L4@*'GHE<NN)M6EG8
M0HBN-Z  Z.[\H0!FJ_%Z-41!:+_)2<><2D,F*6F2N*\TL>9M29:>%2/E55$
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M#ZYB+LR<I=MI,YR.^_++=T8V$S0<U^(P-C%VJ;BXE/.T=_WC5Z9U"N"E:?9
MQH%JI7V)?;GJ]4M-=XNO:E;K%@^FEQXID6A+%OR' CM!24KX3H._$:,/4A.O
M=5  1? #L6H[#VC^ZD11 P4POCX4 H?@07\F&J#CV W_(K^)P_]//>>R&VVG
MT.D1)"0P"VH^Q_0W?%C]#_66_YY.A/]\=.7?.-02^'<R=,X1FQ&_QQD5%0Q&
MI7E%:!1JFX;:ZMW-A%:M\,,E&C]L=<HE;67-G%Z)FZA+RC/[S7/0@QGC#B@
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M<+5$C)/9"V.]+M@6BQ3I?'!1SD][O*+LUSDIV'%VB6=IS)B.IHFRBWWD\9^
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M^.*Q<#A*#L!CBFD/?>K&)^$G#2>W(C?)G5/QD["3)J.;KH,S\__^?T; (A3
M^5BR7O'I$/[>'+2:!%_<](UM([#%D6)<S/[1J.?_&A%C#&IUHCYN!!4$)[TA
MNB"C&QTF/?7U!W9G#\P,<VS=FIYSB$!OYBY:]7Q"6%T&P8_IVA@X%*IF/+[Z
MPXZI7U;'TDLF++& +(GSB/(T@3WPTO) !8*COB>^G#VY1Y?3V=0N$4TZ?O>+
M\S229X2YT%14./8$CO7?9 G%H,(FGCIA@:L;7[V+<W:A?13 +U>G&S8"D9N#
MI[M'B.PJ\RU?1_S"OXQ;^=?^O__5C/3W] [^=6TP%Y3X%@V,H!] ;M$(/N^!
ML<&;ZX&VQ7LGQ]0DX0=G-724W.92<A_XQC&^C/$E:QOHI1,%8%E\!]K6=@RA
M[1W-"^W;AL8">R-=* "HY*D3RX*1CG:%'LN:9,A*U8#R<@?<:1E"!.2?J_DU
M'960<<2(#\ ./-_%"$G[P)";(YFUYO3B[%W[0,N3IN'Q%1\)0MOD G_)5EA:
MMFKL#/.G7Y,[?G4%7:*R')F+(GZ<KSA6'D=-59@O))Q[]^E2 ]*\ZF[+V2YN
MELK:V )?HZ5JDP* X X*U3/\T?]H$L-_;A"-$,"6J#!/ 3,I '8R+V8+O!^6
MZ_88S%^92#8&\Y[E$AB.#4-3M U:G']>72RH+7W@=/I<0$J;7AWJ+H255_"8
M>1B,_\&?0:MT0G4@ 1SP2:_&)%QG+%70>S2^?)66,_O-@@#N(GZI(<$SZG*S
M\M-"Y\["Z$:4KB;X'WWK?[O!R'/P))R\,$\\MS4.RL_I0!$3?PF300B3?:+W
MT8\'FQ0 %?JDZUP.>PNYV7AAR]OKN0.+RWA[OR0'_"'XMT [..1%D7]IO4Y,
MO<?(9BC>#?EAEJE$E0*8TVIG3P>K\3"%UC+BN:8)RD>^%(#3).CK&2;F9WW5
M,+F3-=RM5(3?-(/H2BK@4 2:7+%::/*ZG;UADL[H,6*$WH,'_24+#FYX9]P^
M<.>.Y  C[8G$\@SMR?K6CCS2MRR(F]MKZ<N2?BH%<)\"H'U;?Q;)7MZ%S0FJ
M$?W#S=T PX>+3F^GD^$?3::'7/=,:+'YB*97/O%=;KYJF@S(!'][USG=]_RK
MO[:U&Z=S+J=FEHJ%3FY(G)P[QC^:M^5[<O_MMS%];:66?@ UU>AY^-(&.P;I
M#!2UGW1WYTY;_*@TK&A.?WVNL9_H*2(BCD6OX-=;NE9/]:HMWY]SI@  ^"+Q
M1@I@\V " "W>?L"/N0Z]2I9Q_:73$'H(1D),*@ZD3,GL!VP\K<4.NI9Y$C4#
M]CPY7T0I@'/'%(#)C%+U>PI@(_H4\N(:2!&)02R+4ZWP#D7*C<YI!Y/B0;4S
M4=NTP_MK%,#!4]"H@B<[67"XX/F'#. &5PK,QD=E Q,]UYB/E:,*[M9T$W.W
MXRNL="^26@4>:[15''@@Z6"C*YF,F4;OD@KXJ2_-M[D9L-P1>[8@\Z?TB8T,
M0$#54-H*BS:8E^YMG!>]+'JE\SA#ZY9\XF9S,6:C)PMX:QTWBBGPH "Z3 Z)
MT,93D*>!0F !-!^'EOB>ND^$9H.KTQJ'X;1>UU!)U);JVZJ-V@;4-FX3#M5B
M/+OWG.K/K[B_+0_BX_ H]4\H%7MG4TJ\A7EN_OR"'6N">,&[LK;+#9< 2^2\
M0W;OR!V^W3I.V@40/4*M/2T-^&,?-90>N=$4V0]M'RS:@V;]>6,6QD6NF/4&
MJ4R/+CJ1:5)K:Z'V\%,/VG6Y(0/XL=DH0=;GQ4YCB<?UQS;0G]=H3T*D:/%<
M,\?5M:/?%7 ;>4=(3-EZ6"09N#I\GV"VAW.TA< :-VN?,H\$/E#ZML6Z:2#]
MR$(*9=TNGGU0];N%Q=&O"D4*+,<$'+*M35U&LRH]C!)&C5GN<%7KBI[:K<14
M/V)C, T18JB(!W8=JK$^P^83(HC26ZRAR3/'MOBEXZ-?R+N2F%*5.M&?\TCO
M;5"OZF,1\;WQNUM3D1FY)8>.TC_$:'1+Y]>NXTJB5K2TGR5Z^<VGD/QG^1WQ
M5=,ZO!YKR' &[>@?T3+GY#TFUU[\HJ8+*W1 K>/FT/UC4<?&Y*V@G8QNM?,3
M]DEYS)[O;G1?^!T</V-/>Y+W%3R&<W!:V\2T5,8:.A0 17: ZV=!H_>@>\&+
M67J2:'PRC6'1VHBM0OR6A*S+8=%;=9W5DO6U^ )F1*XWK1V><Z+@6K% 1=YC
M](H!+/?V8Q[H/ 4 7&+;8>:H]]Y\S-B[/O$_N'OOL":7K6_X5E1L@ T+"$%1
M4!"Q@"!((KH142 @51#8@(J $'J'J*@H*)&.(@2EA([20@^*$*I!.@0(O22$
MGH2T.U\\^WG/6\X^[]GG/>VYOC]R7<G*S-QSKUGEMV;6S&C-OR?8UUA&O#A]
MR>VRG.9F<\@9+2<HH?6#;+,YG*DZ\Z:>ZQQXXFTM.HUPV)\6L\8#+$D<P0[D
M9["6P<7J\X!R-.+GKKA_HP$$<++33T1>\=V#W/T#2L/'!U[2*F@3#J4\H/\3
M/;AEQ<\R#C=(:O*Z7?F.>!.N8IU]E6G+ \[!GVI EK0G2*8^A<W#J"*5W@ZB
M>@[J(G9E3Z^Q26=[0JM9[Y%KD3*OGIO5A'+AL*3F(&9+GR4XH;3T2^KF46>+
MOJD5C"%6;G6GJ>G^=G<W\5NI/28;LC[B=K/]:"(GB6S9F<55K?4D'%2F5']M
M$'9P.2E4>4B"K5U&=BOWG_5(N18JLCEH3.PC[.#9#\&GV@U"GO2>Q9:ZA"58
MB*?N&%)_8&%?]:1/D'O';RW;-96DXA/?S0/L3NI?E KXE;E7?Y_HRNP7CEG\
M:Q[P#K)Z-\S"6NA#KTSF5J>U9O::7'7TM:2]-(Z;1MR"D>-GHAT7VB$X?[4S
M5]598^X[_(;-I(ZR!OQ+7E"WQ]=EF"]C*\PU[&@==XGUN*G\Z%"((I-N1C#;
M8V5]JLBM&S<VASS188%>PZVN>L6#NBM=\%=,]JGS>(,2DBHCM;E D6SQ-O:)
M*E?M,;:&'>HYWN \YI_+A](!))GP0\@N>VJA)OI;^TM!9\YKT-_*XJV8F!-W
MKHIX+SPANO6ZKPRI(!-,>+IEDQOT?>"ED47IYSL.)=+?"+)[U60'[5-T7,?1
MCZ1 3:./VY81 IQT%B,?=0MYMB""F'QS!9LSW>SRFF:$^S!<3IB@1'K2_2_=
MQIL$EQKU=*C:$+5,MQ>DDR<G@FJ&$5N37)--28^[-YM-GPP%D:T?APMZOVY]
M7(DUDMM0)YLA;&[&@8;E'@*M_,"P(4O%:<6'06[K[C>7Z[./#58,Q_5R,5:)
M[;UW?6L5)?2,%.[B#R6\,\\^.9JRZPYF[OY6G<]2L#;#9EOWNY(4LN717\8>
M"3M^<T@;_M3@N;-36_")MX">U(;ZSO=.EPN),]'*2XNC5$$'Y*G:6J;F<J-<
M<,6JMKV/_@)5* :7Y?S*X;S-9P^C6T@?22L+_?/'KS5OO_IK^ZWM2;F!^U9%
M5+X28^K=CN]OT+VB$*3OOKK)+G%BI<GW_E27\##-8&XY3DOO4M.XXRIH)89Z
M2U+T@;?!)HE$+NYQ5MHW!^E\"C5W@*V6Z;G9=&C(,E#CFK.[_V99LY<Q?;K7
MI:R>?QR+NVJYI;M*>+WR\VX#:4FG+\^NU:)4K+H7DK3#-0[VOK\6,T46,<(E
M*JX*I<U!:V=YP$NN;2W?X9G[+#K34);&BR&S0[1M0I)X8H78;O&[NXXF/$R^
M\MGIOMC; W&25[;C6BZ5^&KTTA>\]AR[\CAB+/;5>^9,OJ<PIZS7P *;I"R8
MO>5)Z4HFL I#W^2WC3R+BT5\*\@F2BCR9?^4VOB#]/P/A</J1=A%\JIZF+O#
M/G+S7;-YG&-*\ 43CXVH#<[1;9:X%3JM;>?*S4U^RN%%'X[7Z,-< BR+7 -#
M^M:6OM"!@V[0,%,XX;6G?I15Q#!;>DQD-9#J2F >,#3Y'! S"<?K180.)J-C
M\"8-+]CYA5LNP7>6[F.-;+Y]8OBV\8687[5JWMYVB?84/)UDZ9EI?AAH:%>6
MC9+^2,R^UE"9/X\Y+V8DJ45(D1\.7\:@A=]48:9.US&-.#T@L!B2>RBOS\#%
M"3HQ0$24R"^7J@>$ND^GX4WA<3%;Y?#Q 8?]XB,8B4[6&R"9T^+ZWXBG&SSW
M?2QZ?'QO4S1F8W4(:=5K9*ZROF*AX\6+[ ]'TS;F"(I8F!U<FVWWVFRUC_0=
M._/LDO+G;1_7J[K3I/*C>HYI&6TY6!RY;5,_#[@<'%:! DTHMBSD(&KJ1V^7
M"+LD@2NUPFR&%^==S,FR9*[,WPCLXK:1!!F'E$BW%QFZ7J#&+X'ZQ7UWXY"I
M)(1D3$0  @J%PJ8,(RN95K>OH[^K,&TOKSCGAN0N-&?-U8[3[S]/N]X!TY$2
MH8&UW1[&UK#35B*S&K"1 .>W!X5&6J>1=7MS?C0L0%X0)Z8.M/B B)H(W 6&
M _5T5[M= *$0&SGZ?=RG]'3_SO87>K@M,A?M<QP-"AXI::<^WUPX[U)ACEL@
M;BTSQNY.;(K2"6L0TA\^5;*#'!R@@#T[LN +L3@^>D[O"!13WL'Y?GULKN/M
MDH@GQ[D9>2$8)]@8@LF="XENYSB,$)&Y<ROEX37EONHN9()"R%@ZZFC]<?+9
MY@.)NRYC)K=T;]1WN)W97WH'GI\6.Z>4:J&L(TIHP6BH?-)QD&!BPX>D?WT'
M"&:<@/Y@!ZO=#KK)+.V&B()\G'?N,-+?K&<^Y3.)!YST6)E@VP5969OM#O\^
M;A>7M",Q0+Y&0NN>>'5L@ZM)/ ](W[^MHLO.:N1KBWP0- 5J4?+XQL3*&*<2
MF>#_1-TY^Q5&+DT4Z,AA=8L0^C[@,U065&88J[ !R+$ UR0%DV7TN*"1:W"<
MSD!/M^C!09>>Y!''$^:?LDWNQ\MY98F9O_FRGXHQ^*P\#^O1B[RY;5HF,.Y>
M)_S;HC7D5Q!Y:JWVW,4P'U8+8*N:"4A@6B%AK8?P:+,6;)$(V7+HI,1['D#4
MZW[KH;T!+)"XP:A-^@/1\B7(DJ(X6(GL&!DN'0,+$RPJ5W_.T%TY%PSK9^^U
M6.;_:/TH7,&V_)V&M*=QH[=X0*LR'_E+UA,Q=%(QI^9TR3I2<27R+3?6Z]Y_
MAP#K[T@6^8,-O?@J!TBAZR:1M3/#N1C!0F\#]#F^+]_?-5?N$>R[#);%A/@$
M=TG85'XMT!8HRY'>+[^G"#VNS)!9CK*WG5%H8>]VH6\T?(^V.?)#K_V+;N:!
MKK8U':A4T-GA&DQETF18\]3W>^[, .QP8I ^^7B1>MJ1(SW[X:<LJ!S5S]6&
MDDXAH?1M"+MGQ9:7T$W^:"P=#-Y]HZA%65F^+JI.^"#S9QY(KN>,I'U#^412
MH LIE[ EA3]LLO^:C9E*2X9F7\Q>-]\RF#IQ+G;C\[+G%26=/;=0']Y!&FH6
M<WO?2N(2-0SPK4A45<38H@-5\0U),O><>N"#PW,/#Z>N/B9<<74?0W%V?ID\
M\MG(^4R-?/#%ZMR)QU)9HMPPS"VWSH.=<9DA]IRP_!<AYQG3)*9\IZ5EV9+M
M@\GOMPZ;(K>@,>+1WUA%2F1HI;7Z;AX@RM)F1&T]+8#,J=E^)/L%)C/DQQ1;
M#<)-F_M;]UC^9P@W,WZ;NL1S=VK48'F JUH&J;XWG=2" T=P0^@EFQ@<NPKA
M[[(@PLF)1]OS 'SE8W\S\":5!UQ@$=5'CM"@_WTG@/Z"\%@3L6+/E(X":8L_
M0*SN'3Y2H%G@Y/C* VO$A3<6;S"+MFZFGMMD2"OK\,[/R3RQ#S).2Q5[J'G+
M7-2X>^N!45(_PWYJQW!+[0$ZW\BP@I-_N;.X>*V])4.W )J1!5R"]P/Y4 >!
MOIP#))P2+!&]*MQ*^,RRWQ$_:"F7ER]J+9LCLK3=_&0GXY!+JUQI,\UZNX=V
M]_H^=OS#B[Z._496-.TU<R/Z.]2*B&:OU.((>151@87<+,G97.C5T20B$'7K
ME;SAC<T>EV8#SM3LYL2?68^]@VU*:;G8]NQ7=F5-7-^K\G[5<9K_32[W ;8[
M +<?.C#D7V:89%['5.3K99N:2K_&L\@C>KW+,[(1RKO$MCO W1O5!YZK>B-J
M;)97TRNO2NAH]20[EM"?'MO-6#(LB5.VB5 PA/G &NNY$_UV+NT.D*Q1/0YA
M/2"YK-:R>&!+%$+K\,9' #=6PG0^^.4(9#_H&51,'<8MAU5681\RMH@79"T-
M#)?2C??E7*@Y%W?RO+S""X/K6X9L6('*5<2TZM)'ZM<^J.[:6BCP38#NO9]J
M&<>07F1GCB%< CUI5\Y?_N%XZU&&J%5'>)_AQ"UXRM8U7!L*M\]O+],Q*"H+
MNU;0D'T,:7F2;G7@E$7ACI*(5=B:R-43P?U#PDAO&Y"(9#M25,'[$LR#TJ#X
MS<EDG$J3';X+O$S/E+Q38L-\@&%WH]=$]"'>!2A.$8('S!/!P0!^8"SLN"(/
MTK KLCQ _2QN&1X"YFGR .U-W&(>D)3# PI*&5RQ!=Q(/@^@^%KS@# EIBC?
M!Q&9>WE <B)I'8-#FDKQ@+0G(0,\H+T/UV?!!E_[VBR:\@!:58'-TC1."KEH
MP0..(E=QX@L\H*<<.3L&H2:!I;1"6G<MOZ8)B=V#XR(H3Y%MQ;C)3<AZEZ!8
M9QZ0G=< POIL D+,RBYR1]$T&\ZP$\1WD?"GWDOS/RX"!<BEJ1HNOS<#3/F?
MO2E<Q]0@3?)QLZ.X,CA+$(/K"W3[^0 >0"WC 661G["K:M1! ]MV'G :%1O;
MM1%Q%:ZLX+U(Z!QB=SXTUDAPI'?P@ X-F7+&?1\QS.!B6.N:'/+N)!+Z)&2=
M21E(KNF6R.^)1;92INZ?RRVZ(#PY:#SPKB7@]LFYZ>:NK=?+GM7D*3+!E)Y^
MEVW.1W5/Q^ZS._\.PDAYR2Q,OL:P]\1>Z/-K==^"+-ZN^45TV4E(!#-@S0]-
MZR4^)PTB1:%0E^$?KW*_N.[T-;<]^_:.J?WA!W)'LO _JDYY?-7N2$'V(S_1
MM2JNV%?;(D)U0SN*8_/TRKI<:#+IFS=-R#RIAGX/+5@%K9$'V.-R><_A!<ML
M$6_C+&F/AZ7@O#%ZJ9,'3'K;&+AVM^C5Y)9-RR?CSM3 <R:X-L4?K>WI]0^G
M;3,#M0S<1U(G.+!)<JJZ(-,[J'T]N-H2&W*:KN_IV]7% ^)Z[[&^IE-?]:B\
MN5-P57AK6DN\2LVS)E:],\IN%BM1Z/=",UC447_Z(N0!#Y#1;LVZ G>NB"$F
M]0[1D\CRQM5GC\XI"X1MDJE0T))N2GG-:"#-)$"EU;5Z<4IG1)7R]4P_&?LL
M=-=EJG]1W23PGMBRV>3<R4LO#NF%,9]?VA7"I3)KPAH^MRESE06D.(VPA'DR
M?!)5S=EOAJNJP*QA-M:>MY/%CRG;X:1(6.G\)ZS%SW380Q==5R[%9?C%2!7L
M3*/<'7!C>6_=,^V.M#WU7%07RT/CVP%U2Q=JIM$P!9_7,.C_1&(0LK_)^7GH
MJL2VVHXUSW^CR18N"#_\5+3$)+9;U'RP<D-D06H!K,'1J6D2B1)@\8 :=E%Y
M!!NR2KM]1.5:Q01*SFLW1G-MZWA,>J6=O$T"1=>>"^O#P!9#"*BSI)-+M1G.
M;%B\X/7O/8[.,3OXU26?WI$<(1*=]_1+? ZOH[ZZIS"0M62LY%=IG\4-,MS3
MAUWG :BBMZZNOD%W](&UC:%TX=C;]5N&$YV<R3J@0V:+4'+)Y]M!"[-XE]?8
MFXE#+=GHH5CSP2.&"3LU[ JN-IB[*KL[@UL9B(*]LJ'A3 [+@6%[?N>[G8^<
M42N1Q=3DXI*R M6Q,I]^HOI5<<QBH[SKCUOVCGJWEIO#OZ&7L) ^4L%TA6/6
MV17 *W?N2-BX,ELG'P:M)!)A]USBVCJI"H5E],7EASE3*C"&1W@,A&$R:]K9
MM[4B#K$N!>BL#:$1M?-=IHYAZX),EI.\ZD.@&1J7S0-$[IQAPQU'BRZVI>QP
MHN9)&GG<#5EU-_W183CA1"$KK.6^17,^B2?U\VV484AP9GE51?Y]B; 5PCRE
M8U#3]D;,2O8*:$P6GJ$4U)!DWA4'/I2(J<PYZSCQL=F5(Z1@>0LUJV>%6F/M
MX%ZDYR&JXM"SC1N8;T1T,HCSBN<RPIKVH@<ZQRW,+T'LZH*Q2Q-7SM)+90<M
M2#84!*%O\'9F97G2-_@;?DS#N0/9B,3.6,>(![I0J=FAF42VI8OMA?@]*03M
MEP->2N:L #NA4B7#@,2D.V@Z9&RAT$_Q7G(!],L4J)^W%'/=]A@KQOJ-O]ZS
M'^M.EZ95-(H"ND0C1KQAON5GO9-L]K[*;#4>WUQ-4TOD3H[R@&H2BS207,)^
M-O;L'N#GH)RZ)?GHN\$.\(6LP*8]UPLSSW:EP'/4T+YB066CE--%PW%O#,5N
M;.=$?OTVV=V%2G<CY,('-JI>X &V5$W2Z7S"L[U*-@\$(6B3*F+>]-@.9,UN
M]"IMLYKB1]V4ZY7:V9M_V3B%^Q%_$HF1.@@@&&AO<=KW\-9R%8?XQZ KFHM_
M4-Q5]Y!)ALW,N51=*&L;2>PF5I%<7(:'(\U![MFDK^$H:=V$<?*]BBUT#K(0
M7_0:Z^/R3N30+V$V47QG)&)6\_GY&,ZXJW53Y,?,EH'=.R4,!BS/.I<YUG;(
M(@QY0/D3OC=:4$>MJ(M#\!<^0VR<[2OC;20AA^V?JR(O>4WZE/E,NA,.+[/=
M4XION>AAM)+SAU6'/Y=EJSRW?GWR7-77, DMCMW'=Z3I7'D805YR&T? 51'Q
M8.<3,B03,S,=T/_T>Y";VZ5B3;J_=RL[O^S:I'J32SZ6NYB&1VX'V=NW*X[S
M@(=;T,7LUD-! <C!0@1]I+O!TW,,CI@^.S735QN]?5N.8V.<$J5RN+#$XVVU
MY%2[BU6Q6>79$\+$H;=J<I?RO:&/Z]+R/KU5Y5S(1885#9>-M:.[-&#W SZ'
M2^FN1 NF9A5.=;GZ%ER KC8;WL<^_SK KCKYPN"L:&"$XX])IZS+^XL5G$^G
M0D.C",6;ABW:E2RVB1"O!-@M=!Y/:NRYP=QX&5:<76JI?M=L>M8SSA+A*M2%
MG84271:V$->0@:\R#;8^#R\MX::\$2ITPXZ*!";Y>L$WO2K;@!$N.657EO02
MDYA-F)KITDUVZ1.Z^K[1^.%I7(H$)?Z0RQC<LO1$._16 0]8.G_B-GQ$5ZBI
MIJ%93:^)7M3G7E[TJN4R83=\IB^2N%?KB=L9367(D;G.*O'G]2X<%QD1@9?I
M1#^Y+36BDH(0[=<9Z7*PB=CC>?X@V@9?5#& /3L^ M><TI?0V&=@(;8,.^<4
M$#R#8D3QT0,?6""H^V2Y8I*Q:/2=FHJ>@+\=;$T(<OAV,AHYKI%3-L9$HM.Q
ME]3V=OW,:WC^I[R&?;3?SVO8<9$'".#Z%3G:GZ8I7.S\;)<S/[RW3M*(\W+\
MYWJ+P<@8VJ(CR_ WBI,:O*\&\X>C+2%[3C"?1OBK>0I^N.*?UR?_EFR:(?&W
M^W.$+?BIS-?")9B 8X"3&8-$=:=;VH9OV[I3??V/2;X1['D)6XF@0:P!:,]M
MJ4K1L1]>6)G]V\_!M_LC<_OR/4&MH-E%U+O B@#%B?CA84ND[62B80'I*P^(
M<?#LR, /W\L)XUB<?;0G9&A7^&D'6?*6^,"+CZL-;73=,9K,@CWW.IX:!RQ!
M' C,-0=0$:FH%]9=?ZB:#5]7L:4_E(;8//_B!*MS\P9(] G6W9Q\Q/"[IHLU
M8.TWL?B#I<H[_$6.@$C"1X9/;)S%X^D@ K.RR% VO@MY[0",$JC_7DWO #,
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M'0/-E8E%3B%KS+";4.TC,;D7WQ\P< W 5<<[A8/(EPO-6V5TH+C)ODW1076
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M 3Z@M50!7R[R0V>V+S<XC$W]^6XP763^&1X0@F-W\%\T .Z*7(<_MTZ2F!J
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MDULB]S3$Z/@<7ACB+/299_  K*T82%@2I "LGBL LC![9>8E"6(BK)QD>DV
MF5@.X3.7B_U]YZUC]A%-SQW=%>=.?5@WMJ,1*EQW/9\[,"!Q?@Z28>;LU<-2
M"OE)'KO([5K#.M9AU*Y&NO!,$_2_K!#"E-.K+UV#Z@FA>O?VFO0\];OCL4B.
MM_'TT>M,OWC=S'^$])W>H+$I9NG359B).<P!@1 Y%%JH=_JBX=Y)L=%IIHGG
MLDQFV15:*$%<6"4_.U+NEU)C$CJCC\Z;B.(^[%AC5>:\)SB:>MGM9#>L[&F*
MYUQ+G\P;<9VR]OR@),$N/_\IKW'3;4N4QH&*)N,?>3;G\%UIQ^[?];?3V=5W
M<?Z\.$VBTU$(P=HUJ7P@_K.5NWZX OA<'K+IIG;2]I<I7*X$WYWAYD\6% O]
MM/4OIDU>78@Q/XD#DQKPS=W?GEQO]/"8T(FY4)V2N0%OOPB+$K_V/C;!#AO@
M'M^E\>%))V7QB4,170.W!+'G.N/2\C*MCRJ?T-(]4U*RR!]@C')7,!R_;5=E
M&^PCKQV@QQN0BU<MNW"QRV:5I! Q_^'>5,>#YQ*M[IVNJMN:D(!LZ!:TH;2-
M21XBS_/TME9N.>>JUJL,H/IL\UG'RMU-UI;0&_;[>4M,>Z>0\5V77G_ QS[F
M&TQIU2687.P9\R^J]&C[DEZY^^W@TNJ]!E,;G@2%&8SN[R#^9%R5(0U*D!CY
MF!:O"_0;1B/#.D@G'MC.S.%V:GB*?+9^B1L_.XG%F5,ZO[>9/>H\8JM\+VQ.
M+*ID6B.TD$MY=="?<]#5ZE2TU?3(1O$6V<=2[7[1M3,^GI>NE*'T2V^ON^BY
M_88JI=W'+D)Y57KC^\9]Q9HJ-Q/GRG_48KRV.Q53^.:5S]DGH8ZU%8D$B\?B
MA+@Q_\/@@MX&IR4ZN[ASDA]EL4V8>G?IT"V8=XZ,!M;DXL^NT?? 'Q@ZC4=M
MI/;CLAWLM&I0K$VP3F"_Q'2\]2EB)AK%MO=2 +8!!;I1)6FBHBZ&E+A.%/%&
MUK/VZ9[C.L['3!(MZ9;^L JTQ*1\+I_,I]([=.F$U?/\H8NFEKKY<I?M8&M<
M1$_CS,X 4.^MG%K@$VPMO0R98^_Q%0"&$8Q2R7AD0B0<4KHN\-6Y,_#=R:,A
M>R[.$?AZ^7;!AN>M6T6(AACB*/?"BW&K4U7GIT:0U"F^^LZ9-NW*$CY_U+69
MT9F 'RNU_Q"QE8 \OMM[#1UA9?W$[BF! TDGQU0JW&M<(_NB!1NFP-W?2CM&
M8P;VIK :B/4+Z+F(/@C!I81LQ#2.N+E/0Z1I05"WL>O_&,3[)T%@*I.%F+KO
M\62&8I]CV'WIBQ#U%57>X;V\02\Z^L 23Q'2QDOR["5Q_J,-F5F7JTL0C-BG
M;-(\TD36#=<94\0T'N<8V6/5I55SD:S=/,=##SBKO/MJH.Y.UT/$4]ZV8 3X
MN=TX//'Z.++95(BM*S/Y4A1['JS$E9@F]J<52];FS3\NZ5()4RO1B25KW'J3
M1555DF"$%@$AE.!!WT[A"ZQ?E-[HYI#55]X_%6YO0,21+MK%0*SU\,)=<H9E
M=]K[7MSYZO.84:A2 5 ('B@Q6-/XX"VHEXN]G4CY7[X-?80B__8J4RHRKVG+
M5P#U(20R^ E\;>\^14[E?T!7D)5$PX\:BZCD+JR/X%RSRK(CUU/O@DT>.W0_
M/WM<:!$S]/9U\UKGVA>#/6"D&FI/VU9LF@#?RGN-A=KB*U(?1OTX<U>C(#[[
M?>'*^)D5@6&M]OH=4DQ9 (FT'[S6LJ;HRTRG-R-E6=BA%7GG+%?LO&_R?@%U
M8)(O"F,(@KA^'NONT>I]&L/.]%P:WK_.G_M5ZY'6QHA!A(D)1N\![VHL0O ?
M=X]_@#!GW[2W$/#_IO<-'M\C:T@LR"#)?EJMQD^:3$+-S2+_I #<WX S*>7%
M0BVI"DF<S.Q#'C(9!4M>*X#IL^"]@(X@1],!#E3$XN3[]D%$6V-PAGCG0_V5
M2'7,)04 L"]VFE\F2^UDVDGJ>:G%_,LM!'?^WWN#^I?/89.H='D(%7S'SZ )
M?4X2:9'05^(-!=#_V<U3WC8H'T3DH*:L%( +A'^/\@&[U!5 M!-T@+(6,82"
M@=/@[$E'\#!' ?2$[!E;.LZ217HH@"8P@J\MY$$GX %<!2<_M 816L!>ZB3&
M*QU&14+^KA""@\CA7_5)=P'FA?=T9IW7=,8X(/(3Z3B5N"_R)7]<8!-,=!.;
MP;H?%< (Z?*W:BG8 :F&[H 0@H"X*!B]Y___<I+\NX1,DWE0%M0%?D8R+W"Z
MKXLL?AM4L%H#V%LM'\&>H9?>A3>]4+,1I4EIPWC_%TJ\E719M&_<)!&L4 #^
MH@%D@"O:MM&'**<P<E&3NB)3N2NQZU5!(")* 2@=_%;7CQBUD<7:,\G_X:GA
M#R=37>V% MAL2/C"33)[^]VRNMC( [\KC/.]O%KEW%5V]?QHYH2:ABD_^C+[
M>B\8Q'Z_RZIZ@B#P]QY9M#8H)&HV.H2UP84G3/OJ4MH-V?W:(E;WYJ6%0A?#
MCWW;PE^<,#N^[Q?UOH,Y\*"ZUR:R XGHC:U+K8,C*J=-G+C(A7&,T7\P<ZID
M\#Q7SM UQ,CRW3UJ=Q/N,_?M$5[X::\".+.XA#HLHO)9C-"?/$_C B7O/Z>L
MUA)[7RT],AS'X\B2M=(A&^M"AZUDZU5MO%IT5W)&*Q;T1V]IP,CD@E1R"]8K
M_4<KL9%8DC373]/$%?*TR+J^[4"._SN$']KFL]+$I!R7PFF!&^)$4GW^U>NZ
M>15'??JX'B%<9-BVT*/';M]HNSH1C:9O>;*)K(EJC[^$H@O?+?ZI*> 9KMS4
M8G[C)F(<_KO2>U?9JS*3GW_:'YDXU8JAF&-"QV)C3W8!'6B1^FOR^M=.\0K@
M$O*!7\;)^PH@%A5Y6".V<KL"<$;U:3A0<TBFN'_PC/=_6ABTZ<2YB&7K8+@_
M>UDP-O, PNW>!^%6O>T@UPQ1![*\F+R5EV:-J,)]?RY?7(R8<1('W!<_MXFB
MLE<K@*!X\;GXD =T>_]%/P[(6811;CM[/Z<ANI<PM@W"I^'4H>JH'=?IB,4Y
M==4SCW%/.A1 ]T&81S6!U?14U?V@&'%" 9S,P SG\YU04?Q@8J]-3>T+&L,-
MUEFUS4Z"_<A7MVK;^L!.!?# >Y_H7H&;>NCHBA3A1G8&?N^U/$0=%2^[U24N
MC6Z<:&9MK6M?Z1]06]K?PC#%5:,7NFQ5;Q4*!G?UJJ2Y7FR:P.)#ZW-?7:Q9
M8@DF[C2A,3A3;*W!-$=AALA-=6^[AUOM?>HXLF;M_2?1S_E[YQ1<'LI8(!WF
M;GX)[O8<.I>MO[ZL+,?G/%A]"O=0 ;03W&X-U9]Q)_<8"0L-X)G34*%\*'#]
M[M%N?T=M+?6-EHQ(>T<;4G<5T"T4@)$GH?LA(V9 J8VAKC[IN<O4KG2W0.WQ
M_=>!#QT.'ED". P]&@B2FSP(*6(<"W>[^@1YY#04H !HC4X&X\(R],^V71[J
M9IYVVTR]E'6RNYJR#CU7U8G=MR D@0,OVAO>!V1S<>[J'8C:\91:5KZ_\7K-
M.6'$/2_"_%DD^9N!'5]U/7[6A4HHM)SV#M&^97'+Q6HH5%W:R;HXH4;MP,EQ
MPZ./>C46[M4\<@[<V,BS&H!%EA*=4)W'BOD ,>,C$/TR8VV4@8F5([3)6_5V
M45Y[^^U7+:T1=W"DPMR0QHA:CRUT]"EV4<6+&:JA;)E:OGF,IX3Q?BL0W;"H
M*9GZU7LIJ\+) LV(YM8T9:0V[PA,W7XG_*!2FL92E_U!X@3^<$VRV*BKW>1A
M=[?=8M7]WKSOCSK?2,H]V!\OY5U$VQQ]<3KK15K\P_.K@TI.UQ[/<1QK4]G_
M,RW(5+>2_%R)%M(Q[ (!A\=ES?F?_,QFP_GTKC&)/;*F2AFO>]:-OG95<?R*
MA/5J=ZF;RM8-:9]L%6D[<LVS[B5^YYGWF>:-%#GH)?WXH>%[VO%6E-=II>X%
M6FQX2C$=OJ/7%C#]^@[WA1Y?&Q+)%2B TR-67P,;C?:YIY68W[C24IAX+'&N
MY<)4RX6VRPX\UMK[53[9Q'3JW$5(\ UUD8!P3QI[/I3W>65?E:I)J)%'F&Z;
M)V6>X7Q'MZM >[N*VN@U6$_FC"VUG)C!G=22.<H<Y><Y5&_VG\Z@6T#\*,H2
M^4\__/L'KKC^B(FD<+J=)J)HC$G/+.IZ1N>;8C"#U:JW&-4J]$E)J<-]OC#-
M$L<W"DQ6^:2W8SWWZ)M;65LN*?4JTS%WF/56:7GT[-UJ+RA5^O6[';P_O=RB
MWT(;ZH1Z,(B(%*J6D,;C)G"?6:ECNI57CU^[[_DZ=]W2(Y^6QGNQ>QS7Z38X
MWISY:9M7NZUATI<!Y^@GP8\KDB-7*SV 3,JQ2A?WR#P'41_:K(ZL-U2J#)'_
M(D "IY6G7>5@-<.3V>0*3GIH'!*-Q_T_P@,CT>!.U6 '!3!#[=Q_*RP"76+8
MJN+I'ID2+D,#>W,WR>2M:\X?1+R0XXA3W[['M&@]'D=$BK\8$Y"TH<;Z,HU!
MI1]6ODX\.^>8VN!'RBKBH &SIE12E8L_<&W[?&OTV4%&@-L0:3-3)3;OW"\H
MX,R@_4(HV5=+=AS9V!FH;A8A\_82&B%8D&:L-'4ZA6=>T?^QOS3S;65K_\D?
MC@B;$5S7M@]/L3@\>3T8TMR%NND=E[\5G#Q#5\/_#]L)ZL/<W$684!6>CCN%
M^/7EE9)L52_^N&167%RJWA4C,/:L7@$KT!P;SYG3A\@>,I?%GN+793#L% L(
M/;;2A9BDK@,.QG8RK52C;HS(L)/(^Z  -#3<ON5D!DP[=\K<N.1J^9EF-1'U
M#JWBB/1COZ=2@\_.L9136RM29,B?D.'X@KE)L@ 1V>2W]UY9 IY+J>B?V#4O
M432I&C8FHU, 8^JG(I/E7/0H5!_V>>ZT M"K)Y2(VK7T>9D*H (]@SZM ,H*
M)#"R/H4:J&N,@<XVN4 7P55?<Q4 OF):,JD =FDZ8Y6P\/];&"0^<0BI+%X$
MEK:;?%4  T$9\T3K9AH"^#KQ[+,AGS_FR)[B2<(J9D5LRM3HZ?L@IH..</?Y
MO1.*O^/L9C-F8@O8/JN]6;E6";VC>?&WVYGO5?^07!,-9T.I!T'GM66F.6T<
M.74,QI5F62::T<C7_Q^&\_K#A/.7Y$K0(K GI(RJ26FY !9"59!6IT4FO.Y4
M[[_^W$]-]B-&4"TS+9#O-&Y[ZF(':? "<<%$<0R%_)Z)GBFB>0HU!^4D^1<Y
MM7=D8S',=6'L%9Y1+DSY&TKX(;J++[Y]-/1A&181T/+($&I/LDV=Y&L?-3<_
MHP#NOF$?^6I;FN9QGOANGM3J[D(3#"TK?\6EA,?P-)/.QMPC^@F_B&MEP5Q?
M_7*C_7NXS[89N^2T-W[>LG=#^#7$442S1-KRX+5Q<1QB8]/=>/HGA[D$6CRJ
M$U_XS\V1-R.ZJE^T=7>@JF]HWIMG42M>>1=>_WQ<@I@0]JW\,%K:P,^;R67Z
M,PDQY*4-R/AB=>T6N_?Y7&-"CDB9.3/_"%B7GL>"=+-NKG=H$;6@3,8'/B&[
M4 OY8C CQ#S]P=B9[IF[\(YPDB$O>K^8 6E@KK#:@:/V+[ZU PN1<KCSQZ@:
M/XZH#:<:7C,:N^RW0-9C=WPNFZ)]O;G01UOJ]$)-2B^X6.5^L!9Y7$Y9YWZ[
M\0CB(+BKK3YNX/M#^__%"YE9.8J&:L%LL(?23<U%L?FC'3,P=QEJO%(/=J!)
MD-8!E%P962-%R<*K92WL>4QPZ+H"2+T-.8301-X8_K2<TQ,_HW3X*8^K %JG
MV6^8$#/D LP>;YM"?-PSFNPE=9@GDU$.:T$V,"M,NJ( JC$)IK*F.0H@3V7*
M468L_0EL7UOJ>?4M>;'>"CEQ<.3".*S'>QM1IRW0$W%1OGX'W< (5%U=<BD&
M=[@NM >E43H>O>-1_MG+[,@EYEL/H3JW7:5*5>1*;=,>YF1F/N-)8Z2\)$4S
MC7RK_@"K+O=\UY.%[H^TONOG#Z->I)PET7&/&:T( _R<0!]>-$K?379H3-[7
M%CZ.N]9;WS^UKS0AJ&;.G>T%G]H[/]EQ!)M&LQ)*<TJ+GYILHV-.[\/7XJ_$
M'K+39/D;[7)_O2Y$&EZHPW#L<S]QD!D]N:)JP9SW#X@.TYW8V_[@SV"8U,^W
M;W1/NS+I25EI.EDEZCVTQ>*8(6FSNY1IY3/P%-.I8N3L&ZRLTUTI*U0 ,6GJ
M?OGWI6^YMFY+KQG533(4P%M"?G/&V>29Z<:]'=O=8A%F @N](F5F:4)F?.<;
M:DE2*N+$(ZECI0*PD_/N7NJ*;2I]Z[1BSCO!'M"&ZYX2']P%70\).>A9H_84
M%]X30UQ>+"34A\E'UAZP^.ERAF%PI73/_&N'K==\/R1+7KELEVM,=KPKDW##
M]UNWV0WG%Y_WJ6$N+FW4WS/5Q?@X>A]B-]-.-YQ8,2=V1 '4QIXC32^?X75J
M')T W<QBQCT^BPWEJ*DC[J(%(]V,SI-K9=&7&C^O*+CT87.H,(*[9KU)#+/I
M9Z%/KGV5'V[SF7C;Y/<IM>_C?*;9>T1F5[H,Y??;LSZ4NF(3MPX4[%+9E*_9
M:OV1?O?KBIJ?C:F;*Z[+;A'[7O>//;.YY.[>CE5*N[4.O.8>L.C>UVN[HS0F
M3T9\?)S;-J5K^<!H\]WC.9+[5IWN5LCA".O0M2>5M WV?15[ZPP[>#/L(A</
ME0\/7RO0[]55???#!KU;=O<EX<WDJ<CN?6.L2OS#E/<OGRSHN',JN['6TNPS
M1R@X66T)MG\9D#\6.5PEC/ 0=S?D: VKF4L1>+(LZTJ=Y=K5CTRN.L^5(=<A
M".OU/1D0/OL7-:%R=;MV[-9)UEZ^ M U#J>D]&$AHBPD05V]D=H;(A^3SB4$
MI9UC2!&" ,TRD<7?L(_[[YWN_5%"TAL[S1\+[['DQ;#RHN;YT<#G"&30Z"<^
MP6A!+IQDE6"#?0L=:ML9R17W"APZMO6T/%/BK[Q&15C@*[Z5''$W>IF(R>=.
MC2RF!7XLS\_KPE2LO/%MRGI>G.9=G^R4*1MV:33W Z-;4*Q<%Q$?:GA=&WG^
M3EQ@<&;P+;/)VG<I<PE?)=BO8;?+%SM?(=Q_HM]Y"X?'D#/5I91;TU5W&$G<
M1?D[]0*_.F@>6;G9_Y)JT>I>PCO6B"D"?6E-@@2?A_G(9ZL7&?O]/SP;&ZUQ
MN_$#*XA/Y8M<72KBP.4I_2LQ*9P+FH3TF%[J=."ZR]M#]6JZL&VD:^E=61.Q
M'VTS$!EA^)Z2*))G5K%P']-]@;CP<7F5*XE_%(!U_C'.<G]=&MFD#YF[X=#>
M3=W U.OK_L?E:=LT7Z78W3])=;<Y-_];V N\R5L0?:=AN9UFJ:.GEV!/<RHT
MVHS\D_KS)VWGOZ=%[7'*+W:G'K*)Z_HY8(>>VFI=NYCO5ZDA5LW+K\S+Q[S$
M$[DD3P_&^:YNU7IPNW><2R]Y[YNS<8!R7% [5O1N:#,Y@)\J4^')3D-$LQ;]
M_(Z2K1)PAJ O;5( Q/<\SI;W"B !):WAV*)9A13?8#X7$?9JOU& .[+//*Q]
M?_1V=C>Q>-1H4Y7E[N==IUHNJ;QPY"L14\H3A?M=7%7<JZS+F7,1#P+(*:?I
MQ?0<,^R-M:RC&."^SCU.==:S(FTL_^RZN<Y)-@$^ :5<\XJ\S;'WGCU^7GWB
M2M$>S/0,A2:]' KST^U,YO?%2>7E2O-AI*ZFF61.]BTX_FB/T;(["(?(&&RA
M,1W;I@#F=.*2\HQ,G!O7#L4SUGTA:)UUB83<CZ7K0^2,#J ]A0$/96W1+?!]
MY<#42$^53W#@S/"K::N3$-@W<FH1&F$EQ[VR<&DDM?C#P+^4]/<7X@I(DJKY
MX9':(UL4 !JY?/>;K3R+B.3UX9 "&,/0B1]2A;[E3[VP;[*&$5P;F5P=3>TD
MK7D#F:8'0'[=Q%9L7=]P^V>WGB\==E1M!'8LO?E($3E4;R!U!;5J2H?EG'9]
MWL71]9-RY+>*K[?DK<&L%3:KFDC8T^<JJ*@I/.Z8YE#W!8]5J@Z]J1,CM@]N
M7AOY NI4]+,7DR>6#UBH>_E2'7JG5W\CE[IP;I9\ZPO]TF(EGA;?S]JK>P:[
MHM'#)+@7APO!T8;J1#W94'2[D<?;R0',%-3S(#"!<N&HDT?=S0O'#RL_"1[3
M)#J=6WRDQU[7/B*A^K(T)BTOZN0CZ'NXVHGVU9FQ1\U/2%8[NG"Q\OD*@(%W
MQ&8%>3]=9K<#LYTEBU5YU^W&&M@C+ST.>&^[H0"2Y__ZVN*)=(-D!8J!;B0'
M*45*J$0'D<,_86G\IX2K3Z%YI%EKE!ON=_#?P^WY>MAU_$-_C#P?=&%8U9(J
M^0AV$>\ 6E(>8FJ(4)-0T"=(URBH/S\0$Q)_<_:9B;K)A%7$0>8,G;P?;'5X
M*OG&K7AF3.":'I7_Z:-4J,4;\T^7_4U-.M,(6B)31JK^Q)W^7.5_R8SL,I)0
MQ4:0 :_;YCR'0/7Q^+.%9*&&^N^#-_R6_'LAU(FG_%X('4]X(MZN<@M/;&8K
M%:ZBLB%[(Y^PPOLS+S;Y@M,_C65-6U!]3JSR*_=S1EAH^CN[@&WJ/B(M1G\7
M^6O</;+]-+R )U&M4F-*"*P^YX@N5Z?3Z&H!HZC?K=C9@>GE> 60HO9\A1P9
MFFE@;]]HT1$[K)^L+*][OL'@)QB*KEBK+EO!X' [P* :L*KY7KEIVS&[D*_^
M('%Z-))A_\?Q$_YVP@E[3L&N&([[D+#B,K4F+S0].$\T<18L32?,&)F,UV5:
MI>NXT$R;>VG^U\KL,MB&>%F&M*)M5"+HP!)X%&OK%=[K'3,*$?5GNL$V%>Y'
M><$!&T3D*9FG=6^'3*8 /#7#1$7&S']!@FMUAE%:UPA7BI2F;[;SVQG*I9H,
M]HVU&0H@_<MGE6_0E%K!NK1TZ)+W99=.EEP'#,F*ACG)/5.Y:* K0(9JY31\
M455*A=4ZH[\O&OY5Z?&W$V:!2YNG]MM[M)9I3U$7F"OR\4P>'4D9*1#9JV+<
M/.R)77?2#UD3*D]GS\6>/K.N19YW=S'T%LQ59[7S7HGF19X'A164(UW2(O0U
M[((^M;AK2.5]@4+M_8]^1F9=D-D@SH&/E"7+'2LA(D9$=,JZ/H$TY8[^8M>R
M_\'>_.I#*9(?1E^-=])>+,[?%EEZP[?9[3(EJ,T?#'Y [8P@!YTCF//&:;<W
MYSHG;SOIU$0D)V_IV,'U-,G7-%KL;3N9I?.%J!=A']\J75=B: AF[5=S:1R7
M9Y3N:KSD9[$LG32S=UG3X?.)Z8<HC;0^:M7DS9<]@W:&R2\+/XREB .LRFT[
MQB=F-C&%7W\T^66)UPM.<UM#1\QM4A$><86[PX51YN3.[<+/G?OHQOW%!\Z>
M>V)@-/CZ&E4 Q8F\=NO<6'8)- U!NX\N3G182D[['HBAO<OPEMT8Z>YC,/93
MR$8VCKMQGW.BEQ<9/;MMG5B0]<,Y\QO'%R>V;I,0JQM4L)9Z@W>"(M>:JII@
M)G$K3A1>R.HK7Z*V;E/!ROC^'Y*..NL(O7DO9[C-_II=GP+O97**6>/?LHHR
MA'I:_M76Y_(^A'Z=L_EA^.B@]?7<5K&Z!/M^_.72/D[EBBRU1;(9@;_8E_9%
MPDS1-/I^R';MVKDG&T97]]UK8*Q%NQHLT9ZN1'&I58R5P2SY\H3=G\!/CG0'
M92)'6PK.T(L"M>B%:A8Q[)&?\O@"[XY3!@LL[Z<:S'?7N#DG.OG5O6%+3R<8
ME,*@*F['G5<"OE;6J4MO&]V_HO0QT]YGBORF1#/N;3&"_7:79+<X]5M%8;FN
MSOF6#2<ME1\B6"Z]4>5G>^*]*LFKH(KZK=U#*LF&O5ZV#;B[$R/;+M>L<V#<
M]-#E1NRY].KL(M/Z>U;3)/2;K*1&YA)?DP&&W+K06=BRO\[G&GF_F^Q4R$^N
MTU%'"\U/?O)?FM?Y40$TR.\(,_/M6X=D6TMG6OB?)=RW0==UQYP/7'X$ %ZD
MU]LM\$[QS"3#4(^Z]N =+!EFVCIJA] ;A^Z^.H/@:7?YU5N^BZRR4+[=$O\5
M^TN;+_X <UTO+BC^UJ>86XNKZ7(VTPRKNCPC/H4@L+\L<HC^1QZ;_\<2&D#W
MUG*J22I/S!;6VUGU9],YVXVI4^-,+K+PD.7 72_LIE#7&S]0!\UU]ZA]()=X
M=CY=[+>L%K4 W7Z7.-&<B9:V\SY67\*N;>BNS2%EIYV?BQ:6$H::FL5.@@)[
M]XG\5,<;9]!1W2T7-*NZ-A*:W*O/# [( XYJR\P5 "G74'Y3^Y7:Y"I/UB%9
MR"&J<Q&FZRW%:>6V]YO7XM:'FMN"Q^,(!0H@$_Q@*NT0:K)/LO_%<YC_\;>V
M"N %E#L;1"RMU,.DL 'R6:>:[^$;><PO;'>$E4V;U6!1>$NU MB/C#K=L0@>
MXZ<@C6+R#(-P"['#XFKP\04J^M/G2#-JYS_PAEZZB:2^$Y5$94OJ](O%2G-#
M3RJQVKYU:[2WR"G-2,<.?J>YH;B]7;?#N+/2P'K72>(,4=@SR<+F3_B9/O._
M"\*"<T1MZ_@1G\Y>RI02PNDP/<_DSZ=&_X"/__'529NND@S)/#2*NC!/>QJK
M !Y2^RNX>QOYJ3BTO=2,3[')O*VB8B1%B @W="^EG'W;_'Y@JBHAW>2$S'U<
M]<D[VA7?6 <8N$78>2**=Y]/>%5=)6S2NKMQ?<KH!H/0>PA.4+8%TU1O''V[
M-_R)#4&&D6JLX#%0/*S!@T'EEP>FMK7.(\FT\W/>F2%>=E\] =7;^X2'C$+E
M541_741%[F<%L!1UU0DJ]%%#N&[1EG\%1?$0/E];ILW(<Y:?"8QLW\LT6^1G
M?ST1AA.9"F 21?"L%MT_#N85(")"H$+^6^DO+&CS":E-*@M:WM>^_0M:>#7@
M^_&9S7%%]02AX=3L^?)15,6HYVQ# RH*P%9BB4Q_/EG\:T-A3I68H?WE%>O]
MQ.-N+*^Q;N8)\_Q\QI:)U;I$.S+[J8=1\,Y^_TZ#TP;R0]H2E5O 6^GXX=NG
MM/E[K8\GQQX(6'&+NM6LX$2_2K#!AM;48R;?LUD78/7CIALW(TT[&X])HE9Q
M($W>SY,!=\ G"B!#[D"Y#:LA?1 3,N#RE-+E: FUQ?CCKX868[( 3Y(SJH]K
M$D0O[1N/_>T1N-\'S5B=MH#'//P\)HK19!R6-(+JX]D.BT&35W(4H^7  ^V-
MA*SXTO +A#I':GL6M3^(471;KL49U14\*@VJU#3-NL0&^TR0CX>C$^1O*@I?
M7T@_B@Z2KQL<S33A'/VZARD X>U8CJW5S>]IR0D:_99HS4^')_N;2;P=U7WH
M-B;52_P$#,D^JP FB!;5IM-54ZZ9O2B,+L)NB"D?-/,4$3WMI/P7X*=#, CB
MV)P@%-Q2FWFN  I!6INV G@P(YQ'+$/5A!5$W /U)0;U1@CZ8W>Q1$J5R+^
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MD:&N/?=Y\PDOOCSFY;X!#E3='E<7/7S/^^0Y=(Y@O3DWE!@ZT/%8-XV]#2/
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M&@C^>B3_=PRK+I@X>XX&- _HN[)2TT/UG'0?$*[V'SP@)D?=@+'G96%ME9Q
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M*\O5-DT)(1W5\2,8ME(SAPU1QY"1YD:FS++<MF.X>3&,40]][E?,Y[ZV9PK
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M[1V]IM\C1NHAFI@H(DS,@@MSYB1?2P&H*P"8/].JTQ!>R57VU)04R(";EGU
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M?[%$;5>%4Z_N\I3G$K]@%C:?064YQ8N V@W%.%@5R?E.OB@8]@2D*E7#MBB
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ML566L ]8T90*MM)G[R_%F-B$>4Q,>T:C]. $ZKIL2:&'-TSKU5"B*O0#<Y2
M:,>6>\G+A?3=45AMK![X\Q/,L+M?BQ&-E3VA.&@8F9M$@O'46YBCF468R@I3
M*(R I<VL04.>E!A1&->9ZPMU*^6!5*JA#6RNYO4HL&\-$R/:"B95YXD\M;G<
M%*T-+/9/AC2[DV;VN&6,TXOE8,Z4]%.OU/)N=*T]OXEOG]B#2@(,SF^>"5_H
MO8BY:'SV$29RHN&!:GWJW1$NL[X]S^R-9/7#&X.1"Z)/-PZPTKFLA;I,58PA
M _LFZ-2I]YT[$\?KA=X,'4+]-<O$)E1)8F!M_JUT;K-GLT'9^_U#C-$$CW7Z
M\AJ^OQ*""IEJ?<@UAX)_V[NHOXT4:GS-Y?L.T:=]?/E^K5_<J<ZX'!4.SB>"
M[ODR:W.G2:6;_(,V1PU]-10C7SWHW9-HVE-O.4VR9VE9;5-ZP)IK1+:Z8E>1
MBK1E9)U45>4S[0-IX'U]B7F!NAMDG1,ZJS>R%1@FI9]4D21\7<*Z[A$V_.A^
M7\R(K.KTPY:L7C,N"CKMM<E7!NS:*[2!'<&A#E"0B+:? :;/TR.XZN!;8#B8
M#-;#O%X;.GM*<T38Z2OOVO.UC@QIX2X,\) W7UKM%2.<;QXV'KK=W6,,HVI'
M@!;=36IV^&;]]0FE@ 3A4>38K2>-P3$#LKWDL7CR@X\&:\[G\]S)HY*DZ\D4
M#ELRE7U Q)1J 0(<&;_K6H[\;).(S]=<J? C#CIW1/.-MF1;S@GH"$MI^@QA
M^J&CDCS5;]1#.FGK +8BG^?=3JL;(=MS)'U9Y=,S91,?^S;E6=PMEZX3(QZG
M&\5M:0.,E8Z<S1[M\;4_U5<4=7B#WT1CY"MES'',A ^?ZJO/;N!W85U*#'!>
MQ!LIKKF;CP?>D5KU9&+0UL78,MK7P,<]%C+O39YK&%6RG)$>IW-WKA(C\/Z]
MRII5,0XU:M^F#W\_FZS^[KN)*9V_5H07.%!D/AH\O&*5.IA() ]+KC=DMXRU
M[.RH!:><"LVQ;JCK@VH^9[(UGA-64[9ZGFIL/4UR3-N)<]<4F0?6V]?GOZ\T
M%?7(!#@Q+_%W3/6T&:\7(]9;<Z&8;S1\;H73'C6N:?+"Y*.Q0_V4%WT/P::1
MU_B N%MO1&5G)""!B% 8Q<<F^9+J*2(JK"AU&;[-BZ3_V@@-8([EIW^YL?*7
MF6K__8WXOW%'_E]NOOQ1YT]\'G[/OP^N\)>5_HR!_^$ 0]D\H%(TMD0ZYL$
M04.^K'>FYU^4+#4:%B.0G*7,CMXU$&I&"VZZF_@3'1=1[GMRNK6Z@A,]EBKA
MIO(S?6=X:G?XE72E%>;<%ZI7GMR(CLTO*@KO .8;+F)WM<8U98%:J ;9]<"(
M VVJN-@=QW(T2GM-N#F:S;MR?$__'?>-C]Z F/DK$<&4825KEGIC\CSP0XS(
M;3Q1O//TPB;@X0_(=+)1E#CUEZE%S"@_L7+'E<6('27;P7XY9!99NCE="%)K
M]&0I?<K>1JG/L>?TT.?;6BF[P,K&DTS5Z__L;R_(R2RJ.Z>A6K'LG(]:WU#5
M P6>&/$.7PS+9M]6,_(;V^;R]/8WX^YWARG#DT*%X06#FT#']$Q#R[AF^Y4H
MUL1CQ"10P+?^.X\^P4@LVO'2;RKH*W?,A P!T?-^\!.XNS47!U"L+('I&=]G
MR ^:FH[Y1WPO 95M5!],50T9.N%Z8$L\01,PPK6Z4?@I:C*B8:13V8_X(8:D
M"$/^[!]N[2+:"\F]5@T3 GWXA FSO[7*U*68A3'H/_::EZXJ$P>@A:6O^WLD
MA/-'!TOT1)X+E@J6!OA?^"*=HPP3,2) ^%" UD 9ME>0;@OC)NR>\LJC(=^/
M2R=[Z,&I"6?QF!M78I&:+]XZQ+\!^J#RGA99BN!],W:5,U EY.M-_Z)VF2LH
ME?:9$QXQ4[Q]/X[X%I>@QL\1.26"50N2:MW.D'SQ:_S[3#T9]Z.8&:K0LK.&
MH$V*]<5$HG;>PN1%Y#@I2J7?A[EJ7#JTP)!$]B'O2.8,A_B3NCYQ"1T%*_C6
MG]%V;O1;V"8'8GE!NUM2S^\XN;/5I\6(VRAKS;@>$242.+<V2:];76JZ)[/0
M?@]Y2RZ*>+GIZ,6L 3W63I @F,8'9ZK*F%_UJR5OQ2@6_:&\W<E@39O7GZ8I
MX7]/7.O?F,N6"KE/?Y[[7C[GAK48\8PN(@AFN/2\9@O?&8B60JO(3!F<H83)
M!+DX[LCX,!Y5H.R:GQB$FTE!<9&$?$K-\;;KJWK =R:WF!#KF2\7/SB]-P9?
M<E>@OZ F\  C&)KW,@MB6LQIM&":QR_@PG(M2ZN/OA;+]9_.2+T@X1B6W7W>
M?H"![21#>B0E]0<,W:D5JI-#LR!-4!V$Q!7%/2CF1SHFA),&C.&E/H8T"DNL
M^OE&1B:X_.!=6 6(2)87($;(:9WO]VZQC_M>N:S\&#A\AO(0U7)5*B &]?4+
M%#?%XC0#=IJ=?CW1R$2_,Z\&XY[*6M$+(1J:R:2VHC@2HE58'<)84W (EJ/7
MGK0VQF&1<^I(5,G2E:CIM6 *8-B._D/@Z&;_I9+[G[ZHA?N_;7)WR+]MUZNQ
M?N)?^OG75:59_&N+=F I'NK?^,J!,5%#9JK($6CGE &DCF3H9#M)MB?.%CRC
M7OQ]P*ZD\F'[2HFYPJR8]0W\[TC/S74YV]W<)'^@YI'SK%^.MOFBWND5#9 P
M%!QZ"S9JVM]5$CZ&GB]%U5FC1KVYK[Q,E^/X[Y, M)^WEO%5$R-07NZSQ:4;
M\5J@HI_<]+1#Q-Q"NCO&8:;V/:G"H=;0_*;V^0$%6X7?1*5>Q_F:-T8*^V%T
MW:G<M=LGF7 "+TEKNLXIH\VW%145[U)X=ED.L>P6=!:7GC-"[O#"UD 7.3YG
ML5+5=.\LE:)!J=SGCH>L7V[\BG@,D&9<:CB'*N\4'.9+RM<]D1#V$<EIJ-$0
MJ\)17OLT\YS_BEBU7>M.$P=/-;P9&&F,<##BI3\J#Z<L<I+OC3]'GFP_:B/4
MI&?B(I:"5/S'^1[RB;-_9&,WI(0)P4'-R<),RRF@.F8VA7N4MOBNZ%8Z:FM)
MM'K>F?#7(I7J!UI6->:0R:3'P@UGQ8)LN3K5U(V%Y\[CCG(#B#0(-&3C=GN[
M_)KXL?7P?1?=W,CFDT_V>FW4N>66?WR\L]\IQPN]@E@FR;N65HC29HD1WDM4
M8YN^I'_[PXI"F=*=QDE],__(B8Q$@R&UQ.[HD!Q#P2:N014&?F4BFALD,+SW
MZ+%O99/;(' >'PL&I!P1(YX+C? S..&G7UL&I0NZWQV:$+8OY1'P;M7\Z)V^
M_^C1.!X8 !U.NCP=[(CQI"L*/[0B\S?7B!$$9%=[L^6?-$*"U>CX3VI0FN\2
M@OOW;?W97#&"HJ:M$P+MU2-LFZ&4I6HUSGGCE; XTBTQ0M,K^D]MW& X\1_V
M-[YSVN*5UA(#.Y9@[N'@19^17E499OQZ();2"/L; 3UW&M/K_[QO.?A@])->
M^< \?4:@7@D-5^J)RO$G&'*M-/,IE% K/V)M<61HU#<;A&WJTXHQ2)7A@L,.
M)!8Z4Y[(:2Y7B7F8VVLUB[S_ ^I[/V']JMM<WG$HY5@T=MD+JM7AE>#<[T?W
MKU14^4!Y=:/68!<PIT(NB!F('DPX^=H84 RV#CQ]-<F#Y_I.C#C7"R,1K8!D
M8'%-A1C!DB\3W89I##V??T141P;+'<2(,5D*CV_$=/C00=MO:_[003::;*"W
M.6"MMGZ(,@9#>IE?3EJ8SM$_4F@CSY#0W'Z+=NL&>'_%(W:8=G-N#0H6 L\E
M@HN]+$8DN<)_8<<!&X'L\=$L =9IR';./&R]7E1%ZU,]<UT+]H<UMK& UCJ]
M702V&!$D:'[9TK]M8-B+%IGPD\H;=IVZ=+QPTNO2)?5;:VQMSS0.C1_<MI[:
M$0,DP%A*1-,+7'7:"U?PL8)H*2_"8*^DD@MR;%(XOWN4ZBI:)88Q#[N<>_;&
MI*T%Q!R$6>YW5=0 LQ=+NG#XTO5GI/B!/2<]*".G4),\FP2]'A2;P*$S\(FS
M>I?*"[W$",6P2-FB'+?WFK>8I=?[NEM9RE9IUP8.'CI>D+Q%)/A&Y?MZRO6]
M'XT>_+TK [%](OHB@P'F'*^$D5YV*R.C_ZO5;@$CT>K%VYBP"<R;6OH$E 7,
M4=R"'GER8P5VD&.F9[$N^<YMWXHFKZH:X[XS4YMO7G+%/?B:+I@9W#*VWY3*
M(T[JPX:/2RISW)!(6P>,!POY4LS'Z%\1E'DF<AXU/-YWR<$KT,\%?P1LA\H'
MB9ES%+UDH3G^ -@VU>(Z]L/'=-&::1"BM^ $<;"V1^-GXQD3&C1,FS9_C#%.
M8N*_>ITY;M8A,QMED1F1IB856OR;U*5'.=?%B'V2T$$'7U!NY(:-:#P*O4G9
M95[3>M!"VBAZ0A':/H?<L;B7<35[$A^0GT.SN>M@F4\SUW%JNZ?@$HE/OJQ_
M>:6I[N-\D[=Y9@[*UD^6#?7%EX:BC"57."U_QUL\0,[*RWFN@VP9]]V<J;U1
M>(!KO&N^;B[BL\_2N?6Y.1U1OX$8L9$Y0W<1(RZSP=RFW<.]D6)$+ U4XDM^
M1J;RD9_5;?9_2)W42IZ"LFM&.U!R;B7WF2GX9,,;>2I'\I?=>'Y9Y!H# ATT
MHVF77W:'#YL%(S*[FA*[LIG>>_RSR;.K'I^6@'P#[%K$"%@D"N2:/2@ R[<O
MG$L28>8L]G$<N[J\9^SOJSA.4^]RW-I[3@5=COP^<GQL]XK6NEKJOK//$GSC
M")E#!-^0!_Y!1Q%[=\U.3)%>\%%K'.=/HUA@&&,JG1),HV%6!W<+S+?K!51:
M'<INC?39+P/^GIA(JE[89'B\_,MW2*]L^R=!]*8$2=+"Y,N[_J4'*=A,?=;4
MKV++;TG,%=W>5R-R%52X--/>%X^2*8&_W^INQ-<OBL@2T99]Q%G.@'/%(^WX
M(?0G]:2"H*HY!1];,<)N!)+^J)K1VBT;3#XAD,$S165%*@5>X>H^T$;-XYDO
M;)VLY-(EF_R?%@)3>,W)0WV[DW7U(K5 1Z^R[X_[4&MN099EZDP'"EGE.G)S
M04&&ZNH7M$);O<J!66X )(M&H\]Z!AXL+!IJ@[B"WK8?I3MN6 M[U1Y6?Y]\
MD;^0R:?8Z"O^HLF:4PK<1FCX9')!R$AGVSTM<&UQ<K+=+N.0:\HU&Z/](&!J
MH8;ST"9JU>L+R[#$NGAS_[)/BZHH<U&(TR0RE.>ZSB'%![SGZ!#AUQ7MZ:0I
MWYKX9$BX":@\-$F3^6GBZB8R(1?QWWJJ<ARJ1W8_NZ0F0FN'^)5HONOI\'9T
MV(72>?04-B-*+$]7YU+(.^@6?6A:L2,S[<5)D=E-GS\\ =[\GP1E^S"S>P*6
M]JW6:?)I(DQ=2H\GF-KPV:]S*/:O;_LV2\+@4P(&S-2L:M88;W$I LLGMD'S
MW]K[^\^S8?WW%F37P-[1^@_WV?K7ZN]S;0Y%OR%WMV51[SE * 9R$8KI+I 5
M(R9YKHDCR:NT^O)?<YVN>F''R'=8+L=)U)HW3,V0JB? W'1K_H/3- BY0Q"6
M1JLV*L]'Y>Y-@A[F&5*:R<PA2"X3VU=L\!=SJBL_)H]I9:.K^G[&Q@+39K8M
M0R6HY9*C%H&K09&1LV]YZ_>877<T<@62O&)OS(M8?AOX2(PX/5FBXCCJAV/T
MK!H*N!BDZA?_8YVD,#ZA F!2"V3SET%IBX(U.\"43P?Q'8G_S#1Y<$G^27W@
MB?FB$3'BX)>)J^E.:7@@$'OV4 N$AKUM 7O8VC!S-I/KE>0@A1X$:F&S(V^V
M>RO[3SG-L*GP /]*V/M_5_!'$!=MRHD<%DK>]SXC)*0KROGX@)W3)Q/?G\NN
M..-8#TC.5[3\=,_DBA%96SF7AP9BM4<(#:\@F[C#RLF*?7AZ1,3\E$WME>O
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MG_@>XFG 2'>L,T"@& 3V9!0)R";_HB]9<V+$<DH?0)U@03$3@[ _QQ7CJ";
M0O;2+1!Z;Y(Z^'6R2.N\,*!FYG6^V>5%S6LI[YYJEW/JU^>?VC0)NKT-<3P2
M+T9\?07LPPA727CS.,_Y;!FM%B?J8&$_FNO4?DE@P;0_<QM5QG$2(S38 6PS
MYJ+L'O:6J@K&SOV*2ELO^X)UJ86"J, W6C&S@Z:_M?DJ?QWW+'5T<>0%)&2$
MKNN7V0C;:C&B@VT4&"#L/:G1$O*4.97CO@H%Z'7C#:ZKL 6T*_GY+P(@B?L_
MAM_#,J"&(EIEF/5BRXHI?%'<M:CR^(GDS0H*6LTK <7G*N8YV'8QHIAC:V#K
M1%P\\E@3!1(PNV8_C9$EO@-/9\H*$@FN#BD5D.&5.+]3*&+NSA[SB9DDK4;O
M.(?IHX3@6[U(YAZ6X'C[8>]0IHBZIV<]>D[M-&H>1;P@\S,\/XJ.)@FQ/4UB
MQ.I)9=+-LJ+V_PZ7T,*:SE>#;%P7<)D+UIV?WE8LO]>@@UUS+7:]K<)[:BMJ
MH@ZO5QHV_.IU]/$"(0P.*/4=ZF5S-#/'L2F89NI>#!B]C>(7 C;FVRC"U1A6
M1Z>"%D"\N17U37U@NM<\"?JW';Z%,0VT!D\J^N-\?CP%R10C)$W4A#_.H$3'
M? C=J!V'](36O]XDR@9WK]$\Q?KP,Y@28)TP^MW(R-]P$2C&@L[AE?<<!C<H
M25!%QU'#VX3\*@K>,UAU=77[M_+?-J@FONF-6[BC+_?$4^XI3_I5AE8$/XS1
MB1Y:BJ:T]CT?F9LD)VK_\TDZ])]^H__;<Q4F(-D-DE_0>F1<-.K-"+5&^(2;
MEK^1F[^[5/!1V.[+$#1Q8&QYSR&=K_VC,9@?K'O$VJ'RW&AZZH)H9=?[5-,N
ME*PSIA=;G&YN<E^E^_WIP/>J![H[SY,U5BVGZS!DZE7D-A5WS#UF-3^6''9B
MX]Z7U[L\'=7,Z[*0R&@K/21]XNORG6L^GGB#M\,HIF_LO)S\=]Z>_:-@5?G%
ML?YN<*=@R$GY&BE,MI76'*O4(1P^&"\"T\NB[.,FL<L6&K2A^X5\@PSGQRMP
M\HQ,TP!8 @>^^M- !8Z?TW"=_=$<M2*4C;YA*# E1GR4Z"WK_-Y(^I($V23E
M3E^/.=!1='NVS>60&/%:GL?O0N#1?#%B3J)'!F6QLF@(9DYO<'2R^N5_UK6L
M<3)J QP>8UFHRSV8*2M\EZ//:7[>"9$F]6(]O5UF+>@+C711O(\-<9_<?96Z
M6V_Q^?H_MGYGL/1$6OE6V"N?K1]Z:\_)9-X1%H:\P3"R66:L'@I_?9L8T50.
MJ[,%MAQ#_H)BQ76+[HD^X: Z>5,QHJM&C/B\'R/:SLR<@CW[(H@U%R-N'<V%
MMD,+'92NAY-$EDP<S+D5B/R3W82I,DX=.Z8,RJ/9I!&S<#/L6^HDT078=C<&
MDI8N:_P_?MXA."(RA^*<Q8AQ/6,QXH+ FK^ GQ>5>8L>%33<!.Y,T1FY+"P_
MN X>@RQ:)#-#[XB>B6!.T:<,"KQJ!)*W*5TVDPTLF4QX .J9?-4^,2)S*PJ@
MB1$Z. PKB>:+R4W+ V2*W0*M#WWK&"GD/W#>?%,I67BKKWMGQZE2\ ,,'DGI
M^(0NYCSP1N)S;<C;%R^>!3Y[:3WQ:)PA):WYM$B>6 ^%LV6+/TRCOH-=K83\
M+FVR3K\VAIRY#JP.I,8 \M IS6;%7S%BA!._;ON)A=-;BW82J *45SBP,3'S
MKJKFB=''D<%5VC<#>Q8+A3$JF>^^I*D C--L:UE!;&/9/KK;#U7GW1&;%L>W
M8U^++E H!GX][VR(\VMD*\T"QT3.I*[6V_7*)/9+2L$G/<EN@ZAE_"WSJ ^;
MIRCPW.:*+HPNS6TJ]!IVXJS:(3Z0Q\ID)=/  6*N**8(S*EI ]G.X+B^V=)-
M'!)K&JXQ8P% >3+85*B![34 U0&W: TD'"P4TFLHG YV!XL],R9 PY)S*TAQ
M$RHWHZ%:K@#6 \J7)0I,:2-R"5B=AJT@0(,EKCWQ!P_9U:$$?TH)WQ$K6JT
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MJ'!$E@X4#S%MF6HDE=ND4Y3Z[BUKB(79*#N-)?*V1AV^W#]A#Z"8#Z!#-,T
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M*5$$V.)?(CI"W@/C-+?5HII)\UY#O;U$QZG[*_D$M^D6'JO>4PB9IR*7XW/
M0IX(ET5[-+/&U5EPZLK/GEAIC7Q704J^:= EG?2'VUR$D,.9:]F/@W#).EP
M.4?,0Z@O,!3\7A'UBY%E=S>M67=CS7<HMV017>^/:_Q(+MF2KLS,?&B4))^Y
MS(ROMTP1X3T=M1#G^T2#4S$'0$'.7! !E-?74,7-_SK"=4;0-194WAVTC!ZF
M=>/3Y;!W+J3#3GW.Y5G'^A&YW9]F88)9;R&D$4G\Q.0\W?Q*%>7T7>]B8+)G
M=/W%GC TNS\H;S58QM19!%^==OHU?3:5T)RWN'-DDM5I(F-''IA(\C3S;Z"7
MHP^T[?0(_4EKOV-WX<MCOR#>0)+D+8-+$<6A+S["RK*+&B"ZI&S$!N<[+,^3
MA\ZJW6S33LVY.ZOX+?ZV(!YSL"V_0_L3IS-0X^(BVK>*<(9DF:?L^:TZS\&S
M_:O1O8\"^&BFD91/T%+ALA!R?TKLAWE^+V$O45(5]^NIIJ*=H6L;1EJD*Y7W
M+-7ZETS0OR96=;0YD KRO?9 $>6_& F*+EB9[)!<@7; $Y=)E?'5;!5V<>S#
M=*2;KO3ZIBN!_ JN5<3>,.WQ''8\#'^=$*:&(+JMD+)*?:V].ZU5 AN;BKUX
M&:=T5AXK73 8WN<2=5DUZVSX@^3YU%Z_8R,AK$JC!M4-9I:J3P\/(6I*]U'B
MCQFV/HG#?;/5LIA%R/_$]*W@PX40A2<993-^2]%JR=P!M\(+M!F-.R6QKAT/
M$[X%_A*Y3\+W?<FV>VLD8:B<FHT=,F78W$M;"6EYZX^FZPZV#R$U>?YEMS\H
M,@] H.IM^.YO9#CNB)8"D6U%X_%C>,'5_7EO)=Z:H-J&,JZ>:=4&#S%Z;;&,
MLIK K C?RLYUM-<,'3&F#6)D4O*:Q[7)F;B!ERR,0-?\S61.VIUE&@QZ5Y%_
M_9/;\D'1G T"1!;X/@B?-YOF3352SC7%-LU!3J>G)GQ#Q=!"X>13 94C"R3R
MT:\N18YC_ >:7,:!]@SOM/;^Q6><4K[?Q.Z/1^C4I;+JP NE%$,!-=7WS\?Z
M_U"*\!_95ZO;6A.?;()Q0,]X3"#N^J/W,WY!Q);:=4K(8DK+(:/4JS?:*+;+
M+1MN&0MLS]K@TTDS]BBZX52D#GEJ8>?%AV,B[R:$-.0^<CL4PE(J<0D)X+KE
MWY+2_>78^-&-_?Z_+L&.7SKREF"N'*NU30B1A V(8%4PH]=+ F$0O[7O4:.'
MIB&S#87]JRW-#QB@RV^5)%B\AG@?>L"5L;[RZO<E;^5<-9>CZD+(]Z1C6P-%
M_6R6#U5D]W[B$/C>'E*\',DW#3&4UGWDMS;\/N..]MQ]&K'$K'NPX:5R,S$T
M6T+D!U\M'[2\!V11LR^T2=7==CX.G9=5Y^FU5B;_0:$AA4Y!T"I[ #= $BD/
M4V#SN%<Y"&ZF#M^8D0/4@08?(R&"H"QCT/2MKN9L;.;M^1,T;[,=HL<.R34M
MTED"XX>F'P+M,'O8J&_#C-V]U$8I[K4 \"SIMED>Q8CXIZ(7?R?$LN4:MKCT
M]L6%3&"3Z!ABY&OC(;8R+;O9CKQ[MQ%L_F(S3/?Q&%]DLSZRV$E>8<1/E!\<
M+/VEE^"'@^>UI3<;=#EK(OEE*8AAK[92JVH.M!>AH&*O:V9<O"<W(CKI]@;'
M[^2J-K,PJ.)@RME=Z(3A.99-J5^LIHQGNIJV/N;6 BB>B"S']E14E:%F)MW.
M'=^=NL?[^UYLJU@/U%RWYJ.@^2!;5;\2CYSC^CV[=2.KP^\K>K%#H+-L\/X_
MJ>;\^RGQ_W$V_[?WC=/!WAB<OH)<!IXS(X1T;W? \V\[Q@@A9;U!I9U=",Z)
M[Z)8+28=WX?G'*K[-](@^D^D 2H8O^(P Q-,NLE]M9H'ZEP7! H<\P0S(F+^
M1A%OURIA< 4;#E)Z??F^>ZLHN5;,]C]*=)0((?W:8OQ=X#'6K;15S;)I(:06
M^.:[3_"F#/K[R3!BO"!P/6[E*'LO_2)^R4<\-+L2UL G*0@BW<O_/V1:_%>E
MP?YRON%O?NOJBY(GL*$9*ZB!=YR1SH+M2E%H_7U;N/%4B9'Z=$]TT-J>I#V(
M?NW#.6^:I*4Q'>H0W".9B4,6L2'%^K479X-V4!+MF1IBA@,1Y!%9<6"K&NC$
MG]@*1SEW2,7Q"G'+DKZ3PVWMUA.(NOE#X-W*UR)KI9/_-JGZ.N<U#,]':;:<
M.+#V6:V@5%8:>*+:^1^6JW9Y>>6)14;MQAN\&72NDE=KF(L@J#"&EQ7W&^;7
MQX ^FKNT#C8.R+6KR?.O!+6) (P9K;/HTHH!XK=A]\O+J&I\%.EJ:M*#$6?$
M_F*70\%V!8*>WGNPI>O59X60.IV^O?A3 SRHN;XAWS*-'1H":A'ME%_8S$XW
M,J>KF9L7'OTL*QXQ*8Q>.VFQ'LVNHCW6V/!Z+R8I;=USS5O'=1K2@N',R8J7
M0LB1J:V;<13Z0R3?F-YQ 3Q%RL8K=;<)(8OX3A?S!I+G5R[0T(XCO31KP]*+
M'UJW>AUF:.A?K92O>'+"#C%9>_QSE:"4R&.0]K;YX!L(8@H-:1K$$A[BLQ)4
MW]W&>N8QD8\ZN\*F=96Y(A%C3D_-N7GL0;O(?B/@:_N#$[#J+T!0THZ"R@V>
M:=92=X60\+@(S]Q?EK,FZ;F:ZL\9TYG98?"+S?R]1![4KZ5Y#!DVT>9QXV+&
MTL7)6E]B.G<F57DQUCS;,P7>7(W@6SQ*=FV_9<:_U1X!GP6>0ORZHRXG!D,1
M^+%6V]UOVQLQ&F)=JKLT4OX(A=4*_:P&L_=00CG)?:='R<F2BH^V?LZ_C!CQ
MN,9X]#JXOR>7$('LAZ(A\NMQ,0L<=UII5"$!/R]',E&9GV7F5,VGC8 3G'-=
M)DS^EGN/3RRS];_\-'!K3R[>M1LZ)*BY"A]D_/::)]^7:QU\T)S%YY>I%A1G
MB5DI$.<7$),+&@X?'RW&>RN \N,:S\WD!:A3+Z)!C!8RC0=SU**>]5"B<]W^
MVRDW23S#56.;]EK#=S5SKD:.)/J UW>>ZK*AH& P_D.+;_@,]O32!#V)UQGL
M:Z_)I/=.QCV,-M^=-A3AA.@00GS8.-2KUO;8"=\L_$?!B;<)X)E>->6/&AMF
M:47E.H7IZ4].JE]83)2/.H-Z\0"Z!X:;6WXFNHIL=U@P&"MXFK$UV__S15Q^
M5B3;UR,26[OPSL^Z@"%#Z;.S'_F(2?RHJLGWH[V+PU,U_ KRRE]X71!?N\4P
M]-)/'"BG<%8Y4?UPKH/#>DX_;';Y)6]ZOIS5T/>":MIF=I%CD['6,^]#T_A)
M^I5XU/#X8QDJIQ:!%EQB!_=5Y/H>.<WU8'J_)"K,@12:*3FC\Q77JL0N+8B-
M93[U4:#%;++ZN"?N7OU(>IY)>U3WYH(WE%8@NM/45( &UPJ )[TKP5MED+2.
MJ0'!C$J .-"^,"Y&DU6K!.\.GU,C2D8E==,D'<>_LKC\OAVY:;4F^!6) _+C
MR+'>4A8AKYQ<VC&CKG5U7;OWF_,I8K0Q_$K^'MZT*6.JF4HCKK3_!+N@-\92
MO@DAIQSI!U(?3S5F*ZA\+MZ<+;C4_U2'-XUI4%H^3WI]F>4F"Y7!HPH2]0BD
M1,M=ZY0;<05\@8<0LJVN A@;Z4<L?*.+_-H:$H.?K,WS3>/O%F'H^DLB4S/2
MB9KMI1% K&FG$-*")8!OEF=6MCB11XZ"5-"I2 A9;P?4GQ%"7@LA^%Q#T7UH
M#%>!CS=T"R'-Z^\((;XP)B\+TX@^(H)4"@*F(#2^@M>1+(3,[15"E!:6ND +
M\^[APWXP>^,O8HAI\4(A!/D%M4S&"B%/4VWL% ?XS3Q9<W!+.FL@F^8CNIWN
MGZCIW'SZK>T/*B]Y3@_J)VR0]V"QJ 7+63>%D!TIM<8/+-Y(BG%59$!*"R^0
MB+U#9@?RJ_S+GID9=4OIY1R'6\HZ$CMZ)_$D9?ZP:9<+Z\+XLIY2> 4L /U=
M4&/6?]>B\]-X+5.R]1L#E3:ZS"9,PI.2V^:XX2P5TTFU>0>H_ 2X9[E0H+G8
MT><+S/G'OR.*#U<[9C\R0!^XI8W40G[K.%JJ/"3 %3;8+EX]V1_A7XDY%607
MZS) %=-;K/$:KAS\SD9:4TWO^R9MEBIX[! B JEC*[<KW^N(L9"2_5)/O9<C
MX56\O3Y-X].T:$=U:HLO= &TW.W661KFY_*(A[-+*'?3\IDP'*,([DRVIQ^=
M2+^7G)28_"GY4^JG\Q(2$AM&QT#YB9GD8MY#<P?X5D!LQ;>J;AJ>'.D,6'P8
M:\@&4=>%$((]0] OA%2"\7TE06FYFY@$IT7&OY;O7RW'V4%F-/L-<:?AQ9-
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M0.>BZK6$U$Z7:1LV[=U1[1?]G*.@)O %87/;<CF*+1AY.4.[G_PJN:E7;7?
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MHE10D*4(K#BBG@A#S7TB7S=I]KM N\%'ON&7,<-#?'H67;Q>XE_US>YXTQX
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M4CU^43RG0H:E7'S[X5U)9:H4)B#+*TD$!LLD,P%& ?M;@:PGB^Q=_@UJ]AB
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M8:?;L^F$RCL#&EW,90H/GPSZYFLE&>L;9$U>3_@W;AA* X35@W> 7)ZYT?;
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M9UJO!M^6(!LX>YIAEKL*:V[T,K& ZK:.EP1E3HT$<'JZF$_HF_I=(WVY^6K
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M]3QQ!B\>N=K3V&=#90(H</!P=(WN^^(G^EY#9KO6#4'9MQS0UT"-[R68 -!
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M%!41E:8@1$5 0$! 06D1$1 $(M*DBRB]B/0:$06E1;K2 M)KZ*$(02FA&B!
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M-]M+=&=5MF">?8M5Y&\9JD5B&A6FM@^UK(?=O*4;/7^DD=.3/8K*3EU=0LI
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MLNW^U ,JN7"Z%7<4FMN9Z&7'(1!/@*S7W"$Z)\0>-5HS]9GEE>L//7# _,U
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M=^7$7%J\0'<C\1B(-C$Q#94JE"!2^H\,W2O1]Q_B.'$2Q^(4TP?O2RF?J "
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M\VY%GCADD7B>LEW&0*9ZH=Q 28 L"4=Q8F^935Y&U('05,#+,@-3 )/NN.X
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M'' 8'^\GYSEZD^-=4;[_&UFYIKG=S)3^.T(OZ(+>@NF!FAL7AIM(O:TJ3E3
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MF8A_UWL5W*:[)(7QP2GI]*%"&RD;G&#5RS$;VWSFNUB@N<<P4];W(F%PE_]
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M!@KU96.8I$:DKP*G.75!8A5NSS>IP"M, Q%>B(]^*D3NP"GC_-A*R0%+:^M
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MW0M"HZW84U&[PEUQ1>)CXN+O9!6Y_;T]&BQ#'V<II\8\KZ64"%,!!L6:QK:
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MLV!P#(AS[UF_2<M%!Y/WH0(R,DM6D Y4@!0P[9=J:\"S8UH<;A9\[>/>=8N
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MTE-.WF5?G6/+APG^ W3ZN^N0Q7X%_,@DMC9-^%/3%19]@;OM%8^:[(K]ZZF
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M7"SPB^!]'?<\F3K&'>8W*WK+0!Q:YVWK5]N%5:)J)V@@0H:LT.TJB6IKP1[
M4E>ELA#;R(N-^)\MUWR"'O675$S[ZJV8JCXHO-,0[:U%;]":[$WB\@,V2/-7
MWGW=:B&?/\:PH@:C9<C!/5YF,?&EH%P2'WV5R1^3!_\=M,]M*DJO]L<Z+KSE
M,C^&R4"2M8H4"BP:&>.18[B"^LJ^-J;QBDF-8<?!#HX:8.OM%(L6%*^QD*/$
MDN.8QT9P&(86M7^MP4U-"LQN&%0]\G_E(,S_VDMI:"]XQP2$9HI@7%X3;7JS
MO.%"7HD=!S[V_W>IU?\V@+3!N[N>VR'UQ/A1P5?_^JK:\"O!1S8A>Y)=TX<
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M_3'=\:T#%U7.N]$IY=D^T+E+[+=;4CUK2I+\75L'[F0AP+.K.DYLG([ JZS
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M49'=&)MCC] XVFD*5F2+3KV=U;LZ%ZPXR]K6\OF@([9O9/U[LK6K15_!(6
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MK_I^. 1HQ^X^WUG?/PG+D8UZ(Y0)7?/RF!91M4;BX97[;,PHAK:\<#E]A2'
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M\O;2[JG>[=/0V47Y,D;@$F.#3%U=Q%LJP'/6G2@BMCL9MQV)Y4E.<W:%&'M
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MVKS=+3WOCB8*9;SS@HQQ(9!@!32$5 /=K$;+R?O[:<W$;/_2;O3J/!.2UK]
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M51:5'MJ3LD]%)J3B+N 8D>7>R@0DIW%="2+-V['9]RSU'Y\?S)QM;2>'JCT
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M)B33%=7EFW!9#II-0W=$FR/H+09JMU<_']Q>24<V67#%*93Q,[.PR0!-M*F
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M #7(FL=\ZC\FU2&# B1=3$T"L@N,4[WE]_O[R_Y,1/RQ41&_<PI<"X?];9R
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M3D@WWLTS?^>$A<R$,L@!O3@S_S4@2R55(MVPOT3V)I9&=@?2CO,NYO(BUZF
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MAP>-3C=L>_5<:%)5W R-SC@G!LJ.E#\A7&][]7KR,?_&7<BDF 1FA[4(_/2
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MU&YDW]B19(#7;%O7]05O['NS%R#%.VUBTK^A"V5Z5D@*H@(>"6DTXF*A_B8
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M/1DQC_N]B=,Q=S]*@]J7C)KC FW:QTH7W;PRAV-]'BNJ<ARZM)[LF1SSH4&
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MF5FP)-61LS'A#$^+"O8:C,6NXG"[D*,S&:3G6].KJG@(+=U )_=W#7NM,4_
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MP //L9,X9XSYU!)+\UIC&[//\';,TA*EA#L:".V;%KPV%?NUC4X%-G:9/1.
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MM4_51X,*8RFD'A"WL5ALS@=KWC4MRC;R&QT=2@#L+YJG2WH00SMZIO*W'"^
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MKV]AJ?&(K[1U<FTQ3R .;RN][>%YC-Y9C]1^J&[S,TH^BVM#,:OI")]WH(Q
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MLAL1XX]BJ6D0LEGPYO-2D_%80"?&X=9?QMX]21H9[-]2[![E7TV>2>Z^8B<
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M37V<TOUL?@\9N(O2V?%L(C1N)769-7Z<_#C1S5MNNQ7;^EG)7:]"@RG/[/H
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ME.I&W,D]GZI<,Q#]?YH]_?]>P?'8?P!02P,$%     @ B(OI6!K5\[Q?0 (
M_Z #  X   !T:6UA9V5?,# S+FIP9^R]!UA3W9HOOA45.R(@ D*4*DV4+@@1
M$1 0D:X@H%3IHH06((H"2B\" D*D=R(=@Q !Z2+22P@1Z;T30LK^A^^;F6?N
MG3EGYM[_S#F>.ZSG8</^[;7>]:ZULMZVWFS 0? G<$I#55T5V+=_WSZ1?2(
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MUL5(RT16#&S1$N453R&00_#HK>*!/RO3J-^;'[6FF;$@P$U;\P+8LC@(U()
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M0K=V\-O:ME312AW$\M \_M$=R^W_18DC?SI75FRQSWC\#A'6OPX80M;W4Y]
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M&;^:32C+$+/3MV7^Z"?X84^0N=$+Y([RYWYB)/_X[V>-*)#1* ZO4)( T,4
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MCSAZ:1U?)3EJ:DQ')UT["=%G2BXH/N1M6:'Z+/D>=""GA+<&\OVB$3[5A,4
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M6W(T9P3]ZU=_'H)IM.M%\[LO15P5ZQUQ-P;[K<(NR^EZ5^IAB2UV')<.!%Y
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MOO2Q_)+KXR.6Y\U6,/E,W/N#@45=N-A&3-]O=2,X2_G=>]F7DTW.5SY>!0C
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M8.GP0>DR["8&M%+;AH[(F[4F:_1TTO'SGDE631":>7-.]>FDPC2W;Y#41\5
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M&)EN-K9*&W5OVA!<>=3([K)JQZPJ=(I(SLN'%O^,KDG)Z9'Z2#$=MA*[.1W
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M#1+A9&])*PB$>,?&"21:]+SKU30K,*5-".$(XXD);D:4W*YIXOLHK*13=AL
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M6I>)Z-[TW4;OD0%=36&=5(!G*>+*FBH*_8"EUVP[ )4/M=LJOXCMXK([9%%
M'*'DK R5B_/.Z'ZJ5]C[6O$J,_ -AD=Q 06F"G*=A;J7@:!M=VXL>I>^3I<
MX&Y=GY_2]Y\/VU4>:NG?94C0:#W;4[$0F('MX[L0N<%,"II3@A"==C76$'FS
M,:8IQ!]S1Z-H%4_F6\I%M#[:$^,8M.K?HQ6QHV.T*7@]CP!P/+^X.6UX_[CQ
M57;VF4P] ?#G1FT,*MR,3\8T*88#F\LIJ 7.&'6QUWTS0(WW4+N1<(??TXM,
M=?+2I.2]=!.EJ-+N[O7'$1TJT=[J"!W]G+!@?<67O6L">S9$*T*@@T^+QP?@
M\A)P=MD%)2RI)!:40C2P=D%WI.*#"\Q''1Y(]<K&_=V32JA%6\6FQN;P_MD0
M@-2X59!S:4#>)U#TD2>LD3_0&,U]_/NZ91R=IU>D/ D? 8"QXK;/FFZ&XR$L
MJ=#ZXJ 2EA9US+3U4[=G: !O<D$6+D4U/:'_*Y'.WBV_+2^8\QF02%M;P5!S
MAIC3V9M$/Z9@A^3356JIS=@P5\??]MV%]3V138%B>7G(D02M[N[MKV3ENKO#
M:I\Q0Z_N>>%ZA:2HC"]40+A!<%+K1=1E$0'@\09F_Z?LJ_$> ;"Y4"!-<19U
MR!B3?H=$D !HRQ!$2&H,_%B L;)I)=P-E (9.B*831XP:RH6]@44_B4WNW5>
M2P#$@M= .UMHER-<$EY<O!QTH47%PG]$EF4_JYN1MO:-E\7#22U\OJ*>81_$
MKBWI<>- T'MDW#>]0WIC=H9QWN(ESM@HS(DB+#6175@;%PU*B(3&QA;Z,;)3
MC!U9V9E&9(A9]GZB[<P1?/+I"TZ;N+C?04$M2X](O_K5\V,R"*LTK$"\+@;7
M^A<V/-G>VG=0T] NB*MNX=G?E=Z<G?#5-75C')]-6V474:95%/!^W)@%I;^!
M8B(/[5P;>UNNO.A^^$B;^@?'XG][0R(&*;?NYTU'E:=&H<B@7$J,[K<SJTJ<
M0#$MV[,&F]A>'&)A]O7[-.L#TDR,O=N>4O8W1,)18[#?TLZ6OKFE3@0TT>:[
M9E;!4J!<<YAHA\!T6TD0B<EUM@B#=WWFJ??)K0.'* S%&QS>-]CVU-/31!IT
MOF_?V*AZV5YU+@^PL.4TF6MTJ?UH^3"O,)23,L[BK 8Z^G;XH9)EJB#Q.XPL
MK11]3#XJ+[I!W<Y0"^=G)WCD[G/_#>CK9ZHEHN%KK2V,W\'%HV,#F$-&TXPQ
MB !(8^_\Y#A9.'>*76B [_W2 16_B&/]D7=EEV);E-V^HD*-*/H;PPCOMJ5*
M<>>J3)IV%'C76;*77,/AUBC")5G@UVV4'=,Q#OQZ8R'S)H=A%&=LX"+\*YP/
M^E/74?L9HZS)2;?!I^VZA84BX1.:;[->X<J*E5J0&I0/M.>WDEETXFMF(IZ.
M':;^L+N5@K>4*X1.$&R92:JM%-W'JZ-?SH:U_W]0K&\R!W18 -MHQ/TE !+7
M0=U^[.WB.)UNE/^?FBNJJ^>U]N*%I%<:H3VF: %U,Y/<TCY9@R_=P_JDJLYZ
M.Q7'2IP_J\4_?/K/E.HRA4[_YG'CP4H[6U"*)XX3XKF"^8,SXHISQ5GWD1
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M0-Y(=^G57MP#;S\C7G)[#-O0@0$X;Q0_JWMR^GD<ZXP>0$6M$>T"W$Q!*00
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M.FEH!Z@%-G?AK"$6+3JFU:#QAW=:#,+P1568<:0PI&!]\79&1K'B(VB-S*2
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MP!]7L^G6"5LM/YJO8EB+/ O'99$]?J%E?6J NPI9E4XXY/Y'>[N_K2B+Q<:
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MS?QNYG]O,^,YP*'"BR!))HS&%1B0]R3_;*FN:7=*9M6+^I0"*T%UL+EA\"?
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M#]K+8L<) )1^$W*:KEI;0AQQ5]&MQJLYIR:0]G_,SQ5-X#C;\?.7"(#K%01
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M(B*Z'.S-0HFCD7V>WAEI\"?];$'/3.WE(/#S(P$A:7\S*/Z_,5HQO4UUQQ(
M2%#Z @@Z1X 0->BLM&0K2LAE-A7!X-1<?UGM1<++XZZ3SC7PA2X&D?NCVF,J
M8EC)BU4G0)=W!I67_4T\ZF:,WMI&/B-Y?U=>4[8'\W9I9<S*0@@I5RK[F?4^
MDW+,^R'[IOJ_2H=_*_Y7%87A.,Y$_+P[T1,.$0"=D$T"X.PT\#S;!AD]^_=V
M7&O*F!, W=4UP&U_$P*@ 3\36[2\'N+O471R[FFC!3I V'0:&$Y(R/PT)QJM
ML# V&JO/L5V1]<]+=2)!JJ,X><P"3+)"BE'29Z?%$V%NYQ7TO7<MT[F[H3[<
M9L6^[GCLZ]FF]H2::J/JCG(8#7M,6)[B9R'E+[U+W($330X8HX-^RH/N)9FY
MW1=MK#03=(DT"5ODX;.9+*K(Y=QI?UB1$):\M>75R++C^GZLB"B/0"1D7T_E
MN3I'P=Z8O>&*#K%SG[OOSK8*9LY?'S<TFT&2P:S[0S^^5IB8;#V+[+&C8]"Z
MK<'@MV@)]D,]V^NG_RA>O$_E]:K3D)+H/O0W@=F93,O\!JOXX8TR!EC\'.AF
M?84')#?<\_CF(^J8F715_>%V5YL>!0/%L6*ZNE!U[YA@Y_>ES)&*FPP+IJ2Q
MQ&OT3])\FEN:S.1YM>-(]H#GM9UW"N+'#IG9]&#T:$Q119]6N_2+>[B,3M)E
M^\]9RXK<[P4C/P3WW9+;8$3.ZJSU$ "KLY_679/Q+J:U*L,-D'[@0?]64,VD
M[R<&>7SFG<QO8OC9*:.UTM*2%ZIKU^ #S=:A6BR0FUPI3_M7N)B:T 86Q!$H
M %FX!2@8;3'L3B*"<P0-@B<E%=QWI08>S'4,9/>HJ=1QKD*RN4E)O1PCIZ<L
MWZ60^B;U"A>R/#%Z>^XL5;0) ,&<E, W&OOSC3+:. $D/@=3>.!6)0$&'\\M
M3<'8')O%OGCK^8#TM)>.I<[>U3R8Q/"*2-%(97G+?&1)XT-D_C_LO7=05%&W
M)]H&P "B DH&B9(E2P:1#!*;*"(Y-Q*:)K>B@" Y!\G00)-S!I6<<VP:).<F
M)[OIGO:^=Z?J5=VI.Z_F3MUO[GS_KCIGG[W76>'W6V?O=>(> ?53VU"I=W="
MFBY4 W:NUD](;8%^27O#L$N)>DA!U\A7(ZF9J#WDTMSUE=%$\Z9GU[376C]J
M,,1XGZS*W?![G02%\GC^[:OTN2]18L#;E3HUY-W4<W@+J<8V+#6[U_I<F)\'
M#Q<6ELQ+Q52+M%W/UX(]HN2X&Y#+\H2*P2KOH^\^B]EV8+*)^&C%4GS_;_K(
MS_P/0BB!PUL']&F7FS/>PPL';6.S_F+3-'9C;)" <\6MW'E*N&W?8/QD19^1
M"?>+JYT=JTA*)F*K5 /E'"5/H/0N$@@RJ< !8GI.JMZ6*UB)0CO+4WQS0F[$
MEWUVYO$00HPPR--"78 Q/_1O1" ]'HV76H24=.MU<RR^YN$4,\/[JS[O#!X,
M%8%GNLK3VNFP>'_E&TEL;1R3\"U!CY1 >NQ.;8[+BQ>$KH:*ZNK92+G2YF?W
MA[[!N]:9NZV.9G=Z6;,'QC>>E=EG1\)@SW,ML+M(Y_9_=\G_-S6,RL-N+R1?
M9W_L W'G3 VH1 11ZEAN#YEJJ$_Q1D_HZ/RZ(PB<UNLC?Z'DNI;X6NW;TGRQ
MA&);@H7JS44G.WC6X\$>(:"6453T[=/8/V<BEZFVMX/R*12,9J/A<$[.P4[.
ML+#*6SGEZ5>?Y68:56,6Z'1G:6Y9Z:XS=0 ]\V][H$]<5N$;CS*KAR97,HS#
MK0ZO<B+M]5-S&6C7E]$;7HOCPB%UFNW=,N!W)F\7['FY9VM;!\.XD(_[;_:2
MW 5.5B7D>LD^FI1O18\\91_"'HB@$6I2<@\VPI(\7S13VS4X>MHS<FF7R9.9
M, ,UNK.4Y&J\B4-&>/KBL[NMW&:AP;ZB@L"0/BM7"G<+VWU:&$\J9]-+>(Y=
M0925Y08)^?ZC.F-KKY8,RC6@$;2.K[8"/@Q'M(P57SK=(JECOQ%?(<R@M_+E
MUG58M'WAYREO]Y21%E%2U_=[(FK>[UC3[S*T%GR-AY)4!$2R$8!Y>6D?D@87
MO-/HF4@6UQ@0-05^G;!?KD[WI25/CJ!QV=N2>+AF)[+A<H/DGN[8?NEJW04O
M_R_]%?O"Q&)J/7UY;;T8#4IJDXVFJ$YS?6?_SMCY:*Z7-@[5N<5^O,81A]&U
MA X5,K*_.^V 7EIVS*.E0J,?Y<BS";\\&AO>V5LTD*FH.P/YE-%&_LX/++_5
M4.6!OP+H35>N*R+05D89H\T4#"^+M;>4S6(2+VTX9X@&:+ST]@^1XFZ+L(@/
M(M=5U.Y1;0JYM7_CHXRM&@[@L<W^GYWI_RGX_U-D3V0XS-%$^_=@V&5P@"?U
MQ3C Q?[9"-[_ZS7_358A>P7% >B'1W& VGT7["K:33HM+H=D?SCM7P*'4/LC
M?-*VLL$!#GO[H*@ 421#B,$;*</,NB;(W^BR$PA-SOA]Q74L>!7L]^JR\HC9
M[G01!^C%O.RL/R$Z\)/Q]_2$%'OF6KEIQ,^U B/*RA (78@59_%*G_3VB.XX
M&W?.T-<<>(:/3GQ.,=(WQX7P]Y7@D4NM3!I1CUE2,R2WZ1J:#.D@C6D7::)Q
MP@3LE?Z<0[\CF9ORI:LKL-/2-0!)%50[ON_;>!X\/:*G2ZQ>:.4S'V/*D3PQ
MCH=\3*B#"%.N\?:!@2LV3R43)Y+J.E\#)[]*K%:M,R)> LI N-TW">E>F:>!
M^$ZNGQ0I)YQ-H/9L?@\H)?"\H'CG1GEGBMD,C&H\A8WOM.;7MR^K72+KZWQP
M "?4_(.^*R*EB*R?RZZS3N$OJ:.BT/3Y*X'/F2-ADO)K^0()0/*-_+-H:\=,
M,"IJLQLS<T*2N\7P64^*:'J)&/*T9[N- Z.-/4)%+J&01]6B$:)I3A9/!<\-
M:?G,-BL2VEW4;\>_,^U1N7B<28P#.'S;< &CBLBN0G" .1KHKQ+HD3E6#'K0
MNEV.?Y7.E3)@<(;QO7";OOUW.8,'W$&2I[ZZCV3>KVY$%C!KA==H*=?$C>B-
M#>A8ZC_L8&E2.<H5CL=KYZU/;BW6''R^L%\VB#5O8 B2>C8IY5)9+%JTF$ZQ
MF-93&1N;!.K1-DHM77@,&@JJVJY,WB'VHP?&4CDLRI<;=S+KLC==O!8M$JV3
MN,HX3]+#A!^83E7XC"R/&!_L5\^;$4OSVER4LM(?+-%\N\O=CEP<V&NQ!!;V
M3,BSU)RA-1TH6>#YA6BG-O,XIO@:\G>[2.X $.K@*U0"*XRIGS>96!O&7*(C
M+Y/2]U%-J!:2@&O8K@]!_YZX.L@.ZN\YY!2G?4"2$),7'&G(P;4<1Y76I3_9
MLY(J'FV ],U=/KQ5+2'?V/;03WT_8&=VLM4>(15T= &OMWWO9$S7RCM6T+TN
M^-+'"/Z^H'-X2)HST\0Q+$Q10$=QX VV\*^W1&S^!Z7=FE0<($C_]TZ  F8*
MJX0#$(BR;2\8@M*OR(Y-*_Q#PCLD7;GZVBYL.N8FKY0/!M9<#5LVO#F^&5E2
MN!EC%>N;+A24KAIP $Z^"+.^;VL7Q]^O(C#M]J(S6IJF)S369R[O]_]$7,4N
M=C?NPI\[6,!A)4/3!GKCU)C7)L&!;=^5>.C4A95O>RS3<;;.-/VYB_Z?F?M_
MG9\-D1;LM\%AJ0X.&4.[.SYAWE:!7NR+7K/I]$S F"FX/!?7S3N,#Q6B6D=/
M%3$C==VJM<@*QFBY#$8Y2L9 C$\7-MDG#AN0]!8'V'()QP%VR@.R=]JG2\NQ
MNCS0O1R^/Z3YP4]E A?BU6(1C25O?&E11[SR]V-".&[81:2\KI",2=3]25U&
M.K-8]";"F<^\7?/QW<<*O5,T7*5*0RITSR3*:S^T,DS1G-1!2%AMY,DJ1<YL
MW'+I9($V178ET;J*(UN*A>DKX1(^NOHY=YZ<,ZWSFJ2E77 Y5Q$"?4/U7PR9
M<CY0H[8* J02I^IF]330;KKL+_;YMID6M^CK'[\55])PR79X!'[(V1UV5^CV
MY"I\<GOI^Y*PA*Q3^L737PW%XF8!J._O;E$U?$"WJ3KT^_C5.NE!.ZV,8HW6
MLV#'3WUR0P,3%13-)>VHIJ$;[;:-:DG2^.!RVEX7M.:5 =!.9^9;#LQ[[IE_
MTZOD=[10G*PK#6*D):3A[2%W/>O:"1KV9X4R=IUO4HU69[#2:YU>YM&*;!=&
MDX 93/ 9?G%+M%):#Q0Q=U+?),T.=/Y.PCNU2U_3Y1(.VBI(S:ZB$)R9V!=+
MI1K[/G$G'D7]\9XB]9B2^\ [Z47_NGJ$F$!'2J(]\0S$!30:W4;-6;LS^5#8
M &/DE0IA2-(9X4:O@MM]4YK=F.<[HYT1?I B#[K!*L&>.NE$':&/TJU!<N46
M?S*B2!N@)='_S^%UEQ*PIP%(3V<EOX?-@1/#9D;TP-BFH""C'J0_L59D#XNY
MI4(+%ACG=F%28GY=8F68S[%JC78J)L[.U \L*],#)K HAE<0?DP@,7[,Z:IM
M''@]SI;QN')[FHKN5BQ\A*8D+.^C,K'.EX^=MTQY5!];MM>9>4+TQ,K@A3T;
M/J+9HO2*;WML0<X]<9TD/W4?.%A*:SK^SN^R/HZ^QYW^MDIHCC/J1B2555X@
M9X)TBN[[A;H,+8Y&+K;EAFZA>7EJ=>=<*V/6SE]VSRS&@O9#P0[OZ5(XY(G<
M/0?:?8,9;#C8IFK4P:"G GV UE119QUCDVNIKE_P0<-0$&VV<E\82W1=PSS#
M2K<:K-H-!/V2WEC_Y]?;"'6!37$^J/Y(BR>O@[/TBSYB,&DBXJRJ4N=,Z+&8
M_UV&STH%BRBQJT8XW_V4??JM0B:)2SUY_X>E=CW*D594.;T$G&_@I^<S^^IO
M@\32XLK&NT7?6\]OV&0ZIQ0J6&H$L-:$*Q?_\J@E+$3DM1_RI:%'7+7E$W:0
MF3.^7ZV??K#U56V'6HH&+QJ?YF72R.E&=>M^&09:U@VQG"7H43HTW;/.Y!&6
M NN;OP9J3]YVT;6O4Q2Y(.5,A2M:>*T#"]FUA34T@WA+)K5DU4O9TG-65DS9
MSA]1 ;PR:,.V>@:Y'E*2IC$RM7F7?MM#ELI5B23.S\TV%G.ZHLT(OOT8!Z[!
M*("Z,%[R+WI 50J_*=UX 0VV:*N$]!%N_\]T&$5NOSZ9^ESO#<%FL7S#.+F/
M7&M2@-]$T=MJJ'3A?Q00^$_!_Y8*HI&TQM[U4,L+&ILDIV7XB3"YMT_1CD7>
M/57FCCS^R8&?("DDB7ANV*E&^VB4$W2$!)_Y8YEQ@/*,A<+M)OI6[!=?2ZR7
MTPPFAN':[V(GLE5^+/AR:L9DR>Z@I$[-;7\PF#[8/]]4GD+#.$L_4;7_[A/^
M_.0=#O*0[5-=5*2#>-,]^LB+__<C\S9I\"YO'2)MU>?<<W$7&16X5]:?,S^[
MV+7'+3*1U;4I>(JFY_SZ(MJF:E0W/T"?5E(8K#V:#WQ=K!RG&GUG6HD(Z0N+
M[-SF3=[?*:TW1= I3=-EFE8GN</&2O8T/H<M5JT$G_=HA P1.Z5PJB9E4_DI
M*"B0V'TI0&H/L IAE4VC\?J1>3:)-$A"T$A86?N,E!_["I8=-S^5FD$K/:OF
MGVIHH8 8Z.D"]U,7A&_'#ZF$%R-J]?3<+=E@81S/60.I.(S90^_A=9I2=+E^
MA*KW=T&-E6QEI!7OM4W/CDQ+9<\"32V#"H=!&K5,+!KU)W,&.<)S?LQ=Y,J3
MPNX#ZKU?84R%6;[E'L]_?W@I5?JYPSFB,KAS?ZBVGO_EWH-%Q"RMQ\LPZGNT
MKSDT51045-[$3(R/ZTSTT&IUD#O2NL)S..$?I6::[N-Q.$.41#O)/,+=TT-4
M'131ND1%"S)K^2#QK;C"NXEGTR"X("<O%X[TJ!42^-D Y[#G;]@RCV-,("47
MJCG*Y91[7-YT(1O9@S5A&"@H@00L[/'67MX_+"Z'G(\,Z-C6)5[.XCF8"._$
MH,5N(<U;BH:]=,)[&77!94\VQ++36>3[*Z3QZ4<X;<G2*6-HGB:JO)G9UAGT
M<]:DXY'11R2"V7?_C\;,U_Y1*ZU\A2=*-&8D"A1@EBW5/N+1%A!L,.\O5,O>
M'UG_C*DY]US^@=K/Q;0$$.^;SM6Z&[;VU(E*+UPF57SPI@4I$4F"]8"G%#7-
M 9RIXO/BR3F)=U<26,/TC)BMK6__5>,Y7X?FU^OV>0F#YF:35897GDH?]OQE
MD+S#2W0:GY%4\Z2/X5V_^Z9'A_3;013J3^,O*1U#Y/^Z2B['?R1F,Y"YU-(\
M-K]JQ(SX9BX7N&($4)&)VQI#1VZ??:<[FM!/*^LA;VVVW+TER^YS?.G?[]\O
MJJT^(Y_RZ@^72^%4 +*<GI0(R*J1V*-:IZC/>S!L$EARM24]A/&W%AP@Y4+G
M0H&^>V$R;<):Q[-GZ-WQGF'%U7>?*KG$KI[D6>'0J+X?D;MT>C?%1OGO_2;[
MN[C:(XDK%AS@5\R?W'69[HSQ \V-36QLDUII@*P'GN:B>)MP -O5-DC4T75Q
M=3V]*'/#A\Q?@C0Z:8\2L%Q?8<7Y:/&=KX4[?FW4*8^?>M+O(D%7_Y?4(V.;
M]U-$I(\]; Q,BQJ,C-[$WAL;E+OM=D?Z_.6I:7.JL08.(&2% T2*&G]!R^S&
MTOT-M 8)F"*J*&//V"?.]]LJ!XL#;CCYO8^63F*\CP.4R!14#1Q\]<]<WQ7%
M[BI=3[V#CACB ,4<4]_.83.S:3-ED(SQO8,*FENNSG\PBKM^&<KFRZJJDZ.H
M*1OEMKE<5B/6QQP1OZJB9<_KDT1IAG*P]TO;#2:[.%O$R4R>ZFH)C>Z4WZP1
MIK@-ECX)'JAWIY^"F#=_$3%XJ$+2"SE,^AFC6OM6(/YG!R&!QAW&R$)$@#DZ
MZ4K'QI/M<!<T'U<GS>TRA&HPV(GH80).3Y2I4-=91KZ.,1=^K-NE=30]ENJ5
MFMM96S/,HG,54H5T-O,V+.-QV>M*/')Q6;D_"Z]L"V2F9Y43E[,F%)W^":9<
ML&=TAZ:<7^,M3,+5VK\&I-EX/+1_6"^A\8/4E2B\E/^/&R6A11$S=\RELM5S
MMHB!W:TZS-+>@Z'=\O1,P2I31Q%-*GH(W.? WO/)QB^=ZRD;=N?-HW1_.K"I
M\,9')>XS-7F%\MX\'A,"K^\E8[WTHTZ^GM=]:<2^'Y7X%TTU'(DC8&*HW"3W
MYQ'S4S? ?:K4\13$G#!R=)?[N[-^Z2UW#S1_HLQ3QXJZMJ9/\B.V]4.$OZH&
M*/D8O,UIA2?S7^=_[I:->9#4I_D5J4UTO#.+SEVU&EMCV4YU@O@X[U\K%Q/*
M\Y/H/9+^W3NED9\7Z5F@O$O-N'N^24? ::_\A/\1&HH*6&>76C YP=/>@?UQ
MA+#ZAX>=<M1A'V4M+$GD"U6''0PSJDP6^2P\35SL2WD;Q3Y)"/2T&9MQF%%O
MW7[\=A"EEZ[!L&M/_:KFD6*3]DW A>-Y#!9O;9Q8#@M)8=**/\REE5*U"#U'
M\DJ=N@UY%58P;Z)"I(-GGT(8+'(M[A9PJQY%:IL6Q8.W.U(>%X%8Z0+79E\:
M-E:U:W8O@Y\L#,2]/4&42F:\@0@^2?;%BPPQ&W*24PFVI2='34R7@7R+$;_C
M[L+A%2KZK+KIRK8WTU?+S$BEV<^B>LLNKUR:T"+%G@;E^GXY"RDDV?65C>?=
MJRNEQ4,&4YI&PB^5R#1>]HR_PA3:Q:DY/",.N#!8:.V)\71.G'%Y6#[M=%AR
M7".W;M?Y*$NV,^SY$55(+G64^!(*!]B+'$)%";HKKK8(3Q8X;Q3W<>]/+Z_6
M1;I"6&"6U,OI+2R*[ 3D-Q_<\;WLJA2OK_(EO6K=Y]TM0O,6%Z(P($<? ]KF
MWXGW3'.;ZX??OCESC3[L(9[DEWCHKYKO/>5BW]JY".$)[(@%U7V"'SH?T-[/
M4C;:K$+\'B</O,OTBFAP9@#NR]R/9G]Y0+\]ZTYUR]EY0ZQL#F9'P52+%$TK
M=682B->S R9/OG_X05,NY"?I5SHH$@=@$8 R>[Z97J!A7Y71<?&Y5Y:=/;#.
M"7<\F8O(91'4F=:0DD\)F,\H$RI.)U,W']1C[[<LMF"\2$-*8#5GR=ZWI$I$
MS)\C@TZ8&"/G[W9P,>J13_9[< @+3?$**\FV(W/Q>JE"QPP=GT3..0IG\NXG
M??7\NA;K+GR-S.7BWIN0D F.+?\*]"@K??B"3:R#6.:F^*J+YX@##B!8&M24
MR45/*HKT!18SD,0X6?U>K>>]A']3#Z-2#3774-W:Z@C6[0I</'>I/EZ<ZS=(
MG)=4WF.;*)4O!Y<MAA"M]3 &2D;)XP!-/3P(=Q<!WXAZY.YA_N+[J>7&"+0H
MW7;7G:O"0L; %W([9QSVJ[FP@KPO@^;Y@9Q>$0JO$]SL/[TJ:[2V332H> KQ
M]!3E[HSU7VZ)M+;H3F")DR77VP0  %< P/%N_J-N)JV<&L -'</1>U:5+)DZ
M*NRA4K87;\K_H9#V/P7_P53D_R"!4?N0Z%61GP=6EXX@^(#W&K: SBGV.I ,
MZ-HMJYS5FM#;%*P=CVHH\]$VDA)FE:+GHHW3F]*;U%.ZETGPPEW70(,\8Q=)
MSX->\(=,2<DT-B_50'@ES,&1O;,)Z1&M$$5/%SII08KP7.%:(%D5H<WA+YKQ
MK\/[U@HVUKIX$,@CA\$!Q,N)ZL]%/2](?YFEIQ,=%E2+)CP8FVL71NL6NU*F
MYT1O[ECE_4(1G_-F2FDWBVS,C+R)N4>< +IKD<)9N/;L<98 ?AG^-0D>M:<U
M4Y/"0F<UP)K#J;%I'?5:?C4*U9!(P[Q7?2QNS(3Z.O(W[[ P!/P7.ETRKAF
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MAG^7 @F2U&4X^('))Z=F2@KL.5G*"FN^2'3PB,7I/K=D\5^__A'R7=2N9*_
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M$X!A&8Y*"O_9CLANW#<C"I$S-ZZA_>K!V%*O454Q(.T"C)PZ=KH2')N!G2A
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M:C-#?UZ<9UR/3E-L'<*[VZ^83_NO-T^D,9JL*VP+5K0ZO[0(;6U2D)4^SOS
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M H*AL18AHK^-%1B5]<S/$:]?W"?O>Z0K?\2*EWL7ZOH+SUSZC^9Z:O\RL4B
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M7\_Z3'(D+A:,<]B<S.2_&.8!DJJ-U8<U()<,;XL[I4VQ>+X8TIX:/Y.W[ZD
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M]Q[=ZWW'-WOZX]V:FIT0*K/1G.4]Y]HJYP_9C*"^D>N])"55 ":33($<MB2
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M]QE^>S:7J>*V^,"D:R[)\KNS+S>N X3&Q_?OANO%>$ZW&JI^'^]T49G[OSV
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M+]#+XF"7,Z:HL_*,-5;GX=IM(HZJ/W?79;]HD_P-1&(29/UF4%K@> ?^5BN
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M(2:NYNN^/YF* M"*I*U+V/88"7WR\#!R$.^ <T>4Z2L.O8#A\ROIR; 7E9.
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MEU8'>WY3AN)\%*^T-)7NQ'@%^&>;YOC/.75^$XV2D+ROZS,L#-)^+'CU::_
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MOS0_ :[MT+E5_JAG.GA9L"MA4XJ?;[9VBBK 2 7@%; ]!TB+$PI=F6^%"T0
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M#D[Y*;WH68QO@S6W,"ZW,22_ZN.DW-031]GN;NGG$Q R&0#-\>GAE;.V::1
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M= .I_S<W&?ZC[ WXCP'EWF6MJJJYB**ZW],74EFGZ!JRCQX+"(_F?Y0O^Y_
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M9#BO'EQX5U4>KL?%V;+;^SWL  KQRX05Q14Q.WF@R[27R_O%HE?G48NC-$1
M@9>($C[Q[#1J!A?LYT$.<E_R2I-4N3L]K*<"@]%/#IFM*;I.TY;*\[#),D.R
M.R?&IC1U6H!R=[Y8_$EMPSCNV^5^0F%HW[3;!!]R<9_?F9NF5JWU+1;QU*9)
MZ?T 82\#T8&!89#2CB$@H"*VR(XE&-CN"H]20/EF/?D[\)]U_"%N;?W0B_ A
M>6&MJ#F XO04=QD 7@M,]!#Q\9@\'/K@RO +EO'!T3@YMUO8A:_^M8<@MM\\
M+E_2QCHW@C$B.CPE/]Q*8(5>)_O4>*/G72"OQIK4 6-EX**D1%N32)Z4HQ\)
M=G=_^[=(1]EBNZ/?J"-JB,7.L^Q.:&UU@'D5U=,QR9G9L=3LM*WO;-_RNK66
MJ_A6V!:[!Z2U"-LHQW\]G[IQ%2MU$)PK:>$>>G2VC!&WFG0B)._(M2HT"7O0
M'P[9,QJG>CU72LP-5XU&]BQB>N[H#8]V'W09?^75H.UC4MV8WT9IGUY<7<:'
M2^W=##RQ](T@ FHI+AU\J=FR1FO,Y:][ :_'\)IG%^-GJ-2#K9].3X<,+ 6P
MT=TY*9*_TK-S!&X Y3>ZUXJWV:H> ,>]3=++%&L41]@Y=:4O)>'+;2)@10 /
M\>FK$28";!W $>X9_M5>>8&F.VK!=0WB'_>X8F&']=2U97[I%*86A\<-"D\$
M@7%J7(+.)J-WA%W9GG_68HZYU&6!_WJV^N^1K <H@=' UASK=99MSS>QU(FU
M!:#M.[L=FA/K&\EE:.@X!S(ZWJWJR%</5@7?T>-4IU) ,X(B?"-%PU TQL:-
M<8.*%IXQ:@;*-F*Q8,IGRT"*H9+YDPBT:!.NJ:_V9X==W0RHPVLY(=2\CI\U
M:,W.S.B67EVK_CL\DX>]Y JA(NP?@>__ (43T(2Z+;'&$ ]9G01!P;%)7:#Z
MDF X.Y"'*;HK1%:.*>/7DU,+K94K<6J 8Y;\@C2NV-QO(3I:_>W#[(5%3.<
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MO?VE_TUVJ)=^#2V.7B7+[;NE=/?F:"3-K8$@<TFSL3('_\6 %7S6KA6+(XB
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MRHXJ"?HA2/OB0- L"A7V?E+BNY^47P>2GC[,J$=!'HZS5$'\:VL4_S>7X3P
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M#R^$95O15#I4L=[^?GN-O!G\=:=D3H):SE)66XU&1R$U4K@F=L2*?41;YN6
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M*E%WB['4E(*YHQR=!#E<^-R^ ]Q/:5]T<*PX--[<::85X8K6]BGB<JO6^U9
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M</8[=*\K4@AKDY9232J_!B\58[QO:!P?EY7LJ<7;K280=XD6+<.UOJYS97#
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M-\UF\(K0PI8[D$&='+BN@<!"9QY5UL/J,<!&PDMH2T@H4W*^NOA1L@*T__W
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M7,7%?9Q!Y-?Y3P*I -9N/2J O@NL_)-W]@O6YJR9[\S0@G;#;[4>0S7Y+U2
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M^9J51Y_ Q+F!8>+\<[-MN0?H2@70U_EE82>"Z#]1 6'GMR A:*0'[@IQ5N[
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M=G2K#-T1JO+$9-4W1KS!58VBI^BJC'FB0^@H@Z]3NVS9B$ [MC%)+LQ@#^,
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M- ^QG=)W_N@NY%<?Q;.>$H0DC+ZE H:4CVD@%(W:]EC$;@=3 8*T/XK)4U3
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M1.OA7,[,.^\T&&CF.6?971SL>I@3I[ _O.WP2\W#!S* A)Z&M2S8.P>V8:@
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M0PR$S^8 PPI+G$LLN9E>%6Y/?L?1H)&=^&Y\/*(-DMSF$;0_N#"--O8D-U&
M5 !/FS3MMY6.H;48&VT4BK=;N]IWK=8G6#RUX"Z2])J2]"H27KJ7/F25KJWG
M&T9@ @IO#>$;YJ!]""H@2U6DLB8@_FW'DW'+;BH +J=OM;DNV(\)7IPYMIGB
M2$[!^C#ZMHCR3LOV9_>@Q?41=+KK/9U:*71U%[_ 6@A&^0T49S(_R6.'IZ@Q
MIS,FO(\D,H,VK3Z:<.;$KP]Q+J* ]'SN(AR:\G+QW.SV\AR@E<I'+<RBVL4\
M L69RL]OYY?ZGNRA<2BKQWC"(&GV(B1(8#QI#?/JRJ%;:N8O]S'*ZRR/[5$K
M/.="S];+.(V\S$;S?/7,[\-XUV4CXX>X')1[L[=0O*.YMR&+H].;[.<TL[<I
MA<!Y;D51[+$#^F]M?SF7@\<4@LB-C1;&7NY<]*I:&H&W+.R<Y0WISZH8\GHK
MN.YJZC@5^:2YG>D34S[-WT(PC+C9.S,E0M0X']P9T3&ZV(KAVAFMX\U.7(JR
MR=;JP<B\[\WH(%'P[#$/7]P@*3FJ,.J&A=];M 3BP^(_9D6/'9_>95M)^SF5
MHW"'8LF!1DMP>)A/(>AWU0H/JCWV+?W5PZ>G/MT_![%91$;IX&,2<RZJ*#>6
MKVU#0RZ%=>MK-#RZR%<2YXP%XI,AFWT'.00(G@J83SLTWD+^XF#8PY(O'Z?U
M(!?FCU>.1 Y>[4/.#!_W4#@H*TK--X^&")93?D$6-)/.Q/^;M>9GR)^(B^,0
M$46E@Z&N.%Q[X_SZW/)TLT(ZW//WP$%]@6&+Q:5>F2](]))G0^+H^/! ;HRD
MCO(]/3T4;7IH]T#NYD#-B\>G1"(@=Y6@#C;@6U]=^525&#YM!*H]690EU!'"
M1]$-G@/1TT>H+V\&)XPFAR\]G\_OF=2W=BK;V7[ZDL*C>UL;B&^\.(.V\=C,
MJH=)V8]\U\$=EW]Y^RJVMO'MHVX5!<DK2J>T.?B8..1M/OPL*HIZM*A[:/B8
M'$"P6"/\/]:3&<_M$\VS,)!^5#XE0+FM5B(@H%11Z* :Y3S8DLX@T=#0P!'_
M";4\*L#A^_$)G43TXSN.K\\YT86%?M84H1'5D'^M/F:]&L:_<S@K,[1ZND8I
M8\P\-3S4=1,;*HF\ZNR?IHF0,QXP-(1[!WQTN"$H&(QQ^F9G4WQDHU9MX,:?
M^?UD&;OR_%^OBS/&&@8^&-R?W&4AV>W&E0=9>_DR)'$(;!^5;D/_H),?V__8
M[*]/S,AL]%_)R"V-O^WUC-?I#^;W8/L@$,V^%3?^^AN-MG9@1*$F2#H258D;
M@:;7O,4D6\(55<!@WX[L]GG^K\IT',W)+/>V<?3/]J_L_#C,=U(.2VO_QK<7
M3WMA]#]!7?J_46"X[4(*=N>*Y^I7(B4$8KH/C-B\K11!D#HTF>&-KMO:]K@I
M^/BTVWH,.Q9LMB_6D4#A'8U,1FDSO*>G7^+7H;G T#]!-_X+"PQ#=])/1B"!
M"J -@0<9@P(9L;G.*UZD NKYR-YOC'!K.Y*FT<?RN/5 =B4GLU11Y7@*ZP^6
MG!YMZ8\<EQ=Y=/_Z&.BZW'.LNQKE?RC[>MU3^,8'(8&10LG11TG2(_/I9EZ"
M=5#S5W\(/Z8]-7:2TQK$F9+L#]P/-XJ(/;-8Z:,7+13FOJ:2]3J$\M01 TLS
M+,W;8T'L]TH)"/1K<_VPM[7JYU>4I+P$4%SSP\LV9>:0))B 1+S"R[D-C"GX
M?P0//@O%T-L"84%,?([YY:'<SP77DHH[%01:]5&5IL^&DS1:IE..+YRTG776
M78[G(.?[O7OEE&^-=*D,<R.%QN%Y:12!A8G*Q4P%S<*)?IC4G9,S%Z#_4HGW
MN>SR58 P4/2/2:D_5@^A *6)DTPB5E=9Q9A/F,:4&O1^& 2-TZ4RKHDK/TC3
MYE5Y)]J3BP$*G']Q+> &34D5"YV[G(B:E)+0$Y7DSR7;I%]>C*6FEXD9YI*=
M=^JDT@VM@%)O+BR=$&W-$TMID(/.Z24YTV4QW54-_RPXIFL\RF<K=N;-5WDO
M(1Y [X46Z%6&L9->:[T?7OB1K< J[Z^:)=50N=?0!*,9)=*R>^A#!B19H7S,
MQ.T88_*=N#@A5UTM)R>Y[1]O_685Y1XT/3:MT3\QUVL/IG]YPUY++$)X2F.R
MLR/O8EG-GM;.A8+R\'Q,0'XEK>TE.1V_Z'U[CU/YMT6?3VTG'MGN?F#Y'GY*
M*H?_??=IQO%B'7J7W1-#&2[^$OOCH_&PGE&4;),88TA5AF"@_@BT4]Y__(LF
M"V]Y98;VCWA:#U_\BP==3^9Z\M@YEIZ)[UI5>3KW:R>!).B _+SRT(,P2]Y!
M)F4Y\P]_K+X[,1\_6[QKB%UF2&1=XD@#G1^/1GCN&]"$U0VGG0O1AU'G1DRA
MEC1/U _Z/]U2I20WKSPI[76+[.M21T'%]7"-*)^,W/07_$EWOGY<^H%O20DM
M_("(_!>?_(^:?;KKZVN. LXNY65.OTI*2E?**RK*,YSRH@3M1'CKNI?U'BVJ
M"/=_/PM(>GSB/86S0^1[XB33A3J99L>CG!J8ARDNJ./F!$;I]@$#RN(KUMPM
MKB+I661:?I#U <9HSM_7XGG'^!-3R7MTS"\-1&E\J'+WS=9QX@R<WQFD_=H=
M@T#*TLC]&T]HL?V69F%:J$),KTV]J/!>ZA?)E"%>)HGQ:[)ULC)Z#).TIFK\
M3Y1%1]&=O$5L)\-;M#P2N(3E.'.J6C;QKIP#G3TWI8K?VGKYF7\=?/.YT_I7
M?B:<1R_EQ[BA1L*W%599Y\P,B<[+-;1L97JQ?&WGXR%=%K=]8??PR.2H>%6X
MZ,2=[O>EAQS"#Y1..IWQ[ZZ670L%NE<VU(*ZYN>@0TH?9N#*3E9> ?$^[F[M
M"=$WE.-1\U;^42TSO:73W,5%12$RO$EJ;TNB3#Z<'.AE>.H+<OXQ5^^J+QY3
M^&?N%@<V8H8C%.ERV%$=L.CK8W$PG>62-62S7/:N=FK@./GK""XC:S6W,D[&
M]';*CL1UQY18/L1D2_.XG1U=@5@-7471S]"]VY0G)Z8*_G>7_4:?/=_O$6_B
MD=[L$3*5=:290A*!'4KE+VDM3OFNRY0;LS7>[K=Y:!T8YNH\E@*L-UH1Q3&Q
MUU6^3-F)2HWIV#AYF:4PQ8%L0Y2<4$<C!8Z\/8!2O15][8V_]9;FR_IMQ5DT
MFI8RV8TNT\<65_:M['BKT%5]^6(@/I#+^31/PIYS \-$!<1!!KE^QO?$+7P/
M])]!A+7Y+[;"M"1WY6Z5493WNC:)N^FS/C4=$CLO8-R8J<"7)HU1K'Y+OJ5W
MTSS9/40^?*]8Q 24/_XGB6[_EZ\F8M%4@"W0J <3E#P= /-P541.-;%GK\V9
MCH*6/W]=%/7=E-!4,'<#VKU G964E'_>C\<SGMH_^43Z9 $R_R2G%\N?U*YN
M/'L<UN"/]L&S2#5.DBXC%64/SGW?>'W8Z1!K1+^?AO:!!@DL)\DP"1951*6L
MW5^YE@JB0>ZRP^"\0$VR^^M/78(Y[OH+!8-#3?S=RDS7=54NEOBCRAVNWA?\
M2A>N?SM&53)M].0DB=(%RU4J@%QY9U#WV_%^RZTJ(8+5U!<DS]*O@>WSAFTF
M#LY&A1:H9(^B4<>1PM=WR\TR<NDN2LH^L:*UMU?/<&1R9-189VQT8MAHM,-8
MS41=;*Q3V%"04\8Z\3)O8G<,BXDZW87;"2?@Q_.?/SC_Q00&#/WQJW!R#>4T
M(5A_L;J7DPKH==6:_?83=+#<B_MDJ>=^O%>CY_XQ>"6LH*)]7HQ17?B'4_)W
M9_FRF)CNTZ6*&QAZR"ED)JQ]:\6-DDH%3(OC HL=J(!<$;S(X7,*WR1;<C4%
M=<Q+!;!0&/*/VJ.Z@K"S5 "@UQ)'SA:YNO-K1ZT:$_#9M!&2G;ZSL&[1OOE_
MM/>>84UN7;MH7!;4I;(4$ 0A*KU+EQH5 6DBA(" &)'>@@()"H&X5$"IT@6$
M4*2%)KT3%>E->HT(H9= $DHB(=D/W[7;.;_>_>,[W[NOL_@YKER3^8PYQCWN
M>S[CF?->=5QE $>50J"JE54DR0/?3GHYP[_W>E+IQH106$GJ4^?=$C;1T"Q<
M]G-GKNMA$\*Y+I_T!U6Y]8! *W+.:+[MF]2%*)@D$,G$"A06L:.U_2HWL*99
MV>FN@\N2HGR3IA'[TSBHA9FYGI 2YU KEXY&!]F$TUM2# !P^W^#!?G/1X\_
M&)^6C>!=7E%-O>1V]2:5TD>/ VI*:]AM$&>)8[!AVC3A(@1Y>[BJ-RJ_,+<P
M+RS+35\DU#Q^4,R*;_"P4\BJ 2RXU4XW8X%D])_:)AV,3((YFF_X(KEMJ@G3
MUZ$C&'!N1AL+Q!Y^=C>.C:F23DC@'9AS2'3[W57@D/JH[I"IZ+@S.:J&-!L&
MX%V&1)D^DF?AAW&^<#E1QUWEJ;6B Z2C)V)F*C"USKNNM^Y=/M=N85[L96.D
M8LBI8JEK]^,DC(1T " B:?YO3V=L-4WB=O]%54_U=BP;YV^H>69UF81132J*
M!NOKZ+P-7I7 K>*$'<-.^S\7C-470IU^6]1S\_#6VK7;LDL)QHV0#^V4.?HS
MQM ^^W[_*]K(Z M2[BIV(7Q$U<T_K5'BZ41ZZU1MVA3!REK7UPW7]^6-OD[-
MZ'.&[[[GA=P;/75@56 D='$,"R3PZ <+U (_P@+5O@>&7S']ERO^:A$+E!;=
MGK9)R:-;,GJ7^QK6FQJ& RI0.XD02;VFO9!EXYBW!D'XOB=^ GK<B3W&,!WC
MB%;29<2U4@Y+*/2^^+6\XIC540,[*1-2TV@S6!*3NM?*G@CI.GII:ZJX66/3
M-G4"*U0_Y8*&KJV+VJ^_]5_+1Y7,F9RX*C],J(IW^4VJ.%6#RX]\)%/*GUJ0
M4A8;Z4JD=/D&E")K1%M+:@F:ZN0X(M;4*VT]+:FIOB)++;Q$)=I>A^].PVO)
MLETFY-+[7EQC;'V)14FB6P:OY17#)^LO 'PX]Z^=WB:+%_^]UZAND^FW9\OP
MWN1I5MX[L1Z.("K/^%6W?UI_@3H0[_ZAGUJ0W3*FS\5_SP!]VF$E/]URP-A2
MD>N.2J@^,(P5>&%S*[PHZ!CFV_N]31-DV_(Z\WL' CY? 9OD+YW2[,=+[G/[
M(@X(=0%)'J8+?B+.5VT57\+&M".RH&<UG@YE??^DZ^CJF$0(*'[5T/)+U@S]
MAOZ:K+<(=G+:"_)YRE!K1T%^"Z^NAN%<J[,6U262Q46GJ^+9C8:&G>6V6D&9
M\<.T@HF+CF^&A12T@=)UFP72.#M2%7037<&$0=C\1?GUFH,0GOB/_)J4YNH:
M3UBO@':)VA N!><Y@.VS-)74$N5/#3-X;I=7$"-8ZO;43%5",.LLL)0] O_G
MWUK]IQK>8?KQ;P*.TD,8'M.8BPTV+U#G^M9LE^I0NE[^F.R(R@<&/54"G9U#
M"TFG+#4^WVOABBGXE&==%=JJKEL=\OS1H&S]WIT9^K0?>QLF$MPU-,]FA=(=
MG5)->32W<M!"QA)#VS]JR=HZ+1)2^WEHD7FOIF[XGTSYW!U>G!A6_"B,7?B8
M>=9S X/W,X0 7"73L>XLE7R4R5&PE3V7U"G3WKDC0"'1F><8ES<#5^N>69F&
MM))<GI3\W*;.X\0+K]S)F@SP4S6&*HZ^;+U<]D[(\NXB@/RV&RS0HOW6;L6L
M,,9B%T*II'?68.)EUM8^K8@UWS+;=H*X>UKS1UH:R#TXZ#>L>MRMC7^J[GU=
M?%4NV;Y&',<96'([%J)PDP\(G==,&<^^]$D(GS^?!\-_^O7S;67V_-\L$/_@
M5(Z*1\..Y&ZQELR'QQ)9O2925,<K2=R[N1))Z7J)FC)]WZ<!>%7_EP[0^\?P
MOPS%"LR+Z,:?T,,O6)9>_$SC9M1IZ:!G9Z9:%G/!653Z0:EE)4J+\.V7UK7'
M^'J>6JAFHP\G)\SJ88Z9@YNN.OC8R+,?Q<<FCI@L9D>9($FEV%^E_8@(YN,&
MPWE9:P_;I DP9Y">[X*GGQ4C=%F@9<I773;0(X4QK?3Y">5O\93<L.:PG(MN
M'QW1LE(7N'8D.'( \70^2)+A2JMA9#7_U3)Z@[!T<7BY.:;5*^KK>OK\1F.3
MD-((Q<G=K7PBLK7>.YQ+40E)563*SW$*W/B5DQLL>/<*(&\+ Y@<R345EV2B
MZ544E>-C$X_R: 3JG_27>S,=T6_WCTJ>M9!L+_.3-!T<6%@I@XGS?!]PPHDM
MIIR\%GF5G._FN*]]KQ] C^_-__4K])]O> F)QPO5M\SNM4?-T%6F)ZSD^%T'
M]T4EF_QT=-2*$CB$3YKG9F9'3EST"+E7;>"F=K<J6MJ(?.>DS"&)* AMG4G
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MO[L,1I+"91F*FY1R%JC)E0%B@095UDJ9[0"+]T56Z[9-:#I6*B_!D<U]DX3
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M*WC>=+2'HG-5O0<S8Z5L+.]4265:[4@=;_SD8N$>_/N/H)>'0C3[\/N?E*9
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M^K! /7&SHM3KM-8MPU]1H\L;L^_I5P<)TK&3?'[EN]%D7D;(#HF?!6K814'
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M;=L0JX"23DJ$,*(YC!5@=N*9_I<-*N/Z.15=38%,Q6$T(0M6E*1Y/R1#G^F
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M/6K:ALI5+7\V)?-3;-5"*_%QNE0\/3@VQ+]>@C?%H^F)'NQF1RX B3$'=@U
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MU5W44,7*MXCY^&G3VT=?*@-Y[ZYT7!7,0"OP8Q^[ _-8<U!\36^WLD84D:R
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MHT")R@^L&<@N>3057N71/Z*_?]<"3T1XD9T4E@*[8"I6^PP4::\J% /#I.A
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M#^8FBN)H-?#,I>VB9\3DT4R-D3H'Z+5WM,&9R^2,482#:[@AL;C9DY3>O:9
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MO-/@XKL!O=]M&B/(/7CV&D1K=%_1[VYZ>L@]WLE1%_*MG4&[I+X:#Y*ZF+(
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MN^;&?RS74W=W>LI]XFU;@Z,?A_%C%&MYT:OQB6_7-@RPN9.I'R45ZSL9GOA
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M/G$,CB4#HYM?V0#M:<W">KD+K+4D/>3<S4"C%)M'H6_ 7[$3-Y +Z.=7'S2
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M8L(R'JN#,7"7+1.P+WB!N*K4JQ[](?G?Q9#A VJZ@J\33V"F0M+QW/Q 8-E
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ML/G-70@H%U>?NGF_H4&R]LUTV^;.AV09.$*Z>A76VLODU&+]"4?OQULNK6[
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M?#+9*U%M;=%DLD9Q_3.R<M%]FMIS<[/:_55:DQJ3[ZY(=+0&_V!\F!3R-.\
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MHA#K <TGO8<BMW<S;'/?*O!CFZ'U8C6?-ZL:'*X7_$'5U8CD/PU^ND<K1IY
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MSY=G'^S\]NH.VYWWB4D=$^JK]#5ATOE#J_VC,FEZ=]>F?"=6CP8X;:(!*FC
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M&?8)JL.T<GX*]N_M_(^O!IVUEC8"#5%&W_<E/4246C?0@,?6:,#6]ZRKFH?
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MH;@FE97Q<=_CX.G-@)6Z2D0-&N#\%@W@&4.^NY-&U2$3X(Z.J+7V6\=;K.R
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M3GU#Y<,U%GPDO]U2_1S&%<6H]"I0[HY>?R:8I=.;1I8=^A*:#N7T=]O7V-#
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M.Z@]/3XZ6?>LX;V_'B7E;Y 6KZ(!&Z=&+<G<POGN<ZV2&'G@#@&@*WG??N3
MB#3-[;M5Q".MH-(')&Q!94!)$/5Y=#P!D,$RL(C]10 (9T8M2)VM?=K!9_2>
M_I4-=_4U/>>=,OIQ(]YW"E<R8(K"#O8X8 H=Q9,#XM3A6O&%W37K)NE@\!=B
M459PO5M#<TC?+\/ZSW^=HF.N0LL.$.H'6!+!;756\.<<LC<CO@Z?>-7EM+^
MZ5=% ZY9XJ:88Q_?VM T\"9>?Y^Q4@TC*U: 632:[L26)[7M-BBA=WP[(5NK
M/IKFF/M;PV:VUN_W6]WLXF/-M56Y;=CSTCOWV>-DAH,E$LA]OA_WRAH456*;
MQ4+M+H;:[!VH2HXF[Q:S"6I_I69STE3R_("-*LM:]3?"8J$O_(*BSEOP?3V&
MN(7M]J8"\7>Y>_9ELXV^]\U88/X;-6_=[WO_#%G*KHP+C!,F47\3@Y@8!_$^
MOV<DS'OS68EB_>STSQR))V&;UY#WRZ">$]VNXPKZ_>:KYDW)1H5\,,#-F]3+
M;.($?ATI6-SO=C?<Y@XD$S+$>GNZC:_.7WQZS.*"=?5^UX#9&;6ZK-6=S"1@
M0^EQ?:/Q[^:2W!#&X!?,ALVEON4ZZJX3,>.I:I**1P5L35%S0HPB[.T<XEW2
MC="RZ2+[AH'R_O67E8%/H@JYP"$YE8\EJ'^)2SSY:/W*!YIVB*X*Q8:=_NU%
M&ENWPD?U^A>"?E8,GSB:IN(J.!F$)T7$]S+>C<VG/*?O,U"EG%RVYA5H\M;?
M*.F>5%@/9I8H94T(9QC.-]/2L>,G /00V!,X=);X($RK[@W="X:),$9Z>N\1
M<PN5XN-;H?:.B9"CO(7JV4>GQ'MXXS8CI'%68'?$_<7#M3V9'XJP,^[L$&\;
M^^7FHQF3D4Y-G0F=G[R:?627YLC  >5;$6:D9(\KW$A(HY=SBK%Z>+[CK28^
MF">HP];" Q#P)/9F/3]MN3*S<.E54*@"$%V'![<=3T+9+GFQD5!^^_V 1;B@
MCQI9O2BK_7Y?L> ,<TW>/!65>$2&[VR8H4H)@B.Y^>X1E?!YH;"K^*(PB0@D
MG9:AI55/GNK#5^96U6W=H9H^1R$DDM\ZBPE.6G'[#L63.[,1:_$TPUGK9<<:
M/_%NT(X\ H 7ES@P>,;L>/N^4*,WJY_NN)F WY>)Y.?^\Q5V=DUO&VX&ED;S
M*@1EXY]&I;&'I$KVLU<4E-FDV).75\2N'EE6I$[PKP G0;OC4IFC3N3#TP;4
M*-)M5VCP+X#9L] ZT^P/]!&3K-=*_2EP^16<NX'8+-O="HW;A82+( ZIC6L]
M%KT<7LXB#&QDX%\'5LN<9INO"NXY[#1Q,VL:L)84YLW7OHXSN8LKE$S&5"%>
MNPD'EYR_BH4@\#TZJ8=N+1#R%V./;,@B>1JU%'Z]M-T.N92^:%A<=\'!,9OH
MA?."+UO2#O[DJRUHGR#N&>.R-FMKCIS<>61P(Q?*<V=;0#B!CRU64TOKPY;3
MA-J%P6H^9>_WYV-\=1X>'/L#Z5XWMB0E9AOJ9Y<>E)3T61:("*Q >V7EW$S;
MQUUMIUH@7'A2WY(]Q\V.H[,-AZ&=Q546^HO:G^X+"XL9L5=GN^G0H^==-SV^
ME.7A-]<]_.[[ERF?=3!=QGLV?P4Z;9NM)LGGBW$E#M/)=$Z0LFSA2M9'M/\]
M!4V>8Y0XGV;MMET&=HY?+>B)U)R]XZ1[LQY(T=1K_MEMPA6,]TYY&BG2)UC1
MQ$1ELB?7A#$L_.K71JH/9BZYAZ></JI<&_X]'-;6=9V4N"7'KV@.U2?1]SC;
MCL0=#Q-_+<"A]3N2FY7\_&L$P+?3A1UD7:Q)Y6T=FD#KU63/>MH_@D*T!TDD
MSDLYQ>/O;ED63=P/8BQH&&HPJG.I2!1\?+-T9BSH*$X\:%P,Q^6X?*>?)7V1
MJ9G7U-=@E^4DK[G!T772 =D7AK]PV^C#,\#69A!!]U,HVO>,9^NL"]O47;7.
MLU,-9 SKK&^'8,J^-CB_'Z$NNNG;DRUCF]8P"Y-R5:$!D1 ]U'EO_?'\VS%K
M=AHV#\JWF P9%,(FXH#=%I(Y>E@_U[<(CZ=M9QMOO-PBU>][U[Y("?7$M/'O
M;E\^(CNI7MO"=#/8=#S]_8.JW2:N=DP_8W:^X.=+VX49(G$6>UFWU?5QHZEI
MI^8%.=+HHH@04[48=1MY[<DGP:0"83]BIP:YOM.S.>7V,-H4?PNC?DAU&ZRH
M"0#< \@DN/)MPR2^=CF\YS!SL/KTL6_I^+PUA%(HLIC,&DW[LYQM0H*>[H\@
MTZ,.J>ZI)[.1W\Z6H^H4O:?,L,]][V#'<8W^$-_JG?WM*>H$Z-T6P3(AO2ED
MH91"N= #68BI@\U,\["3:E7QV<_99M5:(ZB8EGJB64B(1F-^GNKWD%MNHO"F
MJ /A#S[==W-8AD.961SE\->*4]3G>Y[%%;%DGOV' (6HN:F"=^K NZM1WZVT
MH+P:&Z@1B*BLG>_Z.0K6H&?L>(S,2&GT]K' *!WNMO55XS5/-C]A@!\<C,?K
MA1[LDY\:Z7V/YP#:FW,M#;;?CJ@).@/74\W%OH;%#- K33X+S =3/P&(A[$(
MC+H5]OG9NCFY/4XPW=.4N,VN[,[&Q!;[6V4YG462CB)F CA<B\W<MSPO:F[G
M/^WYU1Z.'(KJ.8NVT,5PB#E9B-U_',TJ_Q)R)S+I=DL-E@0U:<(1OU)]?I10
MPC([91$79?WU9Z?]WM^JKMYS12YQK^DKA?$"6'C3X9LEVD0DP_T-N;6PL(!\
M;-C$9]9;T3+?VAE]M7>A7Q<9)0=6]73"^B/+I_6_6Z\/K3_*<#&J=+*PM1%B
MR'*W;)]\*+OYU-A81D$IZ+5*'QD41@\PD.Y>#H=1CI1V#XF>Z]+BJ:F8BR92
M06QK)U8R]6/M]2-X;\@-V8^X\$4"X+Z_'HZSZZ,'S!ZGMD#-$)A662-AWQ;8
M#S;GACD,+DIIN"W;G#F8$466J9%>Y=C@?"?CT7V,L:E.O+9RUC!C-OFXMW>H
M*@OO8B].J#;L*U90.9ES$4<-V2&!3:#.&'Z]9[EY 14DZ',O])L-68J5.Y8>
MT&/@]GLK58R&L4/YN'Z:64FQ]5EZ2]9/@7.F2ITO Q\PF?T+?EFZ6,GT#/\W
M=,Q2!YE>J:G<CT2B7#&I*URGP5\G'@@Z*6!2_1<B17?+?MSPZ;R[\XZRN13P
MY$O!D&<8.$YY\'X8K#,K;9&OY1A;L7Y1V]C<X^3[>>O],/IB^-H3:;D^1ML]
M;XL685MD===X_T%*"+;4D[H:-D^M-;)A%DU$;M2CK*Q%.K1>PL<)*X"I+$W<
MSZM490W]HWX'>Z%HW:3A!%UJ/K<^V9 +"=Y=N5VFG<U(#WAWW^6+IZP/1O>R
M8QC%ERM9YK[A#OG@FXZ%3%V^S /";+23),)W3.H+!L^*/":UAAR?E;];W#6,
M$"Y_J$O$3V)/'Z!^,ZCD6[$.1Y:0(LO@-'IK#*^K04X58QZKFTT43*RTNE.L
MVZY3*=>]- .1Q>OYQAQ&N"E[NT-^#X=G2*3W[)ED!I6)0HSU,)#>MYTM/G3Q
M\TPEJ0LR"?6PG^!S>L/^%*[J>/TY%>DE%2LG-K6-G='.O!LS:U-UD,2[PUEO
M6_5HM,5\7H?)&=^X)WOC^9NRD9N? ("E.'5%3@* CR4V8[/Q<GJ3XH]C+,,N
M"U+J;%GI:/O\<]M9^)QX6Y+6S)7'@@]ID<\^O?%A("*N79"I*XQV=MM9<%1!
MD6HM\H'7TTQEY*"\#IN6W-)*?0YQ,M;;:2?-8K7O^=08DSJ)FLS-'0-*S7)R
M$5+Z$8"3G&3]X:<+B5U#ODT$K@ZO#N7_NWK.J3R6]MANTVBOM8$ 0%PAVTO.
MK-XO6^T:5\/%-$"*HFNACH?&JPTVZ&$-^:]]NB]$!>E[S%18>9CU)X<:$'7U
M>A/.<F-<SG*R&41-199I'G'S2O6*EH_X>4C+J(:=J'])WUB>H&T9QU/IH7JL
M-5!'OE+;T8EI:8Y:OQLN5M=-A'Q6!)++NX)S<\*BKZGA$O("CG']L0[0L=XH
MI;UM!5HSS*O(M?E6;B%9'\]LHPC]2!1ZG1*;D.54/4OYG1\M[C]@>6*@'X%-
M?2 =6JG$BWU[+5F8I\]'9XWAQQX;W?B<?8VT:W7!PL>\7/P/P=$BD$XPH13#
M]PT:#Z/ZV]CI-8QU9^;$V:@T.Q2C\_-"F:+)WY:SU;6U4MY@-/W6*J.*)0#*
M-L<BHRU\..,VEH.&N ^>%>C8_J+,TH@!  1 KAE%4PA0X\5PE7>2GUGN@-W?
MP5F?M(\'/^WZF7CY&2K)#8+Z_XCXT7887M#JEQD$W"+:OUG]ZNX*N?(K.C.#
M^#S2D%L//!\H4AC*0?_XM#,[V$_BNGRDG!SW?UU>5L(3V_A,3S7>6WS[J=[<
M<N;A?L=TN3I!RB95,L4:OP#^B4SI#E.U>>LR#1H8N)NO</5WZ6Y(K ([7=LG
MP#_-C9GSHD"(9&23LX']FQZZ'"*0$#AB/-B&W/_IEN3"\8Q/">^_RGY:AYNC
M1Q[8?-\UK,R4,/+.R -,5M=!\ERRX14LLG*_/7M.RL45(VK9;!=R7CDO9>ON
MOC'4I^*_D!G^J.:J34#_6=I^ ;,7FUEY@Z?]:'T][6H &ZF7)LLI*)M/>/\,
M$3'ZS8SB$6#B>8[!;H9<\X3F#6SZ9I$=GPWT3['H @LUK.'L3W2$_G/B>TR*
MW_XL.]%51L[LZ;)21Q5%_6")[%[=EM54H'H@3\7-J*445EQ*+0>@\#_:@T?"
M5R$G%$8T:5N_8*&8RBN'K27<DWV^<TW=5:S"E+ACVC_[<$8?<"8_\1?0_'U$
M76V;@$&C -!Q.JVF\I_!VH5S?F=MSN2;\_RFU@67OA;J>2D#YZL4S^WFE6V*
MW]IU5<O9[@!SI9LA#?,'8V]S-VBGI'<L>+7FK/_H'F<O><_PSD)>5?S70K-Q
MY<;^$6A=HY\B S[ VN0M5 :%,]FC=FNKC$(;Q3C/%BO<I\\4*!3GC2V:2VV!
M08?DB[!=-/TGT5-SO+3Q"]NL^U\*E5^;O6&(#Y&@CKQ'2L:X%/WT>(L;OE^[
M,#_7]VA'?VUBHU0XTBE+D.1/)O7.MK^V(_/I3 ;%3$OHJI@VT/VL59\^[&7U
MC*"#3%*]DXY1V3/9 8;D^93(LQ91XT>K L/\Y14!O'&YGCG\OZ3CB+7/$PR^
MF,EO.#MA]7*HY^,4&815RW_M&P: UA.?W-A%+X,F):#L&NL>" A=C7'M,>_F
MW1\2QTGP8Z_EM+<-5C8'_>U-<Z=-WW>=VV6ZZFQKSK<%?<)RM$OK5G?RBXKR
MBJ[9Z2,O.*(9OV^9[[1,$\IX#2,,ZG0K*,G=^GG]_/L,T !*-U2E$J!<F2'P
M!=#]:GA#" ?#&[I-#T>EX2VA_=<!K.VP@"@=[)%'2Q5-^]EE-G4X-I,:<I78
MNKA-&FU^WO<FV18C%LVHIIMAS=A4*RZN<3V2T9L'=_D8Q7L."M'?YYG@"$57
M7I1*6GG,%85L\_V<!N$$"PLT=]^QQ<D.2V\+]QBQV#,V7%.W^X:CD_W[J.[A
M]:KDP2A'2PNTN'2WAHV%+==RUE-8&1IAQI[< QY0Y:VCT%+0T;H5+-*]E\]B
M8:YY\@*DI<V-/KG*X&K;+3^5AP^G8;W.H@?_5FZ]G#B/A:T-XDK/I^<^;[I+
M:AZT-=4XH_=?_)J@3BE!I85[.MA7AH=5TB7.G;\M9]71*'^<F6/=ZV7 +H"H
MT"7F(0#ND;*<WH!H84]H-_Q*C?\(Q\W[U[VC$[SSB!?UH%5.XB1[=305_Q9Z
MYQA^4Y;$;1'D3DP:3C1_6?:B44JJN82;!T4G6K#(D%LJZ2U-->O[6$-$&3R3
M+LI+$^ZUS;,9J,K-EOAXG+.A\D"V4+LC] :&XABU;<5G7V13KY(,P%HMHT2M
M VWE%<M=W@6Q;++C*F%ZQT2S3*HS,C1MJ"M[=-:J[FHY4D:Q2?!4I!'WTI3T
MXN=+[5I'<^>9+9[UG)*0%KM5-&UZ-&(BS"L[3C12NU0UMSYR<?P1K8Z^5NA%
M^T+:8H-9<ZFP?:Y^&MC.4X\X-#J9+J= =D2-F&8C%,=59+-W/"T5C?UX:DD
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MG@]9/8WU V*8,CDQT&XW7^-%<G%_@QW459(K^_\S!]S_=2D8&@ YH_0X%B$
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M!FQAQ^ V77+T*PV5IW/E]C.2BO152Z^X6(^)BJ&#+)O#1M"7)E'='HNVIP2
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M#H] ;\FR?SS#].Z]B PKFF-A_92K-+CW=L$Y)(^AJ7CCAY/C>\O[::SRPB]
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M \Z6"W!7!W[K\=:KCT7NQ#T;^^A!WTV(Y8@ L :7;B.NW_163MK/^U[VPBN
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MRZ3GZD\JRDM]H.IPJ8U++^:^?R'H&R?R1Q%-PA/,*A'XLF%Y"&+!^F,BB(!
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M),@\0(<*FJPAOARY##Q\LWT>FK:WB9^)UN^Y)G#Y>0N21T7(,.VEM20>396
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M3*_UG6JRCG:V^5ISJ'A:POV\@UR]!Q1'"+1JPU-AD3CD@<_:3\XN_5UX+'X
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M6'Q)*3[JZ,F67L29GCC^^V['/,YP1I!PSCIU\J$"9C>_ >N6O/1A%_L5?F@
M6XIRR5B/6!NJ\.4\#B1?ZC@4V^S?W]B--A:O<$)Y-HB&3FKL0'/F$[;IN5O-
M$',MW19V^QJ8]S%'CT=UI.0A84*=?1#][*H;(ECGE,TO@5H>>@&^"LC-#N6,
M59T?FO1['LL:9%#V["J<LL['/RF4M.J?(,$HKB9D*LVAQ!9R57::1:7.$[9
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M"9,>F0>G*JT\63C@6_17PC/3<QQ+_@/L7?Q1!%F@$Z5?9_7A:XI8G7X<<-E
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MWZAVK]T&;1]=E)^.A@S$E$.^&;T#P^?40;NTD[8_);_[XMLRSXVW"7'(Q^"
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M7%STS\;"B:N7<,"G$LAT03GLI"RE'0=(P.W-=&J1O[9!"S17!(6QLOMGI3@
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M PTI*X%RFRKUG2O$3FCW<OOWUT9(_J0MX#>.OZB4,M3!YL(7GJZ<3*]7YN$
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M-2O_-#^J)%T0-"NE(EK+I?_,LLVC#>: )^FVX6>BT!.5HDSD,58M'@?(N>
M\)']'&*X2/=/W?!]LK)C5WAR/";<6M]8Z07?J=J<]0T63)EOKI6W&C!\&W,E
MX[H Y7OG'P@YD2,E%>7A[U'R(L,R-YD0/P+'GC^QX%)4<[T=%"T^Y@/IG<>2
M,<Y#F(\ON[;/KQI4HB^]L>V;C,>N#1P3D5\I942P5F]:6>=VMHJ/>'#?OJ+N
M27#_P=WM5=6\OA]1^:H=JE:?J*?A/2#G1-1[DMHSU?6DY;>6PL9YB-)$M%#-
M[HD\".&'BMX#"<X8L(EI[UJ=I3>)26U_L:/ O!>$[3YV%,J>)9UN@58*9W(7
M%#RL?VA6G).>D5M8Y/:P3R-IX[)J1VI*<$^[XT7ON]HX(,*SP?MG7\P='!#X
M.OP <SJ3?(.!-&'*25Q1448A/1[.G!%VU7*53=_D18;JQ>W5NHNGI2BD+<%W
MEYM@<.1ZCMNKFZI8 \[ATMH&\[^M9HQR8\GYIX0#\.85H\YJN:AYT]X-4[T1
M5C+[M7L_;GHBI7A*;_1504&6()9]^*0UNTA@U"./$(\]X2B&,O=2E ;DNT+#
MP=UA=+2#\KOX X4VC.TLC=^7PAY5,],^\\8>PS=HU[(RMUYKB2JW)MLG/R</
M;+4\2?<K,SF2M*S6[H)<=GS"5\PQT6),GF58.2@75AZ3OM7$ZVJ$E#OFY1='
MCJI[@,.[C\@G-HAB24^:?_FYL_CE9#LTYCG"VLDVK-K5R 4M?]U1Z=[#MU1L
MC[VMU,S/9X]ZYQDZ.6G3;"=COQT>KU4[%<,;RTNFM&!Y#%9UB9/A#&UG0_RH
M.HQ2&VJVGY;(!\VHJ?8;TR.X/4I=ZG# /_:"_E ([>PW0^6KWG"=\! 12W85
MHK&8\3E@>:]7#";>.9)T>MK\&05%$(>QV4"HL)*8W"S%BK PH3\*[OXG-,5K
M6Q']A!J"92C!SV-QLLS<HP,0IF0#!XB.@9&E8RHV($0N/V9?'S+F77)C3L\E
M^$][X*//,'CTK2C/P@'5\;HX8.R+3)/<,0BK/H$#AO'KZ"?4#;:'K&I!#FL-
M#G" ^MDNNU#[S]\^>@5K:["75OH9UL,/2MZR;=0)0]U 3!KE961NL*<D9WK:
MZYMD=6;;$LLTN;*S58:P"5F]B>3D9$.]](OCTW:SS.*-+*ZIL [9,S PJ,S2
MX"^T_QAW>(AV+X6M?D80KBABF D7-?I^^F*-9@TDRT_IV&,V3\4J=U(#IM$!
MQ=*2SJ]W1.)V?AB^FU78[=I-HDZ1GOAA4\2KVC'*= <&+XSLC2QS7R1O'\T4
M[!/O/RT<YML9[^Y>IDBGV%P!QY4B-$ZD,*7E)'I#TUREGL=/)%)KHD415-7&
MWW>(QXHZQ_M6H9<^EJ:W+3,_=>MCI9:7"<S.1OOY\Q5'%:C=0<LY.!]3N[D3
MT[#X#+*?F)RFBNK85\TR;RC6<!E8:B$K>-.*6#)PP/.\4^EY!-DA% D:GO2?
M=5CDB_X&:QU\MTP8V!! A@,()13+"9__;<+[/ZVO% X0X5CMB<5:0'O&*UMX
MMQO@U9_AVV9.ULC^%Z;'MD)=G[*V^P)$-7VIU/3IHEZY]2YQW_=J<7SM8QG/
M9NJ<1!9WS6N\ =6V"_:%[*67)BAC7+%Z7M7[RZMVUL:>.F&VL<,>UMXNV6*=
MZSM%W\=:@]/B.>)WIN2; [Z:YC/EI?FG^C)'_%S+]HD1I>4\_#&"P.-DE<%!
MSDGI =5"/\(,:P#M,5C@]3Z9A;>X4AN0H]$VSA!]*8V$W5Y_U$1CLI=]T%@0
MF[XYX^=V<WXB<KM&YL7B;"WF"I(KTAG:]DSV+CLEI2@ ![#+MV)*8?&I_1LM
M7:2%<U[)C4Y>RW.J5630-J:GPK_>+>T)"!&E2&F1F9K<">&[9VVTSF*:;7BS
MVD&UCVSL61]^IJ9^3]-, YVHNI[59?[BQ^KPXX KH,YY_*IX?CP':60N5@:&
M7#=8'<4!0=FC('1: 'ZUU#/_SED2WB8<L-P_"SVQ-8<<:ZCMSEKL;>ESG+S\
M==902(4#@J_-&!P^&4.:_O/3(P/&T; 5*&@*!^P?C/W0[W$G_=V4]U$MN:M,
M-$@:6YG/DF.P?:E5\CX6Y@\.3UM#,L&:LXT5>W% =*;U#5&]712) ?2%HLDL
MS7^@:?^,#!;M]YLY3Q[F^&M_?N4@)^+#I)05D?64/FRMVR:OJ&WO@HA'9EVH
M'"UPQ^(:S_T%%L4)[M'(FR&D#O07E*\H""1=0!V2PNU0F^Q;R5G3R<:>2Q7U
M#?N"&9TRY!*I5J4U/B_SQ\B+,G/53</N>3TL-:4G)BEKF>RG4CC@FI[6[:0/
MU6/BO3@E;OPR;^$"^,VZ7!W";*/J^_@]\IW(8E[.H6?Y@(8<B(OPUT#]ML:
M<9H[#-8 H:HSGXK56:;D)Q-[96C:-CRT:FTEK?FS"M8:O9W'0K:&* O)X*;Q
MAHY<1=Y-3JU)]O"U&.<\^8;AIKC9MZ2AD#K*:[7DR]M)Z_<4H;[E -3KN.X%
MN7WLDJ)DUM/K96).@K+M;< >(A0S][6N;^M+EI6KUM^T-96_[,(]N'9C>$RI
M]_#HJ> K:V:F_8KD.P(+:$6'G<<]EG12##-6Z[TA6:*2S _" WX$.6.H?9MT
M,[IH"F-=;F:1=I?E@>\EB$KB +/P-!SP:V4)?!",MX,QF T.*#'#<P#F2._.
M\[=)7<_L:F&HY]'(W#/"8>SX;DG&7.(4367U<8LP1TJ75__$<EI.MPR[S.3@
MB F+LZ@\ 1./I!Q=<MFBVUKK%+PR]5W*DDM-37V8K'[#ZROY0]GA9)<NR&(:
MI.H0^K_-+=].9#8O)[-XOD_830792P=;_BN[V-0IP8:S^GK^G_QDR>U=U&HG
MJ W'4G:>J&]DKZQV+Q/DV5.OM\K14LW5TGI,\24FS:VM":R\O")!F9'V="'W
MA^_8MB"CR^Q#+3A\=MD]]HVR_Z=P/L) 47Q,5"DS #E .(!0[<GGKR14&6PE
MED.Z30S*<< Z;1RD>.P8!S!%G;\-D7:J:DN\N]F,3M"#5?&'7G%Z>C@\6DS$
MRZ<@2,3[5$4D>]/BS;-[FLW3!YV5HKE?D,U(^XM#BPQ1?E5Y5AO4"JKNAWH-
MCOZK%>W+L\\&LR4V&2Q5OAI^7E=#,J[S_V4JU%I_+#T_F?!RMJN!*V;"YK&
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M429^$:EJ9<PWY6#9'YK./S]SR5EH "GI4S*V,>QIDX[.;23Z\9'.\=-S2-'
MSWY1^ G[XKUQNL729L?^6Q_ND:A-A,/#GS,"1OB*OH<Z9?&&M51MR2$N)&H:
MTC8B'7^':+4FJ%G@R!%)RNYDMI7C$\3"R$Y2BWU]/NWMQX:G6U5Y>/"+XMKR
M)\>HRB6UT=FQL[]-ZTK@GE#K)H<K!:B]O NK%IW7TW-H+O>T>$&OU7'TTT9<
MYC5^L8K3PL"MSEN4:>P7M^?FS3>%Y!H 3WJ,$FR-"^EC)D[W\:1/J8_+)8'Y
MWD"K/VBIM^%[[)F=]E<--CY<$YN6V[!F<C<=K?6\PJR ,-[(8DE\O2\%C[B)
M; =^XCR1HG<1@3+(T.I&!'R<V]:1-" CNJ6292K>S4NJNJM/(=,\VU\G//G2
M66M9&.]IYH?!%=D'=SDY&S-D*5>V<2DC"#4ZCUG\SOV$0/M%@[T5_)_[3"H%
M%%(U>=EGVNA5PCOS7[Y?,RGX&G["4!1M$R=-]?[=+3.N8)9RIL/Y%+VYZMII
MLM&U.F/J<$$$]3LU^.F[/X:6Q+2@ERXT+J*]=2(UOSJ=[@5I,RB9QXIKLI4$
MS@%?R*ODU5.6!"])@&[_'<1&#3F3<?Y)  - R>D98 "Z?)!FR4T@0F\<[5T"
MWC<HR9\!;GQT0*QB$:SD^M.SYL;=IUZR#J47E5[M%O;Z[7L1B[6U3W_-UGLM
MMC6YIQ\/KM5N3L]KL;HJB/@9"*7U3ZBHJHR_#]61R8\FE9I SA6:B,5.)0>$
M?B>HED/; X^*V"9;3K7+PS+ZBEA+E$TKV:HJEQF[*,N@;@<+D6*)Y)0,:ZWC
MEO)_EF3@=TD0\&W*(G?8T96 5$"M29A=DZ)K1A7JFGCA@*[)Y+H5G/@^\>3B
M,O&DV OEE0_GV#S\MJ@'B]WSZYUKJGHT#:-Q9U?]@61QV,,[KBM^HZ:[QI%2
M5MX[JM[R7D%; 5+0(Z*.K_J-3D<;/Z[">+IA_M>,"ZAX?V]4MOBNBZ!;\#'M
MZ^_.PGQX3AEI+%.R2+MJ7@R 94'*[ZE6<KZ',C+44G9Z'13PP0DQ7CK8*)?M
M9;/F\,G0*SCSJM_L[)FV77PA^D&EV]-[@?:_+;=*T^"5O(,R8B3ZUD6%N59P
M^!:7HG#9F )-T].W+P],>4U4)V[_+8-UI/R@1?>O:2$M5S-1-X_Y,$G(:ZKM
MGK;$Z]W%^-#'4D_2B^ O'_MT"KZP@LJF>%@3_U$@DL9=MU%RS3A^5G'.$M$1
M^MPS] ])-+ZM&H(,E+%X!?VG$&8UK##AT2QF<)_#3E:&QWSN%Q_,&40++=<U
M]I<?%1^O4=2S(/6K[ X*J]12LQ/MY6H8X2=J$N/=Z[$T[R?&5>ZC=I0?*%)C
MY_FQ/!0#.(HIWW0_)7;G</2YW%\PZ+86F11^^V@V>D]A6O?DX?K0FI=@N+W@
M]W6G^H4S?3YN/L$$L4<:JJ 6!?[0=";.O;P.T=U%N[:C8#0Q+ZK0[VGWMR'%
ML=(3]ZJ*4D4U;ZKUW57D<\GH_#+;"!']9V6QS\+F)CX\X,&STB3D5:&5*2O2
M?$2#G9H)!C# L0KYA"JY9#H!KD7^AG\WQP"R%EKH9@26&F=GFOG&7MA*&8WM
M[?W<M2W_U+KYV2FI>9% <Y^N?7K ,"@%)!4]]N1OB6",X%]:P$3-@>6-V>.<
M]:X11.SDI)Y(O1!_8^W2X0Q2%.H+.KBP.A+8_RH6TF-/[U>_Y-V7$"D;TC?6
M(J(ZKH8!1!5Z#/C18$6A-,_WO\VQ?XDYECTU)2ZF0">_V1/X]>G$ 5C>"MR+
M 40@[;4EF+408-'OH33<.)2^=^-K8C4G>E6%]!9FU0SD+8'83R8,I3B!Q%=@
M2@ZC FZ,I#__@D<"[CPCGM<3^L]L0_*>,5PGJ($O8YH>HFL.(![@/O!) P8P
M8;9UR;#+TI"!5@=>?<'.&E_D$[3YYRZ)U]\"!LH+@7N5.1A 1_R,P5FYJW<[
M6A4#B!]&YW  VX#:>@,8P G6MIF@*[\T@F^(;.)JY4PR76R:LS6=%#L>/%B)
MR<9_>C+W(KEPA;ER^"DW15VQ:1"],\#\,:F*1\/6T@N7??A^\S1;^VT)S:=C
MCP6B0AX^9MFTFOITHI %VRC(5+D5\V#M[A'.DGKA=0L9!G#I^ AK-@E3[F(
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MQ(IX(.^!],4N6L81/*R" 4P6>D&N8[#]?,$ 3H? \#W?5XQ(7&3@D9Q=J/;
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M9QI25Z_Z)Z/!.-HZ[\2H1I"60Z&6VE*;@J[O]IA)84:[P<>VFJ@]K)F&F%?
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M =1Q8P <&2@QM67DI+T#%L\_*?YK 29W"JMD($ W\$I-&@:PJ*<) ^6TEWK
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MKF)3K#H+C%-6NEI(T_& ,[1:T$JY9"3* V^ZI'$.$>,]Z'\02=SU=+S_'4'
M\0.F"/6L$6:675F0JRZ+Z7Y9RWP<N:;5FG&7T?&VCQ/=DG7(4I?7'#SH3$XX
M5U_F98S'[3X2_/[9<QN[@$4V.R5:RS>X1#Z]PG)47"Y3=/;S+5T(H4\+#>XF
ML>NX47=Z"*D%U9$\VW7_')?63<-[C8G$WK 1141HLLF=JWL/.) +P3.!MM;=
MBN_!PVC]0&3,F.S59[3#B6O^N=$H^!_Z1I2!4<S%=?SN:F!Z40P@T,+,YJC&
M%]I\E5AP"KK<F4K/JXW<68K3?C0=ZNG*[<'%H_7"J<;RJWR4A@PY47C?TNZB
MNA2*=ADAB5)=H"+@S!AXUBJ887CAX.A6;NQ0 E8%&NW/4<P'PGTA4XBKP1#:
M&86Z]!=DMU++!GY7@KC,4A(/7D%UM I3J):ML#"SJ'K]$K0U"WZ$7K&%K2Q1
MU2$)#UH)]UJ7YGRH;,X%>70C!.W0-[@YWHXF=4!!T=3C*!PL5@HW)N:Y$7YT
M[Y9RB*PM6T2FEO"UDIN-NP4-[RU>UWBETD4LS_C@\ DFOM)6U&OB!%5[:F=Y
MU7]EC?*4Y^[!;;R0$D(3O5UN&-I'*S8IVMKCIX,YM(]A+4T6F06[5:=X#?<(
M$E(MS\\7NXR+34M+4V3Q?0D=QM<*QHP(Y_.H\X)X\P-N8U?"=N<O(;/U @N9
M'.Y8-E:>@<5,!8,;)HL=]!=9\"R>3QT&T%D=A@'X7.ACJ0 <A0&D6;39#I^2
MHG6!-'X\MI/Y(EFQ;:ON%TJ^"Q-_?DR<.^B8%[A'+K2)V*FI=']LB [/P*43
MMWI"K_"]LBA&9+HQWV ]$(42);<C_"JB=X0!;!F8F;22^:1>&E7^ %+5B0X=
M-LI/=80YV^F7=8C5\MF;/%'_WJ4:ZG7)F51DZZ:)^\EJ-PO+XW(^[VQ\O=GS
M4!#2K?Z1<90+W#(ZVGUQ#,%MK,/]"=Q(34VL;.*&.7O8IM^Q/[3KCUIHDO,V
M=:PG$UYBE7DI%%!7?"3 C.=57V@-9RH\X?TEL+,2>N-",3?8TC[2Y49U@A.&
M>Y8CR'FM():F1QYIUQ-4[KPBK+PBJ5/)111K=6\4==5)*L;+3$T8VGJ5YB1D
M8BU8BW(AH(/"1 0U!@ D#)H77U'4] $BIF>U#H,RZ-'/;4L(N_>'JYH.8GDK
M7B^D:A97/+:+2$WJ4+?@C%M-;\4W9TZEB&^;)O/:MMXQM?SMY6ET0ZF(/T[M
MLS*@F @1,SZ"73XF;0>E;4>$"//-C;VR@<.%='(&__FF>>=U?O:QI=F7[/<@
M_&%$4@2_2^$H KR ]#)FG<90:Y\(QTA!#^/HENG&I=W_F1UB!VX7P "8EI%3
M%[\<KNE;H1C GL'-GQA D!-:%791>OAE^4K!5Q$#F('=" L&@+^&@H(/=9<?
MP/ZD7&&%I0*,':"*)HJQ'6$-YG# :IK>JDT.>U?W7PYA:9)SNG+7B<,',*.S
M86G0P<B2KO?E19]?U/Q;V&]D&.[G["(HLMG-O"PHIY,905V80-\H= ?[TO??
M5!HVL,( UBUDY"11F>!$4Q[7HW$)#.!IXUCIVM>G/-8E0:S3TVI<!90-%H4Q
MVN3P@?7T&]Y9:O'_FA,K]WRMUS?B221?C:1^P1H-/-I?N!)<:XA[F8H6R8+5
M'ZD$AG1O;(WM/@2_@'O@IP<2&BU]T?N?PQWWTT6S:0.1FE/8P?*DS]:C!V%C
M=9>$BKH8@"5L)Q%%4Y1V28@!< <[@U=Y!\"'RE4MJY ?RR=:J6B/=2Q\3%V;
M3K> 3V3#T%[CZ)+AR0;O_H\5X/]*OJ:_;IA\AB9YA55D6+UWLKBH!GSBQWV&
MXD*%+"V:!.W)+FTO341-[;76S@M!>1O>"$S.Z6J(^TRYII6K\Z?4?1",52/+
MZ9&VR(=R5E821RC\JH:62];5Y=_)\QBK^0/_!DP$HA@R-H=//^X1G](@XMVH
MK,XR- Z_Y^JFOHI>KE%/IHKQW9+2*-3]B/0*=LY3L2NA#5'.3GP5DV]<\;H;
MTEG#+:5*U'NHLF 5^0553Q#=9GJ!JQJ#.QRRNQT\FL8P!2._\BZ](H?RK=JQ
ME\'M<H)GR:GL2^W\%([K\>F8QU6D5./Z)J8FU3]>R=>0JG/+L8XU]=-451%)
M'YC208A'5ZG#<5[BOJ]K/+/_7U[0#&]B='\P%0808E., >R:CUY\:^[&DH9&
M\# (<EU\%C>/BRH<Q**89L991G' 1:*>\?#?S!Z.9;TFA7'RV\6N*=(G;ZT;
MZW_,>U.P5(JI)A8%97NL%W->-3_NEJ,=PQG3?1?.514$./#:G%B?O]?(3-%_
M?U6\+==0NA1X'T_K:BS^;N37YL2^_<&Z?KN"(APNV?9ODM3&K:91N'DV[W$$
M<P>G9W3KO!P>N"_][KV>VH@I"BUD,<[+RX],/LZFZY92E+O+]%Q:XZXZCE8:
MO_. C(!FXRGITJGGV6F+^43)<V;_1J9<  YC-4FIS9:J?N6A[8R=6ZJ8V6T5
M9JYXVAC0M#)MRL3$-$))M=CELF%Y4F2XKM*5/)3,RW>K!CUBNI$;+B:3W#WE
MJ1++AB/ %ZF@=D@A+[?]*&M<MH<&PN;[8ZMK2\A"SA^G@PP43Z)-6ISW\T0D
M]\WS>U^4^*+#T&O.LB=QVT=$ABF-O&257&-%BDE9.(I$S(^D"WDI-PAR_/Y]
M:=7;F^6@\-&\YKCK#V[K*.I&RU,.N>6W$_[  (*S[2:=H?M4O[%X(V=@?OV/
M*V]^TZ#3"O[5 ML?(L=2@*?/LF$7-BDWL/$4 Z #7JH&_QS>:$,U-,JM4GF
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MF-KQZQ16JP4+WQ=M:69Q%<Q1(>.\TU;YUO]-9MG%S*CSV'EA=KBCH5<Z:_5
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M Q]@]BS]U/H@Y,&#*_S,JMC) V=8;(J^;G9N"SA1'#JZ$K]TL%GSRYN48>/
MW BY'_,G7:7M:U8GJ=S+L[8*FXW3>&L9+O-@5C?NFS#KSR <O/)N\13]CIU0
MUH^R;O*H1[B/(2IX@&D 6^(48UT;LDDKSL^<ATL2)GGDV^)-8=-(M#49)L-B
M).)C7UO=[*VN.6"^C'M,:EA6Y<2\W3-JO>/2M-C/*,EGG(,')HX";I^>JVE^
M948EC*,V%4J[H?#$QO <\<CBG+^?E3G]\:@BX (!O=>@8VIB5^/<6;^<)L&0
MH$4WZ >"BYK9Y$Q\%X]#:@H0;VPZYPB%5 A$\14:67XPDB+GRU\)3-$-Y&ZW
M<O?PVHM!RT[$.%RJI#!5SF.V%XQXKI68#JAJO"134WB8(+2GU"ILZ/=L2.7R
MI_G+!31:E<4<X%O35GT 4+&AV6?U#UJ[@O5Z2;I-7,>&[^%A$^0%EX97D]R#
MS)[6Z--"GT%5*=FA2 6%2WJ"3*@F6:A]P/CS9%MKLA2_]+HEPQ;]T6*S:ZPQ
M.4\.E#@H XJDJ'-GGP^D6D(6R=P<O+Q_B#UVF*ST#L[MZ,]OSG>[89=$+\ZY
M>T[NE%'B X'D%'?B@6B7-*S](3D>T!'# V@%.#8:VB=Q%3%2UXI37<:6X8$^
M0]Z3BEG9W3'#H"H1=WU?$\I0AR5V@5LR@2\RVK1HV"]V1B U%9^'7I=-NR[%
MI?!AZFFT7]HNHOS(AW7VTB1<=358BN4^65[ELI(.0%$CDA\M?L*\!/)P\/"Y
M4V0&C]'(5;E#;&.H@PQ4T@[! _(7D.&G;>'I_T#6?TV)EL%%6PF,!^A@(0(X
MXLT+#(? S$04V_OO?O)T(IS'MOI]M_MZ+M70GOMV86=#MP_\N[NK/#@:!>7E
M6<59(<Y5I%&*DKD<^/=OT*;9'%0?!_%-H(O& L;R/HPA:XD_IXB/74\LAV-?
MY4;9#CT)#3<W):V]'4A (GE<RQBVHR5E,.[V3@4TCIDN82=.\IG#3*2F88G^
MUYQIPYP&7IZIM'*XT>YS#L.?*0*L3@7^(V(DEB(3>51QAK[CY^M]2MR>0/<O
M@?>4SMY_V;YP]OQ+6\G_[_D7&\39\R\ =&403?%?K[\4M4)G)4 =>  !C1WY
M@>LY7MWE]=C'[4]/#"[@]C>_&JEG"YP..J'T_ IJ3F#9[MRDH'N&C75XH)AC
MD#'.S\F0N4Q.FNO^G9<6*2E9X;QNFR6_9_SA/R6)OX&/Q(HA] ]ER80H;MYC
M0*H(9A'.0>:LX+#>Q8]O<"AB;]^LFC6/<X4,77?=+](5^ML+U@)W^T=/(I,_
M^)@Y]&DL\6E2UXE>[U64)D%JUB1]-'>6(=629R)58OI6EA5>8)UTO_?EKX]V
M1[!H1T>>R^OV1??)-1(U*,W9]20N^3SOHR$=X'CE%-G8[^+W]:'_1HW)W7>6
M'SX%%-._*0+/75<[=_PZO6TE -5=42/B;Y1PH9J/8NQKL]U;6'KKM\&N)K4"
MQ7OTG^8-GWPMIWA&6W&NMX;(88)'Y$/\-9UQW;N!Z7FGX,CSM:P!7E%#4S6.
M#QU4[VP:FLG,=5E+?E\#1U*PM;EY8RE&!-RTM5%%R?I<0G?TY//M7 344UX)
M:[-K"[EIJ,BK\:^2?7H2KD&I$Z1C-+V7'/W8<[=Z['IRI*&4S979HM'Z<Z]5
M.+,8'G(.T[C$8QXG.,6CSEWYR?5RIR^$7)OUS4"6U^V^>H(),?X?MQ%*U>[?
M[0"K'K0QM17W0@V".8;:;[\6%KN0VZ0N5'LO_[VM9^])%/M%_KQ#EL4&^%K6
MCH%[1FOW5X05PUB?7:((;W;$#^E)C-]3-&[ZPMY:K42;G]S?4:#]UP<NL,>V
MSO(ET@X;E:?1A?Q4T5SD]R*NO:A1^>B$V(MCW8[#PI'RT9</*:/8\S%;/P>+
M7ANXP=+V+A*X M&6?T^[IJOV[G;K)@D/Z+%^Q#<VK\Z@ L>VJ0,T389\C5'N
M*+)F%=9*G!/-X<FYSN@;&VRIYZUW9X!],GC=E7>""K4'>KER.&)W=8IW8Y<!
M<I+7]QWS^:R+K$T9OL6=N =?])_ML&^8?Y_@N<E=@DPDCN\^9)WMWFIH2)OP
MNCXX<6<\)!]186-SQ&VHV[J>6Q1O\\5VC%WO<5Z.\X_O_6]*@CY[+=]9K3]=
M=.-CE>7P?2L!LM(W/!5=2?@SK2DP6BG,Z#P0;L^SY.HSG:%TNZ$K2UE=<),F
M^;9)Y@?7B!6YF@J?T._UD=[5)4?I=S$-SWV8&X6RK/I=\<#7:,3"BMZA9G_)
MO]:0N'X9'\+99[;)#">QL^*!Z\^NQ$*'%?% Z2'"4<E9N^\V#KR['^0<\\SU
M@!&:D"$R^N[W ;:_/2"+![:S4CLW'--PBL8"/E1Y'KC#M<WO$XB->JC'T8BA
M8^%F^[0.:&Z&\X3W4AR.K/80Z<]?G;"96^XFZ$9_=;#]TK,RB?FH6,+>"%/-
M,OK-3DF<8JI\$)Y'<,AAA)OC!J1'N6-"!S4XH8\'W-TEY],G8OVN[J2Q*\!7
M*I);N1/S0T(X"KLM7KA&=91Q5;G(Y]-K<V\V#"-3_U.J]D>6JKF^G58[R34A
M6JGH:#I9X\N\"VWCWDAV@[SQ@V'H:%&*.R*CHL].'ZS,_/8"_P4)_B'Q\*<1
MMR.*.\S9GMN2N+'(N%D\^\Q,7EDFOM<Q\RO_S>E7IT0=CI#H)Q>6G)#,D<^R
M/_4!"J![R*<0U*Q^XY&CE<MP(M7Q6W6_.('JDK*6IE.=$Q8@4MR)XQWGRQY=
M7*%?IY9PJ-FMGXW2;$/HM(DA):@[)-L&G/AMGU[Z$"H9-8W<C_C?W&%A;QI#
MM]D\T3=[(4L1KV6"BFQ^R+U5 ''U[RS*2G/3$%*KR2B>BNM>"KH485J7E%,I
MV$MMF9V=;\&.8NE>TW=JWZ>%CJY:5,5,;G\[$!<MA"RJ8CIQ-GB +RU:(KO2
MQRS?W5#[YPDJXJM-Q3)D Q/'>MMD6)N%0G)Z7%-LO+S1+":O)*L@B3A?88NK
M@ DI1R?.=XS]4EX?C6I[*=B'?H4YT?:QH<L_G[564D)?Y#$7L5MZK+K=Z6'I
M@0>>'\B'^BZ:1UD?.>YWF\-;/.S,L@2"WH\A$]&VT."?6AG1NNGG<UR)XRAN
M<^1>>UD>/HF4]5/VEA':2#C_T6F%SZ@0-%X<_9?K-72MFNMB0!J#/]WT0B42
M<_2C[,2^ZZ["YPZLUM&(FOG$0:5^R7P8A@F3(H\I'2]ZLF_)L(@'>&4%1GTR
M?M\$ZM^VV8PH8@?R*HIG+N*90G@@\"F//!XPS&+"21UZ5;7*<*_9H,F.&]\?
M*0@]-);"]#[' Y8I%+][W]20*"8<1*5LN^NV[[FF:2&;5Y(?&/Y9+/G^G7QZ
MH5K,M;VS2#UHJY' ^U(1=GB @%-OXP&D_YE0'LU8X(%>XRH\0. (!':X=I9'
M53'&<!"Y.7Q,V.5#-\F$3WK2G+0CQFRV!U0M^0XT^8]QQAAH/)C\AH8\*MO,
MTN["RZS4L[?NWA]A[L-P4Q8S:<<(+ P/?%O?T28L4=__]S26Z0S'&A[8FB_+
M(CA]$3QPF:'U+$_K^_HL?GD(P\DA#E>,%Y%X("0;R7":?O:Q JTO_]Y6[%6A
MKWA@OG<J[=C!"GJDK;DU9;V];L1[_'P96U=P%P^$7ITTWN<9/K2HASKZ?\>=
MZS.+02RD,8SC@9V]X3:C3N^_\6YXGT,]\TBL)AX(URAC032GZO(>@-9:2W%+
MR.C4 &CL/N,$9=3(4-HN:0Q]Y\G#WU[OO^;=1E=-?RV(=/"XX%W9< >*Y/RL
M=H.;"*>'-:TA-C=6&4N2,C)4_#^6M54S)A,_UNMMB>WP9&P]L<0##TMV5WB[
MJ5))GC(Z+X-6Y=#=H#3-^<TG:Z!_]HZ4';'SE2=XP'[I*.=D<I0NN5)X6!+&
M7>,AN]RI\JN4^H4%K:5>/J98GTU"\(8T31XW<W@ZU-C;DICC%9&^)H_U)7!G
M_L^?A)5-QZ&W*OU5,-['=Z>O@G>U(0>21S$E<%:[2ZD3U%[\W,!$#195Y:)+
M^PS%3<>JR*EP6RM;0.%J;DC.(^8(17+354=I+KFZX%3C-,7K!?H47D0.,G(,
MG?D*Q[IXX.H,JK%Y>HQ^!&>F#V,)R4H0,=35'O:\OJ/X5>Q:Z>XU?;88H48Q
M$8J8[N\*<MKSMU8S\PM*4EBQ[66[&23&D*J*%+6TCBHVE 3UI&-(T OIO6P
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MS8()B$+,AL,Z%_U;ZL*[&M\8LW=O1"\4I";%\]M;\&;?D6@>T"<NZXW<DW@
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M:''5;Y:@X-RJH[<MV6/A5#\KEJ,K*85X)#&JW*BK476]Z. NR-@)UM8Q*HP
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M_J-Y\</$R$H@X/=049@2-)H@I?37Z00+K !^E?2<SZE!NTBJE3]9.96'EBM
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M]H0\B$E[+MXIR=M5VR+E V;$P^GQ"4Q60(.N_M*"K ['MQCX"]'V22J>N#7
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M"#E_B.P]RYYEKA^P$PR)@,%0;"41\*AE9<L$#F<JM_0WV!Z8FTV0%FH1]X'
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M;N31@E0).O-R-CG/J[XX%,9<ZGRZ60-+4L)*K9/,]9>C8J]CANZ:9+[:!(Z
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M^V3<'?'9?3GKY8IB#;@\]8/SOI#<G0,=&IO"&$K3)783]^A]9B+@94"&D:$
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MDLKG)G>-_-F\YVX9=Q=O_(?^ 0B++9@G-UV6P';?$O#]34@ ["P!#^ #;>M
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MB%P7O[-W=KC_MG1$YY7W[X G,JC(F:V(C\;KIIA^<0^4[?&^A)]SJ9L19G<
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M'#=G'&$*AS,EA.=<)KD,7>2V/%D%+4G!!/Q5]_?J=3!MH.0ADS/(F[W=7Y9
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M-?5]ZZ)!4!0I*D4Z2N\HO4>D]QJJ2),N(!UI4110>D= >@^]AB(@4D*57D-
M>@V]!4)RX^_<NY]]SS[//><\9Y][_Q_NU[FR5M8::\PQWW>L.=YQS8"'ND-)
M=:RJM<J>$*R6$[L!RW7&4'K_@#*2+S]6=B$V5'/BI;I ,<5@3O5>] "C])$5
M'W\<^Z73-NJ)O$C69]/]$D)<?]@Q+7*^./"QD!7%#W1@X-HL->&=DNM2RVVW
MY!&[? %,-:,*]-WERY]@N#]AKEE=$V]U[F9^%M,_+^7)1*?^-)SF,[SIBIJU
M)"O/9#W]?:"2Z=>-!%6VY$55!D3:5X,H\TA&U@2P;.CT8<4/9UHB[A(=&0 %
MO?]T+(;2I?XY=<SGR\2E2P?XPWDXX1IKAOS;?;2G"+\]PY??>\.=;:_%RZQL
MG2?66JY"(-\RE3BFQY+YKZ(;73=MI8G6_-?(CK,^+IQ<Z2@*+H];%?Z .8M=
M&C -EF !AR6\4S[K&+..!Q>,^LI'TEA L#?&F64UFCGVH+:-;"YYRI\Y.M/@
M/8<S=P+AZ".9 SN*Y([Q[,.8AA&[1G<<TP%A 3% ?>"R:EML4R/TN/:RIKJZ
M85S7^EJY5C(KUI?5_=<JW\=Y&<TF,1%V1M\D">/?>MD,YGZ_:OP):'\]5A6I
M?^+X+?N)XWFB]J%WL&]:?BU(/SQ>/O"GH5/P%.'Q=NQJQXD7JO7H.O<*7-"R
MBR'' DX8SK4-SWZ/STGY5":4M>I)-]PAO*^J(#1.W4X[19CQY*C-6Z'71"-A
M4CJ:I8Y*-.&7!'5-)K<JQ_()%N V087N\7:A[4TA=P01":(!.5B W$X;.)VC
M#[CQ$-U3"Z2_:)S%:#&)M$OX8 &];9N)"#.A.LYS)A\?%XWZN7N'- XU'I:;
MEV,US&3J2?/?T*%L"L=3Y782^<9>DRIJ9>+6#9/$)9VA=TN83H[.MO+]VW\@
M?HB:2>3[9>NUISJ]$RX.(WQ ZMRUX2]K<5C NVC3Z'MPG'9YT?*HXU[U-;1!
MD*;]Y\]+UM[U_*$WGC(BM4]46=+64E+R&91G);X9"JZ533WS4,-'\D^V$%2*
M0T;!0ABYL1FQ;$9U%;H_":^7-T,B458C9FY6U;,5K>'=2#2I9.S#3YTV#N]F
MWVK)WMUV>.Y7;LMK8+SG32(L9RAN&480P3D)@.20$M;*9X4#]!DHO\C>0QL6
MH>R-3F*R(=N.[3I&EBQPD'F:8M-%L RD1A6J- [NP#WW#3]5;9[&6W==&1=7
MR;S\+@+.6DCW!VE[CRR& &?3P"LET2U#3P^*>T3;?/KQ)Y2YXC2%#H *R1S2
M?2R@J3*8$0M8:=X'8PC=DMJ'F;& =]DWSW \XI0"Q[L2]IA.5+  F-T6CD:'
M&I[+KLPOX4L66UDY%^3UG,?V(5J56Q/$E]U3?B(94G]<_#?]BJLVQU%55LWQ
M/('P4M(WR\YA[U=I5Q]NIM[YQZ^V&"\/T A95W3P5G#V-O_?MNI8 !H6E#C5
MYEG?J(4H*X#L3\;RR7W\-:Y+?!HF$-8@M]$G[6:N^SQ%G[6!C$5EKR<RP5B9
MA4JH4)45+0M&7FFZ#1D9CI4[6HDFZ^0+_"0B.V4LFT'E!7["6#$-F;$<C02X
MQ*XMGYBMIKJAG1??RTS520G&6EW8VTT.:L9EXZ5$/F8G!4?3/7IRVJQ9&MNG
M9Z#-9]IKDRX2KJGP&5(7QF/^8B"*6B?B(Q8 9'H=(5:V.PSOLJU+%_MZQK/M
M4XROYF?I#MCX(6N?/X$S(TG?&ZE/ZT;''EO( TV0]HQY_IQ?>=C%[%G]E#!S
M\=-V*;HBT;#7&6(Q"05-*2GA;$;*]*[SR]>0T&F-S]?JC?Q)R>$/"O!1Y!BM
MF.:*'V:1XAF<QR$#?HQ;O6!VEI-=-R))20UO-GX@D_H_8BNW&2@IZ1_JZ^F.
MZRM43^B-3[PLB8?1,N<Q<X)T  "R-YFD_I,\[?Y=CF=+:.ZZE49GY]55F,'Y
MYJLJ^_W9/Z1Q!OO]DD9MC;=?OQ0GKOPR,?Z62,+^B-=JPY'-5K"?->8]>4JM
M96 TX1P(N+YUVY>HI^.E@>TJ[Y)0'B[XW(IIQ."X^P4D%>,?@/]\SF+ <\,.
MT1GB[ Y_[.B&^ADY!/YTINSTEG]\05DY@<>,J0[RU3D3"!EV87-=N.*0/RE&
M$H!3\_AM/^WPLNLX*DYA#N6Q !GA+6J<3ZRXON4/0*F=4@D\9KL_\[8-OBAE
M[\''TGO2DP[9-T?^L(QE+\DIWV1HY:0![0?R/6Q/R)%HB9UQ.^\X&AMWU1&!
MKZ >8P%E4>#!J<UK_BW-*2.PE,O-A]VJ=9L3#KXFNZ]/1[Q]+P@?$T>MJ/W
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MX>?$_MWQQ60A(6'5 ^?IG>"^ECC_"7D,I>[QZL.+#OI@LO&-6HK+YF,O!!:
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M._X12[!M]%8$:0EFT8>=S)EA/NOW3;WE4(()5>,K?.V7W44X;V(!+PQP=A!
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M8C-4726D@?@S%O C%HXIO_**?+M0M.A&JQ+)5\MW6Y&@0H^;NZ&XCS:":+S
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MYWTL(.['*<)*-^8X(\BP+6\3O5D/;"G&,%V.XZA#_L%N\!+F!@N >(!'&?2
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M:73S6G:_EK_?[.B1%J6I--BOJ_-U&39A-*Z53($2=]P\P[U/9Z8!+ #%C);
M&%T2:?3^^DDZA;IO%)N>Z!48M4=O*&N^+CA]^WK/L+N7 Z&/_&&V?>^\7H!-
MH0107@YY\G"_;:I[F%CDP:"V+H5GI[0;\:%&)*^0/'=2 I?-NX&!@6[!.+D[
M?Q-$!C1+-XX_V@&!'SI]H3KC?3=&S<>)+[_9\)9&%5Z/.YVT.7Y+IM*KGX!I
M35&79IK$*=PE8WOJ:Q#>0R$CK)0X-7>F[> BNSXKY5OC W);M(12/IID]:"@
M;)J?[8]\&M[?1=?'4EJ89DH3]XB_):E6L$9CL&"B&*_J)<?_*8V<3T?-0^_D
MQQUQ%_.9DW ;-U(9_"\TA?\7!G+"<0OQ8S4LX"HB%1/V=TEW^?=S]2%32L>0
MV6KQK]]]6XR0_33?7ZY+"<U7F0W3#UTT*]-VB,H;^ .<7/J9APW;M3[H5BT<
M2#Y@^$3"B[SYA%00'1'GS;^?F U%(QXONL;-2KL/J#AJ)5&P%^6\)PZ4CU5N
MQ2$OR?]P:RRMCU&?T?Y[P/3,W$,FUY$VNHZK2"?1XT6*J=8W>LB[AY%RM8*O
M-7S6,$^?9,DS6:Y64'_4G'_ADH.0-Y/L966I3\>W^/N7L.8NOB[34EEF$@U.
M!T*W3*[+<!-97_ SMQBF02ADJU5[C3^ [Y$K<>AK.INW+OFQQ<-NPUA >FX!
M94,]G?-#(XN(3XK2'DI.9<[<I5R6)PJU0U7":E?0QH"B\>P]TK9FUW=(W<LZ
M6E( <1W3"QEP:BE^'@S=!/Q>_!(+$-*\GFT#3P1I+YIQUU6(AMXY^KW9RO2X
MNM1G=>)-W7,KAYH'D\C,ZV;N4*\#UL07T:HK#J7V?(*2O0EMOM;3EE1/IG_P
MK)]_'.?+_O9T<?!N<N^'>[P4Q-/?:=HDH54.+3);2>AUU-DHT^!(Q7F54^"7
M;#]]%YG5MC^[>\(90BY8P/O=WRNE/S?%Z%5!"CQ;Q._27=KT EO2ARA==AB7
M<(^06'A;A7)5P^N3^\+R?)RJQ%-U1X);'G*R+U#XXTOK H.5>9=!1YM2QYY-
M:PO5WF$+F"TP1:K+\AU?&::+):DO\"9MJJ?.7-Z+Q6*W!AV#B$R:\1%6H<4N
M]V' P6(!-QOXBI":0UZR,,=7@&7@R$NFEQ>&@RB&"7.W182'!\S:IW*RUTVF
M:&[^=L_Z6N?ZBI".>AR,3=$B3%G]>51?CYN-S3L>9NIOI2LD9%KPWU#.6G;0
M!TL_@X>Z,(@@"@<>B1PQ%C>4\QG99<\R/%L#VL[#7E:1I"W)F(3,/=J3.#&^
M:MZJI: F;M]=RG *#)%CD[C3F)4TWO]N\D0CW*B.VB?-SMR8<MET!H4_:G?]
MO8+WS7/?YE>//JI]VM8;C-_4"-Q]7;5;!8T6LW[+%S]+81RUN)2_)"7OXD:K
M0;H>$I+JOLP%%:6-%+G#\D[?^EC"WWBW-*%>WC!IREN7M^271,$+ALB[N<4O
M"UU>,%)2YJZ.=RRV0/_5DO#_E9C"Z-3_]HB3PW1IX'O3E+\IAC$3PP+N,,'^
M;G4-_/@7MIV_QFA[=YQSNJTWQ^C#KKEEC$R>8: _E8GI_W:-6$7_K82/?AR
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M?IO[B=]Z_Q3A>V)!F**VD;#;(]Q5\WR 9.BYCF4M+(!M1]#;._K35F9\<XJ
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M<+FC^O2RL)$UE&=K>Y>*0TK/\K5(2<R+@AA^/F1DE^K2/[V'E:0X*Y* )TK
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M.3I[Z^8C(I%.9PP<_,HW98S&<V/KG)EYC22=43K).Z-\)\+$0A'X'H"!P.Z
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MU<AM1E(L6;9,1A?P/8+Z3.3".!LR,\H+VH]N0\1Y_8 L.!7=$YAR*BX]2TY
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M/;IX)TP7!2S.51;WZK$TN2HRMV9+I<>6?+;?>'$2I]E0>0FMIJI"J,X0?WT
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M'4>4F2JK7#5GV0>EML0?++<X.*2]=S+4&:PA-INYE<<2<+KNQ6M['Q8@REB
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M_CP_5^*M>J;6G2DOI\W\M=KY]82-C;S>":$X1+JGM*-CFT="04;4+8_T,*G
M2#*6Q9 TICO2N["7EA(7GPR.JX[@_"53;POJ5?[O4$/]D_!O$)Z#M[.V3BTE
MNBS0%1:8Z^ @// ]/H_'M!L0=!!\HP?1GHL%2&5RP"@18AQTR>>TI\GVE';H
MU?74-9P7/^$L*@;MO!!.P+UVT>[N7=GKFWU\IT%F5J*J#Z_Z/7#;#*LN4GE.
MU%I$#3OYM%DW*+\.6F)'5]4J+>S#"?GGYFT)'5$;8N:J1"*BE4^<XIB*=D_C
M"'URN_0."^Z4&143?\POS$Q/BHEG,ED,:K_3EY>O2OZM?FW2F%T."USIQIB
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MN285"UC?/$6]71UP^4,E-2;  M=4<%*J68,P[%A !;[-C\[!/]&!UR[,T3P
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M[2IKFF4('K%@PH>0VS-MK5(KG^X>F$;\Y*G:NHEK3<-AL2'>[A3?#+ZFYNT
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MZ=-6OEO<]4PZ6*\[@T"L:Y=6@/O^J)WU8>E@2#1DLZ#B=S5!KJ?1NVE)0;$
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M09BCW*7.;PU\K[.+XL^<<IQQ=2Z+S_(5?&\R;N98\7O2![LX><#MF[!;6[2
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MT(K--F&0B$2Q02=&R*:_O4RJ\-M2)D8N#8T;?C5:N')?(+0RI?+]QW,QO]6
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MY9,>3^&@ECJTA5K$<.P/K7X_MVZG,D$8)#Y@ZX)#R&3.\%L/W;<>CV(>H0$
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MA7LI;>7WN)FYCOUJ_WL&8".[[(V-KWA+&?-_86C*V"N:%6; Z:;Z,:R0=(5
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MS?P%<5U:%^7T!%IBO[T<4H2LRC!!-BGLC@7,WMPSF/@T9:W,727O!\KLPM1
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M\+LT:DQEM.P;3/UP5L=,T9_"U7@>N>$RZ]W5D7.F'9EXW'G#/<.KN[:34PQ
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MM.LI%&^OL^U8F!#$@?+7$IC#UV<-YK0[[05:<EA$VX,Y'(D-J?5P'':U*J_
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M#3-PV%)++?@!EHBH4L:5*4ANS#1JS:0&9'I/J7 (>XT[5D'S+OA[\]YM7GL
MMF.8I%4A_Z'.:PU-@A^&NXM6U[M7UZ_Q<;$[.=EIB)VR9SG-2*$7KI&_W+MQ
M]"SJ<L_TH76I=F*OB7.528,NUPN1=6+"?8Z 'OO7IBJ1,44 @(FFJ2$;0%Y'
M)> GP&M-N/IXJ%AA>1>+#:SS=Y)PWD5?$Z68P2%C(Y/S&PM%':8#]V,]@EXI
M6=Y/SLTL?;V0Z&8LJ_LGV))?'IQ@)ZJEM']?=M629/,_*4C]WX)_)0_H3QI
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MWM, \K;K&1,]Z='%1(;G,0JUV[7*MT2,(]._NW Y\EB@5L%?S^P KA,4]HV
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M68:WU%KIQ2 N>.2',H7Q"<I&TY'W#V@814B@A"K:5:6F30/<*U_FFW@)09Z
MU(8ZEN5A/XL&%V":CP<:1-:]K+U!,VFE'-R/;WWK=RY:=W7*R<+$)T _FM,
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MN:5\#B7B$E)M62(*L,=%35EUKK>Z%[FSRD )Z!RA9+J9&+'E 9<H7]J:/3Y
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M&/0PGT2$]S,&\VXY,U4)OUT0R/TD- 37K3/EXF+7JN#DO5 /;PR\Z][Q&#N
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MW^^_^2>V__FW"59YR:RC4[;1.&#SZ!<%*4I@R])H6MHH^GC,=(3E5\NGJNI
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M/PTV_2 D7YH-)V[=*"PMRL,<:;(:Z)M(%C6\O%56EI^39T0#\22E ?T)[QB
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MP@!TE=#^9GIH^;*3S?EM!B# G[GN^1D :LG)=D<^G<.; 9#BI+I!%XW#E1F
M;>Z9DT7 BOHT>( '?88.04M *3BWT,HM_0^Y;+M ;B&E;H^Y%+R"(C0TM  /
MZ_$!G[,WWG:"E/8O%OPP!)>;=2\D7LEE24B[1]_I-- CM X_I0>"^N2IMQ@
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MT!ARTNZ>:D!:ZNR>.S-:#[Q2(A1^T\B+=Q?+#I1$C89WY-Y.PI/ZM_S"*QF
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MXPMBZ@I^+Z[+&/;=,+GV:O:\5*J,LM6?ZIJ/7> '2*2@ 0-08+O8^H:>H<(
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MBRM&H?,@U!](<09 (JYTMJE^6ZP5DRM)?SPY3U0>13C^6":E*=[%_'3D=CT
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MA8.](?3#NFO9]8>-Z)P;^[K/*^\:RB%[[ Q963[7R >A?-S!O:N4,*HGC0%
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MM=-*2H\?JOUL]>'M*RIM7:KK9_>^ CK[1+ICA!+S:%=7RP2655QP:/ES'?J
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M"0CK&@J'OZ_TX3DU$](_@2T0X[W5UVK]I<]=Q%9@65SK,.JM<=R'0\N?M^F
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M49)3T5JAT^7X]%@X//ZWFS &]_?Z-]#HWX*_!7\+_M<3T*?_-U!+ P04
M" "(B^E8T5/E5V+E P KT 0 #@   '1I;6%G95\P,#8N:G!G[+IU4%S=MRW:
M>( 8!(($^W!W=PG2N+L%[R:X:R<0)(V[!8<&&@MNP=V#N[N[=&C@YG?./:?>
MN?6JWKO_W*I7[XRJO5?ML5;5FLOF'+/6?IY_7@>\590#R@%04%%06%%8 8#G
M$P"KNIV3NY.;G9,S%0\[)T!0&JB"=@+X%][^JP4 !8#R'^7S*>"=E)63A37
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MW@<,5ZGZUN]),0Q;$@P_*(HW3)=.'8H=!-(PY1;R)JIFNZAIT,;?M!Z_L0P
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M;_'IEK]R9581IR $BZW>N<W1_7"Y!RM@JAC^B%'$N]Q2:XAZX]7?OL<2A^!
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M/;H9R]:6WL-?==PG37EZ\*1?#"!T,S$H1^I:C)I;^A$FSP#ZUH5E(?B(V4!
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MHCL.;6&? ]W\#&>7&8COZS7DAF[HO__=&Z4 0\$M=AY%D6E:'6,KY.XN-!0
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M >CRDA=N"QA>GZ)[^KCHK+_2)YE3LJ*Q=:Z#?^*F7U8MBZG"!"\(2?;XTG5
MPZJJV^;)LO$[E&5YOSG-61K\J>*;^D&%RZ3-&ILV6D7.EWE=81F<H&DL%:GB
M&=7@F#T4Y(B=.">$G2QF@"/B,?];Z;'X4;^#HE-49G#P8O6M.'T>V:H: ;>/
MPN'[^$I<(!T]3D6UH=X081%X!HKVZN/:]EA1LJ?$JL"1DW,!\_L+[<Q7BZ^Y
MI>Z_H+.#M*#:/&V.-D._1_'0?YJ\Q"P\I1$L7@>B;]:2E&,O')UE/0.(JI\!
M>%7M'%Z4SNHGIM%]EEO]CA2#Q^7MR4>R0B^MODMID6Y=-2(==4&'K@+09,%]
MDB/R6$W:YLGMLSI5=O$T+>TLQ6_ '5-&?7.K/8H 8K9K.0[B^L0G!@S1@\XO
MHMZ6XB:TXN+/ #[*X';ZE@^$TP&V2S/7)DE-=G1#Q^69"RL.37]L:EPTIWK9
M/B8X]*QX^POO^6N?*_'&3=1.R>/4CI/VX?KYGEDT5\O0%#._(HF;E"P*\PH=
MA17\UDT2%79\-8D;^J),A@(E*;8AV['.$'E@Z'-=<%:YJW%>ND5QO_)HOVJR
M%#EO=&5]HI+YB^6VW'-Y9&Y6=^H60]::G30%BY!"/.?T99W__)\5XF.O%3UF
M&=I)K0)F*X*ZA0JG1%$% ^ G=5G,+X41^'*Q?#@U&F[]I>.-W9][K<Q? *;X
MA.$ XD%A%4!)_^OL-CKD,^ ^]\I#()&2W$]:;*;1]Q26E1)X_/EI<>B8O#.<
M+XI:AL[QG8ALS$"_&DO/84VYB+0QP2461L"<\Z(C?ZLXMSHG_"?ST)HE$]73
M:@,(0GCBSU]BS$E5^J:6$]T?+@ST3WFR:7\92.^T:%I\LCI=GE /_FG?E%':
MO&;N2+$ZKF69+9>^'"WRV>*R>K,DD]R$HN&D)R[VXNAE0VORL%M@J,*T'99J
M@U64DB_J<4YV[+A.T_*G.H?7_1J$D_"QZ9L\3"K_,>&W@?S^^_>5EV?P.S57
MI.])I)/Y<4"4N&Z"W^![(H8O@Y_VNGIIKSH3NJP9BVL(7%,MXC;QU8N+I2I^
M#-6++[8O[BW1XJFFZW^1DT*G0">DQ;NEJ+0/(#PD^EX'4!"D"A(-IWH;.#$A
MMVPV+H'XY# B-S>N="ETY5T^VN#<4@\O!7DXGJT4840M6^'@9,Y02&!HL,_Q
M08=IU:TFT^$*!K;Z+]GCN8)<ZZZJS%Y_XS+=DYT>#GJG]<J=.DS%+3J>'P'.
M(?= Q^RJFB36?I\C#'XE!_>PJ'V\F9PQX2(:*/93LH3DI'F:'_.=I F0\Q+C
M?>-\[+]@&/@5H4;.W3O\WEGGJQQ*IYG5[JP&0W#N+Q5#=_7#&4/-'_9F[)'^
M[A.;8%)0J8Y<)F^Y?5?BU7[L#>55^)-IZ]+\@U)IO;R/KM;IZ]Z!X?"CE[#[
MPY.EV525";UW_6\+EQ8>NX/[/EUZ\"@QTXERZ?J #1*U:)N3=[W(6KT^1]%0
MY2$_F9 G/'*7OC?+E"S*5LA=*=\SA_>5G\=7P-<.#!(Q$>KI%^3$9HD0(7%V
M)&_!XOCEFUJ[VV3[@.EIC6.QF-!.:X'=[3$QDBA;P<RFKWF#-O:?BKA[Z-.%
M:=#III6HWQOE5RTQ+-NOETLCE16T#<^G1Z3_"B2ARP/9T6-=]PO2;TAF%!NG
M*FU\T)Y4C'B-OPFBZ2)B5U?$;0;I?_Q';"5Q?L9]6N3.VOIG&EM4$Z?F'.^P
M*H^(FXA\]*AE/ISWZO%7C7H9'ZH )Y!*KJ&R?O!V4]0ZQRGDZ\LH13TE)F:0
M\>^M\4HCTUX?LU=P^9X"0NM*^$]TW=3B\12YAL7721ZZ?MV(/@C'2U7D2L!'
M<;F_6?$O8M%RTYYAIU^FD\N$2SP?&AEDR 3A)PB5B 30[UG$PCOMIF_?Z:@9
MDNC^$<LL8E_EQA85Q2MFLL;G_O.-K2Q&.$1P_'6$D6?#2RU3J4F5#Y).TNL@
MK*%OP<8N8ECM RDM(I1-SX"DL(]>1/Z>NEO'Y">) UX><D?'XMW+W-:EM$5+
M?N/.D](W23>N[]].J&MV$[-O6$(YV5$?=$9G718<N7MQ0C0V)N11]']G+ZH!
MFWQW3LLF@<0UY!X,V\<2'<(Z\LCSOT&$K*76(03!IM"8O%Q9DU!'=U0^A]DC
MI- $UF@S>]%BI!C%<*JJ=X)3_;.8V>DD^[#U-OU>KG8F7].[]N;\QOX9$'E]
M=]9BB/0NYSMP>MU^<)"/^"NG/9]DD=7W%Q<B%8PMENU^,E@_;U4M62(['."S
MH:4N.KNN0@4@NXMY5E/FK!:FC,H2J!!M- ZIT#87S7#!Q^A# ]M/_.M/9,SZ
M7X#KJ,6;^NG_"O&  X?1:<\(N!S@G=0N4%P2)UXM%I 51!F9/1*Q<39<?I!^
MQ)Y^@K/@I^6T ?F59EIV3![2Z)OBPL[+:^=*<)\Y'M&KHZ=!H_+6YT#7>XL]
M3TY%R>O,TR\"'5\A7XKW=60\70 ?#2<6&7:EBI$CYPK71\MBG"1K*[#O1%>Z
M_X%JC7_:DR7DS1/-*9+!V$L -(YEY\BJ/V[QI\;\<^2=PZE6-+TDMXZ@2F7D
ML-[OK;3<1#H5;<YNFK_1]K@,JZS>+^*&@_063?IXF%1O2BL)?>\+W]71G,@W
M_C*\I4;H@8XMV/= LB];6"O7:ZMA:#S&C%5XTW3^_G'1SZV*7_:5ARZ#F)GT
ME07<A7 :3UY,3D0H:D 6&-]E!<I-9J(KK"@HRJ1QCXNE82&X2W[G<+8Q4JC"
MS-+Y=5T;&HJ92A4;X.NY>BA2-_,!DS"WZ&W "R&L:5*\";H4Q J$=5^ I&OX
MDFG.Z1G@_7I&=9G<Z!?MO%JL018:NM^!,X.]*+65]4/=$"EU8!(MJE3VC<UM
M]L*=9AM%[07H;TY^8X^84@%ED5,_WCC\YR:XWG_R=^DOU2N$%U84PBIR2XK*
M\LJ*0N'1U<G6Q5!].(&HJSPU?LR'W)=E!:'H;Q7$!Q2*Y%H)QN,H19X8D*HK
M?F[6R+#3EQRZ>UZ.0RL9SP!'^4:N-,RBTO[/3<4'I1]U$J\3-$EOX97Y0<EA
MHW=U4\JQ$YVB86IUMQG&=X>&!.R$0>F:.3\MN/H2-8'K@$%RNJQ;%LWW<C@*
MM'HCJ%@GI0"L=\9Z!95]:KLB%[@[8U?+Y+93 2FQ@9-+@A[+::;EQV(AC<()
M+A!<S^]Z+"KAR_<C.M:>(MKGH<6P:/TM;CDZKK2W/"DM8GVK>4 "._JO,\D?
M9PY*2+X(KJN 9M@:B!WG\][]E]W3A/P_M'M$\@+-_)T17---CF?[8U.=GI0F
M)VN;58X_0NE)X>!E,=77:?8L7 L_Q+3?6E\(*8)M@130BE#2V.BH3>9]@XC6
M-GL2=#<F75[J7\3O)*4(T2FIL;'FBAQ.MYI-7'Z:<X)Z*'BIMBG5[>1E+4LE
M?GA='IRN[AQ2?#VLC$U<FJL3Z7?J;KS%7.H^9ANF+X:7@$LWBP:G^<E!YQYG
M4K(:FB!7?"TU<L%H@WC>8A@/\;+KS$F9FF@<H<)\*9?UY@MC+YT0%>8ZP@IG
M7_GW-_:B$?B"K%N:7SY\Q:B!HDD9DI+Z6+D'^'G5U4O(W@0^ TY-1X9TS/]<
ME?%G.?D[^:]0O&]P <I"EV+%=#S,%BQ+#H_@^.E90K0>H>GR+\H6%; 69.M:
M5@:JY)C'.K6U<:IX46'!#'/YV# C=ULW677]]'>2&, ^WXV?#WX5(CPE]94^
MQYDS4FF'40=5+IE)#0(IT88X/C_3?.D&9(POIOM?R0H'Y(>YIQ/O0$?B\X2K
M8U0<;R]Y51F'>A6N7KYZ\=CJ*Z1K_1H&EZ3Z$\1B^N7'FW&U[VEKT,:S#(YE
MP:BJBQ@6>2.SZ)/7'=W6PJ<D^7F#:N$4S"]77F'J IFK"29EY4G5:Y,*^D#X
MULG<AVN@1J5@^YPTJ=R/_XR"S#H4.K9^V-3F'@BO=?W^?H-"0OAR1D-QZ@+@
MMG.TTY_3OW5VI7$O<FE?564B/QO0:B:[8)0<9%PQM+"2.;N4#;,7(&03U9P&
M\B^KS(5U5WCUJJ'7 ,D_J/ ZERI?E)DW-%3<LI32<@L'Y4RDD=/B>'MY?UX$
MJV" M+IAZRM4C>;0'JYU$@-<G]LCG<JQI*)L:8$A2#:$()!$QX%, N(9Z>?E
M[713FF#I,;NP1!+8O[Q@MR_S/UA[JZ XVNC==T((!(*$X!:<P&#!W1V"N[L'
M=YT  0+!W0=WM\$AP=W=@KOKP#!LOO_5WE7[7)Q3YZZKNKJ[:O5:ZWE^M?I]
M&VJ5O_+D$_PER5;">DU!?KKPJ[L%6U#%6RY^C?X=@MY&C:(B&A6\=N"XAJ1?
MB.L,1&M*9U)FENFBY%WJS-3_R'YTKI\\W 2$!7=4=]0W&E"<)2YWNVV?O3A?
M"V]NRK:KNGZH;JV1M75:"2:+K+8UW1^XQQ*GX4F^2)/(R6G:K%^U]_DV)+)5
M]B=IKO1@4#M HUJC896B<Y;*-HG#6)SAU<(B0]U0/>^OX^'Z&P2>G^^7.F:N
M\%)L'9E;3X#,M6L94DSA+>PM=&SNJ<M^;1P<;@01:>7.LXN/K3I?JHITK#?C
MK4NS3308E?G*F74[5L4:6/'06O_,YMC,:H4;ORE+?YL@9O/MIF_^ULY<)NEO
M[+),/K8NTK\W'+F$F^F:S4<CESI\C/,LQ&G]P]?;=;,XWGPH!<7Q<=E$#_/:
M:7EI5.F4@T=R K9'7A9H[^^D)%FG<B;4GH___]G#0Y[L(F>]9^-9!U;._^3K
M'OVP3NK:?ND;4TC9[W :UE+N$:J8YL(_\4Y)N49K>[^X/,2J.%FF (4.D[B.
M<^X79?:W0&9/NGA)+57JLAJTHKB604X221_*/1W=#_2$*)I$=.JQD@;26%,%
M</6V?%='H]V."XC'.5-?UEI;N;-?P"*OP9\6")=AOF!L55EY(3J3@H6]>OSL
MG+I<;TJ\+.'BE:S0B.?#/,/A'$#C4_-_FU=% TB0Y3U2V'1[1V5I.:@35&55
M>K-+S:#XGEHN'DK7-'#'%?E:7[MZS[O91<&V%N<G_._G!M"D-6T8DX#>O><,
M(T$Z\*CEL+:FDE-00)1^*TI"19J 2$4$Y]J^0/..BXF(LK[W Z[R!S(,*E41
M7%X!?Q_*W>-PVM8V+4OC.A514[$H%S0$YYZ1<MZU%\ $/]3\N\2YQ)H1Q0O@
MIT6 @ <NMX8'WFKI\7-OVI>)V;F]DLX>= EGT^_+?2J0*U.?=,[D^+1/]$"K
M"+Y?1&)T4$6X(^8WC4LMW8]#"N3TI7QM 127RNF35OE:&Z=4"V5R7O:%H<DE
MIC(Y_0'8?]L9>O)E+ZZA@3!YZ&8M! G^,+&BW7'Z>^E67K;#F9<(M;(XJ8>C
MG*H7RFBI2*3;ZF/[:RLIM_2RD>,/-=;H&$Y9R$KRE&L#3_0F:D)<=_#=1QEA
M826AI"6'CV<,57AH2)@?I9?1WQ^$.+RBH@KH*F&I;8:J'A@@O5,_%C[(Q=;F
M=HI1ND:<_V$G?%CN!HKZ33T\MC@R2.+&1@6MW#)(5CU(T70G:]P"@Z+0Y2T?
M0X!)*M8=D9O>%_;%_KYO[0)_ZS&7<8*A;M0@]H#U0Z%5N#9Q3[/'P%CF"Z"_
M,VU]8HYPK>-JN^#NSK'6CN[PZ%Z(B4(.B Y)Z+&T@-,H%Q.KA^M]F(9:ZI:\
M &RU_8L7F7:#G;27W[!7U1C'E@6)<=KJ?Z0?H!HA%6P;CM=E#_]FZQ8'1)A]
M%X9.37+QY_I@TD_CQ+#^6&GW!3"9!6[M%.LRO56<>MBHX>8RVEFP%M6JHQXW
M+7&:G2:=20WCU-$QB@'3X);11)0U^83$*Q$/47>I$_]DX=R)J_#1'^Z62+2G
MKB5"BGU3_$9423%I:;!V)1]_-H^35JH_MX!4JBBO74%I98X/U@[W(P,$B/L)
M0J,6R CABE9-"]ZBDZ0Q\<=H(1X;JP;"6@8&$<6644UGAJTI)%I @([-89\$
M[C33\GN=_$0IFA6HV-WP'G)S:.U#;=BP#(!1B+RP]DBFN/ISN$-+Z/P1BB:A
M+XR;(51<N3B0W.IDXN0 !%=^ ;!X%&N] *ACHL%T0J;WC?:T7\CP/86N3Z.7
MUS2>RBG4+SP<+@>V#]/+2H]=6G1G$'%F&Q*G4/;-HWF,(\N /U<GFM(\;>Q/
MS88N;@IL 60%/_\IO^E-N$N86<$]4.B@S7H!Q*BUE,*G?@S!?CQG$4Q$@,<A
M4!>_H9-'YK3#@/N%I1;PUQ5B-;^3DRZCD51;-^_/).I073X?N>%:(OX(BY*G
M% U+&1V-7RRKWKI/MC%]Z90?G8V'N_U;98N7G:?;!._FGV\D_D%BR4N%+7,8
MH.YV0CW/Q+>&9.PO@/3B/^ ?:9&T\U#Z-8X,.[\SX'MV@L[.%5\052<[R$3U
MJN^S6%$8KH+J+(ZJ+.((3J,2ZOC48(VW+C>J:^/5\_H5"B2R+A*/&KA 4/X1
M9;![0A*RTM&Y(LH>\N5'+FUV R#=+ 8C!8PNG&K4JP3.<'0Z$_[MWQ*]<5J_
MGU>\KF=9C6W0R*Z=/!2.SCZ_Y9(XF_1;06TK55R#Q$5U^'*$Q+4A3JYD?K]>
M_V04;Q?5]D%!5+.8")>:2(NRD:!:4?M,V4%.%Q]=D8H\IH$(2]=L(:_QR@AZ
M\ )@8HD0+,\Z-)PZMTU?[U]V'9%LNVA[:V;I>:*=WJR=/ZFE95:RFQ-#@8V$
MK48C/Z;872@F<:?:V9-X?D_76RNYZ(5GH0OK-D47\N.3]>Q:UNX*HTXTZ06,
M*4%D>*'.!__</,?/PX6I H0<,!/79->>Q(6G]/C PD*/&][T7Y9K[:\;Z3^U
MT6#X9#"@XUI2V@+I34O<2HLC&SY)"OALIM.3-)W;M-2FZHT0HZ!S5 )UBX(5
M@$3%"$GC/#=-ZW#BDM'!(V7-2MUW.:65-G)H^R-EI[DO@! 2$-WC\S;&E%)<
M2YG7$5OIKS"/!;>[T[R>E+A>._8YV5 =DP)FR?WD-"K)]G@VB0_!]4/$Z45=
MR,,-\R$=7K:5 ?I^S3?:O-F]36#L\:3IF^=6&R4P1J4>!*[@AB]VT^@XF+U\
M:@^N;U7]C14^7FPRM]/G_\Y Z)_V!HESI0R0>E@V3L>4(TY56J"1;Z$[QOF$
MW]Z":2>/("YMB$J&<("L+MM]<W^J=X%U)3=N$1@YFVD%@QM@5?]_S6:N_ULV
M_S?#L@MXI'32&_RH#JY7QH6U-H)-X%&/_\<*<W7AO:$K1^C/NU R>W.N#;7]
M %H_X"(9VZ-=!7O:\WVZG]#3*='!?:(ZSAS!JCU^PH-BWY4JIVZCI(3+SL(I
MM51\5F&@M!YN5B)%,"2*?V5X&"<@4[A@+-Y&ZZJ;0L%55YFU955_4+WD8DLG
M7U7V/.$6U^F==:<WIP"]W(+=A+'ASV< B*93_O9+;W3)X+V1YSX#U[GAENN3
MN/T.VPU/VC43KN+#T/06ZV-NL6:LQ&UC+&.\GH3,MV@Q>@J-K,R4*R\5U%HT
MD1("#48O6."3C^76)I.67CIJH%'&Q_RPT>A?!OC7;0_OM!97Y,UF'16'_MHK
M=J^'5?L\[2#M'*[]@?BL\*=<M2. <=N/Z3;[-;IGI(8;RP+Z$N[G"V:PN.O5
M1KA-"!M*Z5JS62D)5?QUWN+A5(GB?C9V^^&HN1LT]\-RND+E+RN4U8"VH0\=
M,T7-67@\_U^R48.'M#[S_BF)X8?Z^PH#SWG2PV8?,Z?3L];5M/1PP_<V7S/^
MUD60.(@!P[?-0ZO8K(O>643D_K-(/&RQ/54!R\7_+IV4"557Z:U#8J37#P(*
M=!^;>?^HJ]1K/M2DVR2 JOR:MML5!P-O3(3405\G(E\ 'SVY)H_'Q\8=F<96
M,IZ(U3*7UAAF.MQ33T]7#*+SO*DR:+\N\NF6EM8.4:N1EY1:FR5M)U&P<:C^
ME#9KF&BF=T/%<C)8,Q-12BXFU]IAG_Z=\5#Y7I.Z=E!#TX-J/@*E>"),]CS"
M:+1G:V,4HV>M@W,AC;EWB72M]@Y&#'%VZ_*\C38K\>3P*@NG^FEN,K![N(7K
M5CO"@<(@RA&%DDR;I$(;GC5R&K_M&"FW^>V[6UC4M,0LNUPN!\?M]F[WK;S!
M, .$M92BNU134RJWS[I;W1^\>_#AN//R(64*1/D"R&!QY/;S/#M:]6?_=?!\
M?06IYD[4\%ZKKRVIR7!DU_K-CQ$DX,;8PQ 9495/1<*I84\CH7R)K8/:8L_,
MG-,0\S<2A4@R9#YPEZ:;;[SZK\P'93I!'\64CW^8>M)($M]/TY=J=ZM*Q2FQ
M)HC9^EBL=4U8_4.:+?+_\]FQ#0+2V4:B%=Q>:T/>WCM:YV=QG+78+$I5WH7@
M?A8\F&]-G>M!_X935";G4^D6'U(:M670,[R0\#&'W/6B?[J_CGNQHGO_5PDN
M(0'G\;2CQR6"K&G^;T:'0>$58%PT,@\/[V$P=!@&'?0+@.OJ%;<)L3JNKNIM
MM'B,#Y<?&/Y;)!;*]]\R&3AC3,8H@S!P*1(!3SPHB4ZKM?19YQJ#>,;,&[;H
M\?P1^4?XQ=8W*K@_+!>V2UB^GP-$*,?*SLD%IFL5W;==VUM/_W41H>O&P^'@
M[*8*L59D4(S"Z'M%&I(:,I1:869?D*]#=N716F5HOS&WU/:9053FXI)M>Q-7
M>C:]:@QZ?%X,=W+)X&P*1U!ZA Z#OQ)J:ZBQKD?X3LNC]2Q_PH_(*CK72WJ&
MP &.SVZ'C@M])$+L\65(\@ST_3Q?D86T)U)DUK/@#AL??7T;N*25-5X 1>-)
MZ_ZE##.W"+"(@\J!Z0;B5@VLI&!'\VL<9^7YV6':F)X/2CCU]4"Q>/Z\>@CQ
MN[YV>Y;#UNJ!37F2$.$91%,1Z,51G$/-\"9_(J2GDO2M?\@L0H"^CR'L%]S*
MZ*,0DT>V6<%3L-\9B97M=I/4Y(9V93C$ \_(>^<Z]KP]2I,%7QQ24JN>Y,Z;
MV2BI@*['R23P[4*MAT9#.B+KL_)<]HBK7Y#V+,[LL'9=6:ERP1&CB,HJFS4*
M!R[/T3UQ(E=E[DKKC\,WJ5D2@2)OJ.\R46/?*?+=]W;MF5QZ[DD;.SID'4>&
MF7ZO.CMN)Q4Z7,MB6.NP2CI2F%"**$LF4*--/:E@C4AGI5&@B\M-EPH[HX\\
M)"CYV5%])Q_5@J>%:F96:!XU+\'X7W$(.Q(1.0G:+KA$7([:RKCC H<'9WDJ
M"5!CZG>/9S'CP&-OMR;ZUZ?+#D9[UZI7_-<B_JJ<*0S-;I"V^@JNM51P(LE^
MDI/+G-76E2VM-:WBI?3*+RF+MHJ6V;M\;QXM-5<T)+@30#?Y2^'M$*54A321
MG8FN]W3#\0)QHN9ISI%EH5P>>ZR0SYM"O_*!PI0^I3WB2]">U(<&-G_.5LBG
M_4?%7!M^STK(V?#0[=G!R@0'^P3F)0FM:O8K$97(V0;BU*)0VE FDY&GTV/9
M--MCGZ8+*--ME0P/'W03$;'%L^[QP*?F*KG?5[M[F<\I$,H 1U3T0P'[(V3_
M#@KF7@""&S]<3_4MKQ:A0C>G)X@9MBE>CJCPW(?G%L@.OSRQ[MQGWGMW!::/
M!=W#QD7Q.3,**O<V<E/J A]PIMBK22J]"/)_BI>4?)(GPJ<BS4W%P^V38E#1
M#9XVVO#8L54=I2-(C%JDXSV;+@I-RQUC_W8#:K(:58I\>MIF8AGUAZP2*SI&
MN?-+4W7LG.J'2*3:$MFB<<3/S#_ON#OW:,CJ2&LASM:KC"@VRFI&R9E<+[-I
M<*T)8&=82GT*_9"71)V-4VBG.XL5Q,8Z?5!-F4[!5C,I5:G_#IEH(43@N"?P
M(/;$<=_U0L_'0:BU?][<MZORSM')\N!5>CV-'/U :Z16M9ZX'CH6/GQ^#OO#
MRJ+B/HWAHTJ\H91"54U<["G)S%L8UI%FB*W4M>V_D%" %8H"E]%QTAUZ@UJ,
M;V.QTKDU3"5%T(:1_.K!S%%?1LC 740!!',G"AVK_&"GA3MN&_6Y&?=B)??H
MX:&[Y//Q%P"FED]XR5<"79^R&5G4_-"2---@W=1YJ43KN] >&[ +VM2;0@#S
MR?"O1@Y<*W)U*.I"H9;6I4X2AH)V;%G9Z)BHFDA.IG>Z6@D(YP60*MP_D:KS
MO%_+-\+>WM1E?SO']%G<_R;&^1:N5<H=RIQ 3G6AI10\.C,SJR!.D4[S%.&1
M3NT91>UF0X5Y_%SDW\P@@U.N)9_/D$OU:_9G1(RBH,\\G+]. P6M72,I+L3O
M-7G\'MP\!9-OZLLZSX3W[B_VB_GMO&]&&PV&EMNJRVD^W@N"Q&X\ML_T-8?=
MK@BW5Y<8:7"_X:BI#.!4JZ%)>9?>\,D3R441\$%VGS)^S1OV:CX(R%)%=CTJ
MGQ3$@#%^%ZV9A Q[LAK]%N,/>9*C!\!>7> +()%[D!2RPO\$K?%8^^*@YAB=
M5@@%@U?YL7WGS_:'-NGN_G2KF4O,:N"R$_D% .G6;=;P^TBHAZ>!/+Y,>Q]H
M&^2UAZU=D5T.\_$N2:QP:1-AI=/^93OZA*M<A9>^,IP +VOGJTH0W\V7,=B=
MT!NIF?V\$<\^3X7I_:.[-:,A/\?^T^W8X]0C.CL,(4WX=5^$-761;LT4=#MD
MDVN63!:Q\5FSO2K^H^";B\C:<&O) (3E<B6@UNY<5X!>7 D>@RKGKQW6?S-;
M,T5)UY5"_MK<CK":A_,I8;(Z,GI?]D:/)NS<DJ8]*K<9#QI2DPF5'7KN3[V+
M/>$X']2X=+\79V/)XE*[#"D;^-G^W<%9/KTV_,:T+69.'27PGBK*3DXUK9)^
M?QIZEM\4.7R"\,; 4%V 7I'SJIB,.0+_M=ES=X63)BWK(1=?>YW'DN*W/=G1
MX&&7%$!)+^]=W?JYW184RRZ5-UW2=*ESTZN<+BM8Y068!&)(E,-IDCDLKJ^>
M>^FF,='_HG:%,+K@XA;*2%%C9M$)/,I_/D6+_GBLNFC@W(K@_\8"H8OYIU$"
M^-6>G/=%#_?<1)]4GP2,G.O/;R1X_)DV(GN$L*_Y9H-Q"24)24*%412461NF
M.<*W.-7$KLI1**6CSXCJEJRZ(H=S-;\NNP\>$MGRYC!+*@UJ9AGNNT3,]7[7
M;B%JR*MOY%$/00K>\\$5HH/-/5Q>2W\_L^^9XO];SV!0RU[9V$9F>E;98E3K
MR;P\5!J+2G*&S/".69J,X:'PLDW,)&6 /$*+5097$+["M?S'0M<65Q.1K>96
M4U64S.1P16_P_ UK^N1D$&H=6(P 09AU*FO8O-3I833:L"6-KE8=UQLX(,'V
M-2*4*UD,QZ67,N/-T*.OQ#L?C3FQF1> P L@B/>Y,F:]PUX8Y*DY2^S,;7B_
M2LITN>)VI_!Y(L\;J,QU638P.:3THQ1%GGI"7J"H"N@1X6TLLQ>>*;9:[4F,
M$RM-K/E#EM%:_P4@P8XN/AF)_<-Y2NS<XZPUMCY"/3%JE>71'F@=($TUZFZ<
MX;L+&B"=N9S'3&XVW%Q2@[F K68=FT[+(G,&MC;[IXYT=DIM0R)L==.]XPYW
M"])QRB-*=>,V=6--[Y3OL*6Y9Q(=L36S<,[F#J^K4ZJE/K@3#VR%$M&7:S@K
M&?[R&(=[@A'O+<TLI(WBSS^W')^-C$P:^VQW\MMMSQ\?^P=GE(T<<ZA,G45F
M\Q$1Q%>JJ;O,^;?KRK!0 K[;L3"N]1)CU=/(Y\D3#^8XEY5CQ_"AN84*'J%P
M[';;VEA&S:%[>;(%@AGW\U.N8O:J!Y1"O>"0,;^(#=F%)]^&^Q"IP16]^')B
M07M$C<34Q\R":7.@L;0<D4R)#9#:9J?.Q^UW/1U-$__WE7 3U&1@ZR\2:VUF
MY+1R-(QD_75IZS=Q0:$<B!>5'\RAQB39"61H0CYN2A.D;9W<2A(S=^H\_L%9
M_<97,Q[<>CNM%[,D:ZP5>64#D3^M&>AM;=R&*PKXJ/HMHH6I?:J;3UU.OW\R
MX*3LJ*KNGN&3S:W6:.B0G]3A5";R9&!) GTD96F3WP7+NTUXPT /EXMIF?W(
M-7#%V7-&D"+>BGN25WN496]A=#V%.+,JW7I\1*UQ^EL<UW9+RV2.7_6-P4[:
M\JXX">3O3*>-*'-8<SAHBX62BL%:R8<4;E%11'(A?W*!0%<Y-)_+JR/IP:XD
M0<Y+RYBRLC9?WKA^I;6LOKI6XHI:'GT:Q:W*X;. ;F\U0E%T3B!_V?!D9POX
MFXJ/>]V1WM'X7[VK+0J#]]-"(GDLV-D=SNZD5>"/,VJ(AK05JTA\#/X;L*4
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MU5/2'L65@#;23I>EUTY$I"B_]!?AA'3;Z6@4F@>!]RXJ2: RO1P$33W(KAB
M'8&1#HI] ;A;"2>?#Y]=PQ7!C$UW2TNOS<?9 U?SYO!LM-],BTR^Q45M4G6
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M+?67;:L(ED"WR_(2A-""D"\+,0A\3&2"87_0YV!-'ETV2K!N(0G8*71FT<U
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M-T':HDG;B:)1%I 9SV+$84+)'7 (F-I!.>B[P=1Z 3"<3</MP,0^QT5"NB\
MSO-,@YD9J$+IBIYPN]69?>5*!B::AX+*Q-Q6/=0O>JU_CW(%DP2G 4K/6B>
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M38O';0KSL?(B;"V>Y/0D";1? )8L2J>%X%U:ZG6M\6&7 !#F-U= SJOR9)>
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MUO8"B&<QN%U?/K+?")[PJ+I8XWFNWFB\78R*B]O@9W#XIV<YLW]46S.G&88
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MOAS'%\6EGP@X)T+>DR>"5IU5UPH)0FCU.MQ\Q1KN^*[4-Q5#P>)N)?'R&.<
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M26@417O;5H1HA2$1-<A$X40/95_N$ N[+#[A>(:S^7-EE5MOVZ&1OU63S4$
M!PC_>U! C*VVA8 U^=3&_MY6F RH14+A(E44_X2B+2*IKDV]/!I59XL.GUKL
M9@O97W3PF,E83Y/6JB+D@6FE<_%'V)JOPB#@'F>')^[^+W*YA6 S2\<+N)P1
MSC@"GIAK>12\,',_:2MK-K_9&>52M?+R$<)JB^CO;C&5)\2MXZ[@!*G%5/V@
MF>H>=&QABZFKD=&WZU#X*&X>D;80ZKBTOPS/#ONNFHM <=Q<JJ83O^O&/QI<
MA$A&!Y*1.G!U9T9^Z+$INJ>O\3'UY?3I/RU;/<NSM"E?N:L*&73IZ_L<3M&4
MO)R*P=;GEWUNR.-B9FMJ[W;0^GWX!Q"H+EL_<^O(*>O,7?X\Q$,60E?7$(7'
M]2:V<X 5FET\*?NZ=&;241%XU3S(K.ZNKXA.+ &7W ZAR5-&54\DN9_:'G_Z
MQYK'AVRQ-2^ A-T>@7H"6Z-/PZ?HGF0^)P)#F_LC>NJJGYH=K_P+M2;I7.,R
M_7G-UPWE"E@M\$P!<7.\2]R/"0_1:!AH%A)*P@O"0F5#,:7JRJHCSE1UH<('
M]\Y.'X^(J9R^7^J8V6T6.]QA]83VK]6DI,TC*V>4M]<]/-+<DQ^5%3&C(H2!
MW9Z8+$0@$EK:O&J6J-J[W)/,OW>;9SC;BA=V?\W@4!]YZ['4^=/MR_/C@A+X
MX);IO# G$,A#N;KD[$^=J#9]=G00.2I0 O40#XKCH"D,O*4%5:\L]S15/\<&
M')C\@9Q3'YE02JG]]#'3P/YYR%'_+[17=$O^(Y_TB?Y$_9I4*2O9EC*"YU+W
M@.UR6C 1&=9.C_1=>%)L;.[Z?L.^]_<H(^L"A=$@:L&= C'EZ8@B496[5#>-
M.VM,!X_[5O-9WC]3O;PL,>X'L#5)JE*7?ECCEJ FV%A%^\O[O3C9@?]DPS2D
M_SGW K)2MO>+$OC%$D;_;05.ARZH2@JPR)/&\'D\?Z>P14X\)D.OV*6V$@TN
M2N]6EG4N#. \+P#E6T$>WU.]XJ2\I?EFF/F7N[3AE96H-/>:Z6)5%*50C9-!
M22MM0N#H#"BR1F;M22TM-U9+@&1/K8) !OPZ#601YG1\H:= T(W+D(H7X!:M
M)&9'%*%6"9]L*N/CTBM9X=+PY5I97\Q"\2&QLKF]+YZE^%CIDMS_ HAM&UBZ
MSK!L^)KYUDU RPI[H>"GA:,S" (JWBC-X&@\T-.]-\Z8-"#E9>.>S],;GOAS
MP25!RE#OHD24SNKWZFPZSAN53YF^MZ10DU8C45FLY6L,O#NF#J,7%@F %>_5
M>>G[QHD]$W[.++W7DCE'O$,LC&T[QQ;WKPMQ3YNQ5)X9;1X)6+D=>!6*V=$+
M^FCP,>^K:\$>2<W54R9$"%EK5^TY$F_]OO['-AR(NC;\4X3Q+RA;Y3]*M>(1
ML.-_08@>_@*3<;+]1GIIE)Y>,-#K4&1?7BW:=RB^]$;!X+[T!<"?V3.TQM'D
M/2.W\ *@J&<0ZF 40;4H[#6I+S.!>(.^Q3'$<?</47Q>JHC)+U$$ +DII'G2
M@YY6C:AB9'3&Z :E+@J%IB9'FHD>6F"7;*3/HE]\A[*&2I 0C-=%&/#7\*)*
M@#> RD_PUX/08<?_@71F_U.@4H%D<K0P;O"]^'5OAD835?/)P"^XB,=V<:+(
MZ ;AZ&T-CXB81'G>S^\M,Q&+$7F/)S#O#]PJ5J<8?=WKEVPPDN=,51O#]VG'
M?+B>,W#D==: GLR3'\%X.#*^Q:C"=?6BY"XR&>%9\EY+8JZ-/VH>L8V@?TTN
M*??=W8+3Z1YO2]C8\.QC7TH.5(NFJ#)*@OXSMTXK_Z_UGZCYIE1?>K.C:RD3
MK!Q*Z^V)0/E0G/ZBG*=?SO\B]K/?VL/JS_=SR&U^7\O!A8S$9L_RJ!KH"?RM
M=JFW"?OI"O\+@!E%1!4O+M,11#,Y'/1-TVV)EUY/,^S;&HG5$8T59\\2[ UN
M+&84+75T_Y7$X):,O<MA(N?WJ+?-8@&[_L*V(B^ BT\+>I^;A=-M+]T'3G\3
MCXS>)"%.%(:R2HR6G)SN21>M?!1]3_I=V10X@8$.O_ "PG+-_SA%0:*59'YS
MM:[3A=;/H])]"G56J:63HDQ[ ?06WU^MLM. CA>HH?BD'N,MLUF5&A?[GZ?X
MR8KL.LYR%'=2)\EH[0P]PC<E'^\2%SU=&R[(Q 32/^#]BG:S!D<A\NAFE$!L
M# Q>^D>#QO.*NX6/0%BL41JGK."IL<O\T?:/<HD4\VD0@62R] @473G"']"G
M72=!5C9L5$?*?LPH78PWO9$ ,LJDCL\,P,[;/]T9.\O:2$+.4WVH6D7[%^%'
M7RQET2\0[- L'@<<E3K[,+P#TH_=&^8/_G D F'N*Y=G)M/_YDZD!7/)D!;"
M3D[JEQ>W9!ROB5W5]$&$4"SA7U-#W+(1F]%@'1'/'V@A F0IP"4F:&%SZY]O
M%>EFVU'!. E4P&;^[3XD@V\3SYBH$_'"75^]BZVM<X7.B4+: N]\D5WC\ F/
MY[% G==\TX_<OCX=N=AP+CGUJ:?V#N[)+J[6L\$>(40#N-[VO$\@2!UX1&>D
M;L+!2U1,AR>KE,5JF,'O[4YQ,WZ*C_X'B/'J/YR0_"D 7MJT;U ;^-FTB>)6
M[)\N!=U] ]>^D;+=^>K:N>1J\9%811*-K06D]TWQ(SK9XYA< ^HV*O<!P!W3
MV/([NKN_MW.19R0AK*<H EE[L+ZKR-[6DDPFX&$!QCVH.!NWNS^ ;>M':8Q0
MYMU92OSK?3#(RF?Q4->TLP<)WL_8G$8$? 2#Y;ZM$$W?A4680-A<LMKB.1)&
MI^6([#E)P[(:RX+*#^G_NU&LU=6C.,+7[#<SB;$_+L92[OQI>4'XQHZ"U$;I
MS]=9%(6?N,Q9?*]KA?*GCB\W9QN\'Q-7N?Y!'&>+K#HI "OA@.WOT@O@RT5+
M"4YK"7W7<1CRA+$>:L'!_1A-CU]B9/X""#*^W-_23EF:5(Q)%".U5HXNFT';
M;A*4CI' 56FR*\35+"HJ+C(8]<]M>T/';E6:Y)<3!Q:I#&Q5 1B)B8BN)MI9
MS+3Y<F9%9 U+=1RV,\ZXL'<_0U:Q^.6*/3G3G;P\5C4-8JF6(LHEK?/(B0)0
MP\,YP@OE ^F)Q'D73^MA6IAH;[Z'16W]JB=[I.CHG9QSI.U5AYPE^7$4YLE@
M\<:\N]Z3:M'6TW>#$)\W\QK;XL9)$V67&HWCOX7I)*BTB2=,3T+^)-2IB+R?
MGJ);=:CJ/WC?2S>9^5^D'9GH0=W19UO[OWL_9G,-AG;?U_'3/A-:(T=+?,36
M758\Z^I]&!U? #FD6$N; E>-7@IR*%&YI3T26F^4Z;6/OW8C^MXE96;F%E#'
M:<I?MH:WUHA5+:++X-50X?Z4[;#/R1'R*/X]CH\&0+?.,5YFET^8S1'%F T7
MZ0I.2GM0"SMGV&[GL5;<-JH23E$<Q#3HHZVURQ)T:-S.VE*80S11C$C0*$&F
MOE<["F@6ZPL6,I/*+HG/.),<F-+2?@LK_Z%+%XK"4^'+]IO!6G))HY..C46=
ML.BDPB+;Z,]WE0P*'3:XKLSZN+S%!D;:.$ 2FWF)\RWEMX.<9^#M\PO@/K#]
M6>\D>AOE3'4-)N<LGI$(KO<TVM88C$CTD84Y3UO 2XL&,BH""CV*ZOYJ::A7
M3<\(<F>YU*A)0^GA_K_%FC09YF/*=P6[.H*TJ$-PIL@!LSL!?FAA%K)V.?1?
M7:V])NLBE."'DY--=_T#?$IJYT4E&+/MV0146UW3@C(KJP.;]SE7#2:N0<-[
M[/5'V*>Z1,).)VR]"%K4T+3P#S_+.V=FU$RJ>?>#@-H'?-R9<26?R!/5HNGI
MCGHU,&U'-%063I+B\DVE-&/NG#"'G7EIZZ1GXD71L*5>3=ATO7$E_H"7C%$H
M17J@]JK W$$$UO\[@DHHO8;(8"1YW:S3&E;O&;PYUDFUHX>LY'NT7FN@0-OM
M*J3UWO!MX25M-.Z9FY@S@G]9<)'N@$I?J%H/Y_81UVBPQ@;?UNDUN+28ANF$
MRS48,D&%E>$D[L@>$+O"VV1]T[;*!HQ]K)[F,BCS&;O(Q3UIH,U'(>^O+X!O
MT;&-P@E4^!UQ0C=[SR6(-NMSN1I7_>>B%X!H2QS.2=!8K^G#*F/]31OEZK"Z
M\J123U274>[SE<K4]%284Q8%O;4Q7D*H-O]%6RAB=XG8C,%),5*A&*/2A36W
MB6[O6S\41511;95=8DO=E/XU@V]@4,(;(J7\J==I05\DI(M0\CB0@SZ<OAR4
M+X#RNRS(? O!O887]S%[P=&@]<3YH?</'W%?!\ZFC_41=NJ8Q.RLO>RIG(0)
M$-Q-R_;%#.,O)'C^0/XXC<K5^>/GKTDMJ92<U16_:E]%@DBE+;K]%"LDR>H*
M9G8#E6W)\H(DS]_1_=3&Z!5\1>WAW"3!,BT#!M/KOI.#T.&V@3G!MRSD4=FM
MAF#F+?2Y5[7L)?J=-[?DE$$42B\ NYL&)!., N%=$+U/%?$"&!H2G"(4C&S;
M>PC_UN:X<.<(:M%/9E1+P6AM%ILG5"I4@!'6QD'>Y/U\<TRM::A#$UZ6NX!I
M;N)9^:"AJ4P9<T5:K,:06":D]W;'>YC?S=(6ICQ5TCU3V%B&0VI_@*-Y,X9D
MVFBH;KZ)KO?A\&4?EH+,G$;"Y!92K0NRQH82"Q"7<U.%IGDD-2Y$:N"8 '*H
M_F]![GY3-2Q"_SUO>^Q^6MMW)T/[UJ]^>3@K3=;*3K;ZZ'E\6+JN"*E_@((L
MSED*FPK + H4!A65T:+8Q9_O;UX "V3.9L_L?=W13_L;-S3;T;>?.G8"^YZT
M?,)<LXZ2GZ%=+P -U9+:&XH]!/S?4@4R^2)R6QY? #B4X2^ E;'W1WK]'1=J
MP4?QSV7"(B?0?Y^,[@5@\:_1A_P/2*93*^NG%N1OUZ#ESO7S^2/VL>47 &65
MC@$%6(I<64EUH_I*C?M\DEJIDE7-)$?OE34!)XX,=4O_L(Y31'RWG$&6$67Q
M"/7[M_^K1RK]@A= 9]27N[(*9#:/-=I2W^0/YJ_J#W?GV./!']'S2.JZ=HHL
M+(3^%$0RPPH9F(9-9"5E_5_1+KO37O.(8V6(:L^!2JVU'Z[;S?A8=2.4^F3=
ME>>"Y2BW[E%:JE>'5^OY*NY]D7S[[)/WT3,9>%7G5+3MRK=S1K-' @K+?T[C
M95+^'/-^[YTPKE[XI/$QIR+^&)].4H^]?'U+_.9&-HF9?FF2[C,M26XD*-GD
MV&R()LP+1!=_@YV5M%4W1-]J/@G$<N"RF"29T< 8MI2= GC#<LMFPR_@6?=(
MI(DP!X]4KWR#D['0NYOI1!+%\#O6'1:RT+_M.O0,_!2Q94L0Q^WJL=MP V[.
M(44YDNE>WE?T88\!KQ:-'WY\B=#M2]52*!R?H0;Z-19(Z P)TO^2Y7ES'N$Q
MC!/REY!TUB^)[O=L4, 8Q>NG^!< %]<S4>H+( 1E<^[Y$;Q\[$4U?_0"N-16
M?)16B)5[*MQ^ 7#'/Y<VJ+>-M_! )WVIRSL07[YSR/B-^K*0>F4:X#+E$5YS
MG5)6604I:.5BX,NP6%H"31-#Z+=B,T(-%2M7MFG9CVE?0]G3@IH($Z9N5"DH
MYJDMWZB@8KY7WK(DJ3@^*!8255.$_#,6E'_DE%E&:*Y\>_F<W;%S:?..1V"8
M,B\ U"@Z":IQ@&"HR]B]%@YRIO$%4.+@)./[ J!3_G\/,XK"+KWS3\EOC7QI
MK NF+YS?P09OB#V9?^7<?Y")+3]<S'@!^"/2(?5TGFFLO-\T3-UK[)7"G!G'
MN#YH*,,6V37-\<EVDKO+ ]]V4LNL?Z !@_K.9ML-LF0;_K+(06DGP/*^2A"!
M_Q)EIX1[9-V?]3A\.3.3G^TIILX;'MLN"9I? '$-?2<-?V\T=$^>&I9K6Q!U
MS7.T#3SLR_U]7RDKB#)&-RW/[PX&EN3D]?93:@GDX1-5^#09<;O0^LSZB=7^
M'CUYCQ]V!X,BJ&K^$ESW3KW;V.O<XO(W(3F)=;,2P+\_WQ"_0='U\2;-Z&C8
MYZ(ZRU\H:9"@9&'+6LP:E"/+ZM/HDZ>+RF+^^I3;JZ:N_/&#FJ2L?*07L'-D
M/6,\G>NUIHY"3UC8JNK%F>6S0M)D2\63Z M@5C\IHTL._,\P8I#?!<;EP8+2
M.OB1;8_)1*FE01S_A&S^][-H;MK'I?<#Y 32)WY9<ARTA\>LF H3G/$_'?%0
M^O&C<(ZSGS*8$_];HA4R??=*F'I?\2PS!L&S1>5Z8S:TFI&RN@TYF]O$8C<S
M=2GG+Q%20=;=LRRD9C0H-MWV_@DJ3#V/_>%RC>IC T^W3H6N:?EL\!KC$Y"*
M%@A$#Y@0M;5US(VQ?93KP30G$[=RFUE6LRPP?[6N.B7C="GW>5+B8QZJ.T7M
M@3,Y$[Q[OPPH?47QRA?-Z"1->&<*.6O^+&:SDKB\/.M#Y93?EFYP_F@S=VS=
M6+<?!GN4A10.JL]MF99D][21?Q94ZS3[KZ,!?P'E\6]D_:$J1G_QQDBV]-^T
M1-D8T:("2S_>.4&>AK<?DBD_B2[2S.3(AMV>EW"4,<>YJ>99_T-M!R)%P.S"
M[VY!3R0LI[!D^7[T8?C$8J-0''H ]WYLJK( R;QWS["_>V!ZY9E%R)15\!^F
MXQ1!,_@";VK[0=IW:/9>3:57^!_W7MLWYZ21$%-M&<V0,3230O4CX<_VTSJT
MS4SY1=PD#X(A+7V?!,X4X($$Y*F:YZZHL<IAE71^^>+D]7L7:G=9$G!.SEY%
MF,%H+=U3&U'"ZQZ5 *D9"_L_;QX"D"4BLVO"7&>^.-$]D;=BEV(?JXSN8/[Y
M"]>>L_$NJFHBP07![Q/[?G]-.?\)S=.LMHB65OF-I8%'9)XZWH>PU'TWO9AT
M[@A3[%%!%QYL>_^9F #O_.K.;:9D_>\;C<M#O5""7?;]9_<L3JX.#/@S.<1F
MN>;<:).-$>Q;4R;5NA-&63-V?$0!-D9P@LLCXWY]W4^#W866Z5G3*X/E#D5!
M8H;I\N^=-_<YAPW^,#\5<9->;ZX5IGD]8#8V6]Y'4!*)BG_HP7I*?9/!QW6N
M7G?O@1WQ=6X_>@<O[MEJ%;VE82?8U9?%INT(7%'%WV"N=!W<AW78\?7FZ@@+
MEMJYI5\8Q"ITU"?-@TGF2?>!%E]*3Z$66N<LS\ !A,O86$DN"ZC'+E>RD7U(
M-.+H_ENLG7/,^DXW0!<[00IK=::'O@M1]B:\X'VP,TUM'N:XGWT78UD"=.2_
M?#AW&&FIZK %I,R(6C6;+(95>U7E[?7-6PH,OERJ.P5QPK@7 #O0ZUF?*=K>
MQC>6ZM/%*@T+_'L4>8;D^?.YFH3*?09&!5+"7B84LYR]ZN[/*^YHPW8GVL,0
MQ:-97G$M.G0DB";QHE@XPX-ZN](G@?ANJ-]X7>5AGG1J#.4"IK:PQ'UW_!/9
MYKLNK3D6^5!TT\8X)J" ^[?62+;1HBKUN*_.PM69@O._,G+-?J/B857IJL(P
MZ"?J9BD\9_SY6<_CRJ7S!X](S<&[0F'Y=8L#;\L)P=5];0,WJM--;;,-/,OK
M7NWV+*!S?8/^T6A@]'KFR +NCWK71S;;\R'4<-Z$?!@)SR(1OXN@<:\(C%ME
M8R'?E >S5"\E3K./<XCY=Q/;AB5=6H;VM?UUF0<)G3DM!F B'X#*7)BU!M.>
M1[(>L%5<6-X#O.0/1H_N><3.88XSR/ RVQ#OJGD0H?;6L@Z/M\V[KZ;L660)
M)9&.ANZT_2**(JARU:K=F*_6\]&E^%N/35K'Z)3=X+1/QK)38N*YHK(1]D-X
MW=-7'Q"Y'\BLI"_,Z3O BXG3U?A^:-_6F-I3*+!7/PF)(Y%W/Z,.VF:0RT(L
M7F+WT><&/VZC#;:JA&D>/D%I1X^05W$C(@'+SF12W\#/&LFA!ZO=C:W6G']I
M!PB=):4*+VAKJFN6Y-B7N<\&)RHYY,"<&%!C[%^& >=K4]P7RO:.]J8H^E*$
ML<':?!HJI!,Z8BAI69U0EK K@!<H]]G\WB C:^32Q4NZ^ Z5_9D*Q*,^>Y3:
M;J)B6[]L9UW*?5T\-[YAME!TM6DEM/I?PH!@ 1NX.'Q!-L4&7!^N VI\R!!6
M*/#"3P/%><F&"A.7<_=AQRZ4[6>NYYR!W+IYPLC48]"B \[V>2O&YO*JS@(*
M?;X?K^YL+^D-7?2U""?K45G:9H6X+3<L9%'X?++56Z9T:2?'=L1'N'ILW\P>
M]!6HEM%_2R:_%]Z@-PJ#:AO#T%QBPVXMTZ40<2R:)TZE6Z4U0 O2F(/_^BW2
MT*845?63C\^6V#8%N_ZJA[R.)9XVGS<DT2"BJ;NB,(@V]!WN6#6X,[.Q?>K,
MF@?Q1M<ZT0KP%8[=*12^+;=?'>39M'JDS P]X*&WM3'A)X8=KT?EP@2?CD<F
M9I[N(CQ6,(!04G/, !TE,6GPWS=A[C/YUJ.V!/U%!F ^XJQ:8^3 7G@2A'A0
MD/+[W)QZGL&\G9#:H:[^FO?M"P"KYR+ T#E28;47:>![I[2RM:#CS /FAIF(
M55)J#Z;)>OE/P.41-&R#Z1[0P!S/>\@L?MP'3*YZCO?S&0<F3_-DM<^P\#SN
M3:D);8TM;SYL>?JOH^%@*EV-1A<W#^0=Q'FR]CY:OUQUQ_9?0, W.GD7O/2D
M>J'H\ *@/0XX'_LV!]&T/F[6;FBH[Q%:Z5,)B610"2MO#X*1119U*U*P7CD,
MR-!]&2$4[S[@QCU9<*S5T>VC>_V4CXU1]HD^TDT)%^R&R^GQM2W8/NV###A;
M-)_C241$ 43C_UOD8H_SV9"?IKIFTQ7)&%S.+^=AI7^55+'#TTF1V/J(8F)&
MY6&]C%!4CNA3FM[FN.<+^>[5SL4CVVL,]W ;T75TC[#<FJ287WH?.9"G'N$M
M.*#VHR"^.1LO#:\S4T_#^4V7*45 %B5&)4B=&T1]']#;9@TM"GU05A\LXBXB
MIS_B1;Y/Q^EK?,RQ57M$GCQ(N;A\Z%QLOSP(T70=^WOR9Y&*H]FEFJDPM?VT
M< >4"K6@A<4QPV!9:)9;YD1_DS2I ?ZO7K-K-&O:_%)Y 9CQU>+;W1G_ 8%>
M1XH9L(?>-I)*@V!]>/@P2N8T)3SML#"O!Q9O>P3"Z#[OG\-;C1*,K(3/\9S?
MKKEVZU5<2$]):4]V+B=>\A-@MGA2Q1=PY&+\9I^)/-C@Y!N3T<.<V(M(G:Y(
M6ZAG:Q>/49$+C=!%HVT0G!;FH39"RV"(<EYFGXB9H0F1Z=[>H:@CO/A/P7%Y
MQMN7@11GETCUW-?G9"P<E#4DY,[CV[^R,W [*[9-1&7<-^]@.U_]B4NFB7[1
MOAZHKCG"6OL7G1ESC0A3LVJ7LW[F^I790S.K<D@K+57PNCFJTUWJ=<5H&^'1
M4*,;7<_5-?OV=?#<AB7UG*1 U05,:NK>T^KI!7">7"G\F\K1J__D])=G%D%*
MGW7Y^OW'B7^6[#9I<TSUZ'?0' (1Y3VF%__'K*C(P8VO;"H4!GJ3MK#=#U&=
M)G*3X*-F6%GAOSO:J(U:4U6S;SW([G]?'E.:'S0I0XX*Y.-"$,MI-'H&!_/I
MS3)PBQ).Q_Q'JP1 [GFDGVU6=:3T0;TL#G4;_KP P@Q>M[_SXAA3,6W 49VZ
M#;I=>DI-#[#>93EDR>+^0F:(:<H)_%UZJ::>8LG%G#<J7RT-B$4L9=?49_0L
MS7T@8".Z L*3 :]!_5HAVBK-7/*J)0MR]MRRUIMA)*,:RJRB<=)\N$S%FV"W
M<H\\Y%(L#Y)^KB&OL+1[3NGOI24+L5">K2H&IJ/(TV.VDY4S9VLH6(RA^JR[
M'(+G]^9)NGRQ8Y;D@(0*%4HR4W+U;$8D!)O+)0OSV?50BL8KSE>VV+S''/=P
M;E<81Z2 "^J^ML\A4@;E)5&LCH\D5_]L[.5HTA3D]:CVH H*,&6_"6/*C13]
M:<GTG+GA:M@='P=6%)L!O%)(\-F?^?^_J)+/:'QMJ^7*/C[@?&I[/=M];!V0
MDN3OU=YWE)$7O<KK >M1I("P3&]R)ERKJ=:!Y#G >&XD?4"Z4#,EL7%=&>C?
M#5-)HCP6HA_*8J+H EA\-IHJSDP''Q5Q_^!:9+[-[?E'7#!DD^\IP(?@!; /
M/#)XKGS\\@\@WB\ 9JX7P*B%\!Y[[/-^W0O ZU]=WBGD\OL$7R(A]LWF>+9Q
MDA= Y/);L8F/1[_<K79EE:]N5@H6075*,ZH:]&!]A+S#.AR*WQP6E2U#3\";
MB6[R=@"?LX _\F]R'^? !C:^I;41X5V)/MIO-R/8<Q0>56 .MR]:XE1O*[/"
MMT</0A>A[ODGD]JS]/=E]3;3A\N1]1;"P<=MJ54WUY13W9MK[)-N3/;3N%,3
MDV);KM9XHN'%J64.BK47@U-5KO0I:4F&,HS3\?%3_>&X&-F +P!"@)??_J?V
MYO>YGF*N1PI_CT83#_2[5]MTX@J'KY-N5_7L@Y<7(INTI""H3B W\B31J-P&
M/%4B:S:0J)P,MT*-&"&\4WHBH'(%;%,:VP)OS(/7,/T09?J#BYY#*P2#RUB3
M]VC-:!;#X[(3>4%O(NS(^:Q[D="[[:!C^/-3M]-;F8V6.99;@Q[^$K(932 %
M0O5V>DB*9\F&M^@#!T]:+/';.4WGSC=@IU?>QQ6%;K\8I#@B0H;J?W:O6RH*
M*]2R&6EP_E+:1;V*E+HL\&K^.R_\X9G;9?86T9:ZV$'QP%7#3V56R/$U^;L+
MCLIWGDQ;XD;MPK(\DJ-R.2I5 W%F%HK=7V)*F<PI@VFZ2;>-MKOU8N0.TO"9
M:?@1?(80!/"SC[AWWK<V3 UH9N%$TB?@<^GB [GVQW>/&16O7AW9AF5]\.@R
M/<UL.E3\M^)S&9X+=P_#BB9'X,@IA*?%CP8B=M$D*&F8U<EGJBA8SI#JF)BR
MH$#LC A0 %^& (6L.C'>AN<#=K4,:\0AF'6T)RDH]U><!+;][J3YT7J@+ U-
MB89*H%)A;E V!KF1X&>/,3A?0X%+(N7?_?:Z>0JY*HYKT$P"&4OIC0O_CPWJ
M=$9:L"HK[Q($1$^N,BT_?%'=22I%GY)$]VCJ&<J>TEHZVIMH:CAL$447/U4E
M&L.>H 3G106\TCVC8/0(V!S[#^F5/;S1C)/GX9G/D1Y5GORIT7Y99-9-O\Z_
MW8/.?#VSGIR-B-!958RL.F^PM#\?'O..\M31$[2/Q1W]Z;5?"Q>N(%JN1S[Q
M! )#,LPO+09.2'#_:AS2\8SB176L=R]L?F/6+1S9\EC%PEA07+'BV5%P<[/6
M/R,G;DM8YPQ2PY?1 &H"+C]8 TN\@=G"V,?.-IGDCK(EF3.Q_KM1K_:;6*E3
MZUK-1Z(VPA2$C)V^V:[D'-A,S\=?VYI=^^K="&M!I$*#8.4-)X.]IYB8H3^3
MF/<@YQ\QH!&>983C(G2 J=CW?612!;'2<JC#2:-TD:DDZA&ED$ );)&WH/W[
M'S)S8D4F A _ZBD!;#XEJZ?T6KY+R[5ZH3^++;9&1VUED85=UADY-6=.+68?
MHO+R2'_D9_=-2*#2TW/+=4H0,H7Q0E"6Z1(+#4_D.$"L,G3Q.S(#@EJXDJ^+
M *_^ V0#W %\[$]59ZKK9IXGE_,4$^?"FQT6I\G^&-#(]0X^7Y2F"\<>N6<H
M,&VQ^2,4:!@>$\H:5?0>%<#UNA[ATERCASL"9+,LH$C0.'KCE&:)SJZC%IM'
M262L8G$?,+[[6=.Y3,J@0W5L+IW4IC0>]6DVOHQ^T0G?^J;7_/P%@,UKI&#?
M&]"W_^@(WICJ#;<_)DGLLL1T5F^&.VO,MEI>[BL$TH)1F655"1_Y7G_E^7/Z
MJ\VLH:%W<EX8[YG'&ERQT#CHQ6ADC126.SZ "EQCT:;2Y Q/O0!P.+:*<F.2
M93T"XX@<1HL^AK(P+)>7?]26*3 ,*I*/D,U2DOG;A_</R]2_.//-43"^H&=_
M&<5"<\L4?._6'K*'I%*/BNR\FE-;?U VMZRRG+IK;^TVNJDL'!BC!X-Y$>?*
MA70BRJK<DT-4B^9Q&N[DQ*;T7,MR=)DL_!_*G)/H2PZUY^ZO+OZ$-+\NTB?]
M[Y7%C=T>^<&87];;!S&7B=.3[+O(\Z&RAE&0GKUGGYG3S=NW"047=KUQS1A$
MQ05FY!QA:JR\=%&"\*;EDXH/XC6RAWURTL/"/[CW0USNV$:+-B,5X;D!C__M
M61RWQ^^/(A<=CA3.#MI;CY^20>*@Z+H6%C.CVSI 9E;* 7XRK:(RH3,>I0I$
MF882\G-W4<>SF(U,5Z&_ZYR%Z-N]/Y^/.?ZZ4W_.SXOOZ$_!^1TR7KIW"^?E
MZ9_ESB]S^ (*:)9P"%,O9Y[<PQ8^ZUJ<;CXNV%]5RJG1-(W3N[YSS'__Z'#P
MX+F!.2GPZ_L'4RA.HLQ!I78/E!D?B-(G&UAQA%),L7">M=DQ(&#*B'6!D]><
MUWSNAM%D><;MG5-9E;Y@;I;A),/VL5]58;J"QD.W6ZWY07LSVJ.N/:T[*4@J
M(E94.2Q.R(FV0M&:8CR_J/Q5$6:.GW"*H$3^7<5YF#\,;FG^S.<$ ;F*3SXE
M2\_U3#>B%BV<$TMR'+L_=PWYJ;M-A.2XL0^2+/EY'ZV.B@70)<3,BI2UC%$>
MW?HX'W;.4JOMZ0\SFA^3\]M'#^7L+BID[='/MZ%."!JTW*Y^O\Z2O?ZL=[HR
M.:"VX\GC>:3?V'5,WKM96@K/;(:VWLA122GJ)!<GU<,+<[9+TC0L"I/4C>BB
M>N3GXG6!^5%'14QAP\.$2AA,='Y,@+[L_93CO%\U-/ DD"'AZSZ&_)^9C-&:
MS.T"5UA4ML9"(LI7MHHJKK/:L1SW^B>%AP*L9.V%Z'O9O:5$9(GF0:;F&A1@
ML"S>H6R8>9X?#B$TK_?&-$34V)$$A'=@#9A."RSCC7-SSZQER_LG.WIF_V1'
M_+OQ9+O8C1/%R6G *A;/"\!<;#E]<P/65[:,J#3F:'(^RAB8)B$?-2GY,DP9
M52W[$/812%]:8!+1Q=\BAR<]R'<W)3=AD_REUU#&6 V$BE*I3<F+EGIY$&V$
M64YG/EZ9@PF1P[ ;88E*+#DWV\0_41A8D3L?RIESO?V*&#E:65NVG.;W,F[0
MIW*4C#6NTDEJN7-=-K-O0L^-!%J4F&2^FR$RD<( V![N8H1OR$B/YI,NAOR9
MA;,$Z$XK7=OFAR19O],@-,J'!#*+1809!A<C/#?-^O3R9IK:HQ:]WTZV&!7P
M +=5[:^>5PZ&B3]8&G_@([*4L%DMS XG4&,APE6@S[=E4J*;^7&JZ,U=_2Y-
MBA,#=WN^D3:0)&USB/?0TIJ4,:@H!TM$*9L-AUPE]7+?8D[/8HY"N,;NR7FZ
M!<7XVM7 >G6#:ODI=$Y'/<!XO<@W?$913^/&K=68L):[PUD'HJK\.0KU0I&U
MNFTK-J5!L#M9P3@Q=7ZRM+N&% ,C3F:-^<;9+4>:D(8)0O[:#U!<\2HJ\Y9]
M$9$^96.#E='J\DS@8DVQ\&OPN&RJKH$=B'G"PQ@Y^I>>S47XDQB$O+8N 910
M/81Y!B;HX5:8Z"^-$,EWX);_*(.)3AT@BMY/'?7&G;)TCPY5\S4ZM3\0G9<Z
M8%Q0ZEQUXX2_F'/Y5?3=\KB3(%YFOU32J%,!E:+U@5Z>#@0+ G)0FSFN[6,G
M+<QA*2HZ>!.GS!6Z%J3D%4L+C&]<^NCER)I)O<Y0/\NA&%:W9M$7Q&>TMXYW
MITT@=6:A)V#9F;"9U0!CA?6.136-%O9=,=AF/VAP3+@EYLH;R&WSU:#&+#H-
M1?Z>4<7P;@*AK*\37HN/D,ARY*H8ZP@+'31,T65R]F^(J1AC_SVP\RS1O=\M
M =7:9'Z48/Z97<0BTD58*-"LKWS]W-5WI$U9D;W +QE<QN%I&&R\R7<2;3TQ
M];WXK''0.+>P6R1$6H,*FSTSBG<M+)&Y&Z^S!+\73S1(6\.%73.)KLI0QK![
M.LYMMJE"@14:1@CX9R0Q &C,B@KA<YI>&'=2D^FC654>P1L\?=@UJPF2CE$K
M9%2%+L^+_9/>,]W^8>5Q_LQ% <5 <1P2EOTG 4\MQY9E??90T\2YJ*38%)].
M19D<Q%J]M7(?:19$XNW-SXF:&X/)47^%V[W,HGNNZ19$[F.7V:3M:.F1O+%F
MY'*=)0O\W%(52^!L1E0%[I^;U)SD!BQ>2V/.+@[3S(_4H]!$.98H6$KB9)V@
M8"^$VYG[\@7<D#N-=+]S"OJ&"@E$O_?1DSM42#D4RCK RAE?=JQ;0P@J5WV5
M%"Z_:9^&5924$,Y'F##EA67 #\S2VG-5 4*RH?#\XB31*3FNP>%=C0^?G6GE
M/I74$!O]5&> H5#%].D$$?U\8\X$?_US#Y"].2$S\ )@P?G9%!V&D%JWD<L^
M=^Z@Y+OE25EZ\JT]=+59J^C_7IVZ^'"4H2!'T,0X.-3$5*+?0*^](CZ$@T@L
M[N=>K3D:NGU:G0:MAGBI [@ V5\ &$0H,H0H;]PUHJ5[IVP^X9J3$L;E%L)E
M&+)GLZ=_S[:AW65MU2#K]^I=GA=2QZ+-*M>.1EJB%OEK'&^234Y&>Y88/P17
M!##+B$0L:>EN*YB]DD,33<NT2VD>I+Z0+/L<LW+BJV4KQE*:YO2U +THM,@?
M"%%CIL,'BO3R.BLNS?9H:8&@I#*F9E#U6LSN&"#+?Y*.?27<"$_?#[4W)V\M
M?] 4!;ROKVQLZP@)*F_VRB^6"_+G@SHG_9LA'$JGF???Y C7T*>6_J.M*CI3
M=ADATXZ&O"],S.-X%YX;.+T5J0A4OJ&M7:5C&\0BX8S#%H?3PG1F6 V%*K<I
M([S'Q)PQ?W #GDFC7)!7%B2I*,>A+UA2N62&H.IN<)&\)D??%,5&O\>5DCDY
MVF@'XQ?]N+P0 .+@^A@)XE)F/HL(#V;E-^Q\KKKIZ,7 ?-[X"^DR" BHYAE=
M/_IMS7IU$B?UI=O4P=EM,)7625U,54XH8'!^/B"\W6[)5JGWDH(Q*E&<SJX
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M %J[!!OAM:J3ZQAE[2AW@MJAP#YZ]TX->U46/7]%DE[+:S_@NF1\[\>95IN
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M^R*3VKF\RO\O]MXZ*J[F[1+MA! D6'"7T+@%@@7K$()+XV[!W8);!P@0W"%
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M#;X1L3.P)+QZSRYY5@PW,"AG*P:U=?T87;<?N.[+NO$XXUI?]>P3A?2*K?9
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M\1(&?&6E0,\]UL&?G2;U(M;Z5WM_>^,E6-_T;0*&OW@\Z5$V'K3>M#9BG2Q
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M9WQE/QR6QSNLK3\V&&#_54?P*]X&+'765\.L 7CX.0&,<1KN$1:B3^HZ%9
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M6B4RT :=_B^^$*J]L+?1TLIS]G*&(U=[S@8O-HE=ZUAG6,#,6!<J)#'F%R1
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M-ZT:>"KTX@6$REB8"5O;SC^438O<EPLYJJG(([C+A,GKR!,28HS 3:($Q$C
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M60YJL022&!P68%&!I_6"^/LJ?.$)F2&:R(6+]&-.$\^\:-)G60NDIK]'13&
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M'A?+=[8 +&O[XSXDFZ+__$T9_UXRX/]HH!R\(UY3\J]2JHT?FFKB_Y12->'
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M9<LWN(2CB0M6\M."A;)^#R/#( .E_C01"0 *>>-NK<'WWAB];M.JN.,));F
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M*A&AT5W<!?'Q\6YO:M*IHE]T4&#_Z?4I'L]YG:MTCJ(!O_KQES7#P(ZZ.M$
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M/S96S*H@)*1\^VE;]L*85[?E:+*3\!2L^'@3^Y$!6+5>"FO;^HK=:";'=#
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MDIU7D&OQ?)SREHOY0WD5;TZUNW3I+Y:O]SL._A@^F%Z?8D7R8-1+@Y:I! 9
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M3[LA3A&T7333ML6T['1=C#-\YMU52+I'/RE!VXS3%[>&*3L@5IY <+^PZ9^
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MK&YM)0\@7OA)JHP>Y?RKRZK#B#>'7GS;^R5.-)M#7ZQ)4=M.S X00HD3*#B
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MS?]OW[OW+R:M;-VN\LLI\6M72K=TG&JA*5\9F@;%#795^?@HOBZSU#6LC9T
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MWA;N4O\!MSV+VO@)-9'C1[95!%8,QNF[2*:6S=?5:#,7>QQ_A3?V,_WDHJ5
ME>*-BK-H_U-&8]?%J5WX"OIW1:FOR:L5GY/E>?0/GEO39(#O?IWWF[4:H/U-
M1N#LN.XRQ"A5DUJ_Q?2?7T=5W-5W4]U+5':J;$\%@[%*RD$KIL;9[Q2WS^P$
M "W5DP?7F#/I],2>=]FSV4EZ9BMJZOP1ZWM=.PM ?14S:NZ_&TIY8/SB2O5;
MSJ3%C+*I!='IQZGIWG<,82?#A*[CX5NIKJU]("UZ#1,)L*8J71WX%N^+DF$V
M+59]&@D:R@QT(C0@MQLE'K>>7!&,&EHZ?(<1:;\K\Z4LFD_+1"LVTB&_.*_H
M4R9;F-\72]ZH9PLQHPD)8=3>D5ZK5,4-7;O;*Y:&+QM/.UV[TLM)"-O6R]H6
MX45]]H.*M"F#O;QJ1R6SOQ0]?%72:P(&">>^,!@S ($-I7*E]_N$B[F]L1F*
M LU^B(*SSSZ^T_;8,_JL"7-V^RD?KMW%66V_.-#3T)[QP/G)L4XF27"\-LQ4
MO< )5OW7OVTVE"]FDMZC^ST1_D]MO1 O L:W(_?F.),:"V43N^98B'=6<^$\
M,?VR87[/[$I^CH^+Q,G=6$MA2KLQ3VUXQE81#U14$21*D[8- S[OOO,)A07T
MQ!;.^M]V=]WMF#O/$;_,G*6-:74?GV-)/UDO__[=^8L*IIC#<'S\BJ%250B,
M,L9U2UH<>R[)P#N1O9&D<J(WMZM7AS1:?_A03F^FR,G6K)1C3\=<'7RIC]Z2
M/I!9#<JI+OK\KXF_5Y]7"5*KI4.A_R.3_@/(K:)SE-0?F-5X.JT&-6R7'1[9
MR;B88,^LUFU(FO-\@=6KJ AP\&76?YKVO7M:4X;6U?73D%R8?OY+WD0!38JV
M#(%%(Y3;>0**L(PQ"S=&.)&A.U$S^(2F@W.YM<N3W4N>CSN"^^R*JVL%=3F#
MGK)K1@PFE[QI4O#[W#4UU:4C_4"HX-/Z)SN*=3WO"(C9"AS"W8 133N@_'V^
M#<;'V,%=93*@VAKUWONY V-EL8O@HTE#^\4/;]QD F;.AIABUC*K;+\,'FW=
M-*'0%V8%Y,8FL:E0\:.7FTD_?6':]/E^QBM"/(H]*O![6L8V+)0,\,G=>;@_
M5&DSK_.- C,!MEAPN1;";<EXE1I E?_C$+N9^(7@=(!:^21G/!D0O$L'M(#E
MMZ-F,Y@GI1-JF0G%K1N8G>L?=,*Z]/5MMH1+6(8$N9Q#/S@)\EQ@^I;"IRG#
MY##_QUC_$*M(KR%7VIFP"VU3"P<++PQ\3G9#@TO<CJ+-=^;) .\]L]2 W&AF
M&5LW2WCXT$9AU;%DE\B;*?#H^)BN9/+]E$UA=O\*KTI\ K&#=(^X'.ZE>M#0
M))$VX+4CDZO\>>K]#H-YV6G0@DSY01?1T\G=C$YOI;M+)*:Y2VEFLB"SHV@C
M49;ZH4(KOD'N-4-7&O2@Z&_<]WPWA,L4/I=6QKES;K56'QV#1\?&U?K#'N1F
M!5?<MP0KE<>HZFAI*8.?#W\;[^0M+PR<;KXI)&>%RIH;WXM(]&3],GOD'V0Y
M#6F2 CM]RLGK'A]GZW,IWBQ^E,<G+9V5EZ@5)O*L=(SYNANV;=+ON.+P \E"
MN6G&W+ST1+ROE=,'%K3I5(^P=)3RO^WC.E31A/,N1#(H.N]93-%PUO@J>W5P
M:%X65S81;JYU#GUB1'E_-X62-826K^,K7X2Q=^:Q8CB,Z+"(#VK!7M3)H@9V
M"97O SLB0R2>ZD$$5#4O_\W6ZJ8FU05^*@KF#=,N71^=I,R?_@2)A'Y!#6SP
M$_&T]?YP^B2"YY1RX)77>^W?"WYL&%OXL'VW7G"(>X2?0(U-O?/$?XV\9/I>
M\@;MDT)G_4MO>S.W%ZZED &QRN)UI"?'FUVE4SAG=_RN94A;RU-;U\>RBY '
MSI6<OLJ<LA ^%>W48%<-63;G]$\<S^J:KK\7XHU3EWS>OTR9!\?_95%Q%Y)$
M!IQHP1XB#BS]:\B ]Z5P*EL2(P,^)OI8!$H0(TG>OI<JZ#R.0?W N,!O>_KL
M RSLW(5^:('M9ZN)FA"<%?B!#S0[YQ93.4ID>-63N?D@\>4JQ^,6VL-[[\^.
M4G'KKLOOT_ZXF0Z/+1+X%*C FZ%);/^.A:WEX6@VXO1U(&A_@34'VYH#Q7:0
MJ(9VPVM7/Y' RTOYA66IMZ7#3U,XAHV-39-9/4:EGO-*=4M^?K.!7&@=N#PG
MX3ZU3:.)OU1]J_?O$+T_;O.$W-1^<7QY%D<&3.V\74P?Y'-*( -8U;(K1=3?
M;;MRW6,[V/;B7H_$?21VX.4.R("6M\P'TWMTB<,ASB=J84IN%VLSY3/IOZHU
M29AS3*JA*1OZB[/-O9GH=[O#B@+'_F\S)ZX+-;TFD@&ZY],G?_Y!")GH'&B!
M[_D_+%>:?0(3.]Z%;M"K6')#K#.C_@N\ZG++^1I0D_@2L]"Y 'O@K^EX1 :
MW2 U%ALGBP2[7Z-=_-K@X-2,:ZUU,MZ&S3VT2A)]2L-_J[/_6_PI T7 D60
M08/8MOO<5_LH:9"SPG*&0(Q@*<O[@&X1\/(&#$U,*6K2RCXH\;%^-)%05\?
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M]A50#?TU*K:P\%=*\=NWN7^I<3V_KI&O97EG!Y-]:D.+I%A25-( X\8?^V3
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M!0P?F[F?[Y#:%@/+JNLO*<*$K8X5_2LPKW_C9N6KF8XD5SSVQR=-QGZ%FT)
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M8G1TO=K33O"W_:_5Y8+BBKRO=ZK;,\U2.,J$GMO&49LX)/WKVR*Y/OY5"F2
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M3T0626*V1?-F6M]%AI26E.'8Q:X7Z>%@N6VT=I*-& 7@\LF Z(N&.C(@<6^
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MIC>6D1\G3I.AS&!%_I[!F457.;M%(BM!O>UH_>UN<]HD$S*,[4[X)%IY6FR
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MV$)5">P+,U*5&D85O_K6,[MMQ3[(1*-4GANQO"A7%@T D1$."? ?X-Z=U$F
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MB<L0_!AE7I4:186>N##')8X_#<!<HE'3ZSVGJNR\GM&N_6"S/"QFOO$LL?#
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M;G<6LPYJT#;(BL>"+8O^X;ZXL$Q;)"IR7+MGS%:=V ^M1,/9]YE9;5]?W1N
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M_$_O=! PITGEG:9.#GJJNDQNV1%K&MO@/KAZW+$W@T\MKMN7>K _INEZW4%
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M<GEWC7J0Q KE?NF!+4MX\1N9MOO7+WIZG<H^!MLR9_G,T2;\1ROL_]_14(+
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M6#VLL0YRVJ?L_HE<,K*^._8SJMFS%W!(>D=)W+]Q^ N:4="L'QU%HW3$;*Z
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MCT:25>&+$4^=.@]M"-^7?1)VHN*3%=E;]A+\'L1K(?BE;QX4;71B'7#.UP!
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M,]>.JDQUDKSQH'/"_&9N[$850MH[/V]F[?Y,/&K/J$)9ICC:DA(]TN?]A88
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M>V[.56529&582)*3C/E#:SV97AFSB5>9%_W/HLS[?]@9^Q>#N#U,)4+]RNX
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MRK!% 3BI4(#PMQ(IL]8YY7^)<IH5.B$Y-_J>^4-=.Z:-[X\-#^4Z9EMYIW3
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M53DRH&%O^?Y8- #X+*N_$HYWBRW<*XC-'3;-LK_$^EJPE!V7P- ?=Q#8>T:
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MW);E[TI$!0H[O(C&3/C:V2_9&?V-:&",(/DK4;>+;J/08.E4_TRI:G[+':Q
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MP\U6)U+9GP=6)>$ZR;> )[3WZ0*LQ4^3W#%*F'5" 4^V9;Z1:2KUC:8:8=6
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MJ2[!C$M$&S6% "@[H"&_I)1+\ZB+S4F0;>'2U,1C_C;V./T]S6#SIC>_)5D
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M:2NB494'^@5SUC_8@3:]7SC?X:4>43-J.B, <3.9 [:PRUJ!*H&W_G^CN^;
M#-#*Y<[YTP=I@TNI*Y7Q#^*ZLVX5OQ,++^\+KGX>O+OO/&=Q[4, 2(7S2M"@
MA-%1,2,';H.IEK5+E#93WVCQ$("@$. :RU97^[/K0Q7]!5DF"29)HQN+V <
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M&DSWZJIO "YY4S^^R_^[]RI3#VZ]3^I^M> 35^F!-0D-S+4W.9WB&Q-35",
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M^MP89E <DB)*/+S&:.=!SHB%"0&(#^D%?G&]CQWS8E^_.3Q3K.ST8)\:VO1
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MAN>3Y1+>%&=X*(O;8',+S76@UE<BFQ_Z]P-.$H0K_"UB7Z<LGG?A]B87/F/
MZPT^I#3-\5??UDKYN>RGT0PI>0[."4( ,HLS=['6=F;Z_-<50_YI49I_I8$Q
MCC.1"J;6D"R1PI+25A:WBVE4DTO_Z_GZ^]IJEZ'Z<Q&'S(\;)4R6(^MGBAJ,
M+-75[\^[E?ODV0.EUY0>L5)GN>L8T3F8H8]M>^ ?^6@0:1  [OO.*00 A],
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M >@#'?R;:U-U1\!=65F5*P@ @3B5*SL/C0ZD^ @!^-INVE!PQ]0F;04./,+
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M7+%,@@:$B*TUPKQOEY0[\B7WI&+5L^#S6<59\T1=%UMFADG1%#Z2(;K-O6/
M/O]2T3LI-_:7GHEYP5$@]A'B0<RRS(3D"X;NOA6_\5S"K=$>9&D']6T_L0\
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MA'>TC+/B%81^AW!F&H*F@>+"RVX8YO_)UQ$-P/MV641MO"?(E:97>^7.,&6
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M$]%IEJ6?K@S(<"8SZINNV=IK^8A]2/!EF:\5<8!6U(CW@^XE?5WY$IWJ\ZN
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M[9H[B'CWS06G:Y7_SJR&+: 9=79J3 #EDX^.I0/#4K*O(+2LJC103,"FW*K
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M:>)429DDN0)-Z>&37--I58A[A2,U1.\>\">B^>=8>?> 9-HKKK.<ZZ#0]'M
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MDL\9R)V(S_;$?EB,Q"\V)Z(+\VRW3YP6 5F0X/#7<O4N7KCUQZX(;XFY:"R
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M??$]4C8Z*X+!B!NO(;5'*4WHCLM8JK)/NMV*I3YQN+?'.;8@?T]"++?@EP9
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M\C#P)[2R[#5WT%*BM=SZXBT_R0RJ0'C63P,G@J:<TKRBG &Q:N6IR6%"\ZT
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MW<I,Y)G &WT2W#6*:<>9V!^%F_CKLA]_S. FK(,MD !LM=W-.[O_ZXF[?W\
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M19JF.T.*9H9%GN["@P/)T$(LEMN 2SC+6#.M/UA@&MBEDL-RR+&[%YH<!?,
MN@^KLKG@?37.FB6MTS2B^R!'*Z.0G&EZJR0.V;#VTI#&BL@R>G/HY=& B)$*
M!L /"I1!*ZC4^&ALO[./ 3.\W,L?H'!\JNYM=K?!TM(T=%FZ3X?"Q>HH*U6G
MI>@4U).E.XF&3#1F)=CD'/HN\UJ<W%[]-/+$H%7B[+ 0@ATWH!34U_:A*/N+
MCO:QD R'W_#=Y[Z-/HU6S258NF&INA@ !_!38W0$!H!]CEUN'_,<3!4$E0'I
M2!9C &+C27Y^N 3(#LZ29?#5GJ*08GM+3SX2K0KG2HI:Q0".2.:X3NR-ESM=
MP& Y!G4@AZJ* O'R+'EV0<_C5EEENJ4[<SQJS,JKM@2-[(_AJPLPL_.Z)KL_
M*H3VVP!./73Y3,9UC7#!T[?()1N5KD'W,3*#.UA%6Y*^L>^^.#NE-]9%TKB"
MRF-']Y7+(:(M@\!]1&X]^3F;];:IH<[F@5Z# $$&KXF@KJP.D9IX!KL<17[W
M&Y55QO6TWL'6*:(@07@QA>7-,7">@GSR8X_ 8[\PIVNR X/$# =VO"L.:TP'
M*\VM'!0E&O(3'@GQ/^5B^3S+45MJ1R_.D[[[ZID2?O'BV$;(X:9-&2@9IC6\
M8C@-?%H'JJAS=1YIB)X,*_W@2BG$%6%)EI-5\$Y-+?E='AEQH*LXOY3^W9"M
MWP(V8;H_T(88 .[EL];O!.&7=\F5F.XP\3;*7D$8RE\/@L)$0B4,);%$2XTN
MI,X:7Y^(DA,\#R4F?_5YQ@WAU3[7:W@TD5C%)A7=8DS3K2)-.!&__F'N&> C
MG]% /40^6>B?# K^RGTDGVO/BHUTU'<YK#LXLK-CMTG$R*'I9@-CVX(%'7[^
M&3UZ^R-;>T07[%%<'0:PJW,-RC+_/83C?_4+ L=-8@#+92>5KM]KTO[?5&5P
MQC_#Z2B.V)MY_?.,1--&Z%**PHZ(7MZ(@K@Z6NJBJ8?^AC_MF[YS2X_<>+3"
MGTQ$#A0#H+<)"NTIWD6VS"7'#'D6)UC*,8^.R7RG5N+3-\@NSLAM,]F(^(#7
M?P+^E+N*?S4ND2/_I5',0Y2>]R@#68U0]LXY;#&]=M-]>&.%YE4-E?1E)%]H
MIZV9CT05YQ&+.JW4LEUSR27YZDC<H=YTTFF0.VITYBJDO/R2Q&'7>WX,#OY^
M#_VHY 981D7].:(3W'P*'^H $\J@WB1).KB02=4"+J?<3_(L1.1+_/^?:5._
M']+RGH=B";-ZA5TBYEH1#:SDV=\%A%%3S#RQ5IWJTGUL)J1BQ<[ 3+4V%=+2
MN@<XC40XOQT]6)N"HMGMCHO?V(SOYZS&'DR^,L]?+/"UMO/HVC]0=8,2)0C2
M0:TT-X^19M,V]^*&M_.@D"%YRE=+O@?WTSH.)<YA7I8>'KI+R+W0<X(J<T16
M9I3C]C:-R18BX[6S=!6YW.HEW_>:R!J;@IJA[6W<$\FM*:7O9,ZTUNSK'P;!
MP] [UU9]QS9KEK!\0"XN,R<C>TY5M4)%@+:%;D[65E&2]7D.'EYUEB'7Q[GQ
MWXXKB$ )0/HZUU77'@Q@=5%EV',IR&71H;&HRIQ#F4+.A2S;KP14;__0#;%9
ML+F9_VA3NC V2 ;0&]HM<I9N*:$FQDS6E+J^95)BZYSZ-]!T: Y*(,SC%2[F
M,X\(J:WE&.I8]G4:9IUV92?SA2C%M/?(Z-!)SP1D)B_6\@;[Z3N_%M)XI4NI
M=GL7+3?9U- S:J?G-T]_MJ>\&Y-'1!B?W!65^_&V:CT=?OS/0(^VCSRL7'VA
MA6/!X!./H'$Q/N?U(+T ]6R^>I7S/B\S)X6FN@H;KY0IO@L//Z\Q O+;BP5N
M%KBPZ2;L@]JP%S<D+7OI]FA>DFF]EO7)H[0-F'\>XZE^/@_IYZD.NS&' 0 O
MS0I<'UBZ.0X9M@DOA&(]O0,G4 A'X^A1W/ M$\N)%5,$"_:S>I<4N3WK#(V9
M?P&*)VG=74-:S;L]+][5J4J<39@-=^";S8M/[[1Y]VDGO##3SS@GJVMX2$:%
M5;&A_ 9)N.9=Q_>I/JQ,8[$<=W(W.J L]T27T8#CV\+?553Q"O7TU?D9.<4'
MUUW5/(H>MN3/("V)WEFP%"ABQ[;N\$'R'#LR@$UH9B_]'=+#EZ<*'<)!\QEL
M% XKJ:XGPC@.4B\^^3YQ9]Z@#V^0Q1*?JJ(%=(+?4P^/N]>74;<(#D6TO VM
M+)F0  J'O],0<<'K(>,3%*4IY;H4V8@X93^40*O/QI$5JRR%#DRKT"O#\5+J
M^DT]-K^H1G 1MJQ84+_T633THZ2/P:6*V)8QVQ4^,[2L4>9AND@T.<8 ?%C,
M*#SH:E=VRK>5B@9-&V."K_UU/'3_%V$D!O"I#0-@+^KLX8'/@6CK$.#$?(6:
MGWN]XBX)L=]FC8Q[=BX022+Z91%JA:JI3!&%W7159QFNOLO$A_O(#'TQT%K2
MMX%DD7.5=.U4&Y?)O(RVL+"?"^-7.WK^W:G\QSBI2#F7O2W7F*:7UU99=W^S
MFXD^C%:8>H<_BW.L91E7^:0>"MD9_1(NSMI!R>4K#4 G75[_4O?.GA.T1KO?
M[78NX;NE2 GVDEQ*6@Q NZ:J+7E[/Y3.>'19* R8D[;%JM<]?KYQ$G*/2PB$
M&F-TE6.C:.?7LAV:JZ^<PHN?7+,!(VT6O+[PJ09RM-U\M$7WUBT$6ORUPJNM
MV*4\!KCQE"^45.V3_9*W5QA5L;N=9Z4BVU[+M29/]_V!FI!VVZ=*,?)7D,#!
M /"@FU,>W9_G@!3"<J+8]Q04P@@O18$T5Z6OE4FL=5M2W&=EB#E');5E-(.B
MQZ9ENCR_8(G!JQW%RX5'9AU0_JOP6&&3"F49[8$-_!N7V,0/+Q761PRA+Q20
MBO.ZY^O;=JO)X]HC)&(4/5R>!%8FAT1[#*D<Y<(DGNO+B=Q?Z%Z7&4E9X#'
MZ"-E8"R.,?!;Y-&YK0>1B18M!Z)$G&O:GQW66*C.>E\\,BT/^<Q'"X"CLB)A
M)B#ATM3UQ:,,DYO74L3O6LWV]%%@5Y_\_B2-$'%X4W"<KAK!=,ZHIA88WK(E
MMCP[4#7];GYB]W1]T"<*VF&+D]J3?]^]22',YBL!: <':7#-);*>,#2A__Z
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MOK9HH.+EM#(5^>\FK623 6H= _C\THMC%O3(I<9*!)65TXF"G8/&]8@N8%?
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MTZ.E]KX4)$,C5T]5OI\V/'GEBG_Q]&S5@1^P"L7)7+[Z1GON%D]!6DAR=8[
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M4 D\DEOQF\PJEM)+S,XW?4[C@T]W\Q75G#A#J8![OT*_-)K3_MT*1K#(C'5
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MU+M_@2LK1?,/"&T=^#":,FBZEN[R3*&[..>W?&8H+U)[=M00GU)EII=*ORJ
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MO4J"7I'C2]6%<)Z8!\:F7!,6UF">#^8 Q36< ],.<)9NMX>(;3Q"-,I #*D
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M@.W**D]X>EP4^-))6$NH@@KXS$_HQ^/99>BZ1+()N\7B>$YWOY]85@,?=^8
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M@OK@\"!&Y076252/'A;V*K-Y4VZR3G;/M[Q7X;D_S3)G4P%IKA6(I@^-5E2
M*"0TQ8+?-'+2!TAZ>,#0R]ZEXY"5EA'J"P^:=![Z:>>09V?S+.T%WW+HRYX'
M4EEZ/W0-U"YR!_/17$OZ 7]'OA^""N#%SVN2*P5<)D*N]&[@4V]N!1_7U!Q\
M%HEJG_N*N+FZ4DWP_:7*2 4T9V,V-DCEA!XF/2Z#)GO)XV))FHM:>X5,A/3(
MS+<M4.Q&@)T6/X-@Y.?$T!H_F3TW!G/R!Q(W(8#U>"$WQ+A>!"TMY B%@ZW\
M^#EU%43X9K\'@PLM$YQU#==X[S9WL3O5'SY>(FQ37%!=;HZBBY"R1A?-$9.
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M99$?]:$6IMK!0V$7G[$LLF_-TM*V](NMS(<J*"LYM"1^C8KQ+#3I(WR&$\(
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MX=.+@Z(<NTU7+TRI(S/C#IL(5M=JK]?H/_;J=N(=[#-5!O\310'_M]CW?_G
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M8LEX2A_)&H3=O]D5)GS^&%NAO?E:%S]\TTX]HSEBA/8YBRH7NUFW]F/-<_H
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M^MS]9Z_$BIY)$ E:SGQ+Q^?B\"('VVT"I^[EWG1T9K[[,[:I\@_Z6T5>!#N
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M &=:L9K@7CBD) L^*5G7[,KNMPGMA/?S"FG8/BCN'1KK\#UJX#X>K<?;67
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MTPRD,;YZC$9XRKD36(JGFU3E^#$D&3E3(Z'XX>(&\/98L*?7IEI=XU21*5%
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M;YE75E3X1.KI[===&KU1%ROAHGG:W 1QPI9R,W9<9U7R&2OZ=3]#0OK!S$0
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MQ=VH6;V,GG>2YA9D8D/8#R3MJ!E4E$_V?R>)6:K]1?0ZW@6K4B6B*#FC6RI
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MJJS !=$U<&<'] 8 D+*/+9![Y0:*H5W&/Y/P?N_.M&6][1UPF*7 _M[VS)B
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MAW988AKIC[C^I?B)[)-7UCV%4A?R@"S)",*@GW6,>\C,24ON:TI]B&(1KV+
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M><-45ZDRO7E*4%CKV4P"Y]U@GK:595W:.UBM.];.T/7( =.?1VEB"SO7VD!
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M&A,*KP_?BC@D0]JA"?RH&?C""F8R>5]7 '\$#P2! W0H"*R  .KY' A,UX)
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M%'G ==TCVM6J1Q.#BDIC$IP]UIZ6WS1=?VY?O/!X8,>SN$3.^&*U$KUB\>E
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MK +9V+W <G&6DUEI<J_4&*4IM:(DJC18N<.O+YMOGR*M$]^(_S3E>8&E()"
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M$#@)D[Q%:K;MP"?BS8I<BJD& =:6.@)U2VCGP2U6$A%U!7139>I=CYPWPVM
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MCI>^<&VHZ_*CM!#&NY23>'634QEZC9,^N7WCLH)#5Z$RRQU.I!0XSS%TGBW
M(>:"F/(<)]\'B4YJ5Y,'J75FBY'F9BV8=Q>3OIY_ZK:$8817>#@_=A"L$L-:
M.WO5+WB'F]*5WXG69S"PS$(8Q!HLU4]W!/>^9SB4"TNY:J;^T<]KYZ2"2M+!
M."Q$<-SG5-0/,V'#Q^Z,4$T=:]ZMD>J5E(PP(<]1BABA)D:%D^=FW/E6TY6+
MZ_QQF7>E'=\JW)^'%RQ)[)2)UZO H&*PT@K?%61>^UK'6W1 6D$N9T&2\ML
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M&?4)1VQUK%QYW7K,BF[V@UBC60659Y_[\N!3"Y9B%3<E0G]QX1F"Z7M  (G
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M+<.%'0,8PA.DK):=<W2,?A?M/M9=M6_K%6Z!<T!VV5FT.M2 MMCY %S;,<0
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MW2[R/.[?[KU+,  DHP#:8O4,#P/H_KV\B@@FK.H51GI SOIIKPRR1]F<&S&
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M.(0H[>2K3ROM@&! ].AY0QMZ]\O)%'"1I@UEU4S%2UCUE-I2.0>V:<#_<$M
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MX:JI?2ODARH,X():'@,P>+JH@<1')_QI7<D/7)1%9P W.O,*#GFAGG\_.T6
M\,6?$PXO;I%TNF"'YLRUE63 VF A,-&#^-SW&?RTSILG=9PFKG4D$Y/3TFKW
MQ>G/IXEDSFM8P\FUP]XJT+H?UJ*7Q4=7K^LQ !9DI$P7VC%KD#NO\K*<2*IG
MW*_FJM]8X_.BMYNB5PE%P1X/I2FXO$Z/:A(#>/)34\*?>^.%;U<[;)DE'4W6
M@JSMP=-\U8,!_"AK"ABG6C>PL"?).4NWC;X*W.<O.HYR>'4\+!O>Q=';#'^/
M>'5] !0DW X791]%:T &V6ERY^>;/O::BQGZE0Q/6U[.,+)&'L44QEIS-LID
MAO&=/F/:7DHD*'!;WV*C$&^&&[A?$%!6>AQIN >L'I1-2[:WZ-R;]67!GT]?
M))=*&;#O6>LQL\D>MK#9RP45A&7BA<@SV])%,IGHSKPM(?F(30-;?I!Y^_+N
MMJMY' CT'D7<V@Q?:+U[0=X>>]C!R'))L8]5F>XZS $2,]2W_6P]4_X=VQ,&
M,G+RL@*U[[BWC&6:^)K=#P/XZ49[BH0-T79!@K(XVH&7(:9)D/8 ;[] *#4H
MJ$-MRD/ 99A_?<C,:LD@I %W<<?]XRYS<5%A?H_T+93D/7>KTPA+E;OE981-
M*[ KQ<]H:=KAT"W@:7^OTTA^V6$8,$YXHYW__N;HED</= Y5,3^FL28@32.)
MS^?ONC]T^)("RA\63TZO&4["ZSK6O\&E<JL8)2U7;TXD2X2RKIW]G*]2M:J/
M+U">BB>^)O:B%_7<*3?R:X.#31XHP:5/YGD@X[KBHB$=+1TE32AN/^O([QB)
M6YT>O[7 7S:VX(GBIY-=YY?G0UMP; R K%T:F7[5UL#==),"A1D\FJ)L>:$8
M!BKRTC)K%TLRSX]4K:9_+!4;2Y%;T0S7Z?B3?@ [5=D"]8J'(F0?0@(4/>I7
MH&Q930)4!K(XF4NQ6H/X,@JV^FE3^2JUA<4N+.KC4WU\SPVY&@0J65CKKQO(
MF.[R5)*^D)8CO0L9<LM<API+@+6UL,?(>$DW5+9F"F]M["W1&^UV2C4>QKJF
MT?8S.8PL6])<]C\],M-P8JH?TJK"\TM/KFQ>+M)V:BTHH)\JP]<SI( ,UY>X
M>-,F\[=$-C@MB7@MB*I2"WUED=LN$QN(^IP^O2^0[!% 7#*A9DA/H;4!(JPI
MFVKKSO@[MNVK&F9U.U$4&:$+>;:B9^Z46_HQZ142@(V &T&+?!]MB9L??D!]
M6#3@TZCCW^3IIWE%*TGRSO*[4I)^<2KUBAY@2E,@DJ- XGF+"%D&MV[FUX#,
M:YT6J W88V9CT;N\<ZDTIW[Q "JW7O0C>I;4.O(=O5JXP!(KJY8[.2E$ISD!
M9G)#=B8L#$%X$L?G+[_Y\4K[8.@K_GLUA_<B9@)Z:IOOB$2^ZOHS$?/5?2N@
MB$GP<AIMNXNC_;Q!"]1T&;(YW_3]V""9T""LOX-%ZGG1E\^,\1^/!2E>?6^<
MV!TJ?5!UN<NW5TZMB].Y4K%$:9HLWN9)>D^;H6:JMG&( =]>28E'X]>V'IC^
M>^ENG. WZ6()"VUG7FX>_IU!T&/O\S<>O5+V[4L(_=;1E?6S6DY4';LG45]<
M2KFNI)!<5'Q7Z=#  X+\#/:<%#Y)C1+2"OGVRJO^*J%)SO3OS-S"T6^42J[<
MM8V[JB:2L,E?A/"J;4_(S>QO!121G!UUPV:"-/*H#]N,P?F'H]&4"*S6,V_1
MN@97!,AAAUO+^[V_#&[8^]*Q'U\B62955!YXC_T:TA0+BDHS4'7MJV#1*=2S
MF8!O<+QSPG78B5Y-[\0W;'!)]],<C<P>U*BC5E+2'&^54Q+Y;!'V3"J2$:3%
M"OTLR63*.SPS[5-UY.!V]!]A9_$?,V#GC@'@DL.8J=MBT+JW7RRQ\X66CO4%
MZ/3BNK?&EW83R\SETXXM_X[AT1N7X<QERZ"X-V"8#3]:P^E@H=\T*,UJEH20
MF>VEYO#39K@&!I!Q- ()\6]#E@E'@WRRZIOSMG!LD>/S7LI%5PV3AJ+MQVVA
MC0(R:ZMOJ#2]?H1PD,KKL6E(-$!MK4_Y>&H5F%J9*$F+XIZM+OMF@[;\R=;1
M'R"<&$#<TZ'HF,6TW(!H&$<4)>CZ_V+OK>/:C-9TT;04J" MQ=V=4KS%4HI#
M<8);<:>XDP(M%'<H4-R#NT-;)+B[%H=@)6@@))?NN;/OOG=^,V>?.W?/G'-G
M\E_6+]_*^M9ZU_L^SY+G]45V'K\K<WDLUOYU5<0)K]7)Q6JS1YWY13#1UQ52
M!'UI6:)$=#YGS3."+^$WE6Y5*!>QX^E504^K[\9;K2>^U1XJGA<[[G[#NQ6G
MA\+B%<O/CK\*9FFY$;\U6%E;?CTPQ* ]8;KNTU3]6[7<KK<^'J$%F)#*]ZUT
MK]GYYUM;)'/@@6.$]\7(Y=)MTCP8_UK$UVEY/P4R>M0^W^3AIOMXX7IATMO6
MUM(5(F^PL(D&?*3$MZQR2DGN8XCV!LG<+ZT"^'T4HTNQ;\B(:%.KI6;,C0?S
M"A>J7"F.<-,$P\!9.@;2C*1(+8;MZ/6>#5:V!"@EX172052UBQP-L*"/(M(,
M %!WMYUMRW.E1LG71\9[Q2L^'^?FR);*>)--0@# CKWGLP"<(\F1_1>#+R<^
M_G.SD<30R0"///V8M]F_,2D;.H'(*X(K:3QG9VXV9%!Z]Z95N!@9=VQ63AW.
M;32!K-DW+)>N^V!H7&=[4O=<:Q0'8=]#>9I@R#%TG4;UXX$YE@MF+J7>I>A-
M<PXL*"^GZU%S@.1PK9"_UL9^&Y'XZ1=U#?LAR^<LLCCJ NHM@VH:C B?ICKU
M#/SLOBB6W<>.NG82TQ ?;H8-3RN3*A%P]6_WA!E/<Y%D_ZXTZ'!2X</^V #3
MTWYV#45>*B7@\9<MW<)(DB?4K;;8U(;:\F2G,,^^M(S9I!4@E>US,KS%E>FD
M_E^]F^RY%2$IC--7TU]$IR:4*!/WU0J".0C,ZJ>-8*(=_MYM+>H[@L:NGD97
M\V95@@%"9H>X249V^YE97%BJT_T5S(F2N?)4;:@'FICWI2(/C@X+5 *?=%4^
MU8]1<!S<C^[Y?M$.='.W!%(U<4"<Q\T:F1<K( JR7R4)-)*C\KUB2S6@^!,@
M-Z\?3VA-.\X>%N#KT\[D%:?K5[8*58L8/UG(* F!.K#C%LG5W?C:3V@QN54R
M8LE$RY._9GI<RC_*9NGNP4'^Y<RG_2H6$]L(D* Q(W;YZ7#TV-+>D;IBP7"Y
MUHXPJLK0>4ZXS2<D+@D'+F4;//^SWT%NC2C/*T*NZ'M,;>73@)6\<Z"4XQ#0
M^.*(182*>+[\H.7U'@^%!_GQ>IR9UJM28AK.O@F.94@27BI5FW.)Y0NWRE2(
M#[P<6UZLO:[CK<04(CH%M6[*4\<_=_B#4"2M2 Q#0,H]?E3'>F]=/IQ_.D%N
MG+%&U!E*L:):X'3L3E2IEU,@K+HIG%!5=%4;M/^E 56^(YN45EB$B]3Z[)9G
ML<\>[/^CA##T@BFJC(4E0W#J(34.AU&;YD0&GDA$.>.*&)O2+-$P-0.M1^9R
M3E2?;GQ:+3857V]1K^X[.]%[E#E";Q<>;2S;21J5*X2[Z?'HR[99OR1U^"P]
M2>4KG]"CJ"+);6INTF-!GYR6&I4?SZ:E[>%UANW/S59]6Q![[:"V/VWM+RSV
MRI:XU]3YZ\Z-!A,1+A=_84@4S^^4S_>;PQ_42)*9*&2O28=N+%H584M;U?A<
M5C>L.DUX G7?%S=JUC?M5K=&.&F"H-)T)]_K6J8+XE_V_89BAO.X>1WU]:FT
M!K%)3C\4*-Y+?U0E$BJR>B-9)]0PV[/QN_,'+__YU-5!CX">65X637Q!>+2%
M]Z?SYW4)#'(G4B=&=ECW*%G""(N, #/M3#R&^O,9DJ"6#Q2^D(8BFU^G1/%:
M#N5=2?SB/F_[<[1RV+^X9GM%L.3R#@S%ZWY],8BQHUQ'&,-^)F)Z7?G!ZMKX
M=?7ECT6O86AS=K)MR**7GKV[ /\8O_IXJGK\J]SB>#:3L *+^QMC419X[J5B
M3LK"6-6$8+;?(KP1D&H169(WSA.R$A)SA/,#YB?JTL D'?S7UUR3:D5PTG;F
MYW2<GFK0<M7?>U9S_KISJ?[+)\=T#Q,\HB(2>Z:.#?NY+)A%84&M-*+G]Q]9
MALNJ5PT-5,L<$+V=JR898Q"S#X[.;,0V.%J*Z6_/Z5S_67;#3=7 P9,J6JH]
M4:S+DC,HL<%_^ KR813T>-F$ ]8LB",3V",\3U8I@<=1ZLM7;-NHC.'DKC5U
M*$IM6J,P7-_D4A@Z*J?+SS[%I(;GAO_,_$Q&5S=>D0^SVL1O;_IMW)91)/7<
M0D9>&"QM@11RX8%?4TJNL*M/UKC'QOHL\$WB^2.EQUV<E01$-LGT1%\Q\4H\
M2F@SR^YAY/8T7P_6-6X3ISB:"U/8K@E]S$SB-<R0_@I=5W=JM"#05%24+B#;
MT4?PAW$7?UU38B\U>7,*RW^^-7ZYX&7CL3VSZ!O@TU"9A?FQ:VV[PD0BM3KQ
MY.=$^M+U /%FPBACIO_83FFD&QKP/\QK_V\7]/#_UI"Q*$YCI:<D8XZ5RD4#
MIJHQ;G?^./>E&$OW$?H-EDY!_^?!3D0R&WGR^'O7LMLS#B7R->D8KM#VL7-(
M=!R")O:6*^+!U 46N3X%S=JXIB5PZA:3\?GJ.?YEUJY#.TNY+14S<+X0UH\&
MK,\).=IN<DH2U=M:P(6V-/H86KFW+ZZ=P;YC/C/5LS07[V&VMSJ.B4??$I5!
MM,7^F39YEG9Z1S4#Q<FT,):/CF\NRX$\,^=^,8;@ J.#OKU7*C&O^;]$&;V[
M.,_M?DW<'JDA_4S#M%.;^5+?@"9@0LSG(F]OEON8I1\V9I12(7R*16DCQR>2
M"E?^7&GID?>5 ;)TG[@[UMZ;>!E;KV2_BPR>V4;&LM0N'P3_0 LUL]L_PT*N
MY+*<<_^RLQ D 1K_)2-718PA,KC\;-;SG(M0G6""F;OB9+/H3&>3F>R/9/$O
M-*#R&$2=X1@Z6V&\JP(>D:] 8,ZIZ[Z%(L4?5GNT'Y=*E9=E<GHQ9)5?K>3L
MS=1E&;704%37SM<LERZ369J^VP.U0Z/?<N=7W?F5V4FGY>N8/6B[[8WP2E9C
MA3-2:V^#7ER2Y-O0EYYXT<R=\@_<Y]4AUCK&$?.=&"OGF?79;@C%D\9\ZS.O
M!CPQI+UNP#Z#H>$Y&@#:@22HH@$8SL=ZH_ICPAJ39ZL:&L;0F46ZBASP@. T
MD_$D2J\;B0;$3*'\847E>U1LUA<>8]!\YS$'PT9)RG>5!&J_]FR"$NO#/X6]
MH?\Y<ZWC>ZYBE+UW3>[%EE@@^O3[YXC$$($O!&](:CYRFXCMEY^G__,1'Z%%
M-Q3X" UXL(OB0 -8_!NO8O8.I*M>&Q-DC:,!62WW3\L"6(+1 "'@SDA@Y3]K
MYAU(_T6/[_[M_^9J?__56Z[A7$?<ITI!S6&C,H:B D,77146*,1ED52L=8WY
MQ>#"SC4:\:B=)C2@I/8?N\+?P_]RJHM+3$I-4V-*FI'O![^IIELBD;F["2@I
M,5:"F"'XCVR(FC@/TCZ&V57^Y#AODM=VE=:E?^J*J.2TKV<!_"H;CDCM-[T^
M)Y!G1MU52"GVMY=WL?N4BWLOH1*7H;*6.07%79="JA[&FA;9%0]^GBV'?2[O
M5DZP.?=*8X?B.[HE./K?/5K9"'^ \#Z)V"B"+R\"GW9(.6467WV&*_[*U*Z_
MOME24;S$0_2>=\CB&RHU\>GV+M4*FN;&BT9SO(XJBZ!U<4O0W!AL&_^A>2+U
M1XA%6F1C!^H_C_R.H@/_C/:5W4"1",3L@;?Q%WT1XN1KO*^N[07P8'UGVZOQ
M\;7>IN2DU#4&GB:.7V@UT[2LYS2"XB2%EE,NC6#C'91HP&O\3XG  32@7%S*
M4P7LOF-P%/!EM[VU%B5SK@Q;Z@]9(>4ZG7Z59J"UOC#A$)G0U<PR-)A>&$_^
M$!=#Q8BE,/X9:X;.'5G*1P,^W;B-VI[3P,?V_8X]'<(/8Q: ]"(L+1T:CE$)
MB=&0Q]\4+CLV*H;,;-A-R\/)FVSQZ$Y.Y2G[MZ*VS&/W<?^L;U7^<2%$JYVD
M**!?X2)I5 J<H_A"Q?E0%,M';#QD\6;_:2I$SSY2\YPP0I=0V:W\[21(LY<"
M1B!+LR ^K6>L9-+SRT.&_E,.NUPQ/S09^YV!OJP;_P#D%_GX1_HVCJS&<F4T
M(*VQ&Q@))@2FX</Y"ZZ6)ZA\)\X6-[9F!HJ7QPXH";VD^SI6#\3K]9@ACU#.
M)<DUQ;+@"2;P_I'L5GGOQH?%2WQJV81WV,H-7 I0 1MC/;S ].5O6BD> 03L
M6FJ&[)C6)Q-U-SY+.TN&8_O_$!LO?BU:*/1$4BUA<).UV@LFQ0O2-F=7CR:=
M"C"2)U.3O?X3SJ6[^%8$;A:O0I;V,N+B5H_95:++E\E(L_"#@X<>O[+9.A&3
M )DJ8'VIN<ZSP6[]7$1= FD3KO0_'%].K>;EDDQ<),/YA"U1-/B+C7EP?+ ,
MC]AZ'9.2(HJ T<GY0X&<Z2\3'_MP]\K94R>4>WL*,O^R< 9F%#&7#F: I_L=
M/+S\-+U<\*FTO.<PJKW)%L:Z5\K8VZ4FR>1HQL L7*<AP?6V1X7@,>2K1;2M
M]79>8XJV]"FLJ>,^&O"S6]SVH./W0E-E%G^[]](JM="+C9+\E<44*_<><>BR
MB&/":WW&..WU%)RI*V0&,1Y;,I^T.*_"0(O<4_]3K?VTG(YO^WO.X0-FM5_;
M')WP]57BNRU96>%?VZ(8@ZPA;#7/RL:4GD=3OS9UMV (>BA^UZE9_XLH>?['
M%-3[H@&?,9&EB'9\-S]LE$[G@U:MT(U*"_!+W*XYK^7)U0G+S47WIC:C2072
M@"ZRA*!,O0/-TW(+0TF0V58,LWE104%N/$NQI9/[46D>$QKPB ^QT\R>SM,"
MS)3]L,U7[]P]_QB9/+"B6Z+[,R(8I+9 ;Y.D]+.6/9[3K7+,M](M>5'$#G'G
M*'[ZHER1&/L5$XCS!,3J"?>.4(##:$SS2LL!YS;(A72^45#Q>:A? Q]54XU(
M?"4^,\=5#Y.I8O1 N8#9VRFB?I),LMEEW_*3OW7):J76Q7!-=Z^#*":! /&.
M-!]V&/D< 80L!R))635,&!@OER]C86'!/B!'^\?WY^9, P$HW#-M\UE/&D4_
M\:O1::KJ.#)0Z4% VQY5<^VIE!5-OUY)?#94 D0P ^1[N*7&=ON^_.[)/*Y6
MCY")U1L[H9K+E=G%UEDK1[U'U?HQ-D=+3(*;O>9LMM+YA>799>&V>A!O;%BT
M3BH%'/^N[S^B/EXYG7"OQX[$1*Z2^W!G9[E^'=DLAE&7_SQ'3J]3D1/4^%E0
M\4_S]*HIY$?WE0FPAS!FN1]%IOSM0/X#\GMG[WB>>\RO+,98.7X;- ]1,=ND
M[U^3IM+[\2R>[%<QM3E/<YQ?XLEO,J^F3J'+*IN9+Y5OA=K=._X3+/B'!DA1
M]EEF36%F,E%'"<12AU"'P''H#3$@JW+L^9\W.>58\@=]CI>K$0NN6T^CU]*A
M'>K2IX\+(']%+JNUL:N%!JC Q([E]_5"Y80[$S,$<#H=8D8W7<]#UMDYF9<J
MBN-E*'<C!Q_PM#Z[I?Z3#1A?;T;XB\@E,)YDT9]D\361Z0.7K:K]CY%+,9=V
MY)\VIGUYZC_?P1Z*R=-]O0[92MP;. ?[O9ZS:)+[4?F<BQ%^DS.!O@9??]UX
ME[U&?4<#GL2-%(OYG*L4&88#DUZ;>9]22=>_#^"*R:L<>)?2*&REFV-Z#WBT
M2$Q<I0'^IW3 X-R1PP'7+ 2&\0-[SK-6)\OQ]2^XOI^*H^6^Z6L WEET*C[_
M %A^ ]^?8AFM!-=L*1DI.AK-'M[^[+W.R?(D]WK=?DCR>2!:Z6/L/=>_\(J+
MZ!KHB7$13@2SY+.TH;TFZ?XCGTO 4R\LMC63%Q*WQJI $NR%4:,Q8=V-:XZB
MZK2 Q8J&MA8GIW72K<%;>=';^30T0.,.3-Z[(K[(]5F)%=8Q:Y 9[%J\DAE;
MN&H'%EUYW(\/F64\6?_L,"ATXWKK#VMWS&#[_OA^,>#NHP, 8JRTK!K>_+^W
M 5Q?/'RAWP'<15>AVZO&V'_(Q;Z5@_!?M)5&ES&;DP2NP(=HP,Y*L''U7Y+-
M)71N!(RT*0>M/-I?_:L4UDWW_G]__Q]]AX&(B$K9'AI):SYPO:4$Q[0HW!8=
M '_MS='1S=Z^1 /P93CF1$J$_F%S'L8L22<1EETQL&57?/*US8)*69(IOD^S
M@$A,3(R /T%%=((72L@C4S9R\ ,D84E[_P_*SL?OP[^ZF^<>'MQ6Q[=AR++.
ME)!3A%!-"QI ]T+8<6V95&RT#>N-+-_;^I-#PYRWMLY>D%K"&&DN2V];6WHW
M[Q+6+>VB/QB4*OHN4FJ!A0*J>)V <9T#N"77M4_-BI?<YXY:#XY27DY"/5+3
M13+REW1@&AL/0I,#D^P5L6A4W(\:$"@]FB'/7&":2L\0]@!>2(Q(2,]PQH"]
M/Z*JT:20S*&^Z0*I.:EMRA'%.#DY)+Y2$UZ1[+5Y/S<<DF89_<A(P:M]MJ6*
MYF\V7,;5CE6":!ZA5!Q%+7\C*$Y8-F)\'(<$@/,;0D![MY'5U>:'V6?@A/"A
M)$PE28T8\H!).3-B#)6[GHQ<(7D2LN@5:;FZV/3-$AOC<TY!SUK55[V'U6YN
MB5.L#"&9:6D/HDEI0P1 <N-$S]Z  $_^B.!5.G8&TF!?KGZ81 :O=#X-X'=<
M@1>4%O9)+_K&Y#=L6WVX'7[JC*FQ9<LSH26O_=!U(V/+1GTPI_?3Y%UCZ_[7
MD(3\:T&$OKYT5$%F)X.VHH2D(H422%=?-;%:)N+<AM&E.!S(&'L'(MP,:OPO
MC5M*BQ;;J>IAGC/J;#A$^KD=9#Q7PGP(&Q;7Y\J:+H3\/E >_JS\5:57YTJ@
MM:EO5F]'F_9++K'='2$KW8-OUWT,.Y\+\F'+K$Z0RR$M73J5'(L9C9BB1L7/
M2R<K;2JI(YF(B(@%DQ_CN#-Q8>)RVN%R41$)J_>0<X^;1=W/944" )=&E5.5
M=[WF=^?+UDS1@,&=SFHPE\?JZ?V%11:>5I2HTU'Q/)5W1Z/E_63[QDLS%WN9
MRD"SX1X<EJL ;I8(/]_Q&9&OYA"%%N]WO(_?:QRUSQ2A 7@H,N07Q-K*(M]&
M9V]TYX!3.1K0YI*8Z#(EK<3O5<9%66D;.?.K#XHS;OIAZAEVLD\880;'1M!K
M"#6K^5T7'G%/^Q*GEUYW50B/A%<H7(NWSND#32>TW_&WC3M0^HN+O];!PY!+
M7(NYRKIK.;?_?_X>)<@;V>.;@D@_5U8L64,995'X5'8ZS[=0;7';3GE([MH;
M3!&8R5"QH@&K^W45]3:"<OV[D&W";9K\8".UQ0O]->YCWS 3VJ+/:^$P;"T(
M*K*-M6ZM^P2.XTJULF=K=KN(XS*K'58VJ<2_5P2#]I8;B8JV[1O??J.Y4J^\
MW<]:O[Q500/.!@\L;H(3@+MK[C?XM]5G9+>'0V@ /-3I1O:V[OSXX@-X3:'S
ML@(<L7H.1 ,FN3L#?FV.7K\R#.A" ^S]?2\;^="  :K.0YJ+R=G.^1]WKH@=
M#5AI1G&#I]  -.!=Q^W?U'Y^O+(TB@:P>J !=>!%%2,TP H;15B*!OCL7+7?
MA6LTX);WYO(([QT:D/=Y]@!X 9WM]'4%(G,64>-H@(.8[[]H_/%JTVL^5#2)
M<14:L$AC]-^-_^_&__^L\<9./>7CJR*3&VB SE%,PB*%TWFE__9+C2D/HYZ%
MPBND@PMHJC=V(FL]M;5WJD09#3AQ+SY_?1XS46UTBEO?/A5F><AXKX2BL7L0
MYJN!$A8?R<=MD=\*)-]ZJZ!) OI5OHWM"OYTVXZ_,BBL_W_I>I*<>J.4VVF0
MB]>M9B:>%:=+RSS+_CQQPSLM'!T-(!QOA0,B(W<VU'IFP^>=O-?OI,[Y7\'"
MV#;ZU#3+ZJK%N!SXR)[\64ETR_J=?KP3'"0P%Y6!1-ZTB-7R/U/+=_&D<3Q,
M$.5X*DEYQM\*J<E0PQ!F]Q\*U[A5S@V^HZW#R);.-8'Y@$"$V&PG?T< <O$0
M/]/P9')".@Z&8W18/+#YLDDT2 HEO)"V/)@TL@6';T"8XGT>R$"[,!6@FK\'
MV648[@*";<S?[8GU.N^8OAEXVQ ->#F*-,)=1@.:7MY0NG9"[=  T;B[$6[!
M@<\^B4'L):#\]ZWQ30(^_6/CQ 0?UUPK!D:<@8R=SZ&!EFIL83!=9F%^DKN_
MZ!=X2 SH:@H3#2"IOFQQAYQ5A>ML1[_.B6,*T90W368AX. ,@@W\7$L*?/#4
M7O:._S;_FR0F'?[:7HL:OV5P\^2JQ6[O)C+*W(UG]=HN*<D)!5UM.;<9TTU'
M8$SZ@OLX/"^(<^7Z-8BI\D=YWH/E;EAW5!VY7+YCG#,LUV66%KO%H &6BF3)
M$X(J^A<!I_#E[++L19GDN"GC*7:J^22ECL*GKZ]78WPG]V?J9T,-[B 6&D![
MZH3ZU:)-TKCW';BEW^G9PV/Z&@W@4?F5^@*SO.!SGW YM%/5YQR6L#7[K#%
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M^_HAW0I;$9!;\'PH7@XG[*'A2VE*=1&;:I?[MNK7(1^G?.:%94$WBG!H2_8
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ML_^]=K_6AU\_5?W(?5<]=9?!^GA#\XZ-*&)!=': T%V%@O<)H]X$+Z2"DKF
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M?SWO&W"TV[$&/ZR*;\],1=%-HFZZ.&PL#XS'P[NEDFP]B A4# V_](YK_!X
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MZXTM"B%+>MA"_AJW%*5=$99FU=&4TG- +!K^KA:+OJ ,F]]@75/M1]6+;''
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M!]QIO\8)ZHDN19QFP[O!)*'Q4<,L)@JT[^@M7WQ>6_ O8_AGI.LOJ>@G,;>
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M27JWDW*Y1NC,F;)K  G: SQEOO0H\6'# YY%I_/$^=?WK*V*;%ET#2CE!GT
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M!$^YUQ<F.ZFHWHM.W8#9A9Q[X)2C[L/N6?$E1-;DB6!^ZTC=]E6KIUS'^[E
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MV:4&BC2_6A)X;I\^R2A)XY)=YAV5P* +4&3&G#N:2G*7;RCC&I<_&['V^S@
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M=EY=?HW8YN &)&QLXX)0RTTVK+0HJ^ZV$*0P':AG6G>>R6,R]?<H8;\=081
MWL':;@S.K1&F?H4H30B]L-T.L=?1\O!N,8:?!U7[ITM1\(NJZ=Q@"L30Z+C\
MEPP_,0&?5G3_V_<GRJKJ1CH1B7ER#_J9;45P()D/J;=VD%4!/'[J1V%3.':5
M8")\[YWKV4ZE:CXM4K&1Q<3P,6!(5BQ]+.OKCA;SP_D,>NZI(:QJEV*7X7*F
MAFOMZ'^1&.__IB#];@3Y,^ C,@9Q-F7"$&"%_+Z?LC6Z0N:KZ7R%T7.<=7!4
M#I0R(>20D1'I9@QA44<*X^,IRAI)!\$*K?/[R.;M[6W:!0H3LM.<AN.$!:8X
MXE:<6%7=\'I<^&"8DVCAV9X?B_C%\'*&5:)&J0+T&A:OGQV7,<A GY.N?7_Y
M!4X"XB=]S!% \TOF:=;4C6^8$,7_V\T,_[[@OS14P28LF'=K4'(V536[&/+Q
MLN;/',$[LDGOUWG)8+/]?-I4H(11YO=]P@1F=BURM[^:C;,R0/#> [@AFRM+
M&(V^M0BKWR$7W'N4Q0'[]CF$C)O'0WF4'.@(J[+DYT'%79;<AU%/\ ;J!?S!
MK'PS-I:/LO_>\RZ+0;F)$P480=ZI;G&=I];FV[2\<#_ILA=8.. <F0=.C,TX
M-#?9\I)'TS'(L!H*"%+IX))O;X2'KN;/,^IX?F/,HSI8\A<42JL7BFX1,!8L
M_R-;>87AY($R7ND0+--W_(-]$IH8YC*4P59>3<C7+0VU28SN*Y$JS2'^FSS"
M\_^G%%28=C%W#ZC-O@?0E"$-E*A12)7B:UI73V3T-34BXQZ@N[U+.9AV;!3_
MEV @;?T -.*R(D7UG[,AE%\MKP\XW0UA?+#WR<M+;4FQ$V9SGO@3+$ST1U$C
M4'R+MIQ24D-Z;)S7(TZ*<H9T/\P.%O9T?B$A/"NPZZ@)FU;=S(4@:ER]K2F9
MB?UX12=.AOUX)QYL)1)]_,/G)\'>Q4K#RK^"3?UW"]RQD.%M)\T39P?-5SW:
M4[)2<XT1N;Y2Z#/ BA0V'$^N+Z5YG0K=W0-4[Q7 (OX8U;>&45)N+X:?AUN&
M]6+@??YEBH#^3KJDAY,2T:+'?/QZBJ4UFC920GL/B&_ULFH10'Y8(6F ;&^$
MW?#7"8#O#C&/>V\2XVXHJWTUW>63<[A'*R>F=@IM*Q(;YO_HD[&"85K?;1B^
MC0V;0M/Z7563P;^7!1^;5U6?-\BN&7$<EG>E0U$ =0!]JNC4)%M1OE2\8[)C
MI>EMEP,F[TW<D1VY' 59  _I=X"W^1I2U,"ZAW-\MVRS YDW?%"VW#C1;"<F
M=>(P-YM".).2,C7N/FS@K'VBI$)'KAKJ7X-0[A$31J<@R2XI+(PKB-,M#.T@
M%S6B=^NY[2H9J;L]_DPF\5H:9@V3Y)')'U2,?X0NZ $@6'WB+$=Z-"[51ZZ=
M><(2%?JA-%@ [ &@>:^;WZ5LUYGV1J@4=_/7=!12"&4M;&V&[-HM5C6XZNG#
M"1?]?)9:25^9[>OCO[73>P_ SLY(W%'RL S@B6>)8"Q5-Y$493H=DC[8QN&^
M)KK]TU61"$;,RY7DG1[+L#$F,;M*\P,Z*; YBH#"3]!%DJW RA,=3=\U%+^%
M=BB,L2H2H-.0H?& &MPG]WO/+DRV<($.]X ;=1W%$\[-LH+<O;3OPDQ61Y1G
M==3DP-B>U<)K%5RVR&XKMB<BO%"0OO)0<\VYJI8:NRN]S3$I =JPX1Q3<@P3
M#( UH\$KD_YIG-WQ<XP6-.5E[_LSVBK2/<?+!FEJ[O9Q.%UM&!O\N19GF<Q;
M&FR-=(XV,JV-C)4Z7RXS"+_X#OYIQ*NS.+>Y%*Y3;=/%I?(E7W\K0W;O9^=:
M>H5D)*!E9GB. =WG#LUV<T]"C1&]#>U :*8:L'9>N1?9ZC7SI3WI3V37"TT]
M-5*];^O"%HYT!"8"QF%<G+3;)>MS#A'?*7,LX=*EGSH+U)[]$HKRNTA;$Z5K
M>7Y]K>Y'C+*!# 7&[Q@C>CQP/U[EF74U->3Y@ D\7#0MP)V(HY&8,5C9J>++
MW)+N38&!<<WOQ!H:_E7<\=DV69J#MX;(H0H'A^IN2[DL[OZH3PH#F0Q",60S
M&LW*(ONJS@SAT#\<$1ZMQ,=TMI3& I&19*(:KV3>KO8#RJ+0U_@";@B;*^[Z
M+DX0$?> =WY<^N!AMPT9KJ+S.\A4@G].I88?ZMHH7KXF?R?^45A1819_Y:^P
MN2+VF"-ZBRF=CD>Q()9]&FPWI1>U#@80SJ8HCA$H?4PEZ@?9_'OTGX^QAGKX
M,)6???1I^?6Z>?'O]&@L,:IO;2J(JL>/T^GQ[^(P$D%:+V6!&[-3K1@U(=HG
M92FM YH(&%BU@ZJG;VJ[MAK2/M21\,)(+R[8UBSDN7)PUXR>+2BG*<I_TGO1
M4%V%8$A5D50W2-NV?D3$5_NB5M:;;"_,F#6)]>/^&28"A^]T,2JIO(]P8+8+
M_YC<\F!!&!2Y0(2A.7IUXW$AUC#I;18C#!GR;4&I@3'.:6Z:&QM[;+4^W@HW
M-1*7K!Z?$6$J/%8R%A/MB6V? 6K2.S.RYKV]*:G6/^-C(^!59F"E813&J']A
M5UZS'?KM*$W+.3L7/=\2]O4CMDIZQB(:MMRC.IVL .?6AC33[]O*7&PRC "J
MJ>./<MUPA1S)-B;5C%TQE-O*(%WF+=.:B0J2Z<:@CKA>8-B:9=)7T]=).2VP
M-.TY+'/./4JQIJ9=1^2-QCW BZ>Z[@\H*%L'KN#CY[?'9W/^6IIJX;QD*&Z#
M<ZL>_05M_RY,(BI42WBO;S3C&\<GO:#G&7NE7BMKC16*;'3KWZGXK"04F/4)
ME=^'ED #B>F9^=&R,NP>3LBKA<.T-$B?-<*.):-T]DZJ7&!Z==F7)_/KC-K4
M1_!N-K007DBHE9-V\B;%,S97K7_YV8XW&3?!510NTTJ?>=4)^:_2>H/W<M@D
M<IN;5+3ASB47-%99F/7P,<YKREH'@M$O!@RL.2\QT=Y@?V!OI5%A=G7Z2P3;
MB%]5ZW1^WJ-UV86CT&AG+[8_E]Q:PUTG1Q\;[32ZX<87-:5*P3S3,VH).JM0
M]I4ES,KW97\2$SIW4.3KOW'9BW4F]$%9O(H].%%$(1A]NNIB=V(Q@3'-08Q0
M3H\P&_WN"MT'YQ$T>O>)7T.1**+:>44XHDL\>$Y\AZ->3'6-%W%4U"RT4MR@
MB/!R:,*6F?*/#8VGE!5[\"F+"?TI33;<[UAW#8YS\Z'Q4I/3$H_?],K$U5K'
M!@VO)K^M>:W_CC[UCPR>W4<Y8-0S>''ZU688>O2HHYW)RA%VEF/ 6W9ZK>"I
M1\IHL1SD8#5N=!WT3;D#CPBOH\F>Z>@>EC-\#PB/^+9_;>N/7 6'LD8WLU93
MI-GPB3Y[=8#P\ZJ=HL$N:;U:L6&R?A_6R7:Q^9+.23ZT<W[?,QU1+5<+/<4;
M 8=JA#L14.CX@X\'W^1[J>FOX?I3(9BV)5HL^V1/QXW&+ST+V5X2+?89T9+5
M%5)\LLT.9+8KC!$*D1/?LKO8V'HZC4 _@ZS*="#00Y+7 X0W<2TV:C"<CW$R
MAK8*/4OG<F5 _D4P:",5Z&RTJ8)?24QNS^25* A:V%J>$PRS%#GKG]:8-SRN
M:)>>"Z9C9V/_*,GV2H]<46TZYF+Z$0V((;84N')L7O?%"2;AT F_<:UR5!K+
MYY,LD&;13R5S9I- =Q(^(?N3])_4<180*_< H91D9-J?RB*K]/W]XS/$BW,,
MWCKG.]ZIO<@T] @; >\>3G..^-Y?BGKLSNHM)N2$HA1OR)+^0#]3*!.H:TU*
M'C=/22.?W@."A)%12_< 3J&(==D+N1MN\<X",;F=I_/[8ITAMHXMY4%L@J*>
M<ZLLYU[8^TP%I=TZ(^Q\>%NV/+1\)39+^1JI>F(32[Y%9T<CF_7(&N&032YU
M9%F?G^7< O&FK"+XJO-XJ6CN3GIS?[]P<,?$BCNQX9WG$Z+7!6?"X0Q%G>/%
M95$]DUK?E/I4U=&5Z=(\CDMX_VGX,UUV#SA-6$'$0P8? #?Q%T_(,998#\7)
MV?P]8(0>LN;X1:2Z?0/E8_& /WWFT6>I,P3_PW5&.<Z9;LK^$![BKBX[-:)>
M821W^-Z5+?ZZOJX5$NLYYD?Q+2--EN(C@(Z4FK*U#=99M:<G9>6-::^3EX2#
MX;DM$=8S:I3EBAHH!8:RWJQJH.K7)?W"9P6[56GIDV&2%F$Y%!-%Z67:BD>E
M*?]2L=__G*!H9<?S@OGF]I28N)JYD5!0Y>XHH#L?&EW\1[C8Y6RGEM%RWUI?
M;EO!EC%82)^QT!1SB.X@2>UT7 HHQ"<!'!#)\!QBWZ9DH?B8:!6S!WWSQ-7&
M3;+-F92/=#?$;YO-/TBG:W)X\]EZ&"BJC^:CEL\](%)KU%VR0#QU[L!_K=PE
MC;?E*3+IQG.F.3$AH^<0-;<2P[-U9O=4@69L)!9FKTT%8LGPB"W,7^6/=9_L
MK^9ZA9OQ86>!UYN\9LG7P9->0;&+-&N28G< 1$K@.*J"@14%\R0:#KR:][6(
M_ 1_^X196B8KG.EI$?RI,L8+5L3.A:P3\O5-;#-*JV72>")KP=JBHQ8<)^R6
M.Z?4F;S!(A61=[85,, 8<YI-&*%EH<]R*?L*:/"3AJX?V;0X!*'\!L%J::@W
MTG]/QWU4.'DU'DLJ^LSS: LL+-O(5LR9Q,PWJ1<8-CH1;B<%*TS&1>ZAG+8$
MGN+6SB#>7)<XJ5O5=.-#I%K /:XC#7C*S<EYP0TBS91\HO[D4VVS>W$YXJY\
M-G>J].K[43+GM[[5/6P&J.NO2L5CNUZ8CVCA#8JDWT@)F,1I?%Y(#Y-_C2J^
M!S1F<U<4[>M]H7R,KI;Y1@5;HF=K*O@2XT)PS_CL!G<.(GK%B>L2GC5EP%MY
MT5A6YC8QOE'QT[*A@P+Q_%15A LH5SF3I7Y7W%91Y>$LM_NU"H3?NKF04ND>
M 8HIK:=BT"%DUM;&)*<APTQ:KZ/+(,SCD?3]N/#5%$HKS)/T].D;>6-Z'9(A
M'B$5I W*)L5N?@4-?^<>$'"$%.\6JXIG:+:EZ=STW%LY5Z4:+2OHEHG1#!/
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MO\?99$6^W"WF=ZA?G*/KP:KHAF/*%="Q]C)+D[ \"GI.P/^+;J1DQ/S)!-L
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M58U$1^N[^-O.;W6)0JHP/#G4V_K0L89TJ%^^5N)_>Z&[C%P%4GDW@<MK3J+
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MY=;\8DQ^QIVJ"->Z7S$+*H31W_2H<2AH.;8V8Z)F#J87_WR-FM'.-J!3_X<
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M>S%-1,<R:./)_#A=N*R8+QLKWQ^"7(9'G;E/P,6WD3SIN[0VS(D(>>!;>UQ
M.5]"?)Y8DL@'W_^R]T=BG".YJ+5G*/?R-+;$/Z1=<K=@7^!WB$GYM1^5R9]Q
M0 'TH3<%Z5F&0.7M>?D< WIP13I@>W:PS7>5";)YBA]#$CXCV^]J)JO+=@,H
MXM.=KWUI'E>XQ.F+.#@4OV9$!TBA!9B0B^("WO=FN=Y&3Y'\F!!B_SJ_ CE'
M#WS(..YJ+1^"5X^O:9?:T59- P4]*=M+THEDD0MPQKG@?=M)JE7$;"$WHW](
MQC:*FT.9M]9K*6A#?)-\DO="A%#$1^NF%#YI?RZV^QF@SO:RZ.[%;S^,7'4_
MSLXA?I-__[3E_V=7CX<)&.)K3:G(J^W@&[R&F(^GP=!ZUXI"$K>MK3.@?4)2
MB,/ !@BI&X@PE,=,\;W2%C9"$\"V-/.[L#>_+D%CYO+9%TW+GV%*?3_P(K/$
MG(]CY(;NM&"H24N52\EO'O? [,3(^5\IK_@O  H\SY\!>Q']:U_ _H[6_EL^
MVJJ[O&/B#BHF5]<S/:-@7M*@DI^]=9#HWNF@8]#[<>5XKE@\?CDN=JX"N0(9
MX7E?X$7&0AJ4X2TP<?YK'/O/>F[ NA)? N9K;"F#ZAO'>H8?B]]&WXDRP5T^
ME3?2?7\LG,MKWBB]$+N=N[#W=2:MG&]YFCD<VY_WZ1N#"Z>>5"5E![::0SC_
MY :3,'&W,LCE:6C(&JDWC!)JBI[W1C,D@3-\.2[2J>2VV14P(N15D&X3/XPQ
M2I&OG[ULX*K"EN,)LFI:S2X0/1L*J\(%%8AB9S.($1"C%DO9J<V1ECW9FA )
M,+8)JU^R;):L&>%U!5%LUF6E-[YO!_TRT(]S8'EM1U4S;L[@NO#0M6*VO\F%
MAZ.IG#)7.J Z2-B5VNO?N3T\+&!OT##)Y6W)9(S]O?=S\;LOT@UN0 #>4'-)
MH/U(TPWGN--B@;\KZ,$(#<VW+@&VB(Q*FX+1V4%YIX%H]L .N.0=Q$Y>XJWH
ME+!H(]K2QO;:=3=*!/.$(R')M9K83 ]J";V>+G6<I ET=#AE8L:O*H+\B55[
MQ<VI,3).^&FY]<.1/;BY-DD6XP89$&LTWU<9@A'1DX?W>4IW N<%+DTT"S#L
M:=6^04Y2-8)_01.5ZZ5R:'5IQ"9ZLH2$*CHP^,]W8;3AN265>M,%$?KRZQQG
MAEO'M>3\@S(.7+!P\:$QH0\OCSK&3(86J+(4]\I5PX+#ER%?10.0^:9<,>7L
M)QF0EYUSZ:AIME"=/DM!D5YCH^*3VVLQ:RU]4#X5=;O[8V2D]31/F&VO3)G4
M3WLK&C$^+N2L%DVD4!N#D]W<?J?FV]$X1##87P4[[O89D+5X2[+0[/VKN#RU
M3M4I(\W040A+4.Q!.B#6U+1"YKH@GYA_E#B(WN,EK-7O_/QT7N8]04\=+L1.
M0QI4!< =K*+?FT@+7%U<7#I<%:6<PA>VE7#)VY2K1F;<4?Z>JQ(L./YMI7Z1
MZ&,EAZ[P,^! &Q9UJ!BLXOQT<=@X?V_C)2R52)^%F1)-8]R/%I&9J@YL ^I&
M:XH6]\@"WCN1+CGQL D>FF;]>35*C!-)'?[3L^JUBTLQ2,*8Y-VB>U7V3,4[
M',BFQA]?BT])<[>H]S*$V@6I-3)(.UWCP?$F&&06Y@(F5. +\#.@@>'HT]T2
MR*_91NOZP_X8CR VI^KF_F]A:B_9AV0E'*Z8=P09;.J8\6E.B"\&HKC4H@0T
MB;-\A2CA)>:O Y%59(ARKIP;['#2F"DHWN%E+X=J2*DJ"_EX$#[(/MGF$@69
M7-,&%S?MTC6W.7<TS5(Z/&D4"4M<77B6[.!R'><?FI?HM]W)_8%0<W+9Z4]7
MXC!5X>2Y1?/"%<'SE 81[$I(/*DYJV),4B!][9!X]@0.3'Z%A@N:3O@N#8X,
M0ZPT?0*$7'^J88#JF#85KU0\5S%@_=#I!L%]KK#9W_?[&LE9)9JY*>\X=B6Y
MWX)BJ5X3_I49DY2E.I=5(S&GY&-<R>>T0CQ%$(W@8>6&9AMS3SK=$E/529'E
MI&=-CZI![TM.<5T\ )*J%/YZ' E]_:IY9VL.% GX1;J)W):_3^J-N:OB#,;=
M9=:ARN[[*:/1<Y/M\7[,FM#C*)+Q,P'B!2SH6NNR,D.N@S%O'&\I!#IM#3Q/
MUI164B[.>J=<" .^KBA')>G:\8]M&UJ\EHZIFJ2D1FY77M8,"Q7=D&??Y*\J
M06#NC%R7$W,1>M:B%[9HJH;3P<J(^6E7+![NGSY<[Y+5%"]DB6PK2P1Z15A)
MS D(E-I=8Y$QM^[& =N5!9T8R@.<MJO[MG@V!JS2?C P<DQHJG S Z?5%<EG
M_A ] QQX21J+< 1?4,8;#%>EL7F ]Y&WM.VXBFW+13$:*3O>Z[GW9=_EQUI!
MJ0YT+U_[ 359Q 601?53S5$+50D]VDY.]IQ/P?GWZ'Z>532LGMY-WA7 G6(X
M1CRDLXDD-&KQ96R1_&#]@MXY_B*^.600 Z1U?:'9CE.4T.9;D,:EU.COV0)/
MI(9TAUKA?364I;*++'[)C)\$)00"N%\W4)6>((;&^A;9-^4MN-*[)2A[.=7W
M "\D]'&D^$RO+ )1UXRTSIU!7M[>ER5'Q:N!KIUE--6_=P_RDQ)K%)A2KKB@
M7!=%[E.S:E IKO?=3,"SH9@B%U14)W_+>ZX31[=OU!+2&M>:;Z7$7KT5PR>?
M\2"O[8QVB[0)_4(558&]L)<@UHU"OGZYL7+?XWZUI^!U_0Q8$' Y(=FK;>L*
M/L$L;)#XZQ^B=GC&:*N;OA!5J-O='[90AM_-+IZX7EVOKKTT4B%VX_GJ^T[O
M=E_;%#U(=*Z4I=C6W%MJ9JARJ/#L+2H2UZ;K;,JCU(7[CHC+Y(/A,3P9,7EN
MT/H,R"CU\%:RHCVY_28>K@SZ#6-R"J:2W1/X5I+G8,V1YO?&]0I;/W%80T5*
MC>F;V2E$TXW1;:>"N6%Y:7G!H*>YYPV]E_V5NJ*Y.A>[B^$AM>V?)!&6?# F
M?,_EK1+F2)VQ @6F _WEP=N4.?UO_*\SO:WV78]FKTC/*D U_RH1__\=T!+9
MJW\&.,L]B9G<-F6(/-YFZ\$EMT\0='"1"XFGVM$)@1\BRV!61,4S0*1O%IJS
MU1DN]-]D:MH<(F<_[ILP^,A<YU;855,1]K%JVG!4A3=YILH_<.(E@(3*2<E4
M?M8FWK<R2U!AJFL/N\?IBO_OKNC_K0&/-P$1MSO3)HQ^]=Q3V8@&ZK5 JQ9[
MEU:,V7FEX?1%\P*C#BT\1R(A8YPN(N,/A&7FR>+05]92LY7('3\<!3KZ^_B7
M%SLC/ZIJ3U4IB8)Z*C#"9+ 2G00\!"IIT;_-Q,I7Z=D7A1.H8[\5O'M[_:%_
M,=NLMLE9_UB0B\C;XNH:NG1/9V-*7Y)6P$]L#"V*"@]+I,Z1LTFT.S"-8CN7
M/V<S4C[NK97S=+M)$IQ*&CL>._:I9V=2%I*KD2?_YIAH(2:EA9;G@E80$B3J
M47D-4?X/.4P/](!OB(]39+C\T=[>D(&<P24AI1DP81I:U7 'KY%>2>G7V:&4
MRYDS&<)!-1T#/0UJU6GUZ1YF*<FQ1(GW ]TJ;3=:TW,BXQ(([VNL9\"1$WC
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ML#D?B<WO/N^%.C_?2$RWO2OWU*^F^B9M[ET @&MK82Z>VUI)YMX@,/>KTC#
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M4XFV]">\KM<^AY5F_,!^OV'C+AY]&W5Y>WM'X*NBGQ[!H"?2*A9;+06&DKH
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M5>\3*?>,K=#N3-\U]4:\6),P*3<V9NG$&.6I*47D-DN0W5K1#J=0UUSD7%_
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MG&6]]QAH\*I_.+.&G[[%=XR0'*L22S=\^BUQ<'!"S3G3G*ZW*-,"1?E<&?Q
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MVCR1U!A@HCR\Q.KKGI7NF]YHQA29E[<.9[V33\5.5W)7Y462#GMQ?,&CO=O
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MK:JQ!7T:>;.$ >#.9'HT];N135B_,**S&;M[C .8W*K  <Z$CJBP]3:I.SC
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MJS,)]9DH[,[D"*VKP17@,J--1<KF# 4.$"*F/X8@D)A_/A4WO_.#?4]'9)'
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M%HP:: [O=F5.V4@:C#Q[O93;++RTG!]X>XD[ B(GI:XU!WD-E#O"])5M*"/
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MX^=)26<8N5,1:]$I_G,5]$?+5_'2T>:#^O$Q\1=&7E?IRQ<_!6(]EVZ\Y;K
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MY?MZCEZ;%VYAL[/;2^-O4#\E]$M%V>E@TZW$"M(6LYY=2]=& )QA^+<Q[U6
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MG]%FH4N$I=UM 8CH9E:G+R\D[/TO(G>\@>AXU$^E4'I6NJ OA+A8FMZI?V3
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MM;6\;G.C$86D6VO%DR]TI!\6 $6P'1M$_?UW5"PCFKG9E#H]LBNM1P0K\BU
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M=G 02A0(<O1^[9+7"9E_\JQW4MQ ]D0=4EKQZ)2G][(O.$A[;^2V5*.TV4P
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M4]_HU*X)RMW.A$GS*N&!I.:>T]ZY/_,_F#OOOB:3-]RSZZK[4Y%50$0$UE5
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M%OP781WN=>NMIHF:_ETW^ZQ([=M3+CJ& =2<$!?6V_T>F^UMQ)'4#C6ZB ;
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MH:\QW8ZFT BT4N[ .!"#0TIU4M$L;#/&T#]L/380*KY*)N&O5D3HLX.&VK$
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MMR[HO5A0 ? 5!4+@#NIJ"L::SGW;N6-O9IK,6MNB%$_K\3>#0#DZDL]P3ZS
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M_HSI[SU37^/"F5$N^!OB56WLFN+!5T1QR518"U;9W_#76&D^A7L=2)F-C'1
M\LA3T3EV(Q,]?W%=;H;-]$YU'_A%P;;32@N!S-5 LTJT>)&Z?B3NVY:]L!L(
M[OT<)T.Z22#:H6_9O:[L,7TV1)8P\KNNE@!7C5&,0"AZWGCY<O7+>2O2.2!'
MQ4__'O_E0#U"/M>I 95%J0]+G"(L_8#A"M65_?Q3N/I7XM.K%;$]9TRZ--4L
M?*=+.;C3ZFHV?HKKNUV<CYO\#Y>7%:^:YA6B64'DMR9?3V!3Q%[FQ=).WNQ>
MZ80SIKO4SW;7:7QTI\,%^)9ZRB&U%?OD:Q/54JD1S:-@4\OA^^G=@*M0:MT^
ME\=Z]#?1\N?'-X+'WWNNU^TRHM.Z#*OB?S-W$L-#X$/68J&1!@38PB+K+C^9
M7+9%C(']5H&BLIH^Q]J"[P-[F<_?/$#(\&A%Z]G%SASF1HA-9V=?4%,'2#\*
M'!D;-K?0.2_WAL&JHKU=&YRN1GN$1FJ(10C7J$PHT[\=92&;U;GH:E^=T?HW
M.$%^GR_K.H/=MM<B3O["(@(:P!SB?J/0<.<.GY'W'ZO*/V55B]GJ)_R93( 4
MDX\.\U#'XC1&JGV0(X/QWDU'_J0%[T[\+-E& "2.SIBN)A!.7O\]Y9 \?$CX
M^MEYPZBTMMG!<NBK'K(V4\_JLIV_;@H\_I;Z2^Q#49??&)/6;: U@W#=U36;
MU7":R3:TDNIVL'FZM9[4>6J;!SOI;A]=%OCJ#)F!WMJ =P\,F3Y>VLYS^+SF
M-5M2XB"JF3SH(OC;?5_Y8,9<KT>.'SJU8!^ H13LK ,0%6T+2NY(C@5P0V+G
MC>UJL9P@=>&VT.6AJ F#^O2K'RJG<Q@B?']*E2.(I=1"^WUUAR^JLDK-OC'=
MY-Z/?H?S5W P/H"DJ'<-H9>_T'9U)Z#JZ/B*" :/R=.C!#>78Y_LC]^"<$8\
M3]9S5?EV<PA/T&HXX.CMG8_A$71Z-Q*?[P<-V_ ,W.?^N]#-XQE#LU3&TJ#^
M=V9)IVX:?;!%/^+A,5%-:X00/P3XY2#K"^DF>34/-\2*]8Y8]ILP[+2-YVG=
M>5_9(G_A;G*!QX9'^<8E57F0SB]:=IIJNBBJ)K&GYG4C4>*,*2_;:@FMY1/Y
MKC/$$G]JZ9":9#RVAL41\U@>P9H@WKZ]>LAU:E)O]\]9K_+M?>4[@S]'7+E,
M>,7M/>V'M<\K,035?:&2B>E_KE<WG#KELT00&\!JPKO7:)Q-XM&>]++R; WB
M%$(M=H><0:[\<-P;MF6;^#TH>'FQ<UYQ7)@'WF645%;:;?E,-[FR4!_!S<@0
MF:W1$O3/AW;T;Z<BD1W^J6JTW=@+LRTSV5_\4SVS5R5+WZ7[/$=:5\RHA:(K
MZ@@&C>"^VS_! WLE\/2[:3U/>V3,N5&Q]F\N"8R%,[XFK#;X^G +#_0/6E1W
MA8H-9D;9T(E"W\D2.EK(MFP3G-3WJ3.F6;6%/^I_O* :]Y E"S6V;0*4=9->
M%2@CW58UVM>^Q*K=$11ET,BADU7U4IIOW.ES!@]T#HO,;7>G)KOXY"_NXS$@
MBF[K TA$1#\*<EVP]:@Z8EKEPY@@[\,P2JMRF6SFK6\EK*A?S0<-C&OO7F40
MTBFPJZ %U.Z A85%0=O7UZ^+$)(1$I+29%C?:Z;Y-+6#S8-[,4WW.0)Q]>4?
M3.E;!$A5"(I:>!Q?!<W2I8B0*Y'&X .#8*AT7[(6V"ER+YJGIIX=,@OS=U>9
M"/)1ZQ:4&@LK&+!<5OP,@V<+JHM=4Y:5&QZVU#(P4'./86;0?SU,M,8!Y^[#
M :ABTM(DCW"#2D,U5ON,2:H_?9MG0<H,<X27&PXWZL[%7Z@-Y3!1!X^O?.KP
MN^$V:3B[\]WY>7G7PII;11I,4/[7N"?E"#$&4EO_ //OT'9FSIAZB,]]H<D:
M@D>96(Z#]L@4FF_&EF/\C(/NNVF:8]N&PU!](%Z#^T._\UH@<$0N;0968R_G
M.TV"/YA?]:I8K+ZRIV?!L'7SJ?N)9C:9;XN.\/14V5":1$-K-')KC,$#!_:.
MXV4$MDE]EL0)OAH%CI^]7,_A$F -0,O];V+CYF%S<?6VCRD2P]]X"!#$Z/^]
MHF:^;>]J="P"[4_3EMI?OWDT=8N\M2C8&GW'"&U7K&2DK3A$BNG?QWH&\O1X
M13HK]N=>D[ALK)TM?6#:+<'/Y1+^]KR<F7TK&<J)=LM>0+83_\3DPT_]N4^)
MJUC"X6;<+)1[6XVS-F*B3''TA)6AY@+;ZM2&-)XHRC:X#!DD&A)N%9-4JGHS
MXC03\FX:1Y0QN,^GA1!G8'89)#3*Q^0= ;0+\0;#5VF#'.09C=Z)MF@9<WKV
MX0[L=008)!4<<! SNSF-26F)2D^N^C;F$NJK7$H\M7=TN?&T$^? 7<(@!#79
MM/R0Z.VM,Z;7?-3&B';^'/ZU:>L;&J%[-X2[*X[/F':V1+4Q!]8FUR42W&:L
M>2,E<AM[>6O8LA,G 2!RTZ?^2"-:\53_B$-)VQUJ],0@5#6A-'#?:9?WVR R
M>)(WV9[$ !S/%Z%N([[#0\/:5O'5'7L*0J3IA/V2]^U9U<5%>G8'YR]P>)WZ
MTGVVU*;& -NEB:VU*(V&8+-0(:5YYQ!CX0NULF9G3!#/ V$]TC6)!(CV;[GX
M/Q?6ZYH:_3F 9#ZOGQ$/2HHC'4\F4+5)[SO&P%N[Z3UT5 <(X/HR A=VQB0\
M^_<T$% /$2AIB I7DP2;(2',TAEX.?50;FVK=_UQMV,J:KX;S%4^P?9$Y ;
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M=\CY>[3_1^[],;T(I5MSJD[2G#@)3(3'WS9#(0=.!EV";L>MT['0AF!V_.M
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M6+"9*/ ]9I>IT)+PF]T@""OIANXU=_7Z\][<VSRMF>8>0*W3CMMJ ]"%T/D
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MD*'):A-C40M(Q:SUFLGC?+71XUWNMM4=6H+]4Q/3A(KRCM'1CDL^3\U'NH:
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M4W_$YEH/8?XG'JRRST#O1ZO[G"Y.GC'Q(9U"0<8S6]B^CHGEH]T2.0B5.X'
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MZ/V3RM?LW>P#WDKI!RG;RF0*COE]!H#(E6S I:SNIG$DIB5]?K>FI$?N\$8
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MUNEL4=S]J@\'XY,KODL%<:Q-BSO2. %W.\(TEX#*GPQ0/GA$=\T6?8[&[V=
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MC8FGG@3BJ8UG?^Y46S*/LE-.3 5_^%>!XN??;7;=G8OTP&!APK.<]'_GMW^
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MR6;I6G';J.B2BDAL,WH?&4Y<JIL,'AVUHW^8\GLDEF"BX?BV"@2E)S@2U!(
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M (2>SU>"L?1976F=2W:Q?A(;T=KY\I5^A<W^1ZW36W!I!Z[&!+=#(8X9469
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M*"UYJU:Y%?S3H+<U\+<(:=/NLO=VXYX7/DZ>$ 3)UY^9'# <L:ZRN>,!WSM
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MQ?K.-H,PZ1(A=-4XPAP!OU#4-8VX%N\(O]LO2.RA#]L-@.I8&Q&@6%E;KE"
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M92#48/ZBC3?(+HU8\7B_/8P^,O2+UNX]G;P+FG-J*6W0T%.5BNDH&1..:Y
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M+]BK]WV1LO.%Y^>&GT^%39K?GB#(73W*8\[BNK)F[X]/0R17N+-+@,OQ,GL
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MRVL*,G= =^_K&[*00'_&7W\^ 3H!.O%??S.W0-S:3M 7SB"G?_Y<.0TZJ?^
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M"]FSN0H'5V\4]YJ7^/-RG'NZEH!'E*HS;+)[U6EOD>KVWP;@R4C85FCMN/7
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M1)(%6.]]QUB'WA+V1_H;@P_8[FJ@N75)P2-*E6@K )3X"<?$N5U"/YK&Y2W
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M9274&SX:BI^QA<ULR/?+"!B:_A[A8^V/>/[<)3?NUX)SZM][9(UN>]^QW&Y
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MA?%Q[:%I^N*UUR*OU([//DV\=_U^;GX9NW'U)5P6?[2H&W=O_,F]X3]OW>)
M?4+]@D)%<]QCGX)ZRCX[O;-,=X1LPQDBB.]1&&/KX&W<F%^JS?X=Q@4P+J2S
MX2?)A^;YF)M[IN>']=[L$A[OZ_&LI/I+8W"%+NUI@<0+W,B0Z0.;)WOYW_7%
M(X$$G@VN!,!F,=-P:GBE$LP3JNZ/"Z$)W%_XIV,3-EK:^99D9R-;T%1SY<J5
M$6_NSM[AT?5?:\<;"5=V[\%;W%$C0 ,I&AK@64EF3F(S'EL%90;X%RQW>1*/
M9*AHQ1C$U4K!B!<4*EG26@9]76W<G_BO:P"GL_]'D+/&<LRB2N#3<:V8HB>_
M]Q:R]VZ? Z P$#&O8@>)/2IT85)9SZ]=X_2;OU5 T.;;KB^>*RE8EQN+M3AH
M_3@S:FYEY;(;$F;RY[9!9+OL785S=@)!50H&TJ/" -5+ P-L<672^81#J2([
MBTR"#S;?Y1[+(S9E?1P55)0_ZZ_J=\)A[LDL<Y-].8=]OR2]NK[%*(W5DD_L
M%_^!,YL.ZHV_X2##7FM^\A;2!DE#]O,L<F\R&,P?&B/-J- S3$%ZZW16Y)84
MX]E^.*]TC5K]5D2)1O1KJ+\30G:R75%D+NF4")CWHK9X>D8R0;"KC$(U"//F
MM@$<; %.KO!@,C:0GZ\3ZYBU_C +[9WFIOJS"&OJ\7!MO9\(C:(=6;V33CGG
M$NCJ[_=X*3'/F7(S-?ZBD7XBH<E01U)65!SI9??'J($*8/IG2 WTJ"M".JT:
M#J[23&#9(>ZS9CMT,S<5",A <L#R+%TZAJ!Z:> B:'3VNIWD$,"=4P4K+MGP
M2JZ4%1VUYOR98+VP6%!:E-.MCCZT.N%@-H9>I2HFMK;JFN]PDG%/F-STPT_X
M^,: 39@_R?E9/?<A21C:Y#9[Q ,.HV]7JZ1K67NC?3+C"CV7_0\>+HJ5=#KC
MLI1!>M(/;  WM D/ >#P%#V!B4%?K9DK9$H-Y6WXUUUUU\\C A1<4]US?-Q?
MY(2#>-W^GG1F (5:C%XE!= &YLWE[<(3L7XC9B//9T1K<7-G;Q2\ XK>96P2
MEBF9N@3M9TWE,,:9!#'2O?)F0M,G36[0-TI_2L"Q1O#' 6N#NP\#N6>"8[9@
M(.P4[<>_FT9/AI=]OO3?M%TM_MZGB#ZT]@#8FU8WK+R5]11Q!3U47@Q&"\LG
M,10C\,UYG'5Y]X1;JCQIQ;-66=#J@BYGS*00'I9^>\/CU3;U>@$ #$V4;P2]
M3->>1$_*S@4P;_<%GG H>)-;JS"7F%+TFOIBC GT<.4Y+;N;<:%5]MQ:)\V$
MB GX^[.79\'TNN=5R0_-OIL"H.:P"^\+4V6_I&1G&VN!E_RJ#&^RU9X46!#P
M5K9W)K@?7PU9 7AOX^QQIUW]SE30T^7)-:_Y1F5;VA&UQ=CK\Z"+_Z!/"I*R
M1-\8+]:&'Y?SB)KJILC;*+<91 K(2!XZK<><<"3I]V#?XQT8I0:[8HQX\K;P
M\S%B8#3)L7-,TXAG4G"T\@ DVK3=E-4<MP:JQ^,57WB9+$+"9D*LZC;6H3-1
M8WN-!'&\![_ P./*[QC !2V0#.16+BG[A&,@LS%U#K$#69_MWBAKQL1Y<SI.
M7UN]D;])I=9-I_(G$MK!IA8*_(M(IR=/QAGNRM'6*G?2OSW_G/,E@WU)952'
M+/4( #+8A%;\#^VZ5-Q*LWZ1IJ(_1:2C?\$]0#A41:+5G^94$.%K]>-%@!LO
M;,7W2^*R6!KN<V+"K6YYU+/ 8G(4^T$$*.-A\"D&CCF/EEI4?Q*<T#[&-&<9
M806W,IW0T<5 *DM,!BI^#4F*>.=Q>)4R,)%Q0#@J4T_9BRM1^DJ\>T[.[[35
M<?;L)YO?/+;9]Z\/MR=;CMI1B#0KA">3=RT5=SAH5-,,%]TN+,4.UST^)!R;
MI%.DB)F(4]PC&U*9LI_*2-H>];XU#^+#Y(W2NQ91KU@+]H%.&?== .( QY(=
M3CA^:R<=X6J4D/UBC)E-KI4>Y!?XAUSY\;]6G3H)BU5JY=VHC#?)'0/XY!H3
M2 0Q/;;5W/Q&WLP40_#E E^+FT9E%8XMMU.-'!P-<L,( T4R6?V$H]MQM])'
M$\DY#I8 W60FM'EI'+^+0;CZ'4*\1)*(M?>TN.TQ'YI%Z(;T@U@]3MJM\(*4
MN(*4(/^85M7/%4 .Z!"Q6P7(Y3+F6, </8E9B%%Z@3;5;N67?YSNF/PEK!:^
M$X)*Y_+7#I#78_;/UR,=]JRY=*V+$WN-3L<8CP_+W6]T?;0N 439$38)RI3B
MK B]1'L'<F3.$-^2Y$#O8+Q7YY+>P.Q;XC:G6K4;2\;7E:<OECFBK8T'693
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MN6FB<$ZC>H&OQY\_H^1LU]9<HD1G=&V/18"(J3[A8$L3FNZ$L2X=;BDN>??
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M)BGXNPY:3X]-F]_.>WK6LL"87!@ZD)'AA,RU&Z4F>1)REK]!Q3&RF>2:+\]
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MMH69C%*,\'90@J[>Z@F+U6YFCIS[@^COKHWQ5X!;VE2@US68]UR \O/O8@B
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M7I5T5G%J=&F9,X_R);-PNF>4>IEY+N);*>:QEN<[.?O3+W4/:SPN&,WA8 C
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MKNZ]WFUNT,B:%$H[E&LXS;<\1QZK&H4S_.4Z5HP]OKY!5^/BGPKBE\R6WGA
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M(A)^[GECII=8E;N+HV16BH9@I.[-F-QVGZWWMAF?KY7V 7_BST_ZI$*JA%>
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M91S+CH4B08T[N.A;?X )+-N!+#Z#U&$T/'QTE>4&'3]!=!9KHG+ %M9]SCU
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MZR9Z*AK[4Q/V[8AZ*?1M=<$J2A&58[_LTP6%'!:R P(V\$F;*Z! R3;9C._
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M[Q2?9Y.,_$RR\Z//5O0E-_8]\^J31\VXJ"<"*_T/,\KS8R'!)^2RO[NJ*-*
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M3?Y4YL]G!=3ZD=_+V)"@\6-CQ1P-/7E512U%12T0)YBS04E"55X9OB)N2E'
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MEK@5*9;S&Y4<[;/2ON<;]+WUV_(<\^!IBZH6?*G I(W#Q"V.) *EHV3"J2B
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MJO5AADQF7%\A0JE3VU-;D%VR^[.(*7F2)H&^UL7S06@07T6C$V!TU$_3E#(
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MGSBF 2(F?O\)R+)=% &2F36JP<9XQ*? !)F(5FD1-_ +_ ?F33;_8$YN:Q'
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M5EW_MKDT/+'P!6FL8$W[<?[(GMO<]!X]EIZ@G1,T!S.)5F)6QLLJ!>>FC^P
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M(H[-\E?(]2_?*0GG5)I29Y;& :#0[2>GX0'$&3:2R>608_43 0BJRA.L:D5
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M:\N),O)<O2\:MQQ;G>P"R$ABVQZ,_,N'Y*])T84F0;J'U7G9=VWWRKE!ZC^
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MB98<RNOH4T!R]4O7P8-&"LK/$.YIU14LCD?_T(N7^Z.X<B6#(+HF[?X1@JK
MR<B38#/,.D]"YU_G4+93)3;$[4TBHOIY>WVW!:[9G>.2F!@QU$PWW@6I!NP
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M.!&&AA'#2\7:O(2H^""1(6V6-86C4:T%>5;?E5+0D 5VUQ#Q_F#_(-6DT1N
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M96N4U;H8B!$$"\G>4J[;-Q#;ZN6?#/5- \,2KJ_%(@3>=VEJPU251X?UUSE
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MCT50>__ZM4B^;2D+2MP[:KE?GH/DSBHL;&?"]OR#!AUT61K/7[=X@)-&0+W
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M\D09P$8C50R0EX\A#</$HBUCHGS14E5]'1$!#' E%'*Q'T_54QW_+XX.C@K
MYDQ=7%5,0UUXYE0].)X4,/_7*23>DX"@-T4"%%<*</U-,69'S9D][\,*F/TV
MO65JKOUL;L'K' N(W<)]\92<XTX%U I$0T#!$"K>EE#E$RR:2EMQ3JSTIBL%
M6H?X\''C>2GXR+ :GM[^O7K5(LUY1W>KKM6F5J^)ZK6(3:@XIU\ WL;'W)SP
MA#OXBJ?7&NH-G4FI@K5NM1$D*4CZVCJ&IF]&\T ;W4= BP A0,0GNOR^-8D-
ME\N^NG)(/IO\[*,;TAI<=_R&B\?9>>9,\N.$=3QY,L-H\&7V->"*W/QF]WCQ
MVO$%0/S3\F;69$B))87$SY])@T;F65ZN, *1+K/(<Q!_F]B'O[%M^?;#\H%]
M=H:0!Y*YD^3V1_K[*_R.)8_5(,^QC48#W3'BZGS0]QFO4ASFF^#)K(/*^,63
M9FVY@&/YEA_/*PFYA3!^09OONP0:3"RSW+$6PZHRJ%RHO#-%.X1EU)_YN9QI
M\[>=#8[/R[2#Z2A#H-$D;]L9I:\181KLC<]7ISZ:?R"^\\*K$$4)UF$+JR:T
M6J<8E'2;K:]TJ7)'Z\0H%C=]*V'!@DBZ:(2;\L=\EN0\4 \9&V-,+,GWAD$Z
M2X*;YK:DCHH-,V6 .MWZT^7$;L]IO68Y\6D:>PXKYXJFW_X_1;X>T=S#$OFP
M/);4YYW#S1O,WXF+2-DH261O.JE)<.^6,:J"P/?MSS3N8NM%B085C/P93#NY
MWKK%U2E6N01\Q?W:,WGJ K^Q&U--U@V8K][M+IYBC;I'-"Z5%UYBH%/"":6A
M5N0..LTCAKV7%O/,'<.YCC6;:'A1JL"\J"[RF[+9*U)$MU7Q)<_]O-3*RD9G
MR?=XL;)5NFCQ2I3A[C96=*\H<!]> *#I#% US:?>JA&)_M;E0Q$$-_(-:B";
M*(#-"ST=\C8O,Z$R"%%"B^"SF%_6%HFG[P/6=I1LGF<^*$IG-3=6$#<O9B"D
M-#<7,+#_LX=,_,;QS6=")<WMMQ-JD[D6(/6*@A 2'! .*(94C[ZW_:G:Q4?)
M/0/QK4(#/Q89;?&(2:Q62BV+%@/M"@=X]%E-A]ZQE$G0LH#6M!G6UX>^5U[H
M6K^"^;3Z2\6:,<_YK1*)[/? 0!4FXQK/^;+1&\N4>UOGA;[!^@7:C -[WI6/
MF(IM"#\X3[U_<_ RAMZYQNIT:+O5OQY:<Q7^@JY<EYR^AV?^*3XZ)U^4SCY,
M%AC^]2U YW.9_$ !^@N E$A)+!I <H%US;;7,&SI_%#!^E6U/URF(O4A1D)L
MR.L:RV=]B&^E<P1_N6$=1X&TVV 15TW+C+HGGP,Q3*NPHL0TX/K/L-MXW"(<
M9CTS8B9LRJBB^['"3\VT=E#U1(5<K"AG0%6)\K%49;!:[9C^5'FMRI[/8[_N
M?1_X8'=0,3-%"_'B4 G>Z>!L:$=<,<B3P.?RY3LYPRZ&*RPZYL,+H $NM'$)
M=%.)6M*WM9Z6GXP<CB^I'&#B;:L3P,VW*MX!7.+67Y_+LPEZ.SV)GBW;(J<Y
MMJ^0VOZFD*J,D].+N43+\_?3/D-NE[.NAA"3*(/F%*?D45(E\T*!5*>%)X:!
MY.$&3I*MC6$@E]UBZK+>XWUKVKR"HDBSPDQ1PXM40C-0BV+3OK59DE)4BJ*B
M;!62RNGK2[;U1DE3"*7NJ1S&KZ^1UD6^]>]0%M5FW(X=&/4=TD[6KILD:&JK
MT$QE\+12!B>4''TY\J8'(S)9,BLFCXZ-+.Q6"I8&>LE7Y-[/;-CJBL<1IH8Q
M(F/:01X2$)OE/E(/HK>L&#YO^L$\,LU6/K>'1@6X#G3VA-PRO@#>7%&0U;C\
M:-8;3KM!7\TX(>AE,ER3[!/\*$3B=<[C *;QNE9IU0#&+*3U8V8&FG^A;+CD
MF%%2<8P5R,_L-1*GY$>P*7Z,[H0K9'J]AUIC'36L+'&^)LRAX%]B*K\G>COW
M^C@M?9W%Y?5Z<T[-JN[*:]??RHEY7Z'3K)I/[09/(N=@C6ZP\A$+'D>O"!=C
MRR#N0(W,(91IOPOFV;4_V4H=P17[YCZJA1LWG,=IE%B+7W4(E$R5]3Q6+%SC
MH21SN]Z:ZRQ'K8E185$TL7122(R4:1T>*&C[U>E/3]"ZOM'E&5V#/N[231HQ
M1=V?3:(7P#1)\^-"1O/Z*'RDK7^4>.QX[).2XQH>]X.-:P_*0@!6N6EQ QU!
MT<-I5&KAB173W\?+-Y**K;)G/S%&@GUF9_D2]$@D\".8HXMQO6'%/Y+?0U?M
MO;YXQDK-G"?].=G2RUB:M *&WV6J^X_5FL8*VCIL&X(;@PS>CE ]?+M?"^Y4
M+F19[_Y0 J/(:9.CJQ,>]CS!/.]TUBU/"U8T0*P%:42_ELUTFF/6^S23?(..
MA[*B'X KQ_ T"*&N*5L<6G;?JC_A6+;7UMO9+ [>@-',]A;#41 "#:M15C(^
M+WC!4BINL8R60_AZHB_-")?'U'^\ZZSOH#NE 9PAUWOP[25D+:?Y\&8D$&I)
M]Y@R.Y/]U<)Y8S-50U7LV[4) &>E]A\&1@L+1;;+ SD:OWK,]9X2J#J3Q)4:
MS=8\DCA/A,&]PZ\0_E![Y$._%E%"A5RI33K$;LE,7(,PPY/S9Y;T["J732@B
M_83RO+C N$L)B(8#A)%?557(!BL$6Y-89VI/JQN'A)J!9Q17+#4WM9EG>3I;
M.\53!:&%TSCD7 9)B#L:^ZC[Z]?L/6V&RR7YXS>D8++-(8V$U#0$>1C=Z\3/
MDB!6U_JWO6R&.J/EA%$"B(:;:B;48Y]O7_DL;-<M45M]%K#6ATN(XJ*%H,SE
M/:6KD,".W1+'180+><9)5P])Y>P"DG'O\5D0XF$2KQ["^B6Q73UD"(JJJFM!
M9 HNV[E.P=U?&"J*7,4D*0X."_NF&TET=YVR62U=L9SG63]=8@X"XJLE'VI>
M ..EA_TW"'';;VY7R!W=3Z67$U*DEGNZGGCKK?4^M\8D1*KL]B..1#2MM2=U
M^+QK/O00\^ZDB)4GRL3#A;TFBUZ;S,>GP]>3791.,DQ,.$:O)?,;2[,8K#\^
M1ZJNDZ*PD&#:.W')' ZX0"SCVB5SW%6V:[;VB!S3!:<U(-.:&'V,P5J*PLLV
MW94[E $6M8(8,<"X!M!6\\+DHC#+[OGI7HK/^6:@HC!:*UGC(S)8I0BY:UJR
M.P-AK,':"L<F8C'US?O,)++T^FTQU_9(VL8=GZWW1,P?#,3O@[I,]W[M3;36
MBM'>N&^F"O(C:?IP?Y!/H1\8Q_27VQ*RMZ[VO-]^&E,IR-&#9K\ T+\TLCOR
M*? :6XRZ *,_@FTO+1#O$2>.DIXB]S#GI"&SILLG(DOJ9!+ 7"+.\<$4[RK[
M^L/1XMED]]Z3%FV;B$SB'1>\4-HA<XOO?&'%*6_?"5#.2:GVE9)\CC,9&9G$
MO^Y8/VNDVKSN2^AQJL!#&?#.Y'+V'T*(;\L=]*&G72!FS7F_*8HQ/2A)$^+(
M\A& \(D!@"T?*QMSG)9M^1_,7?@? J[+2;],:N\>?B@[D((2^F;[3(MS*@JC
M"C+ %%&F,3HH^JLZNO$7;T3@_FN[FU-F3?4IN2E*X.@)V.*4PA$ZZ]B</NO/
M.<%R&ES/G;_.:P'ZJ\?+#4Q.V6(N5.HTK;G1-@7!_'7[;E-D;%KA>TE +GAC
M+WU8CDFBIK2;.MU92I8VE=]%Y +*1?HPNM6<M6*<%9N,@8V"&%#YZC7"%1)6
M5>ZJD<-\K(>.Y7(]:<216K :3=^OS:_5@P <S1\QJC::L1;/I#>8R@[VYC=T
M\NZIN;8?;!W'F0]CJA(N9&LFO\7VL9@[/\CQ:19KXFLB+E"O&&2S.K#>ZKP+
M%]52%;!59?"?,]K-N[_F]$$=Y;87EKYE79/5TZ>B:62Q\26@*SV273&=$$!$
MS$T_Y3NB$/I':!Z@?+C?WKGTP7MH2%[HD_M-0:$UIVY1#(7-HHF$:=\N(:[?
M+*ET$$L4D;R+A62AGD!E8G/!I4E3%'],IIVI')5@EHBNZ =O1Q'LF+>938;+
M)[Y[QB(373$N:)0<GP(03%Y3Q\/"B4.5Y,\_%/&ZU3?BNU3P)P(%96AS1R C
MN:Q*-*&Y[+]C#FIT6NI?/S,EMT4/ 7.)G1%NA8P6E\Z$[>9J<.8N06#C2SPM
M<@XKD(YYS>ER$L,E<L46P.KLA(Y*=HPY+R&6[YZC)"-*>T2I-V($HEP5&P;^
M84G4Z*0J,*6S6="WE<JH-S]53]6.=FDQ ?%Q(H:[6(IV;'2@:H6Q<C0]1UL4
M/=9EU""NCRX-O0!,MG<;HCF:63W>DI_5$JG^C3[.D46M_(2^_(E(-=5?2##5
M*90WJ%?T-"(>95DLUHYM&>Z+SISJ CQGV3=XK.P9H5O"SA-C.BEPH$)7::<'
MN&'^MIEB. JN]^\4^T^*$(?GQ0R,[YL5A'9:GNL2>:9-:Z^*!"=JIS6WZ.*?
M9#%IW.3N"-#O&_%O^J0Y[,_].<ZKX6\^ [MGQ<Y5!]@%]7['_4XN%-]_8S7X
M.& ,!YHD;;#Z<1OSKW'(BEU@5%"U;]*\LBXI9K+>BD&^YM"U6N#'UZ^\)IN
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M7TB*_SDP 5DA5C8XFTO[!9F6,2\O[VF[VT]<*AC<HOW&&!4H]T27TQ!.3?_
M>>,VW'C4X*#O=O1W"=7&<ZJ8^B^TZ+.21(]A(Y]R.R%OV4K#*5C?/0P2OI,!
M\G\$BI6HE//'K_IU-.P>2R7*G@L"; ^VJA)S"35(XKWD7;' (E.JXQ1*GU!Y
MXJYNHX77EEH[9KT:8Q%BA%%_?_!@A/,B&"7I\ X^=M,S7;)-=R";1"L\%+7I
M\2'3J'W2S"72'DLW("/F_+[RH05CC:B&)(R=7HG4 --<V";"DY9 BP A9F;5
MX ,*"%GG-1*&;7-#QI07I,*448A32Z/G[7/E>$7P@M&2O;O6<FCHSV%++E3J
M&$\\$> B"L7OO4)V.]?*O+7354^#F,8:GS2@9EW3BH&P$F7+O0VM6*HWDZ9)
MA\W0X-<HGDZ6E85/H:U^H6-[7LB1.3:IDN+[*"EB 1@9$1ZC9PX[JR67GBN[
MJ)9H-F)E4#2&2PL!Q)&,8@UW>Z;VY>;:Y=0FZ^*Q'5MG9^FBENERS3,:S:*>
M5R;Y(67675=%M[%POQ\^?I'YWXV0U$H0C\3C;N(RFG<Z3J?/6L?VVE8BE%R$
M1[2CHGNBLQX8LL@I)\OO\J==B4LJ<JL\>)EF31S=CA0"^T<:"RM&ILO [[7!
M,C^GU;>D8NZFXV,MA)J^EP*:;Y-WJB+YOM%/BQ27:). ,3^J[>OSBDF>'-K?
M*$1#&E/R=\LW,=VU+O;KPSL($JQZ%[S*W'!)T+4Z,3%C?,*$A@W_F;XT=:\V
MS>,C3/GZ:9GG9QIR9H6W;Y\0[=-W0V<G5GE-]9)SS-=J:N-1W90I;S0*I*12
MF[%3:%9,( 77UP92J;DNO=&JJ@\U6R*R<%2!+V=&C3=PO!'?\3KI7/N6^/P>
M>4Z242V,CG!:+ %F#., 9.ZWW\K'S)V:[.SH<BD3*_+Z5;O$:F;GQN*O#GR(
M7R>*N]R1P*/9Z"/F4"LL;"2)"$SW_]'?BRWK")TX?>QAW+X6!EZY*..L+!5$
M0SD1_50)=@O#+KGI%4/'(U(R$OJEEC$</ZV6-,CB;6A!DQ@1^VJD[D]P 0TP
MR=*B'Q/NV[)>F7'X.P:G* )(8Z22(F8Y\ECT&NIL1 ]I2ZKM;5@HL@U#J+ L
M=*W1H'E@^%W:#2JFB6%?I)=XCB:-F]<A&UO&TW<1)HN=+^HSRY'F]?P>0<V"
M5]?;D67#3&,6FLBEN?0[&)+DV;IPEMM>[Q"7_?MHM_#QR\!>5C_?1<'BF+ (
M7'G[AT]V/-9^'B)6YV_J0#R4$NN5-"AUO<N]7W/25^G8G]M,3M<V+=\AM"*A
M2!.U3"F,ASBHU+:83E7 3"]*<P_,I_SVD^8RKBRWQW[$2Q+L\0KH*1R\-MAB
M=$)P4'"ZIA7>]5L^@SH4'"9^B4065?AK;#0G]YER3M<F-$CO<-!%V$+W4VA&
M_L&F8B(MZE5>F!"X*-03R[=S:8J(YY; +%8%Q:=1OJ0HRE$D5#GIV168I(M]
M3"^@_Y.M6>Q!M4:.LJF6Q9_JXSD56=BW<E"F1SKS9[%-Y9K@?Q9-3?-M/C[$
M4)X3=8DJD7-)"S^@'^E%+^7C1E7B<8O)%]<H(?J>KLD9HE+ZL0:_RFR6&NY3
M/>P$A>^:4<T1?1U\5);F/,1];Y0NBDG![B?8M_3+3*38E@,R=%RJC+LKH!EV
M>F7] 8"2>ECQI@CQG,!:TP(N8,]->@X7)M;6YBE#^+[--5,O4.;'^Q78-#&N
MQI79'_0"T/?!AX<VT5;T7^EUZNW\#'S"I4Q^GD#9FS$Z5NYEVQI#\6!\9C9&
M%W1@?P>VFO1?I5U^JM2"G:(?<?]'KI/_!X *]MATA)B>'2Z#T%HKVO)N,_/$
M3L?-_4UK&X[ZJ>;82FI,D<]MR:G%'P;IHOT7A]\A:3%R76CS_1+!.8;'=]M'
M(X7)\&#E(L@]<W9!\47N-AU:U^97%PU7+[79E^K27$?,6H(XM<('2V5+N$Q-
MXU0"9C+6 -B?//@>#P](W=?D:'M'Z1,+$1.BY%=XIM*%"O2<6+C552A4B61I
MPE< 'Z*10UO'64_T#X-]4-\'2B>*") E9"/Y?@6RY3RKWZ*D-'.FN*=5S2FZ
MB9;];I-Z""UBZA\I5O<]$I\,B]L=V^4QIURXHQFPWBQ1S)#0$]42246.(!Q:
M/[\%'OL%SR\SL[\K;Y$W?L8IP8;/RCX;R)??AJ]&=L3OE#JYJ7P?VF%^CI,%
MGG=\T_Y\4W![_+!0XJ$,+J$H=+?!D":!6G_-LD26R\^1,;GDX+L8FAK3GOH4
M " Z(<9:K.X9-$8FB;K_,+M\XJ 2G77OAG.I(NQ"+OB)IG7VM"AZCMFS+SGZ
MAWM6N<I5<JV75O+!^[A>LZIZ"&QX8M;4-I9(_DM>>>C!X3NB0UG;8AI/,[1]
M^KPB.?S?I"RB*=U.R",F^E[@S6(#>1NFO.*!*XJHX*0&_C2W[OK.!D][B=+D
M;60=%-5#64$\+93+PR5_[GX%<CF[.%D"Q1B+O/2 6E&U%5UC]4\+^&8)\J^@
M-5E8@%O8X[&9R'CSW0_QCV+CF(R/+6,J5EK(-V=)(FC6S(RF3^QD!F XEMAX
MDF1G5:6Z]C]9'^7"G4G06\$S]2?!KT<L/:TJMOI@Q\W8MQ^J=\4I99Z_CG@^
M!%I2UWT;@5O!QG4<:G_9/(\!'=22VN3LGU<O$9IXIG_7D(OZBQA;W\Q]V58!
MWY\W".GZ-)JPZFC@E [+IG9DNF&M#8]*@%!FF$VCUK<<G/>$N"M9[ N W^2Q
M!P8".Q.\>\>M8NEO"1)#NJSF&?&>*9'RH5L?W1R>S]?+_OQ;;K+#SB=-)P_E
M#9X\0HO^W[0##,^]QK_499 [D8MR0V'7L]#Q9GATJLQ.J3C%"3:%2JWN"R"S
M= ['9R'QX!1_]S.P:*)K"@;Z$P_M?Y4YGD7VR=Z(4"E\1$%.7UHN7K?D3S,U
M2=4O[1N\6K5Q5DSU13UYH4,+F2DW:H;V"E2\LIO+]MZ:@7(:5UT-I$CY-QBB
M:)GC?[4/^W%VU0H9*G709[.&U)#7$SNH,M<@=4PN[)W)Q,5,-F%RR)0T;$P\
M:DUS(E3GT-G"1G$@T@[)V:Q8+JIP"OAI0HY1I+9Q>H'9^09NT1Z37^_1X-*K
M'@I<4\&NPA$S4'CL/*OD/>&@K=C#T ]1^$AFDU=WQ<5&3&:7WS8H*FB?F0Q_
M ; KT-*M]A@W%"7PI.YP[3H[&=@I\=1;8R*9I5W,C('P*;XELO@U+4&V==G9
M:#(RO[PI/'E5_@(@(F5>:W_>]=DWQ"QT:*R98=RTT$5Y4.]6];?R9DO&;&\3
MYG=Y"F/""-M<$;1>RJDIR=&E=RK_DDD9/Z#)S8*[KU*AJX,>G7/\D9JY=;35
MK/K<TBQLC%-:%0#'TW0"4LZHU9_HOP $'8!*YB2-/GDG%7(D<?W?!O8VU';E
M[C$FW"!/TG,ZIR6+5VGN,5.EU,Q^-SYTI:;10Z-$+*.DLP96Q0E(JI2 KW-[
M<V/*8BY8MWQ/38->%,QO3L*!H2C8(^= 8#2I)9#:V:^0UHX#PL'A$^NKD%+\
ME!>"%K.7;YT/RAJ3HU&] 4WT_Z_UN_\UL(^TMDXL5.DSHV#$1^;7'I><F-II
MIX3/,;9]R"Z*%'^M4QB3''M*H?LIKCB\^E5[;3K_23D^3?/[CP(TO^O%^HH<
MANK(TF4^]9Z0T[J05+K0!NNM\>GI<U$77S. <VDRZ)544O89C4*%>92*;Z/V
M;/SL?!5>,]*=KQP8"1:XSB%7K F3[XMF9KKPL_(0NQ(]V5P])?PUCX\)\+:+
MVW"M]4I%\&^DC]/#0K*5._>N7,<.,#^C*LN@3L)@NPK#])C?(_:$28SZ&#%I
M>3/GGEE]4YK4SC1A&?SD\PL.KKM/E^XR$3Z56*M5IB'6ZJ*HQ29B4C$S@</^
M<Q<.+'*DHQG+6T;Y:"L&Y&^[2= BWDQVV&0]/C "N1K,I5^?_#SSI*(G;>*<
MW+2E!5_U)O=Z84AHMP>6]0F]Z:WP7QU] >0%GW1LQY[<"NOS'TD\4\$T[7G@
M1/4O $6A8/\_))VL#;>-+B36S\PN.$$2**BFQ7C Z>\1T#Q11G_*FW9D$EY1
MT_22J$2Y(_-!B%YJN+I 86(11<5/9KX$W36SRRXVQ7*:;]=ORKZMB ;I$O(/
MZPP#LMD A !?]AL-E*G@O<G.:I$S")+ZA?N.@ P7H5W* "#Q;H.$N[39=R&1
M[.-[^"GM$?T_E[IT>6?<;L)<B5X/\M!TN)55KIBX7UH0+0<H#R03(N$:^JZN
MG6^MIQ<X("=EZV=U2'OFX([Z^9R_M6DHR0"'V6G*G[YP+-Y(3:,KJMIVW="S
MH0W'V7]>P"U*G/4HNVBF?A(/]"XO$2J9YX2!P+VL>[A:WL31"B/Y6-&]O7_A
MVMTI%:LV%N=I7G^&L2$O\%CZ]E2VO2[B>6QWR.$X7R+R/D+3M__M'- .GM\W
MV'*RW%X(CX%PC63]H97E =)] %+/3AZ+7@<>*]6+-S<\R2NH:!-%E&A0\1JR
M-6OZC0EU\%Y+:RCO70!BT%I6">7ZVN=M6Q?/S&M:)4A5;+VX[KD>@A^;2(+G
MQ>]MDV_&;)98/2(K/D\,"$_E:CK<Y3IM#T&MLO&0R!(-A[V!!^QM'F'H)I#C
ML)T5WG Y6/_/,0+UIUZ(3-S-%2XG-V-&0X5X/BZQ42*E)(=!(V1>OWR;3\LI
M,65\&R6-\T)M[]D__/;D%K+37G'DL6J):OLN;J<X;1#'G]XT  A!5M$<;O7
MTJYJS#!R5%&^,+OE^S2(C"E@G2YR&K]P#!% _+3NH%PM3DZ4)ON8Z47=N+A\
M#(>TYS3AB).BDS@.<UX5%XNZW/JN.GA5)CLT@KZF#0\>QK#)SDCT$]VG,TN3
MU1TNWS3J?+9ZZ+>[OMGM,771;%J1IM%%TVNB+BH4U$4$;]LP_HAT IX3A>L)
MXI0&V&.W^76NLVVOLWOX,'^) $7'F_,("3"(M6=IDKBE$[/3GS0\9M8Y=YR9
M8O;@=)4RR68G]=RE)TU?HU)\?WQ X>[$$IJF%AX/&[0W:"$Y!V&:B\F'<1:E
MR30363L33$$\BOT!CVN;PD9.MTV:M",<2D]4:-4O "]*Z)8H")Y4]2G3@UK!
MV,W+"ON!2&@@^/@<+_.F^04@8@?ZQ=:6FVXQ;.DA8_[VVJ]D5#RJ(,&N06X$
MUQD<XW-)4IT!NMH9ACE[A..4MY>]C;LK&@$M:J@L82LN/*W?JZ^!8V^=VYM4
M_3%E(_Q!\OA/WX6XEE7,3I0B8<\$=7\T/\CS,4VCZ0P6E<2(H[-"S$99S5U+
M"KKS8Q:P$!JKE)[WH"U*6^NK(C5>-@+DM*\"00LHZL^#P\OT;'I/^(,-O0XH
M^&^X^F<79G\\+L1-%2Z11?W_%"S_#X$8^*69L3"V[79#A3>=C=!==T0.*U4I
MN3[JO%QTKCL2K1)/V[<' P7J5]^[DD_TT\?&_9"?<OUS2(*[X\\U+JAOG A)
M<2[9V4Y69FL-[5I3WSLP_&+OB>*J^#(8_RRE210$ A,L&FBW>E?RT@&%Y9A5
MZXXYX$&I@J^YF=^M;L6BAF6KZ!2QTPHW)E(!ZUH,:MZ;KS<\/2PHV%*<6S]$
M5Y]J[*GMBF(CWFR5X>\^RZ][,3O90OKP^7I? +VG$^18XCTX4/3IB#BU2UQ:
MCWHQU9NUV;R(X+MRK*V\0JFH='[1]_/CN-:?<;89;:RXP(! VV&>$.QLLJ'*
M>^*DLVUK7Y0P"1M%S#SRFSPNV !62"M]V\IE35=BWPUSDR8@YQR]"G%8KT9V
M_20YH_KT+*Z]OM6:+LNNG6PMNP@4E8-9+7-W0!=YQ_D"P"DJJAB22E7Z&N4Z
M@YGZ?-MX 60_N6#)62V(-R,<RP(N!91 .;P+X&?T(@[1HL4=45.K@5@--JK1
MOO6U(L$7QD9"5]^/V/)75TN3]4A(F;LC(\#/K$VEU/$FYS'D&D?QV!<E>T:7
MKON^44IC(1B'YATNK]>KEE/8,FIC'AR+B9*?,A0.E5%&)G!> /3.?/"Q^<UU
M^Y#RU,:CU0'L+Q\NQS==MG/IQ[YIO2YL$F/HE6MT\A*K+LRHI WNZY=+^37P
M<,2/]JM"SH7G^UG>SK P(>/<,(NQ%@[I*WG$G35_+W;Z8%_'*OF=W&C'J+:_
M0TA.W)/\( JOS/2+C2(M&;J,R[9L:P@!.2&(3@?&,<U,]Q;S&F(PX(< >K9L
MST0/Y@F]2F[6]*D;:]2:"RL*)Y"<DVF$BFMTE@;R"C)[*:BE)F/#;JIOJ=<A
MK?:7]M5KRWD3/TJ]M4=UB"(>8:KXPR,BOX;X+Y3JUH9MW;'"5;\3D8?)KN#Q
MB"DRB8&R#_Q-W(>FB$P5:M=,6&]/OE3B?3Y +Z*RP ^[)>H<6=I[<#IF\&M>
M$%'RIQW+_#U7]P*(LGGVDPM>'_/ N3-2^6ST=+\A5D&6P0;+_/78\LK#_VEM
M%18;5NIJ47J9(-ZCR6.L)23OGI* I/-H0.*D+D[3+Q]'8KQ-8</B%]%P4FBW
MF&U6W2 ;F^"^J22R&"F'N&LETA+IL6:Y*V;?&F6PYYBX:W,0P<%0HLP0DX6&
MNA&H$1$W.7VW?+[6B6H 6M"_"9DRHP!G0B"'?X,6QIQ4Z<]<BYZDT,$C*@E,
M$4QX#.?<AAGX%<^>LF/$(2-?9(&!Z@\5KC_&CV]\NR]%L!%457313\CKM84A
M/22S(W,/;#,VM?70<-07@'2\/P'BAB&3\\QG@,CSYEJ-Y/\&Y_(_!X)C^TQ=
M>, ?5MJ1R33(-<.$4DE">7CC$]Y :WE%)>1P@UX ,\3D]K]$YJ;RYBYJ% M*
M]F6ICZFI\^;=W9-N+I:,]$&\I9'L)"6$.MYXG\7W 2./X(.1MC,U? +J$"]B
M_0IB=C &461E3FK=_/3/PB=%FQ(@P =_V66/<[E(IEGNX\9F%OU-12Q4+)?T
MUZ+AQ\Z8?*4&?7>ZPH.=ST!:B(U8%^ HD6"S4VEC5VZG>WYW.SRXCUO7>W #
MHTQV7D%FAJ>V/#)B("H$"]3^Z7*/<X51ND4V_OQ/-")<.0=(_8].)N;-KWY*
M)=P,LI$J@6;DCX&\ZA'KQDB^+>35"RON5%$D[DQ!,$)QQ1;&_>JKB<FICXWT
MBCQ7!R2<04IWB)G&@@6IFS*I7KH[=HG.<D!KP4/E^KKZZB!A?6:KC09QJ2A:
MM"QO9%7 H4-#B]J$1UM+9B7_/==I>F74@!:N)J% 3QVA:K$#T8\,,7F]1>JH
M%>I6^AF]'KC LL?3NG5OZ&6>KRL1%[2MBOE^JAW9XUEVQ]"RU$&?1WW\HXBQ
M9FQPP#E.:;0H:N%P5LBCQ"$Y,$EY[^TARDD81 3_U9(;T7N-O SHF.%?L6G"
M?OUKEY3(%AGZ30:Z-?-L@ "<HX]^5/(G7<O\??Z7L4EG'Q_P&AR4KQNZHS5/
MTDO%Y0Q1".5SQ53H.@_;>!<9;0KSL9_R0_H*UE7,B),X'?2K)OW\3PC^L.)!
M>541'H\FEC]OBZGO)+T[AM.HK;P .C-J9,7ZHVM9_7 #)U*.X[*A_\M^#OQ?
MX/\"_Z<#CHDZ&U%R!3&48;A>YHG:.EL1 C.M@]3-:%\C4&FB 61_/36-0>;C
M\ L@:5S)C.G/:MPE_U;8RMC6<+G_*FEUG8MP;.!6E*ZB6ZL'0NS0[@$M,SJR
M+N-L2ED).E>0+:3ZC-^*IF&I@HR[.Y&O\"1?R/@4LL7C-4$N(>V-Q-"9WGF1
M7UD2%(6=EBY.,HN]%7FD[VIJ#2Y3VJL8.!G2(S*K>E*7_08=KP<E-']%2T^%
M#LH==%;4 L]I@0XR+X "?Y-'Y7L\9O4KT*!8Y,E*B$VD&'DE7-+BU/>:(I:;
M!>H3T+O+Q,U#NZ7^,15)+.X)\YM]P^K/ODQ]4Q[PQB8UJ_]0H&%FE%7^\QC8
MX2J/_(^KF6C.P=A_PU.HMS"_*TN#77U[=Q17-[&^%48E9-O?C3"3XZ?:%#VA
MK+[4\FJOLEX\YVG-$(>_%-8>&=[8&+NV"9[%Q1K^69('VQ8J=M60^8P]<O67
MY"VF-RN?ML?[UY](5EU> (OTK4^D>X\Y"L\7Z[M'AC30L]ZGW$IHK?6Y]O.%
MY=;9<Y3]7U%S'+?>$77YK$;[5_\X7+J=O0/>;CY/SG<NUMV5_H6XSV]? "#^
M3R^ &[FS=9#7"X A]@70UGC?<AM.#C^'6NV#%E?SYPS""3(KX00F#D6NM?<-
M[J?+\%16=)8_M?<<*6@S4[4:LB%KW;G&UQH6&8PF/+%T&D\4H#OO*LH:3-!P
M_GK#P_J_<C235N'KYM>G^ :#G8W^\PMP=]2# XOQT\=G9HBQ<7$IE)15I/G3
MK $>ALO,X$$D1F!Z$R#30W9-9I((WT$:#SA<_@Y0S$,N%F1T Q%C>@&L*3[Z
MO0 F1^>!3[$^/OMGP)UW1K>)+P!^\#GU"\"?_804 ^[@ FG?">D_A60W<?B4
M0G9RO,[U@R$[1=S)BC_>CM**Q)E>- U%E* MQ.802$P.= GAB02)5@T,])+*
M&O>0D)6]H<K:*NQT._I75[\)E3:?LURA,ZYEERKAW.(;O@UY*V8CY#8? LN3
M'T.3LZ]Y9B'?1BT82A-3\Z@]MQGSC^V4VML2;]]5%&6Y&^*!::"4LPHYJ=P
M?\N"D_8+T%;#Z:AIP]K,64?B"OP;.W!IT_$?#7CX;'GCBR<N_#J$\2+'9N:U
MQK<BTZ2<:JW5(<9G$%OG"(.3;32!V#SL/VZ_]Y40(Y[:,<46#E>E!LP8.'GP
MFA7S(73\A)%YQ0-FSH)HR5;[G%>XCNW2YA"(N62_BH*<@@JQ'$TL5PY5H@F
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M]7:]ON4N%#V^B;'*>UUT?M_(X-5B(:P2N++UAW0Y^"6N8I=QD^+;#C[Y^42
M+)/2' ,1T+]>$+(#_;5[2QRY]^/K53H%Z$G<WV&A+&9;DW-JJ6ALB(1,K_TC
MJUM?Y ?[;C=*ZWZ,L]EX?'!?FHX=!UO=WORT1[8!GNS'$NA(<<]>)H8(H$,7
M@,XE/+!I4@@B(,Y3!;,)O=AR?C#?/$M*5TDF./9"U8NX(QJV0YF5/"5<9-MN
M(=-R[&8))G!!4!_"#E$+3A]0^>5FAAHWM;3<*N18A!F&!C'$$0*GFMW0G;N(
MN=W^%V\X-R>N6T:Z:X(#92>.?22'^W/KE"TGAA9.'B*=H/-TIQ&$L$92?IP*
MK%G'6QL3 5FD=#9 XIHW)T[8$Y*AB."L\>%9I&^T-DJT;.8I @.D-%1TAD5S
MT^!52!];08$X:3'V[$#;(26-^TCN$$'90++ R7E4=9DFV,,3VL]'^J73_842
M(H"C#;^-#R_J7>7%O6#'Q.!BT/2-8=]GT5>7?4<&A'R8+#>4FY-:]JWZ*#]K
MMC!SYI6=&ZW.U4<\U*PZAD?77YM23(B7R @6M@C:F]L]:_G$ZJ188:"8_OFS
MH!6MT%"ZIO?OLKS')]&V\WNJ6O*OH8%ATJ,$19<WZKW<1]V21PJ"H_)'_8*E
M(TK<%7P>K-%R;/-RC@JLT0JU9Z( CMN9WXS)AG6%NI<GYJ$'R?:K](UN">8V
M"VML"_56-E1:.\\+>[T=T?0S+,PR%2*]LE+7'UK@4^6I5"H0*M&ZY0(5-[J^
MO!-Z]2H@-.D7'(;)I/,S#.A4UBB_LCCI]QU&M=:.,_(G9QW"6I;;OMU3DP4"
M3C'X-!BRY,"G+?5F77K$A<8UFGY<KI>C?$:\SJ87>W9>@?NRFZ([0_G7DU[!
MG?1B/B'E=PX!UE>../$Z5P162'CY+ 1X4@$=1VS4NQ !7TF^:OTO?@PV_HL?
M!9"N")&066"/QJ*9[[.BO<T7ET2 \R);0IN:2M8+A)><KVW#W,O@_(RHIEZA
MX/Q G1MBDI[+YF%QX4+'WO8/^??O/!L.K6M^3O8=E?_D1! ])1172_[8$OL*
M"M.>VQ$9^:]6R;5E(N#VKZ[A"2) L+A:2'!>MYR)?.S13K#[J@JR.,[MN>[3
M\6?/E(J L7[*\KKO&T7&BJ\=[]:P)*3 )!)8\*OD&/';^^^1UH1($M,H0_^_
M3(/\?S,-'P):.^231Q#WO"SV0MT-D'JX$ \[4VQ^#CV$>)% RV=@Y2QW$-_W
M3_'\2V/J*CLK1( BM&42Q3X//KFR_31>X_YKT\@VQF@E1K:I]NB^<M815M,-
M73;Y>WQ7=JC?7%)YIA=8F?^$CI^=;F$\G,WK9!;=NHF *+SMG%3]2*-4'7+?
MT-L7'5*+E7-:LERDU=$#LO(*,4M9??'SZ4C)ZI1,?!Q,X3DVWA*6%Y^SK-,:
MS]TTC^A'K V,G.VJ>Z _6$%;H3\5_K#382F!P3,>(PK/0N/4U*']6YY<3?WB
M)B7;)/$1!0XPGKU_:$\$\$)C&,H4IAC,'ULT"=@W[&KESB>KT,B;$0'OQ%+"
M-',*W3Z.9WQ?N,[",+&4*>BMK$ UVSJ+[6F68]G7=P8MA4,-'Q[P@>XQ*Z(B
M,C",MUQ))X5.MJK_TG^1O<_3)PO'9$>S]VIC_S\ .M1,H+,]_BQ%!,REZAZX
MF:^RY*,;&>149E++Z03'CF5YK>T_"%9A1>YH!I<("=D-;*?$QD&+;SUTHC-K
M>(U-]*F:H= ^U^\KE%&ZY(-F:VB#7NF0G15LB#4:6#DC-'[NV2-[,=# $INF
M1SB';EPM1FT8RLCGLAW$5#+U*.6NO?"X8%6@O<V6FK"]S]Z[M%JVG&/;_K@0
M>.D[9P>6T1\C'=_X;QS7E(Y6S^]=M_JLF']J,O,-%W*/JC<SV4*Y_5 &)P<R
MI\'576[:(+=*&Z;1&L8V?:6#?VPIHQ 'R7+6QAL"HOD695@W.Q/+L@L#0U8E
MS6O.8X^V1)?>7&@Q'_K*"%9(5ECQ\W&W8Z*M5-8\&?]I :"X&[NP( 4C ?B7
M&2)@<(^$X86-HS)$P"U\JGV)$'01#*-#K*W]<78;8/('!W2MGHTM9WKY2BK;
MTI$PQNF%L)S#:?ARH:+5B'%.JSD#5UB:"4T5/#XSM.[7F&#!;N[&Y[1]\Z0,
M5F9!+<(3CN7 !WK L[S)3)ZMV]ENM_DE]'<D09_^F=C\ZKQ@LV\4L!M>LY=6
MT\WX'KO5N(T461LKY=4L>VYML_JBHNHKF(U)F4GVX\OJS0:ZK]SYG"],HY^+
M&V#C[6V?-E?55-3HM7'2VM%ET.;G/\OZ)2TG1;X4E1G%)C.;FP6'YW4L1.H+
MK)JCPE,Q#R>/MF8:&\M?>74&)&;K6O'1Q8T1N-=F2YWKH#1H^@O.\G'C^P]R
MX_ZPWL%VU&/%$-C>(OH.MJ >8-<A\!F_.)/LL]['\K [M\,#X9;BS9!7L O5
MO/:>A9#FOB*D$ZTH,IMTFT?MP)X@E$T?80H<*L#[BH79.][JFC^Q]([NA(ZL
MKC$E"N523L5+L(L:OU771YG9SL7>LT.!"2^GOV7/<_TY+-LIG_OC7YQLL-2U
M_)VK))O!M^T>X[9A@X7X"YJC;5?O!QCK42"[<(K "G1X8N/]G)<C_0Q9_>6Y
MA++T5=]=[><6EDW;O-456ERRK$OREOQ<*NIJH9Q2:?OUFEX3DV[([M<#U>]!
M/SLU#T3AC[_\B)".GAFPS0O_](<Q0NW?R85J)J[91H>CAX6N0)=3YM7,.;S3
M-(.KO].NP>FM"BV3HN4QX\+OS9[^+R+RP7G%.;'<8]5J"A3!I:$W^&?1RN8.
M0B5]9NQAP16P9^(,+,7!I0&%LF\V5,]0VO^U!@08TPWEFRO"U36QV/6/RR5D
MVF%W*>RL/^%\9S+3B8#[,+?)Y?DTN,^8^A_?)2GDQ$FU=51!8H.#DN8+"UP0
MCX'<5$3<&;W;[@B7#_OFO<!4/"WSU4OE/[[S@)/PRTW;)^;P+<8G&"+@M\M1
M=;RN>;S">K1";I)<O&6.:[2N651(-VNTV,LCB6B232H/-L3^+YL<XDY:.=SV
MB+A0L&_O*T5/ 9]*F^_96(_(3@NYST=O]00GT05;]5=763<W2$7\3B^Q3-(K
M?@]V0;S\9AG&0N<N-E85B@A^?"[BI&"W@\B?R;UG%@,*VLRFWJ(%[]C]2&:]
M;A+O=!%&/B5*!( .7&K6:Y!9 _\GP]=J5.^<<PD8IEE#EV%#?1F9Z!WIT;E'
M^(PJ#GX/<0-AZ2*AF"^*.H5'<<6QL:_NYVF&O_V^8UD#>8.8GH48Q/Q]7Y<L
M7Y!C^1USHDNA+!ATW_N#!=?X.'2(O[D?2O"!:4$WMJ8A>*T=(*%FMG8;A$7A
M*8<C]KP&-WP7SL27B("#1.C:G_R^QD_CT?Q%K\(DBDP"'<F>TG;K1 68_!G[
M ]EZ?;Y_VKDZN 3#+^/3&K%IQY= )#X\/\+#9G=\,AGI9"-U_*W'UG"]4F#:
ML+P.,6$7K\C81/[5>/L+RJQ<C%/A=70:PJ\N=3E*93@6R] B*?*JP^':]T47
MBF+1>^[,(4R/A4T=WM_XX5*&PK'39!,!"6Y=O-'80+BO_D[G?..NPO67^Q>[
M"#?$WU^G=P\,ZY6T].L.XB2>B2ORU2$G'L>SQ 2'L&E%=DXL/\UW>!OQ[NC#
ME?,K^[X5Y>&V"$,&CYW42#>_C[?L./-^R@KX.9*_K__@6J&H;5;<QD%%-;T&
M'5^='!Z)CT\*2$H+#DZ[+2XN^C0G.SLG0-S32L_*?8+CQ>;?('6.)WZLMW^E
M<^8# .0UK*3;:4-C DK">\WFX^$MJ](5@B:$_VP.X !!>*XSH5_)AW!5:3;R
M-K@N6)O?"F<Q5T#,#Q4'A?A%%?^\X'QT2^SM]J98@D5\'"4O*5^*D45@K#:9
M_Z:QQ;42 7+@G4&,. :,[?[XW<?G/G21:X&U+#7Q@,8!YQU?$<VS>IA5+<+#
MUU9BJCZA/#D'U]>:8G#Z6OWREWE> -Q]TDZ<1SB.+(-JI2%-]"_488<9[?.P
MZCG7K_'ON4)/;FHW.9.IK \5F<=*P0,O(J,PC/X$X/1$/V&9$/9O!==]N7V'
M[W;A'0$^ ,>5E7_6Y?VGY2&)"$B>[,*Q]^ROO3FJKSTK?5-1+\(R%51Q9B3+
MF5Z8T6UK5(B^,"IK6SLX4N_E$3FP[;TQ1&#_J.JWJ5N"BEJ85W),]=]M:$3H
MRZ<K9;5[>M;RRAR3?0.9B5_?NQ\$9__J99WMJT-PALMQ$6C 8^/X!-R4N+^#
MAMBCO>@IIF:TV%3[QS5/\FGZNR4H]D3V'R._D'+FRZLOWP4O@>@ALV,Y1HN&
M=WSU:GX%)V:'/_'AF&=?_\%RO(G/$)K/ B^J+_3\DV42]H%U#TX@OGK0:4Y<
M(A'0X;-GCS^7B)E)!IWSCQ*LX#AW%P5090S^!1% #F&$>4"&[A0)$'1 O>3U
MT$28:UNY*[>0A$;!68[R=7O'<Q[;:W&/>$+\\B,KELM[.A\YU6]+4/ _%W@4
M?65%<%10<UB),P 3D\@CYCG:'AWA^??BU23K)4R6V7SPVZ9M7&Q"M.KGIX<B
M&/)!>#ZD<S 4SW?(E>,*?7UBU->YLX><_KU0F=/9\BBI4L!0-=B)(<+)E(U2
M(VTVV2^;OLAJZTZW0'6-[#L#UZ:FNEF[G,:&WXUM2:0D"#BZ^NTJP)DWF/7G
M ]&)7Z)WJTC2\_,Z]/G[B[A&_@4^:8%=2U2G4><LE=I4/=?U-ZRQ4K>:!:J5
M691DE17#?S<5S&%>1$S=87O.\)0#E1=^R^$@*":J%GG^0VT'&PI;[JH*EB'\
MRNJZK(LXSXB)5+B[EPS]H=S'<M*]QQPXN0/J+3%!$/X.V$H2:)QW0Q$R9+7"
M$Q"&&N$S-QHMH1O@.REMVFU1[:OE<6/[3++,,DP09<:A7@8NU+,;ZC>95RQ-
MPBU6 C0I:0JT-?[X<;S!4 _SEVM3Y(92OMG>+,=%@I*EJ3"1SBKG*N5<Y5/P
M>":1H/2,W0_W'^L)+5P('@PM2T!M3#(Y;H $!%C%@MVC-!CB/U]!*6O(P9DP
M]?'9J]BM#FUT#FO[?%H^:MR[\;W[A#]ETXEAQUQ0 @6H1UJNJ/OL_B;T=7/7
MP,DTE%X<B""\/F-2TMC9RYC2#_%>BW_F5]CXZC?&RN*@9C4JBJUW_>C9X\>B
MW<QZA;]&EL'5PJXQ$$.T[A\NP5)JWQ%+6.3Q5K1\^?LCL5TUC<FNAXU>,9ZX
MP#V[X?V/'7#O\//=U--:M[WEE$$MR7NF(L^U\U@=:I;UI91EI1FH:#<59#X:
ME @Q4K^-?Z?*']TZP-34,]%))I_YVA^@[<\ZVI<"4U?8H.0.$ZQ07*"Y3V)_
M9UHL>-3GOSTS9T_*7;>D,0W\]4XUTE?M);.J?:>LYD\WV0JCIB%VID5\4^%C
M,\XV0]FTVT&S=+]W.H1$H];R;7+?JV:\F,4&2O5.X\1VW6K %8HR(I?&G($1
M27ZBJI;,YAG,O0X%S-,U<$=\FLD1:'';">H EFO45#E.(N@]:EX#'ZHCS6V7
M@]MQW[;JDG;WA]!9'(_%95(]+4QF)<CY-$/ARDBOAPRR3-P5E_$13Z_3F7 '
M?1CJ8ELUQ&.@3OH!UXMG+5+)[S=]D+9RE'+DY#**@NC=J;E-(<^?38J%E9.]
M63XVALL3^B@GE_U/MBD3?0L, D(0I)OV^*PFS=*Q.^/\2[=<>.=*/J?:\[R"
MO,2;3T*H/]^Z1A.%.+]G^(:NORKCKT.!KN--J:NI)/=Q>=J205[TD0!N'E!:
M@1WUSO(ONK:VS#0S(^]J521/9KJ]5_1DM 8/,JJ.[1GZUYCDP0NFZBODTV7C
M-?,*TTO"7A=DQ\L&6,A(=O<(,_YI>B']X._U!V9T)9(IOD^Q-T]SQ0W-:Y0L
MG'&JDYS0+N^ZN?KE0!P''&-T?L;+6.]?6^0KM<^9]%0#4EG?:V>&V*'E[^RF
MTW2PWY$5=BKES-+-OG$/H\.9^VO[X&7B ]$ $HABPCN2XI];?$]WOVE%!%1?
MH+"#;V\B)<0L+^OTA\MQ%U#I<&7HL2E!]_>,0I&5M!M.-_H1G>Z(?ZVKMG:)
MOWBGI"C.2+NB*<=?M"9<Y*F="B!26\SI]ZWT:;MFT11H3 X0;$D$O. C AJI
MCD_5@/RDB*<.NG/I=3VN%?>Q;0\4.Q??6A'!$)M,D[8=#FN=:&%U7D,*I<V)
M-K@>S*JV'@F6C2Z5*RL;1580 ?=RP>&?V6=\ZN9YF2 .7-;V?E8R8M<\.).H
MTC)OPJ\J.@<LNR-"J2D-"3K JG^:&!XVZ7DW[@\F-_;#]B%1$O-%'O8&DQBF
MZY(.MRFK*Q$K0G1TCQI3*\JH)=3_"G<"]PQD;B<D6=)O<9JE%>KF19O-()*9
MDL9M=IZ./NJEB3=9Z_/NQOM_ YBDKW:T(_GIV:Q@3U>D93*4,![>5_?LUWB.
MN&R=S355560":4;,L"H5A1:<G(A)K9UK!7=B9VL368;IWG]TC_K;OMQ0KA#;
MQ?^6F:-AM#49NF K?(>\OL;8[,DODV/7(Z Q3J[+>X-RE\>T/O:]/_)0A 2\
MH#R(]MZWC:;:B_Z1.>LA'X6?C^[6;944A,WHFS ;**F/57'T:\7T:%T+G5P7
MJ*7_4@HO,&8N1&3JZH^MSPO-&P[ZN$BM]FZEO7^)6O.1 AR1-)-B.>RS;-AU
M:EG AO%9<M'IL2])X4DJCQY:(7F:ZY8*?F#>=SW"MGG5*(;@"2&(IUY'PL]Y
M0&N_24JPU0B*B< W O].$K@?]!$!)=7, Y@V@E;J L$2.M@[8EB/[T<2 <H$
MF<D)@7EA9X%_T7[DF$"[CBOZJ!X,69,:PAJN="T;HQ8)6K9]3(_<BCM>QUXT
MEL\%R5T)TC-X9WF7ZVL=.1' BA6?D%_.@^=;ZJ,'3 ^R\6U>[)OE)95\?V<_
M0'=KX -9;('O]!OC,T[5PA</OZ])07E!"=,3"8TN4UX+!2)K@SL$Q&RM<G+S
MV=VE]KU^6-W7RIO\[CPM/XJ#F^FCLMT4GIGG%?Q4"'_GGJ.4'=S5EVM0B_#;
MNV5K]YGJ6K#6V,$3(J!HE]F0/&I>1)<Z_^\8<U,1I"<+\\NF>4WA4,[Z_#GO
MSE<\#/F8,FX^^4'B2=/(CK</+?_XN*I&-VME:EY]@:&C3E"(O/3\EUPW(<%J
MSM_C??J,V!NK/+&)/\[;B8#VP, U4>#ODSP9)8FX^I]F!B(WF .+N,YD1TJ3
MG*8DWV^TK+E._$WWY_H^JY,23B424J@^5LO]7B_<BB+NNF(1ER!=K L5P[<W
MG"B8E[:IF9F@L175()SQ[\'VRD\<RO?!WL(W&&^]]7+\LO_3YW>N)R:#QNN#
M&V]*#!:X46H9?NR8+1]X%O"X,![5/J9[]=YA1WQFT0^:)>DCIP2W7^?]N3,8
M^4/Y8<X(=MHQD#3+BMSKY%XGZZ^'OLQ<9\S M6W@T27F> [4"UL1OM-TZ6AE
M$.U39#O0OKW3-]J!\!+YI#T^JF4FC/BBZ!+M[:(^J$#W48+E=L/4Y85)PKLA
M3$'>/+9\>O^,Q]PE@&FX2S3+,T)M1>[WB2"+-E)=3Y'U0SA%TSN7DQL7E43
M;5:"[@*+ZQZGX31Z^Q .'92/2)J26I<%(S?YXJR?^J6;8)\%)U665DRM_;;.
MBSJBC8O6J&BHBA2)%OV+[XW"!-I'^4TG+I8RW]WZ5^C67AA=.V$/=*K\K=F;
MT="VC#G8F+,C'1&N[&S@I7>3TCJD,SA)T2OQ&7HN XFT4RMAZ/)^I%R@D=2O
MF<H'.W;>=ZT@Y +B>7F<KI:I5<R!UQG(L/)7\_I7T^DN214R'XBYG-#'((B
MUGCA0'.7M/V+!5S3^VU%GO.0KMT2S)$2*+3+IJ<+4:H>95FA$YZ)3J3-F=/!
MA3N&YUI9'NO*\\6Y;[0%BYL(1FF/RDM6[IX<S,KZ-/TD>\2O[_<XVZ.63N_J
M"A=$G.)^\MS<;4'M:M;@AXLJE0/-H)=5J/.7SLS;&R*D.G6X "9O1(3IHU<7
M3/[JTS3ZJ@LS)Y04.-)6M,6B3HRF/8-3C"QRM(2D9&FE$FJM<N!A#[LIC;B
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M:P?+"U$V!>#?;5FMIB=4Z"%K0@^D X+MM(]HOGSN22KR\F8[O-DZ+J>7<+)
M(FQ&Z'XUWC\CP6;7I[+BP!U?7HG8NV.Y6_S!L2,$C3:GCF@Q/BQ741,R&%X^
M%*WSU+LMNE:8'ZU-W9F1[6K2S5HV,- Q%V32GI)6#+CRS21OX7\M7::VM?F"
MG[::5NBDZK1*ZVNW"E@.3.$B6"UX_$+!.#\OT>A%1MPMBN+;9<(L"]]SY9@;
MAREWFE<AN!JL%XMAXD+S[29QTV-=.0]'CP:PGBT^)ZE;A:7]2&N%'RN=<#6Z
MI,3DMK]D1=6,75U5^;7Y!>@"CYH)<J[T 5^+3#7YU*WT38D9M!C;[E!,^Q#X
M[.3!<G,TY"BO8T+&4/D@),\LB>KYCZZ66OX3V]6@17MA"9X::X?3!PJW(*S*
M&<6]7U3?^O=+MK<&>M3@?D<<N+PQ^2)PTHT5EY22.D0N#Z(*;QWZ4 VGRH[^
MC^;>.ZBI;_L;/B*((H@B0:4C*!U$Z0(1D=Y[$Y J'9$.8@0$)$" 4 U2I'>D
M=X(@A-Y[E2H=(?2T)]_[S-RY]_>\?[SSS+PS;R:923+G[+/7WI^UUN=SSIZU
M]4 ^(M4XRRE356O*$)K<G.Z>VD/QK?<T%=H^7W.L+8>NSNA/[*WOG"<GOU?!
M5PI98WNV7BHR6L5U%4G3$L$9AG3P1_[[<<U=MIC,/BV#E:,$O:]\=BKP?)8X
ME WW]Y+,;BV#E\<G"?K57C<>2>L_TI>*9HSK+H%%Z0>1Q@3\JZH4*ZQE^,[_
M.<V.,I5HO XQG/N[H4\T;X'/9O$_AQ,K+E&EC5VP)J;)EH"*RS.6^$*5^<1;
MJ%E?IGS%V!(8&ZF7U_@T!>4'$2^A=A(^..\3[3<N>X6/DG0H*Y_=^604CV<N
M 1DN X%I M)UD_\N%91Y%GC"HG<:T5EG=Q)C?LIK26:U;!JXVU+7!&.U4>?N
MIC2>OS\?A(*BY<A3.[/[EM4-AVN])?+"6FE+:E9SXBQF)E2*/Z@0X0KY?X!K
MX+_ANF/^O^%:#JE,/C3$'Z:N'N CTO\I'.>VU/H?UA[\?VOMOY>?">X=BJTT
M53W'VI_C]W>-%QJ=RKY^35GXFK+7;IR2"O_8.OXO5U/^EZNE,T+:P&]V8C#<
M$!#DX$&K# '8_+J3@>_"878$P>L"%F=Y! !L_G>5  26[S+=%W1H1/[_H?#F
M_^4?ZL;SG8\7?F[X7'NA9O_$J 1F5:V;"?=0CLI!U.;(,D@Y<73=9U!)TC)I
M7YV--'40%"@M9<N/Y(NDGR(I>0G%%OG+-UC\K'&9PN1.EN?5!NUSC/)X=N7.
MAH"$[V_6$("JT''D88<W ?B#B"< 9:U=&3M>_2R=;OA3R.:M+/#)Q9K;,E$/
M?%,E *:29QAQ,^(71C$WO%\A^'+G8.D_#F[!(Z6BL6)+Z C(SEN%_&GJPOS,
M*O \@ZK+P3SGZ[6[?#ZW/EA'W]0=Z1"0HDQ3.ZY>]$\JABGM\3]WK':Q="NO
MVM$PFQ?T3BW=N,LRTE%LIDPU>T68]EBFY:J83,#T:;K=7(/&IB9F<I,M4H4D
MHZ"_V&#\>B]B];OF#+6<3/! Y#R#Y@]T:HC;[[M\-1C[RC6-ES!Z^QLJ#?8Q
M<\I,>GN"!Z\^%K6F!Z;O-S?5.Y_6^OC8@2D@(;(<?ZF^4;PYIEQO#9B^R'=?
M\&XIT3P1M8OW+:"UA'K'=C6P"(2";<PH+P&QNAZ!INGG&9S5516NCWM7/O;M
M(\(?J&NK?"0 +,KQ(9W"7Z\S$8">XKOZX\9E$C6X2.]!U44QI_MB-PW"V^(-
MTIQE]ZSRLI71Y 4=*2USZQI&BX*BTCVNK;54]%CQ#D%_ON#/]>5.T-4898O3
M=XW)>''7)2Q:!W(R-4L 3AHWJ%?J"$  ^)C\%7('W;W4$4@ Q)/QM9YO-QU7
MNK6UIWZ6R)JJ:AI2QY)!0&K*PO[C=!27C*]?3V.NJC+(<\2!?Y7HC8W3>PG-
M#2:+_GV-LKCURM#D,!N0_^@IS8ZY^>,'T]M/9JCZR9;# PO-Z*L,FDSZBO/Z
MBE)Q=VGCQ\ICU)^_WJX779V!C52;'?C8]7;G1V<B_3(S,R6 RV/Y :FQVO=A
MTV(NTZK'Z3R=ERH/:IYPO$E$.: WB63K[<U"R&K8'@$8$N$D &:!4/#D3@H8
MNH3;)0##3(K@_S)'?-<5-=,2+2L@9[^1V5,J)%^:P_M(0"%H;6(5E #B!JEQ
MLRG<>!S/B- (<V*Q#!RSFZ]U,&!JG_[N%OI#O[4+1+XA'B,T'MWW;:8/.^-\
M9DJW$L^CI?354&42,?+)TH2>7FMX.#V9N??RS@E-:V/\ SE3>/E7[@+WXT30
M1"+-:T5-9>6;XWIJIZ2;T/M]+'^9YZ'<G$GB5CJC361:4CW"5]'2SSS<J7*;
MSWR>DM9%T"O?_TN1F<2Y!I3+:IKZP+KVI,(40;49W*"/HM&\Z_F](QT*Z%'A
M]G3EPF9]+W/]_,1AY4#1(_YR#^N]G<0S]3"NMRUW4M*JKSYX');XO8"VH%2F
M8Y@SH:5KO=6SL:ER9M'2@]+*0#F!C4<#;A U,:I4GJLH1_WC0&XP:TJ_,R:K
MI#S#.!B:E%7F=I\2SV.?[B#,S?/@F.U'?<.9;[:##8SC_&LP]#)>XVM]&G_I
MGP9X*Z/]X/BJ/"GBPZ8D'\ONLI<@]MT"\F(CAP#LE%<,72YXD!^:$NEDQN75
M @_<1S^&<S?D'QH",#GXF2I\"?=VVFOK2_O&X^S^_M<Z*QYZT;"BDN'<N=VU
M*1&0&D)61CBE+^=N5EN&+4,YMUN E,+*QK3(C_.<+]M7]WYW[#W,D EEK-F'
M<*+U1Z?WYD(>_YX8(6M/F2E,[TBP5AL6+;)+HY+I,%.2)@M,G7^N6D@ @B'^
MN@)$MDX (@)C_C:*.^YA>7=E=H;6BW,/E\X3_%V*L#C^GM.>OJ8PHH]8O+1F
MIDO[R,:^,J&BQ;(L3=+0D>$MH(1;P&QJ?"S^];>9E@J7'JU?S ^NIL5>4B!G
MVK<MSI>;(.@!90(P9?'V/\-9$.2_4"FYRW01LAO81/=GKN]U_4Q14>%M&^Y1
M1'Z?THJ$&ZW'.)>Z8DAQAJ79G&/C3#E]U]_R*%JA84>N]\]DQ^/[I/KJ/.PF
MF ]K;LA$I\7Z%H&*\L*!C+_'!""M7\=EGOGM.QO2KA R:/<&K[SD#4[AE%[E
M8L=7=ZJZ*M4L@ZH+;<E*!*1S:VKA1]NSH_2^E=T5I>]X?G&5]^9G2_?BJ8I=
MD0L"-8$BU=3NC^-T\T0$QN\79J*4RUIV^<CMWC"X[W66J_D;CELK]>BB5+7/
M:"M^<N3(,Y[<7!W3JI4L4S\_K?*9%3A5K;#UU^T:9ODQKC5.&2LMR;WNZC G
M@71^7COZZ%(3E(73IYA-('EWT[K>[^1J98"NLY?9-3'VAC&NXPN3!OM"!0$X
M3P/IB-P?"$^?KMH=X<#KG!ENSDU4ISB^X>D$:OHP%YNHNVI:S'"TCZ3S?**3
M@T]S1)2NDK4FF1Q]4+&(;6;^2PZ:W%=/AIB.U6G?YWVW&WE(;AJ9RB!6Z:T3
MU>L;(C=<)$:C !=L;WM2/B1-LA"^A+E;4C6R-]##['5$8[UUY.A>?\Y3B)_-
M,_EB?4W9J7!:N2RQ3'CZIL>N:M51TD[++$,?^^W/$AJGK.. !LFWMP481,O0
M>IGF_)CCPN2?;<2C%%^E!YX5;YZ:>>C+F+&!_P<V[)#_@8T0B__"QA.O.D<7
MV'AFCXUWNRU-!L@0!-+JU9%79D,8?=A:,2IRE,N+*>3PV'W>XBPV1_FCXX-6
M,]38D^8=U3,M2>;W,<3QV''R\:FZ\5FKFQWRX"4BKIC6KB!?I72L06A.SLVV
M3M1(3U2,2NFD)AC^")'3'JK?+"05Q]LR_<XH0-;:5G35S\W639/>8+0QFNSC
M6VDFM^<U99TU2ZYGLZWPQ6<<"#*3D&$]/7R@B//_&PB[[<_I3P[X3HJ%?GCS
M'1:B+1>'N!7W?NCIWOQ,C6*SRTO-[+<VS#RACH7?VSBQTOS22<>LF[2[@K%,
M+I,G,9']-D65Q@4E;SO><&=W&^J$ 4&&'!.T";3P6-G#'LD^JUNIMP,C:F$Z
MBW4%OTZ'BTR9:50\"S%<-^^@23)DL@<=SN02_%2\J^8%F<U^?N0-L+VU@T^!
M%^2O&;%(ZN:X3ETX3)A":^DII@9<'/*]HGD\CCT+HYX^?_+BY/QR>SU/]4J1
M\N3]46Q-D$R_6PMRJ635P>K.8*9>"<<V ?"S-<$%YZ^/7.L[".?8G[KA\NZ,
M3D<H,R!7FTGS>&2>ZX0_A]H\:OP]1P'\UQ;'^X<]C'$_/.,8KRDJZNC')<S?
M^<G\DP/TR$@KZK9_"BAQPNP^[</,J&!J$FJE/?3T<]VR=P2@J\Y.G8L[78Z*
MXWJ,MEELX<WBO4W[%2J^(],3L3M=5 L)'KLHIUG!L]28O!^?FC_IQY!I;__Z
M#?E\<76$6@BMT-/KS=+LT_>3EG1+'JAJ@E!P];%8L/V*?382F'^1/#&F?_[H
MEYNDBMV;8C,!,9K#\BG= 2J9]XZA4;?YO]M8?]0+N(>LQ6RC2EWYOQ* S\^F
MCAX!Y;O;_)%+>#7X:GL _T^V4M)21IO '+[.PE.2CW+9$G4^M]B]EH7F(J_J
M.;D_,))9"2OXJ:UF]T7I4.B)?B?9*WF;Z"#*3X<XZ: #OGT^ ;NJIACU7W91
M-=?"8VXK2:N9&FQ9M[B<II;-B4582^Y$;_9IZX@_H7PJA=(T'_.T_#>/M4[B
MRH<J<<(DOB/$H/:V\G!NJS@59<:X>J[#1IKKK,%4,2W%3W_8<CP1(74G+VKD
M^#+2_3W[C1PWB)3QMNQ/4D_]5OW??ZN9Y"VTY<([1\8I%ZE>':=<JO@%UZA>
MT^9[DAUJ>7+OSS0ZMJS,=N.^CFG$ RG.#B'V\._2+Q=/]C"!=0_-^MRL*=_C
M7K'K/"P\;WE!GCNEZ+)+9JCCS /]QLR<Y?>.]H /O<J5BU!\JNH-5V9]ZPT>
MAP<F>L@OS'I<VXWP8M46 JZQWF*1^=PZOY?J/!_=1]-7US8J4@0?H*?1\(7S
M^#/B0B_C&LL%,(.KIZB>P,CZ]Z4\UN^F]XICRWRMGJE4C\]\J(97NW-3L8<R
M7NDY>_(^K61J/KYQ9NZ37=RZ/.FP7I:NM!6RH2FQ;&"? /"[UO7+IS6+'G7K
MZ84:VS[^Y"Y]*V-WSO,/=O<9\F*EB !DMX1")@E "@%8$H*TP'(R3@[7J"_4
M_JFJ)S@L<DA?21ECY9W^,J4BK^RS@6ZR#NQ-T:#^T!T;J>+[\Z\_4E=PUFM7
M/Y?IN(FU]T3X?P:.@5.!E>>MCG^<"I2?]$J]*J.B?\O.;"3-<N N:"P]X>)6
MBJKS3NYKSEM>B/.KQ8-W/^+!E:]AY4T[/)+T%D>BE(]K7-3>;FW5EJ,:LATK
MF^>EFX,'VT;W3NPEJ_\V\'FLSU(;Q?2GUDY4!.P%-!XXF97Q,W.-E*_,3=RK
M&VH)GT'U?<?<6TJ[DM*S6D%K5.TX7QK(+!IG,S.LR*!OJ*>HKE'.%M8=9BS?
M<WDK\'/^NHQ+;;!3A)T,H[U9H=#OK/RA82^NF8",O;!E/P=+%T>J7T<E0B&.
MP/@NR-'SM]ZQ@[X^2!ND?>=E%A=%41$?\0W2NPG(I+?EP)4?YYP\ VC)M.7O
M YX&,I:0_MP0 G!K7@R_8AL(PS42@,0@Y)\T M">]A*/)0"]44CTPCVLM\;G
MQ9I9C'E=L3^N^'3_6HG>+G_>B5W5W9AO>@]$\=(;_O$BSR/4/L,[RSUZ3I5;
M+"SD6_?QH+7BO'VM1K-0;G:=!/%-RUX&A1'WG@\EKMY-;ZEK3>]-T3/I!_$6
M%3E92![K2<+Y%)ZM:VR@G,EUJS].25!NR;+%,R=4#(^JZC(Z5RHS:(VY:K&'
M!G&[L#E?/Y7>N%:?$;MKMX#"5(Q_OM>A5T%2?Q[E!T[S_WSQ@,\9M[U8*F$9
MOB]X2ZN=W:C]\\LVF^B;[J%'RVI>EA]7F"N3L_*/D/[C5M[>8"O+OK[TI9.1
M80I_;Q9W[,-T>RH5+G*M#XDVL6-<HC0*HY%_%2L.6/<BW!O4&^>'34P>-Z;3
M=PL3 RQ0USU6H+NX:)F$>E.S7MI:VN@*O_Y2L'.91.0*.@Z:>4+6(GE5C'DH
M>57F<COZSZLQ]?"BKM$5L<]Q?K909\3+'ZYF%'3M]+V2W[65[W!<.$3@!]JR
M^MS-O6?K<+5:9+T-\&EZ$KJ:&#2I=DSVATN8CTL$+F-#0VGCII6IFZ_!W#M>
M'<I/.AZ:"@:3D5BE0,F*>CMHUOTBUKC'P;[9B ?6;T;Z:(N8)>Z$4\*BKH-C
M SNB2J*ZV\*N?69Y*-F[N::L_2@Z1*'MZ8_?LMWL:XIJ<]EXZ;1. N#(A\3O
M;$L75!  #V<"L%$$084K^<1<<.QGH <XL>Z-7)!;3\ZC8+_FC]:$?+<O=+V;
M'1[94HGH1;#\_6!J;YC.::NNIAY4,]1 /1\0^<7'%!3F(R]ZPF84T[487L Y
MS<# 6V:\R+PQR,UH$4OYI>3%WZQ.)?%-F0O]J-DF'W]GD])P3;G()2H1>8V7
M\6X=5%+%4B#?C;F)^-%16AAC0DW8NZB[/4\LC"MS!QIN!>P,5'G%>'G'.P$\
MPK_B7C+\ M)YR'@1U *<F<@6@P#1B7ZI&C"_/*-4MU%SH2,)(BRFS4X_D^;>
M^)5<(\IOMTILS#NT@.G75]]1KY&\A%_!3@>$2_8NFU <;D9@1Y.X>!OA#IW+
M8>7>JD_&R@X518?\KL5WF%U91>_KG8X89VV061 -"*Q.+7'&_&R4]^J&]^$0
M/>\'_GQR44;-C"[A4I9@2^@2(J,28+E$[Y9?I@ZR'!Q<ED"&AN-QWBW$P)8
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M(A)/'Y_NX VN$0\G6D_AQ8Q!$P?J*0$8\K0XG)&DO\S'V_J80I9#JI!G::@
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M 0!E83 R,#4Q,C(M,#0N:'1M4$L! A0#%     @ B(OI6#Z4]Z1^ P  90T
M !H              ( !P],. &5A,#(P-3$R,C T97@R,RTQ7V%R8V$N:'1M
M4$L! A0#%     @ B(OI6)K;+W7O 0  T00  !H              ( !>=<.
M &5A,#(P-3$R,C T97@R,RTR7V%R8V$N:'1M4$L! A0#%     @ B(OI6*3L
MWOCM#   S3(  !D              ( !H-D. &5A,#(P-3$R,C T97@X+3%?
M87)C82YH=&U02P$"% ,4    " "(B^E8D+?=UOH+   K,   &0
M    @ '$Y@X 96$P,C U,3(R,#1E>#@M,E]A<F-A+FAT;5!+ 0(4 Q0    (
M (B+Z5@'_X#06=4  $?O   -              "  ?7R#@!T87)C85\P,#$N
M:G!G4$L! A0#%     @ B(OI6$O6)Q6P/P4 ?G0&  X              ( !
M><@/ '1I;6%G95\P,#$N:G!G4$L! A0#%     @ B(OI6-"((U $+ P X0L.
M  X              ( !50@5 '1I;6%G95\P,#(N:G!G4$L! A0#%     @
MB(OI6!K5\[Q?0 ( _Z #  X              ( !A30A '1I;6%G95\P,#,N
M:G!G4$L! A0#%     @ B(OI6+D.()/AI0, 6^$$  X              ( !
M$'4C '1I;6%G95\P,#0N:G!G4$L! A0#%     @ B(OI6.JV,R\_2@$ E=D!
M  X              ( !'1LG '1I;6%G95\P,#4N:G!G4$L! A0#%     @
MB(OI6-%3Y5=BY0, *] $  X              ( !B&4H '1I;6%G95\P,#8N
M:G!G4$L! A0#%     @ B(OI6&K%?!H&@P, C^D$  X              ( !
M%DLL '1I;6%G95\P,#<N:G!G4$L! A0#%     @ B(OI6/WW-Z0C:0  1W,
M  X              ( !2,XO '1L=6-I9%]S:6<N:G!G4$L! A0#%     @
MB(OI6'7KF&+N:P$ KWT!  \              ( !ES<P '1O<G5K85]L;V=O
:+FIP9U!+!08     %  4 /\$  "RHS$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>ea0205122-04_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:abio="http://www.arcabiopharma.com/20240331"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="abio-20240331.xsd" xlink:type="simple"/>
    <context id="c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
        </entity>
        <period>
            <startDate>2022-12-31</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">abio:ClinicalDevelopmentDecisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
        </entity>
        <period>
            <startDate>2023-11-30</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="c82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
        </entity>
        <period>
            <instant>2020-08-29</instant>
        </period>
    </context>
    <context id="c86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
        </entity>
        <period>
            <startDate>2020-08-28</startDate>
            <endDate>2020-08-29</endDate>
        </period>
    </context>
    <context id="c87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
        </entity>
        <period>
            <startDate>2023-10-31</startDate>
            <endDate>2023-10-31</endDate>
        </period>
    </context>
    <context id="c89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abio:UniversityMedicalCenterOfJohannesGutenbergUniversityMainzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abio:PatentAssignmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-07-31</endDate>
        </period>
    </context>
    <context id="c92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abio:CapitalOnDemandSalesAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">abio:JonesTradingInstitutionalServicesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-22</instant>
        </period>
    </context>
    <context id="c93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">abio:JonesTradingInstitutionalServicesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-22</instant>
        </period>
    </context>
    <context id="c94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abio:NewCapitalOnDemandSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abio:NewCapitalOnDemandSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">abio:TwoThousandAndTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-10</instant>
        </period>
    </context>
    <context id="c97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">abio:TwoThousandAndTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">abio:IncentiveStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">abio:IncentiveStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:PrincipalOwnerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">abio:TwoThousandAndThirteenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">abio:TwoThousandAndTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">abio:TwoThousandAndTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">abio:FirstThreePercentPayContributionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">abio:NextTwoPercentPayContributionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:EarliestTaxYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="c115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:LatestTaxYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="c116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-30</instant>
        </period>
    </context>
    <context id="c129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abio:CapitalOnDemandSalesAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">abio:JonesTradingInstitutionalServicesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abio:NewCapitalOnDemandSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abio:NewCapitalOnDemandSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
        </entity>
        <period>
            <startDate>2023-12-31</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">abio:ArcaBiopharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-03</startDate>
            <endDate>2024-04-03</endDate>
        </period>
    </context>
    <context id="c139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">abio:ArcaBiopharmaIncAndOrukaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-03</instant>
        </period>
    </context>
    <context id="c140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">abio:ArcaBiopharmaIncAndOrukaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">abio:ArcaBiopharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-03</instant>
        </period>
    </context>
    <context id="c141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-03</startDate>
            <endDate>2024-04-03</endDate>
        </period>
    </context>
    <context id="c142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abio:MergerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-03</instant>
        </period>
    </context>
    <context id="c143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">abio:ArcaBiopharmaIncAndOrukaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abio:MergerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-03</instant>
        </period>
    </context>
    <context id="c144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abio:MergerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-03</instant>
        </period>
    </context>
    <context id="c145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-03</instant>
        </period>
    </context>
    <context id="c146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abio:FirstMergerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">abio:ArcaBiopharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-03</instant>
        </period>
    </context>
    <context id="c147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">abio:ArcaBiopharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-03</startDate>
            <endDate>2024-04-03</endDate>
        </period>
    </context>
    <context id="c148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abio:FirstMergerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">abio:OrukaTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-03</startDate>
            <endDate>2024-04-03</endDate>
        </period>
    </context>
    <context id="c149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abio:CommonStockAndPreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">abio:OrukaTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-03</startDate>
            <endDate>2024-04-03</endDate>
        </period>
    </context>
    <context id="c150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abio:SeperationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-03</startDate>
            <endDate>2024-04-03</endDate>
        </period>
    </context>
    <context id="c151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:PresidentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abio:SecondAmendmentOfCertainRetentionBonusLettersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-20</startDate>
            <endDate>2024-04-20</endDate>
        </period>
    </context>
    <context id="c152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abio:SecondAmendmentOfCertainRetentionBonusLettersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-20</startDate>
            <endDate>2024-04-20</endDate>
        </period>
    </context>
    <context id="c153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">abio:ThomasAKeuerAndCJeffreyDekkerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-20</instant>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPershares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="pure">
        <measure>pure</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="eur">
        <measure>iso4217:EUR</measure>
    </unit>
    <dei:EntityRegistrantName contextRef="c0" id="ixv-32">ARCA BIOPHARMA, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c0" id="ixv-42">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFilerCategory contextRef="c0" id="ixv-160">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c0" id="ixv-173">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c0" id="ixv-188">false</dei:EntityEmergingGrowthCompany>
    <dei:AmendmentDescription contextRef="c0" id="ixv-458">The issuances of (i)&#160;all shares of ARCA common stock in exchange for each share of Oruka common stock (including shares of Oruka common stock issued in the Oruka pre-closing financing), (ii)&#160;all shares of ARCA common stock issuable upon exercise of pre-funded warrants issued in exchange for pre-funded warrants to purchase shares of Oruka common stock sold in the Oruka pre-closing financing, and (iii)&#160;all shares of ARCA common stock issuable upon conversion of ARCA Series&#160;B Preferred Stock issued in exchange for each share of Oruka preferred stock, are intended to be covered by this registration statement on Form&#160;S-4 of which the accompanying proxy statement/prospectus is a part. There is no difference between the shares of ARCA common stock that will be issued in exchange for each share of Oruka common stock issued in the pre-closing financing, the shares of ARCA common stock that will be issued in exchange for each other share of Oruka common stock, the shares of ARCA common stock that will be issuable upon the exercise of pre-funded warrants that will be issued in exchange for pre-funded warrants to purchase shares of Oruka common stock sold in the pre-closing financing and the shares of ARCA common stock that will be issuable upon conversion of ARCA Series&#160;B Preferred Stock that will be issued in exchange for each share of Oruka preferred stock.</dei:AmendmentDescription>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c1" decimals="-3" id="ixv-37766" unitRef="usd">37431000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c2" decimals="-3" id="ixv-37767" unitRef="usd">42445000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:OtherAssetsCurrent contextRef="c1" decimals="-3" id="ixv-37768" unitRef="usd">161000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="c2" decimals="-3" id="ixv-37769" unitRef="usd">254000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c1" decimals="-3" id="ixv-37770" unitRef="usd">37592000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c2" decimals="-3" id="ixv-37771" unitRef="usd">42699000</us-gaap:AssetsCurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c1" decimals="-3" id="ixv-37772" unitRef="usd">247000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c2" decimals="-3" id="ixv-37773" unitRef="usd">343000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c1" decimals="-3" id="ixv-37774" unitRef="usd">10000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c2" decimals="-3" id="ixv-37775" unitRef="usd">25000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OtherAssetsNoncurrent contextRef="c1" decimals="-3" id="ixv-37776" unitRef="usd">12000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c2" decimals="-3" id="ixv-37777" unitRef="usd">18000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets contextRef="c1" decimals="-3" id="ixv-37778" unitRef="usd">37861000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c2" decimals="-3" id="ixv-37779" unitRef="usd">43085000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="c1" decimals="-3" id="ixv-37780" unitRef="usd">362000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c2" decimals="-3" id="ixv-37781" unitRef="usd">334000</us-gaap:AccountsPayableCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c1" decimals="-3" id="ixv-37782" unitRef="usd">100000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c2" decimals="-3" id="ixv-37783" unitRef="usd">173000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c3" decimals="-3" id="ixv-37784" unitRef="usd">0</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c4" decimals="-3" id="ixv-37785" unitRef="usd">216000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c1" decimals="-3" id="ixv-37786" unitRef="usd">175000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c2" decimals="-3" id="ixv-37787" unitRef="usd">625000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c1" decimals="-3" id="ixv-37788" unitRef="usd">637000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c2" decimals="-3" id="ixv-37789" unitRef="usd">1132000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c1" decimals="-3" id="ixv-37790" unitRef="usd">204000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c2" decimals="-3" id="ixv-37791" unitRef="usd">280000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities contextRef="c1" decimals="-3" id="ixv-37792" unitRef="usd">841000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c2" decimals="-3" id="ixv-37793" unitRef="usd">1412000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c1"
      decimals="INF"
      id="ixv-37794"
      unitRef="usdPershares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c2"
      decimals="INF"
      id="ixv-37795"
      unitRef="usdPershares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c1"
      decimals="INF"
      id="ixv-37796"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c2"
      decimals="INF"
      id="ixv-37797"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c1"
      decimals="INF"
      id="ixv-37798"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c2"
      decimals="INF"
      id="ixv-37799"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c1"
      decimals="INF"
      id="ixv-37800"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c2"
      decimals="INF"
      id="ixv-37801"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c1"
      decimals="INF"
      id="ixv-37802"
      unitRef="usdPershares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c2"
      decimals="INF"
      id="ixv-37803"
      unitRef="usdPershares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c1"
      decimals="INF"
      id="ixv-37804"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c2"
      decimals="INF"
      id="ixv-37805"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="c1"
      decimals="INF"
      id="ixv-37806"
      unitRef="shares">14501143</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c1"
      decimals="INF"
      id="ixv-37807"
      unitRef="shares">14501143</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="c2"
      decimals="INF"
      id="ixv-37808"
      unitRef="shares">14410143</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c2"
      decimals="INF"
      id="ixv-37809"
      unitRef="shares">14410143</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c1" decimals="-3" id="ixv-37810" unitRef="usd">14000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c2" decimals="-3" id="ixv-37811" unitRef="usd">14000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c1" decimals="-3" id="ixv-37812" unitRef="usd">225747000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c2" decimals="-3" id="ixv-37813" unitRef="usd">225061000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c1" decimals="-3" id="ixv-37814" unitRef="usd">-188741000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c2" decimals="-3" id="ixv-37815" unitRef="usd">-183402000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="c1" decimals="-3" id="ixv-37816" unitRef="usd">37020000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c2" decimals="-3" id="ixv-37817" unitRef="usd">41673000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c1" decimals="-3" id="ixv-37818" unitRef="usd">37861000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c2" decimals="-3" id="ixv-37819" unitRef="usd">43085000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c6" decimals="-3" id="ixv-37820" unitRef="usd">6283000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c7" decimals="-3" id="ixv-37821" unitRef="usd">5847000</us-gaap:GeneralAndAdministrativeExpense>
    <abio:ResearchAndDevelopmentExpenseReversed contextRef="c8" decimals="-3" id="ixv-37822" unitRef="usd">-91000</abio:ResearchAndDevelopmentExpenseReversed>
    <abio:ResearchAndDevelopmentExpenseReversed contextRef="c9" decimals="-3" id="ixv-37823" unitRef="usd">432000</abio:ResearchAndDevelopmentExpenseReversed>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c6" decimals="-3" id="ixv-37824" unitRef="usd">1013000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c7" decimals="-3" id="ixv-37825" unitRef="usd">4749000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:OperatingExpenses contextRef="c6" decimals="-3" id="ixv-37826" unitRef="usd">7296000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c7" decimals="-3" id="ixv-37827" unitRef="usd">10596000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c6" decimals="-3" id="ixv-37828" unitRef="usd">-7296000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c7" decimals="-3" id="ixv-37829" unitRef="usd">-10596000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestAndOtherIncome contextRef="c6" decimals="-3" id="ixv-37830" unitRef="usd">1957000</us-gaap:InterestAndOtherIncome>
    <us-gaap:InterestAndOtherIncome contextRef="c7" decimals="-3" id="ixv-37831" unitRef="usd">675000</us-gaap:InterestAndOtherIncome>
    <us-gaap:OtherNonoperatingExpense contextRef="c7" decimals="-3" id="ixv-37832" unitRef="usd">5000</us-gaap:OtherNonoperatingExpense>
    <us-gaap:NetIncomeLoss contextRef="c6" decimals="-3" id="ixv-37833" unitRef="usd">-5339000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c7" decimals="-3" id="ixv-37834" unitRef="usd">-9926000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="c6"
      decimals="2"
      id="ixv-37835"
      unitRef="usdPershares">-0.37</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c7"
      decimals="2"
      id="ixv-37836"
      unitRef="usdPershares">-0.69</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c6"
      decimals="0"
      id="ixv-37837"
      unitRef="shares">14415877</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c7"
      decimals="0"
      id="ixv-37838"
      unitRef="shares">14410143</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c13"
      decimals="0"
      id="ixv-37839"
      unitRef="shares">14410143</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c13" decimals="-3" id="ixv-37840" unitRef="usd">14000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c14" decimals="-3" id="ixv-37841" unitRef="usd">224505000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c15" decimals="-3" id="ixv-37842" unitRef="usd">-173476000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c16" decimals="-3" id="ixv-37843" unitRef="usd">51043000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c18" decimals="-3" id="ixv-37844" unitRef="usd">556000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c7" decimals="-3" id="ixv-37845" unitRef="usd">556000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss contextRef="c19" decimals="-3" id="ixv-37846" unitRef="usd">-9926000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c7" decimals="-3" id="ixv-37847" unitRef="usd">-9926000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c20"
      decimals="0"
      id="ixv-37848"
      unitRef="shares">14410143</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c20" decimals="-3" id="ixv-37849" unitRef="usd">14000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c21" decimals="-3" id="ixv-37850" unitRef="usd">225061000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c22" decimals="-3" id="ixv-37851" unitRef="usd">-183402000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c2" decimals="-3" id="ixv-37852" unitRef="usd">41673000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="c23"
      decimals="0"
      id="ixv-37853"
      unitRef="shares">91000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c24" decimals="-3" id="ixv-37854" unitRef="usd">686000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c6" decimals="-3" id="ixv-37855" unitRef="usd">686000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss contextRef="c25" decimals="-3" id="ixv-37856" unitRef="usd">-5339000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c6" decimals="-3" id="ixv-37857" unitRef="usd">-5339000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c26"
      decimals="0"
      id="ixv-37858"
      unitRef="shares">14501143</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c26" decimals="-3" id="ixv-37859" unitRef="usd">14000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c27" decimals="-3" id="ixv-37860" unitRef="usd">225747000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c28" decimals="-3" id="ixv-37861" unitRef="usd">-188741000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c1" decimals="-3" id="ixv-37862" unitRef="usd">37020000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c6" decimals="-3" id="ixv-37863" unitRef="usd">-5339000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c7" decimals="-3" id="ixv-37864" unitRef="usd">-9926000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationAndAmortization contextRef="c6" decimals="-3" id="ixv-37865" unitRef="usd">15000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c7" decimals="-3" id="ixv-37866" unitRef="usd">20000</us-gaap:DepreciationAndAmortization>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c6" decimals="-3" id="ixv-37867" unitRef="usd">96000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c7" decimals="-3" id="ixv-37868" unitRef="usd">94000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:ShareBasedCompensation contextRef="c6" decimals="-3" id="ixv-37869" unitRef="usd">686000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c7" decimals="-3" id="ixv-37870" unitRef="usd">556000</us-gaap:ShareBasedCompensation>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="c7" decimals="-3" id="ixv-37871" unitRef="usd">-5000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets contextRef="c6" decimals="-3" id="ixv-37872" unitRef="usd">-93000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets contextRef="c7" decimals="-3" id="ixv-37873" unitRef="usd">-808000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets contextRef="c6" decimals="-3" id="ixv-37874" unitRef="usd">-6000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c6" decimals="-3" id="ixv-37875" unitRef="usd">28000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c7" decimals="-3" id="ixv-37876" unitRef="usd">-783000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="c6" decimals="-3" id="ixv-37877" unitRef="usd">-73000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="c7" decimals="-3" id="ixv-37878" unitRef="usd">-752000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities contextRef="c6" decimals="-3" id="ixv-37879" unitRef="usd">-526000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities contextRef="c7" decimals="-3" id="ixv-37880" unitRef="usd">-934000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c6" decimals="-3" id="ixv-37881" unitRef="usd">-5014000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c7" decimals="-3" id="ixv-37882" unitRef="usd">-10912000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c7" decimals="-3" id="ixv-37883" unitRef="usd">2000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c7" decimals="-3" id="ixv-37884" unitRef="usd">-2000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c6" decimals="-3" id="ixv-37885" unitRef="usd">-5014000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c7" decimals="-3" id="ixv-37886" unitRef="usd">-10914000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c2" decimals="-3" id="ixv-37887" unitRef="usd">42445000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c16" decimals="-3" id="ixv-37888" unitRef="usd">53359000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c1" decimals="-3" id="ixv-37889" unitRef="usd">37431000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c2" decimals="-3" id="ixv-37890" unitRef="usd">42445000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock contextRef="c6" id="ixv-20937">&lt;p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;(1)&#160;ARCA and Summary of Significant Accounting Policies&lt;/span&gt;&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Description of Business&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA biopharma, Inc. (&#x201c;ARCA&#x201d;), a Delaware corporation, is headquartered in Westminster, Colorado. ARCA is a clinical&lt;span class="nobreak"&gt;-stage&lt;/span&gt; biopharmaceutical company applying a precision medicine approach to the development and commercialization of genetically targeted therapies for cardiovascular diseases. ARCA&#x2019;s lead product candidate is Gencaro&#x2122; (bucindolol hydrochloride) for the treatment of atrial fibrillation (&#x201c;AF&#x201d;) in patients with chronic heart failure (&#x201c;HF&#x201d;).&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;In April&#160;2022, the Board of Directors established a Special Committee and, in May&#160;2022, retained Ladenburg Thalmann&#160;&amp;amp; Co. Inc. to evaluate strategic options, including transactions involving a merger, sale of all or part of ARCA&#x2019;s assets, or other alternatives with the goal of maximizing stockholder value. ARCA does not have a defined timeline for the strategic review process and the review may not result in any specific action or transaction.&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Liquidity and Going Concern&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA devotes substantially all of its efforts towards obtaining regulatory approval and raising capital necessary to fund its operations and it is subject to a number of risks associated with clinical research and development, including dependence on key individuals, the development of and regulatory approval of commercially viable products, the need to raise adequate additional financing necessary to fund the development and commercialization of its products, and competition from larger companies. ARCA has not generated revenue to date and has incurred substantial losses and negative cash flows from operations since its inception. ARCA has historically funded its operations through issuances of common and preferred stock.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA believes that its current cash and cash equivalents as of December&#160;31, 2023 will be sufficient to fund its operations through the middle of fiscal year 2025. ARCA&#x2019;s review of its strategic options may impact this projection. Changing circumstances may cause ARCA to consume capital significantly faster or slower than currently anticipated. ARCA has based these estimates on assumptions that may prove to be wrong, and ARCA could exhaust its available financial resources sooner than it currently anticipates. Therefore, ARCA will have to raise additional capital for clinical trials of Gencaro. ARCA may not be able to raise sufficient capital on acceptable terms, or at all, to continue development of Gencaro or rNAPc2 or to otherwise continue operations and may not be able to execute any strategic transaction.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA&#x2019;s liquidity, and its ability to raise additional capital or complete any strategic transaction, depends on a number of factors, including, but not limited to, the following:&lt;/p&gt;
		&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;the costs and timing for the potential additional clinical trials in order to gain possible regulatory approval for Gencaro, rNAPc2, or any other product candidate;&lt;/p&gt;
		&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;the market price of ARCA&#x2019;s stock and the availability and cost of additional equity capital from existing and potential new investors;&lt;/p&gt;
		&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;ARCA&#x2019;s ability to retain the listing of its common stock on the Nasdaq Capital Market;&lt;/p&gt;
		&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;general economic and industry conditions affecting the availability and cost of capital, including as a result of deteriorating market conditions due to investor concerns regarding inflation, adverse developments affecting the financial services industry, continued hostilities between Russia and Ukraine and Hamas&#x2019; attack against Israel and the ensuing conflict;&lt;/p&gt;
		&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;ARCA&#x2019;s ability to control costs associated with its operations;&lt;/p&gt;
		&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; and&lt;/p&gt;
		&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:6pt;margin-top:6pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;the terms and conditions of ARCA&#x2019;s existing collaborative and licensing agreements.&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The sale of additional equity or convertible debt securities would likely result in substantial additional dilution to ARCA&#x2019;s stockholders. If ARCA raises additional funds through the incurrence of indebtedness, the obligations related to such indebtedness would be senior to rights of holders of ARCA&#x2019;s capital stock and could contain covenants that would restrict ARCA&#x2019;s operations. ARCA also cannot predict what consideration might be available, if any, to it or its stockholders, in connection with any strategic transaction. Should strategic alternatives or additional capital not be available to ARCA, or not be available on acceptable terms, ARCA may be unable to realize value from its assets and discharge its liabilities in the normal course of business which may, among other alternatives, cause ARCA to further delay, substantially reduce or discontinue operational activities to conserve its cash resources.&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Basis of Presentation&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The accompanying financial statements have been prepared in accordance with U.S.&#160;generally accepted accounting principles (&#x201c;GAAP&#x201d;) and include all adjustments necessary for the fair presentation of ARCA&#x2019;s financial position, results of operations and cash flows for the periods presented. Management has performed an evaluation of ARCA&#x2019;s activities through the date of filing of the Annual Report on Form&#160;10&lt;span class="nobreak"&gt;-K&lt;/span&gt;.&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA reviewed all other recently issued accounting pronouncements and concluded that they were either not applicable or not expected to have a significant impact to the financial statements.&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Accounting Estimates in the Preparation of Financial Statements&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The preparation of financial statements in conformity with accounting principles generally accepted in the United&#160;States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. ARCA bases estimates on various assumptions that are believed to be reasonable under the circumstances. ARCA believes significant judgment was involved in estimating the outsourcing expenses, and in estimating other accrued liabilities and income taxes. Management is continually evaluating and updating these estimates, and it is possible that these estimates will change in the future or that actual results may differ from these estimates.&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Cash Equivalents&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Cash equivalents generally consist of money market funds and debt securities with maturities of 90&#160;days or less at the time of purchase. ARCA invests its excess cash in securities with strong ratings and has established guidelines relative to diversification and maturity with the objective of maintaining safety of principal and liquidity.&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Concentrations of Credit Risk&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Financial instruments that potentially subject ARCA to significant concentrations of credit risk consist primarily of cash and cash equivalents. ARCA has no off&lt;span class="nobreak"&gt;-balance-sheet&lt;/span&gt; concentrations of credit risk, such as foreign exchange contracts, option contracts, or foreign currency hedging arrangements. ARCA maintains cash and cash equivalent balances in the form of bank demand deposits and money market fund accounts with financial institutions that management believes are creditworthy. Such balances may at times exceed the insured amount.&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Property and Equipment&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Property and equipment are stated at cost less accumulated depreciation and amortization. Cost includes expenditures for equipment, leasehold improvements, replacements, and renewals. Maintenance and repairs are charged to expense as incurred. When assets are sold, retired, or otherwise disposed of, the cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is reflected in operations. The cost of &lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;"&gt;property and equipment is depreciated using the straight&lt;span class="nobreak"&gt;-line&lt;/span&gt; method over the estimated useful lives of the related assets. Leasehold improvements are amortized over the shorter of the life of the lease or the estimated useful life of the assets.&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Comprehensive Loss&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Comprehensive loss is defined as the change in equity during a period from transactions and other events and/or circumstances from non&lt;span class="nobreak"&gt;-owner&lt;/span&gt; sources. If ARCA had comprehensive gains (losses), they would be reflected in the statement of operations and comprehensive loss and as a separate component in the statement of stockholders&#x2019; equity. There were no elements of comprehensive loss during the&#160;years ended December&#160;31, 2023 and 2022.&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Leases&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA determines if an arrangement is a lease at inception. Operating leases are included in right&lt;span class="nobreak"&gt;-of-use&lt;/span&gt; (&#x201c;ROU&#x201d;) asset&#160;&#x2014;&#160;operating and lease obligations are included in accrued expenses and other liabilities and operating lease liability on ARCA&#x2019;s December&#160;31, 2023 and 2022 balance sheets.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ROU lease assets represent ARCA&#x2019;s right to use an underlying asset for the lease term and lease obligations represent ARCA&#x2019;s obligation to make lease payments arising from the lease. Operating ROU lease assets are recognized at the commencement date based on the present value of lease payments over the lease term. As ARCA&#x2019;s lease does not provide an implicit rate, ARCA uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. ARCA&#x2019;s lease terms may include options to extend or terminate the lease when it is reasonably certain that ARCA will exercise that option. Lease expense for lease payments is recognized on a straight&lt;span class="nobreak"&gt;-line&lt;/span&gt; basis over the lease term.&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Accrued Outsourcing Expenses&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;As part of the process of preparing its financial statements, ARCA is required to estimate accrued outsourcing expenses. This process involves identifying services that third parties have performed on ARCA&#x2019;s behalf and estimating the level of service performed and the associated cost incurred for these services as of the balance sheet date. Examples of estimated accrued outsourcing expenses include contract service fees, such as fees payable to contract manufacturers in connection with the production of materials related to ARCA&#x2019;s drug product, and service fees and pass through costs from clinical research organizations. ARCA develops estimates of liabilities using its judgment based upon the facts and circumstances known at the time.&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Segments&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA operates in one segment. Management uses one measure of profitability and does not segment its business for internal reporting.&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Research and Development&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Research and development costs are expensed as incurred. These consist primarily of salaries, contract services, and supplies.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Costs, if any, related to clinical trial and drug manufacturing activities are based upon estimates of the services received and related expenses incurred by contract research organizations (&#x201c;CROs&#x201d;), clinical study sites, drug manufacturers, collaboration partners, laboratories, consultants, or otherwise. Related contracts vary significantly in length, and could be for a fixed amount, a variable amount based on actual costs incurred, capped at a certain limit, or for a combination of these elements. Activity levels are monitored through communications with the vendors, including detailed invoices and task completion review, analysis of expenses against budgeted amounts, and pre&lt;span class="nobreak"&gt;-approval&lt;/span&gt; of any changes in scope of the services to be performed. Certain significant vendors may also provide &lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;"&gt;an estimate of costs incurred but not invoiced on a periodic basis. Expenses related to the CROs and clinical studies, as well as contract drug manufacturers, are primarily based on progress made against specified milestones or targets in each period.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;In accordance with certain research and development agreements, ARCA is obligated to make certain upfront payments upon execution of the agreement. ARCA records these upfront payments as prepaid research and development expenses, which are included in Other current assets or Other assets in the accompanying Balance Sheets. Such payments are recorded to research and development expense as services are performed. ARCA evaluates on a quarterly basis whether events and circumstances have occurred that may indicate impairment of remaining prepaid research and development expenses.&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA&#x2019;s stock&lt;span class="nobreak"&gt;-based&lt;/span&gt; compensation cost recognized is based on the estimated grant date fair value. ARCA recognizes compensation costs for its stock&lt;span class="nobreak"&gt;-based&lt;/span&gt; awards on a straight&lt;span class="nobreak"&gt;-line&lt;/span&gt; basis over the requisite service period for the entire award, as adjusted for expected forfeitures.&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Income Taxes&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The current benefit for income taxes represents actual or estimated amounts payable or refundable on tax returns filed or to be filed each year. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the period that includes the enactment date. The overall change in deferred tax assets and liabilities for the period measures the deferred tax expense or benefit for the period. The measurement of deferred tax assets may be reduced by a valuation allowance based on judgmental assessment of available evidence if deemed more likely than not that some or all of the deferred tax assets will not be realized.&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <abio:DescriptionOfBusinessPolicyTextBlock contextRef="c6" id="ixv-20940">&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Description of Business&lt;/span&gt;&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA biopharma, Inc. (&#x201c;ARCA&#x201d;), a Delaware corporation, is headquartered in Westminster, Colorado. ARCA is a clinical&lt;span class="nobreak"&gt;-stage&lt;/span&gt; biopharmaceutical company applying a precision medicine approach to the development and commercialization of genetically targeted therapies for cardiovascular diseases. ARCA&#x2019;s lead product candidate is Gencaro&#x2122; (bucindolol hydrochloride) for the treatment of atrial fibrillation (&#x201c;AF&#x201d;) in patients with chronic heart failure (&#x201c;HF&#x201d;).&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;In April&#160;2022, the Board of Directors established a Special Committee and, in May&#160;2022, retained Ladenburg Thalmann&#160;&amp;amp; Co. Inc. to evaluate strategic options, including transactions involving a merger, sale of all or part of ARCA&#x2019;s assets, or other alternatives with the goal of maximizing stockholder value. ARCA does not have a defined timeline for the strategic review process and the review may not result in any specific action or transaction.&lt;/p&gt;</abio:DescriptionOfBusinessPolicyTextBlock>
    <abio:LiquidityAndGoingConcernPolicyTextBlock contextRef="c6" id="ixv-20948">&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Liquidity and Going Concern&lt;/span&gt;&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA devotes substantially all of its efforts towards obtaining regulatory approval and raising capital necessary to fund its operations and it is subject to a number of risks associated with clinical research and development, including dependence on key individuals, the development of and regulatory approval of commercially viable products, the need to raise adequate additional financing necessary to fund the development and commercialization of its products, and competition from larger companies. ARCA has not generated revenue to date and has incurred substantial losses and negative cash flows from operations since its inception. ARCA has historically funded its operations through issuances of common and preferred stock.&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA believes that its current cash and cash equivalents as of December&#160;31, 2023 will be sufficient to fund its operations through the middle of fiscal year 2025. ARCA&#x2019;s review of its strategic options may impact this projection. Changing circumstances may cause ARCA to consume capital significantly faster or slower than currently anticipated. ARCA has based these estimates on assumptions that may prove to be wrong, and ARCA could exhaust its available financial resources sooner than it currently anticipates. Therefore, ARCA will have to raise additional capital for clinical trials of Gencaro. ARCA may not be able to raise sufficient capital on acceptable terms, or at all, to continue development of Gencaro or rNAPc2 or to otherwise continue operations and may not be able to execute any strategic transaction.&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA&#x2019;s liquidity, and its ability to raise additional capital or complete any strategic transaction, depends on a number of factors, including, but not limited to, the following:&lt;/p&gt;&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;the costs and timing for the potential additional clinical trials in order to gain possible regulatory approval for Gencaro, rNAPc2, or any other product candidate;&lt;/p&gt;&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;the market price of ARCA&#x2019;s stock and the availability and cost of additional equity capital from existing and potential new investors;&lt;/p&gt;&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;ARCA&#x2019;s ability to retain the listing of its common stock on the Nasdaq Capital Market;&lt;/p&gt;&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;general economic and industry conditions affecting the availability and cost of capital, including as a result of deteriorating market conditions due to investor concerns regarding inflation, adverse developments affecting the financial services industry, continued hostilities between Russia and Ukraine and Hamas&#x2019; attack against Israel and the ensuing conflict;&lt;/p&gt;&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;ARCA&#x2019;s ability to control costs associated with its operations;&lt;/p&gt;&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; and&lt;/p&gt;&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:6pt;margin-top:6pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;the terms and conditions of ARCA&#x2019;s existing collaborative and licensing agreements.&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The sale of additional equity or convertible debt securities would likely result in substantial additional dilution to ARCA&#x2019;s stockholders. If ARCA raises additional funds through the incurrence of indebtedness, the obligations related to such indebtedness would be senior to rights of holders of ARCA&#x2019;s capital stock and could contain covenants that would restrict ARCA&#x2019;s operations. ARCA also cannot predict what consideration might be available, if any, to it or its stockholders, in connection with any strategic transaction. Should strategic alternatives or additional capital not be available to ARCA, or not be available on acceptable terms, ARCA may be unable to realize value from its assets and discharge its liabilities in the normal course of business which may, among other alternatives, cause ARCA to further delay, substantially reduce or discontinue operational activities to conserve its cash resources.&lt;/p&gt;</abio:LiquidityAndGoingConcernPolicyTextBlock>
    <us-gaap:Revenues contextRef="c6" decimals="INF" id="ixv-37891" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="c6" id="ixv-20998">&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Basis of Presentation&lt;/span&gt;&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The accompanying financial statements have been prepared in accordance with U.S.&#160;generally accepted accounting principles (&#x201c;GAAP&#x201d;) and include all adjustments necessary for the fair presentation of ARCA&#x2019;s financial position, results of operations and cash flows for the periods presented. Management has performed an evaluation of ARCA&#x2019;s activities through the date of filing of the Annual Report on Form&#160;10&lt;span class="nobreak"&gt;-K&lt;/span&gt;.&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c6" id="ixv-21004">&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA reviewed all other recently issued accounting pronouncements and concluded that they were either not applicable or not expected to have a significant impact to the financial statements.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="c6" id="ixv-21009">&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Accounting Estimates in the Preparation of Financial Statements&lt;/span&gt;&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The preparation of financial statements in conformity with accounting principles generally accepted in the United&#160;States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. ARCA bases estimates on various assumptions that are believed to be reasonable under the circumstances. ARCA believes significant judgment was involved in estimating the outsourcing expenses, and in estimating other accrued liabilities and income taxes. Management is continually evaluating and updating these estimates, and it is possible that these estimates will change in the future or that actual results may differ from these estimates.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="c6" id="ixv-21014">&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Cash Equivalents&lt;/span&gt;&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Cash equivalents generally consist of money market funds and debt securities with maturities of 90&#160;days or less at the time of purchase. ARCA invests its excess cash in securities with strong ratings and has established guidelines relative to diversification and maturity with the objective of maintaining safety of principal and liquidity.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="c6" id="ixv-21019">&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Concentrations of Credit Risk&lt;/span&gt;&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Financial instruments that potentially subject ARCA to significant concentrations of credit risk consist primarily of cash and cash equivalents. ARCA has no off&lt;span class="nobreak"&gt;-balance-sheet&lt;/span&gt; concentrations of credit risk, such as foreign exchange contracts, option contracts, or foreign currency hedging arrangements. ARCA maintains cash and cash equivalent balances in the form of bank demand deposits and money market fund accounts with financial institutions that management believes are creditworthy. Such balances may at times exceed the insured amount.&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:FairValueDisclosureOffbalanceSheetRisksAmountAsset contextRef="c1" decimals="INF" id="ixv-37892" unitRef="usd">0</us-gaap:FairValueDisclosureOffbalanceSheetRisksAmountAsset>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="c6" id="ixv-21025">&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Property and Equipment&lt;/span&gt;&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Property and equipment are stated at cost less accumulated depreciation and amortization. Cost includes expenditures for equipment, leasehold improvements, replacements, and renewals. Maintenance and repairs are charged to expense as incurred. When assets are sold, retired, or otherwise disposed of, the cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is reflected in operations. The cost of &lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;"&gt;property and equipment is depreciated using the straight&lt;span class="nobreak"&gt;-line&lt;/span&gt; method over the estimated useful lives of the related assets. Leasehold improvements are amortized over the shorter of the life of the lease or the estimated useful life of the assets.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <abio:ComprehensiveLossPolicyPolicyTextBlock contextRef="c6" id="ixv-21044">&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Comprehensive Loss&lt;/span&gt;&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Comprehensive loss is defined as the change in equity during a period from transactions and other events and/or circumstances from non&lt;span class="nobreak"&gt;-owner&lt;/span&gt; sources. If ARCA had comprehensive gains (losses), they would be reflected in the statement of operations and comprehensive loss and as a separate component in the statement of stockholders&#x2019; equity. There were no elements of comprehensive loss during the&#160;years ended December&#160;31, 2023 and 2022.&lt;/p&gt;</abio:ComprehensiveLossPolicyPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="c6" id="ixv-21050">&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA determines if an arrangement is a lease at inception. Operating leases are included in right&lt;span class="nobreak"&gt;-of-use&lt;/span&gt; (&#x201c;ROU&#x201d;) asset&#160;&#x2014;&#160;operating and lease obligations are included in accrued expenses and other liabilities and operating lease liability on ARCA&#x2019;s December&#160;31, 2023 and 2022 balance sheets.&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ROU lease assets represent ARCA&#x2019;s right to use an underlying asset for the lease term and lease obligations represent ARCA&#x2019;s obligation to make lease payments arising from the lease. Operating ROU lease assets are recognized at the commencement date based on the present value of lease payments over the lease term. As ARCA&#x2019;s lease does not provide an implicit rate, ARCA uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. ARCA&#x2019;s lease terms may include options to extend or terminate the lease when it is reasonably certain that ARCA will exercise that option. Lease expense for lease payments is recognized on a straight&lt;span class="nobreak"&gt;-line&lt;/span&gt; basis over the lease term.&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <abio:AccruedOutsourcingExpensesPolicyTextBlock contextRef="c6" id="ixv-21059">&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Accrued Outsourcing Expenses&lt;/span&gt;&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;As part of the process of preparing its financial statements, ARCA is required to estimate accrued outsourcing expenses. This process involves identifying services that third parties have performed on ARCA&#x2019;s behalf and estimating the level of service performed and the associated cost incurred for these services as of the balance sheet date. Examples of estimated accrued outsourcing expenses include contract service fees, such as fees payable to contract manufacturers in connection with the production of materials related to ARCA&#x2019;s drug product, and service fees and pass through costs from clinical research organizations. ARCA develops estimates of liabilities using its judgment based upon the facts and circumstances known at the time.&lt;/p&gt;</abio:AccruedOutsourcingExpensesPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="c6" id="ixv-21064">&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Segments&lt;/span&gt;&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA operates in one segment. Management uses one measure of profitability and does not segment its business for internal reporting.&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments contextRef="c6" decimals="0" id="ixv-37893" unitRef="pure">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="c6" id="ixv-21069">&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Research and Development&lt;/span&gt;&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Research and development costs are expensed as incurred. These consist primarily of salaries, contract services, and supplies.&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Costs, if any, related to clinical trial and drug manufacturing activities are based upon estimates of the services received and related expenses incurred by contract research organizations (&#x201c;CROs&#x201d;), clinical study sites, drug manufacturers, collaboration partners, laboratories, consultants, or otherwise. Related contracts vary significantly in length, and could be for a fixed amount, a variable amount based on actual costs incurred, capped at a certain limit, or for a combination of these elements. Activity levels are monitored through communications with the vendors, including detailed invoices and task completion review, analysis of expenses against budgeted amounts, and pre&lt;span class="nobreak"&gt;-approval&lt;/span&gt; of any changes in scope of the services to be performed. Certain significant vendors may also provide &lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;"&gt;an estimate of costs incurred but not invoiced on a periodic basis. Expenses related to the CROs and clinical studies, as well as contract drug manufacturers, are primarily based on progress made against specified milestones or targets in each period.&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;In accordance with certain research and development agreements, ARCA is obligated to make certain upfront payments upon execution of the agreement. ARCA records these upfront payments as prepaid research and development expenses, which are included in Other current assets or Other assets in the accompanying Balance Sheets. Such payments are recorded to research and development expense as services are performed. ARCA evaluates on a quarterly basis whether events and circumstances have occurred that may indicate impairment of remaining prepaid research and development expenses.&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="c6" id="ixv-21092">&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA&#x2019;s stock&lt;span class="nobreak"&gt;-based&lt;/span&gt; compensation cost recognized is based on the estimated grant date fair value. ARCA recognizes compensation costs for its stock&lt;span class="nobreak"&gt;-based&lt;/span&gt; awards on a straight&lt;span class="nobreak"&gt;-line&lt;/span&gt; basis over the requisite service period for the entire award, as adjusted for expected forfeitures.&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="c6" id="ixv-21100">&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The current benefit for income taxes represents actual or estimated amounts payable or refundable on tax returns filed or to be filed each year. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the period that includes the enactment date. The overall change in deferred tax assets and liabilities for the period measures the deferred tax expense or benefit for the period. The measurement of deferred tax assets may be reduced by a valuation allowance based on judgmental assessment of available evidence if deemed more likely than not that some or all of the deferred tax assets will not be realized.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerShareTextBlock contextRef="c6" id="ixv-21105">&lt;p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;(2)&#160;Net Loss Per Share&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA calculates basic loss per share by dividing net loss by the weighted average common shares outstanding during the period. Diluted loss per share is computed by dividing net loss by the weighted average number of common shares outstanding during the period increased to include, if dilutive, the number of additional common shares that would have been outstanding if the potential common shares had been issued. ARCA&#x2019;s potentially dilutive shares include stock options and restricted stock units.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Because ARCA reported a net loss for the&#160;years ended December&#160;31, 2023 and 2022, all potentially dilutive shares of ARCA common stock have been excluded from the computation of the dilutive net loss per share for all periods presented. Such potentially dilutive shares of ARCA common stock consist of the following:&lt;/p&gt;
		&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;



					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Years Ended&lt;br/&gt;December&#160;31,&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;2023&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;2022&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Potentially dilutive securities, excluded:&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Outstanding stock options&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;616,707&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;704,960&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Unvested restricted stock units&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-70; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;91,000&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;616,707&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;795,960&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="c6" id="ixv-37894">Because ARCA reported a net loss for the&#160;years ended December&#160;31, 2023 and 2022, all potentially dilutive shares of ARCA common stock have been excluded from the computation of the dilutive net loss per share for all periods presented. Such potentially dilutive shares of ARCA common stock consist of the following:&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;



					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Years Ended&lt;br/&gt;December&#160;31,&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;2023&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;2022&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Potentially dilutive securities, excluded:&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Outstanding stock options&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;616,707&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;704,960&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Unvested restricted stock units&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-70; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;91,000&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;616,707&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;795,960&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c62"
      decimals="0"
      id="ixv-37895"
      unitRef="shares">616707</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c63"
      decimals="0"
      id="ixv-37896"
      unitRef="shares">704960</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c65"
      decimals="0"
      id="ixv-37897"
      unitRef="shares">91000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c6"
      decimals="0"
      id="ixv-37898"
      unitRef="shares">616707</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c7"
      decimals="0"
      id="ixv-37899"
      unitRef="shares">795960</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="c6" id="ixv-21170">&lt;p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;(3)&#160;Fair Value Disclosures&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (&#x201c;exit price&#x201d;). Inputs used to measure fair value are classified into the following hierarchy:&lt;/p&gt;
		&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;Level 1 &#x2014;&#160;Unadjusted quoted prices in active markets for identical assets or liabilities. ARCA&#x2019;s Level 1 assets consist of money market investments. ARCA does not have any Level 1 liabilities.&lt;/p&gt;
		&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;Level 2 &#x2014;&#160;Unadjusted quoted prices in active markets for similar assets or liabilities; unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active; or inputs other than quoted prices that are observable for the asset or liability. ARCA&#x2019;s Level 2 assets consist of corporate bonds and commercial paper securities. ARCA does not have any Level 2 liabilities.&lt;/p&gt;
		&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;Level 3 &#x2014;&#160;Unobservable inputs for the asset or liability. ARCA does not have any Level 3 assets or liabilities.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;As of December&#160;31, 2023 and 2022, ARCA had $37.4&#160;million and $42.4&#160;million, respectively, of cash equivalents consisting of money market funds with original maturities of 90&#160;days or less. ARCA has the ability to liquidate these investments without restriction. ARCA determines fair value for these money market funds with Level 1 inputs through quoted market prices. There were &lt;span style="-sec-ix-hidden: hidden-fact-73"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-74"&gt;no&lt;/span&gt;&lt;/span&gt; transfers between any fair value hierarchy levels in 2023 or 2022.&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Fair Value of Other Financial Instruments&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The carrying amount of other financial instruments, including accounts payable, approximated fair value due to their short maturities. As of December&#160;31, 2023 and 2022, ARCA did &lt;span style="-sec-ix-hidden: hidden-fact-71"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-72"&gt;not&lt;/span&gt;&lt;/span&gt; have any debt outstanding.&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c66" decimals="-5" id="ixv-37900" unitRef="usd">37400000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c67" decimals="-5" id="ixv-37901" unitRef="usd">42400000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="c6" id="ixv-21191">&lt;p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;(4)&#160;Property and Equipment&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Property and equipment consist of the following (in thousands):&lt;/p&gt;
		&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;"&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;/td&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;	&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Estimated&lt;br/&gt;Life&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;	&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;December&#160;31,&lt;br/&gt;2023&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;	&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;December&#160;31,&lt;br/&gt;2022&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Computer equipment&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;3&#160;years&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;39&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;39&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Lab equipment&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;5&#160;years&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;130&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;130&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Furniture and fixtures&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;5&#160;years&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;37&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;44&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Computer software&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;3&#160;years&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;16&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;16&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;222&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;229&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Accumulated depreciation and amortization&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(212&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(204&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Property and equipment, net&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;10&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;25&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;/table&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;For the&#160;years ended December&#160;31, 2023 and 2022, depreciation and amortization expense was $15,000 and $20,000, respectively.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c6" id="ixv-37902">Property and equipment consist of the following (in thousands):&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;"&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;/td&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;	&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Estimated&lt;br/&gt;Life&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;	&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;December&#160;31,&lt;br/&gt;2023&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;	&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;December&#160;31,&lt;br/&gt;2022&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Computer equipment&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;3&#160;years&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;39&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;39&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Lab equipment&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;5&#160;years&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;130&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;130&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Furniture and fixtures&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;5&#160;years&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;37&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;44&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Computer software&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;3&#160;years&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;16&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;16&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;222&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;229&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Accumulated depreciation and amortization&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(212&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(204&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Property and equipment, net&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;10&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;25&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c69" id="ixv-37903">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c69" decimals="-3" id="ixv-37904" unitRef="usd">39000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c70" decimals="-3" id="ixv-37905" unitRef="usd">39000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c71" id="ixv-37906">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c71" decimals="-3" id="ixv-37907" unitRef="usd">130000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c72" decimals="-3" id="ixv-37908" unitRef="usd">130000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c73" id="ixv-37909">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c73" decimals="-3" id="ixv-37910" unitRef="usd">37000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c74" decimals="-3" id="ixv-37911" unitRef="usd">44000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c75" id="ixv-37912">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c75" decimals="-3" id="ixv-37913" unitRef="usd">16000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c76" decimals="-3" id="ixv-37914" unitRef="usd">16000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c1" decimals="-3" id="ixv-37915" unitRef="usd">222000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c2" decimals="-3" id="ixv-37916" unitRef="usd">229000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c1" decimals="-3" id="ixv-37917" unitRef="usd">212000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c2" decimals="-3" id="ixv-37918" unitRef="usd">204000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c1" decimals="-3" id="ixv-37919" unitRef="usd">10000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c2" decimals="-3" id="ixv-37920" unitRef="usd">25000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationAndAmortization contextRef="c6" decimals="-3" id="ixv-37921" unitRef="usd">15000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c7" decimals="-3" id="ixv-37922" unitRef="usd">20000</us-gaap:DepreciationAndAmortization>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="c6" id="ixv-21351">&lt;p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;(5)&#160;Related Party Arrangements&lt;/span&gt;&lt;/p&gt;
		&lt;p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="Italic" style="font-style:italic;font-weight:normal;"&gt;Transactions with ARCA&#x2019;s President and Chief Executive Officer&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA has entered into unrestricted research grants with its President and Chief Executive Officer&#x2019;s academic research laboratory at the University of Colorado. Funding of any unrestricted research grants is contingent upon ARCA&#x2019;s financial condition, and can be deferred or terminated at ARCA&#x2019;s discretion. Total expense under these arrangements for the&#160;years ended December&#160;31, 2023 and 2022 was $(91,000) and $432,000, respectively. In December&#160;2023, ARCA made a payment of $125,000 for the grant period July&#160;2022 through December&#160;2023 under these arrangements.&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <abio:ResearchAndDevelopmentExpenseReversed contextRef="c77" decimals="0" id="ixv-37923" unitRef="usd">-91000</abio:ResearchAndDevelopmentExpenseReversed>
    <abio:ResearchAndDevelopmentExpenseReversed contextRef="c78" decimals="0" id="ixv-37924" unitRef="usd">432000</abio:ResearchAndDevelopmentExpenseReversed>
    <abio:PaymentOfUnrestrictedResearchGrants contextRef="c79" decimals="0" id="ixv-37925" unitRef="usd">125000</abio:PaymentOfUnrestrictedResearchGrants>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c6" id="ixv-21364">&lt;p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;(6)&#160;Commitments and Contingencies&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA has or is subject to the following commitments and contingencies:&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Employment Agreements and Reduction of Workforce&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA maintains employment agreements with several key executive employees. The agreements may be terminated at any time by ARCA with or without cause upon written notice to the employee, and entitle the employee to wages in lieu of notice for periods not exceeding one calendar year from date of termination without cause or by the employee for good reason. Certain of these agreements also provide for payments to be made under certain conditions related to a change in control of ARCA.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;In December&#160;2022, ARCA&#x2019;s Board of Directors approved retention bonuses for certain employees, subject to continued employment with ARCA through the earlier of a change in control of ARCA or certain clinical development decisions totaling $265,000. In November&#160;2023, the retention bonuses were amended to increase the aggregate amount of the retention bonus by 50% and in order to assist with tax obligations associated with the vesting of certain Company restricted stock unit awards in December&#160;2023, a total of $86,000 was paid in December&#160;2023. As of December&#160;31, 2023, the unpaid retention bonuses totaled $311,000, none of which was accrued as of December&#160;31, 2023, since there had not been a change in control or clinical development decision.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA and Christopher D.&#160;Ozeroff, the Secretary, Senior Vice President and General Counsel of ARCA mutually agreed to conclude Mr.&#160;Ozeroff&#x2019;s employment effective March&#160;31, 2023. Pursuant to Mr.&#160;Ozeroff&#x2019;s existing employment agreement, as previously amended, ARCA will provide Mr.&#160;Ozeroff severance benefits pursuant to the terms of his existing employment agreement with ARCA, as previously amended. The severance benefits include severance payments and reimbursement to cover out&lt;span class="nobreak"&gt;-of-pocket&lt;/span&gt; costs to continue group health insurance benefits under COBRA, whether he elects or is eligible to receive COBRA (provided, that even if he does not elect or is not eligible to receive COBRA, he will receive the equivalent of such out&lt;span class="nobreak"&gt;-of-pocket&lt;/span&gt; expenses paid by him not to exceed the costs that the benefits would equal under COBRA if he were so eligible). During the year ended December&#160;31, 2023, ARCA recorded an expense of $159,000 for these severance benefits, &lt;span style="-sec-ix-hidden: hidden-fact-75"&gt;none&lt;/span&gt; of which remains unpaid.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;In 2022, ARCA implemented a strategic reduction of the workforce by approximately 67%, or 12 employees. Personnel reductions were primarily focused in research and development and general and administrative functions. The restructuring was a result of ARCA&#x2019;s decision to manage operating costs and expenses. During the year ended December&#160;31, 2022, ARCA recorded total restructuring charges of approximately $755,000, of which $470,000 and $285,000 were recognized in research and development and general and administrative expenses, respectively, in connection with the restructuring, all in the form of one&lt;span class="nobreak"&gt;-time&lt;/span&gt; termination benefits, none of which remains unpaid.&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Operating Lease&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;On August&#160;29, 2020 ARCA entered into a lease agreement for approximately 5,200 square feet of office facilities in Westminster, Colorado which serves as ARCA&#x2019;s primary business office effective October&#160;1, 2020 (&#x201c;October&#160;2020 Lease&#x201d;). The lease term is 42&#160;months beginning October&#160;1, 2020 and includes an option to renew for an additional 36&lt;span class="nobreak"&gt; &lt;/span&gt;month term at the then prevailing rental rate. The exercise of the lease renewal option is at ARCA&#x2019;s sole discretion. The amounts recorded assume ARCA will exercise its renewal option. In June&#160;2021, ARCA entered into a sublease agreement for approximately 3,000 square feet of additional office facilities in its primary business office (&#x201c;2021 Lease&#x201d;). The sublease term was 29&#160;months and terminated in October&#160;2023. The leases include real estate taxes and insurance, which is not a lease component and is not included in the lease obligation. In addition, common area maintenance charges are based on actual costs incurred and are a non&lt;span class="nobreak"&gt;-lease&lt;/span&gt; component that is not included in the lease obligation.&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Future minimum commitments due under the October&#160;2020 Lease agreement as of December&#160;31, 2023 are as follows (in thousands):&lt;/p&gt;
		&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;



						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;2024&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;93&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;2025&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;96&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;2026&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;100&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;2027&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;25&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Total remaining lease payments&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;314&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Less: imputed lease interest&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(34&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Less: Current portion&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(76&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Operating lease liability, net of current portion&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;204&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Rent expense, which is included in general and administrative expense, under these leases for the&#160;years ended December&#160;31, 2023 and 2022 was $119,000 and $125,000, respectively.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;As of December&#160;31, 2023, the lease liability was $280,000 and the current portion is included in accrued expenses and other liabilities and the non&lt;span class="nobreak"&gt;-current&lt;/span&gt; portion is in operating lease liability, net of current portion in the accompanying balance sheet. Cash paid for amounts included in the measurement of lease liabilities and the operating cash flows from operating leases for the&#160;years ended December&#160;31, 2023 and 2022 were $127,000 and $131,000, respectively. The weighted&lt;span class="nobreak"&gt;-average&lt;/span&gt; remaining lease term for the operating lease as of December&#160;31, 2023 is 3.2&#160;years. The weighted&lt;span class="nobreak"&gt;-average&lt;/span&gt; discount rate for the operating lease is 7%.&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Patent Agreement&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;In July&#160;2021, ARCA entered into a patent assignment agreement (the &#x201c;Agreement&#x201d;) with the University Medical Center of Johannes Gutenberg University Mainz, Germany.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Under the terms of the Agreement, ARCA received exclusive world&lt;span class="nobreak"&gt;-wide&lt;/span&gt; patent rights relating to the use of rNAPc2 as a potential treatment for COVID&lt;span class="nobreak"&gt;-19&lt;/span&gt;, and other indications, based on the research and discoveries from Univ.&lt;span class="nobreak"&gt;-Prof&lt;/span&gt;. Dr.&#160;Wolfram Ruf, the Scientific Director and Alexander von Humboldt Professor at the Center for Thrombosis and Hemostasis (&#x201c;CTH&#x201d;) of the University Medical Center Mainz, and his collaborators. ARCA has upfront and potential milestone obligations to the University Medical Center Mainz that could total approximately &#x20ac;1.6&#160;million and royalty obligations in the low single digit range, if rNAPc2 receives regulatory approval and is commercialized. The term of the Agreement extends to the date of expiration of the last to expire of any of the assigned patents.&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Gencaro License&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA has licensed worldwide rights to all preclinical and clinical data through the BEST trial for development of bucindolol. The patents that were the subject of this license are expired. If the license agreement is deemed enforceable, ARCA would incur milestone and royalty obligations upon the occurrence of certain events, including if the FDA grants marketing approval for Gencaro, upon regulatory marketing approval in Europe and Japan and based on achievement of specified product sales levels.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <abio:RetentionBonuses contextRef="c80" decimals="0" id="ixv-37926" unitRef="usd">265000</abio:RetentionBonuses>
    <abio:PercentageOfRetentionBonuses contextRef="c81" decimals="2" id="ixv-37927" unitRef="pure">0.50</abio:PercentageOfRetentionBonuses>
    <abio:RetentionBonusPaid contextRef="c6" decimals="0" id="ixv-37928" unitRef="usd">86000</abio:RetentionBonusPaid>
    <abio:RetentionBonuses contextRef="c1" decimals="0" id="ixv-37929" unitRef="usd">311000</abio:RetentionBonuses>
    <us-gaap:SeveranceCosts1 contextRef="c6" decimals="0" id="ixv-37930" unitRef="usd">159000</us-gaap:SeveranceCosts1>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent contextRef="c7" decimals="2" id="ixv-37931" unitRef="pure">0.67</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated contextRef="c7" decimals="0" id="ixv-37932" unitRef="pure">12</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated>
    <us-gaap:RestructuringCharges contextRef="c82" decimals="0" id="ixv-37933" unitRef="usd">755000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c83" decimals="0" id="ixv-37934" unitRef="usd">470000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c84" decimals="0" id="ixv-37935" unitRef="usd">285000</us-gaap:RestructuringCharges>
    <us-gaap:AreaOfRealEstateProperty contextRef="c85" decimals="0" id="ixv-37936" unitRef="sqft">5200</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="c85" id="ixv-37937">P42M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseOptionToExtend contextRef="c86" id="ixv-21381">option to renew for an additional 36 month term at the then prevailing rental rate.</us-gaap:LesseeOperatingLeaseOptionToExtend>
    <us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="c85" id="ixv-37938">P36M</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <abio:AreaOfRealEstatePropertySubleaseAdditionalOfficeFacilities contextRef="c87" decimals="0" id="ixv-37939" unitRef="sqft">3000</abio:AreaOfRealEstatePropertySubleaseAdditionalOfficeFacilities>
    <abio:LesseeOperatingSubleaseTermOfContract contextRef="c88" id="ixv-37940">P29M</abio:LesseeOperatingSubleaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseAssumptionsAndJudgmentsAllocationOfLeaseAndNonleaseComponent contextRef="c6" id="ixv-21383">The leases include real estate taxes and insurance, which is not a lease component and is not included in the lease obligation. In addition, common area maintenance charges are based on actual costs incurred and are a non-lease component that is not included in the lease obligation.</us-gaap:LesseeOperatingLeaseAssumptionsAndJudgmentsAllocationOfLeaseAndNonleaseComponent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="c6" id="ixv-37941">Future minimum commitments due under the October&#160;2020 Lease agreement as of December&#160;31, 2023 are as follows (in thousands):&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;



						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;2024&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;93&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;2025&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;96&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;2026&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;100&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;2027&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;25&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Total remaining lease payments&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;314&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Less: imputed lease interest&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(34&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Less: Current portion&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(76&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Operating lease liability, net of current portion&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;204&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c1" decimals="-3" id="ixv-37942" unitRef="usd">93000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="c1" decimals="-3" id="ixv-37943" unitRef="usd">96000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="c1" decimals="-3" id="ixv-37944" unitRef="usd">100000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour contextRef="c1" decimals="-3" id="ixv-37945" unitRef="usd">25000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c1" decimals="-3" id="ixv-37946" unitRef="usd">314000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="c1" decimals="-3" id="ixv-37947" unitRef="usd">34000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c1" decimals="-3" id="ixv-37948" unitRef="usd">76000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c1" decimals="-3" id="ixv-37949" unitRef="usd">204000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseCost contextRef="c89" decimals="0" id="ixv-37950" unitRef="usd">119000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c90" decimals="0" id="ixv-37951" unitRef="usd">125000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseLiability contextRef="c1" decimals="0" id="ixv-37952" unitRef="usd">280000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeasePayments contextRef="c6" decimals="0" id="ixv-37953" unitRef="usd">127000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments contextRef="c7" decimals="0" id="ixv-37954" unitRef="usd">131000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c1" id="ixv-37955">P3Y2M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c1" decimals="2" id="ixv-37956" unitRef="pure">0.07</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <abio:PotentialUpfrontAndMilestoneObligationsAndRoyaltyObligations contextRef="c91" decimals="-5" id="ixv-37957" unitRef="eur">1600000</abio:PotentialUpfrontAndMilestoneObligationsAndRoyaltyObligations>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c6" id="ixv-21494">&lt;p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;(7)&#160;Equity Financings&lt;/span&gt;&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;At the Market Equity Financing&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;On July&#160;22, 2020, ARCA entered into a Capital on Demand&lt;span class="Superscript" style="vertical-align:super;font-size:58%;"&gt;TM&lt;/span&gt; Sales Agreement (the &#x201c;Sales Agreement&#x201d;) with JonesTrading Institutional Services LLC, as agent (&#x201c;JonesTrading&#x201d;), pursuant to which ARCA may offer and sell, from time to time through JonesTrading, shares of ARCA&#x2019;s common stock, par value $0.001 per share (&#x201c;ARCA&#160;common stock&#x201d;), having an aggregate offering price of up to $54.0&#160;million (the &#x201c;Shares&#x201d;).&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Under the Sales Agreement, JonesTrading may sell the Shares by any method permitted by law and deemed to be an &#x201c;at the market offering&#x201d; as defined in Rule&#160;415 promulgated under the Securities Act&#160;of&#160;1933, as amended, including sales made directly on or through the Nasdaq Capital Market, on any other existing trading market for ARCA common stock or to or through a market maker. In addition, under the amended Sales Agreement, JonesTrading may sell the Shares by any other method permitted by law, including in negotiated transactions. ARCA may instruct JonesTrading not to sell Shares if the sales cannot be effected at or above the price designated by ARCA from time to time.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA is not obligated to make any sales of the Shares under the Sales Agreement. The offering of Shares pursuant to the Sales Agreement will terminate upon the earlier of (a)&#160;the sale of all of the Shares subject to the Sales Agreement or (b)&#160;the termination of the Sales Agreement by JonesTrading or ARCA, as permitted therein.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA paid JonesTrading a commission rate equal to 3.0% of the aggregate gross proceeds from each sale of Shares and agreed to provide JonesTrading with customary indemnification and contribution rights. ARCA will also reimburse JonesTrading for certain specified expenses in connection with entering into the Sales Agreement.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;No sales were made in 2023 or 2022.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;In April&#160;2021, ARCA amended the 2020 Sales Agreement and the amount available for the offering under its prospectus to ARCA&#x2019;s registration statement on Form&#160;S&lt;span class="nobreak"&gt;-3&lt;/span&gt; (No.&#160;333&lt;span class="nobreak"&gt;-254585&lt;/span&gt;). The amount available for the offering under the prospectus supplement is subject to the limitation of not selling a total value amount of shares exceeding more than one&lt;span class="nobreak"&gt;-third&lt;/span&gt; of ARCA&#x2019;s public float in any 12&lt;span class="nobreak"&gt;-month&lt;/span&gt; period.&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c92"
      decimals="INF"
      id="ixv-37958"
      unitRef="usdPershares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <abio:CommonStockAuthorizedOfferingAmountUnderAgreementToSell contextRef="c92" decimals="-5" id="ixv-37959" unitRef="usd">54000000</abio:CommonStockAuthorizedOfferingAmountUnderAgreementToSell>
    <abio:SellingCommissionPerAdditionalSharesSoldPercentage contextRef="c93" decimals="3" id="ixv-37960" unitRef="pure">0.03</abio:SellingCommissionPerAdditionalSharesSoldPercentage>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c94"
      decimals="0"
      id="ixv-37961"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c95"
      decimals="0"
      id="ixv-37962"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c6" id="ixv-21521">&lt;p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;(8)&#160;Share-based Compensation&lt;/span&gt;&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Stock Plans&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA&#x2019;s equity incentive plan, &lt;span class="Italic" style="font-style:italic;font-weight:normal;"&gt;the 2020 Equity Incentive Plan &lt;/span&gt;(the &#x201c;Equity Plan&#x201d;),&lt;span class="Italic" style="font-style:italic;font-weight:normal;"&gt; &lt;/span&gt;was approved by stockholders on December&#160;10, 2020. The maximum number of shares issuable under this plan is 1,167,425&lt;span class="nobreak"&gt; &lt;/span&gt;shares.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The Equity Plan provides for the granting of stock options (including indexed options), restricted stock units, stock appreciation rights, restricted stock purchase rights, restricted stock bonuses, performance shares, performance units and deferred stock units. Under the Equity Plan, awards may be granted to employees, directors and consultants of ARCA, except for incentive stock options, which may be granted only to employees. As of December&#160;31, 2023, options to purchase 601,900&lt;span class="nobreak"&gt; &lt;/span&gt;shares with a weighted average exercise price of $3.45 per share were outstanding under the Equity Plan, and 459,718&lt;span class="nobreak"&gt; &lt;/span&gt;shares were reserved for future awards.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;In general, the Equity Plan authorizes the grant of stock options that vest at rates set by the Board of Directors or the Compensation Committee thereof. Generally, stock options granted by ARCA under the equity incentive plans become exercisable ratably for a period of &lt;span style="-sec-ix-hidden: hidden-fact-97"&gt;three&lt;/span&gt; to &lt;span style="-sec-ix-hidden: hidden-fact-98"&gt;four&lt;/span&gt;&#160;years from the date of grant and have a maximum term of &lt;span style="-sec-ix-hidden: hidden-fact-99"&gt;ten&lt;/span&gt;&#160;years. The exercise prices of stock options under the equity incentive plan generally meet the following criteria: the exercise price of incentive stock options must be at least 100% of the fair market value on the grant date and exercise price of options granted to 10% (or greater) stockholders must be at least 110% of the fair market value on the grant date.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;In conjunction with the adoption of the Equity Plan, ARCA discontinued grants under the 2013 Plan, effective December&#160;10, 2020. As of December&#160;31, 2023, options to purchase 14,807&lt;span class="nobreak"&gt; &lt;/span&gt;shares with a weighted average exercise price of $57.73 per share were outstanding under the 2013 plan.&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA did not grant options in 2023. ARCA granted options to purchase an aggregate of 60,000&lt;span class="nobreak"&gt; &lt;/span&gt;shares of ARCA common stock in the year ended December&#160;31, 2022. The fair values of employee stock options granted in the year ended December&#160;31, 2022 were estimated at the date of grant using the Black&lt;span class="nobreak"&gt;-Scholes&lt;/span&gt; model with the following assumptions and had the following estimated weighted average grant date fair value per share:&lt;/p&gt;
		&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;"&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;/td&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;	&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Year Ended&lt;br/&gt;December&#160;31,&lt;br/&gt;2022&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Expected term&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;5.5&#160;years&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Expected volatility&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;107&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;%&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Risk-free interest rate&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;3.56&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;%&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Expected dividend yield&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;0&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;%&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Weighted-average grant date fair value per share&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;1.87&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;/table&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;A summary of ARCA&#x2019;s stock option activities for the&#160;years ended December&#160;31, 2023 and 2022, and related information as of December&#160;31, 2023, is as follows:&lt;/p&gt;
		&lt;table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;/td&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TCH" colspan="10" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 61.11%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;	&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Options Outstanding&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-17" style="height:12pt;"&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;	&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Number of&lt;br/&gt;Options&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;	&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;	&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term (in&#160;years)&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;	&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Aggregate&lt;br/&gt;Intrinsic Value&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Options outstanding&#160;&#x2013;&#160;December&#160;31,&#160;2021&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;904,123&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;5.59&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Granted&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;60,000&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;2.31&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Exercised&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-76; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-77; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Forfeited and cancelled&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(259,163&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;4.74&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Options outstanding&#160;&#x2013;&#160;December&#160;31,&#160;2022&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;704,960&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;5.62&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;8.29&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;18&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Granted&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-78; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-79; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Exercised&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-80; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-81; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Forfeited and cancelled&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(88,253&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;11.68&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Options outstanding&#160;&#x2013;&#160;December&#160;31,&#160;2023&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;616,707&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;4.76&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;7.35&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-82; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Options exercisable&#160;&#x2013;&#160;December&#160;31,&#160;2023&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;463,068&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;5.28&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;7.29&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-83; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-18" style="background: #CCEEFF;height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Options vested and expected to vest&#160;&#x2013;&#160;December&#160;31,&#160;2023&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;616,661&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;4.76&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;7.35&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-84; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;/table&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The aggregate intrinsic value in the table above represents the total intrinsic value, based on ARCA&#x2019;s closing price as of December&#160;31 of the respective year, which would have been received by the option holders had all the option holders with in&lt;span class="nobreak"&gt;-the-money&lt;/span&gt; options exercised as of that date. As of December&#160;31, 2023, the unrecognized compensation expense related to unvested options, excluding estimated forfeitures, was $367,000 which is expected to be recognized over a weighted average period of 1.1&#160;years. ARCA recognizes compensation costs for its share&lt;span class="nobreak"&gt;-based&lt;/span&gt; awards on a straight&lt;span class="nobreak"&gt;-line&lt;/span&gt; basis over the requisite service period for the entire award, as adjusted for expected forfeitures.&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Restricted Stock Units&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA granted restricted stock units (&#x201c;RSUs&#x201d;) under the Equity Plan to employees during 2022. The fair value of RSU awards is the closing price of ARCA common stock on the date of the grant and is recognized as compensation expense on a straight&lt;span class="nobreak"&gt;-line&lt;/span&gt; basis over the respective vesting period. The stock awards granted had a requisite service period of &lt;span style="-sec-ix-hidden: hidden-fact-100"&gt;one&lt;/span&gt; year.&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;A summary of RSU activity for the year ended December&#160;31, 2023 is presented below:&lt;/p&gt;
		&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;



					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="5" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Restricted Stock Units&lt;br/&gt;Outstanding&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-19" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Grant Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;RSUs outstanding&#160;&#x2013;&#160;December&#160;31, 2021&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-85; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-86; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Granted&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;91,000&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;2.21&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Vested and released&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-87; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-88; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Forfeited and cancelled&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-89; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-90; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;RSUs outstanding&#160;&#x2013;&#160;December&#160;31, 2022&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;91,000&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;2.21&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Granted&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-91; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-92; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Vested and released&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(91,000&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;2.21&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Forfeited and cancelled&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-93; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-94; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;RSUs outstanding&#160;&#x2013;&#160;December&#160;31, 2023&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-95; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-96; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;As of December&#160;31, 2023, there was no unrecognized compensation cost related to unvested stock awards.&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Non-cash Stock-based Compensation&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;For the&#160;years ended December&#160;31, 2023 and 2022, ARCA recognized the following non&lt;span class="nobreak"&gt;-cash&lt;/span&gt;, share&lt;span class="nobreak"&gt;-based&lt;/span&gt; compensation expense (in thousands):&lt;/p&gt;
		&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;



					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="5" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Years Ended&lt;br/&gt;December&#160;31,&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;2023&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;2022&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;General and administrative&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;526&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;423&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Research and development&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;160&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;133&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Total&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;686&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;556&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA did not recognize any tax benefit related to employee stock&lt;span class="nobreak"&gt;-based&lt;/span&gt; compensation cost as a result of the full valuation allowance on its net deferred tax assets.&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c96"
      decimals="INF"
      id="ixv-37963"
      unitRef="shares">1167425</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c97"
      decimals="INF"
      id="ixv-37964"
      unitRef="shares">601900</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c97"
      decimals="2"
      id="ixv-37965"
      unitRef="usdPershares">3.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c97"
      decimals="INF"
      id="ixv-37966"
      unitRef="shares">459718</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="c100"
      decimals="INF"
      id="ixv-37967"
      unitRef="pure">1</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <abio:PercentageHoldingForStockOptionsExercisePrice
      contextRef="c98"
      decimals="INF"
      id="ixv-37968"
      unitRef="pure">0.10</abio:PercentageHoldingForStockOptionsExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="c101"
      decimals="INF"
      id="ixv-37969"
      unitRef="pure">1.10</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c102"
      decimals="INF"
      id="ixv-37970"
      unitRef="shares">14807</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c102"
      decimals="2"
      id="ixv-37971"
      unitRef="usdPershares">57.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="c103"
      decimals="INF"
      id="ixv-37972"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <abio:PurchaseAggregateShares
      contextRef="c104"
      decimals="0"
      id="ixv-37973"
      unitRef="shares">60000</abio:PurchaseAggregateShares>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="c6" id="ixv-21552">The fair values of employee stock options granted in the year ended December&#160;31, 2022 were estimated at the date of grant using the Black&lt;span class="nobreak"&gt;-Scholes&lt;/span&gt; model with the following assumptions and had the following estimated weighted average grant date fair value per share:&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;"&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;/td&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;	&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Year Ended&lt;br/&gt;December&#160;31,&lt;br/&gt;2022&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Expected term&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;5.5&#160;years&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Expected volatility&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;107&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;%&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Risk-free interest rate&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;3.56&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;%&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Expected dividend yield&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;0&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;%&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Weighted-average grant date fair value per share&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;1.87&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c6" id="ixv-37974">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c6" decimals="2" id="ixv-37975" unitRef="pure">1.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c6" decimals="4" id="ixv-37976" unitRef="pure">0.0356</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c6" decimals="2" id="ixv-37977" unitRef="pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c6"
      decimals="2"
      id="ixv-37978"
      unitRef="usdPershares">1.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c6" id="ixv-37979">A summary of ARCA&#x2019;s stock option activities for the&#160;years ended December&#160;31, 2023 and 2022, and related information as of December&#160;31, 2023, is as follows:&lt;table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;/td&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TCH" colspan="10" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 61.11%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;	&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Options Outstanding&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-17" style="height:12pt;"&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;	&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Number of&lt;br/&gt;Options&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;	&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;	&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term (in&#160;years)&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;	&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Aggregate&lt;br/&gt;Intrinsic Value&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Options outstanding&#160;&#x2013;&#160;December&#160;31,&#160;2021&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;904,123&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;5.59&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Granted&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;60,000&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;2.31&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Exercised&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-76; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-77; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Forfeited and cancelled&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(259,163&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;4.74&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Options outstanding&#160;&#x2013;&#160;December&#160;31,&#160;2022&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;704,960&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;5.62&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;8.29&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;18&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Granted&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-78; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-79; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Exercised&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-80; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-81; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Forfeited and cancelled&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(88,253&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;11.68&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Options outstanding&#160;&#x2013;&#160;December&#160;31,&#160;2023&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;616,707&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;4.76&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;7.35&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-82; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Options exercisable&#160;&#x2013;&#160;December&#160;31,&#160;2023&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;463,068&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;5.28&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;7.29&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-83; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-18" style="background: #CCEEFF;height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Options vested and expected to vest&#160;&#x2013;&#160;December&#160;31,&#160;2023&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;616,661&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;4.76&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;7.35&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-84; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c16"
      decimals="INF"
      id="ixv-37980"
      unitRef="shares">904123</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c16"
      decimals="2"
      id="ixv-37981"
      unitRef="usdPershares">5.59</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c7"
      decimals="INF"
      id="ixv-37982"
      unitRef="shares">60000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c7"
      decimals="2"
      id="ixv-37983"
      unitRef="usdPershares">2.31</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="c7"
      decimals="INF"
      id="ixv-37984"
      unitRef="shares">259163</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="c7"
      decimals="2"
      id="ixv-37985"
      unitRef="usdPershares">4.74</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c2"
      decimals="INF"
      id="ixv-37986"
      unitRef="shares">704960</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c2"
      decimals="2"
      id="ixv-37987"
      unitRef="usdPershares">5.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c7" id="ixv-37988">P8Y3M14D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c2" decimals="-3" id="ixv-37989" unitRef="usd">18000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="c6"
      decimals="INF"
      id="ixv-37990"
      unitRef="shares">88253</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="c6"
      decimals="2"
      id="ixv-37991"
      unitRef="usdPershares">11.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c1"
      decimals="INF"
      id="ixv-37992"
      unitRef="shares">616707</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c1"
      decimals="2"
      id="ixv-37993"
      unitRef="usdPershares">4.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c6" id="ixv-37994">P7Y4M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c1"
      decimals="INF"
      id="ixv-37995"
      unitRef="shares">463068</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c1"
      decimals="2"
      id="ixv-37996"
      unitRef="usdPershares">5.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c6" id="ixv-37997">P7Y3M14D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="c1"
      decimals="INF"
      id="ixv-37998"
      unitRef="shares">616661</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="c1"
      decimals="2"
      id="ixv-37999"
      unitRef="usdPershares">4.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="c6" id="ixv-38000">P7Y4M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="c105" decimals="0" id="ixv-38001" unitRef="usd">367000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c106" id="ixv-38002">P1Y1M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock contextRef="c6" id="ixv-38003">A summary of RSU activity for the year ended December&#160;31, 2023 is presented below:&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;



					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="5" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Restricted Stock Units&lt;br/&gt;Outstanding&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-19" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Grant Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;RSUs outstanding&#160;&#x2013;&#160;December&#160;31, 2021&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-85; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-86; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Granted&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;91,000&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;2.21&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Vested and released&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-87; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-88; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Forfeited and cancelled&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-89; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-90; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;RSUs outstanding&#160;&#x2013;&#160;December&#160;31, 2022&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;91,000&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;2.21&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Granted&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-91; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-92; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Vested and released&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(91,000&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;2.21&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Forfeited and cancelled&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-93; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-94; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;RSUs outstanding&#160;&#x2013;&#160;December&#160;31, 2023&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-95; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-96; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c7"
      decimals="INF"
      id="ixv-38004"
      unitRef="shares">91000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c7"
      decimals="2"
      id="ixv-38005"
      unitRef="usdPershares">2.21</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c2"
      decimals="INF"
      id="ixv-38006"
      unitRef="shares">91000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c2"
      decimals="2"
      id="ixv-38007"
      unitRef="usdPershares">2.21</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c6"
      decimals="INF"
      id="ixv-38008"
      unitRef="shares">91000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c6"
      decimals="2"
      id="ixv-38009"
      unitRef="usdPershares">2.21</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="c108"
      decimals="INF"
      id="ixv-38010"
      unitRef="usd">0</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="c6" id="ixv-22033">For the&#160;years ended December&#160;31, 2023 and 2022, ARCA recognized the following non&lt;span class="nobreak"&gt;-cash&lt;/span&gt;, share&lt;span class="nobreak"&gt;-based&lt;/span&gt; compensation expense (in thousands):&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;



					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="5" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Years Ended&lt;br/&gt;December&#160;31,&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;2023&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;2022&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;General and administrative&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;526&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;423&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Research and development&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;160&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;133&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Total&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;686&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;556&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c89" decimals="-3" id="ixv-38011" unitRef="usd">526000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c90" decimals="-3" id="ixv-38012" unitRef="usd">423000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c109"
      decimals="-3"
      id="ixv-38013"
      unitRef="usd">160000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c110"
      decimals="-3"
      id="ixv-38014"
      unitRef="usd">133000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c6" decimals="-3" id="ixv-38015" unitRef="usd">686000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c7" decimals="-3" id="ixv-38016" unitRef="usd">556000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock contextRef="c6" id="ixv-22096">&lt;p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;(9)&#160;Employee Benefit Plans&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA has a 401(k)&#160;plan and makes a matching contribution equal to 100% of the employee&#x2019;s first 3% of the employee&#x2019;s contributions and 50% of the employee&#x2019;s next 2% of contributions. ARCA adopted the plan in 2006 and contributed $56,000 and $96,000 for the&#160;years ended December&#160;31, 2023 and 2022, respectively.&lt;/p&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans contextRef="c6" id="ixv-38017">matching contribution equal to 100% of the employee&#x2019;s first 3% of the employee&#x2019;s contributions and 50% of the employee&#x2019;s next 2% of contributions.</us-gaap:DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="c111"
      decimals="INF"
      id="ixv-38018"
      unitRef="pure">1</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="c111"
      decimals="2"
      id="ixv-38019"
      unitRef="pure">0.03</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="c112"
      decimals="2"
      id="ixv-38020"
      unitRef="pure">0.50</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="c112"
      decimals="2"
      id="ixv-38021"
      unitRef="pure">0.02</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <us-gaap:DefinedContributionPlanCostRecognized contextRef="c6" decimals="0" id="ixv-38022" unitRef="usd">56000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized contextRef="c7" decimals="0" id="ixv-38023" unitRef="usd">96000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c6" id="ixv-22100">&lt;p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;(&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;10)&#160;Income Taxes&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Effective June&#160;1, 2005, ARCA changed from an S&lt;span class="nobreak"&gt;-Corporation&lt;/span&gt; to a C&lt;span class="nobreak"&gt;-Corporation&lt;/span&gt;. As an S&lt;span class="nobreak"&gt;-Corporation&lt;/span&gt;, the net operating loss carryforwards were distributed to ARCA&#x2019;s stockholders; such amounts were not significant. As of December&#160;31, 2023, ARCA has net operating loss carryforwards of approximately $208.1&#160;million, and approximately $2.4&#160;million of research and development credits that may be used to offset future taxable income. ARCA&#x2019;s net operating loss carryforwards through December&#160;31, 2017 will expire beginning &lt;span style="-sec-ix-hidden: hidden-fact-107"&gt;2025&lt;/span&gt; through &lt;span style="-sec-ix-hidden: hidden-fact-108"&gt;2037&lt;/span&gt;. The net operating loss carryforwards beginning in 2018, have no expiration. Utilization of net operating losses and tax credits, including those acquired as a result of the Merger, will be subject to an annual limitation due to ownership change limitations provided by Internal Revenue Code Section&#160;382. ARCA believes that an ownership change limitation as defined under Section&#160;382 of the U.S.&#160;Internal Revenue Code occurred as a result of its various historical financing transactions. Future utilization of the federal net operating losses and tax credit &lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;"&gt;carryforwards accumulated from June&#160;2005 to the change in ownership date will be subject to annual limitations to offset future taxable income. The annual limitation may result in the expiration of the net operating losses and credits before utilization. As such, a portion of ARCA&#x2019;s net operating loss carryforwards may be limited.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the period in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. Due primarily to ARCA&#x2019;s history of operating losses, management is unable to conclude that it is more likely than not that ARCA will realize the benefits of these deductible differences, and accordingly has provided a valuation allowance against the entire net deferred tax assets and liabilities of approximately $55.5&#160;million at December&#160;31, 2023, reflecting an increase of approximately $1.2&#160;million from December&#160;31, 2022. The deferred tax assets are primarily comprised of net operating loss carryforwards and research and experimentation credit carryforwards. As of December&#160;31, 2023, ARCA has not performed an Internal Revenue Code Section&#160;382 limitation study. Depending on the outcome of such a study, the gross amount of net operating losses recognizable in future tax periods could be limited. A limitation in the carryforwards would decrease the carrying amount of the gross amount of the net operating loss carryforwards, with a corresponding decrease in the valuation allowance recorded against these gross deferred tax assets.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Income tax benefit attributable to ARCA&#x2019;s loss from operations before income taxes differs from the amounts computed by applying the U.S.&#160;federal statutory income tax rate of 21% for 2023 and 2022, as a result of the following (in thousands):&lt;/p&gt;
		&lt;table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;



					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Years ended&lt;br/&gt;December&#160;31,&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;2023&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;2022&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;U.S.&#160;federal income tax benefit at statutory rates&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(1,121&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(2,085&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;State income tax benefit, net of federal benefit&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(192&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(357&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Research and experimentation credits&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-101; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-102; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Deferred tax asset adjustment&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;47&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;2&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Other&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;107&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;186&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Change in valuation allowance&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;1,159&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;2,254&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Income tax benefit&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-103; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-104; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting and the amounts used for income tax purposes, as well as operating loss and tax credit carryforwards. The income tax effects of temporary differences and carryforwards that give rise to significant portions of ARCA&#x2019;s net deferred tax assets and liabilities consisted of the following (in thousands):&lt;/p&gt;
		&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;



					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;As of December&#160;31,&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;2023&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;2022&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Deferred tax assets:&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Net operating loss carryforwards&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;51,190&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;50,008&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Charitable contribution carryforwards&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;371&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;393&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Research and experimentation credits&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;2,420&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;2,420&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Capitalized research and development costs&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;951&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;979&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Capitalized intangibles&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;354&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;356&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Stock-based compensation&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;232&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;205&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Accrued compensation&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;7&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;6&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Lease liabilities&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;69&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;94&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Total deferred tax assets&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;55,594&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;54,461&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Valuation allowance&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(55,531&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(54,372&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Deferred tax assets, net of valuation allowance&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;63&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;89&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Deferred tax liabilities:&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Right-of-use asset&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(61&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(84&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Depreciation and amortization&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(2&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(5&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Net deferred tax liability&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-105; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-106; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Since ARCA is in a loss carryforward position, it is generally subject to U.S.&#160;federal and state income tax examinations by tax authorities for all&#160;years for which a loss carryforward is available. Thus, ARCA&#x2019;s open tax&#160;years extend back to &lt;span style="-sec-ix-hidden: hidden-fact-109"&gt;2009&lt;/span&gt;. ARCA believes that its tax filing positions and deductions related to tax periods subject to examination will be sustained upon audit and does not anticipate any adjustment will result in a material adverse effect on ARCA&#x2019;s financial condition, result of operations, or cash flow. For the&#160;years ended December&#160;31, 2023 and 2022, ARCA has no reserve for uncertain tax positions. ARCA does not expect that the total amounts of unrecognized tax benefits will significantly increase or decrease within the subsequent twelve&#160;months. In the event ARCA concludes it is subject to interest or penalties arising from uncertain tax positions, it will record interest and penalties as a component of other income and expense. No interest or penalties were recognized in the financial statements for the&#160;years ended December&#160;31, 2023 and 2022.&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:OperatingLossCarryforwards contextRef="c1" decimals="-5" id="ixv-38024" unitRef="usd">208100000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="c113"
      decimals="-5"
      id="ixv-38025"
      unitRef="usd">2400000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardDescription contextRef="c6" id="ixv-38026">The net operating loss carryforwards beginning in 2018, have no expiration.</us-gaap:TaxCreditCarryforwardDescription>
    <us-gaap:TaxCreditCarryforwardLimitationsOnUse contextRef="c116" id="ixv-38027">Utilization of net operating losses and tax credits, including those acquired as a result of the Merger, will be subject to an annual limitation due to ownership change limitations provided by Internal Revenue Code Section&#160;382. ARCA believes that an ownership change limitation as defined under Section&#160;382 of the U.S.&#160;Internal Revenue Code occurred as a result of its various historical financing transactions. Future utilization of the federal net operating losses and tax credit carryforwards accumulated from June&#160;2005 to the change in ownership date will be subject to annual limitations to offset future taxable income. The annual limitation may result in the expiration of the net operating losses and credits before utilization. As such, a portion of ARCA&#x2019;s net operating loss carryforwards may be limited.</us-gaap:TaxCreditCarryforwardLimitationsOnUse>
    <abio:DeferredTaxAssetsAndLiabilitiesValuationAllowance contextRef="c1" decimals="-5" id="ixv-38028" unitRef="usd">55500000</abio:DeferredTaxAssetsAndLiabilitiesValuationAllowance>
    <abio:ValuationAllowanceDeferredTaxAssetsAndLiabilitiesChangeInAmount contextRef="c6" decimals="-5" id="ixv-38029" unitRef="usd">1200000</abio:ValuationAllowanceDeferredTaxAssetsAndLiabilitiesChangeInAmount>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="c6" id="ixv-38030">Income tax benefit attributable to ARCA&#x2019;s loss from operations before income taxes differs from the amounts computed by applying the U.S.&#160;federal statutory income tax rate of 21% for 2023 and 2022, as a result of the following (in thousands):&lt;table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;



					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Years ended&lt;br/&gt;December&#160;31,&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;2023&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;2022&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;U.S.&#160;federal income tax benefit at statutory rates&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(1,121&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(2,085&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;State income tax benefit, net of federal benefit&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(192&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(357&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Research and experimentation credits&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-101; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-102; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Deferred tax asset adjustment&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;47&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;2&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Other&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;107&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;186&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Change in valuation allowance&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;1,159&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;2,254&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Income tax benefit&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-103; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-104; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c6" decimals="2" id="ixv-38031" unitRef="pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c7" decimals="2" id="ixv-38032" unitRef="pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="c6" decimals="-3" id="ixv-38033" unitRef="usd">-1121000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="c7" decimals="-3" id="ixv-38034" unitRef="usd">-2085000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="c6" decimals="-3" id="ixv-38035" unitRef="usd">-192000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="c7" decimals="-3" id="ixv-38036" unitRef="usd">-357000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <abio:IncomeTaxReconciliationAdjustmentToDeferredTaxAsset contextRef="c6" decimals="-3" id="ixv-38037" unitRef="usd">47000</abio:IncomeTaxReconciliationAdjustmentToDeferredTaxAsset>
    <abio:IncomeTaxReconciliationAdjustmentToDeferredTaxAsset contextRef="c7" decimals="-3" id="ixv-38038" unitRef="usd">2000</abio:IncomeTaxReconciliationAdjustmentToDeferredTaxAsset>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments contextRef="c6" decimals="-3" id="ixv-38039" unitRef="usd">107000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments contextRef="c7" decimals="-3" id="ixv-38040" unitRef="usd">186000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c6" decimals="-3" id="ixv-38041" unitRef="usd">1159000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c7" decimals="-3" id="ixv-38042" unitRef="usd">2254000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="c6" id="ixv-38043">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting and the amounts used for income tax purposes, as well as operating loss and tax credit carryforwards. The income tax effects of temporary differences and carryforwards that give rise to significant portions of ARCA&#x2019;s net deferred tax assets and liabilities consisted of the following (in thousands):&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;



					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;As of December&#160;31,&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;2023&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;2022&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Deferred tax assets:&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Net operating loss carryforwards&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;51,190&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;50,008&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Charitable contribution carryforwards&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;371&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;393&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Research and experimentation credits&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;2,420&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;2,420&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Capitalized research and development costs&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;951&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;979&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Capitalized intangibles&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;354&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;356&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Stock-based compensation&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;232&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;205&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Accrued compensation&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;7&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;6&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Lease liabilities&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;69&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;94&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Total deferred tax assets&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;55,594&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;54,461&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Valuation allowance&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(55,531&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(54,372&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Deferred tax assets, net of valuation allowance&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;63&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;89&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Deferred tax liabilities:&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Right-of-use asset&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(61&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(84&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Depreciation and amortization&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(2&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(5&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Net deferred tax liability&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-105; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-106; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration contextRef="c1" decimals="-3" id="ixv-38044" unitRef="usd">51190000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration contextRef="c2" decimals="-3" id="ixv-38045" unitRef="usd">50008000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
    <us-gaap:DeferredTaxAssetsCharitableContributionCarryforwards contextRef="c1" decimals="-3" id="ixv-38046" unitRef="usd">371000</us-gaap:DeferredTaxAssetsCharitableContributionCarryforwards>
    <us-gaap:DeferredTaxAssetsCharitableContributionCarryforwards contextRef="c2" decimals="-3" id="ixv-38047" unitRef="usd">393000</us-gaap:DeferredTaxAssetsCharitableContributionCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="c1" decimals="-3" id="ixv-38048" unitRef="usd">2420000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="c2" decimals="-3" id="ixv-38049" unitRef="usd">2420000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <abio:DeferredTaxAssetResearchAndDevelopment contextRef="c1" decimals="-3" id="ixv-38050" unitRef="usd">951000</abio:DeferredTaxAssetResearchAndDevelopment>
    <abio:DeferredTaxAssetResearchAndDevelopment contextRef="c2" decimals="-3" id="ixv-38051" unitRef="usd">979000</abio:DeferredTaxAssetResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets contextRef="c1" decimals="-3" id="ixv-38052" unitRef="usd">354000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets contextRef="c2" decimals="-3" id="ixv-38053" unitRef="usd">356000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="c1" decimals="-3" id="ixv-38054" unitRef="usd">232000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="c2" decimals="-3" id="ixv-38055" unitRef="usd">205000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits contextRef="c1" decimals="-3" id="ixv-38056" unitRef="usd">7000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits contextRef="c2" decimals="-3" id="ixv-38057" unitRef="usd">6000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits>
    <abio:DeferredTaxAssetsLeaseLiabilities contextRef="c1" decimals="-3" id="ixv-38058" unitRef="usd">69000</abio:DeferredTaxAssetsLeaseLiabilities>
    <abio:DeferredTaxAssetsLeaseLiabilities contextRef="c2" decimals="-3" id="ixv-38059" unitRef="usd">94000</abio:DeferredTaxAssetsLeaseLiabilities>
    <us-gaap:DeferredTaxAssetsGross contextRef="c1" decimals="-3" id="ixv-38060" unitRef="usd">55594000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross contextRef="c2" decimals="-3" id="ixv-38061" unitRef="usd">54461000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c1" decimals="-3" id="ixv-38062" unitRef="usd">55531000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c2" decimals="-3" id="ixv-38063" unitRef="usd">54372000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet contextRef="c1" decimals="-3" id="ixv-38064" unitRef="usd">63000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet contextRef="c2" decimals="-3" id="ixv-38065" unitRef="usd">89000</us-gaap:DeferredTaxAssetsNet>
    <abio:DeferredTaxLiabilitiesRightOfUseAsset contextRef="c1" decimals="-3" id="ixv-38066" unitRef="usd">61000</abio:DeferredTaxLiabilitiesRightOfUseAsset>
    <abio:DeferredTaxLiabilitiesRightOfUseAsset contextRef="c2" decimals="-3" id="ixv-38067" unitRef="usd">84000</abio:DeferredTaxLiabilitiesRightOfUseAsset>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment contextRef="c1" decimals="-3" id="ixv-38068" unitRef="usd">2000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment contextRef="c2" decimals="-3" id="ixv-38069" unitRef="usd">5000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:LiabilityForUncertainTaxPositionsCurrent contextRef="c1" decimals="INF" id="ixv-38070" unitRef="usd">0</us-gaap:LiabilityForUncertainTaxPositionsCurrent>
    <us-gaap:LiabilityForUncertainTaxPositionsCurrent contextRef="c2" decimals="0" id="ixv-38071" unitRef="usd">0</us-gaap:LiabilityForUncertainTaxPositionsCurrent>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense contextRef="c6" decimals="0" id="ixv-38072" unitRef="usd">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense contextRef="c7" decimals="0" id="ixv-38073" unitRef="usd">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c5" decimals="-3" id="ixv-38074" unitRef="usd">35903000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c1" decimals="-3" id="ixv-38075" unitRef="usd">37431000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:OtherAssetsCurrent contextRef="c5" decimals="-3" id="ixv-38076" unitRef="usd">767000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="c1" decimals="-3" id="ixv-38077" unitRef="usd">161000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c5" decimals="-3" id="ixv-38078" unitRef="usd">36670000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c1" decimals="-3" id="ixv-38079" unitRef="usd">37592000</us-gaap:AssetsCurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c5" decimals="-3" id="ixv-38080" unitRef="usd">17000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c1" decimals="-3" id="ixv-38081" unitRef="usd">247000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c5" decimals="-3" id="ixv-38082" unitRef="usd">7000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c1" decimals="-3" id="ixv-38083" unitRef="usd">10000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OtherAssetsNoncurrent contextRef="c5" decimals="-3" id="ixv-38084" unitRef="usd">12000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c1" decimals="-3" id="ixv-38085" unitRef="usd">12000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets contextRef="c5" decimals="-3" id="ixv-38086" unitRef="usd">36706000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c1" decimals="-3" id="ixv-38087" unitRef="usd">37861000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="c5" decimals="-3" id="ixv-38088" unitRef="usd">529000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c1" decimals="-3" id="ixv-38089" unitRef="usd">362000</us-gaap:AccountsPayableCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c5" decimals="-3" id="ixv-38090" unitRef="usd">84000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c1" decimals="-3" id="ixv-38091" unitRef="usd">100000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c5" decimals="-3" id="ixv-38092" unitRef="usd">968000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c1" decimals="-3" id="ixv-38093" unitRef="usd">175000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c5" decimals="-3" id="ixv-38094" unitRef="usd">1581000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c1" decimals="-3" id="ixv-38095" unitRef="usd">637000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c1" decimals="-3" id="ixv-38096" unitRef="usd">204000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities contextRef="c5" decimals="-3" id="ixv-38097" unitRef="usd">1581000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c1" decimals="-3" id="ixv-38098" unitRef="usd">841000</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c5"
      decimals="INF"
      id="ixv-38099"
      unitRef="usdPershares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c1"
      decimals="INF"
      id="ixv-38100"
      unitRef="usdPershares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c5"
      decimals="INF"
      id="ixv-38101"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c1"
      decimals="INF"
      id="ixv-38102"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="c5"
      decimals="INF"
      id="ixv-38103"
      unitRef="shares">14501143</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="c1"
      decimals="INF"
      id="ixv-38104"
      unitRef="shares">14501143</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c5"
      decimals="INF"
      id="ixv-38105"
      unitRef="shares">14501143</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c1"
      decimals="INF"
      id="ixv-38106"
      unitRef="shares">14501143</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c5" decimals="-3" id="ixv-38107" unitRef="usd">14000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c1" decimals="-3" id="ixv-38108" unitRef="usd">14000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c5" decimals="-3" id="ixv-38109" unitRef="usd">225861000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c1" decimals="-3" id="ixv-38110" unitRef="usd">225747000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c5" decimals="-3" id="ixv-38111" unitRef="usd">-190750000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c1" decimals="-3" id="ixv-38112" unitRef="usd">-188741000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="c5" decimals="-3" id="ixv-38113" unitRef="usd">35125000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c1" decimals="-3" id="ixv-38114" unitRef="usd">37020000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c5" decimals="-3" id="ixv-38115" unitRef="usd">36706000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c1" decimals="-3" id="ixv-38116" unitRef="usd">37861000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c0" decimals="-3" id="ixv-38117" unitRef="usd">2317000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c10" decimals="-3" id="ixv-38118" unitRef="usd">1406000</us-gaap:GeneralAndAdministrativeExpense>
    <abio:ResearchAndDevelopmentExpenseReversed contextRef="c11" decimals="-3" id="ixv-38119" unitRef="usd">0</abio:ResearchAndDevelopmentExpenseReversed>
    <abio:ResearchAndDevelopmentExpenseReversed contextRef="c12" decimals="-3" id="ixv-38120" unitRef="usd">108000</abio:ResearchAndDevelopmentExpenseReversed>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c0" decimals="-3" id="ixv-38121" unitRef="usd">165000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c10" decimals="-3" id="ixv-38122" unitRef="usd">390000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:OperatingExpenses contextRef="c0" decimals="-3" id="ixv-38123" unitRef="usd">2482000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c10" decimals="-3" id="ixv-38124" unitRef="usd">1796000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c0" decimals="-3" id="ixv-38125" unitRef="usd">-2482000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c10" decimals="-3" id="ixv-38126" unitRef="usd">-1796000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestAndOtherIncome contextRef="c0" decimals="-3" id="ixv-38127" unitRef="usd">473000</us-gaap:InterestAndOtherIncome>
    <us-gaap:InterestAndOtherIncome contextRef="c10" decimals="-3" id="ixv-38128" unitRef="usd">450000</us-gaap:InterestAndOtherIncome>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="-3" id="ixv-38129" unitRef="usd">-2009000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c10" decimals="-3" id="ixv-38130" unitRef="usd">-1346000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="c0"
      decimals="2"
      id="ixv-38131"
      unitRef="usdPershares">-0.14</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c10"
      decimals="2"
      id="ixv-38132"
      unitRef="usdPershares">-0.09</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c0"
      decimals="0"
      id="ixv-38133"
      unitRef="shares">14501143</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c10"
      decimals="0"
      id="ixv-38134"
      unitRef="shares">14410143</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c20"
      decimals="0"
      id="ixv-38135"
      unitRef="shares">14410143</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c20" decimals="-3" id="ixv-38136" unitRef="usd">14000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c21" decimals="-3" id="ixv-38137" unitRef="usd">225061000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c22" decimals="-3" id="ixv-38138" unitRef="usd">-183402000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c2" decimals="-3" id="ixv-38139" unitRef="usd">41673000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c30" decimals="-3" id="ixv-38140" unitRef="usd">204000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c10" decimals="-3" id="ixv-38141" unitRef="usd">204000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss contextRef="c31" decimals="-3" id="ixv-38142" unitRef="usd">-1346000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c10" decimals="-3" id="ixv-38143" unitRef="usd">-1346000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c32"
      decimals="0"
      id="ixv-38144"
      unitRef="shares">14410143</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c32" decimals="-3" id="ixv-38145" unitRef="usd">14000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c33" decimals="-3" id="ixv-38146" unitRef="usd">225265000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c34" decimals="-3" id="ixv-38147" unitRef="usd">-184748000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c35" decimals="-3" id="ixv-38148" unitRef="usd">40531000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c37" decimals="-3" id="ixv-38149" unitRef="usd">187000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c39" decimals="-3" id="ixv-38150" unitRef="usd">187000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss contextRef="c38" decimals="-3" id="ixv-38151" unitRef="usd">-1480000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c39" decimals="-3" id="ixv-38152" unitRef="usd">-1480000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c40"
      decimals="0"
      id="ixv-38153"
      unitRef="shares">14410143</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c40" decimals="-3" id="ixv-38154" unitRef="usd">14000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c41" decimals="-3" id="ixv-38155" unitRef="usd">225452000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c42" decimals="-3" id="ixv-38156" unitRef="usd">-186228000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c43" decimals="-3" id="ixv-38157" unitRef="usd">39238000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c45" decimals="-3" id="ixv-38158" unitRef="usd">154000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c47" decimals="-3" id="ixv-38159" unitRef="usd">154000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss contextRef="c46" decimals="-3" id="ixv-38160" unitRef="usd">-1424000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c47" decimals="-3" id="ixv-38161" unitRef="usd">-1424000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c48"
      decimals="0"
      id="ixv-38162"
      unitRef="shares">14410143</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c48" decimals="-3" id="ixv-38163" unitRef="usd">14000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c49" decimals="-3" id="ixv-38164" unitRef="usd">225606000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c50" decimals="-3" id="ixv-38165" unitRef="usd">-187652000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c51" decimals="-3" id="ixv-38166" unitRef="usd">37968000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="c52"
      decimals="0"
      id="ixv-38167"
      unitRef="shares">91000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c53" decimals="-3" id="ixv-38168" unitRef="usd">141000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c55" decimals="-3" id="ixv-38169" unitRef="usd">141000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss contextRef="c54" decimals="-3" id="ixv-38170" unitRef="usd">-1089000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c55" decimals="-3" id="ixv-38171" unitRef="usd">-1089000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c26"
      decimals="0"
      id="ixv-38172"
      unitRef="shares">14501143</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c26" decimals="-3" id="ixv-38173" unitRef="usd">14000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c27" decimals="-3" id="ixv-38174" unitRef="usd">225747000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c28" decimals="-3" id="ixv-38175" unitRef="usd">-188741000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c1" decimals="-3" id="ixv-38176" unitRef="usd">37020000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c57" decimals="-3" id="ixv-38177" unitRef="usd">114000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c0" decimals="-3" id="ixv-38178" unitRef="usd">114000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss contextRef="c58" decimals="-3" id="ixv-38179" unitRef="usd">-2009000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="-3" id="ixv-38180" unitRef="usd">-2009000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c59"
      decimals="0"
      id="ixv-38181"
      unitRef="shares">14501143</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c59" decimals="-3" id="ixv-38182" unitRef="usd">14000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c60" decimals="-3" id="ixv-38183" unitRef="usd">225861000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c61" decimals="-3" id="ixv-38184" unitRef="usd">-190750000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c5" decimals="-3" id="ixv-38185" unitRef="usd">35125000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="-3" id="ixv-38186" unitRef="usd">-2009000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c10" decimals="-3" id="ixv-38187" unitRef="usd">-1346000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationAndAmortization contextRef="c0" decimals="-3" id="ixv-38188" unitRef="usd">3000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c10" decimals="-3" id="ixv-38189" unitRef="usd">4000</us-gaap:DepreciationAndAmortization>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c0" decimals="-3" id="ixv-38190" unitRef="usd">16000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c10" decimals="-3" id="ixv-38191" unitRef="usd">25000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:ShareBasedCompensation contextRef="c0" decimals="-3" id="ixv-38192" unitRef="usd">114000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c10" decimals="-3" id="ixv-38193" unitRef="usd">204000</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets contextRef="c0" decimals="-3" id="ixv-38194" unitRef="usd">606000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets contextRef="c10" decimals="-3" id="ixv-38195" unitRef="usd">598000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c0" decimals="-3" id="ixv-38196" unitRef="usd">167000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c10" decimals="-3" id="ixv-38197" unitRef="usd">32000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="c0" decimals="-3" id="ixv-38198" unitRef="usd">-16000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="c10" decimals="-3" id="ixv-38199" unitRef="usd">62000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities contextRef="c0" decimals="-3" id="ixv-38200" unitRef="usd">803000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities contextRef="c10" decimals="-3" id="ixv-38201" unitRef="usd">22000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c0" decimals="-3" id="ixv-38202" unitRef="usd">-1528000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c10" decimals="-3" id="ixv-38203" unitRef="usd">-1595000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c0" decimals="-3" id="ixv-38204" unitRef="usd">-1528000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c10" decimals="-3" id="ixv-38205" unitRef="usd">-1595000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c1" decimals="-3" id="ixv-38206" unitRef="usd">37431000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c2" decimals="-3" id="ixv-38207" unitRef="usd">42445000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c5" decimals="-3" id="ixv-38208" unitRef="usd">35903000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c35" decimals="-3" id="ixv-38209" unitRef="usd">40850000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c0" decimals="-3" id="ixv-38210" unitRef="usd">214000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock contextRef="c0" id="ixv-24333">&lt;p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;(1)&#160;ARCA and Summary of Significant Accounting Policies&lt;/span&gt;&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;margin-top:8pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Description of Business&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA biopharma, Inc. (&#x201c;ARCA&#x201d;), a Delaware corporation, is headquartered in Westminster, Colorado. ARCA is dedicated to applying a precision medicine approach to the development and commercialization of genetically targeted therapies for cardiovascular diseases. ARCA&#x2019;s lead product candidate is Gencaro&#x2122; (bucindolol hydrochloride) for the treatment of atrial fibrillation (&#x201c;AF&#x201d;) in patients with chronic heart failure (&#x201c;HF&#x201d;).&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;In April&#160;2022, ARCA established a Special Committee of the board of directors (the &#x201c;Board&#x201d;) of ARCA to conduct a comprehensive review of strategic alternatives. As part of the strategic review process, ARCA explored potential strategic alternatives that included, without limitation, an acquisition, merger, business combination or other transactions. ARCA has and is continuing to explore strategic alternatives related to its product candidates and related assets, including, without limitation, licensing transactions and asset sales.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;On April&#160;3, 2024, following a comprehensive review of strategic alternatives, ARCA, Atlas Merger Sub Corp., a Delaware corporation and a wholly&lt;span class="nobreak"&gt;-owned&lt;/span&gt; subsidiary of ARCA (&#x201c;Merger Sub&#160;I&#x201d;), Atlas Merger Sub&#160;II LLC, a Delaware limited liability company and a wholly&lt;span class="nobreak"&gt;-owned&lt;/span&gt; subsidiary of ARCA (&#x201c;Merger Sub&#160;II&#x201d;) and Oruka Therapeutics, Inc., a Delaware corporation (&#x201c;Oruka&lt;span class="CharOverride-1" style="text-decoration:underline;"&gt;&#x201d;&lt;/span&gt;), entered into an Agreement and Plan of Merger and Reorganization (the &#x201c;Merger Agreement&#x201d;), pursuant to which, among other matters, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Merger Sub&#160;I will merge with and into Oruka, with Oruka continuing as a wholly owned subsidiary of ARCA and the surviving corporation of the merger (the &#x201c;First Merger&#x201d;) and as part of the same overall transaction, the surviving corporation in the First Merger will merge with and into Merger Sub&#160;II with Merger Sub&#160;II continuing as a wholly owned subsidiary of ARCA and the surviving entity of the merger (the &#x201c;Second Merger&#x201d; and together with the First Merger, the &#x201c;Merger&#x201d;). The Merger is intended to qualify for federal income tax purposes as a tax&lt;span class="nobreak"&gt;-free&lt;/span&gt; reorganization under the provisions of Section&#160;368(a)&#160;of the Internal Revenue Code of 1986, as amended.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA&#x2019;s future operations are highly dependent on the success of the Merger and there can be no assurances that the Merger will be successfully consummated. In the event that ARCA does not complete the Merger, it may explore strategic alternatives, including, without limitation, another strategic transaction and/or pursue a dissolution and liquidation of ARCA. See Note&#160;10.&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Liquidity and Going Concern&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA devotes substantially all of its efforts towards obtaining regulatory approval and raising capital necessary to fund its operations and it is subject to a number of risks associated with clinical research and development, including dependence on key individuals, the development of and regulatory approval of commercially viable products, the need to raise adequate additional financing necessary to fund the development and commercialization of its products, and competition from larger companies. ARCA has not generated revenue to date and has incurred substantial losses and negative cash flows from operations since its inception. ARCA has historically funded its operations through issuances of common and preferred stock.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA believes that its current cash and cash equivalents as of March&#160;31, 2024 will be sufficient to fund its operations through the middle of fiscal year 2025. The future viability of ARCA beyond that point is dependent on the results of the strategic review process and its ability to raise additional capital to fund its operations. ARCA expects to continue to incur costs and expenditures in connection with the process of evaluating strategic alternatives. There can be no assurance, however, that ARCA will be able to successfully consummate any particular strategic transaction, including the Merger Agreement. The process of continuing to evaluate these strategic options may be very costly, time&lt;span class="nobreak"&gt;-consuming&lt;/span&gt; and complex and ARCA has incurred, and may in the future incur, significant costs related to this continued evaluation, such as legal, accounting and advisory fees and expenses and other related charges, see Note&#160;10 regarding the Merger Agreement. Should ARCA pursue additional clinical trials for its product candidates, it will have to raise additional capital for clinical trials of Gencaro. ARCA may not be able to raise sufficient capital on acceptable terms, or at all, to continue development of Gencaro or rNAPc2 or to otherwise continue operations and may not be &lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;"&gt;able to execute any strategic transaction. Changing circumstances may cause ARCA to consume capital significantly faster or slower than currently anticipated. ARCA has based these estimates on assumptions that may prove to be wrong, and it could exhaust its available financial resources sooner than it currently anticipates. Depending on the results of the strategic review process, ARCA may have to raise additional capital for clinical trials of Gencaro and to fund its operations. ARCA may not be able to raise sufficient capital on acceptable terms, or at all, to continue development of Gencaro or rNAPc2 or to otherwise continue operations and may not be able to execute any strategic transaction.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA&#x2019;s liquidity, and its ability to raise additional capital or complete any strategic transaction, depends on a number of factors, including, but not limited to, the following:&lt;/p&gt;
		&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;the timing and outcome of the strategic review process;&lt;/p&gt;
		&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;the consummation of any particular strategic transactions, including the Merger;&lt;/p&gt;
		&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;the costs and timing for the potential additional clinical trials in order to gain possible regulatory approval for Gencaro, rNAPc2, or any other product candidate;&lt;/p&gt;
		&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;the market price of ARCA&#x2019;s stock and the availability and cost of additional equity capital from existing and potential new investors;&lt;/p&gt;
		&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;ARCA&#x2019;s ability to retain the listing of its common stock on the Nasdaq Capital Market;&lt;/p&gt;
		&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;general economic and industry conditions affecting the availability and cost of capital, including as a result of deteriorating market conditions due to investor concerns regarding inflation, adverse developments affecting the financial services industry, continued hostilities between Russia and Ukraine and Hamas&#x2019; attack against Israel and the ensuing conflict;&lt;/p&gt;
		&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;ARCA&#x2019;s ability to control costs associated with its operations;&lt;/p&gt;
		&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; and&lt;/p&gt;
		&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;the terms and conditions of ARCA&#x2019;s existing collaborative and licensing agreements.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The sale of additional equity or convertible debt securities would likely result in substantial additional dilution to ARCA&#x2019;s stockholders. If ARCA raises additional funds through the incurrence of indebtedness, the obligations related to such indebtedness would be senior to rights of holders of ARCA&#x2019;s capital stock and could contain covenants that would restrict ARCA&#x2019;s operations. ARCA also cannot predict what consideration might be available, if any, to it or its stockholders, in connection with any strategic transaction. Should strategic alternatives or additional capital not be available to ARCA, or not be available on acceptable terms, ARCA may be unable to realize value from its assets and discharge its liabilities in the normal course of business which may, among other alternatives, cause ARCA to further delay, substantially reduce or discontinue operational activities to conserve its cash resources.&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Basis of Presentation&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The accompanying unaudited financial statements of ARCA were prepared in accordance with generally accepted accounting principles for interim financial information and pursuant to Regulation&#160;S&lt;span class="nobreak"&gt;-X&lt;/span&gt;.&#160;Accordingly, these financial statements do not include all of the information and footnotes required by accounting principles generally accepted in the United&#160;States of America (&#x201c;GAAP&#x201d;) for complete financial statements. In the opinion of management, these financial statements include all normal and recurring adjustments considered necessary for a fair presentation of these interim financial statements. The results of operations for the three&#160;months ended March&#160;31, 2024 are not necessarily indicative of results expected for the full year ending December&#160;31, 2024. ARCA has generated no revenue to date and its activities have consisted of seeking regulatory approval, research and development, exploring &lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;"&gt;strategic alternatives for further developing and commercializing Gencaro and rNAPc2, and raising capital. These unaudited financial statements should be read in conjunction with the audited financial statements and footnotes thereto for the year ended December&#160;31, 2023 included elsewhere in this proxy statement/prospectus. Amounts presented are rounded to the nearest thousand, where indicated, except per share data and par values.&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Concentrations of Credit Risk&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Financial instruments that potentially subject ARCA to significant concentrations of credit risk consist primarily of cash and cash equivalents. ARCA has no off&lt;span class="nobreak"&gt;-balance-sheet&lt;/span&gt; concentrations of credit risk, such as foreign exchange contracts, option contracts, or foreign currency hedging arrangements. ARCA maintains cash and cash equivalent balances in the form of bank demand deposits and money market fund accounts with financial institutions that management believes are creditworthy. Such balances may at times exceed the insured amount.&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Comprehensive Loss&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Comprehensive loss is defined as the change in equity during a period from transactions and other events and/or circumstances from non&lt;span class="nobreak"&gt;-owner&lt;/span&gt; sources. If ARCA had comprehensive gains (losses), they would be reflected in the statement of operations and comprehensive loss and as a separate component in the statement of stockholders&#x2019; equity. There were no elements of comprehensive loss during the three&#160;months ended March&#160;31, 2024 and 2023.&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Leases&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA determines if an arrangement is a lease at inception. Operating leases are included in right&lt;span class="nobreak"&gt;-of-use&lt;/span&gt; (&#x201c;ROU&#x201d;) asset&#160;&#x2014;&#160;operating and lease obligations are included in accrued expenses and other liabilities and operating lease liability on ARCA&#x2019;s March&#160;31, 2024 and December&#160;31, 2023 balance sheets.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ROU lease assets represent ARCA&#x2019;s right to use an underlying asset for the lease term and lease obligations represent ARCA&#x2019;s obligation to make lease payments arising from the lease. Operating ROU lease assets are recognized at the commencement date based on the present value of lease payments over the lease term. As ARCA&#x2019;s leases do not provide an implicit rate, ARCA uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. ARCA&#x2019;s lease terms may include options to extend or terminate a lease when it is reasonably certain that ARCA will exercise that option. Lease expense for lease payments is recognized on a straight&lt;span class="nobreak"&gt;-line&lt;/span&gt; basis over the lease term.&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Accrued Outsourcing Expenses&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;As part of the process of preparing its financial statements, ARCA is required to estimate accrued outsourcing expenses. This process involves identifying services that third parties have performed on ARCA&#x2019;s behalf and estimating the level of service performed and the associated cost incurred for these services as of the balance sheet date. Examples of estimated accrued outsourcing expenses include contract service fees, such as fees payable to contract manufacturers in connection with the production of materials related to ARCA&#x2019;s drug product, and service fees and pass through costs from clinical research organizations. ARCA develops estimates of liabilities using its judgment based upon the facts and circumstances known at the time.&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA reviewed recently issued accounting pronouncements and concluded that they were either not applicable or not expected to have a significant impact to the financial statements.&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <abio:DescriptionOfBusinessPolicyTextBlock contextRef="c0" id="ixv-24336">&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;margin-top:8pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Description of Business&lt;/span&gt;&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA biopharma, Inc. (&#x201c;ARCA&#x201d;), a Delaware corporation, is headquartered in Westminster, Colorado. ARCA is dedicated to applying a precision medicine approach to the development and commercialization of genetically targeted therapies for cardiovascular diseases. ARCA&#x2019;s lead product candidate is Gencaro&#x2122; (bucindolol hydrochloride) for the treatment of atrial fibrillation (&#x201c;AF&#x201d;) in patients with chronic heart failure (&#x201c;HF&#x201d;).&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;In April&#160;2022, ARCA established a Special Committee of the board of directors (the &#x201c;Board&#x201d;) of ARCA to conduct a comprehensive review of strategic alternatives. As part of the strategic review process, ARCA explored potential strategic alternatives that included, without limitation, an acquisition, merger, business combination or other transactions. ARCA has and is continuing to explore strategic alternatives related to its product candidates and related assets, including, without limitation, licensing transactions and asset sales.&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;On April&#160;3, 2024, following a comprehensive review of strategic alternatives, ARCA, Atlas Merger Sub Corp., a Delaware corporation and a wholly&lt;span class="nobreak"&gt;-owned&lt;/span&gt; subsidiary of ARCA (&#x201c;Merger Sub&#160;I&#x201d;), Atlas Merger Sub&#160;II LLC, a Delaware limited liability company and a wholly&lt;span class="nobreak"&gt;-owned&lt;/span&gt; subsidiary of ARCA (&#x201c;Merger Sub&#160;II&#x201d;) and Oruka Therapeutics, Inc., a Delaware corporation (&#x201c;Oruka&lt;span class="CharOverride-1" style="text-decoration:underline;"&gt;&#x201d;&lt;/span&gt;), entered into an Agreement and Plan of Merger and Reorganization (the &#x201c;Merger Agreement&#x201d;), pursuant to which, among other matters, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Merger Sub&#160;I will merge with and into Oruka, with Oruka continuing as a wholly owned subsidiary of ARCA and the surviving corporation of the merger (the &#x201c;First Merger&#x201d;) and as part of the same overall transaction, the surviving corporation in the First Merger will merge with and into Merger Sub&#160;II with Merger Sub&#160;II continuing as a wholly owned subsidiary of ARCA and the surviving entity of the merger (the &#x201c;Second Merger&#x201d; and together with the First Merger, the &#x201c;Merger&#x201d;). The Merger is intended to qualify for federal income tax purposes as a tax&lt;span class="nobreak"&gt;-free&lt;/span&gt; reorganization under the provisions of Section&#160;368(a)&#160;of the Internal Revenue Code of 1986, as amended.&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA&#x2019;s future operations are highly dependent on the success of the Merger and there can be no assurances that the Merger will be successfully consummated. In the event that ARCA does not complete the Merger, it may explore strategic alternatives, including, without limitation, another strategic transaction and/or pursue a dissolution and liquidation of ARCA. See Note&#160;10.&lt;/p&gt;</abio:DescriptionOfBusinessPolicyTextBlock>
    <abio:LiquidityAndGoingConcernPolicyTextBlock contextRef="c0" id="ixv-24351">&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Liquidity and Going Concern&lt;/span&gt;&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA devotes substantially all of its efforts towards obtaining regulatory approval and raising capital necessary to fund its operations and it is subject to a number of risks associated with clinical research and development, including dependence on key individuals, the development of and regulatory approval of commercially viable products, the need to raise adequate additional financing necessary to fund the development and commercialization of its products, and competition from larger companies. ARCA has not generated revenue to date and has incurred substantial losses and negative cash flows from operations since its inception. ARCA has historically funded its operations through issuances of common and preferred stock.&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA believes that its current cash and cash equivalents as of March&#160;31, 2024 will be sufficient to fund its operations through the middle of fiscal year 2025. The future viability of ARCA beyond that point is dependent on the results of the strategic review process and its ability to raise additional capital to fund its operations. ARCA expects to continue to incur costs and expenditures in connection with the process of evaluating strategic alternatives. There can be no assurance, however, that ARCA will be able to successfully consummate any particular strategic transaction, including the Merger Agreement. The process of continuing to evaluate these strategic options may be very costly, time&lt;span class="nobreak"&gt;-consuming&lt;/span&gt; and complex and ARCA has incurred, and may in the future incur, significant costs related to this continued evaluation, such as legal, accounting and advisory fees and expenses and other related charges, see Note&#160;10 regarding the Merger Agreement. Should ARCA pursue additional clinical trials for its product candidates, it will have to raise additional capital for clinical trials of Gencaro. ARCA may not be able to raise sufficient capital on acceptable terms, or at all, to continue development of Gencaro or rNAPc2 or to otherwise continue operations and may not be &lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;"&gt;able to execute any strategic transaction. Changing circumstances may cause ARCA to consume capital significantly faster or slower than currently anticipated. ARCA has based these estimates on assumptions that may prove to be wrong, and it could exhaust its available financial resources sooner than it currently anticipates. Depending on the results of the strategic review process, ARCA may have to raise additional capital for clinical trials of Gencaro and to fund its operations. ARCA may not be able to raise sufficient capital on acceptable terms, or at all, to continue development of Gencaro or rNAPc2 or to otherwise continue operations and may not be able to execute any strategic transaction.&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA&#x2019;s liquidity, and its ability to raise additional capital or complete any strategic transaction, depends on a number of factors, including, but not limited to, the following:&lt;/p&gt;&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;the timing and outcome of the strategic review process;&lt;/p&gt;&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;the consummation of any particular strategic transactions, including the Merger;&lt;/p&gt;&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;the costs and timing for the potential additional clinical trials in order to gain possible regulatory approval for Gencaro, rNAPc2, or any other product candidate;&lt;/p&gt;&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;the market price of ARCA&#x2019;s stock and the availability and cost of additional equity capital from existing and potential new investors;&lt;/p&gt;&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;ARCA&#x2019;s ability to retain the listing of its common stock on the Nasdaq Capital Market;&lt;/p&gt;&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;general economic and industry conditions affecting the availability and cost of capital, including as a result of deteriorating market conditions due to investor concerns regarding inflation, adverse developments affecting the financial services industry, continued hostilities between Russia and Ukraine and Hamas&#x2019; attack against Israel and the ensuing conflict;&lt;/p&gt;&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;ARCA&#x2019;s ability to control costs associated with its operations;&lt;/p&gt;&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; and&lt;/p&gt;&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;the terms and conditions of ARCA&#x2019;s existing collaborative and licensing agreements.&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The sale of additional equity or convertible debt securities would likely result in substantial additional dilution to ARCA&#x2019;s stockholders. If ARCA raises additional funds through the incurrence of indebtedness, the obligations related to such indebtedness would be senior to rights of holders of ARCA&#x2019;s capital stock and could contain covenants that would restrict ARCA&#x2019;s operations. ARCA also cannot predict what consideration might be available, if any, to it or its stockholders, in connection with any strategic transaction. Should strategic alternatives or additional capital not be available to ARCA, or not be available on acceptable terms, ARCA may be unable to realize value from its assets and discharge its liabilities in the normal course of business which may, among other alternatives, cause ARCA to further delay, substantially reduce or discontinue operational activities to conserve its cash resources.&lt;/p&gt;</abio:LiquidityAndGoingConcernPolicyTextBlock>
    <us-gaap:Revenues contextRef="c0" decimals="INF" id="ixv-38211" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="c0" id="ixv-24413">&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Basis of Presentation&lt;/span&gt;&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The accompanying unaudited financial statements of ARCA were prepared in accordance with generally accepted accounting principles for interim financial information and pursuant to Regulation&#160;S&lt;span class="nobreak"&gt;-X&lt;/span&gt;.&#160;Accordingly, these financial statements do not include all of the information and footnotes required by accounting principles generally accepted in the United&#160;States of America (&#x201c;GAAP&#x201d;) for complete financial statements. In the opinion of management, these financial statements include all normal and recurring adjustments considered necessary for a fair presentation of these interim financial statements. The results of operations for the three&#160;months ended March&#160;31, 2024 are not necessarily indicative of results expected for the full year ending December&#160;31, 2024. ARCA has generated no revenue to date and its activities have consisted of seeking regulatory approval, research and development, exploring &lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;"&gt;strategic alternatives for further developing and commercializing Gencaro and rNAPc2, and raising capital. These unaudited financial statements should be read in conjunction with the audited financial statements and footnotes thereto for the year ended December&#160;31, 2023 included elsewhere in this proxy statement/prospectus. Amounts presented are rounded to the nearest thousand, where indicated, except per share data and par values.&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="c0" id="ixv-24433">&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Concentrations of Credit Risk&lt;/span&gt;&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Financial instruments that potentially subject ARCA to significant concentrations of credit risk consist primarily of cash and cash equivalents. ARCA has no off&lt;span class="nobreak"&gt;-balance-sheet&lt;/span&gt; concentrations of credit risk, such as foreign exchange contracts, option contracts, or foreign currency hedging arrangements. ARCA maintains cash and cash equivalent balances in the form of bank demand deposits and money market fund accounts with financial institutions that management believes are creditworthy. Such balances may at times exceed the insured amount.&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:FairValueDisclosureOffbalanceSheetRisksAmountAsset contextRef="c5" decimals="INF" id="ixv-38212" unitRef="usd">0</us-gaap:FairValueDisclosureOffbalanceSheetRisksAmountAsset>
    <abio:ComprehensiveLossPolicyPolicyTextBlock contextRef="c0" id="ixv-24439">&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Comprehensive Loss&lt;/span&gt;&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Comprehensive loss is defined as the change in equity during a period from transactions and other events and/or circumstances from non&lt;span class="nobreak"&gt;-owner&lt;/span&gt; sources. If ARCA had comprehensive gains (losses), they would be reflected in the statement of operations and comprehensive loss and as a separate component in the statement of stockholders&#x2019; equity. There were no elements of comprehensive loss during the three&#160;months ended March&#160;31, 2024 and 2023.&lt;/p&gt;</abio:ComprehensiveLossPolicyPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="c0" id="ixv-24445">&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA determines if an arrangement is a lease at inception. Operating leases are included in right&lt;span class="nobreak"&gt;-of-use&lt;/span&gt; (&#x201c;ROU&#x201d;) asset&#160;&#x2014;&#160;operating and lease obligations are included in accrued expenses and other liabilities and operating lease liability on ARCA&#x2019;s March&#160;31, 2024 and December&#160;31, 2023 balance sheets.&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ROU lease assets represent ARCA&#x2019;s right to use an underlying asset for the lease term and lease obligations represent ARCA&#x2019;s obligation to make lease payments arising from the lease. Operating ROU lease assets are recognized at the commencement date based on the present value of lease payments over the lease term. As ARCA&#x2019;s leases do not provide an implicit rate, ARCA uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. ARCA&#x2019;s lease terms may include options to extend or terminate a lease when it is reasonably certain that ARCA will exercise that option. Lease expense for lease payments is recognized on a straight&lt;span class="nobreak"&gt;-line&lt;/span&gt; basis over the lease term.&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <abio:AccruedOutsourcingExpensesPolicyTextBlock contextRef="c0" id="ixv-24454">&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Accrued Outsourcing Expenses&lt;/span&gt;&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;As part of the process of preparing its financial statements, ARCA is required to estimate accrued outsourcing expenses. This process involves identifying services that third parties have performed on ARCA&#x2019;s behalf and estimating the level of service performed and the associated cost incurred for these services as of the balance sheet date. Examples of estimated accrued outsourcing expenses include contract service fees, such as fees payable to contract manufacturers in connection with the production of materials related to ARCA&#x2019;s drug product, and service fees and pass through costs from clinical research organizations. ARCA develops estimates of liabilities using its judgment based upon the facts and circumstances known at the time.&lt;/p&gt;</abio:AccruedOutsourcingExpensesPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c0" id="ixv-24459">&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA reviewed recently issued accounting pronouncements and concluded that they were either not applicable or not expected to have a significant impact to the financial statements.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:EarningsPerShareTextBlock contextRef="c0" id="ixv-24472">&lt;p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;(2)&#160;Net Loss Per Share&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA calculates basic loss per share by dividing net loss by the weighted average common shares outstanding during the period. Diluted loss per share is computed by dividing net loss by the weighted average number of common shares outstanding during the period increased to include, if dilutive, the number of additional common shares that would have been outstanding if the potential common shares had been issued. ARCA&#x2019;s potentially dilutive shares include stock options and restricted stock units.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Because ARCA reported a net loss for the three&#160;months ended March&#160;31, 2024 and 2023, all potentially dilutive shares of ARCA common stock have been excluded from the computation of the dilutive net loss per share for all periods presented. Such potentially dilutive shares of ARCA common stock consist of the following:&lt;/p&gt;
		&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;



					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;March&#160;31,&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;2024&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;2023&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Potentially dilutive securities, excluded:&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Outstanding stock options&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;645,845&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;664,857&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Unvested restricted stock units&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-110; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;91,000&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;645,845&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;755,857&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="c0" id="ixv-38213">Because ARCA reported a net loss for the three&#160;months ended March&#160;31, 2024 and 2023, all potentially dilutive shares of ARCA common stock have been excluded from the computation of the dilutive net loss per share for all periods presented. Such potentially dilutive shares of ARCA common stock consist of the following:&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;



					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;March&#160;31,&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;2024&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;2023&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Potentially dilutive securities, excluded:&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Outstanding stock options&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;645,845&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;664,857&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Unvested restricted stock units&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-110; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;91,000&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;645,845&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;755,857&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c117"
      decimals="0"
      id="ixv-38214"
      unitRef="shares">645845</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c118"
      decimals="0"
      id="ixv-38215"
      unitRef="shares">664857</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c120"
      decimals="0"
      id="ixv-38216"
      unitRef="shares">91000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c0"
      decimals="0"
      id="ixv-38217"
      unitRef="shares">645845</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c10"
      decimals="0"
      id="ixv-38218"
      unitRef="shares">755857</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="c0" id="ixv-24529">&lt;p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;(3)&#160;Fair Value Disclosures&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;There were &lt;span style="-sec-ix-hidden: hidden-fact-111"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-112"&gt;no&lt;/span&gt;&lt;/span&gt; marketable securities as of March&#160;31, 2024 or December&#160;31, 2023.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (&#x201c;exit price&#x201d;). Inputs used to measure fair value are classified into the following hierarchy:&lt;/p&gt;
		&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;Level 1 &#x2014;&#160;Unadjusted quoted prices in active markets for identical assets or liabilities. ARCA&#x2019;s Level 1 assets consist of money market investments. ARCA does not have any Level 1 liabilities.&lt;/p&gt;
		&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;Level 2 &#x2014;&#160;Unadjusted quoted prices in active markets for similar assets or liabilities; unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active; or inputs other than quoted prices that are observable for the asset or liability. ARCA does not have any Level 2 assets or liabilities.&lt;/p&gt;
		&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;Level 3 &#x2014;&#160;Unobservable inputs for the asset or liability. ARCA does not have any Level 3 assets or liabilities.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;As of March&#160;31, 2024 and December&#160;31, 2023, ARCA had $35.9&#160;million and $37.4&#160;million, respectively, of cash equivalents consisting of money market funds with original maturities of 90&#160;days or less. ARCA has the ability to liquidate these investments without restriction. ARCA determines fair value for these money market funds with Level 1 inputs through quoted market prices. There were &lt;span style="-sec-ix-hidden: hidden-fact-113"&gt;no&lt;/span&gt; transfers of assets between fair value hierarchy levels during the three&#160;months ended March&#160;31, 2024.&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Fair Value of Other Financial Instruments&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The carrying amount of other financial instruments, including accounts payable, approximated fair value due to their short maturities.&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="c121"
      decimals="-5"
      id="ixv-38219"
      unitRef="usd">35900000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c66" decimals="-5" id="ixv-38220" unitRef="usd">37400000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="c0" id="ixv-24558">&lt;p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;(4)&#160;Property and Equipment&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Property and equipment consist of the following (in thousands):&lt;/p&gt;
		&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-11" style="height:12pt;"&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;/td&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;	&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Estimated&lt;br/&gt;Life&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;	&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;March&#160;31,&lt;br/&gt;2024&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;	&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;December&#160;31,&lt;br/&gt;2023&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Computer equipment&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;3&#160;years&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;39&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;39&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Lab equipment&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;5&#160;years&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;130&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;130&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Furniture and fixtures&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;5&#160;years&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;37&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;37&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Computer software&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;3&#160;years&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;16&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;16&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;222&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;222&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Accumulated depreciation and amortization&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(215&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(212&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Property and equipment, net&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;7&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;10&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;/table&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;For the three&#160;months ended March&#160;31, 2024 and 2023, depreciation and amortization expense was $3,000 and $4,000 respectively.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c0" id="ixv-38221">Property and equipment consist of the following (in thousands):&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-11" style="height:12pt;"&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;/td&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;	&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Estimated&lt;br/&gt;Life&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;	&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;March&#160;31,&lt;br/&gt;2024&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;	&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;December&#160;31,&lt;br/&gt;2023&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Computer equipment&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;3&#160;years&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;39&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;39&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Lab equipment&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;5&#160;years&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;130&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;130&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Furniture and fixtures&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;5&#160;years&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;37&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;37&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Computer software&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;3&#160;years&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;16&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;16&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;222&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;222&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Accumulated depreciation and amortization&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(215&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(212&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Property and equipment, net&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;7&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;10&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c122" id="ixv-38222">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c122"
      decimals="-3"
      id="ixv-38223"
      unitRef="usd">39000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c69" decimals="-3" id="ixv-38224" unitRef="usd">39000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c123" id="ixv-38225">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c123"
      decimals="-3"
      id="ixv-38226"
      unitRef="usd">130000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c71" decimals="-3" id="ixv-38227" unitRef="usd">130000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c124" id="ixv-38228">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c124"
      decimals="-3"
      id="ixv-38229"
      unitRef="usd">37000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c73" decimals="-3" id="ixv-38230" unitRef="usd">37000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c125" id="ixv-38231">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c125"
      decimals="-3"
      id="ixv-38232"
      unitRef="usd">16000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c75" decimals="-3" id="ixv-38233" unitRef="usd">16000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c5" decimals="-3" id="ixv-38234" unitRef="usd">222000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c1" decimals="-3" id="ixv-38235" unitRef="usd">222000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c5" decimals="-3" id="ixv-38236" unitRef="usd">215000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c1" decimals="-3" id="ixv-38237" unitRef="usd">212000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c5" decimals="-3" id="ixv-38238" unitRef="usd">7000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c1" decimals="-3" id="ixv-38239" unitRef="usd">10000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationAndAmortization contextRef="c0" decimals="-3" id="ixv-38240" unitRef="usd">3000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c10" decimals="-3" id="ixv-38241" unitRef="usd">4000</us-gaap:DepreciationAndAmortization>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="c0" id="ixv-24718">&lt;p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;(5)&#160;Related Party Arrangements&lt;/span&gt;&lt;/p&gt;
		&lt;p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="Italic" style="font-style:italic;font-weight:normal;"&gt;Transactions with ARCA&#x2019;s Former President and Chief Executive Officer&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA has entered into unrestricted research grants with its former President and Chief Executive Officer&#x2019;s academic research laboratory at the University of Colorado. Funding of any unrestricted research grants is contingent upon ARCA&#x2019;s financial condition, and can be deferred or terminated at ARCA&#x2019;s discretion. There was no expense under these arrangements for the three&#160;months ended March&#160;31, 2024. Total expense under these arrangements for the three&#160;months ended March&#160;31, 2023 was $108,000. In December&#160;2023, ARCA made a payment of $125,000 for the grant period July&#160;2022 through December&#160;2023 under these arrangements. In April&#160;2024, the President and Chief Executive Officer resigned, see Note&#160;10.&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <abio:ResearchAndDevelopmentExpenseReversed contextRef="c127" decimals="0" id="ixv-38242" unitRef="usd">0</abio:ResearchAndDevelopmentExpenseReversed>
    <abio:ResearchAndDevelopmentExpenseReversed contextRef="c126" decimals="0" id="ixv-38243" unitRef="usd">108000</abio:ResearchAndDevelopmentExpenseReversed>
    <abio:PaymentOfUnrestrictedResearchGrants contextRef="c77" decimals="0" id="ixv-38244" unitRef="usd">125000</abio:PaymentOfUnrestrictedResearchGrants>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c0" id="ixv-24724">&lt;p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;(6)&#160;Commitments and Contingencies&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA has or is subject to the following commitments and contingencies.&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Employment Agreements and Reduction of Workforce&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA maintains employment agreements with several key executive employees. The agreements may be terminated at any time by ARCA with or without cause upon written notice to the employee, and entitle the employee to wages in lieu of notice for periods not exceeding one calendar year from the date of termination without cause or by the employee for good reason. Certain of these agreements also provide for payments to be made under certain conditions related to a change in control of ARCA.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;In December&#160;2022, ARCA&#x2019;s Board of Directors approved retention bonuses for certain employees, subject to continued employment with ARCA through the earlier of a change in control of ARCA or certain clinical development decisions totaling $265,000. In November&#160;2023, the retention bonuses were amended to increase the aggregate amount of the retention bonus by 50% and in order to assist with tax obligations associated with the vesting of certain Company restricted stock unit awards in December&#160;2023, a total of $86,000 was paid in December&#160;2023. As of March&#160;31, 2024, the unpaid retention bonuses totaled $311,000, none of which was accrued as of March&#160;31, 2024, since there had not been a change in control or clinical development decision. In April&#160;2024, the retention bonuses were again amended to increase the aggregate amount of the retention bonus, with the unpaid retention bonus increasing to $444,000. See Note&#160;10.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA and Christopher D.&#160;Ozeroff, the former Secretary, Senior Vice President and General Counsel of ARCA mutually agreed to conclude Mr.&#160;Ozeroff&#x2019;s employment effective March&#160;31, 2023. Pursuant to Mr.&#160;Ozeroff&#x2019;s existing employment agreement, as previously amended, ARCA provided Mr.&#160;Ozeroff severance benefits pursuant to the terms &lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;"&gt;of his existing employment agreement with ARCA, as previously amended. The severance benefits included severance payments and reimbursement to cover out&lt;span class="nobreak"&gt;-of-pocket&lt;/span&gt; costs to continue group health insurance benefits under COBRA, whether he elects or is eligible to receive COBRA.&#160;During the year ended December&#160;31, 2023, ARCA recorded an expense of $159,000 for these severance benefits, &lt;span style="-sec-ix-hidden: hidden-fact-115"&gt;none&lt;/span&gt; of which remains unpaid.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA and Dr.&#160;Michael Bristow, former President, Chief Executive Officer and a member of the board of directors of ARCA mutually agreed to conclude Dr.&#160;Bristow&#x2019;s employment and service as a director, effective April&#160;3, 2024. See Note&#160;10.&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Operating Leases&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;On August&#160;29, 2020 ARCA entered into a lease agreement for approximately 5,200 square feet of office facilities in Westminster, Colorado which serves as its primary business office effective October&#160;1, 2020 (&#x201c;October&#160;2020 Lease&#x201d;). The lease term was 42&#160;months beginning October&#160;1, 2020. In March&#160;2024, ARCA entered into an amendment to extend the lease term six (6)&#160;months through September&#160;2024. If ARCA elects to stay in the property after September&#160;2024, it will pay rent month to month equal to 125% of the base rent paid in September&#160;2024. In June&#160;2021, ARCA entered into a sublease agreement for approximately 3,000 square feet of additional office facilities in its primary business office (&#x201c;2021 Lease&#x201d;). The sublease term was 29&#160;months and terminated in October&#160;2023. The leases include real estate taxes and insurance, which is not a lease component and is not included in the lease obligation. In addition, common area maintenance charges are based on actual costs incurred and are a non&lt;span class="nobreak"&gt;-lease&lt;/span&gt; component that is not included in the lease obligation.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Future minimum commitments due under the October&#160;2020 Lease agreement, as amended, as of March&#160;31, 2024 are as follows (in thousands):&lt;/p&gt;
		&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;



						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;2024&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;49&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Total remaining lease payments&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;49&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Less: imputed lease interest&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(1&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Less: Current portion&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(48&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Operating lease liability, net of current portion&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-114; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Rent expense, which is included in general and administrative expense, for the three&#160;months ended March&#160;31, 2024 and 2023 was $22,000 and $31,000, respectively.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;As of March&#160;31, 2024, the lease liability was $48,000, it is all current and is included in accrued expenses and other liabilities in the accompanying balance sheet. Cash paid for amounts included in the measurement of lease liabilities and the operating cash flows from operating leases for the three&#160;months ended March&#160;31, 2024 and 2023 were $23,000 and $33,000, respectively. The weighted&lt;span class="nobreak"&gt;-average&lt;/span&gt; remaining lease term for the operating lease as of March&#160;31, 2024 is 0.5&#160;years. The discount rate for the operating lease is 7%.&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Patent Agreement&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;In July&#160;2021, ARCA entered into a patent assignment agreement (the &#x201c;Agreement&#x201d;) with the University Medical Center of Johannes Gutenberg University Mainz, Germany.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Under the terms of the Agreement, ARCA received exclusive world&lt;span class="nobreak"&gt;-wide&lt;/span&gt; patent rights relating to the use of rNAPc2 as a potential treatment for COVID&lt;span class="nobreak"&gt;-19&lt;/span&gt;, and other indications, based on the research and discoveries from Univ.&lt;span class="nobreak"&gt;-Prof&lt;/span&gt;. Dr.&#160;Wolfram Ruf, the Scientific Director and Alexander von Humboldt Professor at the Center for Thrombosis and Hemostasis (&#x201c;CTH&#x201d;) of the University Medical Center Mainz, and his collaborators. ARCA has upfront and potential milestone obligations to the University Medical Center Mainz that could total approximately &#x20ac;1.6&#160;million and royalty obligations in the low single digit range, if rNAPc2 receives regulatory approval and is commercialized. The term of the Agreement extends to the date of expiration of the last to expire of any of the assigned patents.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <abio:RetentionBonuses contextRef="c80" decimals="0" id="ixv-38245" unitRef="usd">265000</abio:RetentionBonuses>
    <abio:PercentageOfRetentionBonuses contextRef="c81" decimals="2" id="ixv-38246" unitRef="pure">0.50</abio:PercentageOfRetentionBonuses>
    <abio:RetentionBonusPaid contextRef="c6" decimals="0" id="ixv-38247" unitRef="usd">86000</abio:RetentionBonusPaid>
    <abio:RetentionBonuses contextRef="c5" decimals="0" id="ixv-38248" unitRef="usd">311000</abio:RetentionBonuses>
    <abio:RetentionBonuses contextRef="c128" decimals="0" id="ixv-38249" unitRef="usd">444000</abio:RetentionBonuses>
    <us-gaap:SeveranceCosts1 contextRef="c6" decimals="0" id="ixv-38250" unitRef="usd">159000</us-gaap:SeveranceCosts1>
    <us-gaap:AreaOfRealEstateProperty contextRef="c85" decimals="0" id="ixv-38251" unitRef="sqft">5200</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="c85" id="ixv-38252">P42M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseOptionToExtend contextRef="c0" id="ixv-38253">to extend the lease term six (6)&#160;months through September&#160;2024</us-gaap:LesseeOperatingLeaseOptionToExtend>
    <us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend contextRef="c0" id="ixv-38254">false</us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend>
    <us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="c5" id="ixv-38255">P6M</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <abio:OperatingLeasesExtendedExpiryYearsAndMonth contextRef="c0" id="ixv-38256">September&#160;2024</abio:OperatingLeasesExtendedExpiryYearsAndMonth>
    <abio:PercentageOfBaseRentToBePaidMonthly contextRef="c0" decimals="2" id="ixv-38257" unitRef="pure">1.25</abio:PercentageOfBaseRentToBePaidMonthly>
    <abio:AreaOfRealEstatePropertySubleaseAdditionalOfficeFacilities contextRef="c87" decimals="0" id="ixv-38258" unitRef="sqft">3000</abio:AreaOfRealEstatePropertySubleaseAdditionalOfficeFacilities>
    <abio:LesseeOperatingSubleaseTermOfContract contextRef="c131" id="ixv-38259">P29M</abio:LesseeOperatingSubleaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseAssumptionsAndJudgmentsAllocationOfLeaseAndNonleaseComponent contextRef="c0" id="ixv-24752">The leases include real estate taxes and insurance, which is not a lease component and is not included in the lease obligation. In addition, common area maintenance charges are based on actual costs incurred and are a non-lease component that is not included in the lease obligation.</us-gaap:LesseeOperatingLeaseAssumptionsAndJudgmentsAllocationOfLeaseAndNonleaseComponent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="c0" id="ixv-38260">Future minimum commitments due under the October&#160;2020 Lease agreement, as amended, as of March&#160;31, 2024 are as follows (in thousands):&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;



						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;2024&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;49&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Total remaining lease payments&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;49&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Less: imputed lease interest&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(1&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Less: Current portion&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(48&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Operating lease liability, net of current portion&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-114; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear contextRef="c5" decimals="-3" id="ixv-38261" unitRef="usd">49000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c5" decimals="-3" id="ixv-38262" unitRef="usd">49000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="c5" decimals="-3" id="ixv-38263" unitRef="usd">1000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c5" decimals="-3" id="ixv-38264" unitRef="usd">48000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseCost contextRef="c129" decimals="0" id="ixv-38265" unitRef="usd">22000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c130" decimals="0" id="ixv-38266" unitRef="usd">31000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseLiability contextRef="c5" decimals="0" id="ixv-38267" unitRef="usd">48000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeasePayments contextRef="c0" decimals="0" id="ixv-38268" unitRef="usd">23000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments contextRef="c10" decimals="0" id="ixv-38269" unitRef="usd">33000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c5" id="ixv-38270">P0Y6M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c5" decimals="2" id="ixv-38271" unitRef="pure">0.07</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <abio:PotentialUpfrontAndMilestoneObligationsAndRoyaltyObligations contextRef="c91" decimals="-5" id="ixv-38272" unitRef="eur">1600000</abio:PotentialUpfrontAndMilestoneObligationsAndRoyaltyObligations>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c0" id="ixv-24825">&lt;p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;(7)&#160;&lt;/span&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;font-style:normal;font-weight:bold;"&gt;Equity Financings&lt;/span&gt;&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;margin-top:8pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;At the Market Equity Financing&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;In 2020, ARCA entered into a Capital on Demand&#x2122; Sales Agreement (the &#x201c;Sales Agreement&#x201d;) with JonesTrading Institutional Services LLC, as agent (&#x201c;JonesTrading&#x201d;), pursuant to which ARCA may offer and sell, from time to time through JonesTrading, shares of ARCA&#x2019;s common stock, par value $0.001 per share (&#x201c;ARCA common stock&#x201d;).&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;In 2021, ARCA amended the 2020 Sales Agreement and the amount available for the offering under its prospectus to ARCA&#x2019;s registration statement on Form&#160;S&lt;span class="nobreak"&gt;-3&lt;/span&gt; (No.&#160;333&lt;span class="nobreak"&gt;-254585&lt;/span&gt;), which expired in March&#160;2024. In April&#160;2024, ARCA terminated the Sales Agreement in accordance with its terms.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;No sales were made under the Sales Agreement in 2024 or 2023.&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Merger Agreement&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;See &#x201c;Financing Transaction&#x201d; discussion in Note&#160;10 below.&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c132"
      decimals="INF"
      id="ixv-38273"
      unitRef="usdPershares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c133"
      decimals="INF"
      id="ixv-38274"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c134"
      decimals="INF"
      id="ixv-38275"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c0" id="ixv-24839">&lt;p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;(8)&#160;Share-based Compensation&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;orphans:99;widows:1;margin-top:8pt;"&gt;For the three&#160;months ended March&#160;31, 2024 and 2023, ARCA recognized the following non&lt;span class="nobreak"&gt;-cash&lt;/span&gt;, share&lt;span class="nobreak"&gt;-based&lt;/span&gt; compensation expense in the statements of operations (in thousands):&lt;/p&gt;
		&lt;table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-11" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;



					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="5" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Three&#160;Months Ended&lt;br/&gt;March&#160;31,&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;2024&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;2023&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;General and administrative&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;114&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;163&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Research and development&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-116; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;41&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Total&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;114&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;204&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Stock option transactions for the three&#160;months ended March&#160;31, 2024 under ARCA&#x2019;s stock incentive plans were as follows:&lt;/p&gt;
		&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;"&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;/td&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 46.15%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;	&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Options Outstanding&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-15" style="height:12pt;"&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;	&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Number of&lt;br/&gt;Options&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;	&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;	&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&lt;br/&gt;(in&#160;years)&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Options outstanding&#160;&#x2013;&#160;December&#160;31, 2023&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;616,707&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;4.76&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;7.35&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Granted&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;42,000&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;1.64&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Exercised&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-117; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-118; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Forfeited and cancelled&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(12,862&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;17.45&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Options outstanding&#160;&#x2013;&#160;March&#160;31, 2024&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;645,845&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;4.30&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;6.82&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Options exercisable&#160;&#x2013;&#160;March&#160;31, 2024&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;502,517&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;4.71&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;6.55&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Options vested and expected to vest&#160;&#x2013;&#160;March&#160;31, 2024&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;645,816&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;4.30&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;6.82&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;/table&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="c0" id="ixv-24843">For the three&#160;months ended March&#160;31, 2024 and 2023, ARCA recognized the following non&lt;span class="nobreak"&gt;-cash&lt;/span&gt;, share&lt;span class="nobreak"&gt;-based&lt;/span&gt; compensation expense in the statements of operations (in thousands):&lt;table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-11" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;



					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="5" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Three&#160;Months Ended&lt;br/&gt;March&#160;31,&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;2024&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;2023&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;General and administrative&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;114&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;163&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Research and development&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-116; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;41&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Total&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;114&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;204&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c129"
      decimals="-3"
      id="ixv-38276"
      unitRef="usd">114000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c130"
      decimals="-3"
      id="ixv-38277"
      unitRef="usd">163000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c136"
      decimals="-3"
      id="ixv-38278"
      unitRef="usd">41000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c0" decimals="-3" id="ixv-38279" unitRef="usd">114000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c10" decimals="-3" id="ixv-38280" unitRef="usd">204000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c0" id="ixv-38281">Stock option transactions for the three&#160;months ended March&#160;31, 2024 under ARCA&#x2019;s stock incentive plans were as follows:&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;"&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;/td&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 46.15%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;	&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Options Outstanding&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-15" style="height:12pt;"&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;	&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Number of&lt;br/&gt;Options&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;	&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;	&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&lt;br/&gt;(in&#160;years)&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Options outstanding&#160;&#x2013;&#160;December&#160;31, 2023&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;616,707&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;4.76&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;7.35&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Granted&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;42,000&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;1.64&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Exercised&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-117; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-118; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Forfeited and cancelled&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(12,862&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;17.45&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Options outstanding&#160;&#x2013;&#160;March&#160;31, 2024&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;645,845&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;4.30&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;6.82&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Options exercisable&#160;&#x2013;&#160;March&#160;31, 2024&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;502,517&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;4.71&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;6.55&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Options vested and expected to vest&#160;&#x2013;&#160;March&#160;31, 2024&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;645,816&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;4.30&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;6.82&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c1"
      decimals="INF"
      id="ixv-38282"
      unitRef="shares">616707</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c1"
      decimals="2"
      id="ixv-38283"
      unitRef="usdPershares">4.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c137" id="ixv-38284">P7Y4M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c0"
      decimals="INF"
      id="ixv-38285"
      unitRef="shares">42000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c0"
      decimals="2"
      id="ixv-38286"
      unitRef="usdPershares">1.64</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="c0"
      decimals="INF"
      id="ixv-38287"
      unitRef="shares">12862</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="c0"
      decimals="2"
      id="ixv-38288"
      unitRef="usdPershares">17.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c5"
      decimals="INF"
      id="ixv-38289"
      unitRef="shares">645845</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c5"
      decimals="2"
      id="ixv-38290"
      unitRef="usdPershares">4.3</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c0" id="ixv-38291">P6Y9M25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c5"
      decimals="INF"
      id="ixv-38292"
      unitRef="shares">502517</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c5"
      decimals="2"
      id="ixv-38293"
      unitRef="usdPershares">4.71</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c0" id="ixv-38294">P6Y6M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="c5"
      decimals="INF"
      id="ixv-38295"
      unitRef="shares">645816</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="c5"
      decimals="2"
      id="ixv-38296"
      unitRef="usdPershares">4.3</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="c0" id="ixv-38297">P6Y9M25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c0" id="ixv-25053">&lt;p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;(9)&#160;Income Taxes&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;In accordance with GAAP, a valuation allowance should be provided if it is more likely than not that some or all of ARCA&#x2019;s deferred tax assets will not be realized. ARCA&#x2019;s ability to realize the benefit of its deferred tax assets will depend on the generation of future taxable income. Due to the uncertainty of future profitable operations and taxable income, ARCA has recorded a full valuation allowance against its net deferred tax assets. ARCA believes its tax filing positions and deductions related to tax periods subject to examination will be sustained upon audit and, therefore, has &lt;span style="-sec-ix-hidden: hidden-fact-119"&gt;no&lt;/span&gt; reserve for uncertain tax positions.&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:SubsequentEventsTextBlock contextRef="c0" id="ixv-25058">&lt;p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;(10)&#160;Subsequent Events&lt;/span&gt;&lt;/p&gt;
		&lt;p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Merger Agreement&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;On April&#160;3, 2024, ARCA, Merger Sub&#160;I, Merger Sub&#160;II and Oruka, entered into the Merger Agreement, pursuant to which, among other matters, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Merger Sub&#160;I will merge with and into Oruka, with Oruka continuing as a wholly owned subsidiary of ARCA and the surviving corporation of the merger and as part of the same overall transaction, the surviving corporation in the First Merger will merge with and into Merger Sub&#160;II with Merger Sub&#160;II continuing as a wholly owned subsidiary of ARCA and the surviving entity of the merger. The Merger is intended to qualify for federal income tax purposes as a tax&lt;span class="nobreak"&gt;-free&lt;/span&gt; reorganization under the provisions of Section&#160;368(a)&#160;of the Internal Revenue Code of 1986, as amended.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Subject to the terms and conditions of the Merger Agreement, at the closing of the First Merger, (a)&#160;each then&lt;span class="nobreak"&gt;-outstanding&lt;/span&gt; share of Oruka common stock (including shares of Oruka common stock issued in the financing transaction described below) will be converted solely into the right to receive a number of shares of ARCA common stock calculated in accordance with the Merger Agreement (the &#x201c;Exchange Ratio&#x201d;), (b)&#160;each then&lt;span class="nobreak"&gt;-outstanding&lt;/span&gt; share of Oruka preferred stock will be converted into the right to receive a number of shares of Series&#160;B Preferred Stock (as defined below) of ARCA, calculated in accordance with the Merger Agreement (c)&#160;each then&lt;span class="nobreak"&gt;-outstanding&lt;/span&gt; option to purchase Oruka common stock will be assumed by ARCA, subject to adjustment as set forth in the Merger Agreement and (d)&#160;each then&lt;span class="nobreak"&gt;-outstanding&lt;/span&gt; warrant to purchase shares of Oruka common stock will be converted into a warrant to purchase shares of ARCA common stock, subject to adjustment as set forth in the Merger Agreement and form of warrant. Under the terms of the Merger Agreement, prior to the closing of the transaction, the Board will accelerate the vesting of all equity awards of ARCA then outstanding but not then vested or exercisable, and cancel each option (the &#x201c;Out of the Money Options&#x201d;) to acquire shares of ARCA common stock with an exercise price per share greater than the volume weighted average closing trading price of a share of ARCA common stock on The Nasdaq Stock Market LLC (&#x201c;Nasdaq&#x201d;) for the five (5)&#160;consecutive&#160;trading days ending three (3)&#160;days immediately prior to the closing date of the First Merger (the &#x201c;Parent Closing Price&#x201d;), in each case, in accordance with the terms of the Merger Agreement. At the closing of the First Merger, each option to acquire shares of ARCA common stock with an exercise price less than or equal to the Parent Closing Price will be cancelled and converted into the right to receive an amount in cash, without interest, equal to the Parent Closing Price less the exercise price of such option.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Under the Exchange Ratio formula in the Merger Agreement, upon the closing of the First Merger, on a pro forma basis and based upon the number of shares of ARCA common stock expected to be issued in the First Merger, pre&lt;span class="nobreak"&gt;-First&lt;/span&gt; Merger Oruka stockholders (including Oruka stockholders issued shares of Oruka common stock and pre&lt;span class="nobreak"&gt;-funded&lt;/span&gt; warrants in the financing transaction described below) will own approximately 97.62% of the combined company and pre&lt;span class="nobreak"&gt;-First&lt;/span&gt; Merger ARCA stockholders will own approximately 2.38% of the combined company. For purposes of calculating the Exchange Ratio, (i)&#160;shares of ARCA common stock underlying warrants and other rights to receive shares (other than Options to acquire shares of ARCA common stock, to the extent cancelled at or prior to closing of the First Merger in accordance with the Merger Agreement) outstanding as of immediately prior to the closing of the First Merger will be deemed to be outstanding, and (ii)&#160;all shares of Oruka common stock underlying outstanding Oruka stock options and warrants will be deemed to be outstanding. The Exchange Ratio will be &lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;"&gt;adjusted to the extent that ARCA&#x2019;s net cash at closing is less than $5.0&#160;million and will be based on the amount of proceeds actually received by Oruka in the financing transaction described below, as further described in the Merger Agreement.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;In addition, prior to the closing of the First Merger, ARCA expects to declare a cash dividend to the pre&lt;span class="nobreak"&gt;-First&lt;/span&gt; Merger ARCA stockholders equal in the aggregate to ARCA&#x2019;s reasonable, good faith approximation of the amount by which ARCA&#x2019;s net cash (as determined pursuant to the Merger Agreement) will exceed $5,000,000.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;In connection with the Merger, ARCA is required to seek the approval of its stockholders to, among other things, (a)&#160;issue shares of ARCA common stock issuable in connection with the First Merger (including the shares of ARCA common stock issuable under the Series&#160;B Preferred Stock) under the rules of Nasdaq, and (b)&#160;amend its amended and restated certificate of incorporation, to (i)&#160;effect a reverse stock split of ARCA common stock (if deemed necessary by ARCA and Oruka), (ii)&#160;increase the number of shares of ARCA common stock that ARCA is authorized to issue, and (iii)&#160;such other changes as are mutually agreeable to ARCA and Oruka (the &#x201c;ARCA Voting Proposals&#x201d;).&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Each of ARCA and Oruka has agreed to customary representations, warranties and covenants in the Merger Agreement, including, among others, covenants relating to (1)&#160;using commercially reasonable efforts to obtain the requisite approval of its stockholders, (2)&#160;non&lt;span class="nobreak"&gt;-solicitation&lt;/span&gt; of alternative acquisition proposals, (3)&#160;the conduct of their respective businesses during the period between the date of signing the Merger Agreement and the closing of the Merger, (4)&#160;ARCA using commercially reasonable efforts to maintain the existing listing of the ARCA common stock on Nasdaq and cause the shares of ARCA common stock to be issued in connection with the First Merger to be approved for listing on Nasdaq prior to the closing of the First Merger, and (5)&#160;ARCA filing with the U.S.&#160;Securities and Exchange Commission (the &#x201c;SEC&#x201d;) and causing to become effective a registration statement to register shares of ARCA common stock to be issued in connection with the First Merger, except as set forth in the Merger Agreement (the &#x201c;Registration Statement&#x201d;).&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Consummation of the Merger is subject to certain closing conditions, including, among other things, (1)&#160;approval by ARCA stockholders of the ARCA Voting Proposals, (2)&#160;approval by the requisite Oruka stockholders of the adoption and approval of the Merger Agreement and the transactions contemplated thereby, (3)&#160;Nasdaq&#x2019;s approval of the initial listing application to be submitted in connection with the First Merger, (4)&#160;the effectiveness of the Registration Statement, (5)&#160;the expiration of any applicable waiting periods (or extensions thereof) under the Hart Scott&lt;span class="nobreak"&gt;-Rodino&lt;/span&gt; Antitrust Improvements Act&#160;of&#160;1976, as amended, (6)&#160;the subscription agreements (described below) being in full force and effect providing for the receipt of proceeds of not less than $175,000,000 (including in the proceeds any notes contributed as consideration in the financing transaction described below) and (7)&#160;to the extent ARCA has declared the cash dividend described above, ARCA delivering the aggregate amount distributable to the pre&lt;span class="nobreak"&gt;-First&lt;/span&gt; Merger ARCA stockholders to ARCA&#x2019;s transfer agent for further distribution to the pre&lt;span class="nobreak"&gt;-First&lt;/span&gt; Merger ARCA stockholders. Each party&#x2019;s obligation to consummate the Merger is also subject to other specified customary conditions, including regarding the accuracy of the representations and warranties of the other party, subject to the applicable materiality standard, and the performance in all material respects by the other party of its obligations under the Merger Agreement required to be performed on or prior to the date of the closing of the Merger.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The Merger Agreement contains certain termination rights of each of ARCA and Oruka. Upon termination of the Merger Agreement under specified circumstances, ARCA and Oruka may each be required to pay the other party a termination fee of $440,000.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Pursuant to a Certificate of Designation of Preferences, Rights and Limitations of the Series&#160;B Non&lt;span class="nobreak"&gt;-Voting&lt;/span&gt; Convertible Preferred Stock to be filed by ARCA with the Secretary of State of the State of Delaware (the &#x201c;Certificate of Designation&#x201d;) in connection with the Merger Agreement and the transactions thereunder, ARCA will establish the terms of a new series of preferred stock of ARCA designated as Series&#160;B Non&lt;span class="nobreak"&gt;-Voting&lt;/span&gt; Convertible Preferred Stock, par value $0.001 per share (the &#x201c;Series&#160;B Preferred Stock&#x201d;). Holders of the Series&#160;B Preferred Stock will be entitled to receive dividends on shares of Series&#160;B Preferred Stock equal to, on an as&lt;span class="nobreak"&gt;-if-converted-to-ARCA&lt;/span&gt; common stock &lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;"&gt;basis, and in the same form as dividends actually paid on shares of the ARCA common stock. Except as otherwise required by the Certificate of Designation or law, the Series&#160;B Preferred Stock will not have voting rights. However, as long as any shares of Series&#160;B Preferred Stock are outstanding, ARCA will not, without the affirmative vote of the holders of a majority of the then outstanding shares of the Series&#160;B Preferred Stock, (a)&#160;alter or change adversely the powers, preferences or rights given to the Series&#160;B Preferred Stock, (b)&#160;alter or amend the Certificate of Designation, (c)&#160;amend its certificate of incorporation, bylaws or other charter documents in any manner that adversely affects any rights of the holders of the Series&#160;B Preferred Stock, (d)&#160;file any articles of amendment, certificate of designations, preferences, limitations and relative rights of any series of Preferred Stock (as defined in the Certificate of Designation), if such action would adversely alter or change the preferences, rights, privileges or powers of, or restrictions provided for the benefit of the Series&#160;B Preferred Stock, (e)&#160;issue further shares of the Series&#160;B Preferred Stock or increase or decrease (other than by conversion) the number of authorized shares of the Series&#160;B Preferred Stock, (f)&#160;at any time while at least 30% of the originally issued Series&#160;B Preferred Stock remains issued and outstanding, consummate either (A)&#160;a Fundamental Transaction (as defined in the Certificate of Designation) or (B)&#160;any merger or consolidation of ARCA or other business combination in which the stockholders of ARCA immediately before such transaction do not hold at least a majority of the capital stock of ARCA immediately after such transaction, or (f)&#160;enter into any agreement with respect to any of the foregoing. The Series&#160;B Preferred Stock does not have a preference upon any liquidation, dissolution or winding&lt;span class="nobreak"&gt;-up&lt;/span&gt; of ARCA.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Following the closing of the First Merger, each share of Series&#160;B Preferred Stock then outstanding shall be convertible, at any time and from time to time, at the option of the holder of the Series&#160;B Preferred Stock, into a number of shares equal to 1,000&lt;span class="nobreak"&gt; &lt;/span&gt;shares of ARCA common stock, subject to certain limitations, including that a holder of Series&#160;B Preferred Stock is prohibited from converting shares of Series&#160;B Preferred Stock into shares of ARCA common stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than a specified percentage (initially set at 9.99%) of the total number of shares of ARCA common stock issued and outstanding immediately after giving effect to such conversion.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;At the effective time of the First Merger (the &#x201c;First Effective Time&#x201d;), the combined company&#x2019;s board of directors is expected to consist of five (5)&#160;members, all of whom will be designated by Oruka. Upon the closing of the transaction, the combined company will be led by Oruka&#x2019;s chief executive officer.&lt;/p&gt;
		&lt;p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Financing Transaction&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Concurrently with the execution and delivery of the Merger Agreement, certain parties have entered into a subscription agreements with Oruka, pursuant to which they have agreed, subject to the terms and conditions of such agreements, to purchase immediately prior to the consummation of the First Merger, shares of Oruka common stock and pre&lt;span class="nobreak"&gt;-funded&lt;/span&gt; warrants to purchase shares of Oruka common stock (together, the &#x201c;PIPE Securities&#x201d;) for an aggregate purchase price of approximately $275.0&#160;million. The consummation of the transactions contemplated by such agreements is conditioned on the satisfaction or waiver of the conditions set forth in the Merger Agreement and in the subscription agreement. Shares of Oruka common stock and pre&lt;span class="nobreak"&gt;-funded&lt;/span&gt; warrants to purchase shares of Oruka common stock issued pursuant to this financing transaction will be converted into shares of ARCA common stock and pre&lt;span class="nobreak"&gt;-funded&lt;/span&gt; warrants to acquire shares ARCA common stock, in accordance with the Exchange Ratio and the Merger Agreement.&lt;/p&gt;
		&lt;p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Separation of Michael Bristow, M.D., President, Chief Executive Officer and Director&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Effective April&#160;3, 2024, ARCA and Dr.&#160;Michael Bristow, President, Chief Executive Officer and a member of the Board mutually agreed to conclude Dr.&#160;Bristow&#x2019;s employment and service as a director.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;In connection with Dr.&#160;Bristow&#x2019;s separation, ARCA and Dr.&#160;Bristow entered into a separation agreement (the &#x201c;Separation Agreement&#x201d;) on April&#160;3, 2024. Pursuant to the terms of the Separation Agreement, ARCA provided to Dr.&#160;Bristow a lump sum payment equal to (i)&#160;twelve (12)&#160;months of Dr.&#160;Bristow&#x2019;s base salary as of the last date of his employment and (ii)&#160;a cash payment of $25,000, less applicable withholdings. The severance benefits were conditioned on the non&lt;span class="nobreak"&gt;-revocation&lt;/span&gt; by Dr.&#160;Bristow of a legal release of claims.&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA and Dr.&#160;Bristow entered into a consulting agreement, effective April&#160;3, 2024 (the &#x201c;Consulting Agreement&#x201d;), pursuant to which Dr.&#160;Bristow is providing certain consulting services provided for in the Consulting Agreement to ARCA until the earlier of (i)&#160;the completion of services under the Consulting Agreement, (ii)&#160;a termination in accordance with the terms of the Consulting Agreement, and (iii)&#160;upon a Change of Control (as defined in ARCA&#x2019;s 2020 Equity Incentive Plan (the &#x201c;Plan&#x201d;)). Pursuant to the Consulting Agreement, Dr.&#160;Bristow provision of services under the Consulting Agreement are deemed to be a Continuous Service (as defined in the Plan) and, as a result, his equity awards under the Plan continue to vest during the term of the Consulting Agreement.&lt;/p&gt;
		&lt;p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Appointment of Thomas Keuer as President&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Effective as of April&#160;3, 2024, the Board appointed Thomas A.&#160;Keuer, ARCA&#x2019;s Chief Operating Officer, to serve as ARCA&#x2019;s President and principal executive officer. Mr.&#160;Keuer has been with ARCA since 2006, and as its Chief Operating Officer for the last nine&#160;years, a position he will continue to serve in. Mr.&#160;Keuer will not receive any additional compensation in connection with his appointment as President and principal executive officer. Mr.&#160;Keuer&#x2019;s position will end upon closing of the merger transaction with Oruka Therapeutics, Inc. as previously disclosed on a Current Report on Form&#160;8&lt;span class="nobreak"&gt;-K&lt;/span&gt; filed with the SEC on April&#160;3, 2024.&lt;/p&gt;
		&lt;p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Second Amendment to Retention Bonus Letter of Thomas A.&#160;Keuer and C.&#160;Jeffrey Dekker&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;On April&#160;20, 2024, the board of directors of ARCA approved the second amendment of certain retention bonus letters between ARCA and each of Thomas A.&#160;Keuer and C.&#160;Jeffrey Dekker to increase the aggregate amount of the retention bonus with respect to each such executive to $200,000. The remaining portion of the retention bonus with respect to Thomas A. Keuer and C. Jeffrey Dekker, consisting of $165,000, will become payable consistent with the original terms of the applicable retention bonus letter and first amendment to retention bonus letter. Any payment related to the retention bonuses of Thomas A. Keuer and C. Jeffrey Dekker will be paid by ARCA via payroll within&#160;30 business days of the date of occurrence of the applicable &#x201c;Payment Event Date&#x201d; (as such term is otherwise defined in the applicable second amendment to the retention bonus letter). Each such retention bonus letter and first amendment to retention bonus letter will otherwise remain subject to their original terms and conditions.&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <abio:NumberOfConsecutiveTradingDays contextRef="c138" id="ixv-38298">P5D</abio:NumberOfConsecutiveTradingDays>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="c139"
      decimals="4"
      id="ixv-38299"
      unitRef="pure">0.9762</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners
      contextRef="c140"
      decimals="4"
      id="ixv-38300"
      unitRef="pure">0.0238</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <abio:ThresholdAmountOfAdjustedExchangeRatio
      contextRef="c138"
      decimals="-5"
      id="ixv-38301"
      unitRef="usd">5000000</abio:ThresholdAmountOfAdjustedExchangeRatio>
    <abio:ThresholdAmountOfDeclaredCashDividend contextRef="c141" decimals="0" id="ixv-38302" unitRef="usd">5000000</abio:ThresholdAmountOfDeclaredCashDividend>
    <abio:SubscriptionAgreementReceiptAmount
      contextRef="c142"
      decimals="INF"
      id="ixv-38303"
      unitRef="usd">175000000</abio:SubscriptionAgreementReceiptAmount>
    <abio:PaymentOfOtherPartyTerminationFee contextRef="c143" decimals="0" id="ixv-38304" unitRef="usd">440000</abio:PaymentOfOtherPartyTerminationFee>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c144"
      decimals="INF"
      id="ixv-38305"
      unitRef="usdPershares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <abio:MinimumPercentageOfOriginallyIssuedShares
      contextRef="c145"
      decimals="2"
      id="ixv-38306"
      unitRef="pure">0.30</abio:MinimumPercentageOfOriginallyIssuedShares>
    <abio:MinimumPercentageOfOriginallyIssuedOutstanding
      contextRef="c145"
      decimals="2"
      id="ixv-38307"
      unitRef="pure">0.30</abio:MinimumPercentageOfOriginallyIssuedOutstanding>
    <us-gaap:PreferredStockConvertibleSharesIssuable
      contextRef="c146"
      decimals="0"
      id="ixv-38308"
      unitRef="shares">1000</us-gaap:PreferredStockConvertibleSharesIssuable>
    <abio:InitiallySpecifiedPercentageForBeneficialNumberOfShares
      contextRef="c147"
      decimals="4"
      id="ixv-38309"
      unitRef="pure">0.0999</abio:InitiallySpecifiedPercentageForBeneficialNumberOfShares>
    <abio:ExceptedNumberOfBoardMembers
      contextRef="c148"
      decimals="0"
      id="ixv-38310"
      unitRef="pure">5</abio:ExceptedNumberOfBoardMembers>
    <abio:AggregatePurchasePrice
      contextRef="c149"
      decimals="-5"
      id="ixv-38311"
      unitRef="usd">275000000</abio:AggregatePurchasePrice>
    <abio:NumberOfMonthsBaseSalary contextRef="c150" id="ixv-38312">P12M</abio:NumberOfMonthsBaseSalary>
    <abio:CashPayment contextRef="c150" decimals="0" id="ixv-38313" unitRef="usd">25000</abio:CashPayment>
    <abio:IncreaseOfRetentionBonusToEachExecutive contextRef="c151" decimals="0" id="ixv-38314" unitRef="usd">200000</abio:IncreaseOfRetentionBonusToEachExecutive>
    <abio:IncreaseOfRetentionBonusToEachExecutive contextRef="c152" decimals="0" id="ixv-38315" unitRef="usd">200000</abio:IncreaseOfRetentionBonusToEachExecutive>
    <abio:RetentionBonuses contextRef="c153" decimals="0" id="ixv-38316" unitRef="usd">165000</abio:RetentionBonuses>
    <dei:DocumentType contextRef="c0" id="hidden-fact-0">S-4/A</dei:DocumentType>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c1"
      id="hidden-fact-1"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c2"
      id="hidden-fact-2"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="c1"
      id="hidden-fact-3"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="c2"
      id="hidden-fact-4"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="c5"
      id="hidden-fact-5"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherNonoperatingExpense
      contextRef="c6"
      id="hidden-fact-6"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c6"
      decimals="2"
      id="hidden-fact-7"
      unitRef="usdPershares">-0.37</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c7"
      decimals="2"
      id="hidden-fact-8"
      unitRef="usdPershares">-0.69</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c7"
      decimals="0"
      id="hidden-fact-9"
      unitRef="shares">14410143</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c6"
      decimals="0"
      id="hidden-fact-10"
      unitRef="shares">14415877</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c10"
      decimals="2"
      id="hidden-fact-11"
      unitRef="usdPershares">-0.09</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c0"
      decimals="2"
      id="hidden-fact-12"
      unitRef="usdPershares">-0.14</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c10"
      decimals="0"
      id="hidden-fact-13"
      unitRef="shares">14410143</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c0"
      decimals="0"
      id="hidden-fact-14"
      unitRef="shares">14501143</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c17"
      id="hidden-fact-15"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c19"
      id="hidden-fact-16"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c17"
      id="hidden-fact-17"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c18"
      id="hidden-fact-18"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="c23"
      id="hidden-fact-19"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="c24"
      id="hidden-fact-20"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="c25"
      id="hidden-fact-21"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="c6"
      id="hidden-fact-22"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c23"
      id="hidden-fact-23"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c25"
      id="hidden-fact-24"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c23"
      id="hidden-fact-25"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c24"
      id="hidden-fact-26"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c29"
      id="hidden-fact-27"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c31"
      id="hidden-fact-28"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c29"
      id="hidden-fact-29"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c30"
      id="hidden-fact-30"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c36"
      id="hidden-fact-31"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c38"
      id="hidden-fact-32"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c36"
      id="hidden-fact-33"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c37"
      id="hidden-fact-34"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c44"
      id="hidden-fact-35"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c46"
      id="hidden-fact-36"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c44"
      id="hidden-fact-37"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c45"
      id="hidden-fact-38"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="c52"
      id="hidden-fact-39"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="c53"
      id="hidden-fact-40"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="c54"
      id="hidden-fact-41"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="c55"
      id="hidden-fact-42"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c52"
      id="hidden-fact-43"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c54"
      id="hidden-fact-44"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c52"
      id="hidden-fact-45"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c53"
      id="hidden-fact-46"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c56"
      id="hidden-fact-47"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c58"
      id="hidden-fact-48"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c56"
      id="hidden-fact-49"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c57"
      id="hidden-fact-50"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="c6"
      id="hidden-fact-51"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="c7"
      id="hidden-fact-52"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="c6"
      id="hidden-fact-53"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="c6"
      id="hidden-fact-54"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="c6"
      id="hidden-fact-55"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="c7"
      id="hidden-fact-56"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:InterestPaidNet
      contextRef="c6"
      id="hidden-fact-57"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:InterestPaidNet
      contextRef="c7"
      id="hidden-fact-58"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIncomeTaxRefunds
      contextRef="c6"
      id="hidden-fact-59"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIncomeTaxRefunds
      contextRef="c7"
      id="hidden-fact-60"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="c0"
      id="hidden-fact-61"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="c10"
      id="hidden-fact-62"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="c0"
      id="hidden-fact-63"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="c10"
      id="hidden-fact-64"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:InterestPaidNet
      contextRef="c0"
      id="hidden-fact-65"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:InterestPaidNet
      contextRef="c10"
      id="hidden-fact-66"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIncomeTaxRefunds
      contextRef="c0"
      id="hidden-fact-67"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIncomeTaxRefunds
      contextRef="c10"
      id="hidden-fact-68"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="c10"
      id="hidden-fact-69"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c64"
      id="hidden-fact-70"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:DebtLongtermAndShorttermCombinedAmount
      contextRef="c1"
      id="hidden-fact-71"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DebtLongtermAndShorttermCombinedAmount
      contextRef="c2"
      id="hidden-fact-72"
      unitRef="usd"
      xsi:nil="true"/>
    <abio:FairValueAssetsBetweenHierarchyLevelsTransfersAmount
      contextRef="c6"
      id="hidden-fact-73"
      unitRef="usd"
      xsi:nil="true"/>
    <abio:FairValueAssetsBetweenHierarchyLevelsTransfersAmount
      contextRef="c68"
      id="hidden-fact-74"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RestructuringReserveCurrent
      contextRef="c1"
      id="hidden-fact-75"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c7"
      id="hidden-fact-76"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c7"
      id="hidden-fact-77"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c6"
      id="hidden-fact-78"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c6"
      id="hidden-fact-79"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c6"
      id="hidden-fact-80"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c6"
      id="hidden-fact-81"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="c1"
      id="hidden-fact-82"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="c1"
      id="hidden-fact-83"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="c1"
      id="hidden-fact-84"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c16"
      id="hidden-fact-85"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c16"
      id="hidden-fact-86"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c7"
      id="hidden-fact-87"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c7"
      id="hidden-fact-88"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c7"
      id="hidden-fact-89"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c7"
      id="hidden-fact-90"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c6"
      id="hidden-fact-91"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c6"
      id="hidden-fact-92"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c6"
      id="hidden-fact-93"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c6"
      id="hidden-fact-94"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c1"
      id="hidden-fact-95"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c1"
      id="hidden-fact-96"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c98" id="hidden-fact-97">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c99" id="hidden-fact-98">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c6" id="hidden-fact-99">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1 contextRef="c107" id="hidden-fact-100">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="c6"
      id="hidden-fact-101"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="c7"
      id="hidden-fact-102"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c6"
      id="hidden-fact-103"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c7"
      id="hidden-fact-104"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="c1"
      id="hidden-fact-105"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="c2"
      id="hidden-fact-106"
      unitRef="usd"
      xsi:nil="true"/>
    <abio:OperatingLossCarryforwardsExpirationYear contextRef="c114" id="hidden-fact-107">2025</abio:OperatingLossCarryforwardsExpirationYear>
    <abio:OperatingLossCarryforwardsExpirationYear contextRef="c115" id="hidden-fact-108">2037</abio:OperatingLossCarryforwardsExpirationYear>
    <us-gaap:OpenTaxYear contextRef="c6" id="hidden-fact-109">2009</us-gaap:OpenTaxYear>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c119"
      id="hidden-fact-110"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="c5"
      id="hidden-fact-111"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="c1"
      id="hidden-fact-112"
      unitRef="usd"
      xsi:nil="true"/>
    <abio:FairValueAssetsBetweenHierarchyLevelsTransfersAmount
      contextRef="c0"
      id="hidden-fact-113"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="c5"
      id="hidden-fact-114"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RestructuringReserveCurrent
      contextRef="c1"
      id="hidden-fact-115"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c135"
      id="hidden-fact-116"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c0"
      id="hidden-fact-117"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c0"
      id="hidden-fact-118"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:LiabilityForUncertainTaxPositionsCurrent
      contextRef="c5"
      id="hidden-fact-119"
      unitRef="usd"
      xsi:nil="true"/>
    <dei:AmendmentFlag contextRef="c0" id="ixv-38439">true</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="c0" id="ixv-38440">0000907654</dei:EntityCentralIndexKey>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140399531276800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ARCA BIOPHARMA, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">S-4/A<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentDescription', window );">Amendment Description</a></td>
<td class="text">The issuances of (i)&#160;all shares of ARCA common stock in exchange for each share of Oruka common stock (including shares of Oruka common stock issued in the Oruka pre-closing financing), (ii)&#160;all shares of ARCA common stock issuable upon exercise of pre-funded warrants issued in exchange for pre-funded warrants to purchase shares of Oruka common stock sold in the Oruka pre-closing financing, and (iii)&#160;all shares of ARCA common stock issuable upon conversion of ARCA Series&#160;B Preferred Stock issued in exchange for each share of Oruka preferred stock, are intended to be covered by this registration statement on Form&#160;S-4 of which the accompanying proxy statement/prospectus is a part. There is no difference between the shares of ARCA common stock that will be issued in exchange for each share of Oruka common stock issued in the pre-closing financing, the shares of ARCA common stock that will be issued in exchange for each other share of Oruka common stock, the shares of ARCA common stock that will be issuable upon the exercise of pre-funded warrants that will be issued in exchange for pre-funded warrants to purchase shares of Oruka common stock sold in the pre-closing financing and the shares of ARCA common stock that will be issuable upon conversion of ARCA Series&#160;B Preferred Stock that will be issued in exchange for each share of Oruka preferred stock.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000907654<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of changes contained within amended document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140399530961792">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 35,903<span></span>
</td>
<td class="nump">$ 37,431<span></span>
</td>
<td class="nump">$ 42,445<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">767<span></span>
</td>
<td class="nump">161<span></span>
</td>
<td class="nump">254<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">36,670<span></span>
</td>
<td class="nump">37,592<span></span>
</td>
<td class="nump">42,699<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use asset &#8211; operating</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">247<span></span>
</td>
<td class="nump">343<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">36,706<span></span>
</td>
<td class="nump">37,861<span></span>
</td>
<td class="nump">43,085<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">529<span></span>
</td>
<td class="nump">362<span></span>
</td>
<td class="nump">334<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation and employee benefits</a></td>
<td class="nump">84<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">173<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued expenses and other liabilities</a></td>
<td class="nump">968<span></span>
</td>
<td class="nump">175<span></span>
</td>
<td class="nump">625<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">1,581<span></span>
</td>
<td class="nump">637<span></span>
</td>
<td class="nump">1,132<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, net of current portion</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">204<span></span>
</td>
<td class="nump">280<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">1,581<span></span>
</td>
<td class="nump">841<span></span>
</td>
<td class="nump">1,412<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; 5 million shares authorized; no shares issued or outstanding at December 31, 2023 and 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, value</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">225,861<span></span>
</td>
<td class="nump">225,747<span></span>
</td>
<td class="nump">225,061<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(190,750)<span></span>
</td>
<td class="num">(188,741)<span></span>
</td>
<td class="num">(183,402)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">35,125<span></span>
</td>
<td class="nump">37,020<span></span>
</td>
<td class="nump">41,673<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 36,706<span></span>
</td>
<td class="nump">$ 37,861<span></span>
</td>
<td class="nump">$ 43,085<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140399528929424">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets (Unaudited) (Parentheticals) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued expenses and other liabilities - related party (in Dollars)</a></td>
<td class="nump">$ 968<span></span>
</td>
<td class="nump">$ 175<span></span>
</td>
<td class="nump">$ 625<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in Dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">14,501,143<span></span>
</td>
<td class="nump">14,501,143<span></span>
</td>
<td class="nump">14,410,143<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">14,501,143<span></span>
</td>
<td class="nump">14,501,143<span></span>
</td>
<td class="nump">14,410,143<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=us-gaap_RelatedPartyMember', window );">Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued expenses and other liabilities - related party (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 216<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140399530346448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Operations (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">$ 2,317<span></span>
</td>
<td class="nump">$ 1,406<span></span>
</td>
<td class="nump">$ 6,283<span></span>
</td>
<td class="nump">$ 5,847<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">165<span></span>
</td>
<td class="nump">390<span></span>
</td>
<td class="nump">1,013<span></span>
</td>
<td class="nump">4,749<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total costs and expenses</a></td>
<td class="nump">2,482<span></span>
</td>
<td class="nump">1,796<span></span>
</td>
<td class="nump">7,296<span></span>
</td>
<td class="nump">10,596<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(2,482)<span></span>
</td>
<td class="num">(1,796)<span></span>
</td>
<td class="num">(7,296)<span></span>
</td>
<td class="num">(10,596)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestAndOtherIncome', window );">Interest and other income</a></td>
<td class="nump">473<span></span>
</td>
<td class="nump">450<span></span>
</td>
<td class="nump">1,957<span></span>
</td>
<td class="nump">675<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingExpense', window );">Other loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (2,009)<span></span>
</td>
<td class="num">$ (1,346)<span></span>
</td>
<td class="num">$ (5,339)<span></span>
</td>
<td class="num">$ (9,926)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net loss per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in Dollars per share)</a></td>
<td class="num">$ (0.14)<span></span>
</td>
<td class="num">$ (0.09)<span></span>
</td>
<td class="num">$ (0.37)<span></span>
</td>
<td class="num">$ (0.69)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_WeightedAverageSharesOutstandingAbstract', window );"><strong>Weighted average shares outstanding:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in Shares)</a></td>
<td class="nump">14,501,143<span></span>
</td>
<td class="nump">14,410,143<span></span>
</td>
<td class="nump">14,415,877<span></span>
</td>
<td class="nump">14,410,143<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_WeightedAverageSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_WeightedAverageSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestAndOtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestAndOtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140399531202240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Operations (Unaudited) (Parentheticals) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted</a></td>
<td class="num">$ (0.14)<span></span>
</td>
<td class="num">$ (0.09)<span></span>
</td>
<td class="num">$ (0.37)<span></span>
</td>
<td class="num">$ (0.69)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted</a></td>
<td class="nump">14,501,143<span></span>
</td>
<td class="nump">14,410,143<span></span>
</td>
<td class="nump">14,415,877<span></span>
</td>
<td class="nump">14,410,143<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_ResearchAndDevelopmentExpenseReversed', window );">Related party expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 108<span></span>
</td>
<td class="num">$ (91)<span></span>
</td>
<td class="nump">$ 432<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_ResearchAndDevelopmentExpenseReversed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and development expense (reversed).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_ResearchAndDevelopmentExpenseReversed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140399528371936">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Statements of Stockholders&#8217; Equity (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">$ 224,505<span></span>
</td>
<td class="num">$ (173,476)<span></span>
</td>
<td class="nump">$ 51,043<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2021</a></td>
<td class="nump">14,410,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">556<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">556<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(9,926)<span></span>
</td>
<td class="num">(9,926)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">225,061<span></span>
</td>
<td class="num">(183,402)<span></span>
</td>
<td class="nump">$ 41,673<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2022</a></td>
<td class="nump">14,410,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,410,143<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">204<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 204<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(1,346)<span></span>
</td>
<td class="num">(1,346)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2023</a></td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">225,265<span></span>
</td>
<td class="num">(184,748)<span></span>
</td>
<td class="nump">40,531<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in Shares) at Mar. 31, 2023</a></td>
<td class="nump">14,410,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">225,061<span></span>
</td>
<td class="num">(183,402)<span></span>
</td>
<td class="nump">$ 41,673<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2022</a></td>
<td class="nump">14,410,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,410,143<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Issuance of common stock upon vesting of Restricted Stock Units</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock upon vesting of Restricted Stock Units (in Shares)</a></td>
<td class="nump">91,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">686<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">686<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(5,339)<span></span>
</td>
<td class="num">(5,339)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2023</a></td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">225,747<span></span>
</td>
<td class="num">(188,741)<span></span>
</td>
<td class="nump">$ 37,020<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2023</a></td>
<td class="nump">14,501,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,501,143<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2023</a></td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">225,265<span></span>
</td>
<td class="num">(184,748)<span></span>
</td>
<td class="nump">$ 40,531<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in Shares) at Mar. 31, 2023</a></td>
<td class="nump">14,410,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">187<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">187<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(1,480)<span></span>
</td>
<td class="num">(1,480)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2023</a></td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">225,452<span></span>
</td>
<td class="num">(186,228)<span></span>
</td>
<td class="nump">39,238<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in Shares) at Jun. 30, 2023</a></td>
<td class="nump">14,410,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">154<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">154<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(1,424)<span></span>
</td>
<td class="num">(1,424)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2023</a></td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">225,606<span></span>
</td>
<td class="num">(187,652)<span></span>
</td>
<td class="nump">37,968<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in Shares) at Sep. 30, 2023</a></td>
<td class="nump">14,410,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Issuance of common stock upon vesting of Restricted Stock Units</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock upon vesting of Restricted Stock Units (in Shares)</a></td>
<td class="nump">91,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">141<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">141<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(1,089)<span></span>
</td>
<td class="num">(1,089)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2023</a></td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">225,747<span></span>
</td>
<td class="num">(188,741)<span></span>
</td>
<td class="nump">$ 37,020<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2023</a></td>
<td class="nump">14,501,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,501,143<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">114<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 114<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2,009)<span></span>
</td>
<td class="num">(2,009)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2024</a></td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">$ 225,861<span></span>
</td>
<td class="num">$ (190,750)<span></span>
</td>
<td class="nump">$ 35,125<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in Shares) at Mar. 31, 2024</a></td>
<td class="nump">14,501,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,501,143<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140399528251360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Cash Flows (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (2,009)<span></span>
</td>
<td class="num">$ (1,346)<span></span>
</td>
<td class="num">$ (5,339)<span></span>
</td>
<td class="num">$ (9,926)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization of right-of-use asset &#8211; operating</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="nump">96<span></span>
</td>
<td class="nump">94<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">114<span></span>
</td>
<td class="nump">204<span></span>
</td>
<td class="nump">686<span></span>
</td>
<td class="nump">556<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss from disposal of property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Change in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets', window );">Other current assets</a></td>
<td class="num">(606)<span></span>
</td>
<td class="num">(598)<span></span>
</td>
<td class="nump">93<span></span>
</td>
<td class="nump">808<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">167<span></span>
</td>
<td class="nump">32<span></span>
</td>
<td class="nump">28<span></span>
</td>
<td class="num">(783)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Accrued compensation and employee benefits</a></td>
<td class="num">(16)<span></span>
</td>
<td class="nump">62<span></span>
</td>
<td class="num">(73)<span></span>
</td>
<td class="num">(752)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued expenses and other liabilities</a></td>
<td class="nump">803<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="num">(526)<span></span>
</td>
<td class="num">(934)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(1,528)<span></span>
</td>
<td class="num">(1,595)<span></span>
</td>
<td class="num">(5,014)<span></span>
</td>
<td class="num">(10,912)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash and cash equivalents</a></td>
<td class="num">(1,528)<span></span>
</td>
<td class="num">(1,595)<span></span>
</td>
<td class="num">(5,014)<span></span>
</td>
<td class="num">(10,914)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, beginning of year</a></td>
<td class="nump">37,431<span></span>
</td>
<td class="nump">42,445<span></span>
</td>
<td class="nump">42,445<span></span>
</td>
<td class="nump">53,359<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, end of year</a></td>
<td class="nump">35,903<span></span>
</td>
<td class="nump">40,850<span></span>
</td>
<td class="nump">37,431<span></span>
</td>
<td class="nump">42,445<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIncomeTaxRefunds', window );">Income tax refund received</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental disclosure of noncash investing and financing transactions:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Leased assets and operating lease liabilities &#8211; amended lease term</a></td>
<td class="nump">$ 214<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIncomeTaxRefunds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income tax refund received from tax jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIncomeTaxRefunds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140399531998848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ARCA and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>ARCA and Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">ARCA and Summary of Significant Accounting Policies</a></td>
<td class="text"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(1)&#160;ARCA and Summary of Significant Accounting Policies</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;margin-top:8pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Description of Business</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA biopharma, Inc. (&#8220;ARCA&#8221;), a Delaware corporation, is headquartered in Westminster, Colorado. ARCA is dedicated to applying a precision medicine approach to the development and commercialization of genetically targeted therapies for cardiovascular diseases. ARCA&#8217;s lead product candidate is Gencaro&#8482; (bucindolol hydrochloride) for the treatment of atrial fibrillation (&#8220;AF&#8221;) in patients with chronic heart failure (&#8220;HF&#8221;).</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In April&#160;2022, ARCA established a Special Committee of the board of directors (the &#8220;Board&#8221;) of ARCA to conduct a comprehensive review of strategic alternatives. As part of the strategic review process, ARCA explored potential strategic alternatives that included, without limitation, an acquisition, merger, business combination or other transactions. ARCA has and is continuing to explore strategic alternatives related to its product candidates and related assets, including, without limitation, licensing transactions and asset sales.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On April&#160;3, 2024, following a comprehensive review of strategic alternatives, ARCA, Atlas Merger Sub Corp., a Delaware corporation and a wholly<span class="nobreak">-owned</span> subsidiary of ARCA (&#8220;Merger Sub&#160;I&#8221;), Atlas Merger Sub&#160;II LLC, a Delaware limited liability company and a wholly<span class="nobreak">-owned</span> subsidiary of ARCA (&#8220;Merger Sub&#160;II&#8221;) and Oruka Therapeutics, Inc., a Delaware corporation (&#8220;Oruka<span class="CharOverride-1" style="text-decoration:underline;">&#8221;</span>), entered into an Agreement and Plan of Merger and Reorganization (the &#8220;Merger Agreement&#8221;), pursuant to which, among other matters, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Merger Sub&#160;I will merge with and into Oruka, with Oruka continuing as a wholly owned subsidiary of ARCA and the surviving corporation of the merger (the &#8220;First Merger&#8221;) and as part of the same overall transaction, the surviving corporation in the First Merger will merge with and into Merger Sub&#160;II with Merger Sub&#160;II continuing as a wholly owned subsidiary of ARCA and the surviving entity of the merger (the &#8220;Second Merger&#8221; and together with the First Merger, the &#8220;Merger&#8221;). The Merger is intended to qualify for federal income tax purposes as a tax<span class="nobreak">-free</span> reorganization under the provisions of Section&#160;368(a)&#160;of the Internal Revenue Code of 1986, as amended.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s future operations are highly dependent on the success of the Merger and there can be no assurances that the Merger will be successfully consummated. In the event that ARCA does not complete the Merger, it may explore strategic alternatives, including, without limitation, another strategic transaction and/or pursue a dissolution and liquidation of ARCA. See Note&#160;10.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Liquidity and Going Concern</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA devotes substantially all of its efforts towards obtaining regulatory approval and raising capital necessary to fund its operations and it is subject to a number of risks associated with clinical research and development, including dependence on key individuals, the development of and regulatory approval of commercially viable products, the need to raise adequate additional financing necessary to fund the development and commercialization of its products, and competition from larger companies. ARCA has not generated revenue to date and has incurred substantial losses and negative cash flows from operations since its inception. ARCA has historically funded its operations through issuances of common and preferred stock.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA believes that its current cash and cash equivalents as of March&#160;31, 2024 will be sufficient to fund its operations through the middle of fiscal year 2025. The future viability of ARCA beyond that point is dependent on the results of the strategic review process and its ability to raise additional capital to fund its operations. ARCA expects to continue to incur costs and expenditures in connection with the process of evaluating strategic alternatives. There can be no assurance, however, that ARCA will be able to successfully consummate any particular strategic transaction, including the Merger Agreement. The process of continuing to evaluate these strategic options may be very costly, time<span class="nobreak">-consuming</span> and complex and ARCA has incurred, and may in the future incur, significant costs related to this continued evaluation, such as legal, accounting and advisory fees and expenses and other related charges, see Note&#160;10 regarding the Merger Agreement. Should ARCA pursue additional clinical trials for its product candidates, it will have to raise additional capital for clinical trials of Gencaro. ARCA may not be able to raise sufficient capital on acceptable terms, or at all, to continue development of Gencaro or rNAPc2 or to otherwise continue operations and may not be </p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">able to execute any strategic transaction. Changing circumstances may cause ARCA to consume capital significantly faster or slower than currently anticipated. ARCA has based these estimates on assumptions that may prove to be wrong, and it could exhaust its available financial resources sooner than it currently anticipates. Depending on the results of the strategic review process, ARCA may have to raise additional capital for clinical trials of Gencaro and to fund its operations. ARCA may not be able to raise sufficient capital on acceptable terms, or at all, to continue development of Gencaro or rNAPc2 or to otherwise continue operations and may not be able to execute any strategic transaction.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s liquidity, and its ability to raise additional capital or complete any strategic transaction, depends on a number of factors, including, but not limited to, the following:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the timing and outcome of the strategic review process;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the consummation of any particular strategic transactions, including the Merger;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the costs and timing for the potential additional clinical trials in order to gain possible regulatory approval for Gencaro, rNAPc2, or any other product candidate;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the market price of ARCA&#8217;s stock and the availability and cost of additional equity capital from existing and potential new investors;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s ability to retain the listing of its common stock on the Nasdaq Capital Market;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>general economic and industry conditions affecting the availability and cost of capital, including as a result of deteriorating market conditions due to investor concerns regarding inflation, adverse developments affecting the financial services industry, continued hostilities between Russia and Ukraine and Hamas&#8217; attack against Israel and the ensuing conflict;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s ability to control costs associated with its operations;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the terms and conditions of ARCA&#8217;s existing collaborative and licensing agreements.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The sale of additional equity or convertible debt securities would likely result in substantial additional dilution to ARCA&#8217;s stockholders. If ARCA raises additional funds through the incurrence of indebtedness, the obligations related to such indebtedness would be senior to rights of holders of ARCA&#8217;s capital stock and could contain covenants that would restrict ARCA&#8217;s operations. ARCA also cannot predict what consideration might be available, if any, to it or its stockholders, in connection with any strategic transaction. Should strategic alternatives or additional capital not be available to ARCA, or not be available on acceptable terms, ARCA may be unable to realize value from its assets and discharge its liabilities in the normal course of business which may, among other alternatives, cause ARCA to further delay, substantially reduce or discontinue operational activities to conserve its cash resources.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Basis of Presentation</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The accompanying unaudited financial statements of ARCA were prepared in accordance with generally accepted accounting principles for interim financial information and pursuant to Regulation&#160;S<span class="nobreak">-X</span>.&#160;Accordingly, these financial statements do not include all of the information and footnotes required by accounting principles generally accepted in the United&#160;States of America (&#8220;GAAP&#8221;) for complete financial statements. In the opinion of management, these financial statements include all normal and recurring adjustments considered necessary for a fair presentation of these interim financial statements. The results of operations for the three&#160;months ended March&#160;31, 2024 are not necessarily indicative of results expected for the full year ending December&#160;31, 2024. ARCA has generated no revenue to date and its activities have consisted of seeking regulatory approval, research and development, exploring </p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">strategic alternatives for further developing and commercializing Gencaro and rNAPc2, and raising capital. These unaudited financial statements should be read in conjunction with the audited financial statements and footnotes thereto for the year ended December&#160;31, 2023 included elsewhere in this proxy statement/prospectus. Amounts presented are rounded to the nearest thousand, where indicated, except per share data and par values.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Concentrations of Credit Risk</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Financial instruments that potentially subject ARCA to significant concentrations of credit risk consist primarily of cash and cash equivalents. ARCA has no off<span class="nobreak">-balance-sheet</span> concentrations of credit risk, such as foreign exchange contracts, option contracts, or foreign currency hedging arrangements. ARCA maintains cash and cash equivalent balances in the form of bank demand deposits and money market fund accounts with financial institutions that management believes are creditworthy. Such balances may at times exceed the insured amount.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Comprehensive Loss</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Comprehensive loss is defined as the change in equity during a period from transactions and other events and/or circumstances from non<span class="nobreak">-owner</span> sources. If ARCA had comprehensive gains (losses), they would be reflected in the statement of operations and comprehensive loss and as a separate component in the statement of stockholders&#8217; equity. There were no elements of comprehensive loss during the three&#160;months ended March&#160;31, 2024 and 2023.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Leases</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA determines if an arrangement is a lease at inception. Operating leases are included in right<span class="nobreak">-of-use</span> (&#8220;ROU&#8221;) asset&#160;&#8212;&#160;operating and lease obligations are included in accrued expenses and other liabilities and operating lease liability on ARCA&#8217;s March&#160;31, 2024 and December&#160;31, 2023 balance sheets.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ROU lease assets represent ARCA&#8217;s right to use an underlying asset for the lease term and lease obligations represent ARCA&#8217;s obligation to make lease payments arising from the lease. Operating ROU lease assets are recognized at the commencement date based on the present value of lease payments over the lease term. As ARCA&#8217;s leases do not provide an implicit rate, ARCA uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. ARCA&#8217;s lease terms may include options to extend or terminate a lease when it is reasonably certain that ARCA will exercise that option. Lease expense for lease payments is recognized on a straight<span class="nobreak">-line</span> basis over the lease term.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Accrued Outsourcing Expenses</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As part of the process of preparing its financial statements, ARCA is required to estimate accrued outsourcing expenses. This process involves identifying services that third parties have performed on ARCA&#8217;s behalf and estimating the level of service performed and the associated cost incurred for these services as of the balance sheet date. Examples of estimated accrued outsourcing expenses include contract service fees, such as fees payable to contract manufacturers in connection with the production of materials related to ARCA&#8217;s drug product, and service fees and pass through costs from clinical research organizations. ARCA develops estimates of liabilities using its judgment based upon the facts and circumstances known at the time.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Recent Accounting Pronouncements</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA reviewed recently issued accounting pronouncements and concluded that they were either not applicable or not expected to have a significant impact to the financial statements.</p><span></span>
</td>
<td class="text"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(1)&#160;ARCA and Summary of Significant Accounting Policies</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Description of Business</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA biopharma, Inc. (&#8220;ARCA&#8221;), a Delaware corporation, is headquartered in Westminster, Colorado. ARCA is a clinical<span class="nobreak">-stage</span> biopharmaceutical company applying a precision medicine approach to the development and commercialization of genetically targeted therapies for cardiovascular diseases. ARCA&#8217;s lead product candidate is Gencaro&#8482; (bucindolol hydrochloride) for the treatment of atrial fibrillation (&#8220;AF&#8221;) in patients with chronic heart failure (&#8220;HF&#8221;).</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In April&#160;2022, the Board of Directors established a Special Committee and, in May&#160;2022, retained Ladenburg Thalmann&#160;&amp; Co. Inc. to evaluate strategic options, including transactions involving a merger, sale of all or part of ARCA&#8217;s assets, or other alternatives with the goal of maximizing stockholder value. ARCA does not have a defined timeline for the strategic review process and the review may not result in any specific action or transaction.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Liquidity and Going Concern</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA devotes substantially all of its efforts towards obtaining regulatory approval and raising capital necessary to fund its operations and it is subject to a number of risks associated with clinical research and development, including dependence on key individuals, the development of and regulatory approval of commercially viable products, the need to raise adequate additional financing necessary to fund the development and commercialization of its products, and competition from larger companies. ARCA has not generated revenue to date and has incurred substantial losses and negative cash flows from operations since its inception. ARCA has historically funded its operations through issuances of common and preferred stock.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA believes that its current cash and cash equivalents as of December&#160;31, 2023 will be sufficient to fund its operations through the middle of fiscal year 2025. ARCA&#8217;s review of its strategic options may impact this projection. Changing circumstances may cause ARCA to consume capital significantly faster or slower than currently anticipated. ARCA has based these estimates on assumptions that may prove to be wrong, and ARCA could exhaust its available financial resources sooner than it currently anticipates. Therefore, ARCA will have to raise additional capital for clinical trials of Gencaro. ARCA may not be able to raise sufficient capital on acceptable terms, or at all, to continue development of Gencaro or rNAPc2 or to otherwise continue operations and may not be able to execute any strategic transaction.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s liquidity, and its ability to raise additional capital or complete any strategic transaction, depends on a number of factors, including, but not limited to, the following:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the costs and timing for the potential additional clinical trials in order to gain possible regulatory approval for Gencaro, rNAPc2, or any other product candidate;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the market price of ARCA&#8217;s stock and the availability and cost of additional equity capital from existing and potential new investors;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s ability to retain the listing of its common stock on the Nasdaq Capital Market;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>general economic and industry conditions affecting the availability and cost of capital, including as a result of deteriorating market conditions due to investor concerns regarding inflation, adverse developments affecting the financial services industry, continued hostilities between Russia and Ukraine and Hamas&#8217; attack against Israel and the ensuing conflict;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s ability to control costs associated with its operations;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the terms and conditions of ARCA&#8217;s existing collaborative and licensing agreements.</p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The sale of additional equity or convertible debt securities would likely result in substantial additional dilution to ARCA&#8217;s stockholders. If ARCA raises additional funds through the incurrence of indebtedness, the obligations related to such indebtedness would be senior to rights of holders of ARCA&#8217;s capital stock and could contain covenants that would restrict ARCA&#8217;s operations. ARCA also cannot predict what consideration might be available, if any, to it or its stockholders, in connection with any strategic transaction. Should strategic alternatives or additional capital not be available to ARCA, or not be available on acceptable terms, ARCA may be unable to realize value from its assets and discharge its liabilities in the normal course of business which may, among other alternatives, cause ARCA to further delay, substantially reduce or discontinue operational activities to conserve its cash resources.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Basis of Presentation</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The accompanying financial statements have been prepared in accordance with U.S.&#160;generally accepted accounting principles (&#8220;GAAP&#8221;) and include all adjustments necessary for the fair presentation of ARCA&#8217;s financial position, results of operations and cash flows for the periods presented. Management has performed an evaluation of ARCA&#8217;s activities through the date of filing of the Annual Report on Form&#160;10<span class="nobreak">-K</span>.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Recent Accounting Pronouncements</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA reviewed all other recently issued accounting pronouncements and concluded that they were either not applicable or not expected to have a significant impact to the financial statements.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Accounting Estimates in the Preparation of Financial Statements</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The preparation of financial statements in conformity with accounting principles generally accepted in the United&#160;States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. ARCA bases estimates on various assumptions that are believed to be reasonable under the circumstances. ARCA believes significant judgment was involved in estimating the outsourcing expenses, and in estimating other accrued liabilities and income taxes. Management is continually evaluating and updating these estimates, and it is possible that these estimates will change in the future or that actual results may differ from these estimates.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Cash Equivalents</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Cash equivalents generally consist of money market funds and debt securities with maturities of 90&#160;days or less at the time of purchase. ARCA invests its excess cash in securities with strong ratings and has established guidelines relative to diversification and maturity with the objective of maintaining safety of principal and liquidity.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Concentrations of Credit Risk</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Financial instruments that potentially subject ARCA to significant concentrations of credit risk consist primarily of cash and cash equivalents. ARCA has no off<span class="nobreak">-balance-sheet</span> concentrations of credit risk, such as foreign exchange contracts, option contracts, or foreign currency hedging arrangements. ARCA maintains cash and cash equivalent balances in the form of bank demand deposits and money market fund accounts with financial institutions that management believes are creditworthy. Such balances may at times exceed the insured amount.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Property and Equipment</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Property and equipment are stated at cost less accumulated depreciation and amortization. Cost includes expenditures for equipment, leasehold improvements, replacements, and renewals. Maintenance and repairs are charged to expense as incurred. When assets are sold, retired, or otherwise disposed of, the cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is reflected in operations. The cost of </p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">property and equipment is depreciated using the straight<span class="nobreak">-line</span> method over the estimated useful lives of the related assets. Leasehold improvements are amortized over the shorter of the life of the lease or the estimated useful life of the assets.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Comprehensive Loss</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Comprehensive loss is defined as the change in equity during a period from transactions and other events and/or circumstances from non<span class="nobreak">-owner</span> sources. If ARCA had comprehensive gains (losses), they would be reflected in the statement of operations and comprehensive loss and as a separate component in the statement of stockholders&#8217; equity. There were no elements of comprehensive loss during the&#160;years ended December&#160;31, 2023 and 2022.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Leases</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA determines if an arrangement is a lease at inception. Operating leases are included in right<span class="nobreak">-of-use</span> (&#8220;ROU&#8221;) asset&#160;&#8212;&#160;operating and lease obligations are included in accrued expenses and other liabilities and operating lease liability on ARCA&#8217;s December&#160;31, 2023 and 2022 balance sheets.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ROU lease assets represent ARCA&#8217;s right to use an underlying asset for the lease term and lease obligations represent ARCA&#8217;s obligation to make lease payments arising from the lease. Operating ROU lease assets are recognized at the commencement date based on the present value of lease payments over the lease term. As ARCA&#8217;s lease does not provide an implicit rate, ARCA uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. ARCA&#8217;s lease terms may include options to extend or terminate the lease when it is reasonably certain that ARCA will exercise that option. Lease expense for lease payments is recognized on a straight<span class="nobreak">-line</span> basis over the lease term.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Accrued Outsourcing Expenses</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As part of the process of preparing its financial statements, ARCA is required to estimate accrued outsourcing expenses. This process involves identifying services that third parties have performed on ARCA&#8217;s behalf and estimating the level of service performed and the associated cost incurred for these services as of the balance sheet date. Examples of estimated accrued outsourcing expenses include contract service fees, such as fees payable to contract manufacturers in connection with the production of materials related to ARCA&#8217;s drug product, and service fees and pass through costs from clinical research organizations. ARCA develops estimates of liabilities using its judgment based upon the facts and circumstances known at the time.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Segments</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA operates in one segment. Management uses one measure of profitability and does not segment its business for internal reporting.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Research and Development</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Research and development costs are expensed as incurred. These consist primarily of salaries, contract services, and supplies.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Costs, if any, related to clinical trial and drug manufacturing activities are based upon estimates of the services received and related expenses incurred by contract research organizations (&#8220;CROs&#8221;), clinical study sites, drug manufacturers, collaboration partners, laboratories, consultants, or otherwise. Related contracts vary significantly in length, and could be for a fixed amount, a variable amount based on actual costs incurred, capped at a certain limit, or for a combination of these elements. Activity levels are monitored through communications with the vendors, including detailed invoices and task completion review, analysis of expenses against budgeted amounts, and pre<span class="nobreak">-approval</span> of any changes in scope of the services to be performed. Certain significant vendors may also provide </p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">an estimate of costs incurred but not invoiced on a periodic basis. Expenses related to the CROs and clinical studies, as well as contract drug manufacturers, are primarily based on progress made against specified milestones or targets in each period.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In accordance with certain research and development agreements, ARCA is obligated to make certain upfront payments upon execution of the agreement. ARCA records these upfront payments as prepaid research and development expenses, which are included in Other current assets or Other assets in the accompanying Balance Sheets. Such payments are recorded to research and development expense as services are performed. ARCA evaluates on a quarterly basis whether events and circumstances have occurred that may indicate impairment of remaining prepaid research and development expenses.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Stock-Based Compensation</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s stock<span class="nobreak">-based</span> compensation cost recognized is based on the estimated grant date fair value. ARCA recognizes compensation costs for its stock<span class="nobreak">-based</span> awards on a straight<span class="nobreak">-line</span> basis over the requisite service period for the entire award, as adjusted for expected forfeitures.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Income Taxes</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The current benefit for income taxes represents actual or estimated amounts payable or refundable on tax returns filed or to be filed each year. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the period that includes the enactment date. The overall change in deferred tax assets and liabilities for the period measures the deferred tax expense or benefit for the period. The measurement of deferred tax assets may be reduced by a valuation allowance based on judgmental assessment of available evidence if deemed more likely than not that some or all of the deferred tax assets will not be realized.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/275/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140399532105008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net Loss Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(2)&#160;Net Loss Per Share</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA calculates basic loss per share by dividing net loss by the weighted average common shares outstanding during the period. Diluted loss per share is computed by dividing net loss by the weighted average number of common shares outstanding during the period increased to include, if dilutive, the number of additional common shares that would have been outstanding if the potential common shares had been issued. ARCA&#8217;s potentially dilutive shares include stock options and restricted stock units.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Because ARCA reported a net loss for the three&#160;months ended March&#160;31, 2024 and 2023, all potentially dilutive shares of ARCA common stock have been excluded from the computation of the dilutive net loss per share for all periods presented. Such potentially dilutive shares of ARCA common stock consist of the following:</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">March&#160;31,</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2024</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Potentially dilutive securities, excluded:</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Outstanding stock options</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">645,845</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">664,857</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Unvested restricted stock units</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-110; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">91,000</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">645,845</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">755,857</p>	</td>
				</tr>

		</table><span></span>
</td>
<td class="text"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(2)&#160;Net Loss Per Share</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA calculates basic loss per share by dividing net loss by the weighted average common shares outstanding during the period. Diluted loss per share is computed by dividing net loss by the weighted average number of common shares outstanding during the period increased to include, if dilutive, the number of additional common shares that would have been outstanding if the potential common shares had been issued. ARCA&#8217;s potentially dilutive shares include stock options and restricted stock units.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Because ARCA reported a net loss for the&#160;years ended December&#160;31, 2023 and 2022, all potentially dilutive shares of ARCA common stock have been excluded from the computation of the dilutive net loss per share for all periods presented. Such potentially dilutive shares of ARCA common stock consist of the following:</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Years Ended<br/>December&#160;31,</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2022</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Potentially dilutive securities, excluded:</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Outstanding stock options</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">616,707</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">704,960</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Unvested restricted stock units</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-70; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">91,000</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">616,707</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">795,960</p>	</td>
				</tr>

		</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140399532201424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Disclosures<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Disclosures</a></td>
<td class="text"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(3)&#160;Fair Value Disclosures</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">There were <span style="-sec-ix-hidden: hidden-fact-111"><span style="-sec-ix-hidden: hidden-fact-112">no</span></span> marketable securities as of March&#160;31, 2024 or December&#160;31, 2023.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (&#8220;exit price&#8221;). Inputs used to measure fair value are classified into the following hierarchy:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Level 1 &#8212;&#160;Unadjusted quoted prices in active markets for identical assets or liabilities. ARCA&#8217;s Level 1 assets consist of money market investments. ARCA does not have any Level 1 liabilities.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Level 2 &#8212;&#160;Unadjusted quoted prices in active markets for similar assets or liabilities; unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active; or inputs other than quoted prices that are observable for the asset or liability. ARCA does not have any Level 2 assets or liabilities.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Level 3 &#8212;&#160;Unobservable inputs for the asset or liability. ARCA does not have any Level 3 assets or liabilities.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of March&#160;31, 2024 and December&#160;31, 2023, ARCA had $35.9&#160;million and $37.4&#160;million, respectively, of cash equivalents consisting of money market funds with original maturities of 90&#160;days or less. ARCA has the ability to liquidate these investments without restriction. ARCA determines fair value for these money market funds with Level 1 inputs through quoted market prices. There were <span style="-sec-ix-hidden: hidden-fact-113">no</span> transfers of assets between fair value hierarchy levels during the three&#160;months ended March&#160;31, 2024.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Fair Value of Other Financial Instruments</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The carrying amount of other financial instruments, including accounts payable, approximated fair value due to their short maturities.</p><span></span>
</td>
<td class="text"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(3)&#160;Fair Value Disclosures</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (&#8220;exit price&#8221;). Inputs used to measure fair value are classified into the following hierarchy:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Level 1 &#8212;&#160;Unadjusted quoted prices in active markets for identical assets or liabilities. ARCA&#8217;s Level 1 assets consist of money market investments. ARCA does not have any Level 1 liabilities.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Level 2 &#8212;&#160;Unadjusted quoted prices in active markets for similar assets or liabilities; unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active; or inputs other than quoted prices that are observable for the asset or liability. ARCA&#8217;s Level 2 assets consist of corporate bonds and commercial paper securities. ARCA does not have any Level 2 liabilities.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Level 3 &#8212;&#160;Unobservable inputs for the asset or liability. ARCA does not have any Level 3 assets or liabilities.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of December&#160;31, 2023 and 2022, ARCA had $37.4&#160;million and $42.4&#160;million, respectively, of cash equivalents consisting of money market funds with original maturities of 90&#160;days or less. ARCA has the ability to liquidate these investments without restriction. ARCA determines fair value for these money market funds with Level 1 inputs through quoted market prices. There were <span style="-sec-ix-hidden: hidden-fact-73"><span style="-sec-ix-hidden: hidden-fact-74">no</span></span> transfers between any fair value hierarchy levels in 2023 or 2022.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Fair Value of Other Financial Instruments</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The carrying amount of other financial instruments, including accounts payable, approximated fair value due to their short maturities. As of December&#160;31, 2023 and 2022, ARCA did <span style="-sec-ix-hidden: hidden-fact-71"><span style="-sec-ix-hidden: hidden-fact-72">not</span></span> have any debt outstanding.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140399532125072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(4)&#160;Property and Equipment</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Property and equipment consist of the following (in thousands):</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">	<tr class="No-Table-Style _idGenTableRowColumn-11" style="height:12pt;">	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Estimated<br/>Life</span></p>	</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">March&#160;31,<br/>2024</span></p>	</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">December&#160;31,<br/>2023</span></p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Computer equipment</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">3&#160;years</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">39</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">39</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Lab equipment</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">5&#160;years</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">130</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">130</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Furniture and fixtures</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">5&#160;years</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">37</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">37</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Computer software</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">3&#160;years</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">16</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">16</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">222</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">222</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accumulated depreciation and amortization</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(215</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(212</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Property and equipment, net</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">7</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">10</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	</tr>	</table>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">For the three&#160;months ended March&#160;31, 2024 and 2023, depreciation and amortization expense was $3,000 and $4,000 respectively.</p><span></span>
</td>
<td class="text"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(4)&#160;Property and Equipment</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Property and equipment consist of the following (in thousands):</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">	<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Estimated<br/>Life</span></p>	</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">December&#160;31,<br/>2023</span></p>	</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">December&#160;31,<br/>2022</span></p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Computer equipment</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">3&#160;years</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">39</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">39</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Lab equipment</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">5&#160;years</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">130</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">130</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Furniture and fixtures</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">5&#160;years</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">37</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">44</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Computer software</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">3&#160;years</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">16</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">16</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">222</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">229</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accumulated depreciation and amortization</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(212</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(204</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Property and equipment, net</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">10</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">25</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	</tr>	</table>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">For the&#160;years ended December&#160;31, 2023 and 2022, depreciation and amortization expense was $15,000 and $20,000, respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140399532165072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Arrangements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Arrangements</a></td>
<td class="text"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(5)&#160;Related Party Arrangements</span></p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Transactions with ARCA&#8217;s Former President and Chief Executive Officer</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA has entered into unrestricted research grants with its former President and Chief Executive Officer&#8217;s academic research laboratory at the University of Colorado. Funding of any unrestricted research grants is contingent upon ARCA&#8217;s financial condition, and can be deferred or terminated at ARCA&#8217;s discretion. There was no expense under these arrangements for the three&#160;months ended March&#160;31, 2024. Total expense under these arrangements for the three&#160;months ended March&#160;31, 2023 was $108,000. In December&#160;2023, ARCA made a payment of $125,000 for the grant period July&#160;2022 through December&#160;2023 under these arrangements. In April&#160;2024, the President and Chief Executive Officer resigned, see Note&#160;10.</p><span></span>
</td>
<td class="text"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(5)&#160;Related Party Arrangements</span></p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Transactions with ARCA&#8217;s President and Chief Executive Officer</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA has entered into unrestricted research grants with its President and Chief Executive Officer&#8217;s academic research laboratory at the University of Colorado. Funding of any unrestricted research grants is contingent upon ARCA&#8217;s financial condition, and can be deferred or terminated at ARCA&#8217;s discretion. Total expense under these arrangements for the&#160;years ended December&#160;31, 2023 and 2022 was $(91,000) and $432,000, respectively. In December&#160;2023, ARCA made a payment of $125,000 for the grant period July&#160;2022 through December&#160;2023 under these arrangements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140399532135584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(6)&#160;Commitments and Contingencies</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA has or is subject to the following commitments and contingencies.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Employment Agreements and Reduction of Workforce</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA maintains employment agreements with several key executive employees. The agreements may be terminated at any time by ARCA with or without cause upon written notice to the employee, and entitle the employee to wages in lieu of notice for periods not exceeding one calendar year from the date of termination without cause or by the employee for good reason. Certain of these agreements also provide for payments to be made under certain conditions related to a change in control of ARCA.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In December&#160;2022, ARCA&#8217;s Board of Directors approved retention bonuses for certain employees, subject to continued employment with ARCA through the earlier of a change in control of ARCA or certain clinical development decisions totaling $265,000. In November&#160;2023, the retention bonuses were amended to increase the aggregate amount of the retention bonus by 50% and in order to assist with tax obligations associated with the vesting of certain Company restricted stock unit awards in December&#160;2023, a total of $86,000 was paid in December&#160;2023. As of March&#160;31, 2024, the unpaid retention bonuses totaled $311,000, none of which was accrued as of March&#160;31, 2024, since there had not been a change in control or clinical development decision. In April&#160;2024, the retention bonuses were again amended to increase the aggregate amount of the retention bonus, with the unpaid retention bonus increasing to $444,000. See Note&#160;10.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA and Christopher D.&#160;Ozeroff, the former Secretary, Senior Vice President and General Counsel of ARCA mutually agreed to conclude Mr.&#160;Ozeroff&#8217;s employment effective March&#160;31, 2023. Pursuant to Mr.&#160;Ozeroff&#8217;s existing employment agreement, as previously amended, ARCA provided Mr.&#160;Ozeroff severance benefits pursuant to the terms </p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">of his existing employment agreement with ARCA, as previously amended. The severance benefits included severance payments and reimbursement to cover out<span class="nobreak">-of-pocket</span> costs to continue group health insurance benefits under COBRA, whether he elects or is eligible to receive COBRA.&#160;During the year ended December&#160;31, 2023, ARCA recorded an expense of $159,000 for these severance benefits, <span style="-sec-ix-hidden: hidden-fact-115">none</span> of which remains unpaid.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA and Dr.&#160;Michael Bristow, former President, Chief Executive Officer and a member of the board of directors of ARCA mutually agreed to conclude Dr.&#160;Bristow&#8217;s employment and service as a director, effective April&#160;3, 2024. See Note&#160;10.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Operating Leases</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On August&#160;29, 2020 ARCA entered into a lease agreement for approximately 5,200 square feet of office facilities in Westminster, Colorado which serves as its primary business office effective October&#160;1, 2020 (&#8220;October&#160;2020 Lease&#8221;). The lease term was 42&#160;months beginning October&#160;1, 2020. In March&#160;2024, ARCA entered into an amendment to extend the lease term six (6)&#160;months through September&#160;2024. If ARCA elects to stay in the property after September&#160;2024, it will pay rent month to month equal to 125% of the base rent paid in September&#160;2024. In June&#160;2021, ARCA entered into a sublease agreement for approximately 3,000 square feet of additional office facilities in its primary business office (&#8220;2021 Lease&#8221;). The sublease term was 29&#160;months and terminated in October&#160;2023. The leases include real estate taxes and insurance, which is not a lease component and is not included in the lease obligation. In addition, common area maintenance charges are based on actual costs incurred and are a non<span class="nobreak">-lease</span> component that is not included in the lease obligation.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Future minimum commitments due under the October&#160;2020 Lease agreement, as amended, as of March&#160;31, 2024 are as follows (in thousands):</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2024</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">49</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total remaining lease payments</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">49</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Less: imputed lease interest</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(1</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Less: Current portion</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(48</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Operating lease liability, net of current portion</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-114; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>

		</table>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Rent expense, which is included in general and administrative expense, for the three&#160;months ended March&#160;31, 2024 and 2023 was $22,000 and $31,000, respectively.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of March&#160;31, 2024, the lease liability was $48,000, it is all current and is included in accrued expenses and other liabilities in the accompanying balance sheet. Cash paid for amounts included in the measurement of lease liabilities and the operating cash flows from operating leases for the three&#160;months ended March&#160;31, 2024 and 2023 were $23,000 and $33,000, respectively. The weighted<span class="nobreak">-average</span> remaining lease term for the operating lease as of March&#160;31, 2024 is 0.5&#160;years. The discount rate for the operating lease is 7%.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Patent Agreement</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In July&#160;2021, ARCA entered into a patent assignment agreement (the &#8220;Agreement&#8221;) with the University Medical Center of Johannes Gutenberg University Mainz, Germany.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Under the terms of the Agreement, ARCA received exclusive world<span class="nobreak">-wide</span> patent rights relating to the use of rNAPc2 as a potential treatment for COVID<span class="nobreak">-19</span>, and other indications, based on the research and discoveries from Univ.<span class="nobreak">-Prof</span>. Dr.&#160;Wolfram Ruf, the Scientific Director and Alexander von Humboldt Professor at the Center for Thrombosis and Hemostasis (&#8220;CTH&#8221;) of the University Medical Center Mainz, and his collaborators. ARCA has upfront and potential milestone obligations to the University Medical Center Mainz that could total approximately &#8364;1.6&#160;million and royalty obligations in the low single digit range, if rNAPc2 receives regulatory approval and is commercialized. The term of the Agreement extends to the date of expiration of the last to expire of any of the assigned patents.</p><span></span>
</td>
<td class="text"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(6)&#160;Commitments and Contingencies</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA has or is subject to the following commitments and contingencies:</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Employment Agreements and Reduction of Workforce</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA maintains employment agreements with several key executive employees. The agreements may be terminated at any time by ARCA with or without cause upon written notice to the employee, and entitle the employee to wages in lieu of notice for periods not exceeding one calendar year from date of termination without cause or by the employee for good reason. Certain of these agreements also provide for payments to be made under certain conditions related to a change in control of ARCA.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In December&#160;2022, ARCA&#8217;s Board of Directors approved retention bonuses for certain employees, subject to continued employment with ARCA through the earlier of a change in control of ARCA or certain clinical development decisions totaling $265,000. In November&#160;2023, the retention bonuses were amended to increase the aggregate amount of the retention bonus by 50% and in order to assist with tax obligations associated with the vesting of certain Company restricted stock unit awards in December&#160;2023, a total of $86,000 was paid in December&#160;2023. As of December&#160;31, 2023, the unpaid retention bonuses totaled $311,000, none of which was accrued as of December&#160;31, 2023, since there had not been a change in control or clinical development decision.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA and Christopher D.&#160;Ozeroff, the Secretary, Senior Vice President and General Counsel of ARCA mutually agreed to conclude Mr.&#160;Ozeroff&#8217;s employment effective March&#160;31, 2023. Pursuant to Mr.&#160;Ozeroff&#8217;s existing employment agreement, as previously amended, ARCA will provide Mr.&#160;Ozeroff severance benefits pursuant to the terms of his existing employment agreement with ARCA, as previously amended. The severance benefits include severance payments and reimbursement to cover out<span class="nobreak">-of-pocket</span> costs to continue group health insurance benefits under COBRA, whether he elects or is eligible to receive COBRA (provided, that even if he does not elect or is not eligible to receive COBRA, he will receive the equivalent of such out<span class="nobreak">-of-pocket</span> expenses paid by him not to exceed the costs that the benefits would equal under COBRA if he were so eligible). During the year ended December&#160;31, 2023, ARCA recorded an expense of $159,000 for these severance benefits, <span style="-sec-ix-hidden: hidden-fact-75">none</span> of which remains unpaid.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In 2022, ARCA implemented a strategic reduction of the workforce by approximately 67%, or 12 employees. Personnel reductions were primarily focused in research and development and general and administrative functions. The restructuring was a result of ARCA&#8217;s decision to manage operating costs and expenses. During the year ended December&#160;31, 2022, ARCA recorded total restructuring charges of approximately $755,000, of which $470,000 and $285,000 were recognized in research and development and general and administrative expenses, respectively, in connection with the restructuring, all in the form of one<span class="nobreak">-time</span> termination benefits, none of which remains unpaid.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Operating Lease</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On August&#160;29, 2020 ARCA entered into a lease agreement for approximately 5,200 square feet of office facilities in Westminster, Colorado which serves as ARCA&#8217;s primary business office effective October&#160;1, 2020 (&#8220;October&#160;2020 Lease&#8221;). The lease term is 42&#160;months beginning October&#160;1, 2020 and includes an option to renew for an additional 36<span class="nobreak"> </span>month term at the then prevailing rental rate. The exercise of the lease renewal option is at ARCA&#8217;s sole discretion. The amounts recorded assume ARCA will exercise its renewal option. In June&#160;2021, ARCA entered into a sublease agreement for approximately 3,000 square feet of additional office facilities in its primary business office (&#8220;2021 Lease&#8221;). The sublease term was 29&#160;months and terminated in October&#160;2023. The leases include real estate taxes and insurance, which is not a lease component and is not included in the lease obligation. In addition, common area maintenance charges are based on actual costs incurred and are a non<span class="nobreak">-lease</span> component that is not included in the lease obligation.</p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Future minimum commitments due under the October&#160;2020 Lease agreement as of December&#160;31, 2023 are as follows (in thousands):</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2024</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">93</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2025</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">96</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2026</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">100</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2027</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">25</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total remaining lease payments</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">314</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Less: imputed lease interest</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(34</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Less: Current portion</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(76</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Operating lease liability, net of current portion</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">204</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>

		</table>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Rent expense, which is included in general and administrative expense, under these leases for the&#160;years ended December&#160;31, 2023 and 2022 was $119,000 and $125,000, respectively.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of December&#160;31, 2023, the lease liability was $280,000 and the current portion is included in accrued expenses and other liabilities and the non<span class="nobreak">-current</span> portion is in operating lease liability, net of current portion in the accompanying balance sheet. Cash paid for amounts included in the measurement of lease liabilities and the operating cash flows from operating leases for the&#160;years ended December&#160;31, 2023 and 2022 were $127,000 and $131,000, respectively. The weighted<span class="nobreak">-average</span> remaining lease term for the operating lease as of December&#160;31, 2023 is 3.2&#160;years. The weighted<span class="nobreak">-average</span> discount rate for the operating lease is 7%.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Patent Agreement</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In July&#160;2021, ARCA entered into a patent assignment agreement (the &#8220;Agreement&#8221;) with the University Medical Center of Johannes Gutenberg University Mainz, Germany.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Under the terms of the Agreement, ARCA received exclusive world<span class="nobreak">-wide</span> patent rights relating to the use of rNAPc2 as a potential treatment for COVID<span class="nobreak">-19</span>, and other indications, based on the research and discoveries from Univ.<span class="nobreak">-Prof</span>. Dr.&#160;Wolfram Ruf, the Scientific Director and Alexander von Humboldt Professor at the Center for Thrombosis and Hemostasis (&#8220;CTH&#8221;) of the University Medical Center Mainz, and his collaborators. ARCA has upfront and potential milestone obligations to the University Medical Center Mainz that could total approximately &#8364;1.6&#160;million and royalty obligations in the low single digit range, if rNAPc2 receives regulatory approval and is commercialized. The term of the Agreement extends to the date of expiration of the last to expire of any of the assigned patents.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Gencaro License</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA has licensed worldwide rights to all preclinical and clinical data through the BEST trial for development of bucindolol. The patents that were the subject of this license are expired. If the license agreement is deemed enforceable, ARCA would incur milestone and royalty obligations upon the occurrence of certain events, including if the FDA grants marketing approval for Gencaro, upon regulatory marketing approval in Europe and Japan and based on achievement of specified product sales levels.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140399532159280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Financings<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity Financings [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Equity Financings</a></td>
<td class="text"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(7)&#160;</span><span class="BoldItalic" style="font-style:italic;font-weight:bold;font-style:normal;font-weight:bold;">Equity Financings</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;margin-top:8pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">At the Market Equity Financing</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In 2020, ARCA entered into a Capital on Demand&#8482; Sales Agreement (the &#8220;Sales Agreement&#8221;) with JonesTrading Institutional Services LLC, as agent (&#8220;JonesTrading&#8221;), pursuant to which ARCA may offer and sell, from time to time through JonesTrading, shares of ARCA&#8217;s common stock, par value $0.001 per share (&#8220;ARCA common stock&#8221;).</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In 2021, ARCA amended the 2020 Sales Agreement and the amount available for the offering under its prospectus to ARCA&#8217;s registration statement on Form&#160;S<span class="nobreak">-3</span> (No.&#160;333<span class="nobreak">-254585</span>), which expired in March&#160;2024. In April&#160;2024, ARCA terminated the Sales Agreement in accordance with its terms.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">No sales were made under the Sales Agreement in 2024 or 2023.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Merger Agreement</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">See &#8220;Financing Transaction&#8221; discussion in Note&#160;10 below.</p><span></span>
</td>
<td class="text"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(7)&#160;Equity Financings</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">At the Market Equity Financing</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On July&#160;22, 2020, ARCA entered into a Capital on Demand<span class="Superscript" style="vertical-align:super;font-size:58%;">TM</span> Sales Agreement (the &#8220;Sales Agreement&#8221;) with JonesTrading Institutional Services LLC, as agent (&#8220;JonesTrading&#8221;), pursuant to which ARCA may offer and sell, from time to time through JonesTrading, shares of ARCA&#8217;s common stock, par value $0.001 per share (&#8220;ARCA&#160;common stock&#8221;), having an aggregate offering price of up to $54.0&#160;million (the &#8220;Shares&#8221;).</p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Under the Sales Agreement, JonesTrading may sell the Shares by any method permitted by law and deemed to be an &#8220;at the market offering&#8221; as defined in Rule&#160;415 promulgated under the Securities Act&#160;of&#160;1933, as amended, including sales made directly on or through the Nasdaq Capital Market, on any other existing trading market for ARCA common stock or to or through a market maker. In addition, under the amended Sales Agreement, JonesTrading may sell the Shares by any other method permitted by law, including in negotiated transactions. ARCA may instruct JonesTrading not to sell Shares if the sales cannot be effected at or above the price designated by ARCA from time to time.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA is not obligated to make any sales of the Shares under the Sales Agreement. The offering of Shares pursuant to the Sales Agreement will terminate upon the earlier of (a)&#160;the sale of all of the Shares subject to the Sales Agreement or (b)&#160;the termination of the Sales Agreement by JonesTrading or ARCA, as permitted therein.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA paid JonesTrading a commission rate equal to 3.0% of the aggregate gross proceeds from each sale of Shares and agreed to provide JonesTrading with customary indemnification and contribution rights. ARCA will also reimburse JonesTrading for certain specified expenses in connection with entering into the Sales Agreement.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">No sales were made in 2023 or 2022.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In April&#160;2021, ARCA amended the 2020 Sales Agreement and the amount available for the offering under its prospectus to ARCA&#8217;s registration statement on Form&#160;S<span class="nobreak">-3</span> (No.&#160;333<span class="nobreak">-254585</span>). The amount available for the offering under the prospectus supplement is subject to the limitation of not selling a total value amount of shares exceeding more than one<span class="nobreak">-third</span> of ARCA&#8217;s public float in any 12<span class="nobreak">-month</span> period.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140399532222368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Compensation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-based Compensation</a></td>
<td class="text"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(8)&#160;Share-based Compensation</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;orphans:99;widows:1;margin-top:8pt;">For the three&#160;months ended March&#160;31, 2024 and 2023, ARCA recognized the following non<span class="nobreak">-cash</span>, share<span class="nobreak">-based</span> compensation expense in the statements of operations (in thousands):</p>
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-11" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="5" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Three&#160;Months Ended<br/>March&#160;31,</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2024</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">General and administrative</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">114</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">163</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Research and development</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-116; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">41</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">114</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">204</p>	</td>
				</tr>

		</table>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Stock option transactions for the three&#160;months ended March&#160;31, 2024 under ARCA&#8217;s stock incentive plans were as follows:</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">	<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 46.15%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Options Outstanding</span></p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-15" style="height:12pt;">	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Number of<br/>Options</span></p>	</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Weighted<br/>Average<br/>Exercise<br/>Price</span></p>	</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term<br/>(in&#160;years)</span></p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Options outstanding&#160;&#8211;&#160;December&#160;31, 2023</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">616,707</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4.76</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">7.35</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Granted</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">42,000</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1.64</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Exercised</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-117; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-118; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Forfeited and cancelled</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(12,862</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">17.45</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Options outstanding&#160;&#8211;&#160;March&#160;31, 2024</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">645,845</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4.30</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">6.82</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Options exercisable&#160;&#8211;&#160;March&#160;31, 2024</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">502,517</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4.71</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">6.55</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Options vested and expected to vest&#160;&#8211;&#160;March&#160;31, 2024</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">645,816</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4.30</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">6.82</p>	</td>	</tr>	</table><span></span>
</td>
<td class="text"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(8)&#160;Share-based Compensation</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Stock Plans</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s equity incentive plan, <span class="Italic" style="font-style:italic;font-weight:normal;">the 2020 Equity Incentive Plan </span>(the &#8220;Equity Plan&#8221;),<span class="Italic" style="font-style:italic;font-weight:normal;"> </span>was approved by stockholders on December&#160;10, 2020. The maximum number of shares issuable under this plan is 1,167,425<span class="nobreak"> </span>shares.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Equity Plan provides for the granting of stock options (including indexed options), restricted stock units, stock appreciation rights, restricted stock purchase rights, restricted stock bonuses, performance shares, performance units and deferred stock units. Under the Equity Plan, awards may be granted to employees, directors and consultants of ARCA, except for incentive stock options, which may be granted only to employees. As of December&#160;31, 2023, options to purchase 601,900<span class="nobreak"> </span>shares with a weighted average exercise price of $3.45 per share were outstanding under the Equity Plan, and 459,718<span class="nobreak"> </span>shares were reserved for future awards.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In general, the Equity Plan authorizes the grant of stock options that vest at rates set by the Board of Directors or the Compensation Committee thereof. Generally, stock options granted by ARCA under the equity incentive plans become exercisable ratably for a period of <span style="-sec-ix-hidden: hidden-fact-97">three</span> to <span style="-sec-ix-hidden: hidden-fact-98">four</span>&#160;years from the date of grant and have a maximum term of <span style="-sec-ix-hidden: hidden-fact-99">ten</span>&#160;years. The exercise prices of stock options under the equity incentive plan generally meet the following criteria: the exercise price of incentive stock options must be at least 100% of the fair market value on the grant date and exercise price of options granted to 10% (or greater) stockholders must be at least 110% of the fair market value on the grant date.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In conjunction with the adoption of the Equity Plan, ARCA discontinued grants under the 2013 Plan, effective December&#160;10, 2020. As of December&#160;31, 2023, options to purchase 14,807<span class="nobreak"> </span>shares with a weighted average exercise price of $57.73 per share were outstanding under the 2013 plan.</p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA did not grant options in 2023. ARCA granted options to purchase an aggregate of 60,000<span class="nobreak"> </span>shares of ARCA common stock in the year ended December&#160;31, 2022. The fair values of employee stock options granted in the year ended December&#160;31, 2022 were estimated at the date of grant using the Black<span class="nobreak">-Scholes</span> model with the following assumptions and had the following estimated weighted average grant date fair value per share:</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">	<tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;">	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Year Ended<br/>December&#160;31,<br/>2022</span></p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Expected term</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5.5&#160;years</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Expected volatility</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">107</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Risk-free interest rate</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3.56</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Expected dividend yield</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">0</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Weighted-average grant date fair value per share</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1.87</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	</tr>	</table>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">A summary of ARCA&#8217;s stock option activities for the&#160;years ended December&#160;31, 2023 and 2022, and related information as of December&#160;31, 2023, is as follows:</p>
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">	<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" colspan="10" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 61.11%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Options Outstanding</span></p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-17" style="height:12pt;">	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Number of<br/>Options</span></p>	</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Weighted<br/>Average<br/>Exercise<br/>Price</span></p>	</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term (in&#160;years)</span></p>	</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Aggregate<br/>Intrinsic Value<br/>(in thousands)</span></p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Options outstanding&#160;&#8211;&#160;December&#160;31,&#160;2021</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">904,123</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5.59</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Granted</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">60,000</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2.31</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Exercised</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-76; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-77; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Forfeited and cancelled</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(259,163</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4.74</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Options outstanding&#160;&#8211;&#160;December&#160;31,&#160;2022</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">704,960</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5.62</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">8.29</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">18</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Granted</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-78; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-79; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Exercised</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-80; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-81; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Forfeited and cancelled</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(88,253</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">11.68</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Options outstanding&#160;&#8211;&#160;December&#160;31,&#160;2023</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">616,707</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4.76</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">7.35</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-82; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Options exercisable&#160;&#8211;&#160;December&#160;31,&#160;2023</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">463,068</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5.28</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">7.29</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-83; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-18" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Options vested and expected to vest&#160;&#8211;&#160;December&#160;31,&#160;2023</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">616,661</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4.76</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">7.35</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-84; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>	</td>	</tr>	</table>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The aggregate intrinsic value in the table above represents the total intrinsic value, based on ARCA&#8217;s closing price as of December&#160;31 of the respective year, which would have been received by the option holders had all the option holders with in<span class="nobreak">-the-money</span> options exercised as of that date. As of December&#160;31, 2023, the unrecognized compensation expense related to unvested options, excluding estimated forfeitures, was $367,000 which is expected to be recognized over a weighted average period of 1.1&#160;years. ARCA recognizes compensation costs for its share<span class="nobreak">-based</span> awards on a straight<span class="nobreak">-line</span> basis over the requisite service period for the entire award, as adjusted for expected forfeitures.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Restricted Stock Units</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA granted restricted stock units (&#8220;RSUs&#8221;) under the Equity Plan to employees during 2022. The fair value of RSU awards is the closing price of ARCA common stock on the date of the grant and is recognized as compensation expense on a straight<span class="nobreak">-line</span> basis over the respective vesting period. The stock awards granted had a requisite service period of <span style="-sec-ix-hidden: hidden-fact-100">one</span> year.</p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">A summary of RSU activity for the year ended December&#160;31, 2023 is presented below:</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="5" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Restricted Stock Units<br/>Outstanding</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-19" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Number of<br/>Shares</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Weighted<br/>Average<br/>Grant Date<br/>Fair Value</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">RSUs outstanding&#160;&#8211;&#160;December&#160;31, 2021</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-85; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-86; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Granted</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">91,000</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2.21</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Vested and released</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-87; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-88; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Forfeited and cancelled</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-89; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-90; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">RSUs outstanding&#160;&#8211;&#160;December&#160;31, 2022</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">91,000</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2.21</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Granted</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-91; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-92; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Vested and released</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(91,000</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2.21</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Forfeited and cancelled</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-93; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-94; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">RSUs outstanding&#160;&#8211;&#160;December&#160;31, 2023</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-95; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-96; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>

		</table>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of December&#160;31, 2023, there was no unrecognized compensation cost related to unvested stock awards.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Non-cash Stock-based Compensation</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">For the&#160;years ended December&#160;31, 2023 and 2022, ARCA recognized the following non<span class="nobreak">-cash</span>, share<span class="nobreak">-based</span> compensation expense (in thousands):</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="5" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Years Ended<br/>December&#160;31,</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2022</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">General and administrative</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">526</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">423</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Research and development</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">160</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">133</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">686</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">556</p>	</td>
				</tr>

		</table>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA did not recognize any tax benefit related to employee stock<span class="nobreak">-based</span> compensation cost as a result of the full valuation allowance on its net deferred tax assets.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140399532171360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Employee Benefit Plans [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Employee Benefit Plans</a></td>
<td class="text"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(9)&#160;Employee Benefit Plans</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA has a 401(k)&#160;plan and makes a matching contribution equal to 100% of the employee&#8217;s first 3% of the employee&#8217;s contributions and 50% of the employee&#8217;s next 2% of contributions. ARCA adopted the plan in 2006 and contributed $56,000 and $96,000 for the&#160;years ended December&#160;31, 2023 and 2022, respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480794/715-70-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/715/tableOfContent<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480126/715-20-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480266/715-60-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140399532051952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(9)&#160;Income Taxes</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In accordance with GAAP, a valuation allowance should be provided if it is more likely than not that some or all of ARCA&#8217;s deferred tax assets will not be realized. ARCA&#8217;s ability to realize the benefit of its deferred tax assets will depend on the generation of future taxable income. Due to the uncertainty of future profitable operations and taxable income, ARCA has recorded a full valuation allowance against its net deferred tax assets. ARCA believes its tax filing positions and deductions related to tax periods subject to examination will be sustained upon audit and, therefore, has <span style="-sec-ix-hidden: hidden-fact-119">no</span> reserve for uncertain tax positions.</p><span></span>
</td>
<td class="text"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;">(<span class="Bold" style="font-style:normal;font-weight:bold;">10)&#160;Income Taxes</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Effective June&#160;1, 2005, ARCA changed from an S<span class="nobreak">-Corporation</span> to a C<span class="nobreak">-Corporation</span>. As an S<span class="nobreak">-Corporation</span>, the net operating loss carryforwards were distributed to ARCA&#8217;s stockholders; such amounts were not significant. As of December&#160;31, 2023, ARCA has net operating loss carryforwards of approximately $208.1&#160;million, and approximately $2.4&#160;million of research and development credits that may be used to offset future taxable income. ARCA&#8217;s net operating loss carryforwards through December&#160;31, 2017 will expire beginning <span style="-sec-ix-hidden: hidden-fact-107">2025</span> through <span style="-sec-ix-hidden: hidden-fact-108">2037</span>. The net operating loss carryforwards beginning in 2018, have no expiration. Utilization of net operating losses and tax credits, including those acquired as a result of the Merger, will be subject to an annual limitation due to ownership change limitations provided by Internal Revenue Code Section&#160;382. ARCA believes that an ownership change limitation as defined under Section&#160;382 of the U.S.&#160;Internal Revenue Code occurred as a result of its various historical financing transactions. Future utilization of the federal net operating losses and tax credit </p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">carryforwards accumulated from June&#160;2005 to the change in ownership date will be subject to annual limitations to offset future taxable income. The annual limitation may result in the expiration of the net operating losses and credits before utilization. As such, a portion of ARCA&#8217;s net operating loss carryforwards may be limited.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the period in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. Due primarily to ARCA&#8217;s history of operating losses, management is unable to conclude that it is more likely than not that ARCA will realize the benefits of these deductible differences, and accordingly has provided a valuation allowance against the entire net deferred tax assets and liabilities of approximately $55.5&#160;million at December&#160;31, 2023, reflecting an increase of approximately $1.2&#160;million from December&#160;31, 2022. The deferred tax assets are primarily comprised of net operating loss carryforwards and research and experimentation credit carryforwards. As of December&#160;31, 2023, ARCA has not performed an Internal Revenue Code Section&#160;382 limitation study. Depending on the outcome of such a study, the gross amount of net operating losses recognizable in future tax periods could be limited. A limitation in the carryforwards would decrease the carrying amount of the gross amount of the net operating loss carryforwards, with a corresponding decrease in the valuation allowance recorded against these gross deferred tax assets.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Income tax benefit attributable to ARCA&#8217;s loss from operations before income taxes differs from the amounts computed by applying the U.S.&#160;federal statutory income tax rate of 21% for 2023 and 2022, as a result of the following (in thousands):</p>
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Years ended<br/>December&#160;31,</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2022</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">U.S.&#160;federal income tax benefit at statutory rates</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(1,121</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(2,085</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">State income tax benefit, net of federal benefit</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(192</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(357</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Research and experimentation credits</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-101; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-102; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Deferred tax asset adjustment</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">47</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">107</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">186</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Change in valuation allowance</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,159</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,254</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Income tax benefit</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-103; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-104; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>

		</table><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting and the amounts used for income tax purposes, as well as operating loss and tax credit carryforwards. The income tax effects of temporary differences and carryforwards that give rise to significant portions of ARCA&#8217;s net deferred tax assets and liabilities consisted of the following (in thousands):</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">As of December&#160;31,</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2022</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Deferred tax assets:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net operating loss carryforwards</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">51,190</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">50,008</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Charitable contribution carryforwards</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">371</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">393</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Research and experimentation credits</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,420</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,420</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Capitalized research and development costs</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">951</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">979</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Capitalized intangibles</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">354</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">356</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Stock-based compensation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">232</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">205</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accrued compensation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">7</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">6</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Lease liabilities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">69</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">94</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total deferred tax assets</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">55,594</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">54,461</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Valuation allowance</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(55,531</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(54,372</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Deferred tax assets, net of valuation allowance</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">63</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">89</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Deferred tax liabilities:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Right-of-use asset</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(61</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(84</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Depreciation and amortization</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(2</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(5</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net deferred tax liability</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-105; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-106; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>

		</table>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Since ARCA is in a loss carryforward position, it is generally subject to U.S.&#160;federal and state income tax examinations by tax authorities for all&#160;years for which a loss carryforward is available. Thus, ARCA&#8217;s open tax&#160;years extend back to <span style="-sec-ix-hidden: hidden-fact-109">2009</span>. ARCA believes that its tax filing positions and deductions related to tax periods subject to examination will be sustained upon audit and does not anticipate any adjustment will result in a material adverse effect on ARCA&#8217;s financial condition, result of operations, or cash flow. For the&#160;years ended December&#160;31, 2023 and 2022, ARCA has no reserve for uncertain tax positions. ARCA does not expect that the total amounts of unrecognized tax benefits will significantly increase or decrease within the subsequent twelve&#160;months. In the event ARCA concludes it is subject to interest or penalties arising from uncertain tax positions, it will record interest and penalties as a component of other income and expense. No interest or penalties were recognized in the financial statements for the&#160;years ended December&#160;31, 2023 and 2022.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140399532232768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(10)&#160;Subsequent Events</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Merger Agreement</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On April&#160;3, 2024, ARCA, Merger Sub&#160;I, Merger Sub&#160;II and Oruka, entered into the Merger Agreement, pursuant to which, among other matters, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Merger Sub&#160;I will merge with and into Oruka, with Oruka continuing as a wholly owned subsidiary of ARCA and the surviving corporation of the merger and as part of the same overall transaction, the surviving corporation in the First Merger will merge with and into Merger Sub&#160;II with Merger Sub&#160;II continuing as a wholly owned subsidiary of ARCA and the surviving entity of the merger. The Merger is intended to qualify for federal income tax purposes as a tax<span class="nobreak">-free</span> reorganization under the provisions of Section&#160;368(a)&#160;of the Internal Revenue Code of 1986, as amended.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Subject to the terms and conditions of the Merger Agreement, at the closing of the First Merger, (a)&#160;each then<span class="nobreak">-outstanding</span> share of Oruka common stock (including shares of Oruka common stock issued in the financing transaction described below) will be converted solely into the right to receive a number of shares of ARCA common stock calculated in accordance with the Merger Agreement (the &#8220;Exchange Ratio&#8221;), (b)&#160;each then<span class="nobreak">-outstanding</span> share of Oruka preferred stock will be converted into the right to receive a number of shares of Series&#160;B Preferred Stock (as defined below) of ARCA, calculated in accordance with the Merger Agreement (c)&#160;each then<span class="nobreak">-outstanding</span> option to purchase Oruka common stock will be assumed by ARCA, subject to adjustment as set forth in the Merger Agreement and (d)&#160;each then<span class="nobreak">-outstanding</span> warrant to purchase shares of Oruka common stock will be converted into a warrant to purchase shares of ARCA common stock, subject to adjustment as set forth in the Merger Agreement and form of warrant. Under the terms of the Merger Agreement, prior to the closing of the transaction, the Board will accelerate the vesting of all equity awards of ARCA then outstanding but not then vested or exercisable, and cancel each option (the &#8220;Out of the Money Options&#8221;) to acquire shares of ARCA common stock with an exercise price per share greater than the volume weighted average closing trading price of a share of ARCA common stock on The Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;) for the five (5)&#160;consecutive&#160;trading days ending three (3)&#160;days immediately prior to the closing date of the First Merger (the &#8220;Parent Closing Price&#8221;), in each case, in accordance with the terms of the Merger Agreement. At the closing of the First Merger, each option to acquire shares of ARCA common stock with an exercise price less than or equal to the Parent Closing Price will be cancelled and converted into the right to receive an amount in cash, without interest, equal to the Parent Closing Price less the exercise price of such option.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Under the Exchange Ratio formula in the Merger Agreement, upon the closing of the First Merger, on a pro forma basis and based upon the number of shares of ARCA common stock expected to be issued in the First Merger, pre<span class="nobreak">-First</span> Merger Oruka stockholders (including Oruka stockholders issued shares of Oruka common stock and pre<span class="nobreak">-funded</span> warrants in the financing transaction described below) will own approximately 97.62% of the combined company and pre<span class="nobreak">-First</span> Merger ARCA stockholders will own approximately 2.38% of the combined company. For purposes of calculating the Exchange Ratio, (i)&#160;shares of ARCA common stock underlying warrants and other rights to receive shares (other than Options to acquire shares of ARCA common stock, to the extent cancelled at or prior to closing of the First Merger in accordance with the Merger Agreement) outstanding as of immediately prior to the closing of the First Merger will be deemed to be outstanding, and (ii)&#160;all shares of Oruka common stock underlying outstanding Oruka stock options and warrants will be deemed to be outstanding. The Exchange Ratio will be </p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">adjusted to the extent that ARCA&#8217;s net cash at closing is less than $5.0&#160;million and will be based on the amount of proceeds actually received by Oruka in the financing transaction described below, as further described in the Merger Agreement.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, prior to the closing of the First Merger, ARCA expects to declare a cash dividend to the pre<span class="nobreak">-First</span> Merger ARCA stockholders equal in the aggregate to ARCA&#8217;s reasonable, good faith approximation of the amount by which ARCA&#8217;s net cash (as determined pursuant to the Merger Agreement) will exceed $5,000,000.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In connection with the Merger, ARCA is required to seek the approval of its stockholders to, among other things, (a)&#160;issue shares of ARCA common stock issuable in connection with the First Merger (including the shares of ARCA common stock issuable under the Series&#160;B Preferred Stock) under the rules of Nasdaq, and (b)&#160;amend its amended and restated certificate of incorporation, to (i)&#160;effect a reverse stock split of ARCA common stock (if deemed necessary by ARCA and Oruka), (ii)&#160;increase the number of shares of ARCA common stock that ARCA is authorized to issue, and (iii)&#160;such other changes as are mutually agreeable to ARCA and Oruka (the &#8220;ARCA Voting Proposals&#8221;).</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Each of ARCA and Oruka has agreed to customary representations, warranties and covenants in the Merger Agreement, including, among others, covenants relating to (1)&#160;using commercially reasonable efforts to obtain the requisite approval of its stockholders, (2)&#160;non<span class="nobreak">-solicitation</span> of alternative acquisition proposals, (3)&#160;the conduct of their respective businesses during the period between the date of signing the Merger Agreement and the closing of the Merger, (4)&#160;ARCA using commercially reasonable efforts to maintain the existing listing of the ARCA common stock on Nasdaq and cause the shares of ARCA common stock to be issued in connection with the First Merger to be approved for listing on Nasdaq prior to the closing of the First Merger, and (5)&#160;ARCA filing with the U.S.&#160;Securities and Exchange Commission (the &#8220;SEC&#8221;) and causing to become effective a registration statement to register shares of ARCA common stock to be issued in connection with the First Merger, except as set forth in the Merger Agreement (the &#8220;Registration Statement&#8221;).</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Consummation of the Merger is subject to certain closing conditions, including, among other things, (1)&#160;approval by ARCA stockholders of the ARCA Voting Proposals, (2)&#160;approval by the requisite Oruka stockholders of the adoption and approval of the Merger Agreement and the transactions contemplated thereby, (3)&#160;Nasdaq&#8217;s approval of the initial listing application to be submitted in connection with the First Merger, (4)&#160;the effectiveness of the Registration Statement, (5)&#160;the expiration of any applicable waiting periods (or extensions thereof) under the Hart Scott<span class="nobreak">-Rodino</span> Antitrust Improvements Act&#160;of&#160;1976, as amended, (6)&#160;the subscription agreements (described below) being in full force and effect providing for the receipt of proceeds of not less than $175,000,000 (including in the proceeds any notes contributed as consideration in the financing transaction described below) and (7)&#160;to the extent ARCA has declared the cash dividend described above, ARCA delivering the aggregate amount distributable to the pre<span class="nobreak">-First</span> Merger ARCA stockholders to ARCA&#8217;s transfer agent for further distribution to the pre<span class="nobreak">-First</span> Merger ARCA stockholders. Each party&#8217;s obligation to consummate the Merger is also subject to other specified customary conditions, including regarding the accuracy of the representations and warranties of the other party, subject to the applicable materiality standard, and the performance in all material respects by the other party of its obligations under the Merger Agreement required to be performed on or prior to the date of the closing of the Merger.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Merger Agreement contains certain termination rights of each of ARCA and Oruka. Upon termination of the Merger Agreement under specified circumstances, ARCA and Oruka may each be required to pay the other party a termination fee of $440,000.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Pursuant to a Certificate of Designation of Preferences, Rights and Limitations of the Series&#160;B Non<span class="nobreak">-Voting</span> Convertible Preferred Stock to be filed by ARCA with the Secretary of State of the State of Delaware (the &#8220;Certificate of Designation&#8221;) in connection with the Merger Agreement and the transactions thereunder, ARCA will establish the terms of a new series of preferred stock of ARCA designated as Series&#160;B Non<span class="nobreak">-Voting</span> Convertible Preferred Stock, par value $0.001 per share (the &#8220;Series&#160;B Preferred Stock&#8221;). Holders of the Series&#160;B Preferred Stock will be entitled to receive dividends on shares of Series&#160;B Preferred Stock equal to, on an as<span class="nobreak">-if-converted-to-ARCA</span> common stock </p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">basis, and in the same form as dividends actually paid on shares of the ARCA common stock. Except as otherwise required by the Certificate of Designation or law, the Series&#160;B Preferred Stock will not have voting rights. However, as long as any shares of Series&#160;B Preferred Stock are outstanding, ARCA will not, without the affirmative vote of the holders of a majority of the then outstanding shares of the Series&#160;B Preferred Stock, (a)&#160;alter or change adversely the powers, preferences or rights given to the Series&#160;B Preferred Stock, (b)&#160;alter or amend the Certificate of Designation, (c)&#160;amend its certificate of incorporation, bylaws or other charter documents in any manner that adversely affects any rights of the holders of the Series&#160;B Preferred Stock, (d)&#160;file any articles of amendment, certificate of designations, preferences, limitations and relative rights of any series of Preferred Stock (as defined in the Certificate of Designation), if such action would adversely alter or change the preferences, rights, privileges or powers of, or restrictions provided for the benefit of the Series&#160;B Preferred Stock, (e)&#160;issue further shares of the Series&#160;B Preferred Stock or increase or decrease (other than by conversion) the number of authorized shares of the Series&#160;B Preferred Stock, (f)&#160;at any time while at least 30% of the originally issued Series&#160;B Preferred Stock remains issued and outstanding, consummate either (A)&#160;a Fundamental Transaction (as defined in the Certificate of Designation) or (B)&#160;any merger or consolidation of ARCA or other business combination in which the stockholders of ARCA immediately before such transaction do not hold at least a majority of the capital stock of ARCA immediately after such transaction, or (f)&#160;enter into any agreement with respect to any of the foregoing. The Series&#160;B Preferred Stock does not have a preference upon any liquidation, dissolution or winding<span class="nobreak">-up</span> of ARCA.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Following the closing of the First Merger, each share of Series&#160;B Preferred Stock then outstanding shall be convertible, at any time and from time to time, at the option of the holder of the Series&#160;B Preferred Stock, into a number of shares equal to 1,000<span class="nobreak"> </span>shares of ARCA common stock, subject to certain limitations, including that a holder of Series&#160;B Preferred Stock is prohibited from converting shares of Series&#160;B Preferred Stock into shares of ARCA common stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than a specified percentage (initially set at 9.99%) of the total number of shares of ARCA common stock issued and outstanding immediately after giving effect to such conversion.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">At the effective time of the First Merger (the &#8220;First Effective Time&#8221;), the combined company&#8217;s board of directors is expected to consist of five (5)&#160;members, all of whom will be designated by Oruka. Upon the closing of the transaction, the combined company will be led by Oruka&#8217;s chief executive officer.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Financing Transaction</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Concurrently with the execution and delivery of the Merger Agreement, certain parties have entered into a subscription agreements with Oruka, pursuant to which they have agreed, subject to the terms and conditions of such agreements, to purchase immediately prior to the consummation of the First Merger, shares of Oruka common stock and pre<span class="nobreak">-funded</span> warrants to purchase shares of Oruka common stock (together, the &#8220;PIPE Securities&#8221;) for an aggregate purchase price of approximately $275.0&#160;million. The consummation of the transactions contemplated by such agreements is conditioned on the satisfaction or waiver of the conditions set forth in the Merger Agreement and in the subscription agreement. Shares of Oruka common stock and pre<span class="nobreak">-funded</span> warrants to purchase shares of Oruka common stock issued pursuant to this financing transaction will be converted into shares of ARCA common stock and pre<span class="nobreak">-funded</span> warrants to acquire shares ARCA common stock, in accordance with the Exchange Ratio and the Merger Agreement.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Separation of Michael Bristow, M.D., President, Chief Executive Officer and Director</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Effective April&#160;3, 2024, ARCA and Dr.&#160;Michael Bristow, President, Chief Executive Officer and a member of the Board mutually agreed to conclude Dr.&#160;Bristow&#8217;s employment and service as a director.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In connection with Dr.&#160;Bristow&#8217;s separation, ARCA and Dr.&#160;Bristow entered into a separation agreement (the &#8220;Separation Agreement&#8221;) on April&#160;3, 2024. Pursuant to the terms of the Separation Agreement, ARCA provided to Dr.&#160;Bristow a lump sum payment equal to (i)&#160;twelve (12)&#160;months of Dr.&#160;Bristow&#8217;s base salary as of the last date of his employment and (ii)&#160;a cash payment of $25,000, less applicable withholdings. The severance benefits were conditioned on the non<span class="nobreak">-revocation</span> by Dr.&#160;Bristow of a legal release of claims.</p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA and Dr.&#160;Bristow entered into a consulting agreement, effective April&#160;3, 2024 (the &#8220;Consulting Agreement&#8221;), pursuant to which Dr.&#160;Bristow is providing certain consulting services provided for in the Consulting Agreement to ARCA until the earlier of (i)&#160;the completion of services under the Consulting Agreement, (ii)&#160;a termination in accordance with the terms of the Consulting Agreement, and (iii)&#160;upon a Change of Control (as defined in ARCA&#8217;s 2020 Equity Incentive Plan (the &#8220;Plan&#8221;)). Pursuant to the Consulting Agreement, Dr.&#160;Bristow provision of services under the Consulting Agreement are deemed to be a Continuous Service (as defined in the Plan) and, as a result, his equity awards under the Plan continue to vest during the term of the Consulting Agreement.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Appointment of Thomas Keuer as President</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Effective as of April&#160;3, 2024, the Board appointed Thomas A.&#160;Keuer, ARCA&#8217;s Chief Operating Officer, to serve as ARCA&#8217;s President and principal executive officer. Mr.&#160;Keuer has been with ARCA since 2006, and as its Chief Operating Officer for the last nine&#160;years, a position he will continue to serve in. Mr.&#160;Keuer will not receive any additional compensation in connection with his appointment as President and principal executive officer. Mr.&#160;Keuer&#8217;s position will end upon closing of the merger transaction with Oruka Therapeutics, Inc. as previously disclosed on a Current Report on Form&#160;8<span class="nobreak">-K</span> filed with the SEC on April&#160;3, 2024.</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Second Amendment to Retention Bonus Letter of Thomas A.&#160;Keuer and C.&#160;Jeffrey Dekker</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On April&#160;20, 2024, the board of directors of ARCA approved the second amendment of certain retention bonus letters between ARCA and each of Thomas A.&#160;Keuer and C.&#160;Jeffrey Dekker to increase the aggregate amount of the retention bonus with respect to each such executive to $200,000. The remaining portion of the retention bonus with respect to Thomas A. Keuer and C. Jeffrey Dekker, consisting of $165,000, will become payable consistent with the original terms of the applicable retention bonus letter and first amendment to retention bonus letter. Any payment related to the retention bonuses of Thomas A. Keuer and C. Jeffrey Dekker will be paid by ARCA via payroll within&#160;30 business days of the date of occurrence of the applicable &#8220;Payment Event Date&#8221; (as such term is otherwise defined in the applicable second amendment to the retention bonus letter). Each such retention bonus letter and first amendment to retention bonus letter will otherwise remain subject to their original terms and conditions.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140399530631904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounting Policies, by Policy (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>ARCA and Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_DescriptionOfBusinessPolicyTextBlock', window );">Description of Business</a></td>
<td class="text"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;margin-top:8pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Description of Business</span></p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA biopharma, Inc. (&#8220;ARCA&#8221;), a Delaware corporation, is headquartered in Westminster, Colorado. ARCA is dedicated to applying a precision medicine approach to the development and commercialization of genetically targeted therapies for cardiovascular diseases. ARCA&#8217;s lead product candidate is Gencaro&#8482; (bucindolol hydrochloride) for the treatment of atrial fibrillation (&#8220;AF&#8221;) in patients with chronic heart failure (&#8220;HF&#8221;).</p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In April&#160;2022, ARCA established a Special Committee of the board of directors (the &#8220;Board&#8221;) of ARCA to conduct a comprehensive review of strategic alternatives. As part of the strategic review process, ARCA explored potential strategic alternatives that included, without limitation, an acquisition, merger, business combination or other transactions. ARCA has and is continuing to explore strategic alternatives related to its product candidates and related assets, including, without limitation, licensing transactions and asset sales.</p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On April&#160;3, 2024, following a comprehensive review of strategic alternatives, ARCA, Atlas Merger Sub Corp., a Delaware corporation and a wholly<span class="nobreak">-owned</span> subsidiary of ARCA (&#8220;Merger Sub&#160;I&#8221;), Atlas Merger Sub&#160;II LLC, a Delaware limited liability company and a wholly<span class="nobreak">-owned</span> subsidiary of ARCA (&#8220;Merger Sub&#160;II&#8221;) and Oruka Therapeutics, Inc., a Delaware corporation (&#8220;Oruka<span class="CharOverride-1" style="text-decoration:underline;">&#8221;</span>), entered into an Agreement and Plan of Merger and Reorganization (the &#8220;Merger Agreement&#8221;), pursuant to which, among other matters, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Merger Sub&#160;I will merge with and into Oruka, with Oruka continuing as a wholly owned subsidiary of ARCA and the surviving corporation of the merger (the &#8220;First Merger&#8221;) and as part of the same overall transaction, the surviving corporation in the First Merger will merge with and into Merger Sub&#160;II with Merger Sub&#160;II continuing as a wholly owned subsidiary of ARCA and the surviving entity of the merger (the &#8220;Second Merger&#8221; and together with the First Merger, the &#8220;Merger&#8221;). The Merger is intended to qualify for federal income tax purposes as a tax<span class="nobreak">-free</span> reorganization under the provisions of Section&#160;368(a)&#160;of the Internal Revenue Code of 1986, as amended.</p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s future operations are highly dependent on the success of the Merger and there can be no assurances that the Merger will be successfully consummated. In the event that ARCA does not complete the Merger, it may explore strategic alternatives, including, without limitation, another strategic transaction and/or pursue a dissolution and liquidation of ARCA. See Note&#160;10.</p><span></span>
</td>
<td class="text"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Description of Business</span></p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA biopharma, Inc. (&#8220;ARCA&#8221;), a Delaware corporation, is headquartered in Westminster, Colorado. ARCA is a clinical<span class="nobreak">-stage</span> biopharmaceutical company applying a precision medicine approach to the development and commercialization of genetically targeted therapies for cardiovascular diseases. ARCA&#8217;s lead product candidate is Gencaro&#8482; (bucindolol hydrochloride) for the treatment of atrial fibrillation (&#8220;AF&#8221;) in patients with chronic heart failure (&#8220;HF&#8221;).</p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In April&#160;2022, the Board of Directors established a Special Committee and, in May&#160;2022, retained Ladenburg Thalmann&#160;&amp; Co. Inc. to evaluate strategic options, including transactions involving a merger, sale of all or part of ARCA&#8217;s assets, or other alternatives with the goal of maximizing stockholder value. ARCA does not have a defined timeline for the strategic review process and the review may not result in any specific action or transaction.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_LiquidityAndGoingConcernPolicyTextBlock', window );">Liquidity and Going Concern</a></td>
<td class="text"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Liquidity and Going Concern</span></p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA devotes substantially all of its efforts towards obtaining regulatory approval and raising capital necessary to fund its operations and it is subject to a number of risks associated with clinical research and development, including dependence on key individuals, the development of and regulatory approval of commercially viable products, the need to raise adequate additional financing necessary to fund the development and commercialization of its products, and competition from larger companies. ARCA has not generated revenue to date and has incurred substantial losses and negative cash flows from operations since its inception. ARCA has historically funded its operations through issuances of common and preferred stock.</p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA believes that its current cash and cash equivalents as of March&#160;31, 2024 will be sufficient to fund its operations through the middle of fiscal year 2025. The future viability of ARCA beyond that point is dependent on the results of the strategic review process and its ability to raise additional capital to fund its operations. ARCA expects to continue to incur costs and expenditures in connection with the process of evaluating strategic alternatives. There can be no assurance, however, that ARCA will be able to successfully consummate any particular strategic transaction, including the Merger Agreement. The process of continuing to evaluate these strategic options may be very costly, time<span class="nobreak">-consuming</span> and complex and ARCA has incurred, and may in the future incur, significant costs related to this continued evaluation, such as legal, accounting and advisory fees and expenses and other related charges, see Note&#160;10 regarding the Merger Agreement. Should ARCA pursue additional clinical trials for its product candidates, it will have to raise additional capital for clinical trials of Gencaro. ARCA may not be able to raise sufficient capital on acceptable terms, or at all, to continue development of Gencaro or rNAPc2 or to otherwise continue operations and may not be </p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">able to execute any strategic transaction. Changing circumstances may cause ARCA to consume capital significantly faster or slower than currently anticipated. ARCA has based these estimates on assumptions that may prove to be wrong, and it could exhaust its available financial resources sooner than it currently anticipates. Depending on the results of the strategic review process, ARCA may have to raise additional capital for clinical trials of Gencaro and to fund its operations. ARCA may not be able to raise sufficient capital on acceptable terms, or at all, to continue development of Gencaro or rNAPc2 or to otherwise continue operations and may not be able to execute any strategic transaction.</p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s liquidity, and its ability to raise additional capital or complete any strategic transaction, depends on a number of factors, including, but not limited to, the following:</p><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the timing and outcome of the strategic review process;</p><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the consummation of any particular strategic transactions, including the Merger;</p><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the costs and timing for the potential additional clinical trials in order to gain possible regulatory approval for Gencaro, rNAPc2, or any other product candidate;</p><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the market price of ARCA&#8217;s stock and the availability and cost of additional equity capital from existing and potential new investors;</p><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s ability to retain the listing of its common stock on the Nasdaq Capital Market;</p><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>general economic and industry conditions affecting the availability and cost of capital, including as a result of deteriorating market conditions due to investor concerns regarding inflation, adverse developments affecting the financial services industry, continued hostilities between Russia and Ukraine and Hamas&#8217; attack against Israel and the ensuing conflict;</p><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s ability to control costs associated with its operations;</p><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; and</p><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the terms and conditions of ARCA&#8217;s existing collaborative and licensing agreements.</p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The sale of additional equity or convertible debt securities would likely result in substantial additional dilution to ARCA&#8217;s stockholders. If ARCA raises additional funds through the incurrence of indebtedness, the obligations related to such indebtedness would be senior to rights of holders of ARCA&#8217;s capital stock and could contain covenants that would restrict ARCA&#8217;s operations. ARCA also cannot predict what consideration might be available, if any, to it or its stockholders, in connection with any strategic transaction. Should strategic alternatives or additional capital not be available to ARCA, or not be available on acceptable terms, ARCA may be unable to realize value from its assets and discharge its liabilities in the normal course of business which may, among other alternatives, cause ARCA to further delay, substantially reduce or discontinue operational activities to conserve its cash resources.</p><span></span>
</td>
<td class="text"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Liquidity and Going Concern</span></p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA devotes substantially all of its efforts towards obtaining regulatory approval and raising capital necessary to fund its operations and it is subject to a number of risks associated with clinical research and development, including dependence on key individuals, the development of and regulatory approval of commercially viable products, the need to raise adequate additional financing necessary to fund the development and commercialization of its products, and competition from larger companies. ARCA has not generated revenue to date and has incurred substantial losses and negative cash flows from operations since its inception. ARCA has historically funded its operations through issuances of common and preferred stock.</p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA believes that its current cash and cash equivalents as of December&#160;31, 2023 will be sufficient to fund its operations through the middle of fiscal year 2025. ARCA&#8217;s review of its strategic options may impact this projection. Changing circumstances may cause ARCA to consume capital significantly faster or slower than currently anticipated. ARCA has based these estimates on assumptions that may prove to be wrong, and ARCA could exhaust its available financial resources sooner than it currently anticipates. Therefore, ARCA will have to raise additional capital for clinical trials of Gencaro. ARCA may not be able to raise sufficient capital on acceptable terms, or at all, to continue development of Gencaro or rNAPc2 or to otherwise continue operations and may not be able to execute any strategic transaction.</p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s liquidity, and its ability to raise additional capital or complete any strategic transaction, depends on a number of factors, including, but not limited to, the following:</p><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the costs and timing for the potential additional clinical trials in order to gain possible regulatory approval for Gencaro, rNAPc2, or any other product candidate;</p><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the market price of ARCA&#8217;s stock and the availability and cost of additional equity capital from existing and potential new investors;</p><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s ability to retain the listing of its common stock on the Nasdaq Capital Market;</p><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>general economic and industry conditions affecting the availability and cost of capital, including as a result of deteriorating market conditions due to investor concerns regarding inflation, adverse developments affecting the financial services industry, continued hostilities between Russia and Ukraine and Hamas&#8217; attack against Israel and the ensuing conflict;</p><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s ability to control costs associated with its operations;</p><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; and</p><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the terms and conditions of ARCA&#8217;s existing collaborative and licensing agreements.</p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The sale of additional equity or convertible debt securities would likely result in substantial additional dilution to ARCA&#8217;s stockholders. If ARCA raises additional funds through the incurrence of indebtedness, the obligations related to such indebtedness would be senior to rights of holders of ARCA&#8217;s capital stock and could contain covenants that would restrict ARCA&#8217;s operations. ARCA also cannot predict what consideration might be available, if any, to it or its stockholders, in connection with any strategic transaction. Should strategic alternatives or additional capital not be available to ARCA, or not be available on acceptable terms, ARCA may be unable to realize value from its assets and discharge its liabilities in the normal course of business which may, among other alternatives, cause ARCA to further delay, substantially reduce or discontinue operational activities to conserve its cash resources.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Basis of Presentation</span></p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The accompanying unaudited financial statements of ARCA were prepared in accordance with generally accepted accounting principles for interim financial information and pursuant to Regulation&#160;S<span class="nobreak">-X</span>.&#160;Accordingly, these financial statements do not include all of the information and footnotes required by accounting principles generally accepted in the United&#160;States of America (&#8220;GAAP&#8221;) for complete financial statements. In the opinion of management, these financial statements include all normal and recurring adjustments considered necessary for a fair presentation of these interim financial statements. The results of operations for the three&#160;months ended March&#160;31, 2024 are not necessarily indicative of results expected for the full year ending December&#160;31, 2024. ARCA has generated no revenue to date and its activities have consisted of seeking regulatory approval, research and development, exploring </p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">strategic alternatives for further developing and commercializing Gencaro and rNAPc2, and raising capital. These unaudited financial statements should be read in conjunction with the audited financial statements and footnotes thereto for the year ended December&#160;31, 2023 included elsewhere in this proxy statement/prospectus. Amounts presented are rounded to the nearest thousand, where indicated, except per share data and par values.</p><span></span>
</td>
<td class="text"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Basis of Presentation</span></p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The accompanying financial statements have been prepared in accordance with U.S.&#160;generally accepted accounting principles (&#8220;GAAP&#8221;) and include all adjustments necessary for the fair presentation of ARCA&#8217;s financial position, results of operations and cash flows for the periods presented. Management has performed an evaluation of ARCA&#8217;s activities through the date of filing of the Annual Report on Form&#160;10<span class="nobreak">-K</span>.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Recent Accounting Pronouncements</span></p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA reviewed recently issued accounting pronouncements and concluded that they were either not applicable or not expected to have a significant impact to the financial statements.</p><span></span>
</td>
<td class="text"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Recent Accounting Pronouncements</span></p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA reviewed all other recently issued accounting pronouncements and concluded that they were either not applicable or not expected to have a significant impact to the financial statements.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Accounting Estimates in the Preparation of Financial Statements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Accounting Estimates in the Preparation of Financial Statements</span></p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The preparation of financial statements in conformity with accounting principles generally accepted in the United&#160;States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. ARCA bases estimates on various assumptions that are believed to be reasonable under the circumstances. ARCA believes significant judgment was involved in estimating the outsourcing expenses, and in estimating other accrued liabilities and income taxes. Management is continually evaluating and updating these estimates, and it is possible that these estimates will change in the future or that actual results may differ from these estimates.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash Equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Cash Equivalents</span></p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Cash equivalents generally consist of money market funds and debt securities with maturities of 90&#160;days or less at the time of purchase. ARCA invests its excess cash in securities with strong ratings and has established guidelines relative to diversification and maturity with the objective of maintaining safety of principal and liquidity.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Credit Risk</a></td>
<td class="text"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Concentrations of Credit Risk</span></p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Financial instruments that potentially subject ARCA to significant concentrations of credit risk consist primarily of cash and cash equivalents. ARCA has no off<span class="nobreak">-balance-sheet</span> concentrations of credit risk, such as foreign exchange contracts, option contracts, or foreign currency hedging arrangements. ARCA maintains cash and cash equivalent balances in the form of bank demand deposits and money market fund accounts with financial institutions that management believes are creditworthy. Such balances may at times exceed the insured amount.</p><span></span>
</td>
<td class="text"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Concentrations of Credit Risk</span></p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Financial instruments that potentially subject ARCA to significant concentrations of credit risk consist primarily of cash and cash equivalents. ARCA has no off<span class="nobreak">-balance-sheet</span> concentrations of credit risk, such as foreign exchange contracts, option contracts, or foreign currency hedging arrangements. ARCA maintains cash and cash equivalent balances in the form of bank demand deposits and money market fund accounts with financial institutions that management believes are creditworthy. Such balances may at times exceed the insured amount.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Property and Equipment</span></p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Property and equipment are stated at cost less accumulated depreciation and amortization. Cost includes expenditures for equipment, leasehold improvements, replacements, and renewals. Maintenance and repairs are charged to expense as incurred. When assets are sold, retired, or otherwise disposed of, the cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is reflected in operations. The cost of </p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">property and equipment is depreciated using the straight<span class="nobreak">-line</span> method over the estimated useful lives of the related assets. Leasehold improvements are amortized over the shorter of the life of the lease or the estimated useful life of the assets.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_ComprehensiveLossPolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Comprehensive Loss</span></p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Comprehensive loss is defined as the change in equity during a period from transactions and other events and/or circumstances from non<span class="nobreak">-owner</span> sources. If ARCA had comprehensive gains (losses), they would be reflected in the statement of operations and comprehensive loss and as a separate component in the statement of stockholders&#8217; equity. There were no elements of comprehensive loss during the three&#160;months ended March&#160;31, 2024 and 2023.</p><span></span>
</td>
<td class="text"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Comprehensive Loss</span></p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Comprehensive loss is defined as the change in equity during a period from transactions and other events and/or circumstances from non<span class="nobreak">-owner</span> sources. If ARCA had comprehensive gains (losses), they would be reflected in the statement of operations and comprehensive loss and as a separate component in the statement of stockholders&#8217; equity. There were no elements of comprehensive loss during the&#160;years ended December&#160;31, 2023 and 2022.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Leases</span></p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA determines if an arrangement is a lease at inception. Operating leases are included in right<span class="nobreak">-of-use</span> (&#8220;ROU&#8221;) asset&#160;&#8212;&#160;operating and lease obligations are included in accrued expenses and other liabilities and operating lease liability on ARCA&#8217;s March&#160;31, 2024 and December&#160;31, 2023 balance sheets.</p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ROU lease assets represent ARCA&#8217;s right to use an underlying asset for the lease term and lease obligations represent ARCA&#8217;s obligation to make lease payments arising from the lease. Operating ROU lease assets are recognized at the commencement date based on the present value of lease payments over the lease term. As ARCA&#8217;s leases do not provide an implicit rate, ARCA uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. ARCA&#8217;s lease terms may include options to extend or terminate a lease when it is reasonably certain that ARCA will exercise that option. Lease expense for lease payments is recognized on a straight<span class="nobreak">-line</span> basis over the lease term.</p><span></span>
</td>
<td class="text"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Leases</span></p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA determines if an arrangement is a lease at inception. Operating leases are included in right<span class="nobreak">-of-use</span> (&#8220;ROU&#8221;) asset&#160;&#8212;&#160;operating and lease obligations are included in accrued expenses and other liabilities and operating lease liability on ARCA&#8217;s December&#160;31, 2023 and 2022 balance sheets.</p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ROU lease assets represent ARCA&#8217;s right to use an underlying asset for the lease term and lease obligations represent ARCA&#8217;s obligation to make lease payments arising from the lease. Operating ROU lease assets are recognized at the commencement date based on the present value of lease payments over the lease term. As ARCA&#8217;s lease does not provide an implicit rate, ARCA uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. ARCA&#8217;s lease terms may include options to extend or terminate the lease when it is reasonably certain that ARCA will exercise that option. Lease expense for lease payments is recognized on a straight<span class="nobreak">-line</span> basis over the lease term.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_AccruedOutsourcingExpensesPolicyTextBlock', window );">Accrued Outsourcing Expenses</a></td>
<td class="text"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Accrued Outsourcing Expenses</span></p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As part of the process of preparing its financial statements, ARCA is required to estimate accrued outsourcing expenses. This process involves identifying services that third parties have performed on ARCA&#8217;s behalf and estimating the level of service performed and the associated cost incurred for these services as of the balance sheet date. Examples of estimated accrued outsourcing expenses include contract service fees, such as fees payable to contract manufacturers in connection with the production of materials related to ARCA&#8217;s drug product, and service fees and pass through costs from clinical research organizations. ARCA develops estimates of liabilities using its judgment based upon the facts and circumstances known at the time.</p><span></span>
</td>
<td class="text"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Accrued Outsourcing Expenses</span></p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As part of the process of preparing its financial statements, ARCA is required to estimate accrued outsourcing expenses. This process involves identifying services that third parties have performed on ARCA&#8217;s behalf and estimating the level of service performed and the associated cost incurred for these services as of the balance sheet date. Examples of estimated accrued outsourcing expenses include contract service fees, such as fees payable to contract manufacturers in connection with the production of materials related to ARCA&#8217;s drug product, and service fees and pass through costs from clinical research organizations. ARCA develops estimates of liabilities using its judgment based upon the facts and circumstances known at the time.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Segments</span></p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA operates in one segment. Management uses one measure of profitability and does not segment its business for internal reporting.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Research and Development</span></p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Research and development costs are expensed as incurred. These consist primarily of salaries, contract services, and supplies.</p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Costs, if any, related to clinical trial and drug manufacturing activities are based upon estimates of the services received and related expenses incurred by contract research organizations (&#8220;CROs&#8221;), clinical study sites, drug manufacturers, collaboration partners, laboratories, consultants, or otherwise. Related contracts vary significantly in length, and could be for a fixed amount, a variable amount based on actual costs incurred, capped at a certain limit, or for a combination of these elements. Activity levels are monitored through communications with the vendors, including detailed invoices and task completion review, analysis of expenses against budgeted amounts, and pre<span class="nobreak">-approval</span> of any changes in scope of the services to be performed. Certain significant vendors may also provide </p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">an estimate of costs incurred but not invoiced on a periodic basis. Expenses related to the CROs and clinical studies, as well as contract drug manufacturers, are primarily based on progress made against specified milestones or targets in each period.</p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In accordance with certain research and development agreements, ARCA is obligated to make certain upfront payments upon execution of the agreement. ARCA records these upfront payments as prepaid research and development expenses, which are included in Other current assets or Other assets in the accompanying Balance Sheets. Such payments are recorded to research and development expense as services are performed. ARCA evaluates on a quarterly basis whether events and circumstances have occurred that may indicate impairment of remaining prepaid research and development expenses.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Stock-Based Compensation</span></p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s stock<span class="nobreak">-based</span> compensation cost recognized is based on the estimated grant date fair value. ARCA recognizes compensation costs for its stock<span class="nobreak">-based</span> awards on a straight<span class="nobreak">-line</span> basis over the requisite service period for the entire award, as adjusted for expected forfeitures.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Income Taxes</span></p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The current benefit for income taxes represents actual or estimated amounts payable or refundable on tax returns filed or to be filed each year. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the period that includes the enactment date. The overall change in deferred tax assets and liabilities for the period measures the deferred tax expense or benefit for the period. The measurement of deferred tax assets may be reduced by a valuation allowance based on judgmental assessment of available evidence if deemed more likely than not that some or all of the deferred tax assets will not be realized.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_AccruedOutsourcingExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued outsourcing expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_AccruedOutsourcingExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_ComprehensiveLossPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Comprehensive loss policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_ComprehensiveLossPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_DescriptionOfBusinessPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_DescriptionOfBusinessPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_LiquidityAndGoingConcernPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liquidity and going concern.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_LiquidityAndGoingConcernPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478898/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140399531958672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net Loss Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Potentially Dilutive Shares of Common Stock</a></td>
<td class="text">Because ARCA reported a net loss for the three&#160;months ended March&#160;31, 2024 and 2023, all potentially dilutive shares of ARCA common stock have been excluded from the computation of the dilutive net loss per share for all periods presented. Such potentially dilutive shares of ARCA common stock consist of the following:<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">March&#160;31,</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2024</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Potentially dilutive securities, excluded:</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Outstanding stock options</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">645,845</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">664,857</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Unvested restricted stock units</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-110; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">91,000</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">645,845</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">755,857</p>	</td>
				</tr>

		</table><span></span>
</td>
<td class="text">Because ARCA reported a net loss for the&#160;years ended December&#160;31, 2023 and 2022, all potentially dilutive shares of ARCA common stock have been excluded from the computation of the dilutive net loss per share for all periods presented. Such potentially dilutive shares of ARCA common stock consist of the following:<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Years Ended<br/>December&#160;31,</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2022</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Potentially dilutive securities, excluded:</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Outstanding stock options</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">616,707</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">704,960</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Unvested restricted stock units</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-70; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">91,000</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">616,707</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">795,960</p>	</td>
				</tr>

		</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140399532239872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment</a></td>
<td class="text">Property and equipment consist of the following (in thousands):<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">	<tr class="No-Table-Style _idGenTableRowColumn-11" style="height:12pt;">	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Estimated<br/>Life</span></p>	</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">March&#160;31,<br/>2024</span></p>	</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">December&#160;31,<br/>2023</span></p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Computer equipment</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">3&#160;years</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">39</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">39</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Lab equipment</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">5&#160;years</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">130</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">130</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Furniture and fixtures</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">5&#160;years</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">37</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">37</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Computer software</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">3&#160;years</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">16</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">16</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">222</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">222</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accumulated depreciation and amortization</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(215</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(212</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Property and equipment, net</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">7</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">10</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	</tr>	</table><span></span>
</td>
<td class="text">Property and equipment consist of the following (in thousands):<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">	<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Estimated<br/>Life</span></p>	</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">December&#160;31,<br/>2023</span></p>	</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">December&#160;31,<br/>2022</span></p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Computer equipment</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">3&#160;years</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">39</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">39</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Lab equipment</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">5&#160;years</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">130</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">130</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Furniture and fixtures</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">5&#160;years</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">37</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">44</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Computer software</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">3&#160;years</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">16</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">16</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">222</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">229</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accumulated depreciation and amortization</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(212</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(204</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Property and equipment, net</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">10</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">25</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	</tr>	</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140399532134528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Future Minimum Commitments Due</a></td>
<td class="text">Future minimum commitments due under the October&#160;2020 Lease agreement, as amended, as of March&#160;31, 2024 are as follows (in thousands):<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2024</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">49</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total remaining lease payments</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">49</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Less: imputed lease interest</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(1</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Less: Current portion</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(48</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Operating lease liability, net of current portion</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-114; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>

		</table><span></span>
</td>
<td class="text">Future minimum commitments due under the October&#160;2020 Lease agreement as of December&#160;31, 2023 are as follows (in thousands):<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2024</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">93</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2025</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">96</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2026</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">100</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2027</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">25</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total remaining lease payments</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">314</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Less: imputed lease interest</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(34</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Less: Current portion</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(76</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Operating lease liability, net of current portion</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">204</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>

		</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140399534128384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Estimated Weighted Average Grant Date Fair Value Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The fair values of employee stock options granted in the year ended December&#160;31, 2022 were estimated at the date of grant using the Black<span class="nobreak">-Scholes</span> model with the following assumptions and had the following estimated weighted average grant date fair value per share:<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">	<tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;">	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Year Ended<br/>December&#160;31,<br/>2022</span></p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Expected term</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5.5&#160;years</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Expected volatility</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">107</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Risk-free interest rate</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3.56</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Expected dividend yield</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">0</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Weighted-average grant date fair value per share</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1.87</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	</tr>	</table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Activities</a></td>
<td class="text">Stock option transactions for the three&#160;months ended March&#160;31, 2024 under ARCA&#8217;s stock incentive plans were as follows:<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">	<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 46.15%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Options Outstanding</span></p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-15" style="height:12pt;">	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Number of<br/>Options</span></p>	</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Weighted<br/>Average<br/>Exercise<br/>Price</span></p>	</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term<br/>(in&#160;years)</span></p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Options outstanding&#160;&#8211;&#160;December&#160;31, 2023</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">616,707</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4.76</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">7.35</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Granted</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">42,000</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1.64</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Exercised</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-117; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-118; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Forfeited and cancelled</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(12,862</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">17.45</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Options outstanding&#160;&#8211;&#160;March&#160;31, 2024</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">645,845</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4.30</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">6.82</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Options exercisable&#160;&#8211;&#160;March&#160;31, 2024</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">502,517</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4.71</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">6.55</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Options vested and expected to vest&#160;&#8211;&#160;March&#160;31, 2024</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">645,816</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4.30</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">6.82</p>	</td>	</tr>	</table><span></span>
</td>
<td class="text">A summary of ARCA&#8217;s stock option activities for the&#160;years ended December&#160;31, 2023 and 2022, and related information as of December&#160;31, 2023, is as follows:<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">	<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" colspan="10" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 61.11%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Options Outstanding</span></p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-17" style="height:12pt;">	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Number of<br/>Options</span></p>	</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Weighted<br/>Average<br/>Exercise<br/>Price</span></p>	</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term (in&#160;years)</span></p>	</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Aggregate<br/>Intrinsic Value<br/>(in thousands)</span></p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Options outstanding&#160;&#8211;&#160;December&#160;31,&#160;2021</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">904,123</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5.59</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Granted</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">60,000</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2.31</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Exercised</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-76; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-77; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Forfeited and cancelled</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(259,163</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4.74</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Options outstanding&#160;&#8211;&#160;December&#160;31,&#160;2022</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">704,960</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5.62</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">8.29</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">18</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Granted</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-78; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-79; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Exercised</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-80; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-81; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Forfeited and cancelled</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(88,253</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">11.68</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Options outstanding&#160;&#8211;&#160;December&#160;31,&#160;2023</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">616,707</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4.76</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">7.35</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-82; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Options exercisable&#160;&#8211;&#160;December&#160;31,&#160;2023</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">463,068</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5.28</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">7.29</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-83; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-18" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Options vested and expected to vest&#160;&#8211;&#160;December&#160;31,&#160;2023</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">616,661</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4.76</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">7.35</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-84; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>	</td>	</tr>	</table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of RSU Activity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">A summary of RSU activity for the year ended December&#160;31, 2023 is presented below:<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="5" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Restricted Stock Units<br/>Outstanding</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-19" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Number of<br/>Shares</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Weighted<br/>Average<br/>Grant Date<br/>Fair Value</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">RSUs outstanding&#160;&#8211;&#160;December&#160;31, 2021</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-85; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-86; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Granted</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">91,000</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2.21</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Vested and released</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-87; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-88; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Forfeited and cancelled</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-89; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-90; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">RSUs outstanding&#160;&#8211;&#160;December&#160;31, 2022</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">91,000</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2.21</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Granted</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-91; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-92; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Vested and released</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(91,000</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2.21</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Forfeited and cancelled</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-93; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-94; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">RSUs outstanding&#160;&#8211;&#160;December&#160;31, 2023</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-95; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-96; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>

		</table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Non-cash, Share-based Compensation Expense</a></td>
<td class="text">For the three&#160;months ended March&#160;31, 2024 and 2023, ARCA recognized the following non<span class="nobreak">-cash</span>, share<span class="nobreak">-based</span> compensation expense in the statements of operations (in thousands):<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-11" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="5" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Three&#160;Months Ended<br/>March&#160;31,</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2024</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">General and administrative</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">114</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">163</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Research and development</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-116; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">41</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">114</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">204</p>	</td>
				</tr>

		</table><span></span>
</td>
<td class="text">For the&#160;years ended December&#160;31, 2023 and 2022, ARCA recognized the following non<span class="nobreak">-cash</span>, share<span class="nobreak">-based</span> compensation expense (in thousands):<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="5" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Years Ended<br/>December&#160;31,</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2022</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">General and administrative</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">526</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">423</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Research and development</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">160</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">133</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">686</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">556</p>	</td>
				</tr>

		</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140399532166656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Income Tax Benefit Attributable to Our Loss from Operations</a></td>
<td class="text">Income tax benefit attributable to ARCA&#8217;s loss from operations before income taxes differs from the amounts computed by applying the U.S.&#160;federal statutory income tax rate of 21% for 2023 and 2022, as a result of the following (in thousands):<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Years ended<br/>December&#160;31,</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2022</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">U.S.&#160;federal income tax benefit at statutory rates</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(1,121</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(2,085</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">State income tax benefit, net of federal benefit</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(192</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(357</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Research and experimentation credits</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-101; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-102; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Deferred tax asset adjustment</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">47</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">107</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">186</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Change in valuation allowance</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,159</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,254</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Income tax benefit</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-103; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-104; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>

		</table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Net deferred tax assets and liabilities</a></td>
<td class="text">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting and the amounts used for income tax purposes, as well as operating loss and tax credit carryforwards. The income tax effects of temporary differences and carryforwards that give rise to significant portions of ARCA&#8217;s net deferred tax assets and liabilities consisted of the following (in thousands):<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">As of December&#160;31,</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2022</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Deferred tax assets:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net operating loss carryforwards</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">51,190</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">50,008</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Charitable contribution carryforwards</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">371</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">393</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Research and experimentation credits</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,420</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,420</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Capitalized research and development costs</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">951</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">979</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Capitalized intangibles</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">354</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">356</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Stock-based compensation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">232</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">205</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accrued compensation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">7</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">6</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Lease liabilities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">69</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">94</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total deferred tax assets</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">55,594</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">54,461</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Valuation allowance</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(55,531</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(54,372</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Deferred tax assets, net of valuation allowance</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">63</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">89</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Deferred tax liabilities:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Right-of-use asset</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(61</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(84</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Depreciation and amortization</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(2</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(5</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net deferred tax liability</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-105; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-106; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>

		</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140399531916912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ARCA and Summary of Significant Accounting Policies (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>ARCA and Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosureOffbalanceSheetRisksAmountAsset', window );">Off-balance-sheet concentrations of credit risk</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosureOffbalanceSheetRisksAmountAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of financial assets, which are not recognized in the financial statements (off-balance sheet) because they fail to meet some other criterion for recognition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosureOffbalanceSheetRisksAmountAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140399532878064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Details) - Schedule of Potentially Dilutive Shares of Common Stock - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_PotentiallyDilutiveSecuritiesExcludedAbstract', window );"><strong>Potentially dilutive securities, excluded:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities, excluded</a></td>
<td class="nump">645,845<span></span>
</td>
<td class="nump">755,857<span></span>
</td>
<td class="nump">616,707<span></span>
</td>
<td class="nump">795,960<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember', window );">Outstanding stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_PotentiallyDilutiveSecuritiesExcludedAbstract', window );"><strong>Potentially dilutive securities, excluded:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities, excluded</a></td>
<td class="nump">645,845<span></span>
</td>
<td class="nump">664,857<span></span>
</td>
<td class="nump">616,707<span></span>
</td>
<td class="nump">704,960<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Unvested restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_PotentiallyDilutiveSecuritiesExcludedAbstract', window );"><strong>Potentially dilutive securities, excluded:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities, excluded</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">91,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">91,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_PotentiallyDilutiveSecuritiesExcludedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_PotentiallyDilutiveSecuritiesExcludedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140399621741712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Disclosures (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_FairValueDisclosuresDetailsLineItems', window );"><strong>Fair Value Disclosures (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_FairValueAssetsBetweenHierarchyLevelsTransfersAmount', window );">Fair value hierarchy</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtLongtermAndShorttermCombinedAmount', window );">Debt outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds | Fair Value Measurements, Recurring | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_FairValueDisclosuresDetailsLineItems', window );"><strong>Fair Value Disclosures (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">$ 42.4<span></span>
</td>
<td class="nump">$ 35.9<span></span>
</td>
<td class="nump">$ 37.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_FairValueAssetsBetweenHierarchyLevelsTransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value assets between hierarchy levels transfers amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_FairValueAssetsBetweenHierarchyLevelsTransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_FairValueDisclosuresDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_FairValueDisclosuresDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtLongtermAndShorttermCombinedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the aggregate of total long-term debt, including current maturities and short-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtLongtermAndShorttermCombinedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140399624734688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140399531008144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment (Details) - Schedule of Property and Equipment - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and Equipment, Gross</a></td>
<td class="nump">$ 222<span></span>
</td>
<td class="nump">$ 222<span></span>
</td>
<td class="nump">$ 229<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation and amortization</a></td>
<td class="num">(215)<span></span>
</td>
<td class="num">(212)<span></span>
</td>
<td class="num">(204)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and Equipment, Gross</a></td>
<td class="nump">$ 39<span></span>
</td>
<td class="nump">$ 39<span></span>
</td>
<td class="nump">39<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Lab equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and Equipment, Gross</a></td>
<td class="nump">$ 130<span></span>
</td>
<td class="nump">$ 130<span></span>
</td>
<td class="nump">130<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and Equipment, Gross</a></td>
<td class="nump">$ 37<span></span>
</td>
<td class="nump">$ 37<span></span>
</td>
<td class="nump">44<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Computer software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and Equipment, Gross</a></td>
<td class="nump">$ 16<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140399532465536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Arrangements (Details) - Chief Executive Officer [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_ResearchAndDevelopmentExpenseReversed', window );">Related party expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 108,000<span></span>
</td>
<td class="num">$ (91,000)<span></span>
</td>
<td class="nump">$ 432,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_PaymentOfUnrestrictedResearchGrants', window );">Payment of unrestricted research grants</a></td>
<td class="nump">$ 125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_PaymentOfUnrestrictedResearchGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment of unrestricted research grants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_PaymentOfUnrestrictedResearchGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_ResearchAndDevelopmentExpenseReversed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and development expense (reversed).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_ResearchAndDevelopmentExpenseReversed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140399528765104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2023</div></th>
<th class="th"><div>Oct. 31, 2023</div></th>
<th class="th">
<div>Aug. 29, 2020 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Jul. 31, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_RetentionBonuses', window );">Amount of retention bonuses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 311,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 311,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_PercentageOfRetentionBonuses', window );">Percentage of retention bonuses</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_RetentionBonusPaid', window );">Retention bonus paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">159,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveCurrent', window );">Remains unpaid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent', window );">Workforce reduction percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated', window );">Number of employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Square feet (in Square Feet) | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">42 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseOptionToExtend', window );">Lease renewal option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">option to renew for an additional 36 month term at the then prevailing rental rate.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">to extend the lease term six (6)&#160;months through September&#160;2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_AreaOfRealEstatePropertySubleaseAdditionalOfficeFacilities', window );">Square feet office facilities (in Square Feet) | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_LesseeOperatingSubleaseTermOfContract', window );">Sublease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">29 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">29 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseAssumptionsAndJudgmentsAllocationOfLeaseAndNonleaseComponent', window );">Lessee operating lease description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The leases include real estate taxes and insurance, which is not a lease component and is not included in the lease obligation. In addition, common area maintenance charges are based on actual costs incurred and are a non-lease component that is not included in the lease obligation.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The leases include real estate taxes and insurance, which is not a lease component and is not included in the lease obligation. In addition, common area maintenance charges are based on actual costs incurred and are a non-lease component that is not included in the lease obligation.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 280,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,000<span></span>
</td>
<td class="nump">$ 33,000<span></span>
</td>
<td class="nump">$ 127,000<span></span>
</td>
<td class="nump">$ 131,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend', window );">Indicates (true false) whether lessee has option to extend operating lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_OperatingLeasesExtendedExpiryYearsAndMonth', window );">Additional operating lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">September&#160;2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_PercentageOfBaseRentToBePaidMonthly', window );">Percentage Of Base Rent To Be Paid Monthly</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=abio_ClinicalDevelopmentDecisionMember', window );">Clinical development decisions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_RetentionBonuses', window );">Amount of retention bonuses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">265,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Rent expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,000<span></span>
</td>
<td class="nump">$ 31,000<span></span>
</td>
<td class="nump">$ 119,000<span></span>
</td>
<td class="nump">125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OneTimeTerminationBenefitsMember', window );">One-time Termination Benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">755,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OneTimeTerminationBenefitsMember', window );">One-time Termination Benefits | Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">470,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OneTimeTerminationBenefitsMember', window );">One-time Termination Benefits | General and Administrative Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 285,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_RetentionBonuses', window );">Amount of retention bonuses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 444,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=abio_UniversityMedicalCenterOfJohannesGutenbergUniversityMainzMember', window );">University Medical Center Of Johannes Gutenberg University Mainz | Research and development | Patent Assignment Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_PotentialUpfrontAndMilestoneObligationsAndRoyaltyObligations', window );">Royalty obligations (in Euro) | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_AreaOfRealEstatePropertySubleaseAdditionalOfficeFacilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of real estate property sublease additional office facilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_AreaOfRealEstatePropertySubleaseAdditionalOfficeFacilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_CommitmentsandContingenciesDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_CommitmentsandContingenciesDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_LesseeOperatingSubleaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee operating sublease term of contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_LesseeOperatingSubleaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_OperatingLeasesExtendedExpiryYearsAndMonth">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_OperatingLeasesExtendedExpiryYearsAndMonth</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_PercentageOfBaseRentToBePaidMonthly">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of base rent to be paid monthly.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_PercentageOfBaseRentToBePaidMonthly</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_PercentageOfRetentionBonuses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of retention bonuses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_PercentageOfRetentionBonuses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_PotentialUpfrontAndMilestoneObligationsAndRoyaltyObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential upfront and milestone obligations and royalty obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_PotentialUpfrontAndMilestoneObligationsAndRoyaltyObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_RetentionBonusPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Retention bonus paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_RetentionBonusPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_RetentionBonuses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Retention bonuses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_RetentionBonuses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of a real estate property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseAssumptionsAndJudgmentsAllocationOfLeaseAndNonleaseComponent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of assumptions and judgments used by lessee for allocating contract between lease and nonlease components for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseAssumptionsAndJudgmentsAllocationOfLeaseAndNonleaseComponent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether lessee has option to extend operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of positions eliminated during the period as a result of restructuring activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482047/420-10-45-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of known and estimated obligations associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, which are expected to be paid in the next twelve months or in the normal operating cycle if longer. Costs of such activities include those for one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, relocating employees, and costs associated with an ongoing benefit arrangement, but excludes costs associated with the retirement of a long-lived asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=abio_ClinicalDevelopmentDecisionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=abio_ClinicalDevelopmentDecisionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OneTimeTerminationBenefitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_OneTimeTerminationBenefitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=abio_UniversityMedicalCenterOfJohannesGutenbergUniversityMainzMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=abio_UniversityMedicalCenterOfJohannesGutenbergUniversityMainzMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=abio_PatentAssignmentAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=abio_PatentAssignmentAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140399528265328">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies (Details) - Schedule of Future Minimum Commitments Due - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_ScheduleOfFutureMinimumCommitmentsDueAbstract', window );"><strong>Schedule of Future Minimum Commitments Due [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total remaining lease payments</a></td>
<td class="nump">$ 49<span></span>
</td>
<td class="nump">314<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed lease interest</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(34)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: Current portion</a></td>
<td class="num">(48)<span></span>
</td>
<td class="num">(76)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, net of current portion</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 204<span></span>
</td>
<td class="nump">$ 280<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_ScheduleOfFutureMinimumCommitmentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_ScheduleOfFutureMinimumCommitmentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140399532074928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Financings (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jul. 22, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_EquityFinancingsDetailsLineItems', window );"><strong>Equity Financings (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in Dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=abio_NewCapitalOnDemandSalesAgreementMember', window );">2020 Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_EquityFinancingsDetailsLineItems', window );"><strong>Equity Financings (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sale of common stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=abio_JonesTradingInstitutionalServicesLLCMember', window );">Jones Trading</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_EquityFinancingsDetailsLineItems', window );"><strong>Equity Financings (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_SellingCommissionPerAdditionalSharesSoldPercentage', window );">Percentage of commission rate equal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=abio_JonesTradingInstitutionalServicesLLCMember', window );">Jones Trading | Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_EquityFinancingsDetailsLineItems', window );"><strong>Equity Financings (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_CommonStockAuthorizedOfferingAmountUnderAgreementToSell', window );">Aggregate offering price (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_CommonStockAuthorizedOfferingAmountUnderAgreementToSell">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock, authorized offering amount under agreement to sell.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_CommonStockAuthorizedOfferingAmountUnderAgreementToSell</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_EquityFinancingsDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_EquityFinancingsDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_SellingCommissionPerAdditionalSharesSoldPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Selling commission per additional shares sold percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_SellingCommissionPerAdditionalSharesSoldPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=abio_NewCapitalOnDemandSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=abio_NewCapitalOnDemandSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=abio_JonesTradingInstitutionalServicesLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=abio_JonesTradingInstitutionalServicesLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=abio_CapitalOnDemandSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=abio_CapitalOnDemandSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140399531306672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Compensation (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 10, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_SharebasedCompensationDetailsLineItems', window );"><strong>Share-based Compensation (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Purchase options shares</a></td>
<td class="nump">616,707<span></span>
</td>
<td class="nump">704,960<span></span>
</td>
<td class="nump">645,845<span></span>
</td>
<td class="nump">904,123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price (in Dollars per share)</a></td>
<td class="nump">$ 4.76<span></span>
</td>
<td class="nump">$ 5.62<span></span>
</td>
<td class="nump">$ 4.3<span></span>
</td>
<td class="nump">$ 5.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Stock options award, expiration</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_SharebasedCompensationDetailsLineItems', window );"><strong>Share-based Compensation (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation expense (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 367,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period</a></td>
<td class="text">1 year 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_SharebasedCompensationDetailsLineItems', window );"><strong>Share-based Compensation (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Stock awards granted service period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation cost (in Dollars)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_SharebasedCompensationDetailsLineItems', window );"><strong>Share-based Compensation (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock options award, vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_PercentageHoldingForStockOptionsExercisePrice', window );">Exercise price per share</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Incentive Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_SharebasedCompensationDetailsLineItems', window );"><strong>Share-based Compensation (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Percentage of exercise price</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Incentive Stock Option | Stockholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_SharebasedCompensationDetailsLineItems', window );"><strong>Share-based Compensation (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Percentage of exercise price</a></td>
<td class="nump">110.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_SharebasedCompensationDetailsLineItems', window );"><strong>Share-based Compensation (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock options award, vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=abio_TwoThousandAndTwentyEquityIncentivePlanMember', window );">2020 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_SharebasedCompensationDetailsLineItems', window );"><strong>Share-based Compensation (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares issuable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,167,425<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Purchase options shares</a></td>
<td class="nump">601,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price (in Dollars per share)</a></td>
<td class="nump">$ 3.45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Reserved shares</a></td>
<td class="nump">459,718<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Options granted</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_PurchaseAggregateShares', window );">Purchase aggregate shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=abio_TwoThousandAndThirteenPlanMember', window );">2013 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_SharebasedCompensationDetailsLineItems', window );"><strong>Share-based Compensation (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Purchase options shares</a></td>
<td class="nump">14,807<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price (in Dollars per share)</a></td>
<td class="nump">$ 57.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_PercentageHoldingForStockOptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum ownership percentage for 110% fair market value on the grant date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_PercentageHoldingForStockOptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_PurchaseAggregateShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase aggregate shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_PurchaseAggregateShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_SharebasedCompensationDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_SharebasedCompensationDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=abio_IncentiveStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=abio_IncentiveStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_PrincipalOwnerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_PrincipalOwnerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=abio_TwoThousandAndTwentyEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=abio_TwoThousandAndTwentyEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=abio_TwoThousandAndThirteenPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=abio_TwoThousandAndThirteenPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140399530763872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Compensation (Details) - Schedule of Estimated Weighted Average Grant Date Fair Value Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>$ / shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_ScheduleOfEstimatedWeightedAverageGrantDateFairValuePerShareAbstract', window );"><strong>Schedule of Estimated Weighted Average Grant Date Fair Value Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">5 years 6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">107.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">3.56%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value per share (in Dollars per share)</a></td>
<td class="nump">$ 1.87<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_ScheduleOfEstimatedWeightedAverageGrantDateFairValuePerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_ScheduleOfEstimatedWeightedAverageGrantDateFairValuePerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140399531010336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Compensation (Details) - Schedule of Stock Option Activities - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_ScheduleOfStockOptionActivitiesAbstract', window );"><strong>Schedule of Stock Option Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Options outstanding, ending balance</a></td>
<td class="nump">616,707<span></span>
</td>
<td class="nump">645,845<span></span>
</td>
<td class="nump">616,707<span></span>
</td>
<td class="nump">704,960<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Options outstanding, ending balance</a></td>
<td class="nump">$ 4.76<span></span>
</td>
<td class="nump">$ 4.3<span></span>
</td>
<td class="nump">$ 4.76<span></span>
</td>
<td class="nump">$ 5.62<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term (in years) Options outstanding, ending balance</a></td>
<td class="text">7 years 4 months 6 days<span></span>
</td>
<td class="text">6 years 9 months 25 days<span></span>
</td>
<td class="text">7 years 4 months 6 days<span></span>
</td>
<td class="text">8 years 3 months 14 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Options outstanding, ending balance</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Options, Options exercisable, ending balance</a></td>
<td class="nump">463,068<span></span>
</td>
<td class="nump">502,517<span></span>
</td>
<td class="nump">463,068<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Options exercisable, ending balance</a></td>
<td class="nump">$ 5.28<span></span>
</td>
<td class="nump">$ 4.71<span></span>
</td>
<td class="nump">$ 5.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term (in years), Options exercisable, ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 6 months 18 days<span></span>
</td>
<td class="text">7 years 3 months 14 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Options exercisable, ending balance</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of Options, Options vested and expected to vest, ending balance</a></td>
<td class="nump">616,661<span></span>
</td>
<td class="nump">645,816<span></span>
</td>
<td class="nump">616,661<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Options vested and expected to vest, ending balance</a></td>
<td class="nump">$ 4.76<span></span>
</td>
<td class="nump">$ 4.3<span></span>
</td>
<td class="nump">$ 4.76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term (in years), Options vested and expected to vest, ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 9 months 25 days<span></span>
</td>
<td class="text">7 years 4 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Options vested and expected to vest, ending balance</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Options, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">60,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.64<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 2.31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of Options, Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Number of Options, Forfeited and cancelled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,862)<span></span>
</td>
<td class="num">(88,253)<span></span>
</td>
<td class="num">(259,163)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Forfeited and cancelled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.45<span></span>
</td>
<td class="nump">$ 11.68<span></span>
</td>
<td class="nump">$ 4.74<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_ScheduleOfStockOptionActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_ScheduleOfStockOptionActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140399530584544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Compensation (Details) - Schedule of RSU Activity - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_ScheduleOfRsuActivityAbstract', window );"><strong>Schedule of RSU Activity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Shares, RSUs outstanding, beginning of period</a></td>
<td class="nump">91,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Date Fair Value, RSUs outstanding, beginning of period</a></td>
<td class="nump">$ 2.21<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of Shares, RSUs outstanding, Granted</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">91,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Date Fair Value, RSUs outstanding, Granted</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 2.21<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number of Shares, RSUs outstanding, Vested and released</a></td>
<td class="num">(91,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Date Fair Value, RSUs outstanding, Vested and released</a></td>
<td class="nump">$ 2.21<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Number of Shares, RSUs outstanding, Forfeited and cancelled</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Date Fair Value, RSUs outstanding, Forfeited and cancelled</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Shares, RSUs outstanding, ending balance</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">91,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Date Fair Value, RSUs outstanding, ending balance</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 2.21<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_ScheduleOfRsuActivityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_ScheduleOfRsuActivityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140399532902192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Compensation (Details) - Schedule of Non-cash, Share-based Compensation Expense - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total expenses</a></td>
<td class="nump">$ 114<span></span>
</td>
<td class="nump">$ 204<span></span>
</td>
<td class="nump">$ 686<span></span>
</td>
<td class="nump">$ 556<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total expenses</a></td>
<td class="nump">114<span></span>
</td>
<td class="nump">163<span></span>
</td>
<td class="nump">526<span></span>
</td>
<td class="nump">423<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total expenses</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 41<span></span>
</td>
<td class="nump">$ 160<span></span>
</td>
<td class="nump">$ 133<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>124
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140399532900288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_EmployeeBenefitPlansDetailsLineItems', window );"><strong>Employee Benefit Plans (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans', window );">Matching contribution</a></td>
<td class="text">matching contribution equal to 100% of the employee&#8217;s first 3% of the employee&#8217;s contributions and 50% of the employee&#8217;s next 2% of contributions.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Company's contribution (in Dollars)</a></td>
<td class="nump">$ 56,000<span></span>
</td>
<td class="nump">$ 96,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanNameAxis=abio_FirstThreePercentPayContributionMember', window );">First 3% of pay contributed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_EmployeeBenefitPlansDetailsLineItems', window );"><strong>Employee Benefit Plans (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Employee&#8217;s contribution percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Equal contribution percentage</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanNameAxis=abio_NextTwoPercentPayContributionMember', window );">Next 2% of pay contributed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_EmployeeBenefitPlansDetailsLineItems', window );"><strong>Employee Benefit Plans (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Employee&#8217;s contribution percentage</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Equal contribution percentage</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_EmployeeBenefitPlansDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_EmployeeBenefitPlansDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480794/715-70-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage employer matches of the employee's percentage contribution matched.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of defined contribution pension and other postretirement plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanNameAxis=abio_FirstThreePercentPayContributionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanNameAxis=abio_FirstThreePercentPayContributionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanNameAxis=abio_NextTwoPercentPayContributionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanNameAxis=abio_NextTwoPercentPayContributionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>125
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140399529123376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_IncomeTaxesDetailsLineItems', window );"><strong>Income Taxes (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 208,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardDescription', window );">Operating loss carryforwards, limitations on use</a></td>
<td class="text">The net operating loss carryforwards beginning in 2018, have no expiration.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_DeferredTaxAssetsAndLiabilitiesValuationAllowance', window );">Valuation allowance</a></td>
<td class="nump">$ 55,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_ValuationAllowanceDeferredTaxAssetsAndLiabilitiesChangeInAmount', window );">Increase in net deferred tax assets and liabilities</a></td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal statutory income tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Open Tax Year</a></td>
<td class="text">2009<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUncertainTaxPositionsCurrent', window );">Reserve for uncertain tax positions</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense', window );">Interest or penalties recognized</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember', window );">Research Tax Credit Carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_IncomeTaxesDetailsLineItems', window );"><strong>Income Taxes (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Research and experimentation credits</a></td>
<td class="nump">$ 2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLimitationsOnUse', window );">Tax credit carryforward, limitations on use</a></td>
<td class="text">Utilization of net operating losses and tax credits, including those acquired as a result of the Merger, will be subject to an annual limitation due to ownership change limitations provided by Internal Revenue Code Section&#160;382. ARCA believes that an ownership change limitation as defined under Section&#160;382 of the U.S.&#160;Internal Revenue Code occurred as a result of its various historical financing transactions. Future utilization of the federal net operating losses and tax credit carryforwards accumulated from June&#160;2005 to the change in ownership date will be subject to annual limitations to offset future taxable income. The annual limitation may result in the expiration of the net operating losses and credits before utilization. As such, a portion of ARCA&#8217;s net operating loss carryforwards may be limited.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=us-gaap_EarliestTaxYearMember', window );">Earliest Tax Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_IncomeTaxesDetailsLineItems', window );"><strong>Income Taxes (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_OperatingLossCarryforwardsExpirationYear', window );">Operating loss carryforwards expiration year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=us-gaap_LatestTaxYearMember', window );">Latest Tax Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_IncomeTaxesDetailsLineItems', window );"><strong>Income Taxes (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_OperatingLossCarryforwardsExpirationYear', window );">Operating loss carryforwards expiration year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_DeferredTaxAssetsAndLiabilitiesValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets and liabilities valuation allowance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_DeferredTaxAssetsAndLiabilitiesValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_IncomeTaxesDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_IncomeTaxesDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_OperatingLossCarryforwardsExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforwards expiration year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_OperatingLossCarryforwardsExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_ValuationAllowanceDeferredTaxAssetsAndLiabilitiesChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Valuation allowance deferred tax assets and liabilities change in amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_ValuationAllowanceDeferredTaxAssetsAndLiabilitiesChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of the amounts of estimated penalties and interest recognized in the period arising from income tax examinations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUncertainTaxPositionsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for uncertainty in income taxes classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUncertainTaxPositionsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OpenTaxYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax year that remains open to examination under enacted tax laws, in YYYY format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OpenTaxYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:gYearListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A description of the origin, nature, and characteristics of the tax credit carryforward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardLimitationsOnUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the limitation related to use of the tax credit carryforward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardLimitationsOnUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=us-gaap_EarliestTaxYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=us-gaap_EarliestTaxYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=us-gaap_LatestTaxYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=us-gaap_LatestTaxYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>126
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140399531237008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - Schedule of Income Tax Benefit Attributable to Our Loss from Operations - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_ScheduleOfIncomeTaxBenefitAttributableToOurLossFromOperationsAbstract', window );"><strong>Schedule Of Income Tax Benefit Attributable To Our Loss From Operations Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">U.S. federal income tax benefit at statutory rates</a></td>
<td class="num">$ (1,121)<span></span>
</td>
<td class="num">$ (2,085)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State income tax benefit, net of federal benefit</a></td>
<td class="num">(192)<span></span>
</td>
<td class="num">(357)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">Research and experimentation credits</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_IncomeTaxReconciliationAdjustmentToDeferredTaxAsset', window );">Deferred tax asset adjustment</a></td>
<td class="nump">47<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other</a></td>
<td class="nump">107<span></span>
</td>
<td class="nump">186<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">1,159<span></span>
</td>
<td class="nump">2,254<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_IncomeTaxReconciliationAdjustmentToDeferredTaxAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustment of the carrying value of deferred tax assets during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_IncomeTaxReconciliationAdjustmentToDeferredTaxAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_ScheduleOfIncomeTaxBenefitAttributableToOurLossFromOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_ScheduleOfIncomeTaxBenefitAttributableToOurLossFromOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>127
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140399528315728">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes (Details) - Schedule of Net deferred tax assets and liabilities - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_DeferredTaxAssetsAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 51,190<span></span>
</td>
<td class="nump">$ 50,008<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards', window );">Charitable contribution carryforwards</a></td>
<td class="nump">371<span></span>
</td>
<td class="nump">393<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and experimentation credits</a></td>
<td class="nump">2,420<span></span>
</td>
<td class="nump">2,420<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_DeferredTaxAssetResearchAndDevelopment', window );">Capitalized research and development costs</a></td>
<td class="nump">951<span></span>
</td>
<td class="nump">979<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Capitalized intangibles</a></td>
<td class="nump">354<span></span>
</td>
<td class="nump">356<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">232<span></span>
</td>
<td class="nump">205<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits', window );">Accrued compensation</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_DeferredTaxAssetsLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">69<span></span>
</td>
<td class="nump">94<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">55,594<span></span>
</td>
<td class="nump">54,461<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(55,531)<span></span>
</td>
<td class="num">(54,372)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred tax assets, net of valuation allowance</a></td>
<td class="nump">63<span></span>
</td>
<td class="nump">89<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_DeferredTaxLiabilitiesRightOfUseAsset', window );">Right-of-use asset</a></td>
<td class="num">(61)<span></span>
</td>
<td class="num">(84)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Depreciation and amortization</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax liability</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_DeferredTaxAssetResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from research and development costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_DeferredTaxAssetResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_DeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_DeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_DeferredTaxAssetsLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_DeferredTaxAssetsLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_DeferredTaxLiabilitiesRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from right of use assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_DeferredTaxLiabilitiesRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible charitable contribution carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>128
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140399528361472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Details) - Schedule of Potentially Dilutive Shares of Common Stock - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_PotentiallyDilutiveSecuritiesExcludedAbstract0', window );"><strong>Potentially dilutive securities, excluded:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities, excluded</a></td>
<td class="nump">645,845<span></span>
</td>
<td class="nump">755,857<span></span>
</td>
<td class="nump">616,707<span></span>
</td>
<td class="nump">795,960<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember', window );">Outstanding stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_PotentiallyDilutiveSecuritiesExcludedAbstract0', window );"><strong>Potentially dilutive securities, excluded:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities, excluded</a></td>
<td class="nump">645,845<span></span>
</td>
<td class="nump">664,857<span></span>
</td>
<td class="nump">616,707<span></span>
</td>
<td class="nump">704,960<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Unvested restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_PotentiallyDilutiveSecuritiesExcludedAbstract0', window );"><strong>Potentially dilutive securities, excluded:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities, excluded</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">91,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">91,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_PotentiallyDilutiveSecuritiesExcludedAbstract0">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_PotentiallyDilutiveSecuritiesExcludedAbstract0</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>129
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140399533066352">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment (Details) - Schedule of Property and Equipment - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and Equipment, Gross</a></td>
<td class="nump">$ 222<span></span>
</td>
<td class="nump">$ 222<span></span>
</td>
<td class="nump">$ 229<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation and amortization</a></td>
<td class="num">(215)<span></span>
</td>
<td class="num">(212)<span></span>
</td>
<td class="num">(204)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and Equipment, Gross</a></td>
<td class="nump">$ 39<span></span>
</td>
<td class="nump">$ 39<span></span>
</td>
<td class="nump">39<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Lab Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and Equipment, Gross</a></td>
<td class="nump">$ 130<span></span>
</td>
<td class="nump">$ 130<span></span>
</td>
<td class="nump">130<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and Equipment, Gross</a></td>
<td class="nump">$ 37<span></span>
</td>
<td class="nump">$ 37<span></span>
</td>
<td class="nump">44<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Computer Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and Equipment, Gross</a></td>
<td class="nump">$ 16<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>130
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140399531078128">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies (Details) - Schedule of Future Minimum Commitments Due - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_ScheduleOfFutureMinimumCommitmentsDueAbstract', window );"><strong>Schedule of Future Minimum Commitments Due [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2024</a></td>
<td class="nump">$ 49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total remaining lease payments</a></td>
<td class="nump">49<span></span>
</td>
<td class="nump">$ 314<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed lease interest</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(34)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: Current portion</a></td>
<td class="num">(48)<span></span>
</td>
<td class="num">(76)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, net of current portion</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 204<span></span>
</td>
<td class="nump">$ 280<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_ScheduleOfFutureMinimumCommitmentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_ScheduleOfFutureMinimumCommitmentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>131
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140399531067072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Compensation (Details) - Schedule of Non-cash, Share-based Compensation Expense - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total expenses</a></td>
<td class="nump">$ 114<span></span>
</td>
<td class="nump">$ 204<span></span>
</td>
<td class="nump">$ 686<span></span>
</td>
<td class="nump">$ 556<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total expenses</a></td>
<td class="nump">114<span></span>
</td>
<td class="nump">163<span></span>
</td>
<td class="nump">526<span></span>
</td>
<td class="nump">423<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total expenses</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 41<span></span>
</td>
<td class="nump">$ 160<span></span>
</td>
<td class="nump">$ 133<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>132
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140399531158944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Compensation (Details) - Schedule of Stock Option Activities - $ / shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_ScheduleOfStockOptionActivitiesAbstract', window );"><strong>Schedule of Stock Option Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Options outstanding, ending balance</a></td>
<td class="nump">616,707<span></span>
</td>
<td class="nump">645,845<span></span>
</td>
<td class="nump">616,707<span></span>
</td>
<td class="nump">704,960<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Options outstanding, ending balance</a></td>
<td class="nump">$ 4.76<span></span>
</td>
<td class="nump">$ 4.3<span></span>
</td>
<td class="nump">$ 4.76<span></span>
</td>
<td class="nump">$ 5.62<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term (in years) Options outstanding, ending balance</a></td>
<td class="text">7 years 4 months 6 days<span></span>
</td>
<td class="text">6 years 9 months 25 days<span></span>
</td>
<td class="text">7 years 4 months 6 days<span></span>
</td>
<td class="text">8 years 3 months 14 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Options, Options exercisable, ending balance</a></td>
<td class="nump">463,068<span></span>
</td>
<td class="nump">502,517<span></span>
</td>
<td class="nump">463,068<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Options exercisable, ending balance</a></td>
<td class="nump">$ 5.28<span></span>
</td>
<td class="nump">$ 4.71<span></span>
</td>
<td class="nump">$ 5.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term (in years), Options exercisable, ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 6 months 18 days<span></span>
</td>
<td class="text">7 years 3 months 14 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of Options, Options vested and expected to vest, ending balance</a></td>
<td class="nump">616,661<span></span>
</td>
<td class="nump">645,816<span></span>
</td>
<td class="nump">616,661<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Options vested and expected to vest, ending balance</a></td>
<td class="nump">$ 4.76<span></span>
</td>
<td class="nump">$ 4.3<span></span>
</td>
<td class="nump">$ 4.76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term (in years), Options vested and expected to vest, ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 9 months 25 days<span></span>
</td>
<td class="text">7 years 4 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Options, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">60,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.64<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 2.31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of Options, Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Number of Options, Forfeited and cancelled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,862)<span></span>
</td>
<td class="num">(88,253)<span></span>
</td>
<td class="num">(259,163)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Forfeited and cancelled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.45<span></span>
</td>
<td class="nump">$ 11.68<span></span>
</td>
<td class="nump">$ 4.74<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_ScheduleOfStockOptionActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_ScheduleOfStockOptionActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>133
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140399528482144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Events (Details) - Subsequent Event [Member] - USD ($)<br></strong></div></th>
<th class="th"><div>Apr. 20, 2024</div></th>
<th class="th"><div>Apr. 03, 2024</div></th>
<th class="th"><div>Apr. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_ThresholdAmountOfDeclaredCashDividend', window );">Declared cash dividend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_RetentionBonuses', window );">Retention bonuses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 444,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">ARCA and Oruka</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Percentage of ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97.62%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">ARCA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_NumberOfConsecutiveTradingDays', window );">Number of consecutive trading days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_ThresholdAmountOfAdjustedExchangeRatio', window );">Adjusted exchange ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">ARCA | ARCA and Oruka</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Percentage of noncontrolling ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.38%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Common Stock | ARCA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_InitiallySpecifiedPercentageForBeneficialNumberOfShares', window );">Initially specified percentage for beneficial number of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Common Stock and Pre Funded Warrants [Member] | Oruka Therapeutics Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_AggregatePurchasePrice', window );">Aggregate purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 275,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Merger Agreement | ARCA and Oruka</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_PaymentOfOtherPartyTerminationFee', window );">Payment of other party termination fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">440,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Merger Agreement | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_SubscriptionAgreementReceiptAmount', window );">Subscription agreement receipt amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 175,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">First Merger | Oruka Therapeutics Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_ExceptedNumberOfBoardMembers', window );">Excepted number of board members</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Seperation Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_NumberOfMonthsBaseSalary', window );">Number of months base salary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_CashPayment', window );">Cash payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_PresidentMember', window );">Thomas A. Keuer | Second Amendment of Certain Retention Bonus Letters</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_IncreaseOfRetentionBonusToEachExecutive', window );">Increase of retention bonus to each executive</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ChiefFinancialOfficerMember', window );">C. Jeffrey Dekker | Second Amendment of Certain Retention Bonus Letters</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_IncreaseOfRetentionBonusToEachExecutive', window );">Increase of retention bonus to each executive</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=abio_ThomasAKeuerAndCJeffreyDekkerMember', window );">Thomas A. Keuer and C. Jeffrey Dekker [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_RetentionBonuses', window );">Retention bonuses</a></td>
<td class="nump">$ 165,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_MinimumPercentageOfOriginallyIssuedShares', window );">Minimum percentage of originally issued outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_MinimumPercentageOfOriginallyIssuedOutstanding', window );">Minimum percentage of originally issued outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock | Merger Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock | First Merger | Common Stock | ARCA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleSharesIssuable', window );">Preferred stock convertible shares issuable (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_AggregatePurchasePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate purchase price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_AggregatePurchasePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_CashPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_CashPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_ExceptedNumberOfBoardMembers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excepted Number of Board Members</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_ExceptedNumberOfBoardMembers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_IncreaseOfRetentionBonusToEachExecutive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase of retention bonus to each executive.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_IncreaseOfRetentionBonusToEachExecutive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_InitiallySpecifiedPercentageForBeneficialNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Initially specified percentage for beneficial number of shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_InitiallySpecifiedPercentageForBeneficialNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_MinimumPercentageOfOriginallyIssuedOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum percentage of originally issued outstanding</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_MinimumPercentageOfOriginallyIssuedOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_MinimumPercentageOfOriginallyIssuedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum percentage of originally issued shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_MinimumPercentageOfOriginallyIssuedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_NumberOfConsecutiveTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of consecutive trading days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_NumberOfConsecutiveTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_NumberOfMonthsBaseSalary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of months base salary</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_NumberOfMonthsBaseSalary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_PaymentOfOtherPartyTerminationFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment of other party termination fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_PaymentOfOtherPartyTerminationFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_RetentionBonuses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Retention bonuses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_RetentionBonuses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_SubscriptionAgreementReceiptAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Subscription agreement receipt amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_SubscriptionAgreementReceiptAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_SubsequentEventsDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_SubsequentEventsDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_ThresholdAmountOfAdjustedExchangeRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold amount of adjusted exchange ratio.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_ThresholdAmountOfAdjustedExchangeRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_ThresholdAmountOfDeclaredCashDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold amount of declared cash dividend.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_ThresholdAmountOfDeclaredCashDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleSharesIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common shares issuable upon conversion of preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleSharesIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=abio_ArcaBiopharmaIncAndOrukaTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=abio_ArcaBiopharmaIncAndOrukaTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=abio_ArcaBiopharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=abio_ArcaBiopharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=abio_CommonStockAndPreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=abio_CommonStockAndPreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=abio_OrukaTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=abio_OrukaTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=abio_MergerAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=abio_MergerAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=abio_FirstMergerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=abio_FirstMergerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=abio_SeperationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=abio_SeperationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_PresidentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_PresidentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=abio_SecondAmendmentOfCertainRetentionBonusLettersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=abio_SecondAmendmentOfCertainRetentionBonusLettersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefFinancialOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefFinancialOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=abio_ThomasAKeuerAndCJeffreyDekkerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=abio_ThomasAKeuerAndCJeffreyDekkerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>134
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>154</ContextCount>
  <ElementCount>248</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>50</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="ea0205122-04.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ea0205122-04.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>001 - Statement - Balance Sheets (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet</Role>
      <ShortName>Balance Sheets (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ea0205122-04.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>002 - Statement - Balance Sheets (Unaudited) (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet_Parentheticals</Role>
      <ShortName>Balance Sheets (Unaudited) (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ea0205122-04.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>003 - Statement - Statements of Operations (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement</Role>
      <ShortName>Statements of Operations (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ea0205122-04.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>004 - Statement - Statements of Operations (Unaudited) (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement_Parentheticals</Role>
      <ShortName>Statements of Operations (Unaudited) (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ea0205122-04.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>005 - Statement - Statements of Stockholders??? Equity (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/ShareholdersEquityType2or3</Role>
      <ShortName>Statements of Stockholders??? Equity (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ea0205122-04.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>006 - Statement - Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/ConsolidatedCashFlow</Role>
      <ShortName>Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ea0205122-04.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>007 - Disclosure - ARCA and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/ARCAandSummaryofSignificantAccountingPolicies</Role>
      <ShortName>ARCA and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ea0205122-04.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>008 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/NetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ea0205122-04.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>009 - Disclosure - Fair Value Disclosures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/FairValueDisclosures</Role>
      <ShortName>Fair Value Disclosures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ea0205122-04.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>010 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/PropertyandEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ea0205122-04.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>011 - Disclosure - Related Party Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/RelatedPartyArrangements</Role>
      <ShortName>Related Party Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ea0205122-04.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>012 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ea0205122-04.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>013 - Disclosure - Equity Financings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/EquityFinancings</Role>
      <ShortName>Equity Financings</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ea0205122-04.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>014 - Disclosure - Share-based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/SharebasedCompensation</Role>
      <ShortName>Share-based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ea0205122-04.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>015 - Disclosure - Employee Benefit Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/EmployeeBenefitPlans</Role>
      <ShortName>Employee Benefit Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ea0205122-04.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>016 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ea0205122-04.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>017 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="ea0205122-04.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>996000 - Disclosure - Accounting Policies, by Policy (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/AccountingPoliciesByPolicy</Role>
      <ShortName>Accounting Policies, by Policy (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.arcabiopharma.com/role/ARCAandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="ea0205122-04.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>996001 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/NetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arcabiopharma.com/role/NetLossPerShare</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="ea0205122-04.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>996002 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/PropertyandEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arcabiopharma.com/role/PropertyandEquipment</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="ea0205122-04.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>996003 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/CommitmentsandContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arcabiopharma.com/role/CommitmentsandContingencies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="ea0205122-04.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>996004 - Disclosure - Share-based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/SharebasedCompensationTables</Role>
      <ShortName>Share-based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arcabiopharma.com/role/SharebasedCompensation</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="ea0205122-04.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>996005 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arcabiopharma.com/role/IncomeTaxes</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="ea0205122-04.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>996006 - Disclosure - ARCA and Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/ARCAandSummaryofSignificantAccountingPoliciesDetails</Role>
      <ShortName>ARCA and Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="ea0205122-04.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>996007 - Disclosure - Net Loss Per Share (Details) - Schedule of Potentially Dilutive Shares of Common Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/ScheduleofPotentiallyDilutiveSharesofCommonStockTable</Role>
      <ShortName>Net Loss Per Share (Details) - Schedule of Potentially Dilutive Shares of Common Stock</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arcabiopharma.com/role/NetLossPerShareTables</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="ea0205122-04.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>996008 - Disclosure - Fair Value Disclosures (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/FairValueDisclosuresDetails</Role>
      <ShortName>Fair Value Disclosures (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arcabiopharma.com/role/FairValueDisclosures</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="ea0205122-04.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>996009 - Disclosure - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/PropertyandEquipmentDetails</Role>
      <ShortName>Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arcabiopharma.com/role/PropertyandEquipmentTables</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="ea0205122-04.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>996010 - Disclosure - Property and Equipment (Details) - Schedule of Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable</Role>
      <ShortName>Property and Equipment (Details) - Schedule of Property and Equipment</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arcabiopharma.com/role/PropertyandEquipmentTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="ea0205122-04.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>996011 - Disclosure - Related Party Arrangements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/RelatedPartyArrangementsDetails</Role>
      <ShortName>Related Party Arrangements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arcabiopharma.com/role/RelatedPartyArrangements</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="ea0205122-04.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>996012 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arcabiopharma.com/role/CommitmentsandContingenciesTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="ea0205122-04.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>996013 - Disclosure - Commitments and Contingencies (Details) - Schedule of Future Minimum Commitments Due</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable</Role>
      <ShortName>Commitments and Contingencies (Details) - Schedule of Future Minimum Commitments Due</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arcabiopharma.com/role/CommitmentsandContingenciesTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="ea0205122-04.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>996014 - Disclosure - Equity Financings (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/EquityFinancingsDetails</Role>
      <ShortName>Equity Financings (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arcabiopharma.com/role/EquityFinancings</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="ea0205122-04.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>996015 - Disclosure - Share-based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/SharebasedCompensationDetails</Role>
      <ShortName>Share-based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arcabiopharma.com/role/SharebasedCompensationTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="ea0205122-04.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>996016 - Disclosure - Share-based Compensation (Details) - Schedule of Estimated Weighted Average Grant Date Fair Value Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/ScheduleofEstimatedWeightedAverageGrantDateFairValuePerShareTable</Role>
      <ShortName>Share-based Compensation (Details) - Schedule of Estimated Weighted Average Grant Date Fair Value Per Share</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arcabiopharma.com/role/SharebasedCompensationTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="ea0205122-04.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>996017 - Disclosure - Share-based Compensation (Details) - Schedule of Stock Option Activities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable</Role>
      <ShortName>Share-based Compensation (Details) - Schedule of Stock Option Activities</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arcabiopharma.com/role/SharebasedCompensationTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="ea0205122-04.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>996018 - Disclosure - Share-based Compensation (Details) - Schedule of RSU Activity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/ScheduleofRSUActivityTable</Role>
      <ShortName>Share-based Compensation (Details) - Schedule of RSU Activity</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arcabiopharma.com/role/SharebasedCompensationTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="ea0205122-04.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>996019 - Disclosure - Share-based Compensation (Details) - Schedule of Non-cash, Share-based Compensation Expense</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/ScheduleofNoncashSharebasedCompensationExpenseTable</Role>
      <ShortName>Share-based Compensation (Details) - Schedule of Non-cash, Share-based Compensation Expense</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arcabiopharma.com/role/SharebasedCompensationTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="ea0205122-04.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>996020 - Disclosure - Employee Benefit Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/EmployeeBenefitPlansDetails</Role>
      <ShortName>Employee Benefit Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arcabiopharma.com/role/EmployeeBenefitPlans</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="ea0205122-04.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>996021 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arcabiopharma.com/role/IncomeTaxesTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="ea0205122-04.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>996022 - Disclosure - Income Taxes (Details) - Schedule of Income Tax Benefit Attributable to Our Loss from Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/ScheduleofIncomeTaxBenefitAttributabletoOurLossfromOperationsTable</Role>
      <ShortName>Income Taxes (Details) - Schedule of Income Tax Benefit Attributable to Our Loss from Operations</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arcabiopharma.com/role/IncomeTaxesTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="ea0205122-04.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>996023 - Disclosure - Income Taxes (Details) - Schedule of Net deferred tax assets and liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable</Role>
      <ShortName>Income Taxes (Details) - Schedule of Net deferred tax assets and liabilities</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arcabiopharma.com/role/IncomeTaxesTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="ea0205122-04.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>996024 - Disclosure - Net Loss Per Share (Details) - Schedule of Potentially Dilutive Shares of Common Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/ScheduleofPotentiallyDilutiveSharesofCommonStockTable0</Role>
      <ShortName>Net Loss Per Share (Details) - Schedule of Potentially Dilutive Shares of Common Stock</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arcabiopharma.com/role/NetLossPerShareTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="ea0205122-04.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>996025 - Disclosure - Property and Equipment (Details) - Schedule of Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable0</Role>
      <ShortName>Property and Equipment (Details) - Schedule of Property and Equipment</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arcabiopharma.com/role/PropertyandEquipmentTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="ea0205122-04.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>996026 - Disclosure - Commitments and Contingencies (Details) - Schedule of Future Minimum Commitments Due</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable0</Role>
      <ShortName>Commitments and Contingencies (Details) - Schedule of Future Minimum Commitments Due</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arcabiopharma.com/role/CommitmentsandContingenciesTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="ea0205122-04.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>996027 - Disclosure - Share-based Compensation (Details) - Schedule of Non-cash, Share-based Compensation Expense</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/ScheduleofNoncashSharebasedCompensationExpenseTable0</Role>
      <ShortName>Share-based Compensation (Details) - Schedule of Non-cash, Share-based Compensation Expense</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arcabiopharma.com/role/SharebasedCompensationTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="ea0205122-04.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>996028 - Disclosure - Share-based Compensation (Details) - Schedule of Stock Option Activities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable0</Role>
      <ShortName>Share-based Compensation (Details) - Schedule of Stock Option Activities</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arcabiopharma.com/role/SharebasedCompensationTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="ea0205122-04.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>996029 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arcabiopharma.com/role/SubsequentEvents</ParentRole>
      <Position>48</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>abio-20240331.xsd</File>
    <File>abio-20240331_cal.xml</File>
    <File>abio-20240331_def.xml</File>
    <File>abio-20240331_lab.xml</File>
    <File>abio-20240331_pre.xml</File>
    <File doctype="S-4/A" isDefinitelyFs="true" isUsgaap="true" original="ea0205122-04.htm">ea0205122-04.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>tarca_001.jpg</File>
    <File>timage_001.jpg</File>
    <File>timage_002.jpg</File>
    <File>timage_003.jpg</File>
    <File>timage_004.jpg</File>
    <File>timage_005.jpg</File>
    <File>timage_006.jpg</File>
    <File>timage_007.jpg</File>
    <File>tlucid_sig.jpg</File>
    <File>toruka_logo.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="650">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="9">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>136
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ea0205122-04.htm": {
   "nsprefix": "abio",
   "nsuri": "http://www.arcabiopharma.com/20240331",
   "dts": {
    "schema": {
     "local": [
      "abio-20240331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/sic/2024/sic-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "abio-20240331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "abio-20240331_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "abio-20240331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "abio-20240331_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "ea0205122-04.htm"
     ]
    }
   },
   "keyStandard": 209,
   "keyCustom": 39,
   "axisStandard": 23,
   "axisCustom": 0,
   "memberStandard": 28,
   "memberCustom": 20,
   "hidden": {
    "total": 122,
    "http://fasb.org/us-gaap/2024": 114,
    "http://www.arcabiopharma.com/20240331": 5,
    "http://xbrl.sec.gov/dei/2024": 3
   },
   "contextCount": 154,
   "entityCount": 1,
   "segmentCount": 50,
   "elementCount": 409,
   "unitCount": 6,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 650,
    "http://xbrl.sec.gov/dei/2024": 9
   },
   "report": {
    "R1": {
     "role": "http://www.arcabiopharma.com/role/DocumentAndEntityInformation",
     "longName": "000 - Document - Document And Entity Information",
     "shortName": "Document And Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-04.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-04.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet",
     "longName": "001 - Statement - Balance Sheets (Unaudited)",
     "shortName": "Balance Sheets (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c5",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-04.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c5",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-04.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet_Parentheticals",
     "longName": "002 - Statement - Balance Sheets (Unaudited) (Parentheticals)",
     "shortName": "Balance Sheets (Unaudited) (Parentheticals)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c5",
      "name": "us-gaap:OtherAccruedLiabilitiesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-04.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c1",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "usdPershares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-04.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement",
     "longName": "003 - Statement - Statements of Operations (Unaudited)",
     "shortName": "Statements of Operations (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-04.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-04.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement_Parentheticals",
     "longName": "004 - Statement - Statements of Operations (Unaudited) (Parentheticals)",
     "shortName": "Statements of Operations (Unaudited) (Parentheticals)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c11",
      "name": "abio:ResearchAndDevelopmentExpenseReversed",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-04.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c11",
      "name": "abio:ResearchAndDevelopmentExpenseReversed",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-04.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.arcabiopharma.com/role/ShareholdersEquityType2or3",
     "longName": "005 - Statement - Statements of Stockholders\u2019 Equity (Unaudited)",
     "shortName": "Statements of Stockholders\u2019 Equity (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c13",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-04.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c13",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-04.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.arcabiopharma.com/role/ConsolidatedCashFlow",
     "longName": "006 - Statement - Statements of Cash Flows (Unaudited)",
     "shortName": "Statements of Cash Flows (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-04.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-04.htm",
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.arcabiopharma.com/role/ARCAandSummaryofSignificantAccountingPolicies",
     "longName": "007 - Disclosure - ARCA and Summary of Significant Accounting Policies",
     "shortName": "ARCA and Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-04.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-04.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.arcabiopharma.com/role/NetLossPerShare",
     "longName": "008 - Disclosure - Net Loss Per Share",
     "shortName": "Net Loss Per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-04.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-04.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.arcabiopharma.com/role/FairValueDisclosures",
     "longName": "009 - Disclosure - Fair Value Disclosures",
     "shortName": "Fair Value Disclosures",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-04.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-04.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.arcabiopharma.com/role/PropertyandEquipment",
     "longName": "010 - Disclosure - Property and Equipment",
     "shortName": "Property and Equipment",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-04.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-04.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.arcabiopharma.com/role/RelatedPartyArrangements",
     "longName": "011 - Disclosure - Related Party Arrangements",
     "shortName": "Related Party Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-04.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-04.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.arcabiopharma.com/role/CommitmentsandContingencies",
     "longName": "012 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-04.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-04.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.arcabiopharma.com/role/EquityFinancings",
     "longName": "013 - Disclosure - Equity Financings",
     "shortName": "Equity Financings",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-04.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-04.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.arcabiopharma.com/role/SharebasedCompensation",
     "longName": "014 - Disclosure - Share-based Compensation",
     "shortName": "Share-based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-04.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-04.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.arcabiopharma.com/role/EmployeeBenefitPlans",
     "longName": "015 - Disclosure - Employee Benefit Plans",
     "shortName": "Employee Benefit Plans",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c6",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-04.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c6",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-04.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.arcabiopharma.com/role/IncomeTaxes",
     "longName": "016 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-04.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-04.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.arcabiopharma.com/role/SubsequentEvents",
     "longName": "017 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-04.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-04.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.arcabiopharma.com/role/AccountingPoliciesByPolicy",
     "longName": "996000 - Disclosure - Accounting Policies, by Policy (Policies)",
     "shortName": "Accounting Policies, by Policy (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "abio:DescriptionOfBusinessPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-04.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "abio:DescriptionOfBusinessPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-04.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.arcabiopharma.com/role/NetLossPerShareTables",
     "longName": "996001 - Disclosure - Net Loss Per Share (Tables)",
     "shortName": "Net Loss Per Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-04.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-04.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.arcabiopharma.com/role/PropertyandEquipmentTables",
     "longName": "996002 - Disclosure - Property and Equipment (Tables)",
     "shortName": "Property and Equipment (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-04.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-04.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.arcabiopharma.com/role/CommitmentsandContingenciesTables",
     "longName": "996003 - Disclosure - Commitments and Contingencies (Tables)",
     "shortName": "Commitments and Contingencies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-04.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-04.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.arcabiopharma.com/role/SharebasedCompensationTables",
     "longName": "996004 - Disclosure - Share-based Compensation (Tables)",
     "shortName": "Share-based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c6",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-04.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c6",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-04.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.arcabiopharma.com/role/IncomeTaxesTables",
     "longName": "996005 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c6",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-04.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c6",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-04.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.arcabiopharma.com/role/ARCAandSummaryofSignificantAccountingPoliciesDetails",
     "longName": "996006 - Disclosure - ARCA and Summary of Significant Accounting Policies (Details)",
     "shortName": "ARCA and Summary of Significant Accounting Policies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "ix:continuation",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-04.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "ix:continuation",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-04.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.arcabiopharma.com/role/ScheduleofPotentiallyDilutiveSharesofCommonStockTable",
     "longName": "996007 - Disclosure - Net Loss Per Share (Details) - Schedule of Potentially Dilutive Shares of Common Stock",
     "shortName": "Net Loss Per Share (Details) - Schedule of Potentially Dilutive Shares of Common Stock",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-04.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R27": {
     "role": "http://www.arcabiopharma.com/role/FairValueDisclosuresDetails",
     "longName": "996008 - Disclosure - Fair Value Disclosures (Details)",
     "shortName": "Fair Value Disclosures (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c67",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-04.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c67",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-04.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.arcabiopharma.com/role/PropertyandEquipmentDetails",
     "longName": "996009 - Disclosure - Property and Equipment (Details)",
     "shortName": "Property and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:DepreciationAndAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-04.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R29": {
     "role": "http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable",
     "longName": "996010 - Disclosure - Property and Equipment (Details) - Schedule of Property and Equipment",
     "shortName": "Property and Equipment (Details) - Schedule of Property and Equipment",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c5",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-04.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R30": {
     "role": "http://www.arcabiopharma.com/role/RelatedPartyArrangementsDetails",
     "longName": "996011 - Disclosure - Related Party Arrangements (Details)",
     "shortName": "Related Party Arrangements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c127",
      "name": "abio:ResearchAndDevelopmentExpenseReversed",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-04.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c127",
      "name": "abio:ResearchAndDevelopmentExpenseReversed",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-04.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails",
     "longName": "996012 - Disclosure - Commitments and Contingencies (Details)",
     "shortName": "Commitments and Contingencies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c5",
      "name": "abio:RetentionBonuses",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-04.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c5",
      "name": "abio:RetentionBonuses",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-04.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable",
     "longName": "996013 - Disclosure - Commitments and Contingencies (Details) - Schedule of Future Minimum Commitments Due",
     "shortName": "Commitments and Contingencies (Details) - Schedule of Future Minimum Commitments Due",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c1",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-04.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c1",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-04.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.arcabiopharma.com/role/EquityFinancingsDetails",
     "longName": "996014 - Disclosure - Equity Financings (Details)",
     "shortName": "Equity Financings (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c5",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "usdPershares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-04.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c133",
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-04.htm",
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.arcabiopharma.com/role/SharebasedCompensationDetails",
     "longName": "996015 - Disclosure - Share-based Compensation (Details)",
     "shortName": "Share-based Compensation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-04.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c16",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-04.htm",
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.arcabiopharma.com/role/ScheduleofEstimatedWeightedAverageGrantDateFairValuePerShareTable",
     "longName": "996016 - Disclosure - Share-based Compensation (Details) - Schedule of Estimated Weighted Average Grant Date Fair Value Per Share",
     "shortName": "Share-based Compensation (Details) - Schedule of Estimated Weighted Average Grant Date Fair Value Per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c6",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-04.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c6",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-04.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable",
     "longName": "996017 - Disclosure - Share-based Compensation (Details) - Schedule of Stock Option Activities",
     "shortName": "Share-based Compensation (Details) - Schedule of Stock Option Activities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-04.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-04.htm",
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.arcabiopharma.com/role/ScheduleofRSUActivityTable",
     "longName": "996018 - Disclosure - Share-based Compensation (Details) - Schedule of RSU Activity",
     "shortName": "Share-based Compensation (Details) - Schedule of RSU Activity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-04.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c7",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-04.htm",
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.arcabiopharma.com/role/ScheduleofNoncashSharebasedCompensationExpenseTable",
     "longName": "996019 - Disclosure - Share-based Compensation (Details) - Schedule of Non-cash, Share-based Compensation Expense",
     "shortName": "Share-based Compensation (Details) - Schedule of Non-cash, Share-based Compensation Expense",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-04.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R39": {
     "role": "http://www.arcabiopharma.com/role/EmployeeBenefitPlansDetails",
     "longName": "996020 - Disclosure - Employee Benefit Plans (Details)",
     "shortName": "Employee Benefit Plans (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c6",
      "name": "us-gaap:DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-04.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c6",
      "name": "us-gaap:DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-04.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.arcabiopharma.com/role/IncomeTaxesDetails",
     "longName": "996021 - Disclosure - Income Taxes (Details)",
     "shortName": "Income Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c1",
      "name": "us-gaap:OperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-04.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c1",
      "name": "us-gaap:OperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-04.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.arcabiopharma.com/role/ScheduleofIncomeTaxBenefitAttributabletoOurLossfromOperationsTable",
     "longName": "996022 - Disclosure - Income Taxes (Details) - Schedule of Income Tax Benefit Attributable to Our Loss from Operations",
     "shortName": "Income Taxes (Details) - Schedule of Income Tax Benefit Attributable to Our Loss from Operations",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c6",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-04.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c6",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-04.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable",
     "longName": "996023 - Disclosure - Income Taxes (Details) - Schedule of Net deferred tax assets and liabilities",
     "shortName": "Income Taxes (Details) - Schedule of Net deferred tax assets and liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c1",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-04.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c1",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-04.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.arcabiopharma.com/role/ScheduleofPotentiallyDilutiveSharesofCommonStockTable0",
     "longName": "996024 - Disclosure - Net Loss Per Share (Details) - Schedule of Potentially Dilutive Shares of Common Stock",
     "shortName": "Net Loss Per Share (Details) - Schedule of Potentially Dilutive Shares of Common Stock",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-04.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R44": {
     "role": "http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable0",
     "longName": "996025 - Disclosure - Property and Equipment (Details) - Schedule of Property and Equipment",
     "shortName": "Property and Equipment (Details) - Schedule of Property and Equipment",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c5",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-04.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R45": {
     "role": "http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable0",
     "longName": "996026 - Disclosure - Commitments and Contingencies (Details) - Schedule of Future Minimum Commitments Due",
     "shortName": "Commitments and Contingencies (Details) - Schedule of Future Minimum Commitments Due",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c5",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-04.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c5",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-04.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.arcabiopharma.com/role/ScheduleofNoncashSharebasedCompensationExpenseTable0",
     "longName": "996027 - Disclosure - Share-based Compensation (Details) - Schedule of Non-cash, Share-based Compensation Expense",
     "shortName": "Share-based Compensation (Details) - Schedule of Non-cash, Share-based Compensation Expense",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-04.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R47": {
     "role": "http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable0",
     "longName": "996028 - Disclosure - Share-based Compensation (Details) - Schedule of Stock Option Activities",
     "shortName": "Share-based Compensation (Details) - Schedule of Stock Option Activities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-04.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R48": {
     "role": "http://www.arcabiopharma.com/role/SubsequentEventsDetails",
     "longName": "996029 - Disclosure - Subsequent Events (Details)",
     "shortName": "Subsequent Events (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c141",
      "name": "abio:ThresholdAmountOfDeclaredCashDividend",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-04.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c141",
      "name": "abio:ThresholdAmountOfDeclaredCashDividend",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-04.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "ARCA and Summary of Significant Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r565"
     ]
    },
    "abio_AccruedOutsourcingExpensesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "AccruedOutsourcingExpensesPolicyTextBlock",
     "presentation": [
      "http://www.arcabiopharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued Outsourcing Expenses",
        "documentation": "Accrued outsourcing expenses.",
        "label": "Accrued Outsourcing Expenses Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable",
      "http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accumulated depreciation and amortization",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r84",
      "r413"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital, Common Stock",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid-In Capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r440",
      "r588",
      "r589",
      "r590",
      "r591",
      "r709",
      "r732"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.arcabiopharma.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r20",
      "r239"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "abio_AggregatePurchasePrice": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "AggregatePurchasePrice",
     "crdr": "credit",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate purchase price",
        "documentation": "Aggregate purchase price.",
        "label": "Aggregate Purchase Price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofNoncashSharebasedCompensationExpenseTable",
      "http://www.arcabiopharma.com/role/ScheduleofNoncashSharebasedCompensationExpenseTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total expenses",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r270",
      "r279"
     ]
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://www.arcabiopharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Description",
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.arcabiopharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofPotentiallyDilutiveSharesofCommonStockTable",
      "http://www.arcabiopharma.com/role/ScheduleofPotentiallyDilutiveSharesofCommonStockTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Potentially dilutive securities, excluded",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r135"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofPotentiallyDilutiveSharesofCommonStockTable",
      "http://www.arcabiopharma.com/role/ScheduleofPotentiallyDilutiveSharesofCommonStockTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofPotentiallyDilutiveSharesofCommonStockTable",
      "http://www.arcabiopharma.com/role/ScheduleofPotentiallyDilutiveSharesofCommonStockTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofPotentiallyDilutiveSharesofCommonStockTable",
      "http://www.arcabiopharma.com/role/ScheduleofPotentiallyDilutiveSharesofCommonStockTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "abio_ArcaBiopharmaIncAndOrukaTherapeuticsIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "ArcaBiopharmaIncAndOrukaTherapeuticsIncMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ARCA and Oruka",
        "documentation": "Arca Biopharma Inc and Oruka Therapeutics Inc",
        "label": "Arca Biopharma Inc And Oruka Therapeutics Inc Member"
       }
      }
     },
     "auth_ref": []
    },
    "abio_ArcaBiopharmaIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "ArcaBiopharmaIncMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ARCA",
        "documentation": "ARCA biopharma inc member.",
        "label": "Arca Biopharma Inc Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AreaOfRealEstateProperty": {
     "xbrltype": "areaItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AreaOfRealEstateProperty",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Square feet (in Square Feet)",
        "label": "Area of Real Estate Property",
        "documentation": "Area of a real estate property."
       }
      }
     },
     "auth_ref": []
    },
    "abio_AreaOfRealEstatePropertySubleaseAdditionalOfficeFacilities": {
     "xbrltype": "areaItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "AreaOfRealEstatePropertySubleaseAdditionalOfficeFacilities",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Square feet office facilities (in Square Feet)",
        "documentation": "Area of real estate property sublease additional office facilities.",
        "label": "Area Of Real Estate Property Sublease Additional Office Facilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails",
      "http://www.arcabiopharma.com/role/EquityFinancingsDetails",
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r318"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r66",
      "r86",
      "r106",
      "r139",
      "r143",
      "r155",
      "r156",
      "r163",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r319",
      "r321",
      "r356",
      "r404",
      "r474",
      "r537",
      "r538",
      "r565",
      "r576",
      "r608",
      "r609",
      "r721"
     ]
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r91",
      "r106",
      "r163",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r319",
      "r321",
      "r356",
      "r565",
      "r608",
      "r609",
      "r721"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "crdr": "debit",
     "presentation": [
      "http://www.arcabiopharma.com/role/FairValueDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable securities",
        "label": "Debt Securities, Available-for-Sale",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r162",
      "r166",
      "r334",
      "r399",
      "r556",
      "r559",
      "r600",
      "r712",
      "r713",
      "r714"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.arcabiopharma.com/role/SharebasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r241",
      "r242",
      "r243",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.arcabiopharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Presentation",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "abio_CapitalOnDemandSalesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "CapitalOnDemandSalesAgreementMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/EquityFinancingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales Agreement",
        "documentation": "Capital on demand sales agreement.",
        "label": "Capital On Demand Sales Agreement Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r82",
      "r528"
     ]
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.arcabiopharma.com/role/FairValueDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash equivalents",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r710",
      "r711"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://www.arcabiopharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash Equivalents",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash and cash equivalents, beginning of year",
        "periodEndLabel": "Cash and cash equivalents, end of year",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r43",
      "r104"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net decrease in cash and cash equivalents",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r43"
     ]
    },
    "abio_CashPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "CashPayment",
     "crdr": "credit",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash payment",
        "documentation": "Cash payment",
        "label": "Cash Payment"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ChiefExecutiveOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ChiefExecutiveOfficerMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/RelatedPartyArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Chief Executive Officer",
        "verboseLabel": "Chief Executive Officer [Member]",
        "label": "Chief Executive Officer [Member]"
       }
      }
     },
     "auth_ref": [
      "r599"
     ]
    },
    "srt_ChiefFinancialOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ChiefFinancialOfficerMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "C. Jeffrey Dekker",
        "label": "Chief Financial Officer [Member]"
       }
      }
     },
     "auth_ref": [
      "r599"
     ]
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r87",
      "r88",
      "r89",
      "r106",
      "r129",
      "r130",
      "r132",
      "r134",
      "r141",
      "r142",
      "r163",
      "r182",
      "r184",
      "r185",
      "r186",
      "r189",
      "r190",
      "r194",
      "r195",
      "r199",
      "r202",
      "r208",
      "r356",
      "r431",
      "r432",
      "r433",
      "r434",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r462",
      "r483",
      "r505",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r578",
      "r586",
      "r592"
     ]
    },
    "abio_ClinicalDevelopmentDecisionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "ClinicalDevelopmentDecisionMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Clinical Development Decision [Member]",
        "verboseLabel": "Clinical development decisions",
        "documentation": "Clinical Development Decision Member.",
        "label": "Clinical Development Decision Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and contingencies",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r60",
      "r406",
      "r461"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r176",
      "r177",
      "r524",
      "r602",
      "r607"
     ]
    },
    "abio_CommitmentsandContingenciesDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "CommitmentsandContingenciesDetailsLineItems",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies (Details) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "abio_CommitmentsandContingenciesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "CommitmentsandContingenciesDetailsTable",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "abio_CommonStockAndPreFundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "CommonStockAndPreFundedWarrantsMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock and Pre Funded Warrants [Member]",
        "documentation": "Common stock and pre funded warrants",
        "label": "Common Stock And Pre Funded Warrants Member"
       }
      }
     },
     "auth_ref": []
    },
    "abio_CommonStockAuthorizedOfferingAmountUnderAgreementToSell": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "CommonStockAuthorizedOfferingAmountUnderAgreementToSell",
     "crdr": "credit",
     "presentation": [
      "http://www.arcabiopharma.com/role/EquityFinancingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate offering price (in Dollars)",
        "documentation": "Common stock, authorized offering amount under agreement to sell.",
        "label": "Common Stock Authorized Offering Amount Under Agreement To Sell"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://www.arcabiopharma.com/role/SharebasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reserved shares",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/ShareholdersEquityType2or3",
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r567",
      "r568",
      "r569",
      "r571",
      "r572",
      "r573",
      "r574",
      "r588",
      "r589",
      "r591",
      "r709",
      "r731",
      "r732"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.arcabiopharma.com/role/EquityFinancingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value (in Dollars per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares authorized",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r462"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares issued",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.arcabiopharma.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance (in Shares)",
        "periodEndLabel": "Balance (in Shares)",
        "terseLabel": "Common stock, shares outstanding",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r33",
      "r462",
      "r480",
      "r732",
      "r733"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, value",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r408",
      "r565"
     ]
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Benefit Plans [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "abio_ComprehensiveLossPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "ComprehensiveLossPolicyPolicyTextBlock",
     "presentation": [
      "http://www.arcabiopharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Comprehensive Loss",
        "documentation": "Comprehensive loss policy.",
        "label": "Comprehensive Loss Policy Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable",
      "http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Computer equipment",
        "verboseLabel": "Computer Equipment",
        "label": "Computer Equipment [Member]",
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://www.arcabiopharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentrations of Credit Risk",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r70"
     ]
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostsAndExpensesAbstract",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Costs and expenses:",
        "label": "Costs and Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r110",
      "r111",
      "r191",
      "r197",
      "r385",
      "r395",
      "r403",
      "r529",
      "r531"
     ]
    },
    "us-gaap_DebtLongtermAndShorttermCombinedAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtLongtermAndShorttermCombinedAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.arcabiopharma.com/role/FairValueDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt outstanding",
        "label": "Debt, Long-Term and Short-Term, Combined Amount",
        "documentation": "Represents the aggregate of total long-term debt, including current maturities and short-term debt."
       }
      }
     },
     "auth_ref": []
    },
    "abio_DeferredTaxAssetResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "DeferredTaxAssetResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capitalized research and development costs",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from research and development costs.",
        "label": "Deferred Tax Asset Research And Development"
       }
      }
     },
     "auth_ref": []
    },
    "abio_DeferredTaxAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "DeferredTaxAssetsAbstract",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax assets:",
        "label": "Deferred Tax Assets Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "abio_DeferredTaxAssetsAndLiabilitiesValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "DeferredTaxAssetsAndLiabilitiesValuationAllowance",
     "crdr": "credit",
     "presentation": [
      "http://www.arcabiopharma.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Valuation allowance",
        "documentation": "Deferred tax assets and liabilities valuation allowance.",
        "label": "Deferred Tax Assets And Liabilities Valuation Allowance"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsCharitableContributionCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Charitable contribution carryforwards",
        "label": "Deferred Tax Assets, Charitable Contribution Carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible charitable contribution carryforwards."
       }
      }
     },
     "auth_ref": [
      "r708"
     ]
    },
    "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capitalized intangibles",
        "label": "Deferred Tax Assets, Goodwill and Intangible Assets",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill."
       }
      }
     },
     "auth_ref": [
      "r708"
     ]
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred tax assets",
        "label": "Deferred Tax Assets, Gross",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r297"
     ]
    },
    "abio_DeferredTaxAssetsLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "DeferredTaxAssetsLeaseLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liabilities",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from lease liabilities.",
        "label": "Deferred Tax Assets Lease Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net deferred tax liability",
        "label": "Deferred Tax Assets, Net",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r704"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred tax assets, net of valuation allowance",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r704"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss carryforwards",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates."
       }
      }
     },
     "auth_ref": [
      "r708"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and experimentation credits",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r708"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued compensation",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs."
       }
      }
     },
     "auth_ref": [
      "r708"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r708"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Valuation allowance",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r298"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesAbstract",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax liabilities:",
        "label": "Deferred Tax Liabilities, Gross [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Depreciation and amortization",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment."
       }
      }
     },
     "auth_ref": [
      "r708"
     ]
    },
    "abio_DeferredTaxLiabilitiesRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "DeferredTaxLiabilitiesRightOfUseAsset",
     "crdr": "credit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Right-of-use asset",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from right of use assets.",
        "label": "Deferred Tax Liabilities Right Of Use Asset"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedContributionPlanCostRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.arcabiopharma.com/role/EmployeeBenefitPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company's contribution (in Dollars)",
        "label": "Defined Contribution Plan, Cost",
        "documentation": "Amount of cost for defined contribution plan."
       }
      }
     },
     "auth_ref": [
      "r228"
     ]
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercent",
     "presentation": [
      "http://www.arcabiopharma.com/role/EmployeeBenefitPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equal contribution percentage",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay",
        "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
     "presentation": [
      "http://www.arcabiopharma.com/role/EmployeeBenefitPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee\u2019s contribution percentage",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match",
        "documentation": "Percentage employer matches of the employee's percentage contribution matched."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepreciationAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow",
      "http://www.arcabiopharma.com/role/PropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation",
        "verboseLabel": "Depreciation and amortization expense",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r15"
     ]
    },
    "abio_DescriptionOfBusinessPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "DescriptionOfBusinessPolicyTextBlock",
     "presentation": [
      "http://www.arcabiopharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Description of Business",
        "documentation": "Description of business.",
        "label": "Description Of Business Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans",
     "presentation": [
      "http://www.arcabiopharma.com/role/EmployeeBenefitPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Matching contribution",
        "label": "Defined Contribution Plan, Description",
        "documentation": "Description of defined contribution pension and other postretirement plans."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.arcabiopharma.com/role/SharebasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r238",
      "r240",
      "r271",
      "r272",
      "r274",
      "r552"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "abio_DocumentAndEntityInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "DocumentAndEntityInformationAbstract",
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://www.arcabiopharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationTable",
     "presentation": [
      "http://www.arcabiopharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.arcabiopharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarliestTaxYearMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarliestTaxYearMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earliest Tax Year",
        "label": "Earliest Tax Year [Member]",
        "documentation": "Earliest identified tax year."
       }
      }
     },
     "auth_ref": [
      "r703"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareAbstract",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss Per Share [Abstract]",
        "terseLabel": "Net loss per share:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic (in Dollars per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r117",
      "r118",
      "r119",
      "r120",
      "r121",
      "r122",
      "r127",
      "r129",
      "r132",
      "r133",
      "r134",
      "r138",
      "r314",
      "r317",
      "r331",
      "r332",
      "r400",
      "r417",
      "r532"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r117",
      "r118",
      "r119",
      "r120",
      "r121",
      "r122",
      "r129",
      "r132",
      "r133",
      "r134",
      "r138",
      "r314",
      "r317",
      "r331",
      "r332",
      "r400",
      "r417",
      "r532"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.arcabiopharma.com/role/NetLossPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Loss Per Share",
        "label": "Earnings Per Share [Text Block]",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r135",
      "r136",
      "r137"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "presentation": [
      "http://www.arcabiopharma.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal statutory income tax rate",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r287",
      "r305",
      "r555"
     ]
    },
    "abio_EmployeeBenefitPlansDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "EmployeeBenefitPlansDetailsLineItems",
     "presentation": [
      "http://www.arcabiopharma.com/role/EmployeeBenefitPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Benefit Plans (Details) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "abio_EmployeeBenefitPlansDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "EmployeeBenefitPlansDetailsTable",
     "presentation": [
      "http://www.arcabiopharma.com/role/EmployeeBenefitPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Benefit Plans (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued compensation and employee benefits",
        "label": "Employee-related Liabilities, Current",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofNoncashSharebasedCompensationExpenseTable",
      "http://www.arcabiopharma.com/role/ScheduleofNoncashSharebasedCompensationExpenseTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.arcabiopharma.com/role/SharebasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average period",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r273"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.arcabiopharma.com/role/SharebasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized compensation cost (in Dollars)",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r698"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.arcabiopharma.com/role/SharebasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized compensation expense (in Dollars)",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r698"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/SharebasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Stock Option",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.arcabiopharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r577"
     ]
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityDomain",
     "presentation": [
      "http://www.arcabiopharma.com/role/EquityFinancingsDetails",
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.arcabiopharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r577"
     ]
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.arcabiopharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r577"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.arcabiopharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.arcabiopharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r577"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.arcabiopharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r577"
     ]
    },
    "us-gaap_EquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquipmentMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable",
      "http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lab equipment",
        "verboseLabel": "Lab Equipment",
        "label": "Equipment [Member]",
        "documentation": "Tangible personal property used to produce goods and services."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Financings [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.arcabiopharma.com/role/ShareholdersEquityType2or3",
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r78",
      "r95",
      "r96",
      "r97",
      "r112",
      "r113",
      "r114",
      "r116",
      "r121",
      "r123",
      "r125",
      "r140",
      "r164",
      "r165",
      "r167",
      "r209",
      "r303",
      "r304",
      "r311",
      "r312",
      "r313",
      "r315",
      "r316",
      "r317",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r330",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r364",
      "r365",
      "r378",
      "r416",
      "r423",
      "r424",
      "r425",
      "r440",
      "r505"
     ]
    },
    "abio_EquityFinancingsDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "EquityFinancingsDetailsLineItems",
     "presentation": [
      "http://www.arcabiopharma.com/role/EquityFinancingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Financings (Details) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "abio_EquityFinancingsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "EquityFinancingsDetailsTable",
     "presentation": [
      "http://www.arcabiopharma.com/role/EquityFinancingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Financings (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "abio_ExceptedNumberOfBoardMembers": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "ExceptedNumberOfBoardMembers",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Excepted number of board members",
        "documentation": "Excepted Number of Board Members",
        "label": "Excepted Number Of Board Members"
       }
      }
     },
     "auth_ref": []
    },
    "abio_FairValueAssetsBetweenHierarchyLevelsTransfersAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "FairValueAssetsBetweenHierarchyLevelsTransfersAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.arcabiopharma.com/role/FairValueDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value hierarchy",
        "documentation": "Fair value assets between hierarchy levels transfers amount.",
        "label": "Fair Value Assets Between Hierarchy Levels Transfers Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "presentation": [
      "http://www.arcabiopharma.com/role/FairValueDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Class [Domain]",
        "documentation": "Class of asset."
       }
      }
     },
     "auth_ref": [
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r349",
      "r557"
     ]
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByAssetClassAxis",
     "presentation": [
      "http://www.arcabiopharma.com/role/FairValueDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Class [Axis]",
        "documentation": "Information by class of asset."
       }
      }
     },
     "auth_ref": [
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r349",
      "r557"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.arcabiopharma.com/role/FairValueDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r192",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r333",
      "r335",
      "r336",
      "r337",
      "r338",
      "r347",
      "r348",
      "r350",
      "r390",
      "r391",
      "r392",
      "r545",
      "r546",
      "r548",
      "r549",
      "r550",
      "r556",
      "r559"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://www.arcabiopharma.com/role/FairValueDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r334",
      "r335",
      "r336",
      "r338",
      "r556",
      "r713",
      "r715"
     ]
    },
    "us-gaap_FairValueDisclosureOffbalanceSheetRisksAmountAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosureOffbalanceSheetRisksAmountAsset",
     "crdr": "debit",
     "presentation": [
      "http://www.arcabiopharma.com/role/ARCAandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Off-balance-sheet concentrations of credit risk",
        "label": "Fair Value Disclosure, off-Balance-Sheet Risks, Amount, Asset",
        "documentation": "The fair value of financial assets, which are not recognized in the financial statements (off-balance sheet) because they fail to meet some other criterion for recognition."
       }
      }
     },
     "auth_ref": [
      "r355"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "abio_FairValueDisclosuresDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "FairValueDisclosuresDetailsLineItems",
     "presentation": [
      "http://www.arcabiopharma.com/role/FairValueDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures (Details) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "abio_FairValueDisclosuresDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "FairValueDisclosuresDetailsTable",
     "presentation": [
      "http://www.arcabiopharma.com/role/FairValueDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.arcabiopharma.com/role/FairValueDisclosures"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Disclosures",
        "label": "Fair Value Disclosures [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r343",
      "r345",
      "r346",
      "r347",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r398",
      "r556",
      "r560"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.arcabiopharma.com/role/FairValueDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Inputs, Level 1 [Member]",
        "verboseLabel": "Level 1",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r192",
      "r213",
      "r218",
      "r335",
      "r348",
      "r390",
      "r548",
      "r549",
      "r550",
      "r556"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://www.arcabiopharma.com/role/FairValueDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r334",
      "r335",
      "r336",
      "r338",
      "r556",
      "r713",
      "r715"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.arcabiopharma.com/role/FairValueDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r192",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r333",
      "r335",
      "r336",
      "r337",
      "r338",
      "r347",
      "r348",
      "r350",
      "r390",
      "r391",
      "r392",
      "r545",
      "r546",
      "r548",
      "r549",
      "r550",
      "r556",
      "r559"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/FairValueDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Recurring [Member]",
        "verboseLabel": "Fair Value Measurements, Recurring",
        "label": "Fair Value, Recurring [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r556",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715"
     ]
    },
    "abio_FirstMergerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "FirstMergerMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "First Merger",
        "documentation": "First Merge",
        "label": "First Merger Member"
       }
      }
     },
     "auth_ref": []
    },
    "abio_FirstThreePercentPayContributionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "FirstThreePercentPayContributionMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/EmployeeBenefitPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "First 3% of pay contributed",
        "documentation": "First three percent pay contribution.",
        "label": "First Three Percent Pay Contribution Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable",
      "http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Furniture and fixtures",
        "verboseLabel": "Furniture and Fixtures",
        "label": "Furniture and Fixtures [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Loss from disposal of property and equipment",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "label": "General and Administrative Expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r485"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails",
      "http://www.arcabiopharma.com/role/ScheduleofNoncashSharebasedCompensationExpenseTable",
      "http://www.arcabiopharma.com/role/ScheduleofNoncashSharebasedCompensationExpenseTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and Administrative",
        "verboseLabel": "General and Administrative Expense",
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "abio_IncentiveStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "IncentiveStockOptionMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/SharebasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Incentive Stock Option",
        "documentation": "Incentive stock option.",
        "label": "Incentive Stock Option Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails",
      "http://www.arcabiopharma.com/role/ScheduleofNoncashSharebasedCompensationExpenseTable",
      "http://www.arcabiopharma.com/role/ScheduleofNoncashSharebasedCompensationExpenseTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r168",
      "r169",
      "r172",
      "r340",
      "r344",
      "r349",
      "r420",
      "r422",
      "r490",
      "r527",
      "r558",
      "r730"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails",
      "http://www.arcabiopharma.com/role/ScheduleofNoncashSharebasedCompensationExpenseTable",
      "http://www.arcabiopharma.com/role/ScheduleofNoncashSharebasedCompensationExpenseTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Domain]",
        "documentation": "Location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r169",
      "r172",
      "r340",
      "r344",
      "r349",
      "r420",
      "r422",
      "r490",
      "r527",
      "r558",
      "r730"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.arcabiopharma.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r283",
      "r287",
      "r291",
      "r292",
      "r293",
      "r295",
      "r300",
      "r306",
      "r308",
      "r309",
      "r310",
      "r436",
      "r555"
     ]
    },
    "us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExaminationPenaltiesAndInterestExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.arcabiopharma.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest or penalties recognized",
        "label": "Income Tax Examination, Penalties and Interest Expense",
        "documentation": "The sum of the amounts of estimated penalties and interest recognized in the period arising from income tax examinations."
       }
      }
     },
     "auth_ref": [
      "r702"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ScheduleofIncomeTaxBenefitAttributabletoOurLossfromOperationsTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofIncomeTaxBenefitAttributabletoOurLossfromOperationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Income tax benefit",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r76",
      "r124",
      "r125",
      "r139",
      "r146",
      "r156",
      "r286",
      "r287",
      "r307",
      "r418",
      "r555"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.arcabiopharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r284",
      "r285",
      "r295",
      "r296",
      "r299",
      "r302",
      "r430"
     ]
    },
    "abio_IncomeTaxReconciliationAdjustmentToDeferredTaxAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "IncomeTaxReconciliationAdjustmentToDeferredTaxAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ScheduleofIncomeTaxBenefitAttributabletoOurLossfromOperationsTable": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofIncomeTaxBenefitAttributabletoOurLossfromOperationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax asset adjustment",
        "documentation": "Adjustment of the carrying value of deferred tax assets during the year.",
        "label": "Income Tax Reconciliation Adjustment To Deferred Tax Asset"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ScheduleofIncomeTaxBenefitAttributabletoOurLossfromOperationsTable": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofIncomeTaxBenefitAttributabletoOurLossfromOperationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in valuation allowance",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r290",
      "r555",
      "r699"
     ]
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ScheduleofIncomeTaxBenefitAttributabletoOurLossfromOperationsTable": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofIncomeTaxBenefitAttributabletoOurLossfromOperationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. federal income tax benefit at statutory rates",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r287",
      "r555"
     ]
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ScheduleofIncomeTaxBenefitAttributabletoOurLossfromOperationsTable": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofIncomeTaxBenefitAttributabletoOurLossfromOperationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r555",
      "r699",
      "r700"
     ]
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ScheduleofIncomeTaxBenefitAttributabletoOurLossfromOperationsTable": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofIncomeTaxBenefitAttributabletoOurLossfromOperationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State income tax benefit, net of federal benefit",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r289",
      "r555",
      "r699"
     ]
    },
    "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationTaxCreditsResearch",
     "crdr": "credit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ScheduleofIncomeTaxBenefitAttributabletoOurLossfromOperationsTable": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofIncomeTaxBenefitAttributabletoOurLossfromOperationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Research and experimentation credits",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit."
       }
      }
     },
     "auth_ref": [
      "r555",
      "r699",
      "r701"
     ]
    },
    "abio_IncomeTaxesDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "IncomeTaxesDetailsLineItems",
     "presentation": [
      "http://www.arcabiopharma.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes (Details) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "abio_IncomeTaxesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "IncomeTaxesDetailsTable",
     "presentation": [
      "http://www.arcabiopharma.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses and other liabilities",
        "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities",
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other."
       }
      }
     },
     "auth_ref": [
      "r583"
     ]
    },
    "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued compensation and employee benefits",
        "label": "Increase (Decrease) in Employee Related Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in operating assets and liabilities:",
        "label": "Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherCurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherCurrentAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other current assets",
        "label": "Increase (Decrease) in Other Current Assets",
        "documentation": "Amount of increase (decrease) in current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r583"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other assets",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r583"
     ]
    },
    "abio_IncreaseOfRetentionBonusToEachExecutive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "IncreaseOfRetentionBonusToEachExecutive",
     "crdr": "credit",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase of retention bonus to each executive",
        "documentation": "Increase of retention bonus to each executive.",
        "label": "Increase Of Retention Bonus To Each Executive"
       }
      }
     },
     "auth_ref": []
    },
    "abio_InitiallySpecifiedPercentageForBeneficialNumberOfShares": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "InitiallySpecifiedPercentageForBeneficialNumberOfShares",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Initially specified percentage for beneficial number of shares",
        "documentation": "Initially specified percentage for beneficial number of shares",
        "label": "Initially Specified Percentage For Beneficial Number Of Shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestAndOtherIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestAndOtherIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest and other income",
        "label": "Interest and Other Income",
        "documentation": "The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest paid",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r102",
      "r103"
     ]
    },
    "abio_JonesTradingInstitutionalServicesLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "JonesTradingInstitutionalServicesLLCMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/EquityFinancingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Jones Trading",
        "documentation": "JonesTrading Institutional Services LLC.",
        "label": "Jones Trading Institutional Services LLCMember"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LatestTaxYearMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LatestTaxYearMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Latest Tax Year",
        "label": "Latest Tax Year [Member]",
        "documentation": "Latest identified tax year."
       }
      }
     },
     "auth_ref": [
      "r703"
     ]
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://www.arcabiopharma.com/role/EquityFinancingsDetails",
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.arcabiopharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r369"
     ]
    },
    "us-gaap_LesseeOperatingLeaseAssumptionsAndJudgmentsAllocationOfLeaseAndNonleaseComponent": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseAssumptionsAndJudgmentsAllocationOfLeaseAndNonleaseComponent",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee operating lease description",
        "label": "Lessee, Operating Lease, Assumptions and Judgments, Allocation of Lease and Nonlease Component",
        "documentation": "Description of assumptions and judgments used by lessee for allocating contract between lease and nonlease components for operating lease."
       }
      }
     },
     "auth_ref": [
      "r563"
     ]
    },
    "us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseExistenceOfOptionToExtend",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Indicates (true false) whether lessee has option to extend operating lease",
        "label": "Lessee, Operating Lease, Existence of Option to Extend [true false]",
        "documentation": "Indicates (true false) whether lessee has option to extend operating lease."
       }
      }
     },
     "auth_ref": [
      "r370"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Future Minimum Commitments Due",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r718"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable0": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable",
      "http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total remaining lease payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r376"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r376"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r376"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r376"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r376"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "crdr": "credit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable0": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r718"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable",
      "http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: imputed lease interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r376"
     ]
    },
    "us-gaap_LesseeOperatingLeaseOptionToExtend": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseOptionToExtend",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease renewal option",
        "label": "Lessee, Operating Lease, Option to Extend",
        "documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability."
       }
      }
     },
     "auth_ref": [
      "r370"
     ]
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term",
        "label": "Lessee, Operating Lease, Renewal Term",
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r717"
     ]
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseTermOfContract",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease term",
        "label": "Lessee, Operating Lease, Term of Contract",
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r717"
     ]
    },
    "abio_LesseeOperatingSubleaseTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "LesseeOperatingSubleaseTermOfContract",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sublease term",
        "documentation": "Lessee operating sublease term of contract.",
        "label": "Lessee Operating Sublease Term Of Contract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r25",
      "r26",
      "r27",
      "r28",
      "r29",
      "r30",
      "r31",
      "r106",
      "r163",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r320",
      "r321",
      "r322",
      "r356",
      "r460",
      "r533",
      "r576",
      "r608",
      "r721",
      "r722"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and stockholders\u2019 equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r61",
      "r410",
      "r565",
      "r587",
      "r601",
      "r716"
     ]
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r81",
      "r106",
      "r163",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r320",
      "r321",
      "r322",
      "r356",
      "r565",
      "r608",
      "r721",
      "r722"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilityForUncertainTaxPositionsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilityForUncertainTaxPositionsCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.arcabiopharma.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reserve for uncertain tax positions",
        "label": "Liability for Uncertainty in Income Taxes, Current",
        "documentation": "Amount recognized for uncertainty in income taxes classified as current."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "abio_LiquidityAndGoingConcernPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "LiquidityAndGoingConcernPolicyTextBlock",
     "presentation": [
      "http://www.arcabiopharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liquidity and Going Concern",
        "documentation": "Liquidity and going concern.",
        "label": "Liquidity And Going Concern Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/SharebasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r178",
      "r179",
      "r180",
      "r181",
      "r232",
      "r280",
      "r338",
      "r396",
      "r419",
      "r421",
      "r428",
      "r452",
      "r453",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r525",
      "r526",
      "r540",
      "r547",
      "r551",
      "r559",
      "r560",
      "r561",
      "r562",
      "r566",
      "r610",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728"
     ]
    },
    "abio_MergerAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "MergerAgreementMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Merger Agreement",
        "documentation": "Merger agreement",
        "label": "Merger Agreement Member"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/SharebasedCompensationDetails",
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "verboseLabel": "Minimum [Member]",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r178",
      "r179",
      "r180",
      "r181",
      "r232",
      "r280",
      "r338",
      "r396",
      "r419",
      "r421",
      "r428",
      "r452",
      "r453",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r525",
      "r526",
      "r540",
      "r547",
      "r551",
      "r559",
      "r560",
      "r561",
      "r566",
      "r610",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728"
     ]
    },
    "abio_MinimumPercentageOfOriginallyIssuedOutstanding": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "MinimumPercentageOfOriginallyIssuedOutstanding",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum percentage of originally issued outstanding",
        "documentation": "Minimum percentage of originally issued outstanding",
        "label": "Minimum Percentage Of Originally Issued Outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "abio_MinimumPercentageOfOriginallyIssuedShares": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "MinimumPercentageOfOriginallyIssuedShares",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum percentage of originally issued outstanding",
        "documentation": "Minimum percentage of originally issued shares",
        "label": "Minimum Percentage Of Originally Issued Shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of noncontrolling ownership interest",
        "label": "Subsidiary, Ownership Percentage, Noncontrolling Owner",
        "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MinorityInterestOwnershipPercentageByParent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MinorityInterestOwnershipPercentageByParent",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of ownership interest",
        "label": "Subsidiary, Ownership Percentage, Parent",
        "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/FairValueDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Money Market Funds [Member]",
        "verboseLabel": "Money Market Funds",
        "label": "Money Market Funds [Member]",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r634"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net cash provided by financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r101"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from financing activities:",
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r101"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from investing activities:",
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r44",
      "r45"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from operating activities:",
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow",
      "http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement",
      "http://www.arcabiopharma.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "terseLabel": "Net loss",
        "label": "Net Income (Loss) Attributable to Parent",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r45",
      "r62",
      "r79",
      "r92",
      "r93",
      "r97",
      "r106",
      "r115",
      "r117",
      "r118",
      "r119",
      "r120",
      "r121",
      "r124",
      "r125",
      "r131",
      "r163",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r314",
      "r317",
      "r332",
      "r356",
      "r415",
      "r482",
      "r503",
      "r504",
      "r575",
      "r608"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.arcabiopharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recent Accounting Pronouncements",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "abio_NewCapitalOnDemandSalesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "NewCapitalOnDemandSalesAgreementMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/EquityFinancingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2020 Sales Agreement",
        "documentation": "New Capital on Demand Sales Agreement.",
        "label": "New Capital On Demand Sales Agreement Member"
       }
      }
     },
     "auth_ref": []
    },
    "abio_NextTwoPercentPayContributionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "NextTwoPercentPayContributionMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/EmployeeBenefitPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Next 2% of pay contributed",
        "documentation": "Next two percent pay contribution.",
        "label": "Next Two Percent Pay Contribution Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental disclosure of noncash investing and financing transactions:",
        "label": "Noncash Investing and Financing Items [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "abio_NumberOfConsecutiveTradingDays": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "NumberOfConsecutiveTradingDays",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of consecutive trading days",
        "documentation": "Number of consecutive trading days.",
        "label": "Number Of Consecutive Trading Days"
       }
      }
     },
     "auth_ref": []
    },
    "abio_NumberOfMonthsBaseSalary": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "NumberOfMonthsBaseSalary",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of months base salary",
        "documentation": "Number of months base salary",
        "label": "Number Of Months Base Salary"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://www.arcabiopharma.com/role/ARCAandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of segment",
        "label": "Number of Operating Segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r538",
      "r594"
     ]
    },
    "us-gaap_OneTimeTerminationBenefitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OneTimeTerminationBenefitsMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "One-time Termination Benefits",
        "label": "One-time Termination Benefits [Member]",
        "documentation": "A lump sum payment to an involuntarily terminated employee in conjunction with exit or disposal activities."
       }
      }
     },
     "auth_ref": [
      "r541",
      "r542",
      "r543",
      "r544"
     ]
    },
    "us-gaap_OpenTaxYear": {
     "xbrltype": "gYearListItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OpenTaxYear",
     "presentation": [
      "http://www.arcabiopharma.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Open Tax Year",
        "label": "Open Tax Year",
        "documentation": "Tax year that remains open to examination under enacted tax laws, in YYYY format."
       }
      }
     },
     "auth_ref": [
      "r294"
     ]
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total costs and expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r534",
      "r593",
      "r595",
      "r596",
      "r597",
      "r598"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rent expense",
        "label": "Operating Lease, Cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r371",
      "r564"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liability",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r367"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable",
      "http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: Current portion",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r367"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet",
      "http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable",
      "http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liability, net of current portion",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r367"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating leases",
        "label": "Operating Lease, Payments",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r368",
      "r372"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use asset \u2013 operating",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r366"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of right-of-use asset \u2013 operating",
        "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction",
        "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r584"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average discount rate",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r375",
      "r564"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average remaining lease term",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r374",
      "r564"
     ]
    },
    "abio_OperatingLeasesExtendedExpiryYearsAndMonth": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "OperatingLeasesExtendedExpiryYearsAndMonth",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional operating lease term",
        "label": "Operating Leases Extended Expiry Years And Month"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.arcabiopharma.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss carryforwards",
        "label": "Operating Loss Carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r301"
     ]
    },
    "abio_OperatingLossCarryforwardsExpirationYear": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "OperatingLossCarryforwardsExpirationYear",
     "presentation": [
      "http://www.arcabiopharma.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating loss carryforwards expiration year",
        "documentation": "Operating loss carryforwards expiration year.",
        "label": "Operating Loss Carryforwards Expiration Year"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.arcabiopharma.com/role/ARCAandSummaryofSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ARCA and Summary of Significant Accounting Policies",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r46",
      "r47",
      "r58"
     ]
    },
    "abio_OrukaTherapeuticsIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "OrukaTherapeuticsIncMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Oruka Therapeutics Inc",
        "documentation": "Oruka therapeutics inc member.",
        "label": "Oruka Therapeutics Inc Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet",
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses and other liabilities",
        "verboseLabel": "Accrued expenses and other liabilities - related party (in Dollars)",
        "label": "Other Accrued Liabilities, Current",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "us-gaap_OtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other current assets",
        "label": "Other Assets, Current",
        "documentation": "Amount of current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r565"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other assets",
        "label": "Other Assets, Noncurrent",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r85"
     ]
    },
    "us-gaap_OtherNonoperatingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other loss",
        "label": "Other Nonoperating Expense",
        "documentation": "Amount of expense related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "srt_OwnershipAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "OwnershipAxis",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_OwnershipDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "OwnershipDomain",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "abio_PatentAssignmentAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "PatentAssignmentAgreementMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Patent Assignment Agreement",
        "documentation": "Patent assignment agreement.",
        "label": "Patent Assignment Agreement Member"
       }
      }
     },
     "auth_ref": []
    },
    "abio_PaymentOfOtherPartyTerminationFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "PaymentOfOtherPartyTerminationFee",
     "crdr": "credit",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payment of other party termination fee",
        "documentation": "Payment of other party termination fee",
        "label": "Payment Of Other Party Termination Fee"
       }
      }
     },
     "auth_ref": []
    },
    "abio_PaymentOfUnrestrictedResearchGrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "PaymentOfUnrestrictedResearchGrants",
     "crdr": "credit",
     "presentation": [
      "http://www.arcabiopharma.com/role/RelatedPartyArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payment of unrestricted research grants",
        "documentation": "Payment of unrestricted research grants.",
        "label": "Payment Of Unrestricted Research Grants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "presentation": [
      "http://www.arcabiopharma.com/role/EmployeeBenefitPlans"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Benefit Plans",
        "label": "Retirement Benefits [Text Block]",
        "documentation": "The entire disclosure for retirement benefits."
       }
      }
     },
     "auth_ref": [
      "r210",
      "r211",
      "r212",
      "r218",
      "r219",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r550"
     ]
    },
    "abio_PercentageHoldingForStockOptionsExercisePrice": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "PercentageHoldingForStockOptionsExercisePrice",
     "presentation": [
      "http://www.arcabiopharma.com/role/SharebasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price per share",
        "documentation": "Minimum ownership percentage for 110% fair market value on the grant date.",
        "label": "Percentage Holding For Stock Options Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "abio_PercentageOfBaseRentToBePaidMonthly": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "PercentageOfBaseRentToBePaidMonthly",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage Of Base Rent To Be Paid Monthly",
        "documentation": "Percentage of base rent to be paid monthly.",
        "label": "Percentage Of Base Rent To Be Paid Monthly"
       }
      }
     },
     "auth_ref": []
    },
    "abio_PercentageOfRetentionBonuses": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "PercentageOfRetentionBonuses",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of retention bonuses",
        "documentation": "Percentage of retention bonuses.",
        "label": "Percentage Of Retention Bonuses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.arcabiopharma.com/role/SharebasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.arcabiopharma.com/role/SharebasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697"
     ]
    },
    "abio_PotentialUpfrontAndMilestoneObligationsAndRoyaltyObligations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "PotentialUpfrontAndMilestoneObligationsAndRoyaltyObligations",
     "crdr": "credit",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty obligations (in Euro)",
        "documentation": "Potential upfront and milestone obligations and royalty obligations.",
        "label": "Potential Upfront And Milestone Obligations And Royalty Obligations"
       }
      }
     },
     "auth_ref": []
    },
    "abio_PotentiallyDilutiveSecuritiesExcludedAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "PotentiallyDilutiveSecuritiesExcludedAbstract",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofPotentiallyDilutiveSharesofCommonStockTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Potentially dilutive securities, excluded:",
        "label": "Potentially Dilutive Securities Excluded Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "abio_PotentiallyDilutiveSecuritiesExcludedAbstract0": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "PotentiallyDilutiveSecuritiesExcludedAbstract0",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofPotentiallyDilutiveSharesofCommonStockTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Potentially dilutive securities, excluded:",
        "label": "Potentially Dilutive Securities Excluded Abstract0"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockConvertibleSharesIssuable": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockConvertibleSharesIssuable",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock convertible shares issuable (in Shares)",
        "label": "Preferred Stock, Convertible, Shares Issuable",
        "documentation": "Number of common shares issuable upon conversion of preferred stock."
       }
      }
     },
     "auth_ref": [
      "r196"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, par value (in Dollars per share)",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r194"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares authorized",
        "label": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r462"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, issued",
        "label": "Preferred Stock, Shares Issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r194"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, outstanding",
        "label": "Preferred Stock, Shares Outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r462",
      "r480",
      "r732",
      "r733"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, $0.001 par value; 5 million shares authorized; no shares issued or outstanding at December 31, 2023 and 2022",
        "label": "Preferred Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r407",
      "r565"
     ]
    },
    "srt_PresidentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "PresidentMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thomas A. Keuer",
        "label": "President [Member]"
       }
      }
     },
     "auth_ref": [
      "r599"
     ]
    },
    "us-gaap_PrincipalOwnerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrincipalOwnerMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/SharebasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders",
        "label": "Principal Owner [Member]",
        "documentation": "Owner of record or known beneficial owner of more than 10 percent of the voting interests of the entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIncomeTaxRefunds": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIncomeTaxRefunds",
     "crdr": "debit",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income tax refund received",
        "label": "Proceeds from Income Tax Refunds",
        "documentation": "Amount of income tax refund received from tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r44",
      "r585",
      "r705",
      "r706"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable",
      "http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r377"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://www.arcabiopharma.com/role/PropertyandEquipment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r71",
      "r74",
      "r75"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable",
      "http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment, Gross",
        "label": "Property, Plant and Equipment, Gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r83",
      "r414"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable",
      "http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Property and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r377"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet",
      "http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable",
      "http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Property and equipment, net",
        "terseLabel": "Property and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r377",
      "r402",
      "r414",
      "r565"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://www.arcabiopharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r71",
      "r74",
      "r412"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.arcabiopharma.com/role/PropertyandEquipmentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Property and Equipment",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable",
      "http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r377"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable",
      "http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated Life",
        "label": "Property, Plant and Equipment, Useful Life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "abio_PurchaseAggregateShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "PurchaseAggregateShares",
     "presentation": [
      "http://www.arcabiopharma.com/role/SharebasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase aggregate shares",
        "documentation": "Purchase aggregate shares.",
        "label": "Purchase Aggregate Shares"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.arcabiopharma.com/role/SharebasedCompensationDetails",
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r178",
      "r179",
      "r180",
      "r181",
      "r211",
      "r232",
      "r266",
      "r267",
      "r268",
      "r280",
      "r338",
      "r393",
      "r394",
      "r396",
      "r419",
      "r421",
      "r428",
      "r452",
      "r453",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r525",
      "r526",
      "r540",
      "r547",
      "r551",
      "r559",
      "r560",
      "r561",
      "r562",
      "r566",
      "r569",
      "r603",
      "r610",
      "r713",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/SharebasedCompensationDetails",
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r178",
      "r179",
      "r180",
      "r181",
      "r211",
      "r232",
      "r266",
      "r267",
      "r268",
      "r280",
      "r338",
      "r393",
      "r394",
      "r396",
      "r419",
      "r421",
      "r428",
      "r452",
      "r453",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r525",
      "r526",
      "r540",
      "r547",
      "r551",
      "r559",
      "r560",
      "r561",
      "r562",
      "r566",
      "r569",
      "r603",
      "r610",
      "r713",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728"
     ]
    },
    "abio_RelatedPartyArrangementsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "RelatedPartyArrangementsDetailsTable",
     "presentation": [
      "http://www.arcabiopharma.com/role/RelatedPartyArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Arrangements (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement_Parentheticals",
      "http://www.arcabiopharma.com/role/SharebasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Domain]",
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r161",
      "r220",
      "r382",
      "r383",
      "r405",
      "r411",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r479",
      "r481",
      "r512"
     ]
    },
    "us-gaap_RelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party",
        "label": "Related Party [Member]",
        "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r109",
      "r382",
      "r383",
      "r384",
      "r385",
      "r405",
      "r411",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r479",
      "r481",
      "r512"
     ]
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionAxis",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Axis]",
        "documentation": "Information by type of related party transaction."
       }
      }
     },
     "auth_ref": [
      "r382",
      "r383",
      "r720"
     ]
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionDomain",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Domain]",
        "documentation": "Transaction between related party."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://www.arcabiopharma.com/role/RelatedPartyArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Arrangements [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r161",
      "r486",
      "r487",
      "r490"
     ]
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Arrangements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement_Parentheticals",
      "http://www.arcabiopharma.com/role/RelatedPartyArrangementsDetails",
      "http://www.arcabiopharma.com/role/SharebasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r161",
      "r220",
      "r382",
      "r383",
      "r405",
      "r411",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r479",
      "r481",
      "r512",
      "r720"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://www.arcabiopharma.com/role/RelatedPartyArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Arrangements",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r379",
      "r380",
      "r381",
      "r383",
      "r386",
      "r437",
      "r438",
      "r439",
      "r488",
      "r489",
      "r490",
      "r509",
      "r511"
     ]
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r110",
      "r111",
      "r191",
      "r197",
      "r385",
      "r395",
      "r403",
      "r530",
      "r531"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r282",
      "r527",
      "r537",
      "r729"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails",
      "http://www.arcabiopharma.com/role/ScheduleofNoncashSharebasedCompensationExpenseTable",
      "http://www.arcabiopharma.com/role/ScheduleofNoncashSharebasedCompensationExpenseTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development",
        "verboseLabel": "Research and development",
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.arcabiopharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r281"
     ]
    },
    "abio_ResearchAndDevelopmentExpenseReversed": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "ResearchAndDevelopmentExpenseReversed",
     "crdr": "debit",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement_Parentheticals",
      "http://www.arcabiopharma.com/role/RelatedPartyArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related party expense",
        "documentation": "Research and development expense (reversed).",
        "label": "Research And Development Expense Reversed"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research Tax Credit Carryforward",
        "label": "Research Tax Credit Carryforward [Member]",
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes."
       }
      }
     },
     "auth_ref": [
      "r707"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofPotentiallyDilutiveSharesofCommonStockTable",
      "http://www.arcabiopharma.com/role/ScheduleofPotentiallyDilutiveSharesofCommonStockTable0",
      "http://www.arcabiopharma.com/role/SharebasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unvested restricted stock units",
        "verboseLabel": "Restricted Stock Units",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminated",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of employees",
        "label": "Restructuring and Related Cost, Number of Positions Eliminated",
        "documentation": "The number of positions eliminated during the period as a result of restructuring activities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Workforce reduction percentage",
        "label": "Restructuring and Related Cost, Number of Positions Eliminated, Period Percent",
        "documentation": "The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringCharges",
     "crdr": "debit",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring charges",
        "label": "Restructuring Charges",
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r173",
      "r174",
      "r604"
     ]
    },
    "us-gaap_RestructuringCostAndReserveAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringCostAndReserveAxis",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Type [Axis]",
        "documentation": "Information by type of restructuring cost."
       }
      }
     },
     "auth_ref": [
      "r170",
      "r171",
      "r174",
      "r175"
     ]
    },
    "us-gaap_RestructuringReserveCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringReserveCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remains unpaid",
        "label": "Restructuring Reserve, Current",
        "documentation": "Carrying amount as of the balance sheet date of known and estimated obligations associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, which are expected to be paid in the next twelve months or in the normal operating cycle if longer. Costs of such activities include those for one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, relocating employees, and costs associated with an ongoing benefit arrangement, but excludes costs associated with the retirement of a long-lived asset."
       }
      }
     },
     "auth_ref": [
      "r580",
      "r605",
      "r606"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r53",
      "r409",
      "r426",
      "r427",
      "r435",
      "r463",
      "r565"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r112",
      "r113",
      "r114",
      "r116",
      "r121",
      "r123",
      "r125",
      "r164",
      "r165",
      "r167",
      "r303",
      "r304",
      "r311",
      "r312",
      "r313",
      "r315",
      "r316",
      "r317",
      "r323",
      "r325",
      "r326",
      "r328",
      "r330",
      "r364",
      "r365",
      "r423",
      "r425",
      "r440",
      "r732"
     ]
    },
    "abio_RetentionBonusPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "RetentionBonusPaid",
     "crdr": "debit",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retention bonus paid",
        "documentation": "Retention bonus paid.",
        "label": "Retention Bonus Paid"
       }
      }
     },
     "auth_ref": []
    },
    "abio_RetentionBonuses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "RetentionBonuses",
     "crdr": "credit",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails",
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amount of retention bonuses",
        "verboseLabel": "Retention bonuses",
        "documentation": "Retention bonuses.",
        "label": "Retention Bonuses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetirementPlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetirementPlanNameAxis",
     "presentation": [
      "http://www.arcabiopharma.com/role/EmployeeBenefitPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Plan Name [Axis]",
        "documentation": "Information by name of plan designed to provide retirement benefits. Includes, but is not limited to, legal name of defined benefit and defined contribution plans."
       }
      }
     },
     "auth_ref": [
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r551",
      "r579",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671"
     ]
    },
    "us-gaap_RetirementPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetirementPlanNameDomain",
     "presentation": [
      "http://www.arcabiopharma.com/role/EmployeeBenefitPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Plan Name [Domain]",
        "documentation": "Name of plan designed to provide retirement benefits. Includes, but is not limited to, legal name of defined benefit and defined contribution plans."
       }
      }
     },
     "auth_ref": [
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r551",
      "r579",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671"
     ]
    },
    "us-gaap_Revenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Revenues",
     "crdr": "credit",
     "presentation": [
      "http://www.arcabiopharma.com/role/ARCAandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue",
        "label": "Revenues",
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r64",
      "r98",
      "r106",
      "r139",
      "r144",
      "r145",
      "r154",
      "r156",
      "r158",
      "r159",
      "r160",
      "r163",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r356",
      "r401",
      "r537",
      "r608"
     ]
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leased assets and operating lease liabilities \u2013 amended lease term",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r373",
      "r564"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofPotentiallyDilutiveSharesofCommonStockTable",
      "http://www.arcabiopharma.com/role/ScheduleofPotentiallyDilutiveSharesofCommonStockTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.arcabiopharma.com/role/NetLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Potentially Dilutive Shares of Common Stock",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.arcabiopharma.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Net deferred tax assets and liabilities",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r704"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.arcabiopharma.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Income Tax Benefit Attributable to Our Loss from Operations",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r288",
      "r555",
      "r699"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofNoncashSharebasedCompensationExpenseTable",
      "http://www.arcabiopharma.com/role/ScheduleofNoncashSharebasedCompensationExpenseTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://www.arcabiopharma.com/role/SharebasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Non-cash, Share-based Compensation Expense",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "abio_ScheduleOfEstimatedWeightedAverageGrantDateFairValuePerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "ScheduleOfEstimatedWeightedAverageGrantDateFairValuePerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Estimated Weighted Average Grant Date Fair Value Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "abio_ScheduleOfFutureMinimumCommitmentsDueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "ScheduleOfFutureMinimumCommitmentsDueAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Future Minimum Commitments Due [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "abio_ScheduleOfIncomeTaxBenefitAttributableToOurLossFromOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "ScheduleOfIncomeTaxBenefitAttributableToOurLossFromOperationsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Income Tax Benefit Attributable To Our Loss From Operations Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "abio_ScheduleOfNetDeferredTaxAssetsAndLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "ScheduleOfNetDeferredTaxAssetsAndLiabilitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Net Deferred Tax Assets And Liabilities Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "abio_ScheduleOfNonCashShareBasedCompensationExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "ScheduleOfNonCashShareBasedCompensationExpenseAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Non Cash Share Based Compensation Expense Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
     "presentation": [
      "http://www.arcabiopharma.com/role/SharebasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of RSU Activity",
        "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]",
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "abio_ScheduleOfPotentiallyDilutiveSharesOfCommonStockAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "ScheduleOfPotentiallyDilutiveSharesOfCommonStockAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Potentially Dilutive Shares of Common Stock [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "abio_ScheduleOfPropertyAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "ScheduleOfPropertyAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Property And Equipment Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable",
      "http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r377"
     ]
    },
    "abio_ScheduleOfRsuActivityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "ScheduleOfRsuActivityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of RSU Activity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.arcabiopharma.com/role/SharebasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock Option Activities",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r6",
      "r54"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.arcabiopharma.com/role/SharebasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Estimated Weighted Average Grant Date Fair Value Per Share",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "abio_ScheduleOfStockOptionActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "ScheduleOfStockOptionActivitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stock Option Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "abio_SecondAmendmentOfCertainRetentionBonusLettersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "SecondAmendmentOfCertainRetentionBonusLettersMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Second Amendment of Certain Retention Bonus Letters",
        "documentation": "Second amendment of certain retention bonus letters.",
        "label": "Second Amendment Of Certain Retention Bonus Letters Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.arcabiopharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r157",
      "r159",
      "r535",
      "r536",
      "r539"
     ]
    },
    "abio_SellingCommissionPerAdditionalSharesSoldPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "SellingCommissionPerAdditionalSharesSoldPercentage",
     "presentation": [
      "http://www.arcabiopharma.com/role/EquityFinancingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of commission rate equal",
        "documentation": "Selling commission per additional shares sold percentage.",
        "label": "Selling Commission Per Additional Shares Sold Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "abio_SeperationAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "SeperationAgreementMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Seperation Agreement",
        "documentation": "Seperation agreement",
        "label": "Seperation Agreement Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeriesBPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SeriesBPreferredStockMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series B Preferred Stock",
        "label": "Series B Preferred Stock [Member]",
        "documentation": "Series B preferred stock."
       }
      }
     },
     "auth_ref": [
      "r581",
      "r582",
      "r611"
     ]
    },
    "us-gaap_SeveranceCosts1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SeveranceCosts1",
     "crdr": "debit",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Severance expense",
        "label": "Severance Costs",
        "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1",
     "presentation": [
      "http://www.arcabiopharma.com/role/SharebasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock awards granted service period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period",
        "documentation": "Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r552"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.arcabiopharma.com/role/SharebasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock options award, vesting period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r552"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofRSUActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Shares, RSUs outstanding, Forfeited and cancelled",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r258"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofRSUActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Grant Date Date Fair Value, RSUs outstanding, Forfeited and cancelled",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r258"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofRSUActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Shares, RSUs outstanding, Granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r256"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofRSUActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Grant Date Date Fair Value, RSUs outstanding, Granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r256"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofRSUActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Number of Shares, RSUs outstanding, beginning of period",
        "periodEndLabel": "Number of Shares, RSUs outstanding, ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r253",
      "r254"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofRSUActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted Average Grant Date Date Fair Value, RSUs outstanding, beginning of period",
        "periodEndLabel": "Weighted Average Grant Date Date Fair Value, RSUs outstanding, ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r253",
      "r254"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofRSUActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of Shares, RSUs outstanding, Vested and released",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r257"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofRSUActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Grant Date Date Fair Value, RSUs outstanding, Vested and released",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r257"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofEstimatedWeightedAverageGrantDateFairValuePerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected dividend yield",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r267"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofEstimatedWeightedAverageGrantDateFairValuePerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r266"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofEstimatedWeightedAverageGrantDateFairValuePerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r268"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://www.arcabiopharma.com/role/SharebasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares issuable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r554"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable",
      "http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Options, Options exercisable, ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r247"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable",
      "http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Options exercisable, ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r247"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable",
      "http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of Options, Forfeited and cancelled",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period",
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired."
       }
      }
     },
     "auth_ref": [
      "r678"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable",
      "http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Forfeited and cancelled",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price of options that were either forfeited or expired."
       }
      }
     },
     "auth_ref": [
      "r678"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable",
      "http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Options, Granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r249"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofEstimatedWeightedAverageGrantDateFairValuePerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average grant date fair value per share (in Dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r259"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Aggregate Intrinsic Value, Options outstanding, ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable",
      "http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable0",
      "http://www.arcabiopharma.com/role/SharebasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Number of Options, Options outstanding, ending balance",
        "terseLabel": "Purchase options shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r245",
      "r246"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable",
      "http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable0",
      "http://www.arcabiopharma.com/role/SharebasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Weighted Average Exercise Price, Options outstanding, ending balance",
        "terseLabel": "Weighted average exercise price (in Dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r245",
      "r246"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Intrinsic Value, Options vested and expected to vest, ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r262"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable",
      "http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Options, Options vested and expected to vest, ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r261"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable",
      "http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Options vested and expected to vest, ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r261"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "presentation": [
      "http://www.arcabiopharma.com/role/SharebasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period",
        "documentation": "Number of shares issued under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.arcabiopharma.com/role/SharebasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r241",
      "r242",
      "r243",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable",
      "http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Exercised",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r250"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable",
      "http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Granted",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r249"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://www.arcabiopharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-Based Compensation",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r238",
      "r244",
      "r263",
      "r264",
      "r265",
      "r266",
      "r269",
      "r275",
      "r276",
      "r277",
      "r278"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://www.arcabiopharma.com/role/SharebasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock options award, expiration",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r553"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofEstimatedWeightedAverageGrantDateFairValuePerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected term",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r265"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Intrinsic Value, Options exercisable, ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable",
      "http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Remaining Contractual Term (in years), Options exercisable, ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable",
      "http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Remaining Contractual Term (in years) Options outstanding, ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable",
      "http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Remaining Contractual Term (in years), Options vested and expected to vest, ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r261"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "presentation": [
      "http://www.arcabiopharma.com/role/SharebasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of exercise price",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent",
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value."
       }
      }
     },
     "auth_ref": []
    },
    "abio_SharebasedCompensationDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "SharebasedCompensationDetailsLineItems",
     "presentation": [
      "http://www.arcabiopharma.com/role/SharebasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation (Details) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "abio_SharebasedCompensationDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "SharebasedCompensationDetailsTable",
     "presentation": [
      "http://www.arcabiopharma.com/role/SharebasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SoftwareAndSoftwareDevelopmentCostsMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable",
      "http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Computer software",
        "verboseLabel": "Computer Software",
        "label": "Software and Software Development Costs [Member]",
        "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r87",
      "r88",
      "r89",
      "r106",
      "r129",
      "r130",
      "r132",
      "r134",
      "r141",
      "r142",
      "r163",
      "r182",
      "r184",
      "r185",
      "r186",
      "r189",
      "r190",
      "r194",
      "r195",
      "r199",
      "r202",
      "r208",
      "r356",
      "r431",
      "r432",
      "r433",
      "r434",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r462",
      "r483",
      "r505",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r578",
      "r586",
      "r592"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.arcabiopharma.com/role/ShareholdersEquityType2or3",
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r33",
      "r36",
      "r37",
      "r78",
      "r95",
      "r96",
      "r97",
      "r112",
      "r113",
      "r114",
      "r116",
      "r121",
      "r123",
      "r125",
      "r140",
      "r164",
      "r165",
      "r167",
      "r209",
      "r303",
      "r304",
      "r311",
      "r312",
      "r313",
      "r315",
      "r316",
      "r317",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r330",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r364",
      "r365",
      "r378",
      "r416",
      "r423",
      "r424",
      "r425",
      "r440",
      "r505"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement_Parentheticals",
      "http://www.arcabiopharma.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r113",
      "r114",
      "r140",
      "r365",
      "r397",
      "r429",
      "r451",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r462",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r481",
      "r484",
      "r485",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r505",
      "r570"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement_Parentheticals",
      "http://www.arcabiopharma.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r113",
      "r114",
      "r140",
      "r161",
      "r365",
      "r397",
      "r429",
      "r451",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r462",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r481",
      "r484",
      "r485",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r505",
      "r570"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.arcabiopharma.com/role/EquityFinancingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of common stock",
        "label": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r32",
      "r33",
      "r53",
      "r431",
      "r505",
      "r519"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "presentation": [
      "http://www.arcabiopharma.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock upon vesting of Restricted Stock Units (in Shares)",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r32",
      "r33",
      "r53"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable",
      "http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Options, Exercised",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r32",
      "r33",
      "r53",
      "r250"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross",
     "crdr": "credit",
     "presentation": [
      "http://www.arcabiopharma.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock upon vesting of Restricted Stock Units",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross",
        "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r32",
      "r33",
      "r53"
     ]
    },
    "us-gaap_StockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockOptionMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofPotentiallyDilutiveSharesofCommonStockTable",
      "http://www.arcabiopharma.com/role/ScheduleofPotentiallyDilutiveSharesofCommonStockTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding stock options",
        "label": "Equity Option [Member]",
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option)."
       }
      }
     },
     "auth_ref": [
      "r569"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet",
      "http://www.arcabiopharma.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders\u2019 equity",
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r36",
      "r37",
      "r48",
      "r464",
      "r480",
      "r506",
      "r507",
      "r565",
      "r576",
      "r587",
      "r601",
      "r716",
      "r732"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders\u2019 equity:",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.arcabiopharma.com/role/EquityFinancings"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Financings",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r105",
      "r193",
      "r195",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r209",
      "r329",
      "r508",
      "r510",
      "r523"
     ]
    },
    "abio_SubscriptionAgreementReceiptAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "SubscriptionAgreementReceiptAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subscription agreement receipt amount",
        "documentation": "Subscription agreement receipt amount",
        "label": "Subscription Agreement Receipt Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails",
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event",
        "verboseLabel": "Subsequent Event [Member]",
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r363",
      "r388"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails",
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r363",
      "r388"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r363",
      "r388"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "abio_SubsequentEventsDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "SubsequentEventsDetailsLineItems",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events (Details) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "abio_SubsequentEventsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "SubsequentEventsDetailsTable",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Events",
        "label": "Subsequent Events [Text Block]",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r387",
      "r389"
     ]
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental cash flow information:",
        "label": "Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.arcabiopharma.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and experimentation credits",
        "label": "Tax Credit Carryforward, Amount",
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r301"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardAxis",
     "presentation": [
      "http://www.arcabiopharma.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward [Axis]",
        "documentation": "Information by specific tax credit related to an unused tax credit."
       }
      }
     },
     "auth_ref": [
      "r301"
     ]
    },
    "us-gaap_TaxCreditCarryforwardDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardDescription",
     "presentation": [
      "http://www.arcabiopharma.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating loss carryforwards, limitations on use",
        "label": "Tax Credit Carryforward, Description",
        "documentation": "A description of the origin, nature, and characteristics of the tax credit carryforward."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "us-gaap_TaxCreditCarryforwardLimitationsOnUse": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardLimitationsOnUse",
     "presentation": [
      "http://www.arcabiopharma.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax credit carryforward, limitations on use",
        "label": "Tax Credit Carryforward, Limitations on Use",
        "documentation": "Description of the limitation related to use of the tax credit carryforward."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardNameDomain",
     "presentation": [
      "http://www.arcabiopharma.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward, Name [Domain]",
        "documentation": "The name of the tax credit carryforward."
       }
      }
     },
     "auth_ref": [
      "r301"
     ]
    },
    "us-gaap_TaxPeriodAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxPeriodAxis",
     "presentation": [
      "http://www.arcabiopharma.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Period [Axis]",
        "documentation": "Information by period subject to enacted tax law."
       }
      }
     },
     "auth_ref": [
      "r703"
     ]
    },
    "us-gaap_TaxPeriodDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxPeriodDomain",
     "presentation": [
      "http://www.arcabiopharma.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Period [Domain]",
        "documentation": "Identified tax period."
       }
      }
     },
     "auth_ref": [
      "r703"
     ]
    },
    "abio_ThomasAKeuerAndCJeffreyDekkerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "ThomasAKeuerAndCJeffreyDekkerMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thomas A. Keuer and C. Jeffrey Dekker [Member]",
        "documentation": "Thomas A. Keuer and C. Jeffrey Dekker.",
        "label": "Thomas AKeuer And CJeffrey Dekker Member"
       }
      }
     },
     "auth_ref": []
    },
    "abio_ThresholdAmountOfAdjustedExchangeRatio": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "ThresholdAmountOfAdjustedExchangeRatio",
     "crdr": "debit",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjusted exchange ratio",
        "documentation": "Threshold amount of adjusted exchange ratio.",
        "label": "Threshold Amount Of Adjusted Exchange Ratio"
       }
      }
     },
     "auth_ref": []
    },
    "abio_ThresholdAmountOfDeclaredCashDividend": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "ThresholdAmountOfDeclaredCashDividend",
     "crdr": "debit",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Declared cash dividend",
        "documentation": "Threshold amount of declared cash dividend.",
        "label": "Threshold Amount Of Declared Cash Dividend"
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Axis]"
       }
      }
     },
     "auth_ref": [
      "r599",
      "r719"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "abio_TwoThousandAndThirteenPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "TwoThousandAndThirteenPlanMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/SharebasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2013 Plan",
        "documentation": "Two thousand and thirteen plan.",
        "label": "Two Thousand And Thirteen Plan Member"
       }
      }
     },
     "auth_ref": []
    },
    "abio_TwoThousandAndTwentyEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "TwoThousandAndTwentyEquityIncentivePlanMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/SharebasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2020 Equity Incentive Plan",
        "documentation": "Two thousand and twenty equity incentive plan.",
        "label": "Two Thousand And Twenty Equity Incentive Plan Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails",
      "http://www.arcabiopharma.com/role/EquityFinancingsDetails",
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r318"
     ]
    },
    "us-gaap_TypeOfRestructuringDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfRestructuringDomain",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Type of Restructuring [Domain]",
        "documentation": "Identification of the types of restructuring costs."
       }
      }
     },
     "auth_ref": [
      "r170",
      "r171",
      "r174",
      "r175"
     ]
    },
    "abio_UniversityMedicalCenterOfJohannesGutenbergUniversityMainzMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "UniversityMedicalCenterOfJohannesGutenbergUniversityMainzMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "University Medical Center of Johannes Gutenberg University Mainz",
        "verboseLabel": "University Medical Center Of Johannes Gutenberg University Mainz",
        "documentation": "University medical center of Johannes Gutenberg university Mainz.",
        "label": "University Medical Center Of Johannes Gutenberg University Mainz Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.arcabiopharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting Estimates in the Preparation of Financial Statements",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r13",
      "r14",
      "r68",
      "r69",
      "r72",
      "r73"
     ]
    },
    "abio_ValuationAllowanceDeferredTaxAssetsAndLiabilitiesChangeInAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "ValuationAllowanceDeferredTaxAssetsAndLiabilitiesChangeInAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.arcabiopharma.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase in net deferred tax assets and liabilities",
        "documentation": "Valuation allowance deferred tax assets and liabilities change in amount.",
        "label": "Valuation Allowance Deferred Tax Assets And Liabilities Change In Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r128",
      "r134"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic (in Shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r134"
     ]
    },
    "abio_WeightedAverageSharesOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "WeightedAverageSharesOutstandingAbstract",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average shares outstanding:",
        "label": "Weighted Average Shares Outstanding Abstract"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/275/tableOfContent"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/360/tableOfContent"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r67": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r68": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r69": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r70": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r71": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r72": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r73": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r74": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r75": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7"
  },
  "r76": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r77": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r78": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r79": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r80": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r81": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r82": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r83": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r84": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r85": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r86": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-1"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/715/tableOfContent"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(o)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(p)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(r)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(r)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480126/715-20-S99-2"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480266/715-60-50-3"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "70",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480794/715-70-50-1"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.1.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/850/tableOfContent"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r579": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "SubTopic": "20",
   "Topic": "715",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r580": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r581": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r582": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r583": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r584": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r585": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r586": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r587": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r589": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r590": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r591": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r592": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r593": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r595": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r596": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r597": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r598": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r599": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r600": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r602": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r603": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r604": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482047/420-10-45-3"
  },
  "r605": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r607": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r608": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r609": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r610": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r611": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r612": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r613": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r614": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(10)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r617": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r618": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r619": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r620": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r621": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r622": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r623": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r624": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r625": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r626": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r627": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r628": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r629": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r630": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r631": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r632": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r633": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r634": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r635": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r636": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r637": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r638": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r639": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r640": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r641": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r642": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r643": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r644": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r645": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r646": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r647": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r648": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r649": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r650": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r651": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r652": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r653": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r654": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r655": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r656": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r657": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r658": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r659": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-2"
  },
  "r660": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-3"
  },
  "r661": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-3"
  },
  "r662": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r663": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r664": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r665": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r666": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r667": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r668": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r669": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r670": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r671": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-8"
  },
  "r672": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r673": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r674": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r675": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r676": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r677": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r678": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r679": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r680": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r681": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r682": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r683": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r684": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r685": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r686": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r687": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r688": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r689": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r690": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r691": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r692": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r693": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r694": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r695": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r696": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r697": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r698": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r699": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r700": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r701": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r702": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r703": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r704": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r705": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22"
  },
  "r706": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r707": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r708": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r709": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r710": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r711": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r712": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r713": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r714": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r715": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r716": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r717": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r718": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r719": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r720": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r721": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r722": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r723": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r724": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r725": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r726": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r727": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r728": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r729": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r730": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r731": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r732": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r733": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
